FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Kwak, HB
   Yang, D
   Ha, H
   Lee, JH
   Kim, HN
   Woo, ER
   Lee, S
   Kim, HH
   Lee, ZH
AF Kwak, Han Bok
   Yang, Daum
   Ha, Hyunil
   Lee, Jong Ho
   Kim, Ha Neui
   Woo, Eun Ran
   Lee, Seungbok
   Kim, Hong Hee
   Lee, Zang Hee
TI Tanshinone IIA inhibits osteoclast differentiation through
   down regulation of c Fos and NFATc1
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
DE osteoclasts; tanshinone; Salvia miltiorrhiza; drugs, Chinese herbal;
   osteoporosis; RANK ligand
ID TUMOR NECROSIS FACTOR; KAPPA B LIGAND; SALVIA MILTIORRHIZA;
   BONE RESORPTION; RECEPTOR ACTIVATOR; NUCLEAR FACTOR;
   SIGNAL TRANSDUCTION; CELLS; INFLAMMATION
AB Bone is a dynamic tissue that is regulated by the activity of bone resorbing osteoclasts and bone forming osteoblast. Excessive osteoclast formation causes diseases such as osteoporosis and rheumatoid arthritis. Natural substances may be useful as therapeutic drugs to prevent many diseases in humans because they avoid the many side effects of treatment with chemical compounds. Here we show that tanshinone IIA isolated from Salvia miltiorrhiza Bunge inhibits the receptor activator of NF kappa B ligand (RANKL) mediated osteoclast differentiation of osteoclast precursors. Tanshinone IIA suppressed the expression levels of c Fos and NFATc1 induced by RANKL. However,retrovirus mediated overexpression of c Fos induced the expression of NFATcl despite the presence of tans hinone IIA and reversed the inhibitory effect of tanshinone IIA on osteoclast differentiation. Also, the introduction of osteoclast precursors with the NFATcl retrovirus led to osteoclast differentiation in the presence of tanshinone IIA. Our results suggest that tanshinone IIA may have a role as a therapeutic drug in the treatment of bone disease such as osteroporosis.
C1 Seoul Natl Univ, Dept Cell & Dev Biol, Sch Dent, DRI, Seoul 110749, South Korea.
   Seoul Natl Univ, BK21 Program, Seoul 110749, South Korea.
   Chosun Univ, Res Ctr Proteineous Mat, Kwangju 501759, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Chosun
   University
RP Lee, ZH (通讯作者)，Seoul Natl Univ, Dept Cell & Dev Biol, Sch Dent, DRI, Seoul 110749, South Korea.
EM zang1959@hotmail.com
RI ; Kim, Hee/F 4594 2014; Kim, Jung Wook/AAI 1668 2020; Lee,
   Seungbok/AAS 1529 2021
OI Lee, Seungbok/0000 0002 6620 6269; Ha, Hyunil/0000 0001 5947 9982
CR AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Christgau S, 2004, MENOPAUSE, V11, P508, DOI 10.1097/01.WCB.0000121484.18437.98
   DESIMONE DP, 1993, J BONE MINER RES, V8, P625
   Han YM, 2005, BIOL PHARM BULL, V28, P1795, DOI 10.1248/bpb.28.1795
   Hazra B, 2004, J CHROMATOGR B, V812, P259, DOI 10.1016/j.jchromb.2004.08.007
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Hur JM, 2005, EXP MOL MED, V37, P133, DOI 10.1038/emm.2005.18
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim HH, 2004, BIOCHEM PHARMACOL, V67, P1647, DOI 10.1016/j.bcp.2003.12.031
   Kwak HB, 2004, BIOCHEM PHARMACOL, V67, P1239, DOI 10.1016/j.bcp.2003.10.032
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Liu XD, 2001, J LAB CLIN MED, V137, P208, DOI 10.1067/mlc.2001.113066
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Miyamoto T, 2000, BLOOD, V96, P4335, DOI 10.1182/blood.V96.13.4335.h8004335_4335_4343
   Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015
   Park H, 2005, EXP MOL MED, V37, P524, DOI 10.1038/emm.2005.65
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takahashi K, 2002, BIOCHEM PHARMACOL, V64, P745, DOI 10.1016/S0006 2952(02)01250 9
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Walsh MC, 2003, CYTOKINE GROWTH F R, V14, P251, DOI 10.1016/S1359 6101(03)00027 3
   Wang XJ, 2005, INT J CANCER, V116, P799, DOI 10.1002/ijc.20880
   WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106
   Wu YJ, 1998, ARTERIOSCL THROM VAS, V18, P481, DOI 10.1161/01.ATV.18.3.481
NR 31
TC 61
Z9 68
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD JUN 30
PY 2006
VL 38
IS 3
BP 256
EP 264
DI 10.1038/emm.2006.31
PG 9
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 062DT
UT WOS:000238925500009
PM 16819284
OA gold
DA 2025 08 17
ER

PT J
AU Lin, NY
   Chen, CW
   Kagwiria, R
   Liang, RF
   Beyer, C
   Distler, A
   Luther, J
   Engelke, K
   Schett, G
   Distler, JHW
AF Lin, Neng Yu
   Chen, Chih Wei
   Kagwiria, Rosebeth
   Liang, Ruifang
   Beyer, Christian
   Distler, Alfiya
   Luther, Julia
   Engelke, Klaus
   Schett, Georg
   Distler, Joerg H. W.
TI Inactivation of autophagy ameliorates glucocorticoid induced and
   ovariectomy induced bone loss
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID DENDRITIC CELLS; RHEUMATOID ARTHRITIS; ACTIVATION; MICE;
   DIFFERENTIATION; CHLOROQUINE; SUPPRESSION; INHIBITION; OSTEOPENIA;
   FIBROSIS
AB Objectives Autophagy has recently been shown to regulate osteoclast activity and osteoclast differentiation. Here, we aim to investigate the impact of autophagy inhibition as a potential therapeutic approach for the treatment of osteoporosis in preclinical models.
   Methods Systemic bone loss was induced in mice by glucocorticoids and by ovariectomy (OVX). Autophagy was targeted by conditional inactivation of autophagyrelated gene 7 (Atg7) and by treatment with chloroquine (CQ). Bone density was evaluated by microCT. The role of autophagy on osteoclastogenesis was analysed by osteoclastogenesis and bone resorption assays. The quantification of receptor activator of nuclear factor kappa B ligand and osteoprotegerin proteins in cocultures was performed using ELISA whereas that of osteoclast and osteoblast differentiation markers was by qPCR.
   Results Selective deletion of Atg7 in monocytes from Atg7(fl/fl)_x_LysM Cre mice mitigated glucocorticoid induced and OVX induced osteoclast differentiation and bone loss compared with Atg7(fl/fl) littermates. Pharmacological inhibition of autophagy by treatment with CQ suppressed glucocorticoid induced osteoclastogenesis and protected mice from bone loss. Similarly, inactivation of autophagy shielded mice from OVX induced bone loss. Inhibition of autophagy led to decreased osteoclast differentiation with lower expression of osteoclast markers such as NFATc1, tartrate resistant acid phosphatase, OSCAR and cathepsin K and attenuated bone resorption in vitro. In contrast, osteoblast differentiation was not affected by inhibition of autophagy.
   Conclusions Pharmacological or genetic inactivation of autophagy ameliorated glucocorticoid induced and OVX induced bone loss by inhibiting osteoclastogenesis. These findings may have direct translational implications for the treatment of osteoporosis, since inhibitors of autophagy such as CQ are already in clinical use.
C1 [Lin, Neng Yu; Chen, Chih Wei; Kagwiria, Rosebeth; Liang, Ruifang; Beyer, Christian; Distler, Alfiya; Luther, Julia; Schett, Georg; Distler, Joerg H. W.] Univ Erlangen Nurnberg, Dept Internal Med 3, D 91054 Erlangen, Germany.
   [Lin, Neng Yu; Chen, Chih Wei; Kagwiria, Rosebeth; Liang, Ruifang; Beyer, Christian; Distler, Alfiya; Luther, Julia; Schett, Georg; Distler, Joerg H. W.] Univ Erlangen Nurnberg, Inst Clin Immunol, D 91054 Erlangen, Germany.
   [Engelke, Klaus] Univ Erlangen Nurnberg, Inst Med Phys, D 91054 Erlangen, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg
RP Distler, JHW (通讯作者)，Univ Erlangen Nurnberg, Dept Internal Med 3, D 91054 Erlangen, Germany.; Distler, JHW (通讯作者)，Univ Erlangen Nurnberg, Inst Clin Immunol, D 91054 Erlangen, Germany.
EM joerg.distler@uk erlangen.de
RI Distler, Oliver/AAE 6225 2019
OI LIN, NENG YU/0000 0003 0746 0483
FU Deutsche Forschungsgemeinschaft [DI 1537/5 1, DI 1537/7 1, DI 1537/8 1,
   DI 1537/9 1, SPP1468]; Interdisciplinary Center of Clinical Research
   (IZKF) in Erlangen [A57]; Ernst Jung Foundation; BMBF; Bavarian Research
   Foundation
FX The study was supported by the Deutsche Forschungsgemeinschaft (grants
   DI 1537/5 1, DI 1537/7 1, DI 1537/8 1, DI 1537/9 1) (Heisenberg
   Professorship to JHWD), the Focus Program SPP1468 (Immunobone) of the
   Deutsche Forschungsgemeinschaft and grant A57 of the Interdisciplinary
   Center of Clinical Research (IZKF) in Erlangen. The study was also
   supported by a carrier support award of the Ernst Jung Foundation (to
   JHWD) and the BMBF project Metarthros. N YL was supported by a doctoral
   scholarship by the Bavarian Research Foundation.
CR Akhmetshina A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1734
   Alnaeeli M, 2009, CURR MOL MED, V9, P893, DOI 10.2174/156652409789105507
   Alnaeeli M, 2007, J BONE MINER RES, V22, P775, DOI 10.1359/JBMR.070314
   Caramés B, 2012, ANN RHEUM DIS, V71, P575, DOI 10.1136/annrheumdis 2011 200557
   Dees C, 2011, J EXP MED, V208, P961, DOI 10.1084/jem.20101629
   Deosaran E, 2013, J CELL SCI, V126, P939, DOI 10.1242/jcs.114819
   Distler JHW, 2011, ANN RHEUM DIS, V70, P1197, DOI 10.1136/ard.2010.140657
   Gayetskyy S, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 298
   Grassi F, 2007, P NATL ACAD SCI USA, V104, P15087, DOI 10.1073/pnas.0703610104
   HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Kato M, 2014, ARTHRITIS RHEUMATOL, V66, P40, DOI 10.1002/art.38190
   Lakshminarayanan S, 2001, J RHEUMATOL, V28, P102
   Leibson CL, 2002, J AM GERIATR SOC, V50, P1644, DOI 10.1046/j.1532 5415.2002.50455.x
   Lin NY, 2013, ANN RHEUM DIS, V72, P761, DOI 10.1136/annrheumdis 2012 201671
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mardakheh FK, 2010, MOL CELL BIOL, V30, P5672, DOI 10.1128/MCB.00878 10
   McLaughlin F, 2002, BONE, V30, P924, DOI 10.1016/S8756 3282(02)00737 8
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mok C. C., 2005, Lupus, V14, P106, DOI 10.1191/0961203305lu2039oa
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Rizzoli R, 2015, NAT REV RHEUMATOL, V11, P98, DOI 10.1038/nrrheum.2014.188
   Sasaki H, 2012, ARTHRITIS RHEUM US, V64, P1920, DOI 10.1002/art.34323
   Scholtysek C, 2013, NAT MED, V19, P608, DOI 10.1038/nm.3146
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078 0432.CCR 12 1542
   Strom O, 2011, Arch Osteoporos, V6, P59, DOI 10.1007/s11657 011 0060 1
   Thome R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065913
   Vyas AR, 2013, CANCER RES, V73, P5985, DOI 10.1158/0008 5472.CAN 13 0755
   Wakkach A, 2008, BLOOD, V112, P5074, DOI 10.1182/blood 2008 01 132787
   Whitehouse CA, 2010, P NATL ACAD SCI USA, V107, P12913, DOI 10.1073/pnas.0913058107
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Zhang Y, 2009, P NATL ACAD SCI USA, V106, P19860, DOI 10.1073/pnas.0906048106
   Zhang YT, 2014, ENDOCRINE, V47, P598, DOI 10.1007/s12020 014 0196 z
NR 34
TC 103
Z9 122
U1 1
U2 23
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003 4967
EI 1468 2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2016
VL 75
IS 6
BP 1203
EP 1210
DI 10.1136/annrheumdis 2015 207240
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA DM6DP
UT WOS:000376440900041
PM 26113650
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Liao, JC
   Wei, ZX
   Zhao, C
   Ma, ZP
   Cai, DZ
AF Liao, Jia Cheng
   Wei, Zhao Xia
   Zhao, Chang
   Ma, Zhong Ping
   Cai, Dao Zhang
TI Inhibition of osteoclastogenesis for periprosthetic osteolysis therapy
   through the suppression of p38 signaling by fraxetin
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE osteoclasts; osteolytic disease; fraxetin; p38 signaling; periprosthetic
   osteolysis
ID C FOS; TITANIUM PARTICLES; GENE EXPRESSION; WEAR PARTICLES; TIALV WEAR;
   IN VIVO; INDUCTION; ACTIVATION; NFATC1; DIFFERENTIATION
AB Periprosthetic osteolysis belongs to osteolytic diseases, which often occur due to an imbalance between osteoclast and osteoblast number or activity. Fraxetin, a natural plant extract, inhibits osteoblast apoptosis and has therapeutic potential for treating osteolytic diseases. However, data pertaining to the effects of fraxetin on osteoclasts are limited. In the present study, it was demonstrated that the inhibition of osteoclastogenesis by fraxetin had an important role on the therapy of titanium particle induced osteolysis in vivo. In addition, fraxetin was demonstrated to suppress receptor activator of nuclear factor kappa B ligand (RANKL) mediated osteoclast differentiation and bone resorption in vitro in a dose dependent manner. Fraxetin inhibited osteoclast differentiation and function through the suppression of p38 signaling and subsequently, the suppression of osteoclast specific gene expression, including tartrate resistant acid phosphatase, nuclear factor of activated T cells, cytoplasmic 1, and cathepsin K. In conclusion, fraxetin administration may have potential as a treatment method for periprosthetic osteolysis and other osteolytic diseases.
C1 [Liao, Jia Cheng] Southern Med Univ, Affiliated Peoples Hosp Longhua Dist Shenzhen, Dept Orthoped, Shenzhen 518109, Guangdong, Peoples R China.
   [Wei, Zhao Xia] Guangzhou Med Univ, Affiliated Hosp 3, Liwan Hosp, Dept Neurol, Guangzhou 510000, Guangdong, Peoples R China.
   [Zhao, Chang] Southern Med Univ, Affiliated Hosp 3, Dept Orthoped, Guangzhou 510630, Guangdong, Peoples R China.
   [Ma, Zhong Ping] Inner Mongolia Med Univ, Affiliated Hosp 2, Dept Orthoped, Hohhot 510030, Inner Mongolia, Peoples R China.
   [Cai, Dao Zhang] Southern Med Univ, Affiliated Hosp 3, Dept Orthoped, West 183 Zhongshan Rd, Guangzhou 510630, Guangdong, Peoples R China.
C3 Southern Medical University   China; Guangzhou Medical University;
   Southern Medical University   China; Inner Mongolia Medical University;
   Southern Medical University   China
RP Cai, DZ (通讯作者)，Southern Med Univ, Affiliated Hosp 3, Dept Orthoped, West 183 Zhongshan Rd, Guangzhou 510630, Guangdong, Peoples R China.
EM cai_dz1962@126.com
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Baumann B, 2005, J ORTHOP RES, V23, P1241, DOI 10.1016/j.orthres.2005.02.017
   Baumann B, 2004, ACTA ORTHOP SCAND, V75, P295, DOI 10.1080/00016470410001222
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844
   Helfrich MH, 2005, ARCH ORAL BIOL, V50, P115, DOI 10.1016/j.archoralbio.2004.11.016
   Hirakawa K, 1996, J BIOMED MATER RES, V31, P257, DOI 10.1002/(SICI)1097 4636(199606)31:2<257::AID JBM13>3.0.CO;2 I
   Holt G, 2007, CLIN ORTHOP RELAT R, P240, DOI 10.1097/BLO.0b013e31804b4147
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Jin S, 2011, EXP MOL MED, V43, P411, DOI 10.3858/emm.2011.43.7.045
   Kuo PL, 2006, INT IMMUNOPHARMACOL, V6, P1167, DOI 10.1016/j.intimp.2006.02.010
   Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011
   Lee SS, 2003, CELL SIGNAL, V15, P339, DOI 10.1016/S0898 6568(02)00118 3
   Lin CX, 2018, J CELL PHYSIOL, V233, P6135, DOI 10.1002/jcp.26460
   Liu FX, 2009, BIOMATERIALS, V30, P1756, DOI 10.1016/j.biomaterials.2008.12.018
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Long M, 1998, BIOMATERIALS, V19, P1621, DOI 10.1016/S0142 9612(97)00146 4
   Lucas JJ, 1998, J NEUROSCI, V18, P5537, DOI 10.1523/JNEUROSCI.18 14 05537.1998
   Masui T, 2005, BIOMATERIALS, V26, P1695, DOI 10.1016/j.biomaterials.2004.05.017
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Murali R, 2013, BIOCHIMIE, V95, P1848, DOI 10.1016/j.biochi.2013.06.013
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sharma SM, 2007, J BIOL CHEM, V282, P15921, DOI 10.1074/jbc.M609723200
   Stevenson DA, 2011, CLIN GENET, V80, P566, DOI 10.1111/j.1399 0004.2010.01619.x
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
   Witaicenis A, 2014, PHYTOMEDICINE, V21, P240, DOI 10.1016/j.phymed.2013.09.001
   Zwerina J, 2006, ARTHRITIS RHEUM US, V54, P463, DOI 10.1002/art.21626
NR 37
TC 12
Z9 12
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD SEP
PY 2018
VL 42
IS 3
BP 1257
EP 1264
DI 10.3892/ijmm.2018.3698
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GW4IE
UT WOS:000446875200006
PM 29786751
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Wu, HJ
   Guo, BW
   Zhong, HF
   Ying, H
AF Wu, Haijian
   Guo, Bowen
   Zhong, Hongfa
   Ying, Hui
TI Natural drug asiaticoside inhibits osteoclast differentiation and
   promotes repair of steroid induced osteonecrosis of femoral head via
   RANKL pathway
SO MATERIALS EXPRESS
LA English
DT Article
DE Asiaticoside; RANKL; Osteoclasts; Steroid Induced Necrosis of the
   Femoral Head
ID CENTELLA ASIATICA; RECEPTOR ACTIVATOR; CELLS; EXPRESSION; KINASE; ERK
AB Asiaticoside is one of the most classic traditional Chinese medicines. The interaction between Receptor activator of nuclear factor KB (RANK) and Receptor Activator of Nuclear Factor  K B Ligand (RANKL) activates a series of intracellular signaling pathways. Our research explored the mechanism of asiaticoside inhibiting osteoclast differentiation and repair of steroid induced osteonecrosis of femoral head (SIONFH) through IP: 127 0.0.1 On: Tue, 21 Nov 2023 06:33:19 RANKL pathway. Asiaticoside's effecton oseoclasts was determined by Microneedle Therapy System (MTS) Copyr ght: American Scientific Pub ishers method, and the number of Tartrate resistant acid phosphatase (TRAcP) multinucleated cells (3 nuclei)Delvered by Ingenta was quantitatively analyzed. Under different dose treatments, the changes of bone function were detected by eroded area and TRAcP staining on hydroxyapatite coated plate, and the expression of different osteocyte formation and osteogenic differentiation were detected. Asiaticoside weakened the osteoclast function induced by RANKL. When the concentration of asiaticoside was 10 mu mol/L, osteoclast formation regulatory genes (NFATc1 and Acp5) and osteoclast cell function related genes (AP 1 and P65) were significantly down  regulated in the presence of RANKL. Asiaticoside (10 mu mol/L) significantly decreased calcium oscillations induced by RANKL via preventing RANKL mediated NF  KB activation and Ca2+ oscillation.
C1 [Wu, Haijian; Guo, Bowen; Zhong, Hongfa; Ying, Hui] Ganzhou Peoples Hosp, Dept Trauma Emergency Ctr, Ganzhou 341000, Jiangxi, Peoples R China.
RP Wu, HJ (通讯作者)，Ganzhou Peoples Hosp, Dept Trauma Emergency Ctr, Ganzhou 341000, Jiangxi, Peoples R China.
FU Jiangxi Provincial Health Com mission Science and Technology Plan
   Project [202212445]
FX Acknowledgments: Jiangxi Provincial Health Com mission Science and
   Technology Plan Project (No. 202212445) .
CR Bent S, 2008, J GEN INTERN MED, V23, P854, DOI 10.1007/s11606 008 0632 y
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Bradford JW, 2014, ADV CANCER RES, V121, P125, DOI 10.1016/B978 0 12 800249 0.00003 2
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chen K, 2020, INT J BIOL SCI, V16, P1888, DOI 10.7150/ijbs.40917
   Cheng JW, 2018, J CELL PHYSIOL, V233, P2502, DOI 10.1002/jcp.26126
   Dou C, 2016, OSTEOPOROSIS INT, V27, P2335, DOI 10.1007/s00198 016 3496 8
   Fu WM, 2019, INT ORTHOP, V43, P1083, DOI 10.1007/s00264 018 4011 y
   Gohil KJ, 2010, INDIAN J PHARM SCI, V72, P546, DOI 10.4103/0250 474X.78519
   Gray NE, 2018, PHYTOCHEM REV, V17, P161, DOI 10.1007/s11101 017 9528 y
   Ito S, 2014, MOD RHEUMATOL, V24, P52, DOI 10.3109/14397595.2013.852855
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Li ZR, 2018, J ORTHOP TRANSL, V12, P36, DOI 10.1016/j.jot.2017.11.001
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Peng B, 2015, ENDOCRINOLOGY, V156, P2269, DOI 10.1210/en.2014 1871
   Pengjam Y, 2016, BIOMOL THER, V24, P123, DOI 10.4062/biomolther.2015.106
   Shedoeva A, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/2684108
   Shin HY, 2021, APPL BIOL CHEM, V64, DOI 10.1186/s13765 021 00656 9
   Song DZ, 2018, ARCH BIOCHEM BIOPHYS, V647, P76, DOI 10.1016/j.abb.2018.04.011
   Song DZ, 2018, J CELL BIOCHEM, V119, P4826, DOI 10.1002/jcb.26682
   Steinboeck F, 2005, CELL MOL NEUROBIOL, V25, P1151, DOI 10.1007/s10571 005 8503 0
   Vega D, 2007, J CLIN ENDOCR METAB, V92, P4514, DOI 10.1210/jc.2007 0646
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wang L, 2019, RSC ADV, V9, P38438, DOI 10.1039/c9ra07240c
   Wei QS, 2017, BIOMED PHARMACOTHER, V91, P581, DOI 10.1016/j.biopha.2017.04.019
NR 27
TC 0
Z9 0
U1 0
U2 7
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2158 5849
EI 2158 5857
J9 MATER EXPRESS
JI Mater. Express
PD NOV
PY 2023
VL 13
IS 11
BP 1855
EP 1861
DI 10.1166/mex.2023.2536
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA Z1YZ9
UT WOS:001110119500003
DA 2025 08 17
ER

PT J
AU Ma, XJ
   Liu, YP
   Zhang, Y
   Yu, XB
   Wang, WM
   Zhao, DW
AF Ma, Xiaojun
   Liu, Yupeng
   Zhang, Yao
   Yu, Xiaobing
   Wang, Weiming
   Zhao, Dewei
TI Jolkinolide B inhibits RANKL induced osteoclastokenesis by suppressing
   the activation NF κB and MAPK signaling pathways
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Jolkinolide B; Osteoclast; Bone resorption; NF kappa B; MAPKs
ID TRAP GENE PROMOTER; C FOS; RECEPTOR ACTIVATOR; DIFFERENTIATION;
   EXPRESSION; CELLS; JUN; OSTEOCLASTOGENESIS; APOPTOSIS; FAMILY
AB Osteoclasts together with osteoblasts play pivotal roles in bone remodeling. The unique function and ability of osteoclasts to resorb bone makes them critical in both normal bone homeostasis and pathologic bone diseases such as osteoporosis and rheumatoid arthritis. Thus, new compounds that may inhibit osteoclastogenesis and osteoclast function may be of great value in the treatment of osteoclast related diseases. In the present study, we examined the effect of jolkinolide B (JB), isolated from the root of Euphorbia fischeriana Steud on receptor activator of NF kappa B ligand (RANKL) induced osteoclast formation. We found that JB inhibited RANKL induced osteoclast differentiation from bone marrow macrophages (BMMs) without cytotoxicity. Furthermore, the expression of osteoclastic marker genes, such as tartrate resistant acid phosphatase (TRAP), cathepsin K (CtsK), and calcitonin receptor (CTR), was significantly inhibited. JB inhibited RANKL induced activation of NF kappa B by suppressing RANKL mediated I kappa B alpha degradation. Moreover, JB inhibited RANKL induced phosphorylation of mitogen activated protein kinases (p38, JNK, and ERK). This study thus identifies JB as an inhibitor of osteoclast formation and provides evidence that JB might be an alternative Medicine for preventing and treating osteolysis. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Ma, Xiaojun; Liu, Yupeng; Zhang, Yao; Yu, Xiaobing; Wang, Weiming; Zhao, Dewei] Dalian Univ, Dept Orthopaed, Affiliated Zhongshan Hosp, Dalian 116001, Liaoning Provin, Peoples R China.
C3 Dalian University
RP Wang, WM (通讯作者)，Dalian Univ, Dept Orthopaed, Affiliated Zhongshan Hosp, 6 Jiefang St, Dalian 116001, Liaoning Provin, Peoples R China.
EM oldpal@126.com; ZhaoDW0058@126.com
RI Liu, Yupeng/P 3181 2018; ma, xiaojun/MFH 4215 2025; Zhao,
   Dewei/G 8369 2016
FU national natural science fundation of china [30770531]
FX This research was supported by national natural science fundation of
   china (30770531).
CR Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   Anusaksathien O, 2001, J BIOL CHEM, V276, P22663, DOI 10.1074/jbc.M007104200
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choi HJ, 2010, EUR J PHARMACOL, V636, P28, DOI 10.1016/j.ejphar.2010.03.023
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Ghosh Sankar K.M., 2002, CELL S, V109, P81
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kogawa M, 2013, J BIOL CHEM, V288, P31299, DOI 10.1074/jbc.M113.461848
   Lee Z.H., 2003, BIOCH BIOPHYS RES CO, V305
   Lin Y, 2012, ONCOL REP, V27, P1976, DOI 10.3892/or.2012.1717
   Liu WK, 2002, BIOCHEM PHARMACOL, V63, P951, DOI 10.1016/S0006 2952(01)00938 8
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Mohamed SGK, 2007, BONE, V41, P592, DOI 10.1016/j.bone.2007.05.016
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Uto T, 2012, INT IMMUNOPHARMACOL, V12, P101, DOI 10.1016/j.intimp.2011.10.020
   Wang JH, 2011, MOL CELLS, V32, P451, DOI 10.1007/s10059 011 0137 0
   Weber TJ, 2003, MOL PHARMACOL, V63, P1075, DOI 10.1124/mol.63.5.1075
   Xu HY, 2013, ONCOL REP, V29, P212, DOI 10.3892/or.2012.2113
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Zou W, 2013, MOL CELL BIOL, V33, P830, DOI 10.1128/MCB.00790 12
NR 32
TC 31
Z9 42
U1 1
U2 33
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 7
PY 2014
VL 445
IS 2
BP 282
EP 288
DI 10.1016/j.bbrc.2014.01.145
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AD4NV
UT WOS:000333228700003
PM 24491533
DA 2025 08 17
ER

PT J
AU Reagan, MR
   Mishima, Y
   Glavey, SV
   Zhang, Y
   Manier, S
   Lu, ZN
   Memarzadeh, M
   Zhang, Y
   Sacco, A
   Aljawai, Y
   Shi, JT
   Tai, YT
   Ready, JE
   Kaplan, DL
   Roccaro, AM
   Ghobrial, IM
AF Reagan, Michaela R.
   Mishima, Yuji
   Glavey, Siobhan V.
   Zhang, Yong
   Manier, Salomon
   Lu, Zhi Ning
   Memarzadeh, Masoumeh
   Zhang, Yu
   Sacco, Antonio
   Aljawai, Yosra
   Shi, Jiantao
   Tai, Yu Tzu
   Ready, John E.
   Kaplan, David L.
   Roccaro, Aldo M.
   Ghobrial, Irene M.
TI Investigating osteogenic differentiation in multiple myeloma using a
   novel 3D bone marrow niche model
SO BLOOD
LA English
DT Article
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; STROMAL CELLS;
   EXPRESSION; DISEASE; MICROENVIRONMENT; BISPHOSPHONATES; MECHANISMS;
   ADHESION; THERAPY
AB Clonal proliferation of plasma cells within the bone marrow (BM) affects local cells, such as mesenchymal stromal cells (MSCs), leading to osteolysis and fatality in multiple myeloma (MM). Consequently, there is an urgent need to find better mechanisms of inhibiting myeloma growth and osteolytic lesion development. To meet this need and accelerate clinical translation, better models of myeloma within the BM are required. Herein we have developed a clinically relevant, three dimensional (3D) myeloma BM coculture model that mimics bone cell/cancer cell interactions within the bone microenvironment. The coculture model and clinical samples were used to investigate myeloma growth, osteogenesis inhibition, and myeloma induced abnormalities in MM MSCs. This platform demonstrated myeloma support of capillarylike assembly of endothelial cells and cell adhesion mediated drug resistance (CAM DR). Also, distinct normal donor (ND)and MM MSC miRNA (miR) signatures were identified and used to uncover osteogenic miRs of interest for osteoblast differentiation. More broadly, our 3D platform provides a simple, clinically relevant tool to model cancer growth within the bone useful for investigating skeletal cancer biology, screening compounds, and exploring osteogenesis. Our identification and efficacy validation of novel bone anabolic miRs in MM opens more opportunities for novel approaches to cancer therapy via stromal miR modulation.
C1 [Reagan, Michaela R.; Mishima, Yuji; Glavey, Siobhan V.; Zhang, Yong; Manier, Salomon; Lu, Zhi Ning; Memarzadeh, Masoumeh; Zhang, Yu; Sacco, Antonio; Aljawai, Yosra; Tai, Yu Tzu; Ready, John E.; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Shi, Jiantao] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Ready, John E.] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.
C3 Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Dana Farber Cancer Institute; Harvard University; Harvard
   T.H. Chan School of Public Health; Harvard University; Harvard
   University Medical Affiliates; Brigham & Women's Hospital; Tufts
   University
RP Ghobrial, IM (通讯作者)，Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA.
EM Irene_ghobrial@dfci.harvard.edu
RI ; Sacco, Antonio/K 4681 2016; Manier, Salomon/N 5976 2017; Roccaro,
   Aldo/AAA 8957 2022; Reagan, Michaela/E 3549 2017
OI Ghobrial, Irene/0000 0001 7361 3092; Kaplan, David/0000 0002 9245 7774;
   Roccaro, Aldo/0000 0002 1872 5128; Sacco, Antonio/0000 0003 2945 9416;
   Reagan, Michaela/0000 0003 2884 6481; Li, pengcheng/0009 0004 6334 051X;
   
FU Department of Defense, Peer review Cancer Research Program
   [W81WH 13 1 0390]; National Institutes of Health P41 Center [EB002520];
   National Cancer Institute [R01CA154648]
FX This study was supported by the Department of Defense, Peer review
   Cancer Research Program (W81WH 13 1 0390), the National Institutes of
   Health P41 Center (EB002520) and National Cancer Institute grant
   R01CA154648.
CR Azab AK, 2012, BLOOD, V119, P1468, DOI 10.1182/blood 2011 07 368050
   Azab AK, 2009, BLOOD, V113, P4341, DOI 10.1182/blood 2008 10 186668
   Baker BM, 2012, J CELL SCI, V125, P3015, DOI 10.1242/jcs.079509
   Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Ferrarini M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071613
   Fuhler GM, 2010, EXP CELL RES, V316, P1816, DOI 10.1016/j.yexcr.2010.03.013
   Gonsalves CS, 2010, J IMMUNOL, V184, P3878, DOI 10.4049/jimmunol.0902594
   Gu S, 2013, 63 ANN M AM SOC HUM
   Gu S, 2012, INT J MOL SCI, V13, P8449, DOI 10.3390/ijms13078449
   Gu ZJ, 2000, LEUKEMIA, V14, P188, DOI 10.1038/sj.leu.2401632
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Hughes V, 2011, NATURE, V480, pS48, DOI 10.1038/480S48a
   Jullien N, 2012, J CELL BIOCHEM, V113, P2047, DOI 10.1002/jcb.24076
   Kirshner J, 2008, BLOOD, V112, P2935, DOI 10.1182/blood 2008 02 142430
   Lau E, 2011, J ORTHOP RES, V29, P1075, DOI 10.1002/jor.21334
   Lee DY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004527
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li BJ, 2013, SCI REP UK, V3, DOI 10.1038/srep02425
   Lin EA, 2009, J BIOL CHEM, V284, P11326, DOI 10.1074/jbc.M807709200
   Mandal BB, 2012, P NATL ACAD SCI USA, V109, P7699, DOI 10.1073/pnas.1119474109
   Marcucci G, 2013, J CLIN ONCOL, V31, P2086, DOI 10.1200/JCO.2012.45.6228
   Markovina S, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 176
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Oskowitz AZ, 2008, P NATL ACAD SCI USA, V105, P18372, DOI 10.1073/pnas.0809807105
   Pennisi A, 2009, BLOOD, V114, P1803, DOI 10.1182/blood 2009 01 201954
   Pozzi S, 2011, ONCOLOGIST, V16, P651, DOI 10.1634/theoncologist.2010 0225
   Reagan MR, 2012, J BREAST CANCER, V15, P273, DOI 10.4048/jbc.2012.15.3.273
   Reagan MR, 2012, CLIN CANCER RES, V18, P342, DOI 10.1158/1078 0432.CCR 11 2212
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   SPIRA G, 1994, INT J CLIN LAB RES, V24, P1, DOI 10.1007/BF02592402
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takeuchi K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009870
   Tamama K, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/795385
   Vallet S, 2011, CANCER MICROENVIRON, V4, P339, DOI 10.1007/s12307 011 0090 7
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Wada N, 2014, STEM CELLS DEV
   Xu S, 2012, LEUKEMIA, V26, P2546, DOI 10.1038/leu.2012.126
   Xu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079752
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Zangari M, 2012, CANCER TREAT REV, V38, P968, DOI 10.1016/j.ctrv.2011.12.007
   Zdzisinska B, 2009, FOLIA HISTOCHEM CYTO, V47, P69, DOI 10.2478/v10042 009 0015 1
NR 46
TC 94
Z9 101
U1 0
U2 22
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD NOV 20
PY 2014
VL 124
IS 22
BP 3250
EP 3259
DI 10.1182/blood 2014 02 558007
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA AY3CW
UT WOS:000347463100014
PM 25205118
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Lee, SY
   Kim, GT
   Yun, HM
   Kim, YC
   Kwon, IK
   Kim, EC
AF Lee, So Youn
   Kim, Gyu Tae
   Yun, Hyung Mun
   Kim, Youn Chul
   Kwon, Il Keun
   Kim, Eun Cheol
TI Tectorigenin Promotes Osteoblast Differentiation and in vivo Bone
   Healing, but Suppresses Osteoclast Differentiation and in vivo
   Bone Resorption
SO MOLECULES AND CELLS
LA English
DT Article
DE bone remodeling; differentiation; osteoblast; osteoclast; tectorigenin
ID PERIODONTAL LIGAMENT CELLS; INFLAMMATORY RESPONSES; RAW 264.7;
   OSTEOPOROSIS; INHIBITION; EXPRESSION; TECTORIDIN; INDUCTION; THERAPIES;
   NICOTINE
AB Although tectorigenin (TG), a major compound in the rhizome of Belamcanda chinensis, is conventionally used for the treatment of inflammatory diseases, its effects on osteogenesis and osteoclastogenesis have not been reported. The objective of this study was to investigate the effects and possible underlying mechanism of TG on in vitro osteoblastic differentiation and in vivo bone formation, as well as in vitro osteoclast differentiation and in vivo bone resorption. TG promoted the osteogenic differentiation of primary osteoblasts and periodontal ligament cells. Moreover, TG upregulated the expression of the BMP2, BMP4, and Smad 4 genes, and enhanced the expression of Runx2 and Osterix. In vivo studies involving mouse calvarial bone defects with mu CT and histologic analysis revealed that TG significantly increased new bone formation. Furthermore, TG treatment inhibited osteoclast differentiation and the mRNA levels of osteoclast markers. In vivo studies of mice demonstrated that TG caused the marked attenuation of bone resorption. These results collectively demonstrated that TG stimulated osteogenic differentiation in vitro, increased in vivo bone regeneration, inhibited osteoclast differentiation in vitro, and suppressed inflammatory bone loss in vivo. These novel findings suggest that TG may be useful for bone regeneration and treatment of bone diseases.
C1 [Lee, So Youn; Yun, Hyung Mun; Kim, Eun Cheol] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02453, South Korea.
   [Kim, Gyu Tae] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Radiol, Seoul 02453, South Korea.
   [Kim, Youn Chul] Wonkwang Univ, Coll Pharm, Inst Pharmaceut Res & Dev, Iksan 00000, South Korea.
   [Kwon, Il Keun] Kyung Hee Univ, Sch Dent, Dept Dent Mat, Seoul 02453, South Korea.
C3 Kyung Hee University; Kyung Hee University; Wonkwang University; Kyung
   Hee University
RP Kim, EC (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02453, South Korea.
EM eckim@khu.ac.kr
RI ; Kim, Cheorl Ho/T 6753 2019
OI Kim, Gyu Tae/0000 0002 2075 3136; Kwon, Il Keun/0000 0001 9649 3003; 
FU Bio & Medical Technology Development Program of the National Research
   Foundation (NRF); Korean government (MSIP) [2017M3A9E4048170]; Korean
   government (MOHW) [2017M3A9E4048170]
FX This research was supported by the Bio & Medical Technology Development
   Program of the National Research Foundation (NRF) & funded by the Korean
   government (MSIP&MOHW) (No. 2017M3A9E4048170).
CR Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Bae WJ, 2015, J CELL BIOCHEM, V116, P1241, DOI 10.1002/jcb.25078
   Chen KM, 2005, PHARMAZIE, V60, P939
   Dastmalchi M, 2015, PROTEOMICS, V15, P1646, DOI 10.1002/pmic.201400444
   Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194
   Ferretti M, 2010, J ANAT, V217, P48, DOI 10.1111/j.1469 7580.2010.01242.x
   Han T, 2012, FOOD CHEM TOXICOL, V50, P409, DOI 10.1016/j.fct.2011.10.066
   HERR Y, 1995, J PERIODONTOL, V66, P716, DOI 10.1902/jop.1995.66.8.716
   Jeong GilSaeng Jeong GilSaeng, 2007, Natural Product Sciences, V13, P101
   Kapoor S, 2013, IMMUNOPHARM IMMUNOT, V35, P533, DOI 10.3109/08923973.2013.799685
   Kim HH, 2004, BIOCHEM PHARMACOL, V67, P1647, DOI 10.1016/j.bcp.2003.12.031
   Kim HK, 1999, BIOCHEM PHARMACOL, V58, P759, DOI 10.1016/S0006 2952(99)00160 4
   Kim T. J., 1996, KOREAN RESOURCES PLA, V2, P322
   Kim YP, 1999, BBA MOL CELL BIOL L, V1438, P399, DOI 10.1016/S1388 1981(99)00067 0
   Kitagawa M, 2006, BIOCHEM BIOPH RES CO, V349, P1050, DOI 10.1016/j.bbrc.2006.08.142
   Ha LM, 2013, IMMUNOPHARM IMMUNOT, V35, P336, DOI 10.3109/08923973.2013.770521
   Lee KT, 2001, BIOL PHARM BULL, V24, P1117, DOI 10.1248/bpb.24.1117
   Lee SI, 2015, DIFFERENTIATION, V90, P16, DOI 10.1016/j.diff.2015.08.003
   Lee SK, 2013, J CELL BIOCHEM, V114, P1183, DOI 10.1002/jcb.24461
   Li QY, 2015, PHARM BIOL, V53, P1567, DOI 10.3109/13880209.2014.993038
   Liu MC, 2012, MOLECULES, V17, P6156, DOI 10.3390/molecules17056156
   Ma CH, 2014, CHIN J NAT MEDICINES, V12, P841, DOI 10.1016/S1875 5364(14)60126 6
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Muraki Shigeyuki, 2014, Clin Calcium, V24, P679, DOI CliCa1405679684
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Pan CH, 2008, ARCH PHARM RES, V31, P1447, DOI 10.1007/s12272 001 2129 7
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Shin SY, 2015, J PERIODONTOL, V86, P1405, DOI 10.1902/jop.2015.150123
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tao XF, 2016, PHARMACOL RES, V108, P90, DOI 10.1016/j.phrs.2016.05.003
   Thelen P, 2005, CARCINOGENESIS, V26, P1360, DOI 10.1093/carcin/bgi092
   Wang T, 2015, BIOCHEM BIOPH RES CO, V466, P232, DOI 10.1016/j.bbrc.2015.09.014
   Wu JH, 2010, WORLD J GASTROENTERO, V16, P3911, DOI 10.3748/wjg.v16.i31.3911
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Yang YI, 2012, CARCINOGENESIS, V33, P2488, DOI 10.1093/carcin/bgs302
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
NR 38
TC 14
Z9 14
U1 0
U2 8
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635 4, YUCKSAM DONG, GANGNAM GU, SEOUL 135 703, SOUTH KOREA
SN 1016 8478
EI 0219 1032
J9 MOL CELLS
JI Mol. Cells
PD MAY
PY 2018
VL 41
IS 5
BP 476
EP 485
DI 10.14348/molcells.2018.0056
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GI1LH
UT WOS:000434131500011
PM 29764006
DA 2025 08 17
ER

PT J
AU Li, LJ
   Li, CH
   Chang, PMH
   Lai, TC
   Yong, CY
   Feng, SW
   Hsiao, MC
   Chang, WM
   Huang, CYF
AF Li, Li Jie
   Li, Chien Hsiu
   Chang, Peter Mu Hsin
   Lai, Tsung Ching
   Yong, Chen Yin
   Feng, Sheng Wei
   Hsiao, Michael
   Chang, Wei Min
   Huang, Chi Ying F.
TI Dehydroepiandrosterone (DHEA) Sensitizes Irinotecan to Suppress Head and
   Neck Cancer Stem Like Cells by Downregulation of WNT Signaling
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE dehydroepiandrosterone; head and neck squamous cell carcinoma; WNT;
   stemness; irinotecan
ID SQUAMOUS CARCINOMA; BONE MARROW; PROLIFERATION; INHIBITION; GROWTH;
   DEATH; COMBINATION; RECURRENT; PROMOTE; PATHWAY
AB PurposeCurrent treatment options for head and neck squamous cell carcinoma (HNSCC) are limited, especially for cases with cancer stem cell induced chemoresistance and recurrence. The WNT signaling pathway contributes to maintenance of stemness via translocation of beta catenin into the nucleus, and represents a promising druggable target in HNSCC. Dehydroepiandrosterone (DHEA), a steroid hormone, has potential as an anticancer drug. However, the potential anticancer mechanisms of DHEA including inhibition of stemness, and its therapeutic applications in HNSCC remain unclear. MethodsFirstly, SRB assay and sphere formation assay were used to examine cellular viability and cancer stem cell like phenotype, respectively. The expressions of stemness related factors were measured by RT qPCR and western blotting. The luciferase reporter assay was applied to evaluate transcriptional potential of stemness related pathways. The alternations of WNT signaling pathway were measured by nuclear translocation of beta catenin, RT qPCR and western blotting. Furthermore, to investigate the effect of drugs in vivo, both HNSCC orthotopic and subcutaneous xenograft mouse models were applied. ResultsWe found that DHEA reduced HNSCC cell viability, suppressed sphere formation, and inhibited the expression of cancer stemness markers, such as BMI 1 and Nestin. Moreover, DHEA repressed the transcriptional activity of stemness related pathways. In the WNT pathway, DHEA reduced the nuclear translocation of the active form of beta catenin and reduced the protein expression of the downstream targets, CCND1 and CD44. Furthermore, when combined with the chemotherapeutic drug, irinotecan (IRN), DHEA enhanced the sensitivity of HNSCC cells to IRN as revealed by reduced cell viability, sphere formation, expression of stemness markers, and activation of the WNT pathway. Additionally, this combination reduced in vivo tumor growth in both orthotopic and subcutaneous xenograft mouse models. ConclusionThese findings indicate that DHEA has anti stemness potential in HNSCC and serves as a promising anticancer agent. The combination of DHEA and IRN may provide a potential therapeutic strategy for patients with advanced HNSCC.
C1 [Li, Li Jie] Taipei Med Univ, Coll Oral Med, PhD Program, Sch Dent, Taipei, Taiwan.
   [Li, Li Jie; Chang, Peter Mu Hsin; Huang, Chi Ying F.] Natl Yang Ming Chiao Tung Univ, Inst Biopharmaceut Sci, Taipei, Taiwan.
   [Li, Chien Hsiu; Lai, Tsung Ching; Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei, Taiwan.
   [Chang, Peter Mu Hsin] Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan.
   [Chang, Peter Mu Hsin] Natl Yang Ming Chiao Tung Univ, Fac Med, Taipei, Taiwan.
   [Lai, Tsung Ching] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Pulm Med, Taipei, Taiwan.
   [Yong, Chen Yin] Taipei Med Univ, Wan Fang Hosp, Dept Dent, Div Oral & Maxillofacial Surg, Taipei, Taiwan.
   [Feng, Sheng Wei] Taipei Med Univ, Coll Oral Med, Sch Dent, Taipei, Taiwan.
   [Feng, Sheng Wei] Taipei Med Univ Hosp, Dept Dent, Div Prosthodont, Taipei, Taiwan.
   [Hsiao, Michael; Huang, Chi Ying F.] Kaohsiung Med Univ, Coll Med, Dept Biochem, Kaohsiung, Taiwan.
   [Chang, Wei Min] Taipei Med Univ, Coll Oral Med, Sch Oral Hyg, Taipei, Taiwan.
C3 Taipei Medical University; National Yang Ming Chiao Tung University;
   Academia Sinica   Taiwan; Taipei Veterans General Hospital; National
   Yang Ming Chiao Tung University; Taipei Municipal WanFang Hospital;
   Taipei Medical University; Taipei Medical University; Taipei Municipal
   WanFang Hospital; Taipei Medical University; Taipei Medical University
   Hospital; Taipei Medical University; Kaohsiung Medical University;
   Taipei Medical University
RP Huang, CYF (通讯作者)，Natl Yang Ming Chiao Tung Univ, Inst Biopharmaceut Sci, Taipei, Taiwan.; Huang, CYF (通讯作者)，Kaohsiung Med Univ, Coll Med, Dept Biochem, Kaohsiung, Taiwan.; Chang, WM (通讯作者)，Taipei Med Univ, Coll Oral Med, Sch Oral Hyg, Taipei, Taiwan.
EM weiminchang@tmu.edu.tw; cyhuang5@nycu.edu.tw
RI Li, Chien Hsiu/AAV 7240 2020; Huang, Chi Ying/AFL 7729 2022; Lai,
   Tsung Ching/AAQ 9967 2021; Chang, Weimin/AAP 2883 2020; Hsiao,
   Michael/U 6238 2019
OI Li, Chien Hsiu/0000 0002 4648 3744; Huang, Chi Ying
   F/0000 0003 4898 4937; 
CR Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Catalina F, 2003, EXP BIOL MED, V228, P1303, DOI 10.1177/153537020322801109
   Chang JC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004766
   Chang WM, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1256 2
   Chang WM, 2017, SCI REP UK, V7, DOI 10.1038/srep41131
   Chang WM, 2016, CANCER RES, V76, P7140, DOI 10.1158/0008 5472.CAN 16 1188
   Chen SC, 2016, ONCOLOGIST, V21, P537, DOI 10.1634/theoncologist.2015 0515
   Chen SJ, 2018, CANCER BIOL THER, V19, P153, DOI 10.1080/15384047.2017.1414754
   Chen WC, 2016, INT J MED SCI, V13, P730, DOI 10.7150/ijms.16132
   Chikazawa N, 2010, ANTICANCER RES, V30, P2041
   Chinn Steven B, 2012, Front Endocrinol (Lausanne), V3, P90, DOI 10.3389/fendo.2012.00090
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008 5472.CAN 09 1947
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Colín Val Z, 2017, TOXICOL APPL PHARM, V333, P26, DOI 10.1016/j.taap.2017.08.002
   Dalla Valle L, 1995, MOL CELL ENDOCRINOL, V111, P83, DOI 10.1016/0303 7207(95)03553 J
   de Man FM, 2018, CLIN PHARMACOKINET, V57, P1229, DOI 10.1007/s40262 018 0644 7
   Dillon Joseph S., 2005, Current Drug Targets   Inflammation and Allergy, V4, P377, DOI 10.2174/1568010054022079
   Gilbert J, 2008, CANCER AM CANCER SOC, V113, P186, DOI 10.1002/cncr.23545
   Girón RA, 2009, FEBS J, V276, P5598, DOI 10.1111/j.1742 4658.2009.07253.x
   Hadjimichael C, 2015, WORLD J STEM CELLS, V7, P1150, DOI 10.4252/wjsc.v7.i9.1150
   Ho HY, 2008, INT J ONCOL, V33, P969, DOI 10.3892/ijo_00000084
   Hsieh YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141088
   Jiang YF, 2005, J GASTROENTEROL, V40, P490, DOI 10.1007/s00535 005 1574 3
   Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276 020 0380 6
   Kaler P, 2009, CANCER MICROENVIRON, V2, P69, DOI 10.1007/s12307 009 0030 y
   Kashyap V, 2009, STEM CELLS DEV, V18, P1093, DOI 10.1089/scd.2009.0113
   Kciuk M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144919
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Lamb R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067811
   Li WJ, 2014, STEROIDS, V89, P20, DOI 10.1016/j.steroids.2014.07.011
   Lim YC, 2012, EUR J CANCER, V48, P3310, DOI 10.1016/j.ejca.2012.04.013
   Liu AF, 2013, CHIN J CANCER, V32, P483, DOI 10.5732/cjc.012.10282
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Liu SQ, 2005, CANCER RES, V65, P2269, DOI 10.1158/0008 5472.CAN 04 3079
   Liu YJ, 2017, STEM CELLS, V35, P398, DOI 10.1002/stem.2510
   López Marure R, 2016, CANCER BIOL THER, V17, P915, DOI 10.1080/15384047.2016.1195047
   López Marure R, 2011, EUR J PHARMACOL, V660, P268, DOI 10.1016/j.ejphar.2011.03.040
   Müller M, 2016, STEM CELL RES, V16, P349, DOI 10.1016/j.scr.2016.02.005
   Murphy B A, 2001, Oncology (Williston Park), V15, P47
   Murphy BA, 2005, EXPERT OPIN PHARMACO, V6, P85, DOI 10.1517/14656566.6.1.85
   Muscarella P, 1998, J SURG RES, V79, P154, DOI 10.1006/jsre.1998.5417
   Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184
   Ohtsuka K, 2003, LUNG CANCER, V41, P187, DOI 10.1016/S0169 5002(03)00223 X
   Peitzsch C, 2019, CANCERS, V11, DOI 10.3390/cancers11050616
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Prieto Vila M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122574
   Racchi M, 2003, CNS DRUG REV, V9, P21, DOI 10.1111/j.1527 3458.2003.tb00242.x
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Schatoff EM, 2017, CURR COLORECT CANC R, V13, P101, DOI 10.1007/s11888 017 0354 9
   Schmidt R, 2012, GENOME BIOL, V13, DOI 10.1186/gb 2012 13 10 251
   Shiah SG, 2014, CANCER RES, V74, P7560, DOI 10.1158/0008 5472.CAN 14 0978
   Shrivastava S, 2015, SCI REP UK, V5, DOI 10.1038/srep07819
   Suzuki Keiko, 2010, BMC Res Notes, V3, P294, DOI 10.1186/1756 0500 3 294
   The Cancer Genome Atlas Network, 2015, NATURE, V517, P576, DOI 10.1038/nature14129
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   van Ark Otte J, 1998, BRIT J CANCER, V77, P2171, DOI 10.1038/bjc.1998.362
   Van den Broeck A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073968
   Vegliante R, 2018, VITAM HORM, V108, P273, DOI 10.1016/bs.vh.2018.01.006
   Villaruz LC, 2013, CLIN CANCER RES, V19, P2629, DOI 10.1158/1078 0432.CCR 12 2935
   Wei JCC, 2020, INT J RHEUM DIS, V23, P7, DOI 10.1111/1756 185X.13752
   Wei Z, 2009, STEM CELLS, V27, P2969, DOI 10.1002/stem.231
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 0116 z
   Xu G, 2002, CLIN CANCER RES, V8, P2605
   Yalcin S., 2012, CLIN APPL PHARMACOGE, DOI [10.5772/29966, DOI 10.5772/29966]
   Zhong Z, 2020, MOL PHARMACOL, V97, P72, DOI 10.1124/mol.119.117978
NR 65
TC 9
Z9 10
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2234 943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUL 13
PY 2022
VL 12
AR 775541
DI 10.3389/fonc.2022.775541
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 6I0JM
UT WOS:000885814500001
PM 35912234
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yang, C
   Davis, JL
   Zeng, R
   Vora, P
   Su, XM
   Collins, LI
   Vangveravong, S
   Mach, RH
   Piwnica Worms, D
   Weilbaecher, KN
   Faccio, R
   Novack, DV
AF Yang, Chang
   Davis, Jennifer L.
   Zeng, Rong
   Vora, Paras
   Su, Xinming
   Collins, Lynne I.
   Vangveravong, Suwanna
   Mach, Robert H.
   Piwnica Worms, David
   Weilbaecher, Katherine N.
   Faccio, Roberta
   Novack, Deborah Veis
TI Antagonism of Inhibitor of Apoptosis Proteins Increases Bone Metastasis
   via Unexpected Osteoclast Activation
SO CANCER DISCOVERY
LA English
DT Article
ID NF KAPPA B; BREAST CANCER; ZOLEDRONIC ACID; DOUBLE BLIND; ALPHA; CELLS;
   GROWTH; CIAP1; EFFICACY; SURVIVAL
AB Inhibitor of apoptosis (IAP) proteins play a central role in many types of cancer, and IAP antagonists are in development as anticancer agents. IAP antagonists cause apoptosis in many cells, but they also activate alternative NF kappa B signaling through NF kappa B inducing kinase (NIK), which regulates osteoclasts. In bone metastasis, a positive feedback loop between tumors and osteoclasts promotes tumor growth and osteolysis. We therefore tested the effect of IAP antagonists on the bone microenvironment for metastasis. In both drug sensitive and drug resistant tumors, growth in bone was favored, as compared with other sites during IAP antagonist treatment. These drugs also caused osteoporosis and increased osteoclastogenesis, mediated by NIK, and enhanced tumor associated osteolysis. Cotreatment with zoledronic acid, a potent osteoclast inhibitor, reduced IAP antagonist enhanced tumor growth in bone and osteolysis. Thus, IAP antagonist based cancer treatment may be compromised by osteoporosis and enhanced skeletal metastasis, which may be prevented by antiresorptive agents.
   SIGNIFICANCE: Although IAP antagonists are a class of anticancer agents with proven efficacy in multiple cancers, we show that these agents can paradoxically increase tumor growth and metastasis in the bone by stabilizing NIK and activating the alternative NF kappa B pathway in osteoclasts. Future clinical trials of IAP antagonist based therapy may require detailed examination of this potential for enhanced bone metastasis and osteoporosis, as well as possible combination with antiresorptive agents. Cancer Discov; 3(2);212 23. (C)2012 AACR.
C1 [Piwnica Worms, David] Washington Univ, Sch Med, Dept Cell Biol & Physiol, BRIGHT Inst, St Louis, MO 63110 USA.
   [Faccio, Roberta] Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63110 USA.
   [Novack, Deborah Veis] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL)
RP Novack, DV (通讯作者)，Washington Univ, Sch Med, Dept Med, Div Bone & Mineral Dis, 660 S Euclid Ave,Box 8301, St Louis, MO 63110 USA.
EM novack@wustl.edu
RI ; Su, Xinming/G 1643 2012
OI Mach, Robert/0000 0002 7645 2869; Su, Xinming/0000 0003 0351 2928;
   Novack, Deborah/0000 0001 7101 5582
FU NIH [AR052705, P50 CA94056]; Barnes Jewish Foundation; Washington
   University Center for Musculoskeletal Research; NIH/National Institute
   of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [AR057235]; 
   [AR52921];  [AR53628];  [CA100730]
FX This study was primarily supported by the NIH, grant AR052705 (to D. V.
   Novack), with additional support from AR52921 and AR53628 (to R.
   Faccio), CA100730 (to K.N. Weilbaecher), and the Barnes Jewish
   Foundation (to D. V. Novack). Histologic and mu CT analysis was
   supported in part by the Washington University Center for
   Musculoskeletal Research and the NIH/National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (NIAMS), grant AR057235. The Molecular
   Imaging Center was supported by NIH grant P50 CA94056.
CR Abbas S, 2003, J BIOL CHEM, V278, P20077, DOI 10.1074/jbc.M208619200
   Aya K, 2005, J CLIN INVEST, V115, P1848, DOI 10.1172/JCI23763
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Gross S, 2005, NAT METHODS, V2, P607, DOI 10.1038/NMETH779
   Gyrd Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Hirbe AC, 2007, BLOOD, V109, P3424, DOI 10.1182/blood 2006 09 048686
   Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Lopez M, 2010, PROBE REPORTS NIH MO
   Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105
   Mannhold R, 2010, DRUG DISCOV TODAY, V15, P210, DOI 10.1016/j.drudis.2010.01.003
   Mbalaviele G, 1996, CANCER RES, V56, P4063
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Mucci I, 2009, BIOLOGICALS, V37, P288, DOI 10.1016/j.biologicals.2009.05.004
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Onishi T, 2010, NAT REV CLIN ONCOL, V7, P641, DOI 10.1038/nrclinonc.2010.134
   Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Sasaki Y, 2008, P NATL ACAD SCI USA, V105, P10883, DOI 10.1073/pnas.0805186105
   Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008 5472.CAN 04 1844
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Sun HY, 2008, ACCOUNTS CHEM RES, V41, P1264, DOI 10.1021/ar8000553
   Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105
   Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200
   Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030
   Varfolomeev E, 2009, J BIOL CHEM, V284, P34553, DOI 10.1074/jbc.M109.040139
   Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037
   Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Weisberg E, 2007, MOL CANCER THER, V6, P1951, DOI 10.1158/1535 7163.MCT 06 0810
   Yang C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015383
   Yarilina A, 2011, P NATL ACAD SCI USA, V108, P1573, DOI 10.1073/pnas.1010030108
   Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453
   Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676
   Ziegler DS, 2008, J CLIN INVEST, V118, P3109, DOI 10.1172/JCI34120
NR 45
TC 37
Z9 41
U1 1
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 2159 8274
EI 2159 8290
J9 CANCER DISCOV
JI Cancer Discov.
PD FEB
PY 2013
VL 3
IS 2
BP 212
EP 223
DI 10.1158/2159 8290.CD 12 0271
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 088IA
UT WOS:000314826300026
PM 23269702
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Wei, W
   Zeve, D
   Suh, JM
   Wang, XQ
   Du, Y
   Zerwekh, JE
   Dechow, PC
   Graff, JM
   Wan, YH
AF Wei, Wei
   Zeve, Daniel
   Suh, Jae Myoung
   Wang, Xueqian
   Du, Yang
   Zerwekh, Joseph E.
   Dechow, Paul C.
   Graff, Jonathan M.
   Wan, Yihong
TI Biphasic and Dosage Dependent Regulation of Osteoclastogenesis by
   β Catenin
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID ACTIVATED RECEPTOR GAMMA; INCREASES BONE FORMATION; STEM CELLS;
   OSTEOPROTEGERIN LIGAND; SCLEROSTIN ANTIBODY; MULTIPLE MYELOMA; C JUN;
   WNT; DIFFERENTIATION; MICE
AB Wnt/beta catenin signaling is a critical regulator of skeletal physiology. However, previous studies have mainly focused on its roles in osteoblasts, while its specific function in osteoclasts is unknown. This is a clinically important question because neutralizing antibodies against Wnt antagonists are promising new drugs for bone diseases. Here, we show that in osteoclastogenesis, beta catenin is induced during the macrophage colony stimulating factor (M CSF) mediated quiescence to proliferation switch but suppressed during the RANKL mediated proliferation to differentiation switch. Genetically, beta catenin deletion blocks osteoclast precursor proliferation, while beta catenin constitutive activation sustains proliferation but prevents osteoclast differentiation, both causing osteopetrosis. In contrast, beta catenin heterozygosity enhances osteoclast differentiation, causing osteoporosis. Biochemically, Wnt activation attenuates whereas Wnt inhibition stimulates osteoclastogenesis. Mechanistically, beta catenin activation increases GATA2/Evi1 expression but abolishes RANKL induced c Jun phosphorylation. Therefore, beta catenin exerts a pivotal biphasic and dosage dependent regulation of osteoclastogenesis. Importantly, these findings suggest that Wnt activation is a more effective treatment for skeletal fragility than previously recognized that confers dual anabolic and anti catabolic benefits.
C1 [Wei, Wei; Wang, Xueqian; Du, Yang; Wan, Yihong] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
   [Zeve, Daniel; Suh, Jae Myoung; Graff, Jonathan M.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA.
   [Graff, Jonathan M.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA.
   [Zerwekh, Joseph E.; Graff, Jonathan M.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.
   [Zerwekh, Joseph E.] Univ Texas SW Med Ctr Dallas, Ctr Mineral Metab & Clin Res, Dallas, TX 75390 USA.
   [Dechow, Paul C.] Texas A&M Univ, Hlth Sci Ctr, Dept Biomed Sci, Baylor Coll Dent, Dallas, TX 75246 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center; University of Texas System; University of Texas Southwestern
   Medical Center; University of Texas System; University of Texas
   Southwestern Medical Center; University of Texas System; University of
   Texas Southwestern Medical Center; University of Texas System;
   University of Texas Southwestern Medical Center; Texas A&M University
   System; Texas A&M University College Station; Texas A&M Health Science
   Center
RP Wan, YH (通讯作者)，UT SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Rd,Room ND8 502B, Dallas, TX 75390 USA.
EM yihong.wan@utsouthwestern.edu
RI ; Suh, Jae Myoung/B 3268 2015; du, yang/V 1086 2019; Wan,
   Yihong/J 8681 2012; Suh, Jae/B 3268 2015; Wei, Wei/F 5693 2013
OI Zeve, Daniel/0000 0002 4117 1282; Suh, Jae Myoung/0000 0001 8097 4662; 
FU University of Texas Southwestern Medical Center; BD Biosciences Research
   Grant; CPRIT [RP100841]; March of Dimes [5 FY10 1]; Welch Foundation
   [I 1751]; NIH [R01 DK089113, R01 DK066556, R01 DK064261, R01 DK088220];
   American Heart Association South Central Affiliate
FX This work was supported by the University of Texas Southwestern Medical
   Center Endowed Scholar Startup Fund (Y.W.), a BD Biosciences Research
   Grant Award (Y.W.), CPRIT (RP100841 [Y.W.]), the March of Dimes
   (5 FY10 1 [Y.W.]), the Welch Foundation (I 1751 [Y.W.]), NIH (R01
   DK089113 [Y.W.] and R01 DK066556, R01 DK064261, and R01 DK088220
   [J.M.G.]), and a predoctoral fellowship (D.Z.) from the American Heart
   Association South Central Affiliate. Y.W. is a Virginia Murchison
   Linthicum Scholar in Medical Research.
CR ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092 8674(89)90017 2
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Constien R, 2001, GENESIS, V30, P36, DOI 10.1002/gene.1030
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931
   Haynes DR, 2001, RHEUMATOLOGY, V40, P623, DOI 10.1093/rheumatology/40.6.623
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960 9822(98)70156 3
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100
   Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006 1587
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460 2075.1995.tb07193.x
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092 8674(00)81575 5
   TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0
   Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wei W, 2011, MOL CELL BIOL, V31, P4692, DOI 10.1128/MCB.05979 11
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Yamane T, 2000, EXP HEMATOL, V28, P833, DOI 10.1016/S0301 472X(00)00175 2
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yuasa H, 2005, EMBO J, V24, P1976, DOI 10.1038/sj.emboj.7600679
   Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105
   Zinman B, 2010, J CLIN ENDOCR METAB, V95, P134, DOI 10.1210/jc.2009 0572
NR 55
TC 157
Z9 181
U1 4
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 0270 7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD DEC
PY 2011
VL 31
IS 23
BP 4706
EP 4719
DI 10.1128/MCB.05980 11
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 844ZF
UT WOS:000296791900005
PM 21876000
OA Green Published
DA 2025 08 17
ER

PT J
AU Leikina, E
   Whitlock, JM
   Melikov, K
   Zhang, W
   Bachmann, MP
   Chernomordik, L
AF Leikina, Evgenia
   Whitlock, Jarred M.
   Melikov, Kamran
   Zhang, Wendy
   Bachmann, Michael P.
   Chernomordik, Leonid
TI Formation of multinucleated osteoclasts depends on an oxidized species
   of cell surface associated La protein
SO ELIFE
LA English
DT Article
DE osteoclast; cell fusion; lupus La protein; redox; skeleton; reactive
   oxygen species
ID OXIDATIVE STRESS; N ACETYLCYSTEINE; BONE RESORPTION; DIFFERENTIATION;
   AUTOANTIGEN; ROLES; ROS
AB The bone resorbing activity of osteoclasts plays a critical role in the life long remodeling of our bones that is perturbed in many bone loss diseases. Multinucleated osteoclasts are formed by the fusion of precursor cells, and larger cells   generated by an increased number of cell fusion events   have higher resorptive activity. We find that osteoclast fusion and bone resorption are promoted by reactive oxygen species (ROS) signaling and by an unconventional low molecular weight species of La protein, located at the osteoclast surface. Here, we develop the hypothesis that La's unique regulatory role in osteoclast multinucleation and function is controlled by an ROS switch in La trafficking. Using antibodies that recognize reduced or oxidized species of La, we find that differentiating osteoclasts enrich an oxidized species of La at the cell surface, which is distinct from the reduced La species conventionally localized within cell nuclei. ROS signaling triggers the shift from reduced to oxidized La species, its dephosphorylation and delivery to the surface of osteoclasts, where La promotes multinucleation and resorptive activity. Moreover, intracellular ROS signaling in differentiating osteoclasts oxidizes critical cysteine residues in the C terminal half of La, producing this unconventional La species that promotes osteoclast fusion. Our findings suggest that redox signaling induces changes in the location and function of La and may represent a promising target for novel skeletal therapies.
C1 [Leikina, Evgenia; Whitlock, Jarred M.; Melikov, Kamran; Zhang, Wendy; Chernomordik, Leonid] NIH, Eunice Kennedy Shriver Natl Inst Child Hlth & Huma, Sect Membrane Biol, Bethesda, MD 20892 USA.
   [Bachmann, Michael P.] Tech Univ Dresden, Univ Canc Ctr UCC, Univ Hosp Carl Gustav Carus Dresden, Tumor Immunol, Dresden, Germany.
   [Bachmann, Michael P.] Helmholtz Zentrum Dresden Rossendorf HZDR, Inst Radiopharmaceut Canc Res, Dept Radioimmunol, Dresden, Germany.
   [Bachmann, Michael P.] Tech Univ Dresden, Inst Immunol, Med Fac Carl Gustav Carus Dresden, Dresden, Germany.
   [Whitlock, Jarred M.] Univ Virginia, Charlottesville, VA 22904 USA.
C3 National Institutes of Health (NIH)   USA; NIH Eunice Kennedy Shriver
   National Institute of Child Health & Human Development (NICHD);
   Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   Helmholtz Association; Helmholtz Zentrum Dresden Rossendorf (HZDR);
   Technische Universitat Dresden; University of Virginia
RP Whitlock, JM; Chernomordik, L (通讯作者)，NIH, Eunice Kennedy Shriver Natl Inst Child Hlth & Huma, Sect Membrane Biol, Bethesda, MD 20892 USA.; Whitlock, JM (通讯作者)，Univ Virginia, Charlottesville, VA 22904 USA.
EM aes4xx@virginia.edu; chernoml@mail.nih.gov
OI Whitlock, Jarred/0000 0002 5886 2047; Zhang, Wendy/0009 0006 9245 1184;
   Chernomordik, Leonid/0000 0001 7131 9244
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   Development; National Institutes of Health Department of Transfusion
   Medicine; Intramural Research Program of the Eunice Kennedy Shriver
   National Institute of Child Health and Human Development, National
   Institutes of Health [884515]; Office of Research on Women's Health
   (ORWH) through the Bench to Bedside Program
FX LVC thanks Dr. Alexander Peskin, University of Otago for enjoyable
   discussion. We thank the National Institutes of Health Department of
   Transfusion Medicine for isolating the monocytes used in this study. Our
   work was supported by the Intramural Research Program of the Eunice
   Kennedy Shriver National Institute of Child Health and Human
   Development, National Institutes of Health and by the Office of Research
   on Women's Health (ORWH) through the Bench to Bedside Program award #
   884515.
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Berndt N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22189699
   Berndt N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073377
   Bolamperti S, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00219 8
   Cao JJ, 2014, J NUTR, V144, P289, DOI 10.3945/jn.113.185397
   Chen RC, 2022, EXP MOL MED, V54, P91, DOI 10.1038/s12276 022 00736 w
   Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200
   Craig AWB, 1997, MOL CELL BIOL, V17, P163, DOI 10.1128/MCB.17.1.163
   Cruz Garcia D, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201905028
   Dishman AF, 2018, ACS CHEM BIOL, V13, P1438, DOI 10.1021/acschembio.8b00276
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Duracková Z, 2010, PHYSIOL RES, V59, P459, DOI 10.33549/physiolres.931844
   Forman HJ, 2021, NAT REV DRUG DISCOV, V20, P689, DOI 10.1038/s41573 021 00233 1
   Forman HJ, 2010, BIOCHEMISTRY US, V49, P835, DOI 10.1021/bi9020378
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69
   Hansen JM, 2015, BBA GEN SUBJECTS, V1850, P1527, DOI 10.1016/j.bbagen.2014.12.001
   Huh YJ, 2006, CELL DEATH DIFFER, V13, P1138, DOI 10.1038/sj.cdd.4401793
   Kim AK, 2021, STRUCTURE, V29, P6, DOI 10.1016/j.str.2020.10.006
   Kim HR, 2019, KOREAN J INTERN MED, V34, P210, DOI 10.3904/kjim.2016.329
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kwak MS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01189
   Kwak MS, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101203
   Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004 1021
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lennicke C, 2021, MOL CELL, V81, P3691, DOI 10.1016/j.molcel.2021.08.018
   Liu HP, 2020, MOLECULES, V25, DOI 10.3390/molecules25153440
   Liu XH, 2019, INT J MOL MED, V43, P199, DOI 10.3892/ijmm.2018.3962
   Maraia RJ, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1430
   McDonald MM, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10539
   Mlejnek P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312635
   Moller AMJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176368
   Murphy MP, 2022, NAT METAB, V4, P651, DOI 10.1038/s42255 022 00591 z
   Nilforoushan D, 2009, NITRIC OXIDE BIOL CH, V21, P27, DOI 10.1016/j.niox.2009.04.002
   Ottaviano FG, 2008, CIRC J, V72, P1, DOI 10.1253/circj.72.1
   Pedre B, 2021, PHARMACOL THERAPEUT, V228, DOI 10.1016/j.pharmthera.2021.107916
   PIPER K, 1992, ANAT EMBRYOL, V186, P291
   Prudovsky I, 2008, J CELL BIOCHEM, V103, P1327, DOI 10.1002/jcb.21513
   Reis J, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.745911
   Rutjes SA, 1999, CELL DEATH DIFFER, V6, P976, DOI 10.1038/sj.cdd.4400571
   Sanders KM, 2007, TRANSL RES, V150, P215, DOI 10.1016/j.trsl.2007.03.012
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Schwartz EI, 2004, MOL CELL BIOL, V24, P9580, DOI 10.1128/MCB.24.21.9580 9591.2004
   Smith J, 2000, P NATL ACAD SCI USA, V97, P10032, DOI 10.1073/pnas.170209797
   SUDA N, 1993, BIOCHIM BIOPHYS ACTA, V1157, P318, DOI 10.1016/0304 4165(93)90116 P
   Sun SY, 2010, CANCER BIOL THER, V9, P109, DOI 10.4161/cbt.9.2.10583
   Tan SWS, 2017, STEM CELL REP, V9, P342, DOI 10.1016/j.stemcr.2017.05.034
   Urano Y, 2018, AUTOPHAGY, V14, P1943, DOI 10.1080/15548627.2018.1493043
   van der Reest J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04003 3
   Verma SK, 2018, J BIOL CHEM, V293, P254, DOI 10.1074/jbc.M117.809681
   Verma SK, 2014, BIOCHEM J, V464, P293, DOI 10.1042/BJ20141233
   Wang KK, 2011, J MOL CELL BIOL, V3, P360, DOI 10.1093/jmcb/mjr021
   Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092 8674(00)81404 X
   Whitlock JM, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 36168 x
   Wilson Carol, 2014, Nat Rev Endocrinol, V10, P3, DOI 10.1038/nrendo.2013.225
   Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003
   Yang R, 2022, CELL REP, V40, DOI 10.1016/j.celrep.2022.111330
   Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001
NR 60
TC 1
Z9 1
U1 1
U2 6
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD OCT 2
PY 2024
VL 13
AR RP98665
DI 10.7554/eLife.98665
PG 18
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA I1Z7J
UT WOS:001328313400001
PM 39356057
OA Green Submitted, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Tenta, R
   Sourla, A
   Lembessis, P
   Koutsilieris, M
AF Tenta, R
   Sourla, A
   Lembessis, P
   Koutsilieris, M
TI Bone related growth factors and zoledronic acid regulate the PTHrP/PTH.1
   receptor bioregulation systems in MG 63 human osteosarcoma cells
SO ANTICANCER RESEARCH
LA English
DT Article
DE PTHrP; MG 63 cells; bone related growth factors; zoledronic acid
ID HORMONE RELATED PROTEIN; PROSTATE CANCER CELLS; NUCLEOLAR LOCALIZATION;
   IN VITRO; EXPRESSION; PEPTIDE; DIFFERENTIATION; PTHRP; BISPHOSPHONATES;
   PROLIFERATION
AB Bisphosphonates are known to inhibit osteoclastmediated bone resorption and osteoblast differentiation and are currently used in the treatment of Paget's disease, osteoporosis, metastatic and osteolytic bone disease and hypercalcaemia of malignancy. The parathyroid hormone related peptide (PTHrP) and type I PTH/PTHrP receptor (PTH. 1R) bioregulation systems mediate a wide range of local paracrine/autocrine and intracrine functions in various tissues and modify the actions of pharmaceutical agents on target tissues, both in vivo and in vitro. In addition, bone microenvironment related growth factors, such as insulin like growth factor 1 (IGF 1), transforming growth factor beta 1 (TGF beta 1), basic fibroblast growth factor (bFGF) and interleukin 6 (IL 6), can modify the actions of various pharmaceutical agents, including cytotoxic drugs in malignant cell lines. Wether IGF 1, TGF beta 1, bFGF, IL 6 and zoledronic acid affect the expressions of PTHrP and PTH. 1R in MG 63 osteoblast like osteosarcoma cells was investigated in this study. Relative quantitative PCR (expression at mRNA level) and immunofluorescence analysis (localization of the expression at protein level) were employed to assess PTHrP and PTH.1R expressions. Our data showed that primarily IGF 1, TGF beta 1 and IL 6 (up to 25 ng/ml for 48 h) increased PTHrP mRNA expression and modified its perinuclear localization, while zoledronic acid (up to 100,mu M for 48 h) inhibited cell proliferation and suppressed PTHrP expression in the MG 63 osteosarcoma cells. These growth factors were incapable of reversing the zoledronic acid decrease of the expression of PTHrP in the MG 63 cells, suggesting that zoledronic acid and the growth factors affect PTHrP expression via an independent intracellular signal transduction pathway in these cells. However, no appreciable modulation of the PTH.1R expression by IGF 1, TGF beta 1, bFGF, IL 6 or zoledronic acid was detected in MG 63 cells. Therefore, we conclude that PTHrP expression possibly mediates the action of bone microenvironment related growth factors and of zoledronic acid in MG 63 cells.
C1 Univ Athens, Dept Expt Physiol, Sch Med, Athens 11527, Greece.
   Endo OncoRes Labs, Therapeut & Diagnost Med Ctr, Athens 11527, Greece.
C3 National & Kapodistrian University of Athens
RP Univ Athens, Dept Expt Physiol, Sch Med, 75 Micras Asias, Athens 11527, Greece.
EM mkouts@medscape.com
RI Tenta, Roxane/AAM 9669 2021; Koutsilieris, Michael/AAD 3648 2019
OI Tenta, Roxane/0000 0002 4867 6945; Lembessis,
   Panagiotis/0000 0001 8972 3499
CR AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611
   Babarina AV, 2001, MATRIX BIOL, V20, P205, DOI 10.1016/S0945 053X(01)00132 9
   Bacci G, 2001, J CHEMOTHERAPY, V13, P93, DOI 10.1179/joc.2001.13.1.93
   Bacci G, 2002, J CHEMOTHERAPY, V14, P198, DOI 10.1179/joc.2002.14.2.198
   Body JJ, 2003, BREAST, V12, pS37, DOI 10.1016/S0960 9776(03)80162 5
   Carpio L, 2001, AM J PHYSIOL ENDOC M, V281, pE489, DOI 10.1152/ajpendo.2001.281.3.E489
   Escande B, 2001, SEMIN PERINATOL, V25, P76, DOI 10.1053/sper.2001.23194
   Evdokiou A, 2003, BONE, V33, P216, DOI 10.1016/S8756 3282(03)00223 0
   Fagioli F, 2002, J CLIN ONCOL, V20, P2150, DOI 10.1200/JCO.2002.08.081
   Fiaschi Taesch NM, 2003, ENDOCRINOLOGY, V144, P407, DOI 10.1210/en.2002 220818
   Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043 2760(01)00409 X
   Guillén C, 2004, CALCIFIED TISSUE INT, V75, P153, DOI 10.1007/s00223 004 0113 1
   HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064
   IKEDA K, 1988, MOL ENDOCRINOL, V2, P1230, DOI 10.1210/mend 2 12 1230
   Jans DA, 2003, VITAM HORM, V66, P345, DOI 10.1016/S0083 6729(03)01010 0
   Jemtland R, 1999, J BONE MINER RES, V14, P904, DOI 10.1359/jbmr.1999.14.6.904
   Kawakami A, 1998, BIOCHEM BIOPH RES CO, V247, P46, DOI 10.1006/bbrc.1998.8728
   Koutsilieris M, 1999, MOL MED, V5, P86, DOI 10.1007/BF03402143
   Koutsilieris M, 2000, MOL MED, V6, P251, DOI 10.1007/BF03401935
   Kronenberg HM, 1998, RECENT PROG HORM RES, V53, P283
   Lam MHC, 2000, IMMUNOL CELL BIOL, V78, P395, DOI 10.1046/j.1440 1711.2000.00919.x
   Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391
   Lipton A, 2004, J SUPPORT ONCOL, V2, P219
   Lipton A, 2004, J SUPPORT ONCOL, V2, P216
   Lipton A, 2004, J SUPPORT ONCOL, V2, P213
   Lipton Allan, 2004, J Support Oncol, V2, P205
   Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200
   Mundy, 1999, Expert Opin Investig Drugs, V8, P2009, DOI 10.1517/13543784.8.12.2009
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Odgren PR, 2003, CRIT REV EUKAR GENE, V13, P181, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.110
   ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40
   Qian J, 2003, ENDOCRINOLOGY, V144, P1053, DOI 10.1210/en.2002 220993
   Reinholz GG, 2002, BREAST CANCER RES TR, V71, P257, DOI 10.1023/A:1014418017382
   Reyes Moreno C, 1998, UROLOGY, V52, P341, DOI 10.1016/S0090 4295(98)00182 4
   Saad F, 2004, EUR UROL, V45, P26, DOI 10.1016/j.eururo.2003.10.003
   Schlüter KD, 1999, NEWS PHYSIOL SCI, V14, P243
   Sonnemann J, 2001, ANTI CANCER DRUG, V12, P459, DOI 10.1097/00001813 200106000 00007
   Suda N, 1996, J CELL PHYSIOL, V166, P94, DOI 10.1002/(SICI)1097 4652(199601)166:1<94::AID JCP11>3.0.CO;2 P
   SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618
   Tchetina E, 2003, J BONE MINER RES, V18, P844, DOI 10.1359/jbmr.2003.18.5.844
   Tenta R, 2004, PROSTATE, V59, P120, DOI 10.1002/pros.10363
   Wojcik SF, 1999, EXP CELL RES, V248, P415, DOI 10.1006/excr.1999.4435
   Wu G, 1998, UROLOGY, V51, P110, DOI 10.1016/S0090 4295(98)00077 6
   Wysolmerski JJ, 1998, ANNU REV PHYSIOL, V60, P431, DOI 10.1146/annurev.physiol.60.1.431
NR 44
TC 22
Z9 25
U1 0
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JAN FEB
PY 2006
VL 26
IS 1A
BP 283
EP 291
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 009HZ
UT WOS:000235103800037
PM 16475708
DA 2025 08 17
ER

PT J
AU Posa, F
   Colaianni, G
   Di Cosola, M
   Dicarlo, M
   Gaccione, F
   Colucci, S
   Grano, M
   Mori, G
AF Posa, Francesca
   Colaianni, Graziana
   Di Cosola, Michele
   Dicarlo, Manuela
   Gaccione, Francesco
   Colucci, Silvia
   Grano, Maria
   Mori, Giorgio
TI The Myokine Irisin Promotes Osteogenic Differentiation of Dental
   Bud Derived MSCs
SO BIOLOGY BASEL
LA English
DT Article
DE bone; irisin; osteocalcin; mesenchymal stem cells (MSCs); precision
   medicine; dental stem cells; osteoblastogenesis; translational research
ID MESENCHYMAL STEM CELLS; IN VITRO; BONE; OSTEOCALCIN; OSTEOPONTIN;
   EXPRESSION; THERAPY; BIOLOGY; PROTEIN; GROWTH
AB Simple Summary
   Irisin is a recently discovered protein, mainly produced in the muscle tissue, whose action is proving effective in many other tissues. The crosstalk between muscle and bone has been long since demonstrated, and physical activity has shown to have an impressive positive effect in both tissues. Irisin production increases with exercising and drops with sedentariness and aging, indicating that the molecule is involved in sarcopenia and in bone mass reduction. Although skeleton is target of irisin, its mechanism of action on bone cells has not yet been completely elucidated. The aim of this work is to analyze the effect of irisin on osteoblast differentiation; to this purpose, we used a stem cell model reproducing the osteoblastogenesis and the bone forming processes. We performed an in vitro study exploring the main osteoblast markers in the presence of irisin. We found that irisin has an impressive effect on the most peculiar osteoblast feature: the bone mineral matrix secretion process. Moreover, irisin demonstrated an inductive effect on osteoblast osteocalcin production. Both results suggest a stimulating effect of irisin in bone formation. The association we observed between irisin addition and osteoblast osteocalcin production should be further investigated.
   The myokine irisin, well known for its anabolic effect on bone tissue, has been demonstrated to positively act on osteoblastic differentiation processes in vitro. Mesenchymal stem cells (MSCs) have captured great attention in precision medicine and translational research for several decades due to their differentiation capacity, potent immunomodulatory properties, and their ability to be easily cultured and manipulated. Dental bud stem cells (DBSCs) are MSCs, isolated from dental tissues, that can effectively undergo osteoblastic differentiation. In this study, we analyzed, for the first time, the effects of irisin on DBSC osteogenic differentiation in vitro. Our results indicated that DBSCs were responsive to irisin, showed an enhanced expression of osteocalcin (OCN), a late marker of osteoblast differentiation, and displayed a greater mineral matrix deposition. These findings lead to deepening the mechanism of action of this promising molecule, as part of osteoblastogenesis process. Considering the in vivo studies of the effects of irisin on skeleton, irisin could improve bone tissue metabolism in MSC regenerative procedures.
C1 [Posa, Francesca; Di Cosola, Michele; Mori, Giorgio] Univ Foggia, Dept Clin & Expt Med, Viale Pinto 1, I 71122 Foggia, Italy.
   [Colaianni, Graziana; Dicarlo, Manuela; Gaccione, Francesco; Grano, Maria] Univ Bari, Dept Emergency & Organ Transplantat, I 70124 Bari, Italy.
   [Colucci, Silvia] Univ Bari, Sect Human Anat & Histol, Dept Basic Med Sci Neurosci & Sense Organs, I 70124 Bari, Italy.
C3 University of Foggia; Universita degli Studi di Bari Aldo Moro;
   Universita degli Studi di Bari Aldo Moro
RP Mori, G (通讯作者)，Univ Foggia, Dept Clin & Expt Med, Viale Pinto 1, I 71122 Foggia, Italy.
EM francesca.posa@unifg.it; graziana.colaianni@uniba.it;
   dr.dicosola@gmail.com; manuela.dicarlo25@gmail.com;
   fra.gaccione@gmail.com; silviaconcetta.colucci@uniba.it;
   maria.grano@uniba.it; maria.grano@uniba.it
RI ; Mori, Giorgio/P 1370 2014
OI Grano, Maria/0000 0002 7121 5899; Di Cosola,
   Michele/0000 0002 2756 3212; Mori, Giorgio/0000 0001 6731 0247; Posa,
   Francesca/0000 0001 8099 3505
FU Ministero dell'Istruzione, dell'Universita e della Ricerca [PRIN
   20098KM9RN]; Regione Puglia for Tecnopolo Puglia per la Medicina di
   Precisione [2117]
FX This research was funded by Ministero dell'Istruzione, dell'Universita e
   della RicercaPRIN 20098KM9RN, PI G.M. (Progetto di Ricerca d'Interesse
   Nazionale Grant 2009) and was supported by the special grant from
   Regione Puglia for Tecnopolo Puglia per la Medicina di Precisione D.G.R.
   n. 2117 of 21.11.2018.
CR Ballini A, 2019, EUR REV MED PHARMACO, V23, P2916, DOI 10.26355/eurrev_201904_17570
   Berezovska O, 2019, BONE, V128, DOI 10.1016/j.bone.2019.08.004
   Brunetti G, 2018, ONCOL REP, V39, P2031, DOI 10.3892/or.2018.6272
   CHEN QM, 1994, J BIOL CHEM, V269, P26602
   Colaianni G, 2021, J BONE MINER RES, V36, P305, DOI 10.1002/jbmr.4192
   Colaianni G, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/902186
   Colaianni G, 2019, PEDIATR RES, V85, P484, DOI 10.1038/s41390 019 0278 y
   Colaianni G, 2015, P NATL ACAD SCI USA, V112, P12157, DOI 10.1073/pnas.1516622112
   Di Benedetto A, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00285
   Di Benedetto A, 2018, INT J MED SCI, V15, P944, DOI 10.7150/ijms.24111
   Di Benedetto A, 2015, STEM CELL RES, V15, P618, DOI 10.1016/j.scr.2015.09.011
   Di Benedetto A, 2014, METHODS MOL BIOL, V1210, P117, DOI 10.1007/978 1 4939 1435 7_9
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hanna H, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0942 x
   HAUSCHKA PV, 1982, BIOCHEMISTRY US, V21, P2538, DOI 10.1021/bi00539a038
   Hoang QQ, 2003, NATURE, V425, P977, DOI 10.1038/nature02079
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Kebriaei P, 2009, BIOL BLOOD MARROW TR, V15, P804, DOI 10.1016/j.bbmt.2008.03.012
   Kim H, 2018, CELL, V175, P1756, DOI 10.1016/j.cell.2018.10.025
   Luo Y, 2020, CLIMACTERIC, V23, P496, DOI 10.1080/13697137.2020.1745768
   Luo YY, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 74588 7
   Madonna R, 2009, ARTERIOSCL THROM VAS, V29, P1723, DOI 10.1161/ATVBAHA.109.187179
   Mori G, 2010, J BIOL REG HOMEOS AG, V24, P167
   Mori G, 2011, ANN NY ACAD SCI, V1237, P47, DOI 10.1111/j.1749 6632.2011.06234.x
   Nikel O, 2013, LANGMUIR, V29, P13873, DOI 10.1021/la403203w
   Perakakis N, 2017, NAT REV ENDOCRINOL, V13, P324, DOI 10.1038/nrendo.2016.221
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Posa F, 2020, MATERIALS, V13, DOI 10.3390/ma13204471
   Posa F, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6958713
   Posa F, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9150819
   Poundarik AA, 2012, P NATL ACAD SCI USA, V109, P19178, DOI 10.1073/pnas.1201513109
   PRICE PA, 1982, P NATL ACAD SCI BIOL, V79, P7734, DOI 10.1073/pnas.79.24.7734
   PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447
   Pullisaar H, 2020, ARCH ORAL BIOL, V111, DOI 10.1016/j.archoralbio.2019.104635
   Qiao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep18732
   Rehorová M, 2019, STEM CELL TRANSL MED, V8, P535, DOI 10.1002/sctm.18 0223
   RITTER NM, 1992, J BONE MINER RES, V7, P877
   Rodeo SA, 2019, BONE JOINT J, V101B, P361, DOI 10.1302/0301 620X.101B4.BJJ 2019 0013.R1
   Rodgers K, 2018, ADV DRUG DELIVER REV, V123, P75, DOI 10.1016/j.addr.2017.10.003
   Son JW, 2021, INT ENDOD J, V54, P399, DOI 10.1111/iej.13435
   VANDELOO PGF, 1987, BIOCHEM BIOPH RES CO, V142, P113, DOI 10.1016/0006 291X(87)90458 X
   Zeng RJ, 2018, BIOSCI TRENDS, V12, P580, DOI 10.5582/bst.2018.01207
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 44
TC 26
Z9 29
U1 0
U2 9
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2079 7737
J9 BIOLOGY BASEL
JI Biology Basel
PD APR
PY 2021
VL 10
IS 4
AR 295
DI 10.3390/biology10040295
PG 11
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA RQ9QG
UT WOS:000642745500001
PM 33916859
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Plesselova, S
   Garcia Cerezo, P
   Blanco, V
   Reche Perez, FJ
   Hernandez Mateo, F
   Santoyo Gonzalez, F
   Giron Gonzalez, MD
   Salto Gonzalez, R
AF Plesselova, Simona
   Garcia Cerezo, Pablo
   Blanco, Victor
   Reche Perez, Francisco J.
   Hernandez Mateo, Fernando
   Santoyo Gonzalez, Francisco
   Dolores Giron Gonzalez, Maria
   Salto Gonzalez, Rafael
TI Polyethylenimine Bisphosphonate Cyclodextrin Ternary Conjugates:
   Supramolecular Systems for the Delivery of Antineoplastic Drugs
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID BONE; DOXORUBICIN; CELLS; HYDROXYAPATITE; ALENDRONATE; EXPRESSION;
   APOPTOSIS; PATHWAY; SULFONE; CHARGE
AB Bisphosphonates (BPs) are bone binding molecules that provide targeting capabilities to bone cancer cells when conjugated with drug carrying polymers. This work reports the design, synthesis, and biological evaluation of polyethyleneimine BP cyclodextrin (PEI BP CD) ternary conjugates with supramolecular capabilities for the loading of antineoplastic drugs. A straightforward, modular, and versatile strategy based on the click aza Michael addition reaction of vinyl sulfones (VSs) allows the grafting of BPs targeting ligands and beta CD carrier appendages to the PEI polymeric scaffold. The in vitro evaluation (cytotoxicity, cellular uptake, internalization routes, and subcellular distribution) for the ternary conjugates and their doxorubicin inclusion complexes in different bone related cancer cell lines (MC3T3 E1 osteoblasts, MG 63 sarcoma cells, and MDA MB 231 breast cancer cells) confirmed specificity, mitochondrial targeting, and overall capability to mediate a targeted drug transport to those cells. The in vivo evaluation using xenografts of MG 63 and MDA MB 231 cells on mice also confirmed the targeting of the conjugates.
C1 [Plesselova, Simona; Reche Perez, Francisco J.; Dolores Giron Gonzalez, Maria; Salto Gonzalez, Rafael] Univ Granada, Sch Pharm, Dept Biochem & Mol Biol 2, E 18071 Granada, Spain.
   [Plesselova, Simona; Garcia Cerezo, Pablo; Blanco, Victor; Reche Perez, Francisco J.; Hernandez Mateo, Fernando; Santoyo Gonzalez, Francisco; Dolores Giron Gonzalez, Maria; Salto Gonzalez, Rafael] Univ Granada, Unit Excellence Chem Appl Biomed & Environm, E 18071 Granada, Spain.
   [Garcia Cerezo, Pablo; Blanco, Victor; Hernandez Mateo, Fernando; Santoyo Gonzalez, Francisco] Univ Granada, Sch Sci, Dept Organ Chem, E 18071 Granada, Spain.
   [Santoyo Gonzalez, Francisco] Univ Granada, Biotechnol Inst, E 18071 Granada, Spain.
C3 University of Granada; University of Granada; University of Granada;
   University of Granada
RP Salto Gonzalez, R (通讯作者)，Univ Granada, Sch Pharm, Dept Biochem & Mol Biol 2, E 18071 Granada, Spain.; Santoyo Gonzalez, F; Salto Gonzalez, R (通讯作者)，Univ Granada, Unit Excellence Chem Appl Biomed & Environm, E 18071 Granada, Spain.; Santoyo Gonzalez, F (通讯作者)，Univ Granada, Sch Sci, Dept Organ Chem, E 18071 Granada, Spain.; Santoyo Gonzalez, F (通讯作者)，Univ Granada, Biotechnol Inst, E 18071 Granada, Spain.
EM fsantoyo@ugr.es; rsalto@ugr.es
RI RechePérez, Francisco/A 8634 2019; Reche Perez, Francisco
   Jose/A 8634 2019; Plesselova, Simona/AAT 7671 2020; Giron, Maria
   D/K 2487 2014; Garcia Cerezo, Pablo/F 8181 2019; Giron,
   Maria/K 2487 2014; SANTOYO GONZALEZ, FRANCISCO/AGF 1672 2022; Blanco,
   Victor/K 4612 2014; Salto, Rafael/A 6486 2011; Hernandez Mateo,
   Fernando/A 7165 2008; SANTOYO GONZALEZ, FRANCISCO/A 3306 2008;
   Hernandez Mateo, Fernando/A 7165 2008
OI Reche Perez, Francisco Jose/0000 0002 6583 305X; Giron, Maria
   D/0000 0001 9638 988X; Garcia Cerezo, Pablo/0000 0001 5270 1675; Blanco,
   Victor/0000 0002 6809 079X; Salto, Rafael/0000 0002 7044 3611; Hernandez
   Mateo, Fernando/0000 0003 2737 6211; SANTOYO GONZALEZ,
   FRANCISCO/0000 0002 2142 3067; 
FU Ministerio Espanol de Ciencia [CTQ2014 55474 C2 2 R, CTQ2017 86125 P];
   FEDER funds; Fundacion Marcelino Botin
FX This work was supported by grants CTQ2014 55474 C2 2 R and
   CTQ2017 86125 P from the Ministerio Espan~ol de Ciencia (cofinanced by
   FEDER funds) and Fundacion Marcelino Botin (awarded to R.S.G.).
CR Bao K, 2015, THERANOSTICS, V5, P609, DOI 10.7150/thno.11222
   Barbosa JS, 2021, J MED CHEM, V64, P1260, DOI 10.1021/acs.jmedchem.0c01292
   BEKERS O, 1990, J PHARMACEUT BIOMED, V8, P671, DOI 10.1016/0731 7085(90)80100 4
   Bishop MW, 2016, CURR OPIN PEDIATR, V28, P26, DOI 10.1097/MOP.0000000000000298
   Brunot C, 2007, BIOMATERIALS, V28, P632, DOI 10.1016/j.biomaterials.2006.09.026
   Buondonno I, 2016, MOL CANCER THER, V15, P2640, DOI 10.1158/1535 7163.MCT 16 0048
   Calori IR, 2020, EUR POLYM J, V129, DOI 10.1016/j.eurpolymj.2020.109621
   Carpio L, 2001, AM J PHYSIOL ENDOC M, V281, pE489, DOI 10.1152/ajpendo.2001.281.3.E489
   Chandra P, 2005, AM J PHYSIOL GASTR L, V288, pG1252, DOI 10.1152/ajpgi.00362.2004
   Chang J, 2012, ONCOL LETT, V4, P299, DOI 10.3892/ol.2012.723
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   COLEY HM, 1993, BRIT J CANCER, V67, P1316, DOI 10.1038/bjc.1993.244
   Cui YT, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201901073
   David E, 2019, BIOCONJUGATE CHEM, V30, P1665, DOI 10.1021/acs.bioconjchem.9b00210
   del Castillo T, 2014, CHEMMEDCHEM, V9, P383, DOI 10.1002/cmdc.201300385
   Ebert R, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 265
   ek J, ADV DRUG
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Hallett AJ, 2009, CHEM COMMUN, P4278, DOI 10.1039/b905692k
   Harding IS, 2005, BIOMATERIALS, V26, P6818, DOI 10.1016/j.biomaterials.2005.04.060
   Harris RK, 2001, PURE APPL CHEM, V73, P1795, DOI 10.1351/pac200173111795
   Hein CD, 2010, MACROMOL BIOSCI, V10, P1544, DOI 10.1002/mabi.201000205
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Hiraga T, 2001, CANCER RES, V61, P4418
   Hochdörffer K, 2012, J MED CHEM, V55, P7502, DOI 10.1021/jm300493m
   Hruby M, 2006, J APPL POLYM SCI, V101, P3192, DOI 10.1002/app.23446
   Inoue R, 2005, BRIT J PHARMACOL, V146, P633, DOI 10.1038/sj.bjp.0706373
   Jansen DR, 2009, J INORG BIOCHEM, V103, P1265, DOI 10.1016/j.jinorgbio.2009.07.007
   Jansen DR, 2009, LANGMUIR, V25, P2790, DOI 10.1021/la802485g
   Lopez Jaramillo FJ, 2012, INTEGRATIVE PROTEOMICS, P301
   Kuznik A, 2020, EUR J PHARMACOL, V866, DOI 10.1016/j.ejphar.2019.172773
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Liu XM, 2007, J CONTROL RELEASE, V122, P54, DOI 10.1016/j.jconrel.2007.06.021
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Malhotra K, 2020, CHEM MATER, V32, P4002, DOI 10.1021/acs.chemmater.0c00547
   Marshall Milton V, 2010, Open Surg Oncol J, V2, P12
   Morales Sanfrutos J, 2010, ORG BIOMOL CHEM, V8, P667, DOI 10.1039/b920576d
   Mori M, 2019, ACS MED CHEM LETT, V10, P463, DOI 10.1021/acsmedchemlett.8b00506
   Nadar RA, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601119
   Nair DP, 2014, CHEM MATER, V26, P724, DOI 10.1021/cm402180t
   Ossipov DA, 2015, EXPERT OPIN DRUG DEL, V12, P1443, DOI 10.1517/17425247.2015.1021679
   Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535 7163.MCT 09 0462
   Petrioli R, 2008, CANCER TREAT REV, V34, P710, DOI 10.1016/j.ctrv.2008.05.004
   PRISHCHENKO AA, 1991, ZH OBSHCH KHIM+, V61, P1018
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Riganti C, 2013, MOL PHARMACEUT, V10, P161, DOI 10.1021/mp300311b
   Rivankar S, 2014, J CANCER RES THER, V10, P853, DOI 10.4103/0973 1482.139267
   Rudnick Glick S, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951 016 0233 6
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Santos AC, 2021, DRUG DELIV TRANSL RE, V11, P49, DOI 10.1007/s13346 020 00778 5
   Sebbah Louriki M, 2002, ANTICANCER RES, V22, P3925
   Sun J, 2012, ARCH ORAL BIOL, V57, P728, DOI 10.1016/j.archoralbio.2011.12.007
   Svoboda M, 2011, CURR DRUG METAB, V12, P139, DOI 10.2174/138920011795016863
   Tsubaki M, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 10
   Vicennati P, 2008, CURR MED CHEM, V15, P2826, DOI 10.2174/092986708786242778
   Wang X, 2015, CURR PHARM DESIGN, V21, P6140, DOI 10.2174/1381612821666151027152907
   Webber MJ, 2017, CHEM SOC REV, V46, P6600, DOI 10.1039/c7cs00391a
   Xing LP, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115492
   Ye WL, 2015, SCI REP UK, V5, DOI 10.1038/srep14614
   Zakeri A, 2018, NANO REV EXP, V9, DOI 10.1080/20022727.2018.1488497
   Zeevaart JR, 2003, J RADIOANAL NUCL CH, V257, P83, DOI 10.1023/A:1024745310042
   Zhang JX, 2013, ADV DRUG DELIVER REV, V65, P1215, DOI 10.1016/j.addr.2013.05.001
   Zhang SF, 2007, MACROMOL BIOSCI, V7, P656, DOI 10.1002/mabi.200600286
   Zhao LY, 2017, ADV COLLOID INTERFAC, V249, P308, DOI 10.1016/j.cis.2017.04.008
   Zhong YA, 2014, BIOMACROMOLECULES, V15, P1955, DOI 10.1021/bm5003009
NR 66
TC 16
Z9 18
U1 3
U2 38
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 26
PY 2021
VL 64
IS 16
BP 12245
EP 12260
DI 10.1021/acs.jmedchem.1c00887
EA AUG 2021
PG 16
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA UK5LZ
UT WOS:000692012400026
PM 34369757
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Yu, WQ
   Zhang, YL
   Xu, L
   Sun, SJ
   Jiang, XQ
   Zhang, FQ
AF Yu, Weiqiang
   Zhang, Yilin
   Xu, Ling
   Sun, Shengjun
   Jiang, Xingquan
   Zhang, Fuqiang
TI Microarray based bioinformatics analysis of osteoblasts on
   TiO2 nanotube layers
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Nanotubes; Osteoblast; Gene expression microarray; Molecular mechanism
ID BETA CATENIN; EXPRESSION ANALYSIS; GENE EXPRESSION; IMPLANT SURFACE;
   TITANIUM; CELLS; ANATASE; GROWTH
AB The TiO2 nanotube layers fabricated by electrochemical anodization have received considerable attention in dentistry and orthopedic medicine due to their increased osseointegration compared with the unanodized titanium. The molecular mechanisms underlying the interactions between nanotubes and osteoblasts is unknown. To examine this, the mRNA expression profile of MG 63 osteoblast like cells cultured on the TiO2 nanotubes was explored by DNA microarray. The differentially expressed genes were identified by bioinformatics analysis. Gene ontology (GO) and Go map network analysis indicated that the TiO2 nanotubes enhanced osteoblast proliferation and differentiation and decreased osteoblast adhesion and immunization. The expressions of genes were mainly increased in pathways influencing cell proliferation and differentiation (Cell cycle, Terpenoid backbone biosynthesis, and TGF beta signaling) and were decreased in pathways controlling cell immunization (Cell adhesion molecules (CAMS), Allograft rejection, and Graft versus host disease). Signal network analysis generated from differentially expressed genes suggested that CTNNB1 (beta catenin) was the central gene for increasing osteoblast proliferation and differentiation, and IKBKG (inhibitor of kappa light polypeptide gene enhancer in B cells, kinase gamma) was the central gene for repressing osteoblast immunization on nanotube layers. These two genes were further confirmed by quantitative PCR. The identified signal pathways and central genes in the study are well correlated with osteoblast phenotype. Furthermore, microarray based bioinformatics analysis is a powerful tool in efficiently understanding molecular mechanisms underlying the interactions between osteoblasts and the nanotube layers. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Zhang, Fuqiang] Shanghai Jiao Tong Univ, Shanghai Res Inst Stomatol, Dept Prosthodont, Sch Stomatol, Shanghai 200011, Peoples R China.
   Shanghai Jiao Tong Univ, Shanghai Res Inst Stomatol, Affiliated Peoples Hosp 9, Sch Med, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Zhang, FQ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Res Inst Stomatol, Dept Prosthodont, Sch Stomatol, Shanghai 200011, Peoples R China.
EM fredzc@online.sh.cn
RI zhang, yilin/GOK 2333 2022
FU Shanghai Leading Academic Discipline Project [S30206, T0202]; Science
   and Technology Committee of Shanghai [08DZ2271100, 1052nm04300,
   10JC1408600]; National Natural Science Foundation of China [81070866]
FX The authors would like to thank Xiu li Zhang (Oral Bioengineering Lab,
   Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong
   University) for helpful assistance in experiments. This work was
   supported by Shanghai Leading Academic Discipline Project (project
   number: S30206) and Science and Technology Committee of Shanghai
   (08DZ2271100, 1052nm04300, and 10JC1408600) and Shanghai Leadind
   Academic Discipline Project (T0202), and National Natural Science
   Foundation of China (81070866). Genminix Company provides us with
   technical assistance.
CR ALBREKTSSON T, 1981, ACTA ORTHOP SCAND, V52, P155, DOI 10.3109/17453678108991776
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bigi A, 2007, J BIOMED MATER RES A, V82A, P213, DOI 10.1002/jbm.a.31132
   Bjursten LM, 2010, J BIOMED MATER RES A, V92A, P1218, DOI 10.1002/jbm.a.32463
   Bombonato Prado KF, 2009, J BIOMED MATER RES A, V88A, P401, DOI 10.1002/jbm.a.31701
   Brammer KS, 2009, ACTA BIOMATER, V5, P3215, DOI 10.1016/j.actbio.2009.05.008
   Carinci F, 2004, CLIN ORAL IMPLAN RES, V15, P180, DOI 10.1111/j.1600 0501.2004.00997.x
   Case N, 2010, J CELL BIOCHEM, V110, P545, DOI 10.1002/jcb.22574
   Choi HD, 2011, J PERIODONTAL IMPLAN, V41, P30, DOI 10.5051/jpis.2011.41.1.30
   HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850
   Kalbacova M, 2009, ACTA BIOMATER, V5, P3076, DOI 10.1016/j.actbio.2009.04.020
   Kamel MA, 2010, BONE, V47, P872, DOI 10.1016/j.bone.2010.08.007
   Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063
   Lamers E, 2010, BIOMATERIALS, V31, P3307, DOI 10.1016/j.biomaterials.2010.01.034
   Le Guéhennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025
   Li CY, 2008, BIOINFORMATICS, V24, P1175, DOI 10.1093/bioinformatics/btn081
   Lü XY, 2010, BIOMATERIALS, V31, P1965, DOI 10.1016/j.biomaterials.2009.12.044
   Mao XZ, 2005, BIOINFORMATICS, V21, P3787, DOI 10.1093/bioinformatics/bti430
   Mendonça G, 2008, BIOMATERIALS, V29, P3822, DOI 10.1016/j.biomaterials.2008.05.012
   Oh S, 2006, J BIOMED MATER RES A, V78A, P97, DOI 10.1002/jbm.a.30722
   Oh S, 2009, P NATL ACAD SCI USA, V106, P2130, DOI 10.1073/pnas.0813200106
   Oh SH, 2005, BIOMATERIALS, V26, P4938, DOI 10.1016/j.biomaterials.2005.01.048
   PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460 2075.1992.tb05135.x
   Peng L, 2010, NANO LETT, V10, P143, DOI 10.1021/nl903043z
   Popat KC, 2007, BIOMATERIALS, V28, P3188, DOI 10.1016/j.biomaterials.2007.03.020
   Power KA, 2010, BIOMATERIALS, V31, P6667, DOI 10.1016/j.biomaterials.2010.05.029
   Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535 6108(03)00240 X
   Sato M, 2008, J BIOMED MATER RES A, V84A, P265, DOI 10.1002/jbm.a.31469
   Shiina T, 2004, TISSUE ANTIGENS, V64, P631, DOI 10.1111/j.1399 0039.2004.00327.x
   Siggs OM, 2010, P NATL ACAD SCI USA, V107, P3046, DOI 10.1073/pnas.0915098107
   Silkstone D, 2008, NAT CLIN PRACT RHEUM, V4, P413, DOI 10.1038/ncprheum0838
   Sollazzo V, 2008, J BIOMED MATER RES B, V85B, P29, DOI 10.1002/jbm.b.30912
   Swan EEL, 2005, J BIOMED MATER RES A, V72A, P288, DOI 10.1002/jbm.a.30223
   van der Zande M, 2010, ACTA BIOMATER, V6, P4352, DOI 10.1016/j.actbio.2010.06.013
   Vlacic Zischke J, 2011, BIOMATERIALS, V32, P665, DOI 10.1016/j.biomaterials.2010.09.025
   von Wilmowsky C, 2009, J BIOMED MATER RES B, V89B, P165, DOI 10.1002/jbm.b.31201
   Webster TJ, 2005, BIOMATERIALS, V26, P953, DOI 10.1016/j.biomaterials.2004.03.040
   Webster TJ, 1999, BIOMATERIALS, V20, P1221, DOI 10.1016/S0142 9612(99)00020 4
   Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345
   Yang F, 2009, COMB CHEM HIGH T SCR, V12, P554, DOI 10.2174/138620709788681916
   Yao C, 2008, J BIOMED MATER RES A, V85A, P157, DOI 10.1002/jbm.a.31551
   Yu WQ, 2010, J BIOMED MATER RES A, V94A, P1012, DOI 10.1002/jbm.a.32687
   Zhou SH, 2011, J CELL BIOCHEM, V112, P1651, DOI 10.1002/jcb.23079
NR 43
TC 29
Z9 32
U1 1
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD MAY 1
PY 2012
VL 93
BP 135
EP 142
DI 10.1016/j.colsurfb.2011.12.025
PG 8
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA 920TX
UT WOS:000302431900019
PM 22261177
DA 2025 08 17
ER

PT J
AU Raut, N
   Wicks, SM
   Lawal, TO
   Mahady, GB
AF Raut, Nishikant
   Wicks, Sheila M.
   Lawal, Tempitope O.
   Mahady, Gail B.
TI Epigenetic regulation of bone remodeling by natural compounds
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Anthocyanins; DNA methylation; Ferulic acid; Non coding RNA; Osteoblast;
   Osteoclast; Resveratrol; Sulforaphane; Syringic acid
ID MESENCHYMAL STEM CELLS; DNA METHYLATION; SYRINGIC ACID; RAT MODEL;
   OSTEOBLASTIC DIFFERENTIATION; RESVERATROL SUPPLEMENTATION; PROMOTES
   OSTEOGENESIS; MINERAL DENSITY; VANILLIC ACID; FERULIC ACID
AB Osteoporosis and osteopenia impact more than 54 million Americans, resulting in significant morbidity and mortality. Alterations in bone remodeling are the hallmarks for osteoporosis, and thus the development of novel treatments that will prevent or treat bone diseases would be clinically significant, and improve the quality of life for these patients. Bone remodeling involves the removal of old bone by osteoclasts and the formation of new bone by osteoblasts..This process is tightly coupled, and is essential for the maintenance of bone strength and integrity. Since the osteoclast is the only cell capable of bone resorption, the development of drugs to treat bone disorders has primarily focused on reducing osteoclast differentiation, maturation, and bone resorption mechanisms, and there are few treatments that actually increase bone formation. Evidence from observational, experimental, and clinical studies demonstrate a positive link between naturally occurring compounds and improved indices of bone health. While many natural extracts and compounds are reported to have beneficial effects on bone, only resveratrol, sulforaphane, specific phenolic acids and anthocyanins, have been shown to both increase bone formation and reduce resorption through their effects on the bone epigenome. Each of these compounds alters specific aspects of the bone epigenome to improve osteoblast differentiation, reduce osteoblast apoptosis, improve bone mineralization, and reduce osteoclast differentiation and function. This review focuses on these specific natural compounds and their epigenetic regulation of bone remodeling.
C1 [Raut, Nishikant; Mahady, Gail B.] Univ Illinois, Coll Pharm, Dept Pharm Practice, WHO PAHO Collaborating Ctr Tradit Med, Chicago, IL USA.
   [Raut, Nishikant] Rashtrasant Tukadoji Maharaj Nappur Univ, Dept Pharmaceut Sci, Nagpur, Maharashtra, India.
   [Wicks, Sheila M.] Rush Univ, Dept Cellular & Mol Med, Chicago, IL 60612 USA.
   [Lawal, Tempitope O.] Univ Ibadan, Dept Pharmaceut Microbiol, Ibadan, Nigeria.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Rashtrasant Tukadoji Maharaj
   Nagpur University; Rush University; University of Ibadan
RP Mahady, GB (通讯作者)，Univ Illinois, Coll Pharm, Dept Pharm Practice, WHO Collaborating Ctr Tradit Med, Chicago, IL 60612 USA.
EM gail.mahady@gmail.com
RI ; Raut, Nishikant/ABH 5206 2020
OI Raut, Nishikant/0000 0001 8586 9490; 
FU National Center for Complementary and Integrative Health at the National
   Institutes of Health (NIH) [1R21AT009452 01A1]; Schlumberger Foundation
   Fellowship award; University Grants Commission, Govt. of India
FX This research was funded in part by a grant from the National Center for
   Complementary and Integrative Health at the National Institutes of
   Health (NIH; 1R21AT009452 01A1; GBM); a Schlumberger Foundation
   Fellowship award to TOL; and a Raman Post Doctoral Fellowship by
   University Grants Commission, Govt. of India to NAR. The contents are
   solely the responsibility of the authors and do not necessarily
   represent the official views of the NCCIH or NIH, or the other funding
   agencies.
CR Altaf M, 2007, MUTAT RES FUND MOL M, V618, P81, DOI 10.1016/j.mrfmmm.2006.09.009
   An JH, 2010, BONE, V47, P140, DOI 10.1016/j.bone.2010.04.593
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   [Anonymous], J BONE MINER RES S1
   [Anonymous], FASEB J
   [Anonymous], AM SOC PHARM ANN M L
   [Anonymous], 8 AQ AN MOD HUM DIS
   [Anonymous], 2018, 24 INT C FUNCT FOODS
   [Anonymous], INT J MOL SCI
   [Anonymous], J BONE BIOL OSTEOPOR
   [Anonymous], FASEB J
   [Anonymous], 2018, AM SOC PHARM ANN M J
   [Anonymous], 24 INT C FUNCT FOODS
   [Anonymous], 22 BIOL SCI GRAD C B
   [Anonymous], FASEB
   [Anonymous], 2018, LIFE SCI, DOI DOI 10.1016/j.lfs.2018.06.013
   [Anonymous], J BONE MINER RES
   Arjmandi B.H., 2001, JANA, V4, P50
   Arjmandi BH, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050496
   Arumugam B, 2018, J CELL COMMUN SIGNAL, V12, P561, DOI 10.1007/s12079 018 0449 3
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Bergman Y, 2013, NAT STRUCT MOL BIOL, V20, P274, DOI 10.1038/nsmb.2518
   Bo S, 2018, NUTR DIABETES, V8, DOI 10.1038/s41387 018 0059 4
   Boyce EG, 2018, ANN PHARMACOTHER, V52, P462, DOI 10.1177/1060028017748649
   Britton RG, 2015, ANN NY ACAD SCI, V1348, P124, DOI 10.1111/nyas.12796
   Caetano Lopes J, 2007, ACTA REUMATOL PORT, V32, P103
   Cawthray J, 2017, DRUG DELIV TRANSL RE, V7, P466, DOI 10.1007/s13346 017 0394 3
   Cerletti C, 2017, BRIT J CLIN PHARMACO, V83, P103, DOI 10.1111/bcp.12943
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   Chen JR, 2010, J BONE MINER RES, V25, P2399, DOI 10.1002/jbmr.137
   Clarke JD, 2011, MOL NUTR FOOD RES, V55, P999, DOI 10.1002/mnfr.201000547
   Conte M, 2018, INT J BIOCHEM CELL B, V98, P65, DOI 10.1016/j.biocel.2018.03.004
   Cortet B, 2009, OSTEOPOROSIS INT, V20, P1097, DOI 10.1007/s00198 009 0862 9
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis 2014 207137
   Davidson RK, 2013, ARTHRITIS RHEUM US, V65, P3130, DOI 10.1002/art.38133
   Davis S, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20780
   Desquiret Dumas V, 2013, J BIOL CHEM, V288, P36662, DOI 10.1074/jbc.M113.466490
   Devareddy L, 2008, J NUTR BIOCHEM, V19, P694, DOI 10.1016/j.jnutbio.2007.09.004
   Deyhim F, 2005, MENOPAUSE, V12, P755, DOI 10.1097/01.gme.0000185486.55758.5b
   DIEZ A, 1994, J BONE MINER RES, V9, P825
   Domitrovic R, 2011, CURR MED CHEM, V18, P4454, DOI 10.2174/092986711797287601
   Du KW, 2017, EUR J CELL BIOL, V96, P496, DOI 10.1016/j.ejcb.2017.07.002
   Dudakovic A, 2018, J BIOL CHEM, V293, P12894, DOI 10.1074/jbc.RA118.002983
   Dudakovic A, 2016, J BIOL CHEM, V291, P24594, DOI 10.1074/jbc.M116.740571
   Durbin SM, 2012, APPL PHYSIOL NUTR ME, V37, P1179, DOI 10.1139/h2012 099
   Facchini A, 2011, J CELL PHYSIOL, V226, P1771, DOI 10.1002/jcp.22506
   Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367
   Farghali H, 2013, PHYSIOL RES, V62, P1, DOI 10.33549/physiolres.932434
   Feng QY, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180453
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Franklin M, 2006, BONE, V39, P1331, DOI 10.1016/j.bone.2006.05.024
   Gaddini GW, 2016, ALCOHOL CLIN EXP RES, V40, P657, DOI 10.1111/acer.13000
   Gambari L, 2014, PHARMACOL RES, V87, P99, DOI 10.1016/j.phrs.2014.06.014
   Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069
   Godfrey TC, 2018, CONNECT TISSUE RES, V59, P52, DOI 10.1080/03008207.2017.1408599
   Gong AGW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165486
   Hackl M, 2016, MOL CELL ENDOCRINOL, V432, P93, DOI 10.1016/j.mce.2015.10.015
   He N, 2015, BIOSCI BIOTECH BIOCH, V79, P1779, DOI 10.1080/09168451.2015.1062712
   Hojo H, 2016, DEV CELL, V37, P238, DOI 10.1016/j.devcel.2016.04.002
   Husain A, 2017, CURR OSTEOPOROS REP, V15, P450, DOI 10.1007/s11914 017 0391 y
   Itoh A, 2010, BIOL PHARM BULL, V33, P983, DOI 10.1248/bpb.33.983
   Itoh A, 2009, BIOL PHARM BULL, V32, P1215, DOI 10.1248/bpb.32.1215
   Jiang SD, 2006, OSTEOPOROSIS INT, V17, P180, DOI 10.1007/s00198 005 2028 8
   Kalani A, 2014, MOL CELL BIOCHEM, V395, P89, DOI 10.1007/s11010 014 2114 3
   Kang SN, 2014, NUTRIENTS, V6, P1737, DOI 10.3390/nu6041737
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Kim SJ, 2005, MOL CELLS, V20, P364
   Ko JH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122589
   Ko JY, 2013, BIOMATERIALS, V34, P5359, DOI 10.1016/j.biomaterials.2013.03.066
   Komarova SV, 2000, AM J PHYSIOL CELL PH, V279, pC1220, DOI 10.1152/ajpcell.2000.279.4.C1220
   Kulkarni SS, 2015, BBA MOL BASIS DIS, V1852, P1114, DOI 10.1016/j.bbadis.2014.10.005
   Lai YL, 2006, MOL CELL BIOCHEM, V292, P45, DOI 10.1007/s11010 006 9175 x
   Lançon A, 2012, J AGR FOOD CHEM, V60, P8783, DOI 10.1021/jf301479v
   Lapunzina P, 2010, AM J HUM GENET, V87, P110, DOI 10.1016/j.ajhg.2010.05.016
   Latruffe N, 2015, ANN NY ACAD SCI, V1348, P97, DOI 10.1111/nyas.12819
   Lee AMC, 2014, NUTRIENTS, V6, P5871, DOI 10.3390/nu6125871
   Lee YM, 2011, J PERIODONTAL RES, V46, P712, DOI 10.1111/j.1600 0765.2011.01394.x
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Liang H, 2013, NAT PROD RES, V27, P194, DOI 10.1080/14786419.2012.662649
   Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006
   LOBO RA, 1995, AM J OBSTET GYNECOL, V173, P982, DOI 10.1016/0002 9378(95)90247 3
   Martin SL, 2013, CURR MED CHEM, V20, P4050
   Meeran SM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148 010 0011 5
   Meng J, 2015, PEERJ, V3, DOI 10.7717/peerj.971
   Meyer MH, 2006, ACTA ORTHOP, V77, P944, DOI 10.1080/17453670610013277
   Mizutani K, 2000, J NUTR SCI VITAMINOL, V46, P78, DOI 10.3177/jnsv.46.78
   Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870
   Moriwaki S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097177
   Mulabagal V, 2012, PHARM BIOL, V50, P1289, DOI 10.3109/13880209.2012.674141
   Mulabagal V, 2012, FOOD CHEM, V134, P1156, DOI 10.1016/j.foodchem.2012.02.123
   Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008 5472.CAN 04 1326
   Nakajima Y, 2007, CHEM PHARM BULL, V55, P1222, DOI 10.1248/cpb.55.1222
   Nakamura I, 2012, MOD RHEUMATOL, V22, P167, DOI 10.1007/s10165 011 0530 8
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nikitovic D, 2016, ONCOL REP, V36, P1787, DOI 10.3892/or.2016.4986
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Ornstrup MJ, 2014, J CLIN ENDOCR METAB, V99, P4720, DOI 10.1210/jc.2014 2799
   Pacheco Palencia LA, 2008, J AGR FOOD CHEM, V56, P4631, DOI 10.1021/jf800161u
   Panach L, 2015, CALCIFIED TISSUE INT, V97, P495, DOI 10.1007/s00223 015 0036 z
   Park Min KH, 2018, CELL MOL LIFE SCI, V75, P2519, DOI 10.1007/s00018 018 2817 9
   Pietilä M, 2010, TISSUE ENG PART C ME, V16, P435, DOI 10.1089/ten.tec.2009.0247
   Pouresmaeili F, 2018, THER CLIN RISK MANAG, V14, P2029, DOI 10.2147/TCRM.S138000
   Qiu YY, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0534 5
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rajendran P, 2013, EPIGENETICS US, V8, P612, DOI 10.4161/epi.24710
   Ralston SH, 2010, ANN NY ACAD SCI, V1192, P181, DOI 10.1111/j.1749 6632.2009.05317.x
   Reppe S, 2015, CURR GENOMICS, V16, P384, DOI 10.2174/1389202916666150817202913
   Rizzoli R, 2018, BEST PRACT RES CL EN, V32, P739, DOI 10.1016/j.beem.2018.09.005
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Sagar T, 2016, CYTOTECHNOLOGY, V68, P1963, DOI 10.1007/s10616 016 0009 8
   Fernandes GFS, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111201
   Sassa S, 2003, IN VIVO, V17, P277
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Sehitoglu MH, 2014, ASIAN PAC J CANCER P, V15, P2379, DOI 10.7314/APJCP.2014.15.5.2379
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Shakibaei M, 2011, J BIOL CHEM, V286, P11492, DOI 10.1074/jbc.M110.198713
   Sibai T, 2011, CLIN ORTHOP RELAT R, V469, P2215, DOI 10.1007/s11999 010 1722 9
   Sibonga JD, 2007, BONE, V40, P1013, DOI 10.1016/j.bone.2006.11.002
   Simoncini T, 2011, MATURITAS, V70, P169, DOI 10.1016/j.maturitas.2011.07.004
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Smeriglio A, 2016, PHYTOTHER RES, V30, P1265, DOI 10.1002/ptr.5642
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Song LH, 2006, TOXICOL IN VITRO, V20, P915, DOI 10.1016/j.tiv.2006.01.016
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Su PH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082343
   Takahashi N, 2011, FRONT BIOSCI LANDMRK, V16, P21, DOI 10.2741/3673
   Takaoka M., 1939, NIPPON KAGAKU KAISHI, V60, P1261
   Tanaka T, 2017, J NAT MED TOKYO, V71, P632, DOI 10.1007/s11418 017 1105 6
   TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959 437X(93)90027 M
   Thaler R, 2016, J BIOL CHEM, V291, P6754, DOI 10.1074/jbc.M115.678235
   Thaler R, 2012, EPIGENETICS US, V7, P635, DOI 10.4161/epi.20163
   TONNA EA, 1959, NATURE, V183, P337, DOI 10.1038/183337a0
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Tye CE, 2018, CONNECT TISSUE RES, V59, P35, DOI 10.1080/03008207.2017.1412432
   Wahab A, 2017, MOLECULES, V22, DOI 10.3390/molecules22081329
   Wallace TC, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040401
   Wallace TC, 2015, ADV NUTR, V6, P620, DOI 10.3945/an.115.009233
   Welch A, 2012, J BONE MINER RES, V27, P1872, DOI 10.1002/jbmr.1649
   Wu XL, 2005, J AGR FOOD CHEM, V53, P3101, DOI 10.1021/jf0478861
   Xue MZ, 2008, DIABETES, V57, P2809, DOI 10.2337/db06 1003
   Yan SL, 2016, FOOD CHEM TOXICOL, V98, P119, DOI 10.1016/j.fct.2016.10.025
   Zainabadi K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185236
   Zhang JX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016658
   ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399
   Zhang ZG, 2014, J MOL CELL CARDIOL, V77, P42, DOI 10.1016/j.yjmcc.2014.09.022
   Zhao M, 2018, BRIT J PHARMACOL, V175, P4183, DOI 10.1111/bph.14477
NR 152
TC 43
Z9 50
U1 4
U2 37
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
EI 1096 1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD SEP
PY 2019
VL 147
AR 104350
DI 10.1016/j.phrs.2019.104350
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA JA1GM
UT WOS:000487565500024
PM 31315065
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Pinski, J
   Dorff, TB
AF Pinski, J
   Dorff, TB
TI Prostate cancer metastases to bone: Pathophysiology, pain management,
   and the promise of targeted therapy
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE prostate cancer; bone; metastases; pain; targed therapy; palliation
ID SPINAL CORD COMPRESSION; HORMONE RELATED PROTEIN; SKELETAL
   COMPLICATIONS; ZOLEDRONIC ACID; OSSEOUS METASTASES; TUMOR PROGRESSION;
   SOLUBLE RECEPTOR; CONTROLLED TRIAL; BREAST CANCER; CARCINOMA
AB Bone metastases are a significant cause of pain and morbidity in prostate cancer, especially if they lead to complications such as pathological fractures and spinal cord compression. Palliation of pain can be achieved with radiation, radioisotopes, hormone therapy, chemotherapy, and bisphosphonates. Bisphosphonates also reduce the risk of skeletal complications. Studies with animal models and advances in understanding the molecular basis for bone metastases have yielded new targets for therapy. Some of the promising therapeutic trials are reviewed in this paper. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90089 USA.
C3 University of Southern California
RP Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Div Med Oncol, 1441 Eastlake Ave,Suite 3334, Los Angeles, CA 90089 USA.
EM pinski_j@ccnt.hsc.usc.edu
CR ACHBAROU A, 1994, CANCER RES, V54, P2372
   ARCANGELI G, 1989, RADIOTHER ONCOL, V14, P95, DOI 10.1016/0167 8140(89)90053 4
   Boissier S, 1997, CANCER RES, V57, P3890
   BROWN HK, 2001, CANC PRINCIPLES PRAC, P2713
   CARDUCCI JBN, P ASCO, P23
   Carducci MA, 2003, J CLIN ONCOL, V21, P679, DOI 10.1200/JCO.2003.04.176
   CHARHON SA, 1983, CANCER AM CANCER SOC, V51, P918, DOI 10.1002/1097 0142(19830301)51:5<918::AID CNCR2820510526>3.0.CO;2 J
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   COLEMAN RE, 1996, P ASCO, V15, P528
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100
   Cramer SD, 1996, J UROLOGY, V156, P526, DOI 10.1016/S0022 5347(01)65919 6
   Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008 5472.CAN 03 1382
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   EISENBERGER MA, 2004, P AN M AM SOC CLIN, P23
   Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042
   FLYNN DF, 1991, UROL CLIN N AM, V18, P145
   Goltzman D, 1997, CANCER, V80, P1581, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1581::AID CNCR8>3.0.CO;2 N
   Guise TA, 2003, CANCER AM CANCER SOC, V97, P779, DOI 10.1002/cncr.11129
   HANNA SL, 1991, SKELETAL RADIOL, V20, P79
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   Hortobagyi GN, 2003, SEMIN ONCOL, V30, P161, DOI 10.1053/j.seminoncol.2003.08.018
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Ikeda I, 1996, BRIT J UROL, V77, P102, DOI 10.1046/j.1464 410X.1996.82817.x
   IWAMURA M, 2003, CANCER RES, V53, P1724
   KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299
   Kostenuik PJ, 1997, CLIN EXP METASTAS, V15, P41
   KURIHARA N, 1990, J IMMUNOL, V144, P4226
   McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357 4310(00)01686 5
   McNicol E, 2004, J CLIN ONCOL, V22, P1975, DOI 10.1200/JCO.2004.10.524
   Mertens WC, 1998, CA CANCER J CLIN, V48, P361, DOI 10.3322/canjclin.48.6.361
   MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240
   Mundy GR, 1998, NEW ENGL J MED, V339, P398, DOI 10.1056/NEJM199808063390609
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nelson JB, 1996, CANCER RES, V56, P663
   Olson KB, 1999, ONCOLOGY NY, V13, P1537
   Oosterhof GON, 2003, EUR UROL, V44, P519, DOI 10.1016/S0302 2838(03)00364 6
   Oremek GM, 2003, ANTICANCER RES, V23, P987
   Orr F. William, 2000, Cancer, V88, P2912, DOI 10.1002/1097 0142(20000615)88:12+<2912::AID CNCR6>3.0.CO;2 8
   Oyajobi BO, 2001, CANCER RES, V61, P2572
   Paget S., 1889, Cancer Metastasis Rev, V133, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   PATCHELL R, 2003, P AN M AM SOC CLIN, V22, P21
   Payne R, 1997, CANCER, V80, P1608, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1608::AID CNCR11>3.0.CO;2 3
   Pelger RCM, 1998, BONE, V22, P403, DOI 10.1016/S8756 3282(97)00289 5
   PETRYLAK DP, 2004, P AN M AM SOC CLIN, V23, P2
   Pinski J, 2002, CANCER RES, V62, P986
   Pinski J, 2001, CANCER RES, V61, P6372
   Pollard M, 2000, PROSTATE, V43, P71, DOI 10.1002/(SICI)1097 0045(20000401)43:1<71::AID PROS10>3.0.CO;2 H
   POLLEN JJ, 1981, CANCER AM CANCER SOC, V47, P2585, DOI 10.1002/1097 0142(19810601)47:11<2585::AID CNCR2820471113>3.0.CO;2 U
   PRICE P, 1986, RADIOTHER ONCOL, V6, P247, DOI 10.1016/S0167 8140(86)80191 8
   Reed SD, 2004, J UROLOGY, V171, P1537, DOI 10.1097/01.ju.0000116777.94426.60
   Robson M, 1996, HEMATOL ONCOL CLIN N, V10, P727, DOI 10.1016/S0889 8588(05)70364 6
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosenthal DI, 1997, CANCER, V80, P1595, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1595::AID CNCR10>3.0.CO;2 V
   Rosol TJ, 2003, CANCER AM CANCER SOC, V97, P748, DOI 10.1002/cncr.11150
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Shariat SF, 2001, UROLOGY, V58, P1008, DOI 10.1016/S0090 4295(01)01405 4
   Shreve PD, 1996, RADIOLOGY, V199, P751, DOI 10.1148/radiology.199.3.8638000
   SLEDGE GW, 1995, J NATL CANCER I, V87, P1546, DOI 10.1093/jnci/87.20.1546
   Smith M R., 2002, Prostate cancer: Principles practice, P595
   SORENSEN PS, 1990, CANCER AM CANCER SOC, V65, P1502, DOI 10.1002/1097 0142(19900401)65:7<1502::AID CNCR2820650709>3.0.CO;2 D
   STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951
   TAKUWA Y, 1990, BIOCHEM BIOPH RES CO, V170, P998, DOI 10.1016/0006 291X(90)90491 5
   THALMANN GN, 1994, CANCER RES, V54, P2577
   TONG D, 1982, CANCER AM CANCER SOC, V50, P893, DOI 10.1002/1097 0142(19820901)50:5<893::AID CNCR2820500515>3.0.CO;2 Y
   Tsingotjidou AS, 2001, ANTICANCER RES, V21, P971
   TURNER JH, 1989, J CLIN ONCOL, V7, P1926, DOI 10.1200/JCO.1989.7.12.1926
   YIN JJ, 2000, J BONE MINER RES, V15, P1254
   YUCHENG S, 1992, J UROLOGY, V148, P1270, DOI 10.1016/S0022 5347(17)36890 8
NR 69
TC 34
Z9 38
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD APR
PY 2005
VL 41
IS 6
BP 932
EP 940
DI 10.1016/j.ejca.2004.12.026
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 920IU
UT WOS:000228683400009
PM 15808959
DA 2025 08 17
ER

PT J
AU Tan, SL
   Su, YG
   Huang, LK
   Deng, SY
   Yan, GH
   Yang, X
   Chen, RF
   Xian, YS
   Liang, JM
   Liu, Q
   Cheng, JW
AF Tan, Shaolin
   Su, Yuangang
   Huang, Linke
   Deng, Siyu
   Yan, Guohua
   Yang, Xue
   Chen, Runfeng
   Xian, Yansi
   Liang, Jiamin
   Liu, Qian
   Cheng, Jianwen
TI Corilagin attenuates osteoclastic osteolysis by enhancing HO 1 and
   inhibiting ROS
SO JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
LA English
DT Article
DE Corilagin; heme oxygenase 1; lipopolysaccharide; osteoclasts; osteolytic
   diseases
ID KAPPA B LIGAND; POSTMENOPAUSAL OSTEOPOROSIS; RECEPTOR ACTIVATOR;
   BONE RESORPTION; DRUG; EXPRESSION
AB Chinese herbal medicine has well established therapeutic effects in various diseases. Corilagin (Cor), a gallic acid tannin in Phyllanthus niruri L., has anti inflammatory and antioxidant effects in many diseases. However, its role in osteoclast related bone diseases has not been determined. In vitro, bone marrow macrophages (BMMs) were extracted and isolated to differentiate into osteoclasts. The effects of Cor on osteoclast formation, bone resorption, and reactive oxygen species (ROS) production were performed. In addition, quantitative real time polymerase chain reaction and western blot analysis were used to evaluate the effect of Cor on oxidative stress related pathways, which are nuclear factors kappa B ligand receptor activator (RANKL) stimulates important downstream pathways. Furthermore, microcomputed tomography and bone histomorphometry were performed to analyze the therapeutic effect of Cor in mouse models of lipopolysaccharide (LPS) mediated bone defects in vivo. Cor influenced the nuclear factor of activated T cells 1 (NFATc1) signaling pathway and reduced ROS in RANKL treated osteoclasts, thereby inhibiting osteoclast formation and bone resorption. Moreover, Cor protected against LPS mediated skull defects in vivo. In sum, our results confirm that Cor can inhibit osteoclastogenesis and intracellular oxidative stress. In addition, the inflammatory bone defect induced by LPS was also attenuated by Cor. Accordingly, Cor is a new candidate therapeutic agent for osteoclast mediated osteolytic diseases.
C1 [Tan, Shaolin; Deng, Siyu; Yan, Guohua; Cheng, Jianwen] Guangxi Med Univ, Affiliated Hosp 1, Dept Trauma Orthoped & Hand Surg, Nanning 530021, Guangxi, Peoples R China.
   [Huang, Linke; Liu, Qian; Cheng, Jianwen] Guangxi Med Univ, Affiliated Hosp 1, Dept Orthopaed, Res Ctr Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
   [Tan, Shaolin; Huang, Linke] Guangxi Med Univ, Affiliated Hosp 2, Dept Orthopaed, Nanning, Guangxi, Peoples R China.
   [Tan, Shaolin; Su, Yuangang; Yang, Xue; Chen, Runfeng; Xian, Yansi; Liang, Jiamin; Liu, Qian] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University
RP Cheng, JW (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Dept Trauma Orthoped & Hand Surg, Nanning 530021, Guangxi, Peoples R China.; Liu, Q (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Dept Orthopaed, Res Ctr Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
EM luoboqian@hotmail.com; 1730054162@qq.com
RI ; Huang, Linke/AAL 8295 2020; Su, Yuangang/KKU 6952 2024
OI Yuangang, Su/0000 0002 1308 2688; 
FU Guangxi Science and Technology Base and Talent Special Project
   [GuikeAD19254003]; Natural Science Foundation of Guangxi Province
   [2018GXNSFAA050092]; National Natural Science Foundation of China
   [81960400]
FX Guangxi Science and Technology Base and Talent Special Project,
   Grant/Award Number: GuikeAD19254003; Natural Science Foundation of
   Guangxi Province, Grant/Award Number: 2018GXNSFAA050092; National
   Natural Science Foundation of China, Grant/Award Number: 81960400
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Bhattarai G, 2016, ACTA BIOMATER, V29, P398, DOI 10.1016/j.actbio.2015.10.031
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Chen DL, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104944
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Estell EG, 2020, ELIFE, V9, DOI 10.7554/eLife.58172
   Fink HA, 2019, ANN INTERN MED, V171, P37, DOI 10.7326/M19 0533
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Jeong JW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061439
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee S, 2021, BONE, V145, DOI 10.1016/j.bone.2020.115836
   Lerner UH, 2006, J DENT RES, V85, P596, DOI 10.1177/154405910608500704
   Li FS, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.109
   Li X, 2018, BIOMED PHARMACOTHER, V99, P43, DOI 10.1016/j.biopha.2018.01.030
   Lu JW, 2020, J CELL MOL MED, V24, P10444, DOI 10.1111/jcmm.15657
   Lukert BP, 2020, J CLIN ENDOCR METAB, V105, pE879, DOI 10.1210/clinem/dgaa007
   Lv HM, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 018 0314 2
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Parekh HS, 2009, MOL CANCER, V8, DOI 10.1186/1476 4598 8 21
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Reyes Hinojosa D, 2019, ENVIRON TOXICOL PHAR, V72, DOI 10.1016/j.etap.2019.103219
   Lacativa PGS, 2010, ARQ BRAS ENDOCRINOL, V54, P123, DOI 10.1590/S0004 27302010000200007
   Sánchez de Diego C, 2021, REDOX BIOL, V40, DOI 10.1016/j.redox.2020.101845
   Sánchez de Diego C, 2019, ISCIENCE, V15, P79, DOI 10.1016/j.isci.2019.04.015
   Sohn H, 2015, LASER SURG MED, V47, P745, DOI 10.1002/lsm.22413
   Suzuki K, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9060223
   Terrier CSP, 2017, J INFECTION, V75, P281, DOI 10.1016/j.jinf.2017.07.007
   Tong YP, 2018, J CELL MOL MED, V22, P3795, DOI 10.1111/jcmm.13647
   Vasikaran S, 2011, CLIN CHEM LAB MED, V49, P1271, DOI 10.1515/CCLM.2011.602
   Wada N, 2004, BONE, V35, P629, DOI 10.1016/j.bone.2004.04.023
   Wang YC, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2446 3
   Wu YX, 2016, BIOMED PHARMACOTHER, V82, P399, DOI 10.1016/j.biopha.2016.05.008
   Yang L, 2019, EUR REV MED PHARMACO, V23, P2640, DOI 10.26355/eurrev_201903_17414
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhu X, 2016, J BONE MINER RES, V31, P560, DOI 10.1002/jbmr.2710
   Zur Y, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2002979
   Zwerina J, 2005, FASEB J, V19, P2011, DOI 10.1096/fj.05 4278fje
NR 44
TC 6
Z9 6
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1095 6670
EI 1099 0461
J9 J BIOCHEM MOL TOXIC
JI J. Biochem. Mol. Toxicol.
PD JUL
PY 2022
VL 36
IS 7
AR e23049
DI 10.1002/jbt.23049
EA MAR 2022
PG 10
WC Biochemistry & Molecular Biology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Toxicology
GA 2Z1GP
UT WOS:000770873500001
PM 35307913
DA 2025 08 17
ER

PT J
AU Eskinazi Budge, A
   Manickavasagam, D
   Czech, T
   Novak, K
   Kunzler, J
   Oyewunni, MO
AF Eskinazi Budge, Aaron
   Manickavasagam, Dharani
   Czech, Tori
   Novak, Kimberly
   Kunzler, James
   Oyewunni, Moses O.
TI Preparation of emulsifying wax/glyceryl monooleate nanoparticles and
   evaluation as a delivery system for repurposing simvastatin in bone
   regeneration
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Osteoclasts; osteoblasts; nanoparticles; bone; nanoemulsions; drug
   delivery
ID GELUCIRE STABILIZED NANOPARTICLES; LIQUID CRYSTALLINE PHASES;
   DIFFERENTIATION IN VITRO; OSTEOBLAST DIFFERENTIATION; OSTEOCLAST
   DIFFERENTIATION; GLYCERYL MONOOLEATE; CONTROLLED RELEASE; MC3T3 E1
   CELLS; OSTEOACTIVIN; OSTEOPOROSIS
AB Simvastatin (Sim) is a widely known drug in the treatment of hyperlipidemia, which has attracted so much attention in bone regeneration due to its potential osteoanabolic effect. However, repurposing of Sim in bone regeneration will require suitable delivery systems that can negate undesirable off target/side effects. In this study, we have investigated a new lipid nanoparticle (NP) platform that was fabricated using a binary blend of emulsifying wax (Ewax) and glyceryl monooleate (GMO). Using the binary matrix materials, NPs loaded with Sim (0 500 mu g/mL) were prepared and showed an average particle size of about 150 nm. NP size stability was dependent on Sim concentration loaded in NPs. The suitability of NPs prepared with the binary matrix materials in Sim delivery for potential application in bone regeneration was supported by biocompatibility in pre osteoclastic and pre osteoblastic cells. Additional data demonstrated that biofunctional Sim was released from NPs that facilitated differentiation of osteoblasts (cells that form bones) while inhibiting differentiation of osteoclasts (cells that resorb bones). The overall work demonstrated the preparation of NPs from Ewax/GMO blends and characterization to ascertain potential suitability in Sim delivery for bone regeneration. Additional studies on osteoblast and osteoclast functions are warranted to fully evaluate the efficacy of Sim loaded Ewax/GMO NPs using in vitro and in vivo approaches.
C1 [Eskinazi Budge, Aaron; Manickavasagam, Dharani; Czech, Tori; Novak, Kimberly; Kunzler, James; Oyewunni, Moses O.] Northeast Ohio Med Univ, Coll Pharm, Dept Pharmaceut Sci, Rootstown, OH 44272 USA.
   [Manickavasagam, Dharani; Oyewunni, Moses O.] Kent State Univ, Dept Biomed Sci, Kent, OH 44242 USA.
C3 University System of Ohio; Northeast Ohio Medical University (NEOMED);
   University System of Ohio; Kent State University; Kent State University
   Kent; Kent State University Salem
RP Oyewunni, MO (通讯作者)，Northeast Ohio Med Univ, Dept Pharmaceut Sci, 4209 State Route 44, Rootstown, OH 44272 USA.
EM moyewumi@neomed.edu
OI Oyewumi, Moses/0000 0003 2733 621X
FU NEOMED College of Pharmacy priority project fund; Thomases family
   endowment fund; Dr. Colene Young endowment fund
FX The research was supported, in part, by (1) NEOMED College of Pharmacy
   priority project fund, (2) Thomases family endowment fund, and (3) Dr.
   Colene Young endowment fund. Authors are grateful to Dr. Fayez Safadi at
   NEOMED for useful discussion. Authors do not have personal and/or
   financial conflict of interest.
CR Abdelmagid SM, 2008, EXP CELL RES, V314, P2334, DOI 10.1016/j.yexcr.2008.02.006
   Abdelmagid SM, 2015, J BIOL CHEM, V290, P20128, DOI 10.1074/jbc.M114.624270
   Abdelmagid SM, 2014, AM J PATHOL, V184, P697, DOI 10.1016/j.ajpath.2013.11.031
   Arosarena OA, 2011, J CELL PHYSIOL, V226, P2943, DOI 10.1002/jcp.22639
   Bi LP, 2013, DRUG DELIV TRANSL RE, V3, P318, DOI 10.1007/s13346 013 0130 6
   Cheng BH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070234
   de Miguel L, 2014, INT J PHARMACEUT, V460, P73, DOI 10.1016/j.ijpharm.2013.10.048
   Dong X, 2006, DRUG DEV IND PHARM, V32, P973, DOI 10.1080/03639040600640006
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Drake MT, 2010, MOL INTERV, V10, P141, DOI 10.1124/mi.10.3.5
   Elgindy NA, 2016, INT J PHARMACEUT, V501, P167, DOI 10.1016/j.ijpharm.2016.01.049
   Ganem Quintanar A, 2000, DRUG DEV IND PHARM, V26, P809, DOI 10.1081/DDC 100101304
   Gentile P, 2016, MAT SCI ENG C MATER, V59, P249, DOI 10.1016/j.msec.2015.10.014
   Isakova T, 2016, J BONE MINER RES, V31, P742, DOI 10.1002/jbmr.2750
   Kanis JA, 2008, BONE, V42, P467, DOI 10.1016/j.bone.2007.11.001
   KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133
   Kumar KM, 2004, INT J PHARMACEUT, V272, P151, DOI 10.1016/j.ijpharm.2003.12.025
   Lacombe J, 2016, J BONE MINER RES, V31, P1559, DOI 10.1002/jbmr.2826
   Liu XN, 2013, COLLOID SURFACE B, V102, P420, DOI 10.1016/j.colsurfb.2012.06.037
   Looker Anne C, 2012, NCHS Data Brief, P1
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Makras P, 2015, METABOLISM, V64, P1199, DOI 10.1016/j.metabol.2015.07.011
   Milak S, 2015, INT J PHARMACEUT, V478, P569, DOI 10.1016/j.ijpharm.2014.11.072
   Naito Y, 2014, INT J PHARMACEUT, V461, P157, DOI 10.1016/j.ijpharm.2013.11.046
   Nakashima Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072033
   Nath SD, 2014, J BIOMATER APPL, V28, P1151, DOI 10.1177/0885328213499272
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Oyewumi MO, 2002, DRUG DEV IND PHARM, V28, P317, DOI 10.1081/DDC 120002847
   Oyewumi MO, 2016, PHARM DEV TECHNOL, V21, P647, DOI 10.3109/10837450.2015.1041043
   Papadimitriou K, 2015, J CRANIO MAXILL SURG, V43, P232, DOI 10.1016/j.jcms.2014.11.011
   Park JB, 2012, J SURG RES, V174, P278, DOI 10.1016/j.jss.2010.12.029
   Park JB, 2009, MED ORAL PATOL ORAL, V14, pE485
   Park YS, 2013, AAPS J, V15, P367, DOI 10.1208/s12248 012 9442 6
   Patil SS, 2016, DRUG DEV IND PHARM, V42, P1300, DOI 10.3109/03639045.2015.1128440
   Pauly S, 2009, BONE, V45, P505, DOI 10.1016/j.bone.2009.05.010
   Sallam AS, 2002, EUR J PHARM BIOPHARM, V53, P343, DOI 10.1016/S0939 6411(02)00016 4
   Seo BB, 2015, J CONTROL RELEASE, V209, P67, DOI 10.1016/j.jconrel.2015.04.023
   Shah SR, 2015, NATL SCI REV, V2, P85, DOI 10.1093/nsr/nwu028
   Sheng MHC, 2008, FEBS LETT, V582, P1451, DOI 10.1016/j.febslet.2008.03.030
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Strittmatter SM, 2014, NAT MED, V20, P590, DOI 10.1038/nm.3595
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Suh TT, 2003, CURR OPIN RHEUMATOL, V15, P481, DOI 10.1097/00002281 200307000 00018
   Tanigo T, 2010, J CONTROL RELEASE, V143, P201, DOI 10.1016/j.jconrel.2009.12.027
   Wang HN, 2013, J CONTROL RELEASE, V166, P172, DOI 10.1016/j.jconrel.2012.12.015
   Wehrung D, 2013, J BIOMED NANOTECHNOL, V9, P1029, DOI 10.1166/jbn.2013.1598
   Wehrung D, 2012, J NANOSCI NANOTECHNO, V12, P2901, DOI 10.1166/jnn.2012.5789
   Wehrung D, 2012, J BIOMED NANOTECHNOL, V8, P161, DOI 10.1166/jbn.2012.1361
   Wehrung D, 2012, COLLOID SURFACE B, V94, P259, DOI 10.1016/j.colsurfb.2012.02.005
   Zhang WX, 2008, J BIOL CHEM, V283, P4723, DOI 10.1074/jbc.M704147200
   Zhou XF, 2016, ACTA BIOMATER, V39, P192, DOI 10.1016/j.actbio.2016.05.007
   Zhou YS, 2010, BIOMATERIALS, V31, P5325, DOI 10.1016/j.biomaterials.2010.03.037
NR 52
TC 12
Z9 12
U1 0
U2 17
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0363 9045
EI 1520 5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PY 2018
VL 44
IS 10
BP 1583
EP 1590
DI 10.1080/03639045.2018.1483381
PG 8
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GS7EP
UT WOS:000443863900003
PM 29847182
DA 2025 08 17
ER

PT J
AU Allegra, A
   Mania, M
   D'Ascola, A
   Oteri, G
   Siniscalchi, EN
   Avenoso, A
   Innao, V
   Scuruchi, M
   Allegra, AG
   Musolino, C
   Campo, S
AF Allegra, Alessandro
   Mania, Manuela
   D'Ascola, Angela
   Oteri, Giacomo
   Siniscalchi, Enrico Nastro
   Avenoso, Angela
   Innao, Vanessa
   Scuruchi, Michele
   Allegra, Andrea Gaetano
   Musolino, Caterina
   Campo, Salvatore
TI Altered Long Noncoding RNA Expression Profile in Multiple Myeloma
   Patients with Bisphosphonate Induced Osteonecrosis of the Jaw
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID PROMOTES OSTEOBLAST DIFFERENTIATION; MESENCHYMAL STEM CELLS; OSTEOGENIC
   DIFFERENTIATION; EPIGENETIC REGULATION; LNCRNA DANCR; BONE;
   ANGIOGENESIS; CHROMATIN; IMMUNOTHERAPY; PROLIFERATION
AB Bisphosphonates (BPs) are inhibitors of osteoclast mediated bone resorption used for the treatment of multiple myeloma (MM) patients with osteolytic lesions. Bisphosphonate induced osteonecrosis of the jaw (BONJ) is an infrequent drug caused adverse event of these agents. Long noncoding RNAs (lncRNAs) are a set of more than 200 base pairs, noncoding RNA molecules, which are critical posttranscriptional regulators of gene expression. Our study was aimed at evaluating 17 lncRNAs, whose targets were previously validated as key elements in MM, bone metabolism, and angiogenesis in MM subjects without BONJ (MM group), in MM subjects with BONJ (BONJ group), and a group of healthy controls (CTRL group). Our results demonstrated a different lncRNA profile in BONJ patients compared to MM patients and controls. Two lncRNAs (DANCR and MALAT1) were both downregulated compared to controls and MM, twelve (HOTAIR, MEG3, TP73 AS1, HOTTIP, HIF1A AS2, MANTIS, CTD 2201E18, CTD1 2003C8, R 471B22, RP1 43E13, RP11 553L6.5, and RP1 286D6) were overexpressed in MM with BONJ, and one (H19) was upregulated compared with only MM. Two lncRNAs (JHDMD1 and MTMR9LP) had higher expression, but these differences were not statistically significant. The examined lncRNAs target several genes and metabolic pathways. An altered lncRNA signature could contribute to the onset of BONJ or have a protective action. Targeting these lncRNAs could offer a possibility for the prevention or therapy of BONJ.
C1 [Allegra, Alessandro; Innao, Vanessa; Allegra, Andrea Gaetano; Musolino, Caterina] Univ Messina, Dept Human Pathol Adulthood & Childhood Gaetano B, Div Haematol, I 98125 Messina, Italy.
   [Mania, Manuela; D'Ascola, Angela; Oteri, Giacomo; Siniscalchi, Enrico Nastro; Avenoso, Angela; Campo, Salvatore] Univ Messina, Dept Biochem & Dent Sci & Morphofunct Images, Messina, Italy.
   [Scuruchi, Michele] Univ Messina, Dept Clin & Expt Med, Messina, Italy.
C3 University of Messina; University of Messina; University of Messina
RP Mania, M (通讯作者)，Univ Messina, Dept Biochem & Dent Sci & Morphofunct Images, Messina, Italy.
EM aallegra@unime.it; manuela.mania87@gmail.com; adascola@unime.it;
   giacomo.oteri@unime.it; enastrosiniscalchi@unime.it; aavenoso@unime.it;
   vinnao@unime.it; mscuruchi@unime.it; andrea.allegra@hotmail.it;
   cmusolino@unime.it; scampo@unime.it
RI ; Mania, Manuela/E 5738 2018; Innao, Vanessa/AAS 7720 2020; Allegra,
   Alessandro/LRT 2739 2024; Scuruchi, Michele/K 2533 2018
OI Allegra, Andrea Gaetano/0000 0001 6109 4563; Mania,
   Manuela/0000 0001 5144 8719; Allegra, Alessandro/0000 0001 6156 8239;
   NASTRO SINISCALCHI, Enrico/0000 0002 4424 0917; Oteri,
   Giacomo/0000 0002 0941 1645; d'ascola, angela/0000 0001 7530 1316; 
CR Allegra A, 2019, TOHOKU J EXP MED, V248, P27, DOI 10.1620/tjem.248.27
   Allegra A, 2016, BLOOD CELL MOL DIS, V62, P49, DOI 10.1016/j.bcmd.2016.11.001
   Allegra A, 2015, CRIT REV ONCOL HEMAT, V96, P339, DOI 10.1016/j.critrevonc.2015.06.003
   Allegra A, 2014, J CRANIO MAXILL SURG, V42, P279, DOI 10.1016/j.jcms.2013.05.014
   Allegra A, 2014, LEUKEMIA RES, V38, P1, DOI 10.1016/j.leukres.2013.10.018
   Allegra A, 2013, EUR J HAEMATOL, V90, P441, DOI 10.1111/ejh.12107
   Allegra A, 2011, EUR J HAEMATOL, V86, P93, DOI 10.1111/j.1600 0609.2010.01558.x
   Allegra A, 2010, ACTA HAEMATOL BASEL, V124, P79, DOI 10.1159/000313787
   Alonci A, 2007, LEUKEMIA LYMPHOMA, V48, P1852, DOI 10.1080/10428190701509806
   Andrews SW, 2013, BRIT J BIOMED SCI, V70, P110, DOI 10.1080/09674845.2013.11669945
   Aoyagi H, 2018, J CELL BIOCHEM, V119, P5481, DOI 10.1002/jcb.26710
   Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   Campo S, 2014, BRIT J HAEMATOL, V165, P801, DOI 10.1111/bjh.12828
   Chatterjee M, 2019, J BIOSCIENCES, V44, DOI 10.1007/s12038 018 9820 z
   Chen LL, 2010, CURR OPIN CELL BIOL, V22, P357, DOI 10.1016/j.ceb.2010.03.003
   Chunharojrith P, 2015, MOL CELL ENDOCRINOL, V416, P27, DOI 10.1016/j.mce.2015.08.018
   Cui YG, 2019, J CELL MOL MED, V23, P3843, DOI 10.1111/jcmm.14228
   da Silva RA, 2019, BONE, V125, P74, DOI 10.1016/j.bone.2019.04.026
   Demircan S, 2020, NIGER J CLIN PRACT, V23, P154, DOI 10.4103/njcp.njcp_374_19
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Ettari R, 2018, PHARMACOL THERAPEUT, V182, P176, DOI 10.1016/j.pharmthera.2017.09.001
   Fu WM, 2016, ONCOTARGET, V7, P4712, DOI 10.18632/oncotarget.6731
   Gandolfi MG, 1999, CLIN EXP RHEUMATOL, V17, P327
   Giannasi C, 2019, INT J MED SCI, V16, P23, DOI 10.7150/ijms.27470
   Gordon FE, 2010, ENDOCRINOLOGY, V151, P2443, DOI 10.1210/en.2009 1151
   Gupta SC, 2017, INT J CANCER, V140, P1955, DOI 10.1002/ijc.30546
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Hanna N, 2012, CANCER GENE THER, V19, P374, DOI 10.1038/cgt.2012.10
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Hassan MQ, 2015, BONE, V81, P746, DOI 10.1016/j.bone.2015.05.026
   Hu AX, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694563
   Jiang LT, 2017, J ORAL PATHOL MED, V46, P398, DOI 10.1111/jop.12499
   Jiang SY, 2019, EUR REV MED PHARMACO, V23, P5558, DOI 10.26355/eurrev_201907_18289
   Jiang W, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935 019 0928 5
   Kondo A, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00125 17
   Kumar MM, 2017, CURR TOP MED CHEM, V17, P1750, DOI 10.2174/1568026617666161116144744
   Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704
   Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008
   Malek R, 2017, CANCER RES, V77, P3181, DOI 10.1158/0008 5472.CAN 16 2797
   Man HSJ, 2019, CURR OPIN PHARMACOL, V45, P72, DOI 10.1016/j.coph.2019.04.012
   Manier S, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/157496
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092 8674(93)90573 9
   Mudge JM, 2015, MAMM GENOME, V26, P366, DOI 10.1007/s00335 015 9583 x
   Musolino C, 2018, ANN HEMATOL, V97, P1259, DOI 10.1007/s00277 018 3296 7
   Nardocci G, 2018, J CELL BIOCHEM, V119, P7657, DOI 10.1002/jcb.27113
   Nastro E, 2009, J ORAL MAXIL SURG, V67, P2701, DOI 10.1016/j.joms.2008.05.369
   Nifosi AF, 2019, J KOR ASSOC ORAL MAX, V45, P3, DOI 10.5125/jkaoms.2019.45.1.3
   Qadir AS, 2015, J CELL BIOCHEM, V116, P730, DOI 10.1002/jcb.25026
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev biochem 051410 092902
   Rodrigues Luvizuto E, 2010, Minerva Stomatol, V59, P355
   Shen Y, 2018, LIFE SCI, V196, P133, DOI 10.1016/j.lfs.2018.01.025
   Siqueira MF, 2011, BONE, V48, P1043, DOI 10.1016/j.bone.2011.01.019
   Tang ZY, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0406 8
   Tye CE, 2018, CONNECT TISSUE RES, V59, P35, DOI 10.1080/03008207.2017.1412432
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang QY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27501 2
   Wei BF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169097
   Wu RY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1082 z
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 303
   Yang HH, 2003, J CLIN ONCOL, V21, P4239, DOI 10.1200/JCO.2003.06.001
   Yu B, 2018, THERANOSTICS, V8, P3654, DOI 10.7150/thno.26024
   Zhang JL, 2018, INT J MOL MED, V41, P213, DOI 10.3892/ijmm.2017.3215
   Zhang K, 2014, GENE, V547, P1, DOI 10.1016/j.gene.2014.06.043
   Zhang XG, 2019, CELL CYCLE, V18, P1759, DOI 10.1080/15384101.2019.1632638
   Zhang ZS, 2018, EUR REV MED PHARMACO, V22, P1374, DOI 10.26355/eurrev_201803_14481
   Zhou M, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0219 5
   Zhu L, 2013, BIOCHEM BIOPH RES CO, V432, P612, DOI 10.1016/j.bbrc.2013.02.036
   Zuo CQ, 2013, MOL MED REP, V8, P463, DOI 10.3892/mmr.2013.1540
NR 72
TC 18
Z9 18
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD JUL 3
PY 2020
VL 2020
AR 9879876
DI 10.1155/2020/9879876
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA MQ3MK
UT WOS:000552800700009
PM 32714991
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Pan, TH
   Liu, FS
   Hao, XX
   Wang, SB
   Wasi, M
   Song, JH
   Lewis, VO
   Lin, PP
   Moon, B
   Bird, JE
   Panaretakis, T
   Lin, SH
   Wu, DNL
   Farach Carson, MC
   Wang, LY
   Zhang, NY
   An, ZQ
   Zhang, XHF
   Satcher, RL
AF Pan, Tianhong
   Liu, Fengshuo
   Hao, Xiaoxin
   Wang, Shubo
   Wasi, Murtaza
   Song, Jian H.
   Lewis, Valerae O.
   Lin, Patrick P.
   Moon, Bryan
   Bird, Justin E.
   Panaretakis, Theocharis
   Lin, Sue Hwa
   Wu, Danielle
   Farach Carson, Mary C.
   Wang, Liyun
   Zhang, Ningyan
   An, Zhiqiang
   Zhang, Xiang H.  F.
   Satcher, Robert L.
TI BIGH3 mediates apoptosis and gap junction failure in osteocytes during
   renal cell carcinoma bone metastasis progression
SO CANCER LETTERS
LA English
DT Article
DE Renal cell carcinoma; Bone metastasis; BIGH3/TGFBI; Osteocyte; Apoptosis
ID IN VITRO; CONNEXIN 43; BETA IG H3; PROTEIN; ALPHA(V)BETA(3); ATTACHMENT;
   PROMOTES; SURVIVAL; ADHESION; GROWTH
AB Renal cell carcinoma (RCC) bone metastatis progression is driven by crosstalk between tumor cells and the bone microenvironment, which includes osteoblasts, osteoclasts, and osteocytes. RCC bone metastases (RCCBM) are predominantly osteolytic and resistant to antiresorptive therapy. The molecular mechanisms underlying pathologic osteolysis and disruption of bone homeostasis remain incompletely understood. We previously reported that BIGH3/TGFBI (transforming growth factor  beta  induced protein ig h3, shortened to BIGH3 henceforth) secreted by colonizing RCC cells drives osteolysis by inhibiting osteoblast differentiation, impairing healing of osteolytic lesions, which is reversible with osteoanabolic agents. Here, we report that BIGH3 induces osteocyte apoptosis in both human RCCBM tissue specimens and in a preclinical mouse model. We also demonstrate that BIGH3 reduces Cx43 expression, blocking gap junction (GJ) function and osteocyte network communication. BIGH3 mediated GJ inhibition is blocked by the lysosomal inhibitor hydroxychloroquine (HCQ), but not osteoanabolic agents. Our results broaden the understanding of pathologic osteolysis in RCCBM and indicate that targeting the BIGH3 mechanism could be a combinational strategy for the treatment of RCCBM induced bone disease that overcomes the limited efficacy of antiresorptives that target osteoclasts.
C1 [Pan, Tianhong; Lewis, Valerae O.; Lin, Patrick P.; Moon, Bryan; Bird, Justin E.; Satcher, Robert L.] Univ Texas MD Anderson Canc Ctr, Dept Orthoped Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
   [Liu, Fengshuo; Hao, Xiaoxin; Zhang, Xiang H.  F.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX USA.
   [Wang, Shubo; Wasi, Murtaza] Univ Delaware, Dept Mech Engn, Newark, DE USA.
   [Song, Jian H.; Panaretakis, Theocharis; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA.
   [Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA.
   [Wu, Danielle; Farach Carson, Mary C.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Biomed Sci, Sch Dent, Houston, TX USA.
   [Farach Carson, Mary C.] Rice Univ, Dept Biosci, Houston, TX USA.
   [Farach Carson, Mary C.] Rice Univ, Dept Bioengn, Houston, TX USA.
   [Zhang, Ningyan; An, Zhiqiang] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Mcgovern Med Sch, Houston, TX USA.
   [Zhang, Xiang H.  F.] Baylor Coll Med, Dept Lester, Houston, TX USA.
   [Zhang, Xiang H.  F.] Baylor Coll Med, Sue Smith Breast Ctr, Houston, TX USA.
   [Zhang, Xiang H.  F.] Baylor Coll Med, Dept Dan Duncan Canc Ctr, Houston, TX USA.
   [Zhang, Xiang H.  F.] Baylor Coll Med, Dept Mcnair Med Inst, Houston, TX USA.
C3 University of Texas System; UTMD Anderson Cancer Center; Baylor College
   of Medicine; University of Delaware; University of Texas System; UTMD
   Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer
   Center; University of Texas System; University of Texas Health Science
   Center Houston; Rice University; Rice University; University of Texas
   System; University of Texas Health Science Center Houston; Baylor
   College of Medicine; Baylor College of Medicine; Baylor College of
   Medicine; Baylor College of Medicine
RP Satcher, RL (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Orthoped Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM rlsatcher@mdanderson.org
RI ; An, Zhiqiang/IUO 1781 2023; Satcher, Robert/K 7308 2018; Liu,
   Fengshuo/MFJ 0999 2025; Wang, Shubo/AFG 7311 2022; Panaretakis,
   Theocharis/A 9354 2010
OI Liu, Fengshuo/0000 0003 4651 7710; Wasi, Murtaza/0000 0002 0321 6670;
   An, Zhiqiang/0000 0001 9309 2335; 
FU DOD [W81XWH 20 1 0895]; UT Health Houston and MD Anderson Cancer Center
FX This work was supported by the grant from DOD (W81XWH 20 1 0895) to RLS
   and institutional funds from UT Health Houston and MD Anderson Cancer
   Center.
CR Batra N, 2012, P NATL ACAD SCI USA, V109, P3359, DOI 10.1073/pnas.1115967109
   Bivi N, 2012, CALCIFIED TISSUE INT, V91, P215, DOI 10.1007/s00223 012 9628 z
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Dieudonné SC, 2000, J CELL BIOCHEM, V76, P231, DOI 10.1002/(SICI)1097 4644(20000201)76:2<231::AID JCB7>3.0.CO;2 X
   Dole NS, 2017, CELL REP, V21, P2585, DOI 10.1016/j.celrep.2017.10.115
   Fowler TW, 2017, SCI REP UK, V7, DOI 10.1038/srep44618
   Haugh MG, 2015, J MECH BEHAV BIOMED, V42, P67, DOI 10.1016/j.jmbbm.2014.11.001
   Irigoyen M, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 130
   Jiang GJ, 2017, ONCOL LETT, V13, P857, DOI 10.3892/ol.2016.5471
   Jiang JX, 2007, FRONT BIOSCI LANDMRK, V12, P1450, DOI 10.2741/2159
   Jin JK, 2015, ONCOGENE, V34, P1811, DOI 10.1038/onc.2014.116
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kim JE, 2002, J BIOL CHEM, V277, P46159, DOI 10.1074/jbc.M207055200
   Lee HO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131464
   Ma L, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0050 2
   McKay RR, 2014, EUR UROL, V66, P502, DOI 10.1016/j.eururo.2014.02.040
   McNamara LM, 2009, ANAT REC, V292, P355, DOI 10.1002/ar.20869
   Mondragon AA, 2015, APOPTOSIS, V20, P29, DOI 10.1007/s10495 014 1052 6
   Moritz Robert J, 2016, Int J Clin Med, V7, P496, DOI 10.4236/ijcm.2016.77055
   Pan TH, 2020, MOL CANCER THER, V19, P1266, DOI 10.1158/1535 7163.MCT 19 0174
   Pan TH, 2018, NEOPLASIA, V20, P32, DOI 10.1016/j.neo.2017.11.002
   Pan TH, 2015, CANCER LETT, V365, P89, DOI 10.1016/j.canlet.2015.05.019
   Picoli C, 2019, ASSAY DRUG DEV TECHN, V17, P240, DOI 10.1089/adt.2019.927
   Plotkin LI, 2014, CURR OSTEOPOROS REP, V12, P121, DOI 10.1007/s11914 014 0194 3
   Plotkin LI, 2007, J BIOL CHEM, V282, P24120, DOI 10.1074/jbc.M611435200
   Riquelme MA, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.567844
   Satcher RL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089880
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571
   Solan JL, 2014, FEBS LETT, V588, P1423, DOI 10.1016/j.febslet.2014.01.049
   Thapa N, 2005, BONE, V36, P232, DOI 10.1016/j.bone.2004.08.007
   Thi MM, 2013, P NATL ACAD SCI USA, V110, P21012, DOI 10.1073/pnas.1321210110
   Wang YL, 2007, P NATL ACAD SCI USA, V104, P15941, DOI 10.1073/pnas.0707246104
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Wood SL, 2012, CANCER TREAT REV, V38, P284, DOI 10.1016/j.ctrv.2011.06.011
   Yellowley CE, 2000, J BONE MINER RES, V15, P209, DOI 10.1359/jbmr.2000.15.2.209
NR 38
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD AUG 1
PY 2024
VL 596
AR 217009
DI 10.1016/j.canlet.2024.217009
EA JUN 2024
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA UZ5W5
UT WOS:001251909800001
PM 38849015
OA hybrid
DA 2025 08 17
ER

PT J
AU Machak, GN
   Bruland, OS
   Romanova, TN
   Kovalev, A
AF Machak, Gennady N.
   Bruland, oyvind S.
   Romanova, Tamara N.
   Kovalev, Alexey, V
TI Denosumab induction and Zoledronic acid maintenance therapy for
   recurrent unresectable giant cell tumour of the distal tibia: A case
   report with sustained tumour control after drug withdrawal
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Giant cell tumour of bone; Vicious cycle; Denosumab; Zoledronic acid
ID STROMAL CELLS; OSTEOGENIC DIFFERENTIATION; BONE FORMATION; OPEN LABEL;
   BISPHOSPHONATE; OSTEOCLASTS; EXPRESSION; APOPTOSIS; GROWTH; RANKL
AB A 31  year  old woman was diagnosed with a recurrent and rapidly growing giant cell tumour of distal tibia with skin ulceration after intralesional curettage. The patient started on Denosumab 120 mg subcutaneously, once per month with additional loading doses on Days 8 and 15 attempting to avoid below  knee amputation. Twelve doses of Denosumab were administered in 9 months, resulting in resolution of pain, reduction of tumour size and calcification. Hence, the local surgical treatment was delayed and bisphosphonate maintenance therapy was initiated as skin healing was incomplete. The patient was given Zoledronic acid infusions at a dose of 4 mg. After the third infusion, the skin healed. As tumour remained stable, it was decided to continue maintenance. Overall, six doses of Zoledronic acid at 6 months intervals were administrated over 3 years. At the end of the maintenance, the patient experienced no pain and satisfied with her limb function. Since the lesion remained stable over 3 years after Denosumab discontinuation, it was suggested to stop further medical treatment and proceed to active surveillance. The patient's disease is still stable clinical remission with no serious adverse events 41 months after Denosumab cessation and 10 months after the last bisphosphonate infusion. The present case confirmed the high effectiveness of denosumab as induction therapy in advanced recurrent giant cell tumour. We speculate that following the Denosumab induced tumour ossification, high Zoledronic acid uptake in lesion may prevent tumour reactivation due to its improved pharmacodynamics with an assumed irreversible anti  tumoral effect on residual mutated cells. This hypothesis requires confirmation in future studies.
C1 [Machak, Gennady N.] FSBI Natl Med Res Ctr Traumatol & Orthoped NN Prio, Clin & Diagnost Ctr, Minist Hlth Russian Federat, Moscow, Russia.
   [Bruland, oyvind S.] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway.
   [Bruland, oyvind S.] Univ Oslo, Inst Clin Med, Oslo, Norway.
   [Romanova, Tamara N.] FSBI Natl Med Res Ctr Traumatol & Orthoped NN Prio, Minist Hlth Russian Federat, Dept Radiol, Moscow, Russia.
   [Kovalev, Alexey, V] FSBI Natl Med Res Ctr Traumatol & Orthoped NN Prio, Minist Hlth Russian Federat, Lab Cell Technol & Med Genet, Moscow, Russia.
C3 Ministry of Health of the Russian Federation; University of Oslo;
   University of Oslo; Ministry of Health of the Russian Federation;
   Ministry of Health of the Russian Federation
RP Machak, GN (通讯作者)，FSBI Natl Med Res Ctr Traumatol & Orthoped NN Prio, Clin & Diagnost Ctr, Minist Hlth Russian Federat, Moscow, Russia.
EM machak.gennady@mail.ru; oyvind.bruland@medisin.uio.no;
   tamara.gorsh@yandex.ru
RI Machak, Gennady/AAY 5773 2020; Kovalev, Alexey/AAC 6827 2019
OI Kovalev, Alexey/0000 0003 1277 5228; Machak, Gennady/0000 0003 1222 5066
CR Agarwal MG, 2018, CLIN ORTHOP RELAT R, V476, P1773, DOI 10.1007/s11999.0000000000000243
   Anusitviwat C, 2022, BMJ CASE REP, V15, DOI 10.1136/bcr 2022 248837
   Balke M, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 462
   Beck Nielsen SS, 2023, BONE REP, V18, DOI 10.1016/j.bonr.2023.101687
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Bilgetekin I, 2020, ANTI CANCER DRUG, V31, P533, DOI 10.1097/CAD.0000000000000859
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Chang SS, 2004, CLIN ORTHOP RELAT R, P103, DOI 10.1097/01.blo.0000141372.54456.80
   Chaudhary P, 2011, ONKOLOGIE, V34, P702, DOI 10.1159/000334549
   Chawla S, 2019, LANCET ONCOL, V20, P1719, DOI 10.1016/S1470 2045(19)30663 1
   Cheng YY, 2004, CALCIFIED TISSUE INT, V75, P71, DOI 10.1007/s00223 004 0120 2
   Cheng YY, 2003, ULTRASTRUCT PATHOL, V27, P385, DOI 10.1080/01913120390248629
   Cottone L, 2022, CELL DEATH DIFFER, V29, P2459, DOI 10.1038/s41418 022 01031 x
   Cowan RW, 2013, BONE, V52, P238, DOI 10.1016/j.bone.2012.10.002
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   De Vita A, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10020372
   di Carlo FS, 2020, CANCER LETT, V489, P1, DOI 10.1016/j.canlet.2020.05.031
   Dubey Siddharth, 2019, J Clin Orthop Trauma, V10, P1021, DOI 10.1016/j.jcot.2019.09.011
   Fellenberg J, 2019, CANCER LETT, V448, P61, DOI 10.1016/j.canlet.2019.02.001
   Feng WY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.715552
   Flanagan A.M., 2020, cell tumour of bone. WHO classification of tumours of soft tissue and bone, V5th ed., P440
   Forsyth RG, 2021, CANCERS, V13, DOI 10.3390/cancers13205119
   Furuta T, 2022, ACTA RADIOL, V63, P176, DOI 10.1177/0284185121989515
   Gaston CL, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569 016 0056 0
   Gille O, 2012, SPINE, V37, pE396, DOI 10.1097/BRS.0b013e31823ed70d
   Hayashida K, 2022, J ORTHOP SCI, V27, P215, DOI 10.1016/j.jos.2020.11.005
   Jiang CY, 2022, ONCOLOGIST, V27, P595, DOI 10.1093/oncolo/oyac066
   Khan M, 2017, ENDOCRIN METAB CLIN, V46, P181, DOI 10.1016/j.ecl.2016.09.009
   Khazaei S, 2020, CANCER DISCOV, V10, P1968, DOI 10.1158/2159 8290.CD 20 0461
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   Kudo N, 2009, ANTICANCER RES, V29, P2219
   Kumar A, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.16742
   Kundu ZS, 2018, INDIAN J ORTHOP, V52, P45, DOI 10.4103/ortho.IJOrtho_216_17
   Lau CPY, 2015, CONNECT TISSUE RES, V56, P493, DOI 10.3109/03008207.2015.1075519
   Lau CPY, 2013, CONNECT TISSUE RES, V54, P439, DOI 10.3109/03008207.2013.848202
   Lau CPY, 2011, J ORTHOP RES, V29, P403, DOI 10.1002/jor.21249
   Luengo Alonso G, 2019, ARCH ORTHOP TRAUM SU, V139, P1339, DOI 10.1007/s00402 019 03167 x
   Luo Yi, 2018, Cancer Manag Res, V10, P1901, DOI 10.2147/CMAR.S161871
   Ma QY, 2019, J BIOL CHEM, V294, P11240, DOI 10.1074/jbc.RA119.007625
   NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), 2023, Bone Cancer Version 1.2024
   Nishimura S, 2017, MOL CLIN ONCOL, V6, P307, DOI 10.3892/mco.2017.1137
   Palmerini E, 2017, EUR J CANCER, V76, P118, DOI 10.1016/j.ejca.2017.01.028
   Rajani R, 2015, J FOOT ANKLE SURG, V54, P1141, DOI 10.1053/j.jfas.2014.08.016
   Rodan G, 2004, CURR MED RES OPIN, V20, P1291, DOI 10.1185/030079904125004475
   Rosario M, 2017, ANTICANCER RES, V37, P749, DOI 10.21873/anticanres.11373
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Rutkowski P, 2015, ANN SURG ONCOL, V22, P2860, DOI 10.1245/s10434 015 4634 9
   Sambri A, 2020, J ORTHOP SCI, V25, P513, DOI 10.1016/j.jos.2019.05.003
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Schilcher J, 2015, ACTA ORTHOP, V86, P100, DOI 10.3109/17453674.2015.1004149
   Shibuya I, 2019, PATHOL ONCOL RES, V25, P409, DOI 10.1007/s12253 017 0362 8
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Stepan J J, 2003, Endocr Regul, V37, P225
   Takegahara N, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116353
   Tse LF, 2008, BONE, V42, P68, DOI 10.1016/j.bone.2007.08.038
   Tsukamoto S, 2021, CANCERS, V13, DOI 10.3390/cancers13153647
   Tsukamoto S, 2020, CLIN ORTHOP RELAT R, V478, P1076, DOI 10.1097/CORR.0000000000001074
   Veng Christian, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr 2017 220369
   Wang XD, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.690502
   Yang L, 2022, ANN DIAGN PATHOL, V57, DOI 10.1016/j.anndiagpath.2021.151882
   Yang T, 2013, ASIAN PAC J CANCER P, V14, P5379, DOI 10.7314/APJCP.2013.14.9.5379
   Yayan J, 2020, CANCER CONTROL, V27, DOI 10.1177/1073274820934822
   Yue JJ, 2022, J BONE ONCOL, V35, DOI 10.1016/j.jbo.2022.100441
   Zhao ZQ, 2019, J BONE ONCOL, V14, DOI 10.1016/j.jbo.2018.100209
   Zwolak P, 2010, J BONE JOINT SURG AM, V92A, P162, DOI 10.2106/JBJS.H.01679
NR 65
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD APR
PY 2024
VL 45
AR 100596
DI 10.1016/j.jbo.2024.100596
EA MAR 2024
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA QN6C9
UT WOS:001221581100001
PM 38545297
OA gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Mai, YX
   Li, ZP
   Pang, FX
   Zhou, ST
   Li, N
   Wang, YY
   Zhang, JF
AF Mai, Yong xin
   Li, Zhi peng
   Pang, Feng xiang
   Zhou, Shu ting
   Li, Nan
   Wang, Yu yan
   Zhang, Jin fang
TI Aucubin Promotes Osteogenic Differentiation and Facilitates Bone
   Formation through the lncRNA H19 Driven Wnt/β Catenin Signaling
   Regulatory Axis
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; PATHWAY; H19;
   OSTEOPOROSIS; WNT
AB Objectives. Traditional Chinese medicine Cortex Eucommiae has been used to treat bone fracture for hundreds of years, which exerts a significant improvement in fracture healing. Aucubin, a derivative isolated from Cortex Eucommiae, has been demonstrated to possess anti inflammatory, immunoregulatory, and antioxidative potential. In the present study, our aim was to explore its function in bone regeneration and elucidate the underlying mechanism. Materials and Methods. The effects of Aucubin on osteoblast and osteoclast were examined in mouse bone marrow derived mesenchymal stem cells (BM MSCs) and RAW 264.7 cells, respectively. Moreover, the lncRNA H19 and Wnt/beta catenin signaling were detected by qPCR examination, western blotting, and luciferase activity assays. Using the femur fracture mice model, the in vivo effect of Aucubin on bone formation was monitored by X ray, micro CT, histomorphometry, and immunohistochemistry staining. Results. In the present study, Aucubin was found to significantly promote osteogenic differentiation in vitro and stimulated bone formation in vivo. Regarding to the underlying mechanism, H19 was found to be obviously upregulated by Aucubin in MSCs and thus induced the activation of Wnt/beta catenin signaling. Moreover, H19 knockdown partially reversed the Aucubin induced osteogenic differentiation and successfully suppressed the activation of Wnt/beta catenin signaling. We therefore suggested that Aucubin induced the activation of Wnt/beta catenin signaling through promoting H19 expression. Conclusion. Our results demonstrated that Aucubin promoted osteogenesis in vitro and facilitated fracture healing in vivo through the H19 Wnt/beta catenin regulatory axis.
C1 [Mai, Yong xin; Zhou, Shu ting; Li, Nan; Wang, Yu yan; Zhang, Jin fang] Guangzhou Univ Chinese Med, Canc Ctr, Shenzhen Hosp Futian, Shenzhen 518000, Guangdong, Peoples R China.
   [Mai, Yong xin; Li, Zhi peng; Zhou, Shu ting; Li, Nan; Zhang, Jin fang] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou 510405, Peoples R China.
   [Li, Zhi peng] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Rehabil, Guangzhou 510655, Peoples R China.
   [Pang, Feng xiang] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Tradit Chinese Med, Guangzhou 510630, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Sun Yat Sen University; Sun Yat Sen University
RP Wang, YY; Zhang, JF (通讯作者)，Guangzhou Univ Chinese Med, Canc Ctr, Shenzhen Hosp Futian, Shenzhen 518000, Guangdong, Peoples R China.; Zhang, JF (通讯作者)，Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou 510405, Peoples R China.
EM 20201110039@stu.gzucm.edu.cn; lizhp75@mail.sysu.edu.cn;
   1243537709@qq.com; 853061756@qq.com; 1641844810@qq.com; wyy8120@163.com;
   zhangjf06@gzucm.edu.cn
RI ; zhou, shuting/MGT 4798 2025; Li, Zhipeng/Q 7482 2019
OI Mai, Yong xin/0000 0001 5763 5857; 
FU National Natural Science Foundation of China;  [82272526]
FX This work was partially supported by the National Natural Science
   Foundation of China (No. 82272526).
CR Armenteros T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27581 0
   Bridges MC, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202009045
   Chen SX, 2021, MOL MED, V27, DOI 10.1186/s10020 021 00386 0
   Dahabreh Z, 2009, INT ORTHOP, V33, P1407, DOI 10.1007/s00264 008 0709 6
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dickinson H, 2012, CYTOTECHNOLOGY, V64, P591, DOI 10.1007/s10616 012 9443 4
   Duan PP, 2016, INT J BIOCHEM CELL B, V77, P23, DOI 10.1016/j.biocel.2016.05.015
   Ekegren CL, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15122845
   Fu L, 2019, J CELL MOL MED, V23, P7517, DOI 10.1111/jcmm.14620
   Han H, 2021, AGING US, V13, P18257, DOI 10.18632/aging.203267
   He L, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20192549
   He Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0484 2
   Hu XY, 2018, INT J BIOL SCI, V14, P2003, DOI 10.7150/ijbs.27977
   Huang LC, 2021, CHIN MED UK, V16, DOI 10.1186/s13020 021 00482 7
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Kanakaris NK, 2007, INJURY, V38, pS77, DOI 10.1016/S0020 1383(07)80012 X
   Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Li YT, 2020, AGING US, V12, P2226, DOI 10.18632/aging.102742
   Li YT, 2018, CHEM BIOL INTERACT, V283, P51, DOI 10.1016/j.cbi.2018.02.005
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Liu Q, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.601224
   Liu RD, 2020, BIOCHEM BIOPH RES CO, V524, P1037, DOI 10.1016/j.bbrc.2020.02.034
   Mizokami A, 2017, BIOCHEM PHARMACOL, V132, P1, DOI 10.1016/j.bcp.2017.02.001
   Nakashima A, 2005, J BIOL CHEM, V280, P37660, DOI 10.1074/jbc.M504612200
   Peng SP, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8273648
   Silva AM, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0048 9
   Siu WS, 2019, CHIN MED UK, V14, DOI 10.1186/s13020 019 0278 1
   Wang Y, 2022, HEART LUNG CIRC, V31, P341, DOI 10.1016/j.hlc.2021.10.022
   Wu JJ, 2018, BONE, V108, P62, DOI 10.1016/j.bone.2017.12.013
   Yang X, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.723145
   Yang XC, 2019, AGING US, V11, P8777, DOI 10.18632/aging.102264
   Yue C, 2021, J CELL MOL MED, V25, P10175, DOI 10.1111/jcmm.16954
   Zeng XC, 2020, FITOTERAPIA, V140, DOI 10.1016/j.fitote.2019.104443
   Zhang YF, 2021, PHARM BIOL, V59, P1556, DOI 10.1080/13880209.2021.1996614
   Zhao X, 2020, FOOD SCI NUTR, V8, P4897, DOI 10.1002/fsn3.1779
   Zhong LY, 2021, NEUROCHEM INT, V148, DOI 10.1016/j.neuint.2021.105072
   Zhou QP, 2018, EUR REV MED PHARMACO, V22, P2226, DOI 10.26355/eurrev_201804_14808
   Zhu ZG, 2018, MOL MED REP, V18, P2561, DOI 10.3892/mmr.2018.9286
   Zura R, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.2775
NR 40
TC 6
Z9 6
U1 7
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PD APR 9
PY 2024
VL 2024
AR 5388064
DI 10.1155/2024/5388064
PG 13
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA OG8G4
UT WOS:001206204400001
PM 38633381
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Idrees, M
   Sohail, A
AF Idrees, Muhammad
   Sohail, Ayesha
TI A computational framework and sensitivity analysis for the hormonal
   treatment of bone
SO CLINICAL BIOMECHANICS
LA English
DT Article
DE Intermittent therapy; Bone remodelling; Osteoporosis; Calcitonin
ID SALMON CALCITONIN; MATHEMATICAL MODEL; OSTEOPOROSIS; CALCIUM
AB Background: Osteoporosis is a bone disease identified by disordering of bone formation and resorption cells. It increases the risk of bone fragility and fracture. Autocrine and paracrine signalling of osteoclasts and osteoblasts plays an important role in the regulation of bone remodelling. Calcitonin is an approved pharmacologic agent for the treatment of osteoporosis.
   Methods: A novel mathematical model comprising the interaction among osteoclasts and osteoblasts cells with intermittent administration of calcitonin has been presented to study the dynamics of osteoporotic bone. The stability of model and sensitivity of parameters are also discussed.
   Findings: The population of osteoclastic and osteoblastic cells has been predicted via numerical simulation. The results of Monte Carlo sensitivity analysis are shown via tornado diagram.
   Interpretation: It is concluded that intermittent administration of calcitonin is an effective therapy for the treatment of osteoporosis.
C1 [Idrees, Muhammad; Sohail, Ayesha] Comsats Univ Islamabad, Dept Math, Lahore Campus, Lahore 54000, Pakistan.
   [Sohail, Ayesha] Dept Math, Hounsfield Rd, Sheffield S3 7RH, S Yorkshire, England.
C3 COMSATS University Islamabad (CUI)
RP Sohail, A (通讯作者)，Comsats Univ Islamabad, Dept Math, Lahore Campus, Lahore 54000, Pakistan.
EM asohail@cuilahore.edu.pk
RI ; Sohail, A/AAP 8462 2021
OI sohail, ayesha/0000 0001 6835 6212; Idrees, Muhammad/0000 0002 9250 1317
FU NRPU higher education commision of Pakistan [MM4275]
FX This research is partly funded by project entitled "Mathematical
   modeling of effective Diffusivity in Bone Tissue Engineering'' grant
   number MM4275, through NRPU higher education commision of Pakistan.
CR Garzón Alvarado DA, 2012, COMPUT METHOD BIOMEC, V15, P333, DOI 10.1080/10255842.2010.535522
   [Anonymous], HAND HLTH OST
   [Anonymous], ELECT J DIFFERENTIAL
   [Anonymous], 1991, APPL NONLINEAR CONTR
   [Anonymous], MAMMAL ANATOMY ILLUS
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Chaiya I, 2017, ADV DIFFER EQU NY, DOI 10.1186/s13662 017 1206 2
   Chen Charpentier BM, 2016, J COMPUT APPL MATH, V291, P76, DOI 10.1016/j.cam.2014.11.025
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Civitelli R., 2013, Osteoporosis, VFourth, P1839
   COPP DH, 1961, SCIENCE, V134, P2038, DOI 10.1126/science.134.3495.2038
   COPP DH, 1962, ENDOCRINOLOGY, V70, P638, DOI 10.1210/endo 70 5 638
   Crespo R, 1997, CALCIFIED TISSUE INT, V60, P567, DOI 10.1007/s002239900281
   Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205
   Felsenfeld AJ, 2015, CLIN KIDNEY J, V8, P180, DOI 10.1093/ckj/sfv011
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   GENNARI C, 1985, CURR THER RES CLIN E, V38, P455
   Goodman H., 2003, BASIC MED ENDOCRINOL, VThird
   Javed S, 2019, ADV DIFFER EQU NY, DOI 10.1186/s13662 019 1986 7
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kroll MH, 2000, B MATH BIOL, V62, P163, DOI 10.1006/bulm.1999.0146
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   MAZZUOLI GF, 1986, CALCIFIED TISSUE INT, V38, P3, DOI 10.1007/BF02556587
   Moroz A, 2007, BIOPHYS CHEM, V127, P194, DOI 10.1016/j.bpc.2007.02.001
   Moroz A, 2006, BIOSYSTEMS, V84, P183, DOI 10.1016/j.biosystems.2005.11.002
   MUNDY GR, 1993, J BONE MINER RES, V8, pS505, DOI 10.1002/jbmr.5650081315
   MUSE KN, 1986, J CLIN ENDOCR METAB, V62, P1313, DOI 10.1210/jcem 62 6 1313
   PECK WA, 1993, AM J MED, V94, P646
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Rattanakul C., 2011, SYSTEM, V3, P2
   Rosenberg AE., 1994, Robbins pathologic basis of disease, P1213
   Ryser MD, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002703
   Steele DG, 1988, The anatomy and biology of the human skeleton
   THAMSBORG G, 1991, CALCIFIED TISSUE INT, V48, P302, DOI 10.1007/BF02556148
   Tunç C, 2010, NONLINEAR DYNAM, V62, P945, DOI 10.1007/s11071 010 9776 5
   Wysolmerski JJ., 2018, PARATHYROID HORMONE, P849
NR 37
TC 9
Z9 11
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0268 0033
EI 1879 1271
J9 CLIN BIOMECH
JI Clin. Biomech.
PD MAR
PY 2020
VL 73
BP 9
EP 16
DI 10.1016/j.clinbiomech.2019.12.015
PG 8
WC Engineering, Biomedical; Orthopedics; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Orthopedics; Sport Sciences
GA LG7JO
UT WOS:000528272700002
PM 31918023
DA 2025 08 17
ER

PT J
AU Keller, KK
   Thomsen, JS
   Stengaard Pedersen, K
   Hauge, EM
AF Keller, Kresten Krarup
   Thomsen, Jesper Skovhus
   Stengaard Pedersen, Kristian
   Hauge, Ellen Margrethe
TI Systemic but No Local Effects of Combined Zoledronate and Parathyroid
   Hormone Treatment in Experimental Autoimmune Arthritis
SO PLOS ONE
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; MICRO COMPUTED TOMOGRAPHY; FACTOR MEDIATED
   ARTHRITIS; BONE MINERAL DENSITY; RHEUMATOID ARTHRITIS; INFLAMMATORY
   ARTHRITIS; NECROSIS FACTOR; POSTMENOPAUSAL OSTEOPOROSIS; BISPHOSPHONATE
   THERAPY; STRUCTURAL DAMAGE
AB Introduction: Local bone erosions and osteoporosis in rheumatoid arthritis (RA) are the result of a more pronounced bone resorption than bone formation. Present treatment strategies for RA inhibit inflammation, but do not directly target bone erosions. The aim of the study was in experimental arthritis to investigate the juxtaarticular and systemic effects of simultaneous osteoclast inhibition with zoledronate (ZLN) and osteoblast stimulation with parathyroid hormone (PTH).
   Methods: Arthritis was induced in 36 SKG mice. The mice were randomized to three treatment groups and an untreated group: ZLN, PTH, PTH+ZLN, and untreated. Arthritis score and ankle width measurements were performed. Histological sections were cut from the right hind paw, and design based stereological estimators were used to quantify histological variables of bone volume and bone formation and resorption. The femora were DXA and mu CT scanned, and the bone strength was determined at the femoral neck and mid diaphysis.
   Results: Locally, we found no differences in arthritis score or ankle width throughout the study. Similarly, none of the treatments inhibited bone erosions or stimulated bone formation in the paw. Systemically, all treatments improved bone mineral density, strength of the femoral neck and mid diaphysis, and mu CT parameters of both cortical and trabecular bone. In addition, there was an additive effect of combination treatment compared with single treatments for most trabecular parameters including bone mineral density and bone volume fraction.
   Conclusions: No local effect on bone was found by the combined action of inhibiting bone resorption and stimulating bone formation. However, a clear systemic effect of the combination treatment was demonstrated.
C1 [Keller, Kresten Krarup; Stengaard Pedersen, Kristian; Hauge, Ellen Margrethe] Aarhus Univ Hosp, Dept Rheumatol, DK 8000 Aarhus, Denmark.
   [Thomsen, Jesper Skovhus] Aarhus Univ, Dept Biomed Anat, Aarhus, Denmark.
C3 Aarhus University; Aarhus University
RP Keller, KK (通讯作者)，Aarhus Univ Hosp, Dept Rheumatol, DK 8000 Aarhus, Denmark.
EM kresten@ana.au.dk
RI Thomsen, Jesper/HKN 2794 2023; Keller, Kresten/S 2067 2019
OI Keller, Kresten Krarup/0000 0003 2474 3389; Stengaard Pedersen,
   Kristian/0000 0001 7991 2456; Thomsen, Jesper
   Skovhus/0000 0001 9386 6679
FU Danish Rheumatism Association; A.P. Moller Foundation for the
   Advancement of Medical Science; Aase and Ejnar Danielsens Foundation;
   Horslev Foundation; Clinical Institute Aarhus University; Peter Ryholts
   Grant; Hede Nielsens Family Foundation
FX This work was supported by the Danish Rheumatism Association, The A.P.
   Moller Foundation for the Advancement of Medical Science, Aase and Ejnar
   Danielsens Foundation, the Horslev Foundation, Clinical Institute Aarhus
   University, Peter Ryholts Grant and the Hede Nielsens Family Foundation.
   The mu CT scanner was donated by the Velux Foundation. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR BADDELEY AJ, 1986, J MICROSC OXFORD, V142, P259, DOI 10.1111/j.1365 2818.1986.tb04282.x
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Breuil V, 2006, JOINT BONE SPINE, V73, P349, DOI 10.1016/j.jbspin.2005.10.019
   Caetano Lopes J, 2009, CLIN EXP RHEUMATOL, V27, P475
   Caetano Lopes J, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2908
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Cosman F, 2008, CURR OPIN ENDOCRINOL, V15, P495, DOI 10.1097/MED.0b013e32831a46d6
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Erben RG, 1996, ANAT REC, V246, P39, DOI 10.1002/(SICI)1097 0185(199609)246:1<39::AID AR5>3.0.CO;2 A
   Fukata S, 2004, ARTHRITIS RHEUM US, V50, P4060, DOI 10.1002/art.20728
   Graudal N, 2010, ARTHRITIS RHEUM US, V62, P2852, DOI 10.1002/art.27592
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   GUNDERSEN HJG, 1987, J MICROSC OXFORD, V147, P229, DOI 10.1111/j.1365 2818.1987.tb02837.x
   Hardy R, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4065
   Hashimoto M, 2010, J EXP MED, V207, P1135, DOI 10.1084/jem.20092301
   Hata H, 2004, J CLIN INVEST, V114, P582, DOI 10.1172/JCI200421795
   Hauge E, 1999, BONE, V25, P389, DOI 10.1016/S8756 3282(99)00194 5
   Herrak P, 2004, ARTHRITIS RHEUM US, V50, P2327, DOI 10.1002/art.20384
   Hirota K, 2007, J EXP MED, V204, P41, DOI 10.1084/jem.20062259
   Jarrett SJ, 2006, ARTHRITIS RHEUM US, V54, P1410, DOI 10.1002/art.21824
   Keller KK, 2011, CLIN EXP RHEUMATOL, V29, P536
   Keller KK, 2013, RHEUMATOL INT, V33, P1127, DOI 10.1007/s00296 012 2500 7
   Keller KK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053034
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kobayashi K, 2006, INFLAMM RES, V55, P335, DOI 10.1007/s00011 006 5208 x
   Le Goff B, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2877
   Mosekilde L, 1999, BONE, V24, P71, DOI 10.1016/S8756 3282(98)00169 0
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Rau R, 2006, CLIN EXP RHEUMAT S43, V24, pS
   Recknor C, 2011, EXPERT OPIN PHARMACO, V12, P807, DOI 10.1517/14656566.2011.562201
   Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002 9440(10)63144 6
   Romas E, 2005, BEST PRACT RES CL RH, V19, P1065, DOI 10.1016/j.berh.2005.06.008
   Roux C, 2011, OSTEOPOROSIS INT, V22, P421, DOI 10.1007/s00198 010 1319 x
   Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119
   Schafer AL, 2012, J CLIN ENDOCR METAB, V97, P3522, DOI 10.1210/jc.2012 1844
   Schett G, 2005, ARTHRITIS RHEUM US, V52, P1604, DOI 10.1002/art.21021
   Sims NA, 2004, ARTHRITIS RHEUM US, V50, P2338, DOI 10.1002/art.20382
   Thomsen JS, 2005, J MICROSC OXFORD, V218, P171, DOI 10.1111/j.1365 2818.2005.01469.x
   Valleala H, 2012, CLIN EXP RHEUMATOL, V30, P114
   van Staa TP, 2006, ARTHRITIS RHEUM US, V54, P3104, DOI 10.1002/art.22117
   Walsh NC, 2009, J BONE MINER RES, V24, P1572, DOI [10.1359/JBMR.090320, 10.1359/jbmr.090320]
NR 46
TC 5
Z9 5
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 17
PY 2014
VL 9
IS 3
AR e92359
DI 10.1371/journal.pone.0092359
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AD4XD
UT WOS:000333254100146
PM 24637846
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Xian, YS
   Su, YG
   Liang, JM
   Long, F
   Feng, XL
   Xiao, Y
   Lian, HY
   Xu, JK
   Zhao, JM
   Liu, Q
   Song, FM
AF Xian, Yansi
   Su, Yuangang
   Liang, Jiamin
   Long, Feng
   Feng, Xiaoliang
   Xiao, Yu
   Lian, Haoyu
   Xu, Jiake
   Zhao, Jinmin
   Liu, Qian
   Song, Fangming
TI Oroxylin A reduces osteoclast formation and bone resorption via
   suppressing RANKL induced ROS and NFATc1 activation
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Oroxylin A; Osteoclast; ROS; NFATc1
ID OSTEOPOROSIS; OSTEOLYSIS
AB Excessive bone erosion by osteoclasts is associated with osteoporosis, rheumatoid arthritis, and periprosthetic osteolysis. Targeting osteoclasts may serve as an effective treatment for osteolytic diseases. Although drugs are currently available for the treatment of these diseases, exploring potential anti osteoclast natural compounds with safe and effective treatment remains needed. Oroxylin A (OA), a natural flavonoid isolated from the root of Scutellaria baicalensis Georgi, has numerous beneficial pharmacological characteristics, including antiinflammatory and antioxidant activity. However, its effects and mechanisms on osteoclast formation and bone resorption have not yet been clarified. Our research showed that OA attenuated the formation and function of osteoclast induced by RANKL in a time and concentration dependent manner without any cytotoxicity. Mechanistically, OA suppressed intracellular reactive oxygen species (ROS) levels through the Nrf2 mediated antioxidant response. Moreover, OA inhibited the activity of NFATc1, the master transcriptional regulator of RANKLinduced osteoclastogenesis. OA exhibited protective effects in mouse models of post ovariectomy (OVX) and lipopolysaccharide (LPS) induced bone loss, in accordance with its in vitro anti osteoclastogenic effect. Collectively, our findings highlight the potential of OA as a pharmacological agent for the prevention of osteoclastmediated osteolytic diseases.
C1 [Xian, Yansi; Su, Yuangang; Liang, Jiamin; Long, Feng; Feng, Xiaoliang; Lian, Haoyu; Zhao, Jinmin; Liu, Qian; Song, Fangming] Guangxi Med Univ, Res Ctr Regenerat Med, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Xian, Yansi; Long, Feng; Feng, Xiaoliang; Song, Fangming] Guangxi Med Univ, Guangxi Collaborat Innovat Ctr Biomed, Nanning, Guangxi, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Zhao, Jinmin] Guangxi Med Univ, Affiliated Hosp 1, Orthopaed Dept, Guangxi, Peoples R China.
   [Xiao, Yu] Guangxi Univ, Med Coll, Nanning, Guangxi, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; University of
   Western Australia; Guangxi Medical University; Guangxi University
RP Liu, Q; Song, FM (通讯作者)，Guangxi Med Univ, Res Ctr Regenerat Med, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.; Song, FM (通讯作者)，Guangxi Med Univ, Guangxi Collaborat Innovat Ctr Biomed, Nanning, Guangxi, Peoples R China.
EM liuqian@gxmu.edu.cn; songfangming@gxmu.edu.cn
RI ; Su, Yuangang/KKU 6952 2024; Lian, Haoyu/W 3317 2017; zhao,
   jin/LBH 0351 2024
OI Xiao, Yu/0009 0005 3120 8968; Xu, Jiake/0000 0003 2021 8309; Yuangang,
   Su/0000 0002 1308 2688
FU National Natural Science Foundation of China [82060760, 81960405];
   Natural Science Foundation of Guangxi Province [2017GXNSFBA198061,
   2018GXNSFAA050092]; National Science Foundation for Post doctoral
   Scientists of China [2018M633618XB]; Nanning Qingxiu District Science
   and Technology Bureau key research and development projects [2020028];
   Guangxi Scholarship Fund of Guangxi Education Department (GED); Guangxi
   Institute of Chinese Medicine
FX This study was funded by National Natural Science Foundation of China
   (No. 82060760, No. 81960405), Natural Science Foundation of Guangxi
   Province (2017GXNSFBA198061, 2018GXNSFAA050092), National Science
   Foundation for Post doctoral Scientists of China (No. 2018M633618XB),
   Nanning Qingxiu District Science and Technology Bureau key research and
   development projects (No. 2020028), a scholarship under the Guangxi
   Scholarship Fund of Guangxi Education Department (GED). We also
   appreciate Prof. Guining Wei from Guangxi Institute of Chinese Medicine
   and Pharmaceutical Science for providing valuable opinions on animal
   experiments.
CR AlRahabi MK, 2018, SAUDI MED J, V39, P232, DOI 10.15537/smj.2018.3.20923
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bellezza I, 2018, BBA MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Cao Y, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104981
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Davey RA, 2008, J BONE MINER RES, V23, P1182, DOI [10.1359/jbmr.080310, 10.1359/JBMR.080310]
   Gao Y, 2014, EXP BIOL MED, V239, P1018, DOI 10.1177/1535370214530081
   Gritsaenko T, 2018, JOVE J VIS EXP, DOI 10.3791/56499
   Hamdy RC, 2012, INT J WOMENS HEALTH, V4, P471, DOI 10.2147/IJWH.S24776
   Hashem S, 2021, NUTR CANCER, V73, P181, DOI 10.1080/01635581.2020.1749676
   Hu JJ, 2018, MICROB PATHOGENESIS, V119, P86, DOI 10.1016/j.micpath.2018.03.053
   Huang H, 2021, PHYTOTHER RES, V35, P3821, DOI 10.1002/ptr.7088
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Joung YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159891
   Kang JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103646
   Kang TC, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9070617
   Ke K, 2019, J BONE MINER RES, V34, P1880, DOI 10.1002/jbmr.3759
   Kim Eun Jung, 2018, J Dent Anesth Pain Med, V18, P349, DOI 10.17245/jdapm.2018.18.6.349
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Li QW, 2020, J BONE MINER RES, V35, P1597, DOI 10.1002/jbmr.4015
   Li YT, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110747
   Li ZK, 2018, CALCIFIED TISSUE INT, V103, P324, DOI 10.1007/s00223 018 0425 1
   Liao SJ, 2019, J CELL PHYSIOL, V234, P17600, DOI 10.1002/jcp.28384
   Lin XY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216711
   Liu FL, 2020, PHYTOMEDICINE, V69, DOI 10.1016/j.phymed.2020.153195
   Liu SY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00619
   Mirhadi E, 2021, PHARMACOL RES, V163, DOI 10.1016/j.phrs.2020.105287
   Moller AMJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176368
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Oh SY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.646803
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Pang MH, 2019, J CELL BIOCHEM, V120, P12382, DOI 10.1002/jcb.28504
   Panieri E, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9030193
   Park JH, 2017, MOL CELLS, V40, P706
   Place DE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20807 8
   Qiu H, 2021, J CELL PHYSIOL, V236, P2800, DOI 10.1002/jcp.30045
   Shen M, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106637
   Song FM, 2018, J CELL PHYSIOL, V233, P1723, DOI 10.1002/jcp.26084
   Sun KQ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.629968
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069555
   Wang QQ, 2020, J BONE MINER RES, V35, P1582, DOI 10.1002/jbmr.4025
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Xu WF, 2020, J CELL PHYSIOL, V235, P3022, DOI 10.1002/jcp.29207
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Ye M, 2014, BIOCHEM CELL BIOL, V92, P337, DOI 10.1139/bcb 2014 0030
   Yu PJ, 2020, INT J BIOL MACROMOL, V165, P1634, DOI 10.1016/j.ijbiomac.2020.10.016
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zou BH, 2021, PHYTOMEDICINE, V80, DOI 10.1016/j.phymed.2020.153377
NR 54
TC 66
Z9 70
U1 2
U2 22
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD NOV
PY 2021
VL 193
AR 114761
DI 10.1016/j.bcp.2021.114761
EA SEP 2021
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WJ9PZ
UT WOS:000709370000001
PM 34492273
OA hybrid
DA 2025 08 17
ER

PT J
AU Wang, P
   Shang, GQ
   Xiang, S
   Zhang, HN
   Wang, YZ
   Xu, H
AF Wang, Peng
   Shang, Guang qian
   Xiang, Shuai
   Zhang, Hai ning
   Wang, Ying zhen
   Xu, Hao
TI Zoledronic acid and teriparatide have a complementary therapeutic effect
   on aseptic loosening in a rabbit model
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Aseptic loosening; Wear debris; Osteoblast; Osteoclast; Zoledronic acid;
   Teriparatide
ID INTERMITTENT PARATHYROID HORMONE; LONG TERM; INDUCED OSTEOLYSIS; IMPLANT
   FIXATION; BONE FORMATION; WEAR; BISPHOSPHONATE; OSTEOBLASTS; IMPROVES;
   FAILURE
AB Background Revisions are mainly caused by wear debris induced aseptic loosening. How to effectively suppress debris induced periprosthetic osteolysis has become an urgent problem. Both zoledronic acid and teriparatide can increase the bone mass around prostheses and increase the stability of prostheses. A hypothesis was proposed: the combination of the two drugs may have a better treatment effect than the use of either drug alone. Methods We created a rabbit model to study the effect and mechanism of the combination of zoledronic acid and teriparatide in the treatment of aseptic loosening. Thirty two adult male New Zealand white rabbits were selected and treated with TKA surgery, and a titanium rod prosthesis coated evenly with micrometre sized titanium debris was implanted into the right femoral medullary cavity. All rabbits were randomized into four groups (control group = 8, zoledronic acid group = 8, teriparatide group = 8, and zoledronic acid + teriparatide group = 8). All the animals were sacrificed in the 12th week, and X ray analyses, H&E staining, Goldner Masson trichrome staining, von Kossa staining, and RT PCR and Western blotting of the mRNA and protein of OCN, OPG, RANKL and TRAP5b in the interface membrane tissues around the prostheses were immediately carried out. Results The results shown that both zoledronic acid and teriparatide could inhibit debris induced peri prosthetic osteolysis and promote new bone formation. Zoledronic acid was more capable of inhibiting osteoclast activation and peri prosthetic osteolysis, while teriparatide was more capable of promoting osteoblast function and peri prosthetic bone integration. Conclusion This research confirmed that the combination of zoledronic acid and teriparatide could prevent and treat aseptic loosening of the prosthesis more effectively. However, the safety of this combination and the feasibility of long term application have not been ensured, and the clinical application requires further experiments and clinical research support.
C1 [Wang, Peng; Shang, Guang qian; Xiang, Shuai; Zhang, Hai ning; Wang, Ying zhen; Xu, Hao] Qingdao Univ, Dept Joint Surg, Affiliated Hosp, Qingdao 266000, Shandong, Peoples R China.
C3 Qingdao University
RP Xu, H (通讯作者)，Qingdao Univ, Dept Joint Surg, Affiliated Hosp, Qingdao 266000, Shandong, Peoples R China.
EM 18661806627@163.com
RI Xu, Hao/AAV 8394 2021
CR Abbas S, 2003, J ORTHOPAED RES, V21, P1041, DOI 10.1016/S0736 0266(03)00081 0
   Baker PN, 2010, CLIN ORTHOP RELAT R, V468, P1855, DOI 10.1007/s11999 009 1066 5
   Beraudi A, 2009, ARTIF ORGANS, V33, P538, DOI 10.1111/j.1525 1594.2009.00736.x
   Bloebaum RD, 2007, J BIOMED MATER RES A, V81A, P505, DOI 10.1002/jbm.a.31087
   Brulefert K, 2016, J BIOMED MATER RES A, V104, P2649, DOI 10.1002/jbm.a.35803
   Brunnemann CE, 2010, DEUT MED WOCHENSCHR, V135, P1538, DOI 10.1055/s 0030 1262443
   Cadosch D, 2010, Z ORTHOP UNFALLCHIR, V148, P393, DOI 10.1055/s 0030 1250108
   Casanova M, 2016, BONE, V92, P70, DOI 10.1016/j.bone.2016.08.012
   Daugaard H, 2012, ACTA ORTHOP, V83, P411, DOI 10.3109/17453674.2012.702388
   Daugaard H, 2011, DAN MED BULL, V58
   Dayer R, 2010, OSTEOPOROSIS INT, V21, P957, DOI 10.1007/s00198 009 1031 x
   Dhillon S, 2016, DRUGS, V76, P1683, DOI 10.1007/s40265 016 0662 4
   Dohke T, 2018, J BONE MINER METAB, V36, P499, DOI 10.1007/s00774 017 0865 0
   Geng DC, 2010, J BIOMED MATER RES A, V95A, P321, DOI 10.1002/jbm.a.32836
   Goodman Stuart B, 2013, Instr Course Lect, V62, P201
   Goodship A E, 1994, Ann Oncol, V5 Suppl 7, pS53
   Hegde V, 2016, OSTEOPOROSIS INT, V27, P861, DOI 10.1007/s00198 015 3331 7
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   HOROWITZ SM, 1993, J BONE JOINT SURG AM, V75A, P802, DOI 10.2106/00004623 199306000 00002
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Cale A, 2007, J BONE JOINT SURG AM, V89A, P2779, DOI 10.2106/JBJS.G.00043
   Jiang YP, 2013, ACTA ORTHOP BELG, V79, P1
   Kaneko J, 2018, INFLAMM REGEN, V38, DOI 10.1186/s41232 018 0074 9
   Kim SW, 2005, ENDOCR J, V52, P667, DOI 10.1507/endocrj.52.667
   Koivukangas A, 2003, CLIN ORTHOP RELAT R, P268, DOI 10.1097/01.blo.0000053054.62337.e1
   Koreny T, 2006, ARTHRITIS RHEUM, V54, P3221, DOI 10.1002/art.22134
   Kuriwaka Kido R, 2013, ENDOCRINOLOGY, V154, P1156, DOI 10.1210/en.2013 1915
   Labrinidis A, 2009, CLIN CANCER RES, V15, P3451, DOI 10.1158/1078 0432.CCR 08 1616
   Li CY, 2001, J BONE MINER RES, V16, P429, DOI 10.1359/jbmr.2001.16.3.429
   Lochner K, 2011, INT J MOL MED, V28, P1055, DOI 10.3892/ijmm.2011.778
   Marshall A, 2008, J AM ACAD ORTHOP SUR, V16, pS1, DOI 10.5435/00124635 200800001 00003
   Millett PJ, 2002, J BONE JOINT SURG AM, V84A, P236, DOI 10.2106/00004623 200202000 00011
   Noordin S, 2016, RHEUMATOL INT, V36, P1, DOI 10.1007/s00296 015 3319 9
   Otto M, 2006, PATHOLOGE, V27, P447, DOI 10.1007/s00292 006 0868 4
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Qian YB, 2008, J ARTHROPLASTY, V23, P581, DOI 10.1016/j.arth.2007.06.010
   Ribera A, 2014, J INFECTION, V69, P235, DOI 10.1016/j.jinf.2014.05.003
   Saleh KJ, 2004, CLIN ORTHOP RELAT R, P138, DOI 10.1097/01.blo.0000142288.66246.4d
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P849, DOI 10.1002/jor.1100180602
   Shimizu S, 2010, ARTHRITIS RHEUM US, V62, P1329, DOI 10.1002/art.27400
   Skripitz R, 2009, J ORTHOP SCI, V14, P138, DOI 10.1007/s00776 008 1311 x
   Skripitz R, 2001, CLIN ORTHOP RELAT R, P427
   Standal T, 2014, J ENDOCRINOL, V223, P181, DOI 10.1530/JOE 14 0424
   Sundfeldt M, 2006, ACTA ORTHOP, V77, P177, DOI 10.1080/17453670610045902
   Suratwala SJ, 2008, J BONE JOINT SURG AM, V90A, P2189, DOI 10.2106/JBJS.G.00409
   Talmo CT, 2006, CLIN ORTHOP RELAT R, P254, DOI 10.1097/01.blo.0000246531.59876.a8
   Tang ZL, 2016, PLAST RECONSTR SURG, V137, p347E, DOI 10.1097/01.prs.0000475780.68585.cc
   Tashjian Robert Z, 2008, Orthopedics, V31, P545
   Wang ZH, 2015, AUTOPHAGY, V11, P2358, DOI 10.1080/15548627.2015.1106779
   Wedemeyer C, 2005, BIOMATERIALS, V26, P3719, DOI 10.1016/j.biomaterials.2004.09.026
   Winarno AS, 2014, Z GEBURTSH NEONATOL, V218, P171, DOI 10.1055/s 0034 1382069
   Wise LM, 2005, CALCIFIED TISSUE INT, V77, P367, DOI 10.1007/s00223 005 0062 3
   Yalçin N, 2011, J BONE JOINT SURG BR, V93B, P793, DOI 10.1302/0301 620X.93B6.24257
   Yang SY, 2007, J ORTHOP RES, V25, P603, DOI 10.1002/jor.20342
   Yu XH, 2012, J MATER SCI MATER M, V23, P2177, DOI 10.1007/s10856 012 4682 7
   Zati A, 2011, J RHEUMATOL, V38, P778, DOI 10.3899/jrheum.100980
   Zenios M, 2004, J BIOMED MATER RES B, V71B, P322, DOI 10.1002/jbm.b.30101
   Zhang YY, 2015, REGEN BIOMATER, V2, P197, DOI 10.1093/rb/rbv002
NR 59
TC 4
Z9 4
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD JUN 24
PY 2021
VL 22
IS 1
AR 580
DI 10.1186/s12891 021 04458 4
PG 11
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA TC3XJ
UT WOS:000668574500002
PM 34167511
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU San Cheong, V
   Roberts, BC
   Kadirkamanathan, V
   Dall'Ara, E
AF San Cheong, Vee
   Roberts, Bryant C.
   Kadirkamanathan, Visakan
   Dall'Ara, Enrico
TI Positive interactions of mechanical loading and PTH treatments on
   spatio temporal bone remodelling
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Bone remodelling; Micro CT; Longitudinal imaging; In vivo loading;
   Parathyroid hormone; Osteoporosis
ID STRAIN GRADIENTS CORRELATE; PARATHYROID HORMONE; CORTICAL BONE;
   TOMOGRAPHY; MODEL; SIMULATIONS; ADAPTATION; PREDICTION; SITES; TIME
AB Osteoporosis is one of the most common skeletal diseases, but current therapies are limited to generalized antiresorptive or anabolic interventions, which do not target regions that would benefit from improvements to skeletal health. To improve the evaluation of treatment plans, we used a spatio temporal multiscale approach that combines longitudinal in vivo micro computed tomography (micro CT) and in silico subject specific finite element modeling to quantitatively map bone adaptation changes due to disease and treatment at high resolution. Our findings show time and region dependent modifications in bone remodelling following one and two sets of mechanical loading and/or pharmacological interventions. The multiscale results highlighted that the distal section was unaffected by mechanical loading alone but the proximal tibia had the greatest gain from positive interactions of combined therapies. Mechanical loading abated the catabolic effect of PTH, but the main benefit of combined treatments occurred from the additive interactions of the two therapies in periosteal apposition. These results provide detailed insight into the efficacy of combined treatments, facilitating the optimisation of dosage and treatment duration in preclinical mouse studies, and the development of novel interventions for skeletal diseases.
   Statement of Significance
   Combined mechanical loading and pharmacotherapy have the potential to slow osteoporosis induced bone loss but current therapies do not target the regions in need of strengthening. We show for the first time spatial region dependant interactions between PTH and mechanical loading treatment in OVX mouse tibiae, highlighting local regions in the tibia that benefitted from separate and combined treatments. Combined experimental computational analysis also detailed the lasting period of each treatment per location in the tibia, the extent of positive (or negative) interactions of the combined therapies, and the impact of each treatment on the regulation of bone adaptation spatio temporally. This approach can be used to create hypothesis about the interactions of different treatments to optimise the design of biomaterials and medical interventions. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc.
C1 [San Cheong, Vee; Roberts, Bryant C.; Kadirkamanathan, Visakan; Dall'Ara, Enrico] Univ Sheffield, Insigne Inst Silico Med, Sheffield, S Yorkshire, England.
   [San Cheong, Vee; Kadirkamanathan, Visakan] Univ Sheffield, Dept Automat Control & Syst Engn, Sheffield, S Yorkshire, England.
   [Roberts, Bryant C.; Dall'Ara, Enrico] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield; University of
   Sheffield
RP San Cheong, V (通讯作者)，Univ Sheffield, Insigne Inst Silico Med, Sheffield, S Yorkshire, England.; San Cheong, V (通讯作者)，Univ Sheffield, Dept Automat Control & Syst Engn, Sheffield, S Yorkshire, England.
EM v.cheong@sheffield.ac.uk
RI Dall'Ara, Enrico/ABA 5046 2020
OI Dall'Ara, Enrico/0000 0003 1471 5077; Kadirkamanathan,
   Visakan/0000 0002 4243 2501; Roberts, Bryant/0000 0002 8094 6140
FU Engineering and Physical Sciences Research Council (EPSRC) Frontier
   Multisim Grant [EP/K03877X/1, EP/S032940/1]; National Centre for the
   Replacement, Refinement and Reduction of Animals in Research (NC3Rs)
   [NC/R001073/1]; Engineering and Physical Sciences Research Council
   [EP/K03877X/1] Funding Source: researchfish; EPSRC [EP/K03877X/1,
   EP/S032940/1] Funding Source: UKRI
FX This work was supported by funding from the Engineering and Physical
   Sciences Research Council (EPSRC) Frontier Multisim Grant (EP/K03877X/1
   and EP/S032940/1) and the National Centre for the Replacement,
   Refinement and Reduction of Animals in Research (NC3Rs; NC/R001073/1).
   The authors thank Dr M. Boudiffa, Dr S. Zanjani Pour, Mr H. Arredondo
   Carrera, Dr N. Wang, and Prof A. Gartland for help with the acquisition
   of the data, and Skelet.AL laboratory
   (http://skeletal.group.shef.ac.uk/) for access to the scanning
   facilities.
CR Aido M, 2014, CONNECT TISSUE RES, V55, P15, DOI 10.3109/03008207.2014.923869
   Asgharzadeh P, 2020, ACTA BIOMATER, V106, P193, DOI 10.1016/j.actbio.2020.02.007
   Betts DCTN, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 57461 5
   Birkhold AI, 2017, CALCIFIED TISSUE INT, V100, P255, DOI 10.1007/s00223 016 0217 4
   Birkhold AI, 2016, SCI REP UK, V6, DOI 10.1038/srep23480
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brunner S, 2008, EXP HEMATOL, V36, P1157, DOI 10.1016/j.exphem.2008.03.014
   Brunner S, 2007, AM J PHYSIOL ENDOC M, V293, pE1670, DOI 10.1152/ajpendo.00287.2007
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Carrieroa A, 2018, Bone Rep, V8, P72, DOI 10.1016/j.bonr.2018.02.003
   Chan ME, 2013, CURR OSTEOPOROS REP, V11, P36, DOI 10.1007/s11914 012 0132 1
   Charles JP, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00061
   Cheong VS, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.676867
   De Souza RL, 2005, BONE, V37, P810, DOI 10.1016/j.bone.2005.07.022
   Eyckmans J, 2017, NAT BIOMED ENG, V1, P789, DOI 10.1038/s41551 017 0133 6
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   Gross TS, 1997, J BONE MINER RES, V12, P982, DOI 10.1359/jbmr.1997.12.6.982
   Haas AV, 2018, J ENDOCR SOC, V2, P922, DOI 10.1210/js.2018 00118
   Javaheri B, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax8301
   Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474 9726.2010.00616.x
   Judex S, 1997, J BONE MINER RES, V12, P1737, DOI 10.1359/jbmr.1997.12.10.1737
   Kazakia GJ, 2008, MED PHYS, V35, P3170, DOI 10.1118/1.2924210
   Lambers FM, 2012, CALCIFIED TISSUE INT, V90, P108, DOI 10.1007/s00223 011 9553 6
   Levchuk A, 2014, CLIN BIOMECH, V29, P355, DOI 10.1016/j.clinbiomech.2013.12.019
   Li ZH, 2019, J R SOC INTERFACE, V16, DOI 10.1098/rsif.2018.0667
   Lu YT, 2017, J MECH BEHAV BIOMED, V75, P244, DOI 10.1016/j.jmbbm.2017.07.034
   Lu YT, 2016, J BIOMECH, V49, P2095, DOI 10.1016/j.jbiomech.2016.05.022
   Main RP, 2020, J ORTHOP RES, V38, P233, DOI 10.1002/jor.24466
   Malhotra A, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 81132 8
   Meakin LB, 2017, BONE, V98, P59, DOI 10.1016/j.bone.2017.02.009
   Müller R, 2005, OSTEOPOROSIS INT, V16, pS25, DOI 10.1007/s00198 004 1701 7
   Oliviero S, 2021, BIOMECH MODEL MECHAN, V20, P941, DOI 10.1007/s10237 021 01422 y
   Oliviero S, 2021, J MECH BEHAV BIOMED, V113, DOI 10.1016/j.jmbbm.2020.104190
   Oliviero S, 2018, J MECH BEHAV BIOMED, V86, P172, DOI 10.1016/j.jmbbm.2018.06.022
   Oliviero S, 2017, J BIOMECH, V65, P203, DOI 10.1016/j.jbiomech.2017.10.026
   Oliviero S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225127
   Osagie Clouard L, 2017, BONE JOINT RES, V6, P14, DOI 10.1302/2046 3758.61.BJR 2016 0085.R1
   Pereira AF, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0590
   Peterson AK, 2021, ACTA BIOMATER, V121, P484, DOI 10.1016/j.actbio.2020.11.033
   Razi H, 2015, ACTA BIOMATER, V13, P301, DOI 10.1016/j.actbio.2014.11.021
   Roberts BC, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 65921 1
   Roberts BC, 2019, BONE, V127, P260, DOI 10.1016/j.bone.2019.06.024
   Roux W., 1885, ARCH ANAT PHYSIOL, P120
   Rubin MR, 2002, OSTEOPOROSIS INT, V13, P267, DOI 10.1007/s001980200026
   San Cheong V, 2020, ACTA BIOMATER, V116, P302, DOI 10.1016/j.actbio.2020.09.011
   San Cheong V, 2020, BIOMECH MODEL MECHAN, V19, P985, DOI 10.1007/s10237 019 01266 7
   San Cheong V, 2018, J MECH BEHAV BIOMED, V87, P230, DOI 10.1016/j.jmbbm.2018.07.019
   Scheuren AC, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.566346
   Schulte FA, 2013, BONE, V52, P485, DOI 10.1016/j.bone.2012.09.008
   Sugiyama T, 2008, BONE, V43, P238, DOI 10.1016/j.bone.2008.04.012
   Vicecontia M, 2019, MECH AGEING DEV, V177, P103, DOI 10.1016/j.mad.2018.07.001
   Webster D, 2012, BIOMECH MODEL MECHAN, V11, P221, DOI 10.1007/s10237 011 0305 3
   Wolff J., 1892, GESETZ TRANSFORMATIO
NR 53
TC 16
Z9 16
U1 0
U2 9
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD DEC
PY 2021
VL 136
BP 291
EP 305
DI 10.1016/j.actbio.2021.09.035
EA NOV 2021
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA XW9NT
UT WOS:000735937100022
PM 34563722
OA Green Accepted, hybrid
DA 2025 08 17
ER

PT J
AU Liu, Q
   Xu, YL
   Liu, BW
   Yang, H
   Ma, HB
   Yang, AD
   He, YZ
   Liu, T
AF Liu, Qian
   Xu, Yuling
   Liu, Bowen
   Yang, Hui
   Ma, Hanbin
   Yang, Andi
   He, Yongzhi
   Liu, Tao
TI Identification of the Mechanism of Feiduqing on Viral Pneumonia Based on
   Network Pharmacology Analysis
SO NATURAL PRODUCT COMMUNICATIONS
LA English
DT Article
DE Feiduqing; viral pneumonia; network pharmacology; pharmacodynamic
   experiment
ID GARDENIA JASMINOIDES; IN VITRO; INHIBITION; CONSTITUENTS; REPLICATION
AB Feiduqing (FDQ) is a traditional Chinese medicine formula used for many years in the treatment of viral pneumonia (VP). However, the effective components of FDQ and the mechanism by which it affects VP remain unclear. The purpose of this study is to determine the multitarget mechanism of the effect of FDQ on VP through determination and in vivo pharmacodynamics combined with network pharmacology. Firstly, the compound target pathway network was constructed by using TCMSP, UniProt, GeneCards, STRING, and DAVID databases through Cytoscape 3.7.0. Secondly, the content of the effective components of the original prescription of FDQ was determined. Finally, the pharmacological activity of FDQ in vivo was verified by an animal model, and the active ingredient composition (AIC), selected by network pharmacology was used for antipyretic, antiinflammatory, antitussive, and expectorant symptoms. Seven compounds of FDQ and 22 potential target genes in the treatment of VP with FDQ were identified by network pharmacology analysis. Kyoto Encyclopedia of genes and genomes enrichment analysis results indicated that the mechanism of FDQ in the treatment of VP was mainly related to pathways in cancer, hepatitis b, tumor necrosis factor (TNF) signaling pathway, Chagas disease, tuberculosis, influenza A, human T cell leukemia virus, type 1 infection, toxoplasmosis and toll like receptor signaling pathways, osteoclast differentiation, nonalcoholic fatty liver disease, and leishmaniasis. The results of pharmacodynamic experiments showed that FDQ and AIC possessed antipyretic, cough relieving, and reducing sputum effects. Besides, FDQ and AIC could also significantly reduce the content of prostaglandin E 2, TNF alpha, cyclic adenosine monophosphate, interleukin 1 beta, and myeloperoxidase in vivo, while increasing the content of interleukin 10 in vivo. The active ingredients of FDQ prescriptions could be accurately screened by network pharmacological analysis, as they clarified the mechanism of FDQ in the treatment of VP. The research results provided potential ideas and methods for the screening and purification of active ingredients in traditional Chinese medicine prescriptions.
C1 [Liu, Qian] Chengdu Univ, Sichuan Ind Inst Antibiot, Chengdu, Sichuan, Peoples R China.
   [Liu, Qian] Sichuan Tianyi Coll, Mianzhu, Sichuan, Peoples R China.
   [Xu, Yuling; Liu, Bowen; Yang, Hui; Ma, Hanbin; Yang, Andi; He, Yongzhi; Liu, Tao] Chengdu Univ, Coll Pharm & Biol Engn, Chengdu, Sichuan, Peoples R China.
C3 Chengdu University; Chengdu University
RP Liu, T (通讯作者)，Chengdu Univ, Coll Pharm & Biol Engn, Chengdu, Sichuan, Peoples R China.
EM liutao@cdu.edu.cn
RI bowen, liu/GPP 2455 2022
FU Sichuan Science and Technology Program [2020YJ0477]; National Key R&D
   Program of China [2017YFC1701900]; Technology Innovation R&D Project of
   Chengdu Science and Technology Bureau in 2021 [2021 YF05 00080 SN]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the Sichuan Science and Technology Program (No.
   2020YJ0477), the National Key R&D Program of China (2017YFC1701900), and
   the Technology Innovation R&D Project of Chengdu Science and Technology
   Bureau in 2021 (2021 YF05 00080 SN).
CR Ali SH., 2016, GENOMICS PLANT SOIL
   [Anonymous], 2004, PubChem
   Bergmann E., 1933, Ergebnisse der Physiologie, V35, P158
   Brandt EV, 1999, PLANT POLYPHENOLS 2, P245
   Burow ME, 2001, J CLIN ENDOCR METAB, V86, P1750, DOI 10.1210/jc.86.4.1750
   Chatterjee SS, 1998, LIFE SCI, V63, P499, DOI 10.1016/S0024 3205(98)00299 9
   Chen C., 2011, CHIN J EXP TRADIT ME, V17, P207
   Chen H, 2019, MOLECULES, V24, DOI 10.3390/molecules24244425
   Chen X, 2017, PHARM CLIN CHIN MAT, V8, P35
   Dai XM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00236
   DEAN FM, 1952, FORT CHEM ORG NAT, V9, P225
   ESPANA F, 1983, J LAB CLIN MED, V102, P31
   Esslemont JE, 1899, ARCHIV F EXPT PATHOL, V43, P274
   Everest AE, 1915, J GENET, V4, P361, DOI 10.1007/BF02981727
   FUJIE K, 1992, MUTAT RES, V298, P81, DOI 10.1016/0165 1218(92)90032 U
   Fukai T, 2000, ANTICANCER RES, V20, P2525
   Gustine DL, 1981, PLANT CELL TISS ORGA, V1, P255, DOI DOI 10.1007/BF02318922
   Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017
   He X., 2019, CHIN MOD MED, V26, P34
   Hegnauer R., 1964, CHEMOTAXONOMIE PFLAN, P268
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007 1110
   Huang AG, 2019, AQUACULTURE, V504, P239, DOI 10.1016/j.aquaculture.2019.02.008
   Lewis TE, 2001, MAR BIOTECHNOL, V3, P439, DOI 10.1007/s10126 001 0016 3
   Li Y, 2008, CHIN J INTEGR MED, V14, P167, DOI 10.1007/s11655 008 0167 4
   Lin HY, 2005, J CELL PHYSIOL, V202, P579, DOI 10.1002/jcp.20160
   [刘静 Liu Jing], 2016, [中草药, Chinese Traditional and Herbal Drugs], V47, P2040
   [刘钱 Liu Qian], 2019, [中草药, Chinese Traditional and Herbal Drugs], V50, P903
   Liu T, 2013, CHIN J EXP TRADIT ME, V19, P42
   Liu T., 2013, CHIN J EXP TRADIT ME, V19, P54
   Liu Y., 2011, CHIN J EXP TRADIT ME, V17, P116
   Loria V., 2008, MEDIATORS INFLAMM, V13, P625
   Naidu PS, 2003, PSYCHOPHARMACOLOGY, V167, P418, DOI 10.1007/s00213 003 1428 8
   Oganesyan GB, 2009, CHEM NAT COMPD+, V45, P242, DOI 10.1007/s10600 009 9288 z
   PEEV DR, 1982, PLANT SYST EVOL, V140, P235, DOI 10.1007/BF02407300
   Pejin B, 2012, NAT PROD RES, V26, P696, DOI 10.1080/14786419.2010.550580
   Pejin B, 2013, J ENZYM INHIB MED CH, V28, P876, DOI 10.3109/14756366.2012.677839
   PELEG Y, 1987, PLANT CELL TISS ORG, V9, P207, DOI 10.1007/BF00040806
   Qavi HB, 2002, PHYTOTHER RES, V16, P154, DOI 10.1002/ptr.949
   RALSTON AW, 1937, OIL SOAP, V14, P5
   Sasaki T, 2014, PLANTA MED, V80, P557, DOI 10.1055/s 0034 1368400
   [史永平 Shi Yongping], 2019, [中草药, Chinese Traditional and Herbal Drugs], V50, P281
   SPEDDING G, 1989, ANTIVIR RES, V12, P99, DOI 10.1016/0166 3542(89)90073 9
   Su BN, 2002, J NAT PROD, V65, P163, DOI 10.1021/np010451c
   Sun D, 2018, CHIN TRADIT HERB DRU, V49, P26
   Sun T, 2011, THESIS CHENGDU U
   Tan RX, 1996, PHYTOCHEMISTRY, V42, P1305, DOI 10.1016/0031 9422(96)00149 5
   TOMASBARBERAN FA, 1990, PLANT SYST EVOL, V173, P109, DOI 10.1007/BF00940856
   [王翰华 Wang Hanhua], 2019, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V34, P2474
   Wang X, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00156
   Wang YF, 2006, CHEM BIODIVERS, V3, P646, DOI 10.1002/cbdv.200690067
   Xiang SY, 2019, COMPUT BIOL MED, V110, P1, DOI 10.1016/j.compbiomed.2019.05.007
   Xu Y., 2014, J CHENGDU U, V33, P110
   [徐玉玲 Xu Yuling], 2016, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V22, P23
   Yang J, 2014, J CHROMATOGR B, V945, P17, DOI 10.1016/j.jchromb.2013.11.023
   Zeng Q, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109370
   Zhang JP, 2001, ACTA PHARMACOL SIN, V22, P183
   Zhu BC, 2018, BIOMED PHARMACOTHER, V105, P159, DOI 10.1016/j.biopha.2018.04.054
NR 57
TC 1
Z9 1
U1 3
U2 33
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1934 578X
EI 1555 9475
J9 NAT PROD COMMUN
JI Nat. Prod. Commun.
PD AUG
PY 2021
VL 16
IS 8
DI 10.1177/1934578X211031404
PG 16
WC Chemistry, Medicinal; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Food Science & Technology
GA UD5HE
UT WOS:000687236600001
OA gold
DA 2025 08 17
ER

PT J
AU Som, A
   Tu, SM
   Liu, J
   Wang, X
   Qiao, W
   Logothetis, C
   Corn, PG
AF Som, A.
   Tu, S M
   Liu, J.
   Wang, X.
   Qiao, W.
   Logothetis, C.
   Corn, P. G.
TI Response in bone turnover markers during therapy predicts overall
   survival in patients with metastatic prostate cancer: analysis of three
   clinical trials
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE prostate cancer; bone; predictive biomarkers; metastases
ID ANDROGEN DEPRIVATION THERAPY; TARGETED THERAPY; MEN; CARCINOMA; BIOLOGY;
   DISEASE; SCAN
AB BACKGROUND: The bone forming metastases of prostate cancer result from complex stromal epithelial interactions within the tumour microenvironment. Autocrine paracrine signalling pathways between prostate cancer epithelial cells, osteoblasts, and osteoclasts stimulate aberrant bone remodelling, and the activity of these three cell populations can be quantitatively measured using prostate specific antigen (PSA), bone specific alkaline phosphatase (BAP) and urine N telopeptide (uNTx), respectively. The purpose of the present study was to test the hypothesis that serial measurements of BAP and uNTx during therapy would facilitate monitoring of disease activity and predict the overall survival (OS) in patients with metastatic prostate cancer receiving therapy.
   METHODS: Radionuclide bone scan, PSA, BAP, and uNTx data were retrospectively analysed from three clinical trials in patients with metastatic prostate cancer conducted at our institution. Qualitative changes in bone scans and quantitative changes in PSA, BAP, and uNTx concentrations during therapy were correlated with OS.
   RESULTS: Baseline levels of BAP, but not PSA, were prognostic for OS in both androgen dependent and castrate resistant disease. A reduction in PSA, BAP, uNTx, or BAP/uNTx on therapy was predictive of improved OS in both patient groups. Conversely, an increase in PSA, or BAP on therapy was predictive of worse OS in both patient groups. Baseline number of lesions and response on bone scan during therapy were neither prognostic nor predictive of OS in either patient group.
   CONCLUSION: These observations support the concept that serial measurements of bone turnover metabolites during therapy function as clinically informative predictive biomarkers in patients with advanced prostate cancer and skeletal metastases. PSA measurements and bone scans remain essential to monitor the overall disease activity and determine the anatomic distribution of skeletal metastases. British Journal of Cancer (2012) 107, 1547 1553. doi:10.1038/bjc.2012.436 www.bjcancer.com Published online 2 October 2012 (C) 2012 Cancer Research UK
C1 [Som, A.; Tu, S M; Logothetis, C.; Corn, P. G.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, Houston, TX 77230 USA.
   [Liu, J.; Wang, X.; Qiao, W.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77230 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center
RP Corn, PG (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, 1155 Herman Pressler, Houston, TX 77230 USA.
EM pcorn@mdanderson.org
RI ; Som, Avik/KGM 5847 2024
OI Som, Avik/0000 0002 2198 7575; Corn, Paul/0000 0002 4106 6335
FU NCI NIH HHS [P30 CA016672] Funding Source: Medline
CR Araujo JC, 2012, CANCER AM CANCER SOC, V118, P63, DOI 10.1002/cncr.26204
   Armstrong AJ, 2009, ONCOLOGIST, V14, P816, DOI 10.1634/theoncologist.2009 0043
   Bilen MA, 2011, J CLIN ONCOL S, V29
   Cook RJ, 2006, CLIN CANCER RES, V12, P3361, DOI 10.1158/1078 0432.CCR 06 0269
   Dayyani F, 2011, JNCI J NATL CANCER I, V103, P1665, DOI 10.1093/jnci/djr362
   Dotan ZA, 2008, NAT CLIN PRACT UROL, V5, P434, DOI 10.1038/ncpuro1190
   Efstathiou E, 2012, J CLIN ONCOL, V30, P637, DOI 10.1200/JCO.2010.33.7675
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Hussain M, 2011, ASCO S
   Imbriaco M, 1998, CLIN CANCER RES, V4, P1765
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Logothetis CJ, 2008, CLIN CANCER RES, V14, P1599, DOI 10.1158/1078 0432.CCR 07 4603
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Mathew P, 2007, CLIN CANCER RES, V13, P5816, DOI 10.1158/1078 0432.CCR 07 1269
   Messiou C, 2011, EUR RADIOL, V21, P2169, DOI 10.1007/s00330 011 2173 8
   Messiou C, 2009, BRIT J CANCER, V101, P1225, DOI 10.1038/sj.bjc.6605334
   Parker C, 2012, J CLIN ONCOL S
   POLLEN JJ, 1984, AM J ROENTGENOL, V142, P773, DOI 10.2214/ajr.142.4.773
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Sabbatini P, 1999, J CLIN ONCOL, V17, P948, DOI 10.1200/JCO.1999.17.3.948
   Sadik M, 2006, NUCL MED COMMUN, V27, P417, DOI 10.1097/00006231 200605000 00002
   Sartor O, 2011, ASIAN J ANDROL, V13, P783, DOI 10.1038/aja.2011.120
   Sartor Oliver, 2004, Rev Urol, V6 Suppl 10, pS3
   Saylor PJ, 2011, J CLIN ONCOL, V29, P3705, DOI 10.1200/JCO.2010.34.4994
   Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777
   Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845
   Tatem AJ, 2011, LANCET, V377, P30, DOI 10.1016/S0140 6736(11)61226 9
   Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140 6736(00)03639 4
NR 30
TC 27
Z9 28
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007 0920
EI 1532 1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD OCT 23
PY 2012
VL 107
IS 9
BP 1547
EP 1553
DI 10.1038/bjc.2012.436
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 029OS
UT WOS:000310505800015
PM 23033003
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Schmidt, S
   Post, TM
   Peletier, LA
   Boroujerdi, MA
   Danhof, M
AF Schmidt, Stephan
   Post, Teun M.
   Peletier, Lambertus A.
   Boroujerdi, Massoud A.
   Danhof, Meindert
TI Coping with time scales in disease systems analysis: application to bone
   remodeling
SO JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
LA English
DT Article
DE Disease progression modeling; Mathematical model reduction;
   Osteoporosis; Bone cell interaction model; RANK RANKL OPG
ID RANDOMIZED CONTROLLED TRIAL; OSTEOCYTE REGULATION LOOP; POSTMENOPAUSAL
   WOMEN; PARATHYROID HORMONE; MATHEMATICAL MODEL; SEX STEROIDS; VITAMIN D;
   TGF BETA; OSTEOBLAST; RECEPTOR
AB In this study we demonstrate the added value of mathematical model reduction for characterizing complex dynamic systems using bone remodeling as an example. We show that for the given parameter values, the mechanistic RANK RANKL OPG pathway model proposed by Lemaire et al. (J Theor Biol 229:293 309, 2004) can be reduced to a simpler model, which can describe the dynamics of the full Lemaire model to very good approximation. The response of both models to changes in the underlying physiology and therapeutic interventions was evaluated in four physiologically meaningful scenarios: (i) estrogen deficiency/estrogen replacement therapy, (ii) Vitamin D deficiency, (iii) ageing, and (iv) chronic glucocorticoid treatment and its cessation. It was found that on the time scale of disease progression and therapeutic intervention, the models showed negligible differences in their dynamic properties and were both suitable for characterizing the impact of estrogen deficiency and estrogen replacement therapy, Vitamin D deficiency, ageing, and chronic glucocorticoid treatment and its cessation on bone forming (osteoblasts) and bone resorbing (osteoclasts) cells. It was also demonstrated how the simpler model could help in elucidating qualitative properties of the observed dynamics, such as the absence of overshoot and rebound, and the different dynamics of onset and washout.
C1 [Schmidt, Stephan; Boroujerdi, Massoud A.; Danhof, Meindert] Leiden Amsterdam Ctr Drug Res, Div Pharmacol, NL 2300 RA Leiden, Netherlands.
   [Post, Teun M.] Merck Sharp & Dohme Ltd, PPDM, Clin PK PD, Merck Res Labs, NL 5340 BH Oss, Netherlands.
   [Peletier, Lambertus A.] Leiden Univ, Math Inst, NL 2300 RA Leiden, Netherlands.
C3 Leiden University   Excl LUMC; Leiden University; Merck & Company; Merck
   & Company Netherlands; Leiden University   Excl LUMC; Leiden University
RP Danhof, M (通讯作者)，Leiden Amsterdam Ctr Drug Res, Div Pharmacol, Einsteinweg 55,POB 9502, NL 2300 RA Leiden, Netherlands.
EM danhof_m@lacdr.leidenuniv.nl
RI ; Boroujerdi, Massoud/AAO 9177 2020
OI Boroujerdi, Massoud/0000 0002 5722 9645; Post, Teun/0000 0001 9183 2678;
   
FU Dutch Top Institute Pharma [D2 104]
FX The authors would like to thank Drs. Oscar E. Della Pasqua, Rik de Greef
   and Thomas Kerbusch for their valuable comments and suggestions. This
   study was performed within the framework of Dutch Top Institute Pharma,
   "Mechanism based PK/PD modeling platform (project number D2 104)''.
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   [Anonymous], CLIN TRIAL SIMULATIO
   BENDER CM, 1978, ADV MATH METHODS SCI
   Blanchard P., 1998, DIFFERENTIAL EQUATIO
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chan PLS, 2001, ANNU REV PHARMACOL, V41, P625, DOI 10.1146/annurev.pharmtox.41.1.625
   Clarke BL, 2010, ARCH BIOCHEM BIOPHYS, V503, P118, DOI 10.1016/j.abb.2010.07.006
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Danhof M, 2007, ANNU REV PHARMACOL, V47, P357, DOI 10.1146/annurev.pharmtox.47.120505.105154
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Gourlay M, 2007, CLIN RHEUMATOL, V26, P144, DOI 10.1007/s10067 006 0315 1
   Greenspan SL, 2002, ANN INTERN MED, V137, P875, DOI 10.7326/0003 4819 137 11 200212030 00008
   HOLFORD NHG, 2001, ANN M POP APPR GROUP
   Hunter P, 2005, PHYSIOLOGY, V20, P316, DOI 10.1152/physiol.00022.2005
   KAHN A, 1995, CLIN ORTHOP RELAT R, P69
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   LAAN RFJM, 1993, ANN INTERN MED, V119, P963, DOI 10.7326/0003 4819 119 10 199311150 00001
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Marie P, 1997, REV RHUM, V64, P44
   Moroz A, 2006, BIOSYSTEMS, V84, P183, DOI 10.1016/j.biosystems.2005.11.002
   NICOLAS V, 1994, J CLIN ENDOCR METAB, V78, P1011, DOI 10.1210/jc.78.5.1011
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   Peletier LA, 2010, J THEOR BIOL, V265, P657, DOI 10.1016/j.jtbi.2010.05.035
   Peletier LA, 2009, J THEOR BIOL, V256, P253, DOI 10.1016/j.jtbi.2008.09.014
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Pinkerton JV, 2010, ANN NY ACAD SCI, V1204, P169, DOI 10.1111/j.1749 6632.2010.05526.x
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2010, BONE, V47, P181, DOI 10.1016/j.bone.2010.04.601
   Ploeger BA, 2009, PHARM STAT, V8, P225, DOI 10.1002/pst.355
   Post TM, 2010, CLIN PHARMACOKINET, V49, P89, DOI 10.2165/11318150 000000000 00000
   Post TM, 2005, PHARM RES DORDR, V22, P1038, DOI 10.1007/s11095 005 5641 5
   POST TM, 2009, THESIS LEIDEN U
   Rattanakul C, 2003, BIOSYSTEMS, V70, P55, DOI 10.1016/S0303 2647(03)00040 6
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   SEGEL LA, 1988, B MATH BIOL, V50, P579, DOI 10.1016/S0092 8240(88)80057 0
   Slatopolsky E, 1999, KIDNEY INT, V56, pS46, DOI 10.1046/j.1523 1755.1999.07305.x
   Soules M R, 2001, Menopause, V8, P402, DOI 10.1097/00042192 200111000 00004
   St Arnaud R, 2008, ARCH BIOCHEM BIOPHYS, V473, P225, DOI 10.1016/j.abb.2008.03.038
   TITUS L, 1991, J BONE MINER RES, V6, P631
   Van Staa TP, 2005, J BONE MINER RES, V20, P1486, DOI 10.1359/jbmr.2005.20.8.1486
   Wimpenny DI, 2007, BIOSYSTEMS, V90, P295, DOI 10.1016/j.biosystems.2006.09.033
   Xie LY, 1996, AM J PHYSIOL ENDOC M, V270, pE654, DOI 10.1152/ajpendo.1996.270.4.E654
   Zhang R, 2010, NUTR J, V9, DOI 10.1186/1475 2891 9 65
   Zumsande M, 2011, BONE, V48, P910, DOI 10.1016/j.bone.2010.12.010
NR 47
TC 28
Z9 35
U1 0
U2 9
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1567 567X
EI 1573 8744
J9 J PHARMACOKINET PHAR
JI J. Pharmacokinet. Pharmacodyn.
PD DEC
PY 2011
VL 38
IS 6
BP 873
EP 900
DI 10.1007/s10928 011 9224 2
PG 28
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 890VJ
UT WOS:000300173500011
PM 22028207
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Kaur, K
   Sun, YJ
   Kanayama, K
   Morinaga, K
   Hokugo, A
   Nishimura, I
   Jewett, A
AF Kaur, Kawaljit
   Sun, Yujie
   Kanayama, Keiichi
   Morinaga, Kenzo
   Hokugo, Akishige
   Nishimura, Ichiro
   Jewett, Anahid
TI Augmentation of IFN γ by bone marrow derived immune cells in the
   presence of severe suppression of IFN γ in gingivae induced by
   zoledronic acid and denosumab in Hu BLT mice model of ONJ
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE zoledronic acid; denosumab; osteonecrosis of the jaw; NK cells;
   antibody dependent cellular cytotoxicity (ADCC); humanized BLT mice;
   cytotoxicity; IFN gamma
ID NATURAL KILLER CELLS; BISPHOSPHONATE RELATED OSTEONECROSIS; CANCER
   STEM CELLS; NK CELLS; T CELLS; IN VIVO; OSTEOCLAST FORMATION; MOUSE
   MODELS; RESORPTION; JAW
AB Introduction: The potential mechanisms governing drug induced osteonecrosis of the jaw (ONJ) is not well understood, and is one of the objectives of this study. Thus, we tested the release of IFN gamma within different immune compartments including bone marrow and gingivae upon treatment with zoledronic acid (ZOL) and denosumab which are known to induce ONJ in susceptible individuals.Methods: We used humanized BLT mouse model for the in vivo studies reported in this paper. To determine the effects of zoledronic acid and denosumab on IFN gamma secretion and NK cell mediated cytotoxicity; peripheral blood, bone marrow, spleen and gingiva were obtained after the injection of ZOL and denosumab in mice.Results: Percentages of B cells are much higher in wild type mice whereas the proportions of immune subsets in humans and reconstituted hu BLT peripheral blood are similar. Therefore, hu BLT mice are preferable model to study human disease, in particular, immune pathologies induced by ZOL and denosumab. Both agents resulted in a severe suppression of IFN gamma in the gingiva, whereas they heightened the release of IFN gamma and NK cell mediated cytotoxicity by the BM derived immune cells. ZOL increased the IFN gamma secretion by the spleen and peripheral blood immune cells, whereas denosumab decreased the release IFN gamma by these cells significantly.Discussion: ZOL and denosumab may likely suppress IFN gamma secretion in gingiva through different mechanisms. In addition, to the suppression of IFN gamma secretion, denosumab mediated effect could in part be due to the decrease in the bone resorptive function of osteoclasts due to the induction of antibody dependent cellular cytotoxicity and lysis of osteoclasts, whereas ZOL is able to mediate cell death of osteoclasts directly. Suppression of IFN gamma in gingiva is largely responsible for the inhibition of immune cell function, leading to dysregulated osteoblastic and osteoclastic activities. Restoration of IFN gamma in the local microenvironment may result in establishment of homeostatic balance in the gingiva and prevention of osteonecrosis of jaw.
C1 [Kaur, Kawaljit; Sun, Yujie; Kanayama, Keiichi; Morinaga, Kenzo; Hokugo, Akishige; Nishimura, Ichiro; Jewett, Anahid] UCLA, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90095 USA.
   [Kaur, Kawaljit; Nishimura, Ichiro; Jewett, Anahid] Univ Calif Sch Dent, Div Oral Biol & Med, Los Angeles, CA 94143 USA.
   [Sun, Yujie; Kanayama, Keiichi; Morinaga, Kenzo; Nishimura, Ichiro] Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont, Los Angeles, CA 94143 USA.
   [Kanayama, Keiichi] Asahi Univ, Sch Dent, Dept Periodontol, Gifu, Japan.
   [Morinaga, Kenzo] Fukuoka Dent Coll, Dept Oral Rehabil, Fukuoka, Japan.
   [Hokugo, Akishige] UCLA, David Geffen Sch Med, Div Plast Surg, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   Asahi University; Fukuoka Dental College (FDC); University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Nishimura, I; Jewett, A (通讯作者)，UCLA, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90095 USA.; Nishimura, I; Jewett, A (通讯作者)，Univ Calif Sch Dent, Div Oral Biol & Med, Los Angeles, CA 94143 USA.; Nishimura, I (通讯作者)，Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont, Los Angeles, CA 94143 USA.
EM inishimura@dentistry.ucla.edu; ajewett@ucla.edu
RI Kaur, Kawaljit/A 3222 2013
OI Kaur, Kawaljit/0000 0003 1936 5985
FU National Institute on Drug Abuse; National Institute on Aging; National
   Institute of Nursing Research; Eunice Kennedy Shriver National Institute
   of Child Health and Human Development; National Cancer Institute
   [P30AI152501] Funding Source: NIH RePORTER; National Institute on
   Minority Health and Health Disparities; National Institute of Allergy
   and Infectious Diseases; National Heart Lung and Blood Institute;
   National Institute of Diabetes and Digestive and Kidney Diseases;
   National Institute of Dental and Craniofacial Research [P30AI152501]
   Funding Source: NIH RePORTER
CR Allen MR, 2011, IBMS BoneKEy, V8, P141
   Badros AZ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.704722
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   BOONEKAMP PM, 1986, BONE MINER, V1, P27
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Breuil V, 1998, J BONE MINER RES, V13, P1721, DOI 10.1359/jbmr.1998.13.11.1721
   Bui VT, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00576
   CHAMBERS TJ, 1985, J PATHOL, V145, P297, DOI 10.1002/path.1711450403
   Cheng WC, 2014, J CLIN PERIODONTOL, V41, P541, DOI 10.1111/jcpe.12238
   Colucci S, 1998, CALCIFIED TISSUE INT, V63, P230, DOI 10.1007/s002239900519
   Cortés Vieyra R, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1396106
   Degrate L, 2009, LANGENBECK ARCH SURG, V394, P115, DOI 10.1007/s00423 008 0393 4
   Dehari Hironari, 2009, Gan To Kagaku Ryoho, V36, P2587
   Delves PJ, 2000, NEW ENGL J MED, V343, P108, DOI 10.1056/NEJM200007133430207
   Dunstan CR, 2007, NAT CLIN PRACT ONCOL, V4, P42, DOI 10.1038/ncponc0688
   Farag SS, 2006, BLOOD REV, V20, P123, DOI 10.1016/j.blre.2005.10.001
   Fildes JE, 2008, TRANSPL IMMUNOL, V19, P1, DOI 10.1016/j.trim.2008.01.004
   FLANAGAN AM, 1991, CALCIFIED TISSUE INT, V49, P407, DOI 10.1007/BF02555852
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Hiroi Furuya E, 1999, CALCIFIED TISSUE INT, V64, P219, DOI 10.1007/s002239900606
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Ito M, 1999, BONE, V25, P447, DOI 10.1016/S8756 3282(99)00197 0
   Jewett A, 2003, HUM IMMUNOL, V64, P505, DOI 10.1016/S0198 8859(03)00039 9
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kaur K, 2022, CELL IMMUNOL, V375, DOI 10.1016/j.cellimm.2022.104526
   Kaur K, 2020, CANCERS, V12, DOI 10.3390/cancers12010063
   Kaur K, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1426518
   Kaur K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00297
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   KITAYAMA J, 1993, CLIN EXP IMMUNOL, V93, P442, DOI 10.1111/j.1365 2249.1993.tb08198.x
   Kozlowska AK, 2017, FRONT BIOSCI LANDMRK, V22, P370, DOI 10.2741/4489
   Kozlowska AK, 2016, CANCER IMMUNOL IMMUN, V65, P835, DOI 10.1007/s00262 016 1822 9
   Kozlowska AK, 2017, J CANCER, V8, P537, DOI 10.7150/jca.15989
   LERNER UH, 1987, BONE, V8, P179, DOI 10.1016/8756 3282(87)90018 4
   Li HY, 2010, BLOOD, V116, P210, DOI 10.1182/blood 2009 11 255026
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   Moutsopoulos NM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007696
   Park S, 2015, J BIOL CHEM, V290, P17349, DOI 10.1074/jbc.M115.652305
   PIPER K, 1994, CALCIFIED TISSUE INT, V54, P56, DOI 10.1007/BF00316291
   POPOFF SN, 1991, J BONE MINER RES, V6, P263
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Schmiedel BJ., 2010, BLOOD, V116, P2164, DOI [10.1182/blood.V116.21.2164.2164, DOI 10.1182/BLOOD.V116.21.2164.2164]
   Selander KS, 1996, MOL PHARMACOL, V50, P1127
   Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110
   Shimizu S, 2010, BLOOD, V115, P1534, DOI 10.1182/blood 2009 04 215855
   Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311
   Silva N, 2008, J CLIN PERIODONTOL, V35, P206, DOI 10.1111/j.1600 051X.2007.01190.x
   Söderström K, 2010, P NATL ACAD SCI USA, V107, P13028, DOI 10.1073/pnas.1000546107
   Stoddart CA, 2011, VIROLOGY, V417, P154, DOI 10.1016/j.virol.2011.05.013
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Sun YJ, 2016, J BIOL CHEM, V291, P20602, DOI 10.1074/jbc.M116.735795
   Tao LL, 2017, TRENDS IMMUNOL, V38, P181, DOI 10.1016/j.it.2016.12.007
   Thumbigere Math V, 2014, J PERIODONTOL, V85, P226, DOI 10.1902/jop.2013.130017
   Tseng HC, 2015, ONCOTARGET, V6, P20002, DOI 10.18632/oncotarget.4755
   Tseng HC, 2015, ONCOTARGET, V6, P8947, DOI 10.18632/oncotarget.3250
   Tseng HC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011590
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Vatakis DN, 2012, JOVE J VIS EXP, DOI 10.3791/4181
   Vatakis DN, 2011, P NATL ACAD SCI USA, V108, pE1408, DOI 10.1073/pnas.1115050108
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
   Yamazaki T, 2012, INT J ORAL MAX SURG, V41, P1397, DOI 10.1016/j.ijom.2012.06.020
NR 66
TC 5
Z9 5
U1 2
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD JAN 20
PY 2023
VL 14
AR 1111627
DI 10.3389/fendo.2023.1111627
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 8O3KS
UT WOS:000925737000001
PM 36742414
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Pieles, O
   Reichert, TE
   Morsczeck, C
AF Pieles, Oliver
   Reichert, Torsten E.
   Morsczeck, Christian
TI Classical isoforms of protein kinase C (PKC) and Akt regulate the
   osteogenic differentiation of human dental follicle cells via both
   β catenin and NF κB
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Dental follicle cells; Osteogenic differentiation; Mineralization;
   Protein kinase C; Akt; NF kappa B; Canonical Wnt signaling; beta catenin
AB BackgroundHuman dental follicle cells (DFCs) are the precursor cells of the periodontium with a high potential for regenerative therapies of (alveolar) bone. However, the molecular mechanisms of osteogenic differentiation are inadequately understood. Classical isoforms of protein kinase C (PKC) are reported to inhibit osteogenesis of stem/precursor cells. This study evaluated the role of classical PKCs and potential downstream targets on the osteogenic differentiation of DFCs.MethodsDFCs were osteogenic differentiated with dexamethasone or bone morphogenetic protein 2 (BMP2). Expression of PKC and potential upstream/downstream regulators was manipulated using activators, inhibitors, and small interfering ribonucleic acid (siRNA). Expression of proteins was examined by Western blot analysis, while the activation levels of enzymes and transcription factors were examined by their phosphorylation states or by specific activation assays. Expression levels of osteogenic markers were examined by RT qPCR (reverse transcription quantitative polymerase chain reaction) analysis. Activity of alkaline phosphatase (ALP) and accumulation of calcium nodules by Alizarin Red staining were measured as indicators of mineralization.ResultsClassical PKCs like PKC alpha inhibit the osteogenic differentiation of DFCs, but do not interfere with the induction of differentiation. Inhibition of classical PKCs by Go6976 enhanced activity of Akt after osteogenic induction. Akt was also regulated during differentiation and especially disturbed BMP2 induced mineralization. The PKC/Akt axis was further shown to regulate the canonical Wnt signaling pathway and eventually nuclear expression of active beta  catenin during dexamethasone induced osteogenesis. Moreover, the nuclear factor "kappa light chain enhancer" of activated B cells (NF kappa B) pathway is regulated during osteogenic differentiation of DFCs and via the PKC/Akt axis and disturbs the mineralization. Upstream, parathyroid hormone related protein (PTHrP) sustained the activity of PKC, while Wnt5a inhibited it.ConclusionsOur results demonstrate that classical PKCs like PKC alpha and Akt regulate the osteogenic differentiation of DFCs partly via both beta  catenin and NF kappa B.
C1 [Pieles, Oliver; Reichert, Torsten E.; Morsczeck, Christian] Univ Hosp Regensburg, Dept Oral & Maxillofacial Surg, Franz Josef Strauss Allee 11, D 93053 Regensburg, Germany.
C3 University of Regensburg
RP Morsczeck, C (通讯作者)，Univ Hosp Regensburg, Dept Oral & Maxillofacial Surg, Franz Josef Strauss Allee 11, D 93053 Regensburg, Germany.
EM christian.morsczeck@klinik.uni regensburg.de
FU Deutsche Forschungsgemeinschaft [DFG MO1875/10 1]
FX This work was supported by grant of the Deutsche Forschungsgemeinschaft
   (DFG MO1875/10 1). Open Access funding enabled and organized by Projekt
   DEAL.
CR [Anonymous], 2004, PROTEIN KINASE C
   AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen XJ, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108746
   Chu N, 2018, CELL, V174, P897, DOI 10.1016/j.cell.2018.07.003
   do Carmo A, 2013, CANCER BIOL THER, V14, P287, DOI 10.4161/cbt.23615
   Du Y, 2012, CONNECT TISSUE RES, V53, P390, DOI 10.3109/03008207.2012.668980
   Felthaus O, 2014, CELL TISSUE RES, V357, P695, DOI 10.1007/s00441 014 1891 z
   Galea GL, 2014, J BIOL CHEM, V289, P25509, DOI 10.1074/jbc.M114.580365
   Gao QY, 2009, MOL VIS, V15, P2683
   Gu SS, 2015, CELL PHYSIOL BIOCHEM, V36, P1725, DOI 10.1159/000430145
   Han Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06304 x
   Igumenova TI, 2015, BIOCHEMISTRY US, V54, P4953, DOI 10.1021/acs.biochem.5b00565
   Jeong HM, 2012, BBA MOL CELL RES, V1823, P1225, DOI 10.1016/j.bbamcr.2012.05.018
   Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960 9822(99)80265 6
   Kaul N, 1996, FREE RADICAL BIO MED, V21, P401, DOI 10.1016/0891 5849(96)00178 5
   Keller KC, 2016, STEM CELLS DEV, V25, P1020, DOI 10.1089/scd.2015.0367
   Klingelhöffer C, 2016, TISSUE CELL, V48, P334, DOI [10.1016/j.tice.2013.05.007, 10.1016/j.tice.2016.05.007]
   Krivanek J, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00376
   Li XH, 2011, MOL MED REP, V4, P621, DOI 10.3892/mmr.2011.474
   Liu J, 2010, J TISSUE ENG REGEN M, V4, P329, DOI 10.1002/term.242
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luan XG, 2006, STEM CELLS DEV, V15, P595, DOI 10.1089/scd.2006.15.595
   Luo G, 2018, MOL MED REP, V17, P6605, DOI 10.3892/mmr.2018.8698
   MCCULLOCH CAG, 1986, ANAT RECORD, V215, P397, DOI 10.1002/ar.1092150410
   Morsczeck C, 2006, CALCIFIED TISSUE INT, V78, P98, DOI 10.1007/s00223 005 0146 0
   Morsczeck C, 2005, CELL BIOL INT, V29, P567, DOI 10.1016/j.cellbi.2005.03.020
   Morsczeck C, 2019, MOL CELL BIOCHEM, V455, P21, DOI 10.1007/s11010 018 3467 9
   Morsczeck C, 2015, HISTOL HISTOPATHOL, V30, P1161, DOI 10.14670/HH 11 634
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Nakura A, 2011, BONE, V48, P476, DOI 10.1016/j.bone.2010.09.238
   Newton AC, 2017, TRENDS PHARMACOL SCI, V38, P438, DOI 10.1016/j.tips.2017.02.002
   Pieles O, 2020, HISTOCHEM CELL BIOL, V154, P397, DOI 10.1007/s00418 020 01904 7
   Poli A, 2018, FASEB J, V32, P681, DOI 10.1096/fj.201700690R
   Que BG, 1999, ARCH ORAL BIOL, V44, P961, DOI 10.1016/S0003 9969(99)00071 0
   Ren LR, 2017, MED SCI MONITOR, V23, P4579, DOI 10.12659/MSM.903371
   Santos A, 2010, CYTOTHERAPY, V12, P924, DOI 10.3109/14653241003774011
   Saugspier M, 2010, STEM CELLS DEV, V19, P707, DOI [10.1089/scd.2010.0027, 10.1089/scd.2009.0027]
   SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171 2985(11)80543 7
   SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424
   Silvério KG, 2012, J PERIODONTAL RES, V47, P309, DOI 10.1111/j.1600 0765.2011.01433.x
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092 8674(00)81780 8
   Tang YM, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01774 9
   Ullah I, 2016, LIFE SCI, V154, P39, DOI 10.1016/j.lfs.2016.04.026
   Viale Bouroncle S, 2015, MOL CELL BIOCHEM, V406, P199, DOI 10.1007/s11010 015 2437 8
   Viale Bouroncle S, 2015, CELL SIGNAL, V27, P598, DOI 10.1016/j.cellsig.2014.12.008
   Viale Bouroncle S, 2012, STEM CELLS DEV, V21, P1936, DOI 10.1089/scd.2011.0422
   Wang MH, 2017, AGING US, V9, P1326, DOI 10.18632/aging.101230
   Xu Y, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152722
   Xue N, 2018, CELL PHYSIOL BIOCHEM, V48, P1771, DOI 10.1159/000492350
   Yan DY, 2020, J CELL MOL MED, V24, P2330, DOI 10.1111/jcmm.14915
   Yao SM, 2003, ARCH ORAL BIOL, V48, P643, DOI 10.1016/S0003 9969(03)00115 8
   Ye JP, 2000, ANN CLIN LAB SCI, V30, P65
   Yuasa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116462
   Zavan B, 2016, STEM CELLS BIOL REG, P1, DOI 10.1007/978 3 319 33299 4
   Zhang JW, 2019, J CELL PHYSIOL, V234, P11900, DOI 10.1002/jcp.27857
   Zhang P, 2018, ARCH ORAL BIOL, V87, P172, DOI 10.1016/j.archoralbio.2017.12.031
   Zhu B, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12709
NR 58
TC 12
Z9 14
U1 2
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD APR 14
PY 2021
VL 12
IS 1
AR 242
DI 10.1186/s13287 021 02313 w
PG 14
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA RN6YR
UT WOS:000640498800006
PM 33853677
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Oh, Y
   Park, R
   Kim, SY
   Park, SH
   Jo, S
   Kim, TH
   Ji, JD
AF Oh, Younseo
   Park, Robin
   Kim, So Yeon
   Park, Sung ho
   Jo, Sungsin
   Kim, Tae Hwan
   Ji, Jong Dae
TI B7 H3 regulates osteoclast differentiation via type I
   interferon dependent IDO induction
SO CELL DEATH & DISEASE
LA English
DT Article
ID NF KAPPA B; DENDRITIC CELLS; T CELLS; INDOLEAMINE 2,3 DIOXYGENASE;
   INFLAMMATORY RESPONSE; RHEUMATOID ARTHRITIS; BONE; LIGAND; IMMUNE;
   EXPRESSION
AB While their function, as immune checkpoint molecules, is well known, B7 family proteins also function as regulatory molecules in bone remodeling. B7 H3 is a receptor ligand of the B7 family that functions primarily as a negative immune checkpoint. While the regulatory function of B7 H3 in osteoblast differentiation has been established, its role in osteoclast differentiation remains unclear. Here we show that B7 H3 is highly expressed in mature osteoclasts and that B7 H3 deficiency leads to the inhibition of osteoclastogenesis in human osteoclast precursors (OCPs). High throughput transcriptomic analyses reveal that B7 H3 inhibition upregulates IFN signaling as well as IFN inducible genes, including IDO. Pharmacological inhibition of type I IFN and IDO knockdown leads to reversal of B7 H3 deficiency mediated osteoclastogenesis suppression. Although synovial fluid macrophages from rheumatoid arthritis patients express B7 H3, inhibition of B7 H3 does not affect their osteoclastogenesis. Thus, our findings highlight B7 H3 as a physiologic positive regulator of osteoclast differentiation and implicate type I IFN IDO signaling as its downstream mechanism.
C1 [Oh, Younseo; Kim, So Yeon; Jo, Sungsin; Kim, Tae Hwan] Hanyang Univ, Inst Rheumatol Res, Seoul, South Korea.
   [Oh, Younseo; Ji, Jong Dae] Korea Univ, Coll Med, Rheumatol, Seoul, South Korea.
   [Park, Robin] Tufts Univ Sch Med, MetroWest Med Ctr, Framingham, MA 01702 USA.
   [Kim, So Yeon] Hanyang Univ, Grad Sch Biomed Sci & Engn, Dept Translat Med, Seoul, South Korea.
   [Park, Sung ho] UNIST, Sch Life Sci, Ulsan 44919, South Korea.
   [Kim, Tae Hwan] Hanyang Univ Hosp Rheumat Dis, Dept Rheumatol, Seoul, South Korea.
C3 Hanyang University; Korea University; Korea University Medicine (KU
   Medicine); Hanyang University; Ulsan National Institute of Science &
   Technology (UNIST); Hanyang University; Hanyang University Hospital
RP Kim, TH (通讯作者)，Hanyang Univ, Inst Rheumatol Res, Seoul, South Korea.; Ji, JD (通讯作者)，Korea Univ, Coll Med, Rheumatol, Seoul, South Korea.; Kim, TH (通讯作者)，Hanyang Univ Hosp Rheumat Dis, Dept Rheumatol, Seoul, South Korea.
EM thkim@hanyang.ac.kr; jjdjmesy@korea.ac.kr
RI park, sungho/ABA 4566 2020; Kim, Tae Hwan/M 3962 2017; Jo,
   Sungsin/AAL 3659 2021
OI Jo, Sungsin/0000 0003 3034 5029; Kim, Tae Hwan/0000 0002 3542 2276; 
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Science, ICT [2019R1A2C1083857,
   2019R1A2C2004214, 2021R1A6A1A03038899]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Science, ICT, and Future (2019R1A2C1083857 to Jong Dae Ji
   and 2019R1A2C2004214, and 2021R1A6A1A03038899 to Tae Hwan Kim).
CR Antoniv TT, 2006, ARTHRITIS RHEUM, V54, P2711, DOI 10.1002/art.22055
   Bozec A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007764
   Ceeraz S, 2013, TRENDS IMMUNOL, V34, P556, DOI 10.1016/j.it.2013.07.003
   Chen XQ, 2012, J IMMUNOL, V189, P347, DOI 10.4049/jimmunol.1103715
   Chen YT, 2020, CELL IMMUNOL, V352, DOI 10.1016/j.cellimm.2020.104077
   Crow MK, 2014, J IMMUNOL, V192, P5459, DOI 10.4049/jimmunol.1002795
   Fallarino F, 2005, INT IMMUNOL, V17, P1429, DOI 10.1093/intimm/dxh321
   Fallarino F, 2012, EUR J IMMUNOL, V42, P1932, DOI 10.1002/eji.201242572
   Gigliotti CL, 2016, J IMMUNOL, V197, P3905, DOI 10.4049/jimmunol.1600424
   Ha H, 2008, J IMMUNOL, V180, P1382, DOI 10.4049/jimmunol.180.3.1382
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Ji JD, 2003, J EXP MED, V197, P1573, DOI 10.1084/jem.20021820
   Kalliolias GD, 2010, ARTHRITIS RHEUM US, V62, P402, DOI 10.1002/art.27200
   Kimura A, 2008, P NATL ACAD SCI USA, V105, P9721, DOI 10.1073/pnas.0804231105
   Li QS, 2016, J IMMUNOL, V197, P962, DOI 10.4049/jimmunol.1502615
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Mellor AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01360
   Orabona C, 2005, J IMMUNOL, V174, P6582, DOI 10.4049/jimmunol.174.11.6582
   Orabona C, 2004, NAT IMMUNOL, V5, P1134, DOI 10.1038/ni1124
   Pallotta MT, 2011, NAT IMMUNOL, V12, P870, DOI 10.1038/ni.2077
   Puccetti P, 2007, NAT REV IMMUNOL, V7, P817, DOI 10.1038/nri2163
   Quintana FJ, 2010, P NATL ACAD SCI USA, V107, P20768, DOI 10.1073/pnas.1009201107
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   SENGUPTA TK, 1995, J EXP MED, V181, P1015, DOI 10.1084/jem.181.3.1015
   Suh WK, 2004, P NATL ACAD SCI USA, V101, P12969, DOI 10.1073/pnas.0405259101
   Sun J, 2015, CLIN IMMUNOL, V159, P23, DOI 10.1016/j.clim.2015.04.012
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tran CN, 2008, J IMMUNOL, V180, P2989, DOI 10.4049/jimmunol.180.5.2989
   Yoon BR, 2016, J BIOL CHEM, V291, P4048, DOI 10.1074/jbc.M115.680298
   Zhang GB, 2010, J IMMUNOL, V185, P3677, DOI 10.4049/jimmunol.0904020
   Zhang J, 2012, FEBS LETT, V586, P3255, DOI 10.1016/j.febslet.2012.06.047
   Zhao B, 2010, TOXICOL SCI, V117, P393, DOI 10.1093/toxsci/kfq217
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
   Zheng X, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1623 0
NR 37
TC 12
Z9 12
U1 1
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT 20
PY 2021
VL 12
IS 11
AR 971
DI 10.1038/s41419 021 04275 6
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA WK0DR
UT WOS:000709405900001
PM 34671026
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chung, CJ
   Long, HY
AF Chung, Chi Jen
   Long, Han Yun
TI Systematic strontium substitution in hydroxyapatite coatings on titanium
   via micro arc treatment and their osteoblast/osteoclast responses
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Micro arc treatment; Strontium containing hydroxyapatite; Osteoblast;
   Osteoclast; Osseointegration
ID BONE FORMATION; SR; OSTEOBLAST; DEPOSITION; OXIDATION; CEMENT
AB This study attempts to enhance the osseointegration of titanium implants by adopting a micro arc treatment (MAT) capable of replacing calcium (Ca) with different percentages of strontium (Sr) in order to fabricate strontium containing hydroxyapatite (Sr HAp) coatings. Sr, regarded as a significant therapy promoting bone mass and bone strength, has a dual mechanism, enhancing osteoblast differentiation and inhibiting osteoclast differentiation. This study also investigates how Sr content affects the microstructure of and osteoblast/osteoclast growth on the coatings. Experimental results indicate that an increase in the Sr content in the electrolyte bath results in a greater degree of Sr substitution at Ca sites within the HAp phase, facilitating the formation of Sr HAp coatings with Sr fully solid soluble in the HAP phase. Irrespective of the Sr content, most coatings are similar in porous morphology and pore size. Additionally, the Sr HAp coating shows higher osteoblast compatibility than raw titanium metal and the HAp coating. Moreover, cell adhesion and proliferation after 48 h was greater than that after 4 h, indicating that Sr can stimulate osteoblast adhesion and proliferation. Further, Sr significantly inhibits osteoclast differentiation when the Sr HAp coatings exceed 38.9 at.% Sr. (C) 2011 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Chung, Chi Jen] Cent Taiwan Univ Sci & Technol, Dept Dent Technol & Mat Sci, Taichung 40601, Taiwan.
   [Long, Han Yun] Feng Chia Univ, Dept Mat Sci & Engn, Taichung 40724, Taiwan.
C3 Central Taiwan University Science & Technology; Feng Chia University
RP Chung, CJ (通讯作者)，Cent Taiwan Univ Sci & Technol, Dept Dent Technol & Mat Sci, 666 Buzih Rd, Taichung 40601, Taiwan.
EM cjchung@seed.net.tw
FU National Science Council of the Republic of China, Taiwan [NSC
   98 2218 E 166 001, NSC 98 2622 8 035 003 A1, NSC 99 2221 E 166 001]
FX The authors would like to thank the National Science Council of the
   Republic of China, Taiwan, for financially supporting this research
   under contracts Nos. NSC 98 2218 E 166 001, NSC 98 2622 8 035 003 A1 and
   NSC 99 2221 E 166 001. Useful discussions with Prof. K.C. Chen and Prof.
   J.L. He. Department of Materials Science and Engineering, Feng Chia
   University, are also appreciated.
CR Bracci B, 2009, J INORG BIOCHEM, V103, P1666, DOI 10.1016/j.jinorgbio.2009.09.009
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Capuccini C, 2008, ACTA BIOMATER, V4, P1885, DOI 10.1016/j.actbio.2008.05.005
   Chang YH, 1999, ENDOCRINOLOGY, V140, P5883, DOI 10.1210/en.140.12.5883
   Cook S D, 1987, Int J Oral Maxillofac Implants, V2, P15
   El Ouenzerfi R, 1999, J LUMIN, V85, P71, DOI 10.1016/S0022 2313(99)00149 0
   Fonseca JE, 2008, RHEUMATOLOGY, V47, P17, DOI 10.1093/rheumatology/ken165
   Gentleman E, 2010, BIOMATERIALS, V31, P3949, DOI 10.1016/j.biomaterials.2010.01.121
   Ito A, 2000, J BIOMED MATER RES, V50, P178, DOI 10.1002/(SICI)1097 4636(200005)50:2<178::AID JBM12>3.0.CO;2 5
   Kawamura H, 2000, J BIOMED MATER RES, V50, P184, DOI 10.1002/(SICI)1097 4636(200005)50:2<184::AID JBM13>3.0.CO;2 3
   KIKUCHI M, 1994, J SOLID STATE CHEM, V113, P373, DOI 10.1006/jssc.1994.1383
   Kim HW, 2005, J BIOMED MATER RES A, V74A, P294, DOI 10.1002/jbm.a.30191
   Kung KC, 2010, SURF COAT TECH, V205, P1714, DOI 10.1016/j.surfcoat.2010.05.018
   Li LH, 2005, J BIOMED MATER RES A, V73A, P48, DOI 10.1002/jbm.a.30244
   Liu WC, 2010, J BIOMED MATER RES B, V95B, P397, DOI 10.1002/jbm.b.31730
   Marie PJ, 2007, BONE, V40, pS5, DOI 10.1016/j.bone.2007.02.003
   Melnikov Petr, 2008, Acta ortop. bras., V16, P54
   Nan KH, 2009, MAT SCI ENG C BIO S, V29, P1554, DOI 10.1016/j.msec.2008.12.018
   Ni GX, 2010, J MATER SCI MATER M, V21, P377, DOI 10.1007/s10856 009 3866 2
   Ni JH, 2008, MATER RES BULL, V43, P45, DOI 10.1016/j.materresbull.2007.02.019
   Nie X, 2000, SURF COAT TECH, V125, P407, DOI 10.1016/S0257 8972(99)00612 X
   O'Donnell MD, 2008, ACTA BIOMATER, V4, P1455, DOI 10.1016/j.actbio.2008.04.018
   Orsini G, 2000, INT J ORAL MAX IMPL, V15, P779
   Parhi P, 2006, J MATER SCI, V41, P1455, DOI 10.1007/s10853 006 7460 4
   Renaudin G, 2008, J MATER CHEM, V18, P3593, DOI 10.1039/b804140g
   Shi, 2009, Mining Science and Technology (China), V19, P220, DOI [DOI 10.1016/S1674 5264, 10.1016/S1674 5264(09)60042 9, DOI 10.1016/S1674 5264(09)60042 9]
   Wong KL, 2009, BIOMATERIALS, V30, P3810, DOI 10.1016/j.biomaterials.2009.04.016
   Xue WC, 2007, SURF COAT TECH, V201, P4685, DOI 10.1016/j.surfcoat.2006.10.012
   Xue WC, 2006, J BIOMED MATER RES A, V79A, P804, DOI 10.1002/jbm.a.30815
   Yan YY, 2010, SURF COAT TECH, V205, P1702, DOI 10.1016/j.surfcoat.2010.09.040
NR 30
TC 147
Z9 153
U1 2
U2 111
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD NOV
PY 2011
VL 7
IS 11
BP 4081
EP 4087
DI 10.1016/j.actbio.2011.07.004
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 837NK
UT WOS:000296210300029
PM 21784178
DA 2025 08 17
ER

PT J
AU Choi, J
   Lee, K
   Kang, M
   Lim, SK
   No, KT
AF Choi, Jiwon
   Lee, Kyungro
   Kang, Myeongmo
   Lim, Sung Kil
   No, Kyoung Tai
TI In silico discovery of quinoxaline derivatives as novel
   LRP5/6 sclerostin interaction inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Wnt/beta catenin signalling pathway; LRP5/6 sclerostin interaction;
   Structure activity relationships; Virtual screening; Osteoporosis
ID SCLEROSTIN; DISEASE; LRP5/6
AB The Wnt/beta catenin signaling pathway is a key regulator of bone homeostasis. Sclerostin act as an extracellular inhibitor of canonical Wnt signaling through high affinity binding to the Wnt co receptor LRP5/6. Disruption of the interaction between LRP5/6 and sclerostin has been recognized as a therapeutic target for osteoporosis. We identified a quinoxaline moiety as a new small molecule inhibitor of the LRP5/6 sclerostin interaction through pharmacophore based virtual screening, docking simulations, and in vitro assays. Structure activity relationship studies and binding mode hypotheses were used to optimize the scaffold and yield the compound BMD4503 2, which recovered the downregulated activity of the Wnt/beta catenin signaling pathway by competitive binding to the LRP5/6 sclerostin complex. Overall, this study showed that the optimized structure based drug design was a promising approach for the development of small molecule inhibitors of the LRP5/6 sclerostin interaction. A novel scaffold offered considerable insights into the structural basis for binding to LRP5/6 and disruption of the sclerostin mediated inhibition of Wnt signaling. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Choi, Jiwon; No, Kyoung Tai] Yonsei Univ, Bioinformat & Mol Design Res Ctr, Seoul 03722, South Korea.
   [Lee, Kyungro; No, Kyoung Tai] Yonsei Univ, Dept Biotechnol, Coll Life Sci & Biotechnol, Seoul 03722, South Korea.
   [Kang, Myeongmo] Yonsei Univ, Coll Med, Severance Biomed Sci Inst, Seoul 03722, South Korea.
   [Lim, Sung Kil] Yonsei Univ, Coll Med, Dept Internal Med, Seoul 03722, South Korea.
C3 Yonsei University; Yonsei University; Yonsei University; Yonsei
   University Health System; Yonsei University; Yonsei University Health
   System
RP No, KT (通讯作者)，Yonsei Univ, Bioinformat & Mol Design Res Ctr, Seoul 03722, South Korea.; Lim, SK (通讯作者)，Yonsei Univ, Coll Med, Dept Internal Med, Seoul 03722, South Korea.
EM lsk@yhus.ac; ktno@yonsei.ac.kr
RI Kim, Ji/AAN 5655 2021; No, Kyoung/P 1644 2015
OI Choi, Jiwon/0000 0002 0786 6187
FU Ministry of Knowledge Economy through the Korea Research Institute of
   Chemical Technology [SI 1105, SI 1205, SI 1304]
FX This work was supported by the Ministry of Knowledge Economy through the
   Korea Research Institute of Chemical Technology (SI 1105, SI 1205,
   SI 1304).
CR Bourhis E, 2011, STRUCTURE, V19, P1433, DOI 10.1016/j.str.2011.07.005
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399 0004.2003.00036.x
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Lewiecki EM, 2011, DISCOV MED, V12, P263
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370
   Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097 2765(03)00484 2
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
NR 11
TC 11
Z9 16
U1 0
U2 23
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 894X
EI 1464 3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD APR 1
PY 2018
VL 28
IS 6
BP 1116
EP 1121
DI 10.1016/j.bmcl.2018.01.050
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA FZ3ZZ
UT WOS:000427531500025
PM 29486968
DA 2025 08 17
ER

PT J
AU Zheng, J
   van Schaick, E
   Wu, LS
   Jacqmin, P
   Ruixo, JJ
AF Zheng, Jenny
   van Schaick, Erno
   Wu, Liviawati Sutjandra
   Jacqmin, Philippe
   Perez Ruixo, Juan Jose
TI Using early biomarker data to predict long term bone mineral density:
   application of semi mechanistic bone cycle model on denosumab data
SO JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
LA English
DT Article
DE Osteoporosis; Pharmacokinetics; Pharmacodynamics; Bone remodeling;
   Denosumab
ID POSTMENOPAUSAL WOMEN; MATHEMATICAL MODEL; OSTEOPOROSIS; MASS;
   MECHANOSTAT; PREVENTION; TURNOVER; THERAPY; PHASE 2; MARKERS
AB Osteoporosis is a chronic skeletal disease characterized by low bone strength resulting in increased fracture risk. New treatments for osteoporosis are still an unmet medical need because current available treatments have various limitations. Bone mineral density (BMD) is an important endpoint for evaluating new osteoporosis treatments; however, the BMD response is often slower and less profound than that of bone turnover markers (BTMs). If the relationship between BTMs and BMD can be quantified, the BMD response can be predicted by the changes in BTM after a single dose; therefore, a decision based on BMD changes can be informed early. We have applied a bone cycle model to a phase 2 denosumab dose ranging study in osteopenic women to quantitatively link serum denosumab pharmacokinetics, BTMs, and lumbar spine (LS) BMD. The data from two phase 3 denosumab studies in patients with low bone mass, FREEDOM and DEFEND, were used for external validation. Both internal and external visual predictive checks demonstrated that the model was capable of predicting LS BMD at the denosumab regimen of 60 mg every 6 months. It has been demonstrated that the model, in combination with the changes in BTMs observed from a single dose study in men, is capable of predicting long term BMD outcomes (e.g., LS BMD response in men after 1 year of treatment) in different populations. We propose that this model can be used to inform drug development decisions for osteoporosis treatment early via evaluating LS BMD response when BTM data become available in early trials.
C1 [Zheng, Jenny; Wu, Liviawati Sutjandra; Perez Ruixo, Juan Jose] Amgen Inc, Pharmacokinet & Drug Metab Div, Thousand Oaks, CA 91320 USA.
   [van Schaick, Erno; Jacqmin, Philippe] SGS Exprimo NV, B 2800 Mechelen, Belgium.
   [Perez Ruixo, Juan Jose] Amgen Inc, Pharmacokinet & Drug Metab Div, Valencia 46530, Spain.
C3 Amgen
RP Ruixo, JJ (通讯作者)，Amgen Inc, Pharmacokinet & Drug Metab Div, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
EM perezruixo@gmail.com
RI ; Ruixo, Juan/AAL 2987 2020
OI PEREZ RUIXO, JUAN JOSE/0000 0001 9890 745X; 
FU Amgen Inc.
FX The authors wish to thank the investigators of the studies included in
   this manuscript, and Andrew T. Chow and Ed Lee for their continuous
   scientific support during the completion of these analyses. We thank
   Geoff Smith, PhD, and Lisa A. Humphries, PhD, of Amgen Inc. for their
   assistance with the editing and formatting of this manuscript. This
   study was funded by Amgen Inc.
CR [Anonymous], STAT AN PROGR S PLUS
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Beal S., 1988, NONMEM User Guides
   Berne RM, 1998, PRINCIPLES PHYSL, P850
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Buenzli PR, 2012, J THEOR BIOL, V307, P42, DOI 10.1016/j.jtbi.2012.04.019
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Curtis JR, 2008, J BONE MINER RES, V23, P1435, DOI 10.1359/JBMR.080418
   Development Core Team, 2007, LANG ENV STAT COMP
   Doshi S, 2012, CLIN CANCER RES, V18, P2648, DOI 10.1158/1078 0432.CCR 11 2944
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Ferretti JL, 2003, MECH AGEING DEV, V124, P269, DOI 10.1016/S0047 6374(02)00194 X
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   Frost HM, 2004, ANGLE ORTHOD, V74, P3
   FROST HM, 1987, BONE MINER, V2, P73
   Gallagher JC, 2002, J CLIN ENDOCR METAB, V87, P4914, DOI 10.1210/jc.2002 020727
   Girard P, 2002, 11 M POP APPR GROUP, P67
   Hernandez CJ, 2001, BONE, V29, P511, DOI 10.1016/S8756 3282(01)00613 5
   Hollister S, 2004, BME 456 BIOSOLID MEC
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Komarova SV, 2005, ENDOCRINOLOGY, V146, P3589, DOI 10.1210/en.2004 1642
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Komarova SV, 2006, ANN NY ACAD SCI, V1068, P557, DOI 10.1196/annals.1346.052
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marathe DD, 2011, BIOPHARM DRUG DISPOS, V32, P471, DOI 10.1002/bdd.770
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Orwoll E, 2012, J CLIN ENDOCR METAB, V97, P3161, DOI 10.1210/jc.2012 1569
   Ravn P, 1998, BONE, V22, P559, DOI 10.1016/S8756 3282(98)00044 1
   Sutjandra L, 2011, CLIN PHARMACOKINET, V50, P793, DOI 10.2165/11594240 000000000 00000
   van Schaick E, 2015, J PHARMACOKINET PHAR, V42, P315, DOI 10.1007/s10928 015 9423 3
   Zajic S, 2011, 20 ANN M POP APPR GR
   Zhang LP, 2003, J PHARMACOKINET PHAR, V30, P387, DOI 10.1023/B:JOPA.0000012998.04442.1f
NR 36
TC 8
Z9 8
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1567 567X
EI 1573 8744
J9 J PHARMACOKINET PHAR
JI J. Pharmacokinet. Pharmacodyn.
PD AUG
PY 2015
VL 42
IS 4
BP 333
EP 347
DI 10.1007/s10928 015 9422 4
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CN1EN
UT WOS:000358160100002
PM 26123919
DA 2025 08 17
ER

PT J
AU Kalyanaraman, H
   Casteel, DE
   China, SP
   Zhuang, SH
   Boss, GR
   Pilz, RB
AF Kalyanaraman, Hema
   Casteel, Darren E.
   China, Shyamsundar Pal
   Zhuang, Shunhui
   Boss, Gerry R.
   Pilz, Renate B.
TI A plasma membrane associated form of the androgen receptor enhances
   nuclear androgen signaling in osteoblasts and prostate cancer cells
SO SCIENCE SIGNALING
LA English
DT Article
ID BONE MINERAL DENSITY; PROTEIN KINASE G; ESTROGEN RECEPTOR; NITRIC OXIDE;
   DNA BINDING; NITROGLYCERIN THERAPY; ORGANIC NITRATES; MALE MICE;
   TESTOSTERONE; ACTIVATION
AB Androgen binding to the androgen receptor (AR) in the cytoplasm induces the AR to translocate to the nucleus, where it regulates the expression of target genes. Here, we found that androgens rapidly activated a plasma membrane associated signaling node that enhanced nuclear AR functions. In murine primary osteoblasts, dihydrotestosterone (DHT) binding to a membrane associated form of AR stimulated plasma membrane associated protein kinase G type 2 (PKG2), leading to the activation of multiple kinases, including ERK. Phosphorylation of AR at Ser515 by ERK increased the nuclear accumulation and binding of AR to the promoter of Ctnnb1, which encodes the transcription factor beta catenin. In male mouse osteoblasts and human prostate cancer cells, DHT induced the expression of Ctnnb1 and CTNN1B, respectively, as well as beta catenin target genes, stimulating the proliferation, survival, and differentiation of osteoblasts and the proliferation of prostate cancer cells in a PKG2 dependent fashion. Because beta catenin is a master regulator of skeletal homeostasis, these results explain the reported male specific osteoporotic phenotype of mice lacking PKG2 in osteoblasts and imply that PKG2 dependent AR signaling is essential for maintaining bone mass in vivo. Our results suggest that widely used pharmacological PKG activators, such as sildenafil, could be beneficial for male and estrogen deficient female patients with osteoporosis but detrimental in patients with prostate cancer.
C1 [Kalyanaraman, Hema; Casteel, Darren E.; China, Shyamsundar Pal; Zhuang, Shunhui; Boss, Gerry R.; Pilz, Renate B.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego
RP Pilz, RB (通讯作者)，Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
EM rpilz@ucsd.edu
RI ; Pal China, Shyamsundar/AAB 8041 2019
OI Casteel, Darren/0000 0002 7673 6597; Pal China,
   Shyamsundar/0000 0003 0062 3593
FU National Institutes of Health [R01   AR  068601, R01  AG070778, P30 
   NS047101]
FX This work was supported by the National Institutes of Health grants R01
     AR  068601 and R01  AG070778 (to R.B.P.) and P30  NS047101 (UCSD
   Microscopy Shared Facility).
CR Ahluwalia A, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqaa175
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Armen TA, 2000, J CELL BIOCHEM, V79, P620, DOI 10.1002/1097 4644(20001215)79:4<620::AID JCB110>3.0.CO;2 H
   Bakker A, 2003, METH MOLEC MED, V80, P19
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460
   Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44
   Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337
   Cole R, 2021, AM J CLIN EXP UROL, V9, P287
   Davey Rachel A, 2016, Clin Biochem Rev, V37, P3
   Denayer S, 2010, MOL ENDOCRINOL, V24, P898, DOI 10.1210/me.2009 0310
   Estrada M, 2003, ENDOCRINOLOGY, V144, P3586, DOI 10.1210/en.2002 0164
   Farah C, 2018, NAT REV CARDIOL, V15, P292, DOI 10.1038/nrcardio.2017.224
   Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092 8674(01)00472 X
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   GRINO PB, 1990, ENDOCRINOLOGY, V126, P1165, DOI 10.1210/endo 126 2 1165
   Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143
   Hammes SR, 2019, J CLIN INVEST, V129, P1818, DOI 10.1172/JCI125755
   Hukkanen M, 2003, BONE, V32, P142, DOI 10.1016/S8756 3282(02)00955 9
   Jamal SA, 2004, J BONE MINER RES, V19, P1512, DOI 10.1359/JBMR.040716
   Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Joshua J, 2014, ENDOCRINOLOGY, V155, P4720, DOI 10.1210/en.2014 1343
   Kalyanaraman H, 2023, J BONE MINER RES, V38, P171, DOI 10.1002/jbmr.4746
   Kalyanaraman H, 2018, NITRIC OXIDE BIOL CH, V76, P62, DOI 10.1016/j.niox.2018.03.007
   Kalyanaraman H, 2018, DIABETES, V67, P607, DOI 10.2337/db17 0965
   Kalyanaraman H, 2017, J BONE MINER RES, V32, P46, DOI 10.1002/jbmr.2909
   Kalyanaraman H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004911
   Kim SM, 2020, P NATL ACAD SCI USA, V117, P14386, DOI 10.1073/pnas.2000950117
   Koryakina Y, 2014, ENDOCR RELAT CANCER, V21, pT131, DOI 10.1530/ERC 13 0472
   Leung JK, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00002
   Levin ER, 2016, NAT REV MOL CELL BIO, V17, DOI 10.1038/nrm.2016.122
   Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004
   LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092 8674(02)00685 2
   Maatta Jorma A, 2013, Bonekey Rep, V2, P440, DOI 10.1038/bonekey.2013.174
   Marathe N, 2012, J BIOL CHEM, V287, P978, DOI 10.1074/jbc.M111.294959
   Mauvais Jarvis F, 2022, ENDOCR REV, V43, P720, DOI 10.1210/endrev/bnab041
   Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406
   Mödder UI, 2012, J CELL BIOCHEM, V113, P2248, DOI 10.1002/jcb.24095
   Murillo Garzón V, 2017, NAT REV UROL, V14, P683, DOI 10.1038/nrurol.2017.144
   Nakanishi R, 2008, J BONE MINER RES, V23, P271, DOI 10.1359/JBMR.071007
   Notini AJ, 2007, J BONE MINER RES, V22, P347, DOI 10.1359/JBMR.061117
   Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586
   Pal S, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115305
   Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200
   Ponguta LA, 2008, J BIOL CHEM, V283, P20989, DOI 10.1074/jbc.M802392200
   Pouwels S, 2010, J CLIN ENDOCR METAB, V95, P1924, DOI 10.1210/jc.2009 2342
   Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101
   Ramdani G, 2018, J ENDOCRINOL, V238, P203, DOI 10.1530/JOE 18 0286
   Rangaswami H, 2012, J BIOL CHEM, V287, P21509, DOI 10.1074/jbc.M112.347245
   Rangaswami H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001423
   Rangaswami H, 2009, J BIOL CHEM, V284, P14796, DOI 10.1074/jbc.M806486200
   Rejnmark L, 2006, J BONE MINER RES, V21, P1811, DOI 10.1359/JBMR.060804
   Schall N, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135355
   Schweizer L, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 4
   Sen A, 2014, P NATL ACAD SCI USA, V111, P3008, DOI 10.1073/pnas.1318978111
   Sen A, 2012, J CLIN INVEST, V122, P2469, DOI 10.1172/JCI62044
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131
   Song RX, 2004, P NATL ACAD SCI USA, V101, P2076, DOI 10.1073/pnas.0308334100
   Suarez J, 2004, AM J PHYSIOL HEART C, V286, pH68, DOI 10.1152/ajpheart.00245.2003
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Thomas P, 2019, ENDOCRINOLOGY, V160, P772, DOI 10.1210/en.2018 00987
   Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175
   Truica CI, 2000, CANCER RES, V60, P4709
   Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008 5472.CAN 04 1121
   Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025
   Vanderschueren D, 2014, ENDOCR REV, V35, P906, DOI 10.1210/er.2014 1024
   Venken K, 2006, J BONE MINER RES, V21, P576, DOI 10.1359/JBMR.060103
   Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240
   Wimalawansa SJ, 2009, J CLIN ENDOCR METAB, V94, P3356, DOI 10.1210/jc.2008 2225
   Xiong WQ, 2015, REPRODUCTION, V150, P507, DOI 10.1530/REP 15 0371
   Xu WW, 2023, CELL REP, V42, DOI 10.1016/j.celrep.2023.112529
   Yu J, 2010, ENDOCRINOLOGY, V151, P1822, DOI 10.1210/en.2009 1048
   Zhao X, 2005, J BIOL CHEM, V280, P32683, DOI 10.1074/jbc.M505486200
   ZHOU ZX, 1994, J BIOL CHEM, V269, P13115
   Zou ZN, 2022, NUCLEIC ACIDS RES, V50, pW175, DOI 10.1093/nar/gkac199
NR 78
TC 6
Z9 6
U1 1
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945 0877
EI 1937 9145
J9 SCI SIGNAL
JI Sci. Signal.
PD JAN 30
PY 2024
VL 17
IS 821
AR eadi7861
DI 10.1126/scisignal.adi7861
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA LI4A7
UT WOS:001186135700002
PM 38289986
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Kamon, M
   Zhao, R
   Sakamoto, K
AF Kamon, Masayoshi
   Zhao, Ran
   Sakamoto, Kazuichi
TI Green tea polyphenol ( ) epigallocatechin gallate suppressed the
   differentiation of murine osteoblastic MC3T3 E1 cells
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE catechin; osteoblast; polyphenol
ID OSTEOCLAST DIFFERENTIATION; RECEPTOR; OSTEOPROTEGERIN; LIGAND;
   EPIGALLOCATECHIN 3 O GALLATE; ACTIVATION; EXPRESSION; MECHANISM
AB Recently, various physiological effects of the tea polyphenol catechin for alleviating diseases such as cancer, arteriosclerosis, hyperlipidaemia and osteoporosis have been reported. However, the physiological effect of catechin on bone metabolism remains unclear. We examined the physiological effect of EGCG [( ) epigallocatechin 3 gallate], which is the main component of green tea catechin, on osteoblast development using the precursor cell line of osteoblasts, MC3T3 E1, and co culture of the osteoblasts from mouse newborn calvaria and mouse bone marrow cells. Although EGCG did not affect the viability and proliferation of MC3T3 E1 cells, EGCG inhibited the osteoblast differentiation. Furthermore, EGCG did not affect the mineralization of differentiated MC3T3 E1 cells, and reduced osteoclast formation in co culture. These results suggest that EGCG can effectively suppress bone resorption, and can be used as an effective medicine in the treatment of the symptoms of osteoporosis.
C1 [Kamon, Masayoshi; Zhao, Ran; Sakamoto, Kazuichi] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
C3 University of Tsukuba
RP Sakamoto, K (通讯作者)，Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
EM sakamoto@biol.tsukuba.ac.jp
FU Ministry of Education, Science, Sports, and Culture of Japan [20580095];
   Grants in Aid for Scientific Research [20580095] Funding Source: KAKEN
FX This work was supported in part by Grants in Aid for Scientific Research
   from the Ministry of Education, Science, Sports, and Culture of Japan
   [grant number 20580095].
CR Amano H, 1998, J BONE MINER RES, V13, P846, DOI 10.1359/jbmr.1998.13.5.846
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Chang JK, 2006, EUR J PHARMACOL, V551, P1, DOI 10.1016/j.ejphar.2006.08.073
   Chen D, 2008, HISTOL HISTOPATHOL, V23, P487, DOI 10.14670/HH 23.487
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Crespy V, 2004, J NUTR, V134, p3431S, DOI 10.1093/jn/134.12.3431S
   Fujimura Y, 2005, BIOCHEM BIOPH RES CO, V336, P674, DOI 10.1016/j.bbrc.2005.08.146
   Hegarty VM, 2000, AM J CLIN NUTR, V71, P1003
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Jimi E, 1996, ENDOCRINOLOGY, V137, P2187
   Jun JH, 2008, J CELL BIOCHEM, V103, P1246, DOI 10.1002/jcb.21508
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Khan N, 2006, CANCER RES, V66, P2500, DOI 10.1158/0008 5472.CAN 05 3636
   Kodaira K, 2006, BIOCHEM BIOPH RES CO, V345, P1224, DOI 10.1016/j.bbrc.2006.05.045
   Kodama H.A., 1981, J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899
   Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Matsumoto M, 2000, FEBS LETT, V486, P23, DOI 10.1016/S0014 5793(00)02231 6
   McKay DL, 2002, J AM COLL NUTR, V21, P1
   Meiyanto E, 2001, BIOCHEM BIOPH RES CO, V282, P278, DOI 10.1006/bbrc.2001.4564
   Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870
   Nagle DG, 2006, PHYTOCHEMISTRY, V67, P1849, DOI 10.1016/j.phytochem.2006.06.020
   Nakagawa H, 2002, BIOCHEM BIOPH RES CO, V292, P94, DOI 10.1006/bbrc.2002.6622
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   RALPH P, 1977, J IMMUNOL, V119, P950
   Saika M, 2001, ENDOCRINOLOGY, V142, P2205, DOI 10.1210/en.142.6.2205
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Takita H, 2002, CONNECT TISSUE RES, V43, P520, DOI 10.1080/03008200290000772
   Ullmann U, 2003, J INT MED RES, V31, P88, DOI 10.1177/147323000303100205
   Umeda D, 2005, BIOCHEM BIOPH RES CO, V333, P628, DOI 10.1016/j.bbrc.2005.05.108
   Vali B, 2007, J NUTR BIOCHEM, V18, P341, DOI 10.1016/j.jnutbio.2006.06.005
   Wang JP, 2007, J PHARMACOL SCI, V104, P82, DOI 10.1254/jphs.FP0061549
   Yanai H, 2004, STATCEL USEFUL ADD I
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Yun JH, 2007, J PERIODONTAL RES, V42, P212, DOI 10.1111/j.1600 0765.2006.00935.x
NR 38
TC 45
Z9 50
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1065 6995
EI 1095 8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD JAN
PY 2010
VL 34
IS 1
BP 109
EP 116
DI 10.1042/CBI20090011
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 592PK
UT WOS:000277391400016
PM 19947947
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Lobo Martins, S
   Ferreira, AR
   Mansinho, A
   Casimiro, S
   Leitzel, K
   Ali, S
   Lipton, A
   Costa, L
AF Lobo Martins, Soraia
   Ferreira, Arlindo R.
   Mansinho, Andre
   Casimiro, Sandra
   Leitzel, Kim
   Ali, Suhail
   Lipton, Allan
   Costa, Luis
TI Impact of Extraskeletal Metastases on Skeletal Related Events in
   Metastatic Castration Resistant Prostate Cancer with Bone Metastases
SO CANCERS
LA English
DT Article
DE prostate cancer; metastatic castration resistant prostate cancer;
   bone targeted agents; bone metastases; visceral metastases
ID TURNOVER MARKERS; ZOLEDRONIC ACID; BISPHOSPHONATES; DENOSUMAB; THERAPY;
   NETWORK
AB The therapeutic landscape of metastatic castration resistant prostate cancer (mCRPC) has substantially evolved over the last decade. Nonetheless, a better understanding of bone targeted agents (BTAs) action in mCRPC remains an unmet need. Theuse of BTAs aims to reduce the incidence of skeletal related events (SREs) in patients with mCRPC. Less frequent BTA schedules are currently being studied to minimize adverse events. In this study, the impact of metastatic compartment (bone and extraskeletal metastases (BESM) vs. bone only metastases (BOM)) on bone biomarker kinetics, time to first on study SRE, and symptomatic skeletal events (SSEs) is evaluated. This is a retrospective analysis of the prospective, randomized, multicenter clinical trial of denosumab vs. zoledronic acid in patients with mCRPC and bone metastases. A total of 1901 patients were included, 1559 (82.0%) with BOM and 342 with BESM (18.0%). Bone metastases burden was balanced between groups. Baseline levels and normalization rates of corrected urinary N terminal telopeptide and bone alkaline phosphatase did not differ between groups. However, BESM patients had a higher risk of SREs (adjusted HR 1.21; 95% CI 1.01 1.46;p= 0.043) and SSEs (adjusted HR 1.30; 95% CI 1.06 1.61;p= 0.014). This difference was more pronounced in the first 12 months of BTA treatment.In mCRPC, strategies of BTA schedule de escalation may take into account presence of extraskeletal metastases.
C1 [Lobo Martins, Soraia; Mansinho, Andre; Costa, Luis] Hosp Santa Maria, Oncol Div, P 1649035 Lisbon, Portugal.
   [Lobo Martins, Soraia; Ferreira, Arlindo R.; Mansinho, Andre; Casimiro, Sandra; Costa, Luis] Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, P 1649028 Lisbon, Portugal.
   [Ferreira, Arlindo R.] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, P 1400038 Lisbon, Portugal.
   [Leitzel, Kim; Ali, Suhail; Lipton, Allan] Penn State Hlth Milton S Hershey Med Ctr, Div Hematol Oncol, Hershey, PA 17033 USA.
C3 Universidade de Lisboa; Hospital Santa Maria; Universidade de Lisboa;
   Fundacao Champalimaud; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Pennsylvania State University; Penn State Health
RP Costa, L (通讯作者)，Hosp Santa Maria, Oncol Div, P 1649035 Lisbon, Portugal.; Costa, L (通讯作者)，Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, P 1649028 Lisbon, Portugal.
EM soraia.l.martins@chln.min saude.pt;
   arlindo.ferreira@fundacaochampalimaud.pt; andr3.m@gmail.com;
   scasimiro@medicina.ulisboa.pt; kleitzel@pennstatehealth.psu.edu;
   Suhail.Ali@va.gov; alipton@pennstatehealth.psu.edu;
   luis.costa@chln.min saude.pt
RI ; Casimiro, Sandra/J 3332 2013; Ferreira, Arlindo/AAD 6340 2020; Costa,
   Luis/E 5117 2015
OI Ferreira, Arlindo/0000 0002 1567 9322; Casimiro,
   Sandra/0000 0002 6917 4477; Mansinho, Andre/0000 0001 8771 0838; Costa,
   Luis/0000 0002 4782 7318; 
CR Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Casimiro S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091415
   Chu GCY, 2019, ASIAN J UROL, V6, P65, DOI 10.1016/j.ajur.2018.11.003
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman R, 2011, CRIT REV ONCOL HEMAT, V80, P411, DOI 10.1016/j.critrevonc.2011.02.005
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   European Commission, ECIS EUR CANC INF SY
   Ferreira A, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.35
   Ferreira AR, 2016, ONCOLOGIST, V21, P1418, DOI 10.1634/theoncologist.2015 0527
   Fizazi K, 2013, J UROLOGY, V189, pS51, DOI 10.1016/j.juro.2012.11.022
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Ford JA, 2013, EUR J CANCER, V49, P416, DOI 10.1016/j.ejca.2012.07.016
   Gdowski AS, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046 017 0578 1
   Gois B.F.A., 2017, THESIS
   Gomez Rivas J, 2019, MINERVA UROL NEFROL, V71, P445, DOI 10.23736/S0393 2249.19.03420 9
   Goodman OB, 2014, PROSTATE CANCER P D, V17, P34, DOI 10.1038/pcan.2013.41
   Guise TA, 2003, CANCER AM CANCER SOC, V97, P779, DOI 10.1002/cncr.11129
   Halabi S, 2016, J CLIN ONCOL, V34, P1652, DOI 10.1200/JCO.2015.65.7270
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Kosaka T, 2018, MOL CLIN ONCOL, V9, P683, DOI 10.3892/mco.2018.1724
   Lipton A, 2016, CLIN CANCER RES, V22, P5713, DOI 10.1158/1078 0432.CCR 15 3086
   Liu C, 2018, CANCER MANAG RES, V10, P3809, DOI 10.2147/CMAR.S176811
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Shupp AB, 2018, CANCERS, V10, DOI 10.3390/cancers10060182
   Som A, 2012, BRIT J CANCER, V107, P1547, DOI 10.1038/bjc.2012.436
   Tanaka R, 2016, ONCOLOGIST, V21, P508, DOI 10.1634/theoncologist.2015 0377
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
NR 28
TC 6
Z9 6
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD AUG
PY 2020
VL 12
IS 8
AR 2034
DI 10.3390/cancers12082034
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA OC1VD
UT WOS:000578949100001
PM 32722128
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Qiu, H
   Hosking, C
   Rothzerg, E
   Samantha, A
   Chen, K
   Kuek, V
   Jin, HM
   Zhu, SP
   Vrielink, A
   Lim, K
   Foley, M
   Xu, JK
AF Qiu, Heng
   Hosking, Christopher
   Rothzerg, Emel
   Samantha, Ariela
   Chen, Kai
   Kuek, Vincent
   Jin, Haiming
   Zhu, Sipin
   Vrielink, Alice
   Lim, Kevin
   Foley, Michael
   Xu, Jiake
TI ADR3, a next generation i body to human RANKL, inhibits osteoclast
   formation and bone resorption
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NUCLEAR FACTOR; RECEPTOR ACTIVATOR; OSTEOPOROSIS; PEPTIDE;
   DIFFERENTIATION; EXPRESSION; PREVENTION; SERVER; GENE
AB Osteoporosis is a chronic skeletal condition characterized by low bone mass and deteriorated microarchitecture of bone tissue and puts tens of millions of people at high risk of fractures. New therapeutic agents like i bodies, a class of next generation sin gle domain antibodies, are needed to overcome some limitations of conventional treatments. An i body is a human immuno globulin scaffold with two long binding loops that mimic the shape and position of those found in shark antibodies, the var iable new antigen receptors of sharks. Its small size ( 12 kDa) and long binding loops provide access to drug targets, which are considered undruggable by traditional monoclonal antibodies. Here, we have successfully identified a human receptor activator of nuclear factor kappa B ligand (RANKL) i body, ADR3, which demonstrates a high binding affinity to human RANKL (hRANKL) with no adverse effect on the survival or proliferation of bone marrow derived macrophages. Differential scanning fluorimetry suggested that ADR3 is stable and able to tolerate a wide range of physical environments (including both tempera ture and pH). In addition, in vitro studies showed a dose dependent inhibitory effect of ADR3 on osteoclast differentia tion, podosome belt formation, and bone resorption activity. Further investigation on the mechanism of action of ADR3 revealed that it can inhibit hRANKL mediated signaling path ways, supporting the in vitro functional observations. These clues collectively indicate that hRANKL antagonist ADR3 at tenuates osteoclast differentiation and bone resorption, with the potential to serve as a novel therapeutic to protect against bone loss.
C1 [Qiu, Heng; Rothzerg, Emel; Kuek, Vincent; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Hosking, Christopher; Lim, Kevin; Foley, Michael] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Bundoora, Vic, Albania.
   [Hosking, Christopher; Lim, Kevin; Foley, Michael] AdAlta Pty Ltd, Bundoora, Vic, Australia.
   [Samantha, Ariela; Chen, Kai; Vrielink, Alice] Univ Western Australia, Sch Mol Sci, Perth, WA, Australia.
   [Kuek, Vincent] Telethon Kids Inst, Telethon Kids Canc Ctr, Perth, WA, Australia.
   [Jin, Haiming; Zhu, Sipin] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Peoples R China.
   [Jin, Haiming; Zhu, Sipin] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
C3 University of Western Australia; University of Western Australia; The
   Kids Research Institute Australia; University of Western Australia;
   Wenzhou Medical University; Wenzhou Medical University
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
EM jiake.xu@uwa.edu.au
RI Samantha, Ariela/GQA 6466 2022; Vrielink, Alice/D 3652 2013; Chen,
   KaiJie/A 1743 2016; Kuek, Vincent/GMX 4212 2022; Jin,
   Haiming/LZE 3453 2025
OI Xu, Jiake/0000 0003 2021 8309; Vrielink, Alice/0000 0001 8197 3725;
   Chen, Kai/0000 0001 6850 1723; Samantha, Ariela/0000 0002 0959 2458;
   Kuek, Vincent/0000 0003 2225 8566; Qiu, Heng/0000 0002 0864 317X; 
FU Australian National Health and Medical Research Council [APP1107828,
   APP1127156, APP1163933]
FX Acknowledgments   The study was supported by the Australian National
   Health and Medical Research Council (Grant No. APP1107828, APP1127156,
   APP1163933) . The authors would also like to thank Prof Robin Anderson
   and Judy Doherty from the Peter MacCallum Cancer Centre who were
   involved in some initial in vitro experiments on ADR3.
CR Anusaksathien O, 2001, J BIOL CHEM, V276, P22663, DOI 10.1074/jbc.M007104200
   Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513
   Asano T, 2019, NAT METAB, V1, P868, DOI 10.1038/s42255 019 0104 1
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Black DM, 2016, NEW ENGL J MED, V374, P2096, DOI 10.1056/NEJMc1602599
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   David JP, 2001, J CELL PHYSIOL, V188, P89, DOI 10.1002/jcp.1099
   Desta IT, 2020, STRUCTURE, V28, P1071, DOI 10.1016/j.str.2020.06.006
   Diker Cohen T, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz322
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Florczyk Soluch U, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29122 1
   FORBES RM, 1953, J BIOL CHEM, V203, P359
   Furuya Y, 2013, J BIOL CHEM, V288, P5562, DOI 10.1074/jbc.M112.426080
   Griffiths K, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 20811 5
   Griffiths K, 2019, MABS AUSTIN, V11, P1331, DOI 10.1080/19420862.2019.1626652
   Griffiths K, 2016, J BIOL CHEM, V291, P12641, DOI 10.1074/jbc.M116.721050
   Kang JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103646
   Ke K, 2015, MOL CELL ENDOCRINOL, V409, P11, DOI 10.1016/j.mce.2015.03.022
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lacombe J, 2013, CELL CYCLE, V12, P2744, DOI 10.4161/cc.25825
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lo MC, 2004, ANAL BIOCHEM, V332, P153, DOI 10.1016/j.ab.2004.04.031
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   McDonald M.M., 2021, CELL, V184, P13
   Ming J, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01283
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321
   Nuttall Stewart D, 2012, Methods Mol Biol, V911, P27, DOI 10.1007/978 1 61779 968 6_3
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Qin A, 2012, INT J BIOCHEM CELL B, V44, P1422, DOI 10.1016/j.biocel.2012.05.014
   Qiu H, 2021, J CELL PHYSIOL, V236, P2800, DOI 10.1002/jcp.30045
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372
   Sambrook J., 1989, Molecular cloning: a laboratory manual
   Sambrook PN, 2002, MED J AUSTRALIA, V176, pS1
   Steffen U, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01483
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Ta HM, 2010, P NATL ACAD SCI USA, V107, P20281, DOI 10.1073/pnas.1011686107
   Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197 1266
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Taxel P, 2018, J ENDOCR SOC, V2, P574, DOI 10.1210/js.2018 00052
   Tu Kristie N, 2018, P T, V43, P92
   Vajda S, 2017, PROTEINS, V85, P435, DOI 10.1002/prot.25219
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wilkins MR, 1999, METH MOL B, V112, P531
   Wu YL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01802
   Wurch T, 2012, TRENDS BIOTECHNOL, V30, P575, DOI 10.1016/j.tibtech.2012.07.006
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
NR 54
TC 7
Z9 8
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB
PY 2023
VL 299
IS 2
AR 102889
DI 10.1016/j.jbc.2023.102889
EA FEB 2023
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA J1AC1
UT WOS:001006991000001
PM 36634847
OA Green Published
DA 2025 08 17
ER

PT J
AU Gomes, PS
   Resende, M
   Fernandes, MH
AF Gomes, Pedro Sousa
   Resende, Marta
   Fernandes, Maria Helena
TI Doxycycline restores the impaired osteogenic commitment of
   diabetic derived bone marrow mesenchymal stromal cells by increasing the
   canonical WNT signaling
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Diabetes; Osteopenia; Osteogenesis; Tetracyclines; Wnt pathway
ID MINERAL DENSITY; IN VITRO; FORMATION MARKERS; FRACTURE RISK; TYPE 1;
   MELLITUS; RATS; TETRACYCLINES; MINOCYCLINE; MECHANISMS
AB Diabetes mellitus comprehends a group of chronic metabolic disorders, associated with damage and dysfunction of distinct tissues, including bone. At the cellular level, an impaired osteoblastogenesis has been reported, affecting the viability, proliferation and functionality of osteoblasts and precursor populations, hampering the bone metabolic activity, remodeling and healing. Tetracyclines embrace a group of broad spectrum antibacterial compounds with potential anabolic effects on the bone tissue, through antibacterial independent mechanisms. Accordingly, this study aims to address the modulatory capability and associated molecular signaling of a low dosage doxycycline   a semi synthetic tetracycline, in the functional activity of osteoblastic progenitor cells (bone marrow derived mesenchymal stromal cells), established from a translational diabetic experimental model.
   Bone marrow derived mesenchymal stromal cells were isolated from streptozotocin induced diabetic Wistar rat with proven osteopenia. Cultures were characterized, in the presence of doxycycline (1 mu g ml( 1)) for proliferation, metabolic activity, apoptosis, collagen synthesis and relevant gene expression with the osteogenic and adipogenic program. The activation of the Wnt/beta catenin pathway was further detailed.
   Doxycycline normalized the viability, proliferation and metabolic activity of the established cultures, further decreasing cell apoptosis, to levels similar to control. The addition of this drug to the culture environment further increased the osteogenic activation, upregulating the expression of osteogenic markers and collagen synthesis, at the same time that a decreased adipogenic priming was attained. These processes were found to me mediated, at least in part, by the restoration of the signaling through the Wnt/beta catenin pathway.
C1 [Gomes, Pedro Sousa; Fernandes, Maria Helena] Univ Porto, Fac Dent Med, BoneLab Lab Bone Metab & Regenerat, R Dr Manuel Pereira da Silva, P 4200393 Porto, Portugal.
   [Gomes, Pedro Sousa; Fernandes, Maria Helena] Univ Porto, LAQV REQUIMTE, P 4160007 Porto, Portugal.
   [Resende, Marta] Univ Porto, Fac Dent Med, R Dr Manuel Pereira da Silva, P 4200393 Porto, Portugal.
C3 Universidade do Porto; Universidade do Porto; Universidade do Porto
RP Gomes, PS (通讯作者)，Univ Porto, Pedro de Sousa Gomes BoneLab, Lab Bone Metab & Regenerat, Fac Dent Med, R Dr Manuel Pereira da Silva, P 4200393 Porto, Portugal.
EM pgomes@fmd.up.pt
RI Fernandes, Maria/K 6917 2014; Fernandes, Maria Helena/K 6917 2014;
   Gomes, Pedro/K 2433 2014; Resende, Marta/AGU 8489 2022
OI Fernandes, Maria Helena/0000 0001 9391 9574; Gomes,
   Pedro/0000 0001 5365 2123; Resende, Marta/0000 0002 1263 0507
FU FCT/MCTES [UIDB/50006/2020]; Faculty of Dental Medicine, U. Porto
FX The work was supported by UIDB/50006/2020 with funding from FCT/MCTES
   through national funds, and by the Faculty of Dental Medicine, U. Porto.
CR Abdallah BM, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929 017 0321 4
   Aggarwal HK, 2010, RENAL FAILURE, V32, P941, DOI 10.3109/0886022X.2010.502606
   Al Qarakhli AMA, 2019, BMC MOL CELL BIOL, V20, DOI 10.1186/s12860 019 0235 y
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Bortolin RH, 2017, BASIC CLIN PHARMACOL, V120, P227, DOI 10.1111/bcpt.12672
   Cao DD, 2019, STEM CELLS DEV, V28, P833, DOI 10.1089/scd.2018.0209
   Cervino G, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5907195
   Chen SX, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0186 y
   Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232 260.2001
   de Figueiredo FAT, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 51702 y
   Durao SF, 2014, OSTEOPOROSIS INT, V25, P1535, DOI 10.1007/s00198 014 2656 y
   Fowlkes JL, 2008, ENDOCRINOLOGY, V149, P1697, DOI 10.1210/en.2007 1408
   Garrido Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139
   Gilowski L, 2012, ORAL DIS, V18, P763, DOI 10.1111/j.1601 0825.2012.01943.x
   Golub LM, 2010, J DENT RES, V89, P644, DOI 10.1177/0022034510363367
   GOLUB LM, 1990, RES COMMUN CHEM PATH, V68, P27
   Golub LM, 2016, INT DENT J, V66, P127, DOI 10.1111/idj.12221
   Gomes KD, 2017, INT J ORAL SCI, V9, P158, DOI 10.1038/ijos.2017.28
   Gomes P., 1997, Arch Oral Biol, V52, P251
   Gomes PS, 2008, ACTA BIOMATER, V4, P630, DOI 10.1016/j.actbio.2007.12.006
   Gomes PS, 2011, LAB ANIM UK, V45, P14, DOI 10.1258/la.2010.010085
   Gomes PS, 2007, ARCH ORAL BIOL, V52, P251, DOI 10.1016/j.archoralbio.2006.10.005
   Griffin MO, 2011, PHARMACOL RES, V63, P102, DOI 10.1016/j.phrs.2010.10.004
   Gunczler P, 2001, J PEDIATR ENDOCR MET, V14, P525
   Gustafson B, 2012, DIABETES, V61, P1217, DOI 10.2337/db11 1419
   Herford AS, 2013, J CRANIOFAC SURG, V24, P1383, DOI 10.1097/SCS.0b013e318292c2ce
   Hie M, 2011, INT J MOL MED, V28, P455, DOI 10.3892/ijmm.2011.697
   Huang Y, 2018, LIFE SCI, V209, P249, DOI 10.1016/j.lfs.2018.08.019
   Kalaitzoglou E, 2016, CURR OSTEOPOROS REP, V14, P310, DOI 10.1007/s11914 016 0329 9
   Kallala R, 2012, EXPERT OPIN DRUG SAF, V11, P15, DOI 10.1517/14740338.2012.643867
   Keenan HA, 2016, CURR OSTEOPOROS REP, V14, P351, DOI 10.1007/s11914 016 0338 8
   King AJF, 2012, BRIT J PHARMACOL, V166, P877, DOI 10.1111/j.1476 5381.2012.01911.x
   Kinugawa S, 2012, J IMMUNOL, V188, P1772, DOI 10.4049/jimmunol.1101174
   Kubota T, 2009, J BONE MINER METAB, V27, P265, DOI 10.1007/s00774 009 0064 8
   Lee JH, 2010, J PHARM PHARMACOL, V62, P1, DOI [10.1211/jpp/62.01.0001, 10.1211/jpp.62.01.0001]
   Lenzen S, 2008, DIABETOLOGIA, V51, P216, DOI 10.1007/s00125 007 0886 7
   Lenzen S., 2020, ANIMAL MODELS DIABET, P69
   López Herradón A, 2013, J CELL BIOCHEM, V114, P1908, DOI 10.1002/jcb.24535
   Lu DS, 2010, EUR J PHARMACOL, V636, P198, DOI 10.1016/j.ejphar.2010.03.010
   Lu HF, 2003, ENDOCRINOLOGY, V144, P346, DOI 10.1210/en.2002 220072
   Martin V, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118821
   Massé PG, 2010, J AM COLL NUTR, V29, P419, DOI 10.1080/07315724.2010.10719859
   McCabe LR, 2011, CRIT REV EUKAR GENE, V21, P187, DOI 10.1615/CritRevEukarGeneExpr.v21.i2.70
   Miao JM, 2005, DIABETES CARE, V28, P2850, DOI 10.2337/diacare.28.12.2850
   Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Nusse R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011163
   Nyman Jeffry S, 2017, Bone Rep, V7, P1, DOI 10.1016/j.bonr.2017.07.001
   Pan H, 2014, DIABETES METAB RES, V30, P531, DOI 10.1002/dmrr.2508
   Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013
   Payne JB, 2011, PHARMACOL RES, V63, P121, DOI 10.1016/j.phrs.2010.10.006
   Peng J, 2016, CONNECT TISSUE RES, V57, P277, DOI 10.3109/03008207.2016.1171858
   Piccinin MA, 2014, ADIPOCYTE, V3, P263, DOI 10.4161/adip.32215
   Rehman K, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929 016 0303 y
   SASAKI T, 1992, CALCIFIED TISSUE INT, V50, P411, DOI 10.1007/BF00296771
   Scott IU, 2014, JAMA OPHTHALMOL, V132, P535, DOI 10.1001/jamaophthalmol.2014.93
   Shen HH, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929 019 0556 3
   Silva J., 2014, DIABETES UNPUB
   Silva JC, 2015, J CELL BIOCHEM, V116, P1658, DOI 10.1002/jcb.25126
   Silva MJ, 2009, J BONE MINER RES, V24, P1618, DOI [10.1359/JBMR.090316, 10.1359/jbmr.090316]
   Silva T, 2018, J BIOMATER APPL, V33, P380, DOI 10.1177/0885328218795290
   Silva T, 2017, BIOMED MATER, V12, DOI 10.1088/1748 605X/aa68b8
   Starup linde J., 2013, Front. En, V4, P1
   Sundararaghavan V, 2017, THER ADV MUSCULOSKEL, V9, P67, DOI 10.1177/1759720X16687480
   Syngle A, 2014, NEUROL SCI, V35, P1067, DOI 10.1007/s10072 014 1647 2
   Tsentidis C, 2017, OSTEOPOROSIS INT, V28, P945, DOI 10.1007/s00198 016 3802 5
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Vestergaard P, 2009, CALCIFIED TISSUE INT, V84, P45, DOI 10.1007/s00223 008 9195 5
   Walter MS, 2014, DENT MATER, V30, P200, DOI 10.1016/j.dental.2013.11.006
   Wei Michael, 2003, Heart Lung Circ, V12, P44, DOI 10.1046/j.1444 2892.2003.00160.x
   Weinberg E, 2014, DIABETES RES CLIN PR, V103, P35, DOI 10.1016/j.diabres.2013.11.015
   Weinberg E, 2014, J MOL ENDOCRINOL, V52, P67, DOI 10.1530/JME 13 0229
   Zhao YF, 2013, INT J MOL MED, V31, P614, DOI 10.3892/ijmm.2013.1227
   Zhou XX, 2010, CALCIFIED TISSUE INT, V86, P163, DOI 10.1007/s00223 009 9328 5
NR 76
TC 8
Z9 10
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
EI 1872 8057
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD DEC 1
PY 2020
VL 518
AR 110975
DI 10.1016/j.mce.2020.110975
PG 10
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA OK0ZN
UT WOS:000584381600027
PM 32758627
DA 2025 08 17
ER

PT J
AU Wang, N
   Wang, F
   Gao, YS
   Yin, PP
   Pan, CH
   Liu, W
   Zhou, ZB
   Wang, JX
AF Wang, Nan
   Wang, Feng
   Gao, Youshui
   Yin, Peipei
   Pan, Chenhao
   Liu, Wei
   Zhou, Zubin
   Wang, Jiaxiang
TI Curcumin protects human adipose derived mesenchymal stem cells against
   oxidative stress induced inhibition of osteogenesis
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Curcumin; Mesenchymal stem cell; Oxidative stress; Osteoblast
   differentiation; Wnt
ID HYDROGEN PEROXIDE; OSTEOCLAST FORMATION; BONE LOSS; DIFFERENTIATION;
   INFLAMMATION; DISEASES; CATENIN; PROLIFERATION; THERAPEUTICS; ACTIVATION
AB The detrimental effects of oxidative stress on the skeletal system have been documented, and understanding the mechanisms is important to design a therapeutic strategy. As an antioxidant and anti inflammatory agent, the active ingredient of turmeric curcumin has been used as medication for numerous complications including bone loss. However, it is unclear if curcumin could influence the osteogenic potential of mesenchymal stem cells (MSCs), particularly in oxidative injuries. Here we demonstrate that curcumin treatment protects cell death caused by hydrogen peroxide (H2O2) exposure in human adipose derived MSCs in vitro. Importantly, curcumin is able to enhance the osteoblast differentiation of human adipose derived MSCs that is inhibited by H2O2. Notably, both oxidative stress and the inhibition of Wnt/beta catenin signaling are attenuated by curcumin treatment. These results suggest that curcumin can promote osteoblast differentiation of MSCs and protect the inhibitory effect elicited by oxidative injury. The findings support potential use of curcumin or related antioxidants in MSC based bone regeneration for disease related with oxidative stress induced bone loss. (C) 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Wang, Nan] Zhengzhou Univ, Affiliated Hosp 1, Dept Emergency, Zhengzhou, Henan, Peoples R China.
   [Wang, Jiaxiang] Zhengzhou Univ, Affiliated Hosp 1, Dept Pediat Surg, 1 East Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Wang, Feng; Gao, Youshui; Yin, Peipei; Pan, Chenhao; Liu, Wei; Zhou, Zubin] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthopaed Surg, Shanghai, Peoples R China.
C3 Zhengzhou University; Zhengzhou University; Shanghai Jiao Tong
   University
RP Wang, JX (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Pediat Surg, 1 East Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
EM jiaxiangwg@sina.com
RI Wang, Jia Xiang/KHV 3596 2024; GAO, YOUSHUI/U 8349 2019; Wang,
   Fu/F 1529 2017
FU National Natural Science Foundation of China [81603471, 81472110];
   Shanghai Municipal Natural Science Foundation [14ZR1431800]; Shanghai's
   Development Acceleration in Traditional Chinese Medicine
   [ZY3 CCCX 3 3044]; Seed Foundation for Shanghai University of Medicine &
   Health Sciences [HMSF 16 21 017]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81603471, 81472110), Shanghai Municipal Natural Science
   Foundation (No. 14ZR1431800), Three year Action Plan (2014 2016) of
   Shanghai's Development Acceleration in Traditional Chinese Medicine (No.
   ZY3 CCCX 3 3044), Seed Foundation for Shanghai University of Medicine &
   Health Sciences (HMSF 16 21 017).
CR Ahn J, 2010, AM J PHYSIOL CELL PH, V298, pC1510, DOI 10.1152/ajpcell.00369.2009
   Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Augello A, 2007, ARTHRITIS RHEUM US, V56, P1175, DOI 10.1002/art.22511
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006
   Chanda D, 2010, J CELL BIOCHEM, V111, P249, DOI 10.1002/jcb.22701
   Chen FH, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2514
   Folwarczna J, 2010, PHARMACOL REP, V62, P900, DOI 10.1016/S1734 1140(10)70350 9
   Fu YM, 2008, MOL PHARMACOL, V73, P399, DOI 10.1124/mol.107.039818
   Gu QL, 2012, PHARMACOGN MAG, V8, P202, DOI 10.4103/0973 1296.99285
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064 006 9128 5
   Kim SJ, 2008, J BIOL CHEM, V283, P14497, DOI 10.1074/jbc.M708373200
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743 7075 4 8
   Le Blanc K, 2005, TRANSPLANTATION, V79, P1607, DOI 10.1097/01.TP.0000159029.48678.93
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004 1021
   Li YY, 2014, CANCER LETT, V346, P197, DOI 10.1016/j.canlet.2014.01.012
   Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21 21 08370.2001
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Malladi P, 2006, AM J PHYSIOL CELL PH, V290, pC1139, DOI 10.1152/ajpcell.00415.2005
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Mujoo K, 2012, PROTEIN CELL, V3, P535, DOI 10.1007/s13238 012 2053 2
   Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94
   Notoya M, 2006, EUR J PHARMACOL, V534, P55, DOI 10.1016/j.ejphar.2006.01.028
   Orozco L, 2013, TRANSPLANTATION, V95, P1535, DOI 10.1097/TP.0b013e318291a2da
   Prasad S, 2014, BIOTECHNOL ADV, V32, P1053, DOI 10.1016/j.biotechadv.2014.04.004
   Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Ren GW, 2012, STEM CELL TRANSL MED, V1, P51, DOI 10.5966/sctm.2011 0019
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910
   Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004
   Yagi H, 2013, J CELL BIOCHEM, V114, P1163, DOI 10.1002/jcb.24459
NR 38
TC 62
Z9 68
U1 1
U2 37
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD NOV
PY 2016
VL 132
IS 3
BP 192
EP 200
DI 10.1016/j.jphs.2016.10.005
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ED1UE
UT WOS:000388629600004
PM 27840063
OA gold
DA 2025 08 17
ER

PT J
AU Venugopal, M
   Nambiar, J
   Nair, BG
AF Venugopal, Meera
   Nambiar, Jyotsna
   Nair, Bipin G.
TI Anacardic acid mediated regulation of osteoblast differentiation
   involves mitigation of inflammasome activation pathways
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Osteoblast; Anacardic acid; Differentiation; Inflammasome; Osteomyelitis
ID NF KAPPA B; GENE EXPRESSION; BONE; LPS; LIPOPOLYSACCHARIDE;
   OSTEOPOROSIS; CROSSTALK; ESTROGEN; INSIGHTS; SUBUNIT
AB Disruption of the finely tuned osteoblast osteoclast balance is the underlying basis of several inflammatory bone diseases, such as osteomyelitis, osteoporosis, and septic arthritis. Prolonged and unrestrained exposure to inflammatory environment results in reduction of bone mineral density by downregulating osteoblast differentiation. Earlier studies from our laboratory have identified that Anacardic acid (AA), a constituent of Cashew nut shell liquid that is used widely in traditional medicine, has potential inhibitory effect on gelatinases (MMP2 and MMP9) which are over expressed in numerous inflammatory conditions (Omanakuttan et al. in Mol Pharmacol, 2012 and Nambiar et al. in Exp Cell Res, 2016). The study demonstrated for the first time that AA promotes osteoblast differentiation in lipopolysaccharide treated osteosarcoma cells (MG63) by upregulating specific markers, like osteocalcin, receptor activator of NF kappa B ligand, and alkaline phosphatase. Furthermore, expression of the negative regulators, such as nuclear factor kappa B, matrix metalloproteinases (MMPs), namely MMP13, and MMP1, along with several inflammatory markers, such as Interleukin 1 beta and Nod like receptor protein 3 were downregulated by AA. Taken together, AA expounds as a novel template for development of potential pharmacological therapeutics for inflammatory bone diseases.
C1 [Venugopal, Meera; Nambiar, Jyotsna; Nair, Bipin G.] Amrita Vishwa Vidyapeetham, Amrita Sch Biotechnol, Clappana PO, Kollam 690525, Kerala, India.
C3 Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Amritapuri
RP Nair, BG (通讯作者)，Amrita Vishwa Vidyapeetham, Amrita Sch Biotechnol, Clappana PO, Kollam 690525, Kerala, India.
EM bipinnair03@gmail.com
RI Nambiar, Jyotsna/KHU 3957 2024
OI Nambiar, Jyotsna/0000 0003 1607 7806
FU CSIR [09/942(0019)/2018 EMR 1]; Bristol Myers Squib (BMS); Amrita Vishwa
   Vidyapeetham
FX This work was supported by CSIR [Grant No. 09/942(0019)/2018 EMR 1];
   Bristol Myers Squib (BMS) and Amrita Vishwa Vidyapeetham.
CR Abbasi N, 2016, IRAN J MED SCI, V41, P118
   Allam E, 2013, OSTEOBLASTS MORPHOLO
   Alonso Pérez A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00504
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Bandow K, 2010, BIOCHEM BIOPH RES CO, V402, P755, DOI 10.1016/j.bbrc.2010.10.103
   Belibasakis GN, 2012, CYTOKINE, V59, P124, DOI 10.1016/j.cyto.2012.03.016
   Dapunt U, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1091 y
   Elefteriou F, 2006, CELL METAB, V4, P441, DOI 10.1016/j.cmet.2006.10.010
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gao AQ, 2013, PEERJ, V1, DOI 10.7717/peerj.51
   GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727
   Gong YN, 2010, CELL RES, V20, P1289, DOI 10.1038/cr.2010.135
   Guo C, 2014, INFLAMMATION, V37, P621, DOI 10.1007/s10753 013 9778 9
   Hengartner NE, 2013, MOL MED, V19, P36, DOI 10.2119/molmed.2012.00058
   Huang RL, 2014, STEM CELLS DEV, V23, P277, DOI 10.1089/scd.2013.0345
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Kany S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236008
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574
   Kubo I, 2003, J AGR FOOD CHEM, V51, P7624, DOI 10.1021/jf034674f
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Li JJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/319651
   Liu JZ, 2009, J BIOL CHEM, V284, P12512, DOI 10.1074/jbc.M809789200
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Lu DG, 2016, EXP CELL RES, V341, P54, DOI 10.1016/j.yexcr.2016.01.009
   Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Nambiar J, 2016, EXP CELL RES, V349, P139, DOI 10.1016/j.yexcr.2016.10.007
   Omanakuttan A, 2012, MOL PHARMACOL, V82, P614, DOI 10.1124/mol.112.079020
   Page McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Qu L, 2017, J ORAL MICROBIOL, V9, DOI 10.1080/20002297.2017.1317578
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Sung B, 2008, BLOOD, V111, P4880, DOI 10.1182/blood 2007 10 117994
   Suvarna V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00981
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Walsh NC, 2009, J BONE MINER RES, V24, P1572, DOI [10.1359/JBMR.090320, 10.1359/jbmr.090320]
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Wojdasiewicz P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/561459
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
   Xiao M, 2009, EXP HEMATOL, V37, P52, DOI 10.1016/j.exphem.2008.09.001
   Zhao PY, 2014, ACTA HISTOCHEM, V116, P1119, DOI 10.1016/j.acthis.2014.05.008
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 45
TC 3
Z9 6
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD FEB
PY 2021
VL 476
IS 2
BP 819
EP 829
DI 10.1007/s11010 020 03947 9
EA OCT 2020
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA QF6AI
UT WOS:000581555500001
PM 33090336
DA 2025 08 17
ER

PT J
AU Bakhshandeh, B
   Soleimani, M
   Hafizi, M
   Paylakhi, SH
   Ghaemi, N
AF Bakhshandeh, Behnaz
   Soleimani, Masoud
   Hafizi, Maryam
   Paylakhi, Seyed Hassan
   Ghaemi, Nasser
TI MicroRNA signature associated with osteogenic lineage commitment
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Osteogenesis; Signaling pathway; Stem cell; Differentiation; MicroRNA
   profiling
ID MESENCHYMAL STEM CELLS; HUMAN ADIPOSE TISSUE; OSTEOBLAST
   DIFFERENTIATION; TRANSCRIPTION FACTOR; PROTEIN EXPRESSION; TARGET
   PREDICTION; GENE EXPRESSION; STROMAL CELLS; BONE MARROW; CORD BLOOD
AB Cell based approaches offer a potential therapeutic strategy for appropriate bone manufacturing. Capable of differentiating into multiple cell types especially osteoblasts spontaneously, unrestricted somatic stem cell (USSC) seems to be a suitable candidate. Recent studies have shown the involvement of microRNAs in several biological processes. miRNA microarray profiling was applied in order to identify the osteo specific miRNA signature. Prior to this analysis, osteogenic commitment of osteoblasts was evaluated by measuring ALPase activity, biomineralization, specific staining and evaluation of some main osteogenic marker genes. To support our findings, various in silico explorations (for both putative targets and signaling pathways) and empirical analyses (miRNA transfections followed by qPCR of osteogenic indicators and ALPase activity measurement) were carried out. The function of GSK 3b inhibitor was also studied to investigate the role of WNT in osteogenesis. Transient modulation of multiple osteo miRs (such as mir 199b, 1274a, 30b) with common targets (such as BMPR, TCFs, SMADs) as mediators of osteogenic pathways including cell cell interactions, WNT and TGF beta pathways, suggests a mechanism for rapid induction of the osteogenesis as an anti miRNA therapy. The results of this research have identified the miRNA signature which regulates the osteogenesis mechanism in USSC. To conclude, our study reveals more details about the allocation of USSCs into osteogenic lineage through modulatory effect of miRNAs on targets and pathways required for creating a tissue specific phenotype and may aid in future clinical interventions.
C1 [Soleimani, Masoud] Tarbiat Modares Univ, Dept Hematol, Fac Med Sci, Tehran, Iran.
   [Bakhshandeh, Behnaz] Univ Tehran, Dept Biotechnol, Coll Sci, Tehran, Iran.
   [Bakhshandeh, Behnaz; Hafizi, Maryam] Stem Cell Technol Res Ctr, Stem Cell Biol Dept, Tehran, Iran.
   [Paylakhi, Seyed Hassan] Damghan Univ, Sch Biol, Damghan, Iran.
   [Ghaemi, Nasser] Univ Tehran, Sch Chem, Coll Sci, Tehran, Iran.
C3 Tarbiat Modares University; University of Tehran; Damghan University;
   University of Tehran
RP Soleimani, M (通讯作者)，Tarbiat Modares Univ, Dept Hematol, Fac Med Sci, Tehran, Iran.
EM soleim_m@modares.ac.ir
RI ; Bakhshandeh, Behnaz/AAF 6693 2021
OI Bakhshandeh, Behnaz/0000 0003 1252 6088; 
FU Stem Cell Biology Department Stem Cell Technology Research Center
FX This work was supported financially by Stem Cell Biology Department Stem
   Cell Technology Research Center. We appreciate Mr. Seyed Zarvan Shahrzad
   for his contribution in English editing.
CR Arnsdorf EJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005388
   Bakhshandeh B, 2011, ACTA PHARMACOL SIN, V32, P626, DOI 10.1038/aps.2011.8
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Bentwich I, 2005, FEBS LETT, V579, P5904, DOI 10.1016/j.febslet.2005.09.040
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Caldas J, 2011, J COMPUT BIOL, V18, P251, DOI 10.1089/cmb.2010.0256
   Chai C, 2007, MOL THER, V15, P467, DOI 10.1038/sj.mt.6300084
   Cho JH, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755 8794 4 8
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Davison TS, 2006, METHOD ENZYMOL, V411, P14, DOI 10.1016/S0076 6879(06)11002 2
   de Gorter DJJ, 2011, J BONE MINER RES, V26, P1178, DOI 10.1002/jbmr.313
   Gao J, 2011, J CELL BIOCHEM, V112, P1844, DOI 10.1002/jcb.23106
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 10 r80
   Guilherme RS, 2010, AM J MED GENET A, V152A, P2865, DOI 10.1002/ajmg.a.33689
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   He J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013558
   Hu R, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176099
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674
   Itoh T, 2010, J BIOL CHEM, V285, P27745, DOI 10.1074/jbc.M110.105080
   Itoh T, 2009, J BIOL CHEM, V284, P19272, DOI 10.1074/jbc.M109.014001
   Kii I, 2004, J BONE MINER RES, V19, P1840, DOI 10.1359/JBMR.040812
   Kim S, 2010, TOHOKU J EXP MED, V221, P141, DOI 10.1620/tjem.221.141
   Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003
   Kim YJ, 2009, J BONE MINER RES, V24, P816, DOI 10.1359/JBMR.081230
   Kögler G, 2004, J EXP MED, V200, P123, DOI 10.1084/jem.20040440
   Kotzot D, 2004, ANN GENET PARIS, V47, P251, DOI 10.1016/j.anngen.2004.03.006
   Krause U, 2010, P NATL ACAD SCI USA, V107, P4147, DOI 10.1073/pnas.0914360107
   Lai KW, 2010, EUR J CANCER, V46, P1456, DOI 10.1016/j.ejca.2010.01.036
   Lössner C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022146
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Malm D, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750 1172 3 21
   Matsumoto T, 2010, J CELL PHYSIOL, V225, P291, DOI 10.1002/jcp.22223
   Meyers VE, 2004, J CELL BIOCHEM, V93, P697, DOI 10.1002/jcb.20229
   Miraoui H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3146re9
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011
   Palmieri A, 2008, BIO MED MATER ENG, V18, P91, DOI 10.3233/BME 2008 0512
   Palmieri A, 2007, J BIOMED SCI, V14, P777, DOI 10.1007/s11373 007 9193 z
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ren JQ, 2009, J TRANSL MED, V7, DOI 10.1186/1479 5876 7 20
   Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104
   Schaap Oziemlak AM, 2010, STEM CELLS DEV, V19, P877, DOI 10.1089/scd.2009.0112
   Schoolmeesters A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005605
   Sheyn D, 2010, TISSUE ENG PT A, V16, P3403, DOI 10.1089/ten.tea.2009.0834
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207
   TABAS JA, 1993, CLIN ORTHOP RELAT R, P310
   Wang XW, 2006, NUCLEIC ACIDS RES, V34, P1646, DOI 10.1093/nar/gkl068
   Wiemer EAC, 2007, EUR J CANCER, V43, P1529, DOI 10.1016/j.ejca.2007.04.002
   Witkos TM, 2011, CURR MOL MED, V11, P93
   Wu X, 2009, BIOINFORMATICS, V25, P832, DOI 10.1093/bioinformatics/btp059
   Yadav VK, 2010, CALCIFIED TISSUE INT, V86, P382, DOI 10.1007/s00223 010 9350 7
   Yamada M, 2006, J BIOL CHEM, V281, P20749, DOI 10.1074/jbc.M602089200
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zhao Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI 10.1016/j.tibs.2007.02.006
   Zhou SH, 2011, J CELL BIOCHEM, V112, P1651, DOI 10.1002/jcb.23079
NR 60
TC 41
Z9 48
U1 0
U2 20
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 4851
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUL
PY 2012
VL 39
IS 7
BP 7569
EP 7581
DI 10.1007/s11033 012 1591 2
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 947CP
UT WOS:000304404600039
PM 22350160
DA 2025 08 17
ER

PT J
AU Picke, AK
   Campbell, GM
   Schmidt, FN
   Busse, B
   Rauner, M
   Simon, JC
   Anderegg, U
   Hofbauer, LC
   Saalbach, A
AF Picke, Ann Kristin
   Campbell, Graeme M.
   Schmidt, Felix N.
   Busse, Bjoern
   Rauner, Martina
   Simon, Jan C.
   Anderegg, Ulf
   Hofbauer, Lorenz C.
   Saalbach, Anja
TI Thy 1 Deficiency Augments Bone Loss in Obesity by Affecting Bone
   Formation and Resorption
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE obesity; Thy 1; bone mass; osteoblast; osteoclast; adipocytes;
   differentiation; TNF alpha
ID TNF ALPHA; OSTEOBLAST DIFFERENTIATION; OSTEOCLASTOGENESIS; MASS; CD90;
   OSTEOPOROSIS; INHIBITION; EXPRESSION; RECEPTOR; CELLS
AB Healthy bone remodeling results from a balanced bone formation and bone resorption realized by bone forming osteoblasts and bone resorbing osteoclasts, respectively. Recently, Thy 1 (CD90) was identified as positive regulator of osteoblast differentiation and activation, thus, promoting bone formation while concurrently inhibiting adipogenesis and obesity in mice. Additionally, Thy 1 did not affect bone resorption. An obesity related co morbidity that is increasing in prevalence is a disturbed bone formation resulting in an increased fracture risk. The underlying mechanisms of obesity induced bone alterations are not yet fully elucidated and therefore therapy options for efficient bone anabolic treatments are limited. Therefore, we investigated the impact of Thy 1 on bone metabolism under obese conditions. Indeed, high fat diet (HFD) induced obese mice lacking Thy 1 (Thy 1( / )) showed increased body fat mass compared to wildtype (WT) mice while bone mass ( 38%) and formation ( 57%) were decreased as shown by micro computed tomography (mu CT) measurement, histological analysis, and fourier transform infrared spectroscopy (FTIR). Interestingly, under obese conditions, lack of Thy 1 affected both osteoblast and osteoclast function. Number ( 30%) and activity of osteoblasts were decreased in obese Thy 1( / ) mice while osteoclast number (+39%) and activity were increased. Facilitated bone marrow fat accumulation (+56%) in obese Thy 1( / ) mice compared to obese WT mice was associated with upregulated tumor necrosis factor alpha (Tnf alpha, +46%) and colony stimulating factor 1 receptor (Csf1r) expression, strong promoters of osteoclast differentiation. Moreover, lack of Thy 1 was accompanied by a reduction of osteoprotegerin (Tnfrsf11b) expression ( 36%), an inhibitor of osteoclast differentiation. Altered Tnf alpha, Csf1r; and Tnfrsf11b expression might be responsible for elevated osteoclast activity in obese Thy 1 deficient mice. In summary, our findings show that lack of Thy 1 promotes obesity under HFD conditions while concurrently decreasing bone mass and formation. Mechanistic studies revealed that under obese conditions lack of Thy 1 impairs both bone formation and bone resorption.
C1 [Picke, Ann Kristin; Rauner, Martina; Hofbauer, Lorenz C.] Tech Univ Dresden, Ctr Hlth Aging, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Dresden, Germany.
   [Picke, Ann Kristin] Ulm Univ, Inst Comparat Mol Endocrinol, Ulm, Germany.
   [Campbell, Graeme M.] TUHH Hamburg Univ Technol, Inst Biomech, Hamburg, Germany.
   [Schmidt, Felix N.; Busse, Bjoern] Univ Med Ctr, Dept Osteol & Biomech, Hamburg, Germany.
   [Simon, Jan C.; Anderegg, Ulf; Saalbach, Anja] Univ Leipzig, Med Fac, Dept Dermatol Venerol & Allergol, Leipzig, Germany.
C3 Technische Universitat Dresden; Ulm University; Hamburg University of
   Technology; University of Hamburg; University Medical Center
   Hamburg Eppendorf; Leipzig University
RP Picke, AK (通讯作者)，Tech Univ Dresden, Ctr Hlth Aging, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Dresden, Germany.; Picke, AK (通讯作者)，Ulm Univ, Inst Comparat Mol Endocrinol, Ulm, Germany.; Saalbach, A (通讯作者)，Univ Leipzig, Med Fac, Dept Dermatol Venerol & Allergol, Leipzig, Germany.
EM ann kristin.picke@uni ulm.de; anja.saalbach@medizin.uni leipzig.de
RI Rauner, Martina/A 1665 2015; Hofbauer, Lorenz C./G 2490 2010; Hofbauer,
   Lorenz/G 2490 2010; Busse, Björn/AAC 4033 2020; Campbell,
   Graeme/JPX 2238 2023; Saalbach, Anja/ABD 4003 2021
OI Busse, Bjorn/0000 0002 3099 8073; Rauner, Martina/0000 0002 4067 6799;
   Hofbauer, Lorenz C./0000 0002 8691 8423; von Brackel,
   Felix/0000 0001 6586 6794; 
FU Deutsche Forschungsgemeinschaft [SA863/2 3, SFB Transregio 67,
   BU2562/3 1]; MeDDrive grant of the medical faculty of the TU Dresden;
   Bausteinforderung of the medical faculty of the Ulm University; Joachim
   Herz Stiftung; PIER Helmholtz Graduate School, University of Hamburg;
   DESY Hamburg
FX This research study was supported by the Deutsche Forschungsgemeinschaft
   (to AS: SA863/2 3, to UA: SFB Transregio 67, project B4, to LH: SFB
   Transregio 67, project B2, to BB: BU2562/3 1). A KP was supported by
   MeDDrive grant of the medical faculty of the TU Dresden and by
   Bausteinforderung of the medical faculty of the Ulm University. FS
   acknowledges the Joachim Herz Stiftung for a Ph.D. Scholarship in
   cooperation with the PIER Helmholtz Graduate School, University of
   Hamburg and DESY Hamburg.
CR Abuna RPF, 2016, J CELL PHYSIOL, V231, P204, DOI 10.1002/jcp.25073
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Boskey A, 2007, BIOMATERIALS, V28, P2465, DOI 10.1016/j.biomaterials.2006.11.043
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Cao JJ, 2011, J ORTHOP SURG RES, V6, DOI 10.1186/1749 799X 6 30
   Cao JJ, 2010, ANN NY ACAD SCI, V1192, P292, DOI 10.1111/j.1749 6632.2009.05252.x
   Cao JJ, 2009, BONE, V44, P1097, DOI 10.1016/j.bone.2009.02.017
   Chung MT, 2013, TISSUE ENG PT A, V19, P989, DOI [10.1089/ten.tea.2012.0370, 10.1089/ten.TEA.2012.0370]
   Cobayashi Fernanda, 2005, J. Pediatr. (Rio J.), V81, P337, DOI 10.2223/JPED.1372
   CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gilbert LC, 2005, AM J PHYSIOL ENDOC M, V288, pE1011, DOI 10.1152/ajpendo.00534.2004
   Greco EA, 2015, THER ADV ENDOCRINOL, V6, P273, DOI 10.1177/2042018815611004
   Halade GV, 2011, EXP GERONTOL, V46, P43, DOI 10.1016/j.exger.2010.09.014
   Hardcastle SA, 2015, BONE, V71, P171, DOI 10.1016/j.bone.2014.10.015
   Hardouin P, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00085
   Hosoya A, 2012, HISTOCHEM CELL BIOL, V137, P733, DOI 10.1007/s00418 012 0928 1
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Hsu YH, 2006, AM J CLIN NUTR, V83, P146
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Jiang YB, 1997, J BONE MINER RES, V12, P820, DOI 10.1359/jbmr.1997.12.5.820
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Kitaura H, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/181849
   Kling JM, 2014, J WOMENS HEALTH, V23, P563, DOI 10.1089/jwh.2013.4611
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Moraes DA, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0359 3
   Nielson CM, 2012, J BONE MINER RES, V27, P1, DOI 10.1002/jbmr.1486
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Paine A, 2018, FASEB J, V32, P3174, DOI 10.1096/fj.201701379R
   Palermo A, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13060544
   Pan JX, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0018 7
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Patsch JM, 2011, METABOLISM, V60, P243, DOI 10.1016/j.metabol.2009.11.023
   Picke AK, 2016, BONE, V82, P108, DOI 10.1016/j.bone.2015.06.001
   Picke AK, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao6806
   Picke AK, 2018, BONE, V116, P120, DOI 10.1016/j.bone.2018.07.015
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Schmidt M, 2015, J INVEST DERMATOL, V135, P1893, DOI 10.1038/jid.2015.86
   Sharma Sudhaa, 2014, J Midlife Health, V5, P6, DOI 10.4103/0976 7800.127782
   Shu L, 2015, CALCIFIED TISSUE INT, V96, P313, DOI 10.1007/s00223 015 9954 z
   Siggelkow H, 2003, J BONE MINER RES, V18, P529, DOI 10.1359/jbmr.2003.18.3.529
   Smit TH, 2002, EUR SPINE J, V11, P137, DOI 10.1007/s005860100346
   Thurner PJ, 2009, WIRES NANOMED NANOBI, V1, P624, DOI 10.1002/wnan.56
   Tu Kristie N, 2018, P T, V43, P92
   VITETTA ES, 1973, EUR J IMMUNOL, V3, P446, DOI 10.1002/eji.1830030714
   Wetzel A, 2004, J IMMUNOL, V172, P3850, DOI 10.4049/jimmunol.172.6.3850
   Woeller CF, 2015, FASEB J, V29, P920, DOI 10.1096/fj.14 257121
   Wu LC, 2017, J CELL BIOCHEM, V118, P1308, DOI 10.1002/jcb.25672
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhao L, 2011, STEM CELLS, V29, P1601, DOI 10.1002/stem.703
   Zhao LJ, 2007, J CLIN ENDOCR METAB, V92, P1640, DOI 10.1210/jc.2006 0572
   Zheng LW, 2017, J INVEST MED, V65, P1014, DOI 10.1136/jim 2017 000426
NR 57
TC 15
Z9 16
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD OCT 2
PY 2018
VL 6
AR 127
DI 10.3389/fcell.2018.00127
PG 13
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA HG9RD
UT WOS:000455345400001
PM 30333974
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, QS
   Li, C
   Xi, S
   Li, XJ
   Ding, LN
   Li, MH
AF Li, Qiushi
   Li, Chen
   Xi, Si
   Li, Xianjing
   Ding, Lina
   Li, Meihua
TI The effects of photobiomodulation therapy on mouse pre osteoblast cell
   line MC3T3 E1 proliferation and apoptosis via miR 503/Wnt3a pathway
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE PBMT; miR 503; Wnt3a; Signaling pathway; Proliferation
ID LEVEL LASER IRRADIATION; OSTEOGENIC DIFFERENTIATION; IMPLANT
   OSSEOINTEGRATION; PAIN RELIEF; BONE; EXPRESSION; PROMOTES; MICRORNAS;
   MODEL; MUCOSITIS
AB Photobiomodulation therapy (PBMT) has been demonstrated as regulating osteoblast proliferation. MicroRNAs (miRNAs) are involved in various pathophysiologic processes in osteoblast, but the role of miRNAs in the PBMT based promotion of osteoblast proliferation remains unclear. This study aimed to investigate the effects of PBMT treatment (3.75J/cm(2)) on mouse pre osteoblast cell line MC3T3 E1 proliferation and apoptosis via the miR 503/Wnt3a pathway; meanwhile, detect the expressions of miR 503 and Wnt3a after PBMT treatment and the role of miR 503 in regulating Wnt signaling molecules Wnt3a,  catenin, Runx2, apoptotic proteins caspase 3, and Bcl 2 in vitro. The PBMT parameters were as follows: 808nm continuous wavelength, 0.401W output power, 0.042W/cm(2) power density, 9.6cm(2) spot size, 36J energy, 3.75J/cm(2) energy density, 90s irradiation for three times per 12h, 14.5cm distance of the laser source and the angle of divergence of the laser beam was 7 degrees. In our present study, the target relationship was predicted and verified by bioinformatics analysis and luciferase reporter assays. Gene mRNA and protein expressions were examined by qPCR and western blot analysis. The MTT method was used to evaluate the effect of miR 503 on MC3T3 E1 cells proliferation. And cell apoptosis was examined by flow cytometry. The results showed that PBMT treatment reduced the expression of miR 503 and increased the level of Wnt3a (p<0.01). Bioinformatics analysis and luciferase reporter assays revealed that Wnt3a was a target of miR 503, and Wnt3a was regulated by miR 503. Furthermore, miR 503 was found to functionally inhibit proliferation and promote apoptosis (p<0.01). And during this process, Wnt3a,  catenin, Runx2, and Bcl 2 expressions were significantly inhibited (p<0.01); however, caspase 3 level was upregulated (p<0.01). These results suggest that miR 503 plays a role in osteoblast proliferation and apoptosis in response to PBMT, which is potentially amenable to therapeutic manipulation for clinical application.
C1 [Li, Qiushi; Ding, Lina] Jilin Univ, Sch & Hosp Stomatol, VIP Integrated Dept, Changchun, Jilin, Peoples R China.
   [Li, Chen] Jilin Univ, Sch & Hosp Stomatol, Dept Oral Med, Changchun, Jilin, Peoples R China.
   [Xi, Si] Hainan Med Univ, Affiliated Hosp, Dept Stomatol, Haikou, Hainan, Peoples R China.
   [Li, Xianjing] Jilin Univ, Sch & Hosp Stomatol, Dept Prosthodont, Changchun, Jilin, Peoples R China.
   [Li, Meihua] Jilin Univ, Hosp 2, Dept Stomatol, 218 Ziqiang St, Changchun 130021, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Hainan Medical University; Jilin
   University; Jilin University
RP Li, MH (通讯作者)，Jilin Univ, Hosp 2, Dept Stomatol, 218 Ziqiang St, Changchun 130021, Jilin, Peoples R China.
EM meihl_699@163.com
CR Aleksic V, 2010, LASER MED SCI, V25, P559, DOI 10.1007/s10103 010 0761 5
   Aliasl J, 2015, J COSMET LASER THER, V17, P41, DOI 10.3109/14764172.2014.968583
   [Anonymous], 2008, PLOS ONE, DOI DOI 10.1371/JOURNAL.PONE.0002557
   Arfat Y, 2015, CURR MED CHEM, V22, P748, DOI 10.2174/0929867321999141106121227
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Chen C, 2014, J BONE MINER RES, V29, P338, DOI 10.1002/jbmr.2032
   Chaves MED, 2014, AN BRAS DERMATOL, V89, P616, DOI 10.1590/abd1806 4841.20142519
   DiVito Enrico E, 2014, Compend Contin Educ Dent, V35, P734
   Feng J, 2015, INT J BIOCHEM CELL B, V66, P59, DOI 10.1016/j.biocel.2015.07.002
   Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105
   Hirata S, 2010, J CELL BIOCHEM, V111, P1445, DOI 10.1002/jcb.22872
   Hwang K, 2005, J CRANIOFAC SURG, V16, P1102, DOI 10.1097/01.scs.0000179740.60671.e5
   Imai H, 1994, No To Shinkei, V46, P397
   Jing D, 2016, SCI REP UK, V6, DOI 10.1038/srep32045
   Jullien N, 2012, J CELL BIOCHEM, V113, P2047, DOI 10.1002/jcb.24076
   Kang Yunlong, 2014, Int J Orthod Milwaukee, V25, P47
   Karlekar A, 2015, ANN CARD ANAESTH, V18, P317, DOI 10.4103/0971 9784.159800
   Karner CM, 2016, J BIOL CHEM, V291, P13028, DOI 10.1074/jbc.M115.708578
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Khori V, 2016, LASER MED SCI, V31, P1775, DOI 10.1007/s10103 016 2049 x
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Li J, 2017, J DENT RES, V96, P822, DOI 10.1177/0022034517700131
   Li LH, 2014, J PATHOL, V234, P488, DOI 10.1002/path.4407
   Li QS, 2017, LASER MED SCI, V32, P1489, DOI 10.1007/s10103 017 2269 8
   Li WH, 2018, LASER SURG MED, V50, P158, DOI 10.1002/lsm.22747
   Li X, 2005, CELL, V123, P1267, DOI 10.1016/j.cell.2005.10.040
   Liu L, 2017, CELL BIOL INT, V41, P112, DOI 10.1002/cbin.10704
   Long JT, 2015, TUMOR BIOL, V36, P8697, DOI 10.1007/s13277 015 3623 8
   Mouraret S, 2014, J CLIN PERIODONTOL, V41, P172, DOI 10.1111/jcpe.12187
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Pagin MT, 2014, LASER MED SCI, V29, P55, DOI 10.1007/s10103 012 1238 5
   Papaioannou G, 2014, CELL MOL LIFE SCI, V71, P4747, DOI 10.1007/s00018 014 1700 6
   Peplow PV, 2011, PHOTOMED LASER SURG, V29, P285, DOI 10.1089/pho.2010.2846
   Pi CX, 2015, FRONT BIOSCI LANDMRK, V20, P119, DOI 10.2741/4301
   Prasad RS, 2013, OR SURG OR MED OR PA, V116, P189, DOI 10.1016/j.oooo.2013.02.011
   Saito Akiyoshi, 2012, Masui, V61, P706
   Schindl A, 2000, J INVEST MED, V48, P312
   Schubert MM, 2007, SUPPORT CARE CANCER, V15, P1145, DOI 10.1007/s00520 007 0238 7
   Shin HR, 2016, J BIOL CHEM, V291, P5555, DOI 10.1074/jbc.M115.698563
   Thompson BJ, 2006, CELL, V126, P767, DOI 10.1016/j.cell.2006.07.013
   Usumez A, 2014, LASER MED SCI, V29, P1807, DOI 10.1007/s10103 013 1336 z
   Wang J, 2012, STEM CELLS DEV, V21, P2508, DOI 10.1089/scd.2011.0695
   Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599
   Wu JJ, 2016, EXP THER MED, V11, P917, DOI 10.3892/etm.2016.2971
   Zhou BS, 2013, CANCER LETT, V333, P159, DOI 10.1016/j.canlet.2013.01.028
   Zhou YH, 2016, J CELL MOL MED, V20, P495, DOI 10.1111/jcmm.12754
NR 49
TC 17
Z9 17
U1 0
U2 26
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD APR
PY 2019
VL 34
IS 3
BP 607
EP 614
DI 10.1007/s10103 018 2636 0
PG 8
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA HP0QU
UT WOS:000461371500020
PM 30218348
DA 2025 08 17
ER

PT J
AU Tran, VNT
   Chaisuparat, R
AF Ngoc Thuy Tran, Vy
   Chaisuparat, Risa
TI Medication related osteonecrosis of the jaw: Osteoclast profile in
   comparison with osteoradionecrosis of the jaw and osteomyelitis of the
   jaw
SO JOURNAL OF ORAL PATHOLOGY & MEDICINE
LA English
DT Article
DE immunohistochemistry; medication related osteonecrosis of the jaw;
   osteoclast
ID BONE RESORPTION; BISPHOSPHONATE; ACTIVATION; APOPTOSIS
AB Background Medication related osteonecrosis of the jaw (MRONJ) is a pathology condition of jaw bone caused by a side effect of medications prescribed for skeletal disease. The mechanism of MRONJ is still unknown now. Osteoclasts are cells directly influenced by the medication and the modification in cells metabolisms by the drugs lead to MRONJ. Thus, this study aimed to investigate the osteoclasts morphology, quantity, and comparing with other necrotic diseases.
   Methods Thirty eight (38) subjects, including cases with MRONJ (n = 11), osteoradionecrosis of the jaw (n = 9), osteomyelitis of the jaw (n = 9), and normal jaw bone (n = 9), were studied. Hematoxylin and eosin stained slides of these diagnosed cases were used to evaluate osteoclasts' characteristics. Immunohistochemistry of TRAP was performed to observed the function of osteoclasts. These characteristics of osteoclasts were also evaluated in the relationship with the histological features using regression analysis.
   Results The results showed that osteoclasts in MRONJ enhance activity by increasing the size and the quantity (p < 0.05). The presence of osteoblasts, inflammatory cells, and bacterial colonies showed a strong correlation with the change in morphology and the number of osteoclasts (p < 0.05). However, the TRAP positive mean number and the TRAP intensity of osteoclasts in MRONJ did not show a significant difference with those in other groups (p > 0.05).
   Conclusion In conclusion, osteoclasts in MRONJ increase the number and become bigger with multi nuclei which might relate to the presence of osteoblasts, inflammation, and microorganisms. This finding supports the idea osteoclasts might be the main key to investigate MRONJ.
C1 [Ngoc Thuy Tran, Vy] Chulalongkorn Univ, Fac Dent, Grad Program Oral Biol, Bangkok, Thailand.
   [Chaisuparat, Risa] Chulalongkorn Univ, Fac Dent, Dept Oral Pathol, Bangkok, Thailand.
C3 Chulalongkorn University; Chulalongkorn University
RP Chaisuparat, R (通讯作者)，Chulalongkorn Univ, Fac Dent, Dept Oral Pathol, Bangkok, Thailand.
EM Risa.C@chula.ac.th
OI Chaisuparat, Risa/0000 0001 6416 773X; Tran, Vy/0000 0002 5356 6185
FU IADR grant (Regional developemental grant for IADR Southeast asia
   division)
FX This research has been supported by IADR grant (Regional developemental
   grant for IADR Southeast asia division). Our thanks goes to Mr. Somchai
   Yodsanga who kindly supported in data collection and laboratory work.
CR Altundal H, 2004, INT J ORAL MAX SURG, V33, P286, DOI 10.1006/ijom.2002.0472
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bedogni A, 2008, ORAL SURG ORAL MED O, V105, P358, DOI 10.1016/j.tripleo.2007.08.040
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   BURSTONE MS, 1959, J HISTOCHEM CYTOCHEM, V7, P39, DOI 10.1177/7.1.39
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Gross C, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1230 8
   Katsarelis H, 2015, J DENT RES, V94, P534, DOI 10.1177/0022034515572021
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Kim HJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061467
   Mac Way F, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472 6890 14 31
   Maruotti N, 2012, EUR J CLIN PHARMACOL, V68, P1013, DOI 10.1007/s00228 012 1216 7
   Marx RE, 2012, INT J ORAL MAX SURG, V41, P283, DOI 10.1016/j.ijom.2011.12.016
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Morita M, 2017, SCI REP UK, V7, DOI 10.1038/srep46322
   Nishida E, 2001, J PERIODONTAL RES, V36, P1, DOI 10.1034/j.1600 0765.2001.00637.x
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Tai TW, 2014, BONE, V67, P166, DOI 10.1016/j.bone.2014.07.003
   Vermeer JAF, 2013, BONE, V57, P242, DOI 10.1016/j.bone.2013.08.007
   Walter C, 2014, CLIN ORAL INVEST, V18, P2221, DOI 10.1007/s00784 014 1205 6
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Yuan A, 2020, OR SURG OR MED OR PA, V129, P133, DOI 10.1016/j.oooo.2019.08.018
NR 27
TC 2
Z9 2
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0904 2512
EI 1600 0714
J9 J ORAL PATHOL MED
JI J. Oral Pathol. Med.
PD AUG
PY 2021
VL 50
IS 7
BP 731
EP 740
DI 10.1111/jop.13202
EA JUN 2021
PG 10
WC Dentistry, Oral Surgery & Medicine; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Pathology
GA UB5TV
UT WOS:000661670200001
PM 34038006
DA 2025 08 17
ER

PT J
AU Wu, LL
   Luo, ZH
   Liu, YT
   Jia, L
   Jiang, YY
   Du, J
   Guo, LJ
   Bai, YX
   Liu, Y
AF Wu, Lili
   Luo, Zhenhua
   Liu, Yitong
   Jia, Lu
   Jiang, Yiyang
   Du, Juan
   Guo, Lijia
   Bai, Yuxing
   Liu, Yi
TI Aspirin inhibits RANKL induced osteoclast differentiation in dendritic
   cells by suppressing NF κB and NFATc1 activation
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Aspirin; Dendritic cells; Osteoclasts; Receptor activator for nuclear
   factor kappa B ligand (RANKL)
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BONE MINERAL DENSITY;
   TRANSDIFFERENTIATION; INDOMETHACIN; PREVENTION; INGROWTH; REPAIR;
   AGENTS; ACID
AB Background: Aspirin has been demonstrated to promote osteoblast mediated bone formation and inhibit osteoclast (OC) mediated bone resorption. However, it remains unclear whether aspirin influences other immune cells during bone resorption. Dendritic cells (DCs), the most potent antigen presenting cells, can also transdifferentiate into active OCs in the presence of receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage colony stimulating factor (M CSF). The effects of aspirin on DC derived OCs (DDOCs) were investigated in the current study.
   Methods: Flow cytometry and mixed lymphocyte reaction (MLR) assays were used for DC identification. The proliferative capacity of DCs was determined by BrdU assays. Apoptosis was examined by flow cytometry. The osteoclastic potential of DCs was tested using tartrate resistant acid phosphatase (TRAP) staining, western blotting, and reverse transcription polymerase chain reaction (RT PCR). Western blotting was also used to examine signaling pathways. A mandibular bone defect model was established to assess the effect of aspirin on bone resorption.
   Results: Aspirin had no influence on the surface phenotype, proliferation, or apoptosis of DCs, though aspirin significantly inhibited osteoclast differentiation in RANKL stimulated DCs. DC osteoclast differentiation was modulated by aspirin via the nuclear factor kappa B (NF kappa B)/nuclear factor of activated T cell, cytoplasmic 1 (NFATc1) signaling pathway. Aspirin treatment also had favorable therapeutic effects on bone regeneration in the bone defect model, and the number of osteoclasts was decreased.
   Conclusions: Aspirin inhibited RANKL induced OC differentiation in DCs via the NF kappa B pathway, downregulating expression of NFATc1. Aspirin treatment promoted bone regeneration by inhibiting DDOC activation in the early stages of inflammation in a rat mandibular bone defect model.
C1 [Wu, Lili; Luo, Zhenhua; Liu, Yitong; Jia, Lu; Jiang, Yiyang; Du, Juan; Liu, Yi] Capital Med Univ, Sch Stomatol, Lab Tissue Regenerat & Immunol, Tian Tan Xi Li 4, Beijing 100050, Peoples R China.
   [Wu, Lili; Luo, Zhenhua; Liu, Yitong; Jia, Lu; Jiang, Yiyang; Du, Juan; Liu, Yi] Capital Med Univ, Sch Stomatol, Dept Periodont, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Tian Tan Xi Li 4, Beijing 100050, Peoples R China.
   [Guo, Lijia; Bai, Yuxing] Capital Med Univ, Sch Stomatol, Dept Orthodont, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University
RP Liu, Y (通讯作者)，Capital Med Univ, Sch Stomatol, Lab Tissue Regenerat & Immunol, Tian Tan Xi Li 4, Beijing 100050, Peoples R China.; Liu, Y (通讯作者)，Capital Med Univ, Sch Stomatol, Dept Periodont, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Tian Tan Xi Li 4, Beijing 100050, Peoples R China.
EM lililiuyi@163.com
RI ; Du, Juan/AAQ 5466 2020; Jia, Lu/HDM 6234 2022; Wu, lili/GQH 6998 2022
OI Jia, Lu/0000 0003 1046 8689; 
FU National Nature Science Foundation of China [81470751, 81800968,
   81600891]; Beijing Municipal Administration of Hospitals Clinical
   Medicine Development of Special Funding Support [ZYLX201703]; Beijing
   Baiqianwan Talents Project [2017A17]; Beijing Municipal Education
   Commission and Science Technology [KM201910025008]
FX This work was supported by grants from the National Nature Science
   Foundation of China 81470751 to Y. L (supporting the research), 81800968
   to ZH. L (supporting experiments process), and 81600891 to L. G
   (supporting the manuscript preparation), the Beijing Municipal
   Administration of Hospitals Clinical Medicine Development of Special
   Funding Support (ZYLX201703 to Y. B, supporting data analysis), the
   Beijing Baiqianwan Talents Project (2017A17 to Y. L, supporting
   interpretation of data), Beijing Municipal Education Commission and
   Science Technology Project of the (KM201910025008 to ZH. L, supporting
   the design of the study).
CR Ahern E, 2018, NAT REV CLIN ONCOL, V15, P676, DOI 10.1038/s41571 018 0095 y
   ALLEN HL, 1980, ACTA ORTHOP SCAND, V51, P595, DOI 10.3109/17453678008990848
   Alnaeeli M, 2007, J BONE MINER RES, V22, P775, DOI 10.1359/JBMR.070314
   Alnaeeli M, 2006, J IMMUNOL, V177, P3314, DOI 10.4049/jimmunol.177.5.3314
   BARATIERI A, 1979, J ORAL PATHOL MED, V8, P198, DOI 10.1111/j.1600 0714.1979.tb01886.x
   Bauer DC, 1996, J BONE MINER RES, V11, P29
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623 200401000 00017
   Cao Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0200 4
   Carbone LD, 2003, J BONE MINER RES, V18, P1795, DOI 10.1359/jbmr.2003.18.10.1795
   CARROLL PB, 1972, ORAL SURG ORAL MED O, V33, P728, DOI 10.1016/0030 4220(72)90440 9
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chen C, 2014, EMBO MOL MED, V6, P322, DOI 10.1002/emmm.201303000
   de la Rica L, 2015, GENOME BIOL, V16, DOI 10.1186/s13059 014 0561 5
   Gallois A, 2010, J BONE MINER RES, V25, P661, DOI 10.1359/jbmr.090829
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Guida L, 2008, INT J IMMUNOPATH PH, V21, P921, DOI 10.1177/039463200802100416
   Kobayashi Y, 2005, J BIOL CHEM, V280, P11395, DOI 10.1074/jbc.M411189200
   Kristensen DM, 2016, NAT REV ENDOCRINOL, V12, P381, DOI 10.1038/nrendo.2016.55
   Lack WD, 2013, J BONE JOINT SURG AM, V95A, P488, DOI 10.2106/JBJS.L.00462
   Lapérine O, 2016, DRUG DISCOV TODAY, V21, P1345, DOI 10.1016/j.drudis.2016.04.022
   Long J, 2002, J BONE JOINT SURG AM, V84A, P1763, DOI 10.2106/00004623 200210000 00004
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Lussana F, 2014, THROMB RES, V134, P599, DOI 10.1016/j.thromres.2014.06.027
   Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544
   Mizuno H, 1990, Meikai Daigaku Shigaku Zasshi, V19, P234
   Mullis BH, 2006, INJURY, V37, P827, DOI 10.1016/j.injury.2005.12.018
   NORRDIN RW, 1990, PROSTAG LEUKOTR ESS, V41, P139, DOI 10.1016/0952 3278(90)90081 U
   Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood 2004 01 0041
   Shi Songtao, 2008, Fut Rheumatol, V3, P499
   Shinohara Masahiro, 2007, Curr Osteoporos Rep, V5, P67
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Speziani C, 2007, EUR J IMMUNOL, V37, P747, DOI 10.1002/eji.200636534
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Take I, 2005, ENDOCRINOLOGY, V146, P5204, DOI 10.1210/en.2005 0451
   Tan EM, 2017, J BONE MINER RES, V32, P846, DOI 10.1002/jbmr.3031
   TRANCIK T, 1989, CLIN ORTHOP RELAT R, P113
   Tucci M, 2013, BRIT J HAEMATOL, V161, P821, DOI 10.1111/bjh.12333
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Yamaza T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002615
   Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948
   Zeng YP, 2016, MOL MED REP, V14, P1957, DOI 10.3892/mmr.2016.5456
   Zhang Y, 2017, J BONE MINER RES, V32, P1829, DOI 10.1002/jbmr.3172
NR 44
TC 69
Z9 80
U1 3
U2 24
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD DEC 5
PY 2019
VL 10
IS 1
AR 375
DI 10.1186/s13287 019 1500 x
PG 11
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA KC6NZ
UT WOS:000507293200001
PM 31805984
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kwan, KKL
   Wong, TY
   Yu, AXD
   Dong, TTX
   Lam, HHL
   Tsim, KWK
AF Kwan, Kenneth K. L.
   Wong, Tin Yan
   Yu, Anna X. D.
   Dong, Tina T. X.
   Lam, Henry H. L.
   Tsim, Karl W. K.
TI The Osteogenic Function of Danggui Buxue Tang, a Herbal Decoction
   Containing Astragali Radix and Angelicae Sinensis Radix, Is Optimized by
   Boiling the Two Herbs Together: Signaling Analyses Revealed by Systems
   Biology
SO PROCESSES
LA English
DT Article
DE mesenchymal stem cells; multi omics; bone differentiation; boiling
   process; mass spectrometry
ID CHINESE; CELLS; EXPRESSION; BONE; ERYTHROPOIETIN; METABOLISM; CALYCOSIN
AB The therapeutic efficacy of a herbal mixture, being multi target, multi function and multi pathway, is the niche of traditional Chinese medicine (TCM). Systems biology can dissect the network of signaling mechanisms in a complex biological system. In preparing TCM decoctions, the boiling of herbs together in water is a common practice; however, the rationale of this specific preparation has not been fully revealed. An approach of mass spectrometry based multi omics was employed to examine the profiles of the cellular pathways, so as to understand the pharmacological efficacy of Danggui Buxue Tang (DBT), a Chinese herbal mixture containing Astragali Radix and Angelicae Sinensis Radix, in cultured rat osteoblasts and mesenchymal stem cells. The results, generated from omics analyses, were compared from DBT treated osteoblasts to those of treating the herbal extract by simple mixing of extracts from Astragali Radix and Angelicae Sinensis Radix, i.e., herbal mixture without boiling together. The signaling pathways responsible for energy metabolism and amino acid metabolism showed distinct activation, as triggered by DBT, in contrast to simple mixing of two herbal extracts. The result supports that boiling the herbs together is designed to maximize the osteoblastic function of DBT, such as in energy and lipid metabolism. This harmony of TCM formulation, by having interactive functions of two herbs during preparation, is being illustrated. The systems biology approach provides new and essential insights into the synergy of herbal preparation. Well defined multiple targets and multiple pathways in different levels of omics are the key to modernizing TCM.
C1 [Kwan, Kenneth K. L.; Yu, Anna X. D.; Dong, Tina T. X.; Tsim, Karl W. K.] Shenzhen Res Inst, Shenzhen Key Lab Edible & Med Bioresources, Hitech Pk, Shenzhen 518000, Peoples R China.
   [Kwan, Kenneth K. L.; Yu, Anna X. D.; Dong, Tina T. X.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Div Life Sci, Clear Water Bay, Hong Kong, Peoples R China.
   [Kwan, Kenneth K. L.; Yu, Anna X. D.; Dong, Tina T. X.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Ctr Chinese Med, Clear Water Bay, Hong Kong, Peoples R China.
   [Wong, Tin Yan; Lam, Henry H. L.] Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Clear Water Bay, Hong Kong, Peoples R China.
C3 Hong Kong University of Science & Technology; Hong Kong University of
   Science & Technology; Hong Kong University of Science & Technology
RP Tsim, KWK (通讯作者)，Shenzhen Res Inst, Shenzhen Key Lab Edible & Med Bioresources, Hitech Pk, Shenzhen 518000, Peoples R China.; Tsim, KWK (通讯作者)，Hong Kong Univ Sci & Technol, Div Life Sci, Clear Water Bay, Hong Kong, Peoples R China.; Tsim, KWK (通讯作者)，Hong Kong Univ Sci & Technol, Ctr Chinese Med, Clear Water Bay, Hong Kong, Peoples R China.
EM klkwan@connect.ust.hk; tywongam@connect.ust.hk; xyuay@connect.ust.hk;
   botina@ust.hk; kehlam@ust.hk; botsim@ust.hk
RI ; YU, Xiaodan/MYQ 5304 2025; Lam, Henry/D 8629 2011
OI Wong, Tin Yan/0000 0002 1651 9275; Lam, Henry/0000 0001 7928 0364
FU Special Project of Foshan University of Science and Technology
   [FSUST19 SRI10]; Key Area Research and Development Program of Guangdong
   Province [2020B1111110006]; Shenzhen Science and Technology Innovation
   Committee [ZDSYS201707281432317, JCYJ201704131737 47440, JCYJ2018030
   6174903174]; Zhongshan Municipal Bureau of Science and Technology
   [ZSST20SC03]; Guangzhou Science and Technology Committee Research Grant
   [GZSTI16SC02, GZSTI17SC02]; Hong Kong RGC Theme Based Research Scheme
   [T13 605/18 W]; Hong Kong Innovation Technology Fund [UIM/340, UIM/385,
   ITS/500/18FP, TCPD/17 9];  [TUYF19SC02];  [PD18SC01];  [HMRF18SC06]; 
   [HMRF20SC07];  [AFD20SC01]
FX This work is supported by the Special Project of Foshan University of
   Science and Technology in 2019 (FSUST19 SRI10); The Key Area Research
   and Development Program of Guangdong Province (2020B1111110006);
   Shenzhen Science and Technology Innovation Committee
   (ZDSYS201707281432317; JCYJ201704131737 47440; JCYJ2018030 6174903174),
   Zhongshan Municipal Bureau of Science and Technology (ZSST20SC03);
   Guangzhou Science and Technology Committee Research Grant (GZSTI16SC02;
   GZSTI17SC02); Hong Kong RGC Theme Based Research Scheme (T13 605/18 W);
   Hong Kong Innovation Technology Fund (UIM/340, UIM/385, ITS/500/18FP;
   TCPD/17 9); TUYF19SC02, PD18SC01 and HMRF18SC06; HMRF20SC07; and
   AFD20SC01. This work is supported by the Special Project of Foshan
   University of Science and Technology in 2019 (FSUST19 SRI10); The
   Key Area Research and Development Program of Guangdong Province
   (2020B1111110006); Shenzhen Science and Technology Innovation Committee
   (ZDSYS201707281432317; JCYJ201704131737 47440; JCYJ2018030 6174903174),
   Zhongshan Municipal Bureau of Science and Technology (ZSST20SC03);
   Guangzhou Science and Technology Committee Research Grant (GZSTI16SC02;
   GZSTI17SC02); Hong Kong RGC Theme Based Research Scheme (T13 605/18 W);
   Hong Kong Innovation Technology Fund (UIM/340, UIM/385, ITS/500/18FP;
   TCPD/17 9); TUYF19SC02, PD18SC01 and HMRF18SC06; HMRF20SC07; and
   AFD20SC01.
CR Bieberich E, 2018, CHEM PHYS LIPIDS, V216, P114, DOI 10.1016/j.chemphyslip.2018.08.003
   Chan PH, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/567893
   Chang WCW, 2020, PHARM BIOL, V58, P545, DOI 10.1080/13880209.2020.1774622
   Choi RCY, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Dong TTX, 2006, J AGR FOOD CHEM, V54, P2767, DOI 10.1021/jf053163l
   Duarte TM, 2014, BIOTECHNOL BIOENG, V111, P2095, DOI 10.1002/bit.25266
   Elliott J T, 2004, IEE Proc Nanobiotechnol, V151, P75, DOI 10.1049/ip nbt:20040640
   Esen E, 2015, J BONE MINER RES, V30, P2137, DOI 10.1002/jbmr.2714
   Fang YY, 2019, CELL BIOL INT, V43, P323, DOI 10.1002/cbin.11102
   Frey JL, 2018, ENDOCRINOLOGY, V159, P272, DOI 10.1210/en.2017 00850
   Gao QT, 2008, PLANTA MED, V74, P392, DOI 10.1055/s 2008 1034322
   Gautam AK, 2011, J NUTR BIOCHEM, V22, P318, DOI 10.1016/j.jnutbio.2010.02.010
   Gong AGW, 2016, J ETHNOPHARMACOL, V189, P81, DOI 10.1016/j.jep.2016.05.035
   Gong AGW, 2016, PLANTA MED, V82, P418, DOI 10.1055/s 0035 1558332
   Hu K, 2016, BONE, V91, P30, DOI 10.1016/j.bone.2016.06.013
   Huck K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020385
   Jun Dae Won, 2012, Korean J Hepatol, V18, P22, DOI 10.3350/kjhep.2012.18.1.22
   Kwan KKL, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00614
   LANGELAND N, 1975, ACTA ENDOCRINOL COP, V80, P775, DOI 10.1530/acta.0.0800775
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lin HQ, 2017, J ETHNOPHARMACOL, V199, P205, DOI 10.1016/j.jep.2017.01.044
   Meier U, 2004, CLIN CHEM, V50, P1511, DOI 10.1373/clinchem.2004.032482
   Paananen J, 2020, BRIEF BIOINFORM, V21, P1937, DOI 10.1093/bib/bbz122
   Rinschen MM, 2019, NAT REV MOL CELL BIO, V20, P353, DOI 10.1038/s41580 019 0108 4
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rong P, 2018, J TRADIT CHIN MED, V38, P504
   Song ZH, 2004, PLANTA MED, V70, P1222, DOI 10.1055/s 2004 835855
   Suzuki A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238992
   Wang H, 2015, REV ENDOCR METAB DIS, V16, P47, DOI 10.1007/s11154 014 9306 8
   Wu X, 2018, CHIN MED UK, V13, DOI 10.1186/s13020 018 0163 3
   Yu AXD, 2020, FASEB J, V34, P4311, DOI 10.1096/fj.201902319RRR
   Zheng KYZ, 2010, J ETHNOPHARMACOL, V132, P259, DOI 10.1016/j.jep.2010.08.029
   Zheng KYZ, 2012, J PHARMACEUT BIOMED, V70, P671, DOI 10.1016/j.jpba.2012.05.018
   Zhu KY, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/731385
NR 35
TC 1
Z9 1
U1 0
U2 25
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9717
J9 PROCESSES
JI Processes
PD JUL
PY 2021
VL 9
IS 7
AR 1119
DI 10.3390/pr9071119
PG 14
WC Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA TO8KJ
UT WOS:000677152800001
OA gold
DA 2025 08 17
ER

PT J
AU Xia, Y
   Fan, DP
   Li, XY
   Lu, XC
   Ye, QB
   Xi, XY
   Wang, Q
   Zhao, HY
   Xiao, C
AF Xia, Ya
   Fan, Danping
   Li, Xiaoya
   Lu, Xiangchen
   Ye, Qinbin
   Xi, Xiaoyu
   Wang, Qiong
   Zhao, Hongyan
   Xiao, Cheng
TI Yi Shen Juan Bi Pill Regulates the Bone Immune Microenvironment
   via the JAK2/STAT3 Signaling Pathway in Vitro
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE rheumatoid arthritis; Yi Shen Juan Bi Pill; osteoclast; regulatory T
   cell; JAK2; STAT3 signaling pathway
ID AUTOIMMUNE ARTHRITIS; T CELLS; OSTEOIMMUNOLOGY; TRANSCRIPTION;
   ADALIMUMAB; ACTIVATION; MECHANISMS; PLACEBO
AB Rheumatoid arthritis (RA) is characterized by an impaired articular bone immune microenvironment, which is associated with regulatory T cells (Tregs) hypofunction and osteoclasts (OCs) hyperfunction and leads to articular bone erosion and systemic bone loss. Studies have shown that Tregs slow bone loss in RA by regulating the bone resorption function of OCs and the JAK/STAT signaling pathway can regulate the immunosuppressive function of Tregs and reduce the bone erosion function of OCs. Yi Shen Juan Bi Pill (YSJB) is a classic Chinese herbal compound for the treatment of RA. However, whether YSJB regulates bone immune microenvironment homeostasis through JAK/STAT signaling pathway remains unclear. Based on in vitro OC single culture, Treg single culture and OC Treg coculture systems, treatments were performed using drug containing serum, AG490 and JAK2 siRNA to explore whether YSJB containing serum regulates the homeostasis of the bone immune microenvironment through the JAK/STAT signaling pathway. In vitro, YSJB treatment decreased the number of TRAP(+) cells and the areas of bone resorption and inhibited the expression of RANK, NFATc1, c fos, JAK2, and STAT3 in both the OC single culture system and the OC Treg coculture system. Tregs further reduced the number of TRAP(+) cells and the areas of bone resorption in the coculture system. YSJB promoted the secretion of IL 10 while inhibiting the expression of JAK2 and STAT3 in Tregs. Moreover, inhibiting the expression of JAK2 with the JAK2 inhibitor AG490 and JAK2 siRNA improved the immunosuppressive functions of Treg, inhibited OC differentiation and bone resorption. Our study demonstrates that YSJB can regulate OC mediated bone resorption and Treg mediated bone immunity through the JAK2/STAT3 signaling pathway. This study provides a new strategy for regulating the bone immune microenvironment in RA with traditional Chinese medicine.
C1 [Xia, Ya; Lu, Xiangchen] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing, Peoples R China.
   [Fan, Danping; Xiao, Cheng] China Japan Friendship Hosp, Dept Emergency, Beijing, Peoples R China.
   [Fan, Danping; Xiao, Cheng] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll, Grad Sch, Beijing, Peoples R China.
   [Fan, Danping; Lu, Xiangchen; Ye, Qinbin; Xi, Xiaoyu; Wang, Qiong; Xiao, Cheng] China Japan Friendship Hosp, Inst Clin Med, Beijing, Peoples R China.
   [Li, Xiaoya] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Plant Dev, Beijing, Peoples R China.
   [Lu, Xiangchen] Beijing Tradit Chinese Med Hosp, Pinggu Hosp, Beijing, Peoples R China.
   [Zhao, Hongyan] China Acad Chinese Med Sci, Beijing Key Lab Res Chinese Med Prevent & Treatme, Expt Res Ctr, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; China Japan Friendship Hospital;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; China Japan Friendship Hospital; Chinese
   Academy of Medical Sciences   Peking Union Medical College; Institute of
   Medicinal Plant Development   CAMS; Peking Union Medical College;
   Experimental Research Center, CACMS; China Academy of Chinese Medical
   Sciences
RP Xiao, C (通讯作者)，China Japan Friendship Hosp, Dept Emergency, Beijing, Peoples R China.; Xiao, C (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll, Grad Sch, Beijing, Peoples R China.; Xiao, C (通讯作者)，China Japan Friendship Hosp, Inst Clin Med, Beijing, Peoples R China.; Zhao, HY (通讯作者)，China Acad Chinese Med Sci, Beijing Key Lab Res Chinese Med Prevent & Treatme, Expt Res Ctr, Beijing, Peoples R China.
EM zhaohongyan1997@163.com; xc2002812@126.com
RI lu, xiangchen/HOC 2483 2023; Li, Xiaoya/Y 8476 2019; Xiao,
   Cheng/AAM 7764 2020
OI xiao, Cheng/0000 0002 5601 9670
FU National Natural Science Foundation of China [81873223]; Fundamental
   Research Funds for the Central Public Welfare Research Institutes
   [ZZ2018001]
FX Funding This study was financially supported by the National Natural
   Science Foundation of China (Grant number 81873223) and the Fundamental
   Research Funds for the Central Public Welfare Research Institutes (Grant
   number ZZ2018001).
CR Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666
   Chen QM, 2018, INT J MED SCI, V15, P666, DOI 10.7150/ijms.23940
   Dar HY, 2018, FRONT BIOSCI LANDMRK, V23, P464, DOI 10.2741/4600
   Fischer L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00578
   Hanada R, 2011, J MOL MED, V89, P647, DOI 10.1007/s00109 011 0749 z
   Kanagawa H, 2016, J BONE MINER METAB, V34, P526, DOI 10.1007/s00774 015 0702 2
   Komatsu N, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00077
   Li CH, 2013, BIOCHEM BIOPH RES CO, V435, P533, DOI 10.1016/j.bbrc.2013.04.084
   Li DY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02104
   Liu W, 2015, MOL MED REP, V11, P3212, DOI 10.3892/mmr.2015.3152
   Mease P, 2017, NEW ENGL J MED, V377, P1537, DOI 10.1056/NEJMoa1615975
   Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914 017 0381 0
   Park JS, 2014, J IMMUNOL, V192, P4417, DOI 10.4049/jimmunol.1300514
   Ponchel F, 2014, ANN RHEUM DIS, V73, P2047, DOI 10.1136/annrheumdis 2013 203566
   Rotta D, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.613720
   Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119
   Sims NA, 2020, EXP MOL MED, V52, P1185
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Srivastava RK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00657
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365 2567.2006.02321.x
   Taylor PC, 2017, NEW ENGL J MED, V376, P652, DOI 10.1056/NEJMoa1608345
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691
   Walsh MC, 2018, NAT REV RHEUMATOL, V14, P146, DOI 10.1038/nrrheum.2017.213
   Xu HH, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8048170
   Zerbini CAF, 2017, OSTEOPOROSIS INT, V28, P429, DOI 10.1007/s00198 016 3769 2
   Zhao HY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00262
   Zhao HY, 2017, INT IMMUNOPHARMACOL, V51, P114, DOI 10.1016/j.intimp.2017.08.013
   Zhao HY, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/102641
NR 31
TC 12
Z9 14
U1 1
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD DEC 14
PY 2021
VL 12
AR 746786
DI 10.3389/fphar.2021.746786
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA YB4JB
UT WOS:000738979700001
PM 34970139
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kim, K
   Ha Kim, J
   Kim, I
   Seong, S
   Koh, JT
   Kim, N
AF Kim, Kabsun
   Ha Kim, Jung
   Kim, Inyoung
   Seong, Semun
   Koh, Jeong Tae
   Kim, Nacksung
TI Sestrin2 inhibits RANKL induced osteoclastogenesis through AMPK
   activation and ROS inhibition
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Sestrin2; Azithromycin; Osteoclast; AMP Activated protein kinase;
   Nuclear factor erythroid derived factor 2 related factor 2; Reactive
   oxygen species
ID AUTOPHAGIC DEGRADATION; NEGATIVE REGULATOR; BONE DESTRUCTION; OXIDATIVE
   STRESS; AZITHROMYCIN; NRF2; MECHANISMS; PATHWAY; KEAP1; OSTEOIMMUNOLOGY
AB Sestrins are stress responsive proteins with antioxidant properties. They participate in cellular redox balance and protect against oxidative damage. This study investigated the effects of Sestrin2 (Sesn2) on osteoclast differ entiation and function. Overexpressing Sesn2 in osteoclast precursor cells significantly inhibited receptor acti vator of nuclear factor KB ligand (RANKL) induced osteoclastogenesis. This was assessed as reduced expression of various osteoclast markers, including c Fos, nuclear factor of activated T cells 1 (NFATc1), osteoclast associated receptor, tartrate resistant acid phosphatase, and cathepsin K. Conversely, downregulation of Sesn2 produced the opposite effect. Mechanistically, Sesn2 overexpression enhanced AMPK activation and the nuclear translocation of nuclear factor erythroid derived factor 2 related factor 2 (Nrf2), promoting antioxidant enzymes. Moreover, azithromycin (Azm) induced Sesn2 expression, which suppressed RANKL induced osteoclast differentiation. Specifically, Azm treatment reduced RANKL induced production of reactive oxygen species in osteoclasts. Furthermore, intraperitoneal administration of Azm ameliorated RANKL induced bone loss by reducing osteo clast activity in mice. Taken together, our results suggested that Azm induced Sesn2 act as a negative regulator of RANKL induced osteoclast differentiation through the AMPK/NFATc1 signaling pathway. Concisely, targeting Sesn2 can be a potential pharmacological intervention in osteoporosis.
C1 [Kim, Kabsun; Ha Kim, Jung; Kim, Inyoung; Seong, Semun; Kim, Nacksung] Chonnam Natl Univ, Med Sch, Dept Pharmacol, Gwangju 61469, South Korea.
   [Ha Kim, Jung; Seong, Semun; Koh, Jeong Tae; Kim, Nacksung] Chonnam Natl Univ, Hard Tissue Biointerface Res Ctr, Sch Dent, Gwangju 61186, South Korea.
   [Koh, Jeong Tae] Chonnam Natl Univ, Sch Dent, Dept Pharmacol & Dent Therapeut, Gwangju 61186, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University
RP Kim, N (通讯作者)，Chonnam Natl Univ, Med Sch, Dept Pharmacol, Gwangju 61469, South Korea.
EM nacksung@jnu.ac.kr
FU National Research Foundation of Korea (NRF)   Korean government (MSIT)
   [NRF  2019R1A5A2027521, 2020R1I1A1A01051943]
FX This work was supported by National Research Foundation of Korea (NRF)
   grants funded by the Korean government (MSIT) (NRF  2019R1A5A2027521 and
   2020R1I1A1A01051943).
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Bae SH, 2013, CELL METAB, V17, P73, DOI 10.1016/j.cmet.2012.12.002
   Chen DL, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.664836
   Dinos GP, 2017, BRIT J PHARMACOL, V174, P2967, DOI 10.1111/bph.13936
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Gannon SC, 2013, J CELL PHYSIOL, V228, P1098, DOI 10.1002/jcp.24259
   Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032
   Gomi K, 2007, J PERIODONTOL, V78, P422, DOI 10.1902/jop.2007.060247
   Gong LN, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.751020
   Haas AN, 2012, J DENT, V40, P556, DOI 10.1016/j.jdent.2012.03.004
   Hahn DL, 2012, J AM BOARD FAM MED, V25, P442, DOI 10.3122/jabfm.2012.04.110309
   Han MLK, 2014, AM J RESP CRIT CARE, V189, P1503, DOI 10.1164/rccm.201402 0207OC
   Hardie DG, 2002, BIOCHEM SOC T, V30, P1064, DOI 10.1042/BST0301064
   Hirsch R, 2012, J PERIODONTAL RES, V47, P137, DOI 10.1111/j.1600 0765.2011.01418.x
   Hirsch R, 2010, AUST DENT J, V55, P193, DOI 10.1111/j.1834 7819.2010.01227.x
   Ho A, 2016, TRENDS BIOCHEM SCI, V41, P621, DOI 10.1016/j.tibs.2016.04.005
   Hou YS, 2015, MOL CELL BIOL, V35, P2740, DOI 10.1128/MCB.00285 15
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Jeyabalan J, 2012, J ENDOCRINOL, V212, P277, DOI 10.1530/JOE 11 0306
   Kang H, 2013, J BIOL CHEM, V288, P12187, DOI 10.1074/jbc.M112.430389
   Kanzaki H, 2017, FASEB J, V31, P781, DOI 10.1096/fj.201600826R
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kim H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10025
   Kim JY, 2015, BONE, V79, P242, DOI 10.1016/j.bone.2015.06.011
   Kim Kabsun, 2022, J Bone Metab, V29, P165, DOI 10.11005/jbm.2022.29.3.165
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Kingah PL, 2014, CLIN TRANSPLANT, V28, P906, DOI 10.1111/ctr.12401
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Lee JH, 2013, CELL METAB, V18, P792, DOI 10.1016/j.cmet.2013.08.018
   Lee JH, 2010, SCIENCE, V327, P1223, DOI 10.1126/science.1182228
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SH, 2012, CALCIFIED TISSUE INT, V90, P404, DOI 10.1007/s00223 012 9584 7
   Lee YS, 2010, BONE, V47, P926, DOI 10.1016/j.bone.2010.08.001
   López M, 2016, NAT REV ENDOCRINOL, V12, P421, DOI 10.1038/nrendo.2016.67
   Mo CF, 2014, ANTIOXID REDOX SIGN, V20, P574, DOI 10.1089/ars.2012.5116
   Morrison A, 2015, FASEB J, V29, P408, DOI 10.1096/fj.14 258814
   Nesse W, 2008, J CLIN PERIODONTOL, V35, P668, DOI 10.1111/j.1600 051X.2008.01249.x
   Noble M, 2005, ANTIOXID REDOX SIGN, V7, P1456, DOI 10.1089/ars.2005.7.1456
   Oh SJ, 2016, BIOCHEM BIOPH RES CO, V475, P125, DOI 10.1016/j.bbrc.2016.05.055
   Oh SY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.646803
   Park HS, 2017, INT IMMUNOPHARMACOL, V47, P212, DOI 10.1016/j.intimp.2017.04.008
   Pasha M, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3296294
   Pollock J, 2021, PULM PHARMACOL THER, V71, DOI 10.1016/j.pupt.2021.102095
   Quinn JMW, 2010, FASEB J, V24, P275, DOI 10.1096/fj.09 137158
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rhee SG, 2015, FREE RADICAL BIO MED, V88, P205, DOI 10.1016/j.freeradbiomed.2015.06.007
   Rho J, 2004, MOL CELLS, V17, P1
   Shin BY, 2012, FREE RADICAL BIO MED, V53, P834, DOI 10.1016/j.freeradbiomed.2012.06.026
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xu Y, 2023, BIOMED PHARMACOTHER, V159, DOI 10.1016/j.biopha.2022.114101
   Yamaguchi N, 2008, FEBS LETT, V582, P451, DOI 10.1016/j.febslet.2007.12.037
   Yang Y., 2014, FASEB J, V28, DOI [10.1096/fasebj.28.1_supplement.869.11, DOI 10.1096/FASEBJ.28.1_SUPPLEMENT.869.11, 10.1096/fasebj.28.1_supplement.869.11,869.11, DOI 10.1096/FASEBJ.28.1_SUPPLEMENT.869.11,869.11]
   Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137 8151.2003
NR 56
TC 7
Z9 7
U1 2
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891 5849
EI 1873 4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD FEB 1
PY 2024
VL 211
BP 77
EP 88
DI 10.1016/j.freeradbiomed.2023.12.009
EA DEC 2023
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA EH3O5
UT WOS:001137993700001
PM 38101586
OA hybrid
DA 2025 08 17
ER

PT J
AU Maria, S
   Samsonraj, RM
   Munmun, F
   Glas, J
   Silvestros, M
   Kotlarczyk, MP
   Rylands, R
   Dudakovic, A
   van Wijnen, AJ
   Enderby, LT
   Lassila, H
   Dodda, B
   Davis, VL
   Balk, J
   Burow, M
   Bunnell, BA
   Witt Enderby, PA
AF Maria, Sifat
   Samsonraj, Rebekah M.
   Munmun, Fahima
   Glas, Jessica
   Silvestros, Maria
   Kotlarczyk, Mary P.
   Rylands, Ryan
   Dudakovic, Amel
   van Wijnen, Andre J.
   Enderby, Larry T.
   Lassila, Holly
   Dodda, Bala
   Davis, Vicki L.
   Balk, Judy
   Burow, Matt
   Bunnell, Bruce A.
   Witt Enderby, Paula A.
TI Biological effects of melatonin on osteoblast/osteoclast cocultures,
   bone, and quality of life: Implications of a role for MT2 melatonin
   receptors, MEK1/2, and MEK5 in melatonin mediated osteoblastogenesis
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Article
DE adipocytes; GLUT4; MEK1/2; MEK5; melatonin; mesenchymal stem cells; MT2
   melatonin receptor; osteoblasts; osteoclasts; PPAR gamma
ID MESENCHYMAL STEM CELLS; MINERAL DENSITY; PPAR GAMMA; ENHANCES
   OSTEOGENESIS; MOLECULAR MECHANISMS; POSTMENOPAUSAL WOMEN; OSTEOCLAST
   FORMATION; DOUBLE BLIND; DIFFERENTIATION; EXPRESSION
AB The Melatonin Osteoporosis Prevention Study (MOPS) demonstrated that nightly melatonin resulted in a time dependent decrease in equilibrium ratios of serum osteoclasts and osteoblasts in perimenopausal women. This study examines mechanisms related to the ratios of osteoblasts and osteoclasts using coculture models (transwell or layered) of human mesenchymal stem cell (MSC) and human peripheral blood monocytes (PBMCs). Human MSC/PBMC cocultures exposed to melatonin in osteogenic (OS+) medium for 21days induced osteoblast differentiation and mineralization; however, only in layered cocultures did melatonin inhibit osteoclastogenesis. Melatonin effects were mediated through MT2 melatonin receptors, MEK1/2, and MEK5. In layered but not transwell cocultures, melatonin increased OPG:RANKL ratios by inhibiting RANKL, suggesting that contact with osteoclasts during osteoblastogenesis inhibits RANKL secretion. Melatonin modulated expression of ERK1/2, ERK5, 1 integrin, GLUT4, and IR that was dependent upon the type of coculture; however, in both cultures, melatonin increased RUNX2 and decreased PPAR expression, indicating a role for metabolic processes that control osteogenic vs adipogenic cell fates of MSCs. Furthermore, melatonin also has osteoblast inducing effects on human adipose derived MSCs. In vivo, one year nightly melatonin (15mg/L) given to neu female mice in their drinking water increased pErk1/2, pErk5, Runx2, and Opg and Rankl levels in bone consistent with melatonin's already reported bone enhancing effects. Finally, analysis of daily logs from the MOPS demonstrated a significant improvement in mood and perhaps sleep quality in women receiving melatonin vs placebo. The osteoblast inducing, bone enhancing effects of melatonin and improvement in quality of life suggest that melatonin is a safe and effective bone loss therapy.
C1 [Maria, Sifat; Munmun, Fahima; Glas, Jessica; Silvestros, Maria; Kotlarczyk, Mary P.; Rylands, Ryan; Dodda, Bala; Davis, Vicki L.; Witt Enderby, Paula A.] Duquesne Univ, Sch Pharm, Div Pharmaceut Adm & Social Sci, Pittsburgh, PA 15219 USA.
   [Samsonraj, Rebekah M.; Dudakovic, Amel; van Wijnen, Andre J.] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA.
   [Enderby, Larry T.] Enderby Healthcare Legal Consulting LLC, Pittsburgh, PA USA.
   [Lassila, Holly] Duquesne Univ, Sch Pharm, Div Clin Sci, Pittsburgh, PA 15219 USA.
   [Balk, Judy] Drexel Univ, West Penn Allegheny Hlth Syst, Pittsburgh, PA USA.
   [Balk, Judy] Temple Univ, Pittsburgh, PA USA.
   [Burow, Matt; Bunnell, Bruce A.] Tulane Univ, Sch Med, Ctr Stem Cell Res, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Burow, Matt; Bunnell, Bruce A.] Tulane Univ, Sch Med, Dept Pharmacol, New Orleans, LA 70112 USA.
C3 Duquesne University; Mayo Clinic; Duquesne University; Drexel
   University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Temple University; Tulane University; Tulane University
RP Witt Enderby, PA (通讯作者)，Duquesne Univ, Div Pharmaceut Adm Social Sci, Pittsburgh, PA 15219 USA.
EM wittp@duq.edu
RI ; van Wijnen, Andre/AAG 3578 2019
OI van Wijnen, Andre J./0000 0002 4458 0946; Dudakovic,
   Amel/0000 0002 8850 3977; Samsonraj, Rebekah/0000 0001 8804 8284;
   Bunnell, Bruce/0000 0001 6196 3722; Kotlarczyk,
   Mary/0000 0002 5846 8461; 
FU National Institute for Arthritis and Musculoskeletal Diseases [NIAMS R15
   AR068605, NIAMS R01 AR049069]; Susan G. Komen for the Cure Duquesne
   University Translational Research
FX National Institute for Arthritis and Musculoskeletal Diseases,
   Grant/Award Number: NIAMS R15 AR068605 and NIAMS R01 AR049069; Susan G.
   Komen for the Cure Duquesne University Translational Research
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Altindag O, 2007, INT J CLIN PRACT, V61, P416, DOI 10.1111/j.1742 1241.2006.01276.x
   Amano S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125054
   Amstrup AK, 2016, CLIN ENDOCRINOL, V84, P342, DOI 10.1111/cen.12942
   Amstrup AK, 2015, J PINEAL RES, V59, P221, DOI 10.1111/jpi.12252
   Armoni M, 2007, TRENDS ENDOCRIN MET, V18, P100, DOI 10.1016/j.tem.2007.02.001
   Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Cardinali DP, 2003, J PINEAL RES, V34, P81, DOI 10.1034/j.1600 079X.2003.00028.x
   Caro JJ, 2004, OSTEOPOROSIS INT, V15, P1003, DOI 10.1007/s00198 004 1652 z
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Clafshenkel WP, 2012, J PINEAL RES, V53, P206, DOI 10.1111/j.1600 079X.2012.00989.x
   CLOVER J, 1992, J CELL SCI, V103, P267
   Crespo Diaz R, 2011, CELL TRANSPLANT, V20, P797, DOI 10.3727/096368910X543376
   Cutando A, 2008, J PINEAL RES, V45, P174, DOI 10.1111/j.1600 079X.2008.00573.x
   Emaus N, 2014, J BONE MINER RES, V29, P2080, DOI 10.1002/jbmr.2232
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Everson CA, 2012, EXP BIOL MED, V237, P1101, DOI 10.1258/ebm.2012.012043
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Feskanich D, 2009, OSTEOPOROSIS INT, V20, P537, DOI 10.1007/s00198 008 0729 5
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Furlan PM, 2005, BIOL PSYCHIAT, V57, P911, DOI 10.1016/j.biopsych.2004.12.033
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189
   Gueldner S.H., 2007, OSTEOPOROSIS CLIN GU
   Helfrich MH, 1996, BONE, V19, P317, DOI 10.1016/S8756 3282(96)00223 2
   Helfrich MH, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P385, DOI 10.1016/B978 0 12 373884 4.00039 2
   Henderson J E., 2000, The osteoporosis primer
   Henriksen K, 2009, BONE, V44, P1026, DOI 10.1016/j.bone.2009.03.671
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Horton M.A., 2000, Integrins and Development: Integrins in Skeletal Cell Function and Development
   Janckila AJ, 2001, J BONE MINER RES, V16, P788, DOI 10.1359/jbmr.2001.16.4.788
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kaneshiro S, 2015, BIOCHEM BIOPH RES CO, V463, P241, DOI 10.1016/j.bbrc.2015.05.035
   Kartsogiannis V, 2008, J BIOL CHEM, V283, P30850, DOI 10.1074/jbc.M801761200
   Kim BK, 2013, CALCIFIED TISSUE INT, V93, P495, DOI 10.1007/s00223 013 9779 6
   Kotlarczyk MP, 2012, J PINEAL RES, V52, P414, DOI 10.1111/j.1600 079X.2011.00956.x
   Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219
   Labouesse MA, 2014, BONE, V64, P138, DOI 10.1016/j.bone.2014.03.047
   Ladizesky MG, 2003, J PINEAL RES, V34, P143, DOI 10.1034/j.1600 079X.2003.00021.x
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lecka Czernik B, 2006, PPAR RES, P1
   Lecka Czernik Beata, 2010, Curr Osteoporos Rep, V8, P178, DOI 10.1007/s11914 010 0027 y
   Li P, 2012, MOL CELL BIOCHEM, V364, P321, DOI 10.1007/s11010 012 1233 y
   Li Z., 2013, Journal of Bone and Mineral Research
   Liao W, 2007, AM J PHYSIOL ENDOC M, V293, pE219, DOI 10.1152/ajpendo.00695.2006
   López Martínez F, 2012, INT J DENT, V2012, DOI 10.1155/2012/628406
   Lucassen EA, 2016, CURR BIOL, V26, P1843, DOI 10.1016/j.cub.2016.05.038
   Mader EK, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 20
   Maria S, 2017, HEALTHY AGEING LONG, V7, P65, DOI 10.1007/978 3 319 64543 8_3
   Maria S, 2017, AGING US, V9, P256, DOI 10.18632/aging.101158
   Maria S, 2014, J PINEAL RES, V56, P115, DOI 10.1111/jpi.12116
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Mizuno M, 2000, J CELL PHYSIOL, V184, P207, DOI 10.1002/1097 4652(200008)184:2<207::AID JCP8>3.3.CO;2 L
   Nakade O, 1999, J PINEAL RES, V27, P106, DOI 10.1111/j.1600 079X.1999.tb00603.x
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Ostrowska Z, 2003, Endocr Regul, V37, P163
   Park KH, 2011, J PINEAL RES, V51, P187, DOI 10.1111/j.1600 079X.2011.00875.x
   Quevedo I, 2010, J CLIN DENSITOM, V13, P467, DOI 10.1016/j.jocd.2010.07.004
   Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600 079X.2006.00318.x
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rao HW, 2006, J BONE MINER RES, V21, P1657, DOI 10.1359/JBMR.060718
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Roth JA, 1999, J BIOL CHEM, V274, P22041, DOI 10.1074/jbc.274.31.22041
   Saidak Z, 2012, AGING CELL, V11, P467, DOI 10.1111/j.1474 9726.2012.00804.x
   SANDYK R, 1992, INT J NEUROSCI, V67, P173, DOI 10.3109/00207459208994783
   Satomura K, 2007, J PINEAL RES, V42, P231, DOI 10.1111/j.1600 079X.2006.00410.x
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Sethi S, 2010, J PINEAL RES, V49, P222, DOI 10.1111/j.1600 079X.2010.00784.x
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Sroga GE, 2012, CURR OSTEOPOROS REP, V10, P141, DOI 10.1007/s11914 012 0103 6
   Suofu Y, 2017, P NATL ACAD SCI USA, V114, pE7997, DOI 10.1073/pnas.1705768114
   Suzuki N, 2002, J PINEAL RES, V33, P253, DOI 10.1034/j.1600 079X.2002.02953.x
   Swanson CM, 2017, J CLIN ENDOCR METAB, V102, P3722, DOI 10.1210/jc.2017 01147
   Takada I, 2007, ANN NY ACAD SCI, V1116, P182, DOI 10.1196/annals.1402.034
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang K, 2015, ENDOCRINE, V49, P538, DOI 10.1007/s12020 014 0493 6
   Witt Enderby PA, 2006, J PINEAL RES, V41, P297, DOI 10.1111/j.1600 079X.2006.00369.x
   Witt Enderby PA, 2012, MELATONIN IN THE PROMOTION OF HEALTH, 2ND EDITION, P261
   Witt Enderby PA, 2012, J PINEAL RES, V53, P374, DOI 10.1111/j.1600 079X.2012.01007.x
   Xu XW, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018 016 0418 6
   Zaminy Arash, 2008, Iran Biomed J, V12, P133
   Zebaze RMD, 2010, LANCET, V375, P1729, DOI 10.1016/S0140 6736(10)60320 0
   Zhang B, 2016, CONNECT TISSUE RES, V57, P299, DOI 10.1080/03008207.2016.1181063
   Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600 079X.2010.00803.x
   Zimmerman D, 2000, DEV BIOL, V220, P2, DOI 10.1006/dbio.2000.9633
NR 90
TC 126
Z9 136
U1 0
U2 72
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0742 3098
EI 1600 079X
J9 J PINEAL RES
JI J. Pineal Res.
PD APR
PY 2018
VL 64
IS 3
AR e12465
DI 10.1111/jpi.12465
PG 22
WC Endocrinology & Metabolism; Neurosciences; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA FY5IX
UT WOS:000426861600005
PM 29285799
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Shuai, YM
   Jiang, ZL
   Yuan, QW
   Tu, SQ
   Zeng, FH
AF Shuai, Yongming
   Jiang, Zhili
   Yuan, Qiuwen
   Tu, Shuqiang
   Zeng, Fanhui
TI Deciphering the Underlying Mechanism of Eucommiae Cortex against
   Osteoporotic Fracture by Network Pharmacology
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID TRADITIONAL CHINESE MEDICINE; OXIDATIVE STRESS; OSTEOGENIC
   DIFFERENTIATION; INFLAMMATORY RESPONSE; STEM CELLS; BONE; ACTIVATION;
   RISK; BISPHOSPHONATES; PROLIFERATION
AB Background. Du Zhong (DZ), or Eucommiae Cortex, a traditional Chinese herbal medicine, has been used to treat osteoporosis. Although it has been reported that DZ can improve bone mass in ovariectomized rats, its pharmacological mechanisms in treating osteoporotic fractures (OPF) remain unclear. Methods. In this study, we used a network pharmacological manner to explore its potential complicated mechanism in treating OPF. We obtained DZ compounds from TCMSP and BATMAN TCM databases and collected potential targets of these compounds through target fishing based on TCMSP and BATMAN TCM databases. Next, we collected the OPF targets by using CTD, GeneCards, OMIM, HPO, and GenCLiP 3 databases. And then the overlapping genes between DZ potential targets and OPF targets were used to build up the protein protein interaction (PPI) network and to analyze their interactions and find out the big hub genes in this network. Subsequently, clusterProfiler package in R language was utilized to conduct the enrichment of Gene Ontology biological process and KEGG pathways. Results. There were totally 93 active compounds and 916 related targets in DZ. After the enrichment analysis, we collected top 25 cellular biological processes and top 25 pathways based on the adjusted P value and found that the DZ anti OPF effect was mainly associated with the regulation of ROS and inflammatory response. Furthermore, 64 hub genes in PPI network, such as MAPK1 (degree. 41), SRC (degree. 39), PIK3R1 (degree. 36), VEGFA (degree. 31), TP53 (degree. 29), EGFR (degree. 29), JUN (degree. 29), AGT (degree. 29), MAPK1, SRC, PIK3R1, VEGFA, and TP53, were considered as potential therapeutic targets, implying the underlying mechanisms of DZ acting on OPF. Conclusion. We investigated the possible therapeutic mechanisms of DZ from a systemic perspective. These key targets and pathways provided promising directions for the future research to reveal the exact regulating mechanisms of DZ in treating OPF.
C1 [Shuai, Yongming; Jiang, Zhili; Yuan, Qiuwen; Tu, Shuqiang; Zeng, Fanhui] Nanchang Hongdu Hosp Tradit Chinese Med, 264 Minde Rd, Nanchang 330006, Jiangxi, Peoples R China.
RP Zeng, FH (通讯作者)，Nanchang Hongdu Hosp Tradit Chinese Med, 264 Minde Rd, Nanchang 330006, Jiangxi, Peoples R China.
EM shuai375150@163.com; 1002989070@qq.com; m13970943780@163.com;
   376587278@qq.com; zengfanghui510@163.com
CR Amberger Joanna S, 2017, Curr Protoc Bioinformatics, V58, DOI 10.1002/cpbi.27
   An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   [Anonymous], 1998, J BIOL CHEM, DOI DOI 10.1074/jbc.273.6.3285
   Aydin A, 2015, BASIC CLIN PHARMACOL, V117, P173, DOI 10.1111/bcpt.12384
   Barbour KE, 2014, J BONE MINER RES, V29, P2057, DOI 10.1002/jbmr.2245
   Camacho PM, 2016, ENDOCR PRACT, V22, P1, DOI 10.4158/EP161435.GL
   Cauley JA, 2013, J GERONTOL A BIOL, V68, P1243, DOI 10.1093/gerona/glt093
   Chow SKH, 2019, EUR CELLS MATER, V38, P228, DOI 10.22203/eCM.v038a16
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   De Ugarte L, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920 015 0149 2
   Ding C, 2008, J CLIN ENDOCR METAB, V93, P1952, DOI 10.1210/jc.2007 2325
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Fan JB, 2015, MOL CELL BIOCHEM, V398, P105, DOI 10.1007/s11010 014 2210 4
   Fukumoto Seiji, 2017, F1000Res, V6, P625, DOI 10.12688/f1000research.10682.1
   Gan DH, 2019, MED SCI MONITOR, V25, P5700, DOI 10.12659/MSM.915170
   Gan XQ, 2015, BIOCHEM BIOPH RES CO, V468, P719, DOI 10.1016/j.bbrc.2015.11.022
   Gertz ER, 2010, J CLIN DENSITOM, V13, P277, DOI 10.1016/j.jocd.2010.04.003
   Grondin CJ, 2018, ENVIRON HEALTH PERSP, V126, DOI [10.1289/EHP2873, 10.1289/ehp2873]
   Gu FL, 2019, AM J TRANSL RES, V11, P6032
   Ha H, 2003, ARCH PHARM RES, V26, P929, DOI 10.1007/BF02980202
   Kharazmi Mohammad, 2019, Lakartidningen, V116
   Kharazmi M, 2014, RHEUMATOLOGY, V53, P1911, DOI 10.1093/rheumatology/keu286
   KIMBLE RB, 1995, ENDOCRINOLOGY, V136, P3054, DOI 10.1210/en.136.7.3054
   Letarouilly JG, 2019, GENOMICS, V111, P793, DOI 10.1016/j.ygeno.2018.05.001
   Lewiecki EM, 2020, OSTEOPOROSIS INT, V31, P1299, DOI 10.1007/s00198 020 05334 y
   Lewiecki EM, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10192
   Li F, 2016, PHARM BIOL, V54, P1857, DOI 10.3109/13880209.2015.1133657
   Li G, 2017, ORGANOGENESIS, V13, P103, DOI 10.1080/15476278.2017.1331196
   Li P, 2009, J TRADIT CHIN MED, V29, P153, DOI 10.1016/S0254 6272(09)60054 6
   Lin JT, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9203934
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Luo GM, 2017, AM J TRANSL RES, V9, P2077
   Missiuro PV, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000350
   Mitchell P, 2016, BEST PRACT RES CL RH, V30, P536, DOI 10.1016/j.berh.2016.09.008
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Mosekilde L, 2000, MATURITAS, V36, P181, DOI 10.1016/S0378 5122(00)00158 4
   Raman Karthik, 2014, Syst Synth Biol, V8, P73, DOI 10.1007/s11693 013 9123 5
   Rebhan M, 1998, BIOINFORMATICS, V14, P656, DOI 10.1093/bioinformatics/14.8.656
   Rivadeneira F, 2006, J BONE MINER RES, V21, P1443, DOI 10.1359/JBMR.060605
   Robinson PN, 2008, AM J HUM GENET, V83, P610, DOI 10.1016/j.ajhg.2008.09.017
   Rossini M, 2016, EXPERT OPIN DRUG SAF, V15, P321, DOI 10.1517/14740338.2016.1136287
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Savaridas T, 2013, BONE JOINT J, V95B, P1263, DOI 10.1302/0301 620X.95B9.31562
   Schröder K, 2019, FREE RADICAL BIO MED, V132, P67, DOI 10.1016/j.freeradbiomed.2018.08.036
   Sham TT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/925302
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sheng SJ, 2014, J ETHNOPHARMACOL, V154, P735, DOI 10.1016/j.jep.2014.04.048
   Swanberg M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047964
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Tang Y, 2015, BIOSYSTEMS, V127, P67, DOI 10.1016/j.biosystems.2014.11.005
   Tao WY, 2013, J ETHNOPHARMACOL, V145, P1, DOI 10.1016/j.jep.2012.09.051
   Thummuri D, 2017, J MOL MED, V95, P1065, DOI 10.1007/s00109 017 1553 1
   Tong YX, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858 015 0031 z
   Wang C, 2012, J BONE MINER RES, V27, P2582, DOI 10.1002/jbmr.1711
   Wang JH, 2020, BIOINFORMATICS, V36, P1973, DOI 10.1093/bioinformatics/btz807
   Wang JS, 2018, BIOL TRACE ELEM RES, V183, P270, DOI 10.1007/s12011 017 1123 y
   Wang J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01364
   Wang NN, 2019, J ETHNOPHARMACOL, V241, DOI 10.1016/j.jep.2019.111977
   Watkins BA, 2001, PROG LIPID RES, V40, P125, DOI 10.1016/S0163 7827(00)00016 3
   Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328
   Xiao LJ, 2017, ADV EXP MED BIOL, V1010, P261, DOI 10.1007/978 981 10 5562 1_13
   Xu W, 2006, EUR J CANCER CARE, V15, P397, DOI 10.1111/j.1365 2354.2006.00685.x
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Zhang WJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00743
   Zhang Y, 2015, ACTA BIOCH BIOPH SIN, V47, P65, DOI 10.1093/abbs/gmu124
   Zhou LP, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00779
NR 68
TC 8
Z9 8
U1 1
U2 18
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD SEP 7
PY 2020
VL 2020
AR 7049812
DI 10.1155/2020/7049812
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA NV6DN
UT WOS:000574409800001
PM 32963568
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Martins Neves, SR
   Paiva Oliveira, DI
   Fontes Ribeiro, C
   Bovée, JVMG
   Cleton Jansen, AM
   Gomes, CMF
AF Martins Neves, Sara R.
   Paiva Oliveira, Daniela I.
   Fontes Ribeiro, Carlos
   Bovee, Judith V. M. G.
   Cleton Jansen, Anne Marie
   Gomes, Celia M. F.
TI IWR 1, a tankyrase inhibitor, attenuates Wnt/β catenin signaling in
   cancer stem like cells and inhibits in vivo the growth of a
   subcutaneous human osteosarcoma xenograft
SO CANCER LETTERS
LA English
DT Article
DE Cancer stem like cells; Osteosarcoma; Wnt/beta catenin signaling;
   Apoptosis; IWR 1; Doxorubicin
ID BETA CATENIN; WNT PATHWAY; SELF RENEWAL; CYCLIN D1; DRIVES
   PROLIFERATION; ELEVATED EXPRESSION; ACTIVATION; DIFFERENTIATION; GENE;
   CHEMOTHERAPY
AB Wnt/beta catenin or canonical Wnt signaling pathway regulates the self renewal of cancer stem like cells (CSCs) and is involved in tumor progression and chemotherapy resistance. Previously, we reported that this pathway is activated in a subset of osteosarcoma CSCs and that doxorubicin induced stemness properties in differentiated cells through Wnt/beta catenin activation. Here, we investigated whether pharmacological Wnt/beta catenin inhibition, using a tankyrase inhibitor (IWR 1), might constitute a strategy to target CSCs and improve chemotherapy efficacy in osteosarcoma.
   IWR 1 was specifically cytotoxic for osteosarcoma CSCs. IWR 1 impaired spheres' self renewal capacity by compromising landmark steps of the canonical Wnt signaling, namely translocation of beta catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/beta catenin downstream targets. IWR 1 also hampered the activity and expression of key stemness related markers. In vitro, IWR 1 induced apoptosis of osteosarcoma spheres and combined with doxorubicin elicited synergistic cytotoxicity, reversing spheres' resistance to this drug. In vivo, IWR 1 co administration with doxorubicin substantially decreased tumor progression, associated with specific down regulation of TCF/LEF transcriptional activity, nuclear beta catenin and expression of the putative CSC marker Sox2.
   We suggest that targeting the Wnt/beta catenin pathway can eliminate CSCs populations in osteosarcoma. Combining conventional chemotherapy with Wnt/beta catenin inhibition may ameliorate therapeutic outcomes, by eradicating the aggressive osteosarcoma CSCs and reducing drug resistance. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Martins Neves, Sara R.; Paiva Oliveira, Daniela I.; Fontes Ribeiro, Carlos; Gomes, Celia M. F.] Univ Coimbra, Fac Med, Fac Med, IBILI,Pharmacology & Expt Therapeut, P 3000354 Azinhaga De Sta Comba, Celas, Portugal.
   [Martins Neves, Sara R.; Paiva Oliveira, Daniela I.; Fontes Ribeiro, Carlos; Gomes, Celia M. F.] Univ Coimbra, CNCIBILI, Coimbra, Portugal.
   [Martins Neves, Sara R.; Gomes, Celia M. F.] Univ Coimbra, CIMAGO, Coimbra, Portugal.
   [Martins Neves, Sara R.; Bovee, Judith V. M. G.; Cleton Jansen, Anne Marie] Leiden Univ, Med Ctr, Dept Pathol, POB 9600,L1 Q, NL 2300 RC Leiden, Netherlands.
C3 Universidade de Coimbra; Universidade de Coimbra; Universidade de
   Coimbra; Leiden University; Leiden University Medical Center (LUMC);
   Leiden University   Excl LUMC
RP Gomes, CMF (通讯作者)，Univ Coimbra, Fac Med, Fac Med, IBILI,Pharmacology & Expt Therapeut, P 3000354 Azinhaga De Sta Comba, Celas, Portugal.
EM cgomes@fmed.uc.pt
RI ; Ribeiro, Carlos/B 7729 2018; Fontes Ribeiro, Carlos/B 7729 2018;
   Bovee, Judith/AFM 4294 2022; Gomes, Celia/HZK 6179 2023
OI Bovee, Judith/0000 0003 1155 0481; Martins Neves, Sara
   R./0000 0002 9370 5899; Fontes Ribeiro, Carlos/0000 0002 9707 4895;
   Gomes, Celia/0000 0002 7497 4129
FU Portuguese Foundation for Science and Technology (FCT) through COMPETE;
   QREN; FEDER [Pest C/SAU/UI3282]; FCT [UID/NEU/04539/2013]; COMPETE
   [POCI 01 0145 FEDER 007440, SFRH/BD/69603/2010]; "Nucleo Regional do
   Centro da Liga Portuguesa Contra o Cancro/CIMAGO" (Bolsas de
   Investigacao em Oncologia NRC LPCC/CIMAGO); Fundação para a Ciência e a
   Tecnologia [SFRH/BD/69603/2010] Funding Source: FCT
FX This work was supported by the Portuguese Foundation for Science and
   Technology (FCT) through COMPETE, QREN and FEDER funding [grant numbers
   Pest C/SAU/UI3282 (IBILI), FCT reference UID/NEU/04539/2013 and COMPETE
   2020 reference POCI 01 0145 FEDER 007440 (CNC.IBILI) and
   SFRH/BD/69603/2010 (PhD scholarship S. Martins Neves)], and also by a
   scholarship from the "Nucleo Regional do Centro da Liga Portuguesa
   Contra o Cancro/CIMAGO" (Bolsas de Investigacao em Oncologia
   NRC LPCC/CIMAGO 2014).
CR Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008 5472.CAN 09 3463
   Arqués O, 2016, CLIN CANCER RES, V22, P644, DOI 10.1158/1078 0432.CCR 14 3081
   Ashton JC, 2015, CANCER RES, V75, P2400, DOI 10.1158/0008 5472.CAN 14 3763
   Atlasi Y, 2014, CURR TOP DEV BIOL, V107, P373, DOI 10.1016/B978 0 12 416022 4.00013 5
   BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812
   Barham W, 2013, CANCER DISCOV, V3, P1286, DOI 10.1158/2159 8290.CD 13 0138
   Basu Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405
   Ben Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Boik JC, 2008, STAT MED, V27, P1040, DOI 10.1002/sim.3005
   Buddingh EP, 2011, CLIN CANCER RES, V17, P2110, DOI 10.1158/1078 0432.CCR 10 2047
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002
   Card DAG, 2008, MOL CELL BIOL, V28, P6426, DOI 10.1128/MCB.00359 08
   Chau WK, 2013, ONCOGENE, V32, P2767, DOI 10.1038/onc.2012.290
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Chen CB, 2015, ONCOTARGET, V6, P17570, DOI 10.18632/oncotarget.4100
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Davidson KC, 2012, P NATL ACAD SCI USA, V109, P4485, DOI 10.1073/pnas.1118777109
   De Robertis A., 2014, PLOS ONE, V9
   Delany AM, 2009, J CELL COMMUN SIGNAL, V3, P227, DOI 10.1007/s12079 009 0076 0
   Dieudonné FX, 2012, J BONE MINER RES, V27, P2118, DOI 10.1002/jbmr.1650
   Dieudonné FX, 2010, CANCER RES, V70, P5399, DOI 10.1158/0008 5472.CAN 10 0090
   Du XL, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 450
   Eselgrim M, 2006, PEDIATR BLOOD CANCER, V47, P42, DOI 10.1002/pbc.20608
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Flahaut M, 2009, ONCOGENE, V28, P2245, DOI 10.1038/onc.2009.80
   Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067
   Garcia Rostan G, 1999, CANCER RES, V59, P1811
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gonçalves C, 2015, LIFE SCI, V130, P47, DOI 10.1016/j.lfs.2015.03.009
   Guan H, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.25
   Guo Y, 2008, CLIN ORTHOP RELAT R, V466, P2039, DOI 10.1007/s11999 008 0344 y
   Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109
   Hattinger CM, 2010, EXPERT OPIN EMERG DR, V15, P615, DOI 10.1517/14728214.2010.505603
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Jiang Y, 2013, MOL CANCER RES, V11, P1597, DOI 10.1158/1541 7786.MCR 13 0332 T
   Kapinas K, 2009, J CELL BIOCHEM, V108, P216, DOI 10.1002/jcb.22243
   Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045
   Krause U, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.67
   Kuijjer M.L., 2013, BMC CANCER, V13, P1
   Kuijjer ML, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755 8794 4 66
   Kulak O, 2015, MOL CELL BIOL, V35, P2425, DOI 10.1128/MCB.00392 15
   Lewis IJ, 2007, JNCI J NATL CANCER I, V99, P112, DOI 10.1093/jnci/djk015
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Ma L, 2015, ONCOTARGET, V6, P25390, DOI 10.18632/oncotarget.4455
   Ma YM, 2013, BIOCHEM BIOPH RES CO, V431, P274, DOI 10.1016/j.bbrc.2012.12.118
   Mao J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.515
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Martins Neves SR, 2016, J CELL PHYSIOL, V231, P876, DOI 10.1002/jcp.25179
   Martins Neves SR, 2016, CANCER LETT, V370, P286, DOI 10.1016/j.canlet.2015.11.013
   Martins Neves SR, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 139
   Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377
   Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031
   Mohseny AB, 2012, EUR J CANCER, V48, P3429, DOI 10.1016/j.ejca.2012.06.018
   Moreb JS, 2017, CANCER CHEMOTH PHARM, V79, P295, DOI 10.1007/s00280 016 3213 5
   Noubissi FK, 2009, CANCER RES, V69, P8572, DOI 10.1158/0008 5472.CAN 09 1500
   Raymond A., 2013, PATHOLOGY GENETICS T, P264
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rubin EM, 2010, MOL CANCER THER, V9, P731, DOI 10.1158/1535 7163.MCT 09 0147
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Schmitz Y, 2013, CELL SIGNAL, V25, P2210, DOI 10.1016/j.cellsig.2013.07.005
   Scholten DJ II, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111431
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Skoda J, 2016, TUMOR BIOL, V37, P9535, DOI 10.1007/s13277 016 4837 0
   Stratford EW, 2014, CANCER MED US, V3, P36, DOI 10.1002/cam4.170
   Suijker J, 2015, ONCOTARGET, V6, P14832, DOI 10.18632/oncotarget.4024
   TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092 8674(81)90037 4
   Tian XH, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756 9966 32 100
   Twarog NR, 2016, SCI REP UK, V6, DOI 10.1038/srep25523
   VANKUPPEVELD FJM, 1992, APPL ENVIRON MICROB, V58, P2606, DOI 10.1128/AEM.58.8.2606 2615.1992
   Vijayakumar S, 2011, CANCER CELL, V19, P601, DOI 10.1016/j.ccr.2011.03.010
   Voronkov A, 2013, CURR PHARM DESIGN, V19, P634, DOI 10.2174/138161213804581837
   Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498
   Yan GN, 2016, CANCER LETT, V370, P268, DOI 10.1016/j.canlet.2015.11.003
   Yi XJ, 2015, MOL MED REP, V12, P5042, DOI 10.3892/mmr.2015.4025
   Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003
NR 78
TC 87
Z9 99
U1 2
U2 26
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD FEB 1
PY 2018
VL 414
BP 1
EP 15
DI 10.1016/j.canlet.2017.11.004
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FS5CK
UT WOS:000419810900001
PM 29126913
DA 2025 08 17
ER

PT J
AU Peng, ZL
   Mai, ZH
   Xiao, F
   Liu, GQ
   Wang, YX
   Xie, SS
   Ai, H
AF Peng, Zhuli
   Mai, Zhihui
   Xiao, Feng
   Liu, Guanqi
   Wang, Yixuan
   Xie, Shanshan
   Ai, Hong
TI MiR 20a: a mechanosensitive microRNA that regulates fluid shear
   stress mediated osteogenic differentiation via the BMP2 signaling
   pathway by targeting BAMBI and SMAD6
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Fluid shear stress (FSS); MC3T3 E1; mouse bone marrow stromal cells
   (mouse BMSCs); miR 20a; osteogenic differentiation
ID MESENCHYMAL STEM CELLS; PERIODONTAL LIGAMENT CELLS; OSTEOBLAST
   DIFFERENTIATION; PROLIFERATION; ACTIVATION; EXPRESSION; RUNX2; FLOW
AB Background: MicroRNAs (miRNAs) are crucial regulators of diverse biological and pathological processes. This study aimed to investigate the role of microRNA 20a (miR 20a) in fluid shear stress (FSS) mediated osteogenic differentiation.
   Methods: In the present study, we subjected osteoblast MC3T3 E1 cells or mouse bone marrow stromal cells (BMSCs) to single bout short duration FSS (12 dyn/cm(2) for 1 hour) using a parallel plate flow system. The expression of miR 20a was quantified by miRNA array profiling and real time quantitative polymerase chain reaction (qRT PCR) during FSS mediated osteogenic differentiation. The expression of osteogenic differentiation markers such as Runt related transcription factor 2 (RUNX2), alkaline phosphatase (ALP), and SP7 transcription factor (SP7) was detected. Bioinformatics analysis and a luciferase assay were performed to confirm the potential targets of miR 20a.
   Results: Osteoblast expressed miR 20a is sensitive to the mechanical environments of FSS, which are differentially up regulated during steady FSS mediated osteogenic differentiation. MiR 20a enhances FSS induced osteoblast differentiation by activating the bone morphogenetic protein 2 (BMP2) signaling pathway. Both BMP and activin membrane bound inhibitor (BAMBI) and mothers against decapentaplegic family member 6 (SMAD6) are targets of miR 20a that negatively regulate the BMP2 signaling pathway.
   Conclusions: MiR 20a is a novel mechanosensitive miRNA that can enhance osteoblast differentiation in FSS mechanical environments, implying that this miRNA might be a target for bone tissue engineering and orthodontic lime remodeling for regenerative medicine applications.
C1 [Peng, Zhuli; Mai, Zhihui; Xiao, Feng; Wang, Yixuan; Xie, Shanshan; Ai, Hong] Sun Yat Sen Univ, Dept Stomatol, Affiliated Hosp 3, 600 Tianhe Rd, Guangzhou 510630, Peoples R China.
   [Liu, Guanqi] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangzhou, Peoples R China.
   [Liu, Guanqi] Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Ai, H (通讯作者)，Sun Yat Sen Univ, Dept Stomatol, Affiliated Hosp 3, 600 Tianhe Rd, Guangzhou 510630, Peoples R China.
EM aih_zssy09@126.com
RI xie, shanshan/GSM 8999 2022; Peng, Shaoliang/JFS 1314 2023
FU National Natural Science Foundation of China [81470766]; Natural Science
   Foundation of Guangdong Province [81070860]; Projects of General Program
   By the Natural Science Foundation of Guangdong Province [2016A030313212]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81470766), the Natural Science Foundation of
   Guangdong Province (No. 81070860) and Projects of General Program By the
   Natural Science Foundation of Guangdong Province (No. 2016A030313212).
CR Aisha MD, 2015, EXP CELL RES, V337, P87, DOI 10.1016/j.yexcr.2015.07.002
   Chen Y, 2007, J CELL BIOCHEM, V102, P52, DOI 10.1002/jcb.21275
   Dong J, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0895 0
   Elashry MI, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02146 7
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Fritton SP, 2009, ANNU REV FLUID MECH, V41, P347, DOI 10.1146/annurev.fluid.010908.165136
   Galea GL, 2011, FEBS LETT, V585, P2450, DOI 10.1016/j.febslet.2011.06.019
   Guan YL, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06910 9
   Heath JM, 2018, CARDIOVASC ENG TECHN, V9, P141, DOI 10.1007/s13239 017 0296 z
   Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Kamiya N, 2011, BIOFACTORS, V37, P75, DOI 10.1002/biof.139
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li L, 2012, J CELL BIOCHEM, V113, P1235, DOI 10.1002/jcb.23457
   Li Y, 2016, J BIOMED MATER RES A, V104, P2978, DOI 10.1002/jbm.a.35848
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Liu DW, 2008, BONE, V42, P644, DOI 10.1016/j.bone.2007.09.058
   Liu LY, 2011, INT J BIOCHEM CELL B, V43, P1591, DOI 10.1016/j.biocel.2011.07.008
   Liu LY, 2010, BIOMECH MODEL MECHAN, V9, P659, DOI 10.1007/s10237 010 0206 x
   Liu L, 2017, CELL BIOL INT, V41, P112, DOI 10.1002/cbin.10704
   Luo T, 2020, CELLS TISSUES ORGANS, V208, P148, DOI 10.1159/000506304
   Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104
   Mai ZH, 2013, CHINESE MED J PEKING, V126, P1544, DOI 10.3760/cma.j.issn.0366 6999.20123137
   Mai ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061600
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Mu WY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136607
   Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223 004 0213 y
   Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794
   Prodanov L, 2013, ACTA BIOMATER, V9, P6653, DOI 10.1016/j.actbio.2013.02.011
   Qi L, 2014, CELL PHYSIOL BIOCHEM, V33, P433, DOI 10.1159/000358624
   Rath B, 2011, BIORHEOLOGY, V48, P37, DOI 10.3233/BIR 2011 0580
   Riddle RC, 2009, J ORTHOP RES, V27, P143, DOI 10.1002/jor.20723
   Sangani R, 2015, MOL CELL ENDOCRINOL, V410, P19, DOI 10.1016/j.mce.2015.01.007
   Schneider I, 2020, J MECH BEHAV BIOMED, V102, DOI 10.1016/j.jmbbm.2019.103481
   Shen R, 2006, J BIOL CHEM, V281, P3569, DOI 10.1074/jbc.M506761200
   Sun YX, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/412327
   Tang M, 2014, J PERIODONTOL, V85, P1806, DOI 10.1902/jop.2014.140244
   Tarbell JM, 2005, ANN BIOMED ENG, V33, P1719, DOI 10.1007/s10439 005 8775 z
   Tipanee J, 2020, MOL THER NUCL ACIDS, V19, P1309, DOI 10.1016/j.omtn.2020.01.015
   Wang H, 2016, SCI REP UK, V6, DOI 10.1038/srep23170
   Wang HN, 2019, MOL MED REP, V20, P4271, DOI 10.3892/mmr.2019.10676
   Wang LA, 2010, CELL PHYSIOL BIOCHEM, V26, P1093, DOI 10.1159/000323987
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang Y, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180448
   Wei FL, 2015, STEM CELLS DEV, V24, P312, DOI 10.1089/scd.2014.0191
   Yang MF, 2014, FEBS LETT, V588, P4761, DOI 10.1016/j.febslet.2014.11.008
   Zhang B, 2021, CONNECT TISSUE RES, V62, P194, DOI 10.1080/03008207.2019.1670650
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
   Zhang W, 2018, DNA CELL BIOL, V37, P199, DOI 10.1089/dna.2017.3936
   Zhou ML, 2014, ENDOCRINE, V45, P302, DOI 10.1007/s12020 013 9986 y
   Zuo B, 2015, J BONE MINER RES, V30, P330, DOI 10.1002/jbmr.2352
NR 52
TC 12
Z9 13
U1 0
U2 16
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305 5839
EI 2305 5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD JUN
PY 2022
VL 10
IS 12
AR 683
DI 10.21037/atm 22 2753
EA JUN 2022
PG 19
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 2U6TX
UT WOS:000822430900001
PM 35845505
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Gao, WH
   Li, JJ
   Shi, JY
   Lan, HB
   Guo, YY
   Fu, DH
AF Gao, Weihang
   Li, Jiao Jiao
   Shi, Jingyu
   Lan, Hongbing
   Guo, Yuanyuan
   Fu, Dehao
TI Ångstrom scale gold particles loaded with alendronate via alpha lipoic
   acid alleviate bone loss in osteoporotic mice
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Osteoporosis; Gold particles; & Aring;ngstrom; Alendronate; Bone
   targeting; Alpha lipoic acid
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; OSTEOCLAST
   DIFFERENTIATION; TURNOVER MARKERS; NANOPARTICLES; FUNCTIONALIZATION;
   NANOCLUSTERS; SIZE; STABILITY; THERAPY
AB Osteoporosis is a highly prevalent metabolic disease characterized by low systemic bone mass and deterioration of bone microarchitecture, resulting in reduced bone strength and increased fracture risk. Current treatment options for osteoporosis are limited by factors such as efficacy, cost, availability, side effects, and acceptability to patients. Gold nanoparticles show promise as an emerging osteoporosis therapy due to their osteogenic effects and ability to allow therapeutic delivery but have inherent constraints, such as low specificity and the potential for heavy metal accumulation in the body. This study reports the synthesis of ultrasmall gold particles almost reaching the & Aring;ngstrom (& Aring;ng) dimension. The antioxidant alpha lipoic acid (LA) is used as a dispersant and stabilizer to coat & Aring;ngstrom scale gold particles (Au & Aring;Ps). Alendronate (AL), an amino bisphosphonate commonly used in drug therapy for osteoporosis, is conjugated through LA to the surface of Au & Aring;Ps, allowing targeted delivery to bone and enhancing antiresorptive therapeutic effects. In this study, alendronate loaded & Aring;ngstrom scale gold particles (Au & Aring;Ps AL) were used for the first time to promote osteogenesis and alleviate bone loss through regulation of the WNT signaling pathway, as shown through in vitro tests. The in vivo therapeutic effects of Au & Aring;Ps AL were demonstrated in an established osteoporosis mouse model. The results of Micro computed Tomography, histology, and tartrate resistant acid phosphatase staining indicated that Au & Aring;Ps AL significantly improved bone density and prevented bone loss, with no evidence of nanoparticle associated toxicity. These findings suggest the possible future application of Au & Aring;Ps AL in osteoporosis therapy and point to the potential of developing new approaches for treating metabolic bone diseases using & Aring;ngstrom scale gold particles.
C1 [Gao, Weihang; Fu, Dehao] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 6, Dept Orthopaed, Shanghai 200233, Peoples R China.
   [Gao, Weihang; Shi, Jingyu; Guo, Yuanyuan] Huazhong Univ Sci & Technol, Liyuan Hosp, Tongji Med Coll, Wuhan 430077, Peoples R China.
   [Li, Jiao Jiao] Univ Technol Sydney, Sch Biomed Engn, Fac Engn & IT, Sydney, NSW 2007, Australia.
   [Lan, Hongbing] Huazhong Univ Sci & Technol, Tongji Sch Pharm, Wuhan 430030, Peoples R China.
   [Guo, Yuanyuan] Huazhong Univ Sci & Technol, Hubei Key Lab Metab Abnormal & Vasc Aging, Wuhan 430077, Peoples R China.
C3 Shanghai Jiao Tong University; Huazhong University of Science &
   Technology; University of Technology Sydney; Huazhong University of
   Science & Technology; Huazhong University of Science & Technology
RP Fu, DH (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 6, Dept Orthopaed, Shanghai 200233, Peoples R China.; Guo, YY (通讯作者)，Huazhong Univ Sci & Technol, Liyuan Hosp, Tongji Med Coll, Wuhan 430077, Peoples R China.; Guo, YY (通讯作者)，Huazhong Univ Sci & Technol, Hubei Key Lab Metab Abnormal & Vasc Aging, Wuhan 430077, Peoples R China.
EM yuanyuanguo@hust.edu.cn; fudehao@sjtu.edu.cn
RI ; Li, Jiao Jiao/W 3268 2019; Fu, Dehao/AAM 4137 2020; Gao,
   Weihang/AAR 9477 2020; guo, yuanyuan/GXM 6237 2022
OI Li, Jiao Jiao/0000 0002 3584 6765; Fu, Dehao/0000 0002 9295 1692; 
FU National Natural Science Foundation of China [82070911, 82370889];
   Intramural Research Program of Liyuan Hospital [2023LYYYGZRP0002]
FX This research has been funded by the National Natural Science Foundation
   of China (82070911 and 82370889) and The Intramural Research Program of
   Liyuan Hospital (No. 2023LYYYGZRP0002).
CR Abdelhalim MAK, 2020, INT J NANOMED, V15, P729, DOI 10.2147/IJN.S192740
   Abdelhalim MAK, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476 511X 10 163
   Alvarez MM, 2016, J PHYS CHEM B, V120, P6430, DOI 10.1021/acs.jpcb.6b04525
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Bolaños K, 2019, INT J NANOMED, V14, P6387, DOI 10.2147/IJN.S210992
   Borromeo GL, 2014, J BONE MINER RES, V29, P1363, DOI 10.1002/jbmr.2179
   Brown C, 2017, Nature, V550, DOI [10.1038/550S15a.p.S15 S17, DOI 10.1038/550S15A.P.S15 S17]
   Chappard D., 2008, Morphologie, V92, P162, DOI 10.1016/j.morpho.2008.10.003
   Chen LY, 2015, ANAL CHEM, V87, P216, DOI 10.1021/ac503636j
   Chen MM, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202101049
   Chen YQ, 2023, J NANOBIOTECHNOL, V21, DOI 10.1186/s12951 023 01872 9
   Choi HS, 2007, NAT BIOTECHNOL, V25, P1165, DOI 10.1038/nbt1340
   Choi SY, 2015, INT J NANOMED, V10, P4383, DOI 10.2147/IJN.S78775
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cui YZ, 2022, BIOACT MATER, V10, P207, DOI 10.1016/j.bioactmat.2021.09.015
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Fan M, 2020, THERANOSTICS, V10, P4944, DOI 10.7150/thno.42471
   Fuchs RK, 2008, J BONE MINER RES, V23, P1689, DOI [10.1359/jbmr.080501, 10.1359/JBMR.080501]
   Ghann William, 2019, J Nanomed Nanotechnol, V10, DOI 10.35248/2157 7439.19.10.539
   Guo YY, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00976 4
   Heo DN, 2014, ACS NANO, V8, P12049, DOI 10.1021/nn504329u
   Heo JS, 2010, MOL CELLS, V30, P449, DOI 10.1007/s10059 010 0139 3
   Hoque J, 2021, BIOMATERIALS, V273, DOI 10.1016/j.biomaterials.2021.120819
   Ivanov MR, 2009, ACS NANO, V3, P386, DOI 10.1021/nn8005619
   Jiang J, 2014, J PHYS CHEM C, V118, P20680, DOI 10.1021/jp5060217
   Jin RC, 2015, NANOSCALE, V7, P1549, DOI 10.1039/c4nr05794e
   Kim BJ, 2020, ENDOCRINOL METAB, V35, P55, DOI 10.3803/EnM.2020.35.1.55
   Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066
   Ko WK, 2015, J COLLOID INTERF SCI, V438, P68, DOI 10.1016/j.jcis.2014.08.058
   Lee JW, 2021, ACS APPL MATER INTER, V13, P42311, DOI 10.1021/acsami.1c10436
   Lee MS, 2016, INT J NANOMED, V11, P4583, DOI 10.2147/IJN.S112415
   Li K, 2020, INT J NANOMED, V15, P4705, DOI 10.2147/IJN.S241163
   Li XY, 2019, BIOMATER SCI UK, V7, P2861, DOI 10.1039/c9bm00242a
   Liang H, 2019, INT J NANOMED, V14, P6151, DOI 10.2147/IJN.S213889
   Liao VS, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 37664 w
   Lin SY, 2004, J PHYS CHEM B, V108, P2134, DOI 10.1021/jp036310w
   Lloyd AA, 2017, P NATL ACAD SCI USA, V114, P8722, DOI 10.1073/pnas.1704460114
   Luhmann T, 2012, J CONTROL RELEASE, V161, P198, DOI 10.1016/j.jconrel.2011.10.001
   Ma XW, 2011, ACS NANO, V5, P8629, DOI 10.1021/nn202155y
   Naylor K, 2012, NAT REV RHEUMATOL, V8, P379, DOI 10.1038/nrrheum.2012.86
   OOMS ME, 1993, J BONE MINER RES, V8, P669
   Ossipov DA, 2015, EXPERT OPIN DRUG DEL, V12, P1443, DOI 10.1517/17425247.2015.1021679
   Cattalini J, 2012, TISSUE ENG PART B RE, V18, P323, DOI 10.1089/ten.teb.2011.0737
   Panahifar A, 2013, ACS APPL MATER INTER, V5, P5219, DOI 10.1021/am4010495
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Phillipi CA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub2
   Pignatello R, 2009, NANOMEDICINE UK, V4, P161, DOI 10.2217/17435889.4.2.161
   Ravichandran R, 2012, BIOMATERIALS, V33, P846, DOI 10.1016/j.biomaterials.2011.10.030
   Roux S, 2005, LANGMUIR, V21, P2526, DOI 10.1021/la048082i
   Ruks T, 2021, ACS APPL BIO MATER, V4, P945, DOI 10.1021/acsabm.0c01424
   Schmidt P, 2023, ANGEW CHEM INT EDIT, V62, DOI 10.1002/anie.202210140
   Sen B, 2008, ENDOCRINOLOGY, V149, P6065, DOI 10.1210/en.2008 0687
   Shang L, 2011, SMALL, V7, P2614, DOI 10.1002/smll.201100746
   Tatangelo G, 2019, J BONE MINER RES, V34, P616, DOI 10.1002/jbmr.3640
   Tay CY, 2014, NANO LETT, V14, P83, DOI 10.1021/nl4032549
   Xi YH, 2023, ARTIF CELL NANOMED B, V51, P131, DOI 10.1080/21691401.2022.2149542
   Xia HB, 2016, LANGMUIR, V32, P5870, DOI 10.1021/acs.langmuir.6b01312
   Yao H, 2021, BIOACT MATER, V6, P1341, DOI 10.1016/j.bioactmat.2020.10.016
   Ye TJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186012
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Zeng L, 2019, J NANOSCI NANOTECHNO, V19, P2166, DOI 10.1166/jnn.2019.15764
   Zhang BH, 2021, SMALL, V17, DOI 10.1002/smll.202004381
   Zhang GD, 2009, BIOMATERIALS, V30, P1928, DOI 10.1016/j.biomaterials.2008.12.038
   Zhang HF, 2023, ACTA PHARMACOL SIN, V44, P1051, DOI 10.1038/s41401 022 00997 1
   Zhao XF, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0085 4
   Zheng J, 2007, ANNU REV PHYS CHEM, V58, P409, DOI 10.1146/annurev.physchem.58.032806.104546
   Zheng J, 2012, NANOSCALE, V4, P4073, DOI 10.1039/c2nr31192e
   Zhu GH, 2021, ACS APPL MATER INTER, V13, P23410, DOI 10.1021/acsami.1c02834
NR 70
TC 6
Z9 6
U1 8
U2 28
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD APR 30
PY 2024
VL 22
IS 1
AR 212
DI 10.1186/s12951 024 02466 9
PG 18
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA OY5B9
UT WOS:001210840600001
PM 38689294
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Galea, GL
   Lanyon, LE
   Price, JS
AF Galea, Gabriel L.
   Lanyon, Lance E.
   Price, Joanna S.
TI Sclerostin's role in bone's adaptive response to mechanical loading
SO BONE
LA English
DT Article
ID ESTROGEN RECEPTOR ALPHA; HUMAN OSTEOBLASTIC CELLS; SOST DOWN REGULATION;
   GROWTH FACTOR I; OSTEOGENIC RESPONSE; CORTICAL BONE;
   PARATHYROID HORMONE; SHEAR STRESS; OSTEOCYTES; EXPRESSION
AB Mechanical loading is the primary functional determinant of bone mass and architecture, and osteocytes play a key role in translating mechanical signals into (re)modelling responses. Although the precise mechanisms remain unclear, Wnt signalling pathway components, and the anti osteogenic canonical Wnt inhibitor Sost/sclerostin in particular, play an important role in regulating bone's adaptive response to loading. Increases in loading engendered.strains down regulate osteocyte sclerostin expression, whereas reduced strains, as in disuse, are associated with increased sclerostin production and bone loss. However, while sclerostin up regulation appears to be necessary for the loss of bone with disuse, the role of sclerostin in the osteogenic response to loading is more complex. While mice unable to down regulate sclerostin do not gain bone with loading, Sost knockout mice have an enhanced osteogenic response to loading. The molecular mechanisms by which osteocytes sense and transduce loading related stimuli into changes in sclerostin expression remain unclear but include several, potentially interlinked, signalling cascades involving periostin/integrin, prostaglandin, estrogen receptor, calcium/NO and lgf signalling. Deciphering the mechanisms by which changes in the mechanical environment regulate sclerostin production may lead to the development of therapeutic strategies that can reverse the skeletal structural deterioration characteristic of disuse and age related osteoporosis and enhance bones' functional adaptation to loading. By enhancing the osteogenic potential of the context in which individual therapies such as sclerostin antibodies act it may become possible to both prevent and reverse the age related skeletal structural deterioration characteristic of osteoporosis. (C) 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Galea, Gabriel L.] UCL, Inst Child Hlth, Newlife Birth Defects Res Ctr, London WCIN LEH, England.
   [Galea, Gabriel L.; Lanyon, Lance E.; Price, Joanna S.] Univ Bristol, Sch Vet Sci, Langford House, Bristol BS40 5DU, Avon, England.
C3 University of London; University College London; University of Bristol
RP Galea, GL (通讯作者)，Inst Child Hlth, Dev Biol Birth Defects, W2 02 2nd Floor,Wellcome Trust Bldg, London WC1N 1EH, England.
EM g.galea@ucl.ac.uk
RI ; Galea, Gabriel/I 9374 2019
OI Galea, Gabriel/0000 0003 2515 1342; 
FU Wellcome Trust [107474/Z/15/Z]; Wellcome Trust [107474/Z/15/Z] Funding
   Source: Wellcome Trust
FX All authors declare they have no conflicts of interest. GLG is supported
   by a Postdoctoral Training Fellowship for Clinicians from the Wellcome
   Trust [107474/Z/15/Z].
CR Aguirre JI, 2007, J BIOL CHEM, V282, P25501, DOI 10.1074/jbc.M702231200
   Almeida M., 2012, BONEKEY REP, V1, P1
   Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Atkins GJ, 2011, J BONE MINER RES, V26, P1425, DOI 10.1002/jbmr.345
   Baertschi S, 2014, J BIOL CHEM, V289, P24995, DOI 10.1074/jbc.M114.564997
   Bao XF, 2013, INT J MOL SCI, V14, P21140, DOI 10.3390/ijms141021140
   Batra N, 2012, P NATL ACAD SCI USA, V109, P3359, DOI 10.1073/pnas.1115967109
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Bonnet N, 2009, J BIOL CHEM, V284, P35939, DOI 10.1074/jbc.M109.060335
   Callewaert F, 2010, J BONE MINER RES, V25, P124, DOI 10.1359/jbmr.091001
   Castillo AB, 2014, AM J PHYSIOL ENDOC M, V306, pE937, DOI 10.1152/ajpendo.00458.2013
   Cohen Kfir E, 2011, ENDOCRINOLOGY, V152, P4514, DOI 10.1210/en.2011 1128
   Delgado Calle J, 2014, CALCIFIED TISSUE INT, V94, P414, DOI 10.1007/s00223 013 9821 8
   Delgado Calle J, 2012, J BONE MINER RES, V27, P926, DOI 10.1002/jbmr.1491
   Farr JN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138347
   FROST HM, 1987, BONE MINER, V2, P73
   Fujita M, 2013, J BIOL CHEM, V288, P3059, DOI 10.1074/jbc.M112.412536
   Galea Gabriel L, 2013, Bonekey Rep, V2, P413, DOI 10.1038/bonekey.2013.147
   Galea GL, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00052
   Galea GL, 2015, J BONE MINER RES, V30, P411, DOI 10.1002/jbmr.2377
   Galea GL, 2013, J BIOL CHEM, V288, P9035, DOI 10.1074/jbc.M112.405456
   Galea GL, 2011, FEBS LETT, V585, P2450, DOI 10.1016/j.febslet.2011.06.019
   Galli C, 2010, J DENT RES, V89, P331, DOI 10.1177/0022034510363963
   Grimston SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044222
   Hagino H, 2005, BONE, V36, P444, DOI 10.1016/j.bone.2004.12.013
   Hassan MQ, 2012, J BIOL CHEM, V287, P42084, DOI 10.1074/jbc.M112.377515
   Holguin N, 2016, J BONE MINER RES
   Ide S, 2010, NEUROPHARMACOLOGY, V58, P241, DOI 10.1016/j.neuropharm.2009.07.005
   Ishihara Y, 2013, BONE, V53, P204, DOI 10.1016/j.bone.2012.12.002
   Jilka RL, 2010, J BONE MINER RES, V25, P2427, DOI 10.1002/jbmr.145
   Kamel MA, 2010, BONE, V47, P872, DOI 10.1016/j.bone.2010.08.007
   Kaneko K, 2014, BIOCHEM BIOPH RES CO, V447, P352, DOI 10.1016/j.bbrc.2014.04.006
   Kang KS, 2015, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00246
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Kitase Y, 2010, J BONE MINER RES, V25, P2381, DOI 10.1002/jbmr.168
   Kogawa M, 2013, J BONE MINER RES, V28, P2436, DOI 10.1002/jbmr.2003
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Lara Castillo N, 2015, BONE, V76, P58, DOI 10.1016/j.bone.2015.03.019
   Lau KHW, 2013, AM J PHYSIOL ENDOC M, V305, pE271, DOI 10.1152/ajpendo.00092.2013
   Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li GH, 2010, ATHEROSCLEROSIS, V208, P358, DOI 10.1016/j.atherosclerosis.2009.07.046
   Liedert A., 2005, MECHANOSENSITIVITY C
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Mamalis A, 2011, ARCH ORAL BIOL, V56, P446, DOI 10.1016/j.archoralbio.2010.11.001
   Meakin LB, 2015, OSTEOPOROSIS INT, V26, P2703, DOI 10.1007/s00198 015 3142 x
   Meakin LB, 2014, J BONE MINER RES, V29, P1859, DOI 10.1002/jbmr.2222
   Melville KM, 2015, J BONE MINER RES, V30, P1468, DOI 10.1002/jbmr.2488
   Morse A, 2014, J BONE MINER RES, V29, P2456, DOI 10.1002/jbmr.2278
   Moustafa A, 2012, OSTEOPOROSIS INT, V23, P1225, DOI 10.1007/s00198 011 1656 4
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Ott CE, 2009, J BONE MINER RES, V24, P1247, DOI [10.1359/JBMR.090206, 10.1359/jbmr.090206]
   Palazzini S, 1998, ANAT EMBRYOL, V197, P349, DOI 10.1007/s004290050145
   Pérez Campo FM, 2016, CALCIFIED TISSUE INT, V99, P302, DOI 10.1007/s00223 016 0144 4
   Pérez Campo FM, 2014, CALCIFIED TISSUE INT, V95, P194, DOI 10.1007/s00223 014 9880 5
   Rangaswami H, 2012, J BIOL CHEM, V287, P21509, DOI 10.1074/jbc.M112.347245
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   RUBIN CT, 1987, J ORTHOP RES, V5, P300, DOI 10.1002/jor.1100050217
   Saegusa J, 2009, J BIOL CHEM, V284, P24106, DOI 10.1074/jbc.M109.013201
   Saxon LK, 2011, BONE, V49, P184, DOI 10.1016/j.bone.2011.03.683
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Sen B, 2011, STEM CELLS, V29, P1829, DOI 10.1002/stem.732
   Sevetson B, 2004, J BIOL CHEM, V279, P13849, DOI 10.1074/jbc.M306249200
   Sinnesael M, 2015, ENDOCRINOLOGY, V156, P1343, DOI 10.1210/en.2014 1673
   Skerry T. M., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P122
   SKERRY TM, 1989, J BONE MINER RES, V4, P783, DOI 10.1002/jbmr.5650040519
   Sugiyama A., 2016, J GASTROENTEROL
   Sun QL, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.26
   Sunters A, 2010, J BIOL CHEM, V285, P8743, DOI 10.1074/jbc.M109.027086
   Sutherland MK, 2004, BONE, V35, P828, DOI 10.1016/j.bone.2004.05.023
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Thompson WR, 2012, GENE, V503, P179, DOI 10.1016/j.gene.2012.04.076
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.126
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   van Bezooijen RL, 2007, J BONE MINER RES, V22, P19, DOI 10.1359/JBMR.061002
   Wallace DP, 2008, AM J PHYSIOL RENAL, V295, pF1463, DOI 10.1152/ajprenal.90266.2008
   Wein Marc N, 2015, J Bone Miner Res, V30, P400, DOI 10.1002/jbmr.2381
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Windahl SH, 2013, P NATL ACAD SCI USA, V110, P2294, DOI 10.1073/pnas.1220811110
   Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Yu LC, 2011, BONE, V49, P1131, DOI 10.1016/j.bone.2011.08.016
   Zaman G, 2000, BONE, V27, P233, DOI 10.1016/S8756 3282(00)00324 0
   Zaman G, 2010, BONE, V46, P628, DOI 10.1016/j.bone.2009.10.021
NR 90
TC 104
Z9 120
U1 0
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2017
VL 96
BP 38
EP 44
DI 10.1016/j.bone.2016.10.008
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EN2OR
UT WOS:000395850300007
PM 27742499
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Jiang, T
   Qin, A
   Shao, ZY
   Tian, B
   Zhai, ZJ
   Li, HW
   Zhu, ZA
   Dai, KR
   Ming, HZ
   Yu, YP
   Jiang, Q
AF Jiang, T.
   Qin, A.
   Shao, Z. Y.
   Tian, B.
   Zhai, Z. J.
   Li, H. W.
   Zhu, Z. A.
   Dai, K. R.
   Ming, H. Zheng
   Yu, Y. P.
   Jiang, Q.
TI OA10 Is a Novel p38alpha Mitogen Activated Protein Kinase Inhibitor That
   Suppresses Osteoclast Differentiation and Bone Resorption
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE O10; OSTEOCLAST DIFFERENTIATION; p38alpha; c Fos NFATc1
ID NF KAPPA B; C FOS; P38 MAPK; TRANSCRIPTION FACTOR; NUCLEAR FACTOR;
   NFATC1; INDUCTION; COMPLEX; TARGET
AB In search of anti bone resorbing agents for the potential treatment of osteoporosis, we synthesized a novel compound Tert butyl 4 (3 [1H indole 2 carboxamido]benzoyl)piperazine 1 carboxylate (OA10) and found that OA10 is capable of inhibiting RANKL mediated osteoclast formation and osteoclastic bone resorption in a dose dependent manner. This biological effect is further supported by the fact that OA10 suppressed osteoclastic specific gene expression, including tartrate resistant acid phosphatase, cathepsin K receptor, and calcitonin receptor. Further molecular mechanism investigation revealed OA10 inhibited p38 phosphorylation, suppressed c fos and NFATc1 expression without affecting NF B or JNK signaling pathways. Taken together, this study suggested that OA10 can inhibit osteoclastogenesis by suppressing p38 c Fos NFATc1 cascade. OA10 may be developed as a therapeutic drug for osteoclast related osteolytic diseases. J. Cell. Biochem. 115: 959 966, 2014. (c) 2013 Wiley Periodicals, Inc.
C1 [Jiang, T.; Jiang, Q.] Nanjing Med Univ, Drum Tower Clin Med Coll, Ctr Diag & Treatment Joint Dis, Nanjing 210008, Jiangsu, Peoples R China.
   [Qin, A.; Ming, H. Zheng] Univ Western Australia, Sch Surg, Ctr Orthopaed Res, Perth, WA 6009, Australia.
   [Qin, A.; Tian, B.; Zhai, Z. J.; Li, H. W.; Zhu, Z. A.; Dai, K. R.] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants,Dept Orthopae, Shanghai 200030, Peoples R China.
   [Shao, Z. Y.; Yu, Y. P.] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
C3 Nanjing Medical University; University of Western Australia; Shanghai
   Jiao Tong University; Zhejiang University
RP Jiang, Q (通讯作者)，Nanjing Med Univ, Drum Tower Clin Med Coll, Ctr Diag & Treatment Joint Dis, Zhongshan Rd 321, Nanjing 210008, Jiangsu, Peoples R China.
EM yyu@zju.edu.cn; jiangqing112@hotmail.com
RI Qin, An/J 2518 2019; Jiang, Qing/JXM 6827 2024; zhang,
   xuyang/GQH 3712 2022
OI Zheng, Minghao/0000 0003 1185 4768
FU National Nature Science Foundation of China [81101338, 81125013];
   National Health and Medical Research Council [1010420]; Shanghai
   Municipal Education Commission [13YZ031]; National Natural Science
   Foundation for the Youth of China [81201364]
FX Grant sponsor: National Nature Science Foundation of China; Grant
   numbers: 81101338, 81125013; Grant sponsor: National Health and Medical
   Research Council; Grant number: 1010420; Grant sponsor: Shanghai
   Municipal Education Commission; Grant number: 13YZ031; Grant sponsor:
   National Natural Science Foundation for the Youth of China; Grant
   number: 81201364.
CR Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756 3282(99)00105 2
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Chambers TJ, 2000, J PATHOL, V192, P4
   Choi SW, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/810563
   Cohen S, 2010, CURR OPIN RHEUMATOL, V22, P330, DOI 10.1097/BOR.0b013e3283378e6f
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hill RJ, 2008, J PHARMACOL EXP THER, V327, P610, DOI 10.1124/jpet.108.139006
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Izawa T, 2012, MOL CELL BIOL, V32, P2943, DOI 10.1128/MCB.00077 12
   Lee Eun Gyeong, 2010, Korean Journal of Internal Medicine, V25, P93, DOI 10.3904/kjim.2010.25.1.93
   Li HW, 2013, BIOCHEM BIOPH RES CO, V430, P951, DOI 10.1016/j.bbrc.2012.12.051
   Lucas JJ, 1998, J NEUROSCI, V18, P5537, DOI 10.1523/JNEUROSCI.18 14 05537.1998
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   Matsumoto M, 2000, FEBS LETT, V486, P23, DOI 10.1016/S0014 5793(00)02231 6
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mozar A, 2012, NEPHROL DIAL TRANSPL, V27, P2176, DOI 10.1093/ndt/gfr647
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132
   Qin A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027155
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sharma SM, 2007, J BIOL CHEM, V282, P15921, DOI 10.1074/jbc.M609723200
   Simic P, 2006, J BIOL CHEM, V281, P25509, DOI 10.1074/jbc.M513276200
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Vanderkerken K, 2007, CANCER RES, V67, P4572, DOI 10.1158/0008 5472.CAN 06 4361
   Wisutsitthiwong C, 2011, BIOCHEM BIOPH RES CO, V415, P361, DOI 10.1016/j.bbrc.2011.10.073
   Wrobleski ST, 2013, BIOORG MED CHEM LETT, V23, P4120, DOI 10.1016/j.bmcl.2013.05.047
   Xing L, 2012, CHEMMEDCHEM, V7, P273, DOI 10.1002/cmdc.201100439
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Zwerina J, 2006, ARTHRITIS RHEUM US, V54, P463, DOI 10.1002/art.21626
NR 34
TC 4
Z9 4
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY
PY 2014
VL 115
IS 5
BP 959
EP 966
DI 10.1002/jcb.24744
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AC2OF
UT WOS:000332340300017
PM 24357524
OA Bronze
DA 2025 08 17
ER

PT J
AU Rauch, DA
   Hurchla, MA
   Harding, JC
   Deng, HJ
   Shea, LK
   Eagleton, MC
   Niewiesk, S
   Lairmore, MD
   Piwnica Worms, D
   Rosol, TJ
   Weber, JD
   Ratner, L
   Weilbaecher, KN
AF Rauch, Daniel A.
   Hurchla, Michelle A.
   Harding, John C.
   Deng, Hongju
   Shea, Lauren K.
   Eagleton, Mark C.
   Niewiesk, Stefan
   Lairmore, Michael D.
   Piwnica Worms, David
   Rosol, Thomas J.
   Weber, Jason D.
   Ratner, Lee
   Weilbaecher, Katherine N.
TI The ARF Tumor Suppressor Regulates Bone Remodeling and Osteosarcoma
   Development in Mice
SO PLOS ONE
LA English
DT Article
ID CONTAINING BISPHOSPHONATES INHIBIT; ZOLEDRONIC ACID; IN VIVO;
   NEUROFIBROMATOSIS TYPE 1; DEFICIENT MICE; GENE; P53; RETINOBLASTOMA;
   OSTEOCLAST; PATHWAY
AB The ARF tumor suppressor regulates p53 as well as basic developmental processes independent of p53, including osteoclast activation, by controlling ribosomal biogenesis. Here we provide evidence that ARF is a master regulator of bone remodeling and osteosarcoma (OS) development in mice. Arf( / ) mice displayed increased osteoblast (OB) and osteoclast (OC) activity with a significant net increase in trabecular bone volume. The long bones of Arf( / ) mice had increased expression of OB genes while Arf( / ) OB showed enhanced differentiation in vitro. Mice transgenic for the Tax oncogene develop lymphocytic tumors with associated osteolytic lesions, while Tax+Arf( / ) mice uniformly developed spontaneous OS by 7 months of age. Tax+Arf( / ) tumors were well differentiated OS characterized by an abundance of new bone with OC recruitment, expressed OB markers and displayed intact levels of p53 mRNA and reduced Rb transcript levels. Cell lines established from OS recapitulated characteristics of the primary tumor, including the expression of mature OB markers and ability to form mineralized tumors when transplanted. Loss of heterozygosity in OS tumors arising in Tax+Arf(+/ ) mice emphasized the necessity of ARF loss in OS development. Hypothesizing that inhibition of ARF regulated bone remodeling would repress development of OS, we demonstrated that treatment of Tax+Arf( / ) mice with zoledronic acid, a bisphosphonate inhibitor of OC activity and repressor of bone turnover, prevented or delayed the onset of OS. These data describe a novel role for ARF as a regulator of bone remodeling through effects on both OB and OC. Finally, these data underscore the potential of targeting bone remodeling as adjuvant therapy or in patients with genetic predispositions to prevent the development of OS.
C1 [Rauch, Daniel A.; Hurchla, Michelle A.; Harding, John C.; Deng, Hongju; Shea, Lauren K.; Eagleton, Mark C.; Weber, Jason D.; Ratner, Lee; Weilbaecher, Katherine N.] Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA.
   [Niewiesk, Stefan; Lairmore, Michael D.; Rosol, Thomas J.] Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA.
   [Niewiesk, Stefan; Lairmore, Michael D.] Ohio State Univ, Ctr Retrovirus Res, Dept Vet Biosci, Columbus, OH 43210 USA.
   [Piwnica Worms, David] Washington Univ, Sch Med, Mol Imaging Ctr, Mallinckrodt Inst Radiol,Dept Dev Biol, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); University System of Ohio; Ohio State
   University; University System of Ohio; Ohio State University; Washington
   University (WUSTL)
RP Rauch, DA (通讯作者)，Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA.
EM KWEILBAE@WUSTL.EDU
RI ; Weber, Jason/KIJ 6396 2024; Rosol, Thomas/G 9585 2011
OI Rosol, Thomas/0000 0003 3737 1190; Ratner, Lee/0000 0003 2744 7294;
   Shea, Lauren/0000 0002 3584 9296; Weber, Jason/0000 0002 1069 6983; 
FU National Institutes of Health [T32 CA113275, P01 CA100730, P50 CA94056,
   R01 CA120436, CA10521, CA63417]; St. Louis Mens' Group Against Cancer
FX This research was supported by grants from the National Institutes of
   Health to MAH (T32 CA113275), MDL (P01 CA100730), DP W (P50 CA94056),
   TJR (P01 CA100730), JDW (R01 CA120436), LR (CA10521, CA63417, P01
   CA100730), KNW, MAH, HD, LKS, MCE (P01 CA100730) and from the St. Louis
   Mens' Group Against Cancer to KNW. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR AFT R, LANCET ONCOL, V11, P421
   Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535 7163.MCT 08 0530
   Apicelli AJ, 2008, MOL CELL BIOL, V28, P1068, DOI 10.1128/MCB.00484 07
   Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105
   Birch JM, 2001, ONCOGENE, V20, P4621, DOI 10.1038/sj.onc.1204621
   Brady SN, 2009, ONCOGENE, V28, P3209, DOI 10.1038/onc.2009.178
   Brown HK, 2009, CURR CANCER DRUG TAR, V9, P807, DOI 10.2174/156800909789760339
   Campbell KJ, 2006, CANCER RES, V66, P929, DOI 10.1158/0008 5472.CAN 05 2234
   Chirgwin JM, 2007, J CELL BIOCHEM, V102, P1333, DOI 10.1002/jcb.21556
   Chowdhry M, 2009, J BONE JOINT SURG BR, V91B, P1223, DOI 10.1302/0301 620X.91B9.22299
   Christiansen BA, 2006, ANN BIOMED ENG, V34, P1149, DOI 10.1007/s10439 006 9133 5
   Cinamon U, 2002, EUR ARCH OTO RHINO L, V259, P540, DOI 10.1007/s00405 002 0497 3
   Edwards CM, 2008, BONE, V42, P1007, DOI 10.1016/j.bone.2008.01.027
   Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658
   Eischen CM, 2002, CANCER RES, V62, P2184
   Gao L, 2005, BLOOD, V106, P4294, DOI 10.1182/blood 2005 04 1730
   Gross S, 2009, NAT MED, V15, P455, DOI 10.1038/nm.1886
   GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216
   Hapidin H, 2007, J BONE MINER METAB, V25, P93, DOI 10.1007/s00774 006 0733 9
   Hirbe AC, 2009, BONE, V44, P908, DOI 10.1016/j.bone.2009.01.010
   Horiuchi K, 2003, J RHEUMATOL, V30, P1799
   Huang CY, 2009, J CELL PHYSIOL, V221, P204, DOI 10.1002/jcp.21846
   Kamijo T, 1999, CANCER RES, V59, P2217
   Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092 8674(00)80452 3
   Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Lane NE, 2005, J BONE MINER RES, V20, P58, DOI 10.1359/JBMR.041017
   LeRoy BE, 2006, PROSTATE, V66, P1213, DOI 10.1002/pros.20408
   Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luo H, 2005, BLOOD, V106, P2452, DOI 10.1182/blood 2005 02 0734
   McKeller RN, 2002, P NATL ACAD SCI USA, V99, P3848, DOI 10.1073/pnas.052484199
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   O'Day K, 2009, EXPERT REV ANTICANC, V9, P511, DOI [10.1586/era.09.7, 10.1586/ERA.09.7]
   Oh JH, 2006, CLIN ORTHOP RELAT R, P216, DOI 10.1097/01.blo.0000188063.56091.69
   PICARDA G, CLIN CANC RES, V16, P2363
   Portis T, 2001, J VIROL, V75, P2185, DOI 10.1128/JVI.75.5.2185 2193.2001
   Rauch D, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742 4690 6 116
   Rauch D, 2009, BLOOD, V113, P1493, DOI 10.1182/blood 2008 07 166462
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Saporita AJ, 2007, CURR MED CHEM, V14, P1815
   Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017
   Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200
   Tiffee JC, 1999, CALCIFIED TISSUE INT, V65, P53, DOI 10.1007/s002239900657
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   WADAYAMA B, 1994, CANCER RES, V54, P3042
   Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808
   Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008 5472.CAN 04 3135
   Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106
   Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991
   Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300
   Xu ZQ, 2009, J BIOL CHEM, V284, P4658, DOI 10.1074/jbc.M804812200
   Zaidi SK, 2007, P NATL ACAD SCI USA, V104, P19861, DOI 10.1073/pnas.0709650104
   Zhou ZC, 2005, CANCER AM CANCER SOC, V104, P1713, DOI 10.1002/cncr.21383
   Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424
   Zucchini C, 2008, INT J ONCOL, V32, P17
NR 61
TC 18
Z9 22
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 30
PY 2010
VL 5
IS 12
AR e15755
DI 10.1371/journal.pone.0015755
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 701DD
UT WOS:000285793600032
PM 21209895
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Zhu, MS
   Shan, J
   Xu, HE
   Xia, GM
   Xu, Q
   Quan, K
   Liu, XQ
   Dai, M
AF Zhu, Meisong
   Shan, Jing
   Xu, Huaen
   Xia, Guoming
   Xu, Qiang
   Quan, Kun
   Liu, Xuqiang
   Dai, Min
TI Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and
   osteoporosis induced by ovariectomy by inhibiting the NF xB and Akt
   pathways
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Glaucocalyxin A; Osteoclastogenesis; Ovariectomized mice; NF xB; Akt;
   Osteoporosis
ID KAPPA B; POSTMENOPAUSAL OSTEOPOROSIS; DIFFERENTIATION; DENOSUMAB; WOMEN
AB Ethnopharmacological relevance: Glaucocalyxin A (GLA), the most abundant active component of the aboveground sections of Rabdosia japonica (Burm. f.) Hara var. glaucocalyx (Maxim.) Hara, possesses various pharmacological activities, such as antioxidant, antithrombosis, anticoagulation, antibacterial, antitumor, anti inflammatory activities. According to previous studies, inflammation is closely associated with osteoclast differentiation and activity. Although GLA has demonstrated effective anti inflammatory properties, its effects on osteoclast differentiation remain unclear.
   Aim of the study: To examine the possible inhibitory effects of GLA and its molecular mechanisms in osteogenesis induced by RANKL as well as ovariectomy (OVX) induced osteoporosis (OP) in mice.
   Materials and methods: Tartrate resistant acid phosphatase (TRAP) staining, F actin staining, and a bone resorption pit assay were applied for identifying the effects of GLA on the differentiation of osteoclasts and the function of bone resorption. The mRNA expression of the genes related to osteoclast differentiation was measured by quantitative PCR. Protein expression of nuclear factor of activated T cells, cytoplasmic 1 (NFATc1), c fos and phosphorylation of inhibitor of nuclear factor kappa B (IxB alpha), protein kinase B (AKT), c Jun N terminal kinase (JNK), extracellular signal regulated kinase (ERK), and p38 in RANKL induced osteoclasts was determined using western blotting. The effect of GLA on OP was studied using a mouse model of OVX.
   Results: At nontoxic concentrations <= 0.5 pM in vitro, GLA suppressed the formation of osteoclasts induced by RANKL with the decreased number and area size of TRAP positive multinuclear osteoclasts, and the resorption of bone function by reducing F actin ring number and bone resorption pit areas. It also reduced the expression of the genes specific for osteoclasts, which included genes encoding NFATc1, cathepsin K, c fos, TRAP, vacuolartype ATPase d2, and dendritic cell specific transmembrane protein. Moreover, GLA repressed NF xB and Akt pathway activation induced by RANKL. Micro CT analysis of femur samples indicated decreased bone loss and greater trabecular bone density after GLA treatment, which showed that GLA played a protective role by inhibiting bone loss in OVX induced OP mice in vivo.
   Conclusions: Our study is the first to show that GLA has significant therapeutic potential in OP, which is the disease of osteoclast increase caused by estrogen deficiency.
C1 [Zhu, Meisong; Shan, Jing; Xu, Huaen; Xia, Guoming; Xu, Qiang; Quan, Kun; Liu, Xuqiang; Dai, Min] Nanchang Univ, Artificial Joints Engn & Technol Res Ctr Jiangxi, Dept Orthoped, Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University
RP Liu, XQ; Dai, M (通讯作者)，Nanchang Univ, Artificial Joints Engn & Technol Res Ctr Jiangxi, Dept Orthoped, Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.
EM zhumeisongv@163.com; 454776398@qq.com; 18370655730@163.com;
   510688327@qq.com; xuqiangyisheng@126.com; quankun201066@sina.cn;
   shliuxuqiang@163.com; daiminyisheng@163.com
FU National Natural Science Foundation for Youths [81601912]; National
   Natural Science Foundation [81660365, 81860404, 81860405]; Key Research
   Plan of Jiangxi Province [20171ACG70006]
FX This work was supported by the National Natural Science Foundation for
   Youths (No. 81601912) , National Natural Science Foundation (No.
   81660365, 81860404, 81860405) and the Key Research Plan of Jiangxi
   Province (20171ACG70006) .
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bone HG, 2013, J CLIN ENDOCR METAB, V98, P4483, DOI 10.1210/jc.2013 1597
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao HL, 2013, J BIOL CHEM, V288, P30399, DOI 10.1074/jbc.M113.469973
   Casas A, 2013, BREAST, V22, P585, DOI 10.1016/j.breast.2013.05.007
   Chen GP, 2019, BIOCHEM BIOPH RES CO, V509, P329, DOI 10.1016/j.bbrc.2018.12.112
   Chen L, 2008, EUR J IMMUNOL, V38, P2845, DOI 10.1002/eji.200838192
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Gan P, 2015, J PHARMACOL SCI, V128, P35, DOI 10.1016/j.jphs.2015.04.005
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Hou XR, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106271
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kim BW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055792
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Li ZK, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00599
   Lin S, 2021, IMMUNOL CELL BIOL, V99, P223, DOI 10.1111/imcb.12401
   Lin TH, 2017, ADV PROTEIN CHEM STR, V107, P117, DOI 10.1016/bs.apcsb.2016.11.002
   Lin WF, 2018, INT J BIOL SCI, V14, P418, DOI 10.7150/ijbs.23602
   Lu JW, 2020, J CELL MOL MED, V24, P10444, DOI 10.1111/jcmm.15657
   Meng JH, 2019, J CELL MOL MED, V23, P6730, DOI 10.1111/jcmm.14551
   Miller PD, 2011, BONE, V49, P77, DOI 10.1016/j.bone.2010.12.024
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Tang S., LIFE SCI, V271
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Xiang ZB, 2014, NAT PROD RES, V28, P2221, DOI 10.1080/14786419.2014.934235
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xu Q, 2019, BIOCHEM BIOPH RES CO, V508, P902, DOI 10.1016/j.bbrc.2018.11.201
   Yang DS, 2020, BIOCHEM BIOPH RES CO, V533, P510, DOI 10.1016/j.bbrc.2020.09.054
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Yu LY, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112873
   Zhao KX, 2019, FASEB J, V33, P9100, DOI 10.1096/fj.201802575RR
NR 37
TC 23
Z9 25
U1 1
U2 21
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD AUG 10
PY 2021
VL 276
AR 114176
DI 10.1016/j.jep.2021.114176
EA MAY 2021
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA SQ3JE
UT WOS:000660251300004
PM 33933570
DA 2025 08 17
ER

PT J
AU Zhao, ZH
   Deng, YL
   Deng, Y
   Chen, ZJ
   Zhou, ZK
AF Zhao, Zehao
   Deng, Yanling
   Deng, Yu
   Chen, Zhuojun
   Zhou, Zhikun
TI Synthesis and Evaluation of Bone Targeting PLGA Nanoparticles Loaded
   with Components of Traditional Chinese Medicine Formulas
SO RECENT PATENTS ON NANOTECHNOLOGY
LA English
DT Article
DE Poly(lactic co glycolic acid); nanoparticles; traditional Chinese
   medicine formula; bone targeting; osteoblasts; solvent evaporation
ID TETRACYCLINE; DELIVERY
AB Background: Targeted nanoparticles' preparation can enhance local drug concentration and reduce the side effects of drugs in non targeted organs. At present, many patents have been applied for in the field of bone targeted nanoparticles' preparations. They play an important role in the treatment and diagnosis of diseases. In this experiment, nanoparticles with bone targeting function were prepared by poly(lactic co glycolic acid) (PLGA) copolymer and tetracycline. These nanoparticles contain active ingredients in the Huangqi Sanxian decoction, a kind of Traditional Chinese Medicine (TCM) compound formula. These nanoparticles are predicted to be useful in the treatment of osteoporosis.Methods: Synthesis of tetracycline targeting groups was performed by acylation reaction, and PLGA nanoparticles were prepared by the Emulsification solvent Evaporation Method. The appearance and particle size of the product were evaluated, and the effects of nanoparticles on the physiological activities of osteoblasts were observed. Finally, the bone targeting ability of targeted nanoparticles in vivo and in vitro was investigated.Results: The average particle size of the nanoparticles was about 200 nm, and the average drug entrapment was 60%. In vitro evaluation of osteoblasts assay showed that the nanoparticles can be well taken by cells. Their good biocompatibility and sustained release properties reduce the toxic side effects of drugs when they promote osteoblasts' physiological activities. The results of the in vitro and in vivo bone targeting ability assays showed that tetracycline modified nanoparticles could effectively accumulate in the bone, indicating the great bone targeting ability of the nanoparticles. The use of PLGA to load active components in the TCM compound formulas and remodel targeting groups is expected to improve drug efficacy, reduce drug dosage, and effects on non  action sites. This may provide new ideas for the development of TCM compound dosage forms.Conclusion: In summary, we prepared PLGA nanoparticles of multiple TCM ingredients with bone targeting ability, and they had good morphological appearance, and a promoting effect on various physiological activities of osteoblasts.
C1 [Zhao, Zehao; Deng, Yanling; Deng, Yu; Chen, Zhuojun; Zhou, Zhikun] Guangdong Med Univ, Dept Pharm, Dongguan 523808, Guangdong, Peoples R China.
C3 Guangdong Medical University
RP Zhou, ZK (通讯作者)，Guangdong Med Univ, Dept Pharm, Dongguan 523808, Guangdong, Peoples R China.
EM zhikunzhou@126.com
FU National Natural Science Foundation of China [81774344]
FX The authors are grateful to the National Natural Science Foundation of
   China for their financial support by grant number 81774344.
CR Cao J., 2022, Patent, Patent No. [CN114209890A, 114209890]
   Chen H, 2022, J PHARM SCI US, V111, P1659, DOI 10.1016/j.xphs.2021.11.002
   Chiu HI, 2021, RSC ADV, V11, P9433, DOI 10.1039/d1ra00074h
   Choi S, 2021, YONSEI MED J, V62, P1042, DOI 10.3349/ymj.2021.62.11.1042
   Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232 260.2001
   Dai J, 2018, DRUG DEV IND PHARM, V44, P89, DOI 10.1080/03639045.2017.1373803
   Deng Y., 2022, J Guangzhou Univ Trad. Chin. Med, V39, P898
   Ding DW, 2018, MAT SCI ENG C MATER, V92, P1041, DOI 10.1016/j.msec.2017.12.036
   Hou ZY, 2019, LAB INVEST, V99, P271, DOI 10.1038/s41374 018 0149 x
   Huang C., 2019, Patent, Patent No. [CN109248326A, 109248326]
   Huang W, 2018, BIOTECHNOL J, V13, DOI 10.1002/biot.201700203
   Jin SE, 2021, ACTA BIOMATER, V127, P56, DOI 10.1016/j.actbio.2021.03.067
   Kapoor DN, 2015, THER DELIV, V6, P41, DOI [10.4155/TDE.14.91, 10.4155/tde.14.91]
   Mir M, 2017, COLLOID SURFACE B, V159, P217, DOI 10.1016/j.colsurfb.2017.07.038
   Murshed M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031229
   Nava Arzaluz Maria G, 2012, Recent Pat Drug Deliv Formul, V6, P209
   Ngo W, 2022, ADV DRUG DELIVER REV, V185, DOI 10.1016/j.addr.2022.114238
   Rennick JJ, 2021, NAT NANOTECHNOL, V16, P266, DOI 10.1038/s41565 021 00858 8
   Rocha CV, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23042034
   Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036
   Sánchez AR, 2004, INT J DERMATOL, V43, P709, DOI 10.1111/j.1365 4632.2004.02108.x
   Shi JX, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/8769531
   Su Y, 2021, DRUG DELIV, V28, P1397, DOI 10.1080/10717544.2021.1938756
   Sun NY, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2020.11657
   [铁红云 Tie Hongyun], 2020, [中国药学杂志, Chinese Pharmaceutical Journal], V55, P1609
   Vasir JK, 2008, BIOMATERIALS, V29, P4244, DOI 10.1016/j.biomaterials.2008.07.020
   Wang LT, 2021, DRUG DELIV, V28, P1363, DOI 10.1080/10717544.2021.1943058
   Wang T, 2015, BIOCHEM BIOPH RES CO, V466, P232, DOI 10.1016/j.bbrc.2015.09.014
   Xie Q., 2021, Med Rev, V27, P4811
   Yin X x, 2019, Patent, Patent No. [CN112316154A, 112316154]
   Zhang DW, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/8069930
   Zhang YN, 2016, J CONTROL RELEASE, V240, P332, DOI 10.1016/j.jconrel.2016.01.020
   Zielinska A, 2020, MOLECULES, V25, DOI 10.3390/molecules25163731
NR 33
TC 1
Z9 1
U1 5
U2 16
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1872 2105
EI 2212 4020
J9 RECENT PAT NANOTECH
JI Recent Pat. Nanotechnology
PY 2024
VL 18
IS 1
BP 33
EP 44
DI 10.2174/1872210517666230324103543
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science; Physics
GA EI1P4
UT WOS:001138205500003
PM 36967467
DA 2025 08 17
ER

PT J
AU Zhou, CC
   Zou, J
   Zou, SJ
   Li, XB
AF Zhou, Chenchen
   Zou, Jing
   Zou, Shujuan
   Li, Xiaobing
TI INO80 is Required for Osteogenic Differentiation of Human Mesenchymal
   Stem Cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SELF RENEWAL; OSTEOCALCIN GENE; WDR5; EXPRESSION; REPAIR
AB Bone marrow derived human mesenchymal stem cells (MSC) are a great source in bone tissue engineering. However, how to improve the efficiency of MSC osteogenesis remains a big challenge in bone regenerative medicine. Here, we characterized the role of INO80 chromatin remodeling complex in osteogenic differentiation of MSC. We showed that silencing of subunits of INO80 reduced the mineral deposition of MSC in osteogenic condition. Moreover, INO80 silencing MSC cultured in osteogenic condition expressed lower mRNA levels of osteoblast specific genes, including Runx2, Osx, Col1 alpha 1 and OCN. INO80 can interact with Wdr5 in MSC and positively regulates the canonical Wnt signaling transduction. Importantly, the mice implanted with INO80 silencing MSC displayed less bone formation. Overall, our study provides a new mechanism regarding osteogenic differentiation of MSC and could potentially be applied in clinical tissue engineering and treatment of osteoporosis.
C1 [Zhou, Chenchen; Zou, Jing; Zou, Shujuan; Li, Xiaobing] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Zou, Jing; Zou, Shujuan; Li, Xiaobing] Sichuan Univ, West China Sch Stomatol, Dept Orthodonitcs, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University
RP Li, XB (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.; Li, XB (通讯作者)，Sichuan Univ, West China Sch Stomatol, Dept Orthodonitcs, Chengdu, Peoples R China.
EM lxb_30@hotmail.com
RI Xiao, Li/I 3309 2014; Zhou, Chen/GQA 7454 2022
OI Zou, Jing/0000 0002 3618 9672; Li, Xiaobing/0000 0002 4177 5887
FU National Natural Science Foundation of China (NSFC) [81271178, 81470777]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC 81271178, 81470777).
CR Aleyeidi NA, 2015, J INTEGR MED JIM, V13, P391, DOI 10.1016/S2095 4964(15)60197 2
   Ang YS, 2011, CELL, V145, P183, DOI 10.1016/j.cell.2011.03.003
   [Anonymous], CANC TRANSLATIONAL M
   [Anonymous], ONCOTARGET
   Bonyadi M, 2003, P NATL ACAD SCI USA, V100, P5840, DOI 10.1073/pnas.1036475100
   BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303
   Budnick I, 2016, GENESIS, V54, P415, DOI 10.1002/dvg.22952
   Cai Y, 2007, NAT STRUCT MOL BIOL, V14, P872, DOI 10.1038/nsmb1276
   Chen D., 2015, Cancer Transl. Med, DOI [10.4103/2395 3977.168578, DOI 10.4103/2395 3977.168578]
   Chen D. M., 2015, Journal of Tissue Science Engineering, V06, P1, DOI DOI 10.4172/2157 7552.1000154
   Chen DM, 2012, DEVELOPMENT, V139, P1522, DOI 10.1242/dev.076463
   Cheng Y, 2015, CANCER TRANSL MED, V1, P123
   Ebbert R, 1999, MOL MICROBIOL, V32, P741, DOI 10.1046/j.1365 2958.1999.01390.x
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gori F., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P338
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794
   Pei M, 2009, DIFFERENTIATION, V78, P260, DOI 10.1016/j.diff.2009.08.001
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002 0122
   Sorensen AL, 2010, MOL BIOL CELL, V21, P2066, DOI 10.1091/mbc.E10 01 0018
   Teven CM, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/201371
   Villagra A, 2006, J BIOL CHEM, V281, P22695, DOI 10.1074/jbc.M511640200
   Wang HL, 2014, J INTEGR MED JIM, V12, P469, DOI 10.1016/S2095 4964(14)60053 4
   Wang L, 2014, CELL STEM CELL, V14, P575, DOI 10.1016/j.stem.2014.02.013
   Yuan Q, 2014, J BONE MINER RES, V29, P693, DOI 10.1002/jbmr.2079
   Yuan Q, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002726
   Zhu ED, 2008, J BIOL CHEM, V283, P7361, DOI 10.1074/jbc.M703304200
   Zhu SM, 2010, J BONE MINER RES, V25, P2504, DOI 10.1002/jbmr.144
   Zhun F, 2016, CANCER TRANSL MED, V2, P85
NR 31
TC 21
Z9 22
U1 0
U2 13
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD NOV 2
PY 2016
VL 6
AR 35924
DI 10.1038/srep35924
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EA6HM
UT WOS:000386727500001
PM 27804957
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU D'Eufemia, P
   Finocchiaro, R
   Zarnbrano, A
   Tetti, M
   Ferrucci, V
   Celli, M
AF D'Eufemia, Patrizia
   Finocchiaro, Roberto
   Zarnbrano, Anna
   Tetti, Martina
   Ferrucci, Valentina
   Celli, Mauro
TI Reduction of plasma taurine level in children affected by Osteogenesis
   Imperfecta during bisphosphonate therapy
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE osteogenesis imperfecta; amino acids; bisphosphonates; taurine; children
ID INTRAVENOUS PAMIDRONATE TREATMENT; L ARGININE; STIMULATION; NERIDRONATE;
   ALENDRONATE; INHIBITION
AB Osteogenesis Imperfecta (OI) is a heritable disease of connective tissue characterized by increased bone fragility. To date, bisphosphonates seem to be the most promising therapy, at least for children. In the last decade experimental and clinical studies indicate that several amino acids are implicated in bone mineralization. Particularly, taurine is localized in matrices of the bone and can regulate osteoblast metabolism with anti osteopenic effect. To investigate a possible interaction between pharmacological effects of bisphosphonates and amino acids involved in bone metabolism, we performed plasma and urine amino acids analysis in children affected by OI before and during treatment with bisphosphonates.
   Fourteen prepubertal children with moderate to severe types of 01, 8 males and 6 females, aged from 2 to 11 years (mean (SD) 6,9 +/  2,53) were enrolled in the study. Patients were treated with neridronate infusion (1 mg/Kg/body weight) every three months. Plasma and urine specimens for amino acid analysis were kept at baseline (TO) and three months after each infusion of four consecutive cycles (T1 T4).
   A significant decrease in respect to the pre treatment levels (TO) was observed after the fourth infusion for taurine (p < 0.01). In addition, urinary excretion of this amino acid showed a significant decrease after the fourth infusion. No significant correlations were found between plasma level or urinary excretion of hydroxyproline, taurine, arginine and lysine in respect to bone mineral density.
   The progressive reduction of plasma taurine found in our patients treated with bisphosphonates could be implicated in the action mechanism of this drug in OI and possibly in other disorders of bone metabolism. This knowledge could provide new opportunities to improve treatment with bisphosphonates and address novel strategies for the therapeutic approach to bone disorders. (C) 2006 Elsevier Masson SAS. All rights reserved.
C1 Univ Roma La Sapienza, Dept Pediat, I 00161 Rome, Italy.
C3 Sapienza University Rome
RP D'Eufemia, P (通讯作者)，Univ Roma La Sapienza, Dept Pediat, Viale Regina Elena 324, I 00161 Rome, Italy.
EM patdeufemia@inwind.it
OI CELLI, Mauro/0000 0002 0751 2688
CR Adami S, 2002, CLIN EXP RHEUMATOL, V20, P55
   Adami S, 2003, J BONE MINER RES, V18, P126, DOI 10.1359/jbmr.2003.18.1.126
   Allgrove J, 2002, J PEDIATR ENDOCR MET, V15, P921
   Arikoski P, 2004, BONE, V34, P539, DOI 10.1016/j.bone.2003.11.019
   COHEN SA, 1986, NATURE, V320, P769, DOI 10.1038/320769a0
   DiMeglio LA, 2004, BONE, V35, P1038, DOI 10.1016/j.bone.2004.07.003
   Fleisch H, 2003, EUR SPINE J, V12, pS142, DOI 10.1007/s00586 003 0622 z
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gatti D, 2005, J BONE MINER RES, V20, P758, DOI 10.1359/JBMR.041232
   Gupta RC, 2005, CURR MED CHEM, V12, P2021, DOI 10.2174/0929867054546582
   HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101
   Koide M, 1999, ARCH ORAL BIOL, V44, P711, DOI 10.1016/S0003 9969(99)00067 9
   Kum KY, 2003, J ENDODONT, V29, P28, DOI 10.1097/00004770 200301000 00008
   Lubec B, 1997, LIFE SCI, V60, P2373, DOI 10.1016/S0024 3205(97)00297 X
   Park S, 2001, BIOCHEM PHARMACOL, V62, P1107, DOI 10.1016/S0006 2952(01)00741 9
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140 6736(04)16051 0
   Shaw NJ, 2005, ARCH DIS CHILD, V90, P494, DOI 10.1136/adc.2003.036590
   Sillence D., 2000, Bone (New York), V27, p4S
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Sturman JA., 1980, ADV NUTR RES, P231
   Terauchi A, 1998, AMINO ACIDS, V15, P151, DOI 10.1007/BF01345288
   Torricelli P, 2002, BIOMED PHARMACOTHER, V56, P492, DOI 10.1016/S0753 3322(02)00287 1
   Töyräs A, 2003, EUR J PHARM SCI, V19, P223, DOI 10.1016/S0928 0987(03)00108 8
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Zeitlin L, 2006, BONE, V38, P13, DOI 10.1016/j.bone.2005.07.020
NR 25
TC 5
Z9 5
U1 1
U2 3
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAY
PY 2007
VL 61
IS 4
BP 235
EP 240
DI 10.1016/j.biopha.2006.11.005
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 177DR
UT WOS:000247134300008
PM 17275249
DA 2025 08 17
ER

PT J
AU Xu, Z
   Zhang, ZY
   Zhou, HF
   Lin, S
   Gong, BY
   Li, ZD
   Zhao, SW
   Hou, YL
   Peng, YF
   Bian, YH
AF Xu, Zhe
   Zhang, Zeyu
   Zhou, Huifang
   Lin, Shan
   Gong, Boyang
   Li, Zhaodong
   Zhao, Shuwu
   Hou, Yunlong
   Peng, Yanfei
   Bian, Yuhong
TI Bazi Bushen attenuates osteoporosis in SAMP6 mice by regulating PI3K AKT
   and apoptosis pathways
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE apoptosis; Bazi Bushen; bone homeostasis; bone mesenchymal stem cells;
   osteoporosis; PI3K AKT
ID MESENCHYMAL STEM CELLS; BONE LOSS; PHENOTYPE; PROTOCOL; NETWORK; CULTURE
AB Osteoporosis (OP), a systemic skeletal disease, is characterized by low bone mass, bone tissue degradation and bone microarchitecture disturbance. Bazi Bushen, a Chinese patented medicine, has been demonstrated to be effective in attenuating OP, but the pharmacological mechanism remains predominantly unclear. In this study, the senescence accelerated mouse prone 6 (SAMP6) model was used to explore bone homeostasis and treated intragastrically for 9 weeks with Bazi Bushen. In vivo experiments showed that Bazi Bushen treatment not only upregulated the levels of bone mineral density and bone mineral content but also increased the content of RUNX2 and OSX. Furthermore, the primary culture of bone mesenchymal stem cells (BMSCs) in SAMP6 mice was used to verify the effects of Bazi Bushen on the balance of differentiation between osteoblasts and adipocytes, as well as ROS and aging levels. Finally, the pharmacological mechanism of Bazi Bushen in attenuating OP was investigated through network pharmacology and experimental verification, and we found that Bazi Bushen could significantly orchestrate bone homeostasis and attenuate the progression of OP by stimulating PI3K Akt and inhibiting apoptosis. In summary, our work sheds light on the first evidence that Bazi Bushen attenuates OP by regulating PI3K AKT and apoptosis pathways to orchestrate bone homeostasis.
C1 [Xu, Zhe; Zhang, Zeyu; Zhou, Huifang; Lin, Shan; Gong, Boyang; Li, Zhaodong; Zhao, Shuwu; Peng, Yanfei; Bian, Yuhong] Tianjin Univ Tradit Chinese Med, Sch Integrat Med, Tianjin 301617, Peoples R China.
   [Xu, Zhe; Zhang, Zeyu; Lin, Shan; Gong, Boyang; Li, Zhaodong] Tianjin Univ Tradit Chinese Med, Grad Sch, Tianjin, Peoples R China.
   [Hou, Yunlong] Natl Key Lab Luobing Res & Innovat Chinese Med, Shijiazhuang, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University
   of Traditional Chinese Medicine
RP Xu, Z; Peng, YF; Bian, YH (通讯作者)，Tianjin Univ Tradit Chinese Med, Sch Integrat Med, Tianjin 301617, Peoples R China.
EM tjutcm_xz@163.com; pengyanfei2006@163.com; bianyuhong_2012@163.com
RI Li, Zhaodong/M 5363 2015; Hou, Yunlong/C 4885 2014
OI Xu, Zhe/0000 0002 9705 8924
FU National Key R&D Program of China; S&T Program of Hebei [23379902 L];
   Strategic Research and Consulting Project of the Chinese Academy of
   Engineering [2022 XY 45]; Tianjin Municipal Education Commission Science
   and Technology Plan Project [2021KJ137];  [2018YFC1706500]
FX This study was supported by the S&T Program of Hebei (No. 23379902 L),
   the National Key R&D Program of China (2018YFC1706500), the Strategic
   Research and Consulting Project of the Chinese Academy of Engineering
   (2022 XY 45), and the Tianjin Municipal Education Commission Science and
   Technology Plan Project (2021KJ137).
CR Al Dhubiab BE, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103186
   Azuma K, 2018, MED MOL MORPHOL, V51, P139, DOI 10.1007/s00795 018 0188 9
   Brosig S, 2018, PEDIATR SURG INT, V34, P297, DOI 10.1007/s00383 017 4213 1
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Gong R, 2019, BIOMED RES INT UK, V2019, DOI 10.1155/2019/1907906
   Han DD, 2019, FREE RADICAL BIO MED, V137, P1, DOI 10.1016/j.freeradbiomed.2019.04.014
   Huang D, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.658998
   Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005
   Huang XD, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.860649
   Ivanovska IL, 2015, TRENDS CELL BIOL, V25, P523, DOI 10.1016/j.tcb.2015.04.003
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Kang XP, 2022, J ETHNOPHARMACOL, V294, DOI 10.1016/j.jep.2022.115323
   KAWASE M, 1989, J BONE MINER RES, V4, P359
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim MH, 2021, PHYTOMEDICINE, V80, DOI 10.1016/j.phymed.2020.153397
   Kou YY, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1067085
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Li HZ, 2016, ANN NY ACAD SCI, V1370, P109, DOI 10.1111/nyas.13102
   Li J, 2020, AM J TRANSL RES, V12, P672
   Li L, 2021, J ETHNOPHARMACOL, V271, DOI 10.1016/j.jep.2021.113810
   Li M, 2019, CONNECT TISSUE RES, V60, P189, DOI 10.1080/03008207.2018.1483358
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875 5364(13)60037 0]
   Liu C, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.860413
   Liu JJ, 2018, PHYTOMEDICINE, V42, P43, DOI 10.1016/j.phymed.2018.03.020
   Liu WJ, 2015, AGING US, V7, P205, DOI 10.18632/aging.100728
   Ma M, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.874952
   Mao XJ, 2023, BIOMED PHARMACOTHER, V160, DOI 10.1016/j.biopha.2023.114384
   Marie PJ, 2014, J BONE MINER RES, V29, P1311, DOI 10.1002/jbmr.2190
   Mirza F, 2018, J NUTR BIOCHEM, V52, P54, DOI 10.1016/j.jnutbio.2017.10.002
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Niimi K, 2009, COMPARATIVE MED, V59, P431
   Pham HT, 2021, MATERIALS, V14, DOI 10.3390/ma14010208
   Ravindranath PA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004586
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Sikora M, 2023, STEM CELL RES THER, V14, DOI 10.1186/s13287 023 03271 1
   Sikora M, 2021, J CELL MOL MED, V25, P6634, DOI 10.1111/jcmm.16667
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Versiani MA, 2011, INT ENDOD J, V44, P1000, DOI 10.1111/j.1365 2591.2011.01905.x
   Wang D, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.729909
   Wang J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01175
   Wang JF, 2023, MATER TODAY BIO, V23, DOI 10.1016/j.mtbio.2023.100794
   Wang LN, 2023, PHARM BIOL, V61, P568, DOI 10.1080/13880209.2023.2190773
   Wang ZH, 2020, AGING US, V12, P11386, DOI 10.18632/aging.103186
   Xie H, 2022, PHARM BIOL, V60, P785, DOI 10.1080/13880209.2022.2056208
   Xu Z, 2023, J CELL MOL MED, V27, P2651, DOI 10.1111/jcmm.17833
   Xu Z, 2023, J SCI FOOD AGR, V103, P7273, DOI 10.1002/jsfa.12812
   Yan DY, 2020, J CELL MOL MED, V24, P2330, DOI 10.1111/jcmm.14915
   Yang RL, 2020, AGING CELL, V19, DOI 10.1111/acel.13095
   Yang Y, 2017, J ETHNOPHARMACOL, V201, P91, DOI 10.1016/j.jep.2017.02.033
   Yi LX, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02112 9
   Zhang P, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109520
NR 57
TC 2
Z9 2
U1 7
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT
PY 2024
VL 28
IS 20
AR e70161
DI 10.1111/jcmm.70161
PG 17
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA O0P4J
UT WOS:001368247500001
PM 39469911
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lu, RN
   Wang, Q
   Han, YL
   Li, JY
   Yang, XJ
   Miao, DS
AF Lu, Ruinan
   Wang, Qian
   Han, Yongli
   Li, Jianyong
   Yang, Xiang Jiao
   Miao, Dengshun
TI Parathyroid Hormone Administration Improves Bone Marrow Microenvironment
   and Partially Rescues Haematopoietic Defects in Bmi1 Null Mice
SO PLOS ONE
LA English
DT Article
ID STEM CELL NICHE; OSTEOBLAST DIFFERENTIATION; SELF RENEWAL; NULL MICE;
   TRANSCRIPTION FACTOR; PROGENITOR CELLS; PTH; BMI 1; SKELETAL;
   ABNORMALITIES
AB The epigenetic regulator Bmi1 is key in haematopoietic stem cells, and its inactivation leads to defects in haematopoiesis. Parathyroid hormone (PTH), an important modulator of bone homeostasis, also regulates haematopoiesis, so we asked whether PTH administration improves bone marrow microenvironment and rescues the haematopoietic defects in Bmi1 null mice. The mice were treated with PTH1 34 (containing the first 34 residues of mature PTH), an anabolic drug currently used for treating osteoporosis, and compared with the vehicle treated Bmi1( / ) and wild type littermates in terms of skeletal and haematopoietic phenotypes. We found that the administration significantly increased all parameters related to osteoblastic bone formation and significantly reduced the adipocyte number and PPAR gamma expression. The bone marrow cellularity, numbers of haematopoietic progenitors and stem cells in the femur, and numbers of lymphocytes and other white blood cells in the peripheral blood all increased significantly when compared to vehicle treated Bmi1( / ) mice. Moreover, the number of Jagged1 positive cells and percentage of Notch intracellular domain positive bone marrow cells and protein expression levels of Jagged1 and NICD in bone tissue were also increased in Bmi1( / ) mice upon PTH1 34 administration, whereas the up regulation of PTH on both Notch1 and Jagged1 gene expression was blocked by the Notch inhibitor DAPT administration. These results thus indicate that PTH administration activates the notch pathway and partially rescues haematopoietic defects in Bmi1 null mice, further suggesting that haematopoietic defects in the animals are not only a result of reduced self renewal of haematopoietic stem cells but also due to impaired bone marrow microenvironment.
C1 [Lu, Ruinan; Wang, Qian; Han, Yongli; Miao, Dengshun] Nanjing Med Univ, Dept Human Anat, Res Ctr Bone & Stem Cells, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.
   [Lu, Ruinan; Li, Jianyong] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Nanjing, Jiangsu, Peoples R China.
   [Yang, Xiang Jiao] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ, Canada.
   [Yang, Xiang Jiao] McGill Univ, Dept Biochem, Montreal, PQ, Canada.
   [Yang, Xiang Jiao] McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ, Canada.
C3 Nanjing Medical University; Nanjing Medical University; McGill
   University; McGill University; McGill University
RP Miao, DS (通讯作者)，Nanjing Med Univ, Dept Human Anat, Res Ctr Bone & Stem Cells, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.
EM dsmiao@njmu.edu.cn
OI Miao, Dengshun/0000 0002 2682 3502
FU National Basic Research Program of China [2012CB966902]; MOST in China;
   CIHR in Canada [30911120486]
FX This work was supported by a grant from the National Basic Research
   Program of China (2012CB966902 to D. M.) and by a joint health research
   initiative grant supported by the MOST in China and the CIHR in Canada
   (30911120486 to D. M. and X.J.Y.). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281
   Brunner S, 2008, EXP HEMATOL, V36, P1157, DOI 10.1016/j.exphem.2008.03.014
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Frenette PS, 2013, ANNU REV IMMUNOL, V31, P285, DOI 10.1146/annurev immunol 032712 095919
   Jones DL, 2008, NAT REV MOL CELL BIO, V9, P11, DOI 10.1038/nrm2319
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   LEE K, 1993, BONE, V14, P341, DOI 10.1016/8756 3282(93)90162 4
   Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082
   Lo Celso C, 2011, J CELL SCI, V124, P3529, DOI 10.1242/jcs.074112
   Lyritis GP, 2010, ANN NY ACAD SCI, V1205, P277, DOI 10.1111/j.1749 6632.2010.05666.x
   Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817
   Miao DS, 2004, ENDOCRINOLOGY, V145, P3554, DOI 10.1210/en.2003 1695
   Miao DS, 2004, ENDOCRINOLOGY, V145, P2046, DOI 10.1210/en.2003 1097
   Miao DS, 2002, J HISTOCHEM CYTOCHEM, V50, P333, DOI 10.1177/002215540205000305
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Miao DS, 2001, ENDOCRINOLOGY, V142, P926, DOI 10.1210/en.142.2.926
   Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P4349, DOI 10.1210/en.142.10.4349
   Trevisani VFM, 2008, SAO PAULO MED J, V126, P279, DOI 10.1590/S1516 31802008000500007
   Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505
   Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood 2004 11 4422
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pajcini KV, 2011, LEUKEMIA, V25, P1525, DOI 10.1038/leu.2011.127
   Panda DK, 2004, J BIOL CHEM, V279, P16754, DOI 10.1074/jbc.M310271200
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Ren YX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023060
   Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092 8674(94)90006 X
   Trumpp A, 2010, NAT REV IMMUNOL, V10, P201, DOI 10.1038/nri2726
   Tsomaia N, 2004, BIOCHEMISTRY US, V43, P690, DOI 10.1021/bi035703i
   VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   WATSON P, 1995, BONE, V16, P357, DOI 10.1016/8756 3282(94)00051 4
   Whitfield JF, 2005, J CELL BIOCHEM, V96, P278, DOI 10.1002/jcb.20526
   Xue YB, 2005, J BONE MINER RES, V20, P1766, DOI 10.1359/JBMR.050608
   Xue YB, 2005, HUM MOL GENET, V14, P1515, DOI 10.1093/hmg/ddi160
   Yang D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
   Zhang HW, 2010, J BONE MINER RES, V25, P640, DOI 10.1359/jbmr.090812
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 41
TC 13
Z9 17
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2014
VL 9
IS 4
AR e93864
DI 10.1371/journal.pone.0093864
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AE6MJ
UT WOS:000334107500081
PM 24705625
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Kim, JY
   Kim, JY
   Cheon, YH
   Kwak, SC
   Baek, JM
   Kim, YC
   Yoon, KH
   Oh, J
   Lee, MS
AF Kim, Ju Young
   Kim, Jung Young
   Cheon, Yoon Hee
   Kwak, Sung Chul
   Baek, Jong Min
   Kim, Youn Chul
   Yoon, Kwon Ha
   Oh, Jaemin
   Lee, Myeung Su
TI 9 Hydroxy 6,7 dimethoxydalbergiquinol inhibits osteoclast
   differentiation through down regulation of Akt, c Fos and NFATc1
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Osteoclasts; RANKL; Osteoporosis; 9 Hydroxy 6,7 dimethoxydalbergiquinol
ID FACTOR KAPPA B; DALBERGIA ODORIFERA; BONE RESORPTION; NUCLEAR FACTOR;
   TRANSCRIPTION FACTOR; RECEPTOR ACTIVATOR; T CELLS; EXPRESSION; TARGET;
   MICE
AB Recently, natural plant derived products have been recognized as one of the main sources for drug discovery and development in human disease. 9 Hydroxy 6,7 dimethoxydalbergiquinol (HDDQ) isolated from the heart wood of Dalbergia odorifera is widely used in oriental medicine, however, the pharmacological effect of HDDQ in osteoclast associated diseases remains unknown. In this study, HDDQ dose dependently inhibited the early stage of RANKL mediated osteoclast differentiation in bone marrow macrophages (BMMs) without cytotoxicity. HDDQ strongly inhibited Akt phosphorylation in RANKL stimulated BMMs and did not show any effects on p38, JNK, and I kappa B phosphorylation and I kappa B degradation. Interestingly, we found that HDDQ down regulated the induction by RANKL of c Fos protein by suppressing its translation. Also, ectopic overexpression of c Fos and NFATc1 rescued the inhibition of osteoclast differentiation by HDDQ. Furthermore, the Akt/c Fos/NFATc1 regulated expression of genes required for osteoclastogenesis, such as OSCAR and TRAP, was inhibited by HDDQ. These findings suggest that HDDQ prevents osteoclast differentiation via down regulation of Akt, c Fos, and NFATc1 signaling molecules, suggesting a potential therapeutic value of HDDQ for bone disorders associated with increased bone resorption. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Kim, Ju Young; Yoon, Kwon Ha; Oh, Jaemin; Lee, Myeung Su] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Kim, Jung Young] Daejeon Univ, Dept Oriental Med, Taejon 300716, South Korea.
   [Cheon, Yoon Hee; Kwak, Sung Chul; Baek, Jong Min; Oh, Jaemin] Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
   [Cheon, Yoon Hee; Kwak, Sung Chul; Baek, Jong Min; Oh, Jaemin] Wonkwang Univ, Grad Sch, Plus Program BK21, Iksan 570749, Jeonbuk, South Korea.
   [Cheon, Yoon Hee; Kwak, Sung Chul; Baek, Jong Min; Oh, Jaemin] Wonkwang Univ, Grad Sch, Dept Smart Life Care Convergence, Iksan 570749, Jeonbuk, South Korea.
   [Kim, Youn Chul] Wonkwang Univ, Coll Pharm, Standardized Mat Bank New Bot Drugs, Iksan 570749, Jeonbuk, South Korea.
   [Yoon, Kwon Ha] Wonkwang Univ, Sch Med, Dept Radiol, Iksan 570749, Jeonbuk, South Korea.
   [Oh, Jaemin; Lee, Myeung Su] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su] Wonkwang Univ, Sch Med, Div Rheumatol, Dept Internal Med, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Daejeon University; Wonkwang University; Wonkwang
   University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University; Wonkwang University
RP Oh, J (通讯作者)，Wonkwang Univ, Sch Med, Dept Anat, 344 2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea.
EM jmoh@wku.ac.kr; ckhlms@wku.ac.kr
RI Kim, Kyunghoon/AGO 0079 2022; Kim, Sung/F 7292 2013; Lee,
   Sang Hoon/ABH 6210 2020
FU Korean Health Technology RD Project; Ministry of Health & Welfare,
   Republic of Korea [A120152]; National Research Foundation of Korea (NRF)
     Ministry of Education, Republic of Korea [2012 0736]
FX This study was supported by a grant of the Korean Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (A120152) and
   Basic Science Research Program through the National Research Foundation
   of Korea (NRF) funded by the Ministry of Education, Republic of Korea
   (2012 0736).
CR An RB, 2008, CHEM PHARM BULL, V56, P1722, DOI 10.1248/cpb.56.1722
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074 7613(02)00329 1
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   GODA Y, 1985, CHEM PHARM BULL, V33, P5606
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Ha H, 2006, J IMMUNOL, V176, P111, DOI 10.4049/jimmunol.176.1.111
   Jia M, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/364604
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Lee SH, 2009, INFLAMM RES, V58, P257, DOI 10.1007/s00011 008 8183 6
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Pan WH, 2005, J BIOL CHEM, V280, P4888, DOI 10.1074/jbc.M409052200
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   So H, 2003, J BIOL CHEM, V278, P24209, DOI 10.1074/jbc.M302940200
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Sugiyama A, 2002, CIRC J, V66, P182, DOI 10.1253/circj.66.182
   Takasu H, 2006, J CLIN INVEST, V116, P528, DOI 10.1172/JCI24742
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599
NR 32
TC 19
Z9 21
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD MAY
PY 2014
VL 20
IS 1
BP 213
EP 220
DI 10.1016/j.intimp.2014.03.001
PG 8
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA AH7TL
UT WOS:000336337900028
PM 24630975
DA 2025 08 17
ER

PT J
AU Ruilian, Z
   Ying, G
   Hongmei, S
   Lihua, G
AF Ruilian, Zhao
   Ying, Gao
   Hongmei, Shen
   Lihua, Guo
TI 被撤回的出版物: Exploration of the Effect of Icariin on Nude Mice with Lung
   Cancer Bone Metastasis via the OPG/RANKL/RANK System (Retracted Article)
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article; Retracted Publication
ID ZOLEDRONIC ACID; POSTMENOPAUSAL OSTEOPOROSIS; SKELETAL METASTASES; SOLID
   TUMORS; DOUBLE BLIND; PHASE III; PATHOPHYSIOLOGY; CHONDROCYTES;
   MANAGEMENT; EPIMEDIUM
AB Epimedium is a traditional Chinese medicine that is most commonly prescribed by practitioners of Chinese medicine for the clinical treatment of malignant tumor bone metastasis. The main component of Epimedium is icariin (ICA). Studies have shown that ICA inhibits bone resorption of osteoclasts through the OPG/RANKL/RANK signaling pathway. Osteoclasts are the only cells in the body that have a bone destroying capability. The OPG/RANKL/RANK system consists of cytokines that play major roles in osteoclast formation. Therefore, our study selected the OPG/RANKL/RANK system as the research target to investigate the effect of ICA on nude mice with lung cancer bone metastasis. We established the model of bone metastasis in nude mice, intervened the model with icariin and zoledronic acid, and detected the levels of OPG and RANKL by ELISA and western blot. The results showed that ICA had a significant inhibitory effect on bone metastases in nude mice. ICA achieved its antibone metastasis effect in nude mice with lung cancer via inhibiting RANKL expression and simultaneously increasing OPG expression. ICA not only alleviated osteolytic bone destruction caused by bone metastases, but it also reduced weight loss in tumor bearing nude mice at the late stage of the experiment. The role of ICA in preventing bone metastasis of lung cancer merits further investigation.
C1 [Ruilian, Zhao; Hongmei, Shen] Tumor Hosp Yunnan Prov, Affiliated Hosp 3, Dept Integrated Tradit & Western Med, Kunming Med Coll, Kunming 650118, Yunnan, Peoples R China.
   [Ruilian, Zhao] Nanjing Univ Tradit Chinese Med, Coll Clin Med, Nanjing 210000, Jiangsu, Peoples R China.
   [Ying, Gao] Second Peoples Hosp Kunming, Dept Physiatry, Kunming 650000, Yunnan, Peoples R China.
   [Lihua, Guo] Tradit Chinese Med Hosp Yunnan Prov, Kunming 650000, Yunnan, Peoples R China.
C3 Kunming Medical University; Nanjing University of Chinese Medicine
RP Lihua, G (通讯作者)，Tradit Chinese Med Hosp Yunnan Prov, Kunming 650000, Yunnan, Peoples R China.
EM zruilian2007@163.com; kmsdermyygaoying@163.com; lilyydfz@126.com;
   ynszyyguolihua@163.com
RI ying, gao/KHX 8149 2024
FU Science Research Fund Project of Yunnan Provincial Health Department
   Establishment of Research Institutes [2016NS099]; Science Research Fund
   Project of Yunnan Provincial Department of Education [2018JS225]
FX AcknowledgmentsThis work was supported by the Science Research Fund
   Project of Yunnan Provincial Health Department Establishment of Research
   Institutes (No. 2016NS099) and the Science Research Fund Project of
   Yunnan Provincial Department of Education (No. 2018JS225).
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Berenson JR, 2006, CANCER BIOL THER, V5, P1078, DOI 10.4161/cbt.5.9.3306
   Chen Yang, 2011, Zhong Xi Yi Jie He Xue Bao, V9, P1179, DOI 10.3736/jcim20111104
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Guo YN, 2018, CHEM BIODIVERS, V15, DOI 10.1002/cbdv.201700578
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Joshi AD, 2011, CLIN THER, V33, P291, DOI 10.1016/j.clinthera.2011.04.002
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   LeVasseur N, 2016, CANCER TREAT REV, V50, P183, DOI 10.1016/j.ctrv.2016.09.013
   Lin J, 2017, BIOSCI TRENDS, V11, P496, DOI 10.5582/bst.2017.01216
   Liu Yi Jie, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P1221
   Liu Y, 2017, CELL MOL BIOL, V63, P124, DOI 10.14715/cmb/2017.63.11.22
   Ma HP, 2011, J ETHNOPHARMACOL, V134, P519, DOI 10.1016/j.jep.2011.01.001
   Ma Xiao ni, 2013, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V35, P432, DOI 10.3881/j.issn.1000 503X.2013.04.014
   McGrath EE, 2011, J THORAC ONCOL, V6, P1468, DOI 10.1097/JTO.0b013e318229421f
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Selvaggi G, 2005, CRIT REV ONCOL HEMAT, V56, P365, DOI 10.1016/j.critrevonc.2005.03.011
   Shi DB, 2014, CELL BIOCHEM BIOPHYS, V69, P523, DOI 10.1007/s12013 014 9827 5
   Sun LJ, 2021, CURR PHARM BIOTECHNO, V22, P168, DOI 10.2174/1389201021666200123102550
   Tang D, 2018, J BONE MINER METAB, V36, P180, DOI 10.1007/s00774 017 0831 x
   Tang YH, 2021, BIOENGINEERED, V12, P2984, DOI 10.1080/21655979.2021.1943602
   Wang Z, 2018, OSTEOPOROSIS INT, V29, P535, DOI 10.1007/s00198 017 4255 1
   Wei CC, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9529630
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Wu JZ, 2018, CELL PHYSIOL BIOCHEM, V46, P1727, DOI 10.1159/000489248
   Wu XT, 2020, J INT MED RES, V48, DOI 10.1177/0300060520925644
   Xiao Ya Ping, 2018, Zhongguo Zhong Yao Za Zhi, V43, P21, DOI 10.19540/j.cnki.cjcmm.20171106.002
   Xu JH, 2016, MENOPAUSE, V23, P1152, DOI 10.1097/GME.0000000000000673
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
   Zarogoulidis K, 2009, INT J CANCER, V125, P1705, DOI 10.1002/ijc.24470
   Zhang L, 2012, PHYTOTHER RES, V26, P1385, DOI 10.1002/ptr.3733
   Zhang XD, 2018, BIOMED PHARMACOTHER, V99, P810, DOI 10.1016/j.biopha.2018.01.139
   Zhao JY, 2010, TISSUE ENG PT A, V16, P233, DOI [10.1089/ten.tea.2009.0165, 10.1089/ten.TEA.2009.0165]
NR 36
TC 4
Z9 4
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748 670X
EI 1748 6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD MAY 28
PY 2022
VL 2022
AR 2011625
DI 10.1155/2022/2011625
PG 9
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Mathematical & Computational Biology
GA 1X9UB
UT WOS:000807792500001
PM 35669373
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Aasebo, E
   Brenner, AK
   Hernandez Valladares, M
   Birkeland, E
   Berven, FS
   Selheim, F
   Bruserud, O
AF Aasebo, Elise
   Brenner, Annette K.
   Hernandez Valladares, Maria
   Birkeland, Even
   Berven, Frode S.
   Selheim, Frode
   Bruserud, Oystein
TI Proteomic Comparison of Bone Marrow Derived Osteoblasts and Mesenchymal
   Stem Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE bone marrow; osteoblast; mesenchymal stem cell; proteome; in vitro
   culture; ex vivo handling
ID ACUTE MYELOID LEUKEMIA; IN VITRO CULTURE; EXTRACELLULAR MATRIX; PROTEIN
   RELEASE; FATE DECISION; PROLIFERATION; NICHE; MICROENVIRONMENT;
   DIFFERENTIATION; HETEROGENEITY
AB Mesenchymal stem cells (MSCs) can differentiate into osteoblasts, and therapeutic targeting of these cells is considered both for malignant and non malignant diseases. We analyzed global proteomic profiles for osteoblasts derived from ten and MSCs from six healthy individuals, and we quantified 5465 proteins for the osteoblasts and 5420 proteins for the MSCs. There was a large overlap in the profiles for the two cell types; 156 proteins were quantified only in osteoblasts and 111 proteins only for the MSCs. The osteoblast specific proteins included several extracellular matrix proteins and a network including 27 proteins that influence intracellular signaling (Wnt/Notch/Bone morphogenic protein pathways) and bone mineralization. The osteoblasts and MSCs showed only minor age  and sex dependent proteomic differences. Finally, the osteoblast and MSC proteomic profiles were altered by ex vivo culture in serum free media. We conclude that although the proteomic profiles of osteoblasts and MSCs show many similarities, we identified several osteoblast specific extracellular matrix proteins and an osteoblast specific intracellular signaling network. Therapeutic targeting of these proteins will possibly have minor effects on MSCs. Furthermore, the use of ex vivo cultured osteoblasts/MSCs in clinical medicine will require careful standardization of the ex vivo handling of the cells.
C1 [Aasebo, Elise; Brenner, Annette K.; Bruserud, Oystein] Univ Bergen, Dept Clin Sci, N 5020 Bergen, Norway.
   [Aasebo, Elise; Hernandez Valladares, Maria; Birkeland, Even; Berven, Frode S.; Selheim, Frode] Univ Bergen, Univ Bergen PROBE, Prote Facil, N 5020 Bergen, Norway.
   [Bruserud, Oystein] Haukeland Hosp, Dept Med, N 5021 Bergen, Norway.
C3 University of Bergen; University of Bergen; University of Bergen;
   Haukeland University Hospital
RP Bruserud, O (通讯作者)，Univ Bergen, Dept Clin Sci, N 5020 Bergen, Norway.; Bruserud, O (通讯作者)，Haukeland Hosp, Dept Med, N 5021 Bergen, Norway.
EM elise.aasebo@uib.no; annette.brenner@uib.no;
   maria.hernandez valladares@uib.no; even.birkeland@uib.no;
   frode.berven@uib.no; frode.selheim@uib.no;
   oystein.bruserud@helse bergen.no
RI Hernandez Valladares, Maria del Carmen/GXF 7320 2022;
   Hernandez Valladares, Maria/GXF 7320 2022
OI Hernandez Valladares, Maria del Carmen/0000 0001 9347 7841; Aasebo,
   Elise/0000 0002 6939 8059
FU Norwegian Cancer Society [100933]; Research Council of Norway
   INFRASTRUKTUR program [295910]
FX This research was funded by the Norwegian Cancer Society (grant number
   100933). The Proteomic Facility at the University of Bergen is a member
   of the National Network of Advanced Proteomics Infrastructure (NAPI),
   which is funded by the Research Council of Norway INFRASTRUKTUR program
   (project number: 295910).
CR Aasebo E, 2021, CANCERS, V13, DOI 10.3390/cancers13071509
   Aasebo E, 2021, CANCERS, V13, DOI 10.3390/cancers13010062
   Aasebo E, 2018, PROTEOMES, V7, DOI 10.3390/proteomes7010001
   Alonso Pérez A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00504
   Arntzen MO, 2011, J PROTEOME RES, V10, P913, DOI 10.1021/pr1009977
   Arthur A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.598612
   Aslani S, 2019, J CELL PHYSIOL, V234, P8082, DOI 10.1002/jcp.27582
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Baker N, 2015, BONE, V70, P37, DOI 10.1016/j.bone.2014.10.014
   Bergfeld SA, 2010, CANCER METAST REV, V29, P249, DOI 10.1007/s10555 010 9222 7
   Brenner AK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00106
   Brenner AK, 2016, MOLECULES, V21, DOI 10.3390/molecules21111512
   Brommage R, 2020, HANDB EXP PHARMACOL, V262, P451, DOI 10.1007/164_2019_329
   Brommage R, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0038 3
   Brommage R, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.34
   Bruserud O, 1999, J HEMATOTHER, V8, P63, DOI 10.1089/106161299320587
   Bruserud O, 2005, J CANCER RES CLIN, V131, P377, DOI 10.1007/s00432 004 0650 z
   Bruserud O, 2004, HAEMATOLOGICA, V89, P391
   Bruserud O, 2020, CANCERS, V12, DOI 10.3390/cancers12071966
   Brylka LJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02182
   Cahill RA, 2004, BIOL BLOOD MARROW TR, V10, P709, DOI 10.1016/j.bbmt.2004.06.001
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Clézardin P, 2017, JOINT BONE SPINE, V84, P677, DOI 10.1016/j.jbspin.2017.05.006
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   d'Angelo M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155241
   Desai S, 2020, BIOENGINEERING BASEL, V7, DOI 10.3390/bioengineering7030086
   Domingues MJ, 2017, J CELL BIOCHEM, V118, P1984, DOI 10.1002/jcb.25905
   Dumont N, 2014, EXP HEMATOL, V42, P741, DOI 10.1016/j.exphem.2014.04.009
   Ehninger A, 2011, J EXP MED, V208, P421, DOI 10.1084/jem.20110132
   Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415
   Frostad S, 1998, STEM CELLS, V16, P334, DOI 10.1002/stem.160334
   Garg P, 2017, ORTHOP SURG, V9, P13, DOI 10.1111/os.12304
   Gasson SB, 2021, STEM CELLS DEV, V30, P214, DOI 10.1089/scd.2020.0144
   Hauzeur JP, 2020, CLIN ORTHOP RELAT R, V478, P1307, DOI 10.1097/CORR.0000000000001107
   Hernandez Valladares M, 2016, BIOL PROCED ONLINE, V18, DOI 10.1186/s12575 016 0043 0
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Hughes CS, 2019, NAT PROTOC, V14, P68, DOI 10.1038/s41596 018 0082 x
   Kaushansky K, 2020, ANN NY ACAD SCI, V1466, P17, DOI 10.1111/nyas.14028
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kim SJ, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471 2474 10 20
   Klamer S, 2014, CELL ADHES MIGR, V8, P563, DOI 10.4161/19336918.2014.968501
   Kolb AD, 2019, CANCERS, V11, DOI 10.3390/cancers11071020
   Kornblau SM, 2018, HAEMATOLOGICA, V103, P810, DOI 10.3324/haematol.2017.172429
   Kumar B, 2018, LEUKEMIA, V32, P575, DOI 10.1038/leu.2017.259
   Kunisaki Y, 2013, NATURE, V502, P637, DOI 10.1038/nature12612
   Liao YJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202155
   Liu BN, 2021, IMMUN INFLAMM DIS, V9, P340, DOI 10.1002/iid3.416
   Liu F, 1997, EXP CELL RES, V232, P97, DOI 10.1006/excr.1997.3501
   Mott A, 2020, BONE JOINT OPEN, V1, P628, DOI 10.1302/2633 1462.110.BJO 2020 0129
   Murphy MG, 2005, J CLIN ENDOCR METAB, V90, P2022, DOI 10.1210/jc.2004 2126
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Olweus J, 1996, BLOOD, V88, P1594
   Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914 017 0381 0
   Pennypacker B, 2009, BONE, V44, P199, DOI 10.1016/j.bone.2008.08.130
   Ren GW, 2015, J MOL MED, V93, P1203, DOI 10.1007/s00109 015 1329 4
   Sangaletti S, 2017, CANCER IMMUNOL IMMUN, V66, P1059, DOI 10.1007/s00262 017 2014 y
   Schölz C, 2015, NAT METHODS, V12, P1003, DOI 10.1038/nmeth.3621
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shaw AT, 2016, SEMIN CELL DEV BIOL, V49, P2, DOI 10.1016/j.semcdb.2015.10.013
   Shupp AB, 2018, CANCERS, V10, DOI 10.3390/cancers10060182
   Squecco R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073645
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   Vedi A, 2016, ANN NY ACAD SCI, V1370, P5, DOI 10.1111/nyas.12981
   Vizoso FJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091852
   Wu J, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/1540148
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xie Y, 2019, EUR REV MED PHARMACO, V23, P1214, DOI 10.26355/eurrev_201902_17014
   Yamada M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205199
   Yu VWC, 2016, CURR TOP DEV BIOL, V118, P21, DOI 10.1016/bs.ctdb.2016.01.009
   Zheng HQ, 2017, CANCER CELL, V32, P731, DOI 10.1016/j.ccell.2017.11.002
NR 71
TC 19
Z9 20
U1 0
U2 17
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2021
VL 22
IS 11
AR 5665
DI 10.3390/ijms22115665
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SQ1VE
UT WOS:000660146600001
PM 34073480
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shu, HY
   Zhao, HX
   Shi, YJ
   Lu, C
   Li, L
   Zhao, N
   Lu, AP
   He, XJ
AF Shu, Haiyang
   Zhao, Hanxiao
   Shi, Yingjie
   Lu, Cheng
   Li, Li
   Zhao, Ning
   Lu, Aiping
   He, Xiaojuan
TI Transcriptomics based analysis of the mechanism by which Wang Bi capsule
   alleviates joint destruction in rats with collagen induced arthritis
SO CHINESE MEDICINE
LA English
DT Article
DE Wang Bi capsule; Rheumatoid arthritis; Joint destruction; Molecular
   mechanism; Transcriptomic
ID RHEUMATOID ARTHRITIS; OSTEOCLAST FORMATION; BONE DESTRUCTION;
   GENE EXPRESSION; DIFFERENTIATION; INFLAMMATION; PATHWAY; DAMAGE;
   CHONDROCYTES; CYTOKINES
AB Background Rheumatoid arthritis (RA) is a chronic autoimmune disease accompanied with joint destruction that often leads to disability. Wang Bi capsule (WB), a traditional Chinese medicine based herbs formula, has exhibited inhibition effect on joint destruction of collagen induced arthritis (CIA) animal model in our previous study. But its molecular mechanisms are still obscure. Methods CIA rats were treated intragastrical with WB for eight weeks, and the effect of joints protection were evaluated by hematoxylin and eosin (H&E) staining, safranin O fast green staining, tartrate resistant acid phosphatase (TRAP) staining and micro CT scanning analysis. The transcriptomic of tarsal joints were used to investigate how WB alleviated joint destruction. Results The histological examination of ankle joints showed WB alleviated both cartilage damage and bone destruction of CIA rats. This protective effect on joints were further evidenced by micro CT analysis. The transcriptomic analysis showed that WB prominently changed 12 KEGG signaling pathways ("calcium signaling pathway", "cAMP signaling pathway", "cell adhesion molecules", "chemokine signaling pathway", "complement and coagulation cascades", "MAPK signaling pathway", "NF kappa B signaling pathway", "osteoclast differentiation", "PI3K Akt signaling pathway", "focal adhesion", "Gap junction" and "Rap1 signaling pathway") associated with bone or cartilage. Several genes (including Il6, Tnfsf11, Ffar2, Plg, Tnfrsf11b, Fgf4, Fpr1, Siglec1, Vegfd, Cldn1, Cxcl13, Chad, Arrb2, Fgf9, Egfr) regulating bone resorption, bone formation and cartilage development were identified by further analysis. Meanwhile, these differentially expressed genes were validated by real time quantitative PCR. Conclusions Overall, the protective effect of WB treatment on joint were confirmed in CIA rats, and its basic molecular mechanisms may be associated with regulating some genes (including Il6, Tnfsf11, Ffar2 and Plg etc.) involved in bone resorption, bone formation and cartilage development.
C1 [Shu, Haiyang; Zhao, Hanxiao] Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou 510006, Peoples R China.
   [Shu, Haiyang; Zhao, Hanxiao; Shi, Yingjie; Lu, Cheng; Li, Li; Zhao, Ning; He, Xiaojuan] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China.
   [Shi, Yingjie] Shanghai Univ Tradit Chinese Med, Shanghai Innovat Ctr TCM Hlth Serv, Shanghai, Peoples R China.
   [Lu, Aiping] Hong Kong Baptist Univ, Sch Chinese Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Kowloon, Hong Kong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Institute of Basic Research In
   Clinical Medicine, CACMS; China Academy of Chinese Medical Sciences;
   Shanghai University of Traditional Chinese Medicine; Hong Kong Baptist
   University
RP He, XJ (通讯作者)，China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China.; Lu, AP (通讯作者)，Hong Kong Baptist Univ, Sch Chinese Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Kowloon, Hong Kong, Peoples R China.
EM aipinglu@hkbu.edu.hk; hxj19@126.com
RI LU, Aiping/JDX 0577 2023; Shi, Yingjie/AED 8830 2022; zhao,
   ning/JSL 2925 2023
FU National Key R&D Program of China [2018YFC1705205]
FX This research is supported by the National Key R&D Program of China
   (2018YFC1705205).
CR Aletaha D., 2018, Electronic, V25, P1538
   Alshbool FZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114357
   Aronovich A, 2013, BLOOD, V122, P2562, DOI 10.1182/blood 2012 08 447458
   Batista MA, 2014, MATRIX BIOL, V38, P84, DOI 10.1016/j.matbio.2014.05.008
   Batoon L, 2019, BIOMATERIALS, V196, P51, DOI 10.1016/j.biomaterials.2017.10.033
   Binder NB, 2013, ARTHRITIS RHEUM US, V65, P608, DOI 10.1002/art.37797
   Bonnet N, 2005, MED SCI SPORT EXER, V37, P1493, DOI 10.1249/01.mss.0000177592.82507.95
   Boutin A, 2014, FASEB J, V28, P3446, DOI 10.1096/fj.14 251124
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Campo GM, 2015, MOL CELL BIOCHEM, V399, P201, DOI 10.1007/s11010 014 2246 5
   Carroll SH, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.2
   Chen LL, 2013, TISSUE ENG PT A, V19, P2226, DOI [10.1089/ten.tea.2012.0469, 10.1089/ten.TEA.2012.0469]
   Cho E, 2019, MOLECULES, V24, DOI 10.3390/molecules24183346
   Cui H, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/1015083
   Dai JW, 2012, BIOMATERIALS, V33, P7699, DOI 10.1016/j.biomaterials.2012.07.020
   Denninger KCM, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0531 7
   Ding N, 2020, BMB REP, V53, P154, DOI 10.5483/BMBRep.2020.53.3.147
   Drossaers Bakker KW, 1999, ARTHRITIS RHEUM, V42, P1854, DOI 10.1002/1529 0131(199909)42:9<1854::AID ANR9>3.0.CO;2 F
   Guo QQ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00230
   Hu PF, 2018, EXP THER MED, V16, P1513, DOI 10.3892/etm.2018.6325
   Ilvesaro J, 2003, CRIT REV EUKAR GENE, V13, P133, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.70
   Jeevaratnam K, 2018, ANN NY ACAD SCI, V1433, P18, DOI 10.1111/nyas.13861
   Jing XZ, 2019, J CELL PHYSIOL, V234, P10123, DOI 10.1002/jcp.27678
   Kang H, 2013, J BIOL CHEM, V288, P12187, DOI 10.1074/jbc.M112.430389
   Kanno Y, 2011, J BIOL CHEM, V286, P8952, DOI 10.1074/jbc.M110.152181
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Kim H, 2020, INT J MOL SCI, V21, P7
   Kramer I, 2012, J BONE MINER RES, V27, P360, DOI 10.1002/jbmr.1492
   Kubota K, 2002, BONE, V31, P465, DOI 10.1016/S8756 3282(02)00852 9
   Kuroda S, 1999, BONE, V25, P431, DOI 10.1016/S8756 3282(99)00193 3
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Li JL, 2008, BONE, V43, P469, DOI 10.1016/j.bone.2008.05.018
   Li Z, 2020, BIOCHEM BIOPH RES CO, V531, P497, DOI 10.1016/j.bbrc.2020.07.060
   Matemba SF, 2006, J CELL BIOCHEM, V99, P528, DOI 10.1002/jcb.20866
   Mathieu PS, 2012, TISSUE ENG PART B RE, V18, P436, DOI [10.1089/ten.teb.2012.0014, 10.1089/ten.TEB.2012.0014]
   Mishra R, 2020, DEV CELL, V52, P167, DOI 10.1016/j.devcel.2019.11.016
   Montalvany Antonucci CC, 2019, BONE, V125, P112, DOI 10.1016/j.bone.2019.05.016
   Mukai T, 2015, ARTHRITIS RHEUMATOL, V67, P656, DOI 10.1002/art.38975
   Nguyen TS, 2018, BLOOD, V132, P123, DOI 10.1182/blood 2017 12 768986
   Notomi T, 2015, J BONE MINER RES, V30, P1618, DOI 10.1002/jbmr.2507
   Orlandini M, 2006, J BIOL CHEM, V281, P17961, DOI 10.1074/jbc.M600413200
   Ramazzotti G, 2016, J CELL PHYSIOL, V231, P623, DOI 10.1002/jcp.25107
   Schneider MR, 2009, TRENDS ENDOCRIN MET, V20, P517, DOI 10.1016/j.tem.2009.06.008
   Scott DL, 2000, RHEUMATOLOGY, V39, P122, DOI 10.1093/rheumatology/39.2.122
   Shin MK, 2011, J BIOL CHEM, V286, P17133, DOI 10.1074/jbc.M110.197772
   Sims NA, 2016, INT J BIOCHEM CELL B, V79, P14, DOI 10.1016/j.biocel.2016.08.003
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Smolen JS, 2012, ANN RHEUM DIS, V71, P687, DOI 10.1136/annrheumdis 2011 200395
   Smolen JS, 2005, ARTHRITIS RHEUM, V52, P1020, DOI 10.1002/art.20982
   Su XM, 2012, J CLIN INVEST, V122, P3579, DOI 10.1172/JCI38576
   Su YW, 2018, J CELL PHYSIOL, V233, P2133, DOI 10.1002/jcp.25936
   Su YW, 2016, J BONE MINER RES, V31, P1258, DOI 10.1002/jbmr.2786
   Swift JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106904
   Tarquini C, 2020, AGING US, V12, P10129, DOI 10.18632/aging.103310
   Topol LL, 2009, J BIOL CHEM, V284, P3323, DOI 10.1074/jbc.M808048200
   Valerio MS, 2015, CYTOKINE, V71, P71, DOI 10.1016/j.cyto.2014.08.007
   Xie D, 2007, BONE, V40, P1352, DOI 10.1016/j.bone.2007.01.007
   Xie YL, 2019, INT J NANOMED, V14, P6019, DOI 10.2147/IJN.S203859
   Xu HY, 2018, IMMUNOLOGY, V154, P593, DOI 10.1111/imm.12907
   Xuan WH, 2017, CELL BIOCHEM FUNCT, V35, P171, DOI 10.1002/cbf.3260
   Zhang SC, 2017, BIOMED PHARMACOTHER, V88, P436, DOI 10.1016/j.biopha.2017.01.050
   Zhang XL, 2018, J BONE MINER METAB, V36, P628, DOI 10.1007/s00774 017 0880 1
   Zhao HY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00262
   Zuo S, 2019, DRUG DES DEV THER, V13, P3949, DOI 10.2147/DDDT.S203094
NR 64
TC 10
Z9 10
U1 2
U2 26
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 8546
J9 CHIN MED UK
JI Chin. Med.
PD APR 12
PY 2021
VL 16
IS 1
AR 31
DI 10.1186/s13020 021 00439 w
PG 11
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA RM1VS
UT WOS:000639448700001
PM 33845855
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xue, YL
   Zhao, CL
   Liu, T
AF Xue, Yuanliang
   Zhao, Chuanliang
   Liu, Tao
TI Interferon induced protein with tetratricopeptide repeats 1 (IFIT1)
   accelerates osteoclast formation by regulating signal transducer and
   activator of transcription 3 (STAT3) signalling
SO BIOENGINEERED
LA English
DT Article
DE IFIT1; osteoclast formation; STAT3 signaling; RANKL
ID RECEPTOR ACTIVATOR; BONE LOSS; RANKL; DIFFERENTIATION; PHOSPHATASE;
   OSTEOBLAST; HEAD
AB Osteoclasts (OCs), the main cause of bone resorption irregularities, may ultimately cause various bone diseases, including osteoarthritis. The objective of this study was to investigate the effect of interferon induced protein with tetratricopeptide repeats 1 (IFIT1) on OC formation induced by receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL) and to further explore its underlying mechanism. IFIT1 expression in Raw264.7 cells treated with macrophage colony stimulating factor (M CSF) and RANKL was determined by qRT PCR. OC formation was detected using tartrate resistant acid phosphatase (TRAP) staining. The effect of IFIT1 on STAT3 activation was detected using Western blotting. Additionally, Western blotting was used to measure the change in the expression of OC specific proteins. IFIT1 was highly expressed in Raw264.7 cells after stimulation with M CSF and RANKL. IFIT1 overexpression accelerated the formation of OCs, as evidenced by the increased number and size of multinuclear cells, and the upregulation of OC specific proteins, and activated the STAT3 pathway, by inducing phosphorylation of JAK1 and STAT3. However, silencing of IFIT1 inhibited the formation of OCs and a STAT3 inhibitor Stattic weakened the effects of IFIT1. In conclusion, IFIT1 accelerates the formation of OCs, which is caused by RANKL by STAT3 pathway regulation. This study provides a potential basis for further research and for development of drugs for treating bone resorption related diseases.
C1 [Xue, Yuanliang] Shandong Univ Tradit Chinese Med, Clin Med Coll, Dept Orthoped, Jinan, Shandong, Peoples R China.
   [Zhao, Chuanliang] Laoling Peoples Hosp, Dept Radiol, Dezhou, Shandong, Peoples R China.
   [Liu, Tao] Dezhou Peoples Hosp Shandong, Dept Pediat Surg, Dezhou, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine
RP Liu, T (通讯作者)，Dezhou Peoples Hosp Shandong, 1166 Dongfanghong West Rd, Dezhou 253014, Shandong, Peoples R China.
EM taoliult@aliyun.com
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   BEGG SK, 1993, J EXP MED, V177, P237, DOI 10.1084/jem.177.1.237
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Broadhead ML, 2011, EXPERT OPIN THER TAR, V15, P169, DOI 10.1517/14728222.2011.546351
   Burrage PS, 2006, FRONT BIOSCI LANDMRK, V11, P529, DOI 10.2741/1817
   Chen H, 2021, BIOENGINEERED, V12, P12677, DOI 10.1080/21655979.2021.2008666
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chen XZ, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.015
   Chiu YH, 2016, J CELL PHYSIOL, V231, P2402, DOI 10.1002/jcp.25389
   Dai R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00433
   Deng SJ, 2019, CANCER RES, V79, P1398, DOI 10.1158/0008 5472.CAN 18 0419
   Deng ZT, 2021, BIOMATER SCI UK, V9, P1291, DOI 10.1039/d0bm01256d
   Diamond MS, 2014, CYTOKINE GROWTH F R, V25, P543, DOI 10.1016/j.cytogfr.2014.05.002
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Fensterl V, 2015, J VIROL, V89, P2462, DOI 10.1128/JVI.02744 14
   Gaafar AGA, 2018, EUR J PHARMACOL, V822, P177, DOI 10.1016/j.ejphar.2018.01.009
   Gao LH, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00048
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hillmer EJ, 2016, CYTOKINE GROWTH F R, V31, P1, DOI 10.1016/j.cytogfr.2016.05.001
   Hügle T, 2017, RHEUMATOLOGY, V56, P1461, DOI 10.1093/rheumatology/kew389
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007
   Kim T, 2010, BIOCHEM BIOPH RES CO, V403, P73, DOI 10.1016/j.bbrc.2010.10.117
   Latourte A, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 209757
   Li D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051660
   Li H, 2020, AM J CLIN PATHOL, V153, P618, DOI 10.1093/ajcp/aqz205
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Li YX, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8829212
   Liu Y, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12974
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Park H, 2015, ANTIOXID REDOX SIGN, V22, P63, DOI 10.1089/ars.2013.5748
   Persson E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01164
   Pidugu VK, 2019, ONCOGENE, V38, P3232, DOI 10.1038/s41388 018 0662 9
   Shin J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5380
   Takeno A, 2018, AM J PHYSIOL ENDOC M, V314, pE115, DOI 10.1152/ajpendo.00159.2017
   Wang JL, 2020, DNA CELL BIOL, V39, P1274, DOI 10.1089/dna.2020.5454
   Xing LP, 2012, WORLD J ORTHOP, V3, P212, DOI 10.5312/wjo.v3.i12.212
   Yang GX, 2019, PULM PHARMACOL THER, V56, P69, DOI 10.1016/j.pupt.2019.03.011
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Yin W, 2021, BIOENGINEERED, V12, P8679, DOI 10.1080/21655979.2021.1991160
   Yu MJ, 2009, J BIOL CHEM, V284, P32968, DOI 10.1074/jbc.M109.001016
   Zhou M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133715
   Zhou X, 2013, INT J BIOL SCI, V9, P200, DOI 10.7150/ijbs.5613
NR 43
TC 7
Z9 7
U1 1
U2 17
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165 5979
EI 2165 5987
J9 BIOENGINEERED
JI Bioengineered
PD FEB 1
PY 2022
VL 13
IS 2
BP 2285
EP 2295
DI 10.1080/21655979.2021.2024333
PG 11
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA YH3GL
UT WOS:000743058400001
PM 35034537
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yan, XJ
   Wang, ZJ
   Wang, H
   Wei, MZ
   Chen, YC
   Zhao, YL
   Luo, XD
AF Yan, Xiao Jun
   Wang, Zhao Jie
   Wang, Huan
   Wei, Mei Zhen
   Chen, Yi Chi
   Zhao, Yun Li
   Luo, Xiao Dong
TI Formononetin Derivative for Osteoporosis by Simultaneous Regulating
   Osteoblast and Osteoclast
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID BONE LOSS; POSTMENOPAUSAL OSTEOPOROSIS; ACTIVATION; MODEL
AB Seven new formononetin derivatives (1 7) were designed and prepared from formononetin (phase II phytoestrogen). The derivatives 9 butyl 3 (4 methoxyphenyl) 9,10 dihydro 4H,8H chromeno[8,7 e][1,3]oxazin 4 one (2) and 9 (furan 3 ylmethyl) 3 (4 methoxyphenyl) 9,10 dihydro 4H,8H chromeno[8,7 e][1,3]oxazin 4 one (7) promoted significant osteoblast formation by modulating the BMP/Smad pathway. Compound 7 exhibited potent antiosteoclastogenesis activity in RANKL induced RAW264.7 cells and ovariectomy (OVX) induced osteoporosis in mice by regulation of the RANK/RANKL/OPG pathway. Compound 7 regulated osteoblast and osteoclast simultaneously and showed better effect than the well known drug ipriflavone in vivo, suggesting 7 as a patented antiosteoporosis candidate.
C1 [Yan, Xiao Jun; Wang, Zhao Jie; Wang, Huan; Wei, Mei Zhen; Chen, Yi Chi; Zhao, Yun Li; Luo, Xiao Dong] Yunnan Univ, Sch Chem Sci & Technol, Minist Educ & Yunnan Prov, Key Lab Med Chem Nat Resource,Sch Pharm,Yunnan Cha, Kunming 650500, Peoples R China.
   [Luo, Xiao Dong] Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochemistry & Plant Resources Wes, Kunming 650201, Peoples R China.
C3 Yunnan University; Chinese Academy of Sciences; Kunming Institute of
   Botany, CAS
RP Zhao, YL; Luo, XD (通讯作者)，Yunnan Univ, Sch Chem Sci & Technol, Minist Educ & Yunnan Prov, Key Lab Med Chem Nat Resource,Sch Pharm,Yunnan Cha, Kunming 650500, Peoples R China.; Luo, XD (通讯作者)，Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochemistry & Plant Resources Wes, Kunming 650201, Peoples R China.
EM zhaoyunli@ynu.edu.cn; xdluo@ynu.edu.cn
RI ; Jie, Wang/MVW 1284 2025; Yan, Xiaojun/AAK 7989 2020
OI Zhao, YunLi/0000 0001 9175 8017; 
FU High level Talent Promotion and Training Project of Kunming
   [2022SCP003]; Project of Yunnan Characteristic Plant Screening and R&D
   Service CXO Platform [2022YKZY001]; Major Science and Technology Project
   of Yunnan Province [202302AA310013]; General Program of Applied Basic
   Research of Yunnan province [202201AT070079]
FX This work was financially supported by the High level Talent Promotion
   and Training Project of Kunming (2022SCP003), the Project of Yunnan
   Characteristic Plant Screening and R&D Service CXO Platform
   (2022YKZY001), the Major Science and Technology Project of Yunnan
   Province (202302AA310013), and the General Program of Applied Basic
   Research of Yunnan province (202201AT070079). We thank the Advanced
   Analysis and Measurement Center of Yunnan University for technical
   support.
CR Abdallah BM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929 019 0544 7
   An Q., 2019, ACTA U MED ANHUI, V54, P6
   Chinese Society of Osteoporosis and Bone Mineral Research, 2023, Gen Pract China, V26, P1671, DOI 10.12114/j.issn.1007 9572.2023.0121
   Choi LY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.643482
   Chua S. K., 2019, AGE AGEING, V48, piv13, DOI [10.1093/ageing/afz164.64, DOI 10.1093/AGEING/AFZ164.64]
   Chung HJ, 2019, J NAT PROD, V82, P1398, DOI 10.1021/acs.jnatprod.9b00324
   Djapardy V, 2022, BEST PRACT RES CL OB, V81, P45, DOI 10.1016/j.bpobgyn.2021.09.012
   Duan XH, 2016, THERANOSTICS, V6, P2183, DOI 10.7150/thno.17140
   Fait Tomas, 2023, Cas Lek Cesk, V161, P309
   Gao AG, 2018, EUR REV MED PHARMACO, V22, P4669, DOI 10.26355/eurrev_201807_15527
   Gautam AK, 2011, J NUTR BIOCHEM, V22, P318, DOI 10.1016/j.jnutbio.2010.02.010
   Ge X. L., 1999, BIOCHEMICAL MARKERSO, V2, P5
   Grewe JM, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00205 0
   Guenther C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000308
   Ha H, 2010, ARCH PHARM RES, V33, P625, DOI 10.1007/s12272 010 0418 8
   Halpner AD, 2000, J WOMEN HEALTH GEN B, V9, P995, DOI 10.1089/15246090050200024
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   [胡昆 Hu Kun], 2012, [中国药科大学学报, Journal of China Pharmaceutical University], V43, P113
   Huang CQ, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 05362 y
   Jayusman PA, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1120457
   Jin X, 2022, ACTA ASTRONAUT, V200, P77, DOI 10.1016/j.actaastro.2022.07.049
   KACZMARCZYKSEDL.I, 2013, EVID BASED COMPL ALT, V2013, P1, DOI DOI 10.1155/2013/457052
   Kim C, 2018, CANCER LETT, V431, P123, DOI 10.1016/j.canlet.2018.05.038
   Lee JH, 2012, MOL CELL BIOCHEM, V368, P147, DOI 10.1007/s11010 012 1353 4
   Liu XJ, 2021, STEM CELLS, V39, P1395, DOI 10.1002/stem.3428
   Lowery JW, 2011, CRIT REV EUKAR GENE, V21, P177, DOI 10.1615/CritRevEukarGeneExpr.v21.i2.60
   Mu H, 2009, PHYTOMEDICINE, V16, P314, DOI 10.1016/j.phymed.2008.07.005
   Picca A, 2017, CURR PHARM DESIGN, V23, P6256, DOI 10.2174/1381612823666170526112300
   Saul D, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00400
   Singh KB, 2017, BRIT J NUTR, V117, P1511, DOI 10.1017/S0007114517001556
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Xiu DH, 2018, CYTOKINE, V102, P173, DOI 10.1016/j.cyto.2017.09.003
   Xu YX, 2021, J CELL MOL MED, V25, P5025, DOI 10.1111/jcmm.16451
   Yu X, 2023, CELL SIGNAL, V106, DOI 10.1016/j.cellsig.2023.110651
   Zhang SX, 2021, EUR J MED CHEM, V213, DOI 10.1016/j.ejmech.2021.113185
   Zhu HB, 2014, PLANTA MED, V80, P262, DOI 10.1055/s 0033 1360340
NR 37
TC 2
Z9 2
U1 4
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163 3864
EI 1520 6025
J9 J NAT PROD
JI J. Nat. Prod.
PD JUL 21
PY 2024
VL 87
IS 8
BP 2004
EP 2013
DI 10.1021/acs.jnatprod.4c00437
EA JUL 2024
PG 10
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Plant Sciences; Pharmacology & Pharmacy
GA D6M2I
UT WOS:001273658100001
PM 39033408
DA 2025 08 17
ER

PT J
AU Jayash, SN
   Hamoudi, D
   Stephen, LA
   Argaw, A
   Huesa, C
   Joseph, S
   Wong, SC
   Frenette, J
   Farquharson, C
AF Jayash, Soher Nagi
   Hamoudi, Dounia
   Stephen, Louise A.
   Argaw, Anteneh
   Huesa, Carmen
   Joseph, Shuko
   Wong, Sze Choong
   Frenette, Jerome
   Farquharson, Colin
TI Anti RANKL Therapy Prevents Glucocorticoid Induced Bone Loss and
   Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Anti RANKL; Glucocorticoid; Bone loss; Muscle dysfunction; Duchenne
   muscular dystrophy; Bisphosphonates
ID ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; DENOSUMAB DISCONTINUATION;
   VERTEBRAL FRACTURES; MINERAL DENSITY; OSTEOPOROSIS; OSTEOPROTEGERIN;
   INTERMITTENT; NECROSIS; PLACEBO
AB Bisphosphonates prevent bone loss in glucocorticoid (GC) treated boys with Duchenne muscular dystrophy (DMD) and are recommended as standard of care. Targeting receptor activator of nuclear factor kappa B ligand (RANKL) may have advantages in DMD by ameliorating dystrophic skeletal muscle function in addition to their bone anti resorptive properties. However, the potential effects of anti RANKL treatment upon discontinuation in GC induced animal models of DMD are unknown and need further investigation prior to exploration in the clinical research setting. In the first study, the effects of anti RANKL and deflazacort (DFZ) on dystrophic skeletal muscle function and bone microstructure were assessed in mdx mice treated with DFZ or anti RANKL, or both for 8 weeks. Anti RANKL and DFZ improved grip force performance of mdx mice but an additive effect was not noted. However, anti RANKL but not DFZ improved ex vivo contractile properties of dystrophic muscles. This functional improvement was associated with a reduction in muscle damage and fibrosis, and inflammatory cell number. Anti RANKL treatment, with or without DFZ, also improved trabecular bone structure of mdx mice. In a second study, intravenous zoledronate (Zol) administration (1 or 2 doses) following 2 months of discontinuation of anti RANKL treatment was mostly required to record an improvement in bone microarchitecture and biomechanical properties in DFZ treated mdx mice. In conclusion, the ability of anti RANKL therapy to restore muscle function has profound implications for DMD patients as it offers the possibility of improving skeletal muscle function without the steroid related skeletal side effects.
C1 [Jayash, Soher Nagi; Stephen, Louise A.; Farquharson, Colin] Univ Edinburgh, Roslin Inst, Edinburgh EH25 9RG, Midlothian, Scotland.
   [Jayash, Soher Nagi; Stephen, Louise A.; Farquharson, Colin] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh EH25 9RG, Midlothian, Scotland.
   [Hamoudi, Dounia; Argaw, Anteneh; Frenette, Jerome] Univ Laval, Hosp Univ Laval, Ctr Rech Ctr Hosp, Univ Quebec Ctr, Quebec City, PQ, Canada.
   [Huesa, Carmen] Univ Glasgow, Sch Infect & Immun, Glasgow, Scotland.
   [Joseph, Shuko] Queen Elizabeth Univ Hosp, Royal Hosp Children Glasgow, Sch Med Dent & Nursing Child Health, Glasgow, Scotland.
   [Wong, Sze Choong] Univ Glasgow, Royal Hosp Children Glasgow, Queen Elizabeth Univ Hosp, Sch Med Dent & Nursing Child Hlth, Glasgow, Scotland.
C3 University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology
   and Biological Sciences Research Council (BBSRC); Roslin Institute;
   University of Edinburgh; Laval University; University of Glasgow; Queen
   Elizabeth University Hospital (QEUH); Queen Elizabeth University
   Hospital (QEUH); University of Glasgow
RP Jayash, SN (通讯作者)，Univ Edinburgh, Roslin Inst, Edinburgh EH25 9RG, Midlothian, Scotland.; Jayash, SN (通讯作者)，Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh EH25 9RG, Midlothian, Scotland.
EM sjayash@ed.ac.uk; jerome.frenette@crchudequebec.ulaval.ca
RI ; Jayash, Soher/C 7348 2017; Jayash, soher/C 7348 2017
OI Huesa, Carmen/0000 0002 4989 4258; Stephen, Louise/0000 0001 6795 0383;
   Jayash, Soher/0000 0001 5263 8557; 
FU LifeArc CSO, UK; Duchenne Parent Project, Netherlands; Canadian
   Institutes of Health Research [IC125018]; Biotechnology and Biological
   Sciences Research Council (BBSRC) for Institute Strategic Programme
   [BB/J004316/1]; Biotechnology and Biological Sciences Research Council
   [BBS/E/D/10002071] Funding Source: researchfish; BBSRC
   [BBS/E/RL/230001C, BBS/E/D/10002071] Funding Source: UKRI
FX This work was supported by grants from LifeArc CSO, UK (CF, JF, SCW and
   SJ); Duchenne Parent Project, Netherlands (CF, JF, LS, AA and SCW);
   Canadian Institutes of Health Research IC125018 (JF) and Biotechnology
   and Biological Sciences Research Council (BBSRC) for Institute Strategic
   Programme Grant Funding BB/J004316/1 to (CF, LAS & SAJ). For the purpose
   of open access, the author has applied a CC BY public copyright licence
   to any Author Accepted Manuscript version arising from this submission.
CR Aartsma Rus A, 2016, J MED GENET, V53, P145, DOI 10.1136/jmedgenet 2015 103387
   Abbott D, 2017, NEUROMUSCULAR DISORD, V27, P38, DOI 10.1016/j.nmd.2016.09.022
   Akhter MP, 2004, BONE, V35, P162, DOI 10.1016/j.bone.2004.02.018
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Brown HK, 2012, CLIN EXP METASTAS, V29, P927, DOI 10.1007/s10585 012 9481 5
   Buckner JL, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/928385
   Case SJ, 2023, J PEDIATR ENDOCR MET, V36, P327, DOI 10.1515/jpem 2022 0475
   Choi NK, 2017, J BONE MINER RES, V32, P611, DOI 10.1002/jbmr.3019
   Crabtree NJ, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116248
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dufresne SS, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478 018 0533 1
   Dufresne SS, 2015, AM J PATHOL, V185, P920, DOI 10.1016/j.ajpath.2015.01.006
   Esapa Christopher T, 2012, Curr Protoc Mouse Biol, V2, P365, DOI 10.1002/9780470942390.mo120124
   Evans NP, 2009, AM J PHYS MED REHAB, V88, P502, DOI 10.1097/PHM.0b013e3181a5a24f
   Everts Graber J, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115830
   Everts Graber J, 2020, J BONE MINER RES, V35, P1207, DOI 10.1002/jbmr.3962
   Grimaud E, 2003, AM J PATHOL, V163, P2021, DOI 10.1016/S0002 9440(10)63560 2
   Haider MT, 2014, BONE, V66, P240, DOI 10.1016/j.bone.2014.06.023
   Hamoudi D, 2019, HUM MOL GENET, V28, P3101, DOI 10.1093/hmg/ddz124
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Hao Y, 2015, BONE, V81, P702, DOI 10.1016/j.bone.2015.09.018
   Herbelet S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134596
   Hodgetts S, 2006, NEUROMUSCULAR DISORD, V16, P591, DOI 10.1016/j.nmd.2006.06.011
   Hofbauer LC, 2009, ARTHRITIS RHEUM, V60, P1427, DOI 10.1002/art.24445
   Horne AM, 2018, CALCIFIED TISSUE INT, V103, P55, DOI 10.1007/s00223 018 0404 6
   Huesa C, 2011, BONE, V48, P1066, DOI 10.1016/j.bone.2011.01.010
   Hung C., 2022, JBJS CASE CONNECTOR, V12, DOI [10.2106/jbjs.cc.21.00664, DOI 10.2106/JBJS.CC.21.00664]
   Hussein MR, 2006, INT J EXP PATHOL, V87, P451, DOI 10.1111/j.1365 2613.2006.00470.x
   Ivanyuk A, 2018, NEUROMUSCULAR DISORD, V28, P865, DOI 10.1016/j.nmd.2018.08.004
   Jayash SN, 2017, PEERJ, V5, DOI 10.7717/peerj.3513
   Jayash SN, 2021, FRONT MATER, V8, DOI 10.3389/fmats.2021.640950
   Joseph S, 2016, HORM RES PAEDIAT, V86, P71, DOI 10.1159/000447583
   Joseph S, 2019, NEUROMUSCULAR DISORD, V29, P59, DOI 10.1016/j.nmd.2018.09.005
   Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098
   Kendler David, 2020, J Clin Endocrinol Metab, V105, DOI 10.1210/clinem/dgz095
   Kondo T, 2008, J CELL BIOCHEM, V103, P335, DOI 10.1002/jcb.21414
   Kumaki Daiki, 2018, JBJS Case Connect, V8, pe22, DOI 10.2106/JBJS.CC.17.00190
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Lemon J, 2019, NEUROMUSCULAR DISORD, V29, P567, DOI 10.1016/j.nmd.2019.05.002
   Mah JK, 2016, NEUROPSYCH DIS TREAT, V12, P1795, DOI 10.2147/NDT.S93873
   Marcadet L, 2023, CELLS BASEL, V12, DOI 10.3390/cells12111538
   Marcadet L, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.903657
   McCloskey EV, 2012, J BONE MINER RES, V27, P1480, DOI 10.1002/jbmr.1606
   Mok CC, 2015, BONE, V75, P222, DOI 10.1016/j.bone.2015.03.002
   Nowak KJ, 2004, EMBO REP, V5, P872, DOI 10.1038/sj.embor.7400221
   Park Jung Wee, 2021, J Bone Metab, V28, P339, DOI 10.11005/jbm.2021.28.4.339
   Popp AW, 2018, CALCIFIED TISSUE INT, V103, P50, DOI 10.1007/s00223 018 0394 4
   Quattrocelli M, 2017, J CLIN INVEST, V127, P2418, DOI 10.1172/JCI91445
   Radley HG, 2006, NEUROBIOL DIS, V23, P387, DOI 10.1016/j.nbd.2006.03.016
   Ricotti V, 2013, J NEUROL NEUROSUR PS, V84, P698, DOI 10.1136/jnnp 2012 303902
   Robling AG, 2009, MED SCI SPORT EXER, V41, P2044, DOI 10.1249/MSS.0b013e3181a8c702
   Rosenberg AS, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7322
   Salmaninejad A, 2021, INT J NEUROSCI, V131, P370, DOI 10.1080/00207454.2020.1740218
   Staines KA, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2731 9
   Tang L, 2016, INT J SPORT NUTR EXE, V26, P516, DOI 10.1123/ijsnem.2015 0337
   Ward LM, 2021, J CLIN ENDOCR METAB, V106, pE5222, DOI 10.1210/clinem/dgab458
   Ward LM, 2018, PEDIATRICS, V142, pS34, DOI 10.1542/peds.2018 0333E
   Wasilewska A, 2010, PEDIATR NEPHROL, V25, P2067, DOI 10.1007/s00467 010 1583 1
   Wintzinger M., 2022, MUSCULAR DYSTROPHY T, P467
   Wood CL, 2022, J ENDOCRINOL, V253, P63, DOI 10.1530/JOE 21 0388
   Wood CL, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.040659
NR 64
TC 10
Z9 10
U1 2
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD OCT
PY 2023
VL 113
IS 4
BP 449
EP 468
DI 10.1007/s00223 023 01116 w
EA JUL 2023
PG 20
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA S1AK0
UT WOS:001032601200001
PM 37470794
OA Green Accepted, hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Huang, HS
   Ji, F
   Qi, GB
   Cao, YT
   He, XC
   Wang, H
   Jiang, ZX
AF Huang, Haisheng
   Ji, Fang
   Qi, Guobin
   Cao, Yuting
   He, Xuecheng
   Wang, Hao
   Jiang, Zengxin
TI Rehmannioside A promotes the osteoblastic differentiation of MC3T3 E1
   cells via the PI3K/AKT signaling pathway and inhibits
   glucocorticoid induced bone loss in vivo
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Osteoporosis; Osteoblast; Rehmannioside A; PI3K/AKT signaling pathway
ID KAPPA B; OSTEOPOROSIS
AB Glucocorticoid induced osteoporosis (GIOP) is a widespread disease characterized by low bone density. There remains a lack of effective means for osteoporosis. Rehmannioside A (ReA), an iridoid glycoside, exhibits various pharmacological activities. This study aimed to explore the role and mechanism of ReA in osteogenic differentiation of osteoblasts. Cell viability, reactive oxygen species (ROS) generation, and cell apoptosis were assessed using corresponding assay kits. Real time quantitative polymerase chain reaction, Western blotting, and alkaline phosphatase (ALP) staining were performed to evaluate the osteogenic differentiation of MC3T3 E1 cells. Alizarin red S staining was used to assess the mineralization of MC3T3 E1 cells. Protein expression associated with the phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) signaling pathway was analyzed using Western blotting. Micro computed tomography, histopathological, and immunohistochemical analyses were performed to determine the therapeutic effect of ReA on GIOP in vivo.The results showed that ReA promoted the osteogenic differentiation of MC3T3 E1 cells by regulating the PI3K/AKT signaling pathway and protected mice against glucocorticoid induced bone loss by promoting osteoblast mediated bone formation in vivo. The findings of the current study revealed that ReA is a potential therapeutic agent for osteoporosis.
C1 [Huang, Haisheng] Shanghai Univ TCM, SHANGHAI TCM INTEGRATED Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Ji, Fang] Chongqing Med Univ, Affiliated Hosp 2, Dept Day Ward, Chongqing, Peoples R China.
   [Qi, Guobin; Cao, Yuting; He, Xuecheng; Jiang, Zengxin] Shanghai Sixth Peoples Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Wang, Hao] Chongqing Med Univ, Affiliated Hosp 2, Ctr Joint Surg, Dept Orthoped Surg, Chongqing, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Chongqing Medical
   University; Shanghai Jiao Tong University; Chongqing Medical University
RP Jiang, ZX (通讯作者)，Shanghai Sixth Peoples Hosp, 600 Yishan Rd, Shanghai, Peoples R China.; Wang, H (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Linjiang Rd 76, Chongqing, Peoples R China.
EM haowang@hospital.cqmu.edu.cn; Dr_Jiangzx@163.com
RI Qi, Guobin/IXD 9658 2023
FU Natural Science Foundation of Chongqing [CSTB2023NSCQ BHX0096]; National
   Natural Science Foundation of China [82402850]
FX This work was supported by Natural Science Foundation of Chongqing
   (Grant No. CSTB2023NSCQ BHX0096) and National Natural Science Foundation
   of China (Grant No. 82402850) .
CR Anastasilaki E, 2023, HORM INT J ENDOCRINO, V22, P611, DOI 10.1007/s42000 023 00491 1
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Deng S, 2019, BIOMED PHARMACOTHER, V110, P602, DOI 10.1016/j.biopha.2018.11.103
   Fergusson AD, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15041157
   Fu C, 2022, J ETHNOPHARMACOL, V289, DOI 10.1016/j.jep.2022.115021
   Humphrey MB, 2023, ARTHRIT CARE RES, V75, P2405, DOI 10.1002/acr.25240
   Jia JH, 2023, BIOMED PHARMACOTHER, V168, DOI 10.1016/j.biopha.2023.115809
   Li ZC, 2023, PHARMACOL RES, V187, DOI 10.1016/j.phrs.2022.106635
   Lisco G, 2023, ENDOCR METAB IMMUNE, V23, P1278, DOI 10.2174/1871530323666230330121301
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Lu W, 2024, J PHARMACOL SCI, V154, P113, DOI 10.1016/j.jphs.2023.12.011
   Ma H, 2015, EXP CLIN ENDOCR DIAB, V123, P126, DOI 10.1055/s 0034 1390422
   Pan JM, 2019, J RECEPT SIG TRANSD, V39, P80, DOI 10.1080/10799893.2019.1625061
   Seguro LPC, 2015, OSTEOPOROSIS INT, V26, P459, DOI 10.1007/s00198 014 2860 9
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Sun K, 2020, OSTEOARTHR CARTILAGE, V28, P400, DOI 10.1016/j.joca.2020.02.027
   Sun M, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109492
   Tu Kristie N, 2018, P T, V43, P92
   Urquiaga M, 2022, BEST PRACT RES CL RH, V36, DOI 10.1016/j.berh.2022.101793
   Xu L, 2023, J PHARMACOL SCI, V153, P221, DOI 10.1016/j.jphs.2023.10.002
   Xu YX, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.894832
   Yuan M, 2022, J CHEM NEUROANAT, V125, DOI 10.1016/j.jchemneu.2022.102157
   Zha KK, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.824812
   Zhang GK, 2023, FRONT GENET, V14, DOI 10.3389/fgene.2023.1182363
   Zhang Y, 2023, FOOD SCI NUTR, V11, P5532, DOI 10.1002/fsn3.3509
NR 25
TC 1
Z9 1
U1 2
U2 6
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD DEC
PY 2024
VL 156
IS 4
BP 247
EP 257
DI 10.1016/j.jphs.2024.11.001
EA NOV 2024
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA M2L2R
UT WOS:001355898800001
PM 39608850
DA 2025 08 17
ER

PT J
AU Chen, HJ
   Chen, WL
   Yuan, F
   Guo, QC
   Zhang, XM
   Wang, CG
   Li, XN
AF Chen, Hanjing
   Chen, Weili
   Yuan, Fei
   Guo, Qingcheng
   Zhang, Xunmin
   Wang, Chenguang
   Li, Xuening
TI Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of
   CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE denosumab; biosimilar; pharmacokinetics; pharmacodynamics;
   immunogenicity; osteoporosis; RANKL
ID MONOCLONAL ANTIBODY; RANKL
AB Objective: Pharmacokinetics (PK), pharmacodynamics (PD), safety and immunogenicity studies were conducted to evaluate the bioequivalence of CMAB807, a biosimilar to denosumab (Prolia(R)), which is the only approved RANKL inhibitor for the treatment of osteoporosis.& nbsp;Methods: In this randomized, double blind, single dose phase I study, 132 healthy Chinese male subjects received a subcutaneous injection of 60 mg of CMAB807 or denosumab at a 1:1 ratio. The PK, PD, safety and immunogenicity results were assessed prior to and up to 126 days after administration.Results: The PK profiles of CMAB807 and denosumab were similar. The geometric mean ratios of the maximum concentration (C max), AUC(0 t) and AUC(o & INFIN;) were 102.41, 104.15 and 103.89%, respectively, and the 90% confidence interval was observed to be within 80.00 125.00%, which indicated the bioequivalence of CMAB807 and denosumab. The PD profiles of the two groups were also comparable. The production of the C terminal cross linking telopeptide of type I collagen (CTX1) was inhibited by up to 85% for 10 days, and this inhibition was sustained for up to 126 days in both the CMAB807 and denosumab groups. No subjects in the CMAB807 group, three subjects in the denosumab group before administration, and two subjects in the denosumab group after administration were positive for anti drug antibody (ADA). Adverse events (AEs) were observed in 98.5% of subjects in both groups. The most common AE recorded was increased parathyroid hormone (PTH) levels, with incidences of 92.4 and 95.5% in the CMAB807 and denosumab groups, respectively. No clinically meaningful differences were observed in safety and immunogenicity between CMAB807 and denosumab.& nbsp;Conclusion: CMAB807 represents a new potential treatment option for patients with osteoporosis.
C1 [Chen, Hanjing; Chen, Weili; Yuan, Fei; Li, Xuening] Fudan Univ, Zhongshan Hosp, Dept Clin Pharmacol, Shanghai, Peoples R China.
   [Guo, Qingcheng; Zhang, Xunmin; Wang, Chenguang] Taizhou Mabtech Pharmaceut Co Ltd, Taizhou, Peoples R China.
C3 Fudan University
RP Li, XN (通讯作者)，Fudan Univ, Zhongshan Hosp, Dept Clin Pharmacol, Shanghai, Peoples R China.
EM li.xuening@zs hospital.sh.cn
RI ; Guo, Qingcheng/NUQ 3921 2025; Chen, Weili/R 8907 2016; Chen,
   Hanjing/AAM 2830 2021
OI Chen, Hanjing/0000 0002 2136 2807; 
FU Shanghai Biomabs Pharmaceutical Co., Ltd.
FX This study received funding from Shanghai Biomabs Pharmaceutical Co.,
   Ltd. The funder was not involved in the study design, collection,
   analysis, interpretation of data, the writing of this article or the
   decision to submit it for publication.
CR Amgen, 2021, PROL DEN HIGHL PRESC
   Amgen, 2020, PROL DEN INJ PROD MO
   An GH, 2020, J CLIN PHARMACOL, V60, P149, DOI 10.1002/jcph.1545
   [Anonymous], 2015, SCI CONS DEM BIOS RE
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Chen Q, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197984
   Deeks ED, 2018, DRUG AGING, V35, P261, DOI 10.1007/s40266 018 0535 5
   EMA, 2014, GUID SIM BIOL MED PR
   FDA, 2010, CLIN PHARM BIOPH REV
   Glassman PM, 2016, J PHARMACOKINET PHAR, V43, P427, DOI 10.1007/s10928 016 9482 0
   Gok DE, 2011, J ENDOCRINOL INVEST, V34, P3, DOI [10.1007/BF03346687, 10.3275/6902]
   Grant S, 2009, CELL MOL LIFE SCI, V66, P1163, DOI 10.1007/s00018 008 8539 7
   Khan T.H., 2021, RECEIVED ACCEPTANCE
   Li JY, 2020, J CLIN INVEST, V130, P1767, DOI 10.1172/JCI133473
   Mulcahy A.W., 2018, BIOSIMILAR COST SAVI
   Nakamura Y, 2015, BMC ENDOCR DISORD, V15, DOI 10.1186/s12902 015 0077 3
   NMPA, 2015, GUIDELINES DEV EVALU
   Singh I, 2021, INDIAN J PHARMACOL, V53, P6, DOI 10.4103/ijp.IJP_346_19
   Sutjandra L, 2011, CLIN PHARMACOKINET, V50, P793, DOI 10.2165/11594240 000000000 00000
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Wang W, 2008, CLIN PHARMACOL THER, V84, P548, DOI 10.1038/clpt.2008.170
   Williams C, 2023, StatPearls
   Zhang H, 2021, EXPERT OPIN INV DRUG, V30, P185, DOI 10.1080/13543784.2021.1863371
   Zhang H, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01329
NR 24
TC 5
Z9 5
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 24
PY 2022
VL 13
AR 821944
DI 10.3389/fphar.2022.821944
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA YU6AK
UT WOS:000752123200001
PM 35140619
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Taubmann, J
   Krishnacoumar, B
   Böhm, C
   Faas, M
   Müller, DIH
   Adam, S
   Stoll, C
   Böttcher, M
   Mougiakakos, D
   Sonnewald, U
   Hofmann, J
   Schett, G
   Krönke, G
   Scholtysek, C
AF Taubmann, Jule
   Krishnacoumar, Brenda
   Boehm, Christina
   Faas, Maria
   Mueller, Dorothea I. H.
   Adam, Susanne
   Stoll, Cornelia
   Boettcher, Martin
   Mougiakakos, Dimitrios
   Sonnewald, Uwe
   Hofmann, Joerg
   Schett, Georg
   Kroenke, Gerhard
   Scholtysek, Carina
TI Metabolic reprogramming of osteoclasts represents a therapeutic target
   during the treatment of osteoporosis
SO SCIENTIFIC REPORTS
LA English
DT Article
AB Osteoclasts are specialised bone resorbing cells that control both physiological and pathological bone turnover. Functional changes in the differentiation and activity of osteoclasts are accompanied by active metabolic reprogramming. However, the biological significance and the in vivo relevance of these events has remained unclear. Here we show that bone resorption of differentiated osteoclasts heavily relies on increased aerobic glycolysis and glycolysis derived lactate production. While pharmacological inhibition of glycolysis did not affect osteoclast differentiation or viability, it efficiently blocked bone resorption in vitro and in vivo and consequently ameliorated ovariectomy induced bone loss. Our experiments thus highlight the therapeutic potential of interfering with osteoclast intrinsic metabolic pathways as possible strategy for the treatment of diseases characterized by accelerated bone loss.
C1 [Taubmann, Jule; Krishnacoumar, Brenda; Boehm, Christina; Faas, Maria; Mueller, Dorothea I. H.; Adam, Susanne; Stoll, Cornelia; Schett, Georg; Kroenke, Gerhard; Scholtysek, Carina] Friedrich Alexander Univ Erlangen Nuremberg FAU, Dept Internal Med 3, Erlangen, Germany.
   [Taubmann, Jule; Krishnacoumar, Brenda; Boehm, Christina; Faas, Maria; Mueller, Dorothea I. H.; Adam, Susanne; Stoll, Cornelia; Boettcher, Martin; Mougiakakos, Dimitrios; Schett, Georg; Kroenke, Gerhard; Scholtysek, Carina] Univ Klinikum Erlangen, Erlangen, Germany.
   [Taubmann, Jule; Krishnacoumar, Brenda; Boehm, Christina; Faas, Maria; Mueller, Dorothea I. H.; Adam, Susanne; Stoll, Cornelia; Mougiakakos, Dimitrios; Schett, Georg; Kroenke, Gerhard; Scholtysek, Carina] Univ Erlangen Nurnberg, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany.
   [Boettcher, Martin; Mougiakakos, Dimitrios] Univ Erlangen Nurnberg, Dept Internal Med 5, Erlangen, Germany.
   [Sonnewald, Uwe; Hofmann, Joerg] Univ Erlangen Nurnberg, Div Biochem, Dept Biol, Erlangen, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg
RP Krönke, G; Scholtysek, C (通讯作者)，Friedrich Alexander Univ Erlangen Nuremberg FAU, Dept Internal Med 3, Erlangen, Germany.; Krönke, G; Scholtysek, C (通讯作者)，Univ Klinikum Erlangen, Erlangen, Germany.; Krönke, G; Scholtysek, C (通讯作者)，Univ Erlangen Nurnberg, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany.
EM carina.scholtysek@uk erlangen.de
RI Bottcher, Martin/AFQ 7409 2022; Sonnewald, Uwe/J 7875 2012; Krönke,
   Gerhard/C 6615 2014; Scholtysek, Carina/LXA 1619 2024; Böttcher,
   Martin/AFQ 7409 2022; MOUGIAKAKOS, DIMITRIOS/MBV 4839 2025;
   Krishnacoumar, Brenda/MDT 4452 2025; Kronke, Gerhard/C 6615 2014
OI Bottcher, Martin/0000 0003 2911 8830; Sonnewald,
   Uwe/0000 0003 1835 5339; Adam, Susanne/0000 0002 3394 4767; Hofmann,
   Joerg/0000 0001 7387 1569; Scholtysek, Carina/0009 0001 2197 5179;
   Kronke, Gerhard/0000 0002 7566 4325; Schett, Georg/0000 0001 8740 9615
FU IZKF Erlangen; Deutsche Forschungsgemeinschaft [FG 2886, CRC1181];
   Emerging Field Initiative (EFI) of the Friedrich Alexander University
   Erlangen Nurnberg (FAU); STAEDTLER Stiftung
   [EFI_Verbund_Med_05_MIRACLE]; Bundesministerium fur Bildung und
   Forschung (BMBF); European Union [ERC 2014 StG 640087  SOS, ERC 2018SyG
   nanoSCOPE]
FX The present work was performed in fulfilment of the requirements for
   obtaining the degree "dr. med." We thank Dana Weidner for excellent
   technical assistance. This work was supported by the IZKF Erlangen
   (J.T.), the Deutsche Forschungsgemeinschaft (FG 2886 "PANDORA" to G.K.,
   D.M. and G.S. as well as the CRC1181 to G.K. and G.S). Additional
   support was provided by the Emerging Field Initiative (EFI) of the
   Friedrich Alexander University Erlangen Nurnberg (FAU) and the STAEDTLER
   Stiftung (EFI_Verbund_Med_05_MIRACLE to G.K., U.S. and J. H.) and the
   Bundesministerium fur Bildung und Forschung (BMBF) (METARTHROS to G.K.
   and G.S.) and the European Union (Horizon 2020 ERC 2014 StG 640087  SOS
   to G.K and Horizon 2020 ERC 2018SyG nanoSCOPE as well as RTCure to
   G.S.).
CR Arnett TR, 2018, BONE, V115, P25, DOI 10.1016/j.bone.2017.12.021
   Hofmann J, 2011, FRONT PLANT SCI, V2, DOI 10.3389/fpls.2011.00082
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Krönke G, 2003, J BIOL CHEM, V278, P51006, DOI 10.1074/jbc.M304103200
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Müller DIH, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 65305 5
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Van den Bossche J, 2017, TRENDS IMMUNOL, V38, P395, DOI 10.1016/j.it.2017.03.001
   Xing LP, 2012, WORLD J ORTHOP, V3, P212, DOI 10.5312/wjo.v3.i12.212
NR 13
TC 47
Z9 52
U1 2
U2 27
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD DEC 3
PY 2020
VL 10
IS 1
AR 21020
DI 10.1038/s41598 020 77892 4
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA QD2ZZ
UT WOS:000615394300020
PM 33273570
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Biver, G
   Wang, N
   Gartland, A
   Orriss, I
   Arnett, TR
   Boeynaems, JM
   Robaye, B
AF Biver, Galadrielle
   Wang, Ning
   Gartland, Alison
   Orriss, Isabel
   Arnett, Timothy R.
   Boeynaems, Jean Marie
   Robaye, Bernard
TI Role of the P2Y13 Receptor in the Differentiation of Bone
   Marrow Stromal Cells into Osteoblasts and Adipocytes
SO STEM CELLS
LA English
DT Article
DE P2Y(13) receptor; Knockout mice; Mesenchymal stem cell; Osteoblast;
   Adipocyte; Differentiation
ID MESENCHYMAL STEM CELLS; SIGNALING DOWNSTREAM; TRABECULAR BONE; IN VITRO;
   ADIPOGENESIS; ACTIVATION; MECHANISMS; OSTEOGENESIS; OSTEOPOROSIS;
   NUCLEOTIDES
AB Accumulating evidence indicates that extracellular nucleotides, signaling through purinergic receptors, play a significant role in bone remodeling. Mesenchymal stem cells (MSCs) express functional P2Y receptors whose expression level is regulated during osteoblast or adipocyte differentiation. P2Y(13) deficient mice were previously shown to exhibit a decreased bone turnover associated with a reduction in the number of both osteoblasts and osteoclasts on the bone surfaces. We therefore examined whether P2Y(13)R activation was involved in the osteogenic differentiation of MSC. Our study demonstrated that ADP stimulation of P2Y(13)R(+/+) (but not P2Y(13)R( / )) adherent bone marrow stromal cells (BMSCs) increased significantly the formation of alkaline phosphatase colony forming units (CFU ALP) as well as the expression of osteoblastic markers (osterix, alkaline phosphatase, and collagen I) involved in the maturation of preosteoblasts into osteoblasts. The number of CFU ALP obtained from P2Y(13)R( / ) BMSC and the level of osteoblastic gene expression after osteogenic stimulation were strongly reduced compared to those obtained in wild type cell cultures. In contrast, when P2Y(13)R( / ) BMSCs were incubated in an adipogenic medium, the number of adipocytes generated and the level of adipogenic gene expression (PPAR2 and Adipsin) were higher than those obtained in P2Y(13)R(+/+) MSC. Interestingly, we observed a significant increase of the number of bone marrow adipocytes in tibia of P2Y(13)R( / ) mice. In conclusion, our findings indicate that the P2Y(13)R plays an important role in the balance of osteoblast and adipocyte terminal differentiation of bone marrow progenitors. Therefore, the P2Y(13) receptor can be considered as a new pharmacological target for the treatment of bone diseases like osteoporosis.
C1 [Biver, Galadrielle; Boeynaems, Jean Marie; Robaye, Bernard] Univ Libre Bruxelles, Inst Interdisciplinary Res, Inst Rech Interdisciplinaire Biol Humaine & Mol, B 6041 Gosselies, Belgium.
   [Wang, Ning; Gartland, Alison] Univ Sheffield, Mellanby Ctr Bone Res, Dept Human Metab, Sheffield, S Yorkshire, England.
   [Orriss, Isabel; Arnett, Timothy R.] UCL, Dept Cell & Dev Biol, London, England.
   [Boeynaems, Jean Marie] Free Univ Brussels, Erasme Hosp, Dept Med Chem, B 1050 Brussels, Belgium.
C3 Universite Libre de Bruxelles; University of Sheffield; University of
   London; University College London; Universite Libre de Bruxelles
RP Robaye, B (通讯作者)，Univ Libre Bruxelles, 10 Rue A Bolland, B 6041 Gosselies, Belgium.
EM brobaye@ulb.ac.be
RI ; Arnett, Tim/AAW 4445 2021; Orriss, Isabel/GRS 3934 2022; Wang,
   Ning/HKO 8446 2023; Gartland, Alison/A 2152 2012
OI Orriss, Isabel/0000 0002 7847 050X; WANG, NING/0000 0002 2663 7515;
   Gartland, Alison/0000 0002 3712 2437; 
FU Actions de Recherche Concertes de la Communaute Francaise de Belgique;
   Belgian Program on Interuniversity Poles of Attraction; Fonds National
   de la Recherche Scientifique Medicale; Fonds Emile DEFAY; European
   Commission [202231]; Fonds National de la Recherche Scientifique (FRIA,
   Belgium)
FX We thank Dominique Fokan for excellent help and technical assistance.
   This work was supported by Actions de Recherche Concertes de la
   Communaute Francaise de Belgique, by the Belgian Program on
   Interuniversity Poles of Attraction Initiated by the Belgian State,
   Prime Minister's Office, Federal Service for Science, Technology and
   Culture, by the Fonds National de la Recherche Scientifique Medicale,
   the Fonds Emile DEFAY, and the European Commission under the seventh
   Framework Programme (proposal #202231) performed as a collaborative
   project among the members of the ATPBone Consortium (Copenhagen
   University, University College London, University of Maastricht,
   University of Ferrara, University of Liverpool, University of Sheffield,
   and Universite Libre de Bruxelles). G.B. was supported by the Fonds
   National de la Recherche Scientifique (FRIA, Belgium).
CR Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3
   Alvarenga ÉC, 2010, BONE, V46, P355, DOI 10.1016/j.bone.2009.09.017
   Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<73::AID JCB11>3.0.CO;2 L
   Bäckesjö CM, 2009, CELLS TISSUES ORGANS, V189, P93, DOI 10.1159/000151744
   BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756 3282(87)90015 9
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200
   Coppi E, 2007, STEM CELLS, V25, P1840, DOI 10.1634/stemcells.2006 0669
   Costessi A, 2005, BONE, V36, P418, DOI 10.1016/j.bone.2004.10.016
   Cui XJ, 2010, TOHOKU J EXP MED, V220, P139, DOI 10.1620/tjem.220.139
   Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301 472X(00)00482 3
   Dobson KR, 1999, CALCIFIED TISSUE INT, V65, P411, DOI 10.1007/s002239900723
   Dumas A, 2008, CYTOTECHNOLOGY, V58, P163, DOI 10.1007/s10616 009 9184 1
   Fabre AC, 2010, HEPATOLOGY, V52, P1477, DOI 10.1002/hep.23897
   Ferrari D, 2011, EXP HEMATOL, V39, P360, DOI 10.1016/j.exphem.2010.12.001
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Gallagher J. A., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P432
   Gallagher J. A., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P125
   Gao C, 2012, J ORTHOP RES, V30, P1183, DOI 10.1002/jor.22028
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Glaser T, 2012, PURINERG SIGNAL, V8, P523, DOI 10.1007/s11302 011 9282 3
   Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Guntur AR, 2011, ANN NY ACAD SCI, V1237, P58, DOI 10.1111/j.1749 6632.2011.06213.x
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165 6147(03)00123 8
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Jia B, 2012, PLOS ONE, V7
   Kawai M, 2007, J MOL ENDOCRINOL, V38, P19, DOI 10.1677/jme.1.02154
   Khatiwala CB, 2009, J BONE MINER RES, V24, P886, DOI [10.1359/jbmr.081240, 10.1359/JBMR.081240]
   Kim SP, 2010, BIOCHEM BIOPH RES CO, V399, P55, DOI 10.1016/j.bbrc.2010.07.038
   Komori Toshihisa, 2002, Nihon Rinsho, V60 Suppl 3, P91
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kukulski F, 2005, Purinergic Signal, V1, P193, DOI 10.1007/s11302 005 6217 x
   Lazarowski ER, 2012, PURINERG SIGNAL, V8, P359, DOI 10.1007/s11302 012 9304 9
   Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785
   Malaval C, 2009, CELL SIGNAL, V21, P120, DOI 10.1016/j.cellsig.2008.09.016
   Marteau F, 2003, MOL PHARMACOL, V64, P104, DOI 10.1124/mol.64.1.104
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Menuki K, 2008, BONE, V43, P613, DOI 10.1016/j.bone.2008.04.022
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Noronha Matos JB, 2012, J CELL PHYSIOL, V227, P2694, DOI 10.1002/jcp.23014
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Orriss I, 2011, FRONT BIOSCI, V3, P1038
   Orriss IR, 2007, ENDOCRINOLOGY, V148, P4208, DOI 10.1210/en.2007 0066
   Orriss IR, 2011, ENDOCRINOLOGY, V152, P3706, DOI 10.1210/en.2011 1073
   Pirraco RP, 2013, J TISSUE ENG REGEN M, V7, P392, DOI 10.1002/term.535
   Post S, 2008, BONE, V43, P32, DOI 10.1016/j.bone.2008.03.011
   Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802
   Savopoulos C, 2011, HIPPOKRATIA, V15, P18
   Shi Y, 2011, J CELL PHYSIOL, V226, P2159, DOI 10.1002/jcp.22551
   Syberg S, 2012, J BONE MINER RES, V27, P2373, DOI 10.1002/jbmr.1690
   Takedachi M, 2012, J CELL PHYSIOL, V227, P2622, DOI 10.1002/jcp.23001
   Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630
   TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224
   Wang N, 2012, MOL ENDOCRINOL, V26, P142, DOI 10.1210/me.2011 1083
   WILKISON WO, 1990, J BIOL CHEM, V265, P477
   Yu WH, 2012, INT J BIOCHEM CELL B, V44, P377, DOI 10.1016/j.biocel.2011.11.013
   Zippel N, 2012, STEM CELLS DEV, V21, P884, DOI 10.1089/scd.2010.0576
NR 60
TC 59
Z9 64
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD DEC
PY 2013
VL 31
IS 12
BP 2747
EP 2758
DI 10.1002/stem.1411
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 262LF
UT WOS:000327736000015
PM 23629754
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Romas, E
   Gillespie, MT
AF Romas, Evange
   Gillespie, Matthew T.
TI Inflammation induced bone loss: Can it be prevented?
SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
ID TUMOR NECROSIS FACTOR; COLLAGEN INDUCED ARTHRITIS; EARLY
   RHEUMATOID ARTHRITIS; NF KAPPA B; ACTIVATED T CELLS; OSTEOCLAST
   DIFFERENTIATION FACTOR; MEDIATED JOINT DESTRUCTION; FACTOR ALPHA;
   RECEPTOR ACTIVATOR; TNF ALPHA
AB The inflammatory process in rheumatoid arthritis elicits intense bone loss that is manifest as articular bone erosions, juxta articular osteopenia, and systemic osteoporosis. Key molecular discoveries coupled with elegant animal studies have highlighted a pathogenic role of osteoclasts in bone destruction. The tumor necrosis factor (TNF) family of cytokines, especially TNF alpha and receptor activator of nuclear factor kappa B ligand (RANKL), are pivotal for recruiting and activating osteoclasts and inducing bone loss. Targeted anti TNF therapy or RANKL antagonism prevents inflammation induced bone loss, and the potent new bisphosphonates are an emerging therapeutic tool.
C1 Univ Melbourne, St Vincents Hosp, Fitzroy, Vic 3065, Australia.
   St Vincents Inst, Fitzroy, Vic 3065, Australia.
C3 NSW Health; St Vincents Hospital Sydney; University of Melbourne; St
   Vincent's Health; St Vincent's Hospital Melbourne; St. Vincent's
   Institute of Medical Research
RP Romas, E (通讯作者)，Univ Melbourne, St Vincents Hosp, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.
EM romase@svhm.org.au
CR AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   Bugatti S, 2005, ARTHRITIS RHEUM US, V52, P3448, DOI 10.1002/art.21377
   Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200
   DEBETS JMH, 1988, J IMMUNOL, V141, P1197
   Drossaers Bakker KW, 1999, ARTHRITIS RHEUM, V42, P1854, DOI 10.1002/1529 0131(199909)42:9<1854::AID ANR9>3.0.CO;2 F
   Farrugia MC, 2006, LARYNGOSCOPE, V116, P115, DOI 10.1097/01.mlg.0000187398.51857.3c
   Forsblad DH, 2003, ANN RHEUM DIS, V62, P617
   Fox SW, 2000, BIOCHEM BIOPH RES CO, V276, P868, DOI 10.1006/bbrc.2000.3577
   Genovese MC, 2005, NEW ENGL J MED, V353, P1114, DOI 10.1056/NEJMoa050524
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gilbert LC, 2005, AM J PHYSIOL ENDOC M, V288, pE1011, DOI 10.1152/ajpendo.00534.2004
   Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Golden SM, 2004, DIAGN MICR INFEC DIS, V50, P7, DOI 10.1016/j.diagmicrobio.2004.04.021
   GOLDRING S, 2003, PRIMER METABOLIC BON, P379
   Goldring SR, 2002, J RHEUMATOL, V29, P44
   Goldring SR, 2003, RHEUMATOLOGY, V42, P11, DOI 10.1093/rheumatology/keg327
   Gough A, 1998, J RHEUMATOL, V25, P1282
   GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140 6736(94)91049 9
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Herrak P, 2004, ARTHRITIS RHEUM US, V50, P2327, DOI 10.1002/art.20384
   Higashida J, 2005, J RHEUMATOL, V32, P2109
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Jarrett SJ, 2006, ARTHRITIS RHEUM US, V54, P1410, DOI 10.1002/art.21824
   Jimenez Boj E, 2005, J IMMUNOL, V175, P2579, DOI 10.4049/jimmunol.175.4.2579
   Joosten LAB, 1996, ARTHRITIS RHEUM, V39, P797, DOI 10.1002/art.1780390513
   Juji T, 2002, J BONE MINER METAB, V20, P266, DOI 10.1007/s007740200038
   Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923
   Kinne RW, 1995, ARTHRITIS RHEUM US, V38, P1777, DOI 10.1002/art.1780381211
   KINNE RW, 1995, SCAND J RHEUMATOL, P91
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   KOERNER TJ, 1987, CELL IMMUNOL, V109, P437, DOI 10.1016/0008 8749(87)90326 1
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Lubberts E, 2002, ARTHRITIS RHEUM, V46, P3055, DOI 10.1002/art.10607
   Maini RN, 2004, ARTHRITIS RHEUM US, V50, P1051, DOI 10.1002/art.20159
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mc Gonagle D, 1999, RHEUMATOLOGY, V38, P329, DOI 10.1093/rheumatology/38.4.329
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   McInnes IB, 1997, NAT MED, V3, P189, DOI 10.1038/nm0297 189
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Nakae S, 2003, P NATL ACAD SCI USA, V100, P5986, DOI 10.1073/pnas.1035999100
   Ostergaard M, 2003, ARTHRITIS RHEUM US, V48, P2128, DOI 10.1002/art.11076
   OSTERMAN T, 1995, INFLAMM RES, V44, P258, DOI 10.1007/BF01782979
   Osterman T, 1997, INFLAMM RES, V46, P79, DOI 10.1007/s000110050093
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   Partsch G, 1997, J RHEUMATOL, V24, P518
   Pettit AR, 2006, RHEUMATOLOGY, V45, P1068, DOI 10.1093/rheumatology/kel045
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Pincus T, 2003, CLIN EXP RHEUMATOL, V21, pS179
   Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002 9440(10)63144 6
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Romas E, 2005, BEST PRACT RES CL RH, V19, P1065, DOI 10.1016/j.berh.2005.06.008
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756 3282(01)00682 2
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Sambrook PN, 2000, J RHEUMATOL, V27, P2541
   Schett G, 2005, ARTHRITIS RHEUM US, V52, P3192, DOI 10.1002/art.21343
   Schett G, 2005, ARTHRITIS RHEUM US, V52, P1604, DOI 10.1002/art.21021
   Schett G, 2003, ARTHRITIS RHEUM, V48, P2042, DOI 10.1002/art.11150
   Seitz M, 1998, ARTHRITIS RHEUM US, V41, P2032, DOI 10.1002/1529 0131(199811)41:11<2032::AID ART19>3.3.CO;2 A
   Sharp JT, 2003, J RHEUMATOL, V30, P1102
   Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529 0131(200011)43:11<2523::AID ANR20>3.0.CO;2 Z
   SHIMIZU S, 1985, ARTHRITIS RHEUM, V28, P25, DOI 10.1002/art.1780280105
   Sims NA, 2004, ARTHRITIS RHEUM US, V50, P2338, DOI 10.1002/art.20382
   Smolen JS, 2005, ARTHRITIS RHEUM, V52, P1020, DOI 10.1002/art.20982
   Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109
   Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417
   Strand V, 2004, RHEUMATOLOGY, V43, P10, DOI 10.1093/rheumatology/keh202
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sugiyama T, 2004, NEW ENGL J MED, V350, P189
   Takagi N, 1998, ARTHRITIS RHEUM, V41, P2117, DOI 10.1002/1529 0131(199812)41:12<2117::AID ART6>3.3.CO;2 G
   Takasu Junichiro, 2002, BMC Blood Disord, V2, P3, DOI 10.1186/1471 2326 2 3
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Vincent C, 2005, AUTOIMMUNITY, V38, P17, DOI 10.1080/08916930400022582
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200
   Wong PKK, 2006, ARTHRITIS RHEUM US, V54, P158, DOI 10.1002/art.21537
   Wyzga N, 2004, BONE, V35, P614, DOI 10.1016/j.bone.2004.04.022
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
   Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487
NR 99
TC 63
Z9 73
U1 0
U2 3
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0889 857X
EI 1558 3163
J9 RHEUM DIS CLIN N AM
JI Rheum. Dis. Clin. North Am.
PD NOV
PY 2006
VL 32
IS 4
BP 759
EP +
DI 10.1016/j.rdc.2006.07.004
PG 17
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 121FW
UT WOS:000243144500010
PM 17288976
DA 2025 08 17
ER

PT J
AU Guo, C
   Yang, RJ
   Jang, K
   Zhou, XL
   Liu, YZ
AF Guo, Chun
   Yang, Rui Juan
   Jang, Ke
   Zhou, Xiao ling
   Liu, Yu zhen
TI 被撤回的出版物: Protective Effects of Pretreatment with Quercetin Against
   Lipopolysaccharide Induced Apoptosis and the Inhibition of Osteoblast
   Differentiation via the MAPK and Wnt/β Catenin Pathways in MC3T3 E1
   Cells (Retracted article. See vol. 57, pg. 51, 2023)
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE Quercetin; Lipopolysaccharide; Apoptosis; Osteoblast; Differentiation;
   MAPK; Wnt/beta catenin
ID BETA CATENIN; IN VITRO; BONE RESORPTION; ACTIVATION; LPS; EXPRESSION;
   JNK; OSTEOCLASTS; MECHANISMS; PROMOTES
AB Background/Aims: Quercetin, a flavonoid found in onions and other vegetables, has potential inhibitory effects on bone resorption in vivo and in vitro. In our previous study, we found that quercetin treatment reversed lipopolysaccharide (LPS) induced inhibition of osteoblast differentiation through the mitogen activated protein kinase (MAPK) pathway in MC3T3 E1 cells. In this study, we investigated the underlying mechanisms of pretreatment with quercetin on apoptosis and the inhibition of osteoblast differentiation in MC3T3 E1 cells induced by LPS. Methods: MC3T3 E1 osteoblasts were treated with quercetin for 2 h; cells were then incubated with LPS in the presence of quercetin for the indicated times. Cell viability was measured using the Cell Counting Kit 8 (CCK 8) assay, and cell apoptosis was evaluated using Hoechst 33258 staining. The mRNA expression levels of osteoblast specific genes, Bax and caspase 3 were determined by real time quantitative polymerase chain reaction (qPCR). Protein levels of osteoblast specific genes, caspase 3, Bax, cytochrome c, Bcl 2, Bcl XL, phosphorylated MAPKs and Wnt/beta catenin were measured using Western blot assays. The MAPK and Wnt/beta catenin signalling pathways were blocked prior to pretreatment with quercetin. Results: Pretreatment with quercetin significantly restored LPS suppressed bone mineralization and the mRNA and protein expression levels of osteoblast specific genes such as Osterix (OSX), runt related transcription factor 2 (Runx2), alkaline phosphatase (ALP) and osteocalcin (OCN) in a dose dependent manner. Pretreatment with quercetin also inhibited osteoblast apoptosis, significantly restored the down regulated expression of Bcl 2 and Bcl XL and decreased the upregulated expression of caspase 3, Bax, and cytochrome c in MC3T3 E1 cells induced by LPS. Furthermore, pretreatment with quercetin not only decreased the abundance of phosphorylated p38 MAPK and increased the abundance of phosphorylated extracellular signal regulated kinase (ERK), but also triggered the Wnt/beta catenin pathway through enhancing expression of Wnt3 and beta catenin. Pretreatment with MAPK inhibitors or the Wnt/beta catenin inhibitor XAV939 blocked the protective effects of quercetin against LPS induced apoptosis and the inhibition of osteoblast differentiation. Conclusions: Our findings suggest that pretreatment with quercetin may be a potential drug for preventing abnormal human bone loss induced by LPS in bacteria induced bone diseases. (C) 2017 The Author(s) Published by S. Karger AG, Basel
C1 [Guo, Chun; Yang, Rui Juan; Zhou, Xiao ling; Liu, Yu zhen] Xinxiang Med Univ, Affiliated Hosp 1, Henan Key Lab Neural Regenerat, 88 Jiankang Rd, Weihui, Henan, Peoples R China.
   [Guo, Chun] Henan Univ, Affiliated Hosp 1, Dept Orthoped, Kaifeng, Peoples R China.
   [Jang, Ke] North Sichuan Med Coll, Dept Orthoped, Affiliated Hosp, Nanchong, Sichuan, Peoples R China.
C3 Henan Medical University; Henan University; North Sichuan Medical
   University
RP Guo, C (通讯作者)，Xinxiang Med Univ, Affiliated Hosp 1, Henan Key Lab Neural Regenerat, 88 Jiankang Rd, Weihui, Henan, Peoples R China.
EM guospring@126.com
FU National Natural Science Foundation of China [81371981, 81672190];
   School Fund of Luohe Medical College [2014 DF 002]; Fund of Henan
   Provincial Health Bureau [201203081]
FX This work was supported by funds from the National Natural Science
   Foundation of China (81371981, 81672190), the School Fund of Luohe
   Medical College (2014 DF 002), and the Fund of Henan Provincial Health
   Bureau (201203081).
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Bandow K, 2010, BIOCHEM BIOPH RES CO, V402, P755, DOI 10.1016/j.bbrc.2010.10.103
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Fatokun AA, 2015, NAT PROD RES, V29, P1127, DOI 10.1080/14786419.2014.980252
   Fister S, 2009, CANCER RES, V69, P6473, DOI 10.1158/0008 5472.CAN 08 4657
   Fu HH, 2007, J BIOMED MATER RES A, V83A, P770, DOI 10.1002/jbm.a.31356
   Fuerer C, 2008, EMBO REP, V9, P134, DOI 10.1038/sj.embor.7401159
   Gao M, 2016, CELL PHYSIOL BIOCHEM, V40, P727, DOI 10.1159/000453134
   Gim H, 2015, CELL PHYSIOL BIOCHEM, V35, P2422, DOI 10.1159/000374043
   Guo C, 2015, INT J MOL MED, V35, P1427, DOI 10.3892/ijmm.2015.2130
   Guo C, 2014, INFLAMMATION, V37, P621, DOI 10.1007/s10753 013 9778 9
   Guo C, 2012, CELL PHYSIOL BIOCHEM, V30, P123, DOI 10.1159/000339052
   Gutiérrez Venegas G, 2007, INT IMMUNOPHARMACOL, V7, P1199, DOI 10.1016/j.intimp.2007.05.004
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Hou GQ, 2013, INT J MOL MED, V32, P503, DOI 10.3892/ijmm.2013.1406
   Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Itoh K, 2003, J IMMUNOL, V170, P3688, DOI 10.4049/jimmunol.170.7.3688
   Kadono H, 1999, INFECT IMMUN, V67, P2841, DOI 10.1128/IAI.67.6.2841 2846.1999
   Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200
   Kim HK, 2009, LIFE SCI, V84, P290, DOI 10.1016/j.lfs.2008.12.017
   Kittl M, 2016, CELL PHYSIOL BIOCHEM, V39, P278, DOI 10.1159/000445623
   Lai SL, 2009, CELL RES, V19, P532, DOI 10.1038/cr.2009.41
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092 8674(02)00685 2
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Mörmann M, 2008, MOL IMMUNOL, V45, P3330, DOI 10.1016/j.molimm.2008.04.022
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nam TW, 2008, J BONE MINER METAB, V26, P551, DOI 10.1007/s00774 008 0864 2
   Notoya M, 2004, EUR J PHARMACOL, V485, P89, DOI 10.1016/j.ejphar.2003.11.058
   Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449
   Ochi H, 2010, J ORTHOP RES, V28, P657, DOI 10.1002/jor.21028
   Park GB, 2010, J IMMUNOL, V185, P7274, DOI 10.4049/jimmunol.1001547
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Siddiqui JA, 2011, OSTEOPOROSIS INT, V22, P3013, DOI 10.1007/s00198 010 1519 4
   Son YO, 2006, EUR J PHARMACOL, V529, P24, DOI 10.1016/j.ejphar.2005.10.041
   Trivedi R, 2009, MOL CELL ENDOCRINOL, V302, P86, DOI 10.1016/j.mce.2009.01.011
   Wang XC, 2014, MOL MED REP, V10, P3320, DOI 10.3892/mmr.2014.2633
   Wattel A, 2003, BIOCHEM PHARMACOL, V65, P35, DOI 10.1016/S0006 2952(02)01445 4
   Woo JT, 2004, BIOL PHARM BULL, V27, P504, DOI 10.1248/bpb.27.504
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Xing QA, 2010, J CELL PHYSIOL, V225, P106, DOI 10.1002/jcp.22201
NR 45
TC 77
Z9 85
U1 0
U2 37
PU Cell Physiol Biochem Press GmbH & Co
PI Dsseldorf
PA Herzogstr. 85, Dsseldorf, GERMANY
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 43
IS 4
BP 1547
EP 1561
DI 10.1159/000481978
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FN7TY
UT WOS:000416222900021
PM 29035884
OA gold
DA 2025 08 17
ER

PT J
AU Siu, MK
   Chen, WY
   Tsai, HY
   Chen, HY
   Yin, JJ
   Chen, CL
   Tsai, YC
   Liu, YN
AF Siu, M. K.
   Chen, W Y
   Tsai, H Y
   Chen, H Y
   Yin, J. J.
   Chen, C L
   Tsai, Y C
   Liu, Y N
TI TCF7 is suppressed by the androgen receptor via microRNA 1 mediated
   downregulation and is involved in the development of resistance to
   androgen deprivation in prostate cancer
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article
ID BETA CATENIN; TUMOR SUPPRESSOR; BONE METASTASIS; SIGNALING AXIS;
   CASTRATION; CELLS; PROGRAM; EXPRESSION; THERAPY; PATHWAY
AB BACKGROUND: Resistance to androgen deprivation therapy (ADT) represents a key step in the malignant progression of prostate cancer, and mutation to androgen receptor (AR) is one major driver to an androgen independent phenotype. However, alternative oncogenic pathways that bypass AR signaling have emerged as an important mechanism promoting resistance to ADT. It is known that AR activation can prevent the interaction between beta catenin and T cell factor/lymphoid enhancer binding factor (TCF/LEF) family, inhibiting the Wnt signaling pathway. The aim of this study was to determine the role of transcription factor 7 (TCF7), a transcription factor best known as a Wnt effector that forms a complex with beta catenin, in the development of advanced prostate cancer. We further investigated the molecular mechanisms by which TCF7 is induced when AR signaling is inactivated.
   METHODS: A novel AR signaling pathway that induces microRNA 1 (miR 1) to suppress metastatic prostate cancer was recently demonstrated (AR miR 1 signaling axis), and its regulation of Wnt signaling was explored in the current study. Clinical data sets were analyzed for potential targets of AR miR 1 signaling in the TCF/LEF family, and tissue samples were utilized to validate the relationship. The molecular mechanism and biological functions were demonstrated in prostate cancer cell lines and a mouse xenograft model.
   RESULTS: We demonstrated a molecular mechanism of AR signaling suppressing TCF7 partly through miR 1 mediated downregulation. TCF7 exhibited oncogenic properties and compromised the tumor suppressive effects of miR 1. Our results also showed that overexpression of TCF7 or disruption of miR 1 function promoted androgen independent proliferation.
   CONCLUSIONS: We demonstrated that the AR miR 1 axis negatively regulates the novel oncogenic factor, TCF7. Dysregulation of TCF7 promoted a survival advantage and resistance to androgen deprivation, suggesting its therapeutic potential for castration resistant prostate cancer.
C1 [Siu, M. K.; Tsai, Y C; Liu, Y N] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Biol & Drug Discovery, Taipei, Taiwan.
   [Siu, M. K.; Tsai, Y C; Liu, Y N] Acad Sinica, Taipei, Taiwan.
   [Siu, M. K.; Tsai, H Y; Tsai, Y C; Liu, Y N] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan.
   [Siu, M. K.] Taipei Med Univ, Wan Fang Hosp, Dept Anesthesiol, Taipei, Taiwan.
   [Chen, W Y] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei, Taiwan.
   [Chen, W Y; Chen, C L] Taipei Med Univ, Sch Med, Dept Pathol, Coll Med, Taipei, Taiwan.
   [Chen, W Y; Chen, C L] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan.
   [Chen, H Y] Acad Sinica, Inst Stat Sci, Taipei, Taiwan.
   [Yin, J. J.] NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20892 USA.
   [Chen, C L] Taipei Med Univ, Taipei Med Univ Hosp, Dept Pathol, Taipei, Taiwan.
C3 Taipei Medical University; Academia Sinica   Taiwan; Taipei Medical
   University; Taipei Medical University; Taipei Municipal WanFang
   Hospital; Taipei Municipal WanFang Hospital; Taipei Medical University;
   Taipei Medical University; Taipei Medical University; Academia Sinica  
   Taiwan; National Institutes of Health (NIH)   USA; NIH National Cancer
   Institute (NCI); Taipei Medical University Hospital; Taipei Medical
   University
RP Tsai, YC; Liu, YN (通讯作者)，Taipei Med Univ, 250 Wu Hsing St, Taipei 11031, Taiwan.
EM yuanchin@tmu.edu.tw; liuy@tmu.edu.tw
RI Liu, Yen Nien/AAW 4698 2021; Chen, Hsuan Yu/AAE 8428 2019; Chen,
   yafang/GVS 0304 2022
OI Tsai, Yuan Chin/0000 0003 3264 3513; 
FU Ministry of Science and Technology of Taiwan [MOST 104 2320 B 038 038,
   MOST 105 2628 B 038 006 MY3, MOST 104 2314 B 038 045 MY3, MOST
   104 2320 B 038 055 MY3]; National Health Research Institutes of Taiwan
   [NHRI EX105 10308BC]; Taipei Medical University Wan Fang Hospital
   [104TMU WFH 04]
FX This work was jointly supported by grants from the Ministry of Science
   and Technology of Taiwan to MKS (MOST 104 2320 B 038 038 and MOST
   105 2628 B 038 006 MY3), MOST 104 2314 B 038 045 MY3 to Y NL and MOST
   104 2320 B 038 055 MY3 to Y CT, from the National Health Research
   Institutes of Taiwan (NHRI EX105 10308BC) to Y NL and from Taipei
   Medical University Wan Fang Hospital (104TMU WFH 04) to Y NL.
CR Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008 5472.CAN 08 0144
   Amir AL, 2003, J BIOL CHEM, V278, P30828, DOI 10.1074/jbc.M301208200
   Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056
   Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001
   Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972
   Chen WY, 2015, ONCOTARGET, V6, P441, DOI 10.18632/oncotarget.2690
   Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049
   Cui L, 2013, J CLIN INVEST, V123, P1647, DOI 10.1172/JCI65048
   de la Taille A, 2003, CLIN CANCER RES, V9, P1801
   Ford OH, 2003, J UROLOGY, V170, P1817, DOI 10.1097/01.ju.0000091873.09677.f4
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264
   Hrdlicková R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086990
   Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222
   IWAMURA M, 1994, J HISTOCHEM CYTOCHEM, V42, P783, DOI 10.1177/42.6.8189040
   Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206
   Karatas OF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098675
   Lipianskaya J, 2014, ASIAN J ANDROL, V16, P541, DOI 10.4103/1008 682X.123669
   Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58
   Liu YN, 2015, MOL CELL BIOL, V35, P1940, DOI 10.1128/MCB.00008 15
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Martens Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802
   Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299
   Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Schrader AJ, 2014, EUR UROL, V65, P30, DOI 10.1016/j.eururo.2013.06.042
   Schweizer L, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 4
   Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008 5472.CAN 04 2442
   Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010
   Siu MK, 2015, ONCOGENE, V34, P4767, DOI 10.1038/onc.2014.414
   Stoyanova T, 2013, P NATL ACAD SCI USA, V110, P20111, DOI 10.1073/pnas.1320565110
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Wang G, 2006, ONCOGENE, V25, P7311, DOI 10.1038/sj.onc.1209715
   Wang G, 2008, CANCER RES, V68, P9918, DOI 10.1158/0008 5472.CAN 08 1718
   Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056
   Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955 07
   Yu XP, 2009, PROSTATE, V69, P249, DOI 10.1002/pros.20877
   Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235
NR 43
TC 25
Z9 25
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365 7852
EI 1476 5608
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD JUN
PY 2017
VL 20
IS 2
BP 172
EP 178
DI 10.1038/pcan.2017.2
PG 7
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Urology & Nephrology
GA EU8AU
UT WOS:000401259800006
PM 28220803
DA 2025 08 17
ER

PT J
AU Camacho, A
   Jerez, S
AF Camacho, Ariel
   Jerez, Silvia
TI Nonlinear modeling and control strategies for bone diseases based on
   TGFβ and Wnt factors
SO COMMUNICATIONS IN NONLINEAR SCIENCE AND NUMERICAL SIMULATION
LA English
DT Article
DE Bone remodeling; Osteoporosis; TGF beta signaling; Wnt signaling;
   Bifurcation diagrams; Optimal control
ID TUMOR GROWTH; MATHEMATICAL MODEL; OSTEOBLAST; THERAPY; CELLS; METASTASIS
AB Bone remodeling is regulated by numerous signaling pathways being transforming growth factor beta (TGF beta) and Wnt crucial for coupling bone formation and elimination activities. Bone diseases, such as osteoporosis and bone metastasis, develop when the bone cells cross talk is corrupted which causes unbalanced bone mass production. In this work, we explore the effects of TGF beta and Wnt in bone dynamics based on a proposed mathematical model, and thereby study different disease control strategies. In particular, we find steady states of proposed mathematical models, and show bifurcation diagrams that indicate nonlinear dynamical behavior, such as Hopf bifurcations and hysteresis. The implications of these findings on dynamical behavior are then discussed in the context of bone diseases. Finally, using control theory, we also address the question about how input or inhibition combination therapies may help in the control of osteoporosis and cancer induced bone disease. Numerical simulations are performed to simulate the dynamical behavior of the bone microenvironment and to analyze different treatment combinations (conventional and novel). A discussion of the results is carried out. (C) 2021 Elsevier B.V. All rights reserved.
C1 [Camacho, Ariel; Jerez, Silvia] CIMAT, Ctr Invest Matemat, Guanajuato, Mexico.
C3 CIMAT   Centro de Investigacion en Matematicas
RP Camacho, A (通讯作者)，CIMAT, Ctr Invest Matemat, Guanajuato, Mexico.
EM jose.camacho@cimat.mx; jerez@cimat.mx
RI ; Camacho Gutierrez, Jose Ariel/IAP 6316 2023
OI Jerez, Silvia/0000 0002 7845 4710; 
FU CONACyT [412803]; Mexico CONACyT [CB2016 286437]
FX Ariel Camacho thanks CONACyT for the Graduate Fellowship Grant 412803.
   We thank Hugo Flores and Fernando Saldana for their support with the
   Sobol sensitivity analysis. This work was partially supported by Mexico
   CONACyT Project CB2016 286437. Finally, we thank the anonymous reviewers
   for their valuable comments that helped us to improve this manuscript.
CR [Anonymous], 2007, Optimal Control Applied to Biological Models, DOI DOI 10.1201/9781420011418
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Benzekry S, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003800
   Camacho A, 2019, J MATH BIOL, V78, P497, DOI 10.1007/s00285 018 1281 3
   Camacho DF, 2014, CANCER METAST REV, V33, P545, DOI 10.1007/s10555 013 9476 y
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chiechi A., 2016, METASTATIC BONE DIS, P15
   Clewley R.H., 2007, PYDSTOOL SOFTWARE EN
   Coelho RM, 2016, J THEOR BIOL, V391, P1, DOI 10.1016/j.jtbi.2015.11.024
   Cook LM, 2016, SCI REP UK, V6, DOI 10.1038/srep29384
   Edwards JR, 2010, J BONE MINER RES, V25, P2419, DOI 10.1002/jbmr.139
   Enders GH, 2009, J CLIN INVEST, V119, P758, DOI 10.1172/JCI38973
   Farhat A, 2017, MATH BIOSCI, V294, P1, DOI 10.1016/j.mbs.2017.09.005
   Gerlee P, 2013, CANCER RES, V73, P2407, DOI 10.1158/0008 5472.CAN 12 4355
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Javed S, 2019, ADV DIFFER EQU NY, DOI 10.1186/s13662 019 1986 7
   Jerez S, 2015, MATH BIOSCI, V264, P29, DOI 10.1016/j.mbs.2015.03.003
   Jerez S, 2018, J COMPUT APPL MATH, V330, P866, DOI 10.1016/j.cam.2016.12.026
   Ji B, 2020, COMPUT BIOL MED, V117, DOI 10.1016/j.compbiomed.2020.103619
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Krzeszinski JY, 2015, TRENDS PHARMACOL SCI, V36, P360, DOI [10.1016/J.tips.2015.04.006, 10.1016/j.tips.2015.04.006]
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lemaire V, 2019, B MATH BIOL, V81, P3575, DOI 10.1007/s11538 018 0533 0
   Lemos JM, 2016, BIOMED SIGNAL PROCES, V24, P128, DOI 10.1016/j.bspc.2015.10.004
   Lin SC, 2017, DEV CELL, V41, P467, DOI 10.1016/j.devcel.2017.05.005
   Madrasi K, 2018, J CLIN PHARMACOL, V58, P572, DOI 10.1002/jcph.1071
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Miranda R, 2020, MATHEMATICS BASEL, V8, DOI 10.3390/math8050679
   Moroz A, 2012, MOL BIOSYST, V8, P2974, DOI 10.1039/c2mb25078k
   NORTON L, 1988, CANCER RES, V48, P7067
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   POWELL GJ, 1991, CANCER RES, V51, P3059
   Ryser MD, 2010, SIAM J APPL MATH, V70, P1899, DOI 10.1137/090746094
   Sarapata EA, 2014, B MATH BIOL, V76, P2010, DOI 10.1007/s11538 014 9986 y
   Sharp JA, 2020, J THEOR BIOL, V497, DOI 10.1016/j.jtbi.2020.110277
   Sousa S, 2018, CALCIFIED TISSUE INT, V102, P227, DOI 10.1007/s00223 017 0353 5
   Wang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027494
   Weivoda MM, 2016, J BONE MINER RES, V31, P76, DOI 10.1002/jbmr.2586
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
NR 46
TC 4
Z9 5
U1 1
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1007 5704
EI 1878 7274
J9 COMMUN NONLINEAR SCI
JI Commun. Nonlinear Sci. Numer. Simul.
PD SEP
PY 2021
VL 100
AR 105842
DI 10.1016/j.cnsns.2021.105842
EA APR 2021
PG 21
WC Mathematics, Applied; Mathematics, Interdisciplinary Applications;
   Mechanics; Physics, Fluids & Plasmas; Physics, Mathematical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Mathematics; Mechanics; Physics
GA SS6XM
UT WOS:000661898700002
DA 2025 08 17
ER

PT J
AU Lanzolla, G
   Sabini, E
   Beigel, K
   Khan, MP
   Liu, XS
   Wang, D
   Laslow, B
   Taylor, D
   Bellido, T
   Giaccia, A
   Schipani, E
AF Lanzolla, Giulia
   Sabini, Elena
   Beigel, Katherine
   Khan, Mohd Parvez
   Liu, Xiaowei Sherry
   Wang, Dian
   Laslow, Brittany
   Taylor, Deanne
   Bellido, Teresita
   Giaccia, Amato
   Schipani, Ernestina
TI Pharmacological inhibition of HIF2 protects against bone loss in an
   experimental model of estrogen deficiency
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE hypoxia; hIF2; PT2399; osteoporosis; osteoblasts
ID HYPOXIA INDUCIBLE FACTORS; RENAL CELL CARCINOMA; POSTMENOPAUSAL WOMEN;
   STEM CELLS; PREVENTION; HIF 2 ALPHA; OSTEOPOROSIS; OVARIECTOMY;
   INDUCTION; RECEPTOR
AB Estrogen deficiency, which is linked to various pathological conditions such as primary ovarian insufficiency and postmenopausal osteoporosis, disrupts the delicate balance between bone formation and resorption. This imbalance leads to bone loss and an increased risk of fractures, primarily due to a significant reduction in trabecular bone mass. Trabecular osteoblasts, the cells responsible for bone formation within the trabecular compartment, originate from skeletal progenitors located in the bone marrow. The microenvironment of the bone marrow contains hypoxic (low oxygen) regions, and the hypoxia  inducible factor  2 alpha (HIF2) plays a crucial role in cellular responses to these low  oxygen conditions. This study demonstrates that the loss of HIF2 in skeletal progenitors and their derivatives during development enhances trabecular bone mass cifically inhibits HIF2, effectively prevents trabecular bone loss in ovariectomized adult mice, a model for estrogen  deficient bone loss. Both the genetic and pharmacological approaches result in an increase in osteoblast number, which is linked to the expansion of the pool of skeletal progenitor cells. This expansion either by loss or inhibition of HIF2 uncovers a pivotal mechanism for increasing osteoblast numbers and bone formation, resulting in greater trabecular bone mass.
C1 [Lanzolla, Giulia; Sabini, Elena; Khan, Mohd Parvez; Liu, Xiaowei Sherry; Wang, Dian; Laslow, Brittany; Schipani, Ernestina] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.
   [Beigel, Katherine; Taylor, Deanne] Childrens Hosp Philadelphia, Dept Biomed & Hlth Informat, Philadelphia, PA 19104 USA.
   [Bellido, Teresita] Univ Arkansas, Sch Med, Dept Physiol & Cell Biol, Little Rock, AR 72205 USA.
   [Bellido, Teresita] John L McClellan, Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA.
   [Giaccia, Amato] Univ Oxford, Dept Oncol, Div Med Sci, Oxford OX37DQ, England.
C3 University of Pennsylvania; University of Pennsylvania; Pennsylvania
   Medicine; Childrens Hospital of Philadelphia; University of Arkansas
   System; University of Arkansas Little Rock; University of Arkansas
   Fayetteville; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Central Arkansas Veterans Healthcare System;
   University of Oxford
RP Schipani, E (通讯作者)，Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.
EM ernestina.schipani@pennmedicine.upenn.edu
RI lanzolla, giulia/HKE 3823 2023; Lanzolla, Giulia/HKE 3823 2023; Taylor,
   Deanne/AAY 6296 2020; Liu, Xiaowei/H 1664 2017
OI lanzolla, giulia/0000 0001 9933 4040; Beigel,
   Katherine/0000 0003 3439 6042; Bellido, Teresita/0000 0002 8203 7004
FU NIH [R01 AR073022 01A1]
FX We thank the Penn Cytomics and Cell Sorting Shared Resource Laboratory
   at the University of Pennsylvania (P30 016520) , the Histology and
   Micro CT Cores at Umich (NIH P30 AR069620) , and at UPenn (NIH P30
   AR069619) for their excellent technical support. This study was
   supported by NIH R01 AR073022 01A1 to Ernestina Schipani.
CR Ambrosi TH, 2021, ELIFE, V10, DOI 10.7554/eLife.66063
   Araldi E, 2011, NAT MED, V17, P25, DOI 10.1038/nm0111 25
   Aro E, 2012, J BIOL CHEM, V287, P37134, DOI 10.1074/jbc.M112.352872
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796
   Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Elorza A, 2012, MOL CELL, V48, P681, DOI 10.1016/j.molcel.2012.09.017
   Farahani RM, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/362753
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Gera S, 2020, P NATL ACAD SCI USA, V117, P28971, DOI 10.1073/pnas.2014588117
   Greendale GA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124865
   Guo WD, 2023, SCI TRANSL MED, V15, DOI 10.1126/scitranslmed.abo5217
   Guo XX, 2010, ANAT REC, V293, P200, DOI 10.1002/ar.21036
   Hackenbeck T, 2009, CELL CYCLE, V8, P1386, DOI 10.4161/cc.8.9.8306
   Hiram Bab S, 2015, FASEB J, V29, P1890, DOI 10.1096/fj.14 259085
   Doan H, 2019, ISCIENCE, V21, P509, DOI 10.1016/j.isci.2019.10.047
   Jeffery EC, 2022, CELL STEM CELL, V29, P1547, DOI 10.1016/j.stem.2022.10.002
   Jehan F, 2022, FASEB BIOADV, V4, P524, DOI 10.1096/fba.2021 00092
   Jonasch E, 2021, NEW ENGL J MED, V385, P2036, DOI 10.1056/NEJMoa2103425
   Jones AR, 2024, HUM REPROD, V39, DOI 10.1093/humrep/deae037
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183
   Lanzolla G., NCBI's Gene Expression Omnibus GEO series accession GSE263228
   Lanzolla G, 2024, JBMR PLUS, V8, DOI 10.1093/jbmrpl/ziae052
   Ledesma Colunga MG, 2021, SEMIN HEMATOL, V58, P188, DOI 10.1053/j.seminhematol.2021.06.002
   Lee KE, 2012, CURR OPIN CELL BIOL, V24, P232, DOI 10.1016/j.ceb.2012.01.005
   Lee SY, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0054 y
   Lin LS, 2023, NAT METAB, V5, P821, DOI 10.1038/s42255 023 00803 0
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Looker Anne C, 2012, NCHS Data Brief, P1
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Martin TJ, 2021, ENDOCR REV, V42, P383, DOI 10.1210/endrev/bnab005
   Martin TJ, 2015, REV ENDOCR METAB DIS, V16, P131, DOI 10.1007/s11154 014 9308 6
   Mastrogiannaki M, 2009, J CLIN INVEST, V119, P1159, DOI 10.1172/JCI38499
   Matsushita Y, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 38034 2
   Mazumdar J, 2010, NAT CELL BIOL, V12, P1007, DOI 10.1038/ncb2102
   Mendoza SV, 2023, JBMR PLUS, V7, DOI 10.1002/jbm4.10724
   Merceron C, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0045 z
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Newman PJ, 1997, J CLIN INVEST, V100, pS25
   NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453
   Popat VB, 2009, J CLIN ENDOCR METAB, V94, P2277, DOI 10.1210/jc.2008 1878
   Rankin EB, 2012, CELL, V149, P63, DOI 10.1016/j.cell.2012.01.051
   Rauner M, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00157 x
   Rauner M, 2016, J BONE MINER RES, V31, P1877, DOI 10.1002/jbmr.2857
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111
   Riggs BL, 2008, J BONE MINER RES, V23, P205, DOI 10.1359/JBMR.071020
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Shomento SH, 2010, J CELL BIOCHEM, V109, P196, DOI 10.1002/jcb.22396
   Souma T, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00167
   Spencer JA, 2014, NATURE, V508, P269, DOI 10.1038/nature13034
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Suresh S, 2020, FASEB J, V34, P11685, DOI 10.1096/fj.202000888R
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72
   Trompet D, 2024, J BONE MINER RES, V39, P633, DOI 10.1093/jbmr/zjae069
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02 0445fje
   Wu C, 2015, GENE DEV, V29, P817, DOI 10.1101/gad.255000.114
   Zhang YF, 2015, J BONE MINER RES, V30, P286, DOI 10.1002/jbmr.2322
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhou S, 2018, EXP THER MED, V15, P3623, DOI 10.3892/etm.2018.5839
NR 68
TC 1
Z9 1
U1 1
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 3
PY 2024
VL 121
IS 49
AR e2416004121
DI 10.1073/pnas.241600412
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA P3B4M
UT WOS:001376704900001
PM 39602268
DA 2025 08 17
ER

PT J
AU Vallet, S
   Bashari, MH
   Fan, FJ
   Malvestiti, S
   Schneeweiss, A
   Wuchter, P
   Jäger, D
   Podar, K
AF Vallet, Sonia
   Bashari, Muhammad Hasan
   Fan, Feng Juan
   Malvestiti, Stefano
   Schneeweiss, Andreas
   Wuchter, Patrick
   Jaeger, Dirk
   Podar, Klaus
TI Pre Osteoblasts Stimulate Migration of Breast Cancer Cells via
   the HGF/MET Pathway
SO PLOS ONE
LA English
DT Article
ID HEPATOCYTE GROWTH FACTOR; HUMAN BONE MARROW; MESENCHYMAL STEM CELLS;
   IN VITRO; ADHESION MOLECULE; STROMAL CELLS; GENE EXPRESSION; METASTASIS;
   DIFFERENTIATION; MET
AB Introduction
   The occurrence of skeletal metastases in cancer, e.g. breast cancer (BC), deteriorates patient life expectancy and quality of life. Current treatment options against tumor associated bone disease are limited to anti resorptive therapies and aimed towards palliation. There remains a lack of therapeutic approaches, which reverse or even prevent the development of bone metastases. Recent studies demonstrate that not only osteoclasts (OCs), but also osteoblasts (OBs) play a central role in the pathogenesis of skeletal metastases, partly by producing hepatocyte growth factor (HGF), which promotes tumor cell migration and seeding into the bone. OBs consist of a heterogeneous cell pool with respect to their maturation stage and function. Recent studies highlight the critical role of pre OBs in hematopoiesis. Whether the development of bone metastases can be attributed to a particular OB maturation stage is currently unknown.
   Methods and Results
   Pre OBs were generated from healthy donor (HD) derived bone marrow stromal cells (BMSC) as well as the BMSC line KM105 and defined as ALP(low) OPNlow RUNX2(high) OSXhigh CD166(high). Conditioned media (CM) of pre OBs, but not of undifferentiated cells or mature OBs, enhanced migration of metastatic BC cells. Importantly, HGF mRNA was significantly up regulated in pre OBs versus mature OBs, and CM of pre OBs activated the MET signaling pathway. Highlighting a key role for HGF, CM from HGF negative pre OBs derived from the BMSC line HS27A did not support migration of BC cells. Genetically (siMET) or pharmacologically (INCB28060) targeting MET inhibited both HGF  and pre OB CM mediated BC cell migration.
   Conclusions
   Our data demonstrate for the first time a role for pre OBs in mediating HGF/MET dependent migration of BC cells and strongly support the clinical evaluation of INCB28060 and other MET inhibitors to limit and/or prevent BC associated bone metastases.
C1 [Vallet, Sonia; Bashari, Muhammad Hasan; Fan, Feng Juan; Malvestiti, Stefano; Schneeweiss, Andreas; Jaeger, Dirk; Podar, Klaus] Heidelberg Univ, Dept Med Oncol, Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
   [Bashari, Muhammad Hasan] Padjadjaran State Univ, Fac Med, Dept Pharmacol & Therapy, Bandung, Indonesia.
   [Schneeweiss, Andreas] Heidelberg Univ, Dept Obstet & Gynecol, Heidelberg, Germany.
   [Wuchter, Patrick] Heidelberg Univ, Dept Med 5, Heidelberg, Germany.
   [Jaeger, Dirk] German Canc Res Ctr, Appl Tumor Immun, Heidelberg, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht
   Karls University Heidelberg; National Center for Tumor Diseases;
   Universitas Padjadjaran; Ruprecht Karls University Heidelberg; Ruprecht
   Karls University Heidelberg; Helmholtz Association; German Cancer
   Research Center (DKFZ)
RP Podar, K (通讯作者)，Heidelberg Univ, Dept Med Oncol, Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
EM klaus.podar@nct heidelberg.de
RI Jaeger, Dirk/LTZ 9768 2024; Vallet, Sonia/AHE 3935 2022; Schneeweiss,
   Andreas/HHS 4098 2022; Podar, Klaus/ABD 1112 2020; Fan,
   Fengjuan/I 1213 2016; Bashari, Muhammad Hasan/H 7079 2016; Bashari,
   MH/H 7079 2016
OI Malvestiti, Stefano/0000 0003 1595 2365; Podar,
   Klaus/0000 0002 7414 3632; Vallet, Sonia/0000 0003 0146 8089; Bashari,
   Muhammad Hasan/0000 0001 7298 0317; 
FU German Academic Exchange Service; Novartis Pharma
FX MHB is supported by a scholarship of the German Academic Exchange
   Service; SV and KP received research support by Novartis Pharma. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576
   Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183
   Body JJ, 2011, CURR OPIN ONCOL, V23, P338, DOI 10.1097/CCO.0b013e328347918b
   BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706
   BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Chen W, 2014, P NATL ACAD SCI USA, V111, P8482, DOI 10.1073/pnas.1310617111
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Chitteti BR, 2013, BONE, V54, P58, DOI 10.1016/j.bone.2013.01.038
   Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697
   Degen WGJ, 1998, AM J PATHOL, V152, P805
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Gaasch JA, 2006, GENE, V369, P142, DOI 10.1016/j.gene.2005.10.036
   Gastaldi S, 2013, ONCOGENE, V32, P1428, DOI 10.1038/onc.2012.154
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097 0215(19981209)78:6<766::AID IJC15>3.0.CO;2 L
   Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644
   HARIGAYA K, 1985, P NATL ACAD SCI USA, V82, P3477, DOI 10.1073/pnas.82.10.3477
   HIPP JA, 1989, J ORTHOP RES, V7, P828, DOI 10.1002/jor.1100070609
   Kang JY, 2003, CANCER RES, V63, P1101
   Kassen D, 2016, BRIT J HAEMATOL, V172, P64, DOI 10.1111/bjh.13790
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Krishnan V, 2011, J CELL PHYSIOL, V226, P2150, DOI 10.1002/jcp.22550
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Liu XD, 2011, CLIN CANCER RES, V17, P7127, DOI 10.1158/1078 0432.CCR 11 1157
   Malcherek G, 2014, LEUKEMIA, V28, P2388, DOI 10.1038/leu.2014.273
   Mendoza Villanueva D, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3048
   Mercer RR, 2004, CLIN EXP METASTAS, V21, P427, DOI 10.1007/s10585 004 1867 6
   Molloy AP, 2009, INT J CANCER, V124, P326, DOI 10.1002/ijc.23939
   Muir C, 2006, CLIN EXP METASTAS, V23, P75, DOI 10.1007/s10585 006 9021 2
   Nakamura Y, 2010, BLOOD, V116, P1422, DOI 10.1182/blood 2009 08 239194
   Ohneda O, 2001, BLOOD, V98, P2134, DOI 10.1182/blood.V98.7.2134
   Ono K, 2006, BONE, V39, P27, DOI 10.1016/j.bone.2005.12.006
   Phadke PA, 2006, CLIN CANCER RES, V12, P1431, DOI 10.1158/1078 0432.CCR 05 1806
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   ROECKLEIN BA, 1995, BLOOD, V85, P997, DOI 10.1182/blood.V85.4.997.bloodjournal854997
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sathiakumar N, 2012, BREAST CANCER RES TR, V131, P231, DOI 10.1007/s10549 011 1721 x
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   SOULE HD, 1990, CANCER RES, V50, P6075
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Taichman RS, 2001, BRIT J HAEMATOL, V112, P438, DOI 10.1046/j.1365 2141.2001.02568.x
   TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896 6273(91)90366 8
   Vallet S, 2011, LEUKEMIA, V25, P1174, DOI 10.1038/leu.2011.43
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Welm AL, 2005, P NATL ACAD SCI USA, V102, P4324, DOI 10.1073/pnas.0500470102
   Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535 7163.MCT 11 0264
   Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549 011 1475 5
   Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036
   Zlotnik A, 2011, NAT REV IMMUNOL, V11, P597, DOI 10.1038/nri3049
   zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432 0436.2003.700602.x
NR 54
TC 17
Z9 19
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 2
PY 2016
VL 11
IS 3
AR e0150507
DI 10.1371/journal.pone.0150507
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DG0AN
UT WOS:000371724200098
PM 26934743
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, AG
   Yang, LB
   Geng, XL
   Peng, XM
   Lu, T
   Deng, YJ
   Dong, YZ
AF Li, Aiguo
   Yang, Libin
   Geng, Xiaolin
   Peng, Xingmei
   Lu, Tan
   Deng, Yanjun
   Dong, Yuzheng
TI Rocaglamide A Potentiates Osteoblast Differentiation by Inhibiting NF κB
   Signaling
SO MOLECULES AND CELLS
LA English
DT Article
DE NF kappa B; osteoblast differentiation; rocaglamide A; TNF alpha
ID TUMOR NECROSIS FACTOR; TNF ALPHA; BONE FORMATION; T CELLS;
   RHEUMATOID ARTHRITIS; DERIVATIVES; OSTEOCLASTS; ACTIVATION; EXPRESSION;
   PATHOGENESIS
AB Rheumatoid arthritis is a chronic inflammatory disease that leads to bone and cartilage erosion. The inhibition of osteoblast differentiation by the inflammatory factor TNF alpha is critical for the pathogenesis of rheumatoid arthritis. To modulate TNF alpha mediated inhibition of osteoblast differentiation is required to improve therapeutic efficacy of rheumatoid arthritis. Here, we explored the potential role of rocaglamide A, a component of Aglaia plant, in osteoblast differentiation. Rocaglamide A prevented TNF alpha mediated inhibition of osteoblast differentiation, and promoted osteoblast differentiation directly, in both C2C12 and primary mesenchymal stromal cells. Mechanistically, Rocaglamide A inhibited the phosphorylation of NF kappa B component p65 protein and the accumulation of p65 in nucleus, which resulted in the diminished NF kappa B responsible transcriptional activity. Oppositely, overexpression of p65 reversed rocaglamide A's protective effects on osteoblast differentiation. Collectively, rocaglamide A protected and stimulated osteoblast differentiation via blocking NF kappa B pathway. It suggests that rocaglamide A may be a good candidate to develop as therapeutic drug for rheumatoid arthritis associated bone loss diseases.
C1 [Li, Aiguo; Yang, Libin; Geng, Xiaolin; Lu, Tan; Deng, Yanjun; Dong, Yuzheng] Xinxiang Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Henan, Peoples R China.
   [Peng, Xingmei] Xinxiang Med Univ, Affiliated Hosp 3, Dept Oncol, Henan, Peoples R China.
C3 Henan Medical University; Henan Medical University
RP Li, AG (通讯作者)，Xinxiang Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Henan, Peoples R China.
EM li_aiguo2010@126.com
OI Lu, Tan/0000 0002 0399 7147
CR Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Baumann B, 2002, J BIOL CHEM, V277, P44791, DOI 10.1074/jbc.M208003200
   Bohnenstengel FI, 1999, Z NATURFORSCH C, V54, P55
   CANALIS E, 1987, ENDOCRINOLOGY, V121, P1596, DOI 10.1210/endo 121 5 1596
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Collett GP, 2006, CARCINOGENESIS, V27, P1285, DOI 10.1093/carcin/bgi368
   Dreyer M, 2001, J NAT PROD, V64, P415, DOI 10.1021/np000123x
   Goldring SR, 2000, CURR OPIN RHEUMATOL, V12, P195, DOI 10.1097/00002281 200005000 00006
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Kaneko H, 2000, BONE, V27, P479, DOI 10.1016/S8756 3282(00)00358 6
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kim Soyoung, 2006, Anti Cancer Agents in Medicinal Chemistry, V6, P319, DOI 10.2174/187152006777698123
   Lee HL, 2010, EXP MOL MED, V42, P437, DOI 10.3858/emm.2010.42.6.045
   Lee SK, 1998, CHEM BIOL INTERACT, V115, P215, DOI 10.1016/S0009 2797(98)00073 8
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Mukai T, 2007, BIOCHEM BIOPH RES CO, V356, P1004, DOI 10.1016/j.bbrc.2007.03.099
   Nanjundaiah SM, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/518094
   Proksch P, 2005, J IMMUNOL, V174, P7075, DOI 10.4049/jimmunol.174.11.7075
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Smucker JD, 2006, SPINE, V31, P2813, DOI 10.1097/01.brs.0000245863.52371.c2
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420
   Steer JH, 2000, J BIOL CHEM, V275, P18432, DOI 10.1074/jbc.M906304199
   Walsh NC, 2009, J BONE MINER RES, V24, P1572, DOI [10.1359/JBMR.090320, 10.1359/jbmr.090320]
   Wong DA, 2008, SPINE J, V8, P1011, DOI 10.1016/j.spinee.2007.06.014
   Yamazaki M, 2009, J BIOL CHEM, V284, P35987, DOI 10.1074/jbc.M109.070540
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zara JN, 2011, TISSUE ENG PT A, V17, P1389, DOI [10.1089/ten.TEA.2010.0555, 10.1089/ten.tea.2010.0555]
   Zhu JY, 2009, CELL DEATH DIFFER, V16, P1289, DOI 10.1038/cdd.2009.42
NR 32
TC 12
Z9 13
U1 0
U2 20
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635 4, YUCKSAM DONG, GANGNAM GU, SEOUL 135 703, SOUTH KOREA
SN 1016 8478
EI 0219 1032
J9 MOL CELLS
JI Mol. Cells
PD NOV
PY 2015
VL 38
IS 11
BP 941
EP 949
DI 10.14348/molcells.2015.2353
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CY9QL
UT WOS:000366741300003
PM 26549505
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Cakouros, D
   Raices, RM
   Gronthos, S
   Glackin, CA
AF Cakouros, D.
   Raices, R. M.
   Gronthos, S.
   Glackin, C. A.
TI Twist ing Cell Fate: Mechanistic Insights Into the Role of Twist in
   Lineage Specification/Differentiation and Tumorigenesis
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE TWIST; WNT; BMP; TGF beta; SMAD; MSC; OSTEOBLAST; CHONDROCYTE;
   ADIPOCYTES; CANCER STEM CELLS
ID EPITHELIAL MESENCHYMAL TRANSITION; CANCER STEM CELLS; HUMAN
   BREAST CANCER; HELIX TRANSCRIPTION FACTOR; WNT SIGNALING PATHWAY;
   TGF BETA; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; BONE
   REGENERATION; BHLH PROTEIN
AB Bone marrow derived mesenchymal stem cells (MSCs), are multipotent cells that give rise to multiple lineages including osteoblasts, adipocytes, muscle, and fibroblasts. MSCs are useful for clinical applications such as cell therapy because they can be isolated from an individual and expanded for use in tissue repair, as well as other therapeutic applications, without immune rejection. However, one of the key problems in the use of MSCs for these applications is the efficiency of these cells to engraft and fully regenerate damaged tissues. Therefore, to optimize this process, a comprehensive understanding of the key regulators of MSCs self renewal and maintenance are critical to the success of future cell therapy as well as other clinical applications. The basic helix loop helix transcription factor, Twist, plays a master regulatory role in all of these processes and, therefore, a thorough understanding of the mechanistic insights in the role of Twist in lineage specification/differentiation and tumorigenesis is vital to the success of future clinical applications for the therapeutic use of MSCs. In this article, we highlight the basic mechanisms and signaling pathways that are important to MSC fate, maintenance, and differentiation, as well as the critical role that Twist plays in these processes. In addition, we review the known literature suggesting a critical role for Twist in the generation of cancer stem cells, as this information may contribute to a broader understanding of stem cell biology and stem cell based therapeutics. J. Cell. Biochem. 110: 1288 1298, 2010. (C) 2010 Wiley Liss, Inc.
C1 [Raices, R. M.; Glackin, C. A.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Neurosci, Duarte, CA 91010 USA.
   [Cakouros, D.; Gronthos, S.] Univ Adelaide, Robinson Inst, Ctr Stem Cell Res, Adelaide, SA, Australia.
   [Cakouros, D.; Gronthos, S.] Hanson Inst, Inst Med & Vet Sci, Dept Haematol, Mesenchymal Stem Cell Grp, Adelaide, SA 5000, Australia.
C3 City of Hope; Beckman Research Institute of City of Hope; Robinson
   Research Institute; University of Adelaide; Hanson Institute; Institute
   Medical & Veterinary Science Australia
RP Glackin, CA (通讯作者)，City Hope Natl Med Ctr, Beckman Res Inst, Dept Neurosci, George Familian Res Bldg F203, Duarte, CA 91010 USA.
EM cglackin@coh.org
RI ; Cakouros, Dimitrios/NEU 7365 2025; Gronthos, Stan/Y 4419 2019
OI Gronthos, Stan/0000 0002 6225 3084; 
FU NCI NIH HHS [R21 CA107245] Funding Source: Medline
CR Aboody KS, 2008, GENE THER, V15, P739, DOI 10.1038/gt.2008.41
   Agiostratidou G, 2007, J MAMMARY GLAND BIOL, V12, P127, DOI 10.1007/s10911 007 9044 6
   Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359 6101(00)00011 3
   Al Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005
   Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515
   Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001
   Behrens J, 2000, J CELL SCI, V113, P911
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Bourgeois P, 1998, HUM MOL GENET, V7, P945, DOI 10.1093/hmg/7.6.945
   Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694
   Cariati M, 2008, HISTOPATHOLOGY, V52, P99, DOI 10.1111/j.1365 2559.2007.02895.x
   Castanon I, 2001, DEVELOPMENT, V128, P3145
   CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008 5472.CAN 06 1479
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008 5472.CAN 06 3126
   Connerney J, 2008, DEV BIOL, V318, P323, DOI 10.1016/j.ydbio.2008.03.037
   Connerney J, 2006, DEV DYNAM, V235, P1345, DOI 10.1002/dvdy.20717
   Corsi AK, 2002, DEVELOPMENT, V129, P2761
   Cunningham ML, 2007, ORTHOD CRANIOFAC RES, V10, P67, DOI 10.1111/j.1601 6343.2007.00389.x
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092 8674(00)00056 8
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955 0674(99)80031 3
   ElGhouzzi V, 1997, NAT GENET, V15, P42
   Fang MA, 2001, J CELL BIOCHEM, V80, P550, DOI 10.1002/1097 4644(20010315)80:4<550::AID JCB1009>3.0.CO;2 1
   Fata JE, 2004, BREAST CANCER RES, V6, P1, DOI 10.1186/bcr634
   Firulli AB, 2008, CURR MED CHEM, V15, P2641, DOI 10.2174/092986708785908987
   Firulli BA, 2005, NAT GENET, V37, P373, DOI 10.1038/ng1525
   Fischer L, 2002, J CELL BIOCHEM, V84, P816, DOI 10.1002/jcb.10091
   Galler KM, 2007, J DENT RES, V86, P951, DOI 10.1177/154405910708601007
   Gammill LS, 2003, NAT REV NEUROSCI, V4, P795, DOI 10.1038/nrn1219
   Gavert N, 2008, TRENDS MOL MED, V14, P199, DOI 10.1016/j.molmed.2008.03.004
   Gilles C, 1999, J CELL SCI, V112, P4615
   Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gripp KW, 2000, HUM MUTAT, V15, P479, DOI 10.1002/(SICI)1098 1004(200005)15:5<479::AID HUMU11>3.0.CO;2 X
   Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563
   Harris SE, 2003, FRONT BIOSCI, V8, pS1249, DOI 10.2741/1170
   Hartikka H, 2005, J BONE MINER RES, V20, P783, DOI 10.1359/JBMR.050101
   Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092 8674(01)00222 7
   Hay ED, 1995, ACTA ANAT, V154, P8
   Hayashi M, 2007, J CELL SCI, V120, P1350, DOI 10.1242/jcs.000067
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008 5472.CAN 08 3441
   HILTON M, 2005, DEVELOPMENT, V132, P1971
   Holleville N, 2007, DEV BIOL, V304, P860, DOI 10.1016/j.ydbio.2007.01.003
   Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197 36
   HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393 241
   Hurt EM, 2008, MOL INTERV, V8, P140, DOI 10.1124/mi.8.3.7
   Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371
   Inoue S, 1999, BIOCHEM BIOPH RES CO, V261, P412, DOI 10.1006/bbrc.1999.0874
   Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181
   Ishii M, 2003, DEVELOPMENT, V130, P6131, DOI 10.1242/dev.00793
   JABS E, 2004, TWIST SAETHRE CHOTZE
   Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887
   Johnson D, 1998, AM J HUM GENET, V63, P1282, DOI 10.1086/302122
   Kajiyama H, 2007, INT J ONCOL, V31, P277
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kang Kihwa, 2007, Curr Atheroscler Rep, V9, P72, DOI 10.1007/BF02693931
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kitagaki J, 2003, OSTEOARTHR CARTILAGE, V11, P36, DOI 10.1053/joca.2002.0863
   Kleer CG, 2007, CELLS TISSUES ORGANS, V185, P95, DOI 10.1159/000101308
   Koebernick K, 2002, DIFFERENTIATION, V70, P69, DOI 10.1046/j.1432 0436.2002.700201.x
   Kokkinos MI, 2007, CELLS TISSUES ORGANS, V185, P191, DOI 10.1159/000101320
   Komaki M, 2007, J CELL BIOCHEM, V100, P303, DOI 10.1002/jcb.21038
   Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097 4644(19991215)75:4<566::AID JCB3>3.0.CO;2 0
   Lee YS, 2003, NUCLEIC ACIDS RES, V31, P7165, DOI 10.1093/nar/gkg934
   LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568
   Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118
   Li TS, 2008, BIOCHEM BIOPH RES CO, V366, P1074, DOI 10.1016/j.bbrc.2007.12.095
   Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008 5472.CAN 06 4493
   Lien HC, 2007, ONCOGENE, V26, P7859, DOI 10.1038/sj.onc.1210593
   LIN J, 2005, CELL METAB, V3, P429
   Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Lock GSH, 1998, T CAN SOC MECH ENG, V22, P207, DOI 10.1139/tcsme 1998 0011
   LONG MW, 1995, J CLIN INVEST, V95, P881, DOI 10.1172/JCI117738
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429 440.2000
   McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398
   Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008 5472.CAN 05 0712
   Mo R, 1997, DEVELOPMENT, V124, P113
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349 7006.2007.00550.x
   NAKAMURA T, 1995, ENDOCRINOLOGY, V136, P1276, DOI 10.1210/en.136.3.1276
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   O'Rourke MP, 2002, INT J DEV BIOL, V46, P401
   Pan DN, 2009, CELL, V137, P73, DOI 10.1016/j.cell.2009.01.051
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   REARDON W, 1994, J MED GENET, V31, P393, DOI 10.1136/jmg.31.5.393
   Reinhold MI, 2006, J BIOL CHEM, V281, P1381, DOI 10.1074/jbc.M504875200
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001
   Salazar VS, 2008, J CELL BIOCHEM, V104, P942, DOI 10.1002/jcb.21679
   Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008 5472.CAN 08 3343
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008 5472.CAN 07 2017
   Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188
   Savagner P, 1994, Cancer Treat Res, V71, P229
   Seto ES, 2004, TRENDS CELL BIOL, V14, P45, DOI 10.1016/j.tcb.2003.11.004
   Shah R, 2004, AM J PHYSIOL ENDOC M, V287, pE289, DOI 10.1152/ajpendo.00517.2003
   SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411
   SHALHOUB V, 1989, BIOCHEMISTRY US, V28, P5318, DOI 10.1021/bi00439a002
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Shimoyama A, 2007, MOL BIOL CELL, V18, P2411, DOI 10.1091/mbc.E06 08 0743
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005
   SIMPSON P, 1983, GENETICS, V105, P615
   SOMMERS CL, 1992, CANCER RES, V52, P5190
   Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004
   THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314
   Turley EA, 2008, NAT CLIN PRACT ONCOL, V5, P280, DOI 10.1038/ncponc1089
   Verrecchia Franck, 2002, Curr Rheumatol Rep, V4, P143, DOI 10.1007/s11926 002 0010 4
   Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545
   Weigelt B, 2009, BREAST CANCER RES TR, V117, P273, DOI 10.1007/s10549 008 0197 9
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012 1606(91)90086 I
   Wozney JM, 1998, CLIN ORTHOP RELAT R, P26
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yousfi M, 2001, J CLIN INVEST, V107, P1153, DOI 10.1172/JCI11846
   Zhang YH, 2005, BREAST CANCER RES, V7, pR1080, DOI 10.1186/bcr1351
   Zhong N, 2006, BONE, V39, P5, DOI 10.1016/j.bone.2005.12.008
   Zhou SH, 2004, J BONE MINER RES, V19, P463, DOI 10.1359/JBMR.0301239
   Zhuo WL, 2008, BIOCHEM BIOPH RES CO, V369, P1098, DOI 10.1016/j.bbrc.2008.02.143
NR 141
TC 34
Z9 41
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG 15
PY 2010
VL 110
IS 6
BP 1288
EP 1298
DI 10.1002/jcb.22651
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 633WI
UT WOS:000280537200002
PM 20564230
DA 2025 08 17
ER

PT J
AU Zhang, YJ
   Wang, Y
   Zhu, AN
   Yu, NY
   Xia, JD
   Li, JC
AF Zhang, Yijing
   Wang, Yue
   Zhu, Anni
   Yu, Ningyue
   Xia, Jindong
   Li, Jingchao
TI Dual Targeting Biomimetic Semiconducting Polymer Nanocomposites for
   Amplified Theranostics of Bone Metastasis
SO ANGEWANDTE CHEMIE INTERNATIONAL EDITION
LA English
DT Article
DE Bone Metastasis; Cancer Theranostic; Cell Membrane Camouflage;
   Dual Targeting; Semiconducting Polymer
ID BREAST CANCER; ZOLEDRONIC ACID; MULTIPLE MYELOMA; PHASE III;
   NANOPARTICLES; CELL; THERAPY; IMMUNOTHERAPY; NANOPLATFORM; MECHANISMS
AB Bone metastasis is a type of metastatic tumors that involves the spreads of malignant tumor cells into skeleton, and its diagnosis and treatment remain a big challenge due to the unique tumor microenvironment. We herein develop osteoclast and tumor cell dual targeting biomimetic semiconducting polymer nanocomposites (SPFeNOC) for amplified theranostics of bone metastasis. SPFeNOC contain semiconducting polymer and iron oxide (Fe3O4) nanoparticles inside core and surface camouflaged hybrid membrane of cancer cells and osteoclasts. The hybrid membrane camouflage enables their targeting to both metastatic tumor cells and osteoclasts in bone metastasis through homologous targeting mechanism, thus achieving an enhanced nanoparticle accumulation in tumors. The semiconducting polymer mediates near infrared (NIR) fluorescence imaging and sonodynamic therapy (SDT), and Fe3O4 nanoparticles are used for magnetic resonance (MR) imaging and chemodynamic therapy (CDT). Because both cancer cells and osteoclasts are killed synchronously via the combinational action of SDT and CDT, the vicious cycle in bone metastasis is broken to realize high antitumor efficacy. Therefore, 4T1 breast cancer based bone metastasis can be effectively detected and cured by using SPFeNOC as dual targeting theranostic nanoagents. This study provides an unusual biomimetic nanoplatform that simultaneously targets osteoclasts and cancer cells for amplified theranostics of bone metastasis.
   A dual targeting biomimetic semiconducting polymer nanocomposite is developed for amplified theranostics of bone metastasis. The nanocomposite enables efficient tumor homing after dual targeting effect towards both cancer cells and osteoclasts, and thus achieves bone metastasis diagnosis and effective inhibition of tumor growth via mediating dual model imaging at bone metastasis sites and a combined therapy against cancer cells and osteoclasts.image
C1 [Zhang, Yijing; Zhu, Anni; Yu, Ningyue; Li, Jingchao] Donghua Univ, Coll Biol Sci & Med Engn, State Key Lab Modificat Chem Fibers & Polymer Mat, Shanghai 201620, Peoples R China.
   [Wang, Yue; Xia, Jindong] Shanghai Songjiang Dist Cent Hosp, Dept Radiol, Shanghai 201600, Peoples R China.
C3 Donghua University
RP Li, JC (通讯作者)，Donghua Univ, Coll Biol Sci & Med Engn, State Key Lab Modificat Chem Fibers & Polymer Mat, Shanghai 201620, Peoples R China.; Xia, JD (通讯作者)，Shanghai Songjiang Dist Cent Hosp, Dept Radiol, Shanghai 201600, Peoples R China.
EM xiajd_21@163.com; jcli@dhu.edu.cn
FU Science and Technology Commission of Shanghai Municipality; Program for
   Professor of Special Appointment (Eastern Scholar) at Shanghai
   Institutions of Higher Learning;  [22ZR1401100];  [22490760700]; 
   [23WZ2504600];  [23ZR1457400]
FX This work was financially supported by the Science and Technology
   Commission of Shanghai Municipality (22ZR1401100, 22490760700,
   23WZ2504600 and 23ZR1457400) and Program for Professor of Special
   Appointment (Eastern Scholar) at Shanghai Institutions of Higher
   Learning.
CR Agwa MM, 2023, INT J BIOL MACROMOL, V239, DOI 10.1016/j.ijbiomac.2023.124294
   Albain KS, 2009, LANCET, V374, P379, DOI 10.1016/S0140 6736(09)60737 6
   Bado IL, 2021, DEV CELL, V56, P1100, DOI 10.1016/j.devcel.2021.03.008
   Baek YH, 2019, CANCER EPIDEMIOL, V61, P104, DOI 10.1016/j.canep.2019.05.013
   Chen BD, 2023, NANO TODAY, V51, DOI 10.1016/j.nantod.2023.101931
   Chen HY, 2020, ACTA BIOMATER, V112, P1, DOI 10.1016/j.actbio.2020.05.028
   Chen JY, 2020, THERANOSTICS, V10, P1619, DOI 10.7150/thno.40489
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Coleman RE, 2008, CLIN CANCER RES, V14, P6387, DOI 10.1158/1078 0432.CCR 08 1572
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Dhillon S, 2008, DRUGS, V68, P507, DOI 10.2165/00003495 200868040 00010
   Dong Z, 2022, ANGEW CHEM INT EDIT, V61, DOI 10.1002/anie.202206074
   Fan L, 2014, LANCET ONCOL, V15, pE279, DOI 10.1016/S1470 2045(13)70567 9
   Fang RH, 2023, NAT REV CLIN ONCOL, V20, P33, DOI 10.1038/s41571 022 00699 x
   Fang RH, 2018, ADV MATER, V30, DOI 10.1002/adma.201706759
   Fang RH, 2017, BIOMATERIALS, V128, P69, DOI 10.1016/j.biomaterials.2017.02.041
   Greenlee RT, 2001, CA CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15
   Guan GQ, 2022, ANGEW CHEM INT EDIT, V61, DOI 10.1002/anie.202117229
   Han X, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw6870
   He YF, 2017, J CONTROL RELEASE, V264, P76, DOI 10.1016/j.jconrel.2017.08.024
   He YF, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI157917
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Hu BB, 2022, J CONTROL RELEASE, V350, P377, DOI 10.1016/j.jconrel.2022.08.034
   Huang YJ, 2020, ACTA PHARMACOL SIN B, V10, P2384, DOI 10.1016/j.apsb.2020.06.006
   Kang JN, 2022, CANCER LETT, V530, P156, DOI 10.1016/j.canlet.2022.01.015
   Ke XZ, 2017, DRUG DELIV, V24, P1680, DOI 10.1080/10717544.2017.1396384
   Khosravi N, 2022, J CONTROL RELEASE, V348, P706, DOI 10.1016/j.jconrel.2022.06.026
   Li JC, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 31551 6
   Li RX, 2018, ACTA PHARM SIN B, V8, P14, DOI 10.1016/j.apsb.2017.11.009
   Li YL, 2021, ANGEW CHEM INT EDIT, V60, P15472, DOI 10.1002/anie.202103015
   Lin XH, 2020, ANGEW CHEM INT EDIT, V59, P1682, DOI 10.1002/anie.201912768
   Luk BT, 2015, J CONTROL RELEASE, V220, P600, DOI 10.1016/j.jconrel.2015.07.019
   Luo ZY, 2023, NAT NANOTECHNOL, V18, P647, DOI 10.1038/s41565 023 01374 7
   Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Niu YM, 2022, ACS NANO, V16, P2209, DOI 10.1021/acsnano.1c08269
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Rahikkala A, 2020, RSC ADV, V10, P35198, DOI 10.1039/d0ra05900e
   Rahman MT, 2023, J CONTROL RELEASE, V357, P498, DOI 10.1016/j.jconrel.2023.04.019
   Rosen LS, 2001, CANCER J, V7, P377
   Satcher RL, 2022, NAT REV CANCER, V22, P85, DOI 10.1038/s41568 021 00406 5
   Song GS, 2018, NANO LETT, V18, P182, DOI 10.1021/acs.nanolett.7b03829
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Tan SW, 2015, THERANOSTICS, V5, P863, DOI 10.7150/thno.11852
   Thamake SI, 2012, BIOMATERIALS, V33, P7164, DOI 10.1016/j.biomaterials.2012.06.026
   Thanopoulou E, 2020, CANCERS, V12, DOI 10.3390/cancers12113317
   Vanderburgh J, 2020, ACS NANO, V14, P311, DOI 10.1021/acsnano.9b04571
   Wang BL, 2022, ADV SCI, V9, DOI 10.1002/advs.202201451
   Wang CP, 2015, SMALL, V11, P2080, DOI 10.1002/smll.201403315
   Wang H, 2011, BIOMATERIALS, V32, P2979, DOI 10.1016/j.biomaterials.2011.01.001
   Wang HJ, 2020, BIOMATER SCI UK, V8, P552, DOI 10.1039/c9bm01392j
   Wang YJ, 2020, NANO LETT, V20, P176, DOI 10.1021/acs.nanolett.9b03556
   Wellington K, 2003, DRUGS, V63, P417, DOI 10.2165/00003495 200363040 00009
   Xing HY, 2012, BIOMATERIALS, V33, P1079, DOI 10.1016/j.biomaterials.2011.10.039
   Xiong JQ, 2021, ACS NANO, V15, P19756, DOI 10.1021/acsnano.1c07180
   Xuan MJ, 2018, ANGEW CHEM INT EDIT, V57, P6049, DOI 10.1002/anie.201712996
   Yan Y, 2019, ACS APPL MATER INTER, V11, P160, DOI 10.1021/acsami.8b15827
   Yang CF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21196985
   Yang HB, 2022, J CONTROL RELEASE, V341, P443, DOI 10.1016/j.jconrel.2021.11.005
   Yang J, 2018, J CANCER RES CLIN, V144, P1835, DOI 10.1007/s00432 018 2702 9
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
   Yue ZY, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI144579
   Zhang WJ, 2021, CELL, V184, P2471, DOI 10.1016/j.cell.2021.03.011
   Zhao YN, 2021, BIOMACROMOLECULES, V22, P3149, DOI 10.1021/acs.biomac.1c00440
   Zhen X, 2019, SMALL, V15, DOI 10.1002/smll.201804105
   Zhou FF, 2021, BIOMATERIALS, V265, DOI 10.1016/j.biomaterials.2020.120421
NR 66
TC 18
Z9 19
U1 22
U2 131
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433 7851
EI 1521 3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem. Int. Edit.
PD JAN 8
PY 2024
VL 63
IS 2
DI 10.1002/anie.202310252
EA DEC 2023
PG 11
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA EK2N0
UT WOS:001113841400001
PM 38010197
DA 2025 08 17
ER

PT J
AU Nakaue, E
   Teramachi, J
   Tenshin, H
   Hiasa, M
   Harada, T
   Oda, A
   Inoue, Y
   Shimizu, S
   Higa, Y
   Sogabe, K
   Oura, M
   Hara, T
   Sumitani, R
   Maruhashi, T
   Yamagami, H
   Endo, I
   Tanaka, E
   Abe, M
AF Nakaue, Emiko
   Teramachi, Jumpei
   Tenshin, Hirofumi
   Hiasa, Masahiro
   Harada, Takeshi
   Oda, Asuka
   Inoue, Yusuke
   Shimizu, So
   Higa, Yoshiki
   Sogabe, Kimiko
   Oura, Masahiro
   Hara, Tomoyo
   Sumitani, Ryohei
   Maruhashi, Tomoko
   Yamagami, Hiroki
   Endo, Itsuro
   Tanaka, Eiji
   Abe, Masahiro
TI Mechanisms of preferential bone formation in myeloma bone lesions by
   proteasome inhibitors
SO INTERNATIONAL JOURNAL OF HEMATOLOGY
LA English
DT Article
DE Osteoblast; Osteoclast; Proteasome inhibitor; Pulsatile treatment;
   Multiple myeloma
ID MULTIPLE MYELOMA; OSTEOBLAST DIFFERENTIATION; IN VITRO; BORTEZOMIB;
   ACTIVATION; CARFILZOMIB; DISEASE; OSTEOCLASTS; THERAPY; KINASE
AB Proteasome inhibitors (PIs) can preferentially restore bone in bone defective lesions of patients with multiple myeloma (MM) who respond favorably to these drugs. Most prior in vitro studies on PIs used continuous exposure to low PI concentrations, although pharmacokinetic analysis in patients has shown that serum concentrations of PIs change in a pulsatile manner. In the present study, we explored the effects of pulsatile treatment with PIs on bone metabolism to simulate in vivo PI pharmacokinetics. Pulsatile treatment with bortezomib, carfilzomib, or ixazomib induced MM cell death but only marginally affected the viability of osteoclasts (OCs) with F actin ring formation. Pulsatile PI treatment suppressed osteoclastogenesis in OC precursors and bone resorption by mature OCs. OCs robustly enhanced osteoblastogenesis in cocultures with OCs and MC3T3 E1 pre osteoblastic cells, indicating OC mediated coupling to osteoblastogenesis. Importantly, pulsatile PI treatment did not impair robust OC mediated osteoblastogenesis. These results suggest that PIs might sufficiently reduce MM cell derived osteoblastogenesis inhibitors to permit OC driven bone formation coupling while suppressing OC differentiation and activity in good responders to PIs. OC mediated coupling to osteoblastogenesis appears to be a predominant mechanism for preferential occurrence of bone regeneration at sites of osteoclastic bone destruction in good responders.
C1 [Nakaue, Emiko; Tenshin, Hirofumi; Hiasa, Masahiro; Shimizu, So; Higa, Yoshiki; Tanaka, Eiji] Tokushima Univ, Grad Sch Biomed Sci, Dept Orthodont & Dentofacial Orthoped, Tokushima, Japan.
   [Teramachi, Jumpei] Okayama Univ, Grad Sch, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral Funct & Anat, 2 5 1 Shikata, Okayama 7008525, Japan.
   [Harada, Takeshi; Oda, Asuka; Inoue, Yusuke; Sogabe, Kimiko; Oura, Masahiro; Hara, Tomoyo; Sumitani, Ryohei; Maruhashi, Tomoko; Yamagami, Hiroki; Abe, Masahiro] Tokushima Univ, Grad Sch Biomed Sci, Dept Hematol Endocrinol & Metab, 3 18 15 Kuramoto, Tokushima 7708503, Japan.
   [Endo, Itsuro] Tokushima Univ, Grad Sch Biomed Sci, Dept Bioregulatory Sci, Tokushima, Japan.
C3 Tokushima University; Okayama University; Tokushima University;
   Tokushima University
RP Teramachi, J (通讯作者)，Okayama Univ, Grad Sch, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral Funct & Anat, 2 5 1 Shikata, Okayama 7008525, Japan.; Abe, M (通讯作者)，Tokushima Univ, Grad Sch Biomed Sci, Dept Hematol Endocrinol & Metab, 3 18 15 Kuramoto, Tokushima 7708503, Japan.
EM jumptera@okayama u.ac.jp; masabe@tokushima u.ac.jp
RI 日浅, 雅博/S 1537 2019; Tanaka, Eiji/E 7105 2015
FU JSPS KAKENHI [JP17KK0169, JP21H03111, JP22K19626, JP22H03104,
   JP20K18784, JP22K08455]; Japanese Society of Hematology Research Grant
   [20247]; Research Clusters Program of Tokushima University [1803003,
   2202003]; Okayama University; Grants in Aid for Scientific Research
   [21H03111, 23K19694, 23K15975, 23K27791, 23K21485, 22K08455, 22K19626]
   Funding Source: KAKEN
FX This work was supported in part by JSPS KAKENHI Grants Nos. JP17KK0169,
   JP21H03111, and JP22K19626 to J.T., JP22H03104 to M.A., JP20K18784 to
   H.T., and JP22K08455 to T.H., a Japanese Society of Hematology Research
   Grant (No. 20247 to J.T.), a Research Clusters Program of Tokushima
   University Grant (No. 1803003 to M.A.), and a Research Clusters Program
   of Tokushima University Grant (No. 2202003 to T.H.). The funders had no
   role in the study design, data collection and analysis, decision to
   publish, or manuscript preparation.Open access funding provided by
   Okayama University.
CR Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361
   Anderson KC, 2012, J CLIN ONCOL, V30, P445, DOI 10.1200/JCO.2011.37.8919
   Ashtar M, 2020, CANCERS, V12, DOI 10.3390/cancers12040929
   Assouline SE, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.71
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Duong LT, 2016, CALCIFIED TISSUE INT, V98, P381, DOI 10.1007/s00223 015 0051 0
   Durdan MM, 2022, SEMIN CELL DEV BIOL, V123, P4, DOI 10.1016/j.semcdb.2021.10.008
   Eda H, 2016, J BONE MINER RES, V31, P1225, DOI 10.1002/jbmr.2789
   Fang YP, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/9661200
   Fink EE, 2016, LEUKEMIA, V30, P104, DOI 10.1038/leu.2015.190
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Harada T, 2021, CANCERS, V13, DOI 10.3390/cancers13174441
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Hiasa M, 2015, LEUKEMIA, V29, P207, DOI 10.1038/leu.2014.147
   Hiasa M, 2021, JPN DENT SCI REV, V57, P164, DOI 10.1016/j.jdsr.2021.08.006
   Kuhn DJ, 2007, BLOOD, V110, P3281, DOI 10.1182/blood 2007 01 065888
   Langdahl B, 2012, J BONE MINER RES, V27, P2251, DOI 10.1002/jbmr.1695
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood 2017 03 773341
   Moreau P, 2008, HAEMATOL HEMATOL J, V93, P1908, DOI 10.3324/haematol.13285
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Nakamura S, 2013, INT J HEMATOL, V98, P66, DOI 10.1007/s12185 013 1367 z
   O'Connor OA, 2009, CLIN CANCER RES, V15, P7085, DOI 10.1158/1078 0432.CCR 09 0822
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   Ozaki S, 2007, INT J HEMATOL, V86, P180, DOI 10.1532/IJH97.07030
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Pérez Galán P, 2006, BLOOD, V107, P257, DOI 10.1182/blood 2005 05 2091
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078 0432.CCR 10 1804
   Shinohara H, 2015, J CELL BIOCHEM, V116, P1957, DOI 10.1002/jcb.25151
   Teramachi J, 2021, HAEMATOLOGICA, V106, P1401, DOI 10.3324/haematol.2019.234476
   Teramachi J, 2018, BRIT J HAEMATOL, V180, P581, DOI 10.1111/bjh.14388
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Watahiki A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062893
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zangari M, 2016, BONE, V86, P131, DOI 10.1016/j.bone.2016.02.019
   Zangari M, 2011, EUR J HAEMATOL, V86, P484, DOI 10.1111/j.1600 0609.2011.01602.x
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 40
TC 1
Z9 1
U1 1
U2 6
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0925 5710
EI 1865 3774
J9 INT J HEMATOL
JI Int. J. Hematol.
PD JUL
PY 2023
VL 118
IS 1
BP 88
EP 98
DI 10.1007/s12185 023 03601 2
EA APR 2023
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA J4GW0
UT WOS:000968007500001
PM 37039914
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Costa, S
   Fairfield, H
   Reagan, MR
AF Costa, Samantha
   Fairfield, Heather
   Reagan, Michaela R.
TI Inverse correlation between trabecular bone volume and bone marrow
   adipose tissue in rats treated with osteoanabolic agents
SO BONE
LA English
DT Article
DE Bone marrow adipose; Sclerostin; Bone marrow microenvironment;
   Osteocyte derived factors; Anti sclerostin antibodies; Parathyroid
   hormone; PTH
ID PARATHYROID HORMONE; SCLEROSTIN ANTIBODY; MINERAL DENSITY; OSTEOBLAST
   LINEAGE; CORTICAL BONE; MASS; METABOLISM; RALOXIFENE; GROWTH; PTH
AB There is currently an unmet clinical need for improved treatments for skeletal diseases such as osteoporosis and cancer induced bone disease. This is due in part to a paucity of novel targets and an incomplete understanding of the mechanisms of action for established therapies. We defined the effects of anabolic treatments on bone and the bone marrow adipocyte (BMA). Sclerostin neutralizing antibodies (Scl Ab), romosozumab, human parathyroid hormone (hPTH, 1 34), and hPTH/hPTHrP analogues (e.g. teriparatide and abaloparatide) stimulate bone formation and have been studied in clinical trials for severe osteoporosis. In this study, eight week old male and female rats were administered vehicle, Scl Ab (3 mg/kg or 50 mg/kg) weekly, or hPTH (1 34) (75 mu g/kg) daily for 4 or 26 weeks. Histological analyses of distal femura were performed using a novel ImageJ method for trabecular bone and bone marrow adipose tissue (BMAT). Adipocyte number, circumference, and total adipose area were compared within the tissue area (T.Ar) or the marrow area (Ma.Ar), (defined as the T.Ar minus the trabecular bone area). After 26 weeks of treatment, a significant inverse correlation between bone and tissue adiposity (total adipocyte area divided by T.Ar) were observed in males and females (p < 0.0001). However, there were no significant correlations between bone and marrow adiposity (total adipocyte area divided by Ma.Ar) for either sex after 26 weeks of treatments. Scl Ab treatments also resulted in no effect on adipocytes based on marrow adiposity for either sex after 26 weeks. However, chronic hPTH treatments significantly reduced adipocyte number and adiposity within the T.Ar and within the Ma.Ar in males. Overall, our data suggest that with long term treatment, Scl Abs decrease total tissue adiposity mainly by increasing trabecular bone, resulting in an overall reduction in the space in which adipocytes can reside. These findings were determined by developing and comparing two different methods of assessment of the marrow cavity, defined to either include or exclude trabecular bone. Thus, researchers should consider which adiposity measurement is more informative and relevant for their studies. Overall, our findings should help design improved therapies or combination treatments to target a potential new contributor to bone diseases: the bone marrow adipocyte.
C1 [Costa, Samantha; Fairfield, Heather; Reagan, Michaela R.] Maine Med Ctr, Res Inst, Scarborough, ME USA.
   [Costa, Samantha; Fairfield, Heather; Reagan, Michaela R.] Univ Maine, Grad Sch Biomed Sci & Engn, Orono, ME USA.
   [Costa, Samantha; Fairfield, Heather; Reagan, Michaela R.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
C3 Maine Medical Center; University of Maine System; University of Maine
   Orono; Tufts University
RP Reagan, MR (通讯作者)，Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.; Reagan, MR (通讯作者)，Ctr Translat Res, 81 Res Dr, Scarborough, ME 04074 USA.
EM Mreagan@mmc.org
RI Reagan, Michaela/E 3549 2017
OI Reagan, Michaela/0000 0003 2884 6481; Costa,
   Samantha/0000 0001 5257 0898
FU NIH's National Institute of General Medical Science from: the Phase I
   COBRE in Metabolic Networks [P20GM121301]; NIH [P30 GM106391]; American
   Cancer Society [IRG 16 191 33]; NIH/NIDDK [R24 DK092759 01]; Harvard's
   Skeletal Phenotyping Core [NIH/NIAMS P30 AR066261]; Maine Medical Center
   Research Institute;  [U54GM115516]
FX Support was from the NIH's National Institute of General Medical Science
   from: the Phase I COBRE in Metabolic Networks (P20GM121301), a pilot
   project from NIH P30 GM106391, Phase III COBRE in Progenitor Cells, and
   the U54GM115516 administrative core. The authors' work is supported by
   an American Cancer Society Research Grant #IRG 16 191 33, the NIH/NIDDK
   (R24 DK092759 01), a pilot from Harvard's Skeletal Phenotyping Core
   (NIH/NIAMS P30 AR066261), and start up funds from the Maine Medical
   Center Research Institute.
CR Altman AR, 2015, BONE, V81, P370, DOI 10.1016/j.bone.2015.07.037
   Balani DH, 2019, BONE, V118, P16, DOI 10.1016/j.bone.2018.05.024
   Balani DH, 2017, J CLIN INVEST, V127, P3333, DOI 10.1172/JCI91699
   Beekman KM, 2019, BONE, V118, P62, DOI 10.1016/j.bone.2017.10.011
   Bornstein S, 2017, ENDOCRINOLOGY, V158, P3369, DOI 10.1210/en.2017 00299
   Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Devlin MJ, 2015, LANCET DIABETES ENDO, V3, P141, DOI 10.1016/S2213 8587(14)70007 5
   Devlin MJ, 2011, AM J HUM BIOL, V23, P577, DOI 10.1002/ajhb.21202
   Duque G, 2011, OSTEOPOROSIS INT, V22, P1547, DOI 10.1007/s00198 010 1353 8
   Eliceiri KW, 2012, NAT METHODS, V9, P697, DOI [10.1038/NMETH.2084, 10.1038/nmeth.2084]
   Fairfield H, 2018, J CELL PHYSIOL, V233, P1156, DOI 10.1002/jcp.25976
   Fairfield Heather, 2017, Curr Mol Biol Rep, V3, P114, DOI 10.1007/s40610 017 0057 7
   Fan Y, 2017, CELL METAB, V25, P661, DOI 10.1016/j.cmet.2017.01.001
   Ferreira W. R. T., 2012, IMAGEJ USER GUIDE IJ, V185, DOI [10.1038/nmeth.2019, DOI 10.1038/NMETH.2019]
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Jin J, 2013, J SURG RES, V180, pE21, DOI 10.1016/j.jss.2012.03.018
   Kim SP, 2017, P NATL ACAD SCI USA, V114, pE11238, DOI 10.1073/pnas.1707876115
   Kulkarni NH, 2007, J CELL BIOCHEM, V102, P1504, DOI 10.1002/jcb.21374
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Li ZR, 2018, BONE, V110, P134, DOI 10.1016/j.bone.2018.01.008
   McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood 2017 03 773341
   McDonald MM, 2017, CALCIFIED TISSUE INT, V100, P433, DOI 10.1007/s00223 016 0162 2
   MINISOLA S, 1993, BONE MINER, V23, P183, DOI 10.1016/S0169 6009(08)80095 5
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Ott SM, 2002, J BONE MINER RES, V17, P341, DOI 10.1359/jbmr.2002.17.2.341
   Rickard DJ, 2006, BONE, V39, P1361, DOI 10.1016/j.bone.2006.06.010
   Scheller EL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8808
   Scheller EL, 2014, ANN NY ACAD SCI, V1311, P14, DOI 10.1111/nyas.12327
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624
   Shen W, 2007, OSTEOPOROSIS INT, V18, P641, DOI 10.1007/s00198 006 0285 9
   Shen W, 2012, J CLIN ENDOCR METAB, V97, P1337, DOI 10.1210/jc.2011 2605
   Sims NA, 2014, ARCH BIOCHEM BIOPHYS, V561, P22, DOI 10.1016/j.abb.2014.05.015
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Stagi S, 2015, HORM RES PAEDIAT, V84, P124, DOI 10.1159/000432399
   Suchacki KJ, 2016, CURR OPIN PHARMACOL, V28, P50, DOI 10.1016/j.coph.2016.03.001
   Taylor S, 2016, BONE, V84, P148, DOI 10.1016/j.bone.2015.12.013
   Turner RT, 2018, CURR OSTEOPOROS REP, V16, P95, DOI 10.1007/s11914 018 0422 3
   Turner RT, 2011, BONE, V48, P726, DOI 10.1016/j.bone.2010.12.034
   Wolfe MS, 1996, CALCIFIED TISSUE INT, V59, P51, DOI 10.1007/s002239900085
   Wu J, 2018, Z GERONTOL GERIATR, V51, P550, DOI 10.1007/s00391 017 1219 1
   Yilmaz D, 2005, J BONE MINER METAB, V23, P476, DOI 10.1007/s00774 005 0631 6
   Zhou BO, 2017, NAT CELL BIOL, V19, P891, DOI 10.1038/ncb3570
   2013, ARCH MED RES, V44, P325, DOI DOI 10.1016/J.ARCMED.2013.05
NR 46
TC 27
Z9 27
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2019
VL 123
BP 211
EP 223
DI 10.1016/j.bone.2019.03.038
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HY1PW
UT WOS:000467890000026
PM 30954729
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Park, J
   Kim, S
   Jung, HY
   Bae, EH
   Shin, M
   Park, JI
   Choi, SY
   Yi, SJ
   Kim, K
AF Park, Jisu
   Kim, Sanggil
   Jung, Hye Yeon
   Bae, Eun Hwan
   Shin, Minhye
   Park, Jae Il
   Choi, So Young
   Yi, Sun Ju
   Kim, Kyunghwan
TI Peroxiredoxin 1 Toll like receptor 4 p65 axis inhibits receptor
   activator of nuclear factor kappa B ligandmediated osteoclast
   differentiation
SO ISCIENCE
LA English
DT Article
ID BONE; PRDX1; MACROPHAGE; TUMORIGENESIS; MECHANISM; PATHWAY; PLAYS; CELLS
AB Peroxiredoxin 1 (PRDX1), an intracellular antioxidant enzyme, has emerged as a regulator of inflammatory responses via Toll like receptor 4 (TLR4) signaling. Despite this, the mechanistic details of the PRDX1TLR4 axis and its impact on osteoclast differentiation remain elusive. Here, we show that PRDX1 suppresses RANKL induced osteoclast differentiation. Utilizing pharmacological inhibitors, we reveal that PRDX1 inhibits osteoclastogenesis through both TLR4/TRIF and TLR4/MyD88 pathways. Transcriptome analysis revealed PRDX1 mediated alterations in gene expression, particularly upregulating serum amyloid A3 ( Saa3 ) and aconitate decarboxylase 1 ( Acod1 ). Mechanistically, PRDX1 TLR4 signaling activates p65, promoting Saa3 and Acod1 expression while inhibiting Nfatc1, a master regulator of osteoclastogenesis. Remarkably, PRDX1 redirects p65 binding from Nfatc1 to Saa3 and Acod1 promoters, thereby suppressing osteoclast formation. Structural analysis showed that a monomeric PRDX1 mutant with enhanced TLR4 binding exhibited the potent inhibition of osteoclast differentiation. These findings reveal the PRDX1 TLR4 axis's role in inhibiting osteoclastogenesis, offering potential therapeutic insights for bone disorders.
C1 [Park, Jisu; Yi, Sun Ju; Kim, Kyunghwan] Chungbuk Natl Univ, Dept Biol Sci & Biotechnol, Cheongju, Chungbuk, South Korea.
   [Kim, Sanggil; Choi, So Young] Osong Med Innovat Fdn KBio, New Drug Dev Ctr, Dept Lead Optimizat, 123 Osongsaengmyeng ro, Cheongju, Chungbuk, South Korea.
   [Jung, Hye Yeon; Park, Jae Il] Chonnam Natl Univ, Korea Basic Sci Inst, Gwangju Ctr, Gwangju, South Korea.
   [Bae, Eun Hwan; Shin, Minhye] Inha Univ, Coll Med, Dept Microbiol, Incheon 22212, South Korea.
C3 Chungbuk National University; Korea Basic Science Institute (KBSI);
   Chonnam National University; Inha University
RP Kim, K (通讯作者)，Chungbuk Natl Univ, Dept Biol Sci & Biotechnol, Cheongju, Chungbuk, South Korea.; Kim, S (通讯作者)，Osong Med Innovat Fdn KBio, New Drug Dev Ctr, Dept Lead Optimizat, 123 Osongsaengmyeng ro, Cheongju, Chungbuk, South Korea.
EM kyungkim@chungbuk.ac.kr; kyungkim@chungbuk.ac.kr
FU National Research Foundation of Korea [2021RIS 001, 2023R1A2C1 006401,
   2022R1I1A1A01069534]; Chungbuk National University BK21 program; 
   [2020R1A6A1A06046235]
FX This work was carried out with the support of the National Research
   Foundation of Korea (2020R1A6A1A06046235, 2021RIS 001, and 2023R1A2C1
   006401 to K.K.; 2022R1I1A1A01069534 to S.J.Y.) and the Chungbuk National
   University BK21 program (2022) .
CR Aki T, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11010126
   AlQranei MS, 2021, BMC IMMUNOL, V22, DOI 10.1186/s12865 021 00409 9
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101
   Cheng Z, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa5208
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Ding CB, 2017, J CELL MOL MED, V21, P193, DOI 10.1111/jcmm.12955
   Egler RA, 2005, ONCOGENE, V24, P8038, DOI 10.1038/sj.onc.1208821
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gao Y., 2022, PREPRINT, DOI [10.1101/2022.04.07.487467, DOI 10.1101/2022.04.07.487467]
   Guo WW, 2018, INT J BIOL MACROMOL, V112, P608, DOI 10.1016/j.ijbiomac.2018.02.009
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Han YH, 2012, BMB REP, V45, P560, DOI 10.5483/BMBRep.2012.45.10.082
   Ishii M, 2008, MOD RHEUMATOL, V18, P220, DOI 10.1007/s10165 008 0051 2
   Ito T, 2014, J DERMATOL SCI, V74, P9, DOI 10.1016/j.jdermsci.2013.12.002
   Jang HH, 2006, FEBS LETT, V580, P351, DOI 10.1016/j.febslet.2005.12.030
   Jeong SJ, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10081244
   Jeong SJ, 2018, AUTOPHAGY, V14, P120, DOI 10.1080/15548627.2017.1327942
   Jezierska Drutel A, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 6031 4
   Kikuchi N, 2011, AM J RESP CELL MOL, V45, P600, DOI 10.1165/rcmb.2010 0137OC
   Kim J, 2016, J LEUKOCYTE BIOL, V99, P595, DOI 10.1189/jlb.3A0415 173R
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2016, GENE DEV, V30, P208, DOI 10.1101/gad.268714.115
   Kisucka J, 2008, CIRC RES, V103, P598, DOI 10.1161/CIRCRESAHA.108.174870
   Knoops B, 2016, MOL CELLS, V39, P60, DOI 10.14348/molcells.2016.2341
   Kwon JO, 2019, J IMMUNOL, V202, P3359, DOI 10.4049/jimmunol.1800661
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Li Y, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2022.110391
   Lin JQ, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.669308
   Liu CH, 2021, REDOX BIOL, V46, DOI 10.1016/j.redox.2021.102086
   Liu JZ, 2009, J BIOL CHEM, V284, P12512, DOI 10.1074/jbc.M809789200
   Liu Q, 2019, BIOCHEM BIOPH RES CO, V519, P453, DOI 10.1016/j.bbrc.2019.08.077
   Matsumura T, 2008, J BIOL CHEM, V283, P284, DOI 10.1074/jbc.M705753200
   Nedeva IR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641162
   Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819
   Neumann CA, 2009, CELL CYCLE, V8, P4072, DOI 10.4161/cc.8.24.10242
   Oh E, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.83
   Park HJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179437
   Park YH, 2013, ANTIOXID REDOX SIGN, V19, P482, DOI 10.1089/ars.2011.4421
   Riddell JR, 2010, J IMMUNOL, V184, P1022, DOI 10.4049/jimmunol.0901945
   Robinson MW, 2010, PARASITE IMMUNOL, V32, P305, DOI 10.1111/j.1365 3024.2010.01201.x
   Roy S, 2014, J BIOL CHEM, V289, P1174, DOI 10.1074/jbc.M113.523167
   Sun XW, 2019, FASEB J, V33, P12929, DOI 10.1096/fj.201900887RR
   Szeliga M, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9121203
   Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang YT, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.885879
   Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968 0004(02)00003 8
   Wu RL, 2022, J INTENSIV MED, V2, P78, DOI 10.1016/j.jointm.2022.01.001
   Yi SJ, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00145 1
   Yi SJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133147
   Yim Mijung, 2020, J Bone Metab, V27, P227, DOI 10.11005/jbm.2020.27.4.227
   Zhu XP, 2024, FRONT IMMUNOL, V15, DOI 10.3389/fimmu.2024.1333086
   Zou L, 2013, J IMMUNOL, V191, P5625, DOI 10.4049/jimmunol.1301903
   Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211
NR 61
TC 1
Z9 1
U1 1
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2589 0042
J9 ISCIENCE
JI iScience
PD DEC 20
PY 2024
VL 27
IS 12
AR 111455
DI 10.1016/j.isci.2024.111455
EA DEC 2024
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA P9Y5R
UT WOS:001381371700001
PM 39720522
OA gold
DA 2025 08 17
ER

PT J
AU Wang, Z
   Qi, GB
   Li, ZK
   Cui, X
   Guo, SY
   Zhang, YQ
   Cai, P
   Wang, XH
AF Wang, Zhe
   Qi, Guobin
   Li, Zhuokai
   Cui, Xu
   Guo, Shengyang
   Zhang, Yueqi
   Cai, Pan
   Wang, Xiuhui
TI Effects of urolithin A on osteoclast differentiation induced by receptor
   activator of nuclear factor κB ligand via bone morphogenic protein 2
SO BIOENGINEERED
LA English
DT Article
DE RAW264; 7 cells; osteoclast; urolithin A; RANKL; BMP2; transcriptome
   sequencing
ID STIMULATES OSTEOBLASTIC DIFFERENTIATION; RANKL INDUCED OSTEOCLAST;
   OSTEOGENIC DIFFERENTIATION; RAW264.7 CELLS; DC STAMP; OSTEOPOROSIS;
   APOPTOSIS; PHOSPHATASE; ERK1/2; MODEL
AB Urolithin A (UA) is an intestinal microbial metabolite derived from ellagitannins and a promising agent for treating osteoarthritis. However, its effects on osteoporosis are unclear. This study explored the effects of urolithin A (UA) on receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclasts and its underlying molecular mechanisms. RANKL treatment significantly increased tartrate resistant acid phosphatase (TRACP) or osteoclast marker levels (P < 0.05), while adding UA decreased the RANKL induced levels (P < 0.05) in RAW264.7 cells. Total RNA isolated from RANKL  or RANKL + UA treated cells was sequenced, and the obtained transcriptome dataset revealed 2,399 differentially expressed genes. They were enriched in multiple pathways involved in rheumatoid arthritis, ERK1 and ERK2 cascade, regulation of inflammatory response, ECM receptor interactions, and TNF signaling. Scanning electron microscopy showed that RANKL promoted bone resorption pits in bone biopsy specimens, whereas UA inhibited their formation. When bone morphogenic protein 2 (BMP2) was shRNA silenced, the bone resorption pits were restored. Moreover, while RANKL significantly enhanced the levels of p ERK2/ERK2, p p38/p38, p Akt1/Akt1, p ERK1/ERK1, and osteoclast related proteins (P < 0.05), UA reduced them. BMP2 silencing also reversed the UA inhibitory effect. Thus, UA represses the RANKL induced osteoclast differentiation of RAW264.7 cells by regulating Akt1, p38, and ERK1/2 signaling, and BMP2 likely reverses the UA inhibitory effect via these pathways. We propose BMP2 as a potential drug target for treating bone metabolic diseases, such as osteoporosis.
C1 [Wang, Zhe; Qi, Guobin; Zhang, Yueqi] Fudan Univ, Zhongshan Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Wang, Zhe] Johns Hopkins Univ, Sch Med, Dept Orthoped Surg, Baltimore, MD USA.
   [Li, Zhuokai; Cui, Xu; Guo, Shengyang; Cai, Pan; Wang, Xiuhui] Shanghai Univ Med & Hlth Sci, Dept Orthoped, Affiliated Zhoupu Hosp, Shanghai, Peoples R China.
C3 Fudan University; Johns Hopkins University; Shanghai University of
   Medicine & Health Sciences
RP Wang, XH (通讯作者)，Shanghai Univ Med & Hlth Sci, Affiliated Zhoupu Hosp, 1500 Zhouyuan Rd, Shanghai 201318, Peoples R China.
EM zpyygkwxh@sina.cn
RI zhang, yueqi/JXM 4287 2024; Li, Zhuokai/F 4681 2017; Wang,
   Xiuhui/O 5616 2019; CUI, XU/JYO 8134 2024; Qi, Guobin/IXD 9658 2023
OI Wang, Zhe/0000 0003 1120 030X; 
FU Featured Clinical Discipline Project of Shanghai Pudong New District
   [PWYts2018 2]; Construction of Key Discipline Group of Sanitary System
   of Shanghai Pudong New District [PWZxq2017 12]; Shanghai Pudong Science
   and Technology Development Funding [PKJ2020 Y44]; Shanghai Sailing
   Program [21YF1405800]; Promotion Project of Advanced and Appropriate
   Technology from Shanghai Healthcare Commission [2019SY069]
FX This work was supported by the Featured Clinical Discipline Project of
   Shanghai Pudong New District (PWYts2018 2), the Construction of Key
   Discipline Group of Sanitary System of Shanghai Pudong New District
   (PWZxq2017 12), the Shanghai Pudong Science and Technology Development
   Funding (PKJ2020 Y44), and Shanghai Sailing Program (21YF1405800), and
   Promotion Project of Advanced and Appropriate Technology from Shanghai
   Healthcare Commission (2019SY069).
CR Adami G, 2019, CURR RHEUMATOL REP, V21, DOI 10.1007/s11926 019 0836 7
   Andreux PA, 2019, NAT METAB, V1, P595, DOI 10.1038/s42255 019 0073 4
   Balasuriya N, 2018, GENES BASEL, V9, DOI 10.3390/genes9090450
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen H, 2021, BIOENGINEERED, V12, P12677, DOI 10.1080/21655979.2021.2008666
   Chen P, 2019, NEUROTHERAPEUTICS, V16, P1269, DOI 10.1007/s13311 019 00753 0
   Chen W, 2018, J PATHOL, V244, P271, DOI 10.1002/path.5001
   Chen X, 2011, FOOD CHEM TOXICOL, V49, P2392, DOI 10.1016/j.fct.2011.06.053
   Deng Y, 2021, ANN MED, V53, P1129, DOI 10.1080/07853890.2021.1949487
   Ding SL, 2020, J INFLAMM LOND, V17, DOI 10.1186/s12950 020 00242 8
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Durbano HW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186909
   Fowler TW, 2015, J CELL SCI, V128, P683, DOI 10.1242/jcs.157834
   Fu DH, 2021, J CLIN LAB ANAL, V35, DOI 10.1002/jcla.23653
   Fu X, 2019, FOOD FUNCT, V10, P6135, DOI 10.1039/c9fo01332f
   Fu Y, 2021, BIOENGINEERED, V12, P7714, DOI 10.1080/21655979.2021.1982323
   Fujimoto Mai, 2016, World J Biol Chem, V7, P188, DOI 10.4331/wjbc.v7.i1.188
   Gosch M, 2014, PANMINERVA MED, V56, P133
   Hartman RE, 2006, NEUROBIOL DIS, V24, P506, DOI 10.1016/j.nbd.2006.08.006
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim JH, 2014, CELL, V156, P730, DOI 10.1016/j.cell.2014.01.007
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim K, 2020, MOL CELLS, V43, P34, DOI 10.14348/molcells.2019.0232
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Koga Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061346
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Lin JL, 2020, FREE RADICAL BIO MED, V150, P109, DOI 10.1016/j.freeradbiomed.2020.02.024
   Lin ZY, 2022, BIOENGINEERED, V13, P2710, DOI 10.1080/21655979.2021.2001237
   Liou YM, 2018, J CELL PHYSIOL, V233, P6888, DOI 10.1002/jcp.26452
   Lopes HB, 2019, J BIOMED MATER RES A, V107, P1303, DOI 10.1002/jbm.a.36643
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Mei L, 2021, BIOENGINEERED, V12, P11756, DOI 10.1080/21655979.2021.2009618
   Miao X, 2021, SPINE, V46, pE234, DOI 10.1097/BRS.0000000000003770
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Norden E, 2019, CARCINOGENESIS, V40, P93, DOI 10.1093/carcin/bgy158
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Pietschmann P, 2016, GERONTOLOGY, V62, P128, DOI 10.1159/000431091
   Qiao H, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533033818784411
   Qiu N, 2012, J CELL BIOCHEM, V113, P967, DOI 10.1002/jcb.23426
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005
   Saha P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156811
   Sekiguchi Y, 2017, MOL MED REP, V16, P1328, DOI 10.3892/mmr.2017.6752
   Shao HY, 2021, BIOENGINEERED, V12, P960, DOI 10.1080/21655979.2021.1900633
   Solberg LB, 2014, CALCIFIED TISSUE INT, V94, P510, DOI 10.1007/s00223 013 9834 3
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Spilmont M, 2015, NUTRIENTS, V7, P9265, DOI 10.3390/nu7115465
   Tian YH, 2021, INT J MOL MED, V47, P633, DOI 10.3892/ijmm.2020.4820
   Weitzmann MN, 2017, TOXICOL PATHOL, V45, P911, DOI 10.1177/0192623317735316
   Yang HC, 2021, CELL J, V23, P474, DOI 10.22074/cellj.2021.7275
   Yue L, 2014, BONE, V60, P112, DOI 10.1016/j.bone.2013.12.011
   Yun H, 2015, CLIN EXP RHEUMATOL, V33, P302
   Zamani M, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0540 7
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhang ND, 2019, BIOCHEM BIOPH RES CO, V519, P790, DOI 10.1016/j.bbrc.2019.09.058
   Zhou N, 2016, CELL TISSUE RES, V366, P101, DOI 10.1007/s00441 016 2403 0
   Zhou ZH, 2015, AGING CLIN EXP RES, V27, P595, DOI 10.1007/s40520 015 0346 z
NR 59
TC 5
Z9 6
U1 1
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165 5979
EI 2165 5987
J9 BIOENGINEERED
JI Bioengineered
PD MAR 1
PY 2022
VL 13
IS 3
BP 5064
EP 5078
DI 10.1080/21655979.2022.2036893
PG 15
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA YZ2LE
UT WOS:000755312000001
PM 35164658
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chilakapati, R
   Mannully, CT
   Pulicherla, KK
AF Chilakapati, Rajeenkanna
   Mannully, Chanchal Thomas
   Pulicherla, K. K.
TI Prospects of Parathyroid Hormone in Therapeutic Intervention
SO INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS
LA English
DT Article
DE Parathyroid hormone; Therapeutic protein; Calcium; Phosphate; Vitamin D;
   Osteoblast signaling
ID INTERVERTEBRAL DISC DEGENERATION; CHRONIC KIDNEY DISEASE;
   ALKALINE PHOSPHATASE; ESCHERICHIA COLI; PROTEIN KINASE; MESSENGER RNA;
   CALCIUM; RECEPTOR; PTH; GENE
AB Biologically active peptides and proteins have wide applications as therapeutic agents as well as diagnostics. Parathyroid hormone (PTH), a polypeptide secreted by the parathyroid chief cells has been found to be an effective therapeutic protein for the treatment of osteoporosis. PTH as an anabolic agent and a potent regulator of ionized calcium and phosphate plays a pivotal role in maintaining active vitamin D metabolite levels in the circulating blood. Though licensed PTH is available in two forms as teriparatide having 1 34 amino acids and intact hormone having 1 84 aminoacids, due to short plasma half life and low activity, their therapeutic purpose has been limited. Protein engineering approaches like PEGylation, conjugation with antibody complexes, and fusion proteins as well as amino terminal modification of intact or truncated PTH has helped to develop PTH and its modified analogs with improved therapeutic value and multitude functions in various fields of medicine. This review covers the significant role of PTH in osteoblast signaling mechanism, regulation of PTH secretion and its transcription, modifications in PTH along with its functional efficacy in different medical areas.
C1 [Chilakapati, Rajeenkanna] Acharya Nagarjuna Univ, Dept Biotechnol, Guntur 522510, Andhra Pradesh, India.
   [Mannully, Chanchal Thomas] Vellore Inst Technol, Vellore 632014, Tamil Nadu, India.
   [Pulicherla, K. K.] Govt India, Minist Sci & Technol, Dept Sci & Technol, New Mehrauli Rd, New Delhi 110016, India.
C3 Acharya Nagarjuna University; Vellore Institute of Technology (VIT); VIT
   Vellore; Department of Science & Technology (India)
RP Pulicherla, KK (通讯作者)，Govt India, Minist Sci & Technol, Dept Sci & Technol, New Mehrauli Rd, New Delhi 110016, India.
EM rajeenkanna@gmail.com; chanchal.thomas@gmail.com; kkpulicherla@gmail.com
CR Abdallah EAA, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004837
   Agas D, 2013, AM J PHYSIOL ENDOC M, V305, pE1185, DOI 10.1152/ajpendo.00290.2013
   Andersson P, 2004, EUR HEART J, V25, P1776, DOI 10.1016/j.ehj.2004.07.010
   ARNOLD A, 1990, J CLIN INVEST, V86, P1084, DOI 10.1172/JCI114811
   Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Bahhtiari Nahid, 2017, Avicenna Journal of Medical Biotechnology, V9, P19
   Ballen K, 2012, BIOL BLOOD MARROW TR, V18, P1851, DOI 10.1016/j.bbmt.2012.06.016
   Ballen KK, 2007, BIOL BLOOD MARROW TR, V13, P838, DOI 10.1016/j.bbmt.2007.03.007
   Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372
   Bibby Susan R S, 2002, Stud Health Technol Inform, V91, P419
   Bilezikian John P, 2008, Curr Osteoporos Rep, V6, P24, DOI 10.1007/s11914 008 0005 9
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Boos N, 2002, SPINE, V27, P2631, DOI 10.1097/00007632 200212010 00002
   Boskey AL, 2010, J DENT RES, V89, P1333, DOI 10.1177/0022034510377791
   BREWER HB, 1974, AM J MED, V56, P759, DOI 10.1016/0002 9343(74)90803 1
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chan HL, 2013, J DENT RES, V92, P18, DOI 10.1177/0022034512464779
   Chiavistelli S, 2015, BONE RES, V3, DOI 10.1038/boneres.2014.49
   Crenshaw TD, 2011, J ANIM SCI, V89, P1957, DOI 10.2527/jas.2010 3411
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Datta NS, 2011, WORLD J ORTHOP, V2, P67, DOI 10.5312/wjo.v2.i8.67
   Dempster DW, 2012, J CLIN ENDOCR METAB, V97, P2799, DOI 10.1210/jc.2012 1262
   Dempster DW., 2015, Nutrition and Bone Health, P37
   Ertl DA, 2012, BONE, V51, P629, DOI 10.1016/j.bone.2012.06.009
   Freemont AJ, 2009, RHEUMATOLOGY, V48, P5, DOI 10.1093/rheumatology/ken396
   Fu Q, 2006, MOL CELL BIOL, V26, P6453, DOI 10.1128/MCB.00356 06
   Fu XY, 2005, BIOTECHNOL PROGR, V21, P1429, DOI 10.1021/bp050137z
   Fukagawa Masafumi, 2006, Clin Exp Nephrol, V10, P175, DOI 10.1007/s10157 006 0432 9
   Garrett G, 2013, CLIN J AM SOC NEPHRO, V8, P299, DOI 10.2215/CJN.09580911
   Gesty Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200
   Goodman WG, 2003, KIDNEY INT, V63, P1, DOI 10.1046/j.1523 1755.2003.00700.x
   Gopalakrishnan R, 2005, CELLS TISSUES ORGANS, V181, P166, DOI 10.1159/000091378
   Guo J, 2017, J BONE MINER RES, V32, P86, DOI 10.1002/jbmr.2917
   Hart TC, 2009, ORTHOD CRANIOFAC RES, V12, P212, DOI 10.1111/j.1601 6343.2009.01455.x
   Hasegawa H, 2010, KIDNEY INT, V78, P975, DOI 10.1038/ki.2010.313
   HAYMAN JA, 1989, J PATHOL, V158, P293, DOI 10.1002/path.1711580405
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   HOLICK MF, 1994, P NATL ACAD SCI USA, V91, P8014, DOI 10.1073/pnas.91.17.8014
   Hristova GI, 2011, J ORTHOP RES, V29, P1888, DOI 10.1002/jor.21456
   Isakova T, 2010, KIDNEY INT, V78, P947, DOI 10.1038/ki.2010.281
   Jacobson JA, 2011, TISSUE ENG PT A, V17, P389, DOI [10.1089/ten.tea.2010.0115, 10.1089/ten.TEA.2010.0115]
   Jia HB, 2016, SCI REP UK, V6, DOI 10.1038/srep27521
   Jin L, 2000, J BIOL CHEM, V275, P27238
   Johansson H, 2015, UPSALA J MED SCI, V120, P72, DOI 10.3109/03009734.2015.1027426
   Jung RE, 2007, CLIN ORAL IMPLAN RES, V18, P319, DOI 10.1111/j.1600 0501.2007.01342.x
   Jung RE, 2007, INT J ORAL MAX IMPL, V22, P258
   Juppner H., 2001, Endocrinology, V2, P969
   Kafetzis ID, 2011, HORM INT J ENDOCRINO, V10, P80, DOI 10.14310/horm.2002.1297
   Kalra Sanjay, 2013, Indian J Endocrinol Metab, V17, P320, DOI 10.4103/2230 8210.109703
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kilav R, 2005, MOL B INT U, P57, DOI 10.1007/0 387 27530 4_5
   Kilav R, 2001, J BIOL CHEM, V276, P8727, DOI 10.1074/jbc.M005471200
   Koh AJ, 2005, ENDOCRINOLOGY, V146, P4584, DOI 10.1210/en.2005 0333
   Koizumi M, 2013, CONTRIB NEPHROL, V180, P110, DOI 10.1159/000346791
   Komaba H, 2010, KIDNEY INT, V77, P292, DOI 10.1038/ki.2009.466
   Komrakova M, 2010, BONE, V47, P480, DOI 10.1016/j.bone.2010.05.013
   Kostenuik PJ, 2007, J BONE MINER RES, V22, P1534, DOI 10.1359/JBMR.070616
   Kumar R, 2011, J AM SOC NEPHROL, V22, P216, DOI 10.1681/ASN.2010020186
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   KWAN JTC, 1993, KIDNEY INT, V43, P1104, DOI 10.1038/ki.1993.155
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lagasse H A Daniel, 2017, F1000Res, V6, P113, DOI 10.12688/f1000research.9970.1
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Lee SH, 2005, BIOCONJUGATE CHEM, V16, P377, DOI 10.1021/bc049735+
   Lee S, 2015, J BONE MINER RES, V30, P1803, DOI 10.1002/jbmr.2532
   Liu CY, 2014, LANGMUIR, V30, P11421, DOI 10.1021/la501689d
   Loreto C, 2011, ANN ANAT, V193, P156, DOI 10.1016/j.aanat.2010.12.001
   Lourida I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127574
   MACCALLUM WG, 1976, NUTR REV, V34, P212
   Madiraju P, 2013, EUR CELLS MATER, V25, P268, DOI 10.22203/eCM.v025a19
   MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210
   Malberti F, 1999, NEPHROL DIAL TRANSPL, V14, P2398, DOI 10.1093/ndt/14.10.2398
   MAYER GP, 1978, ENDOCRINOLOGY, V102, P1036, DOI 10.1210/endo 102 4 1036
   Monier Faugere MC, 2001, KIDNEY INT, V60, P1460, DOI 10.1046/j.1523 1755.2001.00949.x
   Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003 0024
   Nechama M, 2009, J CLIN INVEST, V119, P3102, DOI 10.1172/JCI39522
   Nordenstrom J, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P1, DOI 10.1016/B978 0 12 397166 1.00064 3
   O'Brien CA, 2010, BONE, V46, P911, DOI 10.1016/j.bone.2009.08.050
   Okumura K, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11561 x
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Palmer SC, 2011, JAMA J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308
   PARKINSON DB, 1992, NAT GENET, V1, P149, DOI 10.1038/ng0592 149
   Potts J T Jr, 1980, Ann N Y Acad Sci, V343, P38, DOI 10.1111/j.1749 6632.1980.tb47241.x
   Potts JT, 2005, J ENDOCRINOL, V187, P311, DOI 10.1677/joe.1.06057
   Ratner M, 2015, NAT BIOTECHNOL, V33, P226, DOI 10.1038/nbt0315 226c
   REIS A, 1990, HUM GENET, V84, P119
   Reynolds DG, 2011, BONE, V48, P562, DOI 10.1016/j.bone.2010.10.003
   Rowshan HH, 2010, J ORAL MAXIL SURG, V68, P260, DOI 10.1016/j.joms.2009.09.045
   Salvesen HA, 1923, P SOC EXP BIOL MED, V20, P204
   Sato E, 2016, J INVEST DERMATOL, V136, P1449, DOI 10.1016/j.jid.2016.02.814
   Schaefer F, 2003, NOVART FDN SYMP, P225
   Shen ZJ, 2008, J CLIN INVEST, V118, P479, DOI [10.1172/JC132789, 10.1172/JCI32789]
   Shen ZJ, 2005, NAT IMMUNOL, V6, P1280, DOI 10.1038/ni1266
   Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199
   Shinagawa Y, 2011, ACS MED CHEM LETT, V2, P238, DOI 10.1021/ml100268k
   Silver J, 2009, KIDNEY INT, V75, P898, DOI 10.1038/ki.2008.642
   Sneddon WB, 1998, CELL PHYSIOL BIOCHEM, V8, P261, DOI 10.1159/000016288
   Henríquez MS, 2007, AN MED INTERN, V24, P87
   Sunthornthepvarakul T, 1999, J CLIN ENDOCR METAB, V84, P3792, DOI 10.1210/jc.84.10.3792
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Tella SH, 2017, CUREUS J MED SCIENCE, V9, DOI 10.7759/cureus.1300
   Tong G, 2017, MED SCI MONITOR, V23, P1896, DOI 10.12659/MSM.903699
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Urban JPG, 2003, ARTHRITIS RES THER, V5, P120, DOI 10.1186/ar629
   Usmani SS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181748
   VASICEK TJ, 1983, P NATL ACAD SCI BIOL, V80, P2127, DOI 10.1073/pnas.80.8.2127
   Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423
   Widler L, 2011, FUTURE MED CHEM, V3, P535, DOI [10.4155/fmc.11.17, 10.4155/FMC.11.17]
   Wu M, 2013, J IND MICROBIOL BIOT, V40, P589, DOI 10.1007/s10295 013 1264 8
   Yamashita Junro, 2010, Curr Opin Support Palliat Care, V4, P200, DOI 10.1097/SPC.0b013e32833d303b
   Youn YS, 2007, J CONTROL RELEASE, V117, P371, DOI 10.1016/j.jconrel.2006.11.013
NR 115
TC 1
Z9 1
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1573 3149
EI 1573 3904
J9 INT J PEPT RES THER
JI Int. J. Pept. Res. Ther.
PD SEP
PY 2019
VL 25
IS 3
BP 961
EP 977
DI 10.1007/s10989 018 9744 3
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA IO2ZF
UT WOS:000479249600013
DA 2025 08 17
ER

PT J
AU Xia, HT
   Liu, JY
   Yang, WL
   Liu, M
   Luo, YF
   Yang, ZJ
   Xie, JB
   Zeng, HL
   Xu, R
   Ling, HF
   Zeng, QH
   Xu, HH
   Fang, L
   Wang, HY
   Tong, PJ
   Jin, HT
   Yang, FY
AF Xia, Hanting
   Liu, Jiangyuan
   Yang, Wenlong
   Liu, Min
   Luo, Yunfeng
   Yang, Zhijun
   Xie, Jingbo
   Zeng, Huiliang
   Xu, Rui
   Ling, Houfu
   Zeng, Qinghe
   Xu, Huihui
   Fang, Liang
   Wang, Hongyu
   Tong, Peijian
   Jin, Hongting
   Yang, Fengyun
TI Integrated Strategy of Network Pharmacological Prediction and
   Experimental Validation Elucidate Possible Mechanism of Bu Yang Herbs in
   Treating Postmenopausal Osteoporosis via ESR1
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE network pharmacology; postmenopausal osteoporosis; traditional Chinese
   medicine; Bu Yang; estrogen receptor
ID TRADITIONAL CHINESE MEDICINE; IN VITRO; KAEMPFEROL; DECOCTION; BETA;
   PHARMACOKINETICS; (+) MEDIORESINOL; METABOLISM; EXPRESSION; ICARIIN
AB Postmenopausal osteoporosis (PMOP) is a type of bone metabolism disease related to estrogen deficiency with an increasing incidence. Traditional Chinese (TCM) has always been used and showed effectiveness in treating PMOP. In the current study, Bu Yang herbs were considered to be the most frequently used and efficient TCM herbs in PMOP treatment. However, chemical and pharmacological profiles were not elucidated. Network pharmacology was conducted on representative Bu Yang herbs (Yin Yang Huo. Du Zhong, Bu Gu Zhi, Tu Si Zi) to investigate the mechanism of Bu Yang herbs on PMOP. Chemical compounds, potential targets, and disease related genes were available from the corresponding database. Results showed that Bu Yang herbs could interact with ESR1 and estrogen signaling pathways. For further validation, the Bu Yang decoction (BYD), formula consisted of the above mentioned 4 Bu Yang herbs was presented for experimental validation. In vivo, BYD significantly reversed ovariectomy (OVX) induced osteoporosis progress in a dose dependent manner by up regulation of bone mineral density and amelioration of bone microarchitecture. In vitro, BYD dramatically improved the proliferation and mineral nodules formation of osteoblasts. Both in vitro and in vivo results illustrated that the phenotype change induced by BYD is correlated with up regulated of ESR1 and activation of the beta catenin pathway. Meanwhile, inhibition of ESR1 by ICI182, 780 blocked the osteogenic phenotype and beta catenin pathway activation induced by BYD. In conclusion, the current study suggested that Bu Yang herbs are the most useful TCM herbs in treating PMOP. Furthermore, the integrated strategy of network pharmacology prediction with experimental validation suggested that BYD exerted its anti PMOP via ESR1 and the downstream mechanism might be activation of the beta catenin signaling pathway.
C1 [Xia, Hanting; Xu, Rui; Ling, Houfu; Zeng, Qinghe; Xu, Huihui; Fang, Liang; Tong, Peijian; Jin, Hongting] Zhejiang Chinese Med Univ, Clin Coll 1, Hangzhou, Peoples R China.
   [Xia, Hanting; Xu, Rui; Ling, Houfu; Zeng, Qinghe; Xu, Huihui; Fang, Liang; Tong, Peijian; Jin, Hongting] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Inst Orthopaed & Traumatol, Hangzhou, Peoples R China.
   [Xia, Hanting; Yang, Wenlong; Liu, Min] Jiangxi Univ Chinese Med, Affiliated Hosp, Dept Orthoped, Nanchang, Jiangxi, Peoples R China.
   [Liu, Jiangyuan; Luo, Yunfeng; Yang, Zhijun; Wang, Hongyu; Yang, Fengyun] Jiangxi Univ Chinese Med, Grad Sch, Nanchang, Jiangxi, Peoples R China.
   [Xie, Jingbo] Peoples Hosp Fengcheng City, Dept Orthoped, Fengcheng, Peoples R China.
   [Zeng, Huiliang] Foshan Hosp Tradit Chinese Med, Dept Orthoped, Foshan, Peoples R China.
   [Tong, Peijian; Jin, Hongting] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Hangzhou, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Jiangxi University of Traditional Chinese Medicine; Jiangxi
   University of Traditional Chinese Medicine; Zhejiang Chinese Medical
   University
RP Tong, PJ; Jin, HT (通讯作者)，Zhejiang Chinese Med Univ, Clin Coll 1, Hangzhou, Peoples R China.; Tong, PJ; Jin, HT (通讯作者)，Zhejiang Chinese Med Univ, Affiliated Hosp 1, Inst Orthopaed & Traumatol, Hangzhou, Peoples R China.; Yang, FY (通讯作者)，Jiangxi Univ Chinese Med, Grad Sch, Nanchang, Jiangxi, Peoples R China.; Tong, PJ; Jin, HT (通讯作者)，Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Hangzhou, Peoples R China.
EM tongpeijian@163.com; hongtingjin@163.com; yfy@jxutcm.edu.cn
RI xu, rui/KTI 8349 2024; Luo, Yunfeng/C 4824 2015; Xia,
   Hanting/LNP 3775 2024
OI Xia, Hanting/0000 0003 1842 7814; 
FU Health commission of Jiangxi Province (TCM famous master XuHZ studio);
   First class subject construction project of TCM of Jiangxi province
   [JXSYLXK ZHYI012]; Science and Technology Research Project Youth Project
   of Education department of Jiangxi Province [GJJ190686]; Jiangxi
   Provincial Natural Science Foundation [20202BABL206133]; Traditional
   Chinese Medicine foundation of Health commission of Jiangxi Province
   [2018A371]
FX This study was supported by the Health commission of Jiangxi Province
   (TCM famous master XuHZ studio), the First class subject construction
   project of TCM of Jiangxi province (JXSYLXK ZHYI012), Science and
   Technology Research Project Youth Project of Education department of
   Jiangxi Province (GJJ190686), Jiangxi Provincial Natural Science
   Foundation (20202BABL206133) and the Traditional Chinese Medicine
   foundation of Health commission of Jiangxi Province (2018A371).
CR Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Bu YS, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03709 6
   Chauhan S, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2299 1
   Chen CH, 2018, BONE, V112, P212, DOI 10.1016/j.bone.2018.04.019
   Chiavarini M, 2020, CURR OSTEOPOROS REP, V18, P138, DOI 10.1007/s11914 020 00573 8
   Guo W, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01185
   Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514
   Han K, 2018, MOLECULES, V23, DOI 10.3390/molecules23102728
   Hases L, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 73166 1
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   He SB, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9100577
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang JH, 2020, AM J CHINESE MED, V48, P161, DOI 10.1142/S0192415X20500093
   Hwang JH, 2013, APPL BIOCHEM BIOTECH, V170, P1934, DOI 10.1007/s12010 013 0351 7
   Hwang JH, 2012, BIOCHIMIE, V94, P1784, DOI 10.1016/j.biochi.2012.04.010
   Jiang X, 2019, MOL MED REP, V20, P2143, DOI 10.3892/mmr.2019.10468
   Kang SJ, 2015, NUTRIENTS, V7, P2622, DOI 10.3390/nu7042622
   Kim CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010125
   Krela Kazmierczak I, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091306
   Lan XF, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10442 7
   Li JB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10677 0
   Li S, 2007, IET SYST BIOL, V1, P51, DOI 10.1049/iet syb:20060032
   Li T, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12548
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Liu H, 2021, MOL CELL ENDOCRINOL, V520, DOI 10.1016/j.mce.2020.111074
   Liu WJ, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112871
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Lü JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020294
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Park E, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020369
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249579
   Pietschmann P, 2016, GERONTOLOGY, V62, P128, DOI 10.1159/000431091
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raehtz S, 2017, ENDOCRINOLOGY, V158, P2086, DOI 10.1210/en.2016 1821
   Recine F, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111894
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Ruangsuriya J, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 02892 w
   Ryuk JA, 2017, EXP BIOL MED, V242, P593, DOI 10.1177/1535370216683835
   Safran M, 2003, NUCLEIC ACIDS RES, V31, P142, DOI 10.1093/nar/gkg050
   Sharma AR, 2019, J NUTR BIOCHEM, V74, DOI 10.1016/j.jnutbio.2019.108228
   Shen GY, 2020, THERANOSTICS, V10, P4334, DOI 10.7150/thno.42982
   Streicher C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06614 0
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tang YJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00485
   Tao QY, 2020, DRUG DEV IND PHARM, V46, P1345, DOI 10.1080/03639045.2020.1788070
   Vakili S, 2021, J CELL PHYSIOL, V236, P3495, DOI 10.1002/jcp.30087
   Wang Z, 2018, OSTEOPOROSIS INT, V29, P535, DOI 10.1007/s00198 017 4255 1
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Wong SK, 2019, DRUG DES DEV THER, V13, P3497, DOI 10.2147/DDDT.S227738
   Wu Y, 2019, NUCLEIC ACIDS RES, V47, pD1110, DOI 10.1093/nar/gky1021
   Xia QD, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12949
   Xu HY, 2019, NUCLEIC ACIDS RES, V47, pD976, DOI 10.1093/nar/gky987
   Xu J, 2019, OXID MED CELL LONGEV, V2019, DOI [10.1155/2019/7258621, 10.1155/2019/7258624]
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Yang F, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.581991
   Yang HJ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071503
   Yin QD, 2018, J CELL MOL MED, V22, P6112, DOI 10.1111/jcmm.13888
   Yuan Z, 2018, AM J TRANSL RES, V10, P4313
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang XG, 2018, J CELL PHYSIOL, V233, P6798, DOI 10.1002/jcp.26430
   Zhang Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01046
   Zhou LP, 2021, PHYTOMEDICINE, V82, DOI 10.1016/j.phymed.2020.153413
   Zhou SS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00425
   Zhou XZ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5212
NR 66
TC 23
Z9 25
U1 2
U2 40
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAY 11
PY 2021
VL 12
AR 654714
DI 10.3389/fphar.2021.654714
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA SG4XI
UT WOS:000653444200001
PM 34045964
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yuan, N
   Wang, XJ
   He, MH
AF Yuan, Ning
   Wang, Xiaojuan
   He, Minghai
TI Robo2 promotes osteoblast differentiation and mineralization through
   autophagy and is activated by parathyroid hormone induction
SO ANNALS OF ANATOMY ANATOMISCHER ANZEIGER
LA English
DT Article
DE Osteoporosis; Robo2; Differentiation; Mineralization; Autophagy;
   Parathyroid hormone
ID OSTEOPOROSIS; SLIT
AB Background: As a systemic skeletal disorder, osteoporosis can increase fracture risk. This study wants to discuss the mechanism of osteoporosis and find possible molecular therapy. Bone morphogenetic protein 2 (BMP2) was utilized to stimulate MC3T3 E1 to establish a cellular osteoporosis model in vitro.Methods: Initially, the viability of BMP2 induced MC3T3 E1 was assessed with a Cell counting kit 8 (CCK 8) assay. By real time quantitative PCR (RT qPCR) and western blot, Robo2 expression after roundabout (Robo) silencing or overexpression was estimated. Besides, alkaline phosphatase (ALP) expression, mineralization level and LC3II green fluorescent protein (GFP) expression were evaluated using ALP assay, Alizarin red staining and immunofluorescence staining, separately. Additionally, the expression of proteins related to osteoblast differentiation and autophagy was analyzed by RT qPCR and western blot. Then, following au tophagy inhibitor 3 methyladenine (3 MA) treatment, osteoblast differentiation and mineralization were measured again.Results: MC3T3 E1 cells were differentiated into osteoblasts under BMP2 induction and Robo2 expression was greatly ascended. After Robo2 silencing, Robo2 expression was markedly diminished. ALP activity and mineralization level in BMP2 induced MC3T3 E1 cells were declined after depleting Robo2. Robo2 ex pression was conspicuously enhanced after overexpressing Robo2. Robo2 overexpression promoted the differentiation and mineralization of BMP2 induced MC3T3 E1 cells. Rescue experiments revealed that Robo2 silence and its overexpression could regulate the autophagy of BMP2 stimulated MC3T3 E1 cells. After 3 MA treatment, the increased ALP activity and mineralization level of BMP2 induced MC3T3 E1 cells with Robo2 upregulation were reduced. Furthermore, parathyroid hormone 1 34 (PTH1 34) treatment enhanced the expression of ALP, Robo2, LC3II and Beclin 1 and reduced the levels of LC3I and p62 of MC3T3 E1 cells concentration dependently. Conclusion: Collectively, Robo2, which was activated by PTH1 34, promoted osteoblast differentiation and mineralization through autophagy.(c) 2023 Published by Elsevier GmbH.
C1 [Yuan, Ning; Wang, Xiaojuan; He, Minghai] Nanchong Cent Hosp, Dept Endocrinol, 97 Renmin South Rd, Nanchong 637000, Sichuan, Peoples R China.
C3 North Sichuan Medical University
RP Yuan, N (通讯作者)，Nanchong Cent Hosp, Dept Endocrinol, 97 Renmin South Rd, Nanchong 637000, Sichuan, Peoples R China.
EM Yuanning_1122@163.com
CR Arumugam B, 2019, BIOCHIMIE, V158, P43, DOI 10.1016/j.biochi.2018.12.006
   Choi YJ, 2014, PATHOL ONCOL RES, V20, P517, DOI 10.1007/s12253 013 9722 1
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Dickson BJ, 2006, ANNU REV CELL DEV BI, V22, P651, DOI 10.1146/annurev.cellbio.21.090704.151234
   Dong YL, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0589 z
   Engelke R., 2022, FRONT PSYCHIATRY, V13
   Fan XP, 2012, CELL REPORTS, V2, P52, DOI 10.1016/j.celrep.2012.06.002
   Fang SJ, 2015, INT J MOL SCI, V16, P8227, DOI 10.3390/ijms16048227
   Gatti D, 2019, J POPUL THER CLIN PH, V26, pE1, DOI 10.15586/jptcp.v26.i4.646
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Li WW, 2019, MOL MED REP, V19, P3676, DOI 10.3892/mmr.2019.10040
   Pisarek Horowitz A, 2020, AM J PATHOL, V190, P799, DOI 10.1016/j.ajpath.2019.12.009
   Shi C, 2018, FASEB J, V32, P440, DOI 10.1096/fj.201700485RR
   Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445
   Stumpf U, 2022, Z GERONTOL GERIATR, V55, P703, DOI 10.1007/s00391 022 02148 x
   Sun HL, 2009, CELLS TISSUES ORGANS, V190, P69, DOI 10.1159/000178020
   Sung PJ, 2013, CANCER LETT, V328, P168, DOI 10.1016/j.canlet.2012.08.015
   Tanski W, 2021, EUR REV MED PHARMACO, V25, P3557, DOI 10.26355/eurrev_202105_25838
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Xie J., 2020, INT J BIOL SCI
   Xu RF, 2018, CELL BIOL INT, V42, P1643, DOI 10.1002/cbin.11063
   Yi L, 2020, BIOPHYS CHEM, V267, DOI 10.1016/j.bpc.2020.106483
   Zhu L, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.903432
NR 24
TC 3
Z9 3
U1 1
U2 9
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0940 9602
EI 1618 0402
J9 ANN ANAT
JI Ann. Anat. Anat. Anz.
PD JUN
PY 2023
VL 248
AR 152070
DI 10.1016/j.aanat.2023.152070
EA FEB 2023
PG 11
WC Anatomy & Morphology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology
GA 9W3VY
UT WOS:000949009000001
PM 36801365
DA 2025 08 17
ER

PT J
AU Hwang, YH
   Jang, SA
   Kim, T
   Ha, H
AF Hwang, Youn Hwan
   Jang, Seon A
   Kim, Taesoo
   Ha, Hyunil
TI Forsythia suspensa Protects against Bone Loss in Ovariectomized
   Mice
SO NUTRIENTS
LA English
DT Article
DE Forsythia suspensa; osteoporosis; ovariectomy; osteoclast
   differentiation
ID OSTEOCLAST DIFFERENTIATION; INDUCED OSTEOPOROSIS; THUNB. VAHL; C FOS;
   ACTIVATION; INDUCTION; NFATC1; MARROW; P38; FAT
AB In traditional oriental medicine, the fruit of Forsythia suspensa has been used as a nutritional supplement to alleviate inflammation and treat gastrointestinal diseases. However, there is no information available on its beneficial effects on bone. We investigated the beneficial effects of F. suspensa water extract (WFS) on osteoclast differentiation and bone loss. The microarchitecture of trabecular bone was analyzed by micro computed tomography. Osteoclast differentiation was evaluated based on tartrate resistant alkaline phosphatase activity, and bone resorption activity was examined on a bone like mineral surface. The mechanism of action of WFS was assessed by evaluating the expression and activation of signaling molecules. Phytochemical constituents were identified and quantitated by ultrahigh performance liquid chromatography tandem mass spectrometry. WFS reduced ovariectomy induced trabecular bone loss and inhibited receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast formation and resorption activity. WFS suppressed RANKL induced expression of nuclear factor of activated T cells cytoplasmic 1, a crucial transcription factor for osteoclast differentiation by decreasing c Fos protein levels and suppressing the activation of p38 and c Jun N terminal kinase. We also identified 12 phytochemicals in WFS including lignans, phenylethanoids, and flavonoids. Collectively, these results suggest that WFS inhibits osteoclast differentiation and can potentially be used to treat postmenopausal osteoporosis.
C1 [Hwang, Youn Hwan; Jang, Seon A; Kim, Taesoo; Ha, Hyunil] Korea Inst Oriental Med, Herbal Med Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Ha, H (通讯作者)，Korea Inst Oriental Med, Herbal Med Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
EM hyunil74@kiom.re.kr
RI Hwang, Youn Hwan/AAU 9373 2021
OI Hwang, Youn Hwan/0000 0002 4959 2436
FU Korea Institute of Oriental Medicine, Ministry of Education, Science and
   Technology, Korea [KSN1812221]
FX This work was funded by the Korea Institute of Oriental Medicine,
   Ministry of Education, Science and Technology, Korea [grant number
   KSN1812221].
CR Ambrosi TH, 2017, CELL STEM CELL, V20, P771, DOI 10.1016/j.stem.2017.02.009
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Choi SW, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 35
   Dong ZL, 2017, MOLECULES, V22, DOI 10.3390/molecules22091466
   Fazeli PK, 2013, J CLIN ENDOCR METAB, V98, P935, DOI 10.1210/jc.2012 3634
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Ge Y, 2016, J AGR FOOD CHEM, V64, P125, DOI 10.1021/acs.jafc.5b04509
   Ha H, 2014, MOLECULES, V19, P3940, DOI 10.3390/molecules19043940
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Hwang YH, 2019, INT J BIOL MACROMOL, V123, P314, DOI 10.1016/j.ijbiomac.2018.11.075
   Hwang YH, 2018, PLANTA MED, V84, P1101, DOI 10.1055/a 0604 2797
   Hwang YH, 2017, J ETHNOPHARMACOL, V206, P73, DOI 10.1016/j.jep.2017.05.011
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim Yu Li, 2016, J Cancer Prev, V21, P88, DOI 10.15430/JCP.2016.21.2.88
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Kyung TW, 2008, EXP MOL MED, V40, P52, DOI 10.3858/emm.2008.40.1.52
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Ludgero Correia A, 2012, NUTRITION, V28, P316, DOI 10.1016/j.nut.2011.07.014
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Muruganandan S, 2018, CURR OSTEOPOROS REP, V16, P434, DOI 10.1007/s11914 018 0451 y
   Oliveira T, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/704781
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Sophocleous Antonia, 2014, Bonekey Rep, V3, P614, DOI 10.1038/bonekey.2014.109
   Suvarna V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00981
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Wang QL, 2017, EUR REV MED PHARMACO, V21, P1911
   Wang ZY, 2018, J ETHNOPHARMACOL, V210, P318, DOI 10.1016/j.jep.2017.08.040
   Wright LE, 2008, J BONE MINER RES, V23, P1296, DOI 10.1359/JBMR.080309
   Xu KH, 2019, RSC ADV, V9, P12384, DOI 10.1039/c8ra10007a
   Yuan HD, 2016, MOLECULES, V21, DOI 10.3390/molecules21050559
   Zhang ZF, 2016, TROP J PHARM RES, V15, P2451, DOI 10.4314/tjpr.v15i11.21
   Zheng HX, 2018, MOLECULES, V23, DOI 10.3390/molecules23092398
   Zhou RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166751
NR 35
TC 22
Z9 23
U1 0
U2 11
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD AUG
PY 2019
VL 11
IS 8
AR 1831
DI 10.3390/nu11081831
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA IV8HH
UT WOS:000484506000161
PM 31398803
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Scholtysek, C
   Ipseiz, N
   Böhm, C
   Krishnacoumar, B
   Stenzel, M
   Czerwinski, T
   Palumbo Zerr, K
   Rothe, T
   Weidner, D
   Klej, A
   Stoll, C
   Distler, J
   Tuckermann, J
   Herrmann, M
   Fabry, B
   Goldmann, WH
   Schett, G
   Krönke, G
AF Scholtysek, Carina
   Ipseiz, Natacha
   Boehm, Christina
   Krishnacoumar, Brenda
   Stenzel, Martin
   Czerwinski, Tina
   Palumbo Zerr, Katrin
   Rothe, Tobias
   Weidner, Daniela
   Klej, Alexandra
   Stoll, Cornelia
   Distler, Joerg
   Tuckermann, Jan
   Herrmann, Martin
   Fabry, Ben
   Goldmann, Wolfgang H.
   Schett, Georg
   Kroenke, Gerhard
TI NR4A1 Regulates Motility of Osteoclast Precursors and Serves as Target
   for the Modulation of Systemic Bone Turnover
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOCLASTS; CELL MIGRATION; NUCLEAR RECEPTORS; OSTEOPOROSIS;
   OSTEOIMMUNOLOGY
ID TRANSCRIPTION FACTOR NR4A1; OSTEOPONTIN MESSENGER RNA; ORPHAN NUCLEAR
   RECEPTORS; CELL MIGRATION; IN VITRO; EXPRESSION; MACROPHAGES;
   ACTIVATION; RESORPTION; SURVIVAL
AB NR4A1 (Nur77 or NGFI B), an orphan member of the nuclear receptor superfamily, has been identified as a key regulator of the differentiation and function of myeloid, lymphoid, and mesenchymal cells. The detailed role of NR4A1 in bone biology is incompletely understood. Here, we report a role for NR4A1 as novel factor controlling the migration and recruitment of osteoclast precursors during bone remodeling. Myeloid specific but not osteoblast specific deletion of NR4A1 resulted in osteopenia due to an increase in the number of bone lining osteoclasts. Although NR4A1 deficient osteoclast precursors displayed a regular differentiation into mature osteoclasts, they showed a hyper motile phenotype that was largely dependent on increased osteopontin expression, suggesting that expression of NR4A1 negatively controlled osteopontin mediated recruitment of osteoclast precursors to the trabecular bone. Pharmacological activation of NR4A1, in turn, inhibited osteopontin expression and osteopontin dependent migration of osteoclast precursors resulted in reduced abundance of bone resorbing osteoclasts in vivo as well as in an ameliorated bone loss after ovariectomy in mice. This study identifies NR4A1 as a crucial player in the regulation of osteoclast biology and bone remodeling and highlights this nuclear receptor as a promising target for therapeutic intervention during the treatment of osteoporosis. (c) 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
C1 [Scholtysek, Carina; Boehm, Christina; Krishnacoumar, Brenda; Stenzel, Martin; Palumbo Zerr, Katrin; Rothe, Tobias; Weidner, Daniela; Klej, Alexandra; Stoll, Cornelia; Distler, Joerg; Herrmann, Martin; Schett, Georg; Kroenke, Gerhard] Univ Erlangen Nurnberg, Dept Internal Med 3, Gluckstr 6, D 91054 Erlangen, Germany.
   [Scholtysek, Carina; Boehm, Christina; Krishnacoumar, Brenda; Stenzel, Martin; Palumbo Zerr, Katrin; Rothe, Tobias; Weidner, Daniela; Klej, Alexandra; Stoll, Cornelia; Kroenke, Gerhard] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, Erlangen, Germany.
   [Ipseiz, Natacha] Univ Cardiff, Sch Med, Cardiff, S Glam, Wales.
   [Czerwinski, Tina; Fabry, Ben; Goldmann, Wolfgang H.] Univ Erlangen Nurnberg, Dept Biophys, Erlangen, Germany.
   [Tuckermann, Jan] Univ Ulm, Inst Comparat Mol Endocrinol, Ulm, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   Cardiff University; University of Erlangen Nuremberg; Ulm University
RP Scholtysek, C (通讯作者)，Univ Erlangen Nurnberg, Dept Internal Med 3, Gluckstr 6, D 91054 Erlangen, Germany.
EM carina.scherbel@uk erlangen.de
RI Distler, Oliver/AAE 6225 2019; Scholtysek, Carina/LXA 1619 2024; Krönke,
   Gerhard/C 6615 2014; Ipseiz, Natacha/AAG 6390 2019; Kronke,
   Gerhard/C 6615 2014; Goldmann, Wolfgang/H 5572 2013; Herrmann,
   Martin/A 9597 2013; Krishnacoumar, Brenda/MDT 4452 2025; Fabry,
   Ben/C 5496 2013
OI Kronke, Gerhard/0000 0002 7566 4325; Schett, Georg/0000 0001 8740 9615;
   Ipseiz, Natacha/0000 0001 5008 8889; Scholtysek,
   Carina/0009 0001 2197 5179; Herrmann, Martin/0000 0002 0258 2484;
   Stenzel, Martin/0000 0002 1378 2529; Fabry, Ben/0000 0003 1737 0465
FU Deutsche Forschungsgemeinschaft [SPP1468, CRC1181]; emerging field
   initiative (EFI) of the University Erlangen Nurnberg; BMBF (METARTHROS);
   Else Kroner Fresenius Stiftung [2013_A274]; Collaborative Research
   Centre 'Trauma' [1149, INST 40/492 1]; Interdisciplinary Centre for
   Clinical Research, Erlangen [IZKF J48, A55, A68]
FX This study was supported by the Deutsche Forschungsgemeinschaft
   (SPP1468 IMMUNOBONE and CRC1181 to GK, GS, and JT), the emerging field
   initiative (EFI) of the University Erlangen Nurnberg, the
   Interdisciplinary Centre for Clinical Research, Erlangen (IZKF J48 to
   CS, A55 to GK, and A68 to GK and FN), the BMBF (METARTHROS to GK and
   GS), the Else Kroner Fresenius Stiftung (2013_A274 to GK). The work was
   further supported by the Collaborative Research Centre 1149 'Trauma'
   (INST 40/492 1). Vectors encoding for murine Rcor1, Rcor2, and Rcor3
   were donated by S Saleque (Department of Biology, City College of New
   York and Graduate Center of City University of New York, New York, NY,
   USA). The vector pGL4.10[luc2] was kindly provided by Dr J Wittmann,
   Division of Molecular Immunology, University of Erlangen, Germany.
CR Allen WE, 1997, J CELL SCI, V110, P707
   Chang IC, 2010, OSTEOPOROSIS INT, V21, P1401, DOI 10.1007/s00198 009 1107 7
   Chellaiah MA, 2003, MOL BIOL CELL, V14, P173, DOI 10.1091/mbc.E02 06 0354
   Chellaiah MA, 2003, CALCIFIED TISSUE INT, V72, P197, DOI 10.1007/s00223 002 1025 6
   Chen Y, 2015, DIABETES, V64, P2069, DOI 10.2337/db14 1206
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<92::AID JCB13>3.0.CO;2 A
   Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649
   DODDS RA, 1995, J BONE MINER RES, V10, P1666
   Gravallese EM, 2003, J CLIN INVEST, V112, P147, DOI 10.1172/JCI200310109
   Hanna RN, 2011, NAT IMMUNOL, V12, P778, DOI 10.1038/ni.2063
   Huttenlocher A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005074
   Imai Y, 2009, MOL CELL ENDOCRINOL, V310, P3, DOI 10.1016/j.mce.2008.08.015
   Ipseiz N, 2014, SWISS MED WKLY, V144, DOI 10.4414/smw.2014.14055
   Ipseiz N, 2014, J IMMUNOL, V192, P4852, DOI 10.4049/jimmunol.1303377
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Jansson M, 2002, J IMMUNOL, V168, P2096, DOI 10.4049/jimmunol.168.5.2096
   Kleyer A, 2012, J BONE MINER RES, V27, P2442, DOI 10.1002/jbmr.1702
   Krönke G, 2003, J BIOL CHEM, V278, P51006, DOI 10.1074/jbc.M304103200
   Li XX, 2015, ELIFE, V4, DOI 10.7554/eLife.07217
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Martínez González J, 2005, CARDIOVASC RES, V65, P609, DOI 10.1016/j.cardiores.2004.10.002
   Mazzali M, 2002, QJM INT J MED, V95, P3, DOI 10.1093/qjmed/95.1.3
   MERRY K, 1993, J CELL SCI, V104, P1013
   Nevius E, 2015, J EXP MED, V212, P1931, DOI 10.1084/jem.20150088
   Oursler MJ, 2010, J CELL BIOCHEM, V110, P1058, DOI 10.1002/jcb.22640
   Palumbo Zerr K, 2015, NAT MED, V21, P150, DOI 10.1038/nm.3777
   Pei LM, 2006, NAT MED, V12, P1048, DOI 10.1038/nm1471
   Pei LM, 2005, J BIOL CHEM, V280, P29256, DOI 10.1074/jbc.M502606200
   Petrow PK, 2000, ARTHRITIS RHEUM, V43, P1597, DOI 10.1002/1529 0131(200007)43:7<1597::AID ANR25>3.0.CO;2 0
   Poggio P, 2011, J CELL PHYSIOL, V226, P2139, DOI 10.1002/jcp.22549
   Raja R, 2014, ONCOGENE, V33, P2053, DOI 10.1038/onc.2013.171
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473
   Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101
   Rittling SR, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001839
   Scholtysek C, 2013, NAT MED, V19, P608, DOI 10.1038/nm.3146
   Seeling M, 2013, P NATL ACAD SCI USA, V110, P10729, DOI 10.1073/pnas.1301001110
   Shaked I, 2015, NAT IMMUNOL, V16, P1228, DOI 10.1038/ni.3321
   Standal T, 2004, EXP ONCOL, V26, P179
   Stromnes IM, 2007, NAT IMMUNOL, V8, P19, DOI 10.1038/ni0107 19
   Suzuki K, 2002, J BONE MINER RES, V17, P1486, DOI 10.1359/jbmr.2002.17.8.1486
   Tacke R, 2015, SCI REP UK, V5, DOI 10.1038/srep10055
   Takafuji V, 2007, ONCOGENE, V26, P6361, DOI 10.1038/sj.onc.1210463
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tontonoz P, 2015, MOL CELL BIOL, V35, P1125, DOI 10.1128/MCB.00715 14
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200
   Wei QS, 2016, SCAND J CLIN LAB INV, V76, P33, DOI 10.3109/00365513.2015.1087045
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Wingate AD, 2006, BIOCHEM SOC T, V34, P1107, DOI 10.1042/BST0341107
   Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156
   YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhan YP, 2008, NAT CHEM BIOL, V4, P548, DOI 10.1038/nchembio.106
   Zhao Y, 2010, ARTERIOSCL THROM VAS, V30, P1535, DOI 10.1161/ATVBAHA.109.191163
NR 56
TC 19
Z9 19
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2018
VL 33
IS 11
BP 2035
EP 2047
DI 10.1002/jbmr.3533
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GZ8RZ
UT WOS:000449762200015
PM 29949664
OA Bronze
DA 2025 08 17
ER

PT J
AU Lee, JM
   Kim, MJ
   Lee, SJ
   Kim, BG
   Choi, JY
   Lee, SM
   Ham, HJ
   Koh, JM
   Jeon, JH
   Lee, IK
AF Lee, Ji Min
   Kim, Min Ji
   Lee, Sun Joo
   Kim, Byung Gyu
   Choi, Je Yong
   Lee, Seung Mi
   Ham, Hye Jin
   Koh, Jung Min
   Jeon, Jae Han
   Lee, In Kyu
TI PDK2 Deficiency Prevents Ovariectomy Induced Bone Loss in Mice by
   Regulating the RANKL NFATc1 Pathway During Osteoclastogenesis
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE CELL SIGNALING; GENETIC ANIMAL MODEL; OSTEOCLAST; OSTEOPOROSIS;
   TRANSCRIPTION FACTOR
ID PYRUVATE DEHYDROGENASE KINASE; KAPPA B; MITOCHONDRIAL BIOGENESIS;
   RECEPTOR ACTIVATOR; DIFFERENTIATION; METABOLISM; RESORPTION; MECHANISMS;
   EXPRESSION; STEATOSIS
AB Estrogen deficiency leads to osteoporosis as a result of an imbalance in bone remodeling due to greater bone resorption. Estrogen deficiency increases the osteoclastic resorption of bone, and many of the FDA approved therapies for osteoporosis are antiresorptive drugs that mainly act by reducing osteoclast activity. The mitochondrial enzyme pyruvate dehydrogenase kinase (PDK) is a critical regulator of aerobic glycolysis that exerts its effects by phosphorylating the pyruvate dehydrogenase complex (PDC), which is responsible for oxidative phosphorylation. In the present study, we found that during osteoclast differentiation, PDK2 expression increased more than that of the other PDK isoenzymes. Bone loss was delayed and the number of osteoclasts was lower in ovariectomized (OVX) Pdk2( / ) mice than in OVX wild type mice. The differentiation of osteoclasts was suppressed in Pdk2( / ) bone marrow derived monocyte/macrophage lineage cells, which was associated with lower phosphorylation of cAMP response element binding protein (CREB) and c FOS, and a consequent reduction in NFATc1 transcription. Administration of AZD7545, a specific inhibitor of PDK2, prevented the OVX induced bone loss and reduced the phosphorylation of CREB and c FOS, and the protein expression of NFATc1, in osteoclasts. Collectively, these results indicate that the inhibition of PDK2 prevents osteoporosis in estrogen deficient mice by reducing aberrant osteoclast activation, probably via inhibition of the RANKL CREB cFOS NFATc1 pathway. These findings imply that PDK2 inhibitors might be repurposed for the therapy of estrogen deficiency induced osteoporosis. (c) 2020 American Society for Bone and Mineral Research (ASBMR).
C1 [Lee, Ji Min; Lee, In Kyu] Kyungpook Natl Univ, Grad Sch, Dept Biomed Sci, Daegu, South Korea.
   [Lee, Ji Min] Kyungpook Natl Univ, Dept Biomed Sci, BK21 Plus KNU Biomed Convergence Programs, Daegu, South Korea.
   [Kim, Min Ji; Lee, In Kyu] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, 130 Dongdeok Ro, Daegu 41944, South Korea.
   [Lee, Sun Joo] Daegu Gyeongbuk Med Innovat Fdn, New Drug Dev Ctr, Daegu, South Korea.
   [Kim, Byung Gyu] Ulsan Natl Inst Sci & Technol UNIST, Inst Basic Sci IBS, Dept Biol Sci, Ctr Genom Integr CGI, Ulsan, South Korea.
   [Choi, Je Yong] Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Daegu, South Korea.
   [Lee, Seung Mi; Ham, Hye Jin; Jeon, Jae Han; Lee, In Kyu] Kyungpook Natl Univ Hosp, Leading Edge Res Ctr Drug Discovery & Dev Diabet, Daegu, South Korea.
   [Koh, Jung Min] Univ Ulsan, Div Endocrinol & Metab, Asan Med Ctr, Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
   [Jeon, Jae Han] Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Internal Med, 807 Hoguk Ro, Daegu 41404, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   (KNU); Kyungpook National University (KNU); Kyungpook National
   University Hospital (KNUH); Institute for Basic Science   Korea (IBS);
   Ulsan National Institute of Science & Technology (UNIST); Kyungpook
   National University (KNU); Kyungpook National University (KNU);
   Kyungpook National University Hospital (KNUH); University of Ulsan; Asan
   Medical Center; Kyungpook National University (KNU)
RP Lee, IK (通讯作者)，Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, 130 Dongdeok Ro, Daegu 41944, South Korea.; Koh, JM (通讯作者)，Univ Ulsan, Div Endocrinol & Metab, Asan Med Ctr, Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.; Jeon, JH (通讯作者)，Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Internal Med, 807 Hoguk Ro, Daegu 41404, South Korea.
EM jmkoh@amc.seoul.kr; jeonjh@knu.ac.kr; leei@knu.ac.kr
RI ; Lee, Ji Min/KCZ 2783 2024; Choi, Je Yong/AAR 7334 2021; Lee,
   In Kyu/AAR 6374 2021; Kim, Min Ji/Z 5205 2019
OI Kim, Min Ji/0000 0003 4303 502X; Jeon, Jae Han/0000 0002 9217 968X; 
FU Korea Health Technology R&D Project, through the Korea Health Industry
   Development Institute (KHIDI)   Ministry of Health & Welfare, Republic
   of Korea [HI16C1501]; Basic Science Research Program, through the
   National Research Foundation (NRF) of Korea [NRF 2017R1A2B3006406]; Bio
   & Medical Technology Development Program of the NRF   Korean government
   (MSIP) [NRF 2016M3A9B6902872]; NRF   Korean government (MSIT)
   [NRF 2020R1C1C1012729]; Bio & Medical Technology Development Program of
   the NRF   Korean government (MOHW) [NRF 2016M3A9B6902872]
FX This work was supported by grants from the Korea Health Technology R&D
   Project, through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
   (HI16C1501); the Basic Science Research Program, through the National
   Research Foundation (NRF) of Korea (NRF 2017R1A2B3006406); the Bio &
   Medical Technology Development Program of the NRF, funded by the Korean
   government (MSIP&MOHW) (NRF 2016M3A9B6902872); and an NRF grant, funded
   by the Korean government (MSIT) (NRF 2020R1C1C1012729).
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boulatnikov I, 2003, BBA PROTEINS PROTEOM, V1645, P183, DOI 10.1016/S1570 9639(02)00542 3
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Dunford EC, 2011, AM J PHYSIOL REG I, V300, pR1487, DOI 10.1152/ajpregu.00498.2010
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fujiwara Y, 2016, J BIOL CHEM, V291, P24838, DOI 10.1074/jbc.M116.742452
   Gaber T, 2005, ANN RHEUM DIS, V64, P971, DOI 10.1136/ard.2004.031641
   Go Y, 2016, DIABETES, V65, P2876, DOI 10.2337/db16 0223
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Ivashkiv LB, 2015, NAT MED, V21, P212, DOI 10.1038/nm.3815
   Jeong JY, 2012, DIABETES METAB J, V36, P328
   Jones HB, 2014, TOXICOL PATHOL, V42, P1250, DOI 10.1177/0192623314530195
   Kajiya H, 2012, ADV EXP MED BIOL, V740, P917, DOI 10.1007/978 94 007 2888 2_41
   Karner CM, 2018, BONE, V115, P2, DOI 10.1016/j.bone.2017.08.008
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Knowles HJ, 2015, HYPOXIA, V3, P73, DOI 10.2147/HP.S95960
   Knowles HJ, 2009, J PATHOL, V218, P256, DOI 10.1002/path.2534
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Liu ZB, 2014, J BIOL CHEM, V289, P29739, DOI 10.1074/jbc.M114.584821
   Lou MD, 2019, BRIT J PHARMACOL, V176, P2962, DOI 10.1111/bph.14758
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Min BK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00944
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Novack DV, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD 0011 2015
   Park JH, 2017, MOL CELLS, V40, P706
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Takafuji Y, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115298
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thoudam T, 2019, DIABETES, V68, P571, DOI 10.2337/db18 0363
   Wang YY, 2012, BONE, V50, P409, DOI 10.1016/j.bone.2011.07.012
   Zeng R, 2015, J BONE MINER RES, V30, P2287, DOI 10.1002/jbmr.2584
   Zhang Y, 2018, J BONE MINER RES, V33, P1114, DOI 10.1002/jbmr.3398
NR 44
TC 21
Z9 24
U1 2
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2021
VL 36
IS 3
BP 553
EP 566
DI 10.1002/jbmr.4202
EA NOV 2020
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA QU8CU
UT WOS:000593107500001
PM 33125772
OA Bronze
DA 2025 08 17
ER

PT J
AU Masuda, K
   Ikeuchi, M
   Koyama, T
   Yamaguchi, K
   Woo, JT
   Nishimura, T
   Yazawa, K
AF Masuda, Kikuko
   Ikeuchi, Mayumi
   Koyama, Tomoyuki
   Yamaguchi, Kohji
   Woo, Je Tae
   Nishimura, Tomio
   Yazawa, Kazunaga
TI Suppressive effects of Anoectochilus formosanus extract on
   osteoclast formation in vitro and bone resorption in vivo
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Anoectochilus formosanus; osteoporosis; osteoclast; bone resorption;
   RANKL
ID COLONY STIMULATING FACTOR; DIFFERENTIATION FACTOR;
   GYNOSTEMMA PENTAPHYLLUM; STROMAL CELLS; ACTIVATION; OSTEOPOROSIS;
   ANTIOXIDANT; SUFFICIENT; MECHANISMS; RECEPTOR
AB Anoectochilus formosanus, a plant native to Taiwan, is used as a folk medicine. It was found that oral administration of A. formosanus extract (AFE) (500 mg/kg) for 4 weeks suppressed bone weight loss and trabecular bone loss in ovariectomized mice, an experimental model of osteoporosis. Although AFE at 12.5 and 25 mu g/ml inhibited osteoclast formation in co culture of osteoblasts and bone marrow cells, AFE did not inhibit the formation of osteoclast progenitor cells and preosteoclast cells in bone marrow cells and RAW264 cells. However, AFE (at 12.5 and 25 mu g/ml) decreased RANKL expression. These results suggested that AFE might suppress the bone loss caused by estrogen deficiency through suppression of RANKL expression required for osteoclast formation.
C1 [Masuda, Kikuko; Ikeuchi, Mayumi; Koyama, Tomoyuki; Yamaguchi, Kohji; Yazawa, Kazunaga] Tokyo Univ Marine Sci & Technol, Grad Sch Marine Sci & Technol, Lab Nutraceut & Funct Foods Sci, Minato Ku, Tokyo 1088477, Japan.
   [Woo, Je Tae] Chubu Univ, Dept Biol Chem, Aichi, Japan.
   [Nishimura, Tomio] Akatsuka Bot Garden, Tsu, Mie, Japan.
C3 Tokyo University of Marine Science & Technology; Chubu University
RP Yazawa, K (通讯作者)，Tokyo Univ Marine Sci & Technol, Grad Sch Marine Sci & Technol, Lab Nutraceut & Funct Foods Sci, Minato Ku, 4 5 7 Konan, Tokyo 1088477, Japan.
EM yazawa@kaiyodai.ac.jp
OI Ikeuchi, Mayumi/0000 0002 7745 4225
CR ARNAUD CD, 1986, BASIC CLIN ENDOCRINO, P202
   BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Gyda M, 2001, BIOCHEM BIOPH RES CO, V285, P328, DOI 10.1006/bbrc.2001.5128
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Itonaga I, 2004, BONE, V34, P57, DOI 10.1016/j.bone.2003.08.008
   Jimi E, 1999, J IMMUNOL, V163, P434
   KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269
   KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291
   Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118
   LIN JM, 1993, AM J CHINESE MED, V21, P59, DOI 10.1142/S0192415X9300008X
   Miura M, 2002, BIOCHEM BIOPH RES CO, V291, P987, DOI 10.1006/bbrc.2002.6561
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Shih CC, 2002, CLIN EXP PHARMACOL P, V29, P684, DOI 10.1046/j.1440 1681.2002.03717.x
   Shih CC, 2001, J ETHNOPHARMACOL, V77, P233, DOI 10.1016/S0378 8741(01)00302 6
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091
   Uchiyama S, 2004, BIOCHEM PHARMACOL, V67, P1297, DOI 10.1016/j.bcp.2003.11.011
   Woo JT, 2004, BIOL PHARM BULL, V27, P504, DOI 10.1248/bpb.27.504
   Yamaguchi K, 1999, BIOL PHARM BULL, V22, P920
   Yamaguchi K., 1997, J BONE MINER METAB, V15, P138
NR 23
TC 16
Z9 20
U1 1
U2 16
PU SPRINGER TOKYO
PI TOKYO
PA 3 3 13, HONGO, BUNKYO KU, TOKYO, 113 0033, JAPAN
SN 0914 8779
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAR
PY 2008
VL 26
IS 2
BP 123
EP 129
DI 10.1007/s00774 007 0810 8
PG 7
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 268IN
UT WOS:000253573600002
PM 18301967
DA 2025 08 17
ER

PT J
AU Iannitti, T
   Rosini, S
   Lodi, D
   Frediani, B
   Rottigni, V
   Palmieri, B
AF Iannitti, Tommaso
   Rosini, Stefano
   Lodi, Daniele
   Frediani, Bruno
   Rottigni, Valentina
   Palmieri, Beniamino
TI Bisphosphonates: Focus on Inflammation and Bone Loss
SO AMERICAN JOURNAL OF THERAPEUTICS
LA English
DT Article
DE bisphosphonates; bone; inflammation; osteoporosis; pain; rheumatoid
   arthritis; complex regional pain syndrome; ankylosing spondylitis
ID NECROSIS FACTOR ALPHA; ACUTE PHASE RESPONSE; NF KAPPA B; FARNESYL
   PYROPHOSPHATE SYNTHASE; SKELETAL STRUCTURAL ADAPTATIONS;
   RHEUMATOID ARTHRITIS PATIENTS; PULSE PAMIDRONATE TREATMENT; PRIMARY
   BILIARY CIRRHOSIS; COLONY STIMULATING FACTOR; MECHANICAL USAGE SATMU
AB Bisphosphonates are pharmacological compounds that have been used for the prevention and treatment of several pathological conditions including osteoporosis, primary hyperparathyroidism, osteogenesis imperfecta, and other conditions characterized by bone fragility. Many studies have been performed to date to analyze their effects on inflammation and bone remodelling and related pathologies. The aim of this review is, starting from a background on inflammatory processes and bone remodelling, to give an update on the use of bisphosphonates, outlining the possible side effects and proposing new trends for the future. Starting from a brief introduction on inflammation and bone remodelling, we collect and analyze studies involving the use of bisphosphonates for treatment of inflammatory conditions and pathologies characterized by bone loss. Selected articles, including reviews, published between 1976 and 2011, were chosen from Pubmed/Medline on the basis of their content. Bisphosphonates exert a selective activity on inflammation and bone remodelling and related pathologies, which are characterized by an excess in bone resorption. They improve not only skeletal defects, but also general symptoms. Bisphosphonates have found clinical application preventing and treating osteoporosis, osteitis deformans (Paget's disease of bone), bone metastasis (with or without hypercalcaemia), multiple myeloma, primary hyperparathyroidism, osteogenesis imperfecta, and other conditions that feature bone fragility. Further clinical studies involving larger cohorts are needed to optimize the dosage and length of therapy for each of these agents in each clinical field in order to be able to maximize their properties concerning modulation of inflammation and bone remodelling. In the near future, although "old" bisphosphonates will reach the end of their patent life, "new" bisphosphonates will be designed to specifically target a pathological condition.
C1 [Iannitti, Tommaso] Univ Kentucky, Sch Med, Dept Physiol, Med Ctr, Lexington, KY 40536 USA.
   [Rosini, Stefano] CRB, Livorno, Italy.
   [Lodi, Daniele] Univ Modena, Dept Nephrol Dialysis & Transplantat, I 41100 Modena, Italy.
   [Rottigni, Valentina; Palmieri, Beniamino] Reggio Emilia Med Sch, Surg Clin, Modena, Italy.
   [Frediani, Bruno] Univ Siena, Rheumatol Sect, I 53100 Siena, Italy.
   [Rottigni, Valentina; Palmieri, Beniamino] Univ Modena, Dept Gen Surg & Surg Specialties, I 41100 Modena, Italy.
C3 University of Kentucky; Universita di Modena e Reggio Emilia; University
   of Siena; Universita di Modena e Reggio Emilia
RP Iannitti, T (通讯作者)，Univ Kentucky, Sch Med, Dept Physiol, Med Ctr, Lexington, KY 40536 USA.
EM tommaso.iannitti@gmail.com
RI ; Iannitti, Tommaso/C 2728 2013; Benetti, Elisa/AAI 6682 2021; PALMIERI,
   Beniamino/K 3886 2016; Palmieri, Beniamino/K 3886 2016
OI Iannitti, Tommaso/0000 0002 4758 0562; PALMIERI,
   Beniamino/0000 0002 0871 138X; 
CR Abu Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530
   Adami S, 1997, ANN RHEUM DIS, V56, P201, DOI 10.1136/ard.56.3.201
   ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   Alencar VBM, 2002, J PERIODONTOL, V73, P251, DOI 10.1902/jop.2002.73.3.251
   Amin A R, 2000, Curr Rheumatol Rep, V2, P447, DOI 10.1007/s11926 000 0019 5
   [Anonymous], RETINA
   Arabmotlagh M, 2009, J ORTHOP RES, V27, P183, DOI 10.1002/jor.20748
   ARNETT TR, 1990, EUR J ORTHODONT, V12, P81, DOI 10.1093/ejo/12.1.81
   Bal A, 2007, CLIN RHEUMATOL, V26, P211, DOI 10.1007/s10067 006 0283 5
   Balla J, 2005, ONCOLOGIST, V10, P306, DOI 10.1634/theoncologist.10 5 306
   Barak V, 2009, J AUTOIMMUN, V33, P178, DOI 10.1016/j.jaut.2009.09.010
   Bardella MT, 2005, GUT, V54, P1508
   Barrera P, 2000, ARTHRITIS RHEUM US, V43, P1951, DOI 10.1002/1529 0131(200009)43:9<1951::AID ANR5>3.0.CO;2 K
   Bartram SA, 2003, ALIMENT PHARM THER, V18, P1121, DOI 10.1111/j.1365 2036.2003.01794.x
   Bergner R, 2006, ONKOLOGIE, V29, P534, DOI 10.1159/000096056
   Bernateck M, 2007, ANESTH ANALG, V105, P1148, DOI 10.1213/01.ane.0000278867.24601.a0
   Bianchi ML, 2010, ARCH BIOCHEM BIOPHYS, V503, P54, DOI 10.1016/j.abb.2010.06.026
   Bingham CO, 2006, ARTHRITIS RHEUM US, V54, P3494, DOI 10.1002/art.22160
   BIRKEDALHANSEN H, 1993, J PERIODONTAL RES, V28, P500, DOI 10.1111/j.1600 0765.1993.tb02113.x
   Birklein F, 2005, J NEUROL, V252, P131, DOI 10.1007/s00415 005 0737 8
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Bock O., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P144
   Boudou Rouquette P, 2009, ANN ONCOL, V20, P1747, DOI [10.1093/annonc/mdp378, 10.1093/annonc/mdp385]
   Bruehl S, 2010, ANESTHESIOLOGY, V113, P713, DOI 10.1097/ALN.0b013e3181e3db38
   Brunner F, 2009, EUR J PAIN, V13, P17, DOI 10.1016/j.ejpain.2008.03.005
   Buckland Wright JC, 2007, RHEUMATOLOGY, V46, P257, DOI 10.1093/rheumatology/kel213
   Bukata SV, 2011, INJURY, V42, P605, DOI 10.1016/j.injury.2011.03.061
   Cairns AP, 2005, ANN RHEUM DIS, V64, P338, DOI 10.1136/ard.2004.022871
   Cantatore FP, 1996, J RHEUMATOL, V23, P1117
   Cantatore FP, 1999, J RHEUMATOL, V26, P2318
   Cardwell CR, 2010, JAMA J AM MED ASSOC, V304, P657, DOI 10.1001/jama.2010.1098
   Carrère C, 2002, GASTROEN CLIN BIOL, V26, P179
   Cartsos VM, 2008, J AM DENT ASSOC, V139, P23, DOI 10.14219/jada.archive.2008.0016
   Ceponis A, 2001, ARTHRITIS RHEUM, V44, P1908
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Cheng JK, 2008, NEUROCHEM RES, V33, P1970, DOI 10.1007/s11064 008 9711 z
   Chennuru S, 2008, INTERN MED J, V38, P635, DOI 10.1111/j.1445 5994.2007.01580.x
   Conwell LS, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002010.pub2
   Cornish J, 2011, BONE, V49, P710, DOI 10.1016/j.bone.2011.07.020
   Corrado A, 2007, JOINT BONE SPINE, V74, P32, DOI 10.1016/j.jbspin.2006.06.005
   Cremers SCLM, 2004, J RHEUMATOL, V31, P1732
   CRISP AJ, 1983, BRIT J RHEUMATOL, V22, P22
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Crotti T, 2003, J PERIODONTAL RES, V38, P380, DOI 10.1034/j.1600 0765.2003.00615.x
   Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403
   Deo Vikas, 2010, Dent Today, V29, P60
   Dubé C, 2005, GASTROENTEROLOGY, V128, pS57, DOI 10.1053/j.gastro.2005.02.014
   Edwards CJ, 2010, OSTEOPOROSIS INT, V21, P1287, DOI 10.1007/s00198 010 1192 7
   El Shinnawi Una M, 2003, J Int Acad Periodontol, V5, P5
   Fraunfelder FW, 2009, RETINA J RET VIT DIS, V29, P285, DOI 10.1097/IAE.0b013e318191df82
   Fraunfelder FW, 2003, AM J OPHTHALMOL, V135, P219, DOI 10.1016/S0002 9394(02)01840 8
   FREEMONT AJ, 1993, INT J EXP PATHOL, V74, P411
   French DD, 2008, RETINA J RET VIT DIS, V28, P889, DOI 10.1097/IAE.0b013e31816576ef
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   FROST HM, 1990, ANAT RECORD, V226, P403, DOI 10.1002/ar.1092260402
   FROST HM, 1990, ANAT RECORD, V226, P414, DOI 10.1002/ar.1092260403
   FROST HM, 1993, CALCIFIED TISSUE INT, V52, P1, DOI 10.1007/BF00675618
   Garnero P, 2008, OSTEOARTHR CARTILAGE, V16, P660, DOI 10.1016/j.joca.2007.10.002
   Gasche C, 2000, INFLAMM BOWEL DIS, V6, P8, DOI 10.1097/00054725 200002000 00002
   Gertz MA, 2011, LEUKEMIA LYMPHOMA, V52, P736, DOI 10.3109/10428194.2011.554586
   Goldring SR, 2003, CALCIFIED TISSUE INT, V73, P97, DOI 10.1007/s00223 002 1049 y
   Goulet GC, 2007, J BONE MINER RES, V22, pS147
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Green J, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c4444
   Grover R, 2006, ANN RHEUM DIS, V65, P688, DOI 10.1136/ard.2005.041392
   Guañabens N, 2003, AM J GASTROENTEROL, V98, P2268, DOI 10.1016/S0002 9270(03)00550 1
   Haderslev KV, 2000, GASTROENTEROLOGY, V119, P639, DOI 10.1053/gast.2000.16518
   Halabe A, 2000, NEW ENGL J MED, V343, P365
   Hallab NJ, 2003, SPINE, V28, pS125, DOI 10.1097/00007632 200310151 00006
   HARRIS ST, 1993, J CLIN ENDOCR METAB, V76, P1399, DOI 10.1210/jc.76.6.1399
   Hasegawa J, 2003, J RHEUMATOL, V30, P474
   Heckbert SR, 2008, ARCH INTERN MED, V168, P826, DOI 10.1001/archinte.168.8.826
   Herman S, 2008, TRENDS MOL MED, V14, P245, DOI 10.1016/j.molmed.2008.04.001
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   Holt G, 2010, J ARTHROPLASTY, V25, P958, DOI 10.1016/j.arth.2009.07.029
   Holtmeier W, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750 1172 1 3
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Hughes JM, 2010, J MUSCULOSKEL NEURON, V10, P128
   Hukkanen M, 1997, J BONE JOINT SURG BR, V79B, P467, DOI 10.1302/0301 620X.79B3.7469
   Isomaki P, 1996, ARTHRITIS RHEUM, V39, P1693, DOI 10.1002/art.1780391012
   Jacques C, 2006, VITAM HORM, V74, P371, DOI 10.1016/S0083 6729(06)74016 X
   Javier RM, 2011, JOINT BONE SPINE, V78, P445, DOI 10.1016/j.jbspin.2010.11.015
   Kang KY, 2011, JOINT BONE SPINE, V78, P188, DOI 10.1016/j.jbspin.2010.05.010
   Kanzaki H, 2002, J BONE MINER RES, V17, P210, DOI 10.1359/jbmr.2002.17.2.210
   Keller C, 2003, ANN RHEUM DIS, V62, P1128, DOI 10.1136/ard.2003.011023
   Khanal RC, 2008, CLIN EXP PHARMACOL P, V35, P1277, DOI 10.1111/j.1440 1681.2008.05053.x
   Kim HR, 2006, RHEUMATOLOGY, V45, P1197, DOI 10.1093/rheumatology/kel072
   KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Kotake S, 1996, J BONE MINER RES, V11, P88
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lambrinoudaki I, 2006, ANN NY ACAD SCI, V1092, P397, DOI 10.1196/annals.1365.036
   Lane N, 2005, J PERIODONTOL, V76, P1113, DOI 10.1902/jop.2005.76.7.1113
   Lems WF, 2006, OSTEOPOROSIS INT, V17, P716, DOI 10.1007/s00198 005 0037 2
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   LennardJones JE, 1997, EUR J GASTROEN HEPAT, V9, P353, DOI 10.1097/00042737 199704000 00007
   Lewiecki EM, 2011, DRUGS, V71, P791, DOI 10.2165/11585470 000000000 00000
   Li JL, 2000, J BONE MINER RES, V15, P2042, DOI 10.1359/jbmr.2000.15.10.2042
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lie E, 2011, ANN RHEUM DIS, V70, P157, DOI 10.1136/ard.2010.131797
   Little DG, 2005, J BONE MINER RES, V20, P2044, DOI 10.1359/JBMR.050712
   Liu YP, 2011, MED HYPOTHESES, V76, P280, DOI 10.1016/j.mehy.2010.10.023
   Lowe CE, 2000, AM J GASTROENTEROL, V95, P634
   MACDONALD BR, 1993, BAILLIERE CLIN RHEUM, V7, P421, DOI 10.1016/S0950 3579(05)80071 8
   Magrey Marina, 2010, Curr Rheumatol Rep, V12, P332, DOI 10.1007/s11926 010 0122 1
   Makiishi Shimobayashi C, 2001, BIOCHEM BIOPH RES CO, V281, P361, DOI 10.1006/bbrc.2001.4380
   Makins Richard, 2003, Expert Opin Drug Saf, V2, P421, DOI 10.1517/eods.2.4.421.21416
   Makita S, 2004, J IMMUNOL, V173, P3119, DOI 10.4049/jimmunol.173.5.3119
   Maksymowych WP, 1998, J RHEUMATOL, V25, P714
   Maksymowych WP, 2002, ARTHRITIS RHEUM, V46, P766, DOI 10.1002/art.10139
   Maksymowych WP, 2001, J RHEUMATOL, V28, P144
   Manabe T, 2007, BONE, V40, P1475, DOI 10.1016/j.bone.2007.01.015
   Mangashetti LS, 2005, J IMMUNOL, V175, P917, DOI 10.4049/jimmunol.175.2.917
   Manicourt DH, 2004, ARTHRITIS RHEUM US, V50, P3690, DOI 10.1002/art.20591
   MARKS SC, 1988, AM J ANAT, V183, P1, DOI 10.1002/aja.1001830102
   Martel Pelletier J, 2010, OSTEOARTHR CARTILAGE, V18, pS7, DOI 10.1016/j.joca.2010.01.015
   MARTIN TJ, 1988, BAILLIERE CLIN ENDOC, V2, P1
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Matsuo A, 2003, J RHEUMATOL, V30, P1280
   Mawatari T, 2008, ARTHRITIS RHEUM, V58, P3340, DOI 10.1002/art.23988
   Mazzantini M, 2002, AGING CLIN EXP RES, V14, P197, DOI 10.1007/BF03324436
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019
   McQueen F, 2011, ANN RHEUM DIS, V70, P1091, DOI 10.1136/ard.2010.142539
   Mehlhorn AT, 2008, EUR J MED RES, V13, P21
   Mitsuta T, 2002, J PERIODONTOL, V73, P479, DOI 10.1902/jop.2002.73.5.479
   Morishita M, 2008, J RHEUMATOL, V35, P407
   Moschen AR, 2005, GUT, V54, P479, DOI 10.1136/gut.2004.044370
   MUNDY GR, 1991, J PERIODONTAL RES, V26, P213, DOI 10.1111/j.1600 0765.1991.tb01647.x
   Nagase H, 2003, ARTHRITIS RES THER, V5, P94, DOI 10.1186/ar630
   Nagata N, 2003, BONE, V33, P721, DOI 10.1016/S8756 3282(03)00213 8
   Nakahama K, 2010, CELL MOL LIFE SCI, V67, P4001, DOI 10.1007/s00018 010 0479 3
   Nakchbandi IA, 2002, J CLIN ENDOCR METAB, V87, P4946, DOI 10.1210/jc.2001 011814
   Nase JB, 2006, J AM DENT ASSOC, V137, P1115, DOI 10.14219/jada.archive.2006.0350
   Nguyen DL, 2010, BEST PRACT RES CL GA, V24, P647, DOI 10.1016/j.bpg.2010.07.006
   Nishioka T, 2007, J BONE MINER METAB, V25, P179, DOI 10.1007/s00774 006 0743 7
   Okimura A, 1997, ARTHRITIS RHEUM, V40, P1029, DOI 10.1002/art.1780400606
   Olson Karin, 2007, J Oncol Pharm Pract, V13, P223, DOI 10.1177/1078155207080806
   Ott SM, 2011, CLEV CLIN J MED, V78, P619, DOI 10.3949/ccjm.78a.11022
   Otto S, 2011, J CRANIOMAXILLOFAC S
   Paccou J, 2010, CALCIFIED TISSUE INT, V86, P1, DOI 10.1007/s00223 009 9316 9
   Page R C, 1998, Ann Periodontol, V3, P108, DOI 10.1902/annals.1998.3.1.108
   PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600 0765.1991.tb01649.x
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Pazianas M, 2010, J BONE MINER RES, V25, P2, DOI 10.1359/jbmr.091201
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Phillips MB, 2007, AM J MED, V120, pE1, DOI 10.1016/j.amjmed.2006.04.032
   PRICE JS, 1994, EUR J CLIN NUTR, V48, pS131
   Reddy GT, 2005, DRUG DELIV, V12, P217, DOI 10.1080/10717540590952663
   REDDY MS, 1995, J PERIODONTOL, V66, P211, DOI 10.1902/jop.1995.66.3.211
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Rhee CW, 2012, OSTEOPOROSIS INT, V23, P247, DOI 10.1007/s00198 011 1608 z
   Ritchlin C. T., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P276
   Robinson JN, 2004, PAIN MED, V5, P276, DOI 10.1111/j.1526 4637.2004.04038.x
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Romas E, 2000, ARTHRITIS RHEUM, V43, P821, DOI 10.1002/1529 0131(200004)43:4<821::AID ANR12>3.0.CO;2 T
   Romas E, 2006, RHEUM DIS CLIN N AM, V32, P759, DOI 10.1016/j.rdc.2006.07.004
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rossini M, 2009, RHEUMATOLOGY, V48, P773, DOI 10.1093/rheumatology/kep084
   Rudwaleit M, 2004, ANN RHEUM DIS, V63, P665, DOI 10.1136/ard.2003.016386
   Ruimerman R, 2005, ANN BIOMED ENG, V33, P71, DOI 10.1007/s10439 005 8964 9
   Salvi GE, 2005, J CLIN PERIODONTOL, V32, P108, DOI 10.1111/j.1600 051X.2005.00785.x
   Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148
   Sands BE, 2004, GASTROENTEROLOGY, V126, P1518, DOI 10.1053/j.gastro.2004.02.072
   Santra G, 2010, SINGAP MED J, V51, P883
   Sbrocchi AM, PEDIAT INT, V52, P754
   Scheper MA, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755 1536 3 6
   SCHWEITZER DH, 1995, J BONE MINER RES, V10, P956
   Shamji MF, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/1/E3
   Shane E, 2010, NEW ENGL J MED, V362, P1825, DOI 10.1056/NEJMe1003064
   Sharif M, 1997, BRIT J RHEUMATOL, V36, P140
   Shinoda H, 2008, J PHARMACOL SCI, V106, P555, DOI 10.1254/jphs.FM0070272
   Siau K, 2010, JOINT BONE SPINE, V77, P176, DOI 10.1016/j.jbspin.2009.05.017
   Silverberg SJ, 1996, J CLIN ENDOCR METAB, V81, P3448, DOI 10.1210/jc.81.10.3448
   Simm PJ, 2010, BONE, V46, P885, DOI 10.1016/j.bone.2009.11.034
   Slobodin G, 2010, CLIN RHEUMATOL, V29, P793, DOI 10.1007/s10067 010 1378 6
   Soininvaara TA, 2002, CALCIFIED TISSUE INT, V71, P472, DOI 10.1007/s00223 002 1022 9
   Spreafico A, 2006, REUMATISMO, V58, P288, DOI 10.4081/reumatismo.2006.288
   Szalay F, 2003, J HEPATOL, V38, P395, DOI 10.1016/S0168 8278(02)00435 X
   Taki H, 1998, CLIN EXP IMMUNOL, V112, P133
   Tat SK, 2008, CLIN EXP RHEUMATOL, V26, P295
   Tipton DA, 2011, J PERIODONTAL RES, V46, P39, DOI 10.1111/j.1600 0765.2010.01306.x
   Tonyali O, 2010, EXPERT OPIN PHARMACO, V11, P2715, DOI 10.1517/14656566.2010.523699
   Totsuka T, 2009, J IMMUNOL, V182, P6079, DOI 10.4049/jimmunol.0711823
   Toussirot E, 2006, CLIN EXP RHEUMATOL, V24, P348
   Toussirot É, 2007, CURR OPIN RHEUMATOL, V19, P340
   Tsujikawa T, 2009, INTERNAL MED, V48, P933, DOI 10.2169/internalmedicine.48.2005
   Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005
   Väänänen HK, 2000, J CELL SCI, V113, P377
   VAANANEN HK, 1995, J CELL SCI, V108, P2729
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   VANLENT PLEM, 1995, SCAND J RHEUMATOL, P83, DOI 10.3109/03009749509100906
   vanLent PLEM, 1996, ARTHRITIS RHEUM, V39, P1545, DOI 10.1002/art.1780390915
   Vatn Morten H, 2009, Curr Gastroenterol Rep, V11, P481
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   Walsh NC, 2010, IMMUNOL REV, V233, P301, DOI 10.1111/j.0105 2896.2009.00857.x
   Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200
   WEINREB M, 1994, J PERIODONTAL RES, V29, P35, DOI 10.1111/j.1600 0765.1994.tb01088.x
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Wells G, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004523.pub3
   Wells GA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003376.pub3
   Wells GA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001155.pub2
   Wilkinson JM, 2011, BONE, V49, P95, DOI 10.1016/j.bone.2011.01.009
   Wolfhagen FHJ, 1997, J HEPATOL, V26, P325, DOI 10.1016/S0168 8278(97)80048 7
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Wysowski DK, 2009, NEW ENGL J MED, V360, P89, DOI 10.1056/NEJMc0808738
   Wysowski DK, 2005, ARCH INTERN MED, V165, P346, DOI 10.1001/archinte.165.3.346 b
   Xing Z, 2008, J BIOMED MATER RES B, V85B, P37, DOI 10.1002/jbm.b.30913
   Yanik B, 2007, OSTEOPOROSIS INT, V18, P829, DOI 10.1007/s00198 007 0323 2
   Zein CO, 2005, HEPATOLOGY, V42, P762, DOI 10.1002/hep.20866
NR 217
TC 20
Z9 24
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1075 2765
EI 1536 3686
J9 AM J THER
JI Am. J. Ther.
PD MAY
PY 2012
VL 19
IS 3
BP 228
EP 246
DI 10.1097/MJT.0b013e318247148f
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 939QM
UT WOS:000303828200014
PM 22549638
DA 2025 08 17
ER

PT J
AU Zhao, LB
   Cai, C
   Wang, J
   Zhao, LM
   Li, WJ
   Liu, CY
   Guan, HF
   Zhu, YL
   Xiao, J
AF Zhao, Libo
   Cai, Cong
   Wang, Jing
   Zhao, Liming
   Li, Weijin
   Liu, Changyu
   Guan, Hanfeng
   Zhu, Yuanli
   Xiao, Jun
TI Dihydromyricetin Protects against Bone Loss in Ovariectomized Mice by
   Suppressing Osteoclast Activity
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE dihydromyricetin; osteoclast; osteoporosis; RANK; NF kappa B
ID NF KAPPA B; INFLAMMATORY RESPONSES; SIGNALING PATHWAYS; IN VITRO;
   AMPELOPSIS GROSSEDENTATA; DIFFERENTIATION; ACTIVATION; CELLS;
   INHIBITION; MECHANISMS
AB Dihydromyricetin (DMY), the main flavonoid component of Ampelopsis grossedentata, possesses pharmacological activities useful for treatment of diseases associated with inflammation and oxidative damage. Because osteoclasts are often involved in chronic low grade systemic inflammation and oxidative damage, we hypothesized that DMY may be an effective treatment for osteoclast related diseases. The effects of DMY on osteoclast formation and activity were examined in vitro. Female C57BL/6 mice were ovariectomized to mimic menopause induced bone loss and treated with DMY, and femur samples were subjected to bone structure and histological analysis, serum biochemical indicators were also measured. DMY suppressed the activation of nuclear factor kappa B, c Fos and mitogen activated protein kinase, and prevented production of reactive oxygen species. DMY decreased expression of osteoclast specific genes, including Trap, Mmp 9, Cathepsin K, C Fos, Nfatc1, and Rank. In addition, DMY prevented bone loss and decreased serum levels of tumor necrosis factor alpha, interleukin 1 beta, and interleukin 6, and with a decrease in the ratio between receptor activator of wnuclear factor kappa B (RANK) ligand (RANKL) and osteoprotegerin (OPG) in vivo. These findings demonstrate that DMY attenuates bone loss and inhibits osteoclast formation and activity through modulation of multiple pathways both upstream and downstream of RANKL signaling. DMY may thus be a useful option for treatment of osteoclast related diseases such as rheumatoid arthritis and osteoporosis.
C1 [Zhao, Libo; Cai, Cong; Zhao, Liming; Li, Weijin; Liu, Changyu; Guan, Hanfeng; Xiao, Jun] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Orthopaed Surg, Wuhan, Hubei, Peoples R China.
   [Wang, Jing] Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China.
   [Zhu, Yuanli] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pathol, Wuhan, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology; Wuhan University; Huazhong
   University of Science & Technology
RP Xiao, J (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Orthopaed Surg, Wuhan, Hubei, Peoples R China.; Zhu, YL (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pathol, Wuhan, Hubei, Peoples R China.
EM zhuytongji@163.com; xiaojun301@sina.com
RI ; cai, cong/MTA 9728 2025; Zhao, Libo/G 2421 2010; wang,
   jing/GVT 8700 2022; li, zhongkai/AAD 8372 2021; 刘, 长玉/IXN 1731 2023
OI Xiao, Jun/0000 0001 6472 1833; 
FU National Natural Science Foundation of China [81572200]
FX This study was supported by National Natural Science Foundation of China
   (No. 81572200).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753 4887.1998.tb01670.x
   Chen YB, 2016, ONCOTARGET, V7, P76508, DOI 10.18632/oncotarget.12894
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Guan HF, 2013, J PATHOL, V229, P775, DOI 10.1002/path.4164
   Guan HF, 2010, BLOOD, V116, P1469, DOI 10.1182/blood 2009 12 256446
   Hou XL, 2015, J NAT PROD, V78, P1689, DOI 10.1021/acs.jnatprod.5b00275
   Huang HC, 2016, CHEM BIOL INTERACT, V258, P166, DOI 10.1016/j.cbi.2016.08.023
   Jiang BP, 2014, BRAIN RES BULL, V109, P117, DOI 10.1016/j.brainresbull.2014.10.010
   Jimi E, 1999, J IMMUNOL, V163, P434
   Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li T, 2015, ONCOTARGET, V6, P31805, DOI 10.18632/oncotarget.5567
   Liu SS, 2016, APOPTOSIS, V21, P1366, DOI 10.1007/s10495 016 1306 6
   Mori G., 2013, Clin. Develop. Immunol, V2013, DOI DOI 10.1155/2013/720504
   Mori G, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/108451
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Ohlsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092368
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Sharma R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093696
   Shen CL, 2016, J INVEST MED, V64, P1151, DOI 10.1136/jim 2016 000190
   Shi J, 2015, BONE, V79, P222, DOI 10.1016/j.bone.2015.06.014
   Soysa NS, 2009, J BONE MINER METAB, V27, P131, DOI 10.1007/s00774 008 0026 6
   Straub RH, 2015, SEMIN ARTHRITIS RHEU, V45, P220, DOI 10.1016/j.semarthrit.2015.04.014
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tang NN, 2016, MOL CELL BIOCHEM, V422, P11, DOI 10.1007/s11010 016 2799 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tsubaki M, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 10
   Wang R, 2016, SCANNING, V38, P901, DOI 10.1002/sca.21339
   Wang Yan, 2002, Zhong Yao Cai, V25, P23
   Welch AA, 2014, CURR OSTEOPOROS REP, V12, P205, DOI 10.1007/s11914 014 0212 5
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Yu XF, 2004, J BONE MINER RES, V19, P2065, DOI 10.1359/JBMR.040910
   Zhang W, 2016, FUND CLIN PHARMACOL, V30, P596, DOI 10.1111/fcp.12225
   Zhang ZQ, 2014, OSTEOPOROSIS INT, V25, P497, DOI 10.1007/s00198 013 2418 2
   Zhou DZ, 2017, FREE RADICAL RES, V51, P517, DOI 10.1080/10715762.2017.1328552
   Zupan J, 2012, J BIOMED SCI, V19, DOI 10.1186/1423 0127 19 28
NR 44
TC 21
Z9 25
U1 2
U2 24
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD DEC 19
PY 2017
VL 8
AR 928
DI 10.3389/fphar.2017.00928
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FQ3RE
UT WOS:000418273500001
PM 29311931
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Monteagudo, S
   Cornelis, FMF
   Wang, X
   de Roover, A
   Peeters, T
   Quintiens, J
   Sermon, A
   de Almeida, RC
   Meulenbelt, 
   Lories, RJ
AF Monteagudo, S.
   Cornelis, F. M. F.
   Wang, X.
   de Roover, A.
   Peeters, T.
   Quintiens, J.
   Sermon, A.
   de Almeida, R. C.
   Meulenbelt, I
   Lories, R. J.
TI ANP32A represses Wnt signaling across tissues thereby protecting against
   osteoarthritis and heart disease
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE ANP32A; Wnt signaling; Histone acetylation; Articular cartilage; Cardiac
   hypertrophy
ID GENOME WIDE ASSOCIATION; HISTONE ACETYLATION; PROTEIN PHOSPHATASE 2A;
   CARTILAGE; MODEL; INHAT; GENE; TRANSCRIPTION; PATHOGENESIS; ACTIVATION
AB Objectives: To investigate how ANP32A, previously linked to the antioxidant response, regulates Wnt signaling as unraveled by transcriptome analysis of Anp32a deficient mouse articular cartilage, and its implications for osteoarthritis (OA) and diseases beyond the joint.
   Methods: Anp32a knockdown chondrogenic ATDC5 cells were cultured in micromasses. Wnt target genes, differentiation markers and matrix deposition were quantified. Wnt target genes were determined in articular cartilage from Anp32a deficient mice and primary human articular chondrocytes upon ANP32A silencing, using qPCR, luciferase assays and immunohistochemistry. Co immunoprecipitation, immunofluorescence and chromatin immunoprecipitation quantitative PCR probed the molecular mechanism via which ANP32A regulates Wnt signaling. Anp32a deficient mice were subjected to the destabilization of the medial meniscus (DMM) OA model and treated with a Wnt inhibitor and an antioxidant. Severity of OA was assessed by cartilage damage and osteophyte formation. Human Protein Atlas data analysis identified additional organs where ANP32A may regulate Wnt signaling. Wnt target genes were determined in heart and hippocampus from Anp32a deficient mice, and cardiac hypertrophy and fibrosis quantified.
   Results: Anp32a loss triggered Wnt signaling hyper activation in articular cartilage. Mechanistically, ANP32A inhibited target gene expression via histone acetylation masking. Wnt antagonist treatment reduced OA severity in Anp32a deficient mice by preventing osteophyte formation but not cartilage degradation, contrasting with antioxidant treatment. Dual therapy ameliorated more OA features than individual treatments. Anp32a deficient mice also showed Wnt hyper activation in the heart, potentially explaining the cardiac hypertrophy phenotype found.
   Conclusions: ANP32A is a novel translationally relevant repressor of Wnt signaling impacting osteoarthritis and cardiac disease. (C) 2022 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Monteagudo, S.; Cornelis, F. M. F.; Wang, X.; de Roover, A.; Peeters, T.; Quintiens, J.] Katholieke Univ Leuven, Dept Dev & Regenerat, Lab Tissue Homeostasis & Dis, Skeletal Biol & Engn Res Ctr, Leuven, Belgium.
   [Sermon, A.; Lories, R. J.] Univ Hosp Leuven, Dept Trauma Surg, Leuven, Belgium.
   [Sermon, A.] Katholieke Univ Leuven, Dept Dev & Regenerat, Leuven, Belgium.
   [de Almeida, R. C.; Meulenbelt, I] Leiden Univ, Dept Biomed Data Sci, Sect Mol Epidemiol, Med Ctr, Leiden, Netherlands.
   [Meulenbelt, I] Integrated Res Dev Determinants Ageing & Longev I, Leiden, Netherlands.
   [Lories, R. J.] Univ Hosp Leuven, Div Rheumatol, Herestr 49, B 3000 Leuven, Belgium.
C3 KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; Leiden
   University   Excl LUMC; Leiden University; Leiden University Medical
   Center (LUMC); KU Leuven; University Hospital Leuven
RP Lories, RJ (通讯作者)，Univ Hosp Leuven, Div Rheumatol, Herestr 49, B 3000 Leuven, Belgium.
EM silvia.monteagudo@kuleuven.be; frederique.cornelis@kuleuven.be;
   xiangdongwang@hust.edu.cn; astrid.deroover@kuleuven.be;
   tine.peeters1989@gmail.com; jolien.quintiens@kuleuven.be;
   an.sermon@kuleuven.be; R.Coutinho_de_Almeida@lumc.nl;
   I.Meulenbelt@lumc.nl; Rik.Lories@kuleuven.be
RI ; Lories, Rik/T 2196 2017; Meulenbelt, Ingrid/F 4756 2011; De Roover,
   Astrid/HTN 0913 2023
OI Cornelis, Frederique/0000 0002 4144 5861; Lories,
   Rik/0000 0002 5986 3092; Meulenbelt, Ingrid/0000 0001 7786 7081; Wang,
   Xiangdong/0000 0001 8686 4894; De Roover, Astrid/0000 0003 0321 2896;
   MONTEAGUDO, SILVIA/0000 0002 3849 6270; 
FU Flanders Research Foundation (FWO Vlaanderen); Excellence of Science
   (EOS); Dutch Arthritis Association [DAA_10_1 402]; Dutch Scientific
   Research council NWO/ZonMW VICI scheme [91816631/528]; Leiden University
   Medical Center
FX This work was supported by the Flanders Research Foundation
   (FWO Vlaanderen), Excellence of Science (EOS), the Dutch Arthritis
   Association (DAA_10_1 402), the Dutch Scientific Research council
   NWO/ZonMW VICI scheme (nr. 91816631/528), and the Leiden University
   Medical Center.
CR Arkill KP, 2008, OSTEOARTHR CARTILAGE, V16, P708, DOI 10.1016/j.joca.2007.10.001
   Beecher B R, 2007, Iowa Orthop J, V27, P1
   Bergmann MW, 2010, CIRC RES, V107, P1198, DOI 10.1161/CIRCRESAHA.110.223768
   Betancourt MCC, 2012, P NATL ACAD SCI USA, V109, P8218, DOI 10.1073/pnas.1119899109
   Chai GS, 2018, J ALZHEIMERS DIS, V63, P1537, DOI 10.3233/JAD 180090
   Chai GS, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024 017 0178 8
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cornelis FMF, 2019, OSTEOARTHR CARTILAGE, V27, P513, DOI 10.1016/j.joca.2018.11.008
   Cornelis FMF, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar8426
   Corr M, 2008, NAT CLIN PRACT RHEUM, V4, P550, DOI 10.1038/ncprheum0904
   De Ferrari GV, 2014, CNS NEUROL DISORD DR, V13, P745
   Dell'Accio F, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2029
   DiDomenico CD, 2018, NAT REV RHEUMATOL, V14, P393, DOI 10.1038/s41584 018 0033 5
   Feng Q, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00104
   Freeman J, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0475 1
   Gao J, 2018, CAN J PHYSIOL PHARM, V96, P701, DOI 10.1139/cjpp 2017 0585
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Ittisoponpisan S, 2017, HUM MUTAT, V38, P289, DOI 10.1002/humu.23155
   Jia L, 2019, MOL BRAIN, V12, DOI 10.1186/s13041 019 0525 5
   Kadota S, 2011, J CELL SCI, V124, P892, DOI 10.1242/jcs.078253
   Karsdal MA, 2016, OSTEOARTHR CARTILAGE, V24, P2013, DOI 10.1016/j.joca.2016.07.017
   Lietman C, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96308
   Lories RJ, 2020, RHEUMATOL THER, V7, P259, DOI 10.1007/s40744 020 00205 8
   Lories RJU, 2007, ARTHRITIS RHEUM US, V56, P4095, DOI 10.1002/art.23137
   Lotz MK, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3046
   Loughlin J, 2004, P NATL ACAD SCI USA, V101, P9757, DOI 10.1073/pnas.0403456101
   Monteagudo S, 2017, NAT REV RHEUMATOL, V13, P670, DOI 10.1038/nrrheum.2017.171
   Monteagudo S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15889
   Nakagawa S, 2010, J ORTHOP RES, V28, P156, DOI 10.1002/jor.20976
   Nalesso G, 2017, ANN RHEUM DIS, V76, P218, DOI 10.1136/annrheumdis 2015 208577
   Opal P, 2004, MOL CELL BIOL, V24, P3140, DOI 10.1128/MCB.24.8.3140 3149.2004
   Palomer E, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00227
   Reilly PT, 2014, BIOESSAYS, V36, P1062, DOI 10.1002/bies.201400058
   Schneider R, 2004, J BIOL CHEM, V279, P23859, DOI 10.1074/jbc.C400151200
   Seo SB, 2002, J BIOL CHEM, V277, P14005, DOI 10.1074/jbc.M112455200
   Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092 8674(01)00196 9
   Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029
   Stylianidis V, 2017, HANDB EXP PHARMACOL, V243, P371, DOI 10.1007/164_2016_56
   Tanimukai H, 2005, AM J PATHOL, V166, P1761, DOI 10.1016/S0002 9440(10)62486 8
   Tapia Rojas C, 2018, NEURAL REGEN RES, V13, P1705, DOI 10.4103/1673 5374.238606
   Tsujio I, 2005, FEBS LETT, V579, P363, DOI 10.1016/j.febslet.2004.11.097
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Valdes AM, 2008, AM J HUM GENET, V82, P1231, DOI 10.1016/j.ajhg.2008.04.006
   Verdone L, 2005, BIOCHEM CELL BIOL, V83, P344, DOI 10.1139/o05 041
   Wang SS, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/207347
   Wang X, 2019, OSTEOARTHR CARTILAGE, V27, P1702, DOI 10.1016/j.joca.2019.07.007
   Yao YC, 2013, J CELL BIOCHEM, V114, P1223, DOI 10.1002/jcb.24467
   Zhu M, 2009, J BONE MINER RES, V24, P12, DOI [10.1359/jbmr.080901, 10.1359/JBMR.080901]
NR 49
TC 10
Z9 11
U1 2
U2 6
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD MAY
PY 2022
VL 30
IS 5
BP 724
EP 734
DI 10.1016/j.joca.2022.02.615
EA APR 2022
PG 11
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 3Y9IF
UT WOS:000844035200012
PM 35227892
OA Green Accepted, Green Published, Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Zheng, T
   Lin, ZJ
   Jiang, GY
   Chen, HX
   Yang, YC
   Zeng, XB
AF Zheng, Tao
   Lin, Zhengjun
   Jiang, Guangyao
   Chen, Hongxuan
   Yang, Yaocheng
   Zeng, Xiangbin
TI Pogostone attenuates osteolysis in breast cancer by inhibiting the NF kB
   and JNK signaling pathways of osteoclast
SO LIFE SCIENCES
LA English
DT Article
DE Pogostone; Breast cancer; NF kB; Bone metastasis; Osteoclast
ID KAPPA B; BONE MICROENVIRONMENT; TUMOR CELLS; IN VITRO; METASTASIS;
   MECHANISMS; DIFFERENTIATION; CHALLENGES
AB Aims: Breast cancer is the most prevalent cancer in females, and approximately 70 % of all patients have evidence of metastatic bone disease, which substantially affects the quality of life and survival rate of breast cancer patients. Osteoporosis has become a global public health problem, and the abnormal activation of osteoclasts is the key to the progression of osteoporosis and the key to both diseases lies in the osteoclasts. Effective drug treatments are lacking and there is an urgent need to explore new drugs.
   Materials and methods: We observed the effects of pogostone (PO) on osteoclast differentiation, bone resorption function and other indicators, and F actin ring formation by using Trap staining, SEM and immunofluorescence, and further explored the targets of pogostone in regulating osteoclast differentiation and function using qPCR and Western Blot. In addition, we used CCK 8, Transwell, and flow cytometry to study the effects of pogostone on proliferation, invasion, migration, and apoptosis of MDA MB 231 cells. Animal models were also constructed for in vivo validation.
   Key findings: Pogostone inhibits osteoclast differentiation, bone resorption, formation of F actin ring, and the expression of specific genes by attenuated NF kB degradation and phosphorylation of JNK. In vitro, pogostone suppresses invasion of breast cancer cells, migration, and promotes their apoptosis. In mouse models, pogostone attenuated osteoclast formation and bone resorption, blocked breast cancer cells migration, and supprsed breast cancer induced osteolysis and ovariectomized (OVX) mediated osteoporosis.
   Significance: These biological functions of pogostone make it a potential drug for treatment of breast cancerassociated bone metastasis in the future.
C1 [Zheng, Tao; Lin, Zhengjun; Jiang, Guangyao; Chen, Hongxuan; Yang, Yaocheng] Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Peoples R China.
   [Zeng, Xiangbin] Second Peoples Hosp Huaihua City, Dept Orthoped, Huaihua, Peoples R China.
C3 Central South University
RP Yang, YC (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Peoples R China.; Zeng, XB (通讯作者)，Second Peoples Hosp Huaihua City, Dept Orthoped, Huaihua, Peoples R China.
EM yangyaocheng@csu.edu.cn; zxb1278@163.com
FU National Natural Science Foundation of China [81672176, 81871783,
   82072441]; Hunan Province Outstanding Youth Fund [2022JJ10095]; Hunan
   Provincial Natural Science Foundation [2022JJ50303]
FX This work was funded by the National Natural Science Foundation of China
   (81672176, 81871783, 82072441), the Hunan Province Outstanding Youth
   Fund (Grant No, 2022JJ10095), the Hunan Provincial Natural Science
   Foundation (2022JJ50303).
CR Bidard FC, 2016, MOL ONCOL, V10, P418, DOI 10.1016/j.molonc.2016.01.001
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Cao ZX, 2017, J ETHNOPHARMACOL, V202, P20, DOI 10.1016/j.jep.2016.07.028
   Casas A, 2013, BREAST, V22, P585, DOI 10.1016/j.breast.2013.05.007
   Chen YC, 2009, CARCINOGENESIS, V30, P1941, DOI 10.1093/carcin/bgp227
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Ding D, 2022, INT J MOL MED, V49, DOI 10.3892/ijmm.2021.5059
   Futakuchi M, 2016, ADV DRUG DELIVER REV, V99, P206, DOI 10.1016/j.addr.2015.11.017
   Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005
   Guo HH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0261127
   Han GH, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9010017
   Iwai Kaori, 2007, Allergol Int, V56, P457, DOI 10.2332/allergolint.O 07 488
   Jiang PL, 2019, THERANOSTICS, V9, P2950, DOI 10.7150/thno.29617
   Kawatani M, 2009, CANCER SCI, V100, P1999, DOI 10.1111/j.1349 7006.2009.01294.x
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Leong W, 2022, PHARMACOL RES, V176, DOI 10.1016/j.phrs.2022.106082
   Li YC, 2014, J ETHNOPHARMACOL, V157, P212, DOI 10.1016/j.jep.2014.09.023
   Liu W, 2015, MOL MED REP, V11, P3212, DOI 10.3892/mmr.2015.3152
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Monteiro AC, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115755
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   Ouyang PY, 2016, PHYSIOL PLANTARUM, V158, P272, DOI 10.1111/ppl.12466
   Ouyang ZX, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00584
   Peng F, 2014, CHINESE MED J PEKING, V127, P4001, DOI 10.3760/cma.j.issn.0366 6999.20140494
   Poorhosseini Seyed Mohammad, 2016, Asian Pac J Cancer Prev, V17, P155
   Reddi AH, 2003, J BONE MINER RES, V18, P190, DOI 10.1359/jbmr.2003.18.2.190
   Roy B, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00439
   Scully OJ, 2012, CANCER GENOM PROTEOM, V9, P311
   Sun CY, 2016, INT IMMUNOPHARMACOL, V32, P55, DOI 10.1016/j.intimp.2016.01.007
   Takahashi Shunji, 2012, Gan To Kagaku Ryoho, V39, P89
   Thirukonda GJ, 2016, J BONE MINER METAB, V34, P395, DOI 10.1007/s00774 015 0683 1
   Valkenburg KC, 2013, CHIN J CANCER, V32, P380, DOI 10.5732/cjc.012.10218
   Wang Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0417 0
   Wang YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061213
   Yan W, 2014, ACTA PHARMACOL SIN, V35, P124, DOI 10.1038/aps.2013.152
   Yang HM, 2018, INT IMMUNOPHARMACOL, V62, P15, DOI 10.1016/j.intimp.2018.06.029
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
NR 41
TC 6
Z9 7
U1 1
U2 16
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD SEP 1
PY 2023
VL 328
AR 121611
DI 10.1016/j.lfs.2023.121611
EA JUN 2023
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA N0EF2
UT WOS:001033845300001
PM 37068706
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, ZG
   Li, Y
   Guo, FY
   Zhang, C
   Song, GR
   Yang, JH
   Chen, DS
AF Liu, Zige
   Li, Yan
   Guo, Fengying
   Zhang, Chen
   Song, Guorui
   Yang, Jiahao
   Chen, Desheng
TI Tetrandrine Inhibits Titanium Particle Induced Inflammatory Osteolysis
   through the Nuclear Factor κB Pathway
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID OVARIECTOMIZED HYPERTENSIVE RATS; PREVENTS BONE LOSS; AMELIORATES
   OSTEOPOROSIS; SIGNALING PATHWAY; NF B; ACTIVATION; OSTEOCLASTOGENESIS;
   RANK/RANKL; OSTEOBLAST; PROTECTS
AB Peri implant osteolysis (PIO) and the subsequent aseptic loosening are the main reasons for artificial joint implant failure. Existing methods for treating aseptic loosening are far from satisfactory, necessitating advanced drug exploration. This study is aimed at investigating the effect and underlying mechanism of tetrandrine (Tet) on inflammatory osteolysis. We established a Ti particle induced inflammatory osteolysis mouse model and administered Tet or an equal volume of phosphate buffered saline (PBS). Two weeks later, specimens were collected. Histological staining showed that Tet administration inhibited Ti stimulated osteolysis. Tartrate resistant acid phosphate (TRAP) staining and transmission electron microscopy (TEM) demonstrated that osteoclast formation was remarkably inhibited in the groups treated with Tet in a dose dependent manner. In addition, relevant inflammatory cytokines (tumor necrosis factor (TNF) alpha, interleukin (IL) 1 beta, and IL 6) were also significantly reduced in the calvaria of the Tet treated groups. Exposure of receptor activator for nuclear factor kappa B ligand  (RANKL ) induced bone marrow derived macrophages (BMMs) and RAW264.7 cells to Tet significantly reduced osteoclast formation, F actin ring formation, bone resorption, and the expression of relevant genes (matrix metallopeptidase 9 (MMP 9), TRAP, and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1)) during osteoclastogenesis in vitro. Mechanistic studies using Western blotting demonstrated that Tet inhibited the nuclear factor (NF) kappa B signaling pathway by decreasing the phosphorylation of inhibitor of NF kappa B alpha (I kappa B alpha) and p65, which play important roles in osteoclast formation. Collectively, our data indicate that Tet suppressed Ti induced inflammatory osteolysis and osteoclast formation in mice, suggesting that Tet has the potential to be developed to treat and prevent wear particle induced inflammatory osteolysis.
C1 [Liu, Zige; Zhang, Chen; Song, Guorui; Chen, Desheng] Ningxia Med Univ, Dept Orthoped Surg, Gen Hosp, Yinchuan 750004, Ningxia, Peoples R China.
   [Liu, Zige; Yang, Jiahao] Shimane Univ, Sch Clin Med, Izumo, Shimane 6938501, Japan.
   [Li, Yan; Guo, Fengying] Ningxia Med Univ, Sch Basic Med Sci, Yinchuan 750004, Ningxia, Peoples R China.
C3 Ningxia Medical University; Shimane University; Ningxia Medical
   University
RP Chen, DS (通讯作者)，Ningxia Med Univ, Dept Orthoped Surg, Gen Hosp, Yinchuan 750004, Ningxia, Peoples R China.
EM bunnyrabbit_lzg@outlook.com; liyan@nxmu.edu.cn; arsenal fov@live.com;
   zhangchen@nxmu.edu.cn; songguorui@nxmu.edu.cn;
   jiahao@med.shimane u.ac.jp; chendesheng@nxmu.edu.cn
RI Liu, Zige/LKN 9859 2024; GUO, Fengying/IZD 7024 2023
FU National Science Foundation of China [81760405, 81760395, 82060408]
FX We thank Jie Huang, MD; Yao Luo, MD; and Huiming Ma, PhD, for their
   helpful discussions; Jia Tian, MD; and Yang Liu, MS, for kindly
   assisting with the experiments; and Xiaoyu Li, PhD, for revising the
   draft. This work was supported by the National Science Foundation of
   China (grant nos. 81760405, 81760395, and 82060408).
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Amarasekara DS, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/832127
   An SB, 2018, CELL PHYSIOL BIOCHEM, V50, P1100, DOI 10.1159/000494537
   Bahraminasab M, 2013, MATER DESIGN, V44, P155, DOI 10.1016/j.matdes.2012.07.066
   Bao G, 2016, BIOMED PHARMACOTHER, V84, P925, DOI 10.1016/j.biopha.2016.10.007
   Baum R, 2014, CURR OSTEOPOROS REP, V12, P9, DOI 10.1007/s11914 013 0183 y
   Bhagya N, 2018, BIOMED PHARMACOTHER, V97, P624, DOI 10.1016/j.biopha.2017.10.116
   Bhagya N, 2016, PHYTOCHEMISTRY, V125, P5, DOI 10.1016/j.phytochem.2016.02.005
   Chen D, 2015, GENET MOL RES, V14, P40, DOI 10.4238/2015.January.15.6
   Chen DS, 2012, INT J MOL MED, V30, P1417, DOI 10.3892/ijmm.2012.1145
   Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0
   Gao LN, 2016, J ORTHOP RES, V34, P1557, DOI 10.1002/jor.23155
   Guo C, 2015, ACTA CHIN MED PHARM, V43, P33
   Hu XY, 2017, ACTA BIOMATER, V48, P479, DOI 10.1016/j.actbio.2016.11.022
   Huang J, 2018, THERANOSTICS, V8, P2435, DOI 10.7150/thno.22144
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Jia YG, 2018, FASEB J, V32, P3398, DOI 10.1096/fj.201701148RR
   Jiang YP, 2020, PHYTOCHEM REV, V19, P449, DOI 10.1007/s11101 020 09673 w
   Kim JY, 2015, J NAT PROD, V78, P2167, DOI 10.1021/acs.jnatprod.5b00233
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Koivu H, 2017, FOOT ANKLE SURG, V23, P108, DOI 10.1016/j.fas.2017.03.016
   Liu Wenchao, 2012, Int J Biomed Sci, V8, P28
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   McArthur BA, 2019, HSS J, V15, P286, DOI 10.1007/s11420 018 9641 5
   Neuprez A, 2020, CLIN RHEUMATOL, V39, P861, DOI 10.1007/s10067 019 04811 y
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Ponzetti M, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00236
   Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132
   Sandmann S, 1999, J CLIN BASIC CARDIOL, V2, P187
   Sawyer A, 2003, BIOTECH HISTOCHEM, V78, P271, DOI 10.1080/10520290310001646668
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Shi JP, 2016, CHIN J INTEGR MED, V22, P925, DOI 10.1007/s11655 015 2303 2
   Shimizu H, 2012, CURR CARDIOVASC RISK, V6, P274, DOI 10.1007/s12170 012 0248 y
   Shimizu H, 2012, HYPERTENS RES, V35, P77, DOI 10.1038/hr.2011.143
   Takahashi T, 2012, BIOL PHARM BULL, V35, P1765, DOI 10.1248/bpb.b12 00445
   Wooley PH, 2002, BIOMATERIALS, V23, P517, DOI 10.1016/S0142 9612(01)00134 X
   Wozniak W, 2004, ACTA ORTHOP SCAND, V75, P549, DOI 10.1080/00016470410001402
   Wu CJ, 2011, TOXICOL IN VITRO, V25, P1834, DOI 10.1016/j.tiv.2011.09.024
   Xu J, 2016, MOL MED REP, V13, P5177, DOI 10.3892/mmr.2016.5187
   Yang C, 2021, CONNECT TISSUE RES, V62, P485, DOI 10.1080/03008207.2020.1778680
   Zhang F, 2011, BIOCHIMIE, V93, P296, DOI 10.1016/j.biochi.2010.10.001
   Zhang J, 2020, EXP THER MED, V19, P2195, DOI 10.3892/etm.2020.8431
   Zhang ST, 2020, EXP CELL RES, V387, DOI 10.1016/j.yexcr.2019.111800
   Zhang Y, 2017, J BONE MINER RES, V32, P1829, DOI 10.1002/jbmr.3172
   Zhang ZX, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0678 6
   Zhu SJ, 2016, SCI REP UK, V6, DOI 10.1038/srep36251
NR 46
TC 12
Z9 15
U1 0
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962 9351
EI 1466 1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PD NOV 29
PY 2020
VL 2020
AR 1926947
DI 10.1155/2020/1926947
PG 16
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA PE4NS
UT WOS:000598342500001
PM 33312069
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tu, YB
   Wang, K
   Tan, LH
   Han, B
   Hu, YJ
   Ding, H
   He, CW
AF Tu, Yanbei
   Wang, Kai
   Tan, Lihua
   Han, Bing
   Hu, Yuanjia
   Ding, Hang
   He, Chengwei
TI Dolichosin A, a coumestan isolated from Glycine tabacina,
   inhibits IL 1β induced inflammation in SW982 human synovial cells and
   suppresses RANKL induced osteoclastogenesis: From network pharmacology
   to experimental pharmacology
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Glycine tabacina (Labill.) benth; Dolichosin A; Rheumatoid arthritis;
   Inflammation; Osteoclastogenesis; Network pharmacology
ID SIGNAL TRANSDUCTION PATHWAYS; RHEUMATOID ARTHRITIS; THERAPEUTIC TARGETS;
   MECHANISMS; DISEASE; PLANTS
AB Ethnopharmacological relevance: Glycine tabacina (Labill.) Benth has been used as a traditional Chinese herbal medicine for the treatment of rheumatoid arthritis (RA) and joint infection. It is also one of the sources of the renowned native herbal medicine 'I Tiao Gung' in Taiwan.
   Aim of the study: This study aimed to investigate anti arthritic effects and underlying mechanisms of dolichosin A (DoA), a coumestan compound isolated from G. tabacina, by the integration of network pharmacology and experimental pharmacology.
   Materials and methods: Putative therapeutic targets and potential pharmacological mechanisms of DoA for RA treatment were predicted by network pharmacology approach. The regulated network of DoA acting on RA was constructed using Cytoscape 3.7.1. Anti arthritic effects of DoA and predicted mechanisms were further validated using IL 1 beta induced SW982 human synovial cell model and RANKL induced osteoclastogenesis model. Results: A regulatory network of DoA targets pathways RA was successfully constructed using network pharmacology approach. In this network, 65 candidate targets of DoA related to its therapeutic effect on RA were identified and the functional enrichment analysis revealed that these candidate targets were significantly involved in 12 central signaling pathways such as PI3K/AKT pathway, MAPK pathway and osteoclast differentiation. Furthermore, we found that DoA could significantly inhibit IL 1 beta induced inflammation in SW982 human synovial cells, as evidenced by the decreased levels of pro inflammatory mediators (TNF alpha, IL 6 and COX 2) and MMP 3. DoA also suppressed RANKL induced osteoclastogenesis in vitro, as evidenced by decreased number of TRAP positive multinucleated osteoclasts and reduced TRAP activity. Further experimental mechanism evidence confirmed the predicted results of network pharmacology that the blockade of PI3K/AKT and MAPK pathways activation was closely associated with these regulated processes of DoA.
   Conclusions: Our results demonstrated that DoA exhibited strong anti arthritic activity through suppressing PI3K/AKT and MAPK pathways activation in activated synovial cells and osteoclasts, suggesting its potential as a hopeful candidate for the development of novel agents for the prevention and treatment of RA.
C1 [Tu, Yanbei; Wang, Kai; Tan, Lihua; Han, Bing; Hu, Yuanjia; He, Chengwei] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa 999078, Macao, Peoples R China.
   [Ding, Hang] Guangdong Med Univ, Dept Biochem & Mol Biol, Dongguan 523808, Guangdong, Peoples R China.
C3 University of Macau; Guangdong Medical University
RP He, CW (通讯作者)，Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa 999078, Macao, Peoples R China.; Ding, H (通讯作者)，Guangdong Med Univ, Dept Biochem & Mol Biol, Dongguan 523808, Guangdong, Peoples R China.
EM dinghang 1@163.com; chengweihe@um.edu.mo
RI ; Hu, Yuanjia/AAW 7721 2021; Wang, Kai/AIE 2501 2022; He,
   Chengwei/J 7090 2015
OI He, Chengwei/0000 0003 4701 2984; yuanjia, Hu/0000 0001 5244 8577; Tu,
   Yanbei/0000 0002 0877 0427
FU Macao Science and Technology Development Fund, Macau SAR [070/2017/A2];
   University of Macau [MYRG2018 00176 ICMS]; Medical Scientific Research
   Foundation of Guangdong Province [A2018520]
FX This work was supported by The Macao Science and Technology Development
   Fund, Macau SAR (File No. 070/2017/A2), University of Macau (File No.
   MYRG2018 00176 ICMS) and Medical Scientific Research Foundation of
   Guangdong Province (A2018520).
CR Abbasi M, 2019, J CELL PHYSIOL, V234, P10018, DOI 10.1002/jcp.27860
   Alghasham A, 2014, AUTOIMMUNITY, V47, P77, DOI 10.3109/08916934.2013.873413
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Boissier MC, 2011, JOINT BONE SPINE, V78, P230, DOI 10.1016/j.jbspin.2010.08.017
   Carvalho AMS, 2019, PHYTOMEDICINE, V57, P137, DOI 10.1016/j.phymed.2018.10.028
   Chen X, 2016, BRIEF BIOINFORM, V17, P696, DOI 10.1093/bib/bbv066
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Clark AM, 2015, J CHEM INF MODEL, V55, P1246, DOI 10.1021/acs.jcim.5b00144
   Cutolo M, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2630
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Dinesh P, 2018, PHARMACOL RES, V134, P31, DOI 10.1016/j.phrs.2018.05.016
   Guo QQ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00230
   Han JP, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/741476
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007 1110
   Hosseininejad Z, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006545
   Huang SS, 2016, BOT STUD, V57, DOI 10.1186/s40529 016 0153 7
   Jiang MY, 2019, PLANTA MED, V85, P112, DOI 10.1055/a 0746 8622
   Kibble M, 2015, NAT PROD REP, V32, P1249, DOI 10.1039/c5np00005j
   Kizaki K, 2014, FREE RADICAL BIO MED, V76, pS62, DOI 10.1016/j.freeradbiomed.2014.10.372
   Kongdang P, 2019, PHYTOMEDICINE, V59, DOI 10.1016/j.phymed.2018.11.015
   Kourbeti IS, 2014, CLIN INFECT DIS, V58, P1649, DOI 10.1093/cid/ciu185
   Krishnan H, 2019, DRUG DISCOV TODAY, V24, P241, DOI 10.1016/j.drudis.2018.07.009
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lefèvre S, 2015, CURR PHARM DESIGN, V21, P130
   Li J, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/149762
   Li T.S. C., 2006, TAIW NAT MED PLANTS
   Lian JJ, 2016, J FUNCT FOODS, V27, P214, DOI 10.1016/j.jff.2016.09.003
   Lin SJ, 2005, J FOOD DRUG ANAL, V13, P260
   Lü SW, 2015, J ETHNOPHARMACOL, V176, P177, DOI 10.1016/j.jep.2015.10.010
   Castejón ML, 2017, FOOD FUNCT, V8, P1890, DOI [10.1039/c7fo00210f, 10.1039/C7FO00210F]
   Luo Q, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/1410495
   Martocchia A, 2011, CURR TOP MED CHEM, V11, P1668
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Morel J, 2004, JOINT BONE SPINE, V71, P503, DOI 10.1016/j.jbspin.2004.03.004
   Muhammad J, 2018, CURR TOP MED CHEM, V18, P949, DOI 10.2174/1568026618666180330141351
   Neumann E, 2010, TRENDS MOL MED, V16, P458, DOI 10.1016/j.molmed.2010.07.004
   Rengasamy KRR, 2019, PHARMACOL THERAPEUT, V194, P107, DOI 10.1016/j.pharmthera.2018.09.009
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Shelly S, 2012, AUTOIMMUN REV, V11, pA465, DOI 10.1016/j.autrev.2011.11.009
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Steffen U, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01483
   Sun W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07626 8
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Tas SW, 2005, CURR PHARM DESIGN, V11, P581, DOI 10.2174/1381612053381918
   Tu YB, 2019, J FUNCT FOODS, V62, DOI 10.1016/j.jff.2019.103528
   Tu YB, 2019, J ETHNOPHARMACOL, V237, P20, DOI 10.1016/j.jep.2019.03.035
   Wang BC, 2016, VALUE HEALTH, V19, pA239, DOI 10.1016/j.jval.2016.03.1115
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zampeli E, 2015, J AUTOIMMUN, V65, P1, DOI 10.1016/j.jaut.2015.10.003
   Zhang C, 2017, REDOX BIOL, V11, P1, DOI 10.1016/j.redox.2016.10.019
   Zhang LM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00280
   Zhang RZ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00123
   Zhang ZY, 2019, IMMUNOTHERAPY UK, V11, P321, DOI 10.2217/imt 2018 0113
   Zhao HY, 2017, INT IMMUNOPHARMACOL, V51, P114, DOI 10.1016/j.intimp.2017.08.013
NR 57
TC 11
Z9 12
U1 5
U2 71
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD AUG 10
PY 2020
VL 258
AR 112855
DI 10.1016/j.jep.2020.112855
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA LT2FI
UT WOS:000536887800010
PM 32376366
DA 2025 08 17
ER

PT J
AU Zurek, A
   Mizerska Kowalska, M
   Slawinska Brych, A
   Kalawaj, K
   Bojarska Junak, A
   Kandefer Szerszen, M
   Zdzisinska, B
AF Zurek, Aleksandra
   Mizerska Kowalska, Magdalena
   Slawinska Brych, Adrianna
   Kalawaj, Katarzyna
   Bojarska Junak, Agnieszka
   Kandefer Szerszen, Martyna
   Zdzisinska, Barbara
TI Alpha ketoglutarate exerts a pro osteogenic effect in osteoblast cell
   lines through activation of JNK and mTOR/S6K1/S6 signaling pathways
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Alpha ketoglutarate; Osteoblasts; Differentiation; C Jun N terminal
   protein kinase; Mammalian target of rapamycin; G protein coupled
   receptor 99
ID MECHANICAL PROPERTIES; TRANSCRIPTION FACTOR; PROTEIN SYNTHESIS; BONE
   HOMEOSTASIS; DIFFERENTIATION; PHOSPHORYLATION; PROLIFERATION;
   EXPRESSION; GROWTH; OSTERIX
AB Although numerous in vivo studies have suggested that alpha ketoglutarate (AKG), i.e. the key intermediate in the Krebs cycle, may have an anabolic effect on bone tissue, the direct influence of AKG on osteoblasts and the underlying mechanism of its action have not been investigated so far. The aim of this study was to assess the impact of AKG (disodium salt dihydrate) on osteogenesis in vitro and identification of some signaling mechanisms involved in this activity. The human and mouse normal osteoblast cell lines hFOB 1.19 and MC3T3 E1 were used in this study. The results showed that AKG did not increase the proliferation of osteoblasts; however, it upregulated the expression of transcription factors RUNX2 and Osterix, the mRNA and protein levels of osteoblast differentiation markers (alkaline phosphatase, type I collagen, bone sialoprotein II, osteopontin, osteocalcin), and the mineralization levels in the hFOB 1.19 and MC3T3 E1 cell cultures. Moreover, AKG increased JNK, mTOR, S6K1, and S6 phosphorylation and decreased ERK1/2 phosphorylation in both osteoblast cell lines. The JNK inhibitor and rapamycin, but not the ERK inhibitor, abolished the AKG promoted osteoblast differentiation. Using immunofluorescence staining, qRT PCR, and Western blot analysis, we detected the presence of an AKG receptor GPR99 activated by alpha ketoglutaric acid in the tested osteoblast cell lines. However, AKG salt did not activate GPR99. Our findings suggest that AKG salt activates the JNK and mTOR/S6K1/S6 signaling pathways to promote differentiation of osteoblasts, independently of GPR99 activation. We can conclude that AKG salts might be promising candidates for bone anabolic drugs used for prevention or/and treatment of osteoporosis.
C1 [Zurek, Aleksandra; Mizerska Kowalska, Magdalena; Kalawaj, Katarzyna; Kandefer Szerszen, Martyna; Zdzisinska, Barbara] Marie Curie Sklodowska Univ, Dept Virol & Immunol, Akad 19, PL 20033 Lublin, Poland.
   [Slawinska Brych, Adrianna] Marie Curie Sklodowska Univ, Dept Cell Biol, Lublin, Poland.
   [Bojarska Junak, Agnieszka] Med Univ Lublin, Chair & Dept Clin Immunol, Lublin, Poland.
C3 Maria Curie Sklodowska University; Maria Curie Sklodowska University;
   Medical University of Lublin
RP Zdzisinska, B (通讯作者)，Marie Curie Sklodowska Univ, Dept Virol & Immunol, Akad 19, PL 20033 Lublin, Poland.
EM basiaz@poczta.umcs.lublin.pl
RI ; Mizerska Kowalska, Magdalena/AAG 9713 2020; Bojarska Junak,
   Agnieszka/AAK 3714 2021
OI Zdzisinska, Barbara/0000 0002 0920 3192; Bojarska Junak,
   Agnieszka/0000 0003 2340 9442
FU State Funds for Scientific Research National Science Centre (NCN),
   Poland [2013/11/B/NZ4/04557]
FX This work was supported by research Grant No 2013/11/B/NZ4/04557 from
   the State Funds for Scientific Research National Science Centre (NCN),
   Poland.
CR Aussel C, 1996, CELL BIOL INT, V20, P359, DOI 10.1006/cbir.1996.0042
   Cai XC, 2016, SCI REP UK, V6, DOI 10.1038/srep26802
   Chaudhuri J, 2014, APOPTOSIS, V19, P135, DOI 10.1007/s10495 013 0904 9
   Chen Jia Shing, 2014, BMC Res Notes, V7, P15, DOI 10.1186/1756 0500 7 15
   Cheng J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115339
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Dai QG, 2017, CELL DEATH DIFFER, V24, P1886, DOI 10.1038/cdd.2017.110
   Dobrowolski PJ, 2008, SCAND J GASTROENTERO, V43, P551, DOI 10.1080/00365520701824951
   Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532
   Filip RS, 2007, INT J VITAM NUTR RES, V77, P89, DOI 10.1024/0300 9831.77.2.89
   Fitter S, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00668 16
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Franceschi Renny T, 2017, Curr Mol Biol Rep, V3, P122, DOI 10.1007/s40610 017 0059 5
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Harrison AP, 2004, BONE, V35, P204, DOI 10.1016/j.bone.2004.03.016
   He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488
   Igarashi M, 2004, J MOL HISTOL, V35, P3, DOI 10.1023/B:HIJO.0000020883.33256.fe
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Karner CM, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00253 16
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905
   Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Martin TD, 2014, AM J PHYSIOL ENDOC M, V306, pE1397, DOI 10.1152/ajpendo.00064.2014
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Mizuno N, 2009, NEUROSIGNALS, V17, P42, DOI 10.1159/000186689
   Mosekilde L, 2011, CURR DRUG SAF, V6, P62, DOI 10.2174/157488611795684712
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200
   Pietschmann P, 2016, GERONTOLOGY, V62, P128, DOI 10.1159/000431091
   Radzki RP, 2012, J BONE MINER METAB, V30, P651, DOI 10.1007/s00774 012 0377 x
   Ruijtenberg S, 2016, CELL CYCLE, V15, P196, DOI 10.1080/15384101.2015.1120925
   Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Shin S, 2015, MOL CELL, V59, P382, DOI 10.1016/j.molcel.2015.06.020
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Slawinska Brych A, 2016, TOXICOLOGY, V357, P65, DOI 10.1016/j.tox.2016.06.008
   Sliwa E, 2010, J ANIM PHYSIOL AN N, V94, pe86, DOI 10.1111/j.1439 0396.2009.00985.x
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Tatara MR, 2007, SMALL RUMINANT RES, V67, P179, DOI 10.1016/j.smallrumres.2005.09.031
   Tatara MR, 2006, BONE, V39, P100, DOI 10.1016/j.bone.2005.12.016
   Tatara MR, 2012, NUTR METAB, V9, DOI 10.1186/1743 7075 9 39
   Tatara MR, 2005, POULTRY SCI, V84, P1604, DOI 10.1093/ps/84.10.1604
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xu R, 2017, J BONE MINER RES, V32, P1811, DOI 10.1002/jbmr.3184
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yao K, 2012, AMINO ACIDS, V42, P2491, DOI 10.1007/s00726 011 1060 6
   Zdzisinska B, 2017, ARCH IMMUNOL THER EX, V65, P21, DOI 10.1007/s00005 016 0406 x
   Zhang Y, 2012, SCI WORLD J, DOI 10.1100/2012/793823
NR 55
TC 28
Z9 30
U1 2
U2 25
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0041 008X
EI 1096 0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD JUL 1
PY 2019
VL 374
BP 53
EP 64
DI 10.1016/j.taap.2019.04.024
PG 12
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA IA9RD
UT WOS:000469893600006
PM 31051157
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Yan, M
   Yu, QF
   Yang, PF
   Zhang, HD
   Sun, YH
   Zhang, ZF
   Gao, YF
AF Zhang, Yun
   Yan, Ming
   Yu, Qing feng
   Yang, Pei fan
   Zhang, Hai dong
   Sun, Yong hong
   Zhang, Zhi fen
   Gao, Yun feng
TI Puerarin Prevents LPS Induced Osteoclast Formation and Bone Loss
   via Inhibition of Akt Activation
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE puerarin; lipopolysaccharide (LPS); osteoclastogenesis; bone loss; Akt
ID RECEPTOR ACTIVATOR; ESTROGEN RECEPTOR; IN VITRO; LIPOPOLYSACCHARIDE;
   CELLS; DIFFERENTIATION; PATHWAY; RATS; MICE; OSTEOBLASTS
AB Osteolysis induced by chronic Gram negative bacterial infection underlies many bone diseases such as osteomyelitis, septic arthritis, and periodontitis. Drugs that inhibit lipopolysaccharide (LPS) induced osteolysis are critically needed for the prevention of bone destruction in infective bone diseases. In this study, we assessed the effect of puerarin, a natural isoflavone isolated from Pueraria lobata OHWI root, on LPS induced osteoclastogenesis and bone loss. Our in vitro study showed that puerarin significantly inhibited LPS induced osteoclast differentiation from osteoclast precursor RAW264.7 cells. The inhibition occurred through suppressing the production of osteoclast activating factor tumor necrosis factor (TNF) alpha, interleukin (IL) 1 beta and prostaglandin E 2 (PGE(2)), which led to down regulating mRNA expression of osteoclastogenic genes including tartrate resistant acid phosphatase (TRAP), cathepsin K and matrix metalloprotein 9 (MMP 9). Furthermore, LPS triggered activation of Akt in osteoclast precursor RAW264.7 cells, which was inhibited by puerarin treatment. In vivo, puerarin attenuated LPS induced bone loss in a murine calvarial osteolysis model. Collectively, puerarin prevents LPS induced osteoclast formation, function and bone loss, where the inhibition of Akt activation plays an important role. These findings provide evidences that puerarin might be beneficial as a promising candidate drug for the prevention and treatment of bacteria induced bone destruction disease, and give new insights for understanding its possible mechanism.
C1 [Zhang, Yun; Yu, Qing feng; Yang, Pei fan; Zhang, Hai dong; Zhang, Zhi fen; Gao, Yun feng] Shaoxing Univ, Coll Med, Huancheng West Rd 508, Shaoxing 312000, Peoples R China.
   [Yan, Ming] Hangzhou Dianzi Univ, Coll Life Informat Sci & Instrument Engn, Dept Biomed Engn, 2nd Ave 1158, Hangzhou 310018, Zhejiang, Peoples R China.
   [Sun, Yong hong] Zhejiang Univ, Dept Biomed Engn, Zhejiang Prov Key Lab Cardiocerebral Vasc Detect, Hangzhou 310027, Zhejiang, Peoples R China.
C3 Shaoxing University; Hangzhou Dianzi University; Zhejiang University
RP Zhang, Y (通讯作者)，Shaoxing Univ, Coll Med, Huancheng West Rd 508, Shaoxing 312000, Peoples R China.; Yan, M (通讯作者)，Hangzhou Dianzi Univ, Coll Life Informat Sci & Instrument Engn, Dept Biomed Engn, 2nd Ave 1158, Hangzhou 310018, Zhejiang, Peoples R China.
EM zhangyunbme@126.com; yanming@hdu.edu.cn
RI gao, yunfeng/LRC 6280 2024
FU Zhejiang Provincial Natural Science Foundation of China [LY17H060007,
   LY15H180012, LY13H060003]; National Natural Science Foundation of China
   [30900301]; Applied Research Program of Public Good in Zhejiang Province
   [2011C33046]; Scientific Research Foundation of Traditional Chinese
   Medicine in Zhejiang Province [2012ZB161]
FX This work was supported by Zhejiang Provincial Natural Science
   Foundation of China (LY17H060007, LY15H180012 and LY13H060003), National
   Natural Science Foundation of China (30900301), Applied Research Program
   of Public Good in Zhejiang Province (2011C33046) and Scientific Research
   Foundation of Traditional Chinese Medicine in Zhejiang Province
   (2012ZB161).
CR Decker C, 2013, J BIOL CHEM, V288, P33634, DOI 10.1074/jbc.M113.477281
   Hada N, 2012, BONE, V50, P226, DOI 10.1016/j.bone.2011.10.028
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Karieb S, 2012, BRIT J NUTR, V108, P1736, DOI 10.1017/S0007114511007355
   Karieb S, 2011, J CELL BIOCHEM, V112, P476, DOI 10.1002/jcb.22935
   Kim JY, 2015, BIOL PHARM BULL, V38, P66, DOI 10.1248/bpb.b14 00567
   Li H, 2016, PHARM BIOL, V54, P111, DOI 10.3109/13880209.2015.1017885
   Lim DW, 2013, NUTRIENTS, V5, P2734, DOI 10.3390/nu5072734
   Liu M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/485927
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Ma JQ, 2014, FOOD CHEM TOXICOL, V71, P264, DOI 10.1016/j.fct.2014.06.017
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Michihara S, 2012, J NUTR SCI VITAMINOL, V58, P202, DOI 10.3177/jnsv.58.202
   Mizutani H, 2013, J PERIODONTAL RES, V48, P748, DOI 10.1111/jre.12065
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nason R, 2009, JARO J ASSOC RES OTO, V10, P151, DOI 10.1007/s10162 008 0153 8
   Sena K, 2005, ULTRASOUND MED BIOL, V31, P703, DOI 10.1016/j.ultrasmedbio.2005.01.013
   Shugg RPP, 2013, J BIOL CHEM, V288, P35346, DOI 10.1074/jbc.M113.507525
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Wang PP, 2012, J ASIAN NAT PROD RES, V14, P897, DOI 10.1080/10286020.2012.702757
   Wang Y, 2014, PHYTOMEDICINE, V21, P1032, DOI 10.1016/j.phymed.2014.04.012
   Xiong FL, 2006, EUR J PHARMACOL, V529, P1, DOI 10.1016/j.ejphar.2005.10.024
   Yang X, 2015, J PERIODONTAL RES, V50, P748, DOI 10.1111/jre.12261
   Yao XJ, 2012, J ETHNOPHARMACOL, V141, P322, DOI 10.1016/j.jep.2012.02.038
   Zhang Y, 2007, PLANTA MED, V73, P341, DOI 10.1055/s 2007 967168
   Zhang Y, 2012, TOXICOLOGY, V297, P57, DOI 10.1016/j.tox.2012.04.002
   Zhao SS, 2015, NEUROTOXICOLOGY, V51, P166, DOI 10.1016/j.neuro.2015.10.010
   Zheng MX, 2014, INT ORTHOP, V38, P627, DOI 10.1007/s00264 013 2184 y
   Zhou XX, 2012, J SURG RES, V173, pE47, DOI 10.1016/j.jss.2011.11.004
NR 29
TC 50
Z9 59
U1 1
U2 26
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD DEC
PY 2016
VL 39
IS 12
BP 2028
EP 2035
DI 10.1248/bpb.b16 00522
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ED7DA
UT WOS:000389014700016
PM 27904045
OA gold
DA 2025 08 17
ER

PT J
AU Xiao, Y
   Chen, YQ
   Huang, Y
   Xiao, Y
AF Xiao, Yao
   Chen, Yiqian
   Huang, Yan
   Xiao, Yuan
TI Atypical femur fracture associated with common anti osteoporosis drugs
   in FDA adverse event reporting system
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PATIENT RECEIVING DENOSUMAB; SUPPRESSED BONE TURNOVER; FEMORAL
   FRACTURES; POSTMENOPAUSAL WOMEN; BISPHOSPHONATE USE; STRESS FRACTURES;
   CANCER PATIENTS; ALENDRONATE; RISK; TERIPARATIDE
AB Atypical femur fracture (AFF) is a rare but catastrophic adverse event first reported in the long term use of alendronate, one of the most commonly used drugs for osteoporosis currently. However, further evidence is needed to learn more regarding other common anti osteoporosis drugs and the risk for AFF. In this study, reports of AFF were identified from Food and Drug Administration Adverse Event Reporting System database. Disproportionality analyses were performed to examine the reporting odds ratio (ROR), information component (IC) and adjusted ROR (adj. ROR) signals for AFF for common anti osteoporosis drugs. A total of 1692 unique AFF reports were identified. The disproportionality signals (the lower bound of 95% confidence interval > 1 for ROR and adjusted ROR, and > 0 for IC) were detected for alendronate, denosumab, pamidronate, risedronate, zoledronate, ibandronate, and teriparatide while no signal was detected for raloxifene, abaloparatide, and romosozumab. When restricted in patients with osteoporosis, the disproportionality signals were still detected for alendronate, pamidronate, risedronate, denosumab, and ibandronate. Our results suggest that alendronate has the largest risk signal, while the risks varied among different bisphosphonates. In addition, denosumab was found statistically associated with AFF in both the entire database and patients with osteoporosis.
C1 [Xiao, Yao; Huang, Yan; Xiao, Yuan] Cent South Univ, Endocrinol Res Ctr, Dept Endocrinol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
   [Chen, Yiqian] Cent South Univ, Dept Gastroenterol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
   [Xiao, Yuan] Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Hunan, Peoples R China.
C3 Central South University; Central South University; Central South
   University
RP Xiao, Y (通讯作者)，Cent South Univ, Endocrinol Res Ctr, Dept Endocrinol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.; Xiao, Y (通讯作者)，Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Hunan, Peoples R China.
EM xiaoyuan2021@csu.edu.cn
RI ; Xiao, Yao/AEX 1775 2022
OI yiqian, chen/0000 0001 8071 6823; 
CR Abrahamsen B, 2016, BMJ BRIT MED J, V353, DOI 10.1136/bmj.i3365
   Adler RA, 2018, EUR J ENDOCRINOL, V178, pR81, DOI 10.1530/EJE 17 1002
   Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Akagawa M, 2022, ACTA MED OKAYAMA, V76, P333, DOI 10.18926/AMO/63744
   Alshahrani F, 2012, J CLIN DENSITOM, V15, P380, DOI 10.1016/j.jocd.2012.03.003
   Armamento Villareal R, 2006, NEW ENGL J MED, V355, P2048, DOI 10.1056/NEJMc062268
   Austin DC, 2017, ACTA ORTHOP, V88, P351, DOI 10.1080/17453674.2016.1277412
   Bate A, 2009, PHARMACOEPIDEM DR S, V18, P427, DOI 10.1002/pds.1742
   Bate A, 1998, EUR J CLIN PHARMACOL, V54, P315, DOI 10.1007/s002280050466
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Black DM, 2019, ENDOCR REV, V40, P333, DOI 10.1210/er.2018 00001
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bonora BM, 2021, CARDIOVASC DIABETOL, V20, DOI 10.1186/s12933 021 01243 4
   Brown JP, 2017, TOXICOL PATHOL, V45, P859, DOI 10.1177/0192623317737066
   Burckhardt P, 2021, J BONE MINER RES, V36, P1717, DOI 10.1002/jbmr.4335
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Cleto Zepeda G, 2019, Acta Ortop Mex, V33, P39
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Dhodapkar MM, 2022, BMJ BRIT MED J, V379, DOI 10.1136/bmj 2022 071752
   Drampalos E, 2014, ACTA ORTHOP, V85, P3, DOI 10.3109/17453674.2013.854668
   Duggirala HJ, 2016, J AM MED INFORM ASSN, V23, P428, DOI 10.1093/jamia/ocv063
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Edwards BJ, 2016, J BONE MINER RES, V31, P1569, DOI 10.1002/jbmr.2818
   Edwards BJ, 2013, J BONE JOINT SURG AM, V95A, P297, DOI 10.2106/JBJS.K.01181
   Espey Robert, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr 2016 217489
   Everts Graber J, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10681
   Gastaldon C, 2020, PSYCHOTHER PSYCHOSOM, V90, P41, DOI 10.1159/000510703
   Girgis CM, 2010, NEW ENGL J MED, V362, P1848, DOI 10.1056/NEJMc0910389
   Goh JKM, 2022, CALCIFIED TISSUE INT, V111, P96, DOI 10.1007/s00223 022 00952 6
   Goldman A, 2022, EUR J PREV CARDIOL, V29, P1334, DOI 10.1093/eurjpc/zwab209
   Goldman A, 2021, J AM COLL CARDIOL, V78, P1800, DOI 10.1016/j.jacc.2021.08.044
   Gomberg SJ, 2011, J CLIN ENDOCR METAB, V96, P1627, DOI 10.1210/jc.2010 2520
   Greenspan SL, 2018, OSTEOPOROSIS INT, V29, P501, DOI 10.1007/s00198 017 4286 7
   Guthrie Ariane, 2022, Sr Care Pharm, V37, P555, DOI 10.4140/TCP.n.2022.555
   Hegazy A, 2016, J PEDIATR ORTHOPED, V36, P757, DOI 10.1097/BPO.0000000000000552
   Hirano F, 2021, BONE REP, V14, DOI 10.1016/j.bonr.2021.101091
   Hung E, 2023, PHARMACOEPIDEM DR S, V32, P387, DOI 10.1002/pds.5555
   Im Gun Il, 2015, J Bone Metab, V22, P183, DOI 10.11005/jbm.2015.22.4.183
   Jedlowski PM, 2021, AM J CLIN DERMATOL, V22, P891, DOI 10.1007/s40257 021 00625 4
   Jha S, 2015, J BONE MINER RES, V30, P2179, DOI 10.1002/jbmr.2565
   Katsoulis M, 2017, J INTERN MED, V281, P300, DOI 10.1111/joim.12586
   Khaleel MA, 2022, HEALTHCARE BASEL, V10, DOI 10.3390/healthcare10030420
   Khow KSF, 2017, J NUTR HEALTH AGING, V21, P83, DOI 10.1007/s12603 015 0652 3
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   LeBlanc ES, 2017, J BONE MINER RES, V32, P2304, DOI 10.1002/jbmr.3221
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Lo JC, 2016, BONE, V85, P142, DOI 10.1016/j.bone.2016.01.002
   Lyu HC, 2022, J CLIN ENDOCR METAB, V107, pE3366, DOI 10.1210/clinem/dgac262
   Lyu HC, 2020, ANN INTERN MED, V173, P516, DOI 10.7326/M20 0882
   Martin TJ, 2021, ENDOCR REV, V42, P383, DOI 10.1210/endrev/bnab005
   Meier RPH, 2012, ARCH INTERN MED, V172, P930, DOI 10.1001/archinternmed.2012.1796
   Meng L, 2019, INT J CLIN PRACT, V73, DOI 10.1111/ijcp.13331
   Napoli N, 2013, J CLIN ENDOCR METAB, V98, P659, DOI 10.1210/jc.2012 1896
   Nasomyont N, 2020, OSTEOPOROSIS INT, V31, P995, DOI 10.1007/s00198 019 05227 9
   Nguyen HH, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115319
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Ota S, 2017, BREAST CANCER TOKYO, V24, P601, DOI 10.1007/s12282 016 0746 8
   Pan YX, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 15941 w
   Papapoulos S, 2021, J BONE MINER RES, V36, P1225, DOI 10.1002/jbmr.4284
   PECK WA, 1993, AM J MED, V94, P646
   Puhaindran ME, 2011, J BONE JOINT SURG AM, V93A, P1235, DOI 10.2106/JBJS.J.01199
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470 2045(18)30608 9
   Schilcher J, 2014, ACTA ORTHOP, V85, P6, DOI 10.3109/17453674.2014.885355
   Schilcher J, 2015, ACTA ORTHOP, V86, P100, DOI 10.3109/17453674.2015.1004149
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Selga J, 2016, OSTEOPOROSIS INT, V27, P827, DOI 10.1007/s00198 015 3355 z
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Starr J, 2018, CURR OSTEOPOROS REP, V16, P519, DOI 10.1007/s11914 018 0464 6
   Thompson RN, 2014, BONE, V61, P44, DOI 10.1016/j.bone.2013.12.027
   Tsuchie H, 2018, OSTEOPOROSIS INT, V29, P2659, DOI 10.1007/s00198 018 4658 7
   Wells GA, 2022, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004523.pub4
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xia S, 2023, CANCERS, V15, DOI 10.3390/cancers15010240
   Xia S, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.967017
NR 79
TC 8
Z9 9
U1 0
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUL 5
PY 2023
VL 13
IS 1
AR 10892
DI 10.1038/s41598 023 37944 x
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA L6UU6
UT WOS:001024600400034
PM 37407650
OA gold
DA 2025 08 17
ER

PT J
AU Shimo, T
   Kubota, S
   Yoshioka, N
   Ibaragi, S
   Isowa, S
   Eguchi, T
   Sasaki, A
   Takigawa, M
AF Shimo, Tsuyoshi
   Kubota, Satoshi
   Yoshioka, Norie
   Ibaragi, Soichiro
   Isowa, Sachiko
   Eguchi, Takanori
   Sasaki, Akira
   Takigawa, Masaharu
TI Pathogenic role of connective tissue growth factor (CTGF/CCN2) in
   osteolytic metastasis of breast cancer
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE connective tissue growth factor; PTH related peptide; bone resorption;
   mitogen activated protein kinase; extracellular signal regulated kinase
ID HORMONE RELATED PROTEIN; VASCULAR ENDOTHELIAL CELLS;
   CHONDROCYTE SPECIFIC GENE; HUMANIZED MONOCLONAL ANTIBODY;
   OSTEOBLAST LIKE CELLS; ANGIOGENESIS IN VIVO; PARATHYROID HORMONE; BONE
   METASTASIS; NUDE MICE; OSTEOTROPIC HORMONES
AB Introduction: Connective tissue growth factor (CTGF/CCN2) is a mediator of local angiogenesis induced by breast cancer, but its role in osteolytic metastasis has not been evaluated. PTH related peptide (PTHrP) is another critical factor in the development of the osteolytic metastasis. Using both in vivo and in vitro approaches, we studied whether/how neutralization of CCN2 prevented bone metastasis and how PTHrP signaling is related.
   Materials and Methods: A mouse model of bone metastasis by human breast cancer cell line MDA231 was treated with a CCN2 neutralizing antibody, and osteolytic bone metastases were assessed on radiographs and immunohistochemistry. Ccn2 gene expression and transcription were examined by Northern blot and luciferase analysis. Immunoblot analysis and kinase inhibitors were used to identify the signaling pathways implicated. Anti angiogenic/osteoclastogenic effects of ccn2 downregulation were also evaluated.
   Results: Treatment of mice with a CCN2 neutralizing antibody greatly decreased osteolytic bone metastasis, microvasculature, and osteoclasts involved. The antibody also suppressed the growth of subcutaneous tumor in vivo and proliferation and migration of human umbilical vein endothelial cells (HUVECs) in vitro. Downregulation of ccn2 also repressed osteoclastogenesis. CCN2 expression was specifically observed in cancer cells producing PTHrP and type I PTH/PTHrP receptor (PTH1R) invaded the bone marrow, and PTHrP strongly upregulated ccn2 in MDA231 cells in vitro. Activation of protein kinase C (PKC) and protein kinase A (PKA) was necessary and sufficient for the stimulation of ccn2 by PTHrP. Indeed, inhibition of the extracellular signal regulated kinase (ERK1/2), PKC, or PKA by specific inhibitors counteracted the stimulation of ccn2 expression. Incubation of MDA231 cells with PTHrP induced the activation of ERK1/2. Consistent with these findings, inhibition of PKC prevented PTHrP induced ERK1/2 activation, whereas 12 O tetradecanoylphorbol 13 acetate (TPA), a stimulator of PKC, upregulated it.
   Conclusions: CCN2 was critically involved in osteolytic metastasis and was induced by PKA  and PKC dependent activation of ERK1/2 signaling by PTHrP. Thus, CCN2 may be a new molecular target for anti osteolytic therapy to shut off the PTHrP CCN2 signaling pathway.
C1 Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral & Maxillofacial Surg & Biopathol Sci, Okayama 7008525, Japan.
   Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Biochem & Mol Dent, Okayama, Japan.
C3 Okayama University; Okayama University
RP Sasaki, A (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral & Maxillofacial Surg & Biopathol Sci, 2 5 1 Shikatacho, Okayama 7008525, Japan.
EM aksasaki@md.okayama u.ac.jp
RI ; Shimo, Tsuyoshi/AAT 8358 2020; YOSHIOKA, Norie/B 2276 2011
OI Shimo, Tsuyoshi/0000 0002 7811 2366; Eguchi,
   Takanori/0000 0002 3297 6126; 
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826
   Aiyar N, 2002, BIOCHEM PHARMACOL, V63, P1949, DOI 10.1016/S0006 2952(02)00990 5
   Babic AM, 1999, MOL CELL BIOL, V19, P2958
   BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014 5793(93)80155 N
   Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Chaqour B, 2002, AM J PHYSIOL ENDOC M, V283, pE765, DOI 10.1152/ajpendo.00131.2002
   DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.bi.60.070191.003253
   Eguchi T, 2001, J BIOCHEM, V130, P79, DOI 10.1093/oxfordjournals.jbchem.a002965
   Goltzman D, 1999, J BONE MINER RES, V14, P173, DOI 10.1359/jbmr.1999.14.2.173
   Grigoriou V, 2005, J BIOL CHEM, V280, P1733, DOI 10.1074/jbc.M402550200
   Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359 6101(97)00010 5
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guise TA, 1997, CANCER AM CANCER SOC, V80, P1572, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1572::AID CNCR7>3.3.CO;2 D
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092 8674(00)80108 7
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   Henderson MA, 2006, CANCER RES, V66, P2250, DOI 10.1158/0008 5472.CAN 05 2814
   Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505
   JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   KANO J, 1994, BIOCHEM BIOPH RES CO, V199, P271, DOI 10.1006/bbrc.1994.1224
   Kawaki H, 2003, DNA CELL BIOL, V22, P641, DOI 10.1089/104454903770238111
   KIKUCHI K, 1995, J INVEST DERMATOL, V105, P128, DOI 10.1111/1523 1747.ep12313452
   KIKUCHI Y, 1986, GYNECOL ONCOL, V24, P183, DOI 10.1016/0090 8258(86)90026 0
   Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769
   LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Mannstadt M, 1999, AM J PHYSIOL RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665
   Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200
   Miyamoto T, 2000, BLOOD, V96, P4335, DOI 10.1182/blood.V96.13.4335.h8004335_4335_4343
   Morley P, 1999, CURR MED CHEM, V6, P1095
   Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/en.141.1.264
   Nishida T, 2000, J CELL PHYSIOL, V184, P197, DOI 10.1002/1097 4652(200008)184:2<197::AID JCP7>3.0.CO;2 R
   Onuma E, 2004, ANTICANCER RES, V24, P2665
   Parisi MS, 2006, BONE, V38, P671, DOI 10.1016/j.bone.2005.10.005
   Peyruchaud O, 2003, J BIOL CHEM, V278, P45826, DOI 10.1074/jbc.M309024200
   PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024
   Safadi FF, 2003, J CELL PHYSIOL, V196, P51, DOI 10.1002/jcp.10319
   Saito H, 2005, ANTICANCER RES, V25, P3817
   Sasaki A, 1998, CANCER RES, V58, P462
   SASAKI A, 1995, CANCER RES, V55, P3551
   Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097 2765(01)00432 4
   Shimo T, 2004, DEV DYNAM, V229, P607, DOI 10.1002/dvdy.20009
   Shimo T, 1999, J BIOCHEM TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414
   Shimo T, 2001, CANCER LETT, V174, P57, DOI 10.1016/S0304 3835(01)00683 8
   Shimo T, 2001, ONCOLOGY BASEL, V61, P315, DOI 10.1159/000055339
   Shimo T, 2004, DEV DYNAM, V231, P136, DOI 10.1002/dvdy.20109
   Shimo T, 1998, J BIOCHEM TOKYO, V124, P130, DOI 10.1093/oxfordjournals.jbchem.a022071
   Suda T, 1997, METHOD ENZYMOL, V282, P223
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo 122 4 1373
   Takigawa M, 2003, DRUG NEWS PERSPECT, V16, P11, DOI 10.1358/dnp.2003.16.1.829302
   Takigawa M, 2003, J CELL PHYSIOL, V194, P256, DOI 10.1002/jcp.10206
   UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo 125 4 1805
   van der Pluijm G, 2000, CANCER TREAT REV, V26, P11, DOI 10.1053/ctrv.1999.0143
   Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077
   Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423
   Winding B, 2000, J CANCER RES CLIN, V126, P631, DOI 10.1007/PL00008475
   Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008 5472.CAN 05 1702
   Yokoi H, 2001, AM J KIDNEY DIS, V38, pS134, DOI 10.1053/ajkd.2001.27422
   Yoneda T, 1998, EUR J CANCER, V34, P240, DOI 10.1016/S0959 8049(97)10132 0
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Yu CY, 2003, J PATHOL, V201, P609, DOI 10.1002/path.1468
   Zhen XC, 1998, MOL PHARMACOL, V54, P453, DOI 10.1124/mol.54.3.453
NR 68
TC 136
Z9 156
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2006
VL 21
IS 7
BP 1045
EP 1059
DI 10.1359/JBMR.060416
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 057MW
UT WOS:000238600900013
PM 16813525
OA Bronze
DA 2025 08 17
ER

PT J
AU Yuan, AL
   Liu, CQ
   Feng, WQ
   Li, BY
   Zheng, LL
   Tian, JY
   Yu, B
   Zhang, YL
AF Yuan, Anlei
   Liu, Chaoqun
   Feng, Wenqing
   Li, Beiyan
   Zheng, Lulu
   Tian, Jiaye
   Yu, Bin
   Zhang, Yanling
TI Integrating Network Pharmacology, Quantitative Metabolic Network
   Analysis, In Vitro Experiments, and Molecular Dynamics to Explore the
   Mechanism of Angelica Sinensis for Regulating Bone Metabolism
SO COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
LA English
DT Article
DE Angelica sinensis; bone metabolism; network pharmacology; quantitative
   metabolic network analysis; in vitro experiments; molecular dynamics
ID MESENCHYMAL STEM CELLS; DIFFERENTIATION; OSTEOPOROSIS; PROLIFERATION;
   EXTRACT; HDAC4
AB Background: Bone metabolic diseases are serious health issues worldwide. Angelica sinensis (AS) is traditionally used in Chinese medicine for treating bone metabolism diseases clinically. However, the mechanism of AS in regulating bone metabolism remains uncertain. Objective: The current investigation was structured to elucidate the potential mechanisms of AS for modulating bone metabolism. Methods: Firstly, targets of AS regulating bone metabolism were collected by network pharmacology. Then, the transcriptional regulation of RUNX2 was enriched as one of the key pathways for AS to regulate bone metabolism, constructing its metabolic network. Secondly, combining molecular docking, network efficiency, and network flux analyses, we conducted a quantitative evaluation of the metabolic network to reveal the potential mechanisms and components of AS regulating bone metabolism. Finally, we explored the effect of AS on the differentiation of osteoclasts from M CSF and RANKL induced RAW264.7 cells, as well as its impact on the osteogenic induction of MC3T3 E1 cells. We verified the mechanism and key targets of AS on bone metabolism using qRT PCR. Furthermore, the key component was preliminarily validated through molecular dynamics simulation. Results: Quantitative metabolic network of the transcriptional regulation of RUNX2 was constructed to illustrate the potential mechanism of AS for regulating bone metabolism, indicating that ferulic acid may be a pharmacological component of AS that interferes with bone metabolism. AS suppressed osteoclast differentiation in M CSF and RANKL induced RAW264.7 cells and reversed the expressions of osteoclastic differentiation markers, including RUNX2 and SRC. Additionally, AS induced osteogenic generation in MC3T3 E1 cells and reversed the expressions of markers associated with osteoblastic generation, such as RUNX2 and HDAC4. Molecular dynamics simulation displayed a strong binding affinity among ferulic acid, HDAC4 and SRC. Conclusion: This study reveals a systematic perspective on the intervention bone mechanism of AS by transcriptive regulation by RUNX2, guiding the clinical use of AS in treating diseases of the skeletal system.
C1 [Liu, Chaoqun; Feng, Wenqing; Li, Beiyan; Zheng, Lulu; Tian, Jiaye; Yu, Bin; Zhang, Yanling] Beijing Univ Chinese Med, Sch Chinese Mat Med, Key Lab TCM Informat Engineer State Adm TCM, Beijing 102488, Peoples R China.
C3 Beijing University of Chinese Medicine
RP Zhang, YL (通讯作者)，Beijing Univ Chinese Med, Sch Chinese Mat Med, Key Lab TCM Informat Engineer State Adm TCM, Beijing 102488, Peoples R China.
EM zhangyanling@bucm.edu.cn
RI zheng, lulu/AAJ 9192 2020; tian, jiaye/JRW 9602 2023
FU National Natural Science Foundation of China [82073996]; Fundamental
   Research Funds for the Central Universities of Beijing University of
   Chinese Medicine [2023 JYB 900202 054]; Research Funds of Scientific
   Research Institute of Beijing Tongrentang Co. Ltd. [2023110012001598]
FX This work was supported by National Natural Science Foundation of China
   (No.82073996); Fundamental Research Funds for the Central Universities
   of Beijing University of Chinese Medicine (Grants No.
   2023 JYB 900202 054); Research Funds of Scientific Research Institute of
   Beijing Tongrentang Co. Ltd. (Grants No. 2023110012001598).
CR Carletti A, 2024, CELL MOL LIFE SCI, V81, DOI 10.1007/s00018 023 05033 x
   Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018
   Ding MF, 2024, GUT MICROBES, V16, DOI 10.1080/19490976.2023.2290344
   Doss HM, 2018, LIFE SCI, V207, P284, DOI 10.1016/j.lfs.2018.06.013
   Du L, 2016, SCI REP UK, V6, DOI 10.1038/srep32261
   Franzmeier N, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195 018 0358 y
   Gao GC, 2020, EUR REV MED PHARMACO, V24, P526, DOI 10.26355/eurrev_202001_20029
   Gu JY, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321 015 0066 6
   Gu JY, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/425707
   Hojo H, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032979
   Hu Q, 2022, INT J BIOL MACROMOL, V209, P153, DOI 10.1016/j.ijbiomac.2022.03.090
   Hug BA, 2004, CELL, V119, P448, DOI 10.1016/j.cell.2004.10.023
   Jiang LD, 2015, CAN J CHEM, V93, P1199, DOI 10.1139/cjc 2015 0197
   Jung SM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2222
   Kang YS, 2017, MULTIMED TOOLS APPL, V76, P19945, DOI 10.1007/s11042 016 4015 9
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim HJ, 2020, MOL CELLS, V43, P160, DOI 10.14348/molcells.2019.0247
   Kim T, 2023, PHARMACEUTICALS BASE, V16, DOI 10.3390/ph16121718
   Kim YI, 2023, CELL BIOSCI, V13, DOI 10.1186/s13578 023 01088 2
   Kong LB, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 481
   Kong YH, 2022, BIOENGINEERED, V13, P10640, DOI 10.1080/21655979.2022.2065753
   Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701
   Li P, 2014, ANN BIOMED ENG, V42, P1250, DOI 10.1007/s10439 014 0984 x
   Li QA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014774
   Li YL, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 023 03658 z
   Lim DW, 2014, NUTRIENTS, V6, P4362, DOI 10.3390/nu6104362
   Malavkia D, 2020, J CELL PHYSIOL, V235, P7996, DOI 10.1002/jcp.29454
   Matsubara T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105508
   Merrick D, 2019, HUM MOL GENET, V28, P16, DOI 10.1093/hmg/ddy322
   Qin Jun, 2013, Evid Based Complement Alternat Med, V2013, P794761, DOI 10.1155/2013/794761
   Ren MJ, 2024, J FUTURE FOODS, V4, P183, DOI 10.1016/j.jfutfo.2023.07.001
   Sarker SD, 2004, CURR MED CHEM, V11, P1479, DOI 10.2174/0929867043365189
   Stegen S, 2024, NAT REV ENDOCRINOL, V20, P399, DOI 10.1038/s41574 024 00969 x
   Wang KT, 2022, NUTRIENTS, V14, DOI 10.3390/nu14091940
   Weitzmann MN, 2017, J INFECT DIS, V216, P1070, DOI 10.1093/infdis/jix444
   Won GW, 2019, BIOCHEM BIOPH RES CO, V512, P591, DOI 10.1016/j.bbrc.2019.03.097
   Xie FD, 2023, J ETHNOPHARMACOL, V307, DOI 10.1016/j.jep.2023.116216
   Xie X, 2019, BONE JOINT RES, V8, P323, DOI [10.1302/2046 3758.87.BJR 2018 0223.R2, 10.1302/2046 3758.87BJR 2018 0223.R2]
   Yang CF, 2012, J SURG RES, V176, P476, DOI 10.1016/j.jss.2011.08.011
   Yang CLH, 2013, CLIN REV ALLERG IMMU, V44, P284, DOI 10.1007/s12016 012 8329 8
   Yang KD, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829830
   Yao WY, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241310975
   Zhang J, 2024, GENES DIS, V11, DOI 10.1016/j.gendis.2023.101122
   Zhang Q, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00262 z
   Zhao L, 2023, J ETHNOPHARMACOL, V309, DOI 10.1016/j.jep.2023.116306
   Zheng Y, 2023, NUTRIENTS, V15, DOI 10.3390/nu15071794
   Zheng Zi Ran, 2014, Zhongguo Zhong Yao Za Zhi, V39, P3172
   Zhu LJ, 2020, INFLAMMOPHARMACOLOGY, V28, P463, DOI 10.1007/s10787 019 00642 0
NR 48
TC 0
Z9 0
U1 4
U2 19
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1386 2073
EI 1875 5402
J9 COMB CHEM HIGH T SCR
JI Comb. Chem. High Throughput Screen
PY 2025
VL 28
IS 6
BP 1054
EP 1071
DI 10.2174/0113862073313394240430072032
EA MAY 2024
PG 18
WC Biochemical Research Methods; Chemistry, Applied; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA 2HY9R
UT WOS:001217155200001
PM 38706357
DA 2025 08 17
ER

PT J
AU Dunford, JE
   Rogers, MJ
   Ebetino, FH
   Phipps, RJ
   Coxon, FP
AF Dunford, JE
   Rogers, MJ
   Ebetino, FH
   Phipps, RJ
   Coxon, FP
TI Inhibition of protein prenylation by bisphosphonates causes sustained
   activation of Rac, Cdc42, and Rho GTPases
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE bisphosphonate; prenylation; Rac; Rho; osteoclast; p38
ID NITROGEN CONTAINING BISPHOSPHONATES; FARNESYL DIPHOSPHATE SYNTHASE;
   GTP BINDING PROTEINS; SMOOTH MUSCLE CELLS; BREAST CANCER CELLS;
   IN VITRO; BONE RESORPTION; MEVALONATE PATHWAY; NADPH OXIDASE;
   GERANYLGERANYL TRANSFERASE
AB Introduction: Nitrogen containing bisphosphonates (N BPs) are potent inhibitors of bone resorption that act by inhibiting farnesyl diphosphate synthase, thereby indirectly preventing the prenylation of Rho family GTPases that are required for the function and survival of bone resorbing osteoclasts. However, the effect that these drugs have on the activity of Rho family GTPases has not been determined.
   Materials and Methods: The effect of N BPs on the activity of Rho family GTPases in J774 macrophages and osteoclasts was measured using a pull down assay to isolate the GTP bound forms. The effect of N BPs, or decreasing Rac expression using siRNA, on downstream p38 activity was evaluated by Western blotting and apoptosis assessed by measurement of caspase 3/7 activity.
   Results: Rather than inhibiting GTPase function, loss of prenylation after treatment with N BPs caused an increase in the GTP bound form of Rac, Cdc42, and Rho in J774 cells and osteoclast like cells, which paralleled the rate of accumulation of unprenylated small GTPases. Activation of Rac also occurred with other inhibitors of prenylation of Rho family proteins, such as mevastatin and the geranylgeranyl transferase I inhibitor GGTI 298. The Rac GTP that increased after N BP treatment was newly translated, cytoplasmic unprenylated protein, because it was not labeled with [C 14] mevalonate, and the increase in Rac GTP was prevented by cycloheximide. Furthermore, this unprenylated Rac GTP retained at least part of its functional activity in J774 cells, because it mediated N BP induced activation of p38. Paradoxically, although risedronate induces apoptosis of J774 macrophages by inhibiting protein prenylation, the p38 inhibitor SB203580 enhanced N BP induced apoptosis, suggesting that Rac induced p38 activation partially suppresses the proapoptotic effect of N BPs in these cells.
   Conclusions: N BP drugs may disrupt the function of osteoclasts in vivo and affect other cell types in vitro by inhibiting protein prenylation, thereby causing inappropriate and sustained activation, rather than inhibition, of some small GTPases and their downstream signaling pathways.
C1 Univ Aberdeen, Inst Med Sci, Bone Res Grp, Aberdeen AB25 2ZD, Scotland.
   Procter & Gamble Co, Mason, OH USA.
C3 University of Aberdeen; Procter & Gamble
RP Univ Aberdeen, Inst Med Sci, Bone Res Grp, Aberdeen AB25 2ZD, Scotland.
EM f.p.coxon@abdn.ac.uk
OI Dunford, James/0000 0002 9932 4042; Rogers, Michael/0000 0002 1818 9249
CR Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200
   ANDO S, 1992, J BIOL CHEM, V267, P25709
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264 6021:3480241
   Blair HC, 2005, BIOCHEM BIOPH RES CO, V328, P728, DOI 10.1016/j.bbrc.2004.11.077
   Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742
   Carlucci F, 1997, BBA MOL BASIS DIS, V1360, P203, DOI 10.1016/S0925 4439(96)00077 4
   Chaplet ML, 2004, BIOCHEM J, V384, P591, DOI 10.1042/BJ20040380
   Choi SH, 2004, SMART MATER STRUCT, V13, P38, DOI 10.1088/0964 1726/13/1/005
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Coxon FP, 2005, BONE, V37, P349, DOI 10.1016/j.bone.2005.04.021
   Coxon FP, 2003, CALCIFIED TISSUE INT, V72, P80, DOI 10.1007/s00223 002 2017 2
   Coxon FP, 1998, MOL PHARMACOL, V54, P631
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Di Poï N, 2001, BIOCHEMISTRY US, V40, P10014, DOI 10.1021/bi010289c
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Eom YW, 2001, BIOCHEM BIOPH RES CO, V285, P825, DOI 10.1006/bbrc.2001.5233
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Frith JC, 2003, J BONE MINER RES, V18, P204, DOI 10.1359/jbmr.2003.18.2.204
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Geiszt M, 2001, BIOCHEM J, V355, P851, DOI 10.1042/bj3550851
   Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971
   Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   MCGOWAN NW, 2002, BACTERIAL PROTEIN TO, P147
   Merrell M, 2003, BREAST CANCER RES TR, V81, P231, DOI 10.1023/A:1026126430905
   Molnár G, 2001, BIOCHEMISTRY US, V40, P10542, DOI 10.1021/bi011158e
   Nègre Aminou P, 2002, BIOCHEM PHARMACOL, V64, P1483, DOI 10.1016/S0006 2952(02)01388 6
   Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301
   Nishida S, 2003, LIFE SCI, V73, P2655, DOI 10.1016/S0024 3205(03)00664 7
   Patel TR, 2003, SURGERY, V134, P306, DOI 10.1067/msy.2003.241
   Porter KE, 2004, CARDIOVASC RES, V61, P745, DOI 10.1016/j.cardiores.2003.11.032
   Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   Sawada K, 2002, CANCER RES, V62, P6015
   Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Shipman CM, 1998, CANCER RES, V58, P5294
   Symons M, 2000, CURR BIOL, V10, pR535, DOI 10.1016/S0960 9822(00)00588 1
   Takahashi M, 2002, J CARDIOVASC PHARM, V39, P310, DOI 10.1097/00005344 200202000 00018
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   Vecchione C, 2002, CIRC RES, V91, P173, DOI 10.1161/01.RES.0000028004.76218.B8
   Virtanen SS, 2002, CANCER RES, V62, P2708
NR 48
TC 150
Z9 169
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2006
VL 21
IS 5
BP 684
EP 694
DI 10.1359/JBMR.060118
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 036KC
UT WOS:000237069000004
PM 16734383
OA Bronze
DA 2025 08 17
ER

PT J
AU Sun, XD
   Zhang, RB
   Chen, HG
   Du, XL
   Chen, S
   Huang, JL
   Liu, M
   Xu, M
   Luo, FT
   Jin, M
   Su, N
   Qi, HB
   Yang, J
   Tan, QY
   Zhang, DL
   Ni, ZH
   Liang, S
   Zhang, B
   Chen, D
   Zhang, X
   Luo, LF
   Chen, L
   Xie, YL
AF Sun, Xianding
   Zhang, Ruobin
   Chen, Hangang
   Du, Xiaolan
   Chen, Shuai
   Huang, Junlan
   Liu, Mi
   Xu, Meng
   Luo, Fengtao
   Jin, Min
   Su, Nan
   Qi, Huabing
   Yang, Jing
   Tan, Qiaoyan
   Zhang, Dali
   Ni, Zhenhong
   Liang, Sen
   Zhang, Bin
   Chen, Di
   Zhang, Xin
   Luo, Lingfei
   Chen, Lin
   Xie, Yangli
TI Fgfr3 mutation disrupts chondrogenesis and bone ossification in
   zebrafish model mimicking CATSHL syndrome partially via enhanced
   Wnt/β catenin signaling
SO THERANOSTICS
LA English
DT Article
DE FGFR3; CATSHL syndrome; Zebrafish; Skeletal development;
   Wnt/beta catenin
ID FIBROBLAST GROWTH FACTOR; FACTOR RECEPTOR 3; TALL STATURE; MICE;
   DIFFERENTIATION; EVOLUTION; BRAIN; MASS
AB CATSHL syndrome, characterized by camptodactyly, tall stature and hearing loss, is caused by loss of function mutations of fibroblast growth factor receptors 3 (FGFR3) gene. Most manifestations of patients with CATSHL syndrome start to develop in the embryonic stage, such as skeletal overgrowth, craniofacial abnormalities, however, the pathogenesis of these phenotypes especially the early maldevelopment remains incompletely understood. Furthermore, there are no effective therapeutic targets for this skeleton dysplasia.
   Methods: We generated fgfr3 knockout zebrafish by CRISPR/Cas9 technology to study the developmental mechanisms and therapeutic targets of CATSHL syndrome. Several zebrafish transgenic lines labeling osteoblasts and chondrocytes, and live Alizarin red staining were used to analyze the dynamical skeleton development in fgfr3 mutants. Western blotting, whole mount in situ hybridization, Edu labeling based cell proliferation assay and Wnt/beta catenin signaling antagonist were used to explore the potential mechanisms and therapeutic targets.
   Results: We found that fgfr3 mutant zebrafish, staring from early development stage, showed craniofacial bone malformation with microcephaly and delayed closure of cranial sutures, chondroma like lesion and abnormal development of auditory sensory organs, partially resembling the clinical manifestations of patients with CATSHL syndrome. Further studies showed that fgfr3 regulates the patterning and shaping of pharyngeal arches and the timely ossification of craniofacial skeleton. The abnormal development of pharyngeal arch cartilage is related to the augmented hypertrophy and disordered arrangement of chondrocytes, while decreased proliferation, differentiation and mineralization of osteoblasts may be involved in the delayed maturation of skull bones. Furthermore, we revealed that deficiency of fgfr3 leads to enhanced IHH signaling and up regulated canonical Wnt/beta catenin signaling, and pharmacological inhibition of Wnt/beta catenin could partially alleviate the phenotypes of fgfr3 mutants.
   Conclusions: Our study further reveals some novel phenotypes and underlying developmental mechanism of CATSHL syndrome, which deepens our understanding of the pathogenesis of CATSHL and the role of fgfr3 in skeleton development. Our findings provide evidence that modulation of Wnt/beta catenin activity could be a potential therapy for CATSHL syndrome and related skeleton diseases.
C1 [Sun, Xianding; Zhang, Ruobin; Chen, Hangang; Du, Xiaolan; Chen, Shuai; Huang, Junlan; Liu, Mi; Xu, Meng; Luo, Fengtao; Jin, Min; Su, Nan; Qi, Huabing; Yang, Jing; Tan, Qiaoyan; Zhang, Dali; Ni, Zhenhong; Liang, Sen; Zhang, Bin; Chen, Lin; Xie, Yangli] Army Med Univ, Daping Hosp, State Key Lab Trauma Burns & Combined Injury, Dept Wound Repair & Rehabil Med, Chongqing 400042, Peoples R China.
   [Chen, Di] Chinese Acad Sci, Shenzhen Inst Adv Technol, Res Ctr Human Tissues & Organs Degenerat, Shenzhen 518055, Peoples R China.
   [Zhang, Xin] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
   [Zhang, Xin] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
   [Luo, Lingfei] Southwest Univ, Sch Life Sci, Key Lab Freshwater Fish Reprod & Dev, Minist Educ,Lab Mol Dev Biol, Chongqing 400715, Peoples R China.
C3 Army Medical University; Chinese Academy of Sciences; Shenzhen Institute
   of Advanced Technology, CAS; Columbia University; Columbia University;
   Southwest University   China
RP Luo, LF (通讯作者)，Southwest Univ, Sch Life Sci, 2 Tian Sheng Rd, Chongqing 400715, Peoples R China.; Chen, L; Xie, YL (通讯作者)，Army Med Univ, Daping Hosp, Dept Wound Repair & Rehabil Med, Chongqing 400042, Peoples R China.
EM lluo@swu.edu.cn; linchen70@163.com; xieyangli841015@163.com
RI Luo, Fengtao/E 1236 2017; 谭, 乔燕/HNQ 8742 2023; su, nan/GRS 5213 2022;
   Chen, Di/AAJ 3665 2021; luo, ling/MIO 2796 2025; Jin, Min/KFT 2653 2024;
   zhang, bin/HGB 4369 2022
OI zhang, bin/0000 0002 7097 2011; , tan/0000 0002 8534 4763
FU National Key Research and Development Program of China [2018YFA0800802];
   National Natural Science Foundation of China [81530071, 81830075,
   81772306, 81721001]; Key Program of Innovation Project of Military
   Medical Science [16CXZ016]; Innovative Research Team in University
   [IRT1216]
FX We thank Chung Der Hsiao for the fish lines Tg(osterix:EGFP). We thank
   all the members of Drs. Chen's and Luo's laboratory for technical
   support and fruitful discussions. This work is supported by research
   funding from the National Key Research and Development Program of China
   (2018YFA0800802), the National Natural Science Foundation of China (No.
   81530071, 81830075, 81772306, 81721001), the Key Program of Innovation
   Project of Military Medical Science (16CXZ016) and Innovative Research
   Team in University (IRT1216).
CR Abbas L, 2010, FISH PHYSIOL, V29, P123, DOI 10.1016/S1546 5098(10)02904 3
   Agochukwu NB, 2012, J CRANIOFAC SURG, V23, P664, DOI 10.1097/SCS.0b013e31824db8bb
   Aman AJ, 2018, ELIFE, V7, DOI 10.7554/eLife.37001
   [Anonymous], 2012, J CELL PHYSL
   Anthwal N, 2013, J ANAT, V222, P147, DOI 10.1111/j.1469 7580.2012.01526.x
   Bergen DJM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00006
   Brown LT, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005651
   Buchtova M, 2015, BBA MOL BASIS DIS, V1852, P839, DOI 10.1016/j.bbadis.2014.12.020
   Busse B, 2020, J ORTHOP RES, V38, P925, DOI 10.1002/jor.24539
   Chang NN, 2013, CELL RES, V23, P465, DOI 10.1038/cr.2013.45
   Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690
   Chen L, 2001, HUM MOL GENET, V10, P457, DOI 10.1093/hmg/10.5.457
   Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496 390
   Daane JM, 2016, MOL BIOL EVOL, V33, P162, DOI 10.1093/molbev/msv208
   Dale RM, 2011, DEV BIOL, V357, P518, DOI 10.1016/j.ydbio.2011.06.020
   Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092 8674(00)81069 7
   Deng Q, 2019, ELIFE, V8, DOI 10.7554/eLife.50208
   Di Rocco F, 2014, HUM MOL GENET, V23, P2914, DOI 10.1093/hmg/ddu004
   Escobar LF, 2016, AM J MED GENET A, V170, P1908, DOI 10.1002/ajmg.a.37676
   Foldynova Trantirkova S, 2012, HUM MUTAT, V33, P29, DOI 10.1002/humu.21636
   Hall C, 2006, MECH DEVELOP, V123, P925, DOI 10.1016/j.mod.2006.08.006
   Hamad S, 2019, THERANOSTICS, V9, P7222, DOI 10.7150/thno.32058
   Hammond Chrissy L, 2012, Front Endocrinol (Lausanne), V3, P91, DOI 10.3389/fendo.2012.00091
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Iwata T, 2000, HUM MOL GENET, V9, P1603, DOI 10.1093/hmg/9.11.1603
   Jin M, 2012, CELL BIOL INT, V36, P691, DOI 10.1042/CBI20110352
   JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772
   Kague E, 2016, DEV BIOL, V413, P160, DOI 10.1016/j.ydbio.2016.03.011
   Killion CH, 2017, MOL BIOL CELL, V28, P1862, DOI 10.1091/mbc.E17 02 0084
   Krejci P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035826
   Larbuisson A, 2013, DIFFERENTIATION, V86, P192, DOI 10.1016/j.diff.2013.07.006
   Ledwon JK, 2018, GENE EXPR PATTERNS, V29, P32, DOI 10.1016/j.gep.2018.04.002
   Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35
   Li RB, 2017, DEVELOPMENT, V144, P4563, DOI 10.1242/dev.149443
   Long FX, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008334
   Luderman LN, 2017, CURR TOP DEV BIOL, V124, P81, DOI 10.1016/bs.ctdb.2016.11.004
   Luo FT, 2017, INT J BIOL SCI, V13, P32, DOI 10.7150/ijbs.16287
   Makrythanasis P, 2014, HUM MUTAT, V35, P959, DOI 10.1002/humu.22597
   Matsushita T, 2009, HUM MOL GENET, V18, P227, DOI 10.1093/hmg/ddn339
   Mork L, 2015, CURR TOP DEV BIOL, V115, P235, DOI 10.1016/bs.ctdb.2015.07.001
   Muenke M, 1997, AM J HUM GENET, V60, P555
   Nah HD, 2012, CHILD NERV SYST, V28, P1483, DOI 10.1007/s00381 012 1778 9
   Narayana J, 2015, CONNECT TISSUE RES, V56, P427, DOI 10.3109/03008207.2015.1051224
   Ornitz DM, 2019, CURR TOP DEV BIOL, V133, P195, DOI 10.1016/bs.ctdb.2018.11.020
   Ota S, 2009, MECH DEVELOP, V126, P1, DOI 10.1016/j.mod.2008.10.008
   Renn J, 2013, DEV BIOL, V381, P134, DOI 10.1016/j.ydbio.2013.05.030
   Rohner N, 2009, CURR BIOL, V19, P1642, DOI 10.1016/j.cub.2009.07.065
   Shung CY, 2012, HUM MOL GENET, V21, P4628, DOI 10.1093/hmg/dds305
   Su N, 2016, J BONE MINER RES, V31, P1676, DOI 10.1002/jbmr.2839
   Su N, 2010, HUM MOL GENET, V19, P1199, DOI 10.1093/hmg/ddp590
   Sun X, 2019, J BONE MINER RES
   Sun XD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14169 z
   Topczewska JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165775
   Toydemir RM, 2006, AM J HUM GENET, V79, P935, DOI 10.1086/508433
   Valverde Franco G, 2004, HUM MOL GENET, V13, P271, DOI 10.1093/hmg/ddh034
   van Karnebeek CDM, 2016, NAT GENET, V48, P777, DOI 10.1038/ng.3578
   van Opbergen CJM, 2018, THERANOSTICS, V8, P4750, DOI 10.7150/thno.26108
   Wang XF, 2015, AUTOPHAGY, V11, P1998, DOI 10.1080/15548627.2015.1091551
   Weigele J, 2016, J ANAT, V229, P92, DOI 10.1111/joa.12480
   Weinstein M, 1998, DEVELOPMENT, V125, P3615
   Westerfield M, 2007, ZEBRAFISH BOOK GUIDE
   Zhang YL, 2019, THERANOSTICS, V9, P1387, DOI 10.7150/thno.29761
   Zhang YF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.365
NR 63
TC 26
Z9 27
U1 1
U2 37
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2020
VL 10
IS 16
BP 7111
EP 7130
DI 10.7150/thno.45286
PG 20
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA MG4AK
UT WOS:000545974700006
PM 32641982
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Appelman Dijkstra, NM
   Oei, HLDW
   Vlug, AG
   Winter, EM
AF Appelman Dijkstra, Natasha M.
   Oei, H. Ling D. W.
   Vlug, Annegreet G.
   Winter, Elizabeth M.
TI The effect of osteoporosis treatment on bone mass
SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE osteoporosis; fractures; bone mass; denosumab; romosozumab;
   discontinuation
ID POSTMENOPAUSAL WOMEN; SCLEROSTIN ANTIBODY; MINERAL DENSITY;
   DOUBLE BLIND; TERIPARATIDE TREATMENT; ROMOSOZUMAB TREATMENT;
   MONOCLONAL ANTIBODY; PARATHYROID HORMONE; CYNOMOLGUS MONKEYS;
   CLINICAL TRIAL
AB Over the last two decades there have been significant de velopments in the pharmacotherapy of osteoporosis. The thera peutic arsenal has expanded with monoclonal antibodies which have been developed based on discoveries of the molecular mechanisms underlying bone resorption and bone formation. Denosumab, the antibody binding RANKL, inhibits bone resorp tion, and romosozumab, the antibody binding sclerostin, inhibits bone resorption and stimulates bone formation as well. Both an tibodies have shown potent anti fracture efficacy in randomized clinical trials and this review will discuss the preclinical and clinical studies focusing on the effects on bone mass. After discontinuation of these antibodies, bone mineral density quickly returns to baseline and in the case of denosumab, discontinuation can not only induce rebound bone loss, but also the occurrence of vertebral fractures. Therefore, sequential antiresorptive therapy to maintain bone mass gains and anti fracture efficacy is of utmost importance and will also be discussed in this review. (c) 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).
C1 [Appelman Dijkstra, Natasha M.; Oei, H. Ling D. W.; Vlug, Annegreet G.; Winter, Elizabeth M.] Leiden Univ, Med Ctr, Dept Internal Med, Leiden, Netherlands.
   [Appelman Dijkstra, Natasha M.; Oei, H. Ling D. W.; Vlug, Annegreet G.; Winter, Elizabeth M.] Leiden Univ, Med Ctr, Div Endocrinol, Leiden, Netherlands.
   [Appelman Dijkstra, Natasha M.; Oei, H. Ling D. W.; Vlug, Annegreet G.; Winter, Elizabeth M.] Leiden Univ, Med Ctr, Ctr Bone Qual, Albinusdreef 2, NL 2333 ZA Leiden, Netherlands.
   [Oei, H. Ling D. W.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Oei, H. Ling D. W.; Vlug, Annegreet G.] Jan van Goyen Med Ctr, Dept Internal Med, Amsterdam, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University   Excl LUMC; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University   Excl LUMC; Leiden University; Leiden
   University Medical Center (LUMC); Leiden University   Excl LUMC; Erasmus
   University Rotterdam; Erasmus MC
RP Appelman Dijkstra, NM (通讯作者)，Leiden Univ, Med Ctr, Ctr Bone Qual, Albinusdreef 2, NL 2333 ZA Leiden, Netherlands.
EM n.m.appelman dijkstra@lumc.nl; H.L.D.W.Oei Oei@lumc.nl; avlug@jvg.nl;
   E.M.Winter@lumc.nl
RI Oei, Ling/E 8163 2013; Winter, Elizabeth/ABI 7501 2020;
   Appelman Dijkstra, Natasha/V 7322 2018
OI Appelman Dijkstra, Natasha/0000 0001 5035 127X; 
CR Akaberi S, 2008, AM J TRANSPLANT, V8, P2647, DOI 10.1111/j.1600 6143.2008.02423.x
   Anastasilakis AD, 2021, CALCIFIED TISSUE INT, V108, P587, DOI 10.1007/s00223 020 00785 1
   Anastasilakis AD, 2019, J BONE MINER RES, V34, P2220, DOI 10.1002/jbmr.3853
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007 0711
   Boyce RW, 2017, BONE, V101, P77, DOI 10.1016/j.bone.2017.04.005
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chavassieux P, 2019, J BONE MINER RES, V34, P626, DOI 10.1002/jbmr.3631
   Compston JE, 2007, BONE, V40, P1447, DOI 10.1016/j.bone.2006.09.008
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dempster DW, 2012, CLIN THER, V34, P521, DOI 10.1016/j.clinthera.2012.02.002
   Díez Pérez A, 2019, BONE, V120, P1, DOI 10.1016/j.bone.2018.09.020
   Ding LL, 2020, OSTEOPOROSIS INT, V31, P961, DOI 10.1007/s00198 019 05183 4
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Fassio A, 2019, BONE, V123, P191, DOI 10.1016/j.bone.2019.03.019
   Fu Q., J BONE MINER RES, V36
   Glorieux FH, 2017, J BONE MINER RES, V32, P1496, DOI 10.1002/jbmr.3143
   Gonzalez Rodriguez E, 2020, BREAST CANCER RES TR, V179, P153, DOI 10.1007/s10549 019 05458 8
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hernandez AV, 2019, MATURITAS, V129, P12, DOI 10.1016/j.maturitas.2019.08.003
   Ishibashi H, 2017, BONE, V103, P209, DOI 10.1016/j.bone.2017.07.005
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kendler DL, 2019, OSTEOPOROSIS INT, V30, P2437, DOI 10.1007/s00198 019 05146 9
   Kendler DL, 2018, LANCET, V391, P230, DOI 10.1016/S0140 6736(17)32137 2
   LANDMAN JO, 1995, J CLIN ENDOCR METAB, V80, P3465, DOI 10.1210/jc.80.12.3465
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Lewiecki EM, 2018, J CLIN ENDOCR METAB, V103, P3183, DOI 10.1210/jc.2017 02163
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2014, ENDOCRINOLOGY, V155, P4785, DOI 10.1210/en.2013 1905
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Makras P, 2021, J CLIN ENDOCR METAB, V106, pE4155, DOI 10.1210/clinem/dgab321
   Matheny JB, 2017, CALCIFIED TISSUE INT, V101, P82, DOI 10.1007/s00223 017 0258 3
   McClung MR, 2020, OSTEOPOROSIS INT, V31, P2231, DOI 10.1007/s00198 020 05502 0
   McClung MR, 2017, OSTEOPOROSIS INT, V28, P1723, DOI 10.1007/s00198 017 3919 1
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Meier ME, 2021, J BONE MINER RES, V36, P1729, DOI 10.1002/jbmr.4380
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   Obermayer Pietsch BM, 2008, J BONE MINER RES, V23, P1591, DOI 10.1359/JBMR.080506
   Ominsky MS, 2017, J BONE MINER RES, V32, P788, DOI 10.1002/jbmr.3036
   Ominsky MS, 2015, J BONE MINER RES, V30, P1280, DOI 10.1002/jbmr.2480
   Ominsky MS, 2011, BONE, V49, P162, DOI 10.1016/j.bone.2011.04.001
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Papapoulos SE, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115244
   Papapoulos SE, 2008, BEST PRACT RES CL EN, V22, P831, DOI 10.1016/j.beem.2008.07.001
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Recknor CP, 2015, J BONE MINER RES, V30, P1717, DOI 10.1002/jbmr.2489
   Roux S, 2019, BONE, V120, P482, DOI 10.1016/j.bone.2018.12.012
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Seefried L, 2017, J CLIN INVEST, V127, P2148, DOI 10.1172/JCI83731
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims NA, 2014, CURR OSTEOPOROS REP, V12, P98, DOI 10.1007/s11914 014 0196 1
   Sinningen K, 2012, ENDOCRINE, V42, P52, DOI 10.1007/s12020 012 9696 x
   Solling AS, 2020, J BONE MINER RES, V35, P1858, DOI 10.1002/jbmr.4098
   Tourolle DC, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10494
   Tsourdi E, 2021, J CLIN ENDOCR METAB, V106, P264, DOI 10.1210/clinem/dgaa756
   Wen F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234123
NR 73
TC 13
Z9 14
U1 0
U2 5
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1521 690X
EI 1532 1908
J9 BEST PRACT RES CL EN
JI Best Pract. Res. Clin. Endoc. Metab.
PD MAR
PY 2022
VL 36
IS 2
SI SI
AR 101623
DI 10.1016/j.beem.2022.101623
EA MAR 2022
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 0I0FM
UT WOS:000779104100007
PM 35219602
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Abraham, AK
   Maurer, TS
   Kalgutkar, AS
   Gao, X
   Li, M
   Healy, DR
   Petersen, DN
   Griffith, DA
   Mager, DE
AF Abraham, Anson K.
   Maurer, Tristan S.
   Kalgutkar, Amit S.
   Gao, Xiang
   Li, Mei
   Healy, David R.
   Petersen, Donna N.
   Griffith, David A.
   Mager, Donald E.
TI Pharmacodynamic Model of Parathyroid Hormone Modulation by a Negative
   Allosteric Modulator of the Calcium Sensing Receptor
SO AAPS JOURNAL
LA English
DT Article
DE allosteric; bone; calcium sensing receptor; ionized calcium;
   osteoporosis; parathyroid hormone; pharmacodynamics; pharmacokinetics
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; CA2+ RECEPTOR; IN VIVO;
   SECRETION; OSTEOPOROSIS; RATS; ANTAGONIST; TRIAL; HISTOMORPHOMETRY
AB In this study, a pharmacodynamic model is developed, based on calcium parathyroid hormone (PTH) homeostasis, which describes the concentration effect relationship of a negative allosteric modulator of the calcium sensing receptor (CaR) in rats. Plasma concentrations of drug and PTH were determined from plasma samples obtained via serial jugular vein sampling following single subcutaneous doses of 1, 5, 45, and 150 mg/kg to male Sprague Dawley rats (n = 5/dose). Drug pharmacokinetics was described by a one compartment model with first order absorption and linear elimination. Concentration time profiles of PTH were characterized using a model in which the compound allosterically modulates Ca(+2) binding to the CaR that, in turn, modulates PTH through a precursor pool indirect response model. Additionally, negative feedback was incorporated to account for tolerance observed at higher dose levels. Model fitting and parameter estimation were conducted using the maximum likelihood algorithm. The proposed model well characterized the data and provided compound specific estimates of the K (i) and cooperativity constant (alpha) of 1.47 ng/mL and 0.406, respectively. In addition, the estimated model parameters for PTH turnover were comparable to that previously reported. The final generalized model is capable of characterizing both PTH Ca(+2) homeostasis and the pharmacokinetics and pharmacodynamics associated with the negative allosteric CaR modulator. As such, the model provides a simple platform for analysis of drugs targeting the PTH Ca(+2) system.
C1 [Maurer, Tristan S.; Kalgutkar, Amit S.] Pfizer Inc, Pharmacokinet Pharmacodynam & Metab Dept, Groton, CT 06340 USA.
   [Abraham, Anson K.; Mager, Donald E.] SUNY Buffalo, Dept Pharmaceut Sci, Amherst, NY USA.
   [Gao, Xiang] Pfizer Inc, Clin Pharmacol, New London, CT USA.
   [Li, Mei; Healy, David R.; Petersen, Donna N.] Pfizer Inc, Dept Biol, Healthy Aging Translat Pharmacol, Groton, CT 06340 USA.
   [Griffith, David A.] Pfizer Inc, Dept Chem, Healthy Aging Translat Pharmacol, Groton, CT 06340 USA.
C3 Pfizer; Pfizer USA; State University of New York (SUNY) System;
   University at Buffalo, SUNY; Pfizer; Pfizer USA; Pfizer; Pfizer USA;
   Pfizer; Pfizer USA
RP Maurer, TS (通讯作者)，Pfizer Inc, Pharmacokinet Pharmacodynam & Metab Dept, Eastern Point Rd, Groton, CT 06340 USA.
EM tristan.s.maurer@pfizer.com
OI Maurer, Tristan/0009 0007 2994 1954; Griffith,
   David/0000 0002 7592 2478; Abraham, Anson/0000 0002 9579 7483
FU University at Buffalo Pfizer Strategic Alliance
FX This study was funded, in part, by the University at Buffalo Pfizer
   Strategic Alliance.
CR Abraham AK, 2009, J PHARMACOL EXP THER, V330, P169, DOI 10.1124/jpet.109.152033
   [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
   Arey BJ, 2005, ENDOCRINOLOGY, V146, P2015, DOI 10.1210/en.2004 1318
   Balan G, 2009, BIOORG MED CHEM LETT, V19, P3328, DOI 10.1016/j.bmcl.2009.04.044
   Black DM, 2008, J CLIN ENDOCR METAB, V93, P2166, DOI 10.1210/jc.2007 2781
   Brown E M, 2000, Rev Endocr Metab Disord, V1, P307, DOI 10.1023/A:1026570518919
   BROWN EM, 1983, J CLIN ENDOCR METAB, V56, P572, DOI 10.1210/jcem 56 3 572
   Chattopadhyay N, 2000, INT J BIOCHEM CELL B, V32, P789, DOI 10.1016/S1357 2725(00)00031 5
   Chen RA, 2004, AM J PHYSIOL RENAL, V286, pF1005, DOI 10.1152/ajprenal.00013.2004
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   D'Argenio DZ., 1997, ADAPT II user's guide, DOI DOI 10.1182/blood 2004 02 0414
   DAUGAARD H, 1990, KIDNEY INT, V38, P55, DOI 10.1038/ki.1990.166
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   EHLERT FJ, 1988, MOL PHARMACOL, V33, P187
   Friedman P.A., 2006, GOODMAN GILMANS PHAR, V11th
   Friedman PA, 2006, AM J PHYSIOL RENAL, V290, pF975, DOI 10.1152/ajprenal.00336.2005
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038
   Hu JX, 2001, J BIOL CHEM, V276, P6901, DOI 10.1074/jbc.C000865200
   JUPPNER HW, 2001, ENDOCRINOLOGY, P969
   Kenakin T, 2004, MOL INTERV, V4, P222, DOI 10.1124/mi.4.4.6
   KENAKIN T, 2006, ALLOSTERIC DRUG ANTA, P127
   Kumar S, 2010, BONE, V46, P534, DOI 10.1016/j.bone.2009.09.028
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Lotinun S, 2002, ENDOCRINE, V17, P29, DOI 10.1385/ENDO:17:1:29
   Marquis RW, 2009, J MED CHEM, V52, P6599, DOI 10.1021/jm900563e
   Marquis RW, 2009, J MED CHEM, V52, P3982, DOI 10.1021/jm900364m
   MARTIN KJ, 1977, J CLIN INVEST, V60, P808, DOI 10.1172/JCI108834
   Momsen G, 1997, SCAND J CLIN LAB INV, V57, P381, DOI 10.3109/00365519709084585
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323
   Nemeth EF, 2002, CURR PHARM DESIGN, V8, P2077, DOI 10.2174/1381612023393387
   Ostrowska Z, 2002, NEUROENDOCRINOL LETT, V23, P417
   Raposo JF, 2002, J CLIN ENDOCR METAB, V87, P4330, DOI 10.1210/jc.2002 011870
   REEVE J, 1980, BMJ BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340
   REEVE J, 1976, CALC TISS RES, V21, P469
   Sharma A, 1998, J PHARM SCI, V87, P1577, DOI 10.1021/js980171q
   Tarantino Umberto, 2007, Aging Clin Exp Res, V19, P7
   1997, Patent No. 9737967
NR 39
TC 9
Z9 12
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1550 7416
J9 AAPS J
JI AAPS J.
PD JUN
PY 2011
VL 13
IS 2
BP 265
EP 273
DI 10.1208/s12248 011 9266 9
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 758LG
UT WOS:000290165700013
PM 21437757
OA Green Published
DA 2025 08 17
ER

PT J
AU Yang, L
   Wu, Z
   Yin, G
   Liu, HF
   Guan, XJ
   Zhao, XQ
   Wang, JG
   Zhu, JG
AF Yang, Lei
   Wu, Zhong
   Yin, Gang
   Liu, Haifeng
   Guan, Xiaojun
   Zhao, Xiaoqiang
   Wang, Jianguang
   Zhu, Jianguo
TI Stem cell factor (SCF) protects osteoblasts from oxidative stress
   through activating c Kit Akt signaling
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoblasts; Oxidative stress; Stem cell factor; c Kit; Akt
ID TYROSINE KINASE; SURVIVAL; PHOSPHORYLATION; TRANSDUCTION; INHIBITOR;
   INDUCTION; APOPTOSIS; PATHWAY; AMPK
AB Osteoblasts regulate bone formation and remodeling, and are main target cells of oxidative stress in the progression of osteonecrosis. The stem cell factor (SCF) c Kit pathway plays important roles in the proliferation, differentiation and survival in a range of cell types, but little is known about its functions in osteoblasts. In this study, we found that c Kit is functionally expressed in both osteoblastic like MC3T3 E1 cells and primary murine osteoblasts. Its ligand SCF exerted significant cyto protective effects against hydrogen peroxide (H2O2). SCF activated its receptor c Kit in osteoblasts, which was required for its cyto protective effects against H2O2. Pharmacological inhibition (by Imatinib and Dasatinib) or shRNA mediated knockdown of c Kit thus inhibited SCF mediated osteoblast protection. Further investigations showed that protection by SCF against H2O2 was mediated via activation of c Kit dependent Ala pathway. Inhibition of Akt activation, through pharmacological or genetic means, suppressed SCF mediated anti H2O2 activity in osteoblasts. In summary, we have identified a new SCF c Kit Akt physiologic pathway that protects osteoblasts from H2O2 induced damages, and might minimize the risk of osteonecrosis caused by oxidative stress. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Yang, Lei; Yin, Gang; Liu, Haifeng; Guan, Xiaojun; Zhao, Xiaoqiang; Zhu, Jianguo] Jiangsu Univ, Affiliated Hosp, Dept Orthoped, Changzhou Wujin Peoples Hosp South Div, Changzhou, Peoples R China.
   [Wu, Zhong; Wang, Jianguang] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Orthoped, Shanghai 200072, Peoples R China.
C3 Jiangsu University; Tongji University
RP Wang, JG (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Orthoped, Shanghai 200072, Peoples R China.
EM jianguangwang@163.com; gehujianguo68@l63.com
RI Zhao, Xiao Qiang/AEJ 6707 2022
FU Natural Science Foundation of Shanghai City
FX This work is partly supported by the Natural Science Foundation of
   Shanghai City.
CR Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085
   Blume Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960 9822(98)70302 1
   Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
   CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0
   Chang CC, 2006, J ORTHOP RES, V24, P1917, DOI 10.1002/jor.20244
   Edling CE, 2007, INT J BIOCHEM CELL B, V39, P1995, DOI 10.1016/j.biocel.2006.12.005
   Fan JB, 2014, BIOCHEM BIOPH RES CO, V447, P425, DOI 10.1016/j.bbrc.2014.04.002
   Möller C, 2005, BLOOD, V106, P1330, DOI 10.1182/blood 2004 12 4792
   Park YH, 2003, CELL BIOL TOXICOL, V19, P325, DOI 10.1023/B:CBTO.0000004986.51081.c5
   Rönnstrand L, 2004, CELL MOL LIFE SCI, V61, P2535, DOI 10.1007/s00018 004 4189 6
   Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008 5472.CAN 05 2050
   Schrans Stassen BHGJ, 1999, ENDOCRINOLOGY, V140, P5894, DOI 10.1210/en.140.12.5894
   SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460 2075.1995.tb07023.x
   She C, 2014, CELL SIGNAL, V26, P1, DOI 10.1016/j.cellsig.2013.08.046
   Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582 4934.2005.tb00337.x
   Zecevic A, 2009, CELL CYCLE, V8, P2769, DOI 10.4161/cc.8.17.9410
   Zhu YL, 2014, INT J MOL SCI, V15, P11190, DOI 10.3390/ijms150611190
NR 17
TC 22
Z9 24
U1 1
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 12
PY 2014
VL 455
IS 3 4
BP 256
EP 261
DI 10.1016/j.bbrc.2014.11.002
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AX4CP
UT WOS:000346881900021
PM 25449280
DA 2025 08 17
ER

PT J
AU Chen, Q
   Hu, CY
   Liu, YM
   Song, R
   Zhu, WJ
   Zhao, HX
   Nino, A
   Zhang, F
   Liu, Y
AF Chen, Qian
   Hu, Chaoying
   Liu, Yanmei
   Song, Rong
   Zhu, Wenjing
   Zhao, Hongxin
   Nino, Antonio
   Zhang, Fan
   Liu, Yun
TI Pharmacokinetics, pharmacodynamics, safety, and tolerability of
   single dose denosumab in healthy Chinese volunteers: A randomized,
   single blind, placebo controlled study
SO PLOS ONE
LA English
DT Article
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; THERAPY;
   CANCER; METAANALYSIS; ALENDRONATE; METASTASES; PREVENTION; FRACTURES
AB Background
   Denosumab is a fully human monoclonal antibody against receptor activator of nuclear factor kappa B ligand, a cytokine essential for the formation, function and survival of osteoclasts. This study assessed the pharmacokinetics, pharmacodynamics, safety and tolerability of single dose denosumab (60 and 120 mg) in healthy Chinese volunteers.
   Methods
   This randomized (3:3:2), single blind, placebo controlled study enrolled healthy Chinese volunteers to receive single subcutaneous injection of denosumab 60 mg, 120 mg, or placebo. Study consisted of screening period (up to 21 days), treatment and assessment period (19 weeks), and an end of study visit (at week 26). Denosumab pharmacokinetics and pharmacodynamics parameters were estimated using non compartmental analysis. Safety and tolerability were assessed throughout the study.
   Results
   A total of 63 volunteers received the study treatment and 62 (98.4%) completed the study. Denosumab serum concentrations peaked at around Day 10 with dose proportional increase from 60 mg to 120 mg. The mean terminal half life of denosumab 60 mg and 120 mg was 15 days and 26 days, respectively. The serum C terminal cross linking telopeptide of type I collagen concentration time profiles were similar (>80% decrease within 5 days) between denosumab 60 mg and 120 mg groups. The most commonly reported adverse event (AE) was decreased blood calcium levels (denosumab 60 mg, n = 13; denosumab 120 mg, n = 13; placebo, n = 1); however only one volunteer had calcium level below the abnormality value of potential clinical importance and none of the volunteers developed symptoms of hypocalcemia. The majority of AEs were of mild to moderate intensity. There were no deaths, serious AEs, or withdrawal from study due to AEs. No clinically significant findings in vital signs or electrocardiogram were observed.
   Conclusions
   Both denosumab 60 mg and 120 mg were well tolerated with no new safety concerns identified in healthy Chinese volunteers with similar pharmacokinetics and pharmacodynamics profiles to that of Caucasians.
C1 [Chen, Qian; Hu, Chaoying; Liu, Yanmei; Song, Rong; Liu, Yun] Chinese Acad Sci, Shanghai Xuhui Cent Hosp, Cent Lab, Shanghai, Peoples R China.
   [Chen, Qian; Hu, Chaoying; Liu, Yanmei; Song, Rong; Liu, Yun] Chinese Acad Sci, Shanghai Clin Ctr, Shanghai, Peoples R China.
   [Zhu, Wenjing; Zhao, Hongxin] GlaxoSmithKline China R&D Co Ltd, China Med, Shanghai, Peoples R China.
   [Nino, Antonio] GlaxoSmithKline, Metab Pathways & Cardiovasc Therapeut Area Unit, Collegeville, PA USA.
   [Zhang, Fan] GlaxoSmithKline China R&D Co Ltd, Clin Pharmacol Modelling & Simulat, Shanghai, Peoples R China.
C3 Chinese Academy of Sciences; Chinese Academy of Sciences;
   GlaxoSmithKline; Glaxosmithkline China; GlaxoSmithKline; Glaxosmithkline
   USA; GlaxoSmithKline; Glaxosmithkline China
RP Liu, Y (通讯作者)，Chinese Acad Sci, Shanghai Xuhui Cent Hosp, Cent Lab, Shanghai, Peoples R China.; Liu, Y (通讯作者)，Chinese Acad Sci, Shanghai Clin Ctr, Shanghai, Peoples R China.
EM yliu@shxh centerlab.com
RI Liu, Yun/Q 1757 2019; Zhu, Wen/KIA 0726 2024; Zhao,
   Hongxin/AAX 8169 2020
OI Zhao, Hongxin/0000 0001 7906 2797
FU GlaxoSmithKline (China) R&D Company Limited, Shanghai, China
FX Funding for this study was provided by GlaxoSmithKline (China) R&D
   Company Limited, Shanghai, China. The funder provided support in the
   form of salaries for authors WZ, HZ and FZ, but did not have any
   additional role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. The specific
   roles of these authors are articulated in the "author contributions"
   section.Medical writing support was provided by Pravin Bolshete (Tata
   Consultancy Services, India) and was funded by GlaxoSmithKline (China)
   R&D Company Limited, Shanghai, China.
CR Amgen Canada Inc, 2016, PROL DEN SOL INJ SOL
   [Anonymous], 2015, PROL DEN INJ PRESCR
   [Anonymous], 2014, XGEV DEN INJ SUMM OP
   [Anonymous], 2015, XGEV DEN INJ PRESCR
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Delmas PD, 2008, J CLIN DENSITOM, V11, P325, DOI 10.1016/j.jocd.2008.02.002
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Kumagai Y, 2011, BONE, V49, P1101, DOI 10.1016/j.bone.2011.08.007
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   McClung MR, 2012, J BONE MINER RES, V27, P211, DOI 10.1002/jbmr.536
   Miller PD, 2011, J CLIN ENDOCR METAB, V96, P394, DOI 10.1210/jc.2010 1805
   Nakamura T, 2012, OSTEOPOROSIS INT, V23, P1131, DOI 10.1007/s00198 011 1786 8
   Nakamura T, 2014, J CLIN ENDOCR METAB, V99, P2599, DOI 10.1210/jc.2013 4175
   Peddi P, 2013, CANCER TREAT REV, V39, P97, DOI 10.1016/j.ctrv.2012.07.002
   Pitale Shailesh, 2015, Indian J Endocrinol Metab, V19, P148, DOI 10.4103/2230 8210.146871
   Recknor C, 2013, OBSTET GYNECOL, V121, P1291, DOI 10.1097/AOG.0b013e318291718c
   Scott LJ, 2014, DRUG AGING, V31, P555, DOI 10.1007/s40266 014 0191 3
   Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81
   Smith MR, 2009, J UROLOGY, V182, P2670, DOI 10.1016/j.juro.2009.08.048
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Sun L, 2013, AM J CLIN ONCOL CANC, V36, P399, DOI 10.1097/COC.0b013e31824be20e
   Wang ZY, 2015, ONCOLOGIST, V20, P440, DOI 10.1634/theoncologist.2014 0328
NR 26
TC 27
Z9 29
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 22
PY 2018
VL 13
IS 6
AR e0197984
DI 10.1371/journal.pone.0197984
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GK3VI
UT WOS:000436076600005
PM 29933364
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Matsumoto, C
   Takita, M
   Inada, M
   Maruyama, T
   Miyaura, C
AF Matsumoto, Chiho
   Takita, Morichika
   Inada, Masaki
   Maruyama, Takayuki
   Miyaura, Chisato
TI Prostaglandin E receptor EP4 antagonist suppresses
   lipopolysaccharide induced osteoclast formation and inflammatory bone
   loss
SO JOURNAL OF HEALTH SCIENCE
LA English
DT Article
DE prostaglandin E; EP4 receptor; bone resorption; inflammation;
   periodontitis
ID E 2 BIOSYNTHESIS; E SYNTHASE; RESORPTION; IDENTIFICATION; ACTIVATION;
   DIFFERENTIATION; LIGAND
AB Prostaglandin E 2 (PGE(2)) is mainly produced by osteoblasts in bone tissue, and acts as a potent stimulator of bone resorption. In osteoblasts, PGE(2) production was greatly stimulated by lipopolysaccharide (LPS) following the expression of cyclooxygenase (COX) 2 and membrane bound PGE synthase (mPGES) 1 mRNA. In the coculture of mouse bone marrow cells and osteoblasts, LPS induced PGE production and osteoclast formation, and EP4 antagonist completely suppressed osteoclast formation, indicating that the PGE(2) mediated EP4 signal is essential for LPS induced osteoclast formation. Inflammatory bone diseases including periodontitis are known to be accompanied by bone loss with increased osteoclastogenesis. To examine the role of EP4 mediated PGE(2) action in periodontitis, we examined the effects of EP4 antagonist on LPS induced bone resorption using mouse alveolar bone. In an organ culture of alveolar bone, LPS induced bone resorbing activity and EP4 antagonist suppressed this LPS induced bone resorption. In an experimental model of periodontitis, LPS was injected into the lower gingiva, and the bone mineral density of alveolar bone was measured. LPS induced the loss of alveolar bone, which was recovered by the treatment with EP4 antagonist in vivo. Therefore, EP4 antagonist is a possible candidate for the therapy of inflammatory bone disease including periodontitis.
C1 Tokyo & Univ Agr & Technol, Dept Biotechnol & Life Sci, Koganei, Tokyo 1848588, Japan.
   Ono Pharmaceut Co Ltd, Minase Res Inst, Discovery Res Labs 1, Shimamoto, Osaka, Japan.
C3 Tokyo University of Agriculture & Technology; Ono Pharmaceutical Co Ltd
RP Miyaura, C (通讯作者)，Tokyo & Univ Agr & Technol, Dept Biotechnol & Life Sci, 2 24 16 Nakamachi, Koganei, Tokyo 1848588, Japan.
EM miyaura@cc.tuat.ac.jp
RI Takita, Morichika/I 2927 2019; miyaura, chisato/D 1864 2013; inada,
   masaki/D 1581 2013
OI inada, masaki/0000 0002 5066 8506
CR Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Inada M, 2006, J IMMUNOL, V177, P1879, DOI 10.4049/jimmunol.177.3.1879
   Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220
   KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005 2760(93)90003 R
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015
   Miyaura C, 2000, J BIOL CHEM, V275, P19819, DOI 10.1074/jbc.M002079200
   Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200
   Salvi GE, 2005, CURR PHARM DESIGN, V11, P1757, DOI 10.2174/1381612053764878
   Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065 2776(08)60430 7
   Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074 7613(00)80119 3
   Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531
   Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200
   USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929 7855(95)00022 I
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 18
TC 0
Z9 0
U1 0
U2 2
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 201 SHIBUYA, SHIBUYA KU, TOKYO, 150, JAPAN
SN 1344 9702
J9 J HEALTH SCI
JI J. Health Sci.
PD APR
PY 2007
VL 53
IS 2
BP 234
EP 239
DI 10.1248/jhs.53.234
PG 6
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA 166OC
UT WOS:000246387400014
OA Bronze
DA 2025 08 17
ER

PT J
AU Hong, GJ
   Zhou, L
   Han, XR
   Sun, P
   Chen, ZQ
   He, W
   Tickner, J
   Chen, LL
   Shi, XG
   Xu, JK
AF Hong, Guoju
   Zhou, Lin
   Han, Xiaorui
   Sun, Ping
   Chen, Zhenqiu
   He, Wei
   Tickner, Jennifer
   Chen, Leilei
   Shi, Xuguang
   Xu, Jiake
TI Asiatic Acid Inhibits OVX Induced Osteoporosis and Osteoclastogenesis
   Via Regulating RANKL Mediated NF κb and Nfatc1 Signaling Pathways
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE asiatic acid; osteoclast; RANKL; bone resorption; osteoporosis
ID NUCLEAR FACTOR; DIFFERENTIATION; CELLS; ACTIVATION; SURVIVAL; ERK
AB Asiatic acid is a triterpenoid compound extracted from a medicinal plant Centella asiatica. It has been used as a highly efficient compound for the treatment of cancer and hyperlipidemia, as well as possessing potential antiinflammatory properties. However, its effects on bone metabolism and osteoporosis haven't been reported. The purpose of our research were to reveal the biomolecular effects of asiatic acid on osteoclasts, and its underlying molecular mechanisms regulating its effects on receptor activator of NF kappa B ligand (RANKL) induced signaling pathways. We found that asiatic acid inhibited multinucleated tartrate resistant acid phosphatase (TRAcP) positive osteoclast differentiation and osteoclast induced bone loss. Real time PCR showed that asiatic acid reduced the expression of down cascade target genes including Ctsk, Nfatc1, Calcr, and Atp6v0d2. Western blot and luciferase reporter gene assays revealed that asiatic acid inhibits RANKL mediated NF kappa B and NFATc1 signalings. Further, in vivo study demonstrated asiatic acid attenuates estrogen deficiency induced bone loss in ovariectomized mice. MicroCT and histology analyses revealed that osteoclast numbers were significantly suppressed in asiatic acid treated groups. Furthermore, serum levels of TRAcP and CTX 1 were downregulated in treated groups. Taken together, our data show that asiatic acid can inhibit osteoclastic formation and reduce OVX induced bone resorption through RANKL activated NF kappa B or NFATc1 signaling, suggesting that asiatic acid may be a potential and effective natural compound for the therapy of excessive RANKL related osteolytic diseases.
C1 [Hong, Guoju; Chen, Zhenqiu; He, Wei; Chen, Leilei] Guangzhou Univ Chinese Med, Natl Key Discipline & Orthoped Lab, Guangzhou, Peoples R China.
   [Hong, Guoju; Zhou, Lin; Tickner, Jennifer; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Zhou, Lin] Guangzhou Med Univ, Dept Endocrinol, Affiliated Hosp 5, Guangzhou, Peoples R China.
   [Han, Xiaorui] South China Univ Technol, Sch Med, Guangzhou, Peoples R China.
   [Sun, Ping] Guangdong Pharmaceut Univ, Dept Orthoped, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Chen, Zhenqiu; He, Wei; Chen, Leilei] Guangzhou Univ Chinese Med, Dept Orthoped, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Shi, Xuguang] Guangzhou Univ Chinese Med, Coll Chinese Mat Med, Guangzhou, Peoples R China.
   [Hong, Guoju] Univ Alberta, Fac Med & Dent, Div Orthoped Surg, Edmonton, AB, Canada.
C3 Guangzhou University of Chinese Medicine; University of Western
   Australia; Guangzhou Medical University; South China University of
   Technology; Guangdong Pharmaceutical University; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; University
   of Alberta
RP Chen, LL (通讯作者)，Guangzhou Univ Chinese Med, Natl Key Discipline & Orthoped Lab, Guangzhou, Peoples R China.; Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.; Chen, LL (通讯作者)，Guangzhou Univ Chinese Med, Dept Orthoped, Affiliated Hosp 1, Guangzhou, Peoples R China.; Shi, XG (通讯作者)，Guangzhou Univ Chinese Med, Coll Chinese Mat Med, Guangzhou, Peoples R China.
EM yutian_1010@sina.com; sxg6902@126.com; jiake.xu@uwa.edu.au
RI ; Hong, Guoju/AAV 9433 2020; He, Wei/HTT 0020 2023; Tickner,
   Jennifer/H 5965 2014
OI Xu, Jiake/0000 0003 2021 8309; Tickner, Jennifer/0000 0002 5020 0671
FU Australian Health and Medical Research Council [APP1107828, APP1163933,
   APP1127156]; National Natural Science Foundation of China [81673999,
   81704098]; Guangdong Natural Science Funds for Distinguished Young
   Scholars [2015A030306037]; Science and Technology Planning Project of
   Guangdong Province [2014A020221114]
FX This study was supported by grants from Australian Health and Medical
   Research Council: APP1107828, APP1163933, APP1127156; National Natural
   Science Foundation of China: 81673999, 81704098; Guangdong Natural
   Science Funds for Distinguished Young Scholars: 2015A030306037; Science
   and Technology Planning Project of Guangdong Province: 2014A020221114.
   GH was a visiting scholar to UWA.
CR Baud'huin M, 2007, EXPERT REV ANTICANC, V7, P221, DOI 10.1586/14737140.7.2.221
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Caetano Lopes J, 2007, ACTA REUMATOL PORT, V32, P103
   Chen JY, 2014, ASIAN PAC J CANCER P, V15, P963, DOI 10.7314/APJCP.2014.15.2.963
   Fong LY, 2016, PHYTOMEDICINE, V23, P191, DOI 10.1016/j.phymed.2015.11.019
   Goltzman D, 2001, J CLIN INVEST, V107, P1219, DOI 10.1172/JCI13073
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Kajiya H, 2012, ADV EXP MED BIOL, V740, P917, DOI 10.1007/978 94 007 2888 2_41
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955 0674(99)80030 1
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Park JH, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974 017 1009 0
   Qian YS, 2018, FOOD FUNCT, V9, P1048, DOI [10.1039/c7fo01442b, 10.1039/C7FO01442B]
   Ren L, 2016, PHARM BIOL, V54, P2377, DOI 10.3109/13880209.2016.1156709
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Xu XH, 2015, J THORAC DIS, V7, P1787, DOI 10.3978/j.issn.2072 1439.2015.10.41
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 27
TC 26
Z9 27
U1 0
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 27
PY 2020
VL 11
AR 331
DI 10.3389/fphar.2020.00331
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA LC9GD
UT WOS:000525640200001
PM 32292339
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Stoffel, ST
   von Moos, R
   Thurlimann, B
   Cathomas, R
   Gillessen, S
   Zurrer Hardi, U
   von Briel, T
   Anchisi, S
   Feller, A
   Schar, C
   Dietrich, D
   Schwenkglenks, M
   Lupatsch, JE
   Mark, M
AF Stoffel, Sandro T.
   von Moos, Roger
   Thurlimann, Beat
   Cathomas, Richard
   Gillessen, Silke
   Zurrer Hardi, Ursina
   von Briel, Thomas
   Anchisi, Sandro
   Feller, Anita
   Schar, Corinne
   Dietrich, Daniel
   Schwenkglenks, Matthias
   Lupatsch, Judith E.
   Mark, Michael
TI Patterns of care and economic consequences of using bone targeted agents
   for castration sensitive prostate cancer patients with bone metastases
   to prevent skeletal related events in Switzerland   the SAKK 95/16
   prostate study
SO SWISS MEDICAL WEEKLY
LA English
DT Article
DE bone targeting agents; castration sensitive prostate cancer; patterns of
   care; economic consequences; health economic analysis
ID RADICAL PROSTATECTOMY; ZOLEDRONIC ACID; NATURAL HISTORY; MANAGEMENT;
   DENOSUMAB; PROGRESSION; ANTIGEN; DISEASE; HEALTH; MEN
AB BACKGROUND: International guidelines state that bone targeted agents such as denosumab or zoledronic acid at doses used for bone metastasis are not indicated for patients with metastatic castration sensitive prostate cancer (mCSPC) with bone metastases. Whereas denosumab has never been studied in this patient population, zoledronic acid has been shown to be ineffective in decreasing the risk for skeletal related events. This study estimates the prevalence and economic consequences of real world use of bone targeted agents for mCSPC patients in Switzerland.
   METHODS: To estimate the frequency of bone targeted agent administration and skeletal related events, data from a non interventional, cross sectional survey involving oncologists across Switzerland (SAKK 95/16) was combined with data from the Swiss National Institute for Cancer Epidemiology and Registration (NICER). Economic parameters were calculated from the perspective of the healthcare system over the median time to prostate specific antigen (PSA) progression for the extrapolated patient group, using data from NICER. The cost calculation covered costs for bone targeted agents, their administration and skeletal related events. The time to PSA progression (33.2 months), as well as the probability and cost of skeletal related events were derived from the literature.
   RESULTS: The survey was answered by 86 physicians treating 417 patients, of whom 106 (25.4%) had prostate cancer, with 36 (34.0%) of these mCSPC. The majority of mCSPC patients (52.8%, n = 19) received bone targeted agents monthly. Denosumab was the treatment of choice in 84.2% of patients (n = 16). Extrapolation using data from NICER indicated that 568 mCSPC patients may be treated with bone targeted agents at doses used for bone metastasis every year in Switzerland, leading to estimated total costs of more than CHF 8.3 million over 33.2 months. Because of its more frequent prescription and higher price, it appears that almost 93% of the total costs can be attributed to denosumab. For both denosumab and zoledronic acid, the most expensive components were the cost of administration and the drug cost, making up more than 90% of the total costs, with the rest being costs of skeletal related events.
   CONCLUSIONS: This study found that the administration of bone targeted agents in doses used for bone metastatic diseases to prevent skeletal related events is frequent in the setting of mCSPC and results in significant costs for the healthcare system.
C1 [Stoffel, Sandro T.; Schwenkglenks, Matthias; Lupatsch, Judith E.] Univ Basel, Inst Pharmaceut Med, Basel, Switzerland.
   [Stoffel, Sandro T.; Schar, Corinne; Dietrich, Daniel; Lupatsch, Judith E.] Swiss Grp Clin Canc Res SAKK Coordinating Ctr, Bern, Switzerland.
   [von Moos, Roger; Cathomas, Richard; Mark, Michael] Kantonsspital Graubunden, Dept Haematol Oncol, Chur, Switzerland.
   [Thurlimann, Beat] Kantonsspital St Gallen, St Gallen, Switzerland.
   [Gillessen, Silke] EOC Ist Oncol Svizzera Italiana, Bellinzona, Switzerland.
   [Zurrer Hardi, Ursina] Kantonsspital Winterthur, Winterthur, Switzerland.
   [von Briel, Thomas] Klin Hirslanden, Zurich, Switzerland.
   [Anchisi, Sandro] Hop Valais, Sion, Switzerland.
   [Feller, Anita] Univ Zurich, Fdn Natl Inst Canc Epidemiol & Registrat NICER, Zurich, Switzerland.
   [Feller, Anita] Univ Zurich, Natl Agcy Canc Registrat, NICER, Zurich, Switzerland.
C3 University of Basel; Swiss School of Public Health (SSPH+);
   Kantonsspital Graubunden; University of Zurich; University of Zurich
RP Mark, M (通讯作者)，Kantonsspital Graubunden, Loestr 170, CH 7000 Chur, Switzerland.
EM michael.mark@ks gr.ch
RI Gillessen, Silke/C 6093 2019; Cathomas, Richard/LEN 0672 2024; von Moos,
   Roger/AAG 4570 2020
OI Gillessen, Silke/0000 0001 5746 6555; Feller, Anita/0000 0002 3837 8477;
   Schwenkglenks, Matthias/0000 0001 7217 1173; Stoffel, Sandro
   Tiziano/0000 0002 0124 0941
FU Amgen
FX This study was sponsored by Amgen. The funding agreement ensured the
   authors' independence in designing the study, interpreting the data,
   writing, and publishing the report.
CR [Anonymous], SWISSMEDIC J
   [Anonymous], SWISSMEDIC J
   Antonarakis ES, 2012, BJU INT, V109, P32, DOI 10.1111/j.1464 410X.2011.10422.x
   Body JJ, 2012, EXPERT REV ANTICANC, V12, P307, DOI [10.1586/ERA.11.204, 10.1586/era.11.204]
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Davis ID, 2019, NEW ENGL J MED, V381, P121, DOI 10.1056/NEJMoa1903835
   European Medicines Agency, ZOM ZOL AC SUMM PROD
   European Medicines Agency, XGEVA DEN SUMM PROD
   Fizazi K, 2012, ANN ONCOL, V23, P309
   Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Hegemann M, 2017, THER ADV UROL, V9, P81, DOI 10.1177/1756287216686018
   Hofmarcher T, 2020, EUR J CANCER, V129, P41, DOI 10.1016/j.ejca.2020.01.011
   Horwich A, 2013, ANN ONCOL, V24, P1141, DOI 10.1093/annonc/mds624
   James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140 6736(15)01037 5
   Mark M, 2020, J BONE ONCOL, V21, DOI 10.1016/j.jbo.2019.100273
   Miksad RA, 2011, ONCOLOGIST, V16, P121, DOI 10.1634/theoncologist.2010 0183
   Moul JW, 2002, SURGERY, V132, P213, DOI 10.1067/msy.2002.125315
   Najm MS, 2014, ORAL DIS, V20, P94, DOI 10.1111/odi.12080
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Organisation for Economic Co operation and Development, PURCH POW PAR PPP
   Parker C, 2020, ANN ONCOL, V31, P1119, DOI 10.1016/j.annonc.2020.06.011
   Pound CR, 1999, JAMA J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591
   Rothermund C, 2012, ZULASSUNG DENOSUMAB
   Saylor PJ, 2020, J CLIN ONCOL, V38, P1736, DOI 10.1200/JCO.19.03148
   Smith MR, 2014, J CLIN ONCOL, V32, P1143, DOI 10.1200/JCO.2013.51.6500
   Smith MR, 2009, J UROLOGY, V182, P2670, DOI 10.1016/j.juro.2009.08.048
   So A, 2012, CUAJ CAN UROL ASSOC, V6, P465, DOI [10.5489/cuaj.12149, 10.5489/cuaj.117]
   Swiss Federal Office of Public Health, 2019, SPEC LIST
   Tarmed Suisse Online browser, 2020, TARM LIST
   US Bureau of Labor Statistics, CPI INFL CALC
   Wang ZY, 2015, ONCOLOGIST, V20, P440, DOI 10.1634/theoncologist.2014 0328
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
   Yee AJ, 2012, CLIN INTERV AGING, V7, P331, DOI 10.2147/CIA.S14566
NR 34
TC 7
Z9 7
U1 0
U2 2
PU SMW supporting association
PI Basel
PA Tragerverein Swiss Medical Weekly, Malzgasse 15, Basel, SWITZERLAND
SN 1424 7860
EI 1424 3997
J9 SWISS MED WKLY
JI Swiss Med. Wkly.
PD MAR 1
PY 2021
VL 151
AR w20464
DI 10.4414/smw.2021.20464
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA QX0PJ
UT WOS:000629052400003
PM 33705559
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Sánchez, JF
   Ramtani, S
   Boucetta, A
   Velasco, MA
   Vaca González, JJ
   Duque Daza, CA
   Garzón Alvarado, DA
AF Sanchez, Juan Felipe
   Ramtani, Salah
   Boucetta, Abdelkader
   Velasco, Marco Antonio
   Vaca Gonzalez, Juan Jairo
   Duque Daza, Carlos A.
   Garzon Alvarado, Diego A.
TI Is Tumor Growth Influenced by the Bone Remodeling Process?
SO JOURNAL OF COMPUTATIONAL BIOLOGY
LA English
DT Article
DE bone remodeling; tumor; coupling tumor bone; Komarovar's model;
   osteoclasts; osteoblasts
ID HORMONE RELATED PROTEIN; BREAST CANCER; PROSTATE CANCER; SKELETAL
   METASTASES; MATHEMATICAL MODEL; RECEPTOR ACTIVATOR; CLINICAL FEATURES;
   TGF BETA; THERAPY; MECHANISMS
AB In this study, we develop a comprehensive model to investigate the intricate relationship between the bone remodeling process, tumor growth, and bone diseases such as multiple myeloma. By analyzing different scenarios within the Basic Multicellular Unit, we uncover the dynamic interplay between remodeling and tumor progression. The model developed developed in the paper are based on the well accepted Komarova's and Ayati's models for the bone remodeling process, then these models were modified to include the effects of the tumor growth. Our in silico experiments yield results consistent with existing literature, providing valuable insights into the complex dynamics at play. This research aims to improve the clinical management of bone diseases and metastasis, paving the way for targeted interventions and personalized treatment strategies to enhance the quality of life for affected individuals.
C1 [Sanchez, Juan Felipe; Duque Daza, Carlos A.; Garzon Alvarado, Diego A.] Univ Nacl Colombia, Biotechnol Inst, Carrera 30 45A 03,Ed 407,Of 204, Bogota 16486, Colombia.
   [Ramtani, Salah; Boucetta, Abdelkader] Univ Sorbonne Paris Nord, Equipe LBPS, Lab CSPBAT, CNRS UMR 7244, Villetaneuse, France.
   [Velasco, Marco Antonio] Univ Distrital Francisco Jose de Caldas, Bogota, Colombia.
   [Vaca Gonzalez, Juan Jairo] Univ Nacl Colombia, Escuela Pregrad, Direcc Acad, La Paz, Colombia.
C3 Universidad Nacional de Colombia; Centre National de la Recherche
   Scientifique (CNRS); CNRS   Institute of Chemistry (INC); Universidad
   Distrital Francisco Jose de Caldas; Universidad Nacional de Colombia
RP Sánchez, JF (通讯作者)，Univ Nacl Colombia, Biotechnol Inst, Carrera 30 45A 03,Ed 407,Of 204, Bogota 16486, Colombia.
EM jufesagu@gmail.com
RI Vaca González, Juan/GPS 9670 2022; Garzon Alvarado, Diego/AAD 6607 2019;
   VELASCO, MARCO/F 2223 2011; Duque Daza, Carlos/K 8609 2012
OI SANCHEZ GUTIERREZ, JUAN FELIPE/0000 0002 7821 5234; Velasco Pena, Marco
   Antonio/0000 0003 4436 9443
FU Biotechnology Institute Universidad Nacional de Colombia, Laboratoire
   CSPBAT, equipe LBPS, CNRS [UMR 7244]; Universit e Sorbonne Paris Nord;
   Department of Mechanical Engineering; Penn State University; University
   Park
FX This work was supported by Biotechnology Institute Universidad Nacional
   de Colombia, Laboratoire CSPBAT, equipe LBPS, CNRS (UMR 7244), Universit
   e Sorbonne Paris Nord, and Department of Mechanical Engineering, Penn
   State University, University Park.
CR Abd Rahman N., 2017, APOPTOSIS CELL CYCLE
   Aielli F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020280
   Amat Villegas I., 2009, GASTROENT HEPAT BARC, V32, P324
   Arias Moreno AJ, 2011, THESIS
   Atuegwu NC, 2011, MAGN RESON MED, V66, P1689, DOI 10.1002/mrm.23203
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Barbolosi D, 2016, NAT REV CLIN ONCOL, V13, P242, DOI 10.1038/nrclinonc.2015.204
   Bartl R., 2017, CONTROL REGULATION B, P31
   Belfatto A, 2016, IEEE J BIOMED HEALTH, V20, P802, DOI 10.1109/JBHI.2015.2453437
   Bender BC, 2015, BRIT J CLIN PHARMACO, V79, P56, DOI 10.1111/bcp.12258
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Bethge A, 2015, J BIOMED INFORM, V57, P74, DOI 10.1016/j.jbi.2015.07.011
   Bishop RT., 2023, BIORXIV, DOI DOI 10.1101/2022.11.13.516335
   Bonfoh N., 2008, REVUE, V1, P717
   Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100
   Claret L, 2009, J CLIN ONCOL, V27, P4103, DOI 10.1200/JCO.2008.21.0807
   Clohisy DR, 2003, CANCER AM CANCER SOC, V97, P866, DOI 10.1002/cncr.11144
   Coelho RM, 2016, J THEOR BIOL, V391, P1, DOI 10.1016/j.jtbi.2015.11.024
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Davies CDL, 2004, CANCER RES, V64, P547, DOI 10.1158/0008 5472.CAN 03 0576
   De Buck SS, 2014, BRIT J CLIN PHARMACO, V78, P543, DOI 10.1111/bcp.12378
   Dingli D, 2009, CANCER GENE THER, V16, P873, DOI 10.1038/cgt.2009.40
   Durie DBG., 2021, BONE DIS
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Ferlay J, 2018, CANC TODAY
   Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588
   Goltzman D, 1997, CANCER, V80, P1581, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1581::AID CNCR8>3.0.CO;2 N
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Günther T, 2000, TRENDS ENDOCRIN MET, V11, P189, DOI 10.1016/S1043 2760(00)00256 3
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Higinbotham N L, 1965, J Trauma, V5, P792, DOI 10.1097/00005373 196511000 00015
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Huybrechts Y, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00165
   Ihde LL, 2011, RADIOGRAPHICS, V31, P1865, DOI 10.1148/rg.317115093
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Komarova SV, 2006, ANN NY ACAD SCI, V1068, P557, DOI 10.1196/annals.1346.052
   Kosteva J, 2008, CURR OPIN ONCOL, V20, P155, DOI 10.1097/CCO.0b013e3282f54cf2
   Kreps LM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062911
   Kronik N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015482
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lamoureux F, 2008, MOL CANCER THER, V7, P3389, DOI 10.1158/1535 7163.MCT 08 0497
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Lekszycki T., 2005, Journal of Theoretical and Applied Mechanics, V43, P555
   Lerebours C, 2016, BIOMECH MODEL MECHAN, V15, P43, DOI 10.1007/s10237 015 0705 x
   Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Maldonado S, 2006, 2006 28TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1 15, P5842
   MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312
   Martínez G, 2006, MATH COMPUT SIMULAT, V73, P183, DOI 10.1016/j.matcom.2006.06.014
   Momtazi Borojeni AA, 2019, ARCH MED SCI, V15, P559, DOI 10.5114/aoms.2019.84732
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Navet B, 2018, CANCERS, V10, DOI 10.3390/cancers10110398
   Norregaard KS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136865
   Ollier E, 2017, FUND CLIN PHARMACOL, V31, P347, DOI 10.1111/fcp.12259
   Ovejero D, 2022, BONE, V161, DOI 10.1016/j.bone.2022.116450
   Oyajobi BO, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2168
   Panetta JC, 2008, CLIN CANCER RES, V14, P318, DOI 10.1158/1078 0432.CCR 07 1243
   Pang XC, 2019, PHARMACOL RES, V144, P235, DOI 10.1016/j.phrs.2019.04.030
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ramtani S, 2023, BIOMECH MODEL MECHAN, V22, P925, DOI 10.1007/s10237 023 01689 3
   Ren GW, 2015, J MOL MED, V93, P1203, DOI 10.1007/s00109 015 1329 4
   Ribba B, 2014, CPT PHARMACOMET SYST, V3, DOI 10.1038/psp.2014.12
   Ribba B, 2012, CLIN CANCER RES, V18, P5071, DOI 10.1158/1078 0432.CCR 12 0084
   Rockne R, 2010, PHYS MED BIOL, V55, P3271, DOI 10.1088/0031 9155/55/12/001
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140
   Roudier MP, 2003, CLIN EXP METASTAS, V20, P171, DOI 10.1023/A:1022627421000
   Selvaggi G, 2005, CRIT REV ONCOL HEMAT, V56, P365, DOI 10.1016/j.critrevonc.2005.03.011
   Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Swanson KR, 2008, BRIT J CANCER, V98, P113, DOI 10.1038/sj.bjc.6604125
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tezuka K, 2005, J BONE MINER METAB, V23, P1, DOI 10.1007/s00774 004 0533 z
   Wang CH, 2009, CANCER RES, V69, P9133, DOI 10.1158/0008 5472.CAN 08 3863
   Weis JA, 2015, CANCER RES, V75, P4697, DOI 10.1158/0008 5472.CAN 14 2945
   Weis JA, 2013, PHYS MED BIOL, V58, P5851, DOI 10.1088/0031 9155/58/17/5851
   Yin AY, 2019, CPT PHARMACOMET SYST, V8, P720, DOI 10.1002/psp4.12450
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yu RX, 2007, CONTEMP CLIN TRIALS, V28, P18, DOI 10.1016/j.cct.2006.05.011
NR 88
TC 0
Z9 0
U1 2
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1066 5277
EI 1557 8666
J9 J COMPUT BIOL
JI J. Comput. Biol.
PD JAN 1
PY 2025
VL 32
IS 1
BP 104
EP 124
DI 10.1089/cmb.2023.0390
EA DEC 2024
PG 21
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA R9T3L
UT WOS:001383255400001
PM 39723973
DA 2025 08 17
ER

PT J
AU Wang, Z
   Xie, Q
   Yu, Z
   Zhou, HF
   Huang, YZ
   Bi, XP
   Wang, YF
   Shi, WD
   Sun, H
   Gu, P
   Fan, XQ
AF Wang, Zi
   Xie, Qing
   Yu, Zhang
   Zhou, Huifang
   Huang, Yazhuo
   Bi, Xiaoping
   Wang, Yefei
   Shi, Wodong
   Sun, Hao
   Gu, Ping
   Fan, Xianqun
TI A regulatory loop containing miR 26a, GSK3β and C/EBPα regulates the
   osteogenesis of human adipose derived mesenchymal stem cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MARROW STROMAL CELLS; WNT SIGNALING PATHWAY; PROGENITOR CELLS;
   BONE FORMATION; OSTEOBLAST PROLIFERATION; POSITIVE REGULATION; INDUCED
   APOPTOSIS; LUNG CANCER; DIFFERENTIATION; MIR 31
AB Elucidating the molecular mechanisms responsible for osteogenesis of human adipose derived mesenchymal stem cells (hADSCs) will provide deeper insights into the regulatory mechanisms of this process and help develop more efficient methods for cell based therapies. In this study, we analysed the role of miR 26a in the regulation of hADSC osteogenesis. The endogenous expression of miR 26a increased during the osteogenic differentiation. The overexpression of miR 26a promoted hADSC osteogenesis, whereas osteogenesis was repressed by miR 26a knockdown. Additionally, miR 26a directly targeted the 3'UTR of the GSK3 beta, suppressing the expression of GSK3 beta protein. Similar to the effect of overexpressing miR 26a, the knockdown of GSK3 beta promoted osteogenic differentiation, whereas GSK3 beta overexpression inhibited this process, suggesting that GSK3 beta acted as a negative regulator of hADSC osteogenesis. Furthermore, GSK3 beta influences Wnt signalling pathway by regulating beta catenin, and subsequently altered the expression of its downstream target C/EBP alpha. In turn, C/EBP alpha transcriptionally regulated the expression of miR 26a by physically binding to the CTDSPL promoter region. Taken together, our data identified a novel feedback regulatory circuitry composed of miR 26a, GSK3 beta and C/EBP alpha, the function of which might contribute to the regulation of hADSC osteogenesis. Our findings provided new insights into the function of miR 26a and the mechanisms underlying osteogenesis of hADSCs.
C1 [Wang, Zi; Xie, Qing; Yu, Zhang; Zhou, Huifang; Huang, Yazhuo; Bi, Xiaoping; Wang, Yefei; Shi, Wodong; Sun, Hao; Gu, Ping; Fan, Xianqun] Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Dept Ophthalmol, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University
RP Gu, P (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Dept Ophthalmol, Shanghai 200011, Peoples R China.
EM guping2009@hotmail.com; fanxq@sh163.net
RI Wang, Zihao/KFS 2121 2024; Sun, Hao/AAX 1653 2020; bi,
   xiaoping/F 2487 2013; Ping, Gu/JXM 1659 2024
FU National High Technology Research and Develoment Program (863 Program)
   [2015AA020311]; National Natural Science Foundation of China [81470662,
   81170876, 31271029, 81320108010]; Shanghai Municipality Commission for
   Science and Technology [13DZ0500303, 14JC1493103, 124119a9300,
   12441903003]
FX This work was supported by the National High Technology Research and
   Develoment Program (863 Program) (2015AA020311), National Natural
   Science Foundation of China (81470662, 81170876, 31271029, 81320108010),
   and the Shanghai Municipality Commission for Science and Technology
   (13DZ0500303, 14JC1493103, 124119a9300, 12441903003). Sincere thanks are
   given to Dr. Qiao from the Key Laboratory of Medical Molecular Virology,
   Ministry of Education and Public Health, Shanghai Medical School, Fudan
   University, for technical assistance with CLSM imaging.
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   [Anonymous], EVID BASED COMPL ALT
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   Bhatnagar N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.85
   Bojin FM, 2012, STEM CELLS DEV, V21, P507, DOI 10.1089/scd.2011.0491
   Chen H, 2014, FEBS LETT, V588, P429, DOI 10.1016/j.febslet.2013.12.002
   Cook DA, 2014, STEM CELL RES, V12, P415, DOI 10.1016/j.scr.2013.10.002
   Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002
   Davis NE, 2012, BIOMATERIALS, V33, P6691, DOI 10.1016/j.biomaterials.2012.06.015
   Deng Y, 2013, STEM CELLS DEV, V22, P2278, DOI 10.1089/scd.2012.0686
   Deng Y, 2013, BIOMATERIALS, V34, P6717, DOI 10.1016/j.biomaterials.2013.05.042
   Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Estes BT, 2010, NAT PROTOC, V5, P1294, DOI 10.1038/nprot.2010.81
   Fichtner Feigl S, 2014, J IMMUNOL, V192, P3969, DOI 10.4049/jimmunol.1301072
   Fischer EM, 2003, TISSUE ENG, V9, P1179, DOI 10.1089/10763270360728080
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gilmour PS, 2013, TOXICOL APPL PHARM, V272, P399, DOI 10.1016/j.taap.2013.07.001
   Gong YM, 2014, MOL CELL BIOCHEM, V387, P227, DOI 10.1007/s11010 013 1888 z
   Hickey CJ, 2013, BLOOD, V121, P159, DOI 10.1182/blood 2012 05 428573
   Hu R, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176099
   Hu YM, 2013, NEUROSCI LETT, V534, P90, DOI 10.1016/j.neulet.2012.11.006
   Hua DS, 2012, ONCOL REP, V27, P700, DOI 10.3892/or.2011.1555
   Huh JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054551
   Ingham PW, 2011, NAT REV GENET, V12, P393, DOI 10.1038/nrg2984
   Kim JW, 2004, ANN HEMATOL, V83, P733, DOI 10.1007/s00277 004 0918 z
   Kim KM, 2012, J BONE MINER RES, V27, P1669, DOI 10.1002/jbmr.1604
   Kong XW, 2013, BBA GEN SUBJECTS, V1830, P5119, DOI 10.1016/j.bbagen.2013.07.027
   Kushwaha P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.350
   Li DH, 2012, BIOCHEM BIOPH RES CO, V422, P311, DOI 10.1016/j.bbrc.2012.04.155
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lin CY, 2013, BIOMATERIALS, V34, P9401, DOI 10.1016/j.biomaterials.2013.08.051
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Loiselle AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081399
   Lu GD, 2010, GASTROENTEROLOGY, V139, P632, DOI 10.1053/j.gastro.2010.03.051
   Lu TX, 2013, J IMMUNOL, V190, P1576, DOI 10.4049/jimmunol.1202897
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Maureira P, 2012, J BIOMED SCI, V19, DOI 10.1186/1423 0127 19 93
   Mohamed JS, 2010, J BIOL CHEM, V285, P29336, DOI 10.1074/jbc.M110.101147
   Nakayama M, 2009, J BIOL CHEM, V284, P1612, DOI 10.1074/jbc.M806981200
   Ni N, 2014, SCI REP UK, V4, DOI 10.1038/srep06671
   Ogura Naomi, 2004, J Oral Sci, V46, P207, DOI 10.2334/josnusd.46.207
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   PROCKOP DJ, 1997, SCIENCE, V276, P71, DOI [DOI 10.1126/SCIENCE.276.5309.71, 10.1126/science.276.5309.71]
   Pulikkan JA, 2010, BLOOD, V116, P5638, DOI 10.1182/blood 2010 04 281600
   Quertainmont R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039500
   Ringdén O, 2006, TRANSPLANTATION, V81, P1390, DOI 10.1097/01.tp.0000214462.63943.14
   Romano G, 2012, P NATL ACAD SCI USA, V109, P16570, DOI 10.1073/pnas.1207917109
   Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104
   Shao HJ, 2012, J BIOMED MATER RES A, V100A, P3344, DOI 10.1002/jbm.a.34291
   Sheng H, 2013, INT J MED SCI, V10, P782, DOI 10.7150/ijms.6084
   Sisask G, 2013, BONE, V54, P126, DOI 10.1016/j.bone.2013.01.019
   Su J, 2012, INT J ONCOL, V40, P1162, DOI 10.3892/ijo.2011.1322
   Suh JH, 2012, BIOCHEM BIOPH RES CO, V423, P404, DOI 10.1016/j.bbrc.2012.05.138
   Teng Y, 2010, BIOCHEM BIOPH RES CO, V392, P373, DOI 10.1016/j.bbrc.2010.01.028
   Trompeter HI, 2013, BMC GENOMICS, V14, DOI 10.1186/1471 2164 14 111
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072266
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Wang ZL, 2015, MOL MED REP, V12, P3345, DOI 10.3892/mmr.2015.3795
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Xie Q, 2015, BIOMATERIALS, V66, P67, DOI 10.1016/j.biomaterials.2015.07.013
   Xie Q, 2014, BIOCHEM BIOPH RES CO, V446, P98, DOI 10.1016/j.bbrc.2014.02.058
   Yu L, 2013, ONCOL LETT, V5, P1223, DOI 10.3892/ol.2013.1173
   Zeng CX, 2010, HEPATOLOGY, V52, P1702, DOI 10.1002/hep.23875
   Zeng Y, 2012, FEBS LETT, V586, P2375, DOI 10.1016/j.febslet.2012.05.049
   Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377
NR 71
TC 39
Z9 45
U1 0
U2 16
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD OCT 15
PY 2015
VL 5
AR 15280
DI 10.1038/srep15280
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CT4WV
UT WOS:000362809000001
PM 26469406
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Park, SH
   Kang, MA
   Moon, YJ
   Jang, KY
   Kim, JR
AF Park, See Hyoung
   Kang, Mi Ae
   Moon, Young Jae
   Jang, Kyu Yun
   Kim, Jung Ryul
TI Metformin coordinates osteoblast/osteoclast differentiation associated
   with ischemic osteonecrosis
SO AGING US
LA English
DT Article
DE metformin; angiopoietin 1; ischemic osteonecrosis; osteoblastic
   differentiation
ID P38 MAP KINASE; ANTIDIABETIC DRUG METFORMIN; CELL DIFFERENTIATION;
   ALKALINE PHOSPHATASE; BONE MASS; IN VIVO; ANGIOGENESIS; EXPRESSION;
   FRACTURE; RISK
AB In this study, we aimed to identify a candidate drug that can activate endogenous Angiopoietin 1 (Ang1) expression via drug repositioning as a pharmacological treatment for avascular osteonecrosis. After incubation with 821 drugs from the Food and Drug Administration (FDA) approved drug library, Ang1 expression in U2OS cell culture media was examined by ELISA. Metformin, the first line medication for treatment of type 2 diabetes, was selected as a candidate for in vitro and in vivo experimental evaluation. Ang1 was induced, and alkaline phosphatase activity was increased by metformin treatment in U2OS and MG63 cells. Wound healing and migration assay showed increased osteoblastic cell mobility by metformin treatment in U2OS and MG63 cells. Metformin upregulated expression of protein markers for osteoblastic differentiation in U2OS and MG63 cells but inhibited osteoclastic differentiation in Raw264.7 cells. Metformin (25 mg/kg) protected against ischemic necrosis in the epiphysis of the rat femoral head by maintaining osteoblast/osteocyte function and vascular density but inhibiting osteoclast activity in the necrotic femoral head. These findings provide novel insight into the specific biomarkers that are targeted and regulated by metformin in osteoblast differentiation and contribute to understanding the effects of these FDA approved small molecule drugs as novel therapeutics for ischemic osteonecrosis.
C1 [Park, See Hyoung] Hongik Univ, Dept Bio & Chem Engn, Sejong, South Korea.
   [Kang, Mi Ae] Gachon Univ, Dept Biol Sci, Seongnam, South Korea.
   [Moon, Young Jae; Kim, Jung Ryul] Chonbuk Natl Univ, Dept Orthopaed Surg, Med Sch, Biomed Res Inst,Res Inst Clin Med,Hosp & Res Inst, Jeonju, South Korea.
   [Jang, Kyu Yun] Chonbuk Natl Univ, Dept Pathol, Med Sch, Res Inst Clin Med,Biomed Res Inst,Hosp & Res Inst, Jeonju, South Korea.
C3 Hongik University; Gachon University; Jeonbuk National University;
   Jeonbuk National University
RP Kim, JR (通讯作者)，Chonbuk Natl Univ, Dept Orthopaed Surg, Med Sch, Biomed Res Inst,Res Inst Clin Med,Hosp & Res Inst, Jeonju, South Korea.; Jang, KY (通讯作者)，Chonbuk Natl Univ, Dept Pathol, Med Sch, Res Inst Clin Med,Biomed Res Inst,Hosp & Res Inst, Jeonju, South Korea.
EM kyjang@chonbuk.ac.kr; jrkeem@jbnu.ac.kr
FU National Research Foundation of Korea (NRF)   Ministry of Education,
   Science, and Technology [NRF 2017R1E1 A1A01074533,
   NRF 2014R1A6A3A04054307, NRF 2017R1A2B2005730]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, Science, and Technology (NRF 2017R1E1
   A1A01074533, NRF 2014R1A6A3A04054307, and NRF 2017R1A2B2005730).
CR Abdelsaid M, 2015, DIABETES, V64, P1804, DOI 10.2337/db14 1423
   Arbeláez Quintero I, 2017, STROKE RES TREAT, V2017, DOI 10.1155/2017/9756429
   Artigas N, 2014, J BIOL CHEM, V289, P27105, DOI 10.1074/jbc.M114.576793
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Bak EJ, 2010, J PERIODONTOL, V81, P412, DOI 10.1902/jop.2009.090414
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Chai TF, 2012, CELL SIGNAL, V24, P1700, DOI 10.1016/j.cellsig.2012.04.017
   Chow WA, 2009, LANCET ONCOL, V10, P61, DOI 10.1016/S1470 2045(08)70334 6
   de Araújo AA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183506
   DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167 6296(02)00126 1
   FAGAN SC, 2010, PHARMACOTHERAPY S 2, V30, pS5, DOI DOI 10.1592/PHCO.30.PT2.51S
   Gao Y, 2010, EUR J PHARMACOL, V635, P231, DOI 10.1016/j.ejphar.2010.02.051
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Gentile S, 2017, ONCOTARGET, V8, P62039, DOI 10.18632/oncotarget.18816
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Jeyabalan J, 2013, OSTEOPOROSIS INT, V24, P2659, DOI 10.1007/s00198 013 2371 0
   Jin Q, 2014, BRAIN BEHAV IMMUN, V40, P131, DOI 10.1016/j.bbi.2014.03.003
   Jongjitwimol J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094182
   Ortuño MJ, 2013, BONE, V52, P548, DOI 10.1016/j.bone.2012.11.007
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Kargulewicz A, 2016, EUR REV MED PHARMACO, V20, P3868
   Kolb R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13007
   Kostenuik P.J., 1997, American Journal of Physiology Endocrinology and Metabolism, V273, P36, DOI [10.1152/ajpendo.1997.273.6.e1133, DOI 10.1152/AJPENDO.1997.273.6.E1133]
   Kotake S, 1996, J BONE MINER RES, V11, P88
   Li J, 2010, STROKE, V41, P2645, DOI 10.1161/STROKEAHA.110.589697
   Luo M, 2017, SCI REP UK, V7, DOI 10.1038/srep43427
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756 3282(95)00180 L
   Moayeri A, 2017, THER CLIN RISK MANAG, V13, DOI 10.2147/TCRM.S131945
   Montagnani A, 2011, AGING CLIN EXP RES, V23, P84, DOI 10.1007/BF03351073
   Mori T, 2011, INT IMMUNOL, V23, P701, DOI 10.1093/intimm/dxr077
   Park BH, 2009, BONE, V44, P886, DOI 10.1016/j.bone.2009.01.366
   Park SH, 2016, BIOCHEM BIOPH RES CO, V478, P1409, DOI 10.1016/j.bbrc.2016.08.137
   Qiao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep18732
   Rodríguez Carballo E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102032
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Shao XY, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/453940
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Son HJ, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/973986
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092 8674(00)81813 9
   Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468
   Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177
   Suzuki A, 2002, BONE, V30, P91, DOI 10.1016/S8756 3282(01)00660 3
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Thrasher J, 2017, AM J CARDIOL, V120, pS4, DOI 10.1016/j.amjcard.2017.05.009
   Tokubuchi I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171293
   Umezawa S, 2017, CURR PHARM DESIGN, V23, P3629, DOI 10.2174/0929867324666170713150440
   Venna VR, 2014, EUR J NEUROSCI, V39, P2129, DOI 10.1111/ejn.12556
   Wang P, 2018, J TISSUE ENG REGEN M, V12, P437, DOI 10.1002/term.2470
   Wolverton D, 2017, AM J HEALTH SYST PH, V74, P1143, DOI 10.2146/ajhp160319
   Wooller SK, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160180
   Wu ZD, 2017, BIOMED PHARMACOTHER, V94, P1, DOI 10.1016/j.biopha.2017.07.071
   Yang X, 2017, BBA MOL BASIS DIS, V1863, P1984, DOI 10.1016/j.bbadis.2016.09.019
   Ying Y, 2017, ONCOTARGET, V8, P32794, DOI 10.18632/oncotarget.15825
NR 56
TC 24
Z9 24
U1 2
U2 17
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD MAR 31
PY 2020
VL 12
IS 6
BP 4727
EP 4741
DI 10.18632/aging.102796
PG 15
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA KY7DD
UT WOS:000522733300005
PM 32045366
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hsiao, YT
   Jestes, KJ
   Jackson, KL
   Zukosky, T
   Squire, ME
   Hum, JM
   Lowery, JW
AF Hsiao, Yu Tin
   Jestes, Kelli J.
   Jackson, Krista L.
   Zukosky, Tara
   Squire, Maria E.
   Hum, Julia M.
   Lowery, Jonathan W.
TI Neuromedin U (NMU) regulates osteoblast differentiation and activity
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Neuromedin U; NMU; NMUR1; NMUR2; Bone; Osteoblast; Osteoporosis
ID RESPONSES; OSTEOPOROSIS; NEUROPEPTIDE; CELLS
AB Osteoporosis is a disease of low bone mass that places individuals at enhanced risk for fracture, disability, and death. Osteoporosis rates are expected to rise significantly in the coming decades yet there are limited pharmacological treatment options, particularly for long term management of this chronic condition. The drug development pipeline is relatively bereft of new strategies, causing an urgent and unmet need for developing new strategies and targets for treating osteoporosis. Here, we examine a lesser studied bone remodeling pathway, Neuromedin U (NMU), which is expressed in the bone microenvironment along with its cognate receptors NMU receptor 1 (NMUR1) and 2 (NMUR2). We independently corroborate a prior report that global loss of NMU expression leads to high bone mass and test the hypothesis that NMU negatively regulates osteoblast differentiation. Consistent with this, in vitro studies reveal NMU represses osteoblastic differentiation of osteogenic precursors but, in contrast, promotes osteoblastic marker expression, proliferation and activity of osteoblast like cells. Phosphoprofiling arrays were used to detail differential signaling outcomes that may underlie the opposite responses of these cell types. Collectively, our findings indicate that NMU exerts cell type specific responses to regulate osteoblast differentiation and activity. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Hsiao, Yu Tin; Jestes, Kelli J.; Jackson, Krista L.; Hum, Julia M.; Lowery, Jonathan W.] Marian Univ, Coll Osteopath Med, Div Biomed Sci, Indianapolis, IN 46222 USA.
   [Hsiao, Yu Tin; Jestes, Kelli J.; Jackson, Krista L.; Hum, Julia M.; Lowery, Jonathan W.] Marian Univ, Bone & Mineral Res Grp, Indianapolis, IN 46222 USA.
   [Zukosky, Tara; Squire, Maria E.] Univ Scranton, Dept Biol, Scranton, PA 18510 USA.
   [Lowery, Jonathan W.] Indiana Univ, Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46204 USA.
C3 Marian University; Marian University; University of Scranton; Indiana
   University System; Indiana University Indianapolis
RP Lowery, JW (通讯作者)，Marian Univ, Coll Osteopath Med, 3200 Cold Spring Rd, Indianapolis, IN 46222 USA.
EM jlowery@marian.edu
OI Squire, Maria/0000 0002 0303 3233; Lowery, Jonathan/0000 0002 9942 2945;
   Zukosky, Tara/0000 0002 3126 9382; Jackson, Krista/0000 0002 2394 4579
FU Marian University College of Osteopathic Medicine Faculty Research
   Development Award [19 004]
FX We gratefully acknowledge Drs. Christoph Klose (Weill Medical College,
   Cornell University), David Artis (Weill Medical College, Cornell
   University), and Eric Wauson (College of Osteopathic Medicine, Des
   Moines University) for the generous gift of certain samples utilized in
   the course of this study. We also wish to thank the members of the
   Marian University Bone & Mineral Research Group and the Indiana Center
   for Musculoskeletal Health for critical feedback on this project.
   Funding was provided by Marian University College of Osteopathic
   Medicine Faculty Research Development Award 19 004 (issued to JWL) and
   other intramural funds.
CR Brighton PJ, 2004, PHARMACOL REV, V56, P231, DOI 10.1124/pr.56.2.3
   Camacho PM, 2016, ENDOCR PRACT, V22, P1, DOI 10.4158/EP161435.GL
   Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148
   Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0
   Leboime A, 2010, JOINT BONE SPINE, V77, pS107, DOI 10.1016/S1297 319X(10)70004 X
   Martinez VG, 2015, CLIN CHEM, V61, P471, DOI 10.1373/clinchem.2014.231753
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rao SM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3732
   Rucinski M, 2008, INT J MOL MED, V22, P363, DOI 10.3892/ijmm_00000031
   Sato S, 2007, NAT MED, V13, P1234, DOI 10.1038/nm1640
   Shadmand M, 2018, CLIN REV BONE MINER, V16, P95, DOI 10.1007/s12018 018 9250 3
   Singer A, 2015, MAYO CLIN PROC, V90, P53, DOI 10.1016/j.mayocp.2014.09.011
   Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0
   Wallrapp A, 2017, NATURE, V549, P351, DOI 10.1038/nature24029
   Zeng HK, 2006, MOL CELL BIOL, V26, P9352, DOI 10.1128/MCB.01148 06
NR 15
TC 5
Z9 5
U1 1
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 16
PY 2020
VL 524
IS 4
BP 890
EP 894
DI 10.1016/j.bbrc.2020.02.003
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA LE5XY
UT WOS:000526795700015
PM 32057362
DA 2025 08 17
ER

PT J
AU Shao, SY
   Fu, FS
   Wang, ZY
   Song, FM
   Li, C
   Wu, ZX
   Ding, JX
   Li, K
   Xiao, Y
   Su, YJ
   Lin, XX
   Yuan, GX
   Zhao, JM
   Liu, Q
   Xu, JK
AF Shao, Siyuan
   Fu, Fangsheng
   Wang, Ziyi
   Song, Fangming
   Li, Chen
   Wu, Zuo xing
   Ding, Jiaxing
   Li, Kai
   Xiao, Yu
   Su, Yiji
   Lin, Xixi
   Yuan, Guixin
   Zhao, Jinmin
   Liu, Qian
   Xu, Jiake
TI Diosmetin inhibits osteoclast formation and differentiation and prevents
   LPS induced osteolysis in mice
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE diosmetin (DIO); MAPK; nuclear factor of activated T cells 1 (NFATc1);
   osteoclasts; osteolysis
ID NF KAPPA B; RANKL INDUCED OSTEOCLASTOGENESIS; RECEPTOR ACTIVATOR;
   BONE RESORPTION; NUCLEAR FACTOR; C FOS; NFATC1; ERK; MECHANISMS;
   INDUCTION
AB Osteolytic bone diseases are closely linked to the over activation of osteoclasts and enhancement of bone resorption. It has become a major health issue in orthopedic practice worldwide. Inhibition of osteoclasts is proposed to be the main treatment for osteolytic disorders. Diosmetin (DIO) is a natural flavonoid with properties of antioxidant, anti infection, and antishock. The effect of DIO on osteoclast differentiation is poorly understood. In this study project, we found that DIO could inhibit osteoclastic formation induced by receptor activator of nuclear factor kappa B ligand (RANKL) in a dose dependent manner. The expression of the osteoclast differentiation marker genes, cathepsin K, nuclear factor of activated T cells 1 (NFATc1), Acp5, Ctr, Atp6v0d2, and Mmp9 were also decreased by the treatment of DIO. In addition, DIO attenuated the formation of actin ring and the ability of bone resorption. Further, the western blotting showed that DIO inhibits the phosphorylation of the mitogen activated protein kinases signaling pathway induced by RANKL, accompanied by the downregulation of NFATc1 and c Fos expression. We also found that DIO could reduce the accumulation of reactive oxygen species (ROS) induced by RANKL. In vivo, the study revealed that DIO can significantly reduce LPS induced osteolysis in mice. Collectively, our study shows that DIO can inhibit osteoclast formation and activation, and could serve as a potential therapeutic drug for osteolytic bone diseases.
C1 [Shao, Siyuan; Fu, Fangsheng; Song, Fangming; Li, Chen; Wu, Zuo xing; Ding, Jiaxing; Li, Kai; Xiao, Yu; Su, Yiji; Lin, Xixi; Zhao, Jinmin; Liu, Qian; Xu, Jiake] Guangxi Med Univ, Res Ctr Regenerat Med, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Wang, Ziyi; Song, Fangming; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Liu, Qian] Guangxi Med Univ, Dept Trauma Orthoped & Hand Surg, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Yuan, Guixin] Shantou Univ, Coll Med, Affiliated Hosp 2, Dept Orthoped, Shantou, Guangdong, Peoples R China.
C3 Guangxi Medical University; University of Western Australia; Guangxi
   Medical University; Shantou University
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.; Liu, Q (通讯作者)，Guangxi Med Univ, Res Ctr Regenerat Med, Nanning, Guangxi, Peoples R China.
EM luoboqian@hotmail.com; jiake.xu@uwa.edu.au
RI ; xi, lin/JOK 1026 2023; zhao, jin/LBH 0351 2024
OI Wang, Ziyi/0000 0002 5410 3385; Zhao, Jinmin/0000 0002 1047 8820; Zhao,
   Jinmin/0000 0001 8423 0425; Wang, Ziyi/0000 0002 1334 7287; Xiao,
   Yu/0009 0005 3120 8968; Xu, Jiake/0000 0003 2021 8309
FU Australian Health and Medical Research Council [APP1107828, APP1027932,
   APP1163933]; National Natural Science Foundation of China [81501910];
   Natural Science Foundation of Guangxi Province [2015GXNSFCA414001,
   2015GXNSFDA139019]
FX Australian Health and Medical Research Council, Grant/Award Numbers:
   APP1107828, APP1027932, APP1163933; National Natural Science Foundation
   of China, Grant/Award Number: 81501910; Natural Science Foundation of
   Guangxi Province, Grant/Award Numbers: 2015GXNSFCA414001,
   2015GXNSFDA139019
CR Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   Baud'huin M, 2007, EXPERT REV ANTICANC, V7, P221, DOI 10.1586/14737140.7.2.221
   Bi Y., 2010, J BONE MINER RES, V16, P2082
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen Y, 2003, J BIOL CHEM, V278, P23101, DOI 10.1074/jbc.M301021200
   Ciolino HP, 1998, CANCER RES, V58, P2754
   Citak M, 2015, KNEE, V22, P338, DOI 10.1016/j.knee.2015.03.008
   Crotti TN, 2008, J CELL PHYSIOL, V215, P636, DOI 10.1002/jcp.21344
   Deepak V, 2015, CONNECT TISSUE RES, V56, P195, DOI 10.3109/03008207.2014.989320
   Doostdar H, 2000, TOXICOLOGY, V144, P31, DOI 10.1016/S0300 483X(99)00215 2
   Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101
   Enomoto H, 2003, J BIOL CHEM, V278, P23971, DOI 10.1074/jbc.M302457200
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Harris WH, 2001, CLIN ORTHOP RELAT R, P66
   Hotokezaka H., 2010, J CELL BIOCHEM, V101, P122
   Hsu Y. L., 2010, J BONE MINER RES, V23, P949
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Kim H. J., 2016, CELLULAR SIGNALLING, V29, P226
   Koh J. M., 2010, J BONE MINER RES, V21, P1003
   Kovac S, 2015, BBA GEN SUBJECTS, V1850, P794, DOI 10.1016/j.bbagen.2014.11.021
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lee M. S., 2010, J ORTHOPAED RES, V21, P117
   Lee WS, 2014, INFLAMMATION, V37, P1221, DOI 10.1007/s10753 014 9849 6
   Liu YS, 2007, NAT REV IMMUNOL, V7, P202, DOI 10.1038/nri2035
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Maruya M, 2011, P NATL ACAD SCI USA, V108, P722, DOI 10.1073/pnas.1014697108
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Otto Sven, 2011, J Med Case Rep, V5, P477, DOI 10.1186/1752 1947 5 477
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Shimo T, 2007, J CELL COMMUN SIGNAL, V1, P103, DOI 10.1007/s12079 007 0010 2
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Song DZ, 2018, J CELL PHYSIOL, V233, P9674, DOI 10.1002/jcp.26882
   Song FM, 2018, J CELL PHYSIOL, V233, P1723, DOI 10.1002/jcp.26084
   Song FM, 2016, J CELL PHYSIOL, V231, P1983, DOI 10.1002/jcp.25304
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wei CM, 2018, CELL PHYSIOL BIOCHEM, V48, P644, DOI 10.1159/000491892
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yip K. H., 2010, J BONE MINER RES, V20, P1462
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
NR 47
TC 18
Z9 20
U1 3
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD AUG
PY 2019
VL 234
IS 8
BP 12701
EP 12713
DI 10.1002/jcp.27887
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HX2SA
UT WOS:000467240800051
PM 30515812
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Li, XX
   Liang, YJ
   Lian, C
   Peng, FL
   Xiao, YS
   He, YF
   Ma, CX
   Wang, Y
   Zhang, PY
   Deng, YH
   Su, YP
   Luo, C
   Kong, XY
   Yang, QC
   Liu, T
   Hu, GH
AF Li, Xiaoxun
   Liang, Yajun
   Lian, Cheng
   Peng, Fangli
   Xiao, Yansen
   He, Yunfei
   Ma, Chengxin
   Wang, Yuan
   Zhang, Peiyuan
   Deng, Yuhan
   Su, Yunpeng
   Luo, Cheng
   Kong, Xiangyin
   Yang, Qingcheng
   Liu, Tong
   Hu, Guohong
TI CST6 protein and peptides inhibit breast cancer bone metastasis by
   suppressing CTSB activity and osteoclastogenesis
SO THERANOSTICS
LA English
DT Article
DE Breast cancer; Bone metastasis; Osteoclastogenesis; CST6; Peptide drug
ID RAY CRYSTAL STRUCTURE; CATHEPSIN B; CYSTATIN M; STRUCTURAL BASIS;
   DIFFERENTIATION; IDENTIFICATION; INACTIVATION; PATHWAY; RANKL; M/E
AB Background: Bone metastasis is a frequent symptom of breast cancer and current targeted therapy has limited efficacy. Osteoclasts play critical roles to drive osteolysis and metastatic outgrowth of tumor cells in bone. Previously we identified CST6 as a secretory protein significantly downregulated in bone metastatic breast cancer cells. Functional analysis showed that CST6 suppresses breast to bone metastasis in animal models. However, the functional mechanism and therapeutic potential of CST6 in bone metastasis is unknown.
   Methods: Using in vitro osteoclastogenesis and in vivo metastasis assays, we studied the effect and mechanism of extracellular CST6 protein in suppressing osteoclastic niches and bone metastasis of breast cancer. A number of peptides containing the functional domain of CST6 were screened to inhibit bone metastasis. The efficacy, stability and toxicity of CST6 recombinant protein and peptides were evaluated in preclinical metastasis models.
   Results: We show here that CST6 inhibits osteolytic bone metastasis by inhibiting osteoclastogenesis. Cancer cell derived CST6 enters osteoclasts by endocytosis and suppresses the cysteine protease CTSB, leading to up regulation of the CTSB hydrolytic substrate SPHK1. SPHK1 suppresses osteoclast maturation by inhibiting the RANKL induced p38 activation. Importantly, recombinant CST6 protein effectively suppresses bone metastasis in vitro and in vivo. We further identified several peptides mimicking the function of CST6 to suppress cancer cell induced osteoclastogenesis and bone metastasis. Pre clinical analyses of CTS6 recombinant protein and peptides demonstrated their potentials in treatment of breast cancer bone metastasis.
   Conclusion: These findings reveal the CST6 CTSB SPHK1 signaling axis in osteoclast differentiation and provide a promising approach to treat bone diseases with CST6 based peptides.
C1 [Li, Xiaoxun; Deng, Yuhan; Liu, Tong] Harbin Med Univ, Dept Breast Surg, Canc Hosp, Harbin, Peoples R China.
   [Li, Xiaoxun; Liang, Yajun; Lian, Cheng; Peng, Fangli; Xiao, Yansen; He, Yunfei; Ma, Chengxin; Wang, Yuan; Zhang, Peiyuan; Kong, Xiangyin; Hu, Guohong] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai, Peoples R China.
   [Yang, Qingcheng; Hu, Guohong] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthoped, Shanghai, Peoples R China.
   [Su, Yunpeng] Novomab Biopharmaceut Inc, Nanjing, Peoples R China.
   [Luo, Cheng] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Drug Discovery & Design Ctr, Shanghai, Peoples R China.
C3 Harbin Medical University; Chinese Academy of Sciences; Shanghai
   Institute of Nutrition & Health, CAS; University of Chinese Academy of
   Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of
   Sciences; Shanghai Institute of Materia Medica, CAS
RP Liu, T (通讯作者)，Harbin Med Univ, Dept Breast Surg, Canc Hosp, Harbin, Peoples R China.; Hu, GH (通讯作者)，Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai, Peoples R China.; Hu, GH (通讯作者)，Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthoped, Shanghai, Peoples R China.
EM liutong@hrbmu.edu.cn; ghhu@sibs.ac.cn
RI Lian, Cheng/HHS 1095 2022; 胡, 国宏/HOH 6469 2023; Liu, Tong/ITR 9886 2023;
   Chen, Hsing yu/C 3979 2011; he, yun/JMB 6362 2023; liang,
   yajun/MIN 1092 2025
OI Lian, Cheng/0000 0002 9016 832X; LIU, TONG/0000 0001 9234 1328; 
FU National Natural Science Foundation of China [81725017, 81872367,
   82072903]; Ministry of Science and Technology of China [2017YFA0103502,
   2020YFA0112302]; Shanghai Science and Technology Commission
   [19XD1404500]; Heilongjiang Province Natural Science Foundation Joint
   Guidance [LH2020H125]
FX The study was funded by National Natural Science Foundation of China
   (81725017, 81872367, 82072903) , Ministry of Science and Technology of
   China (2017YFA0103502, 2020YFA0112302) , Shanghai Science and Technology
   Commission (19XD1404500) , and Heilongjiang Province Natural Science
   Foundation Joint Guidance (LH2020H125) .
CR Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008 5472.CAN 06 0576
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Briggs JJ, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 17
   Chen XB, 2010, BIOCHEM BIOPH RES CO, V391, P1070, DOI 10.1016/j.bbrc.2009.12.022
   Cheng T, 2006, J BIOL CHEM, V281, P15893, DOI 10.1074/jbc.M600694200
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   D'Costa ZC, 2014, ONCOTARGET, V5, P1609, DOI 10.18632/oncotarget.1707
   Dall E, 2015, ANGEW CHEM INT EDIT, V54, P2917, DOI 10.1002/anie.201409135
   Domschke C, 2014, BREAST CARE, V9, P332, DOI 10.1159/000368844
   Ell B, 2012, CELL, V151, DOI 10.1016/j.cell.2012.10.005
   Jin L, 2012, CELL RES, V22, P1356, DOI 10.1038/cr.2012.90
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Mackiewicz Wysocka M, 2012, EXPERT OPIN INV DRUG, V21, P785, DOI 10.1517/13543784.2012.679928
   Matarrese P, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 207
   Matsumoto K, 1998, BBA PROTEIN STRUCT M, V1383, P93, DOI 10.1016/S0167 4838(97)00187 8
   MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460 2075.1991.tb07771.x
   Muttenthaler M, 2021, NAT REV DRUG DISCOV, V20, P309, DOI 10.1038/s41573 020 00135 8
   Ni J, 1997, J BIOL CHEM, V272, P10853
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   Pulukuri SM, 2009, ONCOGENE, V28, P2829, DOI 10.1038/onc.2009.134
   Rawlings ND, 2012, NUCLEIC ACIDS RES, V40, pD343, DOI [10.1093/nar/gkt953, 10.1093/nar/gkr987]
   Rivenbark AG, 2006, LAB INVEST, V86, P1233, DOI 10.1038/labinvest.3700485
   Rivenbark AG, 2009, FRONT BIOSCI LANDMRK, V14, P453, DOI 10.2741/3254
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Schüttelkopf AW, 2006, J BIOL CHEM, V281, P16570, DOI 10.1074/jbc.M601033200
   Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340
   Siegel RL, 2018, CA CANCER J CLIN, V68, P7, DOI [10.3322/caac.21551, 10.3322/caac.21442]
   Soh H, 2016, MOL CELL BIOL, V36, P1776, DOI 10.1128/MCB.00878 15
   Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Taha TA, 2006, FEBS LETT, V580, P6047, DOI 10.1016/j.febslet.2006.09.070
   TURK B, 1995, BIOL CHEM H S, V376, P225, DOI 10.1515/bchm3.1995.376.4.225
   Veena MS, 2008, GENE CHROMOSOME CANC, V47, P740, DOI 10.1002/gcc.20576
   Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017
   Wang YF, 2014, J CLIN INVEST, V124, P1646, DOI 10.1172/JCI71812
   Zeeuwen PLJM, 2009, J INVEST DERMATOL, V129, P1327, DOI 10.1038/jid.2009.40
NR 38
TC 45
Z9 47
U1 2
U2 24
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2021
VL 11
IS 20
BP 9821
EP 9832
DI 10.7150/thno.62187
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA WY3DG
UT WOS:000719160500009
PM 34815788
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sisay, M
   Mengistu, G
   Edessa, D
AF Sisay, Mekonnen
   Mengistu, Getnet
   Edessa, Dumessa
TI The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem
   cell: potential targets for anticancer therapy
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE cancer; RANK; RANKL; OPG; RANK/RANKL/OPG system; therapeutic; tumor
ID NF KAPPA B; LIGAND RANKL EXPRESSION; HUMAN PROSTATE CANCER;
   BREAST CANCER; RECEPTOR ACTIVATOR; BONE METASTASIS; OSTEOCLAST
   DIFFERENTIATION; OSTEOPROTEGERIN OPG; LUNG CANCER; MESENCHYMAL
   TRANSITION
AB The molecular triad involving receptor activator of nuclear factor k beta (RANK)/RANK ligand (RANKL)/osteoprotegerin cytokine system has been well implicated in several physiological and pathological processes including bone metabolism, mammary gland development, regulation of the immune function, tumorigenesis and metastasis of cancer stem cell, thermoregulation, and vascular calcification. However, this review aimed to summarize several original and up to date articles focusing on the role of this signaling system in cancer cell development and metastasis as well as potential therapeutic agents targeting any of the three tumor necrotic factor super family proteins and/or their downstream signaling pathways. The RANK/RANKL axis has direct effects on tumor cell development. The system is well involved in the development of several primary and secondary tumors including breast cancer, prostate cancer, bone tumors, and leukemia. The signaling of this triad system has also been linked to tumor invasiveness in the advanced stage. Bone is by far the most common site of cancer metastasis. Several therapeutic agents targeting this system have been developed. Among them, a monoclonal antibody, denosumab, was clinically approved for the treatment of osteoporosis and cancer related diseases.
C1 [Sisay, Mekonnen; Mengistu, Getnet] Haramaya Univ, Coll Hlth & Med Sci, Sch Pharm, Dept Pharmacol & Toxicol, POB 235, Harar, Ethiopia.
   [Edessa, Dumessa] Haramaya Univ, Coll Hlth & Med Sci, Sch Pharm, Dept Clin Pharm, Harar, Ethiopia.
C3 Haramaya University; Haramaya University
RP Sisay, M (通讯作者)，Haramaya Univ, Coll Hlth & Med Sci, Sch Pharm, Dept Pharmacol & Toxicol, POB 235, Harar, Ethiopia.
EM mekonnensisay2003@yahoo.com
RI Shiferaw, Mekonnen Sisay/AAD 3257 2020; Negasa, Dumessa/K 2892 2019;
   Mengistu, Getnet/K 5070 2019
OI Assefa, Getnet Mengistu/0000 0002 8367 5315; Sisay,
   Mekonnen/0000 0001 6611 1174; Edessa, Dumessa/0000 0001 6558 5829
CR Albany C, 2014, PROSTATE CANCER P D, V17, P112, DOI 10.1038/pcan.2014.12
   Azim HA, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058 015 0538 7
   Blake ML, 2014, CLIN EXP METASTAS, V31, P233, DOI 10.1007/s10585 013 9624 3
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Brennan TC, 2009, BRIT J PHARMACOL, V157, P1291, DOI 10.1111/j.1476 5381.2009.00305.x
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chen G, 2006, CANCER AM CANCER SOC, V107, P289, DOI 10.1002/cncr.21978
   Chen LM, 2011, J CELL BIOCHEM, V112, P933, DOI 10.1002/jcb.23009
   Chen Y, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0295
   Cheng ML, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00329
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Cui XB, 2015, INT J CLIN EXP PATHO, V8, P2249
   Curioni Fontecedro A, 2013, LUNG CANCER, V82, P506, DOI 10.1016/j.lungcan.2013.08.030
   Cuyàs E, 2017, ONCOTARGET, V8, P35019, DOI 10.18632/oncotarget.16558
   Delea TE, 2006, J THORAC ONCOL, V1, P571, DOI 10.1097/01243894 200607000 00012
   Dougall WC, 2012, CLIN CANCER RES, V18, P326, DOI 10.1158/1078 0432.CCR 10 2507
   Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Fortner RT, 2017, BMC MED, V15, DOI 10.1186/s12916 017 0786 8
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   Grimaud E, 2003, AM J PATHOL, V163, P2021, DOI 10.1016/S0002 9440(10)63560 2
   Ha H, 2014, MOLECULES, V19, P3940, DOI 10.3390/molecules19043940
   Hanada R, 2011, NEUROSCI RES, V71, pE22, DOI 10.1016/j.neures.2011.07.092
   Hanada R, 2009, NATURE, V462, P505, DOI 10.1038/nature08596
   Heath DJ, 2007, CANCER RES, V67, P202, DOI 10.1158/0008 5472.CAN 06 1287
   Herzog CE, 2005, J PEDIAT HEMATOL ONC, V27, P215, DOI 10.1097/01.mph.0000161762.53175.e4
   Heymann MF, 2008, REGUL PEPTIDES, V148, P46, DOI 10.1016/j.regpep.2008.02.004
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Holen I, 2002, CANCER RES, V62, P1619
   Holen I, 2005, BREAST CANCER RES TR, V92, P207, DOI 10.1007/s10549 005 2419 8
   Ibrahim T, 2016, ONCOL LETT, V12, P2970, DOI 10.3892/ol.2016.4977
   Ihn HJ, 2017, BMB REP, V50, P150, DOI 10.5483/BMBRep.2017.50.3.223
   Ito R, 2003, VIRCHOWS ARCH, V443, P146, DOI 10.1007/s00428 003 0845 8
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Khan IS, 2014, J EXP MED, V211, P761, DOI 10.1084/jem.20131889
   Kiesel L, 2016, MATURITAS, V86, P10, DOI 10.1016/j.maturitas.2016.01.001
   Kim H, 2009, J CLIN INVEST, V119, P813, DOI 10.1172/JCI36809
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Lewin J, 2013, DRUG TODAY, V49, P693, DOI 10.1358/dot.2013.49.11.2064725
   Lewis MA, 2011, CA CANCER J CLIN, V61, P287, DOI 10.3322/caac.20124
   Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656
   Ma RF, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 154
   Ma XJ, 2014, BIOCHEM BIOPH RES CO, V445, P282, DOI 10.1016/j.bbrc.2014.01.145
   Mikami S, 2009, J PATHOL, V218, P530, DOI 10.1002/path.2567
   Miller RE, 2008, MOL CANCER THER, V7, P2160, DOI 10.1158/1535 7163.MCT 08 0046
   Miller RE, 2014, J THORAC ONCOL, V9, P345, DOI 10.1097/JTO.0000000000000070
   Mizutani Y, 2004, CANCER AM CANCER SOC, V101, P1794, DOI 10.1002/cncr.20550
   Naidu VGM, 2013, CHEM BIOL INTERACT, V203, P467, DOI 10.1016/j.cbi.2012.12.016
   Ndip A, 2011, DIABETES, V60, P2187, DOI 10.2337/db10 1220
   Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118
   Odero Marah VA, 2008, CELL RES, V18, P858, DOI 10.1038/cr.2008.84
   Osako MK, 2013, ARTERIOSCL THROM VAS, V33, P1287, DOI 10.1161/ATVBAHA.112.301099
   Owen S, 2013, ANTICANCER RES, V33, P199
   Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008 5472.CAN 12 0044
   Palmerini E, 2017, EUR J CANCER, V76, P118, DOI 10.1016/j.ejca.2017.01.028
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Peddi P, 2013, CANCER TREAT REV, V39, P97, DOI 10.1016/j.ctrv.2012.07.002
   Pfitzner BM, 2014, BREAST CANCER RES TR, V145, P307, DOI 10.1007/s10549 014 2955 1
   Reyes ME, 2017, BREAST CANCER RES TR, V164, P57, DOI 10.1007/s10549 017 4233 5
   Santini D, 2011, J CELL PHYSIOL, V226, P780, DOI 10.1002/jcp.22402
   Sasaki A, 2007, ANN SURG ONCOL, V14, P1191, DOI 10.1245/s10434 006 9277 4
   Schmiedel BJ, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23850
   Schmiedel BJ, 2013, CANCER RES, V73, P683, DOI 10.1158/0008 5472.CAN 12 2280
   Schmohl JU, 2016, EUR J HAEMATOL, V97, P517, DOI 10.1111/ejh.12762
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Siampanopoulou M, 2016, HIPPOKRATIA, V20, P133
   Sigl V, 2016, CELL RES, V26, P761, DOI 10.1038/cr.2016.69
   Su T, 2016, TUMOR BIOL, V37, P10745, DOI 10.1007/s13277 016 4860 1
   Takayama K, 2017, CANCER LETT, V397, P103, DOI 10.1016/j.canlet.2017.03.034
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Téletchéa S, 2014, J BONE MINER RES, V29, P1466, DOI 10.1002/jbmr.2170
   Tsubaki M, 2016, TUMOR BIOL, V37, P9099, DOI 10.1007/s13277 015 4761 8
   Tsubaki M, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756 9966 32 62
   van der Heijden L, 2017, EUR J CANCER, V77, P75, DOI 10.1016/j.ejca.2017.02.021
   Weichhaus M, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0390 5
   Widschwendter M, 2015, EBIOMEDICINE, V2, P1331, DOI 10.1016/j.ebiom.2015.08.037
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Zhang LY, 2015, ONCOTARGET, V6, P22918, DOI 10.18632/oncotarget.4382
   Zhao YF, 2013, FEBS LETT, V587, P2958, DOI 10.1016/j.febslet.2013.08.005
NR 81
TC 62
Z9 76
U1 0
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2017
VL 10
BP 3801
EP 3810
DI 10.2147/OTT.S135867
PG 10
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA FC2VM
UT WOS:000406696800004
PM 28794644
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhou, W
   Huang, H
   Zhu, HY
   Zhou, P
   Shi, XL
AF Zhou, Wei
   Huang, Hai
   Zhu, Haiyan
   Zhou, Pei
   Shi, Xunlong
TI New metabolites from the biotransformation of ginsenoside Rb1 by
   Paecilomyces bainier sp.229 and activities in inducing osteogenic
   differentiation by Wnt/β catenin signaling activation
SO JOURNAL OF GINSENG RESEARCH
LA English
DT Article
DE biotransformation; ginsenoside; osteogenic differentiation;
   Wnt/beta catenin signal
ID OSTEOCLAST DIFFERENTIATION; MICROBIAL TRANSFORMATION; INTESTINAL
   BACTERIA; COMPOUND K; IN VIVO; OSTEOBLASTS; SAPONINS; RATS;
   20(S) PROTOPANAXADIOL; NOTOGINSENG
AB Background: Ginseng is a well known traditional Chinese medicine that has been widely used in a range of therapeutic and healthcare applications in East Asian countries. Microbial transformation is regarded as an effective and useful technology in modification of nature products for finding new chemical derivatives with potent bioactivities. In this study, three minor derivatives of ginsenoside compound K were isolated and the inducing effects in the Wingless type MMTV integration site (Wnt) signaling pathway were also investigated.
   Methods: New compounds were purified from scale up fermentation of ginsenoside Rb1 by Paecilomyces bainier sp. 229 through repeated silica gel column chromatography and high pressure liquid chromatography. Their structures were determined based on spectral data and X ray diffraction. The inductive activities of these compounds on the Wnt signaling pathway were conducted on MC3T3 E1 cells by quantitative real time polymerase chain reaction analysis.
   Results: The structures of a known 3 keto derivative and two new dehydrogenated metabolites were elucidated. The crystal structure of the 3 keto derivative was reported for the first time and its conformation was compared with that of ginsenoside compound K. The inductive effects of these compounds on osteogenic differentiation by activating the Wnt/beta catenin signaling pathway were explained for the first time.
   Conclusion: This study may provide a new insight into the metabolic pathway of ginsenoside by microbial transformation. In addition, the results might provide a reasonable explanation for the activity of ginseng in treating osteoporosis and supply good monomer ginsenoside resources for nutraceutical or pharmaceutical development. (C) 2017 The Korean Society of Ginseng, Published by Elsevier Korea LLC.
C1 [Zhou, Wei] Fudan Univ, Dept Chem, Shanghai, Peoples R China.
   [Huang, Hai; Zhu, Haiyan; Zhou, Pei; Shi, Xunlong] Fudan Univ, Sch Pharm, 826 Zhangheng Rd,Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China.
C3 Fudan University; Fudan University
RP Shi, XL (通讯作者)，Fudan Univ, Sch Pharm, 826 Zhangheng Rd,Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China.
EM xunlongshi@fudan.edu.cn
RI zhu, xueqiong/U 1320 2019; shi, xunlong/AAF 9803 2020
FU National Nature Fund of China [81503119]; Shanghai Scientific Fund
   Committee [14DZ1930304]
FX The authors acknowledge the financial support from The National Nature
   Fund of China (Number 81503119) and The Shanghai Scientific Fund
   Committee (Number 14DZ1930304).
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Bae EA, 2002, BIOL PHARM BULL, V25, P743, DOI 10.1248/bpb.25.743
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bhattia HN, 2014, PHYTOMEDICINE, V21, P1597, DOI 10.1016/j.phymed.2014.05.011
   Bi XL, 2014, EUR J PHARMACOL, V742, P145, DOI 10.1016/j.ejphar.2014.08.032
   Chen GT, 2008, APPL MICROBIOL BIOT, V77, P1345, DOI 10.1007/s00253 007 1258 4
   Chen GT, 2013, FITOTERAPIA, V91, P256, DOI 10.1016/j.fitote.2013.09.019
   Cui L, 2001, ACTA PHARMACOL SIN, V22, P428
   Cui L, 2016, J GINSENG RES, V40, P366, DOI 10.1016/j.jgr.2015.11.004
   El Wareth A, 2006, SYNTHETIC COMMUN, V36, P987, DOI 10.1080/00397910500501243
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Hasegawa H, 2004, J PHARMACOL SCI, V95, P153, DOI 10.1254/jphs.FMJ04001X4
   He BC, 2011, INT J ONCOL, V38, P437, DOI 10.3892/ijo.2010.858
   Jia L, 2009, CURR MED CHEM, V16, P2924, DOI 10.2174/092986709788803204
   KARIKURA M, 1991, CHEM PHARM BULL, V39, P2357
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kuban M, 2013, PHYTOCHEMISTRY, V88, P99, DOI 10.1016/j.phytochem.2012.12.007
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Li HF, 2009, PHYTOCHEMISTRY, V70, P1416, DOI 10.1016/j.phytochem.2009.07.041
   Li XW, 2008, ACTA CRYSTALLOGR E, V64, pO165, DOI 10.1107/S1600536807063118
   Lim SI, 2010, J GINSENG RES, V34, P168, DOI 10.5142/jgr.2010.34.3.168
   Liu QH, New use of ginsenoside compound K for the prevention of rheumatoid arthritis, Patent No. [PCT/CN2007/002354, 2007002354]
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Park CS, 2010, APPL MICROBIOL BIOT, V87, P9, DOI 10.1007/s00253 010 2567 6
   Park Jong Dae, 2005, Phytochemistry Reviews, V4, P159, DOI 10.1007/s11101 005 2835 8
   Serigano K, 2010, J ORTHOP RES, V28, P1267, DOI 10.1002/jor.21147
   Sheldrick G.M., 1993, PROGRAM CRYSTAL STRU
   Shin BK, 2015, J GINSENG RES, V39, P287, DOI 10.1016/j.jgr.2014.12.005
   Shin HS, 2014, EUR J PHARMACOL, V730, P82, DOI 10.1016/j.ejphar.2014.02.024
   TAKINO Y, 1994, YAKUGAKU ZASSHI, V114, P550, DOI 10.1248/yakushi1947.114.8_550
   Tanaka H, 2011, BIOCHEM BIOPH RES CO, V411, P690, DOI 10.1016/j.bbrc.2011.07.001
   Thomas GP, 2001, J ENDOCRINOL, V170, P451, DOI 10.1677/joe.0.1700451
   Wang JR, 2014, J AGR FOOD CHEM, V62, P2558, DOI 10.1021/jf405482s
   Zhou W, 2008, J APPL MICROBIOL, V104, P699, DOI 10.1111/j.1365 2672.2007.03586.x
   Zhou W, 2008, J SEP SCI, V31, P921, DOI 10.1002/jssc.200700406
   Zhou W, 2009, CHEM BIODIVERS, V6, P380, DOI 10.1002/cbdv.200700444
NR 39
TC 23
Z9 29
U1 2
U2 55
PU KOREAN SOC GINSENG
PI SEOCHO GU
PA 1807 SEOCHO WORLD OFFICETEL, 1355 3 SEOCHO DONG, SEOCHO GU, SEOUL
   137 862, SOUTH KOREA
SN 1226 8453
EI 2093 4947
J9 J GINSENG RES
JI J. Ginseng Res.
PD APR
PY 2018
VL 42
IS 2
BP 199
EP 207
DI 10.1016/j.jgr.2017.03.004
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA GA8PP
UT WOS:000428602500010
PM 29719467
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lin, RZ
   Xu, JF
   Zhu, SQ
   Hei, XY
   Li, ZJ
   Su, WX
   Wen, S
   Zhang, JC
AF Lin, Rui Zhu
   Xu, Jian Feng
   Zhu, Shi Qiang
   Hei, Xiao Yan
   Li, Zhi Jun
   Su, Wei Xia
   Wen, Sha
   Zhang, Jin Chen
TI Hui Medicine Moxibustion Improves Knee Osteoarthritis in Rabbits by
   Regulation of OPG/RANKL/RANK System
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE knee osteoarthritis; subchondral bone; Hui Medicine moxibustion; OPG;
   RANKL; RANK
ID MATRIX METALLOPROTEINASE; ARTICULAR CARTILAGE; GENE EXPRESSION;
   BONE RESORPTION; IN VITRO; RANKL; HIP; ASSOCIATION; IL 1 BETA; DISEASE
AB Background: The osteoprotegerin (OPG)/receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL) system is closely related to knee osteoarthritis (KOA) subchondral bone osteosclerosis. As a heat sensitive therapy, Hui Medicine mox ibustion (HMm) has a good therapeutic effect on KOA. This study focused on the OPG/RANKL/RANK signaling pathway in KOA subchondral bone reconstruction, and explored the mechanism of HMm action on the reconstruction of KOA subchondral bone.Methods: KOA models were established via Hulth method, and treated with HMm and HMm together with OPG antagonist (anti OPG antibody). Hematoxylin eosin staining and toluidine blue staining were used to characterize the pathological fea tures of tibia. The apoptosis of osteoclasts and osteoblasts were detected by double immunofluorescence. The expression of OPG, RANKL and RANK were detected by immunohistochemistry, Real Time Polymerase Chain Reaction (RT PCR) and west ern blotting. In addition, RT PCR and western blotting were used to detect matalloproteinase 3 (MMP 3), matalloproteinase 9 (MMP 9), interleukin 1 (IL 1), type I collagen (COL I) and osteopontin (OPN). Hydroxyproline, hexosamine, aggrecan and calcium were detected by corresponding kit.Results: After HMm treatment, the loss of cartilage and subchondral bone were significantly decreased. HMm treatment also increased the ratio of apoptotic osteoclasts to apoptotic osteoblasts. Compared with KOA group, HMm treatment promoted the protein level of OPG and decreased the protein level of RANKL. In addition, the expression levels of MMP 3, MMP 9 and IL 1 were markedly decreased and OPN was increased. The components of subchondral bone (hydroxyproline, hexosamine, aggre can and calcium) were significantly promoted in the Hui/KOA group. However, OPG antagonist alleviated these effects of HMm treatment.Conclusions: HMm treatment may improve subchondral bone in KOA by regulating the osteoprotegerin (OPG)/receptor acti vator of nuclear factor kappa B (RANK)/RANK ligand (RANKL) system. This study may provide a basis for KOA treatment.
C1 [Lin, Rui Zhu; Li, Zhi Jun; Su, Wei Xia; Wen, Sha; Zhang, Jin Chen] Ningxia Med Univ, Dept Rehabil Med, Gen Hosp, Yinchuan 750004, Ningxia, Peoples R China.
   [Lin, Rui Zhu; Xu, Jian Feng] Ningxia Med Univ, Key Lab Modernizat Tradit Chinese Med, Yinchuan 750004, Ningxia, Peoples R China.
   [Xu, Jian Feng] Ningxia Med Univ, Gen Hosp, Tradit Chinese Med & Traumatol, Yinchuan 750004, Ningxia, Peoples R China.
   [Zhu, Shi Qiang; Hei, Xiao Yan] Ningxia Med Univ, Sch Clin Med, Dept Rehabil Med, Yinchuan 750004, Ningxia, Peoples R China.
C3 Ningxia Medical University; Ningxia Medical University; Ningxia Medical
   University; Ningxia Medical University
RP Xu, JF (通讯作者)，Ningxia Med Univ, Key Lab Modernizat Tradit Chinese Med, Yinchuan 750004, Ningxia, Peoples R China.; Xu, JF (通讯作者)，Ningxia Med Univ, Gen Hosp, Tradit Chinese Med & Traumatol, Yinchuan 750004, Ningxia, Peoples R China.
EM xjf13519217795@163.com
FU National Natural Science Foundation of China;  [81860893]
FX This study was supported by National Natural Science Foundation of China
   (Grant No.: 81860893) .
CR Baud'huin M, 2007, EXPERT REV ANTICANC, V7, P221, DOI 10.1586/14737140.7.2.221
   Benito MJ, 2005, ANN RHEUM DIS, V64, P1263, DOI 10.1136/ard.2004.025270
   Blom AB, 2007, ARTHRITIS RHEUM, V56, P147, DOI 10.1002/art.22337
   Brouwer GM, 2007, ARTHRITIS RHEUM, V56, P1204, DOI 10.1002/art.22515
   Chen CTC, 2014, ASME 2007 SUMMER BIO
   Chen HB, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2521 4
   Chen HM, 2011, AM J SPORT MED, V39, P1731, DOI 10.1177/0363546511403282
   Chen Y, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/3196427
   Chiba K, 2012, OSTEOPOROSIS INT, V23, P589, DOI 10.1007/s00198 011 1585 2
   Choi TY, 2017, MATURITAS, V100, P33, DOI 10.1016/j.maturitas.2017.03.314
   Dawson J, 2005, ARTHRIT RHEUM ARTHR, V53, P368, DOI 10.1002/art.21180
   Elmouelhi N, 2009, J MED CHEM, V52, P2515, DOI 10.1021/jm801661m
   Evans CH, 2004, GENE THER, V11, P379, DOI 10.1038/sj.gt.3302196
   Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003 4819 133 8 200010170 00016
   Finnilä MAJ, 2017, J ORTHOP RES, V35, P785, DOI 10.1002/jor.23312
   Fu J, 2016, J CLIN INVEST, V126, P1759, DOI 10.1172/JCI80276
   Fu Yong, 2018, Zhongguo Zhen Jiu, V38, P291, DOI 10.13703/j.0255 2930.2018.03.017
   Hei Xiao Yan, 2021, Zhen Ci Yan Jiu, V46, P656, DOI 10.13702/j.1000 0607.200976
   Hochberg MC, 2011, SEMIN ARTHRITIS RHEU, V41, P92, DOI 10.1016/j.semarthrit.2011.06.015
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Horowitz MC, 2001, CYTOKINE GROWTH F R, V12, P9, DOI 10.1016/S1359 6101(00)00030 7
   Izbicka E, 1996, J BIOL CHEM, V271, P23230, DOI 10.1074/jbc.271.38.23230
   James SL, 2018, LANCET, V392, P1789, DOI [10.1016/s0140 6736(18)32335 3, 10.1016/S0140 6736(18)32335 3]
   Jang S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052619
   KADDAM IMS, 1994, ANN CLIN BIOCHEM, V31, P327, DOI 10.1177/000456329403100403
   Kang SH, 2019, IEEE T NEUR SYS REH, V27, P1263, DOI 10.1109/TNSRE.2019.2915812
   Kerkhof HJM, 2014, ANN RHEUM DIS, V73, P2116, DOI 10.1136/annrheumdis 2013 203620
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   Li A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003244
   Li X, 2020, NANOSCALE, V12, P12869, DOI 10.1039/d0nr01824d
   Lin R, 2017, J CHANGCHUN U TRADIT, V33, P34
   Lin RZ, 2014, J GANSU COLL TRADITI, V31, P1
   Liu CL, 2018, J MAGN RESON IMAGING, V48, P669, DOI 10.1002/jmri.25982
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Matsuoka K, 2014, J BONE MINER RES, V29, P1522, DOI 10.1002/jbmr.2187
   Mulcahy LE, 2011, BONE, V48, P182, DOI 10.1016/j.bone.2010.09.014
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Nong XG, 2017, J ACUPUNCT TUINA SCI, V15, P277, DOI 10.1007/s11726 017 1013 z
   Panseri S, 2012, KNEE SURG SPORT TR A, V20, P1182, DOI 10.1007/s00167 011 1655 1
   Park JH, 2017, MOL CELLS, V40, P706
   Prieto Alhambra D, 2014, ANN RHEUM DIS, V73, P1659, DOI 10.1136/annrheumdis 2013 203355
   Ren Xiu Mei, 2011, Zhongguo Zhen Jiu, V31, P1057
   Ryan JW, 2013, CURR DRUG TARGETS, V14, P1683, DOI 10.2174/138945011131400212
   Sandy JD, 1998, BIOCHEM J, V335, P59, DOI 10.1042/bj3350059
   Shintani Y, 2008, J CELL BIOL, V180, P1277, DOI 10.1083/jcb.200708137
   Silva RAB, 2019, INT ENDOD J, V52, P1489, DOI 10.1111/iej.13145
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Silverwood V, 2015, OSTEOARTHR CARTILAGE, V23, P507, DOI 10.1016/j.joca.2014.11.019
   Stoop R, 2000, ARTHRITIS RHEUM, V43, P2121, DOI 10.1002/1529 0131(200009)43:9<2121::AID ANR24>3.0.CO;2 N
   Sun Y, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01648 z
   Tetlow LC, 2001, ARTHRITIS RHEUM US, V44, P585, DOI 10.1002/1529 0131(200103)44:3<585::AID ANR107>3.3.CO;2 3
   Wang Shunji, 2018, Zhongguo Zhen Jiu, V38, P919, DOI 10.13703/j.0255 2930.2018.09.003
   Wang Shunji, 2017, Zhongguo Zhen Jiu, V37, P1047, DOI 10.13703/j.0255 2930.2017.10.006
   Wang TS, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6682581
   Xia B, 2018, CHINESE J ETHNOMEDIC, V27, P20
   Yung S, 1996, KIDNEY INT, V50, P1337, DOI 10.1038/ki.1996.446
   Zhao JJ, 2018, STEM CELL REP, V10, P180, DOI 10.1016/j.stemcr.2017.11.017
   Zhu X, 2016, BIOCHEM PHARMACOL, V104, P118, DOI 10.1016/j.bcp.2016.02.013
NR 59
TC 0
Z9 0
U1 1
U2 11
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393 974X
EI 1724 6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD JUL AUG
PY 2022
VL 36
IS 4
BP 1173
EP 1184
DI 10.23812/j.biol.regul.homeost.agents.20223604.128
PG 12
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA 6Q2SW
UT WOS:000891467600001
DA 2025 08 17
ER

PT J
AU Rauch, A
   Seitz, S
   Baschant, U
   Schilling, AF
   Illing, A
   Stride, B
   Kirilov, M
   Mandic, V
   Takacz, A
   Schmidt Ullrich, R
   Ostermay, S
   Schinke, T
   Spanbroek, R
   Zaiss, MM
   Angel, PE
   Lerner, UH
   David, JP
   Reichardt, HM
   Amling, M
   Schütz, G
   Tuckermann, JP
AF Rauch, Alexander
   Seitz, Sebastian
   Baschant, Ulrike
   Schilling, Arndt F.
   Illing, Anett
   Stride, Brenda
   Kirilov, Milen
   Mandic, Vice
   Takacz, Andrea
   Schmidt Ullrich, Ruth
   Ostermay, Susanne
   Schinke, Thorsten
   Spanbroek, Rainer
   Zaiss, Mario M.
   Angel, Peter E.
   Lerner, Ulf H.
   David, Jean Pierre
   Reichardt, Holger M.
   Amling, Michael
   Schuetz, Guenther
   Tuckermann, Jan P.
TI Glucocorticoids Suppress Bone Formation by Attenuating Osteoblast
   Differentiation via the Monomeric Glucocorticoid Receptor
SO CELL METABOLISM
LA English
DT Article
ID INDUCED OSTEOPOROSIS; GENE EXPRESSION; DNA BINDING; CELL CYCLE; MICE;
   INHIBITION; INTERLEUKIN 11; OSTEOCLAST; MECHANISMS; PHENOTYPE
AB Development of osteoporosis severely complicates long term glucocorticoid (GC) therapy. Using a Cre transgenic mouse line, we now demonstrate that GCs are unable to repress bone formation in the absence of glucocorticoid receptor (GR) expression in osteoblasts as they become refractory to hormone induced apoptosis, inhibition of proliferation, and differentiation. In contrast, GC treatment still reduces bone formation in mice carrying a mutation that only disrupts GR dimerization, resulting in bone loss in vivo, enhanced apoptosis, and suppressed differentiation in vitro. The inhibitory GC effects on osteoblasts can be explained by a mechanism involving suppression of cytokines, such as interleukin 11, via interaction of the monomeric GR with AP 1, but not NF kappa B. Thus, GCs inhibit cytokines independent of GR dimerization and thereby attenuate osteoblast differentiation, which accounts, in part, for bone loss during GC therapy.
C1 [Rauch, Alexander; Baschant, Ulrike; Illing, Anett; Ostermay, Susanne; Tuckermann, Jan P.] FLI, Leibniz Inst Age Res, Tissue Specif Hormone Act, D 07745 Jena, Germany.
   [Seitz, Sebastian; Schilling, Arndt F.; Schinke, Thorsten; Amling, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
   [Stride, Brenda; Kirilov, Milen; Takacz, Andrea; Schuetz, Guenther] German Canc Res Ctr, Div Mol Biol Cell 1, D 69120 Heidelberg, Germany.
   [Angel, Peter E.] German Canc Res Ctr, Div Signal Transduct & Growth Control, D 69120 Heidelberg, Germany.
   [Stride, Brenda] European Mol Biol Lab, D 69117 Heidelberg, Germany.
   [Mandic, Vice; David, Jean Pierre] DRFZ, D 10117 Berlin, Germany.
   [Schmidt Ullrich, Ruth] Max Delbruck Ctr Mol Med, Dept Signal Transduct Tumor Cells, D 13092 Berlin, Germany.
   [Spanbroek, Rainer] Univ Jena, Inst Vasc Med, D 07737 Jena, Germany.
   [Zaiss, Mario M.; David, Jean Pierre] Univ Erlangen Nurnberg, Dept Internal Med Rheumatol & Immunol 3, D 91054 Erlangen, Germany.
   [Lerner, Ulf H.] Univ Gothenburg, Sahlgrenska Acad, Ctr Bone & Arthrit Res, S 40530 Gothenburg, Sweden.
   [Lerner, Ulf H.] Umea Univ, Fac Med, SE 90187 Umea, Sweden.
   [Reichardt, Holger M.] Univ Gottingen, Sch Med, Dept Cellular & Mol Immunol, D 37073 Gottingen, Germany.
C3 Leibniz Association; Leibniz Institut fur Alternsforschung  
   Fritz Lipmann Institut (FLI); Friedrich Loeffler Institute; University
   of Hamburg; University Medical Center Hamburg Eppendorf; Helmholtz
   Association; German Cancer Research Center (DKFZ); Helmholtz
   Association; German Cancer Research Center (DKFZ); European Molecular
   Biology Laboratory (EMBL); Leibniz Association; Deutsches
   Rheuma Forschungszentrum (DRFZ); Helmholtz Association; Max Delbruck
   Center for Molecular Medicine; Friedrich Schiller University of Jena;
   University of Erlangen Nuremberg; University of Gothenburg; Umea
   University; University of Gottingen
RP Tuckermann, JP (通讯作者)，FLI, Leibniz Inst Age Res, Tissue Specif Hormone Act, D 07745 Jena, Germany.
RI Baschant, Ulrike/ABX 3545 2022; Zaiss, Mario/ABE 7125 2021; Rauch,
   Alexander/AAY 5235 2021; Reichardt, Holger/AAF 3048 2020
OI Lerner, Ulf/0000 0002 3579 1960; zaiss, mario/0000 0003 3844 1664;
   Baschant, Ulrike/0000 0002 6862 1650; Rauch,
   Alexander/0000 0002 9429 7356
FU DFG [5FB488, SFB405, SFB636, FOR Ot 165/2 2, GRK 791/1 02, GRK 484,
   Tu 220/3, Schu 51/7 2, RE 1631/1 3]; Fonds der Chemischen Industrie; EU
   [QLG1 CT 2001 01574, LSHM CT 2005 018652/CRESCENDO]; BMBF [FZK
   01GS01117, 01GS0477, KGCV1/01GS0416]; German Polish cooperation project
   [01GZ0310, 0313074C systems biology]; Swedish Research Council for
   Medicine [7525]; Boehringer Ingelheim Stiftung
FX We would like to acknowledge Katrin Buder, Sabine Matz, Anja Grubl, and
   Dominique Galendo for excellent technical assistance and mouse
   husbandry, Jeske Smink and Frank Beier for scientific advice, and Ivonne
   Roppnack Jahnke for editing the manuscript This work was supported by
   the DFG (5FB488, SFB405, SFB636, FOR Ot 165/2 2, GRK 791/1 02, GRK 484,
   Tu 220/3, Schu 51/7 2, RE 1631/1 3), the Fonds der Chemischen Industrie,
   the EU (QLG1 CT 2001 01574 and LSHM CT 2005 018652/CRESCENDO), the BMBF
   (NGFN grants FZK 01GS01117, 01GS0477, and KGCV1/01GS0416), the
   German Polish cooperation project (01GZ0310 and 0313074C systems
   biology) the Swedish Research Council for Medicine (grant number 7525),
   and the Boehringer Ingelheim Stiftung
CR Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982
   Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344
   Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Casanova E, 2001, GENESIS, V31, P37, DOI 10.1002/gene.1078
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chien HH, 2000, CALCIFIED TISSUE INT, V67, P141, DOI 10.1007/s00223001128
   David JP, 2005, J CLIN INVEST, V115, P664, DOI 10.1172/JCI200522877
   DURBRIDGE TC, 1990, CALCIFIED TISSUE INT, V47, P383, DOI 10.1007/BF02555891
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 2009, ARTHRITIS RHEUM, V60, P1427, DOI 10.1002/art.24445
   Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822
   James CG, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 205
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Kalak R, 2009, BONE, V45, P61, DOI 10.1016/j.bone.2009.03.673
   Kassel O, 2007, MOL CELL ENDOCRINOL, V275, P13, DOI 10.1016/j.mce.2007.07.003
   KAUFMANN MH, 2003, ATLAS MOUSE DEV
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Krampera M, 2005, BLOOD, V106, P59, DOI 10.1182/blood 2004 09 3645
   METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092 8674(00)81183 6
   Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168
   Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100
   Schmidt Ullrich R, 2001, DEVELOPMENT, V128, P3843
   Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607
   SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411
   Sher LB, 2006, CALCIFIED TISSUE INT, V79, P118, DOI 10.1007/s00223 005 0297 z
   Sher LB, 2004, ENDOCRINOLOGY, V145, P922, DOI 10.1210/en.2003 0655
   Sims NA, 2005, J BONE MINER RES, V20, P1093, DOI 10.1359/JBMR.050209
   Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200
   Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007
   Stock M, 2005, J CELL BIOCHEM, V95, P506, DOI 10.1002/jcb.20471
   Takeuchi Y, 2002, J BIOL CHEM, V277, P49011, DOI 10.1074/jbc.M207804200
   Tohjima E, 2003, J BONE MINER RES, V18, P1461, DOI 10.1359/jbmr.2003.18.8.1461
   Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703
   Tuckermann JP, 2007, J CLIN INVEST, V117, P1381, DOI 10.1172/JCI28034
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Yoshikawa N, 2009, AM J PHYSIOL ENDOC M, V296, pE1363, DOI 10.1152/ajpendo.90767.2008
NR 41
TC 331
Z9 371
U1 3
U2 41
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550 4131
EI 1932 7420
J9 CELL METAB
JI Cell Metab.
PD JUN 9
PY 2010
VL 11
IS 6
BP 517
EP 531
DI 10.1016/j.cmet.2010.05.005
PG 15
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 610PZ
UT WOS:000278747800010
PM 20519123
OA Bronze
DA 2025 08 17
ER

PT J
AU Brandi, ML
AF Brandi, Maria Luisa
TI Micro architecture, the key to bone quality
SO RHEUMATOLOGY
LA English
DT Article; Proceedings Paper
CT Satellite Symposium on Improvement of Bone Microarchitecture   The
   Foundation for a Better Protection against Osteoporotic Fractures
CY JUN 11, 2009
CL Copenhagen, DENMARK
DE Bone modelling; Bone remodelling; Osteoporosis; Microarchitecture
ID HUMAN TRABECULAR BONE; MINERAL DENSITY; NONVERTEBRAL FRACTURE;
   REGULATORY MECHANISMS; OVARIECTOMIZED RATS; PARATHYROID HORMONE;
   OSTEOPOROSIS; NANOINDENTATION; OSTEOCLAST; STRENGTH
AB Bone has the ability to adapt its shape and size in response to mechanical loads via a process known as modelling in which bones are shaped or reshaped by the independent action of osteoblasts and osteoclasts. Remodelling is a process that maintains mechanical integrity of the skeleton, allowing it to selectively repair and replace damaged bone. During adulthood, bone remodelling is the dominant process, after the age of 40 years, the age related decline in bone mass increases the risk of fracture, especially in women Osteoporosis is defined as a reduction in bone mass and an impairment of bone architecture resulting in thinning and increased cortical porosity, bone fragility and fracture risk As new products and methods have been developed, focusing on bone fragility, effective and sensitive non invasive means able to detect early changes in bone fragility process have also been developed Due to limitations in assessing fracture risk and response to therapy, the evaluation of bone mineral contents by bone densitometry is progressively replaced by new non invasive and/or non destructive techniques able to estimate bone strength, providing structural information about the pathophysiology of bone fragility by quantitative assessments of macro  and microstructural bone features DXA and volumetric QCT quantify bone macrostructure, whereas high resolution CT, microCT, high resolution MR and microMR assess bone microstructure Knowledge of bone microarchitecture is a clue for understanding osteoporosis pathophysiology and improving its diagnosis and treatment; the response of microarchitecture parameters to treatment should allow assessment of the real efficacy of the osteoporosis therapy
C1 Univ Florence, Dept Internal Med, I 50139 Florence, Italy.
C3 University of Florence
RP Brandi, ML (通讯作者)，Univ Florence, Dept Internal Med, Viale Pieraccini 6, I 50139 Florence, Italy.
CR Ammann P, 1996, OSTEOPOROSIS INT, V6, P219, DOI 10.1007/BF01622738
   Ammann P, 1999, OSTEOPOROSIS INT, V10, P369, DOI 10.1007/s001980050242
   Anderson H Clarke, 2003, Curr Rheumatol Rep, V5, P222, DOI 10.1007/s11926 003 0071 z
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Blair HC, 2004, HISTOL HISTOPATHOL, V19, P189, DOI 10.14670/HH 19.189
   Bouxsein ML, 2008, NAT CLIN PRACT RHEUM, V4, P310, DOI 10.1038/ncprheum0798
   Bouxsein ML, 2005, BEST PRACT RES CL RH, V19, P897, DOI 10.1016/j.berh.2005.07.004
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chappard D., 2008, Morphologie, V92, P162, DOI 10.1016/j.morpho.2008.10.003
   Chevalier Y, 2007, J BIOMECH, V40, P3333, DOI 10.1016/j.jbiomech.2007.05.004
   Cummings S. R., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P198
   Delmas PD, 2004, BONE, V34, P599, DOI 10.1016/j.bone.2003.12.022
   Dempster D.W., 2002, DISORDERS BONE MINER, V2, P315
   Dempster David W., 1995, P67
   Dempster DW, 2005, J CELL BIOCHEM, V95, P139, DOI 10.1002/jcb.20388
   Dempster DW., 2006, PRIMER METABOLIC BON, V6th, P7
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   FROST HM, 2003, INTERMEDIARY ORG SKE
   Genant HK, 2008, RHEUMATOLOGY, V47, P9, DOI 10.1093/rheumatology/ken180
   Gielkens PFM, 2008, ARCH ORAL BIOL, V53, P558, DOI 10.1016/j.archoralbio.2007.11.011
   Haapasalo H, 2000, BONE, V27, P351, DOI 10.1016/S8756 3282(00)00331 8
   Hengsberger S, 2002, JSME INT J C MECH SY, V45, P936, DOI 10.1299/jsmec.45.936
   Iwaniec Urszula T., 2008, V447, P325, DOI 10.1007/978 1 59745 242 7_21
   Kalpakcioglu BB, 2008, J BONE JOINT SURG AM, V90A, P68, DOI 10.2106/JBJS.G.01506
   Kanis JA, 2009, FRAX WHO FRACTURE RI
   Kaufman JD, 2007, J BIOMED MATER RES A, V81A, P611, DOI 10.1002/jbm.a.30976
   Kobayashi S, 2003, BONE, V32, P163, DOI 10.1016/S8756 3282(02)00947 X
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Norman J, 2008, J BIOMED MATER RES A, V87A, P196, DOI 10.1002/jbm.a.31766
   Parfitt A.M., 2002, DISORDERS BONE MINER, V2nd, P469
   PARFITT AM, 1995, CALCIFIED TISSUE INT, V56, pS5, DOI 10.1007/BF03354639
   Reddy SV, 2004, CRIT REV EUKAR GENE, V14, P255, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.20
   Rho JY, 1997, BIOMATERIALS, V18, P1325, DOI 10.1016/S0142 9612(97)00073 2
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   STRIS ES, 2004, ARCH INTERN MED, V164, P1108
   Troen BR, 2003, EXP GERONTOL, V38, P605, DOI 10.1016/S0531 5565(03)00069 X
   Ubara Y, 2005, KIDNEY INT, V68, P833, DOI 10.1111/j.1523 1755.2005.00464.x
   Ubara Y, 2003, KIDNEY INT, V63, P1809, DOI 10.1046/j.1523 1755.2003.00916.x
   Watts NB, 2005, J BONE MINER RES, V20, P2097, DOI 10.1359/JBMR.050814
   Zysset PK, 1999, J BIOMECH, V32, P1005, DOI 10.1016/S0021 9290(99)00111 6
NR 42
TC 166
Z9 205
U1 1
U2 38
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462 0324
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD OCT
PY 2009
VL 48
BP IV3
EP IV8
DI 10.1093/rheumatology/kep273
PG 6
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Rheumatology
GA 510PU
UT WOS:000271103200002
PM 19783591
OA Bronze
DA 2025 08 17
ER

PT J
AU Xi, YM
   Chen, Y
AF Xi, Yongming
   Chen, Yan
TI PTEN Plays Dual Roles As a Tumor Suppressor in Osteosarcoma Cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE PTEN; AKT; BONE; OSTEOSARCOMA; OSTEOCLAST
ID PROSTATE CANCER; PROMOTES PROLIFERATION; PHOSPHATASE; PATHWAY;
   METASTASIS; EXPRESSION; INHIBITOR; GENE
AB Osteosarcoma (OS) is the most common primary bone cancer, which occurs primarily in children and adolescents. Functional loss of the tumor suppressor PTEN has been demonstrated in bone malignancies including OS. We have recently reported that Pten expression inversely correlates with OS aggressiveness in mouse models. However, the mechanism whereby PTEN exerts its anti tumor effect remains unknown. In this study, we first examined the expression of PTEN in human OS cell lines including U2OS, MG63 and Saos 2, and found that PTEN expression is reduced as compared to normal human osteoblasts. The downregulation of PTEN also associates with activation of AKT pathway. We then treated previously reported mouse OS tumor cells MOTO Rank(/OC) and human OS cell line U2OS with PTEN inhibitor VO OHpic to investigate how PTEN impacts tumor cell behaviors. Our results showed that PTEN inhibits tumor cell proliferation, migration and invasion, but enhances tumor cell apoptosis. However, PTEN has no effects on tumor cell senescence and chemotaxis. PTEN also fails to induce tumor cells differentiation toward osteoblast lineage. On the other hand, PTEN inhibits tumor associated osteoclast differentiation. Moreover, overexpression of PTEN using gene transfer in U2OS cells inhibits proliferation but increases apoptosis. These findings indicate that PTEN not only targets tumor cells themselves by impacting cell behaviors, but also blocks osteoclast mediated bone destruction, leading to interruption of the vicious cycle during osteosarcomagenesis. Loss of PTEN may consequently facilitate tumor growth and expansion in bone. Restoration of fully functional PTEN using gene therapy represents a potential approach against (C) 2017 Wiley Periodicals, Inc.
C1 [Xi, Yongming] Qingdao Univ, Dept Orthopaed, Affiliated Hosp, Qingdao, Peoples R China.
   [Chen, Yan] Univ Hlth Network, Div Signaling Biol, Princess Margaret Canc Ctr, Rm 13 301,TMDT Bldg,101 Coll St, Toronto, ON, Canada.
C3 Qingdao University; University of Toronto; University Health Network
   Toronto; Princess Margaret Cancer Centre
RP Chen, Y (通讯作者)，Univ Hlth Network, Div Signaling Biol, Princess Margaret Canc Ctr, Rm 13 301,TMDT Bldg,101 Coll St, Toronto, ON, Canada.
EM yyanchen@yahoo.com
CR Blüml S, 2015, ANN RHEUM DIS, V74, P227, DOI 10.1136/annrheumdis 2013 203486
   Chalhoub N, 2009, ANNU REV PATHOL MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Chen Y, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0295
   Davies MA, 2002, CLIN CANCER RES, V8, P1904
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092 8674(00)80674 1
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Dougall William C, 2007, Curr Opin Support Palliat Care, V1, P317, DOI 10.1097/SPC.0b013e3282f335be
   Freeman SS, 2008, CANCER AM CANCER SOC, V113, P1453, DOI 10.1002/cncr.23782
   Gao Y, 2014, BIOCHEM BIOPH RES CO, V444, P230, DOI 10.1016/j.bbrc.2014.01.061
   Georgescu Maria Magdalena, 2010, Genes Cancer, V1, P1170, DOI 10.1177/1947601911407325
   Hopkins BD, 2013, SCIENCE, V341, P399, DOI 10.1126/science.1234907
   Kawano M, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0192 z
   Levine RA, 2002, VET PATHOL, V39, P372, DOI 10.1354/vp.39 3 372
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535 6108(03)00248 4
   Lv C, 2016, TUMOR BIOL, V37, P9333, DOI 10.1007/s13277 016 4807 6
   Mak Lok Hang, 2010, J Chem Biol, V3, P157, DOI 10.1007/s12154 010 0041 7
   Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391
   Namlos HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048086
   Patel M, 2014, MOL CANCER RES, V12, P1610, DOI 10.1158/1541 7786.MCR 14 0006
   Rosivatz E, 2006, ACS CHEM BIOL, V1, P780, DOI 10.1021/cb600352f
   Shen L, 2014, TUMOR BIOL, V35, P2069, DOI 10.1007/s13277 013 1274 1
   Tamura M, 1999, JNCI J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820
   Wu Z, 2007, CARCINOGENESIS, V28, P1393, DOI 10.1093/carcin/bgm050
   Xi YM, 2015, J CELL BIOCHEM, V116, P1837, DOI 10.1002/jcb.25159
   Zhao GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053906
NR 28
TC 24
Z9 26
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP
PY 2017
VL 118
IS 9
BP 2684
EP 2692
DI 10.1002/jcb.25888
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FA5WN
UT WOS:000405515000020
PM 28106296
DA 2025 08 17
ER

PT J
AU Wang, R
   Zheng, J
   Zhang, DS
   Yang, YH
   Zhao, ZF
AF Wang, R.
   Zheng, J.
   Zhang, D.  S.
   Yang, Y.  H.
   Zhao, Z.  F.
TI Wnt1 induced MAFK expression promotes osteosarcoma cell proliferation
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Wnt; MAFK; Osteosarcoma; Proliferation
ID ANTIOXIDANT RESPONSE ELEMENT; THERAPY; GENE; WNT; DIFFERENTIATION;
   DISRUPTION; ACTIVATION; INDUCTION; SUBUNIT; TARGET
AB Osteosarcoma is one of the most common primary bone tumors in children and young adults. In this study, we investigated the role of musculoaponeurotic fibrosarcoma oncogene homolog K (MAFK) in osteosarcoma cell proliferation in vitro and the possible pathways that contributed to MAFK related osteosarcoma development. We first reported that MAFK was expressed at low levels in an osteosarcoma cell line. Furthermore, a significant correlation between MAFK and the Wnt signaling pathway was observed in osteosarcoma by using a gene microarray assay. We found that expression of MAFK could be induced by Wnt1 in a dose dependent manner. Furthermore, Wnt1 induced MAFK expression caused a significant increase of cell viability, whereas a Wnt pathway inhibitor, IWR 1 endo, abolished Wnt1 induced effects on MAFK. Finally, cell cycle analysis showed that enhanced cell proliferation might be attributed to re distribution of the cell cycle. Together, our results suggested that Wnt1 induced MAFK expression promoted cell proliferation in MG63 cells, and that the role of MAFK in osteosarcoma might be closely linked to the Wnt signaling pathway.
C1 [Wang, R.; Zheng, J.; Zhang, D.  S.; Yang, Y.  H.; Zhao, Z.  F.] PLA, Hosp 117, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China.
RP Zhao, ZF (通讯作者)，PLA, Hosp 117, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China.
EM zhaozfag@126.com
RI zhang, dongsheng/LCD 7887 2024
CR Bielack SS, 2008, CURR TREAT OPTION ON, V9, P67, DOI 10.1007/s11864 008 0057 1
   Blank V, 1997, GENOMICS, V44, P147, DOI 10.1006/geno.1997.4847
   Brand M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/nsmb713
   Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248
   Brun J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055034
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Chou Alexander J, 2008, Paediatr Drugs, V10, P315, DOI 10.2165/00148581 200810050 00005
   Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200
   Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898
   Ghosh M, 2014, CURR OPIN ONCOL, V26, P305, DOI 10.1097/CCO.0000000000000064
   Gorjánácz M, 2014, NUCLEUS PHILA, V5, P47, DOI 10.4161/nucl.27928
   Hoang BH, 2012, J AM ACAD ORTHOP SUR, V20, P58, DOI 10.5435/JAAOS 20 01 058
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Kannan MB, 2012, BBA MOL CELL RES, V1823, P1841, DOI 10.1016/j.bbamcr.2012.06.012
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   McQueen P, 2011, EXPERT REV ANTICANC, V11, P1223, DOI [10.1586/era.11.94, 10.1586/ERA.11.94]
   NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604
   Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200
   Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528
   NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711
   Okita Y, 2013, J BIOL CHEM, V288, P20658, DOI 10.1074/jbc.M113.450478
   Siclari VA, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 78
   Siegel HJ, 2008, EXPERT REV ANTICANC, V8, P1257, DOI 10.1586/14737140.8.8.1257
   Trent JC, 2008, CURR OPIN ONCOL, V20, P393, DOI 10.1097/CCO.0b013e328303ba31
   Vinson C, 2006, BBA GENE STRUCT EXPR, V1759, P4, DOI 10.1016/j.bbaexp.2005.12.005
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
   Zhong LZ, 2014, MOL CELL BIOCHEM, V392, P135, DOI 10.1007/s11010 014 2027 1
NR 28
TC 11
Z9 12
U1 0
U2 5
PU FUNPEC EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676 5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2015
VL 14
IS 3
BP 7315
EP 7325
DI 10.4238/2015.July.3.7
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CS9OR
UT WOS:000362421100007
PM 26214410
OA Bronze
DA 2025 08 17
ER

PT J
AU Heckt, T
   Brylka, LJ
   Neven, M
   Amling, M
   Schinke, T
AF Heckt, Timo
   Brylka, Laura J.
   Neven, Mona
   Amling, Michael
   Schinke, Thorsten
TI Deficiency of sphingosine 1 phosphate receptor 3 does not affect the
   skeletal phenotype of mice lacking sphingosine 1 phosphate lyase
SO PLOS ONE
LA English
DT Article
ID SPHINGOSINE 1 PHOSPHATE; BONE MASS; INSIGHTS
AB Albeit osteoporosis is one of the most prevalent disorders in the aged population, treatment options stimulating the activity of bone forming osteoblasts are still limited. We and others have previously identified sphingosine 1 phosphate (S1P) as a bone remodeling coupling factor, which is released by bone resorbing osteoclasts to stimulate bone formation. Moreover, S1pr3, encoding one of the five known S1P receptors (S1P3), was found differentially expressed in osteoblasts, and S1P3 deficiency corrected the moderate high bone mass phenotype of a mouse model (deficient for the calcitonin receptor) with increased S1P release from osteoclasts. In the present study we addressed the question, if S1P3 deficiency would also influence the skeletal phenotype of mice lacking S1P lyase (encoded by Sgpl1), which display markedly increased S1P levels due to insufficient degradation. Consistent with previous reports, the majority of Sgpl1 deficient mice died before or shortly after weaning, and this lethality was not influenced by additional S1P3 deficiency. At 3 weeks of age, Sgpl1 deficient mice displayed increased trabecular bone mass, which was associated with enhanced osteoclastogenesis and bone resorption, but also with increased bone formation. Most importantly however, none of the skeletal parameters assessed by mu CT, histomorphometry and serum analyses were significantly influenced by additional S1P3 deficiency. Taken together, our findings fully support the concept that S1P is a potent osteoanabolic molecule, although S1P3 is not the sole receptor mediating this influence. Since S1P receptors are considered excellent drug targets, it is now required to screen for the impact of other family members on bone formation.
C1 [Heckt, Timo; Brylka, Laura J.; Neven, Mona; Amling, Michael; Schinke, Thorsten] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf
RP Schinke, T (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Hamburg, Germany.
EM schinke@uke.de
RI Brylka, Laura/D 7908 2014
OI Brylka, Laura/0000 0003 4734 9966; Schinke, Thorsten/0000 0002 8576 0177
FU German Research foundation [AM 103/24 1]
FX This work was supported by the German Research foundation (AM 103/24 1).
   The funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Bauer B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6137
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chun J, 2010, PHARMACOL REV, V62, P579, DOI 10.1124/pr.110.003111
   Del Fattore Andrea, 2012, Front Biosci (Elite Ed), V4, P2302
   Don Doncow N, 2018, BR J PHARM
   Henriksen K, 2014, CALCIFIED TISSUE INT, V94, P88, DOI 10.1007/s00223 013 9741 7
   Hisano Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038941
   Hoff AO, 2002, J CLIN INVEST, V110, P1849, DOI 10.1172/JCI200214218
   Ikeda Kyoji, 2014, J Bone Metab, V21, P163, DOI 10.11005/jbm.2014.21.3.163
   Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200
   Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198 012 1964 3
   Kawahara A, 2009, SCIENCE, V323, P524, DOI 10.1126/science.1167449
   Khavandgar Z, 2015, CELL MOL LIFE SCI, V72, P959, DOI 10.1007/s00018 014 1778 x
   Kim MK, 2006, BIOCHEM BIOPH RES CO, V345, P67, DOI 10.1016/j.bbrc.2006.04.042
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Liu X, 2012, MOL CELL BIOCHEM, V363, P21, DOI 10.1007/s11010 011 1154 1
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Mendelson K, 2014, DEVELOPMENT, V141, P5, DOI 10.1242/dev.094805
   Mutoh T, 2012, BRIT J PHARMACOL, V165, P829, DOI 10.1111/j.1476 5381.2011.01622.x
   Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Rachner TD, 2012, PHARMACOL THERAPEUT, V134, P338, DOI 10.1016/j.pharmthera.2012.02.005
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Sims NA, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00041
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Van Veldhoven PP, 2000, METHOD ENZYMOL, V311, P244
   Vogel P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004112
   Weske S, 2018, NAT MED, V24, P667, DOI 10.1038/s41591 018 0005 y
   Yorgan TA, 2015, J BONE MINER RES, V30, P1175, DOI 10.1002/jbmr.2461
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 33
TC 5
Z9 6
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 17
PY 2019
VL 14
IS 7
AR e0219734
DI 10.1371/journal.pone.0219734
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IS7LS
UT WOS:000482331900040
PM 31314788
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Nirmala, FS
   Lee, H
   Kim, JS
   Ha, T
   Jung, CH
   Ahn, J
AF Nirmala, Farida S.
   Lee, Hyunjung
   Kim, Ji Sun
   Ha, Taeyoul
   Jung, Chang Hwa
   Ahn, Jiyun
TI Green Tomato Extract Prevents Bone Loss in Ovariectomized Rats, a Model
   of Osteoporosis
SO NUTRIENTS
LA English
DT Article
DE nutritional supplement; postmenopausal osteoporosis; bone homeostasis;
   green tomatoes
ID MORPHOGENETIC PROTEIN 2; DIFFERENTIATION; ASSOCIATION; TOMATIDINE;
   MANAGEMENT; OSTEOPENIA; RISK
AB Although drug therapies are available for postmenopausal osteoporosis, these drugs are not free of side effects and long term adherence to them are low. A safe and effective nutritional approach to counter postmenopausal osteoporosis is an important research goal. We fed ovariectomized (OVX) Sprague Dawley rats a diet supplemented with 1% or 2% green tomato extract (GTE). After 12 weeks, micro computed tomography scans revealed that GTE supplementation effectively prevented distal femur bone loss. This prevention was due to improved bone formation and suppressed bone resorption as observed by the regulation of osteoblast and osteoclast activities. GTE supplementation also improved bone formation through Bmp2 Smad 1/5/8 Runx2 signaling, while bone resorption was regulated by the receptor activator of nuclear factor kappa B (RANKL)/osteoprogeterin (OPG) pathway. These results suggest that GTE supplementation prevents severe postmenopausal bone loss by maintaining the regulation of bone homeostasis in OVX rats. GTE as a diet supplement might be a potential novel alternative for the prevention of postmenopausal osteoporosis.
C1 [Nirmala, Farida S.; Ha, Taeyoul; Jung, Chang Hwa; Ahn, Jiyun] Univ Sci & Technol, Dept Food Biotechnol, Daejeon 305350, South Korea.
   [Lee, Hyunjung; Kim, Ji Sun; Ha, Taeyoul; Jung, Chang Hwa; Ahn, Jiyun] Korea Food Res Inst, Res Grp Nat Mat & Metab, Wonju 55365, South Korea.
   [Kim, Ji Sun] Korea Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul 02841, South Korea.
C3 University of Science & Technology (UST); Korea Food Research Institute
   (KFRI); Korea University
RP Ahn, J (通讯作者)，Univ Sci & Technol, Dept Food Biotechnol, Daejeon 305350, South Korea.; Ahn, J (通讯作者)，Korea Food Res Inst, Res Grp Nat Mat & Metab, Wonju 55365, South Korea.
EM 50013@kfri.re.kr; hjlee1120@kfri.re.kr; jskim320@gmail.com;
   tyhap@kfri.re.kr; chjung@kfri.re.kr; jyan@kfri.re.kr
OI Jung, Chang Hwa/0000 0002 1076 750X; Ha, Tae Youl/0000 0001 7583 9490;
   Kim, Ji Sun/0000 0002 9568 1114
FU Korea Food Research Institute [E0160500]
FX This research was fully funded by Korea Food Research Institute
   (E0160500).
CR Aggarwal S., 2016, J POSTGRAD MED ED RE, V50, P75, DOI DOI 10.5005/JP JOURNALS 10028 1197
   Ahn J, 2013, EMBO MOL MED, V5, P1602, DOI 10.1002/emmm.201302647
   Bodenner D, 2007, CLIN INTERV AGING, V2, P499
   Chen JH, 2017, J FORMOS MED ASSOC, V116, P888, DOI 10.1016/j.jfma.2017.01.003
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Fang EF, 2017, SCI REP UK, V7, DOI 10.1038/srep46208
   Friedman M, 2009, J AGR FOOD CHEM, V57, P5727, DOI 10.1021/jf900364j
   Fujiwara Y, 2012, J AGR FOOD CHEM, V60, P2472, DOI 10.1021/jf204197r
   Gambacciani M, 2014, MENOPAUSE REV, V13, P213, DOI 10.5114/pm.2014.44996
   Go EM, 2020, EXP MOL MED, V52, P691, DOI 10.1038/s12276 020 0427 8
   Hatefi M, 2018, WORLD NEUROSURG, V114, pE785, DOI 10.1016/j.wneu.2018.03.081
   Hu B, 2019, FASEB J, V33, P2574, DOI 10.1096/fj.201800920R
   Jeon EJ, 2016, MOL NUTR FOOD RES, V60, P2587, DOI 10.1002/mnfr.201600257
   Kim JS, 2019, FASEB J, V33, P3252, DOI [10.1096/fj.201800953R, 10.1096/fj.201800953r]
   Kling JM, 2014, J WOMENS HEALTH, V23, P563, DOI 10.1089/jwh.2013.4611
   Lin H, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1350 6
   Liu DB, 2018, MED SCI MONITOR, V24, P4363, DOI 10.12659/MSM.905958
   Matheson EM, 2009, MENOPAUSE, V16, P756, DOI 10.1097/gme.0b013e31819581a5
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Nakahama K, 2010, CELL MOL LIFE SCI, V67, P4001, DOI 10.1007/s00018 010 0479 3
   Pouresmaeili F, 2018, THER CLIN RISK MANAG, V14, P2029, DOI 10.2147/TCRM.S138000
   Reimers K. J., 2016, Nutrition Today, V51, P198, DOI 10.1097/NT.0000000000000152
   Sheng Bun, 2017, BMC Res Notes, V10, P351, DOI 10.1186/s13104 017 2681 y
   Shu B, 2011, J CELL SCI, V124, P3428, DOI 10.1242/jcs.083659
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sun J, 2015, MOL MED REP, V12, P4230, DOI 10.3892/mmr.2015.3954
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   WALLACE TC, 2017, NUTRIENTS, V9, DOI DOI 10.3390/NU904040128422064
   Watts NB, 2018, J WOMENS HEALTH, V27, P1093, DOI 10.1089/jwh.2017.6706
   Wu X, 2018, FOOD NUTR RES, V62, DOI 10.29219/fnr.v62.1478
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
   Zaidi M, 2018, ENDOCR REV, V39, P701, DOI 10.1210/er.2018 00050
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zizola C, 2015, AM J PHYSIOL HEART C, V308, pH1078, DOI 10.1152/ajpheart.00679.2014
NR 34
TC 5
Z9 5
U1 2
U2 14
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2020
VL 12
IS 10
AR 3210
DI 10.3390/nu12103210
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA ON8MV
UT WOS:000586948600001
PM 33096661
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Dunn, LK
   Mohammad, KS
   Fournier, PGJ
   McKenna, CR
   Davis, HW
   Niewolna, M
   Peng, XH
   Chirgwin, JM
   Guise, TA
AF Dunn, Lauren K.
   Mohammad, Khalid S.
   Fournier, Pierrick G. J.
   McKenna, C. Ryan
   Davis, Holly W.
   Niewolna, Maria
   Peng, Xiang Hong
   Chirgwin, John M.
   Guise, Theresa A.
TI Hypoxia and TGF β Drive Breast Cancer Bone Metastases through Parallel
   Signaling Pathways in Tumor Cells and the Bone Microenvironment
SO PLOS ONE
LA English
DT Article
AB Background: Most patients with advanced breast cancer develop bone metastases, which cause pain, hypercalcemia, fractures, nerve compression and paralysis. Chemotherapy causes further bone loss, and bone specific treatments are only palliative. Multiple tumor secreted factors act on the bone microenvironment to drive a feed forward cycle of tumor growth. Effective treatment requires inhibiting upstream regulators of groups of prometastatic factors. Two central regulators are hypoxia and transforming growth factor (TGF) beta. We asked whether hypoxia (via HIF 1 alpha) and TGF beta signaling promote bone metastases independently or synergistically, and we tested molecular versus pharmacological inhibition strategies in an animal model.
   Methodology/Principal Findings: We analyzed interactions between HIF 1 alpha and TGF beta pathways in MDA MB 231 breast cancer cells. Only vascular endothelial growth factor (VEGF) and the CXC chemokine receptor 4 (CXCR4), of 16 genes tested, were additively increased by both TGF beta and hypoxia, with effects on the proximal promoters. We inhibited HIF 1 alpha and TGF beta pathways in tumor cells by shRNA and dominant negative receptor approaches. Inhibition of either pathway decreased bone metastasis, with no further effect of double blockade. We tested pharmacologic inhibitors of the pathways, which target both the tumor and the bone microenvironment. Unlike molecular blockade, combined drug treatment decreased bone metastases more than either alone, with effects on bone to decrease osteoclastic bone resorption and increase osteoblast activity, in addition to actions on tumor cells.
   Conclusions/Significance: Hypoxia and TGF beta signaling in parallel drive tumor bone metastases and regulate a common set of tumor genes. In contrast, small molecule inhibitors, by acting on both tumor cells and the bone microenvironment, additively decrease tumor burden, while improving skeletal quality. Our studies suggest that inhibitors of HIF 1 alpha and TGF beta may improve treatment of bone metastases and increase survival.
RP Dunn, LK (通讯作者)，Univ Virginia, Dept Med, Div Endocrinol, Charlottesville, VA 22903 USA.
EM tguise@iupui.edu
RI ; Mohammad, Khalid/AFE 4205 2022; Fournier, Pierrick/B 6560 2015
OI Chirgwin, John/0009 0001 7638 0842; Fournier,
   Pierrick/0000 0001 7633 8129
FU NCI NIH HHS [PC040341, PC061185, T32 CA009109, PC051194, R01 CA069158,
   T32 CA009109, R01 CA69158, BC073157] Funding Source: Medline; NIGMS NIH
   HHS [T32 GM007267, T32 GM007267] Funding Source: Medline
CR Akagi Y, 1998, CANCER RES, V58, P4008
   Albertella MR, 2008, CLIN CANCER RES, V14, P1096, DOI 10.1158/1078 0432.CCR 07 4020
   Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008 5472.CAN 06 3946
   Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Bäuerle T, 2008, NEOPLASIA, V10, P511, DOI 10.1593/neo.08220
   Bandyopadhyay A, 2006, CANCER RES, V66, P6714, DOI 10.1158/0008 5472.CAN 05 3565
   Bartholin L, 2007, CANCER LETT, V246, P230, DOI 10.1016/j.canlet.2006.02.019
   Bauerle T., 2008, EUR J RADIOL
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Bendre MS, 2002, CANCER RES, V62, P5571
   Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019
   Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367
   CABIOGLU N, 2009, ANN ONCOL
   Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867
   Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014 5793(98)00359 7
   Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239
   Cicek M, 2007, CANCER RES, V67, P10106, DOI 10.1158/0008 5472.CAN 07 1362
   Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382
   Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008 5472.CAN 05 3560
   Diamond P., 2009, J Bone Miner Res
   Duivenvoorden WCM, 1999, CLIN EXP METASTAS, V17, P27
   Eccles SA, 2008, CANCER RES, V68, P2850, DOI 10.1158/0008 5472.CAN 07 5256
   Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349 7006.2006.00357.x
   Ge RR, 2006, CLIN CANCER RES, V12, P4315, DOI 10.1158/1078 0432.CCR 06 0162
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Hayashi T, 2004, CLIN CANCER RES, V10, P7540, DOI 10.1158/1078 0432.CCR 04 0632
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008 5472.CAN 06 2355
   Hirao M, 2007, J BONE MINER METAB, V25, P266, DOI 10.1007/s00774 007 0765 9
   Iida J, 2007, MELANOMA RES, V17, P205, DOI 10.1097/CMR.0b013e3282a660ad
   Janssen HLK, 2002, INT J RADIAT ONCOL, V54, P1537, DOI 10.1016/S0360 3016(02)03935 4
   Javelaud D, 2007, CANCER RES, V67, P2317, DOI 10.1158/0008 5472.CAN 06 3950
   Jeon SH, 2007, J LEUKOCYTE BIOL, V81, P557, DOI 10.1189/jlb.0806517
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Knowles HJ, 2008, J PATHOL, V215, P56, DOI 10.1002/path.2319
   Knowles HJ., 2009, J Pathol
   Komatsu DE, 2007, J BONE MINER RES, V22, P366, DOI 10.1359/JBMR.061207
   LaVallee TM, 2008, MOL CANCER THER, V7, P1472, DOI 10.1158/1535 7163.MCT 08 0107
   Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008 5472.CAN 06 2701
   Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008
   Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535 6108(03)00077 1
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275
   Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001
   Mooberry Susan L., 2003, Current Opinion in Oncology, V15, P425, DOI 10.1097/00001622 200311000 00004
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234
   Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200
   Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39
   Raleigh JA, 1998, CANCER RES, V58, P3765
   Richert MM, 2009, ONCOL REP, V21, P761, DOI 10.3892/or_00000282
   Ricker JL, 2004, CLIN CANCER RES, V10, P8665, DOI 10.1158/1078 0432.CCR 04 1393
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sánchez Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Sibonga JD, 2003, ENDOCRINOLOGY, V144, P785, DOI 10.1210/en.2002 220632
   Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014 5793(03)00824 X
   Tevaarwerk AJ, 2009, CLIN CANCER RES, V15, P1460, DOI 10.1158/1078 0432.CCR 08 1599
   Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008 5472.CAN 04 1013
   Varia MA, 1998, GYNECOL ONCOL, V71, P270, DOI 10.1006/gyno.1998.5163
   Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555 006 9019 x
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zhang Q, 2008, J BIOL CHEM, V283, P13491, DOI 10.1074/jbc.M708055200
   Zhong H, 1999, CANCER RES, V59, P5830
   Zhou DC, 2008, NEUROL RES, V30, P268, DOI 10.1179/016164107X229920
NR 72
TC 174
Z9 200
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD SEP 3
PY 2009
VL 4
IS 9
AR e6896
DI 10.1371/journal.pone.0006896
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 490RX
UT WOS:000269522900023
PM 19727403
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Fan, JM
   Wei, Q
   Liao, JY
   Zou, YL
   Song, DZ
   Xiong, DM
   Ma, C
   Hu, X
   Qu, XY
   Chen, LQ
   Li, L
   Yu, YC
   Yu, XY
   Zhang, ZC
   Zhao, C
   Zeng, ZY
   Zhang, RY
   Yan, SJ
   Wu, TT
   Wu, XY
   Shu, Y
   Lei, JY
   Li, YS
   Zhang, WW
   Haydon, RC
   Luu, HH
   Huang, AL
   He, TC
   Tang, H
AF Fan, Jiaming
   Wei, Qiang
   Liao, Junyi
   Zou, Yulong
   Song, Dongzhe
   Xiong, Dongmei
   Ma, Chao
   Hu, Xue
   Qu, Xiangyang
   Chen, Liqun
   Li, Li
   Yu, Yichun
   Yu, Xinyi
   Zhang, Zhicai
   Zhao, Chen
   Zeng, Zongyue
   Zhang, Ruyi
   Yan, Shujuan
   Wu, Tingting
   Wu, Xingye
   Shu, Yi
   Lei, Jiayan
   Li, Yasha
   Zhang, Wenwen
   Haydon, Rex C.
   Luu, Hue H.
   Huang, Ailong
   He, Tong Chuan
   Tang, Hua
TI Noncanonical Wnt signaling plays an important role in modulating
   canonical Wnt regulated stemness, proliferation and terminal
   differentiation of hepatic progenitors
SO ONCOTARGET
LA English
DT Article
DE Wnt/beta catenin; noncanonical Wnt signaling; liver stem cells; liver
   cancer; liver regeneration
ID OSTEOGENIC DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; BONE FORMATION;
   CELLS; LIVER; GROWTH; HOMEOSTASIS; BMP9; TUMORIGENESIS; SYNERGIZES
AB The liver provides vital metabolic, exocrine and endocrine functions in the body as such pathological conditions of the liver lead to high morbidity and mortality. The liver is highly regenerative and contains facultative stem cells that become activated during injury to replicate to fully recover mass and function. Canonical Wnt/beta catenin signaling plays an important role in regulating the proliferation and differentiation of liver progenitor cells during liver regeneration. However, possible roles of noncanonical Wnts in liver development and regeneration remain undefined. We previously established a reversibly immortalized hepatic progenitor cell line (iHPx), which retains hepatic differentiation potential. Here, we analyze the expression pattern of the essential components of both canonical and noncanonical Wnt signaling pathways at different postnatal stages of mouse liver tissues and iHPx cells. We find that noncanonical Wnt4, Wnt5a, Wnt9b, Wnt10a and Wnt10b, are highly expressed concordantly with the high levels of canonical Wnts in late stages of liver tissues. Wnt5a, Wnt9b, Wnt10a and Wnt10b are able to antagonize Wnt3a induced beta catenin/TCF activity, reduce the stemness of iHPx cells, and promote hepatic differentiation of liver progenitors. Stem cell implantation assay demonstrates that Wnt5a, Wnt9b, Wnt10a and Wnt10b can inhibit cell proliferation and promote hepatic differentiation of the iHPx progenitor cells. Our results strongly suggest that noncanonical Wnts may play an important role in fine tuning Wnt/beta catenin functions during liver development and liver regeneration. Thus, understanding regulatory mechanisms governing proliferation and differentiation of liver progenitor cells may hold great promise to facilitate liver regeneration and/or progenitor cell based therapies for liver diseases.
C1 [Fan, Jiaming; Tang, Hua] Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Minist Educ China,Inst Viral Hepatitis, Chongqing, Peoples R China.
   [He, Tong Chuan] Univ Chicago, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Med Ctr, Chicago, IL USA.
   [Yu, Xinyi; Zhang, Zhicai; Zhang, Ruyi; Yan, Shujuan] Chongqing Med Univ, Minist Educ, Key Lab Diagnost Med, Chongqing, Peoples R China.
   [Xiong, Dongmei; Chen, Liqun; Wu, Xingye] Sichuan Univ, West China Hosp, Dept Conservat Dent & Endodont, Chengdu, Peoples R China.
   [Yu, Xinyi; Zhao, Chen; Wu, Xingye] Wuhan Univ, Affiliated Zhongnan Hosp, Dept Neurosurg & Otolaryngol Head & Neck Surg, Wuhan, Peoples R China.
   [Zhao, Chen; Shu, Yi] Chongqing Univ, Sch Bioengn, Dept Biomed Engn, Chongqing, Peoples R China.
   [Zhao, Chen; Wu, Tingting] Huazhong Univ Sci Technol, Union Hosp Tongji Med Coll, Dept Orthopaed Surg, Wuhan, Peoples R China.
   [Zou, Yulong; Yu, Yichun] Binzhou Med Univ, Affiliated Yantai Hosp, Dept Lab Med & Clin Diagnost, Yantai, Peoples R China.
C3 Chongqing Medical University; University of Chicago; University of
   Chicago Medical Center; Chongqing Medical University; Sichuan
   University; Wuhan University; Chongqing University; Huazhong University
   of Science & Technology; Binzhou Medical University
RP Tang, H (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Minist Educ China,Inst Viral Hepatitis, Chongqing, Peoples R China.; He, TC (通讯作者)，Univ Chicago, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Med Ctr, Chicago, IL USA.
EM tche@uchicago.edu; tanghua86162003@cqmu.edu.cn
RI Wei, Qiang/HII 4390 2022; Junyi, Liao/AAP 9076 2020; wu,
   tingting/H 8032 2012; Tang, Hua/JNS 7048 2023; YU, XINYI/NKP 6249 2025
OI Zou, Yulong/0000 0002 8461 5306; Zeng, Zongyue/0000 0002 4333 5412
FU National Institutes of Health [AT004418, AR50142]; 973 Program of
   Ministry of Science and Technology (MOST) of China [2011CB707900]; Major
   National S T Program [2013ZX10002002]; Chongqing Science & Technology
   Commission [cstc2013jcyjC10002]; Natural Science Foundation Project of
   CQ CSTC [2010BB5359]; University of Chicago Core Facility Subsidy grant
   from the National Center for Advancing Translational Sciences (NCATS) of
   the National Institutes of Health [UL1 TR000430]
FX The reported work was supported in part by research grants from the
   National Institutes of Health (AT004418, AR50142 to TCH and RCH), the
   973 Program of Ministry of Science and Technology (MOST) of China
   (#2011CB707900 to TCH), the Major National S & T Program (2013ZX10002002
   to ALH), the Major Project of Chongqing Science & Technology Commission
   (cstc2013jcyjC10002 to ALH), and the Natural Science Foundation Project
   of CQ CSTC (2010BB5359 to ALH and HT). This work was also supported in
   part by The University of Chicago Core Facility Subsidy grant from the
   National Center for Advancing Translational Sciences (NCATS) of the
   National Institutes of Health through Grant UL1 TR000430. Funding
   sources were not involved in the study design; in the collection,
   analysis and interpretation of data; in the writing of the report; and
   in the decision to submit the paper for publication.
CR Bi Y, 2013, BRAZ J MED BIOL RES, V46, P559, DOI 10.1590/1414 431X20132455
   Bi Y, 2014, CELL PHYSIOL BIOCHEM, V34, P1318, DOI 10.1159/000366340
   Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254
   Breyer Benjamin, 2001, Current Gene Therapy, V1, P149, DOI 10.2174/1566523013348689
   Chen X, 2013, CELL PHYSIOL BIOCHEM, V32, P1083, DOI 10.1159/000354508
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Denduluri SK, 2016, TISSUE ENG PART C ME, V22, P280, DOI 10.1089/ten.tec.2015.0244
   Deng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113064
   Deng YL, 2016, CELL PHYSIOL BIOCHEM, V39, P871, DOI 10.1159/000447797
   Deng YL, 2015, SCI REP UK, V5, DOI 10.1038/srep17523
   Gao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052589
   Geerts A, 2004, J HEPATOL, V40, P331, DOI 10.1016/j.jhep.2003.12.006
   He BC, 2011, MOL PHARMACOL, V79, P211, DOI 10.1124/mol.110.068668
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   He TC., 2004, ADENOVIRAL VECTORS C
   Hu N, 2013, J CELL SCI, V126, P532, DOI 10.1242/jcs.114231
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032428
   Huang JY, 2009, LIVER INT, V29, P1569, DOI 10.1111/j.1478 3231.2009.02111.x
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kopp JL, 2016, NAT CELL BIOL, V18, P238, DOI 10.1038/ncb3309
   Lampot JD, 2015, CELL TRANSPLANT, V24, P1053, DOI 10.3727/096368914X681054
   Li RD, 2014, CURR CANCER DRUG TAR, V14, P274, DOI 10.2174/1568009614666140305105805
   Li RF, 2016, INT J MED SCI, V13, P8, DOI 10.7150/ijms.13333
   Liao Z, 2015, CURR CANCER DRUG TAR, V15, P726, DOI 10.2174/1568009615666150629132157
   Lu S, 2016, AM J TRANSL RES, V8, P3710
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Miyajima A, 2014, CELL STEM CELL, V14, P561, DOI 10.1016/j.stem.2014.04.010
   Mohammed MK, 2016, GENES DIS, V3, P11, DOI 10.1016/j.gendis.2015.12.004
   Monga SP, 2015, GASTROENTEROLOGY, V148, P1294, DOI 10.1053/j.gastro.2015.02.056
   Monga SPS, 2011, INT J BIOCHEM CELL B, V43, P1021, DOI 10.1016/j.biocel.2009.09.001
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Nusse R, 2008, COLD SH Q B, V73, P59, DOI 10.1101/sqb.2008.73.035
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Si Tayeb K, 2010, DEV CELL, V18, P175, DOI 10.1016/j.devcel.2010.01.011
   Stanger BZ, 2015, ANNU REV PHYSIOL, V77, P179, DOI 10.1146/annurev physiol 021113 170255
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   Wang JF, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0104882, 10.1371/journal.pone.0087451, 10.1371/journal.pone.0107012]
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097316
   Wang XJ, 2014, J BIOMED MATER RES A, V102, P1017, DOI 10.1002/jbm.a.34764
   Wu N, 2014, GENE THER, V21, P629, DOI 10.1038/gt.2014.40
   Yan ZJ, 2015, CELLS TISSUES ORGANS, V201, P38, DOI 10.1159/000439268
   Yang J, 2015, AM J PATHOL, V185, P2194, DOI 10.1016/j.ajpath.2015.04.021
   Yang K, 2016, LAB INVEST, V96, P116, DOI 10.1038/labinvest.2015.144
   Ye JX, 2016, BIOMED MATER, V11, DOI 10.1088/1748 6041/11/2/025021
   Zaret KS, 2008, NAT REV GENET, V9, P329, DOI 10.1038/nrg2318
   Zhang FG, 2017, ONCOTARGET, V8, P12968, DOI 10.18632/oncotarget.14673
   Zhang FG, 2016, GENES DIS, V3, P263, DOI 10.1016/j.gendis.2016.09.004
   Zhang HM, 2015, BIOMATERIALS, V39, P145, DOI 10.1016/j.biomaterials.2014.11.007
   Zhang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132666
   Zhao C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092908
NR 55
TC 81
Z9 96
U1 1
U2 16
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD APR 18
PY 2017
VL 8
IS 16
BP 27105
EP 27119
DI 10.18632/oncotarget.15637
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA ES8PQ
UT WOS:000399819700105
PM 28404920
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, Y
   Xie, Z
   Zhang, YY
   Xia, C
   Yang, MZ
   Hu, XK
AF Chen, Yong
   Xie, Zhong
   Zhang, Yangyang
   Xia, Chao
   Yang, Mingzhi
   Hu, Xiongke
TI Shikonin relieves osteoporosis of ovariectomized mice by inhibiting
   RANKL induced NF κB and NFAT pathways
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Shikonin; Osteoclast; RANKL; NF kappa B and NFAT pathway
ID OSTEOCLAST DIFFERENTIATION; EXPRESSION; APOPTOSIS; INJURY; CELLS; MODEL
AB Postmenopausal osteoporosis is very common in women. Currently, many kinds of new drugs are being developed for this disease. Postmenopausal osteoporosis is closely related to overactivity of osteoclasts in body. Shikonin is purple red naphthoquinone pigment extracted from lithospermum, which has anti inflammation, antivirus, anticancer and other bioactivities. At the same time, it has been proved that shikonin can promote the proliferation and differentiation of osteoblasts, but its influence on osteoclasts and molecular mechanism are unknown. Our study showed that shikonin could inhibit the activity and formation of RANKL mediated osteoclasts depending on dose without affecting the activity of bone marrow macrophages (BMM). In addition, we have also found that shikonin can inhibit the expression of specific marker gene of osteoclasts, including nuclear factor of activated T cells cytoplasmic 1 (NFATc1), cathepsin K (Ctsk), tartrate resistant acid phosphatase (TRAcP) and calcitonin receptor. Shikonin also could promote the proliferation of MC3T3 E1, increasing the expression of mRNA related to osteogenesis, like the expression of bone morphogenetic protein 2 (BMP 2), alkaline phosphatase (ALP), runt related transcription factor 2 (Runx2) and osteocalcin (OCN). Luciferase reporter gene assay and Western blot analysis further indicated that shikonin could inhibit the activity of RANKL induced NF kappa B and NFAT receptors. Moreover, shikonin can also slow down bone loss of ovariectomized (OVX) mice by inhibiting the activity of osteoclasts. This work explains the molecular mechanism of shikonin in RANKL mediated formation of osteoclasts, and reveals the potential of further developing shikonin into a new drug for prevention and treatment of postmenopausal osteoporosis.
C1 [Chen, Yong; Xie, Zhong; Zhang, Yangyang; Xia, Chao; Yang, Mingzhi] Univ South China, Spinal Surg Dept 2, Affiliated Hosp 1, Hengyang 421000, Hunan, Peoples R China.
   [Hu, Xiongke] Cent South Univ, Xiangya Hosp, Movement Syst Injury & Repair Res Ctr, Changsha 410008, Hunan, Peoples R China.
C3 University of South China; Central South University
RP Hu, XK (通讯作者)，Cent South Univ, Xiangya Hosp, Movement Syst Injury & Repair Res Ctr, Changsha 410008, Hunan, Peoples R China.
EM huxiongke@163.com
FU Natural Science Foundation of Hunan Province, China [2019JJ50553]; China
   Postdoctoral Science Foundation [2018M632998]
FX This work was supported by the Natural Science Foundation of Hunan
   Province, China (Grant No. 2019JJ50553) and the China Postdoctoral
   Science Foundation (Grant No. 2018M632998).
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Bandeira L, 2016, EXPERT OPIN DRUG MET, V12, P681, DOI 10.1080/17425255.2016.1175436
   Baud'huin M, 2007, EXPERT REV ANTICANC, V7, P221, DOI 10.1586/14737140.7.2.221
   Bi YH, 2017, CELL PHYSIOL BIOCHEM, V43, P481, DOI 10.1159/000480474
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092 8674(02)01166 2
   Duan DZ, 2014, FREE RADICAL BIO MED, V70, P182, DOI 10.1016/j.freeradbiomed.2014.02.016
   Fang T, 2016, MOL MED REP, V14, P1269, DOI 10.3892/mmr.2016.5363
   Fumimoto R, 2012, J PHARMACOL SCI, V118, P479, DOI 10.1254/jphs.11212FP
   Gupta B, 2016, CAN J PHYSIOL PHARM, V94, P788, DOI 10.1139/cjpp 2015 0465
   Jang SY, 2014, ONCOL REP, V31, P2827, DOI 10.3892/or.2014.3159
   Kim YO, 2010, KOREAN J PHYSIOL PHA, V14, P199, DOI 10.4196/kjpp.2010.14.4.199
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Ko H, 2016, BIOMOL THER, V24, P501, DOI 10.4062/biomolther.2016.008
   Lee CH, 2014, J PHARMACOL SCI, V124, P344, DOI 10.1254/jphs.13174FP
   Lee YS, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/520578
   Liang DJ, 2013, INT IMMUNOPHARMACOL, V16, P475, DOI 10.1016/j.intimp.2013.04.020
   Liu T, 2020, J HEPATOCELL CARCINO, V7, P19, DOI 10.2147/JHC.S237614
   Liu WL, 2019, BIOCHEM BIOPH RES CO, V520, P359, DOI 10.1016/j.bbrc.2019.10.038
   Lu L, 2011, EUR J PHARMACOL, V658, P242, DOI 10.1016/j.ejphar.2011.02.043
   Lü SL, 2020, ACTA PHARMACOL SIN, V41, P47, DOI 10.1038/s41401 019 0308 7
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Miller PD, 2008, CURR MED RES OPIN, V24, P107, DOI 10.1185/030079907X253681
   Ni F, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21570 z
   Prangsaengtong O, 2018, BIOL PHARM BULL, V41, P1659, DOI 10.1248/bpb.b18 00329
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   Shinohara Masahiro, 2007, Curr Osteoporos Rep, V5, P67
   Stefanick ML, 2005, AM J MED, V118, P1407, DOI 10.1016/j.amjmed.2005.10.014
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tian R, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150002
   Wang LN, 2014, NEUROCHEM RES, V39, P97, DOI 10.1007/s11064 013 1194 x
   Yang C, 2018, BIOCHEM BIOPH RES CO, V505, P1, DOI 10.1016/j.bbrc.2018.08.198
   Yang KY, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/631737
   Zhang N, 2020, INT J BIOL SCI, V16, P147, DOI 10.7150/ijbs.36955
   Zhang YH, 2017, BIOMED PHARMACOTHER, V93, P636, DOI 10.1016/j.biopha.2017.06.076
NR 38
TC 6
Z9 7
U1 0
U2 43
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD SEP 1
PY 2020
VL 394
IS 1
AR 112115
DI 10.1016/j.yexcr.2020.112115
PG 7
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA NB5EL
UT WOS:000560535300008
PM 32473224
DA 2025 08 17
ER

PT J
AU Li, YJ
   Zhuang, Q
   Tao, LH
   Zheng, K
   Chen, SS
   Yang, YS
   Feng, CC
   Wang, ZF
   Shi, HW
   Shi, JD
   Fang, YL
   Xiao, L
   Geng, DC
   Wang, ZR
AF Li, Yajun
   Zhuang, Qi
   Tao, Lihong
   Zheng, Kai
   Chen, Shuangshuang
   Yang, Yunshang
   Feng, Chengcheng
   Wang, Zhifang
   Shi, Haiwei
   Shi, Jiandong
   Fang, Yiling
   Xiao, Long
   Geng, Dechun
   Wang, Zhirong
TI Urolithin B suppressed osteoclast activation and reduced bone loss of
   osteoporosis via inhibiting ERK/NF κB pathway
SO CELL PROLIFERATION
LA English
DT Article
ID ELLAGIC ACID; ELLAGITANNINS; ANTIOXIDANT; METABOLITES; MECHANISMS;
   WALNUTS; MICE; RAT
AB Objectives The main target of current drugs for alleviating bone loss is osteoclasts. However, the long term application of such drugs will also cause side effects. Therefore, it is of great need to develop new and safer therapeutics for osteoporosis. In recent years, drug development based on gut microbiota has gradually attracted attention. This manuscript investigates the inhibitory effect of urolithin B (UB) on osteoclastogenesis and differentiation in vitro and in ovariectomized (OVX) mice. Materials and Methods CCK 8 was used to analyse the cytotoxicity of UB; BMMs cells were differentiated into osteoclasts by RANKL, and respectively treated with 1, 5, and 25 mu mol/L UB during this process. After one week of intervention, tartrate resistant acid phosphatase (TRAP) staining was used to analyse the number and average area of osteoclasts. F actin staining and immunofluorescence staining were conducted to evaluate the morphology and function of osteoclasts. Bone resorption function of osteoclasts was detected by Pit Formation Assay. The expression of osteoclast related protein genes in RAW264.7 cells were investigated via western blot and RT PCR assays. Western blot analysis of RANKL mediated activation of MAPK/NF kappa B pathway after 0, 5, 15, 30, 60 min of intervention. For in vivo experiments, OVX mice received intraperitoneal injection of 10, 50 mg/kg every two days, 8 weeks later, the femurs of mice were taken for morphological analysis, and the serum content of CTX 1, a bone metabolism index, was analysed. Results UB could inhibit the osteoclast differentiation of rankl induced bone marrow macrophages (BMMs) and RAW264.7 cells in vitro, suppress the uptake activity of hydroxyapatite and expression of osteoclast related gene MMP9, CTSK, NFATc1 and c fos. Furthermore, UB repressed the rankl induced phosphorylation and degradation of I kappa B and the phosphorylation of P65 in the NF kappa B pathway of RAW264.7 cells, and also down regulated the phosphorylation level of ERK in the MAPK pathway. For in vivo studies, UB treated OVX mice showed more significant improved various parameters of distal femur compared with the control group, with fewer NFATc1, MMP9 and TRAP positive osteoclasts in bone tissues, and less serum content of CTX 1. Conclusion Urolithin B attenuated bone loss in OVX mice by inhibiting the formation and activation of osteoclasts via down regulation of the ERK/NF kappa B signalling pathway.
C1 [Li, Yajun; Zhuang, Qi; Tao, Lihong; Chen, Shuangshuang; Yang, Yunshang; Feng, Chengcheng; Xiao, Long; Wang, Zhirong] Nanjing Univ Chinese Med, Zhangjiagang TCM Hosp, Translat Med Innovat Ctr, Zhangjiagang 215600, Peoples R China.
   [Li, Yajun; Yang, Yunshang; Wang, Zhifang; Shi, Haiwei; Shi, Jiandong; Xiao, Long; Wang, Zhirong] Nanjing Univ Chinese Med, Zhangjiagang TCM Hosp, Dept Orthoped, Zhangjiagang, Peoples R China.
   [Tao, Lihong; Chen, Shuangshuang] Nanjing Univ Chinese Med, Zhangjiagang TCM Hosp, Dept Rheumatol, Zhangjiagang, Peoples R China.
   [Zheng, Kai; Xiao, Long; Geng, Dechun] Soochow Univ, Affiliated Hosp 1, Dept Orthoped, Suzhou 215006, Peoples R China.
   [Fang, Yiling] Soochow Univ, Peoples Hosp Zhangjiagang 1, Dept Gen Practice, Zhangjiagang, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine; Soochow University  
   China; Soochow University   China
RP Xiao, L; Wang, ZR (通讯作者)，Nanjing Univ Chinese Med, Zhangjiagang TCM Hosp, Translat Med Innovat Ctr, Zhangjiagang 215600, Peoples R China.; Geng, DC (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthoped, Suzhou 215006, Peoples R China.
EM zjgfy_spine_xl@njucm.edu.cn; szgengdc@suda.edu.cn;
   zjgfy_spine_wzr@njucm.edu.cn
RI Zheng, Kai/ADE 3025 2022; luo, xiaomin/HNS 7206 2023; Yang,
   Yunshang/ITU 7550 2023; Zhirong, Wang/AAR 5563 2021; chen,
   shuangshuang/KGK 6684 2024; chen, shuang shuang/KGK 6684 2024; Geng,
   Dechun/LMO 1733 2024
OI Zheng, Kai/0000 0002 6248 6275; Long, Xiao/0000 0002 0944 9694; Yang,
   Yunshang/0009 0005 0033 1138; chen, shuang shuang/0009 0009 6549 1449; 
FU National Natural Science Foundation of China [82074473, 82104892];
   Natural Science Foundation of Jiangsu Province [BK20180001, BK20191201,
   BE2020666]; Suzhou Science and Technology Development Plan Project
   [SYSD2017008, SYSD2019007, SYSD2020009, SYSD2021175]; Elderly Health
   Research Project of Jiangsu Province [LK2021043, LR2021024]; Suzhou
   Health Personnel Training Project [GSWS2019074, GSWS2020103];
   Zhangjiagang Health Personnel Training Project [ZJGWSRC2020002];
   Zhangjiagang Health System Youth Science and Technology Project
   [ZJGQNKJ201804, ZJGQNKJ201807, ZJGQNKJ202010, ZJGQNKJ202031,
   ZJGQNKJ202110, ZJGQNKJ202133, ZKS2007, ZKS2121, ZKS2126, ZKS2129,
   ZKS2030, ZKS2032]; Jiangsu Province "333 Project" research project
   [BRA2020129]; Key Disciplines in Suzhou [SZXK202120]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   82074473, 82104892; Natural Science Foundation of Jiangsu Province,
   Grant/Award Numbers: BK20180001, BK20191201, BE2020666; Suzhou Science
   and Technology Development Plan Project, Grant/Award Numbers:
   SYSD2017008, SYSD2019007, SYSD2020009, SYSD2021175; Elderly Health
   Research Project of Jiangsu Province, Grant/Award Numbers: LK2021043,
   LR2021024; Suzhou Health Personnel Training Project, Grant/Award
   Numbers: GSWS2019074, GSWS2020103; Zhangjiagang Health Personnel
   Training Project, Grant/Award Number: ZJGWSRC2020002; Zhangjiagang
   Health System Youth Science and Technology Project, Grant/Award Numbers:
   ZJGQNKJ201804, ZJGQNKJ201807, ZJGQNKJ202010, ZJGQNKJ202031,
   ZJGQNKJ202110, ZJGQNKJ202133, ZKS2007, ZKS2121, ZKS2126, ZKS2129,
   ZKS2030, ZKS2032; Jiangsu Province "333 Project" research project,
   Grant/Award Number: BRA2020129; Key Disciplines in Suzhou, Grant/Award
   Number: SZXK202120
CR Adami G, 2019, CURR OPIN RHEUMATOL, V31, P388, DOI 10.1097/BOR.0000000000000608
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Alzahrani AM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115465
   Bobowska A, 2021, EUR J NUTR, V60, P1957, DOI 10.1007/s00394 020 02386 y
   Catrina AI, 2017, NAT REV RHEUMATOL, V13, P79, DOI 10.1038/nrrheum.2016.200
   Cerdá B, 2005, J AGR FOOD CHEM, V53, P227, DOI 10.1021/jf049144d
   Chen P, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.768097
   Chen P, 2021, FOOD FUNCT, V12, P11938, DOI [10.1039/D1FO02440J, 10.1039/d1fo02440j]
   Cohen LJ, 2017, NATURE, V549, P48, DOI 10.1038/nature23874
   Divan V, 2019, CURR OPIN ENDOCRINOL, V26, P283, DOI 10.1097/MED.0000000000000505
   Dodd D, 2017, NATURE, V551, P648, DOI 10.1038/nature24661
   Evtyugin DD, 2020, MOLECULES, V25, DOI 10.3390/molecules25122745
   Fan Y, 2021, NAT REV MICROBIOL, V19, P55, DOI 10.1038/s41579 020 0433 9
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   González Sarrías A, 2010, MOL NUTR FOOD RES, V54, P311, DOI 10.1002/mnfr.200900152
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Henning SM, 2022, FOOD FUNCT, V13, P5680, DOI [10.1039/D2FO00280A, 10.1039/d2fo00280a]
   Huang X, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/6517266
   Hwang YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072068
   Kats A, 2019, J CELL MOL MED, V23, P1152, DOI 10.1111/jcmm.14015
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kong LB, 2020, J CELL MOL MED, V24, P3271, DOI 10.1111/jcmm.15052
   Lee G, 2019, PHYTOMEDICINE, V55, P50, DOI 10.1016/j.phymed.2018.06.032
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lei F, 2003, J CHROMATOGR B, V796, P189, DOI 10.1016/S1570 0232(03)00610 X
   Li SS, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.717065
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Lin XX, 2020, J CELL PHYSIOL, V235, P5951, DOI 10.1002/jcp.29520
   Lv MY, 2019, J CELL BIOCHEM, V120, P17273, DOI 10.1002/jcb.28989
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Matsumoto N, 2020, EXP CELL RES, V389, DOI 10.1016/j.yexcr.2020.111901
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Piwowarski JP, 2015, MOL NUTR FOOD RES, V59, P2168, DOI 10.1002/mnfr.201500264
   Rantlha M, 2017, ARCH PHARM RES, V40, P79, DOI 10.1007/s12272 016 0790 0
   Rodriguez J, 2017, J CACHEXIA SARCOPENI, V8, P583, DOI 10.1002/jcsm.12190
   Savi M, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933 017 0561 3
   SAVILLE PD, 1969, J AM GERIATR SOC, V17, P155, DOI 10.1111/j.1532 5415.1969.tb03169.x
   Singh R, 2020, METABOLITES, V10, DOI 10.3390/metabo10060258
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Tsubaki M, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 10
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Xian WY, 2021, J AGR FOOD CHEM, V69, P13055, DOI 10.1021/acs.jafc.1c04849
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xu HH, 2020, CHEM BIOL INTERACT, V331, DOI 10.1016/j.cbi.2020.109235
   Yin Z., 2019, EUR J PHARMACOL, V15, P859
   Zebic L., 2019, BMJ CLIN RES ED, V127, P117
   Zhao WH, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201800887
   Zheng DC, 2020, PHARMACOL RES, V153, DOI 10.1016/j.phrs.2020.104655
NR 49
TC 55
Z9 64
U1 2
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0960 7722
EI 1365 2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD OCT
PY 2022
VL 55
IS 10
AR e13291
DI 10.1111/cpr.13291
EA JUN 2022
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 5B0QL
UT WOS:000812286600001
PM 35708050
OA Green Published
DA 2025 08 17
ER

PT J
AU Huang, J
   Freyhult, E
   Buckland, R
   Josefsson, A
   Damber, JE
   Welén, K
AF Huang, Junchi
   Freyhult, Eva
   Buckland, Robert
   Josefsson, Andreas
   Damber, Jan Erik
   Welen, Karin
TI Osteoclasts directly influence castration resistant prostate cancer
   cells
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Castration resistant prostate cancer; Osteoclasts; RNA sequencing; DNA
   repair; Apoptosis
ID BONE METASTASIS; PROGRESSION; OSTEOBLASTS; EXPRESSION; PROMOTE;
   APOPTOSIS; ESTROGEN; RECEPTOR; GROWTH
AB Metastasis to bone is the leading cause of death from prostate cancer. Interaction between tumor cells and bone cells can promote progression and influence tumor phenotype. It is known that prostate cancer cells support osteoclast differentiation, and degradation of bone matrix by osteoclasts releases growth factors stimulating tumor cell proliferation and invasion. In the present study osteolytic (PC 3) and osteoblastic (LNCaP 19) castration resistant prostate cancer (CRPC) cells were co cultured with mature osteoclasts or their precursor cells (RAW 264.7) to characterize direct effects of mature osteoclasts on CRPC cells. Osteoclasts increased proliferation and decrease apoptosis of CRPC cells as assessed with flow cytometry. RNA sequencing revealed that osteolytic CRPC cells were more responsive to osteoclast stimulation regarding gene expression, but the overall induced expression patterns were similar between the prostate cancer cell lines. Genes related to DNA repair were upregulated by osteoclasts, while genes related to endoplasmic reticulum stress induced apoptosis and cholesterol synthesis were downregulated. The results of this study shows that osteoclasts directly influence CRPC cells, increasing proliferation, decreasing apoptosis, and affecting gene expression pathways that can affect sensitivity to DNA damage and endoplasmic reticulum function. This suggests targeting of osteoclasts to be a possible way to affect efficacy of other drugs by combination regimens in treating prostate cancer metastases.
C1 [Huang, Junchi; Josefsson, Andreas; Damber, Jan Erik; Welen, Karin] Univ Gothenburg, Sahlgrenska Acad, Sahlgrenska Ctr Canc Res, Dept Urol,Inst Clin Sci, Gothenburg, Sweden.
   [Freyhult, Eva] Uppsala Univ, Natl Bioinformat Infrastruct Sweden, Dept Cell & Mol Biol, Sci Life Lab, S 75124 Uppsala, Sweden.
   [Buckland, Robert; Josefsson, Andreas] Umea Univ, Urol & Androl, Dept Surg & Perioperat Sci, Umea, Sweden.
   [Josefsson, Andreas] Umea Univ, Wallenberg Ctr Mol Med WCMM, Umea, Sweden.
C3 University of Gothenburg; Uppsala University; Umea University; Umea
   University
RP Welén, K (通讯作者)，Univ Gothenburg, Sahlgrenska Acad, Sahlgrenska Ctr Canc Res, Dept Urol,Inst Clin Sci, Gothenburg, Sweden.
EM karin.welen@gu.se
RI ; WelÃ©n, Karin/AAQ 8765 2020; Buckland, Robert/L 6137 2014; Josefsson,
   Andreas/T 2311 2019; Huang, Junchi/C 2601 2019
OI Josefsson, Andreas/0000 0002 2013 0887; Huang,
   Junchi/0000 0003 2759 7962
FU Swedish Cancer Society [CAN2017/478, CAN 2017/380, 20 1055]; Swedish
   government [ALFGBG 138351]; Swedish Prostate Cancer Federation; Knut and
   Alice Wallenberg Foundation;  [FB19 107]
FX The authors want to acknowledge the help with the performance of the RNA
   sequencing by TATAA Biocenter, Gothenburg, Sweden, the research group of
   Jonas Nilsson, Sahlgrenska Center for Cancer Research, Department of
   Surgery, Institute for Clinical Sciences, University of Gothenburg,
   Sweden for help with setting up the flow cytometry analysis, Manuel
   Luna, Institute of Biomedicine, University of Gothenburg for help with
   preliminary interpretation of sequencing data. This work was supported
   by the Swedish Cancer Society [grant numbers CAN2017/478, CAN 2017/380,
   and 20 1055]; the Swedish state under the agreement between the Swedish
   government and the county councils, the ALF agreement [grant number
   ALFGBG 138351], the Swedish Prostate Cancer Federation, Knut and Alice
   Wallenberg Foundation, and the research foundations of A. Gabrielsson
   [grant number FB19 107], and U and K E. Winberg.
CR Asim M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00393 y
   Atanga E, 2011, BONE, V49, P1090, DOI 10.1016/j.bone.2011.08.003
   CADET J, 1992, J PHOTOCH PHOTOBIO B, V15, P277, DOI 10.1016/1011 1344(92)85135 H
   Ceccaldi R, 2016, NAT REV MOL CELL BIO, V17, P337, DOI 10.1038/nrm.2016.48
   Christopher MJ, 2008, J BONE MINER RES, V23, P1765, DOI 10.1359/JBMR.080612
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Flippot R, 2022, DRUGS, V82, P719, DOI 10.1007/s40265 022 01703 5
   Gorman AM, 2012, PHARMACOL THERAPEUT, V134, P306, DOI 10.1016/j.pharmthera.2012.02.003
   Gustavsson H, 2005, PROSTATE, V62, P364, DOI 10.1002/pros.20145
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Hofbauer LC, 1999, EUR J ENDOCRINOL, V140, P271, DOI 10.1530/eje.0.1400271
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Huang JC, 2021, MOL CELL ENDOCRINOL, V535, DOI 10.1016/j.mce.2021.111380
   Jakob T, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013020.pub2
   Jennbacken K, 2006, PROSTATE, V66, P1631, DOI 10.1002/pros.20469
   Jin JK, 2011, INT J CANCER, V128, P2545, DOI 10.1002/ijc.26024
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Li KX, 2021, CANCERS, V13, DOI 10.3390/cancers13225593
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Marin Aguilera M, 2021, CANCERS, V13, DOI 10.3390/cancers13194960
   Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038
   Mödder UI, 2011, BONE, V49, P202, DOI 10.1016/j.bone.2011.04.015
   Mori K, 2007, BONE, V40, P981, DOI 10.1016/j.bone.2006.11.006
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nordstrand A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041223
   Oades GM, 2002, PROSTATE CANCER P D, V5, P264, DOI 10.1038/sj.pcan.4500607
   Patil S, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.584118
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046 8177(03)00190 4
   Sato R, 2010, ARCH BIOCHEM BIOPHYS, V501, P177, DOI 10.1016/j.abb.2010.06.004
   Sountoulides P, 2013, ISRN Urol, V2013, P1, DOI DOI 10.1155/2013/240108
   Stenbeck G, 2002, SEMIN CELL DEV BIOL, V13, P285, DOI 10.1016/S1084952102000587
   Takayama K, 2017, CANCER LETT, V397, P103, DOI 10.1016/j.canlet.2017.03.034
   Tatem AJ, 2011, LANCET, V377, P30, DOI 10.1016/S0140 6736(11)61226 9
   Thobe Megan N, 2011, Cancers (Basel), V3, P478, DOI 10.3390/cancers3010478
   Thulin MH, 2016, MOL CELL ENDOCRINOL, V422, P182, DOI 10.1016/j.mce.2015.11.013
   Thulin MH, 2014, CLIN EXP METASTAS, V31, P269, DOI 10.1007/s10585 013 9626 1
   Thysell E, 2021, VERIFICATION T UNPUB
   Vessella RL, 2006, CLIN CANCER RES, V12, p6285S, DOI 10.1158/1078 0432.CCR 06 0813
   Villagran MA, 2015, BIOCHEM BIOPH RES CO, V467, P1039, DOI 10.1016/j.bbrc.2015.10.009
   Virk MS, 2011, BONE, V48, P578, DOI 10.1016/j.bone.2010.11.003
   Wang XY, 2022, NEOPLASIA, V24, P86, DOI 10.1016/j.neo.2021.11.004
   Weivoda MM, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115757
   Xu ZZ, 2021, ONCOTARGETS THER, V14, P4285, DOI 10.2147/OTT.S315813
   Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
   Zheng Y, 2014, CLIN EXP METASTAS, V31, P921, DOI 10.1007/s10585 014 9680 3
NR 52
TC 5
Z9 5
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262 0898
EI 1573 7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD OCT
PY 2022
VL 39
IS 5
BP 801
EP 814
DI 10.1007/s10585 022 10179 2
EA AUG 2022
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 4N3HY
UT WOS:000840609500001
PM 35971022
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Blaslov, K
   Katalinic, L
   Kes, P
   Spasovski, G
   Smalcelj, R
   Basic Jukic, N
AF Blaslov, Kristina
   Katalinic, Lea
   Kes, Petar
   Spasovski, Goce
   Smalcelj, Ruzica
   Basic Jukic, Nikolina
TI What is the impact of immunosuppressive treatment on the post transplant
   renal osteopathy?
SO INTERNATIONAL UROLOGY AND NEPHROLOGY
LA English
DT Article
DE mTOR; Sirolimus; Everolimus; Glucocorticoids; Calcineurin inhibitors;
   Post transplant osteopathy; Adynamic bone disease
ID KIDNEY TRANSPLANT PATIENTS; BONE DISEASE; CYCLOSPORINE A;
   MYCOPHENOLATE MOFETIL; ORGAN TRANSPLANTATION; GROWTH PLATE; PHASE III;
   RAPAMYCIN; RECIPIENTS; METABOLISM
AB Although glucocorticoid therapy is considered to be the main pathogenic factor, a consistent body of evidence suggests that other immunosuppressants might also play an important role in the development of the post transplant renal osteopathy (PRO) through their pleiotropic pharmacological effects. Glucocorticoids seem to induce osteoclasts' activity suppressing the osteoblasts while data regarding other immunosuppressive drugs are still controversial. Mycophenolate mofetil and azathioprine appear to be neutral regarding the bone metabolism. However, the study analyzing any independent effect of antimetabolites on bone turnover has not been conducted yet. Calcineurin inhibitors (CNIs) induce trabecular bone loss in rodent, with contradictory results in renal transplant recipients. Suppression of vitamin D receptor is probably the underlying mechanism of renal calcium wasting in renal transplant recipients receiving CNI. In spite of an increased 1,25(OH)2 vitamin D level, the kidney is not able to reserve calcium, suggesting a role of vitamin D resistance that may be related to bone loss. More efforts should be invested to determine the role of CNI in PRO. In particular, data regarding the role of mammalian target of rapamycin inhibitors (mTORi), such as sirolimus and everolimus, in the PRO development are still controversial. Rapamycin markedly decreases bone longitudinal growth as well as callus formation in experimental models, but also lowers the rate of bone resorption markers and glomerular filtration in clinical studies. Everolimus potently inhibits primary mouse and human osteoclast activity as well as the osteoclast differentiation. It also prevents the ovariectomy induced loss of cancellous bone by 60 %, an effect predominantly associated with a decreased osteoclast mediated bone resorption, resulting in a partial preservation of the cancellous bone. At present, there is no clinical study analyzing the effect of everolimus on bone turnover in renal transplant recipients or comparing sirolimus versus everolimus impact on bone, so only general conclusions could be drawn. Hence, the use of mTORi might be useful in patients with PRO due to their possible potential to inhibit osteoclast activity which might lead to a decreased rate of bone resorption. In addition, it should be also emphasized that they might inhibit osteoblast activity which may lead to a decreased bone formation and adynamic bone disease. Further studies are urgently needed to solve these important clinical dilemmas.
C1 [Blaslov, Kristina; Katalinic, Lea; Smalcelj, Ruzica; Basic Jukic, Nikolina] Univ Hosp Ctr Zagreb, Dept Nephrol Arterial Hypertens Dialysis & Transp, Zagreb 10000, Croatia.
   [Kes, Petar; Basic Jukic, Nikolina] Univ Zagreb, Sch Med, Zagreb 41001, Croatia.
   [Spasovski, Goce] Univ Skopje, Fac Med, Univ Dept Nephrol, Skopje, Macedonia.
   [Basic Jukic, Nikolina] Univ Osijek, Sch Med, Osijek, Croatia.
C3 University of Zagreb; UNIVERSITY ZAGREB HOSPITAL; University of Zagreb;
   Saints Cyril & Methodius University of Skopje; University of JJ
   Strossmayer Osijek
RP Basic Jukic, N (通讯作者)，Univ Hosp Ctr Zagreb, Dept Nephrol Arterial Hypertens Dialysis & Transp, Kispaticeva 12, Zagreb 10000, Croatia.
EM spasovski.goce@gmail.com; nina_basic@net.hr
RI Basic Jukic, Nikolina/AFR 5138 2022
OI Basic Jukic, Nikolina/0000 0002 0221 2758
CR Alvarez Garcia O, 2007, PEDIATR NEPHROL, V22, P954, DOI 10.1007/s00467 007 0456 8
   Alvarez García O, 2010, KIDNEY INT, V78, P561, DOI 10.1038/ki.2010.173
   [Anonymous], KIDNEY INT S
   Awumey EM, 1999, BIOCHEM BIOPH RES CO, V254, P248, DOI 10.1006/bbrc.1998.9785
   Bozkaya G, 2008, TRANSPL P, V40, P151, DOI 10.1016/j.transproceed.2007.11.040
   Buchinsky FJ, 1996, ENDOCRINOLOGY, V137, P2278, DOI 10.1210/en.137.6.2278
   Campistol JM, 2005, TRANSPL INT, V18, P1028, DOI 10.1111/j.1432 2277.2005.00163.x
   Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323
   Cunningham J, 2005, TRANSPLANTATION, V79, P629, DOI 10.1097/01.TP.0000149698.79739.EF
   Epstein S, 1996, J BONE MINER RES, V11, P1
   Evenepoel P, 2004, NEPHROL DIAL TRANSPL, V19, P1281, DOI 10.1093/ndt/gfh128
   Ferreira A, 2006, EUR J CLIN INVEST, V36, P2, DOI 10.1111/j.1365 2362.2006.01661.x
   Flechner SM, 2008, CLIN TRANSPLANT, V22, P1, DOI 10.1111/j.1399 0012.2007.00739.x
   Goldsmith DJA, 2010, NEPHROL DIAL TRANSPL, V25, P3823, DOI 10.1093/ndt/gfq513
   GROTZ W, 1994, TRANSPLANT P, V26, P2652
   GROTZ WH, 1995, NEPHROL DIAL TRANSPL, V10, P2096
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092 8674(02)00833 4
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Heaf JG, 2003, TRANSPLANTATION, V75, P315, DOI 10.1097/01.TP.0000043926.74349.6D
   Hernández D, 2011, NEFROLOGIA, V31, P27, DOI 10.3265/Nefrologia.pre2010.Jul.10512
   Holstein JH, 2008, BRIT J PHARMACOL, V154, P1055, DOI 10.1038/bjp.2008.167
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Kuypers DRJ, 2005, DRUG SAFETY, V28, P153, DOI 10.2165/00002018 200528020 00006
   Lee CT, 2011, AM J NEPHROL, V34, P87, DOI 10.1159/000328874
   Lorber MI, 2005, TRANSPLANTATION, V80, P244, DOI 10.1097/01.TP.0000164352.65613.24
   MacDonald AS, 2001, TRANSPLANTATION, V71, P271, DOI 10.1097/00007890 200101270 00019
   Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161
   MCINTYRE HD, 1995, CLIN TRANSPLANT, V9, P20
   Mitterbauer C, 2008, TRANSPL INT, V21, P615, DOI 10.1111/j.1432 2277.2008.00665.x
   Monegal A, 2001, CALCIFIED TISSUE INT, V68, P83, DOI 10.1007/BF02678145
   Morales J, 2007, TRANSPL P, V39, P591, DOI 10.1016/j.transproceed.2006.12.026
   Mutlu M, 2007, J INT MED RES, V35, P692, DOI 10.1177/147323000703500514
   Navaneethan SD, 2006, TRANSPL P, V38, P1320, DOI 10.1016/j.transproceed.2006.02.077
   NISBETH U, 1994, TRANSPLANT P, V26, P1764
   O'Shaughnessy EA, 2002, TRANSPLANTATION, V74, P362, DOI 10.1097/00007890 200208150 00012
   Patel S, 2001, J BONE MINER RES, V16, P1863, DOI 10.1359/jbmr.2001.16.10.1863
   Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046
   Ponticelli C, 2001, LANCET, V357, P1623, DOI 10.1016/S0140 6736(00)04765 6
   Rojas E, 2003, KIDNEY INT, V63, P1915, DOI 10.1046/j.1523 1755.2003.00938.x
   Rostaing L, 2010, J NEPHROL, V23, P133
   Rude RK, 2009, J AM COLL NUTR, V28, P131, DOI 10.1080/07315724.2009.10719764
   Sadideen H, 2008, INT UROL NEPHROL, V40, P171, DOI 10.1007/s11255 007 9310 y
   Schuler W, 1997, TRANSPLANTATION, V64, P36, DOI 10.1097/00007890 199707150 00008
   Sessa A, 2010, TRANSPL P, V42, P1148, DOI 10.1016/j.transproceed.2010.03.069
   STEWART PJ, 1989, HORM METAB RES, V21, P194, DOI 10.1055/s 2007 1009189
   STEWART PJ, 1989, CALCIFIED TISSUE INT, V45, P222, DOI 10.1007/BF02556041
   Tucker Katherine L, 2009, Curr Osteoporos Rep, V7, P111
   Vítko S, 2005, AM J TRANSPLANT, V5, P2521, DOI 10.1111/j.1600 6143.2005.01063.x
   Weisinger JR, 2006, CLIN J AM SOC NEPHRO, V1, P1300, DOI 10.2215/CJN.01510506
   Yip CK, 2010, MOL CELL, V38, P768, DOI 10.1016/j.molcel.2010.05.017
NR 51
TC 10
Z9 10
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 1623
EI 1573 2584
J9 INT UROL NEPHROL
JI Int. Urol. Nephrol.
PD MAY
PY 2014
VL 46
IS 5
BP 1019
EP 1024
DI 10.1007/s11255 013 0596 7
PG 6
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA AG8LG
UT WOS:000335669300024
PM 24217803
DA 2025 08 17
ER

PT J
AU Yang, L
   An, XY
   Gong, W
   Wu, WS
   Liu, B
   Shao, XY
   Xian, YS
   Peng, R
   Guo, BS
   Jiang, Q
AF Yang, Lin
   An, Xueying
   Gong, Wang
   Wu, Wenshu
   Liu, Bin
   Shao, Xiaoyan
   Xian, Yansi
   Peng, Rui
   Guo, Baosheng
   Jiang, Qing
TI Liposomal α cyperone targeting bone resorption surfaces
   suppresses osteoclast differentiation and osteoporosis progression via
   the PI3K/Akt axis
SO NANO RESEARCH
LA English
DT Article
DE osteoporosis; alpha cyperone; osteoclast; phosphoinositide
   3 kinase/protein kinase B (PI3K/Akt); liposome
ID NF KAPPA B; DELIVERY; PATHWAYS; ROTUNDUS
AB Osteoporosis is a metabolic dysregulation of bone that occurs mainly in postmenopausal women, and the hyperfunction of osteoclasts is the primary contributor to postmenopausal osteoporosis. However, the development of effective therapeutic drugs and precise delivery systems remains a challenge in the field of anti absorption therapy. Here, we reported the alpha cyperone (alpha CYP) for anti osteoporosis and developed a liposome based nano drug delivery system of alpha CYP, that specifically targets the bone resorption interface. Firstly, we found that the alpha CYP, one of the major sesquiterpenes of Cyperus rotundus L., attenuated the progression of osteoporosis in ovariectomized (OVX) mice and down regulated the expression of phosphorylated proteins of phosphoinositide 3 kinase (PI3K) and protein kinase B (Akt), causing down regulation of osteoclast related genes/proteins and curbing osteoclast differentiation. Furthermore, alpha CYP reversed the activation of osteoclastic differentiation and enhanced osteoporosis related proteins expression caused by PI3K/Akt agonist (YS 49). More importantly, we adopted the osteoclastic resorption surface targeting peptide Asp8 and constructed the liposome (lipaC@Asp8) to deliver alpha CYP to osteoclasts and confirmed its anti osteoporosis effect and enhanced osteoclast inhibition by blocking PI3K/Akt axis. In conclusion, this study demonstrated that alpha CYP inhibits osteoclast differentiation and osteoporosis development by silencing PI3K/Akt pathway, and the liposome targeting delivery systems loaded with alpha CYP might provide a novel and effective strategy to treat osteoporosis.
C1 [Yang, Lin; Jiang, Qing] Nanjing Med Univ, Dept Orthoped Surg, Div Sports Med & Adult Reconstruct Surg, Nanjing Drum Tower Hosp,Clin Coll, 321 Zhongshan Rd, Nanjing 210008, Peoples R China.
   [Yang, Lin; An, Xueying; Gong, Wang; Wu, Wenshu; Liu, Bin; Peng, Rui; Jiang, Qing] Branch Natl Clin Res Ctr Orthoped Sports Med & Re, Nanjing 210008, Peoples R China.
   [An, Xueying; Gong, Wang; Wu, Wenshu; Liu, Bin; Shao, Xiaoyan; Xian, Yansi; Peng, Rui; Guo, Baosheng; Jiang, Qing] Nanjing Univ, Med Sch, State Key Lab Pharmaceut Biotechnol, Nanjing 210008, Peoples R China.
   [Yang, Lin; Gong, Wang; Wu, Wenshu; Liu, Bin; Shao, Xiaoyan; Xian, Yansi; Peng, Rui; Guo, Baosheng; Jiang, Qing] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Orthoped Surg, Div Sports Med & Adult Reconstruct Surg,Med Sch,A, Nanjing Nanjing2100, Peoples R China.
C3 Nanjing Medical University; Nanjing University; Nanjing University;
   Nanjing University
RP Jiang, Q (通讯作者)，Nanjing Med Univ, Dept Orthoped Surg, Div Sports Med & Adult Reconstruct Surg, Nanjing Drum Tower Hosp,Clin Coll, 321 Zhongshan Rd, Nanjing 210008, Peoples R China.; Jiang, Q (通讯作者)，Branch Natl Clin Res Ctr Orthoped Sports Med & Re, Nanjing 210008, Peoples R China.; Guo, BS; Jiang, Q (通讯作者)，Nanjing Univ, Med Sch, State Key Lab Pharmaceut Biotechnol, Nanjing 210008, Peoples R China.
EM borisguo@nju.edu.cn; qingj@nju.edu.cn
RI Li, Liu/IXD 1917 2023; Peng, Rui/J 3781 2016; Jiang, Qing/JXM 6827 2024;
   Guo, Baosheng/ABD 4800 2021; Shao, Xiaoyan/LSL 7461 2024; Wu,
   Wen Shu/I 1258 2014; Gong, Wang/GPP 3300 2022
FU This work was supported by the National Key Research and Development
   Project (No. 2021YFA1201404), Major Project of the National Natural
   Science Foundation of China (Nos. 81991514, 82272530), Jiangsu Province
   Medical Innovation Center of Orthopedic Surgery [2021YFA1201404];
   National Key Research and Development Project [81991514, 82272530];
   Major Project of the National Natural Science Foundation of China
   [CXZX202214]; Jiangsu Province Medical Innovation Center of Orthopedic
   Surgery; Jiangsu Provincial Key Medical Center Foundation; Jiangsu
   Provincial Medical Outstanding Talent Foundation; Jiangsu Provincial
   Medical Youth Talent Foundation; Jiangsu Provincial Key Medical Talent
   Foundation [14380493, 14380494]; Fundamental Research Funds for the
   Central Universities
FX This work was supported by the National Key Research and Development
   Project (No. 2021YFA1201404), Major Project of the National Natural
   Science Foundation of China (Nos. 81991514, 82272530), Jiangsu Province
   Medical Innovation Center of Orthopedic Surgery (No. CXZX202214),
   Jiangsu Provincial Key Medical Center Foundation, Jiangsu Provincial
   Medical Outstanding Talent Foundation, Jiangsu Provincial Medical Youth
   Talent Foundation, Jiangsu Provincial Key Medical Talent Foundation, and
   the Fundamental Research Funds for the Central Universities (Nos.
   14380493 and 14380494).
CR Alam SSM, 2023, PHARMACOL REP, V75, P907, DOI 10.1007/s43440 023 00507 y
   [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Bobo D, 2016, PHARM RES DORDR, V33, P2373, DOI 10.1007/s11095 016 1958 5
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang ML, 2015, COLLOID SURFACE B, V129, P175, DOI 10.1016/j.colsurfb.2015.03.046
   Dang L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030428
   Dumortier C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.611921
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Guo W, 2021, J ORTHOP TRANSL, V28, P148, DOI 10.1016/j.jot.2021.01.005
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Horn C, 2021, ANTIBIOTICS BASEL, V10, DOI 10.3390/antibiotics10010051
   Huang BX, 2023, INT IMMUNOPHARMACOL, V115, DOI 10.1016/j.intimp.2023.109698
   Huang BX, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00281
   Huang BX, 2018, FOOD FUNCT, V9, P2735, DOI 10.1039/c8fo00057c
   Jia XY, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1091530
   Jung SH, 2013, J ETHNOPHARMACOL, V147, P208, DOI 10.1016/j.jep.2013.02.034
   Kum CJ, 2017, J ETHNOPHARMACOL, V205, P186, DOI 10.1016/j.jep.2017.03.017
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee S, 2021, MAR DRUGS, V19, DOI 10.3390/md19040210
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Liang JY, 2019, ARTIF CELL NANOMED B, V47, P3087, DOI 10.1080/21691401.2019.1637881
   Liu XSBJ, 2019, INT IMMUNOPHARMACOL, V76, DOI 10.1016/j.intimp.2019.105886
   Nirwan N, 2021, EXPERT OPIN DRUG DEL, V18, P761, DOI 10.1080/17425247.2021.1867534
   Pei XD, 2020, EUR J PHARMACOL, V883, DOI 10.1016/j.ejphar.2020.173355
   Sipos W, 2008, CURR MED CHEM, V15, P127, DOI 10.2174/092986708783330638
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Waldrep JC, 1997, CHEST, V111, P316, DOI 10.1378/chest.111.2.316
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Wang TX, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e17603
   Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91
   Wieland K, 2019, NANO RES, V12, P197, DOI 10.1007/s12274 018 2202 x
   Yang FG, 2023, CHIN J NAT MEDICINES, V21, P459, DOI 10.1016/S1875 5364(23)60474 1
   Zeytinoglu M, 2021, ENDOCRIN METAB CLIN, V50, P205, DOI 10.1016/j.ecl.2021.03.004
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang HW, 2021, AGING US, V13, P17690, DOI 10.18632/aging.203259
   Zhang MJ, 2023, PHYTOMEDICINE, V118, DOI 10.1016/j.phymed.2023.154965
NR 39
TC 2
Z9 2
U1 11
U2 47
PU TSINGHUA UNIV PRESS
PI BEIJING
PA B605D, XUE YAN BUILDING, BEIJING, 100084, PEOPLES R CHINA
SN 1998 0124
EI 1998 0000
J9 NANO RES
JI Nano Res.
PD APR
PY 2024
VL 17
IS 4
BP 2949
EP 2959
DI 10.1007/s12274 023 6224 7
EA OCT 2023
PG 11
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA LQ6V8
UT WOS:001094248700005
DA 2025 08 17
ER

PT J
AU Ma, C
   Li, XF
   Xiao, H
   Li, B
   Gu, HW
   Guo, Y
   Wang, H
   Wen, YX
   Chen, LB
AF Ma, Chi
   Li, Xufeng
   Xiao, Hao
   Li, Bin
   Gu, Hanwen
   Guo, Yu
   Wang, Hui
   Wen, Yinxian
   Chen, Liaobin
TI Course , dose , and stage dependent toxic effects of prenatal
   acetaminophen exposure on fetal long bone development
SO TOXICOLOGY LETTERS
LA English
DT Article
DE Prenatal acetaminophen exposure; Bone developmental toxicity; Osteogenic
   function; Osteoclast function; H type vessels
ID ENDOCHONDRAL OSSIFICATION; MASS; PRECURSORS; IDENTIFICATION;
   RETARDATION; OSTEOBLASTS
AB Acetaminophen is a common analgesic and fever reduction medicine for pregnant women. Epidemiological studies suggest that prenatal acetaminophen exposure (PAcE) affects offspring health and development. However, the effects of PAcE on fetal long bone development and its potential mechanisms have not been elucidated. Based on clinical dosing characteristics, fetal mouse femurs were obtained for detection after oral gavage of acetaminophen at different doses (0, 100 or 400 mg/kg d), courses (single or multiple times) or stages (mid  or late pregnancy) during pregnancy in Kunming mice. The results showed that compared with the control group, PAcE reduced the length of total femur and the primary ossification center (POC), delayed the mineralization of POC and the ossification of epiphyseal region, and down regulated the mRNA expression of osteogenic function markers (such as Runx2, Bsp, Ocn , Col1a1) in fetal femur, particularly in the high dose, multiple courses, and mid pregnancy group. Meanwhile, the osteoclast and angiogenic function were also inhibited by PAcE at high dose, multiple courses, and mid pregnancy, but the inhibition level was less than osteogenic function. Moreover, the alteration of canonical Wnt signalling pathway in PAcE fetal bone were consistent with its osteogenesis function changes. In conclusion, PAcE caused development toxicity and multi cellular function inhibition in fetal long bone, particularly in the high dose, multiple treatments and mid pregnancy group, and the alteration of canonical Wnt signalling pathway may be its potential mechanism.
C1 [Ma, Chi; Li, Xufeng; Xiao, Hao; Li, Bin; Gu, Hanwen; Wen, Yinxian; Chen, Liaobin] Wuhan Univ, Dept Orthoped Surg, Div Joint Surg & Sports Med, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   [Xiao, Hao; Li, Bin; Wen, Yinxian; Chen, Liaobin] Wuhan Univ, Joint Dis Res Ctr, Wuhan 430071, Peoples R China.
   [Xiao, Hao; Li, Bin; Guo, Yu; Wang, Hui; Wen, Yinxian; Chen, Liaobin] Hubei Prov Key Lab Dev Originated Dis, Wuhan 430071, Peoples R China.
   [Guo, Yu; Wang, Hui] Wuhan Univ, Sch Basic Med Sci, Dept Pharmacol, Wuhan 430071, Peoples R China.
C3 Wuhan University; Wuhan University; Wuhan University
RP Wen, YX; Chen, LB (通讯作者)，Wuhan Univ, Dept Orthoped Surg, Div Joint Surg & Sports Med, Zhongnan Hosp, Wuhan 430071, Peoples R China.
EM wenyinxian@whu.edu.cn; lbchen@whu.edu.cn
RI 顾, 瀚文/JBJ 4790 2023; Ma, Chi/IAQ 2513 2023; bin, li/GRS 1205 2022
FU National Key Research and Development Program of China [2020YFA0803900];
   National Natural Science Foundation of China [81673524]
FX This work was supported by grants from the National Key Research and
   Development Program of China (No. 2020YFA0803900), the National Natural
   Science Foundation of China (No. 81673524) .
CR Alias L, 2019, BONE, V120, P523, DOI 10.1016/j.bone.2018.10.004
   Aminoshariae A, 2015, J ENDODONT, V41, P588, DOI 10.1016/j.joen.2015.01.024
   ARIYUKI F, 1982, TERATOLOGY, V26, P263, DOI 10.1002/tera.1420260308
   Baker BH, 2020, JAMA PEDIATR, V174, P1073, DOI 10.1001/jamapediatrics.2020.3080
   Bandoli G, 2020, PAEDIATR PERINAT EP, V34, P237, DOI 10.1111/ppe.12595
   Black RA, 2003, AM FAM PHYSICIAN, V67, P2517
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Chen XH, 2021, DIABETOL METAB SYNDR, V13, DOI 10.1186/s13098 021 00732 6
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chen Z, 2018, TOXICOL APPL PHARM, V351, P12, DOI 10.1016/j.taap.2018.05.005
   Corada M, 2010, DEV CELL, V18, P938, DOI 10.1016/j.devcel.2010.05.006
   Deng Y, 2021, TOXICOLOGY, V459, DOI 10.1016/j.tox.2021.152847
   Dufourcq P, 2002, CIRCULATION, V106, P3097, DOI 10.1161/01.CIR.0000039342.85015.5C
   Fernández Iglesias A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020900
   Flint B, 2021, T.P. Physiology, Aging
   García Martínez O, 2011, ARCH ORAL BIOL, V56, P317, DOI 10.1016/j.archoralbio.2010.10.018
   He HY, 2021, FASEB J, V35, DOI 10.1096/fj.202002230R
   Heppe DHM, 2014, J BONE MINER RES, V29, P2584, DOI 10.1002/jbmr.2299
   Hu H, 2018, TOXICOL LETT, V295, P249, DOI 10.1016/j.toxlet.2018.07.005
   Józwiak Bebenista M, 2014, ACTA POL PHARM, V71, P11
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lajic S, 2011, ENDOCR DEV, V20, P96, DOI 10.1159/000321228
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Liew Z, 2021, CURR ENV HLTH REP, V8, P23, DOI 10.1007/s40572 020 00301 5
   Long FX, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008334
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Miller WL, 2013, AM J OBSTET GYNECOL, V208, P354, DOI 10.1016/j.ajog.2012.10.885
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Oichi T, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115368
   Ortega N, 2010, DIS MODEL MECH, V3, P224, DOI 10.1242/dmm.004226
   Ortiz LA, 2003, HYPERTENSION, V41, P328, DOI 10.1161/01.HYP.0000049763.51269.51
   Palmsten K, 2020, PAEDIATR PERINAT EP, V34, P597, DOI 10.1111/ppe.12660
   Pan ZQ, 2016, TOXICOL APPL PHARM, V305, P234, DOI 10.1016/j.taap.2016.06.021
   Segal TR, 2019, FERTIL STERIL, V112, P613, DOI 10.1016/j.fertnstert.2019.08.001
   Shangguan YF, 2021, BIOCHEM PHARMACOL, V185, DOI 10.1016/j.bcp.2021.114414
   Shangguan YF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.546
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Sordillo JE, 2019, J ALLERGY CLIN IMMUN, V144, P1534, DOI 10.1016/j.jaci.2019.07.044
   Suzuki K, 2018, J DEV ORIG HLTH DIS, V9, P266, DOI 10.1017/S2040174417000691
   Syed FA, 2010, INTERD T GERONT GERI, V37, P175, DOI 10.1159/000320001
   Taher L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028358
   Takahashi N, 2010, ADV EXP MED BIOL, V658, P21, DOI 10.1007/978 1 4419 1050 9_3
   Talge NM, 2020, PAEDIATR PERINAT EP, V34, P227, DOI 10.1111/ppe.12659
   Vestergaard P, 2006, CALCIFIED TISSUE INT, V79, P84, DOI 10.1007/s00223 006 0020 8
   Vestergaard P, 2012, OSTEOPOROSIS INT, V23, P1255, DOI 10.1007/s00198 011 1692 0
   Vestergaard P, 2020, HANDB EXP PHARMACOL, V262, P474, DOI 10.1007/164_2019_340
   Vidal B, 2012, ACTA REUMATOL PORT, V37, P294
   Wang JM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04150 5
   Wang L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.36
   Weaver CM, 2016, OSTEOPOROSIS INT, V27, P1281, DOI 10.1007/s00198 015 3440 3
   Xiao H, 2019, FASEB J, V33, P12972, DOI 10.1096/fj.201901145RR
   Xu D, 2011, ENVIRON TOXICOL PHAR, V32, P356, DOI 10.1016/j.etap.2011.08.003
   Ystrom E, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016 3840
   Zhang XR, 2016, BRIT J PHARMACOL, V173, P2250, DOI 10.1111/bph.13506
NR 56
TC 5
Z9 5
U1 1
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 4274
EI 1879 3169
J9 TOXICOL LETT
JI Toxicol. Lett.
PD SEP 15
PY 2023
VL 387
BP 50
EP 62
DI 10.1016/j.toxlet.2023.09.007
EA OCT 2023
PG 13
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA U8DD2
UT WOS:001087043800001
PM 37741353
DA 2025 08 17
ER

PT J
AU Zhong, TL
   Zhong, YL
AF Zhong, Tenglang
   Zhong, Yunlang
TI Effect of atorvastatin, 3 hydroxy 3 methylglutaryl coenzyme a reductase
   inhibitor (HMG CoA) on the prevention of osteoporosis in ovariectomized
   rabbits
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Osteoporosis; ovariectomy; atorvastatin; osteoblasts; osteoclasts
ID INDUCED BONE LOSS; OSTEOBLASTIC DIFFERENTIATION; CONTROLLED RELEASE;
   CALCIUM PHOSPHATE; SIMVASTATIN; MODEL; EXPRESSION; STATINS;
   MICROARCHITECTURE; ALENDRONATE
AB Osteoporosis is a systemic and metabolic skeleton disease characterized as low bone mineral density and micro architectural deterioration, resulting in increased bone fragility and fracture risk. Although current drugs such as bisphosphonates, estrogen replacement treatment, and selective estrogen receptor modulators, had been used to treat osteoporosis in clinical, they are not the ideal ones due to their insufficient curative effects and adverse side effects. Recently, atorvastatin are used to treat osteoporosis more frequently. However, its clinical effect and treatment mechanism is still unknown. In present study, the bilateral ovariectomy of rabbits was duplicated to construct osteoporosis model. The effect of atorvastatin in vivo was determined, and its treatment mechanism was studied in vitro after the curative effect was explored. The results show that atorvastatin significantly increased the mechanical parameters such as maximum load, stiffness, and energy absorbing capacity, and improved the microarchitecture. They indicated that the antiosteoporosis activity of atorvastatin may be due to the promotion of differentiation of osteoblasts by inducing synthesis of vascular endothelial growth factor, bone morphogenetic protein 2 (BMP2), and core binding factor alpha 1 (CBF alpha 1), and inhibition osteoclasts formation through osteoprotegerin(OPG) receptor activator for nuclear factor kappa B ligand (RANKL) system. Atorvastatin was effective in treating experimental osteoporosis. This study provides necessary experimental evidence for the clinical application of atorvastatin in osteoporosis treatment.
C1 [Zhong, Tenglang] Jingmen City First Peoples Hosp, Inst Clin Lab, Jingmen 448000, Peoples R China.
   [Zhong, Yunlang] Jingmen City First Peoples Hosp, Dept Pharm, Jingmen 448000, Peoples R China.
RP Zhong, YL (通讯作者)，Jingmen City First Peoples Hosp, Dept Pharm, Jingmen 448000, Peoples R China.
EM zhongyunlangjm@sina.com
FU National Natural Science Foundation of China [81201101]; Natural Science
   Foundation of Anhui Province [A2014206208]; Natural Science Foundation
   of Bengbu City, China [10S090202, 2014 01 01 A R 07 0006,
   2016 05 06 A R 07 0005]
FX This study was supported by National Natural Science Foundation of China
   (No. 81201101) and the Natural Science Foundation of Anhui Province
   (A2014206208), and the Natural Science Foundation of Bengbu City, China
   (grants 10S090202, 2014 01 01 A R 07 0006, 2016 05 06 A R 07 0005).
CR Chen HY, 2012, J ETHNOPHARMACOL, V142, P80, DOI 10.1016/j.jep.2012.04.017
   Dai L., 2014, J BONE MINER METAB
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Furuzawa M, 2014, EXP GERONTOL, V55, P12, DOI 10.1016/j.exger.2014.03.003
   Hamada H, 2012, J APPL BIOMATER FUNC, V10, P22, DOI 10.5301/JABFM.2012.9272
   Hamrick I, 2015, WIEN MED WOCHENSCHR, V165, P54, DOI 10.1007/s10354 014 0335 4
   Handal JA, 2012, J ORTHOP RES, V30, P872, DOI 10.1002/jor.22030
   Hordon LD, 2006, BONE, V38, P444, DOI 10.1016/j.bone.2005.09.020
   Ito Masako, 2013, Clin Calcium, V23, P1035, DOI CliCa130710351039
   Ito Masako, 2006, Clin Calcium, V16, P2034
   Ito T, 2013, J PHARM PHARMACOL, V65, P494, DOI 10.1111/jphp.12008
   Ito T, 2012, J MATER SCI MATER M, V23, P1291, DOI 10.1007/s10856 012 4597 3
   Jadhav SB, 2006, J PHARM PHARMACOL, V58, P3, DOI 10.1211/jpp.58.1.0002
   Jang H, 2014, BONE, V61, P10, DOI 10.1016/j.bone.2013.12.028
   Johan MF, 2004, BRIT J HAEMATOL, V127, P123, DOI 10.1111/j.1365 2141.2004.05158.x
   Jules J, 2010, EXPERT OPIN THER TAR, V14, P923, DOI 10.1517/14728222.2010.511179
   Kim IS, 2009, J BIOMECH, V42, P2721, DOI 10.1016/j.jbiomech.2009.08.006
   Kim T, 2013, J ETHNOPHARMACOL, V146, P83, DOI 10.1016/j.jep.2012.11.037
   Lasota A, 2004, Rocz Akad Med Bialymst, V49 Suppl 1, P129
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Li LN, 2011, PHYTOMEDICINE, V18, P985, DOI 10.1016/j.phymed.2011.03.002
   Lin S, 2015, CALCIFIED TISSUE INT, V96, P541, DOI 10.1007/s00223 015 9975 7
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   Liu XL, 2012, MED ENG PHYS, V34, P2, DOI 10.1016/j.medengphy.2011.06.010
   Makras P, 2015, METABOLISM, V64, P1199, DOI 10.1016/j.metabol.2015.07.011
   Moshiri A, 2015, CALCIFIED TISSUE INT, V96, P552, DOI 10.1007/s00223 015 9981 9
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nahar Gohad P, 2015, CALCIFIED TISSUE INT, V96, P359, DOI 10.1007/s00223 015 9962 z
   Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756 3282(02)00826 8
   Oryan A, 2015, J CONTROL RELEASE, V215, P12, DOI 10.1016/j.jconrel.2015.07.022
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Park YS, 2013, AAPS J, V15, P367, DOI 10.1208/s12248 012 9442 6
   Peng JH, 2009, CHIN J INTEGR MED, V15, P198, DOI 10.1007/s11655 009 9001 x
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Rajamannan NM, 2015, CARDIOLOGY, V132, P11, DOI 10.1159/000381703
   Schorlemmer S, 2005, BONE, V37, P491, DOI 10.1016/j.bone.2005.05.002
   Sharif PS, 2011, RHEUMATOL INT, V31, P289, DOI 10.1007/s00296 010 1586 z
   Shi Jingli, 2008, J Tradit Chin Med, V28, P211
   Shirke SS, 2008, EXP BIOL MED, V233, P1403, DOI 10.3181/0803 RM 93
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Tan S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/814057
   Tsartsalis AN, 2012, HORM INT J ENDOCRINO, V11, P126, DOI 10.14310/horm.2002.1339
   Wang PS, 2000, JAMA J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   Willson T, 2015, CLIN EPIDEMIOL, V7, P65, DOI 10.2147/CLEP.S40966
   Wong RWK, 2005, BRIT J ORAL MAX SURG, V43, P46, DOI 10.1016/j.bjoms.2004.08.014
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zhao FD, 2009, BONE, V44, P372, DOI 10.1016/j.bone.2008.10.048
NR 48
TC 0
Z9 0
U1 0
U2 6
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936 2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 12
BP 12337
EP 12348
PG 12
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA EF5YP
UT WOS:000390406200017
DA 2025 08 17
ER

PT J
AU Xu, Y
   Ren, CC
   Zhao, X
   Wang, W
   Zhang, N
AF Xu, Yan
   Ren, Chaochao
   Zhao, Xiang
   Wang, Wei
   Zhang, Ning
TI microRNA 132 inhibits osteogenic differentiation of periodontal ligament
   stem cells via GDF5 and the NF κB signaling pathway
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Article
DE Periodontal ligament stem cells; Osteogenic differentiation;
   microRNA 132; NF kappa B signaling pathway; Growth differentiation
   factor 5
ID OSTEOBLAST DIFFERENTIATION
AB Background: Periodontal ligament stem cells (PDLSCs) could differentiate into osteoblasts and have a great prospect in treating bone diseases. microRNAs (miRs) and nuclear factor kappa B (NF kappa B) signaling pathway have proved pivotal in regulating osteogenic differentiation. This study intended to discuss the mechanism of miR 132 and NF kappa B in PDLSC osteogenesis.
   Methods: PDLSCs were firstly cultured, induced, and identified by detecting the surface markers and observing cell morphology. Levels of osteogenic markers alkaline phosphatase (ALP), bone morphogenetic proteins 2 (BMP2), runt related transcription factor 2 (Runx2) and osteocalcin (OCN), along with miR 132 expression were measured. The osteoblast activity and mineral deposition were detected by ALP and alizarin red S (ARS) stainings. The targeting relationship between miR 132 and growth differentiation factor 5 (GDF5) was verified. The gain and loss of function was performed to discuss roles of miR 132 and GDF5 in osteogenic differentiation of PDLSCs. Besides, levels of NF kappa B signaling pathway related proteins were measured.
   Results: In osteogenic differentiation of PDLSCs, levels of ALP, BMP2, Runx2 and OCN were upregulated while miR 132 was downregulated. Overexpressing miR 132 reduced levels of osteogenic markers, osteoblast activity, ALP and ARS intensity and the activation of NF kappa B axis. GDF5 is a target of miR 132 and GDF5 overexpression reversed the inhibitory effects of overexpressed miR 132 on PDLSC osteogenesis.
   Conclusion: Together, miR 132 could inhibit PDLSC osteogenesis via targeting GDF5 and activating NF kappa B axis. These data provide useful information for PDLSC application in periodontal therapy.
C1 [Xu, Yan; Ren, Chaochao; Wang, Wei; Zhang, Ning] Capital Med Univ, Beijing Stomotol Hosp, Dept Orthodont, 11 Xila Alley, Beijing 100006, Peoples R China.
   [Zhao, Xiang] Capital Med Univ, Beijing Stomotol Hosp, Dept Gen Dent, Beijing 100006, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Zhang, N (通讯作者)，Capital Med Univ, Beijing Stomotol Hosp, Dept Orthodont, 11 Xila Alley, Beijing 100006, Peoples R China.
EM drzhangning333@163.com
FU National Natural Science Foundation of China Youth Fund [81500879]
FX This work was supported by the National Natural Science Foundation of
   China Youth Fund (81500879).
CR Albandar JM, 2014, PERIODONTOL 2000, V65, P7, DOI 10.1111/prd.12013
   Alhasan S.A., 2008, EFFECT PULSED ULTRAS
   Bianchi EN, 2009, BONE, V45, P716, DOI 10.1016/j.bone.2009.06.020
   Chen X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.14
   Coleman CM, 2011, CLIN ORTHOP RELAT R, V469, P2915, DOI 10.1007/s11999 011 1912 0
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Gong K, 2016, BIOCHEM BIOPH RES CO, V478, P260, DOI 10.1016/j.bbrc.2016.07.057
   Hu ZB, 2015, SCI REP UK, V5, DOI 10.1038/srep18655
   Huang C, 2017, CELL TISSUE RES, V368, P229, DOI 10.1007/s00441 016 2462 2
   Hupkes M, 2014, BMC MOL BIOL, V15, DOI 10.1186/1471 2199 15 1
   Iwasaki K, 2013, J PERIODONTOL, V84, P1425, DOI 10.1902/jop.2012.120547
   Jeftha A., 2013, S AFRICAN DENT J, V60, P62
   Kidwai F, 2016, STEM CELLS, V34, P2079, DOI 10.1002/stem.2427
   Larsson L, 2016, J DENT RES, V95, P255, DOI 10.1177/0022034515618887
   Li JY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/872139
   Li XF, 2018, 2018 2ND IEEE CONFERENCE ON ENERGY INTERNET AND ENERGY SYSTEM INTEGRATION (EI2), P5
   Lin XP, 2011, INFECT IMMUN, V79, P911, DOI 10.1128/IAI.00944 10
   Liu DY, 2012, J CLIN PERIODONTOL, V39, P1174, DOI 10.1111/jcpe.12009
   Liu OS, 2013, STEM CELLS, V31, P1371, DOI 10.1002/stem.1387
   Liu Y, 2016, INT J MOL MED, V38, P537, DOI 10.3892/ijmm.2016.2652
   O'Keeffe GW, 2016, NEURAL DEV, V11, DOI 10.1186/s13064 016 0060 3
   Qian Y, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00770
   Qu X, 2016, PROCEEDINGS OF THE FIFTEENTH INTERNATIONAL SYMPOSIUM   MANAGEMENT SCIENCE AND ENGINEERING (2016), P18
   Seemann I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068922
   Song LB, 2012, J CLIN INVEST, V122, P3563, DOI 10.1172/JCI62339
   Vaes BLT, 2010, BONE, V46, P514, DOI 10.1016/j.bone.2009.09.033
   Vardar Sengul S, 2009, J PERIODONTOL, V80, P833, DOI 10.1902/jop.2009.080483
   Wang N, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.150258
   Wang YP, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5068258
   Xue ZL, 2018, EUR REV MED PHARMACO, V22, P1580, DOI 10.26355/eurrev_201803_14562
   Ye G, 2014, INT J MED SCI, V11, P1065, DOI 10.7150/ijms.8473
   Zajdel A, 2017, ACTA BIOCHIM POL, V64, P365, DOI 10.18388/abp.2016_1488
   Zhu WJ, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/972313
NR 33
TC 30
Z9 33
U1 1
U2 13
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0344 0338
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PY 2019
VL 215
IS 12
AR 152722
DI 10.1016/j.prp.2019.152722
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA KK1BP
UT WOS:000512485400008
PM 31718857
DA 2025 08 17
ER

PT J
AU Lewiecki, EM
   Bilezikian, JP
   Laster, AJ
   Miller, PD
   Recker, RR
   Russell, RGG
   Whyte, MP
AF Lewiecki, E. Michael
   Bilezikian, John P.
   Laster, Andrew J.
   Miller, Paul D.
   Recker, Robert R.
   Russell, R. Graham G.
   Whyte, Michael P.
TI 2009 Santa Fe Bone Symposium
SO JOURNAL OF CLINICAL DENSITOMETRY
LA English
DT Article; Proceedings Paper
CT Santa Fe Bone Symposium 2009
CY JUL 31 AUG 01, 2009
CL Santa Fe, NM
DE Bisphosphonates; denosumab; emerging therapy; histomorphometry;
   odanacatib; osteoporosis; treatment
ID FAMILIAL EXPANSILE OSTEOLYSIS; HEALTHY POSTMENOPAUSAL WOMEN; STRONTIUM
   RANELATE TREATMENT; CHRONIC KIDNEY DISEASE; RENAL FUNCTION;
   PAGET DISEASE; VERTEBRAL FRACTURES; MINERAL DENSITY; DOUBLE BLIND; OLDER
   WOMEN
AB Osteoporosis is a common skeletal disease with serious clinical consequences because of fractures. Despite the availability of clinical tools to diagnose osteoporosis and assess fracture risk, and drugs proven to reduce fracture risk, it remains a disease that is underdiagnosed and undertreated. When treatment is started, it is commonly not taken correctly or long enough to be effective. Recent advances in understanding of the regulators and mediators of bone remodeling have led to new therapeutic targets and the development of drugs that may offer advantages over current agents in reducing the burden of osteoporotic fractures. Many genetic factors that play a role in the pathogenesis of osteoporosis and metabolic bone disease have now been identified. At the 2009 Santa Fe Bone Symposium, held in Santa Fe, New Mexico, USA, the links between advances in genetics, basic bone science, recent clinical trials, and new and emerging therapeutic agents were presented and explored. Socioeconomic challenges and opportunities in the care of osteoporosis were discussed. This is a collection of medical essays based on key presentations at the 2009 Santa Fe Bone Symposium.
C1 [Lewiecki, E. Michael] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM 87106 USA.
   [Bilezikian, John P.] Columbia Univ Coll Phys & Surg, Nyc, NY USA.
   [Laster, Andrew J.] Arthritis & Osteoporosis Consultants Carolinas, Charlotte, NC USA.
   [Miller, Paul D.] Colorado Ctr Bone Res, Lakewood, CO USA.
   [Recker, Robert R.] Creighton Univ, Sch Med, Omaha, NE USA.
   [Russell, R. Graham G.] Univ Oxford, Botnar Res Ctr, Oxford, England.
   [Whyte, Michael P.] Washington Univ, Sch Med, St Louis, MO USA.
C3 New Mexico Clinical Research & Osteoporosis Center; Columbia University;
   Colorado Center For Bone Research; Creighton University; University of
   Oxford; Washington University (WUSTL)
RP Lewiecki, EM (通讯作者)，New Mexico Clin Res & Osteoporosis Ctr, 300 Oak St NE, Albuquerque, NM 87106 USA.
EM lewiecki@aol.com
RI Russell, Robert Graham G/JEF 5877 2023; Laster, Andrew/CAG 0343 2022;
   Russell, R/JEF 5877 2023; Lewiecki, E./B 3706 2018
OI Russell, Robert Graham G/0000 0002 4136 1828; Laster,
   Andrew/0000 0002 5035 5032; 
CR [Anonymous], ASS COSTS PERF DXA S
   [Anonymous], 2006, FED REG
   [Anonymous], 2009, Pilot Program for Green Technologies Including Greenhouse Gas Reduction
   [Anonymous], Federal Register, V76
   Beck TJ, 2008, J CLIN DENSITOM, V11, P351, DOI 10.1016/j.jocd.2007.12.017
   Bilezikian J. P., 2006, DYNAMICS BONE CARTIL, P629
   Bilezikian JP, 2009, J BONE MINER RES, V24, P373, DOI [10.1359/JBMR.090105, 10.1359/jbmr.090105]
   Bilezikian JP, 2009, AM J MED, V122, P14, DOI 10.1016/j.amjmed.2008.12.003
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Curtis JR, 2009, OSTEOPOROSIS INT, V20, P1553, DOI 10.1007/s00198 008 0821 x
   Elder G, 2002, J BONE MINER RES, V17, P2094, DOI 10.1359/jbmr.2002.17.12.2094
   Ensrud KE, 2007, ARCH INTERN MED, V167, P133, DOI 10.1001/archinte.167.2.133
   Fitzpatrick LA, 2008, J BONE MINER RES, V23, pS50
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH H, 1969, NATURE, V223, P211, DOI 10.1038/223211a0
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   Good DA, 2002, AM J HUM GENET, V70, P517, DOI 10.1086/338658
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Hruska KA, 2009, SEMIN NEPHROL, V29, P156, DOI 10.1016/j.semnephrol.2009.01.008
   Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667
   Jamal SA, 2007, J BONE MINER RES, V22, P503, DOI 10.1359/JBMR.070112
   Jassal SK, 2007, J BONE MINER RES, V22, P203, DOI 10.1359/JBMR.061014
   LANE NE, 2008, ARTHRITIS RHEUM S1, V9, P1
   Laurin N, 2002, AM J HUM GENET, V70, P1582, DOI 10.1086/340731
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   Lewiecki E Michael, 2006, Womens Health (Lond), V2, P825, DOI 10.2217/17455057.2.6.825
   Lewiecki EM, 2009, J CLIN DENSITOM, V12, P135, DOI 10.1016/j.jocd.2009.02.002
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Martin T. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P243
   MASSRY SG, 2003, AM J KIDNEY DIS S, V42, pS10
   McClung M, 2008, J BONE MINER RES, V23, pS82
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   MCKUSICK VA, 1960, HERITABLE DISORDERS
   Meunier PJ, 2009, OSTEOPOROSIS INT, V20, P1663, DOI 10.1007/s00198 008 0825 6
   MEUNIER PJ, 1980, ARTHRITIS RHEUM US, V23, P1095, DOI 10.1002/art.1780231005
   Miller PD, 2008, CLIN J AM SOC NEPHRO, V3, pS140, DOI 10.2215/CJN.02430508
   Miller PD, 2007, SEMIN DIALYSIS, V20, P186, DOI 10.1111/j.1525 139X.2007.00271.x
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Miller PD, 2009, SEMIN NEPHROL, V29, P144, DOI 10.1016/j.semnephrol.2009.01.007
   Miller PD, 2005, J BONE MINER RES, V20, P2105, DOI 10.1359/JBMR.050817
   Moe SM, 2009, KIDNEY INT, V76, pS3, DOI 10.1038/ki.2009.189
   *NAT KIDN DIS ED P, GFR CALC
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Padhi D, 2007, J BONE MINER RES, V22, pS37
   Paget J, 1877, Med Chir Trans, V60, P37
   Pennypacker B, 2009, BONE, V44, P199, DOI 10.1016/j.bone.2008.08.130
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   RECKER RR, 2009, AM J MED S, V122, pS32
   Reginster JY, 2008, ARTHRITIS RHEUM US, V58, P1687, DOI 10.1002/art.23461
   Reid DM, 2000, J BONE MINER RES, V15, P1006, DOI 10.1359/jbmr.2000.15.6.1006
   Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281
   Rosen LS, 2001, CANCER J, V7, P377
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   SIRIS ES, 1994, SEMIN ARTHRITIS RHEU, V23, P222, DOI 10.1016/0049 0172(94)90037 X
   Sprague SM, 2007, ARCH INTERN MED, V167, P115, DOI 10.1001/archinte.167.2.115
   Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332
   Weber TJ, 2003, J BONE MINER RES, V18, P1227, DOI 10.1359/jbmr.2003.18.7.1227
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Whyte MP, 2002, MEDICINE, V81, P101, DOI 10.1097/00005792 200203000 00002
   Whyte MP, 2002, NEW ENGL J MED, V347, P175, DOI 10.1056/NEJMoa013096
   Whyte MP, 2002, J BONE MINER RES, V17, P26, DOI 10.1359/jbmr.2002.17.1.26
NR 63
TC 19
Z9 19
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1094 6950
EI 1559 0747
J9 J CLIN DENSITOM
JI J. Clin. Densitom.
PD JAN MAR
PY 2010
VL 13
IS 1
BP 1
EP 9
DI 10.1016/j.jocd.2009.12.003
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Endocrinology & Metabolism
GA 563HU
UT WOS:000275119600001
PM 20171564
DA 2025 08 17
ER

PT J
AU Larranaga Vera, A
   Toti, KS
   Flatow, JS
   Haraczy, AJ
   Warnick, E
   Rao, HR
   Gao, ZG
   Sussman, SM
   Mediero, A
   Leucht, P
   Jacobson, KA
   Cronstein, BN
AF Larranaga Vera, Ane
   Toti, Kiran S.
   Flatow, James S.
   Haraczy, Alexandra J.
   Warnick, Eugene
   Rao, Harsha
   Gao, Zhan Guo
   Sussman, Sarah M.
   Mediero, Aranzazu
   Leucht, Philipp
   Jacobson, Kenneth A.
   Cronstein, Bruce N.
TI Novel alendronate CGS21680 conjugate reduces bone resorption and induces
   new bone formation in post menopausal osteoporosis and inflammatory
   osteolysis mouse models
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Osteoporosis; Inflammatory osteolysis; A(2a) adenosine receptor; Bone
   formation; Bone resorption
ID BIOACTIVE CERAMIC SCAFFOLDS; OSTEOCLAST FORMATION; KNEE ARTHROPLASTY;
   IN VIVO; ADENOSINE; OSTEOBLAST; ACTIVATION; EXPRESSION; CGS 21680;
   EFFICACY
AB Loss of bone is a common medical problem and, while it can be treated with available therapies, some of these therapies have critical side effects. We have previously demonstrated that CGS21680, a selective A(2A) adenosine receptor agonist, prevents bone loss, but its on target toxicities (hypotension, tachycardia) and frequent dosing requirements make it unusable in the clinic. We therefore generated a novel alendronate CGS21680 conjugate (MRS7216), to target the agonist to bone where it remains for long periods thereby diminishing the frequency of administration and curtailing side effects. MRS7216 was synthesized from CGS21680 by sequential activation of the carboxylic acid moiety and reacting with an appropriate amino acid (PEG, alendronic acid) under basic conditions. MRS7216 was tested on C57BL/6J (WT) mice with established osteoporosis (OP) and WT or A2A KO mice with wear particle induced inflammatory osteolysis (OL). Mice were treated weekly with MRS7216 (10mg/kg). Bone formation was studied after in vivo labeling with calcein/Alizarin Red, and mu CT and histology analyses were performed. In addition, human primary osteoblasts and osteoclasts were cultured using bone marrow discarded after hip replacement. Receptor binding studies demonstrate that MRS7216 efficiently binds the A2A adenosine receptor. MRS7216 treated OP and OL mice had significant new bone formation and reduced bone loss compared to vehicle or alendronate treated mice. Histological analysis showed that MRS7216 treatment significantly reduced osteoclast number and increased osteoblast number in murine models. Interestingly, cultured human osteoclast differentiation was inhibited, and osteoblast differentiation was stimulated by the compound indicating that MRS7216 conjugates represent a novel therapeutic approach to treat osteoporosis and osteolysis.
C1 [Larranaga Vera, Ane; Flatow, James S.; Mediero, Aranzazu; Cronstein, Bruce N.] NYU Langone Hlth, Dept Med, Div Translat Med, 550 First Ave,Med Sci Bldg, New York, NY 10016 USA.
   [Toti, Kiran S.; Haraczy, Alexandra J.; Warnick, Eugene; Rao, Harsha; Gao, Zhan Guo; Jacobson, Kenneth A.] NIDDKD, Mol Recognit Sect, Lab Bioorgan Chem, NIH, Bethesda, MD USA.
   [Sussman, Sarah M.] Augusta Univ, Med Coll Georgia, Augusta, GA USA.
   [Mediero, Aranzazu] IIS Fdn Jimenez Diaz UAM, Bone & Joint Res Unit, Madrid, Spain.
   [Leucht, Philipp] NYU, Langone Orthoped Hosp, Dept Orthoped Surg, New York, NY USA.
   [Leucht, Philipp] NYU, Grossman Sch Med, Dept Cell Biol, New York, NY USA.
   [Cronstein, Bruce N.] NYU Langone Hlth, Dept Med, Div Rheumatol, New York, NY USA.
C3 NYU Langone Medical Center; National Institutes of Health (NIH)   USA;
   NIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK); University System of Georgia; Augusta University; Fundacion
   Jimenez Diaz; New York University; New York University; NYU Langone
   Medical Center
RP Cronstein, BN (通讯作者)，NYU Langone Hlth, Dept Med, Div Translat Med, 550 First Ave,Med Sci Bldg, New York, NY 10016 USA.
EM Bruce.Cronstein@nyulangone.org
RI Jacobson, Kenneth/A 1530 2009; Leucht, Philipp/H 7238 2019; Toti,
   Kiran/AAJ 7406 2021; Cronstein, Bruce/JTD 2507 2023
OI Haraczy, Alexandra/0000 0002 9065 7158; Sussman,
   Sarah/0000 0001 7108 5118
FU NYU School of Medicine Applied Research Support Fund; National
   Institutes of Health; NYU HHC Clinical and Translational Science
   Institute; NYU DART Pathology Core;  [R01 AR068593];  [UL1 TR000038]
FX AcknowledgementsThis work was supported by grants from the NYU School of
   Medicine Applied Research Support Fund and the National Institutes of
   Health (R01 AR068593), by the NYU HHC Clinical and Translational Science
   Institute (UL1 TR000038) and the NYU DART Pathology Core
CR Albert SG, 2017, ENDOCR PRACT, V23, P841, DOI 10.4158/EP161678.RA
   Asadipooya K, 2019, ARTERIOSCL THROM VAS, V39, P1343, DOI 10.1161/ATVBAHA.119.312371
   Bekisz J, 2018, INFLAMMATION, V41, P1135, DOI 10.1007/s10753 018 0781 z
   Bekisz JM, 2018, J CRANIO MAXILL SURG, V46, P237, DOI 10.1016/j.jcms.2017.11.011
   Borhani S, 2019, FASEB J, V33, P7555, DOI 10.1096/fj.201900014R
   Boyce Brendan F., 2005, Keio Journal of Medicine, V54, P127, DOI 10.2302/kjm.54.127
   Bradaschia Correa V, 2017, TISSUE CELL, V49, P545, DOI 10.1016/j.tice.2017.07.001
   Carlin JL, 2018, NEUROPHARMACOLOGY, V139, P268, DOI 10.1016/j.neuropharm.2018.02.035
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cronstein BN, 2017, NAT REV RHEUMATOL, V13, P41, DOI 10.1038/nrrheum.2016.178
   Feig JL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188135
   Fozard JR, 2002, EUR J PHARMACOL, V438, P183, DOI 10.1016/S0014 2999(02)01305 5
   Gallo J, 2013, ACTA BIOMATER, V9, P8046, DOI 10.1016/j.actbio.2013.05.005
   Geng TX, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20187414, 10.1590/1414 431x20187414]
   Geng TX, 2018, MOL MED REP, V18, P1849, DOI 10.3892/mmr.2018.9133
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   He YX, 2011, BONE, V48, P1388, DOI 10.1016/j.bone.2011.03.720
   Ishack S, 2017, J BIOMED MATER RES B, V105, P366, DOI 10.1002/jbm.b.33561
   Khalid AB, 2018, JBMR PLUS, V2, P81, DOI 10.1002/jbm4.10027
   Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222
   Lasseter KC, 2005, CLIN DRUG INVEST, V25, P107, DOI 10.2165/00044011 200525020 00003
   Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771
   Lin JH, 1999, INT J CLIN PRACT, P18
   Lopez CD, 2019, PLAST RECONSTR SURG, V143, P1408, DOI 10.1097/PRS.0000000000005531
   Lopez CD, 2019, ADV DRUG DELIVER REV, V146, P240, DOI 10.1016/j.addr.2018.06.010
   Lopez CD, 2018, BIRTH DEFECTS RES, V110, P1055, DOI 10.1002/bdr2.1345
   Lopez CD, 2018, J SURG RES, V223, P115, DOI 10.1016/j.jss.2017.10.027
   Magone K, 2015, ARCH ORTHOP TRAUM SU, V135, P683, DOI 10.1007/s00402 015 2196 8
   McClung Michael R, 2018, Osteoporos Sarcopenia, V4, P11, DOI 10.1016/j.afos.2018.03.002
   Mediero A, 2018, FASEB J, V32, P3487, DOI 10.1096/fj.201700217R
   Mediero A, 2016, FASEB J, V30, P3887, DOI 10.1096/fj.201600616R
   Mediero A, 2015, FASEB J, V29, P1577, DOI 10.1096/fj.14 265066
   Mediero A, 2014, FASEB J, V28, P4901, DOI 10.1096/fj.14 255703
   Mediero A, 2013, BRIT J PHARMACOL, V169, P1372, DOI 10.1111/bph.12227
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Mediero A, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003393
   Mediero A, 2012, AM J PATHOL, V180, P775, DOI 10.1016/j.ajpath.2011.10.017
   Mingote S, 2008, PHARMACOL BIOCHEM BE, V89, P345, DOI 10.1016/j.pbb.2008.01.006
   Muller Werner E G, 2017, Prog Mol Subcell Biol, V55, P187, DOI 10.1007/978 3 319 51284 6_6
   Rachner TD, 2019, J MOL ENDOCRINOL, V62, pR145, DOI 10.1530/JME 18 0173
   Reid IR, 2015, J INTERN MED, V277, P690, DOI 10.1111/joim.12339
   Shih YRV, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1387
   Takedachi M, 2012, J CELL PHYSIOL, V227, P2622, DOI 10.1002/jcp.23001
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   Tovar N, 2018, J TISSUE ENG REGEN M, V12, P1986, DOI 10.1002/term.2733
   Tsutsumi R, 2008, J ORTHOP RES, V26, P1340, DOI 10.1002/jor.20620
   Vargas Franco JW, 2018, J CELL PHYSIOL, V233, P5696, DOI 10.1002/jcp.26465
   von Knoch M, 2005, BIOMATERIALS, V26, P1803, DOI 10.1016/j.biomaterials.2004.06.010
   Wang MM, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 54726 6
   Witek L, 2019, J ORTHOP RES, V37, P2499, DOI 10.1002/jor.24424
   Yang YJ, 2021, J ORTHOP TRANSL, V26, P92, DOI 10.1016/j.jot.2020.03.001
   Zhang Q, 2005, ARTHRITIS RHEUM US, V52, P2708, DOI 10.1002/art.21236
NR 52
TC 7
Z9 8
U1 2
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD DEC 9
PY 2022
VL 24
IS 1
AR 265
DI 10.1186/s13075 022 02961 0
PG 13
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 6W4LP
UT WOS:000895701700001
PM 36494860
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Berardi, R
   Berruti, A
   Brogelli, L
   Zucali, PA
AF Berardi, R.
   Berruti, A.
   Brogelli, L.
   Zucali, P. A.
TI An Italian survey on the use of denosumab for the management of
   skeletal related events in patients with bone metastases
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Skeletal related events; Bone metastases; Bisphosphonate; Denosumab;
   Survey
ID PROSTATE CANCER; ZOLEDRONIC ACID; METAANALYSIS; RISK; LIFE
AB OBJECTIVE: The Italian Association for Medical Oncology (AIOM) recommends preventive treatment of skeletal related events in order to improve survival and the quality of life of patients with advanced malignancies. The aim of the study was to evaluate whether routine clinical practice is in agreement with recommendations about the use of denosumab.
   PATIENTS AND METHODS: A survey was carried out in Italy in the oncological setting.
   RESULTS: The answers to the survey showed that a large proportion of patients with metastases from solid tumors receive treatment; almost all oncologists administered denosumab every 4 weeks but for a shorter period of time than recommended.
   CONCLUSIONS: This survey showed that Italian oncologists favor the use of bone targeted therapy to prevent skeletal related events in patients affected by metastatic breast. prostate or lung cancer. in agreement with current recommendations.
C1 [Berardi, R.] Univ Politecn Marche, Clin Oncol, AOU Osped Riuniti, Ancona, Italy.
   [Berruti, A.] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Med Oncol, Brescia, Italy.
   [Berruti, A.] ASST Spedali Civili, Brescia, Italy.
   [Brogelli, L.] Polistudium Srl, Milan, Italy.
   [Zucali, P. A.] IRCCS, Dept Oncol, Humanitas Clin & Res Ctr, Milan, Italy.
   [Zucali, P. A.] Humanitas Univ, Dept Biomed Sci, Milan, Italy.
C3 Marche Polytechnic University; University of Brescia; Hospital Spedali
   Civili Brescia; Humanitas University
RP Berruti, A (通讯作者)，Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Med Oncol, Brescia, Italy.
EM alfredo.berruti@gmail.com
RI Zucali, Paolo/AAC 9757 2020; Zucali, Paolo Andrea/AAC 9757 2020
OI Zucali, Paolo Andrea/0000 0002 2274 1702
FU pharmaceutical company, Amgen
FX The survey and the development of the manuscript were carried out by the
   research company, DoxaPharma and funded by the pharmaceutical company,
   Amgen.
CR Angela Y, 2019, CANCER IMMUNOL IMMUN, V68, P1187, DOI 10.1007/s00262 019 02353 5
   [Anonymous], 2018, 2018 EDITION
   Aredia R), 2012, AR PAM DIS FULL PRES
   Berruti A, 1996, BRIT J CANCER, V73, P1581, DOI 10.1038/bjc.1996.298
   Berruti A, 2002, J CLIN ENDOCR METAB, V87, P1910, DOI 10.1210/jcem.87.4.8443
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Bozzo A, 2021, CLIN ORTHOP RELAT R, V479, P2047, DOI 10.1097/CORR.0000000000001749
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Cadieux B, 2022, J BONE ONCOL, V33, DOI 10.1016/j.jbo.2022.100416
   Castellano D, 2011, ONCOLOGIST, V16, P136, DOI 10.1634/theoncologist.2010 0154
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Cook RJ, 2008, J CLIN ONCOL, V26
   Daniele S, 2015, SCI REP UK, V5, DOI 10.1038/srep18670
   European Medicines Agency (EMA), 2014, ZOM ZOL AC SUMM PROD
   European Medicines Agency (EMA). XGEVA<(R), 2014, SUMMARY PRODUCT CHAR
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Grisanti S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213934
   Jensen AO, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 29
   Kuchuk M, 2013, J BONE ONCOL, V2, P22, DOI 10.1016/j.jbo.2012.12.004
   Laganà M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.588862
   Limones A, 2020, MED ORAL PATOL ORAL, V25, pE326, DOI 10.4317/medoral.23324
   Mazziotti G, 2018, ENDOCRINE, V59, P90, DOI 10.1007/s12020 017 1455 6
   Menshawy A, 2018, SUPPORT CARE CANCER, V26, P1029, DOI 10.1007/s00520 018 4060 1
   Miyashita H, 2022, SUPPORT CARE CANCER, V30, P981, DOI 10.1007/s00520 021 06340 4
   Pavlakis N, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub2
   Rosenberg D, 2021, OSTEOPOROSIS INT, V32, P413, DOI 10.1007/s00198 020 05704 6
   Saad F, 2018, CANCER TREAT REV, V68, P25, DOI 10.1016/j.ctrv.2018.04.014
   Santini D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083026
   Saylor PJ, 2013, EUR UROL, V63, P309, DOI 10.1016/j.eururo.2012.10.007
   Smith MR, 2015, ANN ONCOL, V26, P368, DOI 10.1093/annonc/mdu519
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tam AH, 2021, ANN PHARMACOTHER, V55, P697, DOI 10.1177/1060028020967629
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
   Wong MHF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub3
   Yoshida T, 2020, OSTEOPOROSIS INT, V31, P1251, DOI 10.1007/s00198 019 05271 5
   Zheng GZ, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12541
NR 39
TC 4
Z9 4
U1 0
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2022
VL 26
IS 13
BP 4659
EP 4665
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 3P0VK
UT WOS:000837256500016
PM 35856356
DA 2025 08 17
ER

PT J
AU Sullivan, K
   El Hoss, J
   Little, DG
   Schindeler, A
AF Sullivan, Kate
   El Hoss, Jad
   Little, David G.
   Schindeler, Aaron
TI JNK inhibitors increase osteogenesis in Nf1 deficient cells
SO BONE
LA English
DT Article
DE Neurofibromatosis type 1; NF1; Bone morphogenetic protein;
   Mitogen activated protein kinase; c Jun N terminal kinase inhibitor
ID BONE MORPHOGENETIC PROTEIN 2; GROWTH FACTOR BETA; MC3T3 E1 CELLS; NF1;
   RAS; DIFFERENTIATION; NEUROFIBROMIN; ACTIVATION; PSEUDOARTHROSIS;
   RESPONSIVENESS
AB Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder that is associated with a variety of manifestations, including orthopedic complications such as scoliosis and tibial pseudarthrosis. Orthopedic management of these skeletal complications is rendered more challenging due to a lack of standardized adjunctive pharmacotherapies. NF1 leads to disruption of the canonical Ras/Raf 1/MEK/ERK axis, and this has been associated with defects in bone anabolism. The roles of other non canonical Ras effector pathways, such as the c Jun N terminal Kinase (JNK) pathway, are less well understood. In this study we examine the effects of an anthrapyrazolone inhibitor of JNK (SP600125) on inducible osteoprogenitors as well as Nf1 deficient and Nf1 null primary osteoblasts.
   C2C12 cells, which are highly responsive to rhBMP 2, were examined with exogenous rhBMP 2 and a range of SP600125 doses. Based on the expression of early and late bone markers and matrix mineralization, 10 mu M SP600125 was found to be pro osteogenic whether delivered concurrent with or following 2 days of rliBMP 2 treatment. Aberrant INK activity was identified in Nf1 deficient osteoprogenitors (increased rhBMP 2 induced phospho c Jun) and in Nf1 null mature osteoblasts (increased total c Jun). Next, SP600125 was used to treat these cells and was found to facilitate osteogenesis in Nf1 deficient osteoprogenitors, and in Nf1 null osteoblasts when given in conjunction with rhBMP 2. Outcome measures included alkaline phosphatase activity, matrix mineralization, and osteogenic gene expression. In summary, JNK inhibitors represent a class of potentially useful adjunctive agents for orthopedic medicine, particularly in the context of NF1. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Sullivan, Kate; El Hoss, Jad; Little, David G.; Schindeler, Aaron] Childrens Hosp Westmead, Orthopaed Res Er Biotechnol Unit, Sydney, NSW, Australia.
   [Sullivan, Kate; Little, David G.; Schindeler, Aaron] Univ Sydney, Fac Med, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia.
C3 NSW Health; The Children's Hospital at Westmead; University of Sydney;
   University of Sydney
RP Sullivan, K (通讯作者)，Childrens Hosp Westmead, Res Bldg,Locked Bag 4001, Westmead, NSW 2145, Australia.
EM kate.sullivan@sydney.edu.au
OI Schindeler, Aaron/0000 0002 7757 6281
FU Children's Tumor Foundation (New York, USA); University of Sydney;
   National Health & Medical Research Council [1003478]; Neurofibromatosis
   Association of Australia
FX Dr. Schindeler has received support from the Children's Tumor Foundation
   (New York, USA). Jad El Hoss receives a scholarship from the University
   of Sydney. This project has received funding support from the National
   Health & Medical Research Council (Project Grant 1003478) and the
   Neurofibromatosis Association of Australia. We would like to thank
   Lauren Peacock and Kathy Mikulec for assistance animal studies, and
   Renjing Liu and Alyson Morse for technical assistance.
CR Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296 144
   Bosch P, 2006, MOL REPROD DEV, V73, P1393, DOI 10.1002/mrd.20593
   BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019
   Cheung WMW, 2006, FEBS LETT, V580, P121, DOI 10.1016/j.febslet.2005.11.062
   Chung CY, 1999, BIOCHEM BIOPH RES CO, V265, P246, DOI 10.1006/bbrc.1999.1639
   Daginakatte GC, 2008, CANCER RES, V68, P10358, DOI 10.1158/0008 5472.CAN 08 2506
   Elefteriou F, 2006, CELL METAB, V4, P441, DOI 10.1016/j.cmet.2006.10.010
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Klose A, 1998, HUM MOL GENET, V7, P1261, DOI 10.1093/hmg/7.8.1261
   Kolanczyk M, 2007, HUM MOL GENET, V16, P874, DOI 10.1093/hmg/ddm032
   Kuorilehto T, 2006, J HISTOCHEM CYTOCHEM, V54, P363, DOI 10.1369/jhc.5A6784.2005
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296 137
   Lau N, 2000, J NEUROPATH EXP NEUR, V59, P759, DOI 10.1093/jnen/59.9.759
   Liu H, 2011, J BONE MINER RES, V26, P1122, DOI 10.1002/jbmr.296
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Schindeler A, 2005, BIOCHEM BIOPH RES CO, V338, P710, DOI 10.1016/j.bbrc.2005.09.198
   Schindeler A, 2008, BONE, V42, P616, DOI 10.1016/j.bone.2007.11.006
   Schindeler A, 2008, J ORTHOP RES, V26, P1053, DOI 10.1002/jor.20628
   Schindeler A, 2008, J ORTHOP RES, V26, P65, DOI 10.1002/jor.20481
   Schindeler A, 2006, J BONE MINER RES, V21, P1331, DOI 10.1359/JBMR.060603
   Schindeler A, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 105
   Sherman LS, 2000, J BIOL CHEM, V275, P30740, DOI 10.1074/jbc.M001702200
   Stevenson DA, 2006, AM J HUM GENET, V79, P143, DOI 10.1086/504441
   Watanabe Takano H, 2010, EXP CELL RES, V316, P477, DOI 10.1016/j.yexcr.2009.09.028
   Yan JC, 2008, HUM MOL GENET, V17, P936, DOI 10.1093/hmg/ddm366
   Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092
   Yu X, 2005, BONE, V36, P793, DOI 10.1016/j.bone.2005.01.022
   Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101
NR 30
TC 14
Z9 15
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2011
VL 49
IS 6
BP 1311
EP 1316
DI 10.1016/j.bone.2011.09.043
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 856SK
UT WOS:000297663500024
PM 21964323
DA 2025 08 17
ER

PT J
AU Hsu, YH
   Kiel, DP
AF Hsu, Yi Hsiang
   Kiel, Douglas P.
TI Genome Wide Association Studies of Skeletal Phenotypes: What We Have
   Learned and Where We Are Headed
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID BONE MINERAL DENSITY; COPY NUMBER VARIATION; LINKAGE DISEQUILIBRIUM;
   MISSING HERITABILITY; POPULATION STRUCTURE; GENE IDENTIFICATION;
   SEQUENCE VARIANTS; PAGETS DISEASE; GENOTYPE DATA; LOCI
AB Context: The primary goals of genome wide association studies (GWAS) are to discover new molecular and biological pathways involved in the regulation of bone metabolism that can be leveraged for drug development. In addition, the identified genetic determinants may be used to enhance current risk factor profiles.
   Evidence Acquisition: There have been more than 40 published GWAS on skeletal phenotypes, predominantly focused on dual energy x ray absorptiometry derived bone mineral density (BMD) of the hip and spine.
   Evidence Synthesis: Sixty six BMD loci have been replicated across all the published GWAS, confirming the highly polygenic nature of BMD variation. Only seven of the 66 previously reported genes (LRP5, SOST, ESR1, TNFRSF11B, TNFRSF11A, TNFSF11, PTH) from candidate gene association studies have been confirmed by GWAS. Among 59 novel BMD GWAS loci that have not been reported by previous candidate gene association studies, some have been shown to be involved in key biological pathways involving the skeleton, particularly Wnt signaling (AXIN1, LRP5, CTNNB1, DKK1, FOXC2, HOXC6, LRP4, MEF2C, PTHLH, RSPO3, SFRP4, TGFBR3, WLS, WNT3, WNT4, WNT5B, WNT16), bone development: ossification (CLCN7, CSF1, MEF2C, MEPE, PKDCC, PTHLH, RUNX2, SOX6, SOX9, SPP1, SP7), mesenchymal stem cell differentiation (FAM3C, MEF2C, RUNX2, SOX4, SOX9, SP7), osteoclast differentiation (JAG1, RUNX2), and TGF signaling (FOXL1, SPTBN1, TGFBR3). There are still 30 BMD GWAS loci without prior molecular or biological evidence of their involvement in skeletal phenotypes. Other skeletal phenotypes that either have been or are being studied include hip geometry, bone ultrasound, quantitative computed tomography, high resolution peripheral quantitative computed tomography, biochemical markers, and fractures such as vertebral, nonvertebral, hip, and forearm.
   Conclusions: Although several challenges lie ahead as GWAS moves into the next generation, there are prospects of new discoveries in skeletal biology. This review integrates findings from previous GWAS and provides a roadmap for future directions building on current GWAS successes. (J Clin Endocrinol Metab 97: E1958 E1977, 2012)
C1 [Hsu, Yi Hsiang; Kiel, Douglas P.] Hebrew SeniorLife, Inst Aging Res, Beth Israel Deaconess Med, Dept Med,Div Gerontol, Boston, MA 02131 USA.
   Harvard Univ, Sch Med, Boston, MA 02131 USA.
   [Hsu, Yi Hsiang] Harvard Univ, Sch Publ Hlth, Mol & Integrat Physiol Sci Program, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Hebrew
   SeniorLife; Beth Israel Deaconess Medical Center; Harvard University;
   Harvard Medical School; Harvard University; Harvard T.H. Chan School of
   Public Health
RP Kiel, DP (通讯作者)，Hebrew SeniorLife, Inst Aging Res, Beth Israel Deaconess Med, Dept Med,Div Gerontol, 1200 Ctr St, Boston, MA 02131 USA.
EM kiel@hsl.harvard.edu
OI Kiel, Douglas/0000 0001 8474 0310
FU National Institute of Arthritis Musculoskeletal and Skin Diseases;
   National Institute on Aging [R01 AR/AG 41398, R01 AR061162, R21
   AR056405]; Amgen; Merck; Eli Lilly
FX Contributions to this review by Y. H.H. and D.P.K. were funded in part
   from grants from the National Institute of Arthritis Musculoskeletal and
   Skin Diseases and the National Institute on Aging (R01 AR/AG 41398, R01
   AR061162, and R21 AR056405).Y. H.H. has nothing to declare. D.P.K. has
   received grant support from Amgen, Merck, and Eli Lilly and serves as a
   consultant for Amgen, Merck, and Eli Lilly.
CR Albagha OME, 2011, NAT GENET, V43, P685, DOI 10.1038/ng.845
   Albagha OME, 2010, NAT GENET, V42, P520, DOI 10.1038/ng.562
   Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410
   Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298
   Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764
   Anderson CA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000580
   Barabási AL, 2007, NEW ENGL J MED, V357, P404, DOI 10.1056/NEJMe078114
   Barrett JC, 2006, NAT GENET, V38, P659, DOI 10.1038/ng1801
   Billings LK, 2012, DIABETES, V61, P2176, DOI 10.2337/db11 1515
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Cheung CL, 2011, J BONE MINER RES  S1, V26, pS442
   Chew S, 2011, OSTEOPOROSIS INT, V22, P1981, DOI 10.1007/s00198 010 1405 0
   Cho YS, 2009, NAT GENET, V41, P527, DOI 10.1038/ng.357
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Deng FY, 2010, OSTEOPOROSIS INT, V21, P579, DOI 10.1007/s00198 009 0998 7
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197 2456(86)90046 2
   Devlin B, 2004, NAT GENET, V36, P1129, DOI 10.1038/ng1104 1129
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006 341X.1999.00997.x
   Dickson SP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000294
   Duncan EL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001372
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Falush D, 2003, GENETICS, V164, P1567
   Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Freimer N, 2003, NAT GENET, V34, P15, DOI 10.1038/ng0503 15
   Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104
   Goldstein DB, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001008
   Gorlov IP, 2008, AM J HUM GENET, V82, P100, DOI 10.1016/j.ajhg.2007.09.006
   Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547
   Guo Y, 2010, J BONE MINER RES, V25, P1042, DOI 10.1359/jbmr.091040
   Guo Y, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000806
   Heinzen EL, 2010, AM J HUM GENET, V86, P707, DOI 10.1016/j.ajhg.2010.03.018
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521
   Hoffmann TJ, 2011, GENOMICS, V98, P79, DOI 10.1016/j.ygeno.2011.04.005
   Hsu Y, 2010, J BONE MINER RES  S1, V25, pS448
   Hsu YH, 2011, JOINT STAT M AM STAT
   Hsu YH, 2011, 93 ANN M END SOC BOS
   Hsu YH, 2011, J BONE MINER RES  S1, V26, pS56
   Hsu YH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000977
   Jackson R, 2011, J BONE MINER RES  S1, V26, pS346
   Ji WZ, 2008, NAT GENET, V40, P592, DOI 10.1038/ng.118
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198 007 0543 5
   Karasik D, 2008, ANN HUM GENET, V72, P696, DOI 10.1111/j.1469 1809.2008.00447.x
   Kiel DP, 2007, BMC MED GENET, V8, DOI 10.1186/1471 2350 8 S1 S14
   Koller DL, 2010, J CLIN ENDOCR METAB, V95, P1802, DOI 10.1210/jc.2009 1903
   Kou I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019641
   Kryukov GV, 2009, P NATL ACAD SCI USA, V106, P3871, DOI 10.1073/pnas.0812824106
   Kung AWC, 2010, AM J HUM GENET, V86, P229, DOI 10.1016/j.ajhg.2009.12.014
   Lambert CG, 2012, BIOSTATISTICS, V13, P195, DOI 10.1093/biostatistics/kxr055
   Law B, 2003, GENETICS, V164, P381
   Li YR, 2010, NAT GENET, V42, P969, DOI 10.1038/ng.680
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Liu CT, 2012, J BONE MINER RES, V27, P2051, DOI 10.1002/jbmr.1679
   Liu SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022035
   Liu YZ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003160
   Liu YJ, 2006, J BONE MINER RES, V21, P1511, DOI 10.1359/JBMR.051002
   Liu YZ, 2003, J ENDOCRINOL, V177, P147, DOI 10.1677/joe.0.1770147
   MacArthur DG, 2012, SCIENCE, V335, P823, DOI 10.1126/science.1215040
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   Mileyko Y, 2008, P NATL ACAD SCI USA, V105, P16659, DOI 10.1073/pnas.0806239105
   Morris AP, 2010, GENET EPIDEMIOL, V34, P188, DOI 10.1002/gepi.20450
   Nakaoka H, 2009, J HUM GENET, V54, P615, DOI 10.1038/jhg.2009.95
   Nejentsev S, 2009, SCIENCE, V324, P387, DOI 10.1126/science.1167728
   Nielsen R, 2010, NATURE, V467, P1050, DOI 10.1038/4671050a
   O'Roak BJ, 2011, NAT GENET, V43, P585, DOI 10.1038/ng.835
   Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415
   Oei L, 2011, P 61 ANN M AM SOC HU
   Paternoster L, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001217
   Pe'er I, 2006, NAT GENET, V38, P663, DOI 10.1038/ng1816
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Ragoussis J, 2009, ANNU REV GENOM HUM G, V10, P117, DOI 10.1146/annurev genom 082908 150116
   Rannala B, 2001, AM J HUM GENET, V69, P159, DOI 10.1086/321279
   Raychaudhuri S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000534
   Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329
   Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590
   Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168 9525(01)02410 6
   Richards JB, 2008, LANCET, V371, P1505, DOI 10.1016/S0140 6736(08)60599 1
   Richards JB, 2009, ANN INTERN MED, V151, P528, DOI 10.7326/0003 4819 151 8 200910200 00006
   Rivadeneira F, 2009, NAT GENET, V41, P1199, DOI 10.1038/ng.446
   Romeo S, 2007, NAT GENET, V39, P513, DOI 10.1038/ng1984
   Sebastiani P, 2011, SCIENCE, V333, P404, DOI 10.1126/science.333.6041.404 a
   Sims AM, 2008, J BONE MINER RES, V23, P499, DOI 10.1359/JBMR.071113
   Speliotes EK, 2010, NAT GENET, V42, P937, DOI 10.1038/ng.686
   Stahl EA, 2012, NAT GENET, V44, P483, DOI 10.1038/ng.2232
   Stephens M, 2009, NAT REV GENET, V10, P681, DOI 10.1038/nrg2615
   Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678
   Styrkarsdottir U, 2008, NEW ENGL J MED, V358, P2355, DOI 10.1056/NEJMoa0801197
   Styrkarsdottir U, 2009, NAT GENET, V41, P15, DOI 10.1038/ng.284
   Sudmant PH, 2010, SCIENCE, V330, P641, DOI 10.1126/science.1197005
   Tan LJ, 2010, SCI CHINA LIFE SCI, V53, P1065, DOI 10.1007/s11427 010 4056 7
   Thorleifsson G, 2009, NAT GENET, V41, P926, DOI 10.1038/ng.404
   Timpson NJ, 2009, HUM MOL GENET, V18, P1510, DOI 10.1093/hmg/ddp052
   Tran BNH, 2011, J BONE MINER RES, V26, P414, DOI 10.1002/jbmr.219
   Wakefield J, 2007, AM J HUM GENET, V81, P208, DOI 10.1086/519024
   Wang K, 2010, AM J HUM GENET, V86, P730, DOI 10.1016/j.ajhg.2010.04.003
   Whitlock MC, 2005, J EVOLUTION BIOL, V18, P1368, DOI 10.1111/j.1420 9101.2005.00917.x
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Xiong DH, 2009, AM J HUM GENET, V84, P388, DOI 10.1016/j.ajhg.2009.01.025
   Xu XH, 2010, ENDOCR REV, V31, P447, DOI 10.1210/er.2009 0032
   Yang J, 2011, NAT GENET, V43, P519, DOI 10.1038/ng.823
   Yang TL, 2008, AM J HUM GENET, V83, P663, DOI 10.1016/j.ajhg.2008.10.006
   Zhao LJ, 2010, J BONE MINER RES, V25, P320, DOI 10.1359/jbmr.090726
   Zheng W, 2009, NAT GENET, V41, P324, DOI 10.1038/ng.318
   Zuk O, 2012, P NATL ACAD SCI USA, V109, P1193, DOI 10.1073/pnas.1119675109
NR 112
TC 87
Z9 98
U1 0
U2 26
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD OCT 1
PY 2012
VL 97
IS 10
BP E1958
EP E1977
DI 10.1210/jc.2012 1890
PG 20
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 018MH
UT WOS:000309664400018
PM 22965941
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Margulies, BS
   DeBoyace, SD
   Damron, TA
   Allen, MJ
AF Margulies, B. S.
   DeBoyace, S. D.
   Damron, T. A.
   Allen, M. J.
TI Ewing's sarcoma of bone tumor cells produces MCSF that stimulates
   monocyte proliferation in a novel mouse model of Ewing's sarcoma of bone
SO BONE
LA English
DT Article
DE Ewing's sarcoma; Osteoblasts; Monocytes; Osteoclasts; Bone growth; MCSF
ID RADIATION INDUCED DAMAGE; RADIOPROTECTANT DRUGS; IRRADIATION;
   COMBINATION; THERAPY
AB Ewing's sarcoma of bone is a primary childhood malignancy of bone that is treated with X radiation therapy in combination with surgical excision and chemotherapy. To better study Ewing's sarcoma of bone we developed a novel model of primary Ewing's sarcoma of bone and then treated animals with X radiation therapy. We identified that uncontrolled tumor resulted in lyric bone destruction while X radiation therapy decreased lytic bone destruction and increased limb length asymmetry, a common, crippling complication of X radiation therapy. Osteoclasts were indentified adjacent to the tumor, however, we were unable to detect RANK ligand in the Ewing's tumor cells in vitro, which lead us to investigate alternate mechanisms for osteoclast formation. Ewing's sarcoma tumor cells and archival Ewing's sarcoma of bone tumor biopsy samples were shown to express MCSF, which could promote osteoclast formation. Increased monocyte numbers were detected in peripheral blood and spleen in animals with untreated Ewing's sarcoma tumor while monocyte number in animals treated with x radiation had normal numbers of monocytes. Our data suggest that our Ewing's sarcoma of bone model will be useful in the study Ewing's sarcoma tumor progression in parallel with the effects of chemotherapy and X radiation therapy. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Margulies, B. S.; DeBoyace, S. D.; Damron, T. A.] SUNY Upstate Med Univ, Dept Orthoped Surg, Syracuse, NY 13210 USA.
   [Allen, M. J.] Ohio State Univ, Coll Vet Med, Dept Vet Clin Med, Columbus, OH 43210 USA.
C3 State University of New York (SUNY) System; SUNY Upstate Medical
   University; University System of Ohio; Ohio State University
RP Margulies, BS (通讯作者)，SUNY Upstate Med Univ, Inst Human Performance 3113, 750 E Adams St, Syracuse, NY 13210 USA.
EM margulib@upstate.edu
RI Damron, Timothy/AAE 5816 2020
FU Department of Orthopedic Surgery; NIH NCCAM [F31AT001994]; NIH NCI
   [R01CA083892]; David G. Murray Endowed Professorship
FX Margulies: Department of Orthopedic Surgery Funding and NIH NCCAM
   (F31AT001994) F31 Kirschstein NRSA Individual Pre doctoral Fellowship;
   Damron: NIH NCI (R01CA083892) and the David G. Murray Endowed
   Professorship. Judith A. Strauss for tissue processing and Gustavo de la
   Roza, MD for providing access to the human sarcoma tissue samples.
CR Barr JS, 1943, AM J ROENTGENOL RADI, V49, P104
   Bölling T, 2013, CLIN ONCOL UK, V25, P19, DOI 10.1016/j.clon.2012.07.010
   Burchill SA, 2003, J CLIN PATHOL, V56, P96, DOI 10.1136/jcp.56.2.96
   BUTLER MS, 1990, CLIN ORTHOP RELAT R, P235
   Choi Y, 2015, CANC RES TREAT
   Clohisy DR, 1995, J ORTHOPAED RES, V13, P892, DOI 10.1002/jor.1100130613
   COSTANTINO PD, 1995, OTOLARYNG CLIN N AM, V28, P1021
   Damron TA, 2006, RADIAT RES, V165, P350, DOI 10.1667/RR3504.1
   Damron TA, 2004, INT J RADIAT BIOL, V80, P217, DOI 10.1080/09553000410001669524
   Damron TA, 2004, J HISTOCHEM CYTOCHEM, V52, P157, DOI 10.1177/002215540405200203
   Damron TA, 2003, J BONE JOINT SURG AM, V85A, P1302, DOI 10.2106/00004623 200307000 00017
   Erben RG, 1997, J HISTOCHEM CYTOCHEM, V45, P307, DOI 10.1177/002215549704500215
   Fisher MC, 2005, BONE, V37, P741, DOI 10.1016/j.bone.2005.07.024
   Fujiwara T, 2011, AM J PATHOL, V179, P1157, DOI 10.1016/j.ajpath.2011.05.034
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Gurney JG., 1999, CANC INCIDENCE SURVI
   Henriksen K, 2007, OSTEOPOROSIS INT, V18, P681, DOI 10.1007/s00198 006 0286 8
   Koscielniak Ewa, 2002, Paediatr Drugs, V4, P21, DOI 10.2165/00148581 200204010 00003
   Margulies Bryan, 2003, Am J Clin Oncol, V26, pe106, DOI 10.1097/00000421 200308000 00032
   Margulies BS, 2008, J ORTHOP RES, V26, P1512, DOI 10.1002/jor.20679
   Merchant TE, 1999, MED PEDIATR ONCOL, V33, P65, DOI 10.1002/(SICI)1096 911X(199908)33:2<65::AID MPO1>3.0.CO;2 L
   Paulussen M, 2001, Paediatr Drugs, V3, P899, DOI 10.2165/00128072 200103120 00003
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Scotlandi K, 2000, J ORTHOPAED RES, V18, P959, DOI 10.1002/jor.1100180616
   Tamurian RM, 1999, J ORTHOPAED RES, V17, P286, DOI 10.1002/jor.1100170219
   Taylor R, 2011, J PATHOL, V225, P195, DOI 10.1002/path.2869
   Wall JE, 1996, ORTHOPEDICS, V19, P657
NR 27
TC 5
Z9 5
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2015
VL 79
BP 121
EP 130
DI 10.1016/j.bone.2015.05.041
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CO9QF
UT WOS:000359509700018
PM 26051470
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, XQ
   Wang, LP
   Huang, BT
   Gu, YQ
   Luo, Y
   Zhi, X
   Hu, Y
   Zhang, H
   Gu, ZR
   Cui, J
   Cao, LH
   Guo, JW
   Wang, YJ
   Zhou, QR
   Jiang, H
   Fang, C
   Weng, WZ
   Chen, XF
   Chen, X
   Su, JC
AF Li, Xiaoqun
   Wang, Lipeng
   Huang, Biaotong
   Gu, Yanqiu
   Luo, Ying
   Zhi, Xin
   Hu, Yan
   Zhang, Hao
   Gu, Zhengrong
   Cui, Jin
   Cao, Liehu
   Guo, Jiawei
   Wang, Yajun
   Zhou, Qirong
   Jiang, Hao
   Fang, Chao
   Weng, Weizong
   Chen, Xiaofei
   Chen, Xiao
   Su, Jiacan
TI Targeting actin bundling protein L plastin as an anabolic therapy for
   bone loss
SO SCIENCE ADVANCES
LA English
DT Article
ID FUSION; ANGIOGENESIS; OSTEOCLASTS; COMPONENTS; CELLS
AB The actin bundling protein L plastin (LPL) mediates the resorption activity of osteoclasts, but its therapeutic potential in pathological bone loss remains unexplored. Here, we report that LPL knockout mice show increased bone mass and cortical thickness with more mononuclear tartrate resistant acid phosphatase positive cells, osteoblasts, CD31(hi)Emcn(hi) endothelial vessels, and fewer multinuclear osteoclasts in the bone marrow and periosteum. LPL deletion impeded preosteoclasts fusion by inhibiting filopodia formation and increased the number of preosteoclasts, which release platelet derived growth factor BB to promote CD31(hi)Emcn(hi) vessel growth and bone formation. LPL expression is regulated by the phosphatidylinositol 3 kinase/AKT/specific protein 1 axis in response to receptor activator of nuclear factor 0 ligand. Furthermore, we identified an LPL inhibitor, oroxylin A, that could maintain bone mass in ovariectomy induced osteoporosis and accelerate bone fracture healing in mice. In conclusion, we showed that LPL regulates osteoclasts fusion, and targeting LPL serves as a novel anabolic therapy for pathological bone loss.
C1 [Li, Xiaoqun; Zhi, Xin; Hu, Yan; Zhang, Hao; Cui, Jin; Guo, Jiawei; Wang, Yajun; Zhou, Qirong; Jiang, Hao; Fang, Chao; Weng, Weizong; Chen, Xiao; Su, Jiacan] Naval Med Univ, Shanghai Changhai Hosp, Dept Orthoped, 168 Changhai Rd, Shanghai 200433, Peoples R China.
   [Li, Xiaoqun] Naval Med Univ, Hosp 929, Dept Orthoped, Shanghai 200433, Peoples R China.
   [Wang, Lipeng] Naval Med Univ, Shanghai Changhai Hosp, Grad Management Unit, Shanghai 200433, Peoples R China.
   [Huang, Biaotong; Su, Jiacan] Shanghai Univ, Inst Translat Med, Shanghai 201900, Peoples R China.
   [Gu, Yanqiu] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Sch Med, Dept Pharm, Shanghai 201999, Peoples R China.
   [Gu, Yanqiu; Chen, Xiaofei] Naval Med Univ, Sch Pharm, 325 Guohe Rd, Shanghai 200433, Peoples R China.
   [Luo, Ying] Naval Med Univ, Cent Lab, Shanghai Changhai Hosp, Shanghai 200433, Peoples R China.
   [Gu, Zhengrong; Cao, Liehu] Shanghai Baoshan Luodian Hosp, Dept Orthoped, Shanghai 201900, Peoples R China.
   [Chen, Xiao] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
C3 Naval Medical University; Naval Medical University; Naval Medical
   University; Shanghai University; Shanghai Jiao Tong University; Naval
   Medical University; Naval Medical University; Fudan University
RP Chen, X; Su, JC (通讯作者)，Naval Med Univ, Shanghai Changhai Hosp, Dept Orthoped, 168 Changhai Rd, Shanghai 200433, Peoples R China.; Su, JC (通讯作者)，Shanghai Univ, Inst Translat Med, Shanghai 201900, Peoples R China.; Chen, XF (通讯作者)，Naval Med Univ, Sch Pharm, 325 Guohe Rd, Shanghai 200433, Peoples R China.; Chen, X (通讯作者)，Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
EM xfchen2010@163.com; sirchenxiao@126.com; drsujiacan@163.com
RI ; Cui, Jin/HDL 7327 2022; Chen, Xiao/N 1298 2017; Hu, Yan/AFZ 8800 2022;
   Guo, Jiawei/JMH 1084 2023; Su, Jiacan/N 7068 2019; Gu, Jimmy/N 4439 2019
OI Su, Jiacan/0000 0001 7080 263X; Wang, Lipeng/0000 0001 8905 1944; Guo,
   Jiawei/0000 0002 7613 932X; 
FU National Key Research and Development Plan [2018YFC2001500]; National
   Natural Science Foundation (NNSF) [91749204]; National Natural Science
   Foundation of China [81771491, 81871099, 81501052, 81701364, 81901426,
   81703526, 81973291]; Municipal Human Resources Development Program for
   Outstanding Leaders in Medical Disciplines in Shanghai [2017BR011];
   Science and Technology Support Project in Biomedical Field of Shanghai
   Science and Technology Innovation Plan [18431902300]; Shanghai Baoshan
   District Science and Technology Commission Special Funds for Scientific
   and Technological Innovation [17 E 33]; Shanghai Municipal Health and
   Family Planning Commission [201640156, 201740237]; Shanghai Sailing
   Program [19YF1447300]; Natural Science Foundation of Shanghai
   [19ZR1419600]; Shanghai Rising Star Program [19QA1411500]
FX This work was supported by the National Key Research and Development
   Plan (2018YFC2001500), National Natural Science Foundation (NNSF) Key
   Research Program in Aging (91749204), National Natural Science
   Foundation of China (81771491, 81871099, 81501052, 81701364, 81901426,
   81703526, and 81973291), Municipal Human Resources Development Program
   for Outstanding Leaders in Medical Disciplines in Shanghai (2017BR011),
   Science and Technology Support Project in Biomedical Field of Shanghai
   Science and Technology Innovation Plan (18431902300), Shanghai Baoshan
   District Science and Technology Commission Special Funds for Scientific
   and Technological Innovation (17 E 33), Scientific Research Project of
   Shanghai Municipal Health and Family Planning Commission (201640156 and
   201740237), Shanghai Sailing Program (19YF1447300), Natural Science
   Foundation of Shanghai (19ZR1419600), and Shanghai Rising Star Program
   (grant no. 19QA1411500).
CR Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Balta E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11909 z
   Blanchoin L, 2014, PHYSIOL REV, V94, P235, DOI 10.1152/physrev.00018.2013
   Chan JK, 2015, EMBO MOL MED, V7, P547, DOI 10.15252/emmm.201404487
   Chellaiah MA, 2020, BONE RES, V8, DOI 10.1038/s41413 019 0079 2
   Chellaiah MA, 2018, EXP CELL RES, V372, P73, DOI 10.1016/j.yexcr.2018.09.014
   Chen CH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.437
   Chen CC, 2016, INT J CANCER, V138, P74, DOI 10.1002/ijc.29677
   Chen EH, 2005, SCIENCE, V308, P369, DOI 10.1126/science.1104799
   Chen XF, 2012, J CHROMATOGR A, V1242, P67, DOI 10.1016/j.chroma.2012.04.034
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Delanote V, 2010, FASEB J, V24, P105, DOI 10.1096/fj.09 134304
   Ding X, 2016, ANAL CHEM, V88, P12081, DOI 10.1021/acs.analchem.6b02709
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Harvestine JN, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay2387
   Ishida H, 2017, SCI REP UK, V7, DOI 10.1038/srep40662
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Li BE, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 28205 3
   Liu W, 2018, FASEB J, V32, P3033, DOI 10.1096/fj.201701144R
   Lommel MJ, 2016, FASEB J, V30, P1218, DOI 10.1096/fj.15 276311
   Miller DL, 2017, J THER ULTRASOUND, V5, DOI 10.1186/s40349 017 0107 x
   Morley SC, 2013, IMMUNOL REV, V256, P48, DOI 10.1111/imr.12102
   NETO ECD, 1992, J CLIN INVEST, V90, P1037
   Oikawa T, 2012, J CELL BIOL, V197, P553, DOI 10.1083/jcb.201111116
   Pereira M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216267
   Phillips A M, 2005, Injury, V36 Suppl 3, pS5, DOI 10.1016/j.injury.2005.07.027
   Reikeraas O, 1998, ARCH ORTHOP TRAUM SU, V118, P50, DOI 10.1007/s004020050310
   Schenk LK, 2017, FASEB J, V31, P5019, DOI 10.1096/fj.201700142R
   Seeman E, 2009, CRIT REV EUKAR GENE, V19, P219, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.40
   Segal D, 2016, DEV CELL, V38, P291, DOI 10.1016/j.devcel.2016.07.010
   Shinomiya Hiroto, 2012, Int J Cell Biol, V2012, P213492, DOI 10.1155/2012/213492
   Song RL, 2014, GENET MOL RES, V13, P4776, DOI 10.4238/2014.July.2.7
   Van Audenhove I, 2016, J BIOL CHEM, V291, P9148, DOI 10.1074/jbc.M115.706937
   Van den Bossche J, 2012, BLOOD, V119, P1623, DOI 10.1182/blood 2011 10 384289
   Wabnitz GH, 2011, EUR J IMMUNOL, V41, P3157, DOI 10.1002/eji.201041366
   Wang YQ, 2015, BBA MOL CELL RES, V1853, P1715, DOI 10.1016/j.bbamcr.2015.04.001
   Weske S, 2018, NAT MED, V24, P667, DOI 10.1038/s41591 018 0005 y
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Zalli D, 2016, J BONE MINER RES, V31, P1701, DOI 10.1002/jbmr.2851
   Zhou JY, 2016, MOL IMMUNOL, V78, P79, DOI 10.1016/j.molimm.2016.08.012
NR 44
TC 65
Z9 69
U1 2
U2 73
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375 2548
J9 SCI ADV
JI Sci. Adv.
PD NOV
PY 2020
VL 6
IS 47
AR eabb7135
DI 10.1126/sciadv.abb7135
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA OV4HQ
UT WOS:000592173500010
PM 33208358
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Choi, JH
   Jang, AR
   Jeong, HN
   Kim, K
   Kim, YM
   Cho, JY
   Park, JH
AF Choi, Joo Hee
   Jang, Ah Ra
   Jeong, Ha Na
   Kim, Kiok
   Kim, Young Min
   Cho, Jeong Yong
   Park, Jong Hwan
TI Water extract of tendril of Cucurbita Moschata Duch. suppresses
   RANKL induced osteoclastogenesis by down regulating p38 and ERK
   signaling
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Osteoclast differentiation; RANKL; Tendril of Cucurbita Moschata Duch.
   (TCMD)
ID NFATC1 EXPRESSION; IMMUNE RESPONSES; BONE RESORPTION; DIFFERENTIATION;
   ACTIVATION; CELLS
AB Background: Pumpkin (Curcubita sp.) is a natural product that is commonly used in folk medicine. However, the inhibitory effect and molecular mechanisms of tendril of Cucurbita Moschata Duch. (TCMD) on osteoclast differentiation have yet to be clearly elucidated. Thus, the present study aimed to investigate the effect and underlying mechanism of water extract of TCMD on osteoclast differentiation.
   Methods: Bone marrow derived macrophages (BMDMs), osteoclast precursors, were cultured with macrophage colony stimulating factor (M CSF) 30 ng/ml and receptor activator of nuclear factor kappa B ligand (RANKL) 100 ng/ml for four days. We investigated the effect of TCMD on RANKL induced osteoclast differentiation, tartrate resistant acid phosphatase (TRAP) staining, F actin ring formation, and bone resorption assay. RANKL signaling pathways were determined through Western blotting, and osteoclast differentiation marker genes were confirmed by Real time PCR.
   Results: TCMD inhibited the RANKL induced osteoclast differentiation in a dose dependent manner without cytotoxicity. Further, F actin ring formation and bone resorption were reduced by TCMD in RANKL treated BMDMs. In addition, TCMD decreased the phosphorylation of p38 and ERK as well as the expression of osteoclast related genes in BMDMs treated with RANKL.
   Conclusion: These findings suggest that TCMD may have preventive and therapeutic effects for destructive bone diseases.
C1 [Choi, Joo Hee; Jang, Ah Ra; Park, Jong Hwan] Chonnam Natl Univ, Coll Vet Med, Lab Anim Med, 77 Yongbong Ro, Gwangju 61186, South Korea.
   [Choi, Joo Hee; Jang, Ah Ra; Park, Jong Hwan] Chonnam Natl Univ, BK 21 PLUS Project Team, 77 Yongbong Ro, Gwangju 61186, South Korea.
   [Choi, Joo Hee] Daegu Gyeongbuk Med Innovat Fdn, Lab Anim Ctr, Daegu, South Korea.
   [Jeong, Ha Na; Kim, Kiok; Kim, Young Min; Cho, Jeong Yong] Chonnam Natl Univ, Dept Food Sci & Technol, Gwangju, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University
RP Park, JH (通讯作者)，Chonnam Natl Univ, Coll Vet Med, Lab Anim Med, 77 Yongbong Ro, Gwangju 61186, South Korea.; Park, JH (通讯作者)，Chonnam Natl Univ, BK 21 PLUS Project Team, 77 Yongbong Ro, Gwangju 61186, South Korea.
EM jonpark@jnu.ac.kr
FU National Research Foundation (NRF, Korea) [2017 R1D1A1A02019106];
   Technology development Program of the Ministry of SMEs and Startups
   (MSS, Korea) [C0396019]; Korea institute for Advancement of Technology
   (KIAT) through the Encouragement Program for the Industries of Economic
   Cooperation Region [P0008590]
FX This study was supported by a grant from the National Research
   Foundation (NRF, Korea 2017 R1D1A1A02019106), the Technology development
   Program of the Ministry of SMEs and Startups (MSS, Korea C0396019) and
   the Korea institute for Advancement of Technology (KIAT) through the
   Encouragement Program for the Industries of Economic Cooperation Region
   (P0008590).
CR Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Fumimoto R, 2012, J PHARMACOL SCI, V118, P479, DOI 10.1254/jphs.11212FP
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hossain MA, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/3908453
   Kim HY, 2016, IMMUNOPHARM IMMUNOT, V38, P319, DOI 10.1080/08923973.2016.1202960
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Kyung TW, 2008, EXP MOL MED, V40, P52, DOI 10.3858/emm.2008.40.1.52
   정하나, 2017, 한국식품저장유통학회지, V24, P1122
   Lee JE, 2007, EXP HEMATOL, V35, P1100, DOI 10.1016/j.exphem.2007.04.006
   Lee W, 2018, J NAT PROD, V81, P1343, DOI 10.1021/acs.jnatprod.7b00927
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Lestari B., 2018, Indonesian Journal of Cancer Chemoprevention, V9, P92, DOI 10.14499/indonesianjcanchemoprev9iss2pp92 101
   Lestari B, 2019, PHYTOTHER RES PTR
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Matsuo Koichi, 2005, Nihon Rinsho, V63, P1541
   Shim KS, 2018, INTEGR MED RES, V7, P374, DOI 10.1016/j.imr.2018.06.006
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Stevenson DG, 2007, J AGR FOOD CHEM, V55, P4005, DOI 10.1021/jf0706979
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yamasaki T, 2014, J BIOL CHEM, V289, P19191, DOI 10.1074/jbc.M114.551416
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599
NR 32
TC 6
Z9 6
U1 0
U2 2
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2020
VL 17
IS 5
BP 632
EP 639
DI 10.7150/ijms.39622
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA KU7QC
UT WOS:000519906700009
PM 32210713
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Delgado Calle, J
   Anderson, J
   Cregor, MD
   Condon, KW
   Kuhstoss, SA
   Plotkin, LI
   Bellido, T
   Roodman, GD
AF Delgado Calle, J.
   Anderson, J.
   Cregor, M. D.
   Condon, K. W.
   Kuhstoss, S. A.
   Plotkin, L. I.
   Bellido, T.
   Roodman, G. D.
TI Genetic deletion of Sost or pharmacological inhibition of
   sclerostin prevent multiple myeloma induced bone disease without
   affecting tumor growth
SO LEUKEMIA
LA English
DT Article
ID MARROW MICROENVIRONMENT; POSTMENOPAUSAL WOMEN; THERAPEUTIC TARGETS;
   OSTEOCYTE; ANTIBODY; CELLS; MASS; OSTEOPOROSIS; PATHOGENESIS;
   ROMOSOZUMAB
AB Multiple myeloma (MM) causes lytic bone lesions due to increased bone resorption and concomitant marked suppression of bone formation. Sclerostin (Scl), an osteocyte derived inhibitor of Wnt/beta catenin signaling, is elevated in MM patient sera and increased in osteocytes in MM bearing mice. We show here that genetic deletion of Sost, the gene encoding Scl, prevented MM induced bone disease in an immune deficient mouse model of early MM, and that administration of anti Scl antibody (Scl Ab) increased bone mass and decreases osteolysis in immune competent mice with established MM. Sost/Scl inhibition increased osteoblast numbers, stimulated new bone formation and decreased osteoclast number in MM colonized bone. Further, Sost/Scl inhibition did not affect tumor growth in vivo or anti myeloma drug efficacy in vitro. These results identify the osteocyte as a major contributor to the deleterious effects of MM in bone and osteocyte derived Scl as a promising target for the treatment of established MM induced bone disease. Further, Scl did not interfere with efficacy of chemotherapy for MM, suggesting that combined treatment with anti myeloma drugs and Scl Ab should effectively control MM growth and bone disease, providing new avenues to effectively control MM and bone disease in patients with active MM.
C1 [Delgado Calle, J.; Cregor, M. D.; Condon, K. W.; Plotkin, L. I.; Bellido, T.] Indiana Univ, Dept Anat & Cell Biol, Indianapolis, IN 46204 USA.
   [Delgado Calle, J.; Plotkin, L. I.; Bellido, T.; Roodman, G. D.] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN USA.
   [Anderson, J.; Roodman, G. D.] Indiana Univ, Dept Med, Dept Hematol Oncol, Indianapolis, IN USA.
   [Kuhstoss, S. A.] Lilly Res Labs, Indianapolis, IN USA.
   [Bellido, T.] Indiana Univ, Dept Med, Indiana Univ Sch Med, Div Endocrinol, Indianapolis, IN USA.
C3 Indiana University System; Indiana University Indianapolis; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Richard L. Roudebush VA Medical Center; Indiana University System;
   Indiana University Indianapolis; Eli Lilly; Lilly Research Laboratories;
   Indiana University System; Indiana University Indianapolis; Indiana
   University Bloomington
RP Bellido, T (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS5045A, Indianapolis, IN 46202 USA.; Bellido, T (通讯作者)，Indiana Univ Sch Med, Dept Med, 635 Barnhill Dr,MS5045A, Indianapolis, IN 46202 USA.; Roodman, GD (通讯作者)，Indiana Univ Sch Med, Dept Med, 980 W Walnut,Suite C312, Indianapolis, IN 46202 USA.
EM tbellido@iupui.edu; groodman@iu.edu
RI Plotkin, Lilian/H 7188 2019; Delgado Calle, Jesus/AAG 1417 2020
OI Plotkin, Lilian/0000 0002 9537 4544; Bellido,
   Teresita/0000 0002 8203 7004
FU NIH Indiana [CTSI P30, 1R21CA179017 02, R01AR059679, R01AR059357, R01
   DK076007, S10 RR023710 to]; VA (Merit Review); IBMS Gideon and Sevgi
   Rodan Fellowship; ASH Scholar Award
FX We thank Kevin McAndrews, Amy Y. Sato and Dan Zhou for assistance in
   tissue collection. Scl Ab was provided by Eli Lilly (Indianapolis, IN,
   USA). Sost<SUP> / </SUP> mice were provided by Amgen Inc. (Thousand
   Oaks, CA, USA) and UCB (Brussels, Belgium). This work was supported by
   the NIH (Indiana CTSI P30, 1R21CA179017 02 and R01AR059679 to GDR;
   R01AR059357, R01 DK076007 and S10 RR023710 to TB), the VA (Merit Review
   to TB and to GDR). JDC received an IBMS Gideon and Sevgi Rodan
   Fellowship and an ASH Scholar Award.
CR Asosingh K, 2000, Hematol J, V1, P351, DOI 10.1038/sj.thj.6200052
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223 013 9774 y
   Bianchi G, 2015, BLOOD, V125, P3049, DOI 10.1182/blood 2014 11 568881
   Bodine PVN, 2008, CELL RES, V18, P248, DOI 10.1038/cr.2008.13
   D'Souza S, 2011, BLOOD, V118, P6871, DOI 10.1182/blood 2011 04 346775
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Delgado Calle J, 2017, J BONE MINER RES, V32, P522, DOI 10.1002/jbmr.3011
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   Delgado Calle Jesus, 2015, Curr Mol Biol Rep, V1, P157
   Delgado Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008 5472.CAN 15 1703
   Delgado Calle J, 2014, CURR OPIN SUPPORT PA, V8, P407, DOI 10.1097/SPC.0000000000000090
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Eda H, 2016, J BONE MINER RES, V31, P1225, DOI 10.1002/jbmr.2789
   Eshaghian S, 2012, CURR OPIN SUPPORT PA, V6, P330, DOI 10.1097/SPC.0b013e3283565c56
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2012, LEUKEMIA, V26, P1391, DOI 10.1038/leu.2011.381
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kim SW, 2017, J BONE MINER RES, V32, P892, DOI 10.1002/jbmr.3038
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2014, ENDOCRINOLOGY, V155, P4785, DOI 10.1210/en.2013 1905
   Li XD, 2011, ENDOCRINOLOGY, V152, P3312, DOI 10.1210/en.2011 0252
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Papamerkouriou YM, 2015, EXPERT OPIN BIOL TH, V15, P213, DOI 10.1517/14712598.2015.978853
   Plotkin LI, 2016, NAT REV ENDOCRINOL, V12, P593, DOI 10.1038/nrendo.2016.71
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   RADL J, 1988, AM J PATHOL, V132, P593
   Roodman GD, 2010, J BONE MINER METAB, V28, P244, DOI 10.1007/s00774 009 0154 7
   Roodman GD, 2010, J CELL BIOCHEM, V109, P283, DOI 10.1002/jcb.22403
   Roodman GD, 2002, J BONE MINER RES, V17, P1921, DOI 10.1359/jbmr.2002.17.11.1921
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Silbermann R, 2013, J BONE ONCOL, V2, P59, DOI 10.1016/j.jbo.2013.04.001
   Silbermann Rebecca, 2011, Curr Opin Support Palliat Care, V5, P251, DOI 10.1097/SPC.0b013e328349c524
   Terpos E, 2014, EXPERT REV HEMATOL, V7, P113, DOI 10.1586/17474086.2013.874943
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Toscani D, 2016, J BONE MINER RES, V31, P815, DOI 10.1002/jbmr.2741
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yaccoby S, 2010, LEUKEMIA LYMPHOMA, V51, P213, DOI 10.3109/10428190903503438
NR 48
TC 89
Z9 95
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887 6924
EI 1476 5551
J9 LEUKEMIA
JI Leukemia
PD DEC
PY 2017
VL 31
IS 12
BP 2686
EP 2694
DI 10.1038/leu.2017.152
PG 9
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA FO8ZJ
UT WOS:000417177100018
PM 28529307
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Hu, L
   Liu, RJ
   Zhang, LL
AF Hu, Ling
   Liu, Ruijin
   Zhang, Lingling
TI Advance in bone destruction participated by JAK/STAT in rheumatoid
   arthritis and therapeutic effect of JAK/STAT inhibitors
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Rheumatoid arthritis; Osteoblast; Osteoclast; JAK inhibitors; Bone
   destruction
ID OSTEOCLAST FORMATION; MEDIATED OSTEOCLASTOGENESIS; RESORPTION ACTIVITY;
   SIGNALING PATHWAY; JAK INHIBITOR; ACTIVATION; EXPRESSION; STAT3; CELLS;
   COMBINATION
AB Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation and bone erosion. The bones in the human body are constantly undergoing bone remodeling throughout their lives, which is the process of bone resorption by osteoclasts to damaged bone tissue and new bone formation by osteoblasts. Osteoblasts (OBs) are the main functional cells in bone formation, responsible for the synthesis, secretion and mineralization of the bone matrix. On the contrary, osteoclasts (OCs) mediate bone breakdown during natural bone turnover, but excessive breakdown occurs in RA. Under the condition of RA inflammation, many molecules, such as IL 1 beta, IL 6, TNF alpha, IL 17 and hypoxia inducible factor 1 alpha (HIF 1 alpha) are produced that could mediate bone loss. Studies have shown that cytokines mainly promote the formation of OCs and play a role in bone resorption by stimulating OBs to express receptor activator of NF kappa B ligand (RANKL). JAK/STAT plays a crucial role in the process of bone destruction. And JAK/STAT pathway mediates the RANKL/receptor activator of NF kappa B (RANK)/ osteoprotegerin (OPG) axis. Tofacitinib, Baricitinib, Peficitinib and Filgotinib are now being used in patients with moderate to severe RA, as well as in patients with RA who have an inadequate response to methotrexate therapy and bone destruction. Currently, Tofacitinib and Baritinib are approved for the treatment of moderate to  severely active RA. JAK inhibitors have been reported to have better efficacy and lower adverse effects compared with methotrexate and adalimumab. In addition, two JAK inhibitors are currently in development: the JAK1 selective Upadacitinib, and the JAK3 selective inhibitor Decernotinib. In addition to the above JAK in hibitors, some small molecular compounds inhibit bone destruction by inhibiting the Phosphorylation of STAT3. In this paper, the research progress of bone destruction participated by JAK/ STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors were reviewed.
C1 [Hu, Ling; Liu, Ruijin; Zhang, Lingling] Anhui Med Univ, Ctr Rheumatoid Arthrit, Inst Clin Pharmacol, Anhui Collaborat Innovat Ctr Antiinflammatory & Im, Hefei 230032, Peoples R China.
C3 Anhui Medical University
RP Zhang, LL (通讯作者)，Anhui Med Univ, Ctr Rheumatoid Arthrit, Inst Clin Pharmacol, Anhui Collaborat Innovat Ctr Antiinflammatory & Im, Hefei 230032, Peoples R China.
EM ll zhang@hotmail.com
RI zhang, lingling/HDM 2189 2022
FU National Natural Science Foundation of China [U1803129]; Key Research
   and Development Plan of Anhui Province [202104j07020032]
FX This work was supported by the National Natural Science Foundation of
   China (U1803129) and the Key Research and Development Plan of Anhui
   Province in the 2021  Population Health Project (202104j07020032) .
CR Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Aletaha D, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen 2021 001621
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bok K.W.A.K. Han, 2009, BIOL PHARMACOL, V32, P45
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Carrington JM, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882 018 0773 y
   Chen MW, 2017, CANCER RES, V77, P1955, DOI 10.1158/0008 5472.CAN 16 1115
   Claudel M, 2019, FEBS J, V286, P4832, DOI 10.1111/febs.15119
   Deng ZT, 2021, BIOMATER SCI UK, V9, P1291, DOI 10.1039/d0bm01256d
   Diller M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00541
   Doi K, 2022, ARTHRITIS RHEUMATOL, V74, P948, DOI 10.1002/art.42074
   Emori T, 2020, EUR J PHARMACOL, V882, DOI 10.1016/j.ejphar.2020.173238
   Fleischmann R, 2017, ARTHRITIS RHEUMATOL, V69, P506, DOI 10.1002/art.39953
   Fleischmann R, 2012, NEW ENGL J MED, V367, P495, DOI 10.1056/NEJMoa1109071
   Genovese MC, 2019, JAMA J AM MED ASSOC, V322, P315, DOI 10.1001/jama.2019.9055
   Ghoreschi K, 2009, IMMUNOL REV, V228, P273, DOI 10.1111/j.1600 065X.2008.00754.x
   GOTHLIN G, 1976, CLIN ORTHOP RELAT R, P201
   Gyurkovska V, 2014, INFLAMMATION, V37, P995, DOI 10.1007/s10753 014 9820 6
   Hamar A, 2021, OSTEOPOROSIS INT, V32, P1621, DOI 10.1007/s00198 021 05871 0
   Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297
   Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407
   Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551
   Hu XY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00791 1
   Hulley PA, 2017, J PATHOL, V242, P322, DOI 10.1002/path.4906
   Ito M, 2017, J PHARMACOL SCI, V133, P25, DOI 10.1016/j.jphs.2016.12.001
   Karonitsch T, 2018, RHEUMATOLOGY, V57, P572, DOI 10.1093/rheumatology/kex426
   Kim HJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061467
   KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243
   Knowles HJ, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 78003 z
   Lee KM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1184 7
   Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293
   Li CH, 2018, INT IMMUNOPHARMACOL, V58, P136, DOI 10.1016/j.intimp.2018.03.021
   Li CH, 2013, BIOCHEM BIOPH RES CO, V435, P533, DOI 10.1016/j.bbrc.2013.04.084
   Li CH, 2012, BIOCHEM BIOPH RES CO, V429, P156, DOI 10.1016/j.bbrc.2012.10.122
   Li Jiliang, 2013, JAKSTAT, V2, pe23930, DOI 10.4161/jkst.23930
   Liu T, 2012, INT J BIOCHEM CELL B, V44, P1337, DOI 10.1016/j.biocel.2012.04.017
   Ma JD, 2019, ARTHRITIS RHEUMATOL, V71, P1252, DOI 10.1002/art.40868
   Maruotti N, 2017, J CELL PHYSIOL, V232, P2957, DOI 10.1002/jcp.25969
   Miao Ping, 2018, Oncotarget, V9, P20366, DOI 10.18632/oncotarget.23917
   Migita K, 2013, CLIN EXP IMMUNOL, V174, P356, DOI 10.1111/cei.12190
   Migita K, 2011, J RHEUMATOL, V38, P2309, DOI 10.3899/jrheum.101362
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Mori T, 2011, INT IMMUNOL, V23, P701, DOI 10.1093/intimm/dxr077
   Murakami K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181126
   Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092 8674(00)81168 X
   O'Brien W, 2016, ARTHRITIS RHEUMATOL, V68, P2889, DOI 10.1002/art.39837
   Ogura H, 2008, IMMUNITY, V29, P628, DOI 10.1016/j.immuni.2008.07.018
   Park JS, 2014, J IMMUNOL, V192, P4417, DOI 10.4049/jimmunol.1300514
   Qian D, 2007, DEV BIOL, V306, P121, DOI 10.1016/j.ydbio.2007.03.011
   Risner K, 2019, VIRUSES BASEL, V11, DOI 10.3390/v11121151
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Rosengren S, 2012, ANN RHEUM DIS, V71, P440, DOI 10.1136/ard.2011.150284
   Sakamoto K, 2016, GENESIS, V54, P582, DOI 10.1002/dvg.22982
   Schmidt Arras D, 2021, SEMIN IMMUNOPATHOL, V43, P609, DOI 10.1007/s00281 021 00861 0
   Takeuchi T, 2019, ANN RHEUM DIS, V78, P1305, DOI 10.1136/annrheumdis 2019 215164
   Tang Y, 2020, J DENT RES, V99, P1377, DOI 10.1177/0022034520935788
   Tang Y, 2019, J CELL PHYSIOL, V234, P11165, DOI 10.1002/jcp.27765
   Tang YJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.583171
   Tian YY, 2022, ORAL DIS, V28, P428, DOI 10.1111/odi.13745
   Tong XS, 2019, J CELL BIOCHEM, V120, P1630, DOI 10.1002/jcb.27468
   Weston S., 2021, Clin Exp Rheumatol, DOI 10.55563/clinexprheumatol/cfsajk
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Xue YL, 2022, BIOENGINEERED, V13, P2285, DOI 10.1080/21655979.2021.2024333
   Yang YS, 2020, MOL THER METH CLIN D, V17, P922, DOI 10.1016/j.omtm.2020.04.010
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Yokota K, 2021, ARTHRITIS RHEUMATOL, V73, P1145, DOI 10.1002/art.41666
   Yokota K, 2014, ARTHRITIS RHEUMATOL, V66, P121, DOI 10.1002/art.38218
   Zhang YM, 2021, TISSUE ENG REGEN MED, V18, P441, DOI 10.1007/s13770 021 00336 1
   Zhou SR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27273 w
   Zhu J, 2019, J CELL PHYSIOL, V234, P21182, DOI 10.1002/jcp.28721
   Zhu LX, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw6143
NR 71
TC 78
Z9 91
U1 14
U2 70
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD OCT
PY 2022
VL 111
AR 109095
DI 10.1016/j.intimp.2022.109095
EA AUG 2022
PG 7
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 3S1OI
UT WOS:000839371700007
PM 35926270
DA 2025 08 17
ER

PT J
AU Coleman, R
AF Coleman, R.
TI On the horizon: Can bisphosphonates prevent bone metastases?
SO BREAST
LA English
DT Article
DE antitumour; bisphosphonates; bone metastases; skeletal related events
ID BREAST CANCER CELLS; ADJUVANT CLODRONATE TREATMENT;
   FIBROBLAST GROWTH FACTOR; ZOLEDRONIC ACID; IN VITRO; PROSTATE CANCER;
   ANGIOGENESIS; SURVIVAL; AMINOBISPHOSPHONATES; PAMIDRONATE
AB Skeletal complications of bone metastases increase the risk of death and undermine patients' functional independence and quality of life. Although bisphosphonates are integral in the treatment regimen of patients with metastatic bone disease and have demonstrated efficacy in delaying the onset and reducing the incidence of skeletal related events, there is great interest in developing treatments to prevent metastasis to bone. Emerging evidence indicates that the potential benefits of bisphosphonate therapy extend beyond the treatment of metastatic bone lesions. Data from preclinical studies suggest that bisphosphonates may have antitumour activity and may prevent bone metastasis. The mechanisms of these antitumour effects are currently under investigation and may include induction of apoptosis, inhibition of tumour cell invasion and angiogenesis, and tumour growth reduction. Therefore, patients with early stage disease may benefit from early bisphosphonate therapy, before bone metastasis develops, and investigations are ongoing to determine the clinical utility of bisphosphonates in this setting. (C) 2007 Elsevier Ltd. All rights reserved.
C1 Weston Pk Hosp, Canc Res Ctr, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England.
C3 Weston Park Hospital
RP Coleman, R (通讯作者)，Weston Pk Hosp, Canc Res Ctr, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England.
EM r.c.coleman@sheffield.ac.uk
CR [Anonymous], 28 ANN SAN ANT BREAS
   BERGER W, 2005, 96 AM ASS CANC RES A
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Body JJ, 2002, SUPPORT CARE CANCER, V10, P399, DOI 10.1007/s005200100292
   Boissier S, 2000, CANCER RES, V60, P2949
   Boissier S, 1997, CANCER RES, V57, P3890
   Budman DR, 2006, ONCOLOGY BASEL, V70, P147, DOI 10.1159/000093006
   Clézardin P, 2005, CANCER TREAT REV, V31, pS1, DOI 10.1016/j.ctrv.2005.09.002
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   COLEMAN RE, 2006, 29 ANN SAN ANT BREAS
   Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9 90004 28
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Das H, 2001, BLOOD, V98, P1616, DOI 10.1182/blood.V98.5.1616
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Dillon C, 2004, J MAMMARY GLAND BIOL, V9, P207, DOI 10.1023/B:JOMG.0000037163.56461.1e
   Fournier P, 2002, CANCER RES, V62, P6538
   Gnant MFX, 2007, J CLIN ONCOL, V25, P820, DOI 10.1200/JCO.2005.02.7102
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Heikkilä P, 2003, J SURG RES, V111, P45, DOI 10.1016/S0022 4804(03)00000 0
   Heikkilä P, 2002, ANTI CANCER DRUG, V13, P245, DOI 10.1097/00001813 200203000 00006
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Leto G, 2006, ANTICANCER RES, V26, P23
   Michigami T, 2002, BREAST CANCER RES TR, V75, P249, DOI 10.1023/A:1019905111666
   Mystakidou K, 2005, MED ONCOL, V22, P195, DOI 10.1385/MO:22:2:195
   *NED TRIAL REG, TRIAL INF ZEUS STUD
   Neville Webbe HL, 2006, TUMOR BIOL, V27, P92, DOI 10.1159/000092489
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   OTTEWELL PD, 2006, 29 ANN SAN ANT BREAS
   PADALECKI SS, 2003, ONCOLOGY S, V17, P32
   Pecherstorfer M, 2000, J BONE MINER RES, V15, P147, DOI 10.1359/jbmr.2000.15.1.147
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   RACK W, 2004, P AM SOC CLIN ONCO S, V23, P834
   Saad F, 2004, EUR UROL, V45, P26, DOI 10.1016/j.eururo.2003.10.003
   Saarto T, 2004, ACTA ONCOL, V43, P650, DOI 10.1080/02841860410032885
   SANSONI P, 1995, J BONE MINER RES, V10, P1719
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   SANTINI D, 2007, J CLIN ONCOL S, V25, pS152
   Sato K, 2005, INT J CANCER, V116, P94, DOI 10.1002/ijc.20987
   THOMPSON K, 2006, BONEKEY OSTEOVISION, V3, P5, DOI DOI 10.1138/20060224
   Ural AU, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1543
   Ural AU, 2006, ACTA ONCOL, V45, P491, DOI 10.1080/02841860500492083
   *US NIH, CLIN TRIAL ZOL CLODR
   *US NIH, CLIN TRIAL COLDR CHE
   *US NIH, CLIN TRIAL STUD EV S
   *US NIH, CLIN TRIAL CHEM HORM
   van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008 5472.CAN 04 4188
   Vincenzi B, 2005, J INTERF CYTOK RES, V25, P144, DOI 10.1089/jir.2005.25.144
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yoneda Toshiyuki, 2000, Cancer, V88, P2979, DOI 10.1002/1097 0142(20000615)88:12+<2979::AID CNCR13>3.0.CO;2 U
   Zimering MB, 2002, LIFE SCI, V70, P1947, DOI 10.1016/S0024 3205(01)01548 X
NR 54
TC 10
Z9 10
U1 0
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960 9776
EI 1532 3080
J9 BREAST
JI Breast
PD DEC
PY 2007
VL 16
SU 3
BP S21
EP S27
DI 10.1016/j.breast.2007.10.006
PG 7
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA 324AI
UT WOS:000257489500004
PM 17988867
OA hybrid
DA 2025 08 17
ER

PT J
AU Jin, XL
   Xu, J
   Yang, FF
   Chen, J
   Luo, F
   Xu, B
   Xu, J
AF Jin, XiaoLi
   Xu, Jia
   Yang, Fanfan
   Chen, Jin
   Luo, Feng
   Xu, Bin
   Xu, Jian
TI Oridonin Attenuates Thioacetamide Induced Osteoclastogenesis Through
   MAPK/NF κB Pathway and Thioacetamide Inhibited Osteoblastogenesis
   Through BMP 2/RUNX2 Pathway
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Thioacetamide; Oridonin; Osteoclastogenesis; Osteogenesis; Therapeutics
ID BONE MORPHOGENETIC PROTEIN 2; ALVEOLAR BONE; LIVER INJURY; RAT BLOOD;
   EXPRESSION; NFATC1; AKT
AB Osteoporosis, an age related metabolic bone disease, is mainly caused by an imbalance between osteoblast mediated bone formation and osteoclast mediated bone resorption. At present, there are many osteoporosis drugs that can promote bone formation or inhibit bone resorption. However, there were few therapeutic drugs that can simultaneously promote bone formation and inhibit bone resorption. Oridonin (ORI), a tetracyclic diterpenoid compound isolated from Rabdosia rubescens, has been proved to have anti inflammatory, anti tumor effects. However, little is known about the osteoprotective effect of oridonin. Thioacetamide (TAA) is a common organic compound with significant hepatotoxicity. Recent studies have found that there was a certain association between TAA and bone injury. In this work, we investigated the effect and mechanism of ORI on TAA induced osteoclastogenesis and inhibition of osteoblast differentiation. The results showed that TAA could promote the osteoclastogenesis of RAW264.7 by promoting the MAPK/NF kappa B pathway, and also promoted p65 nuclear translocation and activated intracellular ROS generation, and ORI can inhibit these effects to inhibit TAA induced osteoclastogenesis. Moreover, ORI can also promote the osteogenic differentiation pathway and inhibit adipogenic differentiation of BMSCs to promote bone formation. In conclusion, our results revealed that ORI, as a potential therapeutic drug for osteoporosis, could protect against TAA induced bone loss and TAA inhibited bone formation.
C1 [Jin, XiaoLi; Xu, Jia; Yang, Fanfan; Chen, Jin; Xu, Jian] Zhejiang Chinese Med Univ, Sch Med Technol & Informat Engn, Hangzhou 310053, Zhejiang, Peoples R China.
   [Luo, Feng] Zhejiang Chinese Med Univ, Dept Clin Lab, Affiliated Hosp 1, Hangzhou 310006, Peoples R China.
   [Xu, Bin] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Gen Surg, Hangzhou 310016, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Zhejiang University
RP Xu, J (通讯作者)，Zhejiang Chinese Med Univ, Sch Med Technol & Informat Engn, Hangzhou 310053, Zhejiang, Peoples R China.; Xu, B (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Gen Surg, Hangzhou 310016, Zhejiang, Peoples R China.
EM 3304089@zju.edu.cn; 20061036@zcmu.edu.cn
RI Jin, Xiaoli/GRS 9423 2022
FU Natural Science Foundation of Zhejiang Province [LY19H060001];
   Provincial Traditional Chinese Medicine Science and Technology Program
   [2022ZB093]; Zhejiang University Student Science and Technology
   Innovation Activity Plan [2020R410056]
FX This work was supported by the Natural Science Foundation of Zhejiang
   Province (grant no. LY19H060001), Provincial Traditional Chinese
   Medicine Science and Technology Program (grant no. 2022ZB093) and the
   Zhejiang University Student Science and Technology Innovation Activity
   Plan (grant no. 2020R410056).
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Cao HL, 2010, J CLIN INVEST, V120, P2755, DOI 10.1172/JCI42106
   Che XP, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/4340950
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Cheng LY, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12642
   Choi YH, 2014, FEBS J, V281, P3656, DOI 10.1111/febs.12887
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Feng XC, 2020, PHARMACOL THERAPEUT, V216, DOI 10.1016/j.pharmthera.2020.107650
   Han B, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110305
   Hayashi M, 2019, CELL METAB, V29, P627, DOI 10.1016/j.cmet.2018.12.021
   He HB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04947 6
   Hong GJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.392
   Hu X, 2020, MINI REV MED CHEM, V20, P483, DOI 10.2174/1389557519666191029121809
   Iezaki T, 2016, MOL CELL BIOL, V36, P2451, DOI 10.1128/MCB.01075 15
   Jiang JH, 2023, BMC ORAL HEALTH, V23, DOI [10.1186/s12903 023 02827 0, 10.1186/s12870 023 04103 3]
   Jin S, 2007, CANCER BIOL THER, V6, P261, DOI 10.4161/cbt.6.2.3621
   Jin X, 2022, JOVE J VIS EXP, V185, P185
   Jin XL, 2022, BMC PHARMACOL TOXICO, V23, DOI 10.1186/s40360 022 00568 4
   Jin XL, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 02938 4
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kim HJ, 2019, J CELL PHYSIOL, V234, P1659, DOI 10.1002/jcp.27035
   Kwak SC, 2020, PHYTOTHER RES, V34, P3029, DOI 10.1002/ptr.6735
   LASSILA V, 1984, ACTA ANAT, V118, P116
   Li JS, 2018, INT IMMUNOPHARMACOL, V55, P9, DOI 10.1016/j.intimp.2017.11.040
   Lin ZY, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12688
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Nakano A, 1996, J GASTROEN HEPATOL, V11, P1143, DOI 10.1111/j.1440 1746.1996.tb01843.x
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Qi Q, 2020, CELL MOL LIFE SCI, V77, P2407, DOI 10.1007/s00018 019 03289 w
   Sabokbar A, 2003, J ORTHOP RES, V21, P73, DOI 10.1016/S0736 0266(02)00106 7
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sun YT, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110108
   Ti HH, 2020, MINI REV MED CHEM, V20, P2153, DOI 10.2174/1389557520666200807134921
   Tian LJ, 2020, METABOLISM, V105, DOI 10.1016/j.metabol.2020.154189
   VIRTANEN P, 1986, ACTA ANAT, V127, P285
   Wang WS, 2019, CELL METAB, V30, P174, DOI 10.1016/j.cmet.2019.05.005
   Wang YJ, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/2327721
   Wang Z, 2021, REJUV RES, V24, P139, DOI 10.1089/rej.2019.2262
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Xu D, 2019, MOLECULES, V24, DOI 10.3390/molecules24061123
   Yan CL, 2020, FRONT NEUROSCI SWITZ, V14, DOI 10.3389/fnins.2020.557170
   Yang HH, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0366 y
   Yang JW, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.aaz9368
   Zhang Chen, 2021, Journal of China Medical University, V50, P130, DOI 10.12007/j.issn.0258 4646.2021.02.007
   Zhang JF, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0046 1
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhang Y, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.609705
   Zhu MS, 2021, J ETHNOPHARMACOL, V276, DOI 10.1016/j.jep.2021.114176
NR 49
TC 10
Z9 11
U1 1
U2 13
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JUN
PY 2023
VL 112
IS 6
BP 704
EP 715
DI 10.1007/s00223 023 01080 5
EA APR 2023
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA G4DZ1
UT WOS:000966297900001
PM 37032340
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Wang, L
   Zhang, W
   Zhao, CL
   Fu, ZH
AF Wang, Lei
   Zhang, Wei
   Zhao, Cheng long
   Fu, Zhong hua
TI Bisphosphonate  and disumab related gingival disorders: case analysis
   from the US Food and Drug Administration Adverse Event Reporting System
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE antiresorptive drugs; FAERS; gingival disorders; adverse drug reactions;
   bisphosphonates; denosumab
ID ZOLEDRONIC ACID; MECHANISM; CELLS; FIBROBLASTS; DENOSUMAB; THERAPY
AB Prior research has indicated that bisphosphonates (BPs) can improve periodontal disease because of their anti osteoporosis properties. In vitro studies have shown that BPs induce cytotoxicity, inhibit wound healing, and thus affect periodontal disease. Denosumab and BPs have alternative indications. BP and denosumab are not known to correlate with gingival disorders. We assessed such a relationship by applying Bayesian and nonproportional analyses to data in the US FDA Adverse Event Reporting System (FAERS) database. The study analyzed BPs and denosumab reported incidents with preferred terms found in the narrow Standardized MedDRA Queries for gingival disorders. A total of 5863 reported cases of gingival disorders were associated with five BPs (alendronate, pamidronate, ibandronate, risedronate, and zoledronate) and denosumab. More than 15% of patients with gingival disorders related to BPs and denosumab other than denosumab were hospitalized over short  or long term periods. Our findings indicated BPs and denosumab had significant reporting odds ratios (ROR), proportional reporting ratios (PRR), and information components (IC) with respect to gingival disorders. Pamidronate had the highest association (ROR = 64.58, PRR = 57.99, IC = 5.71), while the weakest association was found with denosumab (ROR = 3.61, PRR = 3.60, IC = 1.77). Significant associations were found between the six drugs and gingival pain, gingival recession, gingivitis, periodontal disease, and periodontitis. In conclusion, our comprehensive overview of the correlations, clinical characteristics, and prognoses of BPs and denosumab related gingival disorders suggests that these issues deserve continued surveillance and appropriate management.
C1 [Wang, Lei; Zhang, Wei; Zhao, Cheng long; Fu, Zhong hua] Henan Univ, Peoples Hosp Zhengzhou Univ, Henan Prov Peoples Hosp, Sch Clin Med,Dept Pharm, Zhengzhou, Henan, Peoples R China.
C3 Zhengzhou University; Henan University
RP Fu, ZH (通讯作者)，Henan Univ, Peoples Hosp Zhengzhou Univ, Henan Prov Peoples Hosp, Sch Clin Med,Dept Pharm, Zhengzhou, Henan, Peoples R China.
EM zhaocl725@zzu.edu.cn
CR Akram Z, 2017, BRIT J CLIN PHARMACO, V83, P444, DOI 10.1111/bcp.13147
   Beth Tasdogan NH, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012432.pub2
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Hauben M, 2009, DRUG DISCOV TODAY, V14, P343, DOI 10.1016/j.drudis.2008.12.012
   Jara MA, 2022, BONE, V158, DOI 10.1016/j.bone.2021.115901
   Kass Hout TA, 2016, J AM MED INFORM ASSN, V23, P596, DOI 10.1093/jamia/ocv153
   Kaur K, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1111627
   Koide Y, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen 2021 057768
   Komatsu Y, 2016, INT J MOL MED, V38, P139, DOI 10.3892/ijmm.2016.2582
   Kuroshima S, 2016, CLIN ORAL INVEST, V20, P727, DOI 10.1007/s00784 015 1550 0
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Marcuzzi A, 2011, ORAL ONCOL, V47, P436, DOI 10.1016/j.oraloncology.2011.02.017
   McLeod NMH, 2014, J ORAL MAXIL SURG, V72, P503, DOI 10.1016/j.joms.2013.08.007
   Pabst AM, 2012, CLIN ORAL INVEST, V16, P87, DOI 10.1007/s00784 010 0507 6
   Pavanelli ALR, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/5832009
   Penoni D C, 2018, JDR Clin Trans Res, V3, P378, DOI 10.1177/2380084418787451
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sakaeda T, 2013, INT J MED SCI, V10, P796, DOI 10.7150/ijms.6048
   Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365 2141.2008.07504.x
   Slattery J, 2013, DRUG SAFETY, V36, P687, DOI 10.1007/s40264 013 0075 1
   Soydan SS, 2015, HUM EXP TOXICOL, V34, P1073, DOI 10.1177/0960327115569808
   Stavropoulos A, 2018, CLIN ORAL IMPLAN RES, V29, P54, DOI 10.1111/clr.13282
   Taniguchi N, 2020, J PERIODONTOL, V91, P947, DOI 10.1002/JPER.19 0385
   Tsourdi E, 2011, EUR J ENDOCRINOL, V165, P833, DOI 10.1530/EJE 11 0454
   Wang YF, 2021, J ORAL MAXIL SURG, V79, P2487, DOI 10.1016/j.joms.2021.07.027
   Zago PMW, 2020, CLIN COSMET INV DENT, V12, P327, DOI 10.2147/CCIDE.S259158
NR 27
TC 2
Z9 2
U1 2
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD AUG 22
PY 2024
VL 15
AR 1367607
DI 10.3389/fendo.2024.1367607
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA E6S6O
UT WOS:001304288000001
PM 39239094
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Luo, L
   Cao, HJ
   Zhou, L
   Zhang, GD
   Wu, L
AF Luo, Lin
   Cao, Hongjuan
   Zhou, Liang
   Zhang, Guangdao
   Wu, Lin
TI Anti resorption role of low intensity pulsed ultrasound (LIPUS) during
   large scale bone reconstruction using porous titanium alloy scaffolds
   through inhibiting osteoclast differentiation
SO BIOMATERIALS ADVANCES
LA English
DT Article
DE LIPUS; Ti6Al4V; FTO; m6A
ID OSTEOBLASTS; EXPRESSION; RANKL; METHYLATION; LEUKEMIA; STEM
AB Background: Ti6Al4V biomaterials combine with low intensity pulsed ultrasound (LIPUS) has been reported with great bone regeneration capacity. It is important to better understand how LIPUS benefits bone microenvironment to seek for target of therapeutic medicine. Osteoclast differentiation plays a crucial role in bone resorption. Recent advances in molecular biology have revealed that N6 methyladenosine (m6A) RNA modifications can modulate biological processes, but their role in bone biology, particularly in osteoclast differentiation, remains unclear. We aim to understand how LIPUS regulates bone microenvironment especially osteoclast formation during bone regeneration to provide new therapeutic options for preventing and delaying bone resorption, thus with better bone regeneration efficiency.Results: 1. LIPUS promoted bone ingrowth and bone maturity while inhibiting osteoclast formation within Ti6Al4V scaffolds in large scale bone defect model. 2. LIPUS was found to inhibit osteoclast differentiation by decreasing the overall expression of osteoclast markers in vitro. 3. LIPUS decreases RNA m6A modification level through upregulating FTO expression during osteoclast differentiation during. 4. Inhibiting FTO expression and function leads to less inhibition during osteoclast differentiation.Conclusion: LIPUS suppresses osteoclast differentiation during bone regeneration through reducing m6A modification of osteoclastic RNAs by up regulating FTO expression.
C1 [Luo, Lin; Cao, Hongjuan; Zhou, Liang; Zhang, Guangdao; Wu, Lin] China Med Univ, Sch & Hosp Stomatol, Liaoning Prov Key Lab Oral Dis, Shenyang 110001, Peoples R China.
C3 China Medical University
RP Zhang, GD; Wu, L (通讯作者)，China Med Univ, Sch & Hosp Stomatol, Liaoning Prov Key Lab Oral Dis, Shenyang 110001, Peoples R China.
EM zzggdd@sina.com; lwu@cmu.edu.cn
FU National Natural Science Foundation of China [81801807, 81870811]
FX <BOLD>Acknowledgments</BOLD> This study was supported by the National
   Natural Science Foundation of China (Grant number 81801807 and 81870811)
   .
CR Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Bandow K, 2007, J CELL PHYSIOL, V211, P392, DOI 10.1002/jcp.20944
   Barbieri I, 2017, NATURE, V552, P126, DOI 10.1038/nature24678
   Bighetti Trevisan RL, 2022, BRAZ ORAL RES, V36, DOI 10.1590/1807 3107bor 2022.vol36.0022
   Cao HJ, 2017, MAT SCI ENG C MATER, V80, P7, DOI 10.1016/j.msec.2017.05.078
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V561, P13, DOI 10.1016/j.abb.2014.08.009
   Carina V, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0868 2
   Chen XJ, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00911
   Di Pompo G, 2021, CANCERS, V13, DOI 10.3390/cancers13153848
   Feng LF, 2019, J ULTRAS MED, V38, P191, DOI 10.1002/jum.14683
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gao X, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014005
   Ge YW, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1404915
   Guo LJ, 2014, EXP CELL RES, V321, P142, DOI 10.1016/j.yexcr.2013.12.001
   Hao FY, 2018, MAT SCI ENG C MATER, V88, P53, DOI 10.1016/j.msec.2018.02.024
   He D, 2021, GENE, V768, DOI 10.1016/j.gene.2020.145318
   Jiang XX, 2019, IEEE T BIO MED ENG, V66, P2704, DOI 10.1109/TBME.2018.2889669
   Jin FJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 23642 7
   Jonkhout N, 2017, RNA, V23, P1754, DOI 10.1261/rna.063503.117
   Lence T, 2016, NATURE, V540, P242, DOI 10.1038/nature20568
   Li D, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24021403
   Li D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051660
   Li JB, 2020, J BONE MINER RES, V35, P1535, DOI 10.1002/jbmr.4021
   Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432
   Meng JH, 2018, AM J TRANSL RES, V10, P2901
   Nagao M, 2017, J ORAL SCI, V59, P303, DOI 10.2334/josnusd.16 0624
   Nakao J, 2014, BONE, V58, P17, DOI 10.1016/j.bone.2013.09.018
   Proietto J., 2020, F1000RESEARCH, V9
   Rasheed Z, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42601 3
   Romano G, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00243
   Rosenberger CM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006305
   Schöller E, 2018, RNA, V24, P499, DOI 10.1261/rna.064063.117
   Shen GS, 2018, BBA MOL BASIS DIS, V1864, P3644, DOI 10.1016/j.bbadis.2018.09.015
   Tanaka E, 2020, ANN BIOMED ENG, V48, P2158, DOI 10.1007/s10439 020 02540 x
   Uddin SMZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073914
   Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416
   Wen J, 2018, MOL CELL, V69, P1028, DOI 10.1016/j.molcel.2018.02.015
   Wu L, 2015, TISSUE ENG PT A, V21, P53, DOI [10.1089/ten.tea.2013.0597, 10.1089/ten.TEA.2013.0597]
   Wu YS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06898 4
   Xin ZC, 2016, TRANSL ANDROL UROL, V5, P255, DOI 10.21037/tau.2016.02.04
   Yao YX, 2019, FASEB J, V33, P7529, DOI 10.1096/fj.201802644R
   Yi X, 2020, J ORTHOP RES, V38, P2505, DOI 10.1002/jor.24628
   Ying SQ, 2020, THERANOSTICS, V10, P9789, DOI 10.7150/thno.42508
   Yu B, 2015, NAT MED, V21, P1101, DOI 10.1038/nm0915 1101
   Yu J, 2019, BONE, V127, P376, DOI 10.1016/j.bone.2019.07.009
   Zhang B, 2020, AUTOPHAGY, V16, P1262, DOI 10.1080/15548627.2019.1664705
   Zhang CX, 2017, NATURE, V549, P273, DOI 10.1038/nature23883
   Zhang Q, 2019, P NATL ACAD SCI USA, V116, P17980, DOI 10.1073/pnas.1905489116
   Zhang X, 2019, VIRUS RES, V271, DOI 10.1016/j.virusres.2019.197671
   Zhao DY, 2023, INT J BIOPRINTING, V9, P12, DOI 10.18063/ijb.698
   Zhou J, 2015, NATURE, V526, P591, DOI 10.1038/nature15377
NR 51
TC 1
Z9 1
U1 1
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2772 9508
J9 BIOMATER ADV
JI Biomater. Adv.
PD NOV
PY 2023
VL 154
AR 213634
DI 10.1016/j.bioadv.2023.213634
EA SEP 2023
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA U7WQ4
UT WOS:001086875000001
PM 37783002
DA 2025 08 17
ER

PT J
AU Choudhary, S
   Blackwell, K
   Voznesensky, O
   Roy, AD
   Pilbeam, C
AF Choudhary, Shilpa
   Blackwell, Katherine
   Voznesensky, Olga
   Roy, Abhijit Deb
   Pilbeam, Carol
TI Prostaglandin E2 acts via bone marrow macrophages to
   block PTH stimulated osteoblast differentiation in vitro
SO BONE
LA English
DT Article
DE Cyclooxygenase 2; EP4 receptor; EP2 receptor; Osteoclasts; Bone marrow
   stromal cells; Osteoprotegerin
ID MESENCHYMAL STEM CELLS; PARATHYROID HORMONE; G/H SYNTHASE 2; ADIPOCYTE
   DIFFERENTIATION; SIGNALING PATHWAYS; EP2 RECEPTOR; CYCLOOXYGENASE 2;
   OSTEOCLASTS; EXPRESSION; TRANSCRIPTION
AB Intermittent PTH is the major anabolic therapy for osteoporosis while continuous PTH causes bone loss, PTH acts on the osteoblast (OB) lineage to regulate bone resorption and formation. PTH also induces cyclooxygenase 2 (COX 2), producing prostaglandin E 2 (PGE(2)) that can act on both OBs and osteoclasts (0Cs). Because intermittent PTH is more anabolic in Cox 2 knockout (KO) than wild type (WT) mice, we hypothesized COX 2 might contribute to the effects of continuous PTH by suppressing PTH stimulated differentiation of mesenchymal stem cells into OBs. We compared effects of continuous PTH on bone marrow stromal cells (BMSCs) and primary OBs (POBs) from Cox 2 KO mice, mice with deletion of PGE2 receptors. (Ptger4 and Ptger2 KO mice), and WT controls. PTH increased OB differentiation in BMSCs only in the absence of COX 2 expression or activity. In the absence of COX 2, PTH stimulated differentiation if added during the first week of culture. In Cox 2 KO BMSCs, PTH stimulated differentiation was prevented by adding PGE2 to cultures. Co culture of POBs with M CSF expanded bone marrow macrophages (BMMs) showed that the inhibition of PTH stimulated OB differentiation required not only COX 2 or PGE2 but also BMMs. Sufficient PGE2 to mediate the inhibitory effect was made by either WT POBs or WT BMMs. The inhibitory effect mediated by COX 2/PGE(2) was transferred by conditioned media from RANKL treated BMMs and could be blocked by osteoprotegerin, which interferes with RANKL binding to its receptor on OC lineage cells. Deletion of Ptger4, but not Ptger2, in BMMs prevented the inhibition of PTH stimulated OB differentiation. As expected, PGE2 also stimulated OB differentiation, but when given in combination with PTH, the stimulatory effects of both were abrogated. These data suggest that PGE2, acting via EP4R on BMMs committed to the OC lineage, stimulated secretion of a factor or factors that acted to suppress PTH stimulated OB differentiation. This suppression of OB differentiation could contribute to the bone loss seen with continuous PTH in vivo. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.
C1 Univ Connecticut, Ctr Hlth, New England Musculoskeletal Inst, Farmington, CT 06030 USA.
   Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA.
C3 University of Connecticut; University of Connecticut
RP Pilbeam, C (通讯作者)，Univ Connecticut, Ctr Hlth, 263 Farmington Ave,MC5456, Farmington, CT 06030 USA.
EM pilbeam@nso.uchc.edu
OI Deb Roy, Abhijit/0000 0003 1640 2402
FU NIH [R56DK048361, AR047673, AR060286]
FX We owe much to Larry Raisz who never wavered in his belief that
   prostaglandins were important for bone biology. We are also grateful to
   the reviewers of this manuscript for helping us to clarify our thoughts
   about the PTH PGE<INF>2</INF> interaction. This work was supported by
   NIH grants R56DK048361, AR047673 and AR060286.
CR Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   BELLOWS CG, 1990, ENDOCRINOLOGY, V127, P3111, DOI 10.1210/endo 127 6 3111
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Chikazu D, 2005, J BONE MINER RES, V20, P1887, DOI 10.1359/jbmr.2005.20.10.1887
   Choudhary S, 2008, BIOCHEM BIOPH RES CO, V372, P536, DOI 10.1016/j.bbrc.2008.05.050
   Choudhary S, 2008, PROSTAG OTH LIPID M, V86, P35, DOI 10.1016/j.prostaglandins.2008.02.001
   Choudhary S, 2007, J BONE MINER RES, V22, P1002, DOI 10.1359/JBMR.070321
   Gao Q, 2009, PROSTAG OTH LIPID M, V89, P20, DOI 10.1016/j.prostaglandins.2009.03.003
   Gao Q, 2009, BONE, V45, P98, DOI 10.1016/j.bone.2009.03.667
   Grundt A, 2009, BIOCHEM BIOPH RES CO, V389, P550, DOI 10.1016/j.bbrc.2009.09.026
   Guihard P, 2012, STEM CELLS, V30, P762, DOI 10.1002/stem.1040
   Han SY, 2005, BLOOD, V106, P1240, DOI 10.1182/blood 2004 12 4975
   Henriksen K, 2012, BONE, V51, P353, DOI 10.1016/j.bone.2012.06.007
   Horwitz MJ, 2011, J BONE MINER RES, V26, P2287, DOI 10.1002/jbmr.415
   Iida Klein A, 2005, J ENDOCRINOL, V186, P549, DOI 10.1677/joe.1.06270
   Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491
   Kang YJ, 2007, PROG LIPID RES, V46, P108, DOI 10.1016/j.plipres.2007.01.001
   Karsdal MA, 2007, J BONE MINER RES, V22, P487, DOI 10.1359/JBMR.070109
   KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P1157, DOI 10.1210/en.135.3.1157
   Kennedy CRJ, 1999, NAT MED, V5, P217, DOI 10.1038/5583
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Kobayashi Y, 2005, J BIOL CHEM, V280, P24035, DOI 10.1074/jbc.M500926200
   Kreja L, 2010, J CELL BIOCHEM, V109, P347, DOI 10.1002/jcb.22406
   Lane Nancy E, 2010, Curr Osteoporos Rep, V8, P23, DOI 10.1007/s11914 010 0005 4
   Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   Mbonye UR, 2006, J BIOL CHEM, V281, P35770, DOI 10.1074/jbc.M608281200
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092 8674(95)90125 6
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Nicolaidou V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039871
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Pilbeam C, 1997, ENDOCRINOLOGY, V138, P4672, DOI 10.1210/en.138.11.4672
   Pilbeam CC, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1235, DOI 10.1016/B978 0 12 373884 4.00072 0
   PILBEAM CC, 1995, J BONE MINER RES, V10, P406
   PILBEAM CC, 1993, J BIOL CHEM, V268, P25643
   Potts JT, 2007, ANN NY ACAD SCI, V1117, P196, DOI 10.1196/annals.1402.088
   Rickard DJ, 2006, BONE, V39, P1361, DOI 10.1016/j.bone.2006.06.010
   Robling AG, 2011, ENDOCRINOLOGY, V152, P2963, DOI 10.1210/en.2011 0049
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Sakuma Y, 2004, BONE, V34, P827, DOI 10.1016/j.bone.2003.12.007
   Schneider A, 2004, GENESIS, V40, P7, DOI 10.1002/gene.20048
   Shockley KR, 2009, J CELL BIOCHEM, V106, P232, DOI 10.1002/jcb.21994
   Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Tetradis S, 1997, ENDOCRINOLOGY, V138, P3594, DOI 10.1210/en.138.9.3594
   Tian XY, 2008, BONE, V42, P914, DOI 10.1016/j.bone.2007.12.228
   Uppal S, 2008, NAT GENET, V40, P789, DOI 10.1038/ng.153
   Walker EC, 2008, J BONE MINER RES, V23, P2025, DOI [10.1359/jbmr.080706, 10.1359/JBMR.080706]
   Wang YH, 2005, J BONE MINER RES, V20, P5, DOI 10.1359/JBMR.041016
   Winkler IG, 2010, BLOOD, V116, P4815, DOI 10.1182/blood 2009 11 253534
   Xie C, 2008, BONE, V43, P1075, DOI 10.1016/j.bone.2008.08.109
   Xu MS, 2010, BONE, V47, P341, DOI 10.1016/j.bone.2010.05.006
   Xu Z, 2007, BONE, V41, P68, DOI 10.1016/j.bone.2007.03.009
   Yang D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
   Zhan P, 2005, PROSTAG OTH LIPID M, V78, P19, DOI 10.1016/j.prostaglandins.2004.10.008
NR 60
TC 22
Z9 25
U1 0
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2013
VL 56
IS 1
BP 31
EP 41
DI 10.1016/j.bone.2013.04.017
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 189WS
UT WOS:000322299600006
PM 23639875
OA hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Sanchez, C
   Deberg, MA
   Bellahcnèe, A
   Castronovo, V
   Msika, P
   Delcour, JP
   Crielaard, JM
   Henrotin, YE
AF Sanchez, Christelle
   Deberg, Michelle A.
   Bellahcnee, Akeila
   Castronovo, Vincent
   Msika, Philippe
   Delcour, J. P.
   Crielaard, J. M.
   Henrotin, Yves E.
TI Phenotypic characterization of osteoblasts from the sclerotic zones of
   osteoarthritic subchondral bone
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID GROWTH FACTOR BETA; COLLAGEN METABOLISM; CYNOMOLGUS MACAQUES;
   PROSTAGLANDIN E 2; TRABECULAR BONE; IN VITRO; EXPRESSION; CELLS;
   INTERLEUKIN 6; RECEPTOR
AB Objective. To determine the phenotype of osteoblasts from the sclerotic zones of human osteoarthritic (OA) subchondral bone.
   Methods. Human osteoblasts were isolated from sclerotic or nonsclerotic areas of subchondral bone and cultured for 14 days in monolayer. The expression of 14 genes was investigated by real time reverse transcription polymerase chain reaction. The activities of alkaline phosphatase (AP) and transglutaminases (TGases) were quantified by enzymatic assays. C terminal type I procollagen propeptide (CPI), interleukin 1 beta (IL 1 beta), IL 6, IL 8, transforming growth factor beta 1 (TGF beta 1), osteocalcin (OC), and osteopontin (OPN) were assayed in the culture medium by immunoassay.
   Results. Gene expression levels of matrix metalloproteinase 13, COL1A1 and COL1A2, OPN, tissue nonspecific AP, OC, vascular endothelial growth factor, ANKH, TGase 2, factor XIIIA, and dentin matrix protein I were significantly up regulated in sclerotic osteoblasts compared with nonsclerotic osteoblasts. In contrast, parathyroid hormone receptor gene expression was depressed in sclerotic osteoblasts, but bone sialoprotein levels were unchanged. The activities of AP and TGases were increased in sclerotic osteoblasts, while matrix mineralization, revealed by alizarin red staining, was decreased. In parallel, protein synthesis of CPI, OC, OPN, IL 6, IL 8, and TGF beta 1 was significantly higher in sclerotic osteoblasts than in nonsclerotic osteoblasts, while IL 1 beta production was similar in both groups.
   Conclusion. These findings contribute to a better understanding of the mechanisms involved in subchondral bone sclerosis and identify osteoblasts with an altered phenotype as a potential target for future OA therapies.
C1 [Sanchez, Christelle; Deberg, Michelle A.; Bellahcnee, Akeila; Castronovo, Vincent; Crielaard, J. M.; Henrotin, Yves E.] Univ Liege, B 4000 Sart Tilman Par Liege, Belgium.
   [Delcour, J. P.] Ctr Hosp Bois Abbaye, Seraing, Belgium.
   [Msika, Philippe] Labs Expansci, Epernon, France.
C3 University of Liege
RP Henrotin, YE (通讯作者)，Inst Pathol, Bone & Cartilage Res Unit, CHU Bat B23, B 4000 Liege, Belgium.
EM yhenrotin@ulg.ac.be
OI Henrotin, Yves/0000 0003 1073 449X; sanchez,
   christelle/0000 0002 1005 8172
CR Bailey AJ, 2002, INT J BIOCHEM CELL B, V34, P176, DOI 10.1016/S1357 2725(01)00107 8
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Boyd SK, 2002, J BONE MINER RES, V17, P687, DOI 10.1359/jbmr.2002.17.4.687
   CARLSON CS, 1994, J ORTHOP RES, V12, P331, DOI 10.1002/jor.1100120305
   Carlson CS, 1996, J BONE MINER RES, V11, P1209
   Chow J W, 2000, Exerc Sport Sci Rev, V28, P185
   Day JS, 2004, BIORHEOLOGY, V41, P359
   DEDRICK DK, 1993, ARTHRITIS RHEUM, V36, P1460, DOI 10.1002/art.1780361019
   DEQUEKER J, 1993, ARTHRITIS RHEUM, V36, P1702, DOI 10.1002/art.1780361209
   DODDS RA, 1995, J BONE MINER RES, V10, P1666
   Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903
   Franchimont N, 1997, ENDOCRINOLOGY, V138, P5248, DOI 10.1210/en.138.12.5248
   Franchimont N, 2000, BONE, V26, P249, DOI 10.1016/S8756 3282(99)00275 6
   Franchimont N, 1997, J BIOL CHEM, V272, P12144, DOI 10.1074/jbc.272.18.12144
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   GRYNPAS MD, 1991, CALCIFIED TISSUE INT, V49, P20, DOI 10.1007/BF02555898
   Harada S I, 1995, Connect Tissue Res, V31, P279, DOI 10.3109/03008209509010823
   Harmey D, 2004, AM J PATHOL, V164, P1199, DOI 10.1016/S0002 9440(10)63208 7
   Hilal G, 1998, ARTHRITIS RHEUM, V41, P891, DOI 10.1002/1529 0131(199805)41:5<891::AID ART17>3.0.CO;2 X
   Hilal G, 2001, J BONE MINER RES, V16, P713, DOI 10.1359/jbmr.2001.16.4.713
   Hilal G, 1999, ARTHRITIS RHEUM, V42, P2112, DOI 10.1002/1529 0131(199910)42:10<2112::AID ANR11>3.0.CO;2 N
   Huang ZN, 2007, TISSUE ENG, V13, P2311, DOI 10.1089/ten.2006.0423
   Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059
   Ishida K, 2005, INT J MOL MED, V16, P689
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Johnson K, 2004, OSTEOARTHR CARTILAGE, V12, P321, DOI 10.1016/j.joca.2003.12.004
   Kaartinen MT, 2007, J HISTOCHEM CYTOCHEM, V55, P375, DOI 10.1369/jhc.6A7087.2006
   LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003 2697(80)90165 7
   Lisignoli G, 2002, CYTOKINE, V20, P231, DOI 10.1006/cyto.2002.2006
   Mansell JP, 1997, BRIT J RHEUMATOL, V36, P16
   Mansell JP, 1998, J CLIN INVEST, V101, P1596, DOI 10.1172/JCI867
   Massicotte F, 2006, BONE, V38, P333, DOI 10.1016/j.bone.2005.09.007
   Massicotte F, 2002, OSTEOARTHR CARTILAGE, V10, P491, DOI 10.1053/joca.2002.0528
   Merz D, 2003, J IMMUNOL, V171, P4406, DOI 10.4049/jimmunol.171.8.4406
   Muller Gerbl M, 1998, Adv Anat Embryol Cell Biol, V141, pIII
   Muller Gerbl M., 1998, ADV ANAT EMBRYOL CEL, V141, P1, DOI [10.1007/978 3 642 72019 2, DOI 10.1007/978 3 642 72019 2]
   Ong JL, 1999, INT J ORAL MAX IMPL, V14, P217
   PASH JM, 1995, ENDOCRINOLOGY, V136, P33, DOI 10.1210/en.136.1.33
   RADIN EL, 1970, ARTHRITIS RHEUM, V13, P400, DOI 10.1002/art.1780130406
   Rosenthal AK, 2007, MATRIX BIOL, V26, P96, DOI 10.1016/j.matbio.2006.10.004
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P988, DOI 10.1016/j.joca.2005.07.012
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P979, DOI 10.1016/j.joca.2005.03.008
   Sanchez C, 2003, BIOCHEM PHARMACOL, V65, P377, DOI 10.1016/S0006 2952(02)01485 5
   Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200
   Taguchi Y, 1998, P ASSOC AM PHYSICIAN, V110, P559
   Tang CH, 2005, J BIOL CHEM, V280, P22907, DOI 10.1074/jbc.M500130200
   Truong LH, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2101
   Watson PJ, 1996, ARTHRITIS RHEUM, V39, P1327, DOI 10.1002/art.1780390810
   Westacott CI, 1997, ARTHRITIS RHEUM, V40, P1282, DOI 10.1002/1529 0131(199707)40:7<1282::AID ART13>3.0.CO;2 E
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
NR 50
TC 127
Z9 151
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD FEB
PY 2008
VL 58
IS 2
BP 442
EP 455
DI 10.1002/art.23159
PG 14
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 264BR
UT WOS:000253260700013
PM 18240211
DA 2025 08 17
ER

PT S
AU Thompson, K
   Roelofs, AJ
   Jauhiainen, M
   Mönkkönen, H
   Mönkkönen, J
   Rogers, MJ
AF Thompson, Keith
   Roelofs, Anke J.
   Jauhiainen, Marjo
   Monkkonen, Hannu
   Monkkonen, Jukka
   Rogers, Michael J.
BE Choi, Y
TI Activation of γδ T Cells by Bisphosphonates
SO OSTEOIMMUNOLOGY: INTERACTIONS OF THE IMMUNE AND SKELETAL SYSTEMS II
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Proceedings Paper
CT 2nd International Conference on Osteoimmunology
CY JUN 08 13, 2008
CL Rhodes, GREECE
DE Bisphosphonate; Gamma, delta T cell; Monocytes; Osteoporosis; Mevalonate
   pathway
ID ACUTE PHASE RESPONSE; ZOLEDRONIC ACID; IN VITRO; BONE RESORPTION;
   OSTEOCLAST; VIVO; ALENDRONATE; AMINOBISPHOSPHONATES; PYROPHOSPHATE;
   INTERLEUKIN 6
AB After decades of successful clinical use, the exact molecular mechanisms by which the anti resorptive bisphosphonate drugs (BPs) exert their effects are now being revealed. In addition to their anti resorptive effects, it is now apparent that nitrogen containing BPs (N BPs) have immunomodulatory properties. Specifically, these drugs activate immune cells called gamma, delta T lymphocytes. In this chapter we discuss the mechanism of gamma, delta T cell activation by N BPs and propose that N BPs may provide a safe and effective means for manipulating gamma,delta T cell activity in future immunotherapeutic approaches.
C1 [Thompson, Keith; Roelofs, Anke J.; Rogers, Michael J.] Univ Aberdeen, Bone & Musculoskeletal Res Programme, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.
   [Jauhiainen, Marjo; Monkkonen, Hannu; Monkkonen, Jukka] Univ Kuopio, Dept Pharmaceut, FIN 70211 Kuopio, Finland.
C3 University of Aberdeen; University of Eastern Finland
RP Thompson, K (通讯作者)，Univ Aberdeen, Bone & Musculoskeletal Res Programme, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.
EM k.thompson@abdn.ac.uk; a.roelofs@abdn.ac.uk; marjojauhiainen@uku.fi;
   hannu.monkkonen@uku.fi; jukka.monkkonen@uku.fi; m.j.rogers@abdn.ac.uk
RI ; Roelofs, Anke/ABG 5019 2021
OI Rogers, Michael/0000 0002 1818 9249; Thompson,
   Keith/0000 0002 9167 5147; 
FU Versus Arthritis [18439] Funding Source: Medline; Versus Arthritis
   [18439] Funding Source: researchfish
CR ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Coxon FP, 2003, CALCIFIED TISSUE INT, V72, P80, DOI 10.1007/s00223 002 2017 2
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Das H, 2001, BLOOD, V98, P1616, DOI 10.1182/blood.V98.5.1616
   Delmas PD, 2006, ARTHRITIS RHEUM US, V54, P1838, DOI 10.1002/art.21918
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Espinosa E, 2001, J BIOL CHEM, V276, P18337, DOI 10.1074/jbc.M100495200
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Kunzmann V, 2005, LEUKEMIA LYMPHOMA, V46, P671, DOI 10.1080/10428190500051893
   Kunzmann V, 2000, BLOOD, V96, P384
   Li L, 2008, BLOOD, V111, P5629, DOI 10.1182/blood 2008 02 139899
   Mariani S, 2005, LEUKEMIA, V19, P664, DOI 10.1038/sj.leu.2403693
   Miyagawa F, 2001, J IMMUNOL, V166, P5508, DOI 10.4049/jimmunol.166.9.5508
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   SCHWEITZER DH, 1995, J BONE MINER RES, V10, P956
   SELANDER K, 1994, CALCIFIED TISSUE INT, V55, P368, DOI 10.1007/BF00299317
   Sicard H, 2005, J IMMUNOL, V175, P5471, DOI 10.4049/jimmunol.175.8.5471
   TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood 2002 12 3665
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
   ZIMOLO Z, 1995, J CLIN INVEST, V96, P2277, DOI 10.1172/JCI118283
NR 36
TC 61
Z9 73
U1 0
U2 6
PU SPRINGER VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D 14197 BERLIN, GERMANY
SN 0065 2598
EI 2214 8019
BN 978 1 4419 1049 3
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2010
VL 658
BP 11
EP 20
DI 10.1007/978 1 4419 1050 9_2
PG 10
WC Immunology; Medicine, Research & Experimental
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Research & Experimental Medicine
GA BOD91
UT WOS:000276344400002
PM 19950011
DA 2025 08 17
ER

PT J
AU Chen, HL
   Shen, GY
   Shang, Q
   Zhang, P
   Yu, D
   Yu, X
   Zhang, ZD
   Zhao, WH
   Wu, ZX
   Tang, FY
   Liang, D
   Jiang, XB
   Ren, H
AF Chen, Honglin
   Shen, Gengyang
   Shang, Qi
   Zhang, Peng
   Yu, Die
   Yu, Xiang
   Zhang, Zhida
   Zhao, Wenhua
   Wu, Zixian
   Tang, Fuyu
   Liang, De
   Jiang, Xiaobing
   Ren, Hui
TI Plastrum testudinis extract suppresses osteoclast differentiation
   via the NF κB signaling pathway and ameliorates senile osteoporosis
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Plastrum testudinis extract; Osteoclast differentiation; NF kappa B;
   Senile osteoporosis
ID INFLAMMATION; SENESCENCE; EXPRESSION; RECEPTOR
AB Ethnopharmacological relevance: Plastrum testudinis (PT) is a kind of single traditional Chinese medicine that can tonify kidney and strengthen bone. Plastrum testudinis extract (PTE) has been approved to promote the osteogenic differentiation of bone marrow derived mesenchymal stem cells in vitro. However, the mechanism by which PTE reduces osteoclast differentiation has not yet been reported.
   Aim of the study: To explore the potential of PTE as a therapeutic treatment for bone loss caused by senile osteoporosis (SOP).
   Materials and methods: We evaluated whether PTE could inhibit RANKL induced osteoclast differentiation both in vitro and in vivo, and investigated PTE induced phenotypes of human peripheral blood monocytes.
   Results: We found that PTE inhibited osteoclast differentiation and bone resorption in vitro in a concentration dependent manner and that PTE treatment is most effective during the early stages of osteoclastogenesis. Moreover, we found that PTE could block the NF kappa B signaling pathway in vitro, leading to the down regulation of osteoclast specific genes including C FOS and NFATC1. The results from our in vivo mouse study suggest that PTE treatment suppresses osteoclast formation and mitigates bone loss caused by SOP. Notably, we also found that PTE inhibited RANKL induced osteoclast differentiation in human peripheral blood monocytes.
   Conclusion: Our results suggest that PTE treatment suppresses osteoclastogenesis and ameliorates bone loss caused by SOP by selectively blocking the nuclear translocation of NF kappa B/p50.
C1 [Chen, Honglin; Shen, Gengyang; Yu, Die; Yu, Xiang; Zhang, Zhida; Liang, De; Jiang, Xiaobing; Ren, Hui] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510405, Peoples R China.
   [Shang, Qi; Zhang, Peng; Zhang, Zhida; Zhao, Wenhua; Wu, Zixian] Guangzhou Univ Chinese Med, Guangzhou 510405, Peoples R China.
   [Chen, Honglin; Shen, Gengyang; Shang, Qi; Zhang, Peng; Yu, Die; Yu, Xiang; Zhang, Zhida; Zhao, Wenhua; Wu, Zixian; Jiang, Xiaobing; Ren, Hui] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou 510405, Peoples R China.
   [Tang, Fuyu] Liuzhou Hosp Zhuang Med, Liuzhou Hosp Chinese Med, Liuzhou 545000, Guangxi Zhuang, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine
RP Jiang, XB; Ren, H (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510405, Peoples R China.
EM spinedrjxb@sina.com; renhuispine@163.com
RI Zhida, Zhang/HME 3183 2023; Zhang, Peng/IZP 9286 2023
OI Chen, Honglin/0000 0001 7300 5345; Shang, Qi/0000 0001 9135 2666; Zhang,
   Peng/0000 0003 1777 3790; Shen, Gengyang/0000 0001 8940 7912
FU National Natural Science Foundation of China [81904225, 81774338,
   81674000]; Natural Science Foundation of Guangdong Province
   [2018A030310615]; Guangdong Province Universities and Colleges Pearl
   River Scholar Funded Scheme (2018); Guangxi Natural Science Foundation
   Project [2020GXNSFAA259082]; Scientific Research Project of Guangdong
   Traditional Chinese Medicine Bureau [20191107]; Key Project of Basic
   Research and Applied Basic Research of Department of Education of
   Guangdong Province [2018KZDXM021, 2018KTSCX041]; youth scientific
   research training project of GZUCM [2019QNPY04]; Special Research
   Project for the Construction of the National TCM Clinical Research Base
   of the State Administration of Traditional Chinese Medicine [JDZ
   X2015078]
FX This work was supported by the following grants: National Natural
   Science Foundation of China (81904225, 81774338, 81674000), Natural
   Science Foundation of Guangdong Province (2018A030310615), Guangdong
   Province Universities and Colleges Pearl River Scholar Funded Scheme
   (2018), Guangxi Natural Science Foundation Project (2020GXNSFAA259082),
   Scientific Research Project of Guangdong Traditional Chinese Medicine
   Bureau (20191107), Key Project of Basic Research and Applied Basic
   Research of Department of Education of Guangdong Province (2018KZDXM021,
   2018KTSCX041), The youth scientific research training project of GZUCM
   (2019QNPY04), Special Research Project for the Construction of the
   National TCM Clinical Research Base of the State Administration of
   Traditional Chinese Medicine (JDZ X2015078).
CR Barbezier N, 2014, ANN BIOL CLIN PARIS, V72, P669, DOI 10.1684/abc.2014.1010
   Bernal GM, 2014, AGING US, V6, P931, DOI 10.18632/aging.100702
   Bernard NJ, 2019, NAT REV RHEUMATOL, V15, P128, DOI 10.1038/s41584 019 0181 2
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao QH, 2018, J EXP MED, V215, P1679, DOI 10.1084/jem.20172048
   Ciapetti G, 2017, ACTA BIOMATER, V50, P102, DOI 10.1016/j.actbio.2016.12.013
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Datta NS, 2011, WORLD J ORTHOP, V2, P67, DOI 10.5312/wjo.v2.i8.67
   Forman K, 2016, EXP GERONTOL, V73, P114, DOI 10.1016/j.exger.2015.11.005
   Guo MZ, 2019, FOOD FUNCT, V10, P4792, DOI [10.1039/C9FO00201D, 10.1039/c9fo00201d]
   Jeong E, 2018, CELL DEATH DIFFER, V25, P1364, DOI 10.1038/s41418 017 0048 5
   Jurk D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5172
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kurotaki D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115471
   Leong I, 2018, NAT REV ENDOCRINOL, V14, P379, DOI 10.1038/s41574 018 0036 y
   Li XN, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.593832
   Liang D, 2016, BIOMED PHARMACOTHER, V82, P151, DOI 10.1016/j.biopha.2016.04.068
   Lin X, 2015, CLIN INTERV AGING, V10, P1017, DOI 10.2147/CIA.S54613
   Liu ZX, 2019, NATURE, V568, P249, DOI 10.1038/s41586 019 1041 6
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Ma JD, 2019, ARTHRITIS RHEUMATOL, V71, P1252, DOI 10.1002/art.40868
   Meng J, 2017, REDOX BIOL, V11, P365, DOI 10.1016/j.redox.2016.12.026
   Min SK, 2018, CELL DEATH DIFFER, V25, P268, DOI 10.1038/cdd.2017.153
   Nandy A, 2018, CELL REP, V25, P2110, DOI 10.1016/j.celrep.2018.10.076
   Nighot M, 2019, AM J PATHOL, V189, P797, DOI 10.1016/j.ajpath.2018.12.016
   Nowotny K, 2015, BIOMOLECULES, V5, P194, DOI 10.3390/biom5010194
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Qamar H, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120784
   Ren H, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10614 5
   Shang Q, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/6815620
   Shen GY, 2018, CELL PHYSIOL BIOCHEM, V47, P2307, DOI 10.1159/000491541
   Shen GY, 2020, THERANOSTICS, V10, P4334, DOI 10.7150/thno.42982
   Su SY, 2019, INFLAMMOPHARMACOLOGY, V27, P77, DOI 10.1007/s10787 018 0521 x
   Taetzsch T, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974 019 1446 z
   Tilstra JS, 2012, J CLIN INVEST, V122, P2601, DOI 10.1172/JCI45785
   Usategui Martín R, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115477
   Walsh MC, 2015, IMMUNOL REV, V266, P72, DOI 10.1111/imr.12302
   Yamakawa T, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115494
   Yano T, 2020, J SHOULDER ELB SURG, V29, P1884, DOI 10.1016/j.jse.2020.01.076
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
   Zhang L, 2019, METHODS MOL BIOL, V1896, P231, DOI 10.1007/978 1 4939 8931 7_18
NR 41
TC 14
Z9 23
U1 0
U2 38
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD AUG 10
PY 2021
VL 276
AR 114195
DI 10.1016/j.jep.2021.114195
EA MAY 2021
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA SQ3JF
UT WOS:000660251400005
PM 33974944
DA 2025 08 17
ER

PT J
AU Xie, YL
   Sun, WC
   Yan, FF
   Liu, HW
   Deng, ZM
   Cai, L
AF Xie, Yuanlong
   Sun, Wenchao
   Yan, Feifei
   Liu, Huowen
   Deng, Zhouming
   Cai, Lin
TI Icariin loaded porous scaffolds for bone regeneration through the
   regulation of the coupling process of osteogenesis and osteoclastic
   activity
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE icariin; bone regeneration; osteogenesis; osteoclastic activity; drug
   delivery
ID DELIVERY SYSTEMS; STEM CELLS; IN VITRO; TISSUE; DIFFERENTIATION;
   PROLIFERATION; MINERALIZATION; BIOMATERIALS; COMPOSITES; SUBMUCOSA
AB Objective: Icariin (IC) promotes osteogenic differentiation, and it may be a potential small molecule drug for local application in bone regeneration. Icariin loaded hydroxyapatite/alginate (IC/HAA) porous composite scaffolds were designed in this study for the potential application of the sustainable release of icariin and subsequent bone regeneration.
   Methods: An icariin loaded hydroxyapatite/alginate porous composite scaffold was prepared and characterized by SEM and HPLC for morphology and release behavior, respectively. The mechanical properties, degradation in PBS and cytotoxicity on BMSCs were also evaluated by MTT assay, compression strength and calculation of weight remaining ratio, respectively. Rabbit BMSCs were cocultured with IC/HAA scaffolds, and ALP activity and Alizarin Red staining were performed to evaluate osteogenic differentiation induction. The mRNA and protein expression level of an osteogenic gene was detected by RT PCR and Western blotting, respectively. In vivo animal models of critical bone defects in the radius of rabbit were used. Four and 12 weeks after the implantation of IC/HAA scaffolds in the bone defect, radiographic images of the radius were obtained and scored by using the Lane and Sandhu X ray scoring system. Tissue samples were also evaluated using H&E and Masson staining, and an osteogenic gene and Wnt signaling pathway genes were detected.
   Results: A hydroxyapatite/alginate (HAA) porous composite scaffold loaded icariin was fabricated using a freeze drying method. Our data indicated that the icariin was loaded in alginate scaffold without compromising the macro/microstructure or mechanical properties of the scaffold. Notably, the IC/HAA promoted the proliferation of rBMSCs without exerting cytotoxicity on rBMSCs. In vivo, rabbit radius bone defect experiments demonstrated that the IC/HAA scaffold exhibited better capacity for bone regeneration than HAA, and IC/HAA upregulated the relative expression levels of an osteogenic gene and the Wnt signaling pathway genes. Most notably, the IC/HAA scaffold also inhibited osteoclast activity in vivo.
   Conclusion: Our data suggests a promising application for the use of HAA scaffolds to load icariin and promote bone regeneration in situ through mediation of the coupling processes of osteogenesis induction and osteoclast activity inhibition.
C1 [Xie, Yuanlong; Yan, Feifei; Liu, Huowen; Deng, Zhouming; Cai, Lin] Wuhan Univ, Zhongnan Hosp, Dept Spine Surg & Musculoskeletal Tumor, 169 Donghu Rd, Wuhan, Hubei, Peoples R China.
   [Sun, Wenchao] Wuhan Fourth Hosp, Dept Pain Management, Wuhan, Hubei, Peoples R China.
C3 Wuhan University
RP Cai, L (通讯作者)，Wuhan Univ, Zhongnan Hosp, Dept Spine Surg & Musculoskeletal Tumor, 169 Donghu Rd, Wuhan, Hubei, Peoples R China.
EM orthopedics@whu.edu.cn
RI ; Yan, Feifei/GRX 6364 2022; Xie, Yuanlong/V 7190 2019; Sun,
   Wenchao/H 7738 2017
OI Cai, Lin/0000 0003 3126 6429; 
FU Science and Technology Innovation Team Training Plan of the Wuhan
   Science and Technology Foundation [2015070504020231]; Breeding Key
   Project of Research and Development Plan of the Zhongnan Hospital of
   Wuhan University [znpy2016060]; Health Care of Yellow Crane Talent Plan
   of Wuhan City [17]
FX This study was funded by the Science and Technology Innovation Team
   Training Plan of the Wuhan Science and Technology Foundation (Grant No.
   2015070504020231), the Breeding Key Project of Research and Development
   Plan of the Zhongnan Hospital of Wuhan University (Grant No.
   znpy2016060) and Health Care of Yellow Crane Talent Plan of Wuhan City
   (Grant No. 17). The authors declare no competing financial interests.
CR Balmayor ER, 2016, BIOMATERIALS, V87, P131, DOI 10.1016/j.biomaterials.2016.02.018
   Choi S, 2019, BIOMATERIALS, V198, P95, DOI 10.1016/j.biomaterials.2018.05.002
   Ciriza J, 2018, DRUG DELIV, V25, P1147, DOI 10.1080/10717544.2018.1474966
   de Almeida AD, 2018, J BIOMED MATER RES B, V106, P1799, DOI 10.1002/jbm.b.33995
   Didier P, 2017, MAT SCI ENG C MATER, V74, P399, DOI 10.1016/j.msec.2016.12.031
   El Bialy I, 2017, PHARM RES DORDR, V34, P1152, DOI 10.1007/s11095 017 2147 x
   Elgali I, 2017, EUR J ORAL SCI, V125, P315, DOI 10.1111/eos.12364
   Ghassemi T, 2018, ARCH BONE JT SURG AB, V6, P90
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Kolmas J, 2017, INT J NANOMED, V12, P5633, DOI 10.2147/IJN.S140935
   Lai YX, 2018, BIOMATERIALS, V153, P1, DOI 10.1016/j.biomaterials.2017.10.025
   LANE JM, 1987, ORTHOP CLIN N AM, V18, P213
   Li DH, 2018, BIOMED MATER, V13, DOI 10.1088/1748 605X/aac627
   Li M, 2017, ANN BIOMED ENG, V45, P2673, DOI 10.1007/s10439 017 1900 y
   Li M, 2017, MAT SCI ENG C MATER, V71, P260, DOI 10.1016/j.msec.2016.10.016
   Lin HR, 2004, J BIOMED MATER RES B, V71B, P52, DOI 10.1002/b.30065
   Liu YJ, 2017, CELL PHYSIOL BIOCHEM, V41, P1605, DOI 10.1159/000470896
   Ma BJ, 2018, ACTA BIOMATER, V71, P108, DOI 10.1016/j.actbio.2018.02.033
   Martin V, 2018, MAT SCI ENG C MATER, V82, P363, DOI 10.1016/j.msec.2017.04.038
   Noori A, 2017, INT J NANOMED, V12, P4937, DOI 10.2147/IJN.S124671
   Oh SH, 2007, BIOMATERIALS, V28, P1664, DOI 10.1016/j.biomaterials.2006.11.024
   Polo Corrales L, 2014, J NANOSCI NANOTECHNO, V14, P15, DOI 10.1166/jnn.2014.9127
   Qin SY, 2015, INT J CLIN EXP MED, V8, P7125
   Raftery RM, 2017, BIOMATERIALS, V149, P116, DOI 10.1016/j.biomaterials.2017.09.036
   Ren XX, 2018, LANGMUIR, V34, P6797, DOI 10.1021/acs.langmuir.8b00151
   Reynolds JJ, 2016, SPINE, V41, pS199, DOI 10.1097/BRS.0000000000001834
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   van Griensven M, 2015, ADV DRUG DELIVER REV, V94, P151, DOI 10.1016/j.addr.2015.07.006
   Venkatesan J, 2015, INT J BIOL MACROMOL, V72, P269, DOI 10.1016/j.ijbiomac.2014.07.008
   Wang Q, 2017, INT J NANOMED, V12, P7721, DOI 10.2147/IJN.S141052
   Wang WH, 2017, BIOACT MATER, V2, P224, DOI 10.1016/j.bioactmat.2017.05.007
   Wang YC, 2018, EUR J PHARM BIOPHARM, V127, P223, DOI 10.1016/j.ejpb.2018.02.023
   Wang Z, 2018, OSTEOPOROSIS INT, V29, P535, DOI 10.1007/s00198 017 4255 1
   Wu JZ, 2018, CELL PHYSIOL BIOCHEM, V46, P1727, DOI 10.1159/000489248
   Xie YL, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13353 9
   Zhai YK, 2014, BONE, V66, P189, DOI 10.1016/j.bone.2014.06.016
   Zhang X, 2011, J MATER SCI MATER M, V22, P371, DOI 10.1007/s10856 010 4198 y
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
   Zhao JY, 2010, TISSUE ENG PT A, V16, P233, DOI [10.1089/ten.tea.2009.0165, 10.1089/ten.TEA.2009.0165]
   Zhou J, 2010, BIOMATERIALS, V31, P1171, DOI 10.1016/j.biomaterials.2009.10.043
NR 40
TC 43
Z9 48
U1 1
U2 45
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2019
VL 14
BP 6019
EP 6033
DI 10.2147/IJN.S203859
PG 15
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA IM5UX
UT WOS:000478060400001
PM 31534334
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Triplett, J
   Vijayan, S
   Prince, R
   Kermode, A
AF Triplett, James
   Vijayan, Srimathy
   Prince, Richard
   Kermode, Allan
TI Dimethyl fumarate associated transient bone marrow oedema syndrome
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE Dimethyl fumarate; multiple sclerosis; bone marrow oedema
ID DENSITY
AB Background: Dimethyl fumarate (DMF) is a commonly used and effective treatment for relapsing and remitting multiple sclerosis. Its use results in impairment of the transcription factor nuclear factor erythroid derived 2 (E2) related factor (Nrf2), which is involved in both immunomodulation and bone health. DMF has not previously been reported to cause bone marrow complications, though other fumarates including tenofovir have. The mechanism of fumarate associated bone toxicity remains unclear with altered osteoblastic gene expression and function suggested. Methods: We present a case of a 54 year old female with relapsing remitting multiple sclerosis (RRMS) treated for 30 months with DMF who developed relapsing atraumatic lower limb bone pain. Results: Serial imaging revealed multifocal areas of bone marrow oedema and trabecular fractures. The patient was diagnosed with transient bone marrow oedema syndrome. Management consisted of cessation of therapy and treatment with the pro osteobalstic agent denosumab. Conclusion: In this instance of DMF associated bone marrow oedema, cessation of DMF and treatment with denosumab resulted in symptomatic improvement. DMF therapy may potentially result in bone marrow oedema due to inhibition of common upstream signalling pathways, including the Nrf2 signalling pathway.
C1 [Triplett, James; Vijayan, Srimathy; Kermode, Allan] Sir Charles Gairdner Hosp, Dept Neurol, Hosp Ave, Nedlands, WA 6010, Australia.
   [Prince, Richard; Kermode, Allan] Univ Western Australia, Fac Med, Perth, WA, Australia.
   [Prince, Richard] Sir Charles Gairdner Hosp, Dept Endocrinol, Nedlands, WA, Australia.
   [Kermode, Allan] Perron Inst Neurol & Translat Sci, Ctr Neuromuscular & Neurol Disorders, Perth, WA, Australia.
   [Kermode, Allan] Murdoch Univ, Inst Immunol & Infect Dis, Perth, WA, Australia.
C3 University of Western Australia; Sir Charles Gairdner Hospital;
   University of Western Australia; Sir Charles Gairdner Hospital;
   University of Western Australia; Perron Institute for Neurological &
   Translational Science; Murdoch University
RP Kermode, A (通讯作者)，Sir Charles Gairdner Hosp, Dept Neurol, Hosp Ave, Nedlands, WA 6010, Australia.
EM allan.kermode@uwa.edu.au
RI ; Kermode, Allan/G 3568 2019
OI Triplett, James/0000 0001 9402 1248; Kermode, Allan/0000 0002 4476 4016
CR Gill US, 2015, J INFECT DIS, V211, P374, DOI 10.1093/infdis/jiu471
   Grigsby IF, 2010, THER CLIN RISK MANAG, V6, P41
   Linker RA, 2016, THER ADV CHRONIC DIS, V7, P198, DOI 10.1177/2040622316653307
   Patel S, 2014, RHEUMATOLOGY, V53, P785, DOI 10.1093/rheumatology/ket324
   Radmer S, 2017, CALCIF TISSUE INT S1, V100, P132
   Rolvien T, 2017, INJURY, V48, P874, DOI 10.1016/j.injury.2017.02.020
   Starr AM, 2008, ACTA RADIOL, V49, P771, DOI 10.1080/02841850802161023
   Vera JH, 2012, INT J STD AIDS, V23, P213, DOI [10.1258/ijsa.2009.009358, 10.1258/ijsa.2009.009393]
   Zhao GZ, 2014, BIOCHEM BIOPH RES CO, V448, P303, DOI 10.1016/j.bbrc.2014.02.062
NR 9
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352 4585
EI 1477 0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD MAY
PY 2019
VL 25
IS 6
BP 876
EP 879
DI 10.1177/1352458518791132
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA HT2TS
UT WOS:000464416800016
PM 30051766
DA 2025 08 17
ER

PT J
AU Westermann, LM
   Baranowsky, A
   Di Lorenzo, G
   Danyukova, T
   Soul, J
   Schwartz, JM
   Hendrickx, G
   Amling, M
   Rose John, S
   Garbers, C
   Schinke, T
   Pohl, S
AF Westermann, Lena Marie
   Baranowsky, Anke
   Di Lorenzo, Giorgia
   Danyukova, Tatyana
   Soul, Jamie
   Schwartz, Jean Marc
   Hendrickx, Gretl
   Amling, Michael
   Rose John, Stefan
   Garbers, Christoph
   Schinke, Thorsten
   Pohl, Sandra
TI Transgenic inhibition of interleukin 6 trans signaling does not
   prevent skeletal pathologies in mucolipidosis type II mice
SO SCIENTIFIC REPORTS
LA English
DT Article
AB Severe skeletal alterations are common symptoms in patients with mucolipidosis type II (MLII), a rare lysosomal storage disorder of childhood. We have previously reported that progressive bone loss in a mouse model for MLII is caused by an increased number of bone resorbing osteoclasts, which is accompanied by elevated expression of the cytokine interleukin 6 (IL 6) in the bone microenvironment. In the present study we addressed the question, if pharmacological blockade of IL 6 can prevent the low bone mass phenotype of MLII mice. Since the cellular IL 6 response can be mediated by either the membrane bound (classic signaling) or the soluble IL 6 receptor (trans signaling), we first performed cell culture assays and found that both pathways can increase osteoclastogenesis. We then crossed MLII mice with transgenic mice expressing the recombinant soluble fusion protein sgp130Fc, which represents a natural inhibitor of IL 6 trans signaling. By undecalcified histology and bone specific histomorphometry we found that high circulating sgp130Fc levels do not affect skeletal growth or remodeling in wild type mice. Most importantly, blockade of IL 6 trans signaling did neither reduce osteoclastogenesis, nor increase bone mass in MLII mice. Therefore, our data clearly demonstrate that the bone phenotype of MLII mice cannot be corrected by blocking the IL 6 trans signaling.
C1 [Westermann, Lena Marie; Di Lorenzo, Giorgia; Danyukova, Tatyana; Hendrickx, Gretl; Amling, Michael; Schinke, Thorsten; Pohl, Sandra] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
   [Baranowsky, Anke] Univ Med Ctr Hamburg Eppendorf, Clin Trauma & Orthoped Surg, D 20246 Hamburg, Germany.
   [Soul, Jamie] Newcastle Univ, Biosci Inst, Skeletal Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Schwartz, Jean Marc] Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Manchester M13 9PL, Lancs, England.
   [Rose John, Stefan] Christian Albrechts Univ Kiel, Inst Biochem, D 24098 Kiel, Germany.
   [Garbers, Christoph] Otto von Guericke Univ, Dept Pathol, D 39120 Magdeburg, Germany.
   [Di Lorenzo, Giorgia] Telethon Inst Genet & Med TIGEM, I 80078 Pozzuoli, Italy.
   [Hendrickx, Gretl] Antwerp Univ Hosp, Ctr Med Genet, B 2610 Edegem, Belgium.
   [Hendrickx, Gretl] Univ Antwerp, B 2610 Edegem, Belgium.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   Newcastle University   UK; University of Manchester; University of Kiel;
   Otto von Guericke University; Fondazione Telethon; Telethon Institute of
   Genetics & Medicine (TIGEM); University of Antwerp; University of
   Antwerp
RP Pohl, S (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
EM s.pohl@uke.de
RI Garbers, Christoph/D 9932 2015; Rose John, Stefan/A 7998 2010; Pohl,
   Sandra/AAF 1943 2020; Schwartz, Jean Marc/AAS 8274 2020; Hendrickx,
   Gretl/HHC 1170 2022; Danyukova, Tatyana/AAB 2364 2021
OI Garbers, Christoph/0000 0003 4939 6950; Schwartz,
   Jean Marc/0000 0002 6472 0184; Danyukova, Tatyana/0000 0002 5449 3635;
   Hendrickx, Gretl/0000 0001 6715 9241; Di Lorenzo,
   Giorgia/0000 0001 8659 5268; 
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Adebanjo OA, 1998, J CELL BIOL, V142, P1347, DOI 10.1083/jcb.142.5.1347
   Blair HC, 2005, BIOCHEM BIOPH RES CO, V328, P728, DOI 10.1016/j.bbrc.2004.11.077
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brylka LJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02182
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Danks L, 2011, J BONE MINER RES, V26, P182, DOI 10.1002/jbmr.210
   De Benedetti F, 2009, HORM RES, V72, P26, DOI 10.1159/000229760
   De Benedetti F, 2006, ARTHRITIS RHEUM, V54, P3551, DOI 10.1002/art.22175
   Di Lorenzo G, 2018, MOL CELL PROTEOMICS, V17, P1612, DOI 10.1074/mcp.RA118.000720
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Feng W, 2017, SCI REP UK, V7, DOI 10.1038/srep41411
   Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297 142
   Gao Y, 1998, BONE, V22, P487, DOI 10.1016/S8756 3282(98)00040 4
   Grano M, 2002, CALCIFIED TISSUE INT, V70, P176, DOI 10.1007/s00223 001 2034 6
   He BR, 2020, CAN J PHYSIOL PHARM, V98, P678, DOI 10.1139/cjpp 2019 0632
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Kauffmann Audrey, 2009, Bioinformatics, V25, P415, DOI 10.1093/bioinformatics/btn647
   Kollmann K, 2012, BRAIN, V135, P2661, DOI 10.1093/brain/aws209
   Kollmann K, 2013, EMBO MOL MED, V5, P1871, DOI 10.1002/emmm.201302979
   Kollmann K, 2010, EUR J CELL BIOL, V89, P117, DOI 10.1016/j.ejcb.2009.10.008
   Kotake S, 1996, J BONE MINER RES, V11, P88
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   KURIHARA N, 1990, J IMMUNOL, V144, P4226
   Langub MC, 1996, KIDNEY INT, V50, P515, DOI 10.1038/ki.1996.343
   Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161
   Liu X, 2016, CURR OPIN RHEUMATOL, V28, P152, DOI 10.1097/BOR.0000000000000255
   MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021
   Marschner K, 2011, SCIENCE, V333, P87, DOI 10.1126/science.1205677
   McGregor NE, 2019, J BIOL CHEM, V294, P7850, DOI 10.1074/jbc.RA119.008074
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pohl S, 2018, J BONE MINER RES, V33, P2186, DOI 10.1002/jbmr.3563
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Rabe B, 2008, BLOOD, V111, P1021, DOI 10.1182/blood 2007 07 102137
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581
   Rose John S, 2012, INT J BIOL SCI, V8, P1237, DOI 10.7150/ijbs.4989
   Saftig P, 1997, J BIOL CHEM, V272, P18628, DOI 10.1074/jbc.272.30.18628
   Schaper F, 2015, CYTOKINE GROWTH F R, V26, P475, DOI 10.1016/j.cytogfr.2015.07.004
   Scheidt Nave C, 2001, J CLIN ENDOCR METAB, V86, P2032, DOI 10.1210/jc.86.5.2032
   Scheller J, 2014, SEMIN IMMUNOL, V26, P2, DOI 10.1016/j.smim.2013.11.002
   Schinke T, 2008, BONE, V42, P524, DOI 10.1016/j.bone.2007.11.009
   Schmidt Arras D, 2016, J HEPATOL, V64, P1403, DOI 10.1016/j.jhep.2016.02.004
   Schroers A, 2005, PROTEIN SCI, V14, P783, DOI 10.1110/ps.041117105
   Schulze J, 2011, J BONE MINER RES, V26, P704, DOI 10.1002/jbmr.269
   Sims NA, 2016, INT J BIOCHEM CELL B, V79, P14, DOI 10.1016/j.biocel.2016.08.003
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Teramachi J, 2014, J BONE MINER RES, V29, P1456, DOI 10.1002/jbmr.2158
   Teufel S, 2014, J IMMUNOL, V193, P223, DOI 10.4049/jimmunol.1302713
   Tiede S, 2005, NAT MED, V11, P1109, DOI 10.1038/nm1305
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   Velho RV, 2019, HUM MUTAT, V40, P842, DOI 10.1002/humu.23748
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 2 r14
NR 56
TC 1
Z9 1
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD FEB 11
PY 2021
VL 11
IS 1
AR 3556
DI 10.1038/s41598 021 82802 3
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA QT6UT
UT WOS:000626725100003
PM 33574442
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bennett, CN
   Longo, KA
   Wright, WS
   Suva, LJ
   Lane, TF
   Hankenson, KD
   MacDougald, OA
AF Bennett, CN
   Longo, KA
   Wright, WS
   Suva, LJ
   Lane, TF
   Hankenson, KD
   MacDougald, OA
TI Regulation of osteoblastogenesis and bone mass by Wnt10b
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE adipogenesis; development; stem cells
ID RECEPTOR RELATED PROTEIN 5; BETA CATENIN; C/EBP ALPHA; GENE EXPRESSION;
   PPAR GAMMA; ADIPOGENESIS; DIFFERENTIATION; MARROW; MICE; CELLS
AB Writs comprise a family of secreted signaling proteins that regulate diverse developmental processes. Activation of Writ signaling by Wnt10b inhibits differentiation of preadipocytes and blocks adipose tissue development; however, the effect of Wnt10b on other mesenchymal lineages has not been defined. To explore the physiological role of Writ signaling in bone development, we analyzed FABP4 Wnt10b mice, which express the Wnt10b transgene in marrow. Femurs from FABP4 Wnt10b mice have almost four times as much bone in the distal metaphyses and are mechanically stronger. These mice maintain elevated bone mass at least through 23 months of age. In addition, FABP4 Wnt10b mice are protected from the bone loss characteristic of estrogen deficiency. We used pharmacological and genetic approaches to demonstrate that canonical Wnt signaling stimulates osteoblastogenesis and inhibits adipogenesis of bipotential mesenchymal precursors. Wnt10b shifts cell fate toward the osteoblast lineage by induction of the osteoblastogenic transcription factors Runx2, DIx5, and osterix and suppression of the adipogenic transcription factors C/EBPalpha and PPARgamma. One mechanism whereby Wnt10b promotes osteoblastogenesis is suppression of PPARgamma expression. Finally, Wnt10b /  mice have decreased trabecular bone and serum osteocalcin, confirming that Wnt10b is an endogenous regulator of bone formation.
C1 Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Sch Med, Dept Orthoped Surg, Ann Arbor, MI 48109 USA.
   Univ Arkansas Med Sci, Dept Orthopaed Surg, Ctr Orthopaed Res, Little Rock, AR 72205 USA.
   Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Arkansas System;
   University of Arkansas Medical Sciences; UCLA Jonsson Comprehensive
   Cancer Center; University of California System; University of California
   Los Angeles
RP MacDougald, OA (通讯作者)，Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
EM macdouga@umich.edu
RI MacDougald, Ormond/HTL 2168 2023; Longo, Kenneth/A 5631 2010; Hankenson,
   Kurt/ABI 1547 2020
OI Hankenson, Kurt/0000 0001 6361 143X; Hahn, Wendy/0000 0002 4374 5876;
   MacDougald, Ormond/0000 0001 6907 7960; Suva, Larry/0000 0002 2892 9757;
   Lane, Timothy F./0000 0002 0210 970X
FU National Institute of Dental and Craniofacial Research [T32DE007057]
   Funding Source: NIH RePORTER; NCRR NIH HHS [K01 RR000161, RR00161]
   Funding Source: Medline; NIAMS NIH HHS [P30 AR046024, P30AR046024,
   AR49682, R01 AR049682] Funding Source: Medline; NIDCR NIH HHS [T32
   DE007057, DE07057] Funding Source: Medline; NIDDK NIH HHS [R01 DK051563,
   P60 DK020572, P60 DK20572, N02 DK062876, DK51563] Funding Source:
   Medline
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   BILLS CE, 1971, JOHNS HOPKINS MED J, V128, P194
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200
   Cock TA, 2004, EMBO REP, V5, P1007, DOI 10.1038/sj.embor.7400254
   Derfoul A, 2004, DIFFERENTIATION, V72, P209, DOI 10.1111/j.1432 0436.2004.07205003.x
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hankenson KD, 2000, J BONE MINER RES, V15, P851, DOI 10.1359/jbmr.2000.15.5.851
   Hankenson KD, 2002, J BONE MINER RES, V17, P415, DOI 10.1359/jbmr.2002.17.3.415
   Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913
   Howe LR, 2003, CANCER RES, V63, P1906
   Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200
   Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200
   Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772
   Kang S, 2005, MOL CELL BIOL, V25, P1272, DOI 10.1128/MCB.25.4.1272 1282.2005
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kennell JA, 2003, MOL CELL BIOL, V23, P5366, DOI 10.1128/MCB.23.15.5366 5375.2003
   Kitagaki J, 2003, OSTEOARTHR CARTILAGE, V11, P36, DOI 10.1053/joca.2002.0863
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200
   Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200
   Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756 3282(00)00317 3
   Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074 7613(00)00004 2
   Rosen ED, 2000, GENE DEV, V14, P1293
   Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Tadic T, 2002, J BONE MINER RES, V17, P1008, DOI 10.1359/jbmr.2002.17.6.1008
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
NR 41
TC 736
Z9 904
U1 1
U2 64
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 1
PY 2005
VL 102
IS 9
BP 3324
EP 3329
DI 10.1073/pnas.0408742102
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 903KC
UT WOS:000227423700030
PM 15728361
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Rosner, MH
   Dalkin, AC
AF Rosner, Mitchell H.
   Dalkin, Alan C.
TI Onco Nephrology: The Pathophysiology and Treatment of
   Malignancy Associated Hypercalcemia
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID HORMONE RELATED PROTEIN; PHASE II TRIAL; PARATHYROID HORMONE;
   DOUBLE BLIND; GALLIUM NITRATE; ZOLEDRONIC ACID; BONE RESORPTION;
   BREAST CANCER; SKELETAL METASTASES; LUNG CANCER
AB Hypercalcemia complicates the course of 10% 30% of all patients with malignancies and can be a sign of very poor prognosis and advanced malignancy. Prompt recognition of the nonspecific signs and symptoms of hypercalcemia and institution of therapy can be lifesaving, affording the opportunity to address the underlying etiology. The mechanisms of malignancy associated hypercalcemia generally fall into three categories: humoral hypercalcemia due to secreted factors (such as parathyroid related hormone), local osteolysis due to tumor invasion of bone, and absorptive hypercalcemia due to excess vitamin D produced by malignancies. The mainstays of therapy for hypercalcemia are aggressive intravenous volume expansion with saline, bisphosphonate therapy, and perhaps loop diuretics. Adjunctive therapy may include calcitonin and corticosteroids. In refractory cases, gallium nitrate and perhaps denosumab are alternatives. In patients presenting with severe AKI, hemodialysis with a low calcium bath can be effective. In most cases, therapy normalizes calcium levels and allows for palliation or curative therapy of the malignancy. Clin J Am Soc Nephrol 7: 1722 1729, 2012. doi: 10.2215/CJN.02470312
C1 [Rosner, Mitchell H.] Univ Virginia Hlth Syst, Div Nephrol, Charlottesville, VA 22908 USA.
   [Dalkin, Alan C.] Univ Virginia Hlth Syst, Div Endocrinol, Charlottesville, VA 22908 USA.
C3 University of Virginia; University of Virginia (UVA) Health System;
   University of Virginia; University of Virginia (UVA) Health System
RP Rosner, MH (通讯作者)，Univ Virginia Hlth Syst, Div Nephrol, Box 800133, Charlottesville, VA 22908 USA.
EM mhr9r@virginia.edu
CR Abildgaard N, 2004, HAEMATOLOGICA, V89, P567
   ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   American Dental Association Council on Scientific Affairs, 2006, J Am Dent Assoc, V137, P1144
   AMIN D, 1992, J LIPID RES, V33, P1657
   [Anonymous], 2007, J Am Dent Assoc, V138, P692
   [Anonymous], EUR MULT CANC C STOC
   [Anonymous], FDA REP
   [Anonymous], 53 AM SOC HEN ANN M
   ARGILES A, 1993, KIDNEY INT, V43, P630, DOI 10.1038/ki.1993.92
   Barri YM, 2004, KIDNEY INT, V65, P634, DOI 10.1111/j.1523 1755.2004.00426.x
   Bergner R, 2005, CANCER TREAT REV, V31, pS45
   BILEZIKIAN JP, 1992, NEW ENGL J MED, V326, P1196
   BOCKMAN R S, 1991, Seminars in Oncology, V18, P21
   Bodmer M, 2007, NEPHROL DIAL TRANSPL, V22, P2366, DOI 10.1093/ndt/gfm209
   Body JJ, 2006, EUR J CANCER CARE, V15, P299, DOI 10.1111/j.1365 2354.2005.00641.x
   Body JJ, 1999, J BONE MINER RES, V14, P1557, DOI 10.1359/jbmr.1999.14.9.1557
   BURT ME, 1980, ARCH SURG CHICAGO, V115, P704, DOI 10.1001/archsurg.1980.01380060012004
   Carneiro E, 2006, AM J NEURORADIOL, V27, P1096
   Carter GD, 2003, AUST DENT J, V48, P268
   Castellano D, 2011, ONCOLOGIST, V16, P136, DOI 10.1634/theoncologist.2010 0154
   Castelli I, 1996, J SURG RES, V61, P51, DOI 10.1006/jsre.1996.0080
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Clines GA, 2011, CURR OPIN ENDOCRINOL, V18, P339, DOI 10.1097/MED.0b013e32834b4401
   Cvitkovic FR, 2006, CANCER J, V12, P47, DOI 10.1097/00130404 200601000 00009
   Davidson TG, 2001, AM J HEALTH SYST PH, V58, pS8, DOI 10.1093/ajhp/58.suppl_3.S8
   Desikan R, 2002, BRIT J HAEMATOL, V119, P496, DOI 10.1046/j.1365 2141.2002.03826.x
   DODWELL DJ, 1992, POSTGRAD MED J, V68, P434, DOI 10.1136/pgmj.68.800.434
   EDELSON GW, 1995, MED CLIN N AM, V79, P79, DOI 10.1016/S0025 7125(16)30085 2
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   GRILL V, 1991, J CLIN ENDOCR METAB, V73, P1309, DOI 10.1210/jcem 73 6 1309
   GURNEY H, 1993, LANCET, V341, P1611, DOI 10.1016/0140 6736(93)90756 7
   HALL TJ, 1990, BONE MINER, V8, P211, DOI 10.1016/0169 6009(90)90106 P
   Hatake K, 1997, INT J HEMATOL, V66, P13
   Hebert S C, 1996, Curr Opin Nephrol Hypertens, V5, P45, DOI 10.1097/00041552 199601000 00009
   Heidenreich A, 2002, PROSTATE CANCER P D, V5, P231, DOI 10.1038/sj.pcan.4500574
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hiroi Furuya E, 1999, CALCIFIED TISSUE INT, V64, P219, DOI 10.1007/s002239900606
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Huang CLH, 2006, CELL MOL BIOL, V52, P33
   Iguchi H, 1998, J CLIN ENDOCR METAB, V83, P2653, DOI 10.1210/jc.83.8.2653
   Ijaz Aamir, 2006, J Coll Physicians Surg Pak, V16, P49
   Kacprowicz RF, 2010, HEMATOL ONCOL CLIN N, V24, P553, DOI 10.1016/j.hoc.2010.03.007
   Khanna A, 2006, SEMIN NEPHROL, V26, P244, DOI 10.1016/j.semnephrol.2006.03.004
   Kindgen Milles D, 2008, ASAIO J, V54, P442, DOI 10.1097/MAT.0b013e31817dc3be
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Labriola L, 2009, NEPHROL DIAL TRANSPL, V24, P1834, DOI 10.1093/ndt/gfn747
   LeGrand SB, 2008, ANN INTERN MED, V149, P259, DOI 10.7326/0003 4819 149 4 200808190 00007
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Markowitz GS, 2003, KIDNEY INT, V64, P281, DOI 10.1046/j.1523 1755.2003.00071.x
   Markowitz GS, 2002, AM J KIDNEY DIS, V39, P1118, DOI 10.1053/ajkd.2002.32797
   Markowitz GS, 2001, J AM SOC NEPHROL, V12, P1164, DOI 10.1681/ASN.V1261164
   Mathur Mudit, 2003, Pediatr Crit Care Med, V4, P252, DOI 10.1097/01.PCC.0000059423.62268.02
   Mellis DJ, 2011, J ENDOCRINOL, V211, P131, DOI 10.1530/JOE 11 0212
   NIELSEN SP, 1969, ACTA PHARMACOL TOX, V27, P469
   NUSSBAUM SR, 1993, AM J MED, V95, P297, DOI 10.1016/0002 9343(93)90282 T
   NUSSBAUM SR, 1990, NEW ENGL J MED, V323, P1324, DOI 10.1056/NEJM199011083231907
   Pecherstorfer M, 1996, J CLIN ONCOL, V14, P268, DOI 10.1200/JCO.1996.14.1.268
   Pecherstorfer M, 2003, SUPPORT CARE CANCER, V11, P539, DOI 10.1007/s00520 003 0477 1
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681
   PUROHIT OP, 1995, BRIT J CANCER, V72, P1289, DOI 10.1038/bjc.1995.502
   RALSTON SH, 1990, ANN INTERN MED, V112, P499, DOI 10.7326/0003 4819 112 7 499
   REPO MA, 1988, CALCIFIED TISSUE INT, V43, P300, DOI 10.1007/BF02556640
   RIANCHO JA, 1991, POSTGRAD MED J, V67, P350, DOI 10.1136/pgmj.67.786.350
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2001, CANCER J, V7, P377
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Santarpia L, 2010, HORM METAB RES, V42, P153, DOI 10.1055/s 0029 1241821
   Sargent JTS, 2010, BRIT J HAEMATOL, V149, P465, DOI 10.1111/j.1365 2141.2010.08173.x
   SCHILLING T, 1993, J CLIN ENDOCR METAB, V76, P801, DOI 10.1210/jc.76.3.801
   SEYMOUR JF, 1993, BLOOD, V82, P1383
   SLEEBOOM HP, 1983, LANCET, V2, P239
   Sone S, 2007, CANCER METAST REV, V26, P685, DOI 10.1007/s10555 007 9081 z
   Sourbier C, 2006, CANCER LETT, V240, P170, DOI 10.1016/j.canlet.2005.08.020
   Sramek V, 1998, INTENS CARE MED, V24, P262, DOI 10.1007/s001340050562
   Stewart AF, 2005, NEW ENGL J MED, V352, P373, DOI 10.1056/NEJMcp042806
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   TOFT H, 1971, BRIT MED J, V1, P437, DOI 10.1136/bmj.1.5746.437
   VASSILOPOULOUSELLIN R, 1993, CANCER, V71, P1309, DOI 10.1002/1097 0142(19930215)71:4<1309::AID CNCR2820710423>3.0.CO;2 M
   WALLS J, 1994, BRIT J CANCER, V70, P169, DOI 10.1038/bjc.1994.270
   WARRELL RP, 1988, ANN INTERN MED, V108, P669, DOI 10.7326/0003 4819 108 5 669
   WARRELL RP, 1984, J CLIN INVEST, V73, P1487, DOI 10.1172/JCI111353
   WARRELL RP, 1991, J CLIN ONCOL, V9, P1467, DOI 10.1200/JCO.1991.9.8.1467
   YOSHIMOTO K, 1989, J CLIN ENDOCR METAB, V68, P976, DOI 10.1210/jcem 68 5 976
   Zojer N, 1999, DRUG SAFETY, V21, P389, DOI 10.2165/00002018 199921050 00004
NR 92
TC 103
Z9 108
U1 0
U2 13
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1401 H Street NW, Suite 900, WASHINGTON, DC 20005, UNITED STATES
SN 1555 9041
EI 1555 905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD OCT
PY 2012
VL 7
IS 10
BP 1722
EP 1729
DI 10.2215/CJN.02470312
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 023LV
UT WOS:000310036800025
PM 22879438
OA Bronze
DA 2025 08 17
ER

PT J
AU Stoch, SA
   Wagner, JA
AF Stoch, S. A.
   Wagner, J. A.
TI Cathepsin K inhibitors: A novel target for osteoporosis therapy
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID BONE RESORPTION; POSTMENOPAUSAL WOMEN; POTENT; PYCNODYSOSTOSIS;
   TURNOVER; LOCALIZATION; OSTEOCLASTS; EXPRESSION; BALICATIB; PREVENTS
AB Osteoporosis is characterized by low bone mass with skeletal fragility and an increased risk of fracture. This bone loss is brought about by an imbalance between bone resorption and formation. Cathepsin K is the most abundant cysteine protease expressed in the osteoclast and is believed to be instrumental in bone matrix degradation necessary for bone resorption. Cathepsin K inhibitors represent a novel target for developing agents to treat osteoporosis and other disorders characterized by increased bone resorption.
C1 [Stoch, S. A.; Wagner, J. A.] Merck Res Labs, Dept Clin Pharmacol, Rahway, NJ USA.
C3 Merck & Company
RP Stoch, SA (通讯作者)，Merck Res Labs, Dept Clin Pharmacol, Rahway, NJ USA.
EM aubrey_stoch@merck.com
CR Adami S, 2006, J BONE MINER RES, V21, pS24
   Binkley N, 1998, J BONE MINER RES, V13, P1775, DOI 10.1359/jbmr.1998.13.11.1775
   Bone HG, 2007, J BONE MINER RES, V22, pS37
   Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   FISHER JE, 1993, ENDOCRINOLOGY, V132, P1411, DOI 10.1210/en.132.3.1411
   FLANAGAN A, 1998, METHODS BONE BIOL
   Fratzl Zelman N, 2004, J CLIN ENDOCR METAB, V89, P1538, DOI 10.1210/jc.2003 031055
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Guay J, 1999, BONE, V25, P205, DOI 10.1016/S8756 3282(99)00160 X
   Inui T, 1997, J BIOL CHEM, V272, P8109, DOI 10.1074/jbc.272.13.8109
   James IE, 1999, J BONE MINER RES, V14, P1562, DOI 10.1359/jbmr.1999.14.9.1562
   Kiviranta R, 2001, J BONE MINER RES, V16, P1444, DOI 10.1359/jbmr.2001.16.8.1444
   Lark MW, 2002, BONE, V30, P746, DOI 10.1016/S8756 3282(02)00675 0
   Lazner F, 1999, MOL MED TODAY, V5, P413, DOI 10.1016/S1357 4310(99)01563 4
   Li CS, 2006, BIOORG MED CHEM LETT, V16, P1985, DOI 10.1016/j.bmcl.2005.12.071
   LittlewoodEvans A, 1997, BONE, V20, P81, DOI 10.1016/S8756 3282(96)00351 1
   Marquis RW, 2004, ANNU REP MED CHEM, V39, P79, DOI 10.1016/S0065 7743(04)39007 X
   Marquis RW, 2001, J MED CHEM, V44, P1380, DOI 10.1021/jm000481x
   Nishi Y, 1999, J BONE MINER RES, V14, P1902, DOI 10.1359/jbmr.1999.14.11.1902
   Palmer JT, 2005, J MED CHEM, V48, P7520, DOI 10.1021/jm058198r
   Papanastasiou P, 2006, J BONE MINER RES, V21, pS59
   Pennypacker B, 2006, J BONE MINER RES, V21, pS304
   Pennypacker B, 2006, J BONE MINER RES, V21, pS303
   Pennypacker BL, 1999, J BONE MINER RES, V14, pS549
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Stoch SA, 2006, J BONE MINER RES, V21, pS60
   STOCH SA, 2007, AM SOC CLIN PHARM TH, pP59
   Stroup GB, 2006, J BONE MINER RES, V21, pS160
   TEZUKA K, 1994, J BIOL CHEM, V269, P2126
   Troen BR, 2004, DRUG NEWS PERSPECT, V17, P19, DOI 10.1358/dnp.2004.17.1.829022
   VAES G, 1968, J CELL BIOL, V39, P676, DOI 10.1083/jcb.39.3.676
   Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396
   Yamaza T, 1998, BONE, V23, P499, DOI 10.1016/S8756 3282(98)00138 0
   Yasuma T, 1998, J MED CHEM, V41, P4301, DOI 10.1021/jm9803065
NR 34
TC 142
Z9 159
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0009 9236
EI 1532 6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD JAN
PY 2008
VL 83
IS 1
BP 172
EP 176
DI 10.1038/sj.clpt.6100450
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 254KD
UT WOS:000252584600029
PM 18073778
DA 2025 08 17
ER

PT J
AU Zhang, MZ
   Yang, E
   Qin, XY
   Zhang, S
   Zhu, Y
   Fu, HY
   He, B
AF Zhang, Muzi
   Yang, E.
   Qin, Xiaoyu
   Zhang, Shun
   Zhu, Yong
   Fu, Hongyi
   He, Bin
TI EPSTI1 promotes osteoclast differentiation and bone resorption by PKR/
   NF κB signaling
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoporosis; EPSTI1; Osteoclast differentiation; Bone resorption;
   PKR/NF kappa B pathway
ID EPITHELIAL STROMAL INTERACTION; IDENTIFICATION; EXPRESSION; INVASION;
   GENES
AB Background: Epithelial stromal interaction 1 (EPSTI1) plays an important role in M1 macrophages, which induce osteoclastogenesis. One recent genome wide association study (GWAS) involving 426,824 individuals has shown that EPSTI1 is strongly associated with osteoporosis (P < 5E 8). Therefore, we speculate that EPSTI1 participates in the modulation of osteoporosis through osteoclastogenesis. The roles of EPSTI1 in osteoclastogenesis and bone resorption remain unclear. Methods: Femur specimens were collected from osteoporotic patients and control patients. Immunofluorescence staining was used to detect the expression of EPSTI1 and signaling pathways. The osteoclastic potential of RAW264.7 cells with Sh EPSTI1 lentivirus infection was tested using tartrate resistant acid phosphatase (TRAP) staining, western blotting, and quantitative reverse transcription polymerase chain reaction (qRT PCR). Western blotting was also used to examine signaling pathways. Results: In this study, EPSTI1 was found to be significantly increased in tartrate resistant acid phosphatase positive (ACP5+) osteoclasts of bone sections from osteoporotic patients. Next, we identified EPSTI1 as a positive regulator of osteoclastogenesis and osteoclast differentiation capability. Diminished EPSTI1 expression resulted in reduced osteoclastic resorption. Mechanistically, EPSTI1 driven osteoclastogenesis was regulated by NF kappa B pathway, which was mediated by the phosphorylation of protein kinase R (p PKR). Furthermore, EPSTI1 participating in the modulation of osteoporosis via PKR/NF kappa B pathway was also verified in the bone samples of osteoporotic patients. Conclusions: Collectively, our findings suggest that EPSTI1 may regulate osteoclast differentiation and bone resorption through PKR/NF kappa B pathway and in vivo experiments are needed to further verify EPSTI1 as the therapy target for osteoporosis.
C1 [Zhang, Muzi; Qin, Xiaoyu; Zhang, Shun; Fu, Hongyi; He, Bin] Chongqing Med Univ, Affiliated Hosp 1, Dept Plast Surg, Med Cosmetol Ctr,Branch 1, Chongqing, Peoples R China.
   [Yang, E.] Chongqing Med Univ, Affiliated Hosp 1, Dept Burn & Plast Surg, Chongqing, Peoples R China.
   [Zhu, Yong] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthoped, Chongqing, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University
RP Fu, HY; He, B (通讯作者)，24 Shiyou Rd, Chongqing 400016, Peoples R China.
EM fuhongyi19@163.com; binheing@163.com
RI Zhang, Muzi/GQB 1230 2022
FU National Natural Science Foundation of China [82202772]; China
   Postdoctoral Science Foundation [2022M720602]; Chongqing Special
   Postdoctoral Science Foundation [XmT2022072]; Postdoctoral Science
   Foundation of The First Affiliated Hospital of Chongqing Medical
   University [CYYY BSHPYXM  202302]
FX <BOLD>Funding</BOLD> This study was funded by National Natural Science
   Foundation of China (82202772) , China Postdoctoral Science Foundation
   (2022M720602) , Chongqing Special Postdoctoral Science Foundation
   (XmT2022072) , Postdoctoral Science Foundation of The First Affiliated
   Hospital of Chongqing Medical University (CYYY BSHPYXM  202302) . BH was
   responsible for Study Design, Experiments, Statistical Analysis, Data
   Interpretation, Manuscript Preparation and Literature Search.
CR Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Fujii T, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00120 2
   Fukui S, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01958
   Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710
   Gray J., 2016, Cell Commun. Insights, V2016, P1
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   He B, 2022, MATER DESIGN, V215, DOI 10.1016/j.matdes.2022.110469
   He B, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.790613
   He B, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.738000
   He B, 2022, BONE, V155, DOI 10.1016/j.bone.2021.116266
   He B, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.716681
   Ishii T, 2005, DNA RES, V12, P429, DOI 10.1093/dnares/dsi020
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kari A, 2022, ALLERGOL IMMUNOPATH, V50, P106, DOI 10.15586/aei.v50i3.581
   Kim H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22565 7
   Kim YH, 2018, BIOCHEM BIOPH RES CO, V496, P778, DOI 10.1016/j.bbrc.2017.12.014
   Kosova G, 2012, AM J HUM GENET, V90, P950, DOI 10.1016/j.ajhg.2012.04.016
   Li JT, 2019, CELL DEATH DIFFER, V26, P2652, DOI 10.1038/s41418 019 0328 3
   Li T, 2014, ONCOGENE, V33, P4746, DOI 10.1038/onc.2013.415
   Lu LL, 2015, CANCER LETT, V356, P470, DOI 10.1016/j.canlet.2014.09.027
   Meng XH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/716315
   Moal V, 2013, J INFECT DIS, V207, P125, DOI 10.1093/infdis/jis632
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Nielsen HL, 2002, GENOMICS, V79, P703, DOI 10.1006/geno.2002.6755
   Raterman HG, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3819
   Rivadeneira F, 2009, NAT GENET, V41, P1199, DOI 10.1038/ng.446
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Sun JL, 2020, ANN RHEUM DIS, V79, P518, DOI 10.1136/annrheumdis 2019 216428
   Tallóczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang DJ, 2014, CELL REP, V9, P90, DOI 10.1016/j.celrep.2014.08.049
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Zhang MZ, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 10586 1
   Zheng ZY, 2021, CELL DEATH DIFFER, V28, P2001, DOI 10.1038/s41418 020 00731 6
   Zhu XW, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00143 3
   Zhuang Q, 2023, J AGR FOOD CHEM, V71, P411, DOI 10.1021/acs.jafc.2c05954
NR 37
TC 1
Z9 1
U1 1
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 19
PY 2024
VL 734
AR 150463
DI 10.1016/j.bbrc.2024.150463
EA JUL 2024
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA A8J6A
UT WOS:001284948100001
PM 39083969
DA 2025 08 17
ER

PT J
AU Sánchez, JF
   Ramtani, S
   Boucetta, A
   Velasco, MA
   Vaca González, JJ
   Duque Daza, CA
   Garzón Alvarado, DA
AF Sanchez, Juan Felipe
   Ramtani, Salah
   Boucetta, Abdelkader
   Velasco, Marco Antonio
   Vaca Gonzalez, Juan Jairo
   Duque Daza, Carlos A.
   Garzon Alvarado, Diego A.
TI Tumor growth for remodeling process: A 2D approach
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Article
DE Bone remodeling; Tumor; Coupling tumor bone; Komarova's model;
   Osteoclasts; Osteoblasts
ID BONE; MODEL; MECHANISMS; CANCER; GLIOBLASTOMA; OSTEOBLAST; PREDICTS;
   EFFICACY; THERAPY
AB This paper aims to present a comprehensive framework for coupling tumor bone remodeling processes in a 2 dimensional geometry. This is achieved by introducing a bio inspired damage that represents the growing tumor, which subsequently affects the main populations involved in the remodeling process, namely, osteoclasts, osteoblasts, and bone tissue. The model is constructed using a set of differential equations based on the Komarova's and Ayati's models, modified to incorporate the bio inspired damage that may result in tumor mass formation. Three distinct models were developed. The first two models are based on the Komarova's governing equations, with one demonstrating an osteolytic behavior and the second one an osteoblastic model. The third model is a variation of Ayati's model, where the bio inspired damage is induced through the paracrine and autocrine parameters, exhibiting an osteolytic behavior. The obtained results are consistent with existing literature, leading us to believe that our in silico experiments will serve as a cornerstone for paving the way towards targeted interventions and personalized treatment strategies, ultimately improving the quality of life for those affected by these conditions.
C1 [Sanchez, Juan Felipe; Duque Daza, Carlos A.; Garzon Alvarado, Diego A.] Univ Nacl Colombia, Biotechnol Inst, Bogota, Colombia.
   [Ramtani, Salah; Boucetta, Abdelkader] Univ Sorbonne Paris Nord, CNRS, UMR 7244, Lab CSPBAT,Equipe LBPS, Paris, France.
   [Velasco, Marco Antonio] Univ Distrital Francisco Jose de Caldas, Bogota, Colombia.
   [Vaca Gonzalez, Juan Jairo] Univ Nacl Colombia, Escuela Pregrad, Direcc Acad, Sede La Paz, La Paz, Colombia.
C3 Universidad Nacional de Colombia; Centre National de la Recherche
   Scientifique (CNRS); CNRS   Institute of Chemistry (INC); Universidad
   Distrital Francisco Jose de Caldas; Universidad Nacional de Colombia
RP Sánchez, JF (通讯作者)，Univ Nacl Colombia, Biotechnol Inst, Bogota, Colombia.
EM jufsanchezgu@unal.edu.co; ramtani@univ paris13.fr;
   mavelascop@udistrital.edu.co; caduqued@unal.edu.co
RI Garzon Alvarado, Diego/AAD 6607 2019; Vaca González, Juan/GPS 9670 2022;
   VELASCO, MARCO/F 2223 2011; Duque Daza, Carlos/K 8609 2012
OI Duque Daza, Carlos/0000 0002 6376 5081; SANCHEZ GUTIERREZ, JUAN
   FELIPE/0000 0002 7821 5234; Velasco Pena, Marco
   Antonio/0000 0003 4436 9443; 
FU Biotechnology Institute Universidad Nacional de Colombia, Laboratoire
   CSPBAT, France; Equipe LBPS, France; CNRS, France [UMR 7244]; Universit
   e Sorbonne Paris Nord; Department of Mechanical Engineering, Penn State
   University, University Park
FX This work was supported by Biotechnology Institute Universidad Nacional
   de Colombia, Laboratoire CSPBAT, France, equipe LBPS, France, CNRS,
   France (UMR 7244) , Universit e Sorbonne Paris Nord and Department of
   Mechanical Engineering, Penn State University, University Park.
CR Garzón Alvarado DA, 2012, COMPUT METHOD BIOMEC, V15, P333, DOI 10.1080/10255842.2010.535522
   Alsamraae M, 2021, CANCER METAST REV, V40, P413, DOI 10.1007/s10555 021 09965 3
   Arias Moreno AJ, 2011, THESIS
   Ashrafi M, 2020, BIOMECH MODEL MECHAN, V19, P2499, DOI 10.1007/s10237 020 01353 0
   Avval PT, 2014, J BIOMECH ENG T ASME, V136, DOI 10.1115/1.4026642
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Baratchart E, 2022, PLOS COMPUT BIOL, V18, DOI 10.1371/journal.pcbi.1009839
   BEAUPRE GS, 1990, J ORTHOP RES, V8, P651, DOI 10.1002/jor.1100080506
   Bishop Ryan T., 2023, bioRxiv
   Bolamperti S, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00219 8
   Bonfoh N., 2008, REVUE, V1, P717
   Brian Dr., 2021, Bone disease
   CARTER DR, 1984, CALCIFIED TISSUE INT, V36, pS19, DOI 10.1007/BF02406129
   Chen G, 2007, MED ENG PHYS, V29, P134, DOI 10.1016/j.medengphy.2005.12.008
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   COWIN SC, 1976, J ELASTICITY, V6, P313, DOI 10.1007/BF00041724
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   Deutsch A, 2004, ADV PARALLEL COMPUT, V13, P695
   Farhat A, 2017, MATH BIOSCI, V294, P1, DOI 10.1016/j.mbs.2017.09.005
   Ferlay J, 2018, CANC TODAY
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Frieling John S., 2022, Cancer Metastasis Through the Lymphovascular System
   FYHRIE DP, 1995, J BIOMECH, V28, P135, DOI 10.1016/0021 9290(94)00059 D
   Goltzman D, 1997, CANCER, V80, P1581, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1581::AID CNCR8>3.0.CO;2 N
   Gu GL, 2006, CELL TISSUE RES, V323, P263, DOI 10.1007/s00441 005 0066 3
   Günther T, 2000, TRENDS ENDOCRIN MET, V11, P189, DOI 10.1016/S1043 2760(00)00256 3
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   HUISKES R, 1987, J BIOMECH, V20, P1135, DOI 10.1016/0021 9290(87)90030 3
   Huybrechts Y, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00165
   Ihde LL, 2011, RADIOGRAPHICS, V31, P1865, DOI 10.1148/rg.317115093
   Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232
   Klika V, 2014, J MATH BIOL, V69, P1383, DOI 10.1007/s00285 013 0736 9
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kreps LM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062911
   Lamoureux F, 2008, MOL CANCER THER, V7, P3389, DOI 10.1158/1535 7163.MCT 08 0497
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lerebours C, 2016, BIOMECH MODEL MECHAN, V15, P43, DOI 10.1007/s10237 015 0705 x
   Martin M, 2019, BIOMECH MODEL MECHAN, V18, P1475, DOI 10.1007/s10237 019 01158 w
   MARTIN RB, 1972, J BIOMECH, V5, P447, DOI 10.1016/0021 9290(72)90003 6
   MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Navet B, 2018, CANCERS, V10, DOI 10.3390/cancers10110398
   Norregaard KS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136865
   Ovejero D, 2022, BONE, V161, DOI 10.1016/j.bone.2022.116450
   Oyajobi BO, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2168
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Pastrama MI, 2018, BONE, V107, P208, DOI 10.1016/j.bone.2017.11.009
   Pivonka P, 2013, ENG STRUCT, V47, P134, DOI 10.1016/j.engstruct.2012.09.006
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ramtani S, 2023, J MECH MED BIOL, V23, DOI 10.1142/S0219519423500410
   Ramtani S, 2023, BIOMECH MODEL MECHAN, V22, P925, DOI 10.1007/s10237 023 01689 3
   Rockne R, 2010, PHYS MED BIOL, V55, P3271, DOI 10.1088/0031 9155/55/12/001
   Schaffler MB, 2012, CURR OSTEOPOROS REP, V10, P118, DOI 10.1007/s11914 012 0105 4
   Swanson KR, 2008, BRIT J CANCER, V98, P113, DOI 10.1038/sj.bjc.6604125
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tobeiha M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6910312
   Ulam S. M, 1952, P INT C MATH CAMBR M, V2, P264
   Valentim CA, 2023, COMPUT BIOL MED, V153, DOI 10.1016/j.compbiomed.2022.106481
   von Neumann J., 1951, CEREBRAL MECH BEHAV, P1, DOI DOI 10.1126/SCIENCE.115.2990.440
   Wang CH, 2009, CANCER RES, V69, P9133, DOI 10.1158/0008 5472.CAN 08 3863
   WEINANS H, 1992, J BIOMECH, V25, P1425, DOI 10.1016/0021 9290(92)90056 7
   WEINANS H, 1994, J BIOMECH ENG T ASME, V116, P393, DOI 10.1115/1.2895789
   Weis JA, 2015, CANCER RES, V75, P4697, DOI 10.1158/0008 5472.CAN 14 2945
   Weis JA, 2013, PHYS MED BIOL, V58, P5851, DOI 10.1088/0031 9155/58/17/5851
   Wozniak Maciej K., 2021, SIGSIM PADS '21: Proceedings of the 2021 SIGSIM Conference on Principles of Advanced Discrete Simulation, P13, DOI 10.1145/3437959.3459256
   Zhu XH, 2002, J BIOMECH, V35, P951, DOI 10.1016/S0021 9290(02)00028 3
   Zumsande M, 2011, BONE, V48, P910, DOI 10.1016/j.bone.2010.12.010
NR 69
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022 5193
EI 1095 8541
J9 J THEOR BIOL
JI J. Theor. Biol.
PD MAY 21
PY 2024
VL 585
AR 111781
DI 10.1016/j.jtbi.2024.111781
EA MAR 2024
PG 12
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Mathematical & Computational
   Biology
GA QB5E8
UT WOS:001218425600001
PM 38432504
DA 2025 08 17
ER

PT J
AU Ongkeko, WM
   Burton, D
   Kiang, A
   Abhold, E
   Kuo, SZ
   Rahimy, E
   Yang, M
   Hoffman, RM
   Wang Rodriguez, J
   Deftos, LJ
AF Ongkeko, Weg M.
   Burton, Doug
   Kiang, Alan
   Abhold, Eric
   Kuo, Selena Z.
   Rahimy, Elham
   Yang, Meng
   Hoffman, Robert M.
   Wang Rodriguez, Jessica
   Deftos, Leonard J.
TI Parathyroid Hormone Related Protein Promotes Epithelial to Mesenchymal
   Transition in Prostate Cancer
SO PLOS ONE
LA English
DT Article
ID SIGNALING PATHWAYS; BONE METASTASES; BREAST CANCER; STEM CELLS;
   FLUORESCENT PROTEIN; PTH/PTHRP RECEPTOR; TUMOR PROGRESSION; INDIAN
   HEDGEHOG; E CADHERIN; TGF BETA
AB Parathyroid hormone related protein (PTHrP) possesses a variety of physiological and developmental functions and is also known to facilitate the progression of many common cancers, notably their skeletal invasion, primarily by increasing bone resorption. The purpose of this study was to determine whether PTHrP could promote epithelial to mesenchymal transition (EMT), a process implicated in cancer stem cells that is critically involved in cancer invasion and metastasis. EMT was observed in DU 145 prostate cancer cells stably overexpressing either the 1 141 or 1 173 isoform of PTHrP, where there was upregulation of Snail and vimentin and downregulation of E cadherin relative to parental DU 145. By contrast, the opposite effect was observed in PC 3 prostate cancer cells where high levels of PTHrP were knocked down via lentiviral siRNA transduction. Increased tumor progression was observed in PTHrP overexpressing DU 145 cells while decreased progression was observed in PTHrP knockdown PC 3 cells. PTHrP overexpressing DU 145 formed larger tumors when implanted orthoptopically into nude mice and in one case resulted in spinal metastasis, an effect not observed among mice injected with parental DU 145 cells. PTHrP overexpressing DU 145 cells also caused significant bone destruction when injected into the tibiae of nude mice, while parental DU 145 cells caused little to no destruction of bone. Together, these results suggest that PTHrP may work through EMT to promote an aggressive and metastatic phenotype in prostate cancer, a pathway of importance in cancer stem cells. Thus, continued efforts to elucidate the pathways involved in PTHrP induced EMT as well as to develop ways to specifically target PTHrP signaling may lead to more effective therapies for prostate cancer.
C1 [Ongkeko, Weg M.; Kiang, Alan; Abhold, Eric; Kuo, Selena Z.; Rahimy, Elham] Univ Calif San Diego, Dept Surg, Div Otolaryngol Head & Neck Surg, La Jolla, CA 92093 USA.
   [Burton, Doug; Deftos, Leonard J.] Univ Calif San Diego, Vet Adm San Diego Healthcare Syst, Dept Med, La Jolla, CA 92093 USA.
   [Yang, Meng; Hoffman, Robert M.] AntiCancer Inc, San Diego, CA USA.
   [Wang Rodriguez, Jessica] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA.
   [Wang Rodriguez, Jessica] Vet Adm San Diego Healthcare Syst, San Diego, CA USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   AntiCancer, Inc.; University of California System; University of
   California San Diego
RP Ongkeko, WM (通讯作者)，Univ Calif San Diego, Dept Surg, Div Otolaryngol Head & Neck Surg, La Jolla, CA 92093 USA.
EM wongkeko@ucsd.edu
OI Rahimy, Elham/0000 0001 7356 3996
FU Veterans Administration Merit Award
FX Veterans Administration Merit Award (LJ Deftos) supported this project
   (http://www.research.va.gov/services/csrd/merit_review.cfm#.UcI2KPY uCg)
   . The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agouni A, 2007, CARCINOGENESIS, V28, P1893, DOI 10.1093/carcin/bgm106
   Aguilera Abelardo, 2005, Curr Opin Investig Drugs, V6, P262
   Aklilu F, 1996, AM J PHYSIOL ENDOC M, V271, pE277, DOI 10.1152/ajpendo.1996.271.2.E277
   Ardura JA, 2010, J AM SOC NEPHROL, V21, P237, DOI 10.1681/ASN.2009050462
   Arato Ohshima T, 1999, INT J CANCER, V83, P387, DOI 10.1002/(SICI)1097 0215(19991029)83:3<387::AID IJC15>3.0.CO;2 O
   Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007
   Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852
   Bryden AAG, 2002, BRIT J CANCER, V86, P322, DOI 10.1038/sj/bjc/6600115
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   BURTON DW, 1994, ENDOCRINOLOGY, V135, P253, DOI 10.1210/en.135.1.253
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Chan GK, 2001, ENDOCRINOLOGY, V142, P4900, DOI 10.1210/en.142.11.4900
   Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008 5472.CAN 05 2018
   Datta NS, 2007, J BONE MINER RES, V22, P951, DOI 10.1359/JBMR.070328
   Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458
   Deftos Leonard J., 2000, Cancer, V88, P3002
   Deftos LJ, 2005, BIOCHEM BIOPH RES CO, V327, P468, DOI 10.1016/j.bbrc.2004.11.162
   DELAMATA J, 1995, J CLIN INVEST, V95, P2846, DOI 10.1172/JCI117990
   Ditmer LS, 1996, ENDOCRINOLOGY, V137, P1608, DOI 10.1210/en.137.5.1608
   Downs TM, 2011, CANCER LETT, V306, P52, DOI 10.1016/j.canlet.2011.02.027
   Duband JL, 1995, ACTA ANAT, V154, P63
   Fortino V, 2002, CELL MOL LIFE SCI, V59, P2165, DOI 10.1007/s000180200015
   Gleave Martin E., 1997, P367
   Goltzman D, 1999, J BONE MINER RES, V14, P173, DOI 10.1359/jbmr.1999.14.2.173
   Gonzalez Moreno O, 2010, EXP CELL RES, V316, P554, DOI 10.1016/j.yexcr.2009.11.020
   Greaves M, 2011, NAT MED, V17, P1046, DOI 10.1038/nm.2458
   Grille SJ, 2003, CANCER RES, V63, P2172
   Gujral A, 2001, CANCER RES, V61, P2282
   Hajra KM, 2002, CANCER RES, V62, P1613
   Hastings RH, 2010, CANCER BIOL THER, V10, P1068, DOI 10.4161/cbt.10.10.13374
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Iddon J, 2000, J PATHOL, V191, P170
   Ionescu AM, 2001, J BIOL CHEM, V276, P11639, DOI 10.1074/jbc.M006564200
   Isohata N, 2009, INT J CANCER, V125, P1212, DOI 10.1002/ijc.24400
   Isowa S, 2010, ANTICANCER RES, V30, P2755
   Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011
   Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570
   Katoh Y, 2008, INT J MOL MED, V22, P271, DOI 10.3892/ijmm_00000019
   KEMP BE, 1987, SCIENCE, V238, P1568, DOI 10.1126/science.3685995
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   LI X, 1994, J BIOL CHEM, V269, P6263
   Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Milsom CC, 2008, CANCER RES, V68, P10068, DOI 10.1158/0008 5472.CAN 08 2067
   Nemeth JA, 1999, CANCER RES, V59, P1987
   Rabbani SA, 1999, INT J CANCER, V80, P257, DOI 10.1002/(SICI)1097 0215(19990118)80:2<257::AID IJC15>3.0.CO;2 3
   Sepulveda VAT, 2002, REGUL PEPTIDES, V105, P109, DOI 10.1016/S0167 0115(02)00007 1
   Shen XL, 2007, REGUL PEPTIDES, V141, P61, DOI 10.1016/j.regpep.2006.12.017
   Shimo T, 2006, J BONE MINER RES, V21, P1045, DOI 10.1359/JBMR.060416
   Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008 5472.CAN 05 0616
   Veltmaat JM, 2000, INT J DEV BIOL, V44, P297
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Wu D, 2007, ONCOGENE, V26, P5070, DOI 10.1038/sj.onc.1210316
   Yamamoto T, 2007, BONE, V40, P354, DOI 10.1016/j.bone.2006.09.002
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang M, 2006, CLIN CANCER RES, V12, P2602, DOI 10.1158/1078 0432.CCR 05 2050
   Yang M, 2005, PROSTATE, V62, P374, DOI 10.1002/pros.20125
   Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555 008 9169 0
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
NR 61
TC 35
Z9 36
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2014
VL 9
IS 1
AR e85803
DI 10.1371/journal.pone.0085803
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 297VL
UT WOS:000330283100076
PM 24465715
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Maes, C
   Goossens, S
   Bartunkova, S
   Drogat, B
   Coenegrachts, L
   Stockmans, I
   Moermans, K
   Nyabi, O
   Haigh, K
   Naessens, M
   Haenebalcke, L
   Tuckermann, JP
   Tjwa, M
   Carmeliet, P
   Mandic, V
   David, JP
   Behrens, A
   Nagy, A
   Carmeliet, G
   Haigh, JJ
AF Maes, Christa
   Goossens, Steven
   Bartunkova, Sonia
   Drogat, Benjamin
   Coenegrachts, Lieve
   Stockmans, Ingrid
   Moermans, Karen
   Nyabi, Omar
   Haigh, Katharina
   Naessens, Michael
   Haenebalcke, Lieven
   Tuckermann, Jan P.
   Tjwa, Marc
   Carmeliet, Peter
   Mandic, Vice
   David, Jean Pierre
   Behrens, Axel
   Nagy, Andras
   Carmeliet, Geert
   Haigh, Jody J.
TI Increased skeletal VEGF enhances β catenin activity and results in
   excessively ossified bones
SO EMBO JOURNAL
LA English
DT Article
DE beta catenin; osteoblast; skeleton; vasculature; VEGF
ID ENDOTHELIAL GROWTH FACTOR; HEMATOPOIETIC STEM CELL; GLYCOGEN SYNTHASE
   KINASE 3; CHRONIC IDIOPATHIC MYELOFIBROSIS; BLOOD BRAIN BARRIER;
   OSTEOCLAST DIFFERENTIATION; CONDITIONAL INACTIVATION; MYELOID
   METAPLASIA; SIGNALING CONTROLS; PROGENITOR CELLS
AB Vascular endothelial growth factor (VEGF) and beta catenin both act broadly in embryogenesis and adulthood, including in the skeletal and vascular systems. Increased or deregulated activity of these molecules has been linked to cancer and bone related pathologies. By using novel mouse models to locally increase VEGF levels in the skeleton, we found that embryonic VEGF over expression in osteo chondroprogenitors and their progeny largely pheno copied constitutive beta catenin activation. Adult induction of VEGF in these cell populations dramatically increased bone mass, associated with aberrant vascularization, bone marrow fibrosis and haematological anomalies. Genetic and pharmacological interventions showed that VEGF increased bone mass through a VEGF receptor 2  and phosphatidyl inositol 3 kinase mediated pathway inducing beta catenin transcriptional activity in endothelial and osteoblastic cells, likely through modulation of glycogen synthase kinase 3 beta phosphorylation. These insights into the actions of VEGF in the bone and marrow environment underscore its power as pleiotropic bone anabolic agent but also warn for caution in its therapeutic use. Moreover, the finding that VEGF can modulate beta catenin activity may have widespread physiological and clinical ramifications. The EMBO Journal (2010) 29, 424 441. doi: 10.1038/emboj.2009.361; Published online 10 December 2009
C1 [Goossens, Steven; Bartunkova, Sonia; Drogat, Benjamin; Nyabi, Omar; Haigh, Katharina; Naessens, Michael; Haenebalcke, Lieven; Haigh, Jody J.] Univ Ghent VIB, Dept Mol Biomed Res, Vasc Cell Biol Unit, B 9052 Ghent, Belgium.
   [Maes, Christa; Coenegrachts, Lieve; Stockmans, Ingrid; Moermans, Karen; Carmeliet, Geert] Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Dept Expt Med, Louvain, Belgium.
   [Goossens, Steven; Bartunkova, Sonia; Drogat, Benjamin; Nyabi, Omar; Haigh, Katharina; Naessens, Michael; Haenebalcke, Lieven; Haigh, Jody J.] Univ Ghent, Vasc Cell Biol Unit, Dept Mol Biol, Ghent, Belgium.
   [Tuckermann, Jan P.] Fritz Lipmann Inst, Div Tissue Specif Hormone Act, Leibniz Inst Age Res, Jena, Germany.
   [Tjwa, Marc; Carmeliet, Peter] Katholieke Univ Leuven, Vesalius Res Ctr, Louvain, Belgium.
   [Tjwa, Marc; Carmeliet, Peter] VIB, Vesalius Res Ctr, Leuven, Belgium.
   [Mandic, Vice; David, Jean Pierre] Univ Erlangen Nurnberg, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany.
   [Behrens, Axel] London Res Inst, Lincolns Inn Fields Labs, Canc Res UK, London, England.
   [Nagy, Andras] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
   [Nagy, Andras] Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A1, Canada.
C3 Ghent University; Flanders Institute for Biotechnology (VIB); KU Leuven;
   Ghent University; Leibniz Association; Leibniz Institut fur
   Alternsforschung   Fritz Lipmann Institut (FLI); KU Leuven; Flanders
   Institute for Biotechnology (VIB); University of Erlangen Nuremberg;
   Cancer Research UK; University of Toronto; Sinai Health System Toronto;
   Lunenfeld Tanenbaum Research Institute; University of Toronto
RP Haigh, JJ (通讯作者)，Univ Ghent VIB, Dept Mol Biomed Res, Vasc Cell Biol Unit, Technologiepk 927, B 9052 Ghent, Belgium.
EM Jody.Haigh@dmbr.UGent.be
RI ; Haenebalcke, Lieven/I 3514 2013; Nagy, Andras/G 6465 2013; Carmeliet,
   Peter/AAQ 5140 2020; drogat, benjamin/S 6622 2016
OI Maes, Christa/0000 0003 4243 5486; Goossens, Steven/0000 0002 5693 8570;
   Nagy, Andras/0000 0003 4311 0413; haigh, jody/0000 0002 7319 8922;
   Behrens, Axel/0000 0002 1557 1143; Carmeliet, Peter/0000 0001 7961 1821;
   benjamin, Drogat/0000 0002 0020 4826
FU FWO [0229.04, 0569.07]; KU Leuven Excellentie Financiering [EF/05/08];
   International Bone and Mineral Society
FX We are grateful to Dr Kurt Ballmer Hofer for supplying rcVEGF, to Dr
   Bram De Craene, Dr Geert Berx and Dr Garry Nolan for supplying materials
   for DN TCF4 retroviral experiments, Dr Chris Guerin, Dr Hamida Hammad
   and Dr Bart Lambrechts for assistance on confocal microscopy, to Daisy
   Ginneberge for sorting osteoblasts, to Nico Smets, Sophie Torrekens and
   Riet Van Looveren for skillful technical assistance, and to Leander
   Huyghe and Dr Peter Brouckaert for constructive advice. We thank Dr
   Henry Kronenberg for critically reading the paper. This work was
   partially funded by FWO grants G. 0229.04 and G. 0569.07 to GC and JH,
   KU Leuven Excellentie Financiering EF/05/08, and by a Gideon and Sevgi
   Rodan Fellowship of the International Bone and Mineral Society to CM. CM
   and MT are postdoctoral fellows of the Fund for Scientific Research
   Flanders (FWO Vlaanderen).
CR Akeson AL, 2003, DEV BIOL, V264, P443, DOI 10.1016/j.ydbio.2003.09.004
   Aldridge SE, 2005, BIOCHEM BIOPH RES CO, V335, P793, DOI 10.1016/j.bbrc.2005.07.145
   Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051
   Bock O, 2005, BRIT J HAEMATOL, V130, P76, DOI 10.1111/j.1365 2141.2005.05573.x
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092 8674(00)81010 7
   Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   Chagraoui C, 2003, BLOOD, V101, P2983, DOI 10.1182/blood 2002 09 2839
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460 2075.1996.tb00830.x
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Dai J, 2007, J DENT RES, V86, P937, DOI 10.1177/154405910708601006
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978
   Fiedler J, 2005, BIOCHEM BIOPH RES CO, V334, P561, DOI 10.1016/j.bbrc.2005.06.116
   Ford Hutchinson AF, 2007, J BONE MINER RES, V22, P1245, DOI 10.1359/JBMR.070420
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Giles FJ, 2007, LEUKEMIA RES, V31, P891, DOI 10.1016/j.leukres.2006.12.001
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208
   Haigh JJ, 2003, DEV BIOL, V262, P225, DOI 10.1016/S0012 1606(03)00356 7
   Haigh JJ, 2000, DEVELOPMENT, V127, P1445
   Hattori K, 2003, LEUKEMIA LYMPHOMA, V44, P575, DOI 10.1080/1042819021000037985
   Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hilton MJ, 2005, DEVELOPMENT, V132, P4339, DOI 10.1242/dev.02025
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Ilan N, 2003, LAB INVEST, V83, P1105, DOI 10.1097/01.LAB.0000083531.84403.8B
   Jacobsen KA, 2008, J BONE MINER RES, V23, P596, DOI 10.1359/JBMR.080103
   Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014
   Jinnin M, 2008, NAT MED, V14, P1236, DOI 10.1038/nm.1877
   Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Larsson J, 2008, CELL STEM CELL, V3, P221, DOI 10.1016/j.stem.2008.06.005
   Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092 8674(02)00685 2
   Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104
   Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925 4773(01)00601 3
   Maes C, 2004, J CLIN INVEST, V113, P188, DOI 10.1172/JCI200419383
   Maes Christa, 2008, P79, DOI 10.1007/978 0 387 78632 2_7
   Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100
   Niida S, 2005, P NATL ACAD SCI USA, V102, P14016, DOI 10.1073/pnas.0503544102
   Noble W, 2005, P NATL ACAD SCI USA, V102, P6990, DOI 10.1073/pnas.0500466102
   Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526 968X(200011/12)28:3/4<147::AID GENE90>3.0.CO;2 G
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Ovchinnikov DA, 2000, GENESIS, V26, P145, DOI 10.1002/(SICI)1526 968X(200002)26:2<145::AID GENE14>3.3.CO;2 3
   Ozawa CR, 2004, J CLIN INVEST, V113, P516, DOI 10.1172/JCI200418420
   Panteli K, 2007, HEMATOLOGY, V12, P481, DOI 10.1080/10245330701554664
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979
   Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7
   Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007
   Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594
   Steurer M, 2007, HUM PATHOL, V38, P1057, DOI 10.1016/j.humpath.2006.12.011
   Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992
   Street John, 2009, J Orthop Surg Res, V4, P19, DOI 10.1186/1749 799X 4 19
   Tefferi A, 2005, J CLIN ONCOL, V23, P8520, DOI 10.1200/JCO.2004.00.9316
   van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Walkley CR, 2007, CELL, V129, P1097, DOI 10.1016/j.cell.2007.05.014
   Yang QL, 2008, MATRIX BIOL, V27, P589, DOI 10.1016/j.matbio.2008.06.005
   Zelzer E, 2002, DEVELOPMENT, V129, P1893
   Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200
   Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369
NR 71
TC 163
Z9 184
U1 4
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0261 4189
EI 1460 2075
J9 EMBO J
JI Embo J.
PD JAN 20
PY 2010
VL 29
IS 2
BP 424
EP 441
DI 10.1038/emboj.2009.361
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 545KO
UT WOS:000273731200014
PM 20010698
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Tang, CH
   Yang, RS
   Chien, MY
   Chen, CC
   Fu, WM
AF Tang, Chih Hsin
   Yang, Rong Sen
   Chien, Mei Yin
   Chen, Chien Chich
   Fu, Wen Mel
TI Enhancement of bone morphogenetic protein 2 expression and bone
   formation by coumarin derivatives via p38 and ERK dependent pathway in
   osteoblasts
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE osteoblasts; bone morphogenetic protein; coumarin; p38; ERK
ID CELL DIFFERENTIATION; ANGELICA PUBESCENS; GROWTH FACTOR; OSTHOLE;
   KINASE; ACTIVATION; RECEPTOR; FIBRILLOGENESIS; FIBROBLAST
AB Osteoporosis is a reduction in skeletal mass due to an imbalance between bone resorption and bone formation. Bone morphogenetic protein (BMP) plays important roles in osteoblastic differentiation and bone formation. Therefore, components involved in BMP activation are good targets for the development of anti osteoporosis drugs. In this study, imperatorin and bergapten, two coumarin derivatives, were shown to enhance alkaline phosphatase (ALP) activity, type I collagen synthesis and bone nodule formation in primary cultured osteoblasts. Imperatorin and bergapten increased mRNA levels of BMP 2 using quantitative RT PCR, whereas the BMP 2 antagonist noggin attenuated the increase of ALP activity induced by imperatorin and bergapten, indicating that BMP 2 expression is required for the action of imperatorin and bergapten in osteoblastic maturation. Both imperatorin and bergapten enhanced the phosphorylation of SMAD (transcription factors activated by TGF beta) 1/5/8, p38 and extracellular signal regulated protein (ERK). Pretreatment of osteoblasts with p38 inhibitor (SB203580) or mitogen activated protein kinase inhibitor (PD98059) or transfected with dominant negative mutant of p38 or ERK antagonized the elevation of BMP 2 expression and ALP activity induced by imperatorin and bergapten. Local administration of imperatorin or bergapten into the metaphysis of the tibia via the implantation of a needle cannula significantly increased the BMP 2 immunostaining and bone volume of secondary spongiosa in tibia. Taken together, our results provide evidence that coumarin derivatives increase BMP 2 expression and enhance bone formation in rat via the p38 and ERK dependent signaling pathway. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Tang, Chih Hsin; Fu, Wen Mel] Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 10764, Taiwan.
   [Yang, Rong Sen] Natl Taiwan Univ, Coll Med, Dept Orthopaed, Taipei 10764, Taiwan.
   [Tang, Chih Hsin] China Med Univ, Coll Med, Dept Pharmacol, Taichung, Taiwan.
   [Chen, Chien Chich] Natl Res Inst Chinese Med, Taipei, Taiwan.
   [Chien, Mei Yin] Ko Da Pharmaceut Co LTD, Tao Yuan, Taiwan.
C3 National Taiwan University; National Taiwan University; China Medical
   University Taiwan; National Research Institute of Chinese Medicine
RP Fu, WM (通讯作者)，1,Sec 1,Jen Ai Rd, Taipei, Taiwan.
EM wenmei@ntu.edu.tw
RI ; Tang, Chih/O 5212 2015
OI Yang, Rong Sen/0000 0002 0553 4779; FU, WEN MEI/0000 0003 4157 8987; 
CR Berg C, 2003, NAT REV DRUG DISCOV, V2, P257, DOI 10.1038/nrd1068
   CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27
   Cortizo AM, 2003, MOL CELL BIOCHEM, V250, P1, DOI 10.1023/A:1024934008982
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945 053X(00)00076 7
   Huang RL, 1996, HEPATOLOGY, V24, P508, DOI 10.1002/hep.510240307
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kapur S, 2004, BONE, V35, P525, DOI 10.1016/j.bone.2004.04.007
   KO FN, 1992, EUR J PHARMACOL, V219, P29, DOI 10.1016/0014 2999(92)90576 P
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   Li XX, 2002, BIOL PHARM BULL, V25, P738, DOI 10.1248/bpb.25.738
   Li Z, 1999, BONE, V25, P661, DOI 10.1016/S8756 3282(99)00227 6
   Liu JH, 1998, PLANTA MED, V64, P525, DOI 10.1055/s 2006 957507
   Meng F, 2004, PHARMAZIE, V59, P643
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Prince M, 2006, CARCINOGENESIS, V27, P1204, DOI 10.1093/carcin/bgi303
   REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959 437X(94)90141 O
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sakou T, 1999, J BONE MINER RES, V14, P1145, DOI 10.1359/jbmr.1999.14.7.1145
   Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177
   Sykaras Nikitas, 2003, J Oral Sci, V45, P57
   Tang CH, 2005, J BIOL CHEM, V280, P22907, DOI 10.1074/jbc.M500130200
   Tang CH, 2004, MOL PHARMACOL, V66, P440
   Tang CH, 2003, J BONE MINER RES, V18, P502, DOI 10.1359/jbmr.2003.18.3.502
   Tang CH, 2007, J BIOL CHEM, V282, P2346, DOI 10.1074/jbc.M603070200
   TENG CM, 1994, N S ARCH PHARMACOL, V349, P202
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Xiao Y, 2004, CELL TRANSPLANT, V13, P15, DOI 10.3727/000000004772664851
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
NR 34
TC 96
Z9 103
U1 0
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JAN 28
PY 2008
VL 579
IS 1 3
BP 40
EP 49
DI 10.1016/j.ejphar.2007.10.013
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 259ZK
UT WOS:000252979200005
PM 17980360
DA 2025 08 17
ER

PT J
AU Harshan, S
   Dey, P
   Ragunathan, S
AF Harshan, Shilpa
   Dey, Poulami
   Ragunathan, Srivatsan
TI Effects of rheumatoid arthritis associated transcriptional changes on
   osteoclast differentiation network in the synovium
SO PEERJ
LA English
DT Article
DE Synovium; Rheumatoid arthritis; Interaction network; Gene expression;
   Enriched pathways; Signaling pathways; Osteoclastogenesis; Osteoclast
   differentiation
ID NF KAPPA B; PROTEIN INTERACTION NETWORKS; GENE EXPRESSION OMNIBUS; KEY
   REGULATOR; T LYMPHOCYTES; MAST CELLS; C FOS; ACTIVATION; BONE; CYTOKINES
AB Background: Osteoclast differentiation in the inflamed synovium of rheumatoid arthritis (RA) affected joints leads to the formation of bone lesions. Reconstruction and analysis of protein interaction networks underlying specific disease phenotypes are essential for designing therapeutic interventions. In this study, we have created a network that captures signal flow leading to osteoclast differentiation. Based on transcriptome analysis, we have indicated the potential mechanisms responsible for the phenotype in the RA affected synovium.
   Method: We collected information on gene expression, pathways and protein interactions related to RA from literature and databases namely Gene Expression Omnibus, Kyoto Encyclopedia of Genes and Genomes pathway and STRING. Based on these information, we created a network for the differentiation of osteoclasts. We identified the differentially regulated network genes and reported the signaling that are responsible for the process in the RA affected synovium.
   Result: Our network reveals the mechanisms underlying the activation of the neutrophil cytosolic factor complex in connection to osteoclastogenesis in RA. Additionally, the study reports the predominance of the canonical pathway of NF kappa B activation in the diseased synovium. The network also confirms that the upregulation of T cell receptor signaling and downregulation of transforming growth factor beta signaling pathway favor osteoclastogenesis in RA. To the best of our knowledge, this is the first comprehensive protein protein interaction network describing RA driven osteoclastogenesis in the synovium.
   Discussion: This study provides information that can be used to build models of the signal flow involved in the process of osteoclast differentiation. The models can further be used to design therapies to ameliorate bone destruction in the RA affected joints.
C1 [Harshan, Shilpa; Dey, Poulami; Ragunathan, Srivatsan] Inst Bioinformat & Appl Biotechnol, Bangalore, Karnataka, India.
   [Dey, Poulami] Manipal Acad Higher Educ, Manipal, Karnataka, India.
C3 Manipal Academy of Higher Education (MAHE)
RP Ragunathan, S (通讯作者)，Inst Bioinformat & Appl Biotechnol, Bangalore, Karnataka, India.
EM srivatsan@ibab.ac.in
OI Harshan, Shilpa/0000 0002 5244 2375; raghunathan,
   srivatsan/0000 0002 8901 3128
FU IBAB; Indian Council of Medical Research (ICMR), India [3/1/3
   JRF 2013/HRD 106 (20835)]; Department of Biotechnology, Government of
   India [BTPR 12422/MED/31/287/2014]; Department of IT, BT and S&T of the
   Government of Karnataka
FX The authors were financially supported by the following funding
   agencies: Shilpa Harshan by IBAB; Poulami Dey by the Indian Council of
   Medical Research (ICMR), India, Grant No. 3/1/3 JRF 2013/HRD 106
   (20835); Srivatsan Raghunathan by the Department of Biotechnology,
   Government of India, Grant No. BTPR 12422/MED/31/287/2014. The project
   was also supported by the Department of IT, BT and S&T of the Government
   of Karnataka. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Bartok B, 2012, AM J PATHOL, V180, P1906, DOI 10.1016/j.ajpath.2012.01.030
   Bertrand F, 2010, J IMMUNOL, V185, P2887, DOI 10.4049/jimmunol.1000739
   Broeren MGA, 2016, HUM GENE THER, V27, P244, DOI 10.1089/hum.2015.127
   Browner NC, 2004, AM J PHYSIOL CELL PH, V287, pC88, DOI 10.1152/ajpcell.00039.2004
   Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108
   Chang M, 2011, NAT IMMUNOL, V12, P1002, DOI 10.1038/ni.2090
   Dey P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161306
   Dooley S, 1996, ANN RHEUM DIS, V55, P298, DOI 10.1136/ard.55.5.298
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Fionda C, 2007, J IMMUNOL, V178, P4039, DOI 10.4049/jimmunol.178.7.4039
   Fisher AB, 2009, ANTIOXID REDOX SIGN, V11, P1349, DOI [10.1089/ars.2008.2378, 10.1089/ARS.2008.2378]
   Franca RFO, 2016, SCAND J RHEUMATOL, V45, P8, DOI 10.3109/03009742.2015.1047403
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011
   Grabiec AM, 2015, ANN RHEUM DIS, V74, P1763, DOI 10.1136/annrheumdis 2013 203610
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   GRUBER B, 1988, CLIN EXP IMMUNOL, V71, P289
   Hao RH, 2017, PEERJ, V5, DOI 10.7717/peerj.3078
   HOSACK DA, 2003, GENOME BIOL, V4, P4, DOI [10.1186/gb 2003 4 6 p4, DOI 10.1186/GB 2003 4 6 P4]
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huber R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2485
   Jeong H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176260
   Jung SM, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/263625
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Kang IS, 2016, SCI REP UK, V6, DOI 10.1038/srep38014
   Karst M, 2004, J CELL PHYSIOL, V200, P99, DOI 10.1002/jcp.20036
   KINNE RW, 1995, SCAND J RHEUMATOL, P121
   Kupfer P, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755 8794 7 40
   Lee HM, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3364
   Lee H, 2013, ARTHRITIS RHEUM US, V65, P109, DOI 10.1002/art.37741
   Li XF, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12570 6
   Lories RJ, 2013, NAT REV RHEUMATOL, V9, P328, DOI 10.1038/nrrheum.2013.25
   Ludikhuize J, 2007, ARTHRITIS RHEUM US, V56, P2180, DOI 10.1002/art.22653
   Lutzny G, 2013, CANCER CELL, V23, P77, DOI 10.1016/j.ccr.2012.12.003
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Miao CG, 2013, CELL SIGNAL, V25, P2069, DOI 10.1016/j.cellsig.2013.04.002
   Nevius E, 2016, CLIN REV ALLERG IMMU, V51, P59, DOI 10.1007/s12016 015 8520 9
   OTTERNESS IG, 1994, SEMIN ARTHRITIS RHEU, V24, P91, DOI 10.1016/S0049 0172(05)80003 4
   Patel RK, 2005, IMMUNOL RES, V31, P47, DOI 10.1385/IR:31:1:47
   Pepper SD, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471 2105 8 273
   R Core Team, 2017, R LANG ENV STAT COMP
   Raker VK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00123
   ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156
   Sams M, 2015, RHEUMATOL INT, V35, P1503, DOI 10.1007/s00296 015 3239 8
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shih VFS, 2011, CELL RES, V21, P86, DOI 10.1038/cr.2010.161
   Speirs C, 2018, PHARMACOL RES, V128, P88, DOI 10.1016/j.phrs.2017.10.001
   SZAMEL M, 1993, EUR J IMMUNOL, V23, P3072, DOI 10.1002/eji.1830231205
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tak PP, 1996, CLIN IMMUNOL IMMUNOP, V80, P129, DOI 10.1006/clin.1996.0106
   Tenenbaum D., 2016, KEGGREST CLIENT SIDE, DOI [10.18129/B9.bioc.KEGGREST, DOI 10.18129/B9.BIOC.KEGGREST]
   TETLOW LC, 1995, ANN RHEUM DIS, V54, P896, DOI 10.1136/ard.54.11.896
   Turvey SE, 2014, J ALLERGY CLIN IMMUN, V134, P276, DOI 10.1016/j.jaci.2014.06.015
   Ungethuem U, 2010, PHYSIOL GENOMICS, V42A, P267, DOI 10.1152/physiolgenomics.00004.2010
   Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030
   Vasudevan D, 2015, CURR TOP DEV BIOL, V114, P185, DOI 10.1016/bs.ctdb.2015.07.026
   Wang H, 2017, INT J IMMUNOGENET, V44, P107, DOI 10.1111/iji.12313
   Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb 2005 6 7 226
   Wetteland P, 1996, J INTERN MED, V240, P125, DOI 10.1046/j.1365 2796.1996.30295851000.x
   Wilson CL, 2005, BIOINFORMATICS, V21, P3683, DOI 10.1093/bioinformatics/bti605
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Woetzel D, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4526
   Wu G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010137
   Xiong Q, 2016, JOINT BONE SPINE, V83, P276, DOI 10.1016/j.jbspin.2015.07.010
   You S, 2014, P NATL ACAD SCI USA, V111, P550, DOI 10.1073/pnas.1311239111
   Zhu YL, 2008, BIOINFORMATICS, V24, P2798, DOI 10.1093/bioinformatics/btn520
NR 74
TC 10
Z9 10
U1 0
U2 4
PU PEERJ INC
PI LONDON
PA 341 345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167 8359
J9 PEERJ
JI PeerJ
PD OCT 11
PY 2018
VL 6
AR e5743
DI 10.7717/peerj.5743
PG 33
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GW8HS
UT WOS:000447217300003
PM 30324023
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bielby, R
   Jones, E
   McGonagle, D
AF Bielby, Robert
   Jones, Elena
   McGonagle, Dennis
TI The role of mesenchymal stem cells in maintenance and repair of bone
SO INJURY INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE mesenchymal stem cell; bone; fracture; coupling
ID UMBILICAL CORD BLOOD; MARROW STROMAL CELLS; REGULATES OSTEOCLAST
   DIFFERENTIATION; PROGENITOR CELLS; IN VITRO; CHEMOKINE RECEPTORS;
   OSTEOPROTEGERIN LIGAND; PROMOTING MIGRATION; OSTEOBLASTIC CELLS;
   ADIPOSE TISSUE
AB The maintenance of stable bone mass during adult life, following rapid skeletal growth during childhood, is the result of a carefully controlled balance between the activities of bone forming (osteoblast) and bone resorbing (osteoclast) cells.
   Although skeletal turnover continues throughout adult life, the net effect of formation and resorption on bone mass is zero in healthy individuals. Later in life, bone mass begins to fall as resorption outpaces formation, particularly in postmenopausal women, which leads to increased fracture risk.
   The opposing actions of these two cell types are coupled by molecular interactions between them that are thought to be influenced by the actions of the precursor cells of the osteoblast lineage, mesenchymal stem cells (MSCs). In addition to regulating normal skeletal homeostasis, MSCs also play an important rote in fracture repair. Bone fracture or injury initiates a series of cellular and molecular pathways that commence with hematoma formation and an inflammatory cascade that regulates MSCs activity leading to fracture heating and the reestablishment of skeletal integrity.
   Although tremendous strides have been made in increasing our understanding of bone biology, there is surprisingly little data about the role of MSCs in vivo in the maintenance of skeletal integrity or fracture repair. In recent years, the pivotal importance of anabolic therapies in the setting of osteoporosis in which bone mass is substantially increased above and beyond what is attainable with the bisphosphonate class of drugs has put MSC biology firmly on the scientific agenda.
   Although the biology of cultured MSCs is reasonably well understood, the biology of MSCs in vivo in both bone turnover and fracture repair remains poorly understood. The recent phenotypic characterization of in vivo MSCs and the ability to prospectively purify such cells will open up new avenues of research into a better understanding of the role of MSCs in bone turnover. The purpose of this article is to review bone and fracture biology from the perspective of recent advances in our understanding of MSCs and to highlight the major deficiencies in our current knowledge.
C1 Chapel Allerton Hosp, Acad Unit Musculoskeletal Dis, Leeds LS7 4SA, W Yorkshire, England.
   St James Univ Hosp, Leeds Inst Mol Med, Leeds, W Yorkshire, England.
C3 University of Leeds; Chapel Allerton Hospital; Saint James's University
   Hospital; University of Leeds
RP McGonagle, D (通讯作者)，Chapel Allerton Hosp, Acad Unit Musculoskeletal Dis, Leeds LS7 4SA, W Yorkshire, England.
EM d.g.mcgonagle@leeds.ac.uk
RI Jones, Elena/F 3136 2010
OI Jones, Elena/0000 0001 9365 2283
CR Bhakta S, 2006, CARDIOVASC REVASCULA, V7, P19, DOI 10.1016/j.carrev.2005.10.008
   Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413
   Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22 4 625
   Boiret N, 2005, EXP HEMATOL, V33, P219, DOI 10.1016/j.exphem.2004.11.001
   Brändström H, 1998, BIOCHEM BIOPH RES CO, V247, P338, DOI 10.1006/bbrc.1998.8783
   Brändström H, 2001, BIOCHEM BIOPH RES CO, V280, P831, DOI 10.1006/bbrc.2000.4223
   Bruder SP, 1998, J ORTHOPAED RES, V16, P155, DOI 10.1002/jor.1100160202
   Bruder SP, 1998, J BONE JOINT SURG AM, V80A, P985, DOI 10.2106/00004623 199807000 00007
   Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396
   Campbell AT, 2005, AM J BIOETHICS, V5, P66, DOI 10.1080/15265160500320536
   Cao JJ, 2005, J BONE MINER RES, V20, P1659, DOI 10.1359/JBMR.050503
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   De Bari C, 2006, ARTHRITIS RHEUM, V54, P1209, DOI 10.1002/art.21753
   De Bari C, 2001, ARTHRITIS RHEUM US, V44, P1928, DOI 10.1002/1529 0131(200108)44:8<1928::AID ART331>3.0.CO;2 P
   Deschaseaux F, 2003, BRIT J HAEMATOL, V122, P506, DOI 10.1046/j.1365 2141.2003.04469.x
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365 2141.2000.01986.x
   FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365 2184.1987.tb01309.x
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   Gang EJ, 2004, STEM CELLS, V22, P617, DOI 10.1634/stemcells.22 4 617
   Gimble JM, 2003, CYTOTHERAPY, V5, P362, DOI 10.1080/14653240310003026
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Honczarenko M, 2006, STEM CELLS, V24, P1030, DOI 10.1634/stemcells.2005 0319
   Hong SH, 2005, BIOCHEM BIOPH RES CO, V330, P1153, DOI 10.1016/j.bbrc.2005.03.086
   Horowitz MC, 2001, CYTOKINE GROWTH F R, V12, P9, DOI 10.1016/S1359 6101(00)00030 7
   Hou LL, 2003, INT J HEMATOL, V78, P256, DOI 10.1007/BF02983804
   Jones EA, 2004, ARTHRITIS RHEUM US, V50, P817, DOI 10.1002/art.20203
   Jones EA, 2002, ARTHRITIS RHEUM US, V46, P3349, DOI 10.1002/art.10696
   JONES EA, 2006, IN PRESS CYTOMETRY B
   Kassis I, 2006, BONE MARROW TRANSPL, V37, P967, DOI 10.1038/sj.bmt.1705358
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood 2004 11 4349
   Kraus KH, 2006, VET SURG, V35, P232, DOI 10.1111/j.1532 950X.2006.00142.x
   Kucia M, 2005, BIOL CELL, V97, P133, DOI 10.1042/BC20040069
   Kudlacek S, 2003, BONE, V32, P681, DOI 10.1016/S8756 3282(03)00090 5
   Kuznetsov SA, 2001, J CELL BIOL, V153, P1133, DOI 10.1083/jcb.153.5.1133
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lazarus HM, 1997, J HEMATOTHER, V6, P447, DOI 10.1089/scd.1.1997.6.447
   Le Blanc K, 2004, SCAND J IMMUNOL, V60, P307, DOI 10.1111/j.0300 9475.2004.01483.x
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Lee RH, 2006, BLOOD, V107, P2153, DOI 10.1182/blood 2005 07 2701
   LIVINGSTON TL, 2003, J MAT SCI MATER MED, P14211
   Makhluf HA, 2000, BIOCHEM BIOPH RES CO, V268, P669, DOI 10.1006/bbrc.2000.2182
   Mansilla E, 2006, TRANSPL P, V38, P967, DOI 10.1016/j.transproceed.2006.02.053
   Mbalaviele G, 2000, J BIOL CHEM, V275, P14388, DOI 10.1074/jbc.275.19.14388
   NAKASE T, 1993, BIOCHEM BIOPH RES CO, V195, P1422, DOI 10.1006/bbrc.1993.2202
   Neville Webbe HL, 2004, BREAST CANCER RES TR, V86, P269
   Normanno N, 2005, ENDOCR RELAT CANCER, V12, P471, DOI 10.1677/erc.1.00956
   Nöth U, 2002, J ORTHOP RES, V20, P1060, DOI 10.1016/S0736 0266(02)00018 9
   Park J, 2006, J GENE MED, V8, P112, DOI 10.1002/jgm.826
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pulsatelli L, 2004, BIOGERONTOLOGY, V5, P119, DOI 10.1023/B:BGEN.0000025075.04136.ec
   Quirici N, 2002, EXP HEMATOL, V30, P783, DOI 10.1016/S0301 472X(02)00812 3
   ROCHEFORT GY, 2006, STEM CELLS, DOI DOI 10.1634/STEM CELLS.2006 0164
   Roufosse CA, 2004, INT J BIOCHEM CELL B, V36, P585, DOI 10.1016/j.biocel.2003.10.007
   Shirley D, 2005, J ORTHOP RES, V23, P1013, DOI 10.1016/j.orthres.2005.01.013
   SIMMONS PJ, 1991, BLOOD, V78, P55
   SINDEN J, 2001, P STEM CELLS THER FU
   Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005 0271
   Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03 1100fje
   Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood 2004 09 3507
   Stewart K, 2003, CELL TISSUE RES, V313, P281, DOI 10.1007/s00441 003 0762 9
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Van Overstraeten Schloegel N, 2006, EUR J HAEMATOL, V76, P488, DOI 10.1111/j.1600 0609.2006.00633.x
   Villaron EM, 2004, HAEMATOLOGICA, V89, P1421
   Von Lüttichau I, 2005, STEM CELLS DEV, V14, P329, DOI 10.1089/scd.2005.14.329
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Wexler SA, 2003, BRIT J HAEMATOL, V121, P368, DOI 10.1046/j.1365 2141.2003.04284.x
   Wickham MQ, 2003, CLIN ORTHOP RELAT R, P196, DOI 10.1097/01.blo.0000072467.53786.ca
   Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood 2004 02 0526
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Youn I, 2005, ACTA ORTHOP, V76, P442, DOI 10.1080/17453670510041367
   Yu MJ, 2004, BRIT J HAEMATOL, V124, P666, DOI 10.1111/j.1365 2141.2004.04826.x
   Zhang XP, 2005, J BONE MINER RES, V20, P2124, DOI 10.1359/JBMR.050806
   Zvaifler NJ, 2000, ARTHRITIS RES, V2, P477, DOI 10.1186/ar130
NR 78
TC 184
Z9 233
U1 1
U2 52
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020 1383
EI 1879 0267
J9 INJURY
JI Injury Int. J. Care Inj.
PD MAR
PY 2007
VL 38
SU 1
BP S26
EP S32
DI 10.1016/j.injury.2007.02.007
PG 7
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 173ZW
UT WOS:000246912000004
PM 17383482
DA 2025 08 17
ER

PT J
AU Vallet, S
   Mukherjee, S
   Vaghela, N
   Hideshima, T
   Fulciniti, M
   Pozzi, S
   Santo, L
   Cirstea, D
   Patel, K
   Sohani, AR
   Guimaraes, A
   Xie, WL
   Chauhan, D
   Schoonmaker, JA
   Attar, E
   Churchill, M
   Weller, E
   Munshi, N
   Seehra, JS
   Weissleder, R
   Anderson, KC
   Scadden, DT
   Raje, N
AF Vallet, Sonia
   Mukherjee, Siddhartha
   Vaghela, Nileshwari
   Hideshima, Teru
   Fulciniti, Mariateresa
   Pozzi, Samantha
   Santo, Loredana
   Cirstea, Diana
   Patel, Kishan
   Sohani, Aliyah R.
   Guimaraes, Alex
   Xie, Wanling
   Chauhan, Dharminder
   Schoonmaker, Jesse A.
   Attar, Eyal
   Churchill, Michael
   Weller, Edie
   Munshi, Nikhil
   Seehra, Jasbir S.
   Weissleder, Ralph
   Anderson, Kenneth C.
   Scadden, David T.
   Raje, Noopur
TI Activin A promotes multiple myeloma induced osteolysis and is a
   promising target for myeloma bone disease
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE osteoblasts; osteoclasts; tumor niche
ID MARROW STROMAL CELLS; OSTEOBLAST DIFFERENTIATION; INHIBIN; BETA; DLX5;
   OSTEOCLASTOGENESIS; SUPPRESSION; EXPRESSION; REGULATOR; SYSTEM
AB Understanding the pathogenesis of cancer related bone disease is crucial to the discovery of new therapies. Here we identify activin A, a TGF beta family member, as a therapeutically amenable target exploited by multiple myeloma (MM) to alter its microenvironmental niche favoring osteolysis. Increased bone marrow plasma activin A levels were found in MM patients with osteolytic disease. MM cell engagement of marrow stromal cells enhanced activin A secretion via adhesion mediated JNK activation. Activin A, in turn, inhibited osteoblast differentiation via SMAD2 dependent distalless homeobox 5 down regulation. Targeting activin A by a soluble decoy receptor reversed osteoblast inhibition, ameliorated MM bone disease, and inhibited tumor growth in an in vivo humanized MM model, setting the stage for testing in human clinical trials.
C1 [Vallet, Sonia; Vaghela, Nileshwari; Pozzi, Samantha; Patel, Kishan; Sohani, Aliyah R.; Attar, Eyal; Raje, Noopur] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Hematol & Oncol, Boston, MA 02114 USA.
   [Mukherjee, Siddhartha; Schoonmaker, Jesse A.; Churchill, Michael; Scadden, David T.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst, MGH Ctr Regenerat Med, Cambridge, MA 02138 USA.
   [Hideshima, Teru; Fulciniti, Mariateresa; Santo, Loredana; Cirstea, Diana; Chauhan, Dharminder; Munshi, Nikhil; Anderson, Kenneth C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Fulciniti, Mariateresa; Munshi, Nikhil] Vet Affairs Boston Hlth Care Syst, Dept Med, Boston, MA 02130 USA.
   [Guimaraes, Alex; Weissleder, Ralph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol,Simches Res Facil, Boston, MA 02114 USA.
   [Xie, Wanling; Weller, Edie] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   [Seehra, Jasbir S.] Acceleron Pharma, Cambridge, MA 02139 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard Medical School; Harvard University; Harvard
   University; Harvard University Medical Affiliates; Dana Farber Cancer
   Institute; Harvard University; Harvard University Medical Affiliates;
   Massachusetts General Hospital; Harvard Medical School; Harvard
   University; Harvard University Medical Affiliates; Dana Farber Cancer
   Institute; Acceleron Pharma
RP Raje, N (通讯作者)，Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Hematol & Oncol, Boston, MA 02114 USA.
EM nraje@partners.org
RI ; Pozzi, Samantha/A 7617 2012; Munshi, Nikhil/ABE 2338 2021; Vallet,
   Sonia/AHE 3935 2022; Weller, Edie/LKK 3901 2024; Anderson,
   Kenneth/ACP 5073 2022
OI Vallet, Sonia/0000 0003 0146 8089; Pozzi, Samantha/0000 0001 7917 1774;
   Churchill, Michael/0000 0001 7202 3891; Weissleder,
   Ralph/0000 0003 0828 4143; Patel, Kishan/0000 0002 5526 2900
FU International Myeloma Foundation [K08]; NIH; ASCO CDA; MMRF; LLS CDA;
   NIH SPORE
FX Grant support for this study was received in the form of an
   International Myeloma Foundation junior award (S.V., L.S., S.P.), K08
   (S.M.), NIH (D.T.S.), ASCO CDA, MMRF, LLS CDA, and NIH SPORE (N.R.).
CR Allendorph GP, 2007, BIOCHEMISTRY US, V46, P12238, DOI 10.1021/bi700907k
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Choi SJ, 2001, J CLIN INVEST, V108, P1833, DOI 10.1172/JCI13116
   del Re E, 2004, J BIOL CHEM, V279, P53126, DOI 10.1074/jbc.M408090200
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001 117
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   Fuller K, 2000, BIOCHEM BIOPH RES CO, V268, P2, DOI 10.1006/bbrc.2000.2075
   Funaba M, 2003, CELL SIGNAL, V15, P605, DOI 10.1016/S0898 6568(02)00150 X
   Gaddy Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Holleville N, 2003, DEV BIOL, V257, P177, DOI 10.1016/S0012 1606(03)00059 9
   Ikenoue T, 1999, J CELL BIOCHEM, V75, P206, DOI 10.1002/(SICI)1097 4644(19991101)75:2<206::AID JCB3>3.3.CO;2 K
   Kawabata N, 2007, LIFE SCI, V81, P8, DOI 10.1016/j.lfs.2007.04.011
   Kominsky SL, 2007, J BONE MINER RES, V22, P37, DOI 10.1359/JBMR.061005
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Neri P, 2007, CLIN CANCER RES, V13, P5903, DOI 10.1158/1078 0432.CCR 07 0753
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Perrien DS, 2007, ENDOCRINOLOGY, V148, P1654, DOI 10.1210/en.2006 0848
   Roodman GD, 2006, CLIN CANCER RES, V12, p6270S, DOI 10.1158/1078 0432.CCR 06 0845
   Ruckle J, 2009, J BONE MINER RES, V24, P744, DOI 10.1359/JBMR.081208
   Samee N, 2008, AM J PATHOL, V173, P773, DOI 10.2353/ajpath.2008.080243
   Shao LE, 1998, CYTOKINE, V10, P227, DOI 10.1006/cyto.1997.0282
   Snider JL, 2008, J BIOL CHEM, V283, P13952, DOI 10.1074/jbc.M800289200
   Tanimoto K, 1996, J BIOL CHEM, V271, P32760, DOI 10.1074/jbc.271.51.32760
   Tassone P, 2005, BLOOD, V106, P713, DOI 10.1182/blood 2005 01 0373
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Woodruff TK, 1998, BIOCHEM PHARMACOL, V55, P953, DOI 10.1016/S0006 2952(97)00477 2
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
NR 31
TC 177
Z9 215
U1 0
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 16
PY 2010
VL 107
IS 11
BP 5124
EP 5129
DI 10.1073/pnas.0911929107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 570YI
UT WOS:000275714300059
PM 20194748
OA Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Choi, SW
   Yeon, JT
   Park, KI
   Lee, CH
   Youn, BS
   Oh, J
   Lee, MS
AF Choi, Sik Won
   Yeon, Jeong Tae
   Park, Kie In
   Lee, Chang Hoon
   Youn, Byung Soo
   Oh, Jaemin
   Lee, Myeung Su
TI VapB as a regulator of osteoclastogenesis via modulation of
   PLCγ2 Ca<SUP>2+</SUP> NFAT signaling
SO FEBS LETTERS
LA English
DT Article
DE Osteoclast; VapB; PLC gamma 2; NFATc1
ID AMYOTROPHIC LATERAL SCLEROSIS; ENDOPLASMIC RETICULUM STRESS;
   PHOSPHOLIPASE C; BONE; DIFFERENTIATION; PATHWAY; RANKL; CELLS; BTK
AB VapB has been shown to regulate calcium homeostasis in amyotrophic lateral sclerosis. Calcium signaling is also important in metabolic bone diseases, but the role of VapB in the generation of osteoclasts for bone resorption during osteoclastogenesis is not known. Therefore, we investigated the role of VapB in RANKL induced osteoclast differentiation. Interestingly, VapB is induced during osteoclastogenesis, and regulates osteoclast differentiation by modulating NFATc1. The results also suggest that VapB regulates osteoclastogenesis via PLC gamma 2 Ca2+ NFAT signaling. The involvement of PLC gamma 2 Ca2+ NFAT signaling in VapB regulated osteoclastogenesis was confirmed by a pharmacological study. Taken together, the results indicate that VapB positively regulates RANKL mediated osteoclastogenesis via PLC gamma 2 Ca2+ NFAT signaling. (C) 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Oh, Jaemin] Wonkwang Univ, Dept Anat, Sch Med, Coll Med, Iksan 570749, Jeonbuk, South Korea.
   [Choi, Sik Won; Yeon, Jeong Tae; Oh, Jaemin] Wonkwang Univ, Inst Skeletal Dis, Coll Med, Iksan 570749, Jeonbuk, South Korea.
   [Choi, Sik Won; Yeon, Jeong Tae; Park, Kie In] Chonbuk Natl Univ, Div Biol Sci, Coll Nat Sci, Jeonju 561756, South Korea.
   [Lee, Chang Hoon; Lee, Myeung Su] AdipoGen, Inchon 406840, South Korea.
C3 Wonkwang University; Wonkwang University; Jeonbuk National University
RP Oh, J (通讯作者)，Wonkwang Univ, Dept Anat, Sch Med, Coll Med, 344 2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea.
EM jmoh@wku.ac.kr; ckhlms@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
OI Choi, Sik Won/0000 0003 1726 2536
FU National Research Foundation of Korea (NRF); Ministry of Education,
   Science and Technology [2011 0026632]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, Science and Technology No. 2011 0026632).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Atkin JD, 2008, NEUROBIOL DIS, V30, P400, DOI 10.1016/j.nbd.2008.02.009
   Ilieva EV, 2007, BRAIN, V130, P3111, DOI 10.1093/brain/awm190
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200
   Langou K, 2010, J NEUROCHEM, V114, P795, DOI 10.1111/j.1471 4159.2010.06806.x
   Lee MS, 2009, J IMMUNOL, V183, P3390, DOI 10.4049/jimmunol.0804314
   Lee SH, 2008, J BIOL CHEM, V283, P11526, DOI 10.1074/jbc.M708935200
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Nishimura AL, 2004, AM J HUM GENET, V75, P822, DOI 10.1086/425287
   Nishimura AL, 2005, HUM GENET, V118, P499, DOI 10.1007/s00439 005 0031 y
   Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Takami M, 1997, BIOCHEM BIOPH RES CO, V237, P111, DOI 10.1006/bbrc.1997.7090
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang K., 2011, J MOL CELL BIOL, P1
   Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898 6568(01)00191 7
NR 19
TC 14
Z9 15
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 5793
J9 FEBS LETT
JI FEBS Lett.
PD FEB 3
PY 2012
VL 586
IS 3
BP 263
EP 269
DI 10.1016/j.febslet.2011.12.033
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 890ZW
UT WOS:000300186900011
PM 22245675
DA 2025 08 17
ER

PT J
AU Taverna, S
   Pucci, M
   Giallombardo, M
   Di Bella, MA
   Santarpia, M
   Reclusa, P
   Gil Bazo, I
   Rolfo, C
   Alessandro, R
AF Taverna, Simona
   Pucci, Marzia
   Giallombardo, Marco
   Di Bella, Maria Antonietta
   Santarpia, Mariacarmela
   Reclusa, Pablo
   Gil Bazo, Ignacio
   Rolfo, Christian
   Alessandro, Riccardo
TI Amphiregulin contained in NSCLC exosomes induces osteoclast
   differentiation through the activation of EGFR pathway
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CELL LUNG CANCER; MYELOGENOUS LEUKEMIA CELLS; GROWTH FACTOR; PREDICTORS;
   EXPRESSION; METASTASES; SURVIVAL; SERUM; INVASION; THERAPY
AB Non small cell lung cancer (NSCLC) remains the leading cause of cancer related deaths worldwide. The majority of patients are diagnosed in advanced disease stage. Bone metastasis is the most frequent complication in NSCLC resulting in osteolytic lesions. The perfect balance between bone resorbing osteoclasts and bone forming osteoblasts activity is lost in bone metastasis, inducing osteoclastogenesis. In NSCLC, the epidermal growth factor receptor (EGFR) pathway is constitutively activated. EGFR binds Amphiregulin (AREG) that is overexpressed in several cancers such as colon, breast and lung. Its levels in plasma of NSCLC patients correlate with poor prognosis and AREG was recently found as a signaling molecule in exosomes derived from cancer cell lines. Exosomes have a key role in the cell cell communication and they were recently indicated as important actors in metastatic niche preparation. In the present work, we hypothesize a role of AREG carried by exosomes derived from NSCLC in bone metastasis induction. We observed that NSCLC exosomes, containing AREG, induce EGFR pathway activation in pre osteoclasts that in turn causes an increased expression of RANKL. RANKL is able to induce the expression of proteolytic enzymes, well known markers of osteoclastogenesis, triggering a vicious cycle in osteolytic bone metastasis.
C1 [Taverna, Simona; Pucci, Marzia; Giallombardo, Marco; Di Bella, Maria Antonietta; Alessandro, Riccardo] Univ Palermo, Biopathol & Biomed Methodol Biol & Genet Sect, Palermo, Italy.
   [Taverna, Simona; Alessandro, Riccardo] CNR, Inst Biomed & Mol Immunol IBIM, Palermo, Italy.
   [Santarpia, Mariacarmela] Univ Messina, Dept Human Pathol G Barresi, Med Oncol Unit, Messina, Italy.
   [Reclusa, Pablo; Rolfo, Christian] Antwerp Univ Hosp UZA, Oncol Dept, Phase Early Clin Trials Unit 1, Antwerp, Belgium.
   [Reclusa, Pablo; Rolfo, Christian] Antwerp Univ, Ctr Oncol Res CORE, Antwerp, Belgium.
   [Gil Bazo, Ignacio] Clin Univ Navarra, Ctr Appl Med Res, Pamplona, Spain.
C3 University of Palermo; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy"
   (IBIM CNR); University of Messina; University of Antwerp; University of
   Antwerp; University of Navarra
RP Alessandro, R (通讯作者)，Univ Palermo, Biopathol & Biomed Methodol Biol & Genet Sect, Palermo, Italy.; Alessandro, R (通讯作者)，CNR, Inst Biomed & Mol Immunol IBIM, Palermo, Italy.; Rolfo, C (通讯作者)，Antwerp Univ Hosp UZA, Oncol Dept, Phase Early Clin Trials Unit 1, Antwerp, Belgium.; Rolfo, C (通讯作者)，Antwerp Univ, Ctr Oncol Res CORE, Antwerp, Belgium.
EM christian.rolfo@uza.be; riccardo.alessandro@unipa.it
RI Taverna, Simona/AAE 7135 2020; Gil Bazo, Ignacio/E 4581 2019; Rolfo,
   Christian/AAW 5173 2021; Rolfo, Christian/M 8935 2016
OI Gil Bazo, Ignacio/0000 0002 2626 5109; Taverna,
   Simona/0000 0002 2192 8938; Rolfo, Christian/0000 0002 7860 8417; Rolfo,
   Christian/0000 0002 5109 0267
FU Italian Association for Cancer Research (AIRC); University of Palermo;
   FFR UNIPA
FX This work was supported by Italian Association for Cancer Research
   (AIRC) to R.A., University of Palermo (International Cooperation) to
   R.A.; FFR UNIPA. The human biological material used in this publication
   was provided by Biobank@UZA (Antwerp, Belgium; ID: BE71030031000) and
   Banco de muestras biologivas Centro de investigacion Medica Aplicada
   (CIMA) Universidad de Navarra.
CR Buckle CH, 2010, CURR PHARM DESIGN, V16, P1272, DOI 10.2174/138161210791034021
   Chan BA, 2015, TRANSL LUNG CANCER R, V4, P36, DOI 10.3978/j.issn.2218 6751.2014.05.01
   Chandra Harish, 2015, Breast Dis, V35, P199, DOI 10.3233/BD 150403
   Chang MH, 2011, CANCER AM CANCER SOC, V117, P143, DOI 10.1002/cncr.25560
   Corrado C, 2016, J CELL MOL MED, V20, P1829, DOI 10.1111/jcmm.12873
   Corrado C, 2014, CANCER LETT, V348, P71, DOI 10.1016/j.canlet.2014.03.009
   Escrevente C, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 108
   Fedele C, 2015, J BIOL CHEM, V290, P4545, DOI 10.1074/jbc.C114.617662
   Fontana S, 2013, PROTEOMICS, V13, P1581, DOI 10.1002/pmic.201200398
   Furugaki K, 2011, CLIN EXP METASTAS, V28, P649, DOI 10.1007/s10585 011 9398 4
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Han WW, 2017, CHEM BIODIVERS, V14, DOI 10.1002/cbdv.201600372
   Higginbotham JN, 2011, CURR BIOL, V21, P779, DOI 10.1016/j.cub.2011.03.043
   Ishikawa N, 2005, CANCER RES, V65, P9176, DOI 10.1158/0008 5472.CAN 05 1556
   Jung T, 2009, NEOPLASIA, V11, P1093, DOI 10.1593/neo.09822
   Kasahara K, 2010, CLIN CANCER RES, V16, P4616, DOI 10.1158/1078 0432.CCR 10 0383
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Miller RE, 2014, J THORAC ONCOL, V9, P345, DOI 10.1097/JTO.0000000000000070
   Milovancev A, 2015, ONCOTARGETS THER, V8, P2915, DOI 10.2147/OTT.S91627
   Minguet J, 2016, INT J CANCER, V138, P2549, DOI 10.1002/ijc.29915
   Niu FY, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2169 5
   Owen S, 2013, ANTICANCER RES, V33, P199
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Perisano C, 2012, EUR REV MED PHARMACO, V16, P1908
   Popper HH, 2016, CANCER METAST REV, V35, P75, DOI 10.1007/s10555 016 9618 0
   Raimondi L, 2015, ONCOTARGET, V6, P13772, DOI 10.18632/oncotarget.3830
   Riess Jonathan W, 2012, Clin Adv Hematol Oncol, V10, P226
   Roato I, 2008, LUNG CANCER, V61, P109, DOI 10.1016/j.lungcan.2007.10.016
   Singh R, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 256
   Sugiura H, 2008, CLIN ORTHOP RELAT R, V466, P729, DOI 10.1007/s11999 007 0051 0
   Tang C, 2016, ACTA ONCOL, V55, P1022, DOI 10.3109/0284186X.2016.1154602
   Taverna S, 2016, ONCOTARGET, V7, P28748, DOI 10.18632/oncotarget.7638
   Taverna S, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 169
   Taverna S, 2012, INT J CANCER, V130, P2033, DOI 10.1002/ijc.26217
   Tsuya A, 2007, LUNG CANCER, V57, P229, DOI 10.1016/j.lungcan.2007.03.013
   Wang K, 2004, J BIOL CHEM, V279, P53848, DOI 10.1074/jbc.M403114200
   Weidle UH, 2017, CANCER GENOM PROTEOM, V14, P1, DOI 10.21873/cgp.20015
   Xiao X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089534
   Yi T, 2008, J CELL PHYSIOL, V217, P409, DOI 10.1002/jcp.21511
   Zheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078476
   Zhu J, 2007, J BIOL CHEM, V282, P26656, DOI 10.1074/jbc.M705064200
NR 41
TC 122
Z9 130
U1 0
U2 17
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUN 9
PY 2017
VL 7
AR 3170
DI 10.1038/s41598 017 03460 y
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EX1CM
UT WOS:000402957400051
PM 28600504
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lian, CX
   Gong, W
   Zhao, X
   Sun, P
   Hu, SJ
   Zhou, GF
   Zhang, QY
   Qin, LP
AF Lian, Chenxia
   Gong, Wan
   Zhao, Xuan
   Sun, Peng
   Hu, Sijing
   Zhou, Guifen
   Zhang, Qiaoyan
   Qin, Luping
TI Orcinol gentiobioside inhibits RANKL induced osteoclastogenesis by
   promoting apoptosis and suppressing autophagy via the JNK1 signaling
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Curculigo orchioides Gaertn; Orcinol gentiobioside; Osteoclast; JNK1;
   Apoptosis; Autophagy
ID CURCULIGO ORCHIOIDES; DIFFERENTIATION; RATS
AB Ethnopharmacological relevance: Osteoporosis (OP) is a metabolic disorder characterized by disrupted osteoclastic bone resorption and osteoblastic bone formation. Curculigo orchioides Gaertn has a long history of application in traditional Chinese and Indian medicine for treating OP. Orcinol gentiobioside (OGB) is a principal active constituent derived from Curculigo orchioides Gaertn and has been shown to have anti OP activity. However, the therapeutic efficacy and mechanism of OGB in modulating osteoclastic bone resorption remain undefined. Aim of the study: To evaluate the effect of OGB on the formation, differentiation and function of osteoclasts derived from bone marrow macrophages (BMMs), and further elucidate the underlying action mechanism of OGB in OP. Materials and methods: Osteoclasts derived from BMMs were utilized to evaluate the effect of OGB on osteoclast formation, differentiation and bone resorption. Tartrate resistant acid phosphatase (TRAP) staining and activity assays were conducted to denote the activity of osteoclasts. Osteoclast related genes and proteins were determined by RT PCR and Western blotting assays. The formation of the F actin ring was observed by confocal laser microscopy, and bone resorption pits were observed by inverted microscopy. The target of OGB in osteoclasts was predicted by using molecular docking and further verified by Cellular Thermal Shift Assay (CETSA) and reversal effects of the target activator. The apoptosis of osteoclasts was analyzed by flow cytometry, and autophagic flux in osteoclasts was determined by confocal laser microscopy. Results: OGB inhibited osteoclast formation and differentiation, osteoclast related genes and proteins expression, F actin ring formation, and bone resorption activity. Molecular docking and CETSA analysis demonstrated that OGB exhibited good affinity for c Jun N terminal Kinase 1 (JNK1). In addition, OGB induced apoptosis and inhibited autophagy in osteoclasts, and the JNK agonist anisomycin reversed the increase in apoptosis and inhibition of autophagy induced by OGB in osteoclasts. Conclusion: OGB inhibited osteoclastogenesis by promoting apoptosis and diminishing autophagy via JNK1 signaling.
C1 [Lian, Chenxia; Zhao, Xuan; Sun, Peng; Hu, Sijing; Zhou, Guifen; Zhang, Qiaoyan; Qin, Luping] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Binwen Rd 584, Hangzhou 311053, Peoples R China.
   [Gong, Wan] Zhejiang Chinese Med Univ, Fuyang Res Inst, Hangzhou 311422, Peoples R China.
   [Gong, Wan] Zhejiang Chinese Med Univ, Sch Basic Med Sci, Hangzhou 310053, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Zhejiang Chinese Medical University
RP Zhou, GF; Zhang, QY; Qin, LP (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Binwen Rd 584, Hangzhou 311053, Peoples R China.
EM 20011021@zcmu.edu.cn; zqy1965@163.com; lpqin@zcmu.edu.cn
RI Peng, Suyuan/ABI 6014 2020
OI qin, luping/0000 0002 5056 6497
FU Medical Research Center of the Academy of Chinese Medical Sciences,
   Zhejiang Chinese Medical University
FX <B>Acknowledgements</B> We appreciate the technical support from the
   Medical Research Center of the Academy of Chinese Medical Sciences,
   Zhejiang Chinese Medical University.
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   CP C., 2022, Pharmacopoeia of the people's Republic of China, V1, P105
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Editorial Committee Of Ministry Of Health Of The People'S Republic Of China, 1991, Preparation of Chinese Medicine. Chinese Medicine Science and Technology
   Gong W, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163964
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   He XYX, 2023, PHYTOMEDICINE, V119, DOI 10.1016/j.phymed.2023.154953
   He YQ, 2018, BIOCHEM BIOPH RES CO, V506, P927, DOI 10.1016/j.bbrc.2018.10.100
   Ke DS, 2019, BIOCHIMIE, V167, P217, DOI 10.1016/j.biochi.2019.10.008
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Li TT, 2023, CLIN EXP MED, V23, P1581, DOI 10.1007/s10238 022 00905 1
   Liu CL, 2023, BIOMED PHARMACOTHER, V166, DOI 10.1016/j.biopha.2023.115392
   Liu Lei, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P1419, DOI 10.3736/jcim20121214
   [刘梦琴 Liu Mengqin], 2021, [中国药学杂志, Chinese Pharmaceutical Journal], V56, P99
   McDonald MM, 2021, CELL, V184, P1940, DOI 10.1016/j.cell.2021.03.010
   Montaseri A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101398
   Murali VP, 2016, IMMUNOPHARM IMMUNOT, V38, P264, DOI 10.1080/08923973.2016.1188401
   Nie Y, 2013, J ETHNOPHARMACOL, V147, P547, DOI 10.1016/j.jep.2013.03.066
   Park JH, 2017, MOL CELLS, V40, P706
   Pickering ME, 2024, EUR J PAIN, V28, P3, DOI 10.1002/ejp.2156
   Qiang MM, 2022, CHIN J NAT MEDICINES, V20, P902, DOI 10.1016/S1875 5364(22)60213 9
   Rufus P, 2013, CURR DRUG TARGETS, V14, P1689, DOI 10.2174/1389450114666131220160357
   Su XD, 2022, J VET SCI, V23, DOI 10.4142/jvs.21246
   Wang CM, 2012, J ETHNOPHARMACOL, V144, P33, DOI 10.1016/j.jep.2012.08.020
   Wang J, 2023, AUTOPHAGY, V19, P2409, DOI 10.1080/15548627.2023.2186112
   [汪滢 Wang Ying], 2012, [中国药学杂志, Chinese Pharmaceutical Journal], V47, P375
   Yan Wu J.Z., 2020, Chinese Journal of Traditional Medical, V28, P17
   Yang JC, 2020, CALCIFIED TISSUE INT, V107, P499, DOI 10.1007/s00223 020 00735 x
   Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097 2765(04)00028 0
   Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1387, DOI 10.1038/sj.jcbfm.9600447
   Zhu CY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.898634
NR 32
TC 4
Z9 4
U1 3
U2 22
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUN 28
PY 2024
VL 328
AR 118060
DI 10.1016/j.jep.2024.118060
EA APR 2024
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA RI3A7
UT WOS:001226984000001
PM 38521429
DA 2025 08 17
ER

PT J
AU Soysa, NS
   Alles, N
AF Soysa, Niroshani Surangika
   Alles, Neil
TI Osteoclast function and bone resorbing activity: An overview
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoclast activity; Bone resorption; Podosome; Actin ring formation
ID ALPHA(V)BETA(3) INTEGRIN; C SRC; KINASE; MICE; PYK2; OSTEOPETROSIS;
   DEFICIENCY; PHOSPHORYLATION; REGULATOR; ADHESION
AB Bone resorption is an important cellular function in skeletal development and remodeling of the adult skeleton. Most of the pathological bone disease conditions like osteoporosis reflect increased osteoclast activity; hence, increased bone resorption. Researchers have unraveled most of the intracellular mechanisms responsible for osteoclast bone resorbing activity in last few decades. Therefore, understanding the fundamentals of osteoclast induced bone resorption and the cytokines and other substances that modulate the osteoclast activity unequivocally provide insights into the development of drugs to ameliorate pathological bone diseases with enhanced bone resorption. The aim of this review is to examine the literature on osteoclast function and bone resorbing activity. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Soysa, Niroshani Surangika] Univ Peradeniya, Fac Dent Sci, Pharmacol, Peradeniya, Sri Lanka.
   [Alles, Neil] Univ Peradeniya, Fac Med, Dept Biochem, Peradeniya, Sri Lanka.
C3 University of Peradeniya; University of Peradeniya
RP Soysa, NS (通讯作者)，Univ Peradeniya, Fac Dent Sci, Pharmacol, Peradeniya, Sri Lanka.
EM niroshanis@pdn.ac.lk
CR Aoki K, 1999, BONE, V25, P261, DOI 10.1016/S8756 3282(99)00174 X
   Bruzzaniti A, 2006, REV ENDOCR METAB DIS, V7, P123, DOI 10.1007/s11154 006 9009 x
   Bruzzaniti A, 2009, MOL CELL BIOL, V29, P3644, DOI 10.1128/MCB.00851 08
   Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood 2003 04 1259
   Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665
   Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200
   Chiusaroli R, 2004, MOL BIOL CELL, V15, P234, DOI 10.1091/mbc.e03 04 0207
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900
   Lau KHW, 2012, AM J PHYSIOL CELL PH, V302, pC1676, DOI 10.1152/ajpcell.00042.2012
   Linder S, 2005, J CELL SCI, V118, P2079, DOI 10.1242/jcs.02390
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Motyckova Gabriela, 2002, Current Molecular Medicine (Hilversum), V2, P407, DOI 10.2174/1566524023362401
   Pavlos NJ, 2005, MOL CELL BIOL, V25, P5253, DOI 10.1128/MCB.25.12.5253 5269.2005
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   Sheng MHC, 2009, J BIOL CHEM, V284, P11531, DOI 10.1074/jbc.M808324200
   SLY WS, 1985, NEW ENGL J MED, V313, P139, DOI 10.1056/NEJM198507183130302
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Tehrani S, 2006, MOL BIOL CELL, V17, P2882, DOI 10.1091/mbc.E06 03 0187
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Yaroslavskiy BB, 2005, J CELL SCI, V118, P5479, DOI 10.1242/jcs.02655
   Yaroslavskiy BB, 2010, LAB INVEST, V90, P1533, DOI 10.1038/labinvest.2010.120
   Zhao HB, 2008, DEV CELL, V14, P914, DOI 10.1016/j.devcel.2008.03.022
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
NR 30
TC 102
Z9 120
U1 2
U2 51
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 29
PY 2016
VL 476
IS 3
BP 115
EP 120
DI 10.1016/j.bbrc.2016.05.019
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DP8PD
UT WOS:000378759200001
PM 27157135
DA 2025 08 17
ER

PT J
AU Pawlak, D
   Domaniewski, T
   Sieklucka, B
   Jakuc, M
   Pawlak, K
AF Pawlak, Dariusz
   Domaniewski, Tomasz
   Sieklucka, Beata
   Jakuc, Magdalena
   Pawlak, Krystyna
TI Inhibition of peripheral serotonin synthesis by LP533401 and
   disturbances in calciotropic hormones attenuated excessive
   osteoblastogenesis with simultaneous improvement of bone mineral status
   in 5/6 nephrectomized rats
SO BIOCHIMICA ET BIOPHYSICA ACTA MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Serotonin; Osteoblast proliferation/differentiation; Vitamin D; Bone
   mineral status; LP533401; Rat CKD model
ID CELL CYCLE; C MYC; GENE EXPRESSION; UP REGULATION; PROLIFERATION;
   DIFFERENTIATION; ASSOCIATION; DEFICIENCY; RESORPTION; MARKERS
AB Chronic kidney disease (CKD) is a pathological condition associated with renal osteodystrophy for which there are limited treatment options. Gut derived serotonin (GDS) is one of the key signaling factors controlling the osteoblast proliferation. Previously, we shown that inhibition of GDS synthesis by LP533401 improved bone mineral status of rats with 5/6 nephrectomy induced CKD model. Here, we investigated whether the use of LP533401 can modify GDS dependent molecular pathway involved in osteoblast formation and bone mineralization in CKD rats. The 8 weeks of pharmacological manipulation after a complete CKD development reduced GDS and lead to the advantage of endogenous vitamin D [25(OH)D] over serotonin and parathyroid hormone (PTH) in rats treated with LP533401. The imbalance between GDS   25(OH)D   PTH resulted in the intensified expression of cAMP  responsive element binding protein (Creb), whereas the expression of myelocytomatosis oncogene (c Myc) was simultaneously reduced. This lead to disruption of Foxol activating transcription factor 4 (Atf4) complex, and decrease in the expression of the major osteogenic markers. The weakening of excessive osteoblastogenesis was associated with better bone mineral status in all rats with CKD, and especially in LP533401 treated animals. In conclusion, the inhibition of GDS synthesis resulted in the mitigation of osteoblastogenesis observed in CKD, which translated into improvement of bone mineral status. This study provides key mechanistic insights into how modification of GDS dependent molecular pathway affects bone mineral status in CKD and lays the groundwork for translating the role of functional serotonin signaling in the origin of impaired bone mineral status in patients with CKD.
C1 [Pawlak, Dariusz; Sieklucka, Beata] Med Univ Bialystok, Dept Pharmacodynam, Mickiewicza 2C Str, PL 15222 Bialystok, Poland.
   [Domaniewski, Tomasz; Sieklucka, Beata; Jakuc, Magdalena; Pawlak, Krystyna] Med Univ Bialystok, Dept Monitored Pharmacotherapy, Mickiewicza 2C Str, PL 15222 Bialystok, Poland.
C3 Medical University of Bialystok; Medical University of Bialystok
RP Pawlak, K (通讯作者)，Med Univ Bialystok, Dept Monitored Pharmacotherapy, Mickiewicza 2C Str, PL 15222 Bialystok, Poland.
EM krystynapawlak@poczta.onet.pl
RI Pawlak, Krystyna/T 1139 2018; Sieklucka, Beata/S 9932 2018; Pawlak,
   Dariusz/T 3068 2018
OI Sieklucka, Beata/0000 0001 8384 7116; Pawlak,
   Dariusz/0000 0002 3751 0608; 
FU National Science Centre (NCN), Poland [2013/09/B/NZ7/00046]
FX This manuscript is financially supported by grant No.
   2013/09/B/NZ7/00046 financed by National Science Centre (NCN), Poland.
CR Atkins GJ, 2011, J BONE MINER RES, V26, P1425, DOI 10.1002/jbmr.345
   Bliziotes M, 2006, BONE, V39, P1313, DOI 10.1016/j.bone.2006.06.009
   Cejka D, 2016, KIDNEY INT, V90, P828, DOI 10.1016/j.kint.2016.06.019
   Cejka D, 2014, J CLIN ENDOCR METAB, V99, P248, DOI 10.1210/jc.2013 2786
   Collins FL, 2017, ADV EXP MED BIOL, V1033, P59, DOI 10.1007/978 3 319 66653 2_5
   Datta NS, 2007, J BONE MINER RES, V22, P951, DOI 10.1359/JBMR.070328
   Diem SJ, 2007, ARCH INTERN MED, V167, P1240, DOI 10.1001/archinte.167.12.1240
   Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199
   Eelen G, 2004, J BONE MINER RES, V19, P133, DOI 10.1359/JBMR.0301204
   Eleftheriadis T, 2013, IRAN J KIDNEY DIS, V7, P36
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gustafsson BI, 2006, J CELL BIOCHEM, V98, P139, DOI 10.1002/jcb.20734
   Haney EM, 2007, ARCH INTERN MED, V167, P1246, DOI 10.1001/archinte.167.12.1246
   HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0
   HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748
   Kaesler N, 2018, BONE, V107, P115, DOI 10.1016/j.bone.2017.11.015
   Kode A, 2012, J CLIN INVEST, V122, P3490, DOI 10.1172/JCI64906
   LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0
   Lavoie B, 2017, ADV EXP MED BIOL, V1033, P35, DOI 10.1007/978 3 319 66653 2_3
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MARIE PJ, 1993, BONE, V14, P463, DOI 10.1016/8756 3282(93)90180 I
   McNerny EMB, 2017, CURR OSTEOPOROS REP, V15, P207, DOI 10.1007/s11914 017 0366 z
   Milinkovic NLJ, 2009, CLIN LAB, V55, P333
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Oliveira MC, 2016, J NUTR BIOCHEM, V30, P74, DOI 10.1016/j.jnutbio.2015.11.017
   Pawlak D, 2019, EXPERT OPIN THER TAR, V23, P353, DOI 10.1080/14728222.2019.1586883
   Pawlak D, 2018, BONE, V113, P124, DOI 10.1016/j.bone.2018.05.022
   Pawlak D, 2017, BONE, V105, P1, DOI 10.1016/j.bone.2017.08.004
   Pawlak D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163526
   Pereira RC, 2015, KIDNEY INT, V87, P593, DOI 10.1038/ki.2014.347
   Perry K.W., 2016, CHRONIC KIDNEY DIS M, P1214
   Pimentel A, 2017, KIDNEY INT, V92, P1343, DOI 10.1016/j.kint.2017.07.021
   SMITH E, 1995, CANCER RES, V55, P5019
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Zhang YX, 2018, BIOCHEM BIOPH RES CO, V503, P1401, DOI 10.1016/j.bbrc.2018.07.055
NR 37
TC 5
Z9 7
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925 4439
EI 1879 260X
J9 BBA MOL BASIS DIS
JI Biochim. Biophys. Acta Mol. Basis Dis.
PD NOV 1
PY 2019
VL 1865
IS 11
AR 165528
DI 10.1016/j.bbadis.2019.08.004
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA JB6CO
UT WOS:000488652400010
PM 31398464
OA hybrid
DA 2025 08 17
ER

PT J
AU Li, Y
   Li, AM
   Strait, K
   Zhang, HY
   Nanes, MS
   Weitzmann, MN
AF Li, Yan
   Li, Aimin
   Strait, Karen
   Zhang, Hongying
   Nanes, Mark S.
   Weitzmann, M. Neale
TI Endogenous TNFα lowers maximum peak bone mass and inhibits osteoblastic
   smad activation through NF κB
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE TNF alpha; TGF beta; NF kappa B; Smad; BMP 2
ID TUMOR NECROSIS FACTOR; LOSS IN VIVO; SIGNALING PATHWAYS; T CELLS;
   TRANSFORMING GROWTH FACTOR BETA 1; COLLAGENASE 3 EXPRESSION; MEDIATED
   APOPTOSIS; UP REGULATION; CANCER CELLS; BETA
AB Endogenous TNF alpha prevents the attainment of maximum achievable peak bone mass in vivo. In vitro, TNF alpha suppresses BMP 2  and TGF beta mediated Smad activation through induction of NF kappa B. Consistently, pharmacological suppression of NF kappa B augments osteoblast differentiation and mineralization in vitro.
   Introduction: Osteoporosis is a major health threat. Traditional therapeutic strategies have centered on anti catabolic drugs that block bone resorption. Recently focus; has shifted to anabolic agents that actively rebuild lost bone mass. Future strategies may involve elevating peak bone mass to delay osteoporosis development. Recent in vitro studies show that TNF alpha represses osteoblast differentiation and mineralization; however, the mechanisms are poorly understood and the impact of basal TNF alpha concentrations on the acquisition of peak bone mass in vivo is unknown.
   Materials and Methods: We examined peak BMD, bone volume, and bone turnover makers in mice deficient in TNF alpha or its receptors. We further examined the effect of TNF alpha on Smad induced signaling by TGF beta and BMP 2 in vitro using a Smad responsive reporter. The effect of TNF alpha induced NF kappa B signaling on Smad signaling and on in vitro osteoblast mineralization was examined using specific NF kappa B inhibitors and activators, and effects of TNFa induced NF kappa B signaling on BMP 2 induced Runx2 mRNA were examined using RT PCR.
   Results: Mice null for TNF alpha or its p55 receptor had significantly increased peak bone mass, resulting exclusively from elevated bone formation. In vitro, TNF alpha potently suppressed Smad signaling induced by TGF beta and BMP 2, downregulated BMP 2 mediated Runx2 expression., and inhibited mineralization of osteoblasts. These effects were mimicked by overexpression of NF kappa B and prevented by pharmacological NF kappa B suppression.
   Conclusions: Our data suggest that TNF alpha and NF kappa B antagonists may represent novel anabolic agents for the maximization of peak basal bone mass and/or the amelioration of pathological bone loss.
C1 Emory Univ, Sch Med, Div Endocrinol & Metab & Lipids, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Div Anim Resources, Atlanta, GA 30322 USA.
   Vet Affairs Med Ctr, Atlanta, GA 30033 USA.
C3 Emory University; Emory University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Atlanta VA Health Care System
RP Weitzmann, MN (通讯作者)，Emory Univ, Sch Med, Div Endocrinol & Metab & Lipids, 101 Woodruff Circle,WMRB 1305, Atlanta, GA 30322 USA.
EM mweitzm@emory.edu
FU NIAMS NIH HHS [P30 AR46031] Funding Source: Medline; NIDDK NIH HHS
   [DK067389, T32 DK007298] Funding Source: Medline; PHS HHS [ARAR046452]
   Funding Source: Medline
CR AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   Beamer WG, 1996, BONE, V18, P397, DOI 10.1016/8756 3282(96)00047 6
   Brodt MD, 1999, J BONE MINER RES, V14, P2159, DOI 10.1359/jbmr.1999.14.12.2159
   BROWN A, 1984, SURF INTERFACE ANAL, V6, P1, DOI 10.1002/sia.740060102
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Chen SQ, 2001, J BIOL CHEM, V276, P39259, DOI 10.1074/jbc.M105335200
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200
   Eliseev RA, 2006, EXP CELL RES, V312, P40, DOI 10.1016/j.yexcr.2005.09.016
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546 2559.2004
   Gao YH, 2004, P NATL ACAD SCI USA, V101, P16618, DOI 10.1073/pnas.0404888101
   Gebken J, 1999, J ENDOCRINOL, V161, P503, DOI 10.1677/joe.0.1610503
   Gilbert DA, 2005, ANN PLAS SURG, V55, P101, DOI 10.1097/01.sap.0000169069.57473.aa
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890
   KIMBLE RB, 1995, ENDOCRINOLOGY, V136, P3054, DOI 10.1210/en.136.7.3054
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOOKER AC, 1995, OSTEOPOROSIS INT, V5, P389, DOI 10.1007/BF01622262
   Lu XH, 2006, J BIOL CHEM, V281, P6297, DOI 10.1074/jbc.M507804200
   Lu XH, 2004, J CELL BIOCHEM, V92, P833, DOI 10.1002/jcb.20143
   Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357 4310(00)01814 1
   May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pascher E, 1999, HORM METAB RES, V31, P653, DOI 10.1055/s 2007 978815
   Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002 9440(10)63144 6
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200
   Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200
   Spinella Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756 3282(01)00580 4
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   van Roon JAG, 2003, ANN RHEUM DIS, V62, P113, DOI 10.1136/ard.62.2.113
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhou FH, 2006, J BONE MINER RES, V21, P1075, DOI 10.1359/JBMR.060410
NR 44
TC 152
Z9 167
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2007
VL 22
IS 5
BP 646
EP 655
DI 10.1359/JBMR.070121
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 160IL
UT WOS:000245934000002
PM 17266397
OA Bronze
DA 2025 08 17
ER

PT J
AU Allison, SJ
   Baldock, P
   Sainsbury, A
   Enriquez, R
   Lee, NJ
   Lin, EJD
   Klugman, M
   During, M
   Eisman, JA
   Li, M
   Pan, LC
   Herzog, H
   Gardiner, EM
AF Allison, Susan J.
   Baldock, Paul
   Sainsbury, Amanda
   Enriquez, Ronaldo
   Lee, Nicola J.
   Lin, En Ju Deborah
   Klugman, Matthias
   During, Matthew
   Eisman, John A.
   Li, Mei
   Pan, Lydia C.
   Herzog, Herbert
   Gardiner, Edith M.
TI Conditional deletion of hypothalamic Y2 receptors reverts
   gonadectomy induced bone loss in adult mice
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE; Y2 RECEPTORS; OB/OB MICE;
   OSTEOPOROSIS; BODY; EXPRESSION; OSTEOBLASTS; OVARIECTOMY; ALENDRONATE
AB Reduction in levels of sex hormones at menopause in women is associated with two common, major outcomes, the accumulation of white adipose tissue, and the progressive loss of bone because of excess osteoclastic bone resorption exceeding osteoblastic bone formation. Current antiresorptive therapies can reduce osteoclastic activity but have only limited capacity to stimulate osteoblastic bone formation and restore lost skeletal mass. Likewise, the availability of effective pharmacological weight loss treatments is currently limited. Here we demonstrate that conditional deletion of hypothalamic neuropeptide Y2 receptors can prevent ongoing bone loss in sex hormone deficient adult male and female mice. This benefit is attributable solely to activation of an anabolic osteoblastic bone formation response that counterbalances persistent elevation of bone resorption, suggesting the Y2 mediated anabolic pathway to be independent of sex hormones. Furthermore, the increase in fat mass that typically occurs after ovariectomy is prevented by germ line deletion of Y2 receptors, whereas in male mice body weight and fat mass were consistently lower than wild type regardless of sex hormone status. Therefore, this study indicates a role for Y2 receptors in the accumulation of adipose tissue in the hypogonadal state and demonstrates that hypothalamic Y2 receptors constitutively restrain osteoblastic activity even in the absence of sex hormones. The increase in bone formation after release of this tonic inhibition suggests a promising new avenue for osteoporosis treatment.
C1 St Vincents Hosp, Garvan Inst Med Res, Neurosci Res Program, Sydney, NSW 2010, Australia.
   St Vincents Hosp, Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia.
   Univ Auckland, Dept Mol Med & Pathol, Auckland 1, New Zealand.
   Univ Queensland, Princess Alexandra Hosp, Sch Med, Brisbane, Qld 4120, Australia.
   Pfizer Global Res & Dev Inc, Groton, CT 06340 USA.
C3 NSW Health; St Vincents Hospital Sydney; Garvan Institute of Medical
   Research; Garvan Institute of Medical Research; NSW Health; St Vincents
   Hospital Sydney; University of Auckland; Princess Alexandra Hospital;
   University of Queensland; Pfizer; Pfizer USA
RP Herzog, H (通讯作者)，St Vincents Hosp, Garvan Inst Med Res, Neurosci Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.
EM h.herzog@garvan.org.au
RI ; Eisman, John/C 2886 2014; Herzog, Herbert/B 8294 2008; During,
   Matthew/AAC 1388 2020; lin, en/KFS 0748 2024; Salis, Amanda/A 3187 2011;
   Baldock, Paul/B 3840 2012; Lee, Nicola/B 2038 2013
OI Herzog, Herbert/0000 0002 1713 1029; Salis, Amanda/0000 0001 9176 1574;
   Lee, Nicola/0000 0001 7766 6095
CR Ainslie DA, 2001, INT J OBESITY, V25, P1680, DOI 10.1038/sj.ijo.0801806
   Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588
   Baldock PAJ, 1998, J BONE MINER RES, V13, P1451, DOI 10.1359/jbmr.1998.13.9.1451
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Dénes A, 2005, NEUROSCIENCE, V134, P947, DOI 10.1016/j.neuroscience.2005.03.060
   Escobar CM, 2004, J CLIN ENDOCR METAB, V89, P2338, DOI 10.1210/jc.2003 031899
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Godsland IF, 2004, CLIN ENDOCRINOL, V60, P541, DOI 10.1111/j.1365 2265.2004.02017.x
   Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148
   Inoue K, 1997, J BONE MINER RES, V12, P989, DOI 10.1359/jbmr.1997.12.6.989
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   McCarthy TL, 2001, GROWTH HORM IGF RES, V11, P213, DOI 10.1054/ghir.2001.0236
   Naveilhan P, 2002, PEPTIDES, V23, P1087, DOI 10.1016/S0196 9781(02)00042 6
   POEHLMAN ET, 1995, ANN INTERN MED, V123, P673, DOI 10.7326/0003 4819 123 9 199511010 00005
   REHMAN MTA, 1994, J CLIN PATHOL, V47, P529, DOI 10.1136/jcp.47.6.529
   REID IR, 1992, J CLIN ENDOCR METAB, V75, P45, DOI 10.1210/jc.75.1.45
   ROHOLL PJM, 1994, J BONE MINER RES, V9, P355
   Sainsbury A, 2002, P NATL ACAD SCI USA, V99, P8938, DOI 10.1073/pnas.132043299
   Sainsbury A, 2002, DIABETES, V51, P3420, DOI 10.2337/diabetes.51.12.3420
   Shimizu H, 1996, NEUROSCI LETT, V204, P81, DOI 10.1016/0304 3940(96)12322 3
   Toth MJ, 2000, ANN NY ACAD SCI, V904, P502
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   WRONSKI TJ, 1986, BONE, V7, P119, DOI 10.1016/8756 3282(86)90683 6
   WRONSKI TJ, 1989, CALCIFIED TISSUE INT, V45, P360, DOI 10.1007/BF02556007
   Yudoh K, 2001, J BONE MINER RES, V16, P1453, DOI 10.1359/jbmr.2001.16.8.1453
NR 26
TC 58
Z9 63
U1 1
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 18
PY 2006
VL 281
IS 33
BP 23436
EP 23444
DI 10.1074/jbc.M604839200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 072WE
UT WOS:000239702900018
PM 16785231
OA hybrid
DA 2025 08 17
ER

PT J
AU Tao, XF
   Qi, Y
   Xu, LN
   Yin, LH
   Han, X
   Xu, YW
   Wang, CY
   Sun, HJ
   Peng, JY
AF Tao, Xufeng
   Qi, Yan
   Xu, Lina
   Yin, Lianhong
   Han, Xu
   Xu, Youwei
   Wang, Changyuan
   Sun, Huijun
   Peng, Jinyong
TI Dioscin reduces ovariectomy induced bone loss by enhancing
   osteoblastogenesis and inhibiting osteoclastogenesis
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Dioscin; Osteoblasts; Osteoclasts; Ovariectomy; Postmenopausal
   osteoporosis
ID NATURAL STEROID SAPONIN; LIVER DAMAGE; IN VITRO; OSTEOPOROSIS;
   DIFFERENTIATION; THERAPIES; RANKL; APOPTOSIS; INSIGHT; PATHWAY
AB Our previous studies showed that dioscin can promote osteoblasts proliferation and differentiation in vitro, but its anti osteoporosis effect in vivo and the underlying mechanisms remain unclear. In the present work, the results showed that dioscin significantly increased the viability of MC3T3 E1 cells, ALP level and alizarin red S staining area, markedly decreased the numbers of RANKL induced TRAP positive multinucleated cells and bone resorption pits formation, enhanced the levels of some osteogenic markers including COL1A2, ALP and OC, which suggested that dioscin clearly promoted osteoblasts proliferation and suppressed osteoclasts formation. In vivo experiments demonstrated that dioscin obviously reduced OVX induced body weight increase, and improved the biochemical indexes including ALP, StrACP, OC, DPD/Cr, HOP/Cr, BMD, biomechanics and microarchitecture. Moreover, H&E, TB, TRAP staining, and fluorescent double labeling tests indicated that dioscin enhanced osteoblastogenesis and inhibited osteoclastogenesis. Further researches demonstrated that dioscin promoted osteoblastogenesis through up regulating OPG/RANKL ratio, and inhibited osteoclastogenesis through down regulating the levels of RANKL induced TRAF6 and the downstream signal molecules including MAPKs, Akt, NF kappa B, AP 1, cathepsin K and NFATc1. In addition, dioscin also inhibited TLR4/MyD88 pathway to decrease the levels of TRAF6 and the related proteins. These findings provide new insights to elucidate the effects of dioscin against OVX induced bone loss, which should be developed as a potential candidate for treating postmenopausal osteoporosis in the future. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Tao, Xufeng; Qi, Yan; Xu, Lina; Yin, Lianhong; Han, Xu; Xu, Youwei; Wang, Changyuan; Sun, Huijun; Peng, Jinyong] Dalian Med Univ, Coll Pharm, Western 9 Lvshunnan Rd, Dalian 116044, Peoples R China.
C3 Dalian Medical University
RP Peng, JY (通讯作者)，Dalian Med Univ, Coll Pharm, Western 9 Lvshunnan Rd, Dalian 116044, Peoples R China.
EM jinyongpeng2005@163.com
RI qi, Yan/KIC 1612 2024
FU Program for Liaoning Innovative Research Team in University [LT2013019]
FX This work was financially supported by the Program for Liaoning
   Innovative Research Team in University (LT2013019).
CR Alliston T, 2002, NATURE, V416, P686, DOI 10.1038/416686a
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chen H, 2014, PROTEOMICS, V14, P51, DOI 10.1002/pmic.201300101
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Cho J, 2013, BBA BIOMEMBRANES, V1828, P1153, DOI 10.1016/j.bbamem.2012.12.010
   Curtis JR, 2013, BONE, V55, P1, DOI 10.1016/j.bone.2013.03.003
   Habold C, 2011, J BONE MINER METAB, V29, P15, DOI 10.1007/s00774 010 0187 y
   Huang Q, 2014, BONE, V66, P306, DOI 10.1016/j.bone.2014.06.010
   Iimura Y, 2015, J BONE MINER METAB, V33, P270, DOI 10.1007/s00774 014 0596 4
   Jang YJ, 2011, ARCH ORAL BIOL, V56, P1319, DOI 10.1016/j.archoralbio.2011.05.010
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lamothe B, 2013, MOL CELL BIOL, V33, P582, DOI 10.1128/MCB.01225 12
   Lampropoulos CE, 2012, NAT REV RHEUMATOL, V8, P587, DOI 10.1038/nrrheum.2012.120
   Lane NE, 2006, NAT CLIN PRACT RHEUM, V2, P562, DOI 10.1038/ncprheum0298
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Liu CH, 2013, VIRUS RES, V172, P9, DOI 10.1016/j.virusres.2012.12.001
   Liu M, 2015, SCI REP UK, V5, DOI 10.1038/srep07973
   Lu BN, 2011, PLANTA MED, V77, P407, DOI 10.1055/s 0030 1250461
   Lv LL, 2013, FOOD CHEM TOXICOL, V59, P657, DOI 10.1016/j.fct.2013.07.012
   Marx J, 2004, SCIENCE, V305, P1420, DOI 10.1126/science.305.5689.1420
   Mulder JE, 2006, NAT CLIN PRACT ENDOC, V2, P670, DOI 10.1038/ncpendmet0325
   Qiu SX, 2007, CHEM BIOL, V14, P860, DOI 10.1016/j.chembiol.2007.06.010
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytogfr.2003.10.005
   Tao XF, 2015, FREE RADICAL BIO MED, V84, P103, DOI 10.1016/j.freeradbiomed.2015.03.003
   Tao XF, 2014, RSC ADV, V4, P54026, DOI 10.1039/c4ra09160d
   Tao XF, 2014, TRANSPLANTATION, V98, P604, DOI 10.1097/TP.0000000000000262
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tyagi AM, 2010, MOL CELL ENDOCRINOL, V325, P101, DOI 10.1016/j.mce.2010.05.016
   Wang XX, 2014, NEUROPHARMACOLOGY, V79, P642, DOI 10.1016/j.neuropharm.2014.01.022
   Xu LN, 2014, RSC ADV, V4, P30704, DOI 10.1039/c4ra03948c
   Xu TT, 2014, ARCH TOXICOL, V88, P739, DOI 10.1007/s00204 013 1148 8
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yin LH, 2010, CHROMATOGRAPHIA, V71, P15, DOI 10.1365/s10337 009 1407 2
   Yin LH, 2010, CHEM ENG J, V165, P281, DOI 10.1016/j.cej.2010.09.045
   Zare Bidaki M, 2014, MICROB PATHOGENESIS, V69 70, P28, DOI 10.1016/j.micpath.2014.03.006
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhang CF, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 30
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhang XL, 2015, CHEM COMMUN, V51, P11064, DOI 10.1039/c4cc09160d
   Zhang XL, 2015, SCI REP UK, V5, DOI 10.1038/srep09713
   Zhao XM, 2012, TOXICOL LETT, V214, P69, DOI 10.1016/j.toxlet.2012.08.005
NR 48
TC 48
Z9 51
U1 1
U2 30
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
EI 1096 1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JUN
PY 2016
VL 108
BP 90
EP 101
DI 10.1016/j.phrs.2016.05.003
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DO4CO
UT WOS:000377729600013
PM 27155058
DA 2025 08 17
ER

PT J
AU Yang, L
   Ge, DW
   Cao, XJ
   Ge, YB
   Chen, HT
   Wang, WW
   Zhang, HX
AF Yang, Lei
   Ge, Dawei
   Cao, Xiaojian
   Ge, Yingbin
   Chen, Hongtao
   Wang, Weiwei
   Zhang, Hongxiu
TI MiR 214 Attenuates Osteogenic Differentiation of Mesenchymal Stem Cells
   via Targeting FGFR1
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Postmenopausal osteoporosis; MSCs; miR 214; FGFR1; Osteoblast
   differentiation
ID SKELETAL DEVELOPMENT; BONE; MICRORNAS; GROWTH; OSTEOPOROSIS; EXPRESSION;
   DISEASE; CANCER; REPAIR
AB Background/Aims: Postmenopausal osteoporosis is closely associated with reduction in the differentiation of mesenchymal stem cells (MSCs) into osteoblasts. Previous studies have demonstrated that miR 214 plays an important role in the genesis and development of postmenopausal osteoporosis. Here, we performed this study to investigate the potential mechanism by which miR 214 regulates osteoblast differentiation of MSCs. Methods: First, we explored the expression of miR 214 in MSCs of osteoporotic mice. Next, we examined the change of miR 214 during osteoblast differentiation of MSCs. Then, MSCs were infected with lentiviral vectors expressing miR 214 or miR 214 sponge to investigate the effect of miR 214 on osteoblast differentiation of MSCs. Further, bioinformatics analysis and luciferase reporter assay were performed to identify and validate the target gene of miR 214. Results: MiR 214 was up regulated in MSCs of osteoporotic mice and down regulated during osteoblast differentiation of MSCs. Furthermore, overexpression of miR 214 inhibited osteoblast differentiation of MSCs in vitro, whereas inhibition of miR 214 function promoted this process, evidenced by increased expression of osteoblast specific genes, alkaline phosphatase (ALP) activity, and matrix mineralization. Bioinformatics, Western blot analysis and luciferase reporter assay demonstrated that FGFR1 is a direct target of miR 214. Conclusions: MiR 214 attenuates osteogenesis by inhibiting the FGFR1/FGF signaling pathway. Our findings suggest that targeting miR 214 promises to be a potential therapy in treatment of postmenopausal osteoporosis. (C) 2016 The Author(s) Published by S. Karger AG, Basel
C1 [Yang, Lei; Ge, Dawei; Cao, Xiaojian; Chen, Hongtao] Nanjing Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.
   [Ge, Yingbin] Nanjing Med Univ, Dept Physiol, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, Weiwei; Zhang, Hongxiu] Nanjing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Zhang, HX (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM hongxiuz@hotmail.com
RI Weiwei, Wang/N 8838 2018; Ge, Dawei/KHX 0100 2024; YANG,
   LEI/GQH 4271 2022; Zhou, Weiping/AGI 5344 2022
OI Ge, Dawei/0000 0003 3603 3448; 
FU National Natural Science Foundation of China [81472989]; Jiangsu
   Province Foundation for Women's Health [F201201]; Priority Academic
   Program Development of Jiangsu Higher Education Institutions
FX This work was supported by the National Natural Science Foundation of
   China (No. 81472989, to Hong Xiu Zhang), Jiangsu Province Foundation for
   Women's Health (No. F201201, to Hong Xiu Zhang), and the Priority
   Academic Program Development of Jiangsu Higher Education Institutions.
CR [Anonymous], 2014, PLOS ONE
   Aurora AB, 2012, J CLIN INVEST, V122, P1222, DOI 10.1172/JCI59327
   Bielby R, 2007, INJURY, V38, pS26, DOI 10.1016/j.injury.2007.02.007
   Du XL, 2012, J CELL PHYSIOL, V227, P3731, DOI 10.1002/jcp.24083
   Gámez B, 2014, J MOL ENDOCRINOL, V52, pR179, DOI 10.1530/JME 13 0294
   Güller I, 2010, J PHYSIOL LONDON, V588, P4075, DOI 10.1113/jphysiol.2010.194175
   Hajihosseini MK, 2004, DEVELOPMENT, V131, P325, DOI 10.1242/dev.00940
   He XJ, 2009, J CELL MOL MED, V13, P606, DOI 10.1111/j.1582 4934.2009.00696.x
   Jindra PT, 2010, J IMMUNOL, V185, P990, DOI 10.4049/jimmunol.1000793
   Kim KM, 2014, CURR OPIN PHARMACOL, V16, P133, DOI 10.1016/j.coph.2014.05.001
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Li HQ, 2014, BIOMARKERS, V19, P553, DOI 10.3109/1354750X.2014.935957
   Li JB, 2014, CHEM SOC REV, V43, P506, DOI 10.1039/c3cs60312a
   Miraoui H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3146re9
   Moore Benjamin T, 2013, Microrna, V2, P20
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rodríguez JP, 2004, J CELL BIOCHEM, V92, P745, DOI 10.1002/jcb.20119
   Rosen CJ, 2005, NEW ENGL J MED, V353, P595, DOI 10.1056/NEJMcp043801
   Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010
   Shi KK, 2013, BONE, V55, P487, DOI 10.1016/j.bone.2013.04.002
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Teven CM, 2014, GENES DIS, V1, P199, DOI 10.1016/j.gendis.2014.09.005
   Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470 2045(09)70343 2
   van Mil A, 2012, CARDIOVASC RES, V93, P655, DOI 10.1093/cvr/cvs003
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang X, 2013, INT ORTHOP, V37, P2491, DOI 10.1007/s00264 013 2059 2
   Watanabe T, 2008, DEV DYNAM, V237, P3738, DOI 10.1002/dvdy.21787
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Wu M, 2014, CELL PHYSIOL BIOCHEM, V33, P569, DOI 10.1159/000358635
   Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008 5472.CAN 07 2488
   Yang TS, 2013, CANCER CELL INT, V13, DOI 10.1186/1475 2867 13 68
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
NR 33
TC 64
Z9 75
U1 0
U2 20
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2016
VL 38
IS 2
BP 809
EP 820
DI 10.1159/000443036
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA DF1ER
UT WOS:000371082300030
PM 26872365
OA gold
DA 2025 08 17
ER

PT J
AU Nishida, S
   Tsubaki, M
   Hoshino, M
   Namimatsu, A
   Uji, H
   Yoshioka, S
   Tanimori, Y
   Yanae, M
   Iwaki, M
   Irimajiri, K
AF Nishida, S
   Tsubaki, M
   Hoshino, M
   Namimatsu, A
   Uji, H
   Yoshioka, S
   Tanimori, Y
   Yanae, M
   Iwaki, M
   Irimajiri, K
TI Nitrogen containing bisphosphonate, YM529/ONO 5920 (a novel minodronic
   acid), inhibits RANKL expression in a cultured bone marrow stromal cell
   line ST2
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE bisphosphonate; YM529/ONO 5920; RANKL; ST2 cells; stromal cells
ID PROTEIN KINASE C; KAPPA B LIGAND; OSTEOCLAST DIFFERENTIATION; MEVALONATE
   PATHWAY; RECEPTOR ACTIVATOR; RESORPTION; OSTEOPROTEGERIN; D 3
AB Increase in bone resorption by osteoclasts can cause metabolic bone diseases, such as osteoporosis. Recent attention has been paid to the receptor activator of the NF kappaB ligand (RANKL), an accelerator of osteoclast differentiation. RANKL is expressed on the bone marrow derived stromal cell membrane and induces the differentiation of osteoclasts by binding to RANK expressed on the osteoclast precursor cell membrane. Since the inhibition of RANKL expression can lead to the inhibition of osteoclastic bone resorption, the clinical application of RANKL inhibition could be expected to have a major effect on metabolic bone disease therapy. In this study, we investigated whether or not YM529/ONO 5920, a nitrogen containing bisphosphonate (a novel minodronic acid), inhibits RANKL expression in a bone marrow derived stromal cell line (ST2 cells). Reverse transcription polymerase chain reaction revealed that the administration of YM529/ONO 5920 to ST2 cells inhibited RANKL mRNA expression and reduced RANKL proteins as assessed by Western blot analysis. The inhibition of RANKL mRNA expression was reversed when geranylgeranyl pyrophosphate (GGPP), an intermediate in the mevalonate pathway, was used in combination. Furthermore, YM529/ ONO 5920 reduced phosphorylated extracellular signal regulated kinase 1/2 (ERK1/2), and similarly, U0126, a mitogen activated protein kinase kinase 1/2 inhibitor, inhibited RANKL expression. Pretreatment with GGPP reversed the YM529/ONO 5920 induced decrease in phosphorylation of ERK. Furthermore, YM529/ONO 5920 decreased TRAP positive cells in co culture of ST2 cells and an osteoclast cell line, C7 cells, and this decrease was inhibited by pretreatment with GGPP. This indicates that YM529/ONO 5920 inhibits GGPP biosynthesis in the mevalonate pathway and then signal transduction in the Ras mitogen activated protein kinase pathway, thereby inhibiting RANKL expression on ST2 cells. These results suggest a newly elucidated action of bisphosphonates in the inhibition of bone resorption. (C) 2005 Elsevier Inc. All rights reserved.
C1 Kinki Univ, Sch Pharmaceut Sci, Div Pharmacotherapy, Higashiosaka, Osaka 5778502, Japan.
   Kinki Univ, Sch Pharmaceut Sci, Div Biopharmaceut, Higashiosaka, Osaka 5778502, Japan.
C3 Kindai University (Kinki University); Kindai University (Kinki
   University)
RP Kinki Univ, Sch Pharmaceut Sci, Div Pharmacotherapy, 3 4 1 Kowakae, Higashiosaka, Osaka 5778502, Japan.
EM nishida@phar.kindai.ac.jp
RI 正寛, 椿/JDF 1457 2023
CR Bernardi RJ, 2002, ENDOCRINOLOGY, V143, P2508, DOI 10.1210/en.143.7.2508
   FAN X, 2003, ENDOCRINOLOGY
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Gniadecki R, 1996, J INVEST DERMATOL, V106, P1212, DOI 10.1111/1523 1747.ep12348498
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim YH, 2002, EXP MOL MED, V34, P145, DOI 10.1038/emm.2002.21
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   MATUMOTO M, 2000, J BIOL CHEM, V275, P31155
   Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200
   Miyamoto A, 1998, BIOCHEM BIOPH RES CO, V242, P703, DOI 10.1006/bbrc.1997.8046
   Nishida S, 2003, LIFE SCI, V73, P2655, DOI 10.1016/S0024 3205(03)00664 7
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   SLATER SJ, 1995, J BIOL CHEM, V270, P6639, DOI 10.1074/jbc.270.12.6639
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071
   Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091
   Takami M, 2000, ENDOCRINOLOGY, V141, P4711, DOI 10.1210/en.141.12.4711
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
NR 24
TC 31
Z9 34
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 4
PY 2005
VL 328
IS 1
BP 91
EP 97
DI 10.1016/j.bbrc.2004.12.145
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 894NU
UT WOS:000226799600015
PM 15670755
DA 2025 08 17
ER

PT J
AU Cheng, YH
   Streicher, DA
   Waning, DL
   Chitteti, BR
   Gerard O'Riley, R
   Horowitz, MC
   Bidwell, JP
   Pavalko, FM
   Srour, EF
   Mayo, LD
   Kacena, MA
AF Cheng, Ying Hua
   Streicher, Drew A.
   Waning, David L.
   Chitteti, Brahmananda R.
   Gerard O'Riley, Rita
   Horowitz, Mark C.
   Bidwell, Joseph P.
   Pavalko, Fredrick M.
   Srour, Edward F.
   Mayo, Lindsey D.
   Kacena, Melissa A.
TI Signaling Pathways Involved in Megakaryocyte Mediated Proliferation of
   Osteoblast Lineage Cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID BONE MASS PHENOTYPE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; CYCLE
   CONTROL; TUMOR SUPPRESSOR; NUCLEAR EXPORT; MYELOPROLIFERATIVE SYNDROME;
   PLATELET FORMATION; ONCOPROTEIN MDM2; RB PROTEIN
AB Recent studies suggest that megakaryocytes (MKs) may play a significant role in skeletal homeostasis, as evident by the occurrence of osteosclerosis in multiple MK related diseases (Lennert et al., 1975; Thiele et al., 1999; Chagraoui et al., 2006). We previously reported a novel interaction whereby MKs enhanced proliferation of osteoblast lineage/osteoprogenitor cells (OBs) by a mechanism requiring direct cell cell contact. However, the signal transduction pathways and the downstream effector molecules involved in this process have not been characterized. Here we show that MKs contact with OBs, via beta1 integrin, activate the p38/MAPKAPK2/p90RSK kinase cascade in the bone cells, which causes Mdm2 to neutralizes p53/Rb mediated check point and allows progression through the G1/S. Interestingly, activation of MAPK (ERK1/2) and AKT, collateral pathways that regulate the cell cycle, remained unchanged with MK stimulation of OBs. The MK to OB signaling ultimately results in significant increases in the expression of c fos and cyclin A, necessary for sustaining the OB proliferation. Overall, our findings show that OBs respond to the presence of MKs, in part, via an integrin mediated signaling mechanism, activating a novel response axis that de represses cell cycle activity. Understanding the mechanisms by which MKs enhance OB proliferation will facilitate the development of novel anabolic therapies to treat bone loss associated with osteoporosis and other bone related diseases. J. Cell. Physiol. 230: 578 586, 2015. (c) 2014 Wiley Periodicals, Inc., A Wiley Company
C1 [Cheng, Ying Hua; Streicher, Drew A.; Kacena, Melissa A.] Indiana Univ Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA.
   [Waning, David L.; Srour, Edward F.; Mayo, Lindsey D.] Indiana Univ Sch Med, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.
   [Waning, David L.; Chitteti, Brahmananda R.; Gerard O'Riley, Rita; Srour, Edward F.; Mayo, Lindsey D.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
   [Gerard O'Riley, Rita; Pavalko, Fredrick M.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.
   [Horowitz, Mark C.; Kacena, Melissa A.] Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06510 USA.
   [Bidwell, Joseph P.; Kacena, Melissa A.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Srour, Edward F.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.
   [Mayo, Lindsey D.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; Yale University; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University Bloomington
RP Mayo, LD (通讯作者)，Indiana Univ Sch Med, Wells Ctr Pediat Res, Walther Hall R3 C518,980 West Walnut St, Indianapolis, IN 46202 USA.
EM ldmayo@iupui.edu; mkacena@iupui.edu
FU NIH [UL1TR001108, AR055269, AR060332, AR052682, HL55716, CA109262,
   CA082709, HL110854, DK090948]
FX Contract grant sponsor: NIH;Contract grant numbers: UL1TR001108,
   AR055269, AR060332, AR052682, HL55716, CA109262, CA082709, HL110854,
   DK090948.
CR Berman SD, 2008, MOL CANCER RES, V6, P1440, DOI 10.1158/1541 7786.MCR 08 0176
   Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499
   CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490
   Chagraoui H, 2006, BEST PRACT RES CL HA, V19, P399, DOI 10.1016/j.beha.2005.07.002
   CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092 8674(91)90557 F
   CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562
   Cheng LZ, 2000, J CELL PHYSIOL, V184, P58, DOI 10.1002/(SICI)1097 4652(200007)184:1<58::AID JCP6>3.0.CO;2 B
   Cheng YH, 2013, J BONE MINER RES, V28, P1434, DOI 10.1002/jbmr.1876
   Ciovacco WA, 2010, J CELL BIOCHEM, V109, P774, DOI 10.1002/jcb.22456
   Ciovacco WA, 2009, BONE, V44, P80, DOI 10.1016/j.bone.2008.08.117
   DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772
   Dominici M, 2009, BLOOD, V114, P2333, DOI 10.1182/blood 2008 10 183459
   Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483
   Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288
   Frey BM, 1998, SCHWEIZ MED WSCHR, V128, P1587
   Frey BM, 1998, J IMMUNOL, V160, P691
   Frum R, 2009, MOL CANCER RES, V7, P1253, DOI 10.1158/1541 7786.MCR 08 0334
   Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507
   GJETTING T, 1995, BIOL CHEM H S, V376, P441
   GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092 8674(91)90181 W
   GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0
   HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877
   Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0
   HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092 8674(92)90249 C
   HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959 437X(05)80341 7
   Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955 0674(93)90102 V
   Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014 5793(97)01480 4
   HOROWITZ MC, 1994, ENDOCRINOLOGY, V135, P1032, DOI 10.1210/en.135.3.1032
   Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097 2765(00)80309 3
   HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247
   Jackson MW, 2006, J BIOL CHEM, V281, P16814, DOI 10.1074/jbc.M511617200
   JILKA RL, 1981, ENDOCRINOLOGY, V109, P743, DOI 10.1210/endo 109 3 743
   Kacena MA, 2005, BONE, V36, P215, DOI 10.1016/j.bone.2004.09.024
   Kacena MA, 2004, J BONE MINER RES, V19, P652, DOI 10.1359/JBMR.0301254
   Kacena MA, 2006, BONE, V39, P991, DOI 10.1016/j.bone.2006.05.004
   Kacena MA, 2012, J BIOL CHEM, V287, P17257, DOI 10.1074/jbc.M111.309880
   Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0
   Lemieux JM, 2010, J CELL BIOCHEM, V109, P927, DOI 10.1002/jcb.22468
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   LENNERT K, 1975, CLIN HAEMATOL, V4, P331
   Léveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651
   Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362
   Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198
   MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166
   Miao D, 2004, TISSUE ENG, V10, P807, DOI 10.1089/1076327041348473
   MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092 8674(92)90644 R
   Olson TS, 2013, BLOOD, V121, P5238, DOI 10.1182/blood 2012 10 463414
   Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764
   Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017
   Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200
   Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965
   SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092 8674(95)90531 6
   SIMMONS DJ, 1982, CALCIFIED TISSUE INT, V34, P291, DOI 10.1007/BF02411253
   SROUR EF, 1992, J IMMUNOL, V148, P815
   Suva LJ, 2008, AM J PATHOL, V172, P430, DOI 10.2353/ajpath.2008.070417
   Thiele J, 1999, ANN HEMATOL, V78, P495, DOI 10.1007/s002770050546
   Towler D.A., 2002, Principles of Bone Biology, VSecond, P1503, DOI DOI 10.1016/B978 012098652 1.50190 6
   Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714
   Villeval JL, 1997, BLOOD, V90, P4369
   Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092 8674(95)90385 2
   WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167
   XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0
   Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016
   YAN XQ, 1995, BLOOD, V86, P4025, DOI 10.1182/blood.V86.11.4025.bloodjournal86114025
   Yan XQ, 1996, BLOOD, V88, P402, DOI 10.1182/blood.V88.2.402.bloodjournal882402
   Ying HQ, 2006, CELL CYCLE, V5, P506, DOI 10.4161/cc.5.5.2515
NR 67
TC 14
Z9 19
U1 0
U2 27
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAR
PY 2015
VL 230
IS 3
BP 578
EP 586
DI 10.1002/jcp.24774
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA AU3JI
UT WOS:000345508400011
PM 25160801
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Weske, S
   Vaidya, M
   Reese, A
   Lipinski, KV
   Keul, P
   Bayer, JK
   Fischer, JW
   Flögel, U
   Nelsen, J
   Epple, M
   Scatena, M
   Schwedhelm, E
   Dörr, M
   Völzke, H
   Moritz, E
   Hannemann, A
   Rauch, BH
   Gräler, MH
   Heusch, G
   Levkau, B
AF Weske, Sarah
   Vaidya, Mithila
   Reese, Alina
   Lipinski, Karin von Wnuck
   Keul, Petra
   Bayer, Julia K.
   Fischer, Jens W.
   Floegel, Ulrich
   Nelsen, Jens
   Epple, Matthias
   Scatena, Marta
   Schwedhelm, Edzard
   Doerr, Marcus
   Voelzke, Henry
   Moritz, Eileen
   Hannemann, Anke
   Rauch, Bernhard H.
   Graeler, Markus H.
   Heusch, Gerd
   Levkau, Bodo
TI Targeting sphingosine 1 phosphate lyase as an anabolic therapy for bone
   loss
SO NATURE MEDICINE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; ACTIVATED RECEPTOR GAMMA; OSTEOBLAST
   DIFFERENTIATION; SPHINGOSINE 1 PHOSPHATE; C/EBP ALPHA; PPAR GAMMA;
   GENE EXPRESSION; ADIPOSE TISSUE; MICE; ADIPOGENESIS
AB Sphingosine 1 phosphate (S1P) signaling influences bone metabolism, but its therapeutic potential in bone disorders has remained unexplored. We show that raising S1P levels in adult mice through conditionally deleting or pharmacologically inhibiting S1P lyase, the sole enzyme responsible for irreversibly degrading S1P, markedly increased bone formation, mass and strength and substantially decreased white adipose tissue. S1P signaling through S1P(2) potently stimulated osteoblastogenesis at the expense of adipogenesis by inversely regulating osterix and PPAR gamma, and it simultaneously inhibited osteoclastogenesis by inducing osteoprotegerin through newly discovered p38 GSK3 beta beta catenin and WNT5A LRP5 pathways. Accordingly, S1P(2) deficient mice were osteopenic and obese. In ovariectomy induced osteopenia, S1P lyase inhibition was as effective as intermittent parathyroid hormone (iPTH) treatment in increasing bone mass and was superior to iPTH in enhancing bone strength. Furthermore, lyase inhibition in mice successfully corrected severe genetic osteoporosis caused by osteoprotegerin deficiency. Human data from 4,091 participants of the SHIP Trend population based study revealed a positive association between serum levels of S1P and bone formation markers, but not resorption markers. Furthermore, serum S1P levels were positively associated with serum calcium, negatively with PTH, and curvilinearly with body mass index. Bone stiffness, as determined through quantitative ultrasound, was inversely related to levels of both S1P and the bone formation marker PINP, suggesting that S1P stimulates osteoanabolic activity to counteract decreasing bone quality. S1P based drugs should be considered as a promising therapeutic avenue for the treatment of osteoporotic diseases.
C1 [Weske, Sarah; Vaidya, Mithila; Reese, Alina; Lipinski, Karin von Wnuck; Keul, Petra; Heusch, Gerd; Levkau, Bodo] Univ Duisburg Essen, Univ Hosp Essen, West German Heart & Vasc Ctr, Inst Pathophysiol, Essen, Germany.
   [Bayer, Julia K.; Fischer, Jens W.] Univ Dusseldorf, Inst Pharmacol & Clin Pharmacol, Dusseldorf, Germany.
   [Floegel, Ulrich] Univ Dusseldorf, Inst Mol Cardiol, Dusseldorf, Germany.
   [Fischer, Jens W.; Floegel, Ulrich] Univ Duisburg Essen, Inst Inorgan Chem, Essen, Germany.
   [Scatena, Marta] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Schwedhelm, Edzard] Univ Med Ctr Hamburg Eppendorf, Inst Clin Pharmacol & Toxicol, Hamburg, Germany.
   [Schwedhelm, Edzard] German Ctr Cardiovasc Res DZHK, Partner Site Hamburg, Hamburg, Germany.
   [Doerr, Marcus; Moritz, Eileen; Rauch, Bernhard H.] DZHK, Partner Site Greifswald, Greifswald, Germany.
   [Doerr, Marcus] Univ Med Greifswald, Dept Internal Med B, Greifswald, Germany.
   [Voelzke, Henry] Univ Med Greifswald, Inst Community Med, Greifswald, Germany.
   [Moritz, Eileen; Rauch, Bernhard H.] Univ Med Greifswald, Dept Gen Pharmacol, Inst Pharmacol, Greifswald, Germany.
   [Hannemann, Anke] Univ Med Greifswald, Inst Clin Chem & Lab Med, Greifswald, Germany.
   [Graeler, Markus H.] Univ Hosp Jena, Ctr Sepsis Control & Care, Dept Anesthesiol & Intens Care Med, Jena, Germany.
   [Graeler, Markus H.] Univ Hosp Jena, Ctr Mol Biomed, Jena, Germany.
C3 University of Duisburg Essen; Heinrich Heine University Dusseldorf;
   Heinrich Heine University Dusseldorf; University of Duisburg Essen;
   University of Washington; University of Washington Seattle; University
   of Hamburg; University Medical Center Hamburg Eppendorf; German Centre
   for Cardiovascular Research; German Centre for Cardiovascular Research;
   Universitat Greifswald; Greifswald Medical School; Universitat
   Greifswald; Greifswald Medical School; Universitat Greifswald;
   Greifswald Medical School; Universitat Greifswald; Greifswald Medical
   School; Friedrich Schiller University of Jena; Friedrich Schiller
   University of Jena
RP Levkau, B (通讯作者)，Univ Duisburg Essen, Univ Hosp Essen, West German Heart & Vasc Ctr, Inst Pathophysiol, Essen, Germany.
EM bodo.levkau@uni due.de
RI ; Epple, Matthias/AAX 9694 2020; Dörr, Marcus/F 1919 2010; Flögel,
   Ulrich/AFO 8602 2022; Rauch, Bernhard/Q 6205 2018; Gräler,
   Markus/ABH 1905 2021; Heusch, Gerd/ABE 6675 2020
OI Keul, Petra/0000 0001 6611 4121; Rauch, Bernhard/0000 0002 6003 4662;
   Epple, Matthias/0000 0002 1641 7068; Dorr, Marcus/0000 0001 7471 475X;
   Graler, Markus/0000 0001 6650 7849; 
FU Deutsche Forschungsgemeinschaft [GRK 2098, SFB 1116]; Alexander von
   Humboldt Foundation; Federal Ministry of Education and Research
   [01ZZ9603, 01ZZ0103, 01ZZ0403]; Ministry of Cultural Affairs; Social
   Ministry of the Federal State of Mecklenburg West Pomerania; Deutsches
   Zentrum fur Herz Kreislauf Forschung e.V.
FX We gratefully acknowledge excellent technical help by Kerstin Abou
   Hamed, forthcoming support by the Zentrales Tierlabor,
   Universitatsklinikum Essen (G. Hilken, P. Dammann, A. Wissmann, R.
   Waldschutz) and stimulating discussions with A. Levkau. I dedicate this
   work to my father, Lubomir Levkau. This work was supported in part by
   the Deutsche Forschungsgemeinschaft, GRK 2098, projects 9 11 (B.L.,
   P.K.), SFB 1116, projects A08 (J.W.F.) and B02, B05 (U.F.). The work was
   also supported by the Alexander von Humboldt Foundation through a
   research fellowship awarded to M.V. The SHIP Trend study is part of the
   Community Medicine Research net of the University of Greifswald,
   Germany, funded by the Federal Ministry of Education and Research
   (Grants 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural
   Affairs and the Social Ministry of the Federal State of Mecklenburg West
   Pomerania. This work was also funded in part by grants from the
   Deutsches Zentrum fur Herz Kreislauf Forschung e.V. (B.H.R., M.D.,
   E.S.).
CR A Kumar, 2008, Indian J Community Med, V33, P156, DOI 10.4103/0970 0218.42051
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Bae SJ, 2016, OSTEOPOROSIS INT, V27, P2533, DOI 10.1007/s00198 016 3565 z
   Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854
   Billich A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059630
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyce BF, 2005, CELL METAB, V2, P344, DOI 10.1016/j.cmet.2005.11.011
   Burghoff S, 2013, ARCH PHYSIOL BIOCHEM, V119, P39, DOI 10.3109/13813455.2012.755547
   Carr MC, 2003, J CLIN ENDOCR METAB, V88, P2404, DOI 10.1210/jc.2003 030242
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Declercq H, 2004, BIOMATERIALS, V25, P757, DOI 10.1016/S0142 9612(03)00580 5
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Goetzl EJ, 2007, FASEB J, V21, P638, DOI 10.1096/fj.06 6624hyp
   Günther T, 2007, NAT CELL BIOL, V9, P1229, DOI 10.1038/ncb1107 1229
   Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681
   Hans D, 1996, LANCET, V348, P511, DOI 10.1016/S0140 6736(95)11456 4
   Hashimoto Y, 2015, MOL CELL BIOCHEM, V401, P39, DOI 10.1007/s11010 014 2290 1
   Ishii M, 2013, BBA MOL CELL BIOL L, V1831, P223, DOI 10.1016/j.bbalip.2012.06.002
   Ishii M, 2010, J EXP MED, V207, P2793, DOI 10.1084/jem.20101474
   Ishii T, 2011, MOL CELLS, V31, P399, DOI 10.1007/s10059 011 1010 x
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kawamoto T, 2014, METHODS MOL BIOL, V1130, P149, DOI 10.1007/978 1 62703 989 5_11
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim SW, 2005, BIOCHEM BIOPH RES CO, V327, P811, DOI 10.1016/j.bbrc.2004.12.076
   Kowalski GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072449
   Kraus D, 2014, NATURE, V508, P258, DOI 10.1038/nature13198
   Kunkel GT, 2013, NAT REV DRUG DISCOV, V12, P688, DOI 10.1038/nrd4099
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Lee SH, 2012, J CLIN ENDOCR METAB, V97, pE1421, DOI 10.1210/jc.2012 1044
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   McClung MR, 2017, BONE, V96, P3, DOI 10.1016/j.bone.2016.12.012
   Miao DS, 2002, J HISTOCHEM CYTOCHEM, V50, P333, DOI 10.1177/002215540205000305
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426
   Moritz E, 2017, CLIN CHIM ACTA, V468, P25, DOI 10.1016/j.cca.2017.01.029
   Parham KA, 2015, FASEB J, V29, P3638, DOI 10.1096/fj.14 261289
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Pelletier D, 2012, NEW ENGL J MED, V366, P339, DOI 10.1056/NEJMct1101691
   Peptan IA, 2006, PLAST RECONSTR SURG, V117, P1462, DOI 10.1097/01.prs.0000206319.80719.74
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702
   Rosen H, 2013, ANNU REV BIOCHEM, V82, P637, DOI 10.1146/annurev biochem 062411 130916
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Schürer C, 2015, DTSCH ARZTEBL INT, V112, P365, DOI 10.3238/arztebl.2015.0365
   Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640
   Shockley KR, 2009, J CELL BIOCHEM, V106, P232, DOI 10.1002/jcb.21994
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Stone CJ, 1985, P STAT COMP SECT AM, P45
   Stubbins RE, 2012, EUR J NUTR, V51, P861, DOI 10.1007/s00394 011 0266 4
   Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113
   Takahashi T, 2011, CALCIFIED TISSUE INT, V88, P336, DOI 10.1007/s00223 011 9461 9
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tucci S, 2011, AM J CLIN NUTR, V94, P439, DOI 10.3945/ajcn.111.012948
   Völzke H, 2011, INT J EPIDEMIOL, V40, P294, DOI 10.1093/ije/dyp394
   Vogel P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004112
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Wu L, 2007, MOL CELL BIOCHEM, V301, P83, DOI 10.1007/s11010 006 9399 9
   Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097 2765(00)80306 8
   Yokoyama Noriko, 2007, J Mol Signal, V2, P11, DOI 10.1186/1750 2187 2 11
   Yu WH, 2012, INT J BIOCHEM CELL B, V44, P377, DOI 10.1016/j.biocel.2011.11.013
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhao LJ, 2008, J BONE MINER RES, V23, P17, DOI 10.1359/JBMR.070813
   Zoico E, 2016, ONCOTARGET, V7, P20223, DOI 10.18632/oncotarget.7936
NR 73
TC 98
Z9 104
U1 0
U2 30
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD MAY
PY 2018
VL 24
IS 5
BP 667
EP +
DI 10.1038/s41591 018 0005 y
PG 15
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA GF7CY
UT WOS:000432126800024
PM 29662200
DA 2025 08 17
ER

PT J
AU Rajput, S
   Kulkarni, C
   Sharma, S
   Tomar, MS
   Khatoon, S
   Gupta, A
   Sanyal, S
   Shrivastava, A
   Ghosh, JK
   Chattopadhyay, N
AF Rajput, Swati
   Kulkarni, Chirag
   Sharma, Shivani
   Tomar, Manendra Singh
   Khatoon, Shamima
   Gupta, Arvind
   Sanyal, Sabyasachi
   Shrivastava, Ashutosh
   Ghosh, Jimut Kanti
   Chattopadhyay, Naibedya
TI Osteogenic effect of an adiponectin derived short peptide that
   rebalances bone remodeling: a potential disease modifying approach for
   postmenopausal osteoporosis therapy
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Article
DE Postmenopausal osteoporosis; Mitochondrial biogenesis; Bone remodeling;
   Bone mass; Bone strength; Bone resorption
ID ADIPOR1; RECEPTORS; APOPTOSIS; PROTECTS; EXPRESSION; MECHANISM; ROLES;
   SARCOPENIA; WOMEN; MASS
AB Adiponectin, an adipokine, regulates metabolic processes, including glucose flux, lipid breakdown, and insulin response, by activating adiponectin receptors 1 and 2 (AdipoR1 and AdipoR2). We have previously shown that globular adiponectin (gAd), an endogenous form of adiponectin, has osteoanabolic and anti catabolic effects in rodent models of postmenopausal osteopenia. Moreover, we reported the identification of a 13 mer peptide (ADP 1) from the collagen domain of adiponectin, which exhibited significant adiponectin mimetic properties. Since the clinical development of gAd is constrained by its large size, here, we investigated the osteogenic property of ADP 1. ADP 1 induced osteoblast differentiation more potently than gAd. ADP 1 elicited osteoblast differentiation through two downstream pathways that involved the participation of adiponectin receptors. Firstly, it enhanced mitochondrial biogenesis and OxPhos, leading to osteoblast differentiation. Secondly, it activated the Akt glycogen synthase kinase 3 beta Wnt pathway, thereby increasing osteoblast differentiation. Additionally, ADP 1 suppressed the production of receptor activator of nuclear kappa B ligand from osteoblasts, enabling it to act as a dual action molecule (suppressing osteoclast function besides promoting osteoblast function). In osteopenic ovariectomized rats, ADP 1 increased bone mass and strength and improved trabecular integrity by stimulating bone formation and inhibiting bone resorption. Furthermore, by increasing ATP producing intermediates within the tricarboxylic acid cycle in bones, ADP 1 likely fueled osteoblast function. Given its dual action mechanism and high potency, ADP 1 offers a unique opportunity to address the unmet clinical need to reset the aberrant bone remodeling in osteoporosis to normalcy, potentially offering a disease modifying impact.
C1 [Rajput, Swati; Kulkarni, Chirag; Sharma, Shivani; Chattopadhyay, Naibedya] Cent Drug Res Inst, Ctr Res Anabol Skeletal Targets Hlth & Illness AST, Div Endocrinol, CSIR, Sector 10,Jankipuram Extension,Sitapur Rd, Lucknow 226031, India.
   [Rajput, Swati; Kulkarni, Chirag; Sharma, Shivani; Ghosh, Jimut Kanti; Chattopadhyay, Naibedya] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India.
   [Tomar, Manendra Singh; Shrivastava, Ashutosh] King Georges Med Univ, Fac Med, Ctr Adv Res, Lucknow, India.
   [Khatoon, Shamima; Sanyal, Sabyasachi] Cent Drug Res Inst, Div Biochem & Struct Biol, CSIR, Sector 10,Jankipuram Extension,Sitapur Rd, Lucknow 226031, India.
   [Gupta, Arvind; Ghosh, Jimut Kanti] Cent Drug Res Inst, CSIR, Mol & Struct Biol Div, Sect 10,Jankipuram Extens Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Academy of Scientific &
   Innovative Research (AcSIR); King George's Medical University; Council
   of Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI); Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Central Drug Research Institute (CDRI)
RP Chattopadhyay, N (通讯作者)，Cent Drug Res Inst, Ctr Res Anabol Skeletal Targets Hlth & Illness AST, Div Endocrinol, CSIR, Sector 10,Jankipuram Extension,Sitapur Rd, Lucknow 226031, India.; Chattopadhyay, N (通讯作者)，Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India.
EM n_chattopadhyay@cdri.res.in
RI Sharma, Dr Shivani/LRT 9327 2024; Chattopadhyay, Naibedya/AAF 2058 2019
OI Chattopadhyay, Naibedya/0000 0003 2473 0246
FU Council of Scientific and Industrial Research, Government of India
   [DBT/2018/CDRI/1047]; Council of Scientific and Industrial Research,
   Ministry of Science and Technology, Government of India [MLP 2035,
   IHP0028, 10816]
FX SR acknowledges the Department of Biotechnology, Govt. of India, for
   graduate fellowship (Ref No. DBT/2018/CDRI/1047). NC and JKG acknowledge
   funding from the Council of Scientific and Industrial Research, Ministry
   of Science and Technology, Government of India (MLP 2035), and SS
   acknowledges CDRI in house fund IHP0028. The authors acknowledge the
   CDRI SAIF facility for flow cytometry. The CDRI communication number for
   this article is 10816.
CR Almabouada F, 2013, J BIOL CHEM, V288, P3112, DOI 10.1074/jbc.M112.404624
   Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Alzahrani B, 2018, BBA MOL BASIS DIS, V1864, P700, DOI 10.1016/j.bbadis.2017.12.012
   Bandeira L, 2022, ARCH ENDOCRIN METAB, V66, P707, DOI 10.20945/2359 3997000000566
   Bhattacharyya S, 2018, EUR J PHARMACOL, V826, P39, DOI 10.1016/j.ejphar.2018.02.028
   Bradford PG, 2010, PHYSIOL BEHAV, V99, P181, DOI 10.1016/j.physbeh.2009.04.025
   Buckinx F, 2022, INT J WOMENS HEALTH, V14, P805, DOI 10.2147/IJWH.S340537
   Cannarella R, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101564
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   China SP, 2018, CYTOKINE, V112, P116, DOI 10.1016/j.cyto.2018.06.012
   China SP, 2017, BONE, V105, P75, DOI 10.1016/j.bone.2017.08.005
   Darmawan CC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082833
   Ding C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063878
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Föger Samwald U, 2020, EXCLI J, V19, P1017, DOI 10.17179/excli2020 2591
   Gluenz E, 2008, MOL MICROBIOL, V69, P666, DOI 10.1111/j.1365 2958.2008.06320.x
   Haas AV, 2018, J ENDOCR SOC, V2, P922, DOI 10.1210/js.2018 00118
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Iwabu M, 2010, NATURE, V464, P1313, DOI 10.1038/nature08991
   Jain S, 2017, CANCER INVEST, V35, P473, DOI 10.1080/07357907.2017.1337783
   Jie C, 2021, EUR J MED RES, V26, DOI 10.1186/s40001 021 00496 9
   Keshvari S, 2015, MOL CELL ENDOCRINOL, V409, P121, DOI 10.1016/j.mce.2015.04.003
   Khan MP, 2015, DIABETES, V64, P2609, DOI 10.2337/db14 1611
   Kim DE, 2014, EXP CELL RES, V327, P264, DOI 10.1016/j.yexcr.2014.07.037
   Kim Y, 2018, J AM SOC NEPHROL, V29, P1108, DOI 10.1681/ASN.2017060627
   Kobayashi Y, 2008, JPN DENT SCI REV, V44, P76, DOI 10.1016/j.jdsr.2007.11.002
   Kobza AO, 2020, IMMUNOTHERAPY UK, V12, P965, DOI 10.2217/imt 2020 0158
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Li GQ, 2023, ARTHRITIS RES THER, V25, DOI 10.1186/s13075 022 02981 w
   Liu HX, 2020, EXP NEUROL, V329, DOI 10.1016/j.expneurol.2020.113302
   Logan C, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12091232
   Minisola S, 2019, THER ADV MUSCULOSKEL, V11, DOI 10.1177/1759720X19877994
   Mitsui Y, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 18
   Pal S, 2021, EUR J PHARMACOL, V913, DOI 10.1016/j.ejphar.2021.174634
   Pal S, 2019, BIOCHEM PHARMACOL, V164, P34, DOI 10.1016/j.bcp.2019.03.024
   Pal S, 2016, TOXICOL APPL PHARM, V295, P12, DOI 10.1016/j.taap.2016.02.002
   Parker Duffen JL, 2014, J BIOL CHEM, V289, P16200, DOI 10.1074/jbc.M114.548115
   Porwal K, 2019, TOXICOL SCI, V172, P167, DOI 10.1093/toxsci/kfz172
   Porwal K, 2017, J NUTR BIOCHEM, V44, P22, DOI 10.1016/j.jnutbio.2017.02.011
   POUILLES JM, 1995, J BONE MINER RES, V10, P1531
   Rio DC., 2010, COLD SPRING HARB PRO, DOI [10.1101/pdb.prot5439, DOI 10.1101/PDB.PROT5439]
   Romorini L, 2016, SCI REP UK, V6, DOI 10.1038/srep35660
   Samelson EJ, 2019, LANCET DIABETES ENDO, V7, P34, DOI [10.1016/s2213 8587(18)30308 5, 10.1016/S2213 8587(18)30308 5]
   Sayeed M, 2018, J BIOL CHEM, V293, P13509, DOI 10.1074/jbc.RA118.001801
   Seidlitz EP, 2010, CAN J PHYSIOL PHARM, V88, P929, DOI [10.1139/Y10 070, 10.1139/y10 070]
   Sharan K, 2011, J BONE MINER RES, V26, P2096, DOI 10.1002/jbmr.434
   Sharma S, 2022, FOOD FUNCT, V13, P2184, DOI [10.1039/d1fo03867b, 10.1039/D1FO03867B]
   Shen LY, 2022, CURR OSTEOPOROS REP, V20, P53, DOI 10.1007/s11914 022 00721 2
   Siasos G, 2012, CURR MED CHEM, V19, P1193, DOI 10.2174/092986712799320583
   Singh AK, 2017, MOL CELL ENDOCRINOL, V439, P273, DOI 10.1016/j.mce.2016.09.013
   Singh AK, 2014, DIABETES, V63, P3530, DOI 10.2337/db13 1619
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Stojanovic SS, 2018, ACTA ENDOCRINOL BUCH, V14, P201, DOI 10.4183/aeb.2018.201
   Suh JH, 2022, J DERMATOL SCI, V106, P45, DOI 10.1016/j.jdermsci.2022.03.003
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Nguyen TD, 2020, INT J PREVENTIVE MED, V11, DOI 10.4103/ijpvm.IJPVM_193_20
   Thundyil J, 2012, BRIT J PHARMACOL, V165, P313, DOI 10.1111/j.1476 5381.2011.01560.x
   Tian Y, 2011, MOL CELL BIOCHEM, V355, P211, DOI 10.1007/s11010 011 0856 8
   Wang HF, 2016, SCI REP UK, V6, DOI 10.1038/srep19445
   Wang LT, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065814
   Washimkar KR, 2023, CHEM BIOL INTERACT, V373, DOI 10.1016/j.cbi.2023.110373
   Wijesekara N, 2010, J BIOL CHEM, V285, P33623, DOI 10.1074/jbc.M109.085084
   Yadav SP, 2009, BBA BIOMEMBRANES, V1788, P538, DOI 10.1016/j.bbamem.2008.11.013
   Yamauchi T, 2008, INT J OBESITY, V32, pS13, DOI 10.1038/ijo.2008.233
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Yang J, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00815
   Zaheer S, 2015, EXPERT OPIN DRUG MET, V11, P461, DOI 10.1517/17425255.2015.1000860
   Zhou T, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/8928934
NR 70
TC 2
Z9 2
U1 1
U2 9
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489 3 SUHCHO DONG, SUHCHO KU, SEOUL 137 071, SOUTH KOREA
SN 0253 6269
EI 1976 3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD SEP
PY 2024
VL 47
IS 8 9
BP 736
EP 755
DI 10.1007/s12272 024 01509 x
EA JUL 2024
PG 20
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA I4H9P
UT WOS:001279232800001
PM 39073743
DA 2025 08 17
ER

PT J
AU Conti, F
   Wolosinska, DT
   Pugliese, G
AF Conti, F.
   Wolosinska, D. T.
   Pugliese, G.
TI Diabetes and bone fragility: a dangerous liaison
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Diabetes; Bone fragility; Bone mineral density; Glucose lowering drugs;
   Pathophysiology
ID SCLEROSTIN LEVELS; MICROARCHITECTURE; TURNOVER; TYPE 1
AB Patients with diabetes are at greater risk of fractures not only for bone mineral density (BMD) decrease, showed for type 1 diabetes mellitus (T1DM), but also for bone tissue alterations that reduce bone quality and strength; thus, BMD values do not reflect bone fragility in diabetics. Higher rates of fracture in diabetic patients can be related both to changes in bone quality and in long standing diabetes to microvascular complications that lead to a greater risk of falling. Diabetes leads to impaired bone formation through many mechanisms: insulin deficiency and hyperglycemia, prevalently by AGE/RAGE axis alteration, insulin growth factors reduction, and alterations in osteocalcin and/or Wnt signaling pathways. Therefore, an adequate glycemic control is mandatory in diabetes to preserve bone health. Metformin, incretins, and DPP 4 inhibitors have a potentially positive effect on bone status, while close attention should be paid to a long term therapy with thiazolidinediones, because they are associated to an increased risk of fracture.
C1 [Conti, F.; Wolosinska, D. T.; Pugliese, G.] Univ Roma La Sapienza, Dept Mol Med, I 00185 Rome, Italy.
C3 Sapienza University Rome
RP Conti, F (通讯作者)，Univ Roma La Sapienza, Dept Mol Med, Piazzale Aldo Moro 5, I 00185 Rome, Italy.
EM francesco.conti@uniroma1.it
RI Pugliese, Giuseppe/G 8776 2012
OI Pugliese, Giuseppe/0000 0003 1574 0397
CR Burghardt AJ, 2010, J CLIN ENDOCR METAB, V95, P5045, DOI 10.1210/jc.2010 0226
   Gaudio A, 2012, J CLIN ENDOCR METAB, V97, P3744, DOI 10.1210/jc.2012 1901
   Gennari L, 2012, J CLIN ENDOCR METAB, V97, P1737, DOI 10.1210/jc.2011 2958
   Hein GE, 2006, CLIN CHIM ACTA, V371, P32, DOI 10.1016/j.cca.2006.03.017
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224
   Kanazawa I, 2013, OSTEOPOROSIS INT, V24, P1115, DOI 10.1007/s00198 012 2017 7
   Katayama Y, 1996, J BONE MINER RES, V11, P931, DOI 10.1002/jbmr.5650110709
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Meier C, 2008, ARCH INTERN MED, V168, P820, DOI 10.1001/archinte.168.8.820
   Monami M, 2011, DIABETES CARE, V34, P2474, DOI 10.2337/dc11 1099
   Montagnani A, 2013, DIABETES OBES METAB, V15, P784, DOI 10.1111/dom.12077
   Pritchard JM, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 114
   Seto Young D, 2005, J CLIN ENDOCR METAB, V90, P6099, DOI 10.1210/jc.2005 0469
   Welters HJ, 2008, TRENDS ENDOCRIN MET, V19, P349, DOI 10.1016/j.tem.2008.08.004
NR 15
TC 3
Z9 3
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1594 0667
EI 1720 8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD OCT
PY 2013
VL 25
SU 1
BP S39
EP S41
DI 10.1007/s40520 013 0084 z
PG 3
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA 257MW
UT WOS:000327389800011
PM 23907773
DA 2025 08 17
ER

PT J
AU Krieger, NS
   Bushinsky, DA
AF Krieger, Nancy S.
   Bushinsky, David A.
TI Pharmacological inhibition of intracellular calcium release blocks
   acid induced bone resorption
SO AMERICAN JOURNAL OF PHYSIOLOGY RENAL PHYSIOLOGY
LA English
DT Article
DE acidosis; cyclooxygenase 2; receptor activator of NF kappa B ligand
ID PROTEIN COUPLED RECEPTORS; 2 AMINOETHOXYDIPHENYL BORATE 2 APB; NEONATAL
   MOUSE CALVARIA; RENAL TUBULAR ACIDOSIS; OSTEOBLAST LIKE CELLS; EFFLUX
   IN VITRO; KAPPA B LIGAND; PARATHYROID HORMONE; CYCLOOXYGENASE 2
   EXPRESSION; POTASSIUM BICARBONATE
AB Krieger NS, Bushinsky DA. Pharmacological inhibition of intracellular calcium release blocks acid induced bone resorption. Am J Physiol Renal Physiol 300: F91 F97, 2011. First published November 3, 2010; doi:10.1152/ajprenal.00276.2010. In vivo chronic metabolic acidosis induces net Ca2+ efflux from bone, and incubation of neonatal mouse calvariae in medium simulating physiological metabolic acidosis induces bone resorption. It appears that activation of the proton (H+) receptor OGR1 in the osteoblast leads to an increase in intracellular Ca2+, which is associated with an increase in cyclooxygenase 2 (COX2) and PGE(2) induced receptor activator of NF kappa B ligand (RANKL) and H+ induced osteoclastic bone resorption. To support this hypothesis, we tested whether intracellular Ca(2+)signaling was integral to H+ induced bone resorption by determining whether 8 (N, N diethylamino) octyl 3,4,5 trimethoxybenzoate (TMB 8) and 2 aminoethoxydiphenyl borate (2 APB), inhibitors of inositol trisphosphate mediated Ca2+ signaling, would block H+ induced bone resorption in cultured neonatal calvariae and, if so, would do so by inhibiting H+ induced stimulation of COX2 and RANKL in osteoblastic cells. We found that H+ induced bone resorption is significantly inhibited by TMB 8 and 2 APB. Both compounds also inhibit H+ induced stimulation of COX2 protein in calvariae and COX2 mRNA and protein levels in primary osteoblasts. H+ induced stimulation of RANKL in calvarial cultures, as well as primary cells, is also completely inhibited by TMB 8 and 2 APB. These results support the hypothesis that H+ stimulation of net Ca2+ efflux from bone, mediated by COX2  and subsequent PGE(2) induced RANKL production, is initiated in the osteoblast via activation of Ca2+ signaling.
C1 [Krieger, Nancy S.; Bushinsky, David A.] Univ Rochester, Sch Med & Dent, Div Nephrol, Dept Med, Rochester, NY 14642 USA.
C3 University of Rochester
RP Krieger, NS (通讯作者)，Univ Rochester, Sch Med & Dent, Div Nephrol, Dept Med, 601 Elmwood Ave,Box 675, Rochester, NY 14642 USA.
EM Nancy_Krieger@urmc.rochester.edu
FU National Institutes of Health [AR 46289, DK 75462]; Renal Research
   Institute
FX This work was supported in part by National Institutes of Health Grants
   AR 46289 and DK 75462 and a grant from the Renal Research Institute.
CR ARNETT TR, 1994, J BONE MINER RES, V9, P375
   Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02 0037rev
   Brechter AB, 2007, ARTHRITIS RHEUM US, V56, P910, DOI 10.1002/art.22445
   Brighton CT, 2001, J BONE JOINT SURG AM, V83A, P1514, DOI 10.2106/00004623 200110000 00009
   Bush JO, 2004, P NATL ACAD SCI USA, V101, P7022, DOI 10.1073/pnas.0401025101
   BUSHINSKY DA, 1989, AM J PHYSIOL, V256, pE152, DOI 10.1152/ajpendo.1989.256.1.E152
   BUSHINSKY DA, 1994, J BONE MINER RES, V9, P213
   BUSHINSKY DA, 1985, AM J PHYSIOL, V248, pF785, DOI 10.1152/ajprenal.1985.248.6.F785
   BUSHINSKY DA, 1983, AM J PHYSIOL, V245, pF204, DOI 10.1152/ajprenal.1983.245.2.F204
   Bushinsky DA, 2010, SPECTRUM MINERAL BON, V2, P253
   Domrongkitchaiporn S, 2002, KIDNEY INT, V62, P2160, DOI 10.1046/j.1523 1755.2002.00656.x
   Domrongkitchaiporn S, 2001, KIDNEY INT, V59, P1086, DOI 10.1046/j.1523 1755.2001.0590031086.x
   FALSAFI R, 1991, CALCIFIED TISSUE INT, V49, P333, DOI 10.1007/BF02556256
   FANG MA, 1992, ENDOCRINOLOGY, V131, P2113, DOI 10.1210/en.131.5.2113
   Frick KK, 2009, J BONE MINER RES, V24, P305, DOI 10.1359/JBMR.081015
   Frick KK, 2005, AM J PHYSIOL RENAL, V289, pF1005, DOI 10.1152/ajprenal.00420.2004
   Frick KK, 2003, J BONE MINER RES, V18, P1317, DOI 10.1359/jbmr.2003.18.7.1317
   Ishii S, 2005, J BIOL CHEM, V280, P9083, DOI 10.1074/jbc.M407832200
   Juvin V, 2007, MOL PHARMACOL, V72, P1258, DOI 10.1124/mol.107.037044
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Kondo A, 2004, BIOCHEM PHARMACOL, V68, P1423, DOI 10.1016/j.bcp.2004.06.007
   Krieger NS, 2007, J BONE MINER RES, V22, P907, DOI 10.1359/JBMR.070316
   Krieger NS, 2004, CURR OPIN NEPHROL HY, V13, P423, DOI 10.1097/01.mnh.0000133975.32559.6b
   KRIEGER NS, 1992, J BONE MINER RES, V7, P1105
   KRIEGER NS, 1989, CALCIFIED TISSUE INT, V44, P192, DOI 10.1007/BF02556564
   KRIEGER NS, 1992, AM J PHYSIOL, V262, pF442, DOI 10.1152/ajprenal.1992.262.3.F442
   Krieger NS, 2000, AM J PHYSIOL RENAL, V279, pF1077, DOI 10.1152/ajprenal.2000.279.6.F1077
   Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105
   LEMANN J, 1991, CLIN RES, V39, pA469
   Lemann J, 2003, AM J PHYSIOL RENAL, V285, pF811, DOI 10.1152/ajprenal.00115.2003
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905
   Lyons JM, 2001, J BONE MINER RES, V16, P2035, DOI 10.1359/jbmr.2001.16.11.2035
   Nilius B, 2007, BIOCHEM SOC T, V35, P105, DOI 10.1042/BST0350105
   Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200
   Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143 4160(03)00026 5
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   RABADJIJA L, 1990, BONE MINER, V11, P295, DOI 10.1016/0169 6009(90)90026 C
   Radu CG, 2005, P NATL ACAD SCI USA, V102, P1632, DOI 10.1073/pnas.0409415102
   RAISZ LG, 1995, J NUTR, V125, pS2024, DOI 10.1093/jn/125.suppl_7.2024S
   Rapuano BE, 1997, J CELL BIOCHEM, V65, P198, DOI 10.1002/(SICI)1097 4644(199705)65:2<198::AID JCB6>3.0.CO;2 P
   Reich KM, 1997, ENDOCRINOLOGY, V138, P1014, DOI 10.1210/en.138.3.1014
   SEBASTIAN A, 1994, NEW ENGL J MED, V330, P1776, DOI 10.1056/NEJM199406233302502
   Seuwen K, 2006, J RECEPT SIG TRANSD, V26, P599, DOI 10.1080/10799890600932220
   SMALLRIDGE RC, 1991, ENDOCRINOLOGY, V129, P542, DOI 10.1210/endo 129 1 542
   Su YR, 2002, J LIPID RES, V43, P2180, DOI 10.1194/jlr.D200020 JLR200
   Suda T, 2003, J CELL BIOCHEM, V88, P259, DOI 10.1002/jcb.10331
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   TOKUDA H, 1992, CELL SIGNAL, V4, P261, DOI 10.1016/0898 6568(92)90065 G
   Tomura H, 2005, CELL SIGNAL, V17, P1466, DOI 10.1016/j.cellsig.2005.06.002
   Tomura H, 2008, J BONE MINER RES, V23, P1129, DOI 10.1359/JBMR.080236
   Usui M, 2008, J BONE MINER RES, V23, P314, DOI 10.1359/JBMR.071025
   Voets T, 2007, J PHYSIOL LONDON, V582, P939, DOI 10.1113/jphysiol.2007.132522
NR 55
TC 15
Z9 16
U1 0
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931 857X
EI 1522 1466
J9 AM J PHYSIOL RENAL
JI Am. J. Physiol. Renal Physiol.
PD JAN
PY 2011
VL 300
IS 1
BP F91
EP F97
DI 10.1152/ajprenal.00276.2010
PG 7
WC Physiology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Urology & Nephrology
GA 703FP
UT WOS:000285964000011
PM 21048027
OA Green Published
DA 2025 08 17
ER

PT J
AU Newman, MR
   Russell, SG
   Schmitt, CS
   Marozas, IA
   Sheu, TJ
   Puzas, JE
   Benoit, DSW
AF Newman, Maureen R.
   Russell, Steven G.
   Schmitt, Christopher S.
   Marozas, Ian A.
   Sheu, Tzong Jen
   Puzas, J. Edward
   Benoit, Danielle S. W.
TI Multivalent Presentation of Peptide Targeting Groups Alters Polymer
   Biodistribution to Target Tissues
SO BIOMACROMOLECULES
LA English
DT Article
ID DRUG DELIVERY SYSTEMS; PURPLE ACID PHOSPHATASE; BISPHOSPHONATE
   CONJUGATION; CELL ADHESION; IN VITRO; RAFT POLYMERIZATION;
   BONE FORMATION; BINDING; NANOPARTICLES; COPOLYMERS
AB Drug delivery to bone is challenging, whereby drug distribution is commonly <1% of injected dose, despite development of several bone targeted drug delivery systems specific to hydroxyapatite. These bone targeted drug delivery systems still suffer from poor target cell localization within bone, as at any given time overall bone volume is far greater than acutely remodeling bone volume, which harbors relevant cell targets (osteoclasts or osteoblasts). Thus, there exists a need to target bone acting drugs specifically to sites of bone remodeling. To address this need, this study synthesized oligo(ethylene glycol) copolymers based on a peptide with high affinity to tartrate resistant acid phosphatase (TRAP), an enzyme deposited by osteoclasts during the bone resorption phase of bone remodeling, which provides greater specificity relevant for bone cell drugging. Gradient and random peptide orientations, as well as polymer molecular weights, were investigated. TRAP targeted, high molecular weight (Ms) random copolymers exhibited superior accumulation in remodeling bone, where fracture accumulation was observed for at least 1 week and accounted for 14% of tissue distribution. Intermediate and low M n, random copolymer accumulation was lower, indicating residence time depends on M n High M n gradient polymers were cleared, with only 2% persisting at fractures after 1 week, suggesting TRAP binding depends on peptide density. Peptide density and M n are easily modified in this versatile targeting platform, which can be applied to a range of bone drug delivery applications.
C1 [Newman, Maureen R.; Marozas, Ian A.; Benoit, Danielle S. W.] Univ Rochester, Biomed Engn, Rochester, NY 14627 USA.
   [Russell, Steven G.; Schmitt, Christopher S.; Benoit, Danielle S. W.] Univ Rochester, Chem Engn, Rochester, NY 14627 USA.
   [Newman, Maureen R.; Sheu, Tzong Jen; Puzas, J. Edward; Benoit, Danielle S. W.] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
   [Sheu, Tzong Jen; Puzas, J. Edward; Benoit, Danielle S. W.] Univ Rochester, Med Ctr, Dept Orthopaed, Rochester, NY 14642 USA.
   [Benoit, Danielle S. W.] Univ Rochester, Med Ctr, Ctr Oral Biol, Rochester, NY 14642 USA.
   [Benoit, Danielle S. W.] Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester; University of
   Rochester; University of Rochester; University of Rochester; University
   of Rochester
RP Benoit, DSW (通讯作者)，Univ Rochester, Biomed Engn, Rochester, NY 14627 USA.; Benoit, DSW (通讯作者)，Univ Rochester, Chem Engn, Rochester, NY 14627 USA.; Benoit, DSW (通讯作者)，Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.; Benoit, DSW (通讯作者)，Univ Rochester, Med Ctr, Dept Orthopaed, Rochester, NY 14642 USA.; Benoit, DSW (通讯作者)，Univ Rochester, Med Ctr, Ctr Oral Biol, Rochester, NY 14642 USA.; Benoit, DSW (通讯作者)，Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA.
EM benoit@bme.rochester.edu
RI ; Newman, Maureen/ABE 5409 2020; Benoit, Danielle/HKV 4384 2023
OI Benoit, Danielle/0000 0001 7137 8164; Newman,
   Maureen/0000 0002 9004 3332
FU National Science Foundation [DGE 1419118, CBET 1450987]; National
   Institutes of Health [R01AR064200, P30ES001247, K12ES019852,
   P30AR069655, S10RR026542]; University of Rochester Technology
   Development Fund
FX This work was supported by the National Science Foundation (DGE 1419118,
   CBET 1450987), the National Institutes of Health (R01AR064200,
   P30ES001247, K12ES019852, P30AR069655, S10RR026542), and the University
   of Rochester Technology Development Fund.
CR Abdollahi M, 2007, POLYMER, V48, P25, DOI 10.1016/j.polymer.2006.11.010
   Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833
   [Anonymous], 2009, Tests for In vitro Cytotoxicity ISO 10993 5:2009, P42
   Anthis NJ, 2013, PROTEIN SCI, V22, P851, DOI 10.1002/pro.2253
   Apostolovic B, 2010, BIOMACROMOLECULES, V11, P1891, DOI 10.1021/bm100533g
   Avvakumova S, 2014, TRENDS BIOTECHNOL, V32, P11, DOI 10.1016/j.tibtech.2013.09.006
   Bagalkot V, 2006, ANGEW CHEM INT EDIT, V45, P8149, DOI 10.1002/anie.200602251
   Baranello MP, 2014, BIOMACROMOLECULES, V15, P2629, DOI 10.1021/bm500468d
   Bell A, 2016, ORTHOP CLIN N AM, V47, P365, DOI 10.1016/j.ocl.2015.09.010
   Benoit DSW, 2005, BIOMATERIALS, V26, P5209, DOI 10.1016/j.biomaterials.2005.01.045
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Boyan BD, 1999, J ORTHOPAED RES, V17, P246, DOI 10.1002/jor.1100170214
   Cai L, 2011, BIOMATERIALS, V32, P8497, DOI 10.1016/j.biomaterials.2011.07.087
   Coussen F, 2002, J CELL SCI, V115, P2581
   Ding H, 2007, J DRUG TARGET, V15, P465, DOI 10.1080/10611860701500016
   Doschak MR, 2009, MOL PHARMACEUT, V6, P634, DOI 10.1021/mp8002368
   FLESSNER MF, 1985, AM J PHYSIOL, V248, pH15, DOI 10.1152/ajpheart.1985.248.1.H15
   Francini N, 2015, MACROMOLECULES, V48, P2857, DOI 10.1021/acs.macromol.5b00447
   Fujisaki J, 1997, BIOL PHARM BULL, V20, P1183
   FUKUSHIMA O, 1991, AM J ANAT, V191, P228, DOI 10.1002/aja.1001910303
   Gittens SA, 2005, MOL PHARMACEUT, V2, P392, DOI 10.1021/mp050017u
   Glaffig M, 2015, ORG BIOMOL CHEM, V13, P10150, DOI 10.1039/c5ob01255d
   Gokce I, 2005, J AM CHEM SOC, V127, P9700, DOI 10.1021/ja052632x
   Hamblett KJ, 2004, CLIN CANCER RES, V10, P7063, DOI 10.1158/1078 0432.CCR 04 0789
   He XD, 2015, INT J NANOMED, V10, P1791, DOI 10.2147/IJN.S75186
   Hlavacek WS, 1999, BIOPHYS J, V76, P3031, DOI 10.1016/S0006 3495(99)77456 4
   Holmberg AL, 2015, POLYM CHEM UK, V6, P5728, DOI 10.1039/c5py00291e
   Jahnke W, 2010, CHEMMEDCHEM, V5, P770, DOI 10.1002/cmdc.201000016
   Jin J, 2015, COLLOID SURFACE B, V136, P838, DOI 10.1016/j.colsurfb.2015.10.025
   KALININ NL, 1995, ANAL BIOCHEM, V228, P238, DOI 10.1006/abio.1995.1345
   Kamaly N, 2012, CHEM SOC REV, V41, P2971, DOI 10.1039/c2cs15344k
   Kay BK, 2001, METHODS, V24, P240, DOI 10.1006/meth.2001.1185
   Kenanova V. E., 2010, ENG FC REGION IMPROV, V1
   Knadler MP, 2016, PHARM RES DORDR, V33, P2920, DOI 10.1007/s11095 016 2014 1
   Koo LY, 2002, J CELL SCI, V115, P1423
   Larson N, 2012, CHEM MATER, V24, P840, DOI 10.1021/cm2031569
   Le Neindre M, 2013, POLYM CHEM UK, V4, P5577, DOI 10.1039/c3py00754e
   Li C, 1996, ANTI CANCER DRUG, V7, P642, DOI 10.1097/00001813 199608000 00004
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Liechty WB, 2010, ANNU REV CHEM BIOMOL, V1, P149, DOI 10.1146/annurev chembioeng 073009 100847
   Lindqvist Y, 1999, J MOL BIOL, V291, P135, DOI 10.1006/jmbi.1999.2962
   Lo KWH, 2014, TRENDS BIOTECHNOL, V32, P74, DOI 10.1016/j.tibtech.2013.12.002
   Maheshwari G, 2000, J CELL SCI, V113, P1677
   Mandal S, 2015, ACS CHEM BIOL, V10, P485, DOI 10.1021/cb500455g
   Manju MV., 2012, American Journal of Polymer Science, V2, P22, DOI [10.5923/j.ajps.20120203.01, DOI 10.5923/J.AJPS.20120203.01]
   Marchelli D, 2009, J ORTHOP TRAUMATOL, V10, P55, DOI 10.1007/s10195 009 0047 5
   Minkwitz S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124217
   Mir Sadat Ali, 2015, J Stem Cells, V10, P91
   Moad G, 2005, POLYMER, V46, P8458, DOI 10.1016/j.polymer.2004.12.061
   Moad G, 2008, POLYMER, V49, P1079, DOI 10.1016/j.polymer.2007.11.020
   Moghimi SMF., 2014, Handbook of Nanobiomedical Research: Fundamentals, Applications and Recent Developments, P31
   Moraes J, 2015, POLYM CHEM UK, V6, P7480, DOI 10.1039/c5py90156a
   Moraes J, 2015, POLYM CHEM UK, V6, P3245, DOI 10.1039/c5py00253b
   Mourez M, 2001, NAT BIOTECHNOL, V19, P958, DOI 10.1038/nbt1001 958
   Müller KM, 1998, ANAL BIOCHEM, V261, P149, DOI 10.1006/abio.1998.2725
   Murata H, 1997, MACROMOLECULES, V30, P2902, DOI 10.1021/ma970131t
   Nakaoka R, 1997, J CONTROL RELEASE, V46, P253, DOI 10.1016/S0168 3659(96)01605 7
   Neale JR, 2009, BIOORG MED CHEM LETT, V19, P680, DOI 10.1016/j.bmcl.2008.12.051
   Newman MR, 2016, CURR OPIN BIOTECH, V40, P125, DOI 10.1016/j.copbio.2016.02.029
   Nicolay R, 2012, MACROMOLECULES, V45, P821, DOI 10.1021/ma202344y
   Omlor GW, 2016, ACTA ORTHOP, V87, P425, DOI 10.1080/17453674.2016.1198200
   ORME MW, 1994, BIOORG MED CHEM LETT, V4, P1375, DOI 10.1016/S0960 894X(01)80365 6
   Ouyang L, 2009, LETT ORG CHEM, V6, P272, DOI 10.2174/157017809788489981
   Pan HZ, 2013, BIOMATERIALS, V34, P6528, DOI 10.1016/j.biomaterials.2013.05.003
   Pan LQ, 2013, BIOMATERIALS, V34, P9115, DOI 10.1016/j.biomaterials.2013.08.020
   Patil YB, 2009, BIOMATERIALS, V30, P859, DOI 10.1016/j.biomaterials.2008.09.056
   Petrie TA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001002
   Pisal DS, 2010, J PHARM SCI US, V99, P2557, DOI 10.1002/jps.22054
   Pittenger Mark F., 2008, V449, P27, DOI 10.1007/978 1 60327 169 1_2
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Ponnapakkam T, 2012, CALCIFIED TISSUE INT, V91, P196, DOI 10.1007/s00223 012 9626 1
   Reyes CD, 2008, J CELL PHYSIOL, V217, P450, DOI 10.1002/jcp.21512
   Rodger A., 1997, Circular Dichroism and Linear Dichroism
   Santi DV, 2012, P NATL ACAD SCI USA, V109, P6211, DOI 10.1073/pnas.1117147109
   Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Shen YM, 2014, J CHEM THEORY COMPUT, V10, P4745, DOI 10.1021/ct500592m
   Sheu TJ, 2002, J BONE MINER RES, V17, P915, DOI 10.1359/jbmr.2002.17.5.915
   Singha NK, 2011, BIOMACROMOLECULES, V12, P2908, DOI 10.1021/bm200469a
   Stefanick JF, 2013, ACS NANO, V7, P2935, DOI 10.1021/nn305663e
   STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50
   Sun MC, 2014, COLLOID SURFACE B, V122, P134, DOI 10.1016/j.colsurfb.2014.06.041
   Sunagawa T, 2000, J HAND SURG AM, V25A, P849, DOI 10.1053/jhsu.2000.8639
   Takahashi T, 2008, PHARM RES DORDR, V25, P2881, DOI 10.1007/s11095 008 9605 4
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Uludag H, 2000, BIOTECHNOL PROGR, V16, P1115, DOI 10.1021/bp000066y
   Uludag H, 2002, BIOTECHNOL PROGR, V18, P604, DOI 10.1021/bp0200447
   Van Hove A. H., 2013, JOVE J VIS EXP, V80
   Vauquelin G, 2010, BRIT J PHARMACOL, V161, P488, DOI 10.1111/j.1476 5381.2010.00936.x
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wang D, 2006, J AM CHEM SOC, V128, P9248, DOI 10.1021/ja062710w
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   Wang YC, 2017, ACS NANO, V11, P9445, DOI 10.1021/acsnano.7b05103
   Whitebread S, 2005, DRUG DISCOV TODAY, V10, P1421, DOI 10.1016/S1359 6446(05)03632 9
   Xiao K, 2011, BIOMATERIALS, V32, P3435, DOI 10.1016/j.biomaterials.2011.01.021
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
NR 98
TC 18
Z9 23
U1 0
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525 7797
EI 1526 4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD JAN
PY 2018
VL 19
IS 1
BP 71
EP 84
DI 10.1021/acs.biomac.7b01193
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA FS7SR
UT WOS:000419998600008
PM 29227674
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Hu, CH
   Sui, BD
   Liu, J
   Dang, L
   Chen, J
   Zheng, CX
   Shi, ST
   Zhao, N
   Dang, MY
   He, XN
   Zhang, LQ
   Gao, PP
   Chen, N
   Kuang, HJ
   Chen, K
   Xu, XL
   Yu, XR
   Zhang, G
   Jin, Y
AF Hu, Cheng Hu
   Sui, Bing Dong
   Liu, Jin
   Dang, Lei
   Chen, Ji
   Zheng, Chen Xi
   Shi, Songtao
   Zhao, Na
   Dang, Min Yan
   He, Xiao Ning
   Zhang, Li Qiang
   Gao, Ping Ping
   Chen, Nan
   Kuang, Hui Juan
   Chen, Kai
   Xu, Xiao Lin
   Yu, Xiao Rui
   Zhang, Ge
   Jin, Yan
TI Sympathetic Neurostress Drives Osteoblastic Exosomal MiR 21 Transfer to
   Disrupt Bone Homeostasis and Promote Osteopenia
SO SMALL METHODS
LA English
DT Article
DE bones; depression; exosome; microRNA; sympathetic nervous system
ID MESENCHYMAL STEM CELLS; EXTRACELLULAR VESICLES; OSTEOGENESIS; MECHANISM;
   SYSTEM; MASS; SUPPRESSION; ADIPOCYTE; PREVENTS; DELIVERY
AB Innervation and extracellular vesicle secretion co exist in the local tissue microenvironment for message transfer, but whether they are interconnected to regulate organ homeostasis remains unknown. Sympatho adrenergic activation is implicated in stress induced depression and leads to bone loss, but the mechanisms and therapeutics are incompletely elucidated. Here, it is revealed that sympathetic neurostress through the beta(1/2) adrenergic receptor (beta 1/2 AR) signaling triggers the transcription response of a microRNA, miR 21, in osteoblasts, which is transferred to osteoclast progenitors via exosomes for dictating osteoclastogenesis. After confirming that miR 21 deficiency retards the beta 1/2 AR agonist isoproterenol (ISO) induced osteopenia, it is shown that the pharmacological inhibition of exosome release by two clinically relevant drugs, dimethyl amiloride and omeprazole, suppresses osteoblastic miR 21 transfer and ameliorates bone loss under both ISO and chronic variable stress (CVS) induced depression conditions. A targeted delivery approach to specifically silence osteoblastic miR 21 is further applied, which is effective in rescuing the bone remodeling balance and ameliorating ISO  and CVS induced osteopenias. These results decipher a previously unrecognized paradigm that neural cues drive exosomal microRNA communication to regulate organ homeostasis and help to establish feasible strategies to counteract bone loss under psychological stresses.
C1 [Hu, Cheng Hu; Sui, Bing Dong; Chen, Ji; Zheng, Chen Xi; Dang, Min Yan; He, Xiao Ning; Zhang, Li Qiang; Gao, Ping Ping; Chen, Nan; Chen, Kai; Jin, Yan] Fourth Mil Med Univ, Sch Stomatol, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
   [Hu, Cheng Hu; Sui, Bing Dong; Chen, Ji; Zheng, Chen Xi; Dang, Min Yan; He, Xiao Ning; Zhang, Li Qiang; Gao, Ping Ping; Chen, Nan; Chen, Kai; Jin, Yan] Fourth Mil Med Univ, Sch Stomatol, Natl Clin Res Ctr Oral Dis, Xian 710032, Shaanxi, Peoples R China.
   [Hu, Cheng Hu; Sui, Bing Dong; Chen, Ji; Zheng, Chen Xi; Dang, Min Yan; He, Xiao Ning; Zhang, Li Qiang; Gao, Ping Ping; Chen, Nan; Chen, Kai; Jin, Yan] Fourth Mil Med Univ, Sch Stomatol, Shaanxi Int Joint Res Ctr Oral Dis, Ctr Tissue Engn, Xian 710032, Shaanxi, Peoples R China.
   [Hu, Cheng Hu; Yu, Xiao Rui] Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Xian 710032, Shaanxi, Peoples R China.
   [Liu, Jin; Dang, Lei; Zhang, Ge] Hong Kong Baptist Univ, Sch Chinese Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong 999077, Peoples R China.
   [Shi, Songtao] Sun Yat Sen Univ, South China Ctr Craniofacial Stem Cell Res, Guangzhou 510080, Guangdong, Peoples R China.
   [Zhao, Na; Kuang, Hui Juan] Xi An Jiao Tong Univ, Affiliated Hosp 2, Inst Stem Cell & Regenerat Med, Xian 710032, Shaanxi, Peoples R China.
   [Dang, Min Yan; He, Xiao Ning; Zhang, Li Qiang; Gao, Ping Ping; Kuang, Hui Juan; Xu, Xiao Lin; Jin, Yan] Xian Inst Tissue Engn & Regenerat Med, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University; Xi'an Jiaotong University; Hong Kong Baptist
   University; Sun Yat Sen University; Xi'an Jiaotong University
RP Jin, Y (通讯作者)，Fourth Mil Med Univ, Sch Stomatol, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.; Jin, Y (通讯作者)，Fourth Mil Med Univ, Sch Stomatol, Natl Clin Res Ctr Oral Dis, Xian 710032, Shaanxi, Peoples R China.; Jin, Y (通讯作者)，Fourth Mil Med Univ, Sch Stomatol, Shaanxi Int Joint Res Ctr Oral Dis, Ctr Tissue Engn, Xian 710032, Shaanxi, Peoples R China.; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Sch Chinese Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong 999077, Peoples R China.; Jin, Y (通讯作者)，Xian Inst Tissue Engn & Regenerat Med, Xian 710032, Shaanxi, Peoples R China.
EM zhangge@hkbu.edu.hk; yanjin@fmmu.eclu.cn
RI Dang, MINYan/AAM 6412 2020; Zhang, Ge/N 4150 2013; Zheng,
   Chenxi/GQA 4142 2022; Hu, Cheng Hu/I 4210 2013; JIN, YAN/HPC 7389 2023;
   Sui, Bingdong/HKN 5071 2023
OI Hu, Cheng Hu/0000 0003 2443 6485; 
FU National Key Research and Development Program of China [2017YFA0104900];
   National Natural Science Foundation of China [32000974, 81930025,
   82170988, 31801156, 82100969]; Postdoctoral Innovative Talents Support
   Program of China [BX20190380]; General Program of China Postdoctoral
   Science Foundation [2019M663986]
FX This work was supported by grants from The National Key Research and
   Development Program of China (2017YFA0104900), The National Natural
   Science Foundation of China (32000974, 81930025, 82170988, 31801156, and
   82100969), the Postdoctoral Innovative Talents Support Program of China
   (BX20190380), and the General Program of China Postdoctoral Science
   Foundation (2019M663986).
CR Arranz L, 2014, NATURE, V512, P78, DOI 10.1038/nature13383
   Bonnet N, 2007, BONE, V40, P1209, DOI 10.1016/j.bone.2007.01.006
   Bouxsein ML, 2009, ENDOCRINOLOGY, V150, P144, DOI 10.1210/en.2008 0843
   Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363
   Cappariello A, 2018, J BONE MINER RES, V33, P517, DOI 10.1002/jbmr.3332
   Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483
   Chen DY, 2017, CELL BIOL INT, V41, P8, DOI 10.1002/cbin.10685
   Chen N, 2016, J DENT RES, V95, P1425, DOI 10.1177/0022034516657043
   Cizza G, 2010, HORM METAB RES, V42, P467, DOI 10.1055/s 0030 1252020
   Cizza G, 2009, TRENDS ENDOCRIN MET, V20, P367, DOI 10.1016/j.tem.2009.05.003
   Deng CL, 2021, CELL DEATH DIFFER, V28, P1041, DOI 10.1038/s41418 020 00636 4
   Devi S, 2021, IMMUNITY, V54, P1219, DOI 10.1016/j.immuni.2021.03.025
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Ferraro F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002191
   Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028
   Hanyu R, 2012, P NATL ACAD SCI USA, V109, P7433, DOI 10.1073/pnas.1109036109
   Hu B, 2020, J CLIN INVEST, V130, P3483, DOI 10.1172/JCI131554
   Hu CH, 2017, SCI REP UK, V7, DOI 10.1038/srep43191
   Hu HF, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03430 3
   Jin Y, 2021, EXTRACELL VESICLES, V10
   Jing H, 2016, MOL THER, V24, P217, DOI 10.1038/mt.2015.152
   Kajimura D, 2011, J EXP MED, V208, P841, DOI 10.1084/jem.20102608
   Khosla S, 2018, J CLIN INVEST, V128, P4832, DOI 10.1172/JCI122151
   Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Liu DW, 2018, CELL RES, V28, P918, DOI 10.1038/s41422 018 0070 2
   Lu YJ, 2009, CARDIOVASC RES, V84, P434, DOI 10.1093/cvr/cvp232
   Ma Y, 2011, ENDOCRINOLOGY, V152, P1412, DOI 10.1210/en.2010 0881
   Maryanovich M, 2018, NAT MED, V24, P782, DOI 10.1038/s41591 018 0030 x
   Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556 018 0250 9
   Morhayim J, 2014, ARCH BIOCHEM BIOPHYS, V561, P38, DOI 10.1016/j.abb.2014.05.011
   Morrell AE, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0007 x
   Nagao M, 2011, P NATL ACAD SCI USA, V108, P17767, DOI 10.1073/pnas.1109402108
   Nunes DN, 2015, P NATL ACAD SCI USA, V112, P3770, DOI 10.1073/pnas.1500008112
   PATTERSONBUCKENDAHL P, 1995, BONE, V17, P467, DOI 10.1016/8756 3282(95)00281 X
   Pierroz DD, 2012, J BONE MINER RES, V27, P1252, DOI 10.1002/jbmr.1594
   Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44
   Rudak PT, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108979
   Savina A, 2003, J BIOL CHEM, V278, P20083, DOI 10.1074/jbc.M301642200
   Sui BD, 2020, TRENDS CELL BIOL, V30, P97, DOI 10.1016/j.tcb.2019.11.006
   Sui Bing Dong, 2018, Exp Mol Med, V50, P1, DOI 10.1038/s12276 018 0192 0
   Sui BD, 2017, THERANOSTICS, V7, P1225, DOI 10.7150/thno.18181
   Sui BD, 2019, BIOMATERIALS, V196, P18, DOI 10.1016/j.biomaterials.2017.10.046
   Sui BD, 2016, STEM CELL TRANSL MED, V5, P1238, DOI 10.5966/sctm.2015 0347
   Sui BD, 2016, SCI REP UK, V6, DOI 10.1038/srep30186
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Théry C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   van Wijnen AJ, 2013, CURR OSTEOPOROS REP, V11, P72, DOI 10.1007/s11914 013 0143 6
   Wan QQ, 2021, ADV SCI, V8, DOI 10.1002/advs.202003390
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang XD, 2020, THERANOSTICS, V10, P4839, DOI 10.7150/thno.43771
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Wiens M, 2006, J INTERN MED, V260, P350, DOI 10.1111/j.1365 2796.2006.01695.x
   Wu Q, 2018, OSTEOPOROSIS INT, V29, P1303, DOI 10.1007/s00198 018 4420 1
   Xiong YY, 2020, TRANSL RES, V215, P1, DOI 10.1016/j.trsl.2019.07.013
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Yirmiya R, 2006, P NATL ACAD SCI USA, V103, P16876, DOI 10.1073/pnas.0604234103
   Yu LJ, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12056
   Yu WJ, 2021, BONE RES, V8, DOI 10.1038/s41413 020 00117 x
   Yu Y, 2017, MOL THER, V25, P480, DOI 10.1016/j.ymthe.2016.11.015
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhao P, 2017, AGING CELL, V16, P1083, DOI 10.1111/acel.12635
   Zheng CX, 2020, TRENDS MOL MED, V26, P89, DOI 10.1016/j.molmed.2019.04.008
NR 69
TC 28
Z9 32
U1 6
U2 58
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2366 9608
J9 SMALL METHODS
JI Small Methods
PD MAR
PY 2022
VL 6
IS 3
AR 2100763
DI 10.1002/smtd.202100763
EA DEC 2021
PG 16
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA ZW2PB
UT WOS:000730735500001
PM 35312228
DA 2025 08 17
ER

PT J
AU Zheng, LW
   Wang, WC
   Mao, XZ
   Luo, YH
   Tong, ZY
   Li, D
AF Zheng, Li Wen
   Wang, Wan Chun
   Mao, Xin Zhan
   Luo, Yong Heng
   Tong, Zhong Yi
   Li, Ding
TI TNF α regulates the early development of avascular necrosis of the
   femoral head by mediating osteoblast autophagy and apoptosis via the p38
   MAPK/NF κB signaling pathway
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE apoptosis; autophagy; avascular necrosis of the femoral head (ANFH);
   osteoblast; TNF alpha
ID MODEL; OSTEONECROSIS; ARTHRITIS; THERAPY; P53
AB Previous studies have shown that the tumor necrosis factor alpha (TNF alpha) levels in serum and bone tissues formed in avascular necrosis of femoral head (ANFH) patients were higher than those of normal individuals, indicating TNF alpha might play a role in the pathogenesis of ANFH. However, the underlying mechanisms remain unclear. Hematoxylin and eosin staining was performed to show the pathological changes of ANFH bone tissues. TNF alpha expression in normal and ANFH tissues was examined by quantitative real time polymerase chain reaction and western blot analyses. Osteoblast autophagy and apoptosis, as well as signaling pathways activation, were measured by their corresponding marker proteins. Osteoblast proliferation, autophagy, and apoptosis were evaluated using cell counting kit 8, transmission electron microscopy, and flow cytometry. The structures of bone tissues of ANFH were obviously damaged. TNF alpha expression was significantly upregulated in ANFH bone tissues compared to normal tissues. Autophagy and apoptosis were remarkably promoted, and p38 mitogen activated protein kinase (MAPK)/nuclear factor kappa B (NF kappa B) signaling pathways were markedly activated in ANFH. Suppression of the p38 MAPK/NF kappa B pathway significantly attenuated the TNF alpha induced autophagy, however, enhanced the TNF alpha induced apoptosis in osteoblasts. Increased TNF alpha in ANFH regulated osteoblast autophagy and apoptosis by p38 MAPK/NF kappa B signaling pathways, blocking the pathway by inhibitors exacerbated TNF alpha induced apoptosis through impairing autophagy flux.
C1 [Zheng, Li Wen; Wang, Wan Chun; Mao, Xin Zhan; Li, Ding] Cent South Univ, Xiangya Hosp 2, Dept Orthoped, 139 Renmin Middle Rd, Changsha 410011, Hunan, Peoples R China.
   [Luo, Yong Heng] Cent South Univ, Xiangya Hosp 2, Dept Radiol, Changsha, Hunan, Peoples R China.
   [Tong, Zhong Yi] Cent South Univ, Xiangya Hosp 2, Dept Pathol, Changsha, Hunan, Peoples R China.
C3 Central South University; Central South University; Central South
   University
RP Zheng, LW (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Orthoped, 139 Renmin Middle Rd, Changsha 410011, Hunan, Peoples R China.
EM zhengliwen@csu.edu.cn
RI Li, Ding/MDT 9097 2025
FU Program for Nature Science Plan of Hunan Province [2016JJ3167]
FX Program for Nature Science Plan of Hunan Province, Grant/Award Number:
   2016JJ3167
CR Barquet A, 2014, INJURY, V45, P1848, DOI 10.1016/j.injury.2014.10.054
   Barré B, 2010, MOL CELL, V38, P524, DOI 10.1016/j.molcel.2010.03.018
   Berghen N, 2015, CLIN RHEUMATOL, V34, P1687, DOI 10.1007/s10067 015 3026 7
   Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028
   Colomb Lippa D, 2014, JAAPA J AM ACAD PHYS, V27, P40, DOI 10.1097/01.JAA.0000450811.13707.78
   de Oliveira RA, 2018, EXPERT OPIN THER PAT, V28, P635, DOI 10.1080/13543776.2018.1502748
   Feng Y, 2018, CURR DRUG TARGETS, V19, P1009, DOI 10.2174/1389450117666160819155028
   Goldsmith J, 2014, METHOD ENZYMOL, V542, P25, DOI 10.1016/B978 0 12 416618 9.00002 9
   Hamacher Brady A, 2006, J BIOL CHEM, V281, P29776, DOI 10.1074/jbc.M603783200
   Ishizuka EK, 2016, SCI REP UK, V6, DOI 10.1038/srep32092
   Ji MH, 2014, PROG NEURO PSYCHOPH, V54, P284, DOI 10.1016/j.pnpbp.2014.06.013
   Jones SA, 2013, IMMUNOL CELL BIOL, V91, P250, DOI 10.1038/icb.2012.82
   Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001
   Li L, 2014, FOOD CHEM TOXICOL, V63, P166, DOI 10.1016/j.fct.2013.08.036
   Li S, 2017, AM J TRANSL RES, V9, P2065
   Li Y, 2016, POWER SYST, P1, DOI 10.1007/978 3 662 48627 6
   Liao Y, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00307
   Lin NY, 2013, ANN RHEUM DIS, V72, P761, DOI 10.1136/annrheumdis 2012 201671
   Liu YS, 2015, INT J CLIN EXP PATHO, V8, P3215
   Liuzzi JP, 2014, BIOMETALS, V27, P1087, DOI 10.1007/s10534 014 9773 0
   Lu C, 2017, STROKE VASC NEUROL, V2, P47, DOI 10.1136/svn 2016 000046
   MONT MA, 1995, J BONE JOINT SURG AM, V77A, P459, DOI 10.2106/00004623 199503000 00018
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Ryazantseva NV, 2010, B EXP BIOL MED+, V149, P50, DOI 10.1007/s10517 010 0873 8
   Ryoo S, 2014, J MICROBIOL BIOTECHN, V24, P394, DOI 10.4014/jmb.1311.11057
   Sadat Ali M, 2017, INT J STEM CELLS, V10, P179, DOI 10.15283/ijsc17019
   Shimizu S, 2012, INT J CANCER, V131, P548, DOI 10.1002/ijc.26374
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Vlachopoulos C, 2018, CLIN RHEUMATOL, V37, P515, DOI 10.1007/s10067 017 3657 y
   Xie X, 2018, CLIN RHEUMATOL, V37, P13, DOI 10.1007/s10067 017 3639 0
   Xu S, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7951793
   Yan YQ, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 2208 2
   Yin H, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1199 0
   Zhang HY, 2014, INT IMMUNOPHARMACOL, V20, P95, DOI 10.1016/j.intimp.2014.02.016
   Zhang XL, 2018, EUR REV MED PHARMACO, V22, P2143, DOI 10.26355/eurrev_201804_14748
   Zhang ZH, 2018, MOL MED REP, V17, P801, DOI 10.3892/mmr.2017.7963
   Zheng LW, 2017, J INVEST MED, V65, P1014, DOI 10.1136/jim 2017 000426
NR 37
TC 47
Z9 52
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1065 6995
EI 1095 8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD SEP
PY 2020
VL 44
IS 9
BP 1881
EP 1889
DI 10.1002/cbin.11394
EA JUN 2020
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA NA9JK
UT WOS:000541559300001
PM 32437045
DA 2025 08 17
ER

PT J
AU Wang, BX
   Yang, JK
   Fan, LJ
   Wang, Y
   Zhang, CQ
   Wang, HM
AF Wang, Baixiang
   Yang, Jiakang
   Fan, Lijie
   Wang, Yu
   Zhang, Chenqiu
   Wang, Huiming
TI Osteogenic effects of antihypertensive drug benidipine on mouse MC3T3 E1
   cells in vitro
SO JOURNAL OF ZHEJIANG UNIVERSITY SCIENCE B
LA English
DT Article
DE Benidipine; Osteoblast; Osteogenesis
ID CALCIUM CHANNEL BLOCKER; BONE MINERAL DENSITY; BLOOD PRESSURE;
   DIFFERENTIATION; OSTEOBLAST; OSTEOPOROSIS; HYPERTENSION; MEDICATIONS;
   INHIBITION; PREVALENCE
AB Hypertension is a prevalent systemic disease in the elderly, who can suffer from several pathological skeletal conditions simultaneously, including osteoporosis. Benidipine (BD), which is widely used to treat hypertension, has been proved to have a beneficial effect on bone metabolism. In order to confirm the osteogenic effects of BD, we investigated its osteogenic function using mouse MC3T3 E1 preosteoblast cells in vitro. The proliferative ability of MC3T3 E1 cells was significantly associated with the concentration of BD, as measured by methylthiazolyldiphenyl tetrazolium bromide (MTT) assay and cell cycle assay. With BD treatment, the osteogenic differentiation and maturation of MC3T3 E1 cells were increased, as established by the alkaline phosphatase (ALP) activity test, matrix mineralized nodules formation, osteogenic genetic test, and protein expression analyses. Moreover, our data showed that the BMP2/Smad pathway could be the partial mechanism for the promotion of osteogenesis by BD, while BD might suppress the possible function of osteoclasts through the OPG/RANKL/RANK (receptor activator of nuclear factor  kappa B (NF kappa B)) pathway. The hypothesis that BD bears a considerable potential in further research on its dual therapeutic effect on hypertensive patients with poor skeletal conditions was proved within the limitations of the present study.
C1 [Wang, Baixiang; Fan, Lijie; Wang, Yu; Zhang, Chenqiu; Wang, Huiming] Zhejiang Univ, Affiliated Hosp Stomatol, Sch Stomatol, Sch Med, Hangzhou 310006, Peoples R China.
   [Wang, Baixiang; Fan, Lijie; Wang, Yu; Zhang, Chenqiu; Wang, Huiming] Key Lab Oral Biomed Res Zhejiang Prov, Hangzhou 310006, Peoples R China.
   [Yang, Jiakang] Zhejiang Univ, Sch Stomatol, Sch Med, Hangzhou 310006, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Wang, HM (通讯作者)，Zhejiang Univ, Affiliated Hosp Stomatol, Sch Stomatol, Sch Med, Hangzhou 310006, Peoples R China.; Wang, HM (通讯作者)，Key Lab Oral Biomed Res Zhejiang Prov, Hangzhou 310006, Peoples R China.
EM whmwhm@zju.edu.cn
RI Baixiang, Wang/HGD 2571 2022; Wang, Baixiang/HGD 2571 2022
OI Wang, Baixiang/0000 0002 7034 4189
FU National Natural Science Foundation of China [81600909, 81800934];
   Zhejiang Provincial Medical Science and Technology Project of China
   [2017RC009, 2018RC012, 2021KY773]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 81600909 and 81800934) and the Zhejiang Provincial Medical
   Science and Technology Project of China (Nos. 2017RC009, 2018RC012, and
   2021KY773).
CR Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen MM, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 019 0580 7
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cui ZY, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 019 0670 6
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Gao SW, 2019, J ZHEJIANG UNIV SC B, V20, P467, DOI 10.1631/jzus.B1900197
   Ghosh M, 2014, ENDOCRINE, V46, P397, DOI 10.1007/s12020 014 0167 4
   Higuchi A, 2012, CHEM REV, V112, P4507, DOI 10.1021/cr3000169
   Huang Z, 2010, CYTOKINE, V51, P305, DOI 10.1016/j.cyto.2010.06.002
   Ilic K, 2013, CALCIFIED TISSUE INT, V92, P217, DOI 10.1007/s00223 012 9671 9
   Inayoshi A, 2011, LIFE SCI, V88, P898, DOI 10.1016/j.lfs.2011.03.019
   Kosaka H, 2010, EUR J PHARMACOL, V635, P49, DOI 10.1016/j.ejphar.2010.03.018
   Larijani B, 2004, AM J HUM BIOL, V16, P168, DOI 10.1002/ajhb.20005
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Lim LS, 2009, J AM GERIATR SOC, V57, P855, DOI 10.1111/j.1532 5415.2009.02195.x
   Liu L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00228
   Lynn H, 2006, BONE, V38, P584, DOI 10.1016/j.bone.2005.09.011
   Ma JY, 2019, J ZHEJIANG UNIV SC B, V20, P131, DOI 10.1631/jzus.B1800084
   Ma J, 2018, MED SCI MONITOR, V24, P2045, DOI 10.12659/MSM.905703
   Ma ZP, 2015, CELL TISSUE RES, V361, P467, DOI 10.1007/s00441 015 2115 x
   Metz JA, 1999, BRIT J NUTR, V81, P383, DOI 10.1017/S0007114599000665
   Mundy G R, 2001, Rev Endocr Metab Disord, V2, P105, DOI 10.1023/A:1010015309973
   Neve A, 2013, J CELL PHYSIOL, V228, P1149, DOI 10.1002/jcp.24278
   Nishiya Y, 2002, CALCIFIED TISSUE INT, V70, P30, DOI 10.1007/s00223 001 1010 5
   Nishiya Y, 2001, BIOL PHARM BULL, V24, P628, DOI 10.1248/bpb.24.628
   Noël D, 2004, STEM CELLS, V22, P74, DOI 10.1634/stemcells.22 1 74
   Shimizu H, 2012, CURR CARDIOVASC RISK, V6, P274, DOI 10.1007/s12170 012 0248 y
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Suzuki H, 2007, ARZNEIMITTELFORSCH, V57, P20
   Teti Anna, 2011, Curr Osteoporos Rep, V9, P264, DOI 10.1007/s11914 011 0078 8
   Wang BX, 2014, EXP THER MED, V7, P649, DOI 10.3892/etm.2014.1475
   Wang ZW, 2018, CIRCULATION, V137, P2344, DOI 10.1161/CIRCULATIONAHA.117.032380
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Xue C, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen 2016 013672
   Yang S, 2012, BONE, V51, P969, DOI 10.1016/j.bone.2012.07.013
   Yao K, 2006, J PHARMACOL SCI, V100, P243, DOI 10.1254/jphs.DTJ05001X
   Yu D, 2020, J ZHEJIANG UNIV SC B, V21, P871, DOI 10.1631/jzus.B2000355
NR 41
TC 6
Z9 12
U1 2
U2 13
PU ZHEJIANG UNIV
PI HANGZHOU
PA EDITORIAL BOARD, 20 YUGU RD, HANGZHOU, 310027, PEOPLES R CHINA
SN 1673 1581
EI 1862 1783
J9 J ZHEJIANG UNIV SC B
JI J. Zhejiang Univ. SCI. B
PD MAY
PY 2021
VL 22
IS 5
BP 410
EP 420
DI 10.1631/jzus.B2000628
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA SB5QK
UT WOS:000650048300006
PM 33973422
OA Green Published
DA 2025 08 17
ER

PT J
AU Mo, XY
   Meng, KY
   Li, ZH
   Lan, SW
   Ren, ZD
   Fu, XH
   Li, CL
   Sun, TC
   Xie, DH
   Zhang, ZM
   Chen, HJ
AF Mo, Xiaoyi
   Meng, Keyu
   Li, Zehui
   Lan, Shanwei
   Ren, Zhengda
   Fu, Xihong
   Li, Chenglin
   Sun, Tiancheng
   Xie, Denghui
   Zhang, Zhongmin
   Chen, Hui Jiuan
TI An Integrated Microcurrent Delivery System Facilitates Human Parathyroid
   Hormone Delivery for Enhancing Osteoanabolic Effect
SO SMALL METHODS
LA English
DT Article
DE microchannels; microcurrent; microneedle; osteoanabolic effect; PTH
ID VASCULAR ENDOTHELIAL CADHERIN; MICRONEEDLE ARRAY PATCH; OSTEOPOROSIS;
   DYNAMICS; DURATION; INCREASE; BARRIER; PROTEIN
AB Human parathyroid hormone (1 34) (PTH) exhibits osteoanabolic and osteocatabolic effects, with shorter plasma exposure times favoring bone formation. Subcutaneous injection (SCI) is the conventional delivery route for PTH but faces low delivery efficiency due to limited passive diffusion and the obstruction of the vascular endothelial barrier, leading to prolonged drug exposure times and reduced osteoanabolic effects. In this work, a microcurrent delivery system (MDS) based on multimicrochannel microneedle arrays (MMAs) is proposed, achieving high efficiency and safety for PTH transdermal delivery. The internal microchannels of the MMAs are fabricated using high precision 3D printing technology, providing a concentrated and safe electric field that not only accelerates the movement of PTH but also reversibly increases vascular endothelial permeability by regulating the actin cytoskeleton and interendothelial junctions through Ca2+ dependent cAMP signaling, ultimately promoting PTH absorption and shortening exposure times. The MDS enhances the osteoanabolic effect of PTH in an osteoporosis model by inhibiting osteoclast differentiation on the bone surface compared to SCI. Moreover, histopathological analysis of the skin and organs demonstrated the good safety of PTH delivered by MDS in vivo. In addition to PTH, the MDS shows broad prospects for the high efficiency transdermal delivery of macromolecular drugs.
   This study proposes a microcurrent delivery system (MDS) using multimicrochannel microneedle arrays (MMAs) to improve human parathyroid hormone (1 34) (PTH) transdermal delivery. By accelerating PTH movement and reversibly increasing vascular permeability, the MDS reduces PTH exposure time and enhances its osteoanabolic effects in osteoporosis by inhibiting osteoclast differentiation. The MDS also holds significant potential for the efficient transdermal delivery of other macromolecular drugs. image
C1 [Mo, Xiaoyi; Meng, Keyu; Li, Zehui; Lan, Shanwei; Ren, Zhengda; Zhang, Zhongmin] Southern Med Univ, Nanfang Hosp, Dept Orthopaed, Div Spine Surg, Guangzhou 510515, Peoples R China.
   [Fu, Xihong] Sun Yat Sen Univ, Affiliated Hosp 1, Inst Precis Med, Guangzhou 510080, Peoples R China.
   [Li, Chenglin; Sun, Tiancheng] Sun Yat Sen Univ, Sch Elect & Informat Technol, State Key Lab Optoelect Mat & Technol, Prov Key Lab Display Mat & Technol, Guangzhou 510006, Peoples R China.
   [Xie, Denghui; Chen, Hui Jiuan] Southern Med Univ, Affiliated Hosp 3, Ctr Orthoped Surg, Dept Orthoped Surg, Guangzhou 510630, Peoples R China.
C3 Southern Medical University   China; Sun Yat Sen University; Sun Yat Sen
   University; Southern Medical University   China
RP Zhang, ZM (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Orthopaed, Div Spine Surg, Guangzhou 510515, Peoples R China.; Xie, DH; Chen, HJ (通讯作者)，Southern Med Univ, Affiliated Hosp 3, Ctr Orthoped Surg, Dept Orthoped Surg, Guangzhou 510630, Peoples R China.
EM xiedenghui221122@smu.edu.cn; zzmzzc@smu.edu.cn;
   chenhuix5@mail.sysu.edu.cn
RI LI, CHENGLIN/JUF 8254 2023; S, T.C./JEP 7261 2023; Mo,
   Xiaoyi/ABC 7560 2021; Chen, Yating/AAT 5592 2020; Fu, Xihong/F 4693 2013
FU National Natural Science Foundation of China; Guangdong Basic and
   Applied Basic Research Foundation [2023A1515111003]; China Postdoctoral
   Science Foundation [2024M751327]; President Foundation of Nanfang
   Hospital, Southern Medical University [2023B020];  [32171456]; 
   [82272527];  [82072520]
FX X.M. and K.M. These authors contributed equally to this work. The
   authors would like to acknowledge financial support from the National
   Natural Science Foundation of China (Grant No. 32171456, 82272527,
   82072520), Guangdong Basic and Applied Basic Research Foundation (Grant
   No. 2023A1515111003), the China Postdoctoral Science Foundation (Grant
   No. 2024M751327), the President Foundation of Nanfang Hospital, Southern
   Medical University (Grant No. 2023B020). Additionally, the authors thank
   Material Scientific Cores at Zhejiang Lab for the assistance.
CR Abu Taha A, 2014, CELL ADHES MIGR, V8, P125, DOI 10.4161/cam.28243
   Anastasio C, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25105087
   Baumer Y, 2008, HISTOCHEM CELL BIOL, V129, P765, DOI 10.1007/s00418 008 0422 y
   Beaudart C, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 022 01075 z
   Cancel LM, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27524 9
   Chang H, 2021, NAT BIOMED ENG, V5, P1008, DOI 10.1038/s41551 021 00720 1
   Chen HL, 2022, BIOL PHARM BULL, V45, P1043, DOI 10.1248/bpb.b21 01057
   Choi H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208514
   Choo S, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14040766
   Cosman F, 2020, ENDOCR PRACT, V26, P777, DOI 10.4158/EP 2019 0596
   Daddona PE, 2011, PHARM RES DORDR, V28, P159, DOI 10.1007/s11095 010 0192 9
   Dang M, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201600901
   Davis SP, 2004, J BIOMECH, V37, P1155, DOI 10.1016/j.jbiomech.2003.12.010
   Detamornrat U, 2023, LAB CHIP, V23, P2304, DOI 10.1039/d3lc00160a
   Ding YW, 2024, BIOACT MATER, V38, P95, DOI 10.1016/j.bioactmat.2024.04.020
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   Geyer H, 1999, GLYCOBIOLOGY, V9, P915, DOI 10.1093/glycob/9.9.915
   Graybill PM, 2020, CANCERS, V12, DOI 10.3390/cancers12051132
   Han XY, 2024, ADV MATER, V36, DOI 10.1002/adma.202306993
   He YH, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115326
   Jiang XR, 2024, SMALL METHODS, V8, DOI 10.1002/smtd.202301068
   Khare N, 2021, DRUG DEV IND PHARM, V47, P1183, DOI 10.1080/03639045.2021.1992421
   Kugelmann D, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31408 3
   LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511
   Li LX, 2023, ECOTOX ENVIRON SAFE, V257, DOI 10.1016/j.ecoenv.2023.114940
   Li LY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.723922
   Li XL, 2021, ADV SCI, V8, DOI 10.1002/advs.202100827
   Li YJ, 2021, ACTA BIOMATER, V121, P349, DOI 10.1016/j.actbio.2020.12.023
   Lin L, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202109187
   Markelc B, 2018, J CONTROL RELEASE, V276, P30, DOI 10.1016/j.jconrel.2018.02.032
   Medi BA, 2003, INT J PHARMACEUT, V263, P25, DOI 10.1016/S0378 5173(03)00337 5
   Meulenberg CJW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052713
   Mo X. Y., 2022, MATER DESIGN, V219, P14
   Mo XY, 2021, BMC GERIATR, V21, DOI 10.1186/s12877 021 02313 8
   Nabuchi Y, 1997, PHARMACEUT RES, V14, P1685, DOI 10.1023/A:1012115426306
   Osagie Clouard L, 2017, BONE JOINT RES, V6, P14, DOI 10.1302/2046 3758.61.BJR 2016 0085.R1
   Parker WH, 2016, AM J PHYSIOL CELL PH, V311, pC652, DOI 10.1152/ajpcell.00076.2016
   Parrilla M, 2023, ACS SENSORS, V8, P4161, DOI 10.1021/acssensors.3c01381
   Rahimi N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01847
   Rajagopalan NR, 2024, ANN BIOMED ENG, V52, P89, DOI 10.1007/s10439 023 03211 3
   Rampersad SN, 2010, J BIOL CHEM, V285, P33614, DOI 10.1074/jbc.M110.140004
   Shimizu M, 2016, BIOL PHARM BULL, V39, P625, DOI 10.1248/bpb.b15 00756
   Sun J., 2024, ADV SCI, DOI DOI 10.1002/ADVS.202404190
   Sundaram PM, 2021, LAB CHIP, V21, DOI 10.1039/d0lc00507j
   Suzuki Y, 2002, J PHARM SCI, V91, P350, DOI 10.1002/jps.10019
   Wright TJ, 2002, EXP CELL RES, V280, P159, DOI 10.1006/excr.2002.5636
   Xenikakis I, 2022, J DRUG DELIV SCI TEC, V67, DOI 10.1016/j.jddst.2021.102891
   Yang JB, 2020, MICROSYST NANOENG, V6, DOI 10.1038/s41378 020 00224 z
   Yang Y, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202104092
   Yu B, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.120997
   Yu CC, 2023, ACS APPL MATER INTER, V15, P19976, DOI 10.1021/acsami.3c01139
   ZHAO H, 2023, CARDIOVASC RES, V119, P1981, DOI DOI 10.1093/CVR/CVAD105
NR 53
TC 2
Z9 2
U1 9
U2 18
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2366 9608
J9 SMALL METHODS
JI Small Methods
PD MAR
PY 2025
VL 9
IS 3
DI 10.1002/smtd.202401144
EA OCT 2024
PG 14
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA 0KS1T
UT WOS:001334317500001
PM 39420694
OA hybrid
DA 2025 08 17
ER

PT J
AU Yang, G
   Xu, HK
   Yao, MJ
   Yan, SG
   Wu, MR
   Zhou, CH
AF Yang, Guang
   Xu, Huikang
   Yao, Minjun
   Yan, Shigui
   Wu, Mengrui
   Zhou, Chenhe
TI Norcantharidin ameliorates estrogen deficient mediated bone loss by
   attenuating the activation of extracellular signal regulated
   kinase/ROS/NLRP3 inflammasome signaling
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE osteoclast; osteoporosis; norcantharidin; ERK; ROS; NLRP3 inflammasome
ID NF KAPPA B; CRUCIAL ROLE; RESORPTION; OSTEOPOROSIS; PATHWAY
AB Osteoporosis, characterized by reduced bone mass, aberrant bone architecture, and elevated bone fragility, is driven by a disruption of bone homeostasis between bone resorption and bone formation. However, up to now, no drugs are perfect for osteoporosis treatment due to different defects. In this study, we demonstrated that norcantharidin (NCTD) could inhibit osteoclast formation and bone resorption by attenuating the ERK, ROS and NLRP3 inflammasomes pathways in vitro. Moreover, our in vivo study further confirms its preventive effects on estrogen deficiency bone loss by inhibiting osteoclast formation and functions. Therefore, we could conclude that NCTD might be a potential candidates for the prevention and treatment of osteoporosis.
C1 [Yang, Guang; Yao, Minjun; Yan, Shigui; Zhou, Chenhe] Zhejiang Univ, Affiliated Hosp 2, Dept Orthoped Surg, Sch Med, Hangzhou City, Zhejiang, Peoples R China.
   [Yang, Guang; Yao, Minjun; Yan, Shigui; Zhou, Chenhe] Zhejiang Univ, Orthoped Res Inst, Hangzhou City, Zhejiang, Peoples R China.
   [Yang, Guang; Yao, Minjun; Yan, Shigui; Zhou, Chenhe] Key Lab Motor Syst Dis Res & Precis Therapy Zhejia, Hangzhou City, Zhejiang, Peoples R China.
   [Yang, Guang; Yao, Minjun; Yan, Shigui; Zhou, Chenhe] Clin Res Ctr Motor Syst Dis Zhejiang Prov, Hangzhou City, Peoples R China.
   [Xu, Huikang] Zhejiang Univ, Natl Clin Res Ctr Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Dis, State Key Lab Diag & Treatment Infect Dis,Affiliat, Hangzhou, Peoples R China.
   [Wu, Mengrui] Zhejiang Univ, Coll Life Sci, Dept Cell & Dev Biol, Hangzhou, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University;
   Collaborative Innovation Center for Diagnosis & Treatment of Infectious
   Diseases; Zhejiang University
RP Yan, SG; Zhou, CH (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Dept Orthoped Surg, Sch Med, Hangzhou City, Zhejiang, Peoples R China.; Yan, SG; Zhou, CH (通讯作者)，Zhejiang Univ, Orthoped Res Inst, Hangzhou City, Zhejiang, Peoples R China.; Yan, SG; Zhou, CH (通讯作者)，Key Lab Motor Syst Dis Res & Precis Therapy Zhejia, Hangzhou City, Zhejiang, Peoples R China.; Yan, SG; Zhou, CH (通讯作者)，Clin Res Ctr Motor Syst Dis Zhejiang Prov, Hangzhou City, Peoples R China.; Wu, MR (通讯作者)，Zhejiang Univ, Coll Life Sci, Dept Cell & Dev Biol, Hangzhou, Peoples R China.
EM zrjwsj@zju.edu.cn; wumengrui@zju.edu.cn; andyzhou@zju.edu.cn
RI Zhou, Chenhe/AAI 9226 2020
FU Zhejiang Natural Science Foundation [LQ21H060006]; National Natural
   Science Foundation of China [82001461]; China Postdoctoral Science
   Foundation [2020M671758]
FX This study was supported by research grants from Zhejiang Natural
   Science Foundation (No. LQ21H060006), the National Natural Science
   Foundation of China (No. 82001461), and the fellowship of China
   Postdoctoral Science Foundation (No. 2020M671758).
CR BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006 291X(05)80311 0
   Bernabei R, 2014, CLIN CASES MINER BON, V11, P201, DOI 10.11138/ccmbm/2014.11.3.201
   Bonar SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035979
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chen K, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01046
   Crotti TN, 2004, BIOMATERIALS, V25, P565, DOI 10.1016/S0142 9612(03)00556 8
   Davis Beckley K, 2013, Methods Mol Biol, V1031, P27, DOI 10.1007/978 1 62703 481 4_3
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Ferreira LH Jr, 2021, MINERVA DENT ORAL SC, V70, P49, DOI [10.23736/S0026 4970.20.04306 X, 10.23736/S2724 6329.20.04306 X]
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Huang ZP, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/9825073
   Ivaska KK, 2010, J BONE MINER RES, V25, P393, DOI 10.1359/jbmr.091006
   LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee MS, 2009, J IMMUNOL, V183, P3390, DOI 10.4049/jimmunol.0804314
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li Y, 2012, MOL CELL BIOCHEM, V361, P79, DOI 10.1007/s11010 011 1091 z
   McHugh J, 2017, NAT REV RHEUMATOL, V13, DOI 10.1038/nrrheum.2017.129
   Peng C, 2016, SCI REP UK, V6, DOI 10.1038/srep20500
   Pfister AK, 2006, SOUTH MED J, V99, P123, DOI 10.1097/01.smj.0000202090.30647.61
   Rosen CJ, 2000, BEST PRACT RES CL EN, V14, P181, DOI 10.1053/beem.2000.0068
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Toker H, 2012, J PERIODONTAL RES, V47, P793, DOI 10.1111/j.1600 0765.2012.01497.x
   Wang C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.58
   Wang C, 2020, J BONE MINER RES, V35, P776, DOI 10.1002/jbmr.3927
   Wang GF, 2018, CURR MED CHEM, V25, P2034, DOI 10.2174/0929867324666170414165253
   Wang XY, 2021, INT IMMUNOPHARMACOL, V94, DOI 10.1016/j.intimp.2021.107370
   Wang X, 2018, METABOLISM, V83, P167, DOI 10.1016/j.metabol.2018.01.005
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Yu CC, 2012, INT J ONCOL, V41, P1050, DOI 10.3892/ijo.2012.1511
   Zheng J, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477 7819 12 207
   Zhou CH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00210
   Zhou CH, 2018, BRIT J PHARMACOL, V175, P859, DOI 10.1111/bph.14092
   Zhou JB, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110755
NR 35
TC 3
Z9 3
U1 2
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 3
PY 2022
VL 13
AR 1019478
DI 10.3389/fphar.2022.1019478
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 6I5PA
UT WOS:000886178100001
PM 36408264
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sukhdeo, K
   Mani, M
   Zhang, YY
   Dutta, J
   Yasui, H
   Rooney, MD
   Carrasco, DE
   Zheng, M
   He, HY
   Tai, YT
   Mitsiades, C
   Anderson, KC
   Carrasco, DR
AF Sukhdeo, Kumar
   Mani, Mala
   Zhang, Yunyu
   Dutta, Jui
   Yasui, Hiroshi
   Rooney, Melissa D.
   Carrasco, Daniel E.
   Zheng, Mei
   He, Haiying
   Tai, Yu Tzu
   Mitsiades, Constantine
   Anderson, Kenneth C.
   Carrasco, Daniel R.
TI Targeting the β catenin/TCF transcriptional complex in the treatment of
   multiple myeloma
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE drug therapy; Wnt signaling
ID MARROW STROMAL CELLS; BONE MARROW; STEM CELLS; WNT GENE; APOPTOSIS;
   IDENTIFICATION; EXPRESSION; INHIBITOR; TRANSDUCTION; GROWTH
AB Multiple myeloma (MM) is an invariably fatal form of cancer characterized by clonal proliferation of malignant plasma cells in the bone marrow. The canonical Writ signaling pathway is activated in MM cells through constitutively active beta catenin, a messenger molecule relevant to growth, survival, and migration of MM cells. The identification of a number of small molecular compounds, such as PKF115 584, which disrupt the interaction of the transcriptionally active beta catenin/TCF protein complex, provides valuable new therapeutic tools to target an alternative pathway in MM independent of the proteasome. Here we evaluated the transcriptional, proteomic, signaling changes, and biological sequelae associated with the inhibition of Writ signaling in MM by PKF115 584. The compound blocks expression of Writ target genes and induces cytotoxicity in both patient MM cells and MM cell lines without a significant effect in normal plasma cells. In xenograft models of human MM, PKF115 584 inhibits tumor growth and prolongs survival. Taken together, these data demonstrate the efficacy of disrupting the beta catenin/TCF transcriptional complex to exploit tumor dependence on Writ signaling as a therapeutic approach in the treatment of MM.
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Dana Farber Cancer Institute; Harvard University; Harvard
   Medical School; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Harvard University; Harvard University Medical
   Affiliates; Brigham & Women's Hospital
RP Carrasco, DR (通讯作者)，Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM ruben_carrasco@dfci.harvard.edu
RI Anderson, Kenneth/ACP 5073 2022
OI Sukhdeo, Kumar/0000 0001 8725 6081; Yasui, Hiroshi/0000 0003 0905 6855
FU NIGMS NIH HHS [T32 GM007250] Funding Source: Medline
CR Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092 8674(00)00122 7
   Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019
   Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104
   Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87
   Cormier Stephania A, 2003, BMC Dev Biol, V3, P4, DOI 10.1186/1471 213X 3 4
   Davies FE, 2003, BLOOD, V102, P4504, DOI 10.1182/blood 2003 01 0016
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hideshima T, 2001, CANCER RES, V61, P3071
   Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200
   Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833
   Huang ML, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 221
   Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258
   KIRDNER KW, 1996, CELL, V87, P159
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535 6108(03)00334 9
   McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464
   Mitsiades CS, 2004, CANCER CELL, V6, P439, DOI 10.1016/j.ccr.2004.10.020
   Mostoslavsky G, 2005, MOL THER, V11, P932, DOI 10.1016/j.ymthe.2005.01.005
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Polakis P, 2000, GENE DEV, V14, P1837
   Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239
   Raje N, 2006, BRIT J HAEMATOL, V135, P52, DOI 10.1111/j.1365 2141.2006.06261.x
   Raje N, 2004, BLOOD, V104, P4188, DOI 10.1182/blood 2004 06 2281
   Rajkumar SV, 2005, MAYO CLIN PROC, V80, P1371, DOI 10.4065/80.10.1371
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb 2001 2 2 reviews3004
   SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419
   Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529
   Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665 5679.2000
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Vacca A, 2003, BLOOD, V102, P3340, DOI 10.1182/blood 2003 04 1338
   Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202
   YACCOBY S, 2006, IN PRESS BLOOD
NR 36
TC 208
Z9 222
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 1
PY 2007
VL 104
IS 18
BP 7516
EP 7521
DI 10.1073/pnas.0610299104
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 164MY
UT WOS:000246239400040
PM 17452641
OA Green Published
DA 2025 08 17
ER

PT J
AU Matzno, S
   Nishiguchi, T
   Akiyoshi, T
   Anami, S
   Nakabayashi, T
   Matsuyama, K
AF Matzno, Sumio
   Nishiguchi, Tomoko
   Akiyoshi, Takeshi
   Anami, Setsuko
   Nakabayashi, Toshikatsu
   Matsuyama, Kenji
TI Synergistic action of statins and nitrogen containing bisphosphonates in
   the development of rhabdomyolysis in L6 rat skeletal myoblasts
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE apoptosis; N containing bisphosphonates; protein prenylation; statins
ID COENZYME A REDUCTASE; MEVALONATE PATHWAY; INDUCED APOPTOSIS;
   ALENDRONATE; INHIBITION; GERANYLGERANIOL; OSTEOCLAST; ACTIVATION;
   MECHANISMS; BINDING
AB Objectives Nitrogen containing bisphosphonates, which are widely used to treat osteoporosis, act as inhibitors of farnesyl pyrophosphate synthase, one of the key enzymes of the mevalonate pathway, and thus may have the potential to enhance the effect of statins (inhibitors of 3 hydroxy 3 methylglutaryl coenzyme A reductase). In this study, we evaluated the synergistic effect of two nitrogen containing bisphosphonates, alendronate and risedronate, in statin induced apoptosis in rat skeletal L6 myoblasts.
   Methods L6 rat myoblasts were differentiated with drugs. DNA fragmentation was measured and small GTPase was detected by immunoblotting.
   Key findings Alendronate and risedronate caused dose dependent apoptosis of L6 myoblasts. Risedronate induced detachment of rho GTPase from the cell membrane, followed by activation of the caspase 8 related cascade. Risedronate induced apoptosis was synergistically enhanced with atorvastatin and significantly reduced by addition of geranylgeraniol. By contrast, alendronate did not reduce membrane GTPases and the apoptosis was caspase independent.
   Conclusions These results suggest that risedronate induced apoptosis is related to geranylgeranyl pyrophosphate depletion followed by rho detachment, whereas alendronate affects are independent of rho. Our results suggest a risk of synergistic action between nitrogen containing bisphosphonates and statins in the development of rhabdomyolysis when treating osteoporosis in women with hyperlipidaemia.
C1 [Matzno, Sumio; Nishiguchi, Tomoko; Nakabayashi, Toshikatsu] Mukogawa Womens Univ, Sch Pharmaceut Sci, Nishinomiya, Hyogo 6638179, Japan.
   [Matzno, Sumio] Mukogawa Womens Univ, Inst Biosci, Nishinomiya, Hyogo 6638179, Japan.
   [Akiyoshi, Takeshi; Matsuyama, Kenji] Keio Univ, Fac Pharm, Dept Clin Pharm, Tokyo, Japan.
   [Anami, Setsuko] Sakai Municipal Hosp, Dept Pharm, Osaka, Japan.
C3 Mukogawa Women's University; Mukogawa Women's University; Keio
   University
RP Matzno, S (通讯作者)，Mukogawa Womens Univ, Sch Pharmaceut Sci, 11 68 Kyuban Cho, Nishinomiya, Hyogo 6638179, Japan.
EM smatzno@mukogawa u.ac.jp
RI Akiyoshi, Takeshi/ABG 6192 2021
CR [Anonymous], COCHRANE DATABASE SY
   Baker Danial E, 2002, Rev Gastroenterol Disord, V2, P20
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132
   Dirks AJ, 2006, AM J PHYSIOL CELL PH, V291, pC1208, DOI 10.1152/ajpcell.00226.2006
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Guijarro C, 1998, CIRC RES, V83, P490, DOI 10.1161/01.RES.83.5.490
   Guo RT, 2007, P NATL ACAD SCI USA, V104, P10022, DOI 10.1073/pnas.0702254104
   Heckbert SR, 2008, ARCH INTERN MED, V168, P826, DOI 10.1001/archinte.168.8.826
   Kearney PM, 2006, CURR OPIN LIPIDOL, V17, P418, DOI 10.1097/01.mol.0000236368.42755.25
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Matzno S, 2006, LIFE SCI, V78, P1892, DOI 10.1016/j.lfs.2005.08.003
   Matzno S, 2005, J PHARM PHARMACOL, V57, P1475, DOI 10.1211/jpp.57.11.0014
   Matzno S, 2003, J PHARM PHARMACOL, V55, P795, DOI 10.1211/002235703765951401
   Matzno S, 1997, J LIPID RES, V38, P1639
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Sabbatini M, 2004, J AM SOC NEPHROL, V15, P901, DOI 10.1097/01.ASN.0000119573.01290.AE
   Sakamoto S, 2004, ENDOCRINOLOGY, V145, P2929, DOI 10.1210/en.2003 1350
   Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486
   Tanriverdi HA, 2005, EUR J OBSTET GYN R B, V120, P63, DOI 10.1016/j.ejogrb.2004.08.007
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Van Noorden CJF, 2001, ACTA HISTOCHEM, V103, P241, DOI 10.1078/0065 1281 00601
   Yuen KK, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006250
NR 30
TC 11
Z9 11
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3573
EI 2042 7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD JUN
PY 2009
VL 61
IS 6
BP 781
EP 788
DI 10.1211/jpp/61.06.0011
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 476AU
UT WOS:000268409900011
PM 19505369
OA Bronze
DA 2025 08 17
ER

PT J
AU Kuroshima, S
   Go, VAA
   Yamashita, J
AF Kuroshima, Shinichiro
   Go, Virginia Arlene A.
   Yamashita, Junro
TI Increased Numbers of Nonattached Osteoclasts After Long Term Zoledronic
   Acid Therapy in Mice
SO ENDOCRINOLOGY
LA English
DT Article
ID BISPHOSPHONATE RELATED OSTEONECROSIS; BREAST CANCER PATIENTS; DELTA
   T CELLS; RHEUMATOID ARTHRITIS; BONE RESORPTION; PHOSPHATASE 5B;
   POSTMENOPAUSAL WOMEN; USEFUL MARKER; FEMORAL HEAD; SERUM MARKER
AB Osteoclasts are key players in the maintenance of bone, which is an endocrine target and organ. Bisphosphonates, used for the management of metastatic bone diseases and osteoporosis, suppress osteoclasts. However, the impact of continuously suppressed osteoclasts is unknown. In this study, mice received zoledronic acid (ZA) for 13 months, nearly half the lifespan of mice, and the effects of continual osteoclast suppression on the bone environment and oral wound healing were determined. ZA therapy suppressed osteoclasts, resulting in significantly more bone mass compared with control. Despite continuous and intense suppression of bone loss in mice receiving ZA, serum calcium levels were maintained in the normal range. No differences were noted in serum tartrate resistant acid phosphatase (TRAP) 5b levels between ZA treated and control mice. Histomorphometric analyses of bones revealed that ZA therapy significantly decreased osteoclasts on the bone surface but, instead, substantially increased TRAP(+) mononuclear cells and osteoclasts that were not on the bone surface. When oral trauma was induced, such TRAP(+) mononuclear and nonattached osteoclasts increased considerably with increased inflammatory cell infiltration in the wounds. As a result, oral wound healing was hindered at the connective tissue level. Healing of the epithelium was unaffected. These findings indicate that the continual suppression of osteoclasts does not affect serum calcium levels and that long term ZA therapy stimulates nonattached osteoclast and TRAP(+) mononuclear cell formation that are expanded rapidly in response to oral trauma. Caution should be exercised when using the serum TRAcP5b to estimate the efficacy of antiresorptive therapy. (Endocrinology 153: 17 28, 2012)
C1 [Kuroshima, Shinichiro; Go, Virginia Arlene A.; Yamashita, Junro] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
   [Kuroshima, Shinichiro] Hokkaido Univ, Grad Sch Dent Med, Sapporo, Hokkaido 0608586, Japan.
C3 University of Michigan System; University of Michigan; Hokkaido
   University
RP Yamashita, J (通讯作者)，Univ Michigan, Sch Dent, Dept Biol & Mat Sci, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM yamashit@umich.edu
RI Yamashita, Junro/D 4787 2019
OI Yamashita, Junro/0000 0002 5486 1362; Kuroshima,
   Shinichiro/0000 0001 9891 9987
FU National Institute of Dental and Craniofacial Research [R03DE018923]
FX This work was supported by the National Institute of Dental and
   Craniofacial Research Grant R03DE018923.
CR Aghaloo TL, 2011, J BONE MINER RES, V26, P1871, DOI 10.1002/jbmr.379
   Bäuerle T, 2010, CLIN CANCER RES, V16, P3215, DOI 10.1158/1078 0432.CCR 09 2932
   Barasch A, 2011, J DENT RES, V90, P439, DOI 10.1177/0022034510397196
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chao TY, 2005, CLIN CANCER RES, V11, P544
   Cheung MS, 2009, J BONE MINER RES, V24, P669, DOI 10.1359/JBMR.081225
   Coury F, 2008, NAT MED, V14, P81, DOI 10.1038/nm1694
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Deckers MML, 2002, J BONE MINER RES, V17, P998, DOI 10.1359/jbmr.2002.17.6.998
   Devogelaer JP, 1996, BONE, V18, P141, DOI 10.1016/8756 3282(95)00436 X
   Dobson KR, 1999, CALCIFIED TISSUE INT, V65, P411, DOI 10.1007/s002239900723
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Ferguson VL, 2003, BONE, V33, P387, DOI 10.1016/S8756 3282(03)00199 6
   Fournier P, 2002, CANCER RES, V62, P6538
   GERTZ BJ, 1993, OSTEOPOROSIS INT, V3, pS13
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549 010 0866 3
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337
   Halloran BP, 2002, J BONE MINER RES, V17, P1044, DOI 10.1359/jbmr.2002.17.6.1044
   Hao Q, 2008, AM J PHYSIOL HEART C, V295, pH2250, DOI 10.1152/ajpheart.00083.2008
   Harrison LC, 1996, J EXP MED, V184, P2167, DOI 10.1084/jem.184.6.2167
   Herman S, 2008, ARTHRITIS RHEUM US, V58, P3041, DOI 10.1002/art.23943
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Holoshitz J, 1999, MICROBES INFECT, V1, P197, DOI 10.1016/S1286 4579(99)80034 3
   Huang RC, 2005, SPINE, V30, P2516, DOI 10.1097/01.brs.0000186470.28070.7b
   Janckila AJ, 2008, J BONE MINER RES, V23, P1287, DOI 10.1359/JBMR.080329
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kiesel JR, 2009, J IMMUNOL, V182, P5477, DOI 10.4049/jimmunol.0803897
   Kikuiri T, 2010, J BONE MINER RES, V25, P1668, DOI 10.1002/jbmr.37
   Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774 009 0128 9
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Kubek DJ, 2010, ORTHOD CRANIOFAC RES, V13, P214, DOI 10.1111/j.1601 6343.2010.01497.x
   Kyrgidis A, 2008, J CLIN ONCOL, V26, P4634, DOI 10.1200/JCO.2008.16.2768
   Lai KA, 2005, J BONE JOINT SURG AM, V87A, P2155, DOI 10.2106/JBJS.D.02959
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   LUFKIN EG, 1994, OSTEOPOROSIS INT, V4, P320, DOI 10.1007/BF01622190
   MACDONALD IC, 1995, MICROVASC RES, V49, P64, DOI 10.1006/mvre.1995.1006
   Nenonen A, 2005, J BONE MINER RES, V20, P1804, DOI 10.1359/JBMR.050403
   Ramachandran M, 2007, J BONE JOINT SURG AM, V89A, P1727, DOI 10.2106/JBJS.F.00964
   Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P108, DOI 10.1007/s00223 007 9091 4
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rozental TD, 2009, J HAND SURG AM, V34A, P595, DOI 10.1016/j.jhsa.2008.12.011
   Samadfam R, 2009, ENDOCRINOLOGY, V150, P4835, DOI 10.1210/en.2009 0472
   Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004 1211
   Shen ZX, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1938
   Shidara K, 2008, CALCIFIED TISSUE INT, V82, P278, DOI 10.1007/s00223 008 9127 4
   Shu L, 2011, J BONE MINER RES, V26, P1057, DOI 10.1002/jbmr.300
   Tas F, 2008, MED ONCOL, V25, P346, DOI 10.1007/s12032 008 9043 5
   TAYLOR RD, 1966, AM J CLIN PATHOL, V46, P472
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Yamashita J, 2011, CLIN CANCER RES, V17, P1405, DOI 10.1158/1078 0432.CCR 10 1614
   Yao ZQ, 2008, J BIOL CHEM, V283, P9917, DOI 10.1074/jbc.M706415200
   Zhu XW, 2007, J INFECT DIS, V196, P1076, DOI 10.1086/521030
NR 59
TC 41
Z9 48
U1 0
U2 16
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815 5817 USA
SN 0013 7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD JAN
PY 2012
VL 153
IS 1
BP 17
EP 28
DI 10.1210/en.2011 1439
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 869XC
UT WOS:000298631500003
PM 22109892
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Yang, XB
   Chang, Z
   Ma, R
   Guo, H
   Zhao, QP
   Wang, XD
   Kong, LB
   Hao, DJ
AF Yang, Xiaobin
   Chang, Zhen
   Ma, Rui
   Guo, Hua
   Zhao, Qingpeng
   Wang, Xiaodong
   Kong, Lingbo
   Hao, Dingjun
TI Eleutherococcus senticosus Inhibits RANKL induced osteoclast formation
   by attenuating the NF κB and MAPKs signaling pathway
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Eleutherococcus senticosus; RANKL; osteoclast
ID NECROSIS FACTOR ALPHA; PERIPROSTHETIC OSTEOLYSIS; TOTAL HIP;
   SUPPRESSION; EXPRESSION; BONE; WEAR; ARTHROPLASTY; ASSOCIATION; TITANIUM
AB Natural plant derived eleutherococcus senticosus (ES) has potential therapeutic and preventative effects on treating bone metabolism diseases such as: arthritis and osteoporosis. However, the mechanisms of ES effects on the osteoclastogenesis remains to be investigated. The current study is the first time to explored the effect of ES on RANKL mediated marrow derived macrophages (BMMs) and mice macrophage RAW 264.7 cells in vitro. Here, we found ES can significantly decrease RANKL induced osteoclast differentiation and bone resorption compared with the control in dose dependent manner and showed no cytotoxicity. ES also downregulated the expression of osteoclastic genes such as TRAP and OSCAR. Moreover, ES markedly inhibited the phosphorylation of early signaling pathway such as NF kappa B and MAPKs activity. Furthermore, ES extract significantly decreased the expression of osteoclast key transcriptor c Fos/NFATc 1. Our results collectively demonstrating that as a natural compound, ES may serve as a useful drug in the prevention of bone resorption disease.
C1 [Yang, Xiaobin; Chang, Zhen; Guo, Hua; Zhao, Qingpeng; Wang, Xiaodong; Kong, Lingbo; Hao, Dingjun] Xi An Jiao Tong Univ, Hong Hui Hosp, Coll Med, Youyi West St, Xian 710054, Peoples R China.
   [Ma, Rui] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
C3 Xi'an Jiaotong University; University System of Maryland; University of
   Maryland Baltimore
RP Kong, LB; Hao, DJ (通讯作者)，Xi An Jiao Tong Univ, Hong Hui Hosp, Coll Med, Youyi West St, Xian 710054, Peoples R China.
EM lingbokong@163.com; dhao.honghui@outlook.com
RI kong, lingbo/O 7491 2017
CR Baxter RM, 2011, CLIN ORTHOP RELAT R, V469, P2308, DOI 10.1007/s11999 010 1713 x
   Chaganti RK, 2014, CLIN ORTHOP RELAT R, V472, P584, DOI 10.1007/s11999 013 3235 9
   Chen RZ, 2011, FOOD CHEM, V127, P434, DOI 10.1016/j.foodchem.2010.12.143
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   Davydov M, 2000, J ETHNOPHARMACOL, V72, P345, DOI 10.1016/S0378 8741(00)00181 1
   Dumbleton JH, 2002, J ARTHROPLASTY, V17, P649, DOI 10.1054/arth.2002.33664
   Harris WH, 2001, CLIN ORTHOP RELAT R, P66
   Huang LZ, 2011, PHARMAZIE, V66, P83, DOI 10.1691/ph.2011.0744
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kim HJ, 2014, CAN J PHYSIOL PHARM, V92, P278, DOI 10.1139/cjpp 2013 0392
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kong LB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061013
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lim DW, 2013, MOLECULES, V18, P7998, DOI 10.3390/molecules18077998
   Masui T, 2005, BIOMATERIALS, V26, P1695, DOI 10.1016/j.biomaterials.2004.05.017
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Mohamed SGK, 2007, BONE, V41, P592, DOI 10.1016/j.bone.2007.05.016
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teeny SM, 2003, J ARTHROPLASTY, V18, P954, DOI 10.1016/j.arth.2003.09.001
   Tian B, 2014, BIOMATERIALS, V35, P8937, DOI 10.1016/j.biomaterials.2014.06.055
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 24
TC 4
Z9 4
U1 0
U2 5
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936 2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2017
VL 10
IS 4
BP 4514
EP 4521
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA ET8LF
UT WOS:000400550200053
DA 2025 08 17
ER

PT J
AU Childress, P
   Robling, AG
   Bidwell, JP
AF Childress, Paul
   Robling, Alexander G.
   Bidwell, Joseph P.
TI Nmp4/CIZ: Road block at the intersection of PTH and load
SO BONE
LA English
DT Article
ID NUCLEAR MATRIX PROTEINS; NUCLEOCYTOPLASMIC SHUTTLING PROTEIN;
   ZINC FINGER PROTEIN; I COLLAGEN PROMOTER; FLUID SHEAR STRESS;
   GROWTH FACTOR BETA; PARATHYROID HORMONE; TRANSCRIPTION FACTORS;
   INTERMITTENT PTH; GENE EXPRESSION
AB Teriparatide (parathyroid hormone. [PTH]) is the only FDA approved drug that replaces bone lost to osteoporosis. Enhancing PTH efficacy will improve cost effectiveness and ameliorate contraindications. Combining this hormone with load bearing exercise may enhance therapeutic potential consistent with a growing body of evidence that these agonists are synergistic and share common signaling pathways. Additionally, neutralizing molecules that naturally suppress the anabolic response to PTH may also improve the efficacy of treatment with this hormone. Nmp4/CIZ (nuclear matrix protein 4/cas interacting zinc finger) null mice have enhanced responses to intermittent PTH with respect to increasing trabecular bone mass and are also immune to disuse induced bone loss likely by the removal of Nmp4/CIZ suppressive action on osteoblast function. Nmp4/CIZ activity may be sensitive to changes in the mechanical environment of the bone cell brought about by hormone  or mechanical load induced changes in cell shape and adhesion. Nmp4 was identified in a screen for PTH responsive nuclear matrix architectural transcription factors (ATFs) that we proposed translate hormone induced changes in cell shape and adhesion into changes in target gene DNA conformation. CIZ was independently identified as a nucleocytoplasmic shuttling transcription factor associating with the mechano sensitive focal adhesion proteins p130Cas and zxyin. The p130Cas/zyxin/Nmp4/CIZ pathway resembles the beta catenin/TCF/LEF1 mechanotransduction response limb and both share features with the HMGB1 (high mobility group box 1)/RAGE (receptor for advanced glycation end products) signaling axis. Here we describe Nmp4/CIZ within the context of the PTH induced anabolic response and consider the place of this molecule in the hierarchy of the PTH load response network. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Childress, Paul; Robling, Alexander G.; Bidwell, Joseph P.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Robling, Alexander G.] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Indianapolis; Purdue
   University System; Purdue University; Purdue University in Indianapolis
RP Bidwell, JP (通讯作者)，Indiana Univ, Sch Med, Dept Anat & Cell Biol, Med Sci Bldg 5035,635 Barnhill Dr, Indianapolis, IN 46202 USA.
EM jbidwell@iupui.edu
RI Childress, Paul/AAD 4684 2020
FU NIH NIDDK [DK053796]
FX This work was supported by a grant from NIH NIDDK, contract grant
   number: DK053796, JPB.
CR Allen MR., 2007, IBMS BoneKEy, V4, P49, DOI [10.1138/20060248, DOI 10.1138/20060248]
   Alvarez M, 1998, J CELL BIOCHEM, V69, P336, DOI 10.1002/(SICI)1097 4644(19980601)69:3<336::AID JCB11>3.0.CO;2 A
   Alvarez M, 2005, GENE, V347, P43, DOI 10.1016/j.gene.2004.10.025
   Alvarez M, 2003, GENE, V313, P43, DOI 10.1016/S0378 1119(03)00627 9
   Alvarez M, 1997, ENDOCRINOLOGY, V138, P482, DOI 10.1210/en.138.1.482
   Alvarez MB, 2001, CYTOGENET CELL GENET, V94, P244, DOI 10.1159/000048824
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bidwell JP, 2008, J CELL BIOCHEM, V103, P1671, DOI 10.1002/jcb.21572
   Bidwell JP, 1998, J BONE MINER RES, V13, P155, DOI 10.1359/jbmr.1998.13.2.155
   Blick SKA, 2008, DRUGS, V68, P2709, DOI 10.2165/0003495 200868180 00012
   Bogdanovic Z, 2000, J CELL BIOCHEM, V77, P149, DOI 10.1002/(SICI)1097 4644(20000401)77:1<149::AID JCB15>3.0.CO;2 N
   Bouxsein ML, 2005, J BONE MINER RES, V20, P635, DOI 10.1359/JBMR.041204
   CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418
   Case N, 2008, J BIOL CHEM, V283, P29196, DOI 10.1074/jbc.M801907200
   Cattaruzza M, 2004, HYPERTENSION, V43, P726, DOI 10.1161/01.HYP.0000119189.82659.52
   Charoonpatrapong Panyayong K, 2007, J CELL BIOCHEM, V102, P1202, DOI 10.1002/jcb.21349
   Davies J, 2004, J ENDOCRINOL, V180, P505, DOI 10.1677/joe.0.1800505
   Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003
   DHAWAN J, 1991, J BIOL CHEM, V266, P8470
   Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422
   EGAN JJ, 1991, J CELL BIOCHEM, V45, P101, DOI 10.1002/jcb.240450117
   Feister HA, 2000, BONE, V26, P227, DOI 10.1016/S8756 3282(99)00269 0
   Feister HA, 2000, J CELL BIOCHEM, V79, P506, DOI 10.1002/1097 4644(20001201)79:3<506::AID JCB150>3.0.CO;2 A
   Ferrari SL, 2005, ENDOCRINOLOGY, V146, P1854, DOI 10.1210/en.2004 1282
   FUCHS RK, 2008, REV BONE MINER METAB, V6, P37
   Gieni RS, 2008, J CELL BIOCHEM, V104, P1964, DOI 10.1002/jcb.21364
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Goto K, 1996, BIOCHEMISTRY US, V35, P11005, DOI 10.1021/bi960723o
   Guignandon A, 2001, FASEB J, V15, P2036, DOI 10.1096/fj.00 0837fje
   Hino K, 2007, BONE, V40, P852, DOI 10.1016/j.bone.2006.03.019
   Hirata H, 2008, J CELL SCI, V121, P2795, DOI 10.1242/jcs.030320
   Ho AM, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 35
   Horikawa A, 2000, TOHOKU J EXP MED, V191, P127, DOI 10.1620/tjem.191.127
   Hughes Fulford M, 2006, J CELL BIOCHEM, V99, P435, DOI 10.1002/jcb.20883
   Janssen H, 2006, EXP CELL RES, V312, P1194, DOI 10.1016/j.yexcr.2006.02.001
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jin HL, 2009, HUM MOL GENET, V18, P2729, DOI 10.1093/hmg/ddp205
   Kim W, 2008, MOL BIOL CELL, V19, P2135, DOI 10.1091/mbc.E07 10 0991
   KRAMER I, 2009, J BONE MINER RE 0713
   KREBSBACH PH, 1993, MOL CELL BIOL, V13, P5168, DOI 10.1128/MCB.13.9.5168
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Lenga Y, 2008, CIRC RES, V102, P319, DOI 10.1161/CIRCRESAHA.107.160408
   Li F, 2008, CELL MOTIL CYTOSKEL, V65, P332, DOI 10.1002/cm.20263
   Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849
   MATTHEWS JL, 1981, CLIN ORTHOP RELAT R, P27
   Misteli T, 2007, CELL, V128, P787, DOI 10.1016/j.cell.2007.01.028
   Morinobu M, 2005, J EXP MED, V201, P961, DOI 10.1084/jem.20041097
   Mosekilde L, 2008, CLIN ENDOCRINOL, V69, P1, DOI 10.1111/j.1365 2265.2007.03162.x
   Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649 1658.2000
   Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284
   PHILIP B, 2009, ASBMR 31 ANN M SEPT
   Robling AG, 2009, J CELL PHYSIOL, V219, P734, DOI 10.1002/jcp.21717
   Rowe D. W., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P350
   Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028
   Sato MM, 2009, GENES CELLS, V14, P141, DOI 10.1111/j.1365 2443.2008.01258.x
   Sawada Y, 2006, CELL, V127, P1015, DOI 10.1016/j.cell.2006.09.044
   Shah R, 2004, AM J PHYSIOL ENDOC M, V287, pE289, DOI 10.1152/ajpendo.00517.2003
   Shen ZJ, 2002, J BIOL CHEM, V277, P29840, DOI 10.1074/jbc.M203157200
   Sowa H, 2003, J BIOL CHEM, V278, P52240, DOI 10.1074/jbc.M302566200
   Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479 5876 7 17
   Stewart CL, 2007, SCIENCE, V318, P1408, DOI 10.1126/science.1142034
   Sugiyama T, 2008, BONE, V43, P238, DOI 10.1016/j.bone.2008.04.012
   Thomas CH, 2002, P NATL ACAD SCI USA, V99, P1972, DOI 10.1073/pnas.032668799
   Thunyakitpisal P, 2001, J BONE MINER RES, V16, P10, DOI 10.1359/jbmr.2001.16.1.10
   Torrungruang K, 1998, BONE, V22, P317, DOI 10.1016/S8756 3282(97)00300 1
   Torrungruang K, 2002, J BIOL CHEM, V277, P16153, DOI 10.1074/jbc.M107496200
   Turner CH, 2006, ANN NY ACAD SCI, V1068, P429, DOI 10.1196/annals.1346.039
   Turner RT, 2006, J APPL PHYSIOL, V101, P881, DOI 10.1152/japplphysiol.01622.2005
   Turner RT, 2007, J BONE MINER RES, V22, P64, DOI 10.1359/JBMR.061006
   Woo CH, 2008, CIRC RES, V102, P538, DOI 10.1161/CIRCRESAHA.107.156877
   Zhang JS, 2006, J BONE MINER RES, V21, P1729, DOI 10.1359/JBMR.060722
NR 71
TC 16
Z9 21
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2010
VL 46
IS 2
BP 259
EP 266
DI 10.1016/j.bone.2009.09.014
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 557XG
UT WOS:000274702800002
PM 19766748
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Seales, EC
   Micoli, KJ
   McDonald, JM
AF Seales, EC
   Micoli, KJ
   McDonald, JM
TI Calmodulin is a critical regulator of osteoclastic differentiation,
   function, and survival
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE calmodulin; osteoclast; osteoclastogenesis; calcium; calcineurin;
   calmodulin dependent protein kinase II (CaMKII); acid transport
ID BONE RESORPTION; SIGNALING PATHWAYS; CYCLOSPORINE A; H+ ATPASE; C JUN;
   EXPRESSION; APOPTOSIS; TAMOXIFEN; CALCIUM; FAS
AB Increased osteoclastic resorption and Subsequent bone loss are common features of many debilitating diseases including osteoporosis, bone metastases, Paget's disease, and rheumatoid arthritis. While rapid progress has been made in elucidating the signaling pathways directing osteoclast differentiation and function, a corn(2+) activated regulator calmodulin in prehensive Picture is far from complete. Here, we explore the role of the Ca2+ osteoclastic differentiation, functional bone resorption, and apoptosis. During active bone resorption, calmodulin expression is increased, and calmodulin Concentrates at the ruffled border, the organelle utilized for acid transport and bone dissolution. Pharmacologic inhibitors of calmodulin, several of which are already used clinically as anti cancer and anti psychotic agents, inhibit osteoclastic acid transport, suggesting their potential as bone sparing drugs. Recent studies also implicate calmodulin in osteoclast apoptosis through a mechanism involving its direct interaction with the death receptor Fas. During osteoclastogenesis, RANKL incluction stimulates a rise in intracellular Ca2+ which in turn activates calmodulin and its downstream effectors. In particular, the Ca2+/calmodulin dependent phosphatase calcineurin and its targets, the NFAT family of transcription factors, have been posited as the master regulators of osteoclastogenesis. However, recent in vivo and in vitro studies demonstrate that another Ca2+/calmodulin regulated effector protein, CaMKII, is also involved. CaMKII+/  mutant mice have reduced osteoclast numbers, and CaMKII antagonists inhibit osteoclastogenesis in vitro. Furthermore, CaMKII is known to activate AP 1 transcription factors, which are also required for RANKL induced osteoclast gene transcription, and recent findings suggest that CaMKII can clown regulate gp130, a cytokine receptor involved in bone remodeling and implicated in numerous osteo articular diseases.
C1 Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35233 USA.
   Vet Adm Med Ctr, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham; US
   Department of Veterans Affairs; Veterans Health Administration (VHA)
RP Univ Alabama Birmingham, Dept Pathol, 619,19th St S,W Pavil 220, Birmingham, AL 35233 USA.
EM mcdonald@path.uab.edu
FU NIAMS NIH HHS [P30 AR046031] Funding Source: Medline
CR Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<73::AID JCB11>3.0.CO;2 L
   BEKKER PJ, 1990, J BONE MINER RES, V5, P557
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown OA, 2000, LIFE SCI, V66, P2081, DOI 10.1016/S0024 3205(00)00534 8
   Burgoyne RD, 2003, BBA MOL CELL RES, V1641, P137, DOI 10.1016/S0167 4889(03)00089 2
   Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962 8924(00)01800 6
   Day CJ, 2005, J CELL BIOCHEM, V95, P17, DOI 10.1002/jcb.20410
   Day CJ, 2004, J CELL BIOCHEM, V91, P303, DOI 10.1002/jcb.10780
   Gibson RM, 2000, J BIOL CHEM, V275, P22574, DOI 10.1074/jbc.M907658199
   Gibson RM, 2005, BBA BIOMEMBRANES, V1714, P56, DOI 10.1016/j.bbamem.2005.05.014
   Heymann D, 2000, CYTOKINE, V12, P1455, DOI 10.1006/cyto.2000.0747
   Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092 8674(02)00682 7
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   HORGAN K, 1986, BIOCHEM PHARMACOL, V35, P4463, DOI 10.1016/0006 2952(86)90764 1
   Igarashi K, 2004, BONE, V35, P47, DOI 10.1016/j.bone.2004.02.009
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003 0008
   Kawakami A, 1997, J BONE MINER RES, V12, P1637, DOI 10.1359/jbmr.1997.12.10.1637
   Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Manion MK, 2000, BIOCHEM BIOPH RES CO, V277, P462, DOI 10.1006/bbrc.2000.3691
   Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378
   Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4
   Mishra JP, 2005, J BIOL CHEM, V280, P26825, DOI 10.1074/jbc.M500244200
   MOUNTZ JD, 1994, ARTHRITIS RHEUM, V37, P1415, DOI 10.1002/art.1780371002
   Myers DE, 1999, FEBS LETT, V463, P295, DOI 10.1016/S0014 5793(99)01650 6
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   RADDING W, 1994, J CELL PHYSIOL, V160, P17, DOI 10.1002/jcp.1041600104
   Sims NA, 2004, J CLIN INVEST, V113, P379, DOI 10.1172/JCI200419872
   Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386
   SU B, 1994, CELL, V77, P727, DOI 10.1016/0092 8674(94)90056 6
   Takasu Junichiro, 2002, BMC Blood Disord, V2, P3, DOI 10.1186/1471 2326 2 3
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo 122 3 1146
   Wang X M, 2000, Chin J Dent Res, V3, P26
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Williams JP, 2003, CALCIFIED TISSUE INT, V73, P290, DOI 10.1007/s00223 002 0012 2
   Williams JP, 2003, J BONE MINER RES, V18, P451, DOI 10.1359/jbmr.2003.18.3.451
   Williams JP, 1996, J BIOL CHEM, V271, P12488, DOI 10.1074/jbc.271.21.12488
   Williams JP, 2000, BIOCHEM CELL BIOL, V78, P715, DOI 10.1139/bcb 78 6 715
   Williams JP, 1997, J CELL BIOCHEM, V66, P358, DOI 10.1002/(SICI)1097 4644(19970901)66:3<358::AID JCB8>3.3.CO;2 K
   Wu XJ, 2005, J BIOL CHEM, V280, P29964, DOI 10.1074/jbc.M500710200
   Wu XJ, 2005, J BONE MINER RES, V20, P107, DOI 10.1359/JBMR.041022
   Wu XJ, 2003, ENDOCRINOLOGY, V144, P5545, DOI 10.1210/en.2003 0296
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Zayzafoon M, 2005, J BIOL CHEM, V280, P7049, DOI 10.1074/jbc.M412680200
   Zhang L, 2003, ENDOCRINOLOGY, V144, P4536, DOI 10.1210/en.2003 0147
   Zhang L, 2005, CRIT REV EUKAR GENE, V15, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i1.10
NR 53
TC 71
Z9 81
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN 1
PY 2006
VL 97
IS 1
BP 45
EP 55
DI 10.1002/jcb.20659
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 997EK
UT WOS:000234227600004
PM 16216008
DA 2025 08 17
ER

PT J
AU Ding, MA
   Cho, EJ
   Chen, ZH
   Park, SW
   Lee, TH
AF Ding, Mina
   Cho, Eunjin
   Chen, Zhihao
   Park, Sang Wook
   Lee, Tae Hoon
TI (S) 2 (Cyclobutylamino) N (3 (3,4 dihydroisoquinolin 2(1H)
    yl) 2 hydroxypropyl)isonicotinamide Attenuates RANKL Induced Osteoclast
   Differentiation by Inhibiting NF ?B Nuclear Translocation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoporosis; osteoclast differentiation; PRMT5; NF kappa B; methylation
ID KAPPA B; TRANSCRIPTION FACTOR; VERTEBRAL FRACTURES; LYSINE METHYLATION;
   GENE EXPRESSION; PRMT5; OSTEOPOROSIS; NFATC1; PU.1; RELA
AB Osteoporosis is a common skeletal disease; however, effective pharmacological treatments still need to be discovered. This study aimed to identify new drug candidates for the treatment of osteoporosis. Here, we investigated the effect of EPZ compounds, protein arginine methyltransferase 5 (PRMT5) inhibitors, on RANKL induced osteoclast differentiation via molecular mechanisms by in vitro experiments. EPZ015866 attenuated RANKL induced osteoclast differentiation, and its inhibitory effect was more significant than EPZ015666. EPZ015866 suppressed the F actin ring formation and bone resorption during osteoclastogenesis. In addition, EPZ015866 significantly decreased the protein expression of Cathepsin K, NFATc1, and PU.1 compared with the EPZ015666 group. Both EPZ compounds inhibited the nuclear translocation of NF kappa B by inhibiting the dimethylation of the p65 subunit, which eventually prevented osteoclast differentiation and bone resorption. Hence, EPZ015866 may be a potential drug candidate for the treatment of osteoporosis.
C1 [Ding, Mina; Chen, Zhihao] Chonnam Natl Univ, Biomed Sci Grad Program BMSGP, Gwangju 61186, South Korea.
   [Cho, Eunjin; Park, Sang Wook; Lee, Tae Hoon] Chonnam Natl Univ, Dent Sci Res Inst, Sch Dent, Dept Oral Biochem, Gwangju 61186, South Korea.
C3 Chonnam National University; Chonnam National University
RP Lee, TH (通讯作者)，Chonnam Natl Univ, Dent Sci Res Inst, Sch Dent, Dept Oral Biochem, Gwangju 61186, South Korea.
EM thlee83@jnu.ac.kr
RI Lee, Tae/B 1160 2013; Park, Sang Wook/LEM 5116 2024
FU National Research Foundation of Korea (NRF) grant   Korean government
   (MSIT) [2021R1A2C2094007]; Korean Fund for Regenerative Medicine (KFPM)
   grant   Korean government (the Ministry of Science and ICT, the Ministry
   of Health welfare) [21B0603L1 01]
FX This research was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korean government (MSIT; 2021R1A2C2094007) and
   the Korean Fund for Regenerative Medicine (KFPM) grant funded by the
   Korean government (the Ministry of Science and ICT, the Ministry of
   Health & welfare; 21B0603L1 01).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Alles N, 2010, ENDOCRINOLOGY, V151, P4626, DOI 10.1210/en.2010 0399
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Cai SF, 2019, SEMIN HEMATOL, V56, P84, DOI 10.1053/j.seminhematol.2018.08.001
   Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966 7975.2005
   Chen Z, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.599081
   Cho E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113436
   Cho E, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115707
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Di Lorenzo A, 2011, FEBS LETT, V585, P2024, DOI 10.1016/j.febslet.2010.11.010
   Dong YH, 2017, CELL SIGNAL, V34, P55, DOI 10.1016/j.cellsig.2017.03.004
   Dontas I. A., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P268
   Duncan KW, 2016, ACS MED CHEM LETT, V7, P162, DOI 10.1021/acsmedchemlett.5b00380
   Ea CK, 2009, P NATL ACAD SCI USA, V106, P18972, DOI 10.1073/pnas.0910439106
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Giusti A, 2015, CLIN INTERV AGING, V10, P105, DOI 10.2147/CIA.S44057
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Han GH, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9010017
   Harris DP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148905
   Harris DP, 2014, J BIOL CHEM, V289, P15328, DOI 10.1074/jbc.M114.547349
   Huang B, 2010, CELL SIGNAL, V22, P1282, DOI 10.1016/j.cellsig.2010.03.017
   Huang L, 2020, bioRxiv, DOI [10.1101/2020.08.12.246660, 10.1101/2020.08.12.246660, DOI 10.1101/2020.08.12.246660]
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ishiyama K, 2015, ALLERGOL INT, V64, P241, DOI 10.1016/j.alit.2015.01.006
   Jimi E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121636
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kwon OH, 2005, BIOCHEM BIOPH RES CO, V335, P437, DOI 10.1016/j.bbrc.2005.07.092
   Levy D, 2011, NAT IMMUNOL, V12, P29, DOI 10.1038/ni.1968
   Liang ZZ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.725301
   Lu T, 2015, CANCER RES, V75, P3692, DOI 10.1158/0008 5472.CAN 15 1022
   Lu T, 2013, P NATL ACAD SCI USA, V110, P13510, DOI 10.1073/pnas.1311770110
   Matsubara T, 2006, J BONE MINER METAB, V24, P368, DOI 10.1007/s00774 006 0701 4
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Morales Y, 2016, ARCH BIOCHEM BIOPHYS, V590, P138, DOI 10.1016/j.abb.2015.11.030
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Otero K, 2009, NAT IMMUNOL, V10, P734, DOI 10.1038/ni.1744
   Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838
   Reintjes A, 2016, P NATL ACAD SCI USA, V113, P4326, DOI 10.1073/pnas.1522372113
   Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097 2765(03)00490 8
   So H, 2003, J BIOL CHEM, V278, P24209, DOI 10.1074/jbc.M302940200
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang Xi, 2008, Ai Zheng, V27, P1018
   Wei H, 2013, P NATL ACAD SCI USA, V110, P13516, DOI 10.1073/pnas.1311784110
   Wei X, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148 020 00826 4
   Weigert J, 2009, CYTOKINE, V45, P86, DOI 10.1016/j.cyto.2008.10.017
   Yan YR, 2021, AGING US, V13, P4468, DOI 10.18632/aging.202407
   Zhang FX, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.596230
   Zhang J, 2019, MOL MED REP, V19, P3963, DOI 10.3892/mmr.2019.10111
   Zhang YX, 2015, J BIOCHEM, V158, P445, DOI 10.1093/jb/mvv059
   Zhao L, 2018, CURR TOP MED CHEM, V18, P2395, DOI 10.2174/1568026619666181224095449
   Zhu F, 2019, GENES DIS, V6, P247, DOI 10.1016/j.gendis.2019.06.002
NR 61
TC 10
Z9 11
U1 2
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2023
VL 24
IS 5
AR 4327
DI 10.3390/ijms24054327
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 9V2XX
UT WOS:000948262700001
PM 36901758
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yeon, JT
   Kim, KJ
   Son, YJ
   Park, SJ
   Kim, SH
AF Yeon, Jeong Tae
   Kim, Kwang Jin
   Son, Young Jin
   Park, Sang Joon
   Kim, Seong Hwan
TI Idelalisib inhibits osteoclast differentiation and pre osteoclast
   migration by blocking the PI3Kδ Akt c Fos/NFATc1 signaling cascade
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Article
DE Phosphoinositide 3 kinases; Idelalisib; Osteoclast differentiation
ID CHRONIC LYMPHOCYTIC LEUKEMIA; B CELL MALIGNANCIES; PHOSPHATIDYLINOSITOL
   3 KINASE; PI3K; SURVIVAL; CAL 101; PATHWAY; NFATC1; WORTMANNIN;
   EXPRESSION
AB Since increased number of osteoclasts could lead to impaired bone structure and low bone mass, which are common characteristics of bone disorders including osteoporosis, the pharmacological inhibition of osteoclast differentiation is one of therapeutic strategies for preventing and/or treating bone disorders and related facture. However, little data are available regarding the functional relevance of phosphoinositide 3 kinase (PI3K) isoforms in the osteoclast differentiation process. To elucidate the functional involvement of PI3K delta in osteoclastogenesis, here we investigated how osteoclast differentiation was influenced by idelalisib (also called CAL 101), which is p110 delta selective inhibitor approved for the treatment of specific human B cell malignancies. Here, we found that receptor activator of nuclear factor kappa B ligand (RANKL) induced PI3K delta protein expression, and idelalisib inhibited RANKL induced osteoclast differentiation. Next, the inhibitory effect of idelalisib on RANKL induced activation of the Akt c Fos/NFATc1 signaling cascade was confirmed by western blot analysis and real time PCR. Finally, idelalisib inhibited pre osteoclast migration in the last stage of osteoclast differentiation through down regulation of the Akt c Fos/NFATc1 signaling cascade. It may be possible to expand the clinical use of idelalisib for controlling osteoclast differentiation. Together, the present results contribute to our understanding of the clinical value of PI3K delta as a druggable target and the efficacy of related therapeutics including osteoclastogenesis.
C1 [Yeon, Jeong Tae] Sunchon Natl Univ, Res Inst Basic Sci, Sunchon, South Korea.
   [Kim, Kwang Jin; Son, Young Jin] Sunchon Natl Univ, Dept Pharm, Sunchon, South Korea.
   [Park, Sang Joon] Kyungpook Natl Univ, Coll Vet Med, Dept Histol, 80 Daehakro, Daegu 41566, South Korea.
   [Kim, Seong Hwan] Korea Res Inst Chem Technol, Innovat Target Res Ctr, Bio & Drug Discovery Div, 141 Gajeong Ro, Daejeon 334114, South Korea.
C3 Sunchon National University; Sunchon National University; Kyungpook
   National University (KNU); Korea Research Institute of Chemical
   Technology (KRICT)
RP Park, SJ (通讯作者)，Kyungpook Natl Univ, Coll Vet Med, Dept Histol, 80 Daehakro, Daegu 41566, South Korea.; Kim, SH (通讯作者)，Korea Res Inst Chem Technol, Innovat Target Res Ctr, Bio & Drug Discovery Div, 141 Gajeong Ro, Daejeon 334114, South Korea.
EM psj26@knu.ac.kr; hwan@krict.re.kr
RI Kim, Seong/AAA 6086 2021; Jin Ho, Seo/B 3621 2014
FU National Research Foundation of Korea [KN 1331]; Korea Research
   Institute of Chemical Technology [KK1703 F02, KK1803 F00, KK1932 20]
FX This work was supported by project grants from National Research
   Foundation of Korea (KN 1331) and Korea Research Institute of Chemical
   Technology (KK1703 F02, KK1803 F00 & KK1932 20).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boudot C, 2010, BONE, V46, P1416, DOI 10.1016/j.bone.2010.01.383
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Choi SW, 2015, J BONE MINER RES, V30, P1494, DOI 10.1002/jbmr.2468
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Foster FM, 2003, J CELL SCI, V116, P3037, DOI 10.1242/jcs.00609
   Fruman DA, 2011, CANCER DISCOV, V1, P562, DOI 10.1158/2159 8290.CD 11 0249
   Grey A, 2010, BIOCHEM BIOPH RES CO, V391, P564, DOI 10.1016/j.bbrc.2009.11.099
   Gyori D, 2014, ARTHRITIS RHEUMATOL, V66, P2210, DOI 10.1002/art.38660
   Hawkins PT., 1851, BIOCHIM BIOPHYS ACTA, V6, P882, DOI [10.1016/j.bbalip.2014.12.006, DOI 10.1016/J.BBALIP.2014.12.006]
   Herman SEM, 2010, BLOOD, V116, P2078, DOI 10.1182/blood 2010 02 271171
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda H, 2010, BLOOD, V116, P1460, DOI 10.1182/blood 2009 06 222943
   Juss JK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045933
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Kim HH, 2003, FASEB J, V17, P2163, DOI 10.1096/fj.03 0215fje
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797
   Lannutti BJ, 2011, BLOOD, V117, P591, DOI 10.1182/blood 2010 03 275305
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Marini C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12761 1
   Meadows SA, 2012, BLOOD, V119, P1897, DOI 10.1182/blood 2011 10 386763
   Millar FR, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0069 2016
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Munugalavadla V, 2008, MOL CELL BIOL, V28, P7182, DOI 10.1128/MCB.00920 08
   NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014 5793(95)00153 Z
   Nakamura I, 2012, MOD RHEUMATOL, V22, P167, DOI 10.1007/s10165 011 0530 8
   Norman P, 2011, EXPERT OPIN THER PAT, V21, P1773, DOI 10.1517/13543776.2011.629606
   Papakonstanti EA, 2008, J CELL SCI, V121, P4124, DOI 10.1242/jcs.032763
   Pauls SD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00224
   Pilkington MF, 1998, J BONE MINER RES, V13, P688, DOI 10.1359/jbmr.1998.13.4.688
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   ROSSI JF, 1990, BRIT J HAEMATOL, V76, P469, DOI 10.1111/j.1365 2141.1990.tb07902.x
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Shugg RPP, 2013, J BIOL CHEM, V288, P35346, DOI 10.1074/jbc.M113.507525
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Stark AK, 2015, CURR OPIN PHARMACOL, V23, P82, DOI 10.1016/j.coph.2015.05.017
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600 0765.2005.00814.x
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535
   Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045
   Vanhaesebroeck B, 2016, J MOL MED, V94, P5, DOI 10.1007/s00109 015 1352 5
   Xing R, 2016, INT J MOL MED, V38, P1125, DOI 10.3892/ijmm.2016.2722
   Yamanaka Y, 2013, J ORTHOP RES, V31, P67, DOI 10.1002/jor.22200
   Yap TA, 2015, CURR OPIN PHARMACOL, V23, P98, DOI 10.1016/j.coph.2015.05.016
   Yeon JT, 2014, AMINO ACIDS, V46, P2605, DOI 10.1007/s00726 014 1797 9
NR 53
TC 16
Z9 19
U1 4
U2 15
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489 3 SUHCHO DONG, SUHCHO KU, SEOUL 137 071, SOUTH KOREA
SN 0253 6269
EI 1976 3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD AUG
PY 2019
VL 42
IS 8
BP 712
EP 721
DI 10.1007/s12272 019 01163 8
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA IR6TF
UT WOS:000481571100007
PM 31161369
DA 2025 08 17
ER

PT J
AU Tiede Lewis, LM
   Dallas, SL
AF Tiede Lewis, LeAnn M.
   Dallas, Sarah L.
TI Changes in the osteocyte lacunocanalicular network with aging
SO BONE
LA English
DT Article
DE Aging; Osteocytes; Osteoporosis; Dendrite degeneration; Bone fragility
ID LASER SCANNING MICROSCOPY; AGE RELATED CHANGES; LOW BONE MASS; OXIDATIVE
   STRESS; POSTMENOPAUSAL WOMEN; LACUNAR DENSITY; TRABECULAR BONE; CORTICAL
   BONE; CANALICULAR NETWORKS; SCLEROSTIN ANTIBODY
AB Osteoporosis is an aging related disease of reduced bone mass that is particularly prevalent in post menopausal women, but also affects the aged male population and is associated with increased fracture risk. Osteoporosis is the result of an imbalance whereby bone formation by osteoblasts no longer keeps pace with resorption of bone by osteoclasts. Osteocytes are the most abundant cells in bone and, although previously thought to be quiescent, they are now known to be active, multifunctional cells that play a key role in the maintenance of bone mass by regulating both osteoblast and osteoclast activity. They are also thought to regulate bone mass through their role as mechanoresponsive cells in bone that coordinate adaptive responses to mechanical loading. Osteocytes form an extensive interconnected network throughout the mineralized bone matrix and receive their nutrients as well as hormones and signaling factors through the lacunocanalicular system. Several studies have shown that the extent and connectivity of the lacunocanalicular system and osteocyte networks degenerates in aged humans as well as in animal models of aging. It is also known that the bone anabolic response to loading is decreased with aging. This review summarizes recent research on the degenerative changes that occur in osteocytes and their lacunocanalicular system as a result of aging and discusses the implications for skeletal health and homeostasis as well as potential mechanisms that may underlie these degenerative changes. Since osteocytes are such key regulators of skeletal homeostasis, maintaining the health of the osteocyte network would seem critical for maintenance of bone health. Therefore, a more complete understanding of the structure and function of the osteocyte network, its lacunocanalicular system, and the degenerative changes that occur with aging should lead to advances in our understanding of age related bone loss and potentially lead to improved therapies.
C1 [Tiede Lewis, LeAnn M.; Dallas, Sarah L.] Univ Missouri, Sch Dent, Dept Oral & Craniofacial Sci, 650 E 25th St, Kansas City, MO 64108 USA.
C3 University of Missouri System; University of Missouri Kansas City
RP Dallas, SL (通讯作者)，Univ Missouri, Sch Dent, Dept Oral & Craniofacial Sci, 650 E 25th St, Kansas City, MO 64108 USA.
EM dallass@umkc.edu
OI Dallas, Sarah/0000 0002 5197 891X
FU NIH [P01AG039355, R21AR054449, R21AR062346, R01AR051517, S1 ORR027668,
   S1 00D021665]; UMKC Office of Research Services; UMKC Center of
   Excellence in Dental and Musculoskeletal Tissues
FX The work was supported by NIH grants P01AG039355, R21AR054449,
   R21AR062346 and R01AR051517. We acknowledge use of the UMKC Confocal
   Microscopy Core supported by NIH grants S1 ORR027668 and S1 00D021665,
   the UMKC Office of Research Services and UMKC Center of Excellence in
   Dental and Musculoskeletal Tissues. We thank Anita Xie (UMKC Dept. Oral
   and Craniofacial Biology) for providing the acid  etched electron
   microscopy image in Fig. 2C and Loretta Laughrey and Ganesh Thiagarajan
   (UMKC Dept. Computing and Engineering) for collaboration in generating
   the multiplexed confocal image in Fig. 4A.
CR Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Ashique A M, 2017, Bone Rep, V7, P9, DOI 10.1016/j.bonr.2017.06.002
   Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974
   Bilezikian JP, 1999, TRENDS ENDOCRIN MET, V10, P244, DOI 10.1016/S1043 2760(99)00154 X
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   BLAIR SN, 1995, JAMA J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Bonewald Lynda F, 2006, Bonekey Osteovision, V3, P7
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Buenzli PR, 2015, BONE, V75, P144, DOI 10.1016/j.bone.2015.02.016
   Burra Sirisha, 2011, Commun Integr Biol, V4, P48, DOI 10.4161/cib.4.1.13646
   Burra S, 2010, P NATL ACAD SCI USA, V107, P13648, DOI 10.1073/pnas.1009382107
   Busse B, 2010, AGING CELL, V9, P1065, DOI 10.1111/j.1474 9726.2010.00633.x
   Cabahug Zuckerman P, 2016, J BONE MINER RES, V31, P1356, DOI 10.1002/jbmr.2807
   Carpentier VT, 2012, BONE, V50, P688, DOI 10.1016/j.bone.2011.11.021
   Carriero A, 2014, BONE, V61, P116, DOI 10.1016/j.bone.2013.12.020
   Carter Y, 2013, J STRUCT BIOL, V183, P519, DOI 10.1016/j.jsb.2013.07.004
   Chen H, 2015, MED MOL MORPHOL, V48, P61, DOI 10.1007/s00795 015 0099 y
   Ciani C, 2009, BONE, V44, P1015, DOI 10.1016/j.bone.2009.01.376
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   Coutu DL, 2018, NAT METHODS, V15, P39, DOI [10.1038/NMETH.4503, 10.1038/nmeth.4503]
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Dickstein DL, 2007, AGING CELL, V6, P275, DOI 10.1111/j.1474 9726.2007.00289.x
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Fritton SP, 2009, ANNU REV FLUID MECH, V41, P347, DOI 10.1146/annurev.fluid.010908.165136
   FROST HM, 1960, J BONE JOINT SURG AM, V42, P144, DOI 10.2106/00004623 196042010 00012
   Gilsanz V, 2006, J BONE MINER RES, V21, P1464, DOI 10.1359/JBMR.060612
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Greenbaum A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah6518
   Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673 5374.2013.21.009
   Halloran BP, 2002, J BONE MINER RES, V17, P1044, DOI 10.1359/jbmr.2002.17.6.1044
   Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101
   Harvey N., 2013, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, P348
   Hemmatian H, 2018, BONE, V113, P1, DOI 10.1016/j.bone.2018.05.003
   Hemmatian H, 2017, CURR OSTEOPOROS REP, V15, P401, DOI 10.1007/s11914 017 0402 z
   Heveran CM, 2018, BONE, V110, P115, DOI 10.1016/j.bone.2018.01.018
   Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900
   Holmbeck K, 2005, J CELL SCI, V118, P147, DOI 10.1242/jcs.01581
   Hwang Onyou, 2013, Exp Neurobiol, V22, P11, DOI 10.5607/en.2013.22.1.11
   Igwe JC, 2009, J CELL BIOCHEM, V108, P621, DOI 10.1002/jcb.22294
   Jähn K, 2017, J BONE MINER RES, V32, P1761, DOI 10.1002/jbmr.3167
   Javaheri B, 2014, J BONE MINER RES, V29, P705, DOI 10.1002/jbmr.2064
   Jilka RL, 2016, CURR OSTEOPOROS REP, V14, P16, DOI 10.1007/s11914 016 0297 0
   Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474 9726.2010.00616.x
   Jing D, 2014, FASEB J, V28, P1582, DOI 10.1096/fj.13 237578
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kamel MA, 2010, BONE, V47, P872, DOI 10.1016/j.bone.2010.08.007
   Kamel ElSayed SA, 2015, BONE, V76, P129, DOI 10.1016/j.bone.2015.02.011
   Kamioka H, 2001, BONE, V28, P145, DOI 10.1016/S8756 3282(00)00421 X
   Kamioka H, 2009, MICROSC MICROANAL, V15, P377, DOI 10.1017/S1431927609990420
   Kaya S, 2017, J BONE MINER RES, V32, P688, DOI 10.1002/jbmr.3044
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Kerschnitzki M, 2013, J BONE MINER RES, V28, P1837, DOI 10.1002/jbmr.1927
   Kiel DP, 2015, J BONE MINER RES, V30, P1319, DOI 10.1002/jbmr.2448
   Kitase Y, 2018, CELL REP, V22, P1531, DOI 10.1016/j.celrep.2018.01.041
   Kobayashi K, 2015, SCI REP UK, V5, DOI 10.1038/srep09148
   Kogianni G, 2004, LIFE SCI, V75, P2879, DOI 10.1016/j.lfs.2004.04.048
   Koleske AJ, 2013, NAT REV NEUROSCI, V14, P536, DOI 10.1038/nrn3486
   Kubek DJ, 2010, MICROSC RES TECHNIQ, V73, P182, DOI 10.1002/jemt.20772
   Kulkarni RN, 2012, BIOCHEM BIOPH RES CO, V420, P11, DOI 10.1016/j.bbrc.2012.02.099
   Lai XH, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.9
   Lara Castillo N, 2015, BONE, V76, P58, DOI 10.1016/j.bone.2015.03.019
   Lenaz G, 1998, BBA BIOENERGETICS, V1366, P53, DOI 10.1016/S0005 2728(98)00120 0
   Lewiecki EM, 2018, J CLIN ENDOCR METAB, V103, P3183, DOI 10.1210/jc.2017 02163
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Lirani Galvao APR, 2009, CALCIFIED TISSUE INT, V84, P502, DOI 10.1007/s00223 009 9227 9
   Lu XL, 2012, J BONE MINER RES, V27, P563, DOI 10.1002/jbmr.1474
   Luo D, 2016, OSTEOPOROSIS INT, V27, P1093, DOI 10.1007/s00198 015 3325 5
   Ma YL, 2008, J BIOMECH, V41, P1324, DOI 10.1016/j.jbiomech.2008.01.017
   Malagelada C, 2010, J NEUROSCI, V30, P1166, DOI 10.1523/JNEUROSCI.3944 09.2010
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   Mason DJ, 1997, BONE, V20, P199, DOI 10.1016/S8756 3282(96)00386 9
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   MCNEILL TH, 1988, BRAIN RES, V455, P148, DOI 10.1016/0006 8993(88)90124 2
   Meakin LB, 2014, J BONE MINER RES, V29, P1859, DOI 10.1002/jbmr.2222
   Milovanovic P, 2017, SMALL, V13, DOI 10.1002/smll.201602215
   Milovanovic P, 2013, ACS NANO, V7, P7542, DOI 10.1021/nn401360u
   Mori S, 1997, BONE, V21, P521, DOI 10.1016/S8756 3282(97)00200 7
   Mullender MG, 1996, BONE, V18, P109, DOI 10.1016/8756 3282(95)00444 0
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nicolella DP, 2006, J BIOMECH, V39, P1735, DOI 10.1016/j.jbiomech.2005.04.032
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Okada S, 2002, MICROSC MICROANAL, V8, P104, DOI 10.1017/S1431927601020037
   Onal M, 2013, J BIOL CHEM, V288, P17432, DOI 10.1074/jbc.M112.444190
   Pacureanu A, 2012, MED PHYS, V39, P2229, DOI 10.1118/1.3697525
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010
   Pakkenberg B, 2003, EXP GERONTOL, V38, P95, DOI 10.1016/S0531 5565(02)00151 1
   Peyrin F, 1998, Technol Health Care, V6, P391
   Piemontese M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93771
   Piemontese M, 2016, SCI REP UK, V6, DOI 10.1038/srep24262
   Prideaux M, 2016, CURR OPIN PHARMACOL, V28, P24, DOI 10.1016/j.coph.2016.02.003
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Qiu S, 2002, BONE, V31, P709, DOI 10.1016/S8756 3282(02)00907 9
   Qiu S, 2002, BONE, V31, P313, DOI 10.1016/S8756 3282(02)00819 0
   Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Rolvien T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19803 2
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   Rubinsztein DC, 2010, P NATL ACAD SCI USA, V107, pE181, DOI 10.1073/pnas.1014633107
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Schneider P, 2007, J BONE MINER RES, V22, P1557, DOI 10.1359/JBMR.070703
   Schneider P, 2011, BONE, V49, P304, DOI 10.1016/j.bone.2011.04.005
   Seeman E, 2013, J GERONTOL A BIOL, V68, P1218, DOI 10.1093/gerona/glt071
   Sterck JGH, 1998, AM J PHYSIOL ENDOC M, V274, pE1113, DOI 10.1152/ajpendo.1998.274.6.E1113
   Sugawara Y, 2005, BONE, V36, P877, DOI 10.1016/j.bone.2004.10.008
   Sugawara Y, 2013, BONE, V52, P189, DOI 10.1016/j.bone.2012.09.033
   Tang GM, 2014, NEURON, V83, P1131, DOI 10.1016/j.neuron.2014.07.040
   Tang SY, 2012, J BONE MINER RES, V27, P1936, DOI 10.1002/jbmr.1646
   Tarantino U, 2017, J ORTHOP TRAUMATOL, V18, pS3, DOI 10.1007/s10195 017 0474 7
   Tate MLK, 1998, BONE, V22, P107
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Thi MM, 2013, P NATL ACAD SCI USA, V110, P21012, DOI 10.1073/pnas.1321210110
   Tiede Lewis L, 2018, J BONE MINER RES, V33, P383
   Tiede Lewis LM, 2017, AGING US, V9, P2187, DOI 10.18632/aging.101308
   Tomkinson A, 1998, J BONE MINER RES, V13, P1243, DOI 10.1359/jbmr.1998.13.8.1243
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   TURNER CH, 1995, J BONE MINER RES, V10, P1544
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   van Hove RP, 2009, BONE, V45, P321, DOI 10.1016/j.bone.2009.04.238
   Vashishth D, 2000, BONE, V26, P375, DOI 10.1016/S8756 3282(00)00236 2
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Wang LY, 2004, BONE, V34, P499, DOI 10.1016/j.bone.2003.11.022
   Webster DJ, 2013, BONE, V54, P285, DOI 10.1016/j.bone.2013.01.004
   Weinbaum S, 2011, CELL MOL BIOENG, V4, P510, DOI 10.1007/s12195 011 0179 6
   Weinstein RS, 2010, AGING CELL, V9, P147, DOI 10.1111/j.1474 9726.2009.00545.x
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yagi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142786
   Yang Y, 2013, TRENDS NEUROSCI, V36, P418, DOI 10.1016/j.tins.2013.04.001
   Yaron A, 2016, CURR BIOL, V26, pR628, DOI 10.1016/j.cub.2016.05.025
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
NR 137
TC 78
Z9 91
U1 3
U2 36
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2019
VL 122
BP 101
EP 113
DI 10.1016/j.bone.2019.01.025
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HT7UK
UT WOS:000464769700012
PM 30743014
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Powles, T
   McCroskey, E
   Paterson, A
AF Powles, Trevor
   McCroskey, Eugene
   Paterson, Alexander
TI Oral bisphosphonates as adjuvant therapy for operable breast cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Proceedings Paper
CT Conference on Advances in Treating Metastatic Bone Cancer
CY OCT 28 29, 2005
CL Cambridge, MA
ID BONE METASTASES; CLODRONATE; REDUCTION; WOMEN; PREVENTION; MECHANISMS;
   PLACEBO; MODELS; TUMOR
AB Bone is the most common site of metastatic spread from primary operable breast cancer, causing pain, fractures and hypercalcemia. This spread depends on the release of osteolytic substances by the cancer cells, which activate osteoclasts to cause bone resorption. The osteoclasts also release growth factors that can act back on the cancer cells to activate growth. This viscous circle thereby facilitates the growth of metastases in bone, thus making this a preferential site for relapse. Agents, such as the bisphosphonates, which block osteoclast function have been shown to reduce the progression of established bone metastases. The oral bisphosphonate clodronate (1,600 mg/d) is effective for treatment of patients with bone metastases. When used as adjuvant therapy given to patients with operable breast cancer for 2 years, clodronate has been reported to significantly reduce the risk of bone metastases during the 2 year study period [19 clodronate patients versus 35 placebo patients; hazard ratio (HR) 0.546; P = 0.03] and 5 year study period (51 clodronate patients versus 73 placebo patients; HR, 0.692 P = 0.04) with a significant reduction in mortality (HR 0.768; P = 0.048). This benefit, together with the low toxicity and safety of clodronate, supports its use as additional adjuvant therapy for patients with primary breast cancer. Further similarly designed trials are under way to establish the optimal duration of therapy, the efficacy in stage I disease, and the relative potential of other bisphosphonates particularly the more powerful aminobisphosphonates, such as ibandronate and zoledronate.
C1 Parkside Oncol Clin, London SW19 5NB, England.
   Univ Sheffield, Sheffield, S Yorkshire, England.
   Tom Baker Canc Clin, Calgary, AB, Canada.
C3 University of Sheffield; University of Calgary; Tom Baker Cancer Clinic
RP Powles, T (通讯作者)，Parkside Oncol Clin, 49 Parkside, London SW19 5NB, England.
EM hdummer@parkside hospital.co.uk
CR Atula S, 2003, DRUG SAFETY, V26, P661, DOI 10.2165/00002018 200326090 00005
   Coleman RE, 1998, BRIT J CANCER, V77, P336, DOI 10.1038/bjc.1998.52
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Diel IJ, 2001, SEMIN ONCOL, V28, P75, DOI 10.1053/sonc.2001.25429
   FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495 199142060 00003
   GALASKO CSB, 1976, NATURE, V263, P507, DOI 10.1038/263507a0
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   Jaschke A, 2004, J CLIN ONCOL, V22, p9S
   Kanis JA, 1996, BONE, V19, P663, DOI 10.1016/S8756 3282(96)00285 2
   Kristensen B, 1999, J INTERN MED, V246, P67, DOI 10.1046/j.1365 2796.1999.00507.x
   MCCLOSKEY E, 2005, ASCO M ABSTR, V23, P535
   Mundy G, 2001, SEMIN ONCOL, V28, P2, DOI 10.1053/sonc.2001.25441
   MUNDY GR, 1991, BONE, V12, pS1, DOI 10.1016/8756 3282(91)90057 P
   MUNDY GR, 1995, CLIN ORTHOP RELAT R, P34
   Neville Webbe HL, 2002, CANCER TREAT REV, V28, P305, DOI 10.1016/S0305 7372(02)00095 6
   Padalecki SS, 2002, BREAST CANCER RES, V4, P35, DOI 10.1186/bcr415
   PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Powles TJ, 1998, J NATL CANCER I, V90, P704, DOI 10.1093/jnci/90.9.704
   POWLES TJ, 1976, LANCET, V1, P608
   POWLES TJ, 1973, BRIT J CANCER, V28, P316, DOI 10.1038/bjc.1973.154
   SAARTO T, 2004, P AN M AM SOC CLIN, V23, P8
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Tubiana Hulin M, 2001, B CANCER, V88, P701
NR 25
TC 22
Z9 23
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2006
VL 12
IS 20
SU S
BP 6301S
EP 6304S
DI 10.1158/1078 0432.CCR 06 1211
PN 2
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Oncology
GA 099AC
UT WOS:000241563900017
PM 17062718
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhai, ZJ
   Li, HW
   Liu, GW
   Qu, XH
   Tian, B
   Yan, W
   Lin, Z
   Tang, TT
   Qin, A
   Dai, KR
AF Zhai, Z. J.
   Li, H. W.
   Liu, G. W.
   Qu, X. H.
   Tian, B.
   Yan, W.
   Lin, Z.
   Tang, T. T.
   Qin, A.
   Dai, K. R.
TI Andrographolide suppresses RANKL induced osteoclastogenesis in
   vitro and prevents inflammatory bone loss in vivo
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE andrographolide; osteoclast; osteolysis; NF B; ERK
ID NF KAPPA B; RECEPTOR ACTIVATOR; NUCLEAR FACTOR; REPLACEMENT THERAPY;
   LIGAND RANKL; C FOS; DIFFERENTIATION; ESTROGEN; ALPHA; KINASE
AB Background and PurposeOsteoclasts play a pivotal role in diseases such as osteoporosis, rheumatoid arthritis and tumour bone metastasis. Thus, searching for natural compounds that may suppress osteoclast formation and/or function is promising for the treatment of osteoclast related diseases. Here, we examined changes in osteoclastogenesis and LPS induced osteolysis in response to andrographolide (AP), a diterpenoid lactone isolated from the traditional Chinese and Indian medicinal plant Andrographis paniculata.
   Experimental ApproachEffects of AP on osteoclast differentiation and bone resorption were measured in vitro. Western blots and RT PCR techniques were used to examine the underlying molecular mechanisms. The bone protective activity of APin vivo was assessed in a mouse model of osteolysis.
   Key ResultsAP concentration dependently suppressed RANKL mediated osteoclast differentiation and bone resorption in vitro and reduced the expression of osteoclast specific markers, including tartrate resistant acid phosphatase, calcitonin receptors and cathepsin K. Further molecular analysis revealed that AP impaired RANKL induced NF B signalling by inhibiting the phosphorylation of TGF  activated kinase 1, suppressing the phosphorylation and degradation of IB, and subsequently preventing the nuclear translocation of the NF B p65 subunit. AP also inhibited the ERK/MAPK signalling pathway without affecting p38 or JNK signalling.
   Conclusions and ImplicationsAP suppressed RANKL induced osteoclastogenesis through attenuating NF B and ERK/MAPK signalling pathways in vitro, thus preventing bone loss in vivo. These data indicated that AP is a promising natural compound for the treatment of osteoclast related bone diseases.
C1 [Zhai, Z. J.; Li, H. W.; Qu, X. H.; Tian, B.; Tang, T. T.; Qin, A.; Dai, K. R.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthopaed Implants, Dept Orthopaed,Peoples Hosp 9, Shanghai 200011, Peoples R China.
   [Liu, G. W.] Southeast Univ, Affiliated Hosp, Med Collage, Dept Orthopaed Surg,Cent Hosp Xuzhou, Xuzhou, Peoples R China.
   [Yan, W.] Wendeng Zhenggu Hosp Shandong Prov, Wendeng, Peoples R China.
   [Lin, Z.] Guangdong Gen Hosp, Guangdong Acad Med Sci, Div Orthopaed, Dept Surg, Guangzhou, Guangdong, Peoples R China.
   [Lin, Z.; Qin, A.] Univ Western Australia, Sch Surg, Ctr Orthopaed Res, Perth, WA 6009, Australia.
C3 Shanghai Jiao Tong University; Southeast University   China; Guangdong
   Academy of Medical Sciences & Guangdong General Hospital; Southern
   Medical University   China; University of Western Australia
RP Qin, A (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthopaed Implants, Dept Orthopaed,Peoples Hosp 9, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM dr.qinan@gmail.com; krdai@163.com
RI Qin, An/J 2518 2019; Qu, Xinhua/Q 3950 2016; zhang,
   xuyang/GQH 3712 2022; Tang, Tingting/B 1361 2013
OI Qu, Xinhua/0000 0002 8889 0890; Tang, Tingting/0000 0002 1670 7452
FU Program for Innovative Research Team of Shanghai Municipal Education
   Commission; Shanghai Municipal Education Commission [13YZ031]; Key
   Disciplines of Shanghai Municipal Education Commission of China
   [J50206]; National Natural Science Foundation for the Youth of China
   [81201364]; Scientific Research Foundation for Returned Overseas Chinese
   Scholars from the State Human Resource Ministry
FX This work was supported by the Program for Innovative Research Team of
   Shanghai Municipal Education Commission (Phase I), a grant awarded for
   Innovative Research from Shanghai Municipal Education Commission
   (13YZ031), a grant awarded by the Key Disciplines of Shanghai Municipal
   Education Commission of China (J50206), a grant for scientific research
   from the National Natural Science Foundation for the Youth of China (No.
   81201364) and a grant awarded by the Scientific Research Foundation for
   Returned Overseas Chinese Scholars from the State Human Resource
   Ministry.
CR Abu Ghefreh AA, 2009, INT IMMUNOPHARMACOL, V9, P313, DOI 10.1016/j.intimp.2008.12.002
   Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bao Z, 2009, AM J RESP CRIT CARE, V179, P657, DOI 10.1164/rccm.200809 1516OC
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cappuzzo KA, 2004, ANN PHARMACOTHER, V38, P294, DOI 10.1345/aph.1D353
   CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003 4819 122 1 199501010 00002
   Çetinkaya MB, 2002, J BONE MINER METAB, V20, P44, DOI 10.1007/s774 002 8446 8
   Chen JH, 2004, BIOCHEM PHARMACOL, V67, P1337, DOI 10.1016/j.bcp.2003.12.015
   Colditz GA, 1997, ANN NY ACAD SCI, V833, P129, DOI 10.1111/j.1749 6632.1997.tb48598.x
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Hidalgo MA, 2005, BRIT J PHARMACOL, V144, P680, DOI 10.1038/sj.bjp.0706105
   Hiligsmann M, 2013, EXPERT REV PHARM OUT, V13, P19, DOI [10.1586/erp.12.76, 10.1586/ERP.12.76]
   Huang Qi Quan, 2009, Curr Rheumatol Rep, V11, P357
   Josse R, 2013, CURR MED RES OPIN, V29, P205, DOI 10.1185/03007995.2013.763779
   Keating SE, 2007, J BIOL CHEM, V282, P33435, DOI 10.1074/jbc.M705266200
   Khor EC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070815
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1038/jcbfm.2010.220, 10.1111/j.1476 5381.2010.00872.x]
   Kim BG, 2010, ANAT CELL BIOL, V43, P310, DOI 10.5115/acb.2010.43.4.310
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kogawa M, 2013, J BIOL CHEM, V288, P31299, DOI 10.1074/jbc.M113.461848
   Komine M, 2001, BONE, V28, P474, DOI 10.1016/S8756 3282(01)00420 3
   Kong YY, 2000, IMMUNOL TODAY, V21, P495, DOI 10.1016/S0167 5699(00)01718 7
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lee JM, 2012, J IMMUNOL, V189, P5284, DOI 10.4049/jimmunol.1003738
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476 5381.2010.00873.x
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Negi AS, 2008, MED RES REV, V28, P746, DOI 10.1002/med.20115
   Ninomiya Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Qin A, 2012, INT J BIOCH CELL BIO, V7, P1
   Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132
   Qin A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027155
   Reddy VLN, 2005, NAT PROD RES, V19, P223, DOI 10.1080/14786410410001709197
   Rizzoli R, 2005, J Endocrinol Invest, V28, P50
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Shen YC, 2002, BRIT J PHARMACOL, V135, P399, DOI 10.1038/sj.bjp.0704493
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Stevenson DA, 2011, CLIN GENET, V80, P566, DOI 10.1111/j.1399 0004.2010.01619.x
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475 2484.2001
   Takahashi N, 2003, METH MOLEC MED, V80, P129
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Verron E, 2013, DRUG DISCOV TODAY, V116, P115
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wang YJ, 2007, CELL RES, V17, P933, DOI 10.1038/cr.2007.89
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
   Weitzmann MN, 2006, ANN NY ACAD SCI, V1068, P256, DOI 10.1196/annals.1346.030
   Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888
   Zhang HW, 2013, J BIOL CHEM, V288, P22359, DOI 10.1074/jbc.M112.442459
   Zhao JX, 2002, PHYTOCHEM ANALYSIS, V13, P222, DOI 10.1002/pca.644
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Zou W, 2001, J CELL BIOCHEM, V83, P70, DOI 10.1002/jcb.1202
   Zou W, 2013, MOL CELL BIOL, V33, P830, DOI 10.1128/MCB.00790 12
NR 62
TC 104
Z9 110
U1 2
U2 54
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD FEB
PY 2014
VL 171
IS 3
SI SI
BP 663
EP 675
DI 10.1111/bph.12463
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 287MA
UT WOS:000329544700020
PM 24125472
OA Green Published
DA 2025 08 17
ER

PT J
AU Jiang, A
   Xu, P
   Sun, S
   Zhao, ZD
   Tan, QZ
   Li, WS
   Song, CL
   Leng, HJ
AF Jiang, Ai
   Xu, Peng
   Sun, Shang
   Zhao, Zhenda
   Tan, Qizhao
   Li, Weishi
   Song, Chunli
   Leng, Huijie
TI Cellular alterations and crosstalk in the osteochondral joint in
   osteoarthritis and promising therapeutic strategies
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE Osteoarthritis; crosstalk; cartilage; chondrocytes; osteoblasts;
   osteocytes
AB Osteoarthritis (OA) is a joint disorder involving cartilage degeneration and subchondral bone sclerosis. The bone cartilage interface is implicated in OA pathogenesis due to its susceptibility to mechanical and biological factors. The crosstalk between cartilage and the underlying subchondral bone is elevated in OA due to multiple factors, such as increased vascularization, porosity, microcracks and fissures. Changes in the osteochondral joint are traceable to alterations in chondrocytes and bone cells (osteoblasts, osteocytes and osteoclasts). The phenotypes of these cells can change with the progression of OA. Aberrant intercellular communications among bone cell bone cell and bone cell chondrocyte are of great importance and might be factors OA development. An appreciation of cellular phenotypic changes in OA and the mechanisms by which these cells communicate would be expected to lead to the development of targeted drugs with fewer side effects.
C1 [Jiang, Ai; Sun, Shang; Zhao, Zhenda; Tan, Qizhao; Li, Weishi; Song, Chunli; Leng, Huijie] Peking Univ Third Hosp, Dept Orthopaed, Beijing 100191, Peoples R China.
   [Xu, Peng] Chinese Acad Sci, State Key Lab Systemat & Evolutionary Bot, Inst Bot, Beijing, Peoples R China.
   [Li, Weishi] Minist Educ, Engn Res Ctr Bone & Joint Precis Med, Lisbon, Portugal.
   [Song, Chunli] Beijing Key Lab Spine Dis, Beijing, Peoples R China.
C3 Peking University; Chinese Academy of Sciences; Institute of Botany, CAS
RP Leng, HJ (通讯作者)，Peking Univ Third Hosp, Dept Orthopaed, Beijing 100191, Peoples R China.
EM lenghj@bjmu.edu.cn
RI Leng, Huijie/AGQ 9574 2022; Xu, Peng/GXF 8681 2022; zhao,
   zhenda/E 4695 2017
OI Zhao, Zhenda/0000 0001 5237 6139; Peng, Xu/0000 0003 3471 3511; Leng,
   Huijie/0000 0002 4436 061X; 
FU National Natural Science Foundation of China [11872076, 11472017]
FX This work was supported by the National Natural Science Foundation of
   China (Grant number 11872076, 11472017).
CR Aaron RK, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926 017 0660 x
   Al Dujaili SA, 2011, J CELL BIOCHEM, V112, P2412, DOI 10.1002/jcb.23164
   Arai A, 2019, J BONE MINER RES, V34, P1753, DOI 10.1002/jbmr.3756
   Arkill KP, 2008, OSTEOARTHR CARTILAGE, V16, P708, DOI 10.1016/j.joca.2007.10.001
   Ashraf S, 2011, ARTHRITIS RHEUM US, V63, P2700, DOI 10.1002/art.30422
   Aspera Werz RH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122915
   Bertuglia A, 2016, OSTEOARTHR CARTILAGE, V24, P555, DOI 10.1016/j.joca.2015.10.008
   Bian WG, 2016, BIOMED ENG ONLINE, V15, DOI 10.1186/s12938 016 0200 3
   Botter SM, 2011, ARTHRITIS RHEUM US, V63, P2690, DOI 10.1002/art.30307
   Brew CJ, 2010, ANN RHEUM DIS, V69, P234, DOI 10.1136/ard.2008.097139
   BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401
   Burr DB, 2003, RHEUM DIS CLIN N AM, V29, P675, DOI 10.1016/S0889 857X(03)00061 9
   Charlier E, 2019, BIOCHEM PHARMACOL, V165, P49, DOI 10.1016/j.bcp.2019.02.036
   Chen LZ, 2020, ANN RHEUM DIS, V79, P811, DOI 10.1136/annrheumdis 2020 216942
   Choi JY, 2020, BONE JOINT RES, V9, P29, DOI 10.1302/2046 3758.91.BJR 2019 0085.R2
   Couchourel D, 2009, ARTHRITIS RHEUM US, V60, P1438, DOI 10.1002/art.24489
   Dai ML, 2018, BIOMATERIALS, V180, P91, DOI 10.1016/j.biomaterials.2018.07.011
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   De Bari C, 2018, CURR OPIN PHARMACOL, V40, P74, DOI 10.1016/j.coph.2018.03.009
   Dreier R, 2001, J CELL SCI, V114, P3813
   Duan L, 2015, AM J TRANSL RES, V7, P194
   Dubey NK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103021
   DUNCAN H, 1987, J BONE JOINT SURG AM, V69A, P1212, DOI 10.2106/00004623 198769080 00015
   Fang J, 2016, HISTOL HISTOPATHOL, V31, P1161, DOI 10.14670/HH 11 779
   Findlay DM, 2014, CURR OSTEOPOROS REP, V12, P127, DOI 10.1007/s11914 014 0192 5
   Geurts J, 2016, J ORTHOP RES, V34, P262, DOI 10.1002/jor.23009
   Guilak F, 2018, MATRIX BIOL, V71 72, P40, DOI 10.1016/j.matbio.2018.05.008
   Harrell CR, 2019, BIOMED PHARMACOTHER, V109, P2318, DOI 10.1016/j.biopha.2018.11.099
   Houard X, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926 013 0375 6
   Hügle T, 2017, RHEUMATOLOGY, V56, P1461, DOI 10.1093/rheumatology/kew389
   Imhof H., 2000, Invest Radiol, V35
   Jaiprakash A, 2012, INT J BIOL SCI, V8, P406, DOI 10.7150/ijbs.4221
   Jiang A, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.93
   Jiang J, 2005, BIOCHEM BIOPH RES CO, V338, P762, DOI 10.1016/j.bbrc.2005.10.025
   Jilka RL, 2016, CURR OSTEOPOROS REP, V14, P16, DOI 10.1007/s11914 016 0297 0
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Johanna I, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20187
   Klein Nulend J, 2013, BONE, V54, P182, DOI 10.1016/j.bone.2012.10.013
   Kovács B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184653
   Kumarasinghe DD, 2012, OSTEOARTHR CARTILAGE, V20, P1357, DOI 10.1016/j.joca.2012.07.005
   Laslett LL, 2012, OSTEOARTHR CARTILAGE, V20, P1209, DOI 10.1016/j.joca.2012.07.019
   Li XL, 2016, SCI REP UK, V6, DOI 10.1038/srep24668
   Lian CJ, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0046 y
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Liu Bryan R, 2015, NAT REV RHEUMATOL, V11, P35, DOI 10.1038/nrrheum.2014.162
   Ma YM, 2017, INT J CLIN EXP MED, V10, P3225
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   MANSELL J, 1998, J CLIN INVEST, V101
   Mapp PI, 2012, NAT REV RHEUMATOL, V8, P390, DOI 10.1038/nrrheum.2012.80
   Marriott I, 2004, AM J PATHOL, V164, P1399, DOI 10.1016/S0002 9440(10)63226 9
   Massicotte F, 2002, OSTEOARTHR CARTILAGE, V10, P491, DOI 10.1053/joca.2002.0528
   Mazur CM, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0070 y
   Mizoguchi F, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4282
   Nagai T, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3142
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Nwosu LN, 2017, OSTEOARTHR CARTILAGE, V25, P858, DOI 10.1016/j.joca.2017.01.002
   Ouyang YM, 2019, DRUG DES DEV THER, V13, P2833, DOI 10.2147/DDDT.S203974
   Pan J, 2012, BONE, V51, P212, DOI 10.1016/j.bone.2011.11.030
   Prasadam I, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4333
   Prasadam I, 2012, J RHEUMATOL, V39, P621, DOI 10.3899/jrheum.110777
   Prasadam I, 2010, BONE, V46, P226, DOI 10.1016/j.bone.2009.10.014
   Priam S, 2013, ARTHRITIS RHEUM US, V65, P1831, DOI 10.1002/art.37951
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P988, DOI 10.1016/j.joca.2005.07.012
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P979, DOI 10.1016/j.joca.2005.03.008
   Sanchez C, 2008, ARTHRITIS RHEUM US, V58, P442, DOI 10.1002/art.23159
   Sanchez C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136118
   Sandell L J., 2001, Arthritis Res, V3
   Shiflett LA, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00178
   Siebelt M, 2014, BONE, V66, P163, DOI 10.1016/j.bone.2014.06.009
   Spyropoulou A, 2015, BBA MOL BASIS DIS, V1852, P1700, DOI 10.1016/j.bbadis.2015.05.010
   Staines KA, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2731 9
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Strassle BW, 2010, OSTEOARTHR CARTILAGE, V18, P1319, DOI 10.1016/j.joca.2010.06.007
   Suri S, 2012, BONE, V51, P204, DOI 10.1016/j.bone.2011.10.010
   Tateiwa D, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080818
   TIKU M, 1999, FREE RADICAL RES, V30
   Truong LH, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2101
   Tu ML, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0071 x
   UDAGAWA N, 1999, BONE, V25
   van der Kraan PM, 2012, OSTEOARTHR CARTILAGE, V20, P223, DOI 10.1016/j.joca.2011.12.003
   Walsh DA, 2010, RHEUMATOLOGY, V49, P1852, DOI 10.1093/rheumatology/keq188
   Wang BL, 2015, SCI REP UK, V5, DOI 10.1038/srep13667
   Wang BL, 2014, ARTHRITIS RHEUMATOL, V66, P107, DOI 10.1002/art.38195
   Wang LY, 2018, CURR OSTEOPOROS REP, V16, P32, DOI 10.1007/s11914 018 0414 3
   Wei YL, 2016, CONNECT TISSUE RES, V57, P245, DOI 10.1080/03008207.2016.1177036
   Weizmann S, 2005, MATRIX BIOL, V24, P520, DOI 10.1016/j.matbio.2005.07.003
   Welch T, 2016, SPORTS MED ARTHROSC, V24, P85, DOI 10.1097/JSA.0000000000000115
   Wen X, 2016, J BIOL CHEM, V291, P24912, DOI 10.1074/jbc.M116.730093
   Xie J, 2015, INT J ORAL SCI, V7, P220, DOI 10.1038/ijos.2015.39
   Yang WY, 2018, ACTA BIOMATER, V69, P170, DOI 10.1016/j.actbio.2018.01.039
   Yuan XL, 2014, OSTEOARTHR CARTILAGE, V22, P1077, DOI 10.1016/j.joca.2014.05.023
   Yuan Z, 2010, MED PHYS, V37, P4343, DOI 10.1118/1.3467755
   Zarka M, 2019, BONE, V123, P1, DOI 10.1016/j.bone.2019.03.011
   Zhang Y, 2020, CURR MED CHEM, V27, P1151, DOI 10.2174/0929867325666180801145614
   Zhao HY, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170302
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhou Y, 2017, HAEMATOLOGICA, V102, P1017, DOI 10.3324/haematol.2016.158717
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
NR 99
TC 15
Z9 17
U1 1
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD NOV 2
PY 2021
VL 62
IS 6
BP 709
EP 719
DI 10.1080/03008207.2020.1870969
EA JAN 2021
PG 11
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA XQ8FC
UT WOS:000608312200001
PM 33397157
DA 2025 08 17
ER

PT J
AU Wu, JB
   Fong, YC
   Tsai, HY
   Chen, YF
   Tsuzuki, M
   Tang, CH
AF Wu, Jin Bin
   Fong, Yi Chin
   Tsai, Huei Yann
   Chen, Yuh Fung
   Tsuzuki, Minoru
   Tang, Chih Hsin
TI Naringin induced bone morphogenetic protein 2 expression via PI3K, Akt,
   c Fos/c Jun and AP 1 pathway in osteoblasts
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE naringin; osteoblast; osteoporosis; flavonoid; BMP 2
ID PHOSPHATIDYLINOSITOL 3 KINASE; OSTEOPOROSIS; FLAVONOIDS; RECEPTOR;
   DENSITY; KINASE; SIGNAL; CELLS
AB Osteoporosis is a reduction in skeletal mass due to an imbalance between bone resorption and bone formation. Bone morphogenetic protein (BMP) plays important roles in osteoblastic differentiation and bone formation. Therefore, components involved in BMP activation are good targets for the development of anti osteoporosis drugs. In this study, naringin a polymethoxylated flavonoid, was shown to enhance alkaline phosphatase activity, osteocalcin level, osteopontin synthesis and cell proliferation in primary cultured osteoblasts. Naringin increased mRNA and protein levels of BMP 2 using Western blot, ELISA and RT PCR assay. In addition, naringin also prevented the decreasing of BMP 2 and bone loss inducing by ovariectomy in vivo. The transcriptional regulation of BMP 2 by naringin was mediated by phosphorylation of Akt and activation of the activator protein 1 (AP 1) components c Fos and c Jun. The binding of c Fos and c Jun to the AP 1 element on the BMP 2 promoter was enhanced by naringin. Transfection with dominant negative mutant of p85 and Akt or c Fos and c Jun antisense oligonucleotide inhibited the potentiating action of naringin on BMP 2 production. Taken together, our results provide evidence that naringin increase BMP 2 expression and enhance osteogenic response via the phosphoinositide 3 kinase (PI3K), Akt, c Fos/c Jun and AP 1 dependent signaling pathway. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Tang, Chih Hsin] China Med Univ, Dept Pharmacol, Coll Med, Taichung, Taiwan.
   [Wu, Jin Bin] China Med Univ, Grad Inst Pharmaceut Chem, Taichung, Taiwan.
   [Fong, Yi Chin] China Med Univ Hosp, Dept Orthopaed, Taichung, Taiwan.
   [Tsai, Huei Yann] China Med Univ, Sch Pharm, Taichung, Taiwan.
   [Chen, Yuh Fung] China Med Univ, Grad Inst Chinese Pharmaceut Sci, Coll Pharm, Taichung, Taiwan.
   [Wu, Jin Bin; Tsai, Huei Yann; Tsuzuki, Minoru] China Med Univ, Tsuzuki Inst Tradit Med, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Taiwan; China Medical University Hospital   Taiwan;
   China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Taiwan
RP Tang, CH (通讯作者)，China Med Univ, Dept Pharmacol, Coll Med, 91 Hsueh Shih Rd, Taichung, Taiwan.
EM chtang@mail.cmu.edu.tw
RI Yen, Ching/A 2771 2013; Hung, Chi Feng/AAL 4977 2021; Tang,
   Chih/O 5212 2015
CR Anderson HC, 2000, J HISTOCHEM CYTOCHEM, V48, P1493, DOI 10.1177/002215540004801106
   Berg C, 2003, NAT REV DRUG DISCOV, V2, P257, DOI 10.1038/nrd1068
   CHEN YT, 1990, FREE RADICAL BIO MED, V9, P19, DOI 10.1016/0891 5849(90)90045 K
   Chiu YC, 2007, MOL PHARMACOL, V72, P695, DOI 10.1124/mol.107.036541
   Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Fleet JC, 1996, ENDOCRINOLOGY, V137, P4605, DOI 10.1210/en.137.11.4605
   FRANCIS AR, 1989, CARCINOGENESIS, V10, P1953, DOI 10.1093/carcin/10.10.1953
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Ghosh Choudhury N, 2007, J BIOL CHEM, V282, P4983, DOI 10.1074/jbc.M606706200
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Helvering LM, 2000, GENE, V256, P123, DOI 10.1016/S0378 1119(00)00364 4
   KROYER G, 1986, Z ERNAHRUNGSWISS, V25, P63, DOI 10.1007/BF02023620
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   MARIDONNEAUPARINI I, 1986, PHARMACOL RES COMMUN, V18, P61, DOI 10.1016/0031 6989(86)90159 1
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Matsumoto A, 2001, J PERIODONTAL RES, V36, P175, DOI 10.1034/j.1600 0765.2001.360306.x
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069
   Su JL, 2007, J BIOL CHEM, V282, P19385, DOI 10.1074/jbc.M702452200
   Swiader K., 1996, Fitoterapia, V67, P77
   Sykaras Nikitas, 2003, J Oral Sci, V45, P57
   Tang CH, 2005, J BIOL CHEM, V280, P22907, DOI 10.1074/jbc.M500130200
   Tang CH, 2007, J IMMUNOL, V179, P1292, DOI 10.4049/jimmunol.179.2.1292
   Tang CH, 2007, J BIOL CHEM, V282, P2346, DOI 10.1074/jbc.M603070200
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Van Der Horst G, 2002, BONE, V31, P661, DOI 10.1016/S8756 3282(02)00903 1
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Wei M, 2007, AM J CHINESE MED, V35, P663, DOI 10.1142/S0192415X07005156
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012
   Zhao M, 2006, MOL CELL BIOL, V26, P6197, DOI 10.1128/MCB.02214 05
NR 34
TC 122
Z9 145
U1 0
U2 31
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JUL 7
PY 2008
VL 588
IS 2 3
BP 333
EP 341
DI 10.1016/j.ejphar.2008.04.030
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 319TS
UT WOS:000257187600028
PM 18495116
DA 2025 08 17
ER

PT J
AU Stadelmann, VA
   Gerossier, E
   Kettenberger, U
   Pioletti, DP
AF Stadelmann, Vincent A.
   Gerossier, Estelle
   Kettenberger, Ulrike
   Pioletti, Dominique P.
TI Combining systemic and local osteoporosis treatments: A longitudinal in
   vivo microCT study in ovariectomized rats
SO BONE
LA English
DT Article
DE Osteoporosis; Fracture prevention; Hydrogel; Bisphosphonates; Rat model;
   Combination therapy; Local treatment
ID ZOLEDRONIC ACID; PARATHYROID HORMONE; BONE MASS; STRENGTH; FEMUR;
   TERIPARATIDE; ALENDRONATE; MECHANISMS; STRATEGIES; MANAGEMENT
AB Introduction: Managing osteoporotic patients at immediate fracture risk is challenging, in part due to the slow and localized effects of anti osteoporotic drugs. Combining systemic anti osteoporotic therapies with local bone augmentation techniques offers a promising strategy, but little is known about potential interactions. We hypothesized that integrating systemic treatments with local bone strengthening biomaterials would have an additive effect on bone density and structure. This study investigated interactions and synergies between systemic therapies and injectable biomaterials, HA2 and HA2 ZOL, designed for local bone strengthening. HA2 ZOL incorporates Zoledronate, a bisphosphonate, to enhance anti resorptive effects. These materials were tested in an in vivo rat model of osteoporosis using microCT and histology. Methods: Thirty six ovariectomized Wistar rats were treated systemically with vehicle (VEH), alendronate (ALN), or parathyroid hormone (PTH). One week later, their tibiae were randomly assigned to local treatment groups: HA2, HA2 ZOL, or NaCl control. Bilateral injections targeted metaphyseal trabecular bone, with microCT scans tracking changes over 8 weeks. Regions of interest (ROIs) were identified and analyzed for bone volume fraction (BV/TV), tissue mineral density (TMD), and trabecular morphology. Histological analyses were performed at week 8 to assess bone structure and mineral inclusions. Results: VEH animals with NaCl injections experienced marked bone loss, partially mitigated by ALN and PTH. HA2 injections increased BV/TV by factors of 2.5 to 3.4 across treatments compared to baseline, with effects confined to the injected material. HA2 ZOL amplified this response, with BV/TV increases up to 4.8 fold, particularly in VEH and PTH animals. The effects peaked at 2 4 weeks post injection, followed by remodeling and restoration. Both local treatments increased trabecular thickness, with HA2 ZOL showing slower post peak resorption. Discussion: HA2 injections significantly densified bone, independent of systemic therapy. Zoledronate in HA2ZOL enhanced bone formation and delayed resorption in control and PTH animals, but offered no additional benefit when combined with systemic bisphosphonate. These findings support the hypothesis of an additive effect, suggesting that injectable hydrogels with localized drug delivery can complement systemic therapies by rapidly increasing local bone density, thereby potentially preventing fractures in high risk osteoporotic patients.
C1 [Stadelmann, Vincent A.] Schulthess Klin, Dept Res & Dev, Zurich, Switzerland.
   [Gerossier, Estelle; Pioletti, Dominique P.] Ecole Polytech Fed Lausanne, Inst Bioengn, Lab Biomech Orthoped, Lausanne, Switzerland.
   [Kettenberger, Ulrike] Flowbone SA, Lausanne, Switzerland.
C3 Schulthess Clinic; Swiss Federal Institutes of Technology Domain; Ecole
   Polytechnique Federale de Lausanne
RP Stadelmann, VA (通讯作者)，Schulthess Klin, Lengghalde 2, CH 8008 Zurich, Switzerland.
EM vincent.stadelmann@kws.ch
RI Stadelmann, Vincent/X 1543 2018; Pioletti, Dominique/C 5697 2008
OI Stadelmann, Vincent/0000 0002 8741 2184
FU Swiss Innovation Agency [54723.1 IP LS]
FX This research was funded by the Swiss Innovation Agency (Innosuisse
   grant 54723.1 IP LS).
CR Alves NM, 2010, J MATER CHEM, V20, P2911, DOI 10.1039/b910960a
   [Anonymous], R Core Team
   Balasubramanian A, 2019, OSTEOPOROSIS INT, V30, P79, DOI 10.1007/s00198 018 4732 1
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Buie HR, 2007, BONE, V41, P505, DOI 10.1016/j.bone.2007.07.007
   Casanova M, 2016, BONE, V92, P70, DOI 10.1016/j.bone.2016.08.012
   CHRISTIANSEN C, 1991, AM J MED, V90, P107
   Cornelis FH, 2017, CARDIOVASC INTER RAD, V40, P1070, DOI 10.1007/s00270 017 1613 5
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Ferrari S, 2016, ARCH OSTEOPOROS, V11, DOI 10.1007/s11657 016 0292 1
   Foessl I, 2023, NAT REV ENDOCRINOL, V19, P520, DOI 10.1038/s41574 023 00866 9
   Fuchs RK, 2007, BONE, V41, P290, DOI 10.1016/j.bone.2007.04.179
   Gauthier O, 2005, BIOMATERIALS, V26, P5444, DOI 10.1016/j.biomaterials.2005.01.072
   Gkioni K, 2010, TISSUE ENG PART B RE, V16, P577, DOI 10.1089/ten.TEB.2010.0462
   Gong YN, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1058300
   Grey A, 2012, BONE, V50, P1389, DOI 10.1016/j.bone.2012.03.016
   Hao Y, 2015, BONE, V81, P702, DOI 10.1016/j.bone.2015.09.018
   Harvey NCW, 2017, OSTEOPOROSIS INT, V28, P1507, DOI 10.1007/s00198 016 3894 y
   Howe JG, 2020, OSTEOPOROSIS INT, V31, P921, DOI 10.1007/s00198 019 05230 0
   Hsieh MK, 2024, JBMR PLUS, V8, DOI 10.1093/jbmrpl/ziae031
   Johansson H, 2017, OSTEOPOROSIS INT, V28, P775, DOI 10.1007/s00198 016 3868 0
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P1, DOI 10.1007/s00198 019 05176 3
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kettenberger U, 2017, J TISSUE ENG REGEN M, V11, P1974, DOI 10.1002/term.2094
   Kettenberger U, 2015, J MECH BEHAV BIOMED, V45, P22, DOI 10.1016/j.jmbbm.2015.01.007
   Kim Y, 2021, METHODS MOL BIOL, V2230, P169, DOI 10.1007/978 1 0716 1028 2_11
   Markeviciute V, 2024, ACTA BIOMATER, V179, P354, DOI 10.1016/j.actbio.2024.03.005
   Matos MA, 2010, J ORTHOP TRAUMATOL, V11, P7, DOI 10.1007/s10195 010 0083 1
   McKenzie K, 2011, CLIN ORTHOP RELAT R, V469, P514, DOI 10.1007/s11999 010 1527 x
   Neuerburg C, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1315 6
   Ocarino ND, 2010, CONNECT TISSUE RES, V51, P426, DOI 10.3109/03008201003597049
   Papenberg M, 2024, BRIT J MATH STAT PSY, V77, P80, DOI 10.1111/bmsp.12315
   Papenberg M, 2021, PSYCHOL METHODS, V26, P161, DOI 10.1037/met0000301
   Revel L, 2000, DRUG FUTURE, V25, P803, DOI 10.1358/dof.2000.025.08.589014
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Schulte FA, 2011, BONE, V48, P433, DOI 10.1016/j.bone.2010.10.007
   Seeherman HJ, 2013, J BONE JOINT SURG AM, V95A, P36, DOI 10.2106/JBJS.K.00668
   Shaul JL, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116246
   Shen LX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026267
   Shen YY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.882241
   Singer AJ, 2023, CURR MED RES OPIN, V39, P387, DOI 10.1080/03007995.2022.2141483
   Siverino C, 2024, BONE, V180, DOI 10.1016/j.bone.2023.117011
   Sugie Oya A, 2016, J BONE MINER METAB, V34, P303, DOI 10.1007/s00774 015 0670 6
   Tarantino U, 2022, OSTEOPOROSIS INT, V33, P2467, DOI 10.1007/s00198 022 06482 z
   Torstrick FB, 2014, CURR OSTEOPOROS REP, V12, P33, DOI 10.1007/s11914 014 0191 6
   Varga P, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.86
   Wang Y, 2011, J ORTHOP SURG RES, V6, DOI 10.1186/1749 799X 6 34
   Zhao JD, 2014, CHINESE MED J PEKING, V127, P3906, DOI 10.3760/cma.j.issn.0366 6999.20141670
NR 50
TC 0
Z9 0
U1 5
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2025
VL 192
AR 117373
DI 10.1016/j.bone.2024.117373
EA DEC 2024
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA R5D7R
UT WOS:001391660600001
PM 39675409
OA hybrid
DA 2025 08 17
ER

PT J
AU Boissy, P
   Andersen, TL
   Abdallah, BM
   Kassem, M
   Plesner, T
   Delaissé, JM
AF Boissy, P
   Andersen, TL
   Abdallah, BM
   Kassem, M
   Plesner, T
   Delaissé, JM
TI Resveratrol inhibits myeloma cell growth, prevents osteoclast formation,
   and promotes osteoclast differentiation
SO CANCER RESEARCH
LA English
DT Article
ID NF KAPPA B; COLONY STIMULATING FACTOR; POLYGONUM CUSPIDATUM;
   TRANS RESVERATROL; BONE DESTRUCTION; NUCLEAR FACTOR; APOPTOSIS;
   EXPRESSION; CYCLE; RANKL
AB Multiple myeloma is characterized by the accumulation of clonal malignant plasma cells in the bone marrow, which stimulates bone destruction by osteoclasts and reduces bone formation by osteoblasts. In turn, the changed bone microenvironment sustains survival of myeloma cells. Therefore, a challenge for treating multiple myeloma is discovering drugs targeting not only myeloma cells but also osteoclasts and osteoblasts. Because resveratrol (trans 3,4',5 trihydroxystilbene) is reported to display antitumor activities on a variety of human cancer cells, we investigated the effects of this natural compound on myeloma and bone cells. We found that resveratrol reduces dose dependently the growth of myeloma cell lines (RPMI 8226 and OPM 2) by a mechanism involving cell apoptosis. In cultures of human primary monocytes, resveratrol inhibits dose dependently receptor activator of nuclear factor kappa B (NF kappa B) ligand induced formation of tartrate resistant acid phosphatase (TRACP) positive multinucleated cells, TRACP activity in the medium, up regulation of cathepsin K gene expression, and bone resorption. These inhibitions are associated with a down regulation of RANK expression at both mRNA and cell surface protein levels and a decrease of NFATc1 stimulation and NF kappa B nuclear translocation, whereas the gene expression of c fins, CD14, and CD11a is up regulated. Finally, resveratrol promotes dose dependently the expression of osteoblast markers like osteocalcin and osteopontin in human bone marrow mesenchymal stem cells (hMSC TERT) and stimulates their response to 1,25(OH)(2) vitamin D 3 [1,25(OH)(2)D 3]. Moreover, resveratrol up regulates dose dependently the expression of 1,25(OH)(2)D 3 nuclear receptor. Taken together, these results suggest that resveratrol or its derivatives deserve attention as potential drugs for treating multiple myeloma.
C1 So Denmark Univ Network, Vejile Hosp, Lab L120 I400, Clin Res Unit, DK 7100 Vejle, Denmark.
   So Denmark Univ Network, Vejle Hosp, Div Hematol, DK 7100 Vejle, Denmark.
   Odense Univ Hosp, DK 5000 Odense, Denmark.
C3 University of Southern Denmark; Lillebaelt Hospital; University of
   Southern Denmark; Lillebaelt Hospital; University of Southern Denmark;
   Odense University Hospital
RP Boissy, P (通讯作者)，So Denmark Univ Network, Vejile Hosp, Lab L120 I400, Clin Res Unit, Kabbeltoft 25, DK 7100 Vejle, Denmark.
EM patboi@vgs.vejleamt.dk
RI Kassem, Moustapha/J 7688 2013; Levin Andersen, Thomas/AAY 6777 2021;
   Abdallah, Basem/G 5667 2017; Kassem, Moustapha/O 3819 2019
OI Kassem, Moustapha/0000 0003 1557 0869; Levin Andersen,
   Thomas/0000 0002 6981 7276; Abdallah, Basem/0000 0003 0324 8055;
   Delaisse, Jean Marie/0000 0001 7370 1500; Boissy,
   Patrice/0000 0002 4025 1141; 
CR Abdallah BM, 2004, J BONE MINER RES, V19, P841, DOI 10.1359/JBMR.040118
   Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<73::AID JCB11>3.0.CO;2 L
   Aziz MH, 2003, INT J ONCOL, V23, P17
   Baatout S, 2004, INT J MOL MED, V13, P895
   Banerjee S, 2002, CANCER RES, V62, P4945
   BARILLE S, 1995, BLOOD, V86, P3151
   Barille Nion Sophie, 2003, Hematology Am Soc Hematol Educ Program, P248
   BAYLINK DJ, 1993, J BONE MINER RES, V8, pS565
   Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136
   Boissy P, 1998, J CELL SCI, V111, P2563
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Chen Y, 2004, SURGERY, V136, P57, DOI 10.1016/j.surg.2004.01.017
   Clément MV, 1998, BLOOD, V92, P996
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   De Leenheer E, 2004, CURR OPIN PHARMACOL, V4, P340, DOI 10.1016/j.coph.2004.03.011
   Dong ZG, 2003, MUTAT RES FUND MOL M, V523, P145, DOI 10.1016/S0027 5107(02)00330 5
   Dörrie J, 2001, CANCER RES, V61, P4731
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Goldberg DA, 2003, CLIN BIOCHEM, V36, P79, DOI 10.1016/S0009 9120(02)00397 1
   Gosslau A, 2005, BRIT J CANCER, V92, P513, DOI 10.1038/sj.bjc.6602300
   Gu XL, 1999, J AGR FOOD CHEM, V47, P3223, DOI 10.1021/jf981211e
   Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986
   Henriksen K, 2003, J BIOL CHEM, V278, P48745, DOI 10.1074/jbc.M309193200
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   JANOWSKAWIECZOREK A, 1991, BLOOD, V77, P1796
   Jazirehi AR, 2004, MOL CANCER THER, V3, P71
   Juan ME, 2002, J NUTR, V132, P257, DOI 10.1093/jn/132.2.257
   Kimura Y, 2001, J NUTR, V131, P1844, DOI 10.1093/jn/131.6.1844
   Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108
   Kraichely Dennis M., 1998, Frontiers in Bioscience, V3, pD821
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Liu ZP, 2005, J MED FOOD, V8, P14, DOI 10.1089/jmf.2005.8.14
   Marier JF, 2002, J PHARMACOL EXP THER, V302, P369, DOI 10.1124/jpet.102.033340
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mizutani K, 2000, J NUTR SCI VITAMINOL, V46, P78, DOI 10.3177/jnsv.46.78
   Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03 0168rev
   Roberti M, 2003, J MED CHEM, V46, P3546, DOI 10.1021/jm030785u
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Schneider Y, 2001, NUTR CANCER, V39, P102, DOI 10.1207/S15327914nc391_14
   SELANDER K, 1994, CALCIFIED TISSUE INT, V55, P368, DOI 10.1007/BF00299317
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   TAUBE T, 1992, EUR J HAEMATOL, V49, P192
   Terpos E, 2003, BRIT J HAEMATOL, V123, P758, DOI 10.1046/j.1365 2141.2003.04712.x
   Terpos E, 2004, LEUKEMIA, V18, P1420, DOI 10.1038/sj.leu.2403423
   Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yu CW, 2002, PHARM RES DORDR, V19, P1907, DOI 10.1023/A:1021414129280
   Yu L, 2003, WORLD J GASTROENTERO, V9, P2341
NR 55
TC 170
Z9 186
U1 0
U2 29
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD NOV 1
PY 2005
VL 65
IS 21
BP 9943
EP 9952
DI 10.1158/0008 5472.CAN 05 0651
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 979TF
UT WOS:000232967000045
PM 16267019
OA Bronze
DA 2025 08 17
ER

PT J
AU Ghilardi, JR
   Röhrich, H
   Lindsay, TH
   Sevcik, MA
   Schwei, MJ
   Kubota, K
   Halvorson, KG
   Poblete, J
   Chaplan, SR
   Dubin, AE
   Carruthers, NI
   Swanson, D
   Kuskowski, M
   Flores, CM
   Julius, D
   Mantyh, PW
AF Ghilardi, JR
   Röhrich, H
   Lindsay, TH
   Sevcik, MA
   Schwei, MJ
   Kubota, K
   Halvorson, KG
   Poblete, J
   Chaplan, SR
   Dubin, AE
   Carruthers, NI
   Swanson, D
   Kuskowski, M
   Flores, CM
   Julius, D
   Mantyh, PW
TI Selective blockade of the capsaicin receptor TRPV1 attenuates bone
   cancer pain
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE tumor; skeletal malignancies; vanilloid receptor; metastasis;
   nociception; therapy
ID SPINAL CORD; MOLECULAR MECHANISMS; BREAKTHROUGH PAIN; SKELETAL PAIN;
   MESSENGER RNA; NERVE INJURY; TUMOR GROWTH; CELL LINES; NEURONS;
   NOCICEPTION
AB Cancer colonization of bone leads to the activation of osteoclasts, thereby producing local tissue acidosis and bone resorption. This process may contribute to the generation of both ongoing and movement evoked pain, resulting from the activation of sensory neurons that detect noxious stimuli ( nociceptors). The capsaicin receptor TRPV1 ( transient receptor potential vanilloid subtype 1) is a cation channel expressed by nociceptors that detects multiple pain producing stimuli, including noxious heat and extracellular protons, raising the possibility that it is an important mediator of bone cancer pain via its capacity to detect osteoclast  and tumor mediated tissue acidosis. Here, we show that TRPV1 is present on sensory neuron fibers that innervate the mouse femur and that, in an in vivo model of bone cancer pain, acute or chronic administration of a TRPV1 antagonist or disruption of the TRPV1 gene results in a significant attenuation of both ongoing and movement evoked nocifensive behaviors. Administration of the antagonist had similar efficacy in reducing early, moderate, and severe pain related responses, suggesting that TRPV1 may be a novel target for pharmacological treatment of chronic pain states associated with bone cancer metastasis.
C1 Univ Minnesota, Sch Dent, Neurosyst Ctr, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Prevent Sci, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA.
   Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA.
   Vet Affairs Med Ctr, Res Serv, Minneapolis, MN 55417 USA.
   Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Minneapolis, MN 55417 USA.
   Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.
   Johnson & Johnson Pharmaceut Res & Dev, San Diego, CA 92121 USA.
   Johnson & Johnson Pharmaceut Res & Dev, Spring House, PA 19446 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Minneapolis VA Health Care System; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Minneapolis VA Health Care System;
   Geriatric Research Education & Clinical Center; University of California
   System; University of California San Francisco; Johnson & Johnson;
   Johnson & Johnson USA; Johnson & Johnson; Johnson & Johnson USA
RP Univ Minnesota, Sch Dent, Neurosyst Ctr, 18 208 Moos Tower,515 Delaware SE, Minneapolis, MN 55455 USA.
EM manty001@umn.edu
RI Chaplan, Sandra/R 6369 2019
FU NIDA NIH HHS [DA11986] Funding Source: Medline; NIDCR NIH HHS [DE08973]
   Funding Source: Medline; NINDS NIH HHS [NS23970] Funding Source: Medline
CR Adami S, 1997, CANCER, V80, P1674, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1674::AID CNCR18>3.0.CO;2 X
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166 2236(94)90149 X
   Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306
   Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807
   Clohisy DR, 1998, J ORTHOPAED RES, V16, P660, DOI 10.1002/jor.1100160606
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coyle N, 1990, J Pain Symptom Manage, V5, P83
   Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076
   DAX S, 2002, INT S MED CHEM, V27, P93
   de Wit R, 2001, PAIN, V91, P339, DOI 10.1016/S0304 3959(00)00455 3
   Delaisse Jean Marie, 1992, P289
   Drube S, 2000, BRIT J PHARMACOL, V131, P1553, DOI 10.1038/sj.bjp.0703764
   GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Honore P, 2000, Prog Brain Res, V129, P357
   HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0
   Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896 6273(02)00908 X
   Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019
   KRISHTAL OA, 1980, NEUROSCIENCE, V5, P2325, DOI 10.1016/0306 4522(80)90149 9
   Luger NM, 2001, CANCER RES, V61, P4038
   Mach DB, 2002, NEUROSCIENCE, V113, P155, DOI 10.1016/S0306 4522(02)00165 3
   Major PP, 2000, CANCER, V88, P6, DOI 10.1002/(SICI)1097 0142(20000101)88:1<6::AID CNCR3>3.3.CO;2 4
   Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747
   Marchetti D, 2003, PATHOL ONCOL RES, V9, P147, DOI 10.1007/BF03033729
   Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305 7372(98)90005 6
   Michael GJ, 1999, J NEUROSCI, V19, P1844
   Mujoomdar M, 2003, BIOCHEM PHARMACOL, V66, P1737, DOI 10.1016/S0006 2952(03)00548 3
   Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304 3959(99)00006 8
   Priestley JV, 2002, CAN J PHYSIOL PHARM, V80, P495, DOI 10.1139/y02 034
   Reeh PW, 1996, PROG BRAIN RES, V113, P143, DOI 10.1016/S0079 6123(08)61085 7
   Sabino MAC, 2002, CANCER RES, V62, P7343
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   Sevcik MA, 2004, PAIN, V111, P169, DOI 10.1016/j.pain.2004.06.015
   Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896 6273(00)80564 4
   Tsujino H, 2000, MOL CELL NEUROSCI, V15, P170, DOI 10.1006/mcne.1999.0814
   Tsuzuki K, 2001, PAIN, V91, P351, DOI 10.1016/S0304 3959(00)00456 5
   Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765
   Yoneda Toshiyuki, 2000, Cancer, V88, P2979, DOI 10.1002/1097 0142(20000615)88:12+<2979::AID CNCR13>3.0.CO;2 U
NR 40
TC 311
Z9 384
U1 0
U2 32
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270 6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAR 23
PY 2005
VL 25
IS 12
BP 3126
EP 3131
DI 10.1523/JNEUROSCI.3815 04.2005
PG 6
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA 909JP
UT WOS:000227856500014
PM 15788769
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Sato, D
   Takahata, M
   Ota, M
   Fukuda, C
   Hasegawa, T
   Yamamoto, T
   Amizuka, N
   Tsuda, E
   Okada, A
   Hiruma, Y
   Fujita, R
   Iwasaki, N
AF Sato, Dai
   Takahata, Masahiko
   Ota, Masahiro
   Fukuda, Chie
   Hasegawa, Tomoka
   Yamamoto, Tomomaya
   Amizuka, Norio
   Tsuda, Eisuke
   Okada, Akiko
   Hiruma, Yoshiharu
   Fujita, Ryo
   Iwasaki, Norimasa
TI Siglec 15 targeting therapy protects against glucocorticoid induced
   osteoporosis of growing skeleton in juvenile rats
SO BONE
LA English
DT Article
DE Siglec 15; Glucocorticoid induced osteoporosis; Juvenile osteoporosis;
   Osteoclasts; Growth plate; Alendronate
ID INHIBITS BONE LOSS; OSTEOCLAST DIFFERENTIATION; SIGLEC 15; ALENDRONATE;
   MECHANISMS; OSTEOPETROSIS; OVARIECTOMY; MANAGEMENT; RESORPTION;
   FRACTURES
AB Effective treatment of juvenile osteoporosis, which is frequently caused by glucocorticoid (GC) therapy, has not been established due to limited data regarding the efficacy and adverse effects of antiresorptive therapies on the growing skeleton. We previously demonstrated that sialic acid binding immunoglobulin like lectin 15 (Siglec 15) targeting therapy, which interferes with osteoclast terminal differentiation in the secondary, but not primary, spongiosa, increased bone mass without adverse effects on skeletal growth, whereas bisphosphonate, a first line treatment for osteoporosis, increased bone mass but impaired long bone growth in healthy growing rats. In the present study, we investigated the efficacy of anti Siglec 15 neutralizing antibody (Ab) therapy against GC induced osteoporosis in a growing rat model. GC decreased bone mass and deteriorated mechanical properties of bone, due to a disproportionate increase in bone resorption. Both anti Siglec 15 Ab and alendronate (ALN) showed protective effects against GC induced bone loss by suppressing bone resorption, which was more pronounced with anti Siglec 15 Ab treatment, possibly due to a reduced negative impact on bone formation. ALN induced histological abnormalities in the growth plate and morphological abnormalities in the long bone metaphysis but did not cause significant growth retardation. Conversely, anti Siglec 15 Ab did not show any negative impact on the growth plate and preserved normal osteoclast and chondroclast function at the primary spongiosa. Taken together, these results suggest that anti Siglec 15 targeting therapy could be a safe and efficacious prophylactic therapy for GC induced osteoporosis in juvenile patients.
C1 [Sato, Dai; Takahata, Masahiko; Ota, Masahiro; Fujita, Ryo; Iwasaki, Norimasa] Hokkaido Univ, Fac Med, Dept Orthopaed Surg, Sapporo, Hokkaido 0608638, Japan.
   [Sato, Dai; Takahata, Masahiko; Ota, Masahiro; Fujita, Ryo; Iwasaki, Norimasa] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan.
   [Fukuda, Chie; Tsuda, Eisuke; Okada, Akiko] Daiichi Sankyo Co Ltd, Specialty Med Res Labs 1, Tokyo, Japan.
   [Hasegawa, Tomoka; Yamamoto, Tomomaya; Amizuka, Norio] Hokkaido Univ, Grad Sch Dent Med, Dept Dev Biol Hard Tissue, Sapporo, Hokkaido, Japan.
   [Hiruma, Yoshiharu] Daiichi Sankyo Co Ltd, Pharmacovigilance Dept, Tokyo, Japan.
C3 Hokkaido University; Hokkaido University; Daiichi Sankyo Company
   Limited; Hokkaido University; Daiichi Sankyo Company Limited
RP Takahata, M (通讯作者)，Hokkaido Univ, Grad Sch Med, Dept Orthoped Surg, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0608638, Japan.
EM takamasa@med.hokudai.ac.jp
RI Takahata, Masahiko/E 1929 2012; SATO, DAI/GWC 8640 2022; Amizuka,
   Norio/G 1397 2012
OI Hasegawa, Tomoka/0000 0003 0309 6637; SATO, DAI/0000 0003 1479 3892
FU Daiichi Sankyo Co., Ltd.; JSPS KAKENHI [JP17H04309]
FX This work was supported by a grant for research funding from Daiichi
   Sankyo Co., Ltd. and by JSPS KAKENHI Grant Number JP17H04309.
CR Allen DB, 1996, ENDOCRIN METAB CLIN, V25, P699, DOI 10.1016/S0889 8529(05)70348 0
   AVIOLI LV, 1993, BRIT J RHEUMATOL, V32, P27
   Azuma Y, 1998, J PHARMACOL EXP THER, V286, P128
   Bianchi ML, 2014, J CLIN DENSITOM, V17, P281, DOI 10.1016/j.jocd.2014.01.005
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bushby K, 2010, LANCET NEUROL, V9, P77, DOI 10.1016/S1474 4422(09)70271 6
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dwan K, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub3
   Hiruma Y, 2013, BONE, V53, P87, DOI 10.1016/j.bone.2012.11.036
   Hiruma Y, 2011, BIOCHEM BIOPH RES CO, V409, P424, DOI 10.1016/j.bbrc.2011.05.015
   Humphrey MB, 2004, J BONE MINER RES, V19, P224, DOI 10.1359/JBMR.0301234
   Ishida Kitagawa N, 2012, J BIOL CHEM, V287, P17493, DOI 10.1074/jbc.M111.324194
   Kameda Y, 2013, J BONE MINER RES, V28, P2463, DOI 10.1002/jbmr.1989
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   LeBlanc CMA, 2015, J BONE MINER RES, V30, P1667, DOI 10.1002/jbmr.2511
   LEE ER, 1995, J HISTOCHEM CYTOCHEM, V43, P525, DOI 10.1177/43.5.7730591
   Mäkitie O, 2013, NAT REV RHEUMATOL, V9, P465, DOI 10.1038/nrrheum.2013.45
   Marrani E, 2017, DRUGS, V77, P679, DOI 10.1007/s40265 017 0715 3
   Masuyama R, 2003, J BONE MINER RES, V18, P1217, DOI 10.1359/jbmr.2003.18.7.1217
   Matsushima S, 2011, CELLS TISSUES ORGANS, V194, P320, DOI 10.1159/000324642
   Patschan D, 2001, BONE, V29, P498, DOI 10.1016/S8756 3282(01)00610 X
   Pui CH, 2013, SEMIN HEMATOL, V50, P185, DOI 10.1053/j.seminhematol.2013.06.007
   Rooney M, 2019, ECLINICALMEDICINE, V12, P79, DOI 10.1016/j.eclinm.2019.06.004
   Rudge S, 2005, RHEUMATOLOGY, V44, P813, DOI 10.1093/rheumatology/keh538
   Sato D, 2018, BONE, V116, P172, DOI 10.1016/j.bone.2018.07.026
   SEEDOR JG, 1991, J BONE MINER RES, V6, P339
   Stuible M, 2014, J BIOL CHEM, V289, P6498, DOI 10.1074/jbc.M113.494542
   Takahata M, 2012, ARTHRITIS RHEUM US, V64, P3649, DOI 10.1002/art.34639
   Thiele Sylvia, 2014, Bonekey Rep, V3, P552, DOI 10.1038/bonekey.2014.47
   THOMPSON DD, 1990, J BONE MINER RES, V5, P279, DOI 10.1002/jbmr.5650050312
   Thomsen JS, 1999, BONE, V25, P561, DOI 10.1016/S8756 3282(99)00212 4
   Thudium CS, 2014, CALCIFIED TISSUE INT, V95, P83, DOI 10.1007/s00223 014 9865 4
   TURNER RT, 1994, ENDOCRINOLOGY, V134, P461, DOI 10.1210/en.134.1.461
   Ward L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005324.pub2
   Ward LM, 2016, OSTEOPOROSIS INT, V27, P2147, DOI 10.1007/s00198 016 3515 9
   Zou W, 2010, J CELL SCI, V123, P2955, DOI 10.1242/jcs.069872
NR 36
TC 21
Z9 23
U1 1
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2020
VL 135
AR 115331
DI 10.1016/j.bone.2020.115331
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LJ3LI
UT WOS:000530069000018
PM 32217159
DA 2025 08 17
ER

PT J
AU Li, JX
   Chen, ZX
   Liao, HB
   Zhong, YT
   Hua, JY
   Su, ML
   Li, JH
   Xu, JR
   Cui, L
   Cui, Y
AF Li, Jiaxiao
   Chen, Zexin
   Liao, Hongbo
   Zhong, Yanting
   Hua, Junying
   Su, Miaoling
   Li, Jiahao
   Xu, Jinrong
   Cui, Liao
   Cui, Yang
TI Anti Osteogenic Effect of Danshensu in Ankylosing Spondylitis: An in
   Vitro Study Based on Integrated Network Pharmacology
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE ankylosing spondylitis; Danshensu; network pharmacology; ossification;
   fibroblast; osteoblast
ID OSSIFICATION; FIBROBLASTS; PROMOTES; CELLS; DIFFERENTIATION;
   PATHOPHYSIOLOGY; PROLIFERATION; INFLAMMATION; LIGAMENT
AB Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by abnormal bone metabolism, with few effective treatments available. Danshensu [3 (3,4 dihydroxy phenyl) lactic acid) is a bioactive compound from traditional Chinese medicine with a variety of pharmacologic effects. In the present study, we investigated the pharmacologic effect and molecular mechanism of Danshensu in AS. Potential targets of Danshensu were identified in four drugs genes databases; and potential pharmacologic target genes in AS were identified in three diseases genes databases. Differentially expressed genes related to AS were obtained from the Gene Expression Omnibus database. Overlapping targets of Danshensu and AS were determined and a disease active ingredient target interaction network was constructed with Cytoscape software. Enrichment analyses of the common targets were performed using Bioconductor. To test the validity of the constructed network, an in vitro model was established by treating osteoblasts from newborn rats with low concentrations of tumor necrosis factor (TNF) alpha. Then, the in vitro model and AS fibroblasts were treated with Danshensu (1 10 mu M). Osteogenesis was evaluated by alkaline phosphatase staining and activity assay, alizarin red staining, quantitative PCR, and western blotting. We identified 2944 AS related genes and 406 Danshensu targets, including 47 that were common to both datasets. The main signaling pathways associated with the targets were the c Jun N terminal kinase (JNK) and extracellular signal regulated kinase (ERK) pathways. A low concentration of TNF alpha (0.01 ng/ml) promoted the differentiation of osteoblasts; this was inhibited by Danshensu, which had the same effect on AS fibroblasts but had the opposite effect on normal osteoblasts. Danshensu also decreased the phosphorylation of JNK and ERK in AS fibroblasts. There results provide evidence that Danshensu exerts an anti osteogenic effect via suppression of JNK and ERK signaling, highlighting its therapeutic potential for the treatment of AS.
C1 [Li, Jiaxiao; Cui, Yang] South China Univ Technol, Sch Med, Guangzhou, Peoples R China.
   [Li, Jiaxiao; Cui, Yang] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Rheumatol & Immunol, Guangzhou, Peoples R China.
   [Chen, Zexin] Shenzhen Univ, South China Hosp, Dept Rheumatol & Immunol, Shenzhen, Peoples R China.
   [Liao, Hongbo; Zhong, Yanting; Hua, Junying; Cui, Liao] Guangdong Med Univ, Sch Pharm, Guangdong Prov Key Lab Res & Dev Nat Drugs, Dongguan, Peoples R China.
   [Su, Miaoling; Li, Jiahao; Xu, Jinrong] Guangdong Med Univ, Affiliated Hosp 2, Dept Cardiol, Zhanjiang, Peoples R China.
C3 South China University of Technology; Guangdong Academy of Medical
   Sciences & Guangdong General Hospital; Southern Medical University  
   China; Shenzhen University; Guangdong Medical University; Guangdong
   Medical University
RP Cui, Y (通讯作者)，South China Univ Technol, Sch Med, Guangzhou, Peoples R China.; Cui, Y (通讯作者)，Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Rheumatol & Immunol, Guangzhou, Peoples R China.; Cui, L (通讯作者)，Guangdong Med Univ, Sch Pharm, Guangdong Prov Key Lab Res & Dev Nat Drugs, Dongguan, Peoples R China.; Xu, JR (通讯作者)，Guangdong Med Univ, Affiliated Hosp 2, Dept Cardiol, Zhanjiang, Peoples R China.
EM 13602835538@139.com; cuiliao@163.com; zjeyxjr@163.com
RI Chen, Zexin/HMP 4871 2023
FU Science and Technology General Project of Guangzhou, China
   [201804010028]; Science and Technology Planning Project of Guangdong
   Province, China [2020B1515120052]; Discipline construction project of
   Guangdong Medical University, China [4SG21002G]
FX Funding This work was funded by the Science and Technology General
   Project of Guangzhou, China (grant No. 201804010028), Science and
   Technology Planning Project of Guangdong Province, China (grant No.
   2020B1515120052), and Discipline construction project of Guangdong
   Medical University, China (grant No. 4SG21002G).
CR Bai BL, 2018, J BIOMAT SCI POLYM E, V29, P1207, DOI 10.1080/09205063.2018.1448336
   Chen DC, 2016, CELL TISSUE RES, V363, P765, DOI 10.1007/s00441 015 2277 6
   Frost A, 1997, ACTA ORTHOP SCAND, V68, P91, DOI 10.3109/17453679709003987
   Gao K, 2020, BIODATA MIN, V13, DOI 10.1186/s13040 020 00229 4
   Han I, 2017, ONCOTARGET, V8, P36399, DOI 10.18632/oncotarget.16821
   Lai BN, 2020, CELLS BASEL, V9, DOI 10.3390/cells9112466
   Li CJ, 2010, BIOCHEM PHARMACOL, V79, P926, DOI 10.1016/j.bcp.2009.10.019
   Li DH, 2016, BIOMED PHARMACOTHER, V84, P674, DOI 10.1016/j.biopha.2016.09.091
   Li X, 2018, ARTHRITIS RHEUMATOL, V70, P1056, DOI 10.1002/art.40468
   Li YQ, 2020, J ETHNOPHARMACOL, V254, DOI 10.1016/j.jep.2020.112764
   Liu LF, 2021, J CELL PHYSIOL, V236, P6090, DOI 10.1002/jcp.30313
   Lories RJ, 2018, BEST PRACT RES CL RH, V32, P331, DOI 10.1016/j.berh.2018.12.001
   Magrey MN, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926 017 0644 x
   Maksymowych WP, 2009, ARTHRITIS RHEUM US, V60, P93, DOI 10.1002/art.24132
   Mao DM, 2019, J BIOCHEM MOL TOXIC, V33, DOI 10.1002/jbt.22405
   Meng Y, 2016, INT J MOL MED, V37, P258, DOI 10.3892/ijmm.2015.2419
   Pedersen SJ, 2011, ARTHRITIS RHEUM US, V63, P3789, DOI 10.1002/art.30627
   Poddubnyy D, 2020, CURR RHEUMATOL REP, V22, DOI 10.1007/s11926 020 00924 5
   Poddubnyy D, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926 017 0681 5
   Qin X, 2018, J CELL BIOCHEM, V119, P1074, DOI 10.1002/jcb.26275
   Sanpaolo ER, 2020, MOL BIOL REP, V47, P9087, DOI 10.1007/s11033 020 05910 9
   Schett G, 2017, NAT REV RHEUMATOL, V13, P731, DOI 10.1038/nrrheum.2017.188
   Stegen S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04679 7
   Van Mechelen M, 2018, CALCIFIED TISSUE INT, V102, P547, DOI 10.1007/s00223 017 0356 2
   van Tok MN, 2019, ARTHRITIS RHEUMATOL, V71, P612, DOI 10.1002/art.40770
   Wang HF, 2020, ANN PALLIAT MED, V9, P2279, DOI 10.21037/apm 20 277
   Wang QJ, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20191805
   Wang W, 2022, ACTA PHARMACOL SIN, V43, P771, DOI 10.1038/s41401 021 00714 4
   Xie CP, 2021, EXP THER MED, V21, DOI 10.3892/etm.2020.9550
   Xu DH, 2014, INT J BIOCHEM CELL B, V51, P1, DOI 10.1016/j.biocel.2014.03.005
   Yan XF, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00007
   Yin YF, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02208 w
   Zeng HT, 2017, MOLECULES, V22, DOI 10.3390/molecules22050771
   Zhang JL, 2019, EUR J PHARMACOL, V864, DOI 10.1016/j.ejphar.2019.172710
   Zhang Y, 2021, J CELL MOL MED, V25, P1613, DOI 10.1111/jcmm.16262
   Zou YC, 2020, DOSE RESPONSE, V18, DOI 10.1177/1559325819901239
   Zou YC, 2016, DRUG DES DEV THER, V10, P933, DOI 10.2147/DDDT.S97463
NR 37
TC 8
Z9 11
U1 2
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 25
PY 2021
VL 12
AR 772190
DI 10.3389/fphar.2021.772190
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XM6AC
UT WOS:000728906400001
PM 34899327
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tyagi, AM
   Mansoori, MN
   Srivastava, K
   Khan, MP
   Kureel, J
   Dixit, M
   Shukla, P
   Trivedi, R
   Chattopadhyay, N
   Singh, D
AF Tyagi, Abdul M.
   Mansoori, Mohd N.
   Srivastava, Kamini
   Khan, Mohd P.
   Kureel, Jyoti
   Dixit, Manisha
   Shukla, Priyanka
   Trivedi, Ritu
   Chattopadhyay, Naibedya
   Singh, Divya
TI Enhanced Immunoprotective Effects by Anti IL 17 Antibody Translates to
   Improved Skeletal Parameters Under Estrogen Deficiency Compared With
   Anti RANKL and Anti TNF α Antibodies
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE IMMUNE SYSTEM; ESTROGEN DEFICIENCY; PROINFLAMMATORY CYTOKINES; T CELLS;
   B LYMPHOPOESIS
ID ANTITUMOR NECROSIS FACTOR; T CELL SENESCENCE; BONE LOSS;
   PARATHYROID HORMONE; POSTMENOPAUSAL WOMEN; PANCREATIC ISLETS; ANABOLIC
   ACTIVITY; CORTICAL BONE; IN VITRO; OSTEOPOROSIS
AB Activated T cell has a key role in the interaction between bone and immune system. T cells produce proinflammatory cytokines, including receptor activator of NF kappa B ligand (RANKL), tumor necrosis factor a (TNF alpha), and interleukin 17 (IL 17), all of which augment osteoclastogenesis. RANKL and TNF alpha are targeted by inhibitors such as denosumab, a human monoclonal RANKL antibody, and infliximab, which neutralizes TNF alpha. IL 17 is also an important mediator of bone loss, and an antibody against IL 17 is undergoing phase II clinical trial for rheumatoid arthritis. Although there are a few studies showing suppression of Th17 cell differentiation and induction of regulatory T cells (Tregs) by infliximab, the effect of denosumab remains poorly understood. In this study, we investigated the effects of anti TNF alpha, anti RANKL, or anti IL 17 antibody administration to estrogen deficient mice on CD4(+) T cell proliferation, CD28 loss, Th17/Treg balance and B lymphopoesis, and finally, the translation of these immunomodulatory effects on skeletal parameters. Adult Balb/c mice were treated with anti RANKL/ TNF alpha/ IL 17 subcutaneously, twice a week, postovariectomy (Ovx) for 4 weeks. Animals were then autopsied; bone marrow cells were collected for FACS and RNA analysis and serum collected for ELISA. Bones were dissected for static and dynamic histomorphometry studies. We observed that although anti RANKL and anti TNF alpha therapies had no effect on Ovx induced CD4(+) T cell proliferation and B lymphopoesis, anti IL 17 effectively suppressed both events with concomitant reversal of CD28 loss. Anti IL 17 antibody reduced proinflammatory cytokine production and induced Tregs. All three antibodies restored trabecular microarchitecture with comparable efficacy; however, cortical bone parameters, bone biomechanical properties, and histomorphometry were best preserved by anti IL 17 antibody, likely attributable to its inhibitory effect on osteoblast apoptosis and increased number of bone lining cells and Wnt10b expression. Based on the superior immunoprotective effects of anti IL 17, which appears to translate to a better skeletal preservation, we propose beginning clinical trials using a humanized antibody against IL 17 for treatment of postmenopausal osteoporosis. (C) 2014 American Society for Bone and Mineral Research.
C1 CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow, Uttar Pradesh, India.
   CSIR Cent Drug Res Inst, Ctr Res Anabol Skeletal Targets Hlth & Illness AS, Lucknow, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI)
RP Singh, D (通讯作者)，CSIR Cent Drug Res Inst 8643, Div Endocrinol, BS 10 1,Sect 10, Lucknow, Uttar Pradesh, India.
EM divya_singh@cdri.res.in
RI Malik, Abdul/AAX 5715 2020; Singh, Divya/IUM 7944 2023; Chattopadhyay,
   Naibedya/AAQ 3213 2021; shukla, priyanka/C 9968 2010
OI Malik, Abdul/0000 0001 9012 5779; SRIVASTAVA,
   KAMINI/0000 0002 3928 0885; Trivedi, Ritu/0000 0002 9524 2541; Shukla,
   Priyanka/0009 0004 1682 7114; Chattopadhyay,
   Naibedya/0000 0003 2473 0246
FU Centre for Research in Anabolic Skeletal Targets in Health and Illness
   (ASTHI); Council of Scientific and Industrial Research (CSIR);
   Department of Biotechnology (DBT); Department of Science and Technology
   (DST), Government of India
FX Generous funding from the Centre for Research in Anabolic Skeletal
   Targets in Health and Illness (ASTHI) is acknowledged. Other supporting
   grants are from Council of Scientific and Industrial Research (CSIR),
   Department of Biotechnology (DBT), Department of Science and Technology
   (DST), Government of India. CDRI communication number 8643.
CR Anastasilakis AD, 2012, THER CLIN RISK MANAG, V8, P295, DOI 10.2147/TCRM.S24239
   Atzeni F, 2013, AUTOIMMUN REV, V12, P703, DOI 10.1016/j.autrev.2012.10.021
   Baker PJ, 1999, INFECT IMMUN, V67, P2804, DOI 10.1128/IAI.67.6.2804 2809.1999
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bhargavan B, 2009, J CELL BIOCHEM, V108, P388, DOI 10.1002/jcb.22264
   BIANCHI F, 1993, TISSUE CELL, V25, P817, DOI 10.1016/0040 8166(93)90030 O
   Cairns AP, 2002, ULSTER MED J, V71, P101
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   Dahlén R, 2013, SCAND J IMMUNOL, V78, P275, DOI 10.1111/sji.12081
   Dasgupta A, 2012, NATL MED J INDIA, V25, P341
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295
   Duong Le T, 2012, Bonekey Rep, V1, P67, DOI 10.1038/bonekey.2012.67
   Furuya Y, 2013, J BIOL CHEM, V288, P5562, DOI 10.1074/jbc.M112.426080
   Furuya Y, 2011, J BIOL CHEM, V286, P37023, DOI 10.1074/jbc.M111.246280
   Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742 4933 2 14
   Hale LV, 2007, BONE, V40, P1103, DOI 10.1016/j.bone.2006.11.027
   Horowitz MC, 2005, IMMUNOL REV, V208, P141, DOI 10.1111/j.0105 2896.2005.00328.x
   Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kawai VK, 2012, CURR OPIN RHEUMATOL, V24, P576, DOI 10.1097/BOR.0b013e328356d212
   Kim BJ, 2012, BIOCHEM BIOPH RES CO, V424, P170, DOI 10.1016/j.bbrc.2012.06.100
   Kimble RB, 1997, J BONE MINER RES, V12, P935, DOI 10.1359/jbmr.1997.12.6.935
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kozlowska E, 2007, IMMUNOLOGY, V122, P445, DOI 10.1111/j.1365 2567.2007.02667.x
   Kramer JM, 2007, J PERIODONTOL, V78, P1083, DOI 10.1902/jop.2007.060392
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Li JY, 2014, J BONE MINER RES, V29, P43, DOI 10.1002/jbmr.2044
   Li Y, 2007, J CELL BIOCHEM, V100, P1370, DOI 10.1002/jcb.21121
   MARCHETTI P, 1994, TRANSPLANTATION, V57, P1532
   MASUZAWA T, 1994, J CLIN INVEST, V94, P1090, DOI 10.1172/JCI117424
   McMahon MS, 2008, BULL HOSP JT DIS, V66, P280
   Miller PD, 2011, THER ADV MUSCULOSKEL, V3, P271, DOI 10.1177/1759720X11424220
   Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449
   Navarra SV, 2014, INT J RHEUM DIS, V17, P291, DOI 10.1111/1756 185X.12188
   Ominsky MS, 2008, J BONE MINER RES, V23, P672, DOI 10.1359/JBMR.080109
   Ominsky MS, 2011, BONE, V49, P162, DOI 10.1016/j.bone.2011.04.001
   Pacifici R, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2126
   Picherit C, 2001, J NUTR, V131, P723, DOI 10.1093/jn/131.3.723
   Pinkerton JV, 2013, CLIN OBSTET GYNECOL, V56, P711, DOI 10.1097/GRF.0b013e3182a9fb02
   Raisz LG, 1999, CLIN CHEM, V45, P1353
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Reginster JY, 2013, EXPERT OPIN DRUG SAF, V12, P507, DOI 10.1517/14740338.2013.793669
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   ROSEN CJ, 1990, J BONE MINER RES, V5, P851
   Rosenblum H, 2011, AUTOIMMUN REV, V10, P563, DOI 10.1016/j.autrev.2011.04.010
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schnoke M, 2009, BONE, V45, P590, DOI 10.1016/j.bone.2009.05.006
   Sharan K, 2011, J BONE MINER RES, V26, P2096, DOI 10.1002/jbmr.434
   Shen CL, 2013, CURR DRUG TARGETS, V14, P1619, DOI 10.2174/13894501113146660216
   Shen H, 2010, J INVEST MED, V58, P905, DOI 10.231/JIM.0b013e3181eb9895
   Silvestrini G, 2007, J MOL HISTOL, V38, P261, DOI 10.1007/s10735 007 9096 3
   Sugita S, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3824
   Tarjanyi Oktavia, 2009, Immun Ageing, V6, P8, DOI 10.1186/1742 4933 6 8
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Tyagi AM, 2012, OSTEOPOROSIS INT, V23, P1151, DOI 10.1007/s00198 011 1650 x
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Tyagi AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021216
   Vallejo AN, 2004, TRENDS MOL MED, V10, P119, DOI 10.1016/j.molmed.2004.01.002
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Xu MS, 2010, BONE, V47, P341, DOI 10.1016/j.bone.2010.05.006
   Yasuda H, 2013, WORLD J ORTHOP, V4, P207, DOI 10.5312/wjo.v4.i4.207
   Yuan FL, 2012, MOL BIOL REP, V39, P771, DOI 10.1007/s11033 011 0797 z
   Ziegler SF, 2009, MICROBES INFECT, V11, P594, DOI 10.1016/j.micinf.2009.04.002
NR 66
TC 91
Z9 100
U1 1
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2014
VL 29
IS 9
BP 1981
EP 1992
DI 10.1002/jbmr.2228
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AN8HV
UT WOS:000340846000008
PM 24677326
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, NY
   Chu, NN
   Zhu, LL
   Wu, XJ
   Wei, Q
   Wang, JH
   Hu, XH
   Yu, HY
   Wang, QY
   Yuan, WA
   Huang, K
   Zhang, J
AF Li, Nanyang
   Chu, Nannan
   Zhu, Leilei
   Wu, Xiaojie
   Wei, Qiong
   Wang, Jiahui
   Hu, Xuhui
   Yu, Haoyu
   Wang, Qingyu
   Yuan, Wei'an
   Huang, Kai
   Zhang, Jing
TI Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14
   versus reference denosumab in healthy males: A randomized phase I study
SO CTS CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
ID OSTEOPOROSIS
AB Denosumab is a human IgG2 monoclonal antibody against receptor activator of nuclear factor kappa B ligand (RANKL) for the treatment of osteoporosis and bone loss. HLX14 is a proposed biosimilar of denosumab. This randomized, parallel group, two part, phase I study aimed to compare the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 with reference denosumab in Chinese healthy adult male participants. In Part 1, participants were randomized 1:1 and given HLX14 or reference denosumab sourced from the European Union (EU). In double blind Part 2, participants were randomized 1:1:1:1 to receive HLX14 or denosumab sourced from the United States, EU, or China. All study drugs were administered via subcutaneous injection at a single dose of 60 mg. The primary endpoints were area under the serum drug concentration time curve from time 0 to the last concentration quantifiable time t (AUC0 t), maximum serum drug concentration (Cmax), and area under the serum drug concentration time curve from time 0 to infinity (AUC0 inf). Twenty four participants were randomized in Part 1 and 228 in Part 2. The 90% confidence intervals of geometric mean ratio of AUC0 t, Cmax, and AUC0 inf between HLX14 and denosumab from different sources fell within the pre specified similarity margins of 0.80 1.25 (AUC0 t, 0.91 1.13; Cmax, 0.91 1.13; AUC0 inf, 0.91 1.12), demonstrating pharmacokinetic similarity. No notable difference was observed among treatment groups in pharmacodynamics, safety, or immunogenicity. HLX14 demonstrated highly similar pharmacokinetic characteristics with comparable pharmacodynamics, safety, and immunogenicity to denosumab, supporting its further investigation as a potential denosumab biosimilar.
C1 [Li, Nanyang; Wu, Xiaojie; Wei, Qiong; Zhang, Jing] Fudan Univ, Huashan Hosp, Clin Pharmacol Res Ctr, Shanghai, Peoples R China.
   [Chu, Nannan; Huang, Kai] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Phase Clin Res Ctr 1, 299 Qingyang Rd, Wuxi, Jiangsu, Peoples R China.
   [Zhu, Leilei; Yuan, Wei'an] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Phase Clin Res Ctr 1, 528 Zhangheng Rd, Shanghai, Peoples R China.
   [Wang, Jiahui; Hu, Xuhui; Yu, Haoyu; Wang, Qingyu] Shanghai Henlius Biotech Inc, Shanghai, Peoples R China.
C3 Fudan University; Nanjing Medical University; Shanghai University of
   Traditional Chinese Medicine
RP Huang, K (通讯作者)，Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Phase Clin Res Ctr 1, 299 Qingyang Rd, Wuxi, Jiangsu, Peoples R China.; Yuan, WA (通讯作者)，Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Phase Clin Res Ctr 1, 528 Zhangheng Rd, Shanghai, Peoples R China.; Zhang, J (通讯作者)，Fudan Univ, Huashan Hosp, 12 Middle Wulumuqi Rd, Shanghai, Peoples R China.
EM weian_1980@163.com; hk19820627@sina.com; zhang.j61@fudan.edu.cn
RI ; Wu, Xiaojie/D 8232 2014; Wang, Jiahui/GRO 4604 2022
OI Yuan, Wei'an/0000 0002 6072 118X; 
FU Shanghai Henlius Biotech, Inc.
FX We would like to thank the participants who participated in the trial,
   their families, the principal investigators, clinicians, study
   coordinators, nurses, as well as the clinical study team (Clinical
   Operations: Juan Du, Jing Li; Clinical Pharmacology: Liang Zhou; Medical
   R&D: Lin Wang; Statistics: Yunling Chen, Mengkai Chen), Jun Zhu, and
   Wenjie Zhang from Shanghai Henlius Biotech, Inc. Medical writing support
   was provided by Xiao Zou PhD, Shiqi Zhong PhD and Chen Hu PhD of
   Shanghai Henlius Biotech, Inc., and funded by Shanghai Henlius Biotech,
   Inc.
CR [Anonymous], 2010, FDA APPROVES AMGENS
   [Anonymous], 2020, Amgen Receives National Medical Products Administration Approval For Prolia (Denosumab) in China
   [Anonymous], 2022, China's First Denosumab Biosimilar Boyoubei Approved for Launch by NMPA
   [Anonymous], 2023, Qilu Pharmaceutical's Denosumab Injection (LUKEXIN) Approved for Marketing
   [Anonymous], 2010, Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
   [Anonymous], 2023, Amgen Prolia Receives Approval for New Indication for the Treatment of Osteoporosis in Men at High Risk for Fracture
   [Anonymous], 2024, Sandoz receives FDA approval for first and only denosumab biosimilars
   Chen Q, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197984
   Chinese Society of Osteoporosis and Bone Mineral Research, 2023, Gen Pract China, V26, P1671, DOI 10.12114/j.issn.1007 9572.2023.0121
   .ema.europa.eu, Prolia Summary of Product Characteristics.
   Gu JM, 2023, J ORTHOP TRANSL, V38, P117, DOI 10.1016/j.jot.2022.06.007
   Guo YH, 2023, EXPERT OPIN BIOL TH, V23, P705, DOI 10.1080/14712598.2023.2178298
   Jeka S, 2024, J BONE MINER RES, V39, P202, DOI 10.1093/jbmr/zjae016
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Lyu HC, 2019, J CLIN ENDOCR METAB, V104, P1753, DOI 10.1210/jc.2018 02236
   Morris HA, 2017, CLIN CHIM ACTA, V467, P34, DOI 10.1016/j.cca.2016.06.036
   MSD MANUAL Professional Version, Osteoporosis
   Nakamura Y, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.21
   National Institute of Arthritis and Musculoskeletal and Skin Diseases, Osteoporosis. Reviewed December 2022
   National Osteoporosis Guideline Group, CLIN GUIDELINE PREVE
   Prolia Prescribing Information, Recent major changes in March 2024
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   The World's Second Approved Biosimilars of Denosumab (MAILISHU), 2023, ABOUT US
   Xiao PL, 2022, OSTEOPOROSIS INT, V33, P2137, DOI 10.1007/s00198 022 06454 3
   Zhang H, 2023, ACTA PHARMACOL SIN, V44, P446, DOI 10.1038/s41401 022 00954 y
   Zhang J, 2022, CLIN PHARMACOL THER, V111, pS59
   Zhang LD, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.1005681
NR 27
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1752 8054
EI 1752 8062
J9 CTS CLIN TRANSL SCI
JI CTS Clin. Transl. Sci.
PD DEC
PY 2024
VL 17
IS 12
AR e70089
DI 10.1111/cts.70089
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA P8B9F
UT WOS:001380106600001
PM 39700054
OA gold
DA 2025 08 17
ER

PT J
AU Zhang, J
   Meng, XF
   Ding, C
   Xie, L
   Yang, PF
   Shang, P
AF Zhang, Jian
   Meng, Xiaofeng
   Ding, Chong
   Xie, Li
   Yang, Pengfei
   Shang, Peng
TI Regulation of osteoclast differentiation by static magnetic fields
SO ELECTROMAGNETIC BIOLOGY AND MEDICINE
LA English
DT Article
DE Bone resorption; cell growth; osteoclast formation; RAW264.7 cells;
   static magnetic fields
ID BONE FORMATION; CELLS; MODERATE; OSTEOBLAST; MECHANISM
AB Static magnetic field (SMF) modulates bone metabolism, but little research is concerned with the effects of SMF on osteoclast. Our previous studies show that osteogenic differentiation is strongly correlated with magnetic strength from hypo (500 nT), weak (geomagnetic field, GMF), moderate (0.2 T) to high (16 T) SMFs. We speculated that the intensity that had positive (16 T) or negative (500 nT and 0.2 T) effects on osteoblast differentiation would inversely influence osteoclast differentiation. To answer this question, we examined the profound effects of SMFs on osteoclast differentiation from pre osteoclast Raw264.7 cells. Here, we demonstrated that 500 nT and 0.2 T SMFs promoted osteoclast differentiation, formation and resorption, while 16 T had an inhibitory effect. Almost all the osteoclastogenic genes were highly expressed under 500 nT and 0.2 T, including RANK, matrix metalloproteinase 9 (MMP9), V ATPase, carbonic anhydrase II (Car2) and cathepsin K (CTSK), whereas they were decreased under 16 T. In addition, 16 T disrupted actin formation with remarkably decreased integrin 3 expression. Collectively, these results indicate that osteoclast differentiation could be regulated by altering the intensity of SMF, which is just contrary to that on osteoblast differentiation. Therefore, studies of SMF effects could reveal some parameters that could be used as a physical therapy for various bone disorders.
C1 [Zhang, Jian] Soochow Univ, Coll Med, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Sch Radiat Med & Protect, Suzhou, Peoples R China.
   [Zhang, Jian; Meng, Xiaofeng; Ding, Chong; Xie, Li; Yang, Pengfei; Shang, Peng] Northwestern Polytech Univ, Sch Life Sci, Key Lab Space Biosci & Biotechnol, Inst Special Environm Biophys, POB 707,127 Youyi Xilu, Xian 710072, Shaanxi, Peoples R China.
C3 Soochow University   China; Northwestern Polytechnical University
RP Shang, P (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, Key Lab Space Biosci & Biotechnol, Inst Special Environm Biophys, POB 707,127 Youyi Xilu, Xian 710072, Shaanxi, Peoples R China.
EM shangpeng@nwpu.edu.cn
FU National Natural Science Foundation of China [51477141]; National Basic
   Research Program of China [2011CB710903]; Specialized Research Fund for
   the Doctoral Program of Higher Education of China [20126102110055];
   Fundamental Research Funds for the Central Universities of China
   [3102014KYJD020, 3102014ZD0045]
FX This research was supported by the National Natural Science Foundation
   of China (51477141), National Basic Research Program of China
   (2011CB710903), Specialized Research Fund for the Doctoral Program of
   Higher Education of China (20126102110055) and the Fundamental Research
   Funds for the Central Universities of China (3102014KYJD020,
   3102014ZD0045).
CR [Anonymous], 2011, EVID BASED COMPLEMEN
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chekhun V. F., 2013, INT J PHYSL PATH PHA, V4, P69
   Chionna A, 2005, BIOELECTROMAGNETICS, V26, P275, DOI 10.1002/bem.20081
   Colbert AP, 2009, EVID BASED COMPL ALT, V6, P133, DOI 10.1093/ecam/nem131
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Di SM, 2012, INT J RADIAT BIOL, V88, P806, DOI 10.3109/09553002.2012.698365
   Dini L, 2005, MICRON, V36, P195, DOI 10.1016/j.micron.2004.12.009
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Jia B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105604
   Lin SL, 2008, ELECTROMAGN BIOL MED, V27, P55, DOI 10.1080/15368370701878960
   Markov Marko S., 2007, Environmentalist, V27, P457, DOI 10.1007/s10669 007 9072 1
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Miyakoshi J, 2006, SCI TECHNOL ADV MAT, V7, P305, DOI 10.1016/j.stam.2006.01.004
   Mo WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054775
   Mo WC, 2014, SCI CHINA LIFE SCI, V57, P726, DOI 10.1007/s11427 014 4662 x
   Nilforoushan D, 2009, NITRIC OXIDE BIOL CH, V21, P27, DOI 10.1016/j.niox.2009.04.002
   Puricelli Edela, 2009, Head Face Med, V5, P1, DOI 10.1186/1746 160X 5 1
   Puricelli Edela, 2006, Head Face Med, V2, P43, DOI 10.1186/1746 160X 2 43
   Qian AR, 2013, IEEE T APPL SUPERCON, V23, DOI 10.1109/TASC.2012.2232919
   Qian AR, 2012, IEEE T BIO MED ENG, V59, P68, DOI 10.1109/TBME.2010.2103377
   Qian AR, 2010, ADV SPACE RES, V46, P687, DOI 10.1016/j.asr.2010.04.012
   Qian AR, 2009, IEEE T APPL SUPERCON, V19, P42, DOI 10.1109/TASC.2009.2012422
   Rosen AD, 2003, CELL BIOCHEM BIOPHYS, V39, P163, DOI 10.1385/CBB:39:2:163
   Shang P, 2013, J MECH MED BIOL, V13, DOI 10.1142/S021951941340006X
   Shanmugarajan TS, 2011, TISSUE ENG REGEN MED, V8, P347
   Stenbeck G, 2002, SEMIN CELL DEV BIOL, V13, P285, DOI 10.1016/S1084952102000587
   Sun YL, 2015, IEEE T BIO MED ENG, V62, P900, DOI 10.1109/TBME.2014.2370039
   Taniguchi N, 2004, EVID BASED COMPL ALT, V1, P187, DOI 10.1093/ecam/neh024
   Wang Z, 2014, BIOELECTROMAGNETICS, V35, P251, DOI 10.1002/bem.21847
   Wang Z, 2009, BIOELECTROMAGNETICS, V30, P446, DOI 10.1002/bem.20501
   World Health Organization, 2006, ENV HLTH CRIT, V232
   Xu SZ, 2001, BIO MED MATER ENG, V11, P257
   Yan QC, 1998, MED ENG PHYS, V20, P397, DOI 10.1016/S1350 4533(98)00051 4
   Zhang J, 2014, BIOL TRACE ELEM RES, V162, P153, DOI 10.1007/s12011 014 0157 7
   Zhang J, 2014, PROG BIOPHYS MOL BIO, V114, P146, DOI 10.1016/j.pbiomolbio.2014.02.001
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
   Ziegelberger G, 2009, HEALTH PHYS, V96, P504, DOI 10.1097/01.HP.0000343164.27920.4a
NR 40
TC 45
Z9 51
U1 2
U2 26
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1536 8378
EI 1536 8386
J9 ELECTROMAGN BIOL MED
JI Electromagn. Biol. Med.
PY 2017
VL 36
IS 1
BP 8
EP 19
DI 10.3109/15368378.2016.1141362
PG 12
WC Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Biophysics
GA EC3HG
UT WOS:000388016400002
PM 27355421
DA 2025 08 17
ER

PT J
AU Fleming, A
   Sato, M
   Goldsmith, P
AF Fleming, A
   Sato, M
   Goldsmith, P
TI High throughput in vivo screening for bone anabolic compounds with
   zebrafish
SO JOURNAL OF BIOMOLECULAR SCREENING
LA English
DT Article
ID PARATHYROID HORMONE 1 34; DANIO RERIO; OSTEOPOROSIS; RATS; WOMEN; PTH;
   NOTOCHORD; CARTILAGE; PEPTIDE; SYSTEM
AB Osteoporosis and diseases of bone loss are a major public health problem for the present and the future since longevity and prevalence of the disease are increasing in all parts of the world. The bisphosphonates, widely used in the treatment of osteoporosis, act by inhibiting bone resorption. However, there are few agents that promote or increase bone formation in patients who have suffered substantial bone loss. To facilitate the identification of novel anabolic therapies, the authors have developed a rapid, high throughput in vivo screen using larval zebrafish (Danio rerio) in which they are able to identify agents with anabolic effects in the skeleton within a 6 day time period. Vitamin D, analogs and intermittent parathyroid hormone (PTH) result in dose dependent increases in the formation of mineralized bone, whereas continuous exposure to PTH results in net bone loss. Because this model is fast, economical, and genetically tractable, it provides a powerful adjunct to mammalian models for the identification of new anabolic bone agents and offers the potential for genetic elucidation of pathways important in osteoblastic activity.
C1 DanioLabs Ltd, Cambridge CB5 9TN, England.
   Eli Lilly & Co, Indianapolis, IN 46285 USA.
C3 Eli Lilly
RP Fleming, A (通讯作者)，DanioLabs Ltd, 7330 Cambridge Res Pk, Cambridge CB5 9TN, England.
EM angeleen.fleming@daniolabs.com
OI Fleming, Angeleen/0000 0003 3721 7126
CR Brixen KT, 2004, BASIC CLIN PHARMACOL, V94, P260
   Cubbage CC, 1996, J MORPHOL, V229, P121, DOI 10.1002/(SICI)1097 4687(199608)229:2<121::AID JMOR1>3.0.CO;2 4
   Cushenberry LM, 2002, ANN PHARMACOTHER, V36, P671
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   Dooley K, 2000, CURR OPIN GENET DEV, V10, P252, DOI 10.1016/S0959 437X(00)00074 5
   Du SJ, 2001, DEV BIOL, V238, P239, DOI 10.1006/dbio.2001.0390
   Farber SA, 2001, SCIENCE, V292, P1385, DOI 10.1126/science.1060418
   Fisher S, 1999, NAT GENET, V23, P442, DOI 10.1038/70557
   Fleming A, 2004, DEVELOPMENT, V131, P873, DOI 10.1242/dev.00952
   Flores MV, 2004, GENE EXPR PATTERNS, V4, P573, DOI 10.1016/j.modgep.2004.01.016
   Gensure RC, 2004, ENDOCRINOLOGY, V145, P1634, DOI 10.1210/en.2003 0964
   Goldsmith P, 2004, CURR OPIN PHARMACOL, V4, P504, DOI 10.1016/j.coph.2004.04.005
   Hoare SRJ, 2000, ENDOCRINOLOGY, V141, P3080, DOI 10.1210/en.141.9.3080
   Hodsman AB, 2000, BONE, V27, P311, DOI 10.1016/S8756 3282(00)00316 1
   Hogan BM, 2005, ENDOCRINOLOGY, V146, P547, DOI 10.1210/en.2004 0296
   Huysseune A., 2000, P307, DOI 10.1016/B978 012529650 2/50024 X
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   KELLY WL, 1983, STAIN TECHNOL, V58, P131, DOI 10.3109/10520298309066773
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302
   Kimmel D.B., 1996, OSTEOPOROSIS
   MELTON LJ, 1995, J BONE MINER RES, V10, P175
   Melton LJ, 2004, J BONE MINER RES, V19, P1055, DOI 10.1359/JBMR.040316
   Mitlak BH, 2002, CURR OPIN PHARMACOL, V2, P694, DOI 10.1016/S1471 4892(02)00208 4
   MIYAKE T, 1992, J MORPHOL, V212, P213, DOI 10.1002/jmor.1052120304
   Morin Kensicki EM, 2002, DEVELOPMENT, V129, P3851
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Odenthal J, 1996, DEVELOPMENT, V123, P103
   Ohigashi S, 2003, INTERNAL MED, V42, P1202, DOI 10.2169/internalmedicine.42.1202
   Rubin DA, 1999, J BIOL CHEM, V274, P28185, DOI 10.1074/jbc.274.40.28185
   Sato M, 2002, ENDOCRINOLOGY, V143, P3230, DOI 10.1210/en.2002 220149
   Sato M, 2002, J PHARMACOL EXP THER, V302, P304, DOI 10.1124/jpet.302.1.304
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   Schilling TF, 1996, DEVELOPMENT, V123, P329
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   Tashjian AH, 2002, J BONE MINER RES, V17, P1151, DOI 10.1359/jbmr.2002.17.7.1151
   Thorpe JL, 2004, DEV CELL, V6, P295, DOI 10.1016/S1534 5807(04)00032 2
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   WESTERFIELD M, 1995, ZEBRAFISH BOOK GUIDE
   Witten PE, 2001, J MORPHOL, V250, P197, DOI 10.1002/jmor.1065
NR 40
TC 91
Z9 131
U1 1
U2 28
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087 0571
J9 J BIOMOL SCREEN
JI J. Biomol. Screen
PD DEC
PY 2005
VL 10
IS 8
BP 823
EP 831
DI 10.1177/1087057105279952
PG 9
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry
GA 999RA
UT WOS:000234407000007
PM 16234346
OA hybrid
DA 2025 08 17
ER

PT J
AU Kim, H
   Choe, SA
   Ku, SY
   Kim, SH
   Kim, JG
AF Kim, Hoon
   Choe, Seung Ah
   Ku, Seung Yup
   Kim, Seok Hyun
   Kim, Jung Gu
TI Association between Wnt signaling pathway gene polymorphisms and bone
   response to hormone therapy in postmenopausal Korean women
SO MENOPAUSE THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Hormone therapy; Bone mineral density; Wnt signaling pathway gene;
   Polymorphism; Nonresponder
ID ESTROGEN RECEPTOR ALPHA; VITAMIN D RECEPTOR; MINERAL DENSITY;
   REPLACEMENT THERAPY; MASS; OSTEOPOROSIS; PREVENTION; A1330V; TRIAL; LRP5
AB Objective: The aim of this study was to explore the association between Wnt signaling pathway gene polymorphisms and response to hormone therapy (HT) as related to bone mineral density (BMD) in postmenopausal Korean women.
   Methods: The BMD and serum levels of osteoprotegerin, the soluble receptor activator of the nuclear factor kappa B ligand, and bone turnover markers were measured in 308 postmenopausal women receiving sequential estrogen + progestogen therapy. Results were analyzed according to the low density lipoprotein receptor related protein (LRP5) 5 c.266A > G, c.3893C > T, frizzled receptor 6 gene c.1033A > C, axin II c.148C > T, adenomatous polyposis coli c.5645T > A, and T cell factor 1 c.766G > A polymorphisms.
   Results: The rates of 1 year changes in BMD and changes at 6 months in osteoprotegerin, soluble receptor activator of the nuclear factor kappa B ligand, and bone turnover markers after HT did not differ significantly between all single and haplotype genotypes of the genes studied. When a nonresponder was defined as a woman who had lost more than 3% of BMD per year after HT, women with T allele of the LRP5 c.3893C > T polymorphism showed a significantly higher risk of nonresponse at both the lumbar spine and femoral neck than did women with C allele. The risk of nonresponse at the lumbar spine was significantly higher in women with G allele of the LRP5 c.266A > G polymorphism than that in women with A allele, and the c.266G/c.3893T (GT) haplotype allele showed a similar trend.
   Conclusions: The LRP5 c.266A >9 G and c.3893C > T polymorphisms may be associated with risk of nonresponse to HT in postmenopausal Korean women.
C1 [Choe, Seung Ah; Ku, Seung Yup; Kim, Seok Hyun; Kim, Jung Gu] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 110744, South Korea.
   [Kim, Hoon] Incheon Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea.
   [Ku, Seung Yup; Kim, Seok Hyun; Kim, Jung Gu] Seoul Natl Univ Hosp, Clin Res Inst, Seoul 110744, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital
RP Kim, JG (通讯作者)，Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, 28 Yeungun Dong, Seoul 110744, South Korea.
EM kimjg@plaza.snu.ac.kr
RI ; Choe, Seung Ah/AAD 2282 2020; Ku, Seung Yup/J 5375 2012; Kim,
   Jung/J 5433 2012; Kim, Seok/J 5405 2012
OI Choe, Seung Ah/0000 0001 6270 5020; 
FU Ministry of Health, Welfare and Family Affairs, Republic of Korea
   [A080012]
FX This study was supported by a grant (A080012) from the Korea Health
   Technology R&D project, Ministry of Health, Welfare and Family Affairs,
   Republic of Korea.
CR [Anonymous], NIH CONSENS STATEMEN
   Brodowska A, 2009, GYNECOL ENDOCRINOL, V25, P315, DOI 10.1080/09513590802630138
   Deng HW, 1998, HUM GENET, V103, P576, DOI 10.1007/s004390050872
   Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526
   Ezura Y, 2007, BONE, V40, P997, DOI 10.1016/j.bone.2005.06.025
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   HASSAGER C, 1994, OSTEOPOROSIS INT, V4, P36, DOI 10.1007/BF02352259
   Johnson ML, 2004, J BONE MINER RES, V19, P1749, DOI 10.1359/JBMR.040816
   JOUANNY P, 1995, ARTHRITIS RHEUM, V38, P61, DOI 10.1002/art.1780380110
   Kim JG, 2003, MENOPAUSE, V10, P544, DOI 10.1097/01.GME.0000070525.74726.51
   Kim JG, 2009, J KOREAN MED SCI, V24, P443, DOI 10.3346/jkms.2009.24.3.443
   Komulainen M, 2000, OSTEOPOROSIS INT, V11, P211, DOI 10.1007/s001980050283
   Komulainen M, 1999, J CLIN ENDOCR METAB, V84, P546, DOI 10.1210/jc.84.2.546
   Lee DY, 2010, MENOPAUSE, V17, P1064, DOI 10.1097/gme.0b013e3181da4da3
   Lee YH, 2009, RHEUMATOL INT, V29, P539, DOI 10.1007/s00296 008 0745 y
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Ralston SH, 2010, ANN NY ACAD SCI, V1192, P181, DOI 10.1111/j.1749 6632.2009.05317.x
   Rawadi G, 2005, EXPERT OPIN THER TAR, V9, P1063, DOI 10.1517/14728222.9.5.1063
   Rosen CJ, 2001, RHEUM DIS CLIN N AM, V27, P215, DOI 10.1016/S0889 857X(05)70195 2
   Silvestri S, 2006, MENOPAUSE, V13, P451, DOI 10.1097/01.gme.0000182804.14385.a2
   Sims AM, 2008, J BONE MINER RES, V23, P499, DOI 10.1359/JBMR.071113
   Yim CH, 2005, J BONE MINER METAB, V23, P395, DOI 10.1007/s00774 005 0619 2
   Zhang ZL, 2005, ACTA PHARMACOL SIN, V26, P1111, DOI 10.1111/j.1745 7254.2005.00173.x
NR 23
TC 10
Z9 10
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 1072 3714
J9 MENOPAUSE
JI Menopause J. N. Am. Menopause Soc.
PD JUL
PY 2011
VL 18
IS 7
BP 808
EP 813
DI 10.1097/gme.0b013e318208f9b2
PG 6
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA 781IO
UT WOS:000291924300013
PM 21471826
DA 2025 08 17
ER

PT J
AU Kroon, T
   Bhadouria, N
   Niziolek, P
   Edwards, D 
   Choi, R
   Clinkenbeard, EL
   Robling, A
   Holguin, N
AF Kroon, Tori
   Bhadouria, Neharika
   Niziolek, Paul
   Edwards, Daniel, III
   Choi, Roy
   Clinkenbeard, Erica L.
   Robling, Alexander
   Holguin, Nilsson
TI Suppression of Sost/Sclerostin and Dickkopf 1 Augment Intervertebral
   Disc Structure in Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ANABOLIC THERAPEUTICS; CHONDROCYTE AND CARTILAGE BIOLOGY; GENETIC ANIMAL
   MODELS; PRECLINICAL STUDIES; WNT/beta CATENIN/LRPs
ID BONE FORMATION; NEGATIVE REGULATOR; NOTOCHORDAL CELL; SCLEROSTIN; WNT;
   ACTIVATION; EXPRESSION; DKK1
AB Intervertebral disc (IVD) degeneration is a leading cause of low back pain, characterized by accelerated extracellular matrix breakdown and IVD height loss, but there is no approved pharmacological therapeutic. Deletion of Wnt ligand competitor Lrp5 induces IVD degeneration, suggesting that Wnt signaling is essential for IVD homeostasis. Therefore, the IVD may respond to neutralization of Wnt ligand competitors sost(gene)/sclerostin(protein) and/or dickkopf 1 (dkk1). Anti sclerostin antibody (scl Ab) is an FDA approved bone therapeutic that activates Wnt signaling. We aimed to (i) determine if pharmacological neutralization of sclerostin, dkk1, or their combination would stimulate Wnt signaling and augment IVD structure and (ii) determine the prolonged adaptation of the IVD to global, persistent deletion of sost. Nine week old C57Bl/6J female mice (n   6 7/group) were subcutaneously injected 2x/week for 5.5 weeks with scl Ab (25 mg/kg), dkk1 Ab (25 mg/kg), 3:1 scl Ab/dkk1 Ab (18.75:6.25 mg/kg), or vehicle (veh). Separately, IVD of sost KO and wild type (WT) mice (n   8/group) were harvested at 16 weeks of age. First, compared with vehicle, injection of scl Ab, dkk1 Ab, and 3:1 scl Ab/dkk1 Ab similarly increased lumbar IVD height and beta catenin gene expression. Despite these similarities, only injection of scl Ab alone strengthened IVD mechanical properties and decreased heat shock protein gene expressions. Genetically and compared with WT, sost KO enlarged IVD height, increased proteoglycan staining, and imbibed IVD hydration. Notably, persistent deletion of sost was compensated by upregulation of dkk1, which consequently reduced the cell nuclear fraction for Wnt signaling co transcription factor beta catenin in the IVD. Lastly, RNA sequencing pathway analysis confirmed the compensatory suppression of Wnt signaling and revealed a reduction of cellular stress related pathways. Together, suppression of sost/sclerostin or dkk1 each augmented IVD structure by stimulating Wnt signaling, but scl Ab outperformed dkk1 Ab in strengthening the IVD. Ultimately, postmenopausal women prescribed scl Ab injections to prevent vertebral fracture may also benefit from a restoration of IVD height and health. (C) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
C1 [Kroon, Tori] IUPUI, Dept Biomed Engn, Indianapolis, IN USA.
   [Bhadouria, Neharika] Purdue Univ, Dept Mech Engn, W Lafayette, IN 47907 USA.
   [Niziolek, Paul] IUPUI, Radiol & Imaging Sci, Indianapolis, IN USA.
   [Edwards, Daniel, III; Clinkenbeard, Erica L.; Robling, Alexander; Holguin, Nilsson] Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN USA.
   [Choi, Roy; Robling, Alexander; Holguin, Nilsson] IUPUI, Dept Anat & Cell Biol, Indianapolis, IN USA.
   [Holguin, Nilsson] IUPUI, Dept Mech & Energy Engn, Indianapolis, IN USA.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; Purdue University System; Purdue University; Purdue
   University in Indianapolis; Indiana University System; Indiana
   University Indianapolis; Indiana University System; Indiana University
   Indianapolis; Purdue University System; Purdue University; Purdue
   University in Indianapolis
RP Holguin, N (通讯作者)，Icahn Sch Med Mt Sinai, Dept Orthopaed, 1268 Madison Ave, New York, NY 10025 USA.
EM nilsson.holguin@mssm.edu
RI BHADOURIA, NEHARIKA/MGU 9927 2025; Edwards, Dorothy/L 6720 2016
OI , Daniel F. Edwards III, Daniel F. Edwards, Daniel
   Edwards/0009 0003 4781 0270; Clinkenbeard, Erica/0000 0001 6687 1106;
   BHADOURIA, NEHARIKA/0000 0002 8947 2551
FU Biomedical Research Grant; Biomechanics and Biomaterials Research Center
   grant; Startup; ORS Spine Section Travel Fellowship; Indiana Center for
   Musculoskeletal Health (ICMH)
FX Funding was provided by Biomedical Research Grant (EC), Biomechanics and
   Biomaterials Research Center grant (NH), Startup (NH), and ORS Spine
   Section Travel Fellowship (NB). We thank the Indiana Center for
   Musculoskeletal Health (ICMH) for their support. In addition, we thank
   Washington University in St. Louis for access to the Structure and
   Strength Core. Authors' roles: TK: data curation; formal analysis;
   methodology; writing original draft; writing review and editing. NB:
   data curation; formal analysis; writing original draft. PJN: formal
   analysis; writing original draft. DFE: formal analysis. ELC: data
   curation; formal analysis; methodology; writing original draft;
   writingreview and editing. AGR: methodology; resources; writingoriginal
   draft; writing review and editing. NH: conceptualization; formal
   analysis; funding acquisition; investigation; methodology; project
   administration; resources; supervision; validation; writing original
   draft; writing review and editing.
CR Aigner T, 1998, CALCIFIED TISSUE INT, V63, P263, DOI 10.1007/s002239900524
   [Anonymous], 2019, CASE MED RES, DOI [10.31525/fda2 ucm635653.htm, DOI 10.31525/FDA2 UCM635653.HTM]
   Basso M, 2017, Musculoskelet Surg, V101, P93, DOI 10.1007/s12306 017 0462 3
   BEIGHTON P, 1976, ANN INTERN MED, V84, P393, DOI 10.7326/0003 4819 84 4 393
   Bourhis E, 2010, J BIOL CHEM, V285, P9172, DOI 10.1074/jbc.M109.092130
   Bowles RD, 2017, BIOMATERIALS, V129, P54, DOI 10.1016/j.biomaterials.2017.03.013
   Cappello R, 2006, SPINE, V31, P873, DOI 10.1097/01.brs.0000209302.00820.fd
   Cardinal M, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.705505
   Chooi WH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161615
   Chooi WH, 2016, SCI REP UK, V6, DOI 10.1038/srep26449
   Clinkenbeard EL, 2014, J BONE MINER RES, V29, P361, DOI 10.1002/jbmr.2049
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dowdell J, 2017, NEUROSURGERY, V80, pS46, DOI 10.1093/neuros/nyw078
   Duffy DJ, 2012, DEV BIOL, V362, P271, DOI 10.1016/j.ydbio.2011.11.014
   Ettenberg SA, 2010, P NATL ACAD SCI USA, V107, P15473, DOI 10.1073/pnas.1007428107
   Grunert P, 2014, SPINE, V39, pE369, DOI 10.1097/BRS.0000000000000194
   Hiyama A, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4379
   Hodgkinson T, 2019, JOR SPINE, V2, DOI 10.1002/jsp2.1045
   Holdsworth G, 2019, J MOL ENDOCRINOL, V62, pR167, DOI 10.1530/JME 18 0176
   Holguin N, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29352 3
   Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900
   Holguin N, 2014, BONE, V65, P83, DOI 10.1016/j.bone.2014.05.006
   Holguin N, 2014, J APPL PHYSIOL, V116, P1551, DOI 10.1152/japplphysiol.01322.2013
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kiani C, 2002, CELL RES, V12, P19, DOI 10.1038/sj.cr.7290106
   Kondo N, 2011, SPINE, V36, pE513, DOI 10.1097/BRS.0b013e3181f52cb5
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Liu JW, 2015, J BIOMECH, V48, P2189, DOI 10.1016/j.jbiomech.2015.04.040
   Livshits G, 2010, ANN RHEUM DIS, V69, P2102, DOI 10.1136/ard.2010.131441
   Loibl M, 2019, JOR SPINE, V2, DOI 10.1002/jsp2.1043
   Lojk J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910840
   Maier JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055528
   Marinelli NL, 2009, SPINE, V34, P520, DOI 10.1097/BRS.0b013e318195dd44
   Minogue BM, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2929
   Mundy C, 2011, DEV BIOL, V351, P70, DOI 10.1016/j.ydbio.2010.12.022
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   Silva MJ, 2020, FASEB J, V34, P1970, DOI 10.1096/fj.201902109R
   Smolders LA, 2012, J ORTHOP RES, V30, P950, DOI 10.1002/jor.22000
   Takao T, 2002, SPINE, V27, P361, DOI 10.1097/00007632 200202150 00007
   Tam V, 2018, J ORTHOP RES, V36, P233, DOI 10.1002/jor.23637
   Tomlinson RE, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00646
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   van Dinther M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062295
   Vasiliadis ES, 2014, MOL MED, V20, P400, DOI 10.2119/molmed.2014.00145
   Vo NV, 2016, J ORTHOP RES, V34, P1289, DOI 10.1002/jor.23195
   Wei QS, 2019, CONNECT TISSUE RES, V60, P209, DOI 10.1080/03008207.2018.1499731
   Weivoda MM, 2017, BONE, V96, P45, DOI 10.1016/j.bone.2016.11.024
   Winkler T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098444
   Witcher PC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98673
   Yee CS, 2018, J BONE MINER RES, V33, P1748, DOI 10.1002/jbmr.3467
   Zhou XP, 2018, FASEB J, V32, P6582, DOI 10.1096/fj.201800373R
   Zhu M, 2009, J BONE MINER RES, V24, P12, DOI [10.1359/jbmr.080901, 10.1359/JBMR.080901]
NR 54
TC 10
Z9 10
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2022
VL 37
IS 6
BP 1156
EP 1169
DI 10.1002/jbmr.4546
EA APR 2022
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 1X3LJ
UT WOS:000784046600001
PM 35278242
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Buijs, JT
   Que, I
   Löwik, CWGM
   Papapoulos, SE
   van der Pluijm, G
AF Buijs, Jeroen T.
   Que, Ivo
   Lowik, Clemens W. G. M.
   Papapoulos, Socrates E.
   van der Pluijm, Gabri
TI Inhibition of bone resorption and growth of breast cancer in the bone
   microenvironment
SO BONE
LA English
DT Article
DE Osteoprotegerin; Zoledronic acid; Breast cancer; Bone turnover; Bone
   metastasis
ID ZOLEDRONIC ACID; SKELETAL COMPLICATIONS; PROSTATE CANCER; MURINE MODEL;
   IN VITRO; BISPHOSPHONATES; METASTASES; OSTEOPROTEGERIN; CARCINOMA; CELLS
AB Breast cancer frequently metastasizes to bone, where tumor cells induce osteoclasts to locally destroy bone. During bone resorption, growth factors are locally released that may support bone metastatic growth. Differently from most other tissues, drugs that can limit local turnover, such as bisphosphonates and osteoprotegerin (OPG), are available for bone.
   We examined the hypothesis that inhibition of bone resorption by two different mechanisms may also affect the growth of cancer cells in bone. For this, we tested the effects of high doses of OPG and zoledronic acid (ZOL) on progression of MDA 231 B/Luc+ breast cancer Cells in the bone microenvironment using whole body bioluminescent reporter imaging (BLI).
   Both treatments significantly inhibited the development of radiographically detectable osteolytic lesions. Histologic examination corroborated the radiographic findings, showing that both treatments preserved the integrity of bone trabeculae and prevented bone destruction (significantly higher trabecular bone volumes vs. vehicle). However, whereas practically no TRAcP positive osteoclasts were observed in tibiae preparations of animals treated with Fc OPG.
   TRAcP positive osteoclasts were still present in the animals treated with ZOL. Intra bone tumor burden was reduced with ZOL and Fc OPG treatment. Although there appeared to be a trend for less overall total tumor burden upon treatment with both compounds, this was not significant as assessed by BLI and histomorphometric analysis due to the extramedullary growth of cancer cells which was not affected by these treatments. Collectively, anti resorptive agents with different mechanisms of action   ZOL and OPG   significantly reduced cancer induced osteolysis and intra osseous tumor burden, but failed to restrain local tumor growth. However, interference with the bone micro environmental growth support could still be of therapeutic relevance when given to patients early in the course of bone metastatic disease. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Buijs, Jeroen T.; Que, Ivo; Lowik, Clemens W. G. M.; Papapoulos, Socrates E.; van der Pluijm, Gabri] Leiden Univ, Med Ctr, Dept Endocrinol, NL 2333 ZA Leiden, Netherlands.
   [van der Pluijm, Gabri] Leiden Univ, Med Ctr, Dept Urol, NL 2333 ZA Leiden, Netherlands.
C3 Leiden University   Excl LUMC; Leiden University; Leiden University
   Medical Center (LUMC); Leiden University; Leiden University Medical
   Center (LUMC); Leiden University   Excl LUMC
RP Buijs, JT (通讯作者)，Leiden Univ, Med Ctr, Dept Endocrinol, C4 R,Albinusdreef 2, NL 2333 ZA Leiden, Netherlands.
EM J.T.Buijs@LUMC.nl
RI ; Buijs, Jeroen/E 6082 2011
OI van der Pluijm, Gabri/0000 0002 1351 1884; Buijs,
   Jeroen/0000 0001 5816 9739; 
FU Dutch Cancer Society [RUL 2001 2485]; Amgen Inc. Thousand Oaks, USA
FX This work was supported by Dutch Cancer Society grant RUL 2001 2485 and
   Amgen Inc. Thousand Oaks, CA 91320. USA.
CR Alakangas A, 2002, CALCIFIED TISSUE INT, V70, P40, DOI 10.1007/s002230010047
   ARGUELLO F, 1992, INT J CANCER, V52, P802, DOI 10.1002/ijc.2910520522
   Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Coleman RE, 2005, ANN ONCOL, V16, P687, DOI 10.1093/annonc/mdi162
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Costa L, 2002, J CLIN ONCOL, V20, P850, DOI 10.1200/JCO.20.3.850
   Croucher PI, 2003, CANCER AM CANCER SOC, V97, P818, DOI 10.1002/cncr.11125
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   ELTE JWF, 1986, EUR J CANCER CLIN ON, V22, P493, DOI 10.1016/0277 5379(86)90117 3
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Hill P A, 1998, Br J Orthod, V25, P101
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Jemal A, 2006, CA CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   KOSTENUIK PJ, 1992, CLIN EXP METASTAS, V10, P411, DOI 10.1007/BF00133470
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Michaelson MD, 2005, J CLIN ONCOL, V23, P8219, DOI 10.1200/JCO.2005.02.9579
   Morony S, 2005, ENDOCRINOLOGY, V146, P3235, DOI 10.1210/en.2004 1583
   Morony S, 1999, J BONE MINER RES, V14, P1478, DOI 10.1359/jbmr.1999.14.9.1478
   Morony S, 2001, CANCER RES, V61, P4432
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158
   Paget S., 1889, Cancer Metastasis Rev, V133, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Sasaki A, 1998, INT J CANCER, V77, P279, DOI 10.1002/(SICI)1097 0215(19980717)77:2<279::AID IJC18>3.0.CO;2 6
   SASAKI A, 1995, CANCER RES, V55, P3551
   Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004 1211
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Väänänen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018
   van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008 5472.CAN 04 4188
   Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077
   van der Pluijm G, 2001, AM J PATHOL, V159, P971, DOI 10.1016/S0002 9440(10)61773 7
   Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002 9440(10)64934 6
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zheng Y, 2007, BONE, V40, P471, DOI 10.1016/j.bone.2006.09.016
NR 50
TC 36
Z9 44
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2009
VL 44
IS 2
BP 380
EP 386
DI 10.1016/j.bone.2008.10.047
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 403PN
UT WOS:000263094600022
PM 19041433
DA 2025 08 17
ER

PT J
AU Schmeel, FC
   Schmeel, LC
   Kim, Y
   Schmidt Wolf, IGH
AF Schmeel, Frederic Carsten
   Schmeel, Leonard Christopher
   Kim, Young
   Schmidt Wolf, Ingo G. H.
TI Piceatannol exhibits selective toxicity to multiple myeloma cells and
   influences the Wnt/beta catenin pathway
SO HEMATOLOGICAL ONCOLOGY
LA English
DT Article
DE myeloma; Wnt pathway; Wnt inhibitor; beta catenin; signaling; immuno
   therapy
ID FACTOR KAPPA B; BETA CATENIN; BONE MARROW; TRANSPLANTATION; RESVERATROL;
   PROGRESSION; INHIBITION; LYMPHOMA; DISEASE; KINASE
AB Aberrant activation of Wnt/ catenin signaling promotes development and progression of various malignant neoplasms. Recent studies observed that the Wnt pathway is constitutively active in myeloma cells and promotes an exaggerated proliferation. Thus, the Wnt signaling pathway might be an attractive therapeutic target for multiple myeloma. In this study, we identified piceatannol as an inhibitor of the Wnt/ catenin pathway and as a potent inducer of apoptosis in myeloma cells. Interestingly, healthy cells remained mainly unaffected. These results reveal a significant selective induction of apoptosis by piceatannol and suggest a significant in vivo effect against multiple myeloma. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Schmeel, Frederic Carsten; Schmeel, Leonard Christopher; Kim, Young; Schmidt Wolf, Ingo G. H.] Univ Hosp Bonn, CIO, Dept Internal Med 3, D 53105 Bonn, Germany.
   Univ Hosp Bonn, CIO, D 53105 Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Schmidt Wolf, IGH (通讯作者)，Univ Hosp Bonn, CIO, Sigmund Freud Str 25, D 53105 Bonn, Germany.
EM Ingo.Schmidt Wolf@ukb.uni bonn.de
OI Schmeel, Frederic/0000 0003 0985 1517
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Alas S, 2003, CLIN CANCER RES, V9, P316
   Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004
   [Anonymous], ISRN UROL
   Ashihara E, 2009, CLIN CANCER RES, V15, P2731, DOI 10.1158/1078 0432.CCR 08 1350
   Bharti AC, 2004, BLOOD, V103, P3175, DOI 10.1182/blood 2003 06 2151
   Bringhen S, 2006, EXPERT OPIN INV DRUG, V15, P1565, DOI 10.1517/13543784.15.12.1565
   Cantos E, 2003, J AGR FOOD CHEM, V51, P1208, DOI 10.1021/jf020939z
   Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   Dutta Simmons J, 2009, BLOOD, V114, P2699, DOI 10.1182/blood 2008 12 194290
   FERRIGNI NR, 1984, J NAT PROD, V47, P347, DOI 10.1021/np50032a019
   Fowler JA, 2012, CANCER RES, V72, P2183, DOI 10.1158/0008 5472.CAN 11 2067
   Frost P, 2004, BLOOD, V104, P4181, DOI 10.1182/blood 2004 03 1153
   Harousseau JL, 2009, NEW ENGL J MED, V360, P2645, DOI 10.1056/NEJMct0805626
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   HSUS J, 2001, BLOOD, V98, P2853
   HUS L, 2003, BLOOD, V101, P3126
   Jayasooriya RGPT, 2013, ONCOL LETT, V5, P341, DOI 10.3892/ol.2012.968
   Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003
   KIMS EJ, 2009, J MED FOOD, V12, P943
   KIMS Y, 2011, ANTICANCER RES, V31, P725
   KIMS Y, 2012, LEUKEMIA RES, V36, P598
   KIMS Y, 2011, IN VIVO, V25, P887
   KITA Y, 2012, J BIOMED BIOTECHNOL, V2012, DOI DOI 10.1155/2012/672416
   Kocemba KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030359
   KOS HS, 2012, J AGR FOOD CHEM, V60, P4083
   Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746
   KUS KL, 2005, J AGR FOOD CHEM, V53, P3877
   KWONS GT, 2012, J NUTR BIOCH, V3, P228
   Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099
   Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427
   Moreau P, 2006, BLOOD, V107, P397, DOI 10.1182/blood 2005 06 2573
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Polakis P, 2000, GENE DEV, V14, P1837
   Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239
   Rimando AM, 2004, J AGR FOOD CHEM, V52, P4713, DOI 10.1021/jf040095e
   Rosiñol L, 2008, BLOOD, V112, P3591, DOI 10.1182/blood 2008 02 141598
   Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104
   Takada Y, 2004, J IMMUNOL, V173, P1066, DOI 10.4049/jimmunol.173.2.1066
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Wieder T, 2001, LEUKEMIA, V15, P1735, DOI 10.1038/sj.leu.2402284
   Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006
   Wolter F, 2002, J NUTR, V132, P298
NR 46
TC 23
Z9 27
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0278 0232
EI 1099 1069
J9 HEMATOL ONCOL
JI Hematol. Oncol.
PD DEC
PY 2014
VL 32
IS 4
BP 197
EP 204
DI 10.1002/hon.2122
PG 8
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA AU9LL
UT WOS:000345914200005
PM 24470348
DA 2025 08 17
ER

PT J
AU Smith, HS
   Barkin, RL
AF Smith, Howard S.
   Barkin, Robert L.
TI Painful Boney Metastases
SO AMERICAN JOURNAL OF THERAPEUTICS
LA English
DT Article
DE pain; osseous; bone; cancer; metastases; denosumab; radiation;
   radiopharmaceuticals
ID RESISTANT PROSTATE CANCER; ORALLY ADMINISTERED DICLOFENAC; RANDOMIZED
   CONTROLLED TRIAL; DOUBLE BLIND EVALUATION; PHASE II TRIAL; KINASE C SRC;
   ZOLEDRONIC ACID; BREAST CANCER; CATHEPSIN K; PERCUTANEOUS VERTEBROPLASTY
AB Up to 90% of patients with metastatic or advanced stage cancer will experience significant cancer related pain. Approximately half or more of patients diagnosed with cancer may experience bone pain. It has been estimated that tumor metastases to the skeleton affects roughly 400,000 US citizens annually. Carcinoma from breast, lung, and prostate cancers account for approximately 80% of secondary metastatic bone disease. Bone metastases may cause devastating clinical complications associated with dramatic reductions in quality of life, mobility, and independence, as well as excruciating refractory pain. Associated complications from osseous metastases also present a substantial economic burden. Currently, there are still a significantly high number of patients suffering with unrelieved pain from osseous metastases. Treatments for painful osseous metastases may not only diminish pain but also may improve quality of life and independence/mobility, and reduce skeletal morbidity, potential pathologic fractures, spinal cord compression, and other skeletal related events. Treatment strategies for painful osseous metastases include the following: systemic analgesics, intrathecal analgesics, glucocorticoids, radiation (external beam radiation, radiopharmaceuticals), ablative techniques (radiofrequency ablation and cryoablation), bisphosphonates, chemotherapeutic agents, inhibitors of RANKL RANK interaction (eg, denosumab), hormonal therapies, interventional techniques (eg, kyphoplasty), and surgical approaches. Although the mechanisms underlying the development of bone metastases remain incompletely understood, there appears to be important bi directional interactions between the tumor and the bone microenvironment. A greater understanding of the pathophysiology of painful osseous metastases may lead to better and more selective targeted analgesic therapy. Additionally, potential future therapeutic approaches to painful osseous metastases may revolutionize approaches to analgesia for this condition, leading to optimal outcomes with maximal pain relief and minimal adverse effects.
C1 [Smith, Howard S.] Albany Med Coll, Dept Anesthesiol, Albany, NY 12208 USA.
   [Barkin, Robert L.] Rush Univ, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA.
   [Barkin, Robert L.] Rush Univ, Coll Med, Dept Family Med, Chicago, IL 60612 USA.
   [Barkin, Robert L.] Rush Univ, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA.
   [Barkin, Robert L.] Northshore Univ Hlth Syst, Dept Anaesthesiol, Evanston, IL USA.
   [Barkin, Robert L.] Skokie Hosp Pain Ctr, Skokie, IL USA.
C3 Albany Medical College; Rush University; Rush University; Rush
   University; NorthShore University Health System
RP Smith, HS (通讯作者)，Albany Med Coll, Dept Anesthesiol, 47 New Scotland Ave,MC 131, Albany, NY 12208 USA.
EM smithh@mail.amc.edu
CR Alberts AS, 1997, RADIOTHER ONCOL, V43, P175, DOI 10.1016/S0167 8140(97)01912 9
   Amir E, 2009, CLIN EXP METASTAS, V26, P479, DOI 10.1007/s10585 009 9247 x
   [Anonymous], 1997, MED LETT DRUGS THER, V39, P83
   [Anonymous], 2008, Ninth Periodic Report, P3
   Araujo J, 2009, J CLIN ONCOL, V27
   Araujo J, 2009, INT J CANCER, V124, P1, DOI 10.1002/ijc.23998
   ARCANGELI G, 1989, RADIOTHER ONCOL, V14, P95, DOI 10.1016/0167 8140(89)90053 4
   Barkin RL, 2011, POSTGRAD MED, V123, P143, DOI 10.3810/pgm.2011.09.2470
   Barkin RL, 2010, DRUG AGING, V27, P775, DOI 10.2165/11539430 000000000 00000
   BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210
   BAYOUTH JE, 1994, J NUCL MED, V35, P63
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Berruti A, 2000, J UROLOGY, V164, P1248, DOI 10.1016/S0022 5347(05)67149 2
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   BLAIR HC, 1991, AM J PHYSIOL, V260, pC1315, DOI 10.1152/ajpcell.1991.260.6.C1315
   Body JJ, 2010, BONE, V46, pS36, DOI 10.1016/j.bone.2010.01.078
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Boissier S, 2000, CANCER RES, V60, P2949
   Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079
   Bruera E, 2003, JAMA J AM MED ASSOC, V290, P2476, DOI 10.1001/jama.290.18.2476
   Burton A W, 2001, Pain Pract, V1, P236
   Buvanendran A, 2007, DRUG TODAY, V43, P137, DOI 10.1358/dot.2007.43.3.1062673
   Callstrom MR, 2007, TECH VASC INTERV RAD, V10, P120, DOI 10.1053/j.tvir.2007.09.003
   Caraceni A, 2008, PALLIATIVE MED, V22, P392, DOI 10.1177/0269216308089304
   Caraceni A, 2004, J CLIN ONCOL, V22, P2909, DOI 10.1200/jco.2004.08.141
   Carducci MA, 2003, J CLIN ONCOL, V21, P679, DOI 10.1200/JCO.2003.04.176
   Carducci MA, 2007, CANCER AM CANCER SOC, V110, P1959, DOI 10.1002/cncr.22996
   CASEY ML, 1992, J CLIN ENDOCR METAB, V74, P223, DOI 10.1210/jc.74.1.223
   Chew C, 2011, CLIN RADIOL, V66, P63, DOI 10.1016/j.crad.2010.09.011
   Chow E, 2007, J CLIN ONCOL, V25, P1423, DOI 10.1200/JCO.2006.09.5281
   Cleeland CS, 2010, 33 ANN SAN ANT BREAS
   Clemons MJ, 2006, J CLIN ONCOL, V24, P4895, DOI 10.1200/JCO.2006.05.9212
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   COLLINS C, 1993, J NUCL MED, V34, P1839
   Colvin L, 2008, EUR J CANCER, V44, P1083, DOI 10.1016/j.ejca.2008.03.001
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   Deal C, 2009, CURR OPIN RHEUMATOL, V21, P380, DOI 10.1097/BOR.0b013e32832cbc2a
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Deer T, 2007, NEUROMODULATION, V10, P300, DOI 10.1111/j.1525 1403.2007.00128.x
   Deer TR, 2011, PAIN PHYSICIAN, V14, pE283
   Delaisse Jean Marie, 1992, P289
   Delaney A, 2008, BRIT J ANAESTH, V101, P87, DOI 10.1093/bja/aen100
   Dodd GD, 2001, AM J ROENTGENOL, V177, P777, DOI 10.2214/ajr.177.4.1770777
   Donovan Rodriguez T, 2005, ANESTHESIOLOGY, V102, P132, DOI 10.1097/00000542 200501000 00022
   Dupuy DE, 2000, AM J ROENTGENOL, V175, P1263, DOI 10.2214/ajr.175.5.1751263
   ESTAPE J, 1990, J INT MED RES, V18, P298, DOI 10.1177/030006059001800406
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Everdingen MHJVDBV, 2007, PAIN, V132, P312, DOI 10.1016/j.pain.2007.08.022
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   FARHANGHI M, 1992, J NUCL MED, V33, P1451
   Finlay OG, 2005, LANCET ONCOL, V6, P392, DOI 10.1016/S1470 2045(05)70206 0
   Finley RS, 2002, SEMIN ONCO, V129, P32
   Finn RS, 2008, ANN ONCOL, V19, P1379, DOI 10.1093/annonc/mdn291
   Finn RS, 2007, BREAST CANCER RES TR, V105, P319, DOI 10.1007/s10549 006 9463 x
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   FRIEDELL HL, 1950, AM J ROENTGENOL, V64, P559
   FUCCELLA LM, 1975, CLIN PHARMACOL THER, V17, P277
   Fulfaro F, 1998, PAIN, V78, P157, DOI 10.1016/S0304 3959(98)00135 3
   Fulfaro F, 2005, J CHEMOTHERAPY, V17, P555, DOI 10.1179/joc.2005.17.5.555
   Furlow B, 2006, LANCET ONCOL, V7, P894, DOI 10.1016/S1470 2045(06)70927 5
   Furuse S, 2009, ANESTHESIOLOGY, V111, P173, DOI 10.1097/ALN.0b013e3181a51e0d
   GALASKO CSB, 1982, CLIN ORTHOP RELAT R, P20
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Ghilardi JR, 2010, MOL PAIN, V6, DOI 10.1186/1744 8069 6 87
   Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815 04.2005
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Granot Attas S, 2009, MOL BIOL CELL, V20, P4324, DOI 10.1091/mbc.E08 11 1158
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Halvorson KG, 2005, CANCER RES, V65, P9426, DOI 10.1158/0008 5472.CAN 05 0826
   HANKS GW, 1988, CANCER SURV, V7, P87
   Hawley P, 2009, PAIN RES MANAG, V14, P371, DOI 10.1155/2009/538675
   Heidenreich A, 2008, EUR UROL, V53, P68, DOI 10.1016/j.eururo.2007.09.002
   Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002 9440(10)63712 1
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   HOLMES RA, 1992, SEMIN NUCL MED, V22, P41, DOI 10.1016/S0001 2998(05)80156 4
   Honore P, 2000, PAIN MED, V1, P303, DOI 10.1046/j.1526 4637.2000.00047.x
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Huang EH, 2009, J SURG RES, V155, P231, DOI 10.1016/j.jss.2008.06.044
   Ibrahim MM, 2005, P NATL ACAD SCI USA, V102, P3093, DOI 10.1073/pnas.0409888102
   Ibrahim MM, 2006, PAIN, V122, P36, DOI 10.1016/j.pain.2005.12.018
   Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790
   James ND, 2010, BJU INT, V106, P966, DOI 10.1111/j.1464 410X.2010.09638.x
   James ND, 2009, EUR UROL, V55, P1112, DOI 10.1016/j.eururo.2008.11.002
   Janjan NA, 1998, J PAIN SYMPTOM MANAG, V16, P171, DOI 10.1016/S0885 3924(98)00069 4
   Jansen I, 2006, J BONE MINER RES  S1, V21
   Jensen AB, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.1023
   Jeremic B, 2001, J PAIN SYMPTOM MANAG, V22, P1048, DOI 10.1016/S0885 3924(01)00359 1
   Jimenez Andrade JM, 2010, J NEUROSCI, V30, P14649, DOI 10.1523/JNEUROSCI.3300 10.2010
   Jimenez Andrade JM, 2010, ANN NY ACAD SCI, V1198, P173, DOI 10.1111/j.1749 6632.2009.05429.x
   Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019
   Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003
   Kaan TKY, 2010, BRAIN, V133, P2549, DOI 10.1093/brain/awq194
   Kaisary AV, 2001, PROSTATE CANCER P D, V4, P196, DOI 10.1038/sj.pcan.4500531
   Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Kassamali RH, 2011, ANN ONCOL, V22, P782, DOI 10.1093/annonc/mdq605
   Kawatani M, 2009, CANCER SCI, V100, P1999, DOI 10.1111/j.1349 7006.2009.01294.x
   Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   KOUTSILIERIS M, 1995, CRIT REV ONCOL HEMAT, V18, P51, DOI 10.1016/1040 8428(94)00122 A
   KOUTSILIERIS M, 1993, ANTICANCER RES, V13, P443
   KOUTSILIERIS M, 1992, ANTICANCER RES, V12, P905
   KOUTSILIERIS M, 1993, ANTICANCER RES, V13, P481
   Kraeber Bodéré F, 2000, EUR J NUCL MED, V27, P1487, DOI 10.1007/s002590000315
   Kreeger L, 1999, J PAIN SYMPTOM MANAG, V17, P2
   Lamb HM, 1997, DRUG AGING, V11, P413, DOI 10.2165/00002512 199711050 00007
   Le Gall C, 2007, CANCER RES, V67, P9894, DOI 10.1158/0008 5472.CAN 06 3940
   Lee B, 2009, EUR J CANCER, V45, P1597, DOI 10.1016/j.ejca.2009.01.021
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Liang ZX, 2004, CANCER RES, V64, P4302, DOI 10.1158/0008 5472.CAN 03 3958
   Liepe K, 2009, CURR OPIN INVEST DR, V10, P1346
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Lipton A, 2006, CLIN CANCER RES, V12, p6305S, DOI 10.1158/1078 0432.CCR 06 1157
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Lozano Ondoua AN, 2010, LIFE SCI, V86, P646, DOI 10.1016/j.lfs.2010.02.014
   Malan TP, 2003, CURR OPIN PHARMACOL, V3, P62, DOI 10.1016/S1471 4892(02)00004 8
   Mantyh PW, 2006, NAT REV NEUROSCI, V7, P797, DOI 10.1038/nrn1914
   MARTINEZ MJ, 2003, COCHRANE DB SYST REV
   Martinez Zapata MJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003223.pub2
   Masaki T, 2000, J CARDIOVASC PHARM, V35, pS3, DOI 10.1097/00005344 200000002 00002
   Massi P, 2006, CURR PHARM DESIGN, V12, P3135, DOI 10.2174/138161206777947425
   Meuser Thomas, 2001, Pain, V93, P247, DOI 10.1016/S0304 3959(01)00324 4
   Mikami Y, 2011, JPN J RADIOL, V29, P202, DOI 10.1007/s11604 010 0542 x
   MINOTTI V, 1989, PAIN, V36, P177, DOI 10.1016/0304 3959(89)90021 3
   Minotti V, 1998, PAIN, V74, P133, DOI 10.1016/S0304 3959(97)00157 7
   Mitsiades CS, 2001, EXPERT OPIN INV DRUG, V10, P1099, DOI 10.1517/13543784.10.6.1099
   Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Miyazaki Tsuyoshi, 2006, Mod Rheumatol, V16, P68
   Molina A, 2001, J UROLOGY, V185, P787
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mori K, 2007, BONE, V40, P981, DOI 10.1016/j.bone.2006.11.006
   Mottet N, 2011, EUR UROL, V59, P572, DOI 10.1016/j.eururo.2011.01.025
   Msaouel P, 2008, BEST PRACT RES CL EN, V22, P341, DOI 10.1016/j.beem.2008.01.011
   Mystakidou K, 1999, J PAIN SYMPTOM MANAG, V18, P323, DOI 10.1016/S0885 3924(99)00081 0
   Nelson JB, 2003, J UROLOGY, V170, pS65, DOI 10.1097/01.ju.0000096372.07687.86
   Nelson JB, 2005, WORLD J UROL, V23, P19, DOI 10.1007/s00345 004 0478 9
   Nelson JB, 2003, J UROLOGY, V169, P1143, DOI 10.1097/01.ju.0000042162.08938.27
   NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995 944
   Newsome S, 2008, CURR PAIN HEADACHE R, V12, P249, DOI 10.1007/s11916 008 0043 0
   Niiyama Y, 2007, NEUROSCIENCE, V148, P560, DOI 10.1016/j.neuroscience.2007.05.049
   Niiyama Y, 2009, BRIT J ANAESTH, V102, P251, DOI 10.1093/bja/aen347
   Nishi Y, 1999, J BONE MINER RES, V14, P1902, DOI 10.1359/jbmr.1999.14.11.1902
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Paes FM, 2010, SEMIN NUCL MED, V40, P89, DOI 10.1053/j.semnuclmed.2009.10.003
   Pantano F, 2011, EXPERT OPIN EMERG DR, V16, P403, DOI 10.1517/14728214.2011.588600
   Papachristou DJ, 2012, MED RES REV, V32, P611, DOI 10.1002/med.20224
   Payne R, 1998, PROG PAIN RES MANAG, V12, P269
   Peh WCG, 2003, BRIT J RADIOL, V76, P69, DOI 10.1259/bjr/10254271
   Peh WCG, 2002, RADIOLOGY, V223, P121, DOI 10.1148/radiol.2231010234
   Perlmutter Mark A, 2007, Rev Urol, V9 Suppl 1, pS3
   Pistevou Gombaki K, 2002, J EXP CLIN CANC RES, V21, P429
   POULTER CA, 1992, INT J RADIAT ONCOL, V23, P207, DOI 10.1016/0360 3016(92)90563 W
   Pound CR, 1999, JAMA J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591
   PrayerGaletti T, 1997, J UROLOGY, V157, P2334, DOI 10.1016/S0022 5347(01)64776 1
   PUROHIT OP, 1994, BRIT J CANCER, V70, P554, DOI 10.1038/bjc.1994.344
   Qian ZL, 2011, J CLIN NEUROSCI, V18, P763, DOI 10.1016/j.jocn.2010.09.021
   Rachner TD, 2010, CANCER LETT, V287, P109, DOI 10.1016/j.canlet.2009.06.003
   Rades D, 2010, NAT REV CLIN ONCOL, V7, P220, DOI 10.1038/nrclinonc.2010.17
   Rajesh M, 2007, AM J PHYSIOL HEART C, V293, pH2210, DOI 10.1152/ajpheart.00688.2007
   REYESMORENO C, 1995, PROSTATE, V26, P260, DOI 10.1002/pros.2990260506
   Richert MM, 2009, ONCOL REP, V21, P761, DOI 10.3892/or_00000282
   Robinson R G, 1989, Radiographics, V9, P271
   ROBINSON RG, 1992, SEMIN NUCL MED, V22, P28, DOI 10.1016/S0001 2998(05)80154 0
   Romero Sandoval A, 2008, ANESTHESIOLOGY, V108, P722, DOI 10.1097/ALN.0b013e318167af74
   Figuls MRI, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003347.pub2
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rucci N, 2008, ANTI CANCER AGENT ME, V8, P342, DOI 10.2174/187152008783961905
   Rucci N, 2006, J PHARMACOL EXP THER, V318, P161, DOI 10.1124/jpet.106.102004
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Sabino MAC, 2002, CANCER RES, V62, P7343
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Saliou G, 2010, RADIOLOGY, V254, P882, DOI 10.1148/radiol.09081698
   Santini D, 2010, CANCER TREAT REV, V36, pS6, DOI 10.1016/S0305 7372(10)70013 X
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   Santini D, 2006, EXPERT OPIN BIOL TH, V6, P1333, DOI 10.1517/14712598.6.12.1333
   Sartor O, 2007, CANCER AM CANCER SOC, V109, P637, DOI 10.1002/cncr.22431
   Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140 6736(10)60172 9
   Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835
   Schwarz EM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2171
   Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756 3282(99)00278 1
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Sharifi N, 2010, ENDOCR RELAT CANCER, V17, pR305, DOI 10.1677/ERC 10 0187
   Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400
   SILBERSTEIN EB, 1993, SEMIN ONCOL, V20, P10
   SILBERSTEIN EB, 1985, J NUCL MED, V26, P345
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SLY WS, 1983, P NATL ACAD SCI BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752
   Smith Howard, 2004, Am J Hosp Palliat Care, V21, P303, DOI 10.1177/104990910402100415
   Smith HS, 2008, PAIN PHYSICIAN, V11, pS89
   Smith HS, 2003, DRUGS PAIN, P489
   Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008 5472.CAN 04 1844
   Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Stambaugh J, 1988, J Clin Pharmacol, V28, pS34
   STAQUET MJ, 1989, J CLIN PHARMACOL, V29, P1031, DOI 10.1002/j.1552 4604.1989.tb03274.x
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Sumitani H, 2001, J ORAL PATHOL MED, V30, P41, DOI 10.1034/j.1600 0714.2001.300107.x
   Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109
   Sunshine A, 1988, J Clin Pharmacol, V28, pS47
   Sze WM, 2003, CLIN ONCOL UK, V15, P345, DOI 10.1016/S0936 6555(03)00113 4
   Tancioni Flavio, 2011, J Support Oncol, V9, P4, DOI 10.1016/j.suponc.2011.01.001
   Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   TETI A, 1989, J CLIN INVEST, V83, P227, DOI 10.1172/JCI113863
   Thompson SWN, 2000, NAT MED, V6, P504, DOI 10.1038/74977
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   TONG D, 1982, CANCER AM CANCER SOC, V50, P893, DOI 10.1002/1097 0142(19820901)50:5<893::AID CNCR2820500515>3.0.CO;2 Y
   Tsavaris N, 2006, ONCOL REP, V16, P871
   Vallejo R, 2011, PAIN PHYSICIAN, V14, pE343
   Van Poppel Hendrik, 2010, Cancer Manag Res, V2, P39
   VENTAFRIDDA V, 1975, CLIN PHARMACOL THER, V17, P284
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Vincenzi B, 2005, J INTERF CYTOK RES, V25, P144, DOI 10.1089/jir.2005.25.144
   von Moos R, 2008, SUPPORT CARE CANCER, V16, P1105, DOI 10.1007/s00520 008 0487 0
   Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396
   Walley J, 2006, P BRIT PAIN SOC, pA45
   Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555 006 9019 x
   Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009 0009
   Whiteside GT, 2007, CURR MED CHEM, V14, P917, DOI 10.2174/092986707780363023
   Wilson NM, 2011, BRAIN BEHAV IMMUN, V25, P565, DOI 10.1016/j.bbi.2010.12.014
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Woodward JKL, 2005, ANTI CANCER DRUG, V16, P845, DOI 10.1097/01.cad.0000175582.01446.6f
   Wu JSY, 2003, INT J RADIAT ONCOL, V55, P594, DOI 10.1016/S0360 3016(02)04147 0
   Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366
   ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304 3959(95)00017 M
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
   Zivi A, 2010, CLIN GENITOURIN CANC, V8, P17, DOI 10.3816/CGC.2010.n.003
NR 236
TC 23
Z9 29
U1 1
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1075 2765
EI 1536 3686
J9 AM J THER
JI Am. J. Ther.
PD MAR APR
PY 2014
VL 21
IS 2
BP 106
EP 130
DI 10.1097/MJT.0b013e3182456dff
PG 25
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AC9EA
UT WOS:000332835900020
PM 23344095
OA Green Published
DA 2025 08 17
ER

PT J
AU Keller, H
   Kneissel, M
AF Keller, H
   Kneissel, M
TI SOST is a target gene for PTH in bone
SO BONE
LA English
DT Article
DE PTH and PTH/RP; osteoblasts; gene expression; histomorphometry animal
ID OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE 1 34; ANABOLIC
   ACTION; GROWTH FACTOR; INTERMITTENT TREATMENT; OSTEOPROGENITOR CELLS;
   CANCELLOUS BONE; TRABECULAR BONE; EXPRESSION; OSTEOPROTEGERIN
AB Intermittent parathyroid hormone (PTH) application is an established pharmacological principle to Stimulate bone formation. Yet, the molecular mechanisms underlying this bone anabolic action are not fully understood. Recently, SOST (sclerostin) was identified as a potent osteocyte expressed negative regulator of bone formation in vitro, in murine models and in patients with the bone overgrowth disorders Sclerosteosis and Van Buchem disease. Therefore, we have studied the impact of PTH on SOST regulation. First, we analyzed SOST expression during PTH induced bone formation in a classical model of local bone formation. 8 month old mice received intermittently 100 nM hPTH(1 34) or vehicle onto the calvaria for 5 days. PTH stimulated bone formation as assessed by fluorochrome marker based histomorphometry. SOST expression was reduced in PTH treated calvariae 4 h after the last administration as evaluated by real time quantitative PCR. Next, we observed a decrease of SOST expression in femoral cortical bone of 6 month old rats following single subcutaneous systemic administration of 80 mu g/kg PTH(1 34). Finally, we studied SOST mRNA expression in bone of I I month old osteopenic estrogen deprived (OVX) rats following 8 week systemic intermittent administration of 5 mu g/kg PTH(1 34). PTH treated animals displayed increases in bone mineral density as detected by pQCT, while SOST mRNA levels were decreased compared to vehicle treated OVX and SHAM controls. PTH decreased SOST expression also in vitro. 100 nM PTH(1 34) inhibited expression in mouse calvaria organ cultures and in osteoblastic UMR 106 cells within 6 It by 95%. An IC50 of 1 nM was determined for PTH(1 34) in UMR 106 cells, whereas the PTH antagonist (D Trp(12), Tyr(34)) bPTH(7 34) did not efficiently reduce SOST expression. Furthermore, SOST inhibition by PTH was not blocked by the protein synthesis inhibitor cycloheximide, indicating direct regulation, and PTH did not influence SOST mRNA degradation, implying transcriptional regulation. Finally, we observed full Suppression of SOST by the cAMP inducer forskolin, partial inhibition by ionomycin, and no effect with PMA, indicating that PTH action is mainly mediated via the cAMP/PKA pathway. In summary, we have shown that PTH directly inhibits SOST transcription in vivo and in vitro, suggesting that SOST regulation may play a role in mediating PTH action in bone. (c) 2005 Elsevier Inc. All rights reserved.
C1 Novartis Inst BioMed Res, Bone & Cartilage Unit, CH 4002 Basel, Switzerland.
C3 Novartis
RP Keller, H (通讯作者)，Novartis Inst BioMed Res, Bone & Cartilage Unit, WKL 125 9 02, CH 4002 Basel, Switzerland.
EM hansjoerg.keller@novartis.com; michaela.kneissel@novartis.com
CR ArmamentoVillareal R, 1997, J BONE MINER RES, V12, P384, DOI 10.1359/jbmr.1997.12.3.384
   Avsian Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003 0227
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   Bodine PVN, 1996, ENDOCRINOLOGY, V137, P4592, DOI 10.1210/en.137.11.4592
   BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo 125 3 1142
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Chen HL, 2002, J BIOL CHEM, V277, P19374, DOI 10.1074/jbc.M108913200
   Demiralp B, 2002, ENDOCRINOLOGY, V143, P4038, DOI 10.1210/en.2002 220221
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Garrett IR, 2003, METH MOLEC MED, V80, P183
   GOLDMAN ME, 1988, ENDOCRINOLOGY, V123, P2597, DOI 10.1210/endo 123 5 2597
   Gray C, 1998, BONE, V23, P453, DOI 10.1016/S8756 3282(98)00129 X
   Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399 0004.2003.00036.x
   Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743
   HU ZW, 1993, MOL PHARMACOL, V44, P1105
   Isogai Y, 1996, J BONE MINER RES, V11, P1384
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kneissel M, 2001, BONE, V28, P237, DOI 10.1016/S8756 3282(00)00448 8
   Kondo H, 1997, J BONE MINER RES, V12, P2089, DOI 10.1359/jbmr.1997.12.12.2089
   Kostenuik PJ, 1999, J BONE MINER RES, V14, P21, DOI 10.1359/jbmr.1999.14.1.21
   Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002 0225
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Langub MC, 2001, J BONE MINER RES, V16, P448, DOI 10.1359/jbmr.2001.16.3.448
   LEAFFER D, 1995, ENDOCRINOLOGY, V136, P3624, DOI 10.1210/en.136.8.3624
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Liang JD, 1999, CALCIFIED TISSUE INT, V65, P369, DOI 10.1007/s002239900715
   MARSHALL MJ, 2003, BONE RES PROTOCOLS, P169
   McClelland P, 1998, J CELL BIOCHEM, V70, P391
   Meng XW, 1996, J BONE MINER RES, V11, P421
   Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P4349, DOI 10.1210/en.142.10.4349
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   NISHIDA S, 1994, BONE, V15, P717, DOI 10.1016/8756 3282(94)90322 0
   ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756 3282(95)00332 2
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   RIXON RH, 1994, J BONE MINER RES, V9, P1179
   SCHMIDT IU, 1995, ENDOCRINOLOGY, V136, P5127, DOI 10.1210/en.136.11.5127
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sutherland MK, 2004, BONE, V35, P448, DOI 10.1016/j.bone.2004.04.019
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Wergedal JE, 2003, J CLIN ENDOCR METAB, V88, P5778, DOI 10.1210/jc.2003 030201
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Wronski TJ, 2001, J BONE MINER RES, V16, P1399, DOI 10.1359/jbmr.2001.16.8.1399
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 51
TC 474
Z9 545
U1 1
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2005
VL 37
IS 2
BP 148
EP 158
DI 10.1016/j.bone.2005.03.018
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 951RQ
UT WOS:000230948800002
PM 15946907
DA 2025 08 17
ER

PT J
AU He, YZ
   Childress, P
   Hood, M
   Alvarez, M
   Kacena, MA
   Hanlon, M
   McKee, B
   Bidwell, JP
   Yang, FC
AF He, Yongzheng
   Childress, Paul
   Hood, Mark, Jr.
   Alvarez, Marta
   Kacena, Melissa A.
   Hanlon, Michael
   McKee, Bryce
   Bidwell, Joseph P.
   Yang, Feng Chun
TI Nmp4/CIZ Suppresses the Parathyroid Hormone Anabolic Window by
   Restricting Mesenchymal Stem Cell and Osteoprogenitor Frequency
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID BONE MARROW; T CELLS; CFU GM; DIFFERENTIATION; OSTEOBLAST;
   PROLIFERATION; PTH; OSTEOPOROSIS; TRANSIENT; PROTEIN
AB Parathyroid hormone (PTH) anabolic osteoporosis therapy is intrinsically limited by unknown mechanisms. We previously showed that disabling the transcription factor Nmp4/CIZ in mice expanded this anabolic window while modestly elevating bone resorption. This enhanced bone formation requires a lag period to materialize. Wild type (WT) and Nmp4 knockout (KO) mice exhibited equivalent PTH induced increases in bone at 2 weeks of treatment, but by 7 weeks, the null mice showed more new bone. At 3 week treatment, serum osteocalcin, a bone formation marker, peaked in WT mice, but continued to increase in null mice. To determine if 3 weeks is the time when the addition of new bone diverges and to investigate its cellular basis, we treated 10 week old null and WT animals with human PTH (1 34) (30 mu g/kg/day) or vehicle before analyzing femoral trabecular architecture and bone marrow (BM) and peripheral blood phenotypic cell profiles. PTH treated Nmp4 KO mice gained over 2 fold more femoral trabecular bone than WT by 3 weeks. There was no difference between genotypes in BM cellularity or profiles of several blood elements. However, the KO mice exhibited a significant elevation in CFU F cells, CFU FAlkPhos+ cells (osteoprogenitors), and a higher percentage of CFU FAlkPhos+ cells/CFU F cells consistent with an increase in CD45 /CD146+/CD105+/nestin+ mesenchymal stem cell frequency. Null BM exhibited a 2 fold enhancement in CD8+ T cells known to support osteoprogenitor differentiation and a 1.6 fold increase in CFU GM colonies (osteoclast progenitors). We propose that Nmp4/CIZ limits the PTH anabolic window by restricting the number of BM stem, progenitor, and blood cells that support anabolic bone remodeling.
C1 [He, Yongzheng; Yang, Feng Chun] Indiana Univ, Dept Pediat, Sch Med, Indianapolis, IN 46202 USA.
   [He, Yongzheng; Yang, Feng Chun] Herman B Wells Ctr Pediat Res, Indianapolis, IN USA.
   [Childress, Paul; Hood, Mark, Jr.; Alvarez, Marta; Hanlon, Michael; McKee, Bryce; Bidwell, Joseph P.; Yang, Feng Chun] Indiana Univ, Dept Anat & Cell Biol, Sch Med, Indianapolis, IN 46202 USA.
   [Kacena, Melissa A.] Indiana Univ, Dept Orthopaed Surg, Sch Med, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Indianapolis; Indiana
   University System; Indiana University Indianapolis; Indiana University
   System; Indiana University Indianapolis
RP Yang, FC (通讯作者)，Indiana Univ, Dept Pediat, Sch Med, R4 427,1044 W Walnut St, Indianapolis, IN 46202 USA.
EM jbidwell@iupui.edu; fyang@iupui.edu
RI Childress, Paul/AAD 4684 2020
FU Leukemia & Lymphoma Society [6234 12]; Department of Defense [NF100087];
   NIH National Institute of Diabetes and Digestive and Kidney Diseases
   (NIDDK) [DK053796]
FX This work was supported by grants from the Leukemia & Lymphoma Society
   (6234 12, FCY), Department of Defense (NF100087, FCY), and from NIH
   National Institute of Diabetes and Digestive and Kidney Diseases
   (NIDDK), contract grant number DK053796 (JPB).
CR Allen MR, 2006, CLIN REV BONE MINER, V4, P259, DOI 10.1385/BMM:4:4:259
   Alvarez MB, 2012, J CELL PHYSIOL, V227, P1873, DOI 10.1002/jcp.22915
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Becker TC, 2005, J IMMUNOL, V174, P1269, DOI 10.4049/jimmunol.174.3.1269
   Bedi B, 2012, P NATL ACAD SCI USA, V109, pE725, DOI 10.1073/pnas.1120735109
   Bilezikian John P, 2008, Curr Osteoporos Rep, V6, P24, DOI 10.1007/s11914 008 0005 9
   Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019
   Childress P, 2011, CALCIFIED TISSUE INT, V89, P74, DOI 10.1007/s00223 011 9496 y
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Cusano N.E., 2010, IBMS BoneKEy, V7, P84
   Cusano NE, 2011, CURR MED RES OPIN, V27, P1705, DOI 10.1185/03007995.2011.599837
   Ding M, 2000, BONE, V26, P291, DOI 10.1016/S8756 3282(99)00281 1
   Friedenstein AJ., 1988, CIBA F SYMP, P42
   Herndler Brandstetter D, 2011, J IMMUNOL, V186, P6965, DOI 10.4049/jimmunol.1100243
   Hodge JM, 2004, J BONE MINER RES, V19, P190, DOI 10.1359/JBMR.0301232
   Isogai Y, 1996, J BONE MINER RES, V11, P1384
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Karreth F, 2004, DEVELOPMENT, V131, P5717, DOI 10.1242/dev.01414
   Krane SM, 2005, J EXP MED, V201, P841, DOI 10.1084/jem.20050354
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Mazo IB, 2005, IMMUNITY, V22, P259, DOI 10.1016/j.immuni.2005.01.008
   Menaa C, 2000, BIOCHEM BIOPH RES CO, V267, P943, DOI 10.1006/bbrc.1999.2042
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Morinobu M, 2005, J EXP MED, V201, P961, DOI 10.1084/jem.20041097
   NISHIDA S, 1994, BONE, V15, P717, DOI 10.1016/8756 3282(94)90322 0
   Niziolek PJ, 2009, J CELL PHYSIOL, V221, P579, DOI 10.1002/jcp.21887
   Onyia JE, 1997, BONE, V20, P93, DOI 10.1016/S8756 3282(96)00350 X
   Qin L, 2005, J BIOL CHEM, V280, P3974, DOI 10.1074/jbc.M409807200
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Robling AG, 2009, J CELL PHYSIOL, V219, P734, DOI 10.1002/jcp.21717
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Satija NK, 2007, STEM CELLS DEV, V16, P7, DOI 10.1089/scd.2006.9998
   Shen ZJ, 2002, J BIOL CHEM, V277, P29840, DOI 10.1074/jbc.M203157200
   Silverman S, 2012, OSTEOPOROSIS INT, V23, P797, DOI 10.1007/s00198 011 1775 y
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Thunyakitpisal P, 2001, J BONE MINER RES, V16, P10, DOI 10.1359/jbmr.2001.16.1.10
   Trivedi R, 2010, EXPERT OPIN INV DRUG, V19, P995, DOI 10.1517/13543784.2010.501077
   Wang YH, 2005, J BONE MINER RES, V20, P5, DOI 10.1359/JBMR.041016
   Wang YH, 2007, AM J PHYSIOL ENDOC M, V292, pE594, DOI 10.1152/ajpendo.00216.2006
   Yang FC, 1998, BLOOD, V92, P4632, DOI 10.1182/blood.V92.12.4632.424k28_4632_4640
   Yang ZQ, 2010, J CELL PHYSIOL, V223, P435, DOI 10.1002/jcp.22057
NR 41
TC 15
Z9 21
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD FEB
PY 2013
VL 22
IS 3
BP 492
EP 500
DI 10.1089/scd.2012.0308
PG 9
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 072MX
UT WOS:000313677000013
PM 22873745
OA Green Published
DA 2025 08 17
ER

PT J
AU Wu, XX
   Fu, X
   Qin, XB
AF Wu, Xiaoxiao
   Fu, Xi
   Qin, Xiabing
TI Effect of Icariin on Osteoclasts and Its Mechanism
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE Icariin; Osteoclasts; Bone Differentiation; Bone Resorption; RANKL
ID DC STAMP
AB Background: The paper aimed to elucidate the molecular mechanism of Icariin regulating RANKL induced osteoclast ogenesis and bone resorption, and to investigate whether Icariin could be a potential therapeutic drug for diseases of bone loss related to osteoclast. Material and methods: Osteoclasts were cultured. MTT to determine cell viability. Von Kossa to determine the effect of Icariin on bone resorption. F actin ring staining to measure the expressions of various proteins, and WB method was used to measure the expression of p 65. Results: MTT showed that Icariin is not toxic to osteoclasts. The bone resorption result showed that RANKL mediated osteoclast bone resorption was reduced in the early stage, and the higher the intervention concentration, the smaller the bone resorption area. F actin ring staining indicated that it is possible to reduce the differentiation and bone resorption capacity of osteoclasts by hindering the formation of F actin ring in the early stage, and in a concentration dependent manner. Significantly reduced the expressions of key transcription factors NFATc1 and c Fos. It significantly inhibited the phosphorylation and nucleation of NF kappa B subunit p65 induced by RANKL, and significantly inhibited the phosphorylation of ERK and p38 proteins in the MAPK pathway activated by RANKL. Conclusion: lcariin can effectively inhibit osteoclast differentiation, F actin ring formation, and bone resorption. By inhibiting the key transcription factors NFATc1 and c Fos to down regulate related expressions, thereby impeding osteoclast differentiation, Icariin may regulate key transcription factors NFATc1 and c Fos through NF kappa B and MAPK signaling pathways. Studies have suggested that lcariin could be a potential treatment for diseases of bone loss related to osteoclasts.
C1 [Wu, Xiaoxiao; Qin, Xiabing] Hubei Univ Med, Dept Orthoped, Affiliated Taihe Hosp, Shiyan City 442000, Hubei, Peoples R China.
   [Fu, Xi] Hubei Univ Med, Dept Rehabil, Affiliated Taihe Hosp, Shiyan City 442000, Hubei, Peoples R China.
C3 Hubei University of Medicine; Hubei University of Medicine
RP Qin, XB (通讯作者)，Hubei Univ Med, Dept Orthoped, Affiliated Taihe Hosp, Shiyan City 442000, Hubei, Peoples R China.
CR Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chiu YH, 2016, J CELL PHYSIOL, V231, P2402, DOI 10.1002/jcp.25389
   Gao E, 2017, J NAT PROD, V80, P2923, DOI 10.1021/acs.jnatprod.7b00457
   Garcia Caballero A, 2016, MOL PAIN, V12, DOI 10.1177/1744806916642444
   Hiligsmann M, 2012, ARTHRIT CARE RES, V64, P744, DOI 10.1002/acr.21607
   Jin ZX, 2015, MOL ENDOCRINOL, V29, P172, DOI 10.1210/me.2014 1316
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Liu SJ, 2016, DRUG DES DEV THER, V10, P1461, DOI 10.2147/DDDT.S93559
   Lupsa BC, 2015, ENDOCRIN METAB CLIN, V44, P517, DOI 10.1016/j.ecl.2015.05.002
   Mansour A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00954
   Marino Silvia, 2014, Bonekey Rep, V3, P570, DOI 10.1038/bonekey.2014.65
   Ning BL, 2019, NEUROCHEM RES, V44, P1159, DOI 10.1007/s11064 019 02757 w
   Park JH, 2017, MOL CELLS, V40, P706
   Ruscitti P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/782382
   Takito J, 2015, J CELL PHYSIOL, V230, P395, DOI 10.1002/jcp.24723
   Yang YX, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/8516518
   Zhang CC, 2014, J CELL PHYSIOL, V229, P1330, DOI 10.1002/jcp.24553
NR 17
TC 1
Z9 2
U1 1
U2 19
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2157 9083
EI 2157 9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD DEC
PY 2020
VL 10
IS 12
BP 1807
EP 1812
DI 10.1166/jbt.2020.2509
PG 6
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA PU0DZ
UT WOS:000608979500011
DA 2025 08 17
ER

PT J
AU Chen, Q
   Yao, Y
   Chen, K
   Chen, XH
   Li, BW
   Li, R
   Mo, LDZ
   Hu, WH
   Zhang, MJ
   Wang, Z
   Wu, YP
   Wu, YM
   Liu, FF
AF Chen, Qi
   Yao, Yan
   Chen, Kun
   Chen, Xihui
   Li, Bowen
   Li, Rui
   Mo, Lidangzhi
   Hu, Weihong
   Zhang, Mengjie
   Wang, Zhen
   Wu, Yaoping
   Wu, Yuanming
   Liu, Fangfang
TI Aberrant activation of TGF β1 induces high bone turnover via Rho
   GTPases mediated cytoskeletal remodeling in Camurati Engelmann disease
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE Camurati Engelmann disease; osteoclast; TGF beta 1; Rho GTPases;
   cytoskeletal remodeling
ID LATENCY ASSOCIATED PEPTIDE; MESENCHYMAL STEM CELLS; TRANSFORMING
   GROWTH FACTOR BETA 1; TGF BETA; CHINESE FAMILY; MUTATION; GENE;
   OSTEOCLASTS; DIAGNOSIS
AB In the adult skeleton, the bone remodeling process involves a dynamic coordination between osteoblasts and osteoclasts, which is disrupted in diseases with high bone turnover rates and dysregulated transforming growth factor beta 1 (TGF beta 1). However, little is known about how TGF beta 1 signaling mediates bone resorption. Here, we described a pedigree with a heterozygous variant in TGF beta 1 (R218C) that resulted in aberrant activation of TGF beta 1 through an activating mechanism that caused Camurati Engelmann disease (CED). We showed that CED patients have high levels of active Rho GTPases and the migration related proteins Integrin beta 1 and Integrin beta 3 in their peripheral blood. HEK293T cells transfected with a plasmid encoding this mutant expressed high levels of TGF beta 1 and active Rho GTPases. Furthermore, activation of Rho by TGF beta 1 increased osteoclast formation and bone resorption, with increased migration of pre osteoclasts, as well as cytoskeletal remodeling of pre osteoclasts and mature osteoclasts. Importantly, pharmacological inhibition of Rho GTPases effectively rescued hyperactive TGF beta 1 induced osteoclastogenesis in vitro. Overall, we propose that Rho GTPases mediate TGF beta 1 induced osteoclastogenesis and suggest that Rho TGF beta 1 crosstalk is associated with high bone turnover in CED.
C1 [Chen, Qi; Yao, Yan; Chen, Xihui; Li, Bowen; Li, Rui; Mo, Lidangzhi; Wu, Yuanming] Air Force Med Univ, Sch Basic Med, Dept Biochem & Mol Biol, Xian, Peoples R China.
   [Chen, Qi; Chen, Xihui; Li, Bowen; Li, Rui; Mo, Lidangzhi; Wu, Yuanming] Air Force Med Univ, Shaanxi Prov Key Lab Clin Genet, Xian, Peoples R China.
   [Yao, Yan; Hu, Weihong; Zhang, Mengjie] Yanan Univ, Dept Cell Biol & Genet, Med Coll, Yanan, Peoples R China.
   [Chen, Kun] Air Force Med Univ, Sch Basic Med, Dept Anat Histol & Embryol & KK Leung Brain Res Ct, Xian, Peoples R China.
   [Wang, Zhen; Wu, Yaoping] Air Force Med Univ, Affiliated Hosp 1, Dept Orthoped, Xian, Peoples R China.
   [Liu, Fangfang] Air Force Med Univ, Sch Basic Med, Dept Neurobiol, Xian, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Yanan
   University; Air Force Medical University; Air Force Medical University;
   Air Force Medical University
RP Wu, YM (通讯作者)，Air Force Med Univ, Sch Basic Med, Dept Biochem & Mol Biol, Xian, Peoples R China.; Wu, YM (通讯作者)，Air Force Med Univ, Shaanxi Prov Key Lab Clin Genet, Xian, Peoples R China.; Wu, YP (通讯作者)，Air Force Med Univ, Affiliated Hosp 1, Dept Orthoped, Xian, Peoples R China.; Liu, FF (通讯作者)，Air Force Med Univ, Sch Basic Med, Dept Neurobiol, Xian, Peoples R China.
EM horikawadavid@vip.Sina.com; wuym@fmmu.edu.cn; lianpipi@fmmu.edu.cn
RI Wang, Zhen/A 2389 2011; liu, fangfang/AAI 1172 2019
FU Key Innovative Project in Shaanxi; National Natural Science Foundation
   of China;  [2019SF 059];  [2020SF 204];  [2021ZDLSF02 02];  [81671476]; 
   [31570906]
FX Funding This study was supported by grant/award in Shaanxi (Grant/Award
   Number: 2019SF 059 and 2020SF 204), the Key Innovative Project in
   Shaanxi (Grant/Award Number: 2021ZDLSF02 02) and the National Natural
   Science Foundation of China (Grant/Award Number: 81671476 and 31570906).
CR Almpani K, 2022, J MED GENET, V59, P938, DOI 10.1136/jmedgenet 2021 107695
   Araújo Jorge TC, 2002, J INFECT DIS, V186, P1823, DOI 10.1086/345882
   Campos Xavier AB, 2001, HUM GENET, V109, P653, DOI 10.1007/s00439 001 0644 8
   Carlson ML, 2010, ARCH OTOLARYNGOL, V136, P566, DOI 10.1001/archoto.2010.68
   Castro GRW, 2005, CLIN RHEUMATOL, V24, P398, DOI 10.1007/s10067 004 1056 7
   Chen Y, 2017, MOL MED REP, V15, P235, DOI 10.3892/mmr.2016.6024
   Combier A, 2018, JOINT BONE SPINE, V85, P649, DOI 10.1016/j.jbspin.2018.01.015
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Das A, 2021, J BONE MINER RES, V36, P199, DOI 10.1002/jbmr.4165
   Fabregat I, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00357
   Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082
   Goggs R, 2015, BIOCHEM J, V466, P431, DOI 10.1042/BJ20141404
   Gori I, 2021, ELIFE, V10, DOI 10.7554/eLife.63545
   Iba K, 2008, J BONE MINER METAB, V26, P107, DOI 10.1007/s00774 007 0783 7
   Ichimura S, 2017, EXP ANIM TOKYO, V66, P137, DOI 10.1538/expanim.16 0085
   Iqbal J, 2009, NAT MED, V15, P729, DOI 10.1038/nm0709 729
   Janssens K, 2000, NAT GENET, V26, P273, DOI 10.1038/81563
   Janssens K, 2006, J MED GENET, V43, P1, DOI 10.1136/jmg.2005.033522
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Janssens K, 2003, J BIOL CHEM, V278, P7718, DOI 10.1074/jbc.M208857200
   Jeong KJ, 2012, ONCOGENE, V31, P4279, DOI 10.1038/onc.2011.595
   Khan R, 2006, IMMUNOLOGY, V118, P10, DOI 10.1111/j.1365 2567.2006.02336.x
   Kim JM, 2016, MOL CELL ENDOCRINOL, V437, P261, DOI 10.1016/j.mce.2016.08.042
   Kim YM, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010309
   Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128
   McGowan NWA, 2003, J CLIN ENDOCR METAB, V88, P3321, DOI 10.1210/jc.2002 020564
   Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441 011 1201 y
   Ota K, 2013, ENDOCRINOLOGY, V154, P3745, DOI 10.1210/en.2013 1272
   Pardali E, 2010, TRENDS CELL BIOL, V20, P556, DOI 10.1016/j.tcb.2010.06.006
   Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04 06 0522
   Shao JS, 2006, ARTERIOSCL THROM VAS, V26, P1423, DOI 10.1161/01.ATV.0000220441.42041.20
   Shi W, 2021, CELL REGEN, V10, DOI 10.1186/s13619 020 00071 3
   Simsek Kiper PO, 2014, AM J MED GENET A, V164, P2667, DOI 10.1002/ajmg.a.36692
   Strzelecka Kiliszek A, 2017, BBA GEN SUBJECTS, V1861, P1009, DOI 10.1016/j.bbagen.2017.02.005
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tu S, 2019, CELLS BASEL, V8, DOI 10.3390/cells8101235
   Verstraeten A, 2016, HUM MUTAT, V37, P524, DOI 10.1002/humu.22977
   Wakle M., 2012, ELECTRON J BIOL, V8, P15
   Walton KL, 2010, J BIOL CHEM, V285, P17029, DOI 10.1074/jbc.M110.110288
   Wang GY, 2005, J BONE MINER RES, V20, P1022, DOI 10.1359/JBMR.050113
   Wang L, 2021, NAT GENET, V53, P500, DOI 10.1038/s41588 021 00803 4
   Wang YF, 2014, J CLIN INVEST, V124, P1646, DOI 10.1172/JCI71812
   Wu SL, 2007, BONE, V40, P1630, DOI 10.1016/j.bone.2007.02.025
NR 44
TC 8
Z9 10
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD OCT 17
PY 2022
VL 13
AR 913979
DI 10.3389/fendo.2022.913979
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 5W6TS
UT WOS:000878045000001
PM 36325441
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Dong, SK
   Ge, JX
   Meng, Q
   Yuan, T
   Wang, Y
   Li, Y
   Lu, QZ
   Song, WN
   Li, ZQ
   Sun, S
AF Dong, Shankun
   Ge, Jianxun
   Meng, Qi
   Yuan, Tao
   Wang, Yi
   Li, Yi
   Lu, Qizhen
   Song, Wenao
   Li, Ziqing
   Sun, Shui
TI Crebanine mitigates glucocorticoid induced osteonecrosis of the femoral
   head by restoring bone remodelling homeostasis via attenuating oxidative
   stress
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE crebanine; network pharmacology; Nrf2; ONFH; osteoblast; osteoclast; ROS
ID OSTEOCLAST DIFFERENTIATION; ACTIVATION; MECHANISMS
AB The onset of osteonecrosis of the femoral head (ONFH) is intimately associated with the extensive administration of glucocorticoids (GCs). Long term stimulation of GCs can induce oxidative stress in both osteoclasts (OCs) and osteoblasts (OBs), resulting in the disturbance of bone remodelling. An alkaloid named crebanine (CN) demonstrates pharmacological properties including anti inflammation and reactive oxygen species (ROS) modulation. Our objective is to assess the therapeutic potential of CN in treating ONFH and elucidate the associated underlying mechanisms. The network pharmacology analysis uncovered that CN played a role in regulating ROS metabolism. In vitro, CN demonstrated its ability to reduce the dexamethasone (DEX) stimulated generation of OCs and suppress their resorptive function by downregulating the level of osteoclast marker genes. Concurrently, CN also mitigated DEX induced damage to OBs, facilitating the restoration of osteoblast marker gene expression, cellular differentiation and function. These effects were achieved by CN augmenting the antioxidant system to reduce intracellular ROS levels. Furthermore, in vitro results were corroborated by micro CT and histological data, which also showed that CN attenuated MPS induced ONFH in mice. This study highlights the therapeutic potential of CN in counteracting GCs induced ONFH.
C1 [Dong, Shankun; Ge, Jianxun; Meng, Qi; Yuan, Tao; Sun, Shui] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Joint Surg, Jinan, Shandong, Peoples R China.
   [Wang, Yi; Li, Yi; Lu, Qizhen; Li, Ziqing; Sun, Shui] Shandong First Med Univ, Shandong Prov Hosp, Dept Joint Surg, Jinan 250021, Shandong, Peoples R China.
   [Wang, Yi; Li, Yi; Lu, Qizhen; Li, Ziqing; Sun, Shui] Shandong First Med Univ & Shandong Acad Med Sci, Med Sci & Technol Innovat Ctr, Orthopaed Res Lab, Jinan, Shandong, Peoples R China.
   [Song, Wenao] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Clin Lab, Jinan, Shandong, Peoples R China.
C3 Shandong University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; Shandong First Medical University &
   Shandong Academy of Medical Sciences; Shandong First Medical University
   & Shandong Academy of Medical Sciences; Shandong University; Shandong
   First Medical University & Shandong Academy of Medical Sciences
RP Li, ZQ; Sun, S (通讯作者)，Shandong First Med Univ, Shandong Prov Hosp, Dept Joint Surg, Jinan 250021, Shandong, Peoples R China.; Sun, S (通讯作者)，Shandong Univ, Shandong Prov Hosp, Dept Joint Surg, Jinan 250012, Shandong, Peoples R China.
EM liziqing@sdfmu.edu.cn; sunshui@sdfmu.edu.cn
RI Li, Ziqing/GST 4574 2022; MENG, QI/KRO 4878 2024; Lu,
   qizhen/LJK 7788 2024
OI sun, shui/0000 0002 9744 1595
FU Natural Science Foundation of Shandong Province [ZR2021MH264,
   ZR2021QH077]; National Natural Science Foundation of China [82100936,
   82272485]
FX Natural Science Foundation of Shandong Province, Grant/Award Number:
   ZR2021MH264 and ZR2021QH077; National Natural Science Foundation of
   China, Grant/Award Number: 82100936 and 82272485
CR Ackova DG, 2023, PHARMACEUTICALS BASE, V16, DOI 10.3390/ph16060850
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Arbab D, 2016, DTSCH ARZTEBL INT, V113, P31, DOI 10.3238/arztebl.2016.0031
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Bhambhani S, 2021, MOLECULES, V26, DOI 10.3390/molecules26113374
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen JZ, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/3182368
   Cui L., 2022, Front Pharmacol, V13
   Cui ZC, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/4913534
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Egbujor MC, 2023, MOLECULES, V28, DOI 10.3390/molecules28062751
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Feng YL, 2014, CHEM BIOL INTERACT, V207, P26, DOI 10.1016/j.cbi.2013.11.004
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Hartmann K, 2016, PHYSIOL REV, V96, P409, DOI 10.1152/physrev.00011.2015
   Hines JT, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e177
   Intayoung P, 2016, BIOL PHARM BULL, V39, P54, DOI 10.1248/bpb.b15 00479
   Kang JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103646
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kito H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910459
   Lee Yun Jong, 2019, J Bone Metab, V26, P13, DOI 10.11005/jbm.2019.26.1.13
   Li WW, 2017, FRONT PHARMACOL, V8, P15, DOI 10.3389/fphar.2017.00074
   Li ZQ, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779 020 00292 2
   Li ZQ, 2019, J BONE MINER RES, V34, P752, DOI 10.1002/jbmr.3645
   Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401
   Liu LH, 2017, CHINESE MED J PEKING, V130, P2601, DOI 10.4103/0366 6999.217094
   Liu Q, 2023, TOXICOL APPL PHARM, V475, DOI 10.1016/j.taap.2023.116649
   Lu JS, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52513 x
   Lv ZY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03792 8
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev pharmtox 011112 140320
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mei LW, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.734774
   Meng Q, 2023, GENE REP, V33, DOI 10.1016/j.genrep.2023.101833
   Messinis DE, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1011184
   Muhamad MLN, 2022, NUTRIENTS, V14, DOI 10.3390/nu14224851
   Papaiahgari S, 2006, ANTIOXID REDOX SIGN, V8, P43, DOI 10.1089/ars.2006.8.43
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Rojsanga P, 2012, LIFE SCI, V91, P107, DOI 10.1016/j.lfs.2012.06.017
   Safran M, 2010, DATABASE OXFORD, DOI 10.1093/database/baq020
   Sato AY, 2015, BONE, V73, P60, DOI 10.1016/j.bone.2014.12.012
   Sun F, 2022, BIOCHEM BIOPH RES CO, V602, P149, DOI 10.1016/j.bbrc.2022.02.112
   Sun YX, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929 015 0212 5
   Sun Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006588
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   Tan JJ, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1069093
   Tonelli C, 2018, ANTIOXID REDOX SIGN, V29, P1727, DOI 10.1089/ars.2017.7342
   Veis DJ, 2023, ANNU REV PATHOL MECH, V18, P257, DOI 10.1146/annurev pathmechdis 031521 040919
   Wang H, 2016, MOLECULES, V21, DOI 10.3390/molecules21121555
   Wang Y, 2024, INFLAMMATION, V47, P626, DOI 10.1007/s10753 023 01933 z
   Xu JZ, 2018, INT ORTHOP, V42, P1729, DOI 10.1007/s00264 018 3956 1
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Yan GQ, 2020, INFLAMMATION, V43, P1279, DOI 10.1007/s10753 020 01207 y
   Yang N, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.447
   Yang YQ, 2023, PHYTOMEDICINE, V120, DOI 10.1016/j.phymed.2023.155044
   Zhou JX, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110351
NR 59
TC 5
Z9 5
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD AUG
PY 2024
VL 28
IS 16
AR e70044
DI 10.1111/jcmm.70044
PG 17
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA D9X1C
UT WOS:001299626300001
PM 39205463
OA gold
DA 2025 08 17
ER

PT J
AU Li, FM
   Li, QH
   Huang, XQ
   Wang, YT
   Ge, C
   Qi, Y
   Guo, W
   Sun, HT
AF Li, Feimeng
   Li, Qihuo
   Huang, Xiaoqing
   Wang, Yunting
   Ge, Chana
   Qi, Yong
   Guo, Wei
   Sun, Hongtao
TI Psoralen stimulates osteoblast proliferation through the activation of
   nuclear factor κB mitogen activated protein kinase signaling
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE psoralen; osteoblasts; proliferation; signal pathway
ID CELL PROLIFERATION; BONE STRENGTH; DIFFERENTIATION; OSTEOPOROSIS;
   RALOXIFENE; EXPRESSION; MINERALIZATION; PHYTOESTROGENS; FRACTIONS;
   BENEFITS
AB Osteoporosis is a systemic skeletal disease that leads to increased bone fragility and susceptibility to fracture. Approximately 50% of postmenopausal women develop osteoporosis as a result of postmenopausal estrogen deficiency. To reduce fractures related to osteoporosis in women, previous studies have focused on therapeutic strategies that aim to increase bone formation or decrease bone resorption. However, pharmacological agents that aim to improve bone fracture susceptibility exhibit side effects. Current studies are investigating natural alternatives that possess the benefits of selective estrogen receptor modulators (SERMs) without the adverse effects. Recent studies have indicated that phytoestrogen may be an ideal natural SERM for the treatment of osteoporosis. In Chinese herbal medicine, psoralen, as the predominant substance of Psoralea corylifolia, is considered to be a phytoestrogen and is used as a remedy for osteoporosis. A number of studies have demonstrated the efficacy of psoralen in bone formation. However, the pathways and underlying molecular mechanisms that participate in psoralen induced osteoblast formation are not well understood. In the present study, hFOB1.19 cells were treated with psoralen at different concentrations (0, 5, 10, 15 and 20 mu M) for 0, 24, 36, 48 and 72 h, respectively. Reverse transcription quantitative polymerase chain reaction and western blot assays were performed to detect glucose transporter 3 (GLUT3) expression. A cell counting kit 8 assay was used to analyze cell proliferation. In addition the effects of mitogen activated protein kinase inhibitors on extracellular signal regulated kinase (ERK), phosphorylated (p) ERK, p38, p p38, c Jun N terminal kinase (JNK) and p JNK expressions and cell proliferation were measured, as was the effect of nuclear factor (NF) kappa B inhibitor on P65 and GLUT3 expressions and cell proliferation. The results indicated that psoralen stimulates hFOB1.19 cell proliferation in a dose dependent manner (P<0.05). Phospho ERK, p38 and JNK were markedly increased by psoralen compared with the control group (P<0.05), and the specific inhibitors of ERK (SCH772984), p38 (SB203580) and JNK (SP600125) reversed the stimulatory effects of psoralen on signal marker phosphorylation (P<0.05). The rate of psoralen induced cell proliferation was significantly suppressed by inhibitors of ERK, JNK and p38 compared with psoralen treatment alone (P<0.05). In addition, psoralen stimulated osteoblast proliferation via the NF kappa B signaling pathway. Therefore, the present findings suggest that psoralen may be a potential natural alternative to SERMs in the treatment of osteoporosis and fractures.
C1 [Li, Feimeng] Guangdong Second Prov Gen Hosp, Guangdong Tradit Med & Sports Injury Rehabil Res, Guangzhou 510317, Guangdong, Peoples R China.
   [Li, Qihuo; Wang, Yunting; Ge, Chana; Guo, Wei] Guangzhou Univ Chinese Med, Dept Orthoped 4, Affiliated Hosp 1, Guangzhou 510006, Guangdong, Peoples R China.
   [Huang, Xiaoqing] Guangdong Second Prov Gen Hosp, Dept Chinese Med, Guangzhou 510317, Guangdong, Peoples R China.
   [Qi, Yong; Sun, Hongtao] Guangdong Second Prov Gen Hosp, Dept Orthoped, 466 Xinggang Rd, Guangzhou 510317, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine
RP Sun, HT (通讯作者)，Guangdong Second Prov Gen Hosp, Dept Orthoped, 466 Xinggang Rd, Guangzhou 510317, Guangdong, Peoples R China.
EM sunhongtao2002@gmail.com
RI Huang, Xiaoqing/I 5186 2013
CR Aaboe M, 2006, CANCER RES, V66, P3434, DOI 10.1158/0008 5472.CAN 05 3456
   [Anonymous], 2016, EVID BASED COMPL ALT, DOI DOI 10.1155/2016/8981650
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BELL GI, 1993, J BIOL CHEM, V268, P19161
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cassidy A, 2003, INT J VITAM NUTR RES, V73, P120, DOI 10.1024/0300 9831.73.2.120
   Chen SQ, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3524307
   Chen WQ, 2014, P NATL ACAD SCI USA, V111, P6040, DOI 10.1073/pnas.1318859111
   Choi EM, 2001, PHYTOCHEMISTRY, V56, P733, DOI 10.1016/S0031 9422(00)00484 2
   Choi YJ, 2014, INFLAMMATION, V37, P1496, DOI 10.1007/s10753 014 9875 4
   Ciric Zorica, 2012, Med Arch, V66, P385
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   Deng LY, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005287.pub4
   Fitzpatrick LA, 1999, MAYO CLIN PROC, V74, P601, DOI 10.4065/74.6.601
   Fujiwara S, 2014, CLIN INTERV AGING, V9, P1879, DOI 10.2147/CIA.S70307
   Goldstein SR, 2011, MENOPAUSE, V18, P17, DOI 10.1097/gme.0b013e3181e84bb4
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kim C, 2014, EMBO MOL MED, V6, P970, DOI 10.15252/emmm.201303541
   Kimura S, 2017, OSTEOPOROSIS INT, V28, P1109, DOI 10.1007/s00198 016 3812 3
   Kong XH, 2012, INT J MOL MED, V29, P1090, DOI 10.3892/ijmm.2012.941
   Li WD, 2014, PHYTOMEDICINE, V21, P400, DOI 10.1016/j.phymed.2013.09.015
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lóránd T, 2010, CURR MED CHEM, V17, P3542, DOI 10.2174/092986710792927813
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Maeda SS, 2014, ARQ BRAS ENDOCRINOL, V58, P162, DOI 10.1590/0004 2730000003039
   Masin M, 2014, CANCER METAB, V2, DOI 10.1186/2049 3002 2 11
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Miura H, 1996, PLANTA MED, V62, P150, DOI 10.1055/s 2006 957839
   Muruganandan S, 2014, IMPACT BONE MARROW A
   Oh H, 2013, IMMUNOL REV, V252, P41, DOI 10.1111/imr.12033
   Qiao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep21053
   Ranasinghe S, 2015, J ETHNOPHARMACOL, V166, P200, DOI 10.1016/j.jep.2015.03.028
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Sugimoto E, 2000, BIOCHEM PHARMACOL, V59, P471, DOI 10.1016/S0006 2952(99)00351 2
   Sun Y, 2015, J RECEPT SIG TRANSD, V35, P600, DOI 10.3109/10799893.2015.1030412
   Tang DZ, 2011, BIOCHEM BIOPH RES CO, V405, P256, DOI 10.1016/j.bbrc.2011.01.021
   ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968 0004(99)01519 4
   TURNER CH, 1994, ENDOCRINOLOGY, V135, P2001, DOI 10.1210/en.135.5.2001
   Usui T, 2006, ENDOCR J, V53, P7, DOI 10.1507/endocrj.53.7
   Vaz CV, 2012, INT J BIOCHEM CELL B, V44, P2077, DOI 10.1016/j.biocel.2012.08.013
   Wang LL, 2016, CURR PHARM DESIGN, V22, P328, DOI 10.2174/1381612822666151112145907
   Wong RWK, 2011, J ORTHOP RES, V29, P158, DOI 10.1002/jor.21124
   Xiong XC, 2015, INT J MOL SCI, V16, P10337, DOI 10.3390/ijms160510337
   Xiong Z, 2003, PHARMAZIE, V58, P925
   Yao ZQ, 2014, J BONE MINER RES, V29, P866, DOI 10.1002/jbmr.2108
   Yu Y, 2012, HISTOCHEM CELL BIOL, V137, P513, DOI 10.1007/s00418 011 0908 x
   Zhai YK, 2017, EUR J PHARMACOL, V801, P62, DOI 10.1016/j.ejphar.2017.03.001
   Zoidis E, 2011, MOL CELL BIOCHEM, V348, P33, DOI 10.1007/s11010 010 0634 z
NR 51
TC 22
Z9 30
U1 1
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD SEP
PY 2017
VL 14
IS 3
BP 2385
EP 2391
DI 10.3892/etm.2017.4771
PN A
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FF0MW
UT WOS:000408596800079
PM 28962172
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Canon, J
   Bryant, R
   Roudier, M
   Branstetter, DG
   Dougall, WC
AF Canon, Jude
   Bryant, Rebecca
   Roudier, Martine
   Branstetter, Daniel G.
   Dougall, William C.
TI RANKL inhibition combined with tamoxifen treatment increases anti tumor
   efficacy and prevents tumor induced bone destruction in an estrogen
   receptor positive breast cancer bone metastasis model
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE RANKL; Bone metastases; Osteoprotegerin; Tamoxifen; Estrogen receptor
   positive; Breast cancer
ID PROSTATE CANCER; ZOLEDRONIC ACID; SKELETAL COMPLICATIONS; IMPROVES
   SURVIVAL; LUNG CANCER; OSTEOPROTEGERIN; DISEASE; BURDEN; MECHANISMS;
   DOCETAXEL
AB Tumor cells in bone can induce the activation of osteoclasts, which mediate bone resorption and release of growth factors and calcium from the bone matrix, resulting in a cycle of tumor growth and bone breakdown. Targeting the bone microenvironment by the inhibition of RANKL, an essential mediator of osteoclast function, not only prevents tumor induced osteolysis but also decreases skeletal tumor burden in preclinical models. The inhibition of skeletal tumor progression after the inhibition of osteoclasts is via interruption of the "vicious cycle" of tumor/bone interactions. The majority of breast cancer patients at risk for bone metastases harbor estrogen receptor positive (ER+) tumors. We developed a mouse model for ER+ breast cancer bone metastasis and evaluated the effect of RANKL inhibition on tumor induced osteolysis and skeletal tumor growth both alone and in combination with tamoxifen. Luciferase labeled MCF 7 cells (MCF 7Luc) formed metastatic foci in the hind limbs following intracardiac injection and caused mixed osteolytic/osteoblastic lesions. RANKL inhibition by OPG Fc treatment blocked osteoclast activity and prevented tumor induced osteolysis, as well as caused a marked decrease in skeletal tumor burden. Tamoxifen as a single agent reduced MCF 7Luc tumor growth in the hind limbs. In a combination experiment, OPG Fc plus tamoxifen resulted in significantly greater tumor growth inhibition than either single agent alone. Histologic analysis revealed a decrease in the proliferation of tumor cells by both single agents, which was enhanced in the combination treatment. Upon treatment with OPG Fc alone or in combination with tamoxifen, there was a complete absence of osteolytic lesions, demonstrating the ability of RANKL inhibition to prevent skeletal related morbidity in an ER+ model. The combination approach of targeting osteoclasts and the bone microenvironment by RANKL inhibition and the tumor directly via hormonal therapy may provide additional benefit to reducing skeletal tumor progression in ER+ breast cancer patients.
C1 [Canon, Jude; Bryant, Rebecca] Amgen Inc, Dept Oncol Res, Thousand Oaks, CA 91320 USA.
   [Roudier, Martine; Branstetter, Daniel G.] Amgen Inc, Dept Pathol, Seattle, WA USA.
   [Dougall, William C.] Amgen Inc, Dept Oncol Res, Seattle, WA USA.
C3 Amgen; Amgen; Amgen
RP Canon, J (通讯作者)，Amgen Inc, Dept Oncol Res, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
EM jcanon@amgen.com
OI Dougall, William/0000 0001 9487 251X
CR Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Canon J, 2010, BONE, V46, P1613, DOI 10.1016/j.bone.2010.03.001
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Finch AJ, 2009, MOL CELL BIOL, V29, P5306, DOI 10.1128/MCB.01745 08
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   Hess KR, 2003, BREAST CANCER RES TR, V78, P105, DOI 10.1023/A:1022166517963
   Holland PM, 2010, CANCER BIOL THER, V9, P539, DOI 10.4161/cbt.9.7.11266
   Ignatoski KMW, 2008, PROSTATE, V68, P820, DOI 10.1002/pros.20744
   James JJ, 2003, BRIT J CANCER, V89, P660, DOI 10.1038/sj.bjc.6601198
   Kim TH, 2011, J BIOL CHEM, V286, P11427, DOI 10.1074/jbc.M110.188797
   Miller RE, 2008, MOL CANCER THER, V7, P2160, DOI 10.1158/1535 7163.MCT 08 0046
   Morony S, 2001, CANCER RES, V61, P4432
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Smith MR, 2011, J GERONTOL B PSYCHOL, DOI [10.1016/S0140 6736, DOI 10.1016/S0140 6736(11)61226 9]
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tannehill Gregg SH, 2006, CLIN EXP METASTAS, V23, P19, DOI 10.1007/s10585 006 9008 z
   Visvanathan K, 2009, J CLIN ONCOL, V27, P3235, DOI 10.1200/JCO.2008.20.5179
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
NR 25
TC 32
Z9 39
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167 6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD OCT
PY 2012
VL 135
IS 3
BP 771
EP 780
DI 10.1007/s10549 012 2222 2
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 003ZB
UT WOS:000308648800014
PM 22926264
DA 2025 08 17
ER

PT J
AU Siddiqui, NA
   Owen, JM
AF Siddiqui, Nashat A.
   Owen, John M.
TI Clinical Advances in Bone Regeneration
SO CURRENT STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Bone; bone graft; osteoblasts; osteoclasts; osteoconduction;
   osteogenesis; osteoinduction; regeneration
ID OSTEOGENESIS IMPERFECTA; GROWTH HORMONE; FRACTURE; CELLS; ULTRASOUND;
   MANAGEMENT; THERAPY
AB Understanding of the biology of bone regeneration has been increasing rapidly, with greater appreciation for the importance of biochemical aspects as well as the mechanical requirements for bone to heal. There are a number of situations where there is difficulty in bone healing such as fracture non union; or growth such as osteogenesis imperfecta; or a requirement for surplus bone to reconstruct defects such as following surgery for tumour excision or limb lengthening.
   There is a greater understanding of the complex interplay between osteoblasts and osteoclasts, and the chemical mediators that that provide signalling along complex pathways. Although we have known about substances such as Bone Morphogenic Proteins and Growth Hormones for some time, their application in clinical practice is still not widespread, and we need to study them more to understand their role in bone healing.
   With newer technologies such as stem cells and gene therapy being developed there is the potential for vast improvement in bone regenerative techniques, although we are not at a stage where we can be confident that these techniques will work.
   In this review article we discuss the basic healing process of bone and how our understanding of this has led to improved techniques as well as the potential for future developments in new technologies.
C1 [Siddiqui, Nashat A.; Owen, John M.] Southmead Hosp, Avon Orthopaed Ctr, Bristol BS10 5NB, Avon, England.
C3 Southmead Hospital
RP Siddiqui, NA (通讯作者)，Southmead Hosp, Avon Orthopaed Ctr, Bristol BS10 5NB, Avon, England.
EM nashat75@gmail.com
RI Siddiqui, Nashat/E 3152 2012
CR Adie S, 2011, J BONE JOINT SURG AM, V93A, P1569, DOI 10.2106/JBJS.J.00869
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Argintar E, 2011, INJURY, V42, P730, DOI 10.1016/j.injury.2010.11.016
   Aronson J, 1997, J BONE JOINT SURG AM, V79A, P1243, DOI 10.2106/00004623 199708000 00019
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Assiotis A, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749 799X 7 24
   Bab IA, 2012, PRINCIPLES BONE REGE, V2012, P11
   Bab I, 2009, ANN MED, V41, P560, DOI 10.1080/07853890903121025
   Bab IA, 2012, PRINCIPLES OF BONE REGENERATION, P11, DOI 10.1007/978 1 4614 2059 0_2
   Barnes GL, 2008, J BONE JOINT SURG AM, V90A, P120, DOI 10.2106/JBJS.G.01443
   Bates P., 2007, Basic Orthopaedic Sciences, P123
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Brammer KS, 2012, TRENDS BIOTECHNOL, V30, P315, DOI 10.1016/j.tibtech.2012.02.005
   Buckwalter J A, 1987, Instr Course Lect, V36, P27
   Buijze GA, 2012, J HAND SURG AM, V37A, P1095, DOI 10.1016/j.jhsa.2012.03.002
   Chissas D, 2010, INJURY, V41, P687, DOI 10.1016/j.injury.2009.10.011
   Cole JD, 2001, INJURY, V32, pD129
   Delgado Martínez AD, 1998, J ORTHOP RES, V16, P650, DOI 10.1002/jor.1100160604
   Dubois EA, 2011, BRIT J CLIN PHARMACO, V71, P804, DOI 10.1111/j.1365 2125.2011.03969.x
   Gabet Y, 2004, BONE, V35, P65, DOI 10.1016/j.bone.2004.03.025
   Garrison KR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006950.pub2
   Gazit D, 1999, J GENE MED, V1, P121, DOI 10.1002/(SICI)1521 2254(199903/04)1:2<121::AID JGM26>3.0.CO;2 J
   GAZIT D, 1990, ENDOCRINOLOGY, V126, P2607, DOI 10.1210/endo 126 5 2607
   Giannoudis PV, 2007, OSTEOPOROSIS INT, V18, P1565, DOI 10.1007/s00198 007 0441 x
   Giannoudis PV, 2007, INJURY, V38, pS3, DOI 10.1016/S0020 1383(08)70003 2
   Giannoudis PV, 2011, INJURY, V42, P591, DOI 10.1016/j.injury.2011.03.036
   Goater JJ, 2002, J ORTHOPAED RES, V20, P169, DOI 10.1016/S0736 0266(01)00083 3
   Hak DJ, 2011, J AM ACAD ORTHOP SUR, V19, P563, DOI 10.5435/00124635 201109000 00007
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   JARRY L, 1960, J BONE JOINT SURG BR, V42, P126, DOI 10.1302/0301 620X.42B1.126
   Khaled E G, 2011, Open Orthop J, V5 Suppl 2, P289, DOI 10.2174/1874325001105010289
   Knoepfler PS, 2009, STEM CELLS, V27, P1050, DOI 10.1002/stem.37
   Koester MC, 2006, CLIN SPORT MED, V25, P63, DOI 10.1016/j.csm.2005.08.004
   Komatsubara Satoshi, 2009, Clin Calcium, V19, P660, DOI CliCa0905660666
   Krieg AH, 2011, ACTA ORTHOP, V82, P344, DOI 10.3109/17453674.2011.584209
   Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623 199707000 00002
   Lai CH, 2011, ULTRASOUND MED BIOL, V37, P1635, DOI 10.1016/j.ultrasmedbio.2011.06.014
   Mafi P, 2012, CURR STEM CELL RES T, V7, P302, DOI 10.2174/157488812800793045
   Matassi F, 2011, CLIN CASES MINER BON, V8, P21
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   MUELLER M, 1991, J BONE MINER RES, V6, P401
   Niyibizi C, 2001, J CELL BIOCHEM, V83, P84, DOI 10.1002/jcb.1209
   Nogueira GD, 2008, IMPLANT DENT, V17, P461, DOI 10.1097/ID.0b013e31818c5a2a
   PALEY D, 1990, CLIN ORTHOP RELAT R, P81
   Pelled G, 2012, PRINCIPLES OF BONE REGENERATION, P81, DOI 10.1007/978 1 4614 2059 0_7
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Pinheiro ALB, 2003, INT CONGR SER, V1248, P69, DOI 10.1016/S0531 5131(03)00059 1
   Skoglund B, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 98
   Stevenson S, 2000, ORTHOPAEDIC BASIC SC, P571
   Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102
   Tran GT, 2009, EXPERT OPIN INV DRUG, V18, P887, DOI 10.1517/13543780902893069
   Unnanuntana A, 2011, CLIN ORTHOP RELAT R, V469, P2194, DOI 10.1007/s11999 010 1694 9
   Waris E, 2004, J HAND SURG AM, V29A, P452, DOI 10.1016/j.jhsa.2004.01.013
   Warnke PH, 2004, LANCET, V364, P766, DOI 10.1016/S0140 6736(04)16935 3
   Watanabe Y, 2010, J ORTHOP TRAUMA, V24, pS56, DOI 10.1097/BOT.0b013e3181d2efaf
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Yamamoto Y, 2006, ENDOCRINOLOGY, V147, P3366, DOI 10.1210/en.2006 0216
NR 58
TC 11
Z9 12
U1 0
U2 27
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574 888X
EI 2212 3946
J9 CURR STEM CELL RES T
JI Curr. Stem Cell Res. Ther.
PD MAY
PY 2013
VL 8
IS 3
BP 192
EP 200
PG 9
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 129NL
UT WOS:000317847600003
PM 23317467
DA 2025 08 17
ER

PT J
AU Galvan, ML
   Paradise, CR
   Kubrova, E
   Jerez, S
   Khani, F
   Thaler, R
   Dudakovic, A
   van Wijnen, AJ
AF Galvan, M. Lizeth
   Paradise, Christopher R.
   Kubrova, Eva
   Jerez, Sofia
   Khani, Farzaneh
   Thaler, Roman
   Dudakovic, Amel
   van Wijnen, Andre J.
TI Multiple pharmacological inhibitors targeting the epigenetic suppressor
   enhancer of zeste homolog 2 (Ezh2) accelerate osteoblast differentiation
SO BONE
LA English
DT Article
DE Bone; Skeletal development; Osteoblast; Osteogenesis; Osteoporosis;
   Differentiation; Chromatin; Nucleosome; Methylation; Histone; Ezh2;
   Polycomb; Inhibitor; Pharmacology; Pharmacotherapy
ID BONE FORMATION; OSTEOGENIC DIFFERENTIATION; HISTONE MODIFICATIONS;
   POLYCOMB; SPECIFICATION; DETERMINANTS; METHYLATION; REGULATORS;
   MAINTAINS; DELETION
AB Skeletal development and bone formation are regulated by epigenetic mechanisms that either repress or enhance osteogenic commitment of mesenchymal stromal/stem cells and osteoblasts. The transcriptional suppressive trimethylation of histone 3 lysine 27 (H3K27me3) hinders differentiation of pre committed osteoblasts. Osteoblast maturation can be stimulated by genetic loss of the H3K27 methyltransferase Ezh2 which can also be mimicked pharmacologically using the classical Ezh2 inhibitor GSK126. Identification of other Ezh2 inhibitors (iEzh2) that enhance osteogenic potential would increase chemical options for developing new bone stimulatory compounds. In this study, we examined a panel of iEzh2s and show that all eight inhibitors we tested are capable of accelerating osteoblast differentiation to different degrees at concentrations that are well below cytotoxic concentrations. Inhibition of Ezh2 is commensurate with loss of cellular H3K27me3 levels while forced expression of Ezh2 reverses the effect of Ezh2 suppression. Reduced Ezh2 function by siRNA depletion of Ezh2 mRNA and protein levels also stimulates osteoblastogenesis, consistent with the specificity of iEzh2 to target the active site of Ezh2. Diminished Ezh2 levels preempt the effects of iEzh2s on H3K27me3. GSK126, EPZ 6438 and siRNA depletion of Ezh2 each are effective in reducing H3K27me3 levels. However, EPZ 6438 is more potent than GSK126 in stimulating osteoblastogenesis, as reflected by increased extracellular matrix mineralization. Collectively, our data indicate that Ezh2 inhibitors properly target Ezh2 consistent with their biochemical affinities. The range of compounds capable of promoting osteogenesis presented in this study offers the opportunity to develop diverse bone anabolic strategies for distinct clinical scenarios, including spine fusion, non union of bone and dental implant enhancement.
C1 [Galvan, M. Lizeth; Paradise, Christopher R.; Kubrova, Eva; Jerez, Sofia; Khani, Farzaneh; Thaler, Roman; Dudakovic, Amel; van Wijnen, Andre J.] Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.
   [Paradise, Christopher R.; van Wijnen, Andre J.] Mayo Clin, Ctr Regenerat Med, Rochester, MN USA.
   [Dudakovic, Amel; van Wijnen, Andre J.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Dudakovic, A; van Wijnen, AJ (通讯作者)，Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.
EM GalvanTenorio.Miriam@mayo.edu; Kubrova.Eva@mayo.edu;
   JerezOrtega.Joselin@mayo.edu; Thaler.Roman@mayo.edu;
   Dudakovic.Amel@mayo.edu; Vanwijnen.Andre@mayo.edu
RI Jerez, Sofia/MTC 0549 2025; van Wijnen, Andre/AAG 3578 2019
OI van Wijnen, Andre J./0000 0002 4458 0946; Paradise,
   Christopher/0000 0002 5882 709X; Dudakovic, Amel/0000 0002 8850 3977
FU National Institute of Health [R01 AR069049]; Career Development Award in
   Orthopedics Research; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [R01AR049069] Funding Source: NIH
   RePORTER
FX This work was supported by funding from the National Institute of Health
   grant R01 AR069049 (AJvW) and a Career Development Award in Orthopedics
   Research (AD) . We also thank William and Karen Eby for their generous
   philanthropic support.
CR Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59
   Camilleri ET, 2018, J BIOL CHEM, V293, P19001, DOI 10.1074/jbc.RA118.003909
   Carpio LR, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf3273
   Chen YH, 2016, STEM CELLS, V34, P2183, DOI 10.1002/stem.2400
   Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111
   Dudakovic, 2017, CURRENT MOL BIOL REP, V3, P94, DOI [DOI 10.1007/S40610 017 0064 8, DOI 10.1007/s40610 017 0064 8]
   Dudakovic A, 2020, J BIOL CHEM, V295, P7877, DOI 10.1074/jbc.RA119.011685
   Dudakovic A, 2018, J BIOL CHEM, V293, P12894, DOI 10.1074/jbc.RA118.002983
   Dudakovic A, 2017, GENE, V609, P28, DOI 10.1016/j.gene.2017.01.019
   Dudakovic A, 2016, J BIOL CHEM, V291, P24594, DOI 10.1074/jbc.M116.740571
   Dudakovic A, 2015, J BIOL CHEM, V290, P27604, DOI 10.1074/jbc.M115.672345
   Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732
   Fang C, 2016, J IMMUNOL, V196, P4452, DOI 10.4049/jimmunol.1501466
   Feigenson M, 2017, J BONE MINER RES, V32, P2453, DOI 10.1002/jbmr.3236
   Galea Gabriel L, 2020, Gene X, V5, P100027, DOI 10.1016/j.gene.2020.100027
   Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224
   Gordon JAR, 2015, BONE, V81, P739, DOI 10.1016/j.bone.2015.03.011
   Hemming S, 2017, FASEB J, V31, P1011, DOI 10.1096/fj.201600748R
   Hemming S, 2014, STEM CELLS, V32, P802, DOI 10.1002/stem.1573
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Jing H, 2016, MOL THER, V24, P217, DOI 10.1038/mt.2015.152
   Kannus P., 2003, International osteoporosis foundation: The facts about osteoporosis and its impact
   Khani F, 2017, J CELL BIOCHEM, V118, P1262, DOI 10.1002/jcb.25787
   Krause C., 2008, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Signal Transduction Cascades Controlling Osteoblast Differentiation, V7th, P10
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee CH, 2019, GENE DEV, V33, P1428, DOI 10.1101/gad.328773.119
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liu XY, 2016, NATURE, V537, P558, DOI 10.1038/nature19362
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Lui JC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13685
   Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Meyer MB, 2016, J BIOL CHEM, V291, P17829, DOI 10.1074/jbc.M116.736538
   Najafova Z, 2017, NUCLEIC ACIDS RES, V45, P127, DOI 10.1093/nar/gkw826
   Paradise CR, 2020, J CELL PHYSIOL, V235, P5293, DOI 10.1002/jcp.29415
   Pike JW, 2015, BONE, V81, P757, DOI 10.1016/j.bone.2015.03.012
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Ren JH, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578 020 0378 8
   Rojas A, 2019, J CELL PHYSIOL, V234, P6244, DOI 10.1002/jcp.27355
   Rojas A, 2015, J BIOL CHEM, V290, P28329, DOI 10.1074/jbc.M115.657825
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Schuettengruber B, 2009, DEVELOPMENT, V136, P3531, DOI 10.1242/dev.033902
   Schwarz D, 2014, DEVELOPMENT, V141, P867, DOI 10.1242/dev.094342
   Sen B, 2020, J BONE MINER RES, V35, P1149, DOI 10.1002/jbmr.3975
   Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002 0122
   Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016
   Stephens AS, 2011, J BIOL CHEM, V286, P30071, DOI 10.1074/jbc.M111.253518
   Su PH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082343
   Thaler R, 2016, J BIOL CHEM, V291, P6754, DOI 10.1074/jbc.M115.678235
   Thaler R, 2012, EPIGENETICS US, V7, P635, DOI 10.4161/epi.20163
   van Wijnen AJ, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115659
   van Wijnen AJ, 2019, J ORTHOP RES, V37, P1465, DOI 10.1002/jor.24305
   van Wijnen AJ, 2013, CURR OSTEOPOROS REP, V11, P72, DOI 10.1007/s11914 013 0143 6
   Wang HR, 2016, SCI REP UK, V6, DOI 10.1038/srep36988
   Wang XY, 2019, GENE DEV, V33, P1416, DOI 10.1101/gad.328849.119
   Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139
   Woodhouse S, 2013, J CELL SCI, V126, P565, DOI 10.1242/jcs.114843
   Wu H, 2017, BBA GENE REGUL MECH, V1860, P438, DOI 10.1016/j.bbagrm.2017.01.003
   Wyngaarden LA, 2011, DEVELOPMENT, V138, P3759, DOI 10.1242/dev.063180
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Zhu XX, 2016, ONCOTARGET, V7, P63561, DOI 10.18632/oncotarget.11538
NR 61
TC 33
Z9 35
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2021
VL 150
AR 115993
DI 10.1016/j.bone.2021.115993
EA MAY 2021
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA TF0MS
UT WOS:000670402300001
PM 33940225
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Karsdal, MA
   Qvist, P
   Christiansen, C
   Tankó, LB
AF Karsdal, Morten A.
   Qvist, Per
   Christiansen, Claus
   Tanko, Laszlo B.
TI Optimising antiresorptive therapies in postmenopausal women  : Why do we
   need to give due consideration to the degree of suppression?
SO DRUGS
LA English
DT Article
ID BONE MINERAL DENSITY; HORMONE REPLACEMENT THERAPY; FARNESYL DIPHOSPHATE
   SYNTHASE; FRACTURE INTERVENTION TRIAL; BIOCHEMICAL MARKERS; MICRODAMAGE
   ACCUMULATION; VERTEBRAL FRACTURES; ELDERLY WOMEN; ZOLEDRONIC ACID; HIP
   FRACTURE
AB Accelerated bone turnover with bone resorption exceeding bone formation is a major mechanism underlying postmenopausal bone loss and hence the development of osteoporosis. Accordingly, inhibition of bone resorption is a rational approach for the prevention of osteoporosis. In this context, the most logical option, hormone replacement therapy, reverses the rate of bone turnover to premenopausal levels, whereas the magnitude of inhibition by amino bisphosphonates and the recently introduced anti receptor activator of NF kappa B ligand (RANKL) antibody often exceeds this. As bone turnover has crucial implications for the continuous renewal of bone tissue, the over suppression of bone turnover has potential consequences for bone quality and strength. Long term treatment with potent bisphosphonates has recently been associated with osteonecrosis of the jaw and dose dependent increases in micro crack accumulation in animals. Although these observations are the subject of ongoing discussions, it is timely to discuss whether the over suppression of bone turnover below premenopausal levels is really our ultimate goal when defining the success criteria for antiresorptive agents.
   In this review, the implications of high and excessively low bone turnover of endogenous origin for bone quality, fracture risk and integrity of the jaw are discussed. In addition, animal and clinical research revealing initial findings regarding the potential adverse effects of drug induced suppression of bone remodeling are summarised. The inhibition of bone resorption, which is either transient between doses (e.g. with calcitonin) or does not exceed premenopausal levels (with hormone replacement therapy or selective estrogen receptor modulators), is preferable because it not only provides similar antiftacture efficacy but can also assist in the maintenance of the dynamic repair of micro cracks/microfractures. Bone is a dynamic tissue that is continuously remodelled throughout life not only to maintain circulating calcium homeostasis but also to repair tissue damage (micro cracks) that impairs bone quality.([1]) This continuous remodelling of bone involves the function of cells that are associated with the resorption of old bone (osteoclasts) and formation of new bone (osteoblasts).
   The homeostatic balance between bone resorption and formation is influenced by various factors including, but not restricted to, local cytokines, systernic hormones and mechanical Stimuli.([2 4]) The loss of ovarian sex steroids in postmenopausal women results in an acceleration of bone turnover with a predominance of bone resorption over bone formation. The related negative calcium balance promotes bone loss and increases bone fragility, thereby increasing the risk of osteoporotic fractures.([5]) A rational approach to counter these unwanted processes is the inhibition of bone resorption; however, this also leads to the inhibition of bone formation as a result of the coupling of these cellular events.([6 8]) Accordingly, pronounced inhibition of osteoclast function can be expected to impair the dynamic renewal of skeletal tissue, leading to an alteration of bone quality and strength.([9])
   To draw attention to the need for due consideration of this aspect of antiresorptive therapy, this review surnmarises selected experimental and clinical observations illustrating the links between bone turnover and the maintenance of the normal skeletal phenotype.
   The literature search considered publications on PubMed from 1980 to 2006, as well as abstracts from the American Society of Bone and Mineral Research meetings between 1998 and 2005. The search strategy focused on bone turnover and the pathology of bone, taking into account experimental models of low bone turnover and pharmacological suppression of bone turnover (antiresorptive strategies).
C1 Nordic Biosci AS, DK 2730 Herlev, Denmark.
   Ctr Clin & Basic Res, Ballerup, Denmark.
C3 Center Clinical & Basic Research
RP Karsdal, MA (通讯作者)，Nordic Biosci AS, Hovedgase 207, DK 2730 Herlev, Denmark.
EM mk@nordicbioscience.com
OI Karsdal, Morten/0000 0001 5026 8740
CR Adami S, 2004, BONE, V34, P881, DOI 10.1016/j.bone.2004.01.007
   Bagger YZ, 2003, BONE, V33, P301, DOI 10.1016/S8756 3282(03)00112 1
   Baron R., 2003, ASBMR, P1
   Bathi RJ, 2000, INT J ORAL MAX SURG, V29, P439, DOI 10.1034/j.1399 0020.2000.290609.x
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Boonen S, 2005, OSTEOPOROSIS INT, V16, P1291, DOI 10.1007/s00198 005 1945 x
   Burr DB, 2003, BONE, V33, P960, DOI 10.1016/j.bone.2003.08.004
   Capparelli C, 2003, J BONE MINER RES, V18, P852, DOI 10.1359/jbmr.2003.18.5.852
   Chapurlat RD, 2000, BONE, V27, P283, DOI 10.1016/S8756 3282(00)00325 2
   Collette J, 2003, Gynecol Obstet Fertil, V31, P434, DOI 10.1016/S1297 9589(03)00118 8
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Dai XM, 2004, J BONE MINER RES, V19, P1441, DOI 10.1359/JBMR.040514
   Delmas PD, 2004, J BONE MINER RES, V19, P330, DOI 10.1359/JBMR.0301228
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   EASTELL R, 1999, 26 EUR S CALC TISS
   Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
   Eviö S, 2004, J CLIN ENDOCR METAB, V89, P626, DOI 10.1210/jc.2003 030198
   Fall PM, 2000, OSTEOPOROSIS INT, V11, P481, DOI 10.1007/s001980070089
   Faulkner KG, 2000, J BONE MINER RES, V15, P183, DOI 10.1359/jbmr.2000.15.2.183
   Ficarra G, 2005, J CLIN PERIODONTOL, V32, P1123, DOI 10.1111/j.1600 051X.2005.00842.x
   Fratzl Zelman N, 2004, J CLIN ENDOCR METAB, V89, P1538, DOI 10.1210/jc.2003 031055
   Gamero P., 1996, J BONE MINER RES, V11, P337
   Garnero P, 1998, OSTEOPOROSIS INT, V8, P563, DOI 10.1007/s001980050100
   Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526
   Garnero P, 1996, J BONE MINER RES, V11, P1531
   Harris ST, 2001, J CLIN ENDOCR METAB, V86, P1890, DOI 10.1210/jc.86.5.1890
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Hoffman RM, 2005, J GEN INTERN MED, V20, P55
   HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523
   Jimenez Soriano Yolanda, 2005, Med Oral Patol Oral Cir Bucal, V10 Suppl 2, pE88
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Li J, 2001, CALCIFIED TISSUE INT, V69, P281, DOI 10.1007/s002230010036
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Li JL, 2005, J BONE MINER METAB, V23, P48, DOI 10.1007/BF03026323
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Lindsay R, 1999, J CLIN ENDOCR METAB, V84, P3076, DOI 10.1210/jc.84.9.3076
   MANOLIOS N, 1987, CLIN RHEUMATOL, V6, P408, DOI 10.1007/BF02206841
   MARTINEZ E, 1993, DIFFER GEOM APPL, V3, P1, DOI 10.1016/0926 2245(93)90020 2
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   Mashiba T, 2005, J BONE MINER METAB, V23, P36, DOI 10.1007/BF03026321
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Migliorati CA, 2005, CANCER, V104, P83, DOI 10.1002/cncr.21130
   Miller PD, 2005, J BONE MINER RES, V20, pS284
   Motyckova Gabriela, 2002, Current Molecular Medicine (Hilversum), V2, P407, DOI 10.2174/1566524023362401
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   ORCEL P, 1991, ENDOCRINOLOGY, V128, P1638, DOI 10.1210/endo 128 3 1638
   Purcell PM, 2005, MED J AUSTRALIA, V182, P417, DOI 10.5694/j.1326 5377.2005.tb06762.x
   Quarello P, 2004, J BONE MINER RES, V19, P1194, DOI 10.1359/JBMR.040407
   Ravn P, 1999, BONE, V24, P237, DOI 10.1016/S8756 3282(98)00183 5
   Ravn P, 2003, BONE, V33, P150, DOI 10.1016/S8756 3282(03)00168 6
   Ravn P, 1999, J CLIN ENDOCR METAB, V84, P2363, DOI 10.1210/jc.84.7.2363
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P5018, DOI 10.1210/jc.2004 1750
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   Riggs BL, 2002, J BONE MINER RES, V17, P11, DOI 10.1359/jbmr.2002.17.1.11
   Robinson NA, 2004, ANN ACAD MED SINGAP, V33, P48
   RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rosen CJ, 1997, J CLIN ENDOCR METAB, V82, P1904, DOI 10.1210/jc.82.6.1904
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Sakagami N, 2005, MICRON, V36, P688, DOI 10.1016/j.micron.2005.06.008
   Sarkar S, 2004, J BONE MINER RES, V19, P394, DOI 10.1359/JBMR.0301243
   Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756 3282(99)00278 1
   SILVERMAN SL, 1999, 26 EUR S CALC TISS 1
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Thompson K, 2002, BIOCHEM BIOPH RES CO, V290, P869, DOI 10.1006/bbrc.2001.6289
   Ulrich Vinther M, 2005, CALCIFIED TISSUE INT, V76, P280, DOI 10.1007/s00223 004 0126 9
   Vannucchi Alessandro M, 2005, Br J Haematol, V128, P738, DOI 10.1111/j.1365 2141.2005.05382.x
   Wasnich Richard D, 2004, Menopause, V11, P622
   WATTS N, 1999, 26 EUR S CALC TISS 1
   WIKTORJEDRZEJCZAK W, 1991, EXP HEMATOL, V19, P1049
   WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
NR 80
TC 29
Z9 30
U1 0
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012 6667
EI 1179 1950
J9 DRUGS
JI Drugs
PY 2006
VL 66
IS 15
BP 1909
EP 1918
DI 10.2165/00003495 200666150 00002
PG 10
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 113RY
UT WOS:000242616200002
PM 17100403
DA 2025 08 17
ER

PT J
AU Kringelbach, TM
   Aslan, D
   Novak, I
   Ellegaard, M
   Syberg, S
   Andersen, CKB
   Kristiansen, KA
   Vang, O
   Schwarz, P
   Jorgensen, NR
AF Kringelbach, Tina M.
   Aslan, Derya
   Novak, Ivana
   Ellegaard, Maria
   Syberg, Susanne
   Andersen, Christina K. B.
   Kristiansen, Kim A.
   Vang, Ole
   Schwarz, Peter
   Jorgensen, Niklas R.
TI Fine tuned ATP signals are acute mediators in osteocyte
   mechanotransduction
SO CELLULAR SIGNALLING
LA English
DT Article
DE Osteocyte; Mechanotransduction; ATP release; P2 receptors; Vesicles
ID FUNCTIONAL GAP JUNCTIONS; OSTEOBLASTIC CELLS; P2X7 RECEPTORS;
   SHEAR STRESS; FLUID FLOW; IN VITRO; RELEASE; HEMICHANNELS; BONE;
   CONNEXIN 43
AB Osteocytes are considered the primary mechanosensors of bone, but the signaling pathways they apply in mechanotransduction are still incompletely investigated and characterized. A growing body of data strongly indicates that P2 receptor signaling among osteoblasts and osteoclasts has regulatory effects on bone remodeling. Therefore, we hypothesized that ATP signaling is also applied by osteocytes in mechanotransduction. We applied a short fluid pulse on MLO Y4 osteocyte like cells during real time detection of ATP and demonstrated that mechanical stimulation activates the acute release of ATP and that these acute ATP signals are fine tuned according to the magnitude of loading. ATP release was then challenged by pharmacological inhibitors, which indicated a vesicular release pathway for acute ATP signals. Finally, we showed that osteocytes express functional P2X2 and P2X7 receptors and respond to even low concentrations of nucleotides by increasing intracellular calcium concentration. These results indicate that in osteocytes, vesicular ATP release is an acute mediator of mechanical signals and the magnitude of loading. These and previous results, therefore, implicate purinergic signaling as an early signaling pathway in osteocyte mechanotransduction. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Kringelbach, Tina M.; Aslan, Derya; Ellegaard, Maria; Syberg, Susanne; Andersen, Christina K. B.; Schwarz, Peter; Jorgensen, Niklas R.] Univ Copenhagen, Glostrup Hosp, Res Ctr Ageing & Osteoporosis, Dept Diagnost, Glostrup, Denmark.
   [Kringelbach, Tina M.; Aslan, Derya; Ellegaard, Maria; Syberg, Susanne; Andersen, Christina K. B.; Schwarz, Peter; Jorgensen, Niklas R.] Univ Copenhagen, Glostrup Hosp, Res Ctr Ageing & Osteoporosis, Dept Med, Glostrup, Denmark.
   [Kringelbach, Tina M.; Jorgensen, Niklas R.] Univ Copenhagen, Hvidovre Hosp, Dept Endocrinol, Osteoporosis & Bone Metab Unit, DK 2650 Hvidovre, Denmark.
   [Kringelbach, Tina M.; Jorgensen, Niklas R.] Univ Copenhagen, Hvidovre Hosp, Dept Clin Biochem, Osteoporosis & Bone Metab Unit, DK 2650 Hvidovre, Denmark.
   [Novak, Ivana] Univ Copenhagen, Dept Biol, Copenhagen O, Denmark.
   [Kristiansen, Kim A.] Univ Copenhagen, Glostrup Hosp, Dept Clin Res, Glostrup, Denmark.
   [Vang, Ole] Roskilde Univ, Dept Sci Syst & Models, Roskilde, Denmark.
   [Schwarz, Peter] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen; University of
   Copenhagen; University of Copenhagen; University of Copenhagen;
   University of Copenhagen; Roskilde University; University of Copenhagen
RP Jorgensen, NR (通讯作者)，Glostrup Cty Hosp, Res Ctr Ageing & Osteoporosis, Dept Diagnost, Ndr Ringvej 57, DK 2600 Glostrup, Denmark.
EM Niklas@dadlnet.dk
RI Schwarz, Peter/AAF 1558 2020; Vang, Ole/K 9842 2015; Jørgensen,
   Niklas/B 6003 2012; Kringelbach, Tina/L 3950 2017; Novak,
   Ivana/M 2791 2014
OI Kringelbach, Tina/0009 0002 7886 707X; Vang, Ole/0000 0002 3901 8545;
   Schwarz, Peter/0000 0002 0483 8594; Novak, Ivana/0000 0002 8917 8010;
   Jorgensen, Niklas Rye/0000 0001 9624 5210
FU European Commission [202231]; Faculty of Health Sciences, Copenhagen
   University [211 0457/08 3012]; Danish Council for Independent Research,
   Medical Sciences [271080789]; Toyota Foundation [OH/BG 6360]; Danish
   Council for Independent Research, Natural Sciences [10 085217]
FX Nynne Christensen and Center for Advanced Bioimaging at the University
   of Copenhagen are gratefully acknowledged for their help in staining and
   imaging of vesicles. The work was kindly supported by the European
   Commission under the 7th Framework Program (proposal #202231) performed
   as a collaborative project among the members of the ATPBone Consortium
   (Copenhagen University, University College London, University of
   Maastricht, University of Ferrara, University of Liverpool, University
   of Sheffield, and Universite Libre de Bruxelles), and is a sub study
   under the main study "Fighting osteoporosis by blocking nucleotides:
   purinergic signaling in bone formation and homeostasis". The work was
   also supported by the Faculty of Health Sciences, Copenhagen University
   (grant# 211 0457/08 3012), the Danish Council for Independent Research,
   Medical Sciences (grant# 271080789) and Natural Sciences (10 085217) and
   the Toyota Foundation (grant# OH/BG 6360).
CR Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Al Dujaili SA, 2011, J CELL BIOCHEM, V112, P2412, DOI 10.1002/jcb.23164
   Bao L, 2004, FEBS LETT, V572, P65, DOI 10.1016/j.febslet.2004.07.009
   Bao XY, 2007, P NATL ACAD SCI USA, V104, P4919, DOI 10.1073/pnas.0603154104
   Bao XY, 2004, AM J PHYSIOL CELL PH, V286, pC647, DOI 10.1152/ajpcell.00295.2003
   Bivi N, 2012, CALCIFIED TISSUE INT, V91, P215, DOI 10.1007/s00223 012 9628 z
   Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344 200112000 00012
   Brown SG, 2002, J PHARMACOL EXP THER, V300, P673, DOI 10.1124/jpet.300.2.673
   Bruzzone R, 2005, J NEUROCHEM, V92, P1033, DOI 10.1111/j.1471 4159.2004.02947.x
   Chaytor AT, 1997, J PHYSIOL LONDON, V503, P99, DOI 10.1111/j.1469 7793.1997.099bi.x
   Civitelli R, 2008, ARCH BIOCHEM BIOPHYS, V473, P188, DOI 10.1016/j.abb.2008.04.005
   Dahl G, 2006, IUBMB LIFE, V58, P409, DOI 10.1080/15216540600794526
   Donnelly Roberts DL, 2009, BRIT J PHARMACOL, V157, P1203, DOI 10.1111/j.1476 5381.2009.00233.x
   Feranchak AP, 2010, J BIOL CHEM, V285, P8138, DOI 10.1074/jbc.M109.065482
   Gagliardi S, 1999, CURR MED CHEM, V6, P1197
   Gartland A, 2012, FRONT BIOSCI LANDMRK, V17, P16, DOI 10.2741/3912
   Genetos DC, 2007, J CELL PHYSIOL, V212, P207, DOI 10.1002/jcp.21021
   Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009
   Haanes KA, 2010, BIOCHEM J, V429, P303, DOI 10.1042/BJ20091337
   Hawat G, 2008, PFLUG ARCH EUR J PHY, V456, P519, DOI 10.1007/s00424 007 0426 9
   Huang Y, 2007, GLIA, V55, P46, DOI 10.1002/glia.20435
   Jorgensen NR, 2002, J BIOL CHEM, V277, P7574, DOI 10.1074/jbc.M104608200
   Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497
   Jorgensen NR, 2000, J BONE MINER RES, V15, P1024, DOI 10.1359/jbmr.2000.15.6.1024
   Juszczak GR, 2009, PROG NEURO PSYCHOPH, V33, P181, DOI 10.1016/j.pnpbp.2008.12.014
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017
   Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200
   Locovei S, 2007, FEBS LETT, V581, P483, DOI 10.1016/j.febslet.2006.12.056
   Lu D, 2012, FASEB J, V26, P2580, DOI 10.1096/fj.12 204677
   Ma WH, 2009, J PHARMACOL EXP THER, V328, P409, DOI 10.1124/jpet.108.146365
   Neve A, 2012, ACTA PHYSIOL, V204, P317, DOI 10.1111/j.1748 1716.2011.02385.x
   Orriss IR, 2009, J CELL PHYSIOL, V220, P155, DOI 10.1002/jcp.21745
   Penuela S, 2008, CELL COMMUN ADHES, V15, P133, DOI 10.1080/15419060802014115
   Praetorius HA, 2009, PURINERG SIGNAL, V5, P433, DOI 10.1007/s11302 009 9146 2
   Price C, 2011, J BONE MINER RES, V26, P277, DOI 10.1002/jbmr.211
   Qin YX, 2003, J BIOMECH, V36, P1427, DOI 10.1016/S0021 9290(03)00127 1
   Ralevic V, 1998, PHARMACOL REV, V50, P413
   Reyes Juan P, 2011, Front Biosci (Schol Ed), V3, P1101
   Rudnick G, 2008, P NATL ACAD SCI USA, V105, P5949, DOI 10.1073/pnas.0802774105
   Sawada K, 2008, P NATL ACAD SCI USA, V105, P5683, DOI 10.1073/pnas.0800141105
   Solon E, 1996, DEV COMP IMMUNOL, V20, P307, DOI 10.1016/S0145 305X(96)00022 5
   Sorensen CE, 2001, J BIOL CHEM, V276, P32925, DOI 10.1074/jbc.M103313200
   Suadicani SO, 2006, J NEUROSCI, V26, P1378, DOI 10.1523/JNEUROSCI.3902 05.2006
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Thi MM, 2003, AM J PHYSIOL CELL PH, V284, pC389, DOI 10.1152/ajpcell.00052.2002
   Tokunaga A, 2010, J BIOL CHEM, V285, P17406, DOI 10.1074/jbc.M110.112417
   Wang JJ, 2007, AM J PHYSIOL CELL PH, V293, pC1112, DOI 10.1152/ajpcell.00097.2007
   Wang N., 1828, BIOCHIM BIOPHYS ACTA, V2013, P35
   Wu D, 2013, P NATL ACAD SCI USA, V110, P12096, DOI 10.1073/pnas.1310003110
   Yang WC, 2009, BONE, V44, P32, DOI 10.1016/j.bone.2008.08.133
   Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23 09 03588.2003
   Yegutkin GG, 2006, J BIOL CHEM, V281, P29441, DOI 10.1074/jbc.M602480200
   Yellowley CE, 2000, J BONE MINER RES, V15, P209, DOI 10.1359/jbmr.2000.15.2.209
   Zhang KQ, 2006, MOL CELL BIOL, V26, P4539, DOI 10.1128/MCB.02120 05
NR 55
TC 36
Z9 43
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0898 6568
EI 1873 3913
J9 CELL SIGNAL
JI Cell. Signal.
PD DEC
PY 2015
VL 27
IS 12
BP 2401
EP 2409
DI 10.1016/j.cellsig.2015.08.016
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DA0KQ
UT WOS:000367486400009
PM 26327582
DA 2025 08 17
ER

PT J
AU Zhang, ZC
   Guo, YY
   Gao, XJ
   Wang, XY
   Jin, CY
AF Zhang, Zhichun
   Guo, Yanyan
   Gao, Xuejun
   Wang, Xiaoyan
   Jin, Chanyuan
TI Role of histone methyltransferase KMT2D in BMSC osteogenesis via AKT
   signaling
SO REGENERATIVE THERAPY
LA English
DT Article
DE Marrow mesenchymal stem cell; Osteogenesis; KMT2D; AKT signaling;
   Histone methyltransferase
ID MESENCHYMAL STEM CELLS; KABUKI SYNDROME; DIFFERENTIATION; ENHANCERS;
   THERAPY; GROWTH; CANCER
AB Understanding the precise mechanism of BMSC (bone marrow mesenchymal stem cell) osteogenesis is critical for metabolic bone diseases and bone reconstruction. The histone lysine N methyltransferase 2D (KMT2D) acts as an important methyltransferase related with congenital skeletal disorders, yet the function of KMT2D in osteogenesis was unclear. Here we found that KMT2D expression was decreased in BMSCs collected from ovariectomized mice. Moreover, during human BMSC differentiation under mineralization induction, the mRNA level of KMT2D was gradually elevated. After KMT2D knockdown, the in vitro osteogenic differentiation of BMSCs was inhibited, while the in vivo bone formation potential of BMSCs was attenuated. Further, in BMSCs, KMT2D knockdown reduced the level of phosphorylated protein kinase B (p AKT). SC 79, a common activator of AKT signaling, reversed the suppressing influence of KMT2D knockdown on BMSCs differentiation towards osteoblast. These results indicate that the KMT2D AKT pathway plays an essential role in the osteogenesis process of human BMSCs (hBMSCs), which might provide new avenues for the molecular medicine of bone diseases and regeneration. (c) 2024 The Author(s). Published by Elsevier BV on behalf of The Japanese Society for Regenerative Medicine. This is an open access article under the CC BY NC ND license (http://creativecommons.org/ licenses/by nc nd/4.0/).
C1 [Zhang, Zhichun; Gao, Xuejun; Wang, Xiaoyan] Peking Univ, Sch & Hosp Stomatol, Dept Cariol & Endodontol, Beijing 100081, Peoples R China.
   [Guo, Yanyan; Jin, Chanyuan] Peking Univ, Sch & Hosp Stomatol, Clin Div 2, Beijing 100101, Peoples R China.
   [Zhang, Zhichun; Guo, Yanyan; Gao, Xuejun; Wang, Xiaoyan; Jin, Chanyuan] Natl Ctr Stomatol, Beijing 100081, Peoples R China.
   [Zhang, Zhichun; Guo, Yanyan; Gao, Xuejun; Wang, Xiaoyan; Jin, Chanyuan] Natl Clin Res Ctr Oral Dis, Beijing 100081, Peoples R China.
   [Zhang, Zhichun; Guo, Yanyan; Gao, Xuejun; Wang, Xiaoyan; Jin, Chanyuan] Natl Engn Lab Digital & Mat Technol Stomatol, Beijing 100081, Peoples R China.
   [Zhang, Zhichun; Guo, Yanyan; Gao, Xuejun; Wang, Xiaoyan; Jin, Chanyuan] Beijing Key Lab Digital Stomatol, Beijing 100081, Peoples R China.
C3 Peking University; Peking University
RP Jin, CY (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Clin Div 2, Beijing 100101, Peoples R China.; Jin, CY (通讯作者)，Natl Ctr Stomatol, Beijing 100081, Peoples R China.; Jin, CY (通讯作者)，Natl Clin Res Ctr Oral Dis, Beijing 100081, Peoples R China.; Jin, CY (通讯作者)，Natl Engn Lab Digital & Mat Technol Stomatol, Beijing 100081, Peoples R China.; Jin, CY (通讯作者)，Beijing Key Lab Digital Stomatol, Beijing 100081, Peoples R China.
EM jinchanyuanjcy@163.com
FU National Science Foundation of China [81800942]; Young Elite Scientists
   Sponsorship Program by CAST [2022QNRC001]
FX <BOLD>Fundings</BOLD> The work was supported by grants from the National
   Science Foundation of China (Grant number 81800942) and Young Elite
   Scientists Sponsorship Program by CAST (2022QNRC001) .
CR Alexanian AR, 2015, INT J BIOCHEM CELL B, V64, P190, DOI 10.1016/j.biocel.2015.04.010
   Ang SY, 2016, DEVELOPMENT, V143, P810, DOI 10.1242/dev.132688
   Arthur A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249759
   Ashokkumar D, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.186999
   Barkhordarian A, 2011, BIOINFORMATION, V5, P278, DOI 10.6026/97320630005278
   Barry KK, 2022, GENES BASEL, V13, DOI 10.3390/genes13101761
   Bianco P, 2006, METHOD ENZYMOL, V419, P117, DOI 10.1016/S0076 6879(06)19006 0
   Bjornsson HT, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009278
   Boniel S, 2021, GENES BASEL, V12, DOI 10.3390/genes12040468
   Chan WCW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115445
   Charbord P, 2010, HUM GENE THER, V21, P1045, DOI 10.1089/hum.2010.115
   Cocciadiferro D, 2018, HUM MOL GENET, V27, P3651, DOI 10.1093/hmg/ddy241
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Fahrner JA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129380
   Froimchuk E, 2017, GENE, V627, P337, DOI 10.1016/j.gene.2017.06.056
   Ghasroldasht MM, 2014, CELL BIOL INT, V38, P1081, DOI 10.1002/cbin.10293
   Golden CS, 2023, BIRTH DEFECTS RES, V115, P1809, DOI 10.1002/bdr2.2183
   Guo CC, 2013, ONCOTARGET, V4, P2144, DOI 10.18632/oncotarget.1555
   Huang B, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0018 0
   Hwang NS, 2009, WIRES SYST BIOL MED, V1, P97, DOI 10.1002/wsbm.26
   Jin CY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01965 4
   Jin CY, 2017, J BONE MINER RES, V32, P508, DOI 10.1002/jbmr.3009
   Jung YL, 2023, HUM MOL GENET, V32, P2251, DOI 10.1093/hmg/ddad059
   Komori T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207513
   Kubo N, 2024, MOL CELL, V84, DOI 10.1016/j.molcel.2024.02.030
   Lai BB, 2017, NUCLEIC ACIDS RES, V45, P6388, DOI 10.1093/nar/gkx234
   Lee JE, 2013, ELIFE, V2, DOI 10.7554/eLife.01503
   Lee YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106661
   Lin Shiao E, 2018, GENE DEV, V32, P181, DOI 10.1101/gad.306241.117
   Liu H, 2021, BIOSCI BIOTECH BIOCH, V85, P332, DOI 10.1093/bbb/zbaa010
   Lu J, 2016, MOL MED REP, V14, P3641, DOI 10.3892/mmr.2016.5683
   Lui H, 2021, TISSUE ENG PT A, V27, P1084, DOI [10.1089/ten.tea.2020.0218, 10.1089/ten.TEA.2020.0218]
   Luperchio TR, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1072
   Oton Gonzalez L, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031500
   Pang LP, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20211148
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Schott DA, 2016, AM J MED GENET A, V170, P3172, DOI 10.1002/ajmg.a.37930
   Schwenty Lara J, 2020, HUM MOL GENET, V29, P305, DOI 10.1093/hmg/ddz284
   Shpargel KB, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.187997
   Toska E, 2017, SCIENCE, V355, P1324, DOI 10.1126/science.aah6893
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wang CC, 2016, P NATL ACAD SCI USA, V113, P11871, DOI 10.1073/pnas.1606857113
   Xie KJ, 2023, ATHEROSCLEROSIS, V364, P1, DOI 10.1016/j.atherosclerosis.2022.11.017
   Yang C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1168 2
   Yang Y, 2023, CANCER RES TREAT, V55, P778, DOI 10.4143/crt.2022.1042
   Yu ZY, 2022, CIRC RES, V131, P280, DOI 10.1161/CIRCRESAHA.122.320783
   Zhang JQ, 2023, BIOCHEM BIOPH RES CO, V655, P35, DOI 10.1016/j.bbrc.2023.02.083
   Zhang ZD, 2019, MOL MED REP, V19, P3505, DOI 10.3892/mmr.2019.10051
NR 48
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD JUN
PY 2024
VL 26
BP 775
EP 782
DI 10.1016/j.reth.2024.08.022
EA SEP 2024
PG 8
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA G0G5W
UT WOS:001313504000001
PM 39309396
OA gold
DA 2025 08 17
ER

PT J
AU Ganesan, K
   Xu, C
   Wu, S
   Sui, Y
   Du, B
   Zhang, JH
   Gao, F
   Chen, JP
   Tang, HL
AF Ganesan, Kumar
   Xu, Cong
   Wu, Song
   Sui, Yue
   Du, Bing
   Zhang, Jinhui
   Gao, Fei
   Chen, Jianping
   Tang, Hailin
TI Ononin Inhibits Tumor Bone Metastasis and Osteoclastogenesis By
   Targeting Mitogen Activated Protein Kinase Pathway in Breast Cancer
SO RESEARCH
LA English
DT Article
ID PHORBOL 12 MYRISTATE 13 ACETATE; MESENCHYMAL TRANSITION; CELL;
   DIFFERENTIATION; MECHANISMS; MCF 7; AXIS
AB Breast cancer (BC) often spreads to bones, leading to bone metastasis (BM). Current targeted therapies have limited effectiveness in the treatment of this condition. Osteoclasts, which contribute to bone destruction, are crucial in supporting tumor cell growth in the bones. Breast cancer bone metastasis (BCBM) treatments have limited efficacy and can cause adverse effects. Ononin exhibits anticancer properties against various cancers. The study examined the impact of ononin on the BCBM and the signaling pathways involved. Our study utilized a variety of experimental techniques, including cell viability assays, colony formation assays, wound healing assays, Transwell migration assays, Western blot analysis, and tartrate resistant acid phosphatase (TRAP) staining. We examined the effects of ononin on osteoclastogenesis induced in MDA MB 231 conditioned medium  and RANKL treated RAW 264.7 cells. In a mouse model of BCBM, ononin reduced tumor induced bone destruction. Ononin treatment effectively inhibited proliferation and colony formation and reduced the metastatic capabilities of MDA MB 231 cells by suppressing cell adhesion, invasiveness, and motility and reversing epithelial mesenchymal transition (EMT) markers. Ononin markedly suppressed osteoclast formation and osteolysis associated factors in MDA MB 231 cells, as well as blocked the activation of the mitogen activated protein kinase (MAPK) pathway in RAW 264.7 cells. Ononin treatment down regulated the phosphorylation of MAPK signaling pathways, as confirmed using MAPK agonists or inhibitors. Ononin treatment had no adverse effects on the organ function. Our findings suggest that ononin has therapeutic potential as a BCBM treatment by targeting the MAPK pathway.
C1 [Ganesan, Kumar; Xu, Cong; Sui, Yue; Chen, Jianping] Univ Hong Kong, LKS Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.
   [Wu, Song; Zhang, Jinhui; Tang, Hailin] Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol South China, Guangzhou, Peoples R China.
   [Du, Bing] South China Agr Univ, Coll Food Sci, Guangzhou, Guangdong, Peoples R China.
   [Gao, Fei] Chengdu Univ Tradit Chinese Med, Sch Pharm, Lab Southwestern Chinese Med Resources, Chengdu, Peoples R China.
C3 University of Hong Kong; Sun Yat Sen University; State Key Lab Oncology
   South China; South China Agricultural University; Chengdu University of
   Traditional Chinese Medicine
RP Chen, JP (通讯作者)，Univ Hong Kong, LKS Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.; Tang, HL (通讯作者)，Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol South China, Guangzhou, Peoples R China.; Gao, F (通讯作者)，Chengdu Univ Tradit Chinese Med, Sch Pharm, Lab Southwestern Chinese Med Resources, Chengdu, Peoples R China.
EM feigao207@yeah.net; abchen@hku.hk; tanghl@sysucc.org.cn
RI Du, Bing/JRY 9497 2023; Tang, Hailin/AFJ 8662 2022; Ganesan,
   Kumar/Q 4030 2019
OI Tang, Hailin/0000 0002 3206 782X; Ganesan, Kumar/0000 0002 3198 6066
FU Guangxi Science and Technology Key Research and Development Program
   [AB16450012]
FX This study was supported by the Guangxi Science and Technology Key
   Research and Development Program (no. AB16450012).
CR Alqahtani MS, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.618411
   Babu RL, 2019, GENES DIS, V6, P159, DOI 10.1016/j.gendis.2018.12.001
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown BA, 2024, CANCER RES, V84, P1764, DOI 10.1158/0008 5472.CAN 22 2945
   Cheng Y, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.950122
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Coleman RE, 2001, SEMIN ONCOL, V28, P11, DOI 10.1053/sonc.2001.24155
   Coleman R, 2021, ADV THER, V38, P4569, DOI 10.1007/s12325 021 01812 9
   Coniglio SJ, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00313
   Cui JJ, 2019, RSC ADV, V9, P24471, DOI 10.1039/c9ra04701h
   Ethiraj P, 2021, J CELL BIOCHEM, V122, P1534, DOI 10.1002/jcb.30076
   Ganesan K, 2024, SCI CHINA LIFE SCI, V67, P1849, DOI 10.1007/s11427 023 2499 2
   Ganesan K, 2024, J DRUG DELIV SCI TEC, V96, DOI 10.1016/j.jddst.2024.105609
   Ganesan K, 2024, CHEM BIOL INTERACT, V396, DOI 10.1016/j.cbi.2024.111037
   Gong GW, 2024, INT IMMUNOPHARMACOL, V132, DOI 10.1016/j.intimp.2024.111959
   Gong GW, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/5122448
   Gu JF, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.714322
   Guise T. A., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P570
   Hodgson K, 2024, EBIOMEDICINE, V104, DOI 10.1016/j.ebiom.2024.105163
   Huang XJ, 2024, ONCOL RES, V32, P241, DOI 10.32604/or.2023.046582
   Insua Rodríguez J, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809003
   Kim JH, 2018, BONE, V107, P188, DOI 10.1016/j.bone.2017.12.005
   Kong LB, 2021, J CELL MOL MED, V25, P4649, DOI 10.1111/jcmm.16390
   Lacroix M, 2004, ONCOL REP, V12, P701
   Li B, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.824117
   Liang YR, 2020, SEMIN CANCER BIOL, V60, P14, DOI 10.1016/j.semcancer.2019.08.012
   Lin W, 2024, P NATL ACAD SCI USA, V121, DOI 10.1073/pnas.2320709121
   Lipton A, 2010, BREAST CANCER RES TR, V122, P627, DOI 10.1007/s10549 010 0935 7
   Louw du Toit R., 2023, J Steroid Biochem Mol Biol, V237
   Luo LY, 2018, J AGR FOOD CHEM, V66, P2917, DOI 10.1021/acs.jafc.8b00035
   Morgos DT, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25031848
   Onishi T, 2010, NAT REV CLIN ONCOL, V7, P641, DOI 10.1038/nrclinonc.2010.134
   Pennanen P, 2021, MOL BIOL REP, V48, P1243, DOI 10.1007/s11033 020 06128 5
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sharma U, 2024, J BIOCHEM MOL TOXIC, V38, DOI 10.1002/jbt.23735
   Siegel RL, 2023, CA CANCER J CLIN, V73, P17, DOI [10.3322/caac.21763, 10.3322/caac.21820]
   Singh SP, 2024, CANCER RES, V84, P1320, DOI 10.1158/0008 5472.CAN 23 1200
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Song XL, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.855609
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Tang YH, 2023, RESEARCH CHINA, V6, DOI 10.34133/research.0289
   Tian YH, 2021, INT J MOL MED, V47, P633, DOI 10.3892/ijmm.2020.4820
   Tomczak S, 2024, METABOLITES, V14, DOI 10.3390/metabo14080439
   Wang SKL, 2023, CELL BIOSCI, V13, DOI 10.1186/s13578 023 01171 8
   Wang YF, 2014, J CLIN INVEST, V124, P1646, DOI 10.1172/JCI71812
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wu QH, 2020, J ENZYM INHIB MED CH, V35, P574, DOI 10.1080/14756366.2020.1720013
   Wu S, 2024, CANCER LETT, V581, DOI 10.1016/j.canlet.2023.216508
   Wu XQ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00076
   Ye B, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.939646
   Ye F, 2023, MOL CANCER, V22, DOI 10.1186/s12943 023 01805 y
   Yue ZY, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI144579
   Zgórka G, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15060699
   Zhou RJ, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2148 2
   Zhou T, 2017, ONCOL REP, V38, P3599, DOI 10.3892/or.2017.6011
NR 56
TC 15
Z9 15
U1 8
U2 10
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2096 5168
EI 2639 5274
J9 RESEARCH CHINA
JI Research
PD DEC 16
PY 2024
VL 7
AR 0553
DI 10.34133/research.0553
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA Q1A8P
UT WOS:001382109700001
PM 39687715
OA gold
DA 2025 08 17
ER

PT J
AU Ardura, JA
   Alonso, V
   Esbrit, P
   Friedman, PA
AF Ardura, Juan A.
   Alonso, Veronica
   Esbrit, Pedro
   Friedman, Peter A.
TI Oxidation inhibits PTH receptor signaling and trafficking
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE PTH; PTH receptor; Hydrogen peroxide (PubChem CID:784); Oxidative
   stress; Signaling; Trafficking
ID PARATHYROID HORMONE; BETA 2 ADRENERGIC RECEPTOR; BIOLOGICAL ACTIVITY;
   REDOX REGULATION; STRESS; CYSTEINE; PROTEIN; PEPTIDE; CAMP;
   PHOSPHORYLATION
AB Reactive Oxygen Species (ROS) increase during aging, potentially affecting many tissues including brain, heart, and bone. ROS alter signaling pathways and constitute potential therapeutic targets to limit oxidative damaging effects in aging associated diseases. Parathyroid hormone receptors (PTHR) are widely expressed and PTH is the only anabolic therapy for osteoporosis. The effects of oxidative stress on PTHR signaling and trafficking have not been elucidated. Here, we used Fluorescence Resonance Energy Transfer (FRET) based cAMP, ERK, and calcium fluorescent biosensors to analyze the effects of ROS on PTHR signaling and trafficking by live cell imaging. PTHR internalization and recycling were measured in HEK 293 cells stably transfected with HA PTHR. PTH increased cAMP production, ERK phosphorylation, and elevated intracellular calcium. Pre incubation with H2O2 reduced all PTH dependent signaling pathways. These inhibitory effects were not a result of PTH oxidation since PTH incubated with H2O2 triggered similar responses. PTH promoted internalization and recycling of the PTHR. Both events were significantly reduced by H2O2 pre incubation. These findings highlight the role of oxidation on PTHR signaling and trafficking, and suggest the relevance of ROS as a putative target in diseases associated with oxidative stress such as age related osteoporosis. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Ardura, Juan A.; Alonso, Veronica] Univ San Pablo CEU, IMMA, Madrid, Spain.
   [Ardura, Juan A.; Esbrit, Pedro] UAM, Lab Metabol Mineral & Oseo, IIS, Fdn Jimenez Diaz, Madrid, Spain.
   [Ardura, Juan A.; Esbrit, Pedro] Inst Salud Carlos III, Red Temat Invest Cooperat Envejecimiento & Fragil, Madrid, Spain.
   [Friedman, Peter A.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Lab GPCR Biol, Pittsburgh, PA 15260 USA.
C3 San Pablo CEU University; Autonomous University of Madrid; Fundacion
   Jimenez Diaz; Instituto de Salud Carlos III; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh
RP Friedman, PA (通讯作者)，Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Lab GPCR Biol, Pittsburgh, PA 15260 USA.
EM paf10@pitt.edu
RI Ardura, Juan/F 3378 2017; RODRIGUEZ, VERONICA/F 3364 2017
OI Ardura Rodriguez, Juan Antonio/0000 0002 2827 3364; Alonso,
   Veronica/0000 0002 2813 3257
FU Spanish Instituto de Salud Carlos III [PI11/00449, RETICEF
   RD12/0043/0008]; National Institutes (NIH) [DK105811]
FX This work was supported by grants from the Spanish Instituto de Salud
   Carlos III (PI11/00449 and RETICEF RD12/0043/0008) to PE and by the
   National Institutes (NIH) (DK105811) to PAF.
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Aguilar Gaytan R, 2003, BIOCHEM BIOPH RES CO, V305, P510, DOI 10.1016/S0006 291X(03)00796 4
   Almeida M., 2010, INT BONE MINERAL DEN, V7, P340, DOI DOI 10.1138/20100467
   Alonso V, 2011, J BONE MINER RES, V26, P143, DOI 10.1002/jbmr.167
   Ardura J. A., 2016, J CELL PHYSL
   Banday AA, 2007, AM J PHYSIOL RENAL, V293, pF306, DOI 10.1152/ajprenal.00108.2007
   BAUD L, 1986, AM J PHYSIOL, V251, pF765, DOI 10.1152/ajprenal.1986.251.5.F765
   Betts M.J., 2003, BIOINFORMATICS GENET, DOI [DOI 10.1002/0470867302.CH14, DOI 10.1002/9780470059180.CH13]
   Burns RN, 2011, J PHARMACOL EXP THER, V339, P914, DOI 10.1124/jpet.111.185975
   Cheng J, 2006, CELL BIOCHEM BIOPHYS, V45, P177, DOI 10.1385/CBB:45:2:177
   Clemens TL, 2001, BRIT J PHARMACOL, V134, P1113, DOI 10.1038/sj.bjp.0704378
   Feinstein TN, 2011, NAT CHEM BIOL, V7, P278, DOI 10.1038/nchembio.545
   Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206
   Forbes JM, 2008, DIABETES, V57, P1446, DOI 10.2337/db08 0057
   FRELINGER AL, 1984, J BIOL CHEM, V259, P5507
   FRELINGER AL, 1986, ARCH BIOCHEM BIOPHYS, V244, P641, DOI 10.1016/0003 9861(86)90632 6
   GALCERAN T, 1984, ENDOCRINOLOGY, V115, P2375, DOI 10.1210/endo 115 6 2375
   Gesty Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200
   Hanyaloglu AC, 2008, ANNU REV PHARMACOL, V48, P537, DOI 10.1146/annurev.pharmtox.48.113006.094830
   Hocher B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040242
   HORIUCHI N, 1988, J BONE MINER RES, V3, P353, DOI 10.1002/jbmr.5650030316
   Ihara Y, 2002, BIOCHEM BIOPH RES CO, V297, P353, DOI 10.1016/S0006 291X(02)02195 2
   Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474 9726.2010.00616.x
   Khan EM, 2006, J BIOL CHEM, V281, P14486, DOI 10.1074/jbc.M509332200
   Komatsu N, 2011, MOL BIOL CELL, V22, P4647, DOI 10.1091/mbc.E11 01 0072
   LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488
   LIGGETT SB, 1989, BIOCHEM BIOPH RES CO, V165, P257, DOI 10.1016/0006 291X(89)91063 2
   Lipton SA, 2002, TRENDS NEUROSCI, V25, P474, DOI 10.1016/S0166 2236(02)02245 2
   Ma JH, 2014, J BIOL CHEM, V289, P133, DOI 10.1074/jbc.M113.533240
   Mahalingam CD, 2013, J ENDOCRINOL, V216, P315, DOI 10.1530/JOE 12 0372
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   McGarvey JC, 2016, J BIOL CHEM, V291, P10986, DOI 10.1074/jbc.M115.697045
   Mougeolle A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122654
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200
   ODOWD BF, 1989, J BIOL CHEM, V264, P7564
   ORIORDAN JL, 1974, J ENDOCRINOL, V63, P117, DOI 10.1677/joe.0.0630117
   Paulsen CE, 2012, NAT CHEM BIOL, V8, P57, DOI 10.1038/nchembio.736
   Pavlos N. J., 2016, TRENDS ENDOCRINOL ME
   Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008
   ROSENBLATT M, 1976, J BIOL CHEM, V251, P159
   Sneddon WB, 2004, ENDOCRINOLOGY, V145, P2815, DOI 10.1210/en.2003 1185
   Thomas BE, 2007, J BONE MINER RES, V22, P609, DOI 10.1359/JBMR.070101
   Truong TH, 2012, BIOCHEMISTRY US, V51, P9954, DOI 10.1021/bi301441e
   Wang B, 2007, J BIOL CHEM, V282, P36214, DOI 10.1074/jbc.M707263200
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   ZULL JE, 1990, J BIOL CHEM, V265, P5671
NR 48
TC 12
Z9 12
U1 0
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 22
PY 2017
VL 482
IS 4
BP 1019
EP 1024
DI 10.1016/j.bbrc.2016.11.150
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA EK1XB
UT WOS:000393720000076
PM 27908723
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zheng, JC
   Li, XY
   Zhang, FK
   Li, CW
   Zhang, XK
   Wang, F
   Qi, J
   Cui, WG
   Deng, LF
AF Zheng, Jiancheng
   Li, Xiaoyan
   Zhang, Fangke
   Li, Changwei
   Zhang, Xingkai
   Wang, Fei
   Qi, Jin
   Cui, Wenguo
   Deng, Lianfu
TI Targeting Osteoblast Osteoclast Cross Talk Bone Homeostasis Repair
   Microcarriers Promotes Intervertebral Fusion in Osteoporotic Rats
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE intervertebral fusion; microfluidics; mRNA@LNP; OB OC cross talk; USP26
ID STRESS
AB Balancing osteoblast osteoclast (OB OC) cross talk is crucial for restoring bone tissue structure and function. Current clinical drugs targeting either osteogenesis or osteoclastogenesis fail to effectively regulate cross talk, impeding efficient bone repair in osteoporosis patients. Ubiquitin specific protease 26 (USP26) is shown to coordinate OB OC cross talk by independently regulating beta catenin and I kappa b alpha. However, effective drugs for activating USP26 are still lacking. Here, they constructed bone homeostasis repair microcarriers (BHRC) that encapsulate Usp26 mRNA loaded lipid nanoparticles (mRNA@LNP) within MMPs responsive GelMA hydrogel microspheres. These microcarriers target the osteoporotic microenvironment and regulate OB OC cross talk, thereby facilitating intervertebral fusion in osteoporotic rats. Results demonstrate that mRNA@LNP exhibits uniform particle size and high transfection efficiency, while GelMA hydrogel microspheres possess excellent biocompatibility and MMP responsiveness, providing favorable cell survival space and controllable release of mRNA@LNP. The released LNP upregulates USP26 protein expression, effectively promoting osteogenesis while suppressing osteoclast formation. In vivo experiments show that injecting BHRC into the defect site of intervertebral discs in osteoporotic rats significantly promotes tail vertebrae fusion by responding to the microenvironment and regulating cell to cell cross talk. Thus, the BHRC holds great potential in regulating osteoporotic homeostasis, particularly in challenging bone defects such as intervertebral fusion in osteoporotic environments.
C1 [Zheng, Jiancheng; Zhang, Fangke; Li, Changwei; Zhang, Xingkai; Wang, Fei; Qi, Jin; Cui, Wenguo; Deng, Lianfu] Ruijin Hosp, Dept Orthopaed, Shanghai Key Lab Prevent & Treatment Bone & Joint, Shanghai Inst Traumatol & Orthopaed, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
   [Li, Xiaoyan] Jining Med Univ, Dept Orthoped, Affiliated Hosp, Jining City 272029, Shandong, Peoples R China.
C3 Shanghai Jiao Tong University; Jining Medical University
RP Qi, J; Cui, WG; Deng, LF (通讯作者)，Ruijin Hosp, Dept Orthopaed, Shanghai Key Lab Prevent & Treatment Bone & Joint, Shanghai Inst Traumatol & Orthopaed, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
EM qj40347@rjh.com.cn; WGCUI80@HOTMAIL.COM; lf_deng@126.com
RI ; Li, Changwei/AAS 9984 2020
OI Cui, Wenguo/0000 0002 6938 9582; 
FU National Natural Science Foundation of China [82272556, 5227313];
   Postdoctoral Fellowship Program of CPSF [GZB20230444]; Shanghai
   Municipal Health and Family Planning Commission [2022XD055]
FX J.Z., X.L., and F.Z. contributed equally to this work. This work was
   supported by the National Natural Science Foundation of China (82272556
   and 5227313), and Postdoctoral Fellowship Program of CPSF (GZB20230444),
   Shanghai Municipal Health and Family Planning Commission (2022XD055).
CR Antas P, 2024, TRENDS MOL MED, V30, P136, DOI 10.1016/j.molmed.2023.11.009
   Borciani G, 2020, ACTA BIOMATER, V108, P22, DOI 10.1016/j.actbio.2020.03.043
   Cai CD, 2022, ADV MATER, V34, DOI 10.1002/adma.202106564
   Chang HZ, 2022, SMALL METHODS, V6, DOI 10.1002/smtd.202101201
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chen KZ, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.721561
   Chen W, 2023, ADV MATER, V35, DOI 10.1002/adma.202301037
   Chen WK, 2023, RESEARCH CHINA, V6, DOI 10.34133/research.0089
   Chen ZH, 2022, MATER FUTURES, V1, DOI 10.1088/2752 5724/ac39ff
   Deshmukh T, 2023, HEART LUNG CIRC, V32, P798, DOI 10.1016/j.hlc.2023.05.018
   Ebert T, 2022, MOL ASPECTS MED, V86, DOI 10.1016/j.mam.2022.101099
   Greenblatt MB, 2015, J EXP MED, V212, P1283, DOI 10.1084/jem.20150407
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Jadhav SG, 2021, NAT MATER, V20, P575, DOI 10.1038/s41563 021 00988 3
   Li CW, 2022, CELL DEATH DIFFER, V29, P1123, DOI 10.1038/s41418 021 00904 x
   Liu ZC, 2021, EXP CELL RES, V398, DOI 10.1016/j.yexcr.2020.112359
   Mao JY, 2024, MED CAMBRIDGE, V5, P148, DOI 10.1016/j.medj.2024.01.006
   Maus Alexander, 2021, Eng Regen, V2, P31, DOI 10.1016/j.engreg.2021.03.001
   Miao QJ, 2022, BIOMED MATER, V17, DOI 10.1088/1748 605X/ac4323
   Pei H, 2022, MATTER US, V5, P1670, DOI 10.1016/j.matt.2022.03.006
   Shen Y., 2022, Smart Med, V1
   Tian H, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.780590
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang F, 2016, ACTA BIOMATER, V29, P94, DOI 10.1016/j.actbio.2015.10.034
   Wang G, 2022, ADV FIBER MATER, V4, P1304, DOI 10.1007/s42765 022 00179 y
   Wang J, 2024, SCI BULL, V69, P1249, DOI 10.1016/j.scib.2024.03.013
   Wang Q., 2023, Smart Med., V2
   Wang S, 2024, ADV MATER, V36, DOI 10.1002/adma.202311964
   Wen ZQ, 2023, MILITARY MED RES, V10, DOI 10.1186/s40779 023 00485 5
   Xu W, 2024, Biomed Techn, V5, P102
   Yang K, 2022, J MED CHEM, V65, P10992, DOI 10.1021/acs.jmedchem.2c00081
   Yang Nengjie, 2024, Engineered Regeneration, V5, P153, DOI 10.1016/j.engreg.2024.02.002
   Zhang FK, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202211644
   Zhang L, 2023, CLIN TRANSL MED, V13, DOI 10.1002/ctm2.1369
   Zheng JC, 2024, SMALL METHODS, V8, DOI 10.1002/smtd.202301375
   Zheng JC, 2021, BIOCHEM BIOPH RES CO, V555, P46, DOI 10.1016/j.bbrc.2021.03.088
NR 36
TC 5
Z9 5
U1 12
U2 45
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD DEC
PY 2024
VL 13
IS 31
AR 2402117
DI 10.1002/adhm.202402117
EA AUG 2024
PG 13
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA S1F0S
UT WOS:001292606700001
PM 39155412
DA 2025 08 17
ER

PT J
AU Song, FM
   Zhou, L
   Zhao, JM
   Liu, Q
   Yang, ML
   Tan, RX
   Xu, J
   Zhang, G
   Quinn, JMW
   Tickner, J
   Huang, YJ
   Xu, JK
AF Song, Fangming
   Zhou, Lin
   Zhao, Jinmin
   Liu, Qian
   Yang, Mingli
   Tan, Renxiang
   Xu, Jun
   Zhang, Ge
   Quinn, Julian M. W.
   Tickner, Jennifer
   Huang, Yuanjiao
   Xu, Jiake
TI Eriodictyol Inhibits RANKL Induced Osteoclast Formation and Function Via
   Inhibition of NFATc1 Activity
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID NF KAPPA B; BONE RESORPTION; MURINE MACROPHAGES; RECEPTOR ACTIVATOR;
   SIGNALING PATHWAY; HEME OXYGENASE 1; RAW264.7 CELLS; KEY REGULATOR;
   C FOS; DIFFERENTIATION
AB Receptor activator of nuclear factor kappa B ligand (RANKL) induces differentiation and function of osteoclasts through triggering multiple signaling cascades, including NF kappa B, MAPK, and Ca2+ dependent signals, which induce and activate critical transcription factor NFATc1. Targeting these signaling cascades may serve as an effective therapy against osteoclast related diseases. Here, by screening a panel of natural plant extracts with known anti inflammatory, anti tumor, or anti oxidant properties for possible anti osteoclastogenic activities we identified Eriodictyol. This flavanone potently suppressed RANKL induced osteoclastogenesis and bone resorption in a dose dependent manner without detectable cytotoxicity, suppressing RANKL induced NF kappa B, MAPK, and Ca2+ signaling pathways. Eriodictyol also strongly inhibited RANKL induction of c Fos levels (a critical component of AP 1 transcription factor required by osteoclasts) and subsequent activation of NFATc1, concomitant with reduced expression of osteoclast specific genes including cathepsin K (Ctsk), V ATPase d2 subunit, and tartrate resistant acid phosphatase (TRAcP/Acp5). Taken together, these data provide evidence that Eriodictyol could be useful for the prevention and treatment of osteolytic disorders associated with abnormally increased osteoclast formation and function. (C) 2016 Wiley Periodicals, Inc.
C1 [Song, Fangming; Zhao, Jinmin; Liu, Qian; Huang, Yuanjiao; Xu, Jiake] Guangxi Med Univ, Key Lab Biol Mol Med Res Guangxi Higher Educ, Guangxi Key Lab Regenerat Med, Dept Biochem & Mol Biol, Nanning, Guangxi, Peoples R China.
   [Song, Fangming; Zhou, Lin; Yang, Mingli; Tickner, Jennifer; Xu, Jiake] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA, Australia.
   [Song, Fangming] Guangxi Med Univ, Pharmaceut Coll, Nanning, Guangxi, Peoples R China.
   [Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Nanning, Guangxi, Peoples R China.
   [Tan, Renxiang] Nanjing Univ, Inst Funct Biomol, Sch Med, Nanjing, Jiangsu, Peoples R China.
   [Xu, Jun] Sun Yat Sen Univ, Sch Pharmaceut Sci, Res Ctr Drug Discovery RCDD, Guangzhou, Guangdong, Peoples R China.
   [Zhang, Ge] Hong Kong Baptist Univ, Inst Adv Translat Med Bone & Joint Dis, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.
   [Quinn, Julian M. W.] Garvan Inst Med Res, Darlinghurst, NSW, Australia.
   [Huang, Yuanjiao] Guangxi Med Univ, Med Sci Res Ctr, Nanning, Guangxi, Peoples R China.
C3 Guangxi Medical University; University of Western Australia; Guangxi
   Medical University; Guangxi Medical University; Nanjing University; Sun
   Yat Sen University; Hong Kong Baptist University; Garvan Institute of
   Medical Research; Guangxi Medical University
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Pathol & Lab Med, Perth, WA, Australia.; Huang, YJ (通讯作者)，Guangxi Med Univ, Med Sci Res Ctr, Dept Biochem & Mol Biol, Key Lab Biol Mol Med Res Guangxi Higher Educ, Nanning, Guangxi, Peoples R China.
EM hyjgxmu@126.com; jiake.xu@uwa.edu.au
RI Zhang, Ge/KGL 7634 2024; Zhang, Jun/H 5904 2017; zhao,
   jin/LBH 0351 2024; Zhang, Ge/N 4150 2013; Tickner, Jennifer/H 5965 2014
OI Xu, Jiake/0000 0003 2021 8309; Zhao, Jinmin/0000 0002 1047 8820;
   Tickner, Jennifer/0000 0002 5020 0671
FU National Health and Medical Research Council of Australia, Natural
   Science Foundation of Guangxi Province [2015GXNSFDA139019]; Innovation
   Project of Guangxi Graduate Education; Co innovation Centre for
   Bio Medicine, Guangxi Key Laboratory of Regenerative Medicine, Guangxi
   Medical University
FX Contract grant sponsor: National Health and Medical Research Council of
   Australia, Natural Science Foundation of Guangxi Province;Contract grant
   number: No. 2015GXNSFDA139019.Contract grant sponsor: Innovation Project
   of Guangxi Graduate Education.Contract grant sponsor: Co innovation
   Centre for Bio Medicine, Guangxi Key Laboratory of Regenerative
   Medicine, Guangxi Medical University.
CR Abu Amer Y, 2009, CURR OPIN PHARMACOL, V9, P427, DOI 10.1016/j.coph.2009.06.007
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Baud'huin M, 2007, EXPERT REV ANTICANC, V7, P221, DOI 10.1586/14737140.7.2.221
   Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756 3282(99)00105 2
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kim JL, 2012, MOL NUTR FOOD RES, V56, P1223, DOI 10.1002/mnfr.201100831
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee E, 2013, BMB REP, V46, P594, DOI 10.5483/BMBRep.2013.46.12.092
   Lee JK, 2011, ARCH PHARM RES, V34, P671, DOI 10.1007/s12272 011 0418 3
   Lee MY, 2012, INFLAMMATION, V35, P746, DOI 10.1007/s10753 011 9370 0
   Lee SE, 2015, INT J MOL SCI, V16, P14526, DOI 10.3390/ijms160714526
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Lippuner K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13624
   Liu YY, 2013, EUR J PHARMACOL, V698, P95, DOI 10.1016/j.ejphar.2012.10.013
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Shinohara Masahiro, 2007, Curr Osteoporos Rep, V5, P67
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Zhang HF, 2013, FOOD CHEM TOXICOL, V55, P70, DOI 10.1016/j.fct.2012.12.043
NR 49
TC 30
Z9 35
U1 0
U2 52
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD SEP
PY 2016
VL 231
IS 9
BP 1983
EP 1993
DI 10.1002/jcp.25304
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA DQ4FJ
UT WOS:000379159100014
PM 26754483
DA 2025 08 17
ER

PT J
AU Chen, Q
   Liu, K
   Robinson, AR
   Clauson, CL
   Blair, HC
   Robbins, PD
   Niedernhofer, LJ
   Ouyang, HJ
AF Chen, Qian
   Liu, Kai
   Robinson, Andria R.
   Clauson, Cheryl L.
   Blair, Harry C.
   Robbins, Paul D.
   Niedernhofer, Laura J.
   Ouyang, Hongjiao
TI DNA damage drives accelerated bone aging via an NF κB dependent
   mechanism
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; OSTEOBLASTS; OSTEOCLASTS; BONE; NUCLEOTIDE EXCISION
   REPAIR; PROGERIA; AGING; NF B TRANSCRIPTION FACTOR; ERCC1 XPF
   ENDONUCLEASE
ID NUCLEOTIDE EXCISION REPAIR; GENOTOXIC STRESS; B ACTIVATION; NUCLEAR
   ABNORMALITIES; MICE; SENESCENCE; PROTEIN; DIFFERENTIATION; ENDONUCLEASE;
   OSTEOPOROSIS
AB Advanced age is one of the most important risk factors for osteoporosis. Accumulation of oxidative DNA damage has been proposed to contribute to age related deregulation of osteoblastic and osteoclastic cells. Excision repair cross complementary group 1xeroderma pigmentosum group F (ERCC1 XPF) is an evolutionarily conserved structure specific endonuclease that is required for multiple DNA repair pathways. Inherited mutations affecting expression of ERCC1 XPF cause a severe progeroid syndrome in humans, including early onset of osteopenia and osteoporosis, or anomalies in skeletal development. Herein, we used progeroid ERCC1 XPFdeficient mice, including Ercc1 null (Ercc1/) and hypomorphic (Ercc1/) mice, to investigate the mechanism by which DNA damage leads to accelerated bone aging. Compared to their wild type littermates, both Ercc1/ and Ercc1/ mice display severe, progressive osteoporosis caused by reduced bone formation and enhanced osteoclastogenesis. ERCC1 deficiency leads to atrophy of osteoblastic progenitors in the bone marrow stromal cell (BMSC) population. There is increased cellular senescence of BMSCs and osteoblastic cells, as characterized by reduced proliferation, accumulation of DNA damage, and a senescence associated secretory phenotype (SASP). This leads to enhanced secretion of inflammatory cytokines known to drive osteoclastogenesis, such as interleukin 6 (IL 6), tumor necrosis factor (TNF), and receptor activator of NF B ligand (RANKL), and thereby induces an inflammatory bone microenvironment favoring osteoclastogenesis. Furthermore, we found that the transcription factor NF B is activated in osteoblastic and osteoclastic cells of the Ercc1 mutant mice. Importantly, we demonstrated that haploinsufficiency of the p65 NF B subunit partially rescued the osteoporosis phenotype of Ercc1/ mice. Finally, pharmacological inhibition of the NF B signaling via an I B kinase (IKK) inhibitor reversed cellular senescence and SASP in Ercc1/ BMSCs. These results demonstrate that DNA damage drives osteoporosis through an NF Bdependent mechanism. Therefore, the NF B pathway represents a novel therapeutic target to treat aging related bone disease. (c) 2013 American Society for Bone and Mineral Research.
C1 [Chen, Qian; Ouyang, Hongjiao] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA.
   [Liu, Kai] Univ Pittsburgh, Sch Dent Med, Dept Oral Biol, Pittsburgh, PA 15261 USA.
   [Robinson, Andria R.] Univ Pittsburgh, Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Robinson, Andria R.; Clauson, Cheryl L.; Robbins, Paul D.; Niedernhofer, Laura J.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15261 USA.
   [Clauson, Cheryl L.; Robbins, Paul D.; Niedernhofer, Laura J.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15261 USA.
   [Blair, Harry C.] Pittsburgh Vet Affairs Med Ctr, Pittsburgh, PA USA.
   [Blair, Harry C.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA.
   [Ouyang, Hongjiao] Univ Pittsburgh, Sch Dent Med, Dept Restorat Dent & Comprehens Care, Pittsburgh, PA 15261 USA.
   [Ouyang, Hongjiao] Univ Pittsburgh, Sch Dent Med, Ctr Craniofacial Regenerat, Pittsburgh, PA 15261 USA.
   [Ouyang, Hongjiao] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15261 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Ouyang, HJ (通讯作者)，Univ Pittsburgh, Sch Dent Med, Dept Restorat Dent & Comprehens Care, 630 Salk Hall 3550 Terrace St, Pittsburgh, PA 15261 USA.
EM hoo1@pitt.edu
RI Chen, Qian/AAV 1871 2020; Niedernhofer, Laura/LTD 0324 2024
FU NIH/NIDCR [RO1DE017439]; NIH/NCI [R21CA161150]; multiple myeloma
   research foundation (MMRF); Ellison Medical Foundation [AG NS 0303 05];
   Scoliosis Research Society (SRS); Department of Veterans Affairs; 
   [R01AR055208];  [AG033907];  [AR051456];  [NS058451];  [AG024827]; 
   [ES016114];  [P30AG024827];  [P30CA047904]
FX This work was supported by NIH/NIDCR (RO1DE017439), NIH/NCI
   (R21CA161150), and the multiple myeloma research foundation (MMRF) tumor
   microenvironment award to HO, R01AR055208 to HCB, AG033907, AR051456,
   NS058451, and AG024827 to PDR, ES016114, P30AG024827, P30CA047904, and
   Ellison Medical Foundation AG NS 0303 05 to LJN, and the New
   Investigator Grant of Scoliosis Research Society (SRS) to QC. The
   opinions expressed are not those of the Department of Veterans Affairs
   or of the U. S. Government. We thank Dr. G. David Roodman (Indiana
   University) and Mr. Kenneth Patrene (University of Pittsburgh) for the
   bone mu CT analyses, Dr. Tao Chen (University of Pittsburgh) for
   providing the lentiviral construct, and Matthew H. Pham and Andrew
   Stypula (University of Pittsburgh) for preparing histological sections.
   We thank the VA Pittsburgh Healthcare System for providing common
   facilities and the support of the Department of Veterans Affairs.
CR Acharyya S, 2007, J CLIN INVEST, V117, P889, DOI 10.1172/JCI30556
   Ahmad A, 2008, MOL CELL BIOL, V28, P5082, DOI 10.1128/MCB.00293 08
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Cheung CL, 2010, NAT REV RHEUMATOL, V6, P507, DOI 10.1038/nrrheum.2010.106
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   Dai JL, 2000, J CLIN INVEST, V106, P887, DOI 10.1172/JCI10483
   Derheimer FA, 2010, FEBS LETT, V584, P3675, DOI 10.1016/j.febslet.2010.05.031
   Dollé MET, 2011, PATHOBIOL AGING AGE, V1, DOI 10.3402/pba.v1i0.7219
   Gregg SQ, 2011, DNA REPAIR, V10, P781, DOI 10.1016/j.dnarep.2011.04.026
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615
   HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092 8674(95)90070 5
   Jaspers NGJ, 2007, AM J HUM GENET, V80, P457, DOI 10.1086/512486
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Lavasani M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1611
   Mabb AM, 2006, NAT CELL BIOL, V8, P986, DOI 10.1038/ncb1458
   Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003
   MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193 217
   Miyamoto S, 2011, CELL RES, V21, P116, DOI 10.1038/cr.2010.179
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Niedernhofer LJ, 2006, NATURE, V444, P1038, DOI 10.1038/nature05456
   Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776 5787.2004
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655
   Prasher JM, 2005, EMBO J, V24, P861, DOI 10.1038/sj.emboj.7600542
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Saeed H, 2011, J BONE MINER RES, V26, P1494, DOI 10.1002/jbmr.349
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097 4652(200003)182:3<311::AID JCP1>3.0.CO;2 9
   Sharpless NE, 2004, EXP GERONTOL, V39, P1751, DOI 10.1016/j.exger.2004.06.025
   Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011
   SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201
   Sijbers AM, 1996, NUCLEIC ACIDS RES, V24, P3370, DOI 10.1093/nar/24.17.3370
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Srinivasan V, 2010, AGING CELL, V9, P933, DOI 10.1111/j.1474 9726.2010.00622.x
   Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092 8674(00)80413 4
   Stewart SA, 2006, ANNU REV CELL DEV BI, V22, P531, DOI 10.1146/annurev.cellbio.22.010305.104518
   Tian M, 2004, MOL CELL BIOL, V24, P2237, DOI 10.1128/MCB.24.6.2237 2242.2004
   Undale A, 2010, BONE, V47, P83, DOI 10.1016/j.bone.2010.03.018
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Wang CF, 2009, AGING CELL, V8, P311, DOI 10.1111/j.1474 9726.2009.00481.x
   Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960 9822(06)00190 4
   Wu ZH, 2007, J MOL MED, V85, P1187, DOI 10.1007/s00109 007 0227 9
   Zhang W, 2008, J BONE MINER RES, V23, P1118, DOI [10.1359/jbmr.080304, 10.1359/JBMR.080304]
   Zineldeen DH, 2010, CURR DRUG METAB, V11, P266
NR 49
TC 101
Z9 110
U1 0
U2 23
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2013
VL 28
IS 5
BP 1214
EP 1228
DI 10.1002/jbmr.1851
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 131VF
UT WOS:000318024300026
PM 23281008
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Bergamin, LS
   Penolazzi, L
   Lambertini, E
   Falzoni, S
   Sarti, AC
   Molle, CM
   Gendron, FP
   De Bonis, P
   Di Virgilio, F
   Piva, R
AF Bergamin, Leticia Scussel
   Penolazzi, Letizia
   Lambertini, Elisabetta
   Falzoni, Simonetta
   Sarti, Alba Clara
   Molle, Caroline M.
   Gendron, Fernand Pierre
   De Bonis, Pasquale
   Di Virgilio, Francesco
   Piva, Roberta
TI Expression and function of the P2X7 receptor in human osteoblasts: The
   role of NFATc1 transcription factor
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE bone mineralization; gene expression regulation; human osteoblasts;
   NFATc1; purinergic signaling
ID PURINERGIC RECEPTORS; BONE; ACTIVATION; DIFFERENTIATION; HOMEOSTASIS;
   ALPHA; CELLS
AB Bone mineralization is an orchestrated process by which mineral crystals are deposited by osteoblasts; however, the detailed mechanisms remain to be elucidated. The presence of P2X7 receptor (P2X7R) in immature and mature bone cells is well established, but contrasting evidence on its role in osteogenic differentiation and deposition of calcified bone matrix remains. To clarify these controversies in the present study, we investigated P2X7R participation in bone maturation. We demonstrated that the P2X7R is expressed and functional in human primary osteoblasts, and identified in theP2RX7promoter several binding sites for transcription factors involved in bone mineralization. Of particular interest was the finding that P2X7R expression is enhanced by nuclear factor of activated T cells cytoplasmic 1 (NFATc1) overexpression, and accordingly, NFATc1 is recruited at theP2RX7gene promoter in SaOS2 osteoblastic like cells. In conclusion, our data provide further insights into the regulation of P2X7R expression and support the development of drugs targeting this receptor for the therapy of bone diseases.
C1 [Bergamin, Leticia Scussel; Penolazzi, Letizia; Lambertini, Elisabetta; Piva, Roberta] Univ Ferrara, Dept Biomed & Specialty Surg Sci, Via Fossato di Mortara 74, I 44121 Ferrara, Italy.
   [Falzoni, Simonetta; Sarti, Alba Clara; Di Virgilio, Francesco] Univ Ferrara, Dept Med Sci, Ferrara, Italy.
   [Molle, Caroline M.; Gendron, Fernand Pierre] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Immunol & Cell Biol, Sherbrooke, PQ, Canada.
   [De Bonis, Pasquale] S Anna Univ Hosp, Dept Neurosurg, Ferrara, Italy.
C3 University of Ferrara; University of Ferrara; University of Sherbrooke;
   University of Ferrara; Arcispedale Sant'Anna
RP Piva, R (通讯作者)，Univ Ferrara, Dept Biomed & Specialty Surg Sci, Via Fossato di Mortara 74, I 44121 Ferrara, Italy.
EM piv@unife.it
RI ; Sarti, Alba/AAO 7737 2020; de bonis, pasquale/LGY 7253 2024; Di
   Virgilio, Francesco/J 3754 2018; Gendron, Fernand Pierre/AAN 2965 2021
OI Penolazzi, Letizia/0000 0002 1293 5087; Piva,
   Roberta/0000 0003 2663 6210; Bergamin, Leticia/0000 0002 8363 795X;
   Falzoni, Simonetta/0000 0002 6594 0357; Di Virgilio,
   Francesco/0000 0003 3566 1362; Gendron,
   Fernand Pierre/0000 0002 4731 4352
FU Ministry of Education of Italy [20178YTNWC]; Italian Association for
   Cancer Research (AIRC) [IG 13025, IG 18581, IG 22883]
FX Ministry of Education of Italy, Grant/Award Number: n. 20178YTNWC;
   Italian Association for Cancer Research (AIRC) grants, Grant/Award
   Numbers: IG 13025, IG 18581, IG 22883
CR Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04 11 1025
   Adinolfi E, 2018, BIOCHEM PHARMACOL, V151, P234, DOI 10.1016/j.bcp.2017.12.021
   Agrawal A, 2017, BONE, V95, P91, DOI 10.1016/j.bone.2016.11.011
   Agrawal A, 2015, J MOL ENDOCRINOL, V54, pR75, DOI 10.1530/JME 14 0226
   Amoroso F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.105
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bilodeau MS, 2015, BIOCHEM CELL BIOL, V93, P38, DOI 10.1139/bcb 2014 0098
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Brandao Burch Andrea, 2012, Front Endocrinol (Lausanne), V3, P41, DOI 10.3389/fendo.2012.00041
   Burnstock G, 2011, ADV PHARMACOL, V61, P333, DOI 10.1016/B978 0 12 385526 8.00011 4
   Burnstock G, 2013, PURINERG SIGNAL, V9, P541, DOI 10.1007/s11302 013 9381 4
   Demer LL, 2014, ARTERIOSCL THROM VAS, V34, P715, DOI 10.1161/ATVBAHA.113.302070
   Di Virgilio F, 2017, ONCOGENE, V36, P293, DOI 10.1038/onc.2016.206
   Di Virgilio F, 2019, METHOD ENZYMOL, V629, P115, DOI 10.1016/bs.mie.2019.07.043
   Di Virgilio F, 2018, TRENDS CELL BIOL, V28, P392, DOI 10.1016/j.tcb.2018.01.005
   Di Virgilio F, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00039
   Dong YT, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.110010
   FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770
   Fan LH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/239356
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Giuliani AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107224
   Goss M, 2019, MOL GENET METAB, V126, P504, DOI 10.1016/j.ymgme.2019.01.014
   Grol MW, 2016, PURINERG SIGNAL, V12, P509, DOI 10.1007/s11302 016 9517 4
   Grol MW, 2013, J CELL SCI, V126, P3615, DOI 10.1242/jcs.122705
   Hayrapetyan A, 2015, TISSUE ENG PART B RE, V21, P75, DOI [10.1089/ten.teb.2014.0119, 10.1089/ten.TEB.2014.0119]
   Jorgensen NR, 2015, CURR MED CHEM, V22, P902, DOI 10.2174/0929867321666141215094749
   Jorgensen NR, 2018, CURR OPIN IMMUNOL, V52, P32, DOI 10.1016/j.coi.2018.03.016
   Kaebisch C, 2015, COMPUT STRUCT BIOTEC, V13, P75, DOI 10.1016/j.csbj.2014.11.003
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Kim J, 2016, SCI REP UK, V6, DOI 10.1038/srep25437
   Lambertini E, 2008, J CELL PHYSIOL, V216, P101, DOI 10.1002/jcp.21379
   Lambertini E, 2017, ONCOTARGET, V8, P101686, DOI 10.18632/oncotarget.21514
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Noronha Matos JB, 2016, J CELL PHYSIOL, V231, P1852, DOI 10.1002/jcp.25303
   Penolazzi L, 2011, INT J MOL MED, V28, P199, DOI 10.3892/ijmm.2011.701
   Seref Ferlengez Z, 2019, ANN NY ACAD SCI, V1442, P79, DOI 10.1111/nyas.13914
   Sindhavajiva PR, 2017, ARCH ORAL BIOL, V81, P167, DOI 10.1016/j.archoralbio.2017.05.009
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wilson A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01112
   Young MF, 2016, MATRIX BIOL, V52 54, P1, DOI 10.1016/j.matbio.2016.04.003
   Zeng DH, 2019, J CELL PHYSIOL, V234, P2095, DOI 10.1002/jcp.27544
   Zhang Z, 2019, CURR STEM CELL RES T, V14, P239, DOI 10.2174/1574888X14666181205122729
NR 44
TC 11
Z9 12
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JAN
PY 2021
VL 236
IS 1
BP 641
EP 652
DI 10.1002/jcp.29891
EA JUN 2020
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA OT9OU
UT WOS:000542571400001
PM 32583512
DA 2025 08 17
ER

PT J
AU Tremblay, E
   Perreault, S
   Dorais, M
AF Tremblay, Eric
   Perreault, Sylvie
   Dorais, Marc
TI Persistence with denosumab and zoledronic acid among older women: a
   population based cohort study
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE Denosumab; Zoledronic acid; Persistence; Osteoporosis
ID MEDICAL SERVICES CLAIMS; POSTMENOPAUSAL OSTEOPOROSIS; FRACTURE RISK;
   BISPHOSPHONATE THERAPY; HIP FRACTURES; HEALTH PLAN; ADHERENCE;
   METAANALYSIS; DATABASES; IMPACT
AB A Summary Persistence to denosumab or zoledronic acid was increased compared to oral bisphosphonates. Introduction Denosumab and zoledronic acid are alternative therapies to oral bisphosphonates. Few studies have assessed persistence of those agents.
   Methods Incident users of denosumab and zoledronic acid were identified using healthcare databases of public drug insurance plan of Quebec province, Canada. Patients initiating therapy between October 1, 2008, and June 30, 2013, and aged 50 years and over were eligible. A persistence rate was assessed over a 2 year period. We assess the proportion of patients receiving the second, third, and fourth injections within a specific delay of predicted time of renewal of both agents. The predictors of non persistence were analyzed using a Cox regression model only among women.
   Results Among 12,689 incident users, 97.2 % were women. Kaplan Meier analysis showed a slow decline of persistence after initiating zoledronic acid compared to denosumab therapy, dropping to 81.6 and 63.3% after 1 and 2 years of follow up using the permissive gaps of 56 days, in contrast to zoledronic acid, where persistence rate still stays at 74.8 % after 2 years of follow up using the permissive gap of 112 days. The likelihood of non persistence was significantly higher among new users of denosumab and zoledronic acid among older patients and year of initiation; but depression and diabetes are only predictors of non persistence among the zoledronic group. Concomitant use of calcium and vitamin D supplements was at low level which may compromise the clinical efficacy.
   Conclusion The persistence rate to denosumab and zoledronic acid was higher to the published data of oral bisphosphonates. The second intention of treatment seems to target more severe patients which may more likely to be compliant.
C1 [Tremblay, Eric] Inst Excellence Sante & Serv Sociaux INESSS, 2535 Boul Laurier,5e, Quebec City, PQ G1V 4M3, Canada.
   [Perreault, Sylvie] Univ Montreal, Fac Pharm, Montreal, PQ, Canada.
   [Dorais, Marc] StatSciences Inc, Notre Dame De Lile Perro, PQ, Canada.
C3 Universite de Montreal
RP Tremblay, E (通讯作者)，Inst Excellence Sante & Serv Sociaux INESSS, 2535 Boul Laurier,5e, Quebec City, PQ G1V 4M3, Canada.
EM eric.tremblay@inesss.qc.ca
RI Perreault, Sylvie/AAM 8009 2020
FU Quebec Health Ministry
FX This work was supported by public funds from the Quebec Health Ministry.
CR Andrade SE, 2006, PHARMACOEPIDEM DR S, V15, P565, DOI 10.1002/pds.1230
   [Anonymous], PORTR US BISPH DEN C
   Bessette L, 2012, OSTEOPOROSIS INT, V23, P1757, DOI 10.1007/s00198 011 1785 9
   Blouin J, 2009, OSTEOPOROSIS INT, V20, P1571, DOI 10.1007/s00198 008 0818 5
   Blouin J, 2008, BRIT J CLIN PHARMACO, V66, P117, DOI 10.1111/j.1365 2125.2008.03178.x
   Blouin J, 2007, J CLIN ENDOCR METAB, V92, P887, DOI 10.1210/jc.2006 1856
   Bolland MJ, 2010, J CLIN ENDOCR METAB, V95, P1174, DOI 10.1210/jc.2009 0852
   Burden AM, 2012, OSTEOPOROSIS INT, V23, P1075, DOI 10.1007/s00198 011 1645 7
   Cadarette SM, 2012, OSTEOPOROSIS INT, V23, P1475, DOI 10.1007/s00198 011 1771 2
   Cadarette Suzanne M, 2013, CMAJ Open, V1, pE97, DOI 10.9778/cmajo.20130036
   Curtis JR, 2012, ARTHRIT CARE RES, V64, P1054, DOI 10.1002/acr.21638
   Foundation NO, 2013, CLIN GUID PREV TREAT
   Hadji P, 2015, OSTEOPOROSIS INT, V26, P2479, DOI 10.1007/s00198 015 3164 4
   Hadji P, 2015, OSTEOPOROS INT
   Halpern R, 2011, J MANAGE CARE PHARM, V17, P25, DOI 10.18553/jmcp.2011.17.1.25
   Hudson M, 2013, J CLIN EPIDEMIOL, V66, P278, DOI 10.1016/j.jclinepi.2012.10.004
   Hughes Cindy, 2010, Fam Pract Manag, V17, P15
   Institut national de sante publique du Quebec, 2016, RAPPORT SURVEILLANCE, P10
   Kanis JA, 2004, BONE, V35, P375, DOI 10.1016/j.bone.2004.03.024
   Karlsson L, 2015, OSTEOPOROSIS INT, V26, P2401, DOI 10.1007/s00198 015 3253 4
   Lee YK, 2012, OSTEOPOROSIS INT, V23, P2329, DOI 10.1007/s00198 011 1881 x
   Maraka S, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h3783
   Migliore A, 2013, EUR REV MED PHARMACO, V17, P658
   Morin S, 2007, OSTEOPOROSIS INT, V18, P1625, DOI 10.1007/s00198 007 0421 1
   Murad MH, 2012, J CLIN ENDOCR METAB, V97, P1871, DOI 10.1210/jc.2011 3060
   Overman RA, 2014, ARTHRITIS RHEUMATOL, V66, pS1011
   Papaioannou A, 2010, CAN MED ASSOC J, V182, P1864, DOI 10.1503/cmaj.100771
   Ross S, 2011, VALUE HEALTH, V14, P571, DOI 10.1016/j.jval.2010.11.010
   Schousboe JT, 2013, CURR OSTEOPOROS REP, V11, P21, DOI 10.1007/s11914 013 0133 8
   Silverman SL, 2015, OSTEOPOROSIS INT, V26, P361, DOI 10.1007/s00198 014 2871 6
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Siris ES, 2011, J BONE MINER RES, V26, P3, DOI 10.1002/jbmr.189
   Siris ES, 2009, AM J MED, V122, P3, DOI 10.1016/j.amjmed.2008.12.002
   TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895 4356(94)00234 H
   Tamblyn R, 2000, J CLIN EPIDEMIOL, V53, P183, DOI 10.1016/S0895 4356(99)00136 5
   Tarride JE, 2012, OSTEOPOROSIS INT, V23, P2591, DOI 10.1007/s00198 012 1931 z
   Wade SW, 2012, BONE, V50, P870, DOI 10.1016/j.bone.2011.12.021
   WEST SL, 1995, AM J EPIDEMIOL, V142, P1103, DOI 10.1093/oxfordjournals.aje.a117563
   Wilchesky M, 2004, J CLIN EPIDEMIOL, V57, P131, DOI 10.1016/S0895 4356(03)00246 4
   YOLA M, 1994, J CLIN EPIDEMIOL, V47, P731, DOI 10.1016/0895 4356(94)90170 8
NR 40
TC 23
Z9 24
U1 0
U2 12
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862 3522
EI 1862 3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD DEC
PY 2016
VL 11
IS 1
AR 30
DI 10.1007/s11657 016 0282 3
PG 11
WC Endocrinology & Metabolism; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Orthopedics
GA EH0BC
UT WOS:000391426300007
PM 27679503
DA 2025 08 17
ER

PT J
AU Thimmuri, D
   Shantanu, PA
   Syamprasad, NP
   Khan, A
   Gawali, B
   Rajdev, B
   Adhikari, C
   Ravichandiran, V
   Sharma, P
   Naidu, VGM
AF Thimmuri, Dinesh
   Shantanu, P. A.
   Syamprasad, N. P.
   Khan, Aasiya
   Gawali, Basveshwar
   Rajdev, Bishal
   Adhikari, Chanakya
   Ravichandiran, V
   Sharma, Pawan
   Naidu, V. G. M.
TI Hispolon inhibits RANKL induced osteoclast differentiation in
   vitro
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE Hispolon; RANKL; RAW264.7; Osteoclastogenesis; Bone resorption
AB Hispolon (HISP) is a bioactive compound isolated from Phellinu linteus. It has various pharmacological activities, including antioxidant, anti inflammatory, and anti cancer. However, its anti osteoclastogenic activity has not yet been reported. Hence, in the current study, we have explored the anti osteoclastogenic activity of HISP and elucidated the molecular mechanisms. HISP inhibited the RANKL induced differentiation of RAW 264.7 cells into osteoclasts in a dose dependent manner. Mechanistic studies showed that HISP inhibited RANKL mediated activation of NF kappa B and MAPK signaling pathways in osteoclast precursors RAW 264.7 cells. In addition, Hispolon also downregulated the expression of master transcriptional factors essential for osteoclast differentiation, such as NFATc1 and c FOS. In conclusion, these findings establish molecular mechanisms behind the anti osteoclastogenic activity of HISP.
C1 [Thimmuri, Dinesh; Khan, Aasiya] Natl Inst Pharmaceut Educ & Res NIPER Hyderabad, Dept Pharmacol & Toxicol, 40 Balanagar, Hyderabad 500037, Telangana, India.
   [Shantanu, P. A.; Syamprasad, N. P.; Gawali, Basveshwar; Rajdev, Bishal; Adhikari, Chanakya; Naidu, V. G. M.] Natl Inst Pharmaceut Educ & Res NIPER Guwahati, Dept Pharmacol & Toxicol, PO Changsari, Gauhati 781101, Assam, India.
   [Sharma, Pawan] Thomas Jefferson Univ, Ctr Translat Med, Philadelphia, PA 19107 USA.
   [Ravichandiran, V] Natl Inst Pharmaceut Educ & Res NIPER Kolkata, 168 Chunilal Bhawan, Kolkata 700054, W Bengal, India.
C3 National Institute of Pharmaceutical Education & Research, Hyderabad;
   National Institute of Pharmaceutical Education & Research, S.A.S. Nagar
   (Mohali); Thomas Jefferson University
RP Naidu, VGM (通讯作者)，Natl Inst Pharmaceut Educ & Res NIPER Guwahati, Dept Pharmacol & Toxicol, PO Changsari, Gauhati 781101, Assam, India.
EM vgmnaidu@gmail.com
RI NP, Syamprasad/LRC 9207 2024; RAJDEV, BISHAL/LZF 4837 2025; Gawali,
   Basveshwar/GLU 3602 2022; VELAYUTHAM, RAVICHANDIRAN/HGU 8028 2022;
   Sharma, Pawan/D 4314 2016
OI , NIPERKolkata/0000 0003 4906 3988; , Velayutham
   Ravichandiran/0009 0000 8057 399X; Rajdev, Bishal/0000 0001 9644 2740;
   Gawali, Dr Basveshwar/0000 0002 2086 6325; RAVICHANDIRAN,
   V/0000 0001 7820 9486; Sharma, Pawan/0000 0002 2904 2306; NP, Dr
   Syamprasad/0000 0003 4232 0291
FU Department of Pharmaceuticals, Ministry of Chemical and Fertilizers,
   Govt of India; Department of Science and Technology Ministry of Science
   and Technology, Govt. of India [YSS/2014/000764]; National Mission for
   Himalayan studies, Ministry of Environment, Forest and Climate Change,
   Govt of India [GBPI/NMHS/2017 18/HSF 02]
FX This work is supported by the Department of Pharmaceuticals, Ministry of
   Chemical and Fertilizers, Govt of India, Department of Science and
   Technology Ministry of Science and Technology, Govt. of India
   (YSS/2014/000764) and National Mission for Himalayan studies, Ministry
   of Environment, Forest and Climate Change, Govt of India for the
   fellowship provided to authors (GBPI/NMHS/2017 18/HSF 02).
CR Ali NAA, 2003, FITOTERAPIA, V74, P483, DOI 10.1016/S0367 326X(03)00119 9
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Balaji NV, 2017, BIOORG MED CHEM LETT, V27, P11, DOI 10.1016/j.bmcl.2016.11.047
   Balaji NV, 2015, BIOORGAN MED CHEM, V23, P2148, DOI 10.1016/j.bmc.2015.03.002
   Boraschi Diaz I, 2016, CYTOTECHNOLOGY, V68, P105, DOI 10.1007/s10616 014 9759 3
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang HY, 2011, EVID BASED COMPLEMEN, V2011
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   He L, 2012, BONE, V50, P1207, DOI 10.1016/j.bone.2012.03.022
   Hsin MC, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.459
   Huang GJ, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/480714
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   Muchmore D B, 2000, Oncologist, V5, P388, DOI 10.1634/theoncologist.5 5 388
   Rasmusson L, 2014, INT J DENT, V2014, DOI 10.1155/2014/471035
   Roscher Anne, 2016, Bone Rep, V5, P214, DOI 10.1016/j.bonr.2016.07.002
   Rossi M, 2019, BIOORGAN MED CHEM, V27, P3805, DOI 10.1016/j.bmc.2019.07.008
   Stopeck AT, 2016, SUPPORT CARE CANCER, V24, P447, DOI 10.1007/s00520 015 2904 5
   Sun YS, 2015, ONCOL LETT, V10, P536, DOI 10.3892/ol.2015.3220
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thummuri D, 2017, J MOL MED, V95, P1065, DOI 10.1007/s00109 017 1553 1
   Toussaint ND, 2009, CLIN J AM SOC NEPHRO, V4, P221, DOI 10.2215/CJN.02550508
   Van PharmD K., OSTEOPOROSIS REV TRE
   Wei XN, 2020, J INORG BIOCHEM, V202, DOI 10.1016/j.jinorgbio.2019.110857
   Wu QG, 2014, BIOCHEM BIOPH RES CO, V453, P385, DOI 10.1016/j.bbrc.2014.09.098
   Yang LY, 2014, J ETHNOPHARMACOL, V156, P61, DOI 10.1016/j.jep.2014.07.054
NR 30
TC 5
Z9 5
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0165 2478
EI 1879 0542
J9 IMMUNOL LETT
JI Immunol. Lett.
PD MAR
PY 2021
VL 231
BP 35
EP 42
DI 10.1016/j.imlet.2021.01.003
EA JAN 2021
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA RJ0ZS
UT WOS:000637332800006
PM 33428992
DA 2025 08 17
ER

PT J
AU Yi, HY
   Wang, ZY
   Li, XJ
   Yin, M
   Wang, LH
   Aldalbahi, A
   El Sayed, NN
   Wang, H
   Chen, N
   Fan, CH
   Song, HY
AF Yi, Hongyang
   Wang, Zhuyao
   Li, Xiaojiao
   Yin, Min
   Wang, Lihua
   Aldalbahi, Ali
   El Sayed, Nahed Nasser
   Wang, Hui
   Chen, Nan
   Fan, Chunhai
   Song, Haiyun
TI Silica Nanoparticles Target a Wnt Signal Transducer for Degradation and
   Impair Embryonic Development in Zebrafish
SO THERANOSTICS
LA English
DT Article
DE silica nanoparticles; signal transduction; embryonic development;
   obesity; cancer metastasis
ID IN VIVO; GOLD NANOPARTICLES; BETA CATENIN; DELIVERY; PHOSPHORYLATION;
   ADIPOGENESIS; LOCALIZATION; RESISTANCE; AUTOPHAGY; UBIQUITIN
AB Many types of biocompatible nanomaterials have proven of low cytotoxicity and hold great promise for various applications in nanomedicine. Whereas they generally do not cause apparent organ toxicity or tissue damage in adult animals, it is yet to determine their biological consequences in more general contexts. In this study, we investigate how silica nanoparticles (NPs) affect cellular activities and functions under several physiological or pathological conditions. Although silica NPs are generally regarded as "inert" nanocarriers and widely employed in biomedical studies, we find that they actively affect Wnt signaling in various types of cell lines, diminishing its anti adipogenic effect in preadipocytes and pro invasive effect in breast cancer cells, and more significantly, impair Wnt regulated embryonic development in Zebrafish. We further demonstrate that intracellular silica NPs block Wnt signal transduction in a way resembling signaling molecules. Specifically, silica NPs target the Dvl protein, a key component of Wnt signaling cascade, for lysosomal degradation. As Wnt signaling play significant roles in embryonic development and adipogenesis, the observed physiological effects beyond toxicity imply potential risk of obesity, or developmental defects in somitogenesis and osteogenesis upon exposure to silica NPs. In addition, given the clinical implications of Wnt signaling in tumorigenesis and cancer metastasis, our work also establishes for the first time a molecular link between nanomaterials and the Wnt signaling pathway, which opens new door for novel applications of unmodified silica NPs in targeted therapy for cancers and other critical illness.
C1 [Yi, Hongyang; Wang, Zhuyao; Li, Xiaojiao; Wang, Hui; Song, Haiyun] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Food Safety Res, Shanghai 200031, Peoples R China.
   [Yi, Hongyang; Wang, Zhuyao; Li, Xiaojiao; Wang, Hui; Song, Haiyun] Minist Hlth, Key Lab Food Safety Risk Assessment, Beijing 100021, Peoples R China.
   [Yin, Min; Wang, Lihua; Chen, Nan; Fan, Chunhai] Chinese Acad Sci, Shanghai Inst Appl Phys, Div Phys Biol, Shanghai 201800, Peoples R China.
   [Yin, Min; Wang, Lihua; Chen, Nan; Fan, Chunhai] Chinese Acad Sci, Shanghai Inst Appl Phys, CAS Key Lab Interfacial Phys & Technol, Shanghai Synchrotron Radiat Facil,Bioimaging Ctr, Shanghai 201800, Peoples R China.
   [Aldalbahi, Ali; El Sayed, Nahed Nasser] King Saud Univ, Dept Chem, Riyadh 11451, Saudi Arabia.
C3 Chinese Academy of Sciences; Chinese Academy of Sciences; Shanghai
   Institute of Applied Physics, CAS; Chinese Academy of Sciences; Shanghai
   Institute of Applied Physics, CAS; King Saud University
RP Song, HY (通讯作者)，Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Food Safety Res, Shanghai 200031, Peoples R China.; Song, HY (通讯作者)，Minist Hlth, Key Lab Food Safety Risk Assessment, Beijing 100021, Peoples R China.; Chen, N; Fan, CH (通讯作者)，Chinese Acad Sci, Shanghai Inst Appl Phys, Div Phys Biol, Shanghai 201800, Peoples R China.; Chen, N; Fan, CH (通讯作者)，Chinese Acad Sci, Shanghai Inst Appl Phys, CAS Key Lab Interfacial Phys & Technol, Shanghai Synchrotron Radiat Facil,Bioimaging Ctr, Shanghai 201800, Peoples R China.
EM chennan@sinap.ac.cn; fchh@sinap.ac.cn; hysong@sibs.ac.cn
RI ; wang, hui/G 6433 2015; El Sayed, Nahed/JAX 5608 2023; yin,
   min/JKI 3898 2023; Aldalbahi, Ali/E 3511 2015; Nan, Chen/ABG 2783 2020;
   Yi, Hongyang/ISS 1654 2023; Fan, Chunhai/A 7569 2011
OI El Sayed, Nahed Nasser Eid/0000 0001 9771 8956; Chen,
   Nan/0000 0001 8536 6631; Aldalbahi, Ali/0000 0003 1644 2367; Li,
   Xiaojiao/0000 0002 0662 2850; 
FU National Natural Science Foundation of China [31322039, 31371493,
   31571498, U1332119, 31371015, 31470970]; Science and Technology Service
   Network Initiative from Chinese Academy of Sciences [KFJ EW STS 099];
   Youth Innovation Promotion Association from Chinese Academy of Sciences
   [2015211]; Shanghai Municipal Commission for Science and Technology
   [13NM1402300]; Visiting Professor Program at King Saud University
FX We would like to dedicate this article to Professor Qing Huang. This
   study was supported by National Natural Science Foundation of China
   (31322039, 31371493, 31571498, U1332119, 31371015 and 31470970), Science
   and Technology Service Network Initiative from Chinese Academy of
   Sciences (KFJ EW STS 099), Youth Innovation Promotion Association from
   Chinese Academy of Sciences (2015211) and the Shanghai Municipal
   Commission for Science and Technology (13NM1402300). We also acknowledge
   the support from Visiting Professor Program at King Saud University.
CR Agathon A, 2003, NATURE, V424, P448, DOI 10.1038/nature01822
   Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Bai YH, 2010, NAT NANOTECHNOL, V5, P683, DOI [10.1038/NNANO.2010.153, 10.1038/nnano.2010.153]
   Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065
   Bottini M, 2007, J AM CHEM SOC, V129, P7814, DOI 10.1021/ja070245c
   Brookes MJ, 2008, ONCOGENE, V27, P966, DOI 10.1038/sj.onc.1210711
   Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871
   Chen F, 2013, ACS NANO, V7, P9027, DOI [10.1021/nn403617j, 10.1021/nn403617J]
   Chen N, 2014, SMALL, V10, P3603, DOI 10.1002/smll.201303635
   Cheng K, 2009, J AM CHEM SOC, V131, P10637, DOI 10.1021/ja903300f
   Chung TH, 2007, BIOMATERIALS, V28, P2959, DOI 10.1016/j.biomaterials.2007.03.006
   Clague MJ, 2010, CELL, V143, P682, DOI 10.1016/j.cell.2010.11.012
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Cong WS, 2015, BIOMATERIALS, V42, P78, DOI 10.1016/j.biomaterials.2014.11.048
   Deng ZJ, 2011, NAT NANOTECHNOL, V6, P39, DOI [10.1038/nnano.2010.250, 10.1038/NNANO.2010.250]
   Erathodiyil N, 2011, ACCOUNTS CHEM RES, V44, P925, DOI 10.1021/ar2000327
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Gharbi N, 2005, NANO LETT, V5, P2578, DOI 10.1021/nl051866b
   Haglund K, 2012, J CELL SCI, V125, P265, DOI 10.1242/jcs.091280
   He QJ, 2009, SMALL, V5, P2722, DOI 10.1002/smll.200900923
   Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Kokubu C, 2004, DEVELOPMENT, V131, P5469, DOI 10.1242/dev.01405
   Kubota T, 2009, J BONE MINER METAB, V27, P265, DOI 10.1007/s00774 009 0064 8
   Kumar R, 2010, ACS NANO, V4, P699, DOI 10.1021/nn901146y
   Li LL, 2010, ACS NANO, V4, P6874, DOI 10.1021/nn100918a
   Ma XW, 2011, ACS NANO, V5, P8629, DOI 10.1021/nn202155y
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Malvindi MA, 2012, NANOSCALE, V4, P486, DOI 10.1039/c1nr11269d
   Matsuda Y, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2317
   Meng H, 2013, ACS NANO, V7, P994, DOI 10.1021/nn3044066
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   O'Brien WT, 2004, J NEUROSCI, V24, P6791, DOI 10.1523/JNEUROSCI.4753 03.2004
   Prestwich TC, 2007, CURR OPIN CELL BIOL, V19, P612, DOI 10.1016/j.ceb.2007.09.014
   Qian SP, 2013, ADV MATH PHYS, V2013, DOI 10.1155/2013/282390
   Rabolli V, 2010, NANOTOXICOLOGY, V4, P307, DOI 10.3109/17435390.2010.482749
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Rothbächer U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010
   Schwarz Romond T, 2007, NAT STRUCT MOL BIOL, V14, P484, DOI 10.1038/nsmb1247
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Thorpe CJ, 2005, DEVELOPMENT, V132, P1763, DOI 10.1242/dev.01733
   Vivero Escoto JL, 2012, CHEM SOC REV, V41, P2673, DOI 10.1039/c2cs15229k
   Wang B, 2012, SCI REP UK, V2, DOI 10.1038/srep00563
   Wei M, 2012, ANGEW CHEM INT EDIT, V51, P1202, DOI 10.1002/anie.201105187
   Yu T, 2011, ACS NANO, V5, P5717, DOI 10.1021/nn2013904
   Zhang Y, 2016, ADV MATER, V28, P1387, DOI 10.1002/adma.201503893
NR 49
TC 25
Z9 25
U1 0
U2 37
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2016
VL 6
IS 11
BP 1810
EP 1820
DI 10.7150/thno.16127
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA DX1EN
UT WOS:000384108900006
PM 27570552
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Toscani, D
   Palumbo, C
   Dalla Palma, B
   Ferretti, M
   Bolzoni, M
   Marchica, V
   Sena, P
   Martella, E
   Mancini, C
   Ferri, V
   Costa, F
   Accardi, F
   Craviotto, L
   Aversa, F
   Giuliani, N
AF Toscani, Denise
   Palumbo, Carla
   Dalla Palma, Benedetta
   Ferretti, Marzia
   Bolzoni, Marina
   Marchica, Valentina
   Sena, Paola
   Martella, Eugenia
   Mancini, Cristina
   Ferri, Valentina
   Costa, Federica
   Accardi, Fabrizio
   Craviotto, Luisa
   Aversa, Franco
   Giuliani, Nicola
TI The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in
   Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A
   New Function for Proteasome Inhibitors
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOCYTES; CANCER INDUCED BONE DISEASE; MULTIPLE MYELOMA; PROTEASOME
   INHIBITORS; AUTOPHAGY
ID BONE FORMATION; CELL DEATH; OSTEOBLAST DIFFERENTIATION; MINERAL
   HOMEOSTASIS; PARATHYROID HORMONE; IN VITRO; MLO Y4; BISPHOSPHONATES;
   GLUCOCORTICOIDS; ESTABLISHMENT
AB Multiple myeloma (MM) is characterized by severely imbalanced bone remodeling. In this study, we investigated the potential effect of proteasome inhibitors (PIs), a class of drugs known to stimulate bone formation, on the mechanisms involved in osteocyte death induced by MM cells. First, we performed a histological analysis of osteocyte viability on bone biopsies on a cohort of 37 MM patients with symptomatic disease. A significantly higher number of viable osteocytes was detected in patients treated with a bortezomib (BOR) based regimen compared with those treated without BOR. Interestingly, both osteocyte autophagy and apoptosis were affected in vivo by BOR treatment. Thereafter, we checked the in vitro effect of BOR to understand the mechanisms whereby BOR maintains osteocyte viability in bone from MM patients. We found that osteocyte and preosteocyte autophagic death was triggered during coculturing with MM cells. Our evaluation was conducted by analyzing either autophagy markers microtubule associated protein light chain 3 beta (LC3B) and SQSTM1/sequestome 1 (p62) levels, or the cell ultrastructure by transmission electron microscopy. PIs were found to increase the basal levels of LC3 expression in the osteocytes while blunting the myeloma induced osteocyte death. PIs also reduced the autophagic death of osteocytes induced by high dose dexamethasone (DEX) and potentiated the anabolic effect of PTH(1 34). Our data identify osteocyte autophagy as a new potential target in MM bone disease and support the use of PIs to maintain osteocyte viability and improve bone integrity in MM patients. (c) 2015 American Society for Bone and Mineral Research.
C1 [Toscani, Denise; Dalla Palma, Benedetta; Bolzoni, Marina; Marchica, Valentina; Ferri, Valentina; Costa, Federica; Accardi, Fabrizio; Craviotto, Luisa; Aversa, Franco; Giuliani, Nicola] Univ Parma, Dept Clin & Expt Med, Myeloma Unit, Via Gramsci 14, I 43126 Parma, Italy.
   [Palumbo, Carla; Ferretti, Marzia; Sena, Paola] Univ Modena & Reggio Emilia, Sect Human Morphol, Dept Biomed Metab & Neural Sci, Modena, Italy.
   [Dalla Palma, Benedetta; Accardi, Fabrizio; Aversa, Franco; Giuliani, Nicola] Azienda Osped Univ Parma, Hematol Unit, I 43100 Parma, Italy.
   [Martella, Eugenia; Mancini, Cristina] Azienda Osped Univ Parma, Pathol, Parma, Italy.
   [Ferri, Valentina] Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy.
C3 University of Parma; University Hospital of Parma; Universita di Modena
   e Reggio Emilia; University of Parma; University Hospital of Parma;
   University of Parma; University Hospital of Parma; University of
   Insubria
RP Giuliani, N (通讯作者)，Univ Parma, Dept Clin & Expt Med, Myeloma Unit, Via Gramsci 14, I 43126 Parma, Italy.
EM nicola.giuliani@unipr.it
RI Dalla Palma, Anna Benedetta/K 7867 2016; Ferretti, Marzia/F 1153 2016;
   Giuliani, Nicola/AAT 7968 2020; Marchica, Valentina/AAB 9869 2022; Sena,
   Paola/JCO 2014 2023; Accardi, Fabrizio/IQR 8194 2023; Bolzoni,
   Marina/K 4032 2016; toscani, denise/N 8100 2019; Palma,
   Anna/K 7867 2016; Sena, Paola/G 9394 2016; Palumbo, Carla/E 5802 2012;
   Costa, Federica/K 4754 2018
OI Dalla Palma, Anna Benedetta/0000 0002 5198 3452; Ferretti,
   Marzia/0000 0003 0280 3598; Giuliani, Nicola/0000 0003 3457 3774;
   Accardi, Fabrizio/0000 0002 7736 2822; Bolzoni,
   Marina/0000 0002 0821 8093; Toscani, Denise/0000 0003 3492 4415;
   Marchica, Valentina/0000 0002 8536 5409; Sena,
   Paola/0000 0003 4724 8786; Costa, Federica/0000 0002 1742 9212
FU Associazione Italiana per la Ricerca sul Cancro (AIRC): Special Program
   in Molecular Clinical Oncology 5 x 1000 [9965]; Associazione Italiana
   per la Ricerca sul Cancro (AIRC): IG2014 [15531]; Consorzio Spinner;
   FIRC Elda e Attilio Pandolfi [16462]
FX This work was supported in part by a grant from the Associazione
   Italiana per la Ricerca sul Cancro (AIRC): Special Program in Molecular
   Clinical Oncology 5 x 1000 no 9965 (NG) and IG2014 no 15531 (NG); a
   fellowship from the "Consorzio Spinner"; and a fellowship FIRC Elda e
   Attilio Pandolfi ID 16462 (DT).
CR Auner HW, 2015, BRIT J HAEMATOL, V168, P14, DOI 10.1111/bjh.13172
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Bodine PVN, 1996, ENDOCRINOLOGY, V137, P4592, DOI 10.1210/en.137.11.4592
   Bonewald LF, 1999, J BONE MINER METAB, V17, P61, DOI 10.1007/s007740050066
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Calle JD, 2013, BLOOD, V122
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Chen H, 2015, MED MOL MORPHOL, V48, P61, DOI 10.1007/s00795 015 0099 y
   Delgado Calle J, 2014, BLOOD, V124
   Emerton KB, 2010, BONE, V46, P577, DOI 10.1016/j.bone.2009.11.006
   Engelhardt M, 2014, HAEMATOLOGICA, V99, P232, DOI 10.3324/haematol.2013.099358
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Gioia R, 2012, STEM CELLS, V30, P1465, DOI 10.1002/stem.1107
   Giuliani N, 2012, LEUKEMIA, V26, P1391, DOI 10.1038/leu.2011.381
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032
   Hocking LJ, 2012, J BONE MINER RES, V27, P1439, DOI 10.1002/jbmr.1668
   Hui B, 2012, CANCER AM CANCER SOC, V118, P5560, DOI 10.1002/cncr.27586
   Jiang PD, 2015, METHODS, V75, P13, DOI 10.1016/j.ymeth.2014.11.021
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kao C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.468
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Munemasa S, 2008, INT J ONCOL, V33, P129
   Noble BS, 2000, MOL CELL ENDOCRINOL, V159, P7, DOI 10.1016/S0303 7207(99)00174 4
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Onal M, 2013, J BIOL CHEM, V288, P17432, DOI 10.1074/jbc.M112.444190
   PALUMBO C, 1990, BONE, V11, P401, DOI 10.1016/8756 3282(90)90134 K
   Pengo N, 2013, NAT IMMUNOL, V14, P298, DOI 10.1038/ni.2524
   Pennisi A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015233
   Periyasamy Thandavan S, 2010, AUTOPHAGY, V6, P19, DOI 10.4161/auto.6.1.10323
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Rosser J, 2012, METHODS MOL BIOL, V816, P67, DOI 10.1007/978 1 61779 415 5_6
   Selimovic D, 2013, CELL SIGNAL, V25, P308, DOI 10.1016/j.cellsig.2012.10.004
   Sena P, 2014, J ANAT, V224, P659, DOI 10.1111/joa.12176
   Shimazaki C, 2005, LEUKEMIA, V19, P1102, DOI 10.1038/sj.leu.2403758
   Srinivas V, 2009, CELL CYCLE, V8, P391, DOI 10.4161/cc.8.3.7545
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Terpos E, 2014, AM J HEMATOL, V89, P34, DOI 10.1002/ajh.23577
   Teti A, 2009, BONE, V44, P11, DOI 10.1016/j.bone.2008.09.017
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Weinstein RS, 2010, ENDOCRINOLOGY, V151, P2641, DOI 10.1210/en.2009 1488
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Xia XC, 2010, J BONE MINER RES, V25, P2479, DOI 10.1002/jbmr.160
   Yang WC, 2009, BONE, V44, P32, DOI 10.1016/j.bone.2008.08.133
   Yao W, 2013, BONE, V54, P279, DOI 10.1016/j.bone.2013.01.034
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zangari M, 2006, CLIN LYMPHOMA MYELOM, V7, P109, DOI 10.3816/CLM.2006.n.047
   Zangari M, 2014, BONE, V61, P39, DOI 10.1016/j.bone.2013.12.025
   Zangari M, 2011, HAEMATOL HEMATOL J, V96, P333, DOI 10.3324/haematol.2010.031302
NR 57
TC 47
Z9 49
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2016
VL 31
IS 4
BP 815
EP 827
DI 10.1002/jbmr.2741
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DJ2BH
UT WOS:000374008200014
PM 26551485
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Kaczoruk Wieremczuk, M
   Adamska, P
   Adamski, LJ
   Wychowanski, P
   Jereczek Fossa, BA
   Starzynska, A
AF Kaczoruk Wieremczuk, Magdalena
   Adamska, Paulina
   Adamski, Lukasz Jan
   Wychowanski, Piotr
   Jereczek Fossa, Barbara Alicja
   Starzynska, Anna
TI Oral Surgery Procedures in a Patient with Hajdu Cheney Syndrome Treated
   with Denosumab A Rare Case Report
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE tooth extraction; Hajdu Cheney syndrome; HCS; oral surgery; genetic
   disorders; complicated bone healing; systemic disease
ID MEDICATION RELATED OSTEONECROSIS; BISPHOSPHONATE RELATED OSTEONECROSIS;
   ZOLEDRONIC ACID; ANABOLIC THERAPY; JAW; OSTEOPOROSIS; BONE; MANAGEMENT;
   PENTOXIFYLLINE; TOCOPHEROL
AB Background: Hajdu Cheney syndrome (HCS) is a very rare autosomal dominant congenital disease associated with mutations in the NOTCH2 gene. This disorder affects the connective tissue and is characterized by severe bone resorption. Hajdu Cheney syndrome most frequently affects the head and feet bones (acroosteolysis). Case report: We present an extremely rare case of a 34 year old male with Hajdu Cheney syndrome. The patient was admitted to the Department of Oral Surgery, Medical University of Gdansk, in order to perform the extraction of three teeth. These teeth were not eligible for conservative treatment and prosthetic reconstruction. The patient was treated with denosumab (angiogenesis and receptor activator of nuclear factor kappa B RANK ligand inhibitor, RANKL). Discussion: Denosumab is a monoclonal antibody against RANKL. This drug works through a suppression of osteoclast activity. In cases of patients in which the pathway of the RANK/RANKL/osteoprotegerin is dysregulated, denosumab has been approved for the treatment off label. In patients receiving denosumab, a delayed wound healing in the oral cavity and osteonecrosis may occur. Dental procedures involving the alveolar bone process (tooth extractions and bone alveoloplasty) may be a risk factor for medication related osteonecrosis of the jaw (MRONJ). Spontaneous osteonecrosis is rarely observed. MRONJ consists of the destruction of exposed bone, with the exposure persisting for a minimum of 6 8 weeks. This is the first article about an HCS patient treated with denosumab who underwent invasive oral surgery procedures. This case report highlights the difficulties for professionals occurring during the oral surgery procedures in such patients.
C1 [Kaczoruk Wieremczuk, Magdalena; Adamska, Paulina; Adamski, Lukasz Jan; Starzynska, Anna] Med Univ Gdansk, Dept Oral Surg, 7 Debinki St, PL 80211 Gdansk, Poland.
   [Wychowanski, Piotr] Med Univ Warsaw, Dept Oral Surg, 6 St Binieckiego St, PL 02097 Warsaw, Poland.
   [Jereczek Fossa, Barbara Alicja] Univ Milan, Dept Oncol & Hematooncol, 7 Festa Perdono St, I 20112 Milan, Italy.
   [Jereczek Fossa, Barbara Alicja] IEO European Inst Oncol, Div Radiotherapy, IRCCS, 435 Ripamonti St, I 20141 Milan, Italy.
C3 Fahrenheit Universities; Medical University Gdansk; Medical University
   of Warsaw; University of Milan; IRCCS European Institute of Oncology
   (IEO)
RP Starzynska, A (通讯作者)，Med Univ Gdansk, Dept Oral Surg, 7 Debinki St, PL 80211 Gdansk, Poland.
EM mkaczoruk@gumed.edu.pl; paulina.adamska@gumed.edu.pl;
   lukaszadamski@gumed.edu.pl; piotrwychowanski@wychowanski.pl;
   barbara.jereczek@ieo.it; anna.starzynska@gumed.edu.pl
RI ; Starzyńska, Anna/ABI 4599 2020; Wychowanski, Piotr/AAD 5638 2021;
   Adamska, Paulina/N 8775 2018
OI Wychowanski, Piotr/0000 0002 6286 5697; Starzynska,
   Anna/0000 0001 6900 0429; Adamska, Paulina/0000 0003 0514 4997
CR Abed Hassan H., 2018, General Dentistry, V66, P18
   Adami G, 2016, BONE, V92, P150, DOI 10.1016/j.bone.2016.08.025
   Agrillo A, 2012, EUR REV MED PHARMACO, V16, P1741
   Al Mayouf SM, 2006, ANN RHEUM DIS, V65, P1672, DOI 10.1136/ard.2005.035725
   American Dental Association Council on Scientific Affairs, 2006, J Am Dent Assoc, V137, P1144
   Assili Z, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112390
   Bennardo F, 2020, ORAL ONCOL, V106, DOI 10.1016/j.oraloncology.2020.104659
   Brennan AM, 2001, AM J MED GENET, V100, P292, DOI 10.1002/1096 8628(20010515)100:4<292::AID AJMG1308>3.0.CO;2 4
   Campisi G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165998
   Canalis E, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023 014 0200 y
   Cortés Martín J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176174
   Cortese A, 2021, DENT J BASEL, V9, DOI 10.3390/dj9050050
   Dokou P, 2016, OPEN DENT J, V10, P575, DOI 10.2174/1874210601610010575
   Efstathiadou ZA, 2021, ENDOCRINE, V71, P208, DOI 10.1007/s12020 020 02446 7
   Epstein MS, 2010, ORAL SURG ORAL MED O, V110, P593, DOI 10.1016/j.tripleo.2010.05.067
   Fortunato L, 2020, J CRANIO MAXILL SURG, V48, P268, DOI 10.1016/j.jcms.2020.01.014
   Freiberger JJ, 2009, J ORAL MAXIL SURG, V67, P96, DOI 10.1016/j.joms.2008.12.003
   Fujioka H, 2003, J SHOULDER ELB SURG, V12, P97, DOI 10.1067/mse.2003.128197
   Galli Tsinopoulou A, 2012, MINERVA ENDOCRINOL, V32, P283
   Gerard DA, 2014, J ORAL MAXIL SURG, V72, P61, DOI 10.1016/j.joms.2013.06.192
   Hwang S, 2011, YONSEI MED J, V52, P543, DOI 10.3349/ymj.2011.52.3.543
   Jireckova Jitka, 2018, Prague Med Rep, V119, P156, DOI 10.14712/23362936.2019.3
   Jung J, 2017, J BONE MINER RES, V32, P2445, DOI 10.1002/jbmr.3237
   Kalra Sandeep, 2013, J Oral Biol Craniofac Res, V3, P25, DOI 10.1016/j.jobcr.2012.11.001
   Katsarelis H, 2015, J DENT RES, V94, P534, DOI 10.1177/0022034515572021
   Kobayashi T, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120479
   Kumaki D, 2018, J CLIN MED, V7, DOI 10.3390/jcm7040063
   Kwon Yong Dae, 2016, Dent J (Basel), V4, DOI 10.3390/dj4040041
   Laimer J, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081677
   Lee JW, 2018, ORAL DIS, V24, P1037, DOI 10.1111/odi.12859
   Magremanne M, 2014, J ORAL MAXIL SURG, V72, P334, DOI 10.1016/j.joms.2013.06.188
   Marx RE, 2011, ORAL AND INTRAVENOUS BISPHOSPHONATE INDUCED OSTEONECROSIS OF THE JAWS: HISTORY, ETIOLOGY, PREVENTION, AND TREATMENT, SECOND EDITION, P9
   Mattei TA, 2015, EUR SPINE J, V24, P2746, DOI 10.1007/s00586 015 4092 x
   McKiernan FE, 2008, OSTEOPOROSIS INT, V19, P379, DOI 10.1007/s00198 007 0461 6
   McKiernan FE, 2007, OSTEOPOROSIS INT, V18, P245, DOI 10.1007/s00198 006 0221 z
   Midro AT, 2018, AM J MED GENET A, V176, P2382, DOI 10.1002/ajmg.a.40431
   Morris M, 2010, EUR J ONCOL NURS, V14, P205, DOI 10.1016/j.ejon.2009.12.003
   Murtagh Schaffer Catherine, 2008, JAAPA, V21, P31
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Ornetti P, 2012, JOINT BONE SPINE, V79, P514, DOI 10.1016/j.jbspin.2012.03.012
   Otto S, 2021, MEDICINA LITHUANIA, V57, DOI 10.3390/medicina57050463
   Owosho AA, 2016, OR SURG OR MED OR PA, V122, P455, DOI 10.1016/j.oooo.2016.06.019
   Pittaway JFH, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023 018 0795 5
   Polyzos SA, 2019, BONE, V129, DOI 10.1016/j.bone.2019.115048
   Ripamonti CI, 2011, ORAL ONCOL, V47, P185, DOI 10.1016/j.oraloncology.2011.01.002
   Rochoux Q, 2018, JOINT BONE SPINE, V85, P493, DOI 10.1016/j.jbspin.2017.05.025
   Rosella D, 2016, J INT SOC PREV COMMU, V6, P97, DOI 10.4103/2231 0762.178742
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Sakka S, 2017, J CLIN ENDOCR METAB, V102, P4163, DOI 10.1210/jc.2017 01102
   Samuel SS, 2016, J CLIN DIAGN RES, V10, pOD7, DOI 10.7860/JCDR/2016/15782.7203
   Vingerhoedt E, 2010, CLEFT PALATE CRAN J, V47, P645, DOI 10.1597/09 030
NR 52
TC 5
Z9 5
U1 0
U2 2
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 1660 4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD SEP
PY 2021
VL 18
IS 17
AR 9099
DI 10.3390/ijerph18179099
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA UN6OP
UT WOS:000694133700001
PM 34501688
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Luo, YF
   Xia, HT
   Wang, JC
   Hu, Q
   Luo, YH
   Liu, JY
   Yang, ZJ
   Li, W
   Wang, HY
   Li, FW
   Mao, ZC
   Yang, WL
   Yang, FY
AF Luo, Yunfeng
   Xia, Hanting
   Wang, Jiacai
   Hu, Qian
   Luo, Yinghua
   Liu, Jiangyuan
   Yang, Zhijun
   Li, Wei
   Wang, Hongyu
   Li, Fuwei
   Mao, Zhaochong
   Yang, Wenlong
   Yang, Fengyun
TI Jiawei Yanghe Decoction Regulates Bone Lipid Balance through the
   BMP SMAD Signaling Pathway to Promote Osteogenic Differentiation of Bone
   Mesenchymal Stem Cells
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID QUERCETIN; LINEAGE; HEALTH; RISK
AB Background. The Jiawei Yanghe decoction (JWYHD) is a traditional Chinese medicine formula for the treatment of osteoporosis, but its therapeutic mechanism has not been fully elucidated, and the therapeutic target of the intervention disease needs to be further verified. The dysfunction of bone mesenchymal stem cells (BMSCs) is considered to be an important pathogenesis of postmenopausal osteoporosis (PMOP). The purpose of this study was to explore how JWYHD regulates BMSC differentiation through the BMP SMAD signal pathway. Methods. In the in vivo study, we used an ovariectomized PMOP rat (n=36, 2 month old, 200 +/  20g) model and femur micro CT analysis to study the effect of JWYHD on bone loss in rats. By immunofluorescence, the translocation expression of BMP2, a key protein in the pathway, was detected. Serum bone metabolism was detected by an enzyme linked immunosorbent assay (ELISA). Alkaline phosphatase (ALP) activity was detected by alkaline phosphatase staining (ALPS), osteogenesis and matrix mineralization were detected by alizarin red staining (ARS), the adipogenic ability of BMSCs was detected by oil red staining (ORS), and CFU is used to detect the ability of cells to form colonies. The expression of related proteins was detected by western blotting. Results. In vivo and in vitro, the OP phenotypes of SD rats induced by ovariectomy (OVX) included impaired bone mineral density and microstructure, abnormal bone metabolism, and impaired MSC differentiation potential. JWYHD treatment reversed this trend and restored the differentiation potential of MSCs. JWYHD medicated serum and direct intervention of drugs activated the BMP SMAD signaling pathway, promoted the osteogenic differentiation of BMSCs, and inhibited their adipogenic differentiation. Conclusions. Our data identified that JWYHD is an effective alternative drug for the treatment of PMOP that functions to stimulate the differentiation of BMSCs into osteoblasts in the BMP SMAD signaling dependent mechanism.
C1 [Luo, Yunfeng; Liu, Jiangyuan; Yang, Zhijun; Wang, Hongyu; Li, Fuwei; Mao, Zhaochong] Jiangxi Univ Chinese Med, Grad Sch, Nanchang 330000, Jiangxi, Peoples R China.
   [Xia, Hanting; Wang, Jiacai; Yang, Wenlong; Yang, Fengyun] Jiangxi Univ Chinese Med, Affiliated Hosp, Dept Orthoped, Nanchang 330000, Jiangxi, Peoples R China.
   [Xia, Hanting] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Inst Orthopaed & Traumatol, Hangzhou 310005, Zhejiang, Peoples R China.
   [Hu, Qian] Nanchang Cty Hosp Tradit Chinese Med, Dept Internal Med, Nanchang 330000, Jiangxi, Peoples R China.
   [Luo, Yinghua] Jiangxi Univ Chinese Med, Affiliated Hosp, Dept Acupuncture & Moxibust, Nanchang 330000, Jiangxi, Peoples R China.
   [Li, Wei] Shenzhen Pingle Orthopaed Hosp, Dept Orthoped, Shenzhen 518038, Guangdong, Peoples R China.
C3 Jiangxi University of Traditional Chinese Medicine; Jiangxi University
   of Traditional Chinese Medicine; Zhejiang Chinese Medical University;
   Jiangxi University of Traditional Chinese Medicine
RP Yang, WL (通讯作者)，Jiangxi Univ Chinese Med, Affiliated Hosp, Dept Orthoped, Nanchang 330000, Jiangxi, Peoples R China.
EM y378759501@163.com
RI luo, yun feng/GQQ 4630 2022; Li, Fuwei/ABF 3222 2021; Xia,
   Hanting/LNP 3775 2024
OI luo, yun feng/0000 0001 9609 0861; Wang, Hongyu
   Wang/0000 0001 9547 461X; Yang, Zhijun/0000 0001 7281 444X; Jiangyuan,
   Liu/0000 0001 5808 9974
FU Special Fund of Jiangxi Provincial Administration of Traditional Chinese
   Medicine [20202GJ01]; Science and Technology Project Fund of Jiangxi
   Education Department [GJJ190686]; Innovation Special Fund of Jiangxi
   University of Traditional Chinese Medicine [202010412227, 202010412225];
   Jiangxi Province College Students' Innovation and Entrepreneurship
   Training Program [JZYC21S10]
FX This work was supported by the Special Fund of Jiangxi Provincial
   Administration of Traditional Chinese Medicine (20202GJ01), the Science
   and Technology Project Fund of Jiangxi Education Department (GJJ190686),
   the Innovation Special Fund of Jiangxi University of Traditional Chinese
   Medicine (202010412227 and 202010412225), and the Jiangxi Province
   College Students' Innovation and Entrepreneurship Training Program
   (JZYC21S10).
CR Abdallah BM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929 019 0544 7
   Adami G, 2022, THER ADV MUSCULOSKEL, V14, DOI 10.1177/1759720X221083541
   Agarwal S, 2017, MOL THER, V25, P1974, DOI 10.1016/j.ymthe.2017.01.008
   BabuRajendran N, 2010, NUCLEIC ACIDS RES, V38, P3477, DOI 10.1093/nar/gkq046
   Chang BY, 2018, REPRODUCTION, V155, P103, DOI [10.1530/REP 17 0530, 10.1530/rep 17 0530]
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chien SY, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040927
   Csizmadi I, 2002, CAN MED ASSOC J, V166, P187
   Ding JH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00437
   Doucette CR, 2015, J CELL PHYSIOL, V230, P2032, DOI 10.1002/jcp.24954
   Fatima S, 2021, INT J NANOMED, V16, P331, DOI 10.2147/IJN.S285233
   Fei DD, 2019, AGING CELL, V18, DOI 10.1111/acel.12967
   Fernandes MG, 2016, STEM CELL REP, V6, P85, DOI 10.1016/j.stemcr.2015.11.012
   Girnun GD, 2007, CANCER CELL, V11, P395, DOI 10.1016/j.ccr.2007.02.025
   Gong W, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163964
   Güerri Fernandez RC, 2012, THER ADV MUSCULOSKEL, V4, P55, DOI 10.1177/1759720X11435677
   Haring B, 2016, JAMA INTERN MED, V176, P645, DOI 10.1001/jamainternmed.2016.0482
   He J, 2017, REGEN BIOMATER, V4, P269, DOI 10.1093/rb/rbx008
   Huang JL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030422
   Huang P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5063
   Hue TF, 2014, JAMA INTERN MED, V174, P1550, DOI 10.1001/jamainternmed.2014.3634
   Hui Z, 2022, J ETHNOPHARMACOL, V283, DOI 10.1016/j.jep.2021.114634
   Johnston BD, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/635023
   Kato RB, 2014, J CELL PHYSIOL, V229, P1690, DOI 10.1002/jcp.24614
   Kato S, 2009, LIFE SCI, V84, P302, DOI 10.1016/j.lfs.2008.12.011
   Kim JM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16038 6
   Kim M, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 2841 9
   Kruger MC, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060376
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Lee SY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07316 5
   Lin YP, 2020, CAN RESPIR J, V2020, DOI 10.1155/2020/6958283
   Ling XP, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/7795527
   Logozzi M, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9020144
   Ma BE, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.645354
   Manson JE, 2016, JAMA CARDIOL, V1, P776, DOI 10.1001/jamacardio.2016.2662
   Oh JH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218044
   Posa F, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121646
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Roux C, 2007, ANN RHEUM DIS, V66, P931, DOI 10.1136/ard.2006.064071
   Shen BY, 2019, J CELL MOL MED, V23, P4063, DOI 10.1111/jcmm.14293
   Shen WX, 2020, J CELL MOL MED, V24, P12513, DOI 10.1111/jcmm.15792
   Strobel P, 2005, BIOCHEM J, V386, P471, DOI 10.1042/BJ20040703
   Swarnkar G, 2012, BRIT J PHARMACOL, V165, P1526, DOI 10.1111/j.1476 5381.2011.01637.x
   Van de Sande L, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 5658 5
   Vanhatupa S, 2015, STEM CELL TRANSL MED, V4, P1391, DOI 10.5966/sctm.2015 0042
   Wang HT, 2016, J BONE MINER RES, V31, P1652, DOI 10.1002/jbmr.2848
   Wang Z, 2019, AM J TRANSL RES, V11, P4984
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 3 r52
   Wu YS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06898 4
   Xia HT, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.654714
   Xia HT, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109708
   Xie YL, 2019, INT J NANOMED, V14, P6019, DOI 10.2147/IJN.S203859
   Xiong JL, 2022, J ETHNOPHARMACOL, V283, DOI 10.1016/j.jep.2021.114735
   Xu R, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110581
   Xu Y, 2014, REJUV RES, V17, P372, DOI 10.1089/rej.2014.1557
   Yoo SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158481
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhang ND, 2019, BIOCHEM BIOPH RES CO, V519, P790, DOI 10.1016/j.bbrc.2019.09.058
   Zhang QH, 2020, AM J TRANSL RES, V12, P2062
   Zhou Z, 2010, DEV CELL, V19, P90, DOI 10.1016/j.devcel.2010.06.016
   Zhu ZG, 2018, MOL MED REP, V18, P2561, DOI 10.3892/mmr.2018.9286
NR 62
TC 3
Z9 4
U1 0
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD JUN 20
PY 2022
VL 2022
AR 2885419
DI 10.1155/2022/2885419
PG 18
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 3R1SO
UT WOS:000838699800001
PM 35769158
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yoshioka, Y
   Yamachika, E
   Nakanishi, M
   Ninomiya, T
   Akashi, S
   Kondo, S
   Moritani, N
   Kobayashi, Y
   Fujii, T
   Iida, S
AF Yoshioka, Yohsuke
   Yamachika, Eiki
   Nakanishi, Makoto
   Ninomiya, Tadashi
   Akashi, Sho
   Kondo, Sei
   Moritani, Norifumi
   Kobayashi, Yasuhiro
   Fujii, Tatsuo
   Iida, Seiji
TI Intermittent parathyroid hormone 1 34 induces oxidation and
   deterioration of mineral and collagen quality in newly formed mandibular
   bone
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OSTEOPOROSIS; MECHANISMS; INCREASES; MELATONIN; STRENGTH; IMPLANTS;
   THERAPY
AB Intermittent parathyroid hormone (PTH) administration is known to promote bone healing after surgical procedures. However, the mechanism and influence of PTH on the mineral and collagen quality of the jaw are not well understood. Most studies have focused on analyzing the bone density and microstructure of the mandible, and have insufficiently investigated its mineral and collagen quality. Oxidative stress activates osteoclasts, produces advanced glycation end products, and worsens mineral and collagen quality. We hypothesized that PTH induces oxidation and affects the mineral and collagen quality of newly formed mandibular bone. To test this, we examined the mineral and collagen quality of newly formed mandibular bone in rats administered PTH, and analyzed serum after intermittent PTH administration to examine the degree of oxidation. PTH administration reduced mineralization and worsened mineral and collagen quality in newly formed bone. In addition, total anti oxidant capacity in serum was significantly decreased and the oxidative INDEX was increased among PTH treated compared to vehicle treated rats, indicating serum oxidation. In conclusion, intermittent administration of PTH reduced mineral and collagen quality in newly formed mandibular bone. This effect may have been induced by oxidation.
C1 [Yoshioka, Yohsuke; Akashi, Sho; Kondo, Sei; Moritani, Norifumi; Iida, Seiji] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral & Maxillofacial Reconstruct Surg, Kita Ku, 2 5 1 Shikata Cho, Okayama, Japan.
   [Yamachika, Eiki] Okayama Univ Hosp, Dept Oral & Maxillofacial Reconstruct Surg, Kita Ku, 2 5 1 Shikata Cho, Okayama, Japan.
   [Nakanishi, Makoto; Fujii, Tatsuo] Okayama Univ, Grad Sch Nat Sci & Technol, Dept Appl Chem, Kita Ku, 1 1 1 Tsushima Naka, Okayama, Japan.
   [Ninomiya, Tadashi] Nihon Univ, Sch Dent, Dept Anat, Chiyoda Ku, 1 8 13 Kanda Surugadai, Tokyo, Japan.
   [Kobayashi, Yasuhiro] Matsumoto Dent Univ, Inst Oral Sci, Div Hard Tissue Res, 1780 Gobara Hirooka, Nagano, Japan.
C3 Okayama University; Okayama University; Okayama University; Nihon
   University; Matsumoto Dental University
RP Yamachika, E (通讯作者)，Okayama Univ Hosp, Dept Oral & Maxillofacial Reconstruct Surg, Kita Ku, 2 5 1 Shikata Cho, Okayama, Japan.
EM eikiyama@md.okayama u.ac.jp
RI NAKANISHI, Makoto/B 2115 2011; KOBAYASHI, YASUHIRO/AAU 4931 2021
OI Yoshioka, Yohsuke/0000 0003 1510 9300
FU Ministry of Health, Labor and Welfare of Japan; Ministry of Education,
   Culture, Sports, Science and Technology of Japan (JSPS KAKEN)
   [JP18K09721, JP18H06309]
FX This work was supported by Grants in Aid for Scientific Research from
   the Ministry of Health, Labor and Welfare of Japan and the Ministry of
   Education, Culture, Sports, Science and Technology of Japan (JSPS KAKEN
   Grant Number JP18K09721 and JP18H06309).
CR Ali MN, 2012, OR SURG OR MED OR PA, V114, pE36, DOI 10.1016/j.oooo.2011.08.009
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Bhattacharyya S, 2018, EUR J PHARMACOL, V826, P39, DOI 10.1016/j.ejphar.2018.02.028
   Casanova M, 2016, BONE, V92, P70, DOI 10.1016/j.bone.2016.08.012
   Chai J, 2012, INT J ORAL MAX IMPL, V27, P888
   Chou FF, 2005, SURGERY, V137, P426, DOI 10.1016/j.surg.2004.12.010
   Donnelly E, 2010, CALCIFIED TISSUE INT, V87, P450, DOI 10.1007/s00223 010 9404 x
   Ellis R, 2009, CONNECT TISSUE RES, V50, P29, DOI 10.1080/03008200802398422
   Hayashida S, 2017, J BONE MINER RES, V32, P2022, DOI 10.1002/jbmr.3191
   Hernandez CJ, 2006, BONE, V39, P1173, DOI 10.1016/j.bone.2006.06.001
   Hosokawa R, 2013, J PROSTHODONT RES, V57, P1, DOI 10.1016/j.jpor.2013.01.003
   Huja SS, 2006, ANAT REC PART A, V288A, P1243, DOI 10.1002/ar.a.20396
   Hwang Debby, 2006, Implant Dent, V15, P353, DOI 10.1097/01.id.0000247855.75691.03
   Hwang D, 2007, IMPLANT DENT, V16, P13, DOI 10.1097/ID.0b013e31803276c8
   Almagro MI, 2013, CLIN ORAL IMPLAN RES, V24, P1027, DOI 10.1111/j.1600 0501.2012.02495.x
   Kancheva R, 2008, PHYSIOL RES, V57, pS181, DOI 10.33549/physiolres.931503
   Kawai S, 2011, EXP ANIM TOKYO, V60, P481, DOI 10.1538/expanim.60.481
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kuchler U, 2011, J DENT RES, V90, P1001, DOI 10.1177/0022034511407920
   Kuroshima S, 2015, CLIN IMPLANT DENT R, V17, pE699, DOI 10.1111/cid.12318
   Chin VKL, 2013, BRAZ ORAL RES, V27, P423, DOI 10.1590/S1806 83242013000500006
   Morris MD, 2011, CLIN ORTHOP RELAT R, V469, P2160, DOI 10.1007/s11999 010 1692 y
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Nojiri H, 2011, J BONE MINER RES, V26, P2682, DOI 10.1002/jbmr.489
   Oki Y, 2017, J APPL ORAL SCI, V25, P498, DOI 10.1590/1678 7757 2016 0561
   Quintero DG, 2010, J ORAL IMPLANTOL, V36, P97, DOI 10.1563/AAID JOI D 09 00032
   Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s 2007 979057
   REY C, 1995, J BONE MINER RES, V10, P1577
   Saito M, 2014, CURR OSTEOPOROS REP, V12, P181, DOI 10.1007/s11914 014 0202 7
   Seeman E, 2008, J BONE MINER METAB, V26, P1, DOI 10.1007/s00774 007 0793 5
   Shibamoto A, 2018, INT J ORAL SCI, V10, DOI 10.1038/s41368 018 0009 y
   Unal M, 2016, J BONE MINER RES, V31, P1015, DOI 10.1002/jbmr.2768
   Vassalle C, 2012, FERTIL STERIL, V97, P414, DOI 10.1016/j.fertnstert.2011.11.045
   Yerramshetty JS, 2006, BONE, V39, P1236, DOI 10.1016/j.bone.2006.06.002
   Yun JI, 2010, J CLIN PERIODONTOL, V37, P419, DOI 10.1111/j.1600 051X.2010.01547.x
NR 35
TC 6
Z9 6
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAY 29
PY 2019
VL 9
AR 8041
DI 10.1038/s41598 019 44389 8
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IA1KM
UT WOS:000469319300003
PM 31142769
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yin, C
   Tian, Y
   Yu, Y
   Yang, CF
   Su, PH
   Zhao, YP
   Wang, X
   Zhang, KW
   Pei, JW
   Li, DJ
   Chen, ZH
   Zhang, Y
   Miao, ZP
   Qian, AR
AF Yin, Chong
   Tian, Ye
   Yu, Yang
   Yang, Chaofei
   Su, Peihong
   Zhao, Yipu
   Wang, Xue
   Zhang, Kewen
   Pei, Jiawei
   Li, Dijie
   Chen, Zhihao
   Zhang, Yan
   Miao, Zhiping
   Qian, Airong
TI miR 129 5p Inhibits Bone Formation Through TCF4
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE osteoporosis; osteoblast; miR 129 5p; TCF4; recombinant RNA
ID RNAS; OSTEOBLAST; EXPRESSION; CELLS
AB Osteoporosis is a frequently occurring bone disease in middle aged and aged men and women. However, current therapies on this disease are still not ideal. MicroRNAs (miRNAs) are a class of endogenous non protein coding RNA with a length of 18 25 nucleotides. miRNAs have been identified as important regulators for development, metabolism, carcinogenesis, and bone formation. miR 129 5p has been reported as a regulator of cancer and neuroscience, whereas studies about its function on bone formation is still limited. In this study, we investigated the function and mechanism of miR 129 5p on osteoblast differentiation and bone formation. We have assessed the expression of miRNAs in bone mesenchymal stem cells from aging and menopause osteoporosis C57BL6 mice. The expression of miR 129 5p was altered in all osteoporosis models. Besides, the expression of miR 129 5p was negatively correlated with osteoblastic differentiation markers in the femur tissues of C57BL/6 mice of different ages. We further demonstrated that overexpression of miR 129 5p inhibited osteoblast differentiation in MC3T3 E1 cell line, as well as bone formation of C57BL/6 mice. On the other hand, down regulation of miR 129 5p enhanced osteoblast differentiation and bone formation. We also found that miR 129 5p inhibited Wnt/beta catenin pathway in osteoblast. The target gene of miR 129 5p has been forecasted and proved as Tcf4. We further found that plasmid containing Tcf4 3 ' UTR sequence enhanced osteoblast differentiation, as well as Wnt/beta catenin pathway in MC3T3 E1 cells. To further investigate the rescue effect of miR 129 5p inhibitor, we manufactured bioengineered novel recombinant miR 129 5p inhibitor through Escherichia coli system and then tested its function. The results showed that the novel recombinant miR 129 5p inhibitor promoted osteoblast differentiation and greatly ameliorated menopause osteoporosis in C57BL6 mice. In conclusion, we have discovered miR 129 5p as an inhibitor of bone formation. miR 129 5p inhibited downstream transcription factors of Wnt/beta catenin pathway through targeting Tcf4. Moreover, novel recombinant miR 129 5p inhibitor showed rescue effect on osteoporosis. This study has revealed a new mechanism of osteogenic differentiation and provided novel therapeutic strategies for treatment of skeletal disorders.
C1 [Yin, Chong; Tian, Ye; Yang, Chaofei; Su, Peihong; Zhao, Yipu; Wang, Xue; Zhang, Kewen; Pei, Jiawei; Li, Dijie; Chen, Zhihao; Zhang, Yan; Miao, Zhiping; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci,Xian Key Lab Special Med & Hlth Engn, Res Ctr Special Med & Hlth Syst Engn,Lab Bone Met, NPU UAB Joint Lab Bone Metab,Key Lab Space Biosci, Xian, Peoples R China.
   [Yu, Yang] Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin, Peoples R China.
C3 Northwestern Polytechnical University; Tianjin Medical University
RP Qian, AR (通讯作者)，Northwestern Polytech Univ, Sch Life Sci,Xian Key Lab Special Med & Hlth Engn, Res Ctr Special Med & Hlth Syst Engn,Lab Bone Met, NPU UAB Joint Lab Bone Metab,Key Lab Space Biosci, Xian, Peoples R China.
EM qianair@nwpu.edu.cn
RI Yu, Yang/AAI 2652 2020; zhang, kewen/KXR 4680 2024; Li,
   Dijie/KVB 3667 2024; chen, zhihao/GXM 3816 2022; Zhang,
   Yan/MTF 5312 2025; Chen, Zhihao/ACK 3514 2022
OI Zhang, Yan/0000 0001 6213 4416; Chen, Zhihao/0000 0003 0128 1409
FU National Natural Science Foundation of China [81801871, 32000924]; China
   Postdoctoral Science Foundation [2019T120947]; Shaanxi Provincial Key RD
   Program [2018KWZ 10]; Special fund for technological innovation of
   Shaanxi Province [2019QYPY 207]; Shaanxi Provincial Postdoctoral Science
   Foundation [2017BSHEDZZ13]; Fundamental Research Funds for the Central
   Universities [3102019smxy003]
FX This work was supported by the National Natural Science Foundation of
   China (81801871 and 32000924), the China Postdoctoral Science Foundation
   (2019T120947), Shaanxi Provincial Key R&D Program (2018KWZ 10), Special
   fund for technological innovation of Shaanxi Province (2019QYPY 207),
   the Shaanxi Provincial Postdoctoral Science Foundation (2017BSHEDZZ13),
   the Fundamental Research Funds for the Central Universities
   (3102019smxy003).
CR Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Cao JY, 2018, INT UROL NEPHROL, V50, P1811, DOI 10.1007/s11255 018 1959 x
   Cao Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097098
   Chen QX, 2015, NUCLEIC ACIDS RES, V43, P3857, DOI 10.1093/nar/gkv228
   Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757
   Chen ZH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081684
   Furnari F, 2010, NATURE, V465, P1016, DOI 10.1038/4651016a
   Gennari L, 2016, EXPERT OPIN PHARMACO, V17, P1141, DOI 10.1080/14656566.2016.1176147
   Georgiou KR, 2012, AM J STEM CELLS, V1, P205
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Ho PY, 2018, J PHARMACOL EXP THER, V365, P494, DOI 10.1124/jpet.118.247775
   Ho PY, 2016, WIRES RNA, V7, P186, DOI 10.1002/wrna.1324
   Hu LF, 2018, J CELL PHYSIOL, V233, P1574, DOI 10.1002/jcp.26059
   Huang LF, 2013, NAT BIOTECHNOL, V31, P350, DOI 10.1038/nbt.2537
   Jabbar S, 2011, J CLIN PATHOL, V64, P354, DOI 10.1136/jcp.2010.086595
   Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li CX, 2017, NAT MATER, V16, P379, DOI [10.1038/NMAT4780, 10.1038/nmat4780]
   Li G, 2019, ONCOL LETT, V17, P5777, DOI 10.3892/ol.2019.10241
   Li MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077829
   Li X, 2019, ACTA PHARM SIN B, V9, P639, DOI 10.1016/j.apsb.2018.12.002
   Ponchon L, 2009, NAT PROTOC, V4, P947, DOI 10.1038/nprot.2009.67
   Reinhold MI, 2007, J BIOL CHEM, V282, P3653, DOI 10.1074/jbc.M608995200
   Shi ZL, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01754 z
   Ushiku C, 2010, J ORTHOP RES, V28, P1338, DOI 10.1002/jor.21105
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang YX, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2325 3
   Wang YX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1153 1
   Yin C, 2019, J CELL PHYSIOL, V234, P11524, DOI 10.1002/jcp.27815
   Yin C, 2018, J CELL PHYSIOL, V233, P5405, DOI 10.1002/jcp.26374
   Yuan HR, 2019, CELL DEATH DIFFER, V26, P2029, DOI 10.1038/s41418 019 0296 7
   Zeng ZL, 2019, CELL CYCLE, V18, P3095, DOI 10.1080/15384101.2019.1669388
   Zhang P, 2017, CELL PHYSIOL BIOCHEM, V42, P242, DOI 10.1159/000477323
   Zuo B, 2015, J BONE MINER RES, V30, P330, DOI 10.1002/jbmr.2352
NR 35
TC 27
Z9 31
U1 3
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD NOV 6
PY 2020
VL 8
AR 600641
DI 10.3389/fcell.2020.600641
PG 15
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA OT0JX
UT WOS:000590542000001
PM 33240893
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ge, YW
   Feng, K
   Liu, XL
   Chen, HF
   Sun, ZY
   Wang, CF
   Liu, ZQ
   Wang, HW
   Zhang, JW
   Yu, DG
   Mao, YQ
AF Ge, Yu Wei
   Feng, Kai
   Liu, Xiao Liang
   Chen, Hong Fang
   Sun, Zhen Yu
   Wang, Cai Feng
   Liu, Zhi Qing
   Wang, Hao Wei
   Zhang, Jing Wei
   Yu, De Gang
   Mao, Yuan Qing
TI The Recombinant Protein EphB4 Fc Changes the Ti Particle Mediated
   Imbalance of OPG/RANKL via EphrinB2/EphB4 Signaling Pathway and Inhibits
   the Release of Proinflammatory Factors In Vivo
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID NF KAPPA B; INDUCED OSTEOLYSIS; INDUCED OSTEOCLASTOGENESIS; OSTEOBLAST;
   SUPPRESSION; RECEPTORS; NFATC1; MICE
AB Aseptic loosening caused by wear particles is one of the common complications after total hip arthroplasty. We investigated the effect of the recombinant protein ephB4 Fc (erythropoietin producing human hepatocellular receptor 4) on wear particle mediated inflammatory response. In vitro, ephrinB2 expression was analyzed using siRNA NFATc1 (nuclear factor of activated T cells 1) and siRNA c Fos. Additionally, we used Tartrate resistant acid phosphatase (TRAP) staining, bone pit resorption, Enzyme linked immunosorbent assay (ELISA), as well as ephrinB2 overexpression and knockdown experiments to verify the effect of ephB4 Fc on osteoclast differentiation and function. In vivo, a mouse skull model was constructed to test whether the ephB4 Fc inhibits osteolysis and inhibits inflammation by micro CT, H&E staining, immunohistochemistry, and immunofluorescence. The gene expression of ephrinB2 was regulated by c Fos/NFATc1. Titanium wear particles activated this signaling pathway to the promoted expression of the ephrinB2 gene. However, ephrinB2 protein can be activated by osteoblast membrane receptor ephB4 to inhibit osteoclast differentiation. In in vivo experiments, we found that ephB4 could regulate Ti particle mediated imbalance of OPG/RANKL, and the most important finding was that ephB4 relieved the release of proinflammatory factors. The ephB4 Fc inhibits wear particle mediated osteolysis and inflammatory response through the ephrinB2/EphB4 bidirectional signaling pathway, and ephrinB2 ligand is expected to become a new clinical drug therapeutic target.
C1 [Ge, Yu Wei; Feng, Kai; Liu, Xiao Liang; Chen, Hong Fang; Sun, Zhen Yu; Wang, Cai Feng; Liu, Zhi Qing; Zhang, Jing Wei; Yu, De Gang; Mao, Yuan Qing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Orthoped Surg, Shanghai 200011, Peoples R China.
   [Feng, Kai] Shanghai Jiao Tong Univ, Dept Orthoped Surg, Affiliated Peoples Hosp 6, Shanghai, Peoples R China.
   [Wang, Hao Wei] Shanghai Jiao Tong Univ, Sch Med, Dept Oral Implantol,Shanghai Key Lab Stomatol, Dent Clin 2,Peoples Hosp,Coll Stomatol,Natl Clin, Shanghai, Peoples R China.
   [Wang, Hao Wei] Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Zhang, JW; Yu, DG; Mao, YQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Orthoped Surg, Shanghai 200011, Peoples R China.
EM geyw2000@163.com; jsycfk@126.com; abel.liuxl@outlook.com;
   ericchen325927@163.com; aaronsun616@163.com; caifeng.wong@163.com;
   liu_zhiqingkm19@126.com; wanghwsmile@126.com; zjw_ys@163.com;
   ydg163@126.com; yuanqingmao@163.com
RI ydg, nam/GNP 5078 2022; Wang, Huiwen/JED 3206 2023; Feng,
   Kai/JQI 9878 2023
OI , Degang/0000 0002 4969 8070; 
FU National Natural Science Foundation of China [81572158, 81772361,
   81572116]
FX We thank the patient and clinician who participated. We thank the animal
   breeders who help us take care of animals. The present study was
   supported by grants from the National Natural Science Foundation of
   China (grant nos. 81572158, 81772361, and 81572116).
CR Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Ao HY, 2018, BIOACT MATER, V3, P97, DOI 10.1016/j.bioactmat.2017.07.004
   Chen X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00647
   Cheng L, 2018, AM J TRANSL RES, V10, P1457
   Ge YW, 2018, INT J MOL MED, V42, P2031, DOI 10.3892/ijmm.2018.3780
   Gibon E, 2018, BONE JOINT J, V100B, P725, DOI 10.1302/0301 620X.100B6.BJJ 2017 1472.R1
   Jézéquel J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01700 3
   Kapasa ER, 2017, J FUNCT BIOMATER, V8, DOI 10.3390/jfb8040042
   Li C, 2015, J DENT RES, V94, P455, DOI 10.1177/0022034514566431
   Li D, 2018, BIOCHEM BIOPH RES CO, V503, P1115, DOI 10.1016/j.bbrc.2018.06.128
   Li JH, 2018, MOL IMMUNOL, V96, P8, DOI 10.1016/j.molimm.2018.02.008
   Liu FX, 2013, ACTA PHARMACOL SIN, V34, P1457, DOI 10.1038/aps.2013.99
   Liu FX, 2009, BIOMATERIALS, V30, P1756, DOI 10.1016/j.biomaterials.2008.12.018
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Long William J, 2018, Arthroplast Today, V4, P169, DOI 10.1016/j.artd.2017.11.009
   Matsuo K, 2012, CELL ADHES MIGR, V6, P148, DOI 10.4161/cam.20888
   Mundy GR, 2006, CELL, V126, P441, DOI 10.1016/j.cell.2006.07.015
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Pennisi A, 2009, BLOOD, V114, P1803, DOI 10.1182/blood 2009 01 201954
   Raphel J, 2016, BIOMATERIALS, V83, P269, DOI 10.1016/j.biomaterials.2015.12.030
   Sato T, 2016, J BIOMED MATER RES A, V104, P2255, DOI 10.1002/jbm.a.35759
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Shen LL, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6430407
   Takyar FM, 2013, J BONE MINER RES, V28, P912, DOI 10.1002/jbmr.1820
   Tamma Roberto, 2012, Inflammation & Allergy Drug Targets, V11, P196
   Taylor Scott, 2018, Bone Rep, V8, P95, DOI 10.1016/j.bonr.2018.03.002
   Tazaki Y, 2018, COMP BIOCHEM PHYS A, V225, P46, DOI 10.1016/j.cbpa.2018.06.011
   Teramachi J, 2016, J CLIN INVEST, V126, P1012, DOI 10.1172/JCI82012
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Wu M, 2016, INT J MOL MED, V37, P565, DOI 10.3892/ijmm.2016.2457
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhao WH, 2017, LEUKEMIA RES, V63, P28, DOI 10.1016/j.leukres.2017.10.014
   Zhu L, 2017, BIOCHEM BIOPH RES CO, V484, P64, DOI 10.1016/j.bbrc.2017.01.071
NR 35
TC 10
Z9 10
U1 3
U2 23
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942 0900
EI 1942 0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD JUN 6
PY 2020
VL 2020
AR 1404915
DI 10.1155/2020/1404915
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA MB4BJ
UT WOS:000542548400001
PM 32587656
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Fong, JE
   Le Nihouannen, D
   Komarova, SV
AF Fong, Jenna E.
   Le Nihouannen, Damien
   Komarova, Svetlana V.
TI Tumor supportive and Osteoclastogenic Changes Induced by Breast
   Cancer derived Factors Are Reversed by Inhibition of γ Secretase
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BONE METASTASIS; RANK LIGAND; TGF BETA; KAPPA B; CELLS; OSTEOBLASTS;
   EXPRESSION; DIFFERENTIATION; OSTEOPROTEGERIN; PRECURSORS
AB During breast cancer metastasis to bone, tumor cells home to bone marrow, likely targeting the stem cell niche, and stimulate osteoclasts, which mediate osteolysis required for tumor expansion. Although osteoblasts contribute to the regulation of the hematopoietic stem cell niche and control osteoclastogenesis through production of proresorptive cytokine RANKL(receptor activator of NF kappa B ligand), their role in cancer metastases to bone is not fully understood. C57BL/6J mouse bone marrow cells were treated for 3 12 days with ascorbic acid (50 mu g/ml) in the presence or absence of 10% medium conditioned by breast carcinoma cells MDA MB 231, 4T1, or MCF7. Treatment with cancer derived factors resulted in a sustained 40 60% decrease in osteoblast differentiation markers, compared with treatment with ascorbic acid alone, and induced an osteoclastogenic change in the RANKL/osteoprotegerin ratio. Importantly, exposure of bone cells to breast cancer derived factors stimulated the subsequent attachment of cancer cells to immature osteoblasts. Inhibition of gamma secretase using pharmacological inhibitors DAPT and Compound E completely reversed cancer induced osteoclastogenesis as well as cancer induced enhancement of cancer cell attachment, identifying gamma secretase activity as a key mediator of these effects. Thus, we have uncovered osteoblasts as critical intermediary of premetastatic signaling by breast cancer cells and pinpointed gamma secretase as a robust target for developing therapeutics potentially capable of reducing both homing and progression of cancer metastases to bone.
C1 [Fong, Jenna E.; Le Nihouannen, Damien; Komarova, Svetlana V.] McGill Univ, Fac Dent, Montreal, PQ H3A 1A4, Canada.
C3 McGill University
RP Komarova, SV (通讯作者)，740 Dr Penfield Ave 2201, Montreal, PQ H3A 1A4, Canada.
EM svetlana.komarova@mcgill.ca
RI ; Le Nihouannen, Damien/A 1131 2011; Komarova, Svetlana/MTR 5042 2025
OI LE NIHOUANNEN, Damien/0000 0003 1539 5183; Komarova,
   Svetlana/0000 0003 3570 3147; 
FU Institute for Musculoskeletal Health and Arthritis/Canadian Institute
   for Health Research; Canadian Institute for Health Research in Skeletal
   Health Research; McGill University; Canadian Arthritis Network; les
   Fonds de la Recherche en Sante du Quebec
FX This work was supported by the Institute for Musculoskeletal Health and
   Arthritis/Canadian Institute for Health Research. Supported by the
   Canadian Institute for Health Research Training Program in Skeletal
   Health Research and by McGill University. Supported by the Canadian
   Institute for Health Research Training Program in Skeletal Health
   Research, the Canadian Arthritis Network, and les Fonds de la Recherche
   en Sante du Quebec.
CR Armstrong S, 2009, J CELL SCI, V122, P136, DOI 10.1242/jcs.031534
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Baldock PA, 2006, J BONE MINER RES, V21, P1618, DOI 10.1359/JBMR.060714
   Bu GJ, 2008, INT J CANCER, V123, P1034, DOI 10.1002/ijc.23625
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Canalis E, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.117pe17
   Chen HL, 2002, J BIOL CHEM, V277, P19374, DOI 10.1074/jbc.M108913200
   Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159, DOI 10.1615/CritRevEukarGeneExpr.v10.i2.50
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008 5472.CAN 05 3560
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Engin F, 2009, HUM MOL GENET, V18, P1464, DOI 10.1093/hmg/ddp057
   Fromigué O, 2001, J BONE MINER RES, V16, P1600, DOI 10.1359/jbmr.2001.16.9.1600
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Guise TA, 2003, CLIN ORTHOP RELAT R, pS32, DOI 10.1097/01.blo.0000093055.96273.69
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Guo YB, 2008, BONE, V43, P386, DOI 10.1016/j.bone.2008.03.026
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Kaplan RN, 2006, CANCER METAST REV, V25, P521, DOI 10.1007/s10555 006 9036 9
   KIM CJ, 2004, BREAST COMPREHENSIVE
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200
   Lau YS, 2007, BREAST CANCER RES TR, V105, P7, DOI 10.1007/s10549 006 9438 y
   Mendoza M, 2009, INT J BIOCHEM CELL B, V41, P1452, DOI 10.1016/j.biocel.2009.01.015
   Mercer RR, 2004, CLIN EXP METASTAS, V21, P427, DOI 10.1007/s10585 004 1867 6
   Neiva K, 2005, BRAZ J MED BIOL RES, V38, P1449, DOI 10.1590/S0100 879X2005001000001
   Phadke PA, 2006, CLIN CANCER RES, V12, P1431, DOI 10.1158/1078 0432.CCR 05 1806
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008 5472.CAN 06 3958
   Shiozawa Y, 2008, LEUKEMIA, V22, P941, DOI 10.1038/leu.2008.48
   Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208
   Stenbeck G, 2002, SEMIN CELL DEV BIOL, V13, P285, DOI 10.1016/S1084952102000587
   STEWART AF, 1982, J CLIN ENDOCR METAB, V55, P219, DOI 10.1210/jcem 55 2 219
   Taichman RS, 1998, STEM CELLS, V16, P7, DOI 10.1002/stem.160007
   TAUBE T, 1994, BONE, V15, P161, DOI 10.1016/8756 3282(94)90703 X
   Thomas GP, 2001, J ENDOCRINOL, V170, P451, DOI 10.1677/joe.0.1700451
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Tiedemann K, 2009, J BIOL CHEM, V284, P33662, DOI 10.1074/jbc.M109.010785
   Varnum Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091
   Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555 006 9019 x
   Yamada T, 2003, BLOOD, V101, P2227, DOI 10.1182/blood 2002 06 1740
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhu J, 2007, J BIOL CHEM, V282, P26656, DOI 10.1074/jbc.M705064200
NR 52
TC 12
Z9 14
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
SN 0021 9258
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 8
PY 2010
VL 285
IS 41
BP 31427
EP 31434
DI 10.1074/jbc.M110.114496
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 661WX
UT WOS:000282764600037
PM 20679341
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Hayrapetyan, A
   Jansen, JA
   van den Beucken, JJJP
AF Hayrapetyan, Astghik
   Jansen, John A.
   van den Beucken, Jeroen J. J. P.
TI Signaling Pathways Involved in Osteogenesis and Their Application for
   Bone Regenerative Medicine
SO TISSUE ENGINEERING PART B REVIEWS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; OSTEOBLAST LIKE CELLS; MARROW STROMAL CELLS; P38
   MAPK PATHWAYS; OF THE ART; GROWTH FACTOR; TGF BETA; MORPHOGENETIC
   PROTEIN 2; TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTOR
AB Bone regeneration is a well organized but complex physiological process, in which different cell types and their activated signaling pathways are involved. In bone regeneration and remodeling processes, mesenchymal stem cells (MSCs) have a crucial role, and their differentiation during these processes is regulated by specific signaling molecules (growth factors/cytokines and hormones) and their activated intracellular networks. Especially the utilization of the molecular machinery seems crucial to consider prior to developing bone implants, bone substitute materials, and cell based constructs for bone regeneration. The aim of this review is to provide an overview of the signaling mechanisms involved in bone regeneration and remodeling and the osteogenic potential of MSCs to become a key cellular resource for such regeneration and remodeling processes. Additionally, an overview of possibilities to beneficially exploit cell signaling processes to optimize bone regeneration is provided.
C1 [Hayrapetyan, Astghik; Jansen, John A.; van den Beucken, Jeroen J. J. P.] Radboudumc, Dept Biomat, NL 6525 EX Nijmegen, Netherlands.
C3 Radboud University Nijmegen
RP van den Beucken, JJJP (通讯作者)，Radboudumc, Dept Biomat, Ph van Leijdenlaan 25, NL 6525 EX Nijmegen, Netherlands.
EM jeroen.vandenbeucken@radboudumc.nl
RI Jansen, John/H 8055 2014; van den Beucken, Jeroen/N 2910 2013
OI van den Beucken, Jeroen/0000 0002 0301 1966
CR Anam K, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt323
   Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   Barradas A., 2012, BIOMATERIALS, V33, P3025
   Barrère F, 2006, INT J NANOMED, V1, P317
   Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264 007 0424 8
   Boyan BD, 2002, CALCIFIED TISSUE INT, V71, P519, DOI 10.1007/s00223 001 1114 y
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bragdon B, 2012, J CELL PHYSIOL, V227, P2870, DOI 10.1002/jcp.23028
   Cai X., 2012, OSTEOGENESIS, P135
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Chai C, 2007, MOL THER, V15, P467, DOI 10.1038/sj.mt.6300084
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   CLOHISY DR, 1994, J BONE JOINT SURG AM, V76A, P549, DOI 10.2106/00004623 199404000 00009
   Coutu DL, 2011, AGING US, V3, P920, DOI 10.18632/aging.100369
   D'Souza RN, 1999, DEVELOPMENT, V126, P2911
   Daculsi G, 2003, J MATER SCI MATER M, V14, P195, DOI 10.1023/A:1022842404495
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ehrlich M, 2012, FEBS LETT, V586, P1885, DOI 10.1016/j.febslet.2012.01.040
   Ekström K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075227
   Fisher J.e., 2003, Topics in Tissue Engineering, V1, P1
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Freed LE, 1998, ADV DRUG DELIVER REV, V33, P15, DOI 10.1016/S0169 409X(98)00017 9
   Gallagher WM, 2006, BIOMATERIALS, V27, P5871, DOI 10.1016/j.biomaterials.2006.07.040
   Gómez Barrena E, 2011, J CELL MOL MED, V15, P1266, DOI 10.1111/j.1582 4934.2011.01265.x
   Grellier M, 2009, TRENDS BIOTECHNOL, V27, P562, DOI 10.1016/j.tibtech.2009.07.001
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203
   Habas Raymond, 2005, J Biol, V4, P2, DOI 10.1186/jbiol22
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Heinemann C, 2011, EUR CELLS MATER, V21, P80, DOI 10.22203/eCM.v021a07
   Helm GA, 1997, J NEUROSURG, V86, P93, DOI 10.3171/jns.1997.86.1.0093
   Henrich D., 2013, MEDIAT INFLAMM, V2013, P364
   Herford A. S., 2011, PLAST SURG INT, V165, P2011
   Hill CS, 2009, CELL RES, V19, P36, DOI 10.1038/cr.2008.325
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hollinger JO, 2008, J BONE JOINT SURG AM, V90A, P48, DOI 10.2106/JBJS.G.01231
   Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092 8674(00)81250 7
   Huang W., 2007, FRONT BIOSCI, V12, P92
   Hughes Fulford M, 2004, SCI SIGNAL, V12, P2004
   Hyun J.S., 2011, INTECH TISSUE ENG TI, P107, DOI [10.5772/22971, DOI 10.5772/22971]
   Iqbal J, 2005, BIOCHEM BIOPH RES CO, V328, P751, DOI 10.1016/j.bbrc.2004.12.087
   Jacob AL, 2006, DEV BIOL, V296, P315, DOI 10.1016/j.ydbio.2006.05.031
   Jullien N, 2012, J CELL BIOCHEM, V113, P2047, DOI 10.1002/jcb.24076
   Jun JH, 2010, J BIOL CHEM, V285, P36410, DOI 10.1074/jbc.M110.142307
   Kaigler D, 2011, EXPERT OPIN BIOL TH, V11, P375, DOI 10.1517/14712598.2011.554814
   Kanno T, 2007, J CELL BIOCHEM, V101, P1266, DOI 10.1002/jcb.21249
   Kempen DHR, 2010, TISSUE ENG PART B RE, V16, P551, DOI 10.1089/ten.teb.2010.0176
   Khoshniat S, 2011, BONE, V48, P894, DOI 10.1016/j.bone.2010.12.002
   Kimura T, 2010, CLIN CANCER RES, V16, P121, DOI 10.1158/1078 0432.CCR 09 0982
   Koch H, 2005, STEM CELLS DEV, V14, P621, DOI 10.1089/scd.2005.14.621
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kotzsch A, 2008, J BIOL CHEM, V283, P5876, DOI 10.1074/jbc.M706029200
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Kumar A, 2010, TISSUE ENG PT A, V16, P983, DOI [10.1089/ten.tea.2009.0230, 10.1089/ten.TEA.2009.0230]
   Le Guéhennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341
   LeGeros RZ, 2008, CHEM REV, V108, P4742, DOI 10.1021/cr800427g
   Li H, 2006, CELL RES, V16, P169, DOI 10.1038/sj.cr.7310023
   Liedert A, 2006, BIOCHEM BIOPH RES CO, V349, P1, DOI 10.1016/j.bbrc.2006.07.214
   Lincks J, 1998, BIOMATERIALS, V19, P2219, DOI 10.1016/S0142 9612(98)00144 6
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Ma J., 2013, J BIOMED MATER RES A, V1002, P34775
   Ma J., 2013, J TISSUE ENG REGEN M, V1002, P1704
   Ma JL, 2014, STEM CELL TRANSL MED, V3, P98, DOI 10.5966/sctm.2013 0126
   Ma S, 2005, J Oral Implantol, V31, P61, DOI 10.1563/0 742.1
   Major ML, 2007, BIOCHEM BIOPH RES CO, V355, P654, DOI 10.1016/j.bbrc.2007.01.177
   Mamails A., 2011, J ORAL IMPLANTOL, V39, P591
   Marks F., 2009, CELLULAR SIGNAL PROC, P219
   Marletta G, 2007, BIOMATERIALS, V28, P1132, DOI 10.1016/j.biomaterials.2006.10.027
   MARTIN JY, 1995, J BIOMED MATER RES, V29, P389, DOI 10.1002/jbm.820290314
   Massagué J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745
   Massagué J, 2000, GENE DEV, V14, P627
   Matsubara H, 2012, BONE, V51, P168, DOI 10.1016/j.bone.2012.02.017
   Matsunobu T, 2009, DEV BIOL, V332, P325, DOI 10.1016/j.ydbio.2009.06.002
   McLean RR, 2004, NEW ENGL J MED, V350, P2042, DOI 10.1056/NEJMoa032739
   Mikuni Takagaki Y, 1999, J BONE MINER METAB, V17, P57, DOI 10.1007/s007740050065
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Nair MB, 2009, TISSUE ENG PT A, V15, P1619, DOI 10.1089/ten.tea.2008.0229
   Naski M. C., 1998, FETAL PEDIATR PATHOL, V18, P355
   Negishi Koga T, 2009, IBMS BONEKEY, V6, P301
   Ohishi M, 2010, J CELL BIOCHEM, V109, P277, DOI 10.1002/jcb.22399
   Orbay H., 2012, STEM CELLS INT, V2012, P461
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006
   Salgado AJ, 2004, MACROMOL BIOSCI, V4, P743, DOI 10.1002/mabi.200400026
   Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435
   Schindeler A, 2012, IBMS BONEKEY, V9, P1038
   Sethi N., 2012, BoneKEy Rep, V3, P1038
   Shin MK, 2008, CELL SIGNAL, V20, P613, DOI 10.1016/j.cellsig.2007.11.012
   Slósarczyk A, 2005, J MOL STRUCT, V744, P657, DOI 10.1016/j.molstruc.2004.11.078
   Sousa B. R., 2013, CYTOM PART A, V85, P43
   Stolberg Sheryl Gay, 1999, N Y Times Mag, P136
   Szpalski C, 2012, TISSUE ENG PART B RE, V18, P258, DOI [10.1089/ten.TEB.2011.0440, 10.1089/ten.teb.2011.0440]
   Tapp H, 2009, EXP BIOL MED, V234, P1, DOI [10.3181/0805 MR 170, 10.3181/0805/MR 170]
   Tobita M, 2011, DISCOV MED, V11, P160
   Tokunaga A, 2008, J BONE MINER RES, V23, P1519, DOI 10.1359/JBMR.080409
   Tomomura M, 2012, J BIOL CHEM, V287, P17963, DOI 10.1074/jbc.M112.358796
   Tsuda H, 2003, MOL THER, V7, P354, DOI 10.1016/S1525 0016(02)00062 X
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Unadkat HV, 2011, P NATL ACAD SCI USA, V108, P16565, DOI 10.1073/pnas.1109861108
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Wang C., 2012, BIOMATERIALS, V34, P64
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Yang S, 2011, BIOMATERIALS, V32, P2851, DOI 10.1016/j.biomaterials.2011.01.015
   Yun YR, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/218142
   Zhang X, 2006, CALCIFIED TISSUE INT, V79, P169, DOI 10.1007/s00223 006 0083 6
   Zhang Y., 2012, SCI WORLD J, V2012, P793
NR 114
TC 108
Z9 116
U1 0
U2 65
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3368
EI 1937 3376
J9 TISSUE ENG PART B RE
JI Tissue Eng. Part B Rev.
PD FEB 1
PY 2015
VL 21
IS 1
BP 75
EP 87
DI 10.1089/ten.teb.2014.0119
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering;
   Materials Science
GA CA6HG
UT WOS:000349011200007
PM 25015093
DA 2025 08 17
ER

PT J
AU Cai, YQ
   Sun, HJ
   Song, XY
   Zhao, JY
   Xu, D
   Liu, MZ
AF Cai, Yuanqing
   Sun, Huijun
   Song, Xingyu
   Zhao, Jianyu
   Xu, Dong
   Liu, Mozhen
TI The Wnt/B catenin signaling pathway inhibits osteoporosis by regulating
   the expression of TERT: an in vivo and in vitro study
SO AGING US
LA English
DT Article
DE osteoporosis; Wnt signaling pathway; TERT; bilateral ovariectomy
ID STEM CELLS; TELOMERASE; GENE; ACTIVATION; THERAPY
AB Our study was performed to investigate whether the Wingless and int 1 (Wnt) signaling pathway promotes osteogenic differentiation and inhibits apoptosis in bone marrow mesenchymal stem cells (BMSCs) by regulating telomerase reverse transcriptase (TERT) expression. An in vivo model of osteoporosis (OP) in C57BL/6J mice by bilateral ovariectomy (OVX) and an in vitro model of H2O2 induced BMSCs were established separately. Western blotting was used to detect the expression of the pathway related proteins TERT, B catenin, and phosphorylated glycogen synthase kinase 3beta (p GSK3B)/GSK3B, the osteogenic related markers osteopontin (OPN), bone morphogenetic protein 2 (BMP2), and runt related transcription factor 2 (Runx2), and the apoptosis related indicators B cell lymphoma 2 (Bcl 2) and BAX. Osteoblastic phenotypes were also evaluated by alkaline phosphatase (ALP) staining and serum ALP activity assays. Osteogenic differentiation phenotypes in mice were verified by H&E staining, micro CT, and parameter analysis of the femur. Western blotting results showed that the expression of the pathway related proteins TERT, B catenin, p GSK3B/GSK3B was reduced in OVX mice and H2O2 induced BMSCs, accompanied by downregulated protein expression of osteogenic related markers and antiapoptotic indicators and upregulated protein expression of apoptotic proteins compared to those in the control group. Mechanistic studies showed that the activation of Wnt signaling pathway in BMSCs promoted B catenin translocation to the nucleus, as verified by immunofluorescence and facilitated colocalization between B catenin and TERT, as verified by doublelabeling immunofluorescence, thereby promoting osteogenic differentiation and reducing apoptosis. In summary, our experiments confirmed that the GSK3B/B catenin/TERT pathway could regulate the osteogenic differentiation and apoptosis of BMSCs and that TERT might be a promising target for the future treatment of osteoporosis.
C1 [Cai, Yuanqing; Song, Xingyu; Zhao, Jianyu; Xu, Dong; Liu, Mozhen] Dalian Med Univ, Affiliated Hosp 1, Dept Orthopaed, Dalian 116011, Peoples R China.
   [Sun, Huijun] Dalian Med Univ, Coll Pharm, Dept Clin Pharmacol, Dalian 116044, Peoples R China.
C3 Dalian Medical University; Dalian Medical University
RP Liu, MZ (通讯作者)，Dalian Med Univ, Affiliated Hosp 1, Dept Orthopaed, Dalian 116011, Peoples R China.
EM mozhenliu@dmu.edu.cn
RI Zhao, Jianyu/AAW 7608 2021
FU Important Science Fund of Science and Technology Bureau of Liaoning
   Province [2020JH2/10300056]; National Natural Science Foundation of
   China [82073851]
FX <BOLD>Funding</BOLD> This study was supported in part by grants from the
   Important Science Fund of Science and Technology Bureau of Liaoning
   Province (2020JH2/10300056) and the National Natural Science Foundation
   of China (82073851) .
CR Aibar Almazán A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23169465
   Albert SG, 2017, ENDOCR PRACT, V23, P841, DOI 10.4158/EP161678.RA
   Albrecht LV, 2021, ANNU REV CELL DEV BI, V37, P369, DOI 10.1146/annurev cellbio 120319 023657
   Boccardi V, 2012, EMBO MOL MED, V4, P685, DOI 10.1002/emmm.201200246
   Chen C, 2014, EMBO MOL MED, V6, P322, DOI 10.1002/emmm.201303000
   Chen W, 2022, CELLS BASEL, V11, DOI 10.3390/cells11223552
   Chen YS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144923
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Ensrud Kristine E, 2021, JAMA, V325, P96, DOI 10.1001/jama.2020.2923
   Fragkiadaki P, 2020, EXP THER MED, V19, P1626, DOI 10.3892/etm.2019.8370
   Gao QM, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.787118
   Gomatou G, 2024, PULMONOLOGY, V30, P214, DOI 10.1016/j.pulmoe.2021.12.001
   Grafe I, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022202
   Guo JW, 2023, CELL REP MED, V4, DOI 10.1016/j.xcrm.2022.100881
   Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kim JG, 2017, J CELL PHYSIOL, V232, P1104, DOI 10.1002/jcp.25572
   Kim J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19155 4
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kiyoi T, 2018, METHODS MOL BIOL, V1868, P215, DOI 10.1007/978 1 4939 8802 0_22
   Lems WF, 2017, THER ADV MUSCULOSKEL, V9, P299, DOI 10.1177/1759720X17732562
   Li Chao, 2015, Med Sci Monit, V21, P845, DOI 10.12659/MSM.893144
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092 8674(02)00685 2
   Liu H, 2023, COMPOS PART B ENG, V225, DOI 10.1016/j.compositesb.2023.110610
   Liu Z, 2013, ONCOGENE, V32, P4203, DOI 10.1038/onc.2012.441
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Marini F, 2023, OSTEOPOROSIS INT, V34, P213, DOI 10.1007/s00198 022 06523 7
   Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092 8674(00)80538 3
   Morozov A, 2021, UROL ONCOL SEMIN ORI, V39, DOI 10.1016/j.urolonc.2021.01.022
   Mukaiyama K, 2015, AGING CLIN EXP RES, V27, P413, DOI 10.1007/s40520 014 0296 x
   Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Saidak Z, 2015, J BIOL CHEM, V290, P6903, DOI 10.1074/jbc.M114.621219
   Shao R, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00148 y
   Sonoda S, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01818 0
   Tang GH, 2011, J DENT RES, V90, P336, DOI 10.1177/0022034510389180
   Tu Kristie N, 2018, P T, V43, P92
   Wang XM, 2015, CALCIFIED TISSUE INT, V96, P534, DOI 10.1007/s00223 015 0004 7
   Wei LL, 2008, TRANSPL P, V40, P547, DOI 10.1016/j.transproceed.2008.01.028
   Xia MY, 2017, FEBS OPEN BIO, V7, P759, DOI 10.1002/2211 5463.12220
   Xu YX, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2021.153485
   Yin XX, 2004, BIOCHEM BIOPH RES CO, V315, P643, DOI 10.1016/j.bbrc.2003.01.102
   Young W, 2009, CELL TRANSPLANT, V18, P951, DOI 10.3727/096368909X471251
   Zhang H, 2023, SCI ADV, V9, DOI 10.1126/sciadv.abo7868
NR 44
TC 8
Z9 10
U1 1
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD OCT 31
PY 2023
VL 15
IS 20
BP 11471
EP 11488
PG 18
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA AR0G4
UT WOS:001120064000035
PM 37862118
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, WL
   Sheu, SY
   Chen, YS
   Kao, ST
   Fu, YT
   Kuo, TF
   Chen, KY
   Yao, CH
AF Wang, Wen Ling
   Sheu, Shi Yuan
   Chen, Yueh Sheng
   Kao, Shung Te
   Fu, Yuan Tsung
   Kuo, Tzong Fu
   Chen, Kuo Yu
   Yao, Chun Hsu
TI Evaluating the Bone Tissue Regeneration Capability of the Chinese Herbal
   Decoction Danggui Buxue Tang from a Molecular
   Biology Perspective
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID MEDICINE; PROLIFERATION; COMPOSITE; SINENSIS
AB Large bone defects are a considerable challenge to reconstructive surgeons. Numerous traditional Chinese herbal medicines have been used to repair and regenerate bone tissue. This study investigated the bone regeneration potential of Danggui Buxue Tang (DBT), a Chinese herbal decoction prepared from Radix Astragali (RA) and Radix Angelicae Sinensis (RAS), from a molecular biology perspective. The optimal ratio of RA and RAS used in DBT for osteoblast culture was obtained by colorimetric and alkaline phosphatase (ALP) activity assays. Moreover, the optimal concentration of DBT for bone cell culture was also determined by colorimetric, ALP activity, nodule formation, Western blotting, wound healing, and tartrate resistant acid phosphatase activity assays. Consequently, the most appropriate weight ratio of RA to RAS for the proliferation and differentiation of osteoblasts was 5 : 1. Moreover, the most effective concentration of DBT was 1,000 mu g/mL, which significantly increased the number of osteoblasts, intracellular ALP levels, and nodule numbers, while inhibiting osteoclast activity. Additionally, 1,000 mu g/mL of DBT was able to stimulate p ERK and p JNK signal pathway. Therefore, DBT is highly promising for use in accelerating fracture healing in the middle or late healing periods.
C1 [Wang, Wen Ling; Sheu, Shi Yuan; Chen, Yueh Sheng; Kao, Shung Te; Fu, Yuan Tsung; Yao, Chun Hsu] China Med Univ, Sch Chinese Med, Taichung 40402, Taiwan.
   [Wang, Wen Ling; Kao, Shung Te] China Med Univ Hosp, Dept Chinese Internal Med, Taichung 40402, Taiwan.
   [Sheu, Shi Yuan] Chung Shan Med Univ, Sch Med, Taichung 40201, Taiwan.
   [Sheu, Shi Yuan] Chung Shan Med Univ Hosp, Dept Integrated Chinese & Western Med, Taichung 40201, Taiwan.
   [Chen, Yueh Sheng; Yao, Chun Hsu] China Med Univ, Dept Biomed Imaging & Radiol Sci, Taichung 40202, Taiwan.
   [Fu, Yuan Tsung] Buddhist Tzu Chi Med Fdn, Taichung Tzu Chi Hosp, Dept Chinese Med, Taichung 40427, Taiwan.
   [Kuo, Tzong Fu] Natl Taiwan Univ, Sch Vet Med, Dept Vet Med, Taipei 10617, Taiwan.
   [Chen, Kuo Yu] Natl Yunlin Univ Sci & Technol, Dept Chem & Mat Engn, Yunlin 64002, Taiwan.
   [Yao, Chun Hsu] Asia Univ, Dept Biomed Informat, Taichung 41354, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital   Taiwan; Chung Shan Medical University;
   Chung Shan Medical University; Chung Shan Medical University Hospital;
   China Medical University Taiwan; Buddhist Tzu Chi General Hospital;
   Taichung Tzu Chi Hospital; National Taiwan University; National Yunlin
   University Science & Technology; Asia University Taiwan
RP Chen, KY (通讯作者)，Natl Yunlin Univ Sci & Technol, Dept Chem & Mat Engn, Yunlin 64002, Taiwan.
EM chenkuo@yuntech.edu.tw; chyao@mail.cmu.edu.tw
RI Chen, Kuo Yu/I 3646 2019; Guo, yongqing/KDS 5864 2024
OI Chen, Kuo Yu/0000 0002 1654 2715; KUO, TZONG FU/0000 0002 6328 8967
FU National Science Council of the Republic of China, Taiwan
   [NSC98 2221 E 039 005 MY3]; China Medical University [CMU 101 AWARD 05,
   CMU101 S 01]
FX The authors would like to thank the National Science Council of the
   Republic of China, Taiwan (Contract no. NSC98 2221 E 039 005 MY3), and
   the China Medical University (Contract nos. CMU 101 AWARD 05 and
   CMU101 S 01) for financially supporting this research.
CR Chang YM, 2011, EVID BASED COMPL ALT, V2011
   Choi RCY, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085
   Dong TTX, 2006, J AGR FOOD CHEM, V54, P2767, DOI 10.1021/jf053163l
   Gao Qiutao, 2007, Chin Med, V2, P12, DOI 10.1186/1749 8546 2 12
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Huang HF, 1997, AM J CHINESE MED, V25, P351, DOI 10.1142/S0192415X97000391
   Lin CY, 2002, AM J CHINESE MED, V30, P271, DOI 10.1142/S0192415X02000351
   Liu BS, 2003, J BIOMED MATER RES A, V67A, P1163, DOI 10.1002/jbm.a.20017
   Lv J, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/284963
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Peng LH, 2010, J ETHNOPHARMACOL, V131, P282, DOI 10.1016/j.jep.2010.06.039
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320 344.2004
   SMITH R, 1980, CLIN SCI, V59, P215, DOI 10.1042/cs0590215
   Sun JS, 2002, BIOMATERIALS, V23, P3377, DOI 10.1016/S0142 9612(02)00038 8
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Tsim K. W. K., 2004, ASIA PACIFIC BIOTECH, V8, P1316
   Wang XL, 2011, PHYTOMEDICINE, V18, P868, DOI 10.1016/j.phymed.2011.01.022
   Wong RWK, 2006, J ORAL MAXIL SURG, V64, P828, DOI 10.1016/j.joms.2006.01.017
   YAN SQ, 1994, CLIN ORTHOP RELAT R, P239
   Yang Q, 2002, CLIN CHIM ACTA, V324, P89, DOI 10.1016/S0009 8981(02)00210 3
   Yao CH, 2005, J BIOMED MATER RES B, V75B, P277, DOI 10.1002/jbm.b.30294
   Zhang H, 2003, BIOMATERIALS, V24, P2013, DOI 10.1016/S0142 9612(02)00616 6
NR 23
TC 10
Z9 13
U1 0
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 853234
DI 10.1155/2014/853234
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AW0XP
UT WOS:000346014800001
PM 25295277
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Sun, WT
   Han, Y
   Li, ZH
   Ge, K
   Zhang, JC
AF Sun, Wentong
   Han, Yu
   Li, Zhenhua
   Ge, Kun
   Zhang, Jinchao
TI Bone Targeted Mesoporous Silica Nanocarrier Anchored by Zoledronate for
   Cancer Bone Metastasis
SO LANGMUIR
LA English
DT Article
ID BREAST CANCER; DRUG DELIVERY; NANOPARTICLES; BISPHOSPHONATES; ACID;
   THERAPY; INTERLEUKIN 8; MECHANISMS; RESISTANCE; EXPRESSION
AB Once bone metastasis occurs, the chances of survival and quality of life for cancer patients decrease significantly. With the development of nanomedicine, nanocarriers loading bisphosphonates have been built to prevent cancer metastasis based on their enhanced permeability and retention (EPR) effects; however, as a passive mechanism, the EPR effects cannot, apply to the metastatic sites because of their lack of leaky vasculature. In this study, we fabricated 40 nm sized mesoporous silica nanoparticles (MSNs) anchored by zoledronic acid (ZOL) for targeting bone sites and delivered the antitumor drug doxorubicin (DOX) in a spatiotemporally controlled manner. The DOX loading and release behaviors, bone targeting ability, cellular uptake and its mechanisms, subcellular localization, cytotoxicity, and the antimigration effect: of this drug delivery system (DDS) were investigated. The results indicated that MSNs ZOL had better bone targeting ability compared with that of the nontargeted MSNs. The maximum loading capacity of DOX into MSNs and MSNs ZOL was about 1671 and 1547 mg/g, with a loading efficiency of 83.56 and 77.34%, respectively. DOX@MSNs ZOL had obvious pH sensitive DOX release behavior. DOX@MSNs ZOL entered into cells through an ATP dependent pathway and then localized in the lysosome to achieve effective intracellular DOX release. The antitumor results indicated that DOX@MSNs ZOL exhibited the best cytotoxicity against A549 cells and significantly decreased cell migration in vitro. This DDS is promising for the treatment of cancer bone metastasis in the future.
C1 [Sun, Wentong; Han, Yu; Li, Zhenhua; Ge, Kun; Zhang, Jinchao] Hebei Univ, Coll Chem & Environm Sci, Key Lab Chem Biol Hebei Prov, Key Lab Med Chem & Mol Diag,Minist Educ, Baoding 071002, Peoples R China.
   [Ge, Kun] Hebei Univ, Affiliated Hosp, Baoding 071000, Peoples R China.
C3 Hebei University; Hebei University
RP Ge, K; Zhang, JC (通讯作者)，Hebei Univ, Coll Chem & Environm Sci, Key Lab Chem Biol Hebei Prov, Key Lab Med Chem & Mol Diag,Minist Educ, Baoding 071002, Peoples R China.; Ge, K (通讯作者)，Hebei Univ, Affiliated Hosp, Baoding 071000, Peoples R China.
EM kaqikun@163.com; jczhang6970@163.com
RI ; Li, Zhenhua/S 9926 2019; Sun, WT/JDN 1302 2023
OI Li, Zhenhua/0000 0001 9751 0864; Ge, Kun/0000 0001 8972 837X; 
FU National Natural Science Foundation of China [31470961, 21271059]; Key
   Basic Research Special Foundation of Science Technology Ministry of
   Hebei Province [14961302D]; Hebei Province "Hundred Talents Program"
   [BR2 202]; Hebei Province "Three Three Three Talents Program"
   [A201401002]; Natural Science Foundation of Hebei Province [B2016201209,
   B2015201097]; Training Program for Innovative Research Team and Leading
   Talent in Hebei Province University [LJRC024]; Science and Technology
   Support Program of Baoding [15ZF055]
FX This research was supported by the National Natural Science Foundation
   of China (31470961, 21271059), Key Basic Research Special Foundation of
   Science Technology Ministry of Hebei Province (14961302D), Hebei
   Province "Hundred Talents Program" (BR2 202), Hebei Province "Three
   Three Three Talents Program" (A201401002), Natural Science Foundation of
   Hebei Province (B2016201209, B2015201097), Training Program for
   Innovative Research Team and Leading Talent in Hebei Province University
   (LJRC024), and Science and Technology Support Program of Baoding
   (15ZF055).
CR Acharya S, 2009, BIOMATERIALS, V30, P5737, DOI 10.1016/j.biomaterials.2009.07.008
   Au KM, 2016, BIOMATERIALS, V82, P178, DOI 10.1016/j.biomaterials.2015.12.018
   Bednarz Knoll N, 2016, CLIN CHEM, V62, P378, DOI 10.1373/clinchem.2015.246686
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Bhattacharya S, 2015, BIOMATERIALS, V51, P91, DOI 10.1016/j.biomaterials.2015.01.007
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Chebbi I, 2010, INT J PHARMACEUT, V383, P116, DOI 10.1016/j.ijpharm.2009.09.011
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman R, 2011, ANN NY ACAD SCI, V1218, P3, DOI 10.1111/j.1749 6632.2010.05766.x
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Elsabahy M, 2012, CHEM SOC REV, V41, P2545, DOI 10.1039/c2cs15327k
   Engel J, 2003, EUR J CANCER, V39, P1794, DOI 10.1016/S0959 8049(03)00422 2
   Fukutomi T, 2005, HEPATOLOGY, V41, P1096, DOI 10.1002/hep.20668
   Ge K, 2016, J NANOPART RES, V18, DOI 10.1007/s11051 016 3380 7
   Ge K, 2015, ACS APPL MATER INTER, V7, P10905, DOI 10.1021/acsami.5b02146
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Gunawan ST, 2015, ADV MATER, V27, P5153, DOI 10.1002/adma.201502243
   He QJ, 2010, MICROPOR MESOPOR MAT, V131, P314, DOI 10.1016/j.micromeso.2010.01.009
   He Y, 2011, J AM CHEM SOC, V133, P14192, DOI 10.1021/ja2048804
   Horie N, 2007, BRIT J CANCER, V96, P255, DOI 10.1038/sj.bjc.6603548
   Hou ZY, 2010, CHEM EUR J, V16, P14513, DOI 10.1002/chem.201000900
   Hu XX, 2013, J MATER CHEM B, V1, P1109, DOI 10.1039/c2tb00223j
   Jiang LQ, 2013, INT J NANOMED, V8, P1825, DOI 10.2147/IJN.S44342
   Li ZX, 2012, CHEM SOC REV, V41, P2590, DOI 10.1039/c1cs15246g
   Liu X, 2016, POLYM CHEM UK, V7, P1375, DOI 10.1039/c5py01807b
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Orditura M, 2002, J INTERF CYTOK RES, V22, P1129, DOI 10.1089/10799900260442557
   Pan LM, 2014, ADV MATER, V26, P6742, DOI 10.1002/adma.201402752
   Pathi SP, 2011, BIOMATERIALS, V32, P5112, DOI 10.1016/j.biomaterials.2011.03.055
   Peiris PM, 2015, J PHARM SCI US, V104, P2600, DOI 10.1002/jps.24518
   Rebucci M, 2013, BIOCHEM PHARMACOL, V85, P1219, DOI 10.1016/j.bcp.2013.02.017
   Rim H. P., 2011, ANGEW CHEM, V123, P9015
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   Shmeeda H, 2013, J CONTROL RELEASE, V167, P265, DOI 10.1016/j.jconrel.2013.02.003
   Shukla P, 2014, J BIOMED NANOTECHNOL, V10, P3381, DOI 10.1166/jbn.2014.1912
   Singh T, 2015, J DRUG TARGET, V23, P1, DOI 10.3109/1061186X.2014.950668
   Slowing II, 2008, ADV DRUG DELIVER REV, V60, P1278, DOI 10.1016/j.addr.2008.03.012
   Sugiura Hideshi, 2011, Clin Calcium, V21, P439, DOI CliCa1103439445
   Sun TM, 2014, ANGEW CHEM INT EDIT, V53, P12320, DOI 10.1002/anie.201403036
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Tasnim A, 2010, EUR J CANCER, V46, P1223
   Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011
   van Brussel JP, 1999, EUR J CANCER, V35, P664, DOI 10.1016/S0959 8049(98)00435 3
   Vinay R, 2016, DRUG DELIV, V23, P21, DOI 10.3109/10717544.2014.913325
   Vranic S, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743 8977 10 2
   Wang HK, 2015, BIOCHEM BIOPH RES CO, V458, P268, DOI 10.1016/j.bbrc.2015.01.097
   Wang J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad3210
   Xiong MH, 2012, J AM CHEM SOC, V134, P4355, DOI 10.1021/ja211279u
   Xu R, 2016, NAT BIOTECHNOL, V34, P414, DOI 10.1038/nbt.3506
   Ye WL, 2015, SCI REP UK, V5, DOI 10.1038/srep14614
NR 53
TC 54
Z9 58
U1 3
U2 76
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743 7463
J9 LANGMUIR
JI Langmuir
PD SEP
PY 2016
VL 32
IS 36
BP 9237
EP 9244
DI 10.1021/acs.langmuir.6b02228
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA DW0GE
UT WOS:000383318100015
PM 27531422
DA 2025 08 17
ER

PT J
AU Ren, CX
   Hao, XQ
   Wang, L
   Hu, Y
   Meng, L
   Zheng, SZ
   Ren, FL
   Bu, WH
   Wang, H
   Li, DW
   Zhang, K
   Sun, HC
AF Ren, Chunxia
   Hao, Xinqing
   Wang, Lu
   Hu, Yue
   Meng, Lin
   Zheng, Shize
   Ren, Feilong
   Bu, Wenhuan
   Wang, Huan
   Li, Daowei
   Zhang, Kai
   Sun, Hongchen
TI Metformin Carbon Dots for Promoting Periodontal Bone Regeneration via
   Activation of ERK/AMPK Pathway
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE bone regeneration; carbon dots; ERK; AMPK pathway; osteogenesis;
   periodontitis
ID OSTEOBLAST DIFFERENTIATION; ANTIDIABETIC DRUG; STEM CELLS; IN VITRO;
   NANOPARTICLES; MAPK; AMPK; DISRUPTION; SCAFFOLDS; ACID
AB The osteogenic potential of mesenchymal stem cells (MSCs) is severely impaired under persistent inflammation of periodontitis. A highly efficient way to promote or rescue osteogenic potential of MSCs under inflammation remains an unmet goal. Herein, metformin carbon dots (MCDs) with excellent biocompatibility are prepared from metformin hydrochloride and citric acid via a hydrothermal method. The MCDs can more effectively enhance the alkaline phosphatase (ALP) activity, calcium deposition nodules formation, expression of osteogenic genes and proteins in rat bone marrow mesenchymal stem cells (rBMSCs) than metformin under both inflammatory and normal conditions. Moreover, a novel pathway of extracellular signal regulated kinases (ERK)/AMP activated protein kinase (AMPK) signaling is involved in the MCDs induced osteogenesis. In periodontitis rats, MCDs can effectively regenerate the lost alveolar bone, but not the metformin. Taken together, MCDs can be the promising candidate nanomaterial for periodontitis treatment. This work may provide a new pharmacological target of ERK/AMPK pathway for treating bone loss and also give additional insights into developing nanodrugs from the numerous medications.
C1 [Ren, Chunxia; Hao, Xinqing; Wang, Lu; Hu, Yue; Meng, Lin; Zheng, Shize; Ren, Feilong; Li, Daowei; Sun, Hongchen] Jilin Univ, Hosp Stomatol, Changchun 130021, Peoples R China.
   [Ren, Chunxia; Hao, Xinqing; Wang, Lu; Hu, Yue; Meng, Lin; Zheng, Shize; Ren, Feilong; Li, Daowei] Jilin Univ, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Hosp Stomatol, Changchun 130021, Peoples R China.
   [Bu, Wenhuan] China Med Univ, Sch Stomatol, Shenyang 110001, Peoples R China.
   [Wang, Huan] Chinese Acad Sci, State Key Lab Rare Earth Resources Utilizat, Changchun Inst Appl Chem, Changchun 130022, Peoples R China.
   [Zhang, Kai] Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.
C3 Jilin University; Jilin University; China Medical University; Chinese
   Academy of Sciences; Changchun Institute of Applied Chemistry, CAS;
   Jilin University
RP Li, DW; Sun, HC (通讯作者)，Jilin Univ, Hosp Stomatol, Changchun 130021, Peoples R China.; Li, DW (通讯作者)，Jilin Univ, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Hosp Stomatol, Changchun 130021, Peoples R China.; Zhang, K (通讯作者)，Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.
EM jluldw@jlu.edu.cn; zk@jlu.edu.cn; hcsun@jlu.edu.cn
RI ; Li, Daowei/X 7203 2019; Sun, Hongchen/X 7152 2019; Wang,
   Huan/LOR 6602 2024
OI Li, Daowei/0000 0002 4848 9373; wang, huan/0000 0001 9464 2474; Ren,
   Chunxia/0000 0003 2350 727X; 
FU National Natural Science Foundation of China [81870741, 82001023];
   Department of Science and Technology of Jilin Province [JLSZ2019378028];
   Bethune Project of Jilin University [2018A06]
FX The research was supported by grants from the National Natural Science
   Foundation of China (81870741 and 82001023), Department of Science and
   Technology of Jilin Province (JLSZ2019378028), and Bethune Project of
   Jilin University (2018A06).
CR Bahrambeigi S, 2019, BIOMED PHARMACOTHER, V109, P1593, DOI 10.1016/j.biopha.2018.11.032
   Pereira ADBF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113488
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Bradley AD, 2016, J PERIODONTOL, V87, P577, DOI 10.1902/jop.2016.150599
   Chen FM, 2010, BIOMATERIALS, V31, P7892, DOI 10.1016/j.biomaterials.2010.07.019
   Chen JL, 2021, BIOSENS BIOELECTRON, V176, DOI 10.1016/j.bios.2020.112955
   Chen S, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202004680
   Chen SC, 2017, MOL CELL ENDOCRINOL, V440, P57, DOI 10.1016/j.mce.2016.11.011
   Curran JM, 2006, BIOMATERIALS, V27, P4783, DOI 10.1016/j.biomaterials.2006.05.001
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   Dominy SS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau3333
   Eivazzadeh Keihan R, 2019, J ADV RES, V18, P185, DOI 10.1016/j.jare.2019.03.011
   Fan X.L., 2020, CELL MOL LIFE SCI, V77, P2771
   Ferreira MSV, 2012, BIOMATERIALS, V33, P6987, DOI 10.1016/j.biomaterials.2012.06.029
   Genco RJ, 2020, PERIODONTOL 2000, V83, P7, DOI 10.1111/prd.12344
   Gong NQ, 2019, NAT NANOTECHNOL, V14, P379, DOI 10.1038/s41565 019 0373 6
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Han Y, 2019, COLLOID SURFACE B, V179, P1, DOI 10.1016/j.colsurfb.2019.03.035
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Jayaraman P, 2015, ADV DRUG DELIVER REV, V94, P77, DOI 10.1016/j.addr.2015.09.007
   Jeyabalan J, 2013, OSTEOPOROSIS INT, V24, P2659, DOI 10.1007/s00198 013 2371 0
   Kanazawa I, 2018, ENDOCRINOLOGY, V159, P597, DOI 10.1210/en.2017 00357
   Kasai T, 2009, J CELL PHYSIOL, V221, P740, DOI 10.1002/jcp.21917
   Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491
   Keselowsky BG, 2005, P NATL ACAD SCI USA, V102, P5953, DOI 10.1073/pnas.0407356102
   Keselowsky BG, 2004, BIOMATERIALS, V25, P5947, DOI 10.1016/j.biomaterials.2004.01.062
   Kimura Y, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00019
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Könönen E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081135
   Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209
   Li HM, 2019, ADV MATER, V31, DOI 10.1002/adma.201904535
   Li JP, 2021, ADV MATER, V33, DOI 10.1002/adma.202005096
   Li JP, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201800881
   Li Y, 2018, INT J MOL MED, V41, P2535, DOI 10.3892/ijmm.2018.3498
   Li YL, 2017, NANOSCALE, V9, P4862, DOI 10.1039/c7nr00835j
   Li Z, 2013, BIOMATERIALS, V34, P7616, DOI 10.1016/j.biomaterials.2013.06.059
   Lin CJ, 2019, SMALL, V15, DOI 10.1002/smll.201902641
   Liu JJ, 2020, ADV MATER, V32, DOI 10.1002/adma.201906641
   Moentadj R, 2021, ANN RHEUM DIS, V80, P573, DOI 10.1136/annrheumdis 2020 219009
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ni C, 2019, BIOMATERIALS, V206, P115, DOI 10.1016/j.biomaterials.2019.03.039
   Okesola BO, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201906205
   Ouchi T, 2020, REGEN THER, V14, P72, DOI 10.1016/j.reth.2019.12.011
   Peng ZL, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901495
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rajeshwari HR, 2019, J CONTROL RELEASE, V307, P393, DOI 10.1016/j.jconrel.2019.06.038
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Reffitt DM, 2003, BONE, V32, P127, DOI 10.1016/S8756 3282(02)00950 X
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320 344.2004
   Salai M, 2013, BONE JOINT J, V95B, P1575, DOI 10.1302/0301 620X.95B11.31158
   Shao D, 2017, BIOMATER SCI UK, V5, P1820, DOI 10.1039/c7bm00358g
   Slots J, 2002, PERIODONTOL 2000, V28, P106, DOI 10.1034/j.1600 0757.2002.280106.x
   Tang LB, 2013, PART PART SYST CHAR, V30, P523, DOI 10.1002/ppsc.201200131
   Tian XT, 2019, SMALL, V15, DOI 10.1002/smll.201901803
   Tomchuck SL, 2008, STEM CELLS, V26, P99, DOI 10.1634/stemcells.2007 0563
   Wang B, 2019, BIOMATER SCI UK, V7, P5414, DOI 10.1039/c9bm01181a
   Wang QW, 2016, BIOMATERIALS, V86, P11, DOI 10.1016/j.biomaterials.2016.02.004
   Xia CL, 2019, ADV SCI, V6, DOI 10.1002/advs.201901316
   Xia Y, 2018, BIOMATERIALS, V183, P151, DOI 10.1016/j.biomaterials.2018.08.040
   Xu XY, 2019, STEM CELL TRANSL MED, V8, P392, DOI 10.1002/sctm.18 0181
   Xu XY, 2004, J AM CHEM SOC, V126, P12736, DOI 10.1021/ja040082h
   Yan Q, 2015, INFLAMM RES, V64, P63, DOI 10.1007/s00011 014 0784 7
   Yin Y, 2017, J DENT RES, V96, P601, DOI 10.1177/0022034517706070
   Yu XR, 2018, EXP CELL RES, V372, P178, DOI 10.1016/j.yexcr.2018.09.024
   Yuan JM, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045 020 00949 4
   Zhao F, 2011, SMALL, V7, P1322, DOI 10.1002/smll.201100001
   Zhou D, 2019, NANOSCALE HORIZ, V4, P388, DOI 10.1039/c8nh00247a
   Zhou J, 2011, J CELL PHYSIOL, V226, P2081, DOI 10.1002/jcp.22538
NR 72
TC 67
Z9 69
U1 15
U2 253
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD JUN
PY 2021
VL 10
IS 12
AR 2100196
DI 10.1002/adhm.202100196
EA MAY 2021
PG 13
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA SW6CN
UT WOS:000649999700001
PM 33987977
DA 2025 08 17
ER

PT J
AU Walmsley, GG
   Senarath Yapa, K
   Wearda, TL
   Menon, S
   Hu, MS
   Duscher, D
   Maan, ZN
   Tsai, JM
   Zielins, ER
   Weissman, IL
   Gurtner, GC
   Lorenz, HP
   Longaker, MT
AF Walmsley, Graham G.
   Senarath Yapa, Kshemendra
   Wearda, Taylor L.
   Menon, Siddharth
   Hu, Michael S.
   Duscher, Dominik
   Maan, Zeshaan N.
   Tsai, Jonathan M.
   Zielins, Elizabeth R.
   Weissman, Irving L.
   Gurtner, Geoffrey C.
   Lorenz, H. Peter
   Longaker, Michael T.
TI Surveillance of Stem Cell Fate and Function: A System for Assessing Cell
   Survival and Collagen Expression In Situ
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID PARIETAL CALVARIAL BONES; STROMAL CELLS; TISSUE; REPAIR; VIVO;
   TRANSPLANTATION; CAPACITY; THERAPY
AB Cell based therapy is an emerging paradigm in skeletal regenerative medicine. However, the primary means by which transplanted cells contribute to bone repair and regeneration remain controversial. To gain an insight into the mechanisms of how both transplanted and endogenous cells mediate skeletal healing, we used a transgenic mouse strain expressing both the topaz variant of green fluorescent protein under the control of the collagen, type I, alpha 1 promoter/enhancer sequence (Col1a1(GFP)) and membrane bound tomato red fluorescent protein constitutively in all cell types (R26(mTmG)). A comparison of healing in parietal versus frontal calvarial defects in these mice revealed that frontal osteoblasts express Col1a1 to a greater degree than parietal osteoblasts. Furthermore, the scaffold based application of adipose derived stromal cells (ASCs), bone marrow derived mesenchymal stem cells (BM MSCs), and osteoblasts derived from these mice to critical sized calvarial defects allowed for investigation of cell survival and function following transplantation. We found that ASCs led to significantly faster rates of bone healing in comparison to BM MSCs and osteoblasts. ASCs displayed both increased survival and increased Col1a1 expression compared to BM MSCs and osteoblasts following calvarial defect transplantation, which may explain their superior regenerative capacity in the context of bone healing. Using this novel reporter system, we were able to elucidate how cell based therapies impact bone healing and identify ASCs as an attractive candidate for cell based skeletal regenerative therapy. These insights potentially influence stem cell selection in translational clinical trials evaluating cell based therapeutics for osseous repair and regeneration.
C1 [Walmsley, Graham G.; Senarath Yapa, Kshemendra; Wearda, Taylor L.; Menon, Siddharth; Hu, Michael S.; Duscher, Dominik; Maan, Zeshaan N.; Zielins, Elizabeth R.; Gurtner, Geoffrey C.; Lorenz, H. Peter; Longaker, Michael T.] Stanford Univ, Sch Med, Div Plast & Reconstruct Surg, Hagey Lab Pediat Regenerat Med,Dep Surg, Stanford, CA 94305 USA.
   [Walmsley, Graham G.; Hu, Michael S.; Tsai, Jonathan M.; Weissman, Irving L.; Longaker, Michael T.] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University
RP Longaker, MT (通讯作者)，Stanford Univ, Sch Med, Div Plast & Reconstruct Surg, Hagey Lab Pediat Regenerat Med,Dep Surg, 257 Campus Dr Room GK106 MC 5148, Stanford, CA 94305 USA.
EM longaker@stanford.edu
RI Duscher, Dominik/AAH 5330 2020; Weissman, Irv/ABS 2071 2022; Tsai,
   Jonathan/KEH 1552 2024
OI Maan, Zeshaan/0000 0002 7683 1914; Tsai, Jonathan/0000 0001 5868 2305
FU NIH [R01 GM087609, U01 HL099776]; Hagey Laboratory for Pediatric
   Regenerative Medicine; Oak Foundation; Gunn/Olivier fund; NIGMS
   [GM07365]; California Institute for Regenerative Medicine Clinical
   Fellow training grant [TG2 01159]; Plastic Surgery Foundation Research
   Fellowship [114288]; Stanford School of Medicine, the Stanford Medical
   Scientist Training Program
FX This work was supported in part by a grant from the NIH grant R01
   GM087609 (H.P.L.), a gift from Ingrid Lai and Bill Shu in honor of
   Anthony Shu (H.P.L.), the Hagey Laboratory for Pediatric Regenerative
   Medicine and the Oak Foundation (M.T.L., H.P.L., and G.C.G.), the NIH
   grant U01 HL099776 (M.T.L.), and the Gunn/Olivier fund (M.T.L.). G.G.W.
   was supported by the Stanford School of Medicine, the Stanford Medical
   Scientist Training Program, and NIGMS training grant GM07365. M.S.H. was
   supported by the California Institute for Regenerative Medicine Clinical
   Fellow training grant TG2 01159. Z.N.M. was supported by the Plastic
   Surgery Foundation Research Fellowship grant 114288.
CR [Anonymous], INJURY S2
   Barba M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/416391
   Behr B, 2012, TISSUE ENG PT A, V18, P1079, DOI [10.1089/ten.tea.2011.0537, 10.1089/ten.TEA.2011.0537]
   Behr B, 2011, STEM CELLS, V29, P286, DOI 10.1002/stem.581
   Behr B, 2010, BONE, V47, P281, DOI 10.1016/j.bone.2010.05.008
   Bodle JC, 2011, TISSUE ENG PART B RE, V17, P195, DOI [10.1089/ten.TEB.2010.0738, 10.1089/ten.teb.2010.0738]
   Chan CKF, 2013, P NATL ACAD SCI USA, V110, P12643, DOI 10.1073/pnas.1310212110
   Chung MT, 2013, TISSUE ENG PT A, V19, P989, DOI [10.1089/ten.tea.2012.0370, 10.1089/ten.TEA.2012.0370]
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Cutler C, 2005, CLIN CHEST MED, V26, P517, DOI 10.1016/j.ccm.2005.06.016
   Hyun J, 2013, STEM CELL TRANSL MED, V2, P690, DOI 10.5966/sctm.2013 0035
   Hyun JS, 2013, BIOTECHNOL ADV, V31, P736, DOI 10.1016/j.biotechadv.2012.11.003
   Isakson M, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/831095
   Kapur SK, 2015, CLIN PLAST SURG, V42, P155, DOI 10.1016/j.cps.2014.12.010
   Knight MN, 2013, ADV WOUND CARE, V2, P306, DOI 10.1089/wound.2012.0420
   Levi B, 2012, P NATL ACAD SCI USA, V109, P20379, DOI 10.1073/pnas.1218052109
   Levi B, 2011, STEM CELLS, V29, P576, DOI 10.1002/stem.612
   Levi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011177
   Li SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058610
   Li SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014033
   Lin Yi, 2011, Adv Hematol, V2011, P427863, DOI 10.1155/2011/427863
   Minteer DM, 2015, CLIN PLAST SURG, V42, P169, DOI 10.1016/j.cps.2014.12.007
   Panetta NJ, 2009, PANMINERVA MED, V51, P25
   Quarto N, 2010, J BONE MINER RES, V25, P1680, DOI 10.1359/jbmr.091116
   Quarto N, 2009, CELLS TISSUES ORGANS, V190, P158, DOI 10.1159/000202789
   Rosset P, 2014, ORTHOP TRAUMATOL SUR, V100, pS107, DOI 10.1016/j.otsr.2013.11.010
   Stegemann J P, 2014, Eur Cell Mater, V27, P1
   Tevlin R, 2014, J DENT RES, V93, P1187, DOI 10.1177/0022034514547271
   Walmsley GG, 2015, NANOMED NANOTECHNOL, V11, P1253, DOI 10.1016/j.nano.2015.02.013
   Walmsley GG, 2014, CURR STEM CELL RES T, V9, P73, DOI 10.2174/1574888X09666131217004137
   Watson L, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt439
   Wingard JR, 2010, INFECT DIS CLIN N AM, V24, P257, DOI 10.1016/j.idc.2010.01.010
   Zanatta G, 2012, J BIOMED NANOTECHNOL, V8, P211, DOI 10.1166/jbn.2012.1382
   Zigdon Giladi H, 2015, WORLD J STEM CELLS, V7, P630, DOI 10.4252/wjsc.v7.i3.630
NR 34
TC 10
Z9 10
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD JAN 1
PY 2016
VL 22
IS 1 2
BP 31
EP 40
DI 10.1089/ten.tea.2015.0221
PG 10
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA DB4YT
UT WOS:000368520300005
PM 26486617
OA Green Published
DA 2025 08 17
ER

PT J
AU Lee, CH
   Kwak, SC
   Kim, JY
   Oh, HM
   Rho, MC
   Yoon, KH
   Yoo, WH
   Lee, MS
   Oh, J
AF Lee, Chang Hoon
   Kwak, Sung Chul
   Kim, Ju Young
   Oh, Hyun Mee
   Rho, Mun Chual
   Yoon, Kwon Ha
   Yoo, Wan Hee
   Lee, Myeung Su
   Oh, Jaemin
TI Genipin Inhibits RANKL Induced Osteoclast Differentiation Through
   Proteasome Mediated Degradation of c Fos Protein and Suppression of
   NF κB Activation
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE genipin; osteoclast; differentiation; c Fos; NFATc1
ID GARDENIA JASMINOIDES; RECEPTOR ACTIVATOR; IN VITRO; BONE; GENIPOSIDE;
   MICE; MECHANISMS; VIVO
AB People over the age of 50 are at risk of osteoporotic fracture, which may lead to increased morbidity and mortality. Osteoclasts are responsible for bone resorption in bone related disorders. Genipin is a well known geniposide aglycon derived from Gardenia jasminoides, which has long been used in oriental medicine for controlling diverse conditions such as inflammation and infection. We aimed to evaluate the effects of genipin on RANKL induced osteoclast differentiation and its mechanism of action. Genipin dose dependently inhibited early stage RANKL induced osteoclast differentiation in bone marrow macrophages (BMMs) during culture. Genipin inhibited RANKL induced I kappa B degradation and suppressed the mRNA expression of osteoclastic markers such as NFATc1, TRAP, and OSCAR in RANKL treated BMMs, but did not affect c Fos mRNA expression. Interestingly, genipin markedly inhibited c Fos protein expression in BMMs, which was reversed in the presence of the proteosome inhibitor MG 132. Furthermore, genipin inhibited RANKL mediated osteoclast differentiation, which was also rescued by overexpression of c Fos and NFATc1 in BMMs. Taken together, our findings indicate that genipin down regulated RANKL induced osteoclast differentiation through inhibition of c Fos protein proteolysis as well as inhibition of I kappa B degradation. Our findings indicate that genipin could be a useful drug candidate that lacks toxic side effects for the treatment of osteoporosis.
C1 [Lee, Chang Hoon; Lee, Myeung Su] Wonkwang Univ, Sch Med, Dept Internal Med, Div Rheumatol, Iksan 570749, Jeonbuk, South Korea.
   [Kwak, Sung Chul; Kim, Ju Young; Oh, Jaemin] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea.
   [Kim, Ju Young; Yoon, Kwon Ha; Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Oh, Jaemin] Wonkwang Univ, Grad Sch, Plus Program BK21, Iksan 570749, Jeonbuk, South Korea.
   [Oh, Jaemin] Wonkwang Univ, Grad Sch, Dept Smart Life Care Convergence, Iksan 570749, Jeonbuk, South Korea.
   [Oh, Hyun Mee; Rho, Mun Chual] Korea Res Inst Biosci & Biotechnol, Biomat Res Inst, Bioind Proc Res Ctr, Jeongeup 580185, Jeonbuk, South Korea.
   [Yoo, Wan Hee] Chonbuk Natl Univ, Sch Med, Dept Internal Med, Jeonju 561756, Jeonbuk, South Korea.
   [Yoo, Wan Hee] Res Inst Clin Med, Jeonju 561756, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University; Korea Research Institute of Bioscience
   & Biotechnology (KRIBB); Jeonbuk National University
RP Lee, MS (通讯作者)，Wonkwang Univ, Sch Med, Dept Internal Med, Div Rheumatol, Iksan 570749, Jeonbuk, South Korea.
EM ckhlms@wku.ac.kr; jmoh@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
FU Korean Health Technology R&D Project. Ministry of Health & Welfare,
   Republic of Korea [A120152]
FX This study was supported by a grant of the Korean Health Technology R&D
   Project. Ministry of Health & Welfare, Republic of Korea (A120152).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang Y, 2005, J BIOTECHNOL, V120, P207, DOI 10.1016/j.jbiotec.2005.06.029
   Frohbergh ME, 2012, BIOMATERIALS, V33, P9167, DOI 10.1016/j.biomaterials.2012.09.009
   Green JR, 2002, AM J CLIN ONCOL CANC, V25, pS3, DOI 10.1097/00000421 200212001 00002
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hämäläinen H, 2007, JOINT BONE SPINE, V74, P482, DOI 10.1016/j.jbspin.2007.01.021
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hiramatsu K, 2012, ALIMENT PHARM THER, V36, P575, DOI 10.1111/j.1365 2036.2012.05221.x
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ito Y, 2005, BONE, V37, P842, DOI 10.1016/j.bone.2005.04.030
   Kim ES, 2012, ONCOL REP, V27, P567, DOI 10.3892/or.2011.1508
   Koo HJ, 2006, J ETHNOPHARMACOL, V103, P496, DOI 10.1016/j.jep.2005.08.011
   Koo HJ, 2004, EUR J PHARMACOL, V495, P201, DOI 10.1016/j.ejphar.2004.05.031
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li CC, 2012, FOOD CHEM TOXICOL, V50, P2978, DOI 10.1016/j.fct.2012.05.054
   Lin YH, 2013, BIOMATERIALS, V34, P4466, DOI 10.1016/j.biomaterials.2013.02.028
   Liu Z, 2012, BIOMATERIALS, V33, P7336, DOI 10.1016/j.biomaterials.2012.06.080
   Madsen H, 2010, CLIN RESPIR J, V4, P22, DOI 10.1111/j.1752 699X.2009.00138.x
   Park JE, 2002, J AGR FOOD CHEM, V50, P6511, DOI 10.1021/jf020499b
   Shoda J, 2004, HEPATOLOGY, V39, P167, DOI 10.1002/hep.20003
   Song F, 2009, INT J PHARMACEUT, V373, P41, DOI 10.1016/j.ijpharm.2009.02.005
   STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Wang QS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034122
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
NR 29
TC 33
Z9 34
U1 0
U2 15
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD MAR
PY 2014
VL 124
IS 3
BP 344
EP 353
DI 10.1254/jphs.13174FP
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AD8IG
UT WOS:000333509100008
PM 24646621
OA Bronze
DA 2025 08 17
ER

PT J
AU Tao, S
   Yu, FY
   Song, YQ
   Zhou, WT
   Lv, JH
   Zhao, R
   Wang, C
   Hu, FQ
   Yuan, H
AF Tao, Shan
   Yu, Fangying
   Song, Yanqing
   Zhou, Wentao
   Lv, Jianghong
   Zhao, Rui
   Wang, Cheng
   Hu, Fuqiang
   Yuan, Hong
TI Water/pH dual responsive in situ calcium supplement collaborates
   simvastatin for osteoblast promotion mediated osteoporosis therapy via
   oral medication
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE in situ calcium supplement; Simvastatin; Osteoblast promotion;
   Osteoporosis therapy; Oral medication
ID DRUG DELIVERY; NANOPARTICLES; CARBONATE; DIFFERENTIATION;
   BIOAVAILABILITY; BMP 2
AB Calcium supplement is the most commonly adopted treatment for osteoporosis but usually requires high dose and frequency. The modality of calcium supplement is therefore overlooked by current nanomedicine based osteoporosis therapies without proper oral formulations. Herein, we proposed a tetracycline (Tc) modified and monostearin (MS) coated amorphous calcium carbonate (ACC) platform (TMA) as oral bone targeted and osteoporosis microenvironment (water/pH) responsive carrier for in situ calcium supplement. Moreover, current osteoporosis therapies also fall short of finding suitable molecular target and effective therapeutic regimen to further increase the therapeutic efficacy over available treatment means. As a result, the simvastatin (Sim) was loaded into TMA to construct drug delivery system (TMA/Sim) capable of synergistically activating the bone morphogenetic proteins (BMPs) Smad pathway to provide a novel therapeutic regimen for osteoblast promotion mediated osteoporosis therapy. Our results revealed that optimized TMA showed high accessibility and oral availability with targeted drug delivery to bone tissue. Most importantly, benefit from the effective in situ calcium supplement and targeted Sim delivery, this therapeutic regime (TMA/Sim) achieved better synergetic effects than conventional combination strategies with promising osteoporosis reversion performance under low calcium dosage (1/10 of commercial calcium carbonate tablet) and significantly attenuated side effects.
C1 [Tao, Shan; Yu, Fangying; Song, Yanqing; Zhou, Wentao; Hu, Fuqiang; Yuan, Hong] Zhejiang Univ, Coll Pharmaceut Sci, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China.
   [Wang, Cheng] Changzhou Univ, Sch Pharm, Changzhou 213164, Peoples R China.
   [Lv, Jianghong; Zhao, Rui] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, 3 Qingchun East Rd, Hangzhou 310016, Peoples R China.
C3 Zhejiang University; Changzhou University; Zhejiang University
RP Yuan, H (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China.; Wang, C (通讯作者)，Changzhou Univ, Sch Pharm, Changzhou 213164, Peoples R China.
EM wangc90@cczu.edu.cn; yuanhong70@zju.edu.cn
RI wentao, zhou/HHS 6331 2022; Zhao, Rui/AEY 6449 2022
FU National Natural Science Foundation of China [81773644]; Natural Science
   Foundation of Zhejiang Province [LY19H180007, LY20H310002]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81773644) and Natural Science Foundation of Zhejiang Province
   (No. LY19H180007 and LY20H310002).
CR Alsheikh Ali AA, 2002, AM J CARDIOL, V89, P1308, DOI 10.1016/S0002 9149(02)02334 2
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   [Anonymous], 2021, J CONTROL RELEASE, V329, P121
   Becker David J, 2010, Curr Rheumatol Rep, V12, P186, DOI 10.1007/s11926 010 0097 y
   Cai MX, 2017, INT J NANOMED, V12, P7469, DOI 10.2147/IJN.S139775
   Chai GH, 2014, MOL PHARMACEUT, V11, P3716, DOI 10.1021/mp5004674
   Chalisserry EP, 2019, CURR DRUG DELIV, V16, P530, DOI 10.2174/1567201816666190610164303
   CHAPOTEAU E, 1993, CLIN CHEM, V39, P1820
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Chen W, 2019, ACS NANO, V13, P1292, DOI 10.1021/acsnano.8b06655
   Chesnut CH, 2008, OSTEOPOROSIS INT, V19, P479, DOI 10.1007/s00198 007 0490 1
   Ensign LM, 2012, ADV DRUG DELIVER REV, V64, P557, DOI 10.1016/j.addr.2011.12.009
   FARLEY JR, 1983, SCIENCE, V222, P330
   Fromigué O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873
   Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573 018 0007 y
   Gao CX, 2015, INT J NANOMED, V10, P5139, DOI 10.2147/IJN.S85037
   Hanzlik RP, 2005, J PHARMACOL EXP THER, V313, P1217, DOI 10.1124/jpet.104.081893
   Harde H, 2011, EXPERT OPIN DRUG DEL, V8, P1407, DOI 10.1517/17425247.2011.604311
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Itoh T, 2010, J BIOL CHEM, V285, P27745, DOI 10.1074/jbc.M110.105080
   Izquierdo Barba I, 2019, ACTA BIOMATER, V83, P456, DOI 10.1016/j.actbio.2018.11.017
   Kang Y, 2019, ADV SCI, V6, DOI 10.1002/advs.201900716
   Kawashima Y, 2000, PHARM DEV TECHNOL, V5, P77, DOI 10.1081/PDT 100100522
   Khajuria DK, 2016, MAT SCI ENG C MATER, V63, P78, DOI 10.1016/j.msec.2016.02.062
   Kong F, 2016, ADV FUNCT MATER, V26, P6158, DOI 10.1002/adfm.201602715
   Li J, 2010, J CONTROL RELEASE, V142, P416, DOI 10.1016/j.jconrel.2009.11.008
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Mann V, 2001, J CLIN INVEST, V107, P899, DOI 10.1172/JCI10347
   Marie PJ, 2010, BONE, V46, P571, DOI 10.1016/j.bone.2009.07.082
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   Mignani S, 2013, ADV DRUG DELIVER REV, V65, P1316, DOI 10.1016/j.addr.2013.01.001
   MRC/BHF Heart Protection Study Collaborative Group, 2009, BMC Clin Pharmacol, V9, P6, DOI 10.1186/1472 6904 9 6
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nagai N, 2018, INT J NANOMED, V13, P5215, DOI 10.2147/IJN.S173216
   Neale JR, 2009, BIOORG MED CHEM LETT, V19, P680, DOI 10.1016/j.bmcl.2008.12.051
   Niu ZG, 2016, ADV DRUG DELIVER REV, V106, P337, DOI 10.1016/j.addr.2016.04.001
   Owens DE, 2006, INT J PHARMACEUT, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Park JB, 2012, J SURG RES, V174, P278, DOI 10.1016/j.jss.2010.12.029
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Sastry, 2000, Pharm Sci Technol Today, V3, P138
   Smart AL, 2014, EXPERT OPIN DRUG DEL, V11, P1323, DOI 10.1517/17425247.2014.917077
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Sun TF, 2018, INT J NANOMED, V13, P791, DOI 10.2147/IJN.S152698
   Tao S, 2020, RSC ADV, V10, P20445, DOI 10.1039/d0ra00685h
   Wang C, 2020, INT J NANOMED, V15, P4049, DOI 10.2147/IJN.S237156
   Wang C, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900501
   Wang C, 2019, INT J NANOMED, V14, P1503, DOI 10.2147/IJN.S193976
   Wang C, 2018, CHEM COMMUN, V54, P13080, DOI 10.1039/c8cc07694d
   Wang C, 2018, ADV MATER, V30, DOI 10.1002/adma.201706407
   Wang C, 2017, J MATER CHEM B, V5, P2068, DOI 10.1039/c6tb02826h
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Wang JW, 2020, THERANOSTICS, V10, P8591, DOI 10.7150/thno.45142
   Yin N, 2020, J MATER CHEM B, V8, P993, DOI 10.1039/c9tb01795j
   Zhang Y, 2019, CARBOHYD POLYM, V219, P143, DOI 10.1016/j.carbpol.2019.04.041
   Zhuang WH, 2019, THERANOSTICS, V9, P6618, DOI 10.7150/thno.33901
NR 58
TC 30
Z9 32
U1 7
U2 92
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JAN 10
PY 2021
VL 329
BP 121
EP 135
DI 10.1016/j.jconrel.2020.11.059
PG 15
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA QT1EB
UT WOS:000626334700009
PM 33279604
DA 2025 08 17
ER

PT J
AU Kim, H
   Kim, MJ
   Moon, SA
   Cho, HJ
   Lee, YS
   Park, SJ
   Kim, Y
   Baek, IJ
   Kim, BJ
   Lee, SH
   Koh, JM
AF Kim, Hanjun
   Kim, Min Ji
   Moon, Sung Ah
   Cho, Han Jin
   Lee, Young Sun
   Park, So Jeong
   Kim, Yewon
   Baek, In Jeoung
   Kim, Beom Jun
   Lee, Seung Hun
   Koh, Jung Min
TI Aortic carboxypeptidase like protein, a putative myokine, stimulates the
   differentiation and survival of bone forming osteoblasts
SO FASEB JOURNAL
LA English
DT Article
DE ACLP; bone formation; myokine; osteoblasts; oxidative stress
ID GROWTH FACTOR BETA; OXIDATIVE STRESS; LIFE SPAN; APOPTOSIS; FOXO3A;
   P66SHC; METABOLISM; REGULATOR; EXERCISE; KINASE
AB A new target that stimulates bone formation is needed to overcome limitations of current anti osteoporotic drugs. Myokines, factors secreted from muscles, may modulate it. In this study, we investigated the role of aortic carboxypeptidase like protein (ACLP), which is highly expressed in skeletal muscles, on bone formation. MC3T3 E1 cells and/or calvaria osteoblasts were treated with recombinant N terminal mouse ACLP containing a signal peptide [rmACLP (N)]. The expression and secretion of ACLP were higher in skeletal muscle and differentiated myotube than in other tissues and undifferentiated myoblasts, respectively. rmACLP (N) increased bone formation, ALP activity, and phosphorylated p38 mitogen activated protein (MAP) kinase in osteoblasts; reversal was achieved by pre treatment with a TGF beta receptor inhibitor. Under H2O2 treatment, rmACLP (N) increased osteoblast survival, phosphorylated p38 MAP kinase, and the nuclear translocation of FoxO3a in osteoblasts. H2O2 treatment caused rmACLP (N) to suppress its apoptotic, oxidative, and caspase 9 activities. rmACLP (N) stimulated osteoblast survival was reversed by pre treatment with a p38 inhibitor, a TGF beta receptor II blocking antibody, and a FoxO3a shRNA. Conditioned media (CM) from muscle cells stimulated osteoblast survival under H2O2 treatment, in contrast to CM from ACLP knockdown muscle cells. rmACLP (N) increased the expressions of FoxO3a target anti oxidant genes such as Sod2, Trx2, and Prx5. In conclusion, ACLP stimulated the differentiation and survival of osteoblasts. This led to the stimulation of bone formation by the activation of p38 MAP kinase and/or FoxO3a via TGF beta receptors. These findings suggest a novel role for ACLP in bone metabolism as a putative myokine.
C1 [Kim, Hanjun; Kim, Min Ji; Moon, Sung Ah; Cho, Han Jin; Lee, Young Sun; Park, So Jeong] Asan Inst Life Sci, Asan Med Ctr, Seoul, South Korea.
   [Kim, Yewon] Univ Ulsan, AMIST, Asan Med Ctr, Coll Med, Seoul, South Korea.
   [Baek, In Jeoung] Univ Ulsan, Coll Med, Dept Convergence Med, Seoul, South Korea.
   [Kim, Beom Jun; Lee, Seung Hun; Koh, Jung Min] Univ Ulsan, Coll Med, Asan Med Ctr, Div Endocrinol & Metab, Seoul, South Korea.
   [Koh, Jung Min] Univ Ulsan, Asan Med Ctr, Div Endocrinol & Metab, Coll Med, 88 Olympro,43 gil, Seoul 05505, South Korea.
C3 University of Ulsan; Asan Medical Center; University of Ulsan; Asan
   Medical Center; University of Ulsan; University of Ulsan; Asan Medical
   Center; University of Ulsan; Asan Medical Center
RP Koh, JM (通讯作者)，Univ Ulsan, Asan Med Ctr, Div Endocrinol & Metab, Coll Med, 88 Olympro,43 gil, Seoul 05505, South Korea.
EM jmkoh@amc.seoul.kr
RI ; Kim, Yong Won/AAA 2134 2022; Kim, Jong Min/J 5435 2012; Kim,
   Ji/AAU 5043 2020
OI Kim, Beom Jun/0000 0001 8591 1759; Baek, In Jeoung/0000 0002 0641 7208; 
FU National Research Foundation of Korea (NRF) [2020R1A2C300669913,
   2022R1F1A1073578]
FX National Research Foundation of Korea (NRF), Grant/Award Number:
   2020R1A2C300669913 and 2022R1F1A1073578
CR Almeida M, 2010, MOL ENDOCRINOL, V24, P2030, DOI 10.1210/me.2010 0189
   Almeida M, 2010, J BONE MINER RES, V25, P769, DOI 10.1359/jbmr.091017
   Bandeira L, 2017, EXPERT OPIN BIOL TH, V17, P255, DOI 10.1080/14712598.2017.1280455
   Blackburn PR, 2018, AM J HUM GENET, V102, P696, DOI 10.1016/j.ajhg.2018.02.018
   Bodenner D, 2007, CLIN INTERV AGING, V2, P499
   Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471 2121 14 32
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chen N, 2016, DIABETES METAB RES, V32, P51, DOI 10.1002/dmrr.2660
   Dayon L, 2019, J PROTEOME RES, V18, P1162, DOI 10.1021/acs.jproteome.8b00809
   Faherty CS, 2008, TRENDS MICROBIOL, V16, P173, DOI 10.1016/j.tim.2008.02.001
   Ferber EC, 2012, CELL DEATH DIFFER, V19, P968, DOI 10.1038/cdd.2011.179
   Ferron M, 2014, ARCH BIOCHEM BIOPHYS, V561, P137, DOI 10.1016/j.abb.2014.05.022
   Fixen C, 2021, CURR OSTEOPOROS REP, V19, P15, DOI 10.1007/s11914 020 00652 w
   Gagnon A, 2005, EXP CELL RES, V308, P265, DOI 10.1016/j.yexcr.2005.04.031
   Galimov ER, 2010, ACTA NATURAE, V2, P44, DOI 10.32607/20758251 2010 2 4 44 51
   Gertz M, 2010, ANTIOXID REDOX SIGN, V13, P1417, DOI 10.1089/ars.2010.3147
   Gremminger VL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094963
   Gries KJ, 2022, SEMIN CELL DEV BIOL, V123, P57, DOI 10.1016/j.semcdb.2021.10.009
   HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Ho KK, 2012, J BIOL CHEM, V287, P1545, DOI 10.1074/jbc.M111.284224
   Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Kim B, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10815
   Kodani N, 2020, CELLS BASEL, V9, DOI 10.3390/cells9030702
   Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036
   Layne MD, 2001, MOL CELL BIOL, V21, P5256, DOI 10.1128/MCB.21.15.5256 5261.2001
   Layne MD, 1998, J BIOL CHEM, V273, P15654, DOI 10.1074/jbc.273.25.15654
   Lee JY, 2019, BIOCHEM BIOPH RES CO, V517, P749, DOI 10.1016/j.bbrc.2019.07.127
   Liu Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0856 3
   Lone A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 35114 y
   NIHPanel, 2001, JAMA J AM MED ASSOC, V285, P785, DOI DOI 10.1001/JAMA.285.6.785
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Olmos Y, 2009, J BIOL CHEM, V284, P14476, DOI 10.1074/jbc.M807397200
   Pedersen BK, 2007, TRENDS PHARMACOL SCI, V28, P152, DOI 10.1016/j.tips.2007.02.002
   Pellegrini M, 2009, CURR MOL MED, V9, P392, DOI 10.2174/156652409787847254
   Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062
   Ro HS, 2001, GENE, V280, P123, DOI 10.1016/S0378 1119(01)00771 5
   Savino C, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/719407
   Schiaffino S, 2018, FEBS J, V285, P3688, DOI 10.1111/febs.14502
   Severinsen MCK, 2020, ENDOCR REV, V41, DOI 10.1210/endrev/bnaa016
   Silva BC, 2011, J ENDOCRINOL INVEST, V34, P801, DOI 10.3275/7925
   Tran DB., 2023, STATPEARLS
   Tu Kristie N, 2018, P T, V43, P92
   Tumelty KE, 2014, J BIOL CHEM, V289, P2526, DOI 10.1074/jbc.M113.502617
   van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190
   Witcher PC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98673
   Yang JY, 2004, BIOCHEM PHARMACOL, V68, P1027, DOI 10.1016/j.bcp.2004.03.043
   Yang WS, 2008, NAT CELL BIOL, V10, P125, DOI 10.1038/ncb0208 125
   Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366
   Zhang YB, 2011, J SURG RES, V169, pE37, DOI 10.1016/j.jss.2011.02.033
   Zhang ZT, 2020, J CELL MOL MED, V24, P10792, DOI 10.1111/jcmm.15704
NR 52
TC 2
Z9 2
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2023
VL 37
IS 8
AR e23104
DI 10.1096/fj.202300140R
PG 16
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA N2JI5
UT WOS:001035333100001
PM 37486753
OA hybrid
DA 2025 08 17
ER

PT J
AU Zhu, MB
   Xu, WB
   Jiang, JZ
   Wang, YN
   Guo, YJ
   Yang, RJ
   Chang, YQ
   Zhao, B
   Wang, ZY
   Zhang, JF
   Wang, T
   Shangguan, LQ
   Wang, SW
AF Zhu, Mengbo
   Xu, Wenbin
   Jiang, Jiuzhou
   Wang, Yining
   Guo, Yanjing
   Yang, Ruijia
   Chang, Yaqiong
   Zhao, Bin
   Wang, Zhenyu
   Zhang, Jianfeng
   Wang, Te
   Shangguan, Liqin
   Wang, Shaowei
TI Peiminine Suppresses RANKL Induced Osteoclastogenesis by Inhibiting the
   NFATc1, ERK, and NF κB Signaling Pathways
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE peiminine; osteoclast; NFATc1; NF kappa B; osteoporosis
ID ESTROGEN REPLACEMENT THERAPY; ACTIVATED PROTEIN KINASE; DIFFERENTIATION;
   OSTEOPOROSIS; RECEPTOR; LIGAND; EXPRESSION; REGULATOR; FUSION; GROWTH
AB Osteoclasts (OCs) play an important role in osteoporosis, a disease that is mainly characterized by bone loss. In our research, we aimed to identify novel approach for regulating osteoclastogenesis and thereby treating osteoporosis. Previous studies have set a precedent for screening traditional Chinese herbal extracts for effective inhibitors. Peiminine is an alkaloid extracted from the bulb of Fritillaria thunbergii Miq that reportedly has anticancer and anti inflammatory effects. Thus, the potential inhibitory effect of peiminine on OC differentiation was investigated via a series of experiments. According to the results, peiminine downregulated the levels of specific genes and proteins in vitro and consequently suppressed OC differentiation and function. Based on these findings, we further investigated the underlying molecular mechanisms and identified the NF kappa B and ERK1/2 signaling pathways as potential targets of peiminine. In vivo, peiminine alleviated bone loss in an ovariectomized mouse model.
C1 [Zhu, Mengbo; Guo, Yanjing; Yang, Ruijia; Chang, Yaqiong; Zhao, Bin; Wang, Zhenyu; Wang, Shaowei] Shanxi Med Univ, Dept Orthoped, Hosp 2, Taiyuan, Peoples R China.
   [Zhu, Mengbo; Xu, Wenbin; Jiang, Jiuzhou; Zhang, Jianfeng; Shangguan, Liqin] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthoped Surg, Med Coll, Hangzhou, Peoples R China.
   [Wang, Yining; Wang, Te] Wenzhou Med Univ, Dept Orthopaed, Affiliated Hosp 2, Wenzhou, Peoples R China.
   [Wang, Yining; Wang, Te] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
   [Guo, Yanjing; Yang, Ruijia; Wang, Shaowei] Shanxi Med Univ, Basic Med Coll, Dept Biochem, Taiyuan, Peoples R China.
C3 Shanxi Medical University; Zhejiang University; Wenzhou Medical
   University; Wenzhou Medical University; Shanxi Medical University
RP Wang, SW (通讯作者)，Shanxi Med Univ, Dept Orthoped, Hosp 2, Taiyuan, Peoples R China.; Shangguan, LQ (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthoped Surg, Med Coll, Hangzhou, Peoples R China.; Wang, T (通讯作者)，Wenzhou Med Univ, Dept Orthopaed, Affiliated Hosp 2, Wenzhou, Peoples R China.; Wang, T (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.; Wang, SW (通讯作者)，Shanxi Med Univ, Basic Med Coll, Dept Biochem, Taiyuan, Peoples R China.
EM 289726269@qq.com; lqshangguan@zju.edu.cn; dreamkobe@163.com
RI Wang, Liya/AAQ 8579 2021; Zhang, Jian Feng/GQI 0201 2022; WANG,
   YANAN/KCL 4840 2024; Wang, Yining/IQU 9800 2023
OI Wang, Yining/0000 0001 5671 7957
FU National Natural Science Foundation of China [81572207, 81201435,
   82101647]; Natural Science Fund of Zhejiang Province [LQ20H060005];
   Medical Health Science and Technology Project of Zhejiang Provincial
   Health Commission [2021436226]; Health Commission of Shanxi Province
   [2020075]; Public Projects of Zhejiang Province [LGF19H060013]
FX Funding This project was supported by the National Natural Science
   Foundation of China (Grant Nos. 81572207, 81201435, 82101647), Natural
   Science Fund of Zhejiang Province (LQ20H060005) Medical Health Science
   and Technology Project of Zhejiang Provincial Health Commission
   (2021436226), Health Commission of Shanxi Province (Grant No. 2020075),
   and the Public Projects of Zhejiang Province (LGF19H060013).
CR Amin N, 2020, AGING CLIN EXP RES, V32, P363, DOI 10.1007/s40520 019 01223 5
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chao X, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0201864
   Chen GX, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030821
   Chen X, 2019, J CELL MOL MED, V23, P8269, DOI 10.1111/jcmm.14700
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chiu YH, 2016, J CELL PHYSIOL, V231, P2402, DOI 10.1002/jcp.25389
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Du BX, 2020, INFLAMMATION, V43, P1110, DOI 10.1007/s10753 020 01198 w
   Geoghegan IP, 2019, CURR OSTEOPOROS REP, V17, P195, DOI 10.1007/s11914 019 00520 2
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Gong Q, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092637
   Guo H, 2013, MOL MED REP, V7, P1103, DOI 10.3892/mmr.2013.1312
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092 8674(92)90115 S
   Islam R, 2014, J CELL PHYSIOL, V229, P2166, DOI 10.1002/jcp.24679
   Jimi E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121636
   Jin HM, 2019, J CELL MOL MED, V23, P8355, DOI 10.1111/jcmm.14713
   Jin HM, 2019, J CELL MOL MED, V23, P522, DOI 10.1111/jcmm.13955
   JUDD HL, 1983, ANN INTERN MED, V98, P195, DOI 10.7326/0003 4819 98 2 195
   Koga Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061346
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Luo ZC, 2019, FOOD FUNCT, V10, P2198, DOI 10.1039/c9fo00307j
   Lyu Q, 2015, BIOCHEM BIOPH RES CO, V462, P38, DOI 10.1016/j.bbrc.2015.04.102
   Ma XY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00737
   Maraka S, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h3783
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Mensah KA, 2010, J CELL PHYSIOL, V223, P76, DOI 10.1002/jcp.22012
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Ruan X, 2016, MATERIALS, V9, DOI 10.3390/ma9070524
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Ticconi C, 2013, PULM PHARMACOL THER, V26, P617, DOI 10.1016/j.pupt.2013.08.004
   Tobeiha M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6910312
   Wang QQ, 2019, J CELL MOL MED, V23, P380, DOI 10.1111/jcmm.13942
   Zhao BX, 2018, CELL PHYSIOL BIOCHEM, V51, P1566, DOI 10.1159/000495646
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 48
TC 16
Z9 17
U1 3
U2 31
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD SEP 24
PY 2021
VL 12
AR 736863
DI 10.3389/fendo.2021.736863
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA XG8LH
UT WOS:000724998800001
PM 34630331
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ye, CY
   Zhang, W
   Zhao, YZ
   Zhang, K
   Hou, WD
   Chen, M
   Lu, JW
   Wu, JR
   He, RX
   Gao, W
   Zheng, YY
   Cai, XJ
AF Ye, Chenyi
   Zhang, Wei
   Zhao, Yongzheng
   Zhang, Kai
   Hou, Weiduo
   Chen, Mo
   Lu, Jinwei
   Wu, Jianrong
   He, Rongxin
   Gao, Wei
   Zheng, Yuanyi
   Cai, Xiaojun
TI Prussian Blue Nanozyme Normalizes Microenvironment to Delay Osteoporosis
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE microenvironments; nanozymes; osteoclast; osteoporosis; Prussian blue
ID NFATC1
AB Osteoporosis (OP) is the most common orthopedic disease in the elderly and the main cause of age related mortality and disability. However, no satisfactory intervention is currently available in clinical practice. Thus, an effective therapy to prevent or delay the development of OP should be devised. Osteoclastogenesis overactivation and excessive bone resorption are the main characteristics of OP. Accordingly, a paradigm for nanozyme mediated normalization of the disease microenvironment to regulate osteoclast differentiation and delay OP is proposed. Hollow Prussian blue nanozymes (HPBZs) are prepared via template free hydrothermal synthesis and selected as representative nanozymes. The intrinsic osteoclast activity remodeling bioactivities of the HPBZs are explored in vitro and in vivo, focusing on their impact on osteogenesis and specific molecular mechanisms using an OP murine model. The HPBZs significantly normalize the OP microenvironment, thereby inhibiting osteoclast formation and osteoclast resorption, possibly owing to the suppression of intracellular reactive oxygen species generation, the mitogen activated protein kinase, and nuclear factor kappa B signaling pathways. Consistently, in an ovariectomy induced OP murine model, HPBZ treatment significantly attenuates osteoporotic bone loss in vivo. The findings confirm the HPBZ mediated normalization of the disease microenvironment for the treatment of OP and suggest its application to other inflammation related diseases.
C1 [Ye, Chenyi; Zhang, Wei; Hou, Weiduo; Lu, Jinwei; He, Rongxin] Zhejiang Univ, Dept Orthoped Surg, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China.
   [Ye, Chenyi; Zhang, Wei; Hou, Weiduo; Lu, Jinwei; He, Rongxin] Zhejiang Univ, Orthoped Res Inst, Hangzhou 310009, Zhejiang, Peoples R China.
   [Ye, Chenyi; Zhang, Wei; Hou, Weiduo; Lu, Jinwei; He, Rongxin] Key Lab Motor Syst Dis Res & Precis Therapy Zheji, Hangzhou 310009, Zhejiang, Peoples R China.
   [Zhao, Yongzheng; Zhang, Kai; Wu, Jianrong; Gao, Wei; Zheng, Yuanyi; Cai, Xiaojun] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Ultrasound Med, Shanghai 200233, Peoples R China.
   [Chen, Mo] Zhejiang Univ, Dept Rheumatol, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Shanghai Jiao Tong University;
   Zhejiang University
RP He, RX (通讯作者)，Zhejiang Univ, Dept Orthoped Surg, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China.; He, RX (通讯作者)，Zhejiang Univ, Orthoped Res Inst, Hangzhou 310009, Zhejiang, Peoples R China.; He, RX (通讯作者)，Key Lab Motor Syst Dis Res & Precis Therapy Zheji, Hangzhou 310009, Zhejiang, Peoples R China.; Gao, W; Cai, XJ (通讯作者)，Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Ultrasound Med, Shanghai 200233, Peoples R China.
EM herongxin@zju.edu.cn; 1033452945@qq.com; clx2j34@163.com
RI Gao, Wei/AAQ 8992 2021; Zheng, Yuanyi/IWE 2539 2023; Zhang,
   Kai/ABD 1498 2021; Wu, Jianrong/JWA 5552 2024; He, Rongxin/NLN 8611 2025
OI Gao, Wei/0000 0002 4353 6599; Yuanyi Zheng, Chen Hua
   and/0000 0002 5532 7604; 
FU Zhejiang Provincial Natural Science Foundation of China [LQ21H060007,
   LY19H060006]; National Natural Science Foundation of China [82102597,
   82172074]; Shanghai ST Major project [2018SHZDZX05]; Shanghai
   Collaborative Innovation Center for Translational Medicine [TM201724];
   Shanghai Rising Star Program [21QA1407100]; Translational medicine
   national science and technology infrastructure (Shanghai)
   [TMSK 2020 004]; Excellent talent cultivation project of Shanghai Sixth
   People's Hospital [ynyq202104]; Innovative research team of high level
   local universities in Shanghai
FX C.Y., W.Z., and Y.Z. contributed equally to this work. This study was
   supported by the Zhejiang Provincial Natural Science Foundation of China
   (LQ21H060007 and LY19H060006), the National Natural Science Foundation
   of China (Nos. 82102597 and 82172074), Shanghai S&T Major project
   (2018SHZDZX05), Shanghai Collaborative Innovation Center for
   Translational Medicine (No. TM201724), Shanghai Rising Star Program
   (21QA1407100), Translational medicine national science and technology
   infrastructure (Shanghai) open project fund (TMSK 2020 004), Excellent
   talent cultivation project of Shanghai Sixth People's Hospital
   (ynyq202104), and Innovative research team of high level local
   universities in Shanghai.
CR Anastasilakis AD, 2018, EUR J ENDOCRINOL, V179, pR31, DOI 10.1530/EJE 18 0056
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Cai XJ, 2020, BIOMATERIALS, V231, DOI 10.1016/j.biomaterials.2019.119678
   Cai XJ, 2015, ADV FUNCT MATER, V25, P2520, DOI 10.1002/adfm.201403991
   Cao HL, 2010, J CLIN INVEST, V120, P2755, DOI 10.1172/JCI42106
   Chen K, 2021, COORDIN CHEM REV, V432, DOI 10.1016/j.ccr.2020.213751
   Chen SN, 2019, J CELL PHYSIOL, V234, P22960, DOI 10.1002/jcp.28857
   Chen YZ, 2020, INT IMMUNOPHARMACOL, V89, DOI 10.1016/j.intimp.2020.106978
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Ding K, 2020, AGING DIS, V11, P438, DOI 10.14336/AD.2019.0523
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Duan XH, 2018, THERANOSTICS, V8, P5379, DOI 10.7150/thno.28391
   Feng LS, 2021, ACS NANO, V15, P2263, DOI 10.1021/acsnano.0c07973
   Feng LS, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202006581
   Föger Samwald U, 2020, EXCLI J, V19, P1017, DOI 10.17179/excli2020 2591
   Garbe AI, 2012, J BONE MINER RES, V27, P2085, DOI 10.1002/jbmr.1670
   Gür A, 2003, YONSEI MED J, V44, P99
   Hoffman Robert S., 2003, Toxicological Reviews, V22, P29, DOI 10.2165/00139709 200322010 00004
   Hong GJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.392
   Hou R, 2022, ACS NANO, V16, P9559, DOI 10.1021/acsnano.2c02832
   Huang YY, 2019, CHEM REV, V119, P4357, DOI 10.1021/acs.chemrev.8b00672
   Huang YX, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.891351
   Jiang DW, 2019, CHEM SOC REV, V48, P3683, DOI 10.1039/c8cs00718g
   Lewiecki EM, 2018, THER ADV MUSCULOSKEL, V10, P209, DOI 10.1177/1759720X18805759
   Li T, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12548
   Lin XX, 2019, J CELL BIOCHEM, V120, P1990, DOI 10.1002/jcb.27495
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Lu JW, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106550
   Ma XX, 2022, ADV MATER, V34, DOI 10.1002/adma.202106723
   Meng JH, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113715
   Ni S, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12882
   Qin ZG, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800347
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Schröder K, 2019, FREE RADICAL BIO MED, V132, P67, DOI 10.1016/j.freeradbiomed.2018.08.036
   Takakura N, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115316
   Tang XY, 2018, IMMUNOL LETT, V196, P113, DOI 10.1016/j.imlet.2018.01.010
   Tantowi NACA, 2018, CALCIFIED TISSUE INT, V103, P388, DOI 10.1007/s00223 018 0433 1
   Thompson DF, 2001, PHARMACOTHERAPY, V21, P1364, DOI 10.1592/phco.21.17.1364.34426
   Wang SF, 2019, ONCOL REP, V41, P2636, DOI 10.3892/or.2019.7080
   Wang ZR, 2020, MATER TODAY, V41, P81, DOI 10.1016/j.mattod.2020.08.020
   Wu JJX, 2019, CHEM SOC REV, V48, P1004, DOI 10.1039/c8cs00457a
   Xie X, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00819 2
   Ye CY, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12752
   Ye CY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0857 6
   Yin YM, 2017, ANAL CHEM, V89, P1551, DOI 10.1021/acs.analchem.6b03521
   Zhang K, 2019, NANO LETT, V19, P2812, DOI 10.1021/acs.nanolett.8b04729
   Zhang W, 2016, J AM CHEM SOC, V138, P5860, DOI 10.1021/jacs.5b12070
   Zhao JL, 2019, THERANOSTICS, V9, P2843, DOI 10.7150/thno.33727
   Zhao JL, 2018, ACS APPL MATER INTER, V10, P26108, DOI 10.1021/acsami.8b10345
   Zhao XD, 2020, J BONE MINER RES, V35, P1618, DOI 10.1002/jbmr.4095
   Zheng HX, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155303
   Zhong XY, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201907954
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 53
TC 37
Z9 38
U1 10
U2 132
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD OCT
PY 2022
VL 11
IS 19
AR 2200787
DI 10.1002/adhm.202200787
EA JUL 2022
PG 11
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA 5C1GA
UT WOS:000830347300001
PM 35851764
DA 2025 08 17
ER

PT J
AU Patel, HB
   Bombardieri, M
   Sampaio, ALF
   D'Acquisto, F
   Gray, M
   Grieco, P
   Getting, SJ
   Pitzalis, C
   Perretti, M
AF Patel, Hetal B.
   Bombardieri, Michele
   Sampaio, Andre L. F.
   D'Acquisto, Fulvio
   Gray, Mohini
   Grieco, Paolo
   Getting, Stephen J.
   Pitzalis, Costantino
   Perretti, Mauro
TI Anti inflammatory and antiosteoclastogenesis properties of endogenous
   melanocortin receptor type 3 in experimental arthritis
SO FASEB JOURNAL
LA English
DT Article
DE G protein coupled receptor; melanocortins; bone erosion; osteoclasts;
   cytokines
ID MELANOCYTE STIMULATING HORMONE; MAST CELLS; OSTEOCLAST DIFFERENTIATION;
   INFLAMMATORY ARTHRITIS; RHEUMATOID ARTHRITIS; PRECURSOR PROTEASES;
   ALPHA MSH; EXPRESSION; RESOLUTION; DISEASE
AB The development of biological therapies has improved management of rheumatoid arthritis. However, costs and unresponsiveness to therapy in a sizeable proportion of patients limit their use, making it imperative to identify new targets for drug development programs. Here we investigated the melanocortin receptor type 3 (MC3) pathway. Gene deficient mice were subjected to a model of serum transfer induced arthritis and joints analyzed for gene expression (cytokines, MCs) and morphology. Pharmacological analyses were also conducted in this model. Osteoclastogenesis was studied from bone marrow cells. Mc(3)( / ) mice displayed an exacerbated inflammatory arthritis, associated with prominent bone erosion and higher articular expression of Rankl. Osteoclastogenesis studied from Mc(3)( / ) bone marrow cells revealed a higher degree of responsiveness to Rankl, linked to prolonged NF kappa B activation compared to wild types. Up regulation of a discrete set of inflammatory genes, including Il 1 beta, Il 6, and Nos2, was measured in Mc(3)( / ) mice, and a marked up regulation of joint Mc(3) accompanied arthritis resolution in wild type mice. Administration of an MC3 agonist, D[Trp8] gamma MSH, attenuated disease incidence and severity in wild type but not Mc(3)( /)  mice. Overall, these findings identify MC3 mediated signaling as a beneficial pathway in experimental arthritis; hence this receptor is a novel target for the development of therapeutics for arthritis. Patel, H. B., Bombardieri, M., Sampaio, A. L. F., D'Acquisto, F., Gray, M., Grieco, P., Getting, S. J., Pitzalis, C., Perretti, M. Anti inflammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritis. FASEB J. 24, 4835 4843 (2010). www.fasebj.org
C1 [Patel, Hetal B.; Bombardieri, Michele; Sampaio, Andre L. F.; D'Acquisto, Fulvio; Pitzalis, Costantino; Perretti, Mauro] Queen Mary Univ, Barts & London Sch Med, William Harvey Res Inst, London EC1M 6BQ, England.
   [Gray, Mohini] Univ Edinburgh, Med Res Council Ctr Inflammat, Edinburgh, Midlothian, Scotland.
   [Grieco, Paolo] Univ Naples Federico 2, Dept Pharmaceut Chem & Toxicol, Naples, Italy.
   [Getting, Stephen J.] Univ Westminster, London W1R 8AL, England.
C3 University of London; Queen Mary University London; University of
   Edinburgh; University of Naples Federico II; University of Westminster
RP Perretti, M (通讯作者)，Queen Mary Univ, Barts & London Sch Med, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.
EM m.perretti@qmul.ac.uk
RI Franco Sampaio, Andre Luiz/H 9398 2013; Grieco, Paolo/AAB 9034 2019;
   Sampaio, Andre/H 9398 2013; D'Acquisto, Fulvio/E 7204 2018
OI Franco Sampaio, Andre Luiz/0000 0002 5596 6174; Bombardieri,
   Michele/0000 0002 3878 5216; /0000 0003 2977 0466; D'Acquisto,
   Fulvio/0000 0002 4513 1608; Pitzalis, Costantino/0000 0003 1326 5051
FU Arthritis Research UK [17299, 18049]; UK National Institute of Health
   Research; Medical Research Council [G9900991B] Funding Source:
   researchfish
FX The authors thank Drs. Mike Seed and Alessandra Marrelli and Anthony
   Huggins for assistance with histology, TRAP staining, and EMSA analyses,
   respectively. M.P. declares a collaborative project on novel
   melanocortins with Action Pharma A/S (Copenhagen, Denmark). P.G. owns a
   patent on the synthesis of the MC3 agonist used in this study. C.P. and
   M.P. share senior authorship. The study was funded by Arthritis Research
   UK (grants 17299 and 18049). This work forms part of the research themes
   contributing to the translational research portfolio of Barts and the
   London Cardiovascular Biomedical Research Unit, which is supported and
   funded by the UK National Institute of Health Research.
CR Adachi S, 1999, J IMMUNOL, V163, P3363
   Alexander SPH, 2009, BRIT J PHARMACOL, V158, pS1, DOI 10.1111/j.1476 5381.2009.00499.x
   Artuc M, 2006, J INVEST DERMATOL, V126, P1976, DOI 10.1038/sj.jid.5700318
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brzoska T, 2008, ENDOCR REV, V29, P581, DOI 10.1210/er.2007 0027
   Catania A, 2004, PHARMACOL REV, V56, P1, DOI 10.1124/pr.56.1.1
   Ceriani Giuliana, 1994, Neuroimmunomodulation, V1, P28, DOI 10.1159/000097087
   Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254
   Dufton N, 2010, J IMMUNOL, V184, P2611, DOI 10.4049/jimmunol.0903526
   Gantz I, 2003, AM J PHYSIOL ENDOC M, V284, pE468, DOI 10.1152/ajpendo.00434.2002
   Getting SJ, 2001, J LEUKOCYTE BIOL, V69, P98
   Getting SJ, 2006, FASEB J, V20, P2234, DOI 10.1096/fj.06 6339com
   Getting SJ, 2006, PHARMACOL THERAPEUT, V111, P1, DOI 10.1016/j.pharmthera.2005.06.022
   Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383
   Gonzalez Rey E, 2007, NAT REV IMMUNOL, V7, P52, DOI 10.1038/nri1984
   Grässel S, 2009, ARTHRITIS RHEUM US, V60, P3017, DOI 10.1002/art.24846
   Grieco P, 2000, J MED CHEM, V43, P4998, DOI 10.1021/jm000211e
   GUTMAN AB, 1950, AM J MED, V9, P24, DOI 10.1016/0002 9343(50)90004 0
   HENCH PS, 1949, P STAFF M MAYO CLIN, V24, P181
   Huggins A, 2009, FASEB J, V23, P985, DOI 10.1096/fj.08 119040
   Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074 7613(02)00275 3
   Ji H, 2002, J EXP MED, V196, P77, DOI 10.1084/jem.20020439
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092 8674(00)81989 3
   Krönke G, 2009, J IMMUNOL, V183, P3383, DOI 10.4049/jimmunol.0900327
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176
   Leoni G, 2008, FASEB J, V22, P4228, DOI 10.1096/fj.08 113886
   Lipton JM, 1997, IMMUNOL TODAY, V18, P140, DOI 10.1016/S0167 5699(97)01009 8
   Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697
   Matsumoto I, 2002, NAT IMMUNOL, V3, P360, DOI 10.1038/ni772
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   RITTER J, 1994, J RHEUMATOL, V21, P696
   Ruschpler P, 2003, ARTHRITIS RES THER, V5, pR241, DOI 10.1186/ar783
   Schaller M, 2001, NAT IMMUNOL, V2, P746, DOI 10.1038/90696
   Schlesinger N, 2008, DRUGS, V68, P407, DOI 10.2165/00003495 200868040 00002
   Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06 7227rev
   Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Solomon S, 2005, EUR J IMMUNOL, V35, P3064, DOI 10.1002/eji.200526167
   STAR RA, 1995, P NATL ACAD SCI USA, V92, P8016, DOI 10.1073/pnas.92.17.8016
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tolar J, 2004, NEW ENGL J MED, V350, P735, DOI 10.1056/NEJM200402123500723
   Zhong Q, 2005, BONE, V36, P820, DOI 10.1016/j.bone.2005.01.020
   Zhou HF, 2009, FASEB J, V23, P2978, DOI 10.1096/fj.09 129874
NR 46
TC 41
Z9 44
U1 0
U2 5
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD DEC
PY 2010
VL 24
IS 12
BP 4835
EP 4843
DI 10.1096/fj.10 167759
PG 9
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA 688BO
UT WOS:000284824400023
PM 20702773
DA 2025 08 17
ER

PT J
AU Sangadala, S
   Kim, CH
   Fernandes, LM
   Makkar, P
   Beck, GR
   Boden, SD
   Drissi, H
   Presciutti, SM
AF Sangadala, Sreedhara
   Kim, Chi Heon
   Fernandes, Lorenzo M.
   Makkar, Pooja
   Beck, George R.
   Boden, Scott D.
   Drissi, Hicham
   Presciutti, Steven M.
TI Sclerostin small molecule inhibitors promote osteogenesis by activating
   canonical Wnt and BMP pathways
SO ELIFE
LA English
DT Article
DE sclerostin; small molecules; osteogenesis; spinal fusion; canonical Wnt;
   rabbit   other organism; Rat; Other
ID BONE MORPHOGENETIC PROTEIN 2; GROWTH FACTOR; POSTMENOPAUSAL WOMEN;
   SPINAL FUSION; EXPRESSION; ANTIBODY; MUSCLE; MODEL; REGULATOR; COMPOUND
AB Background: The clinical healing environment after a posterior spinal arthrodesis surgery is one of the most clinically challenging bone healing environments across all orthopedic interventions due to the absence of a contained space and the need to form de novo bone. Our group has previously reported that sclerostin in expressed locally at high levels throughout a developing spinal fusion. However, the role of sclerostin in controlling bone fusion remains to be established.
   Methods: We computationally identified two FDA approved drugs, as well as a single novel small molecule drug, for their ability to disrupt the interaction between sclerostin and its receptor, LRP5/6. The drugs were tested in several in vitro biochemical assays using murine MC3T3 and MSCs, assessing their ability to (1) enhance canonical Wnt signaling, (2) promote the accumulation of the active (non phosphorylated) form of beta catenin, and (3) enhance the intensity and signaling duration of BMP signaling. These drugs were then tested subcutaneously in rats as standalone osteoinductive agents on plain collagen sponges. Finally, the top drug candidates (called VA1 and C07) were tested in a rabbit posterolateral spine fusion model for their ability to achieve a successful fusion at 6 wk.
   Results: We show that by controlling GSK3b phosphorylation our three small molecule inhibitors (SMIs) simultaneously enhance canonical Wnt signaling and potentiate canonical BMP signaling intensity and duration. We also demonstrate that the SMIs produce dose dependent ectopic mineralization in vivo in rats as well as significantly increase posterolateral spine fusion rates in rabbits in vivo, both as standalone osteogenic drugs and in combination with autologous iliac crest bone graft.
   Conclusions: Few if any osteogenic small molecules possess the osteoinductive potency of BMP itself   that is, the ability to form de novo ectopic bone as a standalone agent. Herein, we describe two such SMIs that have this unique ability and were shown to induce de novo bone in a stringent in vivo environment. These SMIs may have the potential to be used in novel, cost effective bone graft substitutes for either achieving spinal fusion or in the healing of critical sized fracture defects.
C1 [Sangadala, Sreedhara; Fernandes, Lorenzo M.; Beck, George R.; Drissi, Hicham; Presciutti, Steven M.] Atlanta Vet Affairs Med Ctr, Decatur, GA 30033 USA.
   [Sangadala, Sreedhara; Kim, Chi Heon; Fernandes, Lorenzo M.; Boden, Scott D.; Drissi, Hicham; Presciutti, Steven M.] Emory Univ, Dept Orthopaed, Sch Med, Atlanta, GA 30322 USA.
   [Makkar, Pooja] Panjab Univ, Dept Biotechnol, Chandigarh, India.
   [Beck, George R.] Emory Univ, Div Endocrinol, Atlanta, GA USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Atlanta VA Health Care System; Emory University; Panjab University;
   Emory University
RP Drissi, H; Presciutti, SM (通讯作者)，Atlanta Vet Affairs Med Ctr, Decatur, GA 30033 USA.; Drissi, H; Presciutti, SM (通讯作者)，Emory Univ, Dept Orthopaed, Sch Med, Atlanta, GA 30322 USA.
EM hicham.drissi@emory.edu; prescius33@gmail.com
RI Beck, George/AAO 2117 2020; Presciutti, Steven/LKN 5957 2024; Kim,
   Chi/J 6536 2019
OI drissi, hicham/0000 0002 3322 281X; 
FU U.S. Department of Veterans Affairs [IK2 BX003845, I01BX001516, I01
   BX004708, I01 BX004878]
FX U.S. Department of Veterans Affairs IK2 BX003845 Lorenzo M FernandesU.S.
   Department of Veterans Affairs I01BX001516 George R BeckU.S. Department
   of Veterans Affairs I01 BX004708 Hicham DrissiU.S. Department of
   Veterans Affairs I01 BX004878 Hicham DrissiThe funders had no role in
   study design, data collection and interpretation, or the decision to
   submit the work for publication.
CR Akiyama I, 2014, REPROD SCI, V21, P477, DOI 10.1177/1933719113503411
   [Anonymous], 2010, Drug Discov Today Technol, V7, pe203, DOI 10.1016/j.ddtec.2010.10.003
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Battaglino RA, 2012, BONE, V51, P600, DOI 10.1016/j.bone.2012.04.019
   Blaich G., 2010, Pharmaceutical Sciences Encyclopedia, pps, DOI [10.1002/9780470571224.pse292, DOI 10.1002/9780470571224.PSE292]
   BODEN SD, 1995, SPINE, V20, P412, DOI 10.1097/00007632 199502001 00003
   Boden SD, 2000, TISSUE ENG, V6, P383, DOI 10.1089/107632700418092
   Boden SD, 1995, SPINE, V20, P2633, DOI 10.1097/00007632 199512150 00004
   Boschert V, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160120
   Boschert V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081710
   Camalier CE, 2013, J CELL PHYSIOL, V228, P1536, DOI 10.1002/jcp.24312
   Delgado Calle J, 2017, LEUKEMIA, V31, P2686, DOI 10.1038/leu.2017.152
   Eivers E, 2009, CYTOKINE GROWTH F R, V20, P357, DOI 10.1016/j.cytogfr.2009.10.017
   Fuentealba LC, 2007, CELL, V131, P980, DOI 10.1016/j.cell.2007.09.027
   Gamie Z, 2012, EXPERT OPIN INV DRUG, V21, P1523, DOI 10.1517/13543784.2012.713936
   Huang J, 2017, JBMR PLUS, V1, P86, DOI 10.1002/jbm4.10015
   Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Karczewska Kupczewska M, 2016, J CLIN ENDOCR METAB, V101, P3079, DOI 10.1210/jc.2016 1594
   KIM SS, 1992, SPINE, V17, P957, DOI 10.1097/00007632 199208000 00015
   Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200
   Labbé E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697
   Lewis TC, 2013, BBA GENE REGUL MECH, V1829, P1147, DOI 10.1016/j.bbagrm.2013.08.002
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   MacAulay K, 2003, EUR J BIOCHEM, V270, P3829, DOI 10.1046/j.1432 1033.2003.03777.x
   Mahasenan KV, 2012, J CHEM INF MODEL, V52, P1345, DOI 10.1021/ci300040c
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McDonald MM, 2012, J ORTHOP RES, V30, P1541, DOI 10.1002/jor.22109
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   McGann MR, 2003, BIOPOLYMERS, V68, P76, DOI 10.1002/bip.10207
   Minamide A, 2003, J BONE JOINT SURG AM, V85A, P1030, DOI 10.2106/00004623 200306000 00007
   Montgomery SR, 2014, J BONE MINER RES, V29, P1872, DOI 10.1002/jbmr.2213
   Noshchenko A, 2014, J SPINAL DISORD TECH, V27, P117, DOI 10.1097/01.bsd.0000446752.34233.ca
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Okada M, 2009, CELL BIOCHEM FUNCT, V27, P526, DOI 10.1002/cbf.1615
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Patlewicz G, 2008, SAR QSAR ENVIRON RES, V19, P495, DOI 10.1080/10629360802083871
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Rudnicki MA, 2015, BONE, V80, P60, DOI 10.1016/j.bone.2015.02.009
   SCHIMANDLE JH, 1994, SPINE, V19, P1998, DOI 10.1097/00007632 199409000 00023
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Suen PK, 2016, J ORTHOP TRANSL, V4, P1, DOI 10.1016/j.jot.2015.08.004
   Suen PK, 2014, J ORTHOP RES, V32, P997, DOI 10.1002/jor.22636
   Tagliaferri C, 2015, AGEING RES REV, V21, P55, DOI 10.1016/j.arr.2015.03.002
   Takeda I, 2014, PATHOBIOLOGY, V81, P94, DOI 10.1159/000357238
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Veverka V, 2009, J BIOL CHEM, V284, P10890, DOI 10.1074/jbc.M807994200
   Wong E, 2013, J BONE JOINT SURG AM, V95A, P454, DOI 10.2106/JBJS.L.00275
   Yadav PS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037134
   Yeramaneni S, 2016, CURR REV MUSCULOSKE, V9, P327, DOI 10.1007/s12178 016 9352 9
   Zanella JM, 2006, J NEUROSURG SPINE, V5, P434, DOI 10.3171/spi.2006.5.5.434
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
NR 55
TC 11
Z9 12
U1 2
U2 9
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD AUG 10
PY 2023
VL 12
AR e63402
DI 10.7554/eLife.63402
PG 24
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA P3YL5
UT WOS:001050034900001
PM 37560905
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Khodabandehloo, F
   Taleahmad, S
   Aflatoonian, R
   Rajaei, F
   Zandieh, Z
   Nassiri Asl, M
   Eslaminejad, MB
AF Khodabandehloo, Fatemeh
   Taleahmad, Sara
   Aflatoonian, Reza
   Rajaei, Farzad
   Zandieh, Zahra
   Nassiri Asl, Marjan
   Eslaminejad, Mohamadreza Baghaban
TI Microarray analysis identification of key pathways and interaction
   network of differential gene expressions during osteogenic
   differentiation
SO HUMAN GENOMICS
LA English
DT Article
DE Bone mesenchymal stem cells; Bioinformatics analysis; Osteogenic
   differentiation; Protein protein network
ID MESENCHYMAL STEM CELLS; FOCAL ADHESION KINASE; HUMAN ADIPOSE TISSUE;
   OSTEOBLAST DIFFERENTIATION; BETA CATENIN; PROMOTES OSTEOGENESIS;
   SIGNALING CASCADES; MAPK PATHWAY; GROWTH; PHOSPHORYLATION
AB Background Adult bone marrow derived mesenchymal stem cells (BM MSCs) are multipotent stem cells that can differentiate into three lineages. They are suitable sources for cell based therapy and regenerative medicine applications. This study aims to evaluate the hub genes and key pathways of differentially expressed genes (DEGs) related to osteogenesis by bioinformatics analysis in three different days. The DEGs were derived from the three different days compared with day 0. Results Gene expression profiles of GSE37558 were obtained from the Gene Expression Omnibus (GEO) database. A total of 4076 DEGs were acquired on days 8, 12, and 25. Gene ontology (GO) enrichment analysis showed that the non canonical Wnt signaling pathway and lipopolysaccharide (LPS) mediated signaling pathway were commonly upregulated DEGs for all 3 days. KEGG pathway analysis indicated that the PI3K Akt and focal adhesion were also commonly upregulated DEGs for all 3 days. Ten hub genes were identified by CytoHubba on days 8, 12, and 25. Then, we focused on the association of these hub genes with the Wnt pathways that had been enriched from the protein protein interaction (PPI) by the Cytoscape plugin MCODE. Conclusions These findings suggested further insights into the roles of the PI3K/AKT and Wnt pathways and their association with osteogenesis. In addition, the stem cell microenvironment via growth factors, extracellular matrix (ECM), IGF1, IGF2, LPS, and Wnt most likely affect osteogenesis by PI3K/AKT.
C1 [Khodabandehloo, Fatemeh] Qazvin Univ Med Sci, Dept Mol Med, Qazvin, Iran.
   [Taleahmad, Sara; Eslaminejad, Mohamadreza Baghaban] ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Stem Cells & Dev Biol, Tehran, Iran.
   [Aflatoonian, Reza] ACECR, Royan Inst Reprod Biomed, Reprod Biomed Res Ctr, Dept Endocrinol & Female Infertil, Tehran, Iran.
   [Rajaei, Farzad; Nassiri Asl, Marjan] Qazvin Univ Med Sci, Res Inst Prevent Noncommunicable Dis, Cellular & Mol Res Ctr, Qazvin, Iran.
   [Zandieh, Zahra] Iran Univ Med Sci, Sch Med, Dept Anat, Tehran, Iran.
C3 Qazvin University of Medical Sciences (QUMS); Academic Center for
   Education, Culture & Research (ACECR); Academic Center for Education,
   Culture & Research (ACECR); Qazvin University of Medical Sciences
   (QUMS); Iran University of Medical Sciences
RP Eslaminejad, MB (通讯作者)，ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Stem Cells & Dev Biol, Tehran, Iran.; Nassiri Asl, M (通讯作者)，Qazvin Univ Med Sci, Res Inst Prevent Noncommunicable Dis, Cellular & Mol Res Ctr, Qazvin, Iran.
EM mnassiriasl@qums.ac.ir; eslami@royaninstitute.org
RI Taleahmad, Sara/ABC 5881 2021; Nassiri Asl, Marjan/D 2960 2017; Baghaban
   Eslaminejad, Mohamadreza/S 3645 2017; Zandieh, Zahra/AAY 5143 2020
OI Rajaei, Farzad/0009 0008 0410 089X; Zandieh, Zahra/0000 0002 7720 9465;
   Nassiri Asl, Marjan/0000 0003 3701 0758; Taleahmad,
   Sara/0000 0003 4666 1907; Baghaban Eslaminejad,
   Mohamadreza/0000 0002 1036 0072; 
FU Royan Institute; Qazvin University of Medical Sciences
FX The study was supported by the Royan Institute and the Qazvin University
   of Medical Sciences.
CR Alves RDAM, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 965
   Baker N, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0225 8
   Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536
   Cervenka I, 2011, MOL CELL BIOL, V31, P179, DOI 10.1128/MCB.00550 10
   Chen J, 2013, TISSUE ENG PART B RE, V19, P516, DOI [10.1089/ten.teb.2012.0672, 10.1089/ten.TEB.2012.0672]
   Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567
   Cho HH, 2006, STEM CELLS, V24, P2744, DOI 10.1634/stemcells.2006 0189
   Cho HH, 2010, J CELL PHYSIOL, V223, P168, DOI 10.1002/jcp.22024
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   Davidson G, 2009, DEV CELL, V17, P788, DOI 10.1016/j.devcel.2009.11.006
   Desbois Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064
   Di Benedetto A, 2010, J CELL SCI, V123, P2640, DOI 10.1242/jcs.067777
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Duan XC, 2015, DEVELOPMENT, V142, P1984, DOI 10.1242/dev.117952
   Ehlen Harald W. A., 2006, Birth Defects Research, V78, P267, DOI 10.1002/bdrc.20076
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Felber K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144982
   Fitter S, 2012, J MOL ENDOCRINOL, V48, P229, DOI 10.1530/JME 12 0003
   Franceschi Renny T, 2017, Curr Mol Biol Rep, V3, P122, DOI 10.1007/s40610 017 0059 5
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Golestaneh N, 2009, REPRODUCTION, V138, P151, DOI 10.1530/REP 08 0510
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068
   Gu QG, 2018, CELL PHYSIOL BIOCHEM, V48, P215, DOI 10.1159/000491721
   Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945 053X(97)90008 1
   Hamidouche Z, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 44
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Han L, 2010, BRAIN RES, V1366, P9, DOI 10.1016/j.brainres.2010.09.097
   Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248 9261.2004
   Hayrapetyan A, 2015, TISSUE ENG PART B RE, V21, P75, DOI [10.1089/ten.teb.2014.0119, 10.1089/ten.TEB.2014.0119]
   He WX, 2014, J ENDODONT, V40, P69, DOI 10.1016/j.joen.2013.09.011
   He XQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149876
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Houschyar KS, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00170
   Huang YF, 2012, J BONE MINER RES, V27, P1093, DOI 10.1002/jbmr.1548
   Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567
   Ishii T, 2003, J BIOL CHEM, V278, P26970, DOI 10.1074/jbc.M304113200
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Jiang H, 2019, J CELL PHYSIOL, V234, P7070, DOI 10.1002/jcp.27461
   Kim JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081803
   Kim SJ, 2017, BMB REP, V50, P55, DOI 10.5483/BMBRep.2017.50.2.011
   Kirkham GR, 2007, TOPICS TISSUE ENG, V3, P1
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Kozawa O, 2002, J CELL BIOCHEM, V84, P583, DOI 10.1002/jcb.10056.abs
   Langhammer T S, 2013, PI3K AKT SIGNALING I, DOI [10.1182/blood.V122.21.4886.4886, DOI 10.1182/BLOOD.V122.21.4886.4886]
   Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200
   Li L, 2019, BIOL RES, V52, DOI 10.1186/s40659 019 0215 x
   Liu F, 2016, CURR NANOSCI, V12, P4, DOI 10.2174/1573413711666150706183157
   Liu JP, 2013, BIOCHEM BIOPH RES CO, V435, P514, DOI 10.1016/j.bbrc.2012.11.083
   Logan NJ, 2018, BONE, V117, P149, DOI 10.1016/j.bone.2018.09.008
   Long HT, 2017, DNA CELL BIOL, V36, P715, DOI 10.1089/dna.2017.3657
   Ma KJ, 2018, MIDWEST SYMP CIRCUIT, P186, DOI 10.1109/MWSCAS.2018.8623908
   Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361
   Malysheva K, 2016, CROAT MED J, V57, P89, DOI 10.3325/cmj.2016.57.89
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Moon RT, 2002, NATURE, V417, P239, DOI 10.1038/417239a
   Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660
   Mukherjee A, 2010, MOL CELL BIOL, V30, P1018, DOI 10.1128/MCB.01401 09
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Niehrs C, 2012, EMBO J, V31, P2705, DOI 10.1038/emboj.2012.124
   Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374
   Olsen Jun Jun, 2017, Clin Biochem Rev, V38, P131
   Pataki CA, 2015, J HISTOCHEM CYTOCHEM, V63, P465, DOI 10.1369/0022155415586961
   Qiu XL, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5045827
   Ramazzotti G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20082026
   Ruijtenberg S, 2016, CELL CYCLE, V15, P196, DOI 10.1080/15384101.2015.1120925
   Saidak Z, 2015, J BIOL CHEM, V290, P6903, DOI 10.1074/jbc.M114.621219
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Shen B, 2019, ELIFE, V8, DOI 10.7554/eLife.42274
   Thorfve A, 2014, J BONE MARROW RES, V2, P2
   Thysen S, 2016, LAB INVEST, V96, P570, DOI 10.1038/labinvest.2016.38
   Tornero Esteban P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137170
   Tucker Gordon C, 2006, Curr Oncol Rep, V8, P96, DOI 10.1007/s11912 006 0043 3
   Ulici V, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 40
   Wang JC, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1309 7
   Wang L, 2015, INT ORTHOP, V39, P1013, DOI 10.1007/s00264 015 2683 0
   Wang Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03901 8
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Xu R, 2017, J BONE MINER RES, V32, P1811, DOI 10.1002/jbmr.3184
   Yao W, 2010, J BONE MINER RES, V25, P190, DOI 10.1359/jbmr.090719
   Yokota J, 2014, INT J MOL MED, V33, P534, DOI 10.3892/ijmm.2013.1606
   Zhang C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10601 w
   Zhang ML, 2008, BONE, V43, P511, DOI 10.1016/j.bone.2008.04.021
   Zhang W, 2018, FASEB J, V32, P2280, DOI 10.1096/fj.201700998RR
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
   [No title captured]
NR 90
TC 11
Z9 11
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1473 9542
EI 1479 7364
J9 HUM GENOMICS
JI Hum. Genomics
PD DEC 25
PY 2020
VL 14
IS 1
AR 43
DI 10.1186/s40246 020 00293 1
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA OV9UJ
UT WOS:000592545300001
PM 33234152
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ma, J
   Zhang, ZL
   Hu, XT
   Wang, XT
   Chen, AM
AF Ma, J.
   Zhang, Z L
   Hu, X T
   Wang, X T
   Chen, A M
TI Metformin promotes differentiation of human bone marrow derived
   mesenchymal stem cells into osteoblast via GSK3β inhibition
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Metformin; Mesenchymal stem cells; GSK3 beta; AMPK
ID ANTIDIABETIC DRUG METFORMIN; IN VIVO; PROLIFERATION; ALPHA; RISK
AB OBJECTIVE: Metformin, a common and first line drug for diabetes mellitus, is widely used in the world. Recently, many studies have documented that osteogenesis could be mediated by metformin. However, the specific mechanism by which metformin affects osteogenesis has not been clearly identified. Therefore, the aim of this study is to evaluate the role of GSK3 beta in metformin induced osteogenic differentiation of mesenchymal stem cells (MSCs).
   MATERIALS AND METHODS: Osteoblast marker genes, including Col 1, OCN, and RUNX2, were measured by RT PCR in differentiated MSCs treated with Metformin. Osteogenic differentiation viability was measured by Alkaline phosphatase (ALP) assays and Alizarin Red Staining. The expression of GSK3 beta, beta catenin and AMPK were measured by Western blotting in MSCs treated with metformin.
   RESULTS: We found that metformin at 100 mu M significantly promoted osteogenic differentiation of human mesenchymal stem cells (hBMSCs). Next, we showed that GSK3 beta and Wnt signaling pathway are involved in metformin induced osteogenic differentiation of hBMSCs. Furthermore, osteogenic differentiation of hBMSCs induced by metformin could be eliminated by inhibiting phosphorylation of GSK3 beta.
   CONCLUSIONS: The data suggested that metformin promoted the osteoblast differentiation of MSCs by, at least partly, inhibiting GSK3 beta activity. Additionally, we also found that AMPK plays an essential role in the inhibition of GSK3 beta by metformin.
C1 [Ma, J.; Hu, X T; Chen, A M] Second Mil Med Univ China, Dept Orthoped, ChangZheng Hosp, Shanghai, Peoples R China.
   [Zhang, Z L; Wang, X T] 425 Hosp PLA, Dept Orthoped, Sanya, Hainai, Peoples R China.
C3 Naval Medical University
RP Wang, XT (通讯作者)，425 Hosp PLA, Dept Orthoped, Sanya, Hainai, Peoples R China.
EM pla301hn@163.com
OI Ma, Jun/0000 0002 1796 8283
FU National Natural Science Foundation of China [81571204]
FX This study was sponsored by the National Natural Science Foundation of
   China (No. 81571204).
CR Chen YX, 2017, NANOSCALE, V9, P6765, DOI 10.1039/c7nr00601b
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Gao Y, 2010, EUR J PHARMACOL, V635, P231, DOI 10.1016/j.ejphar.2010.02.051
   Gao Y, 2008, J PHARM PHARMACOL, V60, P1695, DOI 10.1211/jpp.60/12.0017
   Gilbert MP, 2015, ENDOCR REV, V36, P194, DOI 10.1210/er.2012 1042
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hwang JH, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.115
   Felice JI, 2017, DIABETES RES CLIN PR, V126, P202, DOI 10.1016/j.diabres.2017.02.011
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Karnevi E, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 235
   Kim KM, 2012, J BONE MINER RES, V27, P1669, DOI 10.1002/jbmr.1604
   Kong XW, 2013, BBA GEN SUBJECTS, V1830, P5119, DOI 10.1016/j.bbagen.2013.07.027
   Lang UE, 2013, ONCOGENE, V32, P4557, DOI 10.1038/onc.2012.457
   Ma J, 2018, MED SCI MONITOR, V24, P2045, DOI 10.12659/MSM.905703
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   Melton LJ, 2008, J BONE MINER RES, V23, P1334, DOI 10.1359/JBMR.080323
   Muscelli E, 2016, DIABETOLOGIA, V59, P700, DOI 10.1007/s00125 015 3845 8
   Sedlinsky C, 2011, EUR J PHARMACOL, V668, P477, DOI 10.1016/j.ejphar.2011.07.033
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Vestergaard P, 2009, CALCIFIED TISSUE INT, V84, P45, DOI 10.1007/s00223 008 9195 5
   Wang JH, 2017, GENES BASEL, V8, DOI 10.3390/genes8100239
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Zhu ZZ, 2014, FEBS J, V281, P5371, DOI 10.1111/febs.13081
NR 23
TC 45
Z9 50
U1 0
U2 13
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD NOV
PY 2018
VL 22
IS 22
BP 7962
EP 7968
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HD8AA
UT WOS:000452774900045
PM 30536344
DA 2025 08 17
ER

PT J
AU Kito, H
   Kawagishi, R
   Ryu, T
   Endo, K
   Kajikuri, J
   Giles, WR
   Ohya, S
AF Kito, Hiroaki
   Kawagishi, Reiko
   Ryu, Takusei
   Endo, Kyoko
   Kajikuri, Junko
   Giles, Wayne R.
   Ohya, Susumu
TI KCa3.1 regulates cell cycle progression by modulating Ca2+signaling in
   murine preosteoblasts
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Mouse preosteoblast; KCa3.1; Cell cycle; Cell proliferation
ID UP REGULATION; OSTEOBLAST DIFFERENTIATION; POTASSIUM CHANNEL;
   PROLIFERATION; EXPRESSION; GENE; OSTEOCLAST; GROWTH; DEATH
AB Osteoblasts synthesize and deposit essential components of the extracellular bone matrix and collagen scaffolds, leading to mineralized bone formation. Therefore, the proliferation of preosteoblasts (precursors of mature osteoblasts) helps in regulating skeletal homeostasis. This study demonstrated that the functional expression of KCa3.1, an intermediate conductance Ca2+ activated K+ channel, is markedly upregulated in murine preosteoblastic MC3T3 E1 cells in the G0/G1 phase. The enhancement of KCa3.1 is involved in the establishment of more negative membrane potentials in MC3T3 E1 cells. This hyperpolarization can promote intracellular Ca2+ signaling because store operated Ca2+ channels are activated. Treatment with TRAM34, a specific KCa3.1 inhibitor, attenuated the cell cycle progression from the G0/ G1 phase to the S/G2/M phases. In MC3T3 E1 cells, KCa3.1 significantly promoted the transition from the G1 phase to the S phase. KCa3.1 inhibition also caused G0 phase cell accumulation. Furthermore, TRAM  34 decreased the expression of alkaline phosphatase, bone sialoprotein, and osteocalcin, osteoblast differentiation markers in MC3T3 E1 cells, and inhibited the endochondral ossification of murine metatarsals. These results reveal novel ways by which KCa3.1 activity can strongly modulate osteoblast maturation during bone formation.(c) 2023 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY NC ND license (http://creativecommons.org/ licenses/by nc nd/4.0/).
C1 [Kito, Hiroaki; Ryu, Takusei; Endo, Kyoko; Kajikuri, Junko; Ohya, Susumu] Nagoya City Univ, Grad Sch Med Sci, Dept Pharmacol, Nagoya, Japan.
   [Kawagishi, Reiko] Kyoto Pharmaceut Univ, Dept Pharmacol, Div Pathol Sci, Kyoto, Japan.
   [Giles, Wayne R.] Univ Calgary, Cumming Sch Med, Dept Physiol & Pharmacol, Calgary, AB, Canada.
   [Kito, Hiroaki] Nagoya City Univ, Grad Sch Med Sci, Dept Pharmacol, 1,Kawasumi,Mizuho Cho,Mizuho Ku, Nagoya 4678601, Japan.
C3 Nagoya City University; Kyoto Pharmaceutical University; University of
   Calgary; Nagoya City University
RP Kito, H (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Dept Pharmacol, 1,Kawasumi,Mizuho Cho,Mizuho Ku, Nagoya 4678601, Japan.
EM kito@med.nagoya cu.ac.jp
RI Ohya, Susumu/AAB 3618 2020
FU JSPS KAKENHI [JP18K14929, JP21K06600]; Grants in Aid for Scientific
   Research [21K06600, 20K07071] Funding Source: KAKEN
FX The authors sincerely thank Koki Hirakida and Takashi Fuku tome for
   their technical assistance. This work was supported by JSPS KAKENHI
   Grant Numbers JP18K14929 and JP21K06600.
CR Abed E, 2009, MOL MEMBR BIOL, V26, P146, DOI 10.1080/09687680802612721
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Bai YL, 2021, J CLIN LAB ANAL, V35, DOI 10.1002/jcla.23854
   Becchetti A, 2011, AM J PHYSIOL CELL PH, V301, pC255, DOI 10.1152/ajpcell.00047.2011
   Bi D, 2013, J BIOL CHEM, V288, P15843, DOI 10.1074/jbc.M112.427187
   Bury M, 2021, TRENDS CELL BIOL, V31, P331, DOI 10.1016/j.tcb.2021.01.010
   Chittajallu R, 2002, P NATL ACAD SCI USA, V99, P2350, DOI 10.1073/pnas.042698399
   Choi Hyewon, 2018, Bone Rep, V8, P147, DOI 10.1016/j.bonr.2018.03.007
   Friedman E, 2013, INT J MOL SCI, V14, P5560, DOI 10.3390/ijms14035560
   Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200
   Grössinger EM, 2018, J IMMUNOL, V200, P749, DOI 10.4049/jimmunol.1701170
   Guo YS, 2022, BMC MUSCULOSKEL DIS, V23, DOI 10.1186/s12891 022 05311 y
   Houston DA, 2016, JOVE J VIS EXP, DOI 10.3791/54978
   Hwang SY, 2012, CELL CALCIUM, V52, P488, DOI 10.1016/j.ceca.2012.10.001
   Rosendo Pineda MJ, 2020, CELL CALCIUM, V91, DOI 10.1016/j.ceca.2020.102258
   Kang H, 2014, CELL REP, V8, P1210, DOI 10.1016/j.celrep.2014.07.032
   Kawane T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31853 0
   Kito H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910459
   Kito H, 2020, AM J PHYSIOL CELL PH, V319, pC345, DOI 10.1152/ajpcell.00587.2019
   Kito H, 2015, BIOCHEM BIOPH RES CO, V459, P457, DOI 10.1016/j.bbrc.2015.02.127
   Kito H, 2014, J PHARMACOL SCI, V125, P227, DOI 10.1254/jphs.14002SC
   Kito H, 2011, BIOCHEM BIOPH RES CO, V411, P293, DOI 10.1016/j.bbrc.2011.06.128
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lallet Daher H, 2009, ONCOGENE, V28, P1792, DOI 10.1038/onc.2009.25
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Marakhova I, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52571 1
   Marescal O, 2020, DEV CELL, V55, P259, DOI 10.1016/j.devcel.2020.09.029
   Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073
   MURRAY S, 1993, J STEROID BIOCHEM, V46, P227, DOI 10.1016/0960 0760(93)90298 B
   Ohya S, 2016, PHARMACOL THERAPEUT, V160, P11, DOI 10.1016/j.pharmthera.2016.02.001
   Ouadid Ahidouch H, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00220
   OWEN TA, 1990, P NATL ACAD SCI USA, V87, P5129, DOI 10.1073/pnas.87.13.5129
   OWEN TA, 1991, ENDOCRINOLOGY, V128, P1496, DOI 10.1210/endo 128 3 1496
   Robinson LJ, 2019, CELL CALCIUM, V81, P51, DOI 10.1016/j.ceca.2019.06.001
   Robinson LJ, 2012, LAB INVEST, V92, P1071, DOI 10.1038/labinvest.2012.72
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Steudel FA, 2017, MOL ONCOL, V11, P1172, DOI 10.1002/1878 0261.12087
   Tao R, 2008, AM J PHYSIOL CELL PH, V295, pC1409, DOI 10.1152/ajpcell.00268.2008
   Tharp DL, 2006, AM J PHYSIOL HEART C, V291, pH2493, DOI 10.1152/ajpheart.01254.2005
   Urrego D, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0094
   Yamazaki D, 2011, AM J PHYSIOL CELL PH, V300, pC75, DOI 10.1152/ajpcell.00135.2010
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
NR 42
TC 0
Z9 0
U1 0
U2 1
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD NOV
PY 2023
VL 153
IS 3
BP 142
EP 152
DI 10.1016/j.jphs.2023.09.001
EA SEP 2023
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA Y6WR5
UT WOS:001106649400001
PM 37770155
OA gold
DA 2025 08 17
ER

PT J
AU Sun, J
   Sun, B
   Wang, W
   Han, XC
   Liu, HR
   Du, J
   Feng, W
   Liu, B
   Amizuka, N
   Li, MQ
AF Sun, Jing
   Sun, Bao
   Wang, Wei
   Han, Xiuchun
   Liu, Hongrui
   Du, Juan
   Feng, Wei
   Liu, Bo
   Amizuka, Norio
   Li, Minqi
TI Histochemical examination of the effects of high dose
   1,25(OH)2D3 on bone remodeling in young growing
   rats
SO JOURNAL OF MOLECULAR HISTOLOGY
LA English
DT Article
DE 1,25(OH)(2)D 3; Bone loss; Osteoclastogenesis; RANKL/RANK/OPG;
   EphrinB2 EphB4
ID STONE FORMING RATS; VITAMIN D; 1,25 DIHYDROXYVITAMIN D 3; IN VITRO;
   MESSENGER RNA; EXPRESSION; CELLS; MINERALIZATION; ANALOGS; VIVO
AB Vitamin D has an anabolic effect on bone developmental processes and is involved in maintaining skeletal integrity. In recent years, pediatric cases of vitamin D intoxication have attracted attention. Therefore, the aim of this study was to investigate the influence of long term administration of physiologically high dose calcitriol (1,25(OH)(2)D 3) on bone remodeling in young developing rats. Neonatal rats received once daily subcutaneous injection of calcitriol (250 ng/kg body weight), or PBS only as a control, for 3 weeks. At 1, 2 and 4 weeks' post administration, rats were sacrificed and fixed by transcardial perfusion with 4 % paraformaldehyde, following which tibiae were extracted for histochemical analysis. Compared with the control group, the number of tartrate resistant acid phosphatase  and Cathepsin K positive osteoclasts were significantly increased, and the expression of alkaline phosphatase in osteoblasts was decreased in trabecular bone of rats administered high dose 1,25(OH)(2)D 3, leading to decreased trabecular bone volume. In addition, the expression of receptor activator of nuclear factor kappa B ligand (RANKL) was increased, while that of osteoprotegerin was weaker in osteoblasts in the experimental group compared with the control group. Moreover, there was weaker immunoreactivity for EphrinB2 in osteoclasts and EphB4 in osteoblasts of trabecular bone in the experimental group compared with the control group. These findings suggest that long term use of physiologically high dose calcitriol may result in bone loss through RANKL/RANK/osteoprotegerin and EphrinB2 EphB4 signaling pathways, and that these negative effects could continue after drug withdrawal. Therefore, optimal limits for vitamin D administration need to be established for children and adolescents.
C1 [Sun, Jing; Sun, Bao; Wang, Wei; Han, Xiuchun; Liu, Hongrui; Du, Juan; Feng, Wei; Liu, Bo; Li, Minqi] Shandong Univ, Sch Stomatol, Dept Bone Metab, Shandong Prov Key Lab Oral Tissue Regenerat, Wenhua West Rd 44 1, Jinan 250012, Peoples R China.
   [Amizuka, Norio] Hokkaido Univ, Grad Sch Dent Med, Dept Dev Biol Hard Tissue, Sapporo, Hokkaido, Japan.
C3 Shandong University; Hokkaido University
RP Li, MQ (通讯作者)，Shandong Univ, Sch Stomatol, Dept Bone Metab, Shandong Prov Key Lab Oral Tissue Regenerat, Wenhua West Rd 44 1, Jinan 250012, Peoples R China.
EM liminqi@sdu.edu.cn
RI Amizuka, Norio/G 1397 2012; Du, Juan/MHQ 1740 2025
FU National Nature Science Foundation of China [81271965, 81470719,
   8151101150]; Grants in Aid for Scientific Research [16K15771] Funding
   Source: KAKEN
FX This study was partially supported by the National Nature Science
   Foundation of China (Grant Nos. 81271965; 81470719; 8151101150) to Li M.
CR Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Alshamsan FM, 2016, SAUDI MED J, V37, P579, DOI 10.15537/smj.2016.5.14951
   [Anonymous], JRSM OPEN
   Arthur A, 2011, BONE, V48, P533, DOI 10.1016/j.bone.2010.10.180
   Cheng Y, 2015, INT J CLIN EXP PATHO, V8, P394
   COLE AA, 1987, J HISTOCHEM CYTOCHEM, V35, P203, DOI 10.1177/35.2.3540104
   Cong L, 2015, INT J CLIN EXP PATHO, V8, P5988
   Feng W, 2015, MAT SCI ENG C MATER, V54, P133, DOI 10.1016/j.msec.2015.05.037
   Ghergherechi Robabeh, 2012, Pak J Biol Sci, V15, P147, DOI 10.3923/pjbs.2012.147.151
   Hicok KC, 1998, J BONE MINER RES, V13, P205, DOI 10.1359/jbmr.1998.13.2.205
   Idelevich A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020772
   Inada M, 2008, BIOCHEM BIOPH RES CO, V372, P434, DOI 10.1016/j.bbrc.2008.05.041
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Kara C, 2014, PEDIATRICS, V133, pE240, DOI 10.1542/peds.2013 0711
   Li MQ, 2013, HISTOL HISTOPATHOL, V28, P327, DOI 10.14670/HH 28.327
   Li Y, 2008, J STEROID BIOCHEM, V112, P110, DOI 10.1016/j.jsbmb.2008.09.004
   Lieben L, 2013, BONE, V57, P123, DOI 10.1016/j.bone.2013.07.029
   Liu HR, 2015, MAT SCI ENG C MATER, V49, P14, DOI 10.1016/j.msec.2014.12.064
   Lohmann CH, 2000, J BONE MINER RES, V15, P1169, DOI 10.1359/jbmr.2000.15.6.1169
   Martin TJ, 2010, ADV EXP MED BIOL, V658, P51, DOI 10.1007/978 1 4419 1050 9_6
   Martin TJ, 2013, WORLD J ORTHOP, V4, P186, DOI 10.5312/wjo.v4.i4.186
   Ng AH, 2014, CALCIFIED TISSUE INT, V94, P531, DOI 10.1007/s00223 014 9838 7
   Oda K, 1999, J BIOCHEM, V126, P694, DOI 10.1093/oxfordjournals.jbchem.a022505
   Oku Y, 2016, J NUTR BIOCHEM, V32, P85, DOI [10.1016/j.jnutbio.2016.01.013, 10.1016/j.jn]
   Rajakumar K, 2013, CLIN PEDIATR, V52, P82, DOI 10.1177/0009922812439245
   Sakai S, 2009, J BONE MINER METAB, V27, P643, DOI 10.1007/s00774 009 0084 4
   Sato M, 2007, BONE, V40, P293, DOI 10.1016/j.bone.2006.09.007
   Suda T, 2003, J CELL BIOCHEM, V88, P259, DOI 10.1002/jcb.10331
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takahashi Naoyuki, 2014, Bonekey Rep, V3, P495, DOI 10.1038/bonekey.2013.229
   Takasu H, 2006, J CLIN INVEST, V116, P528, DOI 10.1172/JCI24742
   Tanaka H, 2011, BIOCHEM BIOPH RES CO, V411, P690, DOI 10.1016/j.bbrc.2011.07.001
   Ueno Y, 2003, J CELL BIOCHEM, V90, P267, DOI 10.1002/jcb.10623
   van Leeuwen JPTM, 2001, CRIT REV EUKAR GENE, V11, P199, DOI 10.1615/CritRevEukarGeneExpr.v11.i1 3.100
   Woeckel VJ, 2010, J CELL PHYSIOL, V225, P593, DOI 10.1002/jcp.22244
   Yamaguchi M, 2012, INT J MOL MED, V29, P934, DOI 10.3892/ijmm.2012.900
   Yao JJ, 2005, J AM SOC NEPHROL, V16, P1300, DOI 10.1681/ASN.2004110991
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 38
TC 15
Z9 15
U1 0
U2 21
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1567 2379
EI 1567 2387
J9 J MOL HISTOL
JI J. Mol. Histol.
PD AUG
PY 2016
VL 47
IS 4
BP 389
EP 399
DI 10.1007/s10735 016 9681 4
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DQ9KO
UT WOS:000379529000002
PM 27255234
DA 2025 08 17
ER

PT J
AU Chen, JH
   Wu, XK
   Yu, RT
AF Chen, Jinghua
   Wu, Xiaoke
   Yu, Ruitao
TI Unraveling the Therapeutic Mechanism of Saussurea involucrata
   against Rheumatoid Arthritis: A Network Pharmacology and Molecular
   Modeling Based Investigation
SO NUTRIENTS
LA English
DT Article
DE Saussurea involucrata; rheumatoid arthritis; network pharmacology;
   molecular docking; molecular dynamic simulation
ID ACACETIN INHIBITS EXPRESSION; KAPPA B; MAPK; ACTIVATION; PATHWAY
AB Rheumatoid arthritis (RA) is a chronic autoimmune disease with a global prevalence of approximately 0.46%, causing significant impairments in patients' quality of life and an economic burden. Saussurea involucrata (SI) has long been used in traditional medicine to treat RA, but its underlying mechanism remains unclear. This study utilized network pharmacology and molecular docking to explore the potential pharmacological effects of bioactive compounds in SI on RA. A total of 27 active compounds were identified, along with 665 corresponding targets. Additionally, 593 disease related targets were obtained from multiple databases, with 119 common targets shared with SI. The high ranking targets mainly belong to the MAPK family and NF kappa B pathway, including MAPK14, MAPK1, RELA, TNF, and MAPK8, all of which are associated with inflammation and joint destruction in RA. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed significant pathways related to IL 17 signaling, Th17 cell differentiation, and osteoclast differentiation. Molecular docking and dynamic simulations demonstrated strong interactions between several flavonoids and RA related targets. Xuelianlactone, Involucratin, and Flazin exhibit outstanding binding efficacy with targets such as MAPK1, MAPK8, and TNF. These findings provide valuable insights into the therapeutic potential of SI for RA and offer directions for further drug development.
C1 [Chen, Jinghua; Wu, Xiaoke; Yu, Ruitao] Chinese Acad Sci, Northwest Inst Plateau Biol, Qinghai Prov Key Lab Tibetan Med Res, Xining 810001, Peoples R China.
   [Chen, Jinghua; Wu, Xiaoke] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Chen, Jinghua; Wu, Xiaoke; Yu, Ruitao] Chinese Acad Sci, Key Lab Tibetan Med Res, Xining 810001, Peoples R China.
C3 Chinese Academy of Sciences; Chinese Academy of Sciences; University of
   Chinese Academy of Sciences, CAS; Chinese Academy of Sciences
RP Yu, RT (通讯作者)，Chinese Acad Sci, Northwest Inst Plateau Biol, Qinghai Prov Key Lab Tibetan Med Res, Xining 810001, Peoples R China.; Yu, RT (通讯作者)，Chinese Acad Sci, Key Lab Tibetan Med Res, Xining 810001, Peoples R China.
EM chenjinghua@nwipb.cas.cn; yuruitao@nwipb.cas.cn
OI ?, ??/0000 0001 7500 4565; Jinghua, Chen/0009 0003 4185 6569
FU Qinghai Provincial Natural Science Foundation General Project
   [2022 ZJ 930]; Qinghai Provincial Key Laboratory of Tibetan Medicine
   Research Innovation Platform Development Special Project [2022 ZJ Y03]
FX This research was funded by Qinghai Provincial Natural Science
   Foundation General Project (Grant Number: 2022 ZJ 930), and Qinghai
   Provincial Key Laboratory of Tibetan Medicine Research Innovation
   Platform Development Special Project (Grant Number: 2022 ZJ Y03).
CR Abbasi M, 2019, J CELL PHYSIOL, V234, P10018, DOI 10.1002/jcp.27860
   Almutairi K, 2021, RHEUMATOL INT, V41, P863, DOI 10.1007/s00296 020 04731 0
   Alphonse CRW, 2023, J CELL BIOCHEM, V124, P1002, DOI 10.1002/jcb.30426
   Bai X, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 80780 6
   Cao JY, 2022, ARAB J CHEM, V15, DOI 10.1016/j.arabjc.2022.104155
   Cao Zhi Xiu, 2018, Zhongguo Zhong Yao Za Zhi, V43, P4491, DOI 10.19540/j.cnki.cjcmm.20180619.001
   [陈红梅 Chen Hongmei], 2016, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V22, P1168
   Chen WP, 2015, J CELL MOL MED, V19, P1910, DOI 10.1111/jcmm.12564
   Chik WI, 2015, J ETHNOPHARMACOL, V172, P44, DOI 10.1016/j.jep.2015.06.033
   Choi EM, 2010, FOOD CHEM TOXICOL, V48, P2607, DOI 10.1016/j.fct.2010.06.029
   Choi NR, 2023, NUTRIENTS, V15, DOI 10.3390/nu15122644
   Committee N.P., 2020, Pharmacopoeia of People's Republic of China. Part 1, P55
   Dong YZ, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 98925 6
   Fan Wen Xia, 2021, Zhongguo Zhong Yao Za Zhi, V46, P3522, DOI 10.19540/j.cnki.cjcmm.20210430.101
   Fidahic M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012095.pub2
   GOEMAERE S, 1990, J RHEUMATOL, V17, P1620
   Hao J, 2022, ANN PALLIAT MED, DOI 10.21037/apm 21 2203
   Hitchon CA, 2011, CURR OPIN RHEUMATOL, V23, P352, DOI 10.1097/BOR.0b013e3283477b7b
   Hou YA, 2009, CELL BIOL INT, V33, P135, DOI 10.1016/j.cellbi.2008.10.005
   Hu HH, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 34524 x
   Huan WY, 2008, CHIN PRAC MED, V3, P59, DOI 10.3969/j.issn.1673 7555.2008.24.034
   Jiang X, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02253 5
   Jiménez J, 2017, BIOINFORMATICS, V33, P3036, DOI 10.1093/bioinformatics/btx350
   Jing Lin lin, 2015, Zhong Yao Cai, V38, P89
   Khan SA, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105400
   Kim EK, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.490
   Kunwar S, 2016, RHEUMATOL INT, V36, P1065, DOI 10.1007/s00296 016 3480 9
   Li J., 1998, Chinese Pharmaceutical Journal, P3
   Liang Y, 2004, CELL MOL IMMUNOL, V1, P343
   Liu HX, 2022, BIOMED RES INT UK, V2022, DOI 10.1155/2022/3353464
   Liu S, 2021, CLIN IMMUNOL, V230, DOI 10.1016/j.clim.2021.108793
   Liu XR, 2023, INFLAMMOPHARMACOLOGY, V31, P1629, DOI 10.1007/s10787 023 01196 y
   Na Z., 2022, J. Hunan Univ. Chin. Med, V42, P633
   Pantsar T, 2018, MOLECULES, V23, DOI 10.3390/molecules23081899
   Perricone C, 2019, CURR OPIN RHEUMATOL, V31, P517, DOI 10.1097/BOR.0000000000000638
   Ponce C, 2009, REPRODUCTION, V137, P727, DOI 10.1530/REP 08 0407
   Ralph JA, 2008, EXPERT OPIN THER TAR, V12, P795, DOI 10.1517/14728222.12.7.795 
   Ruiping Y., 2000, P INT C TRAD MED BEI, P2
   Saranya Palanisamy, 2023, Vegetos, V36, P188, DOI 10.1007/s42535 022 00525 w
   Shea B, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000951.pub2, 10.3899/jrheum.130738]
   Shi HS, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/4652492
   Song SY, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 13223 z
   Tang MS, 2022, DRUG DES DEV THER, V16, P2043, DOI 10.2147/DDDT.S364759
   Tanigawa N, 2013, IMMUNOPHARM IMMUNOT, V35, P471, DOI 10.3109/08923973.2013.811596
   Tian XP, 2021, RHEUMATOL IMMUNOL RE, V2, P1, DOI 10.2478/rir 2021 0002
   Tu AB, 2021, DRUG DELIV TRANSL RE, V11, P2371, DOI 10.1007/s13346 021 01038 w
   Valdés Tresanco MS, 2021, J CHEM THEORY COMPUT, V17, P6281, DOI 10.1021/acs.jctc.1c00645
   van den Berg WB, 2009, NAT REV RHEUMATOL, V5, P549, DOI 10.1038/nrrheum.2009.179
   van Vollenhoven RF, 2009, BMC MED, V7, DOI 10.1186/1741 7015 7 12
   Vidya Natarajan, 2008, In Silico Biol, V8, P471
   Volin MV, 2005, CURR PHARM DESIGN, V11, P633, DOI 10.2174/1381612053381972
   Wang DX, 2023, TRANSL CANCER RES, V12, P743, DOI 10.21037/tcr 22 2292
   Wang Y., 2020, THESIS CHONGQING U C
   Wang Y, 2022, COMPUT BIOL MED, V145, DOI 10.1016/j.compbiomed.2022.105454
   Wu D, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1051082
   Wu Qi, 2021, Zhongguo Zhong Yao Za Zhi, V46, P4824, DOI 10.19540/j.cnki.cjcmm.20210622.401
   Wu Y, 2022, SCI REP UK, V12, DOI 10.1038/s41598 021 03980 8
   Xiao ZJ, 2020, INT J PHARMACOL, V16, P382, DOI 10.3923/ijp.2020.382.397
   Yan Hai Yan, 2022, Zhongguo Zhong Yao Za Zhi, V47, P1370, DOI 10.19540/j.cnki.cjcmm.20210923.401
   Ye XW, 2022, FRONT AGING NEUROSCI, V14, DOI 10.3389/fnagi.2022.890046
   Yeo J, 2019, NANO LETT, V19, P6716, DOI 10.1021/acs.nanolett.9b00496
   [袁勇 Yuan Yong], 2011, [中国医院药学杂志, Chinese Journal of Hospital Pharmacy], V31, P1407
   Zeng X., 2021, China Rheumatoid Arthritis Development Report 2020
   [曾小峰 Zeng Xiaofeng], 2013, [中国循证医学杂志, Chinese Journal of Evidence Based Medicine], V13, P300
   Zhang W, 2011, CLIN RHEUMATOL, V30, pS25, DOI 10.1007/s10067 010 1637 6
   Zhao Q., 2022, J. At. Mol. Phys, V39, P27, DOI [10.19855/j.1000 0364.2022.061004, DOI 10.19855/J.1000 0364.2022.061004]
   Zimeng A., 2023, Tianjin J Tradit Chin Med, V40, P495
NR 67
TC 8
Z9 9
U1 3
U2 28
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2023
VL 15
IS 19
AR 4294
DI 10.3390/nu15194294
PG 20
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA U5HS2
UT WOS:001085115300001
PM 37836578
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yuan, FL
   Xu, RS
   Jiang, DL
   He, XL
   Su, Q
   Jin, C
   Li, X
AF Yuan, Feng Lai
   Xu, Rui Sheng
   Jiang, Dong Lin
   He, Xing Long
   Su, Qiang
   Jin, Chen
   Li, Xia
TI Leonurine hydrochloride inhibits osteoclastogenesis and prevents
   osteoporosis associated with estrogen deficiency by inhibiting the NF κB
   and PI3K/Akt signaling pathways
SO BONE
LA English
DT Article
DE Leonurine hydrochloride; Osteoclastogenesis; NF kappa B; PI3K/Akt
   signaling; Osteoporosis
ID RANKL MEDIATED OSTEOCLASTOGENESIS; INDUCED INCOMPLETE ABORTION;
   TRANSCRIPTION FACTOR NFATC1; BONE LOSS; REGULATING ACTIVATION; DEPENDENT
   REGULATION; HERBAL FORMULA; C FOS; DIFFERENTIATION; RECEPTOR
AB Osteoclasts, the primary bone resorbing cells, are responsible for destructive bone diseases such as postmenopausal osteoporosis, rheumatoid arthritis, and periodontitis. Many plant derived traditional medicines that might suppress the formation and/or function of osteoclasts are promising treatments for osteoclast related diseases. In this study, we investigated the effects of leonurine hydrochloride (LH) on receptor activator NF kappa B ligand (RANKL) induced osteoclastogenesis and ovariectomy induced bone loss. LH is a synthetic chemical compound based on the structure of leonurine, which is found in motherwort and has been reported to exhibit phytoestrogenic activity. In RAW 264.7 cells and mouse bone marrow monocytes (BMMs), LH suppressed RANKL induced osteoclastogenesis and actin ring formation in a dose dependent manner. LH targeted RANKL induced osteoclastogenesis and bone resorption at an early stage. Molecular analysis demonstrated that LH attenuated RANKL induced NF kappa B signaling by inhibiting the phosphorylation and degradation of IKB alpha and NF kappa B p65 nuclear translocation. LH inhibited the RANK TRAF6 association triggered by RANKL binding and the phosphatidylinosito13 kiriase (PI3K)/Akt axis, without significantly affecting the extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK) and AP 1 signaling pathways. LH attenuated the RANKL stimulated expression of osteociast related genes including NFATc1, tartrate resistant acid phosphatase (TRAP), cathepsin K, and osteoclast associated receptor (OSCAR). Consistent with the in vitro results, LH administration attenuated osteoclast activity, thus preventing bone loss caused by estrogen deficiency in mice. In this study, LH suppressed RANKL induced osteoclastogenesis via RANK TRAF6, NF kappa B, and PI3K/Akt signaling. These data provide the first evidence that LH might be a promising therapeutic compound to treat osteoclast related diseases, such as osteoporosis. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Li, Xia] Nantong Univ, Hosp 3, Dept Orthopaed, Wuxi 214041, Jiangsu, Peoples R China.
   Nantong Univ, Hosp 3, Cent Lab, Wuxi 214041, Jiangsu, Peoples R China.
C3 Nantong University; Nantong University
RP Li, X (通讯作者)，Nantong Univ, Hosp 3, Dept Orthopaed, Wuxi 214041, Jiangsu, Peoples R China.
RI ; li, xia/HHZ 7468 2022; Jiang, Donglin/AFQ 7210 2022
OI Yuan, Fenglai/0000 0003 2141 3122; 
FU Natural Science Foundation of China [81270011, 81101372]
FX This work was supported by Natural Science Foundation of China
   (81270011; 81101372).
CR Abu Amer Y, 2008, AUTOIMMUNITY, V41, P204, DOI 10.1080/08916930701694543
   ADAMS NR, 1990, J REPROD FERTIL, V89, P477, DOI 10.1530/jrf.0.0890477
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806 7819.2004
   Hayashibara T, 2007, J BONE MINER RES, V22, P1743, DOI 10.1359/JBMR.070709
   Huber DM, 2001, ENDOCRINOLOGY, V142, P3800, DOI 10.1210/en.142.9.3800
   Humphrey MB, 2012, BONEKEP REP
   Hwang SY, 2012, FASEB J, V26, P1484, DOI 10.1096/fj.11 194399
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kim JY, 2014, BMB REP, V47, P451, DOI 10.5483/BMBRep.2014.47.8.206
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Leibbrandt A, 2009, ADV EXP MED BIOL, V647, P130, DOI 10.1007/978 0 387 89520 8_9
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Leung Ping Chung, 2013, J Tradit Complement Med, V3, P82, DOI 10.4103/2225 4110.110407
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li X, 2013, FEBS LETT, V587, P3236, DOI 10.1016/j.febslet.2013.08.017
   Li X, 2013, EUR J OBSTET GYN R B, V169, P299, DOI 10.1016/j.ejogrb.2013.02.022
   Li X, 2011, EUR J OBSTET GYN R B, V159, P375, DOI 10.1016/j.ejogrb.2011.09.006
   Lo Iacono N, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/412768
   Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613
   Ma H, 2010, BIOL PHARM BULL, V33, P455, DOI 10.1248/bpb.33.455
   Mandal CC, 2009, ENDOCRINOLOGY, V150, P4989, DOI 10.1210/en.2009 0026
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   NAGASAWA H, 1992, ANTICANCER RES, V12, P141
   OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Shang XF, 2014, J ETHNOPHARMACOL, V152, P14, DOI 10.1016/j.jep.2013.12.052
   Suda T, 2001, Novartis Found Symp, V232, P235
   SUDA T, 2001, NOVART FDN SYMP, V232, P247
   Sun B, 2008, ONCOGENE, V27, P6228, DOI 10.1038/onc.2008.300
   Sun Y, 2008, PHYTOTHER RES, V22, P267, DOI 10.1002/ptr.2291
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang ZQ, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/356260
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Zhang H, 2003, ONCOGENE, V22, P2088, DOI 10.1038/sj.onc.1206310
   Zhao QX, 2007, FRONT BIOSCI LANDMRK, V12, P2519, DOI 10.2741/2252
   Zhu LX, 2012, INT J BIOCHEM CELL B, V44, P1139, DOI 10.1016/j.biocel.2012.04.003
NR 47
TC 106
Z9 114
U1 3
U2 67
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2015
VL 75
BP 128
EP 137
DI 10.1016/j.bone.2015.02.017
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CG1ZQ
UT WOS:000353075100018
PM 25708053
DA 2025 08 17
ER

PT J
AU Baker, EK
   Taylor, S
   Gupte, A
   Chalk, AM
   Bhattacharya, S
   Green, AC
   Martin, TJ
   Strbenac, D
   Robinson, MD
   Purton, LE
   Walkley, CR
AF Baker, Emma K.
   Taylor, Scott
   Gupte, Ankita
   Chalk, Alistair M.
   Bhattacharya, Shreya
   Green, Alanna C.
   Martin, T. John
   Strbenac, Dario
   Robinson, Mark D.
   Purton, Louise E.
   Walkley, Carl R.
TI Wnt inhibitory factor 1 (WIF1) is a marker of osteoblastic
   differentiation stage and is not silenced by DNA methylation in
   osteosarcoma
SO BONE
LA English
DT Article
DE Osteosarcoma; WIF1; HDAC; Methylation; Osteoblast; Osteoporosis
ID VAN BUCHEM DISEASE; MESSENGER RNA EXPRESSION; CANCER CELL LINES;
   BONE MARROW; GENE EXPRESSION; FACTOR I; NEOADJUVANT CHEMOTHERAPY;
   EPIGENETIC REGULATION; STROMAL CELLS; LUNG CANCER
AB Wnt pathway targeting is of high clinical interest for treating bone loss disorders such as osteoporosis. These therapies inhibit the action of negative regulators of osteoblastic Wnt signaling. The report that Wnt inhibitory factor 1 (WIF1) was epigenetically silenced via promoter DNA methylation in osteosarcoma (OS) raised potential concerns for such treatment approaches. Here we confirm that Wif1 expression is frequently reduced in OS. However, we demonstrate that silencing is not driven by DNA methylation. Treatment of mouse and human OS cells showed that Wif1 expression was robustly induced by HDAC inhibition but not by methylation inhibition. Consistent with HDAC dependent silencing, the Wif1 locus in OS was characterized by low acetylation levels and a bivalent H3K4/H3K27 trimethylation state. Wif1 expression marked late stages of normal osteoblast maturation and stratified OS tumors based on differentiation stage across species. Culture of OS cells under differentiation inductive conditions increased expression of Wif1. Together these results demonstrate that Wif1 is not targeted for silencing by DNA methylation in OS. Instead, the reduced expression of Wif1 in OS cells is in context with their stage in differentiation. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Baker, Emma K.; Taylor, Scott; Gupte, Ankita; Chalk, Alistair M.; Bhattacharya, Shreya; Green, Alanna C.; Purton, Louise E.; Walkley, Carl R.] St Vincents Inst Med Res, Stem Cell Regulat Unit, Fitzroy, Vic 3065, Australia.
   [Baker, Emma K.; Chalk, Alistair M.; Bhattacharya, Shreya; Green, Alanna C.; Martin, T. John; Purton, Louise E.; Walkley, Carl R.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia.
   [Martin, T. John] St Vincents Inst Med Res, Bone Cell Biol & Dis Unit, Fitzroy, Vic 3065, Australia.
   [Strbenac, Dario] St Vincents Hosp, Garvan Inst Med Res, Canc Epigenet, Darlinghurst, NSW 2010, Australia.
   [Robinson, Mark D.] Univ Zurich, Inst Mol Life Sci, Zurich, Switzerland.
   [Robinson, Mark D.] Univ Zurich, SIB, Zurich, Switzerland.
C3 St. Vincent's Institute of Medical Research; University of Melbourne;
   NSW Health; St Vincents Hospital Sydney; St Vincent's Health; St
   Vincent's Hospital Melbourne; St. Vincent's Institute of Medical
   Research; NSW Health; St Vincents Hospital Sydney; Garvan Institute of
   Medical Research; University of Zurich; Swiss Institute of
   Bioinformatics; University of Zurich
RP Baker, EK (通讯作者)，St Vincents Inst Med Res, Stem Cell Regulat Unit, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.
EM ebaker@svi.edu.au; cwalkley@svi.edu.au
RI Chalk, Alistair/B 3019 2008; Walkley, Carl/AAO 6021 2020; Purton,
   Louise/AAI 8956 2021; Robinson, Mark/A 6432 2015; Green,
   Adele/P 2736 2014
OI Chalk, Alistair/0000 0002 9630 6236; Green, Alanna/0000 0002 0175 1485;
   Purton, Louise/0000 0001 6593 3168; Robinson, Mark/0000 0002 3048 5518;
   Walkley, Carl/0000 0002 4784 9031
FU Cancer Council of Victoria [1047593]; NHMRC Career Development Award
   [559016]; Cure Cancer Australia Foundation Fellowship; 5point
   foundation; NHMRC [1006485]; NHMRC Senior Research Fellowship [1003339];
   Victorian State Government Operational Infrastructure Support Program
FX This work was supported by grants from the Cancer Council of Victoria
   (to C.W., E.B., M.R.; Grant In Aid 1047593); NHMRC Career Development
   Award (to C.W.; 559016); Cure Cancer Australia Foundation Fellowship (to
   E.B); 5point foundation (to E.B); NHMRC project grant (to L.P.;
   1006485); NHMRC Senior Research Fellowship (to L.P.; 1003339); in part
   by the Victorian State Government Operational Infrastructure Support
   Program (to St. Vincent's Institute). C.W. is the Philip Desbrow Senior
   Research Fellow of the Leukaemia Foundation. We thank the SVI Flow
   Cytometry Core Facility (M Thomson, E Orlowski) for FACS sorting and
   advice.
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Aiden AP, 2010, CELL STEM CELL, V6, P591, DOI 10.1016/j.stem.2010.03.016
   Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614
   Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872
   Bacci G, 2006, CANCER AM CANCER SOC, V106, P1154, DOI 10.1002/cncr.21724
   Bacci G, 2005, EUR J CANCER, V41, P2836, DOI 10.1016/j.ejca.2005.08.026
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   Baker EK, 2010, METHODS MOL BIOL, V596, P183, DOI 10.1007/978 1 60761 416 6_9
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Birch JM, 2001, ONCOGENE, V20, P4621, DOI 10.1038/sj.onc.1204621
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137
   Chan SL, 2007, LAB INVEST, V87, P644, DOI 10.1038/labinvest.3700547
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Daniel VC, 2009, CANCER RES, V69, P3364, DOI 10.1158/0008 5472.CAN 08 4210
   Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105
   El Serafi AT, 2011, DIFFERENTIATION, V81, P35, DOI 10.1016/j.diff.2010.09.183
   Foltz Greg, 2010, Genes Cancer, V1, P81, DOI 10.1177/1947601909356103
   Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399 0004.2003.00036.x
   Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Janeway KA, 2010, LANCET ONCOL, V11, P670, DOI 10.1016/S1470 2045(10)70062 0
   Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367
   Jurado S, 2012, J BIOL CHEM, V287, P3156, DOI 10.1074/jbc.M111.306019
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kresse SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048262
   Kuijjer ML, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755 8794 4 66
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008 5472.CAN 04 1389
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Mutsaers AJ, 2013, BONE, V55, P166, DOI 10.1016/j.bone.2013.02.016
   Närvä E, 2010, NAT BIOTECHNOL, V28, P371, DOI 10.1038/nbt.1615
   Ng AJM, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045 3329 2 19
   Noll JE, 2014, HAEMATOLOGICA, V99, P163, DOI 10.3324/haematol.2013.090977
   Ramachandran I, 2012, ONCOGENE, V31, P2725, DOI 10.1038/onc.2011.455
   Rubin EM, 2010, MOL CANCER THER, V9, P731, DOI 10.1158/1535 7163.MCT 09 0147
   Sadikovic B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002834
   Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood 2004 01 0272
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055
   Takyar FM, 2013, J BONE MINER RES, V28, P912, DOI 10.1002/jbmr.1820
   Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910
   van Lierop AH, 2013, J BONE MINER RES, V28, P848, DOI 10.1002/jbmr.1794
   WADAYAMA B, 1994, CANCER RES, V54, P3042
   Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808
   Wamstad JA, 2012, CELL, V151, P206, DOI 10.1016/j.cell.2012.07.035
NR 51
TC 25
Z9 26
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2015
VL 73
BP 223
EP 232
DI 10.1016/j.bone.2014.12.063
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CC7FJ
UT WOS:000350532800028
PM 25571841
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Schmeel, LC
   Schmeel, FC
   Kim, Y
   Blaum Feder, S
   Endo, T
   Schmidt Wolf, IGH
AF Schmeel, Leonard Christopher
   Schmeel, Frederic Carsten
   Kim, Young
   Blaum Feder, Sabine
   Endo, Tomoyuki
   Schmidt Wolf, Ingo G. H.
TI In Vitro Efficacy of Cinnarizine Against Lymphoma and Multiple
   Myeloma
SO ANTICANCER RESEARCH
LA English
DT Article
DE Cinnarizine; multiple myeloma; lymphoma; cancer therapy; WNT
ID WNT/BETA CATENIN PATHWAY; STEM CELL TRANSPLANTATION; ETHACRYNIC ACID;
   VIVO EFFICACY; WNT INHIBITORS; BETA CATENIN; BONE MARROW; CANCER;
   LENALIDOMIDE; PROGRESSION
AB Background/Aim: Multiple myeloma, a well known but still incurable disease, is a hematological malignancy of B lymphocytes. While standard chemotherapy regimens have been used for years, novel agents, such as lenalidomide and bortezomib, have become an essential part of today's therapies. Nevertheless, new therapeutical strategies are required in the future. Aberrant activation of wingless related integration site (WNT)/beta catenin signaling promotes the development of several types of cancer. Recently, it has been demonstrated that the WNT pathway is also activated in lymphoma and myeloma. Thus, the WNT signaling molecules are attractive candidates for the development of targeted therapies. To this extent, we recently confirmed that the diuretic agent ethacrynic acid (EA) and the antifungal agent ciclopirox olamine (CIC) inhibit WNT signaling. Cinnarizine has similar chemical features to those of CIC. Materials and Methods: Thus, in this study the antitumor effect of cinnarizine on myeloma and lymphoma cells was investigated by DiOC6 and propidium iodide (PI) staining in flow cytometry. Results: Cinnarizine triggered a significant apoptotic activity in all tested myeloma and lymphoma cell lines in a concentration dependent manner. Interestingly, healthy cells were mainly unaffected. Conclusion: These results reveal a significant selective induction of apoptosis by cinnarizine that might result from an inhibition of WNT signaling and suggest an in vivo efficacy against lymphoma and myeloma.
C1 [Schmeel, Leonard Christopher; Schmeel, Frederic Carsten; Kim, Young; Blaum Feder, Sabine; Schmidt Wolf, Ingo G. H.] Univ Hosp Bonn, CIO, Dept Internal Med 3, D 53105 Bonn, Germany.
   [Schmeel, Frederic Carsten] Univ Hosp Bonn, Dept Radiol, D 53105 Bonn, Germany.
   [Endo, Tomoyuki] Hokkaido Univ, Dept Hematol, Grad Sch Med, Sapporo, Hokkaido, Japan.
C3 University of Bonn; University of Bonn; Hokkaido University
RP Schmidt Wolf, IGH (通讯作者)，Univ Hosp Bonn, CIO, Sigmund Freud Str 25, D 53105 Bonn, Germany.
EM Ingo.Schmidt Wolf@ukb.uni bonn.de
OI Schmeel, Christopher/0000 0002 3901 4122; Schmeel,
   Frederic/0000 0003 0985 1517
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Ashihara E, 2009, CLIN CANCER RES, V15, P2731, DOI 10.1158/1078 0432.CCR 08 1350
   Bringhen S, 2006, EXPERT OPIN INV DRUG, V15, P1565, DOI 10.1517/13543784.15.12.1565
   Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   Dutta Simmons J, 2009, BLOOD, V114, P2699, DOI 10.1182/blood 2008 12 194290
   Fowler JA, 2012, CANCER RES, V72, P2183, DOI 10.1158/0008 5472.CAN 11 2067
   Haasler T, 2009, N S ARCH PHARMACOL, V380, P531, DOI 10.1007/s00210 009 0463 3
   Harousseau JL, 2009, NEW ENGL J MED, V360, P2645, DOI 10.1056/NEJMct0805626
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Howlader N., 2014, SEER CANC STAT REV 1
   Kim Y, 2012, LEUKEMIA RES, V36, P598, DOI 10.1016/j.leukres.2012.01.025
   Kim Y, 2011, IN VIVO, V25, P887
   Kim Y, 2011, ANTICANCER RES, V31, P725
   Kim Y, 2011, IN VIVO, V25, P99
   Kocemba KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030359
   Koller CM, 2013, ANTICANCER RES, V33, P2435
   Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746
   Lu DS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008294
   Moreau P, 2006, BLOOD, V107, P397, DOI 10.1182/blood 2005 06 2573
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Polakis P, 2000, GENE DEV, V14, P1837
   Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239
   Rosiñol L, 2008, BLOOD, V112, P3591, DOI 10.1182/blood 2008 02 141598
   SALETU B, 1980, PROG NEURO PSYCHOPHA, V4, P469, DOI 10.1016/0364 7722(80)90017 X
   Schmeel FC, 2014, HEMATOL ONCOL, V32, P197, DOI 10.1002/hon.2122
   Schmeel LC, 2013, ANTICANCER RES, V33, P4719
   Schmidt M, 2011, IN VIVO, V25, P325
   Schmidt M, 2009, BRIT J HAEMATOL, V144, P796, DOI 10.1111/j.1365 2141.2008.07503.x
   SINGH B, 1986, BR J CLIN PHARM S, V21, P109
   Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104
   Tosoni C, 2009, CLIN EXP DERMATOL, V34, P166, DOI 10.1111/j.1365 2230.2008.02891.x
   Von Schulz Hausmann SA, 2014, ANTICANCER RES, V34, P4101
   Wall I, 2014, ANTICANCER RES, V34, P5375
   WILDERSMITH CH, 1991, ACTA ONCOL, V30, P731, DOI 10.3109/02841869109092448
   Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006
NR 37
TC 13
Z9 14
U1 0
U2 2
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD FEB
PY 2015
VL 35
IS 2
BP 835
EP 841
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CB4LG
UT WOS:000349598600028
PM 25667464
DA 2025 08 17
ER

PT J
AU He, L
   Lee, J
   Jang, JH
   Sakchaisri, K
   Hwang, J
   Cha Molstad, HJ
   Kim, KA
   Ryoo, IJ
   Lee, HG
   Kim, SO
   Soung, NK
   Lee, KS
   Kwon, YT
   Erikson, RL
   Ahn, JS
   Kim, BY
AF He, Long
   Lee, Junwon
   Jang, Jae Hyuk
   Sakchaisri, Krisada
   Hwang, Joonsung
   Cha Molstad, Hyun Joo
   Kim, Kyung A.
   Ryoo, In Ja
   Lee, Hee Gu
   Kim, Sun Ok
   Soung, Nak Kyun
   Lee, Kyung Sang
   Kwon, Yong Tae
   Erikson, Raymond Leo
   Ahn, Jong Seog
   Kim, Bo Yeon
TI Osteoporosis regulation by salubrinal through eIF2α mediated
   differentiation of osteoclast and osteoblast
SO CELLULAR SIGNALLING
LA English
DT Article
DE Osteoclast; Osteoblast; Salubrinal; eIF2 alpha; NFATc1
ID ENDOPLASMIC RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; CELL DEATH; ER
   STRESS; PROLIFERATION; TRANSLATION
AB Nuclear factor kappa B (NF kappa B) ligand (RANKL) was shown to induce osteoclast differentiation by increasing the expression of c Fos, NFATc1 and TRAP. Salubrinal treatment to bone marrow macrophage (BMM) cells, however, significantly blocked NFATc1 expression and osteoclast differentiation by RANKL. Overexpression of NFATc1 further confirmed that NFATc1 is a key factor affected by salubrinal in osteoclast differentiation by RANKL. Unexpectedly, NFATc1 and c Fos mRNA expressions were not affected by salubrinal, implicating that NFATc1 expression is regulated at a translational stage. In support of this, salubrinal increased the phosphorylation of a translation factor eIF2 alpha, decreasing the global protein synthesis including NFATc1. In contrast, a phosphorylation mutant plasmid pLenti eIF2 alpha S51A restored RANKL induced NFATc1 expression and osteoclast differentiation even in the presence of salubrinal. Furthermore, knockdown of ATF4 significantly reduced salubrinal induced osteoblast differentiation as evidenced by decreased calcium accumulation and lowered expressions of the osteoblast differentiation markers, alkaline phosphatase and RANKL in MC3T3 E1 osteoblast cells. Salubrinal treatment to co cultured BMM and MC3T3 E1 cells also showed reduction of osteoclast differentiation. Finally, salubrinal efficiently blocked osteoporosis in mice model treated with RANKL as evidenced by elevated bone mineral density (BMD) and other osteoporosis factors. Collectively, our data indicate that salubrinal could affect the differentiation of both osteoblast and osteoclast, and be developed as an excellent anti osteoporosis drug. In addition, modulation of ATF4 and NFATc1 expressions through eIF2 alpha phosphorylation could be a valuable target for the treatment of osteoporosis. (C) 2012 Elsevier Inc. All rights reserved.
C1 [He, Long; Jang, Jae Hyuk; Sakchaisri, Krisada; Hwang, Joonsung; Cha Molstad, Hyun Joo; Kim, Kyung A.; Ryoo, In Ja; Lee, Hee Gu; Kim, Sun Ok; Soung, Nak Kyun; Ahn, Jong Seog; Kim, Bo Yeon] KRIBB, Ochang 363883, Cheongwon, South Korea.
   [Lee, Junwon] Pai Chai Univ, Dept Biomed Sci & Biotechnol, Taejon, South Korea.
   [Lee, Kyung Sang] NCI, Lab Metab, Ctr Canc Res, Bethesda, MD 20892 USA.
   [Kwon, Yong Tae] Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA.
   [Kwon, Yong Tae] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
   [Kwon, Yong Tae] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, World Class Univ WCU Program, Dept Mol Med Biopharm Sci, Seoul, South Korea.
   [Kwon, Yong Tae] Seoul Natl Univ, Coll Med, Seoul, South Korea.
   [Erikson, Raymond Leo] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Pai Chai
   University; National Institutes of Health (NIH)   USA; NIH National
   Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh; Seoul
   National University (SNU); Seoul National University (SNU); Harvard
   University
RP Ahn, JS (通讯作者)，KRIBB, Ochang 363883, Cheongwon, South Korea.
EM jsahn@kribb.re.kr; bykim@kribb.re.kr
RI ; Hwang, Joonsung/F 7607 2013; lee, Jaeho/KEH 5184 2024; Chang,
   Jaerak/E 8033 2015; Kim, Kyung A/ABG 6090 2020
OI Lee, junwon/0009 0006 9313 3612; He, Long/0000 0003 4721 9221; Lee,
   Kyung/0000 0001 8326 7162; 
FU World Class Institute (WCI) Program [WCI 2009 002]; Global R&D Center
   (GRDC) Program; World Class University [R31 2008 000 10103]; National
   Research Foundation of Korea (NRF) [2012 0003778]; Ministry of
   Education, Science and Technology (MEST); Technology Development Program
   for Agriculture and Forestry, Ministry for Agriculture, Forestry and
   Fisheries; KRIBB Research Initiative
FX This work was supported by the World Class Institute (WCI) Program (WCI
   2009 002), Global R&D Center (GRDC) Program, World Class University
   (R31 2008 000 10103) and in part by Basic Research Program
   (2012 0003778) of the National Research Foundation of Korea (NRF) funded
   by the Ministry of Education, Science and Technology (MEST), Technology
   Development Program for Agriculture and Forestry, Ministry for
   Agriculture, Forestry and Fisheries, and also supported by KRIBB
   Research Initiative Program.
CR Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   BISKOBING DM, 1995, J BONE MINER RES, V10, P1025
   Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092 8674(02)00642 6
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Gavilán MP, 2006, NEUROBIOL AGING, V27, P973, DOI 10.1016/j.neurobiolaging.2005.05.010
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lewerenz J, 2009, J BIOL CHEM, V284, P1106, DOI 10.1074/jbc.M807325200
   Liu J, 2012, J BONE MINER RES, V27, P331, DOI 10.1002/jbmr.549
   Manolagas S.C., ENDOCRINE REV, V31, P266
   Naidoo N, 2008, J NEUROSCI, V28, P6539, DOI 10.1523/JNEUROSCI.5685 07.2008
   Naidoo N, 2009, AGEING RES REV, V8, P150, DOI 10.1016/j.arr.2009.03.001
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Rachner T.D., LANCET, V377, P1276
   Reijonen S, 2008, EXP CELL RES, V314, P950, DOI 10.1016/j.yexcr.2007.12.025
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097 2765(01)00265 9
   Smith WW, 2005, HUM MOL GENET, V14, P3801, DOI 10.1093/hmg/ddi396
   Soung NK, 2006, MOL CELL BIOL, V26, P8316, DOI 10.1128/MCB.00671 06
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   TERZIOGLU M, 2007, NOVART FDN SYMP, V287, P208
   Terzioglu Mugen, 2007, Novartis Found Symp, V287, P197
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Wei JW, 2008, J CELL PHYSIOL, V217, P693, DOI 10.1002/jcp.21543
NR 31
TC 66
Z9 75
U1 0
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0898 6568
J9 CELL SIGNAL
JI Cell. Signal.
PD FEB
PY 2013
VL 25
IS 2
BP 552
EP 560
DI 10.1016/j.cellsig.2012.11.015
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 075XS
UT WOS:000313921100017
PM 23178987
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sun, XQ
   Su, J
   Bao, JG
   Peng, T
   Zhang, L
   Zhang, YY
   Yang, YZ
   Zhou, XB
AF Sun, Xiaoqiang
   Su, Jing
   Bao, Jiguang
   Peng, Tao
   Zhang, Le
   Zhang, Yuanyuan
   Yang, Yunzhi
   Zhou, Xiaobo
TI Cytokine combination therapy prediction for bone remodeling in tissue
   engineering based on the intracellular signaling pathway
SO BIOMATERIALS
LA English
DT Article
DE Bone tissue engineering; Bone remodeling; Cytokine combination therapy;
   Systems biology; Osteogenic differentiation; Signaling pathway
ID DELIVERY SYSTEM; DIFFERENTIATION; OSTEOBLAST; BMP 2; HYDROGELS; BIOLOGY;
   DESIGN
AB The long term performance of tissue engineered bone grafts is determined by a dynamic balance between bone regeneration and resorption. We proposed using embedded cytokine slow releasing hydrogels to tune this balance toward a desirable final bone density. In this study we established a systems biology model, and quantitatively explored the combinatorial effects of delivered cytokines from hydrogels on final bone density. We hypothesized that: 1) bone regeneration was driven by transcription factors Runx2 and Osterix, which responded to released cytokines, such as Wnt, BMP2, and TGF beta, drove the development of osteoblast lineage, and contributed to bone mass generation; and 2) the osteoclast lineage, on the other hand, governed the bone resorption, and communications between these two lineages determined the dynamics of bone remodeling. In our model. Intracellular signaling pathways were represented by ordinary differential equations, while the intercellular communications and cellular population dynamics were modeled by stochastic differential equations. Effects of synergistic cytokine combinations were evaluated by Loewe index and Bliss index. Simulation results revealed that the Wnt/BMP2 combinations released from hydrogels showed best control of bone regeneration and synergistic effects, and suggested optimal dose ratios of given cytokine combinations released from hydrogels to most efficiently control the long term bone remodeling. We revealed the characteristics of cytokine combinations of Wnt/BMP2 which could be used to guide the design of in vivo bone scaffolds and the clinical treatment of some diseases such as osteoporosis. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Zhang, Yuanyuan] Wake Forest Univ, Sch Med, Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USA.
   [Sun, Xiaoqiang; Su, Jing; Peng, Tao; Zhou, Xiaobo] Weill Cornell Med Coll, Methodist Hosp Res Inst, Dept Radiol, Houston, TX 77030 USA.
   [Sun, Xiaoqiang; Bao, Jiguang] Beijing Normal Univ, Sch Math Sci, Beijing 100875, Peoples R China.
   [Yang, Yunzhi] Stanford Univ, Dept Orthoped Surg, Stanford, CA 94305 USA.
   [Zhang, Le] Michigan Technol Univ, Dept Math Sci, Houghton, MI 49931 USA.
   [Zhang, Le] Southwest Univ, Coll Comp & Informat Sci, Chongqing 400715, Peoples R China.
C3 Wake Forest University; Houston Methodist; Cornell University; Beijing
   Normal University; Stanford University; Michigan Technological
   University; Southwest University   China
RP Zhang, YY (通讯作者)，Wake Forest Univ, Sch Med, Wake Forest Inst Regenerat Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM yzhang@wfubmc.edu; ypyang@stanford.edu; XZhou@tmhs.org
RI Zhang, Le/AAD 9104 2019; Su, Jing/B 3171 2013; Sun,
   Xiaoqiang/AAU 2148 2020
OI Zhang, Le/0000 0002 3708 1727; Su, Jing/0000 0003 4917 6173; Yang,
   Yunzhi/0000 0002 3891 0574; 
FU NIH [R01LM010185 03, U01HL111560 01, 1R01DE022676 01];  [Uo1
   CA166886 01];  [DODW81XWH 11 2 0168 P4];  [DODW81XWH 10 1 0966]
FX We would like to acknowledge the members of Translational Biosystems Lab
   in Cornell Medical School and Dr. Huiming Peng for the valuable
   discussions. This work was supported by Funding: NIH R01LM010185 03
   (Zhou), NIH U01HL111560 01 (Zhou), NIH 1R01DE022676 01 (Zhou), Uo1
   CA166886 01 (Zhou) and DODW81XWH 11 2 0168 P4 (Zhou & Yang) and
   DODW81XWH 10 1 0966 (Yang).
CR Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258
   Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744 7348.1939.tb06990.x
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   CHANG YS, 1994, CLIN MATER, V17, P181, DOI 10.1016/0267 6605(94)90034 5
   CHOU TC, 1976, J THEOR BIOL, V59, P253, DOI 10.1016/0022 5193(76)90169 7
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Davison A. C., 1997, Bootstrap Methods and their Application, Cambridge Series in Statistical and Probabilistic Mathematics, P11
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Fitzgerald JB, 2006, NAT CHEM BIOL, V2, P458, DOI 10.1038/nchembio817
   Gordeladze JO, 2010, ILAR J, V51, P42, DOI 10.1093/ilar.51.1.42
   Higham DJ, 2001, SIAM REV, V43, P525, DOI 10.1137/S0036144500378302
   Holmes MH, 2007, INTEGRATION PSYCHISC, P5
   Hughes FJ, 2006, PERIODONTOL 2000, V41, P48, DOI 10.1111/j.1600 0757.2006.00161.x
   Jacobs CR, 2010, ANNU REV BIOMED ENG, V12, P369, DOI 10.1146/annurev bioeng 070909 105302
   Jilka RL, 2003, MED PEDIATR ONCOL, V41, P182, DOI 10.1002/mpo.10334
   Kalfas I H, 2001, Neurosurg Focus, V10, pE1
   Kang YQ, 2011, BIOMATERIALS, V32, P6119, DOI 10.1016/j.biomaterials.2011.05.015
   Katare S, 2004, COMPUT CHEM ENG, V28, P2569, DOI 10.1016/j.compchemeng.2004.07.002
   Kempen DHR, 2008, BIOMATERIALS, V29, P3245, DOI 10.1016/j.biomaterials.2008.04.031
   Kim S, 2012, ACTA BIOMATER, V8, P1768, DOI 10.1016/j.actbio.2012.01.009
   Kim S, 2010, BIOMATERIALS, V31, P4157, DOI 10.1016/j.biomaterials.2010.01.139
   Klipp E, 2009, SYSTEMS BIOL TXB, P13
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Koutsopoulos S, 2012, J CONTROL RELEASE, V160, P451, DOI 10.1016/j.jconrel.2012.03.014
   Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010
   Lee JM, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000086
   Lee JM, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752 0509 4 29
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Mather W, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.068105
   Miyoshi K, 2008, J MED INVESTIG, V55, P216, DOI 10.2152/jmi.55.216
   Murray PJ, 2010, BIOPHYS J, V99, P716, DOI 10.1016/j.bpj.2010.05.016
   Nakashima A, 2005, J BIOL CHEM, V280, P37660, DOI 10.1074/jbc.M504612200
   Novák B, 2008, NAT REV MOL CELL BIO, V9, P981, DOI 10.1038/nrm2530
   O'Keefe RJ, 2011, TISSUE ENG PART B RE, V17, P389, DOI [10.1089/ten.teb.2011.0475, 10.1089/ten.TEB.2011.0475]
   Oksendal BK, 2003, STOCHASTIC DIFFERENT, P61
   Peng HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014750
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Sadr N, 2011, BIOMATERIALS, V32, P7479, DOI 10.1016/j.biomaterials.2011.06.034
   Sato MM, 2009, GENES CELLS, V14, P141, DOI 10.1111/j.1365 2443.2008.01258.x
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Schmierer B, 2008, P NATL ACAD SCI USA, V105, P6608, DOI 10.1073/pnas.0710134105
   Straetemans R, 2005, BIOMETRICAL J, V47, P299, DOI 10.1002/bimj.200410124
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tohmonda T, 2011, EMBO REP, V12, P451, DOI 10.1038/embor.2011.34
   Wei L, 2009, BIOMATERIALS, V30, P2606, DOI 10.1016/j.biomaterials.2009.01.006
   Yang JA, 2011, SOFT MATTER, V7, P868, DOI 10.1039/c0sm01011a
   Yavropoulou Maria P, 2007, Hormones (Athens), V6, P279
   Yilgor P, 2009, BIOMATERIALS, V30, P3551, DOI 10.1016/j.biomaterials.2009.03.024
NR 52
TC 48
Z9 55
U1 0
U2 50
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 2012
VL 33
IS 33
BP 8265
EP 8276
DI 10.1016/j.biomaterials.2012.07.041
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 028CS
UT WOS:000310401000008
PM 22910219
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Huang, CY
   Le, HHT
   Tsai, HC
   Tang, CH
   Yu, JH
AF Huang, Chun Yi
   Le, Huynh Hoai Thuong
   Tsai, Hsiao Chi
   Tang, Chih Hsin
   Yu, Jian Hong
TI The effect of low level laser therapy on osteoclast differentiation:
   Clinical implications for tooth movement and bone density
SO JOURNAL OF DENTAL SCIENCES
LA English
DT Article
DE Bone density; Low level laser therapy; Orthodontic tooth movement;
   Osteoclast cell
ID RANKL; RESORPTION; EXPRESSION; PATHWAYS; MMP 9
AB Background/purpose: Osteoclast differentiation is crucial for orchestrating both tooth movement and the maintenance of bone density. Therefore, the current study sought to explore the impact of low level laser therapy (LLLT) on osteoclast differentiation, functional gene expression, molecular signaling pathways, and orthodontic tooth movement in clinical settings. Materials and methods: The RAW 264.7 cell line served as the precursor for osteoclasts, and these cells underwent irradiation using a 808 nm LLLT. Osteoclast differentiation was assessed through tartrate  resistant acid phosphatase (TRAP) staining. Functional gene expression levels were evaluated using real time quantitative polymerase chain reaction (RT qPCR) while signaling molecules were examined through Western blot analysis. In the clinical study, 12 participants were enrolled. Their tooth movement was monitored using a TRIOS desktop scanner. Bone density measurements were conducted using Mimics software, which processed conebeam computed tomography (CBCT) images exported in Digital Imaging and Communications in Medicine (DICOM) format. Results: We found that LLLT effectively promoted receptor activator of nuclear factor  kB ligand (RANKL) dependent osteoclast differentiation and the expression of osteoclast functional genes, including matrix metallopeptidase 9 (MMP9), nuclear factor of activated T  cells cytoplasmic 1(NFATc1), tartrate  resistant acid phosphatase (TRAP) and cathepsin K (CTSK) in RAW264.7 cells. Clinically, the cumulative tooth movement over 90 days was significantly higher in the laser group than in the control group. Conclusion: Our research demonstrates that LLLT not only significantly promotes osteoclast differentiation but is also a valuable adjunct in orthodontic therapy. (c) 2024 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY  NC  ND license (http://creativecommons. org/licenses/by nc nd/4.0/).
C1 [Huang, Chun Yi; Yu, Jian Hong] China Med Univ, Coll Dent, Sch Dent, 91 Xueshi Rd, Taichung 40402, Taiwan.
   [Huang, Chun Yi; Yu, Jian Hong] China Med Univ, Med Ctr, Dept Orthodont, Taichung, Taiwan.
   [Le, Huynh Hoai Thuong; Tang, Chih Hsin] China Med Univ, Coll Med, Grad Inst Biomed Sci, 91 Xueshi Rd, Taichung 40402, Taiwan.
   [Tsai, Hsiao Chi] China Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Taichung, Taiwan.
   [Tsai, Hsiao Chi; Tang, Chih Hsin] China Med Univ, Sch Med, Dept Pharmacol, Col Med, Taichung, Taiwan.
   [Tang, Chih Hsin] Asia Univ, Coll Med & Hlth Sci, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital   Taiwan; China Medical University Taiwan;
   Asia University Taiwan
RP Yu, JH (通讯作者)，China Med Univ, Coll Dent, Sch Dent, 91 Xueshi Rd, Taichung 40402, Taiwan.; Tang, CH (通讯作者)，China Med Univ, Coll Med, Grad Inst Biomed Sci, 91 Xueshi Rd, Taichung 40402, Taiwan.
EM chtang@mail.cmu.edu.tw; kenkoyu@hotmail.com
RI Tang, Chih/O 5212 2015; Huang, Chunyi/ABB 9955 2021
CR Abid Mushriq F, 2021, J Orthod Sci, V10, P6, DOI 10.4103/jos.JOS_36_20
   Alam MK, 2023, APPL SCI BASEL, V13, DOI 10.3390/app13064035
   Aleksic V, 2010, LASER MED SCI, V25, P559, DOI 10.1007/s10103 010 0761 5
   Alhazmi YA, 2023, APPL SCI BASEL, V13, DOI 10.3390/app13148490
   AlQranei MS, 2020, J ORAL BIOSCI, V62, P123, DOI 10.1016/j.job.2020.02.002
   Barolet AC, 2023, PHOTOBIOMOD PHOTOMED, V41, P147, DOI 10.1089/photob.2022.0127
   Boyce BF, 2023, ENDOCRINOL METAB, V38, P504, DOI 10.3803/EnM.2023.501
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   Cruz DR, 2004, LASER SURG MED, V35, P117, DOI 10.1002/lsm.20076
   Domínguez A, 2015, LASER MED SCI, V30, P915, DOI 10.1007/s10103 013 1508 x
   Elango J, 2021, CYTOKINE, V144, DOI 10.1016/j.cyto.2021.155559
   Feng W, 2019, J ORAL BIOSCI, V61, P16, DOI 10.1016/j.job.2019.01.001
   Gabada D, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.46824
   Guo RZ, 2021, ORTHOD CRANIOFAC RES, V24, P165, DOI 10.1111/ocr.12421
   Hasegawa Y, 2020, Lung fibrosis: insights from the bench, pA2253
   Infante M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 018 1001 2
   Jeon HH, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081733
   Jivrajani SJ, 2020, INT ORTHOD, V18, P330, DOI 10.1016/j.ortho.2020.01.008
   Jung HJ, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040772
   Lampiasi N, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10020117
   Ma ZZ, 2019, INFLAMM RES, V68, P157, DOI 10.1007/s00011 018 1209 9
   Meng JH, 2018, AM J TRANSL RES, V10, P2901
   Milligan M, 2017, ARCH ORAL BIOL, V80, P62, DOI 10.1016/j.archoralbio.2017.03.016
   Mistry D, 2020, AM J ORTHOD DENTOFAC, V157, P444, DOI 10.1016/j.ajodo.2019.12.005
   Närhi L, 2022, EUR J ORTHODONT, V44, P377, DOI 10.1093/ejo/cjab070
   Nguyen J, 2020, J DEV BIOL, V8, DOI 10.3390/jdb8030012
   Niu Q, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1034050
   Omi M, 2022, GENESIS, V60, DOI 10.1002/dvg.23490
   Omi M, 2021, ORAL SCI INT, V18, P14, DOI 10.1002/osi2.1078
   Qian Y, 2010, J ORAL PATHOL MED, V39, P592, DOI 10.1111/j.1600 0714.2009.00882.x
   Ramírez DG, 2024, ODONTOLOGY, V112, P399, DOI 10.1007/s10266 023 00851 8
   Rashed F, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.648084
   Sabokbar A, 2016, CLIN REV ALLERG IMMU, V51, P16, DOI 10.1007/s12016 015 8523 6
   Sangle R, 2023, Med Nov Technol Devices, V20
   Sedky Y, 2019, Laser Dent Sci, V3, P99, DOI DOI 10.1007/S41547 019 00055 W
   Shin Sang Hun, 2016, Maxillofac Plast Reconstr Surg, V38, P48, DOI 10.1186/s40902 016 0095 8
   Sicari F, 2023, CHILDREN BASEL, V10, DOI 10.3390/children10101691
   Song JM, 2021, APPL SCI BASEL, V11, DOI 10.3390/app11125360
   Suzuki SS, 2016, J BIOPHOTONICS, V9, P1222, DOI 10.1002/jbio.201600016
   Tonetti MS, 2017, J CLIN PERIODONTOL, V44, pS135, DOI 10.1111/jcpe.12681
   Tsolakis IA, 2023, BIOENGINEERING BASEL, V10, DOI 10.3390/bioengineering10111275
   Xu HH, 2020, CHEM BIOL INTERACT, V331, DOI 10.1016/j.cbi.2020.109235
   Xu SG, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.726361
   Zhao QX, 2007, FRONT BIOSCI LANDMRK, V12, P2519, DOI 10.2741/2252
   Zheng JY, 2021, BMC ORAL HEALTH, V21, DOI 10.1186/s12903 021 01684 z
   Zhu GC, 2022, INT J BIOL SCI, V18, P5522, DOI 10.7150/ijbs.72211
NR 46
TC 0
Z9 1
U1 1
U2 2
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N 412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1991 7902
EI 2213 8862
J9 J DENT SCI
JI J. Dental Sci.
PD JUL
PY 2024
VL 19
IS 3
BP 1452
EP 1460
DI 10.1016/j.jds.2024.03.023
EA JUN 2024
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA XE6Y0
UT WOS:001260058600001
PM 39035342
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shi, JY
   Cui, XH
   Wang, Y
   Song, YL
   Tang, XD
   Fan, JW
   Xu, HY
   Zhu, MM
   Yu, WL
   Yu, L
AF Shi, Jinyang
   Cui, XinHua
   Wang, Yang
   Song, Yuli
   Tang, Xudong
   Fan, Junwen
   Xu, Hongyue
   Zhu, Mingmei
   Yu, Wanlu
   Yu, Lu
TI Study on the Mechanism of the Combination of Methotrexate and
   Leflunomide in the Treatment of Rheumatoid Arthritis Based on Network
   Pharmacology, Molecular Docking, and in vitro Experimental
   Verification
SO COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
LA English
DT Article; Early Access
DE Combination; rheumatoid arthritis; methotrexate and leflunomide;
   mechanism
ID HORMONE RELATED PROTEIN; COLLAGEN INDUCED ARTHRITIS;
   EPIDERMAL GROWTH FACTOR; PARATHYROID HORMONE; DISEASE ACTIVITY; JOINT
   INFLAMMATION; SYNOVIAL FLUID; BONE EROSION; DOUBLE BLIND; EXPRESSION
AB Background To date, disease modifying antirheumatic drugs (DMARDs) are widely used as the primary first line treatment option for patients with rheumatoid arthritis (RA), and the curative effect of methotrexate (MTX) and leflunomide (LEF; MTX + LEF) is greater than that of single agent MTX therapy, but the synergistic mechanism of MTX + LEF is unclear. Methods First, we explored the mechanism of action of MTX + LEF in RA through network pharmacology and molecular docking. Venn diagram analysis revealed 97 overlapping gene targets of MTX + LEF RA and STRING, along with Cytoscape plug in MOCDE and cytoHubba; and GO enrichment analysis revealed that the functions of 97 synergistic targets were related to 123 molecular functions (MF), 63 cell components (CC), and 1,068 biological processes (BP). The Cytoscape plug in ClueGO demonstrated that these targets were enriched in KEGG pathways of 52 terms, whereas 9 pivotal genes were mainly involved in the signaling pathways of estrogen, Ras, Rap1, PI3K Akt, relaxin, TNF, AMPK, FoxO, prolactin, IL 17, and adherens junction. Finally, CETSA and DARTS validated the direct binding of MTX or LEF to the selected target proteins EGFR, PPARG, MMP9, and SRC in RAW264.7 cells. Results We identified 292 MTX targets and 247 LEF targets from 7 databases. Furthermore, 2,814 potential targets of RA were identified by merging 1,925 targets from 7 databases and 999 differentially expressed genes (DEGs) between normal controls and patients with RA extracted from 5 GEO databases. Nine pivotal genes, ESR1, ALB, CASP3, EGFR, HSP90AA1, SRC, MMP9, PPARG, and IGF1, were identified. Molecular docking verified that both MTX and LEF strongly bind to most of the 9 pivotal proteins except ESR1 and IGF1. Conclusion These results contribute to our understanding of the enhancement mechanism of MTX combined with LEF and provide a targeted basis for the clinical treatment of RA.
C1 [Shi, Jinyang; Cui, XinHua; Wang, Yang; Xu, Hongyue; Zhu, Mingmei; Yu, Wanlu; Yu, Lu] First Hosp Jilin Univ, Inst Zoonosis, Coll Vet Med, State Key Lab Diag & Treatment Severe Zoonot Infec, Changchun, Peoples R China.
   [Song, Yuli] Shenzhen Liyunde Biotechnol Co Ltd, Shenzhen 518057, Peoples R China.
   [Tang, Xudong] Tsinghua Univ Shenzhen, Res Inst, Key Lab New Drug Res TCM, Shenzhen 518057, Peoples R China.
   [Fan, Junwen] Beijing Ctr Anim Dis Control & Prevent, Beijing 102629, Peoples R China.
C3 Jilin University; Tsinghua University; Tsinghua Shenzhen International
   Graduate School
RP Yu, L (通讯作者)，First Hosp Jilin Univ, Inst Zoonosis, Coll Vet Med, State Key Lab Diag & Treatment Severe Zoonot Infec, Changchun, Peoples R China.
RI fan, junwen/JJD 4118 2023
OI Wang, Yang/0000 0001 8055 9522
FU National Key Research and Development Program of China [2021YFC2600200];
   Science and Technology Research Project of the Jilin Provincial
   Department of Education [JKH20211179KJ, 2016444]; Jilin Provincial
   Nature Science Foundation of the Jilin Provincial Department of Science
   and Technology [20210101341JC]; National Natural Science Foundation of
   China [81801972]
FX This work was supported by the National Key Research and Development
   Program of China (2021YFC2600200), the Science and Technology Research
   Project of the Jilin Provincial Department of Education (JKH20211179KJ;
   2016444), and the Jilin Provincial Nature Science Foundation of the
   Jilin Provincial Department of Science and Technology (20210101341JC).
   It was also supported by the National Natural Science Foundation of
   China (No. 81801972)
CR Aarvak T, 1999, J IMMUNOL, V162, P1246
   Abreu JRF, 2010, ARTHRITIS RHEUM US, V62, P3289, DOI 10.1002/art.27656
   ADACHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1088, DOI 10.1016/0006 291X(90)90978 V
   Adam O, 2003, RHEUMATOL INT, V23, P27, DOI 10.1007/s00296 002 0234 7
   Adami G, 2016, CALCIFIED TISSUE INT, V99, P360, DOI 10.1007/s00223 016 0161 3
   Aletaha D, 2011, ARTHRITIS RHEUM US, V63, P3702, DOI 10.1002/art.30634
   Amberger JS, 2015, NUCLEIC ACIDS RES, V43, pD789, DOI 10.1093/nar/gku1205
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201
   Bredemeier M, 2021, J RHEUMATOL, V48, P1519, DOI 10.3899/jrheum.201248
   Breedveld FC, 2000, ANN RHEUM DIS, V59, P841, DOI 10.1136/ard.59.11.841
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   BRENNAN FM, 1989, LANCET, V2, P244
   Brown PM, 2016, NAT REV RHEUMATOL, V12, P731, DOI 10.1038/nrrheum.2016.175
   Butler DM, 1995, EUR CYTOKINE NETW, V6, P225
   Byeon SE, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/512926
   Byun HS, 2008, RHEUMATOLOGY, V47, P301, DOI 10.1093/rheumatology/kem368
   Cannon GW, 2004, J RHEUMATOL, V31, P1906
   Chabaud M, 1999, ARTHRITIS RHEUM US, V42, P963, DOI 10.1002/1529 0131(199905)42:5<963::AID ANR15>3.0.CO;2 E
   Chatzidionysiou K, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen 2019 000993
   Chen JF, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1111799
   Chen L, 2017, J ETHNOPHARMACOL, V202, P12, DOI 10.1016/j.jep.2017.03.005
   Chen WJ, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02552 w
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752 0509 8 S4 S11
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   Cronstein BN, 1996, ARTHRITIS RHEUM US, V39, P1951, DOI 10.1002/art.1780391203
   Crotti TN, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4088
   Davis AP, 2017, NUCLEIC ACIDS RES, V45, pD972, DOI 10.1093/nar/gkw838
   Davis JP, 1996, BIOCHEMISTRY US, V35, P1270, DOI 10.1021/bi952168g
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   FUNK JL, 1993, J CLIN INVEST, V92, P2546, DOI 10.1172/JCI116864
   Gandjbakhch F, 2011, J RHEUMATOL, V38, P2039, DOI 10.3899/jrheum.110421
   Gompels LL, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3480
   Gu SZ, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 71030 w
   HAWORTH C, 1991, EUR J IMMUNOL, V21, P2575, DOI 10.1002/eji.1830211039
   Hewett M, 2002, NUCLEIC ACIDS RES, V30, P163, DOI 10.1093/nar/30.1.163
   Hong SJ, 2005, TOXICON, V46, P39, DOI 10.1016/j.toxicon.2005.03.015
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Huang C, 2019, MED SCI MONITOR, V25, P5589, DOI 10.12659/MSM.918250
   Huang CC, 2021, CELLS BASEL, V10, DOI 10.3390/cells10082168
   Ilchovska D, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102741
   Ishizuka M, 2016, ANN SURG ONCOL, V23, P900, DOI 10.1245/s10434 015 4948 7
   Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138
   Ji KY, 2023, BRIEF BIOINFORM, V24, DOI 10.1093/bib/bbad014
   Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169
   Kim KS, 2011, RHEUMATOL INT, V31, P543, DOI 10.1007/s00296 010 1592 1
   Kirkham BW, 2006, ARTHRITIS RHEUM, V54, P1122, DOI 10.1002/art.21749
   Kirsch BM, 2005, ARTHRITIS RES THER, V7, pR694, DOI 10.1186/ar1727
   Koenders MI, 2005, AM J PATHOL, V167, P141, DOI 10.1016/S0002 9440(10)62961 6
   Kop EN, 2005, ARTHRITIS RHEUM US, V52, P442, DOI 10.1002/art.20788
   KREMER JM, 1995, ARTHRITIS RHEUM, V38, P1194, DOI 10.1002/art.1780380904
   Kremer JM, 2002, ANN INTERN MED, V137, P726, DOI 10.7326/0003 4819 137 9 200211050 00007
   Kremer JM, 1999, SEMIN ARTHRITIS RHEU, V29, P14, DOI 10.1016/S0049 0172(99)80034 1
   Kremer JM, 1995, BRIT J RHEUMATOL, V34, P26
   Krüger K, 2014, Z RHEUMATOL, V73, P77, DOI 10.1007/s00393 013 1301 z
   Krüger K, 2005, Z RHEUMATOL, V64, P96, DOI 10.1007/s00393 005 0694 8
   Kurkó J, 2013, CLIN REV ALLERG IMMU, V45, P170, DOI 10.1007/s12016 012 8346 7
   Lee YH, 2014, GENET TEST MOL BIOMA, V18, P341, DOI 10.1089/gtmb.2013.0503
   Li GQ, 2013, MOL IMMUNOL, V53, P227, DOI 10.1016/j.molimm.2012.08.018
   Li XF, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12570 6
   Liang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12163 z
   Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106
   Lorenzo Gomez I., 2020, Osteoarthritis Cartilage, V2, P586
   Lubberts E, 2004, ARTHRITIS RHEUM US, V50, P650, DOI 10.1002/art.20001
   Luo J, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920 020 00740 x
   Malaviya AN, 2016, CURR RHEUMATOL REV, V12, P168, DOI 10.2174/1573397112666160824151801
   Malemud CJ, 2015, FUTURE MED CHEM, V7, P1137, DOI [10.4155/FMC.15.55, 10.4155/fmc.15.55]
   MCCAULEY LK, 1992, ENDOCRINOLOGY, V130, P300, DOI 10.1210/en.130.1.300
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   McInnes IB, 2016, NAT REV RHEUMATOL, V12, P63, DOI 10.1038/nrrheum.2015.171
   Metawi SA, 2011, CLIN RHEUMATOL, V30, P1201, DOI 10.1007/s10067 011 1737 y
   Miyazaki Tsuyoshi, 2006, Mod Rheumatol, V16, P68
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Morel JCM, 2002, J BIOL CHEM, V277, P34679, DOI 10.1074/jbc.M206337200
   Nakayama H, 2012, RHEUMATOL INT, V32, P151, DOI 10.1007/s00296 010 1598 8
   Niu XJ, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.862105
   ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Oh K, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10080703
   Ormseth MJ, 2014, ARTHRITIS RHEUMATOL, V66, P2331, DOI 10.1002/art.38686
   Qu Y, 2016, ONCOTARGET, V7, P74217, DOI 10.18632/oncotarget.12487
   Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168 9525(97)01103 7
   Sahebari M, 2016, BIOL TRACE ELEM RES, V171, P237, DOI 10.1007/s12011 015 0501 6
   Salliot C, 2009, ANN RHEUM DIS, V68, P1100, DOI 10.1136/ard.2008.093690
   Lacativa PGS, 2010, ARQ BRAS ENDOCRINOL, V54, P123, DOI 10.1590/S0004 27302010000200007
   Sapir Koren R, 2017, BONE, V103, P102, DOI 10.1016/j.bone.2017.06.020
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Scott DL, 2015, BMJ BRIT MED J, V350, DOI 10.1136/bmj.h1046
   Shen P, 2020, J CELL MOL MED, V24, P12234, DOI 10.1111/jcmm.15803
   Shiomi A, 2014, J IMMUNOL, V193, P849, DOI 10.4049/jimmunol.1303255
   SHIOZAWA S, 1989, ANN RHEUM DIS, V48, P820, DOI 10.1136/ard.48.10.820
   Sidhu H, 2021, LIFE SCI, V282, DOI 10.1016/j.lfs.2021.119802
   Singh S, 2016, INTERDISCIP SCI, V8, P122, DOI 10.1007/s12539 015 0108 9
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis 2016 210715
   Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140 6736(98)09403 3
   Strand V, 1999, ARCH INTERN MED, V159, P2542, DOI 10.1001/archinte.159.21.2542
   Sumariwalla PF, 2008, ARTHRITIS RHEUM US, V58, P3071, DOI 10.1002/art.23885
   Sun D, 2018, CURR MED SCI, V38, P70, DOI 10.1007/s11596 018 1848 7
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Taha EA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184588
   Tominag T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167967
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   TSUKAZAKI T, 1995, CALCIFIED TISSUE INT, V57, P196, DOI 10.1007/BF00310258
   TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wang ZQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.755844
   Weinblatt ME, 1999, ARTHRITIS RHEUM US, V42, P1322, DOI 10.1002/1529 0131(199907)42:7<1322::AID ANR4>3.0.CO;2 P
   Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401
   Wijesinghe H, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1673 3
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xue ML, 2014, RHEUMATOLOGY, V53, P2270, DOI 10.1093/rheumatology/keu254
   Yamane S, 2008, J INFLAMM LOND, V5, DOI 10.1186/1476 9255 5 5
   Yang SQ, 2021, WIRES COMPUT MOL SCI, V11, DOI 10.1002/wcms.1504
   Yang YH, 2015, CELL PHYSIOL BIOCHEM, V36, P2025, DOI 10.1159/000430170
   Yu MB, 2018, INFLAMMOPHARMACOLOGY, V26, P699, DOI 10.1007/s10787 018 0459 z
   Zavareh R., 2020, Cell Chem. Biol, V10, P5
   Zhang AH, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752 0509 6 20
   Zhang LL, 2022, EUR J PHARMACOL, V919, DOI 10.1016/j.ejphar.2022.174769
   Zhang P., 2016, Xi bao yu fen zi mian yi xue za zhi, V32, P361
   Zhang W, 2018, NAT GENET, V50, P613, DOI 10.1038/s41588 018 0091 2
   Zhao J, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/9980981
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zhu JF, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/1056708
   Ziolkowska N, 2000, J IMMUNOL, V164, P2832, DOI 10.4049/jimmunol.164.5.2832
NR 125
TC 1
Z9 1
U1 0
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1386 2073
EI 1875 5402
J9 COMB CHEM HIGH T SCR
JI Comb. Chem. High Throughput Screen
PD 2024 JUN 20
PY 2024
DI 10.2174/0113862073285626240604093210
EA JUN 2024
PG 17
WC Biochemical Research Methods; Chemistry, Applied; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA WE3U3
UT WOS:001253161900001
PM 38910477
DA 2025 08 17
ER

PT J
AU Xiong, ZY
   Yang, HW
AF Xiong, Zhongyu
   Yang, Huawen
TI Unraveling the Pharmacological Intricacies of Kurarinone in
   Osteoporosis: Insights from a Network Pharmacology Approach
SO PHARMACOGNOSY MAGAZINE
LA English
DT Article
DE Kurarinone; osteoporosis; osteoclastogenesis; network pharmacology;
   molecular docking
AB Background Kurarinone, a compound derived from Sophora flavescens, has been widely studied for its anti inflammatory properties, as well as its potential in treating autoimmune encephalomyelitis and inflammation related musculoskeletal diseases. However, the specific molecular mechanisms by which Kurarinone affects osteoporosis are still not fully understood.Objectives To explore the potential pharmacological targets and molecular mechanisms underlying the therapeutic effects of Kurarinone on osteoporosis.Materials and Methods To confirm the impact of Kurarinone on osteoporosis, network pharmacology techniques were used to analyze the mechanisms of Kurarinone on osteoporosis. Molecular docking was performed to examine the binding of Kurarinone to key targets involved in osteoporosis. Then, we conducted TRAcP staining, quantitative polymerase chain reaction (q PCR), and Western blot experiments to validate the results.Results Utilizing network pharmacology approaches coupled with docking analysis, our investigation revealed that Kurarinone was involved in the osteoclast differentiation and MAPK signaling pathways. According to in vitro experiments, Kurarinone was found to inhibit osteoclast formation through the p38/MAPK pathway.Conclusion This study suggests that Kurarinone may treat osteoporosis by inhibiting MAPK phosphorylation and inhibiting osteoclast formation.
C1 [Xiong, Zhongyu] Chongqing Med Univ, Affiliated Hosp 1, Dept Anaesthesiol, Chongqing, Peoples R China.
   [Yang, Huawen] Chongqing Med Univ, Affiliated Hosp 1, Dept Oral & Maxillofacial Surg, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University
RP Yang, HW (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Oral & Maxillofacial Surg, Chongqing 400016, Peoples R China.
EM 345198910@qq.com
RI 熊, 中玉/JDD 4653 2023
OI Xiong, Zhongyu/0000 0001 8996 839X
CR [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   He JB, 2023, J ADV RES, V53, P235, DOI 10.1016/j.jare.2023.01.003
   Jiang C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.684007
   Jiao XY, 2021, COMPUT BIOL CHEM, V90, DOI 10.1016/j.compbiolchem.2020.107402
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Li ZC, 2022, J ETHNOPHARMACOL, V297, DOI 10.1016/j.jep.2022.115500
   Liu CL, 2023, BIOMED PHARMACOTHER, V166, DOI 10.1016/j.biopha.2023.115392
   Ma C, 2024, INT IMMUNOPHARMACOL, V127, DOI 10.1016/j.intimp.2023.111322
   Ma C, 2023, INT IMMUNOPHARMACOL, V123, DOI 10.1016/j.intimp.2023.110572
   Mo L, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/3921570
   Mo L, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.950030
   Muhammad A, 2018, BIOMED PHARMACOTHER, V107, P571, DOI 10.1016/j.biopha.2018.08.018
   Nishikawa S, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9090842
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xie L, 2018, INT IMMUNOPHARMACOL, V62, P227, DOI 10.1016/j.intimp.2018.06.022
   Ye HL, 2023, PHARMACOGN MAG, V19, P448, DOI 10.1177/09731296221137415
   Zhang JH, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 18287 5
   Zhang RZ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00123
NR 21
TC 0
Z9 0
U1 3
U2 17
PU SAGE PUBLICATIONS INDIA  PVT LTD
PI NEW DELHI
PA B 1 I 1 MOHAN CO OPERATIVE INDUSTRIAL AREA, MATHURA RD, POST BAG NO 7,
   NEW DELHI 110 044, INDIA
SN 0973 1296
EI 0976 4062
J9 PHARMACOGN MAG
JI Pharmacogn. Mag.
PD DEC
PY 2024
VL 20
IS 4
BP 1350
EP 1358
DI 10.1177/09731296241259563
EA JUN 2024
PG 9
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA K6K1V
UT WOS:001252358900001
OA hybrid
DA 2025 08 17
ER

PT J
AU De Luna Bertos, E
   Ramos Torrecillas, J
   García Martínez, O
   Guildford, A
   Santin, M
   Ruiz, C
AF De Luna Bertos, E.
   Ramos Torrecillas, J.
   Garcia Martinez, O.
   Guildford, A.
   Santin, M.
   Ruiz, C.
TI Therapeutic Doses of Nonsteroidal Anti Inflammatory Drugs Inhibit
   Osteosarcoma MG 63 Osteoblast Like Cells Maturation, Viability, and
   Biomineralization Potential
SO SCIENTIFIC WORLD JOURNAL
LA English
DT Article
ID ANTIGENIC PHENOTYPE; CYCLOOXYGENASE 2 INHIBITORS; PHAGOCYTIC CAPACITY;
   IFN GAMMA; DIFFERENTIATION; PROLIFERATION; EXPRESSION; IBUPROFEN;
   ADHESION; GROWTH
AB Nonsteroidal anti inflammatory drugs (NSAIDs) are frequently used to reduce pain and inflammation. However, their effect on bone metabolisms is not well known, and results in the literature are contradictory. The present study focusses on the effect of dexketoprofen, ketorolac, metamizole, and acetylsalicylic acid, at therapeutic doses, on different biochemical and phenotypic pathways in human osteoblast like cells. Osteoblasts (MG 63 cell line) were incubated in culture medium with 1 10 mu M of dexketoprofen, ketorolac, metamizole, and acetylsalicylic acid. Flow cytometry was used to study antigenic profile and phagocytic activity. The osteoblastic differentiation was evaluated by mineralization and synthesis of collagen fibers by microscopy and alkaline phosphatase activity (ALP) by spectrophotometric assay. Short term treatment with therapeutic doses of NSAIDs modulated differentiation, antigenic profile, and phagocyte activity of osteoblast like cells. The treatment reduced ALP synthesis and matrix mineralization. However, nonsignificant differences were observed on collagen syntheses after treatments. The percentage of CD54 expression was increased with all treatments. CD80, CD86, and HLA DR showed a decreased expression, which depended on NSAID and the dose applied. The treatments also decreased phagocyte activity in this cellular population. The results of this paper provide evidences that NSAIDs inhibit the osteoblast differentiation process thus reducing their ability to produce new bone mineralized extracellular matrix.
C1 [De Luna Bertos, E.; Ramos Torrecillas, J.; Garcia Martinez, O.; Ruiz, C.] Univ Granada, Fac Hlth Sci, Dept Nursing, E 18071 Granada, Spain.
   [Guildford, A.; Santin, M.] Univ Brighton, Sch Pharm & Biomol Sci, Brighton BN2 4G1, E Sussex, England.
   [Ruiz, C.] Univ Granada, Fac Med, Inst Neurosci, Granada 18100, Spain.
C3 University of Granada; University of Brighton; University of Granada
RP Ruiz, C (通讯作者)，Univ Granada, Fac Hlth Sci, Dept Nursing, Ave Madrid S N, E 18071 Granada, Spain.
EM crr@ugr.es
RI Ruiz, Concepcion/L 2808 2014; García Martínez, Olga/L 2782 2014;
   Ramos Torrecillas, Javier/F 3746 2012; Garcia Martinez,
   Olga/L 2782 2014; De Luna Bertos, Elvira/F 8544 2016; Concepcion,
   Ruiz/L 2808 2014
OI Ramos Torrecillas, Javier/0000 0002 6631 7866; Garcia Martinez,
   Olga/0000 0003 1912 4639; De Luna Bertos, Elvira/0000 0002 4381 5942;
   Santin, Matteo/0000 0002 5260 7088; Concepcion, Ruiz/0000 0003 4332 6812
FU BIO277 research group (Junta de Andalucia); Department of Nursing,
   Faculty of Health Sciences, University of Granada; research group
   Brighton Studies in Tissue mimicry and Aided Regeneration (BrightSTAR),
   School of Pharmacy & Biomolecular Sciences, University of Brighton
FX This study was supported by the BIO277 research group (Junta de
   Andalucia), by the Department of Nursing, Faculty of Health Sciences,
   University of Granada and by the research group Brighton Studies in
   Tissue mimicry and Aided Regeneration (BrightSTAR), School of Pharmacy &
   Biomolecular Sciences, University of Brighton.
CR Abukawa H, 2009, J ORAL MAXIL SURG, V67, P2412, DOI 10.1016/j.joms.2009.05.434
   Arpornmaeklong P, 2008, INT J ORAL MAX IMPL, V23, P1071
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Boursinos LA, 2009, J MUSCULOSKEL NEURON, V9, P44
   Bufan B, 2009, INT IMMUNOPHARMACOL, V9, P910, DOI 10.1016/j.intimp.2009.03.016
   De Luna Bertos E, 2012, SCI WORLD J, DOI 10.1100/2012/834246
   Díaz Rodríguez L, 2009, ANN NY ACAD SCI, V1173, pE46, DOI 10.1111/j.1749 6632.2009.04950.x
   Díaz Rodríguez L, 2012, J BONE MINER METAB, V30, P554, DOI 10.1007/s00774 012 0356 2
   Díaz Rodríguez L, 2012, BIOL RES NURS, V14, P98, DOI 10.1177/1099800411398933
   Díaz Rodríguez L, 2010, ACTA PHARMACOL SIN, V31, P1495, DOI 10.1038/aps.2010.129
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Gajraj NM, 2003, REGION ANESTH PAIN M, V28, P456, DOI 10.1016/j.rapm.2003.09.001
   García Martínez O, 2006, BIOSCIENCE REP, V26, P39, DOI 10.1007/s10540 006 9006 z
   García Martínez O, 2011, ARCH ORAL BIOL, V56, P317, DOI 10.1016/j.archoralbio.2010.10.018
   Gerstenfeld LC, 2007, J BONE JOINT SURG AM, V89A, P114, DOI 10.2106/JBJS.F.00495
   Hackstein H, 2001, J IMMUNOL, V166, P7053, DOI 10.4049/jimmunol.166.12.7053
   Ing SW, 2011, NUTR REV, V69, P123, DOI 10.1111/j.1753 4887.2011.00376.x
   Manzano Moreno FJ, 2013, CLIN ORAL INVEST, V17, P1349, DOI 10.1007/s00784 012 0811 4
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Krischak GD, 2007, ARCH ORTHOP TRAUM SU, V127, P453, DOI 10.1007/s00402 007 0288 9
   Lisignoli G, 2004, J CELL PHYSIOL, V198, P388, DOI 10.1002/jcp.10427
   Lumawig JMT, 2009, SPINE J, V9, P343, DOI 10.1016/j.spinee.2008.06.455
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Nogueira GT, 2012, LASER MED SCI, V27, P1189, DOI 10.1007/s10103 011 1035 6
   Pape HC, 2010, J ORTHOP TRAUMA, V24, P522, DOI 10.1097/BOT.0b013e3181ed1361
   Pérez E, 2006, BIOSCIENCE REP, V26, P281, DOI 10.1007/s10540 006 9022 z
   Pountos I, 2012, SCI WORLD J, DOI 10.1100/2012/606404
   Reyes Botella C, 2002, CELL PHYSIOL BIOCHEM, V12, P359, DOI 10.1159/000067906
   Reyes Botella C, 2000, J PERIODONTOL, V71, P614, DOI 10.1902/jop.2000.71.4.614
   Rifas L, 2003, J CELL BIOCHEM, V88, P650, DOI 10.1002/jcb.10436
   Ruiz C, 2007, J BONE MINER METAB, V25, P286, DOI 10.1007/s00774 007 0767 7
   Ruiz C, 2003, CELL PHYSIOL BIOCHEM, V13, P309, DOI 10.1159/000074546
   Sandrini E, 2005, J BIOMED MATER RES B, V73B, P392, DOI 10.1002/jbm.b.30241
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Stanley KT, 2006, J BONE MINER RES, V21, P29, DOI 10.1359/JBMR.051004
   Vandrovcová M, 2011, PHYSIOL RES, V60, P403, DOI 10.33549/physiolres.932045
   Vuolteenaho K, 2008, BASIC CLIN PHARMACOL, V102, P10, DOI 10.1111/j.1742 7843.2007.00149.x
   Xu Z, 2006, CANCER RES, V66, P6657, DOI 10.1158/0008 5472.CAN 05 3624
   Zhang J. M, NEUROSCIENCE, V105, P663, DOI [10.1016/s0306 4522(01)00206 8, DOI 10.1016/S0306 4522(01)00206 8]
NR 39
TC 31
Z9 34
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1537 744X
J9 SCI WORLD J
JI Sci. World J.
PY 2013
AR 809891
DI 10.1155/2013/809891
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 226HT
UT WOS:000325026700001
PM 24170983
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Zhang, SA
   Sun, LJ
   Sun, LL
   Zhang, WY
   Dong, R
AF Zhang, Shihan
   Sun, Lijun
   Sun, Lili
   Zhang, Wenyi
   Dong, Rui
TI Analysis of the effect of zoledronic acid on gene differences in rat jaw
SO JOURNAL OF STOMATOLOGY ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
DE Bisphosphonate related osteonecrosis of the; jaw; Zoledronic acid; Bone
   disease; RNA seq
ID INDUCED OSTEOCLAST DIFFERENTIATION; IN VITRO; BISPHOSPHONATES; BONE;
   PAMIDRONATE; EXPRESSION; THERAPY
AB Background: With the widespread use of bisphosphonates, there are more and more complications about bisphosphonates, bisphosphonate related osteonecrosis of the jaw is one.In the past ten years, there have been many studies on the mechanism of bisphosphonate associated jaw necrosis.
   Objective: To investigate the influence and analysis of zoledronic acid on gene differences in rat jaw.
   Methods: Six Sprague Dawley female rats were randomly divided into control group (n = 3) and experimental group (n = 3). The experimental group received zoledronic acid injection for 12 weeks (dose of 0.2 mg / kg, 3 times a week).Control groups were injected with normal saline for 12 weeks. All rats were subjected to left mandibular first molar extraction 12 weeks later.After 8 weeks of tooth extraction, all rats were sacrificed and the mandible was removed.RNA seq was used to analyze differential gene changes in all mandibles. Bio informatics analysis of differential genes.
   Results: Compared with the two rat groups, there were 2,830 different genes, including 1,001 upregulated genes and 1,829 down regulated genes. Gene Ontology analysis revealed that the upregulated genes were mainly associated with immune related pathways. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis revealed that Hedgehog signaling pathway, Notch signaling pathway and Hippo signal ing pathway were associated with upregulated genes. After the Gene Set Enrichment Analysis, the Gene Ontology analysis showed that 2559 / 6588 gene sets are upregulated in phenotype experimental group,and 342 gene sets with p <0.05. The Kyoto Encyclopedia of Genes and Genomes analysis revealed that 95 / 316 gene sets are upregulated in phenotype experimental group, and four gene sets(Notch pathway, other types of O glycan biosynthesis, ovarian steridogenesis and Hippo pathway) with p <0.05.
   Conclusions: Changes in differential genes are mainly related to immune related processes and pathways, and pathways related to bone metabolism. The up regulation of some genes can promote the progress of Bisphosphonate related osteonecrosis of the jaw. (c) 2022 Elsevier Masson SAS. All rights reserved.
C1 [Zhang, Shihan; Sun, Lijun; Sun, Lili; Zhang, Wenyi; Dong, Rui] Tianjin Med Univ, Stomatol Hosp, Dept Oral & Maxillofacial Surg, Tianjin, Peoples R China.
C3 Tianjin Medical University
RP Zhang, WY (通讯作者)，Tianjin Med Univ, Hosp Stomatol, 12 Observ Rd, Tianjin 300070, Peoples R China.
EM zhangwen1228@163.com
FU Tianjin Municipal University Science and Technology Development Fund
   Project [2019KJ174]
FX This study was supported by the Tianjin Municipal University Science and
   Technology Development Fund Project (grant 2019KJ174).
CR Aoyama E, 2015, BONE, V73, P242, DOI 10.1016/j.bone.2014.12.058
   Bae S, 2014, INT J MOL MED, V34, P559, DOI 10.3892/ijmm.2014.1802
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Ballhause TM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031325
   Canalis E, 2018, OSTEOPOROSIS INT, V29, P2611, DOI 10.1007/s00198 018 4694 3
   Chakravorty N, 2014, CLIN ORAL IMPLAN RES, V25, P475, DOI 10.1111/clr.12178
   Gralow JR, 2020, JNCI J NATL CANCER I, V112, P698, DOI 10.1093/jnci/djz215
   Hagelauer N, 2015, CLIN ORAL INVEST, V19, P139, DOI 10.1007/s00784 014 1219 0
   Hinson AM, 2014, INT J DENT, V2014, DOI 10.1155/2014/452737
   Hovav AH, 2020, J DENT RES, V99, P498, DOI 10.1177/0022034520908839
   Imai Y, 2009, ANN NY ACAD SCI, V1173, pE31, DOI 10.1111/j.1749 6632.2009.04954.x
   Jin HM, 2015, ARTHRITIS RHEUMATOL, V67, P2639, DOI 10.1002/art.39244
   Kazmers NH, 2015, BONE, V81, P524, DOI 10.1016/j.bone.2015.09.002
   Li CL, 2017, NAT CELL BIOL, V19, P106, DOI 10.1038/ncb3464
   Lorenzo Pouso AI, 2020, J ORAL PATHOL MED, V49, P190, DOI 10.1111/jop.12963
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   McGowan K, 2018, ORAL DIS, V24, P527, DOI 10.1111/odi.12708
   Nakagawa T, 2015, ARCH ORAL BIOL, V60, P557, DOI 10.1016/j.archoralbio.2014.09.012
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Ohba S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186665
   Otto S, 2021, MEDICINA LITHUANIA, V57, DOI 10.3390/medicina57050463
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   Shimo T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151731
   Stark R, 2019, NAT REV GENET, V20, P631, DOI 10.1038/s41576 019 0150 2
   Tseng HC, 2015, ONCOTARGET, V6, P20002, DOI 10.18632/oncotarget.4755
   Tsika RW, 2008, J BIOL CHEM, V283, P36154, DOI 10.1074/jbc.M807461200
   Tsubaki M, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 10
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Zhang WD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.606043
NR 30
TC 1
Z9 1
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2468 8509
EI 2468 7855
J9 J STOMATOL ORAL MAXI
JI J. Stomatol. Oral Maxillofac. Surg.
PD NOV
PY 2022
VL 123
IS 6
BP E687
EP E693
DI 10.1016/j.jormas.2022.04.001
EA OCT 2022
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 7A4YV
UT WOS:000898464500017
PM 35390513
DA 2025 08 17
ER

PT J
AU Xu, YL
   Song, DZ
   Lin, XX
   Peng, H
   Su, YG
   Liang, JM
   Hai, N
   Zhao, JM
   Liu, Q
AF Xu, Yinglong
   Song, Dezhi
   Lin, Xixi
   Peng, Hui
   Su, Yuangang
   Liang, Jiamin
   Hai, Na
   Zhao, Jinmin
   Liu, Qian
TI Corylifol A protects against ovariectomized induced bone loss and
   attenuates RANKL induced osteoclastogenesis via ROS reduction, ERK
   inhibition, and NFATc1 activation
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Corylifol A; Osteoclast; Osteoporosis; ERK; Reactive oxygen species
ID OXIDATIVE STRESS; PSORALEA CORYLIFOLIA; KAPPA B; CELLS; PATHWAY; HEALTH
AB Osteoclast differentiation and function are critical targets for anti osteoporosis treatment. Oxidative stress also plays an important regulatory role in the differentiation of osteoclasts. Corylifol A (CA) is a flavonoid extracted from the Psoralea fruit. It has anti inflammatory and antioxidant properties despite its unknown effect on osteoporosis. This study found that CA prevented estrogen deficiency induced bone loss and suppressed osteoclastogenesis in ovariectomized (OVX) mice by inhibiting intracellular reactive oxygen species (ROS) levels. In vivo, CA effectively prevented trabecular bone loss and reduced osteoclasts' number on the bone surface in OVX mice, as demonstrated in micro CT, osteometry, and immunohistochemical data. However, CA did not affect cortical bone. In vitro, CA inhibited RANKL induced podosome belt formation, osteoclastogenesis, and bone resorption functions. CA suppressed RANKL induced ROS by boosting antioxidant enzymes (Catalase and NQO1) and NFATc1 signaling pathway related protein expression, including integrin alpha v beta 3, NFATc1 and CTSK. Moreover, CA inhibited osteoclast specific genes, including Ctsk, Acp5, and Mmp9. CA also attenuated the MAPK/ERK pathway, but did not affect the NF kappa B signaling pathway. In terms of osteogenesis, CA did not inhibit or promote osteogenic differentiation and mineralization in vitro. These results reveal that CA could be a new replacement therapy for treating estrogen deficiency osteoporosis via suppressing osteoclastogenesis and intracellular ROS.
C1 [Xu, Yinglong; Song, Dezhi; Peng, Hui; Su, Yuangang; Liang, Jiamin; Hai, Na; Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Res Ctr Regenerat Med, Dept Trauma Orthopaed & Hand Surg, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Xu, Yinglong] Guangxi Med Univ, Dept Trauma Orthopaed & Hand Surg, Affiliated Hosp 5, Nanning, Guangxi, Peoples R China.
   [Xu, Yinglong; Song, Dezhi; Peng, Hui; Su, Yuangang; Liang, Jiamin; Hai, Na; Zhao, Jinmin] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Lin, Xixi] Xiamen Univ, Sch Med, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China.
   [Peng, Hui] Minzu Hosp Guangxi Zhuang Autonomous Reg, Dept Orthopaed, Nanning, Guangxi, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Xiamen University
RP Zhao, JM; Liu, Q (通讯作者)，Guangxi Med Univ, Res Ctr Regenerat Med, Dept Trauma Orthopaed & Hand Surg, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
EM zhaojinmin@126.com; liuqian@gxmu.edu.cn
RI zhao, jin/LBH 0351 2024; Lin, Xixi/AAO 3332 2020; Song,
   Dezhi/AAL 9799 2020; Su, Yuangang/KKU 6952 2024; Peng, Hui/ABB 8324 2021
FU National Natural Science Foundation of China [81960405]; Guangxi Science
   and Technology Base and Talent Special Project [GuikeAD19254003];
   Guangxi Natural Science Foundation [2021GXNSFAA196039]; open research
   fund from the Collaborative Innovation Centre of Regenerative Medicine
   and Medical Bioresource Development and Application
FX This research was supported by the National Natural Science Foun  dation
   of China (Grant No. 81960405) , Guangxi Science and Technology Base and
   Talent Special Project (Grant No. GuikeAD19254003) . Guangxi Natural
   Science Foundation (2021GXNSFAA196039) . It is also supported in part by
   the open research fund from the Collaborative Innovation Centre of
   Regenerative Medicine and Medical Bioresource Development and
   Application Co  constructed by the Province and Ministry, and the
   Training Program for One Thousand Young and Middle aged Backbone
   Teachers in Guangxi Colleges and Universities.
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   Chen JC, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.896108
   Chen LL, 2019, AM J TRANSL RES, V11, P4337
   Cheon YH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176416
   Chu A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136934
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Cui LJ, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 00958 x
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Dong MM, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829741
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Eaton AF, 2021, AM J PHYSIOL CELL PH, V320, pC392, DOI 10.1152/ajpcell.00442.2020
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Feng W, 2019, J ORAL BIOSCI, V61, P16, DOI 10.1016/j.job.2019.01.001
   Fuggle NR, 2020, DRUGS, V80, P1537, DOI 10.1007/s40265 020 01364 2
   Han Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051571
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Huang LK, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.848152
   Ishizu H, 2021, EXPERT REV ENDOCRINO, V16, P217, DOI 10.1080/17446651.2021.1956902
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Jeong JW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061439
   Jimi E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121636
   Joo JH, 2016, SCI REP UK, V6, DOI 10.1038/srep22389
   Kang JA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186825
   Kanis JA, 2008, BONE, V42, P467, DOI 10.1016/j.bone.2007.11.001
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Kim SI, 2020, PHYTOMEDICINE, V79, DOI 10.1016/j.phymed.2020.153351
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lavoie H, 2020, NAT REV MOL CELL BIO, V21, P607, DOI 10.1038/s41580 020 0255 7
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SW, 2012, PLANTA MED, V78, P903, DOI 10.1055/s 0031 1298482
   Li J, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829862
   Li X, 2021, DRUG DISCOV TODAY, V26, P1226, DOI 10.1016/j.drudis.2021.03.002
   Lin TH, 2017, ADV PROTEIN CHEM STR, V107, P117, DOI 10.1016/bs.apcsb.2016.11.002
   Liu GF, 2018, J CELL BIOCHEM, V119, P4469, DOI 10.1002/jcb.26550
   Liu X, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052868
   Liu ZM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243851
   Long F, 2022, INT IMMUNOPHARMACOL, V107, DOI 10.1016/j.intimp.2022.108632
   Maik Rachline G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051194
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   Matsuda H, 2009, BIOL PHARM BULL, V32, P147, DOI 10.1248/bpb.32.147
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   McDonald MM, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10539
   Mohamad NV, 2020, ENDOCR METAB IMMUNE, V20, P1478, DOI 10.2174/1871530320666200604160614
   Mu PY, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.10050
   Mun SH, 2020, EXP MOL MED, V52, P1239
   Muszynska M, 2020, MOLECULES, V25, DOI 10.3390/molecules25081990
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Oh SY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.646803
   Oh Y, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115453
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   PECK WA, 1993, AM J MED, V94, P646
   Ribet ABP, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.644986
   Schröder K, 2019, FREE RADICAL BIO MED, V132, P67, DOI 10.1016/j.freeradbiomed.2018.08.036
   Shieh P, 2019, TOXICOLOGY, V417, P1, DOI 10.1016/j.tox.2019.02.004
   Slack RJ, 2022, NAT REV DRUG DISCOV, V21, P60, DOI 10.1038/s41573 021 00284 4
   Sun Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.788680
   Takagi T, 2022, BMC RES NOTES, V15, DOI 10.1186/s13104 022 05988 3
   Wei LH, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106400
   Wu LW, 2022, EUR J PHARMACOL, V923, DOI 10.1016/j.ejphar.2022.174908
   Xiang BL, 2019, CELL BIOL INT, V43, P1125, DOI 10.1002/cbin.11033
   Xiao GD, 2010, J CHROMATOGR A, V1217, P5470, DOI 10.1016/j.chroma.2010.06.041
   Yao ZQ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010132
   Zhang WK, 2022, CHIN MED UK, V17, DOI 10.1186/s13020 022 00589 5
   Zhao XL, 2021, J BONE MINER RES, V36, P591, DOI 10.1002/jbmr.4215
   Zheng Y, 2022, NUTRIENTS, V14, DOI 10.3390/nu14051020
NR 71
TC 13
Z9 13
U1 3
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891 5849
EI 1873 4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD FEB 20
PY 2023
VL 196
BP 121
EP 132
DI 10.1016/j.freeradbiomed.2023.01.017
EA JAN 2023
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 8N8BY
UT WOS:000925372500001
PM 36649902
OA hybrid
DA 2025 08 17
ER

PT J
AU He, FT
   Luo, SH
   Liu, SJ
   Wan, SQ
   Li, JJ
   Chen, JY
   Zuo, HJ
   Pei, XF
AF He, Fangting
   Luo, Shuhan
   Liu, Sijing
   Wan, Siqi
   Li, Jingjing
   Chen, Jiayi
   Zuo, Haojiang
   Pei, Xiaofang
TI Zanthoxylum bungeanum seed oil inhibits RANKL induced
   osteoclastogenesis by suppressing ERK/c JUN/NFATc1 pathway and
   regulating cell cycle arrest in RAW264.7 cells
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Zanthoxylum bungeanum seed oil; Osteoclastogenesis; RANKL; ERK; Cell
   cycle arrest
ID KEY REGULATOR; BONE LOSS; DIFFERENTIATION; PROLIFERATION; OSTEOPOROSIS;
   ACTIVATION; OSTEOBLAST; IDENTIFICATION; EPIDEMIOLOGY; MECHANISMS
AB Ethnopharmacological relevance: Zanthoxylum bungeanum Maxim (ZBM), a traditional Chinese medicine, is traditionally used for osteoporosis treatment recorded in ancient Chinese medicine work Benjingshuzheng and reported to have the anti bone loss activity in recent studies. However, the anti osteoporotic activities of the seed of ZBM have not been elucidated yet. Our previous study found that Zanthoxylum bungeanum Maxim seed oil (ZBSO) was rich in polyunsaturated fatty acids (PUFAs), which were reported to prevent bone loss. Thus, we propose a hypothesis that ZBSO could be a potential natural resource for anti bone loss. Aim of the study: To investigate whether ZBSO could prevent bone loss by targeting osteoclastogenesis and investigate the potential mechanisms in receptor activator of nuclear factor Kappa B ligand (RANKL) induced RAW264.7 cells.Materials and methods: RAW264.7 cells were treated with RANKL in the presence or absence of ZBSO. The effect of ZBSO on osteoclast differentiation and bone resorption activity of RAW264.7 cells were evaluated by tartrateresistant acid phosphatase (TRAP) staining, F actin ring staining, and bone resorption assay. Differentially expression genes (DEGs) and relevant pathways of different cell groups were obtained from RNA sequencing and protein protein interaction (PPI) network analysis followed by KEGG pathway enrichment analysis. The effect of ZBSO on the RANKL induced cell cycle change was analyzed by flow cytometry assay, and the expression of genes and proteins related to the selected pathways was further verified by RT qPCR and western blot analysis. Results: The inhibitory effects of ZBSO on osteoclast differentiation and bone resorption activity in a dosedependent manner were demonstrated by TRAP staining, F actin ring staining, and bone resorption assay in RANKL induced RAW264.7 cells. Osteoclast differentiation and cell cycle pathways were the most enriched pathways based on DEGs enrichment analysis among different cell groups. The reversion effect of ZBSO on the RANKL induced RAW264.7 cell cycle arrest at the G1 phase was observed by flow cytometry assay. Western blot results showed that ZBSO markedly decreased RANKL induced activation of ERK, as well as the phosphorylation of c JUN and NFATc1 expression, and subsequently suppressed osteoclast specific genes, such as Ctsk , Trap , and Dc stamp.Conclusions: ZBSO exhibited an inhibitory effect on osteoclastogenesis via suppressing the ERK/c JUN/NFATc1 pathway and regulating cell cycle arrest induced by RANKL, suggesting that ZBSO may serve as a promising agent for anti bone loss.
C1 [He, Fangting; Luo, Shuhan; Wan, Siqi; Li, Jingjing; Chen, Jiayi; Zuo, Haojiang; Pei, Xiaofang] Sichuan Univ, West China Sch Publ Hlth, 16,Sect 3,Renmin Nan Rd, Chengdu 610041, Sichuan, Peoples R China.
   [He, Fangting; Luo, Shuhan; Wan, Siqi; Li, Jingjing; Chen, Jiayi; Zuo, Haojiang; Pei, Xiaofang] Sichuan Univ, West China Hosp 4, 16,Sect 3,Renmin Nan Rd, Chengdu 610041, Sichuan, Peoples R China.
   [He, Fangting; Luo, Shuhan; Wan, Siqi; Li, Jingjing; Chen, Jiayi; Zuo, Haojiang; Pei, Xiaofang] Sichuan Univ, West China Sch Publ Hlth, Dept Publ Hlth Lab Sci, Food Safety Monitoring & Risk Assessment Key Lab, Chengdu 610041, Peoples R China.
   [Liu, Sijing] Chengdu Univ Tradit Chinese Med, Coll Med Technol, Chengdu 611137, Peoples R China.
   [Pei, Xiaofang] Sichuan Univ, Noncommunicable Dis Res Ctr, West China PUMC CC Chen Inst Hlth, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Chengdu
   University of Traditional Chinese Medicine; Sichuan University
RP Zuo, HJ; Pei, XF (通讯作者)，Sichuan Univ, West China Sch Publ Hlth, 16,Sect 3,Renmin Nan Rd, Chengdu 610041, Sichuan, Peoples R China.; Zuo, HJ; Pei, XF (通讯作者)，Sichuan Univ, West China Hosp 4, 16,Sect 3,Renmin Nan Rd, Chengdu 610041, Sichuan, Peoples R China.
EM hft0318@163.com; 185552997@qq.com; liusijing@cdutcm.edu.cn;
   wansiqi@stu.scu.edu.cn; 1134638498@qq.com; cjy.210@163.com;
   zuohaojiang@scu.edu.cn; xxpeiscu@163.com
RI ; Chen, Jiayi/GZM 5106 2022
OI Zuo, Haojiang/0000 0002 8311 7006; 
FU Public Health and Preventive Medicine Provincial Experiment Teaching
   Center at Sichuan University; Food Safety Monitoring and Risk Assessment
   Key Laboratory of Sichuan Province
FX We thank the supports of Public Health and Preventive Medicine
   Provincial Experiment Teaching Center at Sichuan University and Food
   Safety Monitoring and Risk Assessment Key Laboratory of Sichuan
   Province.
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Beier F, 1999, MATRIX BIOL, V18, P109, DOI 10.1016/S0945 053X(99)00009 8
   Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031 10
   Cheng XG, 2021, J BONE MINER RES, V36, P427, DOI 10.1002/jbmr.4187
   Chiu YH, 2016, J CELL PHYSIOL, V231, P2402, DOI 10.1002/jcp.25389
   Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407
   Coffman JA, 2004, DEV CELL, V6, P321, DOI 10.1016/S1534 5807(04)00067 X
   Commission C.P., 2015, CHINESE PHARMACOPOEI, P159
   De Falco M, 2010, CURR PHARM DESIGN, V16, P1417, DOI 10.2174/138161210791033914
   Dhanasekaran DN, 2007, ONCOGENE, V26, P3097, DOI 10.1038/sj.onc.1210395
   Everaert C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 01617 3
   Fang YF, 2014, CANCER BIOL THER, V15, P1268, DOI 10.4161/cbt.29691
   Farina EK, 2011, J NUTR, V141, P1146, DOI 10.3945/jn.110.133728
   Habermann B, 2007, ACTA ORTHOP, V78, P221, DOI 10.1080/17453670710013717
   Hartley JW, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742 4690 5 1
   Huang XL, 2019, INT J MOL MED, V44, P582, DOI 10.3892/ijmm.2019.4207
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Järvinen R, 2012, EUR J CLIN NUTR, V66, P496, DOI 10.1038/ejcn.2011.188
   Jiang L, 2017, J FUNCT FOODS, V37, P594, DOI 10.1016/j.jff.2017.07.042
   Jimi E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121636
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Johnell O, 2005, OSTEOPOROSIS INT, V16, pS3, DOI 10.1007/s00198 004 1702 6
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Kim MH, 2017, J ETHNOPHARMACOL, V195, P137, DOI 10.1016/j.jep.2016.10.057
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Krueger CD, 2007, ANN PHARMACOTHER, V41, P276, DOI 10.1345/aph.1H521
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Li XQ, 2017, PHARMACOGN MAG, V13, P363, DOI 10.4103/pm.pm_211_16
   Lin J, 2017, BIOSCI TRENDS, V11, P496, DOI 10.5582/bst.2017.01216
   Liu HL, 2014, CLIN INTERV AGING, V9, P2087, DOI 10.2147/CIA.S72006
   Liu SJ, 2021, MOL NUTR FOOD RES, V65, DOI 10.1002/mnfr.202100014
   Lyu B, 2019, J ENVIRON MANAGE, V238, P235, DOI 10.1016/j.jenvman.2019.03.001
   Martyniak K, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115736
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Ogasawara T, 2004, J BONE MINER RES, V19, P1128, DOI 10.1359/jbmr.2004.19.7.1128
   Pang MH, 2019, J CELL BIOCHEM, V120, P12382, DOI 10.1002/jcb.28504
   Pang WW, 2019, J ETHNOPHARMACOL, V229, P180, DOI 10.1016/j.jep.2018.10.012
   Qi MS, 2005, J CELL SCI, V118, P3569, DOI 10.1242/jcs.02470
   Quinn JMW, 2005, BIOCHEM BIOPH RES CO, V328, P739, DOI 10.1016/j.bbrc.2004.11.076
   Rahman MM, 2015, BONE, V81, P392, DOI 10.1016/j.bone.2015.08.008
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02821 8
   Shaban NZ, 2017, J NUTR HEALTH AGING, V21, P1299, DOI 10.1007/s12603 017 0884 5
   Sharma SM, 2007, J BIOL CHEM, V282, P15921, DOI 10.1074/jbc.M609723200
   Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383
   Siu KT, 2012, CELL CYCLE, V11, P57, DOI 10.4161/cc.11.1.18775
   Spilmont M, 2013, J NUTR BIOCHEM, V24, P1840, DOI 10.1016/j.jnutbio.2013.04.005
   Suh KS, 2018, CHEM BIOL INTERACT, V296, P18, DOI 10.1016/j.cbi.2018.09.005
   Takahashi N, 2010, ADV EXP MED BIOL, V658, P21, DOI 10.1007/978 1 4419 1050 9_3
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang JQ, 2016, MOL MED REP, V13, P4289, DOI 10.3892/mmr.2016.5050
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wu XJ, 2005, J BONE MINER RES, V20, P107, DOI 10.1359/JBMR.041022
   Xia LA, 2011, J AM OIL CHEM SOC, V88, P23, DOI 10.1007/s11746 010 1644 4
   Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018 002 8510 y
   Yang XX, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 00910 z
   Yuan SiYuan Yuan SiYuan, 2015, China Journal of Traditional Chinese Medicine and Pharmacy, V30, P3889
   Zhang J, 2020, CURR OPIN RHEUMATOL, V32, P387, DOI 10.1097/BOR.0000000000000722
   Zhao QX, 2007, FRONT BIOSCI LANDMRK, V12, P2519, DOI 10.2741/2252
   Zou W, 2010, ANN NY ACAD SCI, V1192, P27, DOI 10.1111/j.1749 6632.2009.05245.x
   Zuo Y., 2011, CHIN MED MOD DIST ED, V9, P19
NR 70
TC 16
Z9 19
U1 3
U2 55
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAY 10
PY 2022
VL 289
AR 115094
DI 10.1016/j.jep.2022.115094
EA FEB 2022
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 1V0ZV
UT WOS:000805829700003
PM 35149133
OA hybrid
DA 2025 08 17
ER

PT J
AU Rachner, TD
   Singh, SK
   Schoppet, M
   Benad, P
   Bornhäuser, M
   Ellenrieder, V
   Ebert, R
   Jakob, F
   Hofbauer, LC
AF Rachner, Tilman D.
   Singh, Shiv K.
   Schoppet, Michael
   Benad, Peggy
   Bornhaeuser, Martin
   Ellenrieder, Volker
   Ebert, Regina
   Jakob, Franz
   Hofbauer, Lorenz C.
TI Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in
   breast cancer cells
SO CANCER LETTERS
LA English
DT Article
DE Breast cancer; OPG; TRAIL; Zoledronic acid
ID CONTAINING BISPHOSPHONATES INHIBIT; KAPPA B LIGAND; SKELETAL
   COMPLICATIONS; IN VITRO; OSTEOPROTEGERIN PRODUCTION; RECEPTOR ACTIVATOR;
   BONE METASTASES; EXPRESSION; INDUCTION; SURVIVAL
AB Breast cancer has a propensity to metastasize to bone, thus causing pathological fractures. Bisphosphonates are established drugs in the treatment of bone metastasis that inhibit osteoclast activity and interrupt the vicious cycle of osteoclast tumor cell interactions. We evaluated the direct effects of zoledronic acid on estrogen receptor (ER) negative MDA MB 231 and ER positive MCF 7 breast cancer cells. While zoledronic acid (100 PM) inhibited MDA MB 231 cell proliferation after 72 h, and induced apoptosis via activation of caspase 3 and  7, it had only minor effects on MCF 7 cells. In addition, zoledronic acid induced apoptosis by up regulating TNF related apoptosis inducing ligand (TRAIL) in MDA MB 231 cells (p < 0.01), but had no effect on the expression of its decoy receptor osteoprotegerin (OPG). In MCF 7 cells, both cytokines were suppressed by zoledronic acid. In conclusion, zoledronic acid enhanced the TRAIL to OPG ratio in TRAIL sensitive MDA MB 231 cells, indicating that the TRAIL/OPG cytokine system is a bisphosphonate responsive target in breast cancer. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Rachner, Tilman D.; Benad, Peggy; Hofbauer, Lorenz C.] Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, D 01307 Dresden, Germany.
   [Rachner, Tilman D.; Singh, Shiv K.; Ellenrieder, Volker; Hofbauer, Lorenz C.] Univ Marburg, Div Gastroenterol & Endocrinol, Dept Med, Marburg, Germany.
   [Schoppet, Michael] Univ Marburg, Dept Med, Div Cardiol, Marburg, Germany.
   [Bornhaeuser, Martin] Tech Univ Dresden, Dept Med 1, Div Hematol & Oncol, D 01307 Dresden, Germany.
   [Bornhaeuser, Martin; Hofbauer, Lorenz C.] CRTD, DFG, Dresden, Germany.
   [Ebert, Regina; Jakob, Franz] Univ Wurzburg, Orthoped Ctr Musculoskeletal Res, D 97070 Wurzburg, Germany.
C3 Technische Universitat Dresden; Philipps University Marburg; Philipps
   University Marburg; Technische Universitat Dresden; Technische
   Universitat Dresden; German Research Foundation (DFG); University of
   Wurzburg
RP Hofbauer, LC (通讯作者)，Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Fetscherstr 74, D 01307 Dresden, Germany.
EM lorenz.hofbauer@uniklinikum dresden.de
RI Ebert, Regina/D 5760 2016; Hofbauer, Lorenz/G 2490 2010; Jakob,
   Franz/D 8526 2015; Bornhäuser, Martin/F 8101 2010; Hofbauer, Lorenz
   C./G 2490 2010
OI Ebert, Regina/0000 0002 8192 869X; Singh, Shiv K./0000 0002 5725 4058;
   Hofbauer, Lorenz C./0000 0002 8691 8423
FU Deutsche Forschungsgemeinschaft [1875/5 2]; Wilhelm Sander Stiftung
   [2007.005.1]; Novartis
FX Parts of this study were performed as medical thesis by TDR at
   Philipps University Medical School of Marburg and as PhD thesis by PB at
   Technical University of Dresden. We thank U. Niebergall and T. Reiche
   for their assistance. The study was supported by grants from Deutsche
   Forschungsgemeinschaft (Ho 1875/5 2) to L.C.H. and M.S., and
   SFB/Transregio 67 to L.C.H from Wilhelm Sander Stiftung (2007.005.1) to
   L.C.H., and from Novartis to F.J. and L.C.H.
CR Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   Boissier S, 2000, CANCER RES, V60, P2949
   Busch M, 1998, Eur J Med Res, V3, P427
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   COLEMAN R, 2007, CLIN BREAST CANC S, V1, P29
   Costa L, 2007, BREAST, V16, pS16, DOI 10.1016/j.breast.2007.10.005
   Coxon FP, 1998, MOL PHARMACOL, V54, P631
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Holen I, 2005, BREAST CANCER RES TR, V92, P207, DOI 10.1007/s10549 005 2419 8
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Jänicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Lee MV, 2001, CANCER RES, V61, P2602
   Li YY, 2008, LUNG CANCER, V59, P180, DOI 10.1016/j.lungcan.2007.08.026
   Lipton A, 2007, ONCOLOGIST, V12, P1035, DOI 10.1634/theoncologist.12 9 1035
   Lowe LC, 2005, BIOCHEM BIOPH RES CO, V329, P772, DOI 10.1016/j.bbrc.2005.02.032
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Martin TJ, 2000, ENDOCR RELAT CANCER, V7, P271, DOI 10.1677/erc.0.0070271
   Morony S, 2001, CANCER RES, V61, P4432
   Oura Shoji, 2003, Breast Cancer, V10, P28, DOI 10.1007/BF02967622
   Rachner TD, 2008, BIOCHEM BIOPH RES CO, V368, P736, DOI 10.1016/j.bbrc.2008.01.118
   Rahman M, 2009, BREAST CANCER RES TR, V113, P217, DOI 10.1007/s10549 008 9924 5
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   Van Poznak C, 2006, J CLIN PATHOL, V59, P56, DOI 10.1136/jcp.2005.026534
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Verdijk R, 2007, CANCER LETT, V246, P308, DOI 10.1016/j.canlet.2006.03.011
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
NR 35
TC 57
Z9 63
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD JAN 1
PY 2010
VL 287
IS 1
BP 109
EP 116
DI 10.1016/j.canlet.2009.06.003
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 547OC
UT WOS:000273897900013
PM 19577359
DA 2025 08 17
ER

PT J
AU Tsai, YL
   Yen, CT
   Wang, YF
AF Tsai, Yi Liang
   Yen, Chieh Tsung
   Wang, Yuh Feng
TI Astrocyte Dysregulation and Calcium Ion Imbalance May Link the
   Development of Osteoporosis and Alzheimer's Disease
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Alzheimer's disease; astrocyte; bone; calcium ion; osteoporosis
ID HORMONE RELATED PROTEIN; GENE RELATED PEPTIDE; PARATHYROID HORMONE;
   PINEAL CALCIFICATION; MOLECULAR MECHANISMS; VASCULAR DEMENTIA; PRIMARY
   INSOMNIA; OLDER ADULTS; VITAMIN D; MELATONIN
AB The typical symptoms of patients with Alzheimer's disease (AD) are amyloid beta (A beta) plaques and tau hyperphosphorylation. However, recent studies show that these symptoms are not the cause of the disease but are generated after the pathogenesis. Compared with other types of dementia, AD has the obvious features of pineal gland calcification and decreased melatonin production. The pineal gland is mainly composed of pinealocytes that release melatonin and astrocytes. Astrocytes function to maintain a balanced concentration of calcium ions, provide nerve cell nutrients, and migrate nutrients in vivo. Calcium ions are among the most important neurotransmitters. Once triggered, a calcium wave can be formed between astrocytes to activate other astrocytes to transmit information. Most calcium is stored in the skeleton. Bone tissue is composed mainly of osteocytes, osteoblasts, and osteoclasts. Of these, osteocyte is a kind of astrocyte which regulates the activity of osteoclasts and osteoblasts. The pineal gland is composed mainly of astrocytes; osteocytes are also a kind of astrocyte. Therefore, we conclude that when astrocytes are gradually disabled, calcium may be lost from the bones, prompting osteoporosis. The calcium ions then released into the blood may accumulate and cause ectopic calcification in the pineal gland, which promotes the occurrence of AD. Finally, this study used aspects of drugs and hormones (bone and calcium metabolism hormones and melatonin) to infer the hypothesis, which proposes that astrocyte dysregulation promotes the long term imbalance of calcium ions in vivo and leads to osteoporosis and AD.
C1 [Tsai, Yi Liang; Wang, Yuh Feng] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Nucl Med, 2 Minsheng Rd, Chiayi 622, Taiwan.
   [Tsai, Yi Liang] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Med Res, Chiayi, Taiwan.
   [Yen, Chieh Tsung] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Neurol, Chiayi, Taiwan.
   [Wang, Yuh Feng] Tzu Chi Univ, Sch Med, Dept Radiol, Hualien, Taiwan.
   [Wang, Yuh Feng] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Ctr Prevent Med, Chiayi, Taiwan.
   [Wang, Yuh Feng] Taipei Vet Gen Hosp, Dept Nucl Med, Taipei, Taiwan.
C3 Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu
   Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General
   Hospital; Dalin Tzu Chi Hospital; Tzu Chi University; Buddhist Tzu Chi
   General Hospital; Dalin Tzu Chi Hospital; Taipei Veterans General
   Hospital
RP Tsai, YL (通讯作者)，Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Nucl Med, 2 Minsheng Rd, Chiayi 622, Taiwan.; Wang, YF (通讯作者)，201,Sec 2,Shipai Rd, Taipei 112201, Taiwan.
EM vupm6@gmail.com; yuhfeng@gmail.com
OI Tsai, Yi Liang/0000 0002 3271 2358
CR Admassie Daniel, 2009, Ethiop Med J, V47, P55
   Avenell A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000227.pub4
   BARRES BA, 1991, J NEUROSCI, V11, P3685
   Basgöz BB, 2020, TURK J PH MED REHAB, V66, P193, DOI 10.5606/tftrd.2020.3803
   Bazargani N, 2016, NAT NEUROSCI, V19, P182, DOI 10.1038/nn.4201
   Belarbi K, 2009, CURR ALZHEIMER RES, V6, P152, DOI 10.2174/156720509787602843
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   Björkman MP, 2010, AGING CLIN EXP RES, V22, P164, DOI 10.3275/6626
   Bronner F, 2001, ScientificWorldJournal, V1, P919
   Bumb JM, 2014, J SLEEP RES, V23, P274, DOI 10.1111/jsr.12125
   Bumb JM, 2013, WORLD J RADIOL, V5, P166, DOI 10.4329/wjr.v5.i4.166
   Calsolaro V, 2016, ALZHEIMERS DEMENT, V12, P719, DOI 10.1016/j.jalz.2016.02.010
   CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896 6273(91)90238 U
   Chen YH, 2017, TZU CHI MED J, V29, P138, DOI 10.4103/tcmj.tcmj_54_17
   CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852
   de la Torre JC, 2010, J ALZHEIMERS DIS, V20, P861, DOI 10.3233/JAD 2010 091579
   Díaz Soto G, 2016, INT REV CEL MOL BIO, V327, P321, DOI 10.1016/bs.ircmb.2016.05.004
   Drechsel DA, 2012, NEUROTOX RES, V22, P251, DOI 10.1007/s12640 012 9322 y
   Du H, 2012, ANTIOXID REDOX SIGN, V16, P1467, DOI 10.1089/ars.2011.4277
   Eastell R, 2008, P NUTR SOC, V67, P157, DOI 10.1017/S002966510800699X
   Fiacco TA, 2009, ANNU REV PHARMACOL, V49, P151, DOI 10.1146/annurev.pharmtox.011008.145602
   Friedland R P, 1990, Int Psychogeriatr, V2, P36
   Fuller S, 2010, MUTAT RES FUND MOL M, V690, P40, DOI 10.1016/j.mrfmmm.2009.08.016
   Funk JL, 2001, BRAIN RES, V915, P195, DOI 10.1016/S0006 8993(01)02850 5
   Gaugler J, 2019, ALZHEIMERS DEMENT, V15, P321, DOI 10.1016/j.jalz.2019.01.010
   Golovina VK, 2000, GLIA, V31, P15, DOI 10.1002/(SICI)1098 1136(200007)31:1<15::AID GLIA20>3.0.CO;2 H
   Guo XZ, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00343
   Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19 02 00520.1999
   HAAS CA, 1991, EUR J NEUROSCI, V3, P708, DOI 10.1111/j.1460 9568.1991.tb00856.x
   Hagström E, 2014, J CLIN ENDOCR METAB, V99, P4181, DOI 10.1210/jc.2014 1736
   HASHIMOTO H, 1994, BIOCHEM BIOPH RES CO, V200, P1042, DOI 10.1006/bbrc.1994.1555
   Hassinger TD, 1996, P NATL ACAD SCI USA, V93, P13268, DOI 10.1073/pnas.93.23.13268
   Heaney RP, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1697, DOI 10.1016/B978 0 12 373884 4.00010 0
   Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007
   Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474 4422(12)70291 0
   Jiao KP, 2017, NEUROREPORT, V28, P492, DOI 10.1097/WNR.0000000000000782
   Kacem K, 1998, GLIA, V23, P1
   Keeney JT, 2015, NEUROBIOL DIS, V84, P84, DOI 10.1016/j.nbd.2015.06.020
   Khakh BS, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020404
   Kobayashi Sun J, 2020, BIOCHEM BIOPH RES CO, V530, P644, DOI 10.1016/j.bbrc.2020.07.075
   Kopeikina KJ, 2013, J COMP NEUROL, V521, P1334, DOI 10.1002/cne.23234
   Kruger MC, 1997, PROG LIPID RES, V36, P131, DOI 10.1016/S0163 7827(97)00007 6
   Kushnir MM, 2019, CLIN MASS SPECTROM, V14, P124, DOI 10.1016/j.clinms.2018.10.001
   Kwon MJ, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.786337
   Landel V, 2018, J STEROID BIOCHEM, V177, P129, DOI 10.1016/j.jsbmb.2017.09.008
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   LAZAR P, 1991, NEUROSCI LETT, V130, P99, DOI 10.1016/0304 3940(91)90237 N
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Lee JY, 2018, BBA MOL BASIS DIS, V1864, P2472, DOI 10.1016/j.bbadis.2018.04.006
   Li RN, 2014, MOL CELL ENDOCRINOL, V389, P13, DOI 10.1016/j.mce.2013.12.018
   Liu CY, 2000, RES APPL PSYCHOL, V7, P89
   Loskutova N, 2019, MED HYPOTHESES, V122, P92, DOI 10.1016/j.mehy.2018.10.024
   Lu YJ, 2020, J NEUROSCI, V40, P7355, DOI 10.1523/JNEUROSCI.0115 20.2020
   Lüth HJ, 2003, BRAIN RES, V977, P16, DOI 10.1016/S0006 8993(03)02658 1
   Mahlberg R, 2008, NEUROBIOL AGING, V29, P203, DOI 10.1016/j.neurobiolaging.2006.10.003
   Mahlberg R, 2009, SLEEP MED, V10, P439, DOI 10.1016/j.sleep.2008.05.003
   Maria S, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12465
   McCarthy I, 2006, J BONE JOINT SURG AM, V88A, P4, DOI 10.2106/JBJS.F.00890
   Mehta N. M., 2003, Current Pharmaceutical Design, V9, P2659, DOI 10.2174/1381612033453622
   Misiorowski W, 2011, ENDOKRYNOL POL, V62, P73
   Na H, 2020, NEUROPHARMACOLOGY, V168, DOI 10.1016/j.neuropharm.2020.108017
   Nakade O, 1999, J PINEAL RES, V27, P106, DOI 10.1111/j.1600 079X.1999.tb00603.x
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nölte I, 2009, J MAGN RESON IMAGING, V30, P499, DOI 10.1002/jmri.21872
   Notelovitz M, 1997, AM J MED SCI, V313, P2, DOI 10.1097/00000441 199701000 00002
   Nous A, 2021, ALZHEIMERS RES THER, V13, DOI 10.1186/s13195 021 00788 6
   Obri A, 2018, NAT REV ENDOCRINOL, V14, P174, DOI 10.1038/nrendo.2017.181
   PARKER I, 1991, P ROY SOC B BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154
   Patel S, 2020, INT J NEUROSCI, V130, P464, DOI 10.1080/00207454.2019.1692838
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Raz L, 2016, J CEREBR BLOOD F MET, V36, P172, DOI 10.1038/jcbfm.2015.164
   REDDINGTON M, 1995, CAN J PHYSIOL PHARM, V73, P1047, DOI 10.1139/y95 148
   REITER RJ, 1992, BIOESSAYS, V14, P169, DOI 10.1002/bies.950140307
   REITER RJ, 1994, ANN NY ACAD SCI, V719, P1, DOI 10.1111/j.1749 6632.1994.tb56817.x
   Ringe JD, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 00842 0
   Rizzuto Rosario, 2004, Sci STKE, V2004, pre1, DOI 10.1126/stke.2152004re1
   Rodriguez MPI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167063
   Rohn TT, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/860959
   Roth JA, 1999, J BIOL CHEM, V274, P22041, DOI 10.1074/jbc.274.31.22041
   Sadok SH, 2019, PHARMACOL REP, V71, P701, DOI 10.1016/j.pharep.2019.03.010
   Scemes E, 2000, MOL NEUROBIOL, V22, P167, DOI 10.1385/MN:22:1 3:167
   Scemes E, 2006, GLIA, V54, P716, DOI 10.1002/glia.20374
   Schatz M, 2020, FRONT NEUROENDOCRIN, V59, DOI 10.1016/j.yfrne.2020.100861
   Schliebs R, 2005, NEUROCHEM RES, V30, P895, DOI 10.1007/s11064 005 6962 9
   Schneyer C R, 1991, Md Med J, V40, P469
   Sheppard CA, 1997, J NEUROCHEM, V68, P2317
   Shigetomi E, 2016, TRENDS CELL BIOL, V26, P300, DOI 10.1016/j.tcb.2016.01.003
   Shukla M, 2017, CURR NEUROPHARMACOL, V15, P1010, DOI 10.2174/1570159X15666170313123454
   Silverman SL, 2001, RHEUM DIS CLIN N AM, V27, P187, DOI 10.1016/S0889 857X(05)70193 9
   Singh M, 2006, EXP BIOL MED, V231, P514
   Singh Y, 2017, CNS NEUROSCI THER, V23, P457, DOI 10.1111/cns.12696
   SMITH SJ, 1992, PROG BRAIN RES, V94, P119
   SMITH SJ, 1994, CURR BIOL, V4, P807, DOI 10.1016/S0960 9822(00)00178 0
   STRUCKHOFF G, 1995, BRAIN RES, V676, P1, DOI 10.1016/0006 8993(95)00088 8
   Strydom A, 2013, RES DEV DISABIL, V34, P1881, DOI 10.1016/j.ridd.2013.02.021
   Suchacki KJ, 2017, J ENDOCRINOL, V234, pR67, DOI 10.1530/JOE 17 0147
   Sun CY, 2021, CNS NEUROSCI THER, V27, P1409, DOI 10.1111/cns.13720
   Surveillance Epidemiology and End Results (SEER) Program U.S. National Cancer Institute (NCI), SEER TRAIN MOD SKEL
   Tan DX, 2018, MOLECULES, V23, DOI 10.3390/molecules23020301
   Tate MLK, 2004, INT J BIOCHEM CELL B, V36, P1, DOI 10.1016/S1357 2725(03)00241 3
   Tavares E, 2016, AM J PATHOL, V186, P2723, DOI 10.1016/j.ajpath.2016.06.006
   Tiihonen M, 2016, J ALZHEIMERS DIS, V52, P127, DOI 10.3233/JAD 151181
   Tresguerres FGF, 2020, ANN ANAT, V227, DOI 10.1016/j.aanat.2019.151422
   Turgut Ahmet Tuncay, 2008, Pathophysiology, V15, P41, DOI 10.1016/j.pathophys.2008.02.001
   Vaananen HK, 1996, MATURITAS, V23, pS65
   Volterra A, 2014, NAT REV NEUROSCI, V15, P327, DOI 10.1038/nrn3725
   von Bernhardi R, 2012, ANTIOXID REDOX SIGN, V16, P974, DOI 10.1089/ars.2011.4082
   Wang J, 2021, MOL NEUROBIOL, V58, P1052, DOI 10.1007/s12035 020 02171 2
   Wang J, 2020, J NEUROSCI, V40, P9751, DOI 10.1523/JNEUROSCI.0888 20.2020
   Yalcin A, 2016, J CHEM NEUROANAT, V78, P20, DOI 10.1016/j.jchemneu.2016.07.008
   Yu JT, 2009, PROG NEUROBIOL, V89, P240, DOI 10.1016/j.pneurobio.2009.07.009
   Yuan J, 2019, J ALZHEIMERS DIS, V69, P59, DOI 10.3233/JAD 181249
   Zameer S, 2018, PHARMACOL REP, V70, P900, DOI 10.1016/j.pharep.2018.03.011
   Zhu ZY, 2010, J NEUROCHEM, V114, P374, DOI 10.1111/j.1471 4159.2010.06751.x
   Zou YJ, 2022, J AFFECT DISORDERS, V303, P138, DOI 10.1016/j.jad.2022.02.026
NR 115
TC 9
Z9 9
U1 3
U2 13
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387 2877
EI 1875 8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2022
VL 88
IS 2
BP 439
EP 445
DI 10.3233/JAD 220218
PG 7
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA 3B6FM
UT WOS:000828034300005
PM 35599492
DA 2025 08 17
ER

PT J
AU Shao, WJ
   Orlando, RC
   Awayda, MS
AF Shao, WJ
   Orlando, RC
   Awayda, MS
TI Bisphosphonates stimulate an endogenous nonselective cation channel in
   Xenopus oocytes: potential mechanism of action
SO AMERICAN JOURNAL OF PHYSIOLOGY CELL PHYSIOLOGY
LA English
DT Article
DE membrane depolarization; membrane area; drug action
ID EXTRACELLULAR CA2+; MEVALONATE PATHWAY; CYTOSOLIC CALCIUM;
   ALPHA SUBUNIT; ION CHANNELS; CONDUCTANCE; MAITOTOXIN; MEMBRANE; LAEVIS;
   RAT
AB The mechanisms of action of bisphosphonates (BPs) have been poorly determined. Besides their actions on osteoclasts, these agents exhibit gastrointestinal complications. They have also recently been described as affecting various preparations that express an epithelial Na+ channel (ENaC). To understand the effects of BP on ion channels and the ENaC in particular, we used the Xenopus oocyte expression system. Alendronate, and similarly risedronate, two aminobisphosphonates, caused a large stimulation of an endogenous nonselective cation conductance (NSCC). This stimulation averaged 63 +/  12 mu S (n = 18) 60 min after the addition of 2 mM alendronate. The effects on the endogenous NSCC were blocked by extracellular acidification to pH 6.4. On the other hand, alendronate caused a small inhibition of ENaC conductance at pH 7.4 and 6.4, but the effects at pH 6.4 were more readily observed in the absence of changes of the endogenous conductance. The effects on membrane capacitance were also markedly different, with a clear decrease at pH 6.4 and no consistent changes at pH 7.4. The effects on the endogenous channel were further augmented by genistein and were inhibited by a tyrosine phosphatase inhibitor, indicating the involvement of the tyrosine kinase pathway. Stimulation of NSCC with BP is expected to cause membrane depolarization and may explain, in part, its mechanisms of action in inhibiting osteoclasts.
C1 Tulane Univ, Hlth Sci Ctr, Dept Physiol, New Orleans, LA 70112 USA.
   Vet Affairs Med Ctr, New Orleans, LA USA.
C3 Tulane University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA)
RP Awayda, MS (通讯作者)，Tulane Univ, Hlth Sci Ctr, Dept Physiol, SL39,1430 Tulane Ave, New Orleans, LA 70112 USA.
EM mawayda@tulane.edu
CR ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153
   ARELLANO RO, 1995, J PHYSIOL LONDON, V484, P593, DOI 10.1113/jphysiol.1995.sp020689
   Awayda MS, 2000, J GEN PHYSIOL, V115, P559, DOI 10.1085/jgp.115.5.559
   Awayda MS, 2004, AM J PHYSIOL CELL PH, V287, pC395, DOI 10.1152/ajpcell.00412.2003
   Awayda MS, 2004, J GEN PHYSIOL, V123, P709, DOI 10.1085/jgp.200308983
   Awayda MS, 2000, AM J PHYSIOL CELL PH, V279, pC1896, DOI 10.1152/ajpcell.2000.279.6.C1896
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Bielfeld Ackermann A, 1998, PFLUG ARCH EUR J PHY, V436, P329, DOI 10.1007/s004240050640
   Blank MA, 2000, ALIMENT PHARM THER, V14, P1215
   Chalfant ML, 1999, AM J PHYSIOL CELL PH, V276, pC477, DOI 10.1152/ajpcell.1999.276.2.C477
   David P, 1996, J BONE MINER RES, V11, P1498, DOI 10.1002/jbmr.5650111017
   Diakov A, 2001, PFLUG ARCH EUR J PHY, V442, P700, DOI 10.1007/s004240100593
   Dobrucali A, 2002, AM J PHYSIOL GASTR L, V283, pG576, DOI 10.1152/ajpgi.00014.2002
   Ekhterae D, 2001, AM J PHYSIOL CELL PH, V281, pC157, DOI 10.1152/ajpcell.2001.281.1.C157
   Kajiya H, 2000, J CELL PHYSIOL, V183, P83, DOI 10.1002/(SICI)1097 4652(200004)183:1<83::AID JCP10>3.0.CO;2 W
   Kizer N, 1997, P NATL ACAD SCI USA, V94, P1013, DOI 10.1073/pnas.94.3.1013
   Krick S, 2001, AM J PHYSIOL CELL PH, V280, pC970, DOI 10.1152/ajpcell.2001.280.4.C970
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543
   Mundy, 1999, Expert Opin Investig Drugs, V8, P2009, DOI 10.1517/13543784.8.12.2009
   Orlando RC, 1998, ALIMENT PHARM THERAP, V12, P191
   PAZIANAS M, 1993, BIOCHEM BIOPH RES CO, V192, P1100, DOI 10.1006/bbrc.1993.1530
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   Schmieder S, 1998, J PHYSIOL LONDON, V511, P379, DOI 10.1111/j.1469 7793.1998.379bh.x
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
   VASIKARAN SD, 1994, BONE MINER, V27, P51, DOI 10.1016/S0169 6009(08)80186 9
   VENANT A, 1994, BIOL CELL, V82, P195, DOI 10.1016/S0248 4900(94)80022 7
   Weber WM, 1999, J MEMBRANE BIOL, V170, P1, DOI 10.1007/s002329900532
   WEBER WM, 1995, PFLUG ARCH EUR J PHY, V429, P820, DOI 10.1007/BF00374806
   Weber WM, 2000, PFLUG ARCH EUR J PHY, V439, P363, DOI 10.1007/s004240050951
   Yoshida N, 1998, BONE, V22, P495, DOI 10.1016/S8756 3282(98)00038 6
NR 31
TC 14
Z9 15
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI Rockville
PA 6120 Executive Blvd, Suite 600, Rockville, MD, UNITED STATES
SN 0363 6143
EI 1522 1563
J9 AM J PHYSIOL CELL PH
JI Am. J. Physiol. Cell Physiol.
PD AUG
PY 2005
VL 289
IS 2
BP C248
EP C256
DI 10.1152/ajpcell.00393.2004
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 943CB
UT WOS:000230328300003
PM 15788487
DA 2025 08 17
ER

PT J
AU Duspara, K
   Sikora, R
   Petrovic, A
   Roguljic, LK
   Matic, A
   Kralik, K
   Roguljic, H
   Kizivat, T
   Duspara, M
   Igrec, D
   Bojanic, K
   Smolic, R
   Vcev, A
   Wyszynska, M
   Wu, GY
   Smolic, M
AF Duspara, Kristina
   Sikora, Renata
   Petrovic, Ana
   Roguljic, Lucija Kuna
   Matic, Anita
   Kralik, Kristina
   Roguljic, Hrvoje
   Kizivat, Tomislav
   Duspara, Mirjana
   Igrec, Dunja
   Bojanic, Kristina
   Smolic, Robert
   Vcev, Aleksandar
   Wyszynska, Magdalena
   Wu, George Y.
   Smolic, Martina
TI Changes in Dickkopf 1, but Not Sclerostin, in Gingival Crevicular Fluid
   Are Associated with Peroral Statin Treatment in Patients with
   Periodontitis
SO MEDICINA LITHUANIA
LA English
DT Article
DE DKK 1; GCF; periodontitis; sclerostin; statins; Wnt signaling pathway
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; SIGNALING PATHWAY;
   BONE; OSTEOPOROSIS; ATORVASTATIN; RISK
AB Background and Objectives: Periodontitis is marked by the destruction of alveolar bone. Sclerostin (SOST) and dickkopf 1 (DKK 1) act as inhibitors of the Wingless type (Wnt) signaling pathway, a key regulator of bone metabolism. Recent studies have suggested that statins play a role in bone resorption and formation by influencing Wnt signaling. The aim of this study was to determine the levels of SOST and DKK 1 in periodontal patients with and without peroral statins treatment in their therapy. Materials and Methods: A total of 79 patients with diagnosed periodontitis were divided into two groups: 39 patients on statin therapy (SP group) and 40 patients without statin therapy as a control group (P group). The periodontal clinical examination probing (pocket) depth (PD) and gingival recession (GR) were measured, and approximal plaque was detected, while vertical and horizontal bone resorption was measured using a panoramic radiograph image. Clinical attachment loss (CAL) values were calculated using PD and GR values. Gingival crevicular fluid (GCF) was collected and used for measuring SOST and DKK 1 levels. A questionnaire was used to assess lifestyle habits and statin intake. Patients' medical records were used to obtain biochemical parameters. Results: There was no significant difference in sclerostin concentration between the SP and P group. DKK 1 values were significantly higher in the SP group compared to the control group (p = 0.04). Also, PD (p = 0.001) and GR (p = 0.03) were significantly higher in the SP group. The level of DKK 1 had a positive relationship with the PD, the greater the PD, the higher the level of DKK 1 (Rho = 0.350), while there was no significant association with other parameters. Conclusions: Peroral statins in periodontal patients are associated with GCF levels of DKK 1 but not with sclerostin levels.
C1 [Duspara, Kristina; Sikora, Renata; Petrovic, Ana; Roguljic, Lucija Kuna; Matic, Anita; Igrec, Dunja; Bojanic, Kristina; Smolic, Robert; Vcev, Aleksandar; Smolic, Martina] JJ Strossmayer Univ Osijek, Fac Dent Med & Hlth Osijek, Osijek 31000, Croatia.
   [Duspara, Kristina; Kralik, Kristina; Roguljic, Hrvoje; Kizivat, Tomislav; Bojanic, Kristina] JJ Strossmayer Univ Osijek, Fac Med Osijek, Osijek 31000, Croatia.
   [Duspara, Kristina; Duspara, Mirjana] Med Ctr Dr Mustafa Sehovic, Publ Hlth Sci Inst, Tuzla 75000, Bosnia & Herceg.
   [Sikora, Renata; Bojanic, Kristina] Hlth Ctr Osijek Baranja Cty, Osijek 31000, Croatia.
   [Kizivat, Tomislav] Univ Hosp Ctr Osijek, Osijek 31000, Croatia.
   [Wyszynska, Magdalena] Med Univ Silesia, Div Med Sci Zabrze, 15 Poniatowskiego St, PL 40055 Katowice, Poland.
   [Wu, George Y.] Univ Connecticut, Hlth Ctr, Farmington, CT 06030 USA.
C3 University of JJ Strossmayer Osijek; University of JJ Strossmayer
   Osijek; Medical University of Silesia; University of Connecticut
RP Smolic, M (通讯作者)，JJ Strossmayer Univ Osijek, Fac Dent Med & Hlth Osijek, Osijek 31000, Croatia.
EM dusparakristina5@gmail.com; rsikora@fdmz.hr; anapetrovic@fdmz.hr;
   lkuna@fdmz.hr; anita.matic@fdmz.hr; kristina.kralik@mefos.hr;
   hrvoje.roguljic@mefos.hr; tkizivat@mefos.hr; duspara.mirjana@gmail.com;
   digrec@fdmz.hr; kbojanic@mefos.hr; rsmolic@fdmz.hr; avcev@fdmz.hr;
   magdalena.wyszynska@sum.edu.pl; wu@uchc.edu; msmolic@fdmz.hr
RI Kizivat, Tomislav/L 2024 2017; Matić, Anita/JMB 2655 2023; Smolic,
   Robert/T 6164 2019; Kralik, Kristina/HCI 4811 2022; Petrovic,
   Ana/LFS 2979 2024
OI Sikora, Renata/0000 0001 8594 549X; Kizivat,
   Tomislav/0000 0002 2523 6007; Wyszynska, Magdalena/0000 0003 0483 4902;
   Kralik, Kristina/0000 0002 4481 6365; Bojanic,
   Kristina/0000 0003 4473 5706; Matic, Anita/0000 0002 3374 8512; Vcev,
   Aleksandar/0000 0003 0512 462X; Kuna Roguljic,
   Lucija/0000 0002 0079 2349
FU Croatian Ministry of Science and Education
FX No Statement Available
CR Abdulkareem AA, 2023, J ORAL MICROBIOL, V15, DOI 10.1080/20002297.2023.2197779
   Afrin S, 2022, J CELL MOL MED, V26, P1684, DOI 10.1111/jcmm.17211
   Ashifa Nisha, 2023, J Adv Periodontol Implant Dent, V15, P3, DOI 10.34172/japid.2023.009
   Bao JQ, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.110935
   Battancs E, 2020, DIABETES THER, V11, P2715, DOI 10.1007/s13300 020 00933 8
   Bibi T, 2021, MOLECULES, V26, DOI 10.3390/molecules26051208
   Bojanic K, 2018, J CLIN MED, V7, DOI 10.3390/jcm7090287
   Caton JG, 2018, J CLIN PERIODONTOL, V45, pS1, DOI 10.1111/jcpe.12935
   Cecoro G, 2021, EUR REV MED PHARMACO, V25, P5737, DOI 10.26355/eurrev_202109_26792
   Chirapongsathorn S, 2023, J CLIN TRANSL HEPATO, V11, P88, DOI 10.14218/JCTH.2021.00479
   Choudhary A, 2023, EGYPT HEART J, V75, DOI 10.1186/s43044 023 00327 8
   Corrao G, 2014, DIABETES CARE, V37, P2225, DOI 10.2337/dc13 2215
   Crandall JP, 2017, BMJ OPEN DIAB RES CA, V5, DOI 10.1136/bmjdrc 2017 000438
   de Carvalho RDP, 2021, J ORAL BIOSCI, V63, P232, DOI 10.1016/j.job.2021.06.002
   Di Spirito F, 2021, DENT J BASEL, V9, DOI 10.3390/dj9090100
   Dincel AS, 2023, CALCIFIED TISSUE INT, V112, P243, DOI 10.1007/s00223 022 01020 9
   Donders HCM, 2021, INT J CARDIOL CARDIO, V11, DOI 10.1016/j.ijcrp.2021.200110
   Duan PP, 2016, INT J BIOCHEM CELL B, V77, P23, DOI 10.1016/j.biocel.2016.05.015
   Esfahrood ZR, 2018, J KOR ASSOC ORAL MAX, V44, P289, DOI 10.5125/jkaoms.2018.44.6.289
   Gehrig J. S., 2017, FUNDAMENTALS PERIODO
   Göbel A, 2015, BREAST CANCER RES TR, V154, P623, DOI 10.1007/s10549 015 3624 8
   Guentsch A, 2011, J PERIODONTOL, V82, P1051, DOI 10.1902/jop.2011.100565
   Günday S, 2014, J PERIODONTOL, V85, pE47, DOI 10.1902/jop.2013.130367
   Henssler L, 2021, INJURY, V52, pS49, DOI 10.1016/j.injury.2021.04.068
   Houschyar KS, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00170
   Kozak M, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065231
   Lang NP, 2018, J CLIN PERIODONTOL, V45, pS9, DOI 10.1111/jcpe.12936
   Li C, 2020, ENDOCRINE, V68, P669, DOI 10.1007/s12020 020 02248 x
   Lin SM, 2018, J CLIN ENDOCR METAB, V103, P3439, DOI 10.1210/jc.2018 00652
   Liu JQ, 2017, J DENT SCI, V12, P220, DOI 10.1016/j.jds.2016.11.006
   Napimoga MH, 2014, J CLIN PERIODONTOL, V41, P550, DOI 10.1111/jcpe.12245
   Niedzielski M, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110388
   Ozden FO, 2022, J PERIODONTAL RES, V57, P849, DOI 10.1111/jre.13023
   Pei J, 2020, EPMA J, V11, P197, DOI 10.1007/s13167 020 00202 5
   Petit C, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/6367402
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Pontremoli M, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 35119 7
   Rachner TD, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3616
   Ramenzoni LL, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11030571
   Robinson JG, 2015, CURR OPIN LIPIDOL, V26, P228, DOI 10.1097/MOL.0000000000000172
   Romero Sánchez C, 2022, CURR RHEUMATOL REV, V18, P124, DOI 10.2174/1573397117666211116105118
   Samiei Mohammad, 2019, F1000Res, V8, P128, DOI 10.12688/f1000research.17801.1
   Shao YH, 2025, CURR STEM CELL RES T, V20, P246, DOI 10.2174/011574888X294900240130095058
   Shen YS, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01705 8
   Sousa LH, 2016, J PERIODONTOL, V87, P1206, DOI 10.1902/jop.2016.160075
   Staff P.O., 2015, PLoS ONE, V10
   Tahamtan S, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02326 8
   Tokavanich N, 2021, FRONT DENT MED, V2, DOI 10.3389/fdmed.2021.769134
   Tonetti MS, 2018, J CLIN PERIODONTOL, V45, pS149, DOI [10.1002/JPER.18 0006, 10.1111/jcpe.12945]
   Tong XK, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04784 y
   Wang BX, 2019, EUR REV MED PHARMACO, V23, P10161, DOI 10.26355/eurrev_201911_19586
   Xiao Y, 2022, CELL TRANSPLANT, V31, DOI 10.1177/09636897221075749
   Zhang HY, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0244806
   Zhang M, 2018, EUR REV MED PHARMACO, V22, P2896, DOI 10.26355/eurrev_201805_14992
   Zhang R, 2013, INT J BIOL SCI, V9, P228, DOI 10.7150/ijbs.5476
   Zhou H, 2017, J BONE MINER METAB, V35, P245, DOI 10.1007/s00774 016 0750 2
   Zhou M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.998244
NR 57
TC 1
Z9 1
U1 5
U2 13
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1010 660X
EI 1648 9144
J9 MEDICINA LITHUANIA
JI Med. Lith.
PD MAR
PY 2024
VL 60
IS 3
AR 508
DI 10.3390/medicina60030508
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA MG6S5
UT WOS:001192518100001
PM 38541234
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Choudhary, S
   Huang, H
   Raisz, L
   Pilbeam, C
AF Choudhary, Shilpa
   Huang, Hechang
   Raisz, Lawrence
   Pilbeam, Carol
TI Anabolic effects of PTH in cyclooxygenase 2 knockout osteoblasts in
   vitro
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE prostaglandin; nonsteroidal anti inflammatory drugs; sclerostin; IGF 1;
   MKP 1
ID PARATHYROID HORMONE RECEPTORS; SIGNALING PATHWAYS; GENE DISRUPTION;
   BONE FORMATION; MULTIPLE MECHANISMS; PROSTAGLANDIN E(2); MC3T3 E1 CELLS;
   DIFFERENTIATION; ACTIVATION; INTERMITTENT
AB PTH is a potent bone anabolic agent in vivo but anabolic effects on osteoblast differentiation in vitro are difficult to demonstrate. This study examined the role of cyclooxygenase (COX) 2 and prostaglandin (PG) production in the effects of PTH on osteoblast differentiation in vitro using marrow stromal cell (MSC) and calvarial osteoblast (COB) cultures from COX 2 knockout (KO) and wild type (WT) mice. Cells were treated with PTH (10 nM) or vehicle throughout culture. Alkaline phosphatase (ALP) and osteocalcin (OCN) mRNA levels were measured at days 14 and 21, respectively, and mineralization at day 21. cAMP concentrations were measured in the presence of a phosphodiesterase inhibitor. PTH did not stimulate differentiation in cultures from WT mice but significantly increased ALP and OCN mRNA expression 6  to 7 fold in KO MSC cultures and 2  to 4 fold in KO COB cultures. PTH also increased mineralization in both KO MSC and COB cultures. Effects in KO cells were mimicked in WT MSC cultures treated with NS 398, an inhibitor of COX 2 activity. PTH increased cAMP concentrations similarly in WT and KO COBs. Differential gene responses to PTH in COX 2 KO COBs relative to WT COBs included greater fold increases in the cAMP mediated early response genes, c fos and Nr4a2; increased IGF 1 mRNA expression; and decreased mRNA expression of MAP kinase phosphatase 1. PTH inhibited SOST mRNA expression 91% in COX 2 KO MSC cultures compared to 67% in WT cultures. We conclude that endogenous PGs inhibit the anabolic responses to PTH in vitro, possibly by desensitizing cAMP pathways. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Choudhary, Shilpa; Huang, Hechang; Raisz, Lawrence; Pilbeam, Carol] Univ Connecticut, Ctr Hlth, Div Endocrinol, Dept Med,Musculoskeletal Inst, Farmington, CT 06030 USA.
C3 University of Connecticut
RP Pilbeam, C (通讯作者)，Univ Connecticut, Ctr Hlth, Div Endocrinol, Dept Med,Musculoskeletal Inst, 263 Farmington Ave,MC5456, Farmington, CT 06030 USA.
EM pilbeam@nso.uchc.edu
FU NIDDK NIH HHS [DK48361, R56 DK048361, R01 DK048361] Funding Source:
   Medline
CR [Anonymous], 2002, PRINCIPLES BONE BIOL
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   BELLOWS CG, 1990, ENDOCRINOLOGY, V127, P3111, DOI 10.1210/endo 127 6 3111
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   Chikazu D, 2002, J BONE MINER RES, V17, P1430, DOI 10.1359/jbmr.2002.17.8.1430
   Choudhary S, 2007, J BONE MINER RES, V22, P1002, DOI 10.1359/JBMR.070321
   Demiralp B, 2002, ENDOCRINOLOGY, V143, P4038, DOI 10.1210/en.2002 220221
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   FLANAGAN AM, 1992, ENDOCRINOLOGY, V130, P443, DOI 10.1210/en.130.1.443
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Gesty Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200
   Hilal G, 2001, J BONE MINER RES, V16, P713, DOI 10.1359/jbmr.2001.16.4.713
   Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491
   Isogai Y, 1996, J BONE MINER RES, V11, P1384
   Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756 3282(97)00147 6
   KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P1157, DOI 10.1210/en.135.3.1157
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Koh AJ, 1999, ENDOCRINOLOGY, V140, P3154, DOI 10.1210/en.140.7.3154
   Li M, 2007, INT ORTHOP, V31, P767, DOI 10.1007/s00264 007 0406 x
   Locklin RM, 2003, J CELL BIOCHEM, V89, P180, DOI 10.1002/jcb.10490
   MITCHELL J, 1990, ENDOCRINOLOGY, V126, P2650, DOI 10.1210/endo 126 5 2650
   MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092 8674(95)90125 6
   NAGATA T, 1994, CALCIFIED TISSUE INT, V55, P451, DOI 10.1007/BF00298559
   Okada Y, 2000, J BONE MINER RES, V15, pS217
   Phelps E, 2005, CALCIFIED TISSUE INT, V77, P96, DOI 10.1007/s00223 004 0239 1
   PILBEAM CC, 1993, J BIOL CHEM, V268, P25643
   Pirih FQ, 2005, BIOCHEM BIOPH RES CO, V332, P494, DOI 10.1016/j.bbrc.2005.04.132
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   PUN KK, 1990, J BONE MINER RES, V5, P1193
   Qin L, 2005, J BIOL CHEM, V280, P3104, DOI 10.1074/jbc.M409846200
   Schiller PC, 1999, J BONE MINER RES, V14, P1504, DOI 10.1359/jbmr.1999.14.9.1504
   SCUTT A, 1995, PROSTAGLANDINS, V49, P383, DOI 10.1016/0090 6980(95)00070 Q
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Tetradis S, 1997, ENDOCRINOLOGY, V138, P3594, DOI 10.1210/en.138.9.3594
   van der Horst G, 2005, J BONE MINER RES, V20, P2233, DOI 10.1359/JBMR.050821
   Wang YH, 2005, J BONE MINER RES, V20, P5, DOI 10.1359/JBMR.041016
   Xu M, 2007, J BONE MINER RES, V22, pS66
   Xu Z, 2007, BONE, V41, P68, DOI 10.1016/j.bone.2007.03.009
   Yang D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
   Yang DH, 2008, ENDOCRINOLOGY, V149, P1728, DOI 10.1210/en.2007 0826
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 42
TC 14
Z9 19
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 8
PY 2008
VL 372
IS 4
BP 536
EP 541
DI 10.1016/j.bbrc.2008.05.050
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 323BR
UT WOS:000257419500006
PM 18501188
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Del Fattore, A
   Peruzzi, B
   Rucci, N
   Recchia, I
   Cappariello, A
   Longo, M
   Fortunati, D
   Ballanti, P
   Iacobini, M
   Luciani, M
   Devito, R
   Pinto, R
   Caniglia, M
   Lanino, E
   Messina, C
   Cesaro, S
   Letizia, C
   Bianchini, G
   Fryssira, H
   Grabowski, P
   Shaw, N
   Bishop, N
   Hughes, D
   Kapur, RP
   Datta, HK
   Taranta, A
   Fornari, R
   Migliaccio, S
   Teti, A
AF Del Fattore, A
   Peruzzi, B
   Rucci, N
   Recchia, I
   Cappariello, A
   Longo, M
   Fortunati, D
   Ballanti, P
   Iacobini, M
   Luciani, M
   Devito, R
   Pinto, R
   Caniglia, M
   Lanino, E
   Messina, C
   Cesaro, S
   Letizia, C
   Bianchini, G
   Fryssira, H
   Grabowski, P
   Shaw, N
   Bishop, N
   Hughes, D
   Kapur, RP
   Datta, HK
   Taranta, A
   Fornari, R
   Migliaccio, S
   Teti, A
TI Clinical, genetic, and cellular analysis of 49 osteopetrotic patients:
   implications for diagnosis and treatment
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID AUTOSOMAL DOMINANT OSTEOPETROSIS; ANHYDRASE II DEFICIENCY; RENAL
   TUBULAR ACIDOSIS; BONE RESORPTION; MALIGNANT OSTEOPETROSIS; RECESSIVE
   OSTEOPETROSIS; INTERMEDIATE OSTEOPETROSIS; CEREBRAL CALCIFICATION;
   PROTON TRANSPORT; CLCN7 MUTATIONS
AB Background: Osteopetrosis, a genetic disease characterised by osteoclast failure, is classified into three forms: infantile malignant autosomal recessive osteopetrosis (ARO), intermediate autosomal recessive osteopetrosis (IRO), and autosomal dominant osteopetrosis ( ADO).
   Methods: We studied 49 patients, 21 with ARO, one with IRO, and 27 with type II ADO ( ADO II).
   Results: Most ARO patients bore known or novel ( one case) ATP6i (TCIRG1) gene mutations. Six ADO II patients had no mutations in ClCN7, the only so far recognised gene implicated, suggesting involvement of yet unknown genes. Identical ClCN7 mutations produced differing phenotypes with variable degrees of severity. In ADO II, serum tartrate resistant acid phosphatase was always elevated. Bone alkaline phosphatase (BALP) was generally low, but osteocalcin was high, suggesting perturbed osteoblast differentiation or function. In contrast, BALP was high in ARO patients. Elevated osteoclast surface/bone surface was noted in biopsies from most ARO patients. Cases with high osteoclasts also showed increased osteoblast surface/bone surface. ARO osteoclasts were morphologically normal, with unaltered formation rates, intracellular pH handling, and response to acidification. Their resorption activity was greatly reduced, but not abolished. In control osteoclasts, all resorption activity was abolished by combined inhibition of proton pumping and sodium/proton antiport.
   Conclusions: These findings provide a rationale for novel therapies targeting pH handling mechanisms in osteoclasts and their microenvironment.
C1 Univ Aquila, Dept Expt Med, I 67100 Laquila, Italy.
   Osped Bambino Gesu, Dept Pediat Med, Rome, Italy.
   Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy.
   Univ Roma La Sapienza, Dept Pediat, Rome, Italy.
   Osped Pediat Bambino Gesu, Div Haematol, Rome, Italy.
   Ist Ricovero & Cura Carattere Sci Giannina Gaslin, Dept Pediat Haematol & Oncol, Genoa, Italy.
   Univ Padua, Dept Pediat, Clin Pediat Haematol & Oncol, Padua, Italy.
   Univ Roma La Sapienza, Dept Clin Sci, Div Internal Med, Rome, Italy.
   Univ Athens, Dept Med Genet, Athens, Greece.
   Univ Sheffield, Acad Unit Child Hlth, Sheffield, S Yorkshire, England.
   Childrens Hosp & Reg Med Ctr, Dept Pathol, Seattle, WA USA.
   Univ Newcastle, Sch Med, Sch Clin & Lab Sci, Newcastle Upon Tyne, Tyne & Wear, England.
   Univ Roma La Sapienza, Dept Med Physiopathol, Rome, Italy.
C3 University of L'Aquila; IRCCS Bambino Gesu; Sapienza University Rome;
   Sapienza University Rome; IRCCS Bambino Gesu; University of Padua;
   Sapienza University Rome; National & Kapodistrian University of Athens;
   University of Sheffield; Seattle Children's Hospital; Newcastle
   University   UK; Sapienza University Rome
RP Univ Aquila, Dept Expt Med, Via Vetoio Coppito 2, I 67100 Laquila, Italy.
EM teti@univaq.it
RI Grabowski, Peter/G 2345 2010; Peruzzi, Barbara/K 9455 2016; Cappariello,
   Alfredo/Q 1565 2019; Cesaro, Simone/F 8118 2019; Datta,
   Harish/AAN 5621 2020; Del Fattore, Andrea/H 4409 2015; Luciani,
   Matteo/AAB 3162 2020
OI Grabowski, Peter/0000 0001 5924 1587; Letizia,
   Claudio/0000 0003 4397 0624; Rucci, Nadia/0000 0002 1371 8252; Peruzzi,
   Barbara/0000 0003 1820 5816; Cappariello, Alfredo/0000 0002 1711 3373;
   Cesaro, Simone/0000 0002 8698 9547; Teti, Anna
   Maria/0000 0002 5887 4419; Migliaccio, Silvia/0000 0002 4563 6630; Del
   Fattore, Andrea/0000 0003 3848 412X; De Vito, rita/0000 0002 7450 8398;
   Taranta, Anna/0000 0002 7606 9085
FU Telethon [E.0831] Funding Source: Medline
CR BOLLERSLEV J, 1988, BONE, V9, P7, DOI 10.1016/8756 3282(88)90021 X
   Campos Xavier AB, 2005, AM J MED GENET A, V133A, P216, DOI 10.1002/ajmg.a.30490
   Caselli G, 1997, J BONE MINER RES, V12, P972, DOI 10.1359/jbmr.1997.12.6.972
   Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842
   Cleiren E, 2001, HUM MOL GENET, V10, P2861, DOI 10.1093/hmg/10.25.2861
   Cotter M, 2005, J PEDIAT HEMATOL ONC, V27, P115, DOI 10.1097/01.mph.0000154068.86987.47
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Frattini A, 2003, J BONE MINER RES, V18, P1740, DOI 10.1359/jbmr.2003.18.10.1740
   Glorieux FH, 2000, BONE, V26, P103, DOI 10.1016/S8756 3282(99)00257 4
   HALL TJ, 1990, J CELL PHYSIOL, V142, P420, DOI 10.1002/jcp.1041420227
   Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002 9440(10)63712 1
   Iacobini M, 2001, J BONE MINER RES, V16, P2356, DOI 10.1359/jbmr.2001.16.12.2356
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Lajeunesse D, 1996, J CLIN INVEST, V98, P1835, DOI 10.1172/JCI118984
   Letizia C, 2004, CALCIFIED TISSUE INT, V74, P42, DOI 10.1007/s00223 002 1087 5
   LIAN JB, 1990, ENDOCRINOLOGY, V126, P955, DOI 10.1210/endo 126 2 955
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Meghji S, 2001, AM J PHYSIOL ENDOC M, V280, pE112, DOI 10.1152/ajpendo.2001.280.1.E112
   Migliaccio S, 1999, J BONE MINER RES, V14, P834, DOI 10.1359/jbmr.1999.14.5.834
   Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729
   OHLSSON A, 1986, PEDIATRICS, V77, P371
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   PARFITT AM, 1982, METAB BONE DIS RELAT, V4, P1, DOI 10.1016/0221 8747(82)90002 9
   Pogoda P, 2005, OSTEOPOROSIS INT, V16, pS18, DOI 10.1007/s00198 004 1787 y
   Quarello P, 2004, J BONE MINER RES, V19, P1194, DOI 10.1359/JBMR.040407
   QUINN JM, 2005, BIOCHEM BIOPH RES CO, V18, P739
   Ramírez A, 2004, HUM MUTAT, V23, P471, DOI 10.1002/humu.20028
   SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006 291X(90)91709 2
   SUNDQUIST KT, 1994, J BONE MINER RES, V9, P1575
   Taranta A, 2003, AM J PATHOL, V162, P57, DOI 10.1016/S0002 9440(10)63798 4
   Teti A, 1999, J BONE MINER RES, V14, P2107, DOI 10.1359/jbmr.1999.14.12.2107
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Waguespack SG, 2003, J BONE MINER RES, V18, P1513, DOI 10.1359/jbmr.2003.18.8.1513
   Whyte M.P., 2002, CONNECTIVE TISSUE IT, V2nd, P753
   WHYTE MP, 1993, CLIN ORTHOP RELAT R, P52
NR 38
TC 141
Z9 153
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022 2593
EI 1468 6244
J9 J MED GENET
JI J. Med. Genet.
PD APR
PY 2006
VL 43
IS 4
BP 315
EP 325
DI 10.1136/jmg.2005.036673
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 028EO
UT WOS:000236469900004
PM 16118345
OA Green Published
DA 2025 08 17
ER

PT J
AU Li, N
   Kelsh, RN
   Croucher, P
   Roehl, HH
AF Li, Nan
   Kelsh, Robert N.
   Croucher, Peter
   Roehl, Henry H.
TI Regulation of neural crest cell fate by the retinoic acid and Pparg
   signalling pathways
SO DEVELOPMENT
LA English
DT Article
DE Adipocyte; Osteoprogenitor; Osteoblast; Osteoblastogenesis; All trans
   retinoic acid; Bone; Cephalic neural crest; osterix (sp7); tcf7;
   Mesenchymal stem cell; Adipoprogenitor; Peroxisome
   proliferator activated receptor gamma (Pparg); CCAAT/enhancer binding
   protein alpha (Cebpa); Runt related transcription factor 2 (Runx2; Core
   binding factor a1); Zebrafish
ID ZEBRAFISH DANIO RERIO; OSTEOBLAST DIFFERENTIATION; BONE MARROW;
   STEM CELLS; GENE EXPRESSION; TRANSCRIPTION FACTOR; GAMMA INSUFFICIENCY;
   BINDING PROTEIN; ADIPOSE TISSUE; ADIPOGENESIS
AB Although the regulation of osteoblast and adipocyte differentiation from mesenchymal stem cells has been studied for some time, very little is known about what regulates their appearance in discrete regions of the embryo. Here we show that, as in other vertebrates, zebrafish osteoblasts and adipocytes originate in part from cephalic neural crest (CNC) precursors. We investigated the roles that the retinoic acid (RA) and Peroxisome proliferator activated receptor gamma (Pparg) pathways play in vivo and found that both pathways act on CNC to direct adipocyte differentiation at the expense of osteoblast formation. In addition, we identify two distinct roles for RA in the osteoblast lineage: an early role in blocking the recruitment of osteoblasts and a later role in mature osteoblasts to promote bone matrix synthesis. These findings might help to increase our understanding of skeletal and obesity related diseases and aid in the development of stem cell based regenerative therapies.
C1 [Li, Nan; Roehl, Henry H.] Univ Sheffield, MRC, Ctr Dev & Biomed Genet, Western Bank, Sheffield S10 2TN, S Yorkshire, England.
   [Kelsh, Robert N.] Univ Bath, Dept Biol & Biochem, Ctr Regenerat Med, Bath BA2 7AY, Avon, England.
   [Croucher, Peter] Univ Sheffield, Sch Med, Sect Musculoskeletal Sci, Acad Unit Bone Biol, Sheffield S10 2RX, S Yorkshire, England.
C3 University of Sheffield; University of Bath; University of Sheffield
RP Roehl, HH (通讯作者)，Univ Sheffield, MRC, Ctr Dev & Biomed Genet, Western Bank, Addison Bldg, Sheffield S10 2TN, S Yorkshire, England.
EM h.roehl@sheffield.ac.uk
RI Kelsh, Robert/B 6445 2008; Kelsh, Robert Neil/B 6445 2008
OI Kelsh, Robert Neil/0000 0002 9381 0066; Croucher,
   Peter/0000 0002 7102 2413
FU Wellcome Trust [072346/Z/03/Z]; Cancer Research UK [C11413/A4072];
   European Union; Medical Research Council [G070091]; Medical Research
   Council [G0700091B] Funding Source: researchfish
FX This work was supported by the Wellcome Trust (072346/Z/03/Z), Cancer
   Research UK (C11413/A4072), the European Union `Cells into Organs NoE'
   and the Medical Research Council (G070091). Deposited in PMC for release
   after 6 months.
CR Ahmed N, 2000, CYTOKINE, V12, P289, DOI 10.1006/cyto.1999.0588
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Allen SP, 2002, DEV BIOL, V251, P409, DOI 10.1006/dbio.2002.0816
   Begemann G, 2001, DEVELOPMENT, V128, P3081
   Begemann G, 2004, DEV BIOL, V271, P119, DOI 10.1016/j.ydbio.2004.03.033
   BENAYAHU D, 1994, J CELL BIOCHEM, V56, P62, DOI 10.1002/jcb.240560111
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Billon N, 2007, DEVELOPMENT, V134, P2283, DOI 10.1242/dev.002642
   BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756 3282(87)90015 9
   Carney TJ, 2006, DEVELOPMENT, V133, P4619, DOI 10.1242/dev.02668
   CHOONG PFM, 1993, J ORTHOP RES, V11, P638, DOI 10.1002/jor.1100110505
   Clément A, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000136
   Delfino Machin M, 2007, DEV DYNAM, V236, P3242, DOI 10.1002/dvdy.21314
   Dupin E, 2007, CR BIOL, V330, P521, DOI 10.1016/j.crvi.2007.04.004
   Fisher S, 2003, DEV BIOL, V264, P64, DOI 10.1016/S0012 1606(03)00399 3
   Flores MV, 2004, GENE EXPR PATTERNS, V4, P573, DOI 10.1016/j.modgep.2004.01.016
   Flynn EJ, 2009, J LIPID RES, V50, P1641, DOI 10.1194/jlr.M800590 JLR200
   Gibert Y, 2006, DEVELOPMENT, V133, P2649, DOI 10.1242/dev.02438
   Grey A, 2008, OSTEOPOROSIS INT, V19, P129, DOI 10.1007/s00198 007 0477 y
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772
   Kanatani N, 2006, DEV BIOL, V296, P48, DOI 10.1016/j.ydbio.2006.03.039
   Kawaguchi H, 2005, J BONE MINER METAB, V23, P275, DOI 10.1007/s00774 005 0599 2
   Kazakova N, 2006, DEV BIOL, V297, P1, DOI 10.1016/j.ydbio.2006.03.020
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Koo KH, 1998, RADIOLOGY, V206, P745, DOI 10.1148/radiology.206.3.9494495
   Lang MR, 2006, NAT GENET, V38, P1198, DOI 10.1038/ng1880
   Laue K, 2008, DEVELOPMENT, V135, P3775, DOI 10.1242/dev.021238
   Le Douarin NM, 2004, DEVELOPMENT, V131, P4637, DOI 10.1242/dev.01350
   Leesnitzer LM, 2002, BIOCHEMISTRY US, V41, P6640, DOI 10.1021/bi0159581
   Li N, 2009, DEV DYNAM, V238, P459, DOI 10.1002/dvdy.21838
   Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898
   Linville A, 2004, DEV BIOL, V270, P186, DOI 10.1016/j.ydbio.2004.02.022
   Liu RZ, 2007, FEBS J, V274, P1621, DOI 10.1111/j.1742 4658.2007.05711.x
   Manji SS, 1998, J CELL PHYSIOL, V176, P1
   Meunier P, 1971, CLIN ORTHOP RELAT R, V80, P147, DOI DOI 10.1097/00003086 197110000 00021
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756 3282(00)00317 3
   OHISHI K, 1995, EUR J ENDOCRINOL, V133, P335, DOI 10.1530/eje.0.1330335
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Phillips BW, 2003, PHARMACOL RES, V47, P263, DOI 10.1016/S1043 6618(03)00035 5
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Schlegel A, 2006, BIOCHEMISTRY US, V45, P15179, DOI 10.1021/bi0619268
   Song HM, 2005, J CELL PHYSIOL, V202, P255, DOI 10.1002/jcp.20115
   Song Y, 2007, FASEB J, V21, P2042, DOI 10.1096/fj.06 7503com
   Spoorendonk KM, 2008, DEVELOPMENT, V135, P3765, DOI 10.1242/dev.024034
   Takashima Y, 2007, CELL, V129, P1377, DOI 10.1016/j.cell.2007.04.028
   Thisse B, 2001, R01RR15402 NIH ZFIN
   Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092 8674(94)90006 X
   UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644
   van der Meulen T, 2005, BBA GENE STRUCT EXPR, V1729, P105, DOI 10.1016/j.bbaexp.2005.03.008
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Weston Andrea D., 2003, Birth Defects Research, V69, P156, DOI 10.1002/bdrc.10010
   Wiper Bergeron N, 2007, MOL ENDOCRINOL, V21, P2124, DOI 10.1210/me.2006 0452
   Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540
   Zhao LJ, 2008, J BONE MINER RES, V23, P17, DOI 10.1359/JBMR.070813
NR 60
TC 34
Z9 38
U1 0
U2 14
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0950 1991
EI 1477 9129
J9 DEVELOPMENT
JI Development
PD FEB 1
PY 2010
VL 137
IS 3
BP 389
EP 394
DI 10.1242/dev.044164
PG 6
WC Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology
GA 544WV
UT WOS:000273691600004
PM 20081187
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Merrell, MA
   Wakchoure, S
   Lehenkari, PP
   Harris, KW
   Selander, KS
AF Merrell, Melinda A.
   Wakchoure, Savita
   Lehenkari, Petri P.
   Harris, Kevin W.
   Selander, Katri S.
TI Inhibition of the mevalonate pathway and activation of p38 MAP kinase
   are independently regulated by nitrogen containing bisphosphonates in
   breast cancer cells
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Bisphosphonates; p38; mevalonate pathway; cell cycle
ID ADJUVANT CLODRONATE TREATMENT; INDUCED GROWTH INHIBITION; ZOLEDRONIC
   ACID; CONTROLLED TRIAL; IN VITRO; MEMBRANE LOCALIZATION; SKELETAL
   METASTASES; INDUCE APOPTOSIS; ORAL CLODRONATE; MYELOMA CELLS
AB Bisphosphonates are widely used inhibitors of bone resorption. They also inhibit the growth of various cancer cells in vitro, but the clinical significance of this effect is unclear. The cancer growth inhibitory effects of nitrogen containing bisphosphonates, (i.e. zoledronate) have been attributed to their ability to inhibit the mevalonate pathway. We have shown that bisphosphonates also induce p38 activation, which signals resistance against the drug induced growth inhibition through an unknown mechanism. We show here that zoledronate induces a G1/S cell cycle arrest in human MDA MB 231 breast cancer cells. Furthermore, p38 inhibitor augments bisphosphonate induced growth inhibition by inducing an additional G2 phase cell cycle arrest. We also show that the nitrogen containing bisphosphonate induced effects on p38 phosphorylation occur before accumulation of unprenylated Rap1A or Rac1 activation. Geranylgeranyl pyrophosphate, an end product of the mevalonate pathway, reversed the accumulation of unprenylated Rap1A but not phosphorylation of p38. Geranylgeranyl pyrophosphate also reversed n BP induced growth inhibition, but the completeness of this reversal was nitrogen containing bisphosphonate concentration dependent. Also mevastatin induced the accumulation of unprenylated Rap I A, but it did not induce p38 phosphorylation. In conclusion, our results suggest that in addition to the previously reported effects on apoptosis, nitrogen containing bisphosphonates also inhibit the growth of MDA MB 231 breast cancer cells by inducing G1/S cell cycle arrest. The bisphosphonate induced p38 activation signals for resistance against these drugs, by promoting progression through the G2/M checkpoint. Of these pathways only growth inhibition is mediated via inhibition of the mevalonate pathway in MDA MB 231 cells. Combining p38 inhibitors with bisphosphonates may result in increased anti cancer efficacy. (c) 2007 Elsevier B.V. All rights reserved.
C1 Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA.
   Oulu Univ, Clin Res Ctr, Dept Surg, Oulu, Finland.
   Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Oulu; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Veterans Affairs Medical Center   Birmingham
RP Selander, KS (通讯作者)，Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, WTI T558,1824 6th Ave S, Birmingham, AL 35294 USA.
EM Katri.Selander@ccc.uab.edu
RI Merrell, Melinda/IUO 5528 2023; Selander, Katri/GWM 8685 2022;
   Lehenkari, Petri/O 3009 2016
OI Lehenkari, Petri/0000 0002 0055 5183
CR Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   Berenson JR, 2001, AM J HEALTH SYST PH, V58, pS16, DOI 10.1093/ajhp/58.suppl_3.S16
   Chuah C, 2005, LEUKEMIA, V19, P1896, DOI 10.1038/sj.leu.2403949
   Conte P, 2004, SEMIN ONCOL, V31, P59, DOI 10.1053/j.seminoncol.2004.07.024
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Dumon JC, 2004, EUR UROL, V45, P521, DOI 10.1016/j.eururo.2003.12.012
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Forsea AM, 2004, BRIT J CANCER, V91, P803, DOI 10.1038/sj.bjc.6602052
   Frith JC, 2003, J BONE MINER RES, V18, P204, DOI 10.1359/jbmr.2003.18.2.204
   Iguchi T, 2003, CELL SIGNAL, V15, P719, DOI 10.1016/S0898 6568(03)00007 X
   Journe F, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1363
   Kanis JA, 1996, BONE, V19, P663, DOI 10.1016/S8756 3282(96)00285 2
   Kanno Tomoko, 2002, Physiological Chemistry and Physics and Medical NMR, V34, P1
   Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177
   Lee MV, 2001, CANCER RES, V61, P2602
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Merrell M, 2003, BREAST CANCER RES TR, V81, P231, DOI 10.1023/A:1026126430905
   Merrell MA, 2007, EUR J PHARMACOL, V559, P21, DOI 10.1016/j.ejphar.2006.11.064
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Neville Webbe HL, 2006, TUMOR BIOL, V27, P92, DOI 10.1159/000092489
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Reinholz GG, 2002, BREAST CANCER RES TR, V71, P257, DOI 10.1023/A:1014418017382
   Riebeling C, 2002, BRIT J CANCER, V87, P366, DOI 10.1038/sj.bjc.6600476
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rosen CJ, 2005, NEW ENGL J MED, V353, P595, DOI 10.1056/NEJMcp043801
   Ross JR, 2004, HEALTH TECHNOL ASSES, V8, pIII
   Ross JR, 2003, BMJ BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469
   Saarto T, 2004, ACTA ONCOL, V43, P650, DOI 10.1080/02841860410032885
   Saarto T, 2001, J CLIN ONCOL, V19, P10, DOI 10.1200/JCO.2001.19.1.10
   Segawa H, 2005, BRIT J HAEMATOL, V130, P558, DOI 10.1111/j.1365 2141.2005.05648.x
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Thompson K, 2006, BLOOD, V107, P651, DOI 10.1182/blood 2005 03 1025
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Verdijk R, 2007, CANCER LETT, V246, P308, DOI 10.1016/j.canlet.2006.03.011
   Wakchoure S, 2006, CLIN CANCER RES, V12, P2862, DOI 10.1158/1078 0432.CCR 05 2766
   Woodward JKL, 2005, ANTI CANCER DRUG, V16, P845, DOI 10.1097/01.cad.0000175582.01446.6f
NR 45
TC 35
Z9 39
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 10
PY 2007
VL 570
IS 1 3
BP 27
EP 37
DI 10.1016/j.ejphar.2007.05.075
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 208BP
UT WOS:000249295100004
PM 17640631
DA 2025 08 17
ER

PT J
AU Zhang, DW
   Liu, DD
   Zhang, JC
   Fong, CC
   Yang, MS
AF Zhang, Dawei
   Liu, Dandan
   Zhang, Jinchao
   Fong, Chichun
   Yang, Mengsu
TI Gold nanoparticles stimulate differentiation and mineralization of
   primary osteoblasts through the ERK/MAPK signaling pathway
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Primary osteoblast; Differentiation; Gold nanoparticles; Runt related
   transcription factor 2; Extracellular signal regulated kinases
ID TRANSCRIPTION FACTOR; KINASE; CYTOTOXICITY; INTEGRIN; COLLAGEN; GROWTH;
   PROLIFERATION; ACTIVATION; EXPRESSION; ADHESION
AB Gold nanoparticles (AuNPs) have shown great promise for a variety of applications, including chemistry, biology, and medicine. Recently, AuNPs have found promising applications in cartilage and bone repair. However, to realize the above promised applications, more work needs to be carried out to clarify the interactions between biological systems and AuNPs. In the present study, primary osteoblasts were used to evaluate the biocompatibility of 20 nm and 40 nm AuNPs, including morphology, proliferation, differentiation, gene and protein expression, and the underlying mechanisms. The results demonstrated that AuNPs were taken up by osteoblasts and aggregated in perinuclear compartment and vescular structures, but no morphological changes were observed. AuNPs could significantly promote the proliferation of osteoblasts, enhance the ALP activities, and increase the number of bone nodules and calcium content in vitro. In addition, the expression of BMP 2, Runx 2, OCN and Col 1 was remarkably up regulated in the presence of AuNPs. It is noteworthy that 20 nm AuNPs are more potent than 40 nm AuNPs in regulating osteoblast activities. Besides, AuNPs increased the level of ERR phosphorylation/total ERR, suggesting the activation of ERK/MAPK pathway is involved in above activities. In conclusion, AuNPs exhibited great biocompatibility with osteoblasts, and have tremendous potential to be used as drug and/or gene delivery carrier for bone and tissue engineering in the future. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Zhang, Dawei] Guangdong Med Coll, Dept Pharmacol, Dongguan 523808, Peoples R China.
   [Liu, Dandan; Zhang, Jinchao] Hebei Univ, Coll Chem & Environm Sci, Chem Biol Key Lab Hebei Prov, Minist Educ,Key Lab Med Chem & Mol Diag, Baoding 071002, Peoples R China.
   [Zhang, Dawei; Liu, Dandan; Fong, Chichun; Yang, Mengsu] City Univ Hong Kong, Dept Biomed Sci, Kowloon Tong, Peoples R China.
C3 Guangdong Medical University; Hebei University; City University of Hong
   Kong
RP Zhang, JC (通讯作者)，Hebei Univ, Coll Chem & Environm Sci, Chem Biol Key Lab Hebei Prov, Minist Educ,Key Lab Med Chem & Mol Diag, Baoding 071002, Peoples R China.
EM jczhang6970@163.com; bhmyang@cityu.edu.hk
RI Yang, Mengsu/I 5750 2015; Zhang, Dawei/IAN 9726 2023
OI Yang, Mengsu/0000 0003 2083 2296; 
FU National Natural Science Foundation of China [21271059, 20971034];
   Research Fund for the Doctoral Program of Higher Education of China
   [20111301110004]; Hundred Excellent Innovation Talents Supporting
   Project of Hebei Province [BR2 201]; Training Program for Innovative
   Research Team and Leading Talent in Hebei Province University [LJRC024];
   Administrative Bureau of Traditional Chinese Medicine of Guangdong
   Province [20131260]; Doctor Scientific Start up Fund Projects of
   Guangdong Medical College [B2012007]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 21271059 and 20971034), the Research Fund for the Doctoral
   Program of Higher Education of China (No. 20111301110004), the Hundred
   Excellent Innovation Talents Supporting Project of Hebei Province
   (BR2 201), the Training Program for Innovative Research Team and Leading
   Talent in Hebei Province University (LJRC024), the Administrative Bureau
   of Traditional Chinese Medicine of Guangdong Province (No. 20131260),
   and the Doctor Scientific Start up Fund Projects of Guangdong Medical
   College (B2012007).
CR Aryal S, 2006, J MATER CHEM, V16, P4642, DOI 10.1039/b608300e
   Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079 6107(98)00056 X
   Connor EE, 2005, SMALL, V1, P325, DOI 10.1002/smll.200400093
   Derfus AM, 2004, NANO LETT, V4, P11, DOI 10.1021/nl0347334
   Dhar S, 2009, J AM CHEM SOC, V131, P14652, DOI 10.1021/ja9071282
   El Sayed IH, 2005, NANO LETT, V5, P829, DOI 10.1021/nl050074e
   Filon FL, 2011, NANOTOXICOLOGY, V5, P493, DOI 10.3109/17435390.2010.551428
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359
   Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i
   Gutwein LG, 2002, J NANOPART RES, V4, P231, DOI 10.1023/A:1019920105207
   Hata K, 2007, J BIOMED MATER RES A, V81A, P446, DOI 10.1002/jbm.a.31086
   Hillyer JF, 2001, J PHARM SCI, V90, P1927, DOI 10.1002/jps.1143
   Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804
   Hsu SH, 2007, ARTIF ORGANS, V31, P854, DOI 10.1111/j.1525 1594.2007.00482.x
   Jayakumar P, 2010, P I MECH ENG H, V224, P1415, DOI 10.1243/09544119JEIM821
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Keselowsky BG, 2005, P NATL ACAD SCI USA, V102, P5953, DOI 10.1073/pnas.0407356102
   Khan JA, 2007, CHEMBIOCHEM, V8, P1237, DOI 10.1002/cbic.200700165
   Kirchner C, 2005, NANO LETT, V5, P331, DOI 10.1021/nl047996m
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Li W, 2001, AM J PHYSIOL GASTR L, V280, pG75, DOI 10.1152/ajpgi.2001.280.1.G75
   Liu DR, 2010, ELECTROCHIM ACTA, V55, P1013, DOI 10.1016/j.electacta.2009.09.072
   Mahmood A, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/735420
   Malaval L, 1999, J CELL BIOCHEM, V74, P616
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Qi SJ, 2007, CHEMBIOCHEM, V8, P1115, DOI 10.1002/cbic.200700119
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Shvedova AA, 2003, J TOXICOL ENV HEAL A, V66, P1909, DOI 10.1080/713853956
   Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060
   Sobhana SSL, 2009, J NANOPART RES, V11, P333, DOI 10.1007/s11051 008 9385 0
   Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309
   Van Hoecke K, 2013, NANOTOXICOLOGY, V7, P37, DOI 10.3109/17435390.2011.626566
   Verma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158
   Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Zhang DW, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957 4484/18/47/475102
   [张大威 Zhang Dawei], 2007, [中国药学杂志, Chinese Pharmaceutical Journal], V42, P161
NR 41
TC 117
Z9 126
U1 0
U2 68
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD SEP 1
PY 2014
VL 42
BP 70
EP 77
DI 10.1016/j.msec.2014.04.042
PG 8
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA AN6EJ
UT WOS:000340687400011
PM 25063094
OA Bronze
DA 2025 08 17
ER

PT J
AU Chen, ZJ
   Pan, X
   Huang, H
   Xie, Z
   Ma, Y
   Wang, JY
   Sun, XW
   Shi, PH
AF Chen, Zhijun
   Pan, Xin
   Huang, Hai
   Xie, Ziang
   Ma, Yan
   Wang, Jiying
   Sun, Xuewu
   Shi, Peihua
TI Forsythoside A Inhibits Osteoclast Genesis and Bone Resorption via
   Suppressing NF κB Signaling
SO LATIN AMERICAN JOURNAL OF PHARMACY
LA English
DT Article
DE forsythoside; NF kappa B; osteoclast
ID DIFFERENTIATION; OSTEOPOROSIS; ACTIVATION
AB Over activation of osteoclastogenesis is involved in osteoporosis and inflammatory osteolysis. Limited drugs are used up to now to treat these diseases with minor complications. It is of great importance to explore the mechanism behind these diseases and seek novel target to take control of the disorganized osteoclastogenesis. In our study, we firstly found that forsythoside A (FT A) inhibited LPS induced calvaria osteolysis via suppressing the formation or recruitment of osteoclasts. FT A inhibited osteoclast differentiation and down regulated the osteoclast marker genes including C FOS and NFATC1 in vitro. Mechanically, FT A inhibited RANKL induced NF kappa B signaling via suppressing the degradation of I kappa B alpha and phosphorylation of P65. Thus, FT A might be a promising drug in treating osteoporosis.
C1 [Chen, Zhijun; Pan, Xin; Huang, Hai; Xie, Ziang; Ma, Yan; Sun, Xuewu; Shi, Peihua] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Hangzhou, Zhejiang, Peoples R China.
   [Chen, Zhijun; Pan, Xin; Huang, Hai; Xie, Ziang; Ma, Yan; Wang, Jiying; Sun, Xuewu; Shi, Peihua] Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Shi, PH (通讯作者)，Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Hangzhou, Zhejiang, Peoples R China.; Shi, PH (通讯作者)，Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou, Zhejiang, Peoples R China.
EM shipeihua0228@163.com
RI Wang, Yijun/GXW 1763 2022
FU National Natural Science Fund of China [81874015, 81873985]; Natural
   Science Fund of Zhejiang Province [LY16H060004]
FX National Natural Science Fund of China (Contract grant number: 81874015;
   81873985. Natural Science Fund of Zhejiang Province (Contract grant
   number: LY16H060004).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brumsen C, 1997, MEDICINE, V76, P266, DOI 10.1097/00005792 199707000 00005
   Chen S, 2015, SCI REP UK, V5, DOI 10.1038/srep12853
   Cheng GD, 2014, EXP THER MED, V7, P179, DOI 10.3892/etm.2013.1378
   Cheng L, 2015, INT IMMUNOPHARMACOL, V28, P494, DOI 10.1016/j.intimp.2015.07.011
   Dou C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.69
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gough A, 1998, J RHEUMATOL, V25, P1282
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   Knopp Sihota JA, 2013, BMC GERIATR, V13, DOI 10.1186/1471 2318 13 36
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Ma JJ, 2015, BIOCHEM J, V469, P399, DOI 10.1042/BJ20150151
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Song QJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162791
   Swarnkar G, 2015, P NATL ACAD SCI USA, V112, P154, DOI 10.1073/pnas.1415213112
   Takahashi N, 2003, METH MOLEC MED, V80, P129
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Zhao BH, 2012, J EXP MED, V209, P319, DOI 10.1084/jem.20111566
   Zhu X, 2016, J BONE MINER RES, V31, P560, DOI 10.1002/jbmr.2710
NR 23
TC 0
Z9 0
U1 0
U2 6
PU COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
PI LA PLATA
PA DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA
SN 0326 2383
J9 LAT AM J PHARM
JI Lat. Am. J. Pharm.
PY 2019
VL 38
IS 5
BP 973
EP 978
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA IB2FO
UT WOS:000470085300019
DA 2025 08 17
ER

PT J
AU Zeng, YX
   Pan, ZX
   Yuan, JP
   Song, YQ
   Feng, ZZ
   Chen, ZF
   Ye, ZY
   Li, YS
   Bao, Y
   Ran, ZL
   Li, XY
   Ye, HL
   Zhang, K
   Liu, XJ
   He, Y
AF Zeng, Yaoxun
   Pan, Zhenxing
   Yuan, Jiongpeng
   Song, Yuqiong
   Feng, Zhenzhen
   Chen, Zefeng
   Ye, Zhaoyi
   Li, Yushan
   Bao, Ying
   Ran, Zhili
   Li, Xinyi
   Ye, Huiling
   Zhang, Kun
   Liu, Xujie
   He, Yan
TI Inhibiting Osteolytic Breast Cancer Bone Metastasis by Bone Targeted
   Nanoagent via Remodeling the Bone Tumor Microenvironment Combined with
   NIR II Photothermal Therapy
SO SMALL
LA English
DT Article
DE bone microenvironments; bone targeting; breast cancer bone metastasis;
   RNA seq; synergistic therapies
ID ZOLEDRONIC ACID; NANOPARTICLE; MECHANISMS; DORMANCY; PROMOTE; GROWTH
AB Bone is one of the prone metastatic sites of patients with advanced breast cancer. The "vicious cycle" between osteoclasts and breast cancer cells plays an essential role in osteolytic bone metastasis from breast cancer. In order to inhibit bone metastasis from breast cancer, NIR II photoresponsive bone targeting nanosystems (CuP@PPy ZOL NPs) are designed and synthesized. CuP@PPy ZOL NPs can trigger the photothermal enhanced Fenton response and photodynamic effect to enhance the photothermal treatment (PTT) effect and thus achieve synergistic anti tumor effect. Meanwhile, they exhibit a photothermal enhanced ability to inhibit osteoclast differentiation and promote osteoblast differentiation, which reshaped the bone microenvironment. CuP@PPy ZOL NPs effectively inhibited the proliferation of tumor cells and bone resorption in the in vitro 3D bone metastases model of breast cancer. In a mouse model of breast cancer bone metastasis, CuP@PPy ZOL NPs combined with PTT with NIR II significantly inhibited the tumor growth of breast cancer bone metastases and osteolysis while promoting bone repair to achieve the reversal of osteolytic breast cancer bone metastases. Furthermore, the potential biological mechanisms of synergistic treatment are identified by conditioned culture experiments and mRNA transcriptome analysis. The design of this nanosystem provides a promising strategy for treating osteolytic bone metastases.
C1 [Zeng, Yaoxun; Pan, Zhenxing; Yuan, Jiongpeng; Feng, Zhenzhen; Ye, Zhaoyi; Li, Yushan; Bao, Ying; Ran, Zhili; Li, Xinyi; Ye, Huiling; Zhang, Kun; Liu, Xujie; He, Yan] Guangdong Univ Technol, Sch Biomed & Pharmaceut Sci, Allan H Conney Lab Anticanc Res, Guangzhou 510006, Guangdong, Peoples R China.
   [Song, Yuqiong] Chinese Acad Fishery Sci, South China Sea Fisheries Res Inst, Key Lab Aquat Prod Proc, Minist Agr & Rural Affairs, Guangzhou 510300, Peoples R China.
   [Chen, Zefeng] Hong Kong Baptist Univ, Law Sau Fai Inst Adv Translat Med Bone & Joint Dis, Sch Chinese Med, Kowloon, Hong Kong 999077, Peoples R China.
C3 Guangdong University of Technology; Chinese Academy of Fishery Sciences;
   South China Sea Fisheries Research Institute, CAFS; Hong Kong Baptist
   University
RP Liu, XJ; He, Y (通讯作者)，Guangdong Univ Technol, Sch Biomed & Pharmaceut Sci, Allan H Conney Lab Anticanc Res, Guangzhou 510006, Guangdong, Peoples R China.
EM liuxujie@gdut.edu.cn; heyan129@gdut.edu.cn
RI Li, Yushan/HKE 5889 2023; Li, Xinyi/HGF 1033 2022; xujie,
   liu/AAW 6608 2021; Zhang, Kun/S 5005 2019; Bao, Ying/J 5134 2014; Song,
   Yuqiong/JAC 4922 2023
FU National Natural Science Foundation of China [32171314, 81803000];
   Guangdong Basic and Applied Basic Research Foundation [2022A1515010671];
   Guangzhou Basic and Applied Basic Research Foundation [202201010371];
   University Innovative Team Support for Major Chronic Diseases and Drug
   Development [26330320901]
FX Y.Z. and Z.P. contributed equally to this work. This work was supported
   by the National Natural Science Foundation of China (32171314 and
   81803000), Guangdong Basic and Applied Basic Research Foundation
   (2022A1515010671), Guangzhou Basic and Applied Basic Research Foundation
   (202201010371) and University Innovative Team Support for Major Chronic
   Diseases and Drug Development (26330320901). All animal procedures were
   performed in accordance with the Guidelines for Care and Use of
   Laboratory Animals of Guangdong University of Technology and approved by
   the Animal Ethics Committee of Guangdong University of Technology. The
   authors would like to thank Fu Yanlin from Shiyanjia Lab () for the
   Bio SEM characterization. The authors would like to thank Analysis and
   Test Center of Guangdong University of technology for materials
   characterization. mRNA sequencing analysis was performed using BMKCloud
   ().
CR Bai SB, 2019, NANOMED NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102054
   Body JJ, 2015, NAT REV UROL, V12, P340, DOI 10.1038/nrurol.2015.90
   Chang MY, 2021, ADV MATER, V33, DOI 10.1002/adma.202004788
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Chen L, 2019, ADV MATER, V31, DOI 10.1002/adma.201904997
   Cheng YT, 2021, EXP BIOL MED, V246, P1727, DOI 10.1177/15353702211011052
   Cheng YY, 2020, ACS NANO, V14, P15161, DOI 10.1021/acsnano.0c05392
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Ding BB, 2020, ANGEW CHEM INT EDIT, V59, P16381, DOI 10.1002/anie.202005111
   Ding F, 2020, BIOMATERIALS, V245, DOI 10.1016/j.biomaterials.2020.119976
   Ding XG, 2014, J AM CHEM SOC, V136, P15684, DOI 10.1021/ja508641z
   Dong CH, 2020, ADV SCI, V7, DOI 10.1002/advs.202001549
   Duan Y, 2016, INT J NANOMED, V11, P5697, DOI 10.2147/IJN.S111274
   Feng W, 2019, ADV MATER, V31, DOI 10.1002/adma.201805919
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Galasso M, 2021, FREE RADICAL BIO MED, V172, P264, DOI 10.1016/j.freeradbiomed.2021.06.010
   Gao X, 2021, BIOMATERIALS, V265, DOI 10.1016/j.biomaterials.2020.120404
   Gartrell BA, 2015, NAT REV CLIN ONCOL, V12, P3, DOI 10.1038/nrclinonc.2014.201
   Gu ZK, 2022, NANO RES, V15, P1547, DOI 10.1007/s12274 021 3700 9
   Hadjidemetriou M, 2017, NAT NANOTECHNOL, V12, P288, DOI 10.1038/nnano.2017.61
   Hofbauer LC, 2014, LANCET DIABETES ENDO, V2, P500, DOI 10.1016/S2213 8587(13)70203 1
   Hou L, 2020, J CONTROL RELEASE, V319, P438, DOI 10.1016/j.jconrel.2020.01.014
   Hu ZC, 2022, CHEM ENG J, V446, DOI 10.1016/j.cej.2022.137269
   Huang XL, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2021.12575
   Kim MS, 2021, WATER RES, V201, DOI 10.1016/j.watres.2021.117338
   Kitazawa R, 2018, HISTOCHEM CELL BIOL, V149, P405, DOI 10.1007/s00418 018 1639 z
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Li ZZ, 2020, J MATER CHEM B, V8, P2598, DOI 10.1039/c9tb02529d
   Lin W, 2021, MOL MED, V27, DOI 10.1186/s10020 021 00276 5
   Liu B, 2020, ADV MATER, V32, DOI 10.1002/adma.202004460
   Liu CH, 2019, ACS NANO, V13, P4267, DOI 10.1021/acsnano.8b09387
   Liu Y, 2020, J AM CHEM SOC, V142, P21751, DOI 10.1021/jacs.0c09482
   Liu YX, 2021, ADV MATER, V33, DOI 10.1002/adma.202008615
   Ma K, 2021, SMALL, V17, DOI 10.1002/smll.202104747
   Marlow R, 2013, CANCER RES, V73, P6886, DOI 10.1158/0008 5472.CAN 13 0991
   Massagué J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Neven L, 2022, ANAL CHEM, V94, P5221, DOI [10.1021/acs.analchem.1c04357, 10.1021/ACS.ANALCHEM.1c04357]
   Pang YC, 2020, NANO LETT, V20, P829, DOI 10.1021/acs.nanolett.9b02916
   Qattan A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238905
   Raina DB, 2018, J CONTROL RELEASE, V272, P83, DOI 10.1016/j.jconrel.2018.01.006
   Shang FQ, 2021, BIOACT MATER, V6, P666, DOI 10.1016/j.bioactmat.2020.08.014
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Su JJ, 2021, ADV MATER, V33, DOI 10.1002/adma.202100619
   Sun R, 2022, ADV DRUG DELIVER REV, V191, DOI 10.1016/j.addr.2022.114614
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Suvannasankha A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058 014 0484 9
   Tampieri F, 2021, ANAL CHEM, V93, P3666, DOI 10.1021/acs.analchem.0c04906
   Tang N, 2021, ANGEW CHEM INT EDIT, V60, P6509, DOI 10.1002/anie.202016122
   Tee JK, 2019, CHEM SOC REV, V48, P5381, DOI 10.1039/c9cs00309f
   Tian H, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201703197
   Wang B, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.961941
   Wang CP, 2015, SMALL, V11, P2080, DOI 10.1002/smll.201403315
   Wang C, 2016, ACS APPL MATER INTER, V8, P11262, DOI 10.1021/acsami.6b01103
   Wang JF, 2022, ADV MATER, V34, DOI 10.1002/adma.202106082
   Wang MN, 2020, BONE RES, V8, DOI 10.1038/s41413 020 00105 1
   Wang X, 2019, INT J NANOMED, V14, P4319, DOI 10.2147/IJN.S203077
   Wang YQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10761 5
   Wang YT, 2018, BIOMATERIALS, V183, P10, DOI 10.1016/j.biomaterials.2018.08.033
   Wang Z, 2022, EUR J PHARM BIOPHARM, V179, P126, DOI 10.1016/j.ejpb.2022.09.002
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wu H, 2020, INT J BIOL MACROMOL, V164, P2583, DOI 10.1016/j.ijbiomac.2020.08.068
   Wu YT, 2022, BIOMATER ADV, V133, DOI 10.1016/j.msec.2022.112641
   Xie CK, 2020, ADV SCI, V7, DOI 10.1002/advs.201903512
   Xu LL, 2021, ANGEW CHEM INT EDIT, V60, P11326, DOI 10.1002/anie.202014835
   Yan DY, 2020, J CELL MOL MED, V24, P2330, DOI 10.1111/jcmm.14915
   Yan SQ, 2019, ADV MATER, V31, DOI 10.1002/adma.201905825
   Yang BW, 2018, ADV MATER, V30, DOI 10.1002/adma.201705611
   Yu ZZ, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120459
   Yuan XF, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.943866
   Yuan XX, 2021, THERANOSTICS, V11, P1429, DOI 10.7150/thno.45351
   Yuasa T, 2014, NAT REV UROL, V11, P193, DOI 10.1038/nrurol.2014.56
   Yue WW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09760 3
   Zhang C, 2019, ACS NANO, V13, P11249, DOI 10.1021/acsnano.9b04315
   Zhang HY, 2022, DRUG DELIV, V29, P2491, DOI 10.1080/10717544.2022.2104406
   Zhang Q, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202204182
   Zhao PP, 2019, CHEM ENG J, V359, P1120, DOI 10.1016/j.cej.2018.11.071
   Zhen WY, 2019, NANOSCALE HORIZ, V4, P720, DOI 10.1039/c8nh00440d
   Zhou ZJ, 2019, BIOMATERIALS, V194, P130, DOI 10.1016/j.biomaterials.2018.12.024
   Zhu JH, 2018, NANOSCALE, V10, P18387, DOI 10.1039/c8nr03899f
NR 83
TC 19
Z9 20
U1 19
U2 142
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613 6810
EI 1613 6829
J9 SMALL
JI Small
PD SEP 20
PY 2023
VL 19
IS 38
DI 10.1002/smll.202301003
EA MAY 2023
PG 24
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA AX5R2
UT WOS:000991613300001
PM 37211708
DA 2025 08 17
ER

PT J
AU Takano, M
   Otsuka, F
   Matsumoto, Y
   Inagaki, K
   Takeda, M
   Nakamura, E
   Tsukamoto, N
   Miyoshi, T
   Sada, K
   Makino, H
AF Takano, Mariko
   Otsuka, Fumio
   Matsumoto, Yoshinori
   Inagaki, Kenichi
   Takeda, Masaya
   Nakamura, Eri
   Tsukamoto, Naoko
   Miyoshi, Tomoko
   Sada, Ken ei
   Makino, Hirofumi
TI Peroxisome proliferator activated receptor activity is involved in the
   osteoblastic differentiation regulated by bone morphogenetic proteins
   and tumor necrosis factor α
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Bone morphogenetic protein (BMP); Peroxisome proliferator activated
   receptor (PPAR); Osteoblast; Tumor necrosis factor alpha (TNF alpha)
ID HUMAN OSTEOCLAST FORMATION; RHEUMATOID ARTHRITIS; GROWTH FACTORS;
   IN VITRO; CELLS; TRANSCRIPTION; PATHWAY; MARROW; INDUCTION; THERAPY
AB Recent studies have suggested possible adverse effects of thiazolidinediones on bone metabolism. However, the detailed mechanism by which the activity of PPAR affects bone formation has not been elucidated. Impaired osteoblastic function due to cytokines is critical for the progression of inflammatory bone diseases. In the present study, we investigated the cellular mechanism by which PPAR actions interact with osteoblast differentiation regulated by BMP and TNF alpha using mouse myoblastic C2C12 cells. BMP 2 and  4 potently induced the expression of various bone differentiation markers including Runx2, osteocalcin, type 1 collagen and alkaline phosphatase (ALP) in C2C12 cells. When administered in combination with a PPAR alpha agonist (fenofibric acid) but not with a PPAR gamma agonist (pioglitazone), BMP 4 enhanced osteoblast differentiation through the activity of PPAR alpha. The osteoblastic changes induced by BMP 4 were readily suppressed by treatment with TNF alpha. Interestingly, the activities of PPAR alpha and PPAR gamma agonists reversed the suppression by TNF alpha of osteoblast differentiation induced by BMP 4. Furthermore, TNF alpha induced phosphorylation of MAPKs, NF kappa B, I kappa B and Stat pathways was inhibited in the presence of PPAR alpha and PPAR gamma agonists with reducing TNF alpha receptor expression. In view of the finding that inhibition of SAPK/JNK. Stat and NF kappa B pathways reversed the TNF alpha suppression of osteoblast differentiation, we conclude that these cascades are functionally involved in the actions of PPARs that antagonize TNF alpha induced suppression of osteoblast differentiation. It was further discovered that the PPAR alpha agonist enhanced BMP 4 induced Smad1/5/8 signaling through downregulation of inhibitory Smad6/7 expression, whereas the PPAR gamma agonist impaired this activity by suppressing BMPRII expression. On the other hand, BMPs increased the expression levels of PPAR alpha and PPAR gamma in the process of osteoblast differentiation. Thus, PPAR alpha actions promote BMP induced osteoblast differentiation, while both activities of PPAR alpha and PPAR gamma suppress TNF alpha actions. Collectively, our present data establishes that PPAR activities are functionally involved in modulating the interaction between the BMP system and TNF alpha receptor signaling that is crucial for bone metabolism. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Takano, Mariko; Otsuka, Fumio; Matsumoto, Yoshinori; Inagaki, Kenichi; Takeda, Masaya; Nakamura, Eri; Tsukamoto, Naoko; Miyoshi, Tomoko; Sada, Ken ei; Makino, Hirofumi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Med & Clin Sci, Kita Ku, Okayama 7008558, Japan.
C3 Okayama University
RP Otsuka, F (通讯作者)，Okayama Univ Hosp, Endocrine Ctr, Kita Ku, 2 5 1 Shikata Cho, Okayama 7008558, Japan.
EM fumiotsu@md.okayama u.ac.jp
RI MIYOSHI, Tomoko/B 1859 2011; SADA, KENEI/B 2305 2011
OI Sada, Ken ei/0000 0003 1020 0818; 
FU Grants in Aid for Scientific Research [23791058] Funding Source: KAKEN
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843
   Chan BY, 2007, BONE, V40, P149, DOI 10.1016/j.bone.2006.07.029
   Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649
   Ebisawa T, 1999, J CELL SCI, V112, P3519
   Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163
   Gimble JM, 1996, MOL PHARMACOL, V50, P1087
   GRELL M, 1994, J IMMUNOL, V153, P1963
   Grey A, 2008, OSTEOPOROSIS INT, V19, P129, DOI 10.1007/s00198 007 0477 y
   Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006 2646
   HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671
   Jackson SM, 2000, FEBS LETT, V471, P119, DOI 10.1016/S0014 5793(00)01372 7
   Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200
   Johnson TE, 1999, ENDOCRINOLOGY, V140, P3245, DOI 10.1210/en.140.7.3245
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kudo O, 2002, J PATHOL, V198, P220, DOI 10.1002/path.1190
   Lecka Czernik Beata, 2010, Curr Osteoporos Rep, V8, P84, DOI 10.1007/s11914 010 0016 1
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Matsumoto Y, 2010, MOL CELL ENDOCRINOL, V325, P118, DOI 10.1016/j.mce.2010.05.004
   Mbalaviele G, 2000, J BIOL CHEM, V275, P14388, DOI 10.1074/jbc.275.19.14388
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo 124 1 301
   MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240
   Mukai T, 2007, BIOCHEM BIOPH RES CO, V356, P1004, DOI 10.1016/j.bbrc.2007.03.099
   Otani H, 2007, AM J PHYSIOL RENAL, V292, pF1513, DOI 10.1152/ajprenal.00402.2006
   Otsuka F, 2011, MOL REPROD DEV, V78, P9, DOI 10.1002/mrd.21265
   Otsuka F, 2010, ENDOCR J, V57, P3, DOI 10.1507/endocrj.K09E 310
   Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359 6101(96)00049 4
   Scott DL, 2006, NEW ENGL J MED, V355, P704, DOI 10.1056/NEJMct055183
   Shimasaki S, 2004, ENDOCR REV, V25, P72, DOI 10.1210/er.2003 0007
   Spelsberg TC, 1999, MOL ENDOCRINOL, V13, P819, DOI 10.1210/me.13.6.819
   Takeda M, 2007, J ENDOCRINOL, V194, P87, DOI 10.1677/JOE 07 0138
   Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g
   Wu X, 2000, BONE, V26, P21, DOI 10.1016/S8756 3282(99)00238 0
   Yamashita M, 2008, J ENDOCRINOL, V196, P601, DOI 10.1677/JOE 07 0532
NR 35
TC 24
Z9 26
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JAN 2
PY 2012
VL 348
IS 1
BP 224
EP 232
DI 10.1016/j.mce.2011.08.027
PG 9
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 855BV
UT WOS:000297539400025
PM 21888945
DA 2025 08 17
ER

PT J
AU Menon, P
   Yin, GY
   Smolock, EM
   Zuscik, MJ
   Yan, C
   Berk, BC
AF Menon, Prashanthi
   Yin, Guoyong
   Smolock, Elaine M.
   Zuscik, Michael J.
   Yan, Chen
   Berk, Bradford C.
TI GPCR Kinase 2 Interacting Protein 1 (GIT1) Regulates Osteoclast Function
   and Bone Mass
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID C SRC; ENDOTHELIAL CELLS; ANGIOTENSIN II; ACTIVATION; ORGANIZATION;
   EXPRESSION; FAMILY; OSTEOPETROSIS; PODOSOMES; INTEGRIN
AB G protein coupled receptor (GPCR) kinase 2 interacting protein 1 (GIT1) is a scaffold protein expressed in various cell types including neurons, endothelial, and vascular smooth muscle cells. The GIT1 knockout (KO) mouse has a pulmonary phenotype due to impaired endothelial function. Because GIT1 is tyrosine phosphorylated by Src kinase, we anticipated that GIT1 KO should have a bone phenotype similar to Src KO. Microcomputed tomography of the long bones revealed that GIT1 KO mice have a 2.3 fold increase in bone mass compared to wild type controls. Histomorphometry showed increased trabecular number and connectivity suggesting impaired bone remodeling. Immunoblot analysis of GIT1 expression showed that it was expressed in both osteoclasts and osteoblasts. Osteoblast activity and function assayed by alkaline phosphatase, mineral nodule formation, and in vivo calcein labeling were normal in GIT1 KO mice suggesting that the observed increase in bone mass was due to an osteoclast defect. GIT1 KO bone marrow cells differentiated into multinucleated osteoclasts, but had defective bone resorbing function on dentin slices. This defect was likely caused by loss of podosome belt based on immunofluorescence analysis and previous studies showing that GIT1 is required for podosome formation. Furthermore, we found that GIT1 was a regulator of receptor activator of NF kappa B (RANK) signaling since it was tyrosine phosphorylated in a Src dependent manner and was required for phospholipase C gamma 2 phosphorylation. These data show that GIT1 is a key regulator of bone mass in vivo by regulating osteoclast function and suggest GIT1 as a potential target for osteoporosis therapy. J. Cell. Physiol. 225: 777 785, 2010. (C) 2010 Wiley Liss, Inc.
C1 [Berk, Bradford C.] Univ Rochester, Aab Cardiovasc Res Inst, Med Ctr, Sch Med & Dent, Rochester, NY 14642 USA.
   [Menon, Prashanthi; Yin, Guoyong; Smolock, Elaine M.; Yan, Chen; Berk, Bradford C.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA.
   [Zuscik, Michael J.] Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester; University of
   Rochester
RP Berk, BC (通讯作者)，Univ Rochester, Aab Cardiovasc Res Inst, Med Ctr, Sch Med & Dent, 601 Elmwood Ave,Box CVRI, Rochester, NY 14642 USA.
EM bradford_berk@urmc.rochester.edu
RI Menon, Prashanthi/A 7152 2013
OI Zuscik, Michael/0000 0003 0461 8708; Berk, Bradford/0000 0002 2767 4115;
   Yan, Chen/0000 0002 1397 6358
FU National Institute of Health (NIH) [HL 63462]
FX We would like to thank Dr. Hani Awad, Laura Yanoso, Nathaniel Miller for
   microCT analysis, Dr Kofi Mensah for help with the RAW 264.7 cells, and
   Dr. LianPing Xing for dentine slices. This work was supported by
   National Institute of Health (NIH) grant HL 63462 to B.C.B.
CR Amerongen GPV, 2004, CIRC RES, V94, P1041, DOI 10.1161/01.RES.0000125627.77235.0C
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Bajayo A, 2005, P NATL ACAD SCI USA, V102, P12956, DOI 10.1073/pnas.0502562102
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Epple H, 2008, MOL CELL BIOL, V28, P3610, DOI 10.1128/MCB.00259 08
   Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Haendeler J, 2003, J BIOL CHEM, V278, P49936, DOI 10.1074/jbc.M307317200
   Heckel T, 2009, P NATL ACAD SCI USA, V106, P1451, DOI 10.1073/pnas.0804464106
   Hoefen RJ, 2006, J CELL SCI, V119, P1469, DOI 10.1242/jcs.02925
   Kim HJ, 2009, P NATL ACAD SCI USA, V106, P2325, DOI 10.1073/pnas.0806963106
   Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962 8924(03)00128 4
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Menon P, 2010, BRAIN RES, V1317, P218, DOI 10.1016/j.brainres.2009.11.084
   Metcalf CA, 2002, CURR PHARM DESIGN, V8, P2049, DOI 10.2174/1381612023393323
   MIYAZAKI T, 2004, J BIOL CHEM, V279
   Pang JJ, 2008, ARTERIOSCL THROM VAS, V28, P892, DOI 10.1161/ATVBAHA.107.161349
   Pang JJ, 2009, CIRCULATION, V119, P1524, DOI 10.1161/CIRCULATIONAHA.108.823997
   Sato H, 2008, BIOCHEM BIOPH RES CO, V368, P157, DOI 10.1016/j.bbrc.2008.01.064
   Sawyer TK, 2002, MINI REV MED CHEM, V2, P475, DOI 10.2174/1389557023405765
   Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835
   Slevin M, 2006, AM J PATHOL, V168, P1004, DOI 10.2353/ajpath.2006.050471
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Väänänen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018
   van der Eerden BCJ, 2005, P NATL ACAD SCI USA, V102, P17507, DOI 10.1073/pnas.0505789102
   Wang J, 2009, ARTERIOSCL THROM VAS, V29, P202, DOI 10.1161/ATVBAHA.108.174391
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Yin GY, 2005, J BIOL CHEM, V280, P27705, DOI 10.1074/jbc.M502271200
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
NR 33
TC 36
Z9 43
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2010
VL 225
IS 3
BP 777
EP 785
DI 10.1002/jcp.22282
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 679WI
UT WOS:000284191100017
PM 20568227
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Auh, QS
   Park, KR
   Yun, HM
   Lim, HC
   Kim, GH
   Lee, DS
   Kim, YC
   Oh, H
   Kim, EC
AF Auh, Q Schick
   Park, Kyung Ran
   Yun, Hyung Mun
   Lim, Hyun Chang
   Kim, Ga Hyun
   Lee, Dong Sung
   Kim, Youn Chul
   Oh, Hyuncheol
   Kim, Eun Cheol
TI Sulfuretin promotes osteoblastic differentiation in primary cultured
   osteoblasts and in vivo bone healing
SO ONCOTARGET
LA English
DT Article
DE Osteoblasts; Differentiation; In vitro; In vivo; Osteogenesis; Signal
   pathways; Pathology Section
ID RECEPTOR; CELLS; EXPRESSION; PROLIFERATION; OSTEOPOROSIS; INTERPLAY;
   ESTROGEN; THERAPY; MARKERS; PATHWAY
AB Although sulfuretin, the major flavonoid of Rhus verniciflua Stokes, has a variety of biological actions, its in vitro and in vivo effects on osteogenic potential remain poorly understood. The objective of the present study was to investigate the effects of sulfuretin on in vitro osteoblastic differentiation and the underlying signal pathway mechanisms in primary cultured osteoblasts and on in vivo bone formation using critical sized calvarial defects in mice. Sulfuretin promoted osteogenic differentiation of primary osteoblasts, with increased ALP activity and mineralization, and upregulated differentiation markers, including ALP, osteocalcin, and osteopontin, in a concentration dependent manner. The expression levels of Runx2, BMP 2, and phospho Smad1/5/8 were upregulated by sulfuretin. Moreover, sulfuretin increased phosphorylation of Akt, mTOR, ERK, and JNK. Furthermore, sulfuretin treatment increased mRNA expression of Wnt ligands, phosphorylation of GSK3, and nuclear beta catenin protein expression. In vivo studies with calvarial bone defects revealed that sulfuretin significantly enhanced new bone formation by micro computed tomography and histologic analysis. Collectively, these data suggest that sulfuretin acts through the activation of BMP, mTOR, Wnt/beta catenin, and Runx2 signaling to promote in vitro osteoblast differentiation and facilitate in vivo bone regeneration, and might be have therapeutic benefits in bone disease and regeneration.
C1 [Auh, Q Schick] Kyung Hee Univ, Sch Dent, Dept Oral Med, Seoul, South Korea.
   [Park, Kyung Ran; Kim, Ga Hyun] Kyung Hee Univ, Grad Sch, Dept Oral & Maxillofacial Regenerat, Seoul, South Korea.
   [Yun, Hyung Mun; Kim, Eun Cheol] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul, South Korea.
   [Yun, Hyung Mun; Kim, Eun Cheol] Kyung Hee Univ, Res Ctr Tooth & Periodontal Regenerat MRC, Seoul, South Korea.
   [Lim, Hyun Chang] Kyung Hee Univ, Sch Dent, Dept Periodontol, Seoul, South Korea.
   [Lee, Dong Sung] Konkuk Univ, Coll Hlth & Biomed Sci, Dept Biomed Chem, Chungju, South Korea.
   [Kim, Youn Chul; Oh, Hyuncheol] Wonkwang Univ, Coll Pharm, Inst Pharmaceut Res & Dev, Iksan, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung
   Hee University; Kyung Hee University; Konkuk University; Wonkwang
   University
RP Kim, EC (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul, South Korea.; Kim, EC (通讯作者)，Kyung Hee Univ, Res Ctr Tooth & Periodontal Regenerat MRC, Seoul, South Korea.
EM eckim@khu.ac.kr
RI Kim, Sung/F 7292 2013; Lim, Hyun Chang/AAJ 8755 2020; Lim,
   Hyun Chang/I 3393 2018; Kim, Cheorl Ho/T 6753 2019; Auh,
   Q Schick/AAK 1108 2020; Lee, Dongsung/NWH 1001 2025; Lee, Hyun
   Woo/AAH 8473 2020
OI Lim, Hyun Chang/0000 0001 7695 1708; 
FU National Research Foundation of Korea (NRF) grant   Korea government
   (MEST) [2012R1A5A2051384]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MEST) (No, 2012R1A5A2051384)
CR Aghaloo TL, 2007, J ORTHOP RES, V25, P1488, DOI 10.1002/jor.20437
   Andreopoulou P, 2015, ANNU REV MED, V66, P329, DOI 10.1146/annurev med 070313 022841
   [Anonymous], 1996, KOREA RESOURCE PLANT
   Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854
   Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362
   Blank RD, 1999, J CLIN DENSITOM, V2, P435, DOI 10.1016/S1094 6950(06)60409 5
   Choi J, 2003, PLANTA MED, V69, P899, DOI 10.1055/s 2003 45097
   De Biase P, 2005, INJURY, V36, P43, DOI 10.1016/j.injury.2005.07.034
   dePollak C, 1997, J CELL BIOCHEM, V64, P128, DOI 10.1002/(SICI)1097 4644(199701)64:1<128::AID JCB15>3.3.CO;2 K
   Herberg S, 2014, BONE, V67, P95, DOI 10.1016/j.bone.2014.07.007
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lee DS, 2014, INT J MOL SCI, V15, P8863, DOI 10.3390/ijms15058863
   Lee DW, 2010, EURASIP J WIREL COMM, DOI 10.1155/2010/750173
   Lee SI, 2014, J DENT RES, V93, P678, DOI 10.1177/0022034514535214
   Lee SI, 2015, DIFFERENTIATION
   Lee SK, 2013, J CELL BIOCHEM, V114, P1183, DOI 10.1002/jcb.24461
   Lee YR, 2012, LIFE SCI, V90, P799, DOI 10.1016/j.lfs.2012.04.015
   LINDSAY R, 1984, OBSTET GYNECOL, V63, P759
   Martín Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521 1878(200007)22:7<637::AID BIES6>3.0.CO;2 E
   Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Nune KC, 2016, J BIOMATER APPL, V30, P1182, DOI 10.1177/0885328215617868
   Nune KC, 2016, J BIOMED MATER RES A, V104, P517, DOI 10.1002/jbm.a.35592
   Nune KC, 2015, J BIOMED MATER RES A, V103, P1677, DOI 10.1002/jbm.a.35307
   Pietschmann P, 2016, GERONTOLOGY, V62, P128, DOI 10.1159/000431091
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Song MY, 2010, BIOCHEM BIOPH RES CO, V400, P83, DOI 10.1016/j.bbrc.2010.08.014
   Song NJ, 2015, MOL CELL BIOCH
   Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955 0674(97)80078 6
   Twine NA, 2014, BONE, V67, P23, DOI 10.1016/j.bone.2014.06.027
   Vihtamäki T, 1999, MATURITAS, V33, P99, DOI 10.1016/S0378 5122(99)00047 X
   Wang T, 2015, BIOCHEM BIOPH RES CO, V466, P232, DOI 10.1016/j.bbrc.2015.09.014
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Yun HM, 2007, J BIOL CHEM, V282, P5496, DOI 10.1074/jbc.M606215200
   Yun HM, 2016, SCI REP UK, V6, DOI 10.1038/srep30985
NR 39
TC 22
Z9 25
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 29
PY 2016
VL 7
IS 48
BP 78320
EP 78330
DI 10.18632/oncotarget.12460
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA EE5HH
UT WOS:000389636000011
PM 27713171
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT S
AU Tahara, RK
   Brewer, TM
   Theriault, RL
   Ueno, NT
AF Tahara, Rie K.
   Brewer, Takae M.
   Theriault, Richard L.
   Ueno, Naoto T.
BE Ahmad, A
TI Bone Metastasis of Breast Cancer
SO BREAST CANCER METASTASIS AND DRUG RESISTANCE: CHALLENGES AND PROGRESS,
   2ND EDITION
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Bone; Metastasis; Mechanism of bone metastases; Bone targeted therapy;
   Therapy; Detection; Assessment
ID CIRCULATING TUMOR CELLS; SKELETAL RELATED EVENTS; ZOLEDRONIC ACID;
   FDG PET/CT; PHASE II; CHEMOKINE RECEPTORS; OSSEOUS METASTASES;
   RADIATION THERAPY; RESPONSE CRITERIA; CXCR4 ANTAGONIST
AB Bone is the most common site of metastasis for breast cancer. Bone metastasis significantly affects both quality of life and survival of the breast cancer patient. Clinically, complications secondary to bone metastasis include pain, pathologic fractures, spinal cord compression, and hypercalcemia of malignancy. Because bone metastasis is extremely common in patients with metastatic breast cancer, clinical management of bone metastases is an important and challenging aspect of treatment in the metastatic setting.
   The skeleton is a metabolically active organ system that undergoes continuous remodeling throughout life. A delicate balance of the bone forming osteoblasts and bone resorbing osteoclasts in the dynamic microenvironment of the skeleton maintains normal bone remodeling and integrity. The presence of metastatic lesions in bone disrupts the normal bone microenvironment and upsets the fine balance between the key components. The changes in the bone microenvironment then create a vicious cycle that further promotes bone destruction and tumor progression.
   Various therapeutic options are available for bone metastases of breast cancer. Treatment can be tailored for each patient and, often requires multiple therapeutic interventions. Commonly used modalities include local therapies such as surgery, radiation therapy and radiofrequency ablation (RFA) together with systemic therapies such as endocrine therapy, chemotherapy, monoclonal antibody based therapy, bone enhancing therapy and radioisotope therapy. Despite the use of various therapeutic modalities, bone metastases eventually become resistant to therapy, and disease progresses.
   In this chapter, we describe the clinical picture and biological mechanism of bone metastases in breast cancer. We also discuss known risk factors as well as detection and assessment of bone metastases. We present therapeutic options for bone metastasis using a multidisciplinary approach. Further, we describe future directions for bone metastasis management, focusing on novel bone specific targeted therapies.
C1 [Tahara, Rie K.; Theriault, Richard L.; Ueno, Naoto T.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA.
   [Brewer, Takae M.] Cleveland Clin, Genom Med Inst, Cleveland, OH 44106 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; Cleveland
   Clinic Foundation
RP Ueno, NT (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA.
EM nueno@mdanderson.org
RI ; Brewer, Takae/GVU 8862 2022
OI Ueno, Naoto/0000 0002 0166 7275; Tahara, Rie
   Kawabori/0000 0002 5558 0335
CR Leone BA, 2017, BREAST CANCER RES TR, V161, P537, DOI 10.1007/s10549 016 4066 7
   Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   [Anonymous], 2017, COCHRANE DB SYST REV
   Avril S, 2016, J NUCL MED, V57, p34S, DOI 10.2967/jnumed.115.157875
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Bidard FC, 2014, LANCET ONCOL, V15, P406, DOI 10.1016/S1470 2045(14)70069 5
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Britton Kelly M, 2011, Cancers (Basel), V3, P2106, DOI 10.3390/cancers3022106
   Brücher BLDM, 2001, ANN SURG, V233, P300
   Buck MB, 2004, CLIN CANCER RES, V10, P491, DOI 10.1158/1078 0432.CCR 0320 03
   Bulfoni M, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058 016 0687 3
   Cabioglu N, 2009, ANN ONCOL, V20, P1013, DOI 10.1093/annonc/mdn740
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Carlson RW, 2011, J NATL COMPR CANC NE, V9, P136, DOI 10.6004/jnccn.2011.0016
   Catalano OA, 2015, BRIT J CANCER, V112, P1452, DOI 10.1038/bjc.2015.112
   Chen Z, 2005, CANCER, V104, P1520, DOI 10.1002/cncr.21335
   Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239
   Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159, DOI 10.1615/CritRevEukarGeneExpr.v10.i2.50
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clézardin P, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2835
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   Clines Gregory A, 2004, Clin Adv Hematol Oncol, V2, P295
   Coleman RE, 2001, SEMIN ONCOL, V28, P11, DOI 10.1053/sonc.2001.24155
   Coleman R, 2014, BREAST CANCER RES TR, V145, P411, DOI 10.1007/s10549 014 2939 1
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Colleoni M, 2000, J CLIN ONCOL, V18, P3925, DOI 10.1200/JCO.2000.18.23.3925
   Costelloe CM, 2010, J CANCER, V1, P80
   Cristofanilli M, 2005, J CLIN ONCOL, V23, P1420, DOI 10.1200/JCO.2005.08.140
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   DALAL BI, 1993, AM J PATHOL, V143, P381
   De Giorgi U, 2010, ANN ONCOL, V21, P33, DOI 10.1093/annonc/mdp262
   De Giorgi U, 2010, J NUCL MED, V51, P1213, DOI 10.2967/jnumed.110.076455
   Delpech Y, 2015, BRIT J CANCER, V113, P1003, DOI 10.1038/bjc.2015.308
   Diel IJ, 2007, SUPPORT CARE CANCER, V15, P1243, DOI 10.1007/s00520 007 0244 9
   Domchek SM, 2000, CANCER, V89, P363, DOI 10.1002/1097 0142(20000715)89:2<363::AID CNCR22>3.0.CO;2 3
   Dunn LK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006896
   Dürr HR, 2002, CLIN ORTHOP RELAT R, P191
   Fang YZ, 2013, JNCI J NATL CANCER I, V105, P47, DOI 10.1093/jnci/djs485
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Finlay OG, 2005, LANCET ONCOL, V6, P392, DOI 10.1016/S1470 2045(05)70206 0
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fornier MN, 2011, ANN ONCOL, V22, P2575, DOI 10.1093/annonc/mdr018
   Fu Q, 2006, MOL CELL BIOL, V26, P6453, DOI 10.1128/MCB.00356 06
   Gainford MC, 2005, BMJ BRIT MED J, V330, P769, DOI 10.1136/bmj.330.7494.769
   Ganapathy V, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 122
   Garrison K, 2012, CANCER IMMUNOL IMMUN, V61, P511, DOI 10.1007/s00262 011 1119 y
   Gedmintas L, 2013, J BONE MINER RES, V28, P1729, DOI 10.1002/jbmr.1893
   Gil M, 2013, P NATL ACAD SCI USA, V110, pE1291, DOI 10.1073/pnas.1220580110
   Guise T. A., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P570
   Guise TA, 2003, CANCER AM CANCER SOC, V97, P779, DOI 10.1002/cncr.11129
   Hamaoka T, 2004, J CLIN ONCOL, V22, P2942, DOI 10.1200/jco.2004.08.181
   Hamaoka T, 2010, BRIT J CANCER, V102, P651, DOI 10.1038/sj.bjc.6605546
   Hanrahan EO, 2005, CANCER AM CANCER SOC, V104, P1158, DOI 10.1002/cncr.21305
   Harrington KD, 1997, CANCER, V80, P1614
   Hassan S, 2011, INT J CANCER, V129, P225, DOI 10.1002/ijc.25665
   Hayes DF, 2006, CLIN CANCER RES, V12, P4218, DOI 10.1158/1078 0432.CCR 05 2821
   Henriksen G, 2003, J NUCL MED, V44, P252
   Henry D, 2014, SUPPORT CARE CANCER, V22, P679, DOI 10.1007/s00520 013 2022 1
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Herold CI, 2011, CLIN CANCER RES, V17, P6061, DOI 10.1158/1078 0432.CCR 11 1071
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Huang EH, 2009, J SURG RES, V155, P231, DOI 10.1016/j.jss.2008.06.044
   Incarbone M, 1997, J THORAC CARDIOV SUR, V114, P93, DOI 10.1016/S0022 5223(97)70121 1
   Iyer S, 2005, CANCER BIOL THER, V4, P261, DOI 10.4161/cbt.4.3.1566
   James JJ, 2003, BRIT J CANCER, V89, P660, DOI 10.1038/sj.bjc.6601198
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Khoo BL, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600274
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Lee SJ, 2011, CANCER RES TREAT, V43, P89, DOI 10.4143/crt.2011.43.2.89
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   MARANZANO E, 1995, INT J RADIAT ONCOL, V32, P959, DOI 10.1016/0360 3016(95)00572 G
   Marchini C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014131
   Mathot L, 2012, CANCER SCI, V103, P626, DOI 10.1111/j.1349 7006.2011.02195.x
   Mayer EL, 2011, CLIN CANCER RES, V17, P6897, DOI 10.1158/1078 0432.CCR 11 0070
   Min SJ, 2016, ONCOTARGET, V7, P27848, DOI 10.18632/oncotarget.8425
   Mitri Z, 2016, CLIN CANCER RES, V22, P5706, DOI 10.1158/1078 0432.CCR 15 2845
   Mu ZM, 2015, BREAST CANCER RES TR, V154, P563, DOI 10.1007/s10549 015 3636 4
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001
   Niikura N, 2011, ONCOLOGIST, V16, P155, DOI 10.1634/theoncologist.2010 0350
   Nilsson S, 2007, LANCET ONCOL, V8, P587, DOI 10.1016/S1470 2045(07)70147 X
   O'Flaherty EJ, 2000, TOXICOL SCI, V55, P171, DOI 10.1093/toxsci/55.1.171
   Ocana A, 2017, ONCOTARGET, V8, P73144, DOI 10.18632/oncotarget.17113
   Onishi T, 2010, NAT REV CLIN ONCOL, V7, P641, DOI 10.1038/nrclinonc.2010.134
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Peng SB, 2015, MOL CANCER THER, V14, P480, DOI 10.1158/1535 7163.MCT 14 0850
   PEREZ JE, 1990, AM J CLIN ONCOL CANC, V13, P294, DOI 10.1097/00000421 199008000 00005
   Petrut B, 2008, CURR ONCOL, V15, pS50, DOI 10.3747/co.2008.176
   Pickering LM, 2002, CURR MED RES OPIN, V18, P284, DOI 10.1185/030079902125000543
   Pierga JY, 2012, ANN ONCOL, V23, P618, DOI 10.1093/annonc/mdr263
   Plunkett TA, 2000, EUR J CANCER, V36, P476, DOI 10.1016/S0959 8049(99)00331 7
   Rausch MP, 2009, ANTICANCER RES, V29, P2099
   Richert MM, 2009, ONCOL REP, V21, P761, DOI 10.3892/or_00000282
   Riedl CC, 2017, EUR J NUCL MED MOL I, V44, P1428, DOI 10.1007/s00259 017 3703 7
   Rong J, 2013, SURG ONCOL, V22, P86, DOI 10.1016/j.suronc.2013.01.002
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rose AAN, 2010, FUTURE ONCOL, V6, P55, DOI [10.2217/fon.09.138, 10.2217/FON.09.138]
   Rucci N, 2006, J PHARMACOL EXP THER, V318, P161, DOI 10.1124/jpet.106.102004
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Saad F, 2010, CANCER TREAT REV, V36, P177, DOI 10.1016/j.ctrv.2009.11.005
   Sathiakumar N, 2012, BREAST CANCER RES TR, V131, P231, DOI 10.1007/s10549 011 1721 x
   SCHEID V, 1986, CANCER AM CANCER SOC, V58, P2589, DOI 10.1002/1097 0142(19861215)58:12<2589::AID CNCR2820581206>3.0.CO;2 O
   Schott AF, 2016, BREAST CANCER RES TR, V159, P87, DOI 10.1007/s10549 016 3911 z
   Schwarz JD, 2005, J NUCL MED, V46, P1144
   Shiomi Mouri Y, 2016, BREAST CANCER TOKYO, V23, P120, DOI 10.1007/s12282 014 0539 x
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Smith IC, 2000, J CLIN ONCOL, V18, P1676, DOI 10.1200/JCO.2000.18.8.1676
   Somlo G, 2013, CLIN CANCER RES, V19, P1884, DOI 10.1158/1078 0432.CCR 12 0652
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Theriault RL, 2012, CANCER CONTROL, V19, P92, DOI 10.1177/107327481201900203
   THOMPSON RC, 1992, ORTHOPEDICS, V15, P547
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   TONG D, 1982, CANCER AM CANCER SOC, V50, P893, DOI 10.1002/1097 0142(19820901)50:5<893::AID CNCR2820500515>3.0.CO;2 Y
   Valta MP, 2006, ENDOCRINOLOGY, V147, P2171, DOI 10.1210/en.2005 1502
   Van Poznak C, 2005, CANCER AM CANCER SOC, V104, P443, DOI 10.1002/cncr.21201
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Wang X, 2014, ONCOL LETT, V7, P1997, DOI 10.3892/ol.2014.1982
   Williams SA, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 250
   Wong D, 2008, CLIN CANCER RES, V14, P7975, DOI 10.1158/1078 0432.CCR 07 4846
   Wright LE, 2013, J NAT PROD, V76, P316, DOI 10.1021/np300663v
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Yan WT, 2017, SCI REP UK, V7, DOI 10.1038/srep43464
   Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471 4914(02)02340 7
   Yi B, 2002, CANCER RES, V62, P917
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zhang LY, 2012, APMIS, V120, P549, DOI 10.1111/j.1600 0463.2011.02864.x
NR 133
TC 117
Z9 127
U1 1
U2 74
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH 6330, SWITZERLAND
SN 0065 2598
EI 2214 8019
BN 978 3 030 20301 6; 978 3 030 20300 9
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2019
VL 1152
BP 105
EP 129
DI 10.1007/978 3 030 20301 6_7
D2 10.1007/978 3 030 20301 6
PG 25
WC Oncology; Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine; Pharmacology & Pharmacy
GA BO4LH
UT WOS:000514550100008
PM 31456182
DA 2025 08 17
ER

PT J
AU Sun, T
   Hu, D
   Guo, ZZ
   Gong, HN
   Xin, QW
   Mu, YD
   Weng, J
   Li, JS
   Chen, XY
AF Sun, Tong
   Hu, Dong
   Guo, Zhizhang
   Gong, Hanwen
   Xin, Qiangwei
   Mu, Yandong
   Weng, Jie
   Li, Jianshu
   Chen, Xingyu
TI Hexapeptide decorated β cyclodextrin delivery system for targeted
   therapy of bone infection
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Bone infection; Bone targeted; Antibacterial; Aspartic acid hexapeptide;
   beta Cyclodextrin
ID SELECTIVE DRUG DELIVERY; OSTEOMYELITIS; PREVENTION; BISPHOSPHONATES;
   OLIGOPEPTIDE; OSTEOPONTIN; PEGYLATION; MANAGEMENT; CONJUGATE; ESTRADIOL
AB Successfully treating bone infections is a major orthopedic challenge. Clinically, oral, intravenous, or intramuscular injections of drugs are usually used for direct or complementary treatment. However, once the drug enters the system, it circulates throughout the body, leading to an insufficient local dose and limiting the therapeutic effect because of the lack of targeting in the drug system. In this study, beta cyclodextrin, modified with poly (ethylene glycol) [PEG] and aspartic acid hexapeptide (Asp6 beta CD), was used to specifically target the hydroxyapatite (HA) component of the bone. It was then loaded with norfloxacin (NFX) to treat bone infections. The antibacterial ability of NFX was enhanced by loading it into Asp6 beta CD, because the solubility of Asp6 beta CD@NFX increased significantly. Moreover, Asp6 beta CD could target bone tissue in nude mice and showed significantly enhanced accumulation (10 times) than the unmodified beta CD. In addition, in a rat model of osteomyelitis, Asp6 beta CD@NFX targeted HA well and exerted its antibacterial activity, which reduced inflammation and promoted bone tissue repair. This study indicates that the Asp6 beta CD based drug delivery system can efficiently target bone tissue to enable potential applications for treating bone related diseases.
C1 [Sun, Tong; Weng, Jie; Chen, Xingyu] South West Jiaotong Univ, Sch Mat Sci & Engn, Key Lab Adv Technol Mat, Minist Educ, Chengdu 610031, Peoples R China.
   [Gong, Hanwen; Weng, Jie; Chen, Xingyu] South West Jiaotong Univ, Coll Med, Chengdu 610031, Peoples R China.
   [Hu, Dong] Sixth Peoples Hosp Chengdu, Dept Neurosurg, Chengdu 610051, Peoples R China.
   [Guo, Zhizhang] Shandong First Med Univ, Dept Med Engn Management, Shandong Prov Hosp, Jinan 250021, Peoples R China.
   [Mu, Yandong] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Stomatol Dept, Chengdu 611731, Peoples R China.
   [Xin, Qiangwei; Li, Jianshu] Sichuan Univ, Coll Polymer Sci & Engn, Chengdu 610065, Peoples R China.
C3 Southwest Jiaotong University; Southwest Jiaotong University; Shandong
   First Medical University & Shandong Academy of Medical Sciences; Sichuan
   Provincial People's Hospital; University of Electronic Science &
   Technology of China; Sichuan University
RP Weng, J; Chen, XY (通讯作者)，South West Jiaotong Univ, Sch Mat Sci & Engn, Key Lab Adv Technol Mat, Minist Educ, Chengdu 610031, Peoples R China.
EM jweng@swjtu.edu.cn; chenxy@swjtu.edu.cn
RI Weng, Jie/AAJ 1894 2021; Mu, Yandong/JWO 2699 2024
CR Beck Broichsitter BE, 2015, CURR OPIN INFECT DIS, V28, P240, DOI 10.1097/QCO.0000000000000155
   Caplin JD, 2019, ACTA BIOMATER, V93, P2, DOI 10.1016/j.actbio.2019.01.015
   Chen L, 2022, ACS NANO, V16, P9929, DOI 10.1021/acsnano.2c04566
   Cobb LH, 2020, J ORTHOP RES, V38, P2091, DOI 10.1002/jor.24689
   Crini G, 2014, CHEM REV, V114, P10940, DOI 10.1021/cr500081p
   Dai XY, 2021, ACS APPL BIO MATER, V4, P8536, DOI 10.1021/acsabm.1c01018
   Davis ME, 2004, NAT REV DRUG DISCOV, V3, P1023, DOI 10.1038/nrd1576
   Dym Harry, 2017, Dent Clin North Am, V61, P271, DOI 10.1016/j.cden.2016.12.001
   El Ayadi A., 2018, Total Burn Care, P232, DOI [10.1016/b978 0 323 47661 4.00021 6, DOI 10.1016/B978 0 323 47661 4.00021 6, 10.1016/B978 0 323 47661 4.00021 6..e2, DOI 10.1016/B978 0 323 47661 4.00021 6..E2]
   Ford CA, 2017, EXPERT REV ANTI INFE, V15, P851, DOI 10.1080/14787210.2017.1372192
   Gallarate M, 2021, CURR DRUG DELIV, V18, P532, DOI 10.2174/1567201817666200915093224
   Giachelli CM, 2000, MATRIX BIOL, V19, P615, DOI 10.1016/S0945 053X(00)00108 6
   Harris JM, 2001, CLIN PHARMACOKINET, V40, P539, DOI 10.2165/00003088 200140070 00005
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   HIGUCHI T, 1965, ADV ANAL CHEM INSTRU, V4, P117, DOI DOI 10.1016/S0076 6879(82)87029 8
   Hofstee MI, 2020, AM J PATHOL, V190, P1151, DOI 10.1016/j.ajpath.2020.02.007
   Houghton TJ, 2008, J MED CHEM, V51, P6955, DOI 10.1021/jm801007z
   Huang CY, 2019, INT J ANTIMICROB AG, V53, P246, DOI 10.1016/j.ijantimicag.2019.01.007
   Ishizaki J, 2009, J BONE MINER METAB, V27, P1, DOI 10.1007/s00774 008 0004 z
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Kavanagh N, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00084 17
   Lai Xiongming, 2020, INT J ENV GEOINFORMA, V85, P963, DOI [10.3389/fonc.2022.881641, DOI 10.30897/IJEGEO.704260, 10.1016/j.ymssp.2016.09.027]
   Lalam RK, 2006, SKELETAL RADIOL, V35, P876, DOI 10.1007/s00256 006 0091 7
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Liu YP, 2019, J CONTROL RELEASE, V304, P39, DOI 10.1016/j.jconrel.2019.04.042
   Masters EA, 2022, NAT REV MICROBIOL, V20, P385, DOI 10.1038/s41579 022 00686 0
   Masters EA, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0061 z
   McKee MD, 1996, CONNECT TISSUE RES, V35, P197, DOI 10.3109/03008209609029192
   Nasser A, 2020, MICROB PATHOGENESIS, V148, DOI 10.1016/j.micpath.2020.104431
   Neale JR, 2009, BIOORG MED CHEM LETT, V19, P680, DOI 10.1016/j.bmcl.2008.12.051
   Nielsen JJ, 2021, J CONTROL RELEASE, V329, P570, DOI 10.1016/j.jconrel.2020.09.047
   Nielsen JJ, 2020, CURR OSTEOPOROS REP, V18, P449, DOI 10.1007/s11914 020 00604 4
   Ouyang L, 2011, BIOORGAN MED CHEM, V19, P3750, DOI 10.1016/j.bmc.2011.05.004
   Reddy R, 2008, CHEMMEDCHEM, V3, P1863, DOI 10.1002/cmdc.200800255
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   Rotman SG, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090885
   Roux KM, 2021, ANIM MODEL EXP MED, V4, P59, DOI 10.1002/ame2.12149
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Shi C, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2020.107473
   Stoodley P, 2011, CURR ORTHOP PRACT, V22, P558, DOI 10.1097/BCO.0b013e318230efcf
   Urish KL, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00932 19
   WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P198, DOI 10.1056/NEJM197001222820406
   Wang JT, 2010, J COLLOID INTERF SCI, V349, P578, DOI 10.1016/j.jcis.2010.04.081
   Wang J, 2021, BIOMACROMOLECULES, V22, P534, DOI 10.1021/acs.biomac.0c01401
   Wang Q.J. R., 2010, Effective policies for renewable energy the example of Chinas wind power lessons for Chinas photovoltaic power, V14, P702, DOI DOI 10.1016/J.RSER.2009.08.013
   Warner AJ, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116377
   Wassif RK, 2021, DRUG DELIV, V28, P2392, DOI 10.1080/10717544.2021.1998246
   Wilkinson JM, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115443
   Xu WS, 2021, BIOMACROMOLECULES, V22, P4434, DOI 10.1021/acs.biomac.1c01007
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
   Yu P, 2021, J CONTROL RELEASE, V338, P486, DOI 10.1016/j.jconrel.2021.08.056
   Zimmerli W, 2010, NEW ENGL J MED, V362, P1022, DOI 10.1056/NEJMcp0910753
NR 55
TC 15
Z9 15
U1 8
U2 47
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JAN
PY 2023
VL 353
BP 337
EP 349
DI 10.1016/j.jconrel.2022.11.047
EA DEC 2022
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA M9TG2
UT WOS:001033559500001
PM 36462641
DA 2025 08 17
ER

PT J
AU Bhattarai, G
   Kook, SH
   Kim, JH
   Poudel, SB
   Lim, SS
   Seo, YK
   Lee, JC
AF Bhattarai, Govinda
   Kook, Sung Ho
   Kim, Jae Hwan
   Poudel, Sher Bahadur
   Lim, Shin Saeng
   Seo, Young Kwon
   Lee, Jeong Chae
TI COMP Ang1 prevents periodontitic damages and enhances mandible bone
   growth in an experimental animal model
SO BONE
LA English
DT Article
DE COMP Ang1; Periodontitis; Mandible bone defect; Osteoclastogenesis; Bone
   regeneration; Signal transduction pathways
ID MESENCHYMAL STEM CELLS; COMP ANGIOPOIETIN 1; NF KAPPA B; OSTEOCLAST
   DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; MORPHOGENETIC PROTEIN 2;
   LIGAMENT FIBROBLASTS; RAT MODEL; REGENERATION; PATHWAY
AB COMP Ang1, a chimera of angiopoietin 1 (Ang1) and a short coiled coil domain of cartilage oligomeric matrix protein (COMP), is under consideration as a therapeutic agent enhancing tissue regeneration with increased angiogenesis. However, the effect of COMP Ang1 on periodontitic tissue damages and the related mechanisms are not yet investigated. We initially explored whether a local delivery of COMP Ang1 protects lipopolysaccharide (LPS)/ligature induced periodontal destruction in rats. As the results, mu CT and histological analyses revealed that COMP Ang1 inhibits LPS mediated degradation of periodontium. COMP Ang1 also suppressed osteoclast number and the expression of osteoclast specific and inflammation related molecules in the inflamed region of periodontitis rats. Implanting a COMP Ang1 impregnated scaffold into critical sized mandible bone defects enhanced the amount of bone in the defects with increased expression of bone specific markers. The addition of COMP Ang1 prevented significantly osteoclast differentiation and activation in LPS stimulated RAW264.7 macrophages and inhibited the phosphorylation of c Jun, mitogen activated protein kinases, and cAMP response element binding protein in the cells. On contrary, COMP Ang1 increased the level of phosphatidylinositol 3 kinase (PI3K) in LPS exposed macrophages and a pharmacological PI3K inhibitor diminished the anti osteoclastogenic effect of COMP Ang1. Similarly, COMP Ang1 blocked the expression of inflammation related molecules in LPS stimulated human periodontal ligament fibroblasts (hPLFs). Further, the COMP Ang1 enhanced differentiation of hPLFs into osteoblasts by stimulating the expression of bone specific markers, Tie2, and activator protein 1 subfamily. Collectively, our findings may support the therapeutic potentials of COMP Ang1 in preventing inflammatory periodontal damages and in stimulating new bone growth. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Bhattarai, Govinda; Kook, Sung Ho; Poudel, Sher Bahadur; Lee, Jeong Chae] Chonbuk Natl Univ, Cluster Craniofacial Dev & Regenerat Res, Inst Oral Biosci, Program BK21, Jeonju 54896, South Korea.
   [Bhattarai, Govinda; Kook, Sung Ho; Poudel, Sher Bahadur; Lee, Jeong Chae] Chonbuk Natl Univ, Sch Dent, Jeonju 54896, South Korea.
   [Kook, Sung Ho; Lee, Jeong Chae] Chonbuk Natl Univ, Dept Bioact Mat Sci, Res Ctr Bioact Mat, Jeonju 54896, South Korea.
   [Kim, Jae Hwan] Chonnam Natl Univ, Dent Hosp, Kwangju 61186, South Korea.
   [Lim, Shin Saeng] Seoul Natl Univ, Sch Dent, Seoul 08826, South Korea.
   [Lim, Shin Saeng] Seoul Natl Univ, Dent Res Inst, Seoul 08826, South Korea.
   [Seo, Young Kwon] Dongguk Univ, Biotechnol Res Inst, Seoul 04620, South Korea.
C3 Jeonbuk National University; Jeonbuk National University; Jeonbuk
   National University; Chonnam National University; Seoul National
   University (SNU); Seoul National University (SNU); Dongguk University
RP Lee, JC (通讯作者)，Chonbuk Natl Univ, Sch Dent, Jeonju 54896, South Korea.; Lee, JC (通讯作者)，Chonbuk Natl Univ, Inst Oral Biosci, Jeonju 54896, South Korea.
EM leejc88@jbnu.ac.kr
RI Poudel, Sher/V 3282 2019
FU Basic Science Research Program through the National Research Foundation
   (NRF)   Ministry of Science, ICT and Future Planning, South Korea
   [NRF 2013R1A2A2A01967207]; Research Fellow Program
   [NRF 2014R1A1A2008488]
FX This study was supported by Basic Science Research Program through the
   National Research Foundation (NRF) (NRF 2013R1A2A2A01967207) funded by
   the Ministry of Science, ICT and Future Planning, South Korea. Dr.
   Govinda Bhattarai was supported by a grant from the Research Fellow
   Program (NRF 2014R1A1A2008488).
CR Aghaloo T, 2010, J ORAL MAXIL SURG, V68, P300, DOI 10.1016/j.joms.2009.03.066
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Bateman JP, 2012, J PERIODONTAL RES, V47, P243, DOI 10.1111/j.1600 0765.2011.01428.x
   Bhattarai G, 2016, ACTA BIOMATER, V29, P398, DOI 10.1016/j.actbio.2015.10.031
   BOYCE ST, 1988, J BIOMED MATER RES, V22, P939, DOI 10.1002/jbm.820221008
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Chen SH, 2012, ACTA BIOMATER, V8, P3128, DOI 10.1016/j.actbio.2012.04.030
   Cho CH, 2006, P NATL ACAD SCI USA, V103, P4946, DOI 10.1073/pnas.0506352103
   Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101
   Colombo JS, 2012, J DENT, V40, P338, DOI 10.1016/j.jdent.2012.01.010
   Cui QJ, 2013, CURR PHARM DESIGN, V19, P3374, DOI 10.2174/1381612811319190004
   Das A, 2013, BIOMATERIALS, V34, P9853, DOI 10.1016/j.biomaterials.2013.08.015
   Emerton KB, 2011, J DENT RES, V90, P1416, DOI 10.1177/0022034511423665
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE 08 0568
   HAUSMANN E, 1991, J PERIODONTOL, V62, P570, DOI 10.1902/jop.1991.62.9.570
   Heo JS, 2010, MOL CELLS, V30, P449, DOI 10.1007/s10059 010 0139 3
   Herman S, 2008, TRENDS MOL MED, V14, P245, DOI 10.1016/j.molmed.2008.04.001
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Hisatsune J, 2008, J IMMUNOL, V180, P5017, DOI 10.4049/jimmunol.180.7.5017
   Hou GQ, 2013, INT J MOL MED, V32, P503, DOI 10.3892/ijmm.2013.1406
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jeong BC, 2010, BONE, V46, P479, DOI 10.1016/j.bone.2009.09.019
   Jeong Y.G., 2012, J RHEUM DIS, V19, P82
   KABAN LB, 1981, J DENT RES, V60, P1356, DOI 10.1177/00220345810600071201
   Kim DH, 2009, KIDNEY INT, V76, P1180, DOI 10.1038/ki.2009.387
   Kim S, 2013, J ORTHOP RES, V31, P1920, DOI 10.1002/jor.22453
   Kim T, 2013, J ETHNOPHARMACOL, V146, P83, DOI 10.1016/j.jep.2012.11.037
   Koide N, 2014, IMMUNOL LETT, V161, P31, DOI 10.1016/j.imlet.2014.04.006
   Kook SH, 2014, BIOCHEM BIOPH RES CO, V455, P371, DOI 10.1016/j.bbrc.2014.11.025
   Kook SH, 2014, J PERIODONTOL, V85, P645, DOI 10.1902/jop.2013.130252
   Kook SH, 2012, J CELL PHYSIOL, V227, P1098, DOI 10.1002/jcp.22829
   LANNIGAN FJ, 1993, J LARYNGOL OTOL, V107, P12, DOI 10.1017/S0022215100122005
   Lattanzi W, 2008, GENE THER, V15, P1330, DOI 10.1038/gt.2008.116
   Lee KW, 2014, DENT MATER, V30, pE199, DOI 10.1016/j.dental.2014.03.008
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Lim SS, 2015, J BIOMED MATER RES A, V103, P2942, DOI 10.1002/jbm.a.35439
   Liu XB, 2008, ACTA PHARMACOL SIN, V29, P815, DOI 10.1111/j.1745 7254.2008.00811.x
   Manning CN, 2013, ACTA BIOMATER, V9, P6905, DOI 10.1016/j.actbio.2013.02.008
   Morishita H, 2009, INT IMMUNOL, V21, P457, DOI 10.1093/intimm/dxp015
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Ohnishi K, 1998, LAB INVEST, V78, P1077
   Pang M, 2015, EXP BIOL MED, V240, P1266, DOI 10.1177/1535370215570202
   Park BH, 2011, BONE, V49, P447, DOI 10.1016/j.bone.2011.05.020
   Park BH, 2010, BONE, V46, P1442, DOI 10.1016/j.bone.2010.02.004
   Park SS, 2012, BMB REP, V45, P571, DOI 10.5483/BMBRep.2012.45.10.101
   Parrilla C, 2010, HEAD NECK J SCI SPEC, V32, P310, DOI 10.1002/hed.21185
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Polo Corrales L, 2014, J NANOSCI NANOTECHNO, V14, P15, DOI 10.1166/jnn.2014.9127
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Schwabe K, 2016, ARTHRITIS RHEUMATOL, V68, P138, DOI 10.1002/art.39425
   Seuwen K, 1999, P ASSOC AM PHYSICIAN, V111, P70, DOI 10.1046/j.1525 1381.1999.09866.x
   Standal T, 2004, EXP ONCOL, V26, P179
   Tokunaga K, 2011, J PERIODONTAL RES, V46, P655, DOI 10.1111/j.1600 0765.2011.01386.x
   Tu YK, 2012, J CLIN PERIODONTOL, V39, P303, DOI 10.1111/j.1600 051X.2011.01844.x
   Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Yilmaz S, 2010, J CLIN PERIODONTOL, V37, P544, DOI 10.1111/j.1600 051X.2010.01567.x
   Zong C, 2014, J BIOMED NANOTECHNOL, V10, P1091, DOI 10.1166/jbn.2014.1696
   Zong Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044107
NR 61
TC 14
Z9 16
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2016
VL 92
BP 168
EP 179
DI 10.1016/j.bone.2016.09.002
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DZ2TC
UT WOS:000385693400020
PM 27612438
DA 2025 08 17
ER

PT J
AU Bouxsein, ML
AF Bouxsein, ML
TI Determinants of skeletal fragility
SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
LA English
DT Article
DE biomechanics; skeletal fragility; bone mineral density; bone remodeling;
   microarchitecture; microdamage; mineralization; collagen; bone shape
ID BONE MINERAL DENSITY; AGE RELATED CHANGES; IN VITRO RELATIONSHIP; X RAY
   ABSORPTIOMETRY; PROXIMAL FEMUR; CANCELLOUS BONE; MECHANICAL PROPERTIES;
   PARATHYROID HORMONE; CORTICAL BONE; QUANTITATIVE ULTRASOUND
AB Strategies to reduce fracture risk must be based on a sound understanding of the mechanisms that underline the increased incidence of fractures with age and with certain diseases. There is evidence that in addition to bone minerals density, other factors influence bone strength. The chapter reviews the biomechanical aspects of age related fractures, including the interacting roles of traumatic loading and bone strength, and the factors that determine a bones resistances to fracture. Also discussed are the mechanisms by which anti catabolic and anabolic therapies for osteoporosis may affect bone strength. Finally, several current and future methodologies for improving assessment of bone strength in patients are evaluated.
C1 Harvard Univ, Sch Med, Dept Orthopaed Surg, Boston, MA 02215 USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
C3 Harvard University; Harvard Medical School; Harvard University; Harvard
   University Medical Affiliates; Beth Israel Deaconess Medical Center
RP Bouxsein, ML (通讯作者)，Harvard Univ, Sch Med, Dept Orthopaed Surg, 330 Brookline Ave, Boston, MA 02215 USA.
CR Aaron JE, 2000, BONE, V27, P277, DOI 10.1016/S8756 3282(00)00328 8
   Ahlborg HG, 2003, NEW ENGL J MED, V349, P327, DOI 10.1056/NEJMoa022464
   [Anonymous], 2004, Bone Health and Osteoporosis: A Report of the Surgeon General
   BECK TJ, 1993, CALCIFIED TISSUE INT, V53, pS41, DOI 10.1007/BF01673401
   BELL G. H., 1967, CALCIFIED TISSUE RES, V1, P75, DOI 10.1007/BF02008077
   Boivin G, 2003, OSTEOPOROSIS INT, V14, pS22, DOI 10.1007/s00198 003 1469 1
   Boivin G, 2003, J CLIN ENDOCR METAB, V88, P4199, DOI 10.1210/jc.2002 022020
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   BONADIO J, 1993, J CLIN INVEST, V92, P1697, DOI 10.1172/JCI116756
   Borah B, 2004, BONE, V34, P736, DOI 10.1016/j.bone.2003.12.013
   Bouxsein ML, 1999, BONE, V25, P49, DOI 10.1016/S8756 3282(99)00093 9
   Bouxsein ML, 1997, J BONE MINER RES, V12, P839, DOI 10.1359/jbmr.1997.12.5.839
   Bouxsein ML, 2003, OSTEOPOROSIS INT, V14, pS118, DOI 10.1007/s00198 003 1489 x
   Bouxsien ML., 2001, Osteoporosis, V2nd, P509, DOI [10.1016/B978 012470862 4/50020 9, DOI 10.1016/B978 012470862 4/50020 9, 10.1016/b978 012470862 4/50020 9]
   Burr D, 2003, OSTEOPOROSIS INT, V14, pS67, DOI 10.1007/s00198 003 1476 2
   Burr DB, 1997, J BONE MINER RES, V12, P6, DOI 10.1359/jbmr.1997.12.1.6
   BURR DB, 1988, J BIOMECH, V21, P939, DOI 10.1016/0021 9290(88)90132 7
   Burr DB, 2002, BONE, V30, P2, DOI 10.1016/S8756 3282(01)00619 6
   CARTER DR, 1977, J BONE JOINT SURG AM, V59, P954, DOI 10.2106/00004623 197759070 00021
   CARTER DR, 1976, SCIENCE, V194, P1174, DOI 10.1126/science.996549
   Cheng XG, 1997, BONE, V20, P213, DOI 10.1016/S8756 3282(96)00383 3
   Cheng XG, 1997, J BONE MINER RES, V12, P1721, DOI 10.1359/jbmr.1997.12.10.1721
   Ciarelli TE, 2000, J BONE MINER RES, V15, P32, DOI 10.1359/jbmr.2000.15.1.32
   CURREY JD, 1969, J BIOMECH, V2, P1, DOI 10.1016/0021 9290(69)90036 0
   CURREY JD, 1990, J BIOMECH, V23, P837, DOI 10.1016/0021 9290(90)90030 7
   Currey JD, 1999, J EXP BIOL, V202, P2495
   Currey JD, 2003, OSTEOPOROSIS INT, V14, pS29, DOI 10.1007/s00198 003 1470 8
   Currey JD., 1986, European Society of Biomechics, V5, P104
   Delmas PD, 2000, BONE, V27, P1, DOI 10.1016/S8756 3282(00)00301 X
   Dempster DW, 2002, OSTEOPOROSIS INT, V13, P349, DOI 10.1007/s001980200038
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Duan YB, 2001, J BONE MINER RES, V16, P2276, DOI 10.1359/jbmr.2001.16.12.2276
   Dufresne TE, 2003, CALCIFIED TISSUE INT, V73, P423, DOI 10.1007/s00223 002 2104 4
   Efstathiadou Z, 2001, J BONE MINER RES, V16, P1586, DOI 10.1359/jbmr.2001.16.9.1586
   Genant HK, 2000, HORM RES, V54, P24, DOI 10.1159/000053294
   GIBSON LJ, 1985, J BIOMECH, V18, P317, DOI 10.1016/0021 9290(85)90287 8
   GILSANZ V, 1995, J CLIN INVEST, V95, P2332, DOI 10.1172/JCI117925
   GILSANZ V, 1994, RADIOLOGY, V190, P678, DOI 10.1148/radiology.190.3.8115610
   GOLDSTEIN SA, 1993, CALCIFIED TISSUE INT, V53, pS127, DOI 10.1007/BF01673421
   GOULET RW, 1994, J BIOMECH, V27, P375, DOI 10.1016/0021 9290(94)90014 0
   GREENSPAN SL, 1994, JAMA J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128
   HAYES WC, 1982, SCIENCE, V217, P945, DOI 10.1126/science.7112107
   Hildebrand T, 1999, J BONE MINER RES, V14, P1167, DOI 10.1359/jbmr.1999.14.7.1167
   Hoshaw SJ, 1997, J BIOMECH, V30, P323, DOI 10.1016/S0021 9290(96)00159 5
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   JONES HH, 1977, J BONE JOINT SURG AM, V59, P204, DOI 10.2106/00004623 197759020 00012
   Keaveny TM, 2001, ANNU REV BIOMED ENG, V3, P307, DOI 10.1146/annurev.bioeng.3.1.307
   Keyak JH, 1998, J BIOMECH, V31, P125, DOI 10.1016/S0021 9290(97)00123 1
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Legrand E, 2000, J BONE MINER RES, V15, P13, DOI 10.1359/jbmr.2000.15.1.13
   Link Thomas M, 2004, Curr Osteoporos Rep, V2, P47, DOI 10.1007/s11914 004 0003 5
   Link TM, 2000, RADIOLOGY, V217, P855, DOI 10.1148/radiology.217.3.r00dc06855
   Lochmüller EM, 1998, OSTEOPOROSIS INT, V8, P591, DOI 10.1007/s001980050104
   Lochmüller EM, 2002, BONE, V31, P77, DOI 10.1016/S8756 3282(02)00792 5
   Lochmüller EM, 2002, BONE, V30, P207, DOI 10.1016/S8756 3282(01)00621 4
   Lochmüller EM, 2002, J BONE MINER RES, V17, P1629, DOI 10.1359/jbmr.2002.17.9.1629
   Lochmüller EM, 1998, BONE, V23, P417, DOI 10.1016/S8756 3282(98)00127 6
   LOTZ JC, 1995, OSTEOPOROSIS INT, V5, P252, DOI 10.1007/BF01774015
   Majumdar S, 1998, BONE, V22, P445, DOI 10.1016/S8756 3282(98)00030 1
   Mann V, 2001, J CLIN INVEST, V107, P899, DOI 10.1172/JCI10347
   MCCALDEN RW, 1993, J BONE JOINT SURG AM, V75A, P1193, DOI 10.2106/00004623 199308000 00009
   Meunier PJ, 1997, BONE, V21, P373, DOI 10.1016/S8756 3282(97)00170 1
   Meunier PJ, 1999, INT J CLIN PRACT, P14
   Misof BM, 2003, J CLIN ENDOCR METAB, V88, P1150, DOI 10.1210/jc.2002 021988
   Muller ME, 2003, OSTEOPOROSIS INT, V14, P345, DOI 10.1007/s00198 003 1380 9
   Müller R, 2003, OSTEOPOROSIS INT, V14, pS89, DOI 10.1007/s00198 003 1479 z
   NEVITT MC, 1993, J AM GERIATR SOC, V41, P1226, DOI 10.1111/j.1532 5415.1993.tb07307.x
   Nicholson PHF, 1997, BONE, V20, P219, DOI 10.1016/S8756 3282(96)00370 5
   PARFITT AM, 1984, CALCIFIED TISSUE INT, V36, pS123, DOI 10.1007/BF02406145
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   RICE JC, 1988, J BIOMECH, V21, P155, DOI 10.1016/0021 9290(88)90008 5
   Riggs BL, 2004, J BONE MINER RES, V19, P1945, DOI 10.1359/JBMR.040916
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   RUFF CB, 1988, J ORTHOP RES, V6, P886, DOI 10.1002/jor.1100060613
   Schaffler MB, 1995, BONE, V17, P521, DOI 10.1016/8756 3282(95)00370 3
   SCHAFFLER MB, 1988, J BIOMECH, V21, P13, DOI 10.1016/0021 9290(88)90186 8
   Schaffler MB, 2003, OSTEOPOROSIS INT, V14, pS73
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140 6736(02)08706 8
   Seeman E, 1997, J BONE MINER RES, V12, P509, DOI 10.1359/jbmr.1997.12.4.509
   Silva MJ, 1997, BONE, V21, P191, DOI 10.1016/S8756 3282(97)00100 2
   Skaggs DL, 2001, J BONE MINER RES, V16, P1337, DOI 10.1359/jbmr.2001.16.7.1337
   SMITH RW, 1964, SCIENCE, V145, P156, DOI 10.1126/science.145.3628.156
   Snyder B.D., 1990, BIOMECHANICS DIARTHR, P31
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Turner CH, 2002, OSTEOPOROSIS INT, V13, P97, DOI 10.1007/s001980200000
   Ulrich D, 1999, BONE, V25, P55, DOI 10.1016/S8756 3282(99)00098 8
   van der Linden JC, 2001, J BONE MINER RES, V16, P457, DOI 10.1359/jbmr.2001.16.3.457
   van der Meulen MCH, 2001, BONE, V29, P101, DOI 10.1016/S8756 3282(01)00491 4
   Wehrli Felix W, 2002, Top Magn Reson Imaging, V13, P335, DOI 10.1097/00002142 200210000 00005
   Yeh OC, 1999, BONE, V25, P223, DOI 10.1016/S8756 3282(99)00092 7
NR 90
TC 141
Z9 165
U1 0
U2 5
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1521 6942
EI 1521 1770
J9 BEST PRACT RES CL RH
JI Best Pract. Res. Clin. Rheumatol.
PD DEC
PY 2005
VL 19
IS 6
BP 897
EP 911
DI 10.1016/j.berh.2005.07.004
PG 15
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 992BJ
UT WOS:000233858700003
PM 16301186
DA 2025 08 17
ER

PT J
AU Zhou, LB
   Wu, T
AF Zhou, Libo
   Wu, Tao
TI A Network Pharmacology Based Study on Vital Pharmacological Pathways and
   Targets of Eucommiae Cortex Acting on Osteoporosis
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
AB Background. Eucommiae Cortex is a Chinese herbal medicine with bone protective effects and treats osteoporosis. This study aimed to explore the pharmacological mechanisms of this complex mixture. Methods. The active compounds and disease targets involved in the study were obtained from publicly available websites and databases. Core target genes were identified by protein protein interaction (PPI) network and topology analysis and mapped to critical components by a "component target" regulatory network. Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway analysis and Gene Ontology (GO)analysis were performed to analyze the biological processes of target genes. Moreover, we carried out molecular docking, cell experiments, and quantitative real time PCR to propel the research forward. Results. Eucommiae Cortex contained 28 active ingredients and 85 potential targets for antiosteoporosis. PPI networks and topology analysis screened 17 core target genes. The therapeutic mechanism involves a series of biological reactions, including host virus response, chemical stress, oxidative stress, and cell cycle control. The KEGG enrichment illustrated that the MAPK signaling pathway might play a significant role. The final experiment detected ten genes (EGF, AKT1, JUN, MAPK8, MAPK1, CASP3, FOS, VEGFA, EGFR, and MYC) and three compounds (quercetin, kaempferol, and beta  carotene) in the MAPK pathway. Firstly, the CCK 8 and ALP activity test results showed that three compounds could enhance the proliferation and differentiation of osteoblast like MC3T3 E1 cells. Secondly, molecular docking confirmed the favorable binding potential. Subsequently, we observed that adding 1 * 10( 6) mol/L quercetin, 1 * 10( 5) mol/L kaempferol, and 1 * 10( 5) mol/L beta carotene activated the ERK/JNK cascades and the heterodimer complex AP 1(Fos/Jun) in the MAPK pathway. Conclusion. MAPK pathway might provide an essential mechanism for the antiosteoporosis effect of Eucommiae Cortex. Eucommiae Cortex and its active ingredients have the potential to treat osteoporosis.
C1 [Zhou, Libo] Qinghai Univ, Joint Surg, Xining 810001, Qinghai, Peoples R China.
   [Wu, Tao] Affiliated Hosp Qinghai Univ, Joint Surg, Xining 810001, Qinghai, Peoples R China.
C3 Qinghai University
RP Wu, T (通讯作者)，Affiliated Hosp Qinghai Univ, Joint Surg, Xining 810001, Qinghai, Peoples R China.
EM 2018597273@qq.com
RI Zhou, Libo/AAP 5373 2021
CR Barnsley J, 2021, AGING CLIN EXP RES, V33, P759, DOI 10.1007/s40520 021 01817 y
   Charkos TG, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03733 0
   Deardorff WJ, 2022, JAMA INTERN MED, V182, P33, DOI 10.1001/jamainternmed.2021.6745
   El Gazzar A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020625
   Guo YJ, 2020, EXP THER MED, V19, P1997, DOI 10.3892/etm.2020.8454
   Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Keshet Y, 2010, METHODS MOL BIOL, V661, P3, DOI 10.1007/978 1 60761 795 2_1
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Nishide Y, 2015, INT J ENV RES PUB HE, V12, P13750, DOI 10.3390/ijerph121113750
   Pan YL, 2014, AM J CHINESE MED, V42, P143, DOI 10.1142/S0192415X14500104
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Qi SS, 2019, BIOL TRACE ELEM RES, V187, P172, DOI 10.1007/s12011 018 1362 6
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40
   Wang JX, 2013, PROTEOM CLIN APPL, V7, P181, DOI 10.1002/prca.201200068
   Wei MQ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5217405
   Wen XM, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031464
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Xu R, 2017, J BONE MINER RES, V32, P1811, DOI 10.1002/jbmr.3184
   Zenz R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2338
   [赵继荣 Zhao Jirong], 2020, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V26, P1868
NR 23
TC 4
Z9 4
U1 4
U2 15
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD MAR 31
PY 2022
VL 2022
AR 8510842
DI 10.1155/2022/8510842
PG 14
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 5Z4UP
UT WOS:000879970300001
PM 35402622
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Fukunaga, T
   Zou, W
   Rohatgi, N
   Colca, JR
   Teitelbaum, SL
AF Fukunaga, Tomohiro
   Zou, Wei
   Rohatgi, Nidhi
   Colca, Jerry R.
   Teitelbaum, Steven L.
TI An Insulin Sensitizing Thiazolidinedione, Which Minimally Activates
   PPARγ, Does Not Cause Bone Loss
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE TYPE II DIABETES MELLITUS; THIAZOLIDINEDIONE; OSTEOCLASTS; BONE
   HISTOMORPHOMETRY; BONE mu CT
ID MITOCHONDRIAL PYRUVATE CARRIER; ANTIDIABETIC DRUGS; GENE EXPRESSION;
   ROSIGLITAZONE; MICE; METABOLISM; RESISTANCE; CD36; OSTEOCLASTOGENESIS;
   PHOSPHORYLATION
AB Rosiglitazone is an insulin sensitizing thiazolidinedione (TZD) that activates the transcription factor peroxisome proliferator activated receptor gamma (PPAR gamma). Although rosiglitazone effectively treats type II diabetes mellitus (T2DM), it carries substantial complications, including increased fracture risk. This predisposition to fracture is consistent with the fact that PPAR gamma preferentially promotes formation of adipocytes at the cost of osteoblasts. Rosiglitazone activated PPAR gamma, however, also stimulates osteoclast formation. A new TZD analog with low affinity for binding and activation of PPAR gamma but whose insulin sensitizing properties mirror those of rosiglitazone has been recently developed. Because of its therapeutic implications, we investigated the effects of this new TZD analog (MSDC 0602) on skeletal homeostasis, in vitro and in vivo. Confirming it activates the nuclear receptor in osteoclasts, rosiglitazone enhances expression of the PPAR gamma target gene, CD36. MSDC 0602, in contrast, minimally activates PPAR gamma and does not alter CD36 expression in the bone resorptive cells. Consistent with this finding, rosiglitazone increases receptor activator of NF kappa B ligand (RANKL) induced osteoclast differentiation and number, whereas MSDC 0602 fails to do so. To determine if this new TZD analog is bone sparing, in vivo, we fed adult male C57BL/6 mice MSDC 0602 or rosiglitazone. Six months of a rosiglitazone diet results in a 35% decrease in bone mass with increased number of osteoclasts, whereas that of MSDC 0602 fed mice is indistinguishable from control. Thus, PPAR gamma sparing eliminates the skeletal side effects of TZDs while maintaining their insulin sensitizing properties. (C) 2014 American Society for Bone and Mineral Research.
C1 [Fukunaga, Tomohiro; Zou, Wei; Rohatgi, Nidhi; Teitelbaum, Steven L.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Colca, Jerry R.] Metab Solut Dev Co, Kalamazoo, MI USA.
   [Teitelbaum, Steven L.] Washington Univ, Sch Med, Dept Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Teitelbaum, SL (通讯作者)，Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 South Euclid Ave, St Louis, MO 63110 USA.
EM teitelbs@wustl.edu
RI ; Rohatgi, Nidhi/GWR 1096 2022; Fukunaga, Tomohiro/T 4339 2019
OI Fukunaga, Tomohiro/0000 0003 0533 6454; Zou, Wei/0000 0001 8081 268X;
   Teitelbaum, Steven/0000 0002 4054 6679
FU National Institutes of Health [R01 AR032788, R01 AR057037, R01 AR046523,
   P30 AR057235]
FX This work was supported by National Institutes of Health grants R01
   AR032788, R01 AR057037, R01 AR046523 and P30 AR057235.
CR Ackert Bicknell CL, 2009, ENDOCRINOLOGY, V150, P1330, DOI 10.1210/en.2008 0936
   Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Ballesteros I, 2014, J LEUKOCYTE BIOL, V95, P587, DOI 10.1189/jlb.0613326
   Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097 2765(00)80209 9
   Bricker DK, 2012, SCIENCE, V337, P96, DOI 10.1126/science.1218099
   Bruedigam C, 2010, STEM CELLS, V28, P916, DOI 10.1002/stem.405
   Cariou B, 2012, TRENDS ENDOCRIN MET, V23, P205, DOI 10.1016/j.tem.2012.03.001
   Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336
   Chen ZJ, 2012, J BIOL CHEM, V287, P23537, DOI 10.1074/jbc.M112.363960
   Choi JH, 2011, NATURE, V477, P477, DOI 10.1038/nature10383
   Choi JH, 2010, NATURE, V466, P451, DOI 10.1038/nature09291
   Collot Teixeira S, 2007, CARDIOVASC RES, V75, P468, DOI 10.1016/j.cardiores.2007.03.010
   Craft CS, 2010, J BIOL CHEM, V285, P23858, DOI 10.1074/jbc.M110.113019
   Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464 5491.1999.00023.x
   DeFronzo RA, 2011, J CLIN ENDOCR METAB, V96, P2354, DOI 10.1210/jc.2011 0246
   Divakaruni AS, 2013, P NATL ACAD SCI USA, V110, P5422, DOI 10.1073/pnas.1303360110
   Duan SZ, 2007, J CLIN INVEST, V117, P812, DOI 10.1172/JCI28859
   Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025
   Faccio R, 2003, J CELL BIOCHEM, V90, P871, DOI 10.1002/jcb.10694
   Feinstein DL, 2005, BIOCHEM PHARMACOL, V70, P177, DOI 10.1016/j.bcp.2005.03.033
   Hauner H, 2002, DIABETES METAB RES, V18, pS10, DOI 10.1002/dmrr.249
   Helming L, 2009, J CELL SCI, V122, P453, DOI 10.1242/jcs.037200
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   KLETZIEN RF, 1992, MOL PHARMACOL, V42, P558
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006 1587
   Lee B, 2014, REV ENDOCR METAB DIS, V15, P149, DOI 10.1007/s11154 013 9283 3
   LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953
   Li M, 2006, BONE, V39, P796, DOI 10.1016/j.bone.2006.04.008
   NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Saltiel AR, 2001, NAT MED, V7, P887, DOI 10.1038/90911
   Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3
   Sorocéanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723
   Sottile V, 2004, CALCIFIED TISSUE INT, V75, P329, DOI 10.1007/s00223 004 0224 8
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092 8674(00)81575 5
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wan YH, 2010, TRENDS ENDOCRIN MET, V21, P722, DOI 10.1016/j.tem.2010.08.006
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
NR 44
TC 35
Z9 38
U1 0
U2 14
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2015
VL 30
IS 3
BP 508
EP 515
DI 10.1002/jbmr.2364
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CC0YV
UT WOS:000350066900014
PM 25257948
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Cao, Z
   Niu, XB
   Wang, MH
   Yu, SW
   Wang, MK
   Mu, SL
   Liu, C
   Wang, YX
AF Cao, Zhen
   Niu, Xuben
   Wang, Maihuan
   Yu, Siwang
   Wang, Mingkun
   Mu, Silong
   Liu, Chuan
   Wang, Yaxi
TI Anemoside B4 attenuates RANKL induced osteoclastogenesis by upregulating
   Nrf2 and dampens ovariectomy induced bone loss
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Anemoside B4; Osteoclastogenesis; Bone resorption; Nrf2; Osteoporosis
ID OXIDATIVE STRESS; OSTEOPOROSIS; PATHWAY; FUSION
AB Increased numbers and functional overactivity of osteoclasts are the pathological basis for bone loss diseases such as osteoporosis, which are characterized by cortical bone thinning, decreased trabecular bone quantity, and reduced bone mineral density. Effective inhibition of osteoclast formation and bone resorption are important means of treating such skeletal diseases. Anemoside B4 (AB4), the main active component of Pulsatilla chinensis, possesses a wide range of anti inflammatory and immunoregulatory effects. However, its effect and mechanism in osteoclast differentiation remain unclear. In this study, we found through tartrate resistant acidic phosphatase (TRAcP) staining and immunofluorescence staining that AB4 inhibited the differentiation, fusion, and boneresorption functions of osteoclasts induced by receptor activator of nuclear factor kappa B ligand (RANKL) in vitro. Additionally, real time PCR (RT qPCR) and western blot analysis showed AB4 downregulated the expression of osteoclast marker genes, including Nfatc1, Fos, and Ctsk, while upregulating Nrf2 expression. AB4 (5 mg/kg) alleviated bone loss in ovariectomized mice by inhibiting osteoclast formation. Furthermore, the knockout of Nrf2 weakened the inhibitory effects of AB4 on osteoclast formation and related gene expression. In summary, the results suggest AB4 can inhibit osteoclast differentiation and function by activating Nrf2 and indicate AB4 may be a candidate drug for osteoporosis.
C1 [Cao, Zhen; Niu, Xuben; Wang, Mingkun] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 6, Dept Gastroenterol, Beijing 100048, Peoples R China.
   [Cao, Zhen; Wang, Maihuan; Mu, Silong] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Gen Surg, Beijing 100853, Peoples R China.
   [Cao, Zhen; Niu, Xuben] South China Univ Technol, Sch Med, Dept Gen Surg, Guangzhou 511442, Peoples R China.
   [Yu, Siwang] Peking Univ Sch Pharmaceut Sci, Dept Mol & Cellular Pharmacol, Beijing 100191, Peoples R China.
   [Yu, Siwang] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China.
   [Liu, Chuan] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Orthoped, Beijing 100700, Peoples R China.
   [Wang, Yaxi] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Emergency, Beijing 100700, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese People's
   Liberation Army General Hospital; South China University of Technology;
   Peking University; Chinese People's Liberation Army General Hospital;
   Seventh Medical Center of Chinese PLA General Hospital; Chinese People's
   Liberation Army General Hospital; Seventh Medical Center of Chinese PLA
   General Hospital
RP Liu, C (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Orthoped, Beijing 100700, Peoples R China.; Wang, YX (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Emergency, Beijing 100700, Peoples R China.
EM liuchuan@301hospital.com.cn; wangyaxi@301hospital.com.cn
RI Wang, Yaxi/IUO 6777 2023; Wang, Mingkun/MGW 3921 2025
FU National Natural Science Founda  tion of China [82103507]
FX <BOLD>Funding</BOLD> This study was supported by the National Natural
   Science Founda  tion of China (No. 82103507) .
CR Aibar Almazán A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23169465
   Berry SD, 2019, JAMA J AM MED ASSOC, V321, P2231, DOI 10.1001/jama.2019.5453
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Chang Y, 2022, CHEM BIOL INTERACT, V366, DOI 10.1016/j.cbi.2022.110153
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cuadrado A, 2019, NAT REV DRUG DISCOV, V18, P295, DOI 10.1038/s41573 018 0008 x
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Ding D, 2022, INT J MOL MED, V49, DOI 10.3892/ijmm.2021.5059
   Feng MZ, 2023, J CELL MOL MED, V27, P701, DOI 10.1111/jcmm.17692
   Fujita K, 2012, NAT MED, V18, P589, DOI 10.1038/nm.2659
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Gong Q, 2023, MOLECULES, V28, DOI 10.3390/molecules28030968
   Gong W, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/5410377
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   He X, 2021, AGING US, V13, P25365, DOI 10.18632/aging.203751
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790
   Kang NX, 2019, PHYTOMEDICINE, V64, DOI 10.1016/j.phymed.2019.152934
   Kendler DL, 2022, ADV THER, V39, P58, DOI 10.1007/s12325 021 01936 y
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   LeBoff MS, 2022, NEW ENGL J MED, V387, P299, DOI 10.1056/NEJMoa2202106
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li YH, 2020, PHARMACOL RES, V160, DOI 10.1016/j.phrs.2020.105079
   Long H., 2019, Life Sci.
   Ma HM, 2020, INT IMMUNOPHARMACOL, V87, DOI 10.1016/j.intimp.2020.106794
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Pei L, 2021, CHEM BIOL INTERACT, V345, DOI 10.1016/j.cbi.2021.109534
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rodrigues T, 2016, NAT CHEM, V8, P531, DOI [10.1038/NCHEM.2479, 10.1038/nchem.2479]
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580 020 0230 3
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Veis DJ, 2023, ANNU REV PATHOL MECH, V18, P257, DOI 10.1146/annurev pathmechdis 031521 040919
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xue SY, 2019, AM J TRANSL RES, V11, P2580
   Yao H, 2022, FREE RADICAL BIO MED, V190, P264, DOI 10.1016/j.freeradbiomed.2022.08.016
   Ying SQ, 2020, THERANOSTICS, V10, P9789, DOI 10.7150/thno.42508
   Yuan RYK, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/7502301
   Zhang H, 2023, SCI ADV, V9, DOI 10.1126/sciadv.abo7868
NR 52
TC 3
Z9 4
U1 0
U2 14
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD NOV
PY 2023
VL 167
AR 115454
DI 10.1016/j.biopha.2023.115454
EA SEP 2023
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA T0JJ7
UT WOS:001074933500001
PM 37688987
OA gold
DA 2025 08 17
ER

PT J
AU Zhou, L
   Liu, QL
   Yang, ML
   Wang, T
   Yao, J
   Cheng, JW
   Yuan, JB
   Lin, XX
   Zhao, JM
   Tickner, J
   Xu, JK
AF Zhou, Lin
   Liu, Qian
   Yang, Mingli
   Wang, Tao
   Yao, Jun
   Cheng, Jianwen
   Yuan, Jinbo
   Lin, Xixi
   Zhao, Jinmin
   Tickner, Jennifer
   Xu, Jiake
TI Dihydroartemisinin, an Anti Malaria Drug, Suppresses Estrogen
   Deficiency Induced Osteoporosis, Osteoclast Formation, and RANKL Induced
   Signaling Pathways
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE DIHYDROARTEMISININ; OSTEOCLAST; RANKL; BONE RESORPTION; OSTEOLYSIS
ID NF KAPPA B; REGULATED KINASE; NUCLEAR FACTOR; BREAST CANCER; ACTIVATION;
   NFATC1; CELLS; BONE; ERK; OSTEOPROTEGERIN
AB Osteoporosis is an osteolytic disease that features enhanced osteoclast formation and bone resorption. Identification of agents that can inhibit osteoclast formation and function is important for the treatment of osteoporosis. Dihydroartemisinin is a natural compound used to treat malaria but its role in osteoporosis is not known. Here, we found that dihydroartemisinin can suppress RANKL induced osteoclastogenesis and bone resorption in a dose dependent manner. Dihydroartemisinin inhibited the expression of osteoclast marker genes such as cathepsin K, calcitonin receptor, and tartrate resistant acid phosphatase (TRAcP). Furthermore, dihydroartemisinin inhibited RANKL induced NF kappa B and NFAT activity. In addition, using an in vivo ovariectomized mouse model, we show that dihydroartemisinin is able to reverse the bone loss caused by ovariectomy. Together, this study shows that dihydroartemisinin attenuates bone loss in ovariectomized mice through inhibiting RANKL induced osteoclast formation and function. This indicates that dihydroartemisinin, the first physiology or medicine nobel prize discovery of China, is a potential treatment option against osteolytic bone disease. (C) 2015 American Society for Bone and Mineral Research.
C1 [Zhou, Lin; Liu, Qian; Yang, Mingli; Yao, Jun; Cheng, Jianwen; Yuan, Jinbo; Tickner, Jennifer; Xu, Jiake] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia.
   [Liu, Qian; Wang, Tao; Yao, Jun; Cheng, Jianwen; Lin, Xixi; Zhao, Jinmin; Xu, Jiake] Guangxi Med Univ, Res Ctr Regenerat Med, Guangxi, Peoples R China.
   [Liu, Qian; Wang, Tao; Yao, Jun; Cheng, Jianwen; Lin, Xixi; Zhao, Jinmin; Xu, Jiake] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Guangxi, Peoples R China.
C3 University of Western Australia; Guangxi Medical University; Guangxi
   Medical University
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia.
EM jiake.xu@uwa.edu.au
RI Tickner, Jennifer/H 5965 2014; zhao, jin/LBH 0351 2024; xi,
   lin/JOK 1026 2023
OI Tickner, Jennifer/0000 0002 5020 0671; Zhao, Jinmin/0000 0002 1047 8820;
   Xu, Jiake/0000 0003 2021 8309; Yuan, Jinbo/0000 0002 6240 9333
FU National Health and Medical Research Council of Australia; National
   Natural Science Foundation of China (NSFC) [8122801]; Arthritis
   foundation of Australia; University of Western Australia (UWA); RAINE;
   Chinese Scholarship Council; Co innovation Centre for Bio Medicine;
   Guangxi Colleges and Universities Key Laboratory of Regenerative
   Medicine and Innovation Team of Tissue Repair and Reconstruction
FX This study was supported in part by the National Health and Medical
   Research Council of Australia. This study was also supported by a grant
   from the National Natural Science Foundation of China (NSFC) (No:
   8122801), Arthritis foundation of Australia, The University of Western
   Australia (UWA) Research Collaboration Awards (2014). It is supported by
   RAINE research fellowship to Dr. Jennifer Tickner and a PhD scholarship
   from the Chinese Scholarship Council (Lin Zhou). This project is also
   sponsored in part by Co innovation Centre for Bio Medicine, Guangxi
   Colleges and Universities Key Laboratory of Regenerative Medicine and
   Innovation Team of Tissue Repair and Reconstruction to Dr. Jianwen
   Cheng, Qian Liu, Jun Yao, and Tao Wong, who were Visiting Scholars to
   the University of Western Australia (2014 2015). The authors thank Dr.
   Li Jia for technical assistance. Prof. Jiake Xu and Dr. Lin Zhou made
   mutual collaborative visits to Guangxi Medical University in 2014. We
   acknowledge the facilities, and the scientific and technical assistance
   of the National Imaging Facility at the Centre for Microscopy,
   Characterisation & Analysis, The University of Western Australia, a
   facility funded by the University, State and Commonwealth Governments.
CR Ashley EA, 2005, CLIN INFECT DIS, V41, P425, DOI 10.1086/432011
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Chen H, 2010, J CANCER RES CLIN, V136, P897, DOI 10.1007/s00432 009 0731 0
   Chim SM, 2011, J BIOL CHEM, V286, P22035, DOI 10.1074/jbc.M110.187633
   Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092 8674(02)01166 2
   Dong FY, 2015, INT J MOL MED, V35, P1381, DOI 10.3892/ijmm.2015.2140
   Dong FY, 2014, CANCER BIOL THER, V15, P1479, DOI 10.4161/15384047.2014.955728
   Eckstein Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813
   Ericsson T, 2014, EUR J CLIN PHARMACOL, V70, P1453, DOI 10.1007/s00228 014 1754 2
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Goltzman D, 2001, J CLIN INVEST, V107, P1219, DOI 10.1172/JCI13073
   Gordi T, 2004, TOXICOL LETT, V147, P99, DOI 10.1016/j.toxlet.2003.12.009
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Hwang YP, 2010, BIOCHEM PHARMACOL, V79, P1714, DOI 10.1016/j.bcp.2010.02.003
   Ji Y, 2011, MOL CELL BIOCHEM, V351, P99, DOI 10.1007/s11010 011 0716 6
   Jung M, 2006, BIOORG MED CHEM LETT, V16, P1227, DOI 10.1016/j.bmcl.2005.11.074
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Krishna S, 2008, TRENDS PHARMACOL SCI, V29, P520, DOI 10.1016/j.tips.2008.07.004
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee J, 2012, J CANCER RES CLIN, V138, P2095, DOI 10.1007/s00432 012 1292 1
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   LIN AJ, 1987, J MED CHEM, V30, P2147, DOI 10.1021/jm00394a037
   Liu LK, 2014, ASIAN PAC J CANCER P, V15, P2511, DOI 10.7314/APJCP.2014.15.6.2511
   Liu Q, 2013, BIOCHEM PHARMACOL, V86, P1775, DOI 10.1016/j.bcp.2013.09.017
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174
   Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955 0674(99)80030 1
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Singh NP, 2001, LIFE SCI, V70, P49, DOI 10.1016/S0024 3205(01)01372 8
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Tu YY, 1999, CHINESE MED J PEKING, V112, P976
   US Department of Health and Human Services, 2004, BON HLTH OST REP SUR, V113, P805
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Zhu LL, 2005, BIOCHEM BIOPH RES CO, V326, P131, DOI 10.1016/j.bbrc.2004.10.212
   Zou W, 2010, ANN NY ACAD SCI, V1192, P27, DOI 10.1111/j.1749 6632.2009.05245.x
   Zuo Zhan jie, 2014, Zhongguo Zhong Xi Yi Jie He Za Zhi, V34, P1220
NR 50
TC 90
Z9 95
U1 0
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2016
VL 31
IS 5
BP 964
EP 974
DI 10.1002/jbmr.2771
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DN7PX
UT WOS:000377270400006
PM 26684711
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Rachner, TD
   Göbel, A
   Thiele, S
   Rauner, M
   Benad Mehner, P
   Hadji, P
   Bauer, T
   Muders, MH
   Baretton, GB
   Jakob, F
   Ebert, R
   Bornhäuser, M
   Schem, C
   Hofbauer, LC
AF Rachner, Tilman D.
   Goebel, Andy
   Thiele, Stefanie
   Rauner, Martina
   Benad Mehner, Peggy
   Hadji, Peyman
   Bauer, Thomas
   Muders, Michael H.
   Baretton, Gustavo B.
   Jakob, Franz
   Ebert, Regina
   Bornhaeuser, Martin
   Schem, Christian
   Hofbauer, Lorenz C.
TI Dickkopf 1 is regulated by the mevalonate pathway in breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID MULTIPLE MYELOMA; ZOLEDRONIC ACID; BONE METASTASES; CELLS; EXPRESSION;
   OSTEOPROTEGERIN; INHIBITOR; THERAPY; DISEASE; BISPHOSPHONATES
AB Introduction: Amino bisphosphonates and statins inhibit the mevalonate pathway, and may exert anti tumor effects. The Wnt inhibitor dickkopf 1 (DKK 1) promotes osteolytic bone lesions by inhibiting osteoblast functions and has been implicated as an adverse marker in multiple cancers. We assessed the effects of mevalonate pathway inhibition on DKK 1 expression in osteotropic breast cancer.
   Methods: Regulation of DKK 1 by bisphosphonates and statins was assessed in human breast cancer cell lines, and the role of the mevalonate pathway and downstream targets was analyzed. Moreover, the potential of breast cancer cells to modulate osteoblastogenesis via DKK 1 was studied in mC2C12 cells. Clinical relevance was validated by analyzing DKK 1 expression in the tissue and serum of women with breast cancer exposed to bisphosphonates.
   Results: DKK 1 was highly expressed in receptor negative breast cancer cell lines. Patients with receptor negative tumors displayed elevated levels of DKK 1 at the tissue and serum level compared to healthy controls. Zoledronic acid and atorvastatin potently suppressed DKK 1 in vitro by inhibiting geranylgeranylation of CDC42 and Rho. Regulation of DKK 1 was strongest in osteolytic breast cancer cell lines with abundant DKK 1 expression. Suppression of DKK 1 inhibited the ability of breast cancer cells to block WNT3A induced production of alkaline phosphates and bone protective osteoprotegerin in preosteoblastic C2C12 cells. In line with the in vitro data, treatment of breast cancer patients with zoledronic acid decreased DKK 1 levels by a mean of 60% after 12 months of treatment.
   Conclusion: DKK 1 is a novel target of the mevalonate pathway that is suppressed by zoledronic acid and atorvastatin in breast cancer.
C1 [Rachner, Tilman D.; Goebel, Andy; Thiele, Stefanie; Rauner, Martina; Benad Mehner, Peggy; Hofbauer, Lorenz C.] Tech Univ Dresden, Dept Med 3, Div Endocrinol & Metab Bone Dis, D 01307 Dresden, Germany.
   [Hadji, Peyman; Bauer, Thomas] Univ Marburg, Dept Gynecol & Oncol, D 35034 Marburg, Germany.
   [Muders, Michael H.; Baretton, Gustavo B.] Tech Univ Dresden, Inst Pathol, D 01307 Dresden, Germany.
   [Jakob, Franz; Ebert, Regina] Univ Wurzburg, Orthoped Ctr Musculoskeletal Res, D 97074 Wurzburg, Germany.
   [Bornhaeuser, Martin] Tech Univ Dresden, Dept Med 1, Div Hematol, D 01307 Dresden, Germany.
   [Bornhaeuser, Martin; Hofbauer, Lorenz C.] Tech Univ Dresden, Ctr Regenerat Therapies Dresden, D 01307 Dresden, Germany.
   [Schem, Christian] Univ Med Ctr Schleswig Holstein, Dept Gynecol & Obstet, D 24105 Kiel, Germany.
C3 Technische Universitat Dresden; Philipps University Marburg; Technische
   Universitat Dresden; University of Wurzburg; Technische Universitat
   Dresden; Technische Universitat Dresden; University of Kiel; Schleswig
   Holstein University Hospital
RP Rachner, TD (通讯作者)，Tech Univ Dresden, Dept Med 3, Div Endocrinol & Metab Bone Dis, Fetscherstr 74, D 01307 Dresden, Germany.
EM Tilman.rachner@uniklinikum dresden.de
RI ; Ebert, Regina/D 5760 2016; Hofbauer, Lorenz C./G 2490 2010
OI Rauner, Martina/0000 0002 4067 6799; Conrad,
   Stefanie/0000 0001 9345 026X; Ebert, Regina/0000 0002 8192 869X;
   Hofbauer, Lorenz C./0000 0002 8691 8423
FU MedDrive start up grant from the TU Dresden; Deutsche
   Forschungsgemeinschaft [Forschergruppe 1586];  [RA 2151/2 1]
FX This work was supported by the MedDrive start up grant from the TU
   Dresden to TDR, and grants RA 2151/2 1 (to TDR and LCH) and
   Forschergruppe 1586 SKELMET to TDR, FJ, MB, CS, and LCH from the
   Deutsche Forschungsgemeinschaft. The authors thank Josefa Hotzel for
   technical assistance.
CR Benad P, 2011, CANCER LETT, V312, P101, DOI 10.1016/j.canlet.2011.08.006
   Bu GJ, 2008, INT J CANCER, V123, P1034, DOI 10.1002/ijc.23625
   Canalis E, 2010, J CLIN ENDOCR METAB, V95, P1496, DOI 10.1210/jc.2009 2677
   Chan KKW, 2003, CLIN CANCER RES, V9, P10
   Coleman RE, 2013, J BONE ONCOL, V2, P70, DOI 10.1016/j.jbo.2013.01.002
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Ebert R, 2012, BONE, V50, P723, DOI 10.1016/j.bone.2011.11.025
   Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gavriatopoulou M, 2009, EXPERT OPIN THER TAR, V13, P839, DOI 10.1517/14728220903025770
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Green J, 2010, CANCER INVEST, V28, P944, DOI 10.3109/07357907.2010.512598
   Hadji P, 2013, J BONE ONCOL, V2, P2, DOI 10.1016/j.jbo.2013.01.001
   Hall CL, 2008, PROSTATE, V68, P1396, DOI 10.1002/pros.20805
   Hall CL, 2010, CANCER RES, V70, P9916, DOI 10.1158/0008 5472.CAN 10 0440
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mahtani R, 2010, CLIN BREAST CANCER, V10, P359, DOI 10.3816/CBC.2010.n.047
   Mikheev AM, 2008, BREAST CANCER RES TR, V112, P263, DOI 10.1007/s10549 007 9867 2
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Qiao L, 2008, CANCER LETT, V269, P67, DOI 10.1016/j.canlet.2008.04.032
   Rachner TD, 2013, J BONE ONCOL, V2, P110, DOI 10.1016/j.jbo.2013.05.003
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rachner TD, 2010, CANCER LETT, V287, P109, DOI 10.1016/j.canlet.2009.06.003
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Stein NC, 2008, J BONE MINER RES, V23, P750, DOI 10.1359/JBMR.080203
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Thudi NK, 2011, PROSTATE, V71, P615, DOI 10.1002/pros.21277
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Xu WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037624
   Zhou XL, 2010, ACTA PHARMACOL SIN, V31, P202, DOI 10.1038/aps.2009.200
NR 35
TC 35
Z9 37
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465 542X
EI 1465 5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2014
VL 16
IS 1
AR R20
DI 10.1186/bcr3616
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AL2VI
UT WOS:000338983300027
PM 24528599
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Seo, K
   Yoo, JH
   Kim, J
   Min, SJ
   Heo, DN
   Kwon, I
   Moon, HJ
AF Seo, Kwansung
   Yoo, Ji Hye
   Kim, Jisu
   Min, Sung Jun
   Heo, Dong Nyoung
   Kwon, Il Keun
   Moon, Ho Jin
TI Ginseng derived exosome like nanovesicles extracted by sucrose gradient
   ultracentrifugation to inhibit osteoclast differentiation
SO NANOSCALE
LA English
DT Article
ID NF KAPPA B; OSTEOPOROSIS; RESORPTION
AB Plant derived extracellular nanovesicles contain RNA and proteins with unique and diverse pharmacological mechanisms. The extracellular nanovesicles encapsulating plant extracts resemble exosomes as they have a round, lipid bilayer morphology. Ginseng is anti inflammatory, anti cancer, immunostimulant, and osteogenic/anti osteoporotic. Here, we confirmed that ginseng derived extracellular nanovesicles (GDNs) inhibit osteoclast differentiation and elucidated the associated molecular mechanisms. We isolated GDNs by centrifugation with a sucrose gradient. We measured their dynamic light scattering and zeta potentials and examined their morphology by transmission electron microscopy. We used bone marrow derived macrophages (BMMs) to determine the potential cytotoxicity of GDNs and establish their ability to inhibit osteoclast differentiation. The GDNs treatment maintained high BMM viability and proliferation whilst impeding osteoclastogenesis. Tartrate resistant acid phosphatase and F actin staining revealed that GDNs at concentrations >1 mu g mL( 1) strongly hindered osteoclast differentiation. Moreover, they substantially suppressed the RANKL induced I kappa B alpha, c JUN n terminal kinase, and extracellular signal regulated kinase signaling pathways and the genes regulating osteoclast maturation. The GDNs contained elevated proportions of Rb1 and Rg1 ginsenosides and were more effective than either of them alone or in combination at inhibiting osteoclast differentiation. In vivo bone analysis via microcomputerized tomography, bone volume/total volume ratios, and bone mineral density and bone cavity measurements demonstrated the inhibitory effect of GDNs against osteoclast differentiation in lipopolysaccharide induced bone resorption mouse models. The results of this work suggest that GDNs are anti osteoporotic by inhibiting osteoclast differentiation and are, therefore, promising for use in the clinical prevention and treatment of bone loss diseases.
C1 [Seo, Kwansung; Min, Sung Jun] Kyung Hee Univ, Grad Sch, Dept Dent, 26 Kyungheedae ro, Seoul 02447, South Korea.
   [Yoo, Ji Hye] Kyung Hee Univ, Grad Sch, Dept Biomed Sci & Technol, 26 Kyungheedae ro, Seoul 02447, South Korea.
   [Kim, Jisu] Fudan Univ & Key Lab Smart Drug Delivery, Sch Pharm, Dept Pharmaceut, Minist Educ, Shanghai 201203, Peoples R China.
   [Heo, Dong Nyoung; Kwon, Il Keun; Moon, Ho Jin] Kyung Hee Univ, Sch Dent, Dept Dent Mat, 26 Kyungheedae ro, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University
RP Kwon, I; Moon, HJ (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Dent Mat, 26 Kyungheedae ro, Seoul 02447, South Korea.
EM kwoni@khu.ac.kr; 3216@khu.ac.kr
RI ; Kim, Jisu/JNS 2157 2023
OI Moon, Ho Jin/0000 0002 8056 5313; KIM, JISU/0000 0002 7169 8245; Yoo,
   Jihye/0000 0002 2347 7819; min, sungjun/0000 0002 3984 4505
FU National Research Foundation of Korea (NRF)   Korean government (MSIT)
   [NRF 2020R1A4A1019456, NRF 2020R1A2C2011937]; Ministry of Education
   [2021R1I1A1A01050431]
FX This work was supported by National Research Foundation of Korea (NRF)
   grants from the Korean government (MSIT) (NRF 2020R1A4A1019456 and
   NRF 2020R1A2C2011937) and from the Ministry of Education
   (2021R1I1A1A01050431).
CR Baek KS, 2016, J GINSENG RES, V40, P437, DOI 10.1016/j.jgr.2016.08.003
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chauhan S, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2299 1
   Cheng BB, 2012, FOOD CHEM TOXICOL, V50, P1610, DOI 10.1016/j.fct.2012.02.019
   Cheon YH, 2016, J BONE MINER RES, V31, P403, DOI 10.1002/jbmr.2612
   Cho EG, 2021, CELLS BASEL, V10, DOI 10.3390/cells10030486
   Eleniste Pierre P, 2012, J Signal Transduct, V2012, P296450, DOI 10.1155/2012/296450
   Frohne CC, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425 018 0484 x
   Han SY, 2018, J GINSENG RES, V42, P496, DOI 10.1016/j.jgr.2017.06.003
   HAUSMANN E, 1970, SCIENCE, V168, P862, DOI 10.1126/science.168.3933.862
   He L, 2012, BONE, V50, P1207, DOI 10.1016/j.bone.2012.03.022
   Im DS, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030444
   Jin Y, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12696
   Ju SW, 2013, MOL THER, V21, P1345, DOI 10.1038/mt.2013.64
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kim J, 2022, SN APPL SCI, V4, DOI 10.1007/s42452 022 04943 y
   Konoshenko MY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8545347
   Lee HY, 2015, J FUNCT FOODS, V13, P192, DOI 10.1016/j.jff.2014.12.039
   Lee YY, 2015, J AGR FOOD CHEM, V63, P3472, DOI 10.1021/jf506110y
   Moon H. J., 2012, PHYTOTHER RES, V26, P1648
   Niu Yang Ping, 2001, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V9, P178
   Park KR, 2018, THERANOSTICS, V8, P3087, DOI 10.7150/thno.24426
   Raimondo S, 2015, ONCOTARGET, V6, P19514, DOI 10.18632/oncotarget.4004
   Ramesh T, 2012, EXP GERONTOL, V47, P77, DOI 10.1016/j.exger.2011.10.007
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Siddiqi MH, 2013, J GINSENG RES, V37, P261, DOI 10.5142/jgr.2013.37.261
   Stanly C, 2016, METHODS MOL BIOL, V1459, P259, DOI 10.1007/978 1 4939 3804 9_18
   Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504
   Wang BM, 2014, MOL THER, V22, P522, DOI 10.1038/mt.2013.190
   Wang SY, 2021, J BONE MINER RES, V36, P1850, DOI 10.1002/jbmr.4328
   Wei LH, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106400
   Yang N, 2020, CHIN MED UK, V15, DOI 10.1186/s13020 020 00323 z
   Yang S, 2023, J GINSENG RES, V47, P133, DOI 10.1016/j.jgr.2022.07.005
   Yu LL, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.584391
   Yue M, 2021, IMMUNOL INVEST, V50, P1, DOI [10.1080/08820139.2019.1708384, 10.1145/3422713.3422720]
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
NR 37
TC 62
Z9 65
U1 29
U2 129
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040 3364
EI 2040 3372
J9 NANOSCALE
JI Nanoscale
PD MAR 23
PY 2023
VL 15
IS 12
BP 5798
EP 5808
DI 10.1039/d2nr07018a
EA MAR 2023
PG 11
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 9Z6VL
UT WOS:000941214700001
PM 36857681
DA 2025 08 17
ER

PT J
AU Aravamudhan, A
   Ramos, DM
   Nip, J
   Subramanian, A
   James, R
   Harmon, MD
   Yu, XJ
   Kumbar, SG
AF Aravamudhan, Aja
   Ramos, Daisy M.
   Nip, Jonathan
   Subramanian, Aditi
   James, Roshan
   Harmon, Matthew D.
   Yu, Xiaojun
   Kumbar, Sangamesh G.
TI Osteoinductive Small Molecules: Growth Factor Alternatives for Bone
   Tissue Engineering
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Small molecules; growth factors; bone tissue engineering; osteogenic;
   signaling pathways; stem cells; bone regeneration
ID MESENCHYMAL STEM CELLS; OSTEOBLASTIC DIFFERENTIATION; IN VITRO;
   MORPHOGENETIC PROTEINS; OSTEOCLAST FORMATION; FUNCTIONAL GROUPS;
   MELATONIN; RESVERATROL; PROLIFERATION; PURMORPHAMINE
AB Tissue engineering aims to repair, restore, and regenerate lost or damaged tissues by using biomaterials, cells, mechanical forces and factors (chemical and biological) alone or in combination. Growth factors are routinely used in the tissue engineering approach to expedite the process of regeneration. The growth factor approach has been hampered by several complications including high dose requirements, lower half life, protein instability, higher costs and undesired side effects. Recently a variety of alternative small molecules of both natural and synthetic origin have been explored as alternatives to growth factors for tissue regeneration applications. Small molecules are simple biochemical components that elicit certain cellular responses through signaling cascades. Small molecules present a viable alternative to biological factors. Small molecule strategies can reduce various side effects, maintain bioactivity in a biological environment and minimize cost issues associated with complex biological growth factors. This manuscript focuses on three osteoinductive small molecules, namely melatonin, resveratrol (from natural sources) and purmorphamine (synthetically designed) as inducers of bone formation and osteogenic differentiation of stem cells. Efforts have been made to summarize possible biological pathways involved in the action of each of these drugs. Melatonin is known to affect Mitogen Activated Protein (MAP) kinase, Bone morphogenic protein (BMP) and canonical wnt signaling. Resveratrol is known to activate cascades involving Wnt and NAD dependent deacetylase sirtuin 1 (Sirt1). Purmorphamine is a Hedgehog (Hh) pathway agonist as it acts on Smoothened (Smo) receptors. These mechanisms and the way they are affected by the respective small molecules will also be discussed in the manuscript.
C1 [Aravamudhan, Aja; Ramos, Daisy M.; Nip, Jonathan; Subramanian, Aditi; James, Roshan; Harmon, Matthew D.; Kumbar, Sangamesh G.] Univ Connecticut, Inst Regenerat Engn, Ctr Hlth, Farmington, CT 06030 USA.
   [Aravamudhan, Aja; Ramos, Daisy M.; Nip, Jonathan; Subramanian, Aditi; James, Roshan; Harmon, Matthew D.; Kumbar, Sangamesh G.] Univ Connecticut, Ctr Hlth, Raymond & Beverly Sackler Ctr Biol Phys & Engn Sc, Farmington, CT 06030 USA.
   [Aravamudhan, Aja; Ramos, Daisy M.; James, Roshan; Harmon, Matthew D.; Kumbar, Sangamesh G.] Univ Connecticut, Ctr Hlth, Dept Orthopaed Surg, Farmington, CT 06030 USA.
   [Ramos, Daisy M.; Subramanian, Aditi; Harmon, Matthew D.; Kumbar, Sangamesh G.] Univ Connecticut, Dept Chem Mat & Biomol Engn, Storrs, CT 06269 USA.
   [Yu, Xiaojun] Stevens Inst Technol, Dept Chem Chem Biol & Biomed Engn, Hoboken, NJ 07030 USA.
C3 University of Connecticut; University of Connecticut; University of
   Connecticut; University of Connecticut; Stevens Institute of Technology
RP Kumbar, SG (通讯作者)，Univ Connecticut, Inst Regenerat Engn, Raymond & Beverly Sackler Ctr Biol Phys & Engn Sc, Dept Orthopaed Surg Chem Mat & Biomol Engn, Farmington, CT 06030 USA.
EM Kumbar@uchc.edu
RI Aravamudhan, Aja/AAK 5897 2020; YU, Xiaojun/A 1331 2016; James,
   Roshan/J 3163 2014; /P 6752 2014
OI /0000 0001 7672 4783
CR Alves H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026678
   Andreou V, 2004, J PERIODONTOL, V75, P939, DOI 10.1902/jop.2004.75.7.939
   Aravamudhan A, 2012, P ORTH RES SOC C SAN, P1598
   Aravamudhan A, 2012, P 9 WORLD BIOM C WBC, P3137
   Arias JL, 2008, CHEM REV, V108, P4475, DOI 10.1021/cr078269p
   Ayala R, 2011, BIOMATERIALS, V32, P3700, DOI 10.1016/j.biomaterials.2011.02.004
   Aydin E, 2011, J MATER SCI MATER M, V22, P2413, DOI 10.1007/s10856 011 4435 z
   Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   BARRELL GK, 1989, J ENDOCRINOL, V122, P445, DOI 10.1677/joe.0.1220445
   Barrère F, 2008, MAT SCI ENG R, V59, P38, DOI 10.1016/j.mser.2007.12.001
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Beloti MM, 2005, CELL BIOL INT, V29, P537, DOI 10.1016/j.cellbi.2005.02.007
   Beloti MM, 2005, BIOMATERIALS, V26, P4245, DOI 10.1016/j.biomaterials.2004.10.039
   Benoit DSW, 2008, NAT MATER, V7, P816, DOI 10.1038/nmat2269
   Bettinger CJ, 2009, ANGEW CHEM INT EDIT, V48, P5406, DOI 10.1002/anie.200805179
   Bijlsma MF, 2006, CIRCULATION, V114, P1985, DOI 10.1161/CIRCULATIONAHA.106.619213
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   Boontheekul T, 2007, TISSUE ENG, V13, P1431, DOI 10.1089/ten.2006.0356
   Briscoe J, 2006, NAT CHEM BIOL, V2, P10, DOI 10.1038/nchembio0106 10
   Burg KJL, 2000, BIOMATERIALS, V21, P2347, DOI 10.1016/S0142 9612(00)00102 2
   Chen HJ, 2012, BIOCHEM PHARMACOL, V84, P1143, DOI 10.1016/j.bcp.2012.08.011
   Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600 079X.2000.280401.x
   CORTIZO AM, 1995, MOL CELL BIOCHEM, V145, P97, DOI 10.1007/BF00935481
   Crowley SJ, 2012, PSYCHOPHARMACOLOGY B
   Cutando A, 2008, J PINEAL RES, V45, P174, DOI 10.1111/j.1600 079X.2008.00573.x
   Dai Z, 2007, PHYTOMEDICINE, V14, P806, DOI 10.1016/j.phymed.2007.04.003
   Dosier CR, 2012, J MECH BEHAV BIOMED, V11, P112, DOI 10.1016/j.jmbbm.2011.08.014
   Egermann M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 271
   Emre N, 2007, CURR OPIN CHEM BIOL, V11, P252, DOI 10.1016/j.cbpa.2007.04.024
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445 2197.2007.04175.x
   Giannoudis PV, 2009, INJURY, V40, P1
   Hammerick KE, 2011, TISSUE ENG PT A, V17, P495, DOI [10.1089/ten.tea.2010.0211, 10.1089/ten.TEA.2010.0211]
   Heunis TDJ, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/510682
   Holzwarth JM, 2011, BIOMATERIALS, V32, P9622, DOI 10.1016/j.biomaterials.2011.09.009
   Horiuchi N, 2006, ORAL DIS, V12, P85, DOI 10.1111/j.1601 0825.2005.01172.x
   Huang J, 2012, J CLIN INVEST
   IGUCHI H, 1982, J CLIN ENDOCR METAB, V55, P27, DOI 10.1210/jcem 55 1 27
   Jasmin, 2010, STEM CELLS DEV, V19, P403, DOI 10.1089/scd.2009.0234
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985
   Kotlarczyk MP, 2012, J PINEAL RES, V52, P414, DOI 10.1111/j.1600 079X.2011.00956.x
   Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219
   Kumbar SG, 2008, BIOMED MATER, V3, DOI 10.1088/1748 6041/3/3/034002
   Ladizesky MG, 2003, J PINEAL RES, V34, P143, DOI 10.1034/j.1600 079X.2003.00021.x
   Lee SH, 2007, ADV DRUG DELIVER REV, V59, P339, DOI 10.1016/j.addr.2007.03.016
   Lee YM, 2011, J PERIODONTAL RES, V46, P712, DOI 10.1111/j.1600 0765.2011.01394.x
   Li Y, 2011, ACTA BIOMATER, V7, P751, DOI 10.1016/j.actbio.2010.09.008
   Liu X, 2011, J TISSUE ENG REGEN M
   Lo KWH, 2012, ADV DRUG DELIVER REV, V64, P1277, DOI 10.1016/j.addr.2012.03.014
   Lo KWH, 2012, J TISSUE ENG REGEN M, V6, P40, DOI 10.1002/term.395
   Lo KWH, 2012, REGEN MED, V7, P535, DOI [10.2217/rme.12.33, 10.2217/RME.12.33]
   López Martínez F, 2012, INT J DENT, V2012, DOI 10.1155/2012/628406
   Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055
   Melkoumian Z, 2010, NAT BIOTECHNOL, V28, P606, DOI 10.1038/nbt.1629
   Mendez N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042713
   Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870
   Mrksich M, 2011, NAT MATER, V10, P559, DOI 10.1038/nmat3086
   Muñoz F, 2012, CLIN IMPLANT DENT R, V14, P226, DOI 10.1111/j.1708 8208.2009.00242.x
   Murray P, 2010, BIOCHEM SOC T, V38, P1062, DOI 10.1042/BST0381062
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Oda T, 1999, J MED CHEM, V42, P751, DOI 10.1021/jm980583b
   Okano J, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.397273
   Park KH, 2011, J PINEAL RES, V51, P187, DOI 10.1111/j.1600 079X.2011.00875.x
   Peltz L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037162
   Pereira TS, 2009, BONE, V44, pS314, DOI 10.1016/j.bone.2009.03.589
   Piesiewicz A, 2012, CHRONOBIOL INT
   Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/nmat2441, 10.1038/NMAT2441]
   Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600 079X.2006.00318.x
   RAISZ LG, 1979, PROSTAG OTH LIPID M, V17, P905, DOI 10.1016/0090 6980(79)90061 3
   Ramirez Fernandez MP, 2012, CLIN ORAL INVESTIG
   Ren YJ, 2009, BIOMATERIALS, V30, P1036, DOI 10.1016/j.biomaterials.2008.10.028
   Rose FRAJ, 2002, BIOCHEM BIOPH RES CO, V292, P1, DOI 10.1006/bbrc.2002.6519
   Roth JA, 1999, J BIOL CHEM, V274, P22041, DOI 10.1074/jbc.274.31.22041
   SACK RL, 1986, J PINEAL RES, V3, P379, DOI 10.1111/j.1600 079X.1986.tb00760.x
   Sanchez Hidalgo M, 2007, AM J PHYSIOL REG I, V292, pR2208, DOI 10.1152/ajpregu.00013.2007
   Satomura K, 2007, J PINEAL RES, V42, P231, DOI 10.1111/j.1600 079X.2006.00410.x
   Sethi S, 2010, J PINEAL RES, V49, P222, DOI 10.1111/j.1600 079X.2010.00784.x
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Singh H, 2012, J BIOMATER TISS ENG, V2, P228, DOI 10.1166/jbt.2012.1049
   Sinningen K, 2012, ENDOCRINE, V42, P52, DOI 10.1007/s12020 012 9696 x
   Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Su JL, 2007, J BIOL CHEM, V282, P19385, DOI 10.1074/jbc.M702452200
   Tashjian AH, 1977, BIOL ACTIVITIES PROS
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Uysal T, 2011, ORTHOD CRANIOFAC RES, V14, P80, DOI 10.1111/j.1601 6343.2011.01511.x
   Valmikinathan CM, 2012, BIOFABRICATION, V4, DOI 10.1088/1758 5082/4/3/035006
   Valmikinathan CM, 2009, BIOMACROMOLECULES, V10, P1084, DOI 10.1021/bm8012499
   Wang JP, 2010, J BIOMED MATER RES A, V93A, P753, DOI 10.1002/jbm.a.32591
   Wang P, 2012, MOL CELL BIOCH
   Wu X, 2004, CHEM BIOL, V11, P1229, DOI 10.1016/j.chembiol.2004.06.010
   Yue ZL, 2010, BIOMATERIALS, V31, P8141, DOI 10.1016/j.biomaterials.2010.07.059
   Zaminy Arash, 2008, Iran Biomed J, V12, P133
   Zhang L, 2012, J PINEAL RES
   Zhou HB, 2009, EXP CELL RES, V315, P2953, DOI 10.1016/j.yexcr.2009.07.030
NR 97
TC 80
Z9 87
U1 1
U2 69
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381 6128
EI 1873 4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD JUN
PY 2013
VL 19
IS 19
BP 3420
EP 3428
DI 10.2174/1381612811319190008
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 133RN
UT WOS:000318157300008
PM 23432678
DA 2025 08 17
ER

PT J
AU Horsch, K
   de Wet, H
   Schuurmans, MM
   Allie Reid, F
   Cato, ACB
   Cunningham, J
   Burrin, JM
   Hough, FS
   Hulley, PA
AF Horsch, Kay
   de Wet, Heidi
   Schuurmans, Mace M.
   Allie Reid, Fatima
   Cato, Andrew C. B.
   Cunningham, John
   Burrin, Jacky M.
   Hough, F. Stephen
   Hulley, Philippa A.
TI Mitogen activated protein kinase phosphatase 1/dual specificity
   phosphatase 1 mediates glucocorticoid inhibition of osteoblast
   proliferation
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID ACTIVATED PROTEIN KINASE; SIGNAL REGULATED KINASE; INNATE
   IMMUNE RESPONSES; MAP KINASE; INDUCED OSTEOPOROSIS; PARATHYROID HORMONE;
   GENE EXPRESSION; IN VIVO; COOPERATIVE INTERACTIONS; MOLECULAR MECHANISMS
AB Steroid induced osteoporosis is a common side effect of long term treatment with glucocorticoid ( GC) drugs. GCs have multiple systemic effects that may influence bone metabolism but also directly affect osteoblasts by decreasing proliferation. This may be beneficial at low concentrations, enhancing differentiation. However, high dose treatment produces a severe deficit in the proliferative osteoblastic compartment. We provide causal evidence that this effect of GC is mediated by induction of the dual specificity MAPK phosphatase, MKP 1/DUSP1. Excessive MKP 1 production is both necessary and sufficient to account for the impaired osteoblastic response to mitogens. Overexpression of MKP 1 after either GC treatment or transfection ablates the mitogenic response in osteoblasts. Knockdown of MKP 1 using either immunodepletion of MKP 1 before in vitro dephosphorylation assay or short interference RNA transfection prevents inactivation of ERK by GCs. Neither c jun N terminal kinase nor p38 MAPK is activated by the mitogenic cocktail in 20% fetal calf serum, but their activation by a DNA damaging agent (UV irradiation) was inhibited by either GC treatment or overexpression of MKP 1, indicating regulation of all three MAPKs by MKP 1 in osteoblasts. However, an inhibitor of the MAPK/ERK kinase ERK pathway inhibited osteoblast proliferation whereas inhibitors of c jun N terminal kinase or p38 MAPK had no effect, suggesting that ERK is the MAPK that controls osteoblast proliferation. Regulation of ERK by MKP 1 provides a novel mechanism for control of osteoblast proliferation by GCs.
C1 Univ Stellenbosch, Dept Med, Div Endocrinol & Metab, ZA 7505 Stellenbosch, South Africa.
   Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D 76021 Karlsruhe, Germany.
   UCL Royal Free & Univ Coll Med Sch, Dept Nephrol, London NW3 2PF, England.
   Univ London, St Barts Hosp, Dept Endocrinol, London EC1A 7BE, England.
C3 Stellenbosch University; Helmholtz Association; Karlsruhe Institute of
   Technology; University of London; University College London; UCL Medical
   School; University of London; Queen Mary University London
RP Hulley, PA (通讯作者)，Univ Oxford, Botnar Res Ctr, Oxford OX1 2JD, England.
EM philippa.hulley@ndos.ox.ac.uk
RI Cato, Andrew/H 2071 2013; Hulley, Philippa/A 8538 2011
OI Cato, Andrew/0000 0001 8508 3834; Hulley, Philippa/0000 0002 4994 2264;
   Schuurmans, Mace M./0000 0001 5404 7566; de Wet,
   Heidi/0000 0002 9871 6909
FU Arthritis Research UK [16343] Funding Source: Medline; Wellcome Trust
   [064335] Funding Source: Medline
CR Abraham SM, 2006, J EXP MED, V203, P1883, DOI 10.1084/jem.20060336
   Alesci S, 2005, NEUROIMMUNOMODULAT, V12, P1, DOI 10.1159/000082360
   Bantel H, 2002, FASEB J, V16, P1832, DOI 10.1096/fj.02 0223fje
   Bazuine M, 2004, MOL ENDOCRINOL, V18, P1697, DOI 10.1210/me.2003 0213
   Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6
   Chang EJ, 2005, EXP CELL RES, V303, P197, DOI 10.1016/j.yexcr.2004.09.024
   Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103
   Clark AR, 2003, J ENDOCRINOL, V178, P5, DOI 10.1677/joe.0.1780005
   Cui QJ, 2000, CONNECT TISSUE RES, V41, P45
   Cunningham J, 2005, TRANSPLANTATION, V79, P629, DOI 10.1097/01.TP.0000149698.79739.EF
   Divieti P, 2001, ENDOCRINOLOGY, V142, P916, DOI 10.1210/en.142.2.916
   Dorfman K, 1996, ONCOGENE, V13, P925
   Durham PL, 2000, MOL ENDOCRINOL, V14, P1570, DOI 10.1210/me.14.10.1570
   Engelbrecht Y, 2003, ENDOCRINOLOGY, V144, P412, DOI 10.1210/en.2002 220769
   Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917
   FRIED A, 1993, J CELL PHYSIOL, V155, P472, DOI 10.1002/jcp.1041550306
   Hammer M, 2006, J EXP MED, V203, P15, DOI 10.1084/jem.20051753
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hulley PA, 1998, ENDOCRINOLOGY, V139, P2423, DOI 10.1210/en.139.5.2423
   Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108
   Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802 7811.2002
   Leclerc N, 2004, J MOL ENDOCRINOL, V33, P175, DOI 10.1677/jme.0.0330175
   LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441
   Li XD, 2005, OSTEOPOROSIS INT, V16, P101, DOI 10.1007/s00198 004 1649 7
   Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   PARFITT AM, 1976, METABOLISM, V25, P1157, DOI 10.1016/0026 0495(76)90024 X
   Partridge M, 1996, ANTISENSE NUCLEIC A, V6, P169, DOI 10.1089/oli.1.1996.6.169
   Phillips JE, 2006, J CELL SCI, V119, P581, DOI 10.1242/jcs.02758
   Plotkin LI, 2005, AM J PHYSIOL CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Porter RM, 2003, J CELL BIOCHEM, V90, P13, DOI 10.1002/jcb.10592
   Qin L, 2005, J BIOL CHEM, V280, P3104, DOI 10.1074/jbc.M409846200
   Razandi M, 2004, MOL CELL BIOL, V24, P5900, DOI 10.1128/MCB.24.13.5900 5913.2004
   Roca H, 2005, J BIOL CHEM, V280, P30845, DOI 10.1074/jbc.M503942200
   Sakaue H, 2004, J BIOL CHEM, V279, P39951, DOI 10.1074/jbc.M407353200
   Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899
   Schäcke H, 2006, EXP DERMATOL, V15, P565, DOI 10.1111/j.1600 0625.2006.00453.x
   Schuurmans MM, 2005, SWISS MED WKLY, V135, P562
   Sivagurunathan S, 2005, J BONE MINER RES, V20, P390, DOI 10.1359/JBMR.041233
   Sousa AR, 1999, J ALLERGY CLIN IMMUN, V104, P565, DOI 10.1016/S0091 6749(99)70325 8
   Toh ML, 2004, ARTHRITIS RHEUM US, V50, P3118, DOI 10.1002/art.20580
   van Staa TP, 2000, RHEUMATOLOGY, V39, P1383, DOI 10.1093/rheumatology/39.12.1383
   Vande Berg BC, 1999, ARTHRITIS RHEUM, V42, P1405, DOI 10.1002/1529 0131(199907)42:7<1405::AID ANR14>3.0.CO;2 W
   Walsh S, 2001, RHEUMATOLOGY, V40, P74, DOI 10.1093/rheumatology/40.1.74
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Wu JJ, 2006, CELL METAB, V4, P61, DOI 10.1016/j.cmet.2006.05.010
   Wu JJ, 2005, J BIOL CHEM, V280, P16461, DOI 10.1074/jbc.M501762200
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
   Zalavras C, 2003, CRIT REV EUKAR GENE, V13, P221, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.140
   Zhao Q, 2005, J BIOL CHEM, V280, P8101, DOI 10.1074/jbc.M411760200
NR 54
TC 56
Z9 64
U1 0
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0888 8809
EI 1944 9917
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD DEC
PY 2007
VL 21
IS 12
BP 2929
EP 2940
DI 10.1210/me.2007 0153
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 235OJ
UT WOS:000251243900007
PM 17761948
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yu, HT
   Zhou, W
   Zhong, ZH
   Qiu, RX
   Chen, GQ
   Zhang, P
AF Yu, Haotao
   Zhou, Wei
   Zhong, Zhihong
   Qiu, Ruixin
   Chen, Guoquan
   Zhang, Ping
TI 被撤回的出版物: High mobility group box chromosomal protein 1 deletion
   alleviates osteoporosis in OVX rat model via suppressing the
   osteoclastogenesis and inflammation (Retracted article. See vol. 20,
   2025)
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article; Retracted Publication
DE Targeted therapy; Osteogenesis; Signal pathway
ID AMERICAN SOCIETY; TASK FORCE; BONE LOSS; CYTOKINES; DIFFERENTIATION;
   PROMOTES; INHIBITION; FRACTURE; TARGET; HMGB1
AB Background Osteoporosis is a skeletal metabolic disease that constitutes a great threaten to human health. However, there is currently no gold standard for its treatment. High mobility group box chromosomal protein 1 (HMGB 1) has been reported to play an important role in various orthopedic diseases. Till now, its role in osteoporosis remains elusive. Methods Rats underwent ovariectomy (OVX) were used to construct a postmenopausal model of osteoporosis. Then, rats were divided into sham groups without OVX surgery, OVX model group, HMGB 1 knockdown (HMGB 1 KD) OVX model groups. The expression of HMGB1 was evaluated by qRT PCR and western blotting. Subsequently, the changes of trabeculae were evaluated by micro computed tomography (CT) assay. Skeletal necrosis and metabolism were further analyzed by hematoxylin eosin (HE) staining, Alcian blue staining and Masson's trichrome staining. The contents of serum alkaline phosphatase (ALP) and osteocalcin were detected by ELISA assay. Expression of osteoclast associated receptor (OSCAR) and tartrate resistant acid phosphatase (TRAP) were determined to investigate the effects of HMGB 1 loss on osteoclastogenesis. Results Single HMGB 1 deletion exerted no significant effect on rat trabeculae, serum ALP and osteocalcin. Noticeably, HMGB1 knockdown dramatically ameliorated OVX induced changes in above indexes. Trabeculae structures of OVX rats were sparse with disorder arrangement, which were greatly recovered after HMGB 1 deletion. Enhanced osteoclastogenesis was observed in OVX rats by increasing number of TRAP + cells and expression of TRAP and OSCAR, and loss of HMGB1 ameliorated osteoclastogenesis in OVA rats. Moreover, HMGB 1 deletion antagonized OVX evoked downregulation of osteoblast activity markers osterix (OSX), collagen type I alpha 1(COL1A1) and distal less homeobox 2 (DLX2) protein. Furthermore, loss of HMGB 1 attenuated fluctuation of inflammatory factors in OVX rats. Additionally, HMGB 1 deficiency inhibited OVX evoked activation of the Toll like receptor (TLR) 4/NF kappa B signaling pathway. Moreover, reactivating the TLR4 signaling further aggravated OVX induced osteoporosis, which was reversed by HMGB1 knockdown. Conclusion HMGB 1 deletion alleviated OVX triggered osteoporosis by suppressing osteoclastogenesis and inflammatory disorder via the inhibition of the TLR4 signaling. Therefore, HMGB 1 may be a promising therapeutic target for osteoporosis.
C1 [Yu, Haotao; Zhou, Wei; Zhong, Zhihong; Qiu, Ruixin; Chen, Guoquan; Zhang, Ping] Guangzhou Med Univ, Affiliated Hosp 3, Dept Orthoped, 63 Duobao Rd, Guangzhou 510000, Guangdong, Peoples R China.
C3 Guangzhou Medical University
RP Zhang, P (通讯作者)，Guangzhou Med Univ, Affiliated Hosp 3, Dept Orthoped, 63 Duobao Rd, Guangzhou 510000, Guangdong, Peoples R China.
EM zhangp147369@163.com
FU Third Affiliated Hospital of Guangzhou Medical University
FX Thanks to the assistance of The Third Affiliated Hospital of Guangzhou
   Medical University.
CR Al Daghri NM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005780
   Bliuc D, 2015, OSTEOPOROSIS INT, V26, P1331, DOI 10.1007/s00198 014 3014 9
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Chen Y, 2013, RHEUMATOLOGY, V52, P1739, DOI 10.1093/rheumatology/ket134
   Chirico V, 2014, EUR J PEDIATR, V173, P1123, DOI 10.1007/s00431 014 2327 1
   Feng L, 2019, PHARM BIOL, V57, P586, DOI 10.1080/13880209.2019.1657153
   HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Jeganathan S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104498
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Kaur I, 2020, LIFE SCI, V258, DOI 10.1016/j.lfs.2020.118164
   Khairallah P, 2018, CLIN J AM SOC NEPHRO, V13, P962, DOI 10.2215/CJN.11031017
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Mandke P, 2019, DNA REPAIR, V83, DOI 10.1016/j.dnarep.2019.102701
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   Martineau P, 2017, CURR OPIN ENDOCRINOL, V24, P402, DOI 10.1097/MED.0000000000000365
   Meng Y, 2020, MOL MED REP, V22, P5313, DOI 10.3892/mmr.2020.11594
   Miller CH, 2016, J IMMUNOL, V196, P4977, DOI 10.4049/jimmunol.1502044
   Moreno JL, 2003, BLOOD, V102, P1078, DOI 10.1182/blood 2002 11 3437
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Nogueira Machado JA, 2012, RECENT PATENTS ENDOC, V6, P201, DOI 10.2174/187221412802481784
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Peng SL, 2013, BONE, V55, P230, DOI 10.1016/j.bone.2013.02.012
   Pullerits R, 2011, J RHEUMATOL, V38, P1523, DOI 10.3899/jrheum.110091
   Qu BB, 2014, CELL TISSUE RES, V357, P133, DOI 10.1007/s00441 014 1833 9
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Taniguchi N, 2018, HUM CELL, V31, P1, DOI 10.1007/s13577 017 0182 x
   Ulloa L, 2003, ARTHRITIS RHEUM, V48, P876, DOI 10.1002/art.10854
   Vijayan V, 2014, BRIT J PHARMACOL, V171, P107, DOI 10.1111/bph.12434
   Yang DH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092093
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Zhang JF, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0046 1
   Zhang L, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.902971
   Zhang Y, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 5842
NR 35
TC 10
Z9 11
U1 1
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD APR 12
PY 2022
VL 17
IS 1
AR 232
DI 10.1186/s13018 022 03110 8
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 0M1YU
UT WOS:000781958300006
PM 35414033
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, CX
   Han, Y
   Zhao, XY
   Li, B
   Xu, LW
   Li, DS
   Li, GY
AF Liu, Chuxiao
   Han, Yu
   Zhao, Xingyu
   Li, Bo
   Xu, Liwen
   Li, Dongsong
   Li, Guangyu
TI POLR2A blocks osteoclastic bone resorption and protects against
   osteoporosis by interacting with CREB1
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE bone resorption; CREB1; osteoclastogenesis; osteoporosis; POLR2A
ID DIFFERENTIATION; ELEMENT; RANKL
AB Bone resorbing osteoclasts significantly contribute to osteoporosis, and understanding the mechanisms of osteoclastogenesis is crucial for developing new drugs to treat diseases associated with bone loss. Here, we report that POLR2A is upregulated during osteoclastogenesis. Functional analyses showed that the inhibition of POLR2A decreased osteoclastogenesis, whereas the overexpression of POLR2A had completely opposite effects in vitro. Notably, the osteoclast specific deletion of POLR2A blocks bone resorption in vivo. Furthermore, POLR2A loss of function suppresses estrogen deficiency induced bone resorption. Mechanistically, POLR2A regulates the assembly of CREB1 on the regulatory elements of its target genes. Collectively, using genetic, pharmacological, and disease mouse models, we have identified a previously undescribed protein that interacts with CREB1 to regulate osteoclastic bone resorption.
C1 [Liu, Chuxiao; Li, Bo; Xu, Liwen; Li, Guangyu] Chinese Acad Agr Sci, Inst Special Anim & Plant Sci, State Key Lab Mol Biol Special Econ Anim, 4899 Juye St, Changchun 130112, Peoples R China.
   [Han, Yu; Zhao, Xingyu; Li, Bo; Li, Dongsong] 1 Hosp Jilin Univ, Dept Joint Surg, 71 Xinmin St, Changchun 130021, Peoples R China.
C3 Chinese Academy of Agricultural Sciences; Institute of Special Animal &
   Plant Sciences, CAAS
RP Li, GY (通讯作者)，Chinese Acad Agr Sci, Inst Special Anim & Plant Sci, State Key Lab Mol Biol Special Econ Anim, 4899 Juye St, Changchun 130112, Peoples R China.; Li, DS (通讯作者)，1 Hosp Jilin Univ, Dept Joint Surg, 71 Xinmin St, Changchun 130021, Peoples R China.
EM lidongsong@jlu.edu.cn; liguangyu@caas.cn
RI XU, LIWEN/LFI 1784 2024; ZHAO, Xingyu/JNR 1669 2023; Li,
   Guangyu/M 1999 2018
OI Liu, Chunxiao/0000 0002 1465 9207; 
FU Science and Technology Innovation Project of Chinese Academy of
   Agricultural Sciences [CAAS ASTIP 2016 ISAPS]; Youth Development Fund of
   the first Hospital of Jilin University [JDYY92018025]; Health Special
   Project Task Document of Jilin Province [2018SCZWSZX 053]
FX Science and Technology Innovation Project of Chinese Academy of
   Agricultural Sciences, Grant/Award Number: CAAS ASTIP 2016 ISAPS; Youth
   Development Fund of the first Hospital of Jilin University, Grant/Award
   Number: JDYY92018025; the Health Special Project Task Document of Jilin
   Province, Grant/Award Number: 2018SCZWSZX 053
CR Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Body JJ, 2010, OSTEOPOROSIS INT, V21, P1657, DOI 10.1007/s00198 010 1223 4
   Chai Y, 2019, ONCOL LETT, V17, P468, DOI 10.3892/ol.2018.9508
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Chu YJ, 2018, GENOM PROTEOM BIOINF, V16, P172, DOI 10.1016/j.gpb.2018.04.005
   Clarke VE, 2016, NAT GENET, V48, P1253, DOI 10.1038/ng.3651
   Gee JM, 2014, NEURON, V83, P1058, DOI 10.1016/j.neuron.2014.07.024
   Herault O, 1999, BRIT J HAEMATOL, V104, P530, DOI 10.1046/j.1365 2141.1999.01203.x
   Inoue K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06446 0
   Kim JH, 2018, BONE, V107, P188, DOI 10.1016/j.bone.2017.12.005
   Kim MK, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1915 4
   Li BBX, 2009, CHEMBIOCHEM, V10, P2721, DOI 10.1002/cbic.200900552
   Liu YH, 2015, NATURE, V520, P697, DOI 10.1038/nature14418
   MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756 3282(95)00180 L
   Miller CH, 2016, J IMMUNOL, V196, P4977, DOI 10.4049/jimmunol.1502044
   MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0
   MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682
   Negishi Koga T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7637
   Nelson ER, 2013, BONE, V53, P42, DOI 10.1016/j.bone.2012.11.011
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Park KH, 2017, AM J CHINESE MED, V45, P1725, DOI 10.1142/S0192415X17500938
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tsukasaki M, 2017, J BONE MINER RES, V32, P434, DOI 10.1002/jbmr.2990
   VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Xu JS, 2019, NAT NANOTECHNOL, V14, P388, DOI 10.1038/s41565 019 0381 6
   Xue HY, 2016, TECHNOL CANCER RES T, V15, P729, DOI 10.1177/1533034615604798
   Yamada K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062304
NR 32
TC 7
Z9 9
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2021
VL 236
IS 7
BP 5134
EP 5146
DI 10.1002/jcp.30220
EA FEB 2021
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA RI3KP
UT WOS:000618771200001
PM 33595106
DA 2025 08 17
ER

PT J
AU Lu, L
   Cai, YZ
   Luo, XL
   Wang, ZT
   Fung, SH
   Jia, HH
   Yu, CL
   Chan, WY
   Miu, KK
   Xiao, WD
AF Lu, Li
   Cai, Yanzhen
   Luo, Xiaoling
   Wang, Zhangting
   Fung, Sin Hang
   Jia, Huanhuan
   Yu, Chi Lam
   Chan, Wai Yee
   Miu, Kai Kei
   Xiao, Wende
TI A Core Omnigenic Non coding Trait Governing Dex Induced Osteoporotic
   Effects Identified Without DEXA
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE glucocorticoid; glucocorticoid induced osteoporosis; bone loss; bone
   morphogenetic protein signaling pathway; osteoblasts differentiation;
   cis expression quantitative trait loci
ID BONE MINERAL DENSITY; GLUCOCORTICOID INDUCED OSTEOPOROSIS; INBRED
   STRAINS; THERAPEUTIC TARGETS; STRENGTH; FRACTURE; DISEASE;
   DIFFERENTIATION; ANTAGONISTS; MANAGEMENT
AB Iatrogenic glucocorticoid (GC) induced osteoporosis (GIO) is an idiosyncratic form of secondary osteoporosis. Genetic predisposition among individuals may give rise to variant degree of phenotypic changes but there has yet been a documented unified pathway to explain the idiosyncrasy. In this study, we argue that the susceptibility to epigenetic changes governing molecular cross talks along the BMP and PI3K/Akt pathway may underline how genetic background dictate GC induced bone loss. Concordantly, osteoblasts from BALB/c or C57BL/6 neonatal mice were treated with dexamethasone for transcriptome profiling. Furthermore, we also confirmed that GC pre conditioned mesenchymal stem cells (MSCs) would give rise to defective osteogenesis by instigating epigenetic changes which affected the accessibility of enhancer marks. In line with these epigenetic changes, we propose that GC modulates a key regulatory network involving the scavenger receptor Cd36 in osteoblasts pre conditioning pharmacological idiosyncrasy in GIO.
C1 [Lu, Li; Cai, Yanzhen; Luo, Xiaoling; Jia, Huanhuan] Guangdong Pharmaceut Univ, Sch Life Sci & Biopharm, Guangdong Key Lab Pharmaceut Bioact Subst, Guangzhou, Peoples R China.
   [Wang, Zhangting; Fung, Sin Hang; Yu, Chi Lam; Chan, Wai Yee; Miu, Kai Kei] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Peoples R China.
   [Jia, Huanhuan] Guangdong Lab Anim Monitoring Inst, Guangdong Key Lab Lab Anim, Guangzhou, Peoples R China.
   [Xiao, Wende] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Orthoped, Guangzhou, Peoples R China.
C3 Guangdong Pharmaceutical University; Chinese University of Hong Kong;
   South China University of Technology
RP Miu, KK (通讯作者)，Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Peoples R China.; Xiao, WD (通讯作者)，South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Orthoped, Guangzhou, Peoples R China.
EM eyxiaowende@scut.edu.cn; kelvinmiu@cuhk.edu.hk
RI FUNG, Sin Hang/GSI 7607 2022; yee, chan/X 6470 2018; Luo,
   Xiaoling/JYP 9634 2024; Miu, Kai/AAX 3139 2020; jia,
   huanhuan/KHY 8301 2024; WANG, Zhangting/Y 5019 2019
OI WANG, Zhangting/0000 0001 6040 0469
FU NSFC/RGC Joint Research Scheme   Research Grants Council of the Hong
   Kong Special Administrative Region, China; National Natural Science
   Foundation of China [N_CUHK415/16]; Guangzhou Science and Technology
   Project of China [201904010053]; Research Grants Council General
   Research Fund, Hong Kong [14103418]; Health and Medical Research Fund,
   Hong Kong [06170996]
FX This work described in this paper was partially supported by a grant
   from the NSFC/RGC Joint Research Scheme sponsored by the Research Grants
   Council of the Hong Kong Special Administrative Region, China, the
   National Natural Science Foundation of China (Project No. N_CUHK415/16)
   and Guangzhou Science and Technology Project of China (No.201904010053);
   Research Grants Council General Research Fund, Hong Kong (Project No.
   14103418); Health and Medical Research Fund, Hong Kong (Project No.
   06170996).
CR Amblard D, 2003, J BONE MINER RES, V18, P561, DOI 10.1359/jbmr.2003.18.3.561
   Becker Daniel E, 2013, Anesth Prog, V60, P25, DOI 10.2344/0003 3006 60.1.25
   Björkegren JLM, 2015, J AM COLL CARDIOL, V65, P830, DOI 10.1016/j.jacc.2014.12.033
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038
   Briot K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2014 000014
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Chen SB, 2021, THER ADV MUSCULOSKEL, V13, DOI 10.1177/1759720X211002677
   Choi YJ, 2016, ENDOCRINOL METAB, V31, P25, DOI 10.3803/EnM.2016.31.1.25
   Delitala AP, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041034
   Dovio A, 2004, J CLIN ENDOCR METAB, V89, P4923, DOI 10.1210/jc.2004 0164
   Dwivedi PP, 2013, BONE, V55, P367, DOI 10.1016/j.bone.2013.04.013
   Foot NC, 1933, STAIN TECHNOL, V8, P101, DOI 10.3109/10520293309116112
   Hanna H, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0942 x
   Hayashi K, 2009, BIOCHEM BIOPH RES CO, V379, P261, DOI 10.1016/j.bbrc.2008.12.035
   Holguin N, 2013, CALCIFIED TISSUE INT, V93, P211, DOI 10.1007/s00223 013 9744 4
   Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]
   Huber AM, 2016, SEMIN ARTHRITIS RHEU, V46, P49, DOI 10.1016/j.semarthrit.2016.02.003
   Jay AG, 2015, J BIOL CHEM, V290, P4590, DOI 10.1074/jbc.M114.627026
   Jia HH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00083
   Judex S, 2004, J BONE MINER RES, V19, P607, DOI 10.1359/JBMR.040110
   Kameda H, 2009, INTERNAL MED, V48, P1931, DOI 10.2169/internalmedicine.48.2414
   Kattamuri C, 2012, J MOL BIOL, V424, P313, DOI 10.1016/j.jmb.2012.10.003
   Kenanidis E, 2015, EXPERT OPIN DRUG SAF, V14, P1035, DOI 10.1517/14740338.2015.1040387
   Kevorkova O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077701
   Kim SY, 2019, CALCIFIED TISSUE INT, V105, P205, DOI 10.1007/s00223 019 00552 x
   Li CY, 2005, J BONE MINER RES, V20, P2150, DOI 10.1359/JBMR.050819
   Li Yu ming, 2004, Zhonghua Yi Xue Za Zhi, V84, P1348
   Liu XY, 2019, CELL, V177, P1022, DOI 10.1016/j.cell.2019.04.014
   Luo XQ, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03596 w
   Martineau C, 2014, AM J PHYSIOL ENDOC M, V306, pE48, DOI 10.1152/ajpendo.00421.2013
   Mejía Vilet JM, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.622225
   Mullins N, 2021, NAT GENET, V53, P817, DOI 10.1038/s41588 021 00857 4
   Pierote NR, 2018, NUTRITION, V48, P13, DOI 10.1016/j.nut.2017.10.016
   Roberts A, 2007, MAMM GENOME, V18, P473, DOI 10.1007/s00335 007 9045 1
   Robinson PC, 2021, LANCET RHEUMATOL, V3, pE168, DOI 10.1016/S2665 9913(21)00005 9
   Sabik OL, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108145
   Sabik OL, 2017, TRANSL RES, V181, P15, DOI 10.1016/j.trsl.2016.10.009
   Sachdeva S, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13514
   Sekiya F, 2010, RHEUMATOL INT, V30, P1587, DOI 10.1007/s00296 009 1194 y
   Shen BJ, 2009, INT J BIOL SCI, V5, P192
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tao H, 2015, J LIPID RES, V56, P1449, DOI 10.1194/jlr.M056689
   Tourkova IL, 2019, LAB INVEST, V99, P1850, DOI 10.1038/s41374 019 0311 0
   Turner CH, 2000, J BONE MINER RES, V15, P1126, DOI 10.1359/jbmr.2000.15.6.1126
   Welsh CE, 2012, MAMM GENOME, V23, P706, DOI 10.1007/s00335 012 9410 6
   Wergedal JE, 2005, BONE, V36, P111, DOI 10.1016/j.bone.2004.09.012
   Willinghamm MD, 2010, CALCIFIED TISSUE INT, V86, P470, DOI 10.1007/s00223 010 9359 y
   Witte JS, 2010, ANNU REV PUBL HEALTH, V31, P9, DOI 10.1146/annurev.publhealth.012809.103723
   Xie LX, 2005, RESP RES, V6, DOI 10.1186/1465 9921 6 5
   Xue A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04951 w
   Yoshiki A, 2006, ILAR J, V47, P94, DOI 10.1093/ilar.47.2.94
   Zhao SJ, 2020, THERANOSTICS, V10, P17, DOI 10.7150/thno.36930
   Zheng HF, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001980
NR 54
TC 1
Z9 1
U1 0
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 24
PY 2021
VL 12
AR 750959
DI 10.3389/fphar.2021.750959
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XM9WD
UT WOS:000729166600001
PM 34899306
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, SH
   Qiu, JH
   Guo, AY
   Ren, RZ
   He, W
   Liu, SJ
   Liu, YJ
AF Wang, Shunhao
   Qiu, Jiahuang
   Guo, Anyi
   Ren, Ruanzhong
   He, Wei
   Liu, Sijin
   Liu, Yajun
TI Nanoscale perfluorocarbon expediates bone fracture healing through
   selectively activating osteoblastic differentiation and functions
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Bone fracture; Healing; Nano PFC; Osteoblast; Differentiation
ID IN VITRO; OXYGEN; DELIVERY; NANOPARTICLES; EMULSIONS; CELLS;
   OSTEOCLASTOGENESIS; GENERATION; EXPRESSION; MICROSCOPY
AB Background and rationale Fracture incidence increases with ageing and other contingencies. However, the strategy of accelerating fracture repair in clinical therapeutics remain a huge challenge due to its complexity and a long lasting period. The emergence of nano based drug delivery systems provides a highly efficient, targeted and controllable drug release at the diseased site. Thus far, fairly limited studies have been carried out using nanomedicines for the bone repair applications. Perfluorocarbon (PFC), FDA approved clinical drug, is received increasing attention in nanomedicine due to its favorable chemical and biologic inertness, great biocompatibility, high oxygen affinity and serum resistant capability. In the premise, the purpose of the current study is to prepare nano sized PFC materials and to evaluate their advisable effects on promoting bone fracture repair. Results Our data unveiled that nano PFC significantly enhanced the fracture repair in the rabbit model with radial fractures, as evidenced by increased soft callus formation, collagen synthesis and accumulation of beneficial cytokines (e.g., vascular endothelial growth factor (VEGF), matrix metalloprotein 9 (MMP 9) and osteocalcin). Mechanistic studies unraveled that nano PFC functioned to target osteoblasts by stimulating their differentiation and activities in bone formation, leading to accelerated bone remodeling in the fractured zones. Otherwise, osteoclasts were not affected upon nano PFC treatment, ruling out the potential target of nano PFC on osteoclasts and their progenitors. Conclusions These results suggest that nano PFC provides a potential perspective for selectively targeting osteoblast cell and facilitating callus generation. This study opens up a new avenue for nano PFC as a promising agent in therapeutics to shorten healing time in treating bone fracture.
C1 [Wang, Shunhao; Qiu, Jiahuang; Ren, Ruanzhong; Liu, Sijin] Chinese Acad Sci, State Key Lab Environm Chem & Ecotoxicol, Res Ctr Ecoenvironm Sci, 8 Shuangqing Rd, Beijing 100085, Peoples R China.
   [Wang, Shunhao; Qiu, Jiahuang; Ren, Ruanzhong; Liu, Sijin] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Guo, Anyi; He, Wei; Liu, Yajun] Peking Univ, Hlth Sci Ctr, Beijing Jishuitan Hosp, Clin Hosp 4, 31 East St, Beijing 100035, Peoples R China.
C3 Chinese Academy of Sciences; Chinese Academy of Sciences; University of
   Chinese Academy of Sciences, CAS; Peking University
RP Liu, SJ (通讯作者)，Chinese Acad Sci, State Key Lab Environm Chem & Ecotoxicol, Res Ctr Ecoenvironm Sci, 8 Shuangqing Rd, Beijing 100085, Peoples R China.; Liu, SJ (通讯作者)，Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Liu, YJ (通讯作者)，Peking Univ, Hlth Sci Ctr, Beijing Jishuitan Hosp, Clin Hosp 4, 31 East St, Beijing 100035, Peoples R China.
EM sjliu@rcees.ac.cn; drliuyajun@163.com
RI Liu, Yajun/MVV 3763 2025; qiu, jiahuang/HMU 2827 2023
OI Qiu, Jiahuang/0009 0001 3436 0691; 
FU Beijing Natural Science Foundation [Z171100000417025, 8191002]; National
   Natural Science Foundation of China [21637004, 21920102007]
FX This work was supported under grants from the Beijing Natural Science
   Foundation (Grant Numbers: Z171100000417025 and 8191002) and the
   National Natural Science Foundation of China (Grant Numbers: 21637004
   and 21920102007).
CR Akagawa KS, 1996, BLOOD, V88, P4029, DOI 10.1182/blood.V88.10.4029.bloodjournal88104029
   Al Hadi H, 2015, J DENT, V43, P382, DOI 10.1016/j.jdent.2014.10.006
   Bahney CS, 2019, J ORTHOP RES, V37, P35, DOI 10.1002/jor.24170
   Beamer B, 2010, HSS J, V6, P85, DOI [10.1007/s11420 009 9129 4, DOI 10.1007/S11420 009 9129 4]
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Bootz A, 2004, EUR J PHARM BIOPHARM, V57, P369, DOI 10.1016/S0939 6411(03)00193 0
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Castro CI, 2010, ARTIF ORGANS, V34, P622, DOI 10.1111/j.1525 1594.2009.00944.x
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.394
   Choi MG, 2005, P NATL ACAD SCI USA, V102, P4578, DOI 10.1073/pnas.0500693102
   Collignon AM, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00927
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Davis SC, 2007, ARCH DERMATOL, V143, P1252, DOI 10.1001/archderm.143.10.1252
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   Deng J, 2016, NANO RES, V9, P3683, DOI 10.1007/s12274 016 1239 y
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Fleury C, 2006, BIOMATERIALS, V27, P3351, DOI 10.1016/j.biomaterials.2006.01.035
   Fu YX, 2013, INT J MOL MED, V31, P1411, DOI 10.3892/ijmm.2013.1329
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Hu B, 2019, FASEB J, V33, P2574, DOI 10.1096/fj.201800920R
   Jalani G, 2017, NANOSCALE, V9, P10161, DOI 10.1039/c7nr00378a
   Janjic JM, 2009, WIRES NANOMED NANOBI, V1, P492, DOI 10.1002/wnan.35
   Kargozar S, 2017, MAT SCI ENG C MATER, V75, P688, DOI 10.1016/j.msec.2017.02.097
   Keramaris NC, 2008, INJURY, V39, pS45, DOI 10.1016/S0020 1383(08)70015 9
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Kolar P, 2011, CLIN ORTHOP RELAT R, V469, P3118, DOI 10.1007/s11999 011 1865 3
   Krafft MP, 2001, ADV DRUG DELIVER REV, V47, P209, DOI 10.1016/S0169 409X(01)00107 7
   Kwon TG, 2011, J CELL BIOCHEM, V112, P3582, DOI 10.1002/jcb.23289
   Lavrador P, 2018, J CONTROL RELEASE, V273, P51, DOI 10.1016/j.jconrel.2018.01.021
   Lee DW, 2018, INT J MED SCI, V15, P723, DOI 10.7150/ijms.22713
   Nguyen LT, 2016, BIOMED RES INDIA, V27, P138
   Liu XY, 2016, EXP THER MED, V12, P3541, DOI 10.3892/etm.2016.3801
   Liu YZ, 2018, NANOMED NANOTECHNOL, V14, P2271, DOI 10.1016/j.nano.2018.07.011
   Lu CY, 2007, J ORTHOP RES, V25, P51, DOI 10.1002/jor.20264
   Lu CY, 2013, BONE, V52, P220, DOI 10.1016/j.bone.2012.09.037
   Lv WT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163981
   Ma J, 2017, SMALL, V13, DOI 10.1002/smll.201603830
   Ma RS, 2011, THYROID, V21, P897, DOI 10.1089/thy.2010.0457
   Maes Christa, 2008, P79, DOI 10.1007/978 0 387 78632 2_7
   Maïmoun L, 2011, METABOLISM, V60, P1655, DOI 10.1016/j.metabol.2011.04.005
   Marcos Garcés V, 2017, J MICROSC OXFORD, V267, P130, DOI 10.1111/jmi.12553
   Marenzana M, 2013, BONE RES, V1, P203, DOI 10.4248/BR201303001
   Martino MM, 2015, ADV DRUG DELIVER REV, V94, P41, DOI 10.1016/j.addr.2015.04.007
   Matos MA, 2001, ACTA ORTOP BRAS, V9, P21, DOI [10.1590/S1413 78522001000400003, DOI 10.1590/S1413 78522001000400003]
   Matsubara T, 2020, BONE, V132, DOI 10.1016/j.bone.2019.115209
   Mazdeh DZ, 2018, RES VET SCI, V118, P11, DOI 10.1016/j.rvsc.2017.12.024
   McGonnell Imelda M, 2012, Front Endocrinol (Lausanne), V3, P88, DOI 10.3389/fendo.2012.00088
   Miclau KR, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00045
   Mizerska Kowalska M, 2019, MOLECULES, V24, DOI 10.3390/molecules24142637
   Ogilvie Christian M, 2012, Iowa Orthop J, V32, P90
   Ortega N, 2004, TRENDS CELL BIOL, V14, P86, DOI 10.1016/j.tcb.2003.12.003
   Pabisch S, 2012, CHEM PHYS LETT, V521, P91, DOI 10.1016/j.cplett.2011.11.049
   Puett C, 2014, ULTRASONICS, V54, P2024, DOI 10.1016/j.ultras.2014.05.013
   PUTYATINA TK, 1994, ARTIF CELL BLOOD SUB, V22, P1281, DOI 10.3109/10731199409138827
   Qi H, 2018, EXP THER MED, V16, P3478, DOI 10.3892/etm.2018.6631
   Qian Y, 2017, FRONT CHEM, V5, DOI 10.3389/fchem.2017.00089
   Riess JG, 2005, ARTIF CELL BLOOD SUB, V33, P47, DOI 10.1081/BIO 200046659
   Song XJ, 2016, NANO LETT, V16, P6145, DOI 10.1021/acs.nanolett.6b02365
   Spahn DR, 2002, ANESTHESIOLOGY, V97, P1338, DOI 10.1097/00000542 200212000 00004
   Takizawa H, 2019, VET COMP ORTHOPAED, V32, P297, DOI 10.1055/s 0039 1688772
   Tang KC, 2019, BONE REP, V10, DOI 10.1016/j.bonr.2019.100206
   Tawonsawatruk T, 2014, J ORTHOP RES, V32, P1117, DOI 10.1002/jor.22665
   Vincent C, 2009, J BONE MINER METAB, V27, P114, DOI 10.1007/s00774 008 0018 6
   Wang SH, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5738368
   Wang WG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09389 2
   Wang YC, 2017, ACS NANO, V11, P9445, DOI 10.1021/acsnano.7b05103
   Wilson TJ, 2009, MOL CANCER RES, V7, P1224, DOI 10.1158/1541 7786.MCR 09 0028
   Wolfram J, 2015, CURR DRUG TARGETS, V16, P1671, DOI 10.2174/1389450115666140804124808
   Wrobel E, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0027 8
   Wu CT, 2011, BIOMATERIALS, V32, P7068, DOI 10.1016/j.biomaterials.2011.06.009
   Yamamoto K, 2015, P NATL ACAD SCI USA, V112, P6152, DOI 10.1073/pnas.1420713112
   Zhou ZG, 2018, THERANOSTICS, V8, P4898, DOI 10.7150/thno.27598
   Zirlik K, 2018, ONCOL RES TREAT, V41, P166, DOI 10.1159/000488087
NR 75
TC 17
Z9 17
U1 2
U2 32
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD JUN 3
PY 2020
VL 18
IS 1
AR 84
DI 10.1186/s12951 020 00641 2
PG 17
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA LX3TU
UT WOS:000539758100001
PM 32493334
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Vidal, C
   Li, W
   Santner Nanan, B
   Lim, CK
   Guillemin, GJ
   Ball, HJ
   Hunt, NH
   Nanan, R
   Duque, G
AF Vidal, Christopher
   Li, Wei
   Santner Nanan, Brigitte
   Lim, Chai K.
   Guillemin, Gilles J.
   Ball, Helen J.
   Hunt, Nicholas H.
   Nanan, Ralph
   Duque, Gustavo
TI The Kynurenine Pathway of Tryptophan Degradation is Activated During
   Osteoblastogenesis
SO STEM CELLS
LA English
DT Article
DE Osteoblastogenesis; Mesenchymal stem cells; Interferon gamma;
   Osteoporosis; Picolinic acid; Kynurenine
ID INTERFERON GAMMA; INDOLEAMINE 2,3 DIOXYGENASE; BONE; SEROTONIN; CELLS;
   OSTEOPOROSIS; MODELS
AB The mechanisms involved in the anabolic effect of interferon gamma (IFN gamma) on bone have not been carefully examined. Using microarray expression analysis, we found that IFN gamma upregulates a set of genes associated with a tryptophan degradation pathway, known as the kynurenine pathway, in osteogenic differentiating human mesenchymal stem cells (hMSC). We, therefore, hypothesized that activation of the kynurenine pathway plays a role in osteoblastogenesis even in the absence of IFN gamma. Initially, we observed a strong increase in tryptophan degradation during osteoblastogenesis with and without IFN gamma in the media. We next blocked indoleamine 2,3 dioxygenase  1 (IDO1), the most important enzyme in the kynurenine pathway, using a siRNA and pharmacological approach and observed a strong inhibition of osteoblastogenesis with a concomitant decrease in osteogenic factors. We next examined the bone phenotype of Ido1 knockout (Ido1 2/2) mice. Compared to their wild type littermates, Ido1 2/2 mice exhibited osteopenia associated with low osteoblast and high osteoclast numbers. Finally, we tested whether the end products of the kynurenine pathway have an osteogenic effect on hMSC. We identified that picolinic acid had a strong and dose dependent osteogenic effect in vitro. In summary, we demonstrate that the activation of the kynurenine pathway plays an important role during the commitment of hMSC into the osteoblast lineage in vitro, and that this process can be accelerated by exogenous addition of IFN gamma. In addition, we found that mice lacking IDO1 activity are osteopenic. These data therefore support a new role for the kynurenine pathway and picolinic acid as essential regulators of osteoblastogenesis and as potential new targets of bone forming cells in vivo.
C1 [Vidal, Christopher; Li, Wei; Duque, Gustavo] Sydney Med Sch Nepean, Musculoskeletal Ageing Res Program, Penrith, NSW, Australia.
   [Santner Nanan, Brigitte; Nanan, Ralph] Sydney Med Sch Nepean, Nepean Ctr Perinatal Care, Penrith, NSW, Australia.
   [Lim, Chai K.; Guillemin, Gilles J.] Macquarie Univ, Australian Sch Adv Med, Sydney, NSW 2109, Australia.
   [Lim, Chai K.; Guillemin, Gilles J.] Univ New S Wales, Sch Med Sci, Dept Pharmacol, Sydney, NSW, Australia.
   [Ball, Helen J.; Hunt, Nicholas H.] Univ Sydney, Mol Immunopathol Unit, Discipline Pathol, Sch Med Sci, Sydney, NSW, Australia.
   [Ball, Helen J.; Hunt, Nicholas H.] Univ Sydney, Bosch Inst, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Macquarie University;
   University of New South Wales Sydney; University of Sydney; University
   of Sydney
RP Duque, G (通讯作者)，Nepean Hosp, Sydney Med Sch Nepean, Level 5,South Block, Penrith, NSW 2750, Australia.
EM gustavo.duque@sydney.edu.au
RI Nanan, Ralph/KJL 9638 2024; Duque, Gustavo/HDO 1243 2022; Ball,
   Helen/A 4242 2010; GUILLEMIN, Gilles/C 3878 2015; Lim,
   Edwin/R 5001 2019; Duque, Gustavo/G 6656 2015
OI Nanan, Ralph/0000 0002 1749 6378; Duque, Gustavo/0000 0001 8126 0637;
   Lim, Edwin/0000 0003 3526 8405; Guillemin, Gilles/0000 0001 8105 4470;
   Ball, Helen/0000 0003 3733 9748
FU Australian National Health and Medical Research Council [NHMRC 632767];
   Nepean Medical Research Foundation; Australian Research Council
   [DP0987074]; Australian Research Council [DP0987074] Funding Source:
   Australian Research Council
FX This study was supported by the Australian National Health and Medical
   Research Council (NHMRC 632767), the Nepean Medical Research Foundation,
   and the Australian Research Council (DP0987074).
CR Akter R, 2009, J BONE MINER RES, V24, P283, DOI 10.1359/JBMR.081010
   [Anonymous], TRYPTOPHAN BIOCH HLT
   Apalset EM, 2014, CLIN EXP IMMUNOL, V176, P452, DOI 10.1111/cei.12288
   Baban B, 2004, J REPROD IMMUNOL, V61, P67, DOI 10.1016/j.jri.2003.11.003
   Berry SD, 2007, ARCH INTERN MED, V167, P1971, DOI 10.1001/archinte.167.18.1971
   Bonasera SJ, 2000, PHARMACOL THERAPEUT, V88, P133, DOI 10.1016/S0163 7258(00)00087 5
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chung HCY, 2012, STEM CELLS DEV, V21, P206, DOI 10.1089/scd.2010.0440
   Ciorba MA, 2013, CURR OPIN GASTROEN, V29, P146, DOI 10.1097/MOG.0b013e32835c9cb3
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Ducy P, 2011, CURR OPIN PHARMACOL, V11, P34, DOI 10.1016/j.coph.2011.01.007
   Ducy P, 2010, J CELL BIOL, V191, P7, DOI 10.1083/jcb.201006123
   Duque G, 2011, J BONE MINER RES, V26, P1472, DOI 10.1002/jbmr.350
   Duque G, 2009, STEM CELLS, V27, P550, DOI 10.1634/stemcells.2008 0886
   EVANS GW, 1975, AM J PHYSIOL, V228, P501, DOI 10.1152/ajplegacy.1975.228.2.501
   Forrest CM, 2006, CLIN EXP PHARMACOL P, V33, P1078, DOI 10.1111/j.1440 1681.2006.04490.x
   Goltzman D, 2011, J BONE MINER RES, V26, P1997, DOI 10.1002/jbmr.462
   Guillemin GJ, 2007, J NEUROSCI, V27, P12884, DOI 10.1523/JNEUROSCI.4101 07.2007
   Hsu P, 2014, AM J REPROD IMMUNOL, V71, P217, DOI 10.1111/aji.12195
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Jones SP, 2013, INT J TRYPTOPHAN RES, V6, P57, DOI 10.4137/IJTR.S12626
   Jrad Lamine A, 2011, J BIOL CHEM, V286, P8030, DOI 10.1074/jbc.M110.172114
   Karsenty G, 2011, ANNU REV MED, V62, P323, DOI 10.1146/annurev med 090710 133426
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   LAPIN IP, 1983, J NEURAL TRANSM, V56, P177, DOI 10.1007/BF01243276
   Lim CK, 2013, INT J TRYPTOPHAN RES, V6, P7, DOI 10.4137/IJTR.S11789
   Moffett JR, 2003, IMMUNOL CELL BIOL, V81, P247, DOI 10.1046/j.1440 1711.2003.t01 1 01177.x
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Power M, 2011, CURR DIABETES REP, V11, P173, DOI 10.1007/s11892 011 0184 0
   Saleh A, 2013, ORTHOP CLIN N AM, V44, P137, DOI 10.1016/j.ocl.2013.01.001
   Sas K, 2007, J NEUROL SCI, V257, P221, DOI 10.1016/j.jns.2007.01.033
   Sikander A, 2009, CLIN CHIM ACTA, V403, P47, DOI 10.1016/j.cca.2009.01.028
   Simon R, 2007, CANCER INFORM, V3, P11
   TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934
   Tseng GC, 2001, NUCLEIC ACIDS RES, V29, P2549, DOI 10.1093/nar/29.12.2549
   Vamos E, 2009, J NEUROL SCI, V283, P21, DOI 10.1016/j.jns.2009.02.326
   Vidal C, 2012, STEM CELLS, V30, P1042, DOI 10.1002/stem.1063
   Waddell SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009753
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
NR 40
TC 69
Z9 75
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD JAN
PY 2015
VL 33
IS 1
BP 111
EP 121
DI 10.1002/stem.1836
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA AW8ES
UT WOS:000346494100012
PM 25186311
OA Bronze
DA 2025 08 17
ER

PT J
AU Kobayakawa, T
   Miyazaki, A
   Saito, M
   Suzuki, T
   Takahashi, J
   Nakamura, Y
AF Kobayakawa, Tomonori
   Miyazaki, Akiko
   Saito, Makoto
   Suzuki, Takako
   Takahashi, Jun
   Nakamura, Yukio
TI Denosumab versus romosozumab for postmenopausal osteoporosis treatment
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FRACTURE RISK; SCLEROSTIN ANTIBODY; OSTEOBLAST LINEAGE; BONE; WOMEN;
   BMD; ALENDRONATE; REDUCTION; DENSITY; PLACEBO
AB Denosumab and romosozumab, a recently approved new drug, are effective and widely known molecular targeted drugs for postmenopausal osteoporosis treatment. However, no studies have directly compared their therapeutic effects or safety in postmenopausal osteoporosis. This retrospective observational registry study compared the efficacy of 12 month denosumab or romosozumab treatment in postmenopausal osteoporosis patients. The primary outcome was the change in bone mineral density (BMD) at the lumbar spine. Secondary outcomes included BMD changes at the total hip and femoral neck, changes in bone turnover markers, and adverse events. Propensity score matching was employed to assemble patient groups with similar baseline characteristics. Sixty nine patients each received either denosumab or romosozumab for 12 months. The mean 12 month percentage change from baseline in lumbar spine BMD was 7.2% in the denosumab group and 12.5% in the romosozumab group, indicating a significant difference between the groups. The percentage changes in BMD at both the total hip and femoral neck were also significantly higher at 12 months in the romosozumab group than in the denosumab group. In denosumab patients, bone formation and bone resorption markers were significantly decreased at 6 and 12 months from baseline. In the romosozumab group, the bone formation marker was significantly increased at 6 months and then returned to baseline, while the bone resorption marker was significantly decreased at both time points. Adverse events were few and predominantly minor in both groups, with no remarkable difference in the incidence of new vertebral fractures. Romosozumab showed a higher potential for improving BMD than denosumab in this clinical study of postmenopausal osteoporosis patient treatment.
C1 [Kobayakawa, Tomonori] Kobayakawa Orthoped & Rheumatol Clin, 1969 Kunou, Fukuroi, Shizuoka 4370061, Japan.
   [Miyazaki, Akiko; Suzuki, Takako; Takahashi, Jun; Nakamura, Yukio] Shinshu Univ, Sch Med, Dept Orthopaed Surg, 3 1 1 Asahi, Matsumoto, Nagano 3908621, Japan.
   [Saito, Makoto] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Clin Support Off, Bunkyou Ku, 3 18 22 Honkagome, Tokyo 1138677, Japan.
   [Suzuki, Takako] Tokyo Kasei Gakuin Univ, Fac Human Nutr, Dept Human Nutr, Chiyoda Ku, 22 Sanban Cho, Tokyo 1028341, Japan.
C3 Shinshu University; Tokyo Metropolitan Cancer & Infectious Diseases
   Center Komagome Hospital
RP Nakamura, Y (通讯作者)，Shinshu Univ, Sch Med, Dept Orthopaed Surg, 3 1 1 Asahi, Matsumoto, Nagano 3908621, Japan.
EM yxn14@shinshu u.ac.jp
CR ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1
   Bouxsein ML, 2019, J BONE MINER RES, V34, P632, DOI 10.1002/jbmr.3641
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Chang CY, 2016, OSTEOPOROSIS INT, V27, P665, DOI 10.1007/s00198 015 3238 3
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cummings SR, 2017, J BONE MINER RES, V32, P3, DOI 10.1002/jbmr.3039
   Dempster DW, 2018, J BONE MINER RES, V33, P627, DOI 10.1002/jbmr.3350
   Ebina K, 2020, BONE, V140, DOI 10.1016/j.bone.2020.115574
   ETTINGER B, 1992, J BONE MINER RES, V7, P449
   Gallagher JC, 2005, J CLIN ENDOCR METAB, V90, P1583, DOI 10.1210/jc.2004 0826
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Gennari L, 2016, EXPERT OPIN PHARMACO, V17, P1141, DOI 10.1080/14656566.2016.1176147
   Kanis JA, 2018, OSTEOPOROSIS INT, V29, P1505, DOI 10.1007/s00198 018 4504 y
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Luellen JK, 2005, EVALUATION REV, V29, P530, DOI 10.1177/0193841X05275596
   Miyauchi A, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 019 0608 z
   Nakamura T, 2014, J CLIN ENDOCR METAB, V99, P2599, DOI 10.1210/jc.2013 4175
   Nenonen A, 2005, J BONE MINER RES, V20, P1804, DOI 10.1359/JBMR.050403
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Ominsky MS, 2015, J BONE MINER RES, V30, P1280, DOI 10.1002/jbmr.2480
   Orimo Hajime, 2012, Arch Osteoporos, V7, P3
   Ross P D, 1991, Osteoporos Int, V1, P134, DOI 10.1007/BF01625442
   Shepherd J A, 2006, Osteoporos Int, V17, P1303, DOI 10.1007/s00198 006 0127 9
   Shiraki M, 2011, J BONE MINER METAB, V29, P37, DOI 10.1007/s00774 010 0188 x
   Soen S, 2013, J BONE MINER METAB, V31, P247, DOI [CliCa1403323329, 10.1007/s00774 013 0447 8]
   Tamaki J, 2017, OSTEOPOROSIS INT, V28, P1903, DOI 10.1007/s00198 017 3967 6
   Taylor S, 2016, BONE, V84, P148, DOI 10.1016/j.bone.2015.12.013
   van Geel TACM, 2009, ANN RHEUM DIS, V68, P99, DOI 10.1136/ard.2008.092775
NR 30
TC 57
Z9 61
U1 0
U2 7
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUN 3
PY 2021
VL 11
IS 1
AR 11801
DI 10.1038/s41598 021 91248 6
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA ST1UL
UT WOS:000662236000096
PM 34083636
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wasserman, E
   Webster, D
   Kuhn, G
   Attar Namdar, M
   Müller, R
   Bab, I
AF Wasserman, Elad
   Webster, Duncan
   Kuhn, Gisela
   Attar Namdar, Malka
   Mueller, Ralph
   Bab, Itai
TI Differential load regulated global gene expression in mouse trabecular
   osteocytes
SO BONE
LA English
DT Article
DE Bone remodeling; Differential gene expression; Mechanical loading;
   Osteocytes; Trabecular bone
ID PERIOSTEAL BONE FORMATION; DENTIN MATRIX PROTEIN 1; CORTICAL BONE;
   CANCELLOUS BONE; FUNCTIONAL ADAPTATION; OSTEOGENIC RESPONSE; SIGNALING
   PATHWAYS; RAT OSTEOCYTES; MESSENGER RNA; SCLEROSTIN
AB Osteocytes are considered the skeletal mechanosensors. However, because osteocytes, particularly trabecular, are barely accessible to in vivo molecular analyses, very little is known on the signals transmitted by these cells to the extra trabecular milieu. To investigate so called "osteocytic genes" involved in extracellular signaling, we have used a recently developed model whereby a single caudal mouse vertebra (C5) is subjected to controlled compression loading and further devised a method for the isolation of high quality RNA from trabecular osteocytes. RNA samples from loaded and sham loaded individual vertebrae where then subjected to gene array analysis following the administration of a single or repetitive loading doses (thrice weekly for 4 weeks). Focusing on extracellular genes potentially involved in mediating osteocyte derived signals to the trabecular surface, we identified sets of genes differentially regulated by either single or multiple loading bouts as well as genes affected by both loading protocols. A comparison with published studies on load regulated genes in cortical osteocytes revealed that the majority of these genes are specifically activated/silenced in the trabecular bone. Many of these genes could be clustered according to processes directly relevant to the life cycle and activity of osteoblasts and osteoclasts and their progenitors. The present findings are consistent with an osteocytic role in the control of trabecular bone remodeling and mass and provide a comprehensive database of load regulated genes in trabecular osteocytes that is potentially useful in further mouse genetic studies and identification of drug targets to combat osteoporosis. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Wasserman, Elad; Webster, Duncan; Kuhn, Gisela; Mueller, Ralph] ETH, Inst Biomech, CH 8093 Zurich, Switzerland.
   [Wasserman, Elad; Attar Namdar, Malka; Bab, Itai] Hebrew Univ Jerusalem, Bone Lab, IL 91120 Jerusalem, Israel.
C3 Swiss Federal Institutes of Technology Domain; ETH Zurich; Hebrew
   University of Jerusalem
RP Bab, I (通讯作者)，Hebrew Univ Jerusalem, Bone Lab, POB 12272, IL 91120 Jerusalem, Israel.
EM eladw@ekmd.huji.ac.il; dwebster@ethz.ch; gakuhn@ethz.ch;
   malkaat@savion.huji.ac.il; ram@ethz.ch; babi@cc.huji.ac.il
RI Müller, Ralph/A 1198 2008; Webster, Duncan/A 8909 2012; Muller,
   Ralph/A 1198 2008
OI Webster, Duncan/0000 0001 5028 9218; Muller, Ralph/0000 0002 5811 7725
FU ETH Zurich Strategic Excellence Project [SEP 2 74153 02]; European Union
   Network of Excellence [EXPERTISSUES NMP3 CT 2004 500283]; Lady Davis
   Foundation, Jerusalem
FX This work was supported by grants from ETH Zurich Strategic Excellence
   Project (SEP 2 74153 02), the European Union Network of Excellence
   (EXPERTISSUES NMP3 CT 2004 500283) and Lady Davis Foundation, Jerusalem.
CR Ajubi NE, 1999, AM J PHYSIOL ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171
   Arnsdorf EJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005388
   Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021 9290(00)00231 1
   Biewener AA, 1996, BONE, V19, P1, DOI 10.1016/8756 3282(96)00116 0
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   CHAMBERS TJ, 1993, BONE MINER, V20, P167, DOI 10.1016/S0169 6009(08)80025 6
   CHOW JWM, 1993, AM J PHYSIOL, V265, pE340, DOI 10.1152/ajpendo.1993.265.2.E340
   Colomer J., 2007, V45, P169
   Cullen DM, 2000, J APPL PHYSIOL, V88, P1943, DOI 10.1152/jappl.2000.88.6.1943
   de Jong WC, 2010, BONE, V46, P196, DOI 10.1016/j.bone.2009.10.026
   De Souza RL, 2005, BONE, V37, P810, DOI 10.1016/j.bone.2005.07.022
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   Evans W J, 1998, Gerodontology, V15, P15, DOI 10.1111/j.1741 2358.1998.00015.x
   Feher A, 2010, BONE, V46, P203, DOI 10.1016/j.bone.2009.10.023
   Fritton JC, 2005, BONE, V36, P1030, DOI 10.1016/j.bone.2005.02.013
   Gluhak Heinrich J, 2003, J BONE MINER RES, V18, P807, DOI 10.1359/jbmr.2003.18.5.807
   Gross TS, 2002, J BONE MINER RES, V17, P493, DOI 10.1359/jbmr.2002.17.3.493
   Hagino H, 2005, BONE, V36, P444, DOI 10.1016/j.bone.2004.12.013
   Hankenson KD, 2006, BONE, V38, P310, DOI 10.1016/j.bone.2005.08.027
   HILLAM RA, 1995, J BONE MINER RES, V10, P683
   Holmen SL, 2002, J BIOL CHEM, V277, P34727, DOI 10.1074/jbc.M204989200
   Hsieh YF, 2001, J BONE MINER RES, V16, P918, DOI 10.1359/jbmr.2001.16.5.918
   Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585
   Inman CL, 1999, J APPL PHYSIOL, V87, P189, DOI 10.1152/jappl.1999.87.1.189
   Jurado S, 2010, J CELL BIOCHEM, V110, P304, DOI 10.1002/jcb.22538
   Kalamajski S, 2009, BIOCHEM J, V423, P53, DOI 10.1042/BJ20090542
   Kamioka H, 2001, BONE, V28, P145, DOI 10.1016/S8756 3282(00)00421 X
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kodama Y, 2000, CALCIFIED TISSUE INT, V66, P298, DOI 10.1007/s002230010060
   Kuruvilla S. J., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P71
   LANYON LE, 1993, CALCIFIED TISSUE INT, V53, pS102, DOI 10.1007/BF01673415
   LEAN JM, 1995, AM J PHYSIOL ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318
   Lean JM, 1996, AM J PHYSIOL ENDOC M, V270, pE937, DOI 10.1152/ajpendo.1996.270.6.E937
   Lee KCL, 2002, BONE, V31, P407, DOI 10.1016/S8756 3282(02)00842 6
   Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593
   Lynch ME, 2010, J APPL PHYSIOL, V109, P685, DOI 10.1152/japplphysiol.00210.2010
   Melchers F, 2005, NAT REV IMMUNOL, V5, P578, DOI 10.1038/nri1649
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Mosley JR, 1997, BONE, V20, P191, DOI 10.1016/S8756 3282(96)00385 7
   Moustafa A, 2012, OSTEOPOROSIS INT, V23, P1225, DOI 10.1007/s00198 011 1656 4
   Moustafa A, 2009, BONE, V44, P930, DOI 10.1016/j.bone.2008.12.026
   Mullender MG, 2005, CALCIFIED TISSUE INT, V77, P291, DOI 10.1007/s00223 005 0043 6
   Mullender MG, 1997, BONE, V20, P527, DOI 10.1016/S8756 3282(97)00036 7
   Petersen DN, 2000, J BIOL CHEM, V275, P36172, DOI 10.1074/jbc.M003622200
   Poliachik SL, 2008, BONE, V42, P653, DOI 10.1016/j.bone.2007.12.222
   Power J, 2010, J BONE MINER RES, V25, P1867, DOI 10.1002/jbmr.70
   Reijnders CMA, 2007, J ENDOCRINOL, V192, P131, DOI 10.1677/joe.1.06880
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Robling AG, 2006, J BONE MINER RES, V21, pS72
   Robling AG, 2002, BONE, V31, P562, DOI 10.1016/S8756 3282(02)00871 2
   Robling AG, 2002, J BONE MINER RES, V17, P1545, DOI 10.1359/jbmr.2002.17.8.1545
   Robling AG, 2000, J BONE MINER RES, V15, P1596, DOI 10.1359/jbmr.2000.15.8.1596
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Roosa SMM, 2011, J BONE MINER RES, V26, P100, DOI 10.1002/jbmr.193
   RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711
   RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623 198466030 00012
   Santos A, 2009, J ORTHOP RES, V27, P1280, DOI 10.1002/jor.20888
   Sato A, 2010, EMBO J, V29, P41, DOI 10.1038/emboj.2009.322
   Sone S, 2005, J MOL HISTOL, V36, P281, DOI 10.1007/s10735 005 5534 2
   Srinivasan S, 2002, J BONE MINER RES, V17, P1613, DOI 10.1359/jbmr.2002.17.9.1613
   Sugiyama T, 2008, BONE, V43, P238, DOI 10.1016/j.bone.2008.04.012
   Toyosawa S, 2001, J BONE MINER RES, V16, P2017, DOI 10.1359/jbmr.2001.16.11.2017
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Warden SJ, 2005, J BONE MINER RES, V20, P809, DOI 10.1359/JBMR.041222
   Webster D, 2010, BIOMECH MODEL MECHAN, V9, P737, DOI 10.1007/s10237 010 0210 1
   Webster DJ, 2008, COMPUT METHOD BIOMEC, V11, P435, DOI 10.1080/10255840802078014
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211
   Zaman G, 2010, BONE, V46, P628, DOI 10.1016/j.bone.2009.10.021
   Zhang P, 2009, BONE, V44, P989, DOI 10.1016/j.bone.2009.01.367
   Zhou H, 2003, BONE, V32, P513, DOI 10.1016/S8756 3282(03)00057 7
NR 71
TC 19
Z9 25
U1 0
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2013
VL 53
IS 1
BP 14
EP 23
DI 10.1016/j.bone.2012.11.017
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 080QB
UT WOS:000314257100004
PM 23201221
DA 2025 08 17
ER

PT J
AU Yao, HT
   Du, YG
   Jiang, BL
   Liao, YL
   Zhao, YY
   Yin, MJ
   Li, T
   Sheng, Y
   Ji, YT
   Du, MQ
AF Yao, Hantao
   Du, Yangge
   Jiang, Bulin
   Liao, Yilin
   Zhao, Yaoyu
   Yin, Mengjie
   Li, Ting
   Sheng, Yue
   Ji, Yaoting
   Du, Minquan
TI Sulforaphene suppresses RANKL induced osteoclastogenesis and LPS induced
   bone erosion by activating Nrf2 signaling pathway
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Sulforaphene; Osteoclast differentiation; Nrf2; Bone loss
ID OXIDATIVE STRESS; BREAST CANCER; ISOLIQUIRITIGENIN; OSTEOPOROSIS;
   INHIBITION; DEFICIENCY; CELLS
AB Background and purpose: Inflammatory disorders have been found to induce bone loss through sustained and persistent activation of osteoclast differentiation, leading to heightened bone resorption. The current pharmacological interventions for combating bone loss to harbor adverse effects or contraindications. There is a pressing need to identify drugs with fewer side effects. Experimental approach: The effect and underlying mechanism of sulforaphene (LFS) on osteoclast differentiation were illustrated in vitro and in vivo with RANKL induced Raw264.7 cell line osteoclastogenesis and lipopolysaccharide (LPS) induced bone erosion model. Key results: In this study, LFS has been shown to effectively impede the formation of mature osteoclasts induced from both Raw264.7 cell line and bone marrow macrophages (BMMs), mainly at the early stage. Further mechanistic investigations uncovered that LFS suppressed AKT phosphorylation. SC 79, a potent AKT activator, was found to reverse the inhibitory impact of LFS on osteoclast differentiation. Moreover, transcriptome sequencing analysis revealed that treatment with LFS led to a significant upregulation in the expression of nuclear factor erythroid 2 related factor 2 (Nrf2) and antioxidant related genes. Then it's validated that LFS could promote NRF2 expression and nuclear translocation, as well as effectively resist oxidative stress. NRF2 knockdown reversed the suppression effect of LFS on osteoclast differentiation. In vivo experiments provide convincing evidence that LFS is protective against LPS induced inflammatory osteolysis. Conclusion and implications: These well grounded and promising findings suggest LFS as a promising agent to addressing oxidative stress related diseases and bone loss disorders.
C1 [Ji, Yaoting; Du, Minquan] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hub, Wuhan, Peoples R China.
   Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, Key Lab Oral Biomed, Wuhan, Peoples R China.
C3 Wuhan University; Wuhan University
RP Ji, YT; Du, MQ (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hub, Wuhan, Peoples R China.
EM yaotingji@whu.edu.cn; duminquan@whu.edu.cn
RI Ji, Yaoting/D 2646 2019; Yang, Hongyan/J 9826 2014; Zhao,
   Yaoyu/GQH 3638 2022; liao, yilin/HHZ 4959 2022
OI Ji, Yaoting/0000 0001 9387 4871; 
FU National Natural Science Foundation of China [82172493, 81700772,
   81771084]
FX This work was financially supported by the National Natural Science
   Foundation of China (82172493, 81700772, 81771084) .
CR Altindag O, 2008, RHEUMATOL INT, V28, P317, DOI 10.1007/s00296 007 0452 0
   Bao C, 2016, J AGR FOOD CHEM, V64, P5515, DOI 10.1021/acs.jafc.6b02195
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Chen DL, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.664836
   Chen J, 2018, J AGR FOOD CHEM, V66, P11926, DOI 10.1021/acs.jafc.8b04330
   Chen XR, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00128 8
   Colins JA, 2018, CURR OPIN RHEUMATOL, V30, P101, DOI 10.1097/BOR.0000000000000456
   Galson Deborah L, 2014, J Bone Metab, V21, P85, DOI 10.11005/jbm.2014.21.2.85
   Go YM, 2017, CLIN SCI, V131, P1669, DOI 10.1042/CS20160897
   Han J, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.813057
   Han SC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010060
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Ibáñez L, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/726590
   Jiang JW, 2019, J CELL PHYSIOL, V234, P17549, DOI 10.1002/jcp.28378
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kim JH, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.33
   Kimball JS, 2021, J BONE JOINT SURG AM, V103, P1451, DOI 10.2106/JBJS.20.00989
   Ko MO, 2016, J MICROBIOL BIOTECHN, V26, P2036, DOI 10.4014/jmb.1606.06008
   Lamy O, 2019, CURR OSTEOPOROS REP, V17, P8, DOI 10.1007/s11914 019 00502 4
   Lee JY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094717
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Liu S, 2016, BIOCHEM PHARMACOL, V106, P82, DOI 10.1016/j.bcp.2016.03.002
   Luo TT, 2021, MOLECULES, V26, DOI 10.3390/molecules26020347
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   McGowan NWA, 2001, ENDOCRINOLOGY, V142, P1678, DOI 10.1210/en.142.4.1678
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Neto T, 2016, HEAD NECK J SCI SPEC, V38, P1278, DOI 10.1002/hed.24395
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rana T, 2012, FREE RADICAL BIO MED, V53, P2298, DOI 10.1016/j.freeradbiomed.2012.10.536
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rosen CJ, 1997, ENDOCRIN METAB CLIN, V26, P295, DOI 10.1016/S0889 8529(05)70248 6
   Sakai E, 2017, FASEB J, V31, P4011, DOI 10.1096/fj.201700177R
   Schröder K, 2019, FREE RADICAL BIO MED, V132, P67, DOI 10.1016/j.freeradbiomed.2018.08.036
   SEITZ M, 1985, ANN RHEUM DIS, V44, P438, DOI 10.1136/ard.44.7.438
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Sun YX, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929 015 0212 5
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang HN, 2018, CHEM BIOL INTERACT, V281, P11, DOI 10.1016/j.cbi.2017.12.017
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xu Y, 2023, BIOMED PHARMACOTHER, V159, DOI 10.1016/j.biopha.2022.114101
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Yang M, 2016, ONCOTARGET, V7, P76656, DOI 10.18632/oncotarget.12307
   Yang M, 2016, BREAST CANCER RES TR, V158, P277, DOI 10.1007/s10549 016 3888 7
   Yang W, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4754195
   Zhu LX, 2012, INT J BIOCHEM CELL B, V44, P1139, DOI 10.1016/j.biocel.2012.04.003
NR 55
TC 7
Z9 9
U1 2
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891 5849
EI 1873 4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD OCT
PY 2023
VL 207
BP 48
EP 62
DI 10.1016/j.freeradbiomed.2023.07.009
EA JUL 2023
PG 15
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA O9AE6
UT WOS:001046665100001
PM 37423561
DA 2025 08 17
ER

PT J
AU Lee, SJ
   Jang, SA
   Kim, SC
   Gu, DR
   Yang, H
   Ryuk, JA
   Ha, H
AF Lee, Sung Ju
   Jang, Seon A
   Kim, Seong Cheol
   Gu, Dong Ryun
   Yang, Hyun
   Ryuk, Jin Ah
   Ha, Hyunil
TI Euonymus alatus (Thunb.) Siebold Prevents Osteoclast Differentiation and
   Osteoporosis
SO NUTRIENTS
LA English
DT Article
DE Euonymus alatus (Thunb.) Siebold; osteoporosis; bone loss; ovariectomy
ID RANKL INDUCED OSTEOCLASTOGENESIS; BONE LOSS; CONSTITUENTS; NARINGENIN;
   QUERCITRIN; MECHANISMS; MANAGEMENT; ESTROGEN; CELLS; TWIGS
AB Euonymus alatus (Thunb.) Siebold, a traditional medicinal plant, has been used in China and several other Asian countries to address a variety of health concerns. The extensive research conducted on E. alatus is driven by its diverse pharmacological applications. However, its biological effects on osteoclastogenesis and osteoporosis have not been previously studied. In this research, we investigated the impact of an ethanolic extract of E. alatus (EEEA) on osteoclast differentiation and function as well as estrogen deficiency induced bone loss. We found that EEEA inhibits osteoclast differentiation by downregulating the expression of the receptor activator of nuclear factor kappa B ligand (RANKL) in osteoclast supporting cells and by directly impeding RANKL mediated signaling pathways for osteoclastogenesis in precursor cells. In addition, EEEA inhibited the bone resorptive function of mature osteoclasts in vitro. Furthermore, oral administration of EEEA significantly alleviated bone loss in an ovariectomy induced osteoporosis mouse model. Additionally, we identified phytochemicals in EEEA that have suppressive effects on osteoclast differentiation and bone loss. Collectively, these results suggest that EEEA holds potential as a biotherapeutic candidate for anti postmenopausal osteoporosis.
C1 [Lee, Sung Ju; Kim, Seong Cheol; Gu, Dong Ryun; Yang, Hyun; Ryuk, Jin Ah; Ha, Hyunil] Korea Inst Oriental Med KIOM, KM Convergence Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
   [Jang, Seon A] KT&G Corp, Future Technol Res Ctr, 30 Gajeong Ro, Daejeon 34128, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Ha, H (通讯作者)，Korea Inst Oriental Med KIOM, KM Convergence Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
EM sungjulee@kiom.re.kr; jsa85@ktng.com; iron0907@kiom.re.kr;
   mrwonsin@kiom.re.kr; hyunyang@kiom.re.kr; yukjinah@kiom.re.kr;
   hyunil74@kiom.re.kr
RI Yang, Hyun/P 4126 2014
FU Korea Institute of Oriental Medicine, Ministry of Science and ICT,
   Republic of Korea [KSN2022332]
FX This study was supported by the Korea Institute of Oriental Medicine,
   Ministry of Science and ICT, Republic of Korea [grant number:
   KSN2022332].
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Choi CI, 2015, IND CROP PROD, V76, P1055, DOI 10.1016/j.indcrop.2015.08.031
   Choi EM, 2012, EXP TOXICOL PATHOL, V64, P211, DOI 10.1016/j.etp.2010.08.008
   Fan LH, 2020, J ETHNOPHARMACOL, V259, DOI 10.1016/j.jep.2020.112942
   Fayed HA, 2019, EUR J PHARMACOL, V865, DOI 10.1016/j.ejphar.2019.172785
   Fu QR, 2014, J CHROMATOGR A, V1323, P123, DOI 10.1016/j.chroma.2013.11.015
   Ghiulai R, 2022, MOLECULES, V27, DOI 10.3390/molecules27217359
   Gu DR, 2022, NUTRIENTS, V14, DOI 10.3390/nu14173667
   Gurung P, 2023, NUTRIENTS, V15, DOI 10.3390/nu15010128
   Hak DJ, 2018, INJURY, V49, P1461, DOI 10.1016/j.injury.2018.04.016
   Honma M, 2014, CURR OSTEOPOROS REP, V12, P115, DOI 10.1007/s11914 014 0189 0
   Izawa T., 2017, J. Cytokine Biol, V2, P1000114, DOI [10.4172/2576 3881.1000114, DOI 10.4172/2576 3881.1000114]
   Izawa T, 2016, J IMMUNOL, V197, P4639, DOI 10.4049/jimmunol.1600822
   Jeong DH, 2020, J NAT PROD, V83, P1174, DOI 10.1021/acs.jnatprod.9b01212
   Jeong EJ, 2011, FOOD CHEM TOXICOL, V49, P1394, DOI 10.1016/j.fct.2011.03.028
   Jeong SY, 2015, PHYTOTHER RES, V29, P1540, DOI 10.1002/ptr.5411
   Kang HR, 2015, NAT PROD COMMUN, V10, P1929
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kodama J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165685
   La VD, 2009, J PERIODONTAL RES, V44, P193, DOI 10.1111/j.1600 0765.2008.01107.x
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee S, 2019, MOLECULES, V24, DOI 10.3390/molecules24213848
   Lee S, 2016, CHEM BIODIVERS, V13, P1391, DOI 10.1002/cbdv.201600083
   Lei SS, 2021, INT J BIOL MACROMOL, V193, P1996, DOI 10.1016/j.ijbiomac.2021.11.030
   Lin TH, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/647189
   Liu XK, 2022, FOOD SCI NUTR, V10, P1592, DOI 10.1002/fsn3.2782
   Ma XQ, 2015, PHYTOMEDICINE, V22, P1159, DOI 10.1016/j.phymed.2015.09.003
   Mbese Z, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136869
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Nardone V, 2014, CLINICS, V69, P438, DOI 10.6061/clinics/2014(06)12
   Oh BK, 2011, J ETHNOPHARMACOL, V134, P288, DOI 10.1016/j.jep.2010.12.020
   Park JH, 2017, MOL CELLS, V40, P706
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Shin D, 2023, FOOD NUTR RES, V67, DOI 10.29219/fnr.v67.9422
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Tella SH, 2014, EUR J CLIN PHARMACOL, V70, P1291, DOI 10.1007/s00228 014 1735 5
   Tobeiha M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6910312
   Wang WG, 2018, J CELL BIOCHEM, V119, P2084, DOI 10.1002/jcb.26370
   Wang WG, 2014, INT J MOL SCI, V15, P21913, DOI 10.3390/ijms151221913
   Wang ZL, 2022, J ETHNOPHARMACOL, V284, DOI 10.1016/j.jep.2021.114782
   Wei JY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01025
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Woo Y, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9050449
   Xie BP, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109045
   Xing LZ, 2017, BIOMED PHARMACOTHER, V89, P1136, DOI 10.1016/j.biopha.2017.02.073
   Zhai XF, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/9425714
   Zhao DF, 2020, J CELL BIOCHEM, V121, P152, DOI 10.1002/jcb.28994
   Zhao DF, 2018, J PHARMACOL SCI, V137, P76, DOI 10.1016/j.jphs.2018.03.007
   Zhao HY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6345857
   Zhao X, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11050747
NR 56
TC 4
Z9 6
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD SEP
PY 2023
VL 15
IS 18
AR 3996
DI 10.3390/nu15183996
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA T2XY3
UT WOS:001076677000001
PM 37764779
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mazziotti, G
   Maffezzoni, F
   Doga, M
   Hofbauer, LC
   Adler, RA
   Giustina, A
AF Mazziotti, G.
   Maffezzoni, F.
   Doga, M.
   Hofbauer, L. C.
   Adler, R. A.
   Giustina, A.
TI Outcome of glucose homeostasis in patients with glucocorticoid induced
   osteoporosis undergoing treatment with bone active drugs
SO BONE
LA English
DT Article
DE Glucocorticoids; Glucose metabolism; Osteoporosis; Teriparatide;
   Bisphosphonates; Osteocalcin
ID SERUM OSTEOCALCIN; UNDERCARBOXYLATED OSTEOCALCIN; PARATHYROID HORMONE;
   FAT MASS; METABOLISM; MECHANISMS; EXPRESSION; THERAPIES; RECEPTOR; WOMEN
AB Over the last few years, there has been experimental evidence for the existence of cross talking between bone remodeling and glucose metabolism. Whether this experimental model can be translated to humans is still debated, and it is also unclear whether the modulation of bone turnover by anti osteoporotic drugs may lead to changes in glucose metabolism. The aim of this 12 month prospective study was to investigate whether treatment of glucocorticoid induced osteoporosis (GIO) with bipshosphonates or teriparatide may influence serum glycated hemoglobin (HbA1c) and fasting plasma glucose. One hundred eleven patients (70 F, 41 M, median age 70, range: 55 89) chronically treated with glucocorticoids were evaluated for changes in serum HbA1c and fasting plasma glucose during treatment with bisphosphonates (45 cases) or teriparatide (33 cases) as compared to those occurring during treatment with calcium and vitamin D alone (33 cases).
   In patients treated with teriparatide, but not in those treated with bisphosphonates or calcium and vitamin D alone, a statistically significant (p = 0.01) decrease in serum HbA1c was observed during the follow up, the change being greater (p = 0.01) in patients with diabetes as compared to those without diabetes. In most cases, the decrease of serum HbA1c was relatively limited and in some patients the improvement of glucose homeostasis was concomitant with implementation of anti diabetic treatments. Fasting plasma glucose did not change significantly during either bisphosphonates or teriparatide treatments.
   In conclusion, currently used bone active drugs may produce limited effects on glucose metabolism in patients with GIO. Interestingly, the bone anabolic drug teriparatide was shown to be associated with some improvement in serum HbA1c in this clinical context. (C) 2014 Elsevier Inc All rights reserved.
C1 [Mazziotti, G.; Maffezzoni, F.; Doga, M.; Giustina, A.] Univ Brescia, Dept Clin & Expt Sci, I 25121 Brescia, Italy.
   [Hofbauer, L. C.] Dresden Univ, Med Ctr, Div Endocrinol Diabet & Bone Dis, Dresden, Germany.
   [Adler, R. A.] McGuire Vet Affairs Med Ctr, Richmond, VA USA.
C3 University of Brescia; Technische Universitat Dresden; Hunter Holmes
   McGuire Veterinary Affairs Medical Center
RP Giustina, A (通讯作者)，AO Spedali Civili Brescia, I 25123 Brescia, Italy.
EM a.giustina@libero.it
RI Giustina, Andrea/AAN 5938 2020; Hofbauer, Lorenz/G 2490 2010; Mazziotti,
   Gherardo/AAC 1983 2019; Hofbauer, Lorenz C./G 2490 2010
OI Mazziotti, Gherardo/0000 0001 5458 701X; Hofbauer, Lorenz
   C./0000 0002 8691 8423
FU GIOSEG (Glucocorticoid Induced Osteoporosis Skeletal Endocrinology
   Group); CROMO (Center for Research in Osteoporosis and Bone Metabolism);
   University of Brescia Italy; MIUR (Italian Ministry for University and
   Research)
FX This study was partially supported by GIOSEG (Glucocorticoid Induced
   Osteoporosis Skeletal Endocrinology Group), CROMO (Center for Research
   in Osteoporosis and Bone Metabolism), and University of Brescia Italy
   and MIUR (Italian Ministry for University and Research).
CR Adler Robert A, 2010, Curr Osteoporos Rep, V8, P10, DOI 10.1007/s11914 010 0003 6
   Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc14 S081, 10.2337/dc11 S011, 10.2337/dc13 S067, 10.2337/dc13 S011, 10.2337/dc11 S062, 10.2337/dc10 S062, 10.2337/dc10 S011, 10.2337/dc12 s064, 10.2337/dc12 s011]
   Anastasilakis A, 2007, EXP CLIN ENDOCR DIAB, V115, P108, DOI 10.1055/s 2007 967090
   Brennan Speranza TC, 2012, J CLIN INVEST, V122, P4172, DOI 10.1172/JCI63377
   Burt MG, 2011, J CLIN ENDOCR METAB, V96, P1789, DOI 10.1210/jc.2010 2729
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Clayton RN, 2011, J CLIN ENDOCR METAB, V96, P632, DOI 10.1210/jc.2010 1942
   Ferris HA, 2012, J CLIN INVEST, V122, P3854, DOI 10.1172/JCI66180
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Ferron M, 2012, BONE, V50, P568, DOI 10.1016/j.bone.2011.04.017
   Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002
   Furusyo N, 2013, ENDOCRINE, V43, P635, DOI 10.1007/s12020 012 9803 z
   Griffith JF, 2012, ENDOCRINE, V42, P39, DOI 10.1007/s12020 012 9691 2
   Kanazawa I, 2009, J CLIN ENDOCR METAB, V94, P45, DOI 10.1210/jc.2008 1455
   Kindblom JM, 2009, J BONE MINER RES, V24, P785, DOI 10.1359/JBMR.081234
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Mazziotti G, 2012, ENDOCRINE, V41, P58, DOI 10.1007/s12020 011 9570 2
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Mazziotti G, 2011, TRENDS ENDOCRIN MET, V22, P499, DOI 10.1016/j.tem.2011.09.001
   Mazziotti G, 2011, ENDOCRINE, V40, P102, DOI 10.1007/s12020 011 9486 x
   Mazziotti G, 2010, AM J MED, V123, P877, DOI 10.1016/j.amjmed.2010.02.028
   PECK WA, 1993, AM J MED, V94, P646
   Pittas AG, 2009, J CLIN ENDOCR METAB, V94, P827, DOI 10.1210/jc.2008 1422
   PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem 72 2 382
   REID IR, 1986, J CLIN ENDOCR METAB, V62, P379, DOI 10.1210/jcem 62 2 379
   Rubin MR, 2012, ENDOCRINE, V42, P231, DOI 10.1007/s12020 012 9674 3
   Schafer AL, 2011, J CLIN ENDOCR METAB, V96, pE1982, DOI 10.1210/jc.2011 0587
   Schwartz AV, 2013, J BONE MINER RES, V28, P1348, DOI 10.1002/jbmr.1865
   Sealand R, 2013, CURR DIABETES REP, V13, P411, DOI 10.1007/s11892 013 0376 x
   Torti C, 2012, ENDOCRINE, V41, P512, DOI 10.1007/s12020 011 9586 7
   USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455
   van Raalte DH, 2009, EUR J CLIN INVEST, V39, P81, DOI 10.1111/j.1365 2362.2008.02067.x
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Williams K, 2011, DIABETOLOGIA, V54, P2867, DOI 10.1007/s00125 011 2260 z
   Yeap BB, 2010, EUR J ENDOCRINOL, V163, P265, DOI 10.1530/EJE 10 0414
   Zhou M, 2009, EUR J ENDOCRINOL, V161, P723, DOI 10.1530/EJE 09 0585
NR 36
TC 19
Z9 23
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2014
VL 67
BP 175
EP 180
DI 10.1016/j.bone.2014.07.008
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AO3KJ
UT WOS:000341227800022
PM 25016963
DA 2025 08 17
ER

PT J
AU Movérare Skrtic, S
   Nilsson, KH
   Henning, P
   Funck Brentano, T
   Nethander, M
   Rivadeneira, F
   Nunes, GC
   Koskela, A
   Tuukkanen, J
   Tuckermann, J
   Perret, C
   Souza, PPC
   Lerner, UH
   Ohlsson, C
AF Moverare Skrtic, Sofia
   Nilsson, Karin H.
   Henning, Petra
   Funck Brentano, Thomas
   Nethander, Maria
   Rivadeneira, Fernando
   Nunes, Glaucia Coletto
   Koskela, Antti
   Tuukkanen, Juha
   Tuckermann, Jan
   Perret, Christine
   Chaves Souza, Pedro Paulo
   Lerner, Ulf H.
   Ohlsson, Claes
TI Osteoblast derived NOTUM reduces cortical bone mass in mice and the
   NOTUM locus is associated with bone mineral density in humans
SO FASEB JOURNAL
LA English
DT Article
DE osteoporosis; transgenic; WNT16
ID OSTEOCLAST PROGENITOR; GROWTH HORMONE; SOST GENE; WOMEN; WNT;
   IDENTIFICATION; INHIBITORS; FRAGILITY; DYSPLASIA; MUTATION
AB Osteoporosis is a common skeletal disease, affecting millions of individuals worldwide. Currently used osteoporosis treatments substantially reduce vertebral fracture risk, whereas nonvertebral fracture risk, mainly caused by reduced cortical bone mass, has only moderately been improved by the osteoporosis drugs used, defining an unmet medical need. Because several wingless type MMTV integration site family members (WNTs) and modulators of WNT activity are major regulators of bone mass, we hypothesized that NOTUM, a secreted WNT lipase, might modulate bone mass via an inhibition of WNT activity. To characterize the possible role of endogenous NOTUM as a physiologic modulator of bone mass, we developed global, cell specific, and inducible Notum inactivated mouse models. Notum expression was high in the cortical bone in mice, and conditional Notum inactivation revealed that osteoblast lineage cells are the principal source of NOTUM in the cortical bone. Osteoblast lineage specific Notum inactivation increased cortical bone thickness via an increased periosteal circumference. Inducible Notum inactivation in adult mice increased cortical bone thickness as a result of increased periosteal bone formation, and silencing of Notum expression in cultured osteoblasts enhanced osteoblast differentiation. Large scale human genetic analyses identified genetic variants mapping to the NOTUM locus that are strongly associated with bone mineral density (BMD) as estimated with quantitative ultrasound in the heel. Thus, osteoblast derived NOTUM is an essential local physiologic regulator of cortical bone mass via effects on periosteal bone formation in adult mice, and genetic variants in the NOTUM locus are associated with BMD variation in adult humans. Therapies targeting osteoblast derived NOTUM may prevent nonvertebral fractures. Moverare Skrtic, S., Nilsson, K. H., Henning, P., Funck Brentano, T., Nethander, M., Rivadeneira, F., Coletto Nunes, G., Koskela, A., Tuukkanen, J., Tuckermann, J., Perret, C., Souza, P. P. C., Lerner, U. H., Ohlsson, C. Osteoblast derived NOTUM reduces cortical bone mass in mice and the NOTUM locus is associated with bone mineral density in humans.
C1 [Moverare Skrtic, Sofia; Nilsson, Karin H.; Henning, Petra; Funck Brentano, Thomas; Nethander, Maria; Lerner, Ulf H.; Ohlsson, Claes] Univ Gothenburg, Sahlgrenska Acad, Ctr Bone & Arthrit Res, Dept Internal Med & Clin Nutr,Inst Med, Gothenburg, Sweden.
   [Rivadeneira, Fernando] Erasmus Univ, Dept Internal Med, Rotterdam, Netherlands.
   [Nunes, Glaucia Coletto; Chaves Souza, Pedro Paulo] Sao Paulo State Univ UNESP, Sch Dent, Bone Biol Res Grp, Araraquara, Brazil.
   [Koskela, Antti; Tuukkanen, Juha] Univ Oulu, Fac Med, Inst Canc Res & Translat Med, Dept Anat & Cell Biol, Oulu, Finland.
   [Tuckermann, Jan] Univ Ulm, Inst Gen Zool & Endocrinol, Ulm, Germany.
   [Perret, Christine] Univ Paris 05, Sorbonne Paris Cite, Inst Cochin, INSERM,U1016, Paris, France.
   [Perret, Christine] Equipe Labellisee Ligue Natl Canc, Paris, France.
   [Chaves Souza, Pedro Paulo] Univ Fed Goias, Sch Dent, Goiania, Go, Brazil.
C3 University of Gothenburg; Erasmus University Rotterdam; Erasmus
   University Rotterdam   Excl Erasmus MC; Universidade Estadual Paulista;
   University of Oulu; Ulm University; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universidade
   Federal de Goias
RP Lerner, UH; Ohlsson, C (通讯作者)，Sahlgrens Univ Hosp, Ctr Bone & Arthrit Res, Vita Straket 11, S 41345 Gothenburg, Sweden.
EM ulf.lerner@gu.se; claes.ohlsson@medic.gu.se
RI ; Ohlsson, Claes/AGP 3544 2022; Chaves de Souza, Pedro
   Paulo/G 3801 2011; Tuukkanen, Juha/R 3728 2018; Henning,
   Petra/KIL 4650 2024; Skrtic, Sofia/AAQ 1585 2020; Perret Mayeux,
   Christine/L 3297 2017; de Souza, Pedro/G 3801 2011; Ohlsson,
   Claes/HIR 6959 2022; Rivadeneira, Fernando/O 5385 2015; Funck Brentano,
   Thomas/AAS 7201 2020; Funck Brentano, Thomas/Q 5736 2016
OI Koskela, Antti/0000 0001 7371 2488; Henning, Petra/0000 0002 9330 6265;
   Chaves de Souza, Pedro Paulo/0000 0001 7266 6061; Nethander,
   Maria/0000 0003 3688 906X; Lerner, Ulf/0000 0002 3579 1960; Ohlsson,
   Claes/0000 0002 9633 2805; Rivadeneira, Fernando/0000 0001 9435 9441;
   perret, christine/0000 0003 4710 7051; Funck Brentano,
   Thomas/0000 0001 7684 2405
FU Swedish Research Council; Swedish Foundation for Strategic Research;
   Swedish county councils, the ALF agreement in Gothenburg [238261,
   226481, 237551]; IngaBritt and Arne Lundberg Foundation; Royal 80 Year
   Fund of King Gustav V; Torsten and Ragnar Soderberg's Foundation; Knut
   and Alice Wallenberg Foundation; Novo Nordisk Foundation; Sao Paulo
   Research Foundation [2014/05283 3]; Deutsche Forschungsgemeinschaft
   (DFG) Collaborative Research Centre (CRC) 1149; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [001]; Swedish
   government [238261, 226481, 237551]; Novo Nordisk Fonden
   [NNF13OC0005785, NNF15OC0015080, NNF18OC0033898, NNF14OC0010513] Funding
   Source: researchfish; Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [14/05283 3] Funding Source: FAPESP
FX The authors thank Lotta Uggla, Biljana Aleksic, Anna Westerlund, and
   Anette Hansevi (all from the University of Gothenburg) for excellent
   technical assistance, and Carolina Medina Gomez (Erasmus University
   Rotterdam) for support in the human genetic analyses. This study was
   supported by the Swedish Research Council, the Swedish Foundation for
   Strategic Research, the Swedish state under the agreement between the
   Swedish government and the county councils, the ALF agreement in
   Gothenburg (Grants 238261, 226481, and 237551), the IngaBritt and Arne
   Lundberg Foundation, the Royal 80 Year Fund of King Gustav V, the
   Torsten and Ragnar Soderberg's Foundation, the Knut and Alice Wallenberg
   Foundation, the Novo Nordisk Foundation, and Sao Paulo Research
   Foundation (Grant 2014/05283 3). J.T. was supported by the Deutsche
   Forschungsgemeinschaft (DFG) Collaborative Research Centre (CRC) 1149,
   and G.C.N. was supported by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES; Finance Code 001). S.M. S. and K.H.N. share first
   authorship. The authors declare no conflicts of interest.
CR Ascenzi MG, 2016, BONE, V84, P104, DOI 10.1016/j.bone.2015.10.010
   Ascenzi MG, 2014, J BIOMECH, V47, P2436, DOI 10.1016/j.jbiomech.2014.04.006
   Ascenzi MG, 2013, J COMPUT PHYS, V244, P298, DOI 10.1016/j.jcp.2012.05.027
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Bauer DC, 1997, ARCH INTERN MED, V157, P629, DOI 10.1001/archinte.157.6.629
   Black DM, 2016, NEW ENGL J MED, V374, P2096, DOI 10.1056/NEJMc1602599
   Bonnet N, 2016, MOL CELL ENDOCRINOL, V432, P85, DOI 10.1016/j.mce.2015.12.014
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brommage R, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0038 3
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Canal F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150997
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Funck Brentano T, 2018, J ENDOCRINOL, V238, P13, DOI 10.1530/JOE 18 0153
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gori F, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.36
   Granholm S, 2007, J ENDOCRINOL, V195, P415, DOI 10.1677/JOE 07 0338
   Granholm S, 2013, BONE, V52, P83, DOI 10.1016/j.bone.2012.09.019
   Han Q, 2016, BIOORG MED CHEM LETT, V26, P1184, DOI 10.1016/j.bmcl.2016.01.038
   Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597
   Jenny A, 2010, CURR TOP DEV BIOL, V93, P189, DOI [10.1016/S0070 2153(10)93007 X, 10.1016/B978 0 12 385044 7.00007 2]
   Kakugawa S, 2015, NATURE, V519, P187, DOI 10.1038/nature14259
   Kemp JP, 2017, NAT GENET, V49, P1468, DOI 10.1038/ng.3949
   Kiper POS, 2016, NEW ENGL J MED, V374, P2553, DOI 10.1056/NEJMoa1509342
   Kohn AD, 2005, CELL CALCIUM, V38, P439, DOI 10.1016/j.ceca.2005.06.022
   Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Little RD, 2002, NEW ENGL J MED, V347, P943
   Madan B, 2016, ONCOTARGET, V7, P12386, DOI 10.18632/oncotarget.7157
   Mohan S, 2003, ENDOCRINOLOGY, V144, P929, DOI 10.1210/en.2002 220948
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Nusse R, 2015, NATURE, V519, P163, DOI 10.1038/nature14208
   Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55
   Ohlsson C, 2018, J ENDOCRINOL, V237, P113, DOI 10.1530/JOE 18 0020
   Ohlsson C, 2017, J CLIN ENDOCR METAB, V102, P516, DOI 10.1210/jc.2016 3177
   Peng ZQ, 2004, J BONE MINER RES, V19, P1320, DOI 10.1359/JBMR.040510
   Quarta C, 2017, CELL METAB, V26, P620, DOI 10.1016/j.cmet.2017.08.023
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Shen Z, 2008, J BONE MINER RES, V23, P1217, DOI [10.1359/jbmr.080322, 10.1359/JBMR.080322]
   Sjögren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tarver JE, 2016, BIOORG MED CHEM LETT, V26, P1525, DOI 10.1016/j.bmcl.2016.02.021
   Vidal O, 2000, P NATL ACAD SCI USA, V97, P5474, DOI 10.1073/pnas.97.10.5474
   Vogel P, 2016, VET PATHOL, V53, P853, DOI 10.1177/0300985815626778
   Wergedal JE, 2015, ENDOCRINOLOGY, V156, P1023, DOI 10.1210/en.2014 1702
   Windahl SH, 1999, J CLIN INVEST, V104, P895, DOI 10.1172/JCI6730
   Zebaze RMD, 2010, LANCET, V375, P1729, DOI 10.1016/S0140 6736(10)60320 0
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
NR 51
TC 27
Z9 31
U1 0
U2 8
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD OCT
PY 2019
VL 33
IS 10
BP 11163
EP 11179
DI 10.1096/fj.201900707R
PG 17
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA JC3GG
UT WOS:000489166300049
PM 31307226
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Engelmann, J
   Zarrer, J
   Gensch, V
   Riecken, K
   Berenbrok, N
   Luu, TV
   Beitzen Heineke, A
   Vargas Delgado, ME
   Pantel, K
   Bokemeyer, C
   Bhamidipati, S
   Darwish, IS
   Masuda, E
   Burstyn Cohen, T
   Alberto, EJ
   Ghosh, S
   Rothlin, C
   Hesse, E
   Taipaleenmäki, H
   Ben Batalla, I
   Loges, S
AF Engelmann, Janik
   Zarrer, Jennifer
   Gensch, Victoria
   Riecken, Kristoffer
   Berenbrok, Nikolaus
   The Vinh Luu
   Beitzen Heineke, Antonia
   Vargas Delgado, Maria Elena
   Pantel, Klaus
   Bokemeyer, Carsten
   Bhamidipati, Somasekhar
   Darwish, Ihab S.
   Masuda, Esteban
   Burstyn Cohen, Tal
   Alberto, Emily J.
   Ghosh, Sourav
   Rothlin, Carla
   Hesse, Eric
   Taipaleenmaki, Hanna
   Ben Batalla, Isabel
   Loges, Sonja
TI Regulation of bone homeostasis by MERTK and TYRO3
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RECEPTOR TYROSINE KINASE; ONTOLOGY LEGO VECTORS; CELL LUNG CANCER;
   POSTMENOPAUSAL WOMEN; TAM RECEPTORS; ROMOSOZUMAB; PREVENTION; DISEASE;
   DIFFERENTIATION; PATHOGENESIS
AB The fine equilibrium of bone homeostasis is maintained by bone forming osteoblasts and bone resorbing osteoclasts. Here, we show that TAM receptors MERTK and TYRO3 exert reciprocal effects in osteoblast biology: Osteoblast targeted deletion of MERTK promotes increased bone mass in healthy mice and mice with cancer induced bone loss, whereas knockout of TYRO3 in osteoblasts shows the opposite phenotype. Functionally, the interaction of MERTK with its ligand PROS1 negatively regulates osteoblast differentiation via inducing the VAV2 RHOA ROCK axis leading to increased cell contractility and motility while TYRO3 antagonizes this effect. Consequently, pharmacologic MERTK blockade by the small molecule inhibitor R992 increases osteoblast numbers and bone formation in mice. Furthermore, R992 counteracts cancer induced bone loss, reduces bone metastasis and prolongs survival in preclinical models of multiple myeloma, breast  and lung cancer. In summary, MERTK and TYRO3 represent potent regulators of bone homeostasis with cell type specific functions and MERTK blockade represents an osteoanabolic therapy with implications in cancer and beyond. The TAM family of receptor tyrosine kinases exerts pleiotropic functions in health and disease. Here, the authors show that TAM receptors control osteoblastic bone formation and identified MERTK as a novel target for bone anabolic therapy and mitigation of bone metastasis including its associated osteolytic bone disease
C1 [Engelmann, Janik; Gensch, Victoria; Berenbrok, Nikolaus; The Vinh Luu; Beitzen Heineke, Antonia; Vargas Delgado, Maria Elena; Bokemeyer, Carsten; Ben Batalla, Isabel; Loges, Sonja] Univ Med Ctr Hamburg Eppendorf, Hubertus Wald Comprehens Canc Ctr Hamburg, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany.
   [Engelmann, Janik; Gensch, Victoria; Berenbrok, Nikolaus; The Vinh Luu; Beitzen Heineke, Antonia; Vargas Delgado, Maria Elena; Pantel, Klaus; Ben Batalla, Isabel; Loges, Sonja] Univ Med Ctr Hamburg Eppendorf, Ctr Expt Med, Dept Tumor Biol, Hamburg, Germany.
   [Engelmann, Janik; Gensch, Victoria; Berenbrok, Nikolaus; Vargas Delgado, Maria Elena; Ben Batalla, Isabel; Loges, Sonja] Univ Med Ctr Mannheim, DKFZ Hector Canc Inst, Mannheim, Germany.
   [Engelmann, Janik; Gensch, Victoria; Berenbrok, Nikolaus; Vargas Delgado, Maria Elena; Ben Batalla, Isabel; Loges, Sonja] German Canc Res Ctr, Div Personalized Med Oncol A420, Heidelberg, Germany.
   [Engelmann, Janik; Gensch, Victoria; Berenbrok, Nikolaus; Vargas Delgado, Maria Elena; Ben Batalla, Isabel; Loges, Sonja] Heidelberg Univ, Univ Hosp Mannheim, Med Fac Mannheim, Dept Personalized Oncol, Mannheim, Germany.
   [Zarrer, Jennifer; Taipaleenmaki, Hanna] Univ Med Ctr Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, Mol Skeletal Biol Lab, Hamburg, Germany.
   [Zarrer, Jennifer; Hesse, Eric; Taipaleenmaki, Hanna] Ludwig Maximilians Univ Munchen, Univ Hosp, Inst Musculoskeletal Med, Martinsried, Germany.
   [Zarrer, Jennifer; Hesse, Eric; Taipaleenmaki, Hanna] Ludwig Maximilians Univ Munchen, Univ Hosp, Musculoskeletal Univ Ctr Munich, Martinsried, Germany.
   [Riecken, Kristoffer] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Res Dept Cell & Gene Therapy, Hamburg, Germany.
   [Bhamidipati, Somasekhar; Darwish, Ihab S.; Masuda, Esteban] Rigel Pharmaceut Inc, San Francisco, CA USA.
   [Burstyn Cohen, Tal] Hebrew Univ Jerusalem, Fac Dent Med, Inst Dent Sci, Jerusalem, Israel.
   [Alberto, Emily J.; Rothlin, Carla] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA.
   [Ghosh, Sourav; Rothlin, Carla] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA.
   [Ghosh, Sourav] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   Ruprecht Karls University Heidelberg; Helmholtz Association; German
   Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Munich; University of Munich; University of Hamburg;
   University Medical Center Hamburg Eppendorf; Rigel Pharmaceuticals,
   Inc.; Hebrew University of Jerusalem; Yale University; Yale University;
   Yale University
RP Ben Batalla, I; Loges, S (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Hubertus Wald Comprehens Canc Ctr Hamburg, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany.; Ben Batalla, I; Loges, S (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Ctr Expt Med, Dept Tumor Biol, Hamburg, Germany.; Ben Batalla, I; Loges, S (通讯作者)，Univ Med Ctr Mannheim, DKFZ Hector Canc Inst, Mannheim, Germany.; Ben Batalla, I; Loges, S (通讯作者)，German Canc Res Ctr, Div Personalized Med Oncol A420, Heidelberg, Germany.; Ben Batalla, I; Loges, S (通讯作者)，Heidelberg Univ, Univ Hosp Mannheim, Med Fac Mannheim, Dept Personalized Oncol, Mannheim, Germany.
EM isabel.benbatalla@dkfz heidelberg.de; s.loges@dkfz heidelberg.de
RI Ghosh, Sourav/HSF 3046 2023; Riecken, Kristoffer/AAD 2371 2020; Ben
   Batalla, Isabel/ABG 4360 2021
OI Riecken, Kristoffer/0000 0001 9050 6766; Ben Batalla,
   Isabel/0000 0001 5036 1769; Engelmann, Janik/0009 0003 9983 5058
FU DFG [LO1863/5 1, BE6658/2 1]; University Cancer Center Hamburg (UCCH);
   Heisenberg professorship (DFG); European Research Council (ERC) under
   the European Union [758713]; Hector Stiftung II; German Research
   Foundation [SPP 2084, HE 5208/5 1, TA 1154/2 1, TA 1154/1 1, TA
   1154/1 2]; Projekt DEAL; European Research Council (ERC) [758713]
   Funding Source: European Research Council (ERC)
FX The position of J.E. was supported by the priority program mu bone from
   the DFG (LO1863/5 1) and he received the E.W. Kuhlmann scholarship from
   the University Cancer Center Hamburg (UCCH). S.L. was supported by a
   Heisenberg professorship (DFG), by the priority program mu bone from the
   DFG (LO1863/5 1), and is currently supported by the European Research
   Council (ERC) under the European Union's Horizon 2020 research and
   innovation program (Grant Agreement No. 758713), by the priority program
   mu bone from the DFG (LO1863/5 1) and by the Hector Stiftung II. I.B.B.
   was supported by (BE6658/1 1) and is currently supported by the priority
   program mu bone from the DFG (BE6658/2 1). E.H. and H.T. received
   funding from the German Research Foundation (SPP 2084 to E.H. (HE
   5208/5 1) and H.T (TA 1154/2 1) and Emmy Noether Program to H.T. (TA
   1154/1 1 and TA 1154/1 2)). R992 was obtained from Rigel Inc. (South San
   Francisco, CA, USA). The authors would like to thank Michael Horn and
   theUCCHin vivo optical imaging core facility for help with the
   intracardial injections and imaging of our mouse models. Confocal
   microscopy was conducted at the UKE Microscopy Imaging Facility (DFG
   Research Infrastructure Portal: RI_00489). FACS analysis with BD
   Fortessa was performed at the FACS Sorting Core Unit at University
   Hospital HamburgEppendorf. We thank Bao Uyen Huynh and Sabrina Noster on
   behalf of the Animal Facility (FTH) at University Hospital
   Hamburg Eppendorf for taking care of the mice housing and breeding. Open
   Access funding enabled and organized by Projekt DEAL.
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bosurgi L, 2017, SCIENCE, V356, P1072, DOI 10.1126/science.aai8132
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Burstyn Cohen T, 2009, J CLIN INVEST, V119, P2942, DOI 10.1172/JCI39325
   Chan PY, 2016, SCIENCE, V352, P99, DOI 10.1126/science.aaf1358
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194
   Fourgeaud L, 2016, NATURE, V532, P240, DOI 10.1038/nature17630
   Gadiyar V, 2020, INT REV CEL MOL BIO, V357, P57, DOI 10.1016/bs.ircmb.2020.09.011
   Graham DK, 2014, NAT REV CANCER, V14, P769, DOI 10.1038/nrc3847
   Hesse E, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125543
   Holland SJ, 2016, CANCER RES, V76, DOI 10.1158/1538 7445.AM2016 4869
   Jannie KM, 2015, BIOCHEM J, V465, P383, DOI 10.1042/BJ20140872
   Kolb AD, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058 019 1117 0
   Krishnan V, 2010, IN VITRO CELL DEV AN, V46, P28, DOI 10.1007/s11626 009 9238 x
   Kristinsson SY, 2011, EXPERT REV MOL DIAGN, V11, P593, DOI [10.1586/erm.11.44, 10.1586/ERM.11.44]
   Lee YJ, 2014, J PHARMACOL EXP THER, V350, P563, DOI 10.1124/jpet.114.215673
   Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303
   Lineham Ella, 2018, Oncotarget, V9, P14148, DOI 10.18632/oncotarget.24354
   Linger RM, 2010, EXPERT OPIN THER TAR, V14, P1073, DOI 10.1517/14728222.2010.515980
   Mahajan NP, 2003, J BIOL CHEM, V278, P42596, DOI 10.1074/jbc.M305817200
   Mat MFC, 2016, INT J ONCOL, V49, P2359, DOI 10.3892/ijo.2016.3755
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   O'Donnell EK, 2017, CLIN ADV HEMATOL ONC, V15, P285
   Paton Hough J, 2019, J BONE MINER RES, V34, P783, DOI 10.1002/jbmr.3606
   Prasad D, 2006, MOL CELL NEUROSCI, V33, P96, DOI 10.1016/j.mcn.2006.06.011
   Roodman GD, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.122
   Rossi A, 2012, CURR MED CHEM, V19, P5524, DOI 10.2174/092986712803833209
   Rothlin CV, 2015, ANNU REV IMMUNOL, V33, P355, DOI 10.1146/annurev immunol 032414 112103
   Ruiz Heiland G, 2014, ANN RHEUM DIS, V73, P771, DOI 10.1136/annrheumdis 2012 202907
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Saraon P, 2012, J BIOL CHEM, V287, P34019, DOI 10.1074/jbc.M112.384438
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Shelby SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053964
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Smart SK, 2018, CANCERS, V10, DOI 10.3390/cancers10120474
   Solling ASK, 2018, THER ADV MUSCULOSKEL, V10, P105, DOI 10.1177/1759720X18775936
   Svitkina T, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a018267
   Tang Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117787
   Tojkander S, 2012, J CELL SCI, V125, P1855, DOI 10.1242/jcs.098087
   Tondo G, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/2387614
   Ubil E, 2018, J CLIN INVEST, V128, P2356, DOI 10.1172/JCI97354
   Vallenius T, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.130001
   Vicente Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786
   Waizenegger JS, 2015, LEUKEMIA, V29, P696, DOI 10.1038/leu.2014.236
   Wang M, 2011, OSTEOARTHR CARTILAGE, V19, P751, DOI 10.1016/j.joca.2011.03.004
   Weber K, 2010, GENE THER, V17, P511, DOI 10.1038/gt.2009.149
   Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6
   Xie SZ, 2015, ONCOTARGET, V6, P9206, DOI 10.18632/oncotarget.3280
   Zagórska A, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000694
   Zouani OF, 2013, BIOL OPEN, V2, P872, DOI 10.1242/bio.20134986
NR 56
TC 20
Z9 22
U1 3
U2 13
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD DEC 12
PY 2022
VL 13
IS 1
AR 7689
DI 10.1038/s41467 022 33938 x
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA D6IA3
UT WOS:000969735000001
PM 36509738
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Du, XL
   Yang, JL
   Yang, D
   Tian, W
   Zhu, Z
AF Du, Xiaoling
   Yang, Jilong
   Yang, Da
   Tian, Wei
   Zhu, Ze
TI The genetic basis for inactivation of Wnt pathway in human osteosarcoma
SO BMC CANCER
LA English
DT Article
DE Osteosarcoma; Wnt signal pathway; Genetic aberration; Microarray based
   comparative genomic hybridization
ID BETA CATENIN; STEM CELLS; TRANSCRIPTOMES; CHEMOTHERAPY; EXPRESSION;
   INHIBITOR; DELETIONS; THERAPY; BONE
AB Background: Osteosarcoma is a highly genetically unstable tumor with poor prognosis. We performed microarray based comparative genomic hybridization (aCGH), transcriptome sequencing (RNA seq), and pathway analysis to gain a systemic view of the pathway alterations of osteosarcoma.
   Methods: aCGH experiments were carried out on 10 fresh osteosarcoma samples. The output data (Gene Expression Omnibus Series accession number GSE19180) were pooled with published aCGH raw data (GSE9654) to determine recurrent copy number changes. These were analyzed using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to identify altered pathways in osteosarcoma. Transcriptome sequencing of six osteosarcomas was performed to detect the expression profile of Wnt signaling pathway genes. Protein expression of WNT1, beta catenin, c myc, and cyclin D1 in the Wnt pathway was detected by immunohistochemistry (IHC) in an independent group of 46 osteosarcoma samples.
   Results: KEGG pathway analysis identified frequent deletions of Wnt and other Wnt signaling pathway genes. At the mRNA level, transcriptome sequencing found reduced levels of mRNA expression of Wnt signaling pathway transcripts. While WNT1 protein expression was detected by IHC in 69.6% (32/46) of the osteosarcomas, no beta catenin protein was detected in the nucleus. beta catenin protein expression was, however, detected in the membrane and cytoplasm of 69.6% (32/46) of the osteosarcomas. c myc protein expression was detected in only 47.8% (22/46) and cyclin D1 protein expression in 52.2% (24/46) of osteosarcoma samples. Kaplan Meier survival analysis showed that WNT1 negative patients had a trend towards longer disease free survival than WNT1 positive patients. Interestingly, in WNT1 negative patients, those who were also cyclin D1 negative had significantly longer disease free survival than cyclin D1 positive patients. However, there was no significant association between any of the investigated proteins and overall survival of human osteosarcoma patients.
   Conclusions: Frequent deletions of Wnt and other Wnt signaling pathway genes suggest that the Wnt signaling pathway is genetically inactivated in human osteosarcoma.
C1 [Du, Xiaoling] Tianjin Med Univ, Dept Diagnost, Tianjin 300060, Peoples R China.
   [Du, Xiaoling; Yang, Jilong; Tian, Wei] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Bone & Soft Tissue Tumors, Tianjin 30060, Peoples R China.
   [Yang, Jilong; Yang, Da] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Du, Xiaoling; Zhu, Ze] Tianjin Med Univ, Dept Med Microbiol, Tianjin 300060, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; University of
   Texas System; UTMD Anderson Cancer Center; Tianjin Medical University
RP Yang, JL (通讯作者)，Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Bone & Soft Tissue Tumors, Tianjin 30060, Peoples R China.
EM yangjilong@tjmuch.com; zhuze_2006@126.com
RI Yang, Da/I 9054 2012; Yang, Jilong/ADB 8853 2022
OI Yang, Da/0000 0002 8336 9457
FU National Nature Science Foundation of China [81372872, 81320108022];
   University Cancer Foundation via the Sister Institution Network Fund
   (SINF) at the Tianjin Medical University Cancer Institute & Hospital
   (TMUCIH); Fudan University Shanghai Cancer Center (FUSCC); University of
   Texas MD Anderson Cancer Center (UT MDACC); program for Changjiang
   Scholars and Innovative Research Team in University (PCSIRT) in China
   [IRT1076]; National Key Scientific and Technological Project
   [2011ZX09307 001 04]; Cancer Genomics Core Laboratory
FX This work was partly supported by the National Nature Science Foundation
   of China (81372872 to JY and 81320108022 to KC), the funds from the
   University Cancer Foundation via the Sister Institution Network Fund
   (SINF) at the Tianjin Medical University Cancer Institute & Hospital
   (TMUCIH), Fudan University Shanghai Cancer Center (FUSCC), and
   University of Texas MD Anderson Cancer Center (UT MDACC), program for
   Changjiang Scholars and Innovative Research Team in University (PCSIRT)
   in China (IRT1076), and National Key Scientific and Technological
   Project (2011ZX09307 001 04) (K. Chen).The genomic studies were
   supported by Dr. Wei Zhang (wzhang@mdanderson.org) and the Cancer
   Genomics Core Laboratory. We would like to thank Limei Hu and David
   Cogdell for performing the aCGH experiments.
CR Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362
   Boussen H, 2000, B CANCER, V87, P183
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106
   Daino K, 2009, INT J CANCER, V125, P612, DOI 10.1002/ijc.24392
   De Blasio A, 2005, FEBS LETT, V579, P615, DOI 10.1016/j.febslet.2004.12.028
   Gazitt Y, 2009, INT J ONCOL, V34, P551, DOI 10.3892/ijo_00000181
   Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200
   Gu YJ, 2013, TUMOR BIOL, V34, P1441, DOI 10.1007/s13277 013 0647 9
   Iwaya K, 2003, CLIN EXP METASTAS, V20, P525, DOI 10.1023/A:1025821229013
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 4 r36
   Kresse SH, 2009, GENE CHROMOSOME CANC, V48, P679, DOI 10.1002/gcc.20675
   Leow PC, 2010, INVEST NEW DRUG, V28, P766, DOI 10.1007/s10637 009 9311 z
   Liang S, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746 1596 8 138
   Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377
   MEYERS PA, 1992, J CLIN ONCOL, V10, P5, DOI 10.1200/JCO.1992.10.1.5
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008
   Picci P, 2010, ANN ONCOL, V21, P1366, DOI 10.1093/annonc/mdp502
   Squire JA, 2003, GENE CHROMOSOME CANC, V38, P215, DOI 10.1002/gcc.10273
   Takayama S, 2006, J BIOL CHEM, V281, P17856, DOI 10.1074/jbc.M602290200
   Thomas DM, 2010, J PATHOL, V220, P1, DOI 10.1002/path.2635
   Van Wieringen WN, 2008, BIOSTATISTICS, V9, P484, DOI 10.1093/biostatistics/kxm048
   Yang JL, 2011, CANCER AM CANCER SOC, V117, P4925, DOI 10.1002/cncr.26116
   Yang JL, 2010, CANCER LETT, V291, P31, DOI 10.1016/j.canlet.2009.09.018
NR 26
TC 46
Z9 51
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 18
PY 2014
VL 14
AR 450
DI 10.1186/1471 2407 14 450
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AK1HK
UT WOS:000338166000001
PM 24942472
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wei, CM
   Liu, Q
   Song, FM
   Lin, XX
   Su, YJ
   Xu, JK
   Huang, L
   Zong, SH
   Zhao, JM
AF Wei, Cheng Ming
   Liu, Qian
   Song, Fang Ming
   Lin, Xi Xi
   Su, Yi Ji
   Xu, Jiake
   Huang, Lin
   Zong, Shao Hui
   Zhao, Jin Min
TI Artesunate inhibits RANKL induced osteoclastogenesis and bone resorption
   in vitro and prevents LPS induced bone loss in vivo
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE Artesunate; lytic bone diseases; osteoclast; osteoclastogenesis
ID PARTICLE INDUCED OSTEOLYSIS; FACTOR KAPPA B; RECEPTOR ACTIVATOR;
   NUCLEAR FACTOR; DIFFERENTIATION; LIPOPOLYSACCHARIDE; CELLS;
   OSTEOPROTEGERIN; EXPRESSION; OSTEOBLAST
AB Osteoclasts are multinuclear giant cells responsible for bone resorption in lytic bone diseases such as osteoporosis, arthritis, periodontitis, and bone tumors. Due to the severe side effects caused by the currently available drugs, a continuous search for novel bone protective therapies is essential. Artesunate (Art), the water soluble derivative of artemisinin has been investigated owing to its anti malarial properties. However, its effects in osteoclastogenesis have not yet been reported. In this study, Art was shown to inhibit the nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis, the mRNA expression of osteoclastic specific genes, and resorption pit formation in a dose dependent manner in primary bone marrow derived macrophages cells (BMMs). Furthermore, Art markedly blocked the RANKL induced osteoclastogenesis by attenuating the degradation of IB and phosphorylation of NF kappa B p65. Consistent with the in vitro results, Art inhibited lipopolysaccharide (LPS) induced bone resorption by suppressing the osteoclastogenesis. Together our data demonstrated that Art inhibits RANKL induced osteoclastogenesis by suppressing the NF kappa B signaling pathway and that it is a promising agent for the treatment of osteolytic diseases.
C1 [Wei, Cheng Ming; Liu, Qian; Song, Fang Ming; Lin, Xi Xi; Xu, Jiake; Zong, Shao Hui; Zhao, Jin Min] Guangxi Med Univ, Res Ctr Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
   [Wei, Cheng Ming; Liu, Qian; Song, Fang Ming; Lin, Xi Xi; Xu, Jiake; Zong, Shao Hui; Zhao, Jin Min] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Wei, Cheng Ming; Liu, Qian; Zong, Shao Hui; Zhao, Jin Min] Guangxi Med Univ, Dept Orthopaed, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Wei, Cheng Ming; Su, Yi Ji; Zong, Shao Hui; Zhao, Jin Min] Guangxi Med Univ, Collaborat Innovat Ctr Guangxi Biol Med, Nanning, Peoples R China.
   [Su, Yi Ji] Guangxi Med Univ, Rehabil Dept, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA, Australia.
   [Huang, Lin] Sun Yat Sen Univ, Dept Spine Surg, Dept Orthoped, Res Ctr Spinal & Pelv Tumor,Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University; Guangxi Medical University;
   University of Western Australia; Sun Yat Sen University
RP Zong, SH; Zhao, JM (通讯作者)，Guangxi Med Univ, Res Ctr Regenerat Med, Nanning 530021, Guangxi, Peoples R China.; Huang, L (通讯作者)，Sun Yat Sen Univ, Dept Spine Surg, Dept Orthoped, Res Ctr Spinal & Pelv Tumor,Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China.; Zong, SH; Zhao, JM (通讯作者)，Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Dept Orthopaed, Affiliated Hosp 1,Collaborat Innovat Ctr Guangxi, Nanning 530021, Peoples R China.
EM drhuanglin@139.com; xiaohui3008@126.com; zhaojinmin@126.com
RI Huang, Lin/X 5137 2019; zhao, jin/LBH 0351 2024; xi, lin/JOK 1026 2023
OI Xu, Jiake/0000 0003 2021 8309; Zhao, Jinmin/0000 0002 1047 8820
FU China Postdoctoral Science Foundation Funded Project [2015M572421];
   Guangxi Natural Science Foundation [2015GXNSDA139019, 2015GXNSFCA414001]
FX China Postdoctoral Science Foundation Funded Project, Grant number:
   2015M572421; Guangxi Natural Science Foundation, Grant numbers:
   2015GXNSDA139019, 2015GXNSFCA414001
CR Adesoro O, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913 016 1811 x
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bruzzaniti A, 2006, REV ENDOCR METAB DIS, V7, P123, DOI 10.1007/s11154 006 9009 x
   Canivet C, 2015, ANTIVIR RES, V123, P105, DOI 10.1016/j.antiviral.2015.09.007
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Delaisse Jean Marie, 2014, Bonekey Rep, V3, P561, DOI 10.1038/bonekey.2014.56
   Dou C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.69
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Gignoux E, 2016, NEW ENGL J MED, V374, P23, DOI 10.1056/NEJMoa1504605
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Kefyalew T, 2016, MALARIA J, V15, DOI 10.1186/s12936 016 1561 6
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Thaler R, 2016, J BIOL CHEM, V291, P6754, DOI 10.1074/jbc.M115.678235
   Tian B, 2014, BIOMATERIALS, V35, P8937, DOI 10.1016/j.biomaterials.2014.06.055
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Wada N, 2004, BONE, V35, P629, DOI 10.1016/j.bone.2004.04.023
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang DW, 2010, METHODS MOL BIOL, V625, P41, DOI 10.1007/978 1 60761 579 8_5
   Zhang LX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164838
NR 35
TC 48
Z9 52
U1 0
U2 57
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JAN
PY 2018
VL 233
IS 1
BP 476
EP 485
DI 10.1002/jcp.25907
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FI3BF
UT WOS:000411829600041
PM 28294321
DA 2025 08 17
ER

PT J
AU Granchi, D
   Ochoa, G
   Leonardi, E
   Devescovi, V
   Bagliò, SR
   Osaba, L
   Baldini, N
   Ciapetti, G
AF Granchi, Donatella
   Ochoa, Gorka
   Leonardi, Elisa
   Devescovi, Valentina
   Baglio, Serena Rubina
   Osaba, Lourdes
   Baldini, Nicola
   Ciapetti, Gabriela
TI Gene Expression Patterns Related to Osteogenic Differentiation of Bone
   Marrow Derived Mesenchymal Stem Cells During Ex Vivo Expansion
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; STROMAL CELLS; PROLIFERATION; ANGIOGENESIS;
   RECEPTORS; PROTEINS; BETA; WNT
AB Bone marrow is commonly used as a source of adult multipotent mesenchymal stem cells (MSCs), defined for their ability to differentiate in vitro into multiple lineages. The ex vivo expanded MSCs are currently being evaluated as a strategy for the restoration of function in damaged skeletal tissue, both in cell therapy and tissue engineering applications. The aim of this study was to define gene expression patterns underlying the differentiation of MSCs into mature osteoblasts during the expansion in vitro, and to explore a variety of cell functions that cannot be easily evaluated using morphological, cytochemical, and biochemical assays. Cell cultures were obtained from bone marrow samples of six individuals undergoing total hip replacement, and a large scale transcriptome analysis, using Affymetrix HG U133A Plus 2.0 array (Affymetrix (R), Santa Clara, CA), was performed at the occurrence of specific events, including the appearance of MSC surface markers, formation of colonies, and deposition of mineral nodules. We focused our attention on 213 differentially upregulated genes, some belonging to well known pathways and some having one or more Gene Ontology annotations related to bone cell biology, including angiogenesis, bone related genes, cell communication, development and morphogenesis, transforming growth factor beta signaling, and Wnt signaling. Twenty nine genes, whose role in bone cell pathophysiology has not been described yet, were found. In conclusion, gene expression patterns that characterize the early, intermediate, and late phases of the osteogenic differentiation process of ex vivo expanded MSCs were defined. These signatures represent a useful tool to monitor the osteogenic process, and to analyze a broad spectrum of functions of MSCs cultured on scaffolds, especially when the constructs are conceived for releasing growth factors or other signals to promote bone regeneration.
C1 [Granchi, Donatella; Ochoa, Gorka; Leonardi, Elisa; Devescovi, Valentina; Baglio, Serena Rubina; Baldini, Nicola; Ciapetti, Gabriela] Rizzoll Orthopaed Inst, Lab Orthopaed Pathophysiol & Regenerat Med, I 40136 Bologna, Italy.
   [Osaba, Lourdes] Progenika Biopharma SA, Derio, Spain.
C3 IRCCS Istituto Ortopedico Rizzoli; Grifols
RP Granchi, D (通讯作者)，Rizzoll Orthopaed Inst, Lab Orthopaed Pathophysiol & Regenerat Med, Via Barbiano 1 10, I 40136 Bologna, Italy.
EM donatella.granchi.@ior.it
RI ; Ciapetti, Gabriela/C 6970 2019; Granchi, Donatella/J 3647 2016;
   Baldini, Nicola/J 4806 2016
OI Ciapetti, Gabriela/0000 0001 6740 0357; Baglio, Serena
   Rubina/0000 0003 0503 8908; Granchi, Donatella/0000 0001 7225 0023; ,
   Lourdes Osaba/0009 0004 6690 2266; Baldini, Nicola/0000 0003 2228 3833
FU Sixth Framework European RD Program [NMP3 CT 2005 516943]
FX This work is part of the NANOBIOCOM project supported by the Sixth
   Framework European R&D Program (Project no. NMP3 CT 2005 516943). The
   authors acknowledge Mr. K. Smith for his assistance in the editorial
   management of the article.
CR Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008 5472.CAN 04 0496
   Asaumi K, 2000, BONE, V26, P625, DOI 10.1016/S8756 3282(00)00281 7
   Barrell D, 2009, NUCLEIC ACIDS RES, V37, pD396, DOI 10.1093/nar/gkn803
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Brooke G, 2007, SEMIN CELL DEV BIOL, V18, P846, DOI 10.1016/j.semcdb.2007.09.012
   Ciapetti G, 2006, BIOMATERIALS, V27, P6150, DOI 10.1016/j.biomaterials.2006.08.025
   Dawson JI, 2008, ARCH BIOCHEM BIOPHYS, V473, P124, DOI 10.1016/j.abb.2008.03.024
   Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545
   Deutsch D, 2002, CONNECT TISSUE RES, V43, P425, DOI 10.1080/03008200290001186
   Di Cesare PE, 2000, J ORTHOPAED RES, V18, P713, DOI 10.1002/jor.1100180506
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Foster LJ, 2005, STEM CELLS, V23, P1367, DOI 10.1634/stemcells.2004 0372
   Govoni KE, 2006, AM J PHYSIOL ENDOC M, V291, pE128, DOI 10.1152/ajpendo.00592.2005
   Granchi D, 2008, INT J CANCER, V123, P1526, DOI 10.1002/ijc.23654
   Grundberg E, 2008, PHYSIOL GENOMICS, V33, P301, DOI 10.1152/physiolgenomics.00028.2008
   Ho NC, 2000, J BONE MINER RES, V15, P2095, DOI 10.1359/jbmr.2000.15.11.2095
   Hopwood B, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2301
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Hurson CJ, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 12
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001
   Kim SJ, 2007, GROWTH FACTORS, V25, P77, DOI 10.1080/08977190701398977
   Kronenberg HM, 2007, ANN NY ACAD SCI, V1116, P59, DOI 10.1196/annals.1402.059
   Kudo Y, 2007, HISTOL HISTOPATHOL, V22, P1167, DOI 10.14670/HH 22.1167
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Lægreid A, 2003, GENOME RES, V13, P965, DOI 10.1101/gr.1144503
   Loes S, 2001, MECH DEVELOP, V101, P191, DOI 10.1016/S0925 4773(00)00545 1
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100
   Rockett JC, 2004, GENOMICS, V83, P541, DOI 10.1016/j.ygeno.2003.09.017
   Rosen V, 2006, ANN NY ACAD SCI, V1068, P19, DOI 10.1196/annals.1346.005
   Salomonis N, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471 2105 8 217
   Stains JP, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 7 222
   Turner CH, 2002, CALCIFIED TISSUE INT, V70, P435, DOI 10.1007/s00223 001 1024 z
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   WALCHLI C, 1994, J CELL SCI, V107, P669
   Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007 0226
NR 40
TC 66
Z9 70
U1 1
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD JUN
PY 2010
VL 16
IS 3
BP 511
EP 524
DI 10.1089/ten.tec.2009.0405
PG 14
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 601SJ
UT WOS:000278083900021
PM 19686055
DA 2025 08 17
ER

PT J
AU Morimoto, T
   Kaito, T
   Kashii, M
   Matsuo, Y
   Sugiura, T
   Iwasaki, M
   Yoshikawa, H
AF Morimoto, Tokimitsu
   Kaito, Takashi
   Kashii, Masafumi
   Matsuo, Yohei
   Sugiura, Tsuyoshi
   Iwasaki, Motoki
   Yoshikawa, Hideki
TI Effect of Intermittent Administration of Teriparatide (Parathyroid
   Hormone 1 34) on Bone Morphogenetic Protein Induced Bone Formation in a
   Rat Model of Spinal Fusion
SO JOURNAL OF BONE AND JOINT SURGERY AMERICAN VOLUME
LA English
DT Article
ID ANTERIOR CERVICAL SPINE; POSTMENOPAUSAL WOMEN; ANABOLIC THERAPIES;
   IN VIVO; CELLS; OSTEOPOROSIS; COMPLICATIONS; ENHANCEMENT; MECHANISMS;
   DENSITY
AB Background: Although clinical bone morphogenetic protein (BMP) therapy is effective at enhancing bone formation in patients managed with spinal arthrodesis, the required doses are very high. Teriparatide (parathyroid hormone 1 34) is approved by the U.S. Food and Drug Administration to treat osteoporosis and is a potent anabolic agent. In this study, intermittent administration of parathyroid hormone 1 34 combined with transplantation of BMP was performed to elucidate the effect of parathyroid hormone 1 34 on the fusion rate and quality of newly formed bone in a rat model.
   Methods: A total of forty eight male Sprague Dawley rats underwent posterolateral lumbar spinal arthrodesis with one of three different treatments with recombinant human (rh) BMP 2: (1) 0 mu g (control), (2) 2 mu g (low dose), or (3) 50 mu g (high dose). Each of the rhBMP 2 treatments was studied in combination with intermittent injections of either parathyroid hormone 1 34 (180 mu g/kg/wk) or saline solution starting two weeks before the operation and continuing until six weeks after the operation. Osseous fusion was assessed with use of radiographs and a manual palpation test. Microstructural indices of the newly formed bone were evaluated with use of micro computed tomography. The serum markers of bone metabolism were also quantified.
   Results: The fusion rate in the group treated with 2 mg of rhBMP 2 significantly increased (from 57% to 100%) with the administration of parathyroid hormone 1 34 (p < 0.05). The fusion rates in the other groups did not change significantly with the administration of parathyroid hormone 1 34. The bone volume density of the newly formed bone significantly increased in both the 2 mu g and 50 mu g rhBMP 2 treatment groups with the administration of parathyroid hormone 1 34 (p < 0.01). Micro computed tomography scans of the newly formed bone clearly demonstrated an abundance of trabecular bone formation in the group treated with parathyroid hormone 1 34. In addition, serumlevels of osteocalcin were significantly increased in the parathyroid hormone 1 34 treatment group.
   Conclusions: Intermittent administration of parathyroid hormone 1 34 significantly increased fusion rates in the group treated with low dose rhBMP 2, and it improved the quality of the newly formed bone in both the high and low dose groups in a rat model of rhBMP 2 induced spinal fusion.
C1 [Morimoto, Tokimitsu; Kaito, Takashi; Kashii, Masafumi; Iwasaki, Motoki; Yoshikawa, Hideki] Osaka Univ, Grad Sch Med, Dept Orthoped Surg, Suita, Osaka 5650871, Japan.
   [Matsuo, Yohei; Sugiura, Tsuyoshi] Osaka Univ, Grad Sch Med, Dept Orthoped Biomat Sci, Suita, Osaka 5650871, Japan.
C3 University of Osaka; University of Osaka
RP Morimoto, T (通讯作者)，Osaka Univ, Grad Sch Med, Dept Orthoped Surg, 2 1 Yamadaoka, Suita, Osaka 5650871, Japan.
EM takashikaito@gmail.com
RI Kashii, Masafumi/AAV 7959 2021; Kaito, Takashi/AAJ 3892 2020
OI Kashii, Masafumi/0000 0002 7552 0356; 
CR Abe Y, 2007, BONE, V41, P775, DOI 10.1016/j.bone.2007.06.025
   Arrington ED, 1996, CLIN ORTHOP RELAT R, P300, DOI 10.1097/00003086 199608000 00037
   BODEN SD, 1995, SPINE, V20, P412, DOI 10.1097/00007632 199502001 00003
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Canalis E, 2010, J CLIN ENDOCR METAB, V95, P1496, DOI 10.1210/jc.2009 2677
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   Drake MT, 2011, BONE, V49, P349, DOI 10.1016/j.bone.2011.05.003
   Hernández A, 2012, J BIOMED MATER RES A, V100A, P2382, DOI 10.1002/jbm.a.34183
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kempen DHR, 2010, TISSUE ENG PT A, V16, P3769, DOI [10.1089/ten.tea.2010.0173, 10.1089/ten.TEA.2010.0173]
   Komatsubara S, 2005, BONE, V36, P678, DOI 10.1016/j.bone.2005.02.002
   Ming N, 2012, SPINE, V37, P1275, DOI 10.1097/BRS.0b013e31824ac089
   Miyazaki M, 2009, SPINE J, V9, P22, DOI 10.1016/j.spinee.2008.08.009
   Morgan EF, 2008, BONE, V43, P1031, DOI 10.1016/j.bone.2008.07.251
   Nakao Y, 2009, BONE, V44, P872, DOI 10.1016/j.bone.2009.01.370
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Robertson PA, 2001, SPINE, V26, P1473, DOI 10.1097/00007632 200107010 00018
   Seebach C, 2004, J ORTHOP RES, V22, P472, DOI 10.1016/j.orthers.2003.08.018
   Shields LBE, 2006, SPINE, V31, P542, DOI 10.1097/01.brs.0000201424.27509.72
   Smucker JD, 2006, SPINE, V31, P2813, DOI 10.1097/01.brs.0000245863.52371.c2
   STEINMANN JC, 1992, CLIN ORTHOP RELAT R, P80
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Takase H, 2009, HORM METAB RES, V41, P861, DOI 10.1055/s 0029 1233460
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   Tsiridis E, 2007, J ORTHOP RES, V25, P1193, DOI 10.1002/jor.20420
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   Wang JC, 2003, J BONE JOINT SURG AM, V85A, P905, DOI 10.2106/00004623 200305000 00020
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Yu B, 2012, J BONE MINER RES, V27, P2001, DOI 10.1002/jbmr.1663
   Zara JN, 2011, TISSUE ENG PT A, V17, P1389, DOI [10.1089/ten.TEA.2010.0555, 10.1089/ten.tea.2010.0555]
   ZDEBLICK TA, 1993, SPINE, V18, P983, DOI 10.1097/00007632 199306150 00006
NR 34
TC 42
Z9 49
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0021 9355
EI 1535 1386
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg. Am. Vol.
PD JUL 2
PY 2014
VL 96A
IS 13
AR e107
DI 10.2106/JBJS.M.01097
PG 8
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA AR8AT
UT WOS:000343798700002
PM 24990981
DA 2025 08 17
ER

PT J
AU Fang, K
   Murakami, Y
   Kanda, S
   Shimono, T
   Dang, AT
   Ono, M
   Nishiyama, T
AF Fang, Ke
   Murakami, Yuki
   Kanda, Seiji
   Shimono, Takaki
   Anh Tuan Dang
   Ono, Mitsuaki
   Nishiyama, Toshimasa
TI Unkeito Suppresses RANKL Mediated Osteoclastogenesis via the Blimp1 Bcl6
   and NF κB Signaling Pathways and Enhancing Osteoclast Apoptosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoporosis; postmenopause; NFATc1; p65; caspase 3; Unkeito
ID BONE RESORPTION; DIFFERENTIATION; OSTEOPOROSIS; INDUCTION
AB Osteoporosis is a common bone disease, particularly in menopausal women. Herein, we screened four Kampo medicines (Unkeito (UKT), Kamishoyosan (KSS), Kamikihito (KKT), and Ninjinyoeito (NYT)), frequently used to treat menopausal syndromes, for their effects on receptor activator of nuclear factor kappaB ligand (RANKL) induced osteoclast differentiation in RAW 264 cells. Considering that UKT exhibited the most potent effect, we examined its effect on RANKL induced osteoclastogenesis, the induction of osteoclast apoptosis, and the mechanisms underlying its effects. UKT inhibits RANKL induced osteoclast differentiation in the early stage and decreases osteoclast related genes, including tartrate resistant acid phosphatase (Trap), dendritic cell specific transmembrane protein (Dcstamp), matrix metalloproteinase 9 (Mmp9), and cathepsin K (Ctsk). Specifically, UKT inhibits the nuclear factor of activated T cells 1 (NFATc1), which is essential for osteoclastogenesis. UKT increases Bcl6, which antagonizes NFATc1 and Dc stamp, thereby blocking the progression of osteoclasts to maturation. UKT also decreased nuclear translocation by downregulating the activity of p65/NF kappa B. In addition, UKT enhances mononuclear osteoclast apoptosis via activation of caspase 3. Herein, we demonstrate that UKT suppresses RANKL mediated osteoclastogenesis via the Blimp1 Bcl6 and NF kappa B signaling pathways and enhances mononuclear osteoclast apoptosis. Furthermore, UKT prevents bone loss in OVX mice. Thus, UKT might be a potential therapeutic agent for postmenopausal osteoporosis.
C1 [Fang, Ke; Murakami, Yuki; Kanda, Seiji; Shimono, Takaki; Nishiyama, Toshimasa] Kansai Med Univ, Dept Hyg & Publ Hlth, 2 5 1 Shin Machi, Hirakata, Osaka 5731010, Japan.
   [Murakami, Yuki; Kanda, Seiji; Shimono, Takaki] Kansai Med Univ, Regenerat Res Ctr Intractable Dis, 2 5 1 Shin Machi, Hirakata, Osaka 5731010, Japan.
   [Anh Tuan Dang; Ono, Mitsuaki] Okayama Univ, Dept Mol Biol & Biochem, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008558, Japan.
   [Anh Tuan Dang] Okayama Univ, Dept Oral Rehabil & Regenerat Med, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008558, Japan.
   [Ono, Mitsuaki] Okayama Univ Hosp, Dept Oral Rehabil & Implantol, Okayama 7008558, Japan.
C3 Kansai Medical University; Kansai Medical University; Okayama
   University; Okayama University; Okayama University
RP Kanda, S (通讯作者)，Kansai Med Univ, Dept Hyg & Publ Hlth, 2 5 1 Shin Machi, Hirakata, Osaka 5731010, Japan.; Kanda, S (通讯作者)，Kansai Med Univ, Regenerat Res Ctr Intractable Dis, 2 5 1 Shin Machi, Hirakata, Osaka 5731010, Japan.
EM houka@hirakata.kmu.ac.jp; murakamy@hirakata.kmu.ac.jp;
   kandas@hirakata.kmu.ac.jp; shimonot@hirakata.kmu.ac.jp;
   ppjj5xuj@s.okayama u.ac.jp; mitsuaki@md.okayama u.ac.jp;
   tnishi@hirakata.kmu.ac.jp
RI ; é–å£«, ç¥žç”°/R 2920 2019; Murakami, Yuki/JUF 3086 2023
OI Fang, Ke/0000 0002 7390 8488; 
FU Kansai Medical University Molecular Imaging Center of Diseases
FX This research was funded by Kansai Medical University Molecular Imaging
   Center of Diseases.
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Crowley Lisa C, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot087312
   Fukuma Y, 2018, CLIN EXP PHARMACOL P, V45, P863, DOI 10.1111/1440 1681.12941
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Hidaka S, 1997, CALCIFIED TISSUE INT, V61, P239, DOI 10.1007/s002239900329
   Inui T, 1999, BIOCHEM BIOPH RES CO, V258, P173, DOI 10.1006/bbrc.1999.0473
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Katao Y, 2011, ORTHOD WAVES, V70, P8, DOI 10.1016/j.odw.2010.07.002
   Kim HH, 2003, EXP CELL RES, V289, P368, DOI 10.1016/S0014 4827(03)00288 X
   Kulak J, 2010, ARQ BRAS ENDOCRINOL, V54, P200, DOI 10.1590/S0004 27302010000200016
   Kuo YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040272
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Ma QY, 2020, THERANOSTICS, V10, P6825, DOI 10.7150/thno.45170
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Nishikaw K, 2010, P NATL ACAD SCI USA, V107, P3117, DOI 10.1073/pnas.0912779107
   Nomiyama H, 2005, J INTERF CYTOK RES, V25, P227, DOI 10.1089/jir.2005.25.227
   Park SJ, 2016, SCI REP UK, V6, DOI 10.1038/srep26186
   Saitoh Y, 2007, BIOCHEM BIOPH RES CO, V364, P417, DOI 10.1016/j.bbrc.2007.09.137
   Siris ES, 2006, OSTEOPOROSIS INT, V17, P565, DOI 10.1007/s00198 005 0027 4
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanaka S, 2010, ADV EXP MED BIOL, V658, P111, DOI 10.1007/978 1 4419 1050 9_12
   van't Hof RJ, 2017, BONE, V99, P69, DOI 10.1016/j.bone.2017.03.051
   Wang JQ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4690504
   Wang Yanmao, 2018, Oncotarget, V9, P7372, DOI 10.18632/oncotarget.23677
   Wang ZY, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2170 4
NR 33
TC 10
Z9 10
U1 0
U2 5
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2022
VL 23
IS 14
AR 7814
DI 10.3390/ijms23147814
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 3J0TP
UT WOS:000833117800001
PM 35887169
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kim, B
   Lee, KY
   Park, B
AF Kim, Buyun
   Lee, Ki Yong
   Park, Byoungduck
TI Icariin abrogates osteoclast formation through the regulation of the
   RANKL mediated TRAF6/NF κB/ERK signaling pathway in Raw264.7 cells
SO PHYTOMEDICINE
LA English
DT Article
DE Icariin; Osteoclast; RANKL; TRAF6; NF kappa B; RAW264.7
ID BONE RESORPTION; CANCER; DIFFERENTIATION; INHIBITION; ACTIVATION;
   OSTEOPOROSIS; EXPRESSION
AB Background: Icariin is pharmacologically active prenylated flavonoid glycoside that has various biologic effects such as antioxidant, anticancer, and anti inflammatory activities. In addition, icariin has been used in Chinese medicine for thousands of years to treat osteoporosis and it is still being used today. However, direct mechanism of icariin in the treatment of bone disease is not understood.
   Purpose: The purpose of this study is to investigate whether icariin influences RANKL induced osteoclast formation in murine macrophages.
   Methods: Osteoclastogenesis was determined by TRAP staining and activity assay. Inhibition of signaling pathways and marker protein expression were evaluated by western blot analysis. The NF kappa B (p65) nuclear localization was detected by immunofluorescence assay, and NF kappa B/DNA binding activity was detected by electrophoretic mobility shift assay (EMSA).
   Results: In our study, icariin inhibited the differentiation of pre osteoclast cells into osteoclasts and suppressed expression of various genes involved in osteoclast formation and bone resorption. Also, icariin blocked the osteoclastogenesis induced by MCF7 and MDA MB 231 breast cancer cells through inhibition of NF kappa B activation. We found that icariin inhibited RANKL stimulated TRAF 6 expression, and subsequently suppressed the phosphorylation of ERK, but icariin did not show an effect on p38, JNK, and Akt activation.
   Conclusion: These results indicate that icariin is likely to be a candidate for bone related disease treatment and that icariin provides insights into the molecular mechanisms that influence RANKL induced osteoclast differentiation.
C1 [Kim, Buyun; Park, Byoungduck] Keimyung Univ, Coll Pharm, 1095 Dalgubeoldaero, Daegu 704701, South Korea.
   [Lee, Ki Yong] Korea Univ, Coll Pharm, Sejong Campus 2511 Sejong Ro, Sejong City 339770, South Korea.
C3 Keimyung University; Korea University
RP Park, B (通讯作者)，Keimyung Univ, Coll Pharm, 1095 Dalgubeoldaero, Daegu 704701, South Korea.; Lee, KY (通讯作者)，Korea Univ, Coll Pharm, Sejong Campus 2511 Sejong Ro, Sejong City 339770, South Korea.
EM kylee11@korea.ac.kr; bdpark@kmu.ac.kr
RI Lee, Ki Yong/IAM 7502 2023
OI Lee, Ki Yong/0000 0002 6191 4485
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [NRF 2016R1A6A1A03011325];
   Ministry of Science, ICT & Future Planning [NRF 2016R1A1A1A05921696];
   National Research Foundation of Korea   Korean Government
   [NRF 2014R1A4A1007304]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education(NRF 2016R1A6A1A03011325), and by the Ministry of Science,
   ICT & Future Planning (NRF 2016R1A1A1A05921696). And this work was also
   supported by a National Research Foundation of Korea grant funded by the
   Korean Government (NRF 2014R1A4A1007304).
CR Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Chikatsu N, 2000, BIOCHEM BIOPH RES CO, V267, P632, DOI 10.1006/bbrc.1999.2008
   Choi YH, 2011, BIOCHEM BIOPH RES CO, V411, P637, DOI 10.1016/j.bbrc.2011.07.009
   Cicek M, 2007, CANCER RES, V67, P10106, DOI 10.1158/0008 5472.CAN 07 1362
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Guo C, 2012, CELL PHYSIOL BIOCHEM, V30, P123, DOI 10.1159/000339052
   Guo J, 2010, PHYTOMEDICINE, V17, P950, DOI 10.1016/j.phymed.2010.03.007
   Hayman AR, 2000, J HISTOCHEM CYTOCHEM, V48, P219, DOI 10.1177/002215540004800207
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Hwang SY, 2012, FASEB J, V26, P1484, DOI 10.1096/fj.11 194399
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023
   Kim DK, 2017, MOLECULES, V22, DOI 10.3390/molecules22010122
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Li SG, 2010, CANCER LETT, V298, P222, DOI 10.1016/j.canlet.2010.07.009
   Li X, 2013, FEBS LETT, V587, P3236, DOI 10.1016/j.febslet.2013.08.017
   Mei QG, 2015, BEILSTEIN J ORG CHEM, V11, DOI 10.3762/bjoc.11.135
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Park B, 2014, BIOCHIMIE, V105, P129, DOI 10.1016/j.biochi.2014.07.003
   Pengjam Y, 2016, PHYTOMEDICINE, V23, P417, DOI 10.1016/j.phymed.2016.01.006
   Poblenz AT, 2007, BIOCHEM BIOPH RES CO, V359, P510, DOI 10.1016/j.bbrc.2007.05.151
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Sze SCW, 2010, MOLECULES, V15, P7861, DOI 10.3390/molecules15117861
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Ubellacker JM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058 017 0815 8
   Yao C, 2017, INT J MOL MED, V40, P1067, DOI 10.3892/ijmm.2017.3091
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Zha L, 2018, BIOMED PHARMACOTHER, V102, P369, DOI 10.1016/j.biopha.2018.03.080
   Zhou JM, 2011, INT IMMUNOPHARMACOL, V11, P890, DOI 10.1016/j.intimp.2011.01.007
NR 36
TC 81
Z9 89
U1 1
U2 71
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0944 7113
J9 PHYTOMEDICINE
JI Phytomedicine
PD DEC 1
PY 2018
VL 51
BP 181
EP 190
DI 10.1016/j.phymed.2018.06.020
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA HB9UH
UT WOS:000451438300020
PM 30466615
DA 2025 08 17
ER

PT J
AU Huong, L
   Gal, M
   Kim, O
   Tran, PT
   Nhiem, NX
   Kiem, PV
   Minh, CV
   Dang, NH
   Lee, JH
AF Huong, Le Thanh
   Gal, Minju
   Kim, Okwha
   Tran, Phuong Thao
   Nhiem, Nguyen Xuan
   Kiem, Phan Van
   Minh, Chau Van
   Dang, Nguyen Hai
   Lee, Jeong Hyung
TI 23 Hydroxyursolic acid from Viburnum lutescens inhibits
   osteoclast differentiation in vitro and
   lipopolysaccharide induced bone loss in vivo by suppressing c Fos
   and NF κB signalling
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE 23 Hydroxyursolic acid; Viburnum lutescens Blume; Anti osteoclastogenic
   effect; Osteoclastogenesis
ID URSOLIC ACID; EXPRESSION; PROLIFERATION; TRAF6
AB Bone homeostasis is maintained by a combination of osteoclast mediated bone resorption and osteoblastmediated bone formation. Excessive osteoclast activity is linked to several bone related disorders, including osteoporosis and rheumatoid arthritis. Pharmacological therapy might have a number of adverse effects. Therefore, the development of natural anti osteoclastogenic drugs with greater efficacy and fewer adverse effects is desirable. In this study, the anti osteoclastogenic effects of 23 hydroxyursolic acid (HUA), a triterpene isolated from Viburnum lutescens, were investigated in vitro and in vivo. HUA significantly inhibited receptor activator of nuclear factor kappa B ligand (RANKL) induced mature osteoclast differentiation by reducing the number of tartrate resistant acid phosphatase (TRAP) positive osteoclasts and F actin ring formation. It also inhibited the expression of osteoclast specific marker genes such OSCAR, MMP 9, TRAP, DC STAMP, and CtsK, as well as transcription factors, c Fos and nuclear factor of activated T cells cytoplasmic 1 (NFATc1) in response to RANKL. Mice orally administered with HUA (25 and 50 mg/kg) exhibited significant protection against bone loss and osteoclast formation induced by lipopolysaccharide (LPS). HUA suppressed RANKL induced nuclear factor kappa B (NF kappa B) activation and phosphorylation of JNK and ERK mitogen activated protein kinases (MAPKs). These results suggest that HUA attenuates osteoclast formation in vitro and in vivo by suppressing the RANKL mediated AP1, NF kappa B, and NFATc1 pathways. Therefore, HUA may be a lead compound for the prevention or treatment of osteolytic bone disorders.
C1 [Huong, Le Thanh; Dang, Nguyen Hai] Vietnam Acad Sci & Technol, Univ Sci & Technol Hanoi, 18 Hoang Quoc Viet, Hanoi, Vietnam.
   [Gal, Minju; Tran, Phuong Thao; Lee, Jeong Hyung] Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 24341, Gangwon Do, South Korea.
   [Kim, Okwha; Lee, Jeong Hyung] Kangwon Natl Univ, Kangwon Inst Inclus Technol, Chunchon 24341, Gangwon Do, South Korea.
   [Nhiem, Nguyen Xuan; Kiem, Phan Van; Minh, Chau Van] Vietnam Acad Sci & Technol, Inst Marine Biochem, 18 Hoang Quoc Viet, Hanoi, Vietnam.
C3 Vietnam Academy of Science & Technology (VAST); University of Science &
   Technology of Hanoi (USTH); Kangwon National University; Kangwon
   National University; Vietnam Academy of Science & Technology (VAST)
RP Dang, NH (通讯作者)，Vietnam Acad Sci & Technol, Univ Sci & Technol Hanoi, 18 Hoang Quoc Viet, Hanoi, Vietnam.; Lee, JH (通讯作者)，Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 24341, Gangwon Do, South Korea.
EM nguyen hai.dang@usth.edu.vn; jhlee36@kangwon.ac.kr
OI Nguyen, Hai Dang/0000 0002 4470 8321
FU National Research Foundation (NRF) of Korea [NRF 2020R1A5A8019180];
   Vietnam Academy of Science and Technology [KHCBHH.02/19  21]
FX This research was supported by the grants from the National Research
   Foundation (NRF) of Korea (NRF 2020R1A5A8019180) and from Vietnam
   Academy of Science and Technology (KHCBHH.02/19  21) .
CR Adamopoulos IE, 2018, CURR OPIN RHEUMATOL, V30, P59, DOI 10.1097/BOR.0000000000000449
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Dang NH, 2021, PHYTOCHEM LETT, V45, P13, DOI 10.1016/j.phytol.2021.07.006
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Jiang C, 2015, BIOCHIMIE, V111, P107, DOI 10.1016/j.biochi.2015.02.002
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Lee SU, 2008, PHARMACOL RES, V58, P290, DOI 10.1016/j.phrs.2008.08.008
   Logar DB, 2007, J BONE MINER METAB, V25, P219, DOI 10.1007/s00774 007 0753 0
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Peng MZ, 2019, NITRIC OXIDE BIOL CH, V82, P12, DOI 10.1016/j.niox.2018.11.002
   Tran PT, 2019, PHYTOMEDICINE, V55, P1, DOI 10.1016/j.phymed.2018.10.029
   Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414
   Sethi G, 2007, CHEM BIOL, V14, P738, DOI 10.1016/j.chembiol.2007.07.002
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2007, J BIOL CHEM, V282, P18980, DOI 10.1074/jbc.M610938200
   Tan H, 2015, PHYTOMEDICINE, V22, P498, DOI 10.1016/j.phymed.2015.03.002
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Vu TO, 2021, J NAT MED TOKYO, V75, P56, DOI 10.1007/s11418 020 01444 3
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Yu WF, 2012, J BIOL CHEM, V287, P13694, DOI 10.1074/jbc.M112.355610
NR 31
TC 9
Z9 9
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD OCT
PY 2022
VL 111
AR 109038
DI 10.1016/j.intimp.2022.109038
EA AUG 2022
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 3X3ZW
UT WOS:000842983100002
PM 35932612
DA 2025 08 17
ER

PT J
AU Cui, ZC
   Feng, CG
   Chen, JZ
   Wang, Y
   Meng, Q
   Zhao, SH
   Zhang, YJ
   Feng, DJ
   Li, ZQ
   Sun, S
AF Cui, Zichen
   Feng, Changgong
   Chen, Jiazheng
   Wang, Yi
   Meng, Qi
   Zhao, Shihao
   Zhang, Yuanji
   Feng, Dianjie
   Li, Ziqing
   Sun, Shui
TI Network Pharmacology Deciphers the Action of Bioactive Polypeptide in
   Attenuating Inflammatory Osteolysis via the Suppression of Oxidative
   Stress and Restoration of Bone Remodeling Balance
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; N ACETYLCYSTEINE; REDOX REGULATION; CYCLIC
   PEPTIDE; APOPTOSIS; OSTEONECROSIS; AFFINITY; PATHWAY; CELLS; JNK
AB Oxidative stress involves enormously in the development of chronic inflammatory bone disease, wherein the overproduction of reactive oxygen species (ROS) negatively impacts the bone remodeling via promoting osteoclastogenesis and inhibiting osteogenesis. Lacking effective therapies highlights the importance of finding novel treatments. Our previous study screened a novel bioactive peptide D7 and demonstrated it could enhance the cell behaviors and protect bone marrow mesenchymal stem cells (BMSCs). Since BMSCs are progenitor cells of osteoblast (OB), we therefore ask whether D7 could also protect against the progress of inflammatory osteolysis. To validate our hypothesis and elucidate the underlying mechanisms, we first performed network pharmacology based analysis according to the molecule structure of D7, and then followed by pharmacological evaluation on D7 by in vitro lipopolysaccharide(LPS) induced models. The result from network pharmacology identified 20 candidate targets of D7 for inflammatory osteolysis intervention. The further analysis of Gene Ontology (GO)/KEGG pathway enrichment suggested the therapeutic effect of D7 may primarily affect osteoclast (OC) differentiation and function during the inflammatory osteolysis. Through validating the real effects of D7 on OC and OB as postulated, results demonstrated suppressive effects of D7 on LPS stimulated OC differentiation and resorption, via the inhibition on OC marker genes. Contrarily, by improving the expression of OB marker genes, D7 displayed promotive effects on OB differentiation and alleviated LPS induced osteogenic damage. Further mechanism study revealed that D7 could reduce LPS induced ROS formation and strengthen antioxidants expressions in both OC and OB precursors, ameliorating LPS triggered redox imbalance in bone remodeling. Taken together, our findings unveiled therapeutic effects of D7 against LPS induced inflammatory osteolysis through the suppression of oxidative stress and the restoration of the bone remodeling process, providing a new therapeutic candidate for chronic inflammatory bone diseases.
C1 [Cui, Zichen; Feng, Changgong; Li, Ziqing; Sun, Shui] Shandong First Med Univ, Dept Joint Surg, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China.
   [Cui, Zichen; Feng, Changgong; Li, Ziqing; Sun, Shui] Shandong First Med Univ, Shandong Acad Med Sci, Med Sci & Technol Innovat Ctr, Orthopaed Res Lab, Jinan 250117, Shandong, Peoples R China.
   [Chen, Jiazheng; Wang, Yi; Meng, Qi; Zhao, Shihao; Zhang, Yuanji; Feng, Dianjie; Sun, Shui] Shandong Univ, Shandong Prov Hosp, Dept Joint Surg, Jinan 250012, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; University of Jinan; Shandong First Medical University &
   Shandong Academy of Medical Sciences; Shandong University; Shandong
   First Medical University & Shandong Academy of Medical Sciences
RP Li, ZQ; Sun, S (通讯作者)，Shandong First Med Univ, Dept Joint Surg, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China.; Li, ZQ; Sun, S (通讯作者)，Shandong First Med Univ, Shandong Acad Med Sci, Med Sci & Technol Innovat Ctr, Orthopaed Res Lab, Jinan 250117, Shandong, Peoples R China.; Sun, S (通讯作者)，Shandong Univ, Shandong Prov Hosp, Dept Joint Surg, Jinan 250012, Shandong, Peoples R China.
EM cuizichen292@163.com; 15588799523@163.com; doctorcjz@163.com;
   wangyi950524@163.com; mengqi10020728@163.com; zhaosh2766@163.com;
   zhangyuanji0211@163.com; dianjie1994@126.com; liziqing@sdfmu.edu.cn;
   sunshui@sdfmu.edu.cn
RI MENG, QI/KRO 4878 2024; zhang, yuanji/JDM 3113 2023; Li,
   Ziqing/GST 4574 2022
OI Li, Ziqing/0000 0003 3596 3520; sun, shui/0000 0002 9744 1595; feng,
   changgong/0000 0003 0707 7636; Chen, Jiazheng/0000 0001 8417 0661; 
FU National Natural Science Foundation of China [81972056, 82100936];
   Natural Science Foundation of Shandong Province [ZR2021QH077]
FX AcknowledgmentsThis work was supported by National Natural Science
   Foundation of China (nos. 81972056 and 82100936) and Natural Science
   Foundation of Shandong Province (no. ZR2021QH077).
CR Almeida M, 2013, J GERONTOL A BIOL, V68, P1197, DOI 10.1093/gerona/glt079
   Bardou P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 293
   Boyce BF, 2006, CURR OPIN RHEUMATOL, V18, P427, DOI 10.1097/01.bor.0000231913.32364.32
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chen K, 2020, INT J BIOL SCI, V16, P1888, DOI 10.7150/ijbs.40917
   Cheng MH, 2020, BIOMOL THER, V28, P104, DOI 10.4062/biomolther.2019.047
   Dai PP, 2017, CELL PHYSIOL BIOCHEM, V41, P661, DOI 10.1159/000457945
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Daliri EBM, 2018, CRIT REV FOOD SCI, V58, P2273, DOI 10.1080/10408398.2017.1319795
   Deng S, 2019, BIOMED PHARMACOTHER, V110, P602, DOI 10.1016/j.biopha.2018.11.103
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Duffy F, 2019, METHODS MOL BIOL, V2001, P73, DOI 10.1007/978 1 4939 9504 2_5
   Feno S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9324018
   Fontani F, 2015, CALCIFIED TISSUE INT, V96, P335, DOI 10.1007/s00223 015 9961 0
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gruber R, 2019, J CLIN PERIODONTOL, V46, P52, DOI 10.1111/jcpe.13056
   Guo C, 2014, INFLAMMATION, V37, P621, DOI 10.1007/s10753 013 9778 9
   Guo W, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01185
   Heller M, 2018, J BIOMED MATER RES A, V106, P419, DOI 10.1002/jbm.a.36255
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jo YJ, 2021, J CELL PHYSIOL, V236, P1854, DOI 10.1002/jcp.29968
   Jun JH, 2008, J CELL BIOCHEM, V103, P1246, DOI 10.1002/jcb.21508
   Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898 6568(98)00037 0
   Kim JH, 2019, INT J MOL MED, V44, P913, DOI 10.3892/ijmm.2019.4269
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li L, 2017, MOL MED REP, V16, P8055, DOI 10.3892/mmr.2017.7588
   Li ZQ, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779 020 00292 2
   Li ZQ, 2016, AM J PHYSIOL ENDOC M, V310, pE355, DOI 10.1152/ajpendo.00309.2015
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Ma J, 2018, MED SCI MONITOR, V24, P2045, DOI 10.12659/MSM.905703
   Man ZT, 2018, AM J TRANSL RES, V10, P2480
   MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696
   Ng AYH, 2019, ELIFE, V8, DOI 10.7554/eLife.42951
   Pierzynska Mach A, 2014, CYTOM PART A, V85A, P729, DOI 10.1002/cyto.a.22495
   Placha D, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010064
   Ramaraju H, 2017, BIOMATERIALS, V134, P1, DOI 10.1016/j.biomaterials.2017.04.034
   Romagnoli C, 2013, FEBS J, V280, P867, DOI 10.1111/febs.12075
   Roxin A, 2012, FUTURE MED CHEM, V4, P1601, DOI [10.4155/FMC.12.75, 10.4155/fmc.12.75]
   Rusetskaya NY, 2019, BIOCHEM MOSC SUPPL B, V13, P277, DOI 10.1134/S1990750819040085
   See EYS, 2010, TISSUE ENG PT A, V16, P1421, DOI 10.1089/ten.TEA.2009.0501
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580 020 0230 3
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Suh KS, 2018, CHEM BIOL INTERACT, V296, P18, DOI 10.1016/j.cbi.2018.09.005
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Wang GZ, 2021, AM J TRANSL RES, V13, P967
   Wang GZ, 2019, MOL MED REP, V19, P407, DOI 10.3892/mmr.2018.9626
   Wang HJ, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/9980127
   Wu ZX, 2019, J CELL PHYSIOL, V234, P17812, DOI 10.1002/jcp.28408
   Xiao Y, 1996, BIOPHYS J, V71, P2869, DOI 10.1016/S0006 3495(96)79484 5
   Xiao Y, 2018, INFLAMMATION, V41, P614, DOI 10.1007/s10753 017 0717 z
   Xin JX, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.806829
   Xu GP, 2021, BIOL TRACE ELEM RES, V199, P3781, DOI 10.1007/s12011 020 02508 x
   Yan GQ, 2020, INFLAMMATION, V43, P1279, DOI 10.1007/s10753 020 01207 y
NR 56
TC 11
Z9 12
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1942 0900
EI 1942 0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD APR 14
PY 2022
VL 2022
AR 4913534
DI 10.1155/2022/4913534
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 1I1UV
UT WOS:000797021900001
PM 35578727
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Jeong, DH
   Kwak, SC
   Lee, MS
   Yoon, KH
   Kim, JY
   Lee, CH
AF Jeong, Da Hye
   Kwak, Sung Chul
   Lee, Myeung Su
   Yoon, Kwon Ha
   Kim, Ju Young
   Lee, Chang Hoon
TI Betulinic Acid Inhibits RANKL Induced Osteoclastogenesis via Attenuating
   Akt, NF κB, and PLCγ2 Ca<SUP>2+</SUP> Signaling and Prevents
   Inflammatory Bone Loss
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID DIFFERENTIATION; RESORPTION
AB The increase of bone resorbing osteoclast activity in bone remodeling is the major characteristic of various bone diseases. Thus, inhibiting osteoclastogenesis and bone resorbing function may be an effective therapeutic target for bone diseases. Betulinic acid (BA), a natural plant derived pentacyclic triterpenoid compound, is known to possess numerous pharmacological and biochemical properties including anti inflammatory, anticancer, and antiadipogenic activity. However, the effect of BA on osteoclast differentiation and function in bone metabolism has not been demonstrated so far. In this study, we investigated whether BA could suppress RANKL induced osteoclastogenesis and bone resorption. Interestingly, BA significantly suppressed osteoclastogenesis by decreasing the phosphorylation of Akt and I kappa B, as well as PLC gamma 2 Ca2+ signaling, in pathways involved in early osteoclastogenesis as well as through the subsequent suppression of c Fos and NFATc1. The inhibition of these pathways by BA was once more confirmed by retrovirus infection of constitutively active (CA) Akt and CA Ikk beta retrovirus and measurement of Ca2+ influx. BA also significantly inhibited the expression of osteoclastogenesis specific marker genes. Moreover, we found that BA administration restored the bone loss induced through acute lipopolysaccharide injection in mice by a micro CT and histological analysis. Our findings suggest that BA is a potential therapeutic candidate for bone diseases involving osteoclasts.
C1 [Kim, Ju Young] Wonkwang Univ, Musculoskeletal & Immune Dis Res Inst, Sch Med, Iksan 54538, Jeonbuk, South Korea.
   [Yoon, Kwon Ha; Kim, Ju Young; Lee, Chang Hoon] Wonkwang Univ Hosp, Med Convergence Res Ctr, Iksan 54538, Jeonbuk, South Korea.
   [Jeong, Da Hye; Lee, Myeung Su; Lee, Chang Hoon] Wonkwang Univ, Sch Med, Div Rheumatol, Dept Internal Med, Iksan 54538, Jeonbuk, South Korea.
   [Kwak, Sung Chul] Wonkwang Univ, Sch Med, Dept Anat, Iksan 54538, Jeonbuk, South Korea.
   [Yoon, Kwon Ha] Wonkwang Univ, Sch Med, Dept Radiol, Iksan 54538, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University
RP Kim, JY (通讯作者)，Wonkwang Univ, Musculoskeletal & Immune Dis Res Inst, Sch Med, Iksan 54538, Jeonbuk, South Korea.; Kim, JY; Lee, CH (通讯作者)，Wonkwang Univ Hosp, Med Convergence Res Ctr, Iksan 54538, Jeonbuk, South Korea.; Lee, CH (通讯作者)，Wonkwang Univ, Sch Med, Div Rheumatol, Dept Internal Med, Iksan 54538, Jeonbuk, South Korea.
EM kimjy1014@gmail.com; lck110@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
FU Wonkwang University
FX This study was supported by Wonkwang University in 2019.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Baek JM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030581
   Bennett BD, 2001, ENDOCRINOLOGY, V142, P1968, DOI 10.1210/en.142.5.1968
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brusotti G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05666 6
   Cao HL, 2013, J BIOL CHEM, V288, P30399, DOI 10.1074/jbc.M113.469973
   Chintharlapalli S, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 371
   de Melo CL, 2009, J AGR FOOD CHEM, V57, P8776, DOI 10.1021/jf900768w
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Galgon T, 2005, EXP DERMATOL, V14, P736, DOI 10.1111/j.1600 0625.2005.00352.x
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hsu TI, 2012, MOL PHARMACOL, V82, P1115, DOI 10.1124/mol.112.078485
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kajiya H, 2012, ADV EXP MED BIOL, V740, P917, DOI 10.1007/978 94 007 2888 2_41
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kim KS, 2016, MOLECULES, V21, DOI 10.3390/molecules21091206
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Laavola M, 2016, J NAT PROD, V79, P274, DOI 10.1021/acs.jnatprod.5b00709
   Lingaraju MC, 2015, EUR J PHARM SCI, V70, P12, DOI 10.1016/j.ejps.2015.01.001
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang JB, 2015, INT IMMUNOPHARMACOL, V29, P687, DOI 10.1016/j.intimp.2015.09.009
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Zeng AQ, 2018, ONCOTARGET, V9, P3794, DOI 10.18632/oncotarget.23376
NR 36
TC 19
Z9 19
U1 1
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163 3864
EI 1520 6025
J9 J NAT PROD
JI J. Nat. Prod.
PD APR 24
PY 2020
VL 83
IS 4
BP 1174
EP 1182
DI 10.1021/acs.jnatprod.9b01212
PG 9
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy
GA LI0IJ
UT WOS:000529168400038
PM 32237724
OA Bronze
DA 2025 08 17
ER

PT J
AU Ding, XQ
   Yang, L
   Hu, Y
   Yu, JF
   Tang, Y
   Luo, D
   Zheng, LL
AF Ding, Xiaoqian
   Yang, Lan
   Hu, Yun
   Yu, Jinfeng
   Tang, Yu
   Luo, Dan
   Zheng, Leilei
TI Effect of local application of biphosphonates on improving peri implant
   osseointegration in type 2 diabetic osteoporosis
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Osteoporosis; type 2 diabetes mellitus; implant; bisphosphonates;
   osseointegration
ID BONE MINERAL DENSITY; DISTRACTION OSTEOGENESIS; ALENDRONATE;
   BISPHOSPHONATES; OSTEOBLAST; FIXATION; RISK; ZOLEDRONATE; MECHANISMS;
   DIFFERENTIATION
AB Type 2 diabetes mellitus (T2DM), a leading cause of osteoporosis, remains a contraindication for bone implant therapy. Although associated with side effects when systemically administered, biphosphonates (BPs) play a positive role in diabetic osteoporosis treatment. We hypothesized that local BP therapy would prevent decayed implant osseointegration under T2DM conditions. To assess cell proliferation and determine the optimal BP concentration, bone marrow derived mesenchymal stem cells (BMSCs) and bone marrow macrophages (BMMs) were treated with BPs at various relatively low concentrations (10( 9) mmol/L) for different periods of time. Our in vitro study results demonstrated that BP application reversed the process by which high glucose inhibits bone formation and stimulates bone resorption through osteoclast specific gene and protein expression (P<0.05). In vivo, fat accumulation and insulin resistance were induced in T2DM rats. We used crosslinked hyaluronic acid as the drug delivery vehicle for BPs to ensure that BPs administered at a dose of 30 mu g/kg could settle into the prepared hole in rats. Thereafter, implants were inserted into cylindrical holes of a specific size, created parallel to the long axis of the femora. The outcomes of the in vivo study revealed that BPs promoted bone formation, which reversed the reduction in the DM group according to double fluorescence labeling, micro CT, biomechanical and histomorphometric analyses (P<0.05). Furthermore, intergroup comparisons revealed significant correlation coefficients (P<0.05) between the micro CT and biomechanical parameters. Therefore, local administration of BPs could stimulation bone remodeling and represent an effective treatment strategy for preventing decayed implant osseointegration under T2DM conditions.
C1 [Ding, Xiaoqian; Yang, Lan; Hu, Yun; Yu, Jinfeng; Tang, Yu; Luo, Dan; Zheng, Leilei] Chongqing Med Univ, Coll Stomatol, 426 Northisongshi Rd, Chongqing 401147, Peoples R China.
   [Ding, Xiaoqian; Yang, Lan; Hu, Yun; Yu, Jinfeng; Tang, Yu; Luo, Dan; Zheng, Leilei] Chongqing Key Lab Oral Dis & Biomed Sci, Lab Med Biochem, Chongqing 401147, Peoples R China.
   [Ding, Xiaoqian; Yang, Lan; Hu, Yun; Yu, Jinfeng; Tang, Yu; Luo, Dan; Zheng, Leilei] Chongqing Municipal Key Lab Oral Biomed Engn High, Lab Med Biochem, Chongqing 401147, Peoples R China.
   [Yang, Lan] Peoples Hosp Rongchang Dist, Dept Gen Hosp, Chongqing 402460, Peoples R China.
   [Yu, Jinfeng] Haishu Dist Stomatol Hosp, Dept Orthodont, Ningbo 315000, Zhejiang, Peoples R China.
C3 Chongqing Medical University
RP Zheng, LL (通讯作者)，Chongqing Med Univ, Coll Stomatol, 426 Northisongshi Rd, Chongqing 401147, Peoples R China.
EM zhengleileicqmu@hospi tal.cqmu.edu.cn
RI Tang, Yuyi/HDN 2227 2022
FU Program for the Natural Science Foundation of China [81470772]; Natural
   Science Foundation of Chongqing [cstc2016jcyjA0238]; Medical Scientific
   Research Project of Chongqing [2018ZDXM020]; Program for Innovation Team
   Building at Institutions of Higher Education in Chongqing in 2016
   [CXTDG201602006]
FX This work was supported by Program for the Natural Science Foundation of
   China [grant numbers 81470772]; the Natural Science Foundation of
   Chongqing [grant numbers cstc2016jcyjA0238]; the Medical Scientific
   Research Project of Chongqing [grant numbers 2018ZDXM020]; and the
   Program for Innovation Team Building at Institutions of Higher Education
   in Chongqing in 2016 [grant numbers CXTDG201602006].
CR Abbaspour A, 2008, BONE, V42, P98, DOI 10.1016/j.bone.2007.08.031
   Alghamdi HS, 2014, BIOMATERIALS, V35, P5482, DOI 10.1016/j.biomaterials.2014.03.069
   Alp YE, 2017, J CRANIOFAC SURG, V28, P2174, DOI 10.1097/SCS.0000000000002615
   Baelum V, 2004, J PERIODONTOL, V75, P1404, DOI 10.1902/jop.2004.75.10.1404
   Bandeira F, 2014, ARQ BRAS ENDOCRINOL, V58, P504, DOI 10.1590/0004 2730000003384
   Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Bergman K, 2009, J BIOMED MATER RES A, V91A, P1111, DOI 10.1002/jbm.a.32289
   Bodine PVN, 2006, CLIN REV BONE MINER, V4, P73, DOI 10.1385/BMM:4:2:73
   Bonds DE, 2006, J CLIN ENDOCR METAB, V91, P3404, DOI 10.1210/jc.2006 0614
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brunetti G, 2019, WORLD J PEDIATR, V15, P4, DOI 10.1007/s12519 018 0198 7
   Carracher AM, 2018, J DIABETES, V10, P353, DOI 10.1111/1753 0407.12644
   Chen FP, 2019, MENOPAUSE, V26, P182, DOI 10.1097/GME.0000000000001185
   COOK H P, 1968, Annals of the Royal College of Surgeons of England, V42, P233
   Cuairán C, 2014, AM J ORTHOD DENTOFAC, V145, P737, DOI 10.1016/j.ajodo.2014.01.020
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Di Somma C, 2013, ENDOCRINE, V43, P651, DOI 10.1007/s12020 012 9848 z
   Dolci LS, 2019, INT J PHARMACEUT, V554, P245, DOI 10.1016/j.ijpharm.2018.11.023
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Giro G, 2011, CLIN ORAL IMPLAN RES, V22, P259, DOI 10.1111/j.1600 0501.2010.01989.x
   Guimaraes MB, 2015, INT J ORAL MAX SURG, V44, P1423, DOI 10.1016/j.ijom.2015.05.013
   Guimaraes MB, 2013, IMPLANT DENT, V22, P356, DOI 10.1097/ID.0b013e31828edd13
   Hagiwara T, 2000, J CRANIO MAXILL SURG, V28, P12, DOI 10.1054/jcms.1999.0104
   Hilding M, 2007, ACTA ORTHOP, V78, P795, DOI 10.1080/17453670710014572
   Hu Y, 2015, AM J TRANSL RES, V7, P866
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Jackson RD, 2014, SEMIN REPROD MED, V32, P454, DOI 10.1055/s 0034 1384629
   Jakobsen T, 2007, CLIN ORTHOP RELAT R, P195, DOI 10.1097/BLO.0b013e31813c6696
   Jakobsen T, 2016, J ORTHOP RES, V34, P65, DOI 10.1002/jor.22979
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Kanazawa I, 2019, J BONE MINER METAB, V37, P503, DOI 10.1007/s00774 018 0948 6
   Kettenberger U, 2014, BIOMATERIALS, V35, P9995, DOI 10.1016/j.biomaterials.2014.09.005
   Khan M, 2017, ENDOCRIN METAB CLIN, V46, P181, DOI 10.1016/j.ecl.2016.09.009
   Kisiel M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071683
   Lenzen S, 2008, DIABETOLOGIA, V51, P216, DOI 10.1007/s00125 007 0886 7
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Leslie WD, 2014, OSTEOPOROSIS INT, V25, P2817, DOI 10.1007/s00198 014 2822 2
   Li MC, 2016, CARDIOVASC TOXICOL, V16, P172, DOI 10.1007/s12012 015 9326 y
   Lu HF, 2003, ENDOCRINOLOGY, V144, P346, DOI 10.1210/en.2002 220072
   Maraka S, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h3783
   Marchand F, 2012, DIABETES METAB, V38, P14, DOI 10.1016/j.diabet.2011.10.002
   Massey HM, 1999, BRIT J HAEMATOL, V106, P167
   Mathijssen NMC, 2014, CELL TISSUE BANK, V15, P329, DOI 10.1007/s10561 013 9416 7
   Miettinen SSA, 2009, J ORTHOP SCI, V14, P431, DOI 10.1007/s00776 009 1352 9
   Milat F, 2009, MOL CELL ENDOCRINOL, V310, P52, DOI 10.1016/j.mce.2009.06.002
   Min W, 2018, EXP GERONTOL, V113, P106, DOI 10.1016/j.exger.2018.09.027
   Ohata T, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018 015 0228 2
   Omi H, 2007, J BONE JOINT SURG BR, V89B, P984, DOI 10.1302/0301 620X.89B7.18980
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Pura JA, 2016, CLIN ORTHOP RELAT R, V474, P1224, DOI 10.1007/s11999 016 4714 6
   Reinhold MI, 2007, J BIOL CHEM, V282, P3653, DOI 10.1074/jbc.M608995200
   Ross RD, 2014, CURR OSTEOPOROS REP, V12, P55, DOI 10.1007/s11914 013 0182 z
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Schilling T, 2008, J CELL BIOCHEM, V103, P413, DOI 10.1002/jcb.21415
   Snow AL, 2008, BIOL DIRECT, V3, DOI 10.1186/1745 6150 3 34
   Srinivasan K, 2005, PHARMACOL RES, V52, P313, DOI 10.1016/j.phrs.2005.05.004
   Tekin U, 2008, J ORAL MAXIL SURG, V66, P2042, DOI 10.1016/j.joms.2008.06.023
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Virdi AS, 2015, J BONE JOINT SURG AM, V97A, P133, DOI 10.2106/JBJS.N.00654
   Vohra F, 2014, ARCH ORAL BIOL, V59, P912, DOI 10.1016/j.archoralbio.2014.05.016
   Wang J, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/4368380
   Xiong Y, 2009, J INT MED RES, V37, P407, DOI 10.1177/147323000903700216
   Ye TJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186012
   Zheng LL, 2017, J CELL PHYSIOL, V232, P182, DOI 10.1002/jcp.25406
NR 67
TC 15
Z9 16
U1 0
U2 12
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2019
VL 11
IS 9
BP 5417
EP 5437
PG 21
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA JB0HI
UT WOS:000488232800011
PM 31632520
DA 2025 08 17
ER

PT J
AU Hiraga, T
   Nakamura, H
AF Hiraga, Toru
   Nakamura, Hiroaki
TI Imatinib mesylate suppresses bone metastases of breast cancer by
   inhibiting osteoclasts through the blockade of c Fms signals
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE imatinib mesylate; c Fms; bone metastases; breast cancer; osteoclasts
ID GROWTH FACTOR RECEPTOR; ZOLEDRONIC ACID; CELLS; DIFFERENTIATION;
   EFFICACY; THERAPY; KINASE; SAFETY
AB Imatinib mesylate (imatinib) is a potent and selective inhibitor of the tyrosine kinases, Bcr Abl, c Kit and platelet derived growth factor receptors (PDGFRs). Recently, it has been reported that imatinib also targets the macrophage colony stimulating factor (M CSF) receptor c Fms. M CSF signals are essential for the differentiation of osteoclasts. Bone metastases of breast cancer are frequently associated with osteoclastic bone destruction. Furthermore, several lines of evidence suggest that osteoclasts play central roles in the development and progression of bone metastases. Thus, in the present study, we examined the effects of imatinib on bone metastases of breast cancer. Coimmunoprecipitation assays showed that imatinib inhibited the M CSF induced phosphorylation of c Fms in osteoclast precursor cells as well as the PDGF induced PDGFR phosphorylation in MDA MB 231 human breast cancer cells. Imatinib also markedly reduced osteoclast formation in vitro. In contrast, those concentrations of imatinib did not affect osteoblast differentiation. We then examined the effects of imatinib on bone metastases of MDA MB 231 cells in a nude mouse model. Radiographic and histomorphometric analyses demonstrated that imatinib significantly decreased bone metastases associated with the reduced number of osteoclasts. In support of the notion that the inhibition of c Fms acts to suppress the development of bone metastases, we found that a specific inhibitor of c Fms Ki20227 also decreased bone metastases. In conclusion, these results collectively suggest that imatinib reduced bone metastases, at least in part, by inhibiting osteoclastic bone destruction through the blockade of c Fms signals. Our results also suggest that imatinib may have a protective effect against cancer treatment induced bone loss. (C) 2008 Wiley Liss, Inc.
C1 [Hiraga, Toru; Nakamura, Hiroaki] Matsumoto Dent Univ, Dept Histol & Cell Biol, Nagano 3990781, Japan.
C3 Matsumoto Dental University
RP Hiraga, T (通讯作者)，Matsumoto Dent Univ, Dept Histol & Cell Biol, 1780 Gobara Hirooka, Nagano 3990781, Japan.
EM hiraga@po.mdu.ac.jp
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Carvalho I, 2005, BREAST CANCER RES, V7, pR788, DOI 10.1186/bcr1304
   Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood 2004 08 3097
   Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood 2004 10 3967
   Dewar AL, 2006, BLOOD, V107, P4334, DOI 10.1182/blood 2005 09 3568
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401
   Grey A, 2006, NEW ENGL J MED, V355, P2494, DOI 10.1056/NEJMc062388
   Guilhot F, 2004, ONCOLOGIST, V9, P271, DOI 10.1634/theoncologist.9 3 271
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   Hiraga T, 2003, INT J CANCER, V106, P973, DOI 10.1002/ijc.11330
   Hiraga T, 2001, CANCER RES, V61, P4418
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008 5472.CAN 06 2355
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652
   Kobayashi Y, 2005, J BIOL CHEM, V280, P11395, DOI 10.1074/jbc.M411189200
   KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Lester J, 2005, CANCER TREAT REV, V31, P115, DOI 10.1016/j.ctrv.2005.01.008
   Lev DC, 2005, CLIN CANCER RES, V11, P306
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Morony S, 2001, CANCER RES, V61, P4432
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   Ohno H, 2006, MOL CANCER THER, V5, P2634, DOI 10.1158/1535 7163.MCT 05 0313
   Roodman GD, 2006, ANN NY ACAD SCI, V1068, P100, DOI 10.1196/annals.1346.013
   Roussidis AE, 2004, ANTICANCER RES, V24, P1445
   Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008 5472.CAN 06 0734
   Uehara H, 2003, J NATL CANCER I, V95, P458, DOI 10.1093/jnci/95.6.458
   Wolff NC, 2004, CLIN CANCER RES, V10, P3528, DOI 10.1158/1078 0432.CCR 0957 03
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
NR 31
TC 40
Z9 46
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
EI 1097 0215
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 1
PY 2009
VL 124
IS 1
BP 215
EP 222
DI 10.1002/ijc.23903
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 383HL
UT WOS:000261664600028
PM 18814279
DA 2025 08 17
ER

PT J
AU McMahan, J
   Linneman, T
AF McMahan, Jonathan
   Linneman, Travis
TI A Case of Resistant Hypercalcemia of Malignancy with a Proposed
   Treatment Algorithm
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE bisphosphonates; gallium nitrate; hypercalcemia; PTHrP
ID CANCER RELATED HYPERCALCEMIA; GALLIUM NITRATE; DOUBLE BLIND; PAMIDRONATE
   DISODIUM; ETIDRONATE DISODIUM; MULTIPLE MYELOMA; BISPHOSPHONATES;
   OSTEONECROSIS; MANAGEMENT; CALCITONIN
AB OBJECTIVE: To report and describe a case of refractory hypercalcemia of malignancy (HCM) associated with metastatic, transitional cell carcinoma of the left ureter.
   CASE SUMMARY: A 71 year old male complaining of generalized weakness and night sweats for the past 3 months was sent to the emergency department when routine laboratory tests revealed a corrected serum calcium concentration of 14.4 mg/dL. Intravenous crystalloid fluids and pamidronate were administered with achievement of normocalcemia, and the patient was discharged. Computed tomography scan and liver biopsy revealed recurrent transitional cell carcinoma with extensive liver metastasis. The patient returned approximately 1 week after discharge with a serum calcium level of 13.9 mg/dL. An initial decrease in serum calcium was observed with intravenous fluids, pamidronate, and calcitonin, but the normalization slowed and reversed within 3 days. Normocalcemia was achieved upon administration of zoledronic acid and the patient was discharged on day 14. The patient died 1 week after discharge from complications unrelated to hypercalcemia.
   DISCUSSION: Hypercalcemia is common in patients with malignancy and is associated with potentially life threatening sequelae. Four mechanisms of HCM have been recognized thus far, with ectopic tumor production of parathyroid hormone related protein (PTHrP) being the leading Cause. Treatment of HCM revolves around 2 principles: treatment of the underlying malignancy along with reduction of the serum calcium level. Evidence based therapies for management include: intravenous crystalloid fluids with or without loop diuretics, bisphosphonates, calcitonin, gallium nitrate, and corticosteroids. Therapies used for this patient included aggressive hydration, calcitonin, and 3 distinct treatment courses of intravenous bisphosphonates with varying success. Other potential agents were explored for use in the event of continued hypercalcemia. These therapies remain viable options based on individual patient factors. To our knowledge, no published guidelines or algorithms exist for choosing between additional modalities in the treatment of refractory HCM.
   CONCLUSIONS: For patients with HCM who do not achieve a response from bisphosphonates, or for those who need repeated dosing more often than expected, changing to a different drug class could be an alternative. The specific mechanism of hypercalcemia should be considered when developing a treatment regimen for patients who have had a suboptimal response to initial therapy with bisphosphonates. Multiple treatment modalities exist for the treatment of hypercalcemia, each with a different mechanism of action. As with the treatment of other disease states, we can use this knowledge to more specifically target the mechanism of the patient's disease.
C1 [Linneman, Travis] St Louis Coll Pharm, St Louis, MO 63110 USA.
   [McMahan, Jonathan] John Cochran Vet Affairs Med Ctr, St Louis, MO USA.
C3 University of Health Sciences & Pharmacy in St. Louis
RP Linneman, T (通讯作者)，St Louis Coll Pharm, 4588 Parkview Pl, St Louis, MO 63110 USA.
EM tlinneman@sticop.edu
CR Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Barnett M L, 1999, Semin Oncol Nurs, V15, P190, DOI 10.1016/S0749 2081(99)80007 2
   Berenson JR, 2002, SEMIN ONCOL, V29, P12, DOI 10.1053/sonc.2002.37417
   BINSTOCK ML, 1980, ANN INTERN MED, V93, P269, DOI 10.7326/0003 4819 93 2 269
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Cvitkovic FR, 2006, CANCER J, V12, P47, DOI 10.1097/00130404 200601000 00009
   Davidson TG, 2001, AM J HEALTH SYST PH, V58, pS8, DOI 10.1093/ajhp/58.suppl_3.S8
   GUCALP R, 1992, J CLIN ONCOL, V10, P134, DOI 10.1200/JCO.1992.10.1.134
   GUCALP R, 1994, ARCH INTERN MED, V154, P1935, DOI 10.1001/archinte.154.17.1935
   HASLING C, 1987, AM J MED, V82, P51, DOI 10.1016/0002 9343(87)90487 6
   King AE, 2008, PHARMACOTHERAPY, V28, P667, DOI 10.1592/phco.28.5.667
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Leyland Jones B, 2003, SEMIN ONCOL, V30, P13, DOI 10.1016/S0093 7754(03)00171 4
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   *NOV PHARM CORP, 2004, PACK INS ZOM ZOL AC
   Onuma E, 2005, CLIN CANCER RES, V11, P4198, DOI 10.1158/1078 0432.CCR 04 2531
   OSTENSTAD B, 1992, ACTA ONCOL, V31, P861, DOI 10.3109/02841869209089719
   RALSTON SH, 1990, ANN INTERN MED, V112, P499, DOI 10.7326/0003 4819 112 7 499
   Saunders Y, 2004, PALLIATIVE MED, V18, P418, DOI 10.1191/0269216304pm914ra
   Stewart AF, 2005, NEW ENGL J MED, V352, P373, DOI 10.1056/NEJMcp042806
   WARRELL RP, 1988, ANN INTERN MED, V108, P669, DOI 10.7326/0003 4819 108 5 669
   WARRELL RP, 1991, J CLIN ONCOL, V9, P1467, DOI 10.1200/JCO.1991.9.8.1467
NR 22
TC 6
Z9 7
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1060 0280
EI 1542 6270
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD SEP
PY 2009
VL 43
IS 9
BP 1532
EP 1538
DI 10.1345/aph.1L313
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 491QY
UT WOS:000269595500017
PM 19622757
DA 2025 08 17
ER

PT J
AU Herencia, C
   Diaz Tocados, JM
   Jurado, L
   de Oca, AM
   Rodríguez Ortiz, ME
   Martín Alonso, C
   Martínez Moreno, JM
   Vergara, N
   Rodríguez, M
   Almadén, Y
   Muñoz Castañeda, JR
AF Herencia, Carmen
   Miguel Diaz Tocados, Juan
   Jurado, Lidia
   Montes de Oca, Addy
   Encarnacion Rodriguez Ortiz, Maria
   Martin Alonso, Carmen
   Martinez Moreno, Julio M.
   Vergara, Noemi
   Rodriguez, Mariano
   Almaden, Yolanda
   Munoz Castaneda, Juan R.
TI Procaine Inhibits Osteo/Odontogenesis through Wnt/β Catenin Inactivation
SO PLOS ONE
LA English
DT Article
ID DIFFERENTIATION; SCLEROSTIN; PERIODONTITIS
AB Introduction
   Periodontitis is a complex pathology characterized by the loss of alveolar bone. The causes and the mechanisms that promote this bone resorption still remain unknown. The knowledge of the critical regulators involved in the alteration of alveolar bone homeostasis is of great importance for developing molecular therapies. Procaine is an anesthetic drug with demethylant properties, mainly used by dentists in oral surgeries. The inhibitor role of Wnt signaling of procaine was described in vitro in colon cancer cells.
   Methods
   In this work we evaluated the role of procaine (1 uM) in osteo/odontogenesis of rat bone marrow mesenchymal stem cells. Similarly, the mechanisms whereby procaine achieves these effects were also studied.
   Results
   Procaine administration led to a drastic decrease of calcium content, alkaline phosphatase activity, alizarin red staining and an increase in the expression of Matrix Gla Protein. With respect to osteo/odontogenic markers, procaine decreased early and mature osteo/odontogenic markers. In parallel, procaine inhibited canonical Wnt/beta catenin pathway, observing a loss of nuclear beta catenin, a decrease in Lrp5 and Frizzled 3, a significant increase of sclerostin and Gsk3 beta and an increase of phosphorylated beta catenin. The combination of osteo/odontogenic stimuli and Lithium Chloride decreased mRNA expression of Gsk3 beta, recovered by Procaine. Furthermore it was proved that Procaine alone dose dependently increases the expression of Gsk3 beta and beta catenin phosphorylation. These effects of procaine were also observed on mature osteoblast. Interestingly, at this concentration of procaine no demethylant effects were observed.
   Conclusions
   Our results demonstrated that procaine administration drastically reduced the mineralization and osteo/odontogenesis of bone marrow mesenchymal stem cells inhibiting Wnt/beta catenin pathway through the increase of Gsk3 beta expression and beta catenin phosphorylation.
C1 [Herencia, Carmen; Miguel Diaz Tocados, Juan; Jurado, Lidia; Montes de Oca, Addy; Martin Alonso, Carmen; Martinez Moreno, Julio M.; Vergara, Noemi; Rodriguez, Mariano; Munoz Castaneda, Juan R.] Univ Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC, Hosp Univ Reina Sofia, Serv Nefrol, Cordoba, Spain.
   [Encarnacion Rodriguez Ortiz, Maria] REDinREN, Fdn Jimenez Diaz, Nephrol Lab, Madrid, Spain.
   [Almaden, Yolanda] REDinREN, Lipids & Atherosclerosis Unit, CIBEROBN, Hosp Univ Reina Sofia,IMIBIC, Cordoba, Spain.
C3 Universidad de Cordoba; CIBER   Centro de Investigacion Biomedica en
   Red; CIBEROBN
RP Muñoz Castañeda, JR (通讯作者)，Univ Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC, Hosp Univ Reina Sofia, Serv Nefrol, Cordoba, Spain.
EM juanr.munoz.exts@juntadeandalucia.es
RI Muñoz Castañeda, Juan/AFQ 3443 2022; Martínez, Julio/AAA 6724 2020; Díaz
   Tocados, Juan/I 8254 2018; Herencia, Carmen/AAA 6843 2020;
   Rodriguez Ortiz, Maria Encarnacion/B 2871 2019
OI Martinez, Julio/0000 0002 1945 5078; Diaz Tocados, Juan
   Miguel/0000 0001 5192 5212; Rodriguez, Mariano/0000 0002 9380 6614;
   Rodriguez Ortiz, Maria Encarnacion/0000 0002 3696 582X; Munoz Castaneda,
   Juan R/0000 0002 9341 0724; Herencia Bellido, Carmen
   Maria/0000 0003 0589 4608
FU Consejeria de Economia, Ciencia y Empresa, Junta de Andalucia (Proyecto
   de Excelencia) [P09 CTS 05205]; Consejeria de Salud (Junta de Andalucia)
   [SAS111221]; Instituto de Salud Carlos III [FIS PI11/02055]; Nicolas
   Monardes Programm from Consejeria de Salud from Junta de Andalucia,
   Spain
FX This study was supported by grants from Consejeria de Economia, Ciencia
   y Empresa, Junta de Andalucia (Proyecto de Excelencia: P09 CTS 05205),
   Consejeria de Salud (Junta de Andalucia: SAS111221) and Instituto de
   Salud Carlos III (FIS PI11/02055). JRM C and YA are supported by Nicolas
   Monardes Programm from Consejeria de Salud from Junta de Andalucia,
   Spain. The authors deny any potential conflict of interest related to
   this study and they have no financial affiliations. This study was
   supported by grants from Consejeria de Economia, Ciencia y Empresa,
   Junta de Andalucia (Proyecto de Excelencia: P09 CTS 05205), Consejeria
   de Salud ( Junta de Andalucia: SAS111221) and Instituto de Salud Carlos
   III (FIS PI11/02055). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. JR. M C and YA are supported by Nicolas Monardes Program
   from Consejeria de Salud from Junta de Andalucia, Spain. Authors state
   no conflicts of interest.
CR Abbayya K, 2015, N AM J MED SCI, V7, P241, DOI 10.4103/1947 2714.159325
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Galli C, 2011, J PERIODONTAL RES, V46, P397, DOI 10.1111/j.1600 0765.2011.01354.x
   Gambardella A, 2011, J BONE MINER RES, V26, P811, DOI 10.1002/jbmr.266
   Gao Z, 2009, ONCOL REP, V22, P1479, DOI 10.3892/or_00000590
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Kaipatur NR, 2008, J DENT RES, V87, P839, DOI 10.1177/154405910808700907
   Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491
   Kucher U, 2014, INT J ORAL SCI, V6, P70, DOI 10.1038/ijos.2014.12
   Lee SI, 2014, J DENT RES, V93, P678, DOI 10.1177/0022034514535214
   Lim WH, 2015, J PERIODONTOL, V86, P319, DOI 10.1902/jop.2014.140286
   Lim WH, 2014, AM J ORTHOD DENTOFAC, V146, P337, DOI 10.1016/j.ajodo.2014.05.027
   de Oca AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089525
   de Oca AM, 2010, J BONE MINER RES, V25, P1996, DOI 10.1002/jbmr.93
   Napimoga MH, 2014, J CLIN PERIODONTOL, V41, P550, DOI 10.1111/jcpe.12245
   Pihlstrom BL, 2014, J AM DENT ASSOC, V145, P1208, DOI 10.14219/jada.2014.112
   Qiang YW, 2008, BONE, V42, P669, DOI 10.1016/j.bone.2007.12.006
   Ren YS, 2015, FASEB J, V29, P2702, DOI 10.1096/fj.14 265496
   Rogers CL, 2001, J EXP BIOL, V204, P2657
   Shan TF, 2015, CELL BIOL INT, V39, P35, DOI 10.1002/cbin.10340
   Singh N, 2009, CHEMMEDCHEM, V4, P792, DOI 10.1002/cmdc.200900017
   Taut AD, 2013, J BONE MINER RES, V28, P2347, DOI 10.1002/jbmr.1984
   Villar Garea A, 2003, CANCER RES, V63, P4984
   Yamaguchi Akira, 2010, Clin Calcium, V20, P1669, DOI CliCa101116691676
   Yao YC, 2010, CIRC RES, V107, P485, DOI 10.1161/CIRCRESAHA.110.219071
NR 26
TC 12
Z9 14
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 3
PY 2016
VL 11
IS 6
AR e0156788
DI 10.1371/journal.pone.0156788
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DN8ZV
UT WOS:000377369700127
PM 27257912
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Park, KR
   Kim, S
   Cho, M
   Yun, HM
AF Park, Kyung Ran
   Kim, SooHyun
   Cho, MyoungLae
   Yun, Hyung Mun
TI Limonoid Triterpene, Obacunone Increases Runt Related Transcription
   Factor 2 to Promote Osteoblast Differentiation and Function
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE D; dasycarpus; obacunone; osteoblast differentiation; RUNX2
ID DICTAMNUS DASYCARPUS TURCZ.; ROOT BARK; SIGNALING PATHWAYS; HUMAN
   OSTEOSARCOMA; BONE; CELLS; MECHANISMS; WNT; OSTEOGENESIS; OSTEOPOROSIS
AB Root bark of Dictamnus dasycarpus Turcz. has been widely used as a traditional medicine and is a well known anti inflammatory agent. We isolated limonoid triterpene, obacunone (Obac) from the dried root bark of D. dasycarpus. Obac has been reported to exhibit varieties of biological activities including anti inflammatory, anti cancer, and anti oxidant effects. This study aimed to investigate the beneficial effects and biological mechanisms of Obac in osteoblast differentiation and bone matrix mineralization. In the present study, Obac at concentrations ranging from 1 to 100 mu M showed no proliferation effects in MC3T3 E1. The treatment of Obac (1 and 10 mu M) increased wound healing and migration rates in a dose dependent manner. Alkaline phosphatase (ALP) staining and activity showed that Obac (1 and 10 mu M) enhanced early osteoblast differentiation in a dose dependent manner. Obac also increased late osteoblast differentiation in a dose dependent manner, as indicated by the mineralized nodule formation of ARS staining. The effects of Obac on osteoblast differentiation was validated by the levels of mRNAs encoding the bone differentiation markers, including Alp, bone sialoprotein (Bsp), osteopontin (Opn), and osteocalcin (Ocn). Obac increased the expression of bone morphogenetic protein (BMP), and the phosphorylation of smad1/5/8, and the expression of runt related transcription factor 2 (RUNX2); Obac also inhibited GSK3 beta and upregulated the protein level of beta catenin in a dose dependent manner during osteoblast differentiation. Obac mediated osteoblast differentiation was attenuated by a BMP2 inhibitor, Noggin and a Wnt/beta catenin inhibitor, Dickkopf 1 (Dkk1) with the abolishment of RUNX2 expression and nuclear accumulation by Obac. Taken together, the findings of this study demonstrate that Obac has pharmacological and biological activates to promote osteoblast differentiation and bone mineralization through BMP2, beta catenin, and RUNX2 pathways, and suggest that Obac might be a therapeutic effect for the treatment and prevention of bone diseases such as osteoporosis and periodontitis.
C1 [Park, Kyung Ran; Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
   [Kim, SooHyun; Cho, MyoungLae] Natl Inst Korean Med Dev, Gyongsan 38540, South Korea.
C3 Kyung Hee University
RP Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
EM rudfks282@naver.com; beluga81@nikom.or.kr; meanglae@nikom.or.kr;
   yunhm@khu.ac.kr
FU National Research Foundation of Korea [NRF]   Korea government (MSIP)
   [NRF 2018R1D1A1B07043282]
FX This work was supported by the National Research Foundation of Korea
   [NRF] grant funded by the Korea government (MSIP)
   (NRF 2018R1D1A1B07043282).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Gao Y, 2018, J CELL BIOCHEM, V119, P837, DOI 10.1002/jcb.26248
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Histing T, 2012, J SURG RES, V175, P271, DOI 10.1016/j.jss.2011.03.052
   Ichida M, 2011, FEBS LETT, V585, P4018, DOI 10.1016/j.febslet.2011.11.014
   Iguchi M, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/3979606
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Jeong GS, 2010, ARCH PHARM RES, V33, P1269, DOI 10.1007/s12272 010 0818 9
   Jung HJ, 2000, PLANTA MED, V66, P74, DOI 10.1055/s 0029 1243113
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Kim H, 2013, J ETHNOPHARMACOL, V149, P471, DOI 10.1016/j.jep.2013.06.055
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Liu Y, 2018, MUTAGENESIS, V33, P203, DOI 10.1093/mutage/gey010
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   Lucero CMJ, 2013, J CELL PHYSIOL, V228, P714, DOI 10.1002/jcp.24218
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Maruyama Z, 2007, DEV DYNAM, V236, P1876, DOI 10.1002/dvdy.21187
   Murthy KNC, 2011, FOOD CHEM TOXICOL, V49, P1616, DOI 10.1016/j.fct.2011.04.014
   Numan MS, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S88845
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218059
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155332
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103700
   Park KR, 2020, INT J BIOL SCI, V16, P330, DOI 10.7150/ijbs.37781
   Park KR, 2019, TOXICOLOGY, V422, P95, DOI 10.1016/j.tox.2019.05.010
   Park KR, 2018, THERANOSTICS, V8, P3087, DOI 10.7150/thno.24426
   Park KR, 2017, ARCH PHARM RES, V40, P933, DOI 10.1007/s12272 017 0932 z
   Rucci N, 2008, CLIN CASES MINER BON, V5, P49
   Russow G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010083
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Xu SM, 2016, PROTEIN CELL, V7, P684, DOI 10.1007/s13238 016 0297 y
   Yang B, 2017, PHARMACOGN MAG, V13, P483, DOI 10.4103/0973 1296.211034
   Yoon JS, 2008, J NAT PROD, V71, P208, DOI 10.1021/np070588o
   Yoon JS, 2010, J MOL NEUROSCI, V42, P9, DOI 10.1007/s12031 010 9333 1
   Yun HM, 2015, ONCOTARGET, V6, P20875, DOI 10.18632/oncotarget.5205
   Zheng XG, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20187574, 10.1590/1414 431x20187574]
NR 53
TC 24
Z9 27
U1 2
U2 24
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2021
VL 22
IS 5
AR 2483
DI 10.3390/ijms22052483
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA QV8VP
UT WOS:000628242400001
PM 33801166
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xing, FZ
   Geng, LY
   Guan, HS
   Liu, DH
   Li, YY
   Zeng, LZ
   Chen, Y
   Tian, R
   Li, Z
   Cao, RM
   Zhao, YW
   Yan, P
   Qiang, H
   Kong, N
   Wang, KZ
   Yang, P
AF Xing, Fangze
   Geng, Luying
   Guan, Huanshuai
   Liu, Donghua
   Li, Yiyang
   Zeng, Lizhong
   Chen, Yang
   Tian, Run
   Li, Zhe
   Cao, Ruomu
   Zhao, Yiwei
   Yan, Peng
   Qiang, Hui
   Kong, Ning
   Wang, Kunzheng
   Yang, Pei
TI Astragalin mitigates inflammatory osteolysis by negatively modulating
   osteoclastogenesis via ROS and MAPK signaling pathway
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Astragalin (AST); Inflammatory osteolysis; Osteoclastogenesis; Reactive
   oxygen species (ROS); MAPK; Bone resorption
ID BONE; DIFFERENTIATION; OSTEOMYELITIS; EXPRESSION; CELLS; NRF2
AB Inflammatory bone destruction has gradually attracted attention worldwide and has been observed in several kinds of pathological bone diseases, such as osteoarthritis, osteomyelitis, rheumatic arthritis, and other infectious clinical trials in the skeletal system. In this regard, excessive osteoclasts and bone resorption activity participate in osteolytic processes. Thus, negatively modulating osteoclast differentiation and bone erosion has been considered an effective therapeutic strategy to limit the poor progression of inflammatory osteolysis. Astragalin (AST) is a bioactive component of traditional Chinese drugs, such as Rosa agrestis, which presents anti inflammatory and antioxidant effects. However, it is unclear how AST may play an essential role in regulating the dynamic balance of the bone matrix by affecting osteoclastogenesis. This study found that AST could inhibit osteoclastic formation and bone resorption activity in a dose dependent manner without cytotoxicity. Admin istration of AST also inhibited the expression of cathepsin K, c Fos, NFATc1, and TRAP at different stages of mRNA and protein levels during osteoclastogenesis. Reactive oxygen species (ROS) signalling could also be modulated by treatment with AST during RANKL induced osteoclast differentiation through the Nrf2 HO1 sig nalling pathway. Additionally, AST could negatively regulate mitogen activated protein kinase (MAPK) signal ling in this process. In vivo, AST significantly reduced lipopolysaccharide (LPS) induced bone loss in an osteolytic mouse model. AST might be a promising therapeutic candidate for treating osteolytic bone diseases in the future.
C1 [Xing, Fangze; Guan, Huanshuai; Li, Yiyang; Tian, Run; Li, Zhe; Cao, Ruomu; Zhao, Yiwei; Yan, Peng; Kong, Ning; Wang, Kunzheng; Yang, Pei] Xi An Jiao Tong Univ, Dept Bone & Joint Surg, Affiliated Hosp 2, Xian 710004, Peoples R China.
   [Geng, Luying] Xi An Jiao Tong Univ, Dept Med Oncol, Affiliated Hosp 1, Xian 710061, Peoples R China.
   [Liu, Donghua; Zeng, Lizhong; Chen, Yang] Xi An Jiao Tong Univ, Dept Resp & Crit Care Med, Affiliated Hosp 2, Xian 710004, Peoples R China.
   [Qiang, Hui] Xi An Jiao Tong Univ, Dept Orthopaed Surg, Affiliated Hosp 3, Xian 710068, Peoples R China.
   [Kong, Ning; Wang, Kunzheng; Yang, Pei] Xi An Jiao Tong Univ, Dept Bone & Joint Surg, Affiliated Hosp 2, 157 Xiwu Rd, Xian 710004, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University; Xi'an Jiaotong University; Xi'an Jiaotong University
RP Kong, N; Wang, KZ; Yang, P (通讯作者)，Xi An Jiao Tong Univ, Dept Bone & Joint Surg, Affiliated Hosp 2, 157 Xiwu Rd, Xian 710004, Peoples R China.
EM kongning19940621@stu.xjtu.edu.cn; wkzh1955@163.com; yangpei@xjtu.edu.cn
RI zhao, yiwei/HTL 2193 2023; tian, run/LDT 4484 2024; Liu,
   Donghua/KEJ 1974 2024; Kong, Ning/O 4314 2018; Yang, Pei/HLW 0912 2023
FU National Natural Science Foundation of China; National Key Research and
   Devel opment Program of China; Key Project for Science Research and
   Development of Shaanxi Province;  [82072448];  [2020YFC1107504]; 
   [2019ZDLSF03 07]
FX Acknowledgement This work was supported by the National Natural Science
   Foundation of China (Grant No. 82072448) , the National Key Research and
   Devel opment Program of China (Grant No. 2020YFC1107504) , and the Key
   Project for Science Research and Development of Shaanxi Province (Grant
   No. 2019ZDLSF03 07) .
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Badila AE, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11020318
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cassat JE, 2013, CELL HOST MICROBE, V13, P759, DOI 10.1016/j.chom.2013.05.003
   Chen YQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2612 z
   Claro T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018748
   Deng ZH, 2021, CURR GENE THER, V21, P112, DOI 10.2174/1566523220666201127114845
   Hu JX, 2020, J CELL MOL MED, V24, P1893, DOI 10.1111/jcmm.14885
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Josse J, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00064
   Kim MS, 2011, ARCH PHARM RES, V34, P2101, DOI 10.1007/s12272 011 1213 x
   Lee HB, 2011, J SCI FOOD AGR, V91, P2315, DOI 10.1002/jsfa.4457
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Li X, 2021, DRUG DISCOV TODAY, V26, P1226, DOI 10.1016/j.drudis.2021.03.002
   Long F, 2022, INT IMMUNOPHARMACOL, V107, DOI 10.1016/j.intimp.2022.108632
   Long M, 2016, DIABETES, V65, P780, DOI 10.2337/db15 0564
   Lu SH, 2015, J NAT PROD, V78, P61, DOI 10.1021/np500663y
   Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042
   Moriarty TF, 2010, J MATER SCI MATER M, V21, P1031, DOI 10.1007/s10856 009 3907 x
   Ni S, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12882
   Olson ME, 2013, CELL HOST MICROBE, V13, P629, DOI 10.1016/j.chom.2013.05.015
   Peng L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02058
   Qu DX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8194690
   Riaz A, 2018, ADV PHARMACOL SCI, V2018, DOI 10.1155/2018/9794625
   ROODMAN GD, 1991, CRIT REV ORAL BIOL M, V2, P389, DOI 10.1177/10454411910020030601
   Shao SY, 2019, J CELL PHYSIOL, V234, P12701, DOI 10.1002/jcp.27887
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   Sun F, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/7254708
   Tang RH, 2019, J CELL PHYSIOL, V234, P7645, DOI 10.1002/jcp.27526
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P198, DOI 10.1056/NEJM197001222820406
   Wang B, 2021, GENES DIS, V8, P401, DOI 10.1016/j.gendis.2020.03.009
   Wang H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6095
   Yang J, 2019, FASEB J, V33, P7261, DOI 10.1096/fj.201802172R
   Zheng DH, 2019, ARCH PHARM RES, V42, P704, DOI 10.1007/s12272 019 01171 8
NR 37
TC 23
Z9 23
U1 4
U2 25
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2022
VL 112
AR 109278
DI 10.1016/j.intimp.2022.109278
EA OCT 2022
PG 11
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 5T1TT
UT WOS:000875658800001
PM 36215870
DA 2025 08 17
ER

PT J
AU Ma, Y
   Krueger, JJ
   Redmon, SN
   Uppuganti, S
   Nyman, JS
   Hahn, MK
   Elefteriou, F
AF Ma, Yun
   Krueger, Jessica J.
   Redmon, Sara N.
   Uppuganti, Sasidhar
   Nyman, Jeffry S.
   Hahn, Maureen K.
   Elefteriou, Florent
TI Extracellular Norepinephrine Clearance by the Norepinephrine Transporter
   Is Required for Skeletal Homeostasis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Gene Knockout; Mouse; Nerve; Neurotransmitter Transport; Osteoblasts;
   ADHD; Bone Remodeling; Norepinephrine Transporter; Sympathetic Nervous
   System
ID SYMPATHETIC NERVOUS SYSTEM; REGULATES BONE FORMATION; BLOOD PRESSURE;
   BETA BLOCKERS; MASS; MICE; DIFFERENTIATION; IMMOBILIZATION;
   HYPERACTIVITY; OSTEOPOROSIS
AB Background: The contribution of endogenous norepinephrine (NE) to skeletal homeostasis is unclear. Results: Bone forming cells, not only neurons, express the norepinephrine transporter (NET), and blockade of extracellular NE clearance causes alterations in bone homeostasis. Conclusion: NE clearance by NET is a component of the homeostatic machinery by which sympathetic nerves and osteoblasts control bone remodeling. Significance: NET blockers may increase fracture risk.
   Changes in bone remodeling induced by pharmacological and genetic manipulation of  adrenergic receptor (AR) signaling in osteoblasts support a role of sympathetic nerves in the regulation of bone remodeling. However, the contribution of endogenous sympathetic outflow and nerve derived norepinephrine (NE) to bone remodeling under pathophysiological conditions remains unclear. We show here that differentiated osteoblasts, like neurons, express the norepinephrine transporter (NET), exhibit specific NE uptake activity via NET and can catabolize, but not generate, NE. Pharmacological blockade of NE transport by reboxetine induced bone loss in WT mice. Similarly, lack of NE reuptake in norepinephrine transporter (Net) deficient mice led to reduced bone formation and increased bone resorption, resulting in suboptimal peak bone mass and mechanical properties associated with low sympathetic outflow and high plasma NE levels. Last, daily sympathetic activation induced by mild chronic stress was unable to induce bone loss, unless NET activity was blocked. These findings indicate that the control of endogenous NE release and reuptake by presynaptic neurons and osteoblasts is an important component of the complex homeostatic machinery by which the sympathetic nervous system controls bone remodeling. These findings also suggest that drugs antagonizing NET activity, used for the treatment of hyperactivity disorders, may have deleterious effects on bone accrual.
C1 [Ma, Yun; Elefteriou, Florent] Vanderbilt Univ, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA.
   [Ma, Yun; Uppuganti, Sasidhar; Nyman, Jeffry S.; Elefteriou, Florent] Vanderbilt Ctr Bone Biol, Nashville, TN 37232 USA.
   [Krueger, Jessica J.; Redmon, Sara N.; Hahn, Maureen K.] Vanderbilt Univ, Dept Med, Div Med Genet, Nashville, TN 37232 USA.
   [Hahn, Maureen K.; Elefteriou, Florent] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.
   [Hahn, Maureen K.] Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN 37232 USA.
   [Uppuganti, Sasidhar; Nyman, Jeffry S.] Dept Orthopaed Surg & Rehabil, Nashville, TN 37232 USA.
   [Elefteriou, Florent] Dept Canc Biol, Nashville, TN 37232 USA.
   [Nyman, Jeffry S.] Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Vanderbilt University; Vanderbilt University; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Tennessee Valley
   Healthcare System
RP Elefteriou, F (通讯作者)，Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Bone Biol, 2215 Garland Ave,Light Hall,Room 1255H, Nashville, TN 37232 USA.
EM florent.elefteriou@vanderbilt.edu
RI Ma, Yun/HRD 3253 2023; Nyman, Jeffry/L 5736 2013; Elefteriou,
   Florent/P 2586 2017
OI , Yun/0000 0003 2122 3695; Uppuganti, Sasidhar/0000 0002 0656 2122;
   Nyman, Jeffry/0000 0001 7403 7605; Elefteriou,
   Florent/0000 0002 2972 5633; Krueger, Jessica/0009 0004 3649 7538
FU National Institutes of Health; NIDDK [5R01DK082471 03]; Clinical and
   Translational Science Awards (CTSA) [UL11R000445]
FX This work was supported, in whole or in part, by National Institutes of
   Health, NIDDK Grant 5R01DK082471 03 and Grant UL11R000445 from the
   Clinical and Translational Science Awards (CTSA).
CR Aitken SJ, 2009, ARCH BIOCHEM BIOPHYS, V482, P96, DOI 10.1016/j.abb.2008.11.012
   [Anonymous], [No title captured]
   Bertram D, 2000, AM J PHYSIOL REG I, V279, pR1257, DOI 10.1152/ajpregu.2000.279.4.R1257
   Bonnet N, 2008, J CELL PHYSIOL, V217, P819, DOI 10.1002/jcp.21564
   Bonnet N, 2007, J APPL PHYSIOL, V102, P1502, DOI 10.1152/japplphysiol.00815.2006
   Bonnet N, 2007, BONE, V40, P1209, DOI 10.1016/j.bone.2007.01.006
   Bonnet N, 2006, J PHARMACOL EXP THER, V318, P1118, DOI 10.1124/jpet.106.105437
   Bonnet N, 2005, BONE, V37, P622, DOI 10.1016/j.bone.2005.07.012
   Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363
   Camporeale A, 2013, DRUG SAFETY, V36, P663, DOI 10.1007/s40264 013 0074 2
   Carson RP, 2002, J APPL PHYSIOL, V93, P2192, DOI 10.1152/japplphysiol.00033.2002
   Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009
   Cuscito C, 2011, ANN NY ACAD SCI, V1237, P53, DOI 10.1111/j.1749 6632.2011.06235.x
   Dziedzicka Wasylewska M, 2006, NEUROPSYCHOPHARMACOL, V31, P2424, DOI 10.1038/sj.npp.1301064
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Fonseca TL, 2011, J BONE MINER RES, V26, P591, DOI 10.1002/jbmr.243
   Franquinho F, 2010, FEBS J, V277, P3664, DOI 10.1111/j.1742 4658.2010.07774.x
   Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028
   Gilsbach R, 2006, J NEUROCHEM, V96, P1111, DOI 10.1111/j.1471 4159.2005.03598.x
   Gotoh M, 2005, HYPERTENS RES, V28, P565, DOI 10.1291/hypres.28.565
   Graham S, 2008, EXPERT OPIN INV DRUG, V17, P1281, DOI 10.1517/13543784.17.9.1281 
   Hahn MK, 2009, NEUROPHARMACOLOGY, V57, P694, DOI 10.1016/j.neuropharm.2009.08.002
   Hahn MK, 2005, MOL PHARMACOL, V68, P457, DOI 10.1124/mol.105.011270
   Hart EC, 2009, HYPERTENSION, V53, P571, DOI 10.1161/HYPERTENSIONAHA.108.126391
   HEAL DJ, 1989, BRIT J PHARMACOL, V97, P111, DOI 10.1111/j.1476 5381.1989.tb11930.x
   Hinojosa Laborde CM, 1999, CLIN EXP PHARMACOL P, V26, P122, DOI 10.1046/j.1440 1681.1999.02995.x
   Horvath G, 2003, AM J PHYSIOL LUNG C, V285, pL829, DOI 10.1152/ajplung.00054.2003
   JOHNSTON CC, 1990, NEW ENGL J MED, V323, P1271, DOI 10.1056/NEJM199011013231809
   Joo Y, 2009, NEUROSCI LETT, V461, P121, DOI 10.1016/j.neulet.2009.06.025
   Kajimura D, 2011, J EXP MED, V208, P841, DOI 10.1084/jem.20102608
   Keller NR, 2004, CIRCULATION, V110, P1191, DOI 10.1161/01.CIR.0000141804.90845.E6
   Kessler RC, 2006, AM J PSYCHIAT, V163, P716, DOI 10.1176/appi.ajp.163.4.716
   Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200
   Kondo H, 2011, CALCIFIED TISSUE INT, V88, P23, DOI 10.1007/s00223 010 9421 9
   Lee NJ, 2009, NEUROPEPTIDES, V43, P457, DOI 10.1016/j.npep.2009.08.006
   Li HF, 2010, MOL CELL ENDOCRINOL, V323, P201, DOI 10.1016/j.mce.2010.03.021
   Lin SF, 2012, NUCL MED BIOL, V39, P1081, DOI 10.1016/j.nucmedbio.2012.04.005
   MATKOVIC V, 1994, J CLIN INVEST, V93, P799, DOI 10.1172/JCI117034
   Moldovanova I, 2008, HYPERTENSION, V51, P1203, DOI 10.1161/HYPERTENSIONAHA.107.107433
   Pierroz DD, 2012, J BONE MINER RES, V27, P1252, DOI 10.1002/jbmr.1594
   Reid I. R., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P105
   Ren ZG, 2003, DEV NEUROSCI BASEL, V25, P1, DOI 10.1159/000071462
   Sato T, 2010, J PHARMACOL EXP THER, V334, P99, DOI 10.1124/jpet.110.167643
   Schroeder C, 2004, AM J PHYSIOL REG I, V286, pR851, DOI 10.1152/ajpregu.00689.2003
   Simon V, 2009, BRIT J PSYCHIAT, V194, P204, DOI 10.1192/bjp.bp.107.048827
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   Tank J, 2003, CIRCULATION, V107, P2949, DOI 10.1161/01.CIR.0000072786.99163.FE
   Tjurmina OA, 2002, ENDOCRINOLOGY, V143, P4520, DOI 10.1210/en.2002 220416
   Veldhuis Vlug AG, 2012, J CLIN ENDOCR METAB, V97, pE2093, DOI 10.1210/jc.2012 2823
   WANG TM, 1993, BONE MINER, V20, P251, DOI 10.1016/S0169 6009(08)80006 2
   Watkins MP, 2012, BONE, V51, P787, DOI 10.1016/j.bone.2012.06.018
   Ziere G, 2008, J CLIN PSYCHOPHARM, V28, P411, DOI 10.1097/JCP.0b013e31817e0ecb
NR 53
TC 52
Z9 58
U1 1
U2 15
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 18
PY 2013
VL 288
IS 42
BP 30105
EP 30113
DI 10.1074/jbc.M113.481309
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 291YF
UT WOS:000329868100011
PM 24005671
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Zhang, Z
   Meng, YC
   Lin, T
   Zhang, ZR
   Tao, ZB
   Yin, HZ
   Yang, F
   Zhou, XH
AF Zhang, Zheng
   Meng, Yichen
   Lin, Tao
   Zhang, Zhanrong
   Tao, Zhengbo
   Yin, Haozan
   Yang, Fu
   Zhou, Xuhui
TI Dancr BRG1 regulates Nfatc1 transcription and Pgc1β  dependent metabolic
   shifts in osteoclastogenesis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE LncRNA; Dancr; osteoclast; bone resorption; osteoporosis
ID LNCRNA ANCR PROMOTES; TARGETING EZH2; DIFFERENTIATION; CELLS;
   PROLIFERATION; OSTEOPOROSIS; OSTEOBLASTS; THERAPY
AB Long non  coding RNA (lncRNA) serves as a vital regulator of bone metabolism, but its role in pathologically overactive osteoclast differentiation remains elusive. Here, we identify lncRNA Dancr (Differentiation Antagonizing Non  protein Coding RNA) as a critical suppressor of osteoclastogenesis and bone resorption, which is down  regulated in response to estrogen deficiency. Global or osteoclast  specific Dancr Knockout mice display significant trabecular bone deterioration and enhanced osteoclast activity, but minimal alteration of bone formation. Moreover, the bone  targeted delivery of Dancr by Adeno  associated viral remarkably attenuates ovariectomy  induced osteopenia in mice. Mechanistically, Dancr establishes a direct interaction with Brahma  related gene 1 to prevent its binding and preserve H3K27me3 enrichment at the nuclear factor of activated T cells 1 and proliferator  activated receptor gamma coactivator 1   beta promoters, thereby maintaining appropriate expression of osteoclastic genes and metabolic programs during osteoclastogenesis. These results demonstrate that Dancr is a key molecule maintaining proper osteoclast differentiation and bone homeostasis under physiological conditions, and Dancr overexpression constitutes a potential strategy for treating osteoporosis.
C1 [Zhang, Zheng; Meng, Yichen; Lin, Tao; Zhang, Zhanrong; Tao, Zhengbo; Zhou, Xuhui] Naval Med Univ, Mil Med Univ 2, Changzheng Hosp, Dept Orthoped, Shanghai 200003, Peoples R China.
   [Zhang, Zheng] Qingdao Special Servicemen Recuperat Ctr Peoples L, Dept Orthoped Rehabil, Qingdao 266000, Peoples R China.
   [Yin, Haozan; Yang, Fu] Naval Med Univ, Mil Med Univ 2, Dept Med Genet, Shanghai 200433, Peoples R China.
   [Yang, Fu] Minist Educ, Key Lab Biol Def, Shanghai 200433, Peoples R China.
   [Zhou, Xuhui] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Translat Res Ctr Orthoped, Sch Med, Shanghai 201600, Peoples R China.
C3 Naval Medical University; Naval Medical University; Shanghai Jiao Tong
   University
RP Tao, ZB; Zhou, XH (通讯作者)，Naval Med Univ, Mil Med Univ 2, Changzheng Hosp, Dept Orthoped, Shanghai 200003, Peoples R China.; Zhou, XH (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Translat Res Ctr Orthoped, Sch Med, Shanghai 201600, Peoples R China.
EM yangfusq1997@smmu.edu.cn; zhouxuhui@smmu.edu.cn
RI Zhang, Zheng/AGR 5554 2022; Meng, Yichen/AAN 3085 2020; Yang,
   Fu/L 8441 2019
OI Yang, Fu/0000 0003 2459 3923; Zhang, Zheng/0000 0001 7201 221X; ,
   zhou/0000 0002 5995 519X; 
FU National Natural Science Foundation Projects of China [82172516,
   82002369, 81972657]; National Logistics Major Research Project
   [AWS18C001]; Shanghai Sailing program [19YF1447800]
FX This research was supported by the National Natural Science Foundation
   Projects of China (82172516, 82002369, 81972657) ; the National
   Logistics Major Research Project (AWS18C001) ; Shanghai Sailing program
   (19YF1447800) .
CR Alendar A, 2021, GENE DEV, V35, P1403, DOI 10.1101/gad.348897.121
   Aurilia C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22083909
   Ayers C, 2023, ANN INTERN MED, V176, DOI 10.7326/M22 0684
   Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935
   Cai N, 2019, YONSEI MED J, V60, P751, DOI 10.3349/ymj.2019.60.8.751
   Cajigas I, 2015, DEVELOPMENT, V142, P2641, DOI 10.1242/dev.126318
   de Dieuleveult M, 2016, NATURE, V530, P113, DOI 10.1038/nature16505
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   El Hadidy N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215260
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Ghafouri Fard S, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935 022 02612 z
   Han P, 2014, NATURE, V514, P102, DOI 10.1038/nature13596
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Izawa N, 2019, J BONE MINER RES, V34, P1143, DOI 10.1002/jbmr.3689
   Jiang SY, 2019, EUR REV MED PHARMACO, V23, P5558, DOI 10.26355/eurrev_201907_18289
   Jin FJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 23642 7
   Jin SJ, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01225
   Kretz M, 2012, GENE DEV, V26, P338, DOI 10.1101/gad.182121.111
   Kulkarni JA, 2021, NAT NANOTECHNOL, V16, P630, DOI 10.1038/s41565 021 00898 0
   Kurotaki D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115471
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Liu C, 2019, J CELL PHYSIOL, V234, P1606, DOI 10.1002/jcp.27031
   Lopez Pajares V, 2015, DEV CELL, V32, P693, DOI 10.1016/j.devcel.2015.01.028
   Marino Silvia, 2014, Bonekey Rep, V3, P570, DOI 10.1038/bonekey.2014.65
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Qian XY, 2019, TRENDS BIOCHEM SCI, V44, P33, DOI 10.1016/j.tibs.2018.09.012
   Quan HY, 2018, CELL PHYSIOL BIOCHEM, V46, P401, DOI 10.1159/000488474
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Shaykevich A, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032869
   Shen YY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.882241
   Sun Y, 2019, NAT METAB, V1, P485, DOI 10.1038/s42255 019 0053 8
   Sun ZJ, 2022, BIOCHEM BIOPH RES CO, V594, P117, DOI 10.1016/j.bbrc.2021.12.075
   Tang ZY, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0406 8
   Trotter Kevin W, 2008, Nucl Recept Signal, V6, pe004, DOI 10.1621/nrs.06004
   Tsukasaki M, 2022, INFLAMM REGEN, V42, DOI 10.1186/s41232 022 00213 x
   Veis DJ, 2023, ANNU REV PATHOL MECH, V18, P257, DOI 10.1146/annurev pathmechdis 031521 040919
   Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573 019 0012 9
   Wang N, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1810 z
   Winkle M, 2021, NAT REV DRUG DISCOV, V20, P629, DOI 10.1038/s41573 021 00219 z
   Wu H, 2017, TRENDS GENET, V33, P540, DOI 10.1016/j.tig.2017.05.004
   Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556 019 0311 8
   Yasui T, 2011, J BONE MINER RES, V26, P2665, DOI 10.1002/jbmr.464
   You SL, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6095673
   Zhang CY, 2023, INT J NANOMED, V18, P781, DOI 10.2147/IJN.S395607
   Zhang JL, 2018, INT J MOL MED, V41, P213, DOI 10.3892/ijmm.2017.3215
   Zhang Y, 2020, J BONE MINER RES, V35, P1772, DOI 10.1002/jbmr.4039
   Zhang Z, 2021, EUR REV MED PHARMACO, V25, P1399, DOI 10.26355/eurrev_202102_24848
   Zhang Z, 2023, SCI ADV, V9, DOI 10.1126/sciadv.ade7379
   Zheng CX, 2020, TRENDS MOL MED, V26, P89, DOI 10.1016/j.molmed.2019.04.008
   Zhu L, 2013, BIOCHEM BIOPH RES CO, V432, P612, DOI 10.1016/j.bbrc.2013.02.036
NR 53
TC 3
Z9 3
U1 2
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 30
PY 2024
VL 121
IS 5
AR e2313656121
DI 10.1073/pnas.2313656121
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IP0G7
UT WOS:001167409600006
PM 38252822
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Rove, KO
   Crawford, ED
AF Rove, Kyle O.
   Crawford, E. David
TI Evolution of Treatment Options for Patients With CRPC and Bone
   Metastases: Bone Targeted Agents That Go Beyond Palliation of Symptoms
   to Improve Overall Survival
SO ONCOLOGY NEW YORK
LA English
DT Article
ID REFRACTORY PROSTATE CANCER; PHASE II TRIAL; MITOXANTRONE PLUS
   PREDNISONE; RANDOMIZED CONTROLLED TRIAL; ANDROGEN DEPRIVATION THERAPY;
   PLACEBO CONTROLLED TRIAL; LOCAL FIELD TREATMENT; LONG TERM EFFICACY;
   QUALITY OF LIFE; ZOLEDRONIC ACID
AB Metastasis to bone represents an all too frequent complication of advanced stage prostate cancer (PCa): 50% to 70% of these patients will ultimately develop this devastating complication. PCa preferentially metastasizes to bone, and the skeletal complications increase mortality and decrease quality of life. The clinical consequences of skeletal metastasis also include pain, skeletal related events (SREs), and increased costs of therapy. Recent advances in our understanding of the mechanisms of metastasis and the physiologic changes that occur with it, together with the introduction of new treatments, are furthering our ability to combat this problem. In this review, we examine bone targeted palliative agents, nontargeted systemic cytotoxic therapies, and bone targeted agents that go beyond palliation to also potentially improve progression free and overall survival. We specifically focus on post treatment outcomes including pain relief, decreased opioid use, improvement in quality of life, freedom from SREs or new bony metastases, and increases in overall survival in men with symptomatic, metastatic PCa. Treatments discussed include varied drug classes, such as bisphosphonates and human monoclonal antibodies; beta emitting radiopharmaceuticals; external beam radiotherapy; systemic chemotherapies; Src inhibitors; endothelin A receptor antagonists; clusterin inhibitors; and alpha emitting radiopharmaceuticals.
C1 [Rove, Kyle O.; Crawford, E. David] Univ Colorado, Sect Urol Oncol, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Crawford, ED (通讯作者)，Univ Colorado, Sect Urol Oncol, Anschutz Med Campus,Mail Stop F710,POB 6510, Aurora, CO 80045 USA.
EM david.crawford@ucdenver.edu
CR Akhavan A, 2006, NEOPLASIA, V8, P725, DOI 10.1593/neo.06388
   [Anonymous], NCT00134056 CLIN TRI
   [Anonymous], NCT01083615 CLIN TRI
   [Anonymous], NCT00744497 CLIN TRI
   [Anonymous], NCT00554229 CLIN TRI
   [Anonymous], NCT01188187 CLIN TRI
   [Anonymous], NCT00699751 CLIN TRI
   [Anonymous], NCT00617669 CLIN TRI
   [Anonymous], ASCO GEN CANC S
   [Anonymous], 2011, MEDPAGE TODAY
   Approved drug label: Denosumab, 2011, APPR DRUG LAB DEN
   Araujo J, 2009, J CLIN ONCOL, V27
   Bertelli G, 2006, CANCER CHEMOTH PHARM, V57, P46, DOI 10.1007/s00280 005 0025 4
   Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008
   Bhoopalam N, 2009, J UROLOGY, V182, P2257, DOI 10.1016/j.juro.2009.07.046
   Burch PA, 2004, PROSTATE, V60, P197, DOI 10.1002/pros.20040
   Campbell SC, 2010, UROLOGY, V75, P1138, DOI 10.1016/j.urology.2009.11.083
   Carducci MA, 2003, J CLIN ONCOL, V21, P679, DOI 10.1200/JCO.2003.04.176
   Carducci MA, 2007, CANCER AM CANCER SOC, V110, P1959, DOI 10.1002/cncr.22996
   Carducci MA, 2006, CLIN CANCER RES, V12, p6296S, DOI 10.1158/1078 0432.CCR 06 0929
   Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283
   Chi KN, 2010, J CLIN ONCOL, V28, P4247, DOI 10.1200/JCO.2009.26.8771
   Chow E, 2000, INT J RADIAT ONCOL, V46, P517
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078 0432.CCR 08 0872
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   Finlay OG, 2005, LANCET ONCOL, V6, P392, DOI 10.1016/S1470 2045(05)70206 0
   Fizazi K, 2007, ANN ONCOL, V18, P1765, DOI 10.1093/annonc/mdm086
   FIZAZI K, 2010, J CLIN ONCOL, V28
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fizazi K, 2009, J CLIN ONCOL, V27, P2429, DOI 10.1200/JCO.2008.18.9811
   Frassica DA, 2003, CLIN ORTHOP RELAT R, pS158
   Galasko C, 1981, BONE METASTASIS
   Galsky MD, 2010, NAT REV DRUG DISCOV, V9, P677, DOI 10.1038/nrd3254
   Groot MT, 2003, EUR UROL, V43, P226, DOI 10.1016/S0302 2838(03)00007 1
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   James ND, 2010, BJU INT, V106, P966, DOI 10.1111/j.1464 410X.2010.09638.x
   James ND, 2009, EUR UROL, V55, P1112, DOI 10.1016/j.eururo.2008.11.002
   July LV, 2002, PROSTATE, V50, P179, DOI 10.1002/pros.10047
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597
   Lara PN, 2009, ANTI CANCER DRUG, V20, P179, DOI 10.1097/CAD.0b013e328325a867
   Lewington V, 2010, ASCO GEN CANC S
   LEWINGTON VJ, 1991, EUR J CANCER, V27, P954, DOI 10.1016/0277 5379(91)90257 E
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   Mohammad KS, 2009, ANTI CANCER AGENT ME, V9, P1079, DOI 10.2174/187152009789735008
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nelson JB, 2008, CANCER AM CANCER SOC, V113, P2478, DOI 10.1002/cncr.23864
   Nilsson S, 2005, CLIN CANCER RES, V11, P4451, DOI 10.1158/1078 0432.CCR 04 2244
   Nilsson S, 2007, LANCET ONCOL, V8, P587, DOI 10.1016/S1470 2045(07)70147 X
   Oefelein MG, 2002, J UROLOGY, V168, P1005, DOI 10.1016/S0022 5347(05)64561 2
   Ozturk OH, 2007, CELL BIOL INT, V31, P1069, DOI 10.1016/j.cellbi.2007.02.004
   Paget S., LANCET, V1, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Pecher C, 1942, BIOL INVESTIGATIONS, P117
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   POULTER CA, 1992, INT J RADIAT ONCOL, V23, P207, DOI 10.1016/0360 3016(92)90563 W
   QUILTY PM, 1994, RADIOTHER ONCOL, V31, P33, DOI 10.1016/0167 8140(94)90411 1
   Ratanatharathorn V, 1999, INT J RADIAT ONCOL, V44, P1, DOI 10.1016/S0360 3016(98)00510 0
   Recchia I, 2004, BONE, V34, P65, DOI 10.1016/j.bone.2003.06.004
   Resche I, 1997, EUR J CANCER, V33, P1583, DOI 10.1016/S0959 8049(97)00155 X
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rosenberg JE, 2007, CANCER AM CANCER SOC, V110, P556, DOI 10.1002/cncr.22811
   Rove KO, 2010, ONCOLOGY WILLISTON P, V24, P1318
   Rove KO, 2010, ONCOLOGY NY, V24, P1308
   Saad F, 2004, EUR UROL, V46, P731, DOI 10.1016/j.eururo.2004.08.016
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2011, DENOSUMAB TREATMENT
   Saad F, 2011, CLIN CANCER RES, V17, P5765, DOI 10.1158/1078 0432.CCR 11 0859
   Saad F, 2010, CANCER TREAT REV, V36, P177, DOI 10.1016/j.ctrv.2009.11.005
   Sartor A, 2010, ASCO GEN CANC S
   Sartor O, 2004, UROLOGY, V63, P940, DOI 10.1016/j.urology.2004.01.034
   Sartor O, 2007, CANCER AM CANCER SOC, V109, P637, DOI 10.1002/cncr.22431
   Serafini AN, 1998, J CLIN ONCOL, V16, P1574, DOI 10.1200/JCO.1998.16.4.1574
   Sidana A, 2010, UROLOGY, V75, P1009, DOI 10.1016/j.urology.2009.06.020
   Small EJ, 2000, J CLIN ONCOL, V18, P3894, DOI 10.1200/JCO.2000.18.23.3894
   Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252
   Smith MR, 2009, J UROLOGY, V182, P2670, DOI 10.1016/j.juro.2009.08.048
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Tabernero J, 2007, J CLIN ONCOL, V25, p23s
   Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140 6736(00)03639 4
   Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008 5472.CAN 04 1121
   Weinfurt KP, 2006, ANN ONCOL, V17, P986, DOI 10.1093/annonc/mdl041
   Weinfurt KP, 2004, MED CARE, V42, P164, DOI 10.1097/01.mlr.0000108746.69256.45
   Weinfurt KP, 2002, ANN ONCOL, V13
   WINSTON MA, 1979, SEMIN NUCL MED, V9, P114, DOI 10.1016/S0001 2998(79)80043 4
   Wu JSY, 2003, INT J RADIAT ONCOL, V55, P594, DOI 10.1016/S0360 3016(02)04147 0
   Yu E, 2008, J CLIN ONCOL, V26, p88s
   Yu EY, 2011, UROLOGY, V77, P1166, DOI 10.1016/j.urology.2011.01.006
   Yu EY, 2009, CLIN CANCER RES, V15, P7421, DOI 10.1158/1078 0432.CCR 09 1691
NR 98
TC 15
Z9 18
U1 0
U2 6
PU UBM MEDICA
PI NORWALK
PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA
SN 0890 9091
J9 ONCOLOGY NY
JI Oncology NY
PD DEC
PY 2011
VL 25
IS 14
BP 1362
EP 1387
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 873AB
UT WOS:000298851600011
PM 22329188
DA 2025 08 17
ER

PT J
AU Wu, JY
   Wang, C
   Li, GF
   Tang, ET
   Zheng, QS
AF Wu, Junyi
   Wang, Chen
   Li, Guo Fu
   Tang, En Tzu
   Zheng, Qingshan
TI Quantitative prediction of bone mineral density by using bone turnover
   markers in response to antiresorptive agents in postmenopausal
   osteoporosis: A model based meta analysis
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE biomarkers; modelling and simulation; osteoporosis; pharmacodynamics
ID BIOCHEMICAL MARKERS; FRACTURE RISK; WOMEN; DENOSUMAB; DISEASE;
   METABOLISM; OUTCOMES; PLACEBO; BURDEN; IMPACT
AB Aims This study aimed to predict time course of bone mineral density (BMD) by using corresponding response of bone turnover markers (BTMs) in women with postmenopausal osteoporosis under antiresorptive treatments. Methods Data were extracted from literature searches in accessible public database. Time courses of percent change from baseline in serum C telopeptide of type 1 collagen (sCTX) and N telopeptide of type 1 collagen were described by complex exponential onset models. The relationship between BTM changes and BMD changes at lumbar spine and total hip was described using a multiscale indirect response model. Results The dataset included 41 eligible published trials of 5 US approved antiresorptive agents (alendronate, ibandronate, risedronate, zoledronic acid and denosumab), containing over 28 800 women with postmenopausal osteoporosis. The time courses of BTM changes for different drugs were differentiated by maximal effect and onset rate in developed model, while sCTX responses to zoledronic acid and denosumab were captured by another model formation. Furthermore, asynchronous relationship between BTMs and BMD was described by a bone remodelling based semimechanistic model, including zero order production and first order elimination induced by N telopeptide of type 1 collagen and sCTX, separately. After external and informative validations, the developed models were able to predict BMD increase using 1 year data. Conclusion This exploratory analysis built a quantitative framework linking BTMs and BMD among antiresorptive agents, as well as a modelling approach to enhance comprehension of dynamic relationship between early and later endpoints among agents in a certain mechanism of action. Moreover, the developed models can offer predictions of BMD from BTMs supporting early drug development.
C1 [Wu, Junyi; Wang, Chen; Li, Guo Fu; Zheng, Qingshan] Shanghai Univ Tradit Chinese Med, Ctr Drug Clin Res, 1200 Cailun Rd, Shanghai, Peoples R China.
   [Wu, Junyi; Wang, Chen] Amgen Asia R&D Ctr, Clin Pharmacol, Shanghai, Peoples R China.
   [Wang, Chen] Janssen Res & Dev, China R&D & Med Affairs, Clin Pharmacol, Shanghai, Peoples R China.
   [Li, Guo Fu] Yangzhou Univ, Subei Peoples Hosp, Yangzhou, Jiangsu, Peoples R China.
   [Tang, En Tzu] Amgen Asia R&D Ctr, Biostat, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Yangzhou University
RP Zheng, QS (通讯作者)，Shanghai Univ Tradit Chinese Med, Ctr Drug Clin Res, 1200 Cailun Rd, Shanghai, Peoples R China.
EM qingshan.zheng@drugchina.net
RI Li, Guo Fu/P 4396 2017
OI Li, Guo Fu/0000 0002 4628 9941; Wu, Junyi/0000 0001 9017 9400
FU Ministry of Science and Technology of the People's Republic of China
   [2018ZX09731016, 2018ZX09734005]; Science and Technology Commission of
   Shanghai Municipality [17401970900]
FX Ministry of Science and Technology of the People's Republic of China,
   Grant/Award Numbers: 2018ZX09731016, 2018ZX09734005; Science and
   Technology Commission of Shanghai Municipality, Grant/Award Number:
   17401970900
CR Amin S, 2014, J BONE MINER RES, V29, P581, DOI 10.1002/jbmr.2072
   [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Banks E, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000181
   Berkhout J, 2016, CPT PHARMACOMET SYST, V5, P656, DOI 10.1002/psp4.12135
   Black DM, 2018, J BONE MINER RES, V33, P389, DOI 10.1002/jbmr.3194
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bonjour JP, 2014, NUTR RES REV, V27, P252, DOI 10.1017/S0954422414000183
   Brenneman SK, 2006, J BONE MINER RES, V21, P809, DOI 10.1359/JBMR.060301
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445
   Cummings SR, 2002, JAMA J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Delmas PD, 2009, J BONE MINER RES, V24, P1544, DOI [10.1359/JBMR.090310, 10.1359/jbmr.090310]
   Eastell R., 2017, Medicine, V45, P565, DOI DOI 10.1016/J.MPMED.2017.06.004
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Eastell R, 2014, J BONE MINER RES, V29, P458, DOI 10.1002/jbmr.2047
   Eudy Byrne RJ, 2017, J PHARMACOKINET PHAR, V44, P599, DOI 10.1007/s10928 017 9551 z
   Garnero P, 2014, BONE, V66, P46, DOI 10.1016/j.bone.2014.05.016
   Gross JL, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen 2012 001844
   Hasegawa C, 2018, CPT PHARMACOMET SYST, V7, P562, DOI 10.1002/psp4.12324
   JOHNELL O, 1997, AM J MED, V103, P20, DOI DOI 10.1016/S0002 9343(97)90023 1
   Kanis JA, 2009, BONE, V44, P734, DOI 10.1016/j.bone.2009.01.373
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Leslie WD, 2016, ANN INTERN MED, V165, P465, DOI 10.7326/M15 2937
   Mandema JW, 2014, J CLIN ENDOCR METAB, V99, P3746, DOI 10.1210/jc.2013 3795
   Marcus R, 1999, J BONE MINER RES, V14, P1583, DOI 10.1359/jbmr.1999.14.9.1583
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Miller PD, 2011, THER ADV MUSCULOSKEL, V3, P271, DOI 10.1177/1759720X11424220
   Mould DR, 2012, CLIN PHARMACOL THER, V92, P283, DOI 10.1038/clpt.2012.122
   Naylor K, 2012, NAT REV RHEUMATOL, V8, P379, DOI 10.1038/nrrheum.2012.86
   Nguyen ND, 2007, J BONE MINER RES, V22, P781, DOI 10.1359/JBMR.070315
   Peterson MC, 2012, CPT PHARMACOMET SYST, V1, DOI 10.1038/psp.2012.15
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Post TM, 2010, CLIN PHARMACOKINET, V49, P89, DOI 10.2165/11318150 000000000 00000
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Reddy VP, 2011, CLIN PHARMACOKINET, V50, P429, DOI 10.2165/11590590 000000000 00000
   Riggs M.M., 2012, CPT PHARMACOMET SYST, V1, P1
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Singer A, 2015, MAYO CLIN PROC, V90, P53, DOI 10.1016/j.mayocp.2014.09.011
   Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414
   Taylor BC, 2004, J AM GERIATR SOC, V52, P1479, DOI 10.1111/j.1532 5415.2004.52410.x
   Upreti VV, 2019, CLIN PHARMACOL THER, V106, P981, DOI 10.1002/cpt.1462
   Vasikaran S, 2011, CLIN CHEM LAB MED, V49, P1271, DOI 10.1515/CCLM.2011.602
   Vestergaard P, 2001, MATURITAS, V40, P211, DOI 10.1016/S0378 5122(01)00240 7
NR 47
TC 8
Z9 10
U1 1
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0306 5251
EI 1365 2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD MAR
PY 2021
VL 87
IS 3
BP 1175
EP 1186
DI 10.1111/bcp.14487
EA AUG 2020
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA QQ4NN
UT WOS:000555698000001
PM 32692857
OA Bronze
DA 2025 08 17
ER

PT J
AU Choi, YH
   Kim, GS
   Choi, JH
   Jin, SW
   Kim, HG
   Han, Y
   Lee, DY
   Choi, SI
   Kim, SY
   Ahn, YS
   Lee, KY
   Jeong, HG
AF Choi, You Hee
   Kim, Geum Soog
   Choi, Jae Ho
   Jin, Sun Woo
   Kim, Hyung Gyun
   Han, Younho
   Lee, Dae Young
   Choi, Soo Im
   Kim, Seung Yu
   Ahn, Young Sup
   Lee, Kwang Youl
   Jeong, Hye Gwang
TI Ethanol extract of Lithospermum erythrorhizon Sieb. et Zucc.
   promotes osteoblastogenesis through the regulation of Runx2 and Osterix
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE Lithospermum erythrorhizon; Runx2; Osterix; osteoblast differentiation
ID TRANSCRIPTION FACTOR OSTERIX; BONE MORPHOGENETIC PROTEINS; CHINESE
   HERBAL MEDICINE; GENE EXPRESSION; DIFFERENTIATION; SHIKONIN;
   PHOSPHORYLATION; DLX5; INDUCTION; CBFA1
AB Bone remodeling and homeostasis are largely the result of the coordinated action of osteoblasts and osteoclasts. Osteoblasts are responsible for bone formation. The differentiation of osteoblasts is regulated by the transcription factors, Runx2 and Osterix. Natural products of plant origin are still a major part of traditional medicinal systems in Korea. The root of Lithospermum erythrorhizon Sieb. et Zucc. (LR), the purple gromwell, is an herbal medicine used for inflammatory and infectious diseases. LR is an anti inflammatory and exerts anticancer effects by inducing the apoptosis of cancer cells. However, the precise molecular signaling mechanisms of osteoblastogenesis as regards LR and osteoblast transcription are not yet known. In this study, we investigated the effects of ethanol (EtOH) extract of LR (LES) on the osteoblast differentiation of C2C12 myoblasts induced by bone morphogenetic protein 4 (BMP4) and the potential involvement of Runx2 and Osterix in these effects. We found that the LES exhibited an ability to induce osteoblast differentiation. LES increased the expression of the osteoblast marker, alkaline phosphatase (ALP), as well as its activity, as shown by ALP staining and ALP activity assay. LES also increased mineralization, as shown by Alizarin Red S staining. Treatment with LES increased the protein levels (as shown by immunoblotting), as well as the transcriptional activity of Runx2 and Osterix and enhanced osteogenic activity. These results suggest that LES modulates osteoblast differentiation at least in part through Runx2 and Osterix.
C1 [Choi, You Hee; Han, Younho; Lee, Kwang Youl] Chonnam Natl Univ, Coll Pharm, 300 Yongbong Dong, Kwangju 500757, South Korea.
   [Kim, Geum Soog; Lee, Dae Young; Kim, Seung Yu; Ahn, Young Sup] Natl Inst Hort & Herbal Sci, RDA, Dept Herbal Crop Res, Eumseong 369873, South Korea.
   [Choi, Jae Ho; Jin, Sun Woo; Kim, Hyung Gyun; Jeong, Hye Gwang] Chungnam Natl Univ, Coll Pharm, 220 Gung Dong, Taejon 305764, South Korea.
   [Choi, Soo Im] YD Global Life Sci Co Ltd, Songnam 462807, South Korea.
C3 Chonnam National University; National Institute of Horticultural &
   Herbal Science (NIHHS), Republic of Korea; Rural Development
   Administration (RDA), Republic of Korea; Chungnam National University
RP Lee, KY (通讯作者)，Chonnam Natl Univ, Coll Pharm, 300 Yongbong Dong, Kwangju 500757, South Korea.; Jeong, HG (通讯作者)，Chungnam Natl Univ, Coll Pharm, 220 Gung Dong, Taejon 305764, South Korea.
EM kwanglee@jnu.ac.kr; hgjeong@cnu.ac.kr
RI Kim, Junyoung/JGM 1187 2023; Lee, Dae Young/ADO 9686 2022; Kim, Jang
   Hoon/ABU 7953 2022; jin, sun/HZL 7002 2023
OI Lee, Dae Young/0000 0003 4302 3096; Jeong, Hye Gwang/0000 0002 8020 8914
FU Cooperative Research Program for Agriculture Science and Technology
   Development, Rural Development Administration, Republic of Korea
   [PJ01122302]
FX This study was supported by a grant from the Cooperative Research
   Program for Agriculture Science and Technology Development, Rural
   Development Administration, Republic of Korea (project no. PJ01122302).
CR Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378 1119(00)00081 0
   Blum B, 2004, ORTHOPEDICS, V27, pS161
   Chang MJ, 2008, ARCH DERMATOL RES, V300, P317, DOI 10.1007/s00403 008 0867 9
   Chen HM, 2012, CANCER IMMUNOL IMMUN, V61, P1989, DOI 10.1007/s00262 012 1258 9
   Chen X, 2003, ANTIMICROB AGENTS CH, V47, P2810, DOI 10.1128/AAC.47.9.2810 2816.2003
   Cheng AX, 2010, J BONE MINER RES, V25, P2404, DOI 10.1002/jbmr.174
   Choi YH, 2015, MOL CELL ENDOCRINOL, V407, P85, DOI 10.1016/j.mce.2015.03.010
   Choi YH, 2011, BIOCHEM BIOPH RES CO, V411, P637, DOI 10.1016/j.bbrc.2011.07.009
   Dai QM, 2009, MOL BIOL REP, V36, P1597, DOI 10.1007/s11033 008 9356 7
   Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097 4652(200009)184:3<341::AID JCP8>3.3.CO;2 Q
   Fu HH, 2007, J BIOMED MATER RES A, V83A, P770, DOI 10.1002/jbm.a.31356
   Gao H, 2011, BIOL PHARM BULL, V34, P197, DOI 10.1248/bpb.34.197
   Gwon SY, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 207
   Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248 9261.2004
   Hatta M, 2006, INT J MOL MED, V17, P425
   Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032
   Javed A, 2009, CELLS TISSUES ORGANS, V189, P133, DOI 10.1159/000151719
   Jin CJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098232
   JIN R, 1994, YAKUGAKU ZASSHI, V114, P533, DOI 10.1248/yakushi1947.114.7_533
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Kang ES, 2008, EUR J PHARMACOL, V579, P418, DOI 10.1016/j.ejphar.2007.10.070
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kim BG, 2006, PROTEOMICS, V6, P1166, DOI 10.1002/pmic.200500289
   Kim J, 2013, J MED FOOD, V16, P927, DOI 10.1089/jmf.2012.2734
   Kim SJ, 2014, J ETHNOPHARMACOL, V151, P1064, DOI 10.1016/j.jep.2013.11.055
   Kim YJ, 2006, GENE, V366, P145, DOI 10.1016/j.gene.2005.08.021
   Kim YO, 2010, KOREAN J PHYSIOL PHA, V14, P199, DOI 10.4196/kjpp.2010.14.4.199
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   KONNO C, 1985, PLANTA MED, V51, P157, DOI 10.1055/s 2007 969434
   Kotajima S, 2006, UPSALA J MED SCI, V111, P231, DOI 10.3109/2000 1967 044
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Li GH, 2005, J BONE MINER RES, V20, P1611, DOI 10.1359/JBMR.050513
   Li H, 2008, DEV BIOL, V316, P458, DOI 10.1016/j.ydbio.2008.01.001
   Liu XY, 2008, CHEM BIOL INTERACT, V176, P137, DOI 10.1016/j.cbi.2008.07.003
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   New SA, 2000, AM J CLIN NUTR, V71, P142
   Öberg AI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022510
   Ohba Shinsuke, 2007, Nihon Rinsho, V65 Suppl 9, P71
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Ou MM, 2015, CONNECT TISSUE RES, V56, P204, DOI 10.3109/03008207.2014.996701
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   TEITELBAUM SL, 1993, J BONE MINER RES, V8, pS523
   Thuong PT, 2009, BIOORG MED CHEM LETT, V19, P1815, DOI 10.1016/j.bmcl.2009.01.052
   Tu QS, 2006, BIOCHEM BIOPH RES CO, V341, P1257, DOI 10.1016/j.bbrc.2006.01.092
   Tucker KL, 1999, AM J CLIN NUTR, V69, P727
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Wang XC, 2009, BIOL PHARM BULL, V32, P1565, DOI 10.1248/bpb.32.1565
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Youn YN, 2008, GENES NUTR, V2, P375, DOI 10.1007/s12263 007 0062 1
   Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105
   Zhang ZY, 2003, MECH DEVELOP, V120, P1469, DOI 10.1016/j.mod.2003.09.002
NR 61
TC 17
Z9 17
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD AUG
PY 2016
VL 38
IS 2
BP 610
EP 618
DI 10.3892/ijmm.2016.2655
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA DT2CQ
UT WOS:000381288800029
PM 27353217
OA Bronze
DA 2025 08 17
ER

PT J
AU Schmitt, CP
   Hömme, M
   Schaefer, F
AF Schmitt, CP
   Hömme, M
   Schaefer, F
TI Structural organization and biological relevance of oscillatory
   parathyroid hormone secretion
SO PEDIATRIC NEPHROLOGY
LA English
DT Article; Proceedings Paper
CT 7th Symposium on Growth and Development in Children with Chronic Kidney
   Disease
CY APR 01 03, 2004
CL Heidelberg, GERMANY
SP IPNA
DE parathyroid hormone; circadian; ultradian; RGS 2; calcimimetic compound
ID BONE MINERAL DENSITY; SECONDARY HYPERPARATHYROIDISM; CIRCADIAN RHYTHM;
   CALCIUM SUPPLEMENTATION; HEMODIALYSIS PATIENTS; BIOCHEMICAL MARKERS;
   INSULIN RELEASE; PTH SECRETION; VITAMIN D; INTERMITTENT
AB Parathyroid gland secretory activity exhibits seasonal and circadian fluctuations, which are in synchrony with changes in serum calcium, phosphate, and bone turnover. In addition, an ultradian rhythm exists, which comprises seven pulses per hour, accounts for 30% of basal parathyroid hormone (PTH) release, and is highly sensitive to changes in ionized calcium. Acute hypocalcemia induces a selective, severalfold increase in pulse frequency and amplitude, whereas hypercalcemia suppresses the pulsatile secretion component, as does prolonged calcitriol therapy. Chronic renal failure is associated with a GFR dependent decrease in metabolic PTH clearance accounting for a two  to threefold increase in plasma PTH concentrations, a consistent increase of PTH burst mass and frequency, and a markedly reduced capacity to counteract changes in ionized calcium by modulation of pulsatile PTH release. Continuous PTH excess destroys bone, whereas intermittent administration of pharmacological doses of PTH improves bone morphology and strength in experimental and clinical settings. The molecular mechanisms of the exposure pattern dependent, contrasting biological effects of PTH may involve differential regulation of osteoblastic G protein signaling feedback circuits. In this context, calcimimetic and calcilytic agents are promising new therapeutic tools allowing for tight control of plasma PTH and restoration of circadian PTH rhythmicity.
C1 Heidelberg Univ, Childrens Hosp, Div Pediat Nephrol, D 69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Heidelberg Univ, Childrens Hosp, Div Pediat Nephrol, Neuenheimer Feld 153, D 69120 Heidelberg, Germany.
EM claus_peter_schmitt@med.uni heidelberg.de
RI Schaefer, Franz/G 4365 2010
CR Bergsten P, 2000, DIABETES METAB RES, V16, P179, DOI 10.1002/1520 7560(200005/06)16:3<179::AID DMRR115>3.3.CO;2 3
   BERGSTEN P, 1994, J BIOL CHEM, V269, P8749
   BLACK AJ, 1995, J BONE MINER RES, V10, pS457
   BLUMSOHN A, 1994, J CLIN ENDOCR METAB, V79, P730, DOI 10.1210/jc.79.3.730
   CARDINALI DP, 1985, NEUROENDOCRINOLOGY, V40, P291, DOI 10.1159/000124089
   El Hajj Fuleihan G, 1997, J CLIN ENDOCR METAB, V82, P281, DOI 10.1210/jc.82.1.281
   EPSTEIN S, 1983, CALCIFIED TISSUE INT, V35, P32, DOI 10.1007/BF02405003
   Gogusev J, 1997, KIDNEY INT, V51, P328, DOI 10.1038/ki.1997.41
   Goodman WG, 2003, PEDIATR NEPHROL, V18, P1206, DOI 10.1007/s00467 003 1290 2
   Hodsman AB, 2003, J CLIN ENDOCR METAB, V88, P5212, DOI 10.1210/jc.2003 030768
   HOEMME CPM, 2002, PEDIATR NEPHROL, V17, pC123
   Hömme M, 2003, ENDOCRINOLOGY, V144, P2496, DOI 10.1210/en.2002 0160
   Ishii H, 2000, BONE, V26, P175, DOI 10.1016/S8756 3282(99)00263 X
   Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491
   Kobayashi T, 2002, DEVELOPMENT, V129, P2977
   Kuizon BD, 1998, KIDNEY INT, V53, P205, DOI 10.1046/j.1523 1755.1998.00724.x
   LAKATOS P, 1995, J CLIN ENDOCR METAB, V80, P3185, DOI 10.1210/jc.80.11.3185
   LIU JH, 1987, J CLIN ENDOCR METAB, V64, P1027, DOI 10.1210/jcem 64 5 1027
   Lotinun S, 2002, ENDOCRINE, V17, P29, DOI 10.1385/ENDO:17:1:29
   MARKOWITZ ME, 1988, J CLIN ENDOCR METAB, V67, P1068, DOI 10.1210/jcem 67 5 1068
   MIKI H, 1995, ENDOCRINOLOGY, V136, P2954, DOI 10.1210/en.136.7.2954
   Miller MA, 2000, BONE, V27, P511, DOI 10.1016/S8756 3282(00)00350 1
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323
   PFEILSCHIFTER J, 1995, J CLIN INVEST, V96, P767, DOI 10.1172/JCI118121
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   Schmidt SusanneK., 2000, EUR UNION POLIT, V1, P37, DOI DOI 10.1177/1465116500001001003
   Schmitt CP, 1998, J AM SOC NEPHROL, V9, P54
   Schmitt CP, 2003, J AM SOC NEPHROL, V14, P3245, DOI 10.1097/01.ASN.0000101240.47747.7F
   Schmitt CP, 2003, PEDIATR NEPHROL, V18, P440, DOI 10.1007/s00467 003 1091 7
   Schmitt CP, 2003, J AM SOC NEPHROL, V14, P407, DOI 10.1097/01.ASN.0000043905.35268.86
   Schmitt CP, 1998, J AM SOC NEPHROL, V9, P1832
   Schmitt CP, 1996, J CLIN ENDOCR METAB, V81, P4236, DOI 10.1210/jc.81.12.4236
   STERN JE, 1993, NEUROENDOCRINOL LETT, V15, P221
   Storm D, 1998, J CLIN ENDOCR METAB, V83, P3817, DOI 10.1210/jc.83.11.3817
   Strozecki Pawel, 2002, Pol Arch Med Wewn, V108, P867
   Thang N T, 1993, Fukushima J Med Sci, V39, P29
   Tsuruoka S, 2003, BRIT J CLIN PHARMACO, V55, P531, DOI 10.1046/j.1365 2125.2003.01809.x
   Tsuruoka S, 1999, CLIN PHARMACOL THER, V66, P609, DOI 10.1053/cp.1999.v66.103169001
   Woitge HW, 2000, J BONE MINER RES, V15, P2443, DOI 10.1359/jbmr.2000.15.12.2443
   Zittermann A, 2001, J BONE MINER RES, V16, P1733, DOI 10.1359/jbmr.2001.16.9.1733
NR 41
TC 23
Z9 31
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0931 041X
EI 1432 198X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD MAR
PY 2005
VL 20
IS 3
BP 346
EP 351
DI 10.1007/s00467 004 1767 7
PG 6
WC Pediatrics; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Pediatrics; Urology & Nephrology
GA 907JS
UT WOS:000227713600017
PM 15700141
DA 2025 08 17
ER

PT J
AU Huang, MS
   Morony, S
   Lu, JX
   Zhang, Z
   Bezouglaia, O
   Tseng, W
   Tetradis, S
   Demer, LL
   Tintut, Y
AF Huang, Michael S.
   Morony, Sean
   Lu, Jinxiu
   Zhang, Zina
   Bezouglaia, Olga
   Tseng, Wendy
   Tetradis, Sotirios
   Demer, Linda L.
   Tintut, Yin
TI Atherogenic phospholipids attenuate osteogenic signaling by BMP 2 and
   parathyroid hormone in osteoblasts
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN; LOW DENSITY LIPOPROTEIN; MARROW STROMAL
   CELLS; NF KAPPA B; OXIDIZED PHOSPHOLIPIDS; IN VIVO; VASCULAR
   CALCIFICATION; POSTMENOPAUSAL WOMEN; DIFFERENTIATION; ERK
AB Cardiovascular disease, such as atherosclerosis, has been associated with reduced bone mineral density and fracture risk. A major etiologic factor in atherogenesis is believed to be oxidized phospholipids. We previously found that these phospholipids inhibit spontaneous osteogenic differentiation of marrow stromal cells, suggesting that they may account for the clinical link between atherosclerosis and osteoporosis. Currently, anabolic agents that promote bone formation are increasingly used as a new treatment for osteoporosis. It is not known, however, whether atherogenic phospholipids alter the effects of bone anabolic agents, such as bone morphogenetic protein (BMP) 2 and parathyroid hormone (PTH). Therefore we investigated the effects of oxidized 1 palmitoyl 2 arachidonoyl sn glycero 3 phosphorylcholine (ox PAPC) on osteogenic signaling induced by BMP 2 and PTH in MC3T3 E1 cells. Results showed that ox PAPC attenuated BMP 2 induction of osteogenic markers alkaline phosphatase and osteocalcin. Ox PAPC also inhibited both spontaneous and BMP induced expression of PTH receptor. Consistently, pretreatment of cells with ox PAPC inhibited PTH induced cAMP production and expression of immediate early genes Nurr1 and IL 6. Results from immunofluorescence and Western blot analyses showed that inhibitory effects of ox PAPC on BMP 2 signaling were associated with inhibition of SMAD 1/5/8 but not p38 MAPK activation. These effects appear to be due to ox PAPC activation of the ERK pathway, as the ERK inhibitor PD98059 reversed ox PAPC inhibitory effects on BMP 2 induced alkaline phosphatase activity, osteocalcin expression, and SMAD activation. These results suggest that atherogenic lipids inhibit osteogenic signaling induced by BMP 2 and PTH, raising the possibility that hyperlipidemia and atherogenic phospholipids may interfere with anabolic therapy.
C1 Univ Calif Los Angeles, Sch Dent, Dept Med, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, Sch Dent, Dept Physiol, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, Sch Dent, Dept Mol Cellular Integrat Physiol, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Los Angeles, CA 90095 USA.
   Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91320 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   Amgen
RP Tintut, Y (通讯作者)，Univ Calif Los Angeles, Sch Dent, Dept Med, CHS BH 307,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM ytintut@mednet.ucla.edu
RI Demer, Linda/I 5770 2013
OI Demer, Linda/0000 0002 9618 6895
FU NHLBI NIH HHS [HL081202, R01 HL081202] Funding Source: Medline; NIDDK
   NIH HHS [R21 DK076009, DK076009 01] Funding Source: Medline; NIGMS NIH
   HHS [T32 GM065823] Funding Source: Medline
CR Abedin M, 2006, CIRC RES, V98, P727, DOI 10.1161/01.RES.0000216009.68958.e6
   Bagger YZ, 2006, J INTERN MED, V259, P598, DOI 10.1111/j.1365 2796.2006.01640.x
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Barengolts EI, 1998, CALCIFIED TISSUE INT, V62, P209, DOI 10.1007/s002239900419
   Chae HJ, 2002, IMMUNOPHARM IMMUNOT, V24, P31, DOI 10.1081/IPH 120003401
   Chan GK, 2003, ENDOCRINOLOGY, V144, P5511, DOI 10.1210/en.2003 0273
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134
   Date T, 2004, J ORTHOP SCI, V9, P503, DOI 10.1007/s00776 004 0815 2
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   Furnkranz A, 2005, ARTERIOSCL THROM VAS, V25, P633, DOI 10.1161/01.ATV.0000153106.03644.a0
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Iida Klein A, 2005, J ENDOCRINOL, V186, P549, DOI 10.1677/joe.1.06270
   Jie KSG, 1996, CALCIFIED TISSUE INT, V59, P352, DOI 10.1007/s002239900139
   JOHNSON EE, 1988, CLIN ORTHOP RELAT R, P257
   Ju WJ, 2000, J BONE MINER RES, V15, P1889, DOI 10.1359/jbmr.2000.15.10.1889
   Kadl A, 2002, VASC PHARMACOL, V38, P219, DOI 10.1016/S1537 1891(02)00172 6
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kono SJ, 2007, BONE, V40, P68, DOI 10.1016/j.bone.2006.07.024
   Krönke G, 2003, J BIOL CHEM, V278, P51006, DOI 10.1074/jbc.M304103200
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210
   MA YF, 1995, J BONE MINER RES, V10, P496
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Orozco P, 2004, EUR J EPIDEMIOL, V19, P1105, DOI 10.1007/s10654 004 1706 8
   Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005 0303
   Parhami F, 1999, J BONE MINER RES, V14, P2067, DOI 10.1359/jbmr.1999.14.12.2067
   Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680
   Parhami F, 2001, J BONE MINER RES, V16, P182, DOI 10.1359/jbmr.2001.16.1.182
   Pirih FQ, 2003, BIOCHEM BIOPH RES CO, V306, P144, DOI 10.1016/S0006 291X(03)00931 8
   Pirih FQ, 2005, BIOCHEM BIOPH RES CO, V332, P494, DOI 10.1016/j.bbrc.2005.04.132
   RODAN GA, 1992, BONE S1, V13, P3
   Shao JS, 2003, J BIOL CHEM, V278, P50195, DOI 10.1074/jbc.M308825200
   Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593
   Tintut Y, 2004, ARTERIOSCL THROM VAS, V24, pE6, DOI 10.1161/01.ATV.0000112023.62695.7f
   Tintut Y, 2002, J BIOL CHEM, V277, P14221, DOI 10.1074/jbc.M111551200
   Urist MR, 1997, CONNECT TISSUE RES, V36, P9, DOI 10.3109/03008209709160210
   Velardez MO, 2001, MOL CELL ENDOCRINOL, V172, P7, DOI 10.1016/S0303 7207(00)00399 3
   Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Yamaguchi T, 2002, ENDOCR J, V49, P211, DOI 10.1507/endocrj.49.211
NR 42
TC 40
Z9 45
U1 1
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 20
PY 2007
VL 282
IS 29
BP 21237
EP 21243
DI 10.1074/jbc.M701341200
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 190GP
UT WOS:000248047500051
PM 17522049
OA Green Accepted, hybrid
DA 2025 08 17
ER

PT J
AU Gaffo, AL
   Saag, K
   Doyle, AJ
   Melnick, J
   Horne, A
   Foster, J
   Mudano, A
   Biggers Clark, S
   Redden, D
   Dalbeth, N
AF Gaffo, Angelo L.
   Saag, Kenneth
   Doyle, Anthony J.
   Melnick, Joshua
   Horne, Anne
   Foster, Jeffrey
   Mudano, Amy
   Biggers Clark, Stephanie
   Redden, David
   Dalbeth, Nicola
TI Denosumab did not improve computerized tomography erosion scores when
   added to intensive urate lowering therapy in gout: Results from a pilot
   randomized controlled trial
SO SEMINARS IN ARTHRITIS AND RHEUMATISM
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the American College of Rheumatology (ACR)
CY NOV 05 09, 2020
CL ELECTR NETWORK
SP Amer Coll Rheumatol
ID BONE EROSION; STRUCTURAL DAMAGE; AMERICAN COLLEGE; TOPHACEOUS GOUT;
   DOUBLE BLIND; MANAGEMENT; ANTIBODY; RANKL
AB Background/Purpose: Disordered osteoclast activity has been implicated in the pathogenesis of gouty bone erosion. We sought to determine if the addition of denosumab (a monoclonal antibody targeting the receptor activator of nuclear factor kappa B ligand   RANKL) to intensive urate lowering therapy (ULT) improves gouty bone erosion.
   Methods: Open label, parallel group pilot randomized controlled trial in which 20 participants with gout with at least one confirmed conventional radiographic foot bone erosion were assigned in a 1:1 allocation to receive denosumab (60 mg subcutaneous every 6 months) added to intensive ULT (serum urate <= 5 mg/dL or 300 mu mol/L at the time of randomization and continued for the duration of the study), or intensive ULT alone. The primary outcome was the change in the bilateral foot and ankle computed tomography (CT) bone erosion score from baseline to 12 months, assessed by an experienced musculoskeletal radiologist blinded to study assignment. Secondary outcomes included change in serum C terminal telopeptide (CTX), and patient reported outcomes of pain and function.
   Results: Although serum CTX declined markedly in the denosumab/ULT group compared with the ULT alone group, there was no interval change in CT erosion score in either the denosumab/ULT or ULT alone group after one year of follow up. Other secondary outcomes did not differ between groups. There were two severe adverse events: One patient developed atrial fibrillation (on denosumab/ULT) and another atrial flutter (on ULT alone).
   Conclusions: In this pilot study, denosumab did not offer additional benefit to intensive urate lowering therapy for gouty bone erosion. Published by Elsevier Inc.
C1 [Gaffo, Angelo L.; Saag, Kenneth; Melnick, Joshua; Foster, Jeffrey; Mudano, Amy; Biggers Clark, Stephanie] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL USA.
   [Gaffo, Angelo L.] Birmingham VA Med Ctr, Birmingham, AL USA.
   [Doyle, Anthony J.; Horne, Anne; Dalbeth, Nicola] Univ Auckland, Auckland, New Zealand.
   [Doyle, Anthony J.] Auckland Dist Hlth Board, Auckland, New Zealand.
   [Redden, David] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Veterans Affairs Medical Center   Birmingham; University of Auckland;
   Auckland District Health Board; University of Alabama System; University
   of Alabama Birmingham
RP Gaffo, AL (通讯作者)，SHEL 306,1720 2nd Ave South, Birmingham, AL 35294 USA.
EM agaffo@uabmc.edu
RI ; Gaffo, Angelo/ABD 1653 2021
OI Gaffo, Angelo/0000 0001 7365 7212; 
FU Amgen, Inc [ISS 20159195]
FX This clinical trial was funded by Amgen, Inc (ISS 20159195)
CR Bursill D, 2019, ANN RHEUM DIS, V78, P1592, DOI 10.1136/annrheumdis 2019 215933
   Chhana A, 2016, J RHEUMATOL, V43, P445, DOI 10.3899/jrheum.150738
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Dalbeth N, 2008, ARTHRITIS RHEUM US, V58, P1854, DOI 10.1002/art.23488
   Dalbeth N, 2019, ARTHRITIS RHEUMATOL, V71, P1739, DOI 10.1002/art.40929
   Dalbeth N, 2014, ANN RHEUM DIS, V73, P1044, DOI 10.1136/annrheumdis 2013 205036
   Dalbeth N, 2011, RHEUMATOLOGY, V50, P410, DOI 10.1093/rheumatology/keq335
   FitzGerald JD, 2020, ARTHRIT CARE RES, V72, P744, DOI 10.1002/acr.24180
   Ishiguro N, 2019, RHEUMATOLOGY, V58, P997, DOI 10.1093/rheumatology/key416
   Jarrett SJ, 2006, ARTHRITIS RHEUM US, V54, P1410, DOI 10.1002/art.21824
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lee SJ, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3483
   Neogi T, 2015, ARTHRITIS RHEUMATOL, V67, P2557, DOI [10.1002/art.39254, 10.1136/annrheumdis 2015 208237]
   Ostergaard M, 2005, ANN RHEUM DIS, V64, P3, DOI 10.1136/ard.2004.031773
   Richette P, 2017, ANN RHEUM DIS, V76, P29, DOI [10.1136/annrheumdis 2016 209707, 10.1136/annrheumdis 2016 210356]
   Stewart S, 2020, RHEUMATOLOGY, V59, P1440, DOI 10.1093/rheumatology/kez588
   Takeuchi T, 2019, ANN RHEUM DIS, V78, P899, DOI 10.1136/annrheumdis 2018 214827
NR 17
TC 4
Z9 4
U1 0
U2 3
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0049 0172
EI 1532 866X
J9 SEMIN ARTHRITIS RHEU
JI Semin. Arthritis Rheum.
PD DEC
PY 2021
VL 51
IS 6
BP 1218
EP 1223
DI 10.1016/j.semarthrit.2021.10.002
EA OCT 2021
PG 6
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Rheumatology
GA WS3GE
UT WOS:000715072700003
PM 34706311
DA 2025 08 17
ER

PT J
AU Panicker, LM
   Srikanth, MP
   Castro Gomes, T
   Miller, D
   Andrews, NW
   Feldman, RA
AF Panicker, Leelamma M.
   Srikanth, Manasa P.
   Castro Gomes, Thiago
   Miller, Diana
   Andrews, Norma W.
   Feldman, Ricardo A.
TI Gaucher disease iPSC derived osteoblasts have developmental and
   lysosomal defects that impair bone matrix deposition
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PLASMA MEMBRANE REPAIR; ALKALINE PHOSPHATASE; ENZYME REPLACEMENT;
   MINERAL DENSITY; STEM CELLS; GLUCOCEREBROSIDASE; TYPE 1; DEFICIENCY;
   DIFFERENTIATION; ELIGLUSTAT
AB Gaucher disease (GD) is caused by bi allelic mutations in GBA1, the gene that encodes acid beta glucocerebrosidase (GCase). Individuals affected by GD have hematologic, visceral and bone abnormalities, and in severe cases there is also neurodegeneration. To shed light on the mechanisms by which mutant GBA1 causes bone disease, we examined the ability of human induced pluripotent stem cells (iPSC) derived from patients with Types 1, 2 and 3 GD, to differentiate to osteoblasts and carry out bone deposition. Differentiation of GD iPSC to osteoblasts revealed that these cells had developmental defects and lysosomal abnormalities that interfered with bone matrix deposition. Compared with controls, GD iPSC derived osteoblasts exhibited reduced expression of osteoblast differentiation markers, and bone matrix protein and mineral deposition were defective. Concomitantly, canonical Wnt/beta catenin signaling in the mutant osteoblasts was downregulated, whereas pharmacological Wnt activation with the GSK3 beta inhibitor CHIR99021 rescued GD osteoblast differentiation and bone matrix deposition. Importantly, incubation with recombinant GCase (rGCase) rescued the differentiation and bone forming ability of GD osteoblasts, demonstrating that the abnormal GD phenotype was caused by GCase deficiency. GD osteoblasts were also defective in their ability to carry out Ca2+ dependent exocytosis, a lysosomal function that is necessary for bone matrix deposition. We conclude that normal GCase enzymatic activity is required for the differentiation and bone forming activity of osteoblasts. Furthermore, the rescue of bone matrix deposition by pharmacological activation of Wnt/beta catenin in GD osteoblasts uncovers a new therapeutic target for the treatment of bone abnormalities in GD.
C1 [Panicker, Leelamma M.; Srikanth, Manasa P.; Miller, Diana; Feldman, Ricardo A.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, 685 West Baltimore St,HSF 1,Room 380, Baltimore, MD 21201 USA.
   [Castro Gomes, Thiago; Andrews, Norma W.] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland College Park
RP Feldman, RA (通讯作者)，Univ Maryland, Sch Med, Dept Microbiol & Immunol, 685 West Baltimore St,HSF 1,Room 380, Baltimore, MD 21201 USA.
EM rfeldman@som.umaryland.edu
RI ; Gomes, Thiago/H 5567 2015
OI Feldman, Ricardo A./0000 0001 6090 0439; Andrews,
   Norma/0000 0002 0611 2412; Srikanth, Manasa/0000 0002 9831 4141
FU Maryland Stem Cell Research Fund (MSCRF) [2009 MSCRFII 0082 00];
   UMB/UMCP Research Seed Program Grant; NIH [R01 GM064625]
FX This work was supported by grants from the Maryland Stem Cell Research
   Fund (MSCRF) 2009 MSCRFII 0082 00 (RAF), a UMB/UMCP Research Seed
   Program Grant (RAF and NWA), and NIH R01 GM064625 (NWA).
CR Allen MJ, 1997, QJM MON J ASSOC PHYS, V90, P19
   Andrews NW, 2002, J CELL BIOL, V158, P389, DOI 10.1083/jcb.200205110
   Awad O, 2017, STEM CELL REP, V9, P1853, DOI 10.1016/j.stemcr.2017.10.029
   Awad O, 2015, HUM MOL GENET, V24, P5775, DOI 10.1093/hmg/ddv297
   Barak V, 1999, EUR CYTOKINE NETW, V10, P205
   Barclay JW, 2005, CELL CALCIUM, V38, P343, DOI 10.1016/j.ceca.2005.06.012
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bembi B, 2002, BRIT J RADIOL, V75, pA37, DOI 10.1259/bjr.75.suppl_1.750037
   Biegstraaten M., 2016, BLOOD CELL MOL DIS, V68, P203
   Bijsterbosch MK, 1996, EUR J BIOCHEM, V237, P344, DOI 10.1111/j.1432 1033.1996.00344.x
   Bin Hong Y, 2006, J KOREAN MED SCI, V21, P733, DOI 10.3346/jkms.2006.21.4.733
   Bodine P.V., 2007, BoneKEy Osteovision, V4, P108
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brady RO, 2006, ANNU REV MED, V57, P283, DOI 10.1146/annurev.med.57.110104.115650
   BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006 291X(65)90743 6
   BRADY RO, 1966, J CLIN INVEST, V45, P1112, DOI 10.1172/JCI105417
   Canalis E, 2018, EUR J ENDOCRINOL, V178, pR33, DOI 10.1530/EJE 17 0920
   Castro Gomes T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152583
   Cox TM, 2010, BIOL TARGETS THER, V4, P299, DOI 10.2147/BTT.S7582
   Cox TM, 1997, BAILLIERE CLIN HAEM, V10, P657, DOI 10.1016/S0950 3536(97)80033 9
   Dandana A, 2016, PATHOBIOLOGY, V83, P13, DOI 10.1159/000440865
   Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384
   Du TT, 2015, AUTOPHAGY, V11, P1803, DOI 10.1080/15548627.2015.1086055
   Elstein D, 1997, BAILLIERE CLIN HAEM, V10, P793, DOI 10.1016/S0950 3536(97)80041 8
   Elstein D, 2011, BLOOD CELL MOL DIS, V47, P56, DOI 10.1016/j.bcmd.2011.04.005
   Enquist IB, 2007, P NATL ACAD SCI USA, V104, P17483, DOI 10.1073/pnas.0708086104
   Farfel Becker T, 2011, HUM MOL GENET, V20, P1375, DOI 10.1093/hmg/ddr019
   Fierro FA, 2017, STEM CELLS, V35, P1461, DOI 10.1002/stem.2625
   Fujisawa R, 2012, FRONT BIOSCI LANDMRK, V17, P1891, DOI 10.2741/4026
   Garber K, 2016, NAT REV DRUG DISCOV, V15, P445, DOI 10.1038/nrd.2016.132
   Giuffrida G, 2012, HEMATOL REP, V4, P70, DOI 10.4081/hr.2012.e21
   Goker Alpan O, 2011, MOL GENET METAB, V104, P438, DOI 10.1016/j.ymgme.2011.08.004
   Grabowski G. A., 2014, METABOLIC MOL BASES, P3635
   Gramlich PA, 2016, J BIOTECHNOL, V221, P1, DOI 10.1016/j.jbiotec.2016.01.015
   Huynh C, 2004, P NATL ACAD SCI USA, V101, P16795, DOI 10.1073/pnas.0405905101
   Ishibashi H, 2017, BONE, V103, P209, DOI 10.1016/j.bone.2017.07.005
   Jeon OH, 2016, SCI REP UK, V6, DOI 10.1038/srep26761
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Kamath RS, 2014, SKELETAL RADIOL, V43, P1353, DOI 10.1007/s00256 014 1891 9
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lukina E, 2010, BLOOD, V116, P893, DOI 10.1182/blood 2010 03 273151
   Machaczka M, 2011, J INHERIT METAB DIS, V34, P233, DOI 10.1007/s10545 010 9241 0
   Maor G, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750 1172 8 140
   Mucci JM, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/192761
   Mazzulli JR, 2011, CELL, V146, P37, DOI 10.1016/j.cell.2011.06.001
   Messner MC, 2010, ADV EXP MED BIOL, V688, P156
   Mignot C, 2013, HAND CLINIC, V113, P1709, DOI 10.1016/B978 0 444 59565 2.00040 X
   Mistry PK, 2017, AM J HEMATOL, V92, P1170, DOI 10.1002/ajh.24877
   Mistry PK, 2015, JAMA J AM MED ASSOC, V313, P695, DOI 10.1001/jama.2015.459
   Mistry PK, 2011, BLOOD CELL MOL DIS, V46, P66, DOI 10.1016/j.bcmd.2010.10.011
   Mistry PK, 2010, P NATL ACAD SCI USA, V107, P19473, DOI 10.1073/pnas.1003308107
   Moors T, 2016, MOVEMENT DISORD, V31, P791, DOI 10.1002/mds.26562
   Moran MT, 2000, BLOOD, V96, P1969, DOI 10.1182/blood.V96.5.1969.h8001969_1969_1978
   Mornet E, 2001, J BIOL CHEM, V276, P31171, DOI 10.1074/jbc.M102788200
   Mucci JM, 2013, GENE, V532, P186, DOI 10.1016/j.gene.2013.09.072
   Nabavi N, 2008, J BIOL CHEM, V283, P19678, DOI 10.1074/jbc.M802517200
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Panicker LM, 2014, STEM CELLS, V32, P2338, DOI 10.1002/stem.1732
   Panicker LM, 2012, P NATL ACAD SCI USA, V109, P18054, DOI 10.1073/pnas.1207889109
   Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092 8674(01)00421 4
   Schöndorf DC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5028
   Sgambato JA, 2015, STEM CELL TRANSL MED, V4, P878, DOI 10.5966/sctm.2014 0213
   Sharma U, 2014, INDIAN J CLIN BIOCHE, V29, P269, DOI 10.1007/s12291 013 0408 y
   Sidransky E, 2004, MOL GENET METAB, V83, P6, DOI 10.1016/j.ymgme.2004.08.015
   Sidransky E, 2012, DISCOV MED, V14, P273
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Sun Y, 2010, AUTOPHAGY, V6, P648, DOI 10.4161/auto.6.5.12047
   Suzuki T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069147
   Thomas AS, 2014, BRIT J HAEMATOL, V165, P427, DOI 10.1111/bjh.12804
   TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349
   Tsukimura T, 2008, BIOL PHARM BULL, V31, P1691, DOI 10.1248/bpb.31.1691
   Van Patten SM, 2007, GLYCOBIOLOGY, V17, P467, DOI 10.1093/glycob/cwm008
   Verheyen EM, 2010, DEV DYNAM, V239, P34, DOI 10.1002/dvdy.22019
   Vitner Einat B, 2013, Handb Exp Pharmacol, P405, DOI 10.1007/978 3 7091 1511 4_20
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wong KD, 2004, MOL GENET METAB, V82, P192, DOI 10.1016/j.ymgme.2004.04.011
   Young MF, 2003, OSTEOPOROSIS INT, V14, pS35, DOI 10.1007/s00198 002 1342 7
   Zancan I, 2015, HUM MOL GENET, V24, P1280, DOI 10.1093/hmg/ddu538
   Zhao HB, 2012, TRAFFIC, V13, P1307, DOI 10.1111/j.1600 0854.2012.01395.x
NR 81
TC 29
Z9 31
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964 6906
EI 1460 2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAR 1
PY 2018
VL 27
IS 5
BP 811
EP 822
DI 10.1093/hmg/ddx442
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA FY5AJ
UT WOS:000426838200004
PM 29301038
OA Green Published
DA 2025 08 17
ER

PT J
AU Dou, AX
   Zhang, Y
   Wang, YJ
   Liu, XL
   Guo, YN
AF Dou, Aixia
   Zhang, Ying
   Wang, Yongjing
   Liu, Xiaoli
   Guo, Yanan
TI Reelin depletion alleviates multiple myeloma bone disease by promoting
   osteogenesis and inhibiting osteolysis
SO CELL DEATH DISCOVERY
LA English
DT Article
ID DRUG RESISTANCE; CANCER; CELLS; EXPRESSION; ADHESION; DIFFERENTIATION;
   GENES; TUMOR
AB Extracellular matrix glycoprotein Reelin is associated with tumor metastasis and prognosis in various malignancies. However, its effects on multiple myeloma (MM) are not fully understood. Here, we investigated the regulatory effects of Reelin on MM and its underlying pathogenic mechanisms. Lentivirus plasmid containing short hairpin RNA targeting Reelin (LV3 Reln) was transfected into SP2/0 cells to knockdown Reelin expression. Flow cytometry assay analyzed cell cycle and apoptosis while Transwell assay evaluated invasiveness. BALB/c mice were inoculated with LV3 Reln transfected SP2/0 cells to establish MM model. Primary myeloma cells and osteoblasts/osteoclast were isolated from tumor tissue and limb long bones respectively. ELISA examined serum biomarkers and immunohistochemistry detected immunoglobulin light chain expression. Morphological changes and osteoclast/osteoblast differentiation were observed by histological staining. mRNA and proteins expression were determined by qPCR and WB. In vitro studies showed that Reelin depletion regulated osteolysis and osteogenesis balance, cell cycle, invasiveness, and apoptosis in SP2/0 cells. In LV3 Reln mice, tumor growth and invasiveness were suppressed, meanwhile, reduced osteoclast activation and enhanced osteoblast activity were observed. Reelin knockdown alleviated extramedullary morbidity and inhibited spleen immune cell apoptosis by down regulating CDK5, IL 10, and Cyto C expression. Furthermore, reduced Reelin expression restrained osteoclast differentiation while promoted osteogenesis in the bone of LV3 Reln mice. This was further supported by down regulation of osteolytic specific mRNAs and proteins (Trap, Mmp9, Ctsk, Clcn7) and up regulation of osteogenic specific ones (COL 1, Runx2, beta Catenin). Reelin exerted important impacts on myeloma development through rebalancing osteolysis and osteogenesis, thus might be a potential therapeutic target for MM.
C1 [Dou, Aixia; Zhang, Ying; Wang, Yongjing; Liu, Xiaoli; Guo, Yanan] Shandong Univ, Cheeloo Coll Med, Hosp 2, Dept Hematol, Jinan, Shandong, Peoples R China.
C3 Shandong University
RP Dou, AX (通讯作者)，Shandong Univ, Cheeloo Coll Med, Hosp 2, Dept Hematol, Jinan, Shandong, Peoples R China.
EM douax0110@163.com
RI guo, yanan/AAI 9839 2021
FU Jinan Clinical Medical Science and Technology Innovation Program
   [202019141]
FX lThis work was supported by Jinan Clinical Medical Science and
   Technology Innovation Program (No. 202019141).
CR Abe M, 2011, INT J HEMATOL, V94, P334, DOI 10.1007/s12185 011 0949 x
   Armstrong NC, 2019, INT J BIOCHEM CELL B, V112, P72, DOI 10.1016/j.biocel.2019.04.009
   Bleicher F, 2001, Adv Dent Res, V15, P30
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chao TY, 2010, CLIN CHIM ACTA, V411, P1553, DOI 10.1016/j.cca.2010.06.027
   Colombo M, 2015, ONCOTARGET, V6, P26826, DOI 10.18632/oncotarget.5025
   Dohi O, 2010, INT J ONCOL, V36, P85, DOI 10.3892/ijo_00000478
   Dou AX, 2017, ONCOL REP, V37, P3572, DOI 10.3892/or.2017.5626
   Eda Homare, 2016, Cancer Treat Res, V169, P251
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Hameed A, 2014, CANCER GROWTH METAST, V7, P33, DOI 10.4137/CGM.S16817
   Hong SM, 2008, MODERN PATHOL, V21, P1499, DOI 10.1038/modpathol.2008.157
   Kim JH, 2019, INT J MOL MED, V44, P913, DOI 10.3892/ijmm.2019.4269
   Kobune M, 2007, MOL CANCER THER, V6, P1774, DOI 10.1158/1535 7163.MCT 06 0684
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Lee GH, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00122
   Lin L, 2017, J CANCER, V8, P2212, DOI 10.7150/jca.18808
   Lin L, 2016, ONCOTARGET, V7, P9844, DOI 10.18632/oncotarget.7151
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Perrone G, 2007, MODERN PATHOL, V20, P344, DOI 10.1038/modpathol.3800743
   Qiang YW, 2005, BLOOD, V106, P1786, DOI 10.1182/blood 2005 01 0049
   Qin XD, 2017, SCI REP UK, V7, DOI 10.1038/srep45305
   Sato Y, 2016, J BIOCHEM, V159, P305, DOI 10.1093/jb/mvv102
   Seigel GM, 2007, MOL VIS, V13, P823
   Skottke J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081998
   Stein T, 2010, AM J PATHOL, V177, P2323, DOI 10.2353/ajpath.2010.100209
   Suh KS, 2013, FOOD CHEM TOXICOL, V62, P99, DOI 10.1016/j.fct.2013.08.047
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   Terpos E, 2011, CANCER IMMUNOL IMMUN, V60, P305, DOI 10.1007/s00262 011 0974 x
   Vignot S, 2015, EUR J CANCER, V51, P791, DOI 10.1016/j.ejca.2015.02.012
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wang Q, 2002, CANCER LETT, V179, P71, DOI 10.1016/S0304 3835(01)00846 1
   Yuan Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031802
   Zhang C, 2013, ONCOL REP, V30, P2442, DOI 10.3892/or.2013.2686
NR 35
TC 8
Z9 10
U1 1
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2058 7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PD AUG 25
PY 2021
VL 7
IS 1
AR 219
DI 10.1038/s41420 021 00608 8
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA UF4OD
UT WOS:000688553700001
PM 34433809
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xuan, WH
   Feng, XK
   Qian, C
   Peng, LY
   Shi, YM
   Xu, LX
   Wang, F
   Tan, WF
AF Xuan, Wenhua
   Feng, Xiaoke
   Qian, Chen
   Peng, Liuying
   Shi, Yumeng
   Xu, Lingxiao
   Wang, Fang
   Tan, Wenfeng
TI Osteoclast differentiation gene expression profiling reveals chemokine
   CCL4 mediates RANKL induced osteoclast migration and invasion via PI3K
   pathway
SO CELL BIOCHEMISTRY AND FUNCTION
LA English
DT Article
DE CCL4; chemokine; migration; osteoclast
ID CHEMOTACTIC RECRUITMENT; RHEUMATOID ARTHRITIS; PROMOTES; PRECURSORS;
   MICE; TARGETS; MYELOMA; LIGAND; CELLS
AB The migration of osteoclasts (OCs) from circulation and bone marrow into bone surface plays a critical role in the pathogenesis of some bone resorptive diseases, such as rheumatoid arthritis and osteoporosis. To date, how the migration of OCs remains unclear. We investigated gene expression profiling in osteoclastic differentiation of bone marrow derived macrophages (BMMs) into OCs by microarray analysis. We identified 387 genes overexpressed in osteoclastic differentiation of BMMs. Among them, chemokine CCL4 showed a robust up regulation signal. High expression of CCL4 was validated in primary BMMs and OC precursor cell line RAW264.7 during differentiation into OCs. The CCL4 neutralization decreased RANKL induced OC precursor cell migration and invasion in Matrigel coated transwell membranes assay and in vitro wound healing assay. However, CCL4 inhibition did not affect OCs differentiation and differentiation associated gene expression. The CCL4 inhibition promoted the PI3K phosphorylation at 45 to 60minutes after RANKL stimulation in RAW264.7. This study indicated that chemokine CCL4 is an important regulator for OCs migration via PI3K pathway, providing a novel therapy target for bone resorptive diseases.
C1 [Xuan, Wenhua; Qian, Chen; Peng, Liuying; Shi, Yumeng; Xu, Lingxiao; Tan, Wenfeng] Nanjing Med Univ, Dept Rheumatol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Feng, Xiaoke] Nanjing Med Univ, Affiliated Hosp 1, Dept Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China.
   [Wang, Fang] Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Tan, WF (通讯作者)，Nanjing Med Univ, Dept Rheumatol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.; Wang, F (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM fangwang7608@263.net; tw2006@njmu.edu.cn
RI Shi, Yumeng/AAP 4236 2020
OI Tan, Wenfeng/0000 0002 5160 2023
FU National Natural Science Foundation of China (NSFC) [30701129, 81471611,
   81172845, 81471610]; National Natural Science Foundation of Jiangsu
   province [BK2011851]; clinical medicine from Jiangsu province
   [BL2013034]
FX National Natural Science Foundation of China (NSFC), Grant/Award Number:
   30701129 (WT), 81471611 (FW), 81172845(WT), 81471610(WT); National
   Natural Science Foundation of Jiangsu province, Grant/Award Number:
   BK2011851 (WT); clinical medicine from Jiangsu province, Grant/Award
   Number: BL2013034(WT)
CR Bartok B, 2014, J IMMUNOL, V192, P2063, DOI 10.4049/jimmunol.1300950
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chalabi Dchar M, 2015, GASTROENTEROLOGY, V148, P1452, DOI 10.1053/j.gastro.2015.02.009
   Cheung R, 2009, J LEUKOCYTE BIOL, V86, P833, DOI 10.1189/jlb.0908551
   Crotti TN, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/281287
   Dapunt U, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/728619
   Ferreira SB, 2011, J DENT RES, V90, P632, DOI 10.1177/0022034510395021
   Gan K, 2015, INT IMMUNOPHARMACOL, V24, P239, DOI 10.1016/j.intimp.2014.12.012
   Gao Y, 2015, INT J ONCOL, V47, P690, DOI 10.3892/ijo.2015.3041
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Han KH, 2014, BONE, V61, P91, DOI 10.1016/j.bone.2013.12.032
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Khan UA, 2016, J CELL BIOCHEM, V117, P382, DOI 10.1002/jcb.25282
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Koch AE, 2005, ARTHRITIS RHEUM, V52, P710, DOI 10.1002/art.20932
   Li Y, 2015, ONCOTARGET, V6, P24218, DOI 10.18632/oncotarget.4523
   Maurer M, 2004, INT J BIOCHEM CELL B, V36, P1882, DOI 10.1016/j.biocel.2003.10.019
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Nakayamada Shingo, 2015, Clin Calcium, V25, P1787, DOI CliCa151217871793
   Paparodis R, 2013, ENDOCR PRACT, V19, pE64, DOI 10.4158/EP12367.CR
   Repeke CE, 2010, BONE, V46, P1122, DOI 10.1016/j.bone.2009.12.030
   Russkamp NF, 2015, FASEB J, V29, P3762, DOI 10.1096/fj.15 271635
   Tow K, 2004, LAB INVEST, V84, P1092, DOI 10.1038/labinvest.3700132
   Valerio MS, 2015, CYTOKINE, V71, P71, DOI 10.1016/j.cyto.2014.08.007
   Wintges K, 2013, J BONE MINER RES, V28, P2070, DOI 10.1002/jbmr.1937
   Wright LM, 2005, BONE, V36, P840, DOI 10.1016/j.bone.2005.01.021
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
   Yu XF, 2004, J BONE MINER RES, V19, P2065, DOI 10.1359/JBMR.040910
   Zhang XY, 2016, J BONE MINER RES, V31, P336, DOI 10.1002/jbmr.2693
NR 30
TC 32
Z9 40
U1 1
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0263 6484
EI 1099 0844
J9 CELL BIOCHEM FUNCT
JI Cell Biochem. Funct.
PD APR
PY 2017
VL 35
IS 3
BP 171
EP 177
DI 10.1002/cbf.3260
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA ET0HY
UT WOS:000399944000005
PM 28370169
DA 2025 08 17
ER

PT J
AU Zhang, SX
   Xu, YR
   Xie, C
   Ren, LL
   Wu, GY
   Yang, MZS
   Wu, XG
   Tang, ML
   Hu, YM
   Li, ZW
   Yu, RY
   Liao, XY
   Mo, S
   Wu, JH
   Li, MF
   Song, EW
   Qi, YF
   Song, LB
   Li, J
AF Zhang, Shuxia
   Xu, Yingru
   Xie, Chan
   Ren, Liangliang
   Wu, Geyan
   Yang, Meisongzhu
   Wu, Xingui
   Tang, Miaoling
   Hu, Yameng
   Li, Ziwen
   Yu, Ruyuan
   Liao, Xinyi
   Mo, Shuang
   Wu, Jueheng
   Li, Mengfeng
   Song, Erwei
   Qi, Yanfei
   Song, Libing
   Li, Jun
TI RNF219/α Catenin/LGALS3 Axis Promotes Hepatocellular Carcinoma
   Bone Metastasis and Associated Skeletal Complications
SO ADVANCED SCIENCE
LA English
DT Article
DE bone metastasis; hepatocellular carcinoma; LGALS3; RNF219;
   skeletal&#8208; related events
ID BETA CATENIN; OSTEOCLAST DEVELOPMENT; CLINICAL FEATURES; GALECTIN 3;
   DIFFERENTIATION; METHYLATION; TARGET; BREAST
AB The incidence of bone metastases in hepatocellular carcinoma (HCC) has increased prominently over the past decade owing to the prolonged overall survival of HCC patients. However, the mechanisms underlying HCC bone metastasis remain largely unknown. In the current study, HCC secreted lectin galactoside binding soluble 3 (LGALS3) is found to be significantly upregulated and correlates with shorter bone metastasis free survival of HCC patients. Overexpression of LGALS3 enhances the metastatic capability of HCC cells to bone and induces skeletal related events by forming a bone pre metastatic niche via promoting osteoclast fusion and podosome formation. Mechanically, ubiquitin ligaseRNF219 meidated alpha catenin degradation prompts YAP1/beta catenin complex dependent epigenetic modifications of LGALS3 promoter, resulting in LGALS3 upregulation and metastatic bone diseases. Importantly, treatment with verteporfin, a clinical drug for macular degeneration, decreases LGALS3 expression and effectively inhibits skeletal complications of HCC. These findings unveil a plausible role for HCC secreted LGALS3 in pre metastatic niche and can suggest a promising strategy for clinical intervention in HCC bone metastasis.
C1 [Zhang, Shuxia; Xu, Yingru; Xie, Chan; Li, Jun] Sun Yat Sen Univ, Affiliated Hosp 3, Key Lab Liver Dis Guangdong Prov, Guangzhou 510080, Peoples R China.
   [Zhang, Shuxia; Xu, Yingru; Xie, Chan; Ren, Liangliang; Yang, Meisongzhu; Wu, Xingui; Hu, Yameng; Li, Ziwen; Yu, Ruyuan; Liao, Xinyi; Mo, Shuang; Li, Jun] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou 510080, Peoples R China.
   [Wu, Geyan; Tang, Miaoling; Song, Libing] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510080, Peoples R China.
   [Wu, Jueheng; Li, Mengfeng] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou 510080, Peoples R China.
   [Song, Erwei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Breast Oncol, Guangzhou 510120, Peoples R China.
   [Qi, Yanfei] Univ Sydney, Centenary Inst, Sydney, NSW 2000, Australia.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen
   University; University of Sydney; Centenary Institute
RP Li, J (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 3, Key Lab Liver Dis Guangdong Prov, Guangzhou 510080, Peoples R China.; Li, J (通讯作者)，Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou 510080, Peoples R China.
EM lijun37@mail.sysu.edu.cn
RI ; Zhang, Shuxia/HHS 7408 2022; wu, geyan/MIP 2722 2025; Qi,
   Yanfei/ABC 1242 2021; xu, yingru/HTQ 0909 2023; Ren,
   Liangliang/AAR 6436 2020; Song, LB/AAL 1968 2020
OI yu, ruyuan/0000 0001 6758 4395; Li, Jun/0000 0003 0572 1344; Qi,
   Yanfei/0000 0003 1391 4111; 
FU Natural Science Foundation of China [81830082, 82030078, 91740119,
   82072609, 81621004, 91740118, 82003128, 81773106, 81530082]; Guangzhou
   Science and Technology Plan Projects [201803010098]; Natural Science
   Foundation of Guangdong Province [2018B030311009, 2016A030308002,
   2018B030311060, 2019A1515110118]; Fundamental Research Funds for the
   Central Universities [19ykpy177]; China Postdoctoral Science Foundation
   [2019M653220]
FX S.Z., Y.X., and C.X. contributed equally to this work. This work was
   supported by Natural Science Foundation of China (No. 81830082,
   82030078, 91740119, 82072609, 81621004, 91740118, 82003128, 81773106 and
   81530082); Guangzhou Science and Technology Plan Projects
   (201803010098); Natural Science Foundation of Guangdong Province
   (2018B030311009, 2016A030308002, 2018B030311060, 2019A1515110118); The
   Fundamental Research Funds for the Central Universities [No. 19ykpy177];
   China Postdoctoral Science Foundation (2019M653220).
CR Akens MK, 2010, BREAST CANCER RES TR, V119, P325, DOI 10.1007/s10549 009 0356 7
   An E, 2014, MOL CELL PROTEOMICS, V13, P2687, DOI 10.1074/mcp.M113.034371
   Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Brown JE, 2012, NAT REV CLIN ONCOL, V9, P110, DOI 10.1038/nrclinonc.2011.197
   Burch S, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1921887
   Carina V, 2019, CANCERS, V11, DOI 10.3390/cancers11030348
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Choi SH, 2013, GENE DEV, V27, P2473, DOI 10.1101/gad.229062.113
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coulombe P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10321 x
   Dhar SS, 2012, GENE DEV, V26, P2749, DOI 10.1101/gad.203356.112
   Ell B, 2012, CELL, V151, DOI 10.1016/j.cell.2012.10.005
   Esposito M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031252
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Fortuna Costa A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00138
   Gibault F, 2016, CURR MED CHEM, V23, P1171, DOI 10.2174/0929867323666160316125048
   Greco C, 2011, Q J NUCL MED MOL IM, V55, P337
   Harding JJ, 2018, J NATL COMPR CANC NE, V16, P50, DOI 10.6004/jnccn.2017.7024
   Hervouet E, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148 018 0450 y
   Hou R, 2015, J CANCER RES CLIN, V141, P1931, DOI 10.1007/s00432 015 1958 6
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Liu Nan nan, 2010, Zhonghua Zhong Liu Za Zhi, V32, P203
   Liu X, 2017, CELL, V170, P1028, DOI 10.1016/j.cell.2017.08.003
   Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011
   Liu Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Nakajima K, 2016, CANCER RES, V76, P1391, DOI 10.1158/0008 5472.CAN 15 1793
   Nakajima K, 2014, NEOPLASIA, V16, P939, DOI 10.1016/j.neo.2014.09.005
   Natsuizaka M, 2005, J GASTROEN HEPATOL, V20, P1781, DOI 10.1111/j.1440 1746.2005.03919.x
   Novack DV, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD 0011 2015
   OKAZAKI N, 1985, CANCER AM CANCER SOC, V55, P1991, DOI 10.1002/1097 0142(19850501)55:9<1991::AID CNCR2820550927>3.0.CO;2 F
   Ruvolo PP, 2016, BBA MOL CELL RES, V1863, P427, DOI 10.1016/j.bbamcr.2015.08.008
   Sawant A, 2013, CANCER RES, V73, P4606, DOI 10.1158/0008 5472.CAN 13 0305
   Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555 013 9420 1
   Shah GK, 2009, RETINA J RET VIT DIS, V29, P133, DOI 10.1097/IAE.0b013e3181960a28
   Song J, 2015, MOL CANCER RES, V13, P969, DOI 10.1158/1541 7786.MCR 13 0644
   Song L, 2014, CLIN CHIM ACTA, V431, P185, DOI 10.1016/j.cca.2014.01.019
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Takai H, 2014, CELL REP, V9, P48, DOI 10.1016/j.celrep.2014.08.071
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tsumura Hideki, 2016, Biochem Biophys Rep, V5, P203, DOI 10.1016/j.bbrep.2015.11.023
   Uchino K, 2011, CANCER AM CANCER SOC, V117, P4475, DOI 10.1002/cncr.25960
   Xiang ZL, 2011, ONCOLOGIST, V16, P1028, DOI 10.1634/theoncologist.2010 0358
   Zhang WJ, 2019, TRENDS CANCER, V5, P95, DOI 10.1016/j.trecan.2018.12.004
NR 46
TC 31
Z9 34
U1 1
U2 42
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD FEB
PY 2021
VL 8
IS 4
AR 2001961
DI 10.1002/advs.202001961
EA DEC 2020
PG 17
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA QK9PH
UT WOS:000603668500001
PM 33643786
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jin, WQ
   Zhu, XQ
   Yao, F
   Xu, XH
   Chen, XN
   Luo, ZJ
   Zhao, DQ
   Li, XY
   Leng, XY
   Sun, LW
AF Jin, Wenqi
   Zhu, Xiaoqian
   Yao, Fan
   Xu, Xiaohao
   Chen, Xuenan
   Luo, Zongjian
   Zhao, Daqing
   Li, Xiangyan
   Leng, Xiangyang
   Sun, Liwei
TI Cytoprotective effect of Fufang Lurong Jiangu capsule against hydrogen
   peroxide induced oxidative stress in bone marrow stromal cell derived
   osteoblasts through the Nrf2/HO 1 signaling pathway
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE FLJC; Osteoblasts; Oxidative stress; Apoptosis; Nrf2/HO 1
ID MC3T3 E1 CELLS; DAMAGE; DIFFERENTIATION; OSTEOPOROSIS; SYSTEM
AB Objective: Oxidative stress is increasingly recognized as a risk factor associated with the development and progression of osteoporosis. Fufang Lurong Jiangu Capsule (FLJC) has a known anti osteoporotic effect, but its pharmacological effect on osteoblasts is not clearly understood. This study was designed to investigate FLJC effects/mechanisms on in vitro hydrogen peroxide (H2O2) induced oxidative damage of osteoblasts and on in vivo lipopolysaccharide (LPS) induced mice bone loss. FLJC alleviates osteoporosis via unknown pharmacological mechanisms.
   Methods: Chemical compositions of FLJC preparations were analyzed using high performance liquid chromatographic fingerprinting. After rat bone marrow mesenchymal stem cell differentiation induction, resulting osteoblasts received various 48 h FLJC pretreatments before H2O2 based (200 mu M) oxidative stress exposure. FLJC effects were measured on osteoblast cell viability, morphological changes, levels of intracellular reactive oxygen species (ROS), localization of mitochondria, activity of antioxidant enzymes, alkaline phosphatase (ALP) and mineralization, the secretion of Col I and expression of osteogenic markers. The percentages of apoptosis were determined by flow cytometric analysis; apoptosis related protein levels, including nuclear factor (erythroid derived 2) like 2 (Nrf2) and heme oxygenase 1 (HO 1) with or without Nrf2 inhibitor were analyzed via western blot. Hematoxylin and eosin (H&E) and ALP staining revealed in vivo FLJC effect on mice LPS induced bone loss.
   Results: Five chemical components in FLJC were identified, and fingerprint analysis showed good reproducibility. FLJC pretreatment significantly reduced H2O2 induced ROS levels in osteoblasts and increased anti oxidant enzyme activities to reduce oxidative damage. With regard to osteoblast differentiation, FLJC pretreatment increased ALP expression, as well as levels of mineralization and osteoblast markers. Additionally, FLJC protected against H2O2 induced apoptosis by inhibiting changes in expression of major Bcl 2 family effector proteins of the mitochondrial apoptosis pathway. Furthermore, FLJC protected cells from H2O2 induced oxidative damage by up regulating Nrf2 and HO 1 protein levels. Finally, we confirmed that FLJC administration could reverse the bone loss in LPS induced mice.
   Conclusion: These results indicate that FLJC may significantly attenuate oxidative damage of osteoblasts induced by H2O2 via the Nrf2/HO 1 signaling pathway, providing new insights to guide development of treatments for osteoporosis induced by oxidative injury.
C1 [Jin, Wenqi; Xu, Xiaohao; Chen, Xuenan; Sun, Liwei] Changchun Univ Chinese Med, Res Ctr Tradit Chinese Med, Affiliated Hosp, 1478 Gongnong St, Changchun 130021, Jilin, Peoples R China.
   [Jin, Wenqi; Xu, Xiaohao; Chen, Xuenan; Zhao, Daqing; Li, Xiangyan] Changchun Univ Chinese Med, Jilin Prov Key Lab BioMacromol Chinese Med, Changchun, Jilin, Peoples R China.
   [Zhu, Xiaoqian] Beihua Univ, Coll Sci, Technol Innovat Ctr Chinese Med Biotechnol, Jilin, Jilin, Peoples R China.
   [Yao, Fan] Changchun Univ Chinese Med, Ctr Prevent Treatment Dis, Affiliated Hosp, Changchun, Jilin, Peoples R China.
   [Luo, Zongjian; Leng, Xiangyang] Changchun Univ Chinese Med, Dept Orthoped, Affiliated Hosp, 1035 Boshuo Rd, Changchun 130021, Jilin, Peoples R China.
   [Zhao, Daqing; Li, Xiangyan] Changchun Univ Chinese Med, Jilin Ginseng Acad, Jilin, Jilin, Peoples R China.
C3 Changchun University of Chinese Medicine; Changchun University of
   Chinese Medicine; Beihua University; Changchun University of Chinese
   Medicine; Changchun University of Chinese Medicine; Changchun University
   of Chinese Medicine
RP Sun, LW (通讯作者)，Changchun Univ Chinese Med, Res Ctr Tradit Chinese Med, Affiliated Hosp, 1478 Gongnong St, Changchun 130021, Jilin, Peoples R China.; Leng, XY (通讯作者)，Changchun Univ Chinese Med, Dept Orthoped, Affiliated Hosp, 1035 Boshuo Rd, Changchun 130021, Jilin, Peoples R China.
EM leng_xiangyang@163.com; Sunnylilwei@163.com
RI Li, Xiangyan/JDW 4460 2023
OI Li, Xiangyan/0000 0001 6780 6314
FU Research Fund for the Doctoral Program of Higher Education of China
   [20133107110011]; National Natural Science Foundation of China
   [81803892, 81774111]; Shanghai Three Year Project of Traditional Chinese
   Medicine
FX This study was supported in part by the Research Fund for the Doctoral
   Program of Higher Education of China (20133107110011), National Natural
   Science Foundation of China (81774111), National Natural Science
   Foundation of China (81803892), Shanghai Three Year Project of
   Traditional Chinese Medicine (2018 2020).
CR Al Jallad HF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015893
   Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Barbagallo I, 2010, J BONE MINER METAB, V28, P276, DOI 10.1007/s00774 009 0134 y
   Chen XN, 2017, J GINSENG RES, V41, P411, DOI 10.1016/j.jgr.2017.02.001
   Choi EM, 2016, J AGR FOOD CHEM, V64, P226, DOI 10.1021/acs.jafc.5b05157
   Choi EM, 2010, PHYTOTHER RES, V24, P1037, DOI 10.1002/ptr.3070
   Diao Y, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 30992 8
   Han DD, 2017, ONCOTARGET, V8, P14680, DOI 10.18632/oncotarget.14747
   Huang Q, 2014, BONE, V66, P306, DOI 10.1016/j.bone.2014.06.010
   Hwang MP, 2016, BIOMATERIALS, V103, P22, DOI 10.1016/j.biomaterials.2016.06.052
   Jeon Jin, 2018, Biomater Res, V22, P4, DOI 10.1186/s40824 018 0115 0
   Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474 9726.2010.00616.x
   Kagan VE, 2009, FREE RADICAL BIO MED, V46, P1439, DOI 10.1016/j.freeradbiomed.2009.03.004
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Kozakowska M, 2014, ANTIOXID REDOX SIGN, V20, P1827, DOI 10.1089/ars.2013.5341
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lee D, 2015, BMB REP, V48, P636, DOI 10.5483/BMBRep.2015.48.11.112
   Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002 021496
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Matsugaki A, 2015, J BIOMED MATER RES A, V103, P489, DOI 10.1002/jbm.a.35189
   Ola MS, 2011, MOL CELL BIOCHEM, V351, P41, DOI 10.1007/s11010 010 0709 x
   Poljsak B, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/956792
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Ruan JW, 2018, BIOCHEM BIOPH RES CO, V503, P607, DOI 10.1016/j.bbrc.2018.06.048
   Soreide E, 2018, J CELL BIOCHEM, V119, P5715, DOI 10.1002/jcb.26755
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Wu CC, 2013, ANTIOXID REDOX SIGN, V19, P546, DOI 10.1089/ars.2012.4905
   Xia G, 2017, BIOCHEM BIOPH RES CO, V491, P807, DOI 10.1016/j.bbrc.2017.06.184
   Yan XF, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00007
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
   Zhou QZ, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/7067984
NR 35
TC 29
Z9 33
U1 2
U2 29
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2020
VL 121
AR 109676
DI 10.1016/j.biopha.2019.109676
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA JT1GJ
UT WOS:000500746200125
PM 31810119
OA gold
DA 2025 08 17
ER

PT J
AU Ding, YH
   Liu, YS
   Dou, CL
   Guo, SR
AF Ding, Yanhua
   Liu, Yusi
   Dou, Changlin
   Guo, Shuren
TI A randomized trial comparing LY01011, biosimilar candidate, with the
   reference product denosumab (Xgeva®) in healthy Chinese subjects
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Bone metastasis; Denosumab biosimilar; Pharmacokinetics;
   Pharmacodynamics; Safety; Immunogenicity
AB Background: Complications of bone metastases such as skeletal related events lead to the impaired functional status and quality of life including death in patients with bone metastasis from solid tumors. Denosumab (XGEVA (R)) is indicated for the prevention of skeletal related events in bone metastasis patients with solid tumors. The biosimilar product LY01011, a fully human anti receptor activator of nuclear factor kappa B ligand monoclonal antibody, was developed to be compared with the reference product denosumab.Material and methods: A randomized, double blind, single dose, parallel controlled phase 1 study was conducted in healthy Chinese subjects. A total of 168 enrolled subjects were randomly assigned in a 1:1 ratio to receive a single 120 mg dose of LY01011 (n = 85) or denosumab (n = 83) subcutaneously. The primary pharmacokinetic (PK) parameters, including maximum plasma concentration (Cmax) and area under the concentration time curve from time zero to last quantifiable concentration (AUC0  > t), were collected and measured for evaluation. Other secondary PK parameters included AUC0 infinity, Tmax, CL/F, lambda z, t1/2, Vd/F, etc. Pharmacodynamics (PD), safety and immunogenicity profiles were also accounted for data analysis. Results: The geometric mean ratios (GMRs) of LY01011 and denosumab for the primary PK parameters such as Cmax and AUC0  > t were 98.13% and 100.32%. The 90% confidence intervals (CIs) were all within the acceptance range of 80% 125%. The GMRs of the PD parameters including AUEC0  > t and Emax were 98.71% and 99.80%, which fell within the pre defined acceptance range of 80% 125%. The results also demonstrated PK similarity even if Cmax and AUC0  >infinity had been used as primary endpoints. Safety profiles were tolerable and similar between groups. 4 (4.7%) and 2 (2.4%) subjects had experienced Grade 3 or above treatment emergent adverse events (TEAEs) in LY01011 group and denosumab group. 3 subjects were reported to have serious adverse events (SAEs). None of the Grade 3 or above TEAEs and SAEs were related to the study drug, LY01011. No subject was tested anti drug antibody (ADA) positive in both groups prior to the study drug administration. Following the study drug administration, only one subject in denosumab group was tested ADA positive, whereas no subject with ADA positive was reported in LY01011 group. No neutralizing antibody (Nab) was detected in either group throughout the study.Conclusions: The study demonstrated PK and PD similarity of LY01011, a denosumab biosimilar, to denosumab in healthy Chinese subjects, with comparable safety and immunogenicity profiles.
C1 [Ding, Yanhua; Liu, Yusi] First Hosp Jilin Univ, Phase I Clin Trial Unit, Changchun, Peoples R China.
   [Dou, Changlin; Guo, Shuren] Shandon Boan Biotechnol Co Ltd, Yantai, Peoples R China.
C3 Jilin University
RP Ding, YH (通讯作者)，First Hosp Jilin Univ, Phase I Clin Trial Unit, Changchun, Peoples R China.
EM dingyanh@jlu.edu.cn
FU Shandong Boan Biotech nology Co., Ltd.
FX <B>Funding</B> This work was supported by the sponsor, Shandong Boan
   Biotech nology Co., Ltd. The sponsor fulfilled the responsibilities
   according to the Good Clinical Practice without interfering with
   implementing clin ical trials.
CR Amgen, XGEVA® (denosumab) U.S. Prescribing Information
   Amgen, XGEVA® (denosumab) CHN Prescribing Information
   [Anonymous], 2022, Expert Consensus on Clinical Diagnosis and treatment of malignant bone metastasis and bone related disease, P45
   Center for Drug Evaluation NMPA, 2005, Technical Guidelines for Clinical Pharmacokinetics of Chemical Drugs, P03
   Chen Q, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197984
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Farooki A, 2014, J NATL COMPR CANC NE, V12, P813, DOI 10.6004/jnccn.2014.0196
   Hou J, 2022, INT IMMUNOPHARMACOL, V107, DOI 10.1016/j.intimp.2022.108666
   Okamoto K, 2021, J BONE MINER METAB, V39, P71, DOI 10.1007/s00774 020 01182 2
   Rosen HN, 2000, CALCIFIED TISSUE INT, V66, P100, DOI 10.1007/PL00005830
NR 10
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD OCT
PY 2023
VL 42
AR 100499
DI 10.1016/j.jbo.2023.100499
EA SEP 2023
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA X0ST2
UT WOS:001095642800001
PM 37701913
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Niu, SP
   Chen, M
   Yan, DQ
   Liu, XX
   Guo, SR
   Ou, L
   Fan, HY
   Lv, J
   Wang, Q
   Dong, WL
   Xia, L
   Wang, SM
   Liu, G
   Gu, Q
   Guo, DJ
   Liu, HX
   Rao, HY
   Zheng, QS
   Nie, XY
   Song, HF
   Fang, Y
AF Niu, Suping
   Chen, Min
   Yan, Diqin
   Liu, Xiangxing
   Guo, Shuren
   Ou, Lun
   Fan, Huaying
   Lv, Jie
   Wang, Qian
   Dong, Wenliang
   Xia, Lin
   Wang, Simin
   Liu, Gang
   Gu, Qun
   Guo, Danjie
   Liu, Hongxia
   Rao, Huiying
   Zheng, Qingshan
   Nie, Xiaoyan
   Song, Haifeng
   Fang, Yi
TI A Randomized Controlled Dose Escalation Study of LY06006, a Recombinant
   Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE pharmacokinetics; pharmacodynamics; immunogenicity; denosumab; RANK;
   RANKL; osteoporosis
ID POSTMENOPAUSAL WOMEN; DENOSUMAB EXPOSURE; OSTEOPOROSIS; MEN;
   PHARMACODYNAMICS; EPIDEMIOLOGY; PREVENTION; FRACTURES
AB Background: This study was conducted to explore the safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of LY06006, a recombinant humanized monoclonal antibody to RANKL, when administrated subcutaneously in Chinese healthy adults.Research design and methods: This was a randomized, double blinded, placebo controlled, single ascending dose study performed in 32 healthy Chinese adults, who were randomly assigned to receive a single injection dose of 18, 60, 120 mg study drug or placebo with a follow up of 140 252 days.Results: No deaths or drug related serious adverse events occurred. LY06006 was rapidly absorbed in the 60 mg group with a T max range of 120 480 h and serum LY06006 concentrations decreased slowly 11 13 days after dosing with a long mean (SD) half life of 389.58 (63.44) h. The most frequent AEs were elevated serum parathyroid hormone (PTH) level (83.3%), hypocalcemia (54.2%), and hypophosphatemia (45.8%). None of the 32 subjects tested positive for anti drug antibody during the trial.Conclusion: Single dose subcutaneous administration of LY06006 was safe and well tolerated in healthy Chinese adults. C max showed linear pharmacokinetic characteristics in the dose range of 18 120 mg based on dose exposure proportionality analysis.
C1 [Niu, Suping; Fan, Huaying; Guo, Danjie; Rao, Huiying] Peking Univ Peoples Hosp, Dept Sci & Res, Beijing, Peoples R China.
   [Chen, Min; Yan, Diqin; Liu, Xiangxing; Wang, Qian; Dong, Wenliang; Xia, Lin; Wang, Simin; Liu, Gang; Gu, Qun; Fang, Yi] Peking Univ Peoples Hosp, Dept Pharm, Beijing, Peoples R China.
   [Chen, Min; Yan, Diqin; Dong, Wenliang; Nie, Xiaoyan] Peking Univ, Sch Pharmaceut, Dept Pharm Adm & Clin Pharm, Beijing, Peoples R China.
   [Liu, Xiangxing; Xia, Lin; Wang, Simin] Xuzhou Med Univ, Sch Pharm, Xuzhou, Peoples R China.
   [Guo, Shuren] Shandong Boan Biotechnol Co Ltd, Yantai, Peoples R China.
   [Ou, Lun] Beijing United Power Pharm Tech Co Ltd, Beijing, Peoples R China.
   [Lv, Jie] Peking Univ Peoples Hosp, Dept Intens Care Units, Beijing, Peoples R China.
   [Liu, Hongxia] Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China.
   [Rao, Huiying] Peking Univ Peoples Hosp, Peking Univ Hepatol Inst, Beijing Key Lab Hepatitis C & Immunotherapy Liver, Beijing, Peoples R China.
   [Zheng, Qingshan] Ctr Drug Clin Res Shanghai Univ TCM, Shanghai, Peoples R China.
   [Song, Haifeng] Beijing Inst Life, Beijing Proteome Res Ctr, Natl Ctr Prot Sci Beijing, State Key Lab Prote, Beijing, Peoples R China.
C3 Peking University; Xuzhou Medical University; Shanghai University of
   Traditional Chinese Medicine
RP Fang, Y (通讯作者)，Peking Univ Peoples Hosp, Dept Pharm, Beijing, Peoples R China.; Nie, XY (通讯作者)，Peking Univ, Sch Pharmaceut, Dept Pharm Adm & Clin Pharm, Beijing, Peoples R China.; Song, HF (通讯作者)，Beijing Inst Life, Beijing Proteome Res Ctr, Natl Ctr Prot Sci Beijing, State Key Lab Prote, Beijing, Peoples R China.
EM niexy@pku.edu.cn; songhf@nic.bmi.ac.cn; phaseistudy@163.com
RI Liu, Gang/J 3181 2013; Yan, Diqin/JHT 4609 2023
CR Amgen, 2021, AMG PROLIA DEN PRESC
   An GH, 2020, J CLIN PHARMACOL, V60, P149, DOI 10.1002/jcph.1545
   [Anonymous], 2005, Potential timber damage due to hurricane Katrina in Mississippi, Alabama, and Louisiana  September 22, 2005, P1
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bone HG, 2013, J CLIN ENDOCR METAB, V98, P4483, DOI 10.1210/jc.2013 1597
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen HJ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.821944
   Chen Q, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197984
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dempster DW, 2012, CLIN THER, V34, P521, DOI 10.1016/j.clinthera.2012.02.002
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Kumagai Y, 2011, BONE, V49, P1101, DOI 10.1016/j.bone.2011.08.007
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Nakamura T, 2014, J CLIN ENDOCR METAB, V99, P2599, DOI 10.1210/jc.2013 4175
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   Smith BP, 2000, PHARMACEUT RES, V17, P1278, DOI 10.1023/A:1026451721686
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   Zhang H, 2021, EXPERT OPIN INV DRUG, V30, P185, DOI 10.1080/13543784.2021.1863371
   Zhang H, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01329
   Zhang N, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00325
NR 29
TC 1
Z9 1
U1 3
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 15
PY 2022
VL 13
AR 893166
DI 10.3389/fphar.2022.893166
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 2M6HX
UT WOS:000817799600001
PM 35784742
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gobin, B
   Baud'Huin, M
   Lamoureux, F
   Ory, B
   Charrier, C
   Lanel, R
   Battaglia, S
   Redini, F
   Lezot, F
   Blanchard, F
   Heymann, D
AF Gobin, Berengere
   Baud'Huin, Marc
   Lamoureux, Francois
   Ory, Benjamin
   Charrier, Celine
   Lanel, Rachel
   Battaglia, Severine
   Redini, Francoise
   Lezot, Frederic
   Blanchard, Frederic
   Heymann, Dominique
TI BYL719, a new α specific PI3K inhibitor: Single administration and in
   combination with conventional chemotherapy for the treatment of
   osteosarcoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE osteosarcoma; osteoblast; osteoclast; vascularization; PI3K; mTOR
ID CELL LINE; ONCOSTATIN M; BONE TUMORS; 3 KINASE; METASTASIS; MTOR;
   ANGIOGENESIS; ACTIVATION; EXPRESSION; MUTATIONS
AB It has been established that disturbances in intracellular signaling pathways play a considerable part in the oncologic process. Phosphatidylinositol 3 kinase (PI3K) has become of key interest in cancer therapy because of its high mutation frequency and/or gain in function of its catalytic subunits in cancer cells. We investigated the therapeutic value of BYL719, a new specific PI3K inhibitor that blocks the ATP site, on osteosarcoma and bone cells. The in vitro effects of BYL719 on proliferation, apoptosis, and cell cycle were assessed in human and murine osteosarcoma cell. Its impact on bone cells was determined using human mesenchymal stem cells (hMSC) and human CD14(+) osteoclast precursors. Two different murine preclinical models of osteosarcoma were used to analyze the in vivo biological activities of BYL719. BYL719 decreased cell proliferation by blocking cell cycle in G0/G1 phase with no outstanding effects on apoptosis cell death in HOS and MOS J tumor cells. BYL719 inhibited cell migration and can thus be considered as a cytostatic drug for osteosarcoma. In murine preclinical models of osteosarcoma, BYL719 significantly decreased tumor progression and tumor ectopic bone formation as shown by a decrease of Ki67(+) cells and tumor vascularization. To explore the maximum therapeutic potential of BYL719, the drug was studied in combination with conventional chemotherapeutic drugs, revealing promising efficacy with ifosfamide. BYL719 also exhibited dual activities on osteoblast and osteoclast differentiation. Overall, the present work shows that BYL719 is a promising drug in either a single or multidrug approach to curing bone sarcoma.
   What's new? Mutations in PIK3CA have been identified in various cancers, including osteosarcoma, a disease for which new treatments are desperately needed. One potential therapy for osteosarcoma is BYL719, a novel agent that is active against tumor cells harboring PIK3CA variants. In the present study, BYL719 was found to inhibit the migration and decrease the proliferation of osteosarcoma cells. The drug accomplished the latter by blocking the cell cycle in G0/G1. In pre clinical mouse models of osteosarcoma, BYL719 monotherapy significantly reduced tumor progression, tumor ectopic bone formation, and tumor vascularization. Its therapeutic potential may be augmented by combined use with ifosfamide.
C1 [Gobin, Berengere; Baud'Huin, Marc; Lamoureux, Francois; Ory, Benjamin; Charrier, Celine; Lanel, Rachel; Battaglia, Severine; Redini, Francoise; Lezot, Frederic; Blanchard, Frederic; Heymann, Dominique] INSERM UMR 957, Fac Med, F 44035 Nantes, France.
   [Gobin, Berengere; Baud'Huin, Marc; Lamoureux, Francois; Ory, Benjamin; Charrier, Celine; Lanel, Rachel; Battaglia, Severine; Redini, Francoise; Lezot, Frederic; Blanchard, Frederic; Heymann, Dominique] Univ Nantes, F 44035 Nantes, France.
   [Charrier, Celine; Redini, Francoise; Blanchard, Frederic; Heymann, Dominique] Equipe LIGUE Natl Canc 2012, F 44035 Nantes, France.
   [Redini, Francoise; Heymann, Dominique] CHU Nantes, F 44035 Nantes, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Nantes Universite; Nantes Universite; CHU de Nantes
RP Heymann, D (通讯作者)，INSERM UMR 957, Fac Med, 1 Rue Gaston Veil, F 44035 Nantes, France.
EM dominique.heymann@univ nantes.fr
RI Baud'huin, Marc/K 8519 2015; Lamoureux, Francois/K 8021 2015; Charrier,
   Céline/K 9198 2015; BATTAGLIA, Severine/K 8715 2015; Heymann,
   Dominique/AAC 6014 2019; REDINI, Francoise/K 7981 2015; Lezot,
   Frederic/K 8075 2015; ory, benjamin/K 8231 2015; Blanchard,
   Frederic/K 8018 2015
OI ory, benjamin/0000 0002 2622 7356; Lamoureux,
   Francois/0000 0002 2738 0758; Heymann, Dominique/0000 0001 7777 0669;
   Lezot, Frederic/0000 0001 6274 6981; Blanchard,
   Frederic/0000 0003 1055 2573
FU Region des Pays de la Loire; INSERM
FX Berengere Gobin received a PhD fellowship from the Region des Pays de la
   Loire and INSERM. We thank Martine Berreur for her technical help for
   measuring the resorption activity of osteoclasts.
CR Abdeen A, 2009, CANCER AM CANCER SOC, V115, P5243, DOI 10.1002/cncr.24562
   Ando Kosei, 2013, Cancers (Basel), V5, P591, DOI 10.3390/cancers5020591
   Ando Kosei, 2012, Sarcoma, V2012, P523432, DOI 10.1155/2012/523432
   Baud'Huin M, 2012, METHODS MOL BIOL, V836, P323, DOI 10.1007/978 1 61779 498 8_21
   Baud'Huin M, 2010, J PATHOL, V221, P77, DOI 10.1002/path.2684
   Blay JY, 2011, ANN ONCOL, V22, P280, DOI 10.1093/annonc/mdq307
   Bohic S, 1998, BIOCHEM BIOPH RES CO, V253, P506, DOI 10.1006/bbrc.1998.9781
   Bouacida A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048648
   Brana I, 2012, BMC MED, V10, DOI 10.1186/1741 7015 10 161
   Choy E, 2012, CANCER AM CANCER SOC, V118, P2905, DOI 10.1002/cncr.26617
   Dan S, 2010, CANCER RES, V70, P4982, DOI 10.1158/0008 5472.CAN 09 4172
   De Buck SS, BR J CLIN P IN PRESS
   Fallica B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048024
   Fokas E, 2012, CANCER METAST REV, V31, P823, DOI 10.1007/s10555 012 9394 4
   Fukaya Y, 2005, ONCOL REP, V14, P847
   Furet P, 2013, BIOORG MED CHEM LETT, V23, P3741, DOI 10.1016/j.bmcl.2013.05.007
   Gobin B, 2014, CANCER LETT, V344, P291, DOI 10.1016/j.canlet.2013.11.017
   Graupera M, 2013, EXP CELL RES, V319, P1348, DOI 10.1016/j.yexcr.2013.02.021
   Guihard P, 2012, STEM CELLS, V30, P762, DOI 10.1002/stem.1040
   Hattinger CM, 2010, EXPERT OPIN EMERG DR, V15, P615, DOI 10.1517/14728214.2010.505603
   Hauben EI, 2010, BONE CANCER: PROGRESSION AND THERAPEUTIC APPROACHES, P3
   Heymann D, 2013, BONEKEY REP, P112
   Heymann D., 2011, IBMS BoneKEy, V8, P402
   Janku F, 2012, ONCOTARGET, V3, P1566, DOI 10.18632/oncotarget.716
   Joliat MJ, 2002, IN VIVO, V16, P223
   Juric D, 2012, CANCER RES, V72, DOI 10.1158/0008 5472.SABCS12 P8 10 07
   Kamijo A, 2002, CANCER LETT, V188, P213, DOI 10.1016/S0304 3835(02)00433 0
   Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615
   Kaya M, 2000, CLIN CANCER RES, V6, P572
   KLEIN B, 1977, INT J CANCER, V20, P112, DOI 10.1002/ijc.2910200118
   Kreuter M, 2004, CLIN CANCER RES, V10, P8531, DOI 10.1158/1078 0432.CCR 04 0969
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Lee YH, 1999, EUR J CANCER, V35, P1089, DOI 10.1016/S0959 8049(99)00073 8
   Mahalingam D, 2009, CURR DRUG TARGETS, V10, P937, DOI 10.2174/138945009789577990
   Moriceau G, 2010, CURR PHARM DESIGN, V16, P2981, DOI 10.2174/138161210793563554
   Moriceau G, 2010, CANCER RES, V70, P10329, DOI 10.1158/0008 5472.CAN 10 0578
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750 1172 2 6
   Shinohara M, 2012, J BONE MINER RES, V27, P2464, DOI 10.1002/jbmr.1703
   Smith GC, 2012, BIOCHEM J, V442, P161, DOI 10.1042/BJ20111913
   Sopasakis VR, 2010, CELL METAB, V11, P220, DOI 10.1016/j.cmet.2010.02.002
   Thiery J, 1982, SEM HOP PARIS, V58, P1686
   Tsubaki M, 2012, TOXICOL APPL PHARM, V259, P402, DOI 10.1016/j.taap.2012.01.024
   Vadas O, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002165
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   Vandyke K, 2010, BLOOD, V115, P766, DOI 10.1182/blood 2009 08 237404
   Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882
   Wang KL, 2012, ARCH BIOCHEM BIOPHYS, V526, P38, DOI 10.1016/j.abb.2012.07.003
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Zhao GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053906
NR 50
TC 60
Z9 61
U1 0
U2 43
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
EI 1097 0215
J9 INT J CANCER
JI Int. J. Cancer
PD FEB 15
PY 2015
VL 136
IS 4
BP 784
EP 796
DI 10.1002/ijc.29040
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AW2AG
UT WOS:000346089900026
PM 24961790
OA Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Kikuchi, H
   Amofa, E
   Mcenery, M
   Schey, SA
   Ramasamy, K
   Farzaneh, F
   Calle, Y
AF Kikuchi, Hugh
   Amofa, Eunice
   Mcenery, Maeve
   Schey, Steve Arthur
   Ramasamy, Karthik
   Farzaneh, Farzin
   Calle, Yolanda
TI Inhibition of PI3K Class IA Kinases Using GDC 0941 Overcomes
   Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow
   Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics
SO CANCERS
LA English
DT Article
DE myeloma; tumour microenvironment; co culture system; dexamethasone;
   resistance; osteoclasts; high throughput screening
ID GROWTH FACTOR; SURVIVAL; LENALIDOMIDE; PROLIFERATION; DEXAMETHASONE;
   ORGANIZATION; RESORPTION; RESISTANCE; TARGET; DRUGS
AB Simple Summary The activation of osteoclasts occurs in up to 80% of myeloma patients. Osteoclasts promote myeloma resistance to therapeutic treatments and the formation of bone lytic lesions, resulting in bone pain and fractures in patients. However, the role of osteoclasts in drug resistance is generally overseen when performing preclinical screenings to identify new therapeutics for multiple myeloma. We propose in our study a new methodology, scalable to high throughput for the analysis of drug efficacy to better predict efficacy in myeloma patients that develop bone disease. We have identified GDC 0941 as a drug candidate that, used in combination treatments, could enhance the efficacy of currently used therapeutic drugs for myeloma by overcoming resistance mediated by osteoclasts, as well as bone marrow mesenchymal/fibroblastic stromal cells. Our work supports exploring GDC 0941 in combination with current clinical drugs for myeloma patients with active bone disease. Osteoclasts contribute to bone marrow (BM) mediated drug resistance in multiple myeloma (MM) by providing cytoprotective cues. Additionally, 80% of patients develop osteolytic lesions, which is a major cause of morbidity in MM. Although targeting osteoclast function is critical to improve MM therapies, pre clinical studies rarely consider overcoming osteoclast mediated cytoprotection within the selection criteria of drug candidates. We have performed a drug screening and identified PI3K as a key regulator of a signalling node associated with resistance to dexamethasone lenalidomide, pomalidomide, and bortezomib mediated by osteoclasts and BM fibroblastic stromal cells, which was blocked by the pan PI3K Class IA inhibitor GDC 0941. Additionally, GDC 0941 repressed the maturation of osteoclasts derived from MM patients and disrupted the organisation of the F actin cytoskeleton in sealing zones required for bone degradation, correlating with decreased bone resorption by osteoclasts. In vivo, GDC 0941 improved the efficacy of dexamethasone against MM in the syngeneic GFP 5T33/C57 Rawji mouse model. Taken together, our results indicate that GDC 0941 in combination with currently used therapeutic agents could effectively kill MM cells in the presence of the cytoprotective BM microenvironment while inhibiting bone resorption by osteoclasts. These data support investigating GDC 0941 in combination with currently used therapeutic drugs for MM patients with active bone disease.
C1 [Kikuchi, Hugh; Amofa, Eunice; Mcenery, Maeve; Schey, Steve Arthur; Farzaneh, Farzin] Kings Coll London, Dept Haemato Oncol, London SE5 9NU, England.
   [Schey, Steve Arthur] Guys Hosp, Guys & St ThomasNHS Fdn Trust, Dept Haematol, Guys & St, London SE5 9RS, England.
   [Ramasamy, Karthik] Oxford Univ Hosp, Royal Berkshire Hosp, Oxford OX3 7LE, England.
   [Calle, Yolanda] Univ Roehampton, Sch Life Sci & Hlth, London SW15 4JD, England.
   [Amofa, Eunice] Coventry Univ, Res Ctr Sport, Exercise & Life Sci, Coventry CV1, W Midlands, England.
C3 University of London; King's College London; Guy's & St Thomas' NHS
   Foundation Trust; Royal Berkshire Hospital; Roehampton University;
   Coventry University
RP Calle, Y (通讯作者)，Univ Roehampton, Sch Life Sci & Hlth, London SW15 4JD, England.
EM yolanda.calle patino@roehampton.ac.uk
RI ; Ramasamy, Karthik/LZF 6258 2025; Farzaneh, Farzin/B 4902 2009; Calle,
   Yolanda/AAP 8517 2020
OI Ramasamy, Karthik/0000 0003 3385 3707; Calle,
   Yolanda/0000 0002 1467 5178; 
FU Cancer Research UK [C34579/A14248]
FX This research was funded by Cancer Research UK, grant reference
   C34579/A14248.
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042
   Alici E, 2004, EXP HEMATOL, V32, P1064, DOI 10.1016/j.exphem.2004.07.019
   Amachi R, 2016, ONCOTARGET, V7, P70447, DOI 10.18632/oncotarget.11927
   Anderson G, 2006, BLOOD, V107, P3098, DOI 10.1182/blood 2005 08 3450
   Asosingh K, 2003, Verh K Acad Geneeskd Belg, V65, P127
   Babarovic E, 2012, AM J CLIN PATHOL, V137, P870, DOI 10.1309/AJCPT5Y2JRIUUCUB
   Bolzoni M, 2013, EXP HEMATOL, V41, P387, DOI 10.1016/j.exphem.2012.11.005
   Breitkreutz I, 2008, LEUKEMIA, V22, P1925, DOI 10.1038/leu.2008.174
   Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993
   Dadzie TG, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.999939
   Danziger SA, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003323
   Davies FE, 2022, BLOOD CANCER DISCOV, V3, P273, DOI 10.1158/2643 3230.BCD 21 0205
   Durer C, 2020, BLOOD REV, V39, DOI 10.1016/j.blre.2019.100616
   Frassanito MA, 2014, LEUKEMIA, V28, P904, DOI 10.1038/leu.2013.254
   GARCIA V, 2011, J CLIN ONCOL, V29, P3021
   Ghobrial IM, 2018, NAT REV CLIN ONCOL, V15, P219, DOI 10.1038/nrclinonc.2017.197
   Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043
   Harada T, 2021, CANCERS, V13, DOI 10.3390/cancers13174441
   Heinemann L, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.874325
   Hofmann C, 2014, BRIT J HAEMATOL, V166, P529, DOI 10.1111/bjh.12920
   Ikeda H, 2010, BLOOD, V116, P1460, DOI 10.1182/blood 2009 06 222943
   Keane NA, 2014, EXPERT OPIN THER TAR, V18, P897, DOI 10.1517/14728222.2014.924507
   Kinoshita S, 2018, ONCOL LETT, V15, P9450, DOI 10.3892/ol.2018.8501
   Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797
   Liu JY, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg2697
   Maouche N, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0270854
   McCaughan GJ, 2022, BRIT J HAEMATOL, V199, P190, DOI 10.1111/bjh.18295
   McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112
   Mithraprabhu S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.98
   Moreaux J, 2011, BLOOD, V117, P1280, DOI 10.1182/blood 2010 04 279760
   Munugalavadla V, 2014, ONCOGENE, V33, P316, DOI 10.1038/onc.2012.594
   Noll JE, 2014, HAEMATOLOGICA, V99, P163, DOI 10.3324/haematol.2013.090977
   OSullivan BT, 1997, BIOL PSYCHIAT, V41, P574, DOI 10.1016/S0006 3223(96)00094 7
   Piva R, 2008, BLOOD, V111, P2765, DOI 10.1182/blood 2007 07 100651
   Ramasamy K, 2021, BLOOD REV, V49, DOI 10.1016/j.blre.2021.100808
   Ramasamy K, 2012, BRIT J HAEMATOL, V157, P564, DOI 10.1111/j.1365 2141.2012.09103.x
   Rasch S, 2020, CANCERS, V12, DOI 10.3390/cancers12082113
   Rasche L, 2020, BLOOD, V136, P2491, DOI 10.1182/blood.2019004176
   Richardson PG, 2019, LANCET ONCOL, V20, P781, DOI 10.1016/S1470 2045(19)30152 4
   Saltarella I, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 018 0691 4
   Sarker D, 2015, CLIN CANCER RES, V21, P77, DOI 10.1158/1078 0432.CCR 14 0947
   Sezer O, 2001, EUR J HAEMATOL, V66, P83, DOI 10.1034/j.1600 0609.2001.00348.x
   Shen YJ, 2021, BLOOD, V137, P2360, DOI 10.1182/blood.2020005885
   Shugg RPP, 2013, J BIOL CHEM, V288, P35346, DOI 10.1074/jbc.M113.507525
   Slany A, 2014, J PROTEOME RES, V13, P844, DOI 10.1021/pr400881p
   Solimando AG, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.973836
   Solimando AG, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070997
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   TETI A, 1992, AM J PHYSIOL, V263, pC130, DOI 10.1152/ajpcell.1992.263.1.C130
   Usman MW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0849 6
   Visram A, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408 021 00440 4
   Vrábel D, 2019, BLOOD REV, V34, P56, DOI 10.1016/j.blre.2018.11.003
   Wang L, 2019, ONCOL REP, V41, P1678, DOI 10.3892/or.2019.6968
   Watanabe K, 2021, HAEMATOLOGICA, V106, P1172, DOI 10.3324/haematol.2019.244418
   Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056/NEJMoa070596
   Xin YJ, 2020, CALCIFIED TISSUE INT, V106, P553, DOI 10.1007/s00223 020 00666 7
   Yang L, 2014, BIOCHEM BIOPH RES CO, V453, P582, DOI 10.1016/j.bbrc.2014.09.129
   Zöllinger A, 2008, BLOOD, V112, P3403, DOI 10.1182/blood 2007 11 119362
NR 59
TC 1
Z9 1
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD JAN
PY 2023
VL 15
IS 2
AR 462
DI 10.3390/cancers15020462
PG 21
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 7Y1DC
UT WOS:000914628000001
PM 36672411
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Louka, P
   Orriss, IR
   Pitsillides, AA
AF Louka, Polymnia
   Orriss, Isabel R.
   Pitsillides, Andrew A.
TI Stable Sulforaphane Targets the Early Stages of Osteoclast Formation to
   Engender a Lasting Functional Blockade of Osteoclastogenesis
SO CELLS
LA English
DT Article
DE sulforaphane; osteoclasts; osteoclastogenesis; NRF2 and NF KB
ID CELL CELL FUSION; NRF2 TRANSCRIPTION FACTOR; OXIDATIVE STRESS; CANCER
   CELLS; DC STAMP; BONE; DIFFERENTIATION; INHIBITION; BROCCOLI;
   ISOTHIOCYANATES
AB Sulforaphane, the native but unstable form of SFX 01, is an antioxidant that activates the NRF2 and inhibits the NF KB pathways to achieve its actions. Resolving the mechanism(s) by which SFX 01 serves to control the various osteoclastogenic stages may expose pathways that could be explored for therapeutic use. Here we seek to identify the stage of osteoclastogenesis targeted by SFX 01 and explore whether, like SFN, it exerts its actions via the NRF2 and NF KB pathways. Osteoclasts generated from the bone marrow (BM) of mice were cultured with SFX 01 at different timepoints to examine each phase of osteoclastogenesis separately. This showed that SFX 01 exerted actions throughout the process of osteoclastogenesis, but had its largest effects in the early osteoclast precursor differentiation stage. Thus, treatment with SFX 01 for the duration of culture, for the initial 3 days differentiation or for as little as the first 24 h was sufficient for effective inhibition. This aligned with data suggesting that SFX 01 reduced DC STAMP levels, osteoclast nuclear number and modified cytoskeletal architecture. Pharmacological regulation of the NRF2 pathways, via selective inhibitors/activators, supported the anti osteoclastogenic roles of an SFX 01 mediated by NRF2 activation, as well as the need for tight NF KB pathway regulation in osteoclast formation/function.
C1 [Louka, Polymnia; Orriss, Isabel R.; Pitsillides, Andrew A.] Royal Vet Coll, Skeletal Biol Grp, Comparat Biomed Sci, London NW1 0TU, England.
C3 University of London; University of London Royal Veterinary College
RP Pitsillides, AA (通讯作者)，Royal Vet Coll, Skeletal Biol Grp, Comparat Biomed Sci, London NW1 0TU, England.
EM plouka@rvc.ac.uk; iorriss@rvc.ac.uk; apitsillides@rvc.ac.uk
RI ; Orriss, Isabel/GRS 3934 2022; Louka, Polymnia/KHE 4262 2024
OI Pitsillides, Andrew/0000 0002 3861 998X; Louka,
   Polymnia/0000 0002 0553 0110; Orriss, Isabel/0000 0002 7847 050X
FU BBSRC; EvgenPharma PLC; EPSRC; Osteoarthritis Technology Network Plus
   grant sub project award [EP/N027264/1]
FX This study was supported predominantly by iCASE funding from the BBSRC
   and EvgenPharma PLC and from an EPSRC, Osteoarthritis Technology Network
   Plus grant sub project award entitled: a multidisciplinary approach to
   the prevention and treatment of OA (EP/N027264/1)
CR Alfieri A, 2013, FREE RADICAL BIO MED, V65, P1012, DOI 10.1016/j.freeradbiomed.2013.08.190
   Arlt A, 2013, ONCOGENE, V32, P4825, DOI 10.1038/onc.2012.493
   Bai Y, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/407580
   Bao B, 2019, MOL MED REP, V19, P4890, DOI 10.3892/mmr.2019.10148
   Bello C, 2018, FOOD CHEM, V268, P249, DOI 10.1016/j.foodchem.2018.06.089
   Brandenburg LO, 2010, INFLAMM RES, V59, P443, DOI 10.1007/s00011 009 0116 5
   CHAMBERS TJ, 1984, J CELL SCI, V66, P383
   Colapietro A, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14111082
   Dinkova Kostova AT, 2012, TRENDS MOL MED, V18, P337, DOI 10.1016/j.molmed.2012.04.003
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031 9422(00)00316 2
   Galea I, 2019, MULT SCLER RELAT DIS, V30, P257, DOI 10.1016/j.msard.2019.02.027
   Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Imhoff BR, 2009, BIOCHEM J, V424, P491, DOI 10.1042/BJ20091286
   Javaheri B, 2017, BONE, V103, P308, DOI 10.1016/j.bone.2017.07.028
   Jeong DH, 2020, J NAT PROD, V83, P1174, DOI 10.1021/acs.jnatprod.9b01212
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kensler TW, 2013, TOP CURR CHEM, V329, P163, DOI 10.1007/128_2012_339
   Kim KJ, 2018, J CLIN MED, V7, DOI 10.3390/jcm7060154
   Kim SJ, 2005, MOL CELLS, V20, P364
   Krajka Kuzniak V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158223
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Liu H, 2013, P NATL ACAD SCI USA, V110, P19065, DOI 10.1073/pnas.1318247110
   Louka P, 2022, CELL BIOCHEM FUNCT, V40, P683, DOI 10.1002/cbf.3734
   Luo TT, 2021, MOLECULES, V26, DOI 10.3390/molecules26020347
   Mahn A, 2018, J FOOD SCI TECH MYS, V55, P4687, DOI 10.1007/s13197 018 3395 4
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   Miyamoto H, 2012, J BONE MINER RES, V27, P1289, DOI 10.1002/jbmr.1575
   Orriss IR, 2012, METHODS MOL BIOL, V816, P103, DOI 10.1007/978 1 61779 415 5_8
   Park CK, 2014, BONE, V63, P36, DOI 10.1016/j.bone.2014.01.025
   Poulet B, 2014, ARTHRITIS RHEUMATOL, V66, P1832, DOI 10.1002/art.38616
   Qin WJ, 2017, ACTA BIOCH BIOPH SIN, V49, P696, DOI 10.1093/abbs/gmx067
   Roh JL, 2017, REDOX BIOL, V11, P254, DOI 10.1016/j.redox.2016.12.010
   Schroeter H., 2004, Am. J. Clin. Nutr, V80, P1670, DOI [10.1093/ajcn/80.6.1670, DOI 10.1093/AJCN/80.6.1670]
   Simoes BM, 2020, ONCOGENE, V39, P4896, DOI 10.1038/s41388 020 1335 z
   Sun YX, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929 015 0212 5
   Takagi T, 2017, BIOSCI BIOTECH BIOCH, V81, P1220, DOI 10.1080/09168451.2017.1281729
   Takagi T, 2017, BIOCHEM BIOPH RES CO, V483, P718, DOI 10.1016/j.bbrc.2016.12.075
   Thaler R, 2016, J BIOL CHEM, V291, P6754, DOI 10.1074/jbc.M115.678235
   Vanduchova A, 2019, J MED FOOD, V22, P121, DOI 10.1089/jmf.2018.0024
   Wang XY, 2020, FITOTERAPIA, V142, DOI 10.1016/j.fitote.2020.104482
   Winkel AF, 2015, J BIOL CHEM, V290, P28446, DOI 10.1074/jbc.M115.678136
   Xue P, 2019, BIOCHEM BIOPH RES CO, V511, P637, DOI 10.1016/j.bbrc.2019.02.095
   Yuan C, 2008, FOOD CHEM, V109, P264, DOI 10.1016/j.foodchem.2007.07.051
   Zakkar M, 2009, ARTERIOSCL THROM VAS, V29, P1851, DOI 10.1161/ATVBAHA.109.193375
   Zolnourian AH, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen 2018 028514
NR 47
TC 3
Z9 3
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD JAN
PY 2024
VL 13
IS 2
AR 165
DI 10.3390/cells13020165
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FW3X0
UT WOS:001148861900001
PM 38247857
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU He, Y
   Liu, F
   He, MJ
   Long, FY
   Hu, D
   Chen, JW
   Fang, M
   Wang, ZL
AF He, Yu
   Liu, Fei
   He, Mingjuan
   Long, Fayu
   Hu, Ding
   Chen, Jingwen
   Fang, Miao
   Wang, Zhenlong
TI Molecular mechanism of resveratrol promoting differentiation of
   preosteoblastic MC3T3 E1 cells based on network pharmacology and
   experimental validation
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Integrative medicine; Phytotherapy; Resveratrol; Apoptosis;
   Osteogenesis; Osteoporosis
ID OSTEOPOROSIS; MEDICINE; DATABASE; PATHWAY; KEGG
AB The purpose of this study was to investigate the mechanism by which resveratrol (Res) inhibits apoptosis and promotes proliferation and differentiation of pre osteoblastic MC3T3 E1 cells, laying the groundwork for the treatment of osteoporosis (OP). The TCMSP database was used to find the gene targets for Res. The GeneCards database acquire the gene targets for OP. After discovering the potential target genes, GO, KEGG, and Reactome enrichment analysis were conducted. Verifying the major proteins involved in apoptosis can bind to Res using molecular docking. CCK8 measured the proliferative activity of mouse pre osteoblasts in every group following Res intervention. Alkaline phosphatase staining (ALP) and alizarin red staining to measure the ability of osteogenic differentiation. RT qPCR to determine the expression levels of Runx2 and OPG genes for osteogenic differentiation ability of cells. Western blot to measure the degree of apoptosis related protein activity in each group following Res intervention. The biological processes investigated for GO of Res therapeutic OP involved in cytokine mediated signaling pathway, negative regulation of apoptotic process, Aging, extrinsic apoptotic signaling pathway in absence of ligand, according to potential therapeutic target enrichment study. Apoptosis, FoxO signaling pathway, and TNF signaling pathway are the primary KEGG signaling pathways. Recactome pathways are primarily engaged in Programmed Cell Death, Apoptosis, Intrinsic Apoptotic Pathway, and Caspase activation via extrinsic apoptotic signaling pathways. This research established a new approach for Res treatment of OP by demonstrating how Res controls the apoptosis related proteins TNF, IL6, and CASP3 to suppress osteoblast death and increase osteoclastogenesis.
C1 [He, Yu; He, Mingjuan; Long, Fayu; Hu, Ding; Fang, Miao] Chengdu Second Peoples Hosp, Dept Spine Surg, 2 Huatai Rd, Chengdu 610000, Sichuan, Peoples R China.
   [Liu, Fei] Guangxi Univ Chinese Med, Ruikang Hosp, Dept Spine Surg, Nanning 530011, Guangxi, Peoples R China.
   [Liu, Fei; Chen, Jingwen; Wang, Zhenlong] Southwest Med Univ, Dept Orthoped, Affiliated Tradit Chinese Med Hosp, 182 Chunhui Rd, Luzhou 646000, Sichuan, Peoples R China.
C3 Guangxi University of Chinese Medicine; Southwest Medical University
RP Fang, M (通讯作者)，Chengdu Second Peoples Hosp, Dept Spine Surg, 2 Huatai Rd, Chengdu 610000, Sichuan, Peoples R China.; Wang, ZL (通讯作者)，Southwest Med Univ, Dept Orthoped, Affiliated Tradit Chinese Med Hosp, 182 Chunhui Rd, Luzhou 646000, Sichuan, Peoples R China.
EM 251401073@qq.com; borbylong@swmu.edu.cn
CR Barshir R, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2021.166913
   Bateman A, 2021, NUCLEIC ACIDS RES, V49, pD480, DOI 10.1093/nar/gkaa1100
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Blake J, 2021, MENOPAUSE, V28, P973, DOI 10.1097/GME.0000000000001831
   De Marinis I, 2022, BIOINFORMATICS, V38, P1764, DOI 10.1093/bioinformatics/btab865
   Druart Leo, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030072
   Eberhardt J, 2021, J CHEM INF MODEL, V61, P3891, DOI 10.1021/acs.jcim.1c00203
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Gao ZR, 2022, CHIN MED UK, V17, DOI 10.1186/s13020 022 00640 5
   He S, 2022, J ETHNOPHARMACOL, V282, DOI 10.1016/j.jep.2021.114615
   He XR, 2014, J ETHNOPHARMACOL, V151, P78, DOI 10.1016/j.jep.2013.11.023
   Jassal B, 2020, NUCLEIC ACIDS RES, V48, pD498, DOI 10.1093/nar/gkz1031
   Jia Y, 2022, BIOENGINEERED, V13, P5581, DOI 10.1080/21655979.2022.2038941
   Jiang YX, 2020, LIFE SCI, V246, DOI 10.1016/j.lfs.2020.117422
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kanehisa M, 2023, NUCLEIC ACIDS RES, V51, pD587, DOI 10.1093/nar/gkac963
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kendler DL, 2018, LANCET, V391, P230, DOI 10.1016/S0140 6736(17)32137 2
   Kim S, 2021, NUCLEIC ACIDS RES, V49, pD1388, DOI 10.1093/nar/gkaa971
   Kuriakose A, 2022, J FOOD BIOCHEM, V46, DOI 10.1111/jfbc.14367
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Lei SS, 2021, INT J BIOL MACROMOL, V193, P1996, DOI 10.1016/j.ijbiomac.2021.11.030
   Liu X, 2021, ACTA BIOCH BIOPH SIN, V53, P1495, DOI 10.1093/abbs/gmab135
   Ma J, 2018, MED SCI MONITOR, V24, P2045, DOI 10.12659/MSM.905703
   Miller JL, 2008, EXPLORE NY, V4, P311, DOI 10.1016/j.explore.2008.06.002
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Mobasheri A, 2013, ANN NY ACAD SCI, V1290, P59, DOI 10.1111/nyas.12145
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mosavat SH, 2023, FRONT PUBLIC HEALTH, V11, DOI 10.3389/fpubh.2023.1206665
   Rayalam S, 2011, MOL NUTR FOOD RES, V55, P1177, DOI 10.1002/mnfr.201000616
   Rozenberg S, 2020, OSTEOPOROSIS INT, V31, P2271, DOI 10.1007/s00198 020 05497 8
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sneha P, 2018, ADV PROTEIN CHEM STR, V110, P167, DOI 10.1016/bs.apcsb.2017.07.004
   Wang LH, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.21106
   Wang YX, 2022, CALCIFIED TISSUE INT, V111, P185, DOI 10.1007/s00223 022 00977 x
   Wang YC, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2446 3
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhao BJ, 2016, PLANTA MED, V82, P322, DOI 10.1055/s 0035 1558294
   Zhao HX, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34574 6
   Zhu W, 2022, ANN MED, V54, P541, DOI 10.1080/07853890.2022.2034931
NR 43
TC 2
Z9 3
U1 1
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2662 7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD FEB 29
PY 2024
VL 24
IS 1
AR 108
DI 10.1186/s12906 024 04396 3
PG 15
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA KF7E4
UT WOS:001178600000002
PM 38424533
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wu, FF
   Xu, JT
   Jin, MC
   Jiang, XS
   Xu, Y
   Li, JY
   Li, XF
   Nie, JB
   Yan, SG
   Wang, GR
AF Wu, Fengfeng
   Xu, Juntao
   Jin, Mingchao
   Jiang, Xuesheng
   Xu, Yan
   Li, Jianyou
   Li, Xiongfeng
   Nie, Jiangbo
   Yan, Shigui
   Wang, Guorong
TI Coating of Epimedii Folium Water Extract onto TiO2
   Nanotube Surfaces Promotes Differentiation and Proliferation of
   Osteoblasts
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Epimedii Folium Water Extract; TiO2 Nanotube; EF TNT; MC3T3 E1; Network
   Pharmacology
ID OSTEOGENIC DIFFERENTIATION; INDUCED OSTEOPOROSIS; BONE METABOLISM;
   HERBA EPIMEDII; STEM CELLS; POSSIBLE MECHANISMS; FLAVONOID FRACTION;
   MC3T3 E1 CELLS; GRAPHENE OXIDE; KNOCKOUT MICE
AB The surface modification of titanium is effective in promoting osseointegration and is widely used in the treatment of bone diseases. Epimedii Folium (EF) plays an important role in the treatment of metabolic bone diseases. However, few studies have so far been reported on their combined use in such treatments. In the present study, EF water extract was coated onto the surface of TiO2 nanotubes (TNT) by electrochemical anodization to obtain EF TNT. Through analysis of surface morphology characteristics, it was demonstrated that EF was successfully coated on the surface of TiO2 nanotubes. In vitro drug release data suggested that the quantity of EF water extract released was a significant quantity over 4 days, reaching a total of 80%, the release continuing in total for approximately 2 weeks. By using scanning electron microscopy and immunofluorescent staining, it was found that, EF TNT more strongly promoted adhesion, proliferation, and differentiation of MC3T3 E1 osteoblasts compared with Ti and TNT. Quantitative reverse transcript polymerase chain reaction (qRT PCR) analysis indicated that the expression of key genes for proliferation and differentiation of osteoblasts, such as COL1a1, ALP, OPN, and Runx2, were up regulated by EF TNT. Network pharmacology analysis suggested that EF water extract not only regulated the proliferation and differentiation of osteoblasts but also caused a regulatory effect on osteoclasts via multiple signaling pathways, such as RANKL RANK induced signaling and TGF beta signaling. These findings indicate that the EF TNT promotes differentiation and proliferation of osteoblasts, and represents considerable potential for use in clinical applications.
C1 [Wu, Fengfeng; Jin, Mingchao; Jiang, Xuesheng; Li, Jianyou; Li, Xiongfeng; Nie, Jiangbo; Wang, Guorong] Zhejiang Univ, Huzhou Univ, Affiliated Cent Hosp, Huzhou Hosp,Huzhou Cent Hosp,Dept Orthoped, Huzhou 313000, Zhejiang, Peoples R China.
   [Wu, Fengfeng; Yan, Shigui] Zhejiang Univ, Affiliated Hosp 2, Med Coll, Orthoped Res Inst,Dept Orthoped, Hangzhou 310000, Zhejiang, Peoples R China.
   [Xu, Juntao] Zhejiang Chinese Med Univ, Huzhou Tradit Chinese Med Hosp, Dept Orthoped, Huzhou 313000, Zhejiang, Peoples R China.
   [Xu, Yan] Zhejiang Univ, Huzhou Univ, Affiliated Cent Hosp, Huzhou Hosp,Huzhou Cent Hosp,Dept Rehabil, Huzhou 313000, Zhejiang, Peoples R China.
C3 Zhejiang University; Huzhou University; Zhejiang University; Zhejiang
   Chinese Medical University; Zhejiang University; Huzhou University
RP Wang, GR (通讯作者)，Zhejiang Univ, Huzhou Univ, Affiliated Cent Hosp, Huzhou Hosp,Huzhou Cent Hosp,Dept Orthoped, Huzhou 313000, Zhejiang, Peoples R China.; Yan, SG (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Med Coll, Orthoped Res Inst,Dept Orthoped, Hangzhou 310000, Zhejiang, Peoples R China.
EM zrjwsj@zju.edu.cn; beyondutmost@yeah.net
RI Li, Jiazhen/HPF 9994 2023
FU Science and Technology Bureau Program of Huzhou [2018GY29]; Traditional
   Chinese Medicine Scientific Research and Technology Project of Zhejiang
   Province [2016ZA185]; Research on the Application of Public Welfare
   Technology in Zhejiang Province [2017C33222]
FX The authors gratefully acknowledge Science and Technology Bureau Program
   of Huzhou (Grant number: 2018GY29); the Traditional Chinese Medicine
   Scientific Research and Technology Project of Zhejiang Province (Grant
   number: 2016ZA185); Research on the Application of Public Welfare
   Technology in Zhejiang Province (Grant number: 2017C33222).
CR Bandyopadhyay A, 2019, ACTA BIOMATER, V96, P686, DOI 10.1016/j.actbio.2019.07.028
   Bandyopadhyay A, 2017, ANN BIOMED ENG, V45, P249, DOI 10.1007/s10439 016 1673 8
   Baron L, 2015, IEEE CONF COMPUT, P3, DOI 10.1109/INFCOMW.2015.7179314
   Caetano Lopes J, 2009, AUTOIMMUN REV, V8, P250, DOI 10.1016/j.autrev.2008.07.038
   Cao H, 2012, INT J MOL MED, V29, P435, DOI 10.3892/ijmm.2011.845
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   Chandra A, 2013, J BIOL CHEM, V288, P20488, DOI 10.1074/jbc.M112.447250
   Chen MH, 2019, COLLOID SURFACE B, V175, P663, DOI 10.1016/j.colsurfb.2018.12.023
   Chen WF, 2011, BRIT J NUTR, V105, P180, DOI 10.1017/S0007114510003247
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Dünker N, 2002, ANAT EMBRYOL, V206, P73, DOI 10.1007/s00429 002 0273 6
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Falahati Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942
   FELSON DT, 1994, NEW ENGL J MED, V330, P716
   Ge LN, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/2160175
   Hachim D, 2017, BIOMATERIALS, V112, P95, DOI 10.1016/j.biomaterials.2016.10.019
   Hu HY, 2016, CELL PHYSIOL BIOCHEM, V38, P2375, DOI 10.1159/000445590
   Hung TY, 2010, J ETHNOPHARMACOL, V131, P70, DOI 10.1016/j.jep.2010.05.063
   ILKIM S, 2007, AM J PHYSIOL RENAL, V292, pF147, DOI DOI 10.1152/AJPRENAL.00485.2006
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Iyer S, 2014, J BIOL CHEM, V289, P24069, DOI 10.1074/jbc.M114.561803
   Jiang T, 2018, J NANOSCI NANOTECHNO, V18, P2310, DOI 10.1166/jnn.2018.14311
   Jones JA, 2007, J BIOMED MATER RES A, V83A, P585, DOI 10.1002/jbm.a.31221
   Kawane T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31853 0
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Kim GJ, 2018, J NANOSCI NANOTECHNO, V18, P6726, DOI 10.1166/jnn.2018.15472
   Kim KO, 2018, J NANOSCI NANOTECHNO, V18, P4439, DOI 10.1166/jnn.2018.15404
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Labusca LS, 2018, J NANOSCI NANOTECHNO, V18, P5143, DOI 10.1166/jnn.2018.15330
   Lagonegro P, 2019, J NANOSCI NANOTECHNO, V19, P4665, DOI 10.1166/jnn.2019.16350
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797 307
   Lee J, 2018, NANOSCI NANOTECH LET, V10, P688, DOI 10.1166/nnl.2018.2661
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Li K, 2019, J BIOMED NANOTECHNOL, V15, P477, DOI 10.1166/jbn.2019.2708
   Li P, 2019, J BIOMED NANOTECHNOL, V15, P921, DOI 10.1166/jbn.2019.2749
   Li T, 2019, J PHOTOCH PHOTOBIO B, V197, DOI 10.1016/j.jphotobiol.2019.111515
   Li Y, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5697250
   Liang WN, 2012, INT J MOL MED, V30, P889, DOI 10.3892/ijmm.2012.1079
   Liu AF, 2019, J NANOSCI NANOTECHNO, V19, P91, DOI 10.1166/jnn.2019.16443
   Liu GQ, 2019, FASEB J, V33, P11137, DOI 10.1096/fj.201900436RR
   Liu M, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.14
   Liu MT, 2018, J NANOSCI NANOTECHNO, V18, P3134, DOI 10.1166/jnn.2018.14649
   Liu WW, 2015, INT J NANOMED, V10, P1997, DOI 10.2147/IJN.S74418
   Liu YQ, 2014, PHYTOMEDICINE, V21, P1633, DOI 10.1016/j.phymed.2014.07.016
   Liu Y, 2020, ACTA PHARMACOL SIN, V41, P138, DOI 10.1038/s41401 019 0228 6
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Losic D, 2009, EXPERT OPIN DRUG DEL, V6, P1363, DOI 10.1517/17425240903300857
   Ma AB, 2019, COATINGS, V9, DOI 10.3390/coatings9050327
   MANOLAGAS SC, 1995, INT J IMMUNOPHARMACO, V17, P109, DOI 10.1016/0192 0561(94)00089 7
   Matsunobu T, 2009, DEV BIOL, V332, P325, DOI 10.1016/j.ydbio.2009.06.002
   Moon JJ, 2012, ADV MATER, V24, P3724, DOI 10.1002/adma.201200446
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Neoh KG, 2012, BIOMATERIALS, V33, P2813, DOI 10.1016/j.biomaterials.2012.01.018
   Niu YB, 2012, OSTEOPOROSIS INT, V23, P2649, DOI 10.1007/s00198 012 1932 y
   Niu YB, 2011, PHYTOTHER RES, V25, P1700, DOI 10.1002/ptr.3414
   Nyangoga H, 2010, ACTA BIOMATER, V6, P3310, DOI 10.1016/j.actbio.2010.01.042
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Peng S, 2007, ASSAY DRUG DEV TECHN, V5, P355, DOI 10.1089/adt.2007.056
   Qiao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep18732
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Shen P, 2007, PHYTOCHEMISTRY, V68, P1448, DOI 10.1016/j.phytochem.2007.03.001
   Siu WS, 2013, PHYTOTHER RES, V27, P484, DOI 10.1002/ptr.4743
   Son JS, 2011, J BIOMED MATER RES A, V99A, P638, DOI 10.1002/jbm.a.33223
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Song W, 2019, NANOSCI NANOTECH LET, V11, P973, DOI 10.1166/nnl.2019.2976
   Street John, 2009, J Orthop Surg Res, V4, P19, DOI 10.1186/1749 799X 4 19
   Tang DZ, 2011, BIOCHEM BIOPH RES CO, V405, P256, DOI 10.1016/j.bbrc.2011.01.021
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
   Wagner E.F., 2002, ANN RHEUMATIC DIS S2, V61, pii40
   Wang CY, 2018, J BIOMAT SCI POLYM E, V29, P1595, DOI 10.1080/09205063.2018.1477316
   Wang F, 2019, J NANOSCI NANOTECHNO, V19, P5435, DOI 10.1166/jnn.2019.16509
   Wang H, 2018, NANOSCI NANOTECH LET, V10, P229, DOI 10.1166/nnl.2018.2516
   Wang JJ, 2018, INT J NANOMED, V13, P4029, DOI 10.2147/IJN.S163956
   Wang YB, 2018, NANOSCI NANOTECH LET, V10, P1498, DOI 10.1166/nnl.2018.2820
   Weng ZB, 2015, MOL CELL ENDOCRINOL, V417, P103, DOI 10.1016/j.mce.2015.09.025
   Wu CT, 2014, ACS APPL MATER INTER, V6, P4264, DOI 10.1021/am4060035
   Wu FF, 2020, BIOMED MATER, V15, DOI 10.1088/1748 605X/ab7e79
   Xu Q, 2019, EUR REV MED PHARMACO, V23, P4081, DOI 10.26355/eurrev_201905_17909
   Xu YJ, 2019, J BIOMED NANOTECHNOL, V15, P2351, DOI 10.1166/jbn.2019.2856
   Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612
   Yi H, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.50
   Yu WQ, 2015, COLLOID SURFACE B, V136, P779, DOI 10.1016/j.colsurfb.2015.10.019
   Yuan W, 2018, J NANOSCI NANOTECHNO, V18, P6799, DOI 10.1166/jnn.2018.15519
   Yuan W, 2018, J NANOSCI NANOTECHNO, V18, P4360, DOI 10.1166/jnn.2018.15207
   Zeng L, 2019, J NANOSCI NANOTECHNO, V19, P2166, DOI 10.1166/jnn.2019.15764
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhang RR, 2018, ARTIF CELL NANOMED B, V46, pS1123, DOI 10.1080/21691401.2018.1446442
   Zhang R, 2014, J ETHNOPHARMACOL, V155, P104, DOI 10.1016/j.jep.2014.04.031
   Zhang WX, 2019, INT J NANOMED, V14, P977, DOI 10.2147/IJN.S190766
   Zhang XR, 2011, J BONE MINER RES, V26, P1022, DOI 10.1002/jbmr.295
   Zhang X, 2014, PHYTOTHER RES, V28, P498, DOI 10.1002/ptr.5027
   Zhao BJ, 2016, PLANTA MED, V82, P322, DOI 10.1055/s 0035 1558294
   Zhao HS, 2019, DRUG DES DEV THER, V13, P2997, DOI 10.2147/DDDT.S207823
   Zhao JY, 2010, TISSUE ENG PT A, V16, P233, DOI [10.1089/ten.tea.2009.0165, 10.1089/ten.TEA.2009.0165]
   Zhou HF, 2014, MOL MED REP, V9, P590, DOI 10.3892/mmr.2013.1837
   Zhu SY, 2018, J MOL ENDOCRINOL, V60, P185, DOI 10.1530/JME 17 0218
   Zou WJ, 2015, J BONE MINER METAB, V33, P615, DOI 10.1007/s00774 014 0627 1
NR 103
TC 3
Z9 3
U1 0
U2 27
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 1550 7033
EI 1550 7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD JUN
PY 2020
VL 16
IS 6
BP 885
EP 898
DI 10.1166/jbn.2020.2944
PG 14
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA OS0ZQ
UT WOS:000589893800001
PM 33187584
DA 2025 08 17
ER

PT J
AU Noguchi, T
   Ebina, K
   Hirao, M
   Morimoto, T
   Koizumi, K
   Kitaguchi, K
   Matsuoka, H
   Iwahashi, T
   Yoshikawa, H
AF Noguchi, T.
   Ebina, K.
   Hirao, M.
   Morimoto, T.
   Koizumi, K.
   Kitaguchi, K.
   Matsuoka, H.
   Iwahashi, T.
   Yoshikawa, H.
TI Oxygen ultra fine bubbles water administration prevents bone loss of
   glucocorticoid induced osteoporosis in mice by suppressing osteoclast
   differentiation
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE c Fos; Glucocorticoid induced osteoporosis (GIO); Nuclear factor of
   activated T cells 1 (NFATc1); Osteoblasts; Osteoclasts; Oxygen
   ultra fine bubbles (OUB)
ID IN VITRO; HYPOXIA; MANAGEMENT; MICROBUBBLE; OSTEOBLASTS; RESORPTION;
   THERAPY; GROWTH; MECHANISMS; GENERATION
AB Oxygen ultra fine bubbles (OUB) saline injection prevents bone loss of glucocorti\coid induced osteoporosis in mice, and OUB inhibit osteoclastogenesis via RANK TRAF6 c Fos NFATc1 signaling and RANK p38 MAPK signaling in vitro.
   Ultra fine bubbles (< 200 nm in diameter) have several unique properties, and they are tested in various medical fields. The purpose of this study was to investigate the effects of oxygen ultra fine bubbles (OUB) on glucocorticoid induced osteoporosis (GIO) model mice.
   Prednisolone (PSL, 5 mg) was subcutaneously inserted in 6 month old male C57BL/6J mice, and 200 mu l of saline, OUB diluted saline, or nitrogen ultra fine bubbles (NUB) diluted saline was intraperitoneally injected three times per week for 8 weeks the day after operations. Mice were divided into four groups; (1) control, sham operation + saline; (2) GIO, PSL + saline; (3) GIO + OUB, PSL + OUB saline; (4) GIO + NUB, PSL + NUB saline. The effects of OUB on osteoblasts and osteoclasts were examined by serially diluted OUB medium in vitro.
   Bone mass was significantly decreased in GIO [bone volume/total volume (%): control vs. GIO 12.6 vs. 7.9; p < 0.01] while significantly preserved in GIO + OUB (GIO vs. GIO + OUB 7.9 vs. 12.9; p < 0.05). In addition, tartrate resistant acid phosphatase (TRAP) positive cells in the distal femur [mean osteoclasts number/bone surface (mm( 1))] was significantly increased in GIO (control vs. GIO 6.8 vs. 11.6; p < 0.01) while suppressed in GIO + OUB (GIO vs. GIO + OUB 11.6 vs. 7.5; p < 0.01). NUB did not affect these parameters. In vitro experiments revealed that OUB significantly inhibited osteoclastogenesis by inhibiting RANK TRAF6 c Fos NFATc1 signaling, RANK p38 MAPK signaling, and TRAP/Cathepsin K/DC STAMP mRNA expression in a concentration dependent manner. OUB did not affect osteoblastogenesis in vitro.
   OUB prevent bone loss in GIO mice by inhibiting osteoclastogenesis.
C1 [Noguchi, T.; Ebina, K.; Hirao, M.; Morimoto, T.; Koizumi, K.; Kitaguchi, K.; Matsuoka, H.; Iwahashi, T.; Yoshikawa, H.] Osaka Univ, Grad Sch Med, Dept Orthopaed Surg, 2 2 Yamadaoka, Suita, Osaka 5650871, Japan.
C3 University of Osaka
RP Ebina, K (通讯作者)，Osaka Univ, Grad Sch Med, Dept Orthopaed Surg, 2 2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM k ebina@umin.ac.jp
RI Ebina, Kosuke/AAH 6171 2019
FU Nakatomi funding; Health and Labor Sciences Research Grant of Japan;
   Ligaric Company Limited; West Nippon Expressway Company; Grants in Aid
   for Scientific Research [26293336] Funding Source: KAKEN
FX All oxygen and nitrogen ultra fine bubbles diluted saline and medium
   were prepared by Ligaric Company Limited. This research was funded by
   Nakatomi funding, Health and Labor Sciences Research Grant of Japan,
   Ligaric Company Limited, and West Nippon Expressway Company. The funders
   had no role in the study design, decision to publish, or preparation of
   the manuscript.
CR Abdelsalam M, 2010, RESP CARE, V55, P1483
   Agarwal A, 2011, CHEMOSPHERE, V84, P1175, DOI 10.1016/j.chemosphere.2011.05.054
   Al Hadi H, 2013, J ORTHOP RES, V31, P1839, DOI 10.1002/jor.22443
   Arnett TR, 2010, ARCH BIOCHEM BIOPHYS, V503, P103, DOI 10.1016/j.abb.2010.07.021
   Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Bitterman H, 2009, CRIT CARE, V13, DOI 10.1186/cc7151
   Chiou WF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089159
   Dayton PA, 2001, BIOPHYS J, V80, P1547, DOI 10.1016/S0006 3495(01)76127 9
   Ebina K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065339
   Geis NA, 2012, CURR PHARM DESIGN, V18, P2166, DOI 10.2174/138161212800099946
   Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125
   Hamilton JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045853
   Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394
   He Y., 2012, E Health Telecommun. Syst. Netw, V1, P1, DOI DOI 10.4236/ETSN.2012.11001
   Hirose Y, 2013, UROLITHIASIS, V41, P279, DOI 10.1007/s00240 013 0576 5
   Hsieh CP, 2010, CONNECT TISSUE RES, V51, P497, DOI 10.3109/03008201003746679
   Hu M, 2011, J IMMUNOL, V186, P2910, DOI 10.4049/jimmunol.1002353
   Huang HY, 2015, ADV MATER, V27, P655, DOI 10.1002/adma.201403889
   Imura Y, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 185
   Irwin R, 2007, J CELL BIOCHEM, V100, P762, DOI 10.1002/jcb.21083
   Kawai S, 2011, EXP ANIM TOKYO, V60, P481, DOI 10.1538/expanim.60.481
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Lewis JS, 1999, J LEUKOCYTE BIOL, V66, P889, DOI 10.1002/jlb.66.6.889
   Lindner JR, 2000, CIRCULATION, V101, P668, DOI 10.1161/01.CIR.101.6.668
   Matsuki N, 2012, EUR BIOPHYS J BIOPHY, V41, P571, DOI 10.1007/s00249 012 0811 y
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Noguchi T, 2015, BIOCHEM BIOPH RES CO, V465, P638, DOI 10.1016/j.bbrc.2015.08.077
   Peng HH, 2011, NANOMEDICINE UK, V6, P643, DOI [10.2217/nnm.11.24, 10.2217/NNM.11.24]
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Rizzoli R, 2012, CALCIFIED TISSUE INT, V91, P225, DOI 10.1007/s00223 012 9630 5
   Schmidt K, 2005, J CELL BIOL, V168, P899, DOI 10.1083/jcb.200408013
   Suzuki Y, 2014, J BONE MINER METAB, V32, P337, DOI 10.1007/s00774 014 0586 6
   Takahashi M, 2007, J PHYS CHEM B, V111, P1343, DOI 10.1021/jp0669254
   Tóth M, 2013, CLIN ENDOCRINOL, V79, P1, DOI 10.1111/cen.12189
   TUNCAY OC, 1994, AM J ORTHOD DENTOFAC, V105, P457, DOI 10.1016/S0889 5406(94)70006 0
   Utting JC, 2006, EXP CELL RES, V312, P1693, DOI 10.1016/j.yexcr.2006.02.007
   Utting JC, 2010, CELL BIOCHEM FUNCT, V28, P374, DOI 10.1002/cbf.1660
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Wang Y, 2010, INT J PHARMACEUT, V384, P148, DOI 10.1016/j.ijpharm.2009.09.027
   Xie XY, 2016, DRUG DELIV, V23, P2445, DOI 10.3109/10717544.2015.1008707
   Yoon HY, 2012, J BONE MINER METAB, V30, P509, DOI 10.1007/s00774 012 0350 8
   Zahm AM, 2008, BONE, V43, P25, DOI 10.1016/j.bone.2008.03.010
NR 43
TC 23
Z9 24
U1 1
U2 15
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAR
PY 2017
VL 28
IS 3
BP 1063
EP 1075
DI 10.1007/s00198 016 3830 1
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EK9QC
UT WOS:000394258000035
PM 27896363
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Yao, H
   Xiang, L
   Huang, YC
   Tan, J
   Shen, YM
   Li, FQ
   Geng, FN
   Liu, WW
   Li, XP
   Gao, YX
AF Yao, Huan
   Xiang, Li
   Huang, Yucheng
   Tan, Jin
   Shen, Yongmei
   Li, Fangqiong
   Geng, Funeng
   Liu, Weiwei
   Li, Xueping
   Gao, Yongxiang
TI Guizhi Shaoyao Zhimu granules attenuate bone destruction
   in mice with collagen induced arthritis by promoting mitophagy of
   osteoclast precursors to inhibit osteoclastogenesis
SO PHYTOMEDICINE
LA English
DT Article
DE Guizhi Shaoyao Zhimu granule; Rheumatoid arthritis; Osteoclasts;
   Mitophagy; Reactive oxygen species
ID NF KAPPA B; DECOCTION; DIFFERENTIATION; EROSION
AB Background: Guizhi Shaoyao Zhimu decoction, a traditional Chinese medicine formula used empirically for the treatment of rheumatoid arthritis (RA), has been shown to alleviate bone destruction in rats with collagen induced arthritis (CIA).
   Purpose: The aim of this study is to characterize the effects of Guizhi Shaoyao Zhimu granules (GSZGs) on bone destruction in RA and the underlying mechanism.
   Study design: A CIA arthritis model using DBA/1 mice. The animals were divided into a normal group; CIA model group; low, medium, and high dose GSZG groups (3, 6, and 9 g/kg/day); and a methotrexate group (1.14 mg/kg/ w). In vitro, a cytokine induced osteoclastogenesis model was established.
   Methods: After 28 days of treatment, the paw volume was measured, bone destruction was examined by microCT, and the generation of osteoclasts in bone tissue was evaluated via tartrate resistant acid phosphatase (TRAP) staining. Furthermore, the inhibitory effect and underlying mechanism of action of GSZG on RANKL induced osteoclastogenesis were investigated in vitro.
   Results: The in vivo analyses demonstrated that the paw volume and degree of bone erosion of mice in the medium  and high dose GSZG groups were significantly decreased compared to the CIA model group. In addition, GSZG treatment suppressed the excessive generation of osteoclasts in the bone tissue of CIA mice. In vitro, GSZG inhibited RANKL induced osteoclastogenesis and osteoclast mediated bone resorption. Specifically, it only inhibited the generation of osteoclast precursors (OCPs); it had no significant effect on the fusion of OCPs or maturation of osteoclasts. Finally, we showed that the inhibitory effect of GSZG on osteoclastogenesis was related to the promotion of PTEN induced kinase protein 1 (PINK1)/Parkin pathway mediated mitophagy of osteoclast precursors, which was verified using a PINK1 knockdown small interfering RNA in OCPs.
   Conclusion: These findings indicate that GSZG is a candidate for the treatment of bone destruction in RA and provide a more detailed elucidation of the mechanism of GSZG anti RA bone erosion, i.e., inhibition of the ROS/ NF & kappa;B axis through the PINK1/Parkin mediated mitochondrial autophagic pathway to inhibit osteoclast precursor production, compared to the published literature.
C1 [Yao, Huan] Chengdu Univ Tradit Chinese Med, Chengdu 610072, Sichuan, Peoples R China.
   [Yao, Huan] Sichuan Prov Engn Res Ctr Innovat Redev Famous Cla, Pengzhou 611930, Peoples R China.
   [Xiang, Li; Huang, Yucheng; Li, Xueping; Gao, Yongxiang] Hosp Chengdu Univ Tradit Chinese Med, Chengdu 610072, Sichuan, Peoples R China.
   [Tan, Jin; Shen, Yongmei; Li, Fangqiong; Geng, Funeng] Gooddoctor Pharmaceut Grp Co Ltd, Anzhou Ind Pk, Mianyang 622651, Sichuan, Peoples R China.
   [Liu, Weiwei] Chengdu Univ Tradit Chinese Med, Sch Basic Med Sci, Chengdu 611137, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine; Chengdu University of Traditional
   Chinese Medicine
RP Yao, H (通讯作者)，Chengdu Univ Tradit Chinese Med, Chengdu 610072, Sichuan, Peoples R China.; Yao, H (通讯作者)，Sichuan Prov Engn Res Ctr Innovat Redev Famous Cla, Pengzhou 611930, Peoples R China.; Gao, YX (通讯作者)，Hosp Chengdu Univ Tradit Chinese Med, Chengdu 610072, Sichuan, Peoples R China.
EM Huanyao6620@hotmail.com; xiangli@stu.cdutcm.edu.cn;
   Huangyucheng98@stu.cdutcm.edu.cn; tjv1001@hys.cn; sym0101@hys.cn;
   825087057@qq.com; lixueping@cdutcm.edu.cn; drgaoyx@cdutcm.edu.cn
RI Yao, Huan/AAD 4719 2019; Huan, Yao/AAD 4719 2019; 谭, 锦/ISU 3552 2023;
   Liu, Weiwei/C 2785 2012
OI Huan, Yao/0000 0001 5076 2650; Xiang, Li/0000 0002 4793 1780; 
FU National Natural Science Founda  tion of China [82274247]
FX Funding This study was supported by the National Natural Science Founda 
   tion of China (No. 82274247) .
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Almoiliqy M, 2020, ACTA PHARMACOL SIN, V41, P1208, DOI 10.1038/s41401 020 0359 9
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Feng CX, 2021, THER ADV CHRONIC DIS, V12, DOI 10.1177/2040622321993438
   Garg P, 2017, ORTHOP SURG, V9, P13, DOI 10.1111/os.12304
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246 00101001, 10.1038/s41413 018 0016 9]
   HATTERSLEY G, 1991, BIOCHEM BIOPH RES CO, V177, P526, DOI 10.1016/0006 291X(91)92015 C
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Hong SJ, 2022, MOL CELLS, V45, P749, DOI 10.14348/molcells.2022.0058
   Hou WD, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12111602
   Jakobsson PJ, 2022, J INTERN MED, V292, P745, DOI 10.1111/joim.13537
   Ji L, 2018, MICROB PATHOGENESIS, V124, P223, DOI 10.1016/j.micpath.2018.08.051
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Kim EY, 2023, CELL BIOSCI, V13, DOI 10.1186/s13578 023 00973 0
   Kim JH, 2015, MOL CELLS, V38, P904, DOI 10.14348/molcells.2015.0177
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Lee SY, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02656 4
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Lin YJ, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040880
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Mizoguchi T, 2021, J BONE MINER RES, V36, P1432, DOI 10.1002/jbmr.4410
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Nguyen TN, 2016, TRENDS CELL BIOL, V26, P733, DOI 10.1016/j.tcb.2016.05.008
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Scherer HU, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102400
   Shen JY, 2021, TRIALS, V22, DOI 10.1186/s13063 021 05579 w
   Shim JH, 2018, CALCIFIED TISSUE INT, V102, P533, DOI 10.1007/s00223 017 0373 1
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Takayanagi H, 2021, J BONE MINER METAB, V39, P13, DOI 10.1007/s00774 020 01191 1
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wang Y, 2021, J ETHNOPHARMACOL, V279, DOI 10.1016/j.jep.2021.114368
   Wei SJ, 2021, PHARM BIOL, V59, P262, DOI 10.1080/13880209.2021.1876100
   Yang SS, 2020, MOL CELL BIOCHEM, V467, P1, DOI 10.1007/s11010 019 03667 9
   Yoo SM, 2018, MOL CELLS, V41, P18, DOI 10.14348/molcells.2018.2277
   Zeng ZP, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12101420
   Zerbini CAF, 2017, OSTEOPOROSIS INT, V28, P429, DOI 10.1007/s00198 016 3769 2
   Zhang Q, 2021, J INFLAMM RES, V14, P217, DOI 10.2147/JIR.S287242
   Zhang Q, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109367
NR 43
TC 20
Z9 20
U1 2
U2 47
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD SEP
PY 2023
VL 118
AR 154967
DI 10.1016/j.phymed.2023.154967
EA JUL 2023
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA P1AH7
UT WOS:001048029100001
PM 37490802
DA 2025 08 17
ER

PT J
AU Yang, T
   Chen, WW
   Gan, K
   Wang, CF
   Xie, XX
   Su, YA
   Lian, HY
   Xu, JK
   Zhao, JM
   Liu, Q
AF Yang, Tao
   Chen, Weiwei
   Gan, Kai
   Wang, Chaofeng
   Xie, Xiaoxiao
   Su, Yuangang
   Lian, Haoyu
   Xu, Jiake
   Zhao, Jinmin
   Liu, Qian
TI Myrislignan targets extracellular signal regulated kinase (ERK) and
   modulates mitochondrial function to dampen osteoclastogenesis and
   ovariectomy induced osteoporosis
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE ERK; Mitochondria; Myrislignan; LM22B 10; Osteoclast; Osteoporosis
ID INDUCED BONE LOSS; NF KAPPA B; OXIDATIVE STRESS; CRUCIAL ROLE; NFATC1
AB BackgroundActivated osteoclasts cause excessive bone resorption, and disrupt bone homeostasis, leading to osteoporosis. The extracellular signal regulated kinase (ERK) signaling is the classical pathway related to osteoclast differentiation, and mitochondrial reactive oxygen species are closely associated with the differentiation of osteoclasts. Myrislignan (MRL), a natural product derived from nutmeg, has multiple pharmacological activities; however, its therapeutic effect on osteoporosis is unclear. Here, we investigated whether MRL could inhibit osteoclastogenesis and bone mass loss in an ovariectomy mouse model by suppressing mitochondrial function and ERK signaling.MethodsTartrate resistant and phosphatase (TRAP) and bone resorption assays were performed to observe the effect of MRL on osteoclastogenesis of bone marrow macrophages. MitoSOX RED and tetramethyl rhodamine methyl ester (TMRM) staining was performed to evaluate the inhibitory effect of MRL on mitochondria. Quantitative reverse transcription polymerase chain reaction (qRT PCR) assay was performed to detect whether MRL suppressed the expression of osteoclast specific genes. The impact of MRL on the protein involved in the mitogen activated protein kinase (MAPK) and nuclear factor kappa B pathways was evaluated using western blotting. In addition, a specific ERK agonist LM22B 10, was used to revalidate the inhibitory effect of MRL on ERK. Finally, we established an ovariectomy mouse model to assess the therapeutic effect of MRL on osteoporosis in vivo.ResultsMRL inhibited osteoclast differentiation and the associated bone resorption, by significantly decreasing osteoclastic gene expression. Mechanistically, MRL inhibited the phosphorylation of ERK by suppressing the mitochondrial function, thereby downregulating the nuclear factor of activated T cells 1 (NFATc1) signaling. LM22B 10 treatment further verified the targeted inhibition effect of MRL on ERK. Microscopic computed tomographic and histologic analyses of the tibial tissue sections indicated that ovariectomized mice had lower bone mass and higher expression of ERK compared with normal controls. However, MRL treatment significantly reversed these effects, indicating the anti osteoporosis effect of MRL.ConclusionWe report for the first time that MRL inhibits ERK signaling by suppressing mitochondrial function, thereby ameliorating ovariectomy induced osteoporosis. Our findings can provide a basis for the development of a novel therapeutic strategy for osteoporosis.
C1 [Yang, Tao; Chen, Weiwei; Gan, Kai; Wang, Chaofeng; Xie, Xiaoxiao; Su, Yuangang; Lian, Haoyu; Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Affiliated Hosp 1, Guangxi Key Lab Regenerat Med, Orthopaed Dept, Nanning 530021, Guangxi, Peoples R China.
   [Yang, Tao; Chen, Weiwei; Wang, Chaofeng; Xie, Xiaoxiao; Su, Yuangang; Lian, Haoyu; Liu, Qian] Guangxi Med Univ, Life Sci Inst, Collaborat Innovat Ctr Regenerat Med & Med BioReso, Nanning 530021, Guangxi, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
C3 Guangxi Medical University; Guangxi Medical University; University of
   Western Australia
RP Zhao, JM; Liu, Q (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Guangxi Key Lab Regenerat Med, Orthopaed Dept, Nanning 530021, Guangxi, Peoples R China.; Liu, Q (通讯作者)，Guangxi Med Univ, Life Sci Inst, Collaborat Innovat Ctr Regenerat Med & Med BioReso, Nanning 530021, Guangxi, Peoples R China.; Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
EM jiake.xu@uwa.edu.au; zhaojinmin@126.com; liuqian@gxmu.edu.cn
RI Lian, Haoyu/W 3317 2017; zhao, jin/LBH 0351 2024; Su,
   Yuangang/KKU 6952 2024; Wang, Chaofeng/JKH 9328 2023; xie,
   xiaoxiao/KFA 9850 2024; Yang, Tao/JRW 0606 2023
OI Yang, Tao/0009 0002 6777 2649; Xu, Jiake/0000 0003 2021 8309; 
FU National Natural Science Foundation of China
FX Not applicable.
CR Bhattarai G, 2017, J BIOMED MATER RES A, V105, P2510, DOI 10.1002/jbm.a.36109
   Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Chen FY, 2022, BIOMATER SCI UK, V10, P5925, DOI 10.1039/d2bm00348a
   Chen K, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110067
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen XZ, 2022, THERANOSTICS, V12, P3251, DOI 10.7150/thno.70623
   Chen YH, 2019, CHINESE J PHYSIOL, V62, P70, DOI 10.4103/CJP.CJP_7_19
   Cheon YH, 2021, BIOMED PHARMACOTHER, V139, DOI 10.1016/j.biopha.2021.111697
   Cho E, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23126421
   Fu X, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.921037
   Gal M, 2022, PHYTOMEDICINE, V105, DOI 10.1016/j.phymed.2022.154378
   Goldberg M, 2008, CLIN ORAL INVEST, V12, P1, DOI 10.1007/s00784 007 0162 8
   He JB, 2023, J ADV RES, V53, P235, DOI 10.1016/j.jare.2023.01.003
   Huang LK, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.848152
   Huong L, 2022, INT IMMUNOPHARMACOL, V111, DOI 10.1016/j.intimp.2022.109038
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Javadov S, 2014, PHARMACOL THERAPEUT, V144, P202, DOI 10.1016/j.pharmthera.2014.05.013
   Jie ZW, 2019, FASEB J, V33, P4236, DOI 10.1096/fj.201801977R
   Jimi E, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23147995
   Jin FJ, 2022, INT J BIOL SCI, V18, P4482, DOI 10.7150/ijbs.72487
   Kim HN, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68890 7
   Kim HJ, 2022, EXP MOL MED, V54, P1146, DOI 10.1038/s12276 022 00820 1
   Kim HJ, 2019, J CELL PHYSIOL, V234, P1659, DOI 10.1002/jcp.27035
   Kim YS, 2009, BONE, V45, P68, DOI 10.1016/j.bone.2009.03.658
   Kobayashi K, 2015, SCI REP UK, V5, DOI 10.1038/srep09148
   Laha D, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12091220
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li J, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829862
   Li X, 2021, CELL BIOL TOXICOL, V37, P849, DOI 10.1007/s10565 020 09578 6
   Li XD, 2021, DRUG DES DEV THER, V15, P61, DOI 10.2147/DDDT.S283694
   Liu HJ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.870553
   Liu JJ, 2022, PHYTOMEDICINE, V106, DOI 10.1016/j.phymed.2022.154399
   Liu SS, 2020, J MOL HISTOL, V51, P221, DOI 10.1007/s10735 020 09874 9
   Liu TT, 2022, BIOMED PHARMACOTHER, V151, DOI 10.1016/j.biopha.2022.113140
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Long F, 2022, INT IMMUNOPHARMACOL, V107, DOI 10.1016/j.intimp.2022.108632
   Mukhopadhyay S, 2021, NAT CANCER, V2, P271, DOI 10.1038/s43018 021 00184 x
   Qiu JX, 2022, BIOCHEM PHARMACOL, V205, DOI 10.1016/j.bcp.2022.115155
   Salvadori L, 2022, NUTRIENTS, V14, DOI 10.3390/nu14153053
   Srinivasan S, 2007, ANN NY ACAD SCI, V1117, P51, DOI 10.1196/annals.1402.067
   Suh KS, 2019, FOOD CHEM TOXICOL, V124, P367, DOI 10.1016/j.fct.2018.12.031
   Sun WJ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30625 9
   Tang LY, 2021, J BONE MINER RES, V36, P779, DOI 10.1002/jbmr.4230
   Tao HQ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.875611
   Vacek TP, 2013, CLIN CHEM LAB MED, V51, P579, DOI 10.1515/cclm 2012 0605
   Wang F, 2022, PHYTOMEDICINE, V104, DOI 10.1016/j.phymed.2022.154304
   Wei LH, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106400
   Wu LW, 2022, EUR J PHARMACOL, V923, DOI 10.1016/j.ejphar.2022.174908
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xiong J, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 32435 5
   Xu ZS, 2011, FREE RADICAL BIO MED, V50, P1314, DOI 10.1016/j.freeradbiomed.2011.02.016
   Yang YY, 2022, J MOL MED, V100, P1191, DOI 10.1007/s00109 022 02233 z
   Ye CY, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202200787
   Yu J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042097
   Yuan LC, 2021, THERANOSTICS, V11, P7247, DOI 10.7150/thno.58468
   Zhang JL, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.730222
   Zhang JL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02152
   Zhang XR, 2021, FREE RADICAL BIO MED, V176, P298, DOI 10.1016/j.freeradbiomed.2021.09.027
   Zhang Y, 2020, INT J BIOL SCI, V16, P1629, DOI 10.7150/ijbs.41867
   Zhang YX, 2022, FOOD FUNCT, V13, P8850, DOI [10.1039/D2FO00780K, 10.1039/d2fo00780k]
   Zhao Q, 2018, NAT PRODUCT BIOPROSP, V8, P321, DOI 10.1007/s13659 018 0175 9
NR 63
TC 6
Z9 7
U1 2
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479 5876
J9 J TRANSL MED
JI J. Transl. Med.
PD NOV 22
PY 2023
VL 21
IS 1
AR 839
DI 10.1186/s12967 023 04706 2
PG 19
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA Y9RT4
UT WOS:001108566800001
PM 37993937
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Li, HS
   Deng, W
   Qin, QL
   Lin, YW
   Liu, T
   Mo, GY
   Shao, Y
   Tang, YC
   Yuan, K
   Xu, LL
   Li, YX
   Zhang, SC
AF Li, HaiShan
   Deng, Wei
   Qin, QiuLi
   Lin, YueWei
   Liu, Teng
   Mo, GuoYe
   Shao, Yang
   Tang, YongChao
   Yuan, Kai
   Xu, LiangLiang
   Li, YongXian
   Zhang, ShunCong
TI Isoimperatorin attenuates bone loss by inhibiting the binding of RANKL
   to RANK
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Isoimperatorin; RANKL RANK; MAPK; ROS; Osteoclast; SPR
ID OSTEOCLASTOGENESIS; OSTEOPOROSIS; DIFFERENTIATION; HOMEOSTASIS;
   APOPTOSIS
AB Osteoporosis, an immune disease characterized by bone mass loss and microstructure destruction, is often seen in postmenopausal women. Isoimperatorin (ISO), a bioactive, natural furanocoumarin isolated from many tradi tional Chinese herbal medicines, has therapeutic effects against various diseases; however, its effect on bone homeostasis remains unclear. In this study, we investigated the effect of ISO on the differentiation and activation of osteoclast and its molecular mechanism in vitro, and evaluated the effect of ISO on bone metabolism by ovariectomized (OVX) rat model. In vitro experiments showed that ISO affected RANKL induced MAPK, NFAT, NFATc1 trafficking and expression, osteoclast F actin banding, osteoclast characteristic gene expression, ROS inhibitory activity, and calcium oscillations, NF kappa B signaling pathway. In vivo experiments showed that oral administration of ISO effectively reduced bone loss caused by ovariectomy and retained bone mass.Collectively, ISO inhibits RANK/RANKL binding, thereby reducing the activity of NFATc1, calcium, and ROS and inhibiting osteoclast generation. In addition, ISO protects bone mass by slowing osteoclast production and downregulating NFATc1 gene and protein expression in the bone tissue microenvironment and inhibits OVX induced bone loss in vivo.
C1 [Li, HaiShan; Deng, Wei; Qin, QiuLi; Lin, YueWei; Liu, Teng; Mo, GuoYe; Shao, Yang; Tang, YongChao; Yuan, Kai; Xu, LiangLiang; Li, YongXian; Zhang, ShunCong] Guangzhou Univ Chinese Med, Clin Acad 1, Guangzhou, Peoples R China.
   [Li, HaiShan; Deng, Wei; Qin, QiuLi; Lin, YueWei; Liu, Teng; Shao, Yang] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou, Peoples R China.
   [Li, HaiShan; Deng, Wei; Qin, QiuLi; Lin, YueWei; Liu, Teng; Mo, GuoYe; Shao, Yang; Tang, YongChao; Yuan, Kai; Xu, LiangLiang; Li, YongXian; Zhang, ShunCong] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine
RP Xu, LL; Li, YX; Zhang, SC (通讯作者)，Guangzhou Univ Chinese Med, Clin Acad 1, Guangzhou, Peoples R China.
EM xull 2016@gzucm.edu.cn; liyongxian5886@gzucm.edu.cn; spinezsc@126.com
RI Li, Haishan/NOE 7338 2025; XU, LIANGLIANG/AAZ 7935 2020; qin,
   qiuli/HCH 8075 2022
OI Xu, Liangliang/0000 0002 5249 7480; Zhang, Shuncong/0000 0002 3059 2487;
   Li, Haishan/0000 0002 2102 7021; Deng, Wei/0000 0002 1216 549X
FU Natural Science Foundation of Guangdong Province, China
   [2021A1515012168]; Administration of Traditional Chinese Medicine of
   Guangdong Province, China [20203004, 20221146]; Basic and Applied Basic
   Research Fund Project in Guangdong Province, China [2020A1515110948];
   Application and foundation research project of Guangzhou, China
   [202201020500, 202201020295]
FX This work was supported by the Natural Science Foundation of Guangdong
   Province, China (Number: 2021A1515012168) ; Administration of
   Traditional Chinese Medicine of Guangdong Province, China (Number:
   20203004;20221146) ; Basic and Applied Basic Research Fund Project in
   Guangdong Province, China (Number: 2020A1515110948) ; Application and
   foundation research project of Guangzhou, China (Number:
   202201020500;202201020295) .
CR Bang E, 2021, REDOX BIOL, V44, DOI 10.1016/j.redox.2021.102022
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Buckley L, 2017, ARTHRITIS RHEUMATOL, V69, P1521, DOI [10.1002/art.40137, 10.1002/acr.23279]
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Deardorff WJ, 2022, JAMA INTERN MED, V182, P33, DOI 10.1001/jamainternmed.2021.6745
   Deng W, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1015693
   Fujii T, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00120 2
   Galasso M, 2021, FREE RADICAL BIO MED, V172, P264, DOI 10.1016/j.freeradbiomed.2021.06.010
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Ho MH, 2015, INT J NANOMED, V10, P5941, DOI 10.2147/IJN.S90669
   Hong SE, 2017, FREE RADICAL BIO MED, V112, P191, DOI 10.1016/j.freeradbiomed.2017.07.030
   Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073
   Hu LC, 2022, EXP MOL MED, V54, P961, DOI 10.1038/s12276 022 00799 9
   Hwang YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072068
   Jiang M, 2019, J BONE MINER RES, V34, P361, DOI 10.1002/jbmr.3604
   Jin C, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/5098358
   Jung HY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186911
   Kanis JA, 2009, NAT REV RHEUMATOL, V5, P425, DOI 10.1038/nrrheum.2009.139
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Kumar S, 2020, NEUROCHEM INT, V134, DOI 10.1016/j.neuint.2019.104652
   Laguna E, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12050722
   Lai YN, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.657826
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SE, 2001, J BIOL CHEM, V276, P49343, DOI 10.1074/jbc.M103642200
   Li B, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.824117
   Li YX, 2021, J CELL PHYSIOL, V236, P1950, DOI 10.1002/jcp.29978
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Lorentzon M, 2019, J INTERN MED, V285, P381, DOI 10.1111/joim.12873
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Ma YG, 2022, LIFE SCI, V293, DOI 10.1016/j.lfs.2022.120337
   Marumoto S, 2010, BIOORGAN MED CHEM, V18, P455, DOI 10.1016/j.bmc.2009.10.004
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Moon TC, 2008, ARCH PHARM RES, V31, P210, DOI 10.1007/s12272 001 1143 0
   Ng AYH, 2019, ELIFE, V8, DOI 10.7554/eLife.42951
   Noel SE, 2018, J BONE MINER RES, V33, P396, DOI 10.1002/jbmr.3315
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sobacchi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00629
   Sun H, 2023, BIOACT MATER, V24, P477, DOI 10.1016/j.bioactmat.2022.12.021
   Sun P, 2022, BIOMED PHARMACOTHER, V150, DOI 10.1016/j.biopha.2022.112975
   Tan DQ, 2018, ANTIOXID REDOX SIGN, V29, P149, DOI 10.1089/ars.2017.7273
   Tao MH, 2018, ANN ONCOL, V29, P1476, DOI 10.1093/annonc/mdy097
   Tong KH, 2017, ONCOL LETT, V13, P518, DOI 10.3892/ol.2016.5387
   Verdelli C, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115350
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang J, 2020, PHYTOTHER RES, V34, P2985, DOI 10.1002/ptr.6726
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wang W. J., 2022, PSYCHOL MED, V13, P1343, DOI [10.3390/genes13081343, DOI 10.3390/GENES13081343]
   Wei Y, 2006, J CHROMATOGR A, V1115, P112, DOI 10.1016/j.chroma.2006.02.081
   Wu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1500 x
   Xu HH, 2022, BIOMED PHARMACOTHER, V149, DOI 10.1016/j.biopha.2022.112902
   Xu HH, 2021, INT IMMUNOPHARMACOL, V95, DOI 10.1016/j.intimp.2021.107464
   Xue P, 2021, EXP MOL MED, V53, P667, DOI 10.1038/s12276 021 00596 w
   Yahara Y, 2020, NAT CELL BIOL, V22, P49, DOI 10.1038/s41556 019 0437 8
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang PP, 2022, INT J BIOCHEM CELL B, V151, DOI 10.1016/j.biocel.2022.106276
   Yang WL, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00151 3
   Yu W, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140214
   Yuan LC, 2021, THERANOSTICS, V11, P7247, DOI 10.7150/thno.58468
   Zhang MW, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.810524
NR 61
TC 14
Z9 14
U1 1
U2 17
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAY
PY 2023
VL 211
AR 115502
DI 10.1016/j.bcp.2023.115502
EA MAR 2023
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA C3EM5
UT WOS:000960789200001
PM 36921635
OA hybrid
DA 2025 08 17
ER

PT J
AU Mcallister, BC
   Mesbahi, N
   Dodson, EE
   Abdulsalam, S
   Berkman, CE
   Caromile, LA
AF Mcallister, Brenna C.
   Mesbahi, Nooshin
   Dodson, Esther E.
   Abdulsalam, Sakinah
   Berkman, Clifford E.
   Caromile, Leslie A.
TI Repurposing of PSMA targeted diagnostic and therapeutic agents for the
   detection and treatment of giant cell tumors of bone
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE prostate specific membrane antigen (PSMA); repurposable drugs; Pluvicto;
   Locametz; giant cell tumor of bone (GCTB)
ID MEMBRANE ANTIGEN PSMA; LOCAL RECURRENCE; PHOTODYNAMIC THERAPY;
   ZOLEDRONIC ACID; OPEN LABEL; PROSTATE; DENOSUMAB; INHIBITOR; CANCER; PET
AB Giant cell tumor of bone (GCTB) is a rare bone tumor often necessitating surgical intervention, radiation therapy, or treatment with bisphosphonates or denosumab. 99mTc MDP bone scintigraphy for GCTB has limited specificity, and the relatively high uptake of 18F FDG in GCTB makes it challenging to differentiate it from other benign bone tumors. More specific detection and treatment modalities for GCTB are needed to enhance patient monitoring and outcomes. Prostate Specific Membrane Antigen (PSMA) is present in the neovasculature of various tumors, yet unexplored in GCTB. PSMA targeted imaging and radiotherapeutic agents Locametz and Pluvicto are a powerful theranostic pair for detecting and treating PSMA positive metastatic tumors, including those in bone, and thus have considerable potential to be repurposed for GCTB. This study aimed to determine if the vasculature of GCTB was PSMA positive and whether targeting it with PSMA specific agents was feasible. Using bone core samples from 28 GCTB patients and 9 negative controls, we present the first robust detection of PSMA on the tumor vasculature of GCTB. To demonstrate the potential repurposed use of PSMA targeted agents in detecting and treating GCTB, we used a PSMA specific fluorescent probe (FAM C6 1298) as a model for these radiopharmaceutical agents. Incubation of fresh GCTB tissue samples with FAM C6 1298 showed increased fluorescence intensity compared to controls, indicating successful targeting of PSMA in GCTB tissue. In conclusion, our data established that PSMA is not only present in the tumor vasculature of GCTB patient tissue but can be effectively targeted with repurposed PSMA specific radiopharmaceuticals for diagnosis and therapy.
C1 [Mcallister, Brenna C.; Caromile, Leslie A.] Univ Connecticut, Ctr Vasc Biol, Hlth Ctr, Farmington, CT 06030 USA.
   [Mesbahi, Nooshin; Dodson, Esther E.; Berkman, Clifford E.] Washington State Univ, Dept Chem, Pullman, WA USA.
   [Abdulsalam, Sakinah] Univ Connecticut, Dept Neurosci, Hlth Ctr, Farmington, CT USA.
C3 University of Connecticut; Washington State University; University of
   Connecticut
RP Caromile, LA (通讯作者)，Univ Connecticut, Ctr Vasc Biol, Hlth Ctr, Farmington, CT 06030 USA.
EM caromile@uchc.edu
RI Caromile, Leslie/Q 2980 2016
FU NIH/NCI [R21CA256382, R21CA282396]; NIH/NIDCR [T90DE033006 01]
FX The author(s) declare financial support was received for the research,
   authorship, and/or publication of this article. This study was supported
   by NIH/NCI R21CA282396, NIH/NCI R21CA256382, NIH/NIDCR T90DE033006 01.
CR Adams CP, 2006, HEALTH AFFAIR, V25, P420, DOI 10.1377/hlthaff.25.2.420
   Agarwal MG, 2018, CLIN ORTHOP RELAT R, V476, P1773, DOI 10.1007/s11999.0000000000000243
   Amelio JM, 2016, CANCER EPIDEMIOL, V42, P82, DOI 10.1016/j.canep.2016.03.014
   Aoki J, 2001, RADIOLOGY, V219, P774, DOI 10.1148/radiology.219.3.r01ma08774
   Armando RG, 2020, INT J ONCOL, V56, P651, DOI 10.3892/ijo.2020.4966
   Bacich DJ, 2001, MAMM GENOME, V12, P117, DOI 10.1007/s003350010240
   Balke M, 2008, J CANCER RES CLIN, V134, P969, DOI 10.1007/s00432 008 0370 x
   Becker RG, 2024, ACTA ORTOP BRAS, V32, DOI 10.1590/1413 785220243201e273066
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Borkowska AM, 2022, CANCERS, V14, DOI 10.3390/cancers14092290
   BOSTWICK DG, 1989, CA CANCER J CLIN, V39, P376, DOI 10.3322/canjclin.39.6.376
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Can C, 2021, CLIN NUCL MED, V46, pE233, DOI 10.1097/RLU.0000000000003320
   Chang SS, 1999, CLIN CANCER RES, V5, P2674
   Chang SS, 2001, UROLOGY, V57, P1179, DOI 10.1016/S0090 4295(01)00983 9
   Chatalic KLS, 2016, THERANOSTICS, V6, P849, DOI 10.7150/thno.14744
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Chen ZY, 2018, J BUON, V23, P453
   Chinder PS, 2019, CLIN ORTHOP SURG, V11, P352, DOI 10.4055/cios.2019.11.3.352
   Choy CJ, 2017, THERANOSTICS, V7, P1928, DOI 10.7150/thno.18719
   Choy CJ, 2016, BIOCONJUGATE CHEM, V27, P2206, DOI 10.1021/acs.bioconjchem.6b00422
   Choy CJ, 2016, BIOCONJUGATE CHEM, V27, P824, DOI 10.1021/acs.bioconjchem.6b00027
   Dannoon S, 2016, J MED CHEM, V59, P5684, DOI 10.1021/acs.jmedchem.5b01850
   De Vita A, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10020372
   Dhull A, 2024, NANOSCALE, V16, P5634, DOI 10.1039/d3nr06520k
   Errani C, 2018, J BONE JOINT SURG AM, V100, P496, DOI 10.2106/JBJS.17.00057
   Errani C, 2010, CANCER TREAT REV, V36, P1, DOI 10.1016/j.ctrv.2009.09.002
   Ganesan K GA., 2023, Bisphosphonate
   Ganguly T, 2015, NUCL MED BIOL, V42, P780, DOI 10.1016/j.nucmedbio.2015.06.003
   Ghosh A, 2004, J CELL BIOCHEM, V91, P528, DOI 10.1002/jcb.10661
   Gouin F, 2014, EUR J CANCER, V50, P2425, DOI 10.1016/j.ejca.2014.06.003
   Grant CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041285
   Haberkorn U, 2016, CLIN CANCER RES, V22, P9, DOI 10.1158/1078 0432.CCR 15 0820
   Hasan J, 2002, BRIT J CANCER, V86, P1566, DOI 10.1038/sj.bjc.6600315
   Heitkötter B, 2017, ONCOTARGET, V8, P4268, DOI 10.18632/oncotarget.13994
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   HUDSON TM, 1984, SKELETAL RADIOL, V11, P85, DOI 10.1007/BF00348795
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P591, DOI 10.1007/s11999 010 1501 7
   Knochentumoren A, 2008, J BONE JOINT SURG AM, V90A, P1060, DOI 10.2106/JBJS.D.02771
   Lapi SE, 2009, J NUCL MED, V50, P2042, DOI 10.2967/jnumed.109.066589
   Lau CPY, 2013, CONNECT TISSUE RES, V54, P439, DOI 10.3109/03008207.2013.848202
   Lausten GS, 1996, INT ORTHOP, V20, P172, DOI 10.1007/s002640050057
   Lee J, 2011, ANAL CHEM, V83, P9406, DOI 10.1021/ac202001z
   Ling XX, 2020, MOL IMAGING BIOL, V22, P274, DOI 10.1007/s11307 019 01404 8
   Lipplaa A, 2019, ONCOLOGIST, V24, P889, DOI 10.1634/theoncologist.2019 0280
   Lissbrant IF, 1997, PROSTATE, V33, P38
   Liu H, 1998, CANCER RES, V58, P4055
   Liu TC, 2008, PROSTATE, V68, P955, DOI 10.1002/pros.20753
   Liu TC, 2011, BIOORG MED CHEM LETT, V21, P7013, DOI 10.1016/j.bmcl.2011.09.115
   Liu TC, 2011, INT J ONCOL, V38, P1349, DOI 10.3892/ijo.2011.946
   Liu TC, 2010, BIOORG MED CHEM LETT, V20, P7124, DOI 10.1016/j.bmcl.2010.09.057
   Liu TC, 2010, CANCER LETT, V296, P106, DOI 10.1016/j.canlet.2010.04.003
   Liu TC, 2010, INT J ONCOL, V36, P777, DOI 10.3892/ijo_00000553
   Liu TC, 2009, PROSTATE, V69, P585, DOI 10.1002/pros.20909
   Liu TC, 2008, BIOCHEMISTRY US, V47, P12658, DOI 10.1021/bi801883v
   Martin SE, 2014, BIOCONJUGATE CHEM, V25, P1752, DOI 10.1021/bc500362n
   Moch H., 2020, SOFT TISSUE BONE TUM, V3
   Murphy GP, 2000, PROSTATE, V42, P318
   Nagano A, 2022, JPN J CLIN ONCOL, V52, P411, DOI 10.1093/jjco/hyac018
   NCBI, 2024, ClinicalTrials.gov
   Nedrow Byers JR, 2013, PROSTATE, V73, P355, DOI 10.1002/pros.22575
   Nedrow Byers JR, 2012, PROSTATE, V72, P904, DOI 10.1002/pros.21493
   Noh BJ, 2018, HUM PATHOL, V81, P1, DOI 10.1016/j.humpath.2018.06.017
   Nosengo N, 2016, NATURE, V534, P314, DOI 10.1038/534314a
   Olatunji FP, 2021, BIOCONJUGATE CHEM, V32, P2386, DOI 10.1021/acs.bioconjchem.1c00435
   Palmerini E, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819840000
   Papageorgiou SN, 2022, J ORTHOD, V49, P359, DOI 10.1177/14653125221076142
   Parihar AS, 2020, CLIN NUCL MED, V45, pE57, DOI 10.1097/RLU.0000000000002764
   Park HL, 2017, NUCL MED MOLEC IMAG, V51, P182, DOI 10.1007/s13139 016 0442 9
   Parvathaneni V, 2019, DRUG DISCOV TODAY, V24, P2076, DOI 10.1016/j.drudis.2019.06.014
   Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078
   Perrin DL, 2021, BONE JOINT J, V103B, P184, DOI 10.1302/0301 620X.103B1.BJJ 2020 0274.R1
   Pritchard JLE, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00896
   Rajasekaran AK, 2005, AM J PHYSIOL CELL PH, V288, pC975, DOI 10.1152/ajpcell.00506.2004
   Rutkowski P, 2015, ANN SURG ONCOL, V22, P2860, DOI 10.1245/s10434 015 4634 9
   Sahito B, 2022, EUR J ORTHOP SURG TR, V32, P567, DOI 10.1007/s00590 021 03012 1
   Sharma S, 2005, HISTOPATHOLOGY, V46, P481, DOI 10.1111/j.1365 2559.2005.02142.x
   Smietana K, 2016, NAT REV DRUG DISCOV, V15, P379, DOI 10.1038/nrd.2016.85
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Traub F, 2016, EUR J CANCER, V59, P1, DOI 10.1016/j.ejca.2016.01.006
   Turcotte RE, 2002, CLIN ORTHOP RELAT R, P248
   van der Heijden L, 2014, ONCOLOGIST, V19, P550, DOI 10.1634/theoncologist.2013 0432
   WHO, 2020, In soft tissue and bone, V3, P368
   Wu LY, 2011, PROSTATE, V71, P52, DOI 10.1002/pros.21221
   Yoon H, 2024, BIOORG MED CHEM LETT, V104, DOI 10.1016/j.bmcl.2024.129712
NR 86
TC 2
Z9 2
U1 3
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2234 943X
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 15
PY 2024
VL 14
AR 1504514
DI 10.3389/fonc.2024.1504514
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA N7I6Q
UT WOS:001366033200001
PM 39619440
OA gold
DA 2025 08 17
ER

PT J
AU Liu, JC
   Wang, BY
   Chen, HT
   Yu, X
   Cao, XJ
   Zhang, HX
AF Liu, Jingcheng
   Wang, Binyu
   Chen, Hongtao
   Yu, Xiao
   Cao, Xiaojian
   Zhang, Hongxiu
TI Osteoclast derived exosomes influence osteoblast differentiation in
   osteoporosis progression via the lncRNA AW011738/ miR 24 2 5p/ TREM1
   axis
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Osteoporosis; Exosomes; AW011738; TREM1; Osteogenic Differentiation
ID INDUCED BONE LOSS; RISK
AB Aims: To investigate the molecular mechanism of osteoclast derived exosomes in osteoporosis. Main methods: RANKL induced osteoclast model was screened for significantly differentially expressed lncRNAs and mRNAs by whole RNA sequencing. Exosomes were characterized using electron microscopy, western blotting and nanosight. Overexpression or knockdown of AW011738 was performed to explore its function. The degree of osteoporosis in an osteoporosis model was assessed by mirco CT. The osteoclast model, osteoblast differentiation ability and the molecular mechanism of lncRNA AW011738/miR 24 2 5p/TREM1 axis in osteoporosis were assessed by dual luciferase reporter gene assay, Western blotting (WB), immunofluorescence and ALP staining. Bioinformatics was used to predict interactions of key osteoporosis related genes with miRNAs, transcription factors, and potential drugs after upregulation of AW011738. To predict the protein protein interaction (PPI) network associated with key genes, GO and KEGG analyses were performed on the key genes. The ssGSVA was used to predict changes in the immune microenvironment. Key findings: Osteoclast derived exosomes containing lncRNA AW011738 decreased the osteogenesis related markers and accelerated bone loss in OVX mice. Osteoclast (si AW011738) derived exosomes showed a significant increase in biomarkers of osteoblast differentiation in vitro compared to the si NC group. As analyzed by mirco CT, tail vein injected si AW011738 OVX mice were less osteoporotic than the control group. AW011738 inhibited osteoblast differentiation by regulating TREM1 expression through microRNA. Meanwhile, overexpression of miR 24 2 5p inhibited TREM1 expression to promote osteoblast differentiation. Significance: Osteoclast derived exosomes containing lncRNA AW011738 inhibit osteogenesis in MC3T3 E1 cells through the lncRNA AW011738/miR 24 2 5p/TREM1 axis and exacerbate osteoporosis in OVX mice.
C1 [Liu, Jingcheng; Wang, Binyu; Yu, Xiao; Cao, Xiaojian] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing 210029, Jiangsu, Peoples R China.
   [Zhang, Hongxiu] Nanjing Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.
   [Chen, Hongtao] Nanjing Univ, Affiliated Hosp, Dept Orthoped, Med Sch, Nanjing 210008, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing
   University
RP Cao, XJ (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing 210029, Jiangsu, Peoples R China.; Zhang, HX (通讯作者)，Nanjing Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.
EM liujingcheng6677@foxmail.com; wangbinyuspine@163.com; chtspine@163.com;
   yuxiao.zx@icloud.com; xiaojiancao001@163.com; hongxiuz@njmu.edu.cn
RI Zhou, Weiping/AGI 5344 2022
FU National Natural Science Foun dation of China [81472989, 82350002,
   82272484]; Natural Science Foundation of Jiangsu Province [BK20181494]
FX <BOLD>Funding</BOLD> This project was supported by the National Natural
   Science Foun dation of China [grant numbers 81472989, 82350002 and
   82272484] and the Natural Science Foundation of Jiangsu Province [grant
   number BK20181494] .
CR An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003
   Bisson C, 2012, J CLIN PERIODONTOL, V39, P1141, DOI 10.1111/jcpe.12008
   Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991
   Brown JP, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 03960 z
   Chandran M, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0542 5
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chen YY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12973
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   De Martinis M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238887
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Franz M, 2018, NUCLEIC ACIDS RES, V46, pW60, DOI 10.1093/nar/gky311
   Guo W, 2021, J ORTHOP TRANSL, V28, P148, DOI 10.1016/j.jot.2021.01.005
   Huang JH, 2023, NUCLEIC ACIDS RES, V51, pD46, DOI 10.1093/nar/gkac1067
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim PG, 2021, J EXP MED, V218, DOI 10.1084/jem.20211872
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Lin CJ, 2019, THERANOSTICS, V9, P3780, DOI 10.7150/thno.34493
   Lu L, 2022, GYNECOL ENDOCRINOL, V38, P176, DOI 10.1080/09513590.2021.2015760
   Maeda SS, 2014, ARQ BRAS ENDOCRINOL, V58, P162, DOI 10.1590/0004 2730000003039
   Mattingly CJ, 2003, ENVIRON HEALTH PERSP, V111, P793, DOI 10.1289/ehp.6028
   Meldolesi J, 2018, CURR BIOL, V28, pR435, DOI 10.1016/j.cub.2018.01.059
   Morris Garrett M, 2008, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0814s24
   PRESTWOOD KM, 1995, ANNU REV MED, V46, P249
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Remmert M, 2012, NAT METHODS, V9, P173, DOI [10.1038/NMETH.1818, 10.1038/nmeth.1818]
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Shen YF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2485 1
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Stelzer G., 2016, CURR PROTOC BIOINFOR, V54, p1.30.31, DOI [10.1002/cpbi.5, DOI 10.1002/CPBI.5]
   Strom O, 2011, Arch Osteoporos, V6, P59, DOI 10.1007/s11657 011 0060 1
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Tan EM, 2017, J BONE MINER RES, V32, P846, DOI 10.1002/jbmr.3031
   Tang PF, 2014, RNA BIOL, V11, P1355, DOI 10.1080/15476286.2014.996462
   Tao HQ, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105967
   Tian HL, 2022, J CELL MOL MED, V26, P2163, DOI 10.1111/jcmm.17238
   Vaananen HK, 1996, MATURITAS, V23, pS65
   Wang J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.356
   Wang JY, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109627
   Wang S, 2020, INT J BIOL SCI, V16, P2675, DOI 10.7150/ijbs.46627
   Weaver CM, 2016, OSTEOPOROSIS INT, V27, P367, DOI 10.1007/s00198 015 3386 5
   Xia MJ, 2022, CELL BIOSCI, V12, DOI 10.1186/s13578 022 00816 4
   Xu PF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1777 9
   Xue F, 2021, ELIFE, V10, DOI 10.7554/eLife.64872
   Yan YM, 2020, NAT PROTOC, V15, P1829, DOI 10.1038/s41596 020 0312 x
   Yang Y, 2020, BIOL RES, V53, DOI 10.1186/s40659 020 00309 z
   Yu GC, 2020, METHODS MOL BIOL, V2117, P207, DOI 10.1007/978 1 0716 0301 7_11
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhu LX, 2023, J BONE MINER RES, V38, P335, DOI 10.1002/jbmr.4756
NR 57
TC 2
Z9 2
U1 1
U2 11
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD SEP
PY 2024
VL 178
AR 117231
DI 10.1016/j.biopha.2024.117231
EA AUG 2024
PG 18
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA C2B2S
UT WOS:001287456100001
PM 39094542
OA gold
DA 2025 08 17
ER

PT J
AU Rucci, N
   Capulli, M
   Ventura, L
   Angelucci, A
   Peruzzi, B
   Tillgren, V
   Muraca, M
   Heinegård, D
   Teti, A
AF Rucci, Nadia
   Capulli, Mattia
   Ventura, Luca
   Angelucci, Adriano
   Peruzzi, Barbara
   Tillgren, Viveka
   Muraca, Maurizio
   Heinegard, Dick
   Teti, Anna
TI Proline/arginine rich end leucine rich repeat protein N terminus is a
   novel osteoclast antagonist that counteracts bone loss
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE (PRELP) P hbd; BONE LOSS; OSTEOPOROSIS; BREAST CANCER METASTASIS
ID PRELP BINDS; CANCER; DENOSUMAB
AB (PRELP) P hbd is a peptide corresponding to the N terminal heparin binding domain of the matrix protein proline/arginine rich end leucine rich repeat protein (PRELP). (PRELP) P hbd inhibits osteoclastogenesis entering pre fusion osteoclasts through a chondroitin sulfate  and annexin 2 dependent mechanism and reducing the nuclear factor B transcription factor activity. In this work, we hypothesized that (PRELP) P hbd could have a pharmacological relevance, counteracting bone loss in a variety of in vivo models of bone diseases induced by exacerbated osteoclast activity. In healthy mice, we demonstrated that the peptide targeted the bone and increased trabecular bone mass over basal level. In mice treated with retinoic acid to induce an acute increase of osteoclast formation, the peptide consistently antagonized osteoclastogenesis and prevented the increase of the serum levels of the osteoclast specific marker tartrate resistant acid phosphatase. In ovariectomized mice, in which osteoclast activity was chronically enhanced by estrogen deficiency, (PRELP) P hbd counteracted exacerbated osteoclast activity and bone loss. In mice carrying osteolytic bone metastases, in which osteoclastogenesis and bone resorption were enhanced by tumor cell derived factors, (PRELP) P hbd reduced the incidence of osteolytic lesions, both preventively and curatively, with mechanisms involving impaired tumor cell homing to bone and tumor growth in the bone microenvironment. Interestingly, in tumor bearing mice, (PRELP) P hbd also inhibited breast tumor growth in orthotopic sites and development of metastatic disease in visceral organs, reducing cachexia and improving survival especially when administered preventively. (PRELP) P hbd was retained in the tumor tissue and appeared to affect tumor growth by interacting with the microenvironment rather than by directly affecting the tumor cells. Because safety studies and high dose treatments revealed no adverse effects, (PRELP) P hbd could be employed as a novel biological agent to combat experimentally induced bone loss and breast cancer metastases, with a potential translational impact. (C) 2013 American Society for Bone and Mineral Research.
C1 [Rucci, Nadia; Capulli, Mattia; Angelucci, Adriano; Teti, Anna] Univ Aquila, Dept Biotechnol & Appl Clin Sci, I 67100 Laquila, Italy.
   [Capulli, Mattia] San Salvatore Hosp, Dept Pathol, Laquila, Italy.
   [Peruzzi, Barbara; Muraca, Maurizio] Bambino Gesu Pediat Hosp, IRCCS, Rome, Italy.
   [Tillgren, Viveka; Heinegard, Dick] Lund Univ, Rheumatol Sect, Dept Clin Sci, Lund, Sweden.
C3 University of L'Aquila; IRCCS Bambino Gesu; Lund University
RP Teti, A (通讯作者)，Dept Biotechnol & Appl Clin Sci, Via Vetoio Coppito 2, I 67100 Laquila, Italy.
EM teti@univaq.it
RI Muraca, Maurizio/G 3063 2012; Capulli, Mattia/K 6604 2016; Angelucci,
   Adriano/B 7134 2013; Peruzzi, Barbara/K 9455 2016; Ventura,
   Luca/ABD 4170 2020
OI Capulli, Mattia/0000 0003 0449 6720; Angelucci,
   Adriano/0000 0002 8755 1889; Peruzzi, Barbara/0000 0003 1820 5816; Teti,
   Anna Maria/0000 0002 5887 4419; Rucci, Nadia/0000 0002 1371 8252;
   MURACA, MAURIZIO/0000 0003 1218 097X
FU Swiss Bridge Award; "Associazione Italiana per la Ricerca sul Cancro"
   (AIRC); European Calcified Tissue Society postdoctoral grant; Sweden
   Research Council; "Fondazione Italiana per la Ricerca sul Cancro" (FIRC)
FX We are grateful to Dr Gabri van der Pluijm (Leiden University Medical
   Center, Leiden, The Netherlands) for his valuable support in the
   assessment of the bioluminescence technique; to Dr Anna Rufo for
   histomorphometric evaluation of the bone phenotype; and to Dr Rita Di
   Massimo for her contribution in the editing of the manuscript. This work
   was supported by a Swiss Bridge Award grant to AT and DH; by grants from
   the "Associazione Italiana per la Ricerca sul Cancro" (AIRC) to AT and
   NR; by a European Calcified Tissue Society postdoctoral grant to MC; and
   by a grant from the Sweden Research Council to DH. MC is recipient of
   the "1st Mariuccia Borrini fellowship" from the "Fondazione Italiana per
   la Ricerca sul Cancro" (FIRC).
CR Adler Robert A, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P442, DOI 10.1097/MED.0b013e3282f169b5
   Bachrach Laura Keyes, 2007, Endocr Pract, V13, P513
   BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639
   Bengtsson E, 2002, J BIOL CHEM, V277, P15061, DOI 10.1074/jbc.M108285200
   Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200
   Burkiewicz JS, 2009, ANN PHARMACOTHER, V43, P1445, DOI 10.1345/aph.1M102
   Burnham Jon M, 2004, Curr Rheumatol Rep, V6, P70, DOI 10.1007/s11926 004 0086 0
   Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382
   Coleman R, 2011, ANN NY ACAD SCI, V1218, P3, DOI 10.1111/j.1749 6632.2010.05766.x
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   Del Fattore Andrea, 2012, Front Biosci (Elite Ed), V4, P2302
   Duan ZY, 2012, J SURG RES, V178, P842, DOI 10.1016/j.jss.2012.04.069
   Dunstan CR, 2007, NAT CLIN PRACT ONCOL, V4, P42, DOI 10.1038/ncponc0688
   Happonen KE, 2012, J BIOL CHEM, V287, P8092, DOI 10.1074/jbc.M111.291476
   Heinegard D., 2002, CONNECTIVE TISSUES I, P271
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   McLeod K, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/197454
   Moriceau G, 2010, CURR PHARM DESIGN, V16, P2981, DOI 10.2174/138161210793563554
   Rucci N, 2009, J CELL BIOL, V187, P669, DOI 10.1083/jcb.200906014
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Schwarz EM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2171
   SEKYIOTU A, 1994, J NATL CANCER I, V86, P628, DOI 10.1093/jnci/86.8.628
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
NR 26
TC 18
Z9 18
U1 1
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2013
VL 28
IS 9
BP 1912
EP 1924
DI 10.1002/jbmr.1951
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 202HI
UT WOS:000323204300007
PM 23559035
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhao, Q
   Feng, JJ
   Liu, FB
   Liang, QX
   Xie, ML
   Dong, JM
   Zou, YF
   Ye, JL
   Liu, GL
   Cao, Y
   Guo, ZD
   Qiao, HZ
   Zheng, L
   Zhao, KW
AF Zhao, Qing
   Feng, Junjie
   Liu, Fubin
   Liang, Qianxin
   Xie, Manlin
   Dong, Jiaming
   Zou, Yanfang
   Ye, Jiali
   Liu, Guilong
   Cao, Yue
   Guo, Zhaodi
   Qiao, Hongzhi
   Zheng, Lei
   Zhao, Kewei
TI Rhizoma Drynariae derived nanovesicles reverse osteoporosis by
   potentiating osteogenic differentiation of human bone marrow mesenchymal
   stem cells via targeting ERa signaling
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Article
DE Rhizoma Drynariae  derived nanovesicles; Bone marrow mesenchymal stem
   cells; Bone targeting; Osteogenic differentiation; ERa a signaling;
   Naringin; Bone morphogenetic protein 2; Runt related transcription
   factor 2
ID EXOSOME LIKE NANOVESICLES; EXTRACELLULAR VESICLES; POSTMENOPAUSAL
   OSTEOPOROSIS; ESTROGEN; OSTEOBLAST; CANCER; NANOPARTICLES; PREVENTION;
   THERAPY; COLITIS
AB Although various anti osteoporosis drugs are available, the limitations of these therapies, including drug resistance and collateral responses, require the development of novel anti osteoporosis agents. Rhizoma Drynariae displays a promising anti osteoporosis effect, while the effective component and mechanism remain unclear. Here, we revealed the therapeutic potential of Rhizoma Drynariaederived nanovesicles (RDNVs) for postmenopausal osteoporosis and demonstrated that RDNVs potentiated osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs) by targeting estrogen receptor alpha (ERa). RDNVs, a natural product isolated from fresh Rhizoma Drynariae root juice by differential ultracentrifugation, exhibited potent bone tissue targeting activity and anti osteoporosis efficacy in an ovariectomized mouse model. RDNVs, effectively internalized by hBMSCs, enhanced proliferation and ERa expression levels of hBMSC, and promoted osteogenic differentiation and bone formation. Mechanistically, via the ERa signaling pathway, RDNVs facilitated mRNA and protein expression of bone morphogenetic protein 2 and runt related transcription factor 2 in hBMSCs, which are involved in regulating osteogenic differentiation. Further analysis revealed that naringin, existing in RDNVs, was the active component targeting ERa in the osteogenic effect. Taken together, our study identified that naringin in RDNVs displays exciting bone tissue targeting activity to reverse osteoporosis by promoting hBMSCs proliferation and osteogenic differentiation through estrogen like effects. <feminine ordinal indicator> 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Zhao, Qing; Liu, Fubin; Xie, Manlin; Dong, Jiaming; Zou, Yanfang; Ye, Jiali; Liu, Guilong; Cao, Yue; Guo, Zhaodi; Zheng, Lei; Zhao, Kewei] Guangzhou Univ Chinese Med, Affiliated Hosp 3, Guangzhou Key Lab Chinese Med Res Prevent & Treatm, Guangzhou 510378, Peoples R China.
   [Zhao, Qing; Liu, Fubin; Xie, Manlin; Dong, Jiaming; Zou, Yanfang; Ye, Jiali; Liu, Guilong; Cao, Yue; Guo, Zhaodi; Zheng, Lei; Zhao, Kewei] Guangzhou Univ Chinese Med, Guangdong Engn Res Ctr Chinese Herbal derived Vesi, Guangzhou 510006, Peoples R China.
   [Feng, Junjie; Zheng, Lei] Southern Med Univ, Nanfang Hosp, Dept Lab Med, Guangzhou 510515, Peoples R China.
   [Feng, Junjie; Zheng, Lei] Southern Med Univ, Nanfang Hosp, Res Ctr Rapid Diagnost Biosensors, Guangdong Engn & Technol, Guangzhou 510515, Peoples R China.
   [Liang, Qianxin] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai 519000, Peoples R China.
   [Liu, Guilong] Guangdong Heyou Int Hosp, Dept Blood Transfus, Foshan 528306, Peoples R China.
   [Qiao, Hongzhi] Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210023, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Southern Medical University   China; Southern Medical
   University   China; Sun Yat Sen University; Nanjing University of
   Chinese Medicine
RP Zheng, L; Zhao, KW (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 3, Guangzhou Key Lab Chinese Med Res Prevent & Treatm, Guangzhou 510378, Peoples R China.; Zheng, L; Zhao, KW (通讯作者)，Guangzhou Univ Chinese Med, Guangdong Engn Res Ctr Chinese Herbal derived Vesi, Guangzhou 510006, Peoples R China.; Zheng, L (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Lab Med, Guangzhou 510515, Peoples R China.; Zheng, L (通讯作者)，Southern Med Univ, Nanfang Hosp, Res Ctr Rapid Diagnost Biosensors, Guangdong Engn & Technol, Guangzhou 510515, Peoples R China.; Qiao, HZ (通讯作者)，Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210023, Peoples R China.
EM qiaohz@njucm.edu.cn; nfyyzhenglei@smu.edu.cn; zkw2011@gzucm.edu.cn
RI Zhao, Qing/MXK 4616 2025; Zhao, Kewei/ADY 6907 2022; guilong,
   liu/JDW 1390 2023; Xie, Manlin/KGM 6795 2024; JUNJIE, FENG/KYO 9515 2024
OI liu, guilong/0000 0002 9984 6991; Zhao, Kewei/0000 0002 0500 5295; 
FU National Natural Science Foundation of China [82174119, 81973633,
   82274220]; Science and Technology Projects in Liwan District, Guangzhou,
   China [20230710, 202201009]; Young Talent Support Project of Guangzhou
   Association for Science and Technology, China [QT2023036]; Special focus
   areas for General Universities in Guangdong Province, China
   [2022ZDZX2016]; Guangdong Provincial Administration of Traditional
   Chinese Medicine Project, China [20233025]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 82174119, 81973633 and 82274220) , Science and Technology
   Projects in Liwan District, Guangzhou (Nos. 20230710 and 202201009,
   China) , Young Talent Support Project of Guangzhou Association for
   Science and Technology (No. QT2023036, China) , Special focus areas for
   General Universities in Guangdong Province (No. 2022ZDZX2016, China) ,
   Guangdong Provincial Administration of Traditional Chinese Medicine
   Project (No. 20233025, China) .
CR Abdifetah O, 2019, INT J NANOMED, V14, P5659, DOI 10.2147/IJN.S213229
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Cai Q, 2018, SCIENCE, V360, P1126, DOI 10.1126/science.aar4142
   Cao M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425 019 0817 4
   Cao Y, 2022, PLANT SIGNAL BEHAV, V17, DOI 10.1080/15592324.2022.2129290
   Chen QB, 2022, ACTA PHARM SIN B, V12, P907, DOI 10.1016/j.apsb.2021.08.016
   Chen QB, 2021, ACS APPL MATER INTER, V13, P4861, DOI 10.1021/acsami.0c20268
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev cellbio 101512 122326
   Corsi A, 2017, J ORAL MAXIL SURG, V75, P1679, DOI 10.1016/j.joms.2017.01.008
   Dad HA, 2021, MOL THER, V29, P13, DOI 10.1016/j.ymthe.2020.11.030
   Dancy JG, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax3931
   Deng ZB, 2017, MOL THER, V25, P1641, DOI 10.1016/j.ymthe.2017.01.025
   EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978
   Gambacciani M, 2014, MENOPAUSE REV, V13, P213, DOI 10.5114/pm.2014.44996
   Gan DH, 2019, MED SCI MONITOR, V25, P5700, DOI 10.12659/MSM.915170
   Herrero S, 2016, EUR J PHARMACOL, V779, P8, DOI 10.1016/j.ejphar.2016.02.053
   Ilahibaks NF, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121509
   Jung KO, 2018, BIOMATERIALS, V177, P139, DOI 10.1016/j.biomaterials.2018.05.048
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Landgraf M, 2020, BIOMATERIALS, V240, DOI 10.1016/j.biomaterials.2020.119791
   Lavrador P, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800890
   Lavrador P, 2018, DRUG DISCOV TODAY, V23, P1293, DOI 10.1016/j.drudis.2018.05.012
   Li WY, 2018, ACS APPL MATER INTER, V10, P5240, DOI 10.1021/acsami.7b17620
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Lin J, 2017, BIOSCI TRENDS, V11, P496, DOI 10.5582/bst.2017.01216
   Liu C, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01421 w
   Matsumoto Y, 2010, MOL CELL ENDOCRINOL, V325, P118, DOI 10.1016/j.mce.2010.05.004
   Pang XG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4178021
   Peng Zhang, 2009, EUR J PHARMACOL, V607, P1, DOI 10.1016/j.ejphar.2009.01.035
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Pi FM, 2018, NAT NANOTECHNOL, V13, P82, DOI 10.1038/s41565 017 0012 z
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Rutter BD, 2017, PLANT PHYSIOL, V173, P728, DOI 10.1104/pp.16.01253
   Sautchuk R, 2022, ELIFE, V11, DOI 10.7554/eLife.75023
   Smiley DA, 2009, CURR MED CHEM, V16, P1863, DOI 10.2174/092986709788186093
   Song SH, 2017, MOLECULES, V22, DOI 10.3390/molecules22071033
   Sriwastva MK, 2022, EMBO REP, V23, DOI 10.15252/embr.202153365
   Strong AL, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt493
   Teng Y, 2018, CELL HOST MICROBE, V24, P637, DOI 10.1016/j.chom.2018.10.001
   Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043
   Wan SB, 2010, INT J MOL MED, V26, P447, DOI 10.3892/ijmm_00000484
   Wang HC, 2017, IRAN J BASIC MED SCI, V20, P408, DOI 10.22038/IJBMS.2017.8582
   Wang QL, 2015, CANCER RES, V75, P2520, DOI 10.1158/0008 5472.CAN 14 3095
   Wang QL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2886
   Wang YY, 2020, INT J NANOMED, V15, P7967, DOI 10.2147/IJN.S263756
   Watts NB, 2018, J WOMENS HEALTH, V27, P1093, DOI 10.1089/jwh.2017.6706
   Wiklander OPB, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26316
   Zakhireh S, 2021, BIOL TRACE ELEM RES, V199, P1802, DOI 10.1007/s12011 020 02309 2
   Zhang DW, 2016, CALCIFIED TISSUE INT, V99, P187, DOI 10.1007/s00223 016 0138 2
   Zhang MZ, 2016, BIOMATERIALS, V101, P321, DOI 10.1016/j.biomaterials.2016.06.018
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang W, 2017, ACS NANO, V11, P277, DOI 10.1021/acsnano.6b05630
   Zhang XQ, 2020, J CONTROL RELEASE, V328, P454, DOI 10.1016/j.jconrel.2020.08.066
   Zhao Q, 2024, CHIN HERB MED, V16, P3, DOI 10.1016/j.chmed.2023.11.002
   Zhou J, 2021, EXPLORATION PRC, V1, DOI 10.1002/EXP.20210011
   Zhou N, 2016, CELL TISSUE RES, V366, P101, DOI 10.1007/s00441 016 2403 0
   Zhuang XY, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.28713
NR 57
TC 39
Z9 40
U1 27
U2 56
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211 3835
EI 2211 3843
J9 ACTA PHARM SIN B
JI Acta Pharm. Sin. B
PD MAY
PY 2024
VL 14
IS 5
BP 2210
EP 2227
DI 10.1016/j.apsb.2024.02.005
EA MAY 2024
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA C3E6U
UT WOS:001288221200001
PM 38799625
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shao, HM
   Varamini, P
AF Shao, Huimin
   Varamini, Pegah
TI Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted
   Drug Delivery Systems
SO CELLS
LA English
DT Article
DE breast cancer; bone metastasis; targeted drug delivery system;
   nanomedicine; nanotechnology
ID E CADHERIN; PLGA NANOPARTICLES; ZOLEDRONIC ACID; EXPRESSION; INTEGRIN;
   BISPHOSPHONATES; ALENDRONATE; THERAPY; DOXORUBICIN; MECHANISMS
AB Bone is one of the most common metastatic sites among breast cancer (BC) patients. Once bone metastasis is developed, patients' survival and quality of life will be significantly declined. At present, there are limited therapeutic options for BC patients with bone metastasis. Different nanotechnology based delivery systems have been developed aiming to specifically deliver the therapeutic agents to the bone. The conjugation of targeting agents to nanoparticles can enhance the selective delivery of various payloads to the metastatic bone lesion. The current review highlights promising and emerging advanced nanotechnologies designed for targeted delivery of anticancer therapeutics, contrast agents, photodynamic and photothermal materials to the bone to achieve the goal of treatment, diagnosis, and prevention of BC bone metastasis. A better understanding of various properties of these new therapeutic approaches may open up new landscapes in medicine towards improving the quality of life and overall survival of BC patients who experience bone metastasis.
C1 [Shao, Huimin; Varamini, Pegah] Univ Sydney, Sch Pharm, Fac Med & Hlth, Sydney, NSW 2006, Australia.
   [Varamini, Pegah] Univ Sydney, Sydney Nano Inst, Sydney, NSW 2006, Australia.
C3 University of Sydney; University of Sydney
RP Varamini, P (通讯作者)，Univ Sydney, Sch Pharm, Fac Med & Hlth, Sydney, NSW 2006, Australia.; Varamini, P (通讯作者)，Univ Sydney, Sydney Nano Inst, Sydney, NSW 2006, Australia.
EM hsha0542@uni.sydney.edu.au; pegah.varamini@sydney.edu.au
RI Varamini, Pegah/N 6917 2015; Varamini, Pegah/ABB 2824 2020
OI Varamini, Pegah/0000 0001 8658 9722; 
FU National Breast Cancer Foundation Research fellowship [PF 16 007]
FX FundingThis research received no external funding.
CR Alluri P, 2014, SURG ONCOL CLIN N AM, V23, P567, DOI 10.1016/j.soc.2014.03.003
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   [Anonymous], 2020, COMMON IS BREAST CAN
   [Anonymous], 2021, Breast Cancer
   Asano T, 2019, NAT METAB, V1, P868, DOI 10.1038/s42255 019 0104 1
   Au SH, 2016, P NATL ACAD SCI USA, V113, P4947, DOI 10.1073/pnas.1524448113
   Azamjah Nasrindokht, 2019, Asian Pac J Cancer Prev, V20, P2015, DOI 10.31557/APJCP.2019.20.7.2015
   Bai SB, 2019, NANOMED NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102054
   Beca F, 2014, PATHOL RES PRACT, V210, P571, DOI 10.1016/j.prp.2014.05.011
   Benyettou F, 2009, INT J PHARMACEUT, V379, P324, DOI 10.1016/j.ijpharm.2009.04.010
   Bonzi G, 2015, BIOCONJUGATE CHEM, V26, P489, DOI 10.1021/bc500614b
   BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092 8674(94)90007 8
   Cai SD, 2020, INT J PHARMACEUT, V590, DOI 10.1016/j.ijpharm.2020.119948
   Celin MR, 2020, CURR OSTEOPOROS REP, V18, P486, DOI 10.1007/s11914 020 00621 3
   Chaudhari KR, 2012, ADV FUNCT MATER, V22, P4101, DOI 10.1002/adfm.201102357
   Chen SH, 2020, J MATER CHEM B, V8, P3789, DOI 10.1039/d0tb00046a
   Chillà A, 2015, EXP CELL RES, V337, P68, DOI 10.1016/j.yexcr.2015.07.018
   D'Oronzo S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21083022
   Danhier F, 2012, MOL PHARMACEUT, V9, P2961, DOI 10.1021/mp3002733
   Demirkan B, 2013, J CLIN MED, V2, P264, DOI 10.3390/jcm2040264
   Dong X, 2018, ARTIF CELL NANOMED B, V46, pS168, DOI 10.1080/21691401.2017.1416390
   Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765
   Felding Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Forrest ML, 2008, ADV DRUG DELIVER REV, V60, P861, DOI 10.1016/j.addr.2008.02.013
   Foubert P, 2011, METHODS MOL BIOL, V757, P471, DOI 10.1007/978 1 61779 166 6_27
   GAMALLO C, 1993, AM J PATHOL, V142, P987
   George S, 2015, J CLIN ENDOCR METAB, V100, P4163, DOI 10.1210/jc.2015 2680
   Gerratana L, 2015, CLIN EXP METASTAS, V32, P125, DOI 10.1007/s10585 015 9697 2
   Gillett CE, 2001, J PATHOL, V193, P433, DOI 10.1002/path.831
   Hampson G, 2012, INT J WOMENS HEALTH, V4, P455, DOI 10.2147/IJWH.S24783
   Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140 6736(16)31891 8, 10.1016/S0140 6736(16)31891 8]
   He YF, 2017, J CONTROL RELEASE, V264, P76, DOI 10.1016/j.jconrel.2017.08.024
   Huang YJ, 2020, ACTA PHARMACOL SIN B, V10, P2384, DOI 10.1016/j.apsb.2020.06.006
   Huang YJ, 2020, J CONTROL RELEASE, V319, P119, DOI 10.1016/j.jconrel.2019.12.043
   Jiang ZC, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70659 x
   Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003
   Katsumi H, 2020, CHEM PHARM BULL, V68, P560, DOI 10.1248/cpb.c20 00017
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Kent CL, 2021, ANN PALLIAT MED, V10, P5954, DOI 10.21037/apm 20 1128
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049
   Lababidi N, 2019, BEILSTEIN J NANOTECH, V10, P2280, DOI 10.3762/bjnano.10.220
   Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037
   Le Pape F, 2016, J BONE ONCOL, V5, P93, DOI 10.1016/j.jbo.2016.02.008
   Leto G, 2019, CLIN EXP PHARMACOL P, V46, P968, DOI 10.1111/1440 1681.13139
   Li NN, 2021, PHARMACOECONOMICS, V39, P181, DOI 10.1007/s40273 020 00965 9
   Lim CW, 2021, BIOMATER SCI UK, V9, P1660, DOI 10.1039/d0bm01473g
   Lim SC, 2002, ONCOL REP, V9, P915
   Lin TJ, 2019, CHEM PHYS LETT, V716, P83, DOI 10.1016/j.cplett.2018.12.008
   Liu T, 2019, MOL PHARMACEUT, V16, P2872, DOI 10.1021/acs.molpharmaceut.8b01343
   Marazzi F, 2020, CANCERS, V12, DOI 10.3390/cancers12092390
   Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002
   Massagué J, 2000, CELL, V103, P295, DOI 10.1016/S0092 8674(00)00121 5
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Nehoff H, 2014, INT J NANOMED, V9, P2539, DOI 10.2147/IJN.S47129
   Niemeyer CM, 2001, ANGEW CHEM INT EDIT, V40, P4128, DOI 10.1002/1521 3773(20011119)40:22<4128::AID ANIE4128>3.0.CO;2 S
   Odle TG, 2017, RADIOL TECHNOL, V88, p401M
   Oner G, 2020, BREAST J, V26, P995, DOI 10.1111/tbj.13696
   Otaka A, 2020, J BIOMED MATER RES A, V108, P2090, DOI 10.1002/jbm.a.36968
   Pang YC, 2020, NANO LETT, V20, P829, DOI 10.1021/acs.nanolett.9b02916
   Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6
   Pignatello R, 2009, NANOMEDICINE UK, V4, P161, DOI 10.2217/17435889.4.2.161
   Provenzano E, 2018, PET CLIN, V13, P325, DOI 10.1016/j.cpet.2018.02.004
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Ripamonti C, 2013, J CLIN MED, V2, P151, DOI 10.3390/jcm2030151
   Rkein AM, 2014, DERMATOL CLIN, V32, P415, DOI 10.1016/j.det.2014.03.009
   Ross MH, 2017, CANCER RES, V77, P6299, DOI 10.1158/0008 5472.CAN 17 1225
   Rouach V, 2018, J BONE ONCOL, V12, P91, DOI 10.1016/j.jbo.2018.07.011
   Rudnick Glick S, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951 016 0233 6
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Saha B, 2007, ANTICANCER RES, V27, P3903
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   Satriyo PB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020148
   Schneider JG, 2011, BONE, V48, P54, DOI 10.1016/j.bone.2010.09.016
   Shao GQ, 2017, ONCOTARGET, V8, P75587, DOI 10.18632/oncotarget.17486
   Sihto H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2944
   Silva I, 2011, ACTA REUMATOL PORT, V36, P209
   Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398
   Soki FN, 2012, FUTURE ONCOL, V8, P803, DOI [10.2217/fon.12.76, 10.2217/FON.12.76]
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Sutherland Mark, 2012, Cancers (Basel), V4, P1106, DOI 10.3390/cancers4041106
   Syed V, 2016, J CELL BIOCHEM, V117, P1279, DOI 10.1002/jcb.25496
   Thamake SI, 2012, BIOMATERIALS, V33, P7164, DOI 10.1016/j.biomaterials.2012.06.026
   Tsang JYS, 2020, ADV ANAT PATHOL, V27, P27, DOI 10.1097/PAP.0000000000000232
   Pham TT, 2019, J IND ENG CHEM, V76, P310, DOI 10.1016/j.jiec.2019.03.055
   Vanderburgh J, 2020, ACS NANO, V14, P311, DOI 10.1021/acsnano.9b04571
   Waks AG, 2019, JAMA J AM MED ASSOC, V321, P288, DOI 10.1001/jama.2018.19323
   Wang DY, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 55710 w
   Wang FF, 2014, J CONTROL RELEASE, V196, P222, DOI 10.1016/j.jconrel.2014.10.012
   Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017
   Wang HY, 2017, ONCOTARGET, V8, P26368, DOI 10.18632/oncotarget.14300
   Wang KL, 2018, MOL PHARMACEUT, V15, P2764, DOI 10.1021/acs.molpharmaceut.8b00266
   Wang L, 2019, CANCER SCI, V110, P3157, DOI 10.1111/cas.14172
   Wang MM, 2018, ACS APPL MATER INTER, V10, P41003, DOI 10.1021/acsami.8b07527
   Waning DL, 2019, CELL METAB, V29, P6, DOI 10.1016/j.cmet.2018.12.014
   Wardley A, 2005, BRIT J CANCER, V92, P1869, DOI 10.1038/sj.bjc.6602551
   Wilczewska AZ, 2012, PHARMACOL REP, V64, P1020, DOI 10.1016/S1734 1140(12)70901 5
   Wu H, 2020, INT J BIOL MACROMOL, V164, P2583, DOI 10.1016/j.ijbiomac.2020.08.068
   Wu XQ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00076
   Yang XJ, 2012, ADV MATER, V24, P2890, DOI 10.1002/adma.201104797
   Ye WL, 2015, SCI REP UK, V5, DOI 10.1038/srep14614
   Yoshida R, 2001, INT J ONCOL, V18, P513
   Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217
   Zhang HW, 2018, J BONE ONCOL, V11, P38, DOI 10.1016/j.jbo.2018.01.004
   Zhang XY, 2019, DRUG DES DEV THER, V13, P1357, DOI 10.2147/DDDT.S198400
   Zhao YP, 2017, NANOSCALE, V9, P6264, DOI 10.1039/c7nr00962c
   Zhao Z, 2019, CHEM PHYS LIPIDS, V223, DOI 10.1016/j.chemphyslip.2019.104785
   Zhu JH, 2018, NANOSCALE, V10, P18387, DOI 10.1039/c8nr03899f
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
NR 113
TC 38
Z9 38
U1 4
U2 22
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD FEB
PY 2022
VL 11
IS 3
AR 388
DI 10.3390/cells11030388
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA YY1NG
UT WOS:000754559900001
PM 35159207
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shu, Q
   Shao, YW
   Liu, RL
   Hu, Y
   Peng, Z
   Tian, J
AF Shu, Qing
   Shao, Yuwei
   Liu, Ruolan
   Hu, Yan
   Peng, Zhao
   Tian, Jun
TI Mechanisms by which electroacupuncture mediated histone acetylation
   mitigates bone loss in rats with ovariectomy induced osteoporosis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE osteoporosis; electroacupuncture; histone deacetylase 2; osteoblast;
   osteoclast
ID ACUPUNCTURE; ENDOCRINE; ESTROGEN; HORMONE; DIFFERENTIATION; METABOLISM;
   EXPRESSION; PREVENTION; RECEPTORS; THERAPY
AB The aim of the present study was to investigate the effectiveness of electroacupuncture (EA) on ovariectomy induced osteoporotic rats to elucidate potential mechanisms by which EA regulates acetylation of histones in caput femoris. A total of 40 female Sprague Dawley rats were randomly allocated into four groups: Sham operation, ovariectomy induced osteoporosis (OVX), EA and 17 beta  estradiol (E2) treatments. After 8 weeks of intervention, the trabecular morphology of each group was measured by micro computed tomography. Biomarkers of bone metabolism in serum were detected. The protein expression of histone deacetylase 2 (HDAC2), histone H3, Ac histone H3 and downstream cytokines involved in osteoblast and osteoclast differentiation were detected. The results showed that EA and E2 both prevented bone loss and improved trabecular morphology in OVX rats. EA was found to suppress the protein expression of HDAC2 and promoted the acetylation of histone H3 compared with the OVX model group. The results indicated that EA promoted the differentiation of osteoblasts, and suppressed that of osteoclasts, thereby improving the trabecular morphology. E2 was shown to regulate the expression of runt related transcription factor 2 and receptor activator of nuclear factor kappa B ligand without modulating the expression of HDAC2, and therefore diverged mechanistically from EA. Overall, the results of the present study suggested that the mechanisms through which EA improved bone mineral density and trabecular morphology may involve the modulation of histone H3 acetylation and regulation of osteoblast and osteoclast differentiation.
C1 [Shu, Qing; Shao, Yuwei; Liu, Ruolan; Hu, Yan; Peng, Zhao; Tian, Jun] Wuhan Univ, Dept Rehabil, Zhongnan Hosp, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
   [Shao, Yuwei; Tian, Jun] Wuhan Univ, Clin Coll 2, Wuhan 430071, Hubei, Peoples R China.
C3 Wuhan University; Wuhan University
RP Tian, J (通讯作者)，Wuhan Univ, Dept Rehabil, Zhongnan Hosp, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
EM tianjun@znhospital.cn
RI Liu, Ruolan/HGT 7708 2022; Shu, Qing/HSA 9445 2023
FU Natural Science Foundation of Hubei Province [2017CFB787]; Fundamental
   Research Funds for the Central Universities [2042018kf0097]
FX This work was supported by Natural Science Foundation of Hubei Province
   (grant no. 2017CFB787) and the Fundamental Research Funds for the
   Central Universities (grant no. 2042018kf0097).
CR Amzaleg Y, 2018, J STEROID BIOCHEM, V183, P10, DOI 10.1016/j.jsbmb.2018.05.002
   Axelsson KF, 2017, J INTERN MED, V282, P546, DOI 10.1111/joim.12678
   Chen FJ, 2014, J CELL BIOCHEM, V115, P651, DOI 10.1002/jcb.24700
   Chen GZ, 2010, CHIN J INTEGR MED, V16, P498, DOI 10.1007/s11655 010 0574 1
   Deng YZ, 2016, J BIOL REG HOMEOS AG, V30, P1035
   Dou C, 2016, AM J PHYSIOL CELL PH, V310, pC780, DOI 10.1152/ajpcell.00351.2015
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Fan HL, 2016, MOL MED REP, V13, P2485, DOI 10.3892/mmr.2016.4849
   Fu HY, 2018, LIFE SCI, V197, P109, DOI 10.1016/j.lfs.2018.02.005
   Gambacciani M, 2014, MENOPAUSE REV, V13, P213, DOI 10.5114/pm.2014.44996
   Gräff J, 2013, NAT REV NEUROSCI, V14, P97, DOI 10.1038/nrn3427
   Hiligsmann M, 2019, SEMIN ARTHRITIS RHEU, V49, P184, DOI 10.1016/j.semarthrit.2019.01.006
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Li J, 2016, ACUPUNCT MED, V34, P107, DOI 10.1136/acupmed 2014 010674
   Mak JCS, 2015, ACUPUNCT MED, V33, P440, DOI 10.1136/acupmed 2015 010983
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Manson JE, 2013, JAMA J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040
   Marini F, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081329
   Martin A, 2015, BONE, V75, P96, DOI 10.1016/j.bone.2015.02.007
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Pan H, 2018, AM J CHINESE MED, V46, P489, DOI 10.1142/S0192415X18500258
   Queirolo V, 2016, OSTEOARTHR CARTILAGE, V24, P1451, DOI 10.1016/j.joca.2016.04.003
   Shen Y, 2015, TRENDS PLANT SCI, V20, P614, DOI 10.1016/j.tplants.2015.07.005
   Shu Q, 2020, OBESITY FACTS, V13, P40, DOI 10.1159/000503752
   Sobacchi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00629
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Tu WZ, 2012, NEUROCHEM INT, V60, P379, DOI 10.1016/j.neuint.2012.01.006
   Wang HD, 2015, ACUPUNCT MED, V33, P465, DOI 10.1136/acupmed 2014 010743
   Wang YQ, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12485
   Wang Y, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/1676808
   Xiong Q, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/596789
   Yin CS, 2008, RES VET SCI, V84, P159, DOI 10.1016/j.rvsc.2007.04.004
   Zhang AH, 2016, SCI REP UK, V6, DOI 10.1038/srep19942
   Zhao H, 2003, NEUROSCI LETT, V349, P25, DOI 10.1016/S0304 3940(03)00676 1
   Zheng XF, 2018, ACUPUNCT MED, V36, P176, DOI 10.1136/acupmed 2016 011268
   Zheng XF, 2015, EXP THER MED, V10, P541, DOI 10.3892/etm.2015.2553
   Zhou J, 2014, ACUPUNCT MED, V32, P478, DOI 10.1136/acupmed 2014 010577
NR 38
TC 9
Z9 11
U1 1
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD OCT
PY 2020
VL 22
IS 4
BP 3453
EP 3463
DI 10.3892/mmr.2020.11430
PG 11
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA NW4US
UT WOS:000575004300091
PM 32945471
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Villasante, A
   Marturano Kruik, A
   Robinson, ST
   Liu, Z
   Guo, XE
   Vunjak Novakovic, G
AF Villasante, Aranzazu
   Marturano Kruik, Alessandro
   Robinson, Samuel T.
   Liu, Zen
   Guo, X. Edward
   Vunjak Novakovic, Gordana
TI Tissue Engineered Model of Human Osteolytic Bone Tumor
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
DE tissue engineering; osteolysis; osteoclasts; tumor model; Ewing's
   sarcoma
ID MESENCHYMAL STEM CELLS; ZOLEDRONIC ACID; EWINGS SARCOMA; OSTEOCLAST
   DIFFERENTIATION; CANCER RESEARCH; 3D; METASTASIS; MECHANISMS;
   OSTEOPOROSIS; PATHOGENESIS
AB Ewing's sarcoma (ES) is a poorly differentiated pediatric tumor of aggressive behavior characterized by propensity to metastasize to bone. Interactions between the tumor and bone cells orchestrate a vicious cycle in which tumor cells induce osteoclast differentiation and activation to cause osteolytic lesions, broken bones, pain, and hypercalcemia. The lack of controllable models that can recapitulate osteolysis in ES impedes the development of new therapies and limits our understanding of how tumor cells invade bone. In response to this need, tissue engineered models are now being developed to enable quantitative, predictive studies of human tumors. In this study, we report a novel bioengineered model of ES that incorporates the osteolytic process. Our strategy is based on engineering human bone containing both osteoclasts and osteoblasts within three dimensional mineralized bone matrix. We show that the bone matrix is resorbed by mature osteoclasts while the new bone matrix is formed by osteoblasts, leading to calcium release and bone remodeling. Introduction of ES cell aggregates into the bone niche induced decreases in bone density, connectivity, and matrix deposition. Additionally, therapeutic reagents, such as zoledronic acid, which have demonstrated efficacy in ES treatment, inhibited bone resorption mediated by osteoclasts in the tumor model.
C1 [Villasante, Aranzazu; Marturano Kruik, Alessandro; Robinson, Samuel T.; Liu, Zen; Guo, X. Edward; Vunjak Novakovic, Gordana] Columbia Univ, Dept Biomed Engn, New York, NY USA.
   [Marturano Kruik, Alessandro] Politecn Milan, Dept Chem Mat & Chem Engn G Natta, Milan, Italy.
   [Vunjak Novakovic, Gordana] Columbia Univ, Dept Med, New York, NY USA.
C3 Columbia University; Polytechnic University of Milan; Columbia
   University
RP Vunjak Novakovic, G (通讯作者)，Columbia Univ, 622 West 168th St,VC12 234, New York, NY 10032 USA.
EM gv2131@columbia.edu
RI Villasante, Aranzazu/A 9100 2017; vunjak novakovic, gordana/J 9279 2012;
   Villasante, Aranzazu/AFH 5216 2022
OI Robinson, Samuel/0000 0003 2356 9905; Villasante,
   Aranzazu/0000 0001 7919 9670
FU NIH [EB002520, EB17103]
FX The authors gratefully acknowledge NIH funding of this work (grants
   EB002520 and EB17103 to G.V. N.). They also acknowledge expert help of
   Dr. Llucia Valldeperas and Dr. Freytes (isolation of monocytes),
   Histology Facility at Columbia University (histological services) and
   Dr. Ho, Flow Cytometry Core Facility at the Columbia Center for
   Translational Immunology (cell sorting).
CR Arnaldez FI, 2014, CLIN CANCER RES, V20, P3050, DOI 10.1158/1078 0432.CCR 13 0633
   Arrington SA, 2006, BONE, V38, P359, DOI 10.1016/j.bone.2005.09.013
   Bhumiratana S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5904
   Bi XH, 2013, BONE, V56, P454, DOI 10.1016/j.bone.2013.07.006
   Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bromberg O, 2012, BLOOD, V120, P303, DOI 10.1182/blood 2011 09 377853
   Burdett E, 2010, TISSUE ENG PART B RE, V16, P351, DOI 10.1089/ten.TEB.2009.0676
   Cao JJ, 2014, J NUTR, V144, P289, DOI 10.3945/jn.113.185397
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Chao PHG, 2007, J ORTHOP SCI, V12, P398, DOI 10.1007/s00776 007 1147 9
   Chaplet ML, 2004, BIOCHEM J, V384, P591, DOI 10.1042/BJ20040380
   Chitcholtan K, 2013, EXP CELL RES, V319, P75, DOI 10.1016/j.yexcr.2012.09.012
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Crapo PM, 2011, BIOMATERIALS, V32, P3233, DOI 10.1016/j.biomaterials.2011.01.057
   de Peppo G.M., 2013, P NATL ACAD SCI US
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Grayson WL, 2008, TISSUE ENG PT A, V14, P1809, DOI 10.1089/ten.tea.2007.0255
   Grayson WL, 2011, METHODS MOL BIOL, V698, P231, DOI 10.1007/978 1 60761 999 4_18
   Grayson WL, 2010, P NATL ACAD SCI USA, V107, P3299, DOI 10.1073/pnas.0905439106
   Grayson WL, 2009, SEMIN CELL DEV BIOL, V20, P665, DOI 10.1016/j.semcdb.2008.12.008
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hu L, 2017, STEM CELLS DEV, V26, P123, DOI 10.1089/scd.2016.0173
   Jeon OH, 2016, SCI REP UK, V6, DOI 10.1038/srep26761
   Kimlin LC, 2013, MOL CARCINOGEN, V52, P167, DOI 10.1002/mc.21844
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Lau YS, 2007, BRIT J CANCER, V96, P1716, DOI 10.1038/sj.bjc.6603774
   Lawlor Elizabeth R., 2015, Critical Reviews in Oncogenesis, V20, P155, DOI 10.1615/CritRevOncog.2015013553
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mansour A, 2011, CELL RES, V21, P1102, DOI 10.1038/cr.2011.21
   MERRY K, 1993, J CELL SCI, V104, P1013
   Odri G, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 169
   Odri GA, 2010, CANCER RES, V70, P7610, DOI 10.1158/0008 5472.CAN 09 4272
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Redini F, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00279
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Roodman GD, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.122
   Schmidt C, 2002, J BIOMED MATER RES, V63, P252, DOI 10.1002/jbm.10185
   Schuessler TK, 2014, CANCER RES, V74, P5359, DOI 10.1158/0008 5472.CAN 14 1706
   Seibel Markus J, 2005, Clin Biochem Rev, V26, P97
   Sorensen MG, 2007, J BONE MINER METAB, V25, P36, DOI 10.1007/s00774 006 0725 9
   Sousa S, 2016, J BONE ONCOL, V5, P135, DOI 10.1016/j.jbo.2016.03.004
   Taylor R, 2011, J PATHOL, V225, P195, DOI 10.1002/path.2869
   Toomey EC, 2010, ONCOGENE, V29, P4504, DOI 10.1038/onc.2010.205
   van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245
   Villasante A., 2015, BIOENGINEERED
   Villasante A, 2014, BIOMATERIALS, V35, P5785, DOI 10.1016/j.biomaterials.2014.03.081
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
   Zhang HR, 2015, CIRC RES, V117, P17, DOI 10.1161/CIRCRESAHA.117.305860
   Zhou ZC, 2005, CANCER AM CANCER SOC, V104, P1713, DOI 10.1002/cncr.21383
NR 50
TC 26
Z9 33
U1 0
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD FEB
PY 2017
VL 23
IS 2
BP 98
EP 107
DI 10.1089/ten.tec.2016.0371
PG 10
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA EL2DO
UT WOS:000394430500004
PM 28068876
OA Green Published
DA 2025 08 17
ER

PT J
AU Schepper, JD
   Collins, F
   Rios Arce, ND
   Kang, HJ
   Schaefer, L
   Gardinier, JD
   Raghuvanshi, R
   Quinn, RA
   Britton, R
   Parameswaran, N
   McCabe, LR
AF Schepper, Jonathan D.
   Collins, Fraser
   Rios Arce, Naiomy Deliz
   Kang, Ho Jun
   Schaefer, Laura
   Gardinier, Joseph D.
   Raghuvanshi, Ruma
   Quinn, Robert A.
   Britton, Robert
   Parameswaran, Narayanan
   McCabe, Laura R.
TI Involvement of the Gut Microbiota and Barrier Function in
   Glucocorticoid Induced Osteoporosis
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE DYSBIOSIS; ENDOTOXIN; GLUCOCORTICOID; INTESTINAL PERMEABILITY;
   LACTOBACILLI; LACTOBACILLUS REUTERI; MDY; MICROBIOTA; OSTEOBLAST;
   OSTEOCLAST; AND APOPTOSIS; PREDNISOLONE; TRABECULAR BONE
ID INFLAMMATORY BOWEL DISEASE; INDUCED BONE LOSS;
   LACTOBACILLUS RHAMNOSUS GG; INTESTINAL MICROBIOME; INDUCED APOPTOSIS;
   OSTEOBLAST DIFFERENTIATION; PROBIOTIC REGULATION; PARATHYROID HORMONE;
   IN VIVO; STRESS
AB Glucocorticoids (GCs) are potent immune modulating drugs with significant side effects, including glucocorticoid induced osteoporosis (GIO). GCs directly induce osteoblast and osteocyte apoptosis but also alter intestinal microbiota composition. Although the gut microbiota is known to contribute to the regulation of bone density, its role in GIO has never been examined. To test this, male C57/Bl6J mice were treated for 8 weeks with GC (prednisolone, GC Tx) in the presence or absence of broad spectrum antibiotic treatment (ABX) to deplete the microbiota. Long term ABX prevented GC Tx induced trabecular bone loss, showing the requirement of gut microbiota for GIO. Treatment of GC Tx mice with a probiotic (Lactobacillus reuteri [LR]) prevented trabecular bone loss. Microbiota analyses indicated that GC Tx changed the abundance of Verrucomicobiales and Bacteriodales phyla and random forest analyses indicated significant differences in abundance of Porphyromonadaceae and Clostridiales operational taxonomic units (OTUs) between groups. Furthermore, transplantation of GC Tx mouse fecal material into recipient naive, untreated WT mice caused bone loss, supporting a functional role for microbiota in GIO. We also report that GC caused intestinal barrier breaks, as evidenced by increased serum endotoxin level (2.4 fold), that were prevented by LR and ABX treatments. Enhancement of barrier function with a mucus supplement prevented both GC Tx induced barrier leakage and trabecular GIO. In bone, treatment with ABX, LR or a mucus supplement reduced GC Tx induced osteoblast and osteocyte apoptosis. GC Tx suppression of Wnt10b in bone was restored by the LR and high molecular weight polymer (MDY) treatments as well as microbiota depletion. Finally, we identified that bone specific Wnt10b overexpression prevented GIO. Taken together, our data highlight the previously unappreciated involvement of the gut microbiota and intestinal barrier function in trabecular GIO pathogenesis (including Wnt10b suppression and osteoblast and osteocyte apoptosis) and identify the gut as a novel therapeutic target for preventing GIO. (c) 2019 American Society for Bone and Mineral Research.
C1 [Schepper, Jonathan D.; Collins, Fraser; Rios Arce, Naiomy Deliz; Kang, Ho Jun; Parameswaran, Narayanan; McCabe, Laura R.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.
   [Rios Arce, Naiomy Deliz] Michigan State Univ, Comparat Med & Integrat Biol Program, E Lansing, MI 48824 USA.
   [Schaefer, Laura; Britton, Robert] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
   [Gardinier, Joseph D.] Henry Ford Hlth Syst, Bone & Joint Ctr, Detroit, MI USA.
   [Raghuvanshi, Ruma; Quinn, Robert A.] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
C3 Michigan State University; Michigan State University; Baylor College of
   Medicine; Henry Ford Health System; Henry Ford Hospital; Michigan State
   University
RP McCabe, LR (通讯作者)，Michigan State Univ, Dept Physiol & Radiol, Biomed Phys Sci Bldg,567 Wilson Rd, E Lansing, MI 48824 USA.
EM mccabel@msu.edu
RI ; Parameswaran, Narayanan/V 1969 2019; Britton, Robert/B 5040 2009;
   McCabe, Laura/AGS 5131 2022; Collins, Fraser/AAT 7889 2020
OI McCabe, Laura/0000 0001 5407 162X; Schepper,
   Jonathan/0000 0003 1888 0950; Gardinier, Joseph/0000 0002 8651 8913;
   Parameswaran, Narayanan/0000 0002 8894 5564; Schaefer,
   Laura/0000 0003 1628 2893; 
CR Ahlroos T, 2009, J APPL MICROBIOL, V106, P506, DOI 10.1111/j.1365 2672.2008.04018.x
   Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   [Anonymous], 2013, OTH R LANG ENV STAT
   [Anonymous], 2012, Nature, V486, P207, DOI DOI 10.1038/NATURE11234
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Blanton LV, 2016, SCIENCE, V351, DOI 10.1126/science.aad3311
   Blaser M, 2011, NATURE, V476, P393, DOI 10.1038/476393a
   Bregger MDK, 2007, VET COMP ORTHOPAED, V20, P18
   Briot K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2014 000014
   Britton RA, 2014, J CELL PHYSIOL, V229, P1822, DOI 10.1002/jcp.24636
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07 1403
   Chen ZG, 2016, CLIN EXP PHARMACOL P, V43, P268, DOI 10.1111/1440 1681.12513
   Collins F., 2015, INTESTINAL MICROBIOT
   Collins FL, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.BAD 0015 2016
   Collins FL, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 51293 8
   Collins FL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181979
   Collins FL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153180
   Collins J, 2015, MICROBIOME, V3, DOI 10.1186/s40168 015 0097 2
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Cui HH, 2004, WORLD J GASTROENTERO, V10, P1521
   de Vrese Michael, 2009, Menopause Int, V15, P35, DOI 10.1258/mi.2009.009008
   Ersek A, 2016, SCI REP UK, V6, DOI 10.1038/srep36513
   Ferrier L, 2006, AM J PATHOL, V168, P1148, DOI 10.2353/ajpath.2006.050617
   Fraser LA, 2009, THER ADV MUSCULOSKEL, V1, P71, DOI 10.1177/1759720X09343729
   Frese SA., 2012, Adv Microbiol, V2, P399, DOI [10.4236/aim.2012.23051, DOI 10.4236/AIM.2012.23051]
   Frese SA, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001314
   Gardinier Joseph D, 2018, Bone Rep, V8, P29, DOI 10.1016/j.bonr.2018.01.003
   Gatej SM, 2018, J CLIN PERIODONTOL, V45, P204, DOI 10.1111/jcpe.12838
   Gruver Yates Amanda L, 2013, Cells, V2, P202, DOI 10.3390/cells2020202
   Guo C, 2014, INFLAMMATION, V37, P621, DOI 10.1007/s10753 013 9778 9
   Guss JD, 2017, J BONE MINER RES, V32, P1343, DOI 10.1002/jbmr.3114
   Hansen CHF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034043
   Harris L, 2009, AM J PHYSIOL GASTR L, V296, pG1020, DOI 10.1152/ajpgi.90696.2008
   Hartmann K, 2016, PHYSIOL REV, V96, P409, DOI 10.1152/physrev.00011.2015
   Hofbauer LC, 2009, MOL ENDOCRINOL, V23, P1525, DOI 10.1210/me.2009 0069
   Hsu E, 2018, CALCIFIED TISSUE INT, V102, P512, DOI 10.1007/s00223 017 0321 0
   Huang EY, 2015, INFLAMM BOWEL DIS, V21, P963, DOI 10.1097/MIB.0000000000000332
   Hviid A, 2011, GUT, V60, P49, DOI 10.1136/gut.2010.219683
   Irwin R, 2013, INFLAMM BOWEL DIS, V19, P1586, DOI 10.1097/MIB.0b013e318289e17b
   Ito S, 2007, BONE, V40, P84, DOI 10.1016/j.bone.2006.07.012
   Iwamoto J, 2014, CHINESE J PHYSIOL, V57, P231, DOI 10.4077/CJP.2014.BAC242
   Jackson MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05184 7
   Jernberg C, 2007, ISME J, V1, P56, DOI 10.1038/ismej.2007.3
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kennedy EA, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01534
   Khosla S, 2016, J BONE MINER RES, V31, P1485, DOI 10.1002/jbmr.2888
   Kim KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047713
   Kobayashi R, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00623 9
   Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043 13
   Lane NE, 2019, CURR OSTEOPOROS REP, V17, P1, DOI 10.1007/s11914 019 00498 x
   Lane NE, 1998, ENDOCRIN METAB CLIN, V27, P465, DOI 10.1016/S0889 8529(05)70017 7
   Latousakis D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010136
   Lavretsky H, 2012, AM J GERIAT PSYCHIAT, V20, P729, DOI 10.1097/JGP.0b013e31826573cf
   Le Roy T, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03289
   Lekamwasam S, 2012, OSTEOPOROSIS INT, V23, P2257, DOI 10.1007/s00198 012 1958 1
   Li JY, 2019, J BONE MINER RES, V34, P349, DOI 10.1002/jbmr.3600
   Li JY, 2016, J CLIN INVEST, V126, P2049, DOI 10.1172/JCI86062
   Li J, 2015, INT J CLIN EXP PATHO, V8, P13695
   Lin YP, 2008, INFLAMM BOWEL DIS, V14, P1068, DOI 10.1002/ibd.20448
   Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242
   Livanos AE, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.140, 10.1038/NMICROBIOL.2016.140]
   Loh G, 2012, GUT MICROBES, V3, P544, DOI 10.4161/gmic.22156
   Lovdel A, 2018, END ABSTR, V56, pGP58, DOI [10.1530/endoabs.56.GP58, DOI 10.1530/ENDOABS.56.GP58, DOI 10.1530/END0ABS.56.GP58)]
   Lutgendorff F, 2008, CURR MOL MED, V8, P282, DOI 10.2174/156652408784533779
   Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Manolides AS, 2010, J BONE MINER METAB, V28, P532, DOI 10.1007/s00774 009 0156 5
   Mariat D, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471 2180 9 123
   McCabe L, 2015, CURR OSTEOPOROS REP, V13, P363, DOI 10.1007/s11914 015 0292 x
   McCabe LR, 2019, BONE, V118, P20, DOI 10.1016/j.bone.2018.03.024
   McCabe LR, 2018, CALCIFIED TISSUE INT, V102, P480, DOI 10.1007/s00223 018 0403 7
   Mccabe LR, 2013, J CELL PHYSIOL, V228, P1793, DOI 10.1002/jcp.24340
   McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217
   Montazeri Najafabady N, 2019, PROBIOTICS ANTIMICRO, V11, P1145, DOI 10.1007/s12602 018 9443 6
   Mutus R, 2006, POULTRY SCI, V85, P1621, DOI 10.1093/ps/85.9.1621
   Nilsson AG, 2018, J INTERN MED, V284, P307, DOI 10.1111/joim.12805
   Nitzan O, 2016, WORLD J GASTROENTERO, V22, P1078, DOI 10.3748/wjg.v22.i3.1078
   Noguera JC, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.171743
   Novince CM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06126 x
   O'Mahony SM, 2009, BIOL PSYCHIAT, V65, P263, DOI 10.1016/j.biopsych.2008.06.026
   Oh PL, 2010, ISME J, V4, P377, DOI 10.1038/ismej.2009.123
   Ohlsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092368
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Overman RA, 2013, ARTHRIT CARE RES, V65, P294, DOI 10.1002/acr.21796
   Pacifici R, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031203
   Pan HD, 2019, MICROBIOME, V7, DOI 10.1186/s40168 019 0719 1
   Parvaneh K, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/897639
   Pereira RC, 2004, ENDOCRINOLOGY, V145, P1952, DOI 10.1210/en.2003 0868
   Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756 3282(02)00687 7
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Porter A, 2017, SCI REP UK, V7, DOI 10.1038/srep42505
   Purnell JQ, 2004, J CLIN ENDOCR METAB, V89, P281, DOI 10.1210/jc.2003 030440
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   Qiu DX, 2019, BIOFACTORS, V45, P892, DOI 10.1002/biof.1565
   Quach D, 2018, MSPHERE, V3, DOI 10.1128/mSphereDirect.00545 17
   Quach D, 2017, ADV EXP MED BIOL, V1033, P47, DOI 10.1007/978 3 319 66653 2_4
   Raehtz S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00384
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Ray Katrina, 2012, Nat Rev Endocrinol, V8, P623, DOI [10.1038/nrgastro.2012.175, 10.1038/nrendo.2012.173]
   Ricoldi MST, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179946
   Rizzoli R, 2019, AGING CLIN EXP RES, V31, P743, DOI 10.1007/s40520 019 01131 8
   Rizzoli R, 2018, CALCIFIED TISSUE INT, V102, P489, DOI 10.1007/s00223 017 0317 9
   Rovensky J, 2005, ANN NY ACAD SCI, V1051, P570, DOI 10.1196/annals.1361.101
   Sato AY, 2018, CLIN REV BONE MINER, V16, P33, DOI 10.1007/s12018 018 9242 3
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Sato AY, 2015, BONE, V73, P60, DOI 10.1016/j.bone.2014.12.012
   Schepper J, 2019, FASEB J, V33
   Schepper J, 2017, J BONE MINER RES, V32, pS277
   Schepper JD, 2019, J BONE MINER RES, V34, P681, DOI 10.1002/jbmr.3635
   Schepper JD, 2017, ADV EXP MED BIOL, V1033, P225, DOI 10.1007/978 3 319 66653 2_11
   Segers ME, 2014, MICROB CELL FACT, V13, DOI 10.1186/1475 2859 13 S1 S7
   Shaker JL, 2005, ENDOCRIN METAB CLIN, V34, P341, DOI 10.1016/j.ecl.2005.01.014
   Silvestrini G, 2000, BONE, V26, P33, DOI 10.1016/S8756 3282(99)00245 8
   Sjogren K, 2012, BONE, V50, pS91, DOI [10.1016/j.bone.2012.02.272, 10.1002/jbmr.1588]
   Smith AD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223025
   Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200
   Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200
   Spiller RC, 2007, J GASTROENTEROL, V42, P41, DOI 10.1007/s00535 006 1925 8
   Su H, 2018, EXP THER MED, V16, P2999, DOI 10.3892/etm.2018.6559
   Sylvester FA, 2017, ADV EXP MED BIOL, V1033, P133, DOI 10.1007/978 3 319 66653 2_7
   Tamboli CP, 2004, GUT, V53, P1, DOI 10.1136/gut.53.1.1
   Tavakoli S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 45270 4
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Thiele Sylvia, 2014, Bonekey Rep, V3, P552, DOI 10.1038/bonekey.2014.47
   Thomas CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031951
   Thunhorst RL, 2007, AM J PHYSIOL REG I, V293, pR1444, DOI 10.1152/ajpregu.00294.2007
   Tlaskalová Hogenová H, 2011, CELL MOL IMMUNOL, V8, P110, DOI 10.1038/cmi.2010.67
   Trasande L, 2013, INT J OBESITY, V37, P16, DOI 10.1038/ijo.2012.132
   Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552
   TSUJI A, 1981, J PHARM SCI US, V70, P772, DOI 10.1002/jps.2600700715
   Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653
   Tyagi AM, 2018, IMMUNITY, V49, P1116, DOI 10.1016/j.immuni.2018.10.013
   Ueda S, 2015, MED MOL MORPHOL, V48, P69, DOI 10.1007/s00795 014 0077 9
   Valuckaite V, 2013, J SURG RES, V183, P869, DOI 10.1016/j.jss.2013.02.035
   Valuckaite V, 2009, AM J PHYSIOL GASTR L, V297, pG1041, DOI 10.1152/ajpgi.00328.2009
   van Staa TP, 2006, CALCIFIED TISSUE INT, V79, P129, DOI 10.1007/s00223 006 0019 1
   Vindigni SM, 2016, THER ADV GASTROENTER, V9, P606, DOI 10.1177/1756283X16644242
   Voreades N, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00494
   Weaver CM, 2015, CURR OSTEOPOROS REP, V13, P125, DOI 10.1007/s11914 015 0257 0
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Yan FF, 2019, ANIMAL, V13, P33, DOI [10.1017/S175173111800109X, 10.1017/s175173111800109x]
   Yan J, 2016, P NATL ACAD SCI USA, V113, pE7554, DOI 10.1073/pnas.1607235113
   Yao W, 2008, ARTHRITIS RHEUM, V58, P3485, DOI 10.1002/art.23954
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Zhang J, 2015, ENDOCRINOLOGY, V156, P3169, DOI 10.1210/EN.2015 1308
NR 152
TC 152
Z9 174
U1 3
U2 53
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2020
VL 35
IS 4
BP 801
EP 820
DI 10.1002/jbmr.3947
PG 20
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LB2HW
UT WOS:000524455400019
PM 31886921
OA Bronze
DA 2025 08 17
ER

PT J
AU Cipriani, M
   Rostán, S
   León, I
   Li, ZH
   Gancheff, JS
   Kemmerling, U
   Azar, CO
   Etcheverry, S
   Docampo, R
   Gambino, D
   Otero, L
AF Cipriani, Micaella
   Rostan, Santiago
   Leon, Ignacio
   Li, Zhu Hong
   Gancheff, Jorge S.
   Kemmerling, Ulrike
   Olea Azar, Claudio
   Etcheverry, Susana
   Docampo, Roberto
   Gambino, Dinorah
   Otero, Lucia
TI Multi target heteroleptic palladium bisphosphonate complexes
SO JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
LA English
DT Article
DE Bisphosphonate; Palladium; DNA; Chagas; Toxoplasmosis
ID EFFECTIVE CORE POTENTIALS; TRYPANOSOMA CRUZI; METAL COMPLEXES;
   CHEMOTHERAPEUTIC AGENTS; MOLECULAR CALCULATIONS; POLYPYRIDYL LIGANDS;
   TOXOPLASMA GONDII; BASIS SET; ANTICANCER; PLATINUM
AB Bisphosphonates are the most commonly prescribed drugs for the treatment of osteoporosis and other bone illnesses. Some of them have also shown antiparasitic activity. In search of improving the pharmacological profile of commercial bisphosphonates, our group had previously developed first row transition metal complexes with N containing bisphosphonates (NBPs). In this work, we extended our studies to heteroleptic palladium NBP complexes including DNA intercalating polypyridyl co ligands (NN) with the aim of obtaining potential multi target species. Complexes of the formula [Pd(NBP)(2)(NN)]center dot 2NaCl center dot xH(2)O with NBP = alendronate (ale) or pamidronate (pam) and NN = 1,10 phenanthroline (phen) or 2,2 ' bipyridine (bpy) were synthesized and fully characterized. All the obtained compounds were much more active in vitro against T. cruzi (amastigote form) than the corresponding NBP ligands. In addition, complexes were nontoxic to mammalian cells up to 50 100 mu M. Compounds with phen as ligand were 15 times more active than their bpy analogous. Related to the potential mechanism of action, all complexes were potent inhibitors of two parasitic enzymes of the isoprenoid biosynthetic pathway. No correlation between the anti T. cruzi activity and the enzymatic inhibition results was observed. On the contrary, the high antiparasitic activity of phen containing complexes could be related to their ability to interact with DNA in an intercalative like mode. These rationally designed compounds are good candidates for further studies and good leaders for future drug developments. Graphic abstract Four new palladium heteroleptic complexes with N containing commercial bisphosphonates and DNA intercalating polypyridyl co ligands were synthesized and fully characterized. All complexes displayed high anti T. cruzi activity which could be related to the inhibition of the parasitic farnesyl diphosphate synthase enzyme but mainly to their ability to interact DNA.
C1 [Cipriani, Micaella; Rostan, Santiago; Gancheff, Jorge S.; Gambino, Dinorah; Otero, Lucia] UdelaR, Fac Quim, Quim Inorgan, Montevideo, Uruguay.
   [Leon, Ignacio; Etcheverry, Susana] UNLP, Ctr Quim Inorgan, Fac Ciencias Exactas, CONICET, La Plata, Buenos Aires, Argentina.
   [Li, Zhu Hong; Docampo, Roberto] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA.
   [Li, Zhu Hong; Docampo, Roberto] Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.
   [Kemmerling, Ulrike] Univ Chile, Fac Med, ICBM, Programa Anat & Biol Desarrollo, Santiago, Chile.
   [Olea Azar, Claudio] Univ Chile, Dept Quim Inorgan & Analit, Fac Ciencias Quim & Farmaceut, Santiago, Chile.
C3 Universidad de la Republica, Uruguay; National University of La Plata;
   Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   University System of Georgia; University of Georgia; University System
   of Georgia; University of Georgia; Universidad de Chile; Universidad de
   Chile
RP Otero, L (通讯作者)，UdelaR, Fac Quim, Quim Inorgan, Montevideo, Uruguay.
EM luotero@fq.edu.uy
RI Olea, Claudio/I 1605 2013; OLEA AZAR, CLAUDIO/I 1605 2013; Gambino,
   Dinorah/AFL 6104 2022; Docampo, Roberto/X 9424 2019; leon,
   i/GZL 2093 2022; Kemmerling, Ulrike/H 8783 2013
OI OLEA AZAR, CLAUDIO/0000 0001 5805 0746; Rostan,
   Santiago/0000 0001 6891 099X; Gambino, Dinorah/0000 0001 8678 7374
FU FONDECYT, Chile [1190340]; U.S. National Institute of Health [AI082542]
FX L We thank Melina Galizzi for technical help. Authors thank CSIC,
   PEDECIBA and ANII SNI, Uruguay, and FONDECYT 1190340, Chile. Z H Li and
   R.D. work was funded by the U.S. National Institute of Health (Grant
   AI082542 to R.D).
CR Alam MN, 2016, COORDIN CHEM REV, V316, P36, DOI 10.1016/j.ccr.2016.02.001
   Alvarez Valdes A, 2019, J INORG BIOCHEM, V191, P112, DOI 10.1016/j.jinorgbio.2018.11.010
   [Anonymous], 1990, EFFECT RELATIVITY AT
   APPLETON TG, 1986, INORG CHEM, V25, P726, DOI 10.1021/ic00226a005
   Barone V, 1998, J PHYS CHEM A, V102, P1995, DOI 10.1021/jp9716997
   BARTON JK, 1986, J AM CHEM SOC, V108, P2081, DOI 10.1021/ja00268a057
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098
   Burgos Lopez Y, 2019, INORG CHIM ACTA, V487, P31, DOI 10.1016/j.ica.2018.11.039
   CamposVallette MM, 1996, VIB SPECTROSC, V12, P37, DOI 10.1016/0924 2031(96)00012 4
   Canavaci AMC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000740
   Cavalli A, 2009, J MED CHEM, V52, P7339, DOI 10.1021/jm9004835
   Cossi M, 2003, J COMPUT CHEM, V24, P669, DOI 10.1002/jcc.10189
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Demoro B, 2018, J BIOL INORG CHEM, V23, P303, DOI 10.1007/s00775 018 1535 y
   Demoro B, 2012, DALTON T, V41, P6468, DOI 10.1039/c2dt12179d
   Demoro B, 2010, J INORG BIOCHEM, V104, P1252, DOI 10.1016/j.jinorgbio.2010.08.004
   Docampo R, 2008, CURR PHARM DESIGN, V14, P882, DOI 10.2174/138161208784041079
   Docampo Roberto, 2001, Current Drug Targets   Infectious Disorders, V1, P51, DOI 10.2174/1568005013343191
   Dorosti Z, 2014, FUTURE ONCOL, V10, P2529, DOI 10.2217/fon.14.65
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Fanelli M, 2016, COORDIN CHEM REV, V310, P41, DOI 10.1016/j.ccr.2015.11.004
   Fathy AA, 2018, INORG CHIM ACTA, V473, P44, DOI 10.1016/j.ica.2017.12.015
   Feller D, 1996, J COMPUT CHEM, V17, P1571, DOI 10.1002/(SICI)1096 987X(199610)17:13<1571::AID JCC9>3.0.CO;2 P
   Ferella M, 2006, J BIOL CHEM, V281, P39339, DOI 10.1074/jbc.M607451200
   FRANCL MM, 1982, J CHEM PHYS, V77, P3654, DOI 10.1063/1.444267
   Frik M, 2014, J MED CHEM, V57, P9995, DOI 10.1021/jm5012337
   Frisch MJ, 2013, GAUSSIAN 09 REV A 01
   Fulmer GR, 2010, ORGANOMETALLICS, V29, P2176, DOI 10.1021/om100106e
   Galezowska J, 2018, CHEMMEDCHEM, V13, P289, DOI 10.1002/cmdc.201700769
   Galezowska J, 2012, COORDIN CHEM REV, V256, P105, DOI 10.1016/j.ccr.2011.07.002
   Gambino D, 2019, METAL IONS LIFE SCI, V19, P331, DOI 10.1515/9783110527872 013
   Gambino D, 2011, COORDIN CHEM REV, V255, P2193, DOI 10.1016/j.ccr.2010.12.028
   Garoufis A, 2009, COORDIN CHEM REV, V253, P1384, DOI 10.1016/j.ccr.2008.09.011
   Gong Y, 2006, INORG CHEM, V45, P4987, DOI 10.1021/ic052095h
   HARIHARA.PC, 1973, THEOR CHIM ACTA, V28, P213, DOI 10.1007/BF00533485
   HAY PJ, 1985, J CHEM PHYS, V82, P299, DOI [10.1063/1.448975, 10.1063/1.448799, 10.1063/1.448800]
   Huang RL, 2005, BIOCHEM PHARMACOL, V69, P1009, DOI 10.1016/j.bcp.2005.01.001
   Juribasic M, 2009, J MOL STRUCT, V924, P66, DOI 10.1016/j.molstruc.2008.11.007
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   KINNAMON KE, 1979, ANTIMICROB AGENTS CH, V15, P157, DOI 10.1128/AAC.15.2.157
   Kukushkin YN, 1968, ZH PRIKL KHIM, V41, P2381
   Lakowicz R, 2006, Principles of Fluorescence Spectroscopy, DOI DOI 10.1007/978 0 387 46312 4
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Mansouri Torshizi H, 2010, SPECTROCHIM ACTA A, V77, P312, DOI 10.1016/j.saa.2010.05.029
   Margiotta N, 2008, J INORG BIOCHEM, V102, P2078, DOI 10.1016/j.jinorgbio.2008.07.008
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Matczak Jon E, 2005, COORDIN CHEM REV, V249, P2458, DOI 10.1016/j.ccr.2005.06.001
   Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Mukherjee S, 2019, MOL BIOCHEM PARASIT, V230, P8, DOI 10.1016/j.molbiopara.2019.03.001
   Nardelli SC, 2013, MBIO, V4, DOI 10.1128/mBio.00922 13
   Otero L, 2006, J MED CHEM, V49, P3322, DOI 10.1021/jm0512241
   Pages BJ, 2017, EUR J INORG CHEM, P1613, DOI 10.1002/ejic.201601204
   Recher M, 2013, EUR J MED CHEM, V60, P431, DOI 10.1016/j.ejmech.2012.12.015
   RILLING HC, 1985, METHOD ENZYMOL, V110, P145
   Rodrigues CO, 2000, BIOCHEM J, V349, P737, DOI 10.1042/bj3490737
   Arce ER, 2019, DALTON T, V48, P7644, DOI 10.1039/c9dt01317b
   Arce ER, 2015, DALTON T, V44, P14453, DOI 10.1039/c5dt00557d
   Rodriguez JB, 2016, EXPERT OPIN DRUG DIS, V11, P307, DOI 10.1517/17460441.2016.1143814
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sánchez Delgado RA, 2004, MET IONS BIOL SYST, V41, P379
   Scalese G, 2017, J INORG BIOCHEM, V175, P154, DOI 10.1016/j.jinorgbio.2017.07.014
   Scalese G, 2015, J INORG BIOCHEM, V147, P116, DOI 10.1016/j.jinorgbio.2015.03.002
   Schuchardt KL, 2007, J CHEM INF MODEL, V47, P1045, DOI 10.1021/ci600510j
   Tan CP, 2008, J INORG BIOCHEM, V102, P1644, DOI 10.1016/j.jinorgbio.2008.03.005
   Urbina JA, 2003, TRENDS PARASITOL, V19, P495, DOI 10.1016/j.pt.2003.09.001
   WIMMER S, 1989, J CHEM SOC DALTON, P403, DOI 10.1039/dt9890000403
   Zheng W, 2016, SCI CHINA CHEM, V59, P1240, DOI 10.1007/s11426 016 0178 7
NR 69
TC 6
Z9 7
U1 1
U2 18
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0949 8257
EI 1432 1327
J9 J BIOL INORG CHEM
JI J. Biol. Inorg. Chem.
PD MAY
PY 2020
VL 25
IS 3
BP 509
EP 519
DI 10.1007/s00775 020 01779 y
EA MAR 2020
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LH9HV
UT WOS:000522573100002
PM 32232584
OA Green Published
DA 2025 08 17
ER

PT J
AU Stoddart, A
   Wang, JH
   Hu, CM
   Fernald, AA
   Davis, EM
   Cheng, JX
   Le Beau, MM
AF Stoddart, Angela
   Wang, Jianghong
   Hu, Chunmei
   Fernald, Anthony A.
   Davis, Elizabeth M.
   Cheng, Jason X.
   Le Beau, Michelle M.
TI Inhibition of WNT signaling in the bone marrow niche prevents the
   development of MDS in the Apcdel/+MDS mouse model
SO BLOOD
LA English
DT Article
ID MESENCHYMAL STROMAL CELLS; HEMATOPOIETIC STEM CELLS; ACUTE
   MYELOID LEUKEMIA; MYELODYSPLASTIC SYNDROMES; BETA CATENIN; DEL(5Q)
   GENES; APC; MICROENVIRONMENT; HAPLOINSUFFICIENCY; EXPRESSION
AB There is accumulating evidence that functional alteration(s) of the bone marrow (BM) microenvironment contribute to the development of some myeloid disorders, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In addition to a cell intrinsic role of WNT activation in leukemia stem cells, WNT activation in the BM niche is also thought to contribute to the pathogenesis of MDS and AML. We previously showed that the Apc haploinsufficient mice (Apc(del/+)) model MDS induced by an aberrant BM microenvironment. We sought to determine whether Apc, a multifunctional protein and key negative regulator of the canonical beta catenin (Ctnnb1)/WNT signaling pathway, mediates this disease through modulating WNT signaling, and whether inhibition of WNT signaling prevents the development of MDS in Apc(del/+) mice. Here, we demonstrate that loss of 1 copy of Ctnnb1 is sufficient to prevent the development of MDS in Apc(del/+) mice and that altered canonical WNT signaling in the microenvironment is responsible for the disease. Furthermore, the US Food and Drug Administration (FDA) approved drug pyrvinium delays and/or inhibits disease in Apc(del/+) mice, even when it is administered after the presentation of anemia. Other groups have observed increased nuclear CTNNB1 in stromal cells from a high frequency of MDS/AML patients, a finding that together with our results highlights a potential new strategy for treating some myeloid disorders.
C1 [Stoddart, Angela; Wang, Jianghong; Hu, Chunmei; Fernald, Anthony A.; Davis, Elizabeth M.; Le Beau, Michelle M.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Cheng, Jason X.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Cheng, Jason X.; Le Beau, Michelle M.] Univ Chicago, Med Comprehens Canc Ctr, Chicago, IL 60637 USA.
   [Hu, Chunmei] Jilin Univ, Hosp 2, Changchun, Peoples R China.
C3 University of Chicago; University of Chicago; University of Chicago;
   Robert H. Lurie Comprehensive Cancer Center; Jilin University
RP Stoddart, A (通讯作者)，Univ Chicago, Sect Hematol Oncol, 900 E 57th St,KCBD 7th Floor, Chicago, IL 60637 USA.
EM astoddar@bsd.uchicago.edu
OI Stoddart, Angela/0000 0001 9776 2228
FU Public Health Service, National Institutes of Health (NIH), National
   Cancer Institute (NCI) grant [RO1 CA190372]; Edward P. Evans Foundation;
   NIH/NCI Cancer Center support grant [P30 CA14599]
FX This work was supported by a Public Health Service, National Institutes
   of Health (NIH), National Cancer Institute (NCI) grant (RO1 CA190372),
   and by a grant from the Edward P. Evans Foundation (M.M.L.B.), as well
   as an NIH/NCI Cancer Center support grant awarded to the University of
   Chicago Comprehensive Cancer Center (P30 CA14599).
CR Aanei CM, 2012, STEM CELLS DEV, V21, P1604, DOI 10.1089/scd.2011.0390
   Agarwal P, 2015, ADV CANCER RES, V127, P227, DOI 10.1016/bs.acr.2015.04.007
   Anthony BA, 2014, TRENDS IMMUNOL, V35, P32, DOI 10.1016/j.it.2013.10.002
   BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460 2075.1995.tb00249.x
   Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343
   Boultwood J, 2007, BRIT J HAEMATOL, V139, P578, DOI 10.1111/j.1365 2141.2007.06833.x
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Chamseddine AN, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912 015 0489 2
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Cogle CR, 2015, CURR HEMATOL MALIG R, V10, P272, DOI 10.1007/s11899 015 0269 y
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Falconi G, 2016, EXP HEMATOL, V44, P75, DOI 10.1016/j.exphem.2015.10.005
   Ferrer RA, 2013, HAEMATOLOGICA, V98, P1677, DOI 10.3324/haematol.2013.083972
   Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129
   Geyh S, 2016, LEUKEMIA, V30, P683, DOI 10.1038/leu.2015.325
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Haferlach T, 2014, LEUKEMIA, V28, P241, DOI 10.1038/leu.2013.336
   Jerez A, 2012, J CLIN ONCOL, V30, P1343, DOI 10.1200/JCO.2011.36.1824
   Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123
   Kelaidi C, 2013, LEUKEMIA, V27, P1283, DOI 10.1038/leu.2013.16
   Kfoury Y, 2015, CELL STEM CELL, V16, P239, DOI 10.1016/j.stem.2015.02.019
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883
   Koreth J, 2013, J CLIN ONCOL, V31, P2662, DOI 10.1200/JCO.2012.46.8652
   KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125
   Lane SW, 2010, BLOOD, V115, P3489, DOI 10.1182/blood 2009 11 251728
   Luis TC, 2012, LEUKEMIA, V26, P414, DOI 10.1038/leu.2011.387
   Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017
   Majetl R, 2009, P NATL ACAD SCI USA, V106, P3396, DOI 10.1073/pnas.0900089106
   Medyouf H, 2014, CELL STEM CELL, V14, P824, DOI 10.1016/j.stem.2014.02.014
   Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165
   Papaemmanuil E, 2013, BLOOD, V122, P3616, DOI 10.1182/blood 2013 08 518886
   Pavlaki K, 2014, STEM CELLS DEV, V23, P1568, DOI 10.1089/scd.2013.0283
   Qian ZJ, 2008, J EXP MED, V205, P2163, DOI 10.1084/jem.20080578
   Raaijmakers MHGP, 2012, INT J HEMATOL, V95, P17, DOI 10.1007/s12185 011 1001 x
   Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851
   Rai K, 2010, CELL, V142, P930, DOI 10.1016/j.cell.2010.08.030
   Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120
   Smith SM, 2003, BLOOD, V102, P43, DOI 10.1182/blood 2002 11 3343
   Sridhar K, 2009, BLOOD, V114, P4847, DOI 10.1182/blood 2009 08 236422
   Stoddart A, 2016, HAEMATOLOGICA, V101, pE232, DOI 10.3324/haematol.2015.139527
   Stoddart A, 2015, BLOOD, V126, P2899, DOI 10.1182/blood 2015 10 673228
   Stoddart A, 2014, BLOOD, V123, P228, DOI 10.1182/blood 2013 05 506568
   Stoddart A, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.117.117
   Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453
   Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610
   WAGNER ED, 1963, AM J TROP MED HYG, V12, P60, DOI 10.4269/ajtmh.1963.12.60
   Walkley CR, 2007, CELL, V129, P1081, DOI 10.1016/j.cell.2007.03.055
   Walkley CR, 2007, CELL, V129, P1097, DOI 10.1016/j.cell.2007.05.014
   Walter MJ, 2013, LEUKEMIA, V27, P1275, DOI 10.1038/leu.2013.58
   Wang JH, 2010, BLOOD, V115, P3481, DOI 10.1182/blood 2009 11 251835
   Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624
   Xu J, 2008, BRIT J HAEMATOL, V140, P394, DOI 10.1111/j.1365 2141.2007.06914.x
   Yeung J, 2010, CANCER CELL, V18, P606, DOI 10.1016/j.ccr.2010.10.032
   Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239
   Zhang JY, 2015, CANCER BIOL MED, V12, P10, DOI 10.7497/j.issn.2095 3941.2014.0019
   Zhou JH, 2011, SEMIN DIAGN PATHOL, V28, P258, DOI 10.1053/j.semdp.2011.08.005
   Zimmer SN, 2011, BLOOD, V118, P69, DOI 10.1182/blood 2010 09 307942
NR 58
TC 58
Z9 62
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD JUN 1
PY 2017
VL 129
IS 22
BP 2959
EP 2970
DI 10.1182/blood 2016 08 736454
PG 12
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA EW5GW
UT WOS:000402534800005
PM 28348148
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Bai, SJ
   Han, X
   Lan, YC
   Wang, HD
   Wang, R
   Li, LY
   Song, QH
   Li, AY
AF Bai, Shujun
   Han, Xue
   Lan, Yanchen
   Wang, Haodong
   Wang, Rui
   Li, Liyuan
   Song, Qiuhang
   Li, Aiying
TI Mechanisms of action underlying Shentong Zhuyu decoction based
   treatment of rheumatoid arthritis using systems biology and
   computer aided drug design
SO MEDICINE
LA English
DT Article
DE immune network targets; interleukin 6; system biology; Traditional
   Chinese Medicine
ID NF KAPPA B; KAEMPFEROL INDUCES APOPTOSIS; FIBROBLAST LIKE SYNOVIOCYTES;
   INFLAMMATORY SIGNAL; QUERCETIN; ACTIVATION; PATHWAY
AB Rheumatoid arthritis is an autoimmune disease characterized by chronic polyarticular pain, for which no cure currently exists. In Chinese medicine, rheumatoid arthritis (RA) is believed to be caused by phlegm and blood stagnation. Shentong Zhuyu decoction can be used to treat RA, as it promotes blood circulation, resolves blood stasis, and relieves pain. In our study, we used network pharmacology and computer aided drug design to evaluate the components, active compounds, and targets of Shentong Zhuyu decoction (STZY). Our results suggest that STZY contains active compounds such as quercetin, luteolin, and formononetin that regulate immune network targets. RA associated genes are enriched in pathways including those associated with nuclear factor kappa B, phosphatidylinositol 3 kinase/AKT, and hypoxia inducible factor 1 signaling. The main active compounds in STZY (quercetin and luteolin) were derived from Achyranthis Bidentatae Radix, Carthami Flos, licorice, Cyperi Rhizoma, and Myrrha and targeted the pro inflammatory cytokines interleukin 2, interleukin 1 alpha, interleukin 1 beta, and interleukin 6. In addition, the compounds quercetin, luteolin, and formononetin in these herbs can target the anti inflammatory cytokines interleukin 4 and interleukin 10. Our results suggest that STZY can balance the immune network, promote an anti inflammatory environment, and reduce the clinical symptoms of RA. Based on the close relationship between inflammatory response and osteoclast formation, we hypothesized that STZY may inhibit inflammation and alleviate bone destruction in RA. Our findings indicate that STZY can treat RA through multiple components, targets, and pathways. This study may provide a reference for the clinical application of STZY in RA treatment.
C1 [Bai, Shujun; Han, Xue; Lan, Yanchen; Wang, Haodong; Wang, Rui; Li, Liyuan; Song, Qiuhang; Li, Aiying] Hebei Univ Chinese Med, Coll Basic Med, Shijiazhuang 050200, Peoples R China.
   [Song, Qiuhang; Li, Aiying] Hebei Univ Chinese Med, Hebei Key Lab Chinese Med Res Cardiocerebrovasc Di, Shijiazhuang, Peoples R China.
   [Li, Aiying] Hebei Higher Educ Inst Appl Technol Res Ctr TCM Fo, Shijiazhuang, Peoples R China.
C3 Hebei University of Chinese Medicine; Hebei University of Chinese
   Medicine
RP Song, QH (通讯作者)，Hebei Univ Chinese Med, Coll Basic Med, Shijiazhuang 050200, Peoples R China.
EM bsj275572@126.com; 1838278608@qq.com; 1041071765@qq.com;
   1748229739@qq.com; 1748229739@qq.com; liaiying@hebcm.edu.cn;
   songqiuhang@163.com; liaiying@hebcm.edu.cn
RI ; Li, Ai Ying/AAJ 3453 2021; song, qiuhang/JCD 4525 2023
OI Song, Qiuhang/0000 0001 5670 9412; 
FU Projects of Science and Technology Project of Hebei Education Department
   [QN2021106]; Hebei University of Chinese Medicine [BSZ2020011]; Medical
   Science Research of Hebei Province [20210258]; National College Students
   Innovation and Entrepreneurship Training Program [202214432204]
FX This research was funded by Projects of Science and Technology Project
   of Hebei Education Department (NO. QN2021106); Doctoral Research Funding
   Project of Hebei University of Chinese Medicine (NO. BSZ2020011);
   Medical Science Research of Hebei Province (NO.20210258); National
   College Students Innovation and Entrepreneurship Training Program
   (NO.202214432204)
CR Adapala NS, 2019, BONE REP, V10, DOI 10.1016/j.bonr.2019.100203
   Amberger Joanna S, 2017, Curr Protoc Bioinformatics, V58, DOI 10.1002/cpbi.27
   Aziz N, 2018, J ETHNOPHARMACOL, V225, P342, DOI 10.1016/j.jep.2018.05.019
   Bu DC, 2021, NUCLEIC ACIDS RES, V49, pW317, DOI 10.1093/nar/gkab447
   Chen YC, 2001, BIOCHEM PHARMACOL, V61, P1417, DOI 10.1016/S0006 2952(01)00594 9
   Cho IA, 2019, INFLAMMATION, V42, P1426, DOI 10.1007/s10753 019 01005 1
   Cho SY, 2003, MOL CELL BIOCHEM, V243, P153, DOI 10.1023/A:1021624520740
   Dai JM, 2021, J CELL MOL MED, V25, P5782, DOI 10.1111/jcmm.16604
   Danciu C, 2018, CURR DRUG TARGETS, V19, P841, DOI 10.2174/1389450118666171109150731
   Dinesh P, 2018, CYTOKINE, V106, P54, DOI 10.1016/j.cyto.2018.03.005
   Doncheva NT, 2019, J PROTEOME RES, V18, P623, DOI 10.1021/acs.jproteome.8b00702
   Fujisaki K, 2007, LIFE SCI, V80, P1311, DOI 10.1016/j.lfs.2006.12.037
   Fukai T, 2002, LIFE SCI, V71, P1449, DOI 10.1016/S0024 3205(02)01864 7
   Gabay O, 2010, OSTEOARTHR CARTILAGE, V18, P106, DOI 10.1016/j.joca.2009.08.019
   Haleagrahara N, 2017, BIOMED PHARMACOTHER, V90, P38, DOI 10.1016/j.biopha.2017.03.026
   Han Y, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6187695
   He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183
   Hellwig Bürgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567
   Huang JW., 2018, Guiding J. Traditional Chin. Med. Pharmacol., V24, P104, DOI [10.13862/j.cnki.cn43 1446/r.2018.12.034, DOI 10.13862/J.CNKI.CN43 1446/R.2018.12.034]
   Ji JJ, 2013, AFR J TRADIT COMPLEM, V10, P418, DOI 10.4314/ajtcam.v10i3.5
   Kilani Jaziri S, 2009, CHEM BIOL INTERACT, V181, P85, DOI 10.1016/j.cbi.2009.04.014
   Kripa KG, 2011, J ETHNOPHARMACOL, V134, P1024, DOI 10.1016/j.jep.2011.01.010
   Kumar LD, 2016, BIOMED PHARMACOTHER, V79, P52, DOI 10.1016/j.biopha.2016.02.001
   Li JS, 2015, SCI REP UK, V5, DOI 10.1038/srep15290
   Li Q., 1999, Chinese Pharmaceutical J, V34, P514
   Luo HT, 2011, FOOD CHEM, V128, P513, DOI 10.1016/j.foodchem.2011.03.073
   Machado Alba JE, 2016, INT J CLIN PRACT, V70, P506, DOI 10.1111/ijcp.12809
   Marfe G, 2009, J CELL BIOCHEM, V106, P643, DOI 10.1002/jcb.22044
   Mlcek J, 2016, MOLECULES, V21, DOI 10.3390/molecules21050623
   Pisetsky David S, 2017, N C Med J, V78, P337, DOI 10.18043/ncm.78.5.337
   Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Seo MJ, 2015, J NUTR BIOCHEM, V26, P1308, DOI 10.1016/j.jnutbio.2015.06.005
   Smiljanovic B, 2012, J MOL MED, V90, P1295, DOI 10.1007/s00109 012 0907 y
   Song B, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105685
   Stelzer G., 2016, CURR PROTOC BIOINFOR, V54, p1.30.31, DOI [10.1002/cpbi.5, DOI 10.1002/CPBI.5]
   Stevens T, 2019, PHARMACOGENET GENOM, V29, P136, DOI 10.1097/FPC.0000000000000376
   Suleimanov TA, 2004, CHEM NAT COMPD+, V40, P13, DOI 10.1023/B:CONC.0000025456.09089.84
   Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986
   Valerio M, 2011, INT IMMUNOPHARMACOL, V11, P1012, DOI 10.1016/j.intimp.2011.02.018
   Wang DD, 2020, BIOCHEM BIOPH RES CO, V526, P805, DOI 10.1016/j.bbrc.2020.03.164
   Wang L, 2021, J ETHNOPHARMACOL, V273, DOI 10.1016/j.jep.2021.113988
   Wang P, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.598200
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xue F, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00040
   Yamaguchi R, 2016, J BONE JOINT SURG AM, V98, P1122, DOI 10.2106/JBJS.15.01209
   Yang Y., 2019, J Anhui Agri Sci, V47, P86
   Yi LJ, 2022, J RECEPT SIG TRANSD, V42, P16, DOI 10.1080/10799893.2020.1837873
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 50
TC 0
Z9 0
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD NOV 24
PY 2023
VL 102
IS 47
AR e36287
DI 10.1097/MD.0000000000036287
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA AD3Z5
UT WOS:001116496400115
PM 38013316
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Maykovich, T
   Hardy, S
   Hamann, MT
   Cray, J
AF Maykovich, Tyler
   Hardy, Samantha
   Hamann, Mark T.
   Cray, James
TI Manzamine A Alters In Vitro Calvarial Osteoclast Function
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID THYROXINE EXPOSURE; NATURAL PRODUCTS; SPONGE; ALKALOIDS; DISCOVERY;
   CANCER; ANTIMALARIAL; BIOACTIVITY; INHIBITOR; AGENTS
AB Manzamine A is a marine derived alkaloid that has demonstrated antimalarial and antiproliferative properties and is an emerging drug lead compound as a possible intervention in certain cancers. This compound has been found to modulate SIX1 gene expression, a target that is critical for the proliferation and survival of cells via various developmental pathways. As yet, little research has focused on manzamine A and how its use may affect tissue systems including bone. Here we hypothesized that manzamine A, through its interaction with SIX1, would alter precursor cells that give rise to the bone cell responsible for remodeling: the osteoclast. We further hypothesized reduced effects in differentiated osteoclasts, as these cells are generally not mitotic. We interrogated the effects of manzamine A on preosteoclasts and osteoclasts. qrtPCR, MTS cell viability, Caspase 3/7, and TRAP staining were used as a functional assay. Preosteoclasts show responsiveness to manzamine A treatment exhibited by decreases in cell viability and an increase in apoptosis. Osteoclasts also proved to be affected by manzamine A but only at higher concentrations where apoptosis was increased and activation was reduced. In summary, our presented results suggest manzamine A may have significant effects on bone development and health through multiple cell targets, previously shown in the osteoblast cell lineage, the cell responsible for mineralized tissue formation, and here in the osteoclast, the cell responsible for the removal of mineralized tissue and renewal via precipitation of bone remodeling.
C1 [Maykovich, Tyler; Hardy, Samantha; Cray, James] Ohio State Univ, Coll Med, Dept Biomed Educ & Anat, Columbus, OH 43210 USA.
   [Hamann, Mark T.] Med Univ South Carolina, Coll Pharm, Dept Drug Discovery, Charleston, SC 29425 USA.
   [Hamann, Mark T.] Med Univ South Carolina, Coll Med, Dept Biomed Sci & Publ Hlth, Charleston, SC 29425 USA.
   [Cray, James] Ohio State Coll Dent, Div Biosci, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; Medical University of
   South Carolina; Medical University of South Carolina; University System
   of Ohio; Ohio State University
RP Cray, J (通讯作者)，Ohio State Univ, Coll Med, Dept Biomed Educ & Anat, Columbus, OH 43210 USA.; Cray, J (通讯作者)，Ohio State Coll Dent, Div Biosci, Columbus, OH 43210 USA.
EM cray.30@osu.edu
FU Ohio State Collegeof Medicine; Medicines for Malaria Venture; NIGMS
   [RO1GM145845 01]; NCCIH [RO1AT007318 01]
FX The Ohio State Collegeof Medicine,The Medicines for Malaria Venture,
   NIGMS grant RO1GM145845 01 and NCCIH RO1AT007318 01 are acknowledged for
   support for the generation of purified MA.
CR Abbas S, 2011, MAR DRUGS, V9, P2423, DOI 10.3390/md9112423
   Ang KKH, 2001, PARASITOL RES, V87, P715, DOI 10.1007/s004360000366
   Ang KKH, 2000, ANTIMICROB AGENTS CH, V44, P1645, DOI 10.1128/AAC.44.6.1645 1649.2000
   [Anonymous], 2023, StatPearls
   ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0
   Baser KHC, 2000, PLANTA MED, V66, P674, DOI 10.1055/s 2000 8627
   Boswell Z, 2023, INFECT DRUG RESIST, V16, P2321, DOI 10.2147/IDR.S395203
   Bourel Bonnet L, 2005, J MED CHEM, V48, P1330, DOI 10.1021/jm049841x
   Boyce MA, 2023, ORTHOD CRANIOFAC RES, V26, P415, DOI 10.1111/ocr.12624
   Cooper GM, 2010, PLAST RECONSTR SURG, V125, P1403, DOI 10.1097/PRS.0b013e3181d62ad4
   Cray JJ, 2011, ORTHOD CRANIOFAC RES, V14, P149, DOI 10.1111/j.1601 6343.2011.01520.x
   Cray JJ, 2014, BIRTH DEFECTS RES A, V100, P912, DOI 10.1002/bdra.23323
   Cray JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069067
   Cray J, 2010, J CRANIOFAC SURG, V21, P711, DOI 10.1097/SCS.0b013e3181d80a36
   Durham EL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218376
   Durham E, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117827
   Durham E, 2019, STEM CELL RES, V40, DOI 10.1016/j.scr.2019.101528
   Durham E, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 40796 z
   Durham E, 2017, CALCIFIED TISSUE INT, V101, P300, DOI 10.1007/s00223 017 0278 z
   Durham E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139719
   Durham EL, 2022, LIFE SCI, V311, DOI 10.1016/j.lfs.2022.121158
   Durham EL, 2020, MOL IMMUNOL, V117, P94, DOI 10.1016/j.molimm.2019.10.021
   Durham EL, 2016, BIRTH DEFECTS RES A, V106, P803, DOI 10.1002/bdra.23543
   El Sayed KA, 2008, J NAT PROD, V71, P300, DOI 10.1021/np0703702
   Finney D. J., 1952, PROBIT ANAL ASTATIST, P318
   Gammone MA, 2016, ANTI CANCER AGENT ME, V16, P1549, DOI 10.2174/1871520616666160211123841
   Gul W, 2006, BIOORGAN MED CHEM, V14, P8495, DOI 10.1016/j.bmc.2006.08.042
   Hamann MT, 2003, CURR PHARM DESIGN, V9, P879, DOI 10.2174/1381612033455297
   HAMANN MT, 1991, TETRAHEDRON LETT, V32, P5671, DOI 10.1016/S0040 4039(00)93525 1
   Hanna GS, 2021, J NAT PROD, V84, P3001, DOI 10.1021/acs.jnatprod.1c00625
   Hardy S, 2022, MAR DRUGS, V20, DOI 10.3390/md20100647
   Howie RN, 2018, INT J ORAL SCI, V10, DOI 10.1038/s41368 018 0026 x
   Howie RN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167805
   Howie RN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132520
   Hua HM, 2004, BIOORGAN MED CHEM, V12, P6461, DOI 10.1016/j.bmc.2004.09.026
   Ibrahim MA, 2009, J NAT PROD, V72, P2141, DOI 10.1021/np900499q
   ICHIBA T, 1994, J NAT PROD, V57, P168, DOI 10.1021/np50103a027
   Indraningrat AAG, 2016, MAR DRUGS, V14, DOI 10.3390/md14050087
   Karan D, 2020, J NAT PROD, V83, P286, DOI 10.1021/acs.jnatprod.9b00577
   Kesterke MJ, 2018, J ANAT, V233, P46, DOI 10.1111/joa.12810
   Kishinchand R, 2024, CLEFT PALATE CRAN J, V61, P1389, DOI 10.1177/10556656231163400
   Laport MS, 2009, CURR PHARM BIOTECHNO, V10, P86, DOI 10.2174/138920109787048625
   MCCLINTOCK JB, 1994, J CHEM ECOL, V20, P859, DOI 10.1007/BF02059583
   MCCLINTOCK JB, 1994, J CHEM ECOL, V20, P2539, DOI 10.1007/BF02036190
   Meujo DAF, 2010, INT J FOOD MICROBIOL, V138, P63, DOI 10.1016/j.ijfoodmicro.2009.11.012
   Mioso R, 2017, MOLECULES, V22, DOI 10.3390/molecules22020208
   Mioso R, 2015, REV IBEROAM MICOL, V32, P147, DOI 10.1016/j.riam.2014.01.004
   Na MK, 2010, J NAT PROD, V73, P383, DOI 10.1021/np900281r
   Nair DG, 2015, ACTA PHARMACOL SIN, V36, P158, DOI 10.1038/aps.2014.114
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285
   Newman DJ, 2002, CURR CANCER DRUG TAR, V2, P279, DOI 10.2174/1568009023333791
   Newman DJ, 2009, DIVING HYPERB MED, V39, P216
   Newman DJ, 2000, NAT PROD REP, V17, P215, DOI 10.1039/a902202c
   Palem JR, 2017, Z NATURFORSCH C, V72, P49, DOI 10.1515/znc 2016 0080
   Palem JR, 2011, PLANTA MED, V77, P46, DOI 10.1055/s 0030 1250093
   Peng JN, 2010, J MED CHEM, V53, P61, DOI 10.1021/jm900672t
   Peng JN, 2003, J AM CHEM SOC, V125, P13382, DOI 10.1021/ja030087z
   Pennings SC, 1999, J CHEM ECOL, V25, P735, DOI 10.1023/A:1020832414766
   Radwan M, 2012, CELL CYCLE, V11, P1765, DOI 10.4161/cc.20135
   Rao KV, 2006, J NAT PROD, V69, P1034, DOI 10.1021/np0601399
   Rao KV, 2004, J NAT PROD, V67, P1314, DOI 10.1021/np0400095
   Rao KV, 2003, J NAT PROD, V66, P823, DOI 10.1021/np020592u
   Robert F, 2006, RNA, V12, P717, DOI 10.1261/rna.2346806
   Ross SA, 2000, J NAT PROD, V63, P501, DOI 10.1021/np980414u
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Sarafrazi N., 2021, Osteoporosis or Low Bone Mass in Older Adults: United States, 2017 2018, DOI DOI 10.15620/CDC:103477
   Sebaugh JL, 2011, PHARM STAT, V10, P128, DOI 10.1002/pst.426
   Shen XY, 1998, J NAT PROD, V61, P1302, DOI 10.1021/np980129a
   Shilabin AG, 2008, J NAT PROD, V71, P1218, DOI 10.1021/np800163u
   Spiess Andrej Nikolai, 2010, BMC Pharmacology, V10, P6, DOI 10.1186/1471 2210 10 6
   Thompson MJ, 2012, CHEMMEDCHEM, V7, P578, DOI 10.1002/cmdc.201200002
   Wang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046945
   Waters AL, 2014, FRONT MAR SCI, V1, DOI 10.3389/fmars.2014.00054
   Yousaf M, 2004, J MED CHEM, V47, P3512, DOI 10.1021/jm030475b
   Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471 2105 7 85
   Zamani M, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0540 7
NR 76
TC 0
Z9 0
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163 3864
EI 1520 6025
J9 J NAT PROD
JI J. Nat. Prod.
PD FEB 21
PY 2024
VL 87
IS 3
BP 560
EP 566
DI 10.1021/acs.jnatprod.3c01097
EA FEB 2024
PG 7
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy
GA LV7K1
UT WOS:001174405900001
PM 38383319
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, YB
   Yang, QC
   Fu, ZY
   Sun, P
   Zhang, T
   Wang, KL
   Li, XY
   Qian, Y
AF Wang, Yanben
   Yang, Qichang
   Fu, Ziyuan
   Sun, Peng
   Zhang, Tan
   Wang, Kelei
   Li, Xinyu
   Qian, Yu
TI Hinokitiol inhibits RANKL induced osteoclastogenesis in vitro and
   prevents ovariectomy induced bone loss in vivo
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Hinokitiol; Osteoclast; RANKL; MAPK; NFATc1
ID BETA THUJAPLICIN; UP REGULATION; DC STAMP; DIFFERENTIATION; FUSION;
   EXPRESSION; OSTEOPOROSIS; MACROPHAGES; MECHANISMS; RECEPTOR
AB Osteoporosis is a metabolic bone loss disease characterized by abnormally excessive osteoclast formation and bone resorption. Identification of natural medicines that can inhibit osteoclastogenesis, bone resorption, and receptor activator of nuclear factor kappa B ligand (RANKL) induced signaling is necessary for improved treatment of osteoporosis. In this study, hinokitiol, a tropolone related compound extracted from the heart wood of several cupressaceous plants, was found to inhibit RANKL induced osteoclast formation and bone resorption in vitro. Hinokitiol inhibited early activation of the ERK, p38, and JNK MAPK pathways, thereby suppressing the activity and expression of downstream factors (c Jun, c Fos, and NFATC1). Consistent with the above in vitro findings, hinokitiol treatment protected against ovariectomy induced bone loss in vivo. Collectively, our results imply that hinokitiol can potentially serve as an effective agent for treating osteoclast induced osteoporosis.
C1 [Wang, Yanben; Yang, Qichang; Fu, Ziyuan; Sun, Peng; Zhang, Tan; Wang, Kelei; Li, Xinyu; Qian, Yu] Zhejiang Univ, Sch Med, Shaoxing Hosp, Dept Orthoped, Shaoxing 312000, Zhejiang, Peoples R China.
   [Wang, Yanben; Fu, Ziyuan; Wang, Kelei; Li, Xinyu] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthoped, Hangzhou 310000, Zhejiang, Peoples R China.
   [Yang, Qichang; Sun, Peng] Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou 325000, Zhejiang, Peoples R China.
   [Yang, Qichang; Sun, Peng] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325000, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Wenzhou Medical University;
   Wenzhou Medical University
RP Qian, Y (通讯作者)，Zhejiang Univ, Sch Med, Shaoxing Hosp, Dept Orthoped,Shaoxing Peoples Hosp, Shaoxing 312000, Zhejiang, Peoples R China.
EM doctor120@hotmail.com
RI Li, Xinyu/IQS 0662 2023; Wang, Kelei/HNQ 2430 2023; Sun,
   Peng/KDO 4243 2024
FU National Natural Science Foundation of China, China [82072467,
   81871801]; Natural Science Foundation of Zhejiang Province, China
   [LQ21H060001]
FX This work was supported by the National Natural Science Foundation of
   China, China (grant numbers 82072467 and 81871801], and the Natural
   Science Foundation of Zhejiang Province, China (grant number
   LQ21H060001).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Byeon SE, 2008, PLANTA MED, V74, P828, DOI 10.1055/s 2008 1074548
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Gambacciani M, 2014, PANMINERVA MED, V56, P115
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hiyoshi T, 2020, ARCH ORAL BIOL, V112, DOI 10.1016/j.archoralbio.2020.104679
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Isono T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240329
   Jakob F, 2015, UNFALLCHIRURG, V118, P925, DOI 10.1007/s00113 015 0085 9
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Nemeth K, 2011, J IMMUNOL, V186, P13, DOI 10.4049/jimmunol.1002483
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Pang MH, 2019, J CELL BIOCHEM, V120, P12382, DOI 10.1002/jcb.28504
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Shih MF, 2012, INT J IMMUNOPATH PH, V25, P39, DOI 10.1177/039463201202500106
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Zhang CC, 2014, J CELL PHYSIOL, V229, P1330, DOI 10.1002/jcp.24553
   Zhang GY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1492 6
NR 42
TC 6
Z9 7
U1 0
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUL
PY 2021
VL 96
AR 107619
DI 10.1016/j.intimp.2021.107619
EA APR 2021
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA SV8KY
UT WOS:000664067800007
PM 33831806
DA 2025 08 17
ER

PT J
AU Liu, LB
   Liu, HY
   Lu, XY
   Yin, ZS
   Zhang, W
   Ye, J
   Xu, YY
   Weng, ZZ
   Luo, J
   Wang, XL
AF Liu, Lubing
   Liu, Huiying
   Lu, Xiaoya
   Yin, Zhengshuai
   Zhang, Wei
   Ye, Jing
   Xu, Yingying
   Weng, Zhenzhen
   Luo, Jun
   Wang, Xiaolei
TI Palladium Based Nanocomposites Remodel Osteoporotic Microenvironment by
   Bone Targeted Hydrogen Enrichment and Zincum Repletion
SO RESEARCH
LA English
DT Article
ID AUTOPHAGY; LYSOSOMES; THERAPY; PH
AB Osteoporosis presents a marked global public health challenge, characterized by deficient osteogenesis and a deteriorating immune microenvironment. Conventional clinical interventions primarily target osteoclast mediated bone damage, yet lack a comprehensive therapeutic approach that balances bone formation and resorption. Herein, we introduce a bone targeted nanocomposite, A Z@Pd(H), designed to address these challenges by integrating diverse functional components. The nanocomposite incorporates internal hydrogen carrying nanozymes, which effectively scavenge multiple reactive oxygen species (ROS) and synergistically engage the autophagy lysosome pathway to accelerate endogenous ROS degradation in macrophages. This mechanism disrupts the vicious cycle of autophagic dysfunction ROS accumulation macrophage inflammation. In addition, external metal organic frameworks release zinc ions (Zn2+) in response to the acidic osteoporotic environment, thereby promoting osteogenesis. In a murine model of osteoporosis, intravenous administration of A Z@Pd(H) leads to preferential accumulation in the femur, thereby remodeling the osteoporotic microenvironment through immune regulation, osteogenesis promotion, and osteoclast inhibition. These findings suggest that this system composed of hydrogen therapy and ion therapy may be a promising candidate for bone targeted comprehensive therapy in osteoporosis.
C1 [Liu, Lubing; Liu, Huiying; Ye, Jing; Luo, Jun] Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Dept Rehabil Med, Nanchang 330006, Peoples R China.
   [Liu, Lubing; Liu, Huiying; Ye, Jing; Luo, Jun] Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Jiangxi Prov Key Lab Precis Cell Therapy, Nanchang 330006, Peoples R China.
   [Liu, Lubing; Lu, Xiaoya; Yin, Zhengshuai; Zhang, Wei; Ye, Jing; Xu, Yingying; Weng, Zhenzhen; Wang, Xiaolei] Nanchang Univ, Inst Translat Med, Natl Engn Res Ctr Bioengn Drugs & Technol, Nanchang 330088, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University
RP Luo, J (通讯作者)，Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Dept Rehabil Med, Nanchang 330006, Peoples R China.; Luo, J (通讯作者)，Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Jiangxi Prov Key Lab Precis Cell Therapy, Nanchang 330006, Peoples R China.; Wang, XL (通讯作者)，Nanchang Univ, Inst Translat Med, Natl Engn Res Ctr Bioengn Drugs & Technol, Nanchang 330088, Peoples R China.
EM wangxiaolei@ncu.edu.cn; luojun1786@163.com
FU Jiangxi Province Key Laboratory of Precision Cell Therapy
   [2024SSY06241]; National Key Research and Development Program of China
   [2020YFC2005800]; National Natural Science Foundation of China
   [82360174, 82360424]; Natural Science Foundation of Jiangxi Province
   [20113BCB22005, 20181BCG42001]; Science and Technology Department
   Project of Jiangxi Province [20224ABC03A02]; Second Affiliated Hospital
   of Nanchang University [2022efyB03]; Key Research and Development
   Program of Jiangxi Province [20212BBG73004]; Interdiscipline Innovation
   Fund Project of Nanchang University [PYJX20230001]; Graduate Innovation
   Special Fund Project of Jiangxi Province [YC2023 B046]; Science and
   Technology Program of Jiangxi Provincial Health Commission [202410028]
FX This work was funded by the Jiangxi Province Key Laboratory of Precision
   Cell Therapy (no. 2024SSY06241 to J.L.), the National Key Research and
   Development Program of China (no. 2020YFC2005800 to J.L.), the National
   Natural Science Foundation of China (no. 82360174 to J.L. and no.
   82360424 to J.Y.), the Natural Science Foundation of Jiangxi Province
   (20113BCB22005 and 20181BCG42001 to J.L.), the Science and Technology
   Department Project of Jiangxi Province (20224ABC03A02 to J.L.), the
   Second Affiliated Hospital of Nanchang University funded projects (grant
   no. 2022efyB03 to J.L.), the Key Research and Development Program of
   Jiangxi Province (20212BBG73004 to X.W.), the Interdiscipline Innovation
   Fund Project of Nanchang University (PYJX20230001 to X.W.), the Graduate
   Innovation Special Fund Project of Jiangxi Province (YC2023 B046 to
   L.L.), and the Science and Technology Program of Jiangxi Provincial
   Health Commission (202410028 to H.L.).
CR Alwazeer D, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5513868
   Bae S, 2023, CELL MOL IMMUNOL, V20, P94, DOI 10.1038/s41423 022 00959 x
   Batoon L, 2021, J BONE MINER RES, V36, P2214, DOI 10.1002/jbmr.4413
   Cadwell K, 2016, NAT REV IMMUNOL, V16, P661, DOI 10.1038/nri.2016.100
   Carnovali M, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12020345
   Chen JY, 2023, NANO ENERGY, V106, DOI 10.1016/j.nanoen.2022.108076
   Chen L, 2023, ACS NANO, V17, P3153, DOI 10.1021/acsnano.2c12440
   Chen SQ, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 43618 z
   Chen ZT, 2016, MATER TODAY, V19, P304, DOI 10.1016/j.mattod.2015.11.004
   Ci Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.506
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Diker Cohen T, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz322
   Ding L, 2022, ACS NANO, V16, P15959, DOI 10.1021/acsnano.2c03422
   Dou C, 2021, BIOACT MATER, V6, P4697, DOI 10.1016/j.bioactmat.2021.04.038
   Fang SH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 020 03357 1
   Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401
   Fu H, 2022, J AM CHEM SOC, V144, P8987, DOI 10.1021/jacs.2c00749
   Gros F, 2023, NAT REV NEPHROL, V19, P366, DOI 10.1038/s41581 023 00692 2
   Hao TS, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 39811 9
   HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0
   Hu KY, 2023, J INFLAMM RES, V16, P3563, DOI 10.2147/JIR.S423819
   Huang SCC, 2014, NAT IMMUNOL, V15, P846, DOI 10.1038/ni.2956
   Kirsten TB, 2020, BRAIN BEHAV IMMUN, V87, P489, DOI 10.1016/j.bbi.2020.01.019
   Koo S, 2023, NAT NANOTECHNOL, V18, DOI 10.1038/s41565 023 01523 y
   Li B, 2023, MATER TODAY, V65, P1, DOI 10.1016/j.mattod.2023.03.024
   Li CY, 2017, ADV MATER, V29, DOI 10.1002/adma.201605754
   Li K, 2023, NANO TODAY, V50, DOI 10.1016/j.nantod.2023.101839
   Li QH, 2023, BIOACT MATER, V29, P251, DOI 10.1016/j.bioactmat.2023.07.011
   Li SY, 2019, ACS NANO, V13, P13382, DOI 10.1021/acsnano.9b06780
   Lyu HC, 2023, BMJ BRIT MED J, V381, DOI 10.1136/bmj 2022 073435
   Marcucci G, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12020373
   Matusiak J, 2023, MATER TODAY, V67, P495, DOI 10.1016/j.mattod.2023.06.008
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Muri J, 2021, NAT REV IMMUNOL, V21, P363, DOI 10.1038/s41577 020 00478 8
   Polyzos SA, 2018, ENDOCRINE, V62, P487, DOI 10.1007/s12020 018 1699 9
   Qi XL, 2023, ADV MATER, V35, DOI 10.1002/adma.202306632
   Qin RX, 2020, RESEARCH CHINA, V2020, DOI 10.34133/2020/4172794
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Ren N, 2022, SMALL, V18, DOI 10.1002/smll.202202485
   Riffelmacher T, 2018, AUTOPHAGY, V14, P199, DOI 10.1080/15548627.2017.1362525
   Saxena Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687037
   Song GC, 2023, RESEARCH CHINA, V6, DOI 10.34133/research.0095
   Sun X, 2019, INT J BIOL MACROMOL, V129, P579, DOI 10.1016/j.ijbiomac.2019.02.022
   Sun Y, 2013, OSTEOPOROSIS INT, V24, P969, DOI 10.1007/s00198 012 2028 4
   Wang J, 2023, AUTOPHAGY, V19, P2409, DOI 10.1080/15548627.2023.2186112
   Wang XJ, 2019, HEPATOLOGY, V69, P545, DOI 10.1002/hep.30215
   Wei H, 2024, RESEARCH CHINA, V7, DOI 10.34133/research.0310
   Wei KL, 2023, ACS NANO, V17, P21539, DOI 10.1021/acsnano.3c06551
   Xie YX, 2023, ACS NANO, V17, P15097, DOI 10.1021/acsnano.3c04328
   Xu M, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202104892
   Yang QH, 2016, ANGEW CHEM INT EDIT, V55, P3685, DOI 10.1002/anie.201510655
   Ye J, 2021, ACS NANO, V15, P13692, DOI 10.1021/acsnano.1c04974
   Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076
   Yuan XY, 2023, CHEM ENG J, V464, DOI 10.1016/j.cej.2023.142679
   Zeng X, 2022, MILITARY MED RES, V9, DOI 10.1186/s40779 022 00383 2
   Zhang Q, 2023, MATER TODAY BIO, V20, DOI 10.1016/j.mtbio.2023.100623
   Zhang ZY, 2020, AUTOPHAGY, V16, P1506, DOI 10.1080/15548627.2019.1688488
   Zhao PH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06630 2
   Zheng LM, 2022, BIOACT MATER, V14, P250, DOI 10.1016/j.bioactmat.2021.11.012
   Zhou J, 2022, AUTOPHAGY, V18, P1240, DOI 10.1080/15548627.2021.1984656
   Zhu XW, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00143 3
NR 61
TC 2
Z9 2
U1 9
U2 13
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2096 5168
EI 2639 5274
J9 RESEARCH CHINA
JI Research
PD DEC 17
PY 2024
VL 7
AR 0540
DI 10.34133/research.0540
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA P6Q2C
UT WOS:001379122700001
PM 39691766
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Ye, TT
   Hong, ZP
   Gong, SQ
   Zhou, XS
   Liu, HB
   Qian, J
   Qu, HB
AF Zhang, Yan
   Ye, Tingting
   Hong, Zhuping
   Gong, Shuqing
   Zhou, Xiangshan
   Liu, Haibin
   Qian, Jing
   Qu, Haibin
TI Pharmacological and transcriptome profiling analyses of Fufang E'jiao
   Jiang during chemotherapy induced myelosuppression in mice
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Myelosuppression; 5 FU; Fufang E'jiao Jiang; RNA Seq; Signaling pathway
ID HEMATOPOIETIC STEM CELLS; EXTRACELLULAR MATRIX; MARROW; IDENTIFICATION
AB Ethnopharmacological relevance: Fufang E'jiao Jiang (FEJ), a famous traditional Chinese medicine formula from "Liangyi Ointment", consists of five crude drugs, Colla corii asini, Radix Ginseng Rubra, Radix Rehmanniae Preparata, Codonopsis pilosula, and Crataegus pinnatifida Bge. It has pronounced functions of qi nourishing and blood activating. Recently, it has been widely used in China as a medication against myelosuppression in cancer treatment.
   Aim of the study: We aimed to investigate the complex mode of action and underlying mechanisms of Fufang E'jiao Jiang (FEJ) regarding its hematopoietic effect.
   Main methods: Mice were divided into 5 groups of control, model, high dose FEJ (HFEJ), medium dose FEJ (MFEJ) and low dose FEJ (LFEJ). After 10 days from the administration, bone marrow cells (BMCs) were extracted for nucleated cells counts, flow cytometry analysis of hematopoietic stem cells (HSCs) population, as well as hematopoietic progenitor cells (HPCs) colony forming unit (CFU) assay. A portion of bone marrow nucleated cells (BMNCs) of MFEJ group were prepared for RNA sequencing (RNA Seq). The transcriptome data were analyzed based on the differentially expressed genes (DEGs). The molecular mechanisms of FEJ were deducted based on the biological processes and protein protein interaction (PPI) network.
   Results: FEJ could significantly increase the percentage of HSCs and the quantities of BFU E and CFU GM in BMNCs. FEJ could stimulate the proliferation of HSC and the differentiation of HPC to all lineages, which may thereby accelerate the recovery of hematopoietic function in myelosuppressive mice. By providing transcriptome profile we highlighted several genes and biological processes that might be applicable for FEJ to treat chemotherapy  induced myelosuppression. GO analysis showed that the co expressed DEGs in FEJ vs model and model vs control group were involved in biological processes including ossification, osteoblast differentiation, bone mineralization and bone development. The KEGG pathway analysis pointed out ECM receptor interaction and PI3K AKT signaling pathway as the most relevant pathways to the function of FEJ on myelosuppression. PPI network showed MMP2 and COL1A1 were the relatively large nodes.
   Conclusion: FEJ has the hematopoietic effect in chemotherapy induced myelosuppression mice. It might be achieved by improving the proliferative capacity of HSCs and the differentiation ability of HPCs. The molecular mode of action of FEJ might be the improvement of the bone marrow microenvironment via ECM receptor interaction, the promoted proliferation of HSC through regulation of PI3K AKT signaling pathway, and the involvement of osteoblasts and osteoblasts. MMP2 and COL1A1 appear to be the key relevant regulatory molecules. These results provide significant insight into the hematopoietic effects of FEJ in myelosuppression and point out novel targets for future validating analyses.
C1 [Zhang, Yan; Ye, Tingting; Hong, Zhuping; Gong, Shuqing; Qian, Jing; Qu, Haibin] Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Yan; Zhou, Xiangshan; Liu, Haibin] Dong E E Jiao Co Ltd, Natl Engn Res Ctr Gelatin Based Tradit Chinese Me, Liaocheng, Shandong, Peoples R China.
C3 Zhejiang University
RP Qian, J; Qu, HB (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou, Zhejiang, Peoples R China.
EM jingqian@zju.edu.cn; quhb@zju.edu.cn
RI QIAN, JING/Q 1447 2017; Liu, Haibin/AGX 9622 2022; Qu,
   Haibin/A 1462 2015; ye, ting/HGC 5924 2022
FU Project for Taishan Industry Leading Talents [2018]; National Key
   Research and Development Program of China [2018YFC1706300]
FX This study was financially supported by the Project for Taishan Industry
   Leading Talents (No.2018) and the National Key Research and Development
   Program of China (2018YFC1706300).
CR Adi YA, 2016, AIP CONF PROC, V1723, DOI 10.1063/1.4945059
   Balakumaran A, 2010, EXPERT REV MOL DIAGN, V10, P465, DOI [10.1586/erm.10.31, 10.1586/ERM.10.31]
   Bethel Monique, 2011, Curr Osteoporos Rep, V9, P96, DOI 10.1007/s11914 011 0048 1
   Broxmeyer HE, 2012, STEM CELLS DEV, V21, P1449, DOI 10.1089/scd.2011.0451
   Carey PJ, 2003, DRUG SAFETY, V26, P691, DOI 10.2165/00002018 200326100 00003
   Challen G. A., 2010, CYTOM PART A, V75, P14
   Chen Hui Hui, 2012, Zhongguo Zhong Yao Za Zhi, V37, P3021
   Cheung F, 2011, NATURE, V480, pS82, DOI 10.1038/480S82a
   Clutter SD, 2005, EXP HEMATOL, V33, P1192, DOI 10.1016/j.exphem.2005.06.022
   Friberg LE, 2003, INVEST NEW DRUG, V21, P183, DOI 10.1023/A:1023573429626
   Gazit R, 2013, STEM CELL REP, V1, P266, DOI 10.1016/j.stemcr.2013.07.004
   Jiang C., 2015, A T CELL ACUTE LYMPH, V13, P1
   Jiao LJ, 2017, SCI REP UK, V7, DOI 10.1038/srep46524
   Kharas MG, 2010, BLOOD, V115, P1406, DOI 10.1182/blood 2009 06 229443
   Kishida Y, 2011, ONCOL LETT, V2, P949, DOI 10.3892/ol.2011.348
   Klamer S, 2014, CELL ADHES MIGR, V8, P563, DOI 10.4161/19336918.2014.968501
   Leiva O, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.6
   Li B., 2011, BMC BIOINFORMATICS, V12, P313
   Li X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00616
   Liu MX, 2014, J ETHNOPHARMACOL, V152, P575, DOI 10.1016/j.jep.2014.02.012
   Mann V, 2001, J CLIN INVEST, V107, P899, DOI 10.1172/JCI10347
   Marquez Curtis LA, 2001, BRIT J HAEMATOL, V115, P595, DOI 10.1046/j.1365 2141.2001.03160.x
   Miyamoto T, 2013, WORLD J ORTHOP, V4, P198, DOI 10.5312/wjo.v4.i4.198
   Nii T, 2015, EXP HEMATOL, V43, P901, DOI 10.1016/j.exphem.2015.06.001
   Qi FH, 2010, BIOSCI TRENDS, V4, P297
   Russell PK, 2012, J MOL ENDOCRINOL, V49, P1, DOI 10.1530/JME 12 0014
   Sawai CM, 2016, IMMUNITY, V45, P597, DOI 10.1016/j.immuni.2016.08.007
   Shen LJ, 2016, J PHARMACEUT BIOMED, V117, P363, DOI 10.1016/j.jpba.2015.09.024
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   Wang SS, 2015, LIFE SCI, V123, P86, DOI 10.1016/j.lfs.2015.01.002
   Worlein JM, 2011, AM J PRIMATOL, V73, P98
   Zhang QY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01253
NR 32
TC 27
Z9 29
U1 3
U2 101
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUN 28
PY 2019
VL 238
AR 111869
DI 10.1016/j.jep.2019.111869
PG 8
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA IL0CS
UT WOS:000476964300028
PM 30978457
DA 2025 08 17
ER

PT J
AU Acharya, TK
   Pal, S
   Ghosh, A
   Kumar, S
   Kumar, S
   Chattopadhyay, N
   Goswami, C
AF Acharya, Tusar Kanta
   Pal, Subhashis
   Ghosh, Arijit
   Kumar, Shamit
   Kumar, Satish
   Chattopadhyay, Naibedya
   Goswami, Chandan
TI TRPV4 regulates osteoblast differentiation and mitochondrial function
   that are relevant for channelopathy
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE mitochondria; channelopathy; bone; genetic disorder; bio mineralization
ID POTENTIAL VANILLOID 4; CALCIUM; OSTEOCLAST; ACTIVATION; SENSE
AB Different ion channels present in the osteoblast regulate the cellular functions including bio mineralization, a process that is a highly stochastic event. Cellular events and molecular signaling involved in such process is poorly understood. Here we demonstrate that TRPV4, a mechanosensitive ion channel is endogenously present in an osteoblast cell line (MC3T3 E1) and in primary osteoblasts. Pharmacological activation of TRPV4 enhanced intracellular Ca2+ level, expression of osteoblast specific genes and caused increased bio mineralization. TRPV4 activation also affects mitochondrial Ca2+ levels and mitochondrial metabolisms. We further demonstrate that different point mutants of TRPV4 induce different mitochondrial morphology and have different levels of mitochondrial translocation, collectively suggesting that TRPV4 mutation induced bone disorders and other channelopathies are mostly due to mitochondrial abnormalities. These findings may have broad biomedical implications.
C1 [Acharya, Tusar Kanta; Ghosh, Arijit; Kumar, Shamit; Kumar, Satish; Goswami, Chandan] HBNI, Natl Inst Sci Educ & Res, Sch Biol Sci, Bhubaneswar, Odisha, India.
   [Acharya, Tusar Kanta; Ghosh, Arijit; Kumar, Shamit; Goswami, Chandan] Homi Bhabha Natl Inst, Training Sch Complex, Mumbai, India.
   [Pal, Subhashis; Chattopadhyay, Naibedya] Council Sci & Ind Res CSIR, Cent Drug Res Inst CDRI, Div Endocrinol, Lucknow, India.
   [Pal, Subhashis; Chattopadhyay, Naibedya] Council Sci & Ind Res CSIR, Cent Drug Res Inst CDRI, Ctr Res Anabol Skeletal Target Hlth & Illness ASTH, Lucknow, India.
   [Chattopadhyay, Naibedya] CSIR Cent Drug Res Inst Campus, AcSIR, Lucknow, India.
C3 Homi Bhabha National Institute; National Institute of Science Education
   & Research (NISER); Homi Bhabha National Institute; Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI); Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Central Drug Research Institute (CDRI); Academy
   of Scientific & Innovative Research (AcSIR)
RP Goswami, C (通讯作者)，HBNI, Natl Inst Sci Educ & Res, Sch Biol Sci, Bhubaneswar, Odisha, India.; Goswami, C (通讯作者)，Homi Bhabha Natl Inst, Training Sch Complex, Mumbai, India.
EM chandan@niser.ac.in
RI ; ACHARYA, TUSAR/GOH 1722 2022; Chattopadhyay, Naibedya/AAF 2058 2019;
   Ghosh, Arijit/AAA 7799 2019; Pal, Subhashis/IXD 3635 2023; Acharya,
   Tusar/GOH 1722 2022
OI Pal, Subhashis/0000 0002 3916 5545; ACHARYA, TUSAR/0000 0001 5545 6994;
   Chattopadhyay, Naibedya/0000 0003 2473 0246; Ghosh,
   Arijit/0000 0002 7910 3170; 
FU NISER; DBT [BT/PR8004/MED/30/988/2013]
FX & nbsp;CG acknowledges funding from NISER and DBT (Govt. India, grant
   number BT/PR8004/MED/30/988/2013). CG and all the authors acknowledge
   all the present and former lab members for supporting this work.
CR Acharya TK, 2023, LIFE SCI, V318, DOI 10.1016/j.lfs.2023.121493
   Acharya TK, 2022, MITOCHONDRION, V67, P38, DOI 10.1016/j.mito.2022.10.001
   Acharya TK, 2022, LIFE SCI, V310, DOI 10.1016/j.lfs.2022.121112
   Acharya TK, 2022, CURR TOP MEMBR, V89, P155, DOI 10.1016/bs.ctm.2022.07.002
   Acharya TK, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 81041 w
   Benedetti MG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4840531
   BROOKES M, 1972, J ANAT, V111, P351
   Bryant SL, 2017, BIOPHYS J, V112, p251A, DOI 10.1016/j.bpj.2016.11.1371
   Camacho N, 2010, AM J MED GENET A, V152A, P1169, DOI 10.1002/ajmg.a.33392
   Cao BR, 2019, J CELL PHYSIOL, V234, P6831, DOI 10.1002/jcp.27432
   Chakraborty R, 2022, ACS OMEGA, V7, P9537, DOI 10.1021/acsomega.1c06915
   Clark AL, 2010, ARTHRITIS RHEUM US, V62, P2973, DOI 10.1002/art.27624
   Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200
   Das R, 2023, BBA BIOMEMBRANES, V1865, DOI 10.1016/j.bbamem.2022.184085
   Das R, 2022, CURR TOP MEMBR, V89, P221, DOI 10.1016/bs.ctm.2022.07.004
   Das R, 2022, BIOCHEM BIOPH RES CO, V611, P172, DOI 10.1016/j.bbrc.2022.04.066
   Das R, 2019, BIOCHEM BIOPH RES CO, V517, P566, DOI 10.1016/j.bbrc.2019.07.042
   Du GL, 2020, EXP BIOL MED, V245, P180, DOI 10.1177/1535370219892601
   Forni MF, 2016, STEM CELLS, V34, P743, DOI 10.1002/stem.2248
   Franco Obregón A, 2018, EUR SPINE J, V27, P2621, DOI 10.1007/s00586 018 5688 8
   Genah S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094585
   Guilak F, 2010, ANN NY ACAD SCI, V1192, P404, DOI 10.1111/j.1749 6632.2010.05389.x
   Guntur AR, 2014, ENDOCRINOLOGY, V155, P1589, DOI 10.1210/en.2013 1974
   Hu Fen, 2019, Biophysics Reports, V5, P254, DOI 10.1007/s41048 019 00100 y
   Jiao D, 2019, CLIN TRANSL GASTROEN, V10, DOI 10.14309/ctg.0000000000000041
   Kumar A, 2016, BIOCHEM BIOPH RES CO, V473, P781, DOI 10.1016/j.bbrc.2016.03.071
   Kumari S, 2015, BIOCHEM BIOPH RES CO, V456, P312, DOI 10.1016/j.bbrc.2014.11.077
   Lakk M, 2021, J LIPID RES, V62, DOI 10.1016/j.jlr.2021.100145
   Leddy HA, 2014, RARE DIS, V2, DOI 10.4161/2167549X.2014.962971
   Lieben Liesbet, 2012, Front Endocrinol (Lausanne), V3, P99, DOI 10.3389/fendo.2012.00099
   Liu C, 2015, BIOCHEM BIOPH RES CO, V460, P22, DOI 10.1016/j.bbrc.2015.02.067
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   McDonald F, 2004, SURG J R COLL SURG E, V2, P63, DOI 10.1016/S1479 666X(04)80048 9
   McNulty AL, 2015, N S ARCH PHARMACOL, V388, P437, DOI 10.1007/s00210 014 1078 x
   Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098
   Nilius B, 2013, EMBO REP, V14, P152, DOI 10.1038/embor.2012.219
   Nishimura H, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2020.100268
   Porwal K, 2017, J NUTR BIOCHEM, V44, P22, DOI 10.1016/j.jnutbio.2017.02.011
   Rendina Ruedy E, 2020, CELL METAB, V31, P219, DOI 10.1016/j.cmet.2019.09.015
   Rizzoli R, 1997, LANCET, V349, pS20, DOI 10.1016/S0140 6736(97)90007 6
   Robinson LJ, 2010, ANN NY ACAD SCI, V1192, P351, DOI 10.1111/j.1749 6632.2009.05219.x
   Siddiqui JA, 2011, OSTEOPOROSIS INT, V22, P3013, DOI 10.1007/s00198 010 1519 4
   Siddiqui JA, 2010, MOL CELL ENDOCRINOL, V323, P256, DOI 10.1016/j.mce.2010.03.024
   Suh J, 2023, CELL METAB, V35, P345, DOI 10.1016/j.cmet.2023.01.003
   Suzuki T, 2013, BONE, V54, P172, DOI 10.1016/j.bone.2013.01.001
   Verma P, 2010, CHANNELS, V4, P319, DOI 10.4161/chan.4.4.12905
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 48
TC 11
Z9 12
U1 1
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JUN 12
PY 2023
VL 11
AR 1066788
DI 10.3389/fcell.2023.1066788
PG 11
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA K9PX5
UT WOS:001019693200001
PM 37377733
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pal, S
   Rashid, M
   Singh, SK
   Porwal, K
   Singh, P
   Mohamed, R
   Gayen, JR
   Wahajuddin, M
   Chattopadhyay, N
AF Pal, Subhashis
   Rashid, Mamunur
   Singh, Sandeep Kumar
   Porwal, Konica
   Singh, Priya
   Mohamed, Riyazuddin
   Gayen, Jiaur R.
   Wahajuddin, Muhammad
   Chattopadhyay, Naibedya
TI Skeletal restoration by phosphodiesterase 5 inhibitors in osteopenic
   mice: Evidence of osteoanabolic and osteoangiogenic effects of the drugs
SO BONE
LA English
DT Article
DE Phosphodiesterase inhibition; Osteogenic; Angiogenic; Fracture
ID ENDOTHELIAL GROWTH FACTOR; BONE FORMATION; ERECTILE DYSFUNCTION; PDE5
   INHIBITORS; PROTEIN KINASE; NITRIC OXIDE; VEGF; OSTEOBLAST;
   ANGIOGENESIS; SILDENAFIL
AB Phosphodiesterases (PDEs) hydrolyze cyclic nucleotides and thereby regulate diverse cellular functions. The reports on the skeletal effects of PDE inhibitors are conflicting. Here, we screened 17 clinically used non xanthine PDE inhibitors (selective and non selective) using mouse calvarial osteoblasts (MCO) where the readout was osteoblast differentiation. From this screen, we identified sildenafil and vardenafil (both PDE5 inhibitors) having the least osteogenic EC50. Both drugs significantly increased vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) expressions in MCO and the nitric oxide synthase inhibitor L NAME completely blocked VEGF expression induced by these drugs. Sunitinib, a tyrosine receptor kinase inhibitor that also blocks VEGFR2 blocked sildenafil /vardenafil induced osteoblast differentiation. At half of their human equivalent doses, i.e. 6.0 mg/kg sildenafil and 2.5 mg/kg vardenafil, the maximum bone marrow level of sildenafil was 32% and vardenafil was 21% of their blood levels. At these doses, both drugs enhanced bone regeneration at the femur osteotomy site and completely restored bone mass, microarchitecture, and strength in OVX mice. Furthermore, both drugs increased surface referent bone formation and serum bone formation marker (P1NP) without affecting the resorption marker (CTX 1). Both drugs increased the expression of VEGF and VEGFR2 in bones and osteoblasts and increased skeletal vascularity. Sunitinib completely blocked the bone restorative and vascular effects of sildenafil and vardenafil in OVX mice. Taken together, our study suggested that sildenafil and vardenafil at half of their adult human doses completely reversed osteopenia in OVX mice by an osteogenic mechanism that was associated with enhanced skeletal vascularity.
C1 [Pal, Subhashis; Porwal, Konica; Singh, Priya; Chattopadhyay, Naibedya] Council Sci & Ind Res CSIR, Cent Drug Res Inst CDRI, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [Rashid, Mamunur; Singh, Sandeep Kumar; Mohamed, Riyazuddin; Gayen, Jiaur R.; Wahajuddin, Muhammad] CDRI CSIR, Pharmaceut & Pharmacokinet Div, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI)
RP Chattopadhyay, N (通讯作者)，CSIR Cent Drug Res Inst, Endocrinol Div, Lucknow 226031, Uttar Pradesh, India.
EM n_chattopadhyay@cdri.res.in
RI Chattopadhyay, Naibedya/AAQ 3213 2021; Rashid, Mamunur/AAQ 1623 2021;
   Pal, Subhashis/IXD 3635 2023;   , Wahajuddin/B 4413 2010; Singh,
   Sandeep/GXZ 6801 2022
OI Chattopadhyay, Naibedya/0000 0003 2473 0246; Pal,
   Subhashis/0000 0002 3916 5545; Mohammed, Riyazuddin/0000 0002 1373 2222;
   Rashid, Mamunur/0000 0003 3122 2784; Gayen, Jiaur/0000 0001 7703 9307;
   Singh, Dr Sandeep Kumar/0000 0001 7790 2350; Porwal,
   Konica/0000 0002 6447 4681; 
FU Council of Scientific and Industrial Research, India
FX Council of Scientific and Industrial Research, India.
CR Aicher A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004879
   Alp HH, 2017, EXP BIOL MED, V242, P1051, DOI 10.1177/1535370217703352
   Alves H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026678
   Aversa A, 2010, WORLD J DIABETES, V1, P3, DOI 10.4239/wjd.v1.i1.3
   Basson R, 2000, J UROLOGY, V163, P888, DOI 10.1016/S0022 5347(05)67828 7
   Bellows CG, 2001, J BONE MINER RES, V16, P1983, DOI 10.1359/jbmr.2001.16.11.1983
   Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5
   Berman LA, 2001, J SEX MARITAL THER, V27, P427, DOI 10.1080/713846821
   Bhattacharyya S, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109207
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bischoff E, 2004, INT J IMPOT RES, V16, pS34, DOI 10.1038/sj.ijir.3901213
   Boswell Smith V, 2006, BRIT J PHARMACOL, V147, pS252, DOI 10.1038/sj.bjp.0706495
   Butrous Ghazwan, 2014, Glob Cardiol Sci Pract, V2014, P257, DOI 10.5339/gcsp.2014.42
   Chen JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116549
   DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Esbrit P, 2000, J AM SOC NEPHROL, V11, P1085, DOI 10.1681/ASN.V1161085
   Farahnak P, 2010, CLIN MED INSIGHTS EN, V3, P37
   Feliers D, 2005, KIDNEY INT, V68, P1648, DOI 10.1111/j.1523 1755.2005.00575.x
   Foresta Carlo, 2010, Current Drug Delivery, V7, P274, DOI 10.2174/156720110793360595
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Ghiadoni L, 2008, CURR HYPERTENS REP, V10, P52, DOI 10.1007/s11906 008 0011 4
   Gong Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.510
   Hagiwara Hiromi, 1996, American Journal of Physiology, V270, pC1311
   Haider HK, 2010, AM J PHYSIOL HEART C, V299, pH1395, DOI 10.1152/ajpheart.00437.2010
   Iwamoto J, 2006, YONSEI MED J, V47, P157, DOI 10.3349/ymj.2006.47.2.157
   Jacobsen KA, 2008, J BONE MINER RES, V23, P596, DOI 10.1359/JBMR.080103
   Joshua J, 2014, ENDOCRINOLOGY, V155, P4720, DOI 10.1210/en.2014 1343
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Loran OB, 2009, J SEX MED, V6, P2826, DOI 10.1111/j.1743 6109.2009.01428.x
   Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925 4773(01)00601 3
   Maes C, 2004, J CLIN INVEST, V113, P188, DOI 10.1172/JCI200419383
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361
   Mancini L, 2000, BIOCHEM BIOPH RES CO, V274, P477, DOI 10.1006/bbrc.2000.3164
   Mayr Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756 3282(01)00690 1
   MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240
   Nichols DJ, 2002, BRIT J CLIN PHARMACO, V53, p5S, DOI 10.1046/j.0306 5251.2001.00027.x
   Pagliara F, 2010, ADV SPAT SCI, P1, DOI 10.1007/978 3 642 12788 5_1
   Pal S, 2019, CALCIFIED TISSUE INT, V105, P294, DOI 10.1007/s00223 019 00567 4
   Pal S, 2019, BIOCHEM PHARMACOL, V164, P34, DOI 10.1016/j.bcp.2019.03.024
   Pal S, 2019, BONE, V123, P28, DOI 10.1016/j.bone.2019.03.010
   Pal S, 2019, J ETHNOPHARMACOL, V235, P8, DOI 10.1016/j.jep.2019.01.029
   Pal S, 2016, TOXICOL APPL PHARM, V295, P12, DOI 10.1016/j.taap.2016.02.002
   Porwal K, 2019, TOXICOL SCI, V172, P167, DOI 10.1093/toxsci/kfz172
   Pullamsetti SS, 2011, CIRCULATION, V123, P1194, DOI 10.1161/CIRCULATIONAHA.110.941484
   Ramdani G, 2018, J ENDOCRINOL, V238, P203, DOI 10.1530/JOE 18 0286
   Rangaswami H, 2009, J BIOL CHEM, V284, P14796, DOI 10.1074/jbc.M806486200
   Roskoski R, 2007, BIOCHEM BIOPH RES CO, V356, P323, DOI 10.1016/j.bbrc.2007.02.156
   Sivaraj KK, 2016, DEVELOPMENT, V143, P2706, DOI 10.1242/dev.136861
   Stark S, 2001, EUR UROL, V40, P181, DOI 10.1159/000049770
   Steers William D, 2002, Rev Urol, V4 Suppl 3, pS17
   Swarnkar G, 2012, BRIT J PHARMACOL, V165, P1526, DOI 10.1111/j.1476 5381.2011.01637.x
   Takahiro R, 2015, BIOL PHARM BULL, V38, P58, DOI 10.1248/bpb.b14 00566
   Tripathi JK, 2015, BIOMATERIALS, V56, P92, DOI 10.1016/j.biomaterials.2015.03.046
   Turko IV, 1999, MOL PHARMACOL, V56, P124, DOI 10.1124/mol.56.1.124
   Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877
   Vogt MT, 1997, J BONE MINER RES, V12, P283, DOI 10.1359/jbmr.1997.12.2.283
   Wakabayashi S, 2002, J BONE MINER RES, V17, P249, DOI 10.1359/jbmr.2002.17.2.249
   Yang YQ, 2012, INT J ORAL SCI, V4, P64, DOI 10.1038/ijos.2012.33
   Yao W., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P119
   Zelzer E, 2002, DEVELOPMENT, V129, P1893
NR 62
TC 22
Z9 23
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2020
VL 135
AR 115305
DI 10.1016/j.bone.2020.115305
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LJ3LI
UT WOS:000530069000002
PM 32126313
DA 2025 08 17
ER

PT J
AU Ma, Y
   Nyman, JS
   Tao, HA
   Moss, HH
   Yang, XL
   Elefteriou, F
AF Ma, Yun
   Nyman, Jeffry S.
   Tao, Huan
   Moss, Heather H.
   Yang, Xiangli
   Elefteriou, Florent
TI β2 Adrenergic Receptor Signaling in Osteoblasts Contributes to the
   Catabolic Effect of Glucocorticoids on Bone
SO ENDOCRINOLOGY
LA English
DT Article
ID BETA ADRENERGIC RECEPTORS; SYMPATHETIC NERVOUS SYSTEM; MESSENGER RNA
   LEVELS; STEROID HORMONE RECEPTORS; INDUCED OSTEOPOROSIS; CELL LINE;
   BETA(2) ADRENERGIC RECEPTORS; OVARIECTOMIZED RATS; HIP/FEMUR FRACTURE;
   MINERAL DENSITY
AB The sympathetic nervous system is a physiological regulator of bone homeostasis. Autonomic nerves are indeed present in bone, bone cells express the beta 2 adrenergic receptors (beta 2AR), and pharmacological or genetic disruption of sympathetic outflow to bone induces bone gain in rodents. These recent findings implied that conditions that affect beta 2AR signaling in osteoblasts and/or sympathetic drive to bone may contribute to bone diseases. In this study, we show that dexamethasone stimulates the expression of the beta 2AR in differentiated primary calvarial osteoblasts, as measured by an increase in Adr beta 2 mRNA and beta 2AR protein level after short term dexamethasone treatment. Isoproterenol induced cAMP accumulation and the expression of the beta 2AR target gene Rankl were also significantly increased after dexamethasone pretreatment, indicating that dexamethasone promotes the responsiveness of differentiated osteoblasts to adrenergic stimulation. These in vitro results led to the hypothesis that glucocorticoid induced bone loss, provoked by increased endogenous or high dose exogenous glucocorticoids given for the treatment of inflammatory diseases, might, at least in part, be mediated by increased sensitivity of bone forming cells to the tonic inhibitory effect of sympathetic nerves on bone formation or their stimulatory effect on bone resorption. Supporting this hypothesis, both pharmacological and genetic beta 2AR blockade in mice significantly reduced the bone catabolic effect of high dose prednisolone in vivo. This study emphasizes the importance of sympathetic nerves in the regulation of bone homeostasis and indicates that this neuroskeletal signaling axis can be modulated by hormones or drugs and contribute to enhance pathological bone loss. (Endocrinology 152: 1412 1422, 2011)
C1 [Ma, Yun; Tao, Huan; Moss, Heather H.; Yang, Xiangli; Elefteriou, Florent] Vanderbilt Univ, Dept Med, Med Ctr, Nashville, TN 37232 USA.
   [Nyman, Jeffry S.] Vanderbilt Univ, Dept Orthopaed & Rehabil, Med Ctr, Nashville, TN 37232 USA.
   [Nyman, Jeffry S.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN 37212 USA.
C3 Vanderbilt University; Vanderbilt University; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Tennessee Valley
   Healthcare System
RP Elefteriou, F (通讯作者)，Vanderbilt Univ, Dept Med, Med Ctr, 2215 Garland Ave,MRB 4,Room 1225E, Nashville, TN 37232 USA.
EM florent.elefteriou@vanderbilt.edu
RI ; Elefteriou, Florent/P 2586 2017; Nyman, Jeffry/L 5736 2013; Ma,
   Yun/HRD 3253 2023
OI Nyman, Jeffry/0000 0001 7403 7605; Elefteriou,
   Florent/0000 0002 2972 5633; Elefteriou, Xiangli/0000 0002 2333 8747; ,
   Yun/0000 0003 2122 3695
FU National Institutes of Health/National Institute of Diabetes and
   Digestive and Kidney Diseases [DK074994 01]
FX This work was supported by Grant DK074994 01 from the National
   Institutes of Health/National Institute of Diabetes and Digestive and
   Kidney Diseases.
CR Adcock I M, 2000, Monaldi Arch Chest Dis, V55, P256
   Aksoy MO, 2001, AM J PHYSIOL LUNG C, V281, pL1271, DOI 10.1152/ajplung.2001.281.5.L1271
   BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092 8674(95)90201 5
   Bin W, 2001, AM J PHYSIOL LUNG C, V280, pL675, DOI 10.1152/ajplung.2001.280.4.L675
   Bonnet N, 2008, J CELL PHYSIOL, V217, P819, DOI 10.1002/jcp.21564
   Bonnet N, 2007, J APPL PHYSIOL, V103, P524, DOI 10.1152/japplphysiol.01319.2006
   Bonnet N, 2006, J PHARMACOL EXP THER, V318, P1118, DOI 10.1124/jpet.106.105437
   Bonnet N, 2007, J BONE MINER RES, V22, P578, DOI 10.1359/JBMR.070117
   Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   CHENG JB, 1980, ENDOCRINOLOGY, V107, P1646, DOI 10.1210/endo 107 5 1646
   COLLINS S, 1988, J BIOL CHEM, V263, P9067
   Cooper MS, 2004, CLIN SCI, V107, P111, DOI 10.1042/CS20040070
   Cornett LE, 1998, MOL PHARMACOL, V54, P1016, DOI 10.1124/mol.54.6.1016
   DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460 2075.1987.tb04800.x
   Dangel V, 1996, BIOCHEM J, V317, P925, DOI 10.1042/bj3170925
   de Vries F, 2007, CALCIFIED TISSUE INT, V80, P69, DOI 10.1007/s00223 006 0213 1
   de Vries F, 2007, PHARMACOEPIDEM DR S, V16, P612, DOI 10.1002/pds.1318
   DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995
   Espina B, 2008, J CELL PHYSIOL, V215, P488, DOI 10.1002/jcp.21335
   FEVE B, 1990, J BIOL CHEM, V265, P16343
   Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028
   Gatehouse J, 1995, Methods Mol Biol, V49, P229
   HADCOCK JR, 1989, J BIOL CHEM, V264, P19928
   Henderson N. Kathryn, 1996, Current Opinion in Rheumatology, V8, P365, DOI 10.1097/00002281 199607000 00015
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hulley PA, 1998, ENDOCRINOLOGY, V139, P2423, DOI 10.1210/en.139.5.2423
   Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822
   Jilka RL, 2007, J BONE MINER RES, V22, P1492, DOI 10.1359/JBMR.070518
   Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092 8674(00)81177 0
   Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Lane NE, 2010, ANN NY ACAD SCI, V1192, P81, DOI 10.1111/j.1749 6632.2009.05228.x
   LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003 4819 112 5 352
   MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084
   MALBON CC, 1988, BIOCHEM BIOPH RES CO, V154, P676, DOI 10.1016/0006 291X(88)90192 1
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marenzana M, 2007, BONE, V41, P206, DOI 10.1016/j.bone.2007.04.184
   Marzluff W F Jr, 1978, Methods Cell Biol, V19, P317
   MARZLUFF WF, 1974, BIOCHEMISTRY US, V13, P3689, DOI 10.1021/bi00715a011
   Meisinger C, 2007, OSTEOPOROSIS INT, V18, P1189, DOI 10.1007/s00198 007 0354 8
   NAKADA MT, 1989, BIOCHEM J, V260, P53, DOI 10.1042/bj2600053
   NORRIS JS, 1987, MOL CELL BIOCHEM, V74, P21
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Pasco JA, 2004, J BONE MINER RES, V19, P19, DOI 10.1359/JBMR.0301214
   Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756 3282(02)00687 7
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Rehman Q, 2003, MED PEDIATR ONCOL, V41, P212, DOI 10.1002/mpo.10339
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Reid IR, 2005, J CLIN ENDOCR METAB, V90, P5212, DOI 10.1210/jc.2005 0573
   Rejnmark L, 2006, J HYPERTENS, V24, P581, DOI 10.1097/01.hjh.0000203845.26690.cb
   Rejnmark L, 2004, CALCIFIED TISSUE INT, V75, P365, DOI 10.1007/s00223 004 0222 x
   RODAN SB, 1986, ENDOCRINOLOGY, V118, P2510, DOI 10.1210/endo 118 6 2510
   Sato T, 2010, J PHARMACOL EXP THER, V334, P99, DOI 10.1124/jpet.110.167643
   Schlienger RG, 2004, JAMA J AM MED ASSOC, V292, P1326, DOI 10.1001/jama.292.11.1326
   Silva JE, 2008, THYROID, V18, P157, DOI 10.1089/thy.2007.0252
   Sivagurunathan S, 2005, J BONE MINER RES, V20, P390, DOI 10.1359/JBMR.041233
   SMALE ST, 2009, NUCL RUN ON ASSAY
   Stellato Cristiana, 2004, Proc Am Thorac Soc, V1, P255, DOI 10.1513/pats.200402 015MS
   Swanson C, 2006, ENDOCRINOLOGY, V147, P3613, DOI 10.1210/en.2005 0717
   TAKAHASHI H, 1991, BRIT J DERMATOL, V124, P341, DOI 10.1111/j.1365 2133.1991.tb00594.x
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Ton FN, 2005, J BONE MINER RES, V20, P464, DOI 10.1359/JBMR.041125
   TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459
   Turker S, 2006, CLIN ORTHOP RELAT R, P73, DOI 10.1097/01.blo.0000200242.52802.6d
   Walsh S, 2001, RHEUMATOLOGY, V40, P74, DOI 10.1093/rheumatology/40.1.74
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   Wiens M, 2006, J INTERN MED, V260, P350, DOI 10.1111/j.1365 2796.2006.01695.x
   Yao W, 2008, ARTHRITIS RHEUM, V58, P3485, DOI 10.1002/art.23954
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   ZHONG HY, 1993, MOL PHARMACOL, V44, P1085
NR 74
TC 64
Z9 77
U1 0
U2 5
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD APR
PY 2011
VL 152
IS 4
BP 1412
EP 1422
DI 10.1210/en.2010 0881
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 739EM
UT WOS:000288696300023
PM 21266510
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Yeh, HS
   Berenson, JR
AF Yeh, Howard S.
   Berenson, James R.
TI Treatment for myeloma bone disease
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Proceedings Paper
CT Conference on Advances in Treating Metastatic Bone Cancer
CY OCT 28 29, 2005
CL Cambridge, MA
ID ADVANCED MULTIPLE MYELOMA; HEPATOCYTE GROWTH FACTOR;
   TUMOR NECROSIS FACTOR; ZOLEDRONIC ACID; DOUBLE BLIND; IN VITRO;
   COMPRESSION FRACTURES; MONOCLONAL GAMMOPATHY; BIOCHEMICAL MARKERS;
   OSTEOLYTIC LESIONS
AB Multiple myeloma,(MM) is a B cell malignancy characterized,by, enhanced,bone loss commonly associated with diffuse osteopenia, focal lytic lesions, pathologic fractures; hypercalcemia and bony pain. Bone destruction MM results from asynchronous bone turnover wherein increased in osteoclastic bone resorption is not accompanied by a comparable increase in bone formation. Consequently patients with MM frequently require radiation therapy, surgery, and analgesic meditations. The recent development of minimally invasive surgical procedures such as kyphoplasty allows patients with myeloma with vertebral compression fractures to have immediate improvement in their quality of life with shorter hospital stays. Bisphosphonates are specific inhibitors of osteoclastic activity, and these agents have been evaluated in patients with MM with bone disease during the past 15 years. Monthly i.v. infusions of their pamidronate or zoledronic acid have reduced the skeletal complications among patients with MM and are now a mainstay of myeloma therapy. Orally administered bisphosphonates, in contrast, have shown little ability to slow the development of skeletal complications in these patients. Although preclinical studies suggest that nitrogen containing bisphosphonates have potent antitumor effects clinical trials will be necessary, probably at higher doses given more slowly to establish their possible antitumor effects clinically. Moreover recent advances in the use of bone seeking radiopharmaceutical make these attractive therapeutic candidates to combine with bisphosphonates or radiosensitizing drugs e.g. bortezomib) to achieve a synergistic effect. As our understanding of the pathophysiology of myeloma bone disease continues to grow, new target therapies will continue to energy, offering new and more advanced options for the management of myeloma bone disease.
C1 Inst Myeloma & Bone Canc Res, W Hollywood, CA 90069 USA.
RP Berenson, JR (通讯作者)，Inst Myeloma & Bone Canc Res, 9201 W Sunset Blvd,Suite 300, W Hollywood, CA 90069 USA.
EM jberenson@imbcr.org
CR Abildgaard N, 1997, BRIT J HAEMATOL, V96, P103, DOI 10.1046/j.1365 2141.1997.8672495.x
   Abildgaard N, 2003, BRIT J HAEMATOL, V120, P235, DOI 10.1046/j.1365 2141.2003.04050.x
   ADAMIETZ IA, 1991, RADIOTHER ONCOL, V20, P111, DOI 10.1016/0167 8140(91)90144 6
   Alexandrakis MG, 2003, HEMATOL ONCOL, V21, P17, DOI 10.1002/hon.700
   Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   Barr JD, 2002, SPINE, V27, P2178, DOI 10.1097/00007632 200210010 00019
   BELCH AR, 1991, J CLIN ONCOL, V9, P1397, DOI 10.1200/JCO.1991.9.8.1397
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998
   BOSCH A, 1988, INT J RADIAT ONCOL, V15, P1363, DOI 10.1016/0360 3016(88)90232 5
   Brincker H, 1998, BRIT J HAEMATOL, V101, P280, DOI 10.1046/j.1365 2141.1998.00695.x
   Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.E04 12 1117
   Catell D, 1998, INT J RADIAT ONCOL, V40, P117, DOI 10.1016/S0360 3016(97)00558 0
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104
   Choi SJ, 2000, BLOOD, V96, P671
   COZZOLINO F, 1989, BLOOD, V74, P380
   DEDONK NWC, 2005, CLIN CANCER RES, V11, P429
   Dispenzieri A, 2005, LEUKEMIA, V19, P118, DOI 10.1038/sj.leu.2403575
   Dudeney S, 2002, J CLIN ONCOL, V20, P2382, DOI 10.1200/JCO.2002.09.097
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Elomaa I, 1996, EUR J CANCER, V32A, P1166, DOI 10.1016/0959 8049(95)00653 2
   Fournier P, 2002, CANCER RES, V62, P6538
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   GARRETT IR, 1987, NEW ENGL J MED, V317, P526, DOI 10.1056/NEJM198708273170902
   GILES FJ, 1992, EUR J CANCER, V28A, P1392, DOI 10.1016/0959 8049(92)90527 9
   Giralt S, 2003, BLOOD, V102, P2684, DOI 10.1182/blood 2002 10 3250
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Goel A, 2005, EXP HEMATOL, V33, P784, DOI 10.1016/j.exphem.2005.04.005
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Greipp P, 2001, BLOOD, V98, p775A
   Healey John H., 2000, Cancer, V88, P2940, DOI 10.1002/1097 0142(20000615)88:12+<2940::AID CNCR10>3.0.CO;2 W
   Heim ME, 1995, ONKOLOGIE, V18, P439
   Hjertner O, 1999, BLOOD, V94, P3883
   Hoffman RM, 2005, J GEN INTERN MED, V20, P55
   IULIANO F, 2004, J CLIN ONCOL 2004 S
   Jensen ME, 1997, AM J NEURORADIOL, V18, P1897
   KAWANO M, 1989, BLOOD, V73, P2145
   KYLE RA, 1975, MAYO CLIN PROC, V50, P29
   KYLE RA, 1975, NEW ENGL J MED, V293, P1334, DOI 10.1056/NEJM197512252932602
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lacy MQ, 1999, BLOOD, V93, P300, DOI 10.1182/blood.V93.1.300.401k36_300_305
   LAHTINEN R, 1992, LANCET, V340, P1049, DOI 10.1016/0140 6736(92)93075 X
   Lecouvet F, 1997, BRIT J HAEMATOL, V96, P743, DOI 10.1046/j.1365 2141.1997.d01 2108.x
   Lieberman I, 2003, CLIN ORTHOP RELAT R, pS176, DOI 10.1097/01.blo.0000093841.72468.a8
   Lieberman IH, 2001, SPINE, V26, P1631, DOI 10.1097/00007632 200107150 00026
   Maerevoet M, 2005, NEW ENGL J MED, V353, P100
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   MAN Z, 1990, LANCET, V335, P663, DOI 10.1016/0140 6736(90)90452 B
   McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317
   Melton LJ, 2004, J BONE MINER RES, V19, P25, DOI 10.1359/JBMR.0301212
   Menssen HD, 2002, J CLIN ONCOL, V20, P2353, DOI 10.1200/JCO.2002.02.032
   MIRELS H, 1989, CLIN ORTHOP RELAT R, V249, P256
   MUNDY GR, 1991, BONE, V12, pS1, DOI 10.1016/8756 3282(91)90057 P
   MUNDY GR, 1986, SEMIN ONCOL, V13, P291
   Nawawi H, 1996, CLIN CHIM ACTA, V253, P61, DOI 10.1016/0009 8981(96)06334 6
   Ochiai N, 2005, LEUKEMIA LYMPHOMA, V46, P1619, DOI 10.1080/10428190500221223
   Ochiai N, 2005, INT J HEMATOL, V82, P243, DOI 10.1532/IJH97.05049
   OSHIMA T, 2005, BLOOD
   Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood 2002 12 3905
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   PUROHIT OP, 1994, BRIT J CANCER, V70, P554, DOI 10.1038/bjc.1994.344
   RADL J, 1985, CANCER AM CANCER SOC, V55, P1030, DOI 10.1002/1097 0142(19850301)55:5<1030::AID CNCR2820550518>3.0.CO;2 Y
   Roodman GD, 2004, BLOOD CELL MOL DIS, V32, P290, DOI 10.1016/j.bcmd.2004.01.001
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   ROSTOM AY, 1988, HEMATOL ONCOL, V6, P193, DOI 10.1002/hon.2900060221
   ROUX C, 1994, BONE, V15, P41, DOI 10.1016/8756 3282(94)90890 7
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Savage AD, 1996, BLOOD, V88, P409
   Shipman CM, 2003, CANCER RES, V63, P912
   Shipman CM, 1998, CANCER RES, V58, P5294
   Sordillo EM, 2003, CANCER AM CANCER SOC, V97, P802, DOI 10.1002/cncr.11134
   Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood 2002 04 1190
   STASHENKO P, 1987, J IMMUNOL, V138, P1464
   SUZUKI A, 1994, AM J HEMATOL, V45, P88, DOI 10.1002/ajh.2830450115
   Takahashi R, 2001, LEUKEMIA RES, V25, P77, DOI 10.1016/S0145 2126(00)00087 4
   Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Van Poznak CH, 2004, BREAST CANCER RES TR, V88, pS131
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 83
TC 33
Z9 39
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2006
VL 12
IS 20
SU S
BP 6279S
EP 6284S
DI 10.1158/1078 0432.CCR 06 0681
PN 2
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Oncology
GA 099AC
UT WOS:000241563900013
PM 17062714
DA 2025 08 17
ER

PT J
AU Liu, CX
   Zhao, MD
   Chen, JY
   Xu, LW
   Wang, KY
   Li, GY
AF Liu, Chunxiao
   Zhao, Mengdi
   Chen, Jingyue
   Xu, Liwen
   Wang, Kaiying
   Li, Guangyu
TI Nodakenin alleviates ovariectomy induced osteoporosis by modulating
   osteoblastogenesis and osteoclastogenesis
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Nodakenin; Osteoporosis; Osteoclastogenesis; Osteoblast formation
ID MESENCHYMAL STEM CELLS; NF KAPPA B; OSTEOGENIC DIFFERENTIATION; BONE;
   AKT; INHIBITION; MODEL; RANK; MICE
AB Osteoporosis, a systemic bone disease defined by decreased bone mass and deterioration of bone microarchitecture, is becoming a global concern. Nodakenin (NK) is a furanocoumarin like compound isolated from the traditional Chinese medicine Radix Angelicae biseratae (RAB). NK has been reported to have various pharmacological activities, but osteoporosis has not been reported to be affected by NK. In this study, we used network pharmacology, molecular docking and molecular dynamics simulation techniques to identify potential targets and pathways of NK in osteoporosis. We found that NK treatment significantly promoted osteogenic differentiation of BMSCs while activating the PI3K/AKT/mTOR signalling pathway by measuring alkaline phosphatase activity and the expression of various osteogenic markers. In contrast, LY294002, an inhibitor of PI3K, reversed these changes and inhibited the osteogenic differentiation enabling effect of NK. Meanwhile, prevent the Akt and NF kappa B signalling pathways by down regulating c Src and TRAF6 thereby effectively inhibiting RANKL induced osteoclastogenesis. In addition, oral administration of NK to mice significantly elevated bone mass and ameliorated ovariectomized (OVX) mediated bone microarchitectural disorders. In conclusion, these data suggest that NK attenuates OVX induced bone loss by enhancing osteogenesis and inhibiting osteoclastogenesis.
C1 [Liu, Chunxiao; Chen, Jingyue; Xu, Liwen; Wang, Kaiying] Chinese Acad Agr Sci, Inst Special Anim & Plant Sci, Changchun, Peoples R China.
   [Liu, Chunxiao; Zhao, Mengdi; Li, Guangyu] Qingdao Agr Univ, Coll Anim Sci & Technol, Qingdao, Peoples R China.
   [Zhao, Mengdi] Jilin Agr Univ, Coll Anim Sci & Technol, Changchun, Peoples R China.
   [Li, Guangyu] Qingdao Agr Univ, Coll Anim Sci & Technol, 700 Changcheng St, Qingdao 266109, Peoples R China.
C3 Chinese Academy of Agricultural Sciences; Institute of Special Animal &
   Plant Sciences, CAAS; Qingdao Agricultural University; Jilin
   Agricultural University; Qingdao Agricultural University
RP Li, GY (通讯作者)，Qingdao Agr Univ, Coll Anim Sci & Technol, 700 Changcheng St, Qingdao 266109, Peoples R China.
EM tcslgy@126.com
RI Wang, Kai/H 4361 2011
OI Liu, Chunxiao/0000 0002 1465 9207
FU Start up Fund for Scientific Research of High level Talents of Qingdao
   Agricultural University [1121021]; Shandong Modern Agricultural
   Technology & Industry System [SDAIT 21 01]
FX This study was funded by the Start up Fund for Scientific Research of
   High level Talents of Qingdao Agricultural University (1121021) and
   Shandong Modern Agricultural Technology & Industry System (SDAIT 21 01)
   to Guangyu Li.
CR Berry SD, 2019, JAMA INTERN MED, V179, P1103, DOI 10.1001/jamainternmed.2019.0688
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chapurlat R, 2020, J BONE MINER RES, V35, P833, DOI 10.1002/jbmr.3924
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Colman EG, 2003, J BONE MINER RES, V18, P1125, DOI 10.1359/jbmr.2003.18.6.1125
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204
   Gao Q, 2015, NEUROCHEM RES, V40, P1438, DOI 10.1007/s11064 015 1612 3
   Gopinath V, 2023, MED CLIN N AM, V107, P213, DOI 10.1016/j.mcna.2022.10.013
   Gu XH, 2018, J CELL BIOCHEM, V119, P1041, DOI 10.1002/jcb.26272
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Hao F, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2158971
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Huang M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.783322
   Jin BR, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13083
   Kim BJ, 2018, J CLIN INVEST, V128, P1429, DOI 10.1172/JCI91086
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li B, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.824117
   Li JC, 2020, J CELL MOL MED, V24, P9752, DOI 10.1111/jcmm.15539
   Liao Y, 2021, NEPHROLOGY, V26, P78, DOI 10.1111/nep.13781
   Lim JY, 2021, PHYTOMEDICINE, V81, DOI 10.1016/j.phymed.2020.153411
   LoRusso PM, 2016, J CLIN ONCOL, V34, P3803, DOI 10.1200/JCO.2014.59.0018
   Luo GM, 2017, AM J TRANSL RES, V9, P2077
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Park JH, 2017, MOL CELLS, V40, P706
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Rim HK, 2012, J PHARMACOL EXP THER, V342, P654, DOI 10.1124/jpet.112.194613
   Shi ZG, 2015, J PHYSIOL LONDON, V593, P1633, DOI 10.1113/jphysiol.2014.284638
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Xiong YY, 2014, IMMUNOPHARM IMMUNOT, V36, P341, DOI 10.3109/08923973.2014.947035
   Xu L, 2013, J PHYS CHEM B, V117, P8408, DOI 10.1021/jp404160y
   Yi NX, 2022, INT IMMUNOPHARMACOL, V113, DOI 10.1016/j.intimp.2022.109349
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Zhai X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00348
   Zhang L, 2023, PHYTOTHER RES, V37, P124, DOI 10.1002/ptr.7601
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang ZD, 2019, MOL MED REP, V19, P3505, DOI 10.3892/mmr.2019.10051
   Zhao BK, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.615191
   Zhi X, 2020, J CELL MOL MED, V24, P5122, DOI 10.1111/jcmm.15153
   Zhou HM, 2019, BIOL TRACE ELEM RES, V190, P327, DOI 10.1007/s12011 018 1574 9
NR 44
TC 9
Z9 9
U1 2
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD DEC 5
PY 2023
VL 960
AR 176121
DI 10.1016/j.ejphar.2023.176121
EA OCT 2023
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA X9ZY3
UT WOS:001101969000001
PM 37866743
DA 2025 08 17
ER

PT J
AU Mehta, A
   Ramachandra, CJA
   Sequiera, GL
   Sudibyo, Y
   Nandihalli, M
   Yong, PJA
   Koh, CH
   Shim, W
AF Mehta, Ashish
   Ramachandra, Chrishan J. A.
   Sequiera, Glen L.
   Sudibyo, Yuliansa
   Nandihalli, Manasi
   Yong, Pearly J. A.
   Koh, Cai Hong
   Shim, Winston
TI Phasic modulation of Wnt signaling enhances cardiac differentiation in
   human pluripotent stem cells by recapitulating developmental ontogeny
SO BIOCHIMICA ET BIOPHYSICA ACTA MOLECULAR CELL RESEARCH
LA English
DT Article
DE Pluripotent stem cells; Cardiomyocyte; Differentiation; Wnt signaling;
   Bone morphogenetic protein
ID CARDIOMYOCYTE DIFFERENTIATION; LINEAGE; MESP1; PROLIFERATION;
   SPECIFICATION; INHIBITOR; REGULATOR; PROTEINS; MODELS
AB Cardiomyocytes (CMs) derived from human pluripotent stem cells (hPSCs) offer immense value in studying cardiovascular regenerative medicine. However, intrinsic biases and differential responsiveness of hPSCs towards cardiac differentiation pose significant technical and logistic hurdles that hamper human cardiomyocyte studies. Tandem modulation of canonical and non canonical Wnt signaling pathways may play a crucial role in cardiac development that can efficiently generate cardiomyocytes from pluripotent stem cells. Our Wnt signaling expression profiles revealed that phasic modulation of canonical/non canonical axis enabled orderly recapitulation of cardiac developmental ontogeny. Moreover, evaluation of 8 hPSC lines showed marked commitment towards cardiac mesoderm during the early phase of differentiation, with elevated levels of canonical Wnts (Wnt3 and 3a) and Mesp1. Whereas continued activation of canonical Wnts was counterproductive, its discrete inhibition during the later phase of cardiac differentiation was accompanied by significant up regulation of noncanonical Wnt expression (Wnt5a and 11) and enhanced Nkx2.5(+) (up to 98%) populations. These Nkx2.5(+) populations transited to contracting cardiac troponin T positive CMs with up to 80% efficiency. Our results suggest that timely modulation of Wnt pathways would transcend intrinsic differentiation biases of hPSCs to consistently generate functional CMs that could facilitate their scalable production for meaningful clinical translation towards personalized regenerative medicine. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Mehta, Ashish; Ramachandra, Chrishan J. A.; Sequiera, Glen L.; Sudibyo, Yuliansa; Nandihalli, Manasi; Yong, Pearly J. A.; Koh, Cai Hong; Shim, Winston] Natl Heart Res Inst Singapore, Natl Heart Ctr, Singapore, Singapore.
   [Shim, Winston] DUKE NUS, Singapore, Singapore.
C3 National Heart Centre Singapore; National University of Singapore
RP Mehta, A (通讯作者)，Natl Heart Res Inst Singapore, Natl Heart Ctr Singapore, 5 Hosp Dr,Level 9, Singapore 169609, Singapore.
EM ashish.mehta@nhcs.com.sg; winston.shim.s.n@nhcs.com.sg
RI ; Mehta, Ashish/A 5537 2011
OI Ramachandra, Chrishan/0000 0003 4379 3795; Mehta,
   Ashish/0000 0002 0187 4477
FU National Research Foundation Singapore [NRF CRP 2008 02]; National
   Medical Research Council [NMRC/BNIG/1074/2012]; Goh Foundation Gift
   (Singapore)/Duke NUS Graduate Medical School [GCR/2012/006]
FX This study was supported by the National Research Foundation Singapore
   (NRF CRP 2008 02), National Medical Research Council
   (NMRC/BNIG/1074/2012) and Goh Foundation Gift (Singapore)/Duke NUS
   Graduate Medical School (GCR/2012/006).
CR Afouda BA, 2008, DEVELOPMENT, V135, P3185, DOI 10.1242/dev.026443
   Bondue A, 2008, CELL STEM CELL, V3, P69, DOI 10.1016/j.stem.2008.06.009
   Bondue A, 2010, CIRC RES, V107, P1414, DOI 10.1161/CIRCRESAHA.110.227058
   Bowers SLK, 2010, J MOL CELL CARDIOL, V48, P474, DOI 10.1016/j.yjmcc.2009.08.024
   Braam SR, 2010, STEM CELL RES, V4, P107, DOI 10.1016/j.scr.2009.11.004
   Braam SR, 2009, TRENDS PHARMACOL SCI, V30, P536, DOI 10.1016/j.tips.2009.07.001
   Cao N, 2012, CELL RES, V22, P219, DOI 10.1038/cr.2011.195
   Cha SW, 2008, DEVELOPMENT, V135, P3719, DOI 10.1242/dev.029025
   Cha SW, 2009, CURR BIOL, V19, P1573, DOI 10.1016/j.cub.2009.07.062
   Chen Y, 2006, AM J PHYSIOL HEART C, V291, pH1653, DOI 10.1152/ajpheart.00363.2005
   Davis RP, 2011, TRENDS MOL MED, V17, P475, DOI 10.1016/j.molmed.2011.05.001
   Eisenberg CA, 1997, DEVELOPMENT, V124, P525
   Elliott DA, 2011, NAT METHODS, V8, P1037, DOI [10.1038/NMETH.1740, 10.1038/nmeth.1740]
   Filipczyk AA, 2007, CELL MOL LIFE SCI, V64, P704, DOI 10.1007/s00018 007 6523 2
   Gessert S, 2010, CIRC RES, V107, P186, DOI 10.1161/CIRCRESAHA.110.221531
   Graichen R, 2008, DIFFERENTIATION, V76, P357, DOI 10.1111/j.1432 0436.2007.00236.x
   Kattman SJ, 2011, CELL STEM CELL, V8, P228, DOI 10.1016/j.stem.2010.12.008
   Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327
   Li YQ, 2013, STEM CELLS, V31, P1213, DOI 10.1002/stem.1362
   Lian XJ, 2012, P NATL ACAD SCI USA, V109, pE1848, DOI 10.1073/pnas.1200250109
   Lindsley RC, 2006, DEVELOPMENT, V133, P3787, DOI 10.1242/dev.02551
   Mehta A, 2014, PLOS ONE
   Mehta A, 2014, CARDIOVASC RES, V102, P497, DOI 10.1093/cvr/cvu060
   Mehta A, 2013, CELL TRANSPLANT, V22, P1, DOI 10.3727/096368912X653282
   Mehta A, 2013, TOXICOL SCI, V131, P458, DOI 10.1093/toxsci/kfs309
   Mehta A, 2011, CARDIOVASC RES, V91, P577, DOI 10.1093/cvr/cvr132
   Mehta A, 2010, CELL BIOL INT, V34, P1021, DOI 10.1042/CBI20100283
   Moretti A, 2010, NEW ENGL J MED, V363, P1397, DOI 10.1056/NEJMoa0908679
   Mummery C, 2003, CIRCULATION, V107, P2733, DOI 10.1161/01.CIR.0000068356.38592.68
   Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199
   Noseda M, 2011, CIRC RES, V108, P129, DOI 10.1161/CIRCRESAHA.110.223792
   Osafune K, 2008, NAT BIOTECHNOL, V26, P313, DOI 10.1038/nbt1383
   Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921
   Rajala K, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/383709
   Sequiera GL, 2013, LIFE SCI, V92, P63, DOI 10.1016/j.lfs.2012.10.020
   Tseng AS, 2006, CHEM BIOL, V13, P957, DOI 10.1016/j.chembiol.2006.08.004
   Ueno S, 2007, P NATL ACAD SCI USA, V104, P9685, DOI 10.1073/pnas.0702859104
   van Wijk B, 2007, CARDIOVASC RES, V74, P244, DOI 10.1016/j.cardiores.2006.11.022
   Vidarsson H, 2010, STEM CELL REV REP, V6, P108, DOI 10.1007/s12015 010 9113 x
   Wharton KA, 2001, DEV BIOL, V234, P93, DOI 10.1006/dbio.2001.0238
   Xu XQ, 2008, DIFFERENTIATION, V76, P958, DOI 10.1111/j.1432 0436.2008.00284.x
   Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898
   Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894
   Yazawa M, 2011, NATURE, V471, P230, DOI 10.1038/nature09855
   Zeineddine D, 2006, DEV CELL, V11, P535, DOI 10.1016/j.devcel.2006.07.013
NR 45
TC 21
Z9 28
U1 0
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167 4889
EI 1879 2596
J9 BBA MOL CELL RES
JI Biochim. Biophys. Acta Mol. Cell Res.
PD NOV
PY 2014
VL 1843
IS 11
BP 2394
EP 2402
DI 10.1016/j.bbamcr.2014.06.011
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AQ1FR
UT WOS:000342527800004
PM 24978297
OA Bronze
DA 2025 08 17
ER

PT J
AU Ormazabal, ME
   Pavan, E
   Vaena, E
   Ferino, D
   Biasizzo, J
   Mucci, JM
   Serra, F
   Cifù, A
   Scarpa, M
   Rozenfeld, PA
   Dardis, AE
AF Ormazabal, Maximiliano Emanuel
   Pavan, Eleonora
   Vaena, Emilio
   Ferino, Dania
   Biasizzo, Jessica
   Mucci, Juan Marcos
   Serra, Fabrizio
   Cifu, Adriana
   Scarpa, Maurizio
   Rozenfeld, Paula Adriana
   Dardis, Andrea Elena
TI Exploring the Pathophysiologic Cascade Leading to Osteoclastogenic
   Activation in Gaucher Disease Monocytes Generated via CRISPR/Cas9
   Technology
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Gaucher disease; bone; monocytes; osteoclasts; inflammation
ID LYSOSOMAL STORAGE; STEM CELLS; ENZYME; DIFFERENTIATION; CYTOKINES; MODEL
AB Gaucher disease (GD) is caused by biallelic pathogenic variants in the acid & beta; glucosidase gene (GBA1), leading to a deficiency in the & beta; glucocerebrosidase (GCase) enzyme activity resulting in the intracellular accumulation of sphingolipids. Skeletal alterations are one of the most disabling features in GD patients. Although both defective bone formation and increased bone resorption due to osteoblast and osteoclast dysfunction contribute to GD bone pathology, the molecular bases are not fully understood, and bone disease is not completely resolved with currently available specific therapies. For this reason, using editing technology, our group has developed a reliable, isogenic, and easy to handle cellular model of GD monocytes (GBAKO THP1) to facilitate GD pathophysiology studies and high throughput drug screenings. In this work, we further characterized the model showing an increase in proinflammatory cytokines (Interleukin 1 & beta; and Tumor Necrosis Factor & alpha;) release and activation of osteoclastogenesis. Furthermore, our data suggest that GD monocytes would display an increased osteoclastogenic potential, independent of their interaction with the GD microenvironment or other GD cells. Both proinflammatory cytokine production and osteoclastogenesis were restored at least, in part, by treating cells with the recombinant human GCase, a substrate synthase inhibitor, a pharmacological chaperone, and an anti inflammatory compound. Besides confirming that this model would be suitable to perform high throughput screening of therapeutic molecules that act via different mechanisms and on different phenotypic features, our data provided insights into the pathogenic cascade, leading to osteoclastogenesis exacerbation and its contribution to bone pathology in GD.
C1 [Ormazabal, Maximiliano Emanuel; Pavan, Eleonora; Serra, Fabrizio; Scarpa, Maurizio; Dardis, Andrea Elena] Acad Hosp Udine, Reg Coordinator Ctr Rare Dis, I 33100 Udine, Italy.
   [Ormazabal, Maximiliano Emanuel; Vaena, Emilio; Mucci, Juan Marcos; Rozenfeld, Paula Adriana] Inst Estudios Inmunol & Fisiopatol IIFP, Fac Ciencias Exactas, Dept Ciencias Biol, UNLP,CONICET,Asociado CIC PBA, RA 1900 La Plata, Argentina.
   [Ferino, Dania; Biasizzo, Jessica] Univ Hosp Udine, Inst Clin Pathol, Dept Lab Med, I 33100 Udine, Italy.
   [Cifu, Adriana] Univ Udine, Dipartimento Area Med, I 33100 Udine, Italy.
C3 University of Udine; University Hospital of Udine; Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET); National University of
   La Plata; University of Udine; University Hospital of Udine; University
   of Udine
RP Dardis, AE (通讯作者)，Acad Hosp Udine, Reg Coordinator Ctr Rare Dis, I 33100 Udine, Italy.
EM maxi.ormazabal@gmail.com; pavan.eleonora@gmail.com;
   emiliovaena@gmail.com; dania.ferino@asufc.sanita.fvg.it;
   jessica.biasizzo@asufc.sanita.fvg.it; juanmarcosmucci@gmail.com;
   fabrizio.serra@asufc.sanita.fvg.it; adriana.cifu@uniud.it;
   maurizio.scarpa@asufc.sanita.fvg.it; paularozenfeld@gmail.com;
   andrea.dardis@asufc.sanita.fvg.it
RI Scarpa, Maurizio/LSJ 1834 2024; Cifu', Adriana/AAC 6900 2019; Pavan,
   Eleonora/AAC 2257 2022; Dardis, Andrea/AAB 9900 2022
OI , Paula/0000 0002 8138 3087; Dardis, Andrea Elena/0000 0001 7024 8181;
   Cifu, Adriana/0000 0002 6794 8838; 
CR Aflaki E, 2016, AGING CELL, V15, P77, DOI 10.1111/acel.12409
   Aflaki E, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008659
   Barak V, 1999, EUR CYTOKINE NETW, V10, P205
   Bembi B, 2003, NEUROLOGY, V61, P99, DOI 10.1212/01.WNL.0000072482.70963.D7
   Bolamperti S, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00219 8
   Bondar C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010112
   Borger Daniel K, 2015, Macrophage (Houst), V2, pe712
   Ciana G, 2020, MOL GENET METAB REP, V25, DOI 10.1016/j.ymgmr.2020.100678
   Crivaro A, 2020, MOL GENET METAB, V130, P274, DOI 10.1016/j.ymgme.2020.06.003
   Crivaro AN, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217780
   Delaisse JM, 2020, BONE, V141, DOI [10.1016/j/bone.2020.115628, 10.1016/j.bone.2020.115628]
   Dvir H, 2003, EMBO REP, V4, P704, DOI 10.1038/sj.embor.embor873
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Fois G, 2015, CELL CALCIUM, V58, P628, DOI 10.1016/j.ceca.2015.10.002
   Hughes D, 2019, J BONE MINER RES, V34, P996, DOI 10.1002/jbmr.3734
   Itzchaki M, 2004, ACTA ORTHOP SCAND, V75, P641, DOI 10.1080/00016470410004003
   Kim JH, 2009, J IMMUNOL, V183, P1862, DOI 10.4049/jimmunol.0803007
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Kumar M, 2023, HUM MOL GENET, V32, P1888, DOI 10.1093/hmg/ddad025
   Lampiasi N, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9089610
   Lecourt S, 2012, STEM CELLS DEV, V21, P239, DOI 10.1089/scd.2011.0365
   Lorenz F, 2018, BLOOD CELL MOL DIS, V68, P35, DOI 10.1016/j.bcmd.2016.10.010
   Magalhaes J, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19479 8
   Manea S, 2024, HEALTH SERV MANAG RE, V37, P52, DOI 10.1177/09514848231151814
   Matafora V, 2015, MOL BIOSYST, V11, P1543, DOI 10.1039/c4mb00707g
   Matta MC, 2018, BLOOD CELL MOL DIS, V68, P200, DOI 10.1016/j.bcmd.2016.10.016
   Mela A, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01123
   Messelodi D, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112822
   Michelakakis H, 1996, BBA MOL BASIS DIS, V1317, P219, DOI 10.1016/S0925 4439(96)00056 7
   Mistry PK, 2010, P NATL ACAD SCI USA, V107, P19473, DOI 10.1073/pnas.1003308107
   Mori G, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/720504
   Mucci JM, 2015, BLOOD CELL MOL DIS, V55, P134, DOI 10.1016/j.bcmd.2015.05.009
   Panicker LM, 2018, HUM MOL GENET, V27, P811, DOI 10.1093/hmg/ddx442
   Panicker LM, 2014, STEM CELLS, V32, P2338, DOI 10.1002/stem.1732
   Pavan E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093268
   Peng YY, 2023, MOL THER METH CLIN D, V29, P185, DOI 10.1016/j.omtm.2023.03.007
   Polo G, 2017, CLIN CHEM LAB MED, V55, P403, DOI 10.1515/cclm 2016 0340
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Reed M, 2013, BLOOD CELL MOL DIS, V51, P185, DOI 10.1016/j.bcmd.2013.04.006
   Reed MC, 2018, GENE, V678, P196, DOI 10.1016/j.gene.2018.08.045
   Rigante D, 2017, IMMUNOL LETT, V188, P79, DOI 10.1016/j.imlet.2017.07.004
   Rolph D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00937
   Rozenfeld PA, 2021, MOL GENET METAB, V132, P76, DOI 10.1016/j.ymgme.2020.07.011
   Rybová J, 2018, J INHERIT METAB DIS, V41, P221, DOI 10.1007/s10545 017 0108 5
   Sillence DJ, 2002, J LIPID RES, V43, P1837, DOI 10.1194/jlr.M200232 JLR200
   Sirrs Sandra, 2023, Healthc Pap, V21, P74, DOI 10.12927/hcpap.2023.26992
   Stirnemann J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020441
   Sun Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118771
   Vitner EB, 2012, BRAIN, V135, P1724, DOI 10.1093/brain/aws095
   Zunke F, 2019, NEUROBIOL DIS, V127, P147, DOI 10.1016/j.nbd.2019.01.018
NR 50
TC 4
Z9 4
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2023
VL 24
IS 13
AR 11204
DI 10.3390/ijms241311204
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA M1YZ9
UT WOS:001028220800001
PM 37446383
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cheng, Y
   Liu, HX
   Li, J
   Ma, YJ
   Song, CH
   Wang, YH
   Li, P
   Chen, YJ
   Zhang, ZG
AF Cheng, Yin
   Liu, Haixia
   Li, Jing
   Ma, Yujie
   Song, Changheng
   Wang, Yuhan
   Li, Pei
   Chen, Yanjing
   Zhang, Zhiguo
TI Monascin abrogates RANKL mediated osteoclastogenesis in RAW264.7 cells
   via regulating MAPKs signaling pathways
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE monascin; osteoclast; RAW264.7; bone resorption; mapks; osteoporosis
ID TRANSCRIPTION FACTOR; RECEPTOR ACTIVATOR; BONE LOSS; DIFFERENTIATION;
   EFFICACY; PROTEIN; NFAT2
AB Osteoclasts (OCs) are multinucleated cells that play a major role in osteolytic diseases such as osteoporosis. Monascin (Ms) is one of the active substances in the traditional Chinese medicine red yeast rice. Studies have found that red yeast rice can maintain bone health. In this study, the anti osteoclastogenesis effects of Ms on RANKL induced RAW264.7 cells were assessed, and the underlying mechanism was investigated. Ms exhibited inhibitory effects on OC differentiation and formation in a dose dependent manner and suppressed the bone resorbing activity of mature OCs. Ms blocked OCs typical genes (c Fos, NFATc1, CSTK, MMP 9, TRAP, ITG beta 3, OSCAR and DC STAMP). Furthermore, Ms treatment considerably inhibited the activation of MAPKs, JNK and p38. Taken together, Ms suppresses RANKL induced osteoclastogenesis of RAW264.7 cells by restraining MAPKs signaling pathways and is a potential therapeutic option as a novel OC inhibitor to mitigate bone erosion.
C1 [Cheng, Yin; Liu, Haixia; Ma, Yujie; Song, Changheng; Wang, Yuhan; Li, Pei; Chen, Yanjing; Zhang, Zhiguo] China Acad Chinese Med Sci, Inst Basic Theory, Beijing, Peoples R China.
   [Li, Jing] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Basic Theory for
   Chinese Medicine, CACMS; Institute of Basic Medical Sciences   CAMS;
   Chinese Academy of Medical Sciences   Peking Union Medical College
RP Chen, YJ; Zhang, ZG (通讯作者)，China Acad Chinese Med Sci, Inst Basic Theory, Beijing, Peoples R China.
EM chenyj010@163.com; zzgtcm@163.com
RI ma, yujie/GYA 3957 2022
FU CACMS Innovation Fund [CI2021A00107]; National Natural Science
   Foundation of China [82074297]; Fundamental Research Funds for the
   Central Public Welfare Research Institutes [YZ 202147, YZ 202108]
FX Funding This work was supported by the CACMS Innovation Fund (grant
   number CI2021A00107), the National Natural Science Foundation of China
   (grant number 82074297) and the Fundamental Research Funds for the
   Central Public Welfare Research Institutes (grant numbers YZ 202147,
   YZ 202108).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Blangy A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.244798
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Garbe AI, 2012, J BONE MINER RES, V27, P2085, DOI 10.1002/jbmr.1670
   Georgess D, 2014, CELL ADHES MIGR, V8, P192, DOI 10.4161/cam.27840
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Herbert BA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125387
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Karsenty G, 2012, NATURE, V481, P314, DOI 10.1038/nature10763
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Leibbrandt A, 2009, ADV EXP MED BIOL, V649, P100
   Lin CH, 2017, FOOD FUNCT, V8, P2102, DOI 10.1039/c7fo00406k
   Liu JT, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3831750
   Lv YD, 2015, EXP THER MED, V9, P143, DOI 10.3892/etm.2014.2071
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Nguyen T, 2017, FOODS, V6, DOI 10.3390/foods6030019
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Patakova P, 2013, J IND MICROBIOL BIOT, V40, P169, DOI 10.1007/s10295 012 1216 8
   Qu YL, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8811751
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Sun Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.788680
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Wang H, 2021, BIOCHEM PHARMACOL, V183, DOI 10.1016/j.bcp.2020.114308
   Wang TJ, 2019, AM J CHINESE MED, V47, P323, DOI 10.1142/S0192415X19500150
   Wang YF, 2015, GENET MOL RES, V14, P8137, DOI 10.4238/2015.July.27.2
   Wong Ricky W K, 2008, Chin Med, V3, P4, DOI 10.1186/1749 8546 3 4
   Wu B, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7231827
   Xiong XJ, 2017, CRIT REV FOOD SCI, V57, P1831, DOI 10.1080/10408398.2015.1018987
   Zhang XW, 2020, FOOD FUNCT, V11, P5915, DOI [10.1039/c9fo02410g, 10.1039/C9FO02410G]
   Zhao JY, 2019, J BONE MINER RES, V34, P2149, DOI 10.1002/jbmr.3832
NR 42
TC 6
Z9 6
U1 0
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUL 15
PY 2022
VL 13
AR 950122
DI 10.3389/fphar.2022.950122
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 3K8DZ
UT WOS:000834306100001
PM 35910375
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, JC
   Xu, J
   Gou, LY
   Zhu, Y
   Zhong, WH
   Guo, H
   Du, YJ
AF Chen, Jincheng
   Xu, Jie
   Gou, Lingyun
   Zhu, Yong
   Zhong, Weihua
   Guo, Hai
   Du, Yujuan
TI Integrating transcriptomic and proteomic data for a comprehensive
   molecular perspective on the association between sarcopenia and
   osteoporosis
SO ARCHIVES OF GERONTOLOGY AND GERIATRICS
LA English
DT Article
DE Osteoporosis; Sarcopenia; Osteosarcopenia; Aging diseases; Proteomics;
   Transcriptomics
ID SKELETAL MUSCLE; RNA
AB Background: Osteoporosis and sarcopenia are common age related conditions characterized by the progressive loss of bone density and muscle mass, respectively. Their co occurrence, often referred to as osteosarcopenia, presents significant challenges in elderly care due to increased fragility and functional impairment. Existing studies have identified shared pathological mechanisms between these conditions, including inflammation, hormonal imbalances, and metabolic dysregulation, but a comprehensive understanding of their molecular interplay remains incomplete. Objective: This study aims to deepen our understanding of the molecular interactions between sarcopenia and osteoporosis through an integrated omics approach, revealing potential therapeutic targets and biomarkers. Methods: Employing a combination of proteomics and transcriptomics analyses, this study analyzed bone and muscle tissue samples from patients diagnosed with osteoporosis and osteosarcopenia. Techniques included highthroughput sequencing and label free proteomics, supported by advanced bioinformatics tools for data analysis and functional annotation of genes and proteins. Results: The study found marked differences in gene and protein expressions between osteoporosis and osteosarcopenia tissues. Specifically, genes like PDIA5, TUBB1, and CYFIP2 in bone, along with MYH7 and NCAM1 in muscle, exhibited differential expression at both mRNA and protein levels. Pathway analyses revealed the significance of oxidative reduction balance, cellular metabolism, and immune response in the progression of these conditions. Importantly, the study pinpointed osteoclast differentiation and NF kappa B signaling pathways as critical in the molecular dynamics of osteosarcopenia, suggesting potential targets for therapy. Conclusions: This study utilized transcriptomics and proteomics to identify key genes and proteins impacting sarcopenia and osteoporosis, employing advanced network tools to delineate interaction networks and crucial signaling pathways. It highlighted genes like PDIA5 and TUBB1, consistently expressed in both analyses, involved in pathways such as osteoclast differentiation and cytokine interactions. These insights enhance understanding of the molecular interplay in bone and muscle degeneration with aging, suggesting directions for future research into therapeutic interventions and prevention strategies for age related degenerative diseases.
C1 [Chen, Jincheng; Gou, Lingyun; Zhu, Yong; Zhong, Weihua; Guo, Hai] Guangxi Univ Chinese Med, Affiliated Hosp 3, Liuzhou 545000, Peoples R China.
   [Chen, Jincheng; Xu, Jie] Fujian Med Univ, Fujian Prov Hosp, Dept Orthoped, Fuzhou 350000, Peoples R China.
   [Xu, Jie] Fujian Med Univ, Shengli Clin Med Coll, Fuzhou 350000, Peoples R China.
   [Du, Yujuan] Second Peoples Hosp Kunming, Kunming 650000, Peoples R China.
C3 Guangxi University of Chinese Medicine; Fujian Medical University;
   Fujian Provincial Hospital; Fujian Medical University
RP Chen, JC (通讯作者)，Guangxi Univ Chinese Med, Affiliated Hosp 3, Liuzhou 545000, Peoples R China.; Chen, JC (通讯作者)，Fujian Med Univ, Fujian Prov Hosp, Dept Orthoped, Fuzhou 350000, Peoples R China.
EM chenjinchengphd@163.com
OI xu, jie/0000 0002 9921 8792
FU Guangxi Traditional Chinese Medicine Appropriate Technology Development
   and Promotion Project [GZSY23 85]; Fujian Province Health Science and
   Technology Project [2021CXA007, 2021GGB001]; Joint key projects of
   Fujian Province [2019 WJ 01]; Medical Innovation Project of Fujian
   Provincial Health Department [2019 CX 1]; Natural Science Foundation of
   Fujian Province [2019J1173, 2021J01399]; Bethune Medical Science
   Research Fund [N163CS]; Guangxi Medical and Health Appropriate
   Technology Promotion Project [GZSY22 74]
FX This research was funded by the Guangxi Traditional Chinese Medicine
   Appropriate Technology Development and Promotion Project (GZSY23 85) ,
   Fujian Province Health Science and Technology Project (2021CXA007,
   2021GGB001) , Joint key projects of Fujian Province in 2019 (Grant No.
   2019 WJ 01) , Medical Innovation Project of Fujian Provincial Health
   Department (2019 CX 1) , Natural Science Foundation of Fujian Province
   (2019J1173, 2021J01399) , Bethune Medical Science Research Fund (N163CS)
   , and Guangxi Medical and Health Appropriate Technology Promotion
   Project (GZSY22 74) .
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Apostu D, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10030149
   Barns M, 2014, INT J BIOCHEM CELL B, V53, P174, DOI 10.1016/j.biocel.2014.04.025
   Bleve A, 2023, CLIN REV ALLERG IMMU, V64, P123, DOI 10.1007/s12016 021 08909 7
   Blottner D, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10030378
   Bonewald L, 2019, BONE, V120, P212, DOI 10.1016/j.bone.2018.11.002
   Candow DG, 2022, BONE, V162, DOI 10.1016/j.bone.2022.116467
   Chen XL, 2023, BMC MUSCULOSKEL DIS, V24, DOI 10.1186/s12891 023 06295 z
   Cruz Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034
   Cuervo NZ, 2023, REDOX BIOL, V59, DOI 10.1016/j.redox.2022.102583
   Duszka K, 2020, CELLS BASEL, V9, DOI 10.3390/cells9071708
   Forhead AJ, 2002, AM J PHYSIOL ENDOC M, V282, pE80, DOI 10.1152/ajpendo.00284.2001
   Forte YS, 2023, CELLS BASEL, V12, DOI 10.3390/cells12040521
   Ghosh A, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398 020 00882 7
   Gielen E, 2023, METABOLISM, V145, DOI 10.1016/j.metabol.2023.155638
   Herrmann M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030432
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Huang HS, 2023, ACTA BIOMATER, V157, P609, DOI 10.1016/j.actbio.2022.12.019
   Jafari M, 2019, J CELL PHYSIOL, V234, P2373, DOI 10.1002/jcp.27262
   Jennings MJ, 2022, BRAIN, V145, P3999, DOI 10.1093/brain/awac055
   Jiao LJ, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 022 01285 4
   Kalinkovich A, 2022, DRUG AGING, V39, P673, DOI 10.1007/s40266 022 00960 z
   Kang YJ, 2021, J ORTHOP TRANSL, V29, P10, DOI 10.1016/j.jot.2021.04.009
   Lamont PJ, 2014, HUM MUTAT, V35, P868, DOI 10.1002/humu.22553
   Lee AS, 2023, J MED FOOD, V26, P128, DOI 10.1089/jmf.2022.K.0078
   Li GB, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232113506
   Li GB, 2019, J CELL BIOCHEM, V120, P14262, DOI 10.1002/jcb.28946
   Liu C, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.975647
   Liu MC, 2023, FRONT GENET, V14, DOI 10.3389/fgene.2023.1163162
   Lombardi G, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00060
   Lu LY, 2023, J ENDOCRINOL, V259, DOI 10.1530/JOE 23 0116
   Luke MPS, 2016, NEUROBIOL AGING, V41, P93, DOI 10.1016/j.neurobiolaging.2016.02.003
   Mahmood F, 2021, BIOMED PHARMACOTHER, V143, DOI 10.1016/j.biopha.2021.112110
   Manigandan S, 2022, J CELL BIOCHEM, V123, P863, DOI 10.1002/jcb.30231
   Messi ML, 2016, J GERONTOL A BIOL, V71, P1273, DOI 10.1093/gerona/glv176
   Nicholas A, 2010, MECH AGEING DEV, V131, P445, DOI 10.1016/j.mad.2010.06.001
   Ohguchi H, 2017, LEUKEMIA, V31, P2661, DOI 10.1038/leu.2017.141
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Pin F, 2022, J CACHEXIA SARCOPENI, V13, P481, DOI 10.1002/jcsm.12844
   Powell LE, 2021, CANCER MED US, V10, P2812, DOI 10.1002/cam4.3836
   Salamanna F, 2023, LIFE BASEL, V13, DOI 10.3390/life13030602
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   SCHONTHAL A, 1989, ONCOGENE, V4, P629
   Stoupa A, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809569
   Tanaka K, 2018, P NATL ACAD SCI USA, V115, pE3759, DOI 10.1073/pnas.1719089115
   Tian S., 2023, Biotechnology & Genetic Engineering Reviews, V6, P1
   Tiftik T, 2023, OSTEOPOROSIS INT, V34, P53, DOI 10.1007/s00198 022 06563 z
   Trajanoska K, 2019, CURR OSTEOPOROS REP, V17, P86, DOI 10.1007/s11914 019 00505 1
   Urano T, 2015, ENDOCR J, V62, P475, DOI 10.1507/endocrj.EJ15 0154
   Usategui Martín R, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115477
   Yang JY, 2023, J PAIN RES, V16, P821, DOI 10.2147/JPR.S403648
   Zhao LL, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.533690
   Zhu SY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.873820
NR 53
TC 6
Z9 6
U1 2
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167 4943
EI 1872 6976
J9 ARCH GERONTOL GERIAT
JI Arch. Gerontol. Geriatr.
PD OCT
PY 2024
VL 125
AR 105486
DI 10.1016/j.archger.2024.105486
EA MAY 2024
PG 11
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA J7X0W
UT WOS:001339142500001
PM 38761527
OA hybrid
DA 2025 08 17
ER

PT J
AU Tahara, H
AF Tahara, Hideki
TI Role of Cinacalcet in Management of Mineral Bone Disorder in Chronic
   Kidney Disease (Control of Calcium, Phosphorus and Parathyroid Hormone)
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE Active vitamin D; Cinacalcet; CKD MBD; JSDT guidelines; Pleiotropic
   action
ID VITAMIN D; HEMODIALYSIS PATIENTS; SURVIVAL; MORTALITY; RISK
AB The management of hemodialysis patients with chronic kidney disease mineral bone disorder includes treatment to control levels of calcium, phosphorus and parathyroid hormone, so as to prevent bone and soft tissue complications. Recently, pleiotropic effects of active vitamin D have attracted much attention, and its effect on outcome has also gained recognition. However, administration of active vitamin D may cause hypercalcemia and hyperphosphatemia. Now, the use of a novel class of drugs, cinacalcet hydrochloride, has been proposed as a strategy to reduce parathyroid hormone secretion, while decreasing levels of serum calcium, phosphorus, and calcium x phosphorus products. Among subjects with secondary hyperparathyroidism undergoing hemodialysis, combined therapy with cinacalcet and vitamin D sterols improved achievement of the biochemical targets for chronic kidney disease mineral bone disorder recommended by the guidelines.
C1 Osaka City Univ, Grad Sch Med, Dept Metab Endocrinol & Mol Med, Abeno Ku, Osaka 5458585, Japan.
C3 Osaka Metropolitan University
RP Tahara, H (通讯作者)，Osaka City Univ, Grad Sch Med, Dept Metab Endocrinol & Mol Med, Abeno Ku, 1 4 7 Asahi Cho, Osaka 5458585, Japan.
EM hideki t@ka2.so net.ne.jp
CR Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kovesdy CP, 2008, KIDNEY INT, V73, P1355, DOI 10.1038/ki.2008.35
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   Shoji T, 2004, NEPHROL DIAL TRANSPL, V19, P179, DOI 10.1093/ndt/gfg513
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868
   Wolf M, 2007, KIDNEY INT, V72, P1004, DOI 10.1038/sj.ki.5002451
NR 8
TC 0
Z9 0
U1 0
U2 1
PU WILEY BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1744 9979
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD OCT
PY 2008
VL 12
BP S27
EP S33
DI 10.1111/j.1744 9987.2008.00628.x
PG 7
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Urology & Nephrology
GA 410GZ
UT WOS:000263566800006
PM 19032524
DA 2025 08 17
ER

PT J
AU Yu, BQ
   Bai, JX
   Shi, J
   Shen, JN
   Guo, XB
   Liu, Y
   Ge, GR
   Lin, JY
   Tao, YX
   Yang, HL
   Xu, YZ
   Qu, QX
   Geng, DH
AF Yu, Binqing
   Bai, Jiaxiang
   Shi, Jian
   Shen, Jining
   Guo, Xiaobin
   Liu, Yu
   Ge, Gaoran
   Lin, Jiayi
   Tao, Yunxia
   Yang, Huilin
   Xu, Yaozeng
   Qu, Qiuxia
   Geng, Dechun
TI MiR 106b inhibition suppresses inflammatory bone destruction of wear
   debris induced periprosthetic osteolysis in rats
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE bone formation; bone resorption; miR 106b; periprosthetic osteolysis;
   wear debris
ID NF KAPPA B; PARTICLE INDUCED OSTEOLYSIS; MESENCHYMAL STEM CELLS;
   OSTEOCLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; POLYETHYLENE
   WEAR; DOWN REGULATION; TITANIUM; PREVENTS; RANKL
AB Aseptic loosening caused by periprosthetic osteolysis (PPO) is the main reason for the primary artificial joint replacement. Inhibition of inflammatory osteolysis has become the main target of drug therapy for prosthesis loosening. MiR 106b is a newly discovered miRNA that plays an important role in tumour biology, inflammation and the regulation of bone mass. In this study, we analysed the in vivo effect of miR 106b on wear debris induced PPO. A rat implant loosening model was established. The rats were then administrated a lentivirus mediated miR 106b inhibitor, miR 106b mimics or an equivalent volume of PBS by tail vein injection. The expression levels of miR 106b were analysed by real time PCR. Morphological changes in the distal femurs were assessed via micro CT and histopathological analysis, and cytokine expression levels were examined via immunohistochemical staining and ELISA. The results showed that treatment with the miR 106b inhibitor markedly suppressed the expression of miR 106b in distal femur and alleviated titanium particle induced osteolysis and bone loss. Moreover, the miR 106b inhibitor decreased TRAP positive cell numbers and suppressed osteoclast formation, in addition to promoting the activity of osteoblasts and increasing bone formation. MiR 106b inhibition also significantly regulated macrophage polarization and decreased the inflammatory response as compared to the control group. Furthermore, miR 106b inhibition blocked the activation of the PTEN/PI3K/AKT and NF kappa B signalling pathways. Our findings indicated that miR 106b inhibition suppresses wear particles induced osteolysis and bone destruction and thus may serve as a potential therapy for PPO and aseptic loosening.
C1 [Yu, Binqing; Bai, Jiaxiang; Shen, Jining; Guo, Xiaobin; Liu, Yu; Ge, Gaoran; Lin, Jiayi; Tao, Yunxia; Yang, Huilin; Xu, Yaozeng; Geng, Dechun] Soochow Univ, Affiliated Hosp 1, Dept Orthoped, 188 Shizi Rd, Suzhou 215006, Peoples R China.
   [Shi, Jian] Soochow Univ, Affiliated Hosp 1, Dept Pharm, Suzhou, Peoples R China.
   [Qu, Qiuxia] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Clin Immunol, 188 Shizi Rd, Suzhou 215006, Peoples R China.
C3 Soochow University   China; Soochow University   China; Soochow
   University   China
RP Xu, YZ; Geng, DH (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthoped, 188 Shizi Rd, Suzhou 215006, Peoples R China.; Qu, QX (通讯作者)，Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Clin Immunol, 188 Shizi Rd, Suzhou 215006, Peoples R China.
EM xuyaozeng@163.com; qxqu@suda.edu.cn; szgengdc@163.com
RI Geng, Dechun/LMO 1733 2024; bai, jiaxiang/AAH 3367 2021; Guo,
   Xiaobin/LKL 6231 2024
OI Bai, Jiaxiang/0000 0002 3485 5563; 
FU Basic Applied Research Program of Suzhou City [KJXW2017002, KJXW2017009,
   SYS2018032]; Young Medical Talents of Jiangsu Province [QNRC2016751];
   Natural Science Foundation of Jiangsu Province [BK20180001]; National
   Natural Science Foundation of China [81472077, 81472105, 81672238,
   81771885, 81873990, 81873991]
FX Basic Applied Research Program of Suzhou City, Grant/Award Number:
   KJXW2017002, KJXW2017009 and SYS2018032; Young Medical Talents of
   Jiangsu Province, Grant/Award Number: QNRC2016751; Natural Science
   Foundation of Jiangsu Province, Grant/Award Number: BK20180001; National
   Natural Science Foundation of China, Grant/Award Number: 81472077,
   81472105, 81672238, 81771885, 81873990 and 81873991
CR Abdelmagid SM, 2015, J BIOL CHEM, V290, P20128, DOI 10.1074/jbc.M114.624270
   Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046
   Blüml S, 2015, ANN RHEUM DIS, V74, P227, DOI 10.1136/annrheumdis 2013 203486
   Broomfield JAJ, 2017, J ARTHROPLASTY, V32, P1186, DOI 10.1016/j.arth.2016.10.037
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Charnley J, 2010, CLIN ORTHOP RELAT R, V468, P3149, DOI 10.1007/s11999 010 1545 8
   Cromwell OR, 2015, J AM CHEM SOC, V137, P6492, DOI 10.1021/jacs.5b03551
   Ell Brian, 2014, Bonekey Rep, V3, P549, DOI 10.1038/bonekey.2014.44
   Espinosa Parrilla Y, 2014, INT J CANCER, V135, P2065, DOI 10.1002/ijc.28850
   Fang T, 2016, EXP CELL RES, V347, P74, DOI 10.1016/j.yexcr.2016.07.010
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Gillam MH, 2013, OSTEOARTHR CARTILAGE, V21, P405, DOI 10.1016/j.joca.2012.12.008
   Goodman SB, 2010, BIOMATERIALS, V31, P5045, DOI 10.1016/j.biomaterials.2010.03.046
   Goodship AE, 2008, J ORTHOP RES, V26, P693, DOI 10.1002/jor.20533
   Halleen JM, 2006, CLIN LAB, V52, P499
   Holding CA, 2006, BIOMATERIALS, V27, P5212, DOI 10.1016/j.biomaterials.2006.05.054
   Horwood NJ, 2016, CLIN REV ALLERG IMMU, V51, P79, DOI 10.1007/s12016 015 8519 2
   Huang J, 2014, BIOMATERIALS, V35, P9649, DOI 10.1016/j.biomaterials.2014.08.016
   Huang S, 2014, BONE, V60, P235, DOI 10.1016/j.bone.2013.12.023
   Jang HD, 2013, BONE, V55, P126, DOI 10.1016/j.bone.2013.02.005
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219
   Kauther MD, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 186
   Kubota T, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2298
   Kurtz SM, 2009, J ARTHROPLASTY, V24, P195, DOI 10.1016/j.arth.2007.11.015
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Liu F, 2014, ONCOGENE, V33, P4813, DOI 10.1038/onc.2013.428
   Liu K, 2017, BONE, V97, P130, DOI 10.1016/j.bone.2017.01.014
   Liu S, 2012, ARTHRITIS RHEUM US, V64, P4012, DOI 10.1002/art.37697
   Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104
   Masui T, 2005, BIOMATERIALS, V26, P1695, DOI 10.1016/j.biomaterials.2004.05.017
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   McInnes IB, 2016, NAT REV RHEUMATOL, V12, P63, DOI 10.1038/nrrheum.2015.171
   Miyaki S, 2010, GENE DEV, V24, P1173, DOI 10.1101/gad.1915510
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nakamachi Y, 2016, ANN RHEUM DIS, V75, P601, DOI 10.1136/annrheumdis 2014 206417
   Ni XJ, 2014, CANCER SCI, V105, P18, DOI 10.1111/cas.12309
   Park MC, 2010, RHEUMATOLOGY, V49, P882, DOI 10.1093/rheumatology/keq007
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Ping ZC, 2017, ACTA BIOMATER, V51, P513, DOI 10.1016/j.actbio.2017.01.034
   Polzer K, 2010, ANN RHEUM DIS, V69, P284, DOI 10.1136/ard.2008.104786
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Slaby O, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756 9966 29 90
   Tao YX, 2017, RHEUMATOLOGY, V56, P1804, DOI 10.1093/rheumatology/kex233
   Tian B, 2014, BIOMATERIALS, V35, P8937, DOI 10.1016/j.biomaterials.2014.06.055
   Wang T, 2015, ONCOTARGET, V6, P18980, DOI 10.18632/oncotarget.4223
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
   Zhang B, 2014, INT J CLIN EXP MED, V7, P3746
   Zhang J, 2014, CHINESE MED J PEKING, V127, P2212, DOI 10.3760/cma.j.issn.0366 6999.20133228
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
   Zhu SJ, 2016, SCI REP UK, V6, DOI 10.1038/srep36251
   Zhu S, 2012, NAT MED, V18, P1077, DOI 10.1038/nm.2815
NR 53
TC 14
Z9 16
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUL
PY 2020
VL 24
IS 13
BP 7490
EP 7503
DI 10.1111/jcmm.15376
EA JUN 2020
PG 14
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA MN5DL
UT WOS:000536987500001
PM 32485091
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Rahigude, AB
   Kaulaskar, SV
   Bhutada, PS
AF Rahigude, A. B.
   Kaulaskar, S. V.
   Bhutada, P. S.
TI Possible therapeutic potential of berberine in diabetic osteopathy
SO MEDICAL HYPOTHESES
LA English
DT Article
ID NF KAPPA B; OXIDATIVE STRESS; INSULIN RESISTANCE; PROTEIN KINASE; HIGH
   GLUCOSE; OLDER WOMEN; RAT MODEL; BONE; OSTEOPOROSIS; GLYCATION
AB Diabetic osteopathy is a complication that leads to decreased bone mineral density, bone formation and having high risk of fractures that heals slowly. Diabetic osteopathy is a result of increase in osteoclastogenesis and decrease in osteoblastogenesis. Various factors viz., oxidative stress, increased inflammatory markers, PPAR gamma activation in osteoblast, activation of apoptotic pathway, increased glucose levels and inhibitory effect on parathyroid hormone etc. are mainly responsible for decreased bone mineral density. Berberine is an isoquinoline alkaloid widely used in Asian countries as a traditional medicine. Berberine is extensively reported to be an antioxidant, anti inflammatory, antidiabetic, and having potential to treat diabetic complications and glucocorticoid induced osteoporosis. The osteoclastogenesis decreasing property of berberine can be hypothesized for inhibiting diabetic osteopathy. In addition, chronic treatment of berberine will be helpful for increasing the osteoblastic activity and expression of the modulators that affect osteoblastic differentiation. The apoptotic pathways stimulated due to increased inflammatory markers and nucleic acid damages could be reduced due to berberine. Another important consideration that berberine is having stimulatory effect on glucagon like peptide release and insulin sensitization that will be helpful for decreasing glucose levels and therefore, may exerts osteogenesis. Thiazolidinediones show bone loss due to activation of PPAR gamma in osteoblasts, whereas berberine stimulates PPAR gamma only in adipocytes and not in osteoblasts, and therefore the decreased bone loss due to use of thiazolidinediones may not be observed in berberine treatment conditions. Berberine decreases the advanced glycation end products (AGE) formation in diabetic condition which will be ultimately helpful to decrease the stiffness of collagen fibers due to AGE induced cross linking. Lastly, it is also reported that berberine has inhibitory effect on parathyroid hormone and enhances marker genes like osteocalcin, which are responsible for the osteoblastic activity. From these evidences, we hypothesized that berberine may have potential in the treatment of diabetic osteopathy. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Rahigude, A. B.; Kaulaskar, S. V.; Bhutada, P. S.] Sinhgad Coll Pharm, Postgrad Res Dept, Pune 411041, Maharashtra, India.
C3 Sinhgad College of Pharmacy
RP Bhutada, PS (通讯作者)，Sinhgad Coll Pharm, Postgrad Res Dept, Sinhgad Rd, Pune 411041, Maharashtra, India.
EM psbhutada@live.com
CR Amasheh M, 2010, J CELL SCI, V123, P4145, DOI 10.1242/jcs.070896
   Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Bhutada P, 2011, BEHAV BRAIN RES, V220, P30, DOI 10.1016/j.bbr.2011.01.022
   Cheng Z, 2006, BBA GEN SUBJECTS, V1760, P1682, DOI 10.1016/j.bbagen.2006.09.007
   Chueh WH, 2012, FOOD CHEM, V132, P252, DOI 10.1016/j.foodchem.2011.10.065
   Dvorák Z, 2006, CHEM BIOL INTERACT, V159, P117, DOI 10.1016/j.cbi.2005.10.105
   Fei YR, 2007, MICRON, V38, P637, DOI 10.1016/j.micron.2006.09.003
   GREGORIO F, 1994, DIABETES RES CLIN PR, V23, P43, DOI 10.1016/0168 8227(94)90126 0
   Hamada Y, 2009, BONE, V45, pS35, DOI 10.1016/j.bone.2009.02.004
   Hao M, 2011, EUR J PHARMACOL, V654, P320, DOI 10.1016/j.ejphar.2010.12.030
   Huang C, 2006, BIOCHEM BIOPH RES CO, V348, P571, DOI 10.1016/j.bbrc.2006.07.095
   INABA M, 1995, J BONE MINER RES, V10, P1050
   Jeffcoate W, 2000, DIABETIC MED, V17, P253, DOI 10.1046/j.1464 5491.2000.00233.x
   Ji JD, 2009, MED HYPOTHESES, V73, P201, DOI 10.1016/j.mehy.2009.02.020
   Kanazawa I, 2009, J CLIN ENDOCR METAB, V94, P45, DOI 10.1210/jc.2008 1455
   Ko BS, 2005, BIOL PHARM BULL, V28, P1431, DOI 10.1248/bpb.28.1431
   Kong WJ, 2009, METABOLISM, V58, P109, DOI 10.1016/j.metabol.2008.08.013
   Koroglu BK, 2011, ENDOKRYNOL POL, V62, P429
   Kurra S, 2011, DIABETES METAB RES, V27, P430, DOI 10.1002/dmrr.1197
   La Fontaine J, 2008, J FOOT ANKLE SURG, V47, P424, DOI 10.1053/j.jfas.2008.05.009
   Lecka Czernik Beata, 2010, Curr Osteoporos Rep, V8, P178, DOI 10.1007/s11914 010 0027 y
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Lee YS, 2006, DIABETES, V55, P2256, DOI 10.2337/db06 0006
   Li HY, 1999, BIOL PHARM BULL, V22, P391, DOI 10.1248/bpb.22.391
   Liang W, 2011, EUR J PHARMACOL, V670, P317, DOI 10.1016/j.ejphar.2011.08.014
   Liu WH, 2008, ARCH BIOCHEM BIOPHYS, V475, P128, DOI 10.1016/j.abb.2008.04.022
   Nuche Berenguer B, 2011, J ENDOCRINOL, V209, P203, DOI 10.1530/JOE 11 0015
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Roux C, 2003, BONE, V33, P847, DOI 10.1016/j.bone.2003.07.008
   Sardone LD, 2011, DIABETES, V60, P3271, DOI 10.2337/db10 1672
   Schwartz AV, 2001, J CLIN ENDOCR METAB, V86, P32, DOI 10.1210/jc.86.1.32
   Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891 5849(00)00224 0
   Singh J, 2009, J ETHNOPHARMACOL, V123, P22, DOI 10.1016/j.jep.2009.02.038
   Slater AFG, 1995, TOXICOL LETT, V82 3, P149, DOI 10.1016/0378 4274(95)03474 9
   Thrailkill KM, 2005, AM J PHYSIOL ENDOC M, V289, pE735, DOI 10.1152/ajpendo.00159.2005
   Vogt MT, 2002, J AM GERIATR SOC, V50, P97, DOI 10.1046/j.1532 5415.2002.50014.x
   WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891 5849(91)90040 A
   Wongdee K, 2011, WORLD J DIABETES, V2, P41, DOI 10.4239/wjd.v2.i3.41
   Xu DH, 2010, PLANTA MED, V76, P1809, DOI 10.1055/s 0030 1250040
   Yamamoto Takehisa, 2006, Clin Calcium, V16, P1322
   Yin J, 2002, METABOLISM, V51, P1439, DOI 10.1053/meta.2002.34715
   Yu YL, 2010, BIOCHEM PHARMACOL, V79, P1000, DOI 10.1016/j.bcp.2009.11.017
   Zargar AH, 1998, POSTGRAD MED J, V74, P665, DOI 10.1136/pgmj.74.877.665
   Zhou JY, 2011, FITOTERAPIA, V82, P184, DOI 10.1016/j.fitote.2010.08.019
   Zhou JY, 2009, EUR J PHARMACOL, V606, P262, DOI 10.1016/j.ejphar.2008.12.056
   Zhou LB, 2007, METABOLISM, V56, P405, DOI 10.1016/j.metabol.2006.10.025
NR 46
TC 12
Z9 15
U1 0
U2 15
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2012
VL 79
IS 4
BP 440
EP 444
DI 10.1016/j.mehy.2012.06.016
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 024QF
UT WOS:000310123000004
PM 22840327
DA 2025 08 17
ER

PT J
AU Wagner, EF
AF Wagner, E. F.
TI Bone development and inflammatory disease is regulated by AP 1 (Fos/Jun)
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID JUN PROTEINS; SKIN DISEASE; TRANSCRIPTION; ACTIVATOR; PSORIASIS; FOS
AB The Fos and Jun proteins are members of the AP 1 transcription factor complex, which is a central regulator for many cellular functions. This paper summarises the important functions of Fos proteins in bone development, with special emphasis on the Fos related proteins Fra 1 and Fra 2. These factors determine the functions of osteoblasts and osteoclasts and regulate cytokine signalling during bone development. Likewise, the Jun proteins control the expression of cytokines and chemokines and are probably causally involved in inflammatory skin diseases such as psoriasis. Investigations into the molecular mechanisms responsible for skin inflammation have revealed that Jun proteins control cytokine expression, such as granulocyte colony stimulating factor, IL 6 and tumour necrosis factor alpha by transcriptional and posttranscriptional pathways. Finally, the paper discusses the relevance of the Jun dependent mouse model for psoriasis for preclinical studies in the field of anti angiogenic therapies.
C1 Spanish Natl Canc Ctr CNIO, CNIO Canc Cell Biol Program, BBVA Fdn, E 28029 Madrid, Spain.
C3 Centro Nacional de Investigaciones Oncologicas (CNIO)
RP Wagner, EF (通讯作者)，Spanish Natl Canc Ctr CNIO, CNIO Canc Cell Biol Program, BBVA Fdn, C Melchor Fernandez Almagro 3, E 28029 Madrid, Spain.
EM ewagner@cnio.es
OI Wagner, Erwin F/0000 0001 7872 0196
CR Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380
   Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019
   Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209
   Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282
   Eferl R, 2008, P NATL ACAD SCI USA, V105, P10525, DOI 10.1073/pnas.0801414105
   Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676
   Karreth F, 2004, DEVELOPMENT, V131, P5717, DOI 10.1242/dev.01414
   MEHIC D, J INVEST DERMATOL, V124, P212
   Meixner A, 2008, NAT CELL BIOL, V10, P1003, DOI 10.1038/ncb1761
   Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011
   Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963
   Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534 5807(03)00161 8
   Zenz R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2338
NR 16
TC 119
Z9 131
U1 1
U2 14
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003 4967
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JAN
PY 2010
VL 69
BP 86
EP 88
DI 10.1136/ard.2009.119396
PG 3
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 532HL
UT WOS:000272737400015
PM 19995753
DA 2025 08 17
ER

PT J
AU Kamalakar, A
   Tobin, B
   Kaimari, S
   Robinson, MH
   Toma, A
   Cha, T
   Chihab, S
   Moriarity, I
   Gautam, S
   Bhattaram, P
   Abramowicz, S
   Drissi, H
   Garcia, A
   Wood, L
   Goudy, SL
AF Kamalakar, Archana
   Tobin, Brendan
   Kaimari, Sundus
   Robinson, M. Hope
   Toma, Afra, I
   Cha, Timothy
   Chihab, Samir
   Moriarity, Irica
   Gautam, Surabhi
   Bhattaram, Pallavi
   Abramowicz, Shelly
   Drissi, Hicham
   Garcia, Andres
   Wood, Levi
   Goudy, Steven L.
TI Delivery of a Jagged1 PEG MAL hydrogel with pediatric human bone cells
   regenerates critically sized craniofacial bone defects
SO ELIFE
LA English
DT Article
DE JAGGED1; bone regeneration; craniofacial bone loss; non canonical
   JAG1 NOTCH pathways; tissue regenerative therapy; Human; Mouse
ID NF KAPPA B; NOTCH; RECONSTRUCTION; GRAFTS; PHOSPHORYLATION;
   DIFFERENTIATION; COMPLICATIONS; ACTIVATION; EXPRESSION; JAGGED 1
AB Current treatments for congenital and acquired craniofacial (CF) bone abnormalities are limited and costly. Conventional methods involve surgical correction, short term stabilization, and long term bone grafting, which may include problematic allografts and limited autografts. While bone morphogenetic protein 2 (BMP2) has been used for bone regeneration, it can cause bone overgrowth and life threatening inflammation. Bone marrow derived mesenchymal stem cell therapies, though promising, are not Food and Drug Administration approved and are resource intensive. Thus, there is a need for effective, affordable, and less side effect prone bone regenerative therapies. Previous research demonstrated that JAGGED1 induces osteoblast commitment in murine cranial neural crest cells through a NOTCH dependent non canonical pathway involving JAK2 STAT5. We hypothesize that delivery of JAGGED1 and induction of its downstream NOTCH non canonical signaling in pediatric human osteoblasts constitutes an effective bone regenerative treatment. Delivering pediatric human bone derived osteoblast like cells to an in vivo murine bone loss model of a critically sized cranial defect, we identified that JAGGED1 promotes human pediatric osteoblast commitment and bone formation through p70 S6K phosphorylation. This approach highlights the potential of JAGGED1 and its downstream activators as innovative treatments for pediatric CF bone loss.
C1 [Kamalakar, Archana; Kaimari, Sundus; Robinson, M. Hope; Toma, Afra, I; Cha, Timothy] Emory Univ, Dept Otolaryngol, Atlanta, GA USA.
   [Tobin, Brendan; Garcia, Andres; Wood, Levi] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA USA.
   [Tobin, Brendan] Georgia Tech Coll Engn, Sch Chem & Biomol Engn, Atlanta, GA USA.
   [Kaimari, Sundus; Toma, Afra, I; Wood, Levi] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA USA.
   [Chihab, Samir; Gautam, Surabhi; Bhattaram, Pallavi; Drissi, Hicham] Emory Univ, Dept Orthoped, Atlanta, GA USA.
   [Moriarity, Irica] Georgia Inst Technol, Coll Sci Undergrad Neurosci Program, Atlanta, GA 30332 USA.
   [Bhattaram, Pallavi; Drissi, Hicham] Atlanta Vet Affairs Med Ctr Atlanta, Atlanta, GA USA.
   [Abramowicz, Shelly] Emory Univ, Dept Surg, Div Oral & Maxillofacial Surg, Atlanta, GA USA.
   [Drissi, Hicham] Emory Univ, Dept Cell Biol, Atlanta, GA USA.
   [Garcia, Andres; Wood, Levi] Georgia Tech Coll Engn, George W Woodruff Sch Mech Engn, Atlanta, GA USA.
   [Goudy, Steven L.] Childrens Healthcare Atlanta, Dept Pediat Otolaryngol, Atlanta, GA 30342 USA.
C3 Emory University; University System of Georgia; Georgia Institute of
   Technology; University System of Georgia; Georgia Institute of
   Technology; Emory University; University System of Georgia; Georgia
   Institute of Technology; Emory University; Emory University; Children's
   Healthcare of Atlanta (CHOA)
RP Goudy, SL (通讯作者)，Childrens Healthcare Atlanta, Dept Pediat Otolaryngol, Atlanta, GA 30342 USA.
EM steven.goudy@emory.edu
RI Gautam, Surabhi/IAP 1068 2023
FU National Institute of Dental and Craniofacial Research [R01DE031271];
   National Institutes of Health, National Institute of Dental and
   Craniofacial Research (NIDCR) [DE026762, R01AR062920, R01AR062368];
   National Institutes of Health, National Institute of Arthritis and
   Musculoskeletal and Skin Diseases of the National Institutes of Health
FX Study design: AK, AIT, SA, AJG, LBW, HD, MHR, TC, SC, and SLG. Study
   conduct: AK, SK, and MHR. Data collection: AK, BT, SK, MHR, and IM. Data
   analysis: AK, BT, SK, MHR, AIT, and IM. Data interpretation: All
   authors. Drafting manuscript: AK and SLG. Revising manuscript content:
   All authors. Approving the final version of manuscript: All authors. We
   extend our gratitude to Adrianna Westbrook and Katie Liu from the
   Pediatric Biostatistics Core, Emory University, for their invaluable
   advice on how best to perform the statistics on the data in this
   manuscript. AK and SLG take responsibility for the integrity of the data
   analysis. Research reported in this publication is supported by the
   National Institutes of Health, National Institute of Dental and
   Craniofacial Research (NIDCR) under award number R01DE031271 and
   National Institutes of Health, National Institute of Arthritis and
   Musculoskeletal and Skin Diseases of the National Institutes of Health
   under Award Numbers DE026762, R01AR062920, and R01AR062368,
   respectively. The authors declare no conflict of interest.
CR Albanese A, 2013, IMMUN AGEING, V10, DOI 10.1186/1742 4933 10 23
   Baumhauer J, 2014, FOOT ANKLE INT, V35, P104, DOI 10.1177/1071100713511434
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brylka LJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02182
   Caliceti C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/318714
   Chaushu G, 2010, J PERIODONTOL, V81, P1759, DOI 10.1902/jop.2010.100235
   Chim Harvey, 2010, Semin Plast Surg, V24, P188, DOI 10.1055/s 0030 1255336
   Choi J, 2020, J TRAUMA ACUTE CARE, V88, pE124, DOI 10.1097/TA.0000000000002589
   Dahlin C, 2011, CLIN IMPLANT DENT R, V13, P305, DOI 10.1111/j.1708 8208.2009.00221.x
   De Sousa A, 2010, INDIAN J PLAST SURG, V43, P200, DOI 10.4103/0970 0358.73452
   Dishowitz MI, 2014, J BIOMED MATER RES A, V102, P1558, DOI 10.1002/jbm.a.34825
   Elsalanty ME, 2009, CRANIOMAX TRAUM REC, V2, P125, DOI 10.1055/s 0029 1215875
   Fowler TW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042967
   Gómez Barrena E, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6025918
   Grover Vishakha, 2011, Indian J Dent Res, V22, P496, DOI 10.4103/0970 9290.87084
   Huang RL, 2014, OSTEOARTHR CARTILAGE, V22, P1186, DOI 10.1016/j.joca.2014.06.017
   Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200
   Jehan F, 2022, FASEB BIOADV, V4, P524, DOI 10.1096/fba.2021 00092
   Kakabadze A, 2017, ONCOL LETT, V13, P1811, DOI 10.3892/ol.2017.5647
   Kamalakar A, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115657
   Kamalakar A, 2019, CELL SIGNAL, V54, P130, DOI 10.1016/j.cellsig.2018.12.002
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kornsuthisopon C, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 11596 9
   Kumar BP, 2016, J MAXILLOFAC ORAL SU, V15, P425, DOI 10.1007/s12663 015 0766 5
   Langdahl BL, 2018, BONE, V116, P58, DOI 10.1016/j.bone.2018.07.013
   LAURIE SWS, 1984, PLAST RECONSTR SURG, V73, P933, DOI 10.1097/00006534 198406000 00014
   Lockyer HM, 2007, J IMMUNOL, V179, P5301, DOI 10.4049/jimmunol.179.8.5301
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Luo ZL, 2019, AM J PATHOL, V189, P1495, DOI 10.1016/j.ajpath.2019.05.005
   Mi HY, 2019, NAT PROTOC, V14, P703, DOI 10.1038/s41596 019 0128 8
   Miwa S, 2012, ANTICANCER RES, V32, P3643
   Nardi C, 2020, INSIGHTS IMAGING, V11, DOI 10.1186/s13244 020 0837 0
   Nobta M, 2005, J BIOL CHEM, V280, P15842, DOI 10.1074/jbc.M412891200
   Nosho S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21217967
   Onan D, 2009, ENDOCRINOLOGY, V150, P2244, DOI 10.1210/en.2008 1597
   Osathanon T, 2019, ARCH ORAL BIOL, V99, P134, DOI 10.1016/j.archoralbio.2019.01.013
   Pannequin J, 2009, CANCER RES, V69, P6065, DOI 10.1158/0008 5472.CAN 08 2409
   Phelps EA, 2012, ADV MATER, V24, P64, DOI 10.1002/adma.201103574
   Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008 5472.CAN 04 1890
   Regan J, 2013, CURR OSTEOPOROS REP, V11, P126, DOI 10.1007/s11914 013 0145 4
   Roberts TT, 2012, ORGANOGENESIS, V8, P114, DOI 10.4161/org.23306
   Rowshan HH, 2010, J ORAL MAXIL SURG, V68, P260, DOI 10.1016/j.joms.2009.09.045
   Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605
   Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003
   Ruvinsky I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005618
   Sayers EW, 2021, NUCLEIC ACIDS RES, V49, pD10, DOI 10.1093/nar/gkaa892
   Seto I, 2006, PLAST RECONSTR SURG, V117, P902, DOI 10.1097/01.prs.0000200069.81973.49
   Shah HN, 2021, PLAST RECONSTR SURG, V147, p54E, DOI 10.1097/PRS.0000000000007451
   Svegliati Baroni G, 2003, J HEPATOL, V39, P528, DOI 10.1016/S0168 8278(03)00291 5
   Takayama T, 2017, J BIOMATER APPL, V31, P1049, DOI 10.1177/0885328216686727
   Tannoury CA, 2014, SPINE J, V14, P552, DOI 10.1016/j.spinee.2013.08.060
   Thomas PD, 2022, PROTEIN SCI, V31, P8, DOI 10.1002/pro.4218
   Wu J, 2021, PEERJ, V9, DOI 10.7717/peerj.10693
   Xiao M, 2009, EXP HEMATOL, V37, P52, DOI 10.1016/j.exphem.2008.09.001
   Ye P, 2011, BIOORG MED CHEM LETT, V21, P849, DOI 10.1016/j.bmcl.2010.11.069
   Youngstrom DW, 2016, BONE, V91, P64, DOI 10.1016/j.bone.2016.07.006
   Youngstrom DW, 2017, NPJ REGEN MED, V2, DOI 10.1038/s41536 017 0037 9
   Zanotti S, 2012, CALCIFIED TISSUE INT, V90, P69, DOI 10.1007/s00223 011 9541 x
   Zhang HW, 2014, J CLIN INVEST, V124, P3200, DOI 10.1172/JCI68901
   Zhao SL, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 S10 P16
   Zuk PA, 2008, PEDIATR RES, V63, P478, DOI 10.1203/PDR.0b013e31816bdf36
   Zurek A, 2019, TOXICOL APPL PHARM, V374, P53, DOI 10.1016/j.taap.2019.04.024
NR 62
TC 1
Z9 1
U1 0
U2 2
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD OCT 14
PY 2024
VL 13
AR RP92925
DI 10.7554/eLife.92925; 10.7554/eLife.92925.3.sa1;
   10.7554/eLife.92925.3.sa2; 10.7554/eLife.92925.3.sa3
PG 21
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA J5C6K
UT WOS:001337244400001
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Stoppa, I
   Dianzani, C
   Clemente, N
   Bozza, A
   Bordano, V
   Garelli, S
   Cangemi, L
   Dianzani, U
   Battaglia, L
AF Stoppa, Ian
   Dianzani, Chiara
   Clemente, Nausicaa
   Bozza, Annalisa
   Bordano, Valentina
   Garelli, Sara
   Cangemi, Luigi
   Dianzani, Umberto
   Battaglia, Luigi
TI Alendronate Grafted Nanoemulsions for Bone Targeted Vincristine
   Delivery: Preliminary Studies on Cell and Animal Models
SO BIOMOLECULES
LA English
DT Article
DE nanoemulsion; alendronate; vincristine
ID GINGIVAL FIBROBLASTS; IN VITRO; MIGRATION; PROLIFERATION; NANOPARTICLES;
   OSTEOBLASTS; INVASION
AB Bone is a site of distant metastases, which are a common cause of morbidity and mortality with a high socio economic impact, for many malignant tumours. In order to engineer pharmacological therapies that are suitable for this debilitating disease, this experimental work presents injectable lipid nanoemulsions, which are endowed with a long history of safe clinical usage in parenteral nutrition, their loading with vincristine and their grafting with alendronate, with a dual purpose: merging the anticancer activity of bisphosphonates and vincristine, and enhancing bone targeted delivery. In cell studies, alendronate synergised with the anti migration activity of vincristine, which is important as migration plays a key role in the metastatisation process. In preliminary animal studies, carried out thanks to IVIS technology, alendronate conjugation enhanced the bone targeting of fluorescently labelled nanoemulsions. These encouraging results will drive further studies on suitable animal models of the disease.
C1 [Stoppa, Ian; Clemente, Nausicaa; Dianzani, Umberto] Univ Eastern Piedmont UPO, Interdisciplinary Res Ctr Autoimmune Dis IRCAD, Dept Hlth Sci, Via Solaroli 17, I 28100 Novara, Italy.
   [Dianzani, Chiara; Bozza, Annalisa; Bordano, Valentina; Garelli, Sara; Cangemi, Luigi; Battaglia, Luigi] Univ Turin, Dept Drug Sci & Technol, Via Pietro Giuria 9, I 10125 Turin, Italy.
   [Battaglia, Luigi] Univ Turin, Nanostruct Interfaces & Surfaces NIS Interdept Ctr, I 10124 Turin, Italy.
C3 University of Eastern Piedmont Amedeo Avogadro; University of Turin;
   University of Turin
RP Battaglia, L (通讯作者)，Univ Turin, Dept Drug Sci & Technol, Via Pietro Giuria 9, I 10125 Turin, Italy.; Battaglia, L (通讯作者)，Univ Turin, Nanostruct Interfaces & Surfaces NIS Interdept Ctr, I 10124 Turin, Italy.
EM ian.stoppa@uniupo.it; chiara.dianzani@unito.it;
   nausicaa.clemente@med.uniupo.it; annalisa.bozza@unito.it;
   valentina.bordano@unito.it; saragarelli.sg@gmail.com;
   luigi.cangemi@unito.it; umberto.dianzani@med.uniupo.it;
   luigi.battaglia@unito.it
OI Stoppa, Ian/0009 0004 8721 5537; clemente, nausicaa/0000 0002 9860 0148;
   Bozza, Annalisa/0000 0002 9390 1638; Bordano,
   Valentina/0009 0001 1219 2949; battaglia, luigi/0000 0002 5081 3638;
   Dianzani, Chiara/0000 0002 2246 3183
FU Associazione Italiana Ricerca sul Cancro, Milano Italy
FX Dale Lawson is thanked for his English language proofreading of the
   document.
CR Açil Y, 2012, J CRANIO MAXILL SURG, V40, pE229, DOI 10.1016/j.jcms.2011.10.024
   Açil Y, 2018, J CRANIO MAXILL SURG, V46, P538, DOI 10.1016/j.jcms.2017.12.015
   Adjei IM, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040205
   Battaglia LS, 2022, DRUG DISCOV TODAY, V27, DOI 10.1016/j.drudis.2022.07.006
   Casimiro S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091415
   Chen YL, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.909408
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Coleman R, 2023, J BONE MINER METAB, V41, P290, DOI 10.1007/s00774 023 01434 x
   D'Oronzo S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21083022
   Dianzani C, 2020, CANCERS, V12, DOI 10.3390/cancers12051198
   Foglietta F, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15051358
   Gabano E, 2022, INORG CHIM ACTA, V535, DOI 10.1016/j.ica.2022.120859
   Haugland HK, 1999, ANTICANCER RES, V19, P149
   Hippalgaonkar K, 2010, AAPS PHARMSCITECH, V11, P1526, DOI 10.1208/s12249 010 9526 5
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Jiang ZC, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70659 x
   Katsumi H, 2020, CHEM PHARM BULL, V68, P560, DOI 10.1248/cpb.c20 00017
   LASSMAN LP, 1969, J NEUROSURG, V30, P42, DOI 10.3171/jns.1969.30.1.0042
   Lee H, 2017, CLIN CANCER RES, V23, P4190, DOI 10.1158/1078 0432.CCR 16 3193
   Lobo Martins S, 2020, CANCERS, V12, DOI 10.3390/cancers12082034
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Maeda H, 2015, ADV DRUG DELIVER REV, V91, P3, DOI 10.1016/j.addr.2015.01.002
   Migliorini F, 2020, MOL BIOL REP, V47, P6337, DOI 10.1007/s11033 020 05684 0
   Minegaki T, 2018, J PHARM PHARMACOL, V70, P1040, DOI 10.1111/jphp.12934
   Monge C, 2022, NANOMATERIALS BASEL, V12, DOI 10.3390/nano12234233
   Muntoni E, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11020065
   Najlah M, 2021, THER DELIV, V12, P267, DOI 10.4155/tde 2021 0009
   Refaat A, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01648 7
   Renault K, 2018, BIOCONJUGATE CHEM, V29, P2497, DOI 10.1021/acs.bioconjchem.8b00252
   Sahu A, 2018, NANOSCALE, V10, P13375, DOI 10.1039/c8nr02570c
   Shukla R, 2024, DRUG DELIV TRANSL RE, V14, P1, DOI 10.1007/s13346 023 01389 6
   Sonnemann J, 2003, ANTI CANCER DRUG, V14, P767, DOI 10.1097/01.cad.0000094848.34612.41
   Sung CM, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 019 3014 1
   Thamake SI, 2012, BIOMATERIALS, V33, P7164, DOI 10.1016/j.biomaterials.2012.06.026
   TONN JC, 1995, J NEUROSURG, V82, P1035, DOI 10.3171/jns.1995.82.6.1035
   Xing LP, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115492
   Xue LL, 2022, J AM CHEM SOC, V144, P9926, DOI 10.1021/jacs.2c02706
   Yang HL, 2010, J BIOL CHEM, V285, P32242, DOI 10.1074/jbc.M110.160820
   Yang HB, 2022, J CONTROL RELEASE, V341, P443, DOI 10.1016/j.jconrel.2021.11.005
   Zhang T, 2013, INT J NANOMED, V8, P1185, DOI 10.2147/IJN.S41775
NR 40
TC 1
Z9 1
U1 3
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2218 273X
J9 BIOMOLECULES
JI Biomolecules
PD FEB
PY 2024
VL 14
IS 2
AR 238
DI 10.3390/biom14020238
PG 18
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA JH5K3
UT WOS:001172284400001
PM 38397475
OA gold
DA 2025 08 17
ER

PT J
AU Xiao, LP
   Ueno, D
   Catros, S
   Homer Bouthiette, C
   Charles, L
   Kuhn, L
   Hurley, MM
AF Xiao, Liping
   Ueno, Daisuke
   Catros, Sylvain
   Homer Bouthiette, Collin
   Charles, Lyndon
   Kuhn, Liisa
   Hurley, Marja M.
TI Fibroblast Growth Factor 2 Isoform (Low Molecular Weight/18 kDa)
   Overexpression in Preosteoblast Cells Promotes Bone Regeneration in
   Critical Size Calvarial Defects in Male Mice
SO ENDOCRINOLOGY
LA English
DT Article
ID NON AUG CODONS; MORPHOGENETIC PROTEIN 2; TRANSGENIC MICE;
   NUCLEAR LOCALIZATION; GENE EXPRESSION; FRACTURE REPAIR; FACTOR FGF 2;
   IN VIVO; OSTEOBLASTS; BMP 2
AB Repair of bone defects remains a significant clinical problem. Bone morphogenetic protein 2 (BMP2) is US Food and Drug Administration approved for fracture healing but is expensive and has associated morbidity. Studies have shown that targeted overexpression of the 18 kDa low molecular  weight fibroblast growth factor 2 isoform (LMW) by the osteoblastic lineage of transgenic mice increased bone mass. This study tested the hypotheses that overexpression of LMW would directly enhance healing of a critical size calvarial bone defect in mice and that this overexpression would have a synergistic effect with low dose administration of BMP2 on critical size calvarial bone defect healing. Bilateral calvarial defects were created in LMW transgenic male mice and control/ vector transgenic (Vector) male mice and scaffold with or without BMP2 was placed into the defects. New bone formation was assessed by VIVA computed tomography of live animals over a 27 week period. Radiographic and computed tomography analysis revealed that at all time points, healing of the defect was enhanced in LMW mice compared with that in Vector mice. Although the very low concentration of BMP2 did not heal the defect in Vector mice, it resulted in complete healing of the defect in LMW mice. Histomorphometric and gene analysis revealed that targeted overexpression of LMW in osteoblast precursors resulted in enhanced calvarial defect healing due to increased osteoblast activity and increased canonical Wnt signaling.
C1 [Xiao, Liping; Homer Bouthiette, Collin; Hurley, Marja M.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA.
   [Charles, Lyndon; Kuhn, Liisa] Univ Connecticut, Ctr Hlth, Dept Reconstruct Sci, Farmington, CT 06030 USA.
   [Ueno, Daisuke] Tsurumi Univ, Sch Dent Med, Unit Oral & Maxillofacial Implantol, Yokohama, Kanagawa 230, Japan.
   [Catros, Sylvain] Univ Bordeaux Segalen, INSERM, U1026, F 33076 Bordeaux, France.
C3 University of Connecticut; University of Connecticut; Tsurumi
   University; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Bordeaux
RP Hurley, MM (通讯作者)，Univ Connecticut, Ctr Hlth, Dept Med, 263 Farmington Ave, Farmington, CT 06030 USA.
EM hurley@excange.uchc.edu
OI catros, sylvain/0000 0002 3419 3467; Kuhn, Liisa/0000 0003 1447 0719
FU National Institutes of Health/National Institute on Aging
   [5R01AG021189 10]; ITI Foundation (Basel, Switzerland) [5412007]; ITI
   Foundation scholarships
FX This project was supported in part by the National Institutes of
   Health/National Institute on Aging (Grant 5R01AG021189 10 to M. M. H.),
   the ITI Foundation (Basel, Switzerland; Project 5412007 to L. K.), and
   ITI Foundation scholarships (to D. U. and S. C.).
CR Agas D, 2013, J CELL PHYSIOL, V228, P2149, DOI 10.1002/jcp.24382
   Arese M, 1999, MOL BIOL CELL, V10, P1429, DOI 10.1091/mbc.10.5.1429
   Behr B, 2010, BONE, V47, P281, DOI 10.1016/j.bone.2010.05.008
   Blanquaert F, 1999, J BIOMED MATER RES, V44, P63, DOI 10.1002/(SICI)1097 4636(199901)44:1<63::AID JBM7>3.0.CO;2 S
   Chen WJ, 2004, J BONE MINER METAB, V22, P303, DOI 10.1007/s00774 004 0487 6
   Church VL, 2002, INT J DEV BIOL, V46, P927
   COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861
   Colin S, 1999, MOL PHARMACOL, V55, P74, DOI 10.1124/mol.55.1.74
   Dacic S, 2001, J BONE MINER RES, V16, P1228, DOI 10.1359/jbmr.2001.16.7.1228
   Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014 5793(00)01189 3
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Fakhry A, 2005, BONE, V36, P254, DOI 10.1016/j.bone.2004.10.003
   Fei YR, 2013, CURR PHARM DESIGN, V19, P3354, DOI 10.2174/1381612811319190002
   FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Gospadarowicz D., 1990, Clin Orthop, V257, P231
   Hurley MM, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1103, DOI 10.1016/B978 0 12 373884 4.00065 3
   Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143
   Kawaguchi H, 2010, J BONE MINER RES, V25, P2459, DOI 10.1002/jbmr.146
   KOBAYASHI N., 2010, J ORAL TISSUE ENG, V8, P91, DOI [10.11223/jarde.8.91, DOI 10.11223/JARDE.8.91]
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kwan MD, 2011, J BIOL CHEM, V286, P11307, DOI 10.1074/jbc.M110.180042
   Naganawa T, 2006, BIOCHEM BIOPH RES CO, V339, P490, DOI 10.1016/j.bbrc.2005.10.215
   Naganawa T, 2008, J CELL BIOCHEM, V103, P1975, DOI 10.1002/jcb.21589
   Nakajima A, 2001, BONE, V29, P458, DOI 10.1016/S8756 3282(01)00604 4
   Patel MS, 2002, NEW ENGL J MED, V346, P1572, DOI 10.1056/NEJM200205163462011
   Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432 1033.1996.0295n.x
   Sabbieti MG, 2013, ENDOCRINOLOGY, V154, P2723, DOI 10.1210/en.2013 1025
   Sachse A, 2005, BONE, V37, P699, DOI 10.1016/j.bone.2005.06.011
   Santana RB, 2006, INT J ORAL MAX IMPL, V21, P711
   Sato MM, 2009, GENES CELLS, V14, P141, DOI 10.1111/j.1365 2443.2008.01258.x
   Sobue T, 2005, J CELL BIOCHEM, V95, P83, DOI 10.1002/jcb.20389
   STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11
   Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593
   Tanaka E, 2006, ANN BIOMED ENG, V34, P717, DOI 10.1007/s10439 006 9092 x
   Tcacencu I, 2008, J MATER SCI MATER M, V19, P2015, DOI 10.1007/s10856 007 3284 2
   Touriol C, 2003, BIOL CELL, V95, P169, DOI 10.1016/S0248 4900(03)00033 9
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Xiao LP, 2010, J BIOL CHEM, V285, P2834, DOI 10.1074/jbc.M109.030577
   Xiao LP, 2009, J BIOL CHEM, V284, P3170, DOI 10.1074/jbc.M804900200
   Xie JW, 2004, J BIOMED MATER RES A, V71A, P108, DOI 10.1002/jbm.a.30140
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
NR 43
TC 26
Z9 29
U1 1
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD MAR
PY 2014
VL 155
IS 3
BP 965
EP 974
DI 10.1210/en.2013 1919
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AC2ZF
UT WOS:000332384100032
PM 24424065
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Bok, S
   Shin, DY
   Yallowitz, AR
   Eiseman, M
   Cung, M
   Xu, R
   Li, N
   Sun, J
   Williams, AL
   Scott, JE
   Su, B
   Shim, JH
   Greenblatt, MB
AF Bok, Seoyeon
   Shin, Dong Yeon
   Yallowitz, Alisha R.
   Eiseman, Mark
   Cung, Michelle
   Xu, Ren
   Li, Na
   Sun, Jun
   Williams, Alfred L.
   Scott, John E.
   Su, Bing
   Shim, Jae Hyuck
   Greenblatt, Matthew B.
TI MEKK2 mediates aberrant ERK activation in neurofibromatosis type I
SO NATURE COMMUNICATIONS
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; MYELOPROLIFERATIVE DISEASE; SKELETAL
   DEVELOPMENT; MYELOID LEUKEMIA; BONE DEVELOPMENT; DROSOPHILA NF1; MAPK
   PATHWAY; BETA CATENIN; INHIBITOR; CARDIOTOXICITY
AB Neurofibromatosis type I (NF1) is characterized by prominent skeletal manifestations caused by NF1 loss. While inhibitors of the ERK activating kinases MEK1/2 are promising as a means to treat NF1, the broad blockade of the ERK pathway produced by this strategy is potentially associated with therapy limiting toxicities. Here, we have sought targets offering a more narrow inhibition of ERK activation downstream of NF1 loss in the skeleton, finding that MEKK2 is a novel component of a noncanonical ERK pathway in osteoblasts that mediates aberrant ERK activation after NF1 loss. Accordingly, despite mice with conditional deletion of Nf1 in mature osteoblasts (Nf1(fl/fl);Dmp1 Cre) and Mekk2( / ) each displaying skeletal defects, Nf1(fl/fl);Mekk2( / );Dmp1 Cre mice show an amelioration of NF1 associated phenotypes. We also provide proof of principle that FDA approved inhibitors with activity against MEKK2 can ameliorate NF1 skeletal pathology. Thus, MEKK2 functions as a MAP3K in the ERK pathway in osteoblasts, offering a potential new therapeutic strategy for the treatment of NF1. Neurofibromatosis type I (NF1) is characterized by prominent skeletal abnormalities mediated in part by aberrant ERK pathway activation due to NF1 loss of function. Here, the authors report the MEKK2 is a key mediator of this aberrant ERK activation and that MEKK2 inhibitors, including ponatinib, ameliorate skeletal defects in a mouse model of NF1.
C1 [Bok, Seoyeon; Shin, Dong Yeon; Yallowitz, Alisha R.; Eiseman, Mark; Cung, Michelle; Sun, Jun; Greenblatt, Matthew B.] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.
   [Shin, Dong Yeon] LegoChem BioSci INC, Res Ctr, Daejeon 34302, South Korea.
   [Xu, Ren; Li, Na] Xiamen Univ, Sch Med, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China.
   [Williams, Alfred L.; Scott, John E.] North Carolina Cent Univ, Biomfg Res Inst & Technol Enterprise BRITE, Dept Pharmaceut Sci, Durham, NC 27707 USA.
   [Su, Bing] Shanghai Jiao Tong Univ, Sch Med, Minist Educ,Key Lab Cell Death & Differentiat, Dept Immunol & Microbiol,Shanghai Inst Immunol, Shanghai 200025, Peoples R China.
   [Su, Bing] Shanghai Jiao Tong Univ, Sch Med, Yale Inst Immune Metab, Shanghai 200025, Peoples R China.
   [Shim, Jae Hyuck] Univ Massachusetts, Sch Med, Div Rheumatol, Dept Med, 364 Plantation St, Worcester, MA 01605 USA.
C3 Cornell University; Weill Cornell Medicine; Xiamen University;
   University of North Carolina; North Carolina Central University;
   Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Jiao Tong University; University of Massachusetts System; University of
   Massachusetts Worcester
RP Greenblatt, MB (通讯作者)，Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.
EM mag3003@med.cornell.edu
RI Sun, Jun/KPB 2001 2024; xu, ren/G 6907 2015
OI SUN, JUN/0000 0001 9099 1829; Cung, Michelle/0000 0002 2457 4266; Shim,
   Jae Hyuck/0000 0002 4947 3293; Bok, Seoyeon/0000 0001 6063 1224; xu,
   ren/0000 0001 6578 4553; Scott, John/0000 0002 5987 9334
FU Career Award for Medical Scientists from the Burroughs Wellcome Fund;
   NIH [DP5OD021351, R01AR075585]; Department of Defense [NF150055];
   Pershing Square Sohn Cancer Research Alliance; Basic Science Research
   Program of the National Research Foundation of Korea (NRF)   Ministry of
   Education [2017R1A6A3A03003075]
FX This project was supported by a Career Award for Medical Scientists from
   the Burroughs Wellcome Fund, the NIH under award DP5OD021351 and
   R01AR075585, the Department of Defense under NF150055. This publication
   is based on research supported by the Pershing Square Sohn Cancer
   Research Alliance via an award to M.B.G. This research was supported by
   the award to D.Y.S. through the Basic Science Research Program of the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education (Grant no. 2017R1A6A3A03003075). We thank Graham Su at Yale
   University, the Research Animal Resource Center (RARC), and the
   Microscopy and Image Analysis Core Facilities at Weill Cornell Medicine
   for their technical assistance.
CR Ahmad S, 2018, BIOCHEM BIOPH RES CO, V496, P205, DOI 10.1016/j.bbrc.2018.01.027
   Ahmad S, 2015, BIOCHEM BIOPH RES CO, V463, P888, DOI 10.1016/j.bbrc.2015.06.029
   Ahmad S, 2013, J BIOMOL SCREEN, V18, P388, DOI 10.1177/1087057112466430
   Baht GS, 2017, BONE, V98, P31, DOI 10.1016/j.bone.2017.02.012
   Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361
   Chang T, 2013, J CLIN INVEST, V123, P335, DOI 10.1172/JCI63193
   Choi JP, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau0731
   Chu TF, 2007, LANCET, V370, P2011, DOI 10.1016/S0140 6736(07)61865 0
   Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092 8674(01)00245 8
   Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489
   Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943
   Force T, 2007, NAT REV CANCER, V7, P332, DOI 10.1038/nrc2106
   Fukuno N, 2011, BIOCHEM BIOPH RES CO, V408, P202, DOI 10.1016/j.bbrc.2011.02.127
   Gainor JF, 2015, ONCOLOGIST, V20, P847, DOI 10.1634/theoncologist.2015 0253
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gozgit JM, 2011, MOL CANCER THER, V10, P1028, DOI 10.1158/1535 7163.MCT 10 1044
   Greenblatt MB, 2017, CLIN CHEM, V63, P464, DOI 10.1373/clinchem.2016.259085
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Greenblatt MB, 2016, P NATL ACAD SCI USA, V113, pE1226, DOI 10.1073/pnas.1600813113
   Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795
   Guo ZJ, 2002, MOL CELL BIOL, V22, P5761, DOI 10.1128/MCB.22.16.5761 5768.2002
   Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578
   Kalajzic I, 2004, BONE, V35, P74, DOI 10.1016/j.bone.2004.03.006
   Kamiya N, 2017, J BONE MINER RES, V32, P1716, DOI 10.1002/jbmr.3155
   Kerkelä R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446
   Kim JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081803
   Kolanczyk M, 2007, HUM MOL GENET, V16, P874, DOI 10.1093/hmg/ddm032
   Lu Y, 2007, J DENT RES, V86, P320, DOI 10.1177/154405910708600404
   Matsui H, 2014, J BIOL CHEM, V289, P6438, DOI 10.1074/jbc.M113.536300
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Ndong JD, 2015, J BONE MINER RES, V30, P55, DOI 10.1002/jbmr.2316
   Ndong JD, 2014, NAT MED, V20, P904, DOI 10.1038/nm.3583
   O'Hare T, 2009, CANCER CELL, V16, P401, DOI 10.1016/j.ccr.2009.09.028
   Provot S, 2008, MOL CELL BIOL, V28, P344, DOI 10.1128/MCB.00617 07
   Schaefer BC, 1999, IMMUNITY, V11, P411, DOI 10.1016/S1074 7613(00)80116 8
   Sharma R, 2013, HUM MOL GENET, V22, P4818, DOI 10.1093/hmg/ddt333
   Staser K, 2013, J CLIN INVEST, V123, P329, DOI 10.1172/JCI66167
   Su B, 2001, J BIOL CHEM, V276, P14784, DOI 10.1074/jbc.M010134200
   The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791
   Wang WX, 2011, HUM MOL GENET, V20, P3910, DOI 10.1093/hmg/ddr310
   Welsh SJ, 2015, THER ADV MED ONCOL, V7, P122, DOI 10.1177/1758834014566428
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Zhang DY, 2006, EMBO J, V25, P97, DOI 10.1038/sj.emboj.7600913
   Zou WG, 2011, J CLIN INVEST, V121, P4383, DOI 10.1172/JCI59041
NR 44
TC 14
Z9 14
U1 0
U2 15
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD NOV 11
PY 2020
VL 11
IS 1
AR 5704
DI 10.1038/s41467 020 19555 6
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA OY0WK
UT WOS:000593975100006
PM 33177525
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sun, L
   Zhu, LL
   Lu, P
   Yuen, T
   Li, JH
   Ma, RS
   Baliram, R
   Moonga, SS
   Liu, P
   Zallone, A
   New, MI
   Davies, TF
   Zaidi, M
AF Sun, Li
   Zhu, Ling Ling
   Lu, Ping
   Yuen, Tony
   Li, Jianhua
   Ma, Risheng
   Baliram, Ramkumari
   Moonga, Surinder S.
   Liu, Peng
   Zallone, Alberta
   New, Maria I.
   Davies, Terry F.
   Zaidi, Mone
TI Genetic confirmation for a central role for TNFα in the direct action of
   thyroid stimulating hormone on the skeleton
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE bone metabolism; thyroid disease; bone density
ID MARROW STROMAL CELLS; BONE LOSS; OSTEOCLAST PRECURSORS; THYROTROPIN
   RECEPTOR; POSTMENOPAUSAL WOMEN; TRANSGENIC MICE; IN VIVO; TSH;
   EXPRESSION; OXYTOCIN
AB Clinical data showing correlations between low thyroid stimulating hormone (TSH) levels and high bone turnover markers, low bone mineral density, and an increased risk of osteoporosis related fractures are buttressed by mouse genetic and pharmacological studies identifying a direct action of TSH on the skeleton. Here we show that the skeletal actions of TSH deficiency are mediated, in part, through TNF alpha. Compound mouse mutants generated by genetically deleting the Tnf alpha gene on a Tshr( / ) (homozygote) or Tshr(+/ ) (heterozygote) background resulted in full rescue of the osteoporosis, low bone formation, and hyperresorption that accompany TSH deficiency. Studies using ex vivo bone marrow cell cultures showed that TSH inhibits and stimulates TNF alpha production from macrophages and osteoblasts, respectively. TNF alpha, in turn, stimulates osteoclastogenesis but also enhances the production in bone marrow of a variant TSH beta. This locally produced TSH suppresses osteoclast formation in a negative feedback loop. We speculate that TNF alpha elevations due to low TSH signaling in human hyperthyroidism contribute to the bone loss that has traditionally been attributed solely to high thyroid hormone levels.
C1 [Sun, Li; Zhu, Ling Ling; Lu, Ping; Yuen, Tony; Li, Jianhua; Ma, Risheng; Baliram, Ramkumari; Moonga, Surinder S.; Liu, Peng; Zallone, Alberta; New, Maria I.; Davies, Terry F.; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
   [Sun, Li; Zhu, Ling Ling; Lu, Ping; Yuen, Tony; Li, Jianhua; Ma, Risheng; Baliram, Ramkumari; Moonga, Surinder S.; Liu, Peng; Zallone, Alberta; New, Maria I.; Davies, Terry F.; Zaidi, Mone] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
   [Yuen, Tony; New, Maria I.] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.
   [Ma, Risheng; Baliram, Ramkumari; Davies, Terry F.] James J Peters Vet Affairs Med Ctr, Thyroid Res Unit, Bronx, NY 10468 USA.
   [Zallone, Alberta] Univ Bari, Dept Human Anat & Histol, I 70124 Bari, Italy.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); James J. Peters
   VA Medical Center; Universita degli Studi di Bari Aldo Moro
RP New, MI (通讯作者)，Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
EM maria.new@mssm.edu; mone.zaidi@mssm.edu
OI Zaidi, Mone/0000 0001 5911 9522; Yuen, Tony/0009 0001 6000 8827
FU National Institutes of Health [DK80459, AG23176, AG40132]; Department of
   Veterans Affairs; Maria I. New Children's Hormone Research Foundation;
   Chinese University of Hong Kong
FX We thank Dr. Jay Cao for help with microtomography measurements. This
   work was supported by National Institutes of Health Grants DK80459 (to
   L. S., T. F. D., and M.Z.), AG23176 (to M.Z.), and AG40132 (to M.Z.). T.
   F. D. acknowledges support from the Department of Veterans Affairs
   (Veterans Affairs Merit Award). M.I.N. is supported by the Maria I. New
   Children's Hormone Research Foundation and the Chinese University of
   Hong Kong.
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   Baliram R, 2012, J CLIN INVEST, V122, P3737, DOI 10.1172/JCI63948
   Baliram R, 2011, P NATL ACAD SCI USA, V108, P16277, DOI 10.1073/pnas.1110286108
   Bauer DC, 2001, ANN INTERN MED, V134, P561, DOI 10.7326/0003 4819 134 7 200104030 00009
   Blair HC, 2011, ANN NY ACAD SCI, V1240, P26, DOI 10.1111/j.1749 6632.2011.06287.x
   Byun CH, 2005, J BONE MINER RES, V20, P1125, DOI 10.1359/JBMR.050302
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Colaianni G, 2012, J BIOL CHEM, V287, P29159, DOI 10.1074/jbc.M112.365049
   Colaianni G, 2011, BIOCHEM BIOPH RES CO, V411, P512, DOI 10.1016/j.bbrc.2011.06.158
   Feldmann M, 2010, J IMMUNOL, V185, P791, DOI 10.4049/jimmunol.1090051
   Grimnes G, 2008, THYROID, V18, P1147, DOI 10.1089/thy.2008.0158
   Hase H, 2006, P NATL ACAD SCI USA, V103, P12849, DOI 10.1073/pnas.0600427103
   Iqbal J, 2006, P NATL ACAD SCI USA, V103, P14925, DOI 10.1073/pnas.0606805103
   Ishikawa Y, 1998, J BONE MINER RES, V13, P1398, DOI 10.1359/jbmr.1998.13.9.1398
   Kimble RB, 1997, J BONE MINER RES, V12, P935, DOI 10.1359/jbmr.1997.12.6.935
   Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838
   Kumar RS, 2000, MOL CELL ENDOCRINOL, V167, P1, DOI 10.1016/S0303 7207(00)00304 X
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   LI YP, 1993, MOL CELL BIOL, V13, P3714, DOI 10.1128/MCB.13.6.3714
   Ma RS, 2011, THYROID, V21, P897, DOI 10.1089/thy.2010.0457
   Marians RC, 2002, P NATL ACAD SCI USA, V99, P15776, DOI 10.1073/pnas.242322099
   Mazziotti G, 2005, J BONE MINER RES, V20, P480, DOI 10.1359/JBMR.041126
   Robinson LJ, 2010, BIOCHEM BIOPH RES CO, V394, P12, DOI 10.1016/j.bbrc.2010.02.112
   Sampath TK, 2007, J BONE MINER RES, V22, P849, DOI 10.1359/JBMR.070302
   SAWIN CT, 1989, JAMA J AM MED ASSOC, V261, P2653, DOI 10.1001/jama.261.18.2653
   Schett G, 2003, ARTHRITIS RHEUM, V48, P2042, DOI 10.1002/art.11150
   Senturk T, 2003, CLIN INVEST MED, V26, P58
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Sun L, 2008, BIOCHEM BIOPH RES CO, V371, P900, DOI 10.1016/j.bbrc.2008.03.114
   Sun L, 2008, P NATL ACAD SCI USA, V105, P4289, DOI 10.1073/pnas.0712395105
   Tamma R, 2009, P NATL ACAD SCI USA, V106, P7149, DOI 10.1073/pnas.0901890106
   Vincent BH, 2009, GENES IMMUN, V10, P18, DOI 10.1038/gene.2008.69
   Yamoah K, 2008, MOL ENDOCRINOL, V22, P1141, DOI 10.1210/me.2007 0460
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zaidi M, 2010, P NATL ACAD SCI USA, V107, P8782, DOI 10.1073/pnas.0912176107
   Zhu LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047058
   Zofkova Ivana, 2008, Endocr Regul, V42, P121
NR 38
TC 30
Z9 34
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 11
PY 2013
VL 110
IS 24
BP 9891
EP 9896
DI 10.1073/pnas.1308336110
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 171LM
UT WOS:000320930100068
PM 23716650
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Moe, SM
AF Moe, Sharon M.
TI Calcium Homeostasis in Health and in Kidney Disease
SO COMPREHENSIVE PHYSIOLOGY
LA English
DT Article
ID GROWTH FACTOR 23; CORONARY ARTERY CALCIFICATION; SENSING RECEPTOR CASR;
   SMOOTH MUSCLE CELLS; PATIENTS RECEIVING HEMODIALYSIS; LEFT VENTRICULAR
   HYPERTROPHY; PARATHYROID HORMONE LEVELS; CINACALCET HCL THERAPY;
   COTRANSPORTER NAPI IIA; FGF23 GENE EXPRESSION
AB Calcium is an important ion in cell signaling, hormone regulation, and bone health. Its regulation is complex and intimately connected to that of phosphate homeostasis. Both ions are maintained at appropriate levels to maintain the extracellular to intracellular gradients, allow for mineralization of bone, and to prevent extra skeletal and urinary calcification. The homeostasis involves the target organs intestine, parathyroid glands, kidney, and bone. Multiple hormones converge to regulate the extracellular calcium level: parathyroid hormone, vitamin D (principally 25(OH) D or 1,25(OH)(2)D), fibroblast growth factor 23, and alpha klotho. Fine regulation of calcium homeostasis occurs in the thick ascending limb and collecting tubule segments via actions of the calcium sensing receptor and several channels/transporters. The kidney participates in homeostatic loops with bone, intestine, and parathyroid glands. Initially in the course of progressive kidney disease, the homeostatic response maintains serum levels of calcium and phosphorus in the desired range, and maintains neutral balance. However, once the kidneys are no longer able to appropriately respond to hormones and excrete calcium and phosphate, positive balance ensues leading to adverse cardiac and skeletal abnormalities. (C) 2016 American Physiological Society.
C1 [Moe, Sharon M.] Indiana Univ Sch Med, Div Nephrol, Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA.
   [Moe, Sharon M.] Richard L Roudebush Vet Adm Med Ctr, Nephrol Sect, Indianapolis, IN 46202 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Richard L. Roudebush VA Medical Center; Indiana University System;
   Indiana University Bloomington; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Richard L. Roudebush VA Medical
   Center
RP Moe, SM (通讯作者)，Indiana Univ Sch Med, Div Nephrol, Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA.; Moe, SM (通讯作者)，Richard L Roudebush Vet Adm Med Ctr, Nephrol Sect, Indianapolis, IN 46202 USA.
EM smoe@iu.edu
CR Alexander RT, 2013, AM J PHYSIOL RENAL, V305, pF229, DOI 10.1152/ajprenal.00065.2013
   ALFREY AC, 1976, NEW ENGL J MED, V294, P184, DOI 10.1056/NEJM197601222940402
   ANDRESS DL, 1989, NEW ENGL J MED, V321, P274, DOI 10.1056/NEJM198908033210502
   Ba JM, 2003, AM J PHYSIOL RENAL, V285, pF1233, DOI 10.1152/ajprenal.00249.2003
   Bacchetta J, 2013, J BONE MINER RES, V28, P46, DOI 10.1002/jbmr.1740
   Bacic D, 2006, KIDNEY INT, V69, P495, DOI 10.1038/sj.ki.5000148
   BAKER LRI, 1989, KIDNEY INT, V36, pS140
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bellido T, 2013, BONE, V54, P250, DOI 10.1016/j.bone.2012.09.016
   Belov A. A, 2013, COLD SPRING HARB PER, V5
   Ben Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409
   Benn BS, 2008, ENDOCRINOLOGY, V149, P3196, DOI 10.1210/en.2007 1655
   Bergsland KJ, 2009, AM J PHYSIOL RENAL, V297, pF1017, DOI 10.1152/ajprenal.00223.2009
   Berndt TJ, 2005, AM J PHYSIOL RENAL, V289, pF1170, DOI 10.1152/ajprenal.00072.2005
   Bleyer AJ, 1999, AM J KIDNEY DIS, V33, P694, DOI 10.1016/S0272 6386(99)70221 0
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 2005, KIDNEY INT, V68, P1815, DOI 10.1111/j.1523 1755.2005.00600.x
   Boros S, 2009, PFLUG ARCH EUR J PHY, V458, P99, DOI 10.1007/s00424 008 0602 6
   Boskey AL, 1998, BONE, V23, P187, DOI 10.1016/S8756 3282(98)00092 1
   Brennan SC, 2014, BRIT J NUTR, V111, pS16, DOI 10.1017/S0007114513002250
   Bronner F, 2009, NUTR REV, V67, P109, DOI 10.1111/j.1753 4887.2008.00147.x
   Brown AJ, 2006, NEPHROL DIAL TRANSPL, V21, P644, DOI 10.1093/ndt/gfi186
   BROWN EM, 1983, J CLIN ENDOCR METAB, V56, P572, DOI 10.1210/jcem 56 3 572
   BROWN EM, 1991, J BONE MINER RES, V6, P1217
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371
   BROWN EM, 1995, BONE, V17, pS7, DOI 10.1016/8756 3282(95)00199 N
   Brownstein CA, 2008, P NATL ACAD SCI USA, V105, P3455, DOI 10.1073/pnas.0712361105
   Canalejo R, 2010, J AM SOC NEPHROL, V21, P1125, DOI 10.1681/ASN.2009040427
   Capuano P, 2005, PFLUG ARCH EUR J PHY, V449, P392, DOI 10.1007/s00424 004 1351 9
   Carpenter TO, 2010, J CLIN ENDOCR METAB, V95, pE352, DOI 10.1210/jc.2010 0589
   Cha SK, 2007, J MEMBRANE BIOL, V220, P79, DOI 10.1007/s00232 007 9076 2
   Cha SK, 2013, BBA MOL CELL RES, V1833, P3046, DOI 10.1016/j.bbamcr.2013.08.017
   Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245
   Charytan C, 2005, AM J KIDNEY DIS, V46, P58, DOI 10.1053/j.ajkd.2005.04.013
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   COBURN JW, 1973, KIDNEY INT, V4, P96, DOI 10.1038/ki.1973.88
   COBURN JW, 1973, KIDNEY INT, V3, P264, DOI 10.1038/ki.1973.40
   COCHRAN M, 1973, NEPHRON, V10, P113, DOI 10.1159/000180182
   Conigrave AD, 2013, BEST PRACT RES CL EN, V27, P315, DOI 10.1016/j.beem.2013.05.010
   Cozzolino M, 2003, KIDNEY INT, V64, P1653, DOI 10.1046/j.1523 1755.2003.00284.x
   Cozzolino M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000025782.24383.0D
   Cross HS, 2007, NUTR REV, V65, pS108, DOI 10.1111/j.1753 4887.2007.tb00334.x
   Crouthamel MH, 2013, ARTERIOSCL THROM VAS, V33, P2625, DOI 10.1161/ATVBAHA.113.302249
   D'Amour P, 2012, CLIN BIOCHEM, V45, P964, DOI 10.1016/j.clinbiochem.2012.04.029
   D'Haese PC, 2003, KIDNEY INT, V63, pS73, DOI 10.1046/j.1523 1755.63.s85.18.x
   Danese MD, 2015, NEPHROL DIAL TRANSPL, V30, P1336, DOI 10.1093/ndt/gfv034
   de Borst MH, 2011, J AM SOC NEPHROL, V22, P1603, DOI 10.1681/ASN.2010121251
   Déliot N, 2005, AM J PHYSIOL CELL PH, V289, pC159, DOI 10.1152/ajpcell.00456.2004
   Denda M, 1996, AM J KIDNEY DIS, V28, P596, DOI 10.1016/S0272 6386(96)90473 4
   Dewberry K, 1997, J AM SOC NEPHROL, V8, pA2610
   Di Marco GS, 2014, NEPHROL DIAL TRANSPL, V29, P2028, DOI 10.1093/ndt/gfu190
   de Barboza GD, 2015, WORLD J GASTROENTERO, V21, P7142, DOI 10.3748/wjg.v21.i23.7142
   Dimke H, 2013, AM J PHYSIOL RENAL, V304, pF761, DOI 10.1152/ajprenal.00263.2012
   Divieti P, 2002, ENDOCRINOLOGY, V143, P171, DOI 10.1210/en.143.1.171
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223
   DUSSO AS, 1991, J CLIN ENDOCR METAB, V72, P157, DOI 10.1210/jcem 72 1 157
   DUSSO AS, 1991, ENDOCRINOLOGY, V128, P1687, DOI 10.1210/endo 128 4 1687
   Egbuna O, 2009, AM J PHYSIOL RENAL, V297, pF720, DOI 10.1152/ajprenal.00164.2009
   Farrow EG, 2009, J AM SOC NEPHROL, V20, P955, DOI 10.1681/ASN.2008070783
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   Feng JQ, 2013, BONE, V54, P213, DOI 10.1016/j.bone.2013.01.046
   Galitzer H, 2010, KIDNEY INT, V77, P211, DOI 10.1038/ki.2009.464
   Gardiner EM, 2000, FASEB J, V14, P1908, DOI 10.1096/fj.99 1075com
   Gattineni J, 2009, AM J PHYSIOL RENAL, V297, pF282, DOI 10.1152/ajprenal.90742.2008
   Gauci C, 2008, J AM SOC NEPHROL, V19, P1592, DOI 10.1681/ASN.2007040449
   Giachelli CM, 2003, J AM SOC NEPHROL, V14, pS300, DOI 10.1097/01.ASN.0000081663.52165.66
   Gkika D, 2006, EMBO J, V25, P4707, DOI 10.1038/sj.emboj.7601357
   Glendenning P, 2013, ANN CLIN BIOCHEM, V50, P191, DOI 10.1177/0004563213482892
   Goltzman D, 2015, J STEROID BIOCHEM, V148, P219, DOI 10.1016/j.jsbmb.2014.09.011
   Gong YF, 2014, J AM SOC NEPHROL, V25, P745, DOI 10.1681/ASN.2013050553
   Gong YF, 2012, EMBO J, V31, P1999, DOI 10.1038/emboj.2012.49
   Grabner A, 2015, CELL METAB, V22, P1020, DOI 10.1016/j.cmet.2015.09.002
   Graciolli FG, 2009, NEPHROL DIAL TRANSPL, V24, P1416, DOI 10.1093/ndt/gfn686
   Groschel Charlotte, 2015, Adv Pharmacol, V74, P413, DOI 10.1016/bs.apha.2015.03.002
   Günzel D, 2009, ANN NY ACAD SCI, V1165, P152, DOI 10.1111/j.1749 6632.2009.04051.x
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Gutiérrez OM, 2009, CIRCULATION, V119, P2545, DOI 10.1161/CIRCULATIONAHA.108.844506
   HEALY MD, 1980, ARCH INTERN MED, V140, P1030, DOI 10.1001/archinte.140.8.1030
   HEANEY RP, 1964, J LAB CLIN MED, V64, P29
   Hendy GN, 2006, KIDNEY INT, V69, P218, DOI 10.1038/sj.ki.5000091
   Hendy GN, 2000, HUM MUTAT, V16, P281, DOI 10.1002/1098 1004(200010)16:4<281::AID HUMU1>3.0.CO;2 A
   Hill KM, 2013, KIDNEY INT, V83, P959, DOI 10.1038/ki.2012.403
   Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826
   Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080
   Hoorn EJ, 2013, PEDIATR NEPHROL, V28, P1195, DOI 10.1007/s00467 012 2350 2
   Hu MC, 2015, J AM SOC NEPHROL, V26, P1290, DOI 10.1681/ASN.2014050465
   Hu MC, 2013, SEMIN NEPHROL, V33, P118, DOI 10.1016/j.semnephrol.2012.12.013
   Hu MC, 2010, FASEB J, V24, P3438, DOI 10.1096/fj.10 154765
   Isakova T, 2011, JAMA J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826
   Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47
   Isakova T, 2009, J AM SOC NEPHROL, V20, P388, DOI 10.1681/ASN.2008060609
   Jiang Y, 2007, AM J PHYSIOL RENAL, V292, pF545, DOI 10.1152/ajprenal.00187.2006
   Jones G, 2013, ANNU REV NUTR, V33, P23, DOI 10.1146/annurev nutr 071812 161203
   Kantham L, 2009, AM J PHYSIOL ENDOC M, V297, pE915, DOI 10.1152/ajpendo.00315.2009
   Katsumata K, 2003, KIDNEY INT, V64, P441, DOI 10.1046/j.1523 1755.2003.00126.x
   Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kolek OI, 2005, AM J PHYSIOL GASTR L, V289, pG1036, DOI 10.1152/ajpgi.00243.2005
   Kos CH, 2003, J CLIN INVEST, V111, P1021, DOI 10.1172/JCI200317416
   Krajisnik T, 2010, KIDNEY INT, V78, P1024, DOI 10.1038/ki.2010.260
   Krupp K, 2014, INT J CARDIOL, V176, P1341, DOI 10.1016/j.ijcard.2014.07.142
   Kuro o M, 2010, PEDIATR NEPHROL, V25, P583, DOI 10.1007/s00467 009 1260 4
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Lambers TT, 2007, MOL CELL BIOL, V27, P1486, DOI 10.1128/MCB.01468 06
   LAMBERT PW, 1982, J CLIN INVEST, V69, P722, DOI 10.1172/JCI110501
   Lameris AL, 2015, AM J PHYSIOL GASTR L, V308, pG206, DOI 10.1152/ajpgi.00093.2014
   Lavi Moshayoff V, 2010, AM J PHYSIOL RENAL, V299, pF882, DOI 10.1152/ajprenal.00360.2010
   Lederer ED, 2003, J AM SOC NEPHROL, V14, P1711, DOI 10.1097/01.ASN.0000072744.67971.21
   Lee J, 2005, J GEN PHYSIOL, V126, P439, DOI 10.1085/jgp.200509314
   Lee M, 2009, CURR OPIN NEPHROL HY, V18, P298, DOI 10.1097/MNH.0b013e32832c2264
   Lee SM, 2015, J BIOL CHEM, V290, P18199, DOI 10.1074/jbc.M115.665794
   Li YX, 1996, J CLIN INVEST, V97, P910, DOI 10.1172/JCI118513
   Lieben L, 2010, BONE, V47, P301, DOI 10.1016/j.bone.2010.04.595
   Liu N, 2008, ENDOCRINOLOGY, V149, P4799, DOI 10.1210/en.2008 0060
   Lu P, 2008, NEPHROL DIAL TRANSPL, V23, P3397, DOI 10.1093/ndt/gfn291
   MALLUCHE HH, 1978, MINER ELECTROL METAB, V1, P263
   Markovic V, 2005, AM J CLIN NUTR, V81, P175
   Martino NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111533
   Masuyama R, 2014, J BONE MINER METAB, V32, P1, DOI 10.1007/s00774 013 0508 z
   Mathew S, 2007, J AM SOC NEPHROL, V18, P122, DOI 10.1681/ASN.2006050490
   Miller RT, 2013, BEST PRACT RES CL EN, V27, P345, DOI 10.1016/j.beem.2013.04.009
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe SM, 2006, CLIN J AM SOC NEPHRO, V1, P697, DOI 10.2215/CJN.00560206
   Moe SM, 2015, CIRCULATION, V132, P27, DOI 10.1161/CIRCULATIONAHA.114.013876
   Moe SM, 2015, J AM SOC NEPHROL, V26, P1466, DOI 10.1681/ASN.2014040414
   Moe SM, 2014, J BONE MINER RES, V29, P902, DOI 10.1002/jbmr.2089
   Moe SM, 2009, NEPHROL DIAL TRANSPL, V24, P2371, DOI 10.1093/ndt/gfp078
   Moe SM, 2009, KIDNEY INT, V75, P176, DOI 10.1038/ki.2008.456
   Moe SM, 2003, KIDNEY INT, V63, P1003, DOI 10.1046/j.1523 1755.2003.00820.x
   Moe SM, 2016, KIDNEY, P1822
   Nagano N, 2005, CLIN CALCIUM S1, V15, P39
   Nagano Nobuo, 2005, Clin Calcium, V15 Suppl 1, P35
   NAVEHMANY T, 1989, ENDOCRINOLOGY, V125, P275, DOI 10.1210/endo 125 1 275
   NAVEHMANY T, 1990, J CLIN INVEST, V86, P1313, DOI 10.1172/JCI114840
   Nechama M, 2009, AM J PHYSIOL RENAL, V296, pF795, DOI 10.1152/ajprenal.90625.2008
   Negri AL, 2005, J NEPHROL, V18, P654
   Neves KR, 2007, KIDNEY INT, V71, P1262, DOI 10.1038/sj.ki.5002241
   Nigwekar SU, 2014, BONEKEY REP, V3
   Nijenhuis T, 2006, J AM SOC NEPHROL, V17, P617, DOI 10.1681/ASN.2005070732
   Nikolov IG, 2012, NEPHROL DIAL TRANSPL, V27, P505, DOI 10.1093/ndt/gfr254
   Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201
   NORDAL KP, 1988, J CLIN ENDOCR METAB, V67, P929, DOI 10.1210/jcem 67 5 929
   Olauson H, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003975
   Palmer SC, 2011, JAMA J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   PARFITT AM, 1989, BONE, V10, P87, DOI 10.1016/8756 3282(89)90003 3
   Parfrey PS, 2015, CLIN J AM SOC NEPHRO, V10, P791, DOI 10.2215/CJN.07730814
   Parfrey PS, 2013, J CLIN ENDOCR METAB, V98, P4834, DOI 10.1210/jc.2013 2975
   Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505
   Pike JW, 2008, ENDOCRINOLOGY, V149, P3656, DOI 10.1210/en.2008 0042
   QI QL, 1995, AM J KIDNEY DIS, V26, P622, DOI 10.1016/0272 6386(95)90599 5
   Qunibi W, 2008, AM J KIDNEY DIS, V51, P952, DOI 10.1053/j.ajkd.2008.02.298
   Raggi P, 2004, J HEART VALVE DIS, V13, P134
   RAMIREZ JA, 1993, J CLIN ENDOCR METAB, V76, P1489, DOI 10.1210/jc.76.6.1489
   Ren SY, 2005, J BIOL CHEM, V280, P20604, DOI 10.1074/jbc.M414522200
   Renkema KY, 2009, J AM SOC NEPHROL, V20, P1705, DOI 10.1681/ASN.2008111195
   Reynolds JL, 2004, J AM SOC NEPHROL, V15, P2857, DOI 10.1097/01.ASN.0000141960.01035.28
   Riccardi D, 2013, BEST PRACT RES CL EN, V27, P443, DOI 10.1016/j.beem.2013.02.010
   Ritter CS, 2006, KIDNEY INT, V70, P654, DOI 10.1038/sj.ki.5000394
   Rodriguez Ortiz ME, 2012, J AM SOC NEPHROL, V23, P1190, DOI 10.1681/ASN.2011101006
   Rossol M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2339
   Rudnicki MA, 2015, BONE, V80, P60, DOI 10.1016/j.bone.2015.02.009
   Russo D, 2007, KIDNEY INT, V72, P1255, DOI 10.1038/sj.ki.5002518
   Saint Criq V, 2012, STEROIDS, V77, P918, DOI 10.1016/j.steroids.2012.02.017
   Satoh M, 2012, AM J PHYSIOL RENAL, V303, pF1641, DOI 10.1152/ajprenal.00460.2012
   Shalhoub V, 2012, J CLIN INVEST, V122, P2543, DOI 10.1172/JCI61405
   Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914
   Shi Y, 2009, BIOMETALS, V22, P317, DOI 10.1007/s10534 008 9168 1
   Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081
   Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   SHIMIZU T, 1990, AM J PHYSIOL, V259, pF408, DOI 10.1152/ajprenal.1990.259.3.F408
   Shroff RC, 2008, CIRCULATION, V118, P1748, DOI 10.1161/CIRCULATIONAHA.108.783738
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   SILVER J, 1986, J CLIN INVEST, V78, P1296, DOI 10.1172/JCI112714
   Silver J, 2009, KIDNEY INT, V75, P898, DOI 10.1038/ki.2008.642
   SLATOPOLSKY E, 1973, KIDNEY INT, V4, P141, DOI 10.1038/ki.1973.92
   Slatopolsky E, 1996, J CLIN INVEST, V97, P2534, DOI 10.1172/JCI118701
   SLATOPOLSKY E, 1986, NEW ENGL J MED, V315, P157, DOI 10.1056/NEJM198607173150304
   SLATOPOLSKY E, 1984, J CLIN INVEST, V74, P2136, DOI 10.1172/JCI111639
   SLATOPOLSKY E, 1989, KIDNEY INT, V36, P897, DOI 10.1038/ki.1989.277
   Smith RC, 2012, J CLIN INVEST, V122, P4710, DOI 10.1172/JCI64986
   Song S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082968
   Speer MY, 2009, CIRC RES, V104, P733, DOI 10.1161/CIRCRESAHA.108.183053
   Spence LA, 2005, AM J CLIN NUTR, V81, P916, DOI 10.1093/ajcn/81.4.916
   Sprague SM, 2013, CLIN J AM SOC NEPHRO, V8, P313, DOI 10.2215/CJN.04650512
   Stevens LA, 2004, J AM SOC NEPHROL, V15, P770, DOI 10.1097/01.ASN.0000113243.24155.2F
   SUTTON RAL, 1975, CAN J PHYSIOL PHARM, V53, P979, DOI 10.1139/y75 136
   Takasu H, 1999, J BONE MINER RES, V14, P11, DOI 10.1359/jbmr.1999.14.1.11
   Takeshita K, 2004, CIRCULATION, V109, P1776, DOI 10.1161/01.CIR.0000124224.48962.32
   Talmage D. W., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P108
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Toka HR, 2015, PHYSIOLOGY, V30, P317, DOI 10.1152/physiol.00042.2014
   Tokumoto M, 2009, AM J NEPHROL, V29, P582, DOI 10.1159/000192844
   Torres PU, 2007, KIDNEY INT, V71, P730, DOI 10.1038/sj.ki.5002163
   Touchberry CD, 2013, AM J PHYSIOL ENDOC M, V304, pE863, DOI 10.1152/ajpendo.00596.2012
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   van de Graaf SFJ, 2004, J STEROID BIOCHEM, V89 90, P303, DOI 10.1016/j.jsbmb.2004.03.029
   van de Graaf SFJ, 2008, J BIOL CHEM, V283, P4077, DOI 10.1074/jbc.M706959200
   Wetmore JB, 2011, J CLIN ENDOCR METAB, V96, pE57, DOI 10.1210/jc.2010 1277
   White KE, 2014, CURR OSTEOPOROS REP, V12, P252, DOI 10.1007/s11914 014 0223 2
   Woudenberg Vrenken TE, 2012, AM J PHYSIOL GASTR L, V303, pG879, DOI 10.1152/ajpgi.00089.2012
   Xie J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2240
   Xue YB, 2006, ENDOCRINOLOGY, V147, P4801, DOI 10.1210/en.2006 0403
   Xue YB, 2012, AM J PHYSIOL ENDOC M, V302, pE841, DOI 10.1152/ajpendo.00599.2011
   Yeh BI, 2005, EMBO J, V24, P3224, DOI 10.1038/sj.emboj.7600795
   Yeh BI, 2003, J BIOL CHEM, V278, P51044, DOI 10.1074/jbc.M306326200
   Yu ASL, 2015, J AM SOC NEPHROL, V26, P11, DOI 10.1681/ASN.2014030284
   Zhou YB, 2009, EXP BIOL MED, V234, P908, DOI 10.3181/0811 RM 346
NR 213
TC 44
Z9 50
U1 0
U2 38
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 2040 4603
J9 COMPR PHYSIOL
JI Compr. Physiol.
PD OCT
PY 2016
VL 6
IS 4
BP 1781
EP 1800
DI 10.1002/cphy.c150052
PG 20
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA EI8GK
UT WOS:000392743900008
PM 27783859
DA 2025 08 17
ER

PT J
AU Galán Díez, M
   Borot, F
   Ali, AM
   Zhao, JF
   Gil Iturbe, E
   Shan, XC
   Luo, N
   Liu, YF
   Huang, XP
   Bisikirska, B
   Labella, R
   Kurland, I
   Roth, BL
   Quick, M
   Mukherjee, S
   Rabadán, R
   Carroll, M
   Raza, A
   Kousteni, S
AF Galan Diez, Marta
   Borot, Florence
   Ali, Abdullah Mahmood
   Zhao, Junfei
   Gil Iturbe, Eva
   Shan, Xiaochuan
   Luo, Na
   Liu, Yongfeng
   Huang, Xi Ping
   Bisikirska, Brygida
   Labella, Rossella
   Kurland, Irwin
   Roth, Bryan L.
   Quick, Matthias
   Mukherjee, Siddhartha
   Rabadan, Raul
   Carroll, Martin
   Raza, Azra
   Kousteni, Stavroula
TI Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine
   Drives Acute Myeloid Leukemia
SO CANCER DISCOVERY
LA English
DT Article
ID MESENCHYMAL STROMAL CELLS; HEMATOPOIETIC STEM CELLS; INDOLEAMINE
   2,3 DIOXYGENASE; BONE FORMATION; INHIBITION; GROWTH; NICHE; MICE;
   BLASTS; GENE
AB Remodeling of the microenvironment by tumor cells can activate pathways that favor cancer growth. Molecular delineation and targeting of such malignant cell non autonomous pathways may help overcome resistance to targeted therapies. Herein we leverage genetic mouse models, patient derived xenografts, and patient samples to show that acute myeloid leukemia (AML) exploits peripheral serotonin signaling to remodel the endosteal niche to its advantage. AML progression requires the presence of serotonin receptor 1B (HTR1B) in osteoblasts and is driven by AML secreted kynurenine, which acts as an oncometabolite and HTR1B ligand. AML cells utilize kynurenine to induce a proinfl ammatory state in osteoblasts that, through the acute phase protein serum amyloid A (SAA), acts in a positive feedback loop on leukemia cells by increasing expression of IDO1 the rate limiting enzyme for kynurenine synthesis thereby enabling AML progression. This leukemia osteoblast cross talk, conferred by the kynurenine HTR1B SAA IDO1 axis, could be exploited as a niche focused therapeutic approach against AML, opening new avenues for cancer treatment. SIGNIFICANCE: AML remains recalcitrant to treatments due to the emergence of resistant clones. We show a leukemia cell nonautonomous progression mechanism that involves activation of a kynurenine  HTR1B SAA IDO1 axis between AML cells and osteoblasts. Targeting the niche by interrupting this axis can be pharmacologically harnessed to hamper AML progression and overcome therapy resistance.
C1 [Galan Diez, Marta; Luo, Na; Bisikirska, Brygida; Labella, Rossella; Kousteni, Stavroula] Columbia Univ, Dept Physiol & Cellular Biophys, 650 W 168th St, New York, NY 10032 USA.
   [Borot, Florence; Ali, Abdullah Mahmood; Mukherjee, Siddhartha; Raza, Azra; Kousteni, Stavroula] Columbia Univ, Herbert Irving Comprehens Canc Ctr HICCC, New York, NY 10032 USA.
   [Ali, Abdullah Mahmood; Mukherjee, Siddhartha; Raza, Azra] Columbia Univ, Myelodysplast Syndromes Ctr, New York, NY 10032 USA.
   [Zhao, Junfei; Rabadan, Raul] Columbia Univ, Dept Syst Biol, Program Math Genom, New York, NY 10032 USA.
   [Gil Iturbe, Eva; Quick, Matthias] Columbia Univ, Dept Psychiat, New York, NY 10032 USA.
   [Shan, Xiaochuan; Carroll, Martin] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
   [Liu, Yongfeng; Huang, Xi Ping; Roth, Bryan L.] Univ North Carolina, Med Sch, Dept Pharmacol, NIMH Psychoact Drug Screening Program, Chapel Hill, NC 27515 USA.
   [Kurland, Irwin] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
   [Roth, Bryan L.] Univ North Carolina, Div Chem Biol & Med Chem, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.
   [Quick, Matthias] New York State Psychiat Inst & Hosp, Div Mol Therapeut, New York, NY 10032 USA.
   [Mukherjee, Siddhartha; Raza, Azra; Kousteni, Stavroula] Columbia Univ, Edward P Evans Ctr Myelodysplast Syndromes, New York, NY 10032 USA.
   [Rabadan, Raul] Columbia Univ, Dept Biomed Informat, New York, NY 10032 USA.
   [Kousteni, Stavroula] Columbia Univ, Columbia Stem Cell Initiat, New York, NY 10032 USA.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University; Columbia University; University of Pennsylvania; University
   of North Carolina; University of North Carolina Chapel Hill; National
   Institutes of Health (NIH)   USA; NIH National Institute of Mental
   Health (NIMH); Yeshiva University; Montefiore Medical Center; Albert
   Einstein College of Medicine; University of North Carolina; University
   of North Carolina Chapel Hill; New York State Psychiatry Institute;
   Columbia University; Columbia University; Columbia University
RP Galán Díez, M; Kousteni, S (通讯作者)，Columbia Univ, Dept Physiol & Cellular Biophys, 650 W 168th St, New York, NY 10032 USA.
EM martagalandiez@gmail.com; sk2836@cumc.columbia.edu
RI Liu, Yongfeng/ABG 1361 2020; Roth, Bryan/F 3928 2010; Rabadan,
   Raul/AAZ 7367 2020; Labella, Rossella/JBR 7878 2023; GALAN DIEZ,
   MARTA/A 7037 2019; Gil Iturbe, Eva/C 4387 2018; Ali,
   Abdullah/AAI 4094 2020; Huang, xp/JRX 2837 2023; Galan Diez,
   Marta/A 7037 2019; luo, na/KOC 3893 2024
OI Liu, Yongfeng/0000 0002 8649 7892; Bisikirska,
   Brygida/0000 0002 4681 2827; GALAN DIEZ, MARTA/0000 0002 2092 3414;
   Gil Iturbe, Eva/0000 0002 4046 5756; Labella,
   Rossella/0000 0002 3768 9273
FU NIH [AR054447, HL130937]; Edward P. Evans Foundation for MDS Research;
   Mandl Connective Tissue Research Fellowship; NIH/NCI Cancer Center
   Support Grant [P30CA013696]; Stable Isotope and Metabolomics Core
   Facility of the Diabetes Research and Training Center (DRTC) of the
   Albert Einstein College of Medicine [NIH P60DK020541]
FX We thank Rene Hen, PhD, for the Htr1b<SUP> / </SUP> mice; P. Greengard,
   PhD, for Htr1bfl/fl mice; Roshan P. Shah, MD, for healthy patient
   samples; Mark Heany, MD, for AML samples; Yunping Qiu for technical
   assistance with metabolomic analysis; Michael P. Biagiotti for technical
   assistance with CRISPR/Cas9 assays; Israel S. Fernandez, PhD, for
   metabolomic data analysis and critical discussion; and G. Karsenty, MD,
   PhD, and E. Passegue, PhD, for critical review and comments. We thank
   the Columbia Stem Cell Initiative Flow Cytometry core facility (directed
   by Michael Kissner). Funding for this research was provided by NIH
   AR054447, HL130937, the Edward P. Evans Foundation for MDS Research to
   S. Kousteni, and the Mandl Connective Tissue Research Fellowship awarded
   to M. Galan Diez; NIH/NCI Cancer Center Support Grant P30CA013696 and
   the Stable Isotope and Metabolomics Core Facility of the Diabetes
   Research and Training Center (DRTC) of the Albert Einstein College of
   Medicine (NIH P60DK020541). The Oncology Precision Therapeutics and
   Imaging Core (OPTIC) at the Herbert Irving Comprehensive Cancer Center
   at Columbia University shared resource was used.
CR Abraham M, 2017, LEUKEMIA, V31, P2336, DOI 10.1038/leu.2017.82
   Banús Mulet A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 32306 4
   Ben Batalla I, 2013, BLOOD, V122, P2443, DOI 10.1182/blood 2013 03 491431
   Bowers M, 2015, BLOOD, V125, P2678, DOI 10.1182/blood 2014 06 582924
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chamuleau MED, 2008, HAEMATOL HEMATOL J, V93, P1894, DOI 10.3324/haematol.13113
   Chen CC, 2020, CANCER CELL, V37, P71, DOI 10.1016/j.ccell.2019.12.002
   Chung DJ, 2009, BLOOD, V114, P555, DOI 10.1182/blood 2008 11 191197
   Corm S, 2009, LEUKEMIA RES, V33, P490, DOI 10.1016/j.leukres.2008.06.014
   Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092 8674(00)81269 6
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   DeFalco J, 2001, SCIENCE, V291, P2608, DOI 10.1126/science.1056602
   Djurec M, 2018, P NATL ACAD SCI USA, V115, pE1147, DOI 10.1073/pnas.1717802115
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Döhner H, 2017, BLOOD, V129, P424, DOI 10.1182/blood 2016 08 733196
   Dong L, 2016, NATURE, V539, P304, DOI 10.1038/nature20131
   Duy C, 2021, CANCER DISCOV, V11, P1542, DOI 10.1158/2159 8290.CD 20 1375
   Etxabe A, 2017, LEUKEMIA, V31, P2288, DOI 10.1038/leu.2017.52
   Farge T, 2017, CANCER DISCOV, V7, P716, DOI 10.1158/2159 8290.CD 16 0441
   Folgiero V, 2014, ONCOTARGET, V5, P2052, DOI 10.18632/oncotarget.1504
   Fontana F, 2017, J BONE MINER RES, V32, P1332, DOI 10.1002/jbmr.3112
   Frisch BJ, 2012, BLOOD, V119, P540, DOI 10.1182/blood 2011 04 348151
   Fukuno K, 2015, LEUKEMIA LYMPHOMA, V56, P1398, DOI 10.3109/10428194.2014.953150
   Galán Díez M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031328
   Gaster LM, 1998, J MED CHEM, V41, P1218, DOI 10.1021/jm970457s
   Haltalli MLR, 2020, NAT CELL BIOL, V505, P1
   Hwu P, 2000, J IMMUNOL, V164, P3596, DOI 10.4049/jimmunol.164.7.3596
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Koblish HK, 2010, MOL CANCER THER, V9, P489, DOI 10.1158/1535 7163.MCT 09 0628
   Kode A, 2016, LEUKEMIA, V30, P1, DOI 10.1038/leu.2015.161
   Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883
   Komrokji RS, 2019, CL LYMPH MYELOM LEUK, V19, P157, DOI 10.1016/j.clml.2018.12.005
   Krevvata M, 2014, BLOOD, V124, P2834, DOI 10.1182/blood 2013 07 517219
   Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980
   Lemos H, 2019, NAT REV CANCER, V19, P162, DOI 10.1038/s41568 019 0106 z
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu XD, 2010, BLOOD, V115, P3520, DOI 10.1182/blood 2009 09 246124
   Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470 2045(19)30274 8
   LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059 014 0550 8
   Löwenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407
   Mabuchi R, 2016, LEUKEMIA LYMPHOMA, V57, P92, DOI 10.3109/10428194.2015.1041388
   Medyouf H, 2014, CELL STEM CELL, V14, P824, DOI 10.1016/j.stem.2014.02.014
   Mendez Ferrer S, 2020, NAT REV CANCER, V127, P2375
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Miller PG, 2013, CANCER CELL, V24, P45, DOI 10.1016/j.ccr.2013.05.004
   Mizoguchi T, 2014, DEV CELL, V29, P340, DOI 10.1016/j.devcel.2014.03.013
   Mulero Navarro S, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00045
   Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178
   Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013
   Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363
   Natoni A, 2017, LEUKEMIA, V31, P2642, DOI 10.1038/leu.2017.123
   Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491
   Patel N, 2020, ELIFE, V9, DOI 10.7554/eLife.53779
   Percudani R, 2003, EMBO REP, V4, P850, DOI 10.1038/sj.embor.embor914
   Platten M, 2019, NAT REV DRUG DISCOV, V18, P379, DOI 10.1038/s41573 019 0016 5
   Prendergast GC, 2017, CANCER RES, V77, P6795, DOI 10.1158/0008 5472.CAN 17 2285
   Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214
   Schepers K, 2015, CELL STEM CELL, V16, P254, DOI 10.1016/j.stem.2015.02.014
   Schepers K, 2013, CELL STEM CELL, V13, P285, DOI 10.1016/j.stem.2013.06.009
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432 1327.1999.00657.x
   Virk MS, 2016, P NATL ACAD SCI USA, V113, P734, DOI 10.1073/pnas.1524183113
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Waizenegger JS, 2015, LEUKEMIA, V29, P696, DOI 10.1038/leu.2014.236
   Wang WH, 2016, CANCER RES, V76, P1641, DOI 10.1158/0008 5472.CAN 15 2092
   Witkowski MT, 2020, CANCER CELL, V37, P867, DOI 10.1016/j.ccell.2020.04.015
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yamashita M, 2020, NAT REV CANCER, V20, P365, DOI 10.1038/s41568 020 0260 3
   YATES JW, 1973, CANCER CHEMOTH REP 1, V57, P485
   Ye HB, 2018, CANCER CELL, V34, P659, DOI 10.1016/j.ccell.2018.08.016
   Yue EW, 2017, ACS MED CHEM LETT, V8, P486, DOI 10.1021/acsmedchemlett.6b00391
   Zambetti NA, 2016, CELL STEM CELL, V19, P613, DOI 10.1016/j.stem.2016.08.021
   Zhang B, 2016, BLOOD, V128, P2671, DOI 10.1182/blood 2015 11 679928
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 79
TC 22
Z9 25
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 2159 8274
EI 2159 8290
J9 CANCER DISCOV
JI Cancer Discov.
PD APR
PY 2022
VL 12
IS 4
BP 1106
EP 1127
DI 10.1158/2159 8290.CD 21 0692
PG 22
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 1K3VJ
UT WOS:000798532400001
PM 35046097
OA Green Submitted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Sisli, HB
   Hayal, TB
   Senkal, S
   Bulut, E
   Kiratli, B
   Asutay, AB
   Sahin, F
   Bayrak, ÖF
   Dogan, A
AF Sisli, Hatice Burcu
   Hayal, Taha Bartu
   Senkal, Selinay
   Bulut, Ezgi
   Kiratli, Binnur
   Asutay, Ayla Burcin
   Sahin, Fikrettin
   Bayrak, Omer Faruk
   Dogan, Aysegul
TI Activation of Wnt Pathway Suppresses Growth of MUG Chor1 Chordoma Cell
   Line
SO CELL BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Wnt; GSK3 & beta;; Brachury; & beta; catenin; Chordoma
ID TRANSCRIPTION FACTOR BRACHYURY; SURVIVAL PATTERNS; T BRACHYURY;
   SOFT TISSUE; TARGET; TUMORS; GENE; EXPRESSION; INHIBITORS; TANKYRASE
AB Chordoma as a malignant bone tumor, occurs along the axial skeleton and does not have an effective therapy. Brachyury, which is a crucial player for the formation of early embryonic notochord, is abundantly found in both sporadic and familial chordoma. During embryonic development, Brachyury expression was reported to be regulated by the Wnt pathway. The objective of the study is to investigate the role of Wnt signaling in a human chordoma cell line in terms of proliferation, survival, and invasiveness. We tried to elucidate the signaling events that regulate Chordoma cancer. In this regard, Wnt pathway was activated or inhibited using various strategies including small molecules, siRNA based knockdown and overexpression applications. The results indicated the negative regulatory effect of Wnt signaling activity on proliferation and migration capacity of the chordoma cells. It was revealed that when GSK3 beta was inhibited, the Wnt pathway was activated and negatively regulated T/Bra expression. Activity of the Wnt pathway caused cell cycle arrest, reduced migration potential of the cells, and led to cell death. Therefore, the present study suggests that the Wnt pathway plays a key role in suppressing the proliferation and invasive characteristics of human chordoma cells and has a great potential as a therapeutic target in further clinical studies.
C1 [Sisli, Hatice Burcu; Hayal, Taha Bartu; Senkal, Selinay; Bulut, Ezgi; Kiratli, Binnur; Asutay, Ayla Burcin; Sahin, Fikrettin; Dogan, Aysegul] Yeditepe Univ, Fac Engn, Genet & Bioengn Dept, TR 34755 Istanbul, Turkiye.
   [Bayrak, Omer Faruk] Yeditepe Univ, Sch Med, Dept Med Genet, TR 34755 Istanbul, Turkiye.
C3 Yeditepe University; Yeditepe University
RP Dogan, A (通讯作者)，Yeditepe Univ, Fac Engn, Genet & Bioengn Dept, TR 34755 Istanbul, Turkiye.
EM aysegul.dogan@yeditepe.edu.tr
RI ; Bayrak, Omer Faruk/HCH 6864 2022; Doğan, Ayşegül/AAD 3223 2019; Sisli,
   Hatice Burcu/GPS 9900 2022; Şenkal Turhan, Selinay/GPT 0437 2022; Hayal,
   Taha/JXL 1790 2024; Bulut Okumuş, Ezgi/ADN 8335 2022
OI Bulut Okumus, Ezgi/0000 0001 5842 6088; Dogan,
   Aysegul/0000 0003 4160 2270; hayal, taha bartu/0000 0003 1369 2715; 
FU Yeditepe University; Outstanding Young Scientists Award (TUEBA GEBIdot;P
   2020)
FX This study was supported by Yeditepe University. Ay & scedil;eguel Dogan
   was supported by Outstanding Young Scientists Award (TUEBA GEB & Idot;P
   2020).
CR Akpinar G, 2021, J MEMBRANE BIOL, V254, P409, DOI 10.1007/s00232 021 00190 1
   Al Mefty O, 2017, ACTA NEUROCHIR, V159, P1869, DOI 10.1007/s00701 017 3287 9
   Arnold SJ, 2000, MECH DEVELOP, V91, P249, DOI 10.1016/S0925 4773(99)00309 3
   Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797
   Balogh P, 2020, HISTOPATHOLOGY, V76, P924, DOI 10.1111/his.14056
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   Casás Selves M, 2012, CANCER RES, V72, P4154, DOI 10.1158/0008 5472.CAN 11 2848
   Chambers KJ, 2014, LARYNGOSCOPE, V124, P1097, DOI 10.1002/lary.24420
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Chen KW, 2017, ONCOL LETT, V14, P5533, DOI 10.3892/ol.2017.6839
   Cho HY, 2009, APPL IMMUNOHISTO M M, V17, P131, DOI 10.1097/PAI.0b013e3181866a13
   Choi HJ, 2019, EMBO REP, V20, DOI 10.15252/embr.201948058
   Chugh R, 2007, ONCOLOGIST, V12, P1344, DOI 10.1634/theoncologist.12 11 1344
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Di Maio S, 2012, NEUROSURGERY, V70, P1355, DOI 10.1227/NEU.0b013e3182446783
   Dogan A, 2012, INT J NANOMED, V7, P4849, DOI 10.2147/IJN.S31949
   Duan J, 2018, EXP CELL RES, V370, P461, DOI 10.1016/j.yexcr.2018.07.010
   Edwards YH, 1996, GENOME RES, V6, P226, DOI 10.1101/gr.6.3.226
   Frezza AM, 2019, CURR OPIN ONCOL, V31, P114, DOI 10.1097/CCO.0000000000000502
   Gatta G, 2017, LANCET ONCOL, V18, P1022, DOI 10.1016/S1470 2045(17)30445 X
   Gulluoglu S, 2016, NEUROSURG REV, V39, P185, DOI 10.1007/s10143 015 0663 x
   Hamilton DH, 2015, ONCOTARGET, V6, P4853, DOI 10.18632/oncotarget.3086
   Hayal TB, 2020, TURK J BIOL, V44, P145, DOI 10.3906/biy 1912 83
   HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0
   Hsu W, 2011, J NEUROSURG, V115, P760, DOI 10.3171/2011.5.JNS11185
   Hu TH, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 236
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Jezkova J, 2016, ONCOTARGET, V7, P11478, DOI 10.18632/oncotarget.7202
   Jian BJ, 2010, J NEURO ONCOL, V98, P101, DOI 10.1007/s11060 009 0068 1
   Jo VY, 2014, PATHOLOGY, V46, P95, DOI 10.1097/PAT.0000000000000050
   Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276 020 0380 6
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Lau CSM, 2016, PEDIATR NEUROSURG, V51, P127, DOI 10.1159/000442990
   Liu L, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12588
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Magnaghi P, 2018, MOL CANCER THER, V17, P603, DOI 10.1158/1535 7163.MCT 17 0324
   McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735
   Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010
   Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468
   Miettinen M, 2015, AM J SURG PATHOL, V39, P1305, DOI 10.1097/PAS.0000000000000462
   Otani R, 2018, J NEUROSURG, V128, P1428, DOI 10.3171/2016.12.JNS161444
   Palena C, 2007, CLIN CANCER RES, V13, P2471, DOI 10.1158/1078 0432.CCR 06 2353
   Pandey MK, 2016, THERANOSTICS, V6, P571, DOI 10.7150/thno.14334
   Presneau N, 2011, J PATHOL, V223, P327, DOI 10.1002/path.2816
   Radaelli S, 2016, SPINE, V41, P1049, DOI 10.1097/BRS.0000000000001604
   Rao DB, 2021, DRUG DEVELOP RES, V82, P1182, DOI 10.1002/ddr.21833
   Rinner B, 2012, INT J ONCOL, V40, P443, DOI 10.3892/ijo.2011.1235
   Roselli M, 2012, CLIN CANCER RES, V18, P3868, DOI 10.1158/1078 0432.CCR 11 3211
   Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769
   Shah SR, 2017, CELL REP, V21, P495, DOI 10.1016/j.celrep.2017.09.057
   Sharifnia T, 2019, NAT MED, V25, P292, DOI 10.1038/s41591 018 0312 3
   Shimamatsu S, 2016, ANN SURG ONCOL, V23, pS1012, DOI 10.1245/s10434 016 5530 7
   Shome R, 2021, CELL ONCOL, V44, P405, DOI 10.1007/s13402 020 00576 8
   Showell C, 2004, DEV DYNAM, V229, P201, DOI 10.1002/dvdy.10480
   Singh AM, 2012, CELL STEM CELL, V10, P312, DOI 10.1016/j.stem.2012.01.014
   Smith J., 1997, COLD SPRING HARB SYM
   Smoll NR, 2013, CANCER AM CANCER SOC, V119, P2029, DOI 10.1002/cncr.28032
   Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960 9822(02)70790 2
   Sun X, 2015, CURR REV MUSCULOSKE, V8, P344, DOI 10.1007/s12178 015 9311 x
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tirabosco R, 2008, AM J SURG PATHOL, V32, P572, DOI 10.1097/PAS.0b013e31815b693a
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   Yamada Y, 2013, CURR TREAT OPTION ON, V14, P442, DOI 10.1007/s11864 013 0247 3
   Yamaguchi TP, 1999, GENE DEV, V13, P3185, DOI 10.1101/gad.13.24.3185
   Yan XD, 2019, ONCOTARGETS THER, V12, P9783, DOI 10.2147/OTT.S218930
   Yang XHR, 2009, NAT GENET, V41, P1176, DOI 10.1038/ng.454
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
NR 67
TC 0
Z9 0
U1 1
U2 1
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1085 9195
EI 1559 0283
J9 CELL BIOCHEM BIOPHYS
JI Cell Biochem. Biophys.
PD DEC
PY 2023
VL 81
IS 4
BP 823
EP 837
DI 10.1007/s12013 023 01178 5
EA SEP 2023
PG 15
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA X2BW3
UT WOS:001074205700001
PM 37751039
DA 2025 08 17
ER

PT J
AU Han, S
   Li, X
   Xia, Y
   Yu, ZS
   Cai, NN
   Malwal, SR
   Han, X
   Oldfield, E
   Zhang, YH
AF Han, Shuai
   Li, Xin
   Xia, Yun
   Yu, Zhengsen
   Cai, Ningning
   Malwal, Satish R.
   Han, Xu
   Oldfield, Eric
   Zhang, Yonghui
TI Farnesyl Pyrophosphate Synthase as a Target for Drug Development:
   Discovery of Natural Product Derived Inhibitors and Their Activity in
   Pancreatic Cancer Cells
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID CONTINUOUS SPECTROPHOTOMETRIC ASSAY; ADJUVANT ENDOCRINE THERAPY; PLUS
   ZOLEDRONIC ACID; 62 MONTH FOLLOW UP; DIPHOSPHATE SYNTHASE;
   BREAST CANCER; MULTIPLE MYELOMA; T CELLS; BISPHOSPHONATE; RAS
AB Human farnesyl pyrophosphate synthase (Homo sapiens FPPS, HsFPPS) is a target for treating bone resorption diseases and some cancers. HsFPPS is potently inhibited by bisphosphonates, but due to poor cell penetration and distribution in soft tissue, there is currently interest in the development of non bisphosphonate inhibitors as cancer therapeutics. Here, we report the discovery and development of HsFPPS inhibitors based on the phenolic diterpene carnosic acid (CA), an antimicrobial found in rosemary and sage, which showed better cellular anticancer activities than the bisphosphonate drug zoledronate in pancreatic cancer cell lines, as well as an HsFPPS dependent mechanism of action. Hit to  lead optimization of CA improved HsFPPS inhibition by >100  fold. A slow dissociation inhibition pattern and a noncompetitive allosteric binding mode were found, and cellular mechanism  of action studies showed that these inhibitors inhibit tumor cell growth primarily by inhibiting HsFPPS, leading to downregulation of Ras prenylation and cell apoptosis. The discovery of this series of compounds together with proof of mechanism in pancreatic cancer cells may pave the way for targeting HsFPPS in soft tissue cancers using natural product  derived inhibitors.
C1 [Han, Shuai; Li, Xin; Xia, Yun; Yu, Zhengsen; Cai, Ningning; Zhang, Yonghui] Tsinghua Univ, Sch Pharmaceut Sci, MOE Key Lab Bioorgan Phosphorus Chem & Chem Biol, Beijing 100084, Peoples R China.
   [Li, Xin; Xia, Yun; Zhang, Yonghui] Tsinghua Univ, Sch Life Sci, Joint Grad Program Peking Tsinghua NIBS, Beijing 100084, Peoples R China.
   [Cai, Ningning; Zhang, Yonghui] Sichuan Univ, Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Malwal, Satish R.; Oldfield, Eric] Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
   [Han, Xu] Chinese Acad Sci, Tianjin Inst Ind Biotechnol, Ind Enzymes Natl Engn Lab, Tianjin 300308, Peoples R China.
C3 Tsinghua University; National Institute of Biological Sciences, Beijing;
   Tsinghua University; Sichuan University; University of Illinois System;
   University of Illinois Urbana Champaign; Chinese Academy of Sciences;
   Tianjin Institute of Industrial Biotechnology, CAS
RP Zhang, YH (通讯作者)，Tsinghua Univ, Sch Pharmaceut Sci, MOE Key Lab Bioorgan Phosphorus Chem & Chem Biol, Beijing 100084, Peoples R China.; Zhang, YH (通讯作者)，Tsinghua Univ, Sch Life Sci, Joint Grad Program Peking Tsinghua NIBS, Beijing 100084, Peoples R China.; Zhang, YH (通讯作者)，Sichuan Univ, Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Oldfield, E (通讯作者)，Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
EM eoldfiel@illinois.edu; zhangyonghui@tsinghua.edu.cn
RI ; Xia, Yun/HHT 1276 2022
OI , Yonghui/0000 0002 9842 3049; 
FU National Key R&D Program of China [2015BAI08B03, 2017YFA1014000,
   2017YFA1014001]; National Natural Science Foundation of China
   [81573270]; Beijing Natural Science Foundation [Z190015]; Beijing
   Municipal Science and Technology Commission [Z161100000216154]; 1000
   Young Talents Program; Tsinghua Peking Center for Life Science; Beijing
   Advanced Innovation Centre for Structural Biology; United States Public
   Health Service (NIH) [GM065307]
FX This work was funded in part by grants from the National Key R&D Program
   of China (Grants 2015BAI08B03, 2017YFA1014000, 2017YFA1014001), National
   Natural Science Foundation of China (Grant 81573270), Beijing Natural
   Science Foundation (Grant Z190015), the Beijing Municipal Science and
   Technology Commission (Grant Z161100000216154), the 1000 Young Talents
   Program, the Tsinghua Peking Center for Life Science, the Beijing
   Advanced Innovation Centre for Structural Biology, and in part by the
   United States Public Health Service (NIH Grant GM065307). We thank
   Wolfgang Jahnke for his WaterLOGSY pulse sequence and Yi Xue for his
   assistance with WaterLOGSY experiment. We thank Rey ting Guo and
   Chun Chi Chen for their help and suggestions on binding mode
   investigations. We thank colleagues of Center of Pharmaceutical
   Technology, Tsinghua University, for their help on this project.
CR Al Jamal A. R., 2011, Jordan Journal of Biological Sciences (JJBS), V4, P199
   Aldrich C, 2017, J MED CHEM, V60, P2165, DOI 10.1021/acs.jmedchem.7b00229
   [Anonymous], The PyMOL Molecular Graphics System
   Aoyagi Y, 2006, BIOORGAN MED CHEM, V14, P5285, DOI 10.1016/j.bmc.2006.03.047
   Baell JB, 2016, J NAT PROD, V79, P616, DOI 10.1021/acs.jnatprod.5b00947
   Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]
   Bentinger M, 1998, ARCH BIOCHEM BIOPHYS, V353, P191, DOI 10.1006/abbi.1998.0611
   Birtic S, 2015, PHYTOCHEMISTRY, V115, P9, DOI 10.1016/j.phytochem.2014.12.026
   Bocci G, 2005, BRIT J CANCER, V93, P319, DOI 10.1038/sj.bjc.6602720
   Coleman R, 2011, BREAST CANCER RES TR, V127, P429, DOI 10.1007/s10549 011 1429 y
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Collin H, 2006, HANDBOOK OF HERBS AND SPICES, VOL 3, P126, DOI 10.1533/9781845691717.2.126
   Copeland RA, 2006, NAT REV DRUG DISCOV, V5, P730, DOI 10.1038/nrd2082
   Copeland RA, 2016, NAT REV DRUG DISCOV, V15, P87, DOI 10.1038/nrd.2015.18
   Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111
   Dalvit C, 2000, J BIOMOL NMR, V18, P65, DOI 10.1023/A:1008354229396
   De Schutter JW, 2014, J MED CHEM, V57, P5764, DOI 10.1021/jm500629e
   Del Campo J, 2000, J FOOD PROTECT, V63, P1359, DOI 10.4315/0362 028X 63.10.1359
   Eckert GP, 2009, NEUROBIOL DIS, V35, P251, DOI 10.1016/j.nbd.2009.05.005
   Firn R, 2010, NATURE'S CHEMICALS: THE NATURAL PRODUCTS THAT SHAPED OUR WORLD, P1
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Gnant M, 2011, BONE, V48, pS17, DOI 10.1016/j.bone.2010.10.045
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Gong J, 2017, ONCOL LETT, V13, P1035, DOI 10.3892/ol.2017.5572
   Haney SL, 2019, ONCOGENE, V38, P5308, DOI 10.1038/s41388 019 0794 6
   Hellriegel M, 2011, EUR J CANCER, V47, pS390, DOI 10.1016/S0959 8049(11)71643 4
   Hooff GP, 2010, BBA MOL CELL BIOL L, V1801, P896, DOI 10.1016/j.bbalip.2010.03.014
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Irwin JJ, 2015, J MED CHEM, V58, P7076, DOI 10.1021/acs.jmedchem.5b01105
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   JANNI W, 2018, CANCER RES S, V78
   Johnson JJ, 2011, CANCER LETT, V305, P1, DOI 10.1016/j.canlet.2011.02.005
   Johnston PA, 2011, CURR OPIN CHEM BIOL, V15, P174, DOI 10.1016/j.cbpa.2010.10.022
   Karlsson R, 2006, ANAL BIOCHEM, V349, P136, DOI 10.1016/j.ab.2005.09.034
   Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kim E, 2011, BIOMACROMOLECULES, V12, P880, DOI 10.1021/bm101499a
   Kim WI, 2009, BLOOD, V113, P1086, DOI 10.1182/blood 2008 01 132316
   Kusama T, 2001, CANCER RES, V61, P4885
   Kusama T, 2002, GASTROENTEROLOGY, V122, P308, DOI 10.1053/gast.2002.31093
   Leung CY, 2013, J MED CHEM, V56, P7939, DOI 10.1021/jm400946f
   Lindert S, 2013, CHEM BIOL DRUG DES, V81, P742, DOI 10.1111/cbdd.12121
   Liu JG, 2014, BBA GEN SUBJECTS, V1840, P1051, DOI 10.1016/j.bbagen.2013.11.006
   Liu YL, 2015, ACS MED CHEM LETT, V6, P349, DOI 10.1021/ml500528x
   Liu YL, 2014, P NATL ACAD SCI USA, V111, pE2530, DOI 10.1073/pnas.1409061111
   Marma MS, 2007, J MED CHEM, V50, P5967, DOI 10.1021/jm0702884
   Marzinzik AL, 2015, CHEMMEDCHEM, V10, P1884, DOI 10.1002/cmdc.201500338
   Morgan GJ, 2012, BLOOD, V119, P5374, DOI 10.1182/blood 2011 11 392522
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Palau W, 2013, TALANTA, V114, P211, DOI 10.1016/j.talanta.2013.04.022
   Park J, 2017, J MED CHEM, V60, P2119, DOI 10.1021/acs.jmedchem.6b01888
   Park J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14132
   Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008 5472.CAN 11 2612
   Rieger CE, 1997, ANAL BIOCHEM, V246, P86, DOI 10.1006/abio.1996.9962
   Romo Vaquero M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094687
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822 013 9644 8
   Scagliotti GV, 2012, ANN ONCOL, V23, P2082, DOI 10.1093/annonc/mds128
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822 007 9133 z
   Sicard H, 2001, MOL MED, V7, P711, DOI 10.1007/BF03401961
   Soares KM, 2010, ASSAY DRUG DEV TECHN, V8, P152, DOI 10.1089/adt.2009.0247
   TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   ten Klooster JP, 2007, BIOL CELL, V99, P1, DOI 10.1042/BC20060071
   Tokoroyama T, 2010, EUR J ORG CHEM, V2010, P2009, DOI 10.1002/ejoc.200901130
   Valachis A, 2011, EUR J CANCER, V47, pS377, DOI 10.1016/S0959 8049(11)71599 4
   Viegas A, 2011, J CHEM EDUC, V88, P990, DOI 10.1021/ed101169t
   Wang H, 2011, J IMMUNOL, V187, P5099, DOI 10.4049/jimmunol.1002697
   Wang M, 2016, NAT REV MOL CELL BIO, V17, P110, DOI 10.1038/nrm.2015.11
   Waters AM, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031435
   WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884
   Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood 2002 12 3665
   Xia YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010382
   Xia Y, 2018, CELL, V175, P1059, DOI 10.1016/j.cell.2018.08.070
   Zhang YH, 2010, ANGEW CHEM INT EDIT, V49, P1136, DOI 10.1002/anie.200905933
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 77
TC 29
Z9 30
U1 0
U2 61
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 12
PY 2019
VL 62
IS 23
BP 10867
EP 10896
DI 10.1021/acs.jmedchem.9b01405
PG 30
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA JW5TL
UT WOS:000503114200022
PM 31725297
DA 2025 08 17
ER

PT J
AU Zhao, XQ
   Lin, Y
   Jiang, BJ
   Yin, JH
   Lu, CL
   Wang, J
   Zeng, JR
AF Zhao, Xueqiang
   Lin, Yun
   Jiang, Bijia
   Yin, Jianhua
   Lu, Chunlan
   Wang, Juan
   Zeng, Jinrong
TI Icaritin inhibits lung cancer induced osteoclastogenesis by suppressing
   the expression of IL 6 and TNF a and through AMPK/mTOR signaling pathway
SO ANTI CANCER DRUGS
LA English
DT Article
DE AMPK; icaritin; lung cancer; mTOR; one metastasis; osteoclastogenesis
ID BONE METASTASIS; ACTIVATION; DIFFERENTIATION; SURVIVAL; GROWTH; ALPHA;
   CELLS; CSF
AB Bone metastasis is one of the common phenomena in the late stage of lung cancer. Inhibition of bone metastasis can improve the survival of lung cancer patients. However, the current drugs for the treatment of bone metastasis have shown little effect on overall survival. Therefore, there is an urgent necessity to identify novel drugs capable of preventing and treating bone metastasis of lung cancer. Our study determined that icaritin (ICT) can inhibit lung cancer mediated osteoclastogenesis and induce the apoptosis of osteoclasts. Exposure to ICT increased the activation of adenosine 5' monophosphate activated protein kinase (AMPK), reduced the activation of mammalian target of rapamycin (mTOR) and decreased the expression of bcl 2. The bioactivity of ICT on osteoclastogenesis was associated with the regulation of the AMPK/mTOR signaling pathway. Blocking AMPK significantly increased osteoclast differentiation, decreased osteoclast apoptosis and canceled the effects of ICT on the phosphorylation of AMPK as well as the inhibition of mTOR and bcl 2. Furthermore, ICT decreased the levels of IL 6 and TNF alpha in osteoclasts, while the AMPK inhibitor compound C significantly abolished the inhibitory effects of ICT on IL 6 and TNF alpha. Thus, the present study demonstrated that ICT may be a potential natural agent for the treatment of bone metastasis in patients with lung cancer.
C1 [Zhao, Xueqiang; Lin, Yun; Jiang, Bijia; Yin, Jianhua; Lu, Chunlan; Zeng, Jinrong] Guilin Med Univ, Affiliated Hosp 2, Dept Resp Med, 212 Renming Rd, Guilin 541199, Guangxi Zhuang, Peoples R China.
   [Wang, Juan] Guilin Med Univ, Coll Pharm, Guilin, Guangxi Zhuang, Peoples R China.
   [Wang, Juan] Guilin Med Univ, Res Ctr Sci, Guilin, Guangxi Zhuang, Peoples R China.
C3 Guilin Medical University; Guilin Medical University; Guilin Medical
   University
RP Zeng, JR (通讯作者)，Guilin Med Univ, Affiliated Hosp 2, Dept Resp Med, 212 Renming Rd, Guilin 541199, Guangxi Zhuang, Peoples R China.
EM zjrefy@163.com
RI Shen, Ren/C 4195 2013
FU Middle aged and Young Teachers' Basic Ability Promotion Project of
   Guangxi [2017KY0499]; Scientific Research Project of Guangxi Autonomous
   Region Health and Family Planning Commission [S2017107, Z20170873];
   Young Teachers' Research Project of Guilin Medical University
   [2018glmcy101]
FX This study was supported by Middle aged and Young Teachers' Basic
   Ability Promotion Project of Guangxi (grant no. 2017KY0499), which was
   granted by the Scientific Research Project of Guangxi Autonomous Region
   Health and Family Planning Commission (grant nos. S2017107 and
   Z20170873) and the Young Teachers' Research Project of Guilin Medical
   University(grant no. 2018glmcy101).
CR Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200
   Chen MF, 2010, AMINO ACIDS, V38, P1505, DOI 10.1007/s00726 009 0366 0
   Gao LF, 2018, LIFE SCI, V202, P188, DOI 10.1016/j.lfs.2018.03.059
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Gorny G, 2004, EXP CELL RES, V294, P149, DOI 10.1016/j.yexcr.2003.11.009
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Kang JI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144368
   Kato K, 2012, CELL SIGNAL, V24, P1706, DOI 10.1016/j.cellsig.2012.04.012
   Kim JY, 2015, BONE, V79, P242, DOI 10.1016/j.bone.2015.06.011
   Le AW, 2017, EXP THER MED, V14, P5949, DOI 10.3892/etm.2017.5278
   Li CF, 2016, ONCOL LETT, V12, P3537, DOI 10.3892/ol.2016.5089
   Li SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081657
   Liu SY, 2016, ONCOTARGET, V7, P45158, DOI 10.18632/oncotarget.9783
   Lu PH, 2017, ONCOTARGET, V8, P22800, DOI 10.18632/oncotarget.15205
   Ma HP, 2011, J ETHNOPHARMACOL, V134, P519, DOI 10.1016/j.jep.2011.01.001
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Miller KD, 2019, CA CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Okabe H, 2018, CANCER SCI, V109, P112, DOI 10.1111/cas.13435
   Pruksakorn D, 2018, J BONE ONCOL, V10, P1, DOI 10.1016/j.jbo.2017.10.001
   Sakai G, 2018, FEBS LETT, V592, P1202, DOI 10.1002/1873 3468.13028
   Sarkar D, 2017, EBIOMEDICINE, V19, P6, DOI 10.1016/j.ebiom.2017.04.028
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Sheng H, 2013, INT J MED SCI, V10, P782, DOI 10.7150/ijms.6084
   Sugiura H, 2008, CLIN ORTHOP RELAT R, V466, P729, DOI 10.1007/s11999 007 0051 0
   Tan HL, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00191
   Wang X, 2017, J STEROID BIOCHEM, V171, P318, DOI 10.1016/j.jsbmb.2017.05.009
   Wang ZQ, 2009, CHEM BIOL INTERACT, V179, P375, DOI 10.1016/j.cbi.2008.12.007
   Wo YB, 2008, J CELL BIOCHEM, V103, P1536, DOI 10.1002/jcb.21541
   Wu JF, 2014, FOOD CHEM TOXICOL, V64, P307, DOI 10.1016/j.fct.2013.12.006
   Yang ZZ, 2017, EBIOMEDICINE, V19, P49, DOI 10.1016/j.ebiom.2017.04.017
   Ye WL, 2018, ARTIF CELL NANOMED B, P1
   Yoo HS, 2017, ONCOL REP, V37, P3287, DOI 10.3892/or.2017.5590
   Yu GT, 2018, CELL MOL LIFE SCI, V75, P4223, DOI 10.1007/s00018 018 2863 3
   Zeng YP, 2016, MOL MED REP, V14, P1957, DOI 10.3892/mmr.2016.5456
   Zhao N, 2015, LIFE SCI, V143, P1, DOI 10.1016/j.lfs.2015.10.027
   Zhao X, 2008, AM J PHYSIOL LUNG C, V295, pL497, DOI 10.1152/ajplung.90210.2008
NR 36
TC 15
Z9 22
U1 2
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959 4973
EI 1473 5741
J9 ANTI CANCER DRUG
JI Anti Cancer Drugs
PD NOV
PY 2020
VL 31
IS 10
BP 1004
EP 1011
DI 10.1097/CAD.0000000000000976
PG 8
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA OE2TK
UT WOS:000580389200003
PM 32701561
DA 2025 08 17
ER

PT J
AU Tseng, WP
   Yang, SN
   Lai, CH
   Tang, CH
AF Tseng, Wen Pei
   Yang, Shu Ning
   Lai, Chih Ho
   Tang, Chih Hsin
TI Hypoxia Induces BMP 2 Expression Via ILK, Akt, mTOR, and HIF 1 Pathways
   in Osteoblasts
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID INTEGRIN LINKED KINASE; BONE MORPHOGENETIC PROTEIN 2; INDUCIBLE
   FACTOR I; OXYGEN TENSION; FACTOR 1 ALPHA; ENERGY STRESS; TARGET GENES;
   O 2 TENSION; ACTIVATION; FACTOR 1
AB It has been shown that hypoxia stimulation regulates bone formation, maintenance, and repair. Bone morphogenetic protein (BMP) plays important roles in osteoblastic differentiation and bone formation. However, the effects of hypoxia exposure on BMP 2 expression in cultured osteoblasts are largely unknown. Here we found that hypoxia stimulation increased mRNA and protein levels of BMP 2 by qPCR, Western blot and ELISA assay in osteoblastic cells MG 63, hFOB and bone marrow stromal cells M2 10B4. Integrin linked kinase (ILK) inhibitor (KP 392), Akt inhibitor (IL 6 hydroxymethyl chiro inositol 2 [(R) 2 O methyl 3 O octadecylcarbonate]) or mammalian target of rapamycin (mTOR) inhibitor (rapamycin) inhibited the potentiating action of hypoxia. Exposure to hypoxia increased the kinase activity of ILK and phosphorylation of Akt and mTOR. Furthermore, hypoxia also increased the stability and activity of HIF I protein. The binding of HIF I alpha to the HRE elements after exposure to hypoxia was measured by EMSA assay. Moreover, the use of pharmacological inhibitors or genetic inhibition revealed that both ILK/Akt and mTOR signaling pathway were potentially required for hypoxia induced HIF I alpha activation and subsequent BMP 2 up regulation. Taken together, our results provide evidence that hypoxia enhances BMP 2 expression in osteoblasts by an HIF I alpha dependent mechanism involving the activation of ILK/Akt and mTOR pathways. J. Cell. Physiol. 223: 810 818, 2010. (C) 2010 Wiley Liss, Inc.
C1 [Tang, Chih Hsin] China Med Univ, Dept Pharmacol, Coll Med, Taichung, Taiwan.
   [Lai, Chih Ho] China Med Univ, Dept Microbiol, Taichung, Taiwan.
   [Tang, Chih Hsin] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan.
   [Tseng, Wen Pei; Yang, Shu Ning] Natl Changhua Univ Educ, Grad Inst Sports & Hlth, Changhua, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Taiwan; National Changhua University of Education
RP Tang, CH (通讯作者)，China Med Univ, Dept Pharmacol, Coll Med, 91 Hsueh Shih Rd, Taichung, Taiwan.
EM chtang@mail.cmu.edu.tw
RI Tang, Chih/O 5212 2015; Lai, Chih Ho/M 2433 2013
OI Lai, Chih Ho/0000 0001 7145 784X
FU National Science Council of Taiwan [NSC 97 2320 B 039 031  MY3]; China
   Medical University [CMU98 CT 11, CMU98 CT 20]
FX Contract grant sponsor: National Science Council of Taiwan;Contract
   grant number: NSC 97 2320 B 039 031  MY3.Contract grant sponsor: China
   Medical University;Contract grant numbers: CMU98 CT 11, CMU98 CT 20.
CR Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647 200204000 00003
   Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839
   CORDOVA A, 1994, PHYSIOL BEHAV, V55, P413, DOI 10.1016/0031 9384(94)90093 0
   Dodd JS, 1999, AM J PHYSIOL CELL PH, V277, pC598, DOI 10.1152/ajpcell.1999.277.3.C598
   Epari DR, 2008, BONE, V43, P734, DOI 10.1016/j.bone.2008.06.007
   Fleet JC, 1996, ENDOCRINOLOGY, V137, P4605, DOI 10.1210/en.137.11.4605
   Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200
   Hirao M, 2007, J BONE MINER METAB, V25, P266, DOI 10.1007/s00774 007 0765 9
   Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P1215, DOI 10.1073/pnas.93.3.1215
   Hwang JM, 2008, MOL CELL BIOCHEM, V311, P179, DOI 10.1007/s11010 008 9708 6
   Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363
   Jiang BH, 1996, AM J PHYSIOL CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172
   Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519
   Komatsu DE, 2004, BONE, V34, P680, DOI 10.1016/j.bone.2003.12.024
   Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405 7416.2002
   Lee SP, 2006, CIRCULATION, V114, P150, DOI 10.1161/CIRCULATIONAHA.105.595918
   Lu DY, 2006, BIOCHEM PHARMACOL, V72, P992, DOI 10.1016/j.bcp.2006.06.038
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Matsumoto A, 2001, J PERIODONTAL RES, V36, P175, DOI 10.1034/j.1600 0765.2001.360306.x
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Mojsilovic Petrovic J, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742 2094 4 12
   Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642
   Salim A, 2004, J BIOL CHEM, V279, P40007, DOI 10.1074/jbc.M403715200
   Schipani E, 2006, ANN NY ACAD SCI, V1068, P66, DOI 10.1196/annals.1346.009
   Schneider A, 2008, NEOPLASIA, V10, P1295, DOI 10.1593/neo.08586
   Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006 2952(99)00292 0
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529
   Sharp FR, 2004, NAT REV NEUROSCI, V5, P437, DOI 10.1038/nrn1408
   Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834 5845.2005
   Su JL, 2007, J BIOL CHEM, V282, P19385, DOI 10.1074/jbc.M702452200
   Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535 6108(03)00281 2
   Tan TW, 2009, CARCINOGENESIS, V30, P258, DOI 10.1093/carcin/bgn284
   Tang CH, 2007, J BIOL CHEM, V282, P25406, DOI 10.1074/jbc.M701001200
   Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077
   Wu JB, 2008, EUR J PHARMACOL, V588, P333, DOI 10.1016/j.ejphar.2008.04.030
   Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008 5472.CAN 04 2940
   Zahm AM, 2008, BONE, V43, P25, DOI 10.1016/j.bone.2008.03.010
   Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012
NR 43
TC 80
Z9 96
U1 0
U2 14
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0021 9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUN
PY 2010
VL 223
IS 3
BP 810
EP 818
DI 10.1002/jcp.22104
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 593TF
UT WOS:000277482900030
PM 20232298
OA Bronze
DA 2025 08 17
ER

PT J
AU Dai, JJ
   Hu, ZY
   Zeng, FC
   Gong, XS
   Tang, H
   Deng, JZ
   Li, JM
   Dong, SW
AF Dai, Jingjin
   Hu, Zhaoyang
   Zeng, Fanchun
   Gong, Xiaoshan
   Tang, Hao
   Deng, Jiezhong
   Li, Jianmei
   Dong, Shiwu
TI Osteoclast derived exosomal miR 212 3p suppressed the anabolism and
   accelerated the catabolism of chondrocytes in osteoarthritis by
   targeting TGF β1/Smad2 signaling
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Chondrocytes; Exosomes; miR 212 3p; Smad2; Osteoarthritis
ID HYPERTROPHY; CARTILAGE; CELLS; MODEL
AB Osteoarthritis (OA) is a common aging related disease affecting entire joint structures, encompassing articular cartilage and subchondral bone. Although senescence and dysfunction of chondrocytes are considered crucial factors in the occurrence of OA, the exact pathogenesis remains to be investigated. In our study, chondrocytes were incubated with a conditioned medium obtained from osteoclasts at different differentiation stages, sug gesting that osteoclasts and osteoclast precursors suppressed anabolism and promoted the catabolism of chon drocytes in vitro. In contrast, the function of osteoclasts was more significant than osteoclast precursors. Further blocking of osteoclast exosome secretion by using GW4869 abolished the effect of osteoclasts on chondrocytes. Functionally, exosomal transfer of osteoclast derived miR 212 3p inhibited Smad2 to mediate chondrocyte dysfunction, thus accelerating cartilage matrix degradation in OA via TGF beta 1/Smad2 signaling. The mechanism was also confirmed within the articular cartilage in OA patients and surgery induced OA mice. Our study pro vides new information on intercellular interactions in the bone microenvironment within articular cartilage and subchondral bone during OA progression. The miR 212 3p/Smad2 axis is a potential target for the prevention and therapy of OA.
C1 [Dai, Jingjin; Gong, Xiaoshan; Tang, Hao; Li, Jianmei; Dong, Shiwu] Army Med Univ, Dept Biomed Mat Sci, Chongqing 400038, Peoples R China.
   [Hu, Zhaoyang] 921th Hosp Joint Logist Support Force, Dept Burns, Changsha, Peoples R China.
   [Zeng, Fanchun] Chongqing Univ, Coll Bioengn, Chongqing, Peoples R China.
   [Deng, Jiezhong] Army Med Univ, Southwest Hosp, Dept Orthoped, Chongqing, Peoples R China.
   [Dong, Shiwu] Army Med Univ, State Key Lab Trauma & Chem Poisoning, Chongqing, Peoples R China.
   [Dong, Shiwu] Army Med Univ, Dept Biomed Mat Sci, Chongqing 400038, Peoples R China.
C3 Army Medical University; Chongqing University; Army Medical University;
   Army Medical University; Army Medical University
RP Dong, SW (通讯作者)，Army Med Univ, Dept Biomed Mat Sci, Chongqing 400038, Peoples R China.
EM dongshiwu@163.com
FU Key Program of National Natural Science Foundation of China [81930067];
   Integration Project of NSFC Joint Fund for Regional Innovation and
   Development [U23A6008]; Youth Cultivation Project of Army Medical
   University [2020XQN08]
FX This work was funded by project supported by the Key Program of National
   Natural Science Foundation of China (81930067), the Integration Project
   of NSFC Joint Fund for Regional Innovation and Development (U23A6008)
   and the Youth Cultivation Project of Army Medical University
   (2020XQN08).
CR Andreev D, 2020, J CLIN INVEST, V130, P4811, DOI 10.1172/JCI134214
   Cao Z, 2016, BMB REP, V49, P548, DOI 10.5483/BMBRep.2016.49.10.071
   Chapman K, 2012, BONE, V51, P258, DOI 10.1016/j.bone.2011.11.026
   Chen J, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109186
   Choi WS, 2019, NATURE, V566, P254, DOI 10.1038/s41586 019 0920 1
   Cisternas MG, 2016, ARTHRIT CARE RES, V68, P574, DOI 10.1002/acr.22721
   Dai JJ, 2020, AM J PHYSIOL CELL PH, V319, pC21, DOI 10.1152/ajpcell.00039.2020
   Feng L, 2022, MOL THER NUCL ACIDS, V28, P328, DOI 10.1016/j.omtn.2022.03.016
   Feng L, 2020, MOL THER NUCL ACIDS, V21, P1017, DOI 10.1016/j.omtn.2020.07.018
   Ge Qinwen, 2023, JCI Insight, V8, DOI 10.1172/jci.insight.166688
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95
   Guss JD, 2019, OSTEOARTHR CARTILAGE, V27, P129, DOI 10.1016/j.joca.2018.07.020
   Hata A, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022061
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hojo H, 2016, TRENDS GENET, V32, P774, DOI 10.1016/j.tig.2016.10.001
   Hoshi H, 2017, CELL TISSUE RES, V368, P379, DOI 10.1007/s00441 016 2563 y
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Huang LJ, 2023, DIABETOL METAB SYNDR, V15, DOI 10.1186/s13098 023 01070 5
   James SL, 2018, LANCET, V392, P1789, DOI [10.1016/s0140 6736(18)32335 3, 10.1016/S0140 6736(18)32335 3]
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Lefebvre Veronique, 2005, Birth Defects Research, V75, P200, DOI 10.1002/bdrc.20048
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Liu J, 2021, NATURE AGING, V1, P368, DOI 10.1038/s43587 021 00050 6
   Liu LL, 2022, RHEUMATOLOGY, V61, P2631, DOI 10.1093/rheumatology/keab725
   Maes C, 2012, J BONE MINER RES, V27, P596, DOI 10.1002/jbmr.1487
   Martel Pelletier J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.72
   Moskowitz RW, 2006, OSTEOARTHR CARTILAGE, V14, P1, DOI 10.1016/j.joca.2005.08.015
   Mueller MB, 2008, ARTHRITIS RHEUM US, V58, P1377, DOI 10.1002/art.23370
   Nagata K, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33744 5
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Purushothaman A, 2016, J BIOL CHEM, V291, P1652, DOI 10.1074/jbc.M115.686295
   Qiu M, 2021, LIFE SCI, V269, DOI 10.1016/j.lfs.2020.118987
   Quan HY, 2018, CELL PHYSIOL BIOCHEM, V46, P401, DOI 10.1159/000488474
   Quiros M, 2017, J CLIN INVEST, V127, P3516, DOI 10.1172/JCI90229
   Seong S, 2021, EXP MOL MED, V53, P848, DOI 10.1038/s12276 021 00616 9
   Stevanin M, 2017, EUR J IMMUNOL, V47, P637, DOI 10.1002/eji.201646565
   Sun RP, 2023, INT J MED SCI, V20, P1679, DOI 10.7150/ijms.86665
   Tao YX, 2021, BIOORG CHEM, V113, DOI 10.1016/j.bioorg.2021.104978
   Thielen NGM, 2019, CELLS BASEL, V8, DOI 10.3390/cells8090969
   Wang HL, 2021, PHYTOMEDICINE, V88, DOI 10.1016/j.phymed.2021.153609
   Wang TT, 2018, CYTOKINE GROWTH F R, V44, P38, DOI 10.1016/j.cytogfr.2018.10.002
   Wang Y, 2023, BIOMED PHARMACOTHER, V159, DOI 10.1016/j.biopha.2023.114216
   Weng PW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222011082
   Xia QQ, 2021, BIOENGINEERED, V12, P11225, DOI 10.1080/21655979.2021.1995580
   Xie Y, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974 022 02557 0
   Yang JX, 2020, CELL SIGNAL, V70, DOI 10.1016/j.cellsig.2019.109504
   Yang ZM, 2021, EUR J PHARMACOL, V907, DOI 10.1016/j.ejphar.2021.174265
   Yoon DS, 2023, INT J BIOL SCI, V19, P13, DOI 10.7150/ijbs.74895
   Zheng WW, 2019, FASEB J, V33, P4077, DOI 10.1096/fj.201801851R
NR 51
TC 8
Z9 8
U1 4
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003 9861
EI 1096 0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD JAN
PY 2024
VL 751
AR 109827
DI 10.1016/j.abb.2023.109827
EA NOV 2023
PG 15
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CU5C2
UT WOS:001127753800001
PM 38000494
DA 2025 08 17
ER

PT J
AU Liu, CL
   Ho, TL
   Fang, SY
   Guo, JH
   Wu, CY
   Fong, YC
   Liaw, CC
   Tang, CH
AF Liu, Chun Lin
   Ho, Trung Loc
   Fang, Shuen Yih
   Guo, Jeng Hung
   Wu, Chih Ying
   Fong, Yi Chin
   Liaw, Chih Chuang
   Tang, Chih Hsin
TI Ugonin L inhibits osteoclast formation and promotes osteoclast apoptosis
   by inhibiting the MAPK and NF κB pathways
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Ugonin L; Osteoclast; RANKL; Bone resorption; Apoptosis
ID P38 MAPK; ANGIOGENESIS; ACTIVATION; EXPRESSION; DIFFERENTIATION
AB Bone loss is a major issue for patients with osteoporosis, arthritis, periodontitis, and bone metastasis; however, anti resorption drugs used to treat bone loss have been linked to a variety of adverse effects. Helminthostachys zeylanica (L.) Hook, belonging to the family Ophioglossaceae, is commonly used in traditional Chinese medicine to treat inflammation and liver problems. In the current study, ugonin L extracted from H. zeylanica was shown to reduce the receptor activator of nuclear factor kappa beta ligand (RANKL) induced osteoclastogenesis in RAW264.7 cells in a concentration dependent manner. Ugonin L treatment also inhibited the mRNA expression of osteoclast markers. Ugonin L was also shown to promote cell apoptosis in mature osteoclasts and suppress RANKL induced ERK, p38, JNK, and NF kappa B activation. Taken together, ugonin L appears to be a promising candidate for the development of novel anti resorption therapies.
C1 [Liu, Chun Lin; Ho, Trung Loc; Guo, Jeng Hung; Tang, Chih Hsin] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.
   [Liu, Chun Lin; Guo, Jeng Hung; Wu, Chih Ying] China Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan.
   [Fang, Shuen Yih; Liaw, Chih Chuang] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung, Taiwan.
   [Wu, Chih Ying] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.
   [Wu, Chih Ying] China Med Univ, Dept Neurosurg, Hsinchu Hosp, Hsinchu, Taiwan.
   [Fong, Yi Chin] China Med Univ, Coll Hlth Care, Dept Sports Med, Taichung, Taiwan.
   [Fong, Yi Chin] China Med Univ Hosp, Dept Orthoped Surg, Taichung, Taiwan.
   [Fong, Yi Chin] China Med Univ, Dept Orthoped Surg, Beigang Hosp, Douliu City, Yunlin, Taiwan.
   [Liaw, Chih Chuang] Kaohsiung Med Univ, Grad Inst Nat Prod, Kaohsiung, Taiwan.
   [Tang, Chih Hsin] China Med Univ, Sch Med, Dept Pharmacol, Taichung, Taiwan.
   [Tang, Chih Hsin] China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan.
   [Tang, Chih Hsin] Asia Univ, Coll Med & Hlth Sci, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan.
   [Tang, Chih Hsin] China Med Univ, Hsinchu Hosp, Dept Med Res, Hsinchu, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital   Taiwan; National Sun Yat Sen University;
   China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital   Taiwan; China Medical University Taiwan;
   Kaohsiung Medical University; China Medical University Taiwan; China
   Medical University Taiwan; Asia University Taiwan; China Medical
   University Taiwan
RP Tang, CH (通讯作者)，China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.; Liaw, CC (通讯作者)，Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung, Taiwan.
EM ccliaw@mail.nsysu.edu.tw; chtang@mail.cmu.edu.tw
RI Tang, Chih/O 5212 2015; Liaw, Chih Chuang/AAG 9682 2021; Yen,
   Ching/A 2771 2013
CR Achudhan D, 2022, J FOOD BIOCHEM, V46, DOI 10.1111/jfbc.14022
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chan CY, 2016, BIOMEDICINE TAIWAN, V6, DOI 10.7603/s40681 016 0015 3
   Chang AC, 2019, CANCERS, V11, DOI 10.3390/cancers11121903
   Chen CY, 2017, J BONE MINER RES, V32, P34, DOI 10.1002/jbmr.2926
   Chen CY, 2017, REDOX BIOL, V11, P263, DOI 10.1016/j.redox.2016.12.018
   Chen WC, 2023, BIOCHEM PHARMACOL, V211, DOI 10.1016/j.bcp.2023.115540
   Dou C, 2016, SCI REP UK, V6, DOI 10.1038/srep21499
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Fernandes NAR, 2021, J PERIODONTAL RES, V56, P569, DOI 10.1111/jre.12857
   Hascoët E, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00257 w
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Huang YC, 2009, J NAT PROD, V72, P1273, DOI 10.1021/np900148a
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Lee CH, 2012, EUR J PHARMACOL, V676, P26, DOI 10.1016/j.ejphar.2011.12.001
   Lee CH, 2011, EUR J PHARMACOL, V668, P383, DOI 10.1016/j.ejphar.2011.06.059
   Lee HP, 2020, FOOD AGR IMMUNOL, V31, P193, DOI 10.1080/09540105.2020.1713055
   Lee HP, 2019, FOOD AGR IMMUNOL, V30, P1033, DOI 10.1080/09540105.2019.1660623
   Lee HP, 2019, J FUNCT FOODS, V52, P537, DOI 10.1016/j.jff.2018.11.040
   Lee KT, 2022, J FOOD BIOCHEM, V46, DOI 10.1111/jfbc.14108
   Liu PI, 2021, ONCOGENE, V40, P1503, DOI 10.1038/s41388 020 01613 4
   Liu SC, 2022, J BONE MINER RES, V37, P1944, DOI 10.1002/jbmr.4661
   Liu SC, 2019, FOOD AGR IMMUNOL, V30, P620, DOI 10.1080/09540105.2019.1611745
   Liu SC, 2012, INT IMMUNOPHARMACOL, V12, P494, DOI 10.1016/j.intimp.2012.01.002
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   Sharma P, 2010, BIOCHEM BIOPH RES CO, V399, P129, DOI 10.1016/j.bbrc.2010.07.022
   Su CH, 2022, J ETHNOPHARMACOL, V295, DOI 10.1016/j.jep.2022.115435
   Su CH, 2021, J FUNCT FOODS, V86, DOI 10.1016/j.jff.2021.104729
   Suja SR, 2004, J ETHNOPHARMACOL, V92, P61, DOI 10.1016/j.jep.2004.01.019
   Tai HC, 2022, J PINEAL RES, V72, DOI 10.1111/jpi.12793
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tsai HC, 2014, BBA MOL CELL RES, V1843, P846, DOI 10.1016/j.bbamcr.2014.01.007
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Wang MF, 2019, BIOCHEM PHARMACOL, V166, P23, DOI 10.1016/j.bcp.2019.05.005
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yang YC, 2019, ENVIRON TOXICOL, V34, P203, DOI 10.1002/tox.22674
   Yu W, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140214
NR 40
TC 19
Z9 22
U1 5
U2 17
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2023
VL 166
AR 115392
DI 10.1016/j.biopha.2023.115392
EA AUG 2023
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA W3HP3
UT WOS:001090575000001
PM 37651802
OA gold
DA 2025 08 17
ER

PT J
AU Song, YF
   Yang, JB
   Jing, WG
   Wang, Q
   Liu, Y
   Cheng, XL
   Ye, F
   Tian, JY
   Wei, F
   Ma, SC
AF Song, Yunfei
   Yang, Jianbo
   Jing, Wenguang
   Wang, Qi
   Liu, Yue
   Cheng, Xianlong
   Ye, Fei
   Tian, Jinying
   Wei, Feng
   Ma, Shuangcheng
TI Systemic elucidation on the potential bioactive compounds and
   hypoglycemic mechanism of Polygonum multiflorum based on network
   pharmacology
SO CHINESE MEDICINE
LA English
DT Article
DE Polygonum multiflorum; Diabetes; Systematic pharmacology; Bioactive
   compounds; Hypoglycemic mechanism
ID ALPHA GLUCOSIDASE INHIBITORS; INSULIN RESISTANCE; DIABETES MELLITUS;
   ACID METABOLISM; QUERCETIN; RATS; KAEMPFEROL; APIGENIN;
   PHARMACOKINETICS; RESVERATROL
AB Background Diabetes is a complex metabolic disease characterized by hyperglycemia, plaguing the whole world. However, the action mode of multi component and multi target for traditional Chinese medicine (TCM) could be a promising treatment of diabetes mellitus. According to the previous research, the TCM of Polygonum multiflorum (PM) showed noteworthy hypoglycemic effect. Up to now, its hypoglycemic active ingredients and mechanism of action are not yet clear. In this study, network pharmacology was employed to elucidate the potential bioactive compounds and hypoglycemic mechanism of PM. Methods First, the compounds with good pharmacokinetic properties were screened from the self established library of PM, and the targets of these compounds were predicted and collected through database. Relevant targets of diabetes were summarized by searching database. The intersection targets of compound targets and disease targets were obtained soon. Secondly, the interaction net between the compounds and the filtered targets was established. These key targets were enriched and analyzed by protein protein interactions (PPI) analysis, molecular docking verification. Thirdly, the key genes were used to find the biologic pathway and explain the therapeutic mechanism by genome ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) analysis. Lastly, the part of potential bioactive compounds were under enzyme activity inhibition tests. Results In this study, 29 hypoglycemic components and 63 hypoglycemic targets of PM were filtrated based on online network database. Then the component target interaction network was constructed and five key components resveratrol, apigenin, kaempferol, quercetin and luteolin were further obtained. Sequential studies turned out, AKT1, EGFR, ESR1, PTGS2, MMP9, MAPK14, and KDR were the common key targets. Docking studies indicated that the bioactive compounds could stably bind the pockets of target proteins. There were 38 metabolic pathways, including regulation of lipolysis in adipocytes, prolactin signaling pathway, TNF signaling pathway, VEGF signaling pathway, FoxO signaling pathway, estrogen signaling pathway, linoleic acid metabolism, Rap1 signaling pathway, arachidonic acid metabolism, and osteoclast differentiation closely connected with the hypoglycemic mechanism of PM. And the enzyme activity inhibition tests showed the bioactive ingredients have great hypoglycemic activity. Conclusion In summary, the study used systems pharmacology to elucidate the main hypoglycemic components and mechanism of PM. The work provided a scientific basis for the further hypoglycemic effect research of PM and its monomer components, but also provided a reference for the secondary development of PM.
C1 [Song, Yunfei; Liu, Yue; Ma, Shuangcheng] Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing 102488, Peoples R China.
   [Song, Yunfei; Yang, Jianbo; Jing, Wenguang; Wang, Qi; Cheng, Xianlong; Wei, Feng; Ma, Shuangcheng] Natl Inst Food & Drug Control, Inst Control Chinese Tradit Med & Ethn Med, Beijing 100050, Peoples R China.
   [Ye, Fei; Tian, Jinying] Chinese Acad Med Sci & Peking Union Med Coll, Inst Mat Med, Beijing 100050, Peoples R China.
C3 Beijing University of Chinese Medicine; National Institute of Food &
   Drug Control   China; Chinese Academy of Medical Sciences   Peking Union
   Medical College; Institute of Materia Medica   CAMS; Peking Union
   Medical College
RP Ma, SC (通讯作者)，Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing 102488, Peoples R China.; Wei, F; Ma, SC (通讯作者)，Natl Inst Food & Drug Control, Inst Control Chinese Tradit Med & Ethn Med, Beijing 100050, Peoples R China.
EM weifeng@nifdc.org.cn; masc@nifdc.org.cn
RI Yang, Yi/J 1744 2016; Yang, Jian Bo/AAM 7466 2020
OI Yang, Jian Bo/0000 0002 1368 5294
FU National Natural Science Foundation of China [81703665, 81773874,
   81973476, 81903807]; National Major Scientific and Technological Special
   PCnificant New Drugs Development" [2018ZX09735006]
FX This work was financially supported by the National Natural Science
   Foundation of China (Nos. 81703665, 81773874, 81973476, and 81903807)
   and National Major Scientific and Technological Special PCnificant New
   Drugs Development"(2018ZX09735006).
CR Akash MSH, 2018, J CELL BIOCHEM, V119, P105, DOI 10.1002/jcb.26174
   Alkhalidy H, 2018, J NUTR BIOCHEM, V58, P90, DOI 10.1016/j.jnutbio.2018.04.014
   Bagul PK, 2015, CURR MOL MED, V15, P312, DOI 10.2174/1566524015666150505155702
   Barve A, 2009, BIOPHARM DRUG DISPOS, V30, P356, DOI 10.1002/bdd.677
   Bhatia J, 2018, J HYPERTENS, V36, pE89, DOI 10.1097/01.hjh.0000548352.18841.47
   Boudina S, 2010, REV ENDOCR METAB DIS, V11, P31, DOI 10.1007/s11154 010 9131 7
   Boulton AJM, 2005, DIABETES CARE, V28, P956, DOI 10.2337/diacare.28.4.956
   Bounda GA, 2015, PHARMACOGN RES, V7, P225, DOI 10.4103/0974 8490.157957
   Breuss JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071523
   Bule M, 2019, FOOD CHEM TOXICOL, V125, P494, DOI 10.1016/j.fct.2019.01.037
   Calderón Montaño JM, 2011, MINI REV MED CHEM, V11, P298, DOI 10.2174/138955711795305335
   Chen X, 2005, PHARM RES DORDR, V22, P892, DOI 10.1007/s11095 005 4584 1
   Dahlman I, 2008, PHARMACOGENET GENOM, V18, P967, DOI 10.1097/FPC.0b013e32831101ef
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Dhanya R, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00336
   Eledrisi MS, 2006, AM J MED SCI, V331, P243, DOI 10.1097/00000441 200605000 00002
   Farmer AD, 2012, BRIT J HOSP MED, V73, P451, DOI 10.12968/hmed.2012.73.8.451
   George C, 2018, AM J MED, V131, P1304, DOI 10.1016/j.amjmed.2018.05.043
   Ghani U, 2015, EUR J MED CHEM, V103, P133, DOI 10.1016/j.ejmech.2015.08.043
   Gong LL, 2020, LIFE SCI, V242, DOI 10.1016/j.lfs.2019.117212
   Gorvin CM, 2015, J CLIN TRANSL ENDOCR, V2, P85, DOI 10.1016/j.jcte.2015.05.001
   Gradolatto A, 2005, DRUG METAB DISPOS, V33, P49, DOI 10.1124/dmd.104.000893
   Grahn THM, 2014, J BIOL CHEM, V289, P12029, DOI 10.1074/jbc.M113.539890
   Gu JX, 2018, NEUROCHEM RES, V43, P1905, DOI 10.1007/s11064 018 2608 6
   Guo X, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2020.106201
   HALUSHKA PV, 1985, METABOLISM, V34, P32, DOI 10.1016/S0026 0495(85)80007 X
   Ham Ju Ri, 2019, Prev Nutr Food Sci, V24, P121, DOI 10.3746/pnf.2019.24.2.121
   Ho LT, 2011, CURR TOP MED CHEM, V11, P1476, DOI 10.2174/156802611795860915
   Hong B, 2017, BIOMED RES, V28
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Hsu KC, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 S1 S33
   Hu T, 2020, J CELL MOL MED, V24, P3449, DOI 10.1111/jcmm.15026
   Hu ZA, 2019, ACTA BIOMATER, V84, P402, DOI 10.1016/j.actbio.2018.11.052
   Huang XT, 2019, CHEM BIOL INTERACT, V306, P29, DOI 10.1016/j.cbi.2019.04.001
   Ivanov VV, 2015, BIOCHEMISTRY MOSCOW+, V80, P87, DOI 10.1134/S0006297915010101
   Jeyaraman MM, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011919.pub2
   Jiang YB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01435
   Jing CY, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109381
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Kelly P, 2010, J BIOL CHEM, V285, P15777, DOI 10.1074/jbc.M109.069112
   Khazaei M, 2011, CLINICS, V66, P1419, DOI 10.1590/S1807 59322011000800019
   Konheim YL, 2003, HUM GENET, V113, P377, DOI 10.1007/s00439 003 1000 y
   Lee SM, 2011, DIABETOLOGIA, V54, P1136, DOI 10.1007/s00125 011 2064 1
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875 5364(13)60037 0]
   Li WW, 2017, FRONT PHARMACOL, V8, P15, DOI 10.3389/fphar.2017.00074
   Lin HY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051868
   Lin LC, 2015, J AGR FOOD CHEM, V63, P7700, DOI 10.1021/jf505848z
   Lin LF, 2015, J ETHNOPHARMACOL, V159, P158, DOI 10.1016/j.jep.2014.11.009
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Luo C, 2015, INT IMMUNOPHARMACOL, V28, P744, DOI 10.1016/j.intimp.2015.07.018
   Maiese K, 2015, CURR NEUROVASC RES, V12, P404, DOI 10.2174/1567202612666150807112524
   Malik S, 2017, AM J PHYSIOL RENAL, V313, pF414, DOI 10.1152/ajprenal.00393.2016
   Mishra PK, 2012, CIRCULATION, V126
   Mishra PK, 2012, CAN J PHYSIOL PHARM, V90, P353, DOI [10.1139/Y11 131, 10.1139/y11 131]
   Moore W, 2014, DIABETES, V63, pA504
   Moriya J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004996
   Nakamura Y, 2015, WORLD J DIABETES, V6, P840, DOI 10.4239/wjd.v6.i6.840
   Nishizawa Y, 1991, Nihon Rinsho, V49 Suppl, P3
   Peng J, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/3417306
   Qin WW, 2016, VASC PHARMACOL, V85, P39, DOI 10.1016/j.vph.2016.07.006
   Rosales PF, 2019, BIOORG CHEM, V85, P66, DOI 10.1016/j.bioorg.2018.12.016
   Sadi G, 2015, GENE, V570, P213, DOI 10.1016/j.gene.2015.06.019
   Shi FG, 2018, J SEP SCI, V41, P3830, DOI 10.1002/jssc.201800585
   Shi GJ, 2019, BIOMED PHARMACOTHER, V109, P1085, DOI 10.1016/j.biopha.2018.10.130
   Song XQ, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106179
   SU F, 2010, FASEB J, P00049, DOI DOI 10.1096/fj.09 137034
   Szkudelski T, 2015, BBA MOL BASIS DIS, V1852, P1145, DOI 10.1016/j.bbadis.2014.10.013
   VANDOORMAAL JJ, 1990, NETH J MED, V37, P207
   Venkatakrishnan K, 2019, J FUNCT FOODS, V57, P425, DOI 10.1016/j.jff.2019.04.039
   Wang C, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00841
   Wang N, 2017, IN VITRO CELL DEV AN, V53, P554, DOI 10.1007/s11626 017 0135 4
   Wang P, 2018, BIOFACTORS, V44, P16, DOI 10.1002/biof.1410
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Xu N, 2014, MOL NUTR FOOD RES, V58, P1258, DOI 10.1002/mnfr.201300830
   Yang D, 2014, ANAL METHODS UK, V6, P3353, DOI 10.1039/c4ay00064a
   Yang JT, 2015, J CARDIOVASC PHARM, V65, P349, DOI 10.1097/FJC.0000000000000202
   Yin HL, 2019, PEERJ, V7, DOI 10.7717/peerj.6665
   Youl E, 2010, BRIT J PHARMACOL, V161, P799, DOI 10.1111/j.1476 5381.2010.00910.x
   Zabela V, 2016, FITOTERAPIA, V115, P189, DOI 10.1016/j.fitote.2016.10.008
   Zhang RZ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00123
   Zhang YF, 2019, CLIN GENET, V95, P451, DOI 10.1111/cge.13491
   Zhou T, 2016, CELL PHYSIOL BIOCHEM, V38, P2063, DOI 10.1159/000445565
   Zhou YL, 2016, J INVEST MED, V64, pA14, DOI 10.1136/jim 2016 000328.39
   Zhu L, 2014, AM J PHYSIOL ENDOC M, V306, pE1188, DOI 10.1152/ajpendo.00579.2013
NR 85
TC 23
Z9 26
U1 2
U2 62
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 8546
J9 CHIN MED UK
JI Chin. Med.
PD DEC 18
PY 2020
VL 15
IS 1
AR 121
DI 10.1186/s13020 020 00401 2
PG 15
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA OS9VH
UT WOS:000590503800001
PM 33292335
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Vermeulen, S
   Birgani, ZT
   Habibovic, P
AF Vermeulen, Steven
   Birgani, Zeinab Tahmasebi
   Habibovic, Pamela
TI Biomaterial induced pathway modulation for bone regeneration
SO BIOMATERIALS
LA English
DT Article
DE Regenerative Medicine; Bone; Biomaterials; Pathways
ID MESENCHYMAL STEM CELLS; MORPHOGENETIC PROTEIN 2 EXPRESSION; TITANIUM
   SURFACE ROUGHNESS; ENDOTHELIAL GROWTH FACTOR; OSTEOGENIC
   DIFFERENTIATION; WNT/BETA CATENIN; OSTEOBLAST DIFFERENTIATION;
   EXTRACELLULAR VESICLES; GENE EXPRESSION; SIGNALING PATHWAYS
AB Embryogenic developmental processes involve a tightly controlled regulation between mechanical forces and biochemical cues such as growth factors, matrix proteins, and cytokines. This interplay remains essential in the mature body, with aberrant pathway signaling leading to abnormalities such as atherosclerosis in the cardiovascular system, inflammation in tendon tissue, or osteoporosis in the bone. The aim of bone regenerative strategies is to develop tools and procedures that will harness the body's own self repair ability in order to successfully regenerate even very large and complex bone defects and restore normal function. To achieve this, understanding pathways that govern processes of progenitor differentiation towards the osteogenic lineages, their phenotypical maintenance, and the construction of functional bone tissue is imperative to subsequently develop regenerative therapies that mimic these processes. While a body of literature exists that describes how biochemical stimuli guide cell behavior in the culture dish, due to the lack of an appropriate mechanical environment, these signals are often insufficient or inappropriate for achieving a desirable response in the body. Moreover, bone regenerative therapies rarely rely on a biochemical stimulus, such as a growth factor alone, and instead often comprise a carrier biomaterial that introduces a very different microenvironment from that of a cell culture dish. Therefore, in this review, we discuss which biomaterials elicit or influence pathways relevant for bone regeneration and describe mechanisms behind these effects, with the aim to inspire the development of novel, more effective bone regenerative therapies.
C1 [Vermeulen, Steven; Birgani, Zeinab Tahmasebi; Habibovic, Pamela] Maastricht Univ, MERLN Inst Technol Inspired Regenerat Med, Dept Instruct Biomat Engn, Maastricht, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC)
RP Habibovic, P (通讯作者)，Maastricht Univ, MERLN Inst Technol Inspired Regenerat Med, Dept Instruct Biomat Engn, Maastricht, Netherlands.
EM p.habibovic@maastrichtuniversity.nl
RI ; Vermeulen, Steven/ADS 7474 2022
OI Tahmasebi Birgani, Zeinab (Niloofar)/0000 0003 3899 922X; Habibovic,
   Pamela/0000 0001 8249 5155; Vermeulen, Steven/0000 0001 6797 7084
FU European Union Interreg Vlaanderen Nederland project "BIOMAT on
   microfluidic chip" [0433]; Dutch Province of Limburg (program "Limburg
   INvesteert in haar Kenniseconomie/LINK") [SAS 2014 00837,
   SAS 2018 02477]; Gravitation Program of the Netherlands Organisation for
   Scientific Research (NWO) [024.003.013]; NWO Vidi grant "Bone
   Microfactory" [15604]; NWO Incentive Grant for Women in STEM [18748]
FX SV, ZTB and PH acknowledges the financial support of the European Union
   Interreg Vlaanderen Nederland project "BIOMAT on microfluidic chip"
   (grant no. 0433) and the Dutch Province of Limburg (program "Limburg
   INvesteert in haar Kenniseconomie/LINK"; grant nos. SAS 2014 00837 and
   SAS 2018 02477). PH gratefully acknowledges the Gravitation Program of
   the Netherlands Organisation for Scientific Research (NWO) (project
   `Materials Driven Regeneration'; grant no. 024.003.013) and the NWO Vidi
   grant "Bone Microfactory" (grant no. 15604). ZTB gratefully acknowledges
   the NWO Incentive Grant for Women in STEM (Project "Biotetris", grant
   no. 18748). Pathway figures were created with BioRender.com.
CR Abagnale G, 2017, STEM CELL REP, V9, P654, DOI 10.1016/j.stemcr.2017.06.016
   Abagnale G, 2015, BIOMATERIALS, V61, P316, DOI 10.1016/j.biomaterials.2015.05.030
   Abaricia JO, 2020, BIOMATERIALS, V243, DOI 10.1016/j.biomaterials.2020.119920
   Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258
   Al Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725
   Alakpa EV, 2017, ACS NANO, V11, P6717, DOI 10.1021/acsnano.7b01044
   Allen JL, 2012, MOL BIOL CELL, V23, P3731, DOI 10.1091/mbc.E12 03 0172
   Almiñana C, 2020, THERIOGENOLOGY, V150, P59, DOI 10.1016/j.theriogenology.2020.01.077
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Andersson ER, 2011, DEVELOPMENT, V138, P3593, DOI 10.1242/dev.063610
   Aquino Martínez R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178158
   Ashe HL, 2016, BIOCHEM SOC T, V44, P1465, DOI 10.1042/BST20160111
   Azarin SM, 2012, BIOMATERIALS, V33, P2041, DOI 10.1016/j.biomaterials.2011.11.070
   Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070 2153(06)76004 5
   Barradas AMC, 2013, INTEGR BIOL UK, V5, P920, DOI 10.1039/c3ib40027a
   Barradas AMC, 2012, BIOMATERIALS, V33, P3205, DOI 10.1016/j.biomaterials.2012.01.020
   Beck GR, 2003, J BIOL CHEM, V278, P41921, DOI 10.1074/jbc.M304470200
   Beckstead BL, 2009, J BIOMED MATER RES A, V91A, P436, DOI 10.1002/jbm.a.32214
   Bello DG, 2017, ACTA BIOMATER, V60, P339, DOI 10.1016/j.actbio.2017.07.022
   Bilem I, 2016, ACTA BIOMATER, V36, P132, DOI 10.1016/j.actbio.2016.03.032
   Blair H. C., 2007, V45, P539
   Bohner M, 2020, ACTA BIOMATER, V113, P23, DOI 10.1016/j.actbio.2020.06.022
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Borbiro I, 2017, CURR TOP MEMBR, V79, P245, DOI 10.1016/bs.ctm.2016.10.002
   Boyan BD, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26901 8
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Brinkmann J, 2012, BIOINTERPHASES, V7, DOI 10.1007/s13758 012 0034 x
   Brown TD, 2000, J BIOMECH, V33, P3, DOI 10.1016/S0021 9290(99)00177 3
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Brusatin G, 2018, NAT MATER, V17, P1063, DOI 10.1038/s41563 018 0180 8
   Burroughs L, 2021, BIOMATERIALS, V271, DOI 10.1016/j.biomaterials.2021.120740
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   Buser D, 2004, J DENT RES, V83, P529, DOI 10.1177/154405910408300704
   Bussche L, 2016, J BIOL CHEM, V291, P24390, DOI 10.1074/jbc.M116.726117
   Cabral J, 2018, ADV DRUG DELIVER REV, V129, P394, DOI 10.1016/j.addr.2018.01.018
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Caliari SR, 2016, BIOMATERIALS, V103, P314, DOI 10.1016/j.biomaterials.2016.06.061
   Campbell ID, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004994
   Cappariello A, 2018, J BONE MINER RES, V33, P517, DOI 10.1002/jbmr.3332
   Castro Raucci LMS, 2016, J CELL BIOCHEM, V117, P1718, DOI 10.1002/jcb.25469
   Chairoungdua A, 2010, J CELL BIOL, V190, P1079, DOI 10.1083/jcb.201002049
   Chakravorty N, 2014, CLIN ORAL IMPLAN RES, V25, P475, DOI 10.1111/clr.12178
   Chan JK, 2015, EMBO MOL MED, V7, P547, DOI 10.15252/emmm.201404487
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen KY, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20167324
   Chen XN, 2016, J MATER CHEM B, V4, P2280, DOI 10.1039/c6tb00349d
   Chen Y, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860 015 0067 3
   Choudhary S, 2004, BIOCHEM BIOPH RES CO, V322, P395, DOI 10.1016/j.bbrc.2004.07.129
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082
   Costa DO, 2013, BIOMATERIALS, V34, P7215, DOI 10.1016/j.biomaterials.2013.06.014
   Coste B, 2010, SCIENCE, V330, P55, DOI 10.1126/science.1193270
   Crowder SW, 2016, CELL STEM CELL, V18, P39, DOI 10.1016/j.stem.2015.12.012
   Cui YZ, 2022, BIOACT MATER, V10, P207, DOI 10.1016/j.bioactmat.2021.09.015
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014 5793(03)00055 3
   Danoux CBSS, 2015, ACTA BIOMATER, V17, P1, DOI 10.1016/j.actbio.2015.02.003
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753
   Deng FH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0244 8
   Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200
   Detsch R, 2008, ACTA BIOMATER, V4, P139, DOI 10.1016/j.actbio.2007.03.014
   Docheva D, 2014, BIRTH DEFECTS RES C, V102, P13, DOI 10.1002/bdrc.21059
   Dong YF, 2010, DEVELOPMENT, V137, P1461, DOI 10.1242/dev.042911
   Downing TL, 2013, NAT MATER, V12, P1154, DOI [10.1038/NMAT3777, 10.1038/nmat3777]
   Doyle LM, 2019, CELLS BASEL, V8, DOI 10.3390/cells8070727
   Du J, 2016, SCI REP UK, V6, DOI 10.1038/srep20395
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Eichholz KF, 2020, STEM CELL TRANSL MED, V9, P1431, DOI 10.1002/sctm.19 0405
   Ekström K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075227
   Elbediwy A, 2016, DEVELOPMENT, V143, P1674, DOI 10.1242/dev.133728
   Elosegui Artola A, 2017, CELL, V171, P1397, DOI 10.1016/j.cell.2017.10.008
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Evans JT, 2019, LANCET, V393, P647, DOI 10.1016/S0140 6736(18)31665 9
   Faia Torres AB, 2014, BIOMATERIALS, V35, P9023, DOI 10.1016/j.biomaterials.2014.07.015
   Fong ELS, 2013, P NATL ACAD SCI USA, V110, P6500, DOI 10.1073/pnas.1221403110
   FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235
   FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843
   Froese AR, 2016, AM J RESP CRIT CARE, V194, P84, DOI 10.1164/rccm.201508 1638OC
   Galván Chacón VP, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601478
   Gandavarapu NR, 2014, BIOMATER SCI UK, V2, P352, DOI 10.1039/c3bm60149h
   Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593
   Geiger M, 2003, ADV DRUG DELIVER REV, V55, P1613, DOI 10.1016/j.addr.2003.08.010
   Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   GOLDSPINK DF, 1995, AM J PHYSIOL ENDOC M, V268, pE288, DOI 10.1152/ajpendo.1995.268.2.E288
   Gomez EW, 2010, J CELL BIOCHEM, V110, P44, DOI 10.1002/jcb.22545
   Green DW, 2015, MOL CELLS, V38, P267, DOI 10.14348/molcells.2015.2315
   Grier WK, 2017, EUR CELLS MATER, V33, P227, DOI 10.22203/eCM.v033a17
   Groen N, 2017, ADV MATER, V29, DOI 10.1002/adma.201603259
   Habibovic P, 2010, ADV MATER, V22, P1858, DOI 10.1002/adma.200902778
   Hall GN, 2020, ADV SCI, V7, DOI 10.1002/advs.201902295
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Han TY, 2022, STEM CELL REV REP, V18, P1078, DOI 10.1007/s12015 021 10219 6
   Hayashi Y, 2007, STEM CELLS, V25, P3005, DOI 10.1634/stemcells.2007 0103
   Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hong D, 2009, J STEROID BIOCHEM, V116, P86, DOI 10.1016/j.jsbmb.2009.05.007
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Honig F, 2020, J FUNCT BIOMATER, V11, DOI 10.3390/jfb11030047
   Hou Y, 2020, SMALL, V16, DOI 10.1002/smll.201905422
   Hounjet J, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11091369
   Hsu SH, 2013, BIOMATERIALS, V34, P4725, DOI 10.1016/j.biomaterials.2013.03.031
   Hulshof FFB, 2017, BIOMATERIALS, V137, P49, DOI 10.1016/j.biomaterials.2017.05.020
   Humphries JD, 2007, J CELL BIOL, V179, P1043, DOI 10.1083/jcb.200703036
   Hutcheson JD, 2018, CURR OPIN CARDIOL, V33, P290, DOI 10.1097/HCO.0000000000000510
   Hwang JH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03815 5
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   Itasaki N, 2010, DEV DYNAM, V239, P16, DOI 10.1002/dvdy.22009
   Iwasaki H, 2000, AM J PHYSIOL HEART C, V278, pH521, DOI 10.1152/ajpheart.2000.278.2.H521
   Jacob J, 2018, INFLAMM REGEN, V38, DOI 10.1186/s41232 018 0059 8
   James AW, 2016, TISSUE ENG PART B RE, V22, P284, DOI [10.1089/ten.TEB.2015.0357, 10.1089/ten.teb.2015.0357]
   Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879
   Jenkins TL, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536 019 0076 5
   Jeong J, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 018 0149 3
   Jia YC, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 018 1115 7
   Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075
   Jorgenson AJ, 2017, AM J PHYSIOL CELL PH, V312, pC277, DOI 10.1152/ajpcell.00205.2016
   Julien M, 2009, J BONE MINER RES, V24, P1856, DOI [10.1359/JBMR.090508, 10.1359/jbmr.090508]
   Kabiri M, 2012, BIOCHEM BIOPH RES CO, V419, P142, DOI 10.1016/j.bbrc.2012.01.017
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kanno T, 2007, J CELL BIOCHEM, V101, P1266, DOI 10.1002/jcb.21249
   Kao FC, 2019, SCI TECHNOL ADV MAT, V20, P1103, DOI 10.1080/14686996.2019.1693880
   Katagiri T, 2013, BIOL CHEM, V394, P703, DOI 10.1515/hsz 2012 0310
   Kato A, 2015, OPEN DENT J, V9, P52, DOI 10.2174/1874210601509010052
   Keselowsky BG, 2004, BIOMATERIALS, V25, P5947, DOI 10.1016/j.biomaterials.2004.01.062
   Kieswetter K, 1996, J BIOMED MATER RES, V32, P55, DOI 10.1002/(SICI)1097 4636(199609)32:1<55::AID JBM7>3.0.CO;2 O
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Kim H, 2008, BIOMED MATER, V3, DOI 10.1088/1748 6041/3/2/025011
   KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092 8674(87)90110 3
   Kolind K, 2014, ACTA BIOMATER, V10, P641, DOI 10.1016/j.actbio.2013.11.006
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Kopf J, 2012, BMC BIOL, V10, DOI 10.1186/1741 7007 10 37
   Krencik R, 2011, NAT PROTOC, V6, P1710, DOI 10.1038/nprot.2011.405
   Kumar G, 2011, BIOMATERIALS, V32, P9188, DOI 10.1016/j.biomaterials.2011.08.054
   Kunzler TP, 2007, BIOMATERIALS, V28, P2175, DOI 10.1016/j.biomaterials.2007.01.019
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lachowski D, 2018, FASEB J, V32, P1099, DOI 10.1096/fj.201700721R
   Lancaster MA, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039347
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lee W, 2014, P NATL ACAD SCI USA, V111, pE5114, DOI 10.1073/pnas.1414298111
   Leucht P, 2019, BIOMATERIALS, V196, P46, DOI 10.1016/j.biomaterials.2018.03.029
   Leuning DG, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 25700 5
   Levi B, 2012, P NATL ACAD SCI USA, V109, P20379, DOI 10.1073/pnas.1218052109
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li XH, 2019, ELIFE, V8, DOI 10.7554/eLife.49631
   Li Y, 2017, J CELL PHYSIOL, V232, P2427, DOI 10.1002/jcp.25517
   Liang MM, 2021, MOL THER NUCL ACIDS, V23, P1191, DOI 10.1016/j.omtn.2021.01.031
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Lipski AM, 2008, BIOMATERIALS, V29, P3836, DOI 10.1016/j.biomaterials.2008.06.002
   Liu DW, 2008, BONE, V42, P644, DOI 10.1016/j.bone.2007.09.058
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Liu J, 2011, INNATE IMMUN LONDON, V17, P245, DOI 10.1177/1753425910365733
   Liu M, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.14
   Liu TY, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392 019 0100 7
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Lu CH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312750
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Lv MX, 2018, J ORTHOP RES, V36, P730, DOI 10.1002/jor.23768
   Ma L, 2022, ACS NANO, V16, P415, DOI 10.1021/acsnano.1c07150
   Makihira S, 2007, DENT MATER J, V26, P739, DOI 10.4012/dmj.26.739
   Man K, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.757220
   Marsden M, 2001, DEVELOPMENT, V128, P3635
   MARTIN JY, 1995, J BIOMED MATER RES, V29, P389, DOI 10.1002/jbm.820290314
   Martina M, 2007, POLYM INT, V56, P145, DOI 10.1002/pi.2108
   Martini F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062104
   Martino MM, 2014, SCIENCE, V343, P885, DOI 10.1126/science.1247663
   Martinovic S, 2006, ARCH HISTOL CYTOL, V69, P23, DOI 10.1679/aohc.69.23
   Matsumoto Y, 2016, J CLIN INVEST, V126, P4482, DOI 10.1172/JCI87802
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Matthews Brya G, 2014, Bonekey Rep, V3, P560, DOI 10.1038/bonekey.2014.55
   Mauretti A, 2017, MRS COMMUN, V7, P496, DOI 10.1557/mrc.2017.82
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   Merenda A, 2020, TRENDS CELL BIOL, V30, P60, DOI 10.1016/j.tcb.2019.10.003
   Michigami T, 2018, PHYSIOL REV, V98, P2317, DOI 10.1152/physrev.00022.2017
   Midha S, 2017, ACS BIOMATER SCI ENG, V3, P1062, DOI 10.1021/acsbiomaterials.7b00006
   Mitra A, 2017, P NATL ACAD SCI USA, V114, pE3882, DOI 10.1073/pnas.1618007114
   Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197
   Mizuno M, 2000, J CELL PHYSIOL, V184, P207, DOI 10.1002/1097 4652(200008)184:2<207::AID JCP8>3.3.CO;2 L
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Moroni M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03502 7
   Moya IM, 2019, NAT REV MOL CELL BIO, V20, P211, DOI 10.1038/s41580 018 0086 y
   Mozar A, 2008, J CELL PHYSIOL, V215, P47, DOI 10.1002/jcp.21283
   Munjal A, 2014, DEVELOPMENT, V141, P1789, DOI 10.1242/dev.091645
   Nahar NN, 2008, J BONE MINER METAB, V26, P514, DOI 10.1007/s00774 008 0859 z
   Nakade O, 2001, J BONE MINER METAB, V19, P13, DOI 10.1007/s007740170055
   Nardone G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15321
   Nevado P, 2020, MAT SCI ENG C MATER, V114, DOI 10.1016/j.msec.2020.111013
   Ngiam M, 2009, BONE, V45, P4, DOI 10.1016/j.bone.2009.03.674
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813 8822.2004
   O'Brien K, 2020, NAT REV MOL CELL BIO, V21, P585, DOI 10.1038/s41580 020 0251 y
   Olivares Navarrete R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170312
   Olivares Navarrete R, 2015, BIOMATERIALS, V51, P69, DOI 10.1016/j.biomaterials.2015.01.035
   Otsuru S, 2018, CYTOTHERAPY, V20, P62, DOI 10.1016/j.jcyt.2017.09.012
   Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0
   Pan JX, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0018 7
   Pardo Pastor C, 2018, P NATL ACAD SCI USA, V115, P1925, DOI 10.1073/pnas.1718177115
   Park JS, 2011, BIOMATERIALS, V32, P3921, DOI 10.1016/j.biomaterials.2011.02.019
   Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957
   Passanha FR, 2020, BIOMATERIALS, V254, DOI 10.1016/j.biomaterials.2020.120127
   Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107
   Penido MGMG, 2012, PEDIATR NEPHROL, V27, P2039, DOI 10.1007/s00467 012 2175 z
   Pereira DD, 2022, BIOACT MATER, V8, P241, DOI 10.1016/j.bioactmat.2021.06.036
   Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014
   Pocaterra A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.230425
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Regier MC, 2017, BIOMACROMOLECULES, V18, P709, DOI 10.1021/acs.biomac.6b01469
   Reis J, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/613403
   Ridone Pietro, 2019, Biophys Rev, V11, P795, DOI 10.1007/s12551 019 00584 5
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Ron A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02218 4
   Rosado Olivieri EA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09404 6
   Rouahi M, 2006, BIOMATERIALS, V27, P2829, DOI 10.1016/j.biomaterials.2006.01.001
   Rouwkema J, 2006, TISSUE ENG, V12, P2685, DOI 10.1089/ten.2006.12.2685
   SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092 8674(93)90541 W
   Saleh F A, 2011, Eur Cell Mater, V22, P242
   Sánchez GB, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964 021 00787 y
   Mateos CSC, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008717
   Scheller EL, 2008, J DENT RES, V87, P126, DOI 10.1177/154405910808700206
   Schnatz A, 2021, FASEB BIOADV, V3, P577, DOI 10.1096/fba.2021 00035
   Schroeder Tania M., 2005, Birth Defects Research, V75, P213, DOI 10.1002/bdrc.20043
   Schwarz C, 2013, TISSUE ENG PT A, V19, P247, DOI [10.1089/ten.TEA.2012.0265, 10.1089/ten.tea.2012.0265]
   Scott A, 2008, SPORTS MED, V38, P139, DOI 10.2165/00007256 200838020 00004
   Seib FP, 2009, BIOCHEM BIOPH RES CO, V389, P663, DOI 10.1016/j.bbrc.2009.09.051
   Senderovich H, 2017, RAMBAM MAIMONIDES ME, V8, DOI 10.5041/RMMJ.10308
   Shah SB, 2017, ACTA BIOMATER, V53, P29, DOI 10.1016/j.actbio.2017.01.075
   Shao J, 2018, BONE, V108, P165, DOI 10.1016/j.bone.2018.01.010
   Shao Y, 2017, NAT MATER, V16, P419, DOI [10.1038/NMAT4829, 10.1038/nmat4829]
   SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0
   Smyrek I, 2019, BIOL OPEN, V8, DOI 10.1242/bio.037051
   Standal T, 2004, EXP ONCOL, V26, P179
   Steffi C, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010018
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Strehler E.E., 1996, PRINC MED BIOL, P125
   Sun CH, 2016, J BONE MINER RES, V31, P2227, DOI 10.1002/jbmr.2908
   Sun J, 2008, ADV MAT RES, V47 50, P1335, DOI 10.4028/www.scientific.net/AMR.47 50.1335
   Sun TH, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128674
   Sun WJ, 2019, ELIFE, V8, DOI 10.7554/eLife.47454
   Suzuma I, 2001, DIABETES, V50, P444, DOI 10.2337/diabetes.50.2.444
   Tada H, 2011, BONE, V48, P1409, DOI 10.1016/j.bone.2011.03.675
   Takano Yamamoto T, 2014, JPN DENT SCI REV, V50, P29, DOI 10.1016/j.jdsr.2013.10.004
   Takebe J, 2003, J BIOMED MATER RES A, V64A, P207, DOI 10.1002/jbm.a.10275
   Tamm C, 2011, J CELL SCI, V124, P1136, DOI 10.1242/jcs.075796
   Tan KKB, 2015, BIOMATERIALS, V43, P32, DOI 10.1016/j.biomaterials.2014.11.036
   Tan S, 2014, BIOMATERIALS, V35, P5294, DOI 10.1016/j.biomaterials.2014.02.040
   Tanabe Y, 2000, MOL CELL BIOCHEM, V215, P103, DOI 10.1023/A:1026506801659
   Tandon B, 2018, ACTA BIOMATER, V73, P1, DOI 10.1016/j.actbio.2018.04.026
   Tang ZR, 2018, REGEN BIOMATER, V5, P43, DOI 10.1093/rb/rbx024
   TENENBAUM HC, 1985, ENDOCRINOLOGY, V117, P2211, DOI 10.1210/endo 117 5 2211
   Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231
   Tian Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.2
   TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896 6273(90)90219 6
   Totaro A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15206
   Tourlomousis F, 2019, MICROSYST NANOENG, V5, DOI 10.1038/s41378 019 0055 4
   Trac D, 2019, CIRC RES, V124, P526, DOI 10.1161/CIRCRESAHA.118.313845
   Tsai AC, 2015, TISSUE ENG PT A, V21, P1705, DOI [10.1089/ten.tea.2014.0314, 10.1089/ten.TEA.2014.0314]
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Tung JC, 2014, STEM CELL REP, V2, P271, DOI 10.1016/j.stemcr.2014.01.011
   Tüysüz N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14578
   Ugarte F, 2009, EXP HEMATOL, V37, P867, DOI 10.1016/j.exphem.2009.03.007
   Unadkat HV, 2011, P NATL ACAD SCI USA, V108, P16565, DOI 10.1073/pnas.1109861108
   Upadhya R, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1809064
   Usprech J, 2017, ACTA BIOMATER, V58, P34, DOI 10.1016/j.actbio.2017.05.044
   van Oers RFM, 2015, CURR OSTEOPOROS REP, V13, P61, DOI 10.1007/s11914 015 0256 1
   Varnum Finney B, 2000, J CELL SCI, V113, P4313
   Vassey MJ, 2020, ADV SCI, V7, DOI 10.1002/advs.201903392
   Vermeulen S, 2021, ADV MATER, V33, DOI 10.1002/adma.202102084
   Vermeulen S, 2020, BIOMATERIALS, V259, DOI 10.1016/j.biomaterials.2020.120331
   Vermeulen S, 2021, METHODS, V190, P80, DOI 10.1016/j.ymeth.2020.04.004
   Vermeulen S, 2019, ACTA BIOMATER, V83, P277, DOI 10.1016/j.actbio.2018.10.041
   Vezeridis PS, 2006, BIOCHEM BIOPH RES CO, V348, P1082, DOI 10.1016/j.bbrc.2006.07.146
   Walker M, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64725 7
   Wan S, 2018, BIOMATERIALS, V171, P107, DOI 10.1016/j.biomaterials.2018.04.035
   Wang J, 2019, INT J NANOMED, V14, P7987, DOI 10.2147/IJN.S216182
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wang W, 2012, BIOMATERIALS, V33, P7993, DOI 10.1016/j.biomaterials.2012.07.064
   Wang XK, 2015, J BIOMED MATER RES A, V103, P1907, DOI 10.1002/jbm.a.35323
   Wang XQ, 2021, BASIC CLIN PHARMACOL, V128, P18, DOI 10.1111/bcpt.13478
   Wang YK, 2012, STEM CELLS DEV, V21, P1176, DOI 10.1089/scd.2011.0293
   Wasnik S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw2108
   Wei Q, 2020, ADV SCI, V7, DOI 10.1002/advs.201902931
   Westbroek P, 1998, NATURE, V392, P861, DOI 10.1038/31798
   WHO, 2012, WORLD MALARIA REPORT 2012, P1
   Wilhelmsen K, 2006, MOL CELL BIOL, V26, P2877, DOI 10.1128/MCB.26.8.2877 2886.2006
   Willert Karl H., 2008, V468, P17, DOI 10.1007/978 1 59745 249 6_2
   Worthington JJ, 2011, TRENDS BIOCHEM SCI, V36, P47, DOI 10.1016/j.tibs.2010.08.002
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Xiao Z, 2007, J CELL PHYSIOL, V210, P325, DOI 10.1002/jcp.20826
   Xie B, 2019, J PHYS MATER, V2, DOI 10.1088/2515 7639/ab2563
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Xu JJ, 2019, ELIFE, V8, DOI 10.7554/eLife.48191
   Xu X, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0005 4
   Xu Y, 2018, J CELL PHYSIOL, V233, P6921, DOI 10.1002/jcp.26592
   Xue RY, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0588 0
   Yadin D, 2016, CYTOKINE GROWTH F R, V27, P13, DOI 10.1016/j.cytogfr.2015.11.005
   Yamamoto M, 2014, ARCH ORAL BIOL, V59, P310, DOI 10.1016/j.archoralbio.2013.12.006
   Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325
   Yan HC, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.01015
   Yang C, 2016, P NATL ACAD SCI USA, V113, pE4439, DOI 10.1073/pnas.1609731113
   Yang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056585
   Yang JL, 2014, ACS NANO, V8, P9941, DOI 10.1021/nn504767g
   Yang Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/2174824
   Yeh HY, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 10
   Yeh YC, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14932 6
   Yim EKF, 2010, BIOMATERIALS, V31, P1299, DOI 10.1016/j.biomaterials.2009.10.037
   Yin XL, 2016, CELL STEM CELL, V18, P25, DOI 10.1016/j.stem.2015.12.005
   Yuan C, 2018, BIOMED PHARMACOTHER, V105, P753, DOI 10.1016/j.biopha.2018.04.185
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
   Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200
   Zanotti S, 2016, ENDOCR REV, V37, P223, DOI 10.1210/er.2016 1002
   Zhang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071740
   Zhang JW, 2017, ACTA BIOMATER, V57, P487, DOI 10.1016/j.actbio.2017.04.004
   Zhang LL, 2009, SCI TECHNOL ADV MAT, V10, DOI 10.1088/1468 6996/10/2/025003
   Zhang P, 2012, INT J MOL MED, V29, P1083, DOI 10.3892/ijmm.2012.934
   Zhang SQ, 2017, MOL MED REP, V16, P3994, DOI 10.3892/mmr.2017.7039
   Zhang ZC, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00826 3
   Zhao C, 2017, J CRANIOFAC SURG, V28, P113, DOI 10.1097/SCS.0000000000003252
   Zhao P, 2018, FRONT MECH ENG PRC, V13, P107, DOI 10.1007/s11465 018 0496 8
   Zhao RQ, 2017, INT J EPIDEMIOL, V46, P149, DOI 10.1093/ije/dyw142
   Zhou GY, 2018, MACROMOL BIOSCI, V18, DOI 10.1002/mabi.201800112
   Zhou SB, 2013, STEM CELLS, V31, P2703, DOI 10.1002/stem.1479
   Zhou TF, 2020, ELIFE, V9, DOI 10.7554/eLife.52779
   Zonderland J, 2020, BIOMATERIALS, V240, DOI 10.1016/j.biomaterials.2020.119854
   Zouani OF, 2013, BIOMATERIALS, V34, P2157, DOI 10.1016/j.biomaterials.2012.12.007
   Zujur D, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602875
NR 335
TC 75
Z9 77
U1 12
U2 122
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD APR
PY 2022
VL 283
AR 121431
DI 10.1016/j.biomaterials.2022.121431
EA FEB 2022
PG 23
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 2Q7PH
UT WOS:000820610100002
PM 35231787
OA hybrid
DA 2025 08 17
ER

PT J
AU Rangaswami, H
   Marathe, N
   Zhuang, SH
   Chen, YC
   Yeh, JC
   Frangos, JA
   Boss, GR
   Pilz, RB
AF Rangaswami, Hema
   Marathe, Nisha
   Zhuang, Shunhui
   Chen, Yongchang
   Yeh, Jiunn Chern
   Frangos, John A.
   Boss, Gerry R.
   Pilz, Renate B.
TI Type II cGMP dependent Protein Kinase Mediates Osteoblast
   Mechanotransduction
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NITRIC OXIDE SYNTHASE; FLUID SHEAR STRESS; REQUIRES NUCLEAR
   TRANSLOCATION; INCREASES BONE FORMATION; C FOS EXPRESSION;
   GENE EXPRESSION; CYCLIC GMP; SIGNAL TRANSDUCTION; HYPERTROPHIC
   DIFFERENTIATION; TRANSCRIPTIONAL REGULATION
AB Continuous bone remodeling in response to mechanical loading is critical for skeletal integrity, and interstitial fluid flow is an important stimulus for osteoblast/osteocyte growth and differentiation. However, the biochemical signals mediating osteoblast anabolic responses to mechanical stimulation are incompletely understood. In primary human osteoblasts and murine MC3T3 E1 cells, we found that fluid shear stress induced rapid expression of c fos, fra 1, fra 2, and fosB/Delta fosB mRNAs; these genes encode transcriptional regulators that maintain skeletal integrity. Fluid shear stress increased osteoblast nitric oxide (NO) synthesis, leading to activation of cGMP dependent protein kinase (PKG). Pharmacological inhibition of the NO/cGMP/PKG signaling pathway blocked shear induced expression of all four fos family genes. Induction of these genes required signaling through MEK/Erk, and Erk activation was NO/cGMP/PKG dependent. Treating cells with a membrane permeable cGMP analog partly mimicked the effects of fluid shear stress on Erk activity and fos family gene expression. In cells transfected with small interfering RNAs (siRNA) specific for membrane bound PKG II, shear  and cGMP induced Erk activation and fos family gene expression was nearly abolished and could be restored by transducing cells with a virus encoding an siRNA resistant form of PKG II; in contrast, siRNA mediated repression of the more abundant cytosolic PKG I isoform was without effect. Thus, we report a novel function for PKG II in osteoblast mechanotransduction, and we propose a model wherebyNO/cGMP/PKGII mediated Erk activation and induction of c fos, fra 1, fra 2, and fosB/Delta fosB play a key role in the osteoblast anabolic response to mechanical stimulation.
C1 [Boss, Gerry R.; Pilz, Renate B.] Univ Calif San Diego, Dept Med & Canc Ctr, La Jolla, CA 92093 USA.
   [Yeh, Jiunn Chern; Frangos, John A.] La Jolla Bioengn Inst, La Jolla, CA 92037 USA.
C3 University of California System; University of California San Diego; La
   Jolla Bioengineering Institute
RP Pilz, RB (通讯作者)，Univ Calif San Diego, Dept Med & Canc Ctr, La Jolla, CA 92093 USA.
EM rpilz@ucsd.edu
OI Boss, Gerry/0000 0002 9758 8714
FU National Institutes of Health [R01 AR051300]; Training [T32 HL007261]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant R01 AR051300 (to R. B. P., H. R., S. Z., and J. C.Y.) and
   Training Grant T32 HL007261 (to N.M.).
CR Adiseshaiah P, 2005, ONCOGENE, V24, P4193, DOI 10.1038/sj.onc.1208583
   Adiseshaiah P, 2003, J BIOL CHEM, V278, P47423, DOI 10.1074/jbc.M303505200
   Adiseshaiah P, 2008, BIOCHEM BIOPH RES CO, V371, P304, DOI 10.1016/j.bbrc.2008.04.063
   Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Ajubi NE, 1999, AM J PHYSIOL ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Bacabac RG, 2004, BIOCHEM BIOPH RES CO, V315, P823, DOI 10.1016/j.bbrc.2004.01.138
   Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021 9290(00)00231 1
   Bergula AP, 2004, BONE, V34, P562, DOI 10.1016/j.bone.2003.11.025
   Boo YC, 2003, AM J PHYSIOL CELL PH, V285, pC499, DOI 10.1152/ajpcell.00122.2003
   Broderick KE, 2007, MOL ENDOCRINOL, V21, P1148, DOI 10.1210/me.2005 0389
   Casteel DE, 2002, J BIOL CHEM, V277, P32003, DOI 10.1074/jbc.M112332200
   Chae HJ, 1997, J PHARM PHARMACOL, V49, P897, DOI 10.1111/j.2042 7158.1997.tb06132.x
   Chen NX, 2000, AM J PHYSIOL CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989
   Chen YC, 2003, MOL CELL BIOL, V23, P4066, DOI 10.1128/MCB.23.12.4066 4082.2003
   Chikuda H, 2005, J BONE MINER METAB, V23, P200, DOI 10.1007/s00774 004 0598 8
   Chikuda H, 2004, GENE DEV, V18, P2418, DOI 10.1101/gad.1224204
   Chow JWM, 1998, J BONE MINER RES, V13, P1039, DOI 10.1359/jbmr.1998.13.6.1039
   D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200
   Demiralp B, 2002, ENDOCRINOLOGY, V143, P4038, DOI 10.1210/en.2002 220221
   Donahue SW, 2003, J BIOMECH, V36, P35, DOI 10.1016/S0021 9290(02)00318 4
   Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282
   Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095
   Fitzgerald J, 1999, FASEB J, V13, P553, DOI 10.1096/fasebj.13.3.553
   Fleming I, 2003, AM J PHYSIOL REG I, V284, pR1, DOI 10.1152/ajpregu.00323.2002
   Fox SW, 1996, AM J PHYSIOL ENDOC M, V270, pE955, DOI 10.1152/ajpendo.1996.270.6.E955
   Gallagher JA, 2003, METH MOLEC MED, V80, P3
   GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380
   Gille H, 1996, MOL CELL BIOL, V16, P1094
   Granet C, 2002, CELL SIGNAL, V14, P679, DOI 10.1016/S0898 6568(02)00008 6
   GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685
   Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515
   Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007
   Gudi T, 1996, J BIOL CHEM, V271, P4597
   Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244
   Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143
   Hatton JP, 2003, J BONE MINER RES, V18, P58, DOI 10.1359/jbmr.2003.18.1.58
   Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715
   Hikiji H, 1997, FEBS LETT, V410, P238, DOI 10.1016/S0014 5793(97)00597 8
   HILLSLEY MV, 1994, BIOTECHNOL BIOENG, V43, P573, DOI 10.1002/bit.260430706
   Hughes Fulford Millie, 2004, Sci STKE, V2004, pRE12
   Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489
   Inoue D, 2004, J BIOL CHEM, V279, P49795, DOI 10.1074/jbc.M404096200
   Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021 9290(98)00114 6
   Jamal SA, 2004, J BONE MINER RES, V19, P1512, DOI 10.1359/JBMR.040716
   JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426
   Jiang GL, 2002, AM J PHYSIOL ENDOC M, V283, pE383, DOI 10.1152/ajpendo.00547.2001
   Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676
   Johnson DL, 1996, AM J PHYSIOL ENDOC M, V271, pE205, DOI 10.1152/ajpendo.1996.271.1.E205
   Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756 3282(02)00979 1
   Kawasaki Y, 2008, J CLIN INVEST, V118, P2506, DOI 10.1172/JCI35243
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Klein Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270
   Kletsas D, 2002, J CELL PHYSIOL, V190, P313, DOI 10.1002/jcp.10052
   KUCHAN MJ, 1994, AM J PHYSIOL, V267, pC753, DOI 10.1152/ajpcell.1994.267.3.C753
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lean JM, 1996, AM J PHYSIOL ENDOC M, V270, pE937, DOI 10.1152/ajpendo.1996.270.6.E937
   LIAN JB, 1998, J CELL BIOCHEM, V30, pS62
   Liu DW, 2008, BONE, V42, P644, DOI 10.1016/j.bone.2007.09.058
   MacPherson H, 1999, BONE, V24, P179, DOI 10.1016/S8756 3282(98)00173 2
   Mancini L, 2000, BIOCHEM BIOPH RES CO, V274, P477, DOI 10.1006/bbrc.2000.3164
   Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068
   McAllister TN, 1999, J BONE MINER RES, V14, P930, DOI 10.1359/jbmr.1999.14.6.930
   McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398
   Moalli MR, 2000, J BONE MINER RES, V15, P1346, DOI 10.1359/jbmr.2000.15.7.1346
   Münzel T, 2003, CIRCULATION, V108, P2172, DOI 10.1161/01.CIR.0000094403.78467.C3
   Murakami M, 1999, CELL GROWTH DIFFER, V10, P333
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200
   Orr AW, 2006, DEV CELL, V10, P11, DOI 10.1016/j.devcel.2005.12.006
   Pavalko FM, 1998, AM J PHYSIOL CELL PH, V275, pC1591
   Peake MA, 2000, J APPL PHYSIOL, V89, P2498, DOI 10.1152/jappl.2000.89.6.2498
   Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082
   Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045
   PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465
   RAABCULLEN DM, 1994, CALCIFIED TISSUE INT, V55, P473, DOI 10.1007/BF00298562
   Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028
   RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0
   Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683
   Schlossmann J, 2005, FRONT BIOSCI LANDMRK, V10, P1279, DOI 10.2741/1618
   Serulle Y, 2007, NEURON, V56, P670, DOI 10.1016/j.neuron.2007.09.016
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029
   Stevens HY, 2003, METH MOLEC MED, V80, P381
   Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200
   Vaandrager AB, 1997, J BIOL CHEM, V272, P11816, DOI 10.1074/jbc.272.18.11816
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang HG, 2005, NEURON, V45, P389, DOI 10.1016/j.neuron.2005.01.011
   Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443
   Wimalawansa SJ, 1996, BONE, V18, P301, DOI 10.1016/8756 3282(96)00005 1
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   Zeng Y, 2006, J BIOL CHEM, V281, P16951, DOI 10.1074/jbc.M602099200
   Zhao X, 2005, J BIOL CHEM, V280, P32683, DOI 10.1074/jbc.M505486200
NR 94
TC 78
Z9 95
U1 0
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021 9258
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 29
PY 2009
VL 284
IS 22
BP 14796
EP 14808
DI 10.1074/jbc.M806486200
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 448UT
UT WOS:000266288200015
PM 19282289
OA Green Published, hybrid
DA 2025 08 17
ER

PT S
AU Goltzman, D
AF Goltzman, David
BE Rhim, JS
   Dritschilo, A
   Kremer, R
TI The Aging Skeleton
SO HUMAN CELL TRANSFORMATION: ADVANCES IN CELL MODELS FOR THE STUDY OF
   CANCER AND AGING
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Bone remodeling; Osteoclasts; Osteoblasts; Osteoporosis; Malignancy
ID BONE MINERAL DENSITY; POSITIVE BREAST CANCER; ENDOCRINE THERAPY;
   GENOME WIDE; ESTROGEN; METAANALYSIS; WOMEN; AGE
AB Skeletal aging begins after peak bone mass is reached; progressive bone loss then occurs. Peak bone mass may occur at different ages in different skeletal sites and varies between sexes. Accelerated loss of bone occurs in the perimenopausal period in women, whereas more gradual but progressive loss of bone occurs in aging men. Changes in bone quality as well as bone quantity occur during growth and subsequent aging. These include changes in bone microarchitecture which may differ between cortical and trabecular compartments and in different sites, and may impact on bone size and geometry. Changes in material properties of bone matrix may also occur with aging. Loss of bone quantity and altered bone quality with aging may weaken bones and culminate in osteoporosis with an increased risk of fractures. Both genetic and epigenetic mechanisms may predispose to osteoporosis. Cellular and molecular events underlie the alterations in bone quantity and quality. Osteoclastic bone resorption and osteoblastic bone formation, tightly regulated by hormones, growth factors, and cytokines, are organized in coordinated activities resulting in remodeling and modeling. Malignancies, and anti neoplastic therapies, may impact on the cellular and molecular events in the aging skeleton and produce focal or diffuse skeletal lesions and fractures.
C1 [Goltzman, David] McGill Univ, Dept Med, Montreal, PQ, Canada.
   [Goltzman, David] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
C3 McGill University; McGill University
RP Goltzman, D (通讯作者)，McGill Univ, Dept Med, Montreal, PQ, Canada.; Goltzman, D (通讯作者)，McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
EM david.goltzman@mcgill.ca
FU Canadian Institutes for Health Research
FX This work was supported by a grant from the Canadian Institutes for
   Health Research.
CR Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Berger C, 2008, CAN MED ASSOC J, V178, P1660, DOI 10.1503/cmaj.071416
   Berger C, 2010, J BONE MINER RES, V25, P1948, DOI 10.1002/jbmr.95
   Boskey AL, 2017, ANN NY ACAD SCI, V1410, P93, DOI 10.1111/nyas.13572
   Burnett Bowie SAM, 2009, J CLIN ENDOCR METAB, V94, P4785, DOI 10.1210/jc.2009 0739
   Cheishvili D, 2018, J BONE MINER RES, V33, P1980, DOI 10.1002/jbmr.3527
   Coleman RE, 2013, NAT REV RHEUMATOL, V9, P365, DOI 10.1038/nrrheum.2013.36
   Eriksson AL, 2018, J CLIN ENDOCR METAB, V103, P991, DOI 10.1210/jc.2017 02060
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Falahati Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942
   Glassman D, 2017, ANTICANCER RES, V37, P5329, DOI 10.21873/anticanres.11959
   Goltzman David, 2000, Cancer, V88, P2903, DOI 10.1002/1097 0142(20000615)88:12+<2903::AID CNCR4>3.0.CO;2 G
   Handforth C, 2018, CALCIFIED TISSUE INT, V102, P251, DOI 10.1007/s00223 017 0369 x
   Koller DL, 2013, J BONE MINER RES, V28, P547, DOI 10.1002/jbmr.1796
   Macdonald HM, 2011, J BONE MINER RES, V26, P50, DOI 10.1002/jbmr.171
   Nishiyama KK, 2010, J BONE MINER RES, V25, P882, DOI 10.1359/jbmr.091020
   SEYMOUR JF, 1994, ANN INTERN MED, V121, P633, DOI 10.7326/0003 4819 121 9 199411010 00001
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Spring LM, 2016, JAMA ONCOL, V2, P1477, DOI 10.1001/jamaoncol.2016.1897
   Waning DL, 2014, CLIN CANCER RES, V20, P3071, DOI 10.1158/1078 0432.CCR 13 1590
   YASUDA T, 1989, J BIOL CHEM, V264, P7720
NR 21
TC 34
Z9 39
U1 0
U2 4
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH 6330, SWITZERLAND
SN 0065 2598
EI 2214 8019
BN 978 3 030 22254 3; 978 3 030 22253 6
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2019
VL 1164
BP 153
EP 160
DI 10.1007/978 3 030 22254 3_12
D2 10.1007/978 3 030 22254 3
PG 8
WC Oncology; Cell Biology; Geriatrics & Gerontology; Medicine, Research &
   Experimental
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology; Geriatrics & Gerontology; Research &
   Experimental Medicine
GA BO5AF
UT WOS:000516530900013
PM 31576547
DA 2025 08 17
ER

PT J
AU Feng, J
   Sun, QY
   Liu, L
   Xing, D
AF Feng, Jie
   Sun, Qinyan
   Liu, Lei
   Xing, Da
TI Photoactivation of TAZ via Akt/GSK3β signaling pathway promotes
   osteogenic differentiation
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Osteogentic differentiation; TAZ; LPLI; Akt; GSK3 beta
ID LOW POWER LASER; MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION;
   IRRADIATION LPLI; BONE REPAIR; IN VITRO; PROLIFERATION; THERAPY;
   ACTIVATION; RUNX2
AB Osteogenesis disorder is involved in osteoporosis and other related bone diseases, in which osteogenic differentiation is essential. Osteogenic differentiation is a complicated process regulated by intricate signal transduction networks. It has been reported that low power laser irradiation (LPLI) has an osteogenic potential by promoting osteoblast differentiation. However, the molecular mechanisms remain to be understood. In this study, we reveal a novel mechanism that Akt/GSK3 beta/TAZ (transcriptional co activator with PDZ binding motif) signaling pathway plays a crucial role in LPLI enhanced osteoblast differentiation. Photomodulation by LPLI activated Akt/GSK3 beta pathway which inhibited TAZ phosphorylation, leading to the increase of TAZ protein level and nuclear aggregation. Meanwhile, knockdown of TAZ suppressed osteogenic differentiation promoted by LPLL Further study showed that LPLI promoted the interaction between TAZ and core binding factor 1 (Cbfa1), up regulating the transcription of osteopontin (OPN) and osteocalcin (OCN) and the activity of alkaline phosphatase (ALP). However, inhibition of Akt/GSK3 beta pathway reversed the effects of TAZ on osteogenic differentiation induced by LPLI. Taken together, for the first time, we report that LPLI promotes osteoblast differentiation via TAZ activation dependent on Akt/GSK3 beta signaling pathway. (C) 2015 Published by Elsevier Ltd.
C1 [Xing, Da] S China Normal Univ, MOE Key Lab Laser Life Sci, Guangzhou 510631, Guangdong, Peoples R China.
   S China Normal Univ, Coll Biophoton, Inst Laser Life Sci, Guangzhou 510631, Guangdong, Peoples R China.
C3 South China Normal University; South China Normal University
RP Xing, D (通讯作者)，S China Normal Univ, MOE Key Lab Laser Life Sci, Guangzhou 510631, Guangdong, Peoples R China.
EM xingda@scnu.edu.cn
FU National Basic Research Program of China [2011CB910402, 2010CB732602];
   Program for Changjiang Scholars and Innovative Research Teamin
   University [IRT0829]; National Natural Science Foundation of China
   [81101741, 31101028, 31470072]
FX The authors declare that there is no duality of interest associated with
   this manuscript. This work was supported by the National Basic Research
   Program of China (2011CB910402; 2010CB732602), the Program for
   Changjiang Scholars and Innovative Research Teamin University (IRT0829),
   and the National Natural Science Foundation of China (81101741;
   31101028; 31470072).
CR Alfredo PP, 2012, CLIN REHABIL, V26, P523, DOI 10.1177/0269215511425962
   Antunes HS, 2007, BLOOD, V109, P2250, DOI 10.1182/blood 2006 07 035022
   Bossini PS, 2012, EXP GERONTOL, V47, P136, DOI 10.1016/j.exger.2011.11.005
   Bossini PS, 2011, J TISSUE ENG REGEN M, V5, P229, DOI 10.1002/term.309
   Bouvet Gerbettaz S, 2009, LASER SURG MED, V41, P291, DOI 10.1002/lsm.20759
   Byun MR, 2012, FEBS LETT, V586, P1086, DOI 10.1016/j.febslet.2012.03.008
   Byun MR, 2012, BONE, V50, P364, DOI 10.1016/j.bone.2011.10.035
   Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200
   Cho HH, 2010, J CELL PHYSIOL, V223, P168, DOI 10.1002/jcp.22024
   Chubinskaya S, 2003, INT J BIOCHEM CELL B, V35, P1323, DOI 10.1016/S1357 2725(03)00035 9
   Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048
   Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004 1013.2003
   de Cristofaro T, 2011, EUR J CANCER, V47, P926, DOI 10.1016/j.ejca.2010.11.008
   Di Palma T, 2009, EXP CELL RES, V315, P162, DOI 10.1016/j.yexcr.2008.10.016
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fávaro Pípi E, 2011, PHOTOMED LASER SURG, V29, P311, DOI 10.1089/pho.2010.2841
   Feng J, 2015, NEUROBIOL AGING, V36, P789, DOI 10.1016/j.neurobiolaging.2014.10.007
   Feng J, 2012, CELL SIGNAL, V24, P1116, DOI 10.1016/j.cellsig.2012.01.013
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gao XJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423 0127 16 4
   Hawkins D, 2005, ANN NY ACAD SCI, V1056, P486, DOI 10.1196/annals.1352.040
   Hergovich A, 2010, DEV CELL, V18, P508, DOI 10.1016/j.devcel.2010.04.003
   Hong D, 2009, J STEROID BIOCHEM, V116, P86, DOI 10.1016/j.jsbmb.2009.05.007
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Hou JF, 2008, LASER SURG MED, V40, P726, DOI 10.1002/lsm.20709
   Huang L, 2013, J CELL PHYSIOL, V228, P1045, DOI 10.1002/jcp.24252
   Huang W, 2012, J BIOL CHEM, V287, P26245, DOI 10.1074/jbc.M112.382036
   Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200
   Jang EJ, 2012, MOL CELL BIOL, V32, P4925, DOI 10.1128/MCB.00392 12
   Jeong H, 2010, FASEB J, V24, P3310, DOI 10.1096/fj.09 151324
   Jung H, 2009, BIOCHEM PHARMACOL, V78, P1323, DOI 10.1016/j.bcp.2009.07.001
   Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778
   KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032 198905000 00015
   KARU TI, 1987, IEEE J QUANTUM ELECT, V23, P1703, DOI 10.1109/JQE.1987.1073236
   Kiyosaki T, 2010, PHOTOMED LASER SURG, V28, pS167, DOI 10.1089/pho.2009.2693
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837
   Kwun IS, 2010, BONE, V46, P732, DOI 10.1016/j.bone.2009.11.003
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874 07
   Liang JG, 2012, FREE RADICAL BIO MED, V53, P1459, DOI 10.1016/j.freeradbiomed.2012.08.003
   Liu CY, 2011, J BIOL CHEM, V286, P5558, DOI 10.1074/jbc.M110.194019
   Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942
   Liu XC, 2007, PHOTOMED LASER SURG, V25, P487, DOI 10.1089/pho.2006.2075
   Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434
   Marsell R, 2012, BONE, V50, P619, DOI 10.1016/j.bone.2011.11.007
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Meng CB, 2013, J NEUROSCI, V33, P13505, DOI 10.1523/JNEUROSCI.0918 13.2013
   Murakami M, 2005, P NATL ACAD SCI USA, V102, P18034, DOI 10.1073/pnas.0509109102
   Oliveira DAAP, 2008, PHOTOMED LASER SURG, V26, P401, DOI 10.1089/pho.2007.2101
   Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8
   Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151
   Papachristou DJ, 2009, BIOESSAYS, V31, P794, DOI 10.1002/bies.200800223
   Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200
   Pires Oliveira DAA, 2010, OSTEOPOROSIS INT, V21, P2109, DOI 10.1007/s00198 010 1183 8
   Qu ZH, 2008, BIOCHEM BIOPH RES CO, V370, P332, DOI 10.1016/j.bbrc.2008.03.092
   Renno ACM, 2007, PHOTOMED LASER SURG, V25, P275, DOI 10.1089/pho.2007.2055
   Schett G, 2014, CELL METAB, V20, P394, DOI 10.1016/j.cmet.2014.08.009
   Shakouri SK, 2010, LASER MED SCI, V25, P73, DOI 10.1007/s10103 009 0670 7
   Shefer G, 2001, J CELL PHYSIOL, V187, P73, DOI 10.1002/1097 4652(2001)9999:9999<::AID JCP1053>3.0.CO;2 9
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Stein E, 2008, WIEN KLIN WOCHENSCHR, V120, P112, DOI 10.1007/s00508 008 0932 6
   Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748
   Wrighton KH, 2008, DEV CELL, V15, P8, DOI 10.1016/j.devcel.2008.06.010
   Wu RW, 2011, BONE, V49, P1255, DOI 10.1016/j.bone.2011.08.022
   Wu SN, 2011, FEBS J, V278, P941, DOI 10.1111/j.1742 4658.2011.08010.x
   Xu DH, 2014, INT J BIOCHEM CELL B, V51, P1, DOI 10.1016/j.biocel.2014.03.005
   Zhang H, 2012, CELL SIGNAL, V24, P224, DOI 10.1016/j.cellsig.2011.09.004
   Zhang LL, 2010, J CELL PHYSIOL, V224, P218, DOI 10.1002/jcp.22123
   Zhang LL, 2009, J CELL PHYSIOL, V219, P553, DOI 10.1002/jcp.21697
   Zhao LM, 2010, TISSUE ENG PT A, V16, P725, DOI 10.1089/ten.TEA.2009.0495
   Zhao ZR, 2005, MOL THER, V12, P247, DOI 10.1016/j.ymthe.2005.03.009
   Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200
NR 73
TC 19
Z9 21
U1 0
U2 15
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357 2725
EI 1878 5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD SEP
PY 2015
VL 66
BP 59
EP 68
DI 10.1016/j.biocel.2015.07.002
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CQ9RE
UT WOS:000360951900007
PM 26159930
DA 2025 08 17
ER

PT J
AU Hu, SJ
   Cheng, G
   Zhou, H
   Zhang, Q
   Zhang, QL
   Wang, Y
   Shen, Y
   Lian, CX
   Ma, XQ
   Zhang, QY
   Qin, LP
AF Hu, Si Jing
   Cheng, Gang
   Zhou, Hao
   Zhang, Qi
   Zhang, Quan Long
   Wang, Yang
   Shen, Yi
   Lian, Chen Xia
   Ma, Xue Qin
   Zhang, Qiao Yan
   Qin, Lu Ping
TI Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical
   Compounds and Preliminary Evaluation of Their Anti Osteoporotic Effects
SO MOLECULES
LA English
DT Article
DE cannabinoid CB2 receptor agonists; double luciferase screening system;
   molecular docking and dynamics; osteoblast; osteoclast
ID NF KAPPA B; ENDOCANNABINOID SYSTEM; FLAVOKAWAIN C; APOPTOSIS;
   EXPRESSION; OSTEOCLASTOGENESIS; MODULATION; ACTIVATION; INHIBITION;
   INDUCTION
AB As cannabinoid CB2 receptors (CB2R) possess various pharmacological effects including anti epilepsy, analgesia, anti inflammation, anti fibrosis, and regulation of bone metabolism without the psychoactive side effects induced by cannabinoid CB1R activation, they have become the focus of research and development of new target drugs in recent years. The present study was intended to (1) establish a double luciferase screening system for a CB2R modulator; (2) validate the agonistic activities of the screened compounds on CB2R by determining cAMP accumulation using HEK293 cells that are stably expressing CB2R; (3) predict the binding affinity between ligands and CB2 receptors and characterize the binding modes using molecular docking; (4) analyze the CB2 receptors ligand complex stability, conformational behavior, and interaction using molecular dynamics; and (5) evaluate the regulatory effects of the screened compounds on bone metabolism in osteoblasts and osteoclasts. The results demonstrated that the screening system had good stability and was able to screen cannabinoid CB2R modulators from botanical compounds. Altogether, nine CB2R agonists were identified by screening from 69 botanical compounds, and these CB2R agonists exhibited remarkable inhibitory effects on cAMP accumulation and good affinity to CB2R, as evidenced by the molecular docking and molecular dynamics. Five of the nine CB2R agonists could stimulate osteoblastic bone formation and inhibit osteoclastic bone resorption. All these findings may provide useful clues for the development of novel anti osteoporotic drugs and help elucidate the mechanism underlying the biological activities of CB2R agonists identified from the botanical materials.
C1 [Hu, Si Jing; Cheng, Gang; Zhou, Hao; Zhang, Qi; Zhang, Quan Long; Shen, Yi; Lian, Chen Xia; Zhang, Qiao Yan; Qin, Lu Ping] Zhejiang Univ Tradit Chinese Med, Sch Pharmaceut Sci, Dept Pharmacogonosy, Hangzhou 310053, Peoples R China.
   [Wang, Yang] Zhejiang Tradit Chinese Med & Hlth Ind Grp CO Ltd, Hangzhou 310016, Peoples R China.
   [Ma, Xue Qin] Ningxia Med Univ, Minist Educ, Key Lab Hui Ethn Med Modernizat, Dept Pharmaceut Anal,Sch Pharm, Yinchuan 750004, Ningxia, Peoples R China.
   [Zhang, Qiao Yan; Qin, Lu Ping] Second Mil Med Univ, Sch Pharm, Dept Pharmacogonosy, Shanghai 200433, Peoples R China.
C3 Zhejiang Chinese Medical University; Ningxia Medical University; Naval
   Medical University
RP Zhang, QY; Qin, LP (通讯作者)，Zhejiang Univ Tradit Chinese Med, Sch Pharmaceut Sci, Dept Pharmacogonosy, Hangzhou 310053, Peoples R China.; Ma, XQ (通讯作者)，Ningxia Med Univ, Minist Educ, Key Lab Hui Ethn Med Modernizat, Dept Pharmaceut Anal,Sch Pharm, Yinchuan 750004, Ningxia, Peoples R China.; Zhang, QY; Qin, LP (通讯作者)，Second Mil Med Univ, Sch Pharm, Dept Pharmacogonosy, Shanghai 200433, Peoples R China.
EM hsj960321@163.com; gangcheng@zcmu.edu.cn; zh995315026@163.com;
   zq199305@163.com; zql20161065@zcmu.edu.cn; wangyangsyx@163.com;
   18065148122@163.com; lianchenxia@163.com; maxueqin217@126.com;
   zqy1965@163.com; lpqin@zcmu.edu.cn
RI ma, xueqin/GWR 0125 2022
OI ma, Xueqin/0000 0003 4818 5967
CR Akkol EK, 2020, FOOD CHEM TOXICOL, V144, DOI 10.1016/j.fct.2020.111589
   Al Dhubiab BE, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103186
   Ammon HPT, 2019, PHYTOMEDICINE, V63, DOI 10.1016/j.phymed.2019.153002
   Ammon HPT, 2010, PHYTOMEDICINE, V17, P862, DOI 10.1016/j.phymed.2010.03.003
   Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   Apostu D, 2019, DRUG METAB REV, V51, P65, DOI 10.1080/03602532.2019.1574303
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Bouaboula M, 1999, MOL PHARMACOL, V55, P473
   Brandman R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029377
   Bukke VN, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14100965
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chan YH, 2020, CHEM BIOL INTERACT, V315, DOI 10.1016/j.cbi.2019.108911
   Chou TW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077626
   Cui JH, 2011, NEUROSCI LETT, V493, P67, DOI 10.1016/j.neulet.2010.12.052
   Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495
   Dickson CJ, 2014, J CHEM THEORY COMPUT, V10, P865, DOI 10.1021/ct4010307
   Ding LZ, 2018, INT J MOL MED, V41, P2517, DOI 10.3892/ijmm.2018.3506
   Emperador A, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13020176
   Ferreira JV, 2022, NAT PROD RES, V36, P4221, DOI 10.1080/14786419.2021.1973459
   GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432 1033.1995.tb20780.x
   Geng DC, 2011, CHINESE MED J PEKING, V124, P586, DOI 10.3760/cma.j.issn.0366 6999.2011.04.019
   He JY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072027
   Hong P, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2730 7
   Hseu YC, 2019, J CELL MOL MED, V23, P775, DOI 10.1111/jcmm.13973
   Hsieh GC, 2011, BRIT J PHARMACOL, V162, P428, DOI 10.1111/j.1476 5381.2010.01046.x
   Hu Q, 2020, CHEM RES TOXICOL, V33, P1980, DOI 10.1021/acs.chemrestox.0c00161
   Jiang XW, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2019.116887
   Jyotshna, 2016, BIOFACTORS, V42, P504, DOI 10.1002/biof.1308
   Khan MA, 2016, J ETHNOPHARMACOL, V191, P315, DOI 10.1016/j.jep.2016.06.053
   Kuchta K, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.705077
   Lee D, 2020, MOLECULES, V25, DOI 10.3390/molecules25214968
   Li XT, 2019, CELL, V176, P459, DOI 10.1016/j.cell.2018.12.011
   Li Xuesen, 2021, J Transl Genet Genom, V5, P163, DOI 10.20517/jtgg.2021.22
   LiverTox, 2012, Clinical and research information on drug induced liver injury
   Lozano Ondoua AN, 2013, J BONE MINER RES, V28, P92, DOI 10.1002/jbmr.1732
   Lu CW, 2020, PLANTA MED, V86, P434, DOI 10.1055/a 1107 9337
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Mammana S, 2019, MEDICINA LITHUANIA, V55, DOI 10.3390/medicina55110747
   Manzione MG, 2020, EUR J PHARMACOL, V883, DOI 10.1016/j.ejphar.2020.173344
   Marefati N, 2020, CYTOKINE, V131, DOI 10.1016/j.cyto.2020.155107
   Mazibuko Mbeje SE, 2021, MOLECULES, V26, DOI 10.3390/molecules26206154
   Meyer HC, 2018, NEUROPSYCHOPHARMACOL, V43, P21, DOI 10.1038/npp.2017.143
   Mittal Saurabh, 2020, J Complement Integr Med, V18, P9, DOI 10.1515/jcim 2019 0250
   Mlost J, 2022, NEUROPHARMACOLOGY, V204, DOI 10.1016/j.neuropharm.2021.108908
   Morales P, 2016, EXPERT OPIN THER PAT, V26, P843, DOI 10.1080/13543776.2016.1193157
   Mthembu SXH, 2021, MOLECULES, V26, DOI 10.3390/molecules26206289
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0
   Nakamura A, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101522
   Narayanapillai SC, 2016, CHEM RES TOXICOL, V29, P1828, DOI 10.1021/acs.chemrestox.6b00203
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Phang CW, 2019, EUR J PHARMACOL, V853, P388, DOI 10.1016/j.ejphar.2019.04.032
   Phang CW, 2017, PHARMACOGN MAG, V13, pS321, DOI 10.4103/0973 1296.210180
   Pollastro F, 2018, CURR MED CHEM, V25, P1160, DOI 10.2174/0929867324666170810164636
   Rajendran P, 2021, TOXINS, V13, DOI 10.3390/toxins13110745
   Ran HJ, 2021, ADV CLIN EXP MED, V30, P1195, DOI 10.17219/acem/139130
   Rossi F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081919
   Schatz AR, 1997, TOXICOL APPL PHARM, V142, P278, DOI 10.1006/taap.1996.8034
   Schmiech M, 2021, MOLECULES, V26, DOI 10.3390/molecules26020366
   Sekiguchi Y, 2017, MOL MED REP, V16, P1328, DOI 10.3892/mmr.2017.6752
   Shi JW, 2021, INT IMMUNOPHARMACOL, V94, DOI 10.1016/j.intimp.2021.107459
   Shi Yu, 2021, Hua Xi Kou Qiang Yi Xue Za Zhi, V39, P501, DOI 10.7518/hxkq.2021.05.002
   Siddiqui A, 2021, BIOMED PHARMACOTHER, V144, DOI 10.1016/j.biopha.2021.112250
   Sophocleous A, 2022, PHARMACOL RES, V175, DOI 10.1016/j.phrs.2021.105928
   Sophocleous A, 2015, J BIOL CHEM, V290, P22049, DOI 10.1074/jbc.M115.649608
   Sun YX, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/874982
   Takada Y, 2006, J IMMUNOL, V176, P3127, DOI 10.4049/jimmunol.176.5.3127
   Tian F, 2021, J CELL MOL MED, V25, P2426, DOI 10.1111/jcmm.16128
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tucci MA, 2021, NEUROTRAUMA REP, V2, P270, DOI 10.1089/neur.2020.0059
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang L, 2021, VIRULENCE, V12, P2149, DOI 10.1080/21505594.2021.1962138
   Wilkinson ST, 2014, JAMA J AM MED ASSOC, V311, P2377, DOI 10.1001/jama.2014.6175
   Wu T, 2021, FOOD FUNCT, V12, P11760, DOI [10.1039/d1fo02588k, 10.1039/D1FO02588K]
   Xiong LB, 2019, THERANOSTICS, V9, P7140, DOI 10.7150/thno.35988
   Xu AH, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 0512 6
   Xu G, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.134601
   Yang HL, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/3476212
   Yang LH, 2014, INT J MOL SCI, V15, P13637, DOI 10.3390/ijms150813637
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zhu M, 2019, J BONE MINER RES, V34, P739, DOI 10.1002/jbmr.3637
   Zoete V, 2009, J CELL MOL MED, V13, P238, DOI 10.1111/j.1582 4934.2008.00665.x
NR 81
TC 7
Z9 8
U1 1
U2 25
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD FEB
PY 2022
VL 27
IS 3
AR 702
DI 10.3390/molecules27030702
PG 24
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YY1VJ
UT WOS:000754581700001
PM 35163968
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ominsky, MS
   Boyce, RW
   Li, XD
   Ke, HZ
AF Ominsky, Michael Stuart
   Boyce, Rogely Waite
   Li, Xiaodong
   Ke, Hua Zhu
TI Effects of sclerostin antibodies in animal models of osteoporosis
SO BONE
LA English
DT Article
DE Sclerostin antibody; Animal models; Osteoporosis; Romosozumab; Bone
   formation; Bone quality
ID INCREASES BONE FORMATION; POSTMENOPAUSAL WOMEN; OSTEOBLAST LINEAGE;
   SKELETAL DETERIORATION; CLINICAL TRIAL; RAT MODEL; MASS; STRENGTH;
   OSTEOCYTES; BLOSOZUMAB
AB There is an unmet need for therapies that can restore bone strength and reduce fracture risk among patients at high risk of osteoporotic fracture. To address this need, bone forming therapies that increase osteoblast activity are required to help restore bone structure and strength. Sclerostin is now recognized as a target for osteoporosis therapy. Sclerostin is predominantly secreted by the osteocyte and acts as an extracellular inhibitor of canonical Wnt signaling by binding to the receptors lipoprotein receptor related protein 4, 5 and 6. Monoclonal antibodies to sclerostin (Scl Ab) have been used in both clinical and in preclinical studies of osteoporosis with beneficial outcomes for bone density, structure, strength and fracture risk reduction. In this review paper, we summarize the current literature describing the effects of Scl Ab in animal models of osteoporosis. In addition, we report new pharmacologic data from three animal studies of Scl Ab: 1) a 12 month study evaluating bone quality in ovariectomized (OVX) rats; 2) a 6 month study evaluating bone structure and strength in adolescent cynomolgus monkeys; and 3) the effects of transition from Scl Ab to vehicle or the RANKL inhibitor osteoprotegerin Fc in OVX rats. Together, these results demonstrate that inhibition of sclerostin by Scl Ab increased bone formation, and decreased bone resorption, leading to improved bone structure, bone mass and bone strength while maintaining bone quality in multiple animal models of osteoporosis. Further, gains in bone mass induced by Scl Ab treatment were preserved by antiresorptive agents such as a RANKL inhibitor as a follow on therapy. The bone forming effects of Scl Ab were unaffected by pre  or co treatment with a bisphosphonate, and were restored following a treatment free period after initial dosing. These data support the clinical development of Scl Ab for treatment of conditions with low bone mass such as postmenopausal and male osteoporosis. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Ominsky, Michael Stuart; Boyce, Rogely Waite; Li, Xiaodong] Amgen Inc, One Amgen Ctr Dr, Newbury Pk, CA 91320 USA.
   [Ke, Hua Zhu] UCB Pharma, 208 Bath Rd, Slough SL1 3WE, Berks, England.
C3 Amgen; UCB Pharma SA
RP Boyce, RW (通讯作者)，Amgen Inc, One Amgen Ctr Dr, Newbury Pk, CA 91320 USA.; Ke, HZ (通讯作者)，UCB Pharma, 208 Bath Rd, Slough SL1 3WE, Berks, England.
EM ominsky@umich.edu; rboyce@amgen.com; xli@amgen.com; huazhu.ke@ucb.com
OI Li, Xiaodong/0000 0002 2089 5046
FU Amgen Inc.; UCB Pharma
FX The new nonclinical studies (12 month study evaluating bone quality in
   OVX rats; 6 month study evaluating bone structure and strength in
   adolescent cynomolgus monkeys; effects of transition from Scl Ab to
   vehicle or OPG Fc in OVX rats) presented in this review were funded by
   Amgen Inc. and UCB Pharma. Financial support for the preparation of this
   article was provided by Amgen Inc. and UCB Pharma. Medical writing
   support in the form of editing, formatting this paper was provided by
   Angela Rogers PhD, of Gardiner Caldwell Communications, Maccles field,
   UK and was funded by UCB Pharma.
CR Achiou Z, 2015, BONE, V81, P691, DOI 10.1016/j.bone.2015.09.010
   [Anonymous], 2013, ANN OPER RES, DOI DOI 10.1109/IHMSC.2013.69
   BARNARD AH, 1980, S AFR MED J, V58, P401
   Beggs LA, 2015, J BONE MINER RES, V30, P681, DOI 10.1002/jbmr.2396
   BEIGHTON P, 1988, J MED GENET, V25, P200, DOI 10.1136/jmg.25.3.200
   Bouxsein M., 2012, J BONE MINER RES S1, V27
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Chen XX, 2013, ANN RHEUM DIS, V72, P1732, DOI 10.1136/annrheumdis 2013 203345
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Delgado Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008 5472.CAN 15 1703
   Eda H, 2016, J BONE MINER RES, V31, P1225, DOI 10.1002/jbmr.2789
   Eddleston A, 2009, J BONE MINER RES, V24, P1662, DOI [10.1359/JBMR.090403, 10.1359/jbmr.090403]
   European Medicines Agency (EMA) Committee fot Medicinal Products for Human Use (CHMP), 2007, GUID EV MED PROD TRE
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Halleux C., 2009, J BONE MINER RES S1, V24
   Hamann C, 2013, J BONE MINER RES, V28, P627, DOI 10.1002/jbmr.1803
   Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399 0004.2003.00036.x
   Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210
   Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kedlaya R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006627
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lau A., 2012, J BIOL CHEM, V286, P19489
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Li X., 2010, J BONE MINER RES S1, V25
   Li XD, 2014, ENDOCRINOLOGY, V155, P4785, DOI 10.1210/en.2013 1905
   Li XD, 2011, ENDOCRINOLOGY, V152, P3312, DOI 10.1210/en.2011 0252
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Ma YF, 2013, J BONE MINER RES, V28
   Marenzana M, 2011, ARTHRITIS RHEUM US, V63, P2385, DOI 10.1002/art.30385
   Marenzana M, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4305
   Matheny J., 2015, J BONE MINER RES S1, V30
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   McDonald M., 2016, ANN EUR CALC TISS SO, P14, DOI [10.1530/boneabs.5.CABS.00.4, DOI 10.1530/BONEABS.5.CABS.00.4]
   Moe SM, 2015, J BONE MINER RES, V30, P539, DOI 10.1002/jbmr.2372
   Moustafa A, 2012, OSTEOPOROSIS INT, V23, P1225, DOI 10.1007/s00198 011 1656 4
   Newman CL, 2015, BONE, V77, P50, DOI 10.1016/j.bone.2015.04.021
   Nicodemus KK, 2001, DIABETES CARE, V24, P1192, DOI 10.2337/diacare.24.7.1192
   Nioi P, 2015, J BONE MINER RES, V30, P1457, DOI 10.1002/jbmr.2482
   Niu Q. T., 2015, J BONE MINER RES S1, V30
   Ominsky M. S., 2012, J BONE MINER RES S1, V27
   Ominsky M. S., 2015, J BONE MINER RES S1, V30
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Ominsky MS, 2014, J BONE MINER RES, V29, P1424, DOI 10.1002/jbmr.2152
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Orwoll E. S., 2013, PRIMER METABOLIC BON, P508
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Papapoulos S, 2008, NAT CLIN PRACT ENDOC, V4, P514, DOI 10.1038/ncpendmet0941
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Qin WP, 2015, J BONE MINER RES, V30, P1994, DOI 10.1002/jbmr.2549
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Recknor CP, 2015, J BONE MINER RES, V30, P1717, DOI 10.1002/jbmr.2489
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Ren YS, 2016, MATRIX BIOL, V52 54, P151, DOI 10.1016/j.matbio.2015.12.009
   Ren YS, 2015, FASEB J, V29, P2702, DOI 10.1096/fj.14 265496
   Robinson M, 2013, J BONE MINER RES, V28
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Ross RD, 2014, J BONE MINER RES, V29, P1597, DOI 10.1002/jbmr.2188
   Sato A. Y., 2016, J BONE MINER RES, DOI [10.1002/jbmr2869, DOI 10.1002/JBMR2869]
   Seefried L. B., 2013, J BONE MINER RES S1, V28
   Seeman E, 2008, RHEUMATOLOGY, V47, P2, DOI 10.1093/rheumatology/ken177
   Sims NA, 2016, NAT REV ENDOCRINOL, V12, P314, DOI 10.1038/nrendo.2016.59
   Spatz JM, 2013, J BONE MINER RES, V28, P865, DOI 10.1002/jbmr.1807
   Stolina M, 2014, BONE, V67, P305, DOI 10.1016/j.bone.2014.07.031
   Taut AD, 2013, J BONE MINER RES, V28, P2347, DOI 10.1002/jbmr.1984
   Taylor S, 2016, BONE, V84, P148, DOI 10.1016/j.bone.2015.12.013
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   van Lenthe GH, 2008, BONE, V43, P717, DOI 10.1016/j.bone.2008.06.008
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Veverka V, 2009, J BIOL CHEM, V284, P10890, DOI 10.1074/jbc.M807994200
   Wehmeyer C, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac4351
   Wein M., 2016, ANN M AM SOC BON MIN, P16
   Weinstein RS, 2010, ENDOCRINOLOGY, V151, P2641, DOI 10.1210/en.2009 1488
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Yao W, 2016, OSTEOPOROSIS INT, V27, P283, DOI 10.1007/s00198 015 3308 6
   Zhang DY, 2016, BONE, V87, P161, DOI 10.1016/j.bone.2016.02.005
NR 87
TC 88
Z9 102
U1 0
U2 43
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2017
VL 96
BP 63
EP 75
DI 10.1016/j.bone.2016.10.019
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EN2OR
UT WOS:000395850300010
PM 27789417
DA 2025 08 17
ER

PT J
AU Wang, XJ
   Wang, GW
   Zingales, S
   Zhao, BD
AF Wang, Xiaojing
   Wang, Guowei
   Zingales, Sarah
   Zhao, Baodong
TI Biomaterials Enabled Cell Free Strategies for Endogenous Bone
   Regeneration
SO TISSUE ENGINEERING PART B REVIEWS
LA English
DT Article
DE bone; endogenous regeneration; tissue engineering; cell homing; drug
   delivery
ID PLATELET RICH PLASMA; MESENCHYMAL STEM CELLS; COMBINATORIAL
   GENE THERAPY; OSTEOBLAST DIFFERENTIATION; DISTRACTION OSTEOGENESIS;
   MAXILLOFACIAL SURGERY; EXTRACELLULAR MATRIX; CURRENT KNOWLEDGE;
   GROWTH FACTORS; STROMAL CELLS
AB Repairing bone defects poses a major orthopedic challenge because current treatments are constrained by the limited regenerative capacity of human bone tissue. Novel therapeutic strategies, such as stem cell therapy and tissue engineering, have the potential to enhance bone healing and regeneration, and hence may improve quality of life for millions of people. However, the ex vivo expansion of stem cells and their in vivo delivery pose technical difficulties that hamper clinical translation and commercial development. A promising alternative to cell delivery based strategies is to stimulate or augment the inherent self repair mechanisms of the patient to promote endogenous restoration of the lost/damaged bone. There is growing evidence indicating that increasing the endogenous regenerative potency of bone tissues for therapeutics will require the design and development of new generations of biomedical devices that provide key signaling molecules to instruct cell recruitment and manipulate cell fate for in situ tissue regeneration. Currently, a broad range of biomaterial based deployment technologies are becoming available, which allow for controlled spatial presentation of biological cues required for endogenous bone regeneration. This article aims to explore the proposed concepts and biomaterial enabled strategies involved in the design of cell free endogenous techniques in bone regenerative medicine.
C1 [Wang, Xiaojing; Zhao, Baodong] Qingdao Univ, Affiliated Hosp, Dent Implant Ctr, 59 Haier Rd, Qingdao 266071, Peoples R China.
   [Wang, Xiaojing; Zhao, Baodong] Qingdao Univ, Sch Stomatol, Qingdao, Shandong, Peoples R China.
   [Wang, Guowei] 401 Hosp Chinese Navy, Dept Stomatol, Laoshan Branch, Qingdao, Shandong, Peoples R China.
   [Zingales, Sarah] Georgia Southern Univ, Dept Chem & Biochem, Savannah, GA USA.
C3 Qingdao University; Qingdao University
RP Wang, XJ; Zhao, BD (通讯作者)，Qingdao Univ, Affiliated Hosp, Dent Implant Ctr, 59 Haier Rd, Qingdao 266071, Peoples R China.
EM wangxj_amy@yahoo.com; zbd315@sina.com
RI ; Wang, Susanna/IUM 3484 2023
OI Zingales, Sarah/0000 0002 4908 6226; wang, xiaojing/0000 0001 8771 1099;
   Zhao, Bao dong/0000 0001 8847 3408; 
FU Open Program of State Key Laboratory of Military Stomatology [2017KB03]
FX We wish to acknowledge financial support to Dr. Wang from the Open
   Program of State Key Laboratory of Military Stomatology (No. 2017KB03).
CR Accomasso L, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7920358
   Adam C, 2012, CELL TISSUE RES, V347, P489, DOI 10.1007/s00441 011 1234 2
   Ahmed TAE, 2014, HISTOL HISTOPATHOL, V29, P669, DOI 10.14670/HH 29.669
   Albanese A, 2013, IMMUN AGEING, V10, DOI 10.1186/1742 4933 10 23
   Aquino Martínez R, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0713 0
   Arioka M, 2014, BIOCHEM PHARMACOL, V90, P397, DOI 10.1016/j.bcp.2014.06.011
   Azevedo HS, 2015, ADV DRUG DELIVER REV, V94, P63, DOI 10.1016/j.addr.2015.08.003
   Bara JJ, 2018, J TISSUE ENG REGEN M, V12, pE106, DOI 10.1002/term.2393
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Boos AM, 2010, HANDCHIR MIKROCHIR P, V42, P360, DOI 10.1055/s 0030 1261964
   Boyan BD, 2000, J PERIODONTOL, V71, P1278, DOI 10.1902/jop.2000.71.8.1278
   Bu XF, 2010, J SURG RES, V164, P50, DOI 10.1016/j.jss.2009.03.018
   Bueno EM, 2009, NAT REV RHEUMATOL, V5, P685, DOI 10.1038/nrrheum.2009.228
   Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006
   BURCHARDT H, 1983, CLIN ORTHOP RELAT R, P28
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chambrone D, 2010, QUINTESSENCE INT, V41, P125
   Chambrone Daniela, 2007, Braz. oral res., V21, P241
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Chatterjea A, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/215625
   Chen Cen, 2016, Biomater Res, V20, P10
   Chen FM, 2011, BIOMATERIALS, V32, P3189, DOI 10.1016/j.biomaterials.2010.12.032
   Chen FM, 2009, BIOMATERIALS, V30, P5215, DOI 10.1016/j.biomaterials.2009.06.009
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Chim H, 2012, CELL TISSUE RES, V350, P89, DOI 10.1007/s00441 012 1449 x
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Curry AS, 2016, MATRIX BIOL, V52 54, P397, DOI 10.1016/j.matbio.2016.02.011
   Curtin CM, 2015, ADV HEALTHC MATER, V4, P223, DOI 10.1002/adhm.201400397
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Dawson LA, 2017, REGENERATION, V4, P140, DOI 10.1002/reg2.81
   Day TF, 2008, J BONE JOINT SURG AM, V90A, P19, DOI 10.2106/JBJS.G.01174
   Dee KC, 1998, J BIOMED MATER RES, V40, P371, DOI 10.1002/(SICI)1097 4636(19980605)40:3<371::AID JBM5>3.0.CO;2 C
   Deglurkar I, 2006, HUM GENE THER, V17, P1144, DOI 10.1089/hum.2006.17.1144
   Del Corso M, 2012, CURR PHARM BIOTECHNO, V13, P1207, DOI 10.2174/138920112800624391
   Detienville R, 1979, Inf Dent, V61, P497
   Döri F, 2013, J PERIODONTOL, V84, P1546, DOI 10.1902/jop.2013.120501
   Doiphode AM, 2016, J INT SOC PREV COMMU, V6, P47, DOI 10.4103/2231 0762.181167
   Dutta RC, 2009, BIOTECHNOL ADV, V27, P334, DOI 10.1016/j.biotechadv.2009.02.002
   Fernandes G, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.36
   Ferreira JR, 2013, GENE THER, V20, P158, DOI 10.1038/gt.2012.16
   Fillingham Y, 2016, BONE JOINT J, V98B, P6, DOI [10.1302/0301 620X.98B1.36350, 10.1302/0301 620X.98B.36350]
   Fong ELS, 2011, BIOMATERIALS, V32, P395, DOI 10.1016/j.biomaterials.2010.08.101
   Freymiller EG, 2004, J ORAL MAXIL SURG, V62, P1046, DOI 10.1016/j.joms.2004.05.205
   Fujio M, 2011, BONE, V49, P693, DOI 10.1016/j.bone.2011.06.024
   Fulzele K, 2012, BONE, V50, P452, DOI 10.1016/j.bone.2011.06.018
   Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856
   García JR, 2016, DRUG DELIV TRANSL RE, V6, P77, DOI 10.1007/s13346 015 0236 0
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   GLOWACKI J, 1985, CLIN PLAST SURG, V12, P233
   GOLDBERG VM, 1987, CLIN ORTHOP RELAT R, P7
   Hermann PM, 2008, J EXP BIOL, V211, P491, DOI 10.1242/jeb.013102
   Hernandez Hurtado AA, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7403890
   Ho CY, 2015, TISSUE ENG PT A, V21, P594, DOI [10.1089/ten.tea.2013.0762, 10.1089/ten.TEA.2013.0762]
   Horii A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000190
   Hosseinpour S, 2017, ORAL MAXILLOFAC SURG, V21, P109, DOI 10.1007/s10006 017 0608 3
   Humes H David, 2005, Trans Am Clin Climatol Assoc, V116, P167
   Imagama S, 2017, GLOB SPINE J, V7, P749, DOI 10.1177/2192568217696690
   Intini G, 2009, BIOMATERIALS, V30, P4956, DOI 10.1016/j.biomaterials.2009.05.055
   James EN, 2019, TISSUE ENG PT A, V25, P12, DOI [10.1089/ten.tea.2017.0455, 10.1089/ten.TEA.2017.0455]
   Joo MW, 2017, CELLS TISSUES ORGANS, V203, P327, DOI 10.1159/000454915
   Kang ES, 2017, NANO CONVERG, V4, DOI 10.1186/s40580 017 0096 z
   Kang ML, 2017, J TISSUE ENG REGEN M, V11, P3337, DOI 10.1002/term.2247
   Karnes JM, 2015, BONE, V78, P87, DOI 10.1016/j.bone.2015.05.001
   Kawakami Y, 2015, J BONE MINER RES, V30, P95, DOI 10.1002/jbmr.2318
   Khorsand B, 2017, J CONTROL RELEASE, V248, P53, DOI 10.1016/j.jconrel.2017.01.008
   Kitaori T, 2009, ARTHRITIS RHEUM US, V60, P813, DOI 10.1002/art.24330
   Kochan G., 2012, LENTIVIRAL VECTORS G, P87
   Koh JT, 2008, J DENT RES, V87, P845, DOI 10.1177/154405910808700906
   Kolk A, 2016, J BIOMED MATER RES A, V104, P2441, DOI 10.1002/jbm.a.35773
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   Kumagai K, 2008, J ORTHOP RES, V26, P165, DOI 10.1002/jor.20477
   Kumar V., 2003, TISSUE REPAIR CELL R, P61
   Lacoste E, 2003, J PERIODONTOL, V74, P1498, DOI 10.1902/jop.2003.74.10.1498
   Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood 2005 04 1417
   Lee CH, 2010, LANCET, V376, P440, DOI 10.1016/S0140 6736(10)60668 X
   Lee DJ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13326 y
   Lee JW, 2013, DEV BIOL, V382, P98, DOI 10.1016/j.ydbio.2013.07.020
   Lee SH, 2007, ADV DRUG DELIVER REV, V59, P339, DOI 10.1016/j.addr.2007.03.016
   Lewis EEL, 2016, ACS NANO, V10, P8346, DOI 10.1021/acsnano.6b02841
   Li BC, 2009, J TRAUMA, V66, P450, DOI 10.1097/TA.0b013e3181848cd6
   Li X, 2017, J CELL MOL MED, V21, P3162, DOI 10.1111/jcmm.13286
   Lin D, 2019, BIOMATERIALS, V196, P122, DOI 10.1016/j.biomaterials.2017.11.011
   Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756 3282(96)00138 X
   Lu CH, 2013, BIOTECHNOL ADV, V31, P1695, DOI 10.1016/j.biotechadv.2013.08.015
   Luo ZW, 2015, BIOMATERIALS, V52, P463, DOI 10.1016/j.biomaterials.2015.01.001
   Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602
   Marie PJ, 2012, GROWTH FACTORS, V30, P117, DOI 10.3109/08977194.2012.656761
   Mariner PD, 2013, J ORTHOP RES, V31, P401, DOI 10.1002/jor.22243
   Martino MM, 2015, ADV DRUG DELIVER REV, V94, P41, DOI 10.1016/j.addr.2015.04.007
   Marx RE, 2004, J ORAL MAXIL SURG, V62, P489, DOI 10.1016/j.joms.2003.12.003
   Marx RE, 1998, ORAL SURG ORAL MED O, V85, P638, DOI 10.1016/S1079 2104(98)90029 4
   Masquelet A C, 2000, Ann Chir Plast Esthet, V45, P346
   Miki T, 2005, STEM CELLS, V23, P1549, DOI 10.1634/stemcells.2004 0357
   Morcos MW, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/842975
   Nikolidakis D, 2006, TISSUE ENG, V12, P2555, DOI 10.1089/ten.2006.12.2555
   Ohba Shinsuke, 2012, Muscles Ligaments Tendons J, V2, P193
   Ortega Oller I, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/415289
   Oryan A, 2016, EXPERT OPIN BIOL TH, V16, P213, DOI 10.1517/14712598.2016.1118458
   Panetta NJ, 2010, CURR STEM CELL RES T, V5, P122
   Parikh S N, 2002, J Postgrad Med, V48, P142
   Park W, 2016, J BIOMATER APPL, V30, P1242, DOI 10.1177/0885328215620034
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Pensak MJ, 2013, CURR PHARM DESIGN, V19, P3466, DOI 10.2174/1381612811319190012
   PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857
   Pérez Sánchez MJ, 2010, MED ORAL PATOL ORAL, V15, pE517, DOI 10.4317/medoral.15.e517
   Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/nmat2441, 10.1038/NMAT2441]
   Polo Corrales L, 2014, J NANOSCI NANOTECHNO, V14, P15, DOI 10.1166/jnn.2014.9127
   Quintero AJ, 2010, J ORTHOP TRAUMA, V24, P42, DOI 10.1097/BOT.0b013e3181b2b4eb
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Raisin S, 2016, BIOMATERIALS, V104, P223, DOI 10.1016/j.biomaterials.2016.07.017
   Rezania A, 1999, J ORTHOPAED RES, V17, P615, DOI 10.1002/jor.1100170423
   Russell JL, 1999, ORTHOPEDICS, V22, P524
   Sailhan F, 2011, OSTEOPOROSIS INT, V22, P2011, DOI 10.1007/s00198 011 1613 2
   SALAMA R, 1983, CLIN ORTHOP RELAT R, P113
   Salou L, 2015, NANOMEDICINE UK, V10, P741, DOI [10.2217/NNM.14.223, 10.2217/nnm.14.223]
   Saranya N, 2011, J BIOMED NANOTECHNOL, V7, P238, DOI 10.1166/jbn.2011.1283
   Schwartz Z, 1996, J PERIODONTOL, V67, P918, DOI 10.1902/jop.1996.67.9.918
   Seo BB, 2017, BIOMATERIALS, V122, P91, DOI 10.1016/j.biomaterials.2017.01.016
   Seo S, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/806891
   Shen WL, 2010, BIOMATERIALS, V31, P7239, DOI 10.1016/j.biomaterials.2010.05.040
   Si JW, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/565732
   Silva EA, 2004, CURR TOP DEV BIOL, V64, P181, DOI 10.1016/S0070 2153(04)64008 7
   Simonpieri A, 2012, CURR PHARM BIOTECHNO, V13, P1231, DOI 10.2174/138920112800624472
   Stegen S, 2016, BONE, V87, P176, DOI 10.1016/j.bone.2016.03.014
   Stevens MM, 2005, P NATL ACAD SCI USA, V102, P11450, DOI 10.1073/pnas.0504705102
   Subramanian S, 2015, TISSUE ENG PT A, V21, P2013, DOI [10.1089/ten.tea.2014.0455, 10.1089/ten.TEA.2014.0455]
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Tian K, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018 015 0229 1
   Toles G E, 1969, TIC, V28, P6
   Tong L, 2003, PLAST RECONSTR SURG, V111, P211, DOI 10.1097/01.PRS.0000033180.01581.9A
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Wang XJ, 2010, J ENDODONT, V36, P56, DOI 10.1016/j.joen.2009.09.039
   Wegman F, 2013, BIOTECHNOL GENET ENG, V29, P206, DOI 10.1080/02648725.2013.801227
   Whitaker MJ, 2001, J PHARM PHARMACOL, V53, P1427, DOI 10.1211/0022357011777963
   Woo KM, 2007, BIOMATERIALS, V28, P335, DOI 10.1016/j.biomaterials.2006.06.013
   Wu RX, 2017, ADV BIOSYST, V1, DOI 10.1002/adbi.201700004
   Yang X, 2007, BONE, V41, P928, DOI 10.1016/j.bone.2007.07.022
   Yang YZ, 2012, CELL BIOSCI, V2, DOI 10.1186/2045 3701 2 14
   Yaszemski M.J., 2000, Bone Engineering, P541
   Yelamali T, 2015, J MAXILLOFAC ORAL SU, V14, P410, DOI 10.1007/s12663 014 0638 4
   Yin Y, 2017, J DENT RES, V96, P601, DOI 10.1177/0022034517706070
   Yu YY, 2010, BONE, V47, P65, DOI 10.1016/j.bone.2010.03.012
   Yu Y, 2016, J MATER CHEM B, V4, P569, DOI 10.1039/c5tb02199e
   Zhu W, 2004, J BONE MINER RES, V19, P2021, DOI 10.1359/JBMR.040821
NR 147
TC 31
Z9 33
U1 0
U2 24
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3368
EI 1937 3376
J9 TISSUE ENG PART B RE
JI Tissue Eng. Part B Rev.
PD DEC 1
PY 2018
VL 24
IS 6
BP 463
EP 481
DI 10.1089/ten.teb.2018.0012
EA SEP 2018
PG 19
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering;
   Materials Science
GA HC5ET
UT WOS:000445763600001
PM 29897021
DA 2025 08 17
ER

PT J
AU Premnath, P
   Ferrie, L
   Louie, D
   Boyd, S
   Krawetz, R
AF Premnath, Priyatha
   Ferrie, Leah
   Louie, Dante
   Boyd, Steven
   Krawetz, Roman
TI Absence of p21<SUP>(WAF1/CIP1/SDI1)</SUP> protects against osteopenia
   and minimizes bone loss after ovariectomy in a mouse model
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; P21; THERAPY; P21(WAF1/CIP1); REGENERATION;
   OSTEOGENESIS; OSTEOPOROSIS; EXPRESSION; RESCUES
AB p21((WAF1/CIP1/SDI1)) is a critical sentinel of the cell cycle that plays an important role in determining cell fate with respect to proliferation, differentiation and apoptosis. Recent studies have demonstrated that inhibition/loss of p21 promotes osteo chondro differentiation in progenitor/stem cells, and that p21 knockout (p21( / )) mice demonstrate enhanced bone regeneration compared to wild type controls after a non critical size defect. It was therefore hypothesized that the absence of p21 may also protect against bone loss through enhancing bone formation, tilting the balance away from bone resorption, in an ovariectomy induced osteopenia mouse model, investigated via microCT imaging. While p21( / ) mice demonstrated significantly less bone loss after ovariectomy compared to wild type controls, no increase in the number osteoclasts or osteoblasts in the bone or bone marrow was observed, nor was there an increase in osteoclast activity. Therefore, while the absence of p21 protected mice against estrogen mediated bone loss, the mechanisms/pathways responsible remained elusive. This study demonstrates that p21 may play a significant role in bone remodeling, and a better understanding of how the p21 pathway regulates bone anabolism and catabolism could lead to novel therapies for osteoporosis in the future.
C1 [Premnath, Priyatha; Ferrie, Leah; Louie, Dante; Boyd, Steven; Krawetz, Roman] Univ Calgary, Cumming Sch Med, McCaig Inst Bone & Joint Hlth, Calgary, AB, Canada.
   [Premnath, Priyatha; Krawetz, Roman] Univ Calgary, Cumming Sch Med, Dept Cell Biol & Anat, Calgary, AB, Canada.
   [Ferrie, Leah; Krawetz, Roman] Univ Calgary, Biomed Engn Grad Program, Calgary, AB, Canada.
   [Boyd, Steven] Univ Calgary, Cumming Sch Med, Dept Radiol, Calgary, AB, Canada.
   [Krawetz, Roman] Univ Calgary, Cumming Sch Med, Dept Surg, Calgary, AB, Canada.
C3 University of Calgary; University of Calgary; University of Calgary;
   University of Calgary; University of Calgary
RP Premnath, P (通讯作者)，Univ Calgary, Cumming Sch Med, McCaig Inst Bone & Joint Hlth, Calgary, AB, Canada.; Premnath, P (通讯作者)，Univ Calgary, Cumming Sch Med, Dept Cell Biol & Anat, Calgary, AB, Canada.
EM priyatha.premnath@ucalgary.ca
RI Boyd, Steven/E 9595 2010; PREMNATH, PRIYATHA/AAS 5305 2020
OI Boyd, Steven/0000 0002 2930 5997; 
FU Alberta Innovates postdoctoral fellowship [20160512]; Funder name:
   Alberta Innovates
FX PP received an Alberta Innovates postdoctoral fellowship, Notification
   No: 20160512, Funder name: Alberta Innovates
   (https://albertainnovates.ca/funding healthinnovations/training and earl
   y careerdevelopment/postgraduate fellowship funding/).The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728
   Antebi B, 2014, CURR OSTEOPOROS REP, V12, P41, DOI 10.1007/s11914 013 0184 x
   Bedelbaeva K, 2010, P NATL ACAD SCI USA, V107, P5845, DOI 10.1073/pnas.1000830107
   Buitrago Molina LE, 2013, HEPATOLOGY, V58, P1143, DOI 10.1002/hep.26412
   Chen XM, 2000, J NATL CANCER I, V92, P1403, DOI 10.1093/jnci/92.17.1403
   Cho SW, 2012, TISSUE ENG PT A, V18, P1067, DOI [10.1089/ten.tea.2011.0355, 10.1089/ten.TEA.2011.0355]
   Deng LL, 2015, BONE, V79, P37, DOI 10.1016/j.bone.2015.05.022
   Fend L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073310
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Hawke TJ, 2003, AM J PHYSIOL CELL PH, V285, pC1019, DOI 10.1152/ajpcell.00055.2003
   Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Liu K, 2017, BONE, V97, P130, DOI 10.1016/j.bone.2017.01.014
   Mandal S, 2010, J CELL PHYSIOL, V224, P28, DOI 10.1002/jcp.22078
   Papismadov N, 2017, CELL CYCLE, P1, DOI [10.1080/15384101.2017.1377500, DOI 10.1080/15384101.2017]
   Premnath P, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1790 z
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   Taiani JT, 2014, BONE, V64, P263, DOI 10.1016/j.bone.2014.04.019
   van den Bos C, 1998, CELL TISSUE RES, V293, P463, DOI 10.1007/s004410051138
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Zambetti GP, 2006, J CELL BIOL, V172, P795, DOI 10.1083/jcb.200601114
NR 21
TC 5
Z9 7
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 10
PY 2019
VL 14
IS 4
AR e0215018
DI 10.1371/journal.pone.0215018
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HS6PA
UT WOS:000463992600048
PM 30970032
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Bhullar, KS
   Shang, N
   Wu, JP
AF Bhullar, Khushwant S.
   Shang, Nan
   Wu, Jianping
TI Tripeptide IRW (Ile Arg Trp) as a Potential Nutraceutical Intervention
   in Osteoporosis
SO JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY
LA English
DT Article; Proceedings Paper
CT 22nd International Congress of Nutrition (IUNS ICN)
CY DEC 06 11, 2022
CL Tokyo, JAPAN
DE bone health; IRW; osteoporosis; bioactive peptides; inflammation
ID BONE; DIFFERENTIATION; TRANSCRIPTION; OSTEOBLASTS
AB Bone health is an important medical concern in rapidly aging demographics worldwide. Excessive bone resorption, due to enhanced activity of osteoclasts, is a major underlying cause of bone disorders such as osteoporosis. Inflammation and oxidative stress are key factors contributing to increased osteoclastic activity. Like increased activity of osteoclasts, depletion of osteoblasts also contributes to weakened structural integrity of bone. Considering the epidemiology of bone disorders and aging demographics there is a substantial need for novel bone health therapeutics. IRW (Ile Arg Trp), an egg derived tripeptide, exhibits a spectrum of pharmacological activity. In our recent work, we have shown that IRW inhibits osteoclastogenesis and promotes osteogenesis in the mouse macrophage RAW 264.7 and MC3T3 E1 cells. IRW treatment (25 and 50 mu M) significantly inhibited osteoclastogenesis associated factors [TRAF6 (TNF Receptor Associated Factor 6), Fos Proto Oncogene (c Fos), Nuclear Factor of Activated T Cells 1 (NFATc1), and cathepsin K] and upregulated osteogenesis associated factors [RUNX2 (Runt related transcription factor 2) and RANKL (Receptor activator of nuclear factor kappa B ligand)] in the two cell lines. Currently, we are conducting studies to analyze the impact of IRW on Angiotensin II (Ang II) induced stress in vitro and in vivo. In summary, our recent work presents the ability of IRW to prevent LPS induced inflammatory bone resorption and activation of osteogenesis activity via multiple signaling pathways.
C1 [Bhullar, Khushwant S.; Shang, Nan; Wu, Jianping] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB, Canada.
C3 University of Alberta
RP Wu, JP (通讯作者)，Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB, Canada.
EM jwu3@ualberta.ca
RI Wu, Jianping/H 9150 2012; Shang, Nan/AAP 7536 2021
FU Egg Farmers of Canada; Natural Sciences and Engineering Research Council
   (NSERC) of Canada
FX This research was funded by grants from Egg Farmers of Canada and the
   Natural Sciences and Engineering Research Council (NSERC) of Canada. The
   funders had no role in the study design, data collection, and analysis,
   decision to publish or preparation of this manuscript.
CR Cohen Solal KA, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0404 3
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Gebru Y, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/932691
   Gómez Cerezo N, 2018, J COLLOID INTERF SCI, V528, P309, DOI 10.1016/j.jcis.2018.05.099
   Gu QL, 2017, J ORTHOP TRANSL, V10, P86, DOI 10.1016/j.jot.2017.05.002
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Lóotoing L, 2014, MOL NUTR FOOD RES, V58, P1239, DOI 10.1002/mnfr.201300836
   Mallorie A, 2022, Surgery (Oxford), P33
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Shang N, 2020, J AGR FOOD CHEM, V68, P6132, DOI 10.1021/acs.jafc.0c01159
   Shang N, 2019, BBA GEN SUBJECTS, V1863, P1138, DOI 10.1016/j.bbagen.2019.04.007
   Shuai B, 2015, OSTEOPOROSIS INT, V26, P1063, DOI 10.1007/s00198 014 2992 y
   Souza PPC, 2013, IMMUNOL INVEST, V42, P555, DOI 10.3109/08820139.2013.822766
   Suda T, 2001, Arthritis Research & Therapy, V3, P1
   Sugamori Y, 2016, BIOESSAYS, V38, P717, DOI 10.1002/bies.201600104
   Xia J, 2012, BIOCHEM BIOPH RES CO, V428, P264, DOI 10.1016/j.bbrc.2012.10.043
NR 17
TC 0
Z9 0
U1 2
U2 6
PU CENTER ACADEMIC PUBL JAPAN
PI TOKYO
PA 2 4 16 YAYOI, BUNKYO KU, TOKYO, 113 0032, JAPAN
SN 0301 4800
EI 1881 7742
J9 J NUTR SCI VITAMINOL
JI J. Nutr. Sci. Vitaminol.
PY 2022
VL 68
SU S
BP S113
EP S115
DI 10.3177/jnsv.68.S113
PG 3
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Nutrition & Dietetics
GA U4HV9
UT WOS:001084435000040
PM 36436988
OA gold
DA 2025 08 17
ER

PT J
AU Boyanov, M
   Shinkov, A
   Psachoulia, E
   Intorcia, M
   Petkova, R
AF Boyanov, Mihail
   Shinkov, Alexander
   Psachoulia, Emi
   Intorcia, Michele
   Petkova, Reneta
TI Baseline Characteristics and Changes in Bone Mineral Density T Scores of
   Bulgarian Women with Postmenopausal Osteoporosis Receiving Denosumab in
   Routine Clinical Practice
SO DRUGS IN R&D
LA English
DT Article
ID OVARIECTOMIZED CYNOMOLGUS MONKEYS; HUMAN RANKL ANTIBODY; VITAMIN D;
   FRACTURE; ADHERENCE; CALCIUM; RISK; SUPPLEMENTATION; PREVENTION;
   DIAGNOSIS
AB Background Postmenopausal osteoporosis (PMO) is common among women over 50 years of age and is associated with an increased risk of fracture. Bone targeted agents, such as denosumab, can reduce fracture risk in patients with PMO. Objective The aim was to describe baseline characteristics and changes in bone mineral density (BMD) T scores among women with PMO receiving denosumab in Bulgaria.
   Methods This multicenter chart review included women with PMO receiving denosumab for >= 1 year in Bulgaria (October 2011 August 2013). Participants were required to have a baseline BMD T score of <= 2.5 standard deviations (SDs) at one or more skeletal sites.
   Results Overall, 222 women were included. The mean (SD) age at denosumab initiation was 64.2 (8.5) years; 26.6% reported a previous osteoporotic fracture and 6.8% a previous hip fracture. Only half of those reporting a previous fracture (49.2%) had received prior osteoporosis therapy. At baseline, mean (SD) BMD T scores were lumbar spine  3.2 SD (0.6 SD), total hip  2.3 SD (0.8 SD), and femoral neck  2.7 SD (0.7 SD). After 1 year of denosumab treatment, scores increased significantly at all three sites, reaching  2.7 SD (0.6 SD),  2.1 SD (0.9 SD), and  2.4 SD (0.7 SD), respectively (all p < 0.0001 vs. baseline). No serious adverse drug reactions were identified.
   Conclusion Denosumab is usually prescribed in women with PMO at high fracture risk. In the patients who were persistent with treatment at 1 year, denosumab was well tolerated and effective at increasing BMD T scores at several skeletal sites.
C1 [Boyanov, Mihail] Univ Hosp Alexandrovska, 1 St Georgi Sofiiski St, Sofia 1431, Bulgaria.
   [Shinkov, Alexander] Med Univ Sofia, Univ Hosp Endocrinol, Sofia, Bulgaria.
   [Psachoulia, Emi; Intorcia, Michele] Amgen Europe GmbH, Zug, Switzerland.
   [Petkova, Reneta] Amgen Bulgaria, Sofia, Bulgaria.
C3 Medical University Sofia; Medical University Sofia; Amgen; AMGEN Europe
RP Boyanov, M (通讯作者)，Univ Hosp Alexandrovska, 1 St Georgi Sofiiski St, Sofia 1431, Bulgaria.
EM mihailboyanov@yahoo.com
RI ; Shinkov, Alexander/F 8140 2013
OI Boyanov, Mihail/0000 0002 5695 2831; Shinkov,
   Alexander/0000 0002 9203 4149
FU Amgen (Europe) GmbH
FX Medical writing support was provided by Kim Allcott of Oxford
   PharmaGenesis, Oxford, UK. Funding for this support was provided by
   Amgen (Europe) GmbH.
CR Bone HG, 2015, 10 YEARS DEN TREATM
   Boonen S, 2011, J CLIN ENDOCR METAB, V96, P1727, DOI 10.1210/jc.2010 2784
   Borissova Anna Maria, 2011, Arch Osteoporos, V6, P189, DOI 10.1007/s11657 011 0064 x
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   Gallacher SJ, 2007, OSTEOPOROSIS INT, V18, P185, DOI 10.1007/s00198 006 0211 1
   Hadji P, 2015, OSTEOPOROSIS INT, V26, P2479, DOI 10.1007/s00198 015 3164 4
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Hiligsmann M, 2015, EUR J PUBLIC HEALTH, V25, P20, DOI 10.1093/eurpub/cku119
   Jennings LA, 2010, J AM GERIATR SOC, V58, P650, DOI 10.1111/j.1532 5415.2010.02769.x
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Kanis JA, 2004, BONE, V35, P375, DOI 10.1016/j.bone.2004.03.024
   Kanis JA, 2001, OSTEOPOROSIS INT, V12, P989, DOI 10.1007/s001980170006
   Kostenuik PJ, 2011, BONE, V49, P151, DOI 10.1016/j.bone.2011.03.769
   Kung AW, 2013, BMC WOMENS HEALTH, V13, DOI 10.1186/1472 6874 13 7
   Lips P, 1997, Am J Med, V103, p3S
   Manson JE, 2014, MENOPAUSE, V21, P106, DOI [10.1097/gme.0b013e31829be090, 10.1097/GME.0b013e31829be090]
   McClung MR, 2012, J BONE MINER RES, V27, P211, DOI 10.1002/jbmr.536
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   McGowan B, 2013, IRISH J MED SCI, V182, P601, DOI 10.1007/s11845 013 0935 9
   Munson JC, 2016, JAMA INTERN MED, V176, P1531, DOI 10.1001/jamainternmed.2016.4814
   Ominsky MS, 2011, BONE, V49, P162, DOI 10.1016/j.bone.2011.04.001
   Silverman SL, 2015, OSTEOPOROSIS INT, V26, P361, DOI 10.1007/s00198 014 2871 6
   Siris ES, 2009, AM J MED, V122, P3, DOI 10.1016/j.amjmed.2008.12.002
   Svedbom A, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0137 0
   Teede HJ, 2007, INTERN MED J, V37, P674, DOI 10.1111/j.1445 5994.2007.01503.x
   Teede HJ, 2012, INTERN MED J, V42, pe74, DOI 10.1111/j.1445 5994.2010.02258.x
NR 35
TC 3
Z9 4
U1 0
U2 5
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH 6330, SWITZERLAND
SN 1174 5886
EI 1179 6901
J9 DRUGS R&D
JI Drugs R&D
PD MAR
PY 2017
VL 17
IS 1
BP 125
EP 132
DI 10.1007/s40268 016 0159 3
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EQ5OU
UT WOS:000398133200011
PM 27988913
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Takakura, N
   Matsuda, M
   Khan, M
   Hiura, F
   Aoki, K
   Hirohashi, Y
   Mori, K
   Yasuda, H
   Hirata, M
   Kitamura, C
   Jimi, E
AF Takakura, Nana
   Matsuda, Miho
   Khan, Masud
   Hiura, Fumitaka
   Aoki, Kazuhiro
   Hirohashi, Yuna
   Mori, Kayo
   Yasuda, Hisataka
   Hirata, Masato
   Kitamura, Chiaki
   Jimi, Eijiro
TI A novel inhibitor of NF κB inducing kinase prevents bone loss by
   inhibiting osteoclastic bone resorption in ovariectomized mice
SO BONE
LA English
DT Article
DE NIK; Osteoclasts; Osteoporosis
ID LIVER DEGENERATION; BLOCKS OSTEOCLASTOGENESIS; EMBRYONIC LETHALITY; IKK;
   ACTIVATION; INFLAMMATION; NF KAPPA B2; OSTEOBLAST; LACKING; P100
AB Musculoskeletal diseases and disorders, including osteoporosis and rheumatoid arthritis are diseases that threaten a healthy life expectancy, and in order to extend the healthy life expectancy of elderly people, it is important to prevent bone and joint diseases and disorders. We previously reported that alymphoplasia (aly/aly) mice, which have a loss of function mutation in the Nik gene involved in the processing of p100 to p52 in the alternative NF kappa B pathway, show mild osteopetrosis with a decrease in the osteoclast number, suggesting that the alternative NF kappa B pathway is a potential drug target for ameliorating bone diseases. Recently, the novel NF kappa B inducing kinase (NIK) specific inhibitor compound 33 (Cpd33) was developed, and we examined its effect on osteoclastic bone resorption in vitro and in vivo. Cpd33 inhibited the receptor activator of NF kappa B ligand (RANKL)induced osteoclastogenesis accompanied by a decrease in the expression of nfatc1, dc stamp, and cathepsin K, markers of osteoclast differentiation, without affecting the cell viability, in a dose dependent manner. Cdp33 specifically suppressed the RANKL induced processing of p100 to p52 but not the phosphorylation of p65 or the degradation or resynthesis of I kappa B alpha in osteoclast precursors. Cpd33 also suppressed the bone resorbing activity in mature osteoclasts. Furthermore, Cdp33 treatment prevented bone loss by suppressing the osteoclast formation without affecting the osteoblastic bone formation in ovariectomized mice. Taken together, NIK inhibitors may be a new option for patients with a reduced response to conventional pharmacotherapy or who have serious side effects.
C1 [Takakura, Nana; Matsuda, Miho; Hiura, Fumitaka; Mori, Kayo; Jimi, Eijiro] Kyushu Univ, Fac Dent Sci, Lab Mol & Cellular Biochem, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
   [Takakura, Nana; Kitamura, Chiaki] Kyushu Dent Univ, Dept Sci Oral Funct, Div Endodont & Restorat Dent, Kokurakita Ku, 2 6 1 Manazuru, Kitakyushu, Fukuoka 8038580, Japan.
   [Khan, Masud; Aoki, Kazuhiro; Hirohashi, Yuna] Tokyo Med & Dent Univ, Grad Sch, Dept Basic Oral Hlth Engn, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138549, Japan.
   [Yasuda, Hisataka] Oriental Yeast Co Ltd, Nagahama Inst Biochem Sci, 50 Kano Cho, Nagahama, Shiga 5260804, Japan.
   [Hirata, Masato] Fukuoka Dent Coll, Oral Med Res Ctr, Sawara Ku, 2 15 1 Tamura, Fukuoka 8140193, Japan.
   [Jimi, Eijiro] Kyushu Univ, Fac Dent Sci, Oral Hlth Brain Hlth Total Hlth Res Ctr, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
C3 Kyushu University; Kyushu Dental University; Institute of Science Tokyo;
   Tokyo Medical & Dental University (TMDU); Oriental Yeast Co., Ltd.;
   Fukuoka Dental College (FDC); Kyushu University
RP Jimi, E (通讯作者)，Kyushu Univ, Fac Dent Sci, Oral Hlth Brain Hlth Total Hlth Res Ctr, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
EM ejimi@dent.kyushu u.ac.jp
RI AOKI, Kazuhiro/G 2258 2016; AOKI, Kazuhiro/GRO 6475 2022
OI AOKI, Kazuhiro/0000 0001 6643 6315; 
FU Kyushu University; Japan Society for the Promotion of Science (JSPS)
   KAKENHI Grant [17H01595, 26293406]; Grants in Aid for Scientific
   Research [26293406] Funding Source: KAKEN
FX This study was supported by the research grant for OBT Research Center
   from the Kyushu University (to E.J.) and by the Japan Society for the
   Promotion of Science (JSPS) KAKENHI Grant (17H01595 to M.H., 26293406 to
   C.K.).
CR Alles N, 2010, ENDOCRINOLOGY, V151, P4626, DOI 10.1210/en.2010 0399
   Alswat Khaled A, 2017, J Clin Med Res, V9, P382, DOI 10.14740/jocmr2970w
   Aubin J. E., 2002, PRINCIPLES BONE BIOL, V1, P59, DOI [10.1016/B978 012098652 1.50106 2, DOI 10.1016/B978 012098652 1.50106 2]
   Aya K, 2005, J CLIN INVEST, V115, P1848, DOI 10.1172/JCI23763
   BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0
   Can I, 2016, CLIN EXP OBSTET GYN, V43, P737, DOI 10.12891/ceog3004.2016
   Castanedo GM, 2017, J MED CHEM, V60, P627, DOI 10.1021/acs.jmedchem.6b01363
   da Silva AP, 2016, J NUTR HEALTH AGING, V20, P256, DOI 10.1007/s12603 015 0566 0
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   de Paula FJA, 2013, BONE RES, V1, DOI 10.4248/BR201301005
   Demchenko YN, 2014, ONCOTARGET, V5, P4554, DOI 10.18632/oncotarget.2128
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Grinberg Bleyer Y, 2016, CANCER CELL, V30, P829, DOI 10.1016/j.ccell.2016.11.013
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Jimi E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121636
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Khedgikar V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.294
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321
   Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839
   Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097 2765(00)80262 2
   Maruyama T, 2010, J BONE MINER RES, V25, P1058, DOI 10.1359/jbmr.091032
   McLeod M, 2016, BIOGERONTOLOGY, V17, P497, DOI 10.1007/s10522 015 9631 7
   MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224
   Mortier J, 2010, BIOORG MED CHEM LETT, V20, P4515, DOI 10.1016/j.bmcl.2010.06.027
   Muhammad K, 2014, EUR J IMMUNOL, V44, P3392, DOI 10.1002/eji.201444756
   Myojin T, 2017, J EPIDEMIOL, V27, P75, DOI 10.1016/j.je.2016.09.007
   Nagai Y, 2013, J BONE MINER RES, V28, P2449, DOI 10.1002/jbmr.1936
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Otero JE, 2008, J BIOL CHEM, V283, P24546, DOI 10.1074/jbc.M800434200
   Ren XM, 2017, FASEB J, V31, P711, DOI 10.1096/fj.201600840R
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Saad FA, 2020, ANN NY ACAD SCI, V1462, P37, DOI 10.1111/nyas.14231
   Schmidt Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097 2765(00)80263 4
   Seo Y, 2012, MOL ENDOCRINOL, V26, P414, DOI 10.1210/me.2011 1241
   Serio I, 2018, DRUG TODAY, V54, P219, DOI 10.1358/dot.2018.54.3.2788019
   Shishodia S, 2005, CANCER RES, V65, P9555, DOI 10.1158/0008 5472.CAN 05 1585
   Song PP, 2019, BIOSCI TRENDS, V13, P279, DOI 10.5582/bst.2019.01173
   Soysa NS, 2010, J BONE MINER RES, V25, P809, DOI 10.1359/jbmr.091030
   Strait K, 2008, INT J MOL MED, V21, P521
   Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52
   Suzuki N, 2016, BIOMECH MODEL MECHAN, V15, P1091, DOI 10.1007/s10237 015 0746 1
   Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074 7613(00)80042 4
   Tanaka S, 2019, EFORT OPEN REV, V4, P158, DOI 10.1302/2058 5241.4.180018
   Xue SS, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115163
   Yang C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015383
   Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453
   Yoshimura N, 2016, CLIN REV BONE MINER, V14, P68, DOI 10.1007/s12018 016 9211 7
NR 49
TC 25
Z9 27
U1 0
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2020
VL 135
AR 115316
DI 10.1016/j.bone.2020.115316
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LJ3LI
UT WOS:000530069000009
PM 32169603
DA 2025 08 17
ER

PT J
AU Raje, N
   Terpos, E
   Willenbacher, W
   Shimizu, K
   García Sanz, R
   Durie, B
   Legiec, W
   Krejcí, M
   Laribi, K
   Zhu, L
   Cheng, P
   Warner, D
   Roodman, GD
AF Raje, Noopur
   Terpos, Evangelos
   Willenbacher, Wolfgang
   Shimizu, Kazuyuki
   Garcia Sanz, Ramon
   Durie, Brian
   Legiec, Wojciech
   Krejci, Marta
   Laribi, Kamel
   Zhu, Li
   Cheng, Paul
   Warner, Douglas
   Roodman, G. David
TI Denosumab versus zoledronic acid in bone disease treatment of newly
   diagnosed multiple myeloma: an international, double blind,
   double dummy, randomised, controlled, phase 3 study
SO LANCET ONCOLOGY
LA English
DT Article
ID SURVIVAL; REGRESSION; CELLS; BISPHOSPHONATE; OSTEONECROSIS; TRIAL; JAW;
   IX
AB Background Multiple myeloma is characterised by monoclonal paraprotein production and osteolytic lesions, commonly leading to skeletal related events (spinal cord compression, pathological fracture, or surgery or radiotherapy to affected bone). Denosumab, a monoclonal antibody targeting RANKL, reduces skeletal related events associated with bone lesions or metastases in patients with advanced solid tumours. This study aimed to assess the efficacy and safety of denosumab compared with zoledronic acid for the prevention of skeletal related events in patients with newly diagnosed multiple myeloma.
   Methods In this international, double blind, double dummy, randomised,active controlled, phase 3 study, patients in 259 centres and 29 countries aged 18 years or older with symptomatic newly diagnosed multiple myeloma who had at least one documented lytic bone lesion were randomly assigned (1: 1; centrally, by interactive voice response system using a fixed stratified permuted block randomisation list with a block size of four) to subcutaneous denosumab 120 mg plus intravenous placebo every 4 weeks or intravenous zoledronic acid 4 mg plus subcutaneous placebo every 4 weeks (both groups also received investigators' choice of first line antimyeloma therapy). Stratification was by intent to undergo autologous transplantation, antimyeloma therapy, International Staging System stage, previous skeletal related events, and region. The clinical study team and patients were masked to treatment assignments. The primary endpoint was non inferiority of denosumab to zoledronic acid with respect to time to first skeletal related event in the full analysis set (all randomly assigned patients). All safety endpoints were analysed in the safety analysis set, which includes all randomly assigned patients who received at least one dose of active study drug. This study is registered with ClinicalTrials. gov, number NCT01345019.
   Findings From May 17, 2012, to March 29, 2016, we enrolled 1718 patients and randomly assigned 859 to each treatment group. The study met the primary endpoint; denosumab was non inferior to zoledronic acid for time to first skeletalrelated event (hazard ratio 0.98, 95% CI 0.85 1.14; p non inferiority = 0.010). 1702 patients received at least one dose of the investigational drug and were included in the safety analysis (850 patients receiving denosumab and 852 receiving zoledronic acid). The most common grade 3 or worse treatment emergent adverse events for denosumab and zoledronic acid were neutropenia (126 [15%] vs 125 [15%]), thrombocytopenia (120 [14%] vs 103 [12%]), anaemia (100 [12%] vs 85 [10%]), febrile neutropenia (96 [11%] vs 87 [10%]), and pneumonia (65 [8%] vs 70 [8%]). Renal toxicity was reported in 85 (10%) patients in the denosumab group versus 146 (17%) in the zoledronic acid group; hypocalcaemia adverse events were reported in 144 (17%) versus 106 (12%). Incidence of osteonecrosis of the jaw was not significantly different between the denosumab and zoledronic acid groups (35 [4%] vs 24 [3%]; p=0.147). The most common serious adverse event for both treatment groups was pneumonia (71 [8%] vs 69 [8%]). One patient in the zoledronic acid group died of cardiac arrest that was deemed treatment related.
   Interpretation In patients with newly diagnosed multiple myeloma, denosumab was non inferior to zoledronic acid for time to skeletal related events. The results from this study suggest denosumab could be an additional option for the standard of care for patients with multiple myeloma with bone disease.
C1 [Raje, Noopur] Massachusetts Gen Hosp, Ctr Canc, Ctr Multiple Myeloma, Boston, MA 02114 USA.
   [Terpos, Evangelos] Natl & Kapodistrian Univ Athens, Sch Med, Alexandra Gen Hosp, Athens, Greece.
   [Willenbacher, Wolfgang] Univ Innsbruck Hosp, Innsbruck, Austria.
   [Willenbacher, Wolfgang] OncoTyrol, Ctr Personalized Canc Med, Innsbruck, Austria.
   [Shimizu, Kazuyuki] Natl Hosp Org Higashi Nagoya Natl Hosp, Nagoya, Aichi, Japan.
   [Garcia Sanz, Ramon] Hosp Univ Salamanca, Salamanca, Spain.
   [Durie, Brian] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Legiec, Wojciech] Med Univ Lublin, Lublin, Poland.
   [Krejci, Marta] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic.
   [Laribi, Kamel] Ctr Hosp Le Mans, Dept Hematol, Le Mans, France.
   [Zhu, Li; Cheng, Paul; Warner, Douglas] Amgen Inc, Thousand Oaks, CA USA.
   [Roodman, G. David] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; National & Kapodistrian University of Athens;
   Alexandra Hospital; Medical University of Innsbruck; University of
   Innsbruck Hospital; University of Salamanca; Cedars Sinai Medical
   Center; Medical University of Lublin; University Hospital Brno; Centre
   Hospitalier Le Mans; Amgen; Indiana University System; Indiana
   University Bloomington
RP Raje, N (通讯作者)，Massachusetts Gen Hosp, Ctr Canc, Ctr Multiple Myeloma, Boston, MA 02114 USA.
EM NRAJE@mgh.harvard.edu
RI Terpos, Evangelos/AAD 3667 2019; Garcia Sanz, Ramon/B 7986 2017;
   Shimizu, Kazuyuki/GVT 4698 2022; Krejci, Marta/ABE 2414 2020; Legiec,
   Wojciech Maciej/AAG 2590 2021; Legiec, Wojciech/AAG 2590 2021
OI Garcia Sanz, Ramon/0000 0003 4120 2787; Terpos,
   Evangelos/0000 0001 5133 1422; Krejci, Marta/0000 0001 5216 8778;
   Legiec, Wojciech Maciej/0000 0003 3093 5248; 
FU Amgen
FX Amgen.
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Amgen, 2017, XGEV DEN
   ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976
   Avilés A, 2007, MED ONCOL, V24, P227, DOI 10.1007/BF02698044
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Becker N, 2011, RECENT RESULTS CANC, V183, P25, DOI 10.1007/978 3 540 85772 3_2
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Corso A, 2005, CANCER, V104, P118, DOI 10.1002/cncr.21104
   Delgado Calle J, 2014, CURR OPIN SUPPORT PA, V8, P407, DOI 10.1097/SPC.0000000000000090
   Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284
   Faiman BM, 2011, CLIN J ONCOL NURS, V15, P66, DOI 10.1188/11.CJON.S1.66 76
   García Sanz R, 2015, HAEMATOLOGICA, V100, P1207, DOI 10.3324/haematol.2015.128439
   Gonsalves WI, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.20
   Harrell FE, 2015, SPRINGER SER STAT, P1, DOI 10.1007/978 3 319 19425 7_1
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Lai FPL, 2004, BRIT J HAEMATOL, V126, P192, DOI 10.1111/j.1365 2141.2004.05018.x
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   Moreaux J, 2011, BLOOD, V117, P1280, DOI 10.1182/blood 2010 04 279760
   Morgan GJ, 2013, CLIN CANCER RES, V19, P6030, DOI 10.1158/1078 0432.CCR 12 3211
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Qian Y, 2017, J ONCOL PHARM PRACT, V23, P195, DOI 10.1177/1078155216629826
   Raje N, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2015.96
   Robins JM, 2000, BIOMETRICS, V56, P779, DOI 10.1111/j.0006 341X.2000.00779.x
   Sarasquete ME, 2008, BLOOD, V112, P2709, DOI 10.1182/blood 2008 04 147884
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Tosi P, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/104546
   Wang SJ, 2003, CONTROL CLIN TRIALS, V24, P147, DOI 10.1016/S0197 2456(02)00304 5
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
NR 32
TC 319
Z9 343
U1 2
U2 51
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1470 2045
EI 1474 5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD MAR
PY 2018
VL 19
IS 3
BP 370
EP 381
DI 10.1016/S1470 2045(18)30072 X
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FX9YD
UT WOS:000426466100052
PM 29429912
DA 2025 08 17
ER

PT J
AU Yuen, T
   Stachnik, A
   Iqbal, J
   Sgobba, M
   Gupta, Y
   Lu, P
   Colaianni, G
   Ji, YT
   Zhu, LL
   Kim, SM
   Li, JH
   Liu, P
   Izadmehr, S
   Sangodkar, J
   Bailey, J
   Latif, Y
   Mujtaba, S
   Epstein, S
   Davies, TF
   Bian, Z
   Zallone, A
   Aggarwal, AK
   Haider, S
   New, MI
   Sun, L
   Narla, G
   Zaidi, M
AF Yuen, Tony
   Stachnik, Agnes
   Iqbal, Jameel
   Sgobba, Miriam
   Gupta, Yogesh
   Lu, Ping
   Colaianni, Graziana
   Ji, Yaoting
   Zhu, Ling Ling
   Kim, Se Min
   Li, Jianhua
   Liu, Peng
   Izadmehr, Sudeh
   Sangodkar, Jaya
   Bailey, Jack
   Latif, Yathin
   Mujtaba, Shiraz
   Epstein, Solomon
   Davies, Terry F.
   Bian, Zhuan
   Zallone, Alberta
   Aggarwal, Aneel K.
   Haider, Shozeb
   New, Maria I.
   Sun, Li
   Narla, Goutham
   Zaidi, Mone
TI Bisphosphonates inactivate human EGFRs to exert antitumor actions
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE tyrosine kinase inhibitor; drug repurposing; Her2/neu; receptor tyrosine
   kinase; osteoporosis
ID NITROGEN CONTAINING BISPHOSPHONATES; CELL LUNG CANCER; ZOLEDRONIC ACID;
   THERAPY; ACTIVATION; CYTOTOXICITY; ANGIOGENESIS; ALENDRONATE;
   EXPRESSION; MUTATIONS
AB Bisphosphonates are the most commonly prescribed medicines for osteoporosis and skeletal metastases. The drugs have also been shown to reduce cancer progression, but only in certain patient subgroups, suggesting that there is a molecular entity that mediates bisphosphonate action on tumor cells. Using connectivity mapping, we identified human epidermal growth factor receptors (human EGFR or HER) as a potential new molecular entity for bisphosphonate action. Protein thermal shift and cell free kinase assays, together with computational modeling, demonstrated that N containing bisphosphonates directly bind to the kinase domain of HER1/2 to cause a global reduction in downstream signaling. By doing so, the drugs kill lung, breast, and colon cancer cells that are driven by activating mutations or overexpression of HER1. Knocking down HER isoforms thus abrogates cell killing by bisphosphonates, establishing complete HER dependence and ruling out a significant role for other receptor tyrosine kinases or the enzyme farnesyl pyrophosphate synthase. Consistent with this finding, colon cancer cells expressing low levels of HER do not respond to bisphosphonates. The results suggest that bisphosphonates can potentially be repurposed for the prevention and therapy of HER family driven cancers.
C1 [Yuen, Tony; Stachnik, Agnes; Iqbal, Jameel; Gupta, Yogesh; Lu, Ping; Colaianni, Graziana; Ji, Yaoting; Zhu, Ling Ling; Kim, Se Min; Li, Jianhua; Liu, Peng; Izadmehr, Sudeh; Sangodkar, Jaya; Bailey, Jack; Latif, Yathin; Mujtaba, Shiraz; Epstein, Solomon; Davies, Terry F.; Aggarwal, Aneel K.; New, Maria I.; Sun, Li; Narla, Goutham; Zaidi, Mone] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Yuen, Tony; Stachnik, Agnes; Iqbal, Jameel; Gupta, Yogesh; Lu, Ping; Colaianni, Graziana; Ji, Yaoting; Zhu, Ling Ling; Kim, Se Min; Li, Jianhua; Liu, Peng; Izadmehr, Sudeh; Sangodkar, Jaya; Bailey, Jack; Latif, Yathin; Mujtaba, Shiraz; Epstein, Solomon; Davies, Terry F.; Aggarwal, Aneel K.; New, Maria I.; Sun, Li; Narla, Goutham; Zaidi, Mone] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA.
   [Yuen, Tony; Stachnik, Agnes; Iqbal, Jameel; Gupta, Yogesh; Lu, Ping; Colaianni, Graziana; Ji, Yaoting; Zhu, Ling Ling; Kim, Se Min; Li, Jianhua; Liu, Peng; Izadmehr, Sudeh; Sangodkar, Jaya; Bailey, Jack; Latif, Yathin; Mujtaba, Shiraz; Epstein, Solomon; Davies, Terry F.; Aggarwal, Aneel K.; New, Maria I.; Sun, Li; Narla, Goutham; Zaidi, Mone] Icahn Sch Med Mt Sinai, Dept Chem & Struct Biol, New York, NY 10029 USA.
   [Yuen, Tony; Stachnik, Agnes; Iqbal, Jameel; Gupta, Yogesh; Lu, Ping; Colaianni, Graziana; Ji, Yaoting; Zhu, Ling Ling; Kim, Se Min; Li, Jianhua; Liu, Peng; Izadmehr, Sudeh; Sangodkar, Jaya; Bailey, Jack; Latif, Yathin; Mujtaba, Shiraz; Epstein, Solomon; Davies, Terry F.; Aggarwal, Aneel K.; New, Maria I.; Sun, Li; Narla, Goutham; Zaidi, Mone] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
   [Sgobba, Miriam; Haider, Shozeb] UCL, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England.
   [Colaianni, Graziana; Zallone, Alberta] Univ Bari, Dept Histol, I 70121 Bari, Italy.
   [Ji, Yaoting; Zhu, Ling Ling; Bian, Zhuan] Wuhan Univ, Sch Stomatol, Dept Res, Wuhan 430079, Peoples R China.
   [Narla, Goutham] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA.
   [Narla, Goutham] Case Western Reserve Univ, Inst Transformat Mol Med, Cleveland, OH 44106 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of
   Medicine at Mount Sinai; University of London; University College
   London; University of London School of Pharmacy; Universita degli Studi
   di Bari Aldo Moro; Wuhan University; University System of Ohio; Case
   Western Reserve University; University System of Ohio; Case Western
   Reserve University
RP New, MI (通讯作者)，Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
EM maria.new@mssm.edu; mone.zaidi@mountsinai.org
RI Haider, Shozeb/Q 1599 2019; Ji, Yaoting/D 2646 2019; Narla,
   Goutham/AAZ 5710 2020; Haider, Shozeb/B 3452 2015; Kim,
   Se Min/AAA 5672 2021; Gupta, Yogesh/B 6949 2009
OI Zaidi, Mone/0000 0001 5911 9522; Haider, Shozeb/0000 0003 2650 2925;
   Yuen, Tony/0009 0001 6000 8827; Colaianni, Graziana/0000 0001 8501 5399;
   Narla, Goutham/0000 0003 4098 4203; Kim, Se Min/0000 0003 0877 7562;
   Gupta, Yogesh/0000 0001 6372 5007
FU National Institutes of Health [DK80459, AG40132, AG23176, AR06592,
   AR06066]; Italian Space Agency; National Science Foundation of China,
   Ministry of China; National Center for Advancing Translational Sciences,
   National Institutes of Health, through Icahn School of Medicine at Mount
   Sinai's Clinical and Translational Science Award; Howard Hughes Medical
   Institute Physician Scientist Early Career Award [KL2TR000069]
FX This work was supported in part by National Institutes of Health Grants
   DK80459 (to M.Z. and L.S.), AG40132 (to M.Z.), AG23176 (to M.Z.),
   AR06592 (to M.Z.), and AR06066 (to M.Z); the Italian Space Agency
   (A.Z.); a grant from National Science Foundation of China, Ministry of
   China (International Collaborative Grant to Z.B. and M.Z.); and the
   National Center for Advancing Translational Sciences, National
   Institutes of Health, through Icahn School of Medicine at Mount Sinai's
   Clinical and Translational Science Award (S.I.). G.N., formerly a
   recipient of a Howard Hughes Medical Institute Physician Scientist Early
   Career Award, is a named Harrington Scholar (KL2TR000069).
CR [Anonymous], PATHOL RES INT
   Benzaïd I, 2011, CANCER RES, V71, P4562, DOI 10.1158/0008 5472.CAN 10 3862
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Clézardin P, 2010, CURR PHARM DESIGN, V16, P3007, DOI 10.2174/138161210793563545
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Di Salvatore M, 2011, CELL PROLIFERAT, V44, P139, DOI 10.1111/j.1365 2184.2011.00745.x
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   Gnant M, 2011, CANCER RES, V71, DOI 10.1158/0008 5472.SABCS1151 2
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Inoue R, 2005, BRIT J PHARMACOL, V146, P633, DOI 10.1038/sj.bjp.0706373
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Ljuslinder I, 2007, ACTA ONCOL, V46, P1118, DOI 10.1080/02841860701426823
   Maniar A, 2010, BLOOD, V116, P1726, DOI 10.1182/blood 2009 07 234211
   Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992
   Nishino M, 2011, ACAD RADIOL, V18, P424, DOI 10.1016/j.acra.2010.10.020
   Park JH, 2012, BIOCHEM J, V448, P417, DOI 10.1042/BJ20121513
   Pazianas M, 2012, OSTEOPOROSIS INT, V23, P2693, DOI 10.1007/s00198 012 1902 4
   Rennert G, 2011, J CLIN ONCOL, V29, P1146, DOI 10.1200/JCO.2010.33.7485
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sangodkar J, 2012, J CLIN INVEST, V122, P2637, DOI 10.1172/JCI62058
   Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092 8674(02)00966 2
   Sendur MAN, 2012, MED ONCOL, V29, P2601, DOI 10.1007/s12032 012 0209 9
   Shepard HM, 2008, J CLIN INVEST, V118, P3574, DOI 10.1172/JCI36049
   Stachnik A, 2014, P NATL ACAD SCI USA, V111, P17995, DOI 10.1073/pnas.1421422111
   Stresing V, 2011, BONE, V48, P259, DOI 10.1016/j.bone.2010.09.035
   Tang XD, 2010, INT J CANCER, V126, P90, DOI 10.1002/ijc.24710
   Wilson C, 2012, CANCER TREAT REV, V38, P877, DOI 10.1016/j.ctrv.2012.02.007
   Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105
   Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017
   Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013
NR 33
TC 53
Z9 55
U1 0
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 16
PY 2014
VL 111
IS 50
BP 17989
EP 17994
DI 10.1073/pnas.1421410111
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CL7NY
UT WOS:000357160100003
PM 25453081
OA Green Published
DA 2025 08 17
ER

PT J
AU Wu, P
   Walker, BA
   Brewer, D
   Gregory, WM
   Ashcroft, J
   Ross, FM
   Jackson, GH
   Child, AJ
   Davies, FE
   Morgan, GJ
AF Wu, Ping
   Walker, Brian A.
   Brewer, Daniel
   Gregory, Walter M.
   Ashcroft, John
   Ross, Fiona M.
   Jackson, Graham H.
   Child, Anthony J.
   Davies, Faith E.
   Morgan, Gareth J.
TI A Gene Expression Based Predictor for Myeloma Patients at High Risk of
   Developing Bone Disease on Bisphosphonate Treatment
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CYCLIN D DYSREGULATION; MULTIPLE MYELOMA; MOLECULAR CLASSIFICATION;
   OSTEOLYTIC LESIONS; STAGING SYSTEM; GROWTH FACTOR; CELLS; DKK1;
   TRANSLOCATIONS; TRANSFORMATION
AB Purpose: Myelomabone disease impairs quality of life and is associated with impaired survival. Even with effective bisphosphonate treatment, a significant proportion of patients still develop skeletal related events (SRE). Identifying such patients at presentation would allow treatment modification.
   Experimental Design: To investigate the molecular basis of bone disease at presentation and to develop a predictive signature for patients at high risk of developing SREs on bisphosphonates, 261 presenting myeloma samples were analyzed by global gene expression profiling. The derived "SRE gene signature" was complemented by the integration of associated clinical parameters to generate an optimal predictor.
   Results: Fifty genes were significantly associated with presenting bone disease, including the WNT signaling antagonist DKK1 and genes involved in growth factor signaling and apoptosis. Higher serum calcium level and the presence of bone disease and hyperdiploidy at presentation were associated with high risk of SRE development. A gene signature derived from the fourteen genes overexpressed in the SRE group was able to identify patients at high risk of developing an SRE on treatment. These genes either belonged to the IFN induced family or were involved in cell signaling and mitosis. Multivariate logistic model selection yielded an optimal SRE predictor comprising seven genes and calcium level, which was validated as an effective predictor in a further set of patients.
   Conclusions: The simple expression based SRE predictor can effectively identify individuals at high risk of developing bone disease while being on bisphosphonates. This predictor could assist with developing future trials on novel therapies aimed at reducing myeloma bone disease. Clin Cancer Res; 17(19); 6347 55. (C) 2011 AACR.
C1 [Wu, Ping; Walker, Brian A.; Davies, Faith E.; Morgan, Gareth J.] Inst Canc Res, Sect Haematooncol, Res Unit, Div Mol Pathol, Sutton SM2 5NG, Surrey, England.
   [Brewer, Daniel] Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England.
   [Gregory, Walter M.; Child, Anthony J.] Univ Leeds, Clin Trials & Res Unit, Leeds, W Yorkshire, England.
   [Ashcroft, John] Mid Yorkshire Hosp NHS Trust, Wakefield, England.
   [Ross, Fiona M.] Univ Southampton, Wessex Reg Genet Lab, Salisbury, Wilts, England.
   [Jackson, Graham H.] Royal Victoria Infirm, Newcastle Upon Tyne, England.
C3 University of London; Institute of Cancer Research   UK; University of
   London; Institute of Cancer Research   UK; University of Leeds;
   University of Southampton; Newcastle University   UK
RP Morgan, GJ (通讯作者)，Inst Canc Res, Sect Haematooncol, Res Unit, Div Mol Pathol, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.
EM gareth.morgan@icr.ac.uk
RI Jackson, Graham/GMW 7638 2022; wu, ping/HLX 4062 2023; Ross,
   Fiona/B 4667 2009; Morgan, Gareth/G 3603 2010; Walker,
   Brian/A 4984 2013; Brewer, Daniel/D 6201 2018
OI Walker, Brian/0000 0002 8615 6254; morgan, gareth/0000 0002 4271 6360;
   Davies, Faith/0000 0002 3971 2393; Brewer, Daniel/0000 0003 4753 9794
FU Celgene; Pharmion; Novartis; Ortho Biotech; UK Myeloma Forum
   Cytogenetics Group, Wessex Regional Genetics Laboratory, Salisbury,
   United Kingdom; Myeloma UK; Cancer Research UK; Bud Flanagan Leukaemia
   Fund; Biological Research Centre of the National Institute for Health
   Research at the Royal Marsden Hospital; Medical Research Council
   [G0100132] Funding Source: researchfish; MRC [G0100132] Funding Source:
   UKRI
FX A.J. Child has received unrestricted educational research grants for
   Myeloma IX from Celgene, Pharmion, Novartis, and Ortho Biotech. G. H.
   Jackson has received honoraria from speakers bureau for Celgene and
   Ortho Biotech. G.J. Morgan has received honoraria from speakers bureau
   for Celgene, Novartis, and Johnson and Johnson and is also a consultant
   and is on advisory board of Celgene, Novartis, and Johnson and Johnson.
   The other authors disclosed no potential conflicts of interest.Data and
   samples were collected as part of the MRC Myeloma IX phase III
   trial clinical trial registration (ISRCTN68454111). Overall trial
   statistics were carried out by the Clinical Trials Research Unit,
   University of Leeds, Leeds, United Kingdom. Fluorescence in situ
   hybridization and cytogenetics were carried out by Leukaemia Research
   Fund UK Myeloma Forum Cytogenetics Group, Wessex Regional Genetics
   Laboratory, Salisbury, United Kingdom.The work was supported by Myeloma
   UK, Cancer Research UK, the Bud Flanagan Leukaemia Fund, and the
   Biological Research Centre of the National Institute for Health Research
   at the Royal Marsden Hospital.
CR Abdulkadyrov KM, 2009, BLOOD, V114, P312, DOI 10.1182/blood.V114.22.749.749
   Andersen TL, 2007, J PATHOL, V211, P10, DOI 10.1002/path.2078
   Andersen TL, 2010, BRIT J HAEMATOL, V148, P551, DOI 10.1111/j.1365 2141.2009.07980.x
   BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood 2005 01 0034
   Bergsagel PL, 2003, IMMUNOL REV, V194, P96, DOI 10.1034/j.1600 065X.2003.00052.x
   Broyl A, 2010, BLOOD, V116, P2543, DOI 10.1182/blood 2009 12 261032
   Calvani N, 2005, BRIT J HAEMATOL, V130, P926, DOI 10.1111/j.1365 2141.2005.05710.x
   Chng W, 2006, LEUKEMIA, V20, P807, DOI 10.1038/sj.leu.2404172
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Davies FE, 2003, BLOOD, V102, P4504, DOI 10.1182/blood 2003 01 0016
   De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771
   Dickens NJ, 2010, CLIN CANCER RES, V16, P1856, DOI 10.1158/1078 0432.CCR 09 2831
   DURIE BGM, 1989, BLOOD, V73, P770
   DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097 0142(197509)36:3<842::AID CNCR2820360303>3.0.CO;2 U
   EPSTEIN J, 1990, NEW ENGL J MED, V322, P664, DOI 10.1056/NEJM199003083221005
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Giuliani N, 2007, CANCER RES, V67, P7665, DOI 10.1158/0008 5472.CAN 06 4666
   GROGAN TM, 1989, BLOOD, V73, P763
   Haaber J, 2008, BRIT J HAEMATOL, V140, P25, DOI 10.1111/j.1365 2141.2007.06871.x
   Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097 0258(19960229)15:4<361::AID SIM168>3.0.CO;2 4
   Jakob C, 2008, LEUKEMIA, V22, P1767, DOI 10.1038/leu.2008.159
   Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200
   Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19 5 378
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   MCDONALD DF, 1983, CANCER LETT, V19, P119, DOI 10.1016/0304 3835(83)90145 3
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Robbiani DF, 2004, NEW ENGL J MED, V351, P197, DOI 10.1056/NEJM200407083510223
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Shaughnessy J Jr, 2005, BEST PRACT RES CL HA, V18, P537, DOI 10.1016/j.beha.2005.02.003
   Silvestris F, 2008, LEUKEMIA RES, V32, P611, DOI 10.1016/j.leukres.2007.07.009
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Sprynski AC, 2009, BLOOD, V113, P4614, DOI 10.1182/blood 2008 07 170464
   Standal T, 2002, BLOOD, V100, P3925, DOI 10.1182/blood 2002 05 1406
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614
   Walker BA, 2006, BLOOD, V108, P1733, DOI 10.1182/blood 2006 02 005496
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood 2005 11 013458
   Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745
   1988, ANN STAT, V16, P1141
NR 45
TC 22
Z9 22
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 1
PY 2011
VL 17
IS 19
BP 6347
EP 6355
DI 10.1158/1078 0432.CCR 11 0994
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 827VR
UT WOS:000295457900026
PM 21856767
OA Green Submitted, Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Togloom, A
   Lim, KT
   Kim, JH
   Seonwoo, H
   Garg, P
   Choung, PH
   Cho, CS
   Choung, YH
   Chung, JH
AF Togloom, Ariunaa
   Lim, Ki Taek
   Kim, Jang Ho
   Seonwoo, Hoon
   Garg, Pankaj
   Choung, Pill Hoon
   Cho, Chong Su
   Choung, Yun Hoon
   Chung, Jong Hoon
TI Molecular Responses in Osteogenic Differentiation of Mesenchymal Stem
   Cells Induced by Physical Stimulation
SO TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE physical stimulation; mechanotransduction; signal transduction; gene
   expression; osteogenic differentiation
ID FLUID SHEAR STRESS; NITRIC OXIDE SYNTHASE; OSTEOBLAST LIKE CELLS;
   ACTIVATED PROTEIN KINASE; MARROW STROMAL CELLS; BONE MARROW; MECHANICAL
   STIMULATION; EXTRACELLULAR MATRIX; SIGNALING PATHWAYS; ACTIN
   CYTOSKELETON
AB Mesenchymal stem cells (MSCs) have been recognized as a great source of stem cells in the field of regenerative medicine and regulation of MSCs such as differentiation into specific cells. Particular interest is the use of physical stimulation for the expression of the osteoblast specific genes from MSCs for bone tissue regeneration. The mechanical forces on MSCs, such as fluid flow, enhance the mineralized matrix and specific gene expressions. This process called mechanotransduction comprises of the steps of mechanoreception, biochemical coupling, transmission of signal and effector cell response. Physical stimuli effectively regulate extracellular and intracellular signaling pathways to enhance the expression of specific transcription factors, and the release of osteocytes, ultimately expedite the production of active osteoblasts. Thus understating, identification and functional characterization of the mechanotransduction underlying the physical stimulation of MSCs is a critical issue for devising new bone regenerative treatments for bone related diseases. In this review, we focus on the molecular mechanism responsible for the mechanotransduction of osteogenic differentiation of MSCs induced by physical stimulation.
C1 [Togloom, Ariunaa; Lim, Ki Taek; Kim, Jang Ho; Seonwoo, Hoon; Garg, Pankaj; Chung, Jong Hoon] Seoul Natl Univ, Coll Agr & Life Sci, Dept Biosyst & Biomat Sci & Engn, Seoul 151921, South Korea.
   [Togloom, Ariunaa; Lim, Ki Taek; Kim, Jang Ho; Cho, Chong Su; Chung, Jong Hoon] Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul 151921, South Korea.
   [Choung, Yun Hoon] Ajou Univ, Sch Med, Dept Otolaryngol, Suwon 443721, South Korea.
   [Choung, Pill Hoon] Seoul Natl Univ, Sch Dent, Dept Oral & Maxillofacial Surg, Seoul, South Korea.
   [Choung, Pill Hoon] Seoul Natl Univ, Sch Dent, Dent Res Inst, Seoul, South Korea.
   [Choung, Pill Hoon] Seoul Natl Univ, Sch Dent, Tooth Bioengn Natl Res Lab Post BK21, Seoul 151921, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Ajou
   University; Seoul National University (SNU); Seoul National University
   (SNU); Seoul National University (SNU)
RP Chung, JH (通讯作者)，Seoul Natl Univ, Coll Agr & Life Sci, Dept Biosyst & Biomat Sci & Engn, Seoul 151921, South Korea.
EM yhc@ajou.ac.kr; jchung@snu.ac.kr
RI Chung, Jong/AAR 8179 2021; KIM, Seung Hyun/T 5133 2017; Lim,
   Ki Taek/AAI 9518 2021
OI Lim, Ki Taek/0000 0003 2091 788X; 
FU Ministry of Health & Welfare, Republic of Korea [A090869]
FX This study was carried out with the financial support of the Korea
   Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea
   (A090869).
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Alenghat Francis J, 2002, Sci STKE, V2002, ppe6, DOI 10.1126/stke.2002.119.pe6
   Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Baba HA, 2003, CARDIOVASC RES, V59, P390, DOI 10.1016/S0008 6363(03)00393 6
   Bacabac RG, 2004, BIOCHEM BIOPH RES CO, V315, P823, DOI 10.1016/j.bbrc.2004.01.138
   Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532
   Bancroft GN, 2002, P NATL ACAD SCI USA, V99, P12600, DOI 10.1073/pnas.202296599
   Bergula A, 2004, TRANSOR, V29, P616
   BISSELL MJ, 1987, J CELL SCI, P327
   Charoonpatrapong Panyayong K, 2007, J CELL BIOCHEM, V102, P1202, DOI 10.1002/jcb.21349
   Chen JH, 2010, J BIOMECH, V43, P108, DOI 10.1016/j.jbiomech.2009.09.016
   Chen NX, 2000, AM J PHYSIOL CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Cherian PP, 2003, J BIOL CHEM, V278, P43146, DOI 10.1074/jbc.M302993200
   Damoulis PD, 2007, ANN NY ACAD SCI, V1117, P367, DOI 10.1196/annals.1402.038
   Davies P.F., 2002, CARDIOVASC PATHOL, V11, P25
   DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519
   Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224
   Diwan AD, 2010, EUR SPINE J, V19, P931, DOI 10.1007/s00586 009 1263 7
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   Emily JA, 2009, PLOS ONE, V4, P5388
   Fan M, 2006, J CELL PHYSIOL, V207, P454, DOI 10.1002/jcp.20581
   Fleming I, 2003, AM J PHYSIOL REG I, V284, pR1, DOI 10.1152/ajpregu.00323.2002
   Freed LE, 1997, P NATL ACAD SCI USA, V94, P13885, DOI 10.1073/pnas.94.25.13885
   Fu Q, 2008, J BIOMECH, V41, P3225, DOI 10.1016/j.jbiomech.2008.08.010
   Goessler UR, 2008, INT J MOL MED, V21, P271
   Granet C, 2002, CELL SIGNAL, V14, P679, DOI 10.1016/S0898 6568(02)00008 6
   Grellier M, 2009, J TISSUE ENG REGEN M, V3, P302, DOI 10.1002/term.166
   Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515
   Haasper C, 2008, EXP TOXICOL PATHOL, V59, P355, DOI [10.1016/j.etp.2007.11.008, 10.1016/j.etp.2007.11.013]
   HIRAN P, 2006, ARCH ORAL BIOL, V51, P406
   Holtorf HL, 2005, ANN BIOMED ENG, V33, P1238, DOI 10.1007/s10439 005 5536 y
   Hughes Fulford M, 2004, SCI STKE RE, VRE12
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575
   Iqbal J, 2005, BIOCHEM BIOPH RES CO, V328, P751, DOI 10.1016/j.bbrc.2004.12.087
   Jaasma MJ, 2008, TISSUE ENG PT A, V14, P1213, DOI 10.1089/tea.2007.0321
   Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998
   John R, 2009, GENE EXPR PATTERNS, V9, P381
   Johnson M. L., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P135
   Justus HW, 2010, J ORTHOP RES, V28, P390
   Kamioka Hiroshi, 2008, Clin Calcium, V18, P1287, DOI CliCa080912871293
   KANAI AJ, 1995, CIRC RES, V77, P284, DOI 10.1161/01.RES.77.2.284
   KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483
   Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200
   Kawano S, 2002, CELL CALCIUM, V32, P165, DOI 10.1016/S0143416002001240
   Kido S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013090
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kim JH, 2009, TISSUE ENG REGEN MED, V6, P199
   Kim SH, 2009, TISSUE ENG REGEN MED, V7, P388
   KleinNulend J, 1996, J CELL PHYSIOL, V168, P1, DOI 10.1002/(SICI)1097 4652(199607)168:1<1::AID JCP1>3.0.CO;2 T
   KLEINNULEND J, 1995, J CELL PHYSIOL, V163, P115, DOI 10.1002/jcp.1041630113
   Lee DY, 2008, J BONE MINER RES, V23, P1140, DOI 10.1359/JBMR.080302
   Li JL, 2002, J BONE MINER RES, V17, P1795, DOI 10.1359/jbmr.2002.17.10.1795
   Lian J. B., 2003, Current Pharmaceutical Design, V9, P2677, DOI 10.2174/1381612033453659
   Lim KT, 2009, TISSUE ENG REGEN MED, V6, P1410
   Lim KT, 2009, TISSUE ENG REGEN MED, V6, P675
   Lim KT, 2009, TISSUE ENG REGEN MED, V6, P250
   Liu DW, 2008, BONE, V42, P644, DOI 10.1016/j.bone.2007.09.058
   Liu LY, 2010, BIOMECH MODEL MECHAN, V9, P659, DOI 10.1007/s10237 010 0206 x
   Liu SC, 2000, J CELL SCI, V113, P3563
   Liu XL, 2010, ACTA BIOCH BIOPH SIN, V42, P195, DOI 10.1093/abbs/gmq004
   MacPherson H, 1999, BONE, V24, P179, DOI 10.1016/S8756 3282(98)00173 2
   Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895
   Martino MM, 2009, BIOMATERIALS, V30, P1089, DOI 10.1016/j.biomaterials.2008.10.047
   McAllister TN, 2000, BIOCHEM BIOPH RES CO, V270, P643, DOI 10.1006/bbrc.2000.2467
   McGarry JG, 2005, BIOCHEM BIOPH RES CO, V330, P341, DOI 10.1016/j.bbrc.2005.02.175
   McMahon LA, 2008, J BIOMECH, V41, P2055, DOI 10.1016/j.jbiomech.2008.03.027
   Nemoto E, 2009, BONE, V44, P805, DOI 10.1016/j.bone.2008.12.029
   Ocarino NM, 2008, NITRIC OXIDE BIOL CH, V19, P320, DOI 10.1016/j.niox.2008.08.004
   Papachristou DJ, 2009, BIOESSAYS, V31, P794, DOI 10.1002/bies.200800223
   Patwari P, 2008, CIRC RES, V103, P234, DOI 10.1161/CIRCRESAHA.108.175331
   Pavalko FM, 1998, AM J PHYSIOL CELL PH, V275, pC1591
   Pearson GW, 2006, MOL CELL BIOL, V26, P3039, DOI 10.1128/MCB.26.8.3039 3047.2006
   Phimphilia M, 2006, J BONE MINER RES, V21, P4
   Ponik SM, 2004, J APPL PHYSIOL, V97, P135, DOI 10.1152/japplphysiol.01260.2003
   Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392
   Rangaswami H, 2009, J BIOL CHEM, V284, P14796, DOI 10.1074/jbc.M806486200
   Reich KM, 1997, ENDOCRINOLOGY, V138, P1014, DOI 10.1210/en.138.3.1014
   Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175
   Rodríguez C, 2006, CELL SIGNAL, V18, P1376, DOI 10.1016/j.cellsig.2005.10.016
   Sakai K, 1998, CALCIFIED TISSUE INT, V63, P515, DOI 10.1007/s002239900567
   Sakai K, 1999, J BONE MINER RES, V14, P2089, DOI 10.1359/jbmr.1999.14.12.2089
   Salasznyk RM, 2004, CELL COMMUN ADHES, V11, P137, DOI 10.1080/15419060500242836
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Salter DM, 1997, CLIN ORTHOP RELAT R, V391, P49
   Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079 6107(98)00052 2
   Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402 e65
   Shin MK, 2008, CELL SIGNAL, V20, P613, DOI 10.1016/j.cellsig.2007.11.012
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Sinha S, 2008, CELL SIGNAL, V20, P1927, DOI 10.1016/j.cellsig.2008.05.002
   Stiehler M, 2009, J BIOMED MATER RES A, V89A, P96, DOI 10.1002/jbm.a.31967
   Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955 0674(99)00026 5
   Suzanne RL, 2009, J BONE MINER RES, V24, P3
   Wadhwa S, 2002, BIOCHEM BIOPH RES CO, V297, P46, DOI 10.1016/S0006 291X(02)02124 1
   Weyts FAA, 2002, J CELL BIOCHEM, V87, P85, DOI 10.1002/jcb.10278
   Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384
   Yoo JJ, 2010, TISSUE ENG REGEN MED, V7, P101
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   Yu HC, 2010, J BONE MINER RES, V25, P1128, DOI 10.1002/jbmr.9
   Zhao F, 2005, BIOTECHNOL BIOENG, V91, P482, DOI 10.1002/bit.20532
NR 102
TC 3
Z9 3
U1 0
U2 9
PU KOREAN TISSUE ENGINEERING REGENERATIVE MEDICINE SOC
PI SEOCHO GU
PA 1414 SEOCHO WORLD OFFICETEL 19, SEOUN RO, SEOCHO GU, SEOUL 06732, SOUTH
   KOREA
SN 1738 2696
EI 2212 5469
J9 TISSUE ENG REGEN MED
JI Tissue Eng. Regen. Med.
PD JUN
PY 2011
VL 8
IS 3
BP 271
EP 281
PG 11
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA 773EK
UT WOS:000291289600001
DA 2025 08 17
ER

PT J
AU Pierotti, S
   Gandini, L
   Lenzi, A
   Isidori, AM
AF Pierotti, Silvia
   Gandini, Loredana
   Lenzi, Andrea
   Isidori, Andrea M.
TI Pre receptorial regulation of steroid hormones in bone cells: Insights
   on glucocorticoid induced osteoporosis
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper
CT 12th International Congress on Hormonal Steroids and Hormones and Cancer
CY SEP 13 16, 2006
CL Athens, GREECE
DE osteoporosis; glucocorticoids; 11 beta HSD; androgens; mesenchymal stem
   cell differentiation
ID 11 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1; GROWTH FACTOR BETA;
   ANDROGEN RECEPTOR; OSTEOBLAST DIFFERENTIATION; BINDING PROTEIN; STROMAL
   CELLS; C/EBP BETA; POSTTRANSCRIPTIONAL MECHANISMS; MALE MICE; EXPRESSION
AB In the past decades, concern on glucocorticoid induced osteoporosis has increased with the widespread use of exogenous glucocorticoids (GC). Mature bone forming cells (osteoblasts) are considered to be the principal site of action of GC in the skeleton. More likely, it is the entire cellular and molecular network surrounding these cells that is targeted by pharmacological doses of GC. Not only osteoblast and osteocyte metabolism, but the whole differentiation of mesenchymal stem cell toward the osteoblast lineage has been proven to be sensitive to GC. The effects of GC on this process are different according to the stage of differentiation of bone cell precursors. The presence of intact GC signalling is crucial for normal bone development and physiology, as opposed to the detrimental effect of high dose exposure. Both the physiological and pharmacological effects of GC are locally modulated by the activity of the 11 beta hydroxysteroid dehydrogenase 1 (HSD1) that acts primarily as a glucocorticoid activator converting the inactive glucocorticoid (cortisone) into the active hormone (cortisol). We reviewed the metabolic and differentiation pathways controlled by GC signalling. These data have been merged with the recent evidences that 11 beta HSD1 exert an important role by regulating the vulnerability of bone cells to GC. The different kinetics of 11 beta HSD1 at various stage of differentiation and the GC dependency of enzymatic activity have been presented. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Pierotti, Silvia; Gandini, Loredana; Lenzi, Andrea; Isidori, Andrea M.] Univ Roma La Sapienza, Dept Med Pathophysiol, Rome, Italy.
C3 Sapienza University Rome
RP Isidori, AM (通讯作者)，Univ Roma La Sapienza, Viale Policlin, DFM, Lab 63, 155, I 00161 Rome, Italy.
EM andrea.isidori@uniroma1.it
RI Lenzi, Andrea/I 7711 2015; GANDINI, Loredana/K 3315 2015; Gandini,
   Loredana/K 3315 2015; Isidori, Andrea/F 3062 2010
OI Lenzi, Andrea/0000 0002 7711 0465; GANDINI,
   Loredana/0000 0002 4274 0491; Isidori, Andrea/0000 0002 9037 5417; 
CR Akavia UD, 2006, BMC GENOMICS, V7, DOI 10.1186/1471 2164 7 95
   Bachner D, 1998, DEV DYNAM, V213, P398
   Beavan S, 2001, J BONE MINER RES, V16, P1496, DOI 10.1359/jbmr.2001.16.8.1496
   BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995
   Beloti Márcio Mateus, 2005, Braz. Dent. J., V16, P156
   BENNETT A, 1984, ENDOCRINOLOGY, V115, P1577, DOI 10.1210/endo 115 4 1577
   BENZ DJ, 1991, ENDOCRINOLOGY, V128, P2723, DOI 10.1210/endo 128 6 2723
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bland R, 1999, J ENDOCRINOL, V161, P455, DOI 10.1677/joe.0.1610455
   Braidman IP, 2000, J PATHOL, V192, P90
   Bruley C, 2006, ENDOCRINOLOGY, V147, P2879, DOI 10.1210/en.2005 1621
   Bujalska IJ, 2002, J CLIN ENDOCR METAB, V87, P1205, DOI 10.1210/jc.87.3.1205
   Canalis E, 2002, J BONE MINER RES, V17, P987, DOI 10.1359/jbmr.2002.17.6.987
   Chang PL, 2006, CONNECT TISSUE RES, V47, P67, DOI 10.1080/03008200600584074
   Cooper MS, 2005, CLIN ENDOCRINOL, V62, P692, DOI 10.1111/j.1365 2265.2005.02281.x
   Cooper MS, 1999, J ENDOCRINOL, V163, P159, DOI 10.1677/joe.0.1630159
   Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137
   DEFRANCO DJ, 1992, ENDOCRINOLOGY, V131, P114, DOI 10.1210/en.131.1.114
   DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314
   Delany AM, 2001, MOL ENDOCRINOL, V15, P1781, DOI 10.1210/me.15.10.1781
   DELANY AM, 1995, J BIOL CHEM, V270, P26607, DOI 10.1074/jbc.270.44.26607
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eijken M, 2005, MOL ENDOCRINOL, V19, P621, DOI 10.1210/me.2004 0212
   ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021
   Eyre LJ, 2001, J CELL BIOCHEM, V81, P453, DOI 10.1002/1097 4644(20010601)81:3<453::AID JCB1059>3.0.CO;2 Z
   Fried A, 1996, J CELL BIOCHEM, V62, P476, DOI 10.1002/(SICI)1097 4644(19960915)62:4<476::AID JCB5>3.0.CO;2 J
   FRIED A, 1993, J CELL PHYSIOL, V155, P472, DOI 10.1002/jcp.1041550306
   Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200
   Hata K, 2005, MOL CELL BIOL, V25, P1971, DOI 10.1128/MCB.25.5.1971 1979.2005
   HEINRICHS AAJ, 1993, BIOCHEMISTRY US, V32, P11436, DOI 10.1021/bi00093a022
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Isidori A M, 2005, J Endocrinol Invest, V28, P73
   Isidori AM, 2005, CLIN ENDOCRINOL, V63, P280, DOI 10.1111/j.1365 2265.2005.02339.x
   Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100
   Kenny AM, 2002, J REPROD MED, V47, P63
   KHOSLA S, 1994, BONE, V15, P551, DOI 10.1016/8756 3282(94)90280 1
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kuznetsov SA, 1997, J BONE MINER RES, V12, P1335, DOI 10.1359/jbmr.1997.12.9.1335
   Liegibel UM, 2002, J EXP MED, V196, P1387, DOI 10.1084/jem.20021017
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   ManolagasSCV, 1995, Bone, V16, P63
   Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285
   Minetto M, 2004, OSTEOPOROSIS INT, V15, P855, DOI 10.1007/s00198 004 1616 3
   MOORE SG, 1990, RADIOLOGY, V175, P219, DOI 10.1148/radiology.175.1.2315484
   Movérare S, 2003, P NATL ACAD SCI USA, V100, P13573, DOI 10.1073/pnas.2233084100
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200
   Okazaki R, 2002, ENDOCRINOLOGY, V143, P2349, DOI 10.1210/en.143.6.2349
   PENSLER JM, 1990, J BONE MINER RES, V5, P797
   Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756 3282(02)00687 7
   Pereira RC, 2000, AM J PHYSIOL ENDOC M, V279, pE570, DOI 10.1152/ajpendo.2000.279.3.E570
   RYDZIEL S, 1995, ENDOCRINOLOGY, V136, P4254, DOI 10.1210/en.136.10.4254
   Sher LB, 2004, ENDOCRINOLOGY, V145, P922, DOI 10.1210/en.2003 0655
   Shur I, 2001, J CELL BIOCHEM, V83, P547, DOI 10.1002/jcb.1249
   STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   Taylor Jones JM, 2002, MECH AGEING DEV, V123, P649, DOI 10.1016/S0047 6374(01)00411 0
   Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003 0031
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Venken K, 2006, J BONE MINER RES, V21, P576, DOI 10.1359/JBMR.060103
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350
NR 64
TC 23
Z9 30
U1 0
U2 9
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD FEB
PY 2008
VL 108
IS 3 5
BP 292
EP 299
DI 10.1016/j.jsbmb.2007.09.018
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 273XD
UT WOS:000253964600017
PM 17950597
DA 2025 08 17
ER

PT J
AU Bie, MM
   Tang, Y
   Xia, YX
   Zhang, Q
   Tian, YY
   Cheng, CA
   Li, XZ
   Qi, X
   Kang, FW
AF Bie, Miaomiao
   Tang, Yi
   Xia, Yuxing
   Zhang, Qian
   Tian, Yuanye
   Cheng, Chunan
   Li, Xinzhao
   Qi, Xin
   Kang, Feiwu
TI HIF 1? mediates osteoclast induced disuse osteoporosis via cytoophidia
   in the femur of mice
SO BONE
LA English
DT Article
DE Disuse osteoporosis; Osteoclasts; HIF 1?; Cytoophidia; c Myc
ID BONE LOSS; DIFFERENTIATION; ACTIVATION; EXPRESSION; RESORPTION;
   HIF1 ALPHA; MYC
AB Osteoporosis induced by disuse because of bed rest or the aerospace industry has become one of the most common skeletal disorders. However, mechanisms underlying the disuse osteoporosis remain largely unknown. We validated the tail suspended model in mice and demonstrated that there is bone loss in the trabecular and cortical bones of the femur. Importantly, we showed that genetical deletion of hypoxia inducible factor 1 alpha (HIF 1 alpha) in osteoclasts ameliorated osteoclastic bone resorption in the trabecular bone whereas pharmacological treatment with HIF 1 alpha inhibitor protected the hindlimb unloaded mice from disuse induced osteoporosis in the trabecular and cortical bones. The HIF 1 alpha knockout RAW264.7 cells and RNA sequencing proved that HIF 1 alpha is vital for osteoclastogenesis and bone resorption because it regulated the level of inosine monophosphate de hydrogenase (IMPDH) and cytidine triphosphate synthetase (CTPS) via cellular myelocytomatosis (c Myc) oncogene. The IMPDH and CTPS are vital nucleotide metabolic enzymes which have an important functional role in cell metabolism, and they can assemble into intracellular linear or ring shaped structures to cope with cell stress. Interestingly, both in vitro and in vivo, the IMPDH and CTPS cytoophidia were found in osteoclasts, and the level of HIF 1 alpha correlated with osteoclastogenesis and bone resorbing activity. Our data revealed that HIF 1 alpha/c Myc/cytoophidia signalling might be required for osteoclasts to mediate cell metabolism in disuse induced osteoporosis. Overall, our results revealed a new role of HIF 1 alpha/c Myc/cytoophidia in supporting osteoclasto genesis and bone resorption and exposed evidence for its role in the pathogenesis of disuse osteoporosis, which might provide promising therapeutic targets.
C1 [Bie, Miaomiao; Xia, Yuxing; Zhang, Qian; Tian, Yuanye; Cheng, Chunan; Li, Xinzhao; Qi, Xin; Kang, Feiwu] Tongji Univ, Stomatol Hosp & Dent Sch, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Dept Oral & Maxillofacial Surg, Shanghai, Peoples R China.
   [Bie, Miaomiao; Tang, Yi; Xia, Yuxing; Zhang, Qian; Tian, Yuanye; Cheng, Chunan; Li, Xinzhao; Qi, Xin; Kang, Feiwu] Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Dent Sch, Shanghai, Peoples R China.
   [Tang, Yi] Tongji Univ, Stomatol Hosp, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Dept Periodontol, Shanghai, Peoples R China.
   [Kang, Feiwu] Tongji Univ, Stomatol Hosp, Dept Oral & Maxillofacial Surg, 399 Middle Yan Chang Rd, Shanghai 200072, Peoples R China.
   [Kang, Feiwu] Tongji Univ, Dent Sch, 399 Middle Yan Chang Rd, Shanghai 200072, Peoples R China.
C3 Tongji University; Tongji University; Tongji University; Tongji
   University; Tongji University
RP Kang, FW (通讯作者)，Tongji Univ, Stomatol Hosp, Dept Oral & Maxillofacial Surg, 399 Middle Yan Chang Rd, Shanghai 200072, Peoples R China.; Kang, FW (通讯作者)，Tongji Univ, Dent Sch, 399 Middle Yan Chang Rd, Shanghai 200072, Peoples R China.
EM kfw@tongji.edu.cn
RI Cheng, Chun An/W 8502 2019
FU Shanghai Hospital Development Center Foundation [SHDC12020113]; National
   Natural Science Foundation of China [82271013, 82100955]; Postdoctoral
   Science Foundation of China [2021M692429]
FX We appreciate the technical staff of Shanghai Engineering Research
   Center of Tooth Restoration and Regeneration, and the public instru 
   ment platform of School of Medicine, Tongji University. This study was
   funded by Shanghai Hospital Development Center Foundation (grant
   SHDC12020113) , National Natural Science Foundation of China (grant
   82100955) , Postdoctoral Science Foundation of China (grant 2021M692429)
   , and National Natural Science Foundation of China (grant 82271013) .
CR Aughey GN, 2016, CRIT REV BIOCHEM MOL, V51, P282, DOI 10.3109/10409238.2016.1172555
   Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935
   Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763
   Bettis T, 2018, OSTEOPOROSIS INT, V29, P1713, DOI 10.1007/s00198 018 4570 1
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cabahug Zuckerman P, 2016, J BONE MINER RES, V31, P1356, DOI 10.1002/jbmr.2807
   Calise SJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02789
   Chang CC, 2018, FEBS J, V285, P3753, DOI 10.1111/febs.14624
   Chang CC, 2015, J CELL SCI, V128, P3550, DOI 10.1242/jcs.175265
   Chen KN, 2011, J GENET GENOMICS, V38, P391, DOI 10.1016/j.jgg.2011.08.004
   Choudhry H, 2018, CELL METAB, V27, P281, DOI 10.1016/j.cmet.2017.10.005
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Dai M, 2008, J PINEAL RES, V44, P121, DOI 10.1111/j.1600 079X.2007.00498.x
   Deardorff WJ, 2022, JAMA INTERN MED, V182, P33, DOI 10.1001/jamainternmed.2021.6745
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Gao YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158182
   Gonzalez FJ, 2018, NAT REV ENDOCRINOL, V15, P21, DOI 10.1038/s41574 018 0096 z
   Guo CJ, 2019, BONE, V120, P156, DOI 10.1016/j.bone.2018.10.025
   Han YJ, 2019, J CLIN INVEST, V129, P1895, DOI 10.1172/JCI124590
   Herrmann M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030432
   Hoefflin R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17873 3
   Huang TY, 2020, J BONE MINER RES, V35, P2143, DOI 10.1002/jbmr.4127
   Judex Stefan, 2003, Curr Osteoporos Rep, V1, P11, DOI 10.1007/s11914 003 0003 x
   Keppeke GD, 2020, MOL THER, V28, P1557, DOI 10.1016/j.ymthe.2020.06.006
   Keppeke GD, 2018, CELL DIV, V13, DOI 10.1186/s13008 018 0038 0
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Knowles HJ, 2015, HYPOXIA, V3, P73, DOI 10.2147/HP.S95960
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Kün Darbois JD, 2015, BONE, V77, P75, DOI 10.1016/j.bone.2015.03.023
   Laurent MR, 2016, BONE, V93, P33, DOI 10.1016/j.bone.2016.09.011
   Lescale C, 2015, FASEB J, V29, P455, DOI 10.1096/fj.14 259770
   Li J, 2017, BONE, V97, P2, DOI 10.1016/j.bone.2016.12.009
   Liu JL, 2016, ANNU REV CELL DEV BI, V32, P349, DOI 10.1146/annurev cellbio 111315 124907
   Lowe N, 2014, DEVELOPMENT, V141, P3994, DOI 10.1242/dev.111054
   Ma K, 2021, J CELL PHYSIOL, V236, P6520, DOI 10.1002/jcp.30326
   Meng XY, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00189 x
   Miyamoto Takeshi, 2016, Clin Calcium, V26, P1429
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Ni SW, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.690536
   Peng M, 2021, EXP CELL RES, V405, DOI 10.1016/j.yexcr.2021.112662
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rolvien T, 2022, CALCIFIED TISSUE INT, V110, P592, DOI 10.1007/s00223 021 00836 1
   Sibonga JD, 2007, BONE, V41, P973, DOI 10.1016/j.bone.2007.08.022
   Squire M, 2004, BONE, V35, P1353, DOI 10.1016/j.bone.2004.08.010
   Stegen S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04679 7
   Storlino G, 2020, J BONE MINER RES, V35, P766, DOI 10.1002/jbmr.3944
   Tan JK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810146
   Tando T, 2016, BIOCHEM BIOPH RES CO, V470, P391, DOI 10.1016/j.bbrc.2016.01.033
   Tang Y, 2020, J DENT RES, V99, P1377, DOI 10.1177/0022034520935788
   Van Raemdonck K, 2021, ARTHRITIS RHEUMATOL, V73, P2003, DOI 10.1002/art.41792
   Vitaca T, 2022, LANCET DIABETES ENDO, V10, P273, DOI 10.1016/S2213 8587(22)00012 2
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wang YY, 2012, BONE, V50, P409, DOI 10.1016/j.bone.2011.07.012
   Wu Z, 2019, EXP CELL RES, V376, P159, DOI 10.1016/j.yexcr.2019.02.003
   Yang M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16003
   Zhang YB, 2020, J GENET GENOMICS, V47, P321, DOI 10.1016/j.jgg.2020.06.004
   Zhou X, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026621118
NR 60
TC 7
Z9 7
U1 2
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2023
VL 168
AR 116648
DI 10.1016/j.bone.2022.116648
EA DEC 2022
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 8A4UR
UT WOS:000916236300001
PM 36563716
OA hybrid
DA 2025 08 17
ER

PT J
AU Baek, JM
   Kim, JY
   Ahn, SJ
   Cheon, YH
   Yang, M
   Oh, J
   Choi, MK
AF Baek, Jong Min
   Kim, Ju Young
   Ahn, Sung Jun
   Cheon, Yoon Hee
   Yang, Miyoung
   Oh, Jaemin
   Choi, Min Kyu
TI Dendrobium moniliforme Exerts Inhibitory Effects on Both Receptor
   Activator of Nuclear Factor Kappa B Ligand Mediated Osteoclast
   Differentiation in Vitro and Lipopolysaccharide Induced Bone Erosion
   in Vivo
SO MOLECULES
LA English
DT Article
DE Dendrobium moniliforme (DM); osteoclast; bone resorption; osteoporosis
ID LACKING C FOS; OSTEOPOROSIS; EXTRACT; SIGNALS; NOBILE; RANKL; MICE
AB Dendrobium moniliforme (DM) is a well known plant derived extract that is widely used in Oriental medicine. DM and its chemical constituents have been reported to have a variety of pharmacological effects, including anti oxidative, anti inflammatory, and anti tumor activities; however, no reports discuss the beneficial effects of DM on bone diseases such as osteoporosis. Thus, we investigated the relationship between DM and osteoclasts, cells that function in bone resorption. We found that DM significantly reduced receptor activator of nuclear factor kappa B ligand (RANKL) induced tartrate resistant acid phosphatase (TRAP) positive osteoclast formation; DM directly induced the down regulation of c Fos and nuclear factor of activated T cells c1 (NFATc1) without affecting other RANKL dependent transduction pathways. In the later stages of osteoclast maturation, DM negatively regulated the organization of filamentous actin (F actin), resulting in impaired bone resorbing activity by the mature osteoclasts. In addition, micro computed tomography ( CT) analysis of the murine model revealed that DM had a beneficial effect on lipopolysaccharide (LPS) mediated bone erosion. Histological analysis showed that DM attenuated the degradation of trabecular bone matrix and formation of TRAP positive osteoclasts in bone tissues. These results suggest that DM is a potential candidate for the treatment of metabolic bone disorders such as osteoporosis.
C1 [Baek, Jong Min; Ahn, Sung Jun; Yang, Miyoung; Oh, Jaemin; Choi, Min Kyu] Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
   [Kim, Ju Young; Cheon, Yoon Hee; Oh, Jaemin] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Kim, Ju Young; Oh, Jaemin] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea.
   [Kim, Ju Young; Yang, Miyoung; Choi, Min Kyu] Wonkwang Univ, Inst Environm Sci, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University
RP Choi, MK (通讯作者)，Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.; Choi, MK (通讯作者)，Wonkwang Univ, Inst Environm Sci, Iksan 570749, Jeonbuk, South Korea.
EM phone8418@hanmail.net; Kimjy1014@gmail.com; asj0427@naver.com;
   hanleuni@naver.com; yangm@wku.ac.kr; jmoh@wku.ac.kr; mkchoi@wku.ac.kr
FU Wonkwang University
FX This study was supported by a grant from the Wonkwang University in
   2015.
CR Ahn SJ, 2015, AM J CHINESE MED, V43, P715, DOI 10.1142/S0192415X15500445
   Akisaka T, 2001, J BONE MINER RES, V16, P1248, DOI 10.1359/jbmr.2001.16.7.1248
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cheon YH, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906 015 0801 6
   Clohisy JC, 2004, J ORTHOPAED RES, V22, P13, DOI 10.1016/S0736 0266(03)00156 6
   Fan CQ, 2001, PHYTOCHEMISTRY, V57, P1255, DOI 10.1016/S0031 9422(01)00168 6
   Georgess D, 2014, CELL ADHES MIGR, V8, P192, DOI 10.4161/cam.27840
   HAKEDA Y, 1991, Acta Anatomica Nipponica, V66, P215
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Kim JY, 2014, MOLECULES, V19, P18465, DOI 10.3390/molecules191118465
   Lee W, 2012, AM J CHINESE MED, V40, P1217, DOI [10.1142/S0192415X12500905, 10.1142/s0192415x12500905]
   LEE YH, 1995, PLANTA MED, V61, P178, DOI 10.1055/s 2006 958043
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Süntar I, 2013, CURR DRUG TARGETS, V14, P1611
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Udagawa N, 1992, Nihon Rinsho, V50, P2133
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Zhao WM, 2001, J NAT PROD, V64, P1196, DOI 10.1021/np0102612
   Zhu QY, 2002, J AGR FOOD CHEM, V50, P6929, DOI 10.1021/jf0206163
NR 25
TC 18
Z9 18
U1 0
U2 13
PU MDPI AG
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1420 3049
J9 MOLECULES
JI Molecules
PD MAR
PY 2016
VL 21
IS 3
AR 295
DI 10.3390/molecules21030295
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA DI9DR
UT WOS:000373802200036
PM 26938522
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Zheng, X
   Ye, FC
   Sun, T
   Liu, FJ
   Wu, MJ
   Zheng, WH
   Wu, LF
AF Zheng, Xiang
   Ye, Fang Chen
   Sun, Tao
   Liu, Fei Jun
   Wu, Ming Jian
   Zheng, Wen Hao
   Wu, Ling Feng
TI Delay the progression of glucocorticoid induced osteoporosis: Fraxin
   targets ferroptosis via the Nrf2/GPX4 pathway
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE ferroptosis; Fraxin; glucocorticoid induced osteoporosis; Nrf/GPX4
   pathway
ID OXIDATIVE STRESS; INHIBITION; PREVALENCE; CELLS; AXIS
AB Glucocorticoid induced osteoporosis (GIOP) commonly accelerates bone loss, increasing the risk of fractures and osteonecrosis more significantly than traditional menopausal osteoporosis. The extracellular environment influenced by glucocorticoids heightens fracture and osteonecrosis risks. Fraxin (Fra), a key component of the traditional Chinese herbal remedy Cortex Fraxini, is known for its wide ranging pharmacological effects, but its impact on GIOP remains unexplored. This investigation aims to delineate the effects and underlying mechanisms of Fra in combating dexamethasone (Dex) induced ferroptosis and GIOP. We established a mouse model of GIOP via intraperitoneal injections of Dex and cultured osteoblasts with Dex treatment for in vitro analysis. We evaluated the impact of Fra on Dex treated osteoblasts through assays such as C11 BODIPY and FerroOrange staining, mitochondrial functionality tests, and protein expression analyses via Western blot and immunofluorescence. The influence of Fra on bone microarchitecture of GIOP in mice was assessed using microcomputerized tomography, hematoxylin and eosin staining, double labeling with Calcein Alizarin Red S, and immunohistochemistry at imaging and histological levels. Based on our data, Fra prevented Dex induced ferroptosis and bone loss. In vitro, glutathione levels increased and malondialdehyde, lipid peroxidation, and mitochondrial reactive oxygen species decreased. Fra treatment also increases nuclear factor erythroid 2 related factor 2 (Nrf2), glutathione peroxidase 4 (GPX4), and COL1A1 expression and promotes bone formation. To delve deeper into the mechanism, the findings revealed that Fra triggered the activation of Nrf2/GPX4 signaling. Moreover, the use of siRNA Nrf2 blocked the beneficial effect of Fra in osteoblasts cultivated with Dex. Fra effectively combats GIOP by activating the Nrf2/GPX4 signaling pathway to inhibit ferroptosis.
C1 [Zheng, Xiang; Sun, Tao; Liu, Fei Jun; Wu, Ming Jian; Wu, Ling Feng] Lishui Municipal Cent Hosp, Dept Orthoped, 289 Kuocang Rd, Lishui 323000, Zhejiang, Peoples R China.
   [Zheng, Xiang; Sun, Tao; Liu, Fei Jun; Wu, Ming Jian; Wu, Ling Feng] Wenzhou Med Univ, Affiliated Hosp 5, Dept Orthoped, Lishui, Zhejiang, Peoples R China.
   [Ye, Fang Chen] Nanfang Med Univ, Sch Med 1, Guangzhou, Peoples R China.
   [Zheng, Wen Hao] Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Dept Orthopaed, Wenzhou, Peoples R China.
C3 Wenzhou Medical University; Southern Medical University   China; Wenzhou
   Medical University
RP Wu, LF (通讯作者)，Lishui Municipal Cent Hosp, Dept Orthoped, 289 Kuocang Rd, Lishui 323000, Zhejiang, Peoples R China.
EM wlf0626@126.com
RI ; ye, fangchen/OAJ 3808 2025; Zheng, Wenhao/KBR 3871 2024
OI Wu, Ling feng/0009 0005 1938 0634; Zheng, Wenhao/0000 0002 9618 2456; 
FU Medical Science and Technology Project, Health Department of Zhejiang
   Province [2022KY1430]
FX Medical Science and Technology Project, Health Department of Zhejiang
   Province, Grant/Award Number: 2022KY1430
CR Alam I, 2017, CALCIFIED TISSUE INT, V100, P361, DOI 10.1007/s00223 016 0225 4
   Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Almon RR, 2004, PHARMACOGENOMICS, V5, P525, DOI 10.1517/14622416.5.5.525
   Bécquer Viart MA, 2021, MOLECULES, V26, DOI 10.3390/molecules26113364
   Bellezza I, 2018, BBA MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Cai YH, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11091794
   Cao RC, 2022, J TRANSL MED, V20, DOI 10.1186/s12967 022 03413 8
   Chen DL, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.664836
   Chen JH, 2018, NUTR METAB, V15, DOI 10.1186/s12986 018 0306 7
   Chen L, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9102012
   Cheng PP, 2024, PHYTOMEDICINE, V125, DOI 10.1016/j.phymed.2024.155357
   Dunigan K, 2018, AM J PHYSIOL LUNG C, V315, pL545, DOI 10.1152/ajplung.00214.2018
   Fardet L, 2011, RHEUMATOLOGY, V50, P1982, DOI 10.1093/rheumatology/ker017
   Guo Shuang, 2023, Oxidative Medicine and Cellular Longevity, V2023, P4772134, DOI 10.1155/2023/4772134
   Han SX, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/6400227
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Jiang B, 2020, DIGEST DIS SCI, V65, P1999, DOI 10.1007/s10620 019 05929 4
   Jin C, 2023, J AGR FOOD CHEM, P2745, DOI 10.1021/acs.jafc.2c05632
   Jing XZ, 2021, J CELL MOL MED, V25, P5671, DOI 10.1111/jcmm.16581
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Li M, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/8223737
   Li SY, 2024, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1285442
   Li WF, 2020, FUND CLIN PHARMACOL, V34, P91, DOI 10.1111/fcp.12500
   Li WF, 2019, INT IMMUNOPHARMACOL, V67, P1, DOI 10.1016/j.intimp.2018.12.003
   Li YT, 2020, AGING US, V12, P2226, DOI 10.18632/aging.102742
   Lian CY, 2023, J ADV RES, V46, P87, DOI 10.1016/j.jare.2022.04.016
   Lim S, 2018, MAR DRUGS, V16, DOI 10.3390/md16100374
   Liu P, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2634431
   Liu P, 2022, EXP MOL MED, V54, P765, DOI 10.1038/s12276 022 00764 6
   Liu P, 2016, ONCOTARGETS THER, V9, P5049, DOI 10.2147/OTT.S108169
   Lu JS, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52513 x
   Luo LP, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e18929
   Ma XH, 2019, INFLAMMATION, V42, P1901, DOI 10.1007/s10753 019 01052 8
   Ma YS, 2018, MOL MED REP, V17, P1633, DOI 10.3892/mmr.2017.8065
   Moosmayer D, 2021, ACTA CRYSTALLOGR D, V77, P237, DOI 10.1107/S2059798320016125
   Murphy DR, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 213
   Ngo D, 2013, ARTHRITIS RHEUM US, V65, P1203, DOI 10.1002/art.37858
   Overman RA, 2013, ARTHRIT CARE RES, V65, P294, DOI 10.1002/acr.21796
   Park E, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2064 5
   Rodrigo R, 2022, MOLECULES, V27, DOI 10.3390/molecules27082564
   Shaker NS, 2023, ADV VIROL, V2023, DOI 10.1155/2023/5536933
   Sun F, 2022, BIOCHEM BIOPH RES CO, V602, P149, DOI 10.1016/j.bbrc.2022.02.112
   Tang FL, 2024, INT IMMUNOPHARMACOL, V129, DOI 10.1016/j.intimp.2024.111637
   Wang M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02961 5
   Wang XK, 2023, J BIOCHEM MOL TOXIC, V37, DOI 10.1002/jbt.23368
   Wu YC, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/6177553
   Xu CY, 2024, PHYTOMEDICINE, V125, DOI 10.1016/j.phymed.2024.155342
   Xu MM, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7450151
   Xu QB, 2021, THERANOSTICS, V11, P1937, DOI 10.7150/thno.45511
   Yin H, 2014, NUTRIENTS, V6, P564, DOI 10.3390/nu6020564
   Zeng JR, 2023, EUR J PHARMACOL, V955, DOI 10.1016/j.ejphar.2023.175915
   Zhang C, 2022, MOL CANCER, V21, DOI 10.1186/s12943 022 01530 y
   Zhao TM, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420 022 01173 4
NR 53
TC 9
Z9 9
U1 5
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD NOV
PY 2024
VL 38
IS 11
BP 5203
EP 5224
DI 10.1002/ptr.8310
EA AUG 2024
PG 22
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA M0F5A
UT WOS:001299741000001
PM 39192711
DA 2025 08 17
ER

PT J
AU Wu, CY
   Yang, SF
   Sun, ZP
   Han, XH
   Ye, YY
   Liu, S
AF Wu, Chunyu
   Yang, Shunfang
   Sun, Zhenping
   Han, Xianghui
   Ye, Yiyi
   Liu, Sheng
TI Characterization of the Attenuation of Breast Cancer Bone Metastasis in
   Mice by Zoledronic Acid Using <SUP>99m</SUP>Tc bone Scintigraphy
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Bone metastasis; Breast cancer; Tc 99m MDP bone scintigraphy; Zoleronic
   acid
ID ADJUVANT THERAPY; CELLS; BISPHOSPHONATES; MECHANISMS; ANTITUMOR
AB Metastatic breast cancer often metastasizes to bone. The purposes of the study were (1) to evaluate the use of Tc 99m MDP bone scintigraphy for detection of metastatic bone lesions, and (2) to determine the efficacy of zoledronic acid in mice with breast cancer bone metastasis. All tumor bearing mice were analyzed with radionuclide bone scintigraphy, X ray, and histological analysis. The metastatic bone tissue was also harvested and analyzed by western blotting and real time qPCR. Interestingly, zoledronic acid significantly decreased both the tumor burden and the incidence of bone metastasis in mice. In addition, histomorphometric, stereological, and molecular biology analyses demonstrated that zoledronic acid may function to inhibit breast cancer cell growth in the bone microenvironment and regulate the function of osteoblasts and osteoclasts in tumor bearing mice. Finally, the attenuation of breast cancer bone metastasis using zoledronic acid can be accurately characterized by Tc 99m bone scintigraphy in mice.
C1 [Wu, Chunyu; Sun, Zhenping; Liu, Sheng] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Breast Surg, Shanghai 200032, Peoples R China.
   [Yang, Shunfang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Nucl Med, Shanghai 200030, Peoples R China.
   [Han, Xianghui; Ye, Yiyi; Liu, Sheng] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Pharmacol Lab Tradit Chinese Med, Shanghai 200032, Peoples R China.
   [Liu, Sheng] Shanghai Univ Tradit Chinese Med, Long Hua Hosp, Dept Breast Surg, Shanghai 200032, Peoples R China.
   [Liu, Sheng] Shanghai Univ Tradit Chinese Med, Pharmacol Lab Tradit Chinese Med, Long Hua Hosp, Shanghai 200032, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai Jiao Tong
   University; Shanghai University of Traditional Chinese Medicine;
   Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine
RP Liu, S (通讯作者)，Shanghai Univ Tradit Chinese Med, Long Hua Hosp, Dept Breast Surg, 725 South Wanping Rd, Shanghai 200032, Peoples R China.
EM sliu_tcm@163.com
RI Wu, Chunyu/LBI 5378 2024; WU, CHUNYU/LBI 5378 2024; j, z/JPX 2698 2023
OI Wu, Chunyu/0009 0006 8834 3359; 
FU National Natural Science Foundation of China [30772811, 81102597,
   81173269]; Shanghai Municipal Education Commission; Shanghai Education
   Development Foundation [08GG12]; Shanghai Subject Chief Scientist
   [10XD1404000]
FX This research was supported by The National Natural Science Foundation
   of China (No. 30772811, No. 81102597 and No. 81173269), "Shu Guang"
   project supported by Shanghai Municipal Education Commission and
   Shanghai Education Development Foundation (No. 08GG12) and Sponsored by
   Program of Shanghai Subject Chief Scientist (No. 10XD1404000).
CR Anderson KC, 2010, NCCN CLIN PRACTICE G
   Chen MC, 2010, J AGR FOOD CHEM, V58, P3330, DOI 10.1021/jf904549s
   Chen WQ, 2012, CHINESE J CANCER RES, V24, P1, DOI 10.1007/s11670 012 0001 6
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Costa L, 2007, BREAST, V16, pS16, DOI 10.1016/j.breast.2007.10.005
   El Abdaimi K, 2003, INT J ONCOL, V22, P883
   Even Sapir E, 2005, J NUCL MED, V46, P1356
   Fournier P, 2002, CANCER RES, V62, P6538
   Gallo M, 2012, ANN ONCOL, V23, P597, DOI 10.1093/annonc/mdr159
   Hamaoka T, 2004, J CLIN ONCOL, V22, P2942, DOI 10.1200/jco.2004.08.181
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Hiraga T, 2001, CANCER RES, V61, P4418
   Insalaco L, 2012, J CELL MOL MED, V16, P2186, DOI 10.1111/j.1582 4934.2012.01527.x
   Jeong J, 2011, J KOREAN MED SCI, V26, P1569, DOI 10.3346/jkms.2011.26.12.1569
   Koto K, 2009, CANCER LETT, V274, P271, DOI 10.1016/j.canlet.2008.09.026
   Linos E, 2008, JNCI J NATL CANCER I, V100, P1352, DOI 10.1093/jnci/djn305
   Lipton A, 2009, J NATL COMPR CANC NE, V7, pS1
   Luo KW, 2013, CANCER LETT, V339, P42, DOI 10.1016/j.canlet.2013.07.024
   Mandal MNA, 2006, INVEST OPHTH VIS SCI, V47, P5514, DOI 10.1167/iovs.06 0449
   Niikura N, 2012, CANCER AM CANCER SOC, V118, P2039, DOI 10.1002/cncr.26512
   Padhani A., 1998, IMAGING ONCOLOGY, P765
   Rachner TD, 2010, CANCER LETT, V287, P109, DOI 10.1016/j.canlet.2009.06.003
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Wu CY, 2013, FITOTERAPIA, V91, P205, DOI 10.1016/j.fitote.2013.09.005
   Yang SF, 2009, NUCL MED BIOL, V36, P313, DOI 10.1016/j.nucmedbio.2008.12.007
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
NR 26
TC 4
Z9 4
U1 1
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219 4956
EI 1532 2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD JUL
PY 2014
VL 20
IS 3
BP 747
EP 754
DI 10.1007/s12253 014 9756 z
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA AK2UL
UT WOS:000338274900034
PM 24610002
DA 2025 08 17
ER

PT J
AU Antoniou, J
   Wang, HT
   Hadjab, I
   Aldebeyan, S
   Alaqeel, MA
   Meij, BP
   Tryfonidou, MA
   Mwale, F
AF Antoniou, John
   Wang, Hong Tian
   Hadjab, Insaf
   Aldebeyan, Sultan
   Alaqeel, Motaz A.
   Meij, Bjorn P.
   Tryfonidou, Marianna A.
   Mwale, Fackson
TI The Effects of Naproxen on Chondrogenesis of Human Mesenchymal Stem
   Cells
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLLAGEN TYPE X; BONE MARROW;
   GENE EXPRESSION; STROMAL CELLS; DIFFERENTIATION; CARTILAGE; MATRIX;
   OSTEOARTHRITIS; CHONDROCYTE
AB Currently, there are no established treatments to prevent, stop, or even retard the degeneration of articular cartilage in osteoarthritis (OA). Biological repair of the degenerating articular cartilage would be preferable to surgery. There is no benign site where autologous chondrocytes can be harvested and used as a cell source for cartilage repair, leaving mesenchymal stem cells (MSCs) as an attractive option. However, MSCs from OA patients have been shown to constitutively express collagen type X (COL X), a marker of late stage chondrocyte hypertrophy. We recently found that naproxen (Npx), but not other nonsteroidal anti inflammatory drugs, can induce collagen type X alpha 1 (COL10A1) gene expression in bone marrow derived MSCs from healthy and OA donors. In this study, we determined the effect of Npx on COL10A1 expression and investigated the intracellular signaling pathways that mediate such effect in normal human MSCs during chondrogenesis. MSCs were cultured in standard chondrogenic differentiation media supplemented with or without Npx. Our results show that Npx can regulate chondrogenic differentiation by affecting the gene expression of both Indian hedgehog and parathyroid hormone/parathyroid hormone related protein signaling pathways in a time dependent manner, suggesting a complex interaction of different signaling pathways during the process.
C1 [Antoniou, John; Wang, Hong Tian; Hadjab, Insaf; Aldebeyan, Sultan; Alaqeel, Motaz A.; Mwale, Fackson] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
   [Antoniou, John; Mwale, Fackson] McGill Univ, Div Orthoped Surg, Montreal, PQ H3T 1E2, Canada.
   [Hadjab, Insaf] Ecole Polytech, Montreal, PQ H3C 3A7, Canada.
   [Aldebeyan, Sultan] King Fahad Med City, Dept Orthopaed Surg, Riyadh, Saudi Arabia.
   [Alaqeel, Motaz A.] King Saud Univ, Coll Med, Dept Orthoped, Riyadh 11461, Saudi Arabia.
   [Meij, Bjorn P.; Tryfonidou, Marianna A.] Univ Utrecht, Fac Vet Med, Dept Clin Sci Compan Anim, Utrecht, Netherlands.
C3 Jewish General Hospital   Montreal; McGill University; Lady Davis
   Institute; McGill University; Universite de Montreal; Polytechnique
   Montreal; King Fahad Medical City; King Saud University; Utrecht
   University
RP Mwale, F (通讯作者)，McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Chemin Cote St Catherine, Montreal, PQ H3T 1E2, Canada.
EM fmwale@ldi.jgh.mcgill.ca
RI ; Tryfonidou, Marianna/O 3114 2017
OI HADJAB, Insaf/0000 0002 8570 2460; Tryfonidou,
   Marianna/0000 0002 2333 7162; AlAqeel, Motaz/0000 0001 8906 8367
FU Canadian Institute of Health Research (CIHR); Dutch Arthritis Foundation
   [LLP22]
FX This research was supported by grants from the Canadian Institute of
   Health Research (CIHR). M.T. and B.M. were supported by the Dutch
   Arthritis Foundation (LLP22).
CR Akiyama H, 2008, MOD RHEUMATOL, V18, P213, DOI 10.1007/s10165 008 0048 x
   Alaseem AM, 2015, TISSUE ENG PT A, V21, P234, DOI [10.1089/ten.TEA.2014.0148, 10.1089/ten.tea.2014.0148]
   Almaawi A, 2013, TISSUE ENG PT A, V19, P1039, DOI [10.1089/ten.TEA.2012.0129, 10.1089/ten.tea.2012.0129]
   Amano K, 2014, J BIOL CHEM, V289, P24898, DOI 10.1074/jbc.M114.570507
   Antoniou J, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4113
   Ayers KL, 2010, TRENDS CELL BIOL, V20, P287, DOI 10.1016/j.tcb.2010.02.002
   Barbosa I, 2003, GLYCOBIOLOGY, V13, P647, DOI 10.1093/glycob/cwg082
   Barry F, 2001, EXP CELL RES, V268, P189, DOI 10.1006/excr.2001.5278
   Bertram H, 2009, STEM CELLS DEV, V18, P881, DOI 10.1089/scd.2008.0306
   Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140 6736(13)60900 9
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Deckelbaum RA, 2002, J CELL SCI, V115, P3015
   Djouad F, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2153
   Fischer J, 2014, STEM CELLS DEV, V23, P2513, DOI 10.1089/scd.2014.0101
   Hecht JT, 2005, MATRIX BIOL, V23, P525, DOI 10.1016/j.matbio.2004.09.006
   Hellingman CA, 2012, J TISSUE ENG REGEN M, V6, pe1, DOI 10.1002/term.502
   Kim YJ, 2008, BIOCHEM BIOPH RES CO, V373, P104, DOI 10.1016/j.bbrc.2008.05.183
   Kobayashi T, 2002, DEVELOPMENT, V129, P2977
   Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019
   LeGrand A, 2001, ARTHRITIS RHEUM US, V44, P2078, DOI 10.1002/1529 0131(200109)44:9<2078::AID ART358>3.0.CO;2 J
   Little CB, 2010, CURR DRUG TARGETS, V11, P561
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Lozito TP, 2011, J CELL PHYSIOL, V226, P385, DOI 10.1002/jcp.22344
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   Mak KK, 2008, DEVELOPMENT, V135, P1947, DOI 10.1242/dev.018044
   McCarthy HE, 2012, VET J, V192, P345, DOI 10.1016/j.tvjl.2011.08.036
   MILLER GJ, 1988, BONE, V9, P235, DOI 10.1016/8756 3282(88)90036 1
   Mo R, 1997, DEVELOPMENT, V124, P113
   Mort John S., 2007, V135, P201
   MUIR H, 1995, BIOESSAYS, V17, P1039, DOI 10.1002/bies.950171208
   Mwale F, 2000, DEV DYNAM, V218, P648, DOI 10.1002/1097 0177(200008)218:4<648::AID DVDY1022>3.0.CO;2 P
   Mwale F, 2006, TISSUE ENG, V12, P2639, DOI 10.1089/ten.2006.12.2639
   Mwale F, 2006, J ORTHOP RES, V24, P1791, DOI 10.1002/jor.20200
   Mwale F, 2010, TISSUE ENG PT A, V16, P3449, DOI [10.1089/ten.tea.2010.0091, 10.1089/ten.TEA.2010.0091]
   Mwale Fackson, 2011, J Tissue Eng, V2011, P587547, DOI 10.4061/2011/587547
   Myllyharju J, 2014, CURR OSTEOPOROS REP, V12, P439, DOI 10.1007/s11914 014 0232 1
   Nelea V, 2005, J BIOMED MATER RES A, V75A, P216, DOI 10.1002/jbm.a.30402
   O'Connor JP, 2008, DRUG TODAY, V44, P693, DOI 10.1358/dot.2008.44.9.1251573
   Petit A, 2010, J BIOMED MATER RES A, V94A, P744, DOI 10.1002/jbm.a.32739
   Pountos I, 2011, J CELL MOL MED, V15, P525, DOI 10.1111/j.1582 4934.2010.01006.x
   Rampersad S, 2011, TISSUE ENG PT A, V17, P2551, DOI [10.1089/ten.tea.2010.0723, 10.1089/ten.TEA.2010.0723]
   Richmond J, 2009, J AM ACAD ORTHOP SUR, V17, P591, DOI 10.5435/00124635 200909000 00006
   Rockel JS, 2011, J ORTHOP RES, V29, P810, DOI 10.1002/jor.21372
   Salem O, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4614
   SCHMID TM, 1985, J CELL BIOL, V100, P598, DOI 10.1083/jcb.100.2.598
   SEVELIUS H, 1980, BRIT J CLIN PHARMACO, V10, P259, DOI 10.1111/j.1365 2125.1980.tb01753.x
   Singh A, 2014, BONE JOINT RES, V3, P32, DOI 10.1302/2046 3758.32.2000187
   Studer D, 2012, EUR CELLS MATER, V24, P118, DOI 10.22203/eCM.v024a09
   Williams R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013246
   Winter A, 2003, ARTHRITIS RHEUM US, V48, P418, DOI 10.1002/art.10767
NR 50
TC 8
Z9 8
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD JUL 1
PY 2015
VL 21
IS 13 14
BP 2136
EP 2146
DI 10.1089/ten.tea.2014.0668
PG 11
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA CV0ZP
UT WOS:000363982900017
PM 25873236
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Yao, ZY
   Fan, SY
   Song, ZF
   Li, ZC
AF Yao, Zhi Yuan
   Fan, Shu Yao
   Song, Zhou Feng
   Li, Zhan Chun
TI Network pharmacology based and molecular docking based analysis of
   You Gui Yin for the treatment of osteonecrosis of the femoral head
SO MEDICINE
LA English
DT Article
DE molecular docking; network pharmacology; osteonecrosis of the femoral
   head; traditional Chinese medicine; You Gui Yin
ID INDUCED AVASCULAR NECROSIS; OSTEOBLAST DIFFERENTIATION; BETA SITOSTEROL;
   IN VIVO; PROLIFERATION; HYPOXIA; INFLAMMATION; HIF 1 ALPHA; ACTIVATION;
   APOPTOSIS
AB You Gui Yin (YGY) is a classic prescription for warming up kidney Yang and filling in kidney essence in traditional Chinese medicine, and has been used to treat osteonecrosis of the femoral head (ONFH) effectively. However, the underlying mechanisms are still unknown. This study is aimed at exploring the possible mechanisms of action of the YGY in the treatment of ONFH based on network pharmacology and molecular docking. TCMSP was used to screen the active components and targets of YGY. The disease targets of ONFH were collected in several public databases. The protein protein interaction (PPI) Network was constructed using the STRING platform. The Metascape database platform was used for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The key active components and core target proteins of YGY in the treatment of ONFH were verified by the molecular docking. 120 active components were obtained from YGY, among which 73 components were hit by the 117 drug disease intersection targets. Key effective components included quercetin, kaempferol, beta sitosterol, glycitein, beta carotene, and so on. Core target proteins included ALB, AKT1, TNF, IL6, TP53, and so on. According to GO and KEGG analyses, there were 1762 biological processes, 94 cellular component, 138 molecular function and 187 signaling pathways involved. we selected the top 20 biological processes (BP), cellular components (CC), molecular functions (MF) and signaling pathways to draw the heat maps, showing that Lipid and atherosclerosis signaling pathway, IL 17 signaling pathway, HIF 1 signaling pathway, relaxin signaling pathway and MAPK signaling pathway and other pathways may play a key role in the treatment of ONFH by YGY. The results of molecular docking showed that key effective components and corresponding core target proteins exhibited the good binding activity. YGY can treat ONFH through multicomponents, multitargets, and multipathways, which provides a reference for the subsequent research, development of targeted drugs and clinical application.
C1 [Yao, Zhi Yuan; Song, Zhou Feng; Li, Zhan Chun] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Tradit Chinese Med, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China.
   [Fan, Shu Yao] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Tradit Chinese Med, Dept Breast Surg, Hangzhou, Zhejiang, Peoples R China.
   [Yao, Zhi Yuan] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Tradit Chinese Med, Dept Orthoped, 9 Ninth Ave, Hangzhou 310018, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Zhejiang Chinese Medical University
RP Yao, ZY (通讯作者)，Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Tradit Chinese Med, Dept Orthoped, 9 Ninth Ave, Hangzhou 310018, Zhejiang, Peoples R China.
EM 20163219@zcmu.edu.cn; 201911121511187@zcmu.edu.cn; dengdaijuyi@163.com;
   zhanchun@126.com
FU Scientific Research Project of Zhejiang Education Department
   [Y201942372]; Zhejiang Traditional Chinese Medical Science and
   Technology Planning Project [2023ZL400]
FX This study was financially supported by Scientific Research Project of
   Zhejiang Education Department (No. Y201942372) and Zhejiang Traditional
   Chinese Medical Science and Technology Planning Project (No.2023ZL400).
CR Alcantara EH, 2011, J NUTR BIOCHEM, V22, P1055, DOI 10.1016/j.jnutbio.2010.09.003
   Batiha GE, 2020, FOODS, V9, DOI 10.3390/foods9030374
   Chen GY, 2020, BONE, V133, DOI 10.1016/j.bone.2020.115258
   Chen H, 2021, BIOENGINEERED, V12, P12677, DOI 10.1080/21655979.2021.2008666
   Chen WP, 2012, ACTA BIOCHIM POL, V59, P537
   Cheng SC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122957
   Cohen Rosenblum A, 2019, ORTHOP CLIN N AM, V50, P139, DOI 10.1016/j.ocl.2018.10.001
   Comeau SR, 2004, BIOINFORMATICS, V20, P45, DOI 10.1093/bioinformatics/btg371
   Du X, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/2968075
   Elokely KM, 2013, J CHEM INF MODEL, V53, P1934, DOI 10.1021/ci400040d
   Ferlin A, 2010, BONE, V46, P504, DOI 10.1016/j.bone.2009.10.007
   Folwarczna J, 2016, ACTA BIOCHIM POL, V63, P287, DOI 10.18388/abp.2015_1095
   Gao Z., 2016, Shi Yong Zhong Yi Nei Ke Xue Za Zhi, V30, P117
   Ge YW, 2020, J CELL MOL MED, V24, P3203, DOI 10.1111/jcmm.14995
   Goyal A, 2022, CURR MOL MED, V22, P325, DOI 10.2174/1566524021666210315125330
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007 1110
   Horváthy DB, 2019, J TISSUE ENG REGEN M, V13, P416, DOI 10.1002/term.2803
   Hresko MT, 2002, J BONE JOINT SURG AM, V84A, P1613, DOI 10.2106/00004623 200209000 00014
   Hsu YL, 2009, MOL NUTR FOOD RES, V53, P1452, DOI 10.1002/mnfr.200800483
   Hu X, 2011, BIOL PHARM BULL, V34, P1808, DOI 10.1248/bpb.34.1808
   Huang ZQ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6971503
   Jiang XH, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/152010
   Jung YK, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e2
   Kang JS, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1030 y
   Kim CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010125
   Kim YH, 2010, INT ORTHOP, V34, P1123, DOI 10.1007/s00264 009 0878 y
   LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092 8674(05)80006 6
   Li CM, 2015, FOOD FUNCT, V6, P2266, DOI 10.1039/c5fo00031a
   Li HL, 2017, CELL BIOL INT, V41, P1379, DOI 10.1002/cbin.10869
   Li JC, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 7040
   [李新建 Li Xinjian], 2016, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V31, P3274
   Liao PC, 2018, J AGR FOOD CHEM, V66, P10748, DOI 10.1021/acs.jafc.8b04555
   Linder M, 2018, CELL DEATH DIFFER, V25, P1094, DOI 10.1038/s41418 017 0054 7
   Liu GQ, 2019, FASEB J, V33, P11137, DOI 10.1096/fj.201900436RR
   Liu R, 2019, PHARM BIOL, V57, P161, DOI 10.1080/13880209.2019.1577461
   Liu YS, 2015, INT J CLIN EXP PATHO, V8, P3215
   Lu WT., 2020, Acta Chin Med, V35, P1029
   Mei SS, 2023, COMB CHEM HIGH T SCR, V26, P1167, DOI 10.2174/1386207325666220602114701
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Mutijima E, 2014, CLIN RHEUMATOL, V33, P1791, DOI 10.1007/s10067 014 2607 1
   Ni FF, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.748831
   Pandith H, 2013, J ETHNOPHARMACOL, V147, P434, DOI 10.1016/j.jep.2013.03.033
   Paniagua Pérez R, 2017, AFR J TRADIT COMPLEM, V14, P123, DOI 10.21010/ajtcam.v14i1.13
   Saccol RDP, 2020, J CELL BIOCHEM, V121, P2792, DOI 10.1002/jcb.29502
   Qi XY, 2019, PHYTOMEDICINE, V53, P286, DOI 10.1016/j.phymed.2018.09.014
   Ren YS, 2021, J BONE MINER RES, V36, P357, DOI 10.1002/jbmr.4191
   Shen P, 2021, J ETHNOPHARMACOL, V279, DOI 10.1016/j.jep.2021.114213
   Tang J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7039802
   Tong Pei jian, 2010, Zhongguo Gu Shang, V23, P23
   Ulici V, 2009, BONE, V45, P1133, DOI 10.1016/j.bone.2009.08.003
   Vandoorne K, 2010, MAGN RESON MED, V64, P54, DOI 10.1002/mrm.22395
   Wang F, 2017, LIFE SCI, V174, P15, DOI 10.1016/j.lfs.2017.03.002
   Wang YH, 2023, BIOMED CHROMATOGR, V37, DOI 10.1002/bmc.5619
   Winzer M, 2010, WIEN MED WOCHENSCHR, V160, P446, DOI 10.1007/s10354 010 0811 4
   Wong SK, 2019, DRUG DES DEV THER, V13, P3497, DOI 10.2147/DDDT.S227738
   Wu CL., 2006, Zhong Yi Zheng Gu, V18, P4
   Wu J, 2016, BIOSCI TRENDS, V10, P410, DOI 10.5582/bst.2016.01099
   Wu Yun gang, 2009, Zhongguo Gu Shang, V22, P115
   Yamaguchi R, 2016, J BONE JOINT SURG AM, V98, P1122, DOI 10.2106/JBJS.15.01209
   Yao C., 2016, Zhong Yi Zheng Gu, V28, P7
   Yin H, 2022, J SEP SCI, V45, P832, DOI 10.1002/jssc.202100689
   Yin QZ, 2013, MOL MED REP, V8, P1329, DOI 10.3892/mmr.2013.1670
   Yin YX, 2018, BIOORG MED CHEM LETT, V28, P1525, DOI 10.1016/j.bmcl.2018.03.073
   Yoshida H, 2001, BIOSCI BIOTECH BIOCH, V65, P1211, DOI 10.1271/bbb.65.1211
   Yu Y, 2019, OSTEOPOROSIS INT, V30, P871, DOI 10.1007/s00198 019 04835 9
   Zeng QH, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.925848
   Zeng XF., 2019, Shi Yong Zhong Yi Nei Ke Xue Za Zhi, V33, P38
   Zeng XS, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018 017 0532 0
   Zhang C, 2011, BONE, V48, P507, DOI 10.1016/j.bone.2010.10.006
   Zhang F, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2238 1
   Zhang QK, 2018, J INT MED RES, V46, P2141, DOI 10.1177/0300060517700299
   Zhang WL, 2015, INT J CLIN EXP PATHO, V8, P7210
   Zhang YW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010199
   Zhao HY, 2021, AM J MED SCI, V362, P78, DOI 10.1016/j.amjms.2021.03.005
   Zhao W., 2000, Zhong Guo Zhong Yi Gu Shang Ke Za Zhi, V8, P9
   [赵万军 Zhao Wanjun], 2005, [中国中医骨伤科杂志, Chinese Journal of Traditional Medicine Traumatology and Orthopedics], V13, P23
   Zhao Z., 2010, Tradit Chin Med Res, V23, P52
   Zheng LW, 2020, CELL BIOL INT, V44, P1881, DOI 10.1002/cbin.11394
   Zou DB, 2018, ENDOKRYNOL POL, V69, P283, DOI 10.5603/EP.a2018.0031
NR 81
TC 1
Z9 1
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 27
PY 2023
VL 102
IS 43
AR e35581
DI 10.1097/MD.0000000000035581
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA CG5L3
UT WOS:001124112800010
PM 37904445
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Taguchi, Y
   Kiga, Y
   Gohda, J
   Inoue, J
AF Taguchi, Yuu
   Kiga, Yoko
   Gohda, Jin
   Inoue, Jun ichiro
TI Identification and characterization of anti osteoclastogenic peptides
   derived from the cytoplasmic tail of receptor activator of nuclear
   factor kappa B
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Osteoclast; RANK; Signal transduction; Inhibitor; Gab2
ID LYMPH NODE ORGANOGENESIS; ARGININE RICH PEPTIDES; GENE EXPRESSION;
   PROTEIN KINASE; DEFECTIVE INTERLEUKIN 1; NFATC1 INDUCTION; BONE
   HOMEOSTASIS; KEY REGULATOR; LIGAND RANKL; TRAF6
AB Pathological bone resorption by osteoclasts is primarily treated with bisphosphonates. Because the administration of bisphosphonates is associated with a risk for multiple adverse symptoms, a precise understanding of the mechanisms underlying osteoclastogenesis is required to develop drugs with minimal side effects. Osteoclastogenesis depends on receptor activator of nuclear factor kappa B (RANK) signaling mediated by TRAF6. We previously identified a highly conserved domain in the cytoplasmic tail of RANK (HCR), which did not share any significant homology with other proteins and was essential for osteoclastogenesis. HCR acts as a platform for the formation of Gab2  and Vav3 containing signal complexes, and ectopic expression of the HCR peptide inhibits osteoclastogenesis. Here, we uncover the mechanisms of HCR peptide mediated inhibition of osteoclastogenesis. Expression of either the amino  or carboxyl terminal half of the HCR peptide (N  or C peptide) independently inhibited RANK signaling prior to cell cell fusion. In contrast, expression of the GY peptide, which is a part of the C peptide, did not significantly affect prefusion RANK signaling, but did inhibit cell cell fusion to prevent formation of multinucleated mature osteoclasts. Moreover, Gab2, which is involved in RANK signaling by binding TRAF6, bound the C peptide but not the N peptide, suggesting that the C  and the N peptides sequester TRAF6 in a Gab2 dependent and Gab2 independent manner, respectively. In contrast, the GY peptide did not bind Gab2 but could bind Vav3, which mediates signaling for cell cell fusion. Collectively, we propose that the HCR peptide inhibits osteoclastogenesis through two modes of action inhibition of (1) prefusion RANK signaling and (2) cell cell fusion by blocking TRAF6  and Vav3 mediated signaling, respectively.
C1 [Taguchi, Yuu; Kiga, Yoko; Inoue, Jun ichiro] Univ Tokyo, Div Cellular & Mol Biol, Dept Canc Biol, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan.
   [Gohda, Jin] Univ Tokyo, Res Ctr Asian Infect Dis, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan.
C3 University of Tokyo; University of Tokyo
RP Inoue, J (通讯作者)，Univ Tokyo, Div Cellular & Mol Biol, Dept Canc Biol, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan.
EM jun i@ims.u tokyo.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Takeda Science Foundation; Suzuken Memorial Foundation
FX We thank A. Kudo for providing the CMG14 12 cells, N. Yamaguchi and T.
   Akiyama for helpful discussions and A. Nishizawa, K. Shimizu and S.
   Okada for secretarial assistance. This work was supported by
   Grants in Aid for Scientific Research B, Scientific Research on
   Innovative Area (to J.I.), Young Scientists B (to J.G.) and the Global
   COE Program "Center of Education and Research for the Advanced
   Genome Based Medicine for personalized medicine and the control of
   worldwide infectious diseases " (to Y.T.) from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan, and grants
   from the Takeda Science Foundation (to J.I.) and the Suzuken Memorial
   Foundation (to J.G.).
CR Akiyama T, 2008, IMMUNITY, V29, P423, DOI 10.1016/j.immuni.2008.06.015
   Anusaksathien O, 2001, J BIOL CHEM, V276, P22663, DOI 10.1074/jbc.M007104200
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092 8674(00)00126 4
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Elion EA, 2007, CURR PROTOC MOL BIOL, P17
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200
   Gloeckner CJ, 2007, PROTEOMICS, V7, P4228, DOI 10.1002/pmic.200700038
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Hanada R, 2009, NATURE, V462, P505, DOI 10.1038/nature08596
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745
   Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495
   Kim H, 2009, J CLIN INVEST, V119, P813, DOI 10.1172/JCI36809
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kim Y, 2005, J BIOL CHEM, V280, P32905, DOI 10.1074/jbc.M505820200
   Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kosuge M, 2008, BIOCONJUGATE CHEM, V19, P656, DOI 10.1021/bc700289w
   Li H, 2002, AM J PHYSIOL RENAL, V282, pF1020, DOI 10.1152/ajprenal.00291.2001
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Macián F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Marshall JK, 2000, ALIMENT PHARM THER, V14, P1451, DOI 10.1046/j.1365 2036.2000.00864.x
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   OCHMAN H, 1988, GENETICS, V120, P621
   Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074 7613(02)00272 8
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097 2765(04)00236 9
   Taguchi Y, 2009, GENES CELLS, V14, P1331, DOI 10.1111/j.1365 2443.2009.01351.x
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234
   Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203
   Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597
   Wysowski DK, 2005, ARCH INTERN MED, V165, P346, DOI 10.1001/archinte.165.3.346 b
   Xu DR, 2006, J BIOL CHEM, V281, P4678, DOI 10.1074/jbc.M510383200
   Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612
   Yamazaki K, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000387
NR 54
TC 5
Z9 6
U1 0
U2 5
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0914 8779
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD SEP
PY 2012
VL 30
IS 5
BP 543
EP 553
DI 10.1007/s00774 012 0353 5
PG 11
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 002RP
UT WOS:000308551600007
PM 22543819
DA 2025 08 17
ER

PT J
AU Wan, YH
AF Wan, Yihong
TI Bone marrow mesenchymal stem cells: Fat on and blast off by FGF21
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Bone marrow mesenchymal stem cell; Osteoblast; Adipocyte; FGF21; PPAR
   gamma
ID GAMMA; OSTEOCLASTOGENESIS; DIFFERENTIATION; ROSIGLITAZONE; OSTEOBLAST;
   CATENIN; TISSUE; CHONDROCYTES; PROGENITORS; CARTILAGE
AB Bone marrow mesenchymal stem cells (BMMSCs) are multipotent marrow stromal cells with the ability to differentiate into a variety of cell types required for tissue regeneration including osteoblasts and chondrocytes. Thus, they hold tremendous potential as powerful therapeutic strategies for the prevention and treatment of degenerative disorders including osteoporosis and osteoarthritis. The differentiation of BMMSCs into competing lineages such as osteoblasts and marrow adipocytes is regulated by various environmental cues and intrinsic signaling pathways. Here I highlight recent advances in the understanding of BMMSC function and regulation, including the interaction between BMMSCs with the hematopoietic/immune system, and the identification of novel modulators of BMMSC differentiation such as the metabolic hormone fibroblast growth factor 21 (FGF21). These new findings will further elucidate the dynamic regulation of BMMSCs in the pathophysiological control of skeletal homeostasis, and facilitate the clinical applications of BMMSCs in regenerative medicine. (c) 2013 Elsevier Ltd. All rights reserved.
C1 Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center
RP Wan, YH (通讯作者)，Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
EM yihong.wan@utsouthwestern.edu
RI Wan, Yihong/J 8681 2012
FU UT Southwestern Endowed Scholar Startup Fund, CPRIT [RP100841]; NIH
   [RO1DK089113]; March of Dimes [5 FY10 1]; Welch Foundation [I 1751]
FX I thank all the investigators whose studies contributed to the
   understanding of BMMSCs but could not be cited here due to space
   limitation. Y. Wan is a Virginia Murchison Linthicum Scholar in Medical
   Research. This work was supported by the UT Southwestern Endowed Scholar
   Startup Fund, CPRIT (RP100841), NIH (RO1DK089113), March of Dimes
   (#5 FY10 1) and The Welch Foundation (I 1751). I declare that I have no
   financial conflict of interest.
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Bredella MA, 2009, J CLIN ENDOCR METAB, V94, P2129, DOI 10.1210/jc.2008 2532
   Cantó C, 2012, SCIENCE, V336, P675, DOI 10.1126/science.1222646
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dutchak PA, 2012, CELL, V148, P556, DOI 10.1016/j.cell.2011.11.062
   Dy P, 2012, DEV CELL, V22, P597, DOI 10.1016/j.devcel.2011.12.024
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749 6632.2009.05240.x
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Home PD, 2009, LANCET, V373, P2125, DOI 10.1016/S0140 6736(09)60953 3
   Johnson K, 2012, SCIENCE, V336, P717, DOI 10.1126/science.1215157
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kahn SE, 2008, DIABETES CARE, V31, P845, DOI 10.2337/dc07 2270
   Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Potthoff MJ, 2012, GENE DEV, V26, P312, DOI 10.1101/gad.184788.111
   Shen W, 2007, OSTEOPOROSIS INT, V18, P641, DOI 10.1007/s00198 006 0285 9
   Shi C, 2011, IMMUNITY, V34, P590, DOI 10.1016/j.immuni.2011.02.016
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Strotmeyer Elsa S, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P429, DOI 10.1097/MED.0b013e3282f1cba3
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wan YH, 2010, TRENDS ENDOCRIN MET, V21, P722, DOI 10.1016/j.tem.2010.08.006
   Wei W, 2012, P NATL ACAD SCI USA, V109, P3143, DOI 10.1073/pnas.1200797109
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Zinman B, 2010, J CLIN ENDOCR METAB, V95, P134, DOI 10.1210/jc.2009 0572
NR 30
TC 28
Z9 32
U1 2
U2 22
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357 2725
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD MAR
PY 2013
VL 45
IS 3
BP 546
EP 549
DI 10.1016/j.biocel.2012.12.014
PG 4
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 098HL
UT WOS:000315539900005
PM 23270727
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Harigaya, H
   Chiba Ohkuma, R
   Karakida, T
   Yamamoto, R
   Fujii Abe, K
   Kawahara, H
   Yamakoshi, Y
AF Harigaya, Hiroko
   Chiba Ohkuma, Risako
   Karakida, Takeo
   Yamamoto, Ryuji
   Fujii Abe, Keiko
   Kawahara, Hiroshi
   Yamakoshi, Yasuo
TI Potential for Drug Repositioning of Midazolam as an Inhibitor of
   Inflammatory Bone Resorption
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE midazolam; drug repositioning; inflammation; bone resorption; reactive
   oxygen species; signal transduction
ID ACTIVATED PROTEIN KINASE; BIO OSS; OSTEOCLASTOGENESIS; DYSFUNCTION;
   PATHWAY; CELLS; NOX4
AB Drug repositioning is a method for exploring new effects of existing drugs, the safety and pharmacokinetics of which have been confirmed in humans. Here, we demonstrate the potential drug repositioning of midazolam (MDZ), which is used for intravenous sedation, as an inhibitor of inflammatory bone resorption. We cultured a mouse macrophage like cell line with or without MDZ and evaluated its effects on the induction of differentiation of these cells into osteoclasts. For in vivo investigations, we administered lipopolysaccharide (LPS) together with MDZ (LPS+MDZ) to the parietal region of mice and evaluated the results based on the percentage of bone resorption and calvaria volume. Furthermore, we examined the effects of MDZ on the production of reactive oxygen species (ROS) in cells and on its signaling pathway. MDZ inhibited osteoclast differentiation and bone resorption activity. In animal studies, the LPS+MDZ group showed a decreasing trend associated with the rate of bone resorption. In addition, the bone matrix volume in the LPS+MDZ group was slightly higher than in the LPS only group. MDZ inhibited osteoclast differentiation by decreasing ROS production and thereby negatively regulating the p38 mitogen activated protein kinase pathway. Thus, we propose that MDZ could potentially be used for treating inflammatory bone resorption, for example, in periodontal disease.
C1 [Harigaya, Hiroko; Fujii Abe, Keiko; Kawahara, Hiroshi] Tsurumi Univ, Sch Dent Med, Dept Dent Anesthesiol, 2 1 3 Tsurumi,Tsurumi Ku, Yokohama 2308501, Japan.
   [Chiba Ohkuma, Risako; Karakida, Takeo; Yamamoto, Ryuji; Yamakoshi, Yasuo] Tsurumi Univ, Sch Dent Med, Dept Biochem & Mol Biol, 2 1 3 Tsurumi,Tsurumi Ku, Yokohama 2308501, Japan.
C3 Tsurumi University; Tsurumi University
RP Yamakoshi, Y (通讯作者)，Tsurumi Univ, Sch Dent Med, Dept Biochem & Mol Biol, 2 1 3 Tsurumi,Tsurumi Ku, Yokohama 2308501, Japan.
EM pd21008@stu.tsurumi u.ac.jp; chiba r@tsurumi u.ac.jp;
   karakida t@tsurumi u.ac.jp; yamamoto rj@tsurumi u.ac.jp;
   fujii keiko@tsurumi u.ac.jp; kawahara h@tsurumi u.ac.jp;
   yamakoshi y@tsurumi u.ac.jp
OI Yamakoshi, Yasuo/0000 0003 2134 5860
FU JSPS KAKENHI [JP21K09945, JP22K10027]
FX This study was supported by the JSPS KAKENHI, Grant Numbers JP21K09945
   and JP22K10027.
CR Ago T, 2010, CIRC RES, V106, P1253, DOI 10.1161/CIRCRESAHA.109.213116
   Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200
   Chambrone L, 2018, J PERIODONTOL, V89, P783, DOI 10.1902/jop.2017.170172
   Chen SS, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e15583
   Cuetara BLV, 2006, IN VITRO CELL DEV AN, V42, P182, DOI 10.1290/0510075.1
   Feng H, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.544431
   Gavish M, 1999, PHARMACOL REV, V51, P629
   Gerardi D, 2023, J BIOL REG HOMEOS AG, V37, P2357, DOI 10.23812/j.biol.regul.homeost.agents.20233705.232
   Gestrelius S, 2000, Clin Oral Investig, V4, P120, DOI 10.1007/s007840050127
   Guo J, 2014, J DENT RES, V93, P508, DOI 10.1177/0022034514526886
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hammarstrom L, 1997, CIBA F SYMP, V205, P246
   Hayakawa R, 2012, P JPN ACAD B PHYS, V88, P434, DOI 10.2183/pjab.88.434
   Hidaka Y, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030218
   Jensen T, 2012, CLIN ORAL IMPLAN RES, V23, P263, DOI 10.1111/j.1600 0501.2011.02168.x
   Kanzaki H, 2017, FASEB J, V31, P781, DOI 10.1096/fj.201600826R
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Karakida T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030670
   Keil C, 2021, ANN ANAT, V237, DOI 10.1016/j.aanat.2021.151722
   Kitamura M, 2022, REGEN THER, V21, P104, DOI 10.1016/j.reth.2022.06.001
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Kuroda J, 2005, GENES CELLS, V10, P1139, DOI 10.1111/j.1365 2443.2005.00907.x
   Liang PQ, 2022, J INFLAMM LOND, V19, DOI 10.1186/s12950 022 00319 6
   Liu HL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037168
   Luo TT, 2021, MOLECULES, V26, DOI 10.3390/molecules26020347
   Martins JFB, 2021, FOLIA MORPHOL, V80, P972, DOI 10.5603/FM.a2020.0134
   Matsumoto M, 2000, FEBS LETT, V486, P23, DOI 10.1016/S0014 5793(00)02231 6
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Michaud DS, 2017, EPIDEMIOL REV, V39, P49, DOI 10.1093/epirev/mxx006
   Miyawaki T, 2001, CYTOKINE, V15, P320, DOI 10.1006/cyto.2001.0940
   Miyazaki T, 2010, DENT MATER J, V29, P403, DOI 10.4012/dmj.2009 132
   Olkkola K. T., 2008, V182, P335, DOI 10.1007/978 3 540 74806 9_16
   Omi M, 2022, GENESIS, V60, DOI 10.1002/dvg.23490
   Oortgiesen DAW, 2012, J CLIN PERIODONTOL, V39, P546, DOI 10.1111/j.1600 051X.2012.01877.x
   Park WH, 2007, J CELL BIOCHEM, V102, P98, DOI 10.1002/jcb.21280
   Raka RN, 2022, BMC COMPLEMENT MED, V22, DOI 10.1186/s12906 022 03748 1
   Shirakata Y, 2024, CLIN ORAL INVEST, V28, DOI 10.1007/s00784 024 05674 7
   Vermot A, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10060890
   Zhao H, 2016, J MOL CELL CARDIOL, V101, P11, DOI 10.1016/j.yjmcc.2016.10.017
   Zhuang GY, 2021, BIOENGINEERED, V12, P2155, DOI 10.1080/21655979.2021.1932209
NR 40
TC 2
Z9 3
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2024
VL 25
IS 14
AR 7651
DI 10.3390/ijms25147651
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA ZR4H8
UT WOS:001277003800001
PM 39062893
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Joung, YH
   Lim, EJ
   Darvin, P
   Jang, JW
   Park, KD
   Lee, HK
   Kim, HS
   Cho, BW
   Park, T
   Chung, S
   Park, JH
   Yang, YM
AF Joung, Youn Hee
   Lim, Eun Joung
   Darvin, Pramod
   Jang, Ju Woong
   Park, Kyung Do
   Lee, Hak Kyo
   Kim, Heui Soo
   Cho, Byung Wook
   Park, Taekyu
   Chung, Sumi
   Park, Jong Hwan
   Yang, Young Mok
TI Hwanggeumchal sorghum extract enhances BMP7 and GH signaling
   through the activation of Jak2/STAT5B in MC3T3 E1 osteoblastic cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE Hwanggeumchal sorghum extracts; bone morphogenetic protein 7; Janus
   kinase 2; signal transducers and activators of transcription 5B; growth
   hormone; insulin like growth factor 1 receptor; growth hormone receptor;
   osteoblasts
ID BONE MORPHOGENETIC PROTEIN 7; GROWTH FACTOR I; TYROSINE KINASE; HORMONE;
   IDENTIFICATION; PROLIFERATION; STIMULATION; EXPRESSION; JAK2
AB Sorghum is a principal cereal food in a number of parts of the world and is critical in folk medicine in Asia and Africa. However, its effects on bone are unknown. Growth hormone (GH) is a regulator of bone growth and bone metabolism. GH activates several signaling pathways, including the Janus kinase (Jak)/signal transducer and activator of transcription (STAT) pathways, thereby regulating expression of genes, including insulin like growth factor (IGF) 1. Bone morphogenetic proteins (BMPs) induce the differentiation of cells of the osteoblastic lineage, increasing the pool of IGF 1 target cells, the mature osteoblasts. In the present study, the effects of Hwanggeumchal sorghum extracts (HSE) on GH signaling via the Jak/STAT pathway in osteoblasts were investigated. HSE was not observed to be toxic to osteoblastic cells and increased the expression of BMP7 and GH related proteins, including STAT5B, p STAT5B, IGF 1 receptor (IGF 1R), growth receptor hormone (GHR) and Jak2 in MC3T3 E1 cells. In addition, HSE increased BMP7 and GHR mRNA expression in MC3T3 E1 cells. The expression of HSE induced BMP7 and GHR was inhibited by AG490, a Jak2 kinase inhibitor. The observations indicate that HSE induced signaling is similar to GH signaling via the GHR Jak2 signaling axis. Using small interference RNA (siRNA) analysis, STAT5B was found to play an essential role in HSE induced BMP7 and GH signaling in MC3T3 E1 cells. Results of the current study indicate that HSE promotes bone growth through activation of STAT5B.
C1 [Joung, Youn Hee; Lim, Eun Joung; Darvin, Pramod; Yang, Young Mok] Konkuk Univ, Inst Biomed Sci & Technol, Sch Med, Dept Pathol, Seoul 143701, South Korea.
   [Jang, Ju Woong] Korea Bone Bank Co Ltd, Seoul 153782, South Korea.
   [Park, Kyung Do; Lee, Hak Kyo] Hankyong Natl Univ, Genom Informat Ctr, Anseong 456749, South Korea.
   [Kim, Heui Soo] Pusan Natl Univ, Coll Nat Sci, Dept Biol Sci, Pusan 609735, South Korea.
   [Cho, Byung Wook] Pusan Natl Univ, Coll Life Sci, Dept Anim Sci, Pusan 609735, South Korea.
   [Park, Taekyu] Konkuk Univ, Coll Biomed & Hlth Sci, Dept Biotechnol, Chungju 380701, South Korea.
   [Chung, Sumi] Univ Texas Austin, Dept Business, Austin, TX 78712 USA.
   [Park, Jong Hwan] Dongguk Univ, Coll Pharm, Seoul 100715, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Hankyong National
   University; Pusan National University; Pusan National University; Konkuk
   University; University of Texas System; University of Texas Austin;
   Dongguk University
RP Yang, YM (通讯作者)，Konkuk Univ, Inst Biomed Sci & Technol, Sch Med, Dept Pathol, 1 Hwayang Dong, Seoul 143701, South Korea.
EM ymyang@kku.ac.kr
RI ; Darvin, Pramod/M 1730 2019
OI Darvin, Pramod/0000 0003 3746 109X; Kim, Heui Soo/0000 0002 5226 6594; 
FU Fundamental R&D Program for Technology of World Premier Materials;
   Ministry of Trade, Industry Energy [2010 0012318]; Next Generation
   BioGreen 21 Programs, Rural Development Administration, Republic of
   Korea [PJ0081062011]
FX This study was supported by grants from the Fundamental R&D Program for
   Technology of World Premier Materials funded by the Ministry of Trade,
   Industry & Energy (no. 2010 0012318) and was partially supported by the
   Next Generation BioGreen 21 Programs (no. PJ0081062011), Rural
   Development Administration, Republic of Korea.
CR Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545
   ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092 8674(93)90415 M
   Audran M, 2006, JOINT BONE SPINE, V73, P374, DOI 10.1016/j.jbspin.2006.02.004
   Boon MR, 2011, CYTOKINE GROWTH F R, V22, P221, DOI 10.1016/j.cytogfr.2011.08.001
   Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008 5472.CAN 06 2490
   CANALIS E, 1993, ENDOCRINOLOGY, V133, P33, DOI 10.1210/en.133.1.33
   Canalis Ernesto, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P155
   CARTERSU C, 1994, P SOC EXP BIOL MED, V206, P210
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chung IM, 2004, KOREAN SOC CROP SCI, V8, P5
   DiGirolamo DJ, 2007, J BIOL CHEM, V282, P31666, DOI 10.1074/jbc.M705219200
   Gan YJ, 2010, MOL ENDOCRINOL, V24, P644, DOI 10.1210/me.2009 0357
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526
   Huang Y, 2004, MOL ENDOCRINOL, V18, P1471, DOI 10.1210/me.2003 0418
   Joung YH, 2008, INT J ONCOL, V33, P477, DOI 10.3892/ijo_00000030
   Kamath VG, 2004, J CEREAL SCI, V40, P283, DOI 10.1016/j.jcs.2004.08.004
   KASSEM M, 1994, GROWTH REGULAT, V4, P131
   Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359 6101(97)00036 1
   Laflamme C, 2010, ARCH ORAL BIOL, V55, P689, DOI 10.1016/j.archoralbio.2010.06.010
   NILSSON A, 1995, J CLIN ENDOCR METAB, V80, P3483, DOI 10.1210/jc.80.12.3483
   Pak SH, 2012, INT J ONCOL, V41, P161, DOI 10.3892/ijo.2012.1450
   Park JH, 2012, NUTR RES PRACT, V6, P322, DOI 10.4162/nrp.2012.6.4.322
   Park JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040531
   RYDZIEL S, 1994, ENDOCRINOLOGY, V134, P2541, DOI 10.1210/en.134.6.2541
   Salgado AJ, 2004, MACROMOL BIOSCI, V4, P743, DOI 10.1002/mabi.200400026
   SAMPATH TK, 1992, J BIOL CHEM, V267, P20352
   STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626
   Turner CH, 1991, PLOS ONE, V2, P12
   VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793
   Wang SN, 2001, J AM SOC NEPHROL, V12, P2392, DOI 10.1681/ASN.V12112392
   WOZNEY JM, 1990, J CELL SCI, P149
   Zuo C, 2012, OSTEOPOROSIS INT, V23, P1653, DOI 10.1007/s00198 012 1909 x
NR 35
TC 10
Z9 11
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2013
VL 8
IS 3
BP 891
EP 896
DI 10.3892/mmr.2013.1593
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 205RS
UT WOS:000323463100030
PM 23877734
OA Bronze
DA 2025 08 17
ER

PT J
AU Guo, QY
   Yang, J
   Chen, YM
   Jin, X
   Li, ZM
   Wen, XC
   Xia, Q
   Wang, Y
AF Guo, Qiaoyun
   Yang, Jing
   Chen, Yumeng
   Jin, Xin
   Li, Zongmin
   Wen, Xiaochang
   Xia, Qun
   Wang, Yue
TI Salidroside improves angiogenesis osteogenesis coupling by regulating
   the HIF 1α/VEGF signalling pathway in the bone environment
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Salidroside; Angiogenesis; Osteogenesis; Endothelial cells;
   Hypoxia inducible factor 1 alpha (HIF 1 alpha); Vascular endothelial
   growth factor (VEGF)
ID HYPOXIA INDUCIBLE FACTOR; OSTEOBLAST; VEGF; ACTIVATION; MODEL
AB Angiogenesis is essential for bone formation during skeletal development. HIF 1 alpha and the HIF responsive gene VEGF (vascular endothelial growth factor) are reported to be a key mechanism for coupling osteogenesis and angiogenesis. Salidroside (SAL), a major biologically active compound of Rhodiola rosea L., possesses diverse pharmacological effects. However, whether SAL can protect against bone loss via the HIF 1 alpha/VEGF pathway, specifically by inducing angiogenesis osteogenesis coupling in vivo, remains unknown. Therefore, in the present study, we employed primary human umbilical vein endothelial cells (HUVECs) and the permanent EA.hy926 human endothelial cell line to determine the cellular and molecular effects of SAL on vascular endothelial cells and the HIF 1 alpha VEGF signalling pathway in the coupling of angiogenesis osteogenesis. The in vitro study revealed that the HUVECs and EA.hy926 cells treated with conditioned medium from osteoblast cells (MG 63 cells) treated with SAL or treated directly with SAL showed enhanced proliferation, migration and capillary structure formation. However, supplementation with an anti VEGF antibody during the treatment of endothelial cells (ECs) significantly reversed the pro angiogenic effect of SAL. Moreover, SAL upregulated HIF 1 alpha expression and increased its transcriptional activity, consequently upregulating VEGF expression at the mRNA and protein levels. In addition, our in vivo analysis demonstrated that SAL can stimulate endothelial sprouting from metatarsal bones. Thus, our mechanistic study demonstrated that the pro angiogenic effects of SAL involve HIF 1 alpha VEGF signalling by coordinating the coupling of angiogenesis osteogenesis in the bone environment. Therefore, we have discovered an ideal molecule that simultaneously enhances angiogenesis and osteogenesis and thereby accelerates bone healing.
C1 [Guo, Qiaoyun; Wang, Yue] Tianjin Univ Tradit Chinese Med, Sch Integrat Med, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China.
   [Guo, Qiaoyun; Yang, Jing; Li, Zongmin; Wen, Xiaochang; Wang, Yue] Chinese Peoples Armed Police Forces, Dept Pathogen Biol & Immunol, Logist Coll, Tianjin 300309, Peoples R China.
   [Chen, Yumeng] Tianjin Med Univ, Coll Pharm, Tianjin 300070, Peoples R China.
   [Jin, Xin] Chinese Peoples Armed Police Forces, Dept Pharmacol, Logist Coll, Tianjin 300309, Peoples R China.
   [Li, Zongmin] Chinese Peoples Armed Police Forces, Dept Clin Lab, Shanghai Crops Hosp, Shanghai, Peoples R China.
   [Xia, Qun] Chinese Peoples Armed Police Force, Dept Orthopaed, Characterist Med Ctr, 222 Chenglin Rd, Tianjin 300162, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin Medical
   University
RP Wang, Y (通讯作者)，Tianjin Univ Tradit Chinese Med, Sch Integrat Med, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China.; Xia, Q (通讯作者)，Chinese Peoples Armed Police Force, Dept Orthopaed, Characterist Med Ctr, 222 Chenglin Rd, Tianjin 300162, Peoples R China.
EM xiaqun6@163.com; wangyue6808@126.com
RI guo, qiaoyun/HGD 2206 2022
FU National Natural Science Foundation of China [81572852, 81273520,
   81572199]; Program of Science Foundation of Tianjin [18JCZDJC33200,
   19JCYBJC25300]; Program for Science and Technology of Logistics
   University of Chinese People's Armed Police Force [WHB202002, WHJ202013]
FX We thank Andrew L Kung (Dana Farber Cancer Institute, USA) for providing
   pCMVh HA ssHIF 1 alpha and the control pCMVh HA plasmids. This research
   was supported by grants from the National Natural Science Foundation of
   China (grant numbers 81572852, 81273520, and 81572199), the Program of
   Science Foundation of Tianjin (grant numbers 18JCZDJC33200 and
   19JCYBJC25300) and the Program for Science and Technology of Logistics
   University of Chinese People's Armed Police Force (grant numbers
   WHB202002 and WHJ202013).
CR Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Barnes GL, 1999, J BONE MINER RES, V14, P1805, DOI 10.1359/jbmr.1999.14.11.1805
   Biju MP, 2004, MOL CELL BIOL, V24, P9038, DOI 10.1128/MCB.24.20.9038 9047.2004
   Chim SM, 2015, J CELL PHYSIOL, V230, P82, DOI 10.1002/jcp.24684
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092 8674(03)00154 5
   Gaetano S., 2011, J TRANSL MED, V9, P1, DOI [10.1186/1479 5876 9 7, DOI 10.1186/1479 5876 9 7]
   Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050 1738(00)00074 8
   Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086 199810001 00010
   Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068
   Guo XQ, 2017, CELL TISSUE RES, V367, P197, DOI 10.1007/s00441 016 2535 2
   Hausman MR, 2001, BONE, V29, P560, DOI 10.1016/S8756 3282(01)00608 1
   Hu K, 2016, BONE, V91, P30, DOI 10.1016/j.bone.2016.06.013
   Huang J, 2015, MOL MED REP, V12, P5951, DOI 10.3892/mmr.2015.4122
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Irani C, 2002, AM J PHYSIOL LUNG C, V282, pL854, DOI 10.1152/ajplung.00291.2001
   Kai H., 2015, J CLIN INVEST, V126, P509, DOI [10.1172/K182585, DOI 10.1172/K182585]
   Kaushik AP, 2012, WORLD J ORTHOP, V3, P49, DOI 10.5312/wjo.v3.i5.49
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Kigami R, 2013, IMPLANT DENT, V22, P422, DOI 10.1097/ID.0b013e31829d19f0
   Li L, 2016, SCI REP UK, V6, DOI 10.1038/srep32131
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Marenzana M, 2013, BONE RES, V1, P203, DOI 10.4248/BR201303001
   Martine D., 2000, LAB INVEST, V81, P5, DOI [10.1038/labinvest.33780207, DOI 10.1038/1ABINVES1.33780207]
   O'Toole SA, 2003, CANCER DETECT PREV, V27, P47, DOI 10.1016/S0361 090X(02)00171 X
   Qiao JJ, 2019, EXP THER MED, V17, P1884, DOI 10.3892/etm.2018.7115
   Ramasamy SK, 2016, ANNU REV CELL DEV BI, V32, P649, DOI 10.1146/annurev cellbio 111315 124936
   Sacharidou A, 2012, CELLS TISSUES ORGANS, V195, P122, DOI 10.1159/000331410
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551
   Sivaraj KK, 2016, DEVELOPMENT, V143, P2706, DOI 10.1242/dev.136861
   Song WH, 2015, NAT PROTOC, V10, P1459, DOI 10.1038/nprot.2015.097
   Wan L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102010
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Yen ML, 2005, MOL PHARMACOL, V68, P1061, DOI 10.1124/mol.104.010082
   Zhang FJ, 2009, J BONE MINER RES, V24, P1224, DOI [10.1359/jbmr.090204, 10.1359/JBMR.090204]
   Zhao Q, 2012, BONE, V50, P763, DOI 10.1016/j.bone.2011.12.003
   Zhu K, 2013, J BONE MINER RES, V28, P1870, DOI 10.1002/jbmr.1958
   Zhu Y, 2016, MOLECULES, V21, DOI 10.3390/molecules21081033
NR 39
TC 37
Z9 40
U1 1
U2 50
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD OCT 5
PY 2020
VL 884
AR 173394
DI 10.1016/j.ejphar.2020.173394
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA NR9AZ
UT WOS:000571856400005
PM 32730833
DA 2025 08 17
ER

PT J
AU Arumugam, B
   Balagangadharan, K
   Selvamurugan, N
AF Arumugam, B.
   Balagangadharan, K.
   Selvamurugan, N.
TI Syringic acid, a phenolic acid, promotes osteoblast differentiation by
   stimulation of Runx2 expression and targeting of Smad7 by miR 21 in
   mouse mesenchymal stem cells
SO JOURNAL OF CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE Bone; miR 21; Runx2; Smad7; Syringic acid
ID OSTEOGENIC DIFFERENTIATION; BONE FORMATION; TGF BETA; IN VITRO; INHIBITS
   PROLIFERATION; HISTONE DEACETYLASES; HDAC4; PHOSPHORYLATION; MECHANISMS;
   SCAFFOLDS
AB Syringic acid (SA), a phenolic acid, has been used in Chinese and Indian medicine for treating diabetes but its role in osteogenesis has not yet been investigated. In the present study, at the molecular and cellular levels, we evaluated the effects of SA on osteoblast differentiation. At the cellular level, there was increased alkaline phosphatase (ALP) activity and calcium deposition by SA treatment in mouse mesenchymal stem cells (mMSCs). At the molecular level, SA treatment of these cells stimulated expression of Runx2, a bone transcription factor, and of osteoblast differentiation marker genes such as ALP, type I collagen, and osteocalcin. It is known that Smad7 is an antagonist of TGF beta/Smad signaling and is a negative regulator of Runx2. microRNAs (miRNAs) play a key role in the regulation of osteogenesis genes at the post transcriptional level and studies have reported that Smad7 is one of the target genes of miR 21. We found that there was down regulation of Smad7 and up regulation of miR 21 in SA treated mMSCs. We further identified that the 3' untranslated region (UTR) of Smad7 was directly targeted by miR 21 in these cells. Thus, our results suggested that SA promotes osteoblast differentiation via increased expression of Runx2 by miR 21 mediated down regulation of Smad7. Hence, SA may have potential in orthopedic applications.
C1 [Arumugam, B.; Balagangadharan, K.; Selvamurugan, N.] SRM Inst Sci & Technol, Dept Biotechnol, Sch Bioengn, Kattankulathur 603203, Tamil Nadu, India.
C3 SRM Institute of Science & Technology Chennai
RP Selvamurugan, N (通讯作者)，SRM Inst Sci & Technol, Dept Biotechnol, Sch Bioengn, Kattankulathur 603203, Tamil Nadu, India.
EM selvamn2@yahoo.com
RI ; Selvamurugan, Nagarajan/P 7894 2016; Balasubramanian,
   Arumugam/GNW 3988 2022
OI balasubramanian, arumugam/0000 0002 7333 8542; Selvamurugan,
   Nagarajan/0000 0003 3713 1920; 
FU Department of Biotechnology, India [BT/PR7792/MED/30/950/2013,
   BT/PR15014/BRB/10/1481/2016]
FX This work was supported in part by the Department of Biotechnology,
   India (Grant Nos. BT/PR7792/MED/30/950/2013 and
   BT/PR15014/BRB/10/1481/2016 to N. S). We thank Dr. N. Subbarayan for
   advice on statistical analyses.
CR Al Mamun MA, 2015, BIOL RES, V48, DOI [10.1186/s40659 015 0056 1, 10.1186/S40659 015 0056 1]
   Al Obaidi Mazen M Jamil, 2014, ScientificWorldJournal, V2014, P908098, DOI 10.1155/2014/908098
   [Anonymous], 2013, SCI REP
   Arumugam B, 2017, J CELL PHYSL, DOI [10.1002/jcp, DOI 10.1002/JCP]
   Auh QS, 2016, ONCOTARGET, V7, P78320, DOI 10.18632/oncotarget.12460
   Baselga Escudero L, 2014, NUCLEIC ACIDS RES, V42, P882, DOI 10.1093/nar/gkt1011
   Bir FD, 2017, EUR J MED GENET, V60, P163, DOI 10.1016/j.ejmg.2016.12.007
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Boudin E, 2017, EUR J ENDOCRINOL, V177, pR69, DOI 10.1530/EJE 16 0990
   Bradley EW, 2015, PHYSIOL REV, V95, P1359, DOI 10.1152/physrev.00004.2015
   Cardoso BM, 2010, CLIN DYSMORPHOL, V19, P150, DOI 10.1097/MCD.0b013e32833593a1
   Carpio LR, 2017, CONNECT TISSUE RES, V58, P27, DOI 10.1080/03008207.2016.1236088
   Carpio LR, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926 016 0602 z
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Choi YH, 2018, J CELL BIOCHEM, V119, P748, DOI 10.1002/jcb.26238
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Dai J, 2013, INT J BIOL SCI, V9, P1089, DOI 10.7150/ijbs.7367
   Dhivya S, 2015, J NANOBIOTECHNOL, V13, DOI 10.1186/s12951 015 0099 z
   Du K, 2017, EUR J CELL BIOL, P30102
   Dudaric L, 2015, FOOD RES INT, V77, P290, DOI 10.1016/j.foodres.2015.10.017
   Eliseev RA, 2006, EXP CELL RES, V312, P40, DOI 10.1016/j.yexcr.2005.09.016
   Fan JZ, 2015, BRAZ J MED BIOL RES, V48, P637, DOI [10.1590/1414 431X20154494, 10.1590/1414 431x20154494]
   Fang SJ, 2015, INT J MOL SCI, V16, P8227, DOI 10.3390/ijms16048227
   Feng YY, 2016, J MOL ENDOCRINOL, V56, P189, DOI 10.1530/JME 15 0264
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gaoli Xu, 2017, Hua Xi Kou Qiang Yi Xue Za Zhi, V35, P275, DOI 10.7518/hxkq.2017.03.009
   Gu QL, 2012, PHARMACOGN MAG, V8, P202, DOI 10.4103/0973 1296.99285
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   Guo AJ, 2012, CHIN MED UK, V7, DOI 10.1186/1749 8546 7 10
   Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972
   Horbelt D, 2012, INT J BIOCHEM CELL B, V44, P469, DOI 10.1016/j.biocel.2011.12.013
   Hsu YL, 2009, MOL NUTR FOOD RES, V53, P1452, DOI 10.1002/mnfr.200800483
   Hu ZB, 2015, SCI REP UK, V5, DOI 10.1038/srep18655
   Hug BA, 2004, CELL, V119, P448, DOI 10.1016/j.cell.2004.10.023
   Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075
   Iwai T, 2008, J BIOL CHEM, V283, P27154, DOI 10.1074/jbc.M801175200
   Javed A, 2009, CELLS TISSUES ORGANS, V189, P133, DOI 10.1159/000151719
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Jia J, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.43
   Jung YJ, 2018, J CELL BIOCHEM, V119, P1152, DOI 10.1002/jcb.26283
   Kamiya Y, 2010, J BIOL CHEM, V285, P30804, DOI 10.1074/jbc.M110.166140
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Kim KM, 2012, J BONE MINER RES, V27, P1669, DOI 10.1002/jbmr.1604
   Kim YJ, 2006, BIOCHEM PHARMACOL, V72, P1268, DOI 10.1016/j.bcp.2006.08.021
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kumar JP, 2014, J BIOMED NANOTECHNOL, V10, P970, DOI 10.1166/jbn.2014.1808
   La S, 2013, FASEB J, P862
   Leena RS, 2017, COLLOID SURFACE B, V158, P308, DOI 10.1016/j.colsurfb.2017.06.048
   Lóotoing L, 2014, MOL NUTR FOOD RES, V58, P1239, DOI 10.1002/mnfr.201300836
   Li J, 2016, INT J MOL MED, V37, P901, DOI 10.3892/ijmm.2016.2490
   Li N, 2014, BONE, V67, P46, DOI 10.1016/j.bone.2014.06.033
   Li QL, 2017, Int J Nurs Sci, V4, P12, DOI [10.3390/ijms18050977, 10.1016/j.ijnss.2016.12.001]
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Lin L, 2014, MOL MED REP, V10, P707, DOI 10.3892/mmr.2014.2312
   Ling M, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578 017 0154 6
   Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035
   Lou Y, 2009, HUM MOL GENET, V18, P556, DOI 10.1093/hmg/ddn383
   Luo H, 2017, INT J MOL MED, V39, P1046, DOI 10.3892/ijmm.2017.2918
   McClelland AD, 2015, CLIN SCI, V129, P1237, DOI 10.1042/CS20150427
   Milenkovic D, 2012, PLOS ONE, V7, P156, DOI 10.1371/journal.pone.0029837
   Moorthi A, 2013, INT J BIOL MACROMOL, V56, P181, DOI 10.1016/j.ijbiomac.2013.02.017
   Muthukumaran J, 2013, J ACUTE DIS, V2, P304, DOI 10.1016/S2221 6189(13)60149 3
   Muthusami S, 2011, J CELL BIOCHEM, V112, P1035, DOI 10.1002/jcb.23016
   Nakashima Tomoki, 2016, Clin Calcium, V26, P1685
   Obri A, 2014, J CELL BIOL, V205, P771, DOI 10.1083/jcb.201403138
   Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914 017 0381 0
   Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498
   Parasramka MA, 2012, MOL CARCINOGEN, V51, P213, DOI 10.1002/mc.20822
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rinkel J, 2017, CHEM EUR J, V23, P10501, DOI 10.1002/chem.201702704
   Sainitya R, 2015, INT J BIOL MACROMOL, V80, P481, DOI 10.1016/j.ijbiomac.2015.07.016
   Santangelo Carmela, 2007, Ann Ist Super Sanita, V43, P394
   Saravanan S, 2017, INT J BIOL MACROMOL, V104, P1975, DOI 10.1016/j.ijbiomac.2017.01.034
   Saravanan S, 2015, J BIOMED NANOTECHNOL, V11, P1124, DOI 10.1166/jbn.2015.2057
   Selvamurugan N, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/2450327
   Selvarnurugan N, 2007, J ORTHOP RES, V25, P1213, DOI 10.1002/jor.20409
   Sera SR, 2017, CURR OSTEOPOROS REP, V20, P1
   Shibata A, 2016, MUTAGENESIS, V31, P61, DOI 10.1093/mutage/gev057
   Shimazu J, 2016, CELL REP, V15, P27, DOI 10.1016/j.celrep.2016.03.003
   Shimizu E, 2014, J BIOL CHEM, V289, P21340, DOI 10.1074/jbc.M114.550699
   Shimizu E, 2010, J BIOL CHEM, V285, P9616, DOI 10.1074/jbc.M109.094862
   Singh KB, 2017, BRIT J NUTR, V117, P1511, DOI 10.1017/S0007114517001556
   Sowjanya JA, 2013, COLLOID SURFACE B, V109, P294, DOI 10.1016/j.colsurfb.2013.04.006
   Stevens MM, 2008, MATER TODAY, V11, P18, DOI 10.1016/S1369 7021(08)70086 5
   Sun XY, 2016, MUTAGENESIS, V31, P677, DOI 10.1093/mutage/gew039
   Tang XL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179860
   Tou JC, 2015, BBA MOL BASIS DIS, V1852, P1186, DOI 10.1016/j.bbadis.2014.10.003
   Trzeciakiewicz A, 2010, J NUTR BIOCHEM, V21, P424, DOI 10.1016/j.jnutbio.2009.01.017
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Valcourt U, 2002, J BIOL CHEM, V277, P33545, DOI 10.1074/jbc.M202086200
   Vimalraj S, 2016, INT J BIOL MACROMOL, V93, P1457, DOI 10.1016/j.ijbiomac.2015.12.083
   Vimalraj S, 2015, INT J BIOL MACROMOL, V79, P490, DOI 10.1016/j.ijbiomac.2015.05.017
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Vimalraj S, 2014, J CELL PHYSIOL, V229, P1236, DOI 10.1002/jcp.24557
   Vimalraj S, 2014, INT J BIOL MACROMOL, V66, P194, DOI 10.1016/j.ijbiomac.2014.02.030
   Vimalraj S, 2013, CURR ISSUES MOL BIOL, V15, P7
   Vishal M, 2017, INT J BIOL MACROMOL, V99, P608, DOI 10.1016/j.ijbiomac.2017.03.021
   Vishal M, 2017, J CELL PHYSIOL, V232, P371, DOI 10.1002/jcp.25434
   Vishal M, 2016, CURR PROTEIN PEPT SC, V17, P343, DOI 10.2174/1389203716666150623104017
   Wang JY, 2014, MOL CELL ENDOCRINOL, V392, P163, DOI 10.1016/j.mce.2014.05.018
   Wang ZK, 2014, EPIGENOMICS UK, V6, P139, DOI 10.2217/epi.13.73
   Wei BF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169097
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Wei Xiaoyong, 2012, Evid Based Complement Alternat Med, V2012, P426537, DOI 10.1155/2012/426537
   Westendorf JJ, 2006, J CELL BIOCHEM, V98, P54, DOI 10.1002/jcb.20805
   Wissing MD, 2015, CURR OSTEOPOROS REP, V13, P140, DOI 10.1007/s11914 015 0266 z
   Wu T, 2017, INT J MOL MED, V39, P984, DOI 10.3892/ijmm.2017.2906
   Xiao HH, 2014, J STEROID BIOCHEM, V144, P382, DOI 10.1016/j.jsbmb.2014.08.002
   Xu WA, 2017, BMC MED GENET, V18, DOI 10.1186/s12881 017 0375 x
   Yan JH, 2016, BIOCHEM BIOPH RES CO, V470, P498, DOI 10.1016/j.bbrc.2016.01.133
   Yan XH, 2016, J BIOL CHEM, V291, P382, DOI 10.1074/jbc.M115.694281
   Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018
   Yang F, 2016, PARASITOL INT, V65, P308, DOI 10.1016/j.parint.2016.03.001
   Yano M, 2012, ENDOCR J, V59, P653, DOI 10.1507/endocrj.EJ12 0022
   Yoshizuka M, 2016, J ORTHOP SCI, V21, P852, DOI 10.1016/j.jos.2016.07.021
   Zeng L, 2017, MUTAGENESIS, V32, P437, DOI 10.1093/mutage/gex012
   Zeng Y, 2012, FEBS LETT, V586, P2375, DOI 10.1016/j.febslet.2012.05.049
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhang NW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114241
   Zhang XL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181653
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zhao ZR, 2005, MOL THER, V12, P247, DOI 10.1016/j.ymthe.2005.03.009
   Zhou C, 2014, CELL PROLIFERAT, V47, P124, DOI 10.1111/cpr.12097
   Zhou YN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129605
   Zuo B, 2015, J BONE MINER RES, V30, P330, DOI 10.1002/jbmr.2352
NR 126
TC 53
Z9 57
U1 1
U2 23
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1873 9601
EI 1873 961X
J9 J CELL COMMUN SIGNAL
JI J. Cell Commun. Signal
PD SEP
PY 2018
VL 12
IS 3
BP 561
EP 573
DI 10.1007/s12079 018 0449 3
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HC7GK
UT WOS:000451968600006
PM 29350343
OA Green Published
DA 2025 08 17
ER

PT J
AU Zhou, Y
   Hu, GY
AF Zhou, Yue
   Hu, Guangyao
TI M2 macrophages derived exosomes regulate osteoclast differentiation by
   the CSF2/TNF α axis
SO BMC ORAL HEALTH
LA English
DT Article
DE Exosomes; M2 macrophages; Osteoclast differentiation; CSF2; TNF alpha
ID BONE; INFLAMMATION; EXPRESSION; THERAPY
AB Background Osteoclast mediated bone resorption cause bone loss in several bone diseases. Exosomes have been reported to regulate osteoclast differentiation. M2 polarized macrophages exhibit anti inflammatory activity. This study aimed to explore the effect of exosomes from M2 polarized macrophages (M2 exos) on osteoclastogenesis and molecular mechanisms.Methods M2 exos were isolated from IL 4 induced Raw264.7 cells (M2 macrophages) and used to treat osteoclasts (RANKL induced Raw264.7 cells). Osteoclast differentiation was visualized using tartrate resistant acid phosphatase staining. Quantitative real time PCR (qPCR) was conducted to measure the levels of osteoclastogenesis related genes. The underlying mechanisms of M2 exos were evaluated using qPCR and western blotting.Results M2 exos suppressed osteoclast differentiation induced by RANKL. Additionally, CSF2 was highly expressed in M2 macrophages, and knockdown of CSF2 further enhanced the effects of M2 exos on osteoclast differentiation. Moreover, CSF2 positively regulated TNF alpha signaling, which inhibition promoted differentiation of M2 exo treated osteoclasts.Conclusion M2 exos inhibited RANKL induced osteoclast differentiation by downregulating the CSF2 expression through inactivating the TNF alpha signaling, suggesting the potential application of exosomes in bone disease therapy.
C1 [Zhou, Yue; Hu, Guangyao] Beihua Univ, Affiliated Hosp, Dept Stomatol, Bldg 7,Risheng Rd, Jilin 132011, Jilin, Peoples R China.
C3 Beihua University
RP Hu, GY (通讯作者)，Beihua Univ, Affiliated Hosp, Dept Stomatol, Bldg 7,Risheng Rd, Jilin 132011, Jilin, Peoples R China.
EM huguangyao2023@163.com
FU Jilin Provincial Department of Education Science Research Project
FX Not applicable.
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071
   Chen XT, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01314 y
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gallo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030679
   Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356
   Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Li H, 2022, J CONTROL RELEASE, V341, P16, DOI 10.1016/j.jconrel.2021.11.019
   Li MY, 2021, REGEN BIOMATER, V8, DOI 10.1093/rb/rbab027
   Liao XM, 2022, BMC ORAL HEALTH, V22, DOI 10.1186/s12903 022 02682 5
   Lin YC, 2017, MOL IMMUNOL, V83, P82, DOI 10.1016/j.molimm.2017.01.009
   Liu CB, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018 017 0510 6
   Lu JS, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02512 z
   Luo XT, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.908859
   Ma J, 2023, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.929690
   Magnusson LU, 2016, PROSTATE, V76, P383, DOI 10.1002/pros.23133
   Nakao Y, 2021, ACTA BIOMATER, V122, P306, DOI 10.1016/j.actbio.2020.12.046
   Oishi Y, 2018, INT IMMUNOL, V30, P511, DOI 10.1093/intimm/dxy054
   Orlandi M, 2020, PERIODONTOL 2000, V83, P107, DOI 10.1111/prd.12299
   Oton Gonzalez L, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031500
   Sadek KM, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24054599
   Song X, 2022, PEERJ, V10, DOI 10.7717/peerj.13442
   Umeda JE, 2012, MOL ORAL MICROBIOL, V27, P23, DOI 10.1111/j.2041 1014.2011.00629.x
   Wang TT, 2020, CURR DRUG TARGETS, V21, P213, DOI 10.2174/1389450120666190821161259
   Wang WP, 2022, J PERIODONTAL RES, V57, P891, DOI 10.1111/jre.13027
   Wasti Jyoti, 2021, Indian J Dent Res, V32, P187, DOI 10.4103/ijdr.IJDR_227_20
   Wu LC, 2017, J CELL BIOCHEM, V118, P1308, DOI 10.1002/jcb.25672
   Yu LJ, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12056
   Yuan DF, 2017, BIOMATERIALS, V142, P1, DOI 10.1016/j.biomaterials.2017.07.011
   Yue Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/1585306
   Zhang X, 2021, J EVID BASED DENT PR, V21, DOI 10.1016/j.jebdp.2021.101528
   Zhang Y, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 021 00150 4
   Zhang ZY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.896745
   Zhao MY, 2021, ARCH ORAL BIOL, V132, DOI 10.1016/j.archoralbio.2021.105263
   Zheng Ting, 2017, J Bone Metab, V24, P207, DOI 10.11005/jbm.2017.24.4.207
   Zheng T, 2014, EUR J PHARMACOL, V737, P185, DOI 10.1016/j.ejphar.2014.04.047
   Zheng Y, 2019, J CELL PHYSIOL, V234, P20662, DOI 10.1002/jcp.28671
   Zhu LJ, 2010, J RHEUMATOL, V37, P1658, DOI 10.3899/jrheum.091123
   Zou JL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.757674
   Zou W, 2001, J CELL BIOCHEM, V83, P70, DOI 10.1002/jcb.1202
   Zuo CJ, 2018, ONCOTARGET, V9, P4833, DOI 10.18632/oncotarget.23373
NR 42
TC 8
Z9 8
U1 6
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472 6831
J9 BMC ORAL HEALTH
JI BMC Oral Health
PD JAN 18
PY 2024
VL 24
IS 1
AR 107
DI 10.1186/s12903 023 03842 x
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA FJ5U0
UT WOS:001145414800005
PM 38238696
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Du, JH
   Liu, YL
   Wu, XL
   Sun, JR
   Shi, JF
   Zhang, HM
   Zheng, A
   Zhou, ML
   Jiang, XQ
AF Du, Jiahui
   Liu, Yili
   Wu, Xiaolin
   Sun, Jinrui
   Shi, Junfeng
   Zhang, Hongming
   Zheng, Ao
   Zhou, Mingliang
   Jiang, Xinquan
TI BRD9 mediated chromatin remodeling suppresses osteoclastogenesis through
   negative feedback mechanism
SO NATURE COMMUNICATIONS
LA English
DT Article
ID DIFFERENTIATION; COMPLEX; FOXP1; COMMITMENT; DISEASE; BRD4; BETA
AB Bromodomain containing protein 9 (BRD9), a component of non canonical BAF chromatin remodeling complex, has been identified as a critical therapeutic target in hematological diseases. Despite the hematopoietic origin of osteoclasts, the role of BRD9 in osteoclastogenesis and bone diseases remains unresolved. Here, we show Brd9 deficiency in myeloid lineage enhances osteoclast lineage commitment and bone resorption through downregulating interferon beta (IFN beta) signaling with released constraint on osteoclastogenesis. Notably, we show that BRD9 interacts with transcription factor FOXP1 activating Stat1 transcription and IFN beta signaling thereafter. Besides, function specificity of BRD9 distinguished from BRD4 during osteoclastogenesis has been evaluated. Leveraging advantages of pharmacological modulation of BRD9 and flexible injectable silk fibroin hydrogel, we design a local deliver system for effectively mitigating zoledronate related osteonecrosis of the jaw and alleviating acute bone loss in lipopolysaccharide induced localized aggressive periodontitis. Overall, these results demonstrate the function of BRD9 in osteoclastogenesis and its therapeutic potential for bone diseases. Osteoclast differentiation is critical for bone homeostasis. The authors show the negative feedback regulation of BRD9 mediated chromatin remodeling on osteoclastogenesis via interferon beta signaling and its therapeutic potential for bone diseases.
C1 [Du, Jiahui; Liu, Yili; Wu, Xiaolin; Sun, Jinrui; Shi, Junfeng; Zhang, Hongming; Zheng, Ao; Zhou, Mingliang; Jiang, Xinquan] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Prosthodont, Sch Med, Shanghai 200011, Peoples R China.
   [Du, Jiahui; Liu, Yili; Wu, Xiaolin; Sun, Jinrui; Shi, Junfeng; Zhang, Hongming; Zheng, Ao; Zhou, Mingliang; Jiang, Xinquan] Shanghai Jiao Tong Univ, Coll Stomatol, Shanghai 200011, Peoples R China.
   [Du, Jiahui; Liu, Yili; Wu, Xiaolin; Sun, Jinrui; Shi, Junfeng; Zhang, Hongming; Zheng, Ao; Zhou, Mingliang; Jiang, Xinquan] Shanghai Res Inst Stomatol, Natl Ctr Stomatol, Shanghai Engn Res Ctr Adv Dent Technol & Mat, Natl Clin Res Ctr Oral Dis,Shanghai Key Lab Stoma, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Zhou, ML; Jiang, XQ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Prosthodont, Sch Med, Shanghai 200011, Peoples R China.; Zhou, ML; Jiang, XQ (通讯作者)，Shanghai Jiao Tong Univ, Coll Stomatol, Shanghai 200011, Peoples R China.; Zhou, ML; Jiang, XQ (通讯作者)，Shanghai Res Inst Stomatol, Natl Ctr Stomatol, Shanghai Engn Res Ctr Adv Dent Technol & Mat, Natl Clin Res Ctr Oral Dis,Shanghai Key Lab Stoma, Shanghai 200011, Peoples R China.
EM mingliangzhou@aliyun.com; xinquanjiang@aliyun.com
RI Zheng, Ao/ABG 6623 2020; Zhang, Hongming/ABF 8690 2021; du,
   jiahui/HPC 5938 2023; Zhou, Mingliang/HPC 0298 2023
OI Zhou, Mingliang/0000 0003 4375 3312; Du, Jiahui/0000 0003 3238 0469;
   Jiang, xinquan/0000 0002 1490 281X; 
FU National Natural Science Foundation of China [82201004, 81921002,
   82130027]; Shanghai Pujiang Program [2021PKD033]; innovative research
   team of high level local universities in Shanghai [SHSMU ZLCX20212400]
FX This work was sponsored by funding from the National Natural Science
   Foundation of China (82201004 to J.D., 81921002 to X.J., 82130027 to
   X.J.), Shanghai Pujiang Program (2021PKD033 to J.D.) and the innovative
   research team of high level local universities in Shanghai
   (SHSMU ZLCX20212400 to X.J.). We thank for the sequencing and analysis
   service provided by Shanghai LUOXI Healthcare Technology Co., Ltd. and
   Shanghai Personal Biotechnology Co., Ltd., China.
CR Ahmed NS, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2110812119
   Alfert A, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072 019 0264 y
   Alpsoy A, 2021, CANCER RES, V81, P820, DOI 10.1158/0008 5472.CAN 20 1417
   Alver BH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14648
   An E, 2014, MOL CELL PROTEOMICS, V13, P2687, DOI 10.1074/mcp.M113.034371
   Anesi A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194925
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335
   Baud'huin M, 2017, BONE, V94, P10, DOI 10.1016/j.bone.2016.09.020
   Bi YM, 2010, AM J PATHOL, V177, P280, DOI 10.2353/ajpath.2010.090592
   Börold J, 2021, EMBO REP, V22, DOI 10.15252/embr.202152823
   Braccioli L, 2017, STEM CELL REP, V9, P1530, DOI 10.1016/j.stemcr.2017.10.012
   Brien GL, 2018, ELIFE, V7, DOI 10.7554/eLife.41305
   Caputo VS, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2020.101989
   Chandler RL, 2013, MOL CELL BIOL, V33, P265, DOI 10.1128/MCB.01008 12
   Choudhary C, 2014, NAT REV MOL CELL BIO, V15, P536, DOI 10.1038/nrm3841
   Del Gaudio N, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1570 9
   Devaiah BN, 2016, NAT STRUCT MOL BIOL, V23, P540, DOI 10.1038/nsmb.3228
   Du JH, 2019, J DENT RES, V98, P930, DOI 10.1177/0022034519854704
   Du JH, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108964
   Gatchalian J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07528 9
   Han L, 2018, BLOOD, V132, DOI 10.1182/blood 2018 99 117993
   Inoue K, 2014, J BONE MINER RES, V29, P1823, DOI 10.1002/jbmr.2229
   Irie A, 2017, SCI REP UK, V7, DOI 10.1038/srep46715
   Kodric K, 2019, EXP MOL MED, V51, DOI 10.1038/s12276 019 0294 3
   Konopacki C, 2019, NAT IMMUNOL, V20, P232, DOI 10.1038/s41590 018 0291 z
   Lamoureux F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4511
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li HJ, 2017, J CLIN INVEST, V127, P1241, DOI 10.1172/JCI89511
   Liu BB, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2109133119
   Liu XM, 2022, HEART FAIL REV, V27, P345, DOI 10.1007/s10741 020 09992 2
   Liu Y, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03939 7
   Liu ZX, 2022, BIOCHEM BIOPH RES CO, V591, P124, DOI 10.1016/j.bbrc.2021.11.036
   Morgado Pascual JL, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01315
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Mair NK, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 19648 w
   Makin S, 2022, NATURE, V609, pS41, DOI 10.1038/d41586 022 02860 z
   Mashtalir N, 2020, CELL, V183, P802, DOI 10.1016/j.cell.2020.09.051
   McComb S, 2014, P NATL ACAD SCI USA, V111, pE3206, DOI 10.1073/pnas.1407068111
   Noma K, 2022, CLIN MICROBIOL INFEC, V28, P1429, DOI 10.1016/j.cmi.2022.03.004
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Place DE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20807 8
   Qiao W, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30195 w
   Remillard D, 2017, ANGEW CHEM INT EDIT, V56, P5738, DOI 10.1002/anie.201611281
   Rockwood DN, 2011, NAT PROTOC, V6, P1612, DOI 10.1038/nprot.2011.379
   Seeliger C, 2015, EUR J MED RES, V20, DOI 10.1186/s40001 014 0074 4
   Shi C, 2008, BLOOD, V112, P4699, DOI 10.1182/blood 2008 01 137018
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Stratton MS, 2016, CELL REP, V16, P1366, DOI 10.1016/j.celrep.2016.06.074
   Sun GJ, 2013, EUR REV MED PHARMACO, V17, P1
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   Theodoulou NH, 2016, J MED CHEM, V59, P1425, DOI 10.1021/acs.jmedchem.5b00256
   Wang L, 2021, P NATL ACAD SCI USA, V118, DOI [10.1073/pnas.2109517118|1of9, 10.1073/pnas.2109517118]
   Wang LF, 2021, CELL SIGNAL, V78, DOI 10.1016/j.cellsig.2020.109847
   Wang XF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09891 7
   Wei Z, 2018, CELL, V173, P1135, DOI 10.1016/j.cell.2018.04.013
   Weisberg E, 2022, BLOOD CANCER J, V12, DOI 10.1038/s41408 022 00704 7
   Yasui T, 2011, J BONE MINER RES, V26, P2665, DOI 10.1002/jbmr.464
   Yi SJ, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00145 1
   Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145
   Yuasa K, 2016, GENES CELLS, V21, P25, DOI 10.1111/gtc.12316
   ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092 8674(93)90662 A
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 9 r137
   Zhao HX, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34574 6
   Zhu WW, 2019, FASEB J, V33, P5208, DOI 10.1096/fj.201801791RR
NR 67
TC 27
Z9 27
U1 5
U2 90
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR 14
PY 2023
VL 14
IS 1
AR 1413
DI 10.1038/s41467 023 37116 5
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA Q1NE3
UT WOS:001055247000009
PM 36918560
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Moreno, C
   Bybee, E
   Freitas, CMT
   Pickett, BE
   Weber, KS
AF Moreno, Carlos
   Bybee, Ellie
   Freitas, Claudia M. Tellez
   Pickett, Brett E.
   Weber, K. Scott
TI Meta Analysis of Two Human RNA seq Datasets to Determine Periodontitis
   Diagnostic Biomarkers and Drug Target Candidates
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE periodontitis; RNA seq; diagnostic; biomarker; chronic; inflammation;
   drug; target; SPIA; gingiva
ID MEDICATION RELATED OSTEONECROSIS; OSTEOCLAST LIKE CELLS; CD4(+) T CELLS;
   SIGNALING PATHWAY; DOUBLE BLIND; DENDRITIC CELLS; BONE LOSS; INTERFERON;
   JAW; ACTIVATION
AB Periodontitis is a chronic inflammatory oral disease that affects approximately 42% of adults 30 years of age or older in the United States. In response to microbial dysbiosis within the periodontal pockets surrounding teeth, the host immune system generates an inflammatory environment in which soft tissue and alveolar bone destruction occur. The objective of this study was to identify diagnostic biomarkers and the mechanistic drivers of inflammation in periodontitis to identify drugs that may be repurposed to treat chronic inflammation. A meta analysis comprised of two independent RNA seq datasets was performed. RNA seq analysis, signal pathway impact analysis, protein protein interaction analysis, and drug target analysis were performed to identify the critical pathways and key players that initiate inflammation in periodontitis as well as to predict potential drug targets. Seventy eight differentially expressed genes, 10 significantly impacted signaling pathways, and 10 hub proteins in periodontal gingival tissue were identified. The top 10 drugs that may be repurposed for treating periodontitis were then predicted from the gene expression and pathway data. The efficacy of these drugs in treating periodontitis has yet to be investigated. However, this analysis indicates that these drugs may serve as potential therapeutics to treat inflammation in gingival tissue affected by periodontitis.
C1 [Moreno, Carlos; Bybee, Ellie; Pickett, Brett E.; Weber, K. Scott] Brigham Young Univ, Dept Microbiol & Mol Biol, Provo, UT 84602 USA.
   [Freitas, Claudia M. Tellez] Roseman Univ Hlth Sci, Coll Dent Med, South Jordan Campus, South Jordan, UT 84095 USA.
C3 Brigham Young University
RP Weber, KS (通讯作者)，Brigham Young Univ, Dept Microbiol & Mol Biol, Provo, UT 84602 USA.
EM carlosmoreno943@gmail.com; ellie@bybeemail.com; cfreitas@roseman.edu;
   brett_pickett@byu.edu; scott_weber@byu.edu
RI Pickett, Brett/AAE 3582 2020; Weber, Scott/O 1022 2014; Freitas,
   Claudia/KSS 0817 2024
OI Weber, Scott/0000 0003 3688 2191; Moreno, Carlos
   Mauricio/0000 0003 1688 4990; Tellez Freitas, Claudia
   M./0000 0002 9218 3021; Pickett, Brett/0000 0001 7930 8160
CR Aevermann BD, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.33
   Aljohani S, 2017, J CRANIO MAXILL SURG, V45, P1493, DOI 10.1016/j.jcms.2017.05.028
   Altmäe S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10098 3
   Arimatsu K, 2014, SCI REP UK, V4, DOI 10.1038/srep04828
   Atarashi K, 2017, SCIENCE, V358, P359, DOI 10.1126/science.aan4526
   Bagan J, 2016, ORAL DIS, V22, P324, DOI 10.1111/odi.12447
   Baker PJ, 1999, INFECT IMMUN, V67, P2804, DOI 10.1128/IAI.67.6.2804 2809.1999
   Bartold PM, 2010, PERIODONTOL 2000, V53, P55, DOI 10.1111/j.1600 0757.2010.00347.x
   Batten M, 2010, J EXP MED, V207, P2895, DOI 10.1084/jem.20100064
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Botelho J, 2022, J PERIODONTOL, V93, P373, DOI 10.1002/JPER.21 0111
   Bui FQ, 2019, BIOMED J, V42, P27, DOI 10.1016/j.bj.2018.12.001
   Cardoso EM, 2018, POSTGRAD MED, V130, P98, DOI 10.1080/00325481.2018.1396876
   Chen MY, 2009, EUR J IMMUNOL, V39, P2525, DOI 10.1002/eji.200838879
   Chen M, 2020, BMC ORAL HEALTH, V20, DOI 10.1186/s12903 020 01266 5
   Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752 0509 8 S4 S11
   Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200
   Chou WC, 2006, BLOOD, V108, P3005, DOI 10.1182/blood 2006 05 024430
   Cui WG, 2011, IMMUNITY, V35, P792, DOI 10.1016/j.immuni.2011.09.017
   D'Amico A, 2003, J EXP MED, V198, P293, DOI 10.1084/jem.20030107
   da Silva HB, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/202816
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   de Andrade KQ, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/7241312
   de Molon RS, 2018, MICROSC RES TECHNIQ, V81, P1412, DOI 10.1002/jemt.23101
   Diniz Freitas M, 2018, J CLIN PERIODONTOL, V45, P570, DOI 10.1111/jcpe.12882
   Dutzan N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0797
   Dutzan N, 2016, JOVE J VIS EXP, DOI 10.3791/53736
   Edan G, 2014, J NEUROL NEUROSUR PS, V85, P1183, DOI 10.1136/jnnp 2013 306222
   Eke PI, 2018, J AM DENT ASSOC, V149, P576, DOI 10.1016/j.adaj.2018.04.023
   Esashi E, 2008, IMMUNITY, V28, P509, DOI 10.1016/j.immuni.2008.02.013
   Fagard RH, 1996, J HYPERTENS, V14, pS9, DOI 10.1097/00004872 199609002 00004
   Flint SM, 2015, CURR PHARM DESIGN, V21, P2225, DOI 10.2174/1381612821666150313130256
   FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092 8674(95)90534 0
   Gadani SP, 2012, J IMMUNOL, V189, P4213, DOI 10.4049/jimmunol.1202246
   Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181
   Graves D, 2008, J PERIODONTOL, V79, P1585, DOI 10.1902/jop.2008.080183
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hajishengallis G, 2021, NAT REV IMMUNOL, V21, P426, DOI 10.1038/s41577 020 00488 6
   Hajishengallis G, 2012, NAT REV MICROBIOL, V10, P717, DOI 10.1038/nrmicro2873
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Heo YA, 2020, DRUGS, V80, P1477, DOI 10.1007/s40265 020 01380 2
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Hillmer EJ, 2016, CYTOKINE GROWTH F R, V31, P1, DOI 10.1016/j.cytogfr.2016.05.001
   Ho IC, 2016, ADV EXP MED BIOL, V941, P31, DOI 10.1007/978 94 024 0921 5_3
   Holt SC, 2005, PERIODONTOL 2000, V38, P72, DOI 10.1111/j.1600 0757.2005.00113.x
   HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914
   HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065
   Kaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307
   Kappos L, 2006, NEUROLOGY, V67, P1242, DOI 10.1212/01.wnl.0000237641.33768.8d
   Kieseier BC, 2011, CNS DRUGS, V25, P491, DOI 10.2165/11591110 000000000 00000
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim YG, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246 016 0084 0
   Kitamoto S, 2020, CELL, V182, P447, DOI 10.1016/j.cell.2020.05.048
   Landzberg M, 2015, J PERIODONTAL RES, V50, P330, DOI 10.1111/jre.12211
   Laouar Y, 2003, IMMUNITY, V19, P903, DOI 10.1016/S1074 7613(03)00332 7
   LEE W, 1995, J PERIODONTAL RES, V30, P23, DOI 10.1111/j.1600 0765.1995.tb01249.x
   Liu ZG, 2001, J NEUROIMMUNOL, V112, P153, DOI 10.1016/S0165 5728(00)00403 3
   Loos BG, 2000, J PERIODONTOL, V71, P1528, DOI 10.1902/jop.2000.71.10.1528
   Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135
   Ma TZ, 2017, J COMPUT BIOL, V24, P647, DOI 10.1089/cmb.2017.0056
   Machado V, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.706432
   Matsunaga N, 2011, MOL PHARMACOL, V79, P34, DOI 10.1124/mol.110.068064
   McGowan K, 2018, ORAL DIS, V24, P527, DOI 10.1111/odi.12708
   Nazir Muhammad, 2020, ScientificWorldJournal, V2020, P2146160, DOI 10.1155/2020/2146160
   Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969
   Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009
   Ochoa D, 2021, NUCLEIC ACIDS RES, V49, pD1302, DOI 10.1093/nar/gkaa1027
   Onai N, 2006, J EXP MED, V203, P227, DOI 10.1084/jem.20051645
   Orjuela S, 2019, G3 GENES GENOM GENET, V9, P2089, DOI 10.1534/g3.119.400185
   Otasek D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059 019 1758 4
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Papp KA, 2016, BRIT J DERMATOL, V175, P273, DOI 10.1111/bjd.14493
   Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197
   Peres MA, 2019, LANCET, V394, P249, DOI 10.1016/S0140 6736(19)31146 8
   PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Pompura SL, 2018, J LEUKOCYTE BIOL, V103, P1065, DOI 10.1002/JLB.2MIR0817 349R
   Prakasam A, 2012, J PHARM BIOALLIED SC, V4, pS252, DOI 10.4103/0975 7406.100226
   Reis C, 2014, EXP THER MED, V8, P323, DOI 10.3892/etm.2014.1724
   Ren SC, 2016, MOL CELL PROTEOMICS, V15, P154, DOI 10.1074/mcp.M115.052381
   Rice TW, 2010, CRIT CARE MED, V38, P1685, DOI 10.1097/CCM.0b013e3181e7c5c9
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Schenkein HA, 2020, PERIODONTOL 2000, V83, P90, DOI 10.1111/prd.12304
   Scott Tiana M, 2021, F1000Res, V10, P330, DOI 10.12688/f1000research.52412.1
   Smedley D, 2009, BMC GENOMICS, V10, DOI 10.1186/1471 2164 10 22
   Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582 4934.2005.tb00337.x
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Tanabe N, 2005, LIFE SCI, V77, P615, DOI 10.1016/j.lfs.2004.10.079
   Tarca AL, 2009, BIOINFORMATICS, V25, P75, DOI 10.1093/bioinformatics/btn577
   Taylor KR, 2004, J BIOL CHEM, V279, P17079, DOI 10.1074/jbc.M310859200
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Teughels W, 2014, PERIODONTOL 2000, V65, P107, DOI 10.1111/prd.12020
   Traboulsee A, 2020, LANCET NEUROL, V19, P402, DOI 10.1016/S1474 4422(20)30078 8
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Van den Wyngaert T, 2011, SUPPORT CARE CANCER, V19, P2035, DOI 10.1007/s00520 010 1061 0
   Vergadi E, 2017, J IMMUNOL, V198, P1006, DOI 10.4049/jimmunol.1601515
   Vieira PL, 2000, J IMMUNOL, V164, P4507, DOI 10.4049/jimmunol.164.9.4507
   Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140 6736(17)32154 2
   Wei HX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01315
   Xu K, 2021, SCIENCE, V371, P405, DOI 10.1126/science.abb2683
   Yamazaki T, 2012, INT J ORAL MAX SURG, V41, P1397, DOI 10.1016/j.ijom.2012.06.020
   Yucel Lindberg T, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.8
   Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488
NR 105
TC 9
Z9 9
U1 0
U2 16
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2022
VL 23
IS 10
AR 5580
DI 10.3390/ijms23105580
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 1P1ON
UT WOS:000801787100001
PM 35628390
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Evenepoel, P
   Jorgensen, HS
   Komaba, H
   Mazzaferro, S
   Vervloet, M
   Cavalier, E
   Fukagawa, M
AF Evenepoel, Pieter
   Jorgensen, Hanne Skou
   Komaba, Hirotaka
   Mazzaferro, Sandro
   Vervloet, Marc
   Cavalier, Etienne
   Fukagawa, Masafumi
TI Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared
   to European Patients on Hemodialysis
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE alkaline phosphatase; bone disease; chronic kidney disease mineral and
   bone disorder; kidney failure; chronic; parathyroid hormone; renal
   dialysis
ID RESISTANT ACID PHOSPHATASE; CLINICAL PRACTICE GUIDELINE;
   PARATHYROID HORMONE LEVELS; ALKALINE PHOSPHATASE; DIALYSIS OUTCOMES;
   SERUM CALCIUM; BIOCHEMICAL MARKERS; ADYNAMIC BONE; RISK FACTOR; TRACP 5B
AB Context Parathyroid hormone (PTH) treatment targets for patients receiving hemodialysis (HD) are lower in Japan than in Europe. Whether this translates to lower bone turnover is unknown and could depend on skeletal PTH responsiveness. Objective This study investigates whether skeletal PTH responsiveness is better preserved in Japanese vs European patients receiving HD. Methods This is a post hoc analysis of data from 2 prospective cohort studies, using a case control design. Patients receiving chronic intermittent HD therapy were eligible for inclusion. Participating Belgian and Japanese patients (n = 374) were matched 1:1 by age (59 +/  12 years), sex (66% male), diabetes (34%), and dialysis duration (39 months [22 63 months]). PTH, bone specific alkaline phosphatase (BALP), and tartrate resistant acid phosphatase isoform 5b (TRAP5b) were measured centrally in Liege, Belgium. Results Japanese patients had lower levels of iPTH (207 vs 268 pg/mL; P < .001), BALP (15.3 vs 24.5 mu g/L; P < .001), and TRAP5b (3.35 vs 5.79 U/L; P < .001). Linear regression analyses revealed lower levels of bone turnover markers for any given level of PTH in Japanese vs Belgian patients, indicating lower skeletal PTH responsiveness. Consistently, bone turnover markers were significantly lower in Japanese vs Belgian patients when stratifying or matching according to PTH levels. Male sex, obesity, and hyperphosphatemia were the main determinants of the bone turnover marker/PTH ratios. Conclusion Japanese patients receiving HD have lower bone turnover than their European counterparts, even at similar PTH levels. The rationale for the current regional differences in PTH treatment targets remains obscure and deserves further attention.
C1 [Evenepoel, Pieter; Jorgensen, Hanne Skou] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Nephrol & Renal Transplantat Res Grp, B 3000 Leuven, Belgium.
   [Evenepoel, Pieter] Univ Hosp Leuven, Dept Med, Div Nephrol, Herestr 49, B 3000 Leuven, Belgium.
   [Jorgensen, Hanne Skou] Aarhus Univ Hosp, Dept Renal Med, DK 8200 Aarhus N, Denmark.
   [Komaba, Hirotaka; Fukagawa, Masafumi] Tokai Univ, Sch Med, Div Nephrol Endocrinol & Metab, Isehara, Kanagawa 2591193, Japan.
   [Mazzaferro, Sandro] Policlin Umberto I Hosp, Nephrol Unit, I 00185 Rome, Italy.
   [Mazzaferro, Sandro] Sapienza Univ Rome, Dept Translat & Precis Med, I 00185 Rome, Italy.
   [Vervloet, Marc] Univ Amsterdam, Dept Nephrol, Med Ctr, NL 1081 HV Amsterdam, Netherlands.
   [Vervloet, Marc] Univ Amsterdam, Amsterdam Cardiovasc Sci, Med Ctr, NL 1081 HV Amsterdam, Netherlands.
   [Cavalier, Etienne] Univ Liege, Dept Biochem, B 4000 Liege, Belgium.
C3 KU Leuven; KU Leuven; University Hospital Leuven; Aarhus University;
   Tokai University; Sapienza University Rome; University Hospital Sapienza
   Rome; Sapienza University Rome; University of Amsterdam; University of
   Amsterdam; University of Liege
RP Evenepoel, P (通讯作者)，Univ Hosp Leuven, Dept Med, Div Nephrol, Herestr 49, B 3000 Leuven, Belgium.
EM Pieter.Evenepoel@uzleuven.be
RI Cavalier, Etienne/E 8661 2011; P, Evenepoel/D 9597 2018; Mazzaferro,
   Sandro/E 9321 2012; Komaba, Hirotaka/C 9199 2011; Jørgensen,
   Hanne/AAO 4285 2021; Vervoort, G.M.M./L 4718 2015
OI Cavalier, Etienne/0000 0003 0947 2226; Vervloet,
   Marc/0000 0003 4607 9415; Mazzaferro, Sandro/0000 0003 3071 1893;
   Komaba, Hirotaka/0000 0002 1704 4507; Jorgensen, Hanne Mari
   Skou/0000 0002 0881 2615; 
FU CKD MBD Working Group of the European Renal Association (ERA); Kidney
   Foundation, Japan [JKFB 20 18]; ERA long term fellowship
FX This work was supported by unrestricted grants from the CKD MBD Working
   Group of the European Renal Association (ERA) and from the Kidney
   Foundation, Japan (JKFB 20 18). H.S.J. was supported by an ERA long term
   fellowship during the performance of this work.
CR Broyles DL, 1998, CLIN CHEM, V44, P2139
   Cavalier E, 2022, CLIN CHEM LAB MED, V60, P394, DOI 10.1515/cclm 2021 1190
   Cavalier E, 2014, CLIN CHEM LAB MED, V52, P1137, DOI 10.1515/cclm 2013 1027
   Cavalier E, 2012, NEPHROL DIAL TRANSPL, V27, P1950, DOI 10.1093/ndt/gfr535
   Chan K, 2019, KIDNEY MED, V1, P86, DOI 10.1016/j.xkme.2019.04.004
   Chu PL, 2003, AM J KIDNEY DIS, V41, P1052, DOI 10.1016/S0272 6386(03)00203 8
   de Oliveira RA, 2015, KIDNEY INT, V87, P1039, DOI 10.1038/ki.2014.372
   Debowska M, 2020, BLOOD PURIFICAT, V49, P71, DOI 10.1159/000503623
   Drechsler C, 2011, CLIN J AM SOC NEPHRO, V6, P1752, DOI 10.2215/CJN.10091110
   Duque EJ, 2020, TOXINS, V12, DOI 10.3390/toxins12030189
   Evenepoel P., 2022, SUPPLEMENTARY DATA L
   Evenepoel P, 2019, KIDNEY INT, V95, P1461, DOI 10.1016/j.kint.2018.12.024
   Evenepoel P, 2017, CURR OSTEOPOROS REP, V15, P178, DOI 10.1007/s11914 017 0362 3
   Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744 9987.12058
   Gossiel F, 2022, OSTEOPOROSIS INT, V33, P1357, DOI 10.1007/s00198 022 06311 3
   Haarhaus M, 2021, KIDNEY INT, V100, P546, DOI 10.1016/j.kint.2021.04.043
   Haarhaus M, 2017, NAT REV NEPHROL, V13, P429, DOI 10.1038/nrneph.2017.60
   Halleen JM, 2006, CLIN LAB, V52, P499
   Hansen D, 2022, BONE REP, V16, DOI 10.1016/j.bonr.2022.101593
   Hernando N, 2018, COMPR PHYSIOL, V8, P1065, DOI 10.1002/cphy.c170024
   Iimori S, 2012, NEPHROL DIAL TRANSPL, V27, P345, DOI 10.1093/ndt/gfr317
   Jadoul M, 2006, KIDNEY INT, V70, P1358, DOI 10.1038/sj.ki.5001754
   Jansz TT, 2020, OSTEOPOROSIS INT, V31, P515, DOI 10.1007/s00198 019 05187 0
   Jorgensen HS, 2022, AM J KIDNEY DIS, V79, P667, DOI 10.1053/j.ajkd.2021.07.027
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Ketteler M, 2018, ANN INTERN MED, V168, P422, DOI 10.7326/M17 2640
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kitazawa S, 2003, J CELL BIOCHEM, V89, P771, DOI 10.1002/jcb.10567
   Lamina C, 2020, NEPHROL DIAL TRANSPL, V35, P478, DOI 10.1093/ndt/gfz060
   Maruyama Y, 2014, NEPHROL DIAL TRANSPL, V29, P1532, DOI 10.1093/ndt/gfu055
   MASSRY SG, 1973, ANN INTERN MED, V78, P357, DOI 10.7326/0003 4819 78 3 357
   Merle E, 2016, KIDNEY INT, V89, P666, DOI 10.1016/j.kint.2015.12.001
   Millan JL., 2006, MAMMALIAN ALKALINE P, P107
   Nakagawa Yosuke, 2022, J Clin Endocrinol Metab, V107, pe95, DOI 10.1210/clinem/dgab623
   Nakai S, 2008, THER APHER DIAL, V12, P49, DOI 10.1111/j.1744 9987.2007.00540.x
   Nenonen A, 2005, J BONE MINER RES, V20, P1804, DOI 10.1359/JBMR.050403
   Ott SM, 2021, KIDNEY INT, V100, P502, DOI 10.1016/j.kint.2021.05.024
   PAYNE RB, 1973, BMJ BRIT MED J, V4, P643, DOI 10.1136/bmj.4.5893.643
   Pazianas M, 2020, J BONE MINER RES, V35, P2313, DOI 10.1002/jbmr.4155
   Picton ML, 2000, KIDNEY INT, V58, P1440, DOI 10.1046/j.1523 1755.2000.00306.x
   Pike AF, 2013, BBA MOL BASIS DIS, V1832, P2044, DOI 10.1016/j.bbadis.2013.07.016
   Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P108, DOI 10.1007/s00223 007 9091 4
   Sawaya BP, 2003, KIDNEY INT, V64, P737, DOI 10.1046/j.1523 1755.2003.00129.x
   Shidara K, 2008, CALCIFIED TISSUE INT, V82, P278, DOI 10.1007/s00223 008 9127 4
   Spalding EM, 2002, KIDNEY INT, V61, P655, DOI 10.1046/j.1523 1755.2002.00146.x
   Starup Linde J, 2014, OSTEOPOROSIS INT, V25, P1697, DOI 10.1007/s00198 014 2676 7
   Szulc P, 2012, CLIN BIOCHEM, V45, P907, DOI 10.1016/j.clinbiochem.2012.01.022
   Tabibzadeh N, 2021, NEPHROL DIAL TRANSPL, V36, P160, DOI 10.1093/ndt/gfaa195
   Taniguchi M, 2013, THER APHER DIAL, V17, P221, DOI 10.1111/1744 9987.12030
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tentori F, 2014, KIDNEY INT, V85, P166, DOI 10.1038/ki.2013.279
   Tominaga N, 2021, BMC NEPHROL, V22, DOI 10.1186/s12882 021 02482 z
   Wesseling Perry K, 2010, J CLIN ENDOCR METAB, V95, P2772, DOI 10.1210/jc.2009 1909
NR 53
TC 8
Z9 8
U1 1
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD NOV 25
PY 2022
VL 107
IS 12
BP E4350
EP E4359
DI 10.1210/clinem/dgac522
EA SEP 2022
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 6S5TJ
UT WOS:000860846400001
PM 36068939
OA Green Submitted, Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Gao, Y
   Wu, M
   Rizvi, SAA
   Wei, Q
AF Gao, Yan
   Wu, Meng
   Rizvi, Syed A. A.
   Wei, Qiang
TI Exploring the key pathogenic mechanisms and potential intervention
   targets for Sophorae Flavescentis radix in managing bone
   metastasis of lung cancer based on network pharmacology and molecular
   docking techniques
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Article
DE Traditional Chinese medicine (TCM); Sophorae Flavescentis radix; lung
   cancer; bone metastasis; MMP1
AB Background: Lung cancer often metastasizes to the bone, which significantly complicates treatment and worsens patient prognosis. Thus, new therapeutic strategies need to be established. Using network pharmacology and bioinformatics analysis, this study sought to determine the molecular targets and associated mechanisms of the traditional Chinese medicine (TCM) Sophorae Flavescentis radix in the treatment of lung cancer bone metastasis. Methods: The active components of Sophorae Flavescentis radix were screened using the TCM Systems Pharmacology (TCMSP) platform based on drug likeness and oral bioavailability. The target genes of these active compounds were obtained from the DrugBank database. Differentially expressed genes (DEGs) between primary and bone metastatic lung cancer samples were screened in the GSE175601 dataset from the Gene Expression Omnibus (GEO) database using GEO2R. The intersecting DEGs from both groups were used to construct a Venn diagram to identify the candidate target genes. The expression and prognostic relevance of these genes were validated in The Cancer Genome Atlas (TCGA) database. The GeneMania and Search Tool for Recurring Instances of Neighbouring Genes (STRING) databases were used to generate the protein protein interaction networks. Molecular docking was performed using the PubChem, Protein Data Bank (PDB), and CB DOCK2 databases. A Gene Set Enrichment Analysis (GSEA) was conducted to explore the possible mechanisms of action. Results: In the TCMSP database, 28 active compounds and 227 target genes of the Sophorae Flavescentis radix were identified. In total, 952 DEGs related to lung cancer bone metastasis were found in the GSE175601 dataset from the GEO database. Five common DEGs were identified via Venn diagram construction (i.e., F10, JUN, AKR1B1, MMP1, and CCND1). MMP1 was selected as the candidate gene. MMP1 was upregulated in lung cancer tissues, and patients with low MMP1 expression had better survival rates than those with high MMP1 expression (P<0.05). MMP1 has an affinity of  8.9 with luteolin. The GSEA results suggested that MMP1 might influence biological processes in lung cancer by participating in pathways such as chemokine signaling, apoptosis, Wingless/Integrated (Wnt) signaling, tumor protein p53 regulated cell cycle arrest, Hedgehog signaling, and mitogen activated protein kinase signaling. Conclusions: Patients with lower MMP1 levels had prolonged overall survival and may serve as a novel predictive biomarker for lung cancer. Sophorae Flavescentis radix appears to exert therapeutic effects on lung cancer bone metastasis by inhibiting MMP1 expression and modulating the abnormal activation of the Wnt pathway. Our findings further extend the understanding of the pathogenic mechanisms and potential therapeutic interventions of Sophorae Flavescentis radix in lung cancer bone metastasis, providing a theoretical basis for clinical diagnosis and treatment research.
C1 [Gao, Yan; Wu, Meng] First Peoples Hosp Lianyungang, Dept Oncol, Liangyungang, Peoples R China.
   [Rizvi, Syed A. A.] Larkin Univ, Coll Biomed Sci, Miami, FL USA.
   [Wei, Qiang] Nanjing Med Univ, Jiangsu Canc Hosp, Dept Ultrasound, Nanjing 210009, Peoples R China.
   [Wei, Qiang] Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing 210009, Peoples R China.
   [Wei, Qiang] Nanjing Med Univ, Affiliated Canc Hosp, Nanjing 210009, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Wei, Q (通讯作者)，Nanjing Med Univ, Jiangsu Canc Hosp, Dept Ultrasound, Nanjing 210009, Peoples R China.; Wei, Q (通讯作者)，Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing 210009, Peoples R China.; Wei, Q (通讯作者)，Nanjing Med Univ, Affiliated Canc Hosp, Nanjing 210009, Peoples R China.
EM 13770630278@163.com
RI Rizvi., MD, PhD (Pharmaceutics), PhD (Chemistry), MPH, MBA, MS, MSc,
   BSc, BSN, CMRN, RN, Prof. Syed/Q 8340 2016
CR Asano Y, 2024, INT IMMUNOPHARMACOL, V136, DOI 10.1016/j.intimp.2024.112276
   Chen MH, 2021, PHARMACOL RES, V171, DOI 10.1016/j.phrs.2021.105778
   Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880 019 0368 6
   Feng Y, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms242216306
   Gabasa M, 2021, CANCER LETT, V507, P1, DOI 10.1016/j.canlet.2021.01.028
   Hong S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234927
   Kim D, 2022, J CHEST SURG, V55, P1, DOI 10.5090/jcs.21.105
   Li JJ, 2020, FITOTERAPIA, V143, DOI 10.1016/j.fitote.2020.104556
   Liu XX, 2020, CANCER COMMUN, V40, P611, DOI 10.1002/cac2.12099
   Lu X, 2009, GENE DEV, V23, P1882, DOI 10.1101/gad.1824809
   Luo D, 2023, PHYTOMEDICINE, V116, DOI 10.1016/j.phymed.2023.154909
   Ng L, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031181
   Raeeszadeh Sarmazdeh M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9051313
   Rizvi SAA, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12101442
   Song ZG, 2023, CONGENIT HEART DIS, V18, P693, DOI 10.32604/chd.2024.048081
   Wang L, 2021, TRANSL LUNG CANCER R, V10, P4057, DOI 10.21037/tlcr 21 935
   Wang Q, 2023, INTEGR CANCER THER, V22, DOI 10.1177/15347354231217274
   Xi YM, 2014, CANCER LETT, V353, P8, DOI 10.1016/j.canlet.2014.07.010
   Xin YQ, 2023, CURR PHARM ANAL, V19, P712, DOI 10.2174/0115734129259758230924070432
   Xu YQ, 2020, AGING US, V12, P9311, DOI 10.18632/aging.103207
   Zhang XY, 2021, BIOSCI TRENDS, V15, P283, DOI 10.5582/bst.2021.01318
   Zhou HY, 2020, HEREDITAS, V157, DOI 10.1186/s41065 020 00145 x
   Zhou W, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.742421
NR 23
TC 1
Z9 1
U1 4
U2 6
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2218 676X
EI 2219 6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD OCT 31
PY 2024
VL 13
IS 10
DI 10.21037/tcr 24 1947
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA M8B6Q
UT WOS:001359735400001
PM 39524998
OA gold
DA 2025 08 17
ER

PT J
AU Mason, JB
   Gurda, BL
   Hankenson, KD
   Harper, LR
   Carlson, CS
   Wilson, JM
   Richardson, DW
AF Mason, Jeffrey B.
   Gurda, Brittney L.
   Hankenson, Kurt D.
   Harper, Lindsey R.
   Carlson, Cathy S.
   Wilson, James M.
   Richardson, Dean W.
TI Wnt10b and Dkk 1 gene therapy differentially influenced trabecular bone
   architecture, soft tissue integrity, and osteophytosis in a skeletally
   mature rat model of osteoarthritis
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE Cartilage; gene therapy; osteoarthritis; osteophyte; Wnt; Dkk 1 pathway
ID KNEE OSTEOARTHRITIS; VECTORS; INCREASES; INHIBITION; MICE
AB Aims: Our goals in the current experiments were to determine if (a) upregulation of Wnt signaling would induce osteoarthritis changes in stable stifle joints and (b) if downregulation of Wnt signaling in destabilized joints would influence the progression of OA. Methods: At 37 weeks of age, rats were injected in the stifle joint with a recombinant adeno associated viral vector containing the Wnt inhibitor Dkk 1 or a Wnt10b transgene. At 40 weeks of age, rats underwent surgical destabilization of the joint. At 50 weeks of age, stifle joints were submitted for micro computed tomography and histopathological analysis. Results: Injection of either Wnt10b or Dkk 1 transgenes in stable joints improved bone architectural parameters, but worsened soft tissue integrity. Osteophytosis was decreased by Dkk 1, but unchanged by Wnt10b. Destabilization negatively influenced bone architecture, increased osteophytosis, and decreased soft tissue integrity. Dkk 1 exacerbated the negative effects of destabilization, whereas Wnt10b had little effect on these parameters. Osteophytosis was improved, whereas soft tissue integrity was worsened by both transgenes in destabilized joints. Conclusions: The Wnt inhibitor Dkk 1 does not appear to completely inhibit the effects of Wnt signaling on bone remodeling. In vivo upregulation of Wnt10b and its inhibitor, Dkk 1, can produce both parallel or contrasting phenotypic responses depending on the specific parameter measured and the fidelity of the examined joint. These observations elucidate different roles for Wnt signaling in stable versus destabilized joints and may help to explain the conflicting results previously reported for the role of Dkk 1 in joint disease.
C1 [Mason, Jeffrey B.; Hankenson, Kurt D.; Richardson, Dean W.] Univ Penn, Sch Vet Med, Dept Clin Studies, New Bolton Ctr, Philadelphia, PA 19104 USA.
   [Mason, Jeffrey B.] Utah State Univ, Sch Vet Med, Ctr Integrated BioSyst, Dept Anim Dairy & Vet Sci, 4700 Old Main Hill, Logan, UT 84322 USA.
   [Gurda, Brittney L.; Wilson, James M.] Univ Penn, Sch Med, Gene Therapy Program, Philadelphia, PA 19104 USA.
   [Harper, Lindsey R.; Carlson, Cathy S.] Univ Minnesota, Coll Vet Med, Dept Vet Populat Med, St Paul, MN 55108 USA.
C3 University of Pennsylvania; Utah System of Higher Education; Utah State
   University; University of Pennsylvania; University of Minnesota System;
   University of Minnesota Twin Cities
RP Mason, JB (通讯作者)，Utah State Univ, Sch Vet Med, Ctr Integrated BioSyst, Dept Anim Dairy & Vet Sci, 4700 Old Main Hill, Logan, UT 84322 USA.
EM Jeff.Mason@USU.edu
RI ; Wilson, James/F 9220 2011; Hankenson, Kurt/ABI 1547 2020; Mason,
   Jeffrey/I 8601 2017; Mason, jeffrey/I 8601 2017
OI Gurda, Brittney/0000 0002 0174 9385; Wilson, James/0000 0002 9630 3131;
   Hankenson, Kurt/0000 0001 6361 143X; Mason, Jeffrey/0000 0003 2459 1186;
   
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
   the National Institutes of Health [1F32AR056936 01A2]; University of
   Pennsylvania Vector Core Facility; NIH [2 P30 DK047757 16]
FX Research reported in this publication was supported by the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases of the
   National Institutes of Health under Award Number 1F32AR056936 01A2 to
   J.B.M. Research was also supported by The University of Pennsylvania
   Vector Core Facility and a grant to J.M.W. (NIH Grant
   2 P30 DK047757 16). Recombinant AAV preparations were provided by the
   University of Pennsylvania Vector Core Facility (Philadelphia, PA). The
   content here is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR Auricchio A, 2001, HUM GENE THER, V12, P71, DOI 10.1089/104303401450988
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090
   Calvo E, 2007, OSTEOARTHR CARTILAGE, V15, P69, DOI 10.1016/j.joca.2006.06.006
   Creaby MW, 2010, OSTEOARTHR CARTILAGE, V18, P1380, DOI 10.1016/j.joca.2010.08.013
   Dell'Accio F, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2029
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Farrokhi S, 2012, CLIN BIOMECH, V27, P384, DOI 10.1016/j.clinbiomech.2011.10.009
   Funck Brentano T, 2014, ARTHRITIS RHEUMATOL, V66, P3028, DOI 10.1002/art.38799
   Funck Brentano T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033543
   Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299
   Hildinger M, 2001, J VIROL, V75, P6199, DOI 10.1128/JVI.75.13.6199 6203.2001
   Honsawek S, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 257
   Lane NE, 2007, ARTHRITIS RHEUM US, V56, P3319, DOI 10.1002/art.22867
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Mason JB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145821
   Mason JB, 2013, HUM GENE THER METHOD, V24, P185, DOI 10.1089/hgtb.2012.199
   McNulty MA, 2011, CARTILAGE, V2, P354, DOI 10.1177/1947603511402665
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224 2232.1998
NR 22
TC 6
Z9 7
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PY 2017
VL 58
IS 6
BP 542
EP 552
DI 10.1080/03008207.2016.1267153
PG 11
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA FN3ZK
UT WOS:000415941900006
PM 27937051
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, YC
   Newman, MR
   Ackun Farmmer, M
   Baranello, MP
   Sheu, TJ
   Puzas, JE
   Benoit, DSW
AF Wang, Yuchen
   Newman, Maureen R.
   Ackun Farmmer, Marian
   Baranello, Michael P.
   Sheu, Tzong Jen
   Puzas, J. Edward
   Benoit, Danielle S. W.
TI Fracture Targeted Delivery of β Catenin Agonists via
   Peptide Functionalized Nanoparticles Augments Fracture Healing
SO ACS NANO
LA English
DT Article
DE nanoparticles; fracture healing; peptide; drug delivery; small molecule
   drug
ID DRUG DELIVERY; BONE REGENERATION; IN VITRO; MACROMOLECULAR THERAPEUTICS;
   BLOCK COPOLYMERS; GENE EXPRESSION; SMALL MOLECULES; CANCER THERAPY;
   ASPARTIC ACID; CELLS
AB Despite several decades of progress, bone specific drug delivery is still a major challenge. Current bone acting drugs require high dose systemic administration which decreases therapeutic efficacy and increases off target tissue effects. Here, a bone targeted nanoparticle (NP) delivery system for a beta catenin agonist, 3 amino 6 (4 ((4 methylpiperazin 1 yl)sulfonyl)phenyl) N (pyridin 3 yl)pyrazine 2 carboxamide, a glycogen synthase kinase 3 beta (GSK 3 beta) inhibitor, was developed to enhance fracture healing. The GSK 3 beta inhibitor loading capacity was found to be 15 wt % within highly stable poly(styrene alt maleic anhydride) b poly(styrene) NPs, resulting in similar to 50 nm particles with similar to 30 mV surface charge. A peptide with high affinity for tartrate resistant acid phosphatase (TRAP), a protein deposited by osteoclasts on bone resorptive surfaces, was introduced to the NP corona to achieve preferential delivery to fractured bone. Targeted NPs showed improved pharmacokinetic profiles with greater accumulation at fractured bone, accompanied by significant uptake in regenerative cell types (mesenchymal stem cells (MSCs) and osteoblasts). MSCs treated with drug loaded NPs in vitro exhibited 2 fold greater beta catenin signaling than free drug that was sustained for 5 days. To verify similar activity in vivo, TOPGAL reporter mice bearing fractures were treated with targeted GSK 3 beta inhibitor loaded NPs. Robust beta galactosidase activity was observed in fracture callus and periosteum treated with targeted carriers versus controls, indicating potent beta catenin activation during the healing process. Enhanced bone formation and microarchitecture were observed in mice treated with GSK 3 beta inhibitor delivered via TRAP binding peptide targeted NPs. Specifically, increased bone bridging, similar to 4 fold greater torsional rigidity, and greater volumes of newly deposited bone were observed 28 days after treatment, indicating expedited fracture healing.
C1 [Wang, Yuchen; Newman, Maureen R.; Ackun Farmmer, Marian; Benoit, Danielle S. W.] Univ Rochester, Dept Biomed Engn, 601 Elmwood Ave, Rochester, NY 14627 USA.
   [Baranello, Michael P.; Benoit, Danielle S. W.] Univ Rochester, Dept Chem Engn, Rochester, NY 14627 USA.
   [Wang, Yuchen; Newman, Maureen R.; Ackun Farmmer, Marian; Sheu, Tzong Jen; Puzas, J. Edward; Benoit, Danielle S. W.] Univ Rochester, Med Ctr, Dept Orthopaed, Rochester, NY 14642 USA.
   [Wang, Yuchen; Newman, Maureen R.; Ackun Farmmer, Marian; Sheu, Tzong Jen; Puzas, J. Edward; Benoit, Danielle S. W.] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester; University of
   Rochester; University of Rochester
RP Benoit, DSW (通讯作者)，Univ Rochester, Dept Biomed Engn, 601 Elmwood Ave, Rochester, NY 14627 USA.; Benoit, DSW (通讯作者)，Univ Rochester, Dept Chem Engn, Rochester, NY 14627 USA.; Benoit, DSW (通讯作者)，Univ Rochester, Med Ctr, Dept Orthopaed, Rochester, NY 14642 USA.; Benoit, DSW (通讯作者)，Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
EM danielleswbenoit@rochester.edu
RI ; Wang, Yuchen/Q 1354 2018; Benoit, Danielle/HKV 4384 2023; Newman,
   Maureen/ABE 5409 2020
OI Benoit, Danielle/0000 0001 7137 8164; Newman,
   Maureen/0000 0002 9004 3332; 
FU National Science Foundation (NSF) [DMR1206219, CBET1450987]; National
   Institutes of Health (NIH) [R01 AR064200, R01 AR056696, UL1 TR002001];
   New York State Stem Cell Science (NYSTEM) funding [N11G 035]; NIH funds
   [S10 RR026542, P30 AR069655, S10 RR027340]; Directorate For Engineering;
   Div Of Chem, Bioeng, Env, & Transp Sys [1450987] Funding Source:
   National Science Foundation
FX Funding for this study was provided by National Science Foundation (NSF)
   DMR1206219 and CBET1450987, National Institutes of Health (NIH) R01
   AR064200, R01 AR056696, and UL1 TR002001, and New York State Stem Cell
   Science (NYSTEM) funding N11G 035. Equipment, including the IVIS Live
   Animal Imaging System, Visiopharm software, and whole slide scanner were
   purchased through NIH funds (S10 RR026542, P30 AR069655, and
   S10 RR027340).
CR Alex MRA, 2017, BIOMATERIALS, V133, P94, DOI 10.1016/j.biomaterials.2017.04.022
   Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Andersson G.B. J., 2008, US BONE JOINT DECADE, P97
   [Anonymous], 2016, INT J MOL SCI
   ARO HT, 1990, J ORTHOP RES, V8, P238, DOI 10.1002/jor.1100080213
   Banu J, 2013, DRUG DES DEV THER, V7, P849, DOI 10.2147/DDDT.S46101
   Baranello MP, 2015, CELL MOL BIOENG, V8, P455, DOI 10.1007/s12195 015 0391 x
   Baranello MP, 2014, BIOMACROMOLECULES, V15, P2629, DOI 10.1021/bm500468d
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Benoit DSW, 2006, BIOMATERIALS, V27, P6102, DOI 10.1016/j.biomaterials.2006.06.031
   Benoit DSW, 2012, BIOMACROMOLECULES, V13, P3841, DOI 10.1021/bm301294n
   Benoit DSW, 2011, BIOMACROMOLECULES, V12, P2708, DOI 10.1021/bm200485b
   Blaich G., 2010, Pharmaceutical Sciences Encyclopedia, pps, DOI [10.1002/9780470571224.pse292, DOI 10.1002/9780470571224.PSE292]
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Boraiah S, 2009, CLIN ORTHOP RELAT R, V467, P3257, DOI 10.1007/s11999 009 1039 8
   Carbone EJ, 2017, J NANOSCI NANOTECHNO, V17, P1747, DOI 10.1166/jnn.2017.12855
   Chaubey A, 2013, J ORTHOP TRAUMATOL, V14, P247, DOI 10.1007/s10195 013 0269 4
   Chaudhari KR, 2012, ADV FUNCT MATER, V22, P4101, DOI 10.1002/adfm.201102357
   Chavanpatil MD, 2006, J NANOSCI NANOTECHNO, V6, P2651, DOI 10.1166/jnn.2006.443
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Deal C, 2003, CLEV CLIN J MED, V70, P585, DOI 10.3949/ccjm.70.7.585
   Fröhlich E, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743 8977 9 26
   Gao HL, 2014, INT J PHARMACEUT, V461, P478, DOI 10.1016/j.ijpharm.2013.12.016
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   GOTHLIN G, 1976, CLIN ORTHOP RELAT R, P201
   Han JT, 2008, COLLOID POLYM SCI, V286, P1605, DOI 10.1007/s00396 008 1934 7
   Harrisson S, 2005, CHEM COMMUN, P3259, DOI 10.1039/b504313a
   Heath JR, 2008, ANNU REV MED, V59, P251, DOI 10.1146/annurev.med.59.061506.185523
   Heidel JD, 2011, PHARM RES DORDR, V28, P187, DOI 10.1007/s11095 010 0178 7
   Hermanson GT, 2013, BIOCONJUGATE TECHNIQUES, 3RD EDITION, P1
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Hoffman MD, 2015, J TISSUE ENG REGEN M, V9, pE13, DOI 10.1002/term.1736
   Jia Z, 2015, J CONTROL RELEASE, V200, P23, DOI 10.1016/j.jconrel.2014.12.028
   Jiang T, 2014, INT J PHARMACEUT, V475, P547, DOI 10.1016/j.ijpharm.2014.08.067
   Kaga S, 2006, J MOL CELL CARDIOL, V40, P138, DOI 10.1016/j.yjmcc.2005.09.009
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Keaveny T.M., 2001, BONE MECH HDB
   Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kulkarni NH, 2007, J CELL BIOCHEM, V102, P1504, DOI 10.1002/jcb.21374
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Kyllönen L, 2015, ACTA BIOMATER, V11, P412, DOI 10.1016/j.actbio.2014.09.006
   Larson N, 2011, INT J PHARMACEUT, V420, P111, DOI 10.1016/j.ijpharm.2011.08.011
   Laurencin CT, 2014, DRUG DISCOV TODAY, V19, P794, DOI 10.1016/j.drudis.2014.01.012
   Lee JY, 2014, INT J NANOMED, V9, P2803, DOI 10.2147/IJN.S62806
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   Liang C., 2014, NAT MED, V29, pS36
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Liu XY, 2010, J COLLOID INTERF SCI, V351, P315, DOI 10.1016/j.jcis.2010.04.056
   Lo Kevin W. H., 2011, Recent Patents on Biomedical Engineering, V4, P153, DOI 10.2174/1874764711104030153
   Lo KWH, 2012, REGEN MED, V7, P535, DOI [10.2217/rme.12.33, 10.2217/RME.12.33]
   Loos C, 2014, BEILSTEIN J NANOTECH, V5, P2403, DOI 10.3762/bjnano.5.250
   Low SA, 2015, BIOMACROMOLECULES, V16, P3145, DOI 10.1021/acs.biomac.5b00777
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Metselaar JM, 2004, ANN RHEUM DIS, V63, P348, DOI 10.1136/ard.2003.009944
   Mitchell AC, 2016, ACTA BIOMATER, V30, P1, DOI 10.1016/j.actbio.2015.11.007
   Moad G, 2005, POLYMER, V46, P8458, DOI 10.1016/j.polymer.2004.12.061
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Newman MR, 2016, CURR OPIN BIOTECH, V40, P125, DOI 10.1016/j.copbio.2016.02.029
   Novicoff WM, 2008, J BONE JOINT SURG AM, V90A, P85, DOI 10.2106/JBJS.G.01521
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Patterson J, 2010, BIOMATERIALS, V31, P6772, DOI 10.1016/j.biomaterials.2010.05.047
   Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
   Pilitsis J.G., 2002, NEUROSURG FOCUS, V13, P1, DOI DOI 10.3171/foc.2002.13.6.2
   Potz BA, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003694
   Ratko TA., 2010, Bone Morphogenetic Protein: The State of the Evidence of On Label and Off Label Use
   Reynolds DG, 2007, J BIOMECH, V40, P3178, DOI 10.1016/j.jbiomech.2007.04.004
   REZNIKOFF CA, 1973, CANCER RES, V33, P3231
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   Santolini E, 2015, INJURY, V46, pS8, DOI 10.1016/S0020 1383(15)30049 8
   Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018
   Shea CM, 2003, J CELL BIOCHEM, V90, P1112, DOI 10.1002/jcb.10734
   Shen YM, 2014, J CHEM THEORY COMPUT, V10, P4745, DOI 10.1021/ct500592m
   Sheu TJ, 2002, J BONE MINER RES, V17, P915, DOI 10.1359/jbmr.2002.17.5.915
   SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720
   Sisask G, 2013, BONE, V54, P126, DOI 10.1016/j.bone.2013.01.019
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Tägil M, 2010, BONE, V46, P852, DOI 10.1016/j.bone.2009.11.009
   Tannoury CA, 2014, SPINE J, V14, P552, DOI 10.1016/j.spinee.2013.08.060
   Tautzenberger A, 2012, INT J NANOMED, V7, P4545, DOI 10.2147/IJN.S34127
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Veron L, 2001, J APPL POLYM SCI, V81, P3327, DOI 10.1002/app.1789
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang FF, 2014, J CONTROL RELEASE, V196, P222, DOI 10.1016/j.jconrel.2014.10.012
   Wang GL, 2010, J DRUG TARGET, V18, P611, DOI 10.3109/10611861003622560
   Wang YC, 2017, BIOMATERIALS, V139, P127, DOI 10.1016/j.biomaterials.2017.06.001
   Yardeni T, 2011, LAB ANIMAL, V40, P155, DOI 10.1038/laban0511 155
   Yewle JN, 2011, BIOCONJUGATE CHEM, V22, P2496, DOI 10.1021/bc2003132
   Yuan F, 2012, ADV DRUG DELIVER REV, V64, P1205, DOI 10.1016/j.addr.2012.03.006
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   ZHANG LF, 1995, SCIENCE, V268, P1728, DOI 10.1126/science.268.5218.1728
   Zhang LZ, 2016, BONE RES, V4, DOI 10.1038/boneres.2015.37
   Zhou JY, 2016, J MATER CHEM B, V4, P3075, DOI 10.1039/c5tb02054a
NR 97
TC 65
Z9 79
U1 5
U2 74
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD SEP
PY 2017
VL 11
IS 9
BP 9445
EP 9458
DI 10.1021/acsnano.7b05103
PG 14
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA FI4CV
UT WOS:000411918200096
PM 28881139
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Marcucci, G
   Della Pepa, G
   Brandi, ML
AF Marcucci, Gemma
   Della Pepa, Giuseppe
   Brandi, Maria Luisa
TI Natpara for the treatment of hypoparathyroidism
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE Hypoparathyroidism; parathyroid hormone (PTH); rhPTH (1 84);
   hypocalcemia
ID PARATHYROID HORMONE 1 84; CONTROLLED TRIAL; DOUBLE BLIND; OPEN LABEL;
   VITAMIN D; THERAPY; PTH(1 84); SAFETY; TERIPARATIDE; OSTEOPOROSIS
AB Introduction: Hypoparathyroidism is a rare endocrine disorder characterized by hypocalcaemia and hyperphosphatemia, due to absent or inappropriately low parathyroid hormone levels. For management of chronic hypoparathyroidism, current treatment options involve oral calcium and vitamin D. This standard treatment cannot resolve all problematic aspects of the disease, such as abnormal bone remodeling and reduced quality of life, and is associated with long term complications, including nephrolithiasis, nephrocalcinosis, renal impairment, cataracts and cerebral calcifications.Areas covered: In 2015, the FDA (Food and Drug Administration) approved rhPTH (1 84), named Natpara (R), a bioengineered recombinant human PTH, for the management of hypoparathyroidism of any etiology, except Autosomal Dominant Hypocalcemia, not well controlled with calcium and active vitamin D. Herein, the authors review its chemistry, pharmacodynamics, pharmacokinetics and clinical efficacy for hypoparathyroidism.Expert opinion: Replacement therapy with rhPTH (1 84) is a fundamental step in the treatment of chronic hypoparathyroidism in cases not well controlled by standard therapy, providing the natural hormone that is lacking for the maintenance of normal calcium levels, and reducing long term risks associated with conventional therapy. Nevertheless, given the chronic nature of the disease, in the future, further studies will have to be performed to evaluate long term efficacy and safety of the drug.
C1 [Marcucci, Gemma; Brandi, Maria Luisa] Univ Florence, Dept Surg & Translat Med, Bone Metab Dis Unit, Florence, Italy.
   [Della Pepa, Giuseppe] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy.
C3 University of Florence; University of Naples Federico II
RP Brandi, ML (通讯作者)，Univ Florence, Dept Surg & Translat Med, Bone Metab Dis Unit, Florence, Italy.
EM marialuisa.brandi@unifi.it
RI Della Pepa, Giuseppe/AAK 5488 2020; Marcucci, Gemma/K 5205 2016
OI Della Pepa, Giuseppe/0000 0001 5862 3794; brandi, maria
   luisa/0000 0002 8741 0592
CR Albright F, 1929, J CLIN INVEST, V7, P183, DOI 10.1172/JCI100224
   Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Brandi ML, 2016, J CLIN ENDOCR METAB, V101, P2273, DOI 10.1210/jc.2015 3907
   Capriani C, 2012, J BONE MINER RES, V27, P2419, DOI 10.1002/jbmr.1800
   Chu NN, 2007, PHARMAZIE, V62, P869, DOI 10.1691/ph.2007.11.7576
   Clarke BL, 2014, CLIN THER, V36, P722, DOI 10.1016/j.clinthera.2014.04.001
   Cusano NE, 2014, J CLIN ENDOCR METAB, V99, P3694, DOI 10.1210/jc.2014 2267
   Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P137, DOI 10.1210/jc.2012 2984
   Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961
   Goltzman D, 2015, HYPOPARATHYROIDISM, P69
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Isaia G, 2015, HYPOPARATHYROIDISM, P19
   Jolette J, 2006, TOXICOL PATHOL, V34, P929, DOI 10.1080/01926230601072301
   Khundmiri SJ, 2016, COMPR PHYSIOL, V6, P561, DOI 10.1002/cphy.c140071
   Lakatos P, 2016, ENDOCR PRACT, V22, P523, DOI 10.4158/EP15936.OR
   Mannstadt M, 2013, LANCET DIABETES ENDO, V1, P275, DOI 10.1016/S2213 8587(13)70106 2
   Marx SJ, 2000, NEW ENGL J MED, V343, P1863, DOI 10.1056/NEJM200012213432508
   Mitchell DM, 2012, J CLIN ENDOCR METAB, V97, P4507, DOI 10.1210/jc.2012 1808
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505
   Rubin MR, 2011, J CLIN ENDOCR METAB, V96, P176, DOI 10.1210/jc.2009 2682
   Rubin MR, 2010, OSTEOPOROSIS INT, V21, P1927, DOI 10.1007/s00198 009 1149 x
   Rubin MR, 2016, J CLIN ENDOCR METAB, V101, P2742, DOI 10.1210/jc.2015 4135
   Rubin MR, 2011, J BONE MINER RES, V26, P2727, DOI 10.1002/jbmr.452
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Shoback D, 2008, NEW ENGL J MED, V359, P391, DOI 10.1056/NEJMcp0803050
   Sikjaer T, 2013, J BONE MINER RES, V28, P2232, DOI 10.1002/jbmr.1964
   Sikjaer T, 2012, J BONE MINER RES, V27, P781, DOI 10.1002/jbmr.1493
   Sikjaer T, 2011, J BONE MINER RES, V26, P2358, DOI 10.1002/jbmr.470
   US FDA, 2015, NATP PAR HORM INJ US
   Usdin TB, 1999, NAT NEUROSCI, V2, P941, DOI 10.1038/14724
   USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Winer KK, 2008, J CLIN ENDOCR METAB, V93, P3389, DOI 10.1210/jc.2007 2552
NR 35
TC 27
Z9 27
U1 1
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471 2598
EI 1744 7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD NOV
PY 2016
VL 16
IS 11
BP 1417
EP 1424
DI 10.1080/14712598.2016.1238455
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA DZ0XD
UT WOS:000385562100010
PM 27689826
DA 2025 08 17
ER

PT J
AU Mehnath, S
   Karthikeyan, K
   Rajan, M
   Jeyaraj, M
AF Mehnath, Sivaraj
   Karthikeyan, Kandhasamy
   Rajan, Mariappan
   Jeyaraj, Murugaraj
TI Fabrication of bone targeting hyaluronic acid coupled
   alendronate bioactive glass for osteosarcoma therapy
SO MATERIALS CHEMISTRY AND PHYSICS
LA English
DT Article
DE Osteosarcoma; Bone targeting; Mesoporous bioactive glass; Ceramic
   composites; Alendronate; Osteointegration
ID IN VITRO; DRUG RELEASE; MESOPOROUS BIOGLASSES; DELIVERY; SCAFFOLDS;
   MICELLES; VIVO; SIZE
AB Osteosarcoma is a complicated clinical cancer for patients, which seriously reduces the quality of life. The current conventional treatment is focused on controlling cancer cell proliferation and osteoclast activity. The aim is to develop mesoporous bioactive glass (MBG) with bone targeting hyaluronic acid alendronate (HA ALN) components for osteosarcoma treatment. The prepared MBG was enclosed by the HA ALN to form mesoporous bioactive glass nanocomposites (MBGNCs) and characterized surface functionalization, size, shape, and morphology. MBG nanoparticles were spherical and smooth surfaces; after coating with HA ALN they exhibited a stable structure with changes in the surface textures. Bisphosphonate coupled HA controls the swelling under physiological conditions by preventing rapid degradation of the nanocomposites. It also confirms the drug release, which shows a maximum of 65% DOX release at pH 4.5. Drug release studies confirm the pH variation was slightly altered in the DOX release ratio due to the HA ALN. It also helps in higher binding ability on the hydroxyapatite components, indicating the bone targeting ability and nanocomposites. ALN components actively inhibit osteoclast like cells. MBGNCs witnessed the higher toxicity to the osteosarcoma cancer cells of IC50 value of 4 mu g/mL. MBGNCs inhibitory effects on the viability of the MG 63 osteosarcoma cancer cells were higher compared to free DOX. The bone targeting effect of HA ALN coated MBGNCs shows higher cellular uptake, which helps inhibit tumor growth and helps in the long term of bone tissue regeneration. MBGNCs highly followed the bone targeting, pH dependent drug release contributed to the treatment of bone metastasis and promoted osteoblast differentiation.
C1 [Mehnath, Sivaraj; Jeyaraj, Murugaraj] Univ Madras, Guindy Campus, Chennai 25, Tamil Nadu, India.
   [Karthikeyan, Kandhasamy] Bharathidasan Univ, Tiruchirappalli 24, Tamil Nadu, India.
   [Rajan, Mariappan] Madurai Kamaraj Univ, Sch Chem, Dept Nat Prod Chem, Madurai 21, Tamil Nadu, India.
C3 University of Madras; Bharathidasan University; Madurai Kamaraj
   University
RP Jeyaraj, M (通讯作者)，Univ Madras, Natl Ctr Nanosci & Nanotechnol, Biomat & Nanomed Lab, Guindy Campus, Chennai 600025, Tamil Nadu, India.
EM jeyaraj@unom.in
RI ; Rajan, Mariappan/H 3555 2013; Sivaraj, Mehnath/JDD 4080 2023
OI S, MEHNATH/0000 0003 2798 0064; 
FU Indian Council of Medical Research, New Delhi
   [Fellowship/TB/32/2019/ECD I]; DSTSERB [EEQ/2020/000122]
FX We gratefully acknowledge the support from the Indian Council of Medical
   Research, New Delhi, for the Senior Research Fellowship (ICMR SRF Grant
   no. Fellowship/TB/32/2019/ECD I). We thank DSTSERB for funding this
   project, Grant No. EEQ/2020/000122.
CR Anand A, 2019, J MECH BEHAV BIOMED, V89, P89, DOI 10.1016/j.jmbbm.2018.09.024
   Anand A, 2018, T INDIAN CERAM SOC, V77, P106, DOI 10.1080/0371750X.2018.1465357
   Anirudhan TS, 2016, CARBOHYD POLYM, V136, P1118, DOI 10.1016/j.carbpol.2015.10.019
   Berenson JR, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.34071
   Boccaccini AR, 2007, FARADAY DISCUSS, V136, P27, DOI 10.1039/b616539g
   Chi YY, 2017, J CONTROL RELEASE, V261, P113, DOI 10.1016/j.jconrel.2017.06.027
   Clines GA, 2011, CURR OPIN ENDOCRINOL, V18, P339, DOI 10.1097/MED.0b013e32834b4401
   Couto DS, 2009, ACTA BIOMATER, V5, P115, DOI 10.1016/j.actbio.2008.08.006
   Deka JR, 2018, SOLID STATE SCI, V84, P104, DOI 10.1016/j.solidstatesciences.2018.07.016
   Diba M, 2019, J MATER CHEM B, V7, P796, DOI 10.1039/c8tb03062f
   Dong JL, 2018, INT J BIOL MACROMOL, V116, P1268, DOI 10.1016/j.ijbiomac.2018.05.116
   El Rashidy AA, 2017, ACTA BIOMATER, V62, P1, DOI 10.1016/j.actbio.2017.08.030
   Ge PJ, 2016, BIOMED PHARMACOTHER, V84, P423, DOI 10.1016/j.biopha.2016.09.061
   Gimeno M, 2015, EUR J PHARM BIOPHARM, V96, P264, DOI 10.1016/j.ejpb.2015.08.007
   Greasley SL, 2016, J COLLOID INTERF SCI, V469, P213, DOI 10.1016/j.jcis.2016.01.065
   Gu WY, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S44393
   Gupta N, 2016, J MATER CHEM B, V4, P7605, DOI 10.1039/c6tb01528j
   Islam MT, 2017, J TISSUE ENG, V8, DOI [10.1177/2041731417719170, 10.3329/jesnr.v8i1.24620]
   Kawatani M, 2009, CANCER SCI, V100, P1999, DOI 10.1111/j.1349 7006.2009.01294.x
   Lalzawmliana V, 2020, MAT SCI ENG C MATER, V106, DOI 10.1016/j.msec.2019.110180
   Letaief N, 2014, J NON CRYST SOLIDS, V402, P194, DOI 10.1016/j.jnoncrysol.2014.06.005
   Liu YQ, 2018, ACTA BIOMATER, V73, P531, DOI 10.1016/j.actbio.2018.04.014
   Lopez Noriega A, 2010, CHEM EUR J, V16, P10879, DOI 10.1002/chem.201000137
   Mehnath S, 2020, INT J PHARMACEUT, V584, DOI 10.1016/j.ijpharm.2020.119412
   Mehnath S, 2020, SURF COAT TECH, V392, DOI 10.1016/j.surfcoat.2020.125727
   Mehnath S, 2018, NEW J CHEM, V42, P17021, DOI 10.1039/c8nj03251c
   Mehnath S, 2019, INT J BIOL MACROMOL, V122, P174, DOI 10.1016/j.ijbiomac.2018.10.167
   Mehnath S, 2018, BIOMED PHARMACOTHER, V104, P661, DOI 10.1016/j.biopha.2018.05.096
   Mehnath S, 2017, POLYMER, V133, P119, DOI 10.1016/j.polymer.2017.11.020
   Morton SW, 2014, ADV HEALTHC MATER, V3, P867, DOI 10.1002/adhm.201300465
   Mountziaris PM, 2016, BIOMATER SCI UK, V4, P121, DOI 10.1039/c5bm00175g
   Naruphontjiralcul P, 2018, ACTA BIOMATER, V66, P67, DOI 10.1016/j.actbio.2017.11.008
   Olechnowicz SWZ, 2014, CANCER RES, V74, P1625, DOI 10.1158/0008 5472.CAN 13 2645
   Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535 7163.MCT 09 0462
   Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004
   Prasad SR, 2018, NANOTECHNOLOGY, V29, DOI 10.1088/1361 6528/aa9a21
   Qiao LW, 2015, INT J CLIN EXP MED, V8, P3465
   Ryu TK, 2016, J CONTROL RELEASE, V232, P152, DOI 10.1016/j.jconrel.2016.04.025
   Shoaib M, 2017, MAT SCI ENG C MATER, V77, P725, DOI 10.1016/j.msec.2017.03.288
   Singh RK, 2020, ACS APPL BIO MATER, V3, P2218, DOI 10.1021/acsabm.0c00050
   Sui BY, 2018, ACS APPL MATER INTER, V10, P23548, DOI 10.1021/acsami.8b05616
   Suvannasankha A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058 014 0484 9
   Valkenburg KC, 2013, CHIN J CANCER, V32, P380, DOI 10.5732/cjc.012.10218
   Verron E, 2014, DRUG DISCOV TODAY, V19, P1419, DOI 10.1016/j.drudis.2014.04.004
   Wang YD, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00283
   Wu CT, 2013, J MATER CHEM B, V1, P2710, DOI 10.1039/c3tb20275e
   Wu CT, 2013, BIOMATERIALS, V34, P422, DOI 10.1016/j.biomaterials.2012.09.066
   Wu CT, 2011, ACTA BIOMATER, V7, P3563, DOI 10.1016/j.actbio.2011.06.028
   Xi YH, 2019, INT J NANOMED, V14, P6425, DOI 10.2147/IJN.S211981
   Xia W, 2006, J CONTROL RELEASE, V110, P522, DOI 10.1016/j.jconrel.2005.11.002
   Xia W, 2008, J NON CRYST SOLIDS, V354, P1338, DOI 10.1016/j.jnoncrysol.2006.10.084
   Xu T, 2007, MAT SCI ENG C BIO S, V27, P579, DOI 10.1016/j.msec.2006.05.029
   Xu YY, 2017, BIOMACROMOLECULES, V18, P3168, DOI 10.1021/acs.biomac.7b00828
   Yan HM, 2017, DRUG DELIV, V24, P30, DOI 10.1080/10717544.2016.1228713
   Ye WL, 2015, SCI REP UK, V5, DOI 10.1038/srep14614
   Zhao L, 2019, NANOTECHNOLOGY, V30, DOI 10.1088/1361 6528/ab055f
   Zhao YF, 2008, J BIOMED MATER RES A, V85A, P1032, DOI 10.1002/jbm.a.31545
NR 57
TC 25
Z9 25
U1 0
U2 65
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0254 0584
EI 1879 3312
J9 MATER CHEM PHYS
JI Mater. Chem. Phys.
PD NOV 15
PY 2021
VL 273
AR 125146
DI 10.1016/j.matchemphys.2021.125146
EA AUG 2021
PG 12
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA UJ3IH
UT WOS:000691182800001
DA 2025 08 17
ER

PT J
AU Li, XS
   Fan, C
   Wang, JL
   Li, P
   Xu, XY
   Guo, RX
   Wei, JZ
   Cheng, Y
   Lin, HP
   Fu, XD
AF Li, Xiaosa
   Fan, Chao
   Wang, Jiale
   Li, Ping
   Xu, Xingyan
   Guo, Ruixin
   Wei, Jinzhi
   Cheng, Yang
   Lin, Huiping
   Fu, Xiaodong
TI Follicle stimulating hormone accelerates osteoclast migration by
   enhancing methyltransferase like 3 mediated m6A methylation of cathepsin
   K
SO JOURNAL OF MOLECULAR ENDOCRINOLOGY
LA English
DT Article
DE follicle stimulating hormone; osteoclasts; methyltransferase like 3;
   cathepsin K
ID POSTMENOPAUSAL WOMEN; BONE RESORPTION; DENSITY; EXPRESSION
AB Follicle stimulating hormone (FSH) accelerates osteoporosis in postmenopausal women, while the underlying mechanism remains uncharacterized. N6 methyladenosine (m6A) is one of the most important regulations in the development of osteoporosis. In this study, we aimed to investigate the role of FSH in m6A modification and osteoclast function. Here, we showed that FSH upregulated m6A levels in osteoclasts via stimulating methyltransferase like 3 (METTL3) protein expression. FSH enhanced osteoclast migration, while the knockdown of METTL3 eliminated this enhancement. Both MeRIP seq and RNA sequencing identified that cathepsin K (CTSK) is the potential downstream target of METTL3. Knockdown of CTSK reduced FSH upregulated osteoclast migration. Furthermore, silencing METTL3 decreased CTSK mRNA stability. Finally, FSH induced phosphorylation of cyclic AMP response element binding protein (CREB), while silencing of CREB attenuated the effects of FSH on the promoter transcriptional activity of Mettl3 and CTSK/METTL3 protein. Taken together, these findings indicate that FSH promotes osteoclast migration via the CREB/METTL3/CTSK signaling pathway, which may provide a potential target for suppressing osteoclast mobility and postmenopausal osteoporosis therapy.
C1 [Li, Xiaosa; Fan, Chao; Wang, Jiale; Li, Ping; Xu, Xingyan; Guo, Ruixin; Wei, Jinzhi; Lin, Huiping; Fu, Xiaodong] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou Inst Cardiovasc Dis, Dept Cardiol,Guangdong Key Lab Vasc Dis, Guangzhou, Peoples R China.
   [Cheng, Yang] South China Univ Technol, Guangzhou Peoples Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Fu, Xiaodong] Guangzhou Med Univ, Affiliated Hosp 6, Qingyuan Peoples Hosp, Qingyuan 511518, Guangdong, Peoples R China.
C3 Guangzhou Medical University; South China University of Technology;
   Guangzhou Medical University
RP Lin, HP; Fu, XD (通讯作者)，Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou Inst Cardiovasc Dis, Dept Cardiol,Guangdong Key Lab Vasc Dis, Guangzhou, Peoples R China.; Cheng, Y (通讯作者)，South China Univ Technol, Guangzhou Peoples Hosp 1, Guangzhou, Guangdong, Peoples R China.; Fu, XD (通讯作者)，Guangzhou Med Univ, Affiliated Hosp 6, Qingyuan Peoples Hosp, Qingyuan 511518, Guangdong, Peoples R China.
EM eychengy@scut.edu.cn; 2021390022@gzhmu.edu.cn; fuxiaod@gzhmu.edu.cn
RI Lin, Huiping/HNT 0883 2023; Xu, Xingyan/KVX 7827 2024; wang,
   jiale/GPX 1361 2022; Li, Ping/GON 7455 2022
OI Xu, Xingyan/0000 0003 4526 7035; 
FU Key Discipline of Guangzhou Education Bureau (Basic Medicine)
   [201851839]
FX This project was funded by Key Discipline of Guangzhou Education Bureau
   (Basic Medicine) (grant number 201851839).
CR Amonkar MM, 2002, J COMMUN HEALTH, V27, P335, DOI 10.1023/A:1019836610275
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chandra A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073553
   Chang ML, 2020, INT J BIOCHEM CELL B, V129, DOI 10.1016/j.biocel.2020.105862
   Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683
   Devleta B, 2004, J BONE MINER METAB, V22, P360, DOI 10.1007/s00774 004 0495 1
   Gong R, 2022, J LEUKOCYTE BIOL, V112, P669, DOI 10.1002/JLB.2A0421 221R
   Han XF, 2020, THERIOGENOLOGY, V148, P103, DOI 10.1016/j.theriogenology.2020.03.005
   Hikata T, 2009, BLOOD, V113, P2202, DOI 10.1182/blood 2008 06 162594
   Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556 018 0045 z
   Huang W, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045 021 01129 8
   Iqbal J, 2006, P NATL ACAD SCI USA, V103, P14925, DOI 10.1073/pnas.0606805103
   Ji YT, 2018, P NATL ACAD SCI USA, V115, P2192, DOI 10.1073/pnas.1718144115
   Lee YD, 2015, J BIOL CHEM, V290, P6522, DOI 10.1074/jbc.M114.598581
   Li D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051660
   Li R, 2019, CELL DEATH DIFFER, V26, P2447, DOI 10.1038/s41418 019 0312 y
   Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1038 7
   Li XS, 2017, THERANOSTICS, V7, P4671, DOI 10.7150/thno.21216
   Liu L, 2020, MOL THER, V28, P2177, DOI 10.1016/j.ymthe.2020.06.024
   Liu P, 2017, NATURE, V546, P107, DOI 10.1038/nature22342
   Liu XM, 2015, AGING CELL, V14, P409, DOI 10.1111/acel.12331
   Martin TJ, 2006, NAT MED, V12, P612, DOI 10.1038/nm0606 612
   Sanchez AM, 2016, MOL CELL ENDOCRINOL, V437, P22, DOI 10.1016/j.mce.2016.08.009
   Meyer KD, 2014, NAT REV MOL CELL BIO, V15, P313, DOI 10.1038/nrm3785
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Nevius E, 2015, J EXP MED, V212, P1931, DOI 10.1084/jem.20150088
   Novinec M, 2013, BIOL CHEM, V394, P1163, DOI 10.1515/hsz 2013 0134
   Robinson LJ, 2010, BIOCHEM BIOPH RES CO, V394, P12, DOI 10.1016/j.bbrc.2010.02.112
   Rosen CJ, 2005, NEW ENGL J MED, V353, P595, DOI 10.1056/NEJMcp043801
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   SenGupta S, 2021, NAT REV MOL CELL BIO, V22, P529, DOI 10.1038/s41580 021 00366 6
   Sheng SM, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph192215344
   Sowers MR, 2010, J CLIN ENDOCR METAB, V95, P2155, DOI 10.1210/jc.2009 0659
   Sowers MR, 2006, J CLIN ENDOCR METAB, V91, P1261, DOI 10.1210/jc.2005 1836
   Sowers MR, 2003, OSTEOPOROSIS INT, V14, P44, DOI 10.1007/s00198 002 1307 x
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Sun L, 2010, BIOCHEM BIOPH RES CO, V394, P6, DOI 10.1016/j.bbrc.2010.02.113
   Tan DL, 2021, GENE THER, V28, P155, DOI 10.1038/s41434 020 00195 w
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Troen BR, 2006, ANN NY ACAD SCI, V1068, P165, DOI 10.1196/annals.1346.018
   Wang J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134986
   Wang W, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03915 1
   Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730
   Wayne CM, 2007, MOL ENDOCRINOL, V21, P1940, DOI 10.1210/me.2007 0020
   Wu YS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06898 4
   Xiong J, 2022, NATURE, V603, P470, DOI 10.1038/s41586 022 04463 0
   Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349 7006.2005.00062.x
   Yan G, 2020, MOL THER NUCL ACIDS, V19, P421, DOI 10.1016/j.omtn.2019.12.001
   Yang H, 2020, MOLECULES, V25, DOI 10.3390/molecules25184136
   Yaroslavskiy BB, 2007, J CELL SCI, V120, P2884, DOI 10.1242/jcs.004184
   Zhang HB, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.778941
   Zhang Q, 2019, P NATL ACAD SCI USA, V116, P17980, DOI 10.1073/pnas.1905489116
   Zhu DX, 2018, TRENDS ENDOCRIN MET, V29, P571, DOI 10.1016/j.tem.2018.06.001
   Zhu LL, 2012, P NATL ACAD SCI USA, V109, P14574, DOI 10.1073/pnas.1212806109
NR 55
TC 5
Z9 5
U1 2
U2 13
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0952 5041
EI 1479 6813
J9 J MOL ENDOCRINOL
JI J. Mol. Endocrinol.
PD APR 1
PY 2024
VL 72
IS 3
AR e230130
DI 10.1530/JME 23 0130
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OM9A2
UT WOS:001207796500003
PM 38261314
DA 2025 08 17
ER

PT J
AU Martinez Font, E
   Pérez Capó, M
   Ramos, R
   Felipe, I
   Garcías, C
   Luna, P
   Terrasa, J
   Martín Broto, J
   Vögler, O
   Alemany, R
   Obrador Hevia, A
AF Martinez Font, Esther
   Perez Capo, Marina
   Ramos, Rafael
   Felipe, Irene
   Garcias, Carmen
   Luna, Pablo
   Terrasa, Josefa
   Martin Broto, Javier
   Vogler, Oliver
   Alemany, Regina
   Obrador Hevia, Antonia
TI Impact of Wnt/β Catenin Inhibition on Cell Proliferation through
   CDC25A Downregulation in Soft Tissue Sarcomas
SO CANCERS
LA English
DT Article
DE soft tissue sarcoma; Wnt signaling; beta catenin; CDC25A; PRI 724
ID DRIVES PROLIFERATION; SIGNALING PATHWAY; BINDING PROTEIN; DISTINCT
   ROLES; GENE; P300; APOPTOSIS; GROWTH; CBP; OSTEOSARCOMA
AB Simple Summary: Growing evidence suggests that Wnt signaling may be crucial for tumorigenesis and progression of soft tissue sarcomas (STS). Inhibitors of this pathway are currently in clinical trials or pre clinical studies in order to validate its utility in different neoplasia. One of this inhibitors, PRI 724, is showing promising results for advanced pancreatic adenocarcinoma or ovarian cancer. We found that PRI 724 is able to suppress cell viability/proliferation and to increase cell death rates of soft tissue sarcomas cells in vitro. CDC25A, a target gene of Wnt signaling pathway, is essential for STS proliferation because its downregulation via siRNA was able to mimic the effect of PRT 724 on cell cycle arrest and evaluation of NCBI/GenBank data confirmed its overexpression in STS patients' samples. Moreover, in vitro administration of PRI 724 along with standard STS chemotherapeutic drugs improved the efficacy of chemotherapy, suggesting that Wnt inhibition could be a promising new therapeutic strategy in STS.
   The Wnt signaling pathway is an important cellular mechanism for regulating differentiation processes as well as cell cycle events, and different inhibitors of this pathway, for example, PRI 724, are showing promising results in clinical trials for treatment of advanced pancreatic adenocarcinoma or ovarian cancer. Growing evidence suggests that Wnt signaling may also be crucial for tumorigenesis and progression of soft tissue sarcomas (STS), a malignant neoplasm with few therapeutic options at an advanced state. Our study with several STS cell lines and primary cultures shows that inhibition of Wnt/beta catenin signaling with PRI 724 is able to suppress cell viability/proliferation and to increase cell death rates. TCF/beta catenin mediated transcriptional activity is decreased in treated cells, leading to downregulation of its target genes CCND1 and CDC25A.The latter was critical because its downregulation via siRNA was able to mimic the effect of PRI 724 on cell cycle arrest and cell death induction. An evaluation of NCBI/GenBank data confirmed that CDC25AmRNA is elevated in STS patients. Importantly, PRI 724 in combination with standard STS chemotherapeutics doxorubicin or trabectedin enhanced their antitumoral effect in a synergistic manner according to isobolographic analysis, suggesting that Wnt inhibition through PRI 724 could be a beneficial combination regime in patients with advanced STS.
C1 [Martinez Font, Esther; Perez Capo, Marina; Garcias, Carmen; Terrasa, Josefa; Vogler, Oliver; Alemany, Regina; Obrador Hevia, Antonia] Son Espases Univ Hosp, Hlth Res Inst Balearic Isl IdISBa IUNICS, Grp Adv Therapies & Biomarkers Clin Oncol, Palma De Mallorca 07120, Spain.
   [Martinez Font, Esther; Perez Capo, Marina; Garcias, Carmen; Luna, Pablo; Terrasa, Josefa] Son Espases Univ Hosp, Med Oncol Dept, Palma De Mallorca 07120, Spain.
   [Ramos, Rafael] Son Espases Univ Hosp, Pathol Dept, Palma De Mallorca 07120, Spain.
   [Felipe, Irene] Spanish Natl Canc Res Ctr CNIO, Epithelial Carcinogenesis Grp, Madrid 28029, Spain.
   [Martin Broto, Javier] Univ Hosp Virgen del Rocio, Med Oncol Dept, Seville 41013, Spain.
   [Martin Broto, Javier] Univ Seville, Inst Biomed Sevilla, CSIC, HUVR,IBIS, Seville 41013, Spain.
   [Vogler, Oliver; Alemany, Regina] Univ Balearic Isl, Dept Biol, Grp Clin & Translat Res, Palma De Mallorca 07122, Spain.
   [Obrador Hevia, Antonia] Son Espases Univ Hosp, Mol Diag Unit, Palma De Mallorca 07120, Spain.
C3 Hospital Universitari Son Espases; Hospital Universitari Son Espases;
   Hospital Universitari Son Espases; Centro Nacional de Investigaciones
   Oncologicas (CNIO); Virgen del Rocio University Hospital; Consejo
   Superior de Investigaciones Cientificas (CSIC); University of Sevilla;
   CSIC JA USE   Instituto de Biomedicina de Sevilla (IBIS); Universitat de
   les Illes Balears; Hospital Universitari Son Espases
RP Obrador Hevia, A (通讯作者)，Son Espases Univ Hosp, Hlth Res Inst Balearic Isl IdISBa IUNICS, Grp Adv Therapies & Biomarkers Clin Oncol, Palma De Mallorca 07120, Spain.; Obrador Hevia, A (通讯作者)，Son Espases Univ Hosp, Mol Diag Unit, Palma De Mallorca 07120, Spain.
EM esther.martinez@ssib.es; marina.perez@ssib.es; rafaelf.ramos@ssib.es;
   ifelipe@cnio.es; mariad.garcias@ssib.es; pablo.luna@ssib.es;
   josefa.terrasa@ssib.es; jmartin@mustbesevilla.org; oliver.vogler@uib.es;
   regina.alemany@uib.es; antonia.obrador@ssib.es
RI ; Vögler, Oliver/D 7658 2011; Alemany, Regina/A 2314 2011; Martinez,
   Esther/AAF 2532 2021; Martín Broto, Javier/AAI 2313 2019; Obrador,
   Antònia/AAE 6480 2021; FELIPE, IRENE/ABF 9743 2021
OI Alemany, Regina/0000 0003 2180 1213; Martinez Font,
   Esther/0000 0001 6644 6441; Martin Broto, Javier/0000 0001 7350 6916;
   Felipe Abrio, Irene/0000 0001 7781 1459; 
FU Grupo Espanol de Investigacion en Sarcomas (GEIS); FundacionMari Paz
   Jimenez Casado; Programa Estrategia de Emprendimiento y Empleo Joven,
   Garantia Juvenil (Ministerio de Trabajo, Migraciones y Seguridad
   Social SOIB)
FX This study was financed by Grupo Espanol de Investigacion en Sarcomas
   (GEIS) and FundacionMari Paz Jimenez Casado. MPC is supported by
   Programa Estrategia de Emprendimiento y Empleo Joven, Garantia Juvenil
   (Ministerio de Trabajo, Migraciones y Seguridad Social SOIB).
CR Al Matouq J, 2017, CANCER LETT, V410, P41, DOI 10.1016/j.canlet.2017.09.023
   An T, 2017, BIOCHEM PHARMACOL, V131, P29, DOI 10.1016/j.bcp.2017.02.011
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   [Anonymous], **NON TRADITIONAL**
   Arber N, 1997, CANCER RES, V57, P1569
   Baarsma HA, 2013, PHARMACOL THERAPEUT, V138, P66, DOI 10.1016/j.pharmthera.2013.01.002
   Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619
   Bertucci F, 2017, MOL CANCER THER, V16, P2324, DOI 10.1158/1535 7163.MCT 17 0491
   Broggini M, 2000, ANTICANCER RES, V20, P4835
   Burningham Z, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045 3329 2 14
   Chen CB, 2015, ONCOTARGET, V6, P17570, DOI 10.18632/oncotarget.4100
   Cironi L, 2016, SCI REP UK, V6, DOI 10.1038/srep22113
   Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092 8674(00)00072 6
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Fang Fang, 2018, Oncotarget, V9, P36780, DOI 10.18632/oncotarget.26377
   Harb J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912 019 0763 9
   He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476 5586(04)80048 4
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Kahn M, 2011, FUTURE MED CHEM, V3, P1745, DOI [10.4155/FMC.11.126, 10.4155/fmc.11.126]
   Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538
   Kim J.Y., 2019, ANN ONCOL, V30, pv243, DOI [10.1093/annonc/mdz246.124, DOI 10.1093/ANNONC/MDZ246.124]
   Kleszcz R, 2019, CELL ONCOL, V42, P505, DOI 10.1007/s13402 019 00440 4
   Krishnamurthy N, 2018, CANCER TREAT REV, V62, P50, DOI 10.1016/j.ctrv.2017.11.002
   Kung AL, 2000, GENE DEV, V14, P272
   Lahat G, 2008, SURG CLIN N AM, V88, P451, DOI 10.1016/j.suc.2008.03.006
   Lenz HJ, 2014, CANCER SCI, V105, P1087, DOI 10.1111/cas.12471
   Leow PC, 2010, INVEST NEW DRUG, V28, P766, DOI 10.1007/s10637 009 9311 z
   Li C, 2018, ONCOL LETT, V15, P8973, DOI 10.3892/ol.2018.8491
   Linch M, 2014, NAT REV CLIN ONCOL, V11, P187, DOI 10.1038/nrclinonc.2014.26
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433
   Martinez Font E, 2017, MOL CANCER THER, V16, P1166, DOI 10.1158/1535 7163.MCT 16 0585
   Martins Neves SR, 2018, CANCER LETT, V414, P1, DOI 10.1016/j.canlet.2017.11.004
   Moneo V, 2007, J CELL BIOCHEM, V100, P339, DOI 10.1002/jcb.21073
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   O'Cearbhaill RE, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.2515
   Patel A, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.4_suppl.88
   Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098 2264(199901)24:1<30::AID GCC5>3.0.CO;2 P
   Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052
   Pridgeon MG, 2017, CURR OSTEOPOROS REP, V15, P239, DOI 10.1007/s11914 017 0377 9
   Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499
   Roth JF, 2003, EMBO J, V22, P5186, DOI 10.1093/emboj/cdg473
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Shi ZD, 2012, J NEUROIMMUNE PHARM, V7, P892, DOI 10.1007/s11481 012 9354 3
   Sirvent N, 2000, GENE CHROMOSOME CANC, V29, P117, DOI 10.1002/1098 2264(2000)9999:9999<::AID GCC1014>3.0.CO;2 Q
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takahashi Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078 0432.CCR 09 2943
   Taylor BS, 2011, NAT REV CANCER, V11, P541, DOI 10.1038/nrc3087
   Trautmann M, 2014, ONCOGENE, V33, P5006, DOI 10.1038/onc.2013.443
   Vijayakumar S, 2011, CANCER CELL, V19, P601, DOI 10.1016/j.ccr.2011.03.010
   Wei W, 2010, INT J CANCER, V126, P2426, DOI 10.1002/ijc.24810
   Yan MC, 2017, EXP BIOL MED, V242, P1185, DOI 10.1177/1535370217708198
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
NR 54
TC 18
Z9 19
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD SEP
PY 2020
VL 12
IS 9
AR 2556
DI 10.3390/cancers12092556
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA OE8WP
UT WOS:000580804200001
PM 32911761
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liang, WQ
   Chen, QJ
   Cheng, SS
   Wei, RM
   Li, YJ
   Yao, CF
   Ouyang, ZC
   Kang, DW
   Chen, AJ
   Liu, ZZ
   Li, K
   Bai, XC
   Li, QC
   Huang, B
AF Liang, Wenquan
   Chen, Qingjing
   Cheng, Shasha
   Wei, Ruiming
   Li, Yuejun
   Yao, Chenfeng
   Ouyang, Zhicong
   Kang, Dawei
   Chen, Ajuan
   Liu, Zezheng
   Li, Kai
   Bai, Xiaochun
   Li, Qingchu
   Huang, Bin
TI Skin chronological aging drives age related bone loss via secretion of
   cystatin A
SO NATURE AGING
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; TYROSINE PHOSPHORYLATION; EXFOLIATIVE
   ICHTHYOSIS; PROTEASE INHIBITOR; SRC; KERATINOCYTES; OSTEOBLAST;
   THICKNESS; INSIGHTS; BARRIER
AB Although clinical evidence has indicated an association between skin atrophy and bone loss during aging, their causal relationship and the underlying mechanisms are unknown. Here we show that premature skin aging drives bone loss in mice. We further identify that cystatin A (Csta), a keratinocyte enriched secreted factor, mediates the effect of skin on bone. Keratinocyte derived Csta binds the receptor for activated C kinase 1 in osteoblast and osteoclast progenitors, thus promoting their proliferation but inhibiting osteoclast differentiation. Csta secretion decreases with skin aging in both mice and humans, thereby causing senile osteoporosis by differentially decreasing the numbers of osteoblasts and osteoclasts. In contrast, topical application of calcipotriol stimulates Csta production in the epidermis and alleviates osteoporosis. These results reveal a mode of endocrine regulation of bone metabolism in the skin, and identify Csta as an epidermally derived hormone linking skin aging to age related bone loss. Enhancers of skin Csta levels could serve as a potential topical drug for treatment of senile osteoporosis.
   Skin thickness and bone density decrease with age; however, the interactions between skin and bone during aging are unclear. Here the authors show that cystatin A is a skin derived protein that decreases with age and causes age related bone loss. Further, topical application of calcipotriol stimulates cystatin A production in the skin and alleviates bone loss.
C1 [Liang, Wenquan; Chen, Qingjing; Wei, Ruiming; Yao, Chenfeng; Ouyang, Zhicong; Kang, Dawei; Chen, Ajuan; Liu, Zezheng; Li, Kai; Li, Qingchu; Huang, Bin] Third Affiliated Hosp Southern Med Univ, Acad Orthoped, Dept Orthoped, Guangdong Prov Key Lab Bone & Joint Degenerat Dis, Guangzhou, Guangdong, Peoples R China.
   [Cheng, Shasha] Third Affiliated Hosp Southern Med Univ, Dept Clin Lab, Guangzhou, Peoples R China.
   [Li, Yuejun] Second Peoples Hosp Panyu Dist, Dept Orthoped, Guangzhou, Peoples R China.
   [Bai, Xiaochun] Southern Med Univ, Sch Basic Med Sci, Dept Cell Biol, Guangzhou, Peoples R China.
C3 Southern Medical University   China
RP Huang, B (通讯作者)，Third Affiliated Hosp Southern Med Univ, Acad Orthoped, Dept Orthoped, Guangdong Prov Key Lab Bone & Joint Degenerat Dis, Guangzhou, Guangdong, Peoples R China.
EM binxue483@163.com
RI Li, Yuejun/AAD 7170 2021; Li, Qingchu/AAE 5217 2022; wenquan,
   liang/LOR 6971 2024
OI Chen, Qingjing/0000 0003 4480 4740; Liang, Wenquan/0000 0003 0881 6808;
   /0000 0001 6295 6647
FU National Natural Science Foundation of China [82172507, 81700783,
   81991511]; Guangdong Natural Science Fund Management Committee
   [2019A1515011876, 2018A030313937]; Guangzhou Municipal Science and
   Technology Bureau [202002030176]
FX This research was supported by grant nos. 82172507 (B.H.), 81700783
   (B.H.) and 81991511 (X.B.) from the National Natural Science Foundation
   of China, nos. 2019A1515011876 (B.H.) and 2018A030313937 (Z.L.) from
   Guangdong Natural Science Fund Management Committee and no. 202002030176
   (B.H.) from Guangzhou Municipal Science and Technology Bureau. The
   funders had no role in study design, data collection and analysis,
   decision to publish or preparation of the manuscript.
CR Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038
   Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784
   Adams DR, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 22
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Black M M, 1970, Br Med J, V4, P773
   Blaydon DC, 2011, AM J HUM GENET, V89, P564, DOI 10.1016/j.ajhg.2011.09.001
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chandler Paulette D., 2015, BMC Nutrition, V1, DOI 10.1186/s40795 015 0024 8
   Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002
   Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200
   CHAPPARD D, 1991, ACTA ANAT, V141, P239
   Chen AJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00204 1
   Choi YH, 2015, MOL CELL ENDOCRINOL, V407, P85, DOI 10.1016/j.mce.2015.03.010
   Cunningham TJ, 2017, J CLIN INVEST, V127, P106, DOI 10.1172/JCI89820
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Dayoub JC, 2018, EXP GERONTOL, V110, P230, DOI 10.1016/j.exger.2018.06.019
   Deng P, 2021, CELL STEM CELL, V28, P1057, DOI 10.1016/j.stem.2021.01.010
   Denu RA, 2016, ACTA HAEMATOL BASEL, V136, P85, DOI 10.1159/000445096
   Di Giaimo R, 2002, HUM MOL GENET, V11, P2941, DOI 10.1093/hmg/11.23.2941
   Ekström U, 2008, FEBS J, V275, P4571, DOI 10.1111/j.1742 4658.2008.06600.x
   Giangreco A, 2010, J INVEST DERMATOL, V130, P604, DOI 10.1038/jid.2009.297
   Gil A, 2018, ANN NUTR METAB, V72, P87, DOI 10.1159/000486536
   Hall G, 2005, J AM ACAD DERMATOL, V53, P555, DOI 10.1016/j.jaad.2004.08.039
   Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105 2896.2005.00335.x
   HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo 113 6 1950
   Hu LZ, 2017, J INVEST DERMATOL, V137, P1277, DOI 10.1016/j.jid.2017.01.007
   Huang B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13885
   Huang MJ, 2014, ANN RHEUM DIS, V73, P1719, DOI 10.1136/annrheumdis 2013 203231
   Kato T, 2005, J ALLERGY CLIN IMMUN, V116, P169, DOI 10.1016/j.jaci.2005.03.044
   Kawaguchi H, 1999, J CLIN INVEST, V104, P229, DOI 10.1172/JCI5705
   KRAGBALLE K, 1993, DERMATOL CLIN, V11, P137, DOI 10.1016/S0733 8635(18)30290 0
   Krunic AL, 2013, PEDIATR DERMATOL, V30, pE87, DOI 10.1111/pde.12092
   Lause M, 2017, TRANSL PEDIATR, V6, P300, DOI 10.21037/tp.2017.09.08
   Li FW, 2017, JOVE J VIS EXP, DOI 10.3791/56027
   Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103
   Lin J, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005867
   Mamidipudi V, 2007, ONCOGENE, V26, P2914, DOI 10.1038/sj.onc.1210091
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   MCCONKEY B, 1963, LANCET, V1, P693
   Moosbrugger Martinz V, 2015, BRIT J DERMATOL, V172, P1628, DOI 10.1111/bjd.13545
   Moschen AR, 2005, GUT, V54, P479, DOI 10.1136/gut.2004.044370
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474 9726.2012.00795.x
   Opie SR, 2003, J VIROL, V77, P6995, DOI 10.1128/JVI.77.12.6995 7006.2003
   Ouyang ZC, 2022, BIOMED PHARMACOTHER, V151, DOI 10.1016/j.biopha.2022.113164
   Park JH, 2019, EXP MOL MED, V51, DOI 10.1038/s12276 019 0285 4
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Robinson RJ, 1997, EUR J GASTROEN HEPAT, V9, P945, DOI 10.1097/00042737 199710000 00005
   Rosenfeld L, 2020, J MED CHEM, V63, P7601, DOI 10.1021/acs.jmedchem.0c00418
   Russell Goldman E, 2020, AM J PATHOL, V190, P1356, DOI 10.1016/j.ajpath.2020.03.007
   Sallach J, 2014, MOL THER, V22, P929, DOI 10.1038/mt.2014.14
   SAVVAS M, 1989, BRIT J OBSTET GYNAEC, V96, P1392, DOI 10.1111/j.1471 0528.1989.tb06300.x
   Shuster S, 2020, J ROY SOC MED, V113, P158, DOI 10.1177/0141076820910315
   Sirufo MM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134749
   SMITH EL, 1986, J INVEST DERMATOL, V86, P709, DOI 10.1111/1523 1747.ep12276343
   STEVEN AC, 1994, J CELL SCI, V107, P693
   Stevenson S, 2007, CLIN INTERV AGING, V2, P283
   Takahashi H, 2003, ARCH DERMATOL RES, V295, P80, DOI 10.1007/s00403 003 0396 5
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tohmonda T, 2015, J CLIN INVEST, V125, P3269, DOI 10.1172/JCI76765
   Tong L, 1996, J MOL BIOL, V256, P601, DOI 10.1006/jmbi.1996.0112
   Umbayev B, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7145656
   Van Dijk FS, 2014, AM J MED GENET A, V164, P1470, DOI 10.1002/ajmg.a.36545
   Vasilopoulos Y, 2007, ALLERGY, V62, P514, DOI 10.1111/j.1398 9995.2007.01350.x
   Vasilopoulos Y, 2008, EUR J HUM GENET, V16, P1002, DOI 10.1038/ejhg.2008.40
   Villeneuve D, 2020, JOINT BONE SPINE, V87, P511, DOI 10.1016/j.jbspin.2020.04.004
   WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719
   Whitmore SE, 1998, J AM ACAD DERMATOL, V38, P248, DOI 10.1016/S0190 9622(98)70600 0
   Yi ZA, 2009, BLOOD, V114, P3191, DOI 10.1182/blood 2009 03 207522
   Yousefzadeh MJ, 2021, NATURE, V594, P100, DOI 10.1038/s41586 021 03547 7
   Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073
   Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963
NR 75
TC 24
Z9 25
U1 9
U2 52
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2662 8465
J9 NATURE AGING
JI Nature Aging
PD OCT
PY 2022
VL 2
IS 10
BP 906
EP +
DI 10.1038/s43587 022 00285 x
PG 36
WC Cell Biology; Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology; Neurosciences & Neurology
GA 9C1XW
UT WOS:000935219500010
PM 37118283
DA 2025 08 17
ER

PT J
AU Loberg, RD
   Gayed, BA
   Olson, KB
   Pienta, KJ
AF Loberg, RD
   Gayed, BA
   Olson, KB
   Pienta, KJ
TI A paradigm for the treatment of prostate cancer bone metastases based on
   an understanding of tumor cell microenvironment interactions
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE prostate cancer; bone metastasis; cancer therapy
ID TARGETED THERAPY; TRIAL; CARCINOMA; ANTAGONIST; ANTIGEN; IMMUNOTHERAPY;
   OSTEOCLAST; INHIBITOR; PATTERNS; AUTOPSY
AB The pliability of cancer cells to mutate into several different phenotypes in an attempt to find one that will survive and colonize at the metastatic site is a tremendous "hurdle" to overcome in designing novel cancer therapeutics. New targets of therapy are essential if we are to effectively overcome the evasiveness of cancer. The interaction between the turner cell and the surrounding microenvironment creates a vicious cycle that perpetuates disease survival and progression. The future of cancer therapy resides in the ability to focus on the recruited and exploited relationships of the cancer cell with the host environment. These therapies target cancer cell growth early and interrupt the vicious cycle that is created by the tumor cells interacting with bone components by inhibiting osteoclasts, osteoblasts, stromal cells, and endothelial cells. They alter the bone microenvironment, creating a hostile "soil" that prevents the "seed" from developing into bone metastases and represent a potential new platform for the development of Prostate cancer therapeutics.
C1 Univ Michigan, Urol Ctr, Dept Urol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Urol Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Loberg, RD (通讯作者)，Univ Michigan, Urol Ctr, Dept Urol, 7431 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM rloberg@umich.edu
RI Pienta, Kenneth/E 7679 2015
OI Pienta, Kenneth/0000 0002 4138 2186
FU National Cancer Institute [P01CA093900] Funding Source: NIH RePORTER
CR Abdollahi A, 2003, CANCER RES, V63, P3755
   Adhami VM, 2003, J NUTR, V133, p2417S, DOI 10.1093/jn/133.7.2417S
   Akerley W, 2002, CANCER, V94, P1654, DOI 10.1002/cncr.10437
   BAGSHAW MA, 1990, UROL CLIN N AM, V17, P787
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Burch PA, 2004, PROSTATE, V60, P197, DOI 10.1002/pros.20040
   Chung LWK, 2003, CANCER AM CANCER SOC, V97, P772, DOI 10.1002/cncr.11140
   Dafermou A, 2001, EUR J NUCL MED, V28, P788, DOI 10.1007/s002590100533
   DEVITA VT, 1983, CANCER, V51, P1209, DOI 10.1002/1097 0142(19830401)51:7<1209::AID CNCR2820510707>3.0.CO;2 J
   Diel IJ, 2004, EUR J CANCER, V40, P1704, DOI 10.1016/j.ejca.2004.03.025
   Drevs J, 2005, ANN ONCOL, V16, P558, DOI 10.1093/annonc/mdi118
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Fukatsu A, 2003, UROLOGY, V61, P370, DOI 10.1016/S0090 4295(02)02159 3
   Graham MC, 1999, CLIN CANCER RES, V5, P1307
   GRIMARD L, 1988, INT J RADIAT ONCOL, V14, P565, DOI 10.1016/0360 3016(88)90276 3
   Guise Theresa A, 2004, Cancer Treat Res, V118, P197
   Jiann BP, 2002, LIFE SCI, V70, P3167, DOI 10.1016/S0024 3205(02)01574 6
   Kalikin LM, 2003, CANCER BIOL THER, V2, P656
   Keller ET, 2002, DRUG TODAY, V38, P91, DOI 10.1358/dot.2002.38.2.820105
   Lee David, 2003, Clin Prostate Cancer, V2, P84
   Loberg RD, 2004, NEOPLASIA, V6, P302, DOI 10.1593/neo.03484
   Maragoudakis ME, 2002, BIOCHEM SOC T, V30, P173, DOI 10.1042/BST0300173
   Meerovitch K, 2003, VASC PHARMACOL, V40, P77, DOI 10.1016/S1537 1891(02)00339 7
   MOHAMMAD KS, 2003, CLIN ORTHOP RELAT R, V2, pS67
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nelson JB, 2005, WORLD J UROL, V23, P19, DOI 10.1007/s00345 004 0478 9
   Nelson JB, 2003, J UROLOGY, V169, P1143, DOI 10.1097/01.ju.0000042162.08938.27
   Neves M, 2002, NUCL MED BIOL, V29, P329, DOI 10.1016/S0969 8051(01)00305 5
   NORTON L, 1977, JNCI J NATL CANCER I, V58, P1735, DOI 10.1093/jnci/58.6.1735
   Palmedo H, 2003, J CLIN ONCOL, V21, P2869, DOI 10.1200/JCO.2003.12.060
   Posey JA, 2001, CANCER BIOTHER RADIO, V16, P125, DOI 10.1089/108497801300189218
   Roudier MP, 2003, CLIN EXP METASTAS, V20, P171, DOI 10.1023/A:1022627421000
   Rudek MA, 2001, J CLIN ONCOL, V19, P584, DOI 10.1200/JCO.2001.19.2.584
   Saikali Zeina, 2003, Anticancer Drugs, V14, P773
   SAITOH H, 1984, CANCER AM CANCER SOC, V54, P3078, DOI 10.1002/1097 0142(19841215)54:12<3078::AID CNCR2820541245>3.0.CO;2 U
   Schellhammer PF, 2005, WORLD J UROL, V23, P47, DOI 10.1007/s00345 004 0475 z
   Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008 5472.CAN 03 3437
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140 6736(00)03639 4
   Winquist E, 2004, JNCI J NATL CANCER I, V96, P1183, DOI 10.1093/jnci/djh234
   WITHRINGTON PG, 1989, J CARDIOVASC PHARM, V13, pS209, DOI 10.1097/00005344 198900135 00060
   Yu H, 1997, J UROLOGY, V157, P913, DOI 10.1016/S0022 5347(01)65082 1
   Zonnenberg BA, 2003, CLIN CANCER RES, V9, P2965
NR 45
TC 32
Z9 38
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT 15
PY 2005
VL 96
IS 3
BP 439
EP 446
DI 10.1002/jcb.20522
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 969VG
UT WOS:000232262800001
PM 15988761
OA Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Katchkovsky, S
   Chatterjee, B
   Abramovitch Dahan, CV
   Papo, N
   Levaot, N
AF Katchkovsky, Svetlana
   Chatterjee, Biplab
   Abramovitch Dahan, Chen Viki
   Papo, Niv
   Levaot, Noam
TI Competitive blocking of LRP4 sclerostin binding interface strongly
   promotes bone anabolic functions
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Sclerostin; LRP4; LRP6; Wnt pathway; Bone formation; Drug targets
ID SERUM SCLEROSTIN; KEY REGULATOR; SOST GENE; WNT; LRP4; PROTEIN;
   OSTEOPOROSIS; MUTATIONS; DELETION; DENSITY
AB Induction of bone formation by Wnt ligands is inhibited when sclerostin (Scl), an osteocyte produced antagonist, binds to its receptors, the low density lipoprotein receptor related proteins 5 or 6 (LRP5/6). Recently, it was shown that enhanced inhibition is achieved by Scl binding to the co receptor LRP4. However, it is not clear if the binding of Scl to LRP4 facilitates Scl binding to LRP5/6 or inhibits the Wnt pathway in an LRP5/6 independent manner. Here, using the yeast display system, we demonstrate that Scl exhibits a stronger binding affinity for LRP4 than for LRP6. Moreover, we found stronger Scl binding to LRP6 in the presence of LRP4. We further show that a Scl mutant (Scl(N93A)), which tightly binds LRP4 but not LRP6, does not inhibit the Wnt pathway on its own. We demonstrate that Scl(N93A) competes with Scl for a common binding site on LRP4 and antagonizes Scl inhibition of the Wnt signaling pathway in osteoblasts in vitro. Finally, we demonstrate that 2 weeks of bi weekly subcutaneous injections of Scl(N93A) fused to the fragment crystallizable (Fc) domain of immunoglobulin (Scl(N93A)Fc), which retains the antagonistic activity of the mutant, significantly increases bone formation rate and enhances trabecular volumetric bone fraction, trabecular number, and bone length in developing mice. Our data show that LRP4 serves as an anchor that facilitates Scl LRP6 binding and that inhibition of the Wnt pathway by Scl depends on its prior binding to LRP4. We further provide evidence that compounds that inhibit Scl LRP4 interactions offer a potential strategy to promote anabolic bone functions.
C1 [Katchkovsky, Svetlana; Chatterjee, Biplab; Abramovitch Dahan, Chen Viki; Levaot, Noam] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol & Cell Biol, IL 8410501 Beer Sheva, Israel.
   [Papo, Niv] Ben Gurion Univ Negev, Avram & Stella Goldstein Goren Dept Biotechnol En, IL 8410501 Beer Sheva, Israel.
   [Papo, Niv] Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, IL 8410501 Beer Sheva, Israel.
   [Levaot, Noam] Ben Gurion Univ Negev, Regenerat Med & Stem Cell Res Ctr, IL 8410501 Beer Sheva, Israel.
C3 Ben Gurion University of the Negev; Ben Gurion University of the Negev;
   Ben Gurion University of the Negev; Ben Gurion University of the Negev
RP Levaot, N (通讯作者)，Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol & Cell Biol, IL 8410501 Beer Sheva, Israel.; Papo, N (通讯作者)，Ben Gurion Univ Negev, Avram & Stella Goldstein Goren Dept Biotechnol En, IL 8410501 Beer Sheva, Israel.; Papo, N (通讯作者)，Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, IL 8410501 Beer Sheva, Israel.; Levaot, N (通讯作者)，Ben Gurion Univ Negev, Regenerat Med & Stem Cell Res Ctr, IL 8410501 Beer Sheva, Israel.
EM papo@bgu.ac.il; levaot@bgu.ac.il
RI ; Levaot, Noam/AAA 3052 2022; Sahoo, Prasanta/H 4536 2019
OI Levaot, Noam/0000 0001 7747 3883; Katchkovsky,
   Svetlana/0000 0001 8079 7731; 
FU ISRAEL SCIENCE FOUNDATION [357/18, 1615/19]
FX This work was supported by grants from the ISRAEL SCIENCE FOUNDATION no.
   357/18 (NL) and no. 1615/19 (NP).
CR Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Barik A, 2014, J NEUROSCI, V34, P13892, DOI 10.1523/JNEUROSCI.1733 14.2014
   Boschert V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081710
   Bouaziz W, 2014, OSTEOARTHR CARTILAGE, V22, pS340, DOI 10.1016/j.joca.2014.02.629
   Boudin E, 2017, J BONE MINER RES, V32, P1739, DOI 10.1002/jbmr.3160
   Bourhis E, 2011, STRUCTURE, V19, P1433, DOI 10.1016/j.str.2011.07.005
   Bowen J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041634
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brandenburg VM, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 219
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Bullock WA, 2019, ISCIENCE, V20, P205, DOI 10.1016/j.isci.2019.09.023
   Cejka D, 2014, J CLIN ENDOCR METAB, V99, P248, DOI 10.1210/jc.2013 2786
   Chan BY, 2011, OSTEOARTHR CARTILAGE, V19, P874, DOI 10.1016/j.joca.2011.04.014
   Chang JC, 2018, J BONE MINER RES, V33, P1105, DOI 10.1002/jbmr.3397
   Chang MK, 2014, P NATL ACAD SCI USA, V111, pE5187, DOI 10.1073/pnas.1413828111
   Chao G, 2006, NAT PROTOC, V1, P755, DOI 10.1038/nprot.2006.94
   Desjardins L, 2014, NEPHROL THER, V10, P463, DOI 10.1016/j.nephro.2014.04.002
   Drechsler C, 2015, NEPHROL DIAL TRANSPL, V30, P288, DOI 10.1093/ndt/gfu301
   Dyment NA, 2016, JOVE J VIS EXP, DOI 10.3791/54468
   Fijalkowski I, 2016, J BONE MINER RES, V31, P874, DOI 10.1002/jbmr.2782
   García Ibarbia C, 2013, OSTEOPOROSIS INT, V24, P2449, DOI 10.1007/s00198 013 2302 0
   Gautam M, 2021, F R CELL UNDEFINED 1
   Goel S, 2012, J BIOL CHEM, V287, P16454, DOI 10.1074/jbc.M112.362137
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hartikka H, 2005, J BONE MINER RES, V20, P783, DOI 10.1359/JBMR.050101
   Holdsworth G, 2018, BONE, V107, P93, DOI 10.1016/j.bone.2017.11.003
   Holdsworth G, 2012, J BIOL CHEM, V287, P26464, DOI 10.1074/jbc.M112.350108
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Hudson BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142058
   Jarmoskaite I, 2020, ELIFE, V9, DOI 10.7554/eLife.57264
   Kanbay M, 2014, J CLIN ENDOCR METAB, V99, pE1854, DOI 10.1210/jc.2014 2042
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kim J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19155 4
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kokubu C, 2004, DEVELOPMENT, V131, P5469, DOI 10.1242/dev.01405
   Korvala J, 2012, BMC MED GENET, V13, DOI 10.1186/1471 2350 13 26
   Krause C, 2010, J BIOL CHEM, V285, P41614, DOI 10.1074/jbc.M110.153890
   Laine CM, 2011, EUR J HUM GENET, V19, P875, DOI 10.1038/ejhg.2011.42
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Li JY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7623562
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Lipovsek D, 2007, J MOL BIOL, V368, P1024, DOI 10.1016/j.jmb.2007.02.029
   Lu YQ, 2018, BONE, V114, P144, DOI 10.1016/j.bone.2018.06.018
   Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370
   Medina Gomez C, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002718
   Novo Rodríguez C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199504
   Pyott SM, 2013, AM J HUM GENET, V92, P590, DOI 10.1016/j.ajhg.2013.02.009
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Roetzer KM, 2018, BONE, V107, P154, DOI 10.1016/j.bone.2017.12.002
   Rosenfeld L, 2015, J BIOL CHEM, V290, P26180, DOI 10.1074/jbc.M115.671271
   Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859 017 1934 z
   Schreiber G., 2021, bioRxiv: the preprint server for biology
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043 2760(01)00526 4
   Strohl WR, 2015, BIODRUGS, V29, P215, DOI 10.1007/s40259 015 0133 6
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Tsukamoto M, 2019, BONE, V120, P75, DOI 10.1016/j.bone.2018.10.009
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Van Deventer JA, 2015, PROTEIN ENG DES SEL, V28, P317, DOI 10.1093/protein/gzv043
   Veverka V, 2009, J BIOL CHEM, V284, P10890, DOI 10.1074/jbc.M807994200
   Viaene L, 2013, NEPHROL DIAL TRANSPL, V28, P3024, DOI 10.1093/ndt/gft039
   Weatherbee SD, 2006, DEVELOPMENT, V133, P4993, DOI 10.1242/dev.02696
   Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110
   Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599
   Whyte MP, 2019, BONE, V127, P228, DOI 10.1016/j.bone.2019.05.003
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Xiong L, 2015, P NATL ACAD SCI USA, V112, P3487, DOI 10.1073/pnas.1419714112
   Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540
   Zhang B, 2008, NEURON, V60, P285, DOI 10.1016/j.neuron.2008.10.006
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
   Zhou H, 2009, DEVELOPMENT, V136, P427, DOI 10.1242/dev.027706
NR 76
TC 15
Z9 14
U1 0
U2 5
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420 682X
EI 1420 9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD FEB
PY 2022
VL 79
IS 2
AR 113
DI 10.1007/s00018 022 04127 2
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA YP9FB
UT WOS:000748923300002
PM 35099616
DA 2025 08 17
ER

PT J
AU Pang, Y
   Liu, LL
   Mu, H
   Veeraraghavan, VP
AF Pang, Ying
   Liu, Lili
   Mu, Hong
   Veeraraghavan, Vishnu Priya
TI Nobiletin promotes osteogenic differentiation of human osteoblastic cell
   line (MG 63) through activating the BMP 2/RUNX 2 signaling pathway
SO SAUDI JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE Nobiletin; MG 63 cells; Bone morphogenetic protein; Osteogenesis; BMP 2;
   RUNX2 pathway
ID POSSIBLE INVOLVEMENT; BONE LOSS; PROLIFERATION; OSTEOPOROSIS;
   EXPRESSION; MANAGEMENT; CITRUS; GROWTH
AB Nobiletin (NOB) is polymethoxy flavonoids, which plentifully there in Citrus depressa and they demonstrate numerous pharmacological effects. NOB has an anti proliferative effect, attenuates ovalbumintreated eosinophilic airway inflammation and Type II collagen treated arthritis. NOB noticeably inhibits bone resorption and renovates bone loss in mice model, but role of NOB in bone metabolism is unclear. Human bone is a important organ that sustains its homeostasis among bone resorpting osteoclasts and bone developing osteoblasts. The balances of among these two kind of cell outcomes are implicated in bone remodeling. The current study designed to explore possessions of NOB on differentiation and proliferation of MG 63 cells and contribution of morphogenetic protein signaling. Cell proliferation was analyzed by MTT, mineralization analysis by alizarin red staining and morphogenetic signaling protein by RT PCR. No stimulus outcome of NOB on cell proliferation was found at days of 1, 3 and 7. Accumulation of calcium was augmented after that treatment of NOB. The mRNA expression of BMP 2, COL I, ALP, OCN, RUNX2 and COL1A1 augmented markedly with NOB supplement. Hence, NOB can stimulate osteogenic differentiation of MG 63, almost certainly by promoting RUNX2 and BMP 2 signaling and this result might provide to its action on stimulation of osteoblast development, differentiation and augments of bone mass. (c) 2021 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Pang, Ying; Liu, Lili; Mu, Hong] Cangzhou Cent Hosp, Dent Clin, Cangzhou City 061000, Hebei, Peoples R China.
   [Veeraraghavan, Vishnu Priya] Saveetha Univ, Saveetha Inst Med & Tech Sci, Dept Biochem, Saveetha Dent Coll, Chennai 600077, Tamil Nadu, India.
C3 Saveetha Institute of Medical & Technical Science; Saveetha Dental
   College & Hospital
RP Pang, Y (通讯作者)，Cangzhou Cent Hosp, Dent Clin, Cangzhou City 061000, Hebei, Peoples R China.
EM poiuytre125@sina.com
RI Veeraraghavan, Vishnu Priya/GVT 0445 2022
CR Akao Y, 2008, BIOORGAN MED CHEM, V16, P2803, DOI 10.1016/j.bmc.2008.01.058
   Barbalho SM, 2019, ALTERN THER HEALTH M, V25, P32
   Bique AM, 2016, ELECTROMAGN BIOL MED, V35, P353, DOI 10.3109/15368378.2016.1138124
   Buckley L, 2017, ARTHRIT CARE RES, V69, P1095, DOI 10.1002/acr.23279
   Gu W, 2011, CANCER GENE THER, V18, P897, DOI 10.1038/cgt.2011.58
   Halloran D, 2020, J DEV BIOL, V8, DOI 10.3390/jdb8030019
   Harada S, 2011, J PHARMACOL SCI, V115, P89, DOI 10.1254/jphs.10193SC
   Huang H, 2017, BIOMETALS, V30, P975, DOI 10.1007/s10534 017 0059 1
   Hyun H, 2014, KOREAN J PHYSIOL PHA, V18, P347, DOI 10.4196/kjpp.2014.18.4.347
   Kim BJ, 2020, ENDOCRINOL METAB, V35, P55, DOI 10.3803/EnM.2020.35.1.55
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Li J, 2016, INT J MOL MED, V37, P901, DOI 10.3892/ijmm.2016.2490
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Liu JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099920
   Macías I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051653
   Miyata Y, 2011, LIFE SCI, V88, P613, DOI 10.1016/j.lfs.2011.01.024
   Murakami A, 2007, BIOFACTORS, V30, P179, DOI 10.1002/biof.5520300305
   Pavone V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00803
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Ruiz Gaspa S, 2007, J CELL BIOCHEM, V101, P1430, DOI 10.1002/jcb.21259
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tarrant SM, 2020, WORLD J SURG, V44, P1009, DOI 10.1007/s00268 019 05237 y
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Wang DY, 2020, J PHOTOCH PHOTOBIO B, V202, DOI 10.1016/j.jphotobiol.2019.111652
   Wildman Benjamin J, 2019, Curr Mol Biol Rep, V5, P55, DOI 10.1007/s40610 019 0115 4
   Wu YQ, 2006, LIFE SCI, V78, P2689, DOI 10.1016/j.lfs.2005.10.029
   Xie PG, 2015, INT J CLIN EXP MED, V8, P14764
   Yao H, 2020, INT J MED SCI, V17, P1692, DOI 10.7150/ijms.45786
   Ying XZ, 2014, CELL BIOL INT, V38, P309, DOI 10.1002/cbin.10203
   Yoo HS, 2017, NUTR RES PRACT, V11, P190, DOI 10.4162/nrp.2017.11.3.190
   Yu HQ, 2018, MOL MED REP, V17, P6084, DOI 10.3892/mmr.2018.8628
   Zhang J, 2020, CURR OPIN RHEUMATOL, V32, P387, DOI 10.1097/BOR.0000000000000722
   Zhu JH, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7203584
NR 33
TC 16
Z9 18
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319 562X
EI 2213 7106
J9 SAUDI J BIOL SCI
JI Saudi J. Biol. Sci.
PD SEP
PY 2021
VL 28
IS 9
BP 4916
EP 4920
DI 10.1016/j.sjbs.2021.06.070
EA AUG 2021
PG 5
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA UD0IZ
UT WOS:000686902300010
PM 34466066
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Li, P
   Ma, LH
   Zhan, WQ
   Xie, D
   Hong, GH
   Deng, MZ
   Wu, ZJ
   Lin, PC
   Yan, LH
   Lu, ZF
   Li, CY
   Lin, H
AF Li, Peng
   Ma, Lihua
   Zhan, Weiqiang
   Xie, Dong
   Hong, Guanhao
   Deng, Mingzhu
   Wu, Zijie
   Lin, Peichun
   Yan, Linhong
   Lu, Zifan
   Li, Chengyong
   Lin, Hao
TI Exosome like Nanovesicles Derived from the Mucilage of Pinctada
   Martensii Exhibit Antitumor Activity against 143B Osteosarcoma Cells
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE Pinctada martensii; exosome like nanovesicles; osteosarcoma;
   proliferation; ERK1/2; Wnt; beta catenin signaling
ID FACTOR RECEPTOR BETA; INHIBITS PROLIFERATION; CYCLIN D1; IN VITRO;
   CANCER; GROWTH; APOPTOSIS; BIOLOGY; ERK; DIFFERENTIATION
AB Osteosarcoma is prone to metastasis and has a low long term survival rate. The drug treatment of osteosarcoma, side effects of treatment drugs, and prognosis of patients with lung metastasis continue to present significant challenges, and the efficacy of drugs used in the treatment of osteosarcoma remains low. The development of new therapeutic drugs is urgently needed. In this study, we successfully isolated Pinctada martensii mucilage exosome like nanovesicles (PMMENs). Our findings demonstrated that PMMENs inhibited the viability and proliferation of 143B cells, induced apoptosis, and inhibited cell proliferation by suppressing the activation of the ERK1/2 and Wnt signaling pathways. Furthermore, PMMENs inhibited cell migration and invasion by downregulating N cadherin, vimentin, and matrix metalloprotease 2 protein expression levels. Transcriptomic and metabolomic analyses revealed that differential genes were co enriched with differential metabolites in cancer signaling pathways. These results suggest that PMMENs may exert anti tumor activity by targeting the ERK1/2 and Wnt signaling pathways. Moreover, tumor xenograft model experiments showed that PMMENs can inhibit the growth of osteosarcoma in mice. Thus, PMMENs may be a potential anti osteosarcoma drug.
C1 [Li, Peng; Zhan, Weiqiang; Xie, Dong; Hong, Guanhao; Deng, Mingzhu; Lin, Hao] Guangdong Med Univ, Stem Cell Res & Cellular Therapy Ctr, Orthoped Ctr, Affiliated Hosp, Zhanjiang 524001, Peoples R China.
   [Ma, Lihua; Wu, Zijie; Lin, Peichun; Yan, Linhong; Lu, Zifan; Li, Chengyong] Guangdong Ocean Univ, Shenzhen Inst, Shenzhen 518108, Peoples R China.
   [Ma, Lihua; Wu, Zijie; Yan, Linhong] Guangdong Ocean Univ, Coll Food Sci & Technol, Zhanjiang 518108, Peoples R China.
C3 Guangdong Medical University; Guangdong Ocean University; Guangdong
   Ocean University
RP Lin, H (通讯作者)，Guangdong Med Univ, Stem Cell Res & Cellular Therapy Ctr, Orthoped Ctr, Affiliated Hosp, Zhanjiang 524001, Peoples R China.; Li, CY (通讯作者)，Guangdong Ocean Univ, Shenzhen Inst, Shenzhen 518108, Peoples R China.
EM cyli@gdou.edu.cn; linhao@gdmu.edu.cn
RI Zhan, Weiqiang/A 2077 2010
FU National Natural Science Foundation of China [81570260]; Science and
   Technology Program of Zhanjiang, China [2021A05069]; Special Funds for
   Science Technology Innovation and Industrial Development of Shenzhen
   Dapeng New District [KJYF202001 06]; Doctor Foundation of the Affiliated
   Hospital of Guangdong Medical University [BJ201802]; Special fund for
   Affiliated Hospital of Guangdong Medical University ?Clinical Medicine
   +? CnTech Co construction Platform [CLP2021A001]; Open funding of
   Affiliated Hospital of Guangdong Medical University research of
   autophagy and diseases
FX This work was supported by the National Natural Science Foundation of
   China (81570260), Science and Technology Program of Zhanjiang, China
   (2021A05069), Special Funds for Science Technology Innovation and
   Industrial Development of Shenzhen Dapeng New District (KJYF202001 06),
   Doctor Foundation of the Affiliated Hospital of Guangdong Medical
   University (BJ201802), Special fund for Affiliated Hospital of Guangdong
   Medical University ?Clinical Medicine +? CnTech Co construction Platform
   (CLP2021A001), and Open funding of Affiliated Hospital of Guangdong
   Medical University research of autophagy and diseases.
CR Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Anninga JK, 2011, EUR J CANCER, V47, P2431, DOI 10.1016/j.ejca.2011.05.030
   Belayneh R, 2021, CURR ONCOL REP, V23, DOI 10.1007/s11912 021 01053 7
   Brudvik KW, 2011, MOL CANCER, V10, DOI 10.1186/1476 4598 10 149
   Carrle D, 2006, INT ORTHOP, V30, P445, DOI 10.1007/s00264 006 0192 x
   Chen JL, 2018, STROKE, V49, P1083, DOI 10.1161/STROKEAHA.117.018292
   Chen QB, 2022, ACTA PHARM SIN B, V12, P907, DOI 10.1016/j.apsb.2021.08.016
   Chen TC, 1998, LAB INVEST, V78, P165
   Chin KV, 2002, ANN NY ACAD SCI, V968, P49, DOI 10.1111/j.1749 6632.2002.tb04326.x
   Cui WW, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.864188
   Dai J, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00261 0
   De Robertis M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050742
   Degirmenci U, 2020, CELLS BASEL, V9, DOI 10.3390/cells9010198
   Deng ZB, 2017, MOL THER, V25, P1641, DOI 10.1016/j.ymthe.2017.01.025
   Donigan JM, 2017, APPL IMMUNOHISTO M M, V25, P91, DOI 10.1097/PAI.0000000000000276
   Doyle LM, 2019, CELLS BASEL, V8, DOI 10.3390/cells8070727
   Felx M, 2006, CLIN SCI, V110, P645, DOI 10.1042/CS20050286
   Ferrari S, 2003, J CLIN ONCOL, V21, P710, DOI 10.1200/JCO.2003.03.141
   Ferrari S, 2015, EXPERT OPIN PHARMACO, V16, P2727, DOI 10.1517/14656566.2015.1102226
   Ferreira Silva GA, 2017, TOXICOL IN VITRO, V38, P27, DOI 10.1016/j.tiv.2016.10.011
   Fromigué O, 2008, J BIOL CHEM, V283, P30549, DOI 10.1074/jbc.M801436200
   Fu LL, 2022, J MED CHEM, V65, P13561, DOI 10.1021/acs.jmedchem.2c01244
   Gong C, 2020, HISTOL HISTOPATHOL, V35, P863, DOI 10.14670/HH 18 219
   Gratpain V, 2021, ADV DRUG DELIVER REV, V174, P535, DOI 10.1016/j.addr.2021.05.006
   Han J, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045 020 01025 7
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hara M, 2019, CANCER SCI, V110, P235, DOI 10.1111/cas.13861
   Harris MA, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23073817
   Hassan YA, 2021, N S ARCH PHARMACOL, V394, P2245, DOI 10.1007/s00210 021 02140 z
   He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945
   He JJ, 2020, FISH SHELLFISH IMMUN, V105, P330, DOI 10.1016/j.fsi.2020.07.017
   Huang XY, 2019, J BONE ONCOL, V16, DOI 10.1016/j.jbo.2019.100230
   Jiang YW, 2022, TECHNOL CANCER RES T, V21, DOI 10.1177/15330338211065252
   Jo SH, 2021, TISSUE ENG REGEN MED, V18, P71, DOI 10.1007/s13770 020 00319 8
   Ju SW, 2013, MOL THER, V21, P1345, DOI 10.1038/mt.2013.64
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Khannpnavar B, 2020, CURR OPIN STRUC BIOL, V63, P34, DOI 10.1016/j.sbi.2020.03.003
   Kumar Priti, 2018, Cold Spring Harb Protoc, V2018, DOI 10.1101/pdb.prot095497
   Lieu EL, 2020, EXP MOL MED, V52, P15, DOI 10.1038/s12276 020 0375 3
   Liu WH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0363 x
   Liu XY, 2020, J FOOD SCI, V85, P1125, DOI 10.1111/1750 3841.15055
   Magnadóttir B, 2019, DEV COMP IMMUNOL, V99, DOI 10.1016/j.dci.2019.103397
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Marko TA, 2016, PEDIATR BLOOD CANCER, V63, P1006, DOI 10.1002/pbc.25963
   Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183
   Obeng E., 2021, Braz. J. Biol., V81, P1133, DOI 10.1590/1519 6984.228437
   Oeyen E, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1490143
   Osman I, 2021, J MOL CELL CARDIOL, V156, P20, DOI 10.1016/j.yjmcc.2021.03.005
   Park S, 2019, J NUTR BIOCHEM, V63, P87, DOI 10.1016/j.jnutbio.2018.09.024
   Rajoria S, 2011, ONCOL REP, V25, P491, DOI 10.3892/or.2010.1076
   Rimassa L, 2019, CANCER TREAT REV, V77, P20, DOI 10.1016/j.ctrv.2019.05.004
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Roskoski R, 2018, PHARMACOL RES, V129, P65, DOI 10.1016/j.phrs.2018.01.021
   Routledge D, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.176073
   Sahoo S, 2014, CIRC RES, V114, P333, DOI 10.1161/CIRCRESAHA.114.300639
   Savoia P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061483
   Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012
   Simpson E, 2018, JAAPA J AM ACAD PHYS, V31, P15, DOI 10.1097/01.JAA.0000541477.24116.8d
   Stanly C, 2020, CELLS BASEL, V9, DOI 10.3390/cells9122722
   Suski JM, 2021, CANCER CELL, V39, P759, DOI 10.1016/j.ccell.2021.03.010
   Takino JI, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222011129
   Thies KA, 2021, CANCER RES, V81, P606, DOI 10.1158/0008 5472.CAN 19 3731
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Wang B, 2022, J FUNCT FOODS, V90, DOI 10.1016/j.jff.2022.104968
   Wang YL, 2021, CLIN CHIM ACTA, V512, P100, DOI 10.1016/j.cca.2019.08.023
   Wang YX, 2010, CANCER AM CANCER SOC, V116, P3892, DOI 10.1002/cncr.25107
   Xia W, 2017, ONCOTARGET, V8, P38811, DOI 10.18632/oncotarget.16402
   Xie XL, 2022, ANTI CANCER AGENT ME, V22, P3172, DOI 10.2174/1871520622666220509121627
   Xu KY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02609 0
   Yang FM, 2019, MAR DRUGS, V17, DOI 10.3390/md17120697
   Yang M, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00656 9
   Zhang HY, 2020, EXP HEMATOL ONCOL, V9, DOI 10.1186/s40164 020 00191 1
   Zhang YY, 2020, CANCER RES, V80, P3345, DOI 10.1158/0008 5472.CAN 19 3533
   Zhao N, 2020, MOL IMMUNOL, V128, P268, DOI 10.1016/j.molimm.2020.11.004
   Zhao YT, 2011, CLIN ORTHOP RELAT R, V469, P3190, DOI 10.1007/s11999 011 1939 2
   Zhong ZDA, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100782
NR 76
TC 6
Z9 6
U1 4
U2 37
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD MAY 25
PY 2023
VL 15
IS 22
BP 26227
EP 26240
DI 10.1021/acsami.2c21485
PG 14
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA I7NJ6
UT WOS:001004614500001
PM 37226779
DA 2025 08 17
ER

PT J
AU Tsukazaki, H
   Kikuta, J
   Ao, T
   Morimoto, A
   Fukuda, C
   Tsuda, E
   Minoshima, M
   Kikuchi, K
   Kaito, T
   Ishii, M
AF Tsukazaki, Hiroyuki
   Kikuta, Junichi
   Ao, Tomoka
   Morimoto, Akito
   Fukuda, Chie
   Tsuda, Eisuke
   Minoshima, Masafumi
   Kikuchi, Kazuya
   Kaito, Takashi
   Ishii, Masaru
TI Anti Siglec 15 antibody suppresses bone resorption by inhibiting
   osteoclast multinucleation without attenuating bone formation
SO BONE
LA English
DT Article
DE Siglec 15; Osteoclast; Osteoporosis; Anti resorptive agent; Two photon
   microscope; Bone coupling
ID FUNCTIONAL OSTEOCLASTS; SIGLEC 15; DIFFERENTIATION; RANKL;
   OSTEOPETROSIS; FRACTURES
AB Anti resorptive drugs are widely used for the treatment of osteoporosis, but excessive inhibition of osteoclastogenesis can suppress bone turnover and cause the deterioration of bone quality. Sialic acid binding immunoglobulin like lectin 15 (Siglec 15) is a transmembrane protein expressed on osteoclast precursor cells and mature osteoclasts. Siglec 15 regulates proteins containing immunoreceptor tyrosine based activation motif (ITAM) domains, which then induce nuclear factor of activated T cells 1 (NFATc1), a master transcription factor of osteoclast differentiation. Anti Siglec 15 antibody modulates ITAM signaling in osteoclast precursors and inhibits the maturation of osteoclasts in vitro. However, in situ pharmacological effects, particularly during postmenopausal osteoporosis, remain unclear. Here, we demonstrated that anti Siglec 15 antibody treatment protected against ovariectomy induced bone loss by specifically inhibiting the generation of multinucleated osteoclasts in vivo. Moreover, treatment with anti Siglec 15 antibody maintained bone formation to a greater extent than with risedronate, the first line treatment for osteoporosis. Intravital imaging revealed that antiSiglec 15 antibody treatment did not cause a reduction in osteoclast motility, whereas osteoclast motility declined following risedronate treatment. We evaluated osteoclast activity using a pH sensing probe and found that the bone resorptive ability of osteoclasts was lower following anti Siglec 15 antibody treatment compared to after risedronate treatment. Our findings suggest that anti Siglec 15 treatment may have potential as an antiresorptive therapy for osteoporosis, which substantially inhibits the activity of osteoclasts while maintaining physiological bone coupling.
C1 [Tsukazaki, Hiroyuki; Kikuta, Junichi; Ao, Tomoka; Morimoto, Akito; Ishii, Masaru] Osaka Univ, Grad Sch Med, Dept Immunol & Cell Biol, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
   [Tsukazaki, Hiroyuki; Kikuta, Junichi; Ao, Tomoka; Morimoto, Akito; Ishii, Masaru] Osaka Univ, Frontier Biosci, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
   [Tsukazaki, Hiroyuki; Kaito, Takashi] Osaka Univ, Grad Sch Med, Dept Orthoped Surg, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
   [Kikuta, Junichi; Kikuchi, Kazuya; Ishii, Masaru] Osaka Univ, WPI Immunol Frontier Res Ctr, Osaka, Japan.
   [Kikuta, Junichi; Ao, Tomoka; Ishii, Masaru] Natl Inst Biomed Innovat Hlth & Nutr, Lab Bioimaging & Drug Discovery, 7 6 8 Saito Asagi, Ibaraki, Osaka 5670085, Japan.
   [Fukuda, Chie; Tsuda, Eisuke] Daiichi Sankyo Co Ltd, Specialty Med Res Labs 1, Shinagawa Ku, 1 2 58 Hiromachi, Tokyo 1408710, Japan.
   [Minoshima, Masafumi; Kikuchi, Kazuya] Osaka Univ, Grad Sch Engn, Dept Mat & Life Sci, 2 1 Yamada Oka, Suita, Osaka 5650871, Japan.
C3 University of Osaka; University of Osaka; University of Osaka;
   University of Osaka; Daiichi Sankyo Company Limited; University of Osaka
RP Kikuta, J; Ishii, M (通讯作者)，Osaka Univ, Grad Sch Med, Dept Immunol & Cell Biol, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.; Kikuta, J; Ishii, M (通讯作者)，Osaka Univ, Frontier Biosci, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
EM jkikuta@icb.med.osaka u.ac.jp; mishii@icb.med.osaka u.ac.jp
RI Kaito, Takashi/AAJ 3892 2020; Kikuta, Junichi/HHS 8875 2022
FU CREST, Japan Science and Technology Agency, Japan; Japan Society for the
   Promotion of Science, Japan; PRIME (Japan Agency for Medical Research
   and Development, Japan; Young Scientists from JSPS; Uehara Memorial
   Foundation, Japan; Kanae Foundation, Japan for the Promotion of Medical
   Sciences; Mochida Memorial Foundation for Medical and Pharmaceutical
   Research, Japan; Takeda Science Foundation, Japan
FX This work was supported by funding from CREST, Japan Science and
   Technology Agency, Japan (to M.I.) , Grants in Aid for Scientific
   Research (S) from the Japan Society for the Promotion of Science, Japan
   (JSPS to M.I.) ; PRIME (Japan Agency for Medical Research and
   Development, Japan [AMED] to J.K.) , a Grant in Aid for Young Scientists
   from JSPS (to J.K.) , and grants from the Uehara Memorial Foundation,
   Japan (to M.I.) , the Kanae Foundation, Japan for the Promotion of
   Medical Sciences (to M.I) , the Mochida Memorial Foundation for Medical
   and Pharmaceutical Research, Japan (to M.I.) , and the Takeda Science
   Foundation, Japan (to M.I.) .
CR Angata T, 2007, GLYCOBIOLOGY, V17, P838, DOI 10.1093/glycob/cwm049
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Byrjalsen I, 2008, OSTEOPOROSIS INT, V19, P339, DOI 10.1007/s00198 007 0462 5
   Compston J, 2011, OSTEOPOROSIS INT, V22, P2951, DOI 10.1007/s00198 011 1804 x
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Hiruma Y, 2013, BONE, V53, P87, DOI 10.1016/j.bone.2012.11.036
   Hiruma Y, 2011, BIOCHEM BIOPH RES CO, V409, P424, DOI 10.1016/j.bbrc.2011.05.015
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Ishida Kitagawa N, 2012, J BIOL CHEM, V287, P17493, DOI 10.1074/jbc.M111.324194
   Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923
   Kameda Y, 2015, BONE, V71, P217, DOI 10.1016/j.bone.2014.10.027
   Kameda Y, 2013, J BONE MINER RES, V28, P2463, DOI 10.1002/jbmr.1989
   Kikuta J, 2013, J CLIN INVEST, V123, P866, DOI 10.1172/JCI65054
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Maeda H, 2016, NAT CHEM BIOL, V12, P579, DOI [10.1038/NCHEMBIO.2096, 10.1038/nchembio.2096]
   Miyamoto Takeshi, 2006, Mod Rheumatol, V16, P341
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Park Wyllie LY, 2011, JAMA J AM MED ASSOC, V305, P783, DOI 10.1001/jama.2011.190
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Reid IR, 2012, NAT REV RHEUMATOL, V8, P90, DOI 10.1038/nrrheum.2011.181
   Sato D, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115331
   Sato D, 2018, BONE, V116, P172, DOI 10.1016/j.bone.2018.07.026
   Stuible M, 2014, J BIOL CHEM, V289, P6498, DOI 10.1074/jbc.M113.494542
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2013, J CLIN INVEST, V123, P3914, DOI 10.1172/JCI69493
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
NR 32
TC 9
Z9 10
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2021
VL 152
AR 116095
DI 10.1016/j.bone.2021.116095
EA JUL 2021
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA TU6EY
UT WOS:000681128600015
PM 34216837
OA hybrid
DA 2025 08 17
ER

PT J
AU Jin, ZX
   Liao, XY
   Da, WW
   Zhao, YJ
   Li, XF
   Tang, DZ
AF Jin, Zhen Xiong
   Liao, Xin Yuan
   Da, Wei Wei
   Zhao, Yong Jian
   Li, Xiao Feng
   Tang, De Zhi
TI Osthole enhances the bone mass of senile osteoporosis and stimulates the
   expression of osteoprotegerin by activating β catenin signaling
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Osthole; &#946;  Catenin; Osteoprotegerin; Osteoclast; Osteoporosis
AB Introduction Osthole has a potential therapeutic application for anti osteoporosis. The present study verified whether osthole downregulates osteoclastogenesis via targeting OPG. Methods In vivo, 12 month old male mice were utilized to evaluate the effect of osthole on bone mass. In vitro, bone marrow stem cells (BMSCs) were isolated and extracted from 3 month old OPG( / ) mice and the littermates of OPG(+/+) mice. Calvaria osteoblasts were extracted from 3 day old C57BL/6J mice or 3 day old OPG( / ) mice and the littermates of OPG(+/+) mice. Results Osthole significantly increased the gene and protein levels of OPG in primary BMSCs in a dose dependent manner. The deletion of the OPG gene did not affect beta catenin expression. The deletion of the beta catenin gene inhibited OPG expression in BMSCs, indicating that osthole stimulates the expression of OPG via activation of beta catenin signaling. Conclusion Osthole attenuates osteoclast formation by stimulating the activation of beta catenin OPG signaling and could be a potential drug for the senile osteoporosis.
C1 [Jin, Zhen Xiong; Da, Wei Wei; Zhao, Yong Jian; Li, Xiao Feng; Tang, De Zhi] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai 200032, Peoples R China.
   [Jin, Zhen Xiong; Da, Wei Wei; Zhao, Yong Jian; Li, Xiao Feng; Tang, De Zhi] Shanghai Univ Tradit Chinese Med, Inst Spine, Shanghai 200032, Peoples R China.
   [Liao, Xin Yuan] Navy Med Univ, Shanghai Changzheng Hosp, Spine Ctr, Dept Orthpaed, Shanghai 201705, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine; Naval Medical University
RP Tang, DZ (通讯作者)，Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai 200032, Peoples R China.; Tang, DZ (通讯作者)，Shanghai Univ Tradit Chinese Med, Inst Spine, Shanghai 200032, Peoples R China.
EM dztang702@126.com
RI li, xiaofeng/GXF 9442 2022; Da, Weiwei/AFV 5795 2022
FU National Natural Science Foundation (NSFC) [81973883]; Shanghai Natural
   Science Foundation [19ZR1458000]
FX This study was sponsored by the National Natural Science Foundation
   (NSFC) Gran 81973883 to De Zhi Tang and Shanghai Natural Science
   Foundation (19ZR1458000).
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Appelman Dijkstra NM, 2018, NAT REV ENDOCRINOL, V14, P605, DOI 10.1038/s41574 018 0087 0
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Cai Y, 2018, ACTA PHARMACOL SIN, V39, P74, DOI 10.1038/aps.2017.129
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Curtis M, 2019, CELL METAB, V29, P141, DOI 10.1016/j.cmet.2018.08.007
   Dai XX, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0992 z
   Davaine JM, 2016, EUR J VASC ENDOVASC, V51, P259, DOI 10.1016/j.ejvs.2015.10.004
   Estell EG, 2021, NAT REV ENDOCRINOL, V17, P31, DOI 10.1038/s41574 020 00426 5
   Fan JB, 2021, BIOMATERIALS, V264, DOI 10.1016/j.biomaterials.2020.120445
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gao LN, 2013, BIOMATERIALS, V34, P9937, DOI 10.1016/j.biomaterials.2013.09.017
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Hassanein EHM, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1675957
   Jin ZX, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2851 2
   Kadriu B, 2018, MOL PSYCHIATR, V23, P1626, DOI 10.1038/mp.2017.109
   Kfoury Y, 2015, CELL STEM CELL, V16, P239, DOI 10.1016/j.stem.2015.02.019
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Laine JC, 2020, J BONE JOINT SURG AM, V102, P2077, DOI 10.2106/JBJS.20.00657
   Leslie WD, 2011, J BONE MINER RES, V26, P2419, DOI 10.1002/jbmr.457
   Li B, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110923
   Lv WT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163981
   Ma YG, 2021, J HAZARD MATER, V405, DOI 10.1016/j.jhazmat.2020.124251
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Morgan EF, 2018, ANNU REV BIOMED ENG, V20, P119, DOI [10.1146/annurev bioeng 062117 121139, 10.1146/annurev bioeng 062117121139]
   Odén A, 2013, CALCIFIED TISSUE INT, V92, P42, DOI 10.1007/s00223 012 9666 6
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Sato A, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 01386 2
   Sato MM, 2009, GENES CELLS, V14, P141, DOI 10.1111/j.1365 2443.2008.01258.x
   Shin CS, 2005, J BONE MINER RES, V20, P2200, DOI 10.1359/JBMR.050809
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Unim B, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115752
   Wang BL, 2014, ARTHRITIS RHEUMATOL, V66, P107, DOI 10.1002/art.38195
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Yan Y, 2009, J CELL SCI, V122, P3566, DOI 10.1242/jcs.051904
   Zhang ZR, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060588
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhu M, 2009, J BONE MINER RES, V24, P12, DOI [10.1359/jbmr.080901, 10.1359/JBMR.080901]
NR 43
TC 23
Z9 33
U1 2
U2 23
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD FEB 27
PY 2021
VL 12
IS 1
AR 154
DI 10.1186/s13287 021 02228 6
PG 10
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA QN9GC
UT WOS:000622757300001
PM 33640026
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Araujo, A
   Cook, LM
   Lynch, CC
   Basanta, D
AF Araujo, Arturo
   Cook, Leah M.
   Lynch, Conor C.
   Basanta, David
TI An Integrated Computational Model of the Bone Microenvironment in
   Bone Metastatic Prostate Cancer
SO CANCER RESEARCH
LA English
DT Article
ID GROWTH FACTOR BETA; DENOSUMAB; TURNOVER; RESORPTION; INTERFACE;
   MIGRATION; TISSUE; RISK
AB Bone metastasis will impact most men with advanced prostate cancer. The vicious cycle of bone degradation and formation driven by metastatic prostate cells in bone yields factors that drive cancer growth. Mechanistic insights into this vicious cycle have suggested new therapeutic opportunities, but complex temporal and cellular interactions in the bone microenvironment make drug development challenging. We have integrated biologic and computational approaches to generate a hybrid cellular automata model of normal bone matrix homeostasis and the prostate cancer bone microenvironment. The model accurately reproduces the basic multicellular unit bone coupling process, such that introduction of a single prostate cancer cell yields a vicious cycle similar in cellular composition and pathophysiology to models of prostate to bone metastasis. Notably, the model revealed distinct phases of osteolytic and osteogenic activity, a critical role for mesenchymal stromal cells in osteogenesis, and temporal changes in cellular composition. To evaluate the robustness of the model, we assessed the effect of established bisphosphonate and anti RANKL therapies on bone metastases. At approximately 100% efficacy, bisphosphonates inhibited cancer progression while, in contrast with clinical observations in humans, anti RANKL therapy fully eradicated metastases. Reducing anti RANKL yielded clinically similar results, suggesting that better targeting or dosing could improve patient survival. Our work establishes a computational model that can be tailored for rapid assessment of experimental therapies and delivery of precision medicine to patients with prostate cancer with bone metastases. (C) 2014 AACR.
C1 [Araujo, Arturo; Basanta, David] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Integrated Math Oncol, Tampa, FL 33612 USA.
   [Cook, Leah M.; Lynch, Conor C.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, Tampa, FL 33612 USA.
C3 State University System of Florida; University of South Florida; H Lee
   Moffitt Cancer Center & Research Institute; State University System of
   Florida; University of South Florida; H Lee Moffitt Cancer Center &
   Research Institute
RP Araujo, A (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr,Moffitt Stabile Res Bldg SRB 4, Tampa, FL 33612 USA.
EM arturo@cancerevo.org; conor.lynch@moffitt.org
RI ; Cook, Leah/AAV 9640 2021
OI Cook, Leah/0000 0002 9996 7419; Basanta, David/0000 0002 8527 0776; 
FU NCI [U01CA151924 01A1]; Department of Defense Hypothesis Development
   Award [W81XWH 12 1 0016]; National Cancer Institute [RO1CA143094];
   American Cancer Society [PF 13 175 01 CSM]; Moffitt Analytical
   Microscopy Core facility at the Moffitt Cancer Center
FX This work was supported by an NCI U01 (U01CA151924 01A1; D. Basanta),
   the Department of Defense Hypothesis Development Award
   (W81XWH 12 1 0016; C.C. Lynch and D. Basanta), the National Cancer
   Institute (RO1CA143094; C.C. Lynch), and the American Cancer Society
   Post Doctoral Fellowship (PF 13 175 01 CSM; L.M. Cook). This work was
   also supported, in part, by the Moffitt Analytical Microscopy Core
   facility at the Moffitt Cancer Center.
CR Anderson ARA, 2008, NAT REV CANCER, V8, P227, DOI 10.1038/nrc2329
   Anderson ARA, 2005, MATH MED BIOL, V22, P163, DOI 10.1093/imammb/dqi005
   Basanta D, 2009, CANCER RES, V69, P7111, DOI 10.1158/0008 5472.CAN 08 3957
   Bilezikian J.P., 2008, Principles of Bone Biology
   BLOEBAUM RD, 1994, J BIOMED MATER RES, V28, P537, DOI 10.1002/jbm.820280503
   BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261
   Brown JE, 2012, NAT REV CLIN ONCOL, V9, P110, DOI 10.1038/nrclinonc.2011.197
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Christley S, 2007, PLOS COMPUT BIOL, V3, P743, DOI 10.1371/journal.pcbi.0030076.eor
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Dacquin R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026627
   FERRIER J, 1994, J BONE MINER RES, V9, P1397
   Futakuchi M, 2009, CANCER SCI, V100, P71, DOI 10.1111/j.1349 7006.2008.01012.x
   Horn M, 2013, BLOOD, V121, P378, DOI 10.1182/blood 2012 07 441956
   Jayakumar P, 2010, P I MECH ENG H, V224, P1415, DOI 10.1243/09544119JEIM821
   Johnson LC, 2011, BONE, V48, P141, DOI 10.1016/j.bone.2010.05.033
   Kaminska B, 2005, ACTA BIOCHIM POL, V52, P329
   KANEHISA J, 1988, BONE, V9, P73, DOI 10.1016/8756 3282(88)90106 8
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Lynch CC, 2011, BONE, V48, P44, DOI 10.1016/j.bone.2010.06.007
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669
   Monchau F, 2002, BIOMOL ENG, V19, P143, DOI 10.1016/S1389 0344(02)00023 0
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Murakami Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074178
   Pfeilschifter J, 1998, J BONE MINER RES, V13, P716, DOI 10.1359/jbmr.1998.13.4.716
   Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787
   ROODMAN GD, 1991, CRIT REV ORAL BIOL M, V2, P389, DOI 10.1177/10454411910020030601
   Rucci Nadia, 2010, Front Biosci (Schol Ed), V2, P907
   Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004 1211
   Shin H, 2004, BIOMATERIALS, V25, P895, DOI 10.1016/S0142 9612(03)00602 1
   SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092 8674(92)90029 C
   Swanson KR, 2008, BRIT J CANCER, V98, P113, DOI 10.1038/sj.bjc.6604125
   Thiolloy S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029862
   Thiolloy S, 2009, CANCER RES, V69, P6747, DOI 10.1158/0008 5472.CAN 08 3949
   *UBC, DIFF RAT MOL
   WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932
   WERGEDAL J, 1973, J CLIN INVEST, V52, P1052, DOI 10.1172/JCI107270
   Wilkinson RD, 2013, STAT APPL GENET MOL, V12, P129, DOI 10.1515/sagmb 2013 0010
   Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357
   YONEDA T, 1994, BREAST CANCER RES TR, V32, P73, DOI 10.1007/BF00666208
NR 46
TC 63
Z9 69
U1 1
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2014
VL 74
IS 9
BP 2391
EP 2401
DI 10.1158/0008 5472.CAN 13 2652
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AH1ZH
UT WOS:000335920000003
PM 24788098
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Joseph, J
   Shiozawa, Y
   Jung, YH
   Kim, JK
   Pedersen, E
   Mishra, A
   Zalucha, JL
   Wang, JC
   Keller, ET
   Pienta, KJ
   Taichman, RS
AF Joseph, Jeena
   Shiozawa, Yusuke
   Jung, Younghun
   Kim, Jin Koo
   Pedersen, Elisabeth
   Mishra, Anjali
   Zalucha, Janet Linn
   Wang, Jingcheng
   Keller, Evan T.
   Pienta, Kenneth J.
   Taichman, Russell S.
TI Disseminated Prostate Cancer Cells Can Instruct Hematopoietic Stem and
   Progenitor Cells to Regulate Bone Phenotype
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID SKELETAL COMPLICATIONS; MORPHOGENETIC PROTEINS; INTERLEUKIN 6;
   METASTASIS; GROWTH; OSTEOBLASTS; MECHANISMS; SURVIVAL; MARKERS;
   RECEPTORS
AB Prostate cancer metastases and hematopoietic stem cells (HSC) frequently home to the bone marrow, where they compete to occupy the same HSC niche. We have also shown that under conditions of hematopoietic stress, HSCs secrete the bone morphogenetic proteins (BMP) 2 and BMP 6 that drives osteoblastic differentiation from mesenchymal precursors. As it is not known, we examined whether metastatic prostate cancer cells can alter regulation of normal bone formation by HSCs and hematopoietic progenitor cells (HPC). HSC/HPCs isolated from mice bearing nonmetastatic and metastatic tumor cells were isolated and their ability to influence osteoblastic and osteoclastic differentiation was evaluated. When the animals were inoculated with the LNCaP C4 2B cell line, which produces mixed osteoblastic and osteolytic lesions in bone, HPCs, but not HSCs, were able to induced stromal cells to differentiate down an osteoblastic phenotype. Part of the mechanism responsible for this activity was the production of BMP 2. On the other hand, when the animals were implanted with PC3 cells that exhibits predominantly osteolytic lesions in bone, HSCs derived from these animals were capable of directly differentiating into tartrate resistant acid phosphatase positive osteoclasts through an interleukin 6 mediated pathway. These studies for the first time identify HSC/HPCs as novel targets for future therapy involved in the bone abnormalities of prostate cancer. Mol Cancer Res; 10(3); 282 92. (C)2012 AACR.
C1 [Joseph, Jeena; Shiozawa, Yusuke; Jung, Younghun; Kim, Jin Koo; Mishra, Anjali; Zalucha, Janet Linn; Wang, Jingcheng; Taichman, Russell S.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Pedersen, Elisabeth; Keller, Evan T.; Pienta, Kenneth J.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI USA.
   [Pedersen, Elisabeth; Keller, Evan T.; Pienta, Kenneth J.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP Taichman, RS (通讯作者)，Univ Michigan, Sch Dent, Dept Periodont & Oral Med, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM rtaich@umich.edu
RI Pienta, Kenneth/E 7679 2015; Keller, Evan/M 1446 2016; Kim,
   Jin Koo/AEC 6629 2022; Taichman, Russell/NOF 9711 2025
OI Pienta, Kenneth/0000 0002 4138 2186; Taichman, Russell
   S./0000 0002 7890 0020; Pedersen, Elisabeth/0000 0002 4356 4055
FU National Cancer Institute [CA093900, CA163124]; Department of Defense;
   Prostate Cancer Foundation; American Cancer Society; NIH SPORE in
   prostate cancer [P50 CA69568]; Cancer Center [P30 CA46592]; National
   Cancer Institute [P01CA093900, P30CA046592] Funding Source: NIH RePORTER
FX This work is directly supported by the National Cancer Institute
   (CA093900, K.J. Pienta and R.S. Taichman, CA163124, Y. Shiozawa, K.J.
   Pienta, and R. S. Taichman), the Department of Defense (Y. Shiozawa,
   K.J. Pienta, and R. S. Taichman), and the Prostate Cancer Foundation (Y.
   Shiozawa, K.J. Pienta, and R. S. Taichman). K.J. Pienta receives support
   as an American Cancer Society Clinical Research Professor, NIH SPORE in
   prostate cancer grant P50 CA69568, and the Cancer Center support grant
   P30 CA46592.
CR Al Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Ara T, 2009, CANCER RES, V69, P329, DOI 10.1158/0008 5472.CAN 08 0613
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   BARILLE S, 1995, BLOOD, V86, P3151
   Berruti A, 2005, BRIT J CANCER, V93, P633, DOI 10.1038/sj.bjc.6602767
   Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679
   Chalaris A, 2011, EUR J CELL BIOL, V90, P484, DOI 10.1016/j.ejcb.2010.10.007
   Chen JC, 2008, EXP HEMATOL, V36, P1236, DOI 10.1016/j.exphem.2008.04.012
   Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015
   George DJ, 2005, CLIN CANCER RES, V11, P1815, DOI 10.1158/1078 0432.CCR 04 1560
   Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002 9440(10)63067 2
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Haudenschild DR, 2004, CANCER RES, V64, P8276, DOI 10.1158/0008 5472.CAN 04 2251
   Havens A, 2008, NEOPLASIA, V10, P371, DOI 10.1593/neo.08154
   Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959 437X(96)80064 5
   Jung YG, 2008, STEM CELLS, V26, P2042, DOI 10.1634/stemcells.2008 0149
   Keller ET, 2007, J CELL BIOCHEM, V102, P1095, DOI 10.1002/jcb.21540
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Koeneman KS, 1999, PROSTATE, V39, P246
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Kuroda K, 2007, UROLOGY, V69, P113, DOI 10.1016/j.urology.2006.09.039
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Mizutani K, 2009, NEOPLASIA, V11, P1235, DOI 10.1593/neo.09988
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakchbandi IA, 2002, J CLIN ENDOCR METAB, V87, P4946, DOI 10.1210/jc.2001 011814
   Noguchi M, 2003, UROLOGY, V61, P993, DOI 10.1016/S0090 4295(02)02583 9
   Novotny NM, 2008, CYTOKINE, V43, P215, DOI 10.1016/j.cyto.2008.05.015
   Petrioli R, 2004, UROLOGY, V63, P321, DOI 10.1016/j.urology.2003.09.044
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046 8177(03)00190 4
   SCHOFIELD R, 1978, BLOOD CELLS, V4, P7
   Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008 5472.CAN 04 2442
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384
   Suva LJ, 2009, ENDOCR RELAT CANCER, V16, P703, DOI 10.1677/ERC 09 0012
   Taichman RS, 2002, CANCER RES, V62, P1832
   Taichman RS, 2007, J CLIN INVEST, V117, P2351, DOI 10.1172/JCI31791
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Walczak JR, 2007, MAYO CLIN PROC, V82, P243
   Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048
   Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097 0215(19980911)77:6<887::AID IJC15>3.0.CO;2 Z
   Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
NR 48
TC 35
Z9 36
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1541 7786
EI 1557 3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAR
PY 2012
VL 10
IS 3
BP 282
EP 292
DI 10.1158/1541 7786.MCR 11 0404
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 912EO
UT WOS:000301777700002
PM 22241219
OA Green Accepted, Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Yang, Z
   Zhang, XW
   Zhuo, FF
   Liu, TT
   Luo, QW
   Zheng, YZ
   Li, L
   Yang, H
   Zhang, YC
   Wang, YH
   Liu, D
   Tu, PF
   Zeng, KW
AF Yang, Zhuo
   Zhang, Xiao Wen
   Zhuo, Fang Fang
   Liu, Ting Ting
   Luo, Qian Wei
   Zheng, Yong Zhe
   Li, Ling
   Yang, Heng
   Zhang, Yi Chi
   Wang, Yan Hang
   Liu, Dan
   Tu, Peng Fei
   Zeng, Ke Wu
TI Allosteric Activation of Transglutaminase 2 via Inducing an "Open"
   Conformation for Osteoblast Differentiation
SO ADVANCED SCIENCE
LA English
DT Article
DE allosteric activation; forskolin; mitochondria; osteoblast
   differentiation; transglutaminase 2
ID TISSUE TRANSGLUTAMINASE; CELL PHENOTYPE; BONE FORMATION; STEM CELLS;
   FORSKOLIN; MINERALIZATION; TG2; IDENTIFICATION; OSTEOPOROSIS;
   INFLAMMATION
AB Osteoblasts play an important role in the regulation of bone homeostasis throughout life. Thus, the damage of osteoblasts can lead to serious skeletal diseases, highlighting the urgent need for novel pharmacological targets. This study introduces chemical genetics strategy by using small molecule forskolin (FSK) as a probe to explore the druggable targets for osteoporosis. Here, this work reveals that transglutaminase 2 (TGM2) served as a major cellular target of FSK to obviously induce osteoblast differentiation. Then, this work identifies a previously undisclosed allosteric site in the catalytic core of TGM2. In particular, FSK formed multiple hydrogen bonds in a saddle like domain to induce an "open" conformation of the beta sandwich domain in TGM2, thereby promoting the substrate protein crosslinks by incorporating polyamine. Furthermore, this work finds that TGM2 interacted with several mitochondrial homeostasis associated proteins to improve mitochondrial dynamics and ATP production for osteoblast differentiation. Finally, this work observes that FSK effectively ameliorated osteoporosis in the ovariectomy mice model. Taken together, these findings show a previously undescribed pharmacological allosteric site on TGM2 for osteoporosis treatment, and also provide an available chemical tool for interrogating TGM2 biology and developing bone anabolic agent.
C1 [Yang, Zhuo; Zhang, Xiao Wen; Zhuo, Fang Fang; Liu, Ting Ting; Luo, Qian Wei; Zheng, Yong Zhe; Li, Ling; Yang, Heng; Zhang, Yi Chi; Wang, Yan Hang; Tu, Peng Fei; Zeng, Ke Wu] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China.
   [Liu, Dan] Peking Univ Hlth Sci Ctr, Med & Hlth Analyt Ctr, Prote Lab, Beijing 100191, Peoples R China.
C3 Peking University
RP Zeng, KW (通讯作者)，Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China.
EM zkw@bjmu.edu.cn
RI Tu, Peng Fei/E 2089 2018; Liu, Tingting/F 3317 2019; zhang,
   Xiaowen/HKW 7576 2023; Ke wu, Zeng/U 6930 2019; Zhang, Han/C 8323 2016
FU National Key R&D Program of China [2022YFC3501601]; National Natural
   Sciences Foundation of China [82174008, 81973505]; Fundamental Research
   Funds for the Central Universities
FX This work was financially supported by National Key R&D Program of China
   (2022YFC3501601), National Natural Sciences Foundation of China
   (82174008, 81973505), and the Fundamental Research Funds for the Central
   Universities. Experimental procedures were approved (LA2022506) by the
   Ethical Institutional Animal Care and Use Committee of Peking
   University, Beijing, China.
CR Abe Y, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 56484 x
   Aljohani H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225598
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Cao L, 2012, ONCOGENE, V31, P2521, DOI 10.1038/onc.2011.429
   Chen H, 2015, MED MOL MORPHOL, V48, P61, DOI 10.1007/s00795 015 0099 y
   Ching HS, 2017, CURR STEM CELL RES T, V12, P71, DOI 10.2174/1574888X11666160815095733
   Chopra B, 2021, PHYTOTHER RES, V35, P4660, DOI 10.1002/ptr.7099
   Cong F, 2012, ANNU REV PHARMACOL, V52, P57, DOI 10.1146/annurev pharmtox 010611 134639
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   Doorn J, 2012, TISSUE ENG PT A, V18, P558, DOI [10.1089/ten.tea.2011.0312, 10.1089/ten.TEA.2011.0312]
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Fontecha Barriuso M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020347
   Gao J, 2018, CELL DEATH DIFFER, V25, P229, DOI 10.1038/cdd.2017.144
   Gao YS, 2001, EUR J PHARMACOL, V418, P111, DOI 10.1016/S0014 2999(01)00929 3
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hoac B, 2017, BONE, V101, P37, DOI 10.1016/j.bone.2017.04.007
   Hung V, 2016, NAT PROTOC, V11, P456, DOI 10.1038/nprot.2016.018
   Iannaccone Martina, 2013, Recent Pat CNS Drug Discov, V8, P235
   Karner CM, 2018, BONE, V115, P2, DOI 10.1016/j.bone.2017.08.008
   Keillor JW, 2021, EXPERT OPIN THER TAR, V25, P721, DOI 10.1080/14728222.2021.1989410
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim WS, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11246 5
   Kingham PJ, 2007, EXP NEUROL, V207, P267, DOI 10.1016/j.expneurol.2007.06.029
   Kühlbrandt W, 2019, ANNU REV BIOCHEM, V88, P515, DOI 10.1146/annurev biochem 013118 110903
   Lee CS, 2017, APOPTOSIS, V22, P1057, DOI 10.1007/s10495 017 1396 9
   LEE HT, 2018, CLIN MICROBIOL INFEC, V26, P1175
   Lee SY, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02656 4
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Liang K, 2018, P NATL ACAD SCI USA, V115, P7039, DOI 10.1073/pnas.1801252115
   Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899
   Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106
   Maiuri L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1392 9
   Martucciello S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103673
   Mehta K, 2010, BIOCHEM PHARMACOL, V80, P1921, DOI 10.1016/j.bcp.2010.06.029
   Min B, 2018, BMB REP, V51, P5, DOI 10.5483/BMBRep.2018.51.1.227
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Mousa A, 2017, CELL DEATH DIFFER, V24, P844, DOI 10.1038/cdd.2017.21
   Murshed M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031229
   Nakayama Y, 2012, J ORAL SCI, V54, P251, DOI 10.2334/josnusd.54.251
   Nurminskaya M, 2006, FRONT BIOSCI LANDMRK, V11, P1591, DOI 10.2741/1907
   Park KH, 2018, STEM CELLS DEV, V27, P1125, DOI 10.1089/scd.2018.0023
   Pinkas DM, 2007, PLOS BIOL, V5, P2788, DOI 10.1371/journal.pbio.0050327
   Prat Duran J, 2021, PHARMACOL THERAPEUT, V222, DOI 10.1016/j.pharmthera.2020.107787
   Qian Y, 2021, ACTA PHARM SIN B, V11, P1853, DOI 10.1016/j.apsb.2021.01.011
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rossin F, 2012, AMINO ACIDS, V42, P1793, DOI 10.1007/s00726 011 0899 x
   Ruprecht JJ, 2019, CELL, V176, P435, DOI 10.1016/j.cell.2018.11.025
   Sapio L, 2017, J CELL PHYSIOL, V232, P922, DOI 10.1002/jcp.25650
   SEAMON KB, 1981, P NATL ACAD SCI BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363
   Singh US, 1998, J BIOL CHEM, V273, P1946, DOI 10.1074/jbc.273.4.1946
   Suzuki A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238992
   Tempest R, 2021, CANCERS, V13, DOI 10.3390/cancers13112788
   Walker JE, 2013, BIOCHEM SOC T, V41, P1, DOI 10.1042/BST20110773
   Wang S, 2020, INT J BIOL SCI, V16, P2675, DOI 10.7150/ijbs.46627
   Xu DH, 2022, BMC CANCER, V22, DOI 10.1186/s12885 022 10364 2
   Yin XX, 2012, BRAZ J MED BIOL RES, V45, P693, DOI 10.1590/S0100 879X2012007500060
   You ZP, 2018, MOL MED REP, V17, P2321, DOI 10.3892/mmr.2017.8106
   Zhou QY, 2022, AGING US, V14, P272, DOI 10.18632/aging.203729
NR 59
TC 13
Z9 14
U1 10
U2 118
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD JUN
PY 2023
VL 10
IS 18
DI 10.1002/advs.202206533
EA APR 2023
PG 12
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA K7VO5
UT WOS:000974362300001
PM 37088726
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ramdani, G
   Schall, N
   Kalyanaraman, H
   Wahwah, N
   Moheize, S
   Lee, JJ
   Sah, RL
   Pfeifer, A
   Casteel, DE
   Pilz, RB
AF Ramdani, Ghania
   Schall, Nadine
   Kalyanaraman, Hema
   Wahwah, Nisreen
   Moheize, Sahar
   Lee, Jenna J.
   Sah, Robert L.
   Pfeifer, Alexander
   Casteel, Darren E.
   Pilz, Renate B.
TI cGMP dependent protein kinase 2 regulates bone mass and prevents
   diabetic bone loss
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
DE cGMP dependent protein kinase; osteoblasts; bone formation; diabetic
   osteoporosis; Wnt pathway; sexual dimorphism
ID NITRIC OXIDE SYNTHASE; ISOSORBIDE MONONITRATE; POSTMENOPAUSAL WOMEN;
   REPLACEMENT THERAPY; MINERAL DENSITY; OSTEOBLAST; MICE; LRP5; INCREASES;
   ESTROGEN
AB NO/cGMP signaling is important for bone remodeling in response to mechanical and hormonal stimuli, but the downstream mediator(s) regulating skeletal homeostasis are incompletely defined. We generated transgenic mice expressing a partly activated, mutant cGMP dependent protein kinase type 2 (PKG2(R242Q)) under control of the osteoblast specific Col1a1 promoter to characterize the role of PKG2 in post natal bone formation. Primary osteoblasts from these mice showed a two  to three fold increase in basal and total PKG2 activity; they proliferated faster and were resistant to apoptosis compared to cells from WT mice. Male Col1a1 Prkg2(R242Q) transgenic mice had increased osteoblast numbers, bone formation rates and Wnt/beta catenin related gene expression in bone and a higher trabecular bone mass compared to their WT littermates. Streptozotocin induced type 1 diabetes suppressed bone formation and caused rapid bone loss in WT mice, but male transgenic mice were protected from these effects. Surprisingly, we found no significant difference in bone micro architecture or Wnt/beta catenin related gene expression between female WT and transgenic mice; female mice of both genotypes showed higher systemic and osteoblastic NO/cGMP generation compared to their male counterparts, and a higher level of endogenous PKG2 activity may be responsible for masking effects of the PKG2(R242Q) transgene in females. Our data support sexual dimorphism in Wnt/beta catenin signaling and PKG2 regulation of this crucial pathway in bone homeostasis. This work establishes PKG2 as a key regulator of osteoblast proliferation and post natal bone formation.
C1 [Ramdani, Ghania; Schall, Nadine; Kalyanaraman, Hema; Wahwah, Nisreen; Moheize, Sahar; Casteel, Darren E.; Pilz, Renate B.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Schall, Nadine; Pfeifer, Alexander] Univ Bonn, Inst Pharmacol & Toxicol, Bonn, Germany.
   [Lee, Jenna J.; Sah, Robert L.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of Bonn; University of California System; University of
   California San Diego
RP Pilz, RB (通讯作者)，Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
EM rpilz@ucsd.edu
FU NIH [R01 AR051300, R21 AR065658, P01 AG007996, P30 CA023100,
   P30 NS047101, P30 AR04603]; Deutsche Forschungsgemeinschaft [KI
   1303/2 1]
FX This work was supported by NIH grants R01 AR051300 and R21 AR065658 (to
   R B P); P01 AG007996 (R L S), P30 CA023100 (UCSD Gene Targeting Mouse
   Core), P30 NS047101 (UCSD Neuroscience Microscopy Shared Facility) and
   P30 AR04603 (University of Alabama, Birmingham, Center for Metabolic
   Bone Disease). N S was supported by the Deutsche Forschungsgemeinschaft
   (Project KI 1303/2 1).
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bartels CF, 2004, AM J HUM GENET, V75, P27, DOI 10.1086/422013
   Bocciardi R, 2007, HUM MUTAT, V28, P724, DOI 10.1002/humu.20511
   Bonnet C, 2010, J MED GENET, V47, P377, DOI 10.1136/jmg.2009.071902
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chaudhri RA, 2014, STEROIDS, V81, P74, DOI 10.1016/j.steroids.2013.10.020
   Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098
   Cui R, 2009, J ATHEROSCLER THROMB, V16, P457, DOI 10.5551/jat.No083
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Dubrow S. A., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P166
   Ferrari SL, 2004, AM J HUM GENET, V74, P866, DOI 10.1086/420771
   Grassi F, 2006, ENDOCRINOLOGY, V147, P4392, DOI 10.1210/en.2006 0334
   Guo DC, 2013, AM J HUM GENET, V93, P398, DOI 10.1016/j.ajhg.2013.06.019
   Hagiwara H, 1996, AM J PHYSIOL CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311
   Hannema SE, 2013, J CLIN ENDOCR METAB, V98, pE1988, DOI 10.1210/jc.2013 2358
   Hayashi T, 2000, J GERONTOL A BIOL, V55, pB183, DOI 10.1093/gerona/55.4.B183
   Hofmann Franz, 2009, V191, P137, DOI 10.1007/978 3 540 68964 5_8
   Jamal SA, 2004, J BONE MINER RES, V19, P1512, DOI 10.1359/JBMR.040716
   Joshua J, 2014, ENDOCRINOLOGY, V155, P4720, DOI 10.1210/en.2014 1343
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kalyanaraman H, 2018, NITRIC OXIDE BIOL CH, V76, P62, DOI 10.1016/j.niox.2018.03.007
   Kalyanaraman H, 2018, DIABETES, V67, P607, DOI 10.2337/db17 0965
   Kalyanaraman H, 2017, J BONE MINER RES, V32, P46, DOI 10.1002/jbmr.2909
   Kalyanaraman H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004911
   Kawasaki Y, 2008, J CLIN INVEST, V118, P2506, DOI 10.1172/JCI35243
   Kiel DP, 2007, BONE, V40, P587, DOI 10.1016/j.bone.2006.09.029
   Kondo E, 2015, ENDOCRINOLOGY, V156, P2518, DOI 10.1210/en.2014 1801
   Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200
   Kuhn M, 2016, PHYSIOL REV, V96, P751, DOI 10.1152/physrev.00022.2015
   Lenz A, 2010, PEDIATR RES, V68, P405, DOI 10.1203/PDR.0b013e3181ef7636
   Lipska Zietkiewicz BS, 2011, GENET COUNSEL, V22, P353
   Marathe N, 2012, J BIOL CHEM, V287, P978, DOI 10.1074/jbc.M111.294959
   Markovitz JH, 1997, J HYPERTENS, V15, P955, DOI 10.1097/00004872 199715090 00005
   Mendelsohn ME, 2010, J CLIN INVEST, V120, P2277, DOI 10.1172/JCI43756
   Miura K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042180
   Miyazawa T, 2002, ENDOCRINOLOGY, V143, P3604, DOI 10.1210/en.2002 220307
   Mueck AO, 2001, MATURITAS, V38, P305, DOI 10.1016/S0378 5122(01)00169 4
   Nabhan AF, 2008, INT J GYNECOL OBSTET, V103, P213, DOI 10.1016/j.ijgo.2008.07.011
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082
   Rangaswami H, 2012, J BIOL CHEM, V287, P21509, DOI 10.1074/jbc.M112.347245
   Rangaswami H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001423
   Rangaswami H, 2009, J BIOL CHEM, V284, P14796, DOI 10.1074/jbc.M806486200
   ROSSELLI M, 1995, HYPERTENSION, V25, P848, DOI 10.1161/01.HYP.25.4.848
   Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025
   Vaandrager AB, 2005, FRONT BIOSCI LANDMRK, V10, P2150, DOI 10.2741/1687
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Watanuki M, 2002, J BONE MINER RES, V17, P1015, DOI 10.1359/jbmr.2002.17.6.1015
   Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240
   Wimalawansa SJ, 1996, BONE, V18, P301, DOI 10.1016/8756 3282(96)00005 1
   Wimalawansa SJ, 2007, ANN NY ACAD SCI, V1117, P283, DOI 10.1196/annals.1402.066
   Yao W, 2010, J BONE MINER RES, V25, P190, DOI 10.1359/jbmr.090719
   Zhao X, 2005, J BIOL CHEM, V280, P32683, DOI 10.1074/jbc.M505486200
NR 58
TC 24
Z9 25
U1 0
U2 9
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0022 0795
EI 1479 6805
J9 J ENDOCRINOL
JI J. Endocrinol.
PD SEP
PY 2018
VL 238
IS 3
BP 203
EP 219
DI 10.1530/JOE 18 0286
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HB4RJ
UT WOS:000451042500010
PM 29914933
OA Bronze, Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Xiong, L
   Jung, JU
   Guo, HH
   Pan, JX
   Sun, XD
   Mei, L
   Xiong, WC
AF Xiong, Lei
   Jung, Ji Ung
   Guo, Hao Han
   Pan, Jin Xiu
   Sun, Xiang Dong
   Mei, Lin
   Xiong, Wen Cheng
TI Osteoblastic Lrp4 promotes osteoclastogenesis by regulating ATP release
   and adenosine A2AR signaling
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID NEUROMUSCULAR JUNCTION; ALKALINE PHOSPHATASE; BONE HOMEOSTASIS; IN VIVO;
   RECEPTOR; RANKL; SCLEROSTIN; CELLS; GENE; DIFFERENTIATION
AB Bone homeostasis depends on the functional balance of osteoblasts (OBs) and osteoclasts (OCs). Lrp4 is a transmembrane protein that is mutated in patients with high bone mass. Loss of Lrp4 in OB lineage cells increases bone mass by elevating bone formation by OBs and reducing bone resorption by OCs. However, it is unclear how Lrp4 deficiency in OBs impairs osteoclastogenesis. Here, we provide evidence that loss of Lrp4 in the OB lineage stabilizes the prorenin receptor (PRR) and increases PRR/V ATPase driven ATP release, thereby enhancing the production of the ATP derivative adenosine. Both pharmacological and genetic inhibition of adenosine (2A) receptor (A(2A)R) in culture and Lrp4 mutant mice diminishes the osteoclastogenic deficit and reduces trabecular bone mass. Furthermore, elevated adenosine A(2A)R signaling reduces receptor activator of nuclear factor kappa B (RANK) mediated osteoclastogenesis. Collectively, these results identify a mechanism by which osteoblastic Lrp4 controls osteoclastogenesis, reveal a cross talk between A(2A)R and RANK signaling in osteoclastogenesis, and uncover an unrecognized pathophysiological mechanism of high bone mass disorders.
C1 [Xiong, Lei; Jung, Ji Ung; Guo, Hao Han; Pan, Jin Xiu; Sun, Xiang Dong; Mei, Lin; Xiong, Wen Cheng] Med Coll Georgia, Dept Neurosci & Regenerat Med, Augusta, GA 30912 USA.
   [Xiong, Lei; Jung, Ji Ung; Guo, Hao Han; Pan, Jin Xiu; Sun, Xiang Dong; Mei, Lin; Xiong, Wen Cheng] Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA.
   [Xiong, Lei; Guo, Hao Han; Pan, Jin Xiu; Sun, Xiang Dong; Mei, Lin; Xiong, Wen Cheng] Charlie Norwood VA Med Ctr, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Charlie Norwood VA Medical Center
RP Mei, L; Xiong, WC (通讯作者)，Med Coll Georgia, Dept Neurosci & Regenerat Med, Augusta, GA 30912 USA.; Mei, L; Xiong, WC (通讯作者)，Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA.; Mei, L; Xiong, WC (通讯作者)，Charlie Norwood VA Med Ctr, Augusta, GA 30912 USA.
EM lmei@augusta.edu; wxiong@augusta.edu
RI ; PAN, JIN XIU/O 4840 2019; Sun, Dong/LCE 1669 2024; Jung,
   Jiung/F 5829 2017; Jung, Jiung/P 3940 2019
OI Xiong, Wen Cheng/0000 0001 9071 7598; Xiong, Lei/0000 0002 8083 6902;
   Pan, Jinxiu/0000 0003 4013 1390; Jung, Jiung/0000 0001 5362 5969; 
FU National Institutes of Health; U.S. Department of Veterans Affairs
FX This study was supported in part by grants from the National Institutes
   of Health (to W. C. Xiong and L. Mei) and the U.S. Department of
   Veterans Affairs (to W. C. Xiong).
CR Ahn Y, 2013, DEVELOPMENT, V140, P583, DOI 10.1242/dev.085118
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Bankston LA, 1996, J BIOL CHEM, V271, P17132, DOI 10.1074/jbc.271.29.17132
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972
   Buechling T, 2010, CURR BIOL, V20, P1263, DOI 10.1016/j.cub.2010.05.028
   Burnstock G, 2013, PURINERG SIGNAL, V9, P541, DOI 10.1007/s11302 013 9381 4
   Burr D, 2011, BONE, V49, P1, DOI 10.1016/j.bone.2011.05.019
   Cao Q, 2014, J BIOL CHEM, V289, P23189, DOI 10.1074/jbc.M114.567107
   Chang MK, 2014, P NATL ACAD SCI USA, V111, pE5187, DOI 10.1073/pnas.1413828111
   Chen PM, 2011, CELL BIOSCI, V1, DOI 10.1186/2045 3701 1 10
   CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003 2697(88)90002 4
   Choi HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007930
   Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200
   Cruciat CM, 2010, SCIENCE, V327, P459, DOI 10.1126/science.1179802
   Drögemüller C, 2007, BMC GENET, V8, DOI 10.1186/1471 2156 8 5
   Fijalkowski I, 2016, J BONE MINER RES, V31, P874, DOI 10.1002/jbmr.2782
   Folestad A, 2015, ACTA ORTHOP, V86, P415, DOI 10.3109/17453674.2015.1033606
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009
   GONZALEZROMO P, 1992, ANAL BIOCHEM, V200, P235, DOI 10.1016/0003 2697(92)90458 J
   Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Huang P, 2014, J BIOL CHEM, V289, P17658, DOI 10.1074/jbc.M114.552158
   Ichihara Atsuhiro, 2012, Keio Journal of Medicine, V61, P73
   Idzko M, 2014, NATURE, V509, P310, DOI 10.1038/nature13085
   Irousselle A, 2014, CLIN SCI, V126, P529, DOI 10.1042/CS20130307
   Itoh K, 2000, J BONE MINER RES, V15, P1766, DOI 10.1359/jbmr.2000.15.9.1766
   Khan TN, 2013, EUR J MED GENET, V56, P371, DOI 10.1016/j.ejmg.2013.04.007
   Kim N, 2008, CELL, V135, P334, DOI 10.1016/j.cell.2008.10.002
   King BF, 2007, BRIT J PHARMACOL, V151, P565, DOI 10.1038/sj.bjp.0707266
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Mahamed DA, 2015, INFECT IMMUN, V83, P721, DOI 10.1128/IAI.02536 14
   Mediero A, 2013, BRIT J PHARMACOL, V169, P1372, DOI 10.1111/bph.12227
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Mediero A, 2012, AM J PATHOL, V180, P775, DOI 10.1016/j.ajpath.2011.10.017
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341
   Narisawa S, 2013, J BONE MINER RES, V28, P1587, DOI 10.1002/jbmr.1901
   Nguyen G, 2011, CLIN SCI, V120, P169, DOI 10.1042/CS20100432
   Nishikawa M, 1996, BONE, V18, P9, DOI 10.1016/8756 3282(95)00426 2
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Orriss IR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069057
   Orriss IR, 2009, J CELL PHYSIOL, V220, P155, DOI 10.1002/jcp.21745
   Prosdocimo DA, 2009, AM J PHYSIOL CELL PH, V296, pC828, DOI 10.1152/ajpcell.00619.2008
   Robinson DG, 2004, PROTOPLASMA, V224, P255, DOI 10.1007/s00709 004 0070 6
   Rudnick G, 2008, P NATL ACAD SCI USA, V105, P5949, DOI 10.1073/pnas.0802774105
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Ryan ZC, 2015, J STEROID BIOCHEM, V148, P225, DOI 10.1016/j.jsbmb.2014.11.021
   Sauer AV, 2012, BLOOD, V119, P1428, DOI 10.1182/blood 2011 07 366781
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Shen CY, 2015, BONE, V80, P101, DOI 10.1016/j.bone.2015.05.012
   Shen CY, 2014, DEV CELL, V28, P604, DOI 10.1016/j.devcel.2014.03.010
   Silvestrini G, 2008, J MOL HISTOL, V39, P237, DOI 10.1007/s10735 007 9158 6
   Suzuki Tatsuo, 2004, Nihon Shinkei Seishin Yakurigaku Zasshi, V24, P205
   Takahashi N, 2011, FRONT BIOSCI LANDMRK, V16, P21, DOI 10.2741/3673
   Takai E, 2014, PURINERG SIGNAL, V10, P487, DOI 10.1007/s11302 014 9411 x
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tian QB, 1999, MOL BRAIN RES, V72, P147, DOI 10.1016/S0169 328X(99)00214 4
   Tokunaga A, 2010, J BIOL CHEM, V285, P17406, DOI 10.1074/jbc.M110.112417
   Trepiccione F, 2016, J AM SOC NEPHROL, V27, P3320, DOI 10.1681/ASN.2015080915
   Wang D, 2013, J CELL BIOL, V203, P171, DOI 10.1083/jcb.201309130
   Weatherbee SD, 2006, DEVELOPMENT, V133, P4993, DOI 10.1242/dev.02696
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Wu HT, 2012, NEURON, V75, P94, DOI 10.1016/j.neuron.2012.04.033
   Wu HT, 2010, DEVELOPMENT, V137, P1017, DOI 10.1242/dev.038711
   Xia WF, 2013, J CELL BIOL, V200, P821, DOI 10.1083/jcb.201207154
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xiong L, 2015, P NATL ACAD SCI USA, V112, P3487, DOI 10.1073/pnas.1419714112
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zaiss MM, 2011, J IMMUNOL, V186, P6097, DOI 10.4049/jimmunol.1003487
   Zhang B, 2008, NEURON, V60, P285, DOI 10.1016/j.neuron.2008.10.006
   ZHANG JM, 1994, J BIOL CHEM, V269, P23518
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zong YN, 2012, GENE DEV, V26, P247, DOI 10.1101/gad.180885.111
NR 80
TC 20
Z9 21
U1 0
U2 9
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021 9525
EI 1540 8140
J9 J CELL BIOL
JI J. Cell Biol.
PD MAR
PY 2017
VL 216
IS 3
BP 761
EP 778
DI 10.1083/jcb.201608002
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA EN2FV
UT WOS:000395826200024
PM 28193701
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Sheu, SY
   Tsai, CC
   Sun, JS
   Chen, MH
   Liu, MH
   Sun, MG
AF Sheu Shiow yunn
   Tsai Chia chung
   Sun Jui sheng
   Chen Ming hong
   Liu Man hai
   Sun Man ger
TI Stimulatory effect of puerarin on bone formation through co activation
   of nitric oxide and bone morphogenetic protein 2/mitogen activated
   protein kinases pathways in mice
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE puerarin; nitric oxide; bone morphogenetic protein 2; mitogen activated
   protein kinases; osteoblasts
ID HORMONE REPLACEMENT THERAPY; OSTEOCLAST DIFFERENTIATION; OSTEOCYTE
   APOPTOSIS; ACTIVATION; ESTROGEN; DAIDZEIN; CANCER; PHYTOESTROGENS;
   OSTEOPOROSIS; OSTEOBLASTS
AB Background Estrogen deficiency results in loss of bone mass. Phytoestrogens are plant derived non steroidal compounds with estrogen like activity that bind to estrogen receptors. The main aim of this study was to investigate the effect of the phytoestrogen puerarin on adult mouse osteoblasts.
   Methods Osteoblast cells were harvested from 8 month old female imprinting control region (ICR) mice. The effects of puerarin stimulation on the proliferation, differentiation and maturation of osteoblasts were examined. The production of nitric oxide (NO) and the expression of bone morphogenetic protein 2 (BMP 2), SMAD4, mitogen activated protein kinases (MAPK), core binding factor all runt related transcription factor 2 (Cbfa1/Runx2), osteoprotegerin (OPG), and receptor activator of NF kappa B ligand (RANKL) genes were analyzed. The activation of signal pathways was further confirmed by specific pathway inhibitors.
   Results The osteoblast viability reached its maximum at 10( 8) mol/L puerarin. At this concentration, puerarin increases the proliferation and matrix mineralization of osteoblasts and promotes NO synthesis. With 10( 8) mol/L puerarin treatment, BMP 2, SMAD4, Cbfa1/Runx2, and OPG gene expression were up regulated, while the RANKL gene expression is down regulated. Concurrent treatment involving the (bone morphogenetic protein) BMP antagonist Noggin or the NOS inhibitor L NAME diminishes puerarin induced cell proliferation, Alkaline phosphatase (ALP) activity, NO production, as well as the BMP 2, SMAD4, Cbfa1/Runx2, OPG, and RANKL gene expression.
   Conclusions In this in vitro study, we demonstrate that puerarin is a bone anabolic agent that exerts its osteogenic effects through the induction of BMP 2 and NO synthesis, subsequently regulating Cbfa1/Runx2, OPG, and RANKL gene expression. This effect may contribute to its induction of osteoblast proliferation and differentiation, resulting in bone formation. Chin Med J 2012;125(20):3646 3653
C1 [Sun Jui sheng] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei 11031, Taiwan.
   [Sheu Shiow yunn; Tsai Chia chung] Taipei Med Univ, Sch Pharm, Coll Pharm, Taipei 11031, Taiwan.
   [Sun Jui sheng] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Orthoped Surg, Hsinchu 30059, Taiwan.
   [Chen Ming hong] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Surg, Hsinchu 30059, Taiwan.
   [Liu Man hai] China Univ Sci & Technol, Dept Food Sci, Taipei 11581, Taiwan.
   [Sun Man ger] Univ Western Ontario, Dept Biol, London, ON N6A 5C1, Canada.
C3 Taipei Medical University; Taipei Medical University; National Taiwan
   University; National Taiwan University Hospital; National Taiwan
   University; National Taiwan University Hospital; Western University
   (University of Western Ontario)
RP Sun, JS (通讯作者)，Taipei Med Univ, Grad Inst Clin Med, Coll Med, 250 Wusing St, Taipei 11031, Taiwan.
EM amel@tmu.edu.tw; drjssun@gmail.com
RI ; SUN, Jus Sheng/ITU 1253 2023; Huang, Chen/I 2304 2019
OI Chen, Ming Hong/0000 0001 6306 0818; SUN, JUI SHENG/0000 0001 5142 8777;
   
CR Abe E, 2006, ANN NY ACAD SCI, V1068, P41, DOI 10.1196/annals.1346.007
   Agarwal R, 2000, BIOCHEM PHARMACOL, V60, P1051, DOI 10.1016/S0006 2952(00)00385 3
   An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200
   Barnes S, 2004, J NUTR, V134, p1225S, DOI 10.1093/jn/134.5.1225S
   Beral V, 2005, LANCET, V365, P1543, DOI 10.1016/S0140 6736(05)66455 0
   COLLINOSDOBY P, 1995, J CELL BIOCHEM, V57, P399, DOI 10.1002/jcb.240570305
   Dang ZC, 2004, J BONE MINER RES, V19, P853, DOI 10.1359/JBMR.040120
   Fonseca D, 2004, BONE, V35, P489, DOI 10.1016/j.bone.2004.03.031
   Hazenberg JG, 2007, OSTEOPOROSIS INT, V18, P1, DOI 10.1007/s00198 006 0222 y
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Huber C, 2007, CALCIFIED TISSUE INT, V81, P139, DOI 10.1007/s00223 007 9049 6
   Inzerillo AM, 2002, MT SINAI J MED, V69, P220
   Jamal SA, 2009, OSTEOPOROSIS INT, V20, P737, DOI 10.1007/s00198 008 0727 7
   Jia TL, 2003, BIOCHEM PHARMACOL, V65, P709, DOI 10.1016/S0006 2952(02)01585 X
   Lee KH, 2005, BIOL PHARM BULL, V28, P1948, DOI 10.1248/bpb.28.1948
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Mann V, 2007, BONE, V40, P674, DOI 10.1016/j.bone.2006.10.014
   Messina Mark J, 2002, Nutr Clin Care, V5, P272
   Morabito N, 2002, J BONE MINER RES, V17, P1904, DOI 10.1359/jbmr.2002.17.10.1904
   Mukai T, 2007, BIOCHEM BIOPH RES CO, V356, P1004, DOI 10.1016/j.bbrc.2007.03.099
   Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828
   PRICE KR, 1985, FOOD ADDIT CONTAM A, V2, P73, DOI 10.1080/02652038509373531
   Sun JS, 2007, J BIOMED MATER RES A, V81A, P214, DOI 10.1002/jbm.a.30929
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Urasopon N, 2008, MATURITAS, V59, P137, DOI 10.1016/j.maturitas.2008.01.001
   Wong R, 2007, OSTEOARTHR CARTILAGE, V15, P894, DOI 10.1016/j.joca.2007.02.009
   Yamamoto S, 2003, J NATL CANCER I, V95, P906, DOI 10.1093/jnci/95.12.906
   Zhang Y, 2007, PLANTA MED, V73, P341, DOI 10.1055/s 2007 967168
NR 28
TC 26
Z9 31
U1 1
U2 27
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0366 6999
J9 CHINESE MED J PEKING
JI Chin. Med. J.
PD OCT 20
PY 2012
VL 125
IS 20
BP 3646
EP 3653
DI 10.3760/cma.j.issn.0366 6999.2012.20.009
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 039RV
UT WOS:000311265100009
PM 23075718
DA 2025 08 17
ER

PT J
AU Costa, V
   Carina, V
   Raimondi, L
   De Luca, A
   Bellavia, D
   Conigliaro, A
   Salamanna, F
   Alessandro, R
   Fini, M
   Giavaresi, G
AF Costa, Viviana
   Carina, Valeria
   Raimondi, Lavinia
   De Luca, Angela
   Bellavia, Daniele
   Conigliaro, Alice
   Salamanna, Francesca
   Alessandro, Riccardo
   Fini, Milena
   Giavaresi, Gianluca
TI MiR 33a Controls hMSCS Osteoblast Commitment Modulating the Yap/Taz
   Expression Through EGFR Signaling Regulation
SO CELLS
LA English
DT Article
DE epithelial mesenchymal transition; mesenchymal stromal cells; microRNAs;
   regenerative medicine; EGFR signaling
ID MESENCHYMAL STEM CELLS; EPIDERMAL GROWTH FACTOR; BONE MARROW; OSTEOGENIC
   DIFFERENTIATION; TRANSITION; PATHWAY; MICRORNA; SNAIL; RUNX2; YAP1
AB Mesenchymal stromal cells (hMSCs) display a pleiotropic function in bone regeneration. The signaling involved in osteoblast commitment is still not completely understood, and that determines the failure of current therapies being used. In our recent studies, we identified two miRNAs as regulators of hMSCs osteoblast differentiation driving hypoxia signaling and cytoskeletal reorganization. Other signalings involved in this process are epithelial to mesenchymal transition (EMT) and epidermal growth factor receptor (EGFR) signalings through the regulation of Yes associated protein (YAP)/PDZ binding motif (TAZ) expression. In the current study, we investigated the role of miR 33a family as a (i) modulator of YAP/TAZ expression and (ii) a regulator of EGFR signaling during osteoblast commitments. Starting from the observation on hMSCs and primary osteoblast cell lines (Nh Ost) in which EMT genes and miR 33a displayed a specific expression, we performed a gain and loss of function study with miR 33a 5p and 3p on hMSCs cells and Nh Ost. After 24 h of transfections, we evaluated the modulation of EMT and osteoblast genes expression by qRT PCR, Western blot, and Osteoimage assays. Through bioinformatic analysis, we identified YAP as the putative target of miR 33a 3p. Its role was investigated by gain and loss of function studies with miR 33a 3p on hMSCs; qRT PCR and Western blot analyses were also carried out. Finally, the possible role of EGFR signaling in YAP/TAZ modulation by miR 33a 3p expression was evaluated. Human MSCs were treated with EGF 2 and EGFR inhibitor for different time points, and qRT PCR and Western blot analyses were performed. The above mentioned methods revealed a balance between miR 33a 5p and miR 33a 3p expression during hMSCs osteoblast differentiation. The human MSCs phenotype was maintained by miR 33a 5p, while the maintenance of the osteoblast phenotype in the Nh Ost cell model was permitted by miR 33a 3p expression, which regulated YAP/TAZ through the modulation of EGFR signaling. The inhibition of EGFR blocked the effects of miR 33a 3p on YAP/TAZ modulation, favoring the maintenance of hMSCs in a committed phenotype. A new possible personalized therapeutic approach to bone regeneration was discussed, which might be mediated by customizing delivery of miR 33a in simultaneously targeting EGFR and YAP signaling with combined use of drugs.
C1 [Costa, Viviana; Carina, Valeria; Raimondi, Lavinia; De Luca, Angela; Bellavia, Daniele; Salamanna, Francesca; Fini, Milena; Giavaresi, Gianluca] IRCCS Ist Ortoped Rizzoli, I 40136 Bologna, Italy.
   [Conigliaro, Alice; Alessandro, Riccardo] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, Sect Biol & Genet, I 90133 Palermo, Italy.
   [Alessandro, Riccardo] Ist Ric & Innovaz Biomed, I 90146 Palermo, Italy.
C3 University of Palermo; Consiglio Nazionale delle Ricerche (CNR);
   Istituto Ricerca l'Innovazione Biomedica (IRIB CNR)
RP Costa, V (通讯作者)，IRCCS Ist Ortoped Rizzoli, I 40136 Bologna, Italy.
EM viviana.costa@ior.it; valeria.carina@ior.it; lavinia.raimondi@ior.it;
   angela.deluca@ior.it; daniele.bellavia@ior.it;
   alice.conigliaro@unipa.it; francesca.salamanna@ior.it;
   riccardo.alessandro@ior.it; milena.fini@ior.it;
   gianluca.giavaresi@ior.it
RI ; carina, valeria/K 2001 2016; De Luca, Angela/ABD 3384 2020; Raimondi,
   Lavinia/K 4085 2016; Bellavia, Daniele/H 9774 2019; Conigliaro,
   Alice/ACW 5549 2022; Conigliaro, Alice/J 8717 2016; costa,
   viviana/K 4084 2016; deluca, angela/ABD 3384 2020; COSTA,
   VIVIANA/K 4084 2016; Giavaresi, Gianluca/J 5583 2016; Fini,
   Milena/J 4808 2016; Salamanna, Francesca/J 6032 2016
OI Giavaresi, Gianluca/0000 0001 7843 5969; carina,
   valeria/0000 0002 7323 8023; De Luca, Angela/0000 0001 5493 9441;
   Raimondi, Lavinia/0000 0001 9394 2002; Bellavia,
   Daniele/0000 0003 3308 9112; Conigliaro, Alice/0000 0002 3037 835X;
   costa, viviana/0000 0002 2425 6460; Salamanna,
   Francesca/0000 0001 7402 4054
FU National Operative Program for Research and Competitiveness
   "Potenziamento strutturale di una rete di eccellenza per la ricerca
   preclinica e clinica sulla terapia personalizzata in oncologia e in
   medicina rigenerativa" [PON03_00011]
FX The study was developed with the contribution of the National Operative
   Program for Research and Competitiveness 2007 2013   PON03_00011
   "Potenziamento strutturale di una rete di eccellenza per la ricerca
   preclinica e clinica sulla terapia personalizzata in oncologia e in
   medicina rigenerativa". No benefits in any form were received or will be
   received from a commercial party related directly or indirectly to the
   subject of this article.
CR [Anonymous], 2019, PACKAGE LAVAAN
   Battula VL, 2010, STEM CELLS, V28, P1435, DOI 10.1002/stem.467
   Bellavia D, 2019, BONE, V122, P52, DOI 10.1016/j.bone.2019.02.013
   Bellavia D, 2024, CURR OSTEOPOROS REP, V22, P599, DOI 10.1007/s11914 016 0331 2
   Chang CC, 2018, MOL THER, V26, P593, DOI 10.1016/j.ymthe.2017.11.018
   Corrado C, 2016, J CELL MOL MED, V20, P1829, DOI 10.1111/jcmm.12873
   Costa V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071569
   Costa V, 2017, CYTOTHERAPY, V19, P1412, DOI 10.1016/j.jcyt.2017.09.007
   Costa V, 2018, J CELL PHYSIOL, V233, P1558, DOI 10.1002/jcp.26058
   Costa V, 2017, ONCOTARGET, V8, P24292, DOI 10.18632/oncotarget.14464
   de Frutos CA, 2009, EMBO J, V28, P686, DOI 10.1038/emboj.2009.23
   De Luca A, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 017 0663 5
   Garibaldi F, 2012, CELL DEATH DIFFER, V19, P937, DOI 10.1038/cdd.2011.175
   Gumbiner BM, 2014, J CELL SCI, V127, P709, DOI 10.1242/jcs.140103
   Guo XF, 2016, EUR REV MED PHARMACO, V20, P3011
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kitazaki T, 2005, LUNG CANCER, V49, P337, DOI 10.1016/j.lungcan.2005.03.035
   Knight C, 2019, CELL SIGNAL, V53, P256, DOI 10.1016/j.cellsig.2018.09.021
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Li H, 2017, MOL MED REP, V16, P5659, DOI 10.3892/mmr.2017.7251
   Linder M, 2018, CELL DEATH DIFFER, V25, P1094, DOI 10.1038/s41418 017 0054 7
   Liu ZC, 2014, CELL TISSUE RES, V358, P491, DOI 10.1007/s00441 014 1953 2
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo Dico A, 2016, THERANOSTICS, V6, P1105, DOI 10.7150/thno.14700
   Miraoui H, 2010, J CELL BIOCHEM, V110, P1147, DOI 10.1002/jcb.22628
   Ouimet M, 2015, J CLIN INVEST, V125, P4334, DOI 10.1172/JCI81676
   Piersma B, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00059
   Price NL, 2015, CIRC RES, V117, P225, DOI 10.1161/CIRCRESAHA.117.306949
   Rice SJ, 2013, J BIOL CHEM, V288, P16348, DOI 10.1074/jbc.M113.474643
   Seo E, 2013, CELL REP, V3, P2075, DOI 10.1016/j.celrep.2013.05.029
   Song SM, 2015, CLIN CANCER RES, V21, P2580, DOI 10.1158/1078 0432.CCR 14 2191
   Tamama K, 2006, STEM CELLS, V24, P686, DOI 10.1634/stemcells.2005 0176
   Tang Y, 2017, CELL CYCLE, V16, P399, DOI 10.1080/15384101.2017.1280643
   Tang Y, 2016, NAT CELL BIOL, V18, P917, DOI 10.1038/ncb3394
   Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376
   Wang H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0210 5
   Wang H, 2016, SCI REP UK, V6, DOI 10.1038/srep23170
   Watkins DJ, 2014, J PEDIATR SURG, V49, P938, DOI 10.1016/j.jpedsurg.2014.01.030
   Xia HW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0302 x
   Xue P, 2013, BIOCHEM BIOPH RES CO, V433, P226, DOI 10.1016/j.bbrc.2013.02.088
   Yu S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.363
   Zhang MD, 2016, ONCOTARGET, V7, P78640, DOI 10.18632/oncotarget.12693
   Zhou Y, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756 9966 33 12
   Zhu J, 2011, J CELL BIOCHEM, V112, P1749, DOI 10.1002/jcb.23094
   Zou D, 2011, CELL PROLIFERAT, V44, P234, DOI 10.1111/j.1365 2184.2011.00747.x
   Zuo B, 2015, J BONE MINER RES, V30, P330, DOI 10.1002/jbmr.2352
NR 46
TC 17
Z9 17
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD DEC
PY 2019
VL 8
IS 12
AR 1495
DI 10.3390/cells8121495
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA KB7AN
UT WOS:000506643500025
PM 31771093
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Russell, K
   Amir, E
   Paterson, A
   Josse, R
   Addison, C
   Kuchuk, I
   Clemons, M
AF Russell, Kent
   Amir, Eitan
   Paterson, Alexander
   Josse, Robert
   Addison, Christina
   Kuchuk, Iryna
   Clemons, Mark
TI Does estrogen play a role in response to adjuvant bone targeted
   therapies?
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Estrogen; Breast cancer; Bone targeted therapies; Adjuvant therapy;
   Bisphosphonates
ID BREAST CANCER RISK; SEX HORMONE LEVELS; BODY MASS INDEX; ZOLEDRONIC
   ACID; ANTITUMOR ACTIVITY; ORAL CLODRONATE; BISPHOSPHONATE RISEDRONATE;
   OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; SKELETAL
   COMPLICATIONS
AB Bone remains the most common site of breast cancer recurrence. The results of population studies, pre  clinical research and clinical studies in patients with metastatic disease provided a rationale for testing bone targeted agents in the adjuvant setting. Despite the initial optimism, results from eight prospectively designed, randomized control studies powered to assess the value of adjuvant boric targeted therapy in early breast cancer are conflicting. Data have shown that, where benefit exists, it Lends to be in women with a "low estrogen environment", either through menopause or suppression of ovarian function. In this manuscript, we review clinical data supporting the hypothesis that estrogen levels may play a part in explaining the response of patients to bone targeted agents in the adjuvant setting. The results presented to date suggest that there may be data supporting a unifying role for estrogen in adjuvant trials. However, in the absence of any prospective randomized trials in which estrogen data has been systematically collected we cannot specifically answer this question. We await the results of the Oxford overview analysis of individual patient data with interest. (C) 2013 Elsevier GmbH. All rights reserved.
C1 [Russell, Kent; Kuchuk, Iryna; Clemons, Mark] Univ Ottawa, Div Med Oncol, Ottawa, ON K1H 8L6, Canada.
   [Russell, Kent; Kuchuk, Iryna; Clemons, Mark] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada.
   [Amir, Eitan] Univ Toronto, Div Hematol & Med Oncol, Toronto, ON, Canada.
   [Amir, Eitan] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
   [Paterson, Alexander] Univ Alberta, Tom Baker Canc Ctr, Dept Oncol, Calgary, AB, Canada.
   [Josse, Robert] St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada.
   [Josse, Robert] Univ Toronto, Toronto, ON, Canada.
   [Addison, Christina; Clemons, Mark] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON K1H 8L6, Canada.
C3 University of Ottawa; University of Ottawa; Ottawa Hospital Research
   Institute; University of Toronto; University of Toronto; University
   Health Network Toronto; Princess Margaret Cancer Centre; University of
   Alberta; University of Calgary; Tom Baker Cancer Clinic; University of
   Toronto; Saint Michaels Hospital Toronto; University of Toronto;
   University of Ottawa; Ottawa Hospital Research Institute
RP Clemons, M (通讯作者)，Univ Ottawa, Div Med Oncol, Box 912,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
EM mclemons@toh.on.ca
RI ; Amir, Eitan/L 6052 2019
OI Amir, Eitan/0000 0002 3706 525X; 
CR Adami S, 2008, CALCIFIED TISSUE INT, V82, P341, DOI 10.1007/s00223 008 9126 5
   Baim S, 2009, J BONE MINER RES, V24, P561, DOI [10.1359/JBMR.090203, 10.1359/jbmr.090203]
   Beral V, 2002, LANCET, V360, P187, DOI 10.1016/S0140 6736(02)09454 0
   Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140 6736(97)08233 0
   Beral Valerie, 2003, Lancet, V362, P419
   BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brasso K, 2006, PROSTATE, V66, P503, DOI 10.1002/pros.20311
   CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002 9343(99)80134 X
   Chlebowski RT, 2010, J CLIN ONCOL, V28, P3582, DOI 10.1200/JCO.2010.28.2095
   Chlebowski RT, 2009, NEW ENGL J MED, V360, P573, DOI 10.1056/NEJMoa0807684
   Clemons M, 2012, BREAST CANCER RES TR, V134, P453, DOI 10.1007/s10549 012 2077 6
   Coleman R, 2012, SAN ANTONIO BREAST C
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Dean Colomb W, 2013, BREAST CANCER RES TR, V137, P631, DOI 10.1007/s10549 012 2374 0
   Demers LM, 2003, CLIN ORTHOP RELAT R, pS138, DOI 10.1097/01.blo.0000092979.12414.54
   Diel IJ, 2008, ANN ONCOL, V19, P2007, DOI 10.1093/annonc/mdn429
   Dorgan JF, 2002, JNCI J NATL CANCER I, V94, P606
   Dowsett M, 2005, BREAST CANCER RES, V7, P1, DOI 10.1186/bcr960
   Farhat GN, 2011, JNCI J NATL CANCER I, V103, P562, DOI 10.1093/jnci/djr031
   Glover SJ, 2008, BONE, V42, P623, DOI 10.1016/j.bone.2007.12.218
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Green JR, 2002, AM J CLIN ONCOL CANC, V25, pS3, DOI 10.1097/00000421 200212001 00002
   Gregory W, 2012, 2012 ASCO ANN M CHIC
   HALL DG, 1994, J BONE MINER RES, V9, P221
   HASSAGER C, 1992, J BONE MINER RES, V7, P1307
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Key TJ, 2001, LANCET ONCOL, V2, P133, DOI 10.1016/S1470 2045(00)00254 0
   Key TJ, 2003, J NATL CANCER I, V95, P1218, DOI 10.1093/jnci/djg022
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   KREMPIEN B, 1988, ONCOLOGY BASEL, V45, P41, DOI 10.1159/000226528
   Kristensen B, 2008, ACTA ONCOL, V47, P740, DOI 10.1080/02841860801964988
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Leeming DJ, 2006, CANCER EPIDEM BIOMAR, V15, P32, DOI 10.1158/1055 9965.EPI 05 0492
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lippman ME, 2001, J CLIN ONCOL, V19, P3111, DOI 10.1200/JCO.2001.19.12.3111
   Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008
   Lipton A, 2011, J CLIN ONCOL, V29, P3605, DOI 10.1200/JCO.2010.31.5069
   Magnetto S, 1999, INT J CANCER, V83, P263, DOI 10.1002/(SICI)1097 0215(19991008)83:2<263::AID IJC19>3.0.CO;2 T
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Missmer SA, 2004, JNCI J NATL CANCER I, V96, P1856, DOI 10.1093/jnci/djh336
   Mobus V, SAN ANTONIO BREAST C
   Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158
   Neville Webbe HL, 2010, EUR J CANCER, V46, P1211, DOI 10.1016/j.ejca.2010.02.041
   Neville Webbe HL, 2006, TUMOR BIOL, V27, P92, DOI 10.1159/000092489
   Neville Webbe HL, 2002, CANCER TREAT REV, V28, P305, DOI 10.1016/S0305 7372(02)00095 6
   Newcomb PA, 2010, BRIT J CANCER, V102, P799, DOI 10.1038/sj.bjc.6605555
   Niewoehner CB, 2004, ENDOCRINE PATHOPHYSI
   Padalecki SS, 2002, BREAST CANCER RES, V4, P35, DOI 10.1186/bcr415
   Paterson AHG, 2012, LANCET ONCOL, V13, P734, DOI 10.1016/S1470 2045(12)70226 7
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105
   Ravn P, 1999, J BONE MINER RES, V14, P1622, DOI 10.1359/jbmr.1999.14.9.1622
   RAVN P, 1994, J BONE MINER RES, V9, P1975
   Rennert G, 2010, J CLIN ONCOL, V28, P3577, DOI 10.1200/JCO.2010.28.1113
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rinaldi S, 2001, CANCER EPIDEM BIOMAR, V10, P757
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosner W, 2013, J CLIN ENDOCR METAB, V98, P1376, DOI 10.1210/jc.2012 3780
   Russell K, 2012, J BONE ONCOL, V1, P12, DOI 10.1016/j.jbo.2012.04.003
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Saarto T, 2004, ACTA ONCOL, V43, P650, DOI 10.1080/02841860410032885
   Saika M, 2001, ENDOCRINOLOGY, V142, P2205, DOI 10.1210/en.142.6.2205
   Sasaki A, 1998, INT J CANCER, V77, P279, DOI 10.1002/(SICI)1097 0215(19980717)77:2<279::AID IJC18>3.0.CO;2 6
   SASAKI A, 1995, CANCER RES, V55, P3551
   Sieri S, 2009, CANCER EPIDEM BIOMAR, V18, P169, DOI 10.1158/1055 9965.EPI 08 0808
   Soules MR, 2001, J WOMEN HEALTH GEN B, V10, P843, DOI 10.1089/152460901753285732
   Stanczyk FZ, 2003, STEROIDS, V68, P1173, DOI 10.1016/j.steroids.2003.08.012
   Stuebe AM, 2009, ARCH INTERN MED, V169, P1364, DOI 10.1001/archinternmed.2009.231
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Tucci JR, 1996, AM J MED, V101, P488, DOI 10.1016/S0002 9343(96)00282 3
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Yoneda Toshiyuki, 2000, Cancer, V88, P2979, DOI 10.1002/1097 0142(20000615)88:12+<2979::AID CNCR13>3.0.CO;2 U
   Zeleniuch Jacquotte A, 2004, BRIT J CANCER, V90, P153, DOI 10.1038/sj.bjc.6601517
   Zheng T, 2001, BRIT J CANCER, V84, P1472, DOI 10.1054/bjoc.2001.1793
NR 85
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD DEC
PY 2013
VL 2
IS 4
BP 167
EP 173
DI 10.1016/j.jbo.2013.06.001
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA V37LP
UT WOS:000209277600005
PM 26909288
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hasegawa, T
   Kikuta, J
   Ishii, M
AF Hasegawa, Tetsuo
   Kikuta, Junichi
   Ishii, Masaru
TI Imaging the Bone Immune Cell Interaction in Bone Destruction
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE intravital imaging; two photon microscopy; cellular dynamics; bone;
   osteoclast; pH probe
ID SPHINGOSINE 1 PHOSPHATE; OSTEOCLAST PRECURSORS; A3 ISOFORM; H+ ATPASE;
   SPHINGOSINE 1 PHOSPHATE; OSTEOIMMUNOLOGY; MACROPHAGES; FINGOLIMOD;
   RECEPTORS; DENOSUMAB
AB Bone is a highly dynamic organ that is continuously being remodeled by the reciprocal interactions between bone and immune cells. We have originally established an advanced imaging system for visualizing the in vivo behavior of osteoclasts and their precursors in the bone marrow cavity using two photon microscopy. Using this system, we found that the blood enriched lipid mediator, sphingosine 1 phosphate, controlled the migratory behavior of osteoclast precursors. We also developed pH sensing chemical fluorescent probes to detect localized acidification by bone resorbing osteoclasts on the bone surface in vivo, and identified two distinct functional states of differentiated osteoclasts, "bone resorptive" and "non resorptive." Here, we summarize our studies on the dynamics and functions of bone and immune cells within the bonemarrow. We further discuss how our intravital imaging techniques can be applied to evaluate the mechanisms of action of biological agents in inflammatory bone destruction. Our intravital imaging techniques would be beneficial for studying the cellular dynamics in arthritic inflammation and bone destruction in vivo and would also be useful for evaluating novel therapies in animal models of bone destroying diseases.
C1 [Hasegawa, Tetsuo; Kikuta, Junichi; Ishii, Masaru] Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Immunol & Cell Biol, Osaka, Japan.
   [Hasegawa, Tetsuo] Keio Univ, Sch Med, Dept Internal Med, Div Rheumatol, Tokyo, Japan.
   [Kikuta, Junichi; Ishii, Masaru] Osaka Univ, WPI Immunol Frontier Res Ctr, Osaka, Japan.
C3 University of Osaka; Keio University; University of Osaka
RP Ishii, M (通讯作者)，Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Immunol & Cell Biol, Osaka, Japan.; Ishii, M (通讯作者)，Osaka Univ, WPI Immunol Frontier Res Ctr, Osaka, Japan.
EM mishii@icb.med.osaka u.ac.jp
RI Kikuta, Junichi/HHS 8875 2022
FU CREST, Japan Science and Technology Agency; Japan Society for the
   Promotion of Science (JSPS); Uehara Memorial Foundation; Kanae
   Foundation for the Promotion of Medical Sciences; Mochida Memorial
   Foundation; Takeda Science Foundation
FX This work was supported in part by CREST, Japan Science and Technology
   Agency; Grants in Aid for Scientific Research (A) from the Japan Society
   for the Promotion of Science (JSPS to MI); grants from the Uehara
   Memorial Foundation (to MI); from the Kanae Foundation for the Promotion
   of Medical Sciences (to MI); from Mochida Memorial Foundation (to MI);
   and from the Takeda Science Foundation (to MI).
CR Baeyens A, 2015, TRENDS IMMUNOL, V36, P778, DOI 10.1016/j.it.2015.10.005
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Boleto G, 2017, CLIN RHEUMATOL, V36, P1699, DOI 10.1007/s10067 017 3722 6
   Cahalan MD, 2002, NAT REV IMMUNOL, V2, P872, DOI 10.1038/nri935
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Chun J, 2019, ANNU REV PHARMACOL, V59, P149, DOI 10.1146/annurev pharmtox 010818 021358
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628
   Factor LI, 2002, J IMMUNOL, V169, P3353, DOI [DOI 10.4049/JIMMUNOL.169, 10.4049/jimmunol.169.6.3353, DOI 10.4049/JIMMUNOL.169.6.3353]
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Germain RN, 2006, NAT REV IMMUNOL, V6, P497, DOI 10.1038/nri1884
   Greenblatt Matthew B, 2013, Immune Netw, V13, P111, DOI 10.4110/in.2013.13.4.111
   Hasegawa T, 2017, JOINT BONE SPINE, V84, P379, DOI 10.1016/j.jbspin.2016.05.010
   Hawkins ED, 2016, NATURE, V538, P518, DOI 10.1038/nature19801
   Huwiler A, 2018, PHARMACOL THERAPEUT, V185, P34, DOI 10.1016/j.pharmthera.2017.11.001
   Ishii M, 2010, J EXP MED, V207, P2793, DOI 10.1084/jem.20101474
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Kikuta J, 2013, P NATL ACAD SCI USA, V110, P7009, DOI 10.1073/pnas.1218799110
   Kikuta J, 2013, J CLIN INVEST, V123, P866, DOI 10.1172/JCI65054
   Kozloff KM, 2010, J BONE MINER RES, V25, P1748, DOI 10.1002/jbmr.66
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233
   Loudet A, 2007, CHEM REV, V107, P4891, DOI 10.1021/cr078381n
   Matsuura Y, 2018, ANN RHEUM DIS, V77, P1220, DOI 10.1136/annrheumdis 2017 212880
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400
   Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takayanagi H, 2015, NAT REV RHEUMATOL, V11, P74, DOI 10.1038/nrrheum.2014.219
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760
   Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zaheer S, 2015, EXPERT OPIN DRUG MET, V11, P461, DOI 10.1517/17425255.2015.1000860
NR 39
TC 14
Z9 15
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAR 26
PY 2019
VL 10
AR 596
DI 10.3389/fimmu.2019.00596
PG 7
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA HQ6PW
UT WOS:000462541300002
PM 30972080
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shao, Y
   Hernandez Buquer, S
   Childress, P
   Stayrook, KR
   Alvarez, MB
   Davis, H
   Plotkin, LI
   He, YZ
   Condon, KW
   Burr, DB
   Warden, SJ
   Robling, AG
   Yang, FC
   Wek, RC
   Allen, MR
   Bidwell, JP
AF Shao, Yu
   Hernandez Buquer, Selene
   Childress, Paul
   Stayrook, Keith R.
   Alvarez, Marta B.
   Davis, Hannah
   Plotkin, Lilian I.
   He, Yongzheng
   Condon, Keith W.
   Burr, David B.
   Warden, Stuart J.
   Robling, Alexander G.
   Yang, Feng Chun
   Wek, Ronald C.
   Allen, Matthew R.
   Bidwell, Joseph P.
TI Improving Combination Osteoporosis Therapy in a Preclinical Model of
   Heightened Osteoanabolism
SO ENDOCRINOLOGY
LA English
DT Article
ID BONE MINERAL DENSITY; NUCLEOCYTOPLASMIC SHUTTLING PROTEIN;
   PARATHYROID HORMONE; POSTMENOPAUSAL OSTEOPOROSIS; ZOLEDRONIC ACID;
   IN VITRO; OVARIECTOMIZED MICE; RIBOSOME BIOGENESIS; ANABOLIC ACTIONS;
   CONTROLLED TRIAL
AB Combining anticatabolic agents with parathyroid hormone (PTH) to enhance bone mass has yielded mixed results in osteoporosis patients. Toward the goal of enhancing the efficacy of these regimens, we tested their utility in combination with loss of the transcription factor Nmp4 because disabling this gene amplifies PTH induced increases in trabecular bone in mice by boosting osteoblast secretory activity. We addressed whether combining a sustained anabolic response with an anticatabolic results in superior bone acquisition compared with PTH monotherapy. Additionally, we inquired whether Nmp4 interferes with anticatabolic efficacy. Wild type and Nmp4( / ) mice were ovariectomized at 12 weeks of age, followed by therapy regimens, administered from 16 to 24 weeks, and included individually or combined PTH, alendronate (ALN), zoledronate (ZOL), and raloxifene (RAL). Anabolic therapeutic efficacy generally corresponded with PTH + RAL = PTH + ZOL > PTH + ALN = PTH > vehicle control. Loss of Nmp4 enhanced femoral trabecular bone increases under PTH + RAL and PTH + ZOL. RAL and ZOL promoted bone restoration, but unexpectedly, loss of Nmp4 boosted RAL induced increases in femoral trabecular bone. The combination of PTH, RAL, and loss of Nmp4 significantly increased bone marrow osteoprogenitor number, but did not affect adipogenesis or osteoclastogenesis. RAL, but not ZOL, increased osteoprogenitors in both genotypes. Nmp4 status did not influence bone serum marker responses to treatments, but Nmp4( / ) mice as a group showed elevated levels of the bone formation marker osteocalcin. We conclude that the heightened osteoanabolism of the Nmp4( / ) skeleton enhances the effectiveness of diverse osteoporosis treatments, in part by increasing hyperanabolic osteoprogenitors. Nmp4 provides a promising target pathway for identifying barriers to pharmacologically induced bone formation.
C1 [Shao, Yu; Bidwell, Joseph P.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
   [Hernandez Buquer, Selene; Davis, Hannah; Plotkin, Lilian I.; Condon, Keith W.; Burr, David B.; Robling, Alexander G.; Allen, Matthew R.; Bidwell, Joseph P.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Med Sci Bldg 5035,635 Barnhill Dr, Indianapolis, IN 46202 USA.
   [Childress, Paul; Alvarez, Marta B.] Indiana Univ Sch Med, Dept Orthoped Surg, Indianapolis, IN 46202 USA.
   [Stayrook, Keith R.] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.
   [He, Yongzheng] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.
   [He, Yongzheng] Indiana Univ Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.
   [Warden, Stuart J.] Indiana Univ, Sch Hlth & Rehabil Sci, Ctr Translat Musculoskeletal Res, Indianapolis, IN 46202 USA.
   [Warden, Stuart J.] Indiana Univ, Sch Hlth & Rehabil Sci, Dept Phys Therapy, Indianapolis, IN 46202 USA.
   [Yang, Feng Chun] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA.
   [Wek, Ronald C.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Allen, Matthew R.] Richard A Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University Bloomington; Indiana University System; Indiana University
   Bloomington; Indiana University System; Indiana University Indianapolis;
   Indiana University System; Indiana University Indianapolis; University
   of Miami; Indiana University System; Indiana University Bloomington; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Richard L. Roudebush VA Medical Center
RP Bidwell, JP (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, Med Sci Bldg 5035,635 Barnhill Dr, Indianapolis, IN 46202 USA.
EM jbidwell@iupui.edu
RI Allen, Matthew/A 8799 2015; Childress, Paul/AAD 4684 2020; Plotkin,
   Lilian/H 7188 2019; Warden, Stuart/C 5287 2012
OI Plotkin, Lilian/0000 0002 9537 4544; Warden, Stuart/0000 0002 6415 4936
FU Department of Defense [PR120563]; Indiana University School of Medicine
   CTSI Biomedical Research Grant; National Institutes of Health Grants
   [AR062002, GM049164, AR053237]
FX This work was supported, in whole or in part, by Department of Defense
   Grant PR120563; Indiana University School of Medicine CTSI Biomedical
   Research Grant (to J.P.B.); and National Institutes of Health Grants
   AR062002 (to M.R.A.), GM049164 (to R.C.W.), and AR053237 (to A.G.R.).
CR Black DM, 2013, J BONE MINER RES, V28, P2263, DOI 10.1002/jbmr.2104
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Burr DB, 2015, BONE, V71, P58, DOI 10.1016/j.bone.2014.10.010
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Cano A, 2008, OSTEOPOROSIS INT, V19, P793, DOI 10.1007/s00198 007 0498 6
   Chambers JE, 2014, AM J PHYSIOL CELL PH, V307, pC657, DOI 10.1152/ajpcell.00183.2014
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Childress P, 2015, MOL ENDOCRINOL, V29, P1269, DOI 10.1210/me.2014 1406
   Childress P, 2011, CALCIFIED TISSUE INT, V89, P74, DOI 10.1007/s00223 011 9496 y
   Cordes C, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00074
   Corrado A, 2010, CLIN EXP RHEUMATOL, V28, P873
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Cosman F, 2001, J BONE MINER RES, V16, P925, DOI 10.1359/jbmr.2001.16.5.925
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cusano NE, 2011, CURR MED RES OPIN, V27, P1705, DOI 10.1185/03007995.2011.599837
   Deal C, 2005, J BONE MINER RES, V20, P1905, DOI 10.1359/JBMR.050714
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   Eriksen EF, 2016, BONE, V86, P139, DOI 10.1016/j.bone.2016.02.009
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fox J, 2007, J BONE MINER RES, V22, P260, DOI 10.1359/JBMR.061101
   Giner M, 2011, EUR J PHARMACOL, V650, P682, DOI 10.1016/j.ejphar.2010.10.058
   Hansen S, 2013, J BONE MINER RES, V28, P736, DOI 10.1002/jbmr.1784
   He YZ, 2013, STEM CELLS DEV, V22, P492, DOI 10.1089/scd.2012.0308
   Hino K, 2007, BONE, V40, P852, DOI 10.1016/j.bone.2006.03.019
   Hsiao EC, 2008, P NATL ACAD SCI USA, V105, P1209, DOI 10.1073/pnas.0707457105
   Iida Klein A, 2002, J BONE MINER RES, V17, P808, DOI 10.1359/jbmr.2002.17.5.808
   Jilka RL, 2013, J GERONTOL A BIOL, V68, P1209, DOI 10.1093/gerona/glt046
   Jilka RL, 2009, J BONE MINER RES, V24, P575, DOI [10.1359/JBMR.090228, 10.1359/jbmr.090228]
   Kulkarni NH, 2007, J CELL BIOCHEM, V102, P1504, DOI 10.1002/jcb.21374
   Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Lezcano V, 2014, EXP CELL RES, V324, P30, DOI 10.1016/j.yexcr.2014.03.016
   LI W, 2015, MEDICINE, V94
   Lin Y, 2004, J ENDOCRINOL INVEST, V27, P416, DOI 10.1007/BF03345284
   Liu ZD, 2000, J CELL BIOCHEM, V76, P509, DOI 10.1002/(SICI)1097 4644(20000301)76:3<509::AID JCB17>3.0.CO;2 R
   Lui PPY, 2013, EUR CELLS MATER, V25, P78, DOI 10.22203/eCM.v025a06
   Matsumori H, 2009, J ORTHOP SCI, V14, P640, DOI 10.1007/s00776 009 1357 4
   Miki Y, 2009, J STEROID BIOCHEM, V113, P281, DOI 10.1016/j.jsbmb.2009.01.010
   Mizoguchi T, 2014, DEV CELL, V29, P340, DOI 10.1016/j.devcel.2014.03.013
   Moore D. S., INTRO PRACTICE STAT
   Morinobu M, 2005, J EXP MED, V201, P961, DOI 10.1084/jem.20041097
   Muschitz C, 2013, J BONE MINER RES, V28, P196, DOI 10.1002/jbmr.1716
   Nakamoto T, 2004, GENES CELLS, V9, P575, DOI 10.1111/j.1356 9597.2004.00746.x
   Nakamoto T, 2016, J CELL BIOCHEM, V117, P970, DOI 10.1002/jcb.25382
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Newman CL, 2015, BONE, V77, P50, DOI 10.1016/j.bone.2015.04.021
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Pettway GJ, 2008, BONE, V42, P806, DOI 10.1016/j.bone.2007.11.017
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Robling AG, 2009, J CELL PHYSIOL, V219, P734, DOI 10.1002/jcp.21717
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Seeman E, 2015, J BONE MINER RES, V30, P753, DOI 10.1002/jbmr.2496
   Sheng ZF, 2009, OSTEOPOROSIS INT, V20, P151, DOI 10.1007/s00198 008 0640 0
   Somjen D, 2011, J STEROID BIOCHEM, V125, P226, DOI 10.1016/j.jsbmb.2011.03.006
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Torrungruang K, 2002, J BIOL CHEM, V277, P16153, DOI 10.1074/jbc.M107496200
   Tu XL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002577
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819
   Viereck V, 2003, J CLIN ENDOCR METAB, V88, P4206, DOI 10.1210/jc.2002 021877
   Walker MD, 2013, ENDOCRINE, V44, P237, DOI 10.1007/s12020 012 9819 4
   Wattanachanya L, 2015, EXP CELL RES, V333, P289, DOI 10.1016/j.yexcr.2015.02.009
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Yang Y, 2016, CLIMACTERIC, V19, P285, DOI 10.3109/13697137.2015.1126576
   Yang ZQ, 2010, J CELL PHYSIOL, V223, P435, DOI 10.1002/jcp.22057
   Young SK, 2016, J BIOL CHEM, V291, P13780, DOI 10.1074/jbc.M116.729830
   Yue R, 2016, CELL STEM CELL, V18, P782, DOI 10.1016/j.stem.2016.02.015
NR 74
TC 8
Z9 10
U1 0
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD SEP
PY 2017
VL 158
IS 9
BP 2722
EP 2740
DI 10.1210/en.2017 00355
PG 19
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FF3SU
UT WOS:000408840300005
PM 28637206
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Pillai, ICL
   Li, S
   Romay, M
   Lam, L
   Lu, Y
   Huang, J
   Dillard, N
   Zemanova, M
   Rubbi, L
   Wang, YB
   Lee, J
   Xia, M
   Liang, O
   Xie, YH
   Pellegrini, M
   Lusis, AJ
   Deb, A
AF Pillai, Indulekha C. L.
   Li, Shen
   Romay, Milagros
   Lam, Larry
   Lu, Yan
   Huang, Jie
   Dillard, Nathaniel
   Zemanova, Marketa
   Rubbi, Liudmilla
   Wang, Yibin
   Lee, Jason
   Xia, Ming
   Liang, Owen
   Xie, Ya Hong
   Pellegrini, Matteo
   Lusis, Aldons J.
   Deb, Arjun
TI Cardiac Fibroblasts Adopt Osteogenic Fates and Can Be Targeted to
   Attenuate Pathological Heart Calcification
SO CELL STEM CELL
LA English
DT Article
ID MESENCHYMAL STEM CELLS; MYOCARDIAL CALCIFICATION; VASCULAR
   CALCIFICATION; RENAL FAILURE; IN VITRO; DIFFERENTIATION; MICE;
   MECHANISMS; ORIGIN; BISPHOSPHONATES
AB Mammalian tissues calcify with age and injury. Analogous to bone formation, osteogenic cells are thought to be recruited to the affected tissue and induce mineralization. In the heart, calcification of cardiac muscle leads to conduction system disturbances and is one of the most common pathologies underlying heart blocks. However the cell identity and mechanisms contributing to pathological heart muscle calcification remain unknown. Using lineage tracing, murine models of heart calcification and in vivo transplantation assays, we show that cardiac fibroblasts (CFs) adopt an osteoblast cell like fate and contribute directly to heart muscle calcification. Small molecule inhibition of ENPP1, an enzyme that is induced upon injury and regulates bone mineralization, significantly attenuated cardiac calcification. Inhibitors of bone mineralization completely prevented ectopic cardiac calcification and improved post injury heart function. Taken together, these findings highlight the plasticity of fibroblasts in contributing to ectopic calcification and identify pharmacological targets for therapeutic development.
C1 [Pillai, Indulekha C. L.; Li, Shen; Lu, Yan; Huang, Jie; Dillard, Nathaniel; Zemanova, Marketa; Lusis, Aldons J.; Deb, Arjun] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA.
   [Pillai, Indulekha C. L.; Li, Shen; Romay, Milagros; Lu, Yan; Huang, Jie; Dillard, Nathaniel; Zemanova, Marketa; Wang, Yibin; Lusis, Aldons J.; Deb, Arjun] Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Lab, Los Angeles, CA 90095 USA.
   [Pillai, Indulekha C. L.; Li, Shen; Lam, Larry; Lu, Yan; Huang, Jie; Dillard, Nathaniel; Zemanova, Marketa; Rubbi, Liudmilla; Pellegrini, Matteo; Deb, Arjun] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Sch Letters & Sci, Los Angeles, CA 90095 USA.
   [Pillai, Indulekha C. L.; Li, Shen; Lam, Larry; Lu, Yan; Huang, Jie; Dillard, Nathaniel; Zemanova, Marketa; Rubbi, Liudmilla; Pellegrini, Matteo; Deb, Arjun] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA.
   [Pillai, Indulekha C. L.; Li, Shen; Lam, Larry; Lu, Yan; Huang, Jie; Dillard, Nathaniel; Zemanova, Marketa; Rubbi, Liudmilla; Pellegrini, Matteo; Deb, Arjun] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.
   [Pillai, Indulekha C. L.; Li, Shen; Lam, Larry; Lu, Yan; Huang, Jie; Dillard, Nathaniel; Zemanova, Marketa; Rubbi, Liudmilla; Lee, Jason; Xia, Ming; Liang, Owen; Xie, Ya Hong; Pellegrini, Matteo; Deb, Arjun] Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Romay, Milagros; Lusis, Aldons J.] Univ Calif Los Angeles, Dept Human Genet & Microbiol, Immunol & Mol Genet, Los Angeles, CA 90095 USA.
   [Wang, Yibin] Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90095 USA.
   [Wang, Yibin] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA.
   [Lee, Jason] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Lee, Jason] Univ Calif Los Angeles, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA.
   [Xia, Ming; Liang, Owen; Xie, Ya Hong] Univ Calif Los Angeles, Dept Mat Sci & Engn, Sch Engn, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California System; University of California Los Angeles; University of
   California System; University of California Los Angeles; UCLA Jonsson
   Comprehensive Cancer Center; University of California System; University
   of California Los Angeles; University of California System; University
   of California Los Angeles; University of California System; University
   of California Los Angeles; University of California System; University
   of California Los Angeles; University of California System; University
   of California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California System; University of California Los Angeles
RP Deb, A (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA.; Deb, A (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Lab, Los Angeles, CA 90095 USA.; Deb, A (通讯作者)，Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Sch Letters & Sci, Los Angeles, CA 90095 USA.; Deb, A (通讯作者)，Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA.; Deb, A (通讯作者)，Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.; Deb, A (通讯作者)，Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
EM adeb@mednet.ucla.edu
RI ; , 丁永华/AAW 7982 2020; Pellegrini, Matteo/AFS 3694 2022; Wang,
   Yibin/AES 4559 2022; Yimei, Wang/AAE 4083 2019; Pillai,
   Indulekha/P 8398 2014; Xia, Ming/B 1014 2016
OI Lee, Jason/0000 0003 2590 2011; Romay, Milagros/0000 0003 3593 0462;
   Zemanova, Marketa/0000 0002 9533 7583; Wang, Yibin/0000 0003 0852 0767;
   Pillai, Indulekha/0000 0002 5038 6031; Xia, Ming/0000 0001 6028 4437;
   Pellegrini, Matteo/0000 0001 9355 9564
FU NIH [HL129178, HL28481, HL30568]; California Institute of Regenerative
   Medicine [DISC1 08790]; Department of Defense [PR152219]; Oppenheimer
   Foundation; James Eason Cardiovascular Discovery Award; NIH/NCATS UCLA
   CTSI [ULTR000124]
FX We thank the California Nanosystems Institute, UCLA, the Broad Stem Cell
   Center confocal microscopy facilities, and the Jonsson Comprehensive
   Cancer center Flow Cytometry facilities. This work was supported by
   grants from the NIH (HL129178), California Institute of Regenerative
   Medicine (DISC1 08790), Department of Defense (PR152219), Oppenheimer
   Foundation, and James Eason Cardiovascular Discovery Award to A.D. and
   NIH grants HL28481 and HL30568 to A.J.L. The project in part also
   received support from NIH/NCATS UCLA CTSI (ULTR000124). We also thank
   Dr. Eric Olson, University of Texas Southwestern Medical Center for
   providing us the TCF21 MerCreMer mice and Dr. Andrew Leask, University
   of Western Ontario, Canada for sharing the Col1a2 CreERT mice.
CR Abdallah Basem M., 2008, V455, P89, DOI 10.1007/978 1 59745 104 8_6
   Acharya A, 2011, GENESIS, V49, P870, DOI 10.1002/dvg.20750
   Aherrahrou Z, 2004, AM J PATHOL, V164, P1379, DOI 10.1016/S0002 9440(10)63224 5
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Buttitta LA, 2007, CURR OPIN CELL BIOL, V19, P697, DOI 10.1016/j.ceb.2007.10.004
   Chen C, 2012, J CELL BIOCHEM, V113, P3672, DOI 10.1002/jcb.24240
   Chen KH, 2009, INT J EXP PATHOL, V90, P74, DOI 10.1111/j.1365 2613.2008.00614.x
   Choi YA, 2010, J PROTEOME RES, V9, P2946, DOI 10.1021/pr901110q
   Chong JJH, 2011, CELL STEM CELL, V9, P527, DOI 10.1016/j.stem.2011.10.002
   Côté N, 2012, EUR J PHARMACOL, V689, P139, DOI 10.1016/j.ejphar.2012.05.016
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Czernin J, 2010, J NUCL MED, V51, P1826, DOI 10.2967/jnumed.110.077933
   Demer LL, 2014, ARTERIOSCL THROM VAS, V34, P715, DOI 10.1161/ATVBAHA.113.302070
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   EVANS AS, 1976, YALE J BIOL MED, V49, P175
   Glass AM, 2013, COMPARATIVE MED, V63, P29
   Granéli C, 2014, STEM CELL RES, V12, P153, DOI 10.1016/j.scr.2013.09.009
   Harkness L, 2011, BONE, V48, P231, DOI 10.1016/j.bone.2010.09.023
   Hoshiba T, 2009, J BIOL CHEM, V284, P31164, DOI 10.1074/jbc.M109.054676
   Ivandic BT, 1996, P NATL ACAD SCI USA, V93, P5483, DOI 10.1073/pnas.93.11.5483
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Johnson K, 2003, J BONE MINER RES, V18, P994, DOI 10.1359/jbmr.2003.18.6.994
   Kanisicak O, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12260
   Korff S, 2006, VIRCHOWS ARCH, V448, P630, DOI 10.1007/s00428 005 0071 7
   Langenbach F, 2011, NAT PROTOC, V6, P1726, DOI 10.1038/nprot.2011.394
   Leri A, 2005, PHYSIOL REV, V85, P1373, DOI 10.1152/physrev.00013.2005
   LEV M, 1964, AM J MED, V37, P742, DOI 10.1016/0002 9343(64)90022 1
   Lévesque SA, 2007, BRIT J PHARMACOL, V152, P141, DOI 10.1038/sj.bjp.0707361
   Liu C, 2013, DEVELOPMENT, V140, P4375, DOI 10.1242/dev.097733
   Lomashvili KA, 2009, KIDNEY INT, V75, P617, DOI 10.1038/ki.2008.646
   Miguez PA, 2014, J DENT RES, V93, P406, DOI 10.1177/0022034514521237
   Murray I. R., 2016, PHARM THER IN PRESS
   Olivares Navarrete R, 2011, BIOMATERIALS, V32, P6399, DOI 10.1016/j.biomaterials.2011.05.036
   Pugashetti R, 2011, J AM ACAD DERMATOL, V64, P296, DOI 10.1016/j.jaad.2010.01.046
   Qian L, 2012, NATURE, V485, P593, DOI 10.1038/nature11044
   Romanoski CE, 2010, AM J HUM GENET, V86, P399, DOI 10.1016/j.ajhg.2010.02.002
   Ronchetti Ivonne, 2013, Frontiers in Genetics, V4, P22, DOI 10.3389/fgene.2013.00022
   ROSTAND SG, 1988, AM J MED, V85, P651
   Rutsch F, 2011, CIRC RES, V109, P578, DOI 10.1161/CIRCRESAHA.111.247965
   Sassi Y, 2014, J CLIN INVEST, V124, P5385, DOI 10.1172/JCI74349
   Shackley Brit S, 2011, Cardiovasc Pathol, V20, pe79, DOI 10.1016/j.carpath.2010.04.004
   Simchen MJ, 2006, ULTRASOUND OBST GYN, V27, P325, DOI 10.1002/uog.2689
   Song KH, 2012, NATURE, V485, P599, DOI 10.1038/nature11139
   SPARKS LL, 1955, NATURE, V176, P503, DOI 10.1038/176503a0
   STALLION A, 1994, J PEDIATR SURG, V29, P492, DOI 10.1016/0022 3468(94)90074 4
   Terkeltaub RA, 2001, AM J PHYSIOL CELL PH, V281, pC1, DOI 10.1152/ajpcell.2001.281.1.C1
   Terkeltaub Robert, 2006, Purinergic Signal, V2, P371, DOI 10.1007/s11302 005 5304 3
   Ubil E, 2014, NATURE, V514, P585, DOI 10.1038/nature13839
   Nora CCV, 2012, STEM CELLS DEV, V21, P1761, DOI 10.1089/scd.2011.0030
   Zheng B, 2002, AM J PATHOL, V160, P1609, DOI 10.1016/S0002 9440(10)61108 X
NR 50
TC 94
Z9 101
U1 0
U2 21
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934 5909
EI 1875 9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD FEB 2
PY 2017
VL 20
IS 2
BP 218
EP +
DI 10.1016/j.stem.2016.10.005
PG 20
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA EO0FW
UT WOS:000396374700010
PM 27867037
OA Green Accepted, Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Park, KH
   Choi, Y
   Yoon, DS
   Lee, KM
   Kim, D
   Lee, JW
AF Park, Kwang Hwan
   Choi, Yoorim
   Yoon, Dong Suk
   Lee, Kyoung Mi
   Kim, Dohyun
   Lee, Jin Woo
TI Zinc Promotes Osteoblast Differentiation in Human Mesenchymal Stem Cells
   Via Activation of the cAMP PKA CREB Signaling Pathway
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
DE zinc; bone formation; osteoblast; RUNX2; protein kinase A
ID OSTEOGENIC DIFFERENTIATION; BINDING PROTEIN; BONE LOSS; DEFICIENCY;
   EXPRESSION; SOX2; AGE; PROLIFERATION; MULTIPOTENCY; INHIBITION
AB The crucial trace element zinc stimulates osteogenesis in vitro and in vivo. However, the pathways mediating these effects remain poorly understood. This study aimed to investigate the effects of zinc on osteoblast differentiation in human bone marrow derived mesenchymal stem cells (hBMSCs) and to identify the molecular mechanisms of these effects. In hBMSCs, zinc exposure resulted in a dose dependent increase in osteogenesis and increased mRNA and protein levels of the master transcriptional factor RUNX2. Analyzing the upstream signaling pathways of RUNX2, we found that protein kinase A (PKA) signaling inhibition blocked zinc induced osteogenic effects. Zinc exposure increased transcriptional activity and protein levels of phospho CREB and enhanced translocation of phospho CREB into the nucleus. These effects were reversed by H 89, a potent inhibitor of PKA. Moreover, zinc exposure led to dose dependent increases in levels of intracellular cyclic adenosine monophosphate (cAMP). These findings indicate that zinc activates the PKA signaling pathway by triggering an increase in intracellular cAMP, leading to enhanced osteogenic differentiation in hBMSCs. Our results suggest that zinc exerts osteogenic effects in hBMSCs by activation of RUNX2 via the cAMP PKA CREB signaling pathway. Zinc supplementation may offer a promise as a potential pharmaceutical therapy for osteoporosis and other bone loss conditions.
C1 [Park, Kwang Hwan; Choi, Yoorim; Lee, Kyoung Mi; Kim, Dohyun; Lee, Jin Woo] Yonsei Univ, Dept Orthopaed Surg, Coll Med, 250 Seongsanno, Seoul 120752, South Korea.
   [Choi, Yoorim; Lee, Jin Woo] Yonsei Univ, Brain Korea Plus Project Med Sci 21, Coll Med, Seoul, South Korea.
   [Yoon, Dong Suk] East Carolina Univ, Brody Sch Med, Dept Internal Med, Greenville, NC 27858 USA.
   [Lee, Kyoung Mi; Lee, Jin Woo] Yonsei Univ, Severance Biomed Sci Inst, Coll Med, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System; University of North Carolina; East
   Carolina University; Yonsei University; Yonsei University Health System
RP Lee, JW (通讯作者)，Yonsei Univ, Dept Orthopaed Surg, Coll Med, 250 Seongsanno, Seoul 120752, South Korea.
EM ljwos@yuhs.ac
RI Yoon, Dong/K 1077 2019; lee, min/I 9388 2017
OI Yoon, Dong Suk/0000 0001 5945 5569; Park, Kwang
   Hwan/0000 0002 2110 0559; Lee, Jin Woo/0000 0002 0293 9017
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [NRF 2016R1D1A1B03933182]; Bio
   AMP; Medical Technology Development Program of the National Research
   Foundation (NRF)   Ministry of Science, ICT AMP; Future Planning
   [NRF 2017M3A9E8029722]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (no. NRF 2016R1D1A1B03933182) and from the Bio & Medical
   Technology Development Program of the National Research Foundation (NRF)
   funded by the Ministry of Science, ICT & Future Planning
   (NRF 2017M3A9E8029722).
CR Adhami MD, 2015, J BONE MINER RES, V30, P71, DOI 10.1002/jbmr.2321
   Bir SC, 2012, CARDIOVASC RES, V95, P7, DOI 10.1093/cvr/cvs143
   Byun MR, 2014, BONE, V58, P72, DOI 10.1016/j.bone.2013.09.024
   Chen D, 1999, BIOL TRACE ELEM RES, V68, P225, DOI 10.1007/BF02783905
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Delghandi MP, 2005, CELL SIGNAL, V17, P1343, DOI 10.1016/j.cellsig.2005.02.003
   Eberle J, 1999, J TRACE ELEM MED BIO, V13, P21, DOI 10.1016/S0946 672X(99)80019 4
   Fong L, 2009, BONE, V44, P1151, DOI 10.1016/j.bone.2009.02.011
   FREUDENHEIM JL, 1986, AM J CLIN NUTR, V44, P863, DOI 10.1093/ajcn/44.6.863
   Fukada T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003642
   Grundberg E, 2008, PHYSIOL GENOMICS, V33, P301, DOI 10.1152/physiolgenomics.00028.2008
   Guo BL, 2012, MOL CELL BIOCHEM, V361, P209, DOI 10.1007/s11010 011 1105 x
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Hie M, 2011, BONE, V49, P1152, DOI 10.1016/j.bone.2011.08.019
   Hojyo S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018059
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Hyun TH, 2004, AM J CLIN NUTR, V80, P715
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Jin XL, 2010, BIOL REPROD, V82, P459, DOI 10.1095/biolreprod.109.078758
   Klein C, 2002, J BIOL CHEM, V277, P11859, DOI 10.1074/jbc.M108808200
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kwun IS, 2010, BONE, V46, P732, DOI 10.1016/j.bone.2009.11.003
   Lee S, 2014, STEM CELLS DEV, V23, P1798, DOI 10.1089/scd.2013.0609
   LEEK JC, 1984, AM J CLIN NUTR, V40, P1203, DOI 10.1093/ajcn/40.6.1203
   Litchfield TM, 1998, CALCIFIED TISSUE INT, V62, P341, DOI 10.1007/s002239900442
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Ma ZJ, 2000, J BONE MINER METAB, V18, P264, DOI 10.1007/PL00010640
   Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200
   MOONGA BS, 1995, J BONE MINER RES, V10, P453
   Park KH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478 811X 11 74
   Percival MD, 1997, BIOCHEM BIOPH RES CO, V241, P175, DOI 10.1006/bbrc.1997.7542
   PRASAD AS, 1983, NUTR REV, V41, P197, DOI 10.1111/j.1753 4887.1983.tb07155.x
   Raisz LG, 2001, J BONE MINER RES, V16, P1948, DOI 10.1359/jbmr.2001.16.11.1948
   Rodan GA, 2003, CANCER, V97, P726, DOI 10.1002/cncr.11147
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Samira J, 2015, LIBYAN J MED, V10, DOI 10.3402/ljm.v10.28572
   Skålhegg BS, 2000, FRONT BIOSCI LANDMRK, V5, pD678, DOI 10.2741/Skalhegg
   Stevenson AS, 2001, EXP CELL RES, V263, P118, DOI 10.1006/excr.2000.5107
   STRAUSE L, 1994, J NUTR, V124, P1060, DOI 10.1093/jn/124.7.1060
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   von Bülow V, 2005, J IMMUNOL, V175, P4697, DOI 10.4049/jimmunol.175.7.4697
   Wang SN, 2012, STEM CELL RES, V8, P346, DOI 10.1016/j.scr.2011.12.005
   Wellinghausen N, 1996, CYTOKINE, V8, P767, DOI 10.1006/cyto.1996.0102
   Yamaguchi M, 1996, PEPTIDES, V17, P1207, DOI 10.1016/S0196 9781(96)00114 3
   Yoon DS, 2011, CELL PROLIFERAT, V44, P428, DOI 10.1111/j.1365 2184.2011.00770.x
   Yoon DS, 2015, BIOCHEM BIOPH RES CO, V467, P1026, DOI 10.1016/j.bbrc.2015.10.017
   Yoon DS, 2014, STEM CELLS, V32, P3219, DOI 10.1002/stem.1811
   Yoon DS, 2014, FASEB J, V28, P3273, DOI 10.1096/fj.13 248567
   Zhang JN, 2013, NEURAL DEV, V8, DOI 10.1186/1749 8104 8 7
NR 49
TC 118
Z9 125
U1 1
U2 34
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD AUG
PY 2018
VL 27
IS 16
BP 1125
EP 1135
DI 10.1089/scd.2018.0023
EA JUL 2018
PG 11
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA GQ7KO
UT WOS:000438171300001
PM 29848179
OA Bronze
DA 2025 08 17
ER

PT J
AU Fu, FS
   Shao, SY
   Wang, ZY
   Song, FM
   Lin, XX
   Ding, JX
   Li, C
   Wu, ZX
   Li, K
   Xiao, Y
   Su, YJ
   Zhao, JM
   Liu, Q
   Xu, JK
AF Fu, Fangsheng
   Shao, Siyuan
   Wang, Ziyi
   Song, Fangming
   Lin, Xixi
   Ding, Jiaxin
   Li, Chen
   Wu, Zuoxing
   Li, Kai
   Xiao, Yu
   Su, Yiji
   Zhao, Jinmin
   Liu, Qian
   Xu, Jiake
TI Scutellarein inhibits RANKL induced osteoclast formation in vitro and
   prevents LPS induced bone loss in vivo
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE NFATc1; NF B; osteoclast (OC); osteolysis; scutellarein (Scu)
ID INDUCTION; MICE; ERK; DIFFERENTIATION; ACTIVATION; MUTATIONS; ENDOTOXIN;
   MEDICINE; SURVIVAL; BRAIN
AB Osteoporosis, arthritis, Peget's disease, bone tumor, periprosthetic joint infection, and periprosthetic loosening have a common characteristic of osteolysis, which is characterized by the enhanced osteoclastic bone resorptive function. At present, the treatment target of these diseases is to interfere with osteoclastic formation and function. Scutellarein (Scu), a flavonoids compound, can inhibit the progress of tumor and inflammation. However, the role of Scu in inflammatory osteolysis isn't elucidated clearly. Our study showed that Scu inhibited bone destruction induced by LPS in vivo and OC morphology and function induced by RANKL in vitro. Mechanistic studies revealed that Scu suppressed osteoclastic marker gene expression by RANKL induced, such as Ctsk9, Mmp9, Acp5, and Atp6v0d2. In addition, we found that the inhibition effects of osteoclastogenesis and bone resorption function of Scu were mediated via attenuating NF B and NFAT signaling pathways. In conclusion, the results showed that Scu may become a potential new drug for the treatment of inflammatory osteolysis.
C1 [Fu, Fangsheng; Shao, Siyuan; Song, Fangming; Lin, Xixi; Ding, Jiaxin; Li, Chen; Wu, Zuoxing; Li, Kai; Xiao, Yu; Zhao, Jinmin; Liu, Qian; Xu, Jiake] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Res Ctr Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Wang, Ziyi; Song, Fangming; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Affiliated Hosp 1, Dept Trauma Orthoped & Hand Surg, Nanning, Guangxi, Peoples R China.
   [Su, Yiji] Guangxi Med Univ, Affiliated Hosp 1, Dept Rehabil Med, Nanning, Guangxi, Peoples R China.
C3 Guangxi Medical University; University of Western Australia; Guangxi
   Medical University; Guangxi Medical University
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.; Liu, Q (通讯作者)，Guangxi Med Univ, Res Ctr Regenerat Med, Nanning, Guangxi, Peoples R China.
EM luoboqian@hotmail.com; jiake.xu@uwa.edu.au
RI zhao, jin/LBH 0351 2024; xi, lin/JOK 1026 2023
OI Zhao, Jinmin/0000 0001 8423 0425; Wang, Ziyi/0000 0002 1334 7287; Xu,
   Jiake/0000 0003 2021 8309; Xiao, Yu/0009 0005 3120 8968; Zhao,
   Jinmin/0000 0002 1047 8820; 
FU Australian Health and Medical Research Council [APP1107828, APP1027932,
   APP1163933]; National Natural Science Foundation of China [81501910];
   Natural Science Foundation of Guangxi Province [2015GXNSFCA414001,
   2015GXNSDA139019]; Guangxi Collaborative Innovation Center for
   Biomedicine talent cultivation [GCICB TC 2017001]
FX the Australian Health and Medical Research Council, Grant/Award Numbers:
   APP1107828, NHMRC, APP1027932, APP1163933; National Natural Science
   Foundation of China, Grant/Award Number: 81501910; the Natural Science
   Foundation of Guangxi Province, Grant/Award Numbers: 2015GXNSFCA414001,
   2015GXNSDA139019; the Guangxi Collaborative Innovation Center for
   Biomedicine talent cultivation, Grant/Award Number: GCICB TC 2017001
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bi YM, 2001, J BONE MINER RES, V16, P2082, DOI 10.1359/jbmr.2001.16.11.2082
   Cheng CY, 2014, CHINESE J PHYSIOL, V57, P182, DOI 10.4077/CJP.2014.BAC200
   Crotti TN, 2008, J CELL PHYSIOL, V215, P636, DOI 10.1002/jcp.21344
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Ghosh N, 2014, NAT PROD COMMUN, V9, P1045
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Greenfield E. M., 2010, J BIOMEDICAL MAT R B, V72B
   Greenfield EM, 2002, J ORTHOPAED RES, V20, P1, DOI 10.1016/S0736 0266(01)00070 5
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Guo LL, 2013, EXP TOXICOL PATHOL, V65, P579, DOI 10.1016/j.etp.2012.05.003
   Harminder Singh V., 2012, INDIAN J PHARM SCI, V73, P483
   Hotokezaka H., 2010, J CELL BIOCHEM, V101, P122
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Marino S., 2014, BONE
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Miyazaki Tsuyoshi, 2006, Mod Rheumatol, V16, P68
   Mohan Maruga Raja Muthu Kumaradoss, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P510, DOI 10.3736/jcim20100602
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Pandith H, 2013, J ETHNOPHARMACOL, V147, P434, DOI 10.1016/j.jep.2013.03.033
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615
   Shinohara M, 2014, METHODS MOL BIOL, V1164, P171, DOI 10.1007/978 1 4939 0805 9_14
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Stevenson DA, 2011, CLIN GENET, V80, P566, DOI 10.1111/j.1399 0004.2010.01619.x
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Wada N, 2004, BONE, V35, P629, DOI 10.1016/j.bone.2004.04.023
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Xu J., 2000, BONE, V27, P32, DOI [10.1016/s8756 3282(00)80105 2, DOI 10.1016/S8756 3282(00)80105 2]
   Yip KHM, 2004, J BONE MINER RES, V19, P1905, DOI 10.1359/JBMR.040919
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
   Zou W, 2015, J CELL BIOL, V208, P125, DOI 10.1083/jcb.201410123
NR 47
TC 18
Z9 19
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2019
VL 234
IS 7
BP 11951
EP 11959
DI 10.1002/jcp.27888
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HQ8AL
UT WOS:000462645700186
PM 30552680
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Koli, K
   Ryynänen, MJ
   Keski Oja, J
AF Koli, Katri
   Ryynanen, Merja J.
   Keski Oja, Jorma
TI Latent TGF β binding proteins (LTBPs) 1 and  3 coordinate proliferation
   and osteogenic differentiation of human mesenchymal stem cells
SO BONE
LA English
DT Article
DE LTBP; TGF beta; mesenchymal stem cell; osteoblast
ID GROWTH FACTOR BETA; FIBROBLAST EXTRACELLULAR MATRIX; TRANSFORMING
   GROWTH FACTOR BETA 1; HUMAN BONE; EXPRESSION; LTBP 3; IDENTIFICATION;
   FIBRILLIN 1; DISRUPTION; ACTIVATION
AB Mesenchymal stem cells (MSCs) possess the capability to differentiate into bone forming cells, osteoblasts, and thus represent a new therapeutic tool in regenerative medicine. Transforming growth factor (TGF) beta is abundantly present in bone tissue where it regulates osteoblast and osteoclast functions in a complex manner. Latent TGF beta binding protein (LTBP) 1 mediates the extracellular matrix (ECM) targeting and accumulation of most TGF beta, in the bone. We describe here an important regulatory role for LTBP 3 in TGF beta activation and autocrine growth control in MSCs. LTBP 3 knockdown via siRNA mediated silencing resulted in reduced cell proliferation and reduced osteogenic differentiation. When MSCs were induced to undergo differentiation, LTBP 3 levels became downregulated in parallel with reduced TGF beta activation. These changes coincided with the matrix maturation phase of osteogenic differentiation. The mechanism of LTBP 3 is most likely via TGF beta activation in the early proliferative phase of the differentiation process. Later, when TGF beta activity would inhibit further maturation and mineralization, LTBP 3 expression becomes downregulated and LTBP I containing large latent TGF beta 1 complexes accumulate into the ECM. These complexes represent readily available targets for osteoclast mediated release and activation of TGF beta in bone tissue. Our results provide evidence that LTBP isoforms can differentially regulate TGF beta activation and ECM accumulation during osteogenic differentiation. (c) 2008 Elsevier Inc. All rights reserved.
C1 Univ Helsinki, Helsinki Univ Hosp, FIN 00014 Helsinki, Finland.
   [Koli, Katri] Univ Helsinki, Dept Virol, Haartman Inst, FIN 00014 Helsinki, Finland.
   Univ Helsinki, Dept Pathol, Haartman Inst, FIN 00014 Helsinki, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; University of Helsinki
RP Koli, K (通讯作者)，Univ Helsinki, Dept Virol, Haartman Inst, Biomedicum A506,POB 63,Haartmaninkatu 8, FIN 00014 Helsinki, Finland.
EM katri.koli@helsinki.fi
FU Academy of Finland; Finnish Cancer Foundation; Finnish Cultural
   Foundation; Sigrid Juselius Foundation; Helsinki University Hospital
   Fund; University of Helsinki
FX We would like to thank Sami Starast and Anne Remes for their technical
   assistance. The work was supported by the Academy of Finland, Finnish
   Cancer Foundation, Finnish Cultural Foundation, Sigrid Juselius
   Foundation, Helsinki University Hospital Fund and the University of
   Helsinki.
CR ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042
   Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172
   Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229
   Bax DV, 2007, J CELL SCI, V120, P1383, DOI 10.1242/jcs.003954
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261
   BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend 5 6 741
   Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754
   CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chen Y, 2005, J MOL BIOL, V345, P175, DOI 10.1016/j.jmb.2004.10.039
   Dabovic B, 2005, BONE, V37, P25, DOI 10.1016/j.bone.2005.02.021
   Dabovic B, 2002, J CELL BIOL, V156, P227, DOI 10.1083/jcb.200111080
   Dallas SL, 2005, J BIOL CHEM, V280, P18871, DOI 10.1074/jbc.M410762200
   DALLAS SL, 1994, J BIOL CHEM, V269, P6815
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903
   Hering S, 2001, EXP CLIN ENDOCR DIAB, V109, P217, DOI 10.1055/s 2001 15109
   Hyytiäinen M, 2004, CRIT REV CL LAB SCI, V41, P233, DOI 10.1080/10408360490460933
   Hyytiäinen M, 1998, J BIOL CHEM, V273, P20669, DOI 10.1074/jbc.273.32.20669
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806
   Kantola AK, 2005, GENE, V363, P142, DOI 10.1016/j.gene.2005.07.042
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kassem M, 2008, CELL TISSUE RES, V331, P157, DOI 10.1007/s00441 007 0509 0
   Kitahama S, 2000, BONE, V27, P61, DOI 10.1016/S8756 3282(00)00292 1
   Koli K, 2005, EXP CELL RES, V310, P370, DOI 10.1016/j.yexcr.2005.08.008
   Koli K, 2004, J CELL BIOL, V167, P123, DOI 10.1083/jcb.200403067
   Kraus KH, 2006, VET SURG, V35, P232, DOI 10.1111/j.1532 950X.2006.00142.x
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Penttinen C, 2002, J CELL SCI, V115, P3457
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ritty TM, 2003, BIOCHEM J, V375, P425, DOI 10.1042/BJ20030649
   Roelen Bernard A J, 2003, J Orthop Sci, V8, P740, DOI 10.1007/s00776 003 0702 2
   Saharinen J, 2000, MOL BIOL CELL, V11, P2691, DOI 10.1091/mbc.11.8.2691
   Seth A, 2000, J BONE MINER RES, V15, P1683, DOI 10.1359/jbmr.2000.15.9.1683
   SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267
   Sivakumar P, 2006, J CELL SCI, V119, P1350, DOI 10.1242/jcs.02830
   Sterner Kock A, 2002, GENE DEV, V16, P2264, DOI 10.1101/gad.229102
   STRAUSS PG, 1990, J CELL BIOL, V110, P1369, DOI 10.1083/jcb.110.4.1369
   TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171
   Todorovic V, 2007, DEVELOPMENT, V134, P3723, DOI 10.1242/dev.008599
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 45
TC 46
Z9 56
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2008
VL 43
IS 4
BP 679
EP 688
DI 10.1016/j.bone.2008.06.016
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 355LY
UT WOS:000259711600009
PM 18672106
DA 2025 08 17
ER

PT J
AU Wei, Q
   Ouyang, MH
   Guo, XT
   Fu, XY
   Liu, T
   Luo, YG
   Tang, HJ
   Yang, Y
   Gao, XM
   Mao, HP
AF Wei, Qiu
   Ouyang, MingHui
   Guo, Xiaotong
   Fu, Xiaoyu
   Liu, Ting
   Luo, Yage
   Tang, Huajing
   Yang, Yun
   Gao, Xiumei
   Mao, Haoping
TI Effect of hyperoside on osteoporosis in ovariectomized mice through
   estrogen receptor α/ITGβ3 signaling pathway
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Osteoporosis; Osteoclast differentiation; Ovariectomy; Estrogen receptor
   alpha; Hyperoside
ID REPLACEMENT THERAPY; BONE; PHYTOESTROGENS
AB Osteoporosis is a highly prevalent bone metabolic disease in menopause due to estrogen deficiency. Hyperoside is a main compound in Semen cuscutae. Our team previously reported that Semen cuscutae has anti osteoporosis effect on ovariectomized mice by inhibiting bone resorption of osteoclasts. However, it is still unclear whether hyperoside affects osteoclast differentiation and bone resorption, and whether its anti osteoporosis effect is related to an estrogen like effect. This study investigates the potential mechanism of hyperoside's antiosteoporotic effect by examining its impact on osteoclast differentiation and its relationship with the estrogen receptor. DXA, Micro CT, TRAP staining, HE, and ELISA were used to assess the impact of hyperoside on OVXinduced osteoporosis. The effect of hyperoside on octeoclast differentiation was evaluated using TRAP activity assay, TRAP staining, F actin staining. The activation of the estrogen receptor by hyperoside and its relationship with osteoclast differentiation were detected using dual luciferase reporter assay and estrogen receptor antagonists. Our findings revealed that hyperoside (20 80 mg/kg) protect against OVX induced osteoporosis, including increasing BMD and BMC and improving bone microstructure. Hyperoside inhibited osteoclast differentiation in a concentration dependent manner, whereas estrogen receptor alpha antagonists reversed its inhibitory effect osteoclast differentiation. Western blot results suggested that hyperoside inhibited TRAP, RANKL, cFos and ITG beta 3 protein expression in osteoclast or femoral bone marrow of ovariectomized mice. Our findings suggest that hyperoside inhibits osteoclast differentiation and protects OVX induced osteoporosis through the ER alpha/ITG beta 3 signaling pathway.
C1 [Wei, Qiu; Ouyang, MingHui; Guo, Xiaotong; Fu, Xiaoyu; Liu, Ting; Luo, Yage; Tang, Huajing; Yang, Yun; Gao, Xiumei; Mao, Haoping] Tianjin Univ Tradit Chinese Med, Key Lab Pharmacol Tradit Chinese Med Formulae, Minist Educ, Tianjin, Peoples R China.
   [Wei, Qiu; Ouyang, MingHui; Guo, Xiaotong; Fu, Xiaoyu; Liu, Ting; Luo, Yage; Tang, Huajing; Yang, Yun; Gao, Xiumei; Mao, Haoping] Tianjin Univ Tradit Chinese Med, State Key Lab Component based Chinese Med, Tianjin, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University
   of Traditional Chinese Medicine
RP Gao, XM; Mao, HP (通讯作者)，Tianjin Univ Tradit Chinese Med, Key Lab Pharmacol Tradit Chinese Med Formulae, Minist Educ, Tianjin, Peoples R China.; Gao, XM; Mao, HP (通讯作者)，Tianjin Univ Tradit Chinese Med, State Key Lab Component based Chinese Med, Tianjin, Peoples R China.
EM gaoxiumei@tjutcm.edu.cn; maohaoping@tjutcm.edu.cn
RI mao, haoping/KIH 6773 2024; Guo, Xiaotong/AEL 6638 2022; Wei,
   qiu/MGW 5625 2025; GAO, Xiumei/IWD 8697 2023
FU Key Projects of the Tianjin Education Commission ' s Research Program
   [2021ZD007]
FX This work was supported by the Key Projects of the Tianjin Education
   Commission ' s Research Program (2021ZD007) .
CR Aibar Almazán A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23169465
   Börjesson AE, 2013, CELL MOL LIFE SCI, V70, P4023, DOI 10.1007/s00018 013 1317 1
   Canivenc Lavier MC, 2023, NUTRIENTS, V15, DOI 10.3390/nu15020317
   Cosman F, 2021, CURR OSTEOPOROS REP, V19, P189, DOI 10.1007/s11914 021 00663 1
   Davis SR, 2001, BRIT MED J, V323, P354, DOI 10.1136/bmj.323.7309.354
   DEFAZIO J, 1985, GERIATRICS, V40, P32
   Dobbs M B, 1999, Iowa Orthop J, V19, P43
   Domínguez López I, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082456
   Ensrud Kristine E, 2021, JAMA, V325, P96, DOI 10.1001/jama.2020.2923
   Feng C, 2022, MOLECULES, V27, DOI 10.3390/molecules27133976
   Fuentes N, 2019, ADV PROTEIN CHEM STR, V116, P135, DOI 10.1016/bs.apcsb.2019.01.001
   Gong AX, 2018, J PERIODONTOL, V89, P983, DOI 10.1002/JPER.17 0542
   Karieb S, 2012, BRIT J NUTR, V108, P1736, DOI 10.1017/S0007114511007355
   Khosla S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031211
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Lagari VS, 2014, J STEROID BIOCHEM, V139, P294, DOI 10.1016/j.jsbmb.2012.12.002
   Lagari VS, 2013, J CLIN DENSITOM, V16, P445, DOI 10.1016/j.jocd.2013.08.011
   Langdahl BL, 2021, BRIT J PHARMACOL, V178, P1891, DOI 10.1111/bph.15024
   Li GM, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1197056
   Liu JL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.733808
   Lobo RA, 2017, NAT REV ENDOCRINOL, V13, P220, DOI 10.1038/nrendo.2016.164
   Mirza F, 2015, EUR J ENDOCRINOL, V173, pR131, DOI 10.1530/EJE 15 0118
   Neuberger A, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 38352 5
   Park K, 2014, INT J MOL MED, V33, P178, DOI 10.3892/ijmm.2013.1557
   Parlay D, 2019, BONE, V128, DOI 10.1016/j.bone.2019.08.003
   Patra S, 2023, PHYTOTHER RES, V37, P3097, DOI 10.1002/ptr.7861
   Pignolo RJ, 2023, COMPR PHYSIOL, V13, P4355, DOI 10.1002/cphy.c220012
   Poudel S, 2022, NUTRIENTS, V14, DOI 10.3390/nu14061154
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rietjens IMCM, 2017, BRIT J PHARMACOL, V174, P1263, DOI 10.1111/bph.13622
   Rowe IJ, 2021, CLIMACTERIC, V24, P57, DOI 10.1080/13697137.2020.1863356
   Rowe P, 2024, Physiology. Bone Remodeling
   Sharma A, 2023, BIOMED PHARMACOTHER, V163, DOI 10.1016/j.biopha.2023.114850
   Sommer B, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms242015335
   Vail G, 2019, STEROIDS, V142, P77, DOI 10.1016/j.steroids.2018.01.010
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang LH, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.21106
   Wang Q, 2022, PHYTOTHER RES, V36, P2779, DOI 10.1002/ptr.7478
   Wong RHX, 2020, J BONE MINER RES, V35, P2121, DOI 10.1002/jbmr.4115
   Xu SJ, 2022, MOLECULES, V27, DOI 10.3390/molecules27093009
   Yang Y, 2022, J ETHNOPHARMACOL, V285, DOI 10.1016/j.jep.2021.114834
NR 41
TC 3
Z9 3
U1 6
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD AUG 15
PY 2024
VL 977
AR 176666
DI 10.1016/j.ejphar.2024.176666
EA JUN 2024
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WJ3X1
UT WOS:001254474800001
PM 38797313
DA 2025 08 17
ER

PT J
AU Jing, D
   Cai, J
   Wu, Y
   Shen, GH
   Li, FJ
   Xu, QL
   Xie, KN
   Tang, C
   Liu, J
   Guo, W
   Wu, XM
   Jiang, MG
   Luo, EP
AF Jing, Da
   Cai, Jing
   Wu, Yan
   Shen, Guanghao
   Li, Feijiang
   Xu, Qiaoling
   Xie, Kangning
   Tang, Chi
   Liu, Juan
   Guo, Wei
   Wu, Xiaoming
   Jiang, Maogang
   Luo, Erping
TI Pulsed Electromagnetic Fields Partially Preserve Bone Mass,
   Microarchitecture, and Strength by Promoting Bone Formation in
   Hindlimb Suspended Rats
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PULSED ELECTROMAGNETIC FIELDS; DISUSE; HINDLIMB UNLOADING; THREE POINT
   BENDING TEST; BONE TURNOVER; WNT/LRP5/beta CATENIN SIGNALING
ID AFFECTS OSTEOCLAST FORMATION; HORMONE REPLACEMENT THERAPY; TRABECULAR
   ARCHITECTURE; KNEE OSTEOARTHRITIS; OSTEOPOROSIS; STIMULATION; MODEL;
   SCLEROSTIN; DISUSE; ALENDRONATE
AB A large body of evidence indicates that pulsed electromagnetic fields (PEMF), as a safe and noninvasive method, could promote in vivo and in vitro osteogenesis. Thus far, the effects and underlying mechanisms of PEMF on disuse osteopenia and/or osteoporosis remain poorly understood. Herein, the efficiency of PEMF on osteoporotic bone microarchitecture, bone strength, and bone metabolism, together with its associated signaling pathway mechanism, was systematically investigated in hindlimb unloaded (HU) rats. Thirty young mature (3 month old), male Sprague Dawley rats were equally assigned to control, HU, and HU + PEMF groups. The HU + PEMF group was subjected to daily 2 hour PEMF exposure at 15 Hz, 2.4 mT. After 4 weeks, micro computed tomography (mu CT) results showed that PEMF ameliorated the deterioration of trabecular and cortical bone microarchitecture. Three point bending test showed that PEMF mitigated HU induced reduction in femoral mechanical properties, including maximum load, stiffness, and elastic modulus. Moreover, PEMF increased serum bone formation markers, including osteocalcin (OC) and N terminal propeptide of type 1 procollagen (P1NP); nevertheless, PEMF exerted minor inhibitory effects on bone resorption markers, including C terminal crosslinked telopeptides of type I collagen (CTX I) and tartrate resistant acid phosphatase 5b (TRAcP5b). Bone histomorphometric analysis demonstrated that PEMF increased mineral apposition rate, bone formation rate, and osteoblast numbers in cancellous bone, but PEMF caused no obvious changes on osteoclast numbers. Real time PCR showed that PEMF promoted tibial gene expressions of Wnt1, LRP5, beta catenin, OPG, and OC, but did not alter RANKL, RANK, or Sost mRNA levels. Moreover, the inhibitory effects of PEMF on disuse induced osteopenia were further confirmed in 8 month old mature adult HU rats. Together, these results demonstrate that PEMF alleviated disuse induced bone loss by promoting skeletal anabolic activities, and imply that PEMF might become a potential biophysical treatment modality for disuse osteoporosis. (c) 2014 American Society for Bone and Mineral Research.
C1 [Jing, Da; Shen, Guanghao; Li, Feijiang; Xie, Kangning; Tang, Chi; Liu, Juan; Guo, Wei; Wu, Xiaoming; Jiang, Maogang; Luo, Erping] Fourth Mil Med Univ, Dept Biomed Engn, Xian 710032, Peoples R China.
   [Cai, Jing] Fourth Mil Med Univ, Xijing Hosp, Dept Endocrinol, Xian 710032, Peoples R China.
   [Wu, Yan] Fourth Mil Med Univ, Xijing Hosp, Inst Orthopaed, Xian 710032, Peoples R China.
   [Xu, Qiaoling] Fourth Mil Med Univ, Dept Nursing, Xian 710032, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University; Air Force Medical University
RP Luo, EP (通讯作者)，Fourth Mil Med Univ, Dept Biomed Engn, 17 West Changle Rd, Xian 710032, Peoples R China.
EM erpingluo@hotmail.com
RI Li, Junsheng/AAN 4015 2021; Cai, Jing/JXM 0087 2024; Xie,
   Kangning/AAQ 1496 2020
OI Xie, Kangning/0000 0002 6031 8489; 
FU National Natural Science Foundation of China [51077128, 31270889];
   Doctoral Thesis Foundation of the Fourth Military Medical University
   [2012D01]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 51077128 and 31270889) and the Doctoral Thesis
   Foundation of the Fourth Military Medical University (No. 2012D01).
CR Assiotis A, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749 799X 7 24
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BASSETT CAL, 1982, JAMA J AM MED ASSOC, V247, P623, DOI 10.1001/jama.247.5.623
   BASSETT CAL, 1974, SCIENCE, V184, P575
   Bodamyali T, 1998, BIOCHEM BIOPH RES CO, V250, P458, DOI 10.1006/bbrc.1998.9243
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Caillot Augusseau A, 2000, CLIN CHEM, V46, P1136
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chang K, 2005, J ORTHOP RES, V23, P1308, DOI 10.1016/j.orthres.2005.03.012
   Chang K, 2004, BIOELECTROMAGNETICS, V25, P134, DOI 10.1002/bem.10168
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P189, DOI 10.1002/bem.10078
   Diniz P, 2002, BIOELECTROMAGNETICS, V23, P398, DOI 10.1002/bem.10032
   Eyres KS, 1996, BONE, V18, P505, DOI 10.1016/8756 3282(96)00070 1
   Garland D E, 1999, J Spinal Cord Med, V22, P239
   HALLORAN BP, 1986, ENDOCRINOLOGY, V118, P948, DOI 10.1210/endo 118 3 948
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Jing D, 2011, OSTEOPOROSIS INT, V22, P1885, DOI 10.1007/s00198 010 1447 3
   Jing D, 2013, BONE, V53, P531, DOI 10.1016/j.bone.2013.01.008
   Jing D, 2010, BONE, V46, P487, DOI 10.1016/j.bone.2009.09.021
   Ju YI, 2012, J APPL PHYSIOL, V112, P766, DOI 10.1152/japplphysiol.01219.2011
   Kotani H, 2002, J BONE MINER RES, V17, P1814, DOI 10.1359/jbmr.2002.17.10.1814
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Laib A, 2001, OSTEOPOROSIS INT, V12, P936, DOI 10.1007/s001980170022
   Lam HY, 2008, BONE, V43, P1093, DOI 10.1016/j.bone.2008.07.253
   Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307
   Lang TF, 2006, J BONE MINER RES, V21, P1224, DOI 10.1359/JBMR.060509
   Lau RYC, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/293808
   Lazo MG, 2001, SPINAL CORD, V39, P208, DOI 10.1038/sj.sc.3101139
   LeBlanc A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P157
   Li KR, 2012, HEART, V98, P920, DOI 10.1136/heartjnl 2011 301345
   Lloyd SA, 2012, BONE, V51, P756, DOI 10.1016/j.bone.2012.07.001
   Luo E, 2007, BIOELECTROMAGNETICS, V28, P608, DOI 10.1002/bem.20342
   MACHWATE M, 1995, J CLIN INVEST, V96, P1245, DOI 10.1172/JCI118158
   Macias BR, 2012, J APPL PHYSIOL, V112, P918, DOI 10.1152/japplphysiol.00978.2011
   Mahavni V, 2001, CURR OPIN ONCOL, V13, P384, DOI 10.1097/00001622 200109000 00012
   MCELHANEY J H, 1968, Journal of Biomechanics, V1, P47, DOI 10.1016/0021 9290(68)90037 7
   Morey Holton ER, 2002, J APPL PHYSIOL, V92, P1367, DOI 10.1152/japplphysiol.00969.2001
   Moriishi T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040143
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   OCONNOR BT, 1969, NATURE, V222, P162, DOI 10.1038/222162a0
   PATERSON CR, 1980, LANCET, V1, P1164
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Schriefer JL, 2005, J BIOMECH, V38, P467, DOI 10.1016/j.jbiomech.2004.04.020
   Sert C, 2002, J BONE MINER METAB, V20, P345, DOI 10.1007/s007740200050
   Shahnazari M, 2012, CALCIFIED TISSUE INT, V91, P50, DOI 10.1007/s00223 012 9610 9
   Spatz JM, 2013, J BONE MINER RES, V28, P865, DOI 10.1002/jbmr.1807
   Sun LW, 2009, ACTA BIOMATER, V5, P3506, DOI 10.1016/j.actbio.2009.04.042
   Sun Y, 2013, OSTEOPOROSIS INT, V24, P969, DOI 10.1007/s00198 012 2028 4
   Swift JM, 2011, J BONE MINER RES, V26, P2140, DOI 10.1002/jbmr.407
   Swift JM, 2010, J BONE MINER RES, V25, P564, DOI 10.1359/jbmr.090811
   TABRAH F, 1990, J BONE MINER RES, V5, P437, DOI 10.1002/jbmr.5650050504
   Takata Shinjiro, 2001, Journal of Medical Investigation, V48, P147
   Thamsborg G, 2005, OSTEOARTHR CARTILAGE, V13, P575, DOI 10.1016/j.joca.2005.02.012
   Thomsen JS, 2005, AVIAT SPACE ENVIR MD, V76, P915
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   We SR, 2013, RHEUMATOLOGY, V52, P815, DOI 10.1093/rheumatology/kes063
   Zhang XJ, 2007, ELECTROMAGN BIOL MED, V26, P167, DOI 10.1080/15368370701580756
NR 60
TC 92
Z9 104
U1 0
U2 45
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD OCT
PY 2014
VL 29
IS 10
BP 2250
EP 2261
DI 10.1002/jbmr.2260
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AQ4ZE
UT WOS:000342809800014
PM 24753111
DA 2025 08 17
ER

PT J
AU Decker, AM
   Decker, JT
   Jung, Y
   Cackowski, FC
   Daignault Newton, S
   Morgan, TM
   Shea, LD
   Taichman, RS
AF Decker, Ann M.
   Decker, Joseph T.
   Jung, Younghun
   Cackowski, Frank C.
   Daignault Newton, Stephanie
   Morgan, Todd M.
   Shea, Lonnie D.
   Taichman, Russell S.
TI Adrenergic Blockade Promotes Maintenance of Dormancy in Prostate Cancer
   Through Upregulation of GAS6
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID TUMOR CELLS; GROWTH; RESISTANCE; SURVIVAL; ACTIVATION; MIGRATION;
   BLOCKERS
AB Men diagnosed with localized prostate cancer can develop metastases many years after initial treatment, resulting in a poor prognosis. The purpose of this study was to investigate the mechanisms by which signaling through norepineph rine (NE) may incite relapse of quiescent prostate cancer. We used an unbiased bioinformatics pipeline to examine mechanisms for recurrence related to sympathetic signaling in the bone marrow. A transcription factor cell array iden ti fied ATF1, RAR, and E2F as key nodes in prostate cancer cells exiting quiescence through adrenergic signaling. Sub sequent secretome analysis identi fied GAS6 as affecting activity of these three factors, leading to cell cycle reentry. GAS6 expression was downregulated in osteoblasts through activation of the cAMP pathway and was targeted in vitro and in vivo using pharmacological agents (propranolol and phentolamine). Propranolol increased expression of GAS6 by osteoblasts, and phentolamine signi ficantly inhibited expression. Propranolol treatment was suf ficient to both increase GAS6 expression in marrow osteoblasts as well as eliminate the effects of NE signaling on GAS6 expres sion. These results demonstrate a strong correlation between adrenergic signaling, GAS6 expression, and recurrence in prostate cancer, suggesting a novel therapeutic direction for patients at high risk of metastasis.
C1 [Decker, Ann M.; Jung, Younghun; Cackowski, Frank C.; Taichman, Russell S.] Univ Michigan, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Decker, Joseph T.; Shea, Lonnie D.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Daignault Newton, Stephanie; Morgan, Todd M.] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA.
   [Cackowski, Frank C.] Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
   [Morgan, Todd M.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.
   [Taichman, Russell S.] Univ Alabama Birmingham, Sch Dent, Birmingham, AL 35294 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan;
   University of Alabama System; University of Alabama Birmingham
RP Taichman, RS (通讯作者)，SDB 406,1720 2nd Ave South, Birmingham, AL 35294 USA.
EM taichman@uab.edu
RI Taichman, Russell/NOF 9711 2025; Morgan, Todd/A 8531 2012
OI Decker, Joseph/0000 0001 7914 4741; Morgan, Todd/0000 0002 1140 0603
FU National Institutes of Health [P01CA093900, K01EB028877, T32DE007057];
   National Institute of Biomedical Imaging and Bioengineering
   [K01EB028877] Funding Source: NIH RePORTER; National Institute of
   Diabetes and Digestive and Kidney Diseases [T32DK071212] Funding Source:
   NIH RePORTER
FX This work was funded by the National Institutes of Health grants
   P01CA093900 (R.S.T.), K01EB028877 (J.T.D.), and T32DE007057 (A.M.D.).
CR Balduino A, 2005, CELL TISSUE RES, V319, P255, DOI 10.1007/s00441 004 1006 3
   Beesley LJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7765
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Bernabé BP, 2016, INTEGR BIOL UK, V8, P844, DOI 10.1039/c6ib00093b
   Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861
   Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324
   Cabezas Wallscheid N, 2017, CELL, V169, P807, DOI 10.1016/j.cell.2017.04.018
   Cardwell CR, 2014, CANCER EPIDEMIOL, V38, P279, DOI 10.1016/j.canep.2014.03.011
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Csardi G., 2006, InterJournal, Complex Systems, P1695, DOI DOI 10.3724/SP.J.1087.2009.02191
   Decker AM, 2017, J CELL BIOCHEM, V118, P1956, DOI 10.1002/jcb.25843
   Decker AM, 2017, MOL CANCER RES, V15, P1644, DOI 10.1158/1541 7786.MCR 17 0132
   Decker JT, 2018, ACS SYNTH BIOL, V7, P2063, DOI 10.1021/acssynbio.8b00236
   Decker JT, 2018, BIOTECHNOL BIOENG, V115, P2613, DOI 10.1002/bit.26791
   Decker JT, 2017, BIOTECHNOL BIOENG, V114, P2085, DOI 10.1002/bit.26293
   Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463 8471.1998
   Faith JJ, 2007, PLOS BIOL, V5, P54, DOI 10.1371/journal.pbio.0050008
   Fukuda S, 2005, BLOOD, V105, P3117, DOI 10.1182/blood 2004 04 1440
   Giles KM, 2013, MOL CANCER THER, V12, P2541, DOI 10.1158/1535 7163.MCT 13 0170
   Grytli HH, 2014, EUR UROL, V65, P635, DOI 10.1016/j.eururo.2013.01.007
   Grytli HH, 2013, PROSTATE, V73, P250, DOI 10.1002/pros.22564
   Haury AC, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752 0509 6 145
   Jung YH, 2015, MOL CANCER RES, V13, P197, DOI 10.1158/1541 7786.MCR 14 0118
   Jung YH, 2012, NEOPLASIA, V14, P429, DOI 10.1596/neo.111740
   Kobayashi A., 2011, J EXP MED
   Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008 5472.CAN 08 4490
   Lu H, 2015, ONCOTARGETS THER, V8, P985, DOI 10.2147/OTT.S78836
   Margolin AA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471 2105 7 S1 S7
   Méndez Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685
   Mevik BH, 2007, J STAT SOFTW, V18, P1, DOI 10.18637/jss.v018.i02
   Meyer AS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004155
   Meyer PE, 2007, EURASIP J BIOINFORM, DOI 10.1155/2007/79879
   Morgan TM, 2009, CLIN CANCER RES, V15, P677, DOI 10.1158/1078 0432.CCR 08 1754
   Müller H, 2000, BBA REV CANCER, V1470, pM1, DOI 10.1016/S0304 419X(99)00030 X
   Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27
   Perez D.M., 2006, The Adrenergic Receptors: In the 21st Century, DOI DOI 10.1161/CIRCULATIONAHA.105.622928
   Pierroz DD, 2012, J BONE MINER RES, V27, P1252, DOI 10.1002/jbmr.1594
   Pound CR, 1999, JAMA J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591
   Ren D, 2019, J EXP MED, V216, P428, DOI 10.1084/jem.20180661
   Santala EEE, 2019, INT J CANCER, V144, P440, DOI 10.1002/ijc.31802
   Shiozawa Y, 2008, J CELL BIOCHEM, V105, P370, DOI 10.1002/jcb.21835
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384
   Siegel RL, 2019, CA CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Siletz A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057180
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0 387 29362 0_23
   Sosa MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7170
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Zahalka AH, 2017, SCIENCE, V358, P321, DOI 10.1126/science.aah5072
   Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330
NR 50
TC 18
Z9 18
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936 5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD JUL
PY 2020
VL 13
IS 7
AR 100781
DI 10.1016/j.tranon.2020.100781
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA MP8RS
UT WOS:000552467200010
PM 32361123
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Mazzaferro, S
   Pasquali, M
   Cozzolino, M
AF Mazzaferro, Sandro
   Pasquali, Marzia
   Cozzolino, Mario
TI Treatment of Cardiovascular Calcification in Uremia
SO CURRENT VASCULAR PHARMACOLOGY
LA English
DT Article
DE Vascular calcifications; chronic renal failure; secondary
   hyperparathyroidism; renal osteodystrophy; calcification inhibitors
ID CORONARY ARTERY CALCIFICATION; MATRIX GLA PROTEIN; BONE MORPHOGENETIC
   PROTEIN 7; CHRONIC KIDNEY DISEASE; SERUM OSTEOPROTEGERIN LEVELS;
   VASCULAR CALCIFICATION; VITAMIN D; AORTIC CALCIFICATION;
   HEMODIALYSIS PATIENTS; FETUIN A
AB Uremic subjects, in addition to accelerated atherosclerosis, develop diffuse media vascular calcification (VC) which, in turn, is associated with increased vascular stiffness and mortality risk. Two sets of risk factors for VC can be considered: passive deposition of calcium phosphate and active transformation of vascular smooth muscle cells into osteoblastic like cells. The former is linked with the metabolic imbalance in divalent ions that affects renal patients at any stage of the disease; the latter is secondary to a recently discovered mechanism of cellular trans differentiation caused by deranged local concentration of divalent ions. Also, the role of inhibitors of calcification is under investigation. These include circulating or local, substances like fetuin, matrix GLA protein or osteoprotegerin. Their biologic importance is supported by the occurrence of calcification in transgenic animals lacking these factors. Accordingly, VC is a complex biologic and incompletely understood process that deserves further research, in order to develop specific therapeutic strategies. In general, once established, these calcifications are not considered to be reversible; therefore, prevention is the main treatment option. With this aim, in uremic patients it is now recommended to adopt restricted ranges of serum concentrations for calcium, phosphate and parathyroid hormone which are associated with a lower rate of calcification. To target these recommended ranges, new drugs, like selective vitamin D receptor activators, calcium sensing receptor modulators and calcium free intestinal phosphate binders, have been introduced. Moreover new possible pathogenetic pathways are considered (e. g. vitamin K deficiency). Further, in patients with calciphylaxis, the most severe form of VC, experimental therapies are suggested, with drugs like sodium thiosulphate or bisphosphonates. Drugs capable of reversing the process of trans differentiation from osteoblast like to vascular smooth muscle cells could be developed in the future.
C1 [Mazzaferro, Sandro; Pasquali, Marzia] Univ Roma La Sapienza, Dept Cardiovasc Resp Nephrol & Geriatr Sci, I 00161 Rome, Italy.
   [Cozzolino, Mario] Univ Milan, Dept Med Surg & Dent, Div Renal, Milan, Italy.
C3 Sapienza University Rome; University of Milan
RP Mazzaferro, S (通讯作者)，Univ Roma La Sapienza, Dept Cardiovasc Resp Nephrol & Geriatr Sci, Viale Policlin 155, I 00161 Rome, Italy.
EM sandro.mazzaferro@uniroma1.it
RI Cozzolino, Mario/AAB 9965 2022; Mazzaferro, Sandro/E 9321 2012
OI Cozzolino, Mario/0000 0002 8494 6252; Mazzaferro,
   Sandro/0000 0003 3071 1893
CR Adeney KL, 2009, J AM SOC NEPHROL, V20, P381, DOI 10.1681/ASN.2008040349
   Adragao T, 2009, NEPHROL DIAL TRANSPL, V24, P997, DOI 10.1093/ndt/gfn584
   ALFREY AC, 1993, THER DRUG MONIT, V15, P593, DOI 10.1097/00007691 199312000 00025
   Andress D, 2007, DRUGS, V67, P1999, DOI 10.2165/00003495 200767140 00003
   [Anonymous], 2003, Drugs R D, V4, P349
   ANTON DL, 1983, J BIOL CHEM, V258, P4084
   Ariyoshi T, 2006, CLIN DRUG INVEST, V26, P215, DOI 10.2165/00044011 200626040 00006
   Asplin JR, 2009, J AM SOC NEPHROL, V20, P1246, DOI 10.1681/ASN.2008070754
   Baigent C, 2011, LANCET, V377, P2181, DOI 10.1016/S0140 6736(11)60739 3
   Barreto DV, 2008, NEPHRON CLIN PRACT, V110, pC273, DOI 10.1159/000170783
   Becker LE, 2011, AM J PHYSIOL RENAL, V300, pF77
   Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2005, KIDNEY INT, V68, P1815, DOI 10.1111/j.1523 1755.2005.00600.x
   Boaz M, 2011, NEPHRON CLIN PRACT, V117, pC83, DOI 10.1159/000319654
   Braam LAJLM, 2004, THROMB HAEMOSTASIS, V91, P373, DOI 10.1160/TH03 07 0423
   Brandenburg VM, 2009, KIDNEY INT, V76, pS26, DOI 10.1038/ki.2009.404
   Braun J, 1996, AM J KIDNEY DIS, V27, P394, DOI 10.1016/S0272 6386(96)90363 7
   Brown AJ, 2002, J LAB CLIN MED, V139, P279, DOI 10.1067/mlc.2002.122819
   Brown AJ, 2001, AM J KIDNEY DIS, V38, pS3, DOI 10.1053/ajkd.2001.28111
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chan WLW, 2010, J RENAL NUTR, V20, P270, DOI 10.1053/j.jrn.2009.10.009
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen NX, 2002, KIDNEY INT, V62, P1724, DOI 10.1046/j.1523 1755.2002.00625.x
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Cirillo M, 2010, AM J KIDNEY DIS, V56, P802, DOI 10.1053/j.ajkd.2010.07.002
   Cozzolino M, 2008, AM J NEPHROL, V28, P339, DOI 10.1159/000111827
   Cozzolino M, 2006, AM J NEPHROL, V26, P423, DOI 10.1159/000095782
   Cozzolino M, 2011, NEPHROL DIAL TRANSPL, V26, P402, DOI 10.1093/ndt/gfq691
   Cranenburg ECM, 2009, THROMB HAEMOSTASIS, V101, P359, DOI 10.1160/TH08 04 0241
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   Davies MR, 2003, J AM SOC NEPHROL, V14, P1559, DOI 10.1097/01.ASN.0000068404.57780.DD
   de Francisco ALM, 2006, J AM SOC NEPHROL, V17, pS281, DOI 10.1681/ASN.2006080927
   Arenas MD, 2010, J NEPHROL, V23, P683
   Dorai H, 2000, J CELL PHYSIOL, V184, P37, DOI 10.1002/(SICI)1097 4652(200007)184:1<37::AID JCP4>3.0.CO;2 M
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Edwards CJ, 2002, ARTHRITIS RES, V4, P151, DOI 10.1186/ar399
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Fellström BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177
   Ferramosca E, 2005, AM HEART J, V149, P820, DOI 10.1016/j.ahj.2004.07.023
   Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470
   Geleijnse JM, 2004, J NUTR, V134, P3100, DOI 10.1093/jn/134.11.3100
   Giachelli C M, 2001, Z Kardiol, V90 Suppl 3, P31
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Haas M, 2002, AM J KIDNEY DIS, V39, P580, DOI 10.1053/ajkd.2002.31409
   Hashiba H, 2006, THER APHER DIAL, V10, P59, DOI 10.1111/j.1744 9987.2006.00345.x
   Hayden MR, 2010, SEMIN DIALYSIS, V23, P258, DOI 10.1111/j.1525 139X.2010.00738.x
   Heiss A, 2003, J BIOL CHEM, V278, P13333, DOI 10.1074/jbc.M210868200
   Hendy GN, 2006, KIDNEY INT, V69, P218, DOI 10.1038/sj.ki.5000091
   Henley C, 2005, NEPHROL DIAL TRANSPL, V20, P1370, DOI 10.1093/ndt/gfh834
   Hermans MMH, 2007, BLOOD PURIFICAT, V25, P395, DOI 10.1159/000108629
   Hill JA, 2002, ACAD RADIOL, V9, P1148, DOI 10.1016/S1076 6332(03)80516 0
   Hjelmesæth J, 2006, J AM SOC NEPHROL, V17, P1746, DOI 10.1681/ASN.2005121368
   Holdaas H, 2003, LANCET, V361, P2024, DOI 10.1016/S0140 6736(03)13638 0
   Holden RM, 2007, J NEPHROL, V20, P417
   Holden RM, 2010, CLIN J AM SOC NEPHRO, V5, P590, DOI 10.2215/CJN.06420909
   Husain K, 2010, AM J NEPHROL, V32, P296, DOI 10.1159/000319445
   Ivanovski O, 2009, ATHEROSCLEROSIS, V205, P55, DOI 10.1016/j.atherosclerosis.2008.10.043
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Jono S, 2002, CIRCULATION, V106, P1192, DOI 10.1161/01.CIR.0000031524.49139.29
   Ketteler M, 2003, LANCET, V361, P827, DOI 10.1016/S0140 6736(03)12710 9
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kiechl S, 2004, CIRCULATION, V109, P2175, DOI 10.1161/01.CIR.0000127957.43874.BB
   Koleganova N, 2009, KIDNEY INT, V75, P60, DOI 10.1038/ki.2008.490
   Koos R, 2005, AM J CARDIOL, V96, P747, DOI 10.1016/j.amjcard.2005.05.014
   Krüger T, 2009, INT J ARTIF ORGANS, V32, P67, DOI 10.1177/039139880903200202
   Kudlacek S, 2003, BONE, V32, P681, DOI 10.1016/S8756 3282(03)00090 5
   LEBRETON JP, 1979, J CLIN INVEST, V64, P1118, DOI 10.1172/JCI109551
   Li XW, 2010, ARTERIOSCL THROM VAS, V30, P321, DOI 10.1161/ATVBAHA.109.196576
   Li XM, 2003, J CELL BIOCHEM, V89, P709, DOI 10.1002/jcb.10547
   Lomashvili KA, 2009, KIDNEY INT, V75, P617, DOI 10.1038/ki.2008.646
   London GM, 2003, J AM SOC NEPHROL, V14, pS305, DOI 10.1097/01.ASN.0000081664.65772.EB
   Lopez I, 2006, J AM SOC NEPHROL, V17, P795, DOI 10.1681/ASN.2005040342
   Lopez I, 2009, AM J PHYSIOL RENAL, V296, pF1376, DOI 10.1152/ajprenal.90737.2008
   Lund RJ, 2004, J AM SOC NEPHROL, V15, P359, DOI 10.1097/01.ASN.0000109671.99498.08
   LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808
   Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0
   Massy ZA, 2005, J AM SOC NEPHROL, V16, P109, DOI 10.1681/ASN.2004060495
   Mathew S, 2007, J AM SOC NEPHROL, V18, P122, DOI 10.1681/ASN.2006050490
   MAZZAFERRO S, 1993, NEPHROL DIAL TRANSPL, V8, P335
   Mazzaferro S, 2007, AM J NEPHROL, V27, P75, DOI 10.1159/000099095
   MEHTA RL, 1990, AM J MED, V88, P252, DOI 10.1016/0002 9343(90)90150 C
   Meier M, 2001, EUR RESPIR J, V17, P566, DOI 10.1183/09031936.01.17305660
   Memoli B, 2007, BIOMATERIALS, V28, P4836, DOI 10.1016/j.biomaterials.2007.05.043
   Messa P, 2008, CLIN J AM SOC NEPHRO, V3, P36, DOI 10.2215/CJN.03591006
   Mizobuchi M, 2004, J AM SOC NEPHROL, V15, P2579, DOI 10.1097/01.ASN.0000141016.20133.33
   Mizobuchi M, 2010, J STEROID BIOCHEM, V121, P188, DOI 10.1016/j.jsbmb.2010.03.026
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe SM, 2003, KIDNEY INT, V63, P1003, DOI 10.1046/j.1523 1755.2003.00820.x
   Moe SM, 2005, KIDNEY INT, V67, P2295, DOI 10.1111/j.1523 1755.2005.00333.x
   Morena M, 2006, J AM SOC NEPHROL, V17, P262, DOI 10.1681/ASN.2005030260
   Murshed M, 2004, J CELL BIOL, V165, P625, DOI 10.1083/jcb.200402046
   Nagano N, 2005, J PHARMACOL SCI, V97, P355, DOI 10.1254/jphs.FMJ04007X6
   Nakashima A, 2004, BONE, V34, P579, DOI 10.1016/j.bone.2003.11.016
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Neven EG, 2009, KIDNEY INT, V75, P580, DOI 10.1038/ki.2008.663
   Nitta K, 2004, AM J KIDNEY DIS, V44, P680, DOI 10.1053/j.ajkd.2004.06.009
   Noto L, 2011, J RENAL NUTR, V21, P277, DOI 10.1053/j.jrn.2010.04.007
   Pasch A, 2008, KIDNEY INT, V74, P1444, DOI 10.1038/ki.2008.455
   Pertosa G, 2009, AM J KIDNEY DIS, V53, P467, DOI 10.1053/j.ajkd.2008.10.046
   Pilkey RM, 2007, AM J KIDNEY DIS, V49, P432, DOI 10.1053/j.ajkd.2006.11.041
   PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335
   Price PA, 2004, J BIOL CHEM, V279, P1594, DOI 10.1074/jbc.M305199200
   Price PA, 2003, J BIOL CHEM, V278, P22144, DOI 10.1074/jbc.M300744200
   Price PA, 1998, ARTERIOSCL THROM VAS, V18, P1400, DOI 10.1161/01.ATV.18.9.1400
   Price PA, 2001, ARTERIOSCL THROM VAS, V21, P817, DOI 10.1161/01.ATV.21.5.817
   Qunibi W, 2008, AM J KIDNEY DIS, V51, P952, DOI 10.1053/j.ajkd.2008.02.298
   Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725
   Reynolds JL, 2004, J AM SOC NEPHROL, V15, P2857, DOI 10.1097/01.ASN.0000141960.01035.28
   Rodriguez ME, 2007, AM J PHYSIOL RENAL, V292, pF1390, DOI 10.1152/ajprenal.00262.2006
   Russo D, 2007, KIDNEY INT, V72, P1255, DOI 10.1038/sj.ki.5002518
   Russo D, 2004, AM J KIDNEY DIS, V44, P1024, DOI 10.1053/j.ajkd.2004.07.022
   Schäfer C, 2003, J CLIN INVEST, V112, P357, DOI [10.1172/JCI17202, 10.1172/JCI200317202]
   Schoppet M, 2004, J CLIN ENDOCR METAB, V89, P4104, DOI 10.1210/jc.2003 031432
   Schoppet M, 2011, BIOCHEM BIOPH RES CO, V407, P103, DOI 10.1016/j.bbrc.2011.02.117
   Schurgers LJ, 2007, BLOOD, V109, P3279, DOI 10.1182/blood 2006 08 040709
   Schurgers LJ, 2010, CLIN J AM SOC NEPHRO, V5, P568, DOI 10.2215/CJN.07081009
   Schurgers LJ, 2005, ARTERIOSCL THROM VAS, V25, P1629, DOI 10.1161/01.ATV.0000173313.46222.43
   Shanahan CM, 2005, CLIN NEPHROL, V63, P146
   Shiraishi N, 2006, AM J KIDNEY DIS, V48, P151, DOI 10.1053/j.ajkd.2006.04.062
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Slatopolsky E, 2011, KIDNEY INT, V79, pS3, DOI 10.1038/ki.2011.23
   Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523 1755.2003.00878.x
   Tamura K, 2007, EUR J PHARMACOL, V558, P159, DOI 10.1016/j.ejphar.2006.12.006
   Tankó LB, 2005, OSTEOPOROSIS INT, V16, P184, DOI 10.1007/s00198 004 1662 x
   Tonelli M, 2010, NEW ENGL J MED, V362, P1312, DOI 10.1056/NEJMra0912522
   Toussaint ND, 2010, AM J KIDNEY DIS, V56, P57, DOI 10.1053/j.ajkd.2009.12.039
   Verstuyf A, 2010, KIDNEY INT, V78, P140, DOI 10.1038/ki.2010.17
   Wang AYM, 2005, NEPHROL DIAL TRANSPL, V20, P1676, DOI 10.1093/ndt/gfh891
   Wang S, 2003, KIDNEY INT, V63, P2037, DOI 10.1046/j.1523 1755.2003.00035.x
   Wang SN, 2001, J AM SOC NEPHROL, V12, P2392, DOI 10.1681/ASN.V12112392
   Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545
   Wu Wong JR, 2007, CURR OPIN INVEST DR, V8, P237
   Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200
NR 134
TC 0
Z9 0
U1 0
U2 16
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570 1611
EI 1875 6212
J9 CURR VASC PHARMACOL
JI Current Vascular Pharmacology
PD NOV
PY 2011
VL 9
IS 6
BP 741
EP 749
DI 10.2174/157016111797484161
PG 9
WC Pharmacology & Pharmacy; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Cardiovascular System & Cardiology
GA 882KL
UT WOS:000299562400011
PM 21824104
DA 2025 08 17
ER

PT J
AU Binder, NB
   Niederreiter, B
   Hoffmann, O
   Stange, R
   Pap, T
   Stulnig, TM
   Mack, M
   Erben, RG
   Smolen, JS
   Redlich, K
AF Binder, Nikolaus B.
   Niederreiter, Birgit
   Hoffmann, Oskar
   Stange, Richard
   Pap, Thomas
   Stulnig, Thomas M.
   Mack, Matthias
   Erben, Reinhold G.
   Smolen, Josef S.
   Redlich, Kurt
TI Estrogen dependent and C C chemokine receptor 2 dependent pathways
   determine osteoclast behavior in osteoporosis
SO NATURE MEDICINE
LA English
DT Article
ID KAPPA B LIGAND; BONE LOSS; RECEPTOR ACTIVATOR; NECROSIS FACTOR;
   EXPRESSION; CELLS; CYTOKINE; HORMONE; MCP 1; DIFFERENTIATION
AB Understanding the mechanisms of osteoclastogenesis is crucial for developing new drugs to treat diseases associated with bone loss, such as osteoporosis. Here we report that the C C chemokine receptor 2 (CCR2) is crucially involved in balancing bone mass. CCR2 knockout mice have high bone mass owing to a decrease in number, size and function of osteoclasts. In normal mice, activation of CCR2 in osteoclast progenitor cells results in both nuclear factor kappa B (NF kappa B) and extracellular signal related kinase 1 and 2 (ERK1/2) signaling but not that of p38 mitogen activated protein kinase or c Jun N terminal kinase. The induction of NF kappa B and ERK1/2 signaling in turn leads to increased surface expression of receptor activator of NF kappa B (RANK, encoded by Tnfrsf11a), making the progenitor cells more susceptible to RANK ligand induced osteoclastogenesis. In ovariectomized mice, a model of postmenopausal osteoporosis, CCR2 is upregulated on wild type preosteoclasts, thus increasing the surface expression of RANK on these cells and their osteoclastogenic potential, whereas CCR2 knockout mice are resistant to ovariectomy induced bone loss. These data reveal a previously undescribed pathway by which RANK, osteoclasts and bone homeostasis are regulated in health and disease.
C1 [Binder, Nikolaus B.; Niederreiter, Birgit; Smolen, Josef S.; Redlich, Kurt] Med Univ Vienna, Div Rheumatol, Vienna, Austria.
   [Hoffmann, Oskar] Univ Vienna, Inst Pharmacol & Toxicol, Vienna, Austria.
   [Stange, Richard; Pap, Thomas] Univ Munster, Inst Expt Musculoskeletal Med, Munster, Germany.
   [Stange, Richard] Univ Munster, Dept Trauma Hand & Reconstruct Surg, Munster, Germany.
   [Stulnig, Thomas M.] Med Univ Vienna, Div Endocrinol & Metab, Vienna, Austria.
   [Mack, Matthias] Univ Regensburg, Div Nephrol, Regensburg, Germany.
   [Erben, Reinhold G.] Univ Vet Med Vienna, Inst Pathophysiol, Vienna, Austria.
C3 Medical University of Vienna; University of Vienna; University of
   Munster; University of Munster; Medical University of Vienna; University
   of Regensburg; University of Veterinary Medicine Vienna
RP Redlich, K (通讯作者)，Med Univ Vienna, Div Rheumatol, Vienna, Austria.
EM kurt.redlich@meduniwien.ac.at
RI ; Mack, Matthias/AET 9298 2022; Smolen, Josef/ADI 7087 2022; Pap,
   Thomas/HTS 5206 2023; Erben, Reinhold/AAG 8007 2020
OI Stulnig, Thomas/0000 0003 3300 6161; Stange,
   Richard/0000 0003 0807 3151; Erben, Reinhold/0000 0003 0801 6958; 
CR Arici A, 1999, BIOL REPROD, V61, P85, DOI 10.1095/biolreprod61.1.85
   Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798
   Breitkreutz I, 2007, BRIT J HAEMATOL, V139, P55, DOI 10.1111/j.1365 2141.2007.06747.x
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752
   Choi SJ, 2000, BLOOD, V96, P671
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Hayer S, 2005, J EXP MED, V201, P903, DOI 10.1084/jem.20040852
   Herault O, 1999, BRIT J HAEMATOL, V104, P530, DOI 10.1046/j.1365 2141.1999.01203.x
   Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359 6101(01)00014 4
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Janis K, 2004, AM J REPROD IMMUNOL, V51, P22, DOI 10.1046/j.8755 8920.2003.00117.x
   Jia T, 2008, J IMMUNOL, V180, P6846, DOI 10.4049/jimmunol.180.10.6846
   Kim MS, 2006, J CELL BIOCHEM, V97, P512, DOI 10.1002/jcb.20649
   Kim MS, 2006, J BIOL CHEM, V281, P1274, DOI 10.1074/jbc.M510156200
   Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200
   Koh KK, 2001, INT J CARDIOL, V81, P43, DOI 10.1016/S0167 5273(01)00527 7
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   KRUSE K, 1986, EUR J PEDIATR, V145, P27, DOI 10.1007/BF00441848
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lean JM, 2002, J CELL BIOCHEM, V87, P386, DOI 10.1002/jcb.10319
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756 3282(95)00180 L
   MANOLAGAS SC, 1992, CALCIFIED TISSUE INT, V50, P199, DOI 10.1007/BF00296282
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   Owen JL, 2005, CELL IMMUNOL, V235, P122, DOI 10.1016/j.cellimm.2005.08.032
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002 9440(10)63144 6
   RUSSELL RGG, 1981, METAB BONE DIS RELAT, V3, P255, DOI 10.1016/0221 8747(81)90041 2
   Stepan J J, 2003, Endocr Regul, V37, P225
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919
   TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo 122 3 1146
   Viedt C, 2002, ARTERIOSCL THROM VAS, V22, P914, DOI 10.1161/01.ATV.0000019009.73586.7F
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yamada Y, 2002, GENOMICS, V80, P8, DOI 10.1006/geno.2002.6793
   Zallone A, 2006, ANN NY ACAD SCI, V1068, P173, DOI 10.1196/annals.1346.019
NR 44
TC 163
Z9 176
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD APR
PY 2009
VL 15
IS 4
BP 417
EP 424
DI 10.1038/nm.1945
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 429RG
UT WOS:000264937200029
PM 19330010
DA 2025 08 17
ER

PT J
AU Whyte, MP
   Greenberg, CR
   Salman, NJ
   Bober, MB
   McAlister, WH
   Wenkert, D
   Van Sickle, BJ
   Simmons, JH
   Edgar, TS
   Bauer, ML
   Hamdan, MA
   Bishop, N
   Lutz, RE
   McGinn, M
   Craig, S
   Moore, JN
   Taylor, JW
   Cleveland, RH
   Cranley, WR
   Lim, R
   Thacher, TD
   Mayhew, JE
   Downs, M
   Millán, JL
   Skrinar, AM
   Crine, P
   Landy, H
AF Whyte, Michael P.
   Greenberg, Cheryl R.
   Salman, Nada J.
   Bober, Michael B.
   McAlister, William H.
   Wenkert, Deborah
   Van Sickle, Bradley J.
   Simmons, Jill H.
   Edgar, Terence S.
   Bauer, Martin L.
   Hamdan, Mohamed A.
   Bishop, Nick
   Lutz, Richard E.
   McGinn, Mairead
   Craig, Stanley
   Moore, Jean N.
   Taylor, John W.
   Cleveland, Robert H.
   Cranley, William R.
   Lim, Ruth
   Thacher, Tom D.
   Mayhew, Jill E.
   Downs, Matthew
   Millan, Jose Luis
   Skrinar, Alison M.
   Crine, Philippe
   Landy, Hal
TI Enzyme Replacement Therapy in Life Threatening Hypophosphatasia
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID NONSPECIFIC ALKALINE PHOSPHATASE; INFANTILE HYPOPHOSPHATASIA; MURINE
   HYPOPHOSPHATASIA; INTRAVENOUS INFUSION; BONE; DISEASE; GENE;
   PYRIDOXAL 5' PHOSPHATE; TRANSPLANTATION; MINERALIZATION
AB BACKGROUND
   Hypophosphatasia results from mutations in the gene for the tissue nonspecific isozyme of alkaline phosphatase (TNSALP). Inorganic pyrophosphate accumulates extracellularly, leading to rickets or osteomalacia. Severely affected babies often die from respiratory insufficiency due to progressive chest deformity or have persistent bone disease. There is no approved medical therapy. ENB 0040 is a bone targeted, recombinant human TNSALP that prevents the manifestations of hypophosphatasia in Tnsalp knockout mice.
   METHODS
   We enrolled infants and young children with life threatening or debilitating perinatal or infantile hypophosphatasia in a multinational, open label study of treatment with ENB 0040. The primary objective was the healing of rickets, as assessed by means of radiographic scales. Motor and cognitive development, respiratory function, and safety were evaluated, as well as the pharmacokinetics and pharmacodynamics of ENB 0040.
   RESULTS
   Of the 11 patients recruited, 10 completed 6 months of therapy; 9 completed 1 year. Healing of rickets at 6 months in 9 patients was accompanied by improvement in developmental milestones and pulmonary function. Elevated plasma levels of the TNSALP substrates inorganic pyrophosphate and pyridoxal 5' phosphate diminished. Increases in serum parathyroid hormone accompanied skeletal healing, often necessitating dietary calcium supplementation. There was no evidence of hypocalcemia, ectopic calcification, or definite drug related serious adverse events. Low titers of anti ENB 0040 antibodies developed in four patients, with no evident clinical, biochemical, or autoimmune abnormalities at 48 weeks of treatment.
   CONCLUSIONS
   ENB 0040, an enzyme replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.)
C1 [Whyte, Michael P.; Wenkert, Deborah] Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, St Louis, MO 63131 USA.
   [Whyte, Michael P.] Washington Univ, Sch Med, Div Bone & Mineral Dis, Barnes Jewish Hosp, St Louis, MO 63130 USA.
   [McAlister, William H.] Washington Univ, Sch Med, St Louis Childrens Hosp, Mallinckrodt Inst Radiol, St Louis, MO 63130 USA.
   [Greenberg, Cheryl R.] Univ Manitoba, Winnipeg, MB, Canada.
   [Greenberg, Cheryl R.] Winnipeg Reg Hlth Author, Winnipeg, MB, Canada.
   [Salman, Nada J.; Hamdan, Mohamed A.] Tawam Hosp, Al Ain, U Arab Emirates.
   [Bober, Michael B.] Alfred I Dupont Hosp Children, Wilmington, DE USA.
   [Van Sickle, Bradley J.; Simmons, Jill H.] Vanderbilt Childrens Hosp, Nashville, TN USA.
   [Edgar, Terence S.; Taylor, John W.] Prevea Hlth Clin, Green Bay, WI USA.
   [Taylor, John W.] St Vincents Hosp, Green Bay, WI USA.
   [Bauer, Martin L.] Univ Arkansas Med Sci, Coll Med, Little Rock, AR 72205 USA.
   [Bishop, Nick] Sheffield Childrens Hosp, Sheffield, S Yorkshire, England.
   [McGinn, Mairead; Craig, Stanley] Royal Belfast Hosp Sick Children, Belfast, Antrim, North Ireland.
   [Lutz, Richard E.] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Moore, Jean N.] St Johns Hosp, Springfield, MO USA.
   [Cleveland, Robert H.] Childrens Hosp, Boston, MA 02115 USA.
   [Cranley, William R.] Boston Med Ctr, Boston, MA USA.
   [Lim, Ruth] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Thacher, Tom D.] Mayo Clin, Rochester, MN USA.
   [Mayhew, Jill E.; Skrinar, Alison M.; Crine, Philippe; Landy, Hal] Enobia Pharma, Montreal, PQ, Canada.
   [Downs, Matthew] Stat Collaborat, Washington, DC USA.
   [Millan, Jose Luis] Sanford Burnham Med Res Inst, La Jolla, CA USA.
C3 Barnes Jewish Hospital; Washington University (WUSTL); St. Louis
   Children's Hospital; Washington University (WUSTL); University of
   Manitoba; Nemours Alfred I. duPont Hospital for Children; Vanderbilt
   University; University of Arkansas System; University of Arkansas
   Medical Sciences; Sheffield Children's NHS Foundation Trust; Sheffield
   Children's Hospital; University of Nebraska System; University of
   Nebraska Medical Center; Saint Johns Mercy Medical Center; Harvard
   University; Harvard University Medical Affiliates; Boston Children's
   Hospital; Boston Medical Center; Harvard University; Harvard University
   Medical Affiliates; Massachusetts General Hospital; Mayo Clinic;
   Statistics Collaborative; Sanford Burnham Prebys Medical Discovery
   Institute
RP Whyte, MP (通讯作者)，Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, 2001 S Lindbergh Blvd, St Louis, MO 63131 USA.
EM mwhyte@shrinenet.org
RI Downs, Matt/S 7646 2019; Simmons, Jill/KXS 0978 2024; Thacher,
   Tom/B 3356 2009; Millan, Jose Luis/LXU 4378 2024; Bober,
   Michael/AAH 4553 2021; Taylor, John/AFG 5209 2022
OI Thacher, Tom/0000 0002 7644 8173; Downs, Matt/0000 0002 3623 8059;
   Bober, Michael/0000 0002 6178 1264; Simmons, Jill/0000 0002 4189 6718; 
FU Enobia Pharma Hospital for Children; Shriners Hospital for Children
FX Supported by Enobia Pharma and Shriners Hospitals for Children.
CR Anderson HC, 1997, AM J PATHOL, V151, P1555
   [Anonymous], 2005, BAYL SCAL INF TODDL
   [Anonymous], 1989, NONMEM USERS GUIDE 1
   Baumgartner Sigl S, 2007, BONE, V40, P1655, DOI 10.1016/j.bone.2007.01.020
   Cahill RA, 2007, J CLIN ENDOCR METAB, V92, P2923, DOI 10.1210/jc.2006 2131
   Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.1093/biomet/26.4.404
   Collmann H, 2009, CHILD NERV SYST, V25, P217, DOI 10.1007/s00381 008 0708 3
   Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   Fleisch H, 1995, BISPHOSPHONATES BONE, P149
   FRASER D, 1957, AM J MED, V22, P730, DOI 10.1016/0002 9343(57)90124 9
   Greenberg CR, 2009, 16 ANN CLIN GEN M AM
   Ish Shalom S, 1986, 8 ANN SCI M AM SOC B
   McKee MD, 2011, J DENT RES, V90, P470, DOI 10.1177/0022034510393517
   Millan J.L., 2006, MAMMALIAN ALKALINE P
   Millán JL, 2008, J BONE MINER RES, V23, P777, DOI 10.1359/JBMR.071213
   MORNET E, 2006, TISSUE NONSPECIFIC A
   Mumm S, 2002, MOL GENET METAB, V75, P143, DOI 10.1006/mgme.2001.3283
   Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205
   PRESTON CJ, 1986, BMJ BRIT MED J, V292, P79, DOI 10.1136/bmj.292.6513.79
   RATHBUN JC, 1948, AM J DIS CHILD, V75, P822, DOI 10.1001/archpedi.1948.02030020840003
   RUSSELL RGG, 1965, LANCET, V2, P461
   Rutsch F, 2003, NAT GENET, V34, P379, DOI 10.1038/ng1221
   SESHIA SS, 1990, ARCH DIS CHILD, V65, P130, DOI 10.1136/adc.65.1.130
   Thacher TD, 2000, J TROP PEDIATRICS, V46, P132, DOI 10.1093/tropej/46.3.132
   van den Bos T, 2005, J DENT RES, V84, P1021, DOI 10.1177/154405910508401110
   WEISS MJ, 1988, P NATL ACAD SCI USA, V85, P7666, DOI 10.1073/pnas.85.20.7666
   Wenkert D, 2011, J BONE MINER RES, V26, P2389, DOI 10.1002/jbmr.454
   Whyte MP, 2007, J CLIN ENDOCR METAB, V92, P1203, DOI 10.1210/jc.2006 1902
   Whyte MP, 2012, PEDIATRIC BONE: BIOLOGY & DISEASES, 2ND EDITION, P771, DOI 10.1016/B978 0 12 382040 2.10028 0
   Whyte MP, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1573, DOI 10.1016/B978 0 12 373884 4.00080 X
   Whyte MP, 2000, J BONE MINER RES, V15, pS483
   WHYTE MP, 1988, J CLIN INVEST, V81, P1234, DOI 10.1172/JCI113440
   WHYTE MP, 1984, J PEDIATR US, V105, P926, DOI 10.1016/S0022 3476(84)80079 7
   Whyte MP, 2003, J BONE MINER RES, V18, P624, DOI 10.1359/jbmr.2003.18.4.624
   WHYTE MP, 1992, J BONE MINER RES, V7, pS155
   WHYTE MP, 1982, J PEDIATR US, V101, P379, DOI 10.1016/S0022 3476(82)80061 9
   WHYTE MP, 1985, J CLIN INVEST, V76, P752, DOI 10.1172/JCI112031
   Wilcoxon F., 1945, BIOMETRICS B, V6, P80
   Yadav MC, 2011, BONE, V49, P250, DOI 10.1016/j.bone.2011.03.770
NR 40
TC 413
Z9 456
U1 0
U2 52
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451 1413 USA
SN 0028 4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAR 8
PY 2012
VL 366
IS 10
BP 904
EP 913
DI 10.1056/NEJMoa1106173
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 904CY
UT WOS:000301172500007
PM 22397652
OA Bronze
DA 2025 08 17
ER

PT J
AU Pennisi, A
   Li, X
   Ling, W
   Khan, S
   Zangari, M
   Yaccoby, S
AF Pennisi, Angela
   Li, Xin
   Ling, Wen
   Khan, Sharmin
   Zangari, Maurizio
   Yaccoby, Shmuel
TI The proteasome inhibitor, bortezomib suppresses primary myeloma and
   stimulates bone formation in myelomatous and nonmyelomatous bones in
   vivo
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID SCID HU MICE; MULTIPLE MYELOMA; TUMOR BURDEN; MARROW MICROENVIRONMENT;
   OSTEOLYTIC LESIONS; ZOLEDRONIC ACID; PLASMA CELLS; DISEASE; GROWTH;
   CANCER
AB Multiple myeloma (MM), a hematologic malignancy of terminally differentiated plasma cells is closely associated with induction of osteolytic bone disease, induced by stimulation of osteoclastogenesis and suppression of osteoblastogenesis. The ubiquitin proteasome pathway regulates differentiation of bone cells and MM cell growth. The proteasome inhibitor, bortezomib, is a clinical potent antimyeloma agent. The main goal of this study was to investigate the effect of bortezomib on myeloma induced bone resorption and tumor growth in SCID rab mice engrafted with MM cells from 16 patients. Antimyeloma response of bortezomib, which was evident in >50% of 16 experiments and resembled clinical response, was associated with significant increased bone mineral density (BMD) and osteoblast numbers, and reduced osteoclast numbers in myelomatous bones. This bone anabolic effect, which was also visualized on X ray radiographs and confirmed by static and dynamic histomorphometric analyses, was unique to bortezomib and was not observed in hosts responding to melphalan, a chemotherapeutic drug widely used to treat MM. Bortezomib also increased BMD and osteoblasts number and reduced osteoclasts number in nonmyelomatous implanted bones. In vitro bortezomib directly suppressed human osteoclast formation and promoted maturation of osteoblasts. We conclude that bortezomib promotes bone formation in myelomatous and nonmyelomatous bones by simultaneously inhibiting osteoclastogenesis and stimulating osteoblastogenesis. As clinical and experimental studies indicate that bone disease is both a consequence and necessity of MM progression our results suggest and that bortezomib's effects on bone remodeling contribute to the antimyeloma efficacy of this drug. Am. J. Hematol. 84:6 14,2009. (C) 2008 Wiley Liss, Inc.
C1 [Yaccoby, Shmuel] Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA.
   [Pennisi, Angela] Univ Catania, Osped Ferrarotto, Div Hematol, Catania, Italy.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Catania
RP Yaccoby, S (通讯作者)，Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Myeloma Inst Res & Therapy, 4301 W Markham,Slot 776, Little Rock, AR 72205 USA.
EM yaccobyshmuel@uams.edu
OI Li, Xin/0000 0002 7414 5734
FU National Cancer Institute [CA 93897]; Multiple Myeloma Research
   Foundation; Senior and Translational Research Awards; Millennium
   Pharmaceuticles; Fondazione Catanese per lo Studio a la Cura delle
   Malattie Neoplastiche del Sangue (FON.CA.NE.SA), Italy
FX Contract grant sponsor: National Cancer Institute; Contract grant
   number: CA 93897; Multiple Myeloma Research Foundation, Senior and
   Translational Research Awards; Millennium Pharmaceuticles; Fondazione
   Catanese per lo Studio a la Cura delle Malattie Neoplastiche del Sangue
   (FON.CA.NE.SA), Italy.
CR Attal M, 2006, BLOOD, V108, P3289, DOI 10.1182/blood 2006 05 022962
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Barillé Nion S, 2003, LEUKEMIA LYMPHOMA, V44, P1463, DOI 10.1080/1042819031000082966
   BATAILLE R, 1991, J CLIN INVEST, V88, P62, DOI 10.1172/JCI115305
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Ge Y, 2006, BRIT J HAEMATOL, V133, P83, DOI 10.1111/j.1365 2141.2006.05976.x
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Hideshima T, 2001, CANCER RES, V61, P3071
   LeBlanc R, 2002, CANCER RES, V62, P4996
   Li X, 2008, BLOOD, V112, P159, DOI 10.1182/blood 2007 11 124164
   Li X, 2007, BRIT J HAEMATOL, V138, P802, DOI 10.1111/j.1365 2141.2007.06742.x
   Markowitz GS, 2003, KIDNEY INT, V64, P281, DOI 10.1046/j.1523 1755.2003.00071.x
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Oyajobi BO, 2007, BRIT J HAEMATOL, V139, P434, DOI 10.1111/j.1365 2141.2007.06829.x
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Perrien DS, 2007, ENDOCRINOLOGY, V148, P1654, DOI 10.1210/en.2006 0848
   Qiang YW, 2008, BLOOD, V112, P374, DOI 10.1182/blood 2007 10 120253
   Richardson PG, 2007, ONCOLOGIST, V12, P664, DOI 10.1634/theoncologist.12 6 664
   Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2001, CANCER J, V7, P377
   Stewart JP, 2006, J CELL BIOCHEM, V98, P1, DOI 10.1002/jcb.20774
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vanderkerken K, 2003, CANCER RES, V63, P287
   Yaccoby S, 2008, LEUKEMIA, V22, P406, DOI 10.1038/sj.leu.2405048
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yaccoby S, 1999, BLOOD, V94, P3576, DOI 10.1182/blood.V94.10.3576.422k01_3576_3582
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Yaccoby S, 2005, CLIN CANCER RES, V11, P7599, DOI 10.1158/1078 0432.CCR 05 0523
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
   Yaccoby S, 1998, BLOOD, V92, P2908, DOI 10.1182/blood.V92.8.2908.420a32_2908_2913
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yata K, 2004, LEUKEMIA, V18, P1891, DOI 10.1038/sj.leu.2403513
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zangari M, 2006, CLIN LYMPHOMA MYELOM, V7, P109, DOI 10.3816/CLM.2006.n.047
   Zavrski I, 2005, BIOCHEM BIOPH RES CO, V333, P200, DOI 10.1016/j.bbrc.2005.05.098
NR 43
TC 115
Z9 125
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0361 8609
EI 1096 8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD JAN
PY 2009
VL 84
IS 1
BP 6
EP 14
DI 10.1002/ajh.21310
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 391FT
UT WOS:000262219900003
PM 18980173
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Okuma, S
   Matsuda, Y
   Nariai, Y
   Karino, M
   Suzuki, R
   Kanno, T
AF Okuma, Satoe
   Matsuda, Yuhei
   Nariai, Yoshiki
   Karino, Masaaki
   Suzuki, Ritsuro
   Kanno, Takahiro
TI A Retrospective Observational Study of Risk Factors for
   Denosumab Related Osteonecrosis of the Jaw in Patients with Bone
   Metastases from Solid Cancers
SO CANCERS
LA English
DT Article
DE denosumab related osteonecrosis of the jaw; bone metastasis; denosumab;
   retrospective cohort study
ID MEDICATION RELATED OSTEONECROSIS; QUALITY OF LIFE; POSITION PAPER;
   BREAST CANCER; ZOLEDRONIC ACID; MANAGEMENT; DISEASE; PREVENTION; IMPACT;
   TUMORS
AB This single center retrospective observational study aimed to identify risk factors for developing denosumab related osteonecrosis of the jaw (DRONJ) in stage IV solid cancer patients with bone metastases. In total, 123 consecutive patients who had received 120 mg of denosumab every 4 weeks at least twice between July 2014 and October 2018 were included. We surveyed their demographics, medical history, blood test, underlying disease, and intraoral findings. Fourteen patients (11.4%) developed DRONJ within a mean denosumab administration period of 4 months (range: 2 52 months). Univariate analyses showed a statistically significant correlation between DRONJ and hormone therapy, chemotherapy/molecular target drug, apical periodontitis, periodontal disease, sex and body mass index. Multivariate analysis showed a statistically significant correlation between DRONJ and hormone therapy (odds ratio [OR], 22.07; 95% confidence interval [CI], 2.86 170.24), chemotherapy and/or molecular targeted therapy (OR, 18.61; 95% CI, 2.54 136.27), and apical periodontitis (OR, 22.75; 95% CI, 3.20 161.73). These findings imply that collaborative oral examinations by oral specialists may reduce the risk of development of DRONJ in patients treated with denosumab for bone metastases from solid cancers.
C1 [Okuma, Satoe; Matsuda, Yuhei; Nariai, Yoshiki; Karino, Masaaki; Kanno, Takahiro] Shimane Univ, Fac Med, Dept Oral & Maxillofacial Surg, Matsue, Shimane 6938501, Japan.
   [Nariai, Yoshiki] Matsue City Hosp, Dept Oral & Maxillofacial Surg, Matsue, Shimane 6908509, Japan.
   [Suzuki, Ritsuro] Shimane Univ Hosp, Dept Oncol, Hematol & Innovat Canc Ctr, Matsue, Shimane 6938501, Japan.
C3 Shimane University; Shimane University
RP Kanno, T (通讯作者)，Shimane Univ, Fac Med, Dept Oral & Maxillofacial Surg, Matsue, Shimane 6938501, Japan.
EM okuma125@med.shimane u.ac.jp; yuhei@med.shimane u.ac.jp;
   y.nariai@matsue cityhospital.jp; karino71@med.shimane u.ac.jp;
   rsuzuki@med.shimane u.ac.jp; tkanno@med.shimane u.ac.jp
OI Suzuki, Ritsuro/0000 0002 5974 7614; Matsuda, Yuhei/0000 0001 8922 3582
CR Anastasilakis AD, 2012, THER CLIN RISK MANAG, V8, P295, DOI 10.2147/TCRM.S24239
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Beaudoin C, 2016, OSTEOPOROSIS INT, V27, P2835, DOI 10.1007/s00198 016 3607 6
   Beth Tasdogan NH, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012432.pub2
   Boquete Castro A, 2016, CLIN ORAL IMPLAN RES, V27, P367, DOI 10.1111/clr.12556
   Brown Glaberman U, 2013, CLIN PHARMACOL ADV A, V5, P117, DOI 10.2147/CPAA.S30330
   Brown Glaberman U, 2012, BIOL TARGETS THER, V6, P89, DOI 10.2147/BTT.S20677
   Caldroney S, 2017, INT J ORAL MAX SURG, V46, P871, DOI 10.1016/j.ijom.2017.01.023
   Capocci M, 2017, CLIN TER, V168, pE253, DOI 10.7417/T.2017.2015
   Charopoulos I, 2011, EXPERT OPIN DRUG SAF, V10, P205, DOI 10.1517/14740338.2010.516249
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Coleman R, 2020, LANCET ONCOL, V21, P60, DOI 10.1016/S1470 2045(19)30687 4
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Cramer JA, 2008, VALUE HEALTH, V11, P44, DOI 10.1111/j.1524 4733.2007.00213.x
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   de Groot AF, 2018, CANCER TREAT REV, V62, P18, DOI 10.1016/j.ctrv.2017.10.010
   Di Fede O, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/2684924
   Diniz Freitas M, 2018, J CLIN PERIODONTOL, V45, P570, DOI 10.1111/jcpe.12882
   Egloff Juras C, 2018, J ORAL PATHOL MED, V47, P66, DOI 10.1111/jop.12646
   Gül G, 2016, CURR MED RES OPIN, V32, P133, DOI 10.1185/03007995.2015.1105795
   Hallmer F, 2017, OR SURG OR MED OR PA, V123, P436, DOI 10.1016/j.oooo.2016.11.011
   Hasegawa T, 2017, OSTEOPOROSIS INT, V28, P2465, DOI 10.1007/s00198 017 4063 7
   Haslbauer F, 2020, SUPPORT CARE CANCER, V28, P1855, DOI 10.1007/s00520 019 04988 7
   Karna H, 2018, ORAL ONCOL, V85, P15, DOI 10.1016/j.oraloncology.2018.08.003
   Khan AA, 2017, J CLIN DENSITOM, V20, P8, DOI 10.1016/j.jocd.2016.09.005
   Kiesel L, 2016, MATURITAS, V86, P10, DOI 10.1016/j.maturitas.2016.01.001
   Kim T, 2018, AM J PATHOL, V188, P2318, DOI 10.1016/j.ajpath.2018.06.019
   Maisonneuve P, 2017, ANN ONCOL, V28, P985, DOI 10.1093/annonc/mdx019
   Mhaskar R, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003188.pub3, 10.1002/14651858.CD003188.pub4]
   Narayanan Prasad, 2013, South Asian J Cancer, V2, P272, DOI 10.4103/2278 330X.119895
   Oteri G, 2018, J CRANIOFAC SURG, V29, P403, DOI 10.1097/SCS.0000000000004087
   Oteri G, 2018, DRUG SAFETY, V41, P111, DOI 10.1007/s40264 017 0582 6
   Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007
   Peer A, 2015, J DENT RES, V94, P252, DOI 10.1177/0022034514560768
   Pittman K, 2017, ASIA PAC J CLIN ONCO, V13, P266, DOI 10.1111/ajco.12517
   Ristow O, 2015, J CRANIO MAXILL SURG, V43, P290, DOI 10.1016/j.jcms.2014.11.014
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Shibahara T, 2019, JPN DENT SCI REV, V55, P71, DOI 10.1016/j.jdsr.2018.11.003
   Shinoda Y, 2019, CLIN EXP METASTAS, V36, P441, DOI 10.1007/s10585 019 09983 0
   Silva Fernández L, 2014, SEMIN ARTHRITIS RHEU, V43, P542, DOI 10.1016/j.semarthrit.2013.07.010
   Song Minju, 2019, Restor Dent Endod, V44, pe42, DOI 10.5395/rde.2019.44.e42
   Soutome S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201343
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tsuchiya K, 2019, CLIN INTERV AGING, V14, P1445, DOI 10.2147/CIA.S205971
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
   WAT WZM, 2016, DENT J BASEL, V4, pE38, DOI DOI 10.3390/dj4040038
   Yee AJ, 2018, FUTURE ONCOL, V14, P195, DOI 10.2217/fon 2017 0403
   Yoneda T, 2017, J BONE MINER METAB, V35, P6, DOI 10.1007/s00774 016 0810 7
   Yuan A, 2020, OR SURG OR MED OR PA, V129, P133, DOI 10.1016/j.oooo.2019.08.018
NR 50
TC 17
Z9 17
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD MAY
PY 2020
VL 12
IS 5
AR 1209
DI 10.3390/cancers12051209
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA LW6HT
UT WOS:000539246000150
PM 32408510
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhao, X
   Ai, JQ
   Mao, HP
   Gao, XM
AF Zhao, Xin
   Ai, Juqing
   Mao, Haoping
   Gao, Xiumei
TI Effects of Eclipta prostrata on gut microbiota of SAMp6 mice with
   osteoporosis
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
DE Gut microbiota; Eclipta prostrata; osteoporosis
ID BONE LOSS; DIFFERENTIATION; ABSORPTION; DIVERSITY; SEQUENCES; ALPHA;
   DIET; WNT
AB Purpose. Traditional Chinese medicine (TCM) has been extensively studied for its preventive and treatment properties toward osteoporosis (OP). Pharmacological studies have shown that TCM Eclipta prostrata induce anti OP effects. Considering the growing evidence demonstrating that gut microbiota (GM) is related to OP, we aimed to study the GM dependent function and mechanism of E. prostrata for preventing OP in mice.
   Methodology. Bone micro structure was obtained using micro computed tomography (micro CT) and bone relating factors were detected by molecular biological test. High throughput sequencing of the 16S rRNA V4 region was performed for GM diversity analysis. Growth effects of E. prostrata on potential targeted strains Lactobacillus and Lactococcus were investigated by in vitro bacterial assay. By feeding Lactobacillus and Lactococcus in mice, GM and bone condition were analysed.
   Results. Bone micro structure was significantly improved by E. prostrata with a potential mechanism of inhibiting osteoclast, increasing the number of osteoblasts and regulating the dynamic balance of bone absorption and formation. Sequencing results indicated that E. prostrata altered the bacterial community. The abundance of bacteria genera Lactobacillus and Lactococcus was markedly decreased in individuals with OP and positively correlated with high dose of E. prostrata. GM of the low dose E. prostrata fed group did not significantly differ from that of the chow fed OP group, which was consistent with bone structure test results. Moreover, E. prostrata could promote Lactobacillus and Lactococcus growth in vitro. GM was altered and bone condition was improved via bacterial feeding in vivo.
   Conclusion. Our findings suggested that E. prostrata might be a novel therapy for OP prevention by targeting GM.
C1 [Zhao, Xin; Ai, Juqing; Mao, Haoping; Gao, Xiumei] Tianjin Univ Tradit Chinese Med, Minist Educ, Key Lab Pharmacol Tradit Chinese Med Formulae, Beihua South Rd, Tianjin 301617, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine
RP Mao, HP; Gao, XM (通讯作者)，Tianjin Univ Tradit Chinese Med, Minist Educ, Key Lab Pharmacol Tradit Chinese Med Formulae, Beihua South Rd, Tianjin 301617, Peoples R China.
EM haoping_mao@126.com; gaoxiumei@tjutcm.edu.cn
RI XU, ZHAOFENG/KTT 3291 2024; mao, haoping/KIH 6773 2024; GAO,
   Xiumei/IWD 8697 2023
FU Program for National Natural Science Foundation of China [NSFC81630106,
   NSFC81803959]; Tianjin Municipal Education Commission [2017KJ142];
   Tianjin Natural Science Foundation [18JCQNJC83300]
FX This work was supported by Program for National Natural Science
   Foundation of China (NSFC81630106, NSFC81803959), Tianjin Municipal
   Education Commission research project (2017KJ142) and Tianjin Natural
   Science Foundation (18JCQNJC83300).
CR Ambika Sharma Ambika Sharma, 2011, Journal of Pharmacy Research, V4, P2888
   Anaraki PK, 2015, J BONE MINER RES, V30, P379, DOI 10.1002/jbmr.2350
   [Anonymous], ACTA PHARM SINICA
   Arya RK, 2015, SCI REP UK, V5, DOI 10.1038/srep18457
   Bokulich NA, 2013, NAT METHODS, V10, P57, DOI [10.1038/NMETH.2276, 10.1038/nmeth.2276]
   Britton RA, 2014, J CELL PHYSIOL, V229, P1822, DOI 10.1002/jcp.24636
   Chang CJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8489
   Collins FL, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.BAD 0015 2016
   D'Amelio P, 2017, CALCIFIED TISSUE INT, V9, P242
   Das B, 1992, CHEMINFORM, V23, P282
   Datta K, 2009, J ETHNOPHARMACOL, V124, P450, DOI 10.1016/j.jep.2009.05.023
   De Palma G, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf6397
   Deng YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136572
   DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006 05
   Dong YF, 2004, J CHINESE MED MAT, P8
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]
   Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381
   Fu SF, 2016, MENOPAUSE, V23, P311, DOI 10.1097/GME.0000000000000534
   [高明松 Gao Mingsong], 2012, [中国药房, China Pharmacy], V23, P2658
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gong L, 2016, ANN CLIN LAB SCI, V46, P65
   Han Lifeng, 2015, ScientificWorldJournal, V2015, P980890, DOI 10.1155/2015/980890
   Han Ying, 1998, Zhongguo Zhongyao Zazhi, V23, P680
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   García Vieyra MI, 2014, J MED FOOD, V17, P1247, DOI 10.1089/jmf.2013.0137
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kiernan J, 2017, STEM CELL TRANSL MED, V18, P1
   Kim HK, 2009, LIFE SCI, V84, P290, DOI 10.1016/j.lfs.2008.12.017
   Lansdown RV, 2017, ECLIPTA PROSTRATA IU
   Lee MK, 2009, PHYTOTHER RES, V23, P129, DOI 10.1002/ptr.2560
   Liu JY, 2013, J PHARM PHARMACOL, V65, P621, DOI 10.1111/j.2042 7158.2012.01608.x
   Liu XY, 2001, J 4 MILITARY MED U, P8
   Liu ZQ, 2014, N AM J MED SCI, V6, P160, DOI 10.4103/1947 2714.128482
   Lu S, 1978, GUANGXI J TRADIT CHI, P37
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507
   Manvar D, 2012, J ETHNOPHARMACOL, V144, P545, DOI 10.1016/j.jep.2012.09.036
   Maynard CL, 2012, NATURE, V489, P231, DOI 10.1038/nature11551
   Mccabe LR, 2013, J CELL PHYSIOL, V228, P1793, DOI 10.1002/jcp.24340
   Mulak A, 2015, WORLD J GASTROENTERO, V21, P10609, DOI 10.3748/wjg.v21.i37.10609
   Ohlsson C, 2015, TRENDS ENDOCRIN MET, V26, P69, DOI 10.1016/j.tem.2014.11.004
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   Roux C, 2018, NAT REV RHEUMATOL, V14, P67, DOI 10.1038/nrrheum.2017.218
   Ryu S, 2013, PLANTA MED, V79, P1031, DOI 10.1055/s 0032 1328767
   Sadeghi AA, 2014, PROBIOTICS ANTIMICRO, V6, P136, DOI 10.1007/s12602 014 9170 6
   Sarg T. M., 1981, SCI PHARM, V49, P262
   SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543
   Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541 09
   Shidara K, 2008, CALCIFIED TISSUE INT, V82, P278, DOI 10.1007/s00223 008 9127 4
   Sjogren K, 2012, BONE, V50, pS91, DOI [10.1016/j.bone.2012.02.272, 10.1002/jbmr.1588]
   Steed AL, 2017, SCIENCE, V357, P498, DOI 10.1126/science.aam5336
   Sun WN, 2016, ANN MICROBIOL, V66, P1293, DOI 10.1007/s13213 016 1223 5
   Szafranski SP, 2015, APPL ENVIRON MICROB, V81, P1047, DOI 10.1128/AEM.03534 14
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Wang JH, 2017, PEERJ, V5, DOI 10.7717/peerj.3450
   Wang JH, 2016, SCI REP UK, V6, DOI 10.1038/srep23827
   Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062 07
   Weaver CM, 2015, CURR OSTEOPOROS REP, V13, P125, DOI 10.1007/s11914 015 0257 0
   Xiao HH, 2014, J STEROID BIOCHEM, V143, P141, DOI 10.1016/j.jsbmb.2014.02.019
   Xu XY, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0527 0
   Yamashiro Y, 2017, ANN NUTR METAB, V71, P242, DOI 10.1159/000481627
   Yang B, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859 016 0992 y
   Young VB, 2017, BMJ BRIT MED J, V356, DOI 10.1136/bmj.j831
   [张宝红 Zhang Baohong], 2014, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V20, P1129
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhuang XY, 2010, J MATH MED, V23, P31
NR 67
TC 18
Z9 27
U1 2
U2 25
PU MICROBIOLOGY SOC
PI LONDON
PA 14 16 MEREDITH ST, LONDON, ENGLAND
SN 0022 2615
EI 1473 5644
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD MAR
PY 2019
VL 68
IS 3
BP 402
EP 416
DI 10.1099/jmm.0.000936
PG 15
WC Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology
GA HQ3XF
UT WOS:000462343100018
PM 30735116
OA Bronze
DA 2025 08 17
ER

PT J
AU Pandha, H
   Birchall, L
   Meyer, B
   Wilson, N
   Relph, K
   Anderson, C
   Harrington, K
AF Pandha, Hardev
   Birchall, Lindsay
   Meyer, Brendan
   Wilson, Natalie
   Relph, Kate
   Anderson, Christopher
   Harrington, Kevin
TI Antitumor effects of aminobisphosphonates on renal cell carcinoma cell
   lines
SO JOURNAL OF UROLOGY
LA English
DT Article
DE kidney; carcinoma, renal cell; neoplasm metastasis; bone and bones;
   diphosphonates
ID BREAST CANCER; OSTEOCLAST FORMATION; BISPHOSPHONATES ACT; POTENT
   INHIBITOR; ACID; GROWTH; PAMIDRONATE; OSTEOBLASTS
AB Purpose: Bisphosphonates are established as a supportive therapy for a number of malignancies that metastasize to bone. Previous reports have also suggested potent antitumor and anti angiogenic properties. We investigated the in vitro activity of the 2 aminobisphosphonates pamidronate (Faulding Pharmaceuticals, Paramus, New Jersey) and zoledronic acid (Novartis, Basel, Switzerland) on the growth and survival of the 3 renal cell carcinoma cell lines Caki 2, 769 P (American Type Culture Collection, Manassas, Virginia) and D69581.
   Materials and Methods: Cell lines were exposed to bisphosphonates in vitro and evaluated by MTS (3 (4,5 dimethylahiazol 2 yl) 5 (3 carboxymethoxyphenyl) 2 (4 sulfophenyl) 2H tetrazolium) assay and cell cycle analysis. Mechanisms of apoptotic cell death were investigated by ApoDIRECT assay (BioVision, Mountain View, California) and Kinetworks (TM) analysis.
   Results: Zoledronic acid was consistently more potent than pamidronate for inducing apoptotic cell death. Zoledronic acid was capable of overcoming resistance to pamidronate in 1 cell line. Although it was ultimately less potent, the inhibitory effects of pamidronate appeared earlier than those of zoledronic acid. The pro apoptotic effect of zoledronic acid was achieved through nonmitochondrial pathways and it was associated with the activation of caspase 6 and 3, and poly adenosine diphosphate ribosyltransferase polymerase cleavage. Furthermore, we observed a marked decrease in and intracellular distribution of MSH2, a protein involved in DNA mismatch repair, as well as evidence of a greater cellular response to zoledronic acid as increased expression of superoxide dismutase.
   Conclusions: These findings add further support to the clinical use of aminobisphosphonates, particularly zoledronic acid, in patients with renal cell carcinoma with disease metastatic to bone.
C1 Univ London, Dept Oncol, London SW17 0RE, England.
   Canc Res UK Ctr Cell & Mol Biol, Target Therapy Lab, Inst Canc Res, London, England.
C3 University of London; University of London; Institute of Cancer Research
     UK; Cancer Research UK; Royal Marsden NHS Foundation Trust
RP Pandha, H (通讯作者)，Univ London, Dept Oncol, Cranmer Terrace, London SW17 0RE, England.
EM hpandha@sghms.ac.uk
RI ; Relph, Kate/AAK 3131 2021; Harrington, Kevin/CAH 0578 2022
OI Relph, Kate/0000 0003 3648 7394; Meyer, Brendan/0009 0006 7489 4168; 
CR Amin D, 1996, ARZNEIMITTEL FORSCH, V46, P759
   Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   Derenne S, 1999, J BONE MINER RES, V14, P2048, DOI 10.1359/jbmr.1999.14.12.2048
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   GIUNCIUGLIO D, 1995, CANCER LETT, V97, P69, DOI 10.1016/0304 3835(95)03955 V
   Lee MV, 2001, CANCER RES, V61, P2602
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Nishikawa M, 1996, BONE, V18, P9, DOI 10.1016/8756 3282(95)00426 2
   Ritchie CK, 1997, ENDOCRINOLOGY, V138, P1145, DOI 10.1210/en.138.3.1145
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Shipman CM, 1998, LEUKEMIA LYMPHOMA, V32, P129, DOI 10.3109/10428199809059253
   Tamura H, 1996, SURG ONCOL, V5, P141, DOI 10.1016/S0960 7404(96)80014 4
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Teronen O, 1999, ANN NY ACAD SCI, V878, P453, DOI 10.1111/j.1749 6632.1999.tb07702.x
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
NR 20
TC 24
Z9 26
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0022 5347
EI 1527 3792
J9 J UROLOGY
JI J. Urol.
PD NOV
PY 2006
VL 176
IS 5
BP 2255
EP 2261
DI 10.1016/j.juro.2006.07.053
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 094XR
UT WOS:000241273100104
PM 17070308
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Hu, XT
   Xuan, H
   Du, HP
   Jiang, H
   Huang, JW
AF Hu, Xiaotong
   Xuan, Han
   Du, Huaping
   Jiang, Hao
   Huang, Jinwen
TI Down Regulation of CD9 by Methylation Decreased Bortezomib Sensitivity
   in Multiple Myeloma
SO PLOS ONE
LA English
DT Article
ID MEDIATED DRUG RESISTANCE; ADHESION KINASE PHOSPHORYLATION;
   DIPHTHERIA TOXIN RECEPTOR; BREAST CANCER; MONOCLONAL ANTIBODY; PROTEIN 1
   MRP 1/CD9; TUMOR SUPPRESSOR; COLON CANCER; BONE MARROW; CELL LINES
AB Bortezomib therapy has been proven successful for the treatment of relapsed and/or refractory multiple myeloma ( MM). However, both intrinsic and acquired resistance has already been observed. In this study, we explored the relationship between CD9 expression and bortezomib sensitivity in MM. We found that down regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma. CD9 expression obviously increased bortezomib sensitivity through inducing apoptosis, significantly inhibiting U266 cells' adhesion to HS 5 and primary bone marrow stromal cells, but increasing U266 cells' adhesion to fibronectin. CD9 expression also significantly inhibited U266 cell migration. The mechanisms may include: the endoplasmic reticulum stress pathway, cell adhesion related signaling pathway and osteoclast differentiation related signaling pathway. Combination therapy with de methylation reagent 5 Aza 2 deoxycytidine may prove useful to the development of novel strategies for the treatment of bortezomib resistant MM patients.
C1 [Hu, Xiaotong] Zhejiang Univ, Sir Run Run Shaw Hosp, Biomed Res Ctr, Hangzhou 310003, Zhejiang, Peoples R China.
   [Hu, Xiaotong] Key Lab Biotherapy Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China.
   [Xuan, Han; Du, Huaping; Jiang, Hao; Huang, Jinwen] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Hematol, Hangzhou 310003, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Hu, XT (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Biomed Res Ctr, Hangzhou 310003, Zhejiang, Peoples R China.
EM hxt_hangzhou@sina.com; huangjinwen@gmail.com
RI Hu, Xiao tong/K 5820 2019; huang, jw/KVY 9917 2024; Jiang,
   Hao/JNR 7658 2023
FU Zhejiang Provincial Natural Science Foundation of China [R2100213];
   National Natural Science Foundation of China [81372622]; Major Projects
   in Zhejiang Province [2012C13014 1]
FX This work was supported by grants from the Zhejiang Provincial Natural
   Science Foundation of China [No. R2100213], and the National Natural
   Science Foundation of China [No. 81372622] and Major Projects in
   Zhejiang Province [No. 2012C13014 1]. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anderson Kenneth C, 2004, Curr Hematol Rep, V3, P65
   Barrena S, 2005, LEUKEMIA, V19, P1376, DOI 10.1038/sj.leu.2403822
   BOUCHEIX C, 1983, FEBS LETT, V161, P289, DOI 10.1016/0014 5793(83)81027 8
   BOUCHEIX C, 1991, J BIOL CHEM, V266, P117
   Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933
   Buim MEC, 2010, ORAL ONCOL, V46, P166, DOI 10.1016/j.oraloncology.2009.11.009
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   De Bruyne E, 2008, CLIN CANCER RES, V14, P2918, DOI 10.1158/1078 0432.CCR 07 4489
   Drucker L, 2006, CARCINOGENESIS, V27, P197, DOI 10.1093/carcin/bgi209
   Fan J, 2010, MOL CARCINOGEN, V49, P85, DOI 10.1002/mc.20580
   Hashida H, 2003, BRIT J CANCER, V89, P158, DOI 10.1038/sj.bjc.6601015
   Hazlehurst LA, 2001, CANCER METAST REV, V20, P43, DOI 10.1023/A:1013156407224
   Heller G, 2008, CANCER RES, V68, P44, DOI 10.1158/0008 5472.CAN 07 2531
   Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Higashiyama M, 1997, INT J CANCER, V74, P205, DOI 10.1002/(SICI)1097 0215(19970422)74:2<205::AID IJC12>3.0.CO;2 C
   Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002 9440(10)65639 8
   IWAMOTO R, 1991, J BIOL CHEM, V266, P20463
   KERSEY JH, 1981, J EXP MED, V153, P726, DOI 10.1084/jem.153.3.726
   LANZA F, 1991, J BIOL CHEM, V266, P10638
   Li ZW, 2006, BLOOD REV, V20, P333, DOI 10.1016/j.blre.2005.08.003
   Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523
   MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389
   Miyake M, 1996, CANCER RES, V56, P1244
   Mori M, 1998, CLIN CANCER RES, V4, P1507
   Mujtaba T, 2011, DISCOV MED, V12, P471
   Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313
   Nagaharu K, 2011, AM J PATHOL, V178, P754, DOI 10.1016/j.ajpath.2010.10.015
   Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924
   Neri P, 2012, CURR CANCER DRUG TAR, V12, P776, DOI 10.2174/156800912802429337
   Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596
   PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133
   Richardson MM, 2011, CLIN EXP METASTAS, V28, P261, DOI 10.1007/s10585 010 9365 5
   Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117
   Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097 0215(19981023)79:5<509::AID IJC11>3.0.CO;2 X
   Su B, 2013, ONCOGENE, V32, P2016, DOI 10.1038/onc.2012.218
   Wang HX, 2011, BIOCHEM SOC T, V39, P547, DOI 10.1042/BST0390547
   Won WJ, 2002, J IMMUNOL, V168, P5605, DOI 10.4049/jimmunol.168.11.5605
   Yanamandra N, 2006, CLIN CANCER RES, V12, P591, DOI 10.1158/1078 0432.CCR 05 1792
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Zheng R, 2005, ONCOL RES, V15, P365, DOI 10.3727/096504005776449699
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
   Zöller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543
NR 43
TC 17
Z9 24
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 2
PY 2014
VL 9
IS 5
AR e95765
DI 10.1371/journal.pone.0095765
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AI1ZS
UT WOS:000336655700038
PM 24788635
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Ke, DS
   Ji, LM
   Wang, Y
   Fu, XM
   Chen, JY
   Wang, F
   Zhao, DB
   Xue, Y
   Lan, XH
   Hou, JM
AF Ke, Dianshan
   Ji, Lianmei
   Wang, Yu
   Fu, Xiaomin
   Chen, Jinyan
   Wang, Fan
   Zhao, Dongbao
   Xue, Ying
   Lan, Xuhua
   Hou, Jianming
TI JNK1 regulates RANKL induced osteoclastogenesis via activation of
   a novel Bcl 2 Beclin1 autophagy pathway
SO FASEB JOURNAL
LA English
DT Article
DE metabolic bone diseases; osteoclast precursors; p JNK1; p Bcl 2; LC3
ID INDUCED AUTOPHAGY; BECLIN 1; C JUN; POSTMENOPAUSAL WOMEN; UP REGULATION;
   BONE LOSS; APOPTOSIS; PROTEIN; LIGAND; CELLS
AB JNK1 plays an important role in osteoclastogenesis in response to the osteoclastogenic cytokine receptor activator for nuclear factor kappa B ligand (RANKL). JNK1 is widely accepted as an autophagy regulator under stress conditions. However, the role of JNK1 mediated autophagy in osteoclastogenesis remains largely unknown. In the current study, our data showed that JNK1 inhibition by a pharmacological inhibitor or RNA interference significantly reduced the autophagic response induced by RANKL in osteoclast precursors (OCPs) derived from bone marrow derived macrophages. Overexpression of the key autophagy protein Beclin1 rescued autophagy deficiency and osteoclastogenesis in the presence of a JNK inhibitor (SP600125). In contrast, JNK activator (anisomycin) induced autophagy was blocked by Beclin1 knockdown in OCPs. In addition, JNK1 inhibition increased apoptosis and blocked autophagy, whereas overexpression of Beclin1 reversed the enhanced apoptosis induced by JNK1 inhibition in OCPs. Furthermore, RANKL could induce the phosphorylation of Bcl 2, subsequently dissociating Beclin1 from the Bcl 2 Beclin1 complex, which could be blocked by JNK1 inhibition. Collectively, this study revealed that JNK1 regulated osteoclastogenesis by activating Bcl 2 Beclin1 autophagy signaling in addition to the classic c Jun/activator protein 1 pathway, which provided the first evidence for the contribution of JNK1 signaling to OCP autophagy and the autophagic mechanism underlying JNK1 regulated osteoclastogenesis. An important osteoclastogenesis regulating signaling pathway (JNK1 Bcl 2 Beclin1 autophagy activation) was identified, which provides novel potential targets for the clinical therapy of metabolic bone diseases. Ke, D., Ji, L., Wang, Y., Fu, X., Chen, J., Wang, F., Zhao, D., Xue, Y., Lan, X., Hou, J. JNK1 regulates RANKL induced osteoclastogenesis via activation of a novel Bcl 2 Beclin1 autophagy pathway.
C1 [Ke, Dianshan; Xue, Ying; Lan, Xuhua; Hou, Jianming] Fujian Med Univ, Shengli Clin Med Coll, Fuzhou, Fujian, Peoples R China.
   [Ke, Dianshan] Southern Med Univ, Affiliated Hosp 3, Acad Orthoped Guangdong Prov, Guangzhou, Guangdong, Peoples R China.
   [Ji, Lianmei; Zhao, Dongbao] Naval Med Univ, Changhai Hosp, Dept Rheumatol & Immunol, Shanghai, Peoples R China.
   [Wang, Yu] Chifeng Hosp, Dept Orthopaed, Chifeng, Peoples R China.
   [Fu, Xiaomin] Johns Hopkins Univ, Dept Pediat, Div Metab & Endocrinol, Baltimore, MD USA.
   [Chen, Jinyan; Wang, Fan] Fujian Acad Med Sci, Inst Immunol, Fuzhou, Fujian, Peoples R China.
   [Xue, Ying; Lan, Xuhua; Hou, Jianming] Fujian Prov Hosp, Dept Endocrinol, Key Lab Endocrinol, 134 Dong Jie Rd, Fuzhou 350001, Fujian, Peoples R China.
C3 Fujian Medical University; Southern Medical University   China; Naval
   Medical University; Johns Hopkins University; Fujian Provincial Hospital
RP Hou, JM (通讯作者)，Fujian Prov Hosp, Dept Endocrinol, Key Lab Endocrinol, 134 Dong Jie Rd, Fuzhou 350001, Fujian, Peoples R China.
EM hjm996@126.com
RI ; Chen, Jinyan/JJF 7875 2023
OI Ke, Dianshan/0000 0003 0260 7191; 
FU Fujian Provincial Hospital, Fujian Province [2017LHJJ05]; Fourth Round
   of the Fujian Provincial Joint Tackling Project between the Health and
   Education Joint Research Fund of National Health and the Family Planning
   Commission of China [wkj2016 2 02]; National Natural Science Foundation
   of China [81471607]; Sailing Fund from Fujian Medical University
   [2017XQ1131]
FX The authors thank Professor Lin Chen (Third Military Medical University;
   Chongqing, China) and Dr. Wenquan Liang (Southern Medical University)
   for providing support of experimental technique and Dr. Wang Zheng
   (Center for Cancer and Immunology Research, Children's National Medical
   Center; Washington, D. C., USA) for reviewing the article. This work was
   supported by high level hospital grants from Fujian Provincial Hospital,
   Fujian Province (2017LHJJ05), the Fourth Round of the Fujian Provincial
   Joint Tackling Project between the Health and Education Joint Research
   Fund of National Health and the Family Planning Commission of China
   (wkj2016 2 02), The National Natural Science Foundation of China
   (81471607), and The Sailing Fund from Fujian Medical University
   (2017XQ1131). The authors declare no conflicts of interest.
CR Alayev A, 2014, CELL CYCLE, V13, P371, DOI 10.4161/cc.27355
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Chen YQ, 2017, J CELL COMMUN SIGNAL, V11, P219, DOI 10.1007/s12079 016 0364 4
   Chung YH, 2014, J CELL PHYSIOL, V229, P1963, DOI 10.1002/jcp.24646
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dai QG, 2017, J BIOL CHEM, V292, P196, DOI 10.1074/jbc.M116.764761
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Hariharan N, 2011, ANTIOXID REDOX SIGN, V14, P2179, DOI 10.1089/ars.2010.3488
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844
   He WY, 2012, AUTOPHAGY, V8, P1811, DOI 10.4161/auto.22145
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   Hua F, 2011, J CELL SCI, V124, P3235, DOI 10.1242/jcs.082875
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Jin HO, 2016, SCI REP UK, V6, DOI 10.1038/srep28945
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Karakashev S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03031 3
   Ke DS, 2018, BIOCHEM BIOPH RES CO, V497, P890, DOI 10.1016/j.bbrc.2018.02.164
   Kikuchi Y, 2005, NEPHROL DIAL TRANSPL, V20, P1573, DOI 10.1093/ndt/gfh888
   Kim J, 2012, J CELL BIOCHEM, V113, P220, DOI 10.1002/jcb.23347
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Li RF, 2014, J HISTOCHEM CYTOCHEM, V62, P879, DOI 10.1369/0022155414551367
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Lin NY, 2013, ANN RHEUM DIS, V72, P761, DOI 10.1136/annrheumdis 2012 201671
   Liu WJ, 2014, AUTOPHAGY, V10, P243, DOI 10.4161/auto.27004
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Liu YW, 2016, SCI REP UK, V6, DOI 10.1038/srep33614
   Lu XM, 2009, BIOCHEM BIOPH RES CO, V390, P494, DOI 10.1016/j.bbrc.2009.09.123
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Ni ZH, 2014, FREE RADICAL BIO MED, V70, P194, DOI 10.1016/j.freeradbiomed.2014.02.012
   Ochotny N, 2013, J CELL BIOCHEM, V114, P2823, DOI 10.1002/jcb.24630
   Park H, 2015, ANTIOXID REDOX SIGN, V22, P63, DOI 10.1089/ars.2013.5748
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pattingre S, 2009, AUTOPHAGY, V5, P558, DOI 10.4161/auto.5.4.8390
   Sambandam Y, 2016, J CELL BIOCHEM, V117, P118, DOI 10.1002/jcb.25255
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Smink JJ, 2012, J MOL MED, V90, P25, DOI 10.1007/s00109 011 0823 6
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Tang H, 2009, HEPATOLOGY, V49, P60, DOI 10.1002/hep.22581
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Wang GY, 2017, INT J MED SCI, V14, P698, DOI 10.7150/ijms.19800
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Wu XJ, 2005, J BONE MINER RES, V20, P107, DOI 10.1359/JBMR.041022
   Wu YT, 2008, AUTOPHAGY, V4, P457, DOI 10.4161/auto.5662
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 56
TC 42
Z9 45
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD OCT
PY 2019
VL 33
IS 10
BP 11082
EP 11095
DI 10.1096/fj.201802597RR
PG 14
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA JC3GG
UT WOS:000489166300043
PM 31295022
DA 2025 08 17
ER

PT J
AU Fu, FY
   Huang, ZQ
   Ye, HL
   Tan, B
   Wang, RT
   Chen, WH
AF Fu, Fanyu
   Huang, Zeqing
   Ye, Hengli
   Tan, Biao
   Wang, Rongtian
   Chen, Weiheng
TI Mechanisms and Molecular Targets of the Tao Hong Si Wu Tang Formula for
   Treatment of Osteonecrosis of Femoral Head: A Network Pharmacology Study
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; NONTRAUMATIC OSTEONECROSIS; GENE; DECOCTION;
   BAICALEIN; PATHWAY; STRESS; RISK
AB The Tao Hong Si Wu Tang (THSWT) formula, a classic prescription of traditional Chinese medicine, has long been used for the treatment of osteonecrosis of femoral head (ONFH). However, its mechanisms of action and molecular targets are not comprehensively clear. In the present study, the Traditional Chinese Medicine System Pharmacology (TCMSP) database was employed to retrieve the active compounds of each herb included in the THSWT formula. After identifying the drug targets of active compounds and disease targets of ONFH, intersection analysis was conducted to screen out the shared targets. The protein protein network of the shared targets was built for further topological analysis. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis were then carried out. A gene pathway network was constructed to screen the core target genes. We identified 61 active compounds, 155 drug targets, and 5443 disease targets. However, intersection analysis only screened out 37 shared targets. Kaempferol, luteolin, and baicalein regulated the greatest number of targets associated with ONFH. The THSWT formula may regulate osteocyte function through specific biological processes, including responses to toxic substances and oxidative stress. The regulated pathways included the relaxin, focal adhesion, nuclear factor kappa B, toll like receptor, and AGE/RAGE signaling pathways. RELA, VEGFA, and STAT1 were the important target genes in the gene network associated with the THSWT formula for the treatment of ONFH. Therefore, the present study suggested that the THSWT formula has an action mechanism involving multiple compounds and network targets for the treatment of ONFH.
C1 [Fu, Fanyu; Ye, Hengli] Guizhou Univ Tradit Chinese Med, 50 Shidonglu, Guiyang 550002, Guizhou, Peoples R China.
   [Huang, Zeqing; Tan, Biao] China Acad Chinese Med Sci, Wangjing Hosp, Dept Orthopaed, 6 Zhonghuannanlu, Beijing 100102, Peoples R China.
   [Wang, Rongtian; Chen, Weiheng] Beijing Univ Chinese Med, Affiliated Hosp 3, Dept Orthopaed, 51 Xiaoguan St, Beijing 100029, Peoples R China.
C3 Guizhou University of Traditional Chinese Medicine; Wang Jing Hospital,
   CACMS; China Academy of Chinese Medical Sciences; Beijing University of
   Chinese Medicine
RP Wang, RT; Chen, WH (通讯作者)，Beijing Univ Chinese Med, Affiliated Hosp 3, Dept Orthopaed, 51 Xiaoguan St, Beijing 100029, Peoples R China.
EM yb_fufanyu@163.com; huangzeqing@yeah.net; dryehengli@163.com;
   tan520vip@sina.cn; wrt135@163.com; drchenweiheng@bucm.edu.cn
RI Huang, Zeqing/AAK 7095 2020; Fu, Fanyu/KRQ 2349 2024
OI ye, hengli/0000 0002 3367 8657; Fu, Fanyu/0000 0002 1841 7379; Tan,
   Biao/0000 0001 7262 9850
FU National Natural Science Foundation of China [81973888]; Research and
   Development Project of the G20 Program, Beijing Municipal Commission of
   Science and Technology [Z151100003815028]
FX This study was supported by grants from National Natural Science
   Foundation of China (No. 81973888) and the Research and Development
   Project of the G20 Program, Beijing Municipal Commission of Science and
   Technology (No. Z151100003815028).
CR Adhikary S, 2018, NUTRITION, V53, P64, DOI 10.1016/j.nut.2017.12.003
   Aziz N, 2018, J ETHNOPHARMACOL, V225, P342, DOI 10.1016/j.jep.2018.05.019
   Bao W., 2016, RHEUMATISM ARTHRITIS, V5, P24
   Chen JY, 2017, ORTHOP SURG, V9, P3, DOI 10.1111/os.12302
   Chen WH, 2015, ORTHOP SURG, V7, P200, DOI 10.1111/os.12193
   Clough E, 2016, METHODS MOL BIOL, V1418, P93, DOI 10.1007/978 1 4939 3578 9_5
   Cohen Rosenblum A, 2019, ORTHOP CLIN N AM, V50, P139, DOI 10.1016/j.ocl.2018.10.001
   Cui LQ, 2016, INT ORTHOP, V40, P267, DOI 10.1007/s00264 015 3061 7
   Ferlin A, 2010, BONE, V46, P504, DOI 10.1016/j.bone.2009.10.007
   Gardeniers J., 1993, ARCO NEWS LETT, V5, P79
   Guo X., 1992, P CHIN S AS OST FEM, P310
   Imran M, 2019, PHYTOTHER RES, V33, P263, DOI 10.1002/ptr.6227
   Kim MH, 2008, FOOD CHEM TOXICOL, V46, P3375, DOI 10.1016/j.fct.2008.08.016
   Kobayashi S, 2018, INT ORTHOP, V42, P1661, DOI 10.1007/s00264 018 3980 1
   Larry W., 2008, PRACTICAL EXTRACTION
   Lee JW, 2009, CYTOTECHNOLOGY, V61, P125, DOI 10.1007/s10616 010 9253 5
   Lee Yun Jong, 2019, J Bone Metab, V26, P13, DOI 10.11005/jbm.2019.26.1.13
   Li ZR, 2018, J ORTHOP TRANSL, V12, P36, DOI 10.1016/j.jot.2017.11.001
   Ma WL, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34352 4
   Ma XQ, 2018, EXP THER MED, V15, P182, DOI 10.3892/etm.2017.5381
   Mont MA, 2010, J BONE JOINT SURG AM, V92A, P2165, DOI 10.2106/JBJS.I.00575
   Plotkin LI, 2019, CURR OSTEOPOROS REP, V17, P16, DOI 10.1007/s11914 019 00499 w
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Shelef MA, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0464 6
   Soudy M, 2020, J PROTEOMICS, V213, DOI 10.1016/j.jprot.2019.103613
   Sowndhararajan K, 2017, BIOMED PHARMACOTHER, V95, P1021, DOI 10.1016/j.biopha.2017.08.135
   Tajima K, 2010, J ORTHOP RES, V28, P937, DOI 10.1002/jor.21086
   Tian L, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 18
   Tyml K, 2011, MICROCIRCULATION, V18, P152, DOI 10.1111/j.1549 8719.2010.00080.x
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Wang J, 2018, BIOMED RES INT UK, V2018, DOI 10.1155/2018/2790163
   Wang T, 2019, INT ORTHOP, V43, P519, DOI 10.1007/s00264 018 4172 8
   Wei QS, 2019, J ORTHOP TRANSL, V18, P65, DOI 10.1016/j.jot.2018.11.002
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Wu J, 2016, BIOSCI TRENDS, V10, P410, DOI 10.5582/bst.2016.01099
   Yamagishi SI, 2008, EXPERT OPIN INV DRUG, V17, P983, DOI [10.1517/13543784.17.7.983, 10.1517/13543784.17.7.983 ]
   Yu X, 2018, J ORTHOP SCI, V23, P356, DOI 10.1016/j.jos.2017.12.004
   Zalavras CG, 2014, J AM ACAD ORTHOP SUR, V22, P455, DOI 10.5435/JAAOS 22 07 455
   Zhang YQ, 2014, MOL BIOL REP, V41, P3135, DOI 10.1007/s11033 014 3173 y
   Zhao CL, 2014, J TRADIT CHIN MED, V34, P10
   Zhao DW, 2015, CHINESE MED J PEKING, V128, P2843, DOI 10.4103/0366 6999.168017
   Zhao De wei, 2012, Orthop Surg, V4, P125, DOI 10.1111/j.1757 7861.2012.00192.x
   Zhao DW, 2020, J ORTHOP TRANSL, V21, P100, DOI 10.1016/j.jot.2019.12.004
NR 43
TC 7
Z9 10
U1 4
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD SEP 9
PY 2020
VL 2020
AR 7130105
DI 10.1155/2020/7130105
PG 13
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA NV6DV
UT WOS:000574410600006
PM 32963569
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Chen, S
   Jin, J
   Xu, ZQ
   Han, HW
   Wu, L
   Li, ZW
AF Chen, Shuai
   Jin, Jie
   Xu, Ziqing
   Han, Huawei
   Wu, Lan
   Li, Zhiwei
TI Catalpol attenuates osteoporosis in ovariectomized rats through
   promoting osteoclast apoptosis via the Sirt6 ERα FasL axis
SO PHYTOMEDICINE
LA English
DT Article
DE Catalpol; Osteoclast; Apoptosis; Postmenopausal osteoporosis; Sirt6
ID ESTROGEN RECEPTOR ALPHA; BONE LOSS; OSTEOGENIC DIFFERENTIATION; FAS
   LIGAND; OSTEOBLASTS; CELLS; MICE
AB Background: Catalpol, a major active component of the Chinese herb Rehmannia glutinosa, possesses various pharmacological benefits, including anti inflammatory, antidiabetic, and antitumor properties. Recent studies have reported that catalpol can attenuate bone loss and enhance bone formation. Nevertheless, the molecular mechanisms underlying its effects on osteoporosis pathogenesis remain unclear.
   Purpose: We investigated whether catalpol had a protective effect against postmenopausal osteoporosis (PMOP) and explored its exact mechanism of action.
   Methods: Seventy two rats were randomly divided into six groups: sham, model, low dose catalpol (5 mg/kg/day), medium dose catalpol (10 mg/kg/day), high dose catalpol (20 mg/kg/day), and positive control (alendronate, 2.5 mg/kg). In this experiment, a ovariectomy was performed to establish a female rat model of PMOP. After 12 weeks of gavage, micro computed tomography (micro CT) and histochemical staining were performed to evaluate bone mass, bone microstructure and histological parameters. Furthermore, RAW 264.7 cells were induced by RANKL to form mature osteoclasts to investigate the effect of catalpol on osteoclast differentiation and apoptosis in vitro. Additionally, the osteoclast apoptosis related proteins of Sirt6, ER alpha, FasL, NFATc1, cleaved caspase 8, cleaved caspase 3, and Bax were assessed using western blotting. The expressions of NFATc1, Ctsk, Oscar, and Trap were quantified using RT qPCR. The apoptotic rate of the osteoclasts was determined using flow cytometry. Sirt6 knockdown was performed using siRNA gene silencing in experiments to investigate its role in catalpol mediated osteoclast apoptosis. The deacetylation of ER alpha in osteoclasts was tested via co immunoprecipitation.
   Results: Catalpol (10 and 20 mg/kg) and alendronate (2.5 mg/kg) could significantly improve bone mineral density (BMD) and microstructure and decrease osteoclast density in ovariectomized (OVX) rats. In addition, catalpol (10 and 20 mg/kg) upregulated the expression of Sirt6, ER alpha, FasL, cleaved caspase 8, cleaved caspase 3, Bax, and downregulated the expression of NFATc1, Ctsk, Oscar, Trap both in vivo and in vitro. Catalpol also promoted ER alpha deacetylation and stabilized ER alpha protein to enhance the expression of FasL. In addition, Sirt6 knockdown by siRNA prevented ER alpha deacetylation and eliminated catalpol mediated osteoclast apoptosis.
   Conclusions: The present study demonstrated that catalpol prevents estrogen deficiency induced osteoporosis by promoting osteoclast apoptosis via the Sirt6 ER alpha FasL axis. These findings revealed a novel molecular mechanism underpinning the impact of catalpol in the progression of osteoporosis and provided novel insights into the treatment of osteoporosis.
C1 [Chen, Shuai; Jin, Jie; Xu, Ziqing; Han, Huawei; Li, Zhiwei] Nanjing Univ Chinese Med, Affiliated Hosp 2, Dept Orthopaed, Nanjing, Peoples R China.
   [Wu, Lan] Nanjing Med Univ, Gynecol Hosp, Dept Obstet & Gynecol, Nanjing, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing Medical University
RP Li, ZW (通讯作者)，Nanjing Univ Chinese Med, Affiliated Hosp 2, Dept Orthopaed, Nanjing, Peoples R China.; Wu, L (通讯作者)，Nanjing Med Univ, Gynecol Hosp, Dept Obstet & Gynecol, Nanjing, Peoples R China.
EM 039216235@njucm.edu.cn; fsyy00797@njucm.edu.cn
RI Li, Zhiwei/LUY 2494 2024
FU Foundation of Jiangsu Provincial Science and Technology Plan Special
   Fund Key R & D Plan Social Development Project [BE2023787]; Elderly
   Health Research Project of Jiangsu Commission of Health [LKZ2022008];
   Natural Science Foundation of Nanjing University Of Chinese Medicine
   [XZR2021060]; Foundation of The Second Affiliated Hospital of Nanjing
   University of Chinese Medicine [SEZ202003]
FX This work was supported by the Foundation of Jiangsu Provincial Science
   and Technology Plan Special Fund Key R & D Plan Social Development
   Project (BE2023787) , the Elderly Health Research Project of Jiangsu
   Commission of Health (LKZ2022008) , the Natural Science Foundation of
   Nanjing University Of Chinese Medicine (XZR2021060) , and the Foundation
   of The Second Affiliated Hospital of Nanjing University of Chinese
   Medicine (SEZ202003) .
CR Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cai LX, 2019, IRAN J BASIC MED SCI, V22, P173, DOI 10.22038/IJBMS.2018.29498.7123
   Choi EM, 2012, INT IMMUNOPHARMACOL, V12, P139, DOI 10.1016/j.intimp.2011.11.003
   Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008 5472.CAN 04 2126
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Geng QH, 2019, INT J BIOL SCI, V15, P58, DOI 10.7150/ijbs.25783
   Gong W, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163964
   Gustafsson KL, 2018, J ENDOCRINOL, V238, P129, DOI 10.1530/JOE 18 0183
   Hairi HA, 2018, MOLECULES, V23, DOI 10.3390/molecules23071686
   Imai Y, 2011, EXPERT OPIN THER TAR, V15, P1143, DOI 10.1517/14728222.2011.600690
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kirk B, 2020, J CACHEXIA SARCOPENI, V11, P609, DOI 10.1002/jcsm.12567
   Komano Y, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2046
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Lai NN, 2015, AM J REPROD IMMUNOL, V74, P487, DOI 10.1111/aji.12423
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Li J, 2022, CLIMACTERIC, V25, P562, DOI 10.1080/13697137.2022.2102894
   Li MM, 2022, J ETHNOPHARMACOL, V285, DOI 10.1016/j.jep.2021.114820
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Liu LL, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00476 7
   Lombard DB, 2008, J INTERN MED, V263, P128, DOI 10.1111/j.1365 2796.2007.01902.x
   Ma RF, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/3218313
   Ma XQ, 2018, EXP THER MED, V15, P182, DOI 10.3892/etm.2017.5381
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   Meng JH, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113715
   Moon YJ, 2019, CELL DEATH DIFFER, V26, P2358, DOI 10.1038/s41418 019 0306 9
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raynaud Messina B, 2019, BONE, V127, P315, DOI 10.1016/j.bone.2019.06.023
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   Tokunaga T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030800
   Wan Jun Ming, 2019, Zhongguo Gu Shang, V32, P535, DOI 10.3969/j.issn.1003 0034.2019.06.010
   Yuan YF, 2022, AGING US, V14, P892, DOI 10.18632/aging.203848
   Zhu Y, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1143 y
NR 40
TC 11
Z9 13
U1 9
U2 36
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JAN
PY 2024
VL 123
AR 155262
DI 10.1016/j.phymed.2023.155262
EA DEC 2023
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA EK5V0
UT WOS:001138841700001
PM 38100921
DA 2025 08 17
ER

PT J
AU Liu, F
   Wang, XH
   Zheng, BW
   Li, DN
   Chen, C
   Lee, IS
   Zhong, JL
   Li, D
   Liu, Y
AF Liu, Fan
   Wang, Xiaohong
   Zheng, Bowen
   Li, Danni
   Chen, Cen
   Lee, In seop
   Zhong, Jialin
   Li, Duo
   Liu, Yi
TI USF2 enhances the osteogenic differentiation of PDLCs by promoting ATF4
   transcriptional activities
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE ATF4; MAPK signaling pathway; osteogenic differentiation; periodontal
   ligament cells; USF2
ID PERIODONTAL LIGAMENT; GENE EXPRESSION; UP REGULATION; REGENERATION;
   PROLIFERATION; MEMBRANES; CELLS; RUNX2
AB Objective Our study aimed to elucidate the regulatory molecules related to the osteogenic differentiation of periodontal ligament cells (PDLCs). Background Periodontal ligament cells are a favorable source for cell based therapy in periodontal bone engineering and regeneration due to their potential multilineage differentiation ability. However, the molecular mechanism and signaling pathways related to the osteogenic differentiation of PDLCs are still unclear. Methods Osteoblast specific protein expression levels were examined by ELISA in osteogenic induced PDLCs (induced PDLC group). A microarray assay and a bioinformatics analysis were carried out to reveal significantly expressed genes and the related pathways in induced PDLCs, and these findings were then confirmed by qRT PCR and a luciferase reporter assay. Finally, overexpressing and silencing gene systems were established to identify the specific transcriptional relationship and function of the target genes on the osteogenic differentiation of PDLCs. Results Osteogenically differentiated PDLCs with high levels of osteoblast specific proteins were established. The upstream stimulatory factor 2 (USF2) and activating transcription factor 4 (ATF4) mRNA levels were upregulated the most through the MAPK signaling pathway in the induced PDLC group. USF2 could bind to the transcriptional initiation region of ATF4 and regulate its transcriptional activities. Additionally, the overexpression of USF2 promoted osteoblast specific gene expression and the Alizarin red staining of PDLCs, while simultaneously overexpressing USF2 and silencing ATF4 reversed the favorable osteogenic effect of the induced PDLCs by reducing osteoblast specific gene expression and the Alizarin red staining level. Conclusions Our study demonstrated that USF2 could enhance the osteogenic differentiation of PDLCs by regulating ATF4 transcriptional activities, which provides a new strategy to utilize USF2 and ATF4 as potential target molecules for periodontal bone regeneration.
C1 [Liu, Fan; Zheng, Bowen; Li, Duo; Liu, Yi] China Med Univ, Sch Stomatol, Dept Orthodont, 117 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
   [Liu, Fan; Wang, Xiaohong] China Med Univ, Sch Fundamental Sci, Dept Tissue Engn, Shenyang, Liaoning, Peoples R China.
   [Li, Danni] China Med Univ, Dept Med Oncol, Hosp 1, Shenyang, Liaoning, Peoples R China.
   [Chen, Cen] Zhejiang Sci Tech Univ, Coll Life Sci, Hangzhou, Zhejiang, Peoples R China.
   [Lee, In seop] Yonsei Univ, Inst Nat Sci, Seoul, South Korea.
   [Zhong, Jialin] Guangzhou Med Univ, Guangzhou Inst Oral Dis, Key Lab Oral Med, Stomatol Hosp, Guangzhou, Guangdong, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University; Zhejiang Sci Tech University; Yonsei University; Guangzhou
   Medical University
RP Liu, Y (通讯作者)，China Med Univ, Sch Stomatol, Dept Orthodont, 117 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
EM Liuyi256@126.com
RI Zheng, Bowen/GRS 9430 2022; Zhang, Ziyue/KSL 8395 2024; LEE,
   Sunghee/HCH 4510 2022
OI Liu, Fan/0000 0002 3536 116X; 
FU National Nature Science Foundation of China [51502265, 81571832,
   81701033]; China Medical University [XZR20160017]; 2017 Discipline
   Promotion Project of China Medical University [3110117049]
FX National Nature Science Foundation of China, Grant/Award Number:
   51502265, 81571832 and 81701033; "New Teacher Project" from China
   Medical University, Grant/Award Number: XZR20160017; 2017 Discipline
   Promotion Project of China Medical University, Grant/Award Number:
   3110117049
CR Bottino MC, 2015, FRONT ORAL BIOL, V17, P90, DOI 10.1159/000381699
   Bottino MC, 2012, DENT MATER, V28, P703, DOI 10.1016/j.dental.2012.04.022
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Corre S, 2005, PIGM CELL RES, V18, P337, DOI 10.1111/j.1600 0749.2005.00262.x
   Coulombe P, 2007, BBA MOL CELL RES, V1773, P1376, DOI 10.1016/j.bbamcr.2006.11.001
   Datta P, 2013, J BIOMED NANOTECHNOL, V9, P870, DOI 10.1166/jbn.2013.1592
   Dorotheou D, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00075
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Kim HJ, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19824 x
   Kim SE, 2014, CARBOHYD POLYM, V99, P700, DOI 10.1016/j.carbpol.2013.08.053
   Kumari D, 2005, BIOCHEM J, V386, P297, DOI 10.1042/BJ20041124
   Larsson L, 2016, J DENT RES, V95, P255, DOI 10.1177/0022034515618887
   Lin KL, 2010, J BONE MINER RES, V25, P2489, DOI 10.1002/jbmr.159
   Liu LX, 2016, SIGNAL PROCESS IMAGE, V40, P1, DOI 10.1016/j.image.2015.10.005
   SAWADOGO M, 1988, J BIOL CHEM, V263, P11994
   Sun XL, 2018, J CELL MOL MED, V22, P5629, DOI 10.1111/jcmm.13837
   Tour G, 2012, J DENT RES, V91, P789, DOI 10.1177/0022034512452430
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Verdugo F, 2012, INT J PERIODONT REST, V32, P157
   Verlinden CRA, 2011, J ORAL MAXIL SURG, V69, P899, DOI 10.1016/j.joms.2010.11.026
   Wang WG, 2009, DEVELOPMENT, V136, P4143, DOI 10.1242/dev.043281
   Wutthisathapornchai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102730
   Yamashiro T, 2003, J DENT RES, V82, P172, DOI 10.1177/154405910308200305
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yu SB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007583
   Zhang XY, 2008, J CELL BIOCHEM, V105, P885, DOI 10.1002/jcb.21888
   Zhu MW, 2017, MOL MED REP, V16, P7459, DOI 10.3892/mmr.2017.7514
   Zhu YQ, 2005, DIABETES, V54, P1976, DOI 10.2337/diabetes.54.7.1976
NR 28
TC 20
Z9 22
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD JAN
PY 2020
VL 55
IS 1
BP 68
EP 76
DI 10.1111/jre.12689
EA AUG 2019
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA KK8IV
UT WOS:000482614000001
PM 31448831
DA 2025 08 17
ER

PT J
AU Omiya, T
   Hirose, J
   Hasegawa, T
   Amizuka, N
   Omata, Y
   Izawa, N
   Yasuda, H
   Kadono, Y
   Matsumoto, M
   Nakamura, M
   Miyamoto, T
   Tanaka, S
AF Omiya, Toshinobu
   Hirose, Jun
   Hasegawa, Tomoka
   Amizuka, Norio
   Omata, Yasunori
   Izawa, Naohiro
   Yasuda, Hisataka
   Kadono, Yuho
   Matsumoto, Morio
   Nakamura, Masaya
   Miyamoto, Takeshi
   Tanaka, Sakae
TI The effect of switching from teriparatide to anti RANKL antibody on
   cancellous and cortical bone in ovariectomized mice
SO BONE
LA English
DT Article
DE Osteoporosis; Bone mineral density; Bone formation; Cortical bone;
   Anti RANKL antibody; Teriparatide
ID RANDOMIZED CONTROLLED TRIAL; POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE;
   TARGETED DELETION; MINERAL DENSITY; OSTEOPOROSIS; DENOSUMAB;
   ALENDRONATE; EXTENSION; FRACTURES
AB We examined the effect of teriparatide, and switching from teriparatide to anti RANKL (receptor activator of nuclear factor kappa B ligand) monoclonal antibody, in ovariectomized mice. Twelve week old female C57BL/6 mice were ovariectomized or sham operated. Four weeks after surgery, ovariectomized mice were subjected to one of the following four treatments: phosphate buffered saline (PBS) for 8 weeks; teriparatide for 4 weeks followed by PBS for 4 weeks (PTH4W group); teriparatide for 8 weeks (PTH8W group); or teriparatide for 4 weeks followed by anti RANKL antibody (single subcutaneous injection of 5 mg/kg) (SWITCH group). Twelve weeks after the operation, bone mineral density was increased in PTH8W and SWITCH groups to broadly comparable levels, but these were significantly decreased in the PTH4W group after discontinuation of teriparatide. Histomorphometric analysis demonstrated that cancellous bone formation and resorption were profoundly suppressed in the SWITCH group. Bone formation was also suppressed on the endocortical surface of cortical bone but was maintained on the periosteal surface. Anti RANKL antibody suppressed osteoclast activity immediately after treatment, while bone formation was only gradually decreased. These results suggest that anti RANKL antibody maybe a therapeutic option after discontinuation of teriparatide therapy. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Omiya, Toshinobu; Hirose, Jun; Omata, Yasunori; Izawa, Naohiro; Kadono, Yuho; Tanaka, Sakae] Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, Hongo 7 3 1, Tokyo 1130033, Japan.
   [Hasegawa, Tomoka; Amizuka, Norio] Hokkaido Univ, Grad Sch Dent Med, Dept Dev Biol Hard Tissue, Kita Ku, Kita 13,Nishi 7, Sapporo, Hokkaido 0608586, Japan.
   [Yasuda, Hisataka] Oriental Yeast Co Ltd, Bioind Div, Tokyo 1748505, Japan.
   [Matsumoto, Morio; Nakamura, Masaya; Miyamoto, Takeshi] Keio Univ, Sch Med, Dept Orthoped Surg, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
C3 University of Tokyo; Hokkaido University; Oriental Yeast Co., Ltd.; Keio
   University
RP Tanaka, S (通讯作者)，7 3 1 Hongo,Bunkyo Ku, Tokyo 1130033, Japan.
EM TANAKAS ORT@h.u tokyo.ac.jp
RI Tanaka, Sakae/Y 3061 2019; Hirose, Jun/AAO 8474 2020; Nakamura,
   Masaya/K 4111 2013; Kadono, Yuho/AAO 2405 2020; Amizuka,
   Norio/G 1397 2012
OI Yasuda, Hisataka/0000 0003 3511 609X; Tanaka, Sakae/0000 0001 9210 9414;
   
FU Japan Society for the Promotion of Science [23592204]; Grants in Aid for
   Scientific Research [15H04963, 23592204] Funding Source: KAKEN
FX This work was supported in part by Grant in Aid for Scientific Research
   from Japan Society for the Promotion of Science (23592204). Pacific Edit
   reviewed the manuscript prior to submission.
CR ALBRIGHT F, 1947, ANN INTERN MED, V27, P861, DOI 10.7326/0003 4819 27 6 861
   BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Collette NM, 2012, P NATL ACAD SCI USA, V109, P14092, DOI 10.1073/pnas.1207188109
   Crandall CJ, 2014, ANN INTERN MED, V161, P711, DOI 10.7326/M14 0317
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Eastell R, 2009, J BONE MINER RES, V24, P726, DOI 10.1359/JBMR.081215
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Miller Paul D, 2008, Curr Osteoporos Rep, V6, P12, DOI 10.1007/s11914 008 0003 y
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ominsky M.S., 2016, J BONE MINER RES
   Ominsky MS, 2015, J BONE MINER RES, V30, P1280, DOI 10.1002/jbmr.2480
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   Tokuyama Naoto, 2015, Bone Rep, V2, P1, DOI 10.1016/j.bonr.2014.12.002
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
NR 26
TC 11
Z9 11
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2018
VL 107
BP 18
EP 26
DI 10.1016/j.bone.2017.10.021
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FT2XS
UT WOS:000423009900003
PM 29081377
DA 2025 08 17
ER

PT J
AU Tan, EM
   Li, L
   Indran, IR
   Chew, N
   Yong, EL
AF Tan, Ee Min
   Li, Lei
   Indran, Inthrani Raja
   Chew, Nicholas
   Yong, Eu Leong
TI TRAF6 Mediates Suppression of Osteoclastogenesis and Prevention of
   Ovariectomy Induced Bone Loss by a Novel Prenylflavonoid
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOCLASTS; CELL; TISSUE SIGNALINGTRANSCRIPTION FACTORS; OSTEOPOROSIS;
   ANIMAL MODELS; THERAPEUTICS
ID NF KAPPA B; VERTEBRAL FRACTURES; RECEPTOR ACTIVATOR; SIGNALING COMPLEX;
   IN VITRO; RANKL; DIFFERENTIATION; ICARITIN; EXPRESSION; RAW264.7
AB Given the limitations of current therapeutic options for postmenopausal osteoporosis, there is a need for alternatives with minimal adverse effects. In this study, we evaluated the effects of icaritin (ICT), a natural prenylflavonoid, on osteoclastogenesis both in vitro and in an ovariectomized (OVX) rat model and investigated its underlying molecular mechanism(s) of action. ICT inhibited osteoclast formation in two osteoclast precursor models, RAW 264.7 mouse monocyte cell line and human PBMC. ICT also inhibited sealing zone and resorption pit formation in a dose dependent manner. Mechanistically, ICT inhibited RANKL induced NF B and MAPK/AP 1 pathways to suppress gene expression of nuclear factor of activated T cells (NFAT)c1, the master transcription regulator of osteoclast differentiation. ICT, by inhibiting the TRAF6/c Src/PI3K pathway, suppressed NADPH oxidase 1 activation to attenuate intracellular ROS production and downregulate calcineurin phosphatase activity. As a result, NFATc1 nuclear translocation and activity was suppressed. Crucially, ICT promoted proteasomal degradation of TRAF6, the critical adaptor protein that transduces RANKL/RANK signaling, and the inhibitory effect of ICT on osteoclastogenesis was reversed by the proteasomal inhibitor MG 132. ICT administration inhibited OVX induced bone loss and resorption by suppressing osteoclast formation and activity. Consistent with cellular studies, ICT downregulated TRAF6 and NFATc1 protein expression in CD11b(+)/Gr 1( /low) osteoclast precursors isolated from OVX rats. Put together, we present novel findings that ICT, by downregulating TRAF6, coordinates inhibition of NF B, MAPK/AP 1, and ROS signaling pathways to reduce expression and activity of NFATc1. These results demonstrate the potential of ICT for treatment of postmenopausal osteoporosis and point to TRAF6 as a promising target for novel anti osteoporotic drugs. (c) 2017 American Society for Bone and Mineral Research.
C1 [Tan, Ee Min; Yong, Eu Leong] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Obstet & Gynaecol, Singapore, Singapore.
   [Li, Lei; Chew, Nicholas] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore.
   [Indran, Inthrani Raja] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore.
   [Chew, Nicholas] Natl Univ Singapore Hosp, Univ Med Cluster, Div Infect Dis, Singapore, Singapore.
C3 National University of Singapore; National University of Singapore;
   National University of Singapore; National University of Singapore
RP Chew, N (通讯作者)，Natl Univ Singapore, Dept Med, 1E Kent Ridge Rd,Tower Block Level 10, Singapore 119228, Singapore.; Yong, EL (通讯作者)，Natl Univ Singapore, Dept Obstet & Gynaecol, 1E Kent Ridge Rd,Tower Block Level 12, Singapore 119228, Singapore.
EM nicholas_chew@nuhs.edu.sg; eu_leong_yong@nuhs.edu.sg
OI Yong, Eu Leong/0000 0001 6511 770X
FU Singapore National Medical Research Council [R 174 000 137 275]
FX This work is supported by the grant R 174 000 137 275 from Singapore
   National Medical Research Council.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boudot C, 2010, BONE, V46, P1416, DOI 10.1016/j.bone.2010.01.383
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   Fechtenbaum J, 2005, OSTEOPOROSIS INT, V16, P2175, DOI 10.1007/s00198 005 2023 0
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Fukuda A, 2005, J BONE MINER RES, V20, P2245, DOI 10.1359/JBMR.050816
   Galal N, 2007, INT J MOL MED, V20, P97
   Goldberg SR, 2012, BONE, V51, P145, DOI 10.1016/j.bone.2012.04.018
   Gruenwald K, 2014, J BONE MINER RES, V29, P666, DOI 10.1002/jbmr.2075
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Karieb S, 2011, J CELL BIOCHEM, V112, P476, DOI 10.1002/jcb.22935
   Kennel KA, 2009, MAYO CLIN P, V84, P8
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kharkwal G, 2012, J MOL ENDOCRINOL, V48, P261, DOI 10.1530/JME 11 0061
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   La VD, 2009, J PERIODONTAL RES, V44, P193, DOI 10.1111/j.1600 0765.2008.01107.x
   Lai XQ, 2013, INT IMMUNOPHARMACOL, V16, P41, DOI 10.1016/j.intimp.2013.03.025
   Lee BH, 2016, ENDOCRINOLOGY, V157, P382, DOI 10.1210/en.2015 1733
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SH, 2014, INT J MOL SCI, V15, P10605, DOI 10.3390/ijms150610605
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li J, 2015, SCI REP UK, V5, DOI 10.1038/srep17605
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   McBerry C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038384
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Miller J, 2005, FEBS LETT, V579, P3224, DOI 10.1016/j.febslet.2005.03.042
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384 4394.2004
   Peng SL, 2013, BONE, V55, P230, DOI 10.1016/j.bone.2013.02.012
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Sasaki H, 2009, J MED INVESTIG, V56, P33, DOI 10.2152/jmi.56.33
   Schnell S, 2010, GERIATR ORTHOP SURG, V1, P6, DOI 10.1177/2151458510378105
   Soysa Niroshani Surangika, 2012, J Med Dent Sci, V59, P65
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Suh KS, 2013, FOOD CHEM TOXICOL, V62, P99, DOI 10.1016/j.fct.2013.08.047
   Sun F, 2015, CARCINOGENESIS, V36, P757, DOI 10.1093/carcin/bgv040
   Susa Mira, 2004, J Transl Med, V2, P6, DOI 10.1186/1479 5876 2 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tiong CT, 2012, CARCINOGENESIS, V33, P1089, DOI 10.1093/carcin/bgs110
   Tosteson ANA, 2001, OSTEOPOROSIS INT, V12, P1042, DOI 10.1007/s001980170015
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang WG, 2014, INT J MOL SCI, V15, P21913, DOI 10.3390/ijms151221913
   Wattel A, 2004, J CELL BIOCHEM, V92, P285, DOI 10.1002/jcb.20071
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Yao D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041264
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
   Zarzycka B, 2015, J CHEM INF MODEL, V55, P294, DOI 10.1021/ci500631e
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhang W, 2015, AM J CHINESE MED, V43, P1083, DOI 10.1142/S0192415X15500627
NR 58
TC 74
Z9 87
U1 1
U2 31
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2017
VL 32
IS 4
BP 846
EP 860
DI 10.1002/jbmr.3031
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ES6SE
UT WOS:000399678900021
PM 27813153
OA Bronze
DA 2025 08 17
ER

PT J
AU Su, J
   Liu, C
   Bai, HH
   Cong, W
   Tang, H
   Hu, HG
   Su, L
   He, SP
   Wang, Y
AF Su, Jia
   Liu, Chao
   Bai, Haohao
   Cong, Wei
   Tang, Hua
   Hu, Honggang
   Su, Li
   He, Shipeng
   Wang, Yong
TI Development of novel bone targeting peptide drug conjugate of
   13 aminomethyl 15 thiomatrine for osteoporosis therapy
SO RSC ADVANCES
LA English
DT Article
ID DELIVERY SYSTEM; CATHEPSIN K; MATRINE; BINDING; DEGRADATION; MARROW
AB 13 Aminomethyl 15 thiomatrine (M19) previously developed by our research group was a promising candidate for novel anti osteoporosis drug development. However, the application of M19 was limited by its unsatisfactory druggability including poor chemical stability, excessively broad pharmacological activity and some degree of cytotoxicity. To solve these problems, M19 based bone targeting and cathepsin K sensitive peptide drug conjugates (BTM19 1, BTM19 2 and BTM19 3) were developed to realize precise drug release in the bone tissue. Subsequent studies showed a rapid drug release process via cathepsin K digestion but sufficient stability over several hours in chymotrypsin. Besides, greatly improved chemical stability and strong hydroxyapatite binding affinity were also demonstrated. In biological evaluation studies, these PDCs showed less cytotoxicity and similar osteoclast inhibitory activity compared with the prototype drug. The optimal BTM19 2 could serve as a suitable candidate for further osteoporosis therapy research.
C1 [Su, Jia; Wang, Yong] Wenzhou Hosp Integrated Tradit Chinese & Western, Dept Orthopaed, Wenzhou, Zhejiang, Peoples R China.
   [Liu, Chao; Bai, Haohao; Cong, Wei; Tang, Hua; Hu, Honggang; Su, Li; He, Shipeng] Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China.
C3 Shanghai University
RP Wang, Y (通讯作者)，Wenzhou Hosp Integrated Tradit Chinese & Western, Dept Orthopaed, Wenzhou, Zhejiang, Peoples R China.; Su, L; He, SP (通讯作者)，Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China.
EM suli1020@shu.edu.cn; heshipeng@shu.edu.cn; wyhpi008@163.cam
RI Su, Li/JTV 1337 2023
OI Su, Li/0000 0002 4556 6863; Hu, Hong Gang/0000 0003 0577 3021
FU National Natural Science Foundation of China [91849129, 82003567];
   Shanghai Sailing Program [20YF1414100]
FX This work was supported by the National Natural Science Foundation of
   China (No. 91849129 and 82003567) and the sponsored by Shanghai Sailing
   Program (No. 20YF1414100).
CR Andersen TB, 2015, MOLECULES, V20, P6113, DOI 10.3390/molecules20046113
   Bonn D, 2004, LANCET, V363, P786, DOI 10.1016/S0140 6736(04)15717 6
   Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   Caselli G, 1997, J BONE MINER RES, V12, P972, DOI 10.1359/jbmr.1997.12.6.972
   Chang K, 2008, J NUCL CARDIOL, V15, P417, DOI 10.1016/j.nuclcard.2008.03.001
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.394
   Chipman SD, 2006, INT J NANOMED, V1, P375, DOI 10.2147/nano.2006.1.4.375
   Date K, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 91353 6
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Everts V, 2006, J BONE MINER RES, V21, P1399, DOI 10.1359/JBMR.060614
   Gao HY, 2012, J INFLAMM LOND, V9, DOI 10.1186/1476 9255 9 16
   Gao LM, 2011, J MED CHEM, V54, P869, DOI 10.1021/jm101325h
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Hochdörffer K, 2012, J MED CHEM, V55, P7502, DOI 10.1021/jm300493m
   Hsu CW, 2011, J BIOMED MATER RES A, V98A, P53, DOI 10.1002/jbm.a.33076
   Hu HG, 2010, BIOORG MED CHEM LETT, V20, P7537, DOI 10.1016/j.bmcl.2010.09.075
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Kim ES, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 57685 5
   Leamon CP, 2002, BIOCONJUGATE CHEM, V13, P1200, DOI 10.1021/bc0200430
   Li JZ, 2016, MOLECULES, V21, DOI 10.3390/molecules21050649
   Lorentzon M, 2019, J INTERN MED, V285, P381, DOI 10.1111/joim.12873
   Ma W, 2016, NANO TODAY, V11, P13, DOI 10.1016/j.nantod.2015.11.003
   Mahalingam D, 2016, BRIT J CANCER, V114, P986, DOI 10.1038/bjc.2016.72
   Matsumoto T, 2021, J BONE MINER METAB, V39, P91, DOI 10.1007/s00774 020 01153 7
   Nowakowski GS, 2004, STEM CELLS, V22, P1030, DOI 10.1634/stemcells.22 6 1030
   Page PCB, 2001, TETRAHEDRON, V57, P1837
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Salamanna F, 2021, TRENDS ENDOCRIN MET, V32, P672, DOI 10.1016/j.tem.2021.05.005
   Stone TA, 2017, BBA BIOMEMBRANES, V1859, P577, DOI 10.1016/j.bbamem.2016.08.013
   Su H, 2015, J CONTROL RELEASE, V219, P383, DOI 10.1016/j.jconrel.2015.09.056
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Willson TM, 1996, J MED CHEM, V39, P3030, DOI 10.1021/jm960205b
   Wu H, 2010, BONE, V47, pS413, DOI 10.1016/j.bone.2010.09.216
   Xu J, 2016, INT IMMUNOPHARMACOL, V36, P59, DOI 10.1016/j.intimp.2016.04.022
   Zhang B, 2011, EUR J PHARM SCI, V44, P573, DOI 10.1016/j.ejps.2011.09.020
   Zhou YJ, 2018, J CANCER, V9, P1357, DOI 10.7150/jca.22427
   Zou YM, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 6199 7
NR 39
TC 3
Z9 4
U1 4
U2 35
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046 2069
J9 RSC ADV
JI RSC Adv.
PD DEC 20
PY 2021
VL 12
IS 1
BP 221
EP 227
DI 10.1039/d1ra08136e
PG 7
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA XQ6KV
UT WOS:000731656000001
PM 35424502
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Larsson, S
   Fazzalari, NL
AF Larsson, Sune
   Fazzalari, Nicola L.
TI Anti osteoporosis therapy and fracture healing
SO ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY
LA English
DT Article
DE Anti osteoporotic treatment; Bisphosphonates; Teriparatide; Strontium;
   RANKL; Fracture healing
ID PARATHYROID HORMONE; STRONTIUM RANELATE; FEMORAL SHAFT; MECHANICAL
   STRENGTH; STRESS FRACTURES; CALLUS FORMATION; ZOLEDRONIC ACID;
   BONE FORMATION; RAT; ALENDRONATE
AB A number of medications are approved for treatment of osteoporosis. As mode of action usually is anti catabolic/anti resorptive or anabolic, it is of interest to know whether these drugs affect not only normal bone remodeling, but also fracture healing.
   The purpose of this paper is to give a short overview of the potential effect of various anti osteoporotic medication on fracture healing.
   A narrative literature review was performed to describe the current knowledge.
   Anti catabolic/anti resorptive drugs: for bisphosphonates, the most common class of drugs in this group, experimental studies have shown a larger and stronger callus and delayed remodeling but no evidence of delayed healing. A human monoclonal antibody to RANKL is another anti catabolic drug, with the only report to date showing enhanced healing in an animal model. Strontium ranelate is a drug where both anti catabolic and a weak anabolic effect have been proposed, with experimental data ranging from no effect to significant increase in both callus volume and strength. Anabolic drugs: PTH has demonstrated accelerated healing of various experimental fractures and of distal radius and pelvic fractures in humans. While the exact mechanism is not fully understood, PTH results in increased recruitment and differentiation of chondrocytes and enhancement of endochondral ossification. A monoclonal antibody to block sclerostin is another potential anabolic pathway, where animal data have shown increase in bone mass and strength. The potential effect on fracture healing is yet to be studied.
   There are still large gaps in the understanding of the potential effect of anti osteoporotic drugs on fracture healing, although based on present knowledge a recent or present fracture should not be considered as a contraindication to such treatment.
C1 [Larsson, Sune] Uppsala Univ, Dept Orthoped, SE 75185 Uppsala, Sweden.
   [Fazzalari, Nicola L.] Inst Med & Vet Sci, Bone & Joint Res Lab, Adelaide, SA 5000, Australia.
C3 Uppsala University; Institute Medical & Veterinary Science Australia
RP Larsson, S (通讯作者)，Uppsala Univ, Dept Orthoped, SE 75185 Uppsala, Sweden.
EM sune.larsson@surgsci.uu.se
CR Amanat N, 2007, J BONE MINER RES, V22, P867, DOI 10.1359/JBMR.070318
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Andreassen TT, 2001, ACTA ORTHOP SCAND, V72, P304, DOI 10.1080/00016470152846673
   Aspenberg P, 2010, ACTA ORTHOP, V81, P236, DOI 10.3109/17453671003761946
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Auer JA, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 72
   Bain SD, 2009, OSTEOPOROSIS INT, V20, P1417, DOI 10.1007/s00198 008 0815 8
   Brüel A, 2011, CALCIFIED TISSUE INT, V88, P142, DOI 10.1007/s00223 010 9439 z
   Buehler J, 2001, BONE, V29, P176, DOI 10.1016/S8756 3282(01)00484 7
   Cebesoy O, 2007, JOINT BONE SPINE, V74, P590, DOI 10.1016/j.jbspin.2007.01.034
   Chalidis B, 2007, EXPERT OPIN INV DRUG, V16, P441, DOI 10.1517/13543784.16.4.441
   Einhorn TA, 2011, CLIN CASES MINER BON, V8, P17
   Ellegaard M, 2010, CALCIFIED TISSUE INT, V87, P1, DOI 10.1007/s00223 010 9360 5
   Fleisch H, 2001, J BONE MINER RES, V16, P437, DOI 10.1359/jbmr.2001.16.3.437
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Giangregorio L, 2006, SEMIN ARTHRITIS RHEU, V35, P293, DOI 10.1016/j.semarthrit.2005.11.001
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Goldhahn J, 2010, BONE, V46, P267, DOI 10.1016/j.bone.2009.10.004
   Habermann B, 2010, CALCIFIED TISSUE INT, V86, P82, DOI 10.1007/s00223 009 9317 8
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   Holzer G, 1999, CLIN ORTHOP RELAT R, P258, DOI 10.1097/00003086 199909000 00033
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Koivukangas A, 2003, CLIN ORTHOP RELAT R, P268, DOI 10.1097/01.blo.0000053054.62337.e1
   Kwek EBK, 2008, INJURY, V39, P224, DOI 10.1016/j.injury.2007.08.036
   Li CY, 2001, J BONE MINER RES, V16, P429, DOI 10.1359/jbmr.2001.16.3.429
   Li JL, 1999, J BONE MINER RES, V14, P969, DOI 10.1359/jbmr.1999.14.6.969
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Little DG, 2001, INJURY, V32, pD14
   Little DG, 2001, J BONE JOINT SURG BR, V83B, P1069, DOI 10.1302/0301 620X.83B7.10542
   Ma YFL, 2011, ENDOCRINOLOGY, V152, P1767, DOI 10.1210/en.2010 1112
   Ma YL, 2011, BONE, V48, P972, DOI 10.1016/j.bone.2011.01.012
   Madsen JE, 1998, ACTA ORTHOP SCAND, V69, P532, DOI 10.3109/17453679808997793
   Manabe T, 2007, BONE, V40, P1475, DOI 10.1016/j.bone.2007.01.015
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Peichl P, 2011, J BONE JOINT SURG AM, V93A, P1583, DOI 10.2106/JBJS.J.01379
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Pountos I, 2008, INJURY, V39, P384, DOI 10.1016/j.injury.2007.10.035
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Schilcher J, 2009, ACTA ORTHOP, V80, P413, DOI 10.3109/17453670903139914
   Seeman E, 2007, OSTEOPOROSIS INT, V18, P711, DOI 10.1007/s00198 006 0294 8
   Skripitz R, 2000, ACTA ORTHOP SCAND, V71, P619, DOI 10.1080/000164700317362271
   Skripitz R, 2000, J BONE JOINT SURG BR, V82B, P138, DOI 10.1302/0301 620X.82B1.9729
   TARVAINEN R, 1994, BONE, V15, P701, DOI 10.1016/8756 3282(94)90320 4
   Verhaar H J J, 2009, Arch Gerontol Geriatr, V49, pe130, DOI 10.1016/j.archger.2008.11.004
NR 47
TC 48
Z9 49
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0936 8051
EI 1434 3916
J9 ARCH ORTHOP TRAUM SU
JI Arch. Orthop. Trauma Surg.
PD FEB
PY 2014
VL 134
IS 2
BP 291
EP 297
DI 10.1007/s00402 012 1558 8
PG 7
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 304EL
UT WOS:000330729700017
PM 22684739
DA 2025 08 17
ER

PT J
AU Gorojankina, T
   Hoch, L
   Faure, H
   Roudaut, H
   Traiffort, E
   Schoenfelder, A
   Girard, N
   Mann, A
   Manetti, F
   Solinas, A
   Petricci, E
   Taddei, M
   Ruat, M
AF Gorojankina, Tatiana
   Hoch, Lucile
   Faure, Helene
   Roudaut, Hermine
   Traiffort, Elisabeth
   Schoenfelder, Angele
   Girard, Nicolas
   Mann, Andre
   Manetti, Fabrizio
   Solinas, Antonio
   Petricci, Elena
   Taddei, Maurizio
   Ruat, Martial
TI Discovery, Molecular and Pharmacological Characterization of GSA 10, a
   Novel Small Molecule Positive Modulator of Smoothened
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID PROTEIN KINASE A; HEDGEHOG SIGNAL TRANSDUCTION; SONIC HEDGEHOG; PRIMARY
   CILIUM; PATHWAY; PHOSPHORYLATION; IDENTIFICATION; PROLIFERATION;
   ACYLTHIOUREA; TRAFFICKING
AB Activation of the Smoothened (Smo) receptor mediates Hedgehog (Hh) signaling. Hh inhibitors are in clinical trials for cancer, and small molecule Smo agonists may have therapeutic interests in regenerative medicine. Here, we have generated and validated a pharmacophoric model for Smo agonists and used this model for the virtual screening of a library of commercially available compounds. Among the 20 top scoring ligands, we have identified and characterized a novel quinolinecarboxamide derivative, propyl 4 (1 hexyl 4 hydroxy 2 oxo 1,2 dihydroquinoline 3 carboxamido) benzoate, (GSA 10), as a Smo agonist. GSA 10 fits to the agonist pharmacophoric model with two hydrogen bond acceptor groups and four hydrophobic regions. Using pharmacological, biochemical, and molecular approaches, we provide compelling evidence that GSA 10 acts at Smo to promote the differentiation of multipotent mesenchymal progenitor cells into osteoblasts. However, this molecule does not display the hallmarks of reference Smo agonists. Remarkably, GSA 10 does not recognize the classic bodipy cyclopamine binding site. Its effect on cell differentiation is inhibited by Smo antagonists, such as MRT 83, SANT 1, LDE225, and M25 in the nanomolar range, by GDC 0449 in the micromolar range, but not by cyclopamine and CUR61414. Thus, GSA 10 allows the pharmacological characterization of a novel Smo active site, which is notably not targeted to the primary cilium and strongly potentiated by forskolin and cholera toxin. GSA 10 belongs to a new class of Smo agonists and will be helpful for dissecting Hh mechanism of action, with important implications in physiology and in therapy.
C1 [Gorojankina, Tatiana; Hoch, Lucile; Faure, Helene; Roudaut, Hermine; Traiffort, Elisabeth; Ruat, Martial] CNRS, UPR 3294, Inst Neurobiol Alfred Fessard IFR2118, Lab Neurobiol & Dev, F 91198 Gif Sur Yvette, France.
   [Schoenfelder, Angele; Girard, Nicolas; Mann, Andre] Univ Strasbourg, CNRS, UMR 7200, Lab Innovat Therapeut, Illkirch Graffenstaden, France.
   [Manetti, Fabrizio; Solinas, Antonio; Petricci, Elena; Taddei, Maurizio] Univ Siena, Dipartimento Farmaco Chim Tecnol, I 53100 Siena, Italy.
C3 Universite Paris Saclay; Centre National de la Recherche Scientifique
   (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS  
   Institute of Chemistry (INC); Universites de Strasbourg Etablissements
   Associes; Universite de Strasbourg; University of Siena
RP Ruat, M (通讯作者)，CNRS, UPR 3294, Inst Neurobiol Alfred Fessard IFR2118, Lab Neurobiol & Dev,Signal Transduct & Dev Neurop, 1 Ave Terrasse, F 91198 Gif Sur Yvette, France.
EM ruat@inaf.cnrs gif.fr
RI ; Girard, Nicolas/B 3910 2017; Traiffort, Elisabeth/B 2042 2019;
   Petricci, Elena/AAB 9275 2022; Manetti, Fabrizio/Q 9412 2019; FAURE,
   Helene/E 4641 2010; Ruat, Martial/E 5544 2016
OI FAURE, Helene/0000 0002 0005 9331; PETRICCI, ELENA/0000 0002 9685 6342;
   Girard, Nicolas/0000 0003 4610 9872; Manetti,
   Fabrizio/0000 0002 9598 2339; Traiffort, Elisabeth/0000 0002 9645 6269;
   Hoch, Lucile/0000 0002 7264 9031; 
FU Ministero Istruzione Universita e Ricerca [2009RMW3Z5_006]; La Ligue
   contre le Cancer (comite des Yvelines et de l'Essonne); Neuropole de
   Recherche Francilien [248890]; La Ligue contre le Cancer; Asinex
FX This work was supported by Ministero Istruzione Universita e Ricerca
   within the PRIN 2009 Project [2009RMW3Z5_006 to M. T. and F. M.]; La
   Ligue contre le Cancer (comite des Yvelines et de l'Essonne to M. R.);
   The Neuropole de Recherche Francilien [doctoral fellowship 248890 to H.
   R.]; La Ligue contre le Cancer (to L. H.); and Asinex.
CR Altaba ARI, 1999, DEVELOPMENT, V126, P3205
   Angot E, 2008, STEM CELLS, V26, P2311, DOI 10.1634/stemcells.2008 0297
   Belgacem YH, 2011, P NATL ACAD SCI USA, V108, P4482, DOI 10.1073/pnas.1018217108
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   Bidet M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023834
   Bijlsma MF, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002798
   Brunton SA, 2009, BIOORG MED CHEM LETT, V19, P4308, DOI 10.1016/j.bmcl.2009.05.096
   Charron F, 2005, DEVELOPMENT, V132, P2251, DOI 10.1242/dev.01830
   Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899
   Chinchilla P, 2010, CELL CYCLE, V9, P570, DOI 10.4161/cc.9.3.10591
   Cobourne MT, 2001, J DENT RES, V80, P1974, DOI 10.1177/00220345010800110501
   Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117
   Corcoran RB, 2006, P NATL ACAD SCI USA, V103, P8408, DOI 10.1073/pnas.0602852103
   Dahmane N, 1999, DEVELOPMENT, V126, P3089
   Danjo T, 2011, J NEUROSCI, V31, P1919, DOI 10.1523/JNEUROSCI.5128 10.2011
   Dessole G, 2009, BIOORG MED CHEM LETT, V19, P4191, DOI 10.1016/j.bmcl.2009.05.112
   Epstein DJ, 1996, DEVELOPMENT, V122, P2885
   FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092 8674(95)90398 4
   Ferent J, 2013, J NEUROSCI, V33, P1759, DOI 10.1523/JNEUROSCI.3334 12.2013
   Frank Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475 4924 1 10
   Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774
   Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647
   Heine VM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002731
   Heretsch P, 2010, BIOORGAN MED CHEM, V18, P6613, DOI 10.1016/j.bmc.2010.07.038
   HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896 6273(95)90062 4
   Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007
   Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179
   Jönsson S, 2004, J MED CHEM, V47, P2075, DOI 10.1021/jm031044w
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Low JA, 2010, J CLIN ONCOL, V28, P5321, DOI 10.1200/JCO.2010.27.9943
   Manetti F, 2010, MOL PHARMACOL, V78, P658, DOI 10.1124/mol.110.065102
   Masdeu C, 2006, BIOCHEM BIOPH RES CO, V349, P471, DOI 10.1016/j.bbrc.2006.07.216
   Milenkovic L, 2009, J CELL BIOL, V187, P365, DOI 10.1083/jcb.200907126
   Nachtergaele S, 2012, NAT CHEM BIOL, V8, P211, DOI 10.1038/nchembio.765
   Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079
   Pan Y, 2009, DEV BIOL, V326, P177, DOI 10.1016/j.ydbio.2008.11.009
   Riobo NA, 2006, P NATL ACAD SCI USA, V103, P12607, DOI 10.1073/pnas.0600880103
   Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740
   Rohatgi R, 2009, P NATL ACAD SCI USA, V106, P3196, DOI 10.1073/pnas.0813373106
   Rominger CM, 2009, J PHARMACOL EXP THER, V329, P995, DOI 10.1124/jpet.109.152090
   Roudaut H, 2011, MOL PHARMACOL, V79, P453, DOI 10.1124/mol.110.069708
   Ruat M, 2012, DIFFERENTIATION, V83, pS97, DOI 10.1016/j.diff.2011.11.011
   Schulte G, 2010, PHARMACOL REV, V62, P632, DOI 10.1124/pr.110.002931
   Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713
   Sinha S, 2006, NAT CHEM BIOL, V2, P29, DOI 10.1038/nchembio753
   Solinas A, 2012, J MED CHEM, V55, P1559, DOI 10.1021/jm2013369
   Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008
   Tang JY, 2012, NEW ENGL J MED, V366, P2180, DOI 10.1056/NEJMoa1113538
   Teperino R, 2012, CELL, V151, P414, DOI 10.1016/j.cell.2012.09.021
   Tiecke E, 2007, DEV BIOL, V305, P312, DOI 10.1016/j.ydbio.2007.02.017
   Traiffort E, 2010, J NEUROCHEM, V113, P576, DOI 10.1111/j.1471 4159.2010.06642.x
   Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092 8674(00)80678 9
   Wang JB, 2010, P NATL ACAD SCI USA, V107, P9323, DOI 10.1073/pnas.0910712107
   Wang Y, 2009, P NATL ACAD SCI USA, V106, P2623, DOI 10.1073/pnas.0812110106
   Wilson CW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005182
   Wu X, 2002, J AM CHEM SOC, V124, P14520, DOI 10.1021/ja0283908
   Yam PT, 2009, NEURON, V62, P349, DOI 10.1016/j.neuron.2009.03.022
   Yang HB, 2009, J BIOL CHEM, V284, P20876, DOI 10.1074/jbc.M807648200
   Yao HHC, 2002, DEV BIOL, V246, P356, DOI 10.1006/dbio.2002.0663
   Zhao Y, 2007, NATURE, V450, P252, DOI 10.1038/nature06225
NR 60
TC 35
Z9 38
U1 0
U2 34
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0026 895X
EI 1521 0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD MAY
PY 2013
VL 83
IS 5
BP 1020
EP 1029
DI 10.1124/mol.112.084590
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 125XN
UT WOS:000317575500011
PM 23448715
DA 2025 08 17
ER

PT J
AU Hoare, SRJ
AF Hoare, Sam R. J.
TI Allosteric modulators of class B G protein coupled receptors
SO CURRENT NEUROPHARMACOLOGY
LA English
DT Article
DE allosteric; class B; G protein coupled receptor; secretin;
   corticotropin releasing factor; nonpeptide; glucagon like peptide;
   parathyroid hormone
ID CORTICOTROPIN RELEASING FACTOR; PARATHYROID HORMONE RECEPTOR; 1ST
   EXTRACELLULAR DOMAIN; N TERMINAL DOMAIN; LIGAND BINDING; INTERNATIONAL
   UNION; CRF1 RECEPTOR; PHARMACOLOGICAL CHARACTERIZATION;
   ANTAGONIST BINDING; MAJOR DEPRESSION
AB Class B GPCR's are activated by pcptide ligands, typically 30 40 amino acid residues, that are involved in major physiological functions such as glucose homeostasis (glucagon and glucagon like peptide 1), calcium homeostasis and bone turnover (parathyroid hormone and calcitonin), and control of the stress axis (corticotropin releasing factor). Peptide therapeutics have been developed targeting these receptors but development of nonpeptide ligands, enabling oral administration, has proved challenging. Allosteric modulation of these receptors provides a potential route to developing nonpeptide ligands that inhibit, activate, or potentiate activation of these receptors. Here the known mechanisms of allosteric modulators targeting Class B GPCR's arc reviewed, particularly nonpeptide antagonists of the corticotropin releasing factor 1 receptor and allosteric enhancers of the glucagon like peptide 1 receptor.'Also discussed is the potential for antagonist ligands to operate by competitive inhibition of one of the peptide binding sites, analogous to the Chamicre mechanism. These mechanisms are then used to discuss potential strategies and management of pharmacological complexity in the future development of allosteric modulators for Class B GPCR's.
C1 Neurocrine Biosci Inc, Dept Discovery Biol, San Diego, CA 92130 USA.
C3 Neurocrine Biosciences
RP Hoare, SRJ (通讯作者)，Neurocrine Biosci Inc, Dept Discovery Biol, 12790 El Camino Real, San Diego, CA 92130 USA.
EM shoare@neurocrine.com
RI Hoare, Sam/J 9018 2019
CR Al Sabah S, 2003, BRIT J PHARMACOL, V140, P339, DOI 10.1038/sj.bjp.0705453
   Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410
   Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469
   Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498
   Bringhurst FR., 1998, Williams Textbook of Endocrinology, V9th, P1155
   Cascieri MA, 1999, J BIOL CHEM, V274, P8694, DOI 10.1074/jbc.274.13.8694
   Castro M, 2005, P NATL ACAD SCI USA, V102, P16084, DOI 10.1073/pnas.0503942102
   Chen C, 2004, J MED CHEM, V47, P4787, DOI 10.1021/jm040058e
   Chen YL, 1997, J MED CHEM, V40, P1749, DOI 10.1021/jm960861b
   Christopoulos A, 1999, J PHARMACOL EXP THER, V289, P1220
   Couvineau A, 2006, ANN NY ACAD SCI, V1070, P205, DOI 10.1196/annals.1317.015
   Dautzenberg FM, 2001, PEPTIDES, V22, P753, DOI 10.1016/S0196 9781(01)00388 6
   de Laszlo SE, 1999, BIOORG MED CHEM LETT, V9, P641, DOI 10.1016/S0960 894X(99)00081 5
   de Maturana RL, 2003, J BIOL CHEM, V278, P10195, DOI 10.1074/jbc.M212147200
   Dean T, 2006, MOL ENDOCRINOL, V20, P931, DOI 10.1210/me.2005 0349
   DeFronzo RA, 2005, DIABETES CARE, V28, P1092, DOI 10.2337/diacare.28.5.1092
   Dong MQ, 2006, ANN NY ACAD SCI, V1070, P248, DOI 10.1196/annals.1317.023
   Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014 5793(97)00546 2
   Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140 6736(06)69705 5
   Drucker DJ, 2003, DIABETES CARE, V26, P2929, DOI 10.2337/diacare.26.10.2929
   Dunn AJ, 2004, ANN NY ACAD SCI, V1018, P25, DOI 10.1196/annals.1296.003
   Foord SM, 2002, BIOCHEM SOC T, V30, P473, DOI 10.1042/bst0300473
   Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820
   Gilligan PJ, 2000, BIOORGAN MED CHEM, V8, P181, DOI 10.1016/S0968 0896(99)00271 0
   Gilligan PJ, 2000, J MED CHEM, V43, P1641, DOI 10.1021/jm990590f
   Grace CRR, 2004, P NATL ACAD SCI USA, V101, P12836, DOI 10.1073/pnas.0404702101
   Green SA, 1996, J BIOL CHEM, V271, P24029, DOI 10.1074/jbc.271.39.24029
   Griebel G, 2002, J PHARMACOL EXP THER, V301, P333, DOI 10.1124/jpet.301.1.333
   Grigoriadis DE, 2005, EXPERT OPIN THER TAR, V9, P651, DOI 10.1517/14728222.9.4.651
   Gross RS, 2005, J MED CHEM, V48, P5780, DOI 10.1021/jm049085v
   Harmar AJ, 1998, PHARMACOL REV, V50, P265
   He LQ, 2000, J MED CHEM, V43, P449, DOI 10.1021/jm9904351
   Heinrichs SC, 2004, J PHARMACOL EXP THER, V311, P427, DOI 10.1124/jpet.103.052092
   Hoare SRJ, 2006, BIOCHEM PHARMACOL, V72, P244, DOI 10.1016/j.bcp.2006.04.007
   Hoare SRJ, 2005, DRUG DISCOV TODAY, V10, P417, DOI 10.1016/S1359 6446(05)03370 2
   Hoare SRJ, 2005, PEPTIDES, V26, P457, DOI 10.1016/j.peptides.2004.10.019
   Hoare SRJ, 2001, CURR PHARM DESIGN, V7, P689, DOI 10.2174/1381612013397825
   Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200
   Hoare SRJ, 2004, BIOCHEMISTRY US, V43, P3996, DOI 10.1021/bi036110a
   Hoare SRJ, 2003, MOL PHARMACOL, V63, P751, DOI 10.1124/mol.63.3.751
   Holsboer F, 2001, J AFFECT DISORDERS, V62, P77, DOI 10.1016/S0165 0327(00)00352 9
   HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394
   JACK D, 1991, BRIT J CLIN PHARMACO, V31, P501, DOI 10.1111/j.1365 2125.1991.tb05571.x
   Kehne J, 2002, CNS NEUROL DISORD DR, V1, P467, DOI 10.2174/1568007023339049
   Knudsen LB, 2007, P NATL ACAD SCI USA, V104, P937, DOI 10.1073/pnas.0605701104
   Kurukulasuriya R, 2003, CURR MED CHEM, V10, P123, DOI 10.2174/0929867033368556
   Laburthe M, 2002, RECEPTOR CHANNEL, V8, P137, DOI 10.1080/10606820290005191
   LAZARENO S, 1995, MOL PHARMACOL, V48, P362
   Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048
   Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670
   Mannstadt M, 1999, AM J PHYSIOL RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665
   Mayo KE, 2003, PHARMACOL REV, V55, P167, DOI 10.1124/pr.55.1.6
   McCarthy JR, 1999, CURR PHARM DESIGN, V5, P289
   MCDERMOTT MT, 1987, ENDOCR REV, V8, P377, DOI 10.1210/edrv 8 4 377
   Mesleh MF, 2007, J BIOL CHEM, V282, P6338, DOI 10.1074/jbc.M609816200
   Meyer SE, 2001, DEV PSYCHOPATHOL, V13, P565, DOI 10.1017/S095457940100308X
   Morfis M, 2003, TRENDS PHARMACOL SCI, V24, P596, DOI 10.1016/j.tips.2003.09.001
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nielsen SM, 2000, P NATL ACAD SCI USA, V97, P10277, DOI 10.1073/pnas.97.18.10277
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739
   Perrin MH, 2006, ANN NY ACAD SCI, V1070, P105, DOI 10.1196/annals.1317.065
   Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749 6632.1999.tb08687.x
   Perrin MH, 2003, J BIOL CHEM, V278, P15595, DOI 10.1074/jbc.M210476200
   Perrin MH, 1998, ENDOCRINOLOGY, V139, P566, DOI 10.1210/en.139.2.566
   Pham V, 2005, J BIOL CHEM, V280, P28610, DOI 10.1074/jbc.M503272200
   Potts JT, 2005, J ENDOCRINOL, V187, P311, DOI 10.1677/joe.1.06057
   Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233
   RIVIER J, 1984, SCIENCE, V224, P889, DOI 10.1126/science.6326264
   Rocha e Silva, 1969, Eur J Pharmacol, V6, P294
   RODBELL M, 1971, J BIOL CHEM, V246, P1861
   Rölz C, 1999, BIOCHEMISTRY US, V38, P6397, DOI 10.1021/bi9829276
   Rubin MR, 2003, ENDOCRIN METAB CLIN, V32, P285, DOI 10.1016/S0889 8529(02)00056 7
   Runge S, 2003, BRIT J PHARMACOL, V138, P787, DOI 10.1038/sj.bjp.0705120
   Salvatore CA, 2006, BIOCHEMISTRY US, V45, P1881, DOI 10.1021/bi052044w
   Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033
   Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619
   Shimizu M, 2000, J BIOL CHEM, V275, P19456, DOI 10.1074/jbc.M001596200
   Shimizu N, 2001, J BIOL CHEM, V276, P49003, DOI 10.1074/jbc.M106827200
   SILVA MRE, 1948, J PHARMACOL EXP THER, V93, P457
   Sloop KW, 2005, EXPERT OPIN THER TAR, V9, P593, DOI 10.1517/14728222.9.3.593
   Smagin GN, 2001, PEPTIDES, V22, P713, DOI 10.1016/S0196 9781(01)00384 9
   Steddon S, 2005, LANCET, V365, P2237, DOI 10.1016/S0140 6736(05)66782 7
   STEWART JM, 1976, GEN PHARMACOL, V7, P177, DOI 10.1016/0306 3623(76)90058 6
   STOCKTON JM, 1983, MOL PHARMACOL, V23, P551
   Taché Y, 2004, GUT, V53, P919, DOI 10.1136/gut.2003.036400
   Tibaduiza EC, 2001, J BIOL CHEM, V276, P37787
   TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo 93 6 1349
   Usdin TB, 2003, TRENDS ENDOCRIN MET, V14, P14, DOI 10.1016/S1043 2760(02)00002 4
   Webster EL, 1996, ENDOCRINOLOGY, V137, P5747, DOI 10.1210/en.137.12.5747
   Wysolmerski JJ, 1998, ANNU REV PHYSIOL, V60, P431, DOI 10.1146/annurev.physiol.60.1.431
   Zhang G, 2003, J PHARMACOL EXP THER, V305, P57, DOI 10.1124/jpet.102.046128
   Zobel AW, 2000, J PSYCHIATR RES, V34, P171, DOI 10.1016/S0022 3956(00)00016 9
NR 92
TC 34
Z9 37
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570 159X
EI 1875 6190
J9 CURR NEUROPHARMACOL
JI Curr. Neuropharmacol.
PD SEP
PY 2007
VL 5
IS 3
BP 168
EP 179
DI 10.2174/157015907781695928
PG 12
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 207EM
UT WOS:000249234400004
PM 19305799
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU O'Sullivan, S
   Naot, D
   Callon, KE
   Watson, M
   Gamble, GD
   Ladefoged, M
   Karsdal, MA
   Browett, P
   Cornish, J
   Grey, A
AF O'Sullivan, Susannah
   Naot, Dorit
   Callon, Karen E.
   Watson, Maureen
   Gamble, Greg D.
   Ladefoged, Marianne
   Karsdal, Morten A.
   Browett, Peter
   Cornish, Jillian
   Grey, Andrew
TI Imatinib Mesylate Does Not Increase Bone Volume In Vivo
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Imatinib; Bone; Bone formation; Osteoblast; Osteoclast
ID CHRONIC MYELOID LEUKEMIA; GASTROINTESTINAL STROMAL TUMORS; PATIENTS
   RECEIVING IMATINIB; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; CHRONIC
   MYELOGENOUS LEUKEMIA; COLONY STIMULATING FACTOR; PHASE II TRIAL;
   SECONDARY HYPERPARATHYROIDISM; RESORBING ACTIVITY; KINASE INHIBITOR
AB Imatinib mesylate is a tyrosine kinase inhibitor used in the management of disorders in which activation of c Abl, PDGFR, or c Kit signaling plays a critical role. In vitro, imatinib stimulates osteoblast differentiation, inhibits osteoblast proliferation and survival, and decreases osteoclast development. Patients treated with imatinib exhibit altered bone and mineral metabolism, with stable or increased bone mass. However, recovery from the underlying disease and/or weight gain might contribute to these effects. We therefore investigated the skeletal effects of imatinib in healthy rats. We evaluated the effects of imatinib on bone volume, markers of bone turnover, and bone histomorphometry in mature female rats treated for 5 weeks with either vehicle, imatinib 40 mg/kg daily, or imatinib 70 mg/kg daily. Compared to vehicle, imatinib reduced trabecular bone volume/tissue volume (mean [SD]: vehicle 26.4% [5.4%], low dose imatinib 24.8% [4.9%] [P = 0.5], high dose imatinib 21.1% [5.7%] [P = 0.05]), reduced osteoblast surface (mean [SD]: vehicle 12.8% [5.8%], low dose 6.8% [1.9%] [P < 0.01], high dose 7.8 [3.1%] [P < 0.05]), and reduced serum osteocalcin (mean change from baseline [95% CI]: vehicle  8.2 [ 26.6 to 10.2] ng/ml, low dose  79.7 [ 97.5 to  61.9] ng/ml [P < 0.01 vs. vehicle], high dose  66.0 [ 82.0 to  50.0] ng/ml [P < 0.05 vs. vehicle]). Imatinib did not affect biochemical or histomorphometric indices of bone resorption. These results suggest that, in healthy animals, treatment with imatinib does not increase bone mass and that the improvements in bone density reported in patients receiving imatinib may not be a direct effect of the drug.
C1 [O'Sullivan, Susannah; Naot, Dorit; Callon, Karen E.; Watson, Maureen; Gamble, Greg D.; Cornish, Jillian; Grey, Andrew] Univ Auckland, Dept Med, Auckland, New Zealand.
   [Browett, Peter] Univ Auckland, Dept Mol Med & Pathol, Auckland 1, New Zealand.
   [Ladefoged, Marianne; Karsdal, Morten A.] Nord Biosci, Herlev, Denmark.
C3 University of Auckland; University of Auckland; Nordic Bioscience
RP O'Sullivan, S (通讯作者)，Univ Auckland, Dept Med, Private Bag 92019, Auckland, New Zealand.
EM s.osullivan@auckland.ac.nz
OI Karsdal, Morten/0000 0001 5026 8740; Naot, Dorit/0000 0001 9498 2639;
   Gamble, Greg/0000 0003 0412 3203
FU Novartis; Health Research Council of New Zealand; Australia and New
   Zealand Bone and Mineral Society; University of Auckland; Auckland
   Medical Research Foundation; Danish research foundation (Den Danske
   forskningsfond)
FX P. Browett has received research funding and consulting fees from
   Novartis.This work was funded by the Health Research Council of New
   Zealand. S. O. is the recipient of postgraduate scholarships from the
   Australia and New Zealand Bone and Mineral Society and the University of
   Auckland and a postdoctoral fellowship from the Auckland Medical
   Research Foundation. A. G. is the recipient of a University of Auckland
   Early Career Excellence Award. The work at Nordic Bioscience was
   supported by the Danish research foundation (Den Danske forskningsfond).
   We thank Novartis for the gift of imatinib and Juerg Gasser (Novartis
   Institute for BioMedical Research, Basel Area, Switzerland) for his
   assistance in developing the study protocol.
CR Ando W, 2006, J BONE MINER METAB, V24, P274, DOI 10.1007/s00774 006 0684 1
   [Anonymous], [No title captured]
   Ault P, 2002, LEUKEMIA RES, V26, P881, DOI 10.1016/S0145 2126(02)00046 2
   Baccarani M, 2007, HAEMATOLOGICA, V92, P1173, DOI 10.3324/haematol.11420
   Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140
   Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403
   Breccia M, 2004, J CLIN ONCOL, V22, P4653, DOI 10.1200/JCO.2004.04.217
   Breccia M, 2005, Haematologica, V90 Suppl, pECR21
   Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217
   Day E, 2008, EUR J PHARMACOL, V599, P44, DOI 10.1016/j.ejphar.2008.10.014
   Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461
   Dewar AL, 2005, CELL CYCLE, V4, P851, DOI 10.4161/cc.4.7.1788
   Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood 2004 10 3967
   Dewar AL, 2006, BLOOD, V107, P4334, DOI 10.1182/blood 2005 09 3568
   Dib IE, 2006, EUR J PHARMACOL, V551, P27, DOI 10.1016/j.ejphar.2006.09.007
   Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867
   Eisenberg BL, 2009, J SURG ONCOL, V99, P42, DOI 10.1002/jso.21160
   FELDKAMP LA, 1984, J OPT SOC AM A, V1, P612, DOI 10.1364/JOSAA.1.000612
   Fierro F, 2007, CELL PROLIFERAT, V40, P355, DOI 10.1111/j.1365 2184.2007.00438.x
   Fitter S, 2008, BLOOD, V111, P2538, DOI 10.1182/blood 2007 07 104281
   Gallet M, 2006, APOPTOSIS, V11, P1909, DOI 10.1007/s10495 006 9507 z
   Gambacorti Passerini C, 2003, LANCET, V361, P1954, DOI 10.1016/S0140 6736(03)13554 4
   Grey A, 2006, NEW ENGL J MED, V355, P2494, DOI 10.1056/NEJMc062388
   Hägerkvist R, 2008, CLIN SCI, V114, P65, DOI 10.1042/CS20070122
   Hägerkvist R, 2007, FASEB J, V21, P618, DOI 10.1096/fj.06 6910com
   Hägerkvist R, 2006, CELL BIOL INT, V30, P1013, DOI 10.1016/j.cellbi.2006.08.006
   HAHN M, 1992, BONE, V13, P327, DOI 10.1016/8756 3282(92)90078 B
   Hatfield A, 2007, NAT MED, V13, P13, DOI 10.1038/nm0107 13a
   Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jönsson S, 2008, HAEMATOL HEMATOL J, V93, P1101, DOI 10.3324/haematol.12373
   Kerkelä R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446
   Klion AD, 2004, BLOOD, V103, P473, DOI 10.1182/blood 2003 08 2798
   Myllärniemi M, 1999, CARDIOVASC DRUG THER, V13, P159, DOI 10.1023/A:1007700629728
   O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457
   O'Sullivan S, 2007, J BONE MINER RES, V22, pS236
   O'Sullivan S, 2009, J CLIN ENDOCR METAB, V94, P1131, DOI 10.1210/jc.2008 2324
   Osorio S, 2007, AM J HEMATOL, V82, P394, DOI 10.1002/ajh.20778
   Pardanani A, 2004, LEUKEMIA RES, V28, pS47, DOI 10.1016/j.leukres.2003.10.006
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Parkkila S, 2009, BIOORG MED CHEM LETT, V19, P4102, DOI 10.1016/j.bmcl.2009.06.002
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   Reid IR, 2008, OSTEOPOROSIS INT, V19, P595, DOI 10.1007/s00198 007 0492 z
   Taylor JR, 2006, ONCOGENE, V25, P147, DOI 10.1038/sj.onc.1209007
   Tibullo D, 2009, EXP HEMATOL, V37, P461, DOI 10.1016/j.exphem.2008.12.008
   Tsao AS, 2003, CANCER, V98, P2483, DOI 10.1002/cncr.11812
   Vandyke K, 2010, BLOOD, V115, P766, DOI 10.1182/blood 2009 08 237404
   Veneri D, 2005, NEW ENGL J MED, V352, P1049, DOI 10.1056/NEJM200503103521023
   Verweij J, 2003, EUR J CANCER, V39, P2006, DOI 10.1016/S0959 8049(02)00836 5
   Waarsing JH, 2004, J BONE MINER RES, V19, P1640, DOI 10.1359/JBMR.040705
NR 50
TC 18
Z9 19
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JAN
PY 2011
VL 88
IS 1
BP 16
EP 22
DI 10.1007/s00223 010 9429 1
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 706ES
UT WOS:000286201200003
PM 20978751
DA 2025 08 17
ER

PT J
AU Li, XH
   Han, L
   Nookaew, I
   Mannen, E
   Silva, MJ
   Almeida, M
   Xiong, JH
AF Li, Xuehua
   Han, Li
   Nookaew, Intawat
   Mannen, Erin
   Silva, Matthew J.
   Almeida, Maria
   Xiong, Jinhu
TI Stimulation of Piezo1 by mechanical signals promotes bone anabolism
SO ELIFE
LA English
DT Article
ID KAPPA B LIGAND; GENE EXPRESSION; RECEPTOR ACTIVATOR; CALCIUM RESPONSE;
   MINERAL DENSITY; CELL LINE; CHANNELS; YAP/TAZ; MICE; DIFFERENTIATION
AB Mechanical loading, such as caused by exercise, stimulates bone formation by osteoblasts and increases bone strength, but the mechanisms are poorly understood. Osteocytes reside in bone matrix, sense changes in mechanical load, and produce signals that alter bone formation by osteoblasts. We report that the ion channel Piezo1 is required for changes in gene expression induced by fluid shear stress in cultured osteocytes and stimulation of Piezo1 by a small molecule agonist is sufficient to replicate the effects of fluid flow on osteocytes. Conditional deletion of Piezo1 in osteoblasts and osteocytes notably reduced bone mass and strength in mice. Conversely, administration of a Piezo1 agonist to adult mice increased bone mass, mimicking the effects of mechanical loading. These results demonstrate that Piezo1 is a mechanosensitive ion channel by which osteoblast lineage cells sense and respond to changes in mechanical load and identify a novel target for anabolic bone therapy.
C1 [Li, Xuehua; Nookaew, Intawat; Mannen, Erin; Almeida, Maria; Xiong, Jinhu] Univ Arkansas Med Sci, Ctr Musculoskeletal Dis Res, Little Rock, AR 72205 USA.
   [Li, Xuehua; Mannen, Erin; Almeida, Maria; Xiong, Jinhu] Univ Arkansas Med Sci, Dept Orthopaed Surg, Little Rock, AR 72205 USA.
   [Han, Li; Almeida, Maria] Univ Arkansas Med Sci, Div Endocrinol, Little Rock, AR 72205 USA.
   [Nookaew, Intawat] Univ Arkansas Med Sci, Dept Biomed Informat, Little Rock, AR 72205 USA.
   [Silva, Matthew J.] Washington Univ, Dept Orthopaed Surg, St Louis, MO 63110 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   Washington University (WUSTL)
RP Xiong, JH (通讯作者)，Univ Arkansas Med Sci, Ctr Musculoskeletal Dis Res, Little Rock, AR 72205 USA.; Xiong, JH (通讯作者)，Univ Arkansas Med Sci, Dept Orthopaed Surg, Little Rock, AR 72205 USA.
EM JXIONG@uams.edu
RI xiong, jinhu/E 1849 2011
OI Mannen, Erin/0000 0003 4441 5411; Almeida, Maria/0000 0002 6722 9200
FU National Institute of General Medical Sciences [P20GM125503]; National
   Institute of Arthritis and Musculoskeletal and Skin Diseases
   [R01AR56679, R01AR047867]; University of Arkansas for Medical Sciences
   Bone
FX National Institute of General Medical Sciences P20GM125503 Intawat
   Nookaew Erin Mannen Maria Almeida Jinhu Xiong National Institute of
   Arthritis and Musculoskeletal and Skin Diseases R01AR56679 Maria Almeida
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   R01AR047867 Matthew J Silva University of Arkansas for Medical Sciences
   Bone and Joint Initiative Jinhu Xiong The funders had no role in study
   design, data collection and interpretation, or the decision to submit
   the work for publication.
CR Abed E, 2009, MOL MEMBR BIOL, V26, P146, DOI 10.1080/09687680802612721
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Cahalan SM, 2015, ELIFE, V4, DOI 10.7554/eLife.07370
   Choi D, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125068
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Cox MP, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471 2105 11 485
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Fotiou E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9085
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Gudipaty SA, 2017, NATURE, V543, P118, DOI 10.1038/nature21407
   Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002
   Hinton PS, 2015, BONE, V79, P203, DOI 10.1016/j.bone.2015.06.008
   Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900
   HUNG CT, 1995, CLIN ORTHOP RELAT R, P256
   Ilkan Z, 2017, J BIOL CHEM, V292, P9204, DOI 10.1074/jbc.M116.766196
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Kato T, 2006, J APPL PHYSIOL, V100, P839, DOI 10.1152/japplphysiol.00666.2005
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kelly NH, 2016, BONE, V86, P22, DOI 10.1016/j.bone.2016.02.007
   Klein Nulend J, 2012, EUR CELLS MATER, V24, P278, DOI 10.22203/eCM.v024a20
   Klein Nulend J, 2013, BONE, V54, P182, DOI 10.1016/j.bone.2012.10.013
   Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200
   Lee Kristen L, 2015, Cilia, V4, P7, DOI 10.1186/s13630 015 0016 y
   Lewis KJ, 2017, P NATL ACAD SCI USA, V114, P11775, DOI 10.1073/pnas.1707863114
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp698, 10.1093/bioinformatics/btp352]
   Li J, 2010, J MUSCULOSKEL NEURON, V10, P180
   Li J, 2014, NATURE, V515, P279, DOI 10.1038/nature13701
   Li JL, 2002, J BONE MINER RES, V17, P1795, DOI 10.1359/jbmr.2002.17.10.1795
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lim J, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.49
   Litzenberger JB, 2010, CALCIFIED TISSUE INT, V86, P325, DOI 10.1007/s00223 010 9343 6
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Lu XL, 2012, BONE, V51, P466, DOI 10.1016/j.bone.2012.05.021
   Luther J, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau7137
   Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002
   Meakin LB, 2014, J BONE MINER RES, V29, P1859, DOI 10.1002/jbmr.2222
   Miyamoto T, 2014, J BIOL CHEM, V289, P16565, DOI 10.1074/jbc.M113.528638
   Mizoguchi F, 2008, J CELL PHYSIOL, V216, P47, DOI 10.1002/jcp.21374
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Murthy SE, 2017, NAT REV MOL CELL BIO, V18, P771, DOI 10.1038/nrm.2017.92
   Nakamura H, 2013, J BONE MINER RES, V28, P1457, DOI 10.1002/jbmr.1866
   Nguyen AM, 2013, BONE, V54, P196, DOI 10.1016/j.bone.2012.11.016
   Nookaew I, 2012, NUCLEIC ACIDS RES, V40, P10084, DOI 10.1093/nar/gks804
   O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Pathak MM, 2014, P NATL ACAD SCI USA, V111, P16148, DOI 10.1073/pnas.1409802111
   Rode B, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00429 3
   Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028
   Shao Y, 2005, DEV DYNAM, V234, P54, DOI 10.1002/dvdy.20517
   Sun D, 2018, J ORTHOP RES, V36, P682, DOI 10.1002/jor.23727
   Sun WJ, 2019, ELIFE, V8, DOI 10.7554/eLife.47454
   Suzuki T, 2013, BONE, V54, P172, DOI 10.1016/j.bone.2013.01.001
   Syeda R, 2016, CELL REP, V17, P1739, DOI 10.1016/j.celrep.2016.10.033
   Syeda R, 2015, ELIFE, V4, DOI 10.7554/eLife.07369
   Turner CH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.268pt3
   van der Eerden BCJ, 2013, BONE, V57, P443, DOI 10.1016/j.bone.2013.09.017
   Väremo L, 2013, NUCLEIC ACIDS RES, V41, P4378, DOI 10.1093/nar/gkt111
   Vlachopoulos D, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0543 4
   Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266
   Wang KC, 2016, P NATL ACAD SCI USA, V113, P11525, DOI 10.1073/pnas.1613121113
   Xin M, 2013, P NATL ACAD SCI USA, V110, P13839, DOI 10.1073/pnas.1313192110
   Xiong JH, 2018, BONE, V112, P1, DOI 10.1016/j.bone.2018.04.001
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Zhang TX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01712 z
   Zhao N, 2016, J BONE MINER RES, V31, P430, DOI 10.1002/jbmr.2690
NR 69
TC 253
Z9 292
U1 13
U2 107
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD OCT 7
PY 2019
VL 8
AR e49631
DI 10.7554/eLife.49631
PG 22
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA JC8VT
UT WOS:000489554900001
PM 31588901
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Van Welzen, BJ
   Thielen, MAJ
   Mudrikova, T
   Arends, JE
   Hoepelman, AIM
AF Van Welzen, Berend J.
   Thielen, Matheus A. J.
   Mudrikova, Tania
   Arends, Joop E.
   Hoepelman, Andy I. M.
TI Switching tenofovir disoproxil fumarate to tenofovir alafenamide results
   in a significant decline in parathyroid hormone levels: uncovering the
   mechanism of tenofovir disoproxil fumarate related bone loss?
SO AIDS
LA English
DT Article
ID HIV INFECTED PATIENTS; SECONDARY HYPERPARATHYROIDISM; MINERAL DENSITY;
   DOUBLE BLIND; EMTRICITABINE; ELVITEGRAVIR; COBICISTAT; SURGERY; THERAPY;
   REGIMEN
AB An increasing number of patients have been switched from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide because of its improved bone safety profile, although the pathophysiological mechanism is not fully understood. We show that serum parathyroid hormone levels drop significantly after the switch from TDF to tenofovir alafenamide. This observation supports the theories that TDF related bone loss is parathyroid hormone driven and that this effect is dose dependent.
C1 [Van Welzen, Berend J.; Thielen, Matheus A. J.; Mudrikova, Tania; Arends, Joop E.; Hoepelman, Andy I. M.] Univ Med Ctr Utrecht, Dept Internal Med & Infect Dis, Huispostnummer F 02 126,POB 85500, NL 3508 GA Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center
RP Van Welzen, BJ (通讯作者)，Univ Med Ctr Utrecht, Dept Internal Med & Infect Dis, Huispostnummer F 02 126,POB 85500, NL 3508 GA Utrecht, Netherlands.
EM b.j.vanwelzen@umcutrecht.nl
CR Arribas JR, 2017, JAIDS J ACQ IMM DEF, V75, P211, DOI [10.1097/QAI.0000000000001350, 10.1097/qai.0000000000001350]
   Cotter AG, 2014, AIDS, V28, P2051, DOI 10.1097/QAD.0000000000000353
   Daria P, 2011, AIDS, V25, P1430, DOI 10.1097/QAD.0b013e328349060e
   DeJesus E, 2018, AIDS RES HUM RETROV, V34, P337, DOI [10.1089/aid.2017.0203, 10.1089/AID.2017.0203]
   Goh SSL, 2018, OSTEOPOROSIS INT, V29, P595, DOI 10.1007/s00198 017 4305 8
   Grant PM, 2016, CURR OPIN HIV AIDS, V11, P326, DOI 10.1097/COH.0000000000000248
   Kooij KW, 2015, J INFECT DIS, V211, P539, DOI 10.1093/infdis/jiu499
   Lachâtre M, 2017, AIDS, V31, P451, DOI 10.1097/QAD.0000000000001348
   Martin A, 2009, CLIN INFECT DIS, V49, P1591, DOI 10.1086/644769
   Masiá M, 2012, AIDS RES HUM RETROV, V28, P242, DOI [10.1089/aid.2011.0052, 10.1089/AID.2011.0052]
   Mills A, 2015, JAIDS J ACQ IMM DEF, V69, P439, DOI 10.1097/QAI.0000000000000618
   Mingione A, 2018, BIOMED PHARMACOTHER, V97, P969, DOI 10.1016/j.biopha.2017.11.037
   Noe SC, 2018, CENTRAL EUROPE HORM, V50, P317, DOI DOI 10.1055/S 0043 125073
   Ray AS, 2016, ANTIVIR RES, V125, P63, DOI 10.1016/j.antiviral.2015.11.009
   Rubin MR, 2008, J CLIN ENDOCR METAB, V93, P3462, DOI 10.1210/jc.2007 1215
   Sax Paul E, 2014, J Acquir Immune Defic Syndr, V67, P52, DOI 10.1097/QAI.0000000000000225
   Sax PE, 2015, LANCET, V385, P2606, DOI 10.1016/S0140 6736(15)60616 X
   Stellbrink HJ, 2010, CLIN INFECT DIS, V51, P963, DOI 10.1086/656417
   Vestergaard P, 2000, BRIT MED J, V321, P598, DOI 10.1136/bmj.321.7261.598
NR 19
TC 9
Z9 9
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269 9370
EI 1473 5571
J9 AIDS
JI Aids
PD JUL 15
PY 2019
VL 33
IS 9
BP 1531
EP 1534
DI 10.1097/QAD.0000000000002238
PG 4
WC Immunology; Infectious Diseases; Virology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases; Virology
GA IQ4EP
UT WOS:000480704200015
PM 31021851
OA Bronze
DA 2025 08 17
ER

PT J
AU Himes, R
   Wezeman, FH
   Callaci, JJ
AF Himes, Ryan
   Wezeman, Frederick H.
   Callaci, John J.
TI Identification of novel bone specific molecular targets of binge alcohol
   and ibandronate by transcriptome analysis
SO ALCOHOLISM CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE binge alcohol; bone damage; transcriptome; Wnt signaling; integrin
   signaling
ID CHRONIC ETHANOL EXPOSURE; ACTIVELY GROWING RATS; MINERAL DENSITY;
   STRUCTURAL PROPERTIES; GENE EXPRESSION; CONSUMPTION; DRINKING;
   PROLIFERATION; OSTEOPOROSIS; PREVALENCE
AB Background: Our laboratory established that binge alcohol related bone damage is prevented by aminobisphosphonates, suggesting bone resorption increases following binge exposure. We examined the effects of binge alcohol and antiresorptive therapy on the relationship between bone damage and modulation of the vertebral transcriptome, in an attempt to determine how alcohol induced bone damage and its prevention modulate bone related biological pathways.
   Methods: Male Sprague Dawley rats were assigned to 1 of 6 treatment groups (n = 12/group). (C1) saline ip 3 d/wk for 1 week, (A1) binge alcohol, 3 g/kg, ip 3 d/wk for 1 week, (C4) saline ip, 3 d/wk for 4 weeks, (A4) binge alcohol, ip, 3 g/kg 3 d/wk for 4 weeks, (I4) ibandronate, saline ip 3 d/wk for 4 weeks, plus a single ip injection of ibandronate at 120 mu g/animal, and (AI4) binge alcohol plus ibandronate as above. After 1 or 4 weeks, adjacent lumbar vertebrae were assayed for bone damage or transcriptional changes.
   Results: Bone loss was not observed after 1 week of binge alcohol treatment. After 4 weeks, binge alcohol decreased vertebral BMD by 23% (p < 0.05) and compressive strength by 18% compared to saline controls (p < 0.05). Concurrent ibandronate prevented bone loss, increasing these parameters by 145 and 134% respectively compared to binge alcohol. (p < 0.05). Analysis of the vertebral transcriptome identified gene clusters specific for acute and chronic binge alcohol related bone damage. Acute binge alcohol modulated the expression of integrin signaling specific genes, while chronic binge alcohol modulated canonical Wnt signaling gene expression. Ibandronate normalized the expression of approximately 20% of the genes affected by chronic binge alcohol, allowing the identification of a unique subset of alcohol sensitive, ibandronate responsive genes.
   Conclusions: Identification of bone specific gene expression clusters associated with acute and chronic binge alcohol treatment allowed for the identification of cellular pathways affected by binge treatment with known involvement in bone remodeling (Integrin, Canonical Wnt signaling) not previously identified as alcohol sensitive. This data provides a basis for a plausible mechanistic explanation for the known detrimental effects of alcohol on bone formation and resorption.
C1 [Himes, Ryan; Wezeman, Frederick H.; Callaci, John J.] Loyola Univ, Stritch Sch Med, Dept Orthopaed Surg, Maywood, IL 60153 USA.
   [Himes, Ryan; Wezeman, Frederick H.; Callaci, John J.] Loyola Univ, Stritch Sch Med, Dept Rehabil, Maywood, IL 60153 USA.
   [Wezeman, Frederick H.; Callaci, John J.] Loyola Univ, Stritch Sch Med, Alcohol Res Program, Maywood, IL 60153 USA.
C3 Loyola University Chicago; Loyola University Chicago; Loyola University
   Chicago
RP Callaci, JJ (通讯作者)，Loyola Univ, Stritch Sch Med, Dept Orthopaed Surg & Rehabil, 2160 S 1st Ave, Maywood, IL 60153 USA.
EM jcallaci@lumc.edu
FU NIAAA NIH HHS [R01 AA016138] Funding Source: Medline
CR BARAN DT, 1980, AM J PHYSIOL, V238, pE507, DOI 10.1152/ajpendo.1980.238.6.E507
   Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594
   Bauss F, 2002, J RHEUMATOL, V29, P2200
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   BILKE DD, 1985, ANN INTERN MED, V103, P42
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Callaci JJ, 2006, ALCOHOL CLIN EXP RES, V30, P665, DOI 10.1111/j.1530 0277.2006.00078.x
   Callaci JJ, 2004, ALCOHOL CLIN EXP RES, V28, P182, DOI 10.1097/01.ALC.0000108661.41560.BF
   Cui QJ, 2006, J BONE JOINT SURG AM, V88A, P148, DOI 10.2106/JBJS.F.00534
   Dawson DA, 2004, J STUD ALCOHOL, V65, P477, DOI 10.15288/jsa.2004.65.477
   FARLEY JR, 1985, ARCH BIOCHEM BIOPHYS, V238, P305, DOI 10.1016/0003 9861(85)90169 9
   FELSON DT, 1995, AM J EPIDEMIOL, V142, P485, DOI 10.1093/oxfordjournals.aje.a117664
   FRIDAY KE, 1991, METABOLISM, V40, P562, DOI 10.1016/0026 0495(91)90044 W
   Genant HK, 2003, OSTEOPOROSIS INT, V14, pS43, DOI 10.1007/s00198 002 1348 1
   Glass DA, 2006, CURR TOP DEV BIOL, V73, P43, DOI 10.1016/S0070 2153(05)73002 7
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Grossberg PM, 2004, ANN FAM MED, V2, P474, DOI 10.1370/afm.122
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hogan HA, 1997, ALCOHOL CLIN EXP RES, V21, P809, DOI 10.1097/00000374 199708000 00008
   KHAN Z, 2007, MOL CELL BIOL   0813
   Kuntsche E, 2004, SOC SCI MED, V59, P113, DOI 10.1016/j.socscimed.2003.10.009
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mäkelä P, 2001, ADDICTION, V96, P1575
   McGinnis JM, 1999, P ASSOC AM PHYSICIAN, V111, P109, DOI 10.1046/j.1525 1381.1999.09256.x
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Miller JW, 2004, AM J PREV MED, V27, P197, DOI 10.1016/j.amepre.2004.05.004
   NATION JR, 1993, ALCOHOL, V10, P363, DOI 10.1016/0741 8329(93)90021 F
   Nishiguchi S, 2000, J BONE MINER METAB, V18, P317, DOI 10.1007/s007740070002
   Nishioka N, 2001, INT J ONCOL, V18, P317
   Penland S, 2001, ALCOHOL, V24, P45, DOI 10.1016/S0741 8329(01)00142 2
   Perrien DS, 2003, CYTOKINE, V23, P179, DOI 10.1016/S1043 4666(03)00225 4
   PREEDY VR, 1991, ALCOHOL ALCOHOLISM, V26, P191, DOI 10.1093/oxfordjournals.alcalc.a045100
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Sampson HW, 1996, ALCOHOL CLIN EXP RES, V20, P1375, DOI 10.1111/j.1530 0277.1996.tb01137.x
   Sampson HW, 1997, ALCOHOL CLIN EXP RES, V21, P352, DOI 10.1111/j.1530 0277.1997.tb03772.x
   Sampson HW, 1998, ALCOHOL CLIN EXP RES, V22, P2029, DOI 10.1111/j.1530 0277.1998.tb05912.x
   Sampson HW, 1999, ALCOHOL CLIN EXP RES, V23, P1228, DOI 10.1111/j.1530 0277.1999.tb04282.x
   Stallmach Andreas, 2004, Int J Colorectal Dis, V19, P308, DOI 10.1007/s00384 003 0554 4
   Steinke B, 1999, SPINE, V24, P1, DOI 10.1097/00007632 199901010 00002
   Teitelbaum SL, 2005, J CLIN ENDOCR METAB, V90, P2466, DOI 10.1210/jc.2005 0338
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Wahl EC, 2007, TOXICOL APPL PHARM, V220, P302, DOI 10.1016/j.taap.2007.02.011
   Wang YS, 2003, CLIN ORTHOP RELAT R, P213, DOI 10.1097/01.blo.0000063602.67412.83
   Wezeman FH, 1999, ALCOHOL CLIN EXP RES, V23, P1534, DOI 10.1111/j.1530 0277.1999.tb04678.x
   Wezeman FH, 2000, J BONE MINER RES, V15, P2033, DOI 10.1359/jbmr.2000.15.10.2033
   Wezeman FH, 2004, ALCOHOL CLIN EXP RES, V28, P1091, DOI 10.1097/01.ALC.0000130808.49262.F5
   Wezeman FH, 2007, BONE, V41, P639, DOI 10.1016/j.bone.2007.06.002
   Woerle S, 2007, ALCOHOL CLIN EXP RES, V31, P293, DOI 10.1111/j.1530 0277.2007.00305.x
   Zhang JA, 2002, J BONE MINER RES, V17, P1256, DOI 10.1359/jbmr.2002.17.7.1256
NR 50
TC 23
Z9 26
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0145 6008
EI 1530 0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUL
PY 2008
VL 32
IS 7
BP 1167
EP 1180
DI 10.1111/j.1530 0277.2008.00736.x
PG 14
WC Substance Abuse
WE Science Citation Index Expanded (SCI EXPANDED)
SC Substance Abuse
GA 326XK
UT WOS:000257692600008
PM 18537941
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Baek, A
   Baek, D
   Cho, Y
   Jo, S
   Kim, J
   Hong, Y
   Cho, S
   Kim, SH
   Cho, SR
AF Baek, Ahreum
   Baek, Dawoon
   Cho, Yoonhee
   Jo, Seongmoon
   Kim, Jinyoung
   Hong, Yoontaik
   Cho, Seunghee
   Kim, Sung Hoon
   Cho, Sung Rae
TI 3′ Sialyllactose alleviates bone loss by regulating bone homeostasis
SO COMMUNICATIONS BIOLOGY
LA English
DT Article
ID MESENCHYMAL STEM CELLS; POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; MILK;
   DIFFERENTIATION; GUIDELINES; DIAGNOSIS
AB Osteoporosis is a common skeletal disease that results in an increased risk of fractures. However, there is no definitive cure, warranting the development of potential therapeutic agents. 3 ' Sialyllactose (3 ' SL) in human milk regulates many biological functions. However, its effect on bone metabolism remains unknown. This study aimed to investigate the molecular mechanisms underlying the effect of 3 ' SL on bone homeostasis. Treatment of human bone marrow stromal cells (hBMSCs) with 3 ' SL enhanced osteogenic differentiation and inhibited adipogenic differentiation of hBMSCs. RNA sequencing showed that 3 ' SL enhanced laminin subunit gamma 2 expression and promoted osteogenic differentiation via the phosphatidylinositol 3 kinase/protein kinase B signaling pathway. Furthermore, 3 ' SL inhibited the receptor activator of nuclear factor kappa B ligand induced osteoclast differentiation of bone marrow derived macrophages through the nuclear factor kappa B and mitogen activated protein kinase signaling pathway, ameliorated osteoporosis in ovariectomized mice, and positively regulated bone remodeling. Our findings suggest 3 ' SL as a potential drug for osteoporosis.
   3 ' Sialyllactose alleviates the progression of osteoporosis by regulating bone homeostasis and may have a therapeutic effect as an anti osteoporosis agent.
C1 [Baek, Ahreum; Baek, Dawoon; Kim, Sung Hoon] Yonsei Univ, Wonju Coll Med, Dept Rehabil Med, Wonju, South Korea.
   [Baek, Ahreum; Baek, Dawoon; Jo, Seongmoon; Kim, Jinyoung; Cho, Sung Rae] Yonsei Univ, Grad Sch Med Sci, Dept Rehabil Med, Brain Korea 21 Project,Coll Med, Seoul, South Korea.
   [Cho, Yoonhee] Yonsei Univ, Coll Med, Dept Med, Seoul, South Korea.
   [Jo, Seongmoon; Cho, Sung Rae] Yonsei Univ, Coll Med, Res Inst Rehabil Med, Seoul, South Korea.
   [Kim, Jinyoung; Cho, Sung Rae] Yonsei Univ, Coll Med, Grad Program Biomed Engn, Seoul, South Korea.
   [Hong, Yoontaik; Cho, Seunghee] AAVATAR Therapeut, Gyeonggi Do, South Korea.
   [Cho, Sung Rae] Yonsei Univ, Coll Med, Rehabil Inst Neuromuscular Dis, Seoul, South Korea.
C3 Yonsei University; Yonsei University; Yonsei University Health System;
   Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System; Yonsei University; Yonsei University
   Health System; Yonsei University; Yonsei University Health System
RP Kim, SH (通讯作者)，Yonsei Univ, Wonju Coll Med, Dept Rehabil Med, Wonju, South Korea.; Cho, SR (通讯作者)，Yonsei Univ, Grad Sch Med Sci, Dept Rehabil Med, Brain Korea 21 Project,Coll Med, Seoul, South Korea.; Cho, SR (通讯作者)，Yonsei Univ, Coll Med, Res Inst Rehabil Med, Seoul, South Korea.; Cho, SR (通讯作者)，Yonsei Univ, Coll Med, Grad Program Biomed Engn, Seoul, South Korea.; Cho, SR (通讯作者)，Yonsei Univ, Coll Med, Rehabil Inst Neuromuscular Dis, Seoul, South Korea.
EM kimrehab@yonsei.ac.kr; srcho918@yuhs.ac
OI KIM, JIN YOUNG/0009 0002 6306 9905; HONG, YOON TAIK/0009 0002 6845 0596;
   Baek, Dawoon/0000 0002 3794 6153; Cho, Sung Rae/0000 0003 1429 2684;
   Baek, Ahreum/0000 0002 9926 8482
FU Korea Health Industry Development Institute (KHIDI); Medical
   Illustration & Design, part of the Medical Research Support Services of
   Yonsei University College of Medicine [NRF 2021R1F1A1062829,
   2021R1A6A3A01086535, 2022R1I1A1A01065666, 2022R1A2C1006374]; National
   Research Foundation; Korean Fund for Regenerative Medicine (KFRM)  
   Korea government (the Ministry of Science and ICT) [21A0202L1,
   21C0715L1]; Ministry of Health Welfare; Korean Health Technology R&D
   Project through the Korea Health Industry Development Institute (KHIDI)
   [HI21C1314, HI22C1588]; Ministry of Health & Welfare, Republic of Korea
FX We would like to thank Dr. Hyun Mo Ryoo (Seoul National University
   School of Dentistry, South Korea) for kindly providing Myc tagged mouse
   Runx2 plasmid and 6xOSE/OG2 reporter plasmids. We also thank Medical
   Illustration & Design, part of the Medical Research Support Services of
   Yonsei University College of Medicine, for assistance with the
   preparation of artwork and Editage (www.editage.com) for English
   language editing. This study was supported by the National Research
   Foundation (NRF 2021R1F1A1062829, 2021R1A6A3A01086535,
   2022R1I1A1A01065666, and 2022R1A2C1006374), the Korean Fund for
   Regenerative Medicine (KFRM) grant funded by the Korea government (the
   Ministry of Science and ICT, the Ministry of Health & Welfare; 21A0202L1
   and 21C0715L1), a grant from the Korean Health Technology R&D Project
   through the Korea Health Industry Development Institute (KHIDI), and the
   Ministry of Health & Welfare, Republic of Korea (HI21C1314 and
   HI22C1588).
CR Andreas NJ, 2015, EARLY HUM DEV, V91, P629, DOI 10.1016/j.earlhumdev.2015.08.013
   Baek A, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.609817
   Baek D, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03517 x
   Bagchi DP, 2019, JOVE J VIS EXP, DOI 10.3791/59499
   Baker N, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0225 8
   Bode L, 2012, GLYCOBIOLOGY, V22, P1147, DOI 10.1093/glycob/cws074
   Chen GL, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02004 y
   Chen JR, 2022, COMMUN BIOL, V5, DOI 10.1038/s42003 022 03544 0
   Dai QG, 2018, JOVE J VIS EXP, DOI 10.3791/56468
   Donovan SM, 2016, ANN NUTR METAB, V69, P42, DOI 10.1159/000452818
   Dou AX, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420 021 00608 8
   Eastell R, 2017, CLIN CASES MINER BON, V14, P173, DOI 10.11138/ccmbm/2017.14.1.173
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Fuhrer A, 2010, J EXP MED, V207, P2843, DOI 10.1084/jem.20101098
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hariri H, 2023, J BONE MINER RES, V38, P578, DOI 10.1002/jbmr.4778
   Harris JE, 2020, NAT METAB, V2, P678, DOI 10.1038/s42255 020 0223 8
   Hohenester E, 2019, ESSAYS BIOCHEM, V63, P285, DOI 10.1042/EBC20180075
   Ito Y, 2010, J CLIN INVEST, V120, P1981, DOI 10.1172/JCI39650
   Jeon J, 2018, J CELL MOL MED, V22, P57, DOI 10.1111/jcmm.13292
   Jo S, 2022, BIOELECTROCHEMISTRY, V147, DOI 10.1016/j.bioelechem.2022.108205
   Kang LJ, 2018, BRIT J PHARMACOL, V175, P4295, DOI 10.1111/bph.14486
   Kim SY, 2020, CLIN EXP PEDIATR, V63, P301, DOI 10.3345/cep.2020.00059
   Kim YJ, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23158674
   Kim YJ, 2022, LAB ANIM RES, V38, DOI 10.1186/s42826 022 00119 2
   Kim YK, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00656 0
   Kobza AO, 2020, IMMUNOTHERAPY UK, V12, P965, DOI 10.2217/imt 2020 0158
   Kocijan R, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115104
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee HM, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01714 7
   Li QW, 2020, J BONE MINER RES, V35, P1597, DOI 10.1002/jbmr.4015
   Liang Y, 2018, CELL DEATH DIFFER, V25, P1980, DOI 10.1038/s41418 018 0084 9
   Liu C, 2018, J CELL PHYSIOL, V233, P8971, DOI 10.1002/jcp.26841
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Martín Sosa S, 2003, J DAIRY SCI, V86, P52, DOI 10.3168/jds.S0022 0302(03)73583 8
   Merlotti D, 2019, EXPERT OPIN PHARMACO, V20, P805, DOI 10.1080/14656566.2019.1583208
   Meunier PJ, 1999, OSTEOPOROSIS INT, V10, P330, DOI 10.1007/s001980050236
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Perdijk O, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00094
   Perna VN, 2021, ENZYME MICROB TECH, V148, DOI 10.1016/j.enzmictec.2021.109829
   Porter A, 2017, SCI REP UK, V7, DOI 10.1038/srep42505
   Shoback D, 2020, J CLIN ENDOCR METAB, V105, P587, DOI 10.1210/clinem/dgaa048
   ten Bruggencate SJM, 2014, NUTR REV, V72, P377, DOI 10.1111/nure.12106
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Toda G, 2021, STAR PROTOC, V2, DOI 10.1016/j.xpro.2020.100246
   Udagawa N, 2003, J BONE MINER METAB, V21, P337, DOI 10.1007/s00774 003 0439 1
   Uehara N, 2017, LAB INVEST, V97, P1235, DOI 10.1038/labinvest.2017.55
   Ullah I, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150025
   Watts NB, 2021, ENDOCR PRACT, V27, P379, DOI 10.1016/j.eprac.2021.02.001
   Wicinski M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010266
   Wong CC, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03549 y
   Yang YS, 2020, MOL THER METH CLIN D, V17, P922, DOI 10.1016/j.omtm.2020.04.010
   Ye CY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1904 7
   Yoon H, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6176
   Zaheer S, 2015, EXPERT OPIN DRUG MET, V11, P461, DOI 10.1517/17425255.2015.1000860
   Zhang JY, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0391 3
   Zhang XN, 2023, ISCIENCE, V26, DOI 10.1016/j.isci.2023.106221
NR 58
TC 1
Z9 2
U1 2
U2 17
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2399 3642
J9 COMMUN BIOL
JI Commun. Biol.
PD JAN 19
PY 2024
VL 7
IS 1
AR 110
DI 10.1038/s42003 024 05796 4
PG 15
WC Biology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Science & Technology   Other
   Topics
GA FJ5H5
UT WOS:001145401300002
PM 38243116
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Spina, A
   Sorvillo, L
   Esposito, A
   Borgia, A
   Sapio, L
   Naviglio, S
AF Spina, Annamaria
   Sorvillo, Luca
   Esposito, Antonietta
   Borgia, Alessia
   Sapio, Luigi
   Naviglio, Silvio
TI Inorganic Phosphate as a Signaling Molecule: A Potential Strategy in
   Osteosarcoma Treatment
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Osteosarcoma; inorganic phosphate; combination antitumor therapy;
   naturally occurring molecules; cheap anticancer strategy
ID CELL CYCLE; VASCULAR CALCIFICATION; OSTEOCLAST DIFFERENTIATION;
   BONE RESORPTION; U2OS CELLS; CASPASE 3 ACTIVATION; ENHANCES SENSITIVITY;
   PROTEIN TRANSLATION; DIETARY PHOSPHORUS; PTH SECRETION
AB Inorganic phosphate (Pi) is an essential nutrient to living organisms. It plays a key role in diverse biological processes, including osteoblast differentiation and skeletal mineralization.
   Maintenance of proper Pi homeostasis is a critical event, as any deviation from that state can lead to several acute and chronic disease states and influence the ageing process and lifespan.
   Serum Pi level is maintained within a narrow range through a complex interplay between intestinal absorption, exchange with intracellular and bone storage pools, renal tubular reabsorption and depends mainly on the activity of Na/Pi cotransporters.
   Pi is abundant in the diet and intestinal absorption of Pi is efficient and minimally regulated. The kidney is a major regulator of Pi homeostasis and can increase or decrease its Pi reabsorptive capacity to accommodate Pi need.
   Relevantly, Pi is emerging as an important signalling molecule capable of modulating multiple cellular functions by altering signal transduction pathways, gene expression and protein abundance in many cell types. However, little is known about the initial events involving the detection of changes in serum or local Pi concentrations and the subsequent downstream regulation cascade.
   Previously, we provided evidence that Pi inhibits proliferation and aggressiveness of human osteosarcoma U2OS cells identifying adenylate cyclase, beta3 integrin, Rap1, ERK1/2 as proteins whose expression and function are relevantly affected in response to Pi.
   More recently, we demonstrated that Pi is capable also of inducing sensitization of osteosarcoma cells to doxorubicin in a p53 dependent manner and through a mechanism involving ERK1/2 down regulation.
   This review summarizes the current knowledge regarding inorganic phosphate as a novel specific signaling molecule in bone and other cell types in mammals and discuss how targeting Pi levels at local sites might represent a potential strategy for improving osteosarcoma therapy.
C1 [Spina, Annamaria; Sorvillo, Luca; Esposito, Antonietta; Borgia, Alessia; Sapio, Luigi; Naviglio, Silvio] Univ Naples 2, Dept Biochem Biophys & Gen Pathol, Sch Med, I 80138 Naples, Italy.
C3 Universita della Campania Vanvitelli
RP Naviglio, S (通讯作者)，Univ Naples 2, Dept Biochem Biophys & Gen Pathol, Sch Med, Via L De Crecchio 7, I 80138 Naples, Italy.
EM silvio.naviglio@unina2.it
RI ; Sapio, Luigi/AAH 6334 2021
OI SPINA, Annamaria/0000 0002 2877 3158; NAVIGLIO,
   Silvio/0000 0003 1771 8265
FU Italian Minister for Research
FX Research was supported by the following sources of funding: Italian
   Minister for Research (contract grant sponsor PRIN 2005, PRIN 2009).
CR Abdelalim EM, 2012, BIOCHEM BIOPH RES CO, V420, P605, DOI 10.1016/j.bbrc.2012.03.041
   Adams CS, 2001, J BIOL CHEM, V276, P20316, DOI 10.1074/jbc.M006492200
   Agner J, 2005, EXP CELL RES, V302, P162, DOI 10.1016/j.yexcr.2004.08.035
   Almaden Y, 1996, J BONE MINER RES, V11, P970
   Amatschek S, 2010, EUR J CLIN INVEST, V40, P552, DOI 10.1111/j.1365 2362.2010.02286.x
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Auesukaree C, 2004, J BIOL CHEM, V279, P17289, DOI 10.1074/jbc.M312202200
   BAYLINK DJ, 1993, J BONE MINER RES, V8, pS565
   Beck GR, 2003, J CELL BIOCHEM, V90, P234, DOI 10.1002/jcb.10622
   Beck GR, 2003, J BIOL CHEM, V278, P41921, DOI 10.1074/jbc.M304470200
   Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097 4644(19980201)68:2<269::AID JCB13>3.0.CO;2 A
   Beck GR, 2003, EXP CELL RES, V288, P288, DOI 10.1016/S0014 4827(03)00213 1
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   BELLOWS CG, 1992, BONE MINER, V17, P15, DOI 10.1016/0169 6009(92)90707 K
   Bergwitz C, 2011, ADV CHRONIC KIDNEY D, V18, P132, DOI 10.1053/j.ackd.2011.01.004
   Bergwitz C, 2010, ANNU REV MED, V61, P91, DOI 10.1146/annurev.med.051308.111339
   Berndt TJ, 2005, AM J PHYSIOL RENAL, V289, pF1170, DOI 10.1152/ajprenal.00072.2005
   BEVINGTON A, 1986, CLIN SCI, V71, P729, DOI 10.1042/cs0710729
   Bevington A., 1992, CLIN CHEM ENZYM COMM, V4, P235
   BIBER J, 1988, AM J PHYSIOL, V255, pC155, DOI 10.1152/ajpcell.1988.255.2.C155
   Bourgine A, 2011, ARCH ORAL BIOL, V56, P977, DOI 10.1016/j.archoralbio.2011.03.001
   Bringhurst FR., 2006, Endocrinology, P805
   BRUIN WJ, 1975, ENDOCRINOLOGY, V96, P394, DOI 10.1210/endo 96 2 394
   Bugg NC, 1998, ANAESTHESIA, V53, P895, DOI 10.1046/j.1365 2044.1998.00463.x
   Burchell A, 1996, KIDNEY INT, V49, P953, DOI 10.1038/ki.1996.134
   Camalier CE, 2010, CANCER PREV RES, V3, P359, DOI 10.1158/1940 6207.CAPR 09 0068
   Carpenter TO, 2012, J BONE MINER METAB, V30, P1, DOI 10.1007/s00774 011 0340 2
   Chang SH, 2006, AM J RESP CELL MOL, V35, P528, DOI 10.1165/rcmb.2005 0477OC
   Chiosi E, 2012, ONCOL REP IN PRESS
   Chiosi E, 2007, J INTERF CYTOK RES, V27, P589, DOI 10.1089/jir.2006.0161
   Chou Alexander J, 2008, Paediatr Drugs, V10, P315, DOI 10.2165/00148581 200810050 00005
   Conradas KA, 2005, MOL CELL PROTEOMICS, V4, P1284, DOI 10.1074/mcp.M500082 MCP200
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Cox RF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041679
   Crook M, 1996, ANN CLIN BIOCHEM, V33, P376, DOI 10.1177/000456329603300502
   Cucciolla V, 2007, CELL CYCLE, V6, P2495, DOI 10.4161/cc.6.20.4815
   Dai X, 2011, MED SCI MONITOR, V17, pRA177, DOI 10.12659/MSM.881893
   DeLuca HF, 2004, AM J CLIN NUTR, V80, p1689S, DOI 10.1093/ajcn/80.6.1689S
   Dick Claudia Fernanda, 2011, Enzyme Res, V2011, P103980, DOI 10.4061/2011/103980
   Douhal A, 2007, J Fr Ophtalmol, V30, pe32
   ELDEIRY WS, 1994, CANCER RES, V54, P1169
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   FERREIRA GC, 1993, J BIOENERG BIOMEMBR, V25, P483, DOI 10.1007/BF01108405
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006 2952(98)00307 4
   Giachelli CM, 2001, AM J KIDNEY DIS, V38, pS34, DOI 10.1053/ajkd.2001.27394
   Glinn M, 1998, J NEUROCHEM, V70, P1850
   Go VLW, 2004, J NUTR, V134, p3513S, DOI 10.1093/jn/134.12.3513S
   Graat HCA, 2007, MOL CANCER THER, V6, P1552, DOI 10.1158/1535 7163.MCT 06 0631
   Gutierrez ME, 2009, NAT REV CLIN ONCOL, V6, P259, DOI 10.1038/nrclinonc.2009.38
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   HANSEN NM, 1976, BIOCHIM BIOPHYS ACTA, V451, P549, DOI 10.1016/0304 4165(76)90150 1
   Hattinger CM, 2010, EXPERT OPIN EMERG DR, V15, P615, DOI 10.1517/14728214.2010.505603
   Hedström E, 2009, EXP CELL RES, V315, P451, DOI 10.1016/j.yexcr.2008.11.009
   Hsieh YJ, 2010, CURR OPIN MICROBIOL, V13, P198, DOI 10.1016/j.mib.2010.01.014
   Hulett FM, 1996, MOL MICROBIOL, V19, P933, DOI 10.1046/j.1365 2958.1996.421953.x
   Im YS, 2009, MOL CELLS, V28, P119, DOI 10.1007/s10059 009 0116 x
   Jin H, 2006, TOXICOL SCI, V90, P221, DOI 10.1093/toxsci/kfj066
   Jin H, 2009, AM J RESP CRIT CARE, V179, P59, DOI 10.1164/rccm.200802 306OC
   Jin H, 2008, J NUTR BIOCHEM, V19, P16, DOI 10.1016/j.jnutbio.2006.12.021
   Jin H, 2007, TOXICOL SCI, V100, P215, DOI 10.1093/toxsci/kfm202
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Jüppner H, 2011, KIDNEY INT, V79, pS24, DOI 10.1038/ki.2011.27
   Julien M, 2007, ENDOCRINOLOGY, V148, P530, DOI 10.1210/en.2006 0763
   Julien M, 2009, J BONE MINER RES, V24, P1856, DOI [10.1359/JBMR.090508, 10.1359/jbmr.090508]
   Kanatan M, 2003, J CELL PHYSIOL, V196, P180, DOI 10.1002/jcp.10270
   Kanatani M, 2002, J CELL PHYSIOL, V190, P306, DOI 10.1002/jcp.10067
   Kayne Laurie H, 2001, MASSRY GLASSOCKS TXB
   Kendrick J, 2011, AM J KIDNEY DIS, V58, P826, DOI 10.1053/j.ajkd.2011.07.020
   Khoshniat S, 2011, CELL MOL LIFE SCI, V68, P205, DOI 10.1007/s00018 010 0527 z
   Kido S, 1999, J BIOL CHEM, V274, P28256, DOI 10.1074/jbc.274.40.28256
   Kiela PR, 2009, LAB INVEST, V89, P7, DOI 10.1038/labinvest.2008.114
   Kim SY, 2009, CANCER TREAT RES, V152, P517, DOI 10.1007/978 1 4419 0284 9_31
   Kimata M, 2010, BONE, V47, P938, DOI 10.1016/j.bone.2010.08.006
   KORNBERG A, 1979, CRC CR REV BIOCH MOL, V7, P23, DOI 10.3109/10409237909102568
   KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423
   Kuro O M, 2012, CURR OPIN NEPHROL HY, V21, P362, DOI 10.1097/MNH.0b013e32835422ad
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lamberti M, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756 9966 31 60
   Le Tourneau C, 2010, TARGET ONCOL, V5, P65, DOI 10.1007/s11523 010 0137 6
   Li XW, 2006, CIRC RES, V98, P905, DOI 10.1161/01.RES.0000216409.20863.e7
   Liu DM, 2012, ACTA BIOMATER
   LoghmanAdham M, 1996, GEN PHARMACOL VASC S, V27, P305, DOI 10.1016/0306 3623(95)02017 9
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lopez Heredia MA, 2011, BIOMATERIALS, V32, P5411, DOI 10.1016/j.biomaterials.2011.04.010
   Lu KH, 2005, J ORTHOP RES, V23, P988, DOI 10.1016/j.orthres.2005.01.018
   Malindretos P, 2012, EXPERT OPIN PHARMACO, V13, P2255, DOI 10.1517/14656566.2012.732999
   Maran A, 2008, J CELL BIOCHEM, V104, P1937, DOI 10.1002/jcb.21758
   Mazumder Suparna, 2008, V414, P13
   Meleti Z, 2000, BONE, V27, P359, DOI 10.1016/S8756 3282(00)00346 X
   Min KH, 2012, BIOMATERIALS, V33, P5788, DOI 10.1016/j.biomaterials.2012.04.057
   Miyamae M, 1997, AM J PHYSIOL HEART C, V273, pH566, DOI 10.1152/ajpheart.1997.273.2.H566
   Miyamoto K, 2001, KIDNEY INT, V60, P412, DOI 10.1046/j.1523 1755.2001.060002412.x
   Miyamoto KI, 2011, J PHARM SCI US, V100, P3719, DOI 10.1002/jps.22614
   Mizobuchi M, 2009, J AM SOC NEPHROL, V20, P1453, DOI 10.1681/ASN.2008070692
   Moll UM, 2003, MOL CANCER RES, V1, P1001
   Molony DA, 2011, ADV CHRONIC KIDNEY D, V18, P120, DOI 10.1053/j.ackd.2011.02.004
   Morishita K, 2001, J NUTR, V131, P3182, DOI 10.1093/jn/131.12.3182
   Mozar A, 2008, J CELL PHYSIOL, V215, P47, DOI 10.1002/jcp.21283
   MUFF R, 1992, ANNU REV PHYSIOL, V54, P67, DOI 10.1146/annurev.physiol.54.1.67
   Murer H, 2000, PHYSIOL REV, V80, P1373, DOI 10.1152/physrev.2000.80.4.1373
   Murer H, 2001, MASSRY GLASSOCKS TXB
   Nabuurs CI, 2012, J PHYSL
   Naviglio S, 2012, BIORESEARCH
   Naviglio S, 2006, J CELL BIOCHEM, V98, P1584, DOI 10.1002/jcb.20892
   Naviglio Silvio, 2011, Front Biosci (Elite Ed), V3, P1249
   Ognjanovic S, 2012, CANCER AM CANCER SOC, V118, P1387, DOI 10.1002/cncr.26390
   Ohnishi M, 2009, CIRC CARDIOVASC GENE, V2, P583, DOI 10.1161/CIRCGENETICS.108.847814
   Ottaviani G, 2009, CANCER TREAT RES, V152, P421, DOI 10.1007/978 1 4419 0284 9_23
   PISONI RL, 1991, J BIOL CHEM, V266, P979
   Popp JR, 2011, J TISSUE ENG REGEN M, V5, P780, DOI 10.1002/term.376
   Prié D, 2009, KIDNEY INT, V75, P882, DOI 10.1038/ki.2008.643
   Prough D S, 2000, Anesthesiol Clin North Am, V18, P809, DOI 10.1016/S0889 8537(05)70196 6
   Qin C, 2007, J DENT RES, V86, P1134, DOI 10.1177/154405910708601202
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Raina K, 2007, ACTA PHARMACOL SIN, V28, P1466, DOI 10.1111/j.1745 7254.2007.00691.x
   Ravera S, 2007, AM J PHYSIOL CELL PH, V293, pC606, DOI 10.1152/ajpcell.00064.2007
   Román García P, 2011, MED PRIN PRACT, V20, P203, DOI 10.1159/000323434
   ROTHFIELD L, 1968, ANNU REV BIOCHEM, V37, P463, DOI 10.1146/annurev.bi.37.070168.002335
   Sabbagh Y, 2012, CLIN NEPHROL
   Samyn DR, 2012, BIOCHEM J, V445, P413, DOI 10.1042/BJ20112086
   Santos F, 2012, PEDIAT NEPHROL
   Schmid C, 1998, BIOCHEM BIOPH RES CO, V245, P220, DOI 10.1006/bbrc.1998.8403
   Silver J, 2002, AM J PHYSIOL RENAL, V283, pF367, DOI 10.1152/ajprenal.00061.2002
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Slatopolsky E, 1996, J CLIN INVEST, V97, P2534, DOI 10.1172/JCI118701
   Spagnuolo C, 2012, ANN NY ACAD SCI, V1259, P95, DOI 10.1111/j.1749 6632.2012.06599.x
   Spina A, 2013, J CELL PHYSIOL, V228, P198, DOI 10.1002/jcp.24124
   Stubbs JR, 2007, J AM SOC NEPHROL, V18, P2116, DOI 10.1681/ASN.2006121385
   Su L Joseph, 2012, Methods Mol Biol, V863, P377, DOI 10.1007/978 1 61779 612 8_24
   SUGIMOTO T, 1994, AM J PHYSIOL, V266, pE709, DOI 10.1152/ajpendo.1994.266.5.E709
   Tada H, 2011, BONE, V48, P1409, DOI 10.1016/j.bone.2011.03.675
   Takeda E, 2004, BIOFACTORS, V21, P345, DOI 10.1002/biof.552210167
   Takeda E, 2012, NUTR REV, V70, P311, DOI 10.1111/j.1753 4887.2012.00473.x
   Van TV, 2012, J CLIN BIOCHEM NUTR, V51, P27, DOI 10.3164/jcbn.11 96
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tenenhouse HS, 2007, J STEROID BIOCHEM, V103, P572, DOI 10.1016/j.jsbmb.2006.12.090
   Tentner AR, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.1
   Ternovoi VV, 2006, LAB INVEST, V86, P748, DOI 10.1038/labinvest.3700444
   Tian LQ, 2012, MOL MED REP, V5, P126, DOI 10.3892/mmr.2011.624
   Varmeh S, 2008, MOL CANCER THER, V7, P3789, DOI 10.1158/1535 7163.MCT 08 0838
   Villa Bellosta R, 2007, ARTERIOSCL THROM VAS, V27, P1030, DOI 10.1161/ATVBAHA.106.132266
   Villa Bellosta R, 2009, ARTERIOSCL THROM VAS, V29, P761, DOI 10.1161/ATVBAHA.108.183384
   Werner A, 2001, AM J PHYSIOL REG I, V280, pR301, DOI 10.1152/ajpregu.2001.280.2.R301
   White KE, 2006, ENDOCR REV, V27, P221, DOI 10.1210/er.2005 0019
   Wittrant Y, 2009, BIOCHEM BIOPH RES CO, V381, P259, DOI 10.1016/j.bbrc.2009.02.034
   WOHLRAB H, 1986, BIOCHIM BIOPHYS ACTA, V853, P115, DOI 10.1016/0304 4173(86)90007 8
   Wu CL, 2011, J ORTHOP RES, V29, P1199, DOI 10.1002/jor.21350
   Xu CX, 2008, AM J PHYSIOL GASTR L, V295, pG654, DOI 10.1152/ajpgi.90213.2008
   Xu CX, 2009, J VET SCI, V10, P105, DOI 10.4142/jvs.2009.10.2.105
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   YATES AJ, 1991, J BONE MINER RES, V6, P473
   Yeung BHY, 2012, MOL CELL ENDOCRINOL, V349, P272, DOI 10.1016/j.mce.2011.11.007
   Yoshiko Y, 2007, MOL CELL BIOL, V27, P4465, DOI 10.1128/MCB.00104 07
   Yuan XW, 2007, ACTA PHARMACOL SIN, V28, P1835, DOI 10.1111/j.1745 7254.2007.00662.x
   Zhao PX, 2012, CHEMMEDCHEM, V7, P952, DOI 10.1002/cmdc.201200052
   Zhu JJ, 2005, CANCER BIOL THER, V4, P39
   Zucchini C, 2004, BONE, V34, P672, DOI 10.1016/j.bone.2003.12.008
NR 158
TC 13
Z9 13
U1 0
U2 39
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381 6128
EI 1873 4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD SEP
PY 2013
VL 19
IS 30
BP 5394
EP 5403
DI 10.2174/1381612811319300008
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 193EH
UT WOS:000322540100008
PM 23394088
DA 2025 08 17
ER

PT J
AU Sung, B
   Prasad, S
   Yadav, VR
   Gupta, SC
   Reuter, S
   Yamamoto, N
   Murakami, A
   Aggarwal, BB
AF Sung, Bokyung
   Prasad, Sahdeo
   Yadav, Vivek R.
   Gupta, Subash C.
   Reuter, Simone
   Yamamoto, Norio
   Murakami, Akira
   Aggarwal, Bharat B.
TI RANKL Signaling and Osteoclastogenesis Is Negatively Regulated by
   Cardamonin
SO PLOS ONE
LA English
DT Article
ID NF KAPPA B; METASTATIC BONE DISEASE; RECEPTOR ACTIVATOR;
   CELL PROLIFERATION; CLINICAL FEATURES; KB ACTIVATION; DIFFERENTIATION;
   KINASE; LIGAND; INHIBITOR
AB Bone loss/resorption or osteoporosis is a disease that is accelerated with aging and age associated chronic diseases such as cancer. Bone loss has been linked with human multiple myeloma, breast cancer, and prostate cancer and is usually treated with bisphosphonates, and recently approved denosumab, an antibody against receptor activator of NF kappa B ligand (RANKL). Because of the numerous side effects of the currently available drugs, the search continues for safe and effective therapies for bone loss. RANKL, a member of the TNF superfamily, has emerged as a major mediator of bone loss via activation of osteoclastogenesis. We have identified cardamonin, a chalcone isolated from Alpinia katsumadai Hayata that can affect osteoclastogenesis through modulation of RANKL. We found that treatment of monocytes with cardamonin suppressed RANKL induced NF kappa B activation and this suppression correlated with inhibition of I kappa B alpha kinase and of phosphorylation and degradation of I kappa B alpha, an inhibitor of NF kappa B. Furthermore, cardamonin also downregulated RANKL induced phosphorylation of MAPK including ERK and p38 MAPK. Cardamonin suppressed the RANKL induced differentiation of monocytes to osteoclasts in a dose dependent and time dependent manner. We also found that an inhibitor of NF kappa B essential modulator (NEMO) blocked RANKL induced osteoclastogenesis, indicating a direct link with NF kappa B. Finally, osteoclastogenesis induced by human breast cancer cells or human multiple myeloma cells were completely suppressed by cardamonin. Collectively, our results indicate that cardamonin suppresses osteoclastogenesis induced by RANKL and tumor cells by suppressing activation of the NF kappa B and MAPK pathway.
C1 [Sung, Bokyung; Prasad, Sahdeo; Yadav, Vivek R.; Gupta, Subash C.; Reuter, Simone; Aggarwal, Bharat B.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA.
   [Yamamoto, Norio] House Wellness Foods Corp, Food Sci Res Ctr, Itami, Hyogo, Japan.
   [Murakami, Akira] Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto, Japan.
C3 University of Texas System; UTMD Anderson Cancer Center; Kyoto
   University
RP Aggarwal, BB (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA.
EM aggarwal@mdanderson.org
RI Gupta, Subash/AAF 2563 2019; Aggarwal, Bharat/G 3388 2013; Sung,
   Bokyung/AAX 5697 2021
OI Yamamoto, Norio/0000 0002 0622 5441; Murakami, Akira/0000 0002 5694 2828
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Bheemasankara Rao C, 1976, Planta Med, V29, P391, DOI 10.1055/s 0028 1097682
   Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101
   Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097 0142(20000615)88:12+<2989::AID CNCR14>3.0.CO;2 Q
   Chaisson ML, 2004, J BIOL CHEM, V279, P54841, DOI 10.1074/jbc.M406392200
   Chikatsu N, 2000, BIOCHEM BIOPH RES CO, V267, P632, DOI 10.1006/bbrc.1999.2008
   Chow YL, 2012, INT IMMUNOPHARMACOL, V12, P657, DOI 10.1016/j.intimp.2012.01.009
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   HANAZAWA S, 1987, CALCIFIED TISSUE INT, V41, P31, DOI 10.1007/BF02555128
   Hatziieremia S, 2006, BRIT J PHARMACOL, V149, P188, DOI 10.1038/sj.bjp.0706856
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Jin W, 2008, J CLIN INVEST, V118, P1858, DOI 10.1172/JCI34257
   Jourdan M, 2007, BRIT J HAEMATOL, V138, P160, DOI 10.1111/j.1365 2141.2007.06629.x
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kim MS, 2006, J CELL BIOCHEM, V97, P512, DOI 10.1002/jcb.20649
   Kishida Y, 2007, CLIN CANCER RES, V13, P59, DOI 10.1158/1078 0432.CCR 06 1559
   Kobayashi Y, 2005, J BIOL CHEM, V280, P11395, DOI 10.1074/jbc.M411189200
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lai FPL, 2004, BRIT J HAEMATOL, V126, P192, DOI 10.1111/j.1365 2141.2004.05018.x
   MARIE PJ, 1995, CALCIFIED TISSUE INT, V56, pS13, DOI 10.1007/BF03354642
   Martin TJ, 2001, TRENDS ENDOCRIN MET, V12, P2, DOI 10.1016/S1043 2760(00)00351 9
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Onishi T, 2010, NAT REV CLIN ONCOL, V7, P641, DOI 10.1038/nrclinonc.2010.134
   Reuter S, 2010, MOL CANCER RES, V8, P1425, DOI 10.1158/1541 7786.MCR 10 0141
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Sung B, 2007, MOL PHARMACOL, V71, P1703, DOI 10.1124/mol.107.034512
   Takahashi A, 2011, LIFE SCI, V89, P337, DOI 10.1016/j.lfs.2011.06.027
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132
   Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290
   Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211
NR 44
TC 20
Z9 23
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 17
PY 2013
VL 8
IS 5
AR e64118
DI 10.1371/journal.pone.0064118
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 146RJ
UT WOS:000319107900080
PM 23691159
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Guo, J
   Fei, CM
   Zhao, YS
   Zhao, SD
   Zheng, QQ
   Su, JY
   Wu, D
   Li, X
   Chang, CK
AF Guo, Juan
   Fei, Chengming
   Zhao, Youshan
   Zhao, Sida
   Zheng, Qingqing
   Su, Jiying
   Wu, Dong
   Li, Xiao
   Chang, Chunkang
TI Lenalidomide restores the osteogenic differentiation of bone marrow
   mesenchymal stem cells from multiple myeloma patients via deactivating
   Notch signaling pathway
SO ONCOTARGET
LA English
DT Article
DE mesenchymal stem cells; multiple myeloma; osteogenic differentiation;
   Notch signaling; lenalidomide
ID MULTIPOTENT STROMAL CELLS; OSTEOBLAST DIFFERENTIATION; PROTEASOME
   INHIBITOR; DOWN REGULATION; IN VITRO; DISEASE; THALIDOMIDE; ANALOGS
AB Multiple myeloma (MM) always presents osteolytic bone lesions, resulting from the abnormal osteoblastic and osteoclastic function in patients. MM patients exhibit the impairment of osteogenic differentiation of BMMSCs (bone marrow mesenchymal stem cells) and osteoblast deficiency. Effects of the drug, lenalidomide on the osteoblastic functions and the involved mechanisms remain unexplored. In the present study, it is observed that the osteogenic differentiation of BMMSCs from MM patients (MM MSCs) is impaired and activation of Notch signaling pathway in MM MSCs is abnormal. Notch signaling activation inhibits BMMSCs osteogenesis. Knockdown of Notch1 expression and DAPT application reverse the osteogenic differentiation from MM MSCs. Furthermore, it is shown that the gene expression of Notch signaling molecules, including receptors, ligands and downstream factors are significantly decreased in MM MSCs following lenalidomide treatment, compared with non treated MM MSCs. Taken together, treatment with lenalidomide restores the osteogenic differentiation of MM MSCs via deactivating Notch signaling pathway.
C1 [Guo, Juan; Fei, Chengming; Zhao, Youshan; Zhao, Sida; Zheng, Qingqing; Su, Jiying; Wu, Dong; Li, Xiao; Chang, Chunkang] Shanghai Jiao Tong Univ, Dept Hematol, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University
RP Chang, CK (通讯作者)，Shanghai Jiao Tong Univ, Dept Hematol, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China.
EM changchunkang@sjtu.edu.cn
RI GUO, JUAN/HIK 2220 2022
OI Chang, Chunkang/0000 0001 5318 5879
FU National Natural Science Foundation of China [81570108, 81400090]
FX This project was funded by the National Natural Science Foundation of
   China (Grant No. 81570108 and 81400090).
CR Anderson KC, 2016, CLIN CANCER RES, V22, P5419, DOI 10.1158/1078 0432.CCR 16 0625
   Arnulf B, 2007, LEUKEMIA, V21, P158, DOI 10.1038/sj.leu.2404466
   Artavanis Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Breitkreutz I, 2008, LEUKEMIA, V22, P1925, DOI 10.1038/leu.2008.174
   Canalis E, 2013, J BIOL CHEM, V288, P25614, DOI 10.1074/jbc.M113.470492
   Chiba S, 2006, STEM CELLS, V24, P2437, DOI 10.1634/stemcells.2005 0661
   Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621
   Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164
   DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097 0142(197509)36:3<842::AID CNCR2820360303>3.0.CO;2 U
   Fei CM, 2015, AM J TRANSL RES, V7, P1939
   Fei CM, 2014, TUMOR BIOL, V35, P4307, DOI 10.1007/s13277 013 1565 6
   Ferrer RA, 2013, HAEMATOLOGICA, V98, P1677, DOI 10.3324/haematol.2013.083972
   Garayoa M, 2009, LEUKEMIA, V23, P1515, DOI 10.1038/leu.2009.65
   Ghazanfari R, 2016, STEM CELLS DEV
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Guo J, 2011, EUR J HAEMATOL, V87, P235, DOI 10.1111/j.1600 0609.2011.01635.x
   Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Kassen D, 2014, BRIT J HAEMATOL, V167, P194, DOI 10.1111/bjh.13020
   Kuci S, 2010, HAEMATOL HEMATOL J, V95, P651, DOI 10.3324/haematol.2009.015065
   Kuçi Z, 2013, HAEMATOLOGICA, V98, P1609, DOI 10.3324/haematol.2013.092700
   Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
   Li HZ, 2016, ANN NY ACAD SCI, V1370, P109, DOI 10.1111/nyas.13102
   Munemasa S, 2008, INT J ONCOL, V33, P129
   Noll JE, 2014, HAEMATOLOGICA, V99, P163, DOI 10.3324/haematol.2013.090977
   Pellagatti A, 2007, P NATL ACAD SCI USA, V104, P11406, DOI 10.1073/pnas.0610477104
   Pennisi A, 2009, AM J HEMATOL, V84, P6, DOI 10.1002/ajh.21310
   Reagan MR, 2012, CLIN CANCER RES, V18, P342, DOI 10.1158/1078 0432.CCR 11 2212
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Silbermann R, 2013, J BONE ONCOL, V2, P59, DOI 10.1016/j.jbo.2013.04.001
   Sonneveld P, 2016, BLOOD, V127, P2955, DOI 10.1182/blood 2016 01 631200
   Weber JM, 2010, BONE, V46, P281, DOI 10.1016/j.bone.2009.08.007
   Wobus M, 2012, EXP HEMATOL, V40, P867, DOI 10.1016/j.exphem.2012.06.004
   Xu S, 2012, LEUKEMIA, V26, P2546, DOI 10.1038/leu.2012.126
   Yaccoby S, 2010, BRIT J HAEMATOL, V149, P311, DOI 10.1111/j.1365 2141.2010.08141.x
   Zanotti S, 2008, ENDOCRINOLOGY, V149, P3890, DOI 10.1210/en.2008 0140
   Zanotti S, 2011, J BIOL CHEM, V286, P2648, DOI 10.1074/jbc.M110.183038
   Zhao YS, 2015, HAEMATOLOGICA, V100, P194, DOI 10.3324/haematol.2014.109769
NR 38
TC 18
Z9 19
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD AUG
PY 2017
VL 8
IS 33
BP 55405
EP 55421
DI 10.18632/oncotarget.19265
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FD9ER
UT WOS:000407826100120
PM 28903429
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Thompson, ML
   Jimenez Andrade, JM
   Chartier, S
   Tsai, J
   Burton, EA
   Habets, G
   Lin, PS
   West, BL
   Mantyh, PW
AF Thompson, Michelle L.
   Jimenez Andrade, Juan M.
   Chartier, Stephane
   Tsai, James
   Burton, Elizabeth A.
   Habets, Gaston
   Lin, Paul S.
   West, Brian L.
   Mantyh, Patrick W.
TI Targeting cells of the myeloid lineage attenuates pain and disease
   progression in a prostate model of bone cancer
SO PAIN
LA English
DT Article
DE Macrophage; Mast cell; Osteoblast; Osteoclast; Disease progression;
   Survival; Pain
ID STIMULATING FACTOR 1 RECEPTOR; MU OPIOID RECEPTOR; BREAST CANCER;
   TUMOR GROWTH; NEUROMA FORMATION; MOUSE MODEL; MORPHINE; ANGIOGENESIS;
   SURVIVAL; METASTASIS
AB Tumor cells frequently metastasize to bone where they can generate cancer induced bone pain (CIBP) that can be difficult to fully control using available therapies. Here, we explored whether PLX3397, a high affinity small molecular antagonist that binds to and inhibits phosphorylation of colony stimulating factor 1 receptor, the tyrosine protein kinase c Kit, and the FMS like tyrosine kinase 3, can reduce CIBP. These 3 targets all regulate the proliferation and function of a subset of the myeloid cells including macrophages, osteoclasts, and mast cells. Preliminary experiments show that PLX3397 attenuated inflammatory pain after formalin injection into the hind paw of the rat. As there is an inflammatory component in CIBP, involving macrophages and osteoclasts, the effect of PLX3397 was explored in a prostate model of CIBP where skeletal pain, cancer cell proliferation, tumor metastasis, and bone remodeling could be monitored in the same animal. Administration of PLX3397 was initiated on day 14 after prostate cancer cell injection when the tumor was well established, and tumor induced bone remodeling was first evident. Over the next 6 weeks, sustained administration of PLX3397 attenuated CIBP behaviors by approximately 50% and was equally efficacious in reducing tumor cell growth, formation of new tumor colonies in bone, and pathological tumor induced bone remodeling. Developing a better understanding of potential effects that analgesic therapies have on the tumor itself may allow the development of therapies that not only better control the pain but also positively impact disease progression and overall survival in patients with bone cancer.
C1 [Thompson, Michelle L.; Jimenez Andrade, Juan M.; Chartier, Stephane; Mantyh, Patrick W.] Univ Arizona, Dept Pharmacol, Arizona Canc Ctr, Tucson, AZ USA.
   [Jimenez Andrade, Juan M.] Univ Autonoma Tamaulipas Reynosa, Unidad Acad Multidisciplinaria Reynosa Aztlan, Tamaulipas, Mexico.
   [Tsai, James; Burton, Elizabeth A.; Habets, Gaston; Lin, Paul S.; West, Brian L.] Plexxikon Inc, Translat Pharmacol, Berkeley, CA USA.
C3 Arizona Center Cancer Care; University of Arizona; Universidad Autonoma
   de Tamaulipas; Daiichi Sankyo Company Limited
RP Mantyh, PW (通讯作者)，Dept Pharmacol, 1501 N Campbell Ave,POB 245050, Tucson, AZ 85724 USA.
EM pmantyh@email.arizona.edu
RI ; ANDRADE, JUAN/C 1416 2016
OI Chartier, Stephane/0009 0003 0407 8331; Thompson,
   Michelle/0000 0001 8134 9017; Jimenez Andrade, Juan
   Miguel/0000 0002 2703 9736; West, Brian/0000 0002 5320 3691
FU National Institutes of Health [CA157449, CA1574550, NS23970]; Plexxikon
FX This work was supported by the National Institutes of Health grants
   (CA157449, CA1574550, and NS23970) and a grant from Plexxikon. The
   authors thank Magdalena Kaczmarska and Joseph Ghilardi for their
   technical assistance, reading, and editing of this article.
CR ALCALAY M, 1995, REV RHUM, V62, P632
   ARCANGELI G, 1989, RADIOTHER ONCOL, V14, P95, DOI 10.1016/0167 8140(89)90053 4
   Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200
   Ashley JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025838
   Barki Harrington L, 2001, J UROLOGY, V165, P2121, DOI 10.1016/S0022 5347(05)66305 7
   Barreda DR, 2004, DEV COMP IMMUNOL, V28, P509, DOI 10.1016/j.dci.2003.09.010
   Bercovitch M, 1999, CANCER AM CANCER SOC, V86, P871, DOI 10.1002/(SICI)1097 0142(19990901)86:5<871::AID CNCR25>3.0.CO;2 L
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   BRAGE ME, 1992, ORTHOPEDICS, V15, P589
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Cheng JD, 2002, INT J CANCER, V99, P755, DOI 10.1002/ijc.10409
   Chida Y, 2008, NAT CLIN PRACT ONCOL, V5, P466, DOI 10.1038/ncponc1134
   Chitu V, 2006, CURR OPIN IMMUNOL, V18, P39, DOI 10.1016/j.coi.2005.11.006
   Chitu V, 2012, BLOOD, V120, P3126, DOI 10.1182/blood 2012 04 425595
   Chun L, 1999, J BIOMED MATER RES, V48, P899, DOI 10.1002/(SICI)1097 4636(1999)48:6<899::AID JBM20>3.0.CO;2 E
   Coniglio SJ, 2012, MOL MED, V18, P519, DOI 10.2119/molmed.2011.00217
   Connor SR, 2007, J PAIN SYMPTOM MANAG, V33, P238, DOI 10.1016/j.jpainsymman.2006.10.010
   Conway JG, 2005, P NATL ACAD SCI USA, V102, P16078, DOI 10.1073/pnas.0502000102
   De I, 2014, GLIA, V62, P1955, DOI 10.1002/glia.22717
   DeClerck YA, 2004, AM J PATHOL, V164, P1131, DOI 10.1016/S0002 9440(10)63200 2
   Duncan K, 2012, IUBMB LIFE, V64, P636, DOI 10.1002/iub.1035
   Ettarh R, 2010, PHARMACEUTICALS, V3, P2007, DOI 10.3390/ph3072007
   Farooqui M, 2007, BRIT J CANCER, V97, P1523, DOI 10.1038/sj.bjc.6604057
   Gach K, 2009, CHEM BIOL DRUG DES, V74, P390, DOI 10.1111/j.1747 0285.2009.00875.x
   Gaspani L, 2002, J NEUROIMMUNOL, V129, P18, DOI 10.1016/S0165 5728(02)00165 0
   Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815 04.2005
   Glasner A, 2010, J IMMUNOL, V184, P2449, DOI 10.4049/jimmunol.0903301
   Grant K, 2003, BRIT J CANCER, V88, P163, DOI 10.1038/sj.bjc.6700750
   Gupta K, 2002, CANCER RES, V62, P4491
   Halvorson KG, 2005, CANCER RES, V65, P9426, DOI 10.1158/0008 5472.CAN 05 0826
   Hatzoglou A, 1996, EUR J PHARMACOL, V296, P199, DOI 10.1016/0014 2999(95)00703 2
   HATZOGLOU A, 1995, CANCER RES, V55, P5632
   He Y., 2012, E Health Telecommun. Syst. Netw, V1, P1, DOI DOI 10.4236/ETSN.2012.11001
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   HUDSON PB, 1947, J UROLOGY, V58, P89, DOI 10.1016/S0022 5347(17)69523 5
   HUNSKAAR S, 1985, J NEUROSCI METH, V14, P69, DOI 10.1016/0165 0270(85)90116 5
   Ide H, 2002, P NATL ACAD SCI USA, V99, P14404, DOI 10.1073/pnas.222537099
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jimenez Andrade JM, 2010, J NEUROSCI, V30, P14649, DOI 10.1523/JNEUROSCI.3300 10.2010
   Jimenez Andrade JM, 2011, PAIN, V152, P2564, DOI 10.1016/j.pain.2011.07.020
   Kampa M, 1997, EUR J PHARMACOL, V335, P255, DOI 10.1016/S0014 2999(97)01213 2
   Kenan S., 2003, Holland Frei Cancer Medicine, VEdn
   Kim TS, 2014, CLIN CANCER RES, V20, P2350, DOI 10.1158/1078 0432.CCR 13 3033
   Kleeberger W, 2007, CANCER RES, V67, P9199, DOI 10.1158/0008 5472.CAN 07 0806
   Kress M., 2010, OPEN PAIN J, P97, DOI [10.2174/1876386301003010097, DOI 10.2174/1876386301003010097]
   Krishna LKR, 2010, ANN ACAD MED SINGAP, V39, P790
   Krysan K, 2004, FASEB J, V18, P205, DOI 10.1096/fj.03 0369fje
   Lennon FE, 2012, ANESTHESIOLOGY, V116, P857, DOI 10.1097/ALN.0b013e31824babe2
   LeRoy BE, 2006, PROSTATE, V66, P1213, DOI 10.1002/pros.20408
   Li W, 2012, ONCOL LETT, V4, P1269, DOI 10.3892/ol.2012.929
   Lingen MW, 2001, ARCH PATHOL LAB MED, V125, P67
   Luger NM, 2005, J PAIN SYMPTOM MANAG, V29, pS32, DOI 10.1016/j.jpainsymman.2005.01.008
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304 3959(02)00102 1
   Majuta LA, 2015, PAIN, V156, P157, DOI 10.1016/j.pain.0000000000000017
   MANECKJEE R, 1990, CANCER RES, V50, P2234
   Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747
   Mantyh WG, 2010, NEUROSCIENCE, V171, P588, DOI 10.1016/j.neuroscience.2010.08.056
   Mathew B, 2011, ANESTH ANALG, V112, P558, DOI 10.1213/ANE.0b013e31820568af
   Morita T, 2001, J PAIN SYMPTOM MANAG, V21, P282, DOI 10.1016/S0885 3924(01)00258 5
   Morrissey C, 2013, J BONE MINER RES, V28, P333, DOI 10.1002/jbmr.1749
   Nagae M, 2007, J BONE MINER METAB, V25, P99, DOI 10.1007/s00774 006 0734 8
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Nomiya T, 2010, CLIN J PAIN, V26, P38, DOI 10.1097/AJP.0b013e3181b0c82c
   Ohba T, 2014, J BONE MINER RES, V29, P1431, DOI 10.1002/jbmr.2182
   Ohta T, 2003, INT J ONCOL, V23, P593
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Peters CM, 2005, EXP NEUROL, V193, P85, DOI 10.1016/j.expneurol.2004.11.028
   Pickering V, 2008, EUR J PAIN, V12, P293, DOI 10.1016/j.ejpain.2007.06.001
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Pomonis JD, 2001, J NEUROSCI, V21, P999, DOI 10.1523/JNEUROSCI.21 03 00999.2001
   Prada CE, 2013, ACTA NEUROPATHOL, V125, P159, DOI 10.1007/s00401 012 1056 7
   Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337
   Saad F, 2012, UROL ONCOL SEMIN ORI, V30, P369, DOI 10.1016/j.urolonc.2010.08.007
   Sabino MAC, 2002, CANCER RES, V62, P7343
   Sabino Mary Ann C, 2005, J Support Oncol, V3, P15
   Schmidt BL, 2010, MOL INTERV, V10, P164, DOI 10.1124/mi.10.3.7
   Schweizerhof M, 2009, NAT MED, V15, P802, DOI 10.1038/nm.1976
   Sen Banibrata, 2011, J Signal Transduct, V2011, P865819, DOI 10.1155/2011/865819
   Servet Delprat Christine, 2002, BMC Immunol, V3, P15, DOI 10.1186/1471 2172 3 15
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Shavit Y, 2004, NEUROIMMUNOMODULAT, V11, P255, DOI 10.1159/000078444
   Singleton PA, 2006, MICROVASC RES, V72, P3, DOI 10.1016/j.mvr.2006.04.004
   Soreide K, 2006, J PATHOL, V209, P147, DOI 10.1002/path.1999
   Strachan DC, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26968
   Tegeder I, 2003, CANCER RES, V63, P1846
   Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Thoren LA, 2008, J IMMUNOL, V180, P2045, DOI 10.4049/jimmunol.180.4.2045
   Thorns A, 2000, LANCET, V356, P398, DOI 10.1016/S0140 6736(00)02534 4
   Thudi NK, 2008, PROSTATE, V68, P1116, DOI 10.1002/pros.20776
   Thudi NK, 2011, PROSTATE, V71, P615, DOI 10.1002/pros.21277
   TONG D, 1982, CANCER AM CANCER SOC, V50, P893, DOI 10.1002/1097 0142(19820901)50:5<893::AID CNCR2820500515>3.0.CO;2 Y
   Vakaet LAML, 2004, INT J DEV BIOL, V48, P599, DOI 10.1387/ijdb.041817lv
   Wiesner C, 2008, NEOPLASIA, V10, P996, DOI 10.1593/neo.08618
   Wu X, 2015, MOL MED REP, V12, P1405, DOI 10.3892/mmr.2015.3559
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Ye Y, 2011, MOL CANCER THER, V10, P1667, DOI 10.1158/1535 7163.MCT 11 0123
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304 3959(83)90201 4
NR 98
TC 22
Z9 24
U1 0
U2 25
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0304 3959
EI 1872 6623
J9 PAIN
JI Pain
PD SEP
PY 2015
VL 156
IS 9
BP 1692
EP 1702
DI 10.1097/j.pain.0000000000000228
PG 11
WC Anesthesiology; Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anesthesiology; Neurosciences & Neurology
GA CQ4MQ
UT WOS:000360579400015
PM 25993548
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Park, SJ
   Park, DR
   Bhattarai, D
   Lee, K
   Kim, J
   Bae, YS
   Lee, SY
AF Park, So Jeong
   Park, Doo Ri
   Bhattarai, Deepak
   Lee, Kyeong
   Kim, Jaesang
   Bae, Yun Soo
   Lee, Soo Young
TI 2 (Trimethylammonium) Ethyl (R) 3 Methoxy 3 oxo 2 Stearamidopropyl
   Phosphate Suppresses Osteoclast Maturation and Bone Resorption by
   Targeting Macrophage Colony Stimulating Factor Signaling
SO MOLECULES AND CELLS
LA English
DT Article
DE antiresorptive drugs; bone destruction; osteoclast; osteoclast
   maturation; (R) TEMOSPho
ID RHO GTPASES; C FMS; CELL BIOLOGY; FACTOR I; M CSF; DIFFERENTIATION;
   CYTOSKELETON; SURVIVAL; RECEPTOR; DEFECTS
AB 2 (Trimethylammonium) ethyl (R)/3 methoxy 3 oxo 2 steara midopropyl phosphate [(R) TEMOSPho], a derivative of an organic chemical identified from a natural product library, promotes highly efficient megakaryopoiesis. Here, we show that (R) TEMOSPho blocks osteoclast maturation from progenitor cells of hematopoietic origin, as well as blocking the resorptive function of mature osteoclasts. The inhibitory effect of (R) TEMOSPho on osteoclasts was due to a disruption of the actin cytoskeleton, resulting from impaired downstream signaling of c Fms, a receptor for macrophage colony stimulating factor linked to c Cbl, phosphoinositol 3 kinase (PI3K), Vav3, and Rac1. In addition, (R) TEMOSPho blocked inflammation induced bone destruction by reducing the numbers of osteoclasts produced in mice. Thus, (R) TEMOSPho may represent a promising new class of antiresorptive drugs for the treatment of bone loss associated with increased osteoclast maturation and activity.
C1 [Park, So Jeong; Park, Doo Ri; Kim, Jaesang; Bae, Yun Soo; Lee, Soo Young] Ewha Womans Univ, Dept Life Sci, Seoul 120750, South Korea.
   [Park, So Jeong; Park, Doo Ri; Kim, Jaesang; Bae, Yun Soo; Lee, Soo Young] Ewha Womans Univ, Res Ctr Cellular Homeostasis, Seoul 120750, South Korea.
   [Bhattarai, Deepak; Lee, Kyeong] Dongguk Univ, Coll Pharm, Plus R FIND Team BK21, Goyang 410820, South Korea.
C3 Ewha Womans University; Ewha Womans University; Dongguk University
RP Lee, SY (通讯作者)，Ewha Womans Univ, Dept Life Sci, Seoul 120750, South Korea.
EM leesy@ewha.ac.kr
RI Kim, Jung Kyu/C 3271 2012; Bhattarai, Dharmagat/AFK 8286 2022
FU National Research Foundation of Korea (NRF) grant   Korea Government
   (MSIP) [2013R1A2A1A05005153, 2012R1A5A10 48236, 2012M3A9C5048708]
FX We thank Dr. M. Takami at Showa University for providing the dentin
   slices. This work was supported by the National Research Foundation of
   Korea (NRF) grant funded by the Korea Government (MSIP) (No.
   2013R1A2A1A05005153; No. 2012R1A5A10 48236; No. 2012M3A9C5048708).
CR Adapala NS, 2010, ANN NY ACAD SCI, V1192, P376, DOI 10.1111/j.1749 6632.2009.05346.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092 8674(02)00699 2
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Etienne Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194
   Faccio R, 2007, J BIOL CHEM, V282, P18991, DOI 10.1074/jbc.M610937200
   FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733
   Grey A, 2000, ENDOCRINOLOGY, V141, P2129, DOI 10.1210/en.141.6.2129
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim YA, 2003, J ORG CHEM, V68, P10162, DOI 10.1021/jo034969s
   KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291
   Kwak HB, 2004, BIOCHEM PHARMACOL, V67, P1239, DOI 10.1016/j.bcp.2003.10.032
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Leibbrandt A, 2009, ADV EXP MED BIOL, V649, P100
   Limb J.K., 2012, J TISSUE ENG REGEN M
   MARKS SC, 1992, BONE, V13, P89, DOI 10.1016/8756 3282(92)90365 4
   Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016
   Razzouk S, 1999, EUR J CELL BIOL, V78, P249, DOI 10.1016/S0171 9335(99)80058 2
   Ridley AJ, 2001, J CELL SCI, V114, P2713
   Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962 8924(01)02153 5
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Sakai H, 2006, BONE, V39, P1290, DOI 10.1016/j.bone.2006.06.012
   Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302
   Suda T, 1997, METHOD ENZYMOL, V282, P223
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Väänänen HK, 2000, J CELL SCI, V113, P377
   WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828
NR 34
TC 6
Z9 6
U1 0
U2 3
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635 4, YUCKSAM DONG, GANGNAM GU, SEOUL 135 703, SOUTH KOREA
SN 1016 8478
EI 0219 1032
J9 MOL CELLS
JI Mol. Cells
PD AUG 31
PY 2014
VL 37
IS 8
BP 628
EP 635
DI 10.14348/molcells.2014.0190
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AQ1SO
UT WOS:000342561500009
PM 25139265
OA Green Submitted, hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Xu, Q
   Chen, GP
   Xu, HE
   Xia, GM
   Zhu, MS
   Zhan, HB
   Zhang, B
   Dai, M
   Fan, HX
   Liu, XQ
AF Xu, Qiang
   Chen, Guiping
   Xu, Huaen
   Xia, Guoming
   Zhu, Meisong
   Zhan, Haibo
   Zhang, Bin
   Dai, Min
   Fan, Hongxian
   Liu, Xuqiang
TI Celastrol Attenuates RANKL Induced Osteoclastogenesis in vitro
   and Reduces Titanium Particle Induced Osteolysis and Ovariectomy Induced
   Bone Loss in vivo
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE osteoclast; RANKL (receptor activator for nuclear factor kappa B
   ligand); osteolysis; osteoporosis; TAK1 binding protein 1; celastrol
   derivatives
ID NF KAPPA B; C FOS; DIFFERENTIATION; NFATC1; ACTIVATION; OSTEOPOROSIS;
   SUPPRESSION; INDUCTION; TAK1
AB Excessive bone resorption by osteoclasts contributes significantly to osteoclast related diseases such as periprosthetic osteolysis and osteoporosis. Osteolysis in a titanium particle induced calvarial model and bone loss in an ovariectomized mice model occurred similarly to those in humans; thus, these models can be used to evaluate potential therapies for aseptic prosthetic loosening and osteoporosis. Celastrol, which is extracted from the seeds of the genus Tripterygium, has been thoroughly investigated for its anti inflammatory and anti cancer pharmacological effects. However, the mechanisms involving bone metabolism by which celastrol inhibits osteoclastogenesis are not yet fully understood. We demonstrated that celastrol inhibited the receptor activator of nuclear factor kappa B ligand induced osteoclastogenesis and the bone resorptive function of osteoclasts in vitro by inhibiting the activation of transforming growth factor beta activated kinase 1 mediated NF kappa B and mitogen activated protein kinase signaling pathways and downregulating osteoclastogenesis marker related genes. Furthermore, celastrol was also shown to be beneficial in both the titanium particle induced osteolysis calvarial and the murine ovariectomy induced bone loss. Collectively, our results suggested that celastrol is promising for the prevention of aseptic prosthetic loosening and osteoporosis in the treatment of osteolytic diseases induced by disrupted osteoclast formation and function.
C1 [Xu, Qiang; Chen, Guiping; Xu, Huaen; Xia, Guoming; Zhu, Meisong; Zhan, Haibo; Zhang, Bin; Dai, Min; Fan, Hongxian; Liu, Xuqiang] Nanchang Univ, Affiliated Hosp 1, Artificial Joints Engn & Technol Res Ctr Jiangxi, Dept Orthoped, Nanchang, Jiangxi, Peoples R China.
   [Chen, Guiping; Fan, Hongxian] Nanchang Univ, Affiliated Eye Hosp, Dept Ophthalmol, Nanchang, Jiangxi, Peoples R China.
   Shenzhen Univ, Gen Hosp, Clin Med Acad, Dept Orthopaed, Shenzhen, Peoples R China.
C3 Nanchang University; Nanchang University; Shenzhen University
RP Fan, HX; Liu, XQ (通讯作者)，Nanchang Univ, Affiliated Hosp 1, Artificial Joints Engn & Technol Res Ctr Jiangxi, Dept Orthoped, Nanchang, Jiangxi, Peoples R China.; Fan, HX (通讯作者)，Nanchang Univ, Affiliated Eye Hosp, Dept Ophthalmol, Nanchang, Jiangxi, Peoples R China.
EM thr126@126.com; shliuxuqiang@163.com
RI DAI, M/GPS 8291 2022
FU National Natural Science Foundation [81660365, 81860404, 81860405]
FX This work was supported by the National Natural Science Foundation
   (Grant Nos. 81660365, 81860404 and 81860405).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bone HG, 2013, J CLIN ENDOCR METAB, V98, P4483, DOI 10.1210/jc.2013 1597
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Chen KM, 2007, PHARMAZIE, V62, P388, DOI 10.1691/ph.2007.5.6682
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   D'Amico Lucia, 2012, Bonekey Rep, V1, P82, DOI 10.1038/bonekey.2012.82
   de la Rica L, 2015, GENOME BIOL, V16, DOI 10.1186/s13059 014 0561 5
   Dong L, 2017, MOL IMMUNOL, V83, P46, DOI 10.1016/j.molimm.2017.01.007
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806 7819.2004
   Gan K, 2015, INT IMMUNOPHARMACOL, V24, P239, DOI 10.1016/j.intimp.2014.12.012
   Goss PE, 2011, NEW ENGL J MED, V364, P2381, DOI 10.1056/NEJMoa1103507
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hong GJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00331
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Idris AI, 2010, FASEB J, V24, P4545, DOI 10.1096/fj.10 164095
   Jiang C, 2015, BIOCHIMIE, V111, P107, DOI 10.1016/j.biochi.2015.02.002
   Jung HW, 2007, EXP MOL MED, V39, P715, DOI 10.1038/emm.2007.78
   Kannaiyan R, 2011, CANCER LETT, V303, P9, DOI 10.1016/j.canlet.2010.10.025
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lewiecki EM, 2011, DRUGS, V71, P791, DOI 10.2165/11585470 000000000 00000
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Miyazaki T, 2014, PATIENT PREFER ADHER, V8, P463, DOI 10.2147/PPA.S46192
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Venkatesha SH, 2016, ADV EXP MED BIOL, V928, P267, DOI 10.1007/978 3 319 41334 1_12
   Wang RJ, 2020, CHEM BIODIVERS, V17, DOI 10.1002/cbdv.202000295
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Xu Q, 2019, BIOCHEM BIOPH RES CO, V508, P902, DOI 10.1016/j.bbrc.2018.11.201
   Xu SH, 2021, PHARMACOL RES, V167, DOI 10.1016/j.phrs.2021.105572
   Yao GQ, 2002, CALCIFIED TISSUE INT, V70, P339, DOI 10.1007/s00223 001 1079 x
   Zhang JZ, 2017, BIOCHEM J, V474, P2235, DOI 10.1042/BCJ20170288
   Zhang M, 2019, PHYTOTHER RES, V33, P1191, DOI 10.1002/ptr.6314
   Zhu MS, 2021, J ETHNOPHARMACOL, V276, DOI 10.1016/j.jep.2021.114176
NR 44
TC 11
Z9 12
U1 0
U2 22
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 3
PY 2021
VL 12
AR 682541
DI 10.3389/fphar.2021.682541
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ST1XU
UT WOS:000662244900001
PM 34149427
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tanaka, T
   Takao Kawabata, R
   Takakura, A
   Shimazu, Y
   Nakatsugawa, M
   Ito, A
   Lee, JW
   Kawasaki, K
   Iimura, T
AF Tanaka, Tomoya
   Takao Kawabata, Ryoko
   Takakura, Aya
   Shimazu, Yukari
   Nakatsugawa, Momoko
   Ito, Akitoshi
   Lee, Ji Won
   Kawasaki, Koh
   Iimura, Tadahiro
TI Teriparatide relieves ovariectomy induced hyperalgesia in rats,
   suggesting the involvement of functional regulation in primary sensory
   neurons by PTH mediated signaling
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PEPTIDE RECEPTOR ACTIVATION; DORSAL ROOT GANGLION; QUALITY OF LIFE;
   BACK PAIN; POSTMENOPAUSAL WOMEN; NEUROPATHIC PAIN; SKELETAL PAIN;
   MECHANICAL HYPERALGESIA; 5 HT1A LIKE RECEPTOR; OSTEOPOROSIS
AB Clinical studies have reported that teriparatide (TPTD), a human parathyroid hormone analog, reduces back pain in osteoporotic patients. However, the mechanistic insights of this pharmacological action remain elusive. This study investigated the antinociceptive effect of TPTD mainly on primary sensory neurons in ovariectomized (OVX) rats. The plantar test showed thermal hyperalgesia in the OVX rats, which was significantly, but not fully, recovered immediately after the initial TPTD administration. The von Frey test also demonstrated reduced withdrawal threshold in the OVX rats. This was partially recovered by TPTD. Consistently, the number and size of spinal microglial cells were significantly increased in the OVX rats, while TPTD treatment significantly reduced the number but not size of these cells. RNA sequencing based bioinformatics of the dorsal root ganglia (DRG) demonstrated that changes in neuro protective and inflammatory genes were involved in the pharmacological effect of TPTD. Most neurons in the DRG expressed substantial levels of parathyroid hormone 1 receptor. TPTD treatment of the cultured DRG derived neuronal cells reduced the cAMP level and augmented the intracellular calcium level as the concentration increased. These findings suggest that TPTD targets neuronal cells as well as bone cells to exert its pharmacological action.
C1 [Tanaka, Tomoya; Takao Kawabata, Ryoko; Takakura, Aya; Shimazu, Yukari; Nakatsugawa, Momoko; Ito, Akitoshi; Kawasaki, Koh] Asahi Kasei Pharma Corp, Pharmaceut Res Ctr, 632 1 Mifuku, Izunokuni, Shizuoka 4102321, Japan.
   [Tanaka, Tomoya; Takakura, Aya; Lee, Ji Won; Iimura, Tadahiro] Hokkaido Univ, Grad Sch Dent Med, Dept Pharmacol, N13 W7, Sapporo, Hokkaido 0608586, Japan.
   [Lee, Ji Won; Iimura, Tadahiro] Ehime Univ, Proteosci Ctr PROS, Div Bioimaging, Toon City, Ehime 7910295, Japan.
C3 Asahi Kasei Pharma Corporation; Hokkaido University; Ehime University
RP Takao Kawabata, R (通讯作者)，Asahi Kasei Pharma Corp, Pharmaceut Res Ctr, 632 1 Mifuku, Izunokuni, Shizuoka 4102321, Japan.; Iimura, T (通讯作者)，Hokkaido Univ, Grad Sch Dent Med, Dept Pharmacol, N13 W7, Sapporo, Hokkaido 0608586, Japan.; Iimura, T (通讯作者)，Ehime Univ, Proteosci Ctr PROS, Div Bioimaging, Toon City, Ehime 7910295, Japan.
EM takao.rb@om.asahi kasei.co.jp; iimura@den.hokudai.ac.jp
RI ; Iimura, Tadahiro/P 3550 2018; Takao Kawabata, Ryoko/AGF 7646 2022;
   Lee, Jeeyun/I 7171 2015
OI Tanaka, Tomoya/0009 0000 5050 2314; LEE, JI WON/0000 0003 4578 2168;
   Iimura, Tadahiro/0000 0002 1431 0689; Takao Kawabata,
   Ryoko/0000 0002 6811 7526; 
FU Asahi Kasei Pharma Corporation; Japan Society for the Promotion of
   Science (JSPS KAKENHI) [18H02983, 18K19649]; Institute of Medical
   Science, The University of Tokyo: IMSUT Joint Research Project
   [20162019]; Grants in Aid for Scientific Research [18H02983, 18K19649]
   Funding Source: KAKEN
FX We express sincere thanks to Haruka Matsumori, and Kazuaki Tokunaga at
   Nikon for their expertise in microscopy and image analysis. We also
   thank Mr. Ikuo Takahashi fom LSI Medience Corporation, for assisting
   with the animal management. This study was funded by the Asahi Kasei
   Pharma Corporation. This work was also partly supported by Grant in Aids
   for Scientific Research from the Japan Society for the Promotion of
   Science (JSPS KAKENHI) grant numbers 18H02983 and 18K19649 to T. Iimura,
   respectively. This work was also partly supported by The Institute of
   Medical Science, The University of Tokyo: IMSUT Joint Research Project
   (20162019).
CR Abe Y, 2015, J BONE MINER METAB, V33, P125, DOI 10.1007/s00774 014 0574 x
   Biber K, 2011, EMBO J, V30, P1864, DOI 10.1038/emboj.2011.89
   Bullock CM, 2014, ARTHRITIS RHEUMATOL, V66, P2188, DOI 10.1002/art.38656
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165 0270(94)90144 9
   Cheloha RW, 2015, NAT REV ENDOCRINOL, V11, P712, DOI 10.1038/nrendo.2015.139
   Chen L, 2016, PURINERG SIGNAL, V12, P79, DOI 10.1007/s11302 015 9481 4
   Dobolyi A, 2010, PROG NEUROBIOL, V90, P29, DOI 10.1016/j.pneurobio.2009.10.017
   Dohke T, 2018, J BONE MINER METAB, V36, P499, DOI 10.1007/s00774 017 0865 0
   FORMAN LJ, 1989, LIFE SCI, V45, P447, DOI 10.1016/0024 3205(89)90631 0
   Gandhi R, 2004, J NEUROSCI, V24, P9405, DOI 10.1523/JNEUROSCI.0899 04.2004
   GarciaAnoveros J, 1997, ANNU REV NEUROSCI, V20, P567, DOI 10.1146/annurev.neuro.20.1.567
   Genant HK, 2005, CURR MED RES OPIN, V21, P1027, DOI 10.1185/030079905X49671
   Govea RM, 2012, NEUROSCIENCE, V217, P130, DOI 10.1016/j.neuroscience.2012.05.014
   Guan ZH, 2016, NAT NEUROSCI, V19, P94, DOI 10.1038/nn.4189
   Hadji P, 2012, OSTEOPOROSIS INT, V23, P2141, DOI 10.1007/s00198 011 1856 y
   HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304 3959(88)90026 7
   Hoare SRJ, 1999, ENDOCRINOLOGY, V140, P4419, DOI 10.1210/en.140.10.4419
   Holmes FE, 2003, P NATL ACAD SCI USA, V100, P6180, DOI 10.1073/pnas.0937087100
   Inoue K, 2018, NAT REV NEUROSCI, V19, P138, DOI 10.1038/nrn.2018.2
   Isogai Y, 2015, CALCIFIED TISSUE INT, V97, P412, DOI 10.1007/s00223 015 0026 1
   Ito A, 2004, BONE, V35, P697, DOI 10.1016/j.bone.2004.04.012
   Ito A, 2000, J NEUROSCI, V20, P6302, DOI 10.1523/JNEUROSCI.20 16 06302.2000
   Jakob F, 2012, EUR J ENDOCRINOL, V166, P87, DOI 10.1530/EJE 11 0740
   JI RR, 1995, NEUROSCIENCE, V68, P563, DOI 10.1016/0306 4522(95)94333 T
   Ji RR, 2014, NAT REV DRUG DISCOV, V13, P533, DOI 10.1038/nrd4334
   Kakimoto S, 2008, EUR J PHARMACOL, V589, P98, DOI 10.1016/j.ejphar.2008.05.011
   KONIETZNY F, 1984, HUM NEUROBIOL, V3, P21
   Kras JV, 2013, SPINE, V38, P217, DOI 10.1097/BRS.0b013e3182685ba1
   Kuriwaka Kido R, 2013, ENDOCRINOLOGY, V154, P1156, DOI 10.1210/en.2013 1915
   LaCroix Fralish ML, 2007, PAIN, V131, DOI 10.1016/j.pain.2007.04.041
   Langdahl BL, 2016, CALCIFIED TISSUE INT, V99, P259, DOI 10.1007/s00223 016 0143 5
   Langdahl BL, 2009, CALCIFIED TISSUE INT, V85, P484, DOI 10.1007/s00223 009 9299 6
   Li LH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094312
   Lyritis G, 2010, CURR MED RES OPIN, V26, P1799, DOI 10.1185/03007995.2010.488516
   Mach DB, 2002, NEUROSCIENCE, V113, P155, DOI 10.1016/S0306 4522(02)00165 3
   Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816
   Malin SA, 2010, MOL PAIN, V6, DOI 10.1186/1744 8069 6 21
   Mantyh PW, 2014, EUR J NEUROSCI, V39, P508, DOI 10.1111/ejn.12462
   Marker CL, 2002, NEUROREPORT, V13, P2509, DOI 10.1097/00001756 200212200 00026
   Masuda T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4771
   Mika J, 2010, NEUROSCIENCE, V165, P1420, DOI 10.1016/j.neuroscience.2009.11.064
   Miller PD, 2005, J RHEUMATOL, V32, P1556
   Moshourab RA, 2013, J PHYSIOL LONDON, V591, P5555, DOI 10.1113/jphysiol.2013.261180
   Nevitt MC, 2006, OSTEOPOROSIS INT, V17, P1630, DOI 10.1007/s00198 006 0177 z
   Nevitt MC, 2006, OSTEOPOROSIS INT, V17, P273, DOI 10.1007/s00198 005 2013 2
   Orita S., 2012, OSTEOPOROSIS, P541
   Orita S, 2010, SPINE, V35, P1974, DOI 10.1097/BRS.0b013e3181d5959e
   RYAN PJ, 1992, J BONE MINER RES, V7, P1455
   Sarajari S, 2010, EXP NEUROL, V224, P163, DOI 10.1016/j.expneurol.2010.03.006
   Scharla S, 2006, CURR MED RES OPIN, V22, P2393, DOI 10.1185/030079906X154097
   Shepherd AJ, 2018, EUR J PAIN, V22, P1685, DOI 10.1002/ejp.1251
   Shibata K, 1998, PHARMACOL BIOCHEM BE, V60, P371, DOI 10.1016/S0091 3057(98)00015 X
   Silverman SL, 2005, J RHEUMATOL, V32, P2405
   Sloan AV, 2010, BONE, V47, P235, DOI 10.1016/j.bone.2010.05.015
   Sugie Oya A, 2016, J BONE MINER METAB, V34, P303, DOI 10.1007/s00774 015 0670 6
   Sun RQ, 2004, J NEUROPHYSIOL, V92, P2859, DOI 10.1152/jn.00339.2004
   Suzuki M, 2017, J OSTEOPOROS, V2017, DOI 10.1155/2017/7582716
   Takahashi Y, 2015, J JPN OSTEOPOR SOC, V1, P49
   Thier M, 1999, MOL BRAIN RES, V64, P80, DOI 10.1016/S0169 328X(98)00329 5
   Tsuchie H, 2016, J BONE MINER METAB, V34, P86, DOI 10.1007/s00774 014 0646 y
   Tsuda M, 2013, GLIA, V61, P55, DOI 10.1002/glia.22379
   Tu WZ, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/642081
   Walmsley M, 1998, IMMUNOLOGY, V95, P31
   Wetzel C, 2007, NATURE, V445, P206, DOI 10.1038/nature05394
   Wetzel C, 2017, NAT NEUROSCI, V20, P209, DOI 10.1038/nn.4454
   Yoneda T, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.58
   Zheng XF, 2013, MENOPAUSE, V20, P1074, DOI [10.1097/GME.0b013e31828837a6, 10.1097/gme.0b013e31828837a6]
NR 67
TC 14
Z9 14
U1 1
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 24
PY 2020
VL 10
IS 1
AR 5346
DI 10.1038/s41598 020 62045 4
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NF5XO
UT WOS:000563370200036
PM 32210273
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ho, ML
   Hsu, CJ
   Wu, CW
   Chang, LH
   Chen, JW
   Chen, CH
   Huang, KC
   Chang, JK
   Wu, SC
   Shao, PL
AF Ho, Mei Ling
   Hsu, Chin Jung
   Wu, Che Wei
   Chang, Ling Hua
   Chen, Jhen Wei
   Chen, Chung Hwan
   Huang, Kui Chou
   Chang, Je Ken
   Wu, Shun Cheng
   Shao, Pei Lin
TI Enhancement of Osteoblast Function through Extracellular Vesicles
   Derived from Adipose Derived Stem Cells
SO BIOMEDICINES
LA English
DT Article
DE bone tissue engineering (BTE); adipose derived stem cells (ADSCs);
   extracellular vesicles (EVs); osteoblast function; microRNA (miRNA)
ID MEMBRANE VESICLES; GENE EXPRESSION; BONE FORMATION; EXOSOMES;
   MINERALIZATION; MECHANISM; DIFFERENTIATION; MICROVESICLES; STRATEGIES;
   THERAPIES
AB Adipose derived stem cells (ADSCs) are a type of mesenchymal stem cell that is investigated in bone tissue engineering (BTE). Osteoblasts are the main cells responsible for bone formation in vivo and directing ADSCs to form osteoblasts through osteogenesis is a research topic in BTE. In addition to the osteogenesis of ADSCs into osteoblasts, the crosstalk of ADSCs with osteoblasts through the secretion of extracellular vesicles (EVs) may also contribute to bone formation in ADSC based BTE. We investigated the effect of ADSC secreted EVs (ADSC EVs) on osteoblast function. ADSC EVs (size <= 1000 nm) were isolated from the culture supernatant of ADSCs through ultracentrifugation. The ADSC EVs were observed to be spherical under a transmission electron microscope. The ADSC EVs were positive for CD9, CD81, and Alix, but beta actin was not detected. ADSC EV treatment did not change survival but did increase osteoblast proliferation and activity. The 48 most abundant known microRNAs (miRNAs) identified within the ADSC EVs were selected and then subjected to gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The GO analysis revealed that these miRNAs are highly relevant to skeletal system morphogenesis and bone development. The KEGG analysis indicated that these miRNAs may regulate osteoblast function through autophagy or the mitogen activated protein kinase or Ras related protein 1 signaling pathway. These results suggest that ADSC EVs enhance osteoblast function and can contribute to bone regeneration in ADSC based BTE.
C1 [Ho, Mei Ling; Wu, Che Wei; Chang, Ling Hua; Chen, Jhen Wei; Chen, Chung Hwan; Chang, Je Ken; Wu, Shun Cheng] Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr, Kaohsiung 80787, Taiwan.
   [Ho, Mei Ling; Wu, Che Wei; Chang, Ling Hua; Chen, Jhen Wei; Chen, Chung Hwan; Chang, Je Ken; Wu, Shun Cheng] Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung 80787, Taiwan.
   [Ho, Mei Ling] Kaohsiung Med Univ, Coll Med, Dept Physiol, Kaohsiung 80787, Taiwan.
   [Ho, Mei Ling] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 80787, Taiwan.
   [Ho, Mei Ling] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung 804201, Taiwan.
   [Ho, Mei Ling] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 80756, Taiwan.
   [Hsu, Chin Jung] China Med Univ Hosp, Dept Orthoped, Taichung 404332, Taiwan.
   [Hsu, Chin Jung] China Med Univ, Sch Chinese Med, Taichung 406040, Taiwan.
   [Chen, Chung Hwan; Chang, Je Ken] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthoped, Kaohsiung 80787, Taiwan.
   [Chen, Chung Hwan] Kaohsiung Med Univ, Coll Med, Dept Orthoped, Kaohsiung 80787, Taiwan.
   [Chen, Chung Hwan] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Orthoped, Kaohsiung 80787, Taiwan.
   [Chen, Chung Hwan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthoped, Div Adult Reconstruct Surg, Kaohsiung 80787, Taiwan.
   [Chen, Chung Hwan] Kaohsiung Med Univ, Coll Med, Program Biomed Engn, Kaohsiung 80708, Taiwan.
   [Huang, Kui Chou] Asia Univ Hosp, Dept Orthoped, Taichung 413505, Taiwan.
   [Huang, Kui Chou] Asia Univ, Dept Occupat Therapy, Taichung 41354, Taiwan.
   [Wu, Shun Cheng] Asia Univ, Postbaccalaureate Program Nursing, Taichung 41354, Taiwan.
   [Shao, Pei Lin] Asia Univ, Dept Nursing, Taichung 41354, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; National Sun Yat Sen
   University; Kaohsiung Medical University; Kaohsiung Medical University
   Hospital; China Medical University Taiwan; China Medical University
   Hospital   Taiwan; China Medical University Taiwan; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital; Kaohsiung Medical
   University; Kaohsiung Medical University; Kaohsiung Municipal Ta Tung
   Hospital; Kaohsiung Medical University; Kaohsiung Medical University
   Hospital; Kaohsiung Medical University; Asia University Taiwan; Asia
   University Taiwan; Asia University Taiwan
RP Wu, SC (通讯作者)，Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr, Kaohsiung 80787, Taiwan.; Wu, SC (通讯作者)，Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung 80787, Taiwan.; Wu, SC (通讯作者)，Asia Univ, Postbaccalaureate Program Nursing, Taichung 41354, Taiwan.; Shao, PL (通讯作者)，Asia Univ, Dept Nursing, Taichung 41354, Taiwan.
EM homelin@kmu.edu.tw; jeffrey59835983@gmail.com; tkdiven@gmail.com;
   linghua_chang@yahoo.com.tw; h90085663@gmail.com; hwan@kmu.edu.tw;
   kuichouhuang@gmail.com; jkchang@kmu.edu.tw; shunchengwu@hotmail.com;
   m8951016@gmail.com
RI Wu, Shun Cheng/E 2989 2010; Wu, Che Wei/IVH 9813 2023; Ho,
   Mei Ling/D 5515 2009; Chen, Chung Hwan/D 4036 2009
OI Wu, Che Wei/0000 0001 6464 8525; Shao, Pei Lin/0000 0001 6920 0447;
   Huang, Kui chou/0000 0003 2003 1384; chang, linghua/0000 0002 9569 6033;
   Chang, Je Ken/0000 0001 8485 2574; Wu, Shun Cheng/0000 0003 4219 3413;
   Chen, Chung Hwan/0000 0001 8941 4792
FU Ministry of Science and Technology [MOST 107 2635 B 468 003, MOST
   109 2314 B 037 144 ]; Asia University [ASIA 108 CMUH 13,
   ASIA 109 CMUH 31]; Kaohsiung Medical University Research Center
   [KMU TC109A02 0, KMU TC109A02 1, KMU TC111A02 0, KMUTC111IFSP03]
FX The authors acknowledge the support for this study provided by the
   Ministry of Science and Technology (MOST 107 2635 B 468 003 and MOST
   109 2314 B 037 144 ); the Asia University (grants: ASIA 108 CMUH 13 and
   ASIA 109 CMUH 31); and Kaohsiung Medical University Research Center
   (grants: KMU TC109A02 0, KMU TC109A02 1, KMU TC111A02 0, and
   KMUTC111IFSP03).
CR Al Ghadban S, 2022, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.837464
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Barba M, 2017, EXPERT OPIN BIOL TH, V17, P677, DOI 10.1080/14712598.2017.1315403
   Blankenberg D, 2010, BIOINFORMATICS, V26, P1783, DOI 10.1093/bioinformatics/btq281
   Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278
   Chen HT, 2012, J CELL MOL MED, V16, DOI 10.1111/j.1582 4934.2011.01335.x
   Chen S, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12669
   Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003
   De Jong OG, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00608
   DERFUS BA, 1992, ARTHRITIS RHEUM, V35, P231, DOI 10.1002/art.1780350218
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Eirin A, 2014, GENE, V551, P55, DOI 10.1016/j.gene.2014.08.041
   Gómez Barrena E, 2015, BONE, V70, P93, DOI 10.1016/j.bone.2014.07.033
   György B, 2011, CELL MOL LIFE SCI, V68, P2667, DOI 10.1007/s00018 011 0689 3
   He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945
   Henry J.P, 2021, Histology, osteoblasts, statpearls, statpearls publishing Copyright © 2021
   Ho Shui Ling A, 2018, BIOMATERIALS, V180, P143, DOI 10.1016/j.biomaterials.2018.07.017
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Katsuda T, 2013, SCI REP UK, V3, DOI 10.1038/srep01197
   Kito H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910459
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   Li CJ, 2010, BIOCHEM PHARMACOL, V79, P926, DOI 10.1016/j.bcp.2009.10.019
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp698, 10.1093/bioinformatics/btp352]
   Li WY, 2018, ACS APPL MATER INTER, V10, P5240, DOI 10.1021/acsami.7b17620
   Liang QJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.595108
   Lin TM, 2005, STEM CELLS DEV, V14, P92, DOI 10.1089/scd.2005.14.92
   Liu N, 2021, REGEN MED, V16, P435, DOI 10.2217/rme 2020 0006
   Liu XS, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859 019 2936 9
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lösche W, 2004, PLATELETS, V15, P109, DOI 10.1080/09537100310001649885
   Lötvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913
   Ma WJ, 2007, BIOMATERIALS, V28, P1620, DOI 10.1016/j.biomaterials.2006.12.010
   Magne D, 2003, J BONE MINER RES, V18, P1430, DOI 10.1359/jbmr.2003.18.8.1430
   Makino T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082430
   Marie PJ, 2013, NAT REV ENDOCRINOL, V9, P288, DOI 10.1038/nrendo.2013.4
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Mende W, 2021, CELLS BASEL, V10, DOI 10.3390/cells10050975
   Mou S, 2019, PLAST RECONSTR SURG, V144, P869, DOI 10.1097/PRS.0000000000006046
   Nancarrow Lei R, 2017, CURR STEM CELL RES T, V12, P601, DOI 10.2174/1574888X12666170608124303
   Nemcakova I, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 09183 z
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Ottewell PD, 2016, J BONE ONCOL, V5, P124, DOI 10.1016/j.jbo.2016.03.007
   Pignolo RJ, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10488
   Presen DM, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00352
   Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100
   Purushothaman A, 2019, METHODS MOL BIOL, V1952, P233, DOI 10.1007/978 1 4939 9133 4_19
   Relic B, 2001, J IMMUNOL, V166, P2775, DOI 10.4049/jimmunol.166.4.2775
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Salgado AJ, 2010, CURR STEM CELL RES T, V5, P103
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Shao Y Z, 2020, Zhonghua Kou Qiang Yi Xue Za Zhi, V55, P206, DOI 10.3760/cma.j.issn.1002 0098.2020.03.013
   Storti G, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/3673857
   Struber A, 2022, BIOENGINEERING BASEL, V9, DOI 10.3390/bioengineering9020060
   Takács R, 2013, INT J MOL SCI, V14, P16141, DOI 10.3390/ijms140816141
   Tan SHS, 2020, MATER TODAY BIO, V7, DOI 10.1016/j.mtbio.2020.100067
   Théry C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Tieu A, 2020, ACS NANO, V14, P9728, DOI 10.1021/acsnano.0c01363
   Tofiño Vian M, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/7197598
   Toh WS, 2014, STEM CELL REV REP, V10, P686, DOI 10.1007/s12015 014 9526 z
   Turturici G, 2014, AM J PHYSIOL CELL PH, V306, pC621, DOI 10.1152/ajpcell.00228.2013
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   van der Pol E, 2012, PHARMACOL REV, V64, P676, DOI 10.1124/pr.112.005983
   van Dommelen SM, 2012, J CONTROL RELEASE, V161, P635, DOI 10.1016/j.jconrel.2011.11.021
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wang YJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4243015
   Wei JF, 2014, STEM CELLS DEV, V23, P1452, DOI 10.1089/scd.2013.0600
   Wickham H., 2016, GGPLOT2 ELEGANT GRAP, P189, DOI [10.1007/978 3 319 24277 4_9, DOI 10.1007/978 3 319 24277 4_9]
   Wu SC, 2018, INT J BIOL MACROMOL, V119, P726, DOI 10.1016/j.ijbiomac.2018.07.054
   Wu SC, 2018, ACTA BIOMATER, V66, P224, DOI 10.1016/j.actbio.2017.11.025
   Wu YG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143777
   Xu LJ, 2020, ADV MATER, V32, DOI 10.1002/adma.201907491
   Yang XC, 2019, AGING US, V11, P8777, DOI 10.18632/aging.102264
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yuan HR, 2019, CELL DEATH DIFFER, V26, P2029, DOI 10.1038/s41418 019 0296 7
   Zhang Y, 2021, CYTOTECHNOLOGY, V73, P79, DOI 10.1007/s10616 020 00444 1
   Zhang Y, 2021, LIFE SCI, V272, DOI 10.1016/j.lfs.2021.119204
NR 81
TC 11
Z9 11
U1 2
U2 15
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD JUL
PY 2022
VL 10
IS 7
AR 1752
DI 10.3390/biomedicines10071752
PG 22
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA 3H3MK
UT WOS:000831942800001
PM 35885057
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shin, J
   Jang, H
   Lin, J
   Lee, SY
AF Shin, Jihye
   Jang, Hyunduk
   Lin, Jingjing
   Lee, Soo Young
TI PKCβ Positively Regulates RANKL Induced Osteoclastogenesis by
   Inactivating GSK 3β
SO MOLECULES AND CELLS
LA English
DT Article
DE glycogen synthase kinase 3 beta; osteoclast differentiation; protein
   kinase C beta; receptor activator of NF kappa B ligand
ID PROTEIN KINASE C; GLYCOGEN SYNTHASE KINASE 3 BETA; NECROSIS FACTOR
   RECEPTOR; DIFFERENTIATION; ACTIVATION; LIGAND; CELLS; NFAT;
   PHOSPHORYLATION; INDUCTION
AB Protein kinase C (PKC) family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. However, the role of PKC in receptor activator of NF kappa B ligand (RANKL) signaling has remained elusive. We now demonstrate that PKC beta acts as a positive regulator which inactivates glycogen synthase kinase 3 beta (GSK 3 beta) and promotes NFATc1 induction during RANKL induced osteoclastogenesis. Among PKCs, PKC. expression is increased by RANKL. Pharmacological inhibition of PKC. decreased the formation of osteoclasts which was caused by the inhibition of NFATc1 induction. Importantly, the phosphorylation of GSK 3 beta was decreased by PKC beta inhibition. Likewise, down regulation of PKC beta by RNA interference suppressed osteoclast differentiation, NFATc1 induction, and GSK 3. phosphorylation. The administration of PKC inhibitor to the RANKL injected mouse calvaria efficiently protected RANKL induced bone destruction. Thus, the PKC beta pathway, leading to GSK 3. inactivation and NFATc1 induction, has a key role in the differentiation of osteoclasts. Our results also provide a further rationale for PKC beta's therapeutic targeting to treat inflammation related bone diseases.
C1 [Shin, Jihye; Jang, Hyunduk; Lin, Jingjing; Lee, Soo Young] Ewha Womans Univ, Dept Life Sci, Seoul 120750, South Korea.
   [Shin, Jihye; Jang, Hyunduk; Lin, Jingjing; Lee, Soo Young] Ewha Womans Univ, Res Ctr Cellular Homeostasis, Seoul 120750, South Korea.
C3 Ewha Womans University; Ewha Womans University
RP Lee, SY (通讯作者)，Ewha Womans Univ, Dept Life Sci, Seoul 120750, South Korea.
EM leesy@ewha.ac.kr
OI Lin, Jingjing/0000 0002 9194 6154
FU National Research Foundation of Korea (NRF)   Korea Government (MSIP)
   [2013R1A2A1A05005153, 2012R1A5A1048236, 2012M3A9C5048708]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea Government (MSIP) (No.
   2013R1A2A1A05005153; No. 2012R1A5A1048236; No. 2012M3A9C5048708).
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choi HK, 2013, CELL RES, V23, P524, DOI 10.1038/cr.2013.33
   Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092 8674(02)00699 2
   Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384
   Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099 2110.2002
   Geraldes P, 2010, CIRC RES, V106, P1319, DOI 10.1161/CIRCRESAHA.110.217117
   GOODE N, 1992, J BIOL CHEM, V267, P16878
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Jang HD, 2013, BONE, V55, P126, DOI 10.1016/j.bone.2013.02.005
   Jang HD, 2011, J BIOL CHEM, V286, P39043, DOI 10.1074/jbc.M111.256768
   Kawakami T, 2002, J BIOCHEM, V132, P677, DOI 10.1093/oxfordjournals.jbchem.a003273
   Kim H, 2009, J CLIN INVEST, V119, P813, DOI 10.1172/JCI36809
   Kim JH, 2010, CELL SIGNAL, V22, P1341, DOI 10.1016/j.cellsig.2010.05.001
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee JS, 2007, DIABETES RES CLIN PR, V77, pS49, DOI 10.1016/j.diabres.2007.01.033
   Lee SW, 2003, BONE, V32, P217, DOI 10.1016/S8756 3282(02)00976 6
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Roffey J, 2009, CURR OPIN CELL BIOL, V21, P268, DOI 10.1016/j.ceb.2009.01.019
   Saito N, 2002, J DIABETES COMPLICAT, V16, P4, DOI 10.1016/S1056 8727(01)00200 8
   Schiaffino S, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044 5040 1 4
   Steinberg SF, 2008, PHYSIOL REV, V88, P1341, DOI 10.1152/physrev.00034.2007
   Suda T, 1997, METHOD ENZYMOL, V282, P223
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tan SL, 2003, BIOCHEM J, V376, P545, DOI 10.1042/BJ20031406
   Vilimek D, 2006, BIOCHEM CELL BIOL, V84, P20, DOI 10.1139/O05 154
   Wang JH, 2006, J CELL BIOL, V174, P689, DOI 10.1083/jcb.200605140
   Wang QD, 2006, NEOPLASIA, V8, P781, DOI 10.1593/neo.06259
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhu T, 2010, ONCOGENE, V29, P1050, DOI 10.1038/onc.2009.344
NR 35
TC 22
Z9 24
U1 0
U2 4
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635 4, YUCKSAM DONG, GANGNAM GU, SEOUL 135 703, SOUTH KOREA
SN 1016 8478
EI 0219 1032
J9 MOL CELLS
JI Mol. Cells
PD OCT
PY 2014
VL 37
IS 10
BP 747
EP 752
DI 10.14348/molcells.2014.0220
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AU7DL
UT WOS:000345760800007
PM 25256217
OA Green Submitted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Liu, XL
   Li, CC
   Liu, KJ
   Cui, CY
   Zhang, YZ
   Liu, Y
AF Liu, Xiao Li
   Li, Chang Cheng
   Liu, Ke Jian
   Cui, Cai Yan
   Zhang, Yu Zeng
   Liu, Yun
TI The Influence of Fluoride on the Expression of Inhibitors of
   Wnt/β Catenin Signaling Pathway in Rat Skin Fibroblast Cells
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Fluoride; Fibroblast; Sclerostin; Dickkopf 1
ID BONE FORMATION; SECRETED PROTEIN; SOST GENE; SCLEROSTIN; DELETION;
   OSTEOBLAST; DICKKOPF 1; BINDING; SERUM; DKK1
AB The effective therapy of fluoride induced bone diseases requires an understanding of the mechanism of the disorders. Changes in the inhibitors of the Wnt/beta catenin pathway, Dickkopf 1 (Dkk 1) and Sclerostin (SOST), were studied in supernatants harvested from rat skin fibroblasts cultured with varied doses of fluoride. The contents of SOST and Dkk 1 in fibroblast supernatants were assessed at four exposure time points and investigated by using the method of ELISA. Compared to the relevant controls (0 mg F /L), a significant decrease of the concentrations of SOST and Dkk 1 was observed as the fluoride concentration increased. Compared to the relevant time controls (24 h), a significant decrease of the concentrations of SOST and Dkk 1 was observed with the extension of time. Our results suggest that the Wnt/beta catenin pathway inhibitors Dkk 1 and SOST play an important role in skeletal fluorosis. They can be used as important indications for diagnosing bone metabolism changes caused by fluoride exposure and therapeutic targets in diseases resulting from fluoride exposure.
C1 [Liu, Xiao Li; Li, Chang Cheng; Liu, Ke Jian; Cui, Cai Yan; Zhang, Yu Zeng; Liu, Yun] Huazhong Univ Sci & Technol, Dept Occupat & Environm Hlth, Sch Publ Hlth, Tongji Med Coll, Hubei Wuhan 430030, Peoples R China.
C3 Huazhong University of Science & Technology
RP Liu, KJ (通讯作者)，Huazhong Univ Sci & Technol, Dept Occupat & Environm Hlth, Sch Publ Hlth, Tongji Med Coll, Hubei Wuhan 430030, Peoples R China.
EM abc4933483@163.com
RI Liu, Xiaoli/M 5410 2013; Cui, Caiyan/GXH 3824 2022
FU National Natural Science Foundation of China (NSFC) [81072255]
FX This research was sponsored by the National Natural Science Foundation
   of China (NSFC) (no. 81072255).
CR Ba Y, 2010, CHINESE MED J PEKING, V123, P675, DOI 10.3760/cma.j.issn.0366 6999.2010.06.007
   Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Balemans W, 2008, CALCIFIED TISSUE INT, V82, P445, DOI 10.1007/s00223 008 9130 9
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bourhis E, 2011, STRUCTURE, V19, P1433, DOI 10.1016/j.str.2011.07.005
   Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100 6110.2002
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131
   Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899
   Hussain I, 2012, ENVIRON MONIT ASSESS, V184, P5151, DOI 10.1007/s10661 011 2329 7
   Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Luo KL, 2012, ENVIRON GEOCHEM HLTH, V34, P89, DOI 10.1007/s10653 011 9393 3
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Song Yu e, 2011, Environmental Health and Preventive Medicine, V16, P158, DOI 10.1007/s12199 010 0181 y
   Tamer MN, 2007, SCI TOTAL ENVIRON, V373, P43, DOI 10.1016/j.scitotenv.2006.10.051
   Torra M, 1998, BIOL TRACE ELEM RES, V63, P67, DOI 10.1007/BF02785278
   Zhou ZR, 1997, CHIN J CTRL ENDEM DI, V12, P50
NR 26
TC 22
Z9 30
U1 0
U2 13
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163 4984
EI 1559 0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD JUL
PY 2012
VL 148
IS 1
BP 117
EP 121
DI 10.1007/s12011 012 9333 9
PG 5
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 956ZP
UT WOS:000305128400017
PM 22290293
DA 2025 08 17
ER

PT J
AU He, M
   Wang, JS
   Wang, GB
   Tian, Y
   Jiang, LL
   Ren, ZZ
   Qiu, C
   Fu, Q
AF He, Ming
   Wang, Jiashi
   Wang, Guangbin
   Tian, Ye
   Jiang, Linlin
   Ren, Zhaozhou
   Qiu, Chuang
   Fu, Qin
TI Effect of glucocorticoids on osteoclast function in a mouse model of
   bone necrosis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE glucocorticoid; osteonecrosis; osteoclast; osteoblast
ID TRAUMATIC AVASCULAR NECROSIS; OSTEOBLAST DIFFERENTIATION; FEMORAL HEAD;
   INDUCED OSTEONECROSIS; RANK LIGAND; EXPRESSION; OSTEOPROTEGERIN;
   RABBITS; CELLS; ORCHESTRATION
AB Osteonecrosis, also termed aseptic necrosis, is the cellular death of bone components due to interruption of the blood supply. Glucocorticoid (GC) therapy is a common non traumatic cause of osteonecrosis. However, the mechanism by which GCs induce osteonecrosis remains to be elucidated. The aim of the present study was to investigate the effects of GCs on osteoclast and osteoblast differentiation and function in a GC induced osteonecrosis mouse model. BALB/c male mice (n=40; 4 weeks old) were treated with dexamethasone and asparaginase for 8 weeks. The control group (n=20) was administered normal saline. The results demonstrated that the GC treated group had a lower mean weight compared with the control group. Morphologically, 16/37 (43%) mice demonstrated significant osteonecrotic lesions in the GC treated group. However, osteonecrotic lesions were not observed in the mice of the control group. Furthermore, immunohistochemistry demonstrated that the GC treated group had a higher level of osteoprotegerin compared with the control group, without any change in the expression of receptor activator of nuclear factor kappa B ligand. In addition, tartarate resistant acid phosphatase staining demonstrated significantly decreased osteoclasts in the areas of bone destruction in the GCs treated group. Furthermore, the present study demonstrated that GCs increased expression levels of osterix and osteocalcin, and decreased expression of matrix metallopeptidase 9 to regulate the differentiation and function of osteoblasts and osteoclasts. The results of the present study suggested that GCs influence bone remolding resulting in decreased osteoclasts formation/differentiation. Therefore, regulating the differentiation and activity of the osteoclasts may be beneficial to the control and treatment of osteonecrosis.
C1 [He, Ming; Wang, Jiashi; Wang, Guangbin; Tian, Ye; Jiang, Linlin; Ren, Zhaozhou; Qiu, Chuang; Fu, Qin] China Med Univ, Shengjing Hosp, Dept Orthoped, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China.
C3 China Medical University
RP Fu, Q (通讯作者)，China Med Univ, Shengjing Hosp, Dept Orthoped, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China.
EM topheming56@163.com
RI Ren, Zhaozhou/ADI 5080 2022
FU National Natural Science Foundation of China [81070688]
FX The present study was supported by the National Natural Science
   Foundation of China (no. 81070688).
CR BAKSI DP, 1983, J BONE JOINT SURG BR, V65, P268, DOI 10.1302/0301 620X.65B3.6341373
   Blair JM, 2007, INT J BIOCHEM CELL B, V39, P1077, DOI 10.1016/j.biocel.2006.11.008
   Chao YC, 2003, ALCOHOL ALCOHOLISM, V38, P431, DOI 10.1093/alcalc/agg106
   Dannemann C, 2007, BONE, V40, P828, DOI 10.1016/j.bone.2006.11.023
   DiGiovanni CW, 2007, J AM ACAD ORTHOP SUR, V15, P208, DOI 10.5435/00124635 200704000 00004
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200
   Gao YS, 2010, INT ORTHOP, V34, P457, DOI 10.1007/s00264 009 0905 z
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Grässel S, 2010, INT J MOL MED, V26, P127, DOI 10.3892/ijmm_00000444
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hofbauer LC, 2001, CANCER AM CANCER SOC, V92, P460, DOI 10.1002/1097 0142(20010801)92:3<460::AID CNCR1344>3.0.CO;2 D
   Juéry P, 2007, CAN MED ASSOC J, V176, P814, DOI 10.1503/cmaj.1060165
   Kabata T, 2005, RHEUMATOLOGY, V44, P1233, DOI 10.1093/rheumatology/keh721
   Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lafforgue P, 2006, JOINT BONE SPINE, V73, P500, DOI 10.1016/j.jbspin.2006.01.025
   Laroche M, 2002, JOINT BONE SPINE, V69, P262, DOI 10.1016/S1297 319X(02)00391 3
   LEE CK, 1981, J TRAUMA, V21, P788, DOI 10.1097/00005373 198109000 00006
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Levasseur R, 2008, JOINT BONE SPINE, V75, P639, DOI 10.1016/j.jbspin.2008.10.001
   Lian J. B., 2003, Current Pharmaceutical Design, V9, P2677, DOI 10.2174/1381612033453659
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mackie EJ, 2003, INT J BIOCHEM CELL B, V35, P1301, DOI 10.1016/S1357 2725(03)00107 9
   Martí Carvajal AJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004344.pub3
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Powell C, 2011, CLIN REV ALLERG IMMU, V41, P102, DOI 10.1007/s12016 010 8217 z
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tingart M, 2008, CALCIFIED TISSUE INT, V82, P300, DOI 10.1007/s00223 008 9111 z
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wyles CC, 2015, CLIN ORTHOP RELAT R, V473, P3080, DOI 10.1007/s11999 015 4385 8
   Yamada Y, 2003, MOL GENET METAB, V80, P344, DOI 10.1016/S1096 7192(03)00125 2
   Yamamoto T, 1997, ARTHRITIS RHEUM, V40, P2055, DOI 10.1002/art.1780401119
   YAMAMOTO T, 1995, CLIN ORTHOP RELAT R, P235
   YONEDA T, 1995, CANCER RES, V55, P1989
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 37
TC 15
Z9 19
U1 0
U2 14
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD AUG
PY 2016
VL 14
IS 2
BP 1054
EP 1060
DI 10.3892/mmr.2016.5368
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DQ9UK
UT WOS:000379554600002
PM 27277157
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Hewitt, RE
   Lissina, A
   Green, AE
   Slay, ES
   Price, DA
   Sewell, AK
AF Hewitt, RE
   Lissina, A
   Green, AE
   Slay, ES
   Price, DA
   Sewell, AK
TI The bisphosphonate acute phase response:: rapid and copious production
   of proinflammatory cytokines by peripheral blood γδ T cells in response
   to aminobisphosphonates is inhibited by statins
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE bisphosphonates; acute phase response; proinflammatory cytokines; gamma
   delta T cells; aminobisphosphonates; statins
ID NITROGEN CONTAINING BISPHOSPHONATES; FARNESYL PYROPHOSPHATE SYNTHASE;
   ACTIVATION IN VITRO; NONPEPTIDE ANTIGENS; DIPHOSPHATE SYNTHASE;
   PAGETS DISEASE; AIRWAY HYPERREACTIVITY; ANTIINFLAMMATORY ROLE;
   OSTEOCLAST FORMATION; MEVALONATE PATHWAY
AB The bisphosphonates are a novel class of drug that have been registered for various clinical applications worldwide. Bisphosphonates, and in particular the aminobisphosphonates (nBPs), are known to have a number of side effects including a rise in body temperature and accompanying flu like symptoms that resemble a typical acute phase response. The mechanism for this response has been partially elucidated and appears to be associated with the release of tumour necrosis factor (TNF)alpha and interleukin (IL)6, although the effector cells that release these cytokines and the mechanism of action remain enigmatic. Here, we show that the nBP induced acute phase response differs from the typical acute phase response in that CD14(+) cells such as monocytes and macrophages are not the primary cytokine producing cells. We show that by inhibiting the mevalonate pathway, nBPs induce rapid and copious production of TNFalpha and IL6 by peripheral blood gammadelta T cells. Prior treatment with statins, which inhibit 3 hydroxy 3 methylglutaryl coenzyme A (HMG CoA) reductase, blocks nBP induced production of these proinflammatory cytokines by gammadelta T cells and may offer a means of avoiding the associated acute phase response. In addition, our findings provide a further mechanism for the anti inflammatory effects attributed to inhibitors of HMG CoA reductase.
C1 T Cell Modulat Grp, Oxford OX1 3SY, England.
   Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia.
   NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
C3 University of Oxford; University of South Australia; National Institutes
   of Health (NIH)   USA; NIH National Institute of Allergy & Infectious
   Diseases (NIAID)
RP T Cell Modulat Grp, Peter Medawar Bldg Pathogen Res,S Parks Rd, Oxford OX1 3SY, England.
EM andy.sewell@ndm.ox.ac.uk
RI Price, David/C 7876 2013; Hewitt, Rachel/N 4596 2018; Sewell,
   Andrew/GPT 4220 2022
OI Price, David/0000 0001 9416 2737; Sewell, Andrew/0000 0003 3194 3135;
   Hewitt, Rachel/0000 0002 2367 1822; Fenton May,
   Angharad/0000 0002 6267 1315; Lissina, Anya/0000 0001 9019 9145; 
FU MRC [G108/441] Funding Source: UKRI; Medical Research Council [G108/441]
   Funding Source: Medline; Multiple Sclerosis Society [589] Funding
   Source: Medline
CR ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Berenson JR, 2002, SEMIN ONCOL, V29, P12, DOI 10.1053/sonc.2002.37417
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Blanco Colio LM, 2003, KIDNEY INT, V63, P12, DOI 10.1046/j.1523 1755.2003.00744.x
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Coleman RE, 2002, SEMIN ONCOL, V29, P43, DOI 10.1053/sonc.2002.37415
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Corsini A, 1999, PHARMACOL THERAPEUT, V84, P413, DOI 10.1016/S0163 7258(99)00045 5
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Crisby M, 2003, DRUG TODAY, V39, P137, DOI 10.1358/dot.2003.39.2.740209
   Czyzyk J, 2003, P NATL ACAD SCI USA, V100, P6003, DOI 10.1073/pnas.1031494100
   Das H, 2001, BLOOD, V98, P1616, DOI 10.1182/blood.V98.5.1616
   DAVODEAU F, 1993, J IMMUNOL, V151, P1214
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Delmas PD, 1997, NEW ENGL J MED, V336, P558, DOI 10.1056/NEJM199702203360807
   DEVRIES E, 1982, IMMUNOLOGY, V47, P157
   Diomede L, 2001, ARTERIOSCL THROM VAS, V21, P1327, DOI 10.1161/hq0801.094222
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FITTON A, 1991, DRUGS, V41, P289, DOI 10.2165/00003495 199141020 00009
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607
   GALLACHER SJ, 1989, LANCET, V2, P42
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Gossman W, 2002, J MED CHEM, V45, P4868, DOI 10.1021/jm020224n
   Graham DY, 1997, AM J GASTROENTEROL, V92, P1322
   Green AE, 2004, CLIN EXP IMMUNOL, V136, P472, DOI 10.1111/j.1365 2249.2004.02472.x
   Greenwood J, 2003, FASEB J, V17, P905, DOI 10.1096/fj.02 1014fje
   Hahn YS, 2004, J IMMUNOL, V172, P2894, DOI 10.4049/jimmunol.172.5.2894
   Hahn YS, 2003, J IMMUNOL, V171, P3170, DOI 10.4049/jimmunol.171.6.3170
   Kato Y, 2003, J IMMUNOL, V170, P3608, DOI 10.4049/jimmunol.170.7.3608
   Kato Y, 2001, J IMMUNOL, V167, P5092, DOI 10.4049/jimmunol.167.9.5092
   Kinlay S, 2003, CIRCULATION, V108, P1560, DOI 10.1161/01.CIR.0000091404.09558.AF
   KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Kunzmann V, 2000, BLOOD, V96, P384
   Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219
   Lahn M, 1999, NAT MED, V5, P1150, DOI 10.1038/13476
   Lefranc MP, 2001, T CELL RECEPTOR FACT
   Leung BP, 2003, J IMMUNOL, V170, P1524, DOI 10.4049/jimmunol.170.3.1524
   Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   LUFKIN EG, 1994, OSTEOPOROSIS INT, V4, P320, DOI 10.1007/BF01622190
   Makkonen N, 1999, EUR J PHARM SCI, V8, P109, DOI 10.1016/S0928 0987(98)00065 7
   März W, 2003, J CARDIOVASC RISK, V10, P169, DOI 10.1097/00043798 200306000 00004
   McKay A, 2004, J IMMUNOL, V172, P2903, DOI 10.4049/jimmunol.172.5.2903
   MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481
   Mitchell DY, 2000, J CLIN PHARMACOL, V40, P258, DOI 10.1177/00912700022008928
   Miyagawa F, 2001, J IMMUNOL, V167, P6773, DOI 10.4049/jimmunol.167.12.6773
   Mönkkönen J, 1998, LIFE SCI, V62, pPL95, DOI 10.1016/S0024 3205(97)01178 8
   Nawawi H, 2003, HORM METAB RES, V35, P479
   Nawawi H, 2003, ATHEROSCLEROSIS, V169, P283, DOI 10.1016/S0021 9150(03)00193 X
   Neville Webbe HL, 2002, CANCER TREAT REV, V28, P305, DOI 10.1016/S0305 7372(02)00095 6
   Olsson AG, 2002, ACTA PHYSIOL SCAND, V176, P147, DOI 10.1046/j.1365 201X.2002.01017.x
   Pate Gordon E., 2003, Journal of Cardiovascular Pharmacology and Therapeutics, V8, P201, DOI 10.1177/107424840300800305
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Roux C, 1999, DRUGS, V58, P823, DOI 10.2165/00003495 199958050 00005
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Sanders JM, 2004, J MED CHEM, V47, P375, DOI 10.1021/jm0303709
   Sanders JM, 2003, J MED CHEM, V46, P5171, DOI 10.1021/jm0302344
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   SCHWEITZER DH, 1995, J BONE MINER RES, V10, P956
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   Sparrow CP, 2001, ARTERIOSCL THROM VAS, V21, P115, DOI 10.1161/01.ATV.21.1.115
   Stüve O, 2003, CURR OPIN NEUROL, V16, P393, DOI 10.1097/01.wco.0000073942.19076.d1
   Stüve O, 2003, EXPERT OPIN THER TAR, V7, P613
   Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486
   TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0
   TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   Thompson K, 2002, BIOCHEM BIOPH RES CO, V290, P869, DOI 10.1006/bbrc.2001.6289
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   Weitz Schmidt G, 2002, TRENDS PHARMACOL SCI, V23, P482, DOI 10.1016/S0165 6147(02)02077 1
   Weitz Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058
   Yamashita S, 2003, INT IMMUNOL, V15, P1301, DOI 10.1093/intimm/dxg129
   Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158
   Zuany Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265
NR 80
TC 194
Z9 205
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0009 9104
EI 1365 2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JAN
PY 2005
VL 139
IS 1
BP 101
EP 111
DI 10.1111/j.1365 2249.2005.02665.x
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 879YF
UT WOS:000225754600014
PM 15606619
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Guan, HT
   Wang, W
   Jiang, ZC
   Zhang, BY
   Ye, ZP
   Zheng, JD
   Chen, W
   Liao, YH
   Zhang, YZ
AF Guan, Haitao
   Wang, Wei
   Jiang, Zichao
   Zhang, Boyu
   Ye, Zhipeng
   Zheng, Judun
   Chen, Wei
   Liao, Yuhui
   Zhang, Yingze
TI Magnetic Aggregation Induced Bone Targeting Nanocarrier with Effects of
   Piezo1 Activation and Osteogenic Angiogenic Coupling for Osteoporotic
   Bone Repair
SO ADVANCED MATERIALS
LA English
DT Article
DE nanocarrier; osteogenesis angiogenesis coupling; osteoporotic bone
   defect; Piezo1; targeted delivery
ID MECHANOSENSITIVE PIEZO1; BIOMIMETIC MINERALIZATION; SIGNALING PATHWAY;
   PLGA NANOPARTICLE; ION CHANNELS; IN VITRO; YAP; DELIVERY;
   BISPHOSPHONATES; HOMEOSTASIS
AB Osteoporosis, characterized by an imbalance in bone homeostasis, is a global health concern. Bone defects are difficult to heal in patients with osteoporosis. Classical drug treatments for osteoporotic bone defects have unsatisfactory efficacy owing to side effects and imprecise delivery problems. In this study, a magnetic aggregation induced bone targeting poly(lactic co glycolic acid, PLGA) based nanocarrier (ZOL PLGA@Yoda1/SPIO) is synthesized to realize dual targeted delivery and precise Piezo1 activated therapy for osteoporotic bone defects. Piezo1 is an important mechanotransducer that plays a key role in regulating bone homeostasis. To achieve dual targeting properties, ZOL PLGA@Yoda1/SPIO is fabricated using zoledronate (ZOL) decorated PLGA, superparamagnetic iron oxide (SPIO), and Piezo1 activated molecule Yoda1 via the emulsion solvent diffusion method. Bone targeting molecular mediation and magnetic aggregation induced properties can jointly and effectively achieve precise delivery to localized bone defects. Moreover, Yoda1 loading enables targeted and efficient mimicking of mechanical signals and activation of Piezo1. Experiments in vivo and in vitro demonstrate that ZOL PLGA@Yoda1/SPIO can activate Piezo1 in bone defect areas of osteoporotic mice, improve osteogenesis through YAP/beta catenin signaling axis, promote a well coordinated osteogenesis angiogenesis coupling, and significantly accelerate bone reconstruction within the defects without noticeable side effects. Overall, this novel dual targeting nanocarrier provides a potentially effective strategy for the clinical treatment of osteoporotic bone defects.
   A magnetic aggregation induced bone targeting PLGA based nanocarrier (ZOL PLGA@Yoda1/SPIO) is synthesized to realize dual targeted delivery and precise Piezo1 activated therapy for osteoporotic bone defects. ZOL PLGA@Yoda1/SPIO can activate Piezo1 in bone defect areas of osteoporotic mice, improve osteogenesis through YAP/beta catenin signaling axis, promote a well coordinated osteogenesis angiogenesis coupling, and significantly accelerate bone reconstruction within the defects without noticeable side effects.image
C1 [Guan, Haitao; Zhang, Boyu; Ye, Zhipeng; Zhang, Yingze] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.
   [Guan, Haitao; Zhang, Boyu; Ye, Zhipeng; Chen, Wei; Zhang, Yingze] Third Hosp Hebei Med Univ, Dept Orthopaed Surg, Shijiazhuang 050051, Hebei, Peoples R China.
   [Wang, Wei; Zheng, Judun; Liao, Yuhui] Southern Med Univ, Dermatol Hosp, Mol Diag & Treatment Ctr Infect Dis, Guangzhou 510091, Peoples R China.
   [Jiang, Zichao] Cent South Univ, Dept Orthoped, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
   [Chen, Wei; Zhang, Yingze] Orthopaed Res Inst Hebei Prov, Shijiazhuang 050051, Peoples R China.
C3 Nankai University; Southern Medical University   China; Central South
   University
RP Zhang, YZ (通讯作者)，Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.; Chen, W; Zhang, YZ (通讯作者)，Third Hosp Hebei Med Univ, Dept Orthopaed Surg, Shijiazhuang 050051, Hebei, Peoples R China.; Zheng, JD (通讯作者)，Southern Med Univ, Dermatol Hosp, Mol Diag & Treatment Ctr Infect Dis, Guangzhou 510091, Peoples R China.; Chen, W; Zhang, YZ (通讯作者)，Orthopaed Res Inst Hebei Prov, Shijiazhuang 050051, Peoples R China.
EM zhengjd53815@163.com; 18101515@hebmu.edu.cn; yzling_liu@163.com
RI ; Zi, Ye/GWM 3932 2022; Zhu, Yanbin/ITV 3170 2023; Chen,
   Wei/GRX 2231 2022; zheng, judun/GYE 1067 2022
OI Zheng, Judun/0000 0001 5016 700X; 
FU National Natural Sciences Foundation of China;  [32130052];  [91949203]
FX H.G., W.W., Z.J., and B.Z. contributed equally to this work. This study
   was funded by the National Natural Sciences Foundation of China (NO
   32130052; NO 91949203).
CR Alarcón C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035
   Behzadi S, 2017, CHEM SOC REV, V46, P4218, DOI 10.1039/c6cs00636a
   Ben Ari A, 2009, TISSUE ENG PT A, V15, P2537, DOI 10.1089/ten.tea.2008.0567
   Botello Smith WM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12501 1
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bulte JWM, 2019, ADV DRUG DELIVER REV, V138, P293, DOI 10.1016/j.addr.2018.12.007
   Cahalan SM, 2015, ELIFE, V4, DOI 10.7554/eLife.07370
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Chen P, 2021, CELL CALCIUM, V97, DOI 10.1016/j.ceca.2021.102431
   Choi D, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125068
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Cong YY, 2015, J BIOMAT SCI POLYM E, V26, P629, DOI 10.1080/09205063.2015.1053170
   Coste B, 2010, SCIENCE, V330, P55, DOI 10.1126/science.1193270
   Delmas P, 2013, CELL, V155, P278, DOI 10.1016/j.cell.2013.09.026
   Duan PP, 2016, INT J BIOCHEM CELL B, V77, P23, DOI 10.1016/j.biocel.2016.05.015
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   Evans EL, 2018, BRIT J PHARMACOL, V175, P1744, DOI 10.1111/bph.14188
   Hao LL, 2019, NANOSCALE, V11, P23423, DOI 10.1039/c9nr07170a
   Heller DA, 2013, ADV MATER, V25, P1449, DOI 10.1002/adma.201202881
   Hoque J, 2021, BIOMATERIALS, V273, DOI 10.1016/j.biomaterials.2021.120819
   Huang ZH, 2016, DEVELOPMENT, V143, P2398, DOI 10.1242/dev.130658
   Jiang F, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21178 4
   Jiang YD, 2021, LIFE SCI, V275, DOI 10.1016/j.lfs.2021.119254
   Jiang ZC, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70659 x
   Jing CL, 2021, ACS APPL BIO MATER, V4, P4907, DOI 10.1021/acsabm.1c00199
   Kong Y, 2022, NANO RES, V15, P1153, DOI 10.1007/s12274 021 3618 2
   Lawrence KM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04367 4
   Li JC, 2018, NANO RES, V11, P1247, DOI 10.1007/s12274 017 1738 5
   Li JY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.600156
   Li LJ, 2019, ACTA BIOMATER, V96, P674, DOI 10.1016/j.actbio.2019.07.007
   Li LL, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00164 w
   Li XH, 2019, ELIFE, V8, DOI 10.7554/eLife.49631
   Li ZC, 2023, PHARMACOL RES, V187, DOI 10.1016/j.phrs.2022.106635
   Lin X, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12522
   Lipp L, 2019, ACS OMEGA, V4, P1157, DOI 10.1021/acsomega.8b02781
   Liu YL, 2022, INT J BIOL SCI, V18, P3961, DOI 10.7150/ijbs.71390
   Alves FAM, 2020, J PHOTOCH PHOTOBIO B, V213, DOI 10.1016/j.jphotobiol.2020.112053
   Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638
   Mousavibaygei SR, 2023, SCI TOTAL ENVIRON, V865, DOI 10.1016/j.scitotenv.2022.161117
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Nakamura H, 2013, J BONE MINER RES, V28, P1457, DOI 10.1002/jbmr.1866
   Pan JX, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0018 7
   Pang YC, 2021, BIOACT MATER, V6, P712, DOI 10.1016/j.bioactmat.2020.09.006
   Parthan A, 2013, APPL HEALTH ECON HEA, V11, P485, DOI 10.1007/s40258 013 0047 8
   Parveen S, 2011, EUR J PHARMACOL, V670, P372, DOI 10.1016/j.ejphar.2011.09.023
   Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Poole K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4520
   Qin H, 2014, INT J NANOMED, V9, P2469, DOI 10.2147/IJN.S59753
   Rico P, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 01449 4
   Robling AG, 2009, CRIT REV EUKAR GENE, V19, P319, DOI 10.1615/CritRevEukarGeneExpr.v19.i4.50
   Song JD, 2020, CELL BIOL INT, V44, P1491, DOI 10.1002/cbin.11344
   Sugimoto A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 18089 0
   Sun WJ, 2019, ELIFE, V8, DOI 10.7554/eLife.47454
   Swain SM, 2020, J CLIN INVEST, V130, P2527, DOI 10.1172/JCI134111
   Syeda R, 2015, ELIFE, V4, DOI 10.7554/eLife.07369
   Tang Z, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.750948
   Varelas X, 2010, DEV CELL, V18, P579, DOI 10.1016/j.devcel.2010.03.007
   Wang BJ, 2022, SMALL, V18, DOI 10.1002/smll.202201056
   Wang JS, 2020, J IMMUNOL, V205, P968, DOI 10.4049/jimmunol.1901001
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wang L, 2018, ACS APPL MATER INTER, V10, P42102, DOI 10.1021/acsami.8b16323
   Wang PX, 2021, ACTA PHARM SIN B, V11, P680, DOI 10.1016/j.apsb.2020.10.017
   Wang Y., 2023, ADV HEALTHC MATER, V12
   Wu MH, 2020, INT J BIOL MACROMOL, V162, P1627, DOI 10.1016/j.ijbiomac.2020.08.029
   Wu RW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179476
   Xiao BL, 2020, ANNU REV PHARMACOL, V60, P195, DOI 10.1146/annurev pharmtox 010919 023703
   Xu C, 2020, NANO RES, V13, P2323, DOI 10.1007/s12274 020 2783 z
   Yang X, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2036176
   Ye J, 2021, ACS NANO, V15, P13692, DOI 10.1021/acsnano.1c04974
   Yoneda M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194960
   Yu GY, 2023, OSTEOPOROSIS INT, V34, P641, DOI 10.1007/s00198 022 06626 1
   Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073
   Zhang GD, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00124 y
   Zhang W, 2023, BIOACT MATER, V19, P429, DOI 10.1016/j.bioactmat.2022.04.017
   Zhang YF, 2022, BIOACT MATER, V11, P130, DOI 10.1016/j.bioactmat.2021.09.033
   Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210
   Zhao XJ, 2018, CARBOHYD POLYM, V195, P225, DOI 10.1016/j.carbpol.2018.04.090
   Zhou Q, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202101467
   Zhou TF, 2020, ELIFE, V9, DOI 10.7554/eLife.52779
   Zhou W, 2021, ACS APPL MATER INTER, V13, P56944, DOI 10.1021/acsami.1c17420
   Zhou X, 2021, NANO LETT, V21, P7998, DOI 10.1021/acs.nanolett.1c02150
   Zhu BQ, 2021, MOL THER NUCL ACIDS, V24, P241, DOI 10.1016/j.omtn.2021.02.026
NR 84
TC 40
Z9 45
U1 39
U2 204
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935 9648
EI 1521 4095
J9 ADV MATER
JI Adv. Mater.
PD MAR
PY 2024
VL 36
IS 13
DI 10.1002/adma.202312081
EA DEC 2023
PG 17
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA MM8V5
UT WOS:001135215400001
PM 38102981
DA 2025 08 17
ER

PT J
AU Wan, C
   Gilbert, SR
   Wang, Y
   Cao, X
   Shen, X
   Ramaswamy, G
   Jacobsen, KA
   Alaql, ZS
   Eberhardt, AW
   Gerstenfeld, LC
   Einhorn, TA
   Deng, L
   Clemens, TL
AF Wan, Chao
   Gilbert, Shawn R.
   Wang, Ying
   Cao, Xuemei
   Shen, Xing
   Ramaswamy, Girish
   Jacobsen, Kimberly A.
   Alaql, Zainab S.
   Eberhardt, Alan W.
   Gerstenfeld, Louis C.
   Einhorn, Thomas A.
   Deng, Lianfu
   Clemens, Thomas L.
TI Activation of the hypoxia inducible factor 1α pathway accelerates bone
   regeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE von Hippel Lindau protein; VEGF; angiogenesis; distraction osteogenesis
ID HIF ALPHA; DISTRACTION OSTEOGENESIS; COLLAGEN SYNTHESIS;
   TUMOR SUPPRESSOR; GENE EXPRESSION; FACTOR 1 ALPHA; RABBIT MODEL;
   IN VITRO; GROWTH; INHIBITION
AB The hypoxia inducible factor 1 alpha (HIF 1 alpha) pathway is the central regulator of adaptive responses to low oxygen availability and is required for normal skeletal development. Here, we demonstrate that the HIF 1 alpha pathway is activated during bone repair and can be manipulated genetically and pharmacologically to improve skeletal healing. Mice lacking pVHL in osteoblasts with constitutive HIF 1 alpha activation in osteoblasts had markedly increased vascularity and produced more bone in response to distraction osteogenesis, whereas mice lacking HIF 1 alpha in osteoblasts had impaired angiogenesis and bone healing. The increased vascularity and bone regeneration in the pVHL mutants were VEGF dependent and eliminated by concomitant administration of VEGF receptor antibodies. Small molecule inhibitors of HIF prolyl hydroxylation stabilized HIF/VEGF production and increased angiogenesis in vitro. One of these molecules (DFO) administered in vivo into the distraction gap increased angiogenesis and markedly improved bone regeneration. These results identify the HIF 1 alpha pathway as a critical mediator of neoangiogenesis required for skeletal regeneration and suggest the application of HIF activators as therapies to improve bone healing.
C1 [Wan, Chao; Wang, Ying; Cao, Xuemei; Shen, Xing; Deng, Lianfu; Clemens, Thomas L.] Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA.
   [Gilbert, Shawn R.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.
   [Ramaswamy, Girish; Eberhardt, Alan W.] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA.
   [Jacobsen, Kimberly A.; Alaql, Zainab S.; Gerstenfeld, Louis C.] Boston Univ, Med Ctr, Dept Orthopaed Surg, Boston, MA 02118 USA.
   [Clemens, Thomas L.] Vet Adm Med Ctr, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; Boston
   University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA)
RP Clemens, TL (通讯作者)，Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Volker Hall,G001,1670 Univ Blvd, Birmingham, AL 35294 USA.
EM tclemens@uab.edu
RI Wan, Chao/J 9277 2013
OI Wan, Chao/0000 0001 6780 2006; Einhorn, Thomas/0000 0002 5075 4885;
   /0000 0002 0477 1211
FU NIAMS NIH HHS [R21 AR054771, AR49410, P30 AR046031, P01 AR049920, P01
   AR049920, AR054771, R01 AR049410, P30AR046031] Funding Source: Medline
CR ARONSON J, 1994, CLIN ORTHOP RELAT R, P124
   Balooch G, 2005, P NATL ACAD SCI USA, V102, P18813, DOI 10.1073/pnas.0507417102
   Bickel M, 1998, HEPATOLOGY, V28, P404, DOI 10.1002/hep.510280217
   Carvalho RS, 2004, BONE, V34, P849, DOI 10.1016/j.bone.2003.12.027
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   Chau NM, 2005, CANCER RES, V65, P4918, DOI 10.1158/0008 5472.CAN 04 4453
   Choi IH, 2000, J ORTHOP RES, V18, P698, DOI 10.1002/jor.1100180504
   Choi P, 2004, J ORTHOP RES, V22, P1100, DOI 10.1016/j.orthres.2004.03.008
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092 8674(03)00154 5
   Deckers M, 2001, LAB INVEST, V81, P5, DOI 10.1038/labinvest.3780207
   Doherty MJ, 1998, J BONE MINER RES, V13, P828, DOI 10.1359/jbmr.1998.13.5.828
   Duvall CL, 2004, AM J PHYSIOL HEART C, V287, pH302, DOI 10.1152/ajpheart.00928.2003
   Eckardt H, 2003, J ORTHOP RES, V21, P335, DOI 10.1016/S0736 0266(02)00159 6
   Eckardt H, 2005, J BONE JOINT SURG BR, V87B, P1434, DOI 10.1302/0301 620X.87B10
   EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623 199506000 00016
   Eriksen EF, 2007, J BONE MINER RES, V22, P1, DOI 10.1359/JBMR.060910
   Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925 4773(99)00142 2
   Geiger F, 2005, J BONE MINER RES, V20, P2028, DOI 10.1359/JBMR.050701
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Haase VH, 2005, SEMIN CELL DEV BIOL, V16, P564, DOI 10.1016/j.semcdb.2005.03.006
   Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575
   Hermanns S, 2001, J NEUROSCI METH, V110, P141, DOI 10.1016/S0165 0270(01)00427 7
   Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987
   ILIZAROV GA, 1989, CLIN ORTHOP RELAT R, P249, DOI 10.1097/00003086 198901000 00038
   ILIZAROV GA, 1989, CLIN ORTHOP RELAT R, P263
   Ishida T, 2003, J BIOL CHEM, V278, P34598, DOI 10.1074/jbc.M304890200
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573
   Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519
   Khosla S, 2006, ANN NY ACAD SCI, V1068, P489, DOI 10.1196/annals.1346.022
   Kim I, 2003, WOUND REPAIR REGEN, V11, P368, DOI 10.1046/j.1524 475X.2003.11509.x
   Komatsu DE, 2004, BONE, V34, P680, DOI 10.1016/j.bone.2003.12.024
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   MCCOY BJ, 1980, P SOC EXP BIOL MED, V163, P216
   Mori S, 2006, J ORTHOP RES, V24, P653, DOI 10.1002/jor.20076
   Nwogu JI, 2001, CIRCULATION, V104, P2216, DOI 10.1161/hc4301.097193
   Pacicca DM, 2003, BONE, V33, P889, DOI 10.1016/j.bone.2003.06.002
   Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708
   Philipp S, 2006, EUR J HEART FAIL, V8, P347, DOI 10.1016/j.ejheart.2005.10.009
   Robins JC, 2005, BONE, V37, P313, DOI 10.1016/j.bone.2005.04.040
   Schipani E, 2001, GENE DEV, V15, P2865
   Street J, 2000, CLIN ORTHOP RELAT R, P224, DOI 10.1097/00003086 200009000 00033
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Street JT, 2001, J ORTHOP RES, V19, P1057, DOI 10.1016/S0736 0266(01)00048 1
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Willam C, 2002, P NATL ACAD SCI USA, V99, P10423, DOI 10.1073/pnas.162119399
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534 5807(02)00131 4
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
NR 50
TC 428
Z9 494
U1 0
U2 94
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 15
PY 2008
VL 105
IS 2
BP 686
EP 691
DI 10.1073/pnas.0708474105
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 253XO
UT WOS:000252551100053
PM 18184809
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Nakamura, M
   Ueda, K
   Yamamoto, Y
   Aoki, K
   Zhang, MF
   Saito, N
   Yudasaka, M
AF Nakamura, Maki
   Ueda, Katsuya
   Yamamoto, Yumiko
   Aoki, Kaoru
   Zhang, Minfang
   Saito, Naoto
   Yudasaka, Masako
TI Bisphosphonate type dependent cell viability suppressive effects of
   carbon nanohorn calcium phosphate bisphosphonate nanocomposites
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID IN VITRO; HYDROXYAPATITE; BIODISTRIBUTION; NANOTUBES; APOPTOSIS;
   TOXICITY
AB In the process of bone metastasis, tumor cells spread to the bones to activate osteoclasts, which cause pathological bone resorption and destruction. Bisphosphonates (BPs) inhibit osteoclast activation to resorb bone, reducing bone pain and fracture. We previously developed a nanocomposite for potential localized treatment of bone metastasis by loading a BP compound, ibandronate, onto oxidized carbon nanohorns (OxCNHs), a next generation drug carrier, using calcium phosphates (CaPs) as mediators to generate OxCNH CaP BP nanocomposites. The objective of the present study was to determine nanocomposite formation and biological properties of nanocomposites constructed from two BPs, zoledronate and pamidronate. In vitro tests using murine macrophages (RAW264.7 cells) and osteoclasts differentiated from RAW264.7 cells revealed that the resulting OxCNH CaP BP nanocomposites suppressed cell viability in a BP type dependent manner and more effectively than OxCNHs or BPs alone. The mechanism for the potent and BP type dependent suppression of cell viability by OxCNH CaP BP nanocomposites, based on their relative cellular uptake and reactive oxygen species generation, is also discussed. The present study supports the conclusions that BPs can be loaded onto OxCNHs using CaPs as mediators, and that OxCNH CaP BP nanocomposites are putative medicines for localized treatment of metastatic bone destruction.
C1 [Nakamura, Maki; Yamamoto, Yumiko; Yudasaka, Masako] Natl Inst Adv Ind Sci & Technol, Nanomat Res Inst, Cent 5,1 1 1 Higashi, Tsukuba, Ibaraki 3058565, Japan.
   [Ueda, Katsuya] Shinshu Univ, Grad Sch Med Sci & Technol, Biomed Engn Div, 3 1 1 Asahi, Matsumoto, Nagano 3908621, Japan.
   [Aoki, Kaoru] Shinshu Univ, Sch Hlth Sci, Phys Therapy Div, 3 1 1 Asahi, Matsumoto, Nagano 3908621, Japan.
   [Zhang, Minfang] Natl Inst Adv Ind Sci & Technol, Nano Carbon Device Res Ctr, Cent 5,1 1 1 Higashi, Tsukuba, Ibaraki 3058565, Japan.
   [Saito, Naoto] Shinshu Univ, Inst Biomed Sci, Interdisciplinary Cluster Cutting Edge Res, 3 1 1 Asahi, Matsumoto, Nagano 3908621, Japan.
   [Yudasaka, Masako] Meijo Univ, Fac Sci & Technol, Tenpaku Ku, 1 501 Shiogamaguchi, Nagoya, Aichi 4688502, Japan.
C3 National Institute of Advanced Industrial Science & Technology (AIST);
   Shinshu University; Shinshu University; National Institute of Advanced
   Industrial Science & Technology (AIST); Shinshu University; Meijo
   University
RP Nakamura, M; Yudasaka, M (通讯作者)，Natl Inst Adv Ind Sci & Technol, Nanomat Res Inst, Cent 5,1 1 1 Higashi, Tsukuba, Ibaraki 3058565, Japan.; Saito, N (通讯作者)，Shinshu Univ, Inst Biomed Sci, Interdisciplinary Cluster Cutting Edge Res, 3 1 1 Asahi, Matsumoto, Nagano 3908621, Japan.; Yudasaka, M (通讯作者)，Meijo Univ, Fac Sci & Technol, Tenpaku Ku, 1 501 Shiogamaguchi, Nagoya, Aichi 4688502, Japan.
EM ma ki nakamura@aist.go.jp; saitoko@shinshu u.ac.jp;
   yudasaka.masako@gmail.com
RI ; Zhang, Minfang/L 2082 2018; Nakamura, Maki/M 2737 2018
OI Ueda, Katsuya/0000 0003 1786 9450; Zhang, Minfang/0000 0002 3983 3355;
   Saito, Naoto/0000 0001 6424 087X
FU JSPS KAKENHI [JP17H01584, JP20K21914, JP22H00582]; Grants in Aid for
   Scientific Research [20K21914, 22H00582] Funding Source: KAKEN
FX This study was supported by JSPS KAKENHI, Grant Numbers JP17H01584,
   JP20K21914, and JP22H00582. We thank Dr R. Yuge from NEC Corporation for
   preparation of as grown CNHs, and Dr Y. Ishikawa from AIST for DLS and
   ELS measurements.
CR Azami T, 2008, J PHYS CHEM C, V112, P1330, DOI 10.1021/jp076365o
   Bigi A, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010006
   Cuetara BLV, 2006, IN VITRO CELL DEV AN, V42, P182, DOI 10.1290/0510075.1
   Danese A, 2021, BBA MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2021.119061
   Núñez JD, 2014, CARBON, V79, P590, DOI 10.1016/j.carbon.2014.08.020
   Fan J, 2006, J PHYS CHEM B, V110, P1587, DOI 10.1021/jp0538870
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   Giorgi C, 2018, TRENDS CELL BIOL, V28, P258, DOI 10.1016/j.tcb.2018.01.002
   Hirata E, 2016, NANOSCALE, V8, P14514, DOI 10.1039/c6nr02756c
   Kasai T, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/6/065102
   Kellinsalmi M, 2005, BASIC CLIN PHARMACOL, V97, P382, DOI 10.1111/j.1742 7843.2005.pto_176.x
   Li M, 2013, J MATER CHEM B, V1, P475, DOI 10.1039/c2tb00053a
   Miyawaki J, 2008, ACS NANO, V2, P213, DOI 10.1021/nn700185t
   Miyawaki J, 2009, ACS NANO, V3, P1399, DOI 10.1021/nn9004846
   Moreau MF, 2007, BIOCHEM PHARMACOL, V73, P718, DOI 10.1016/j.bcp.2006.09.031
   Moreno Lanceta A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090850
   Murata K, 2001, J PHYS CHEM B, V105, P10210, DOI 10.1021/jp010754f
   Nakamura M, 2021, ACS APPL MATER INTER, V13, P3701, DOI 10.1021/acsami.0c20923
   Neelgund GM, 2011, MAT SCI ENG C MATER, V31, P1477, DOI 10.1016/j.msec.2011.06.001
   Oyane A, 2016, COLLOID SURFACE B, V141, P519, DOI 10.1016/j.colsurfb.2016.02.010
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Shubhra QTH, 2017, BIOMATER SCI UK, V5, P972, DOI 10.1039/c6bm00870d
   Tahara Y, 2012, BIOMATERIALS, V33, P2762, DOI 10.1016/j.biomaterials.2011.12.023
   Tahara Y, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/26/265106
   Tai TW, 2017, SCI REP UK, V7, DOI 10.1038/srep44245
   Takahashi N, 2007, ODONTOLOGY, V95, P1, DOI 10.1007/s10266 007 0071 y
   Utsumi S, 2005, J PHYS CHEM B, V109, P14319, DOI 10.1021/jp0512661
   Yang M, 2014, TOXICOL APPL PHARM, V280, P117, DOI 10.1016/j.taap.2014.07.022
   Zhang M., 2016, CARBON NANOPARTICLES
   Zhang MF, 2007, ACS NANO, V1, P265, DOI 10.1021/nn700130f
   Zhang MF, 2013, NANOMED NANOTECHNOL, V9, P657, DOI 10.1016/j.nano.2012.11.011
   Zhang MF, 2012, SMALL, V8, P2524, DOI 10.1002/smll.201102595
NR 34
TC 4
Z9 4
U1 1
U2 22
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PD OCT 11
PY 2022
VL 10
IS 20
BP 6037
EP 6048
DI 10.1039/d2bm00822j
EA SEP 2022
PG 12
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 5L4DG
UT WOS:000850826900001
PM 36073144
DA 2025 08 17
ER

EF